7352670
D009599_D006973 NONE Rebound\NN\7309781 <e2>hypertensive</e2>\NN\10405694 after\IN\1740 <e1>sodium\NN\14625458 nitroprusside</e1>\NN\1740 prevented\VBN\1740 by\IN\1740 saralasin\NN\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D009599_D006973 NONE During\IN\1740 the\DT\1740 <e1>SNP</e1>\NN\11493266 infusion\NN\14589223 the\DT\1740 control\NN\5190804 animals\NNS\4475 demonstrated\VBD\2137132 a\DT\13649268 progressive\JJ\1740 <e2>increase\NN\13576355 in\IN\13603305 blood\NN\5397468 pressure</e2>\NN\11419404 to\IN\1740 61\CD\1740 torr\NN\13607985 ,\,\1740 whereas\IN\1740 the\DT\1740 saralasin-treated\JJ\1740 animals\NNS\4475 showed\VBD\2137132 no\DT\7204911 change\NN\7283608 .\.\1740
D012504_D006973 NONE Rebound\NN\7309781 <e2>hypertensive</e2>\NN\10405694 after\IN\1740 sodium\NN\14625458 nitroprusside\NN\1740 prevented\VBN\1740 by\IN\1740 <e1>saralasin</e1>\NN\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D012504_D006973 NONE During\IN\1740 the\DT\1740 SNP\NN\11493266 infusion\NN\14589223 the\DT\1740 control\NN\5190804 animals\NNS\4475 demonstrated\VBD\2137132 a\DT\13649268 progressive\JJ\1740 <e2>increase\NN\13576355 in\IN\13603305 blood\NN\5397468 pressure</e2>\NN\11419404 to\IN\1740 61\CD\1740 torr\NN\13607985 ,\,\1740 whereas\IN\1740 the\DT\1740 <e1>saralasin-treated</e1>\JJ\1740 animals\NNS\4475 showed\VBD\2137132 no\DT\7204911 change\NN\7283608 .\.\1740
D000809_D007022 NONE The\DT\1740 role\NN\719494 of\IN\1740 the\DT\1740 renin\NN\14999106 --\:\1740 <e1>angiotensin</e1>\NN\4522421 system\NN\3575240 in\IN\13603305 the\DT\1740 maintenance\NN\266806 of\IN\1740 blood\NN\5397468 pressure\NN\11419404 during\IN\1740 halothane\NN\3570838 anesthesia\NN\14034177 and\CC\1740 sodium\NN\14625458 nitroprusside\NN\1740 (SNP)-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 was\VBD\836236 evaluated\VBN\670261 .\.\1740
D000809_D007022 NONE This\DT\1740 demonstrates\VBZ\2137132 the\DT\1740 participation\NN\1080366 of\IN\1740 the\DT\1740 renin\NN\14999106 --\:\1740 <e1>angiotensin</e1>\NN\4522421 system\NN\3575240 in\IN\13603305 antagonizing\VBG\1787955 the\DT\1740 combined\JJ\1740 <e2>hypotensive</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 halothane\NN\3570838 and\CC\1740 SNP\NN\11493266 .\.\1740
D006221_D007022 CID The\DT\1740 role\NN\719494 of\IN\1740 the\DT\1740 renin\NN\14999106 --\:\1740 angiotensin\NN\4522421 system\NN\3575240 in\IN\13603305 the\DT\1740 maintenance\NN\266806 of\IN\1740 blood\NN\5397468 pressure\NN\11419404 during\IN\1740 <e1>halothane</e1>\NN\3570838 anesthesia\NN\14034177 and\CC\1740 sodium\NN\14625458 nitroprusside\NN\1740 (SNP)-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 was\VBD\836236 evaluated\VBN\670261 .\.\1740
D006221_D007022 CID This\DT\1740 demonstrates\VBZ\2137132 the\DT\1740 participation\NN\1080366 of\IN\1740 the\DT\1740 renin\NN\14999106 --\:\1740 angiotensin\NN\4522421 system\NN\3575240 in\IN\13603305 antagonizing\VBG\1787955 the\DT\1740 combined\JJ\1740 <e2>hypotensive</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>halothane</e1>\NN\3570838 and\CC\1740 SNP\NN\11493266 .\.\1740
D009599_D007022 CID The\DT\1740 role\NN\719494 of\IN\1740 the\DT\1740 renin\NN\14999106 --\:\1740 angiotensin\NN\4522421 system\NN\3575240 in\IN\13603305 the\DT\1740 maintenance\NN\266806 of\IN\1740 blood\NN\5397468 pressure\NN\11419404 during\IN\1740 halothane\NN\3570838 anesthesia\NN\14034177 and\CC\1740 <e1>sodium\NN\14625458 nitroprusside</e1>\NN\1740 (SNP)-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 was\VBD\836236 evaluated\VBN\670261 .\.\1740
D009599_D007022 CID The\DT\1740 role\NN\719494 of\IN\1740 the\DT\1740 renin\NN\14999106 --\:\1740 angiotensin\NN\4522421 system\NN\3575240 in\IN\13603305 the\DT\1740 maintenance\NN\266806 of\IN\1740 blood\NN\5397468 pressure\NN\11419404 during\IN\1740 halothane\NN\3570838 anesthesia\NN\14034177 and\CC\1740 sodium\NN\14625458 nitroprusside\NN\1740 <e1>(SNP)-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 was\VBD\836236 evaluated\VBN\670261 .\.\1740
D009599_D007022 CID This\DT\1740 demonstrates\VBZ\2137132 the\DT\1740 participation\NN\1080366 of\IN\1740 the\DT\1740 renin\NN\14999106 --\:\1740 angiotensin\NN\4522421 system\NN\3575240 in\IN\13603305 antagonizing\VBG\1787955 the\DT\1740 combined\JJ\1740 <e2>hypotensive</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 halothane\NN\3570838 and\CC\1740 <e1>SNP</e1>\NN\11493266 .\.\1740
15145918
D004967_D007022 NONE Differential\JJ\1740 modulation\NN\7044917 by\IN\1740 <e1>estrogen</e1>\NN\14745635 of\IN\1740 alpha2-adrenergic\JJ\1740 and\CC\1740 I1-imidazoline\JJ\1740 receptor-mediated\JJ\1740 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 female\JJ\1740 rats\NNS\2329401 .\.\1740
D004967_D007022 NONE We\PRP\1740 have\VBP\2108377 recently\RB\1740 shown\VBN\2137132 that\IN\1740 <e1>estrogen</e1>\NN\14745635 negatively\RB\1740 modulates\VBZ\1724459 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 effect\NN\34213 of\IN\1740 clonidine\NN\2721160 (\-LRB-\1740 mixed\JJ\1740 alpha2-/I1-receptor\NN\1740 agonist\NN\9613191 )\-RRB-\1740 in\IN\13603305 female\JJ\1740 rats\NNS\2329401 and\CC\1740 implicates\VBZ\2677097 the\DT\1740 cardiovascular\JJ\1740 autonomic\JJ\1740 control\NN\5190804 in\IN\13603305 this\DT\1740 interaction\NN\37396 .\.\1740
D004967_D007022 NONE These\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 <e1>estrogen</e1>\NN\14745635 downregulates\VBZ\1740 alpha2-\NN\1740 but\CC\1740 not\RB\1740 I1-receptor-mediated\VBN\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 highlight\VB\514463 a\DT\13649268 role\NN\719494 for\IN\1740 the\DT\1740 cardiac\JJ\1740 autonomic\JJ\1740 control\NN\5190804 in\IN\13603305 alpha-methyldopa-estrogen\NN\1740 interaction\NN\37396 .\.\1740
D004967_D007022 NONE These\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 estrogen\NN\14745635 downregulates\VBZ\1740 alpha2-\NN\1740 but\CC\1740 not\RB\1740 I1-receptor-mediated\VBN\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 highlight\VB\514463 a\DT\13649268 role\NN\719494 for\IN\1740 the\DT\1740 cardiac\JJ\1740 autonomic\JJ\1740 control\NN\5190804 in\IN\13603305 <e1>alpha-methyldopa-estrogen</e1>\NN\1740 interaction\NN\37396 .\.\1740
D048288_D007022 NONE Differential\JJ\1740 modulation\NN\7044917 by\IN\1740 estrogen\NN\14745635 of\IN\1740 alpha2-adrenergic\JJ\1740 and\CC\1740 <e1>I1-imidazoline</e1>\JJ\1740 receptor-mediated\JJ\1740 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 female\JJ\1740 rats\NNS\2329401 .\.\1740
D003000_D007022 NONE We\PRP\1740 have\VBP\2108377 recently\RB\1740 shown\VBN\2137132 that\IN\1740 estrogen\NN\14745635 negatively\RB\1740 modulates\VBZ\1724459 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 effect\NN\34213 of\IN\1740 <e1>clonidine</e1>\NN\2721160 (\-LRB-\1740 mixed\JJ\1740 alpha2-/I1-receptor\NN\1740 agonist\NN\9613191 )\-RRB-\1740 in\IN\13603305 female\JJ\1740 rats\NNS\2329401 and\CC\1740 implicates\VBZ\2677097 the\DT\1740 cardiovascular\JJ\1740 autonomic\JJ\1740 control\NN\5190804 in\IN\13603305 this\DT\1740 interaction\NN\37396 .\.\1740
C032302_D007022 CID In\IN\13603305 sham-operated\JJ\1740 rats\NNS\2329401 ,\,\1740 <e1>rilmenidine</e1>\NN\1740 or\CC\3541091 alpha-methyldopa\JJ\1740 elicited\VBN\1617192 similar\JJ\1740 <e2>hypotension</e2>\NN\14057371 that\WDT\1740 lasted\VBD\2704349 at\IN\14622893 least\JJS\1740 5\CD\13741022 h\NN\14622893 and\CC\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 reductions\NNS\351485 in\IN\13603305 standard\JJ\1740 deviation\NN\7337390 of\IN\1740 mean\NN\6021761 arterial\JJ\1740 pressure\NN\11419404 .\.\1740
C032302_D007022 CID Ovx\NNP\1740 significantly\RB\1740 enhanced\VBD\227165 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 response\NN\11410625 to\TO\1740 alpha-methyldopa\JJ\1740 ,\,\1740 in\IN\13603305 contrast\NN\13854649 to\TO\1740 no\DT\7204911 effect\NN\34213 on\IN\1740 <e1>rilmenidine</e1>\JJ\1740 hypotension\NN\14057371 .\.\1740
C032302_D007022 CID Ovx\NNP\1740 significantly\RB\1740 enhanced\VBD\227165 the\DT\1740 hypotensive\JJ\1740 response\NN\11410625 to\TO\1740 alpha-methyldopa\JJ\1740 ,\,\1740 in\IN\13603305 contrast\NN\13854649 to\TO\1740 no\DT\7204911 effect\NN\34213 on\IN\1740 <e1>rilmenidine</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D008750_D007022 CID In\IN\13603305 sham-operated\JJ\1740 rats\NNS\2329401 ,\,\1740 rilmenidine\NN\1740 or\CC\3541091 <e1>alpha-methyldopa</e1>\JJ\1740 elicited\VBN\1617192 similar\JJ\1740 <e2>hypotension</e2>\NN\14057371 that\WDT\1740 lasted\VBD\2704349 at\IN\14622893 least\JJS\1740 5\CD\13741022 h\NN\14622893 and\CC\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 reductions\NNS\351485 in\IN\13603305 standard\JJ\1740 deviation\NN\7337390 of\IN\1740 mean\NN\6021761 arterial\JJ\1740 pressure\NN\11419404 .\.\1740
D008750_D007022 CID Ovx\NNP\1740 significantly\RB\1740 enhanced\VBD\227165 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 response\NN\11410625 to\TO\1740 <e1>alpha-methyldopa</e1>\JJ\1740 ,\,\1740 in\IN\13603305 contrast\NN\13854649 to\TO\1740 no\DT\7204911 effect\NN\34213 on\IN\1740 rilmenidine\JJ\1740 hypotension\NN\14057371 .\.\1740
D008750_D007022 CID Ovx\NNP\1740 significantly\RB\1740 enhanced\VBD\227165 the\DT\1740 hypotensive\JJ\1740 response\NN\11410625 to\TO\1740 <e1>alpha-methyldopa</e1>\JJ\1740 ,\,\1740 in\IN\13603305 contrast\NN\13854649 to\TO\1740 no\DT\7204911 effect\NN\34213 on\IN\1740 rilmenidine\JJ\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D008750_D007022 CID The\DT\1740 enhanced\VBN\227165 <e1>alpha-methyldopa</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 Ovx\JJ\1740 rats\NNS\2329401 was\VBD\836236 paralleled\VBN\2657219 with\IN\1740 further\JJ\1740 reduction\NN\351485 in\IN\13603305 SDRR\NN\1740 and\CC\1740 a\DT\13649268 reduced\VBN\441445 locomotor\NN\1740 activity\NN\30358 .\.\1740
D008750_D007022 CID These\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 estrogen\NN\14745635 downregulates\VBZ\1740 alpha2-\NN\1740 but\CC\1740 not\RB\1740 I1-receptor-mediated\VBN\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 highlight\VB\514463 a\DT\13649268 role\NN\719494 for\IN\1740 the\DT\1740 cardiac\JJ\1740 autonomic\JJ\1740 control\NN\5190804 in\IN\13603305 <e1>alpha-methyldopa-estrogen</e1>\NN\1740 interaction\NN\37396 .\.\1740
D008750_D001523 NONE The\DT\1740 enhanced\VBN\227165 <e1>alpha-methyldopa</e1>\JJ\1740 hypotension\NN\14057371 in\IN\13603305 Ovx\JJ\1740 rats\NNS\2329401 was\VBD\836236 paralleled\VBN\2657219 with\IN\1740 further\JJ\1740 reduction\NN\351485 in\IN\13603305 SDRR\NN\1740 and\CC\1740 <e2>a\DT\13649268 reduced\VBN\441445 locomotor\NN\1740 activity</e2>\NN\30358 .\.\1740
11672959
D012460_D003872 CID A\DT\13649268 34-year-old\JJ\1740 lady\NN\10787470 developed\VBD\1753788 a\DT\13649268 constellation\NN\5728678 of\IN\1740 <e2>dermatitis</e2>\NN\14226056 ,\,\1740 fever\NN\14299637 ,\,\1740 lymphadenopathy\NN\14204950 and\CC\1740 hepatitis\NN\14127211 ,\,\1740 beginning\VBG\941990 on\IN\1740 the\DT\1740 17th\JJ\1740 day\NN\15154774 of\IN\1740 a\DT\13649268 course\NN\883297 of\IN\1740 oral\JJ\1740 <e1>sulphasalazine</e1>\NN\1740 for\IN\1740 sero-negative\JJ\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 .\.\1740
D012460_D005334 CID A\DT\13649268 34-year-old\JJ\1740 lady\NN\10787470 developed\VBD\1753788 a\DT\13649268 constellation\NN\5728678 of\IN\1740 dermatitis\NN\14226056 ,\,\1740 <e2>fever</e2>\NN\14299637 ,\,\1740 lymphadenopathy\NN\14204950 and\CC\1740 hepatitis\NN\14127211 ,\,\1740 beginning\VBG\941990 on\IN\1740 the\DT\1740 17th\JJ\1740 day\NN\15154774 of\IN\1740 a\DT\13649268 course\NN\883297 of\IN\1740 oral\JJ\1740 <e1>sulphasalazine</e1>\NN\1740 for\IN\1740 sero-negative\JJ\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 .\.\1740
D012460_D008206 CID A\DT\13649268 34-year-old\JJ\1740 lady\NN\10787470 developed\VBD\1753788 a\DT\13649268 constellation\NN\5728678 of\IN\1740 dermatitis\NN\14226056 ,\,\1740 fever\NN\14299637 ,\,\1740 <e2>lymphadenopathy</e2>\NN\14204950 and\CC\1740 hepatitis\NN\14127211 ,\,\1740 beginning\VBG\941990 on\IN\1740 the\DT\1740 17th\JJ\1740 day\NN\15154774 of\IN\1740 a\DT\13649268 course\NN\883297 of\IN\1740 oral\JJ\1740 <e1>sulphasalazine</e1>\NN\1740 for\IN\1740 sero-negative\JJ\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 .\.\1740
D012460_D056486 CID A\DT\13649268 34-year-old\JJ\1740 lady\NN\10787470 developed\VBD\1753788 a\DT\13649268 constellation\NN\5728678 of\IN\1740 dermatitis\NN\14226056 ,\,\1740 fever\NN\14299637 ,\,\1740 lymphadenopathy\NN\14204950 and\CC\1740 <e2>hepatitis</e2>\NN\14127211 ,\,\1740 beginning\VBG\941990 on\IN\1740 the\DT\1740 17th\JJ\1740 day\NN\15154774 of\IN\1740 a\DT\13649268 course\NN\883297 of\IN\1740 oral\JJ\1740 <e1>sulphasalazine</e1>\NN\1740 for\IN\1740 sero-negative\JJ\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 .\.\1740
D012460_D001172 NONE A\DT\13649268 34-year-old\JJ\1740 lady\NN\10787470 developed\VBD\1753788 a\DT\13649268 constellation\NN\5728678 of\IN\1740 dermatitis\NN\14226056 ,\,\1740 fever\NN\14299637 ,\,\1740 lymphadenopathy\NN\14204950 and\CC\1740 hepatitis\NN\14127211 ,\,\1740 beginning\VBG\941990 on\IN\1740 the\DT\1740 17th\JJ\1740 day\NN\15154774 of\IN\1740 a\DT\13649268 course\NN\883297 of\IN\1740 oral\JJ\1740 <e1>sulphasalazine</e1>\NN\1740 for\IN\1740 sero-negative\JJ\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 .\.\1740
1664218
D000677_D002289 NONE Phase\NN\15113229 II\CD\13741022 study\NN\635850 of\IN\1740 the\DT\1740 <e1>amsacrine</e1>\NN\1740 analogue\NN\4743605 CI-921\NN\1740 (\-LRB-\1740 NSC\NNP\8123696 343499\CD\1740 )\-RRB-\1740 in\IN\13603305 <e2>non-small\JJ\1740 cell\NN\3080309 lung\NN\5528060 cancer</e2>\NN\14239425 .\.\1740
C042315_D002289 NONE Phase\NN\15113229 II\CD\13741022 study\NN\635850 of\IN\1740 the\DT\1740 amsacrine\NN\1740 analogue\NN\4743605 <e1>CI-921</e1>\NN\1740 (\-LRB-\1740 NSC\NNP\8123696 343499\CD\1740 )\-RRB-\1740 in\IN\13603305 <e2>non-small\JJ\1740 cell\NN\3080309 lung\NN\5528060 cancer</e2>\NN\14239425 .\.\1740
C042315_D002289 NONE Phase\NN\15113229 II\CD\13741022 study\NN\635850 of\IN\1740 the\DT\1740 amsacrine\NN\1740 analogue\NN\4743605 CI-921\NN\1740 (\-LRB-\1740 <e1>NSC\NNP\8123696 343499</e1>\CD\1740 )\-RRB-\1740 in\IN\13603305 <e2>non-small\JJ\1740 cell\NN\3080309 lung\NN\5528060 cancer</e2>\NN\14239425 .\.\1740
6103707
D005445_D010146 CID There\EX\27167 was\VBD\836236 <e2>pain</e2>\NN\14299637 on\IN\1740 i.m.\NN\1740 injection\NN\320852 of\IN\1740 <e1>flunitrazepam</e1>\NN\1740 significantly\RB\1740 more\RBR\1740 often\RB\1740 than\IN\1740 with\IN\1740 isotonic\JJ\1740 saline\NN\14849367 .\.\1740
16787750
D014635_D001927 CID <e1>Valproic\JJ\1740 acid</e1>\NN\14818238 induced\VBD\1627355 <e2>encephalopathy--19</e2>\JJ\1740 new\JJ\1740 cases\NNS\7283608 in\IN\13603305 Germany\NNP\1740 from\IN\1740 1994\CD\1740 to\IN\1740 2003\CD\1740 -\HYPH\1740 -a\NFP\1740 side\NN\8630039 effect\NN\34213 associated\VBN\628491 to\TO\1740 VPA-therapy\NN\1740 not\RB\1740 only\RB\1740 in\IN\13603305 young\JJ\1740 children\NNS\9622049 .\.\1740
D014635_D001927 CID Valproic\JJ\1740 acid\NN\14818238 induced\VBD\1627355 <e2>encephalopathy--19</e2>\JJ\1740 new\JJ\1740 cases\NNS\7283608 in\IN\13603305 Germany\NNP\1740 from\IN\1740 1994\CD\1740 to\IN\1740 2003\CD\1740 -\HYPH\1740 -a\NFP\1740 side\NN\8630039 effect\NN\34213 associated\VBN\628491 to\TO\1740 <e1>VPA-therapy</e1>\NN\1740 not\RB\1740 only\RB\1740 in\IN\13603305 young\JJ\1740 children\NNS\9622049 .\.\1740
D014635_D001927 CID Rare\JJ\1740 serious\JJ\1740 complications\NNS\1073995 may\MD\15209706 occur\VB\2623529 in\IN\13603305 some\DT\1740 patients\NNS\9898892 ,\,\1740 including\VBG\690614 haemorrhagic\JJ\1740 pancreatitis\NN\14336539 ,\,\1740 bone\NN\5286536 marrow\NN\5286536 suppression\NN\13489037 ,\,\1740 <e1>VPA-induced</e1>\JJ\1740 hepatotoxicity\NN\1740 and\CC\1740 VPA-induced\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 .\.\1740
D014635_D001927 CID Rare\JJ\1740 serious\JJ\1740 complications\NNS\1073995 may\MD\15209706 occur\VB\2623529 in\IN\13603305 some\DT\1740 patients\NNS\9898892 ,\,\1740 including\VBG\690614 haemorrhagic\JJ\1740 pancreatitis\NN\14336539 ,\,\1740 bone\NN\5286536 marrow\NN\5286536 suppression\NN\13489037 ,\,\1740 VPA-induced\JJ\1740 hepatotoxicity\NN\1740 and\CC\1740 <e1>VPA-induced</e1>\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 .\.\1740
D014635_D001927 CID The\DT\1740 typical\JJ\1740 signs\NNS\6643763 of\IN\1740 <e1>VPA-induced</e1>\JJ\1740 <e2>encephalopathy</e2>\NN\14084880 are\VBP\836236 impaired\JJ\1740 consciousness\NN\5669934 ,\,\1740 sometimes\RB\1740 marked\JJ\1740 EEG\NN\7000195 background\NN\4921011 slowing\NN\7296428 ,\,\1740 increased\VBD\169651 seizure\JJ\1740 frequency\NN\15286249 ,\,\1740 with\IN\1740 or\CC\3541091 without\IN\1740 hyperammonemia\NN\1740 .\.\1740
D014635_D001927 CID There\EX\27167 is\VBZ\836236 still\RB\1740 no\DT\7204911 proof\NN\5823932 of\IN\1740 causative\JJ\1740 effect\NN\34213 of\IN\1740 <e1>VPA</e1>\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>encephalopathy</e2>\JJ\1740 ,\,\1740 but\CC\1740 only\RB\1740 of\IN\1740 an\DT\6697703 association\NN\8008335 with\IN\1740 an\DT\6697703 assumed\VBN\719734 causal\JJ\1740 relation\NN\2137 .\.\1740
D014635_D001927 CID We\PRP\1740 report\VBP\831651 19\CD\13745420 patients\NNS\9898892 with\IN\1740 <e1>VPA-associated</e1>\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 in\IN\13603305 Germany\NNP\1740 from\IN\1740 the\DT\1740 years\NNS\15144371 1994\CD\1740 to\IN\1740 2003\CD\1740 ,\,\1740 none\NN\15228378 of\IN\1740 whom\WP\1740 had\VBD\2108377 been\VBN\836236 published\VBN\1621555 previously\RB\1740 .\.\1740
D014635_D010195 CID Rare\JJ\1740 serious\JJ\1740 complications\NNS\1073995 may\MD\15209706 occur\VB\2623529 in\IN\13603305 some\DT\1740 patients\NNS\9898892 ,\,\1740 including\VBG\690614 haemorrhagic\JJ\1740 <e2>pancreatitis</e2>\NN\14336539 ,\,\1740 bone\NN\5286536 marrow\NN\5286536 suppression\NN\13489037 ,\,\1740 <e1>VPA-induced</e1>\JJ\1740 hepatotoxicity\NN\1740 and\CC\1740 VPA-induced\JJ\1740 encephalopathy\JJ\1740 .\.\1740
D014635_D010195 CID Rare\JJ\1740 serious\JJ\1740 complications\NNS\1073995 may\MD\15209706 occur\VB\2623529 in\IN\13603305 some\DT\1740 patients\NNS\9898892 ,\,\1740 including\VBG\690614 haemorrhagic\JJ\1740 <e2>pancreatitis</e2>\NN\14336539 ,\,\1740 bone\NN\5286536 marrow\NN\5286536 suppression\NN\13489037 ,\,\1740 VPA-induced\JJ\1740 hepatotoxicity\NN\1740 and\CC\1740 <e1>VPA-induced</e1>\JJ\1740 encephalopathy\JJ\1740 .\.\1740
D014635_D001855 CID Rare\JJ\1740 serious\JJ\1740 complications\NNS\1073995 may\MD\15209706 occur\VB\2623529 in\IN\13603305 some\DT\1740 patients\NNS\9898892 ,\,\1740 including\VBG\690614 haemorrhagic\JJ\1740 pancreatitis\NN\14336539 ,\,\1740 <e2>bone\NN\5286536 marrow\NN\5286536 suppression</e2>\NN\13489037 ,\,\1740 <e1>VPA-induced</e1>\JJ\1740 hepatotoxicity\NN\1740 and\CC\1740 VPA-induced\JJ\1740 encephalopathy\JJ\1740 .\.\1740
D014635_D001855 CID Rare\JJ\1740 serious\JJ\1740 complications\NNS\1073995 may\MD\15209706 occur\VB\2623529 in\IN\13603305 some\DT\1740 patients\NNS\9898892 ,\,\1740 including\VBG\690614 haemorrhagic\JJ\1740 pancreatitis\NN\14336539 ,\,\1740 <e2>bone\NN\5286536 marrow\NN\5286536 suppression</e2>\NN\13489037 ,\,\1740 VPA-induced\JJ\1740 hepatotoxicity\NN\1740 and\CC\1740 <e1>VPA-induced</e1>\JJ\1740 encephalopathy\JJ\1740 .\.\1740
D014635_D056486 CID Rare\JJ\1740 serious\JJ\1740 complications\NNS\1073995 may\MD\15209706 occur\VB\2623529 in\IN\13603305 some\DT\1740 patients\NNS\9898892 ,\,\1740 including\VBG\690614 haemorrhagic\JJ\1740 pancreatitis\NN\14336539 ,\,\1740 bone\NN\5286536 marrow\NN\5286536 suppression\NN\13489037 ,\,\1740 <e1>VPA-induced</e1>\JJ\1740 <e2>hepatotoxicity</e2>\NN\1740 and\CC\1740 VPA-induced\JJ\1740 encephalopathy\JJ\1740 .\.\1740
D014635_D056486 CID Rare\JJ\1740 serious\JJ\1740 complications\NNS\1073995 may\MD\15209706 occur\VB\2623529 in\IN\13603305 some\DT\1740 patients\NNS\9898892 ,\,\1740 including\VBG\690614 haemorrhagic\JJ\1740 pancreatitis\NN\14336539 ,\,\1740 bone\NN\5286536 marrow\NN\5286536 suppression\NN\13489037 ,\,\1740 VPA-induced\JJ\1740 <e2>hepatotoxicity</e2>\NN\1740 and\CC\1740 <e1>VPA-induced</e1>\JJ\1740 encephalopathy\JJ\1740 .\.\1740
D014635_D003244 CID The\DT\1740 typical\JJ\1740 signs\NNS\6643763 of\IN\1740 <e1>VPA-induced</e1>\JJ\1740 encephalopathy\NN\14084880 are\VBP\836236 <e2>impaired\JJ\1740 consciousness</e2>\NN\5669934 ,\,\1740 sometimes\RB\1740 marked\JJ\1740 EEG\NN\7000195 background\NN\4921011 slowing\NN\7296428 ,\,\1740 increased\VBD\169651 seizure\JJ\1740 frequency\NN\15286249 ,\,\1740 with\IN\1740 or\CC\3541091 without\IN\1740 hyperammonemia\NN\1740 .\.\1740
D014635_D012640 NONE The\DT\1740 typical\JJ\1740 signs\NNS\6643763 of\IN\1740 <e1>VPA-induced</e1>\JJ\1740 encephalopathy\NN\14084880 are\VBP\836236 impaired\JJ\1740 consciousness\NN\5669934 ,\,\1740 sometimes\RB\1740 marked\JJ\1740 EEG\NN\7000195 background\NN\4921011 slowing\NN\7296428 ,\,\1740 increased\VBD\169651 <e2>seizure</e2>\JJ\1740 frequency\NN\15286249 ,\,\1740 with\IN\1740 or\CC\3541091 without\IN\1740 hyperammonemia\NN\1740 .\.\1740
D014635_D022124 NONE The\DT\1740 typical\JJ\1740 signs\NNS\6643763 of\IN\1740 <e1>VPA-induced</e1>\JJ\1740 encephalopathy\NN\14084880 are\VBP\836236 impaired\JJ\1740 consciousness\NN\5669934 ,\,\1740 sometimes\RB\1740 marked\JJ\1740 EEG\NN\7000195 background\NN\4921011 slowing\NN\7296428 ,\,\1740 increased\VBD\169651 seizure\JJ\1740 frequency\NN\15286249 ,\,\1740 with\IN\1740 or\CC\3541091 without\IN\1740 <e2>hyperammonemia</e2>\NN\1740 .\.\1740
9931093
D016559_D006973 CID Mechanisms\NNS\13446390 of\IN\1740 <e1>FK\NN\1740 506-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D016559_D006973 CID The\DT\1740 clinical\JJ\1740 utility\NN\8186047 of\IN\1740 <e1>FK\NN\1740 506</e1>\CD\1740 is\VBZ\836236 complicated\VBN\126264 by\IN\1740 substantial\JJ\1740 <e2>hypertension</e2>\NN\14057371 and\CC\1740 nephrotoxicity\NN\1740 .\.\1740
D016559_D006973 CID To\TO\1740 clarify\VB\939277 the\DT\1740 mechanisms\NNS\13446390 of\IN\1740 <e1>FK\NN\1740 506-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 we\PRP\1740 studied\VBD\630380 the\DT\1740 chronic\JJ\1740 effects\NNS\13245626 of\IN\1740 FK\NN\1740 506\CD\1740 on\IN\1740 the\DT\1740 synthesis\NN\13446390 of\IN\1740 endothelin-1\NN\1740 (\-LRB-\1740 ET-1\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 expression\NN\4679549 of\IN\1740 mRNA\NN\14832193 of\IN\1740 ET-1\NN\1740 and\CC\1740 endothelin-converting\JJ\1740 enzyme-1\NN\1740 (\-LRB-\1740 ECE-1\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 endothelial\JJ\1740 nitric\JJ\1740 oxide\NN\14818238 synthase\NN\1740 (\-LRB-\1740 eNOS\NN\1740 )\-RRB-\1740 activity\NN\30358 ,\,\1740 and\CC\1740 the\DT\1740 expression\NN\4679549 of\IN\1740 mRNA\NN\14832193 of\IN\1740 eNOS\NN\1740 and\CC\1740 C-type\JJ\1740 natriuretic\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 CNP\NN\1740 )\-RRB-\1740 in\IN\13603305 rat\NN\2329401 blood\NN\5397468 vessels\NNS\5246511 .\.\1740
D016559_D006973 CID To\TO\1740 clarify\VB\939277 the\DT\1740 mechanisms\NNS\13446390 of\IN\1740 FK\NN\1740 506-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 we\PRP\1740 studied\VBD\630380 the\DT\1740 chronic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>FK\NN\1740 506</e1>\CD\1740 on\IN\1740 the\DT\1740 synthesis\NN\13446390 of\IN\1740 endothelin-1\NN\1740 (\-LRB-\1740 ET-1\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 expression\NN\4679549 of\IN\1740 mRNA\NN\14832193 of\IN\1740 ET-1\NN\1740 and\CC\1740 endothelin-converting\JJ\1740 enzyme-1\NN\1740 (\-LRB-\1740 ECE-1\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 endothelial\JJ\1740 nitric\JJ\1740 oxide\NN\14818238 synthase\NN\1740 (\-LRB-\1740 eNOS\NN\1740 )\-RRB-\1740 activity\NN\30358 ,\,\1740 and\CC\1740 the\DT\1740 expression\NN\4679549 of\IN\1740 mRNA\NN\14832193 of\IN\1740 eNOS\NN\1740 and\CC\1740 C-type\JJ\1740 natriuretic\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 CNP\NN\1740 )\-RRB-\1740 in\IN\13603305 rat\NN\2329401 blood\NN\5397468 vessels\NNS\5246511 .\.\1740
D016559_D006973 CID In\IN\13603305 addition\NN\3081021 ,\,\1740 the\DT\1740 effect\NN\34213 of\IN\1740 the\DT\1740 specific\JJ\1740 endothelin\NN\1740 type\NN\5839024 A\NN\13649268 receptor\NN\5225602 antagonist\NN\7846 FR\NN\14625458 139317\CD\1740 on\IN\1740 <e1>FK\NN\1740 506-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 rats\NNS\2329401 was\VBD\836236 studied\VBN\630380 .\.\1740
D016559_D006973 CID d-1\JJ\1740 )\-RRB-\1740 prevented\VBD\1740 <e1>FK\NN\1740 506-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 rats\NNS\2329401 .\.\1740
D016559_D007674 NONE The\DT\1740 clinical\JJ\1740 utility\NN\8186047 of\IN\1740 <e1>FK\NN\1740 506</e1>\CD\1740 is\VBZ\836236 complicated\VBN\126264 by\IN\1740 substantial\JJ\1740 hypertension\NN\14057371 and\CC\1740 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
D009569_D006973 NONE To\TO\1740 clarify\VB\939277 the\DT\1740 mechanisms\NNS\13446390 of\IN\1740 FK\NN\1740 506-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 we\PRP\1740 studied\VBD\630380 the\DT\1740 chronic\JJ\1740 effects\NNS\13245626 of\IN\1740 FK\NN\1740 506\CD\1740 on\IN\1740 the\DT\1740 synthesis\NN\13446390 of\IN\1740 endothelin-1\NN\1740 (\-LRB-\1740 ET-1\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 expression\NN\4679549 of\IN\1740 mRNA\NN\14832193 of\IN\1740 ET-1\NN\1740 and\CC\1740 endothelin-converting\JJ\1740 enzyme-1\NN\1740 (\-LRB-\1740 ECE-1\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 endothelial\JJ\1740 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 synthase\NN\1740 (\-LRB-\1740 eNOS\NN\1740 )\-RRB-\1740 activity\NN\30358 ,\,\1740 and\CC\1740 the\DT\1740 expression\NN\4679549 of\IN\1740 mRNA\NN\14832193 of\IN\1740 eNOS\NN\1740 and\CC\1740 C-type\JJ\1740 natriuretic\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 CNP\NN\1740 )\-RRB-\1740 in\IN\13603305 rat\NN\2329401 blood\NN\5397468 vessels\NNS\5246511 .\.\1740
C079574_D006973 NONE In\IN\13603305 addition\NN\3081021 ,\,\1740 the\DT\1740 effect\NN\34213 of\IN\1740 the\DT\1740 specific\JJ\1740 endothelin\NN\1740 type\NN\5839024 A\NN\13649268 receptor\NN\5225602 antagonist\NN\7846 <e1>FR\NN\14625458 139317</e1>\CD\1740 on\IN\1740 FK\NN\1740 506-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 rats\NNS\2329401 was\VBD\836236 studied\VBN\630380 .\.\1740
230316
D006912_D020258 NONE <e2>Neurotoxicity</e2>\NN\1740 of\IN\1740 <e1>halogenated\VBN\1740 hydroxyquinolines</e1>\NNS\1740 :\:\1740 clinical\JJ\1740 analysis\NN\633864 of\IN\1740 cases\NNS\7283608 reported\VBN\831651 outside\IN\8630039 Japan\NNP\3631922 .\.\1740
D006912_D020258 NONE An\DT\6697703 analysis\NN\633864 is\VBZ\836236 presented\VBN\2137132 of\IN\1740 220\CD\1740 cases\NNS\7283608 of\IN\1740 possible\JJ\1740 <e2>neurotoxic</e2>\JJ\1740 reactions\NNS\13446390 to\TO\1740 <e1>halogenated\VBN\1740 hydroxyquinolines</e1>\NNS\1740 reported\VBN\831651 from\IN\1740 outside\IN\8630039 Japan\NNP\3631922 .\.\1740
D007464_D009422 NONE In\IN\13603305 six\CD\13741022 of\IN\1740 the\DT\1740 probable\JJ\1740 cases\NNS\7283608 the\DT\1740 <e2>neurological\JJ\1740 disturbance</e2>\NN\407535 consisted\VBD\2603699 of\IN\1740 an\DT\6697703 acute\JJ\1740 reversible\JJ\1740 encephalopathy\RB\1740 usually\RB\1740 related\JJ\1740 to\TO\1740 the\DT\1740 ingestion\NN\13440063 of\IN\1740 a\DT\13649268 high\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>clioquinol</e1>\NN\2720201 over\IN\5867413 a\DT\13649268 short\JJ\1740 period\NN\13575869 .\.\1740
D007464_D001927 CID In\IN\13603305 six\CD\13741022 of\IN\1740 the\DT\1740 probable\JJ\1740 cases\NNS\7283608 the\DT\1740 neurological\JJ\1740 disturbance\NN\407535 consisted\VBD\2603699 of\IN\1740 an\DT\6697703 acute\JJ\1740 reversible\JJ\1740 <e2>encephalopathy</e2>\RB\1740 usually\RB\1740 related\JJ\1740 to\TO\1740 the\DT\1740 ingestion\NN\13440063 of\IN\1740 a\DT\13649268 high\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>clioquinol</e1>\NN\2720201 over\IN\5867413 a\DT\13649268 short\JJ\1740 period\NN\13575869 .\.\1740
D007464_C538178 NONE This\DT\1740 was\VBD\836236 most\RBS\1740 frequently\RB\1740 found\VBN\2426171 in\IN\13603305 children\NNS\9622049 ,\,\1740 many\DT\1740 of\IN\1740 whom\WP\1740 had\VBD\2108377 received\VBN\2210855 <e1>clioquinol</e1>\NN\2720201 as\IN\14622893 treatment\NN\654885 for\IN\1740 <e2>acrodermatitis\NN\1740 enteropathica</e2>\NN\1740 .\.\1740
9727773
D001067_D006976 CID High\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>primary\JJ\1740 pulmonary\JJ\1740 hypertension</e2>\NN\14057371 associated\VBN\628491 with\IN\1740 <e1>appetite\JJ\1740 suppressants</e1>\NNS\3247620 in\IN\13603305 Belgium\NNP\1740 .\.\1740
D001067_D006976 CID <e2>Primary\JJ\1740 pulmonary\JJ\1740 hypertension</e2>\NN\14057371 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 ,\,\1740 progressive\JJ\1740 and\CC\1740 incurable\JJ\1740 disease\NN\14061805 ,\,\1740 which\WDT\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 intake\NN\13440063 of\IN\1740 <e1>appetite\JJ\1740 suppressant</e1>\JJ\1740 drugs\NNS\14778436 .\.\1740
D001067_D006976 CID In\IN\13603305 8\CD\13741022 patients\NNS\9898892 the\DT\1740 diagnosis\NN\152018 of\IN\1740 <e2>primary\JJ\1740 pulmonary\JJ\1740 hypertension</e2>\NN\14057371 was\VBD\836236 uncertain\JJ\1740 ,\,\1740 5\CD\13741022 of\IN\1740 them\PRP\1740 had\VBD\2108377 taken\VBN\2367363 <e1>appetite\JJ\1740 suppressants</e1>\NNS\3247620 .\.\1740
D001067_D006976 CID A\DT\13649268 policy\NN\5902545 of\IN\1740 unrestricted\JJ\1740 prescription\NN\6786629 of\IN\1740 <e1>appetite\JJ\1740 suppressants</e1>\NNS\3247620 may\MD\15209706 lead\VB\1752884 to\TO\1740 a\DT\13649268 high\JJ\1740 incidence\NN\13821570 of\IN\1740 associated\VBN\628491 <e2>primary\JJ\1740 pulmonary\JJ\1740 hypertension</e2>\NN\14057371 .\.\1740
8302922
D000527_D007022 CID Epidural\JJ\1740 blood\NN\5397468 flow\NN\7311115 during\IN\1740 <e1>prostaglandin\NN\5414534 E1</e1>\NN\1740 or\CC\3541091 trimethaphan\NN\1740 induced\VBD\1627355 <e2>hypotension</e2>\NN\14057371 .\.\1740
D000527_D007022 CID To\TO\1740 evaluate\VB\670261 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>prostaglandin\NN\5414534 E1</e1>\NN\1740 (\-LRB-\1740 PGE1\NN\1740 )\-RRB-\1740 or\CC\3541091 trimethaphan\NN\1740 (\-LRB-\1740 TMP\NN\1740 )\-RRB-\1740 induced\VBD\1627355 <e2>hypotension</e2>\NN\14057371 on\IN\1740 epidural\JJ\1740 blood\NN\5397468 flow\NN\7311115 (\-LRB-\1740 EBF\NN\1740 )\-RRB-\1740 during\IN\1740 spinal\JJ\1740 surgery\NN\6045562 ,\,\1740 EBF\NN\1740 was\VBD\836236 measured\VBN\697589 using\VBG\1156834 the\DT\1740 heat\NN\11452218 clearance\NN\5089947 method\NN\5616786 in\IN\13603305 30\CD\13745420 patients\NNS\9898892 who\WP\8299493 underwent\VBD\109660 postero-lateral\JJ\1740 interbody\NN\1740 fusion\NN\7373277 under\IN\1740 isoflurane\NN\3570838 anaesthesia\NN\14034177 .\.\1740
D000527_D007022 CID To\TO\1740 evaluate\VB\670261 the\DT\1740 effect\NN\34213 of\IN\1740 prostaglandin\NN\5414534 E1\NN\1740 (\-LRB-\1740 <e1>PGE1</e1>\NN\1740 )\-RRB-\1740 or\CC\3541091 trimethaphan\NN\1740 (\-LRB-\1740 TMP\NN\1740 )\-RRB-\1740 induced\VBD\1627355 <e2>hypotension</e2>\NN\14057371 on\IN\1740 epidural\JJ\1740 blood\NN\5397468 flow\NN\7311115 (\-LRB-\1740 EBF\NN\1740 )\-RRB-\1740 during\IN\1740 spinal\JJ\1740 surgery\NN\6045562 ,\,\1740 EBF\NN\1740 was\VBD\836236 measured\VBN\697589 using\VBG\1156834 the\DT\1740 heat\NN\11452218 clearance\NN\5089947 method\NN\5616786 in\IN\13603305 30\CD\13745420 patients\NNS\9898892 who\WP\8299493 underwent\VBD\109660 postero-lateral\JJ\1740 interbody\NN\1740 fusion\NN\7373277 under\IN\1740 isoflurane\NN\3570838 anaesthesia\NN\14034177 .\.\1740
D000527_D007022 CID After\IN\1740 starting\VBG\2009433 <e1>PGE1</e1>\NN\1740 or\CC\3541091 TMP\NN\1740 ,\,\1740 MAP\NN\4076846 and\CC\1740 rate\NN\13815152 pressure\NN\11419404 product\NN\3076708 (\-LRB-\1740 RPP\NN\1740 )\-RRB-\1740 decreased\VBD\169651 significantly\RB\1740 compared\VBN\644583 with\IN\1740 preinfusion\NN\1740 values\NNS\5941423 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 the\DT\1740 degree\NN\4916342 of\IN\1740 <e2>hypotension</e2>\NN\14057371 due\IN\5174653 to\TO\1740 PGE1\NN\1740 remained\VBD\2604760 constant\JJ\1740 until\IN\1740 60\CD\13745420 min\NN\15154774 after\IN\1740 its\PRP$\6125041 discontinuation\NN\209943 .\.\1740
D000527_D007022 CID After\IN\1740 starting\VBG\2009433 PGE1\NN\1740 or\CC\3541091 TMP\NN\1740 ,\,\1740 MAP\NN\4076846 and\CC\1740 rate\NN\13815152 pressure\NN\11419404 product\NN\3076708 (\-LRB-\1740 RPP\NN\1740 )\-RRB-\1740 decreased\VBD\169651 significantly\RB\1740 compared\VBN\644583 with\IN\1740 preinfusion\NN\1740 values\NNS\5941423 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 the\DT\1740 degree\NN\4916342 of\IN\1740 <e2>hypotension</e2>\NN\14057371 due\IN\5174653 to\TO\1740 <e1>PGE1</e1>\NN\1740 remained\VBD\2604760 constant\JJ\1740 until\IN\1740 60\CD\13745420 min\NN\15154774 after\IN\1740 its\PRP$\6125041 discontinuation\NN\209943 .\.\1740
D000527_D007022 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 <e1>PGE1</e1>\NN\1740 may\MD\15209706 be\VB\836236 preferable\JJ\1740 to\IN\1740 TMP\NNP\1740 for\IN\1740 <e2>hypotensive</e2>\JJ\1740 anaesthesia\NN\14034177 in\IN\13603305 spinal\JJ\1740 surgery\NN\6045562 because\IN\1740 TMP\NN\1740 decreased\VBD\169651 EBF\NN\1740 .\.\1740
D014294_D007022 CID Epidural\JJ\1740 blood\NN\5397468 flow\NN\7311115 during\IN\1740 prostaglandin\NN\5414534 E1\NN\1740 or\CC\3541091 <e1>trimethaphan</e1>\NN\1740 induced\VBD\1627355 <e2>hypotension</e2>\NN\14057371 .\.\1740
D014294_D007022 CID To\TO\1740 evaluate\VB\670261 the\DT\1740 effect\NN\34213 of\IN\1740 prostaglandin\NN\5414534 E1\NN\1740 (\-LRB-\1740 PGE1\NN\1740 )\-RRB-\1740 or\CC\3541091 <e1>trimethaphan</e1>\NN\1740 (\-LRB-\1740 TMP\NN\1740 )\-RRB-\1740 induced\VBD\1627355 <e2>hypotension</e2>\NN\14057371 on\IN\1740 epidural\JJ\1740 blood\NN\5397468 flow\NN\7311115 (\-LRB-\1740 EBF\NN\1740 )\-RRB-\1740 during\IN\1740 spinal\JJ\1740 surgery\NN\6045562 ,\,\1740 EBF\NN\1740 was\VBD\836236 measured\VBN\697589 using\VBG\1156834 the\DT\1740 heat\NN\11452218 clearance\NN\5089947 method\NN\5616786 in\IN\13603305 30\CD\13745420 patients\NNS\9898892 who\WP\8299493 underwent\VBD\109660 postero-lateral\JJ\1740 interbody\NN\1740 fusion\NN\7373277 under\IN\1740 isoflurane\NN\3570838 anaesthesia\NN\14034177 .\.\1740
D014294_D007022 CID To\TO\1740 evaluate\VB\670261 the\DT\1740 effect\NN\34213 of\IN\1740 prostaglandin\NN\5414534 E1\NN\1740 (\-LRB-\1740 PGE1\NN\1740 )\-RRB-\1740 or\CC\3541091 trimethaphan\NN\1740 (\-LRB-\1740 <e1>TMP</e1>\NN\1740 )\-RRB-\1740 induced\VBD\1627355 <e2>hypotension</e2>\NN\14057371 on\IN\1740 epidural\JJ\1740 blood\NN\5397468 flow\NN\7311115 (\-LRB-\1740 EBF\NN\1740 )\-RRB-\1740 during\IN\1740 spinal\JJ\1740 surgery\NN\6045562 ,\,\1740 EBF\NN\1740 was\VBD\836236 measured\VBN\697589 using\VBG\1156834 the\DT\1740 heat\NN\11452218 clearance\NN\5089947 method\NN\5616786 in\IN\13603305 30\CD\13745420 patients\NNS\9898892 who\WP\8299493 underwent\VBD\109660 postero-lateral\JJ\1740 interbody\NN\1740 fusion\NN\7373277 under\IN\1740 isoflurane\NN\3570838 anaesthesia\NN\14034177 .\.\1740
D014294_D007022 CID After\IN\1740 starting\VBG\2009433 PGE1\NN\1740 or\CC\3541091 <e1>TMP</e1>\NN\1740 ,\,\1740 MAP\NN\4076846 and\CC\1740 rate\NN\13815152 pressure\NN\11419404 product\NN\3076708 (\-LRB-\1740 RPP\NN\1740 )\-RRB-\1740 decreased\VBD\169651 significantly\RB\1740 compared\VBN\644583 with\IN\1740 preinfusion\NN\1740 values\NNS\5941423 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.01\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 the\DT\1740 degree\NN\4916342 of\IN\1740 <e2>hypotension</e2>\NN\14057371 due\IN\5174653 to\TO\1740 PGE1\NN\1740 remained\VBD\2604760 constant\JJ\1740 until\IN\1740 60\CD\13745420 min\NN\15154774 after\IN\1740 its\PRP$\6125041 discontinuation\NN\209943 .\.\1740
D014294_D007022 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 PGE1\NN\1740 may\MD\15209706 be\VB\836236 preferable\JJ\1740 to\IN\1740 <e1>TMP</e1>\NNP\1740 for\IN\1740 <e2>hypotensive</e2>\JJ\1740 anaesthesia\NN\14034177 in\IN\13603305 spinal\JJ\1740 surgery\NN\6045562 because\IN\1740 TMP\NN\1740 decreased\VBD\169651 EBF\NN\1740 .\.\1740
D014294_D007022 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 PGE1\NN\1740 may\MD\15209706 be\VB\836236 preferable\JJ\1740 to\IN\1740 TMP\NNP\1740 for\IN\1740 <e2>hypotensive</e2>\JJ\1740 anaesthesia\NN\14034177 in\IN\13603305 spinal\JJ\1740 surgery\NN\6045562 because\IN\1740 <e1>TMP</e1>\NN\1740 decreased\VBD\169651 EBF\NN\1740 .\.\1740
D007530_D007022 NONE To\TO\1740 evaluate\VB\670261 the\DT\1740 effect\NN\34213 of\IN\1740 prostaglandin\NN\5414534 E1\NN\1740 (\-LRB-\1740 PGE1\NN\1740 )\-RRB-\1740 or\CC\3541091 trimethaphan\NN\1740 (\-LRB-\1740 TMP\NN\1740 )\-RRB-\1740 induced\VBD\1627355 <e2>hypotension</e2>\NN\14057371 on\IN\1740 epidural\JJ\1740 blood\NN\5397468 flow\NN\7311115 (\-LRB-\1740 EBF\NN\1740 )\-RRB-\1740 during\IN\1740 spinal\JJ\1740 surgery\NN\6045562 ,\,\1740 EBF\NN\1740 was\VBD\836236 measured\VBN\697589 using\VBG\1156834 the\DT\1740 heat\NN\11452218 clearance\NN\5089947 method\NN\5616786 in\IN\13603305 30\CD\13745420 patients\NNS\9898892 who\WP\8299493 underwent\VBD\109660 postero-lateral\JJ\1740 interbody\NN\1740 fusion\NN\7373277 under\IN\1740 <e1>isoflurane</e1>\NN\3570838 anaesthesia\NN\14034177 .\.\1740
3437726
D013034_D064420 NONE Therefore\RB\1740 ,\,\1740 patients\NNS\9898892 belonging\VBG\2604760 to\TO\1740 the\DT\1740 poor-metabolizer\JJ\1740 phenotype\NN\4933544 of\IN\1740 <e1>sparteine/debrisoquine</e1>\NN\1740 polymorphism\NN\11418750 in\IN\13603305 drug\NN\14778436 metabolism\NN\13526110 ,\,\1740 which\WDT\1740 constitutes\VBZ\1647229 6.4\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 German\JJ\1740 population\NN\7942152 ,\,\1740 may\MD\15209706 experience\VB\2108377 <e2>adverse\JJ\1740 drug\NN\14778436 reactions</e2>\NNS\13446390 when\WRB\1740 treated\VBN\2376958 with\IN\1740 standard\JJ\1740 doses\NNS\3740161 of\IN\1740 one\CD\13741022 of\IN\1740 these\DT\1740 drugs\NNS\14778436 alone\RB\1740 .\.\1740
D003647_D064420 NONE Therefore\RB\1740 ,\,\1740 patients\NNS\9898892 belonging\VBG\2604760 to\TO\1740 the\DT\1740 poor-metabolizer\JJ\1740 phenotype\NN\4933544 of\IN\1740 <e1>sparteine/debrisoquine</e1>\NN\1740 polymorphism\NN\11418750 in\IN\13603305 drug\NN\14778436 metabolism\NN\13526110 ,\,\1740 which\WDT\1740 constitutes\VBZ\1647229 6.4\CD\1740 %\NN\1740 of\IN\1740 the\DT\1740 German\JJ\1740 population\NN\7942152 ,\,\1740 may\MD\15209706 experience\VB\2108377 <e2>adverse\JJ\1740 drug\NN\14778436 reactions</e2>\NNS\13446390 when\WRB\1740 treated\VBN\2376958 with\IN\1740 standard\JJ\1740 doses\NNS\3740161 of\IN\1740 one\CD\13741022 of\IN\1740 these\DT\1740 drugs\NNS\14778436 alone\RB\1740 .\.\1740
12789195
D008914_D004194 NONE <e2>Pseudoacromegaly</e2>\NNP\1740 induced\VBN\1627355 by\IN\1740 the\DT\1740 long-term\JJ\1740 use\NN\407535 of\IN\1740 <e1>minoxidil</e1>\NN\4522904 .\.\1740
D008914_D004194 NONE We\PRP\1740 present\VBP\2137132 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>pseudoacromegaly</e2>\NN\1740 that\WDT\1740 resulted\VBD\2633881 from\IN\1740 the\DT\1740 long-term\JJ\1740 use\NN\407535 of\IN\1740 <e1>minoxidil</e1>\NN\4522904 at\IN\14622893 an\DT\6697703 unusually\RB\1740 high\JJ\1740 dose\NN\3740161 .\.\1740
D008914_D004194 NONE This\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 case\NN\7283608 report\NN\6470073 of\IN\1740 <e2>pseudoacromegaly</e2>\NN\1740 as\IN\14622893 a\DT\13649268 side\JJ\1740 effect\NN\34213 of\IN\1740 <e1>minoxidil</e1>\NN\4522904 use\NN\407535 .\.\1740
12198388
D000109_D012640 NONE The\DT\1740 relationship\NN\31921 between\IN\1740 hippocampal\NN\1740 <e1>acetylcholine</e1>\NN\14807558 release\NN\3748886 and\CC\1740 cholinergic\JJ\1740 convulsant\NN\1740 sensitivity\NN\5651971 in\IN\13603305 withdrawal\NN\7206096 <e2>seizure-prone</e2>\NN\1740 and\CC\1740 withdrawal\NN\7206096 seizure-resistant\JJ\1740 selected\VBN\697589 mouse\NN\2329401 lines\NNS\8426461 .\.\1740
D000109_D012640 NONE The\DT\1740 relationship\NN\31921 between\IN\1740 hippocampal\NN\1740 <e1>acetylcholine</e1>\NN\14807558 release\NN\3748886 and\CC\1740 cholinergic\JJ\1740 convulsant\NN\1740 sensitivity\NN\5651971 in\IN\13603305 withdrawal\NN\7206096 seizure-prone\NN\1740 and\CC\1740 withdrawal\NN\7206096 <e2>seizure-resistant</e2>\JJ\1740 selected\VBN\697589 mouse\NN\2329401 lines\NNS\8426461 .\.\1740
D000109_D012640 NONE Hippocampal\NN\1740 <e1>ACh</e1>\NN\1740 also\RB\1740 was\VBD\836236 measured\VBN\697589 during\IN\1740 testing\VBG\670261 for\IN\1740 handling-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D000109_D012640 NONE When\WRB\1740 hippocampal\NN\1740 <e1>ACh</e1>\NN\1740 was\VBD\836236 measured\VBN\697589 during\IN\1740 testing\VBG\670261 for\IN\1740 handling-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 ,\,\1740 extracellular\JJ\1740 ACh\NN\1740 was\VBD\836236 significantly\RB\1740 elevated\JJ\1740 (\-LRB-\1740 192\CD\1740 %\NN\1740 )\-RRB-\1740 in\IN\13603305 WSP\NN\1740 mice\NNS\2329401 ,\,\1740 but\CC\1740 was\VBD\836236 nonsignificantly\RB\1740 elevated\JJ\1740 (\-LRB-\1740 59\CD\1740 %\NN\1740 )\-RRB-\1740 in\IN\13603305 WSR\NN\1740 mice\NNS\2329401 .\.\1740
D000109_D012640 NONE When\WRB\1740 hippocampal\NN\1740 ACh\NN\1740 was\VBD\836236 measured\VBN\697589 during\IN\1740 testing\VBG\670261 for\IN\1740 handling-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 ,\,\1740 extracellular\JJ\1740 <e1>ACh</e1>\NN\1740 was\VBD\836236 significantly\RB\1740 elevated\JJ\1740 (\-LRB-\1740 192\CD\1740 %\NN\1740 )\-RRB-\1740 in\IN\13603305 WSP\NN\1740 mice\NNS\2329401 ,\,\1740 but\CC\1740 was\VBD\836236 nonsignificantly\RB\1740 elevated\JJ\1740 (\-LRB-\1740 59\CD\1740 %\NN\1740 )\-RRB-\1740 in\IN\13603305 WSR\NN\1740 mice\NNS\2329401 .\.\1740
D000431_D012640 NONE METHODS\NNS\5616786 :\:\1740 Cholinergic\JJ\1740 convulsant\JJ\1740 sensitivity\NN\5651971 was\VBD\836236 examined\VBN\789138 in\IN\13603305 <e1>alcohol-na</e1>\NN\1740 ve\NN\1740 Withdrawal\NNP\7206096 <e2>Seizure-Prone</e2>\NN\1740 (\-LRB-\1740 WSP\NN\1740 )\-RRB-\1740 and-Resistant\JJ\1740 (\-LRB-\1740 WSR\NN\1740 )\-RRB-\1740 mice\NNS\2329401 .\.\1740
D000431_D012640 NONE CONCLUSIONS\NNS\5837957 :\:\1740 These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 differences\NNS\4723816 in\IN\13603305 cholinergic\JJ\1740 activity\NN\30358 and\CC\1740 postsynaptic\JJ\1740 sensitivity\NN\5651971 to\TO\1740 cholinergic\JJ\1740 <e2>convulsants</e2>\NNS\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 <e1>ethanol</e1>\NN\14708720 withdrawal\NN\7206096 severity\NN\5036394 and\CC\1740 implicate\VB\2677097 cholinergic\NN\1740 mechanisms\NNS\13446390 in\IN\13603305 alcohol\NN\7881800 withdrawal\NN\7206096 .\.\1740
D000431_D012640 NONE CONCLUSIONS\NNS\5837957 :\:\1740 These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 differences\NNS\4723816 in\IN\13603305 cholinergic\JJ\1740 activity\NN\30358 and\CC\1740 postsynaptic\JJ\1740 sensitivity\NN\5651971 to\TO\1740 cholinergic\JJ\1740 <e2>convulsants</e2>\NNS\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 ethanol\NN\14708720 withdrawal\NN\7206096 severity\NN\5036394 and\CC\1740 implicate\VB\2677097 cholinergic\NN\1740 mechanisms\NNS\13446390 in\IN\13603305 <e1>alcohol</e1>\NN\7881800 withdrawal\NN\7206096 .\.\1740
D009538_D014202 NONE Animals\NNS\4475 were\VBD\836236 administered\VBN\2436349 <e1>nicotine</e1>\NN\14712692 ,\,\1740 carbachol\NN\1740 ,\,\1740 or\CC\3541091 neostigmine\NN\2718084 via\IN\1740 timed\VBN\489837 tail\NN\5470189 vein\NN\5417975 infusion\NN\14589223 ,\,\1740 and\CC\1740 the\DT\1740 latencies\NNS\15269513 to\TO\1740 onset\NN\7325190 of\IN\1740 <e2>tremor</e2>\NN\345926 and\CC\1740 clonus\NNS\14082595 were\VBD\836236 recorded\VBN\2225492 and\CC\1740 converted\VBN\126264 to\TO\1740 threshold\JJ\1740 dose\NN\3740161 .\.\1740
D002217_D014202 NONE Animals\NNS\4475 were\VBD\836236 administered\VBN\2436349 nicotine\NN\14712692 ,\,\1740 <e1>carbachol</e1>\NN\1740 ,\,\1740 or\CC\3541091 neostigmine\NN\2718084 via\IN\1740 timed\VBN\489837 tail\NN\5470189 vein\NN\5417975 infusion\NN\14589223 ,\,\1740 and\CC\1740 the\DT\1740 latencies\NNS\15269513 to\TO\1740 onset\NN\7325190 of\IN\1740 <e2>tremor</e2>\NN\345926 and\CC\1740 clonus\NNS\14082595 were\VBD\836236 recorded\VBN\2225492 and\CC\1740 converted\VBN\126264 to\TO\1740 threshold\JJ\1740 dose\NN\3740161 .\.\1740
D009388_D014202 NONE Animals\NNS\4475 were\VBD\836236 administered\VBN\2436349 nicotine\NN\14712692 ,\,\1740 carbachol\NN\1740 ,\,\1740 or\CC\3541091 <e1>neostigmine</e1>\NN\2718084 via\IN\1740 timed\VBN\489837 tail\NN\5470189 vein\NN\5417975 infusion\NN\14589223 ,\,\1740 and\CC\1740 the\DT\1740 latencies\NNS\15269513 to\TO\1740 onset\NN\7325190 of\IN\1740 <e2>tremor</e2>\NN\345926 and\CC\1740 clonus\NNS\14082595 were\VBD\836236 recorded\VBN\2225492 and\CC\1740 converted\VBN\126264 to\TO\1740 threshold\JJ\1740 dose\NN\3740161 .\.\1740
D009538_D012640 CID RESULTS\NNS\34213 :\:\1740 Sensitivity\NN\5651971 to\TO\1740 several\JJ\1740 <e2>convulsion</e2>\NN\14081375 endpoints\NNS\8566028 induced\VBN\1627355 by\IN\1740 <e1>nicotine</e1>\NN\14712692 ,\,\1740 carbachol\NN\1740 ,\,\1740 and\CC\1740 neostigmine\NN\2718084 were\VBD\836236 significantly\RB\1740 greater\JJR\1740 in\IN\13603305 WSR\NN\1740 versus\CC\1740 WSP\NN\1740 mice\NNS\2329401 .\.\1740
D002217_D012640 CID RESULTS\NNS\34213 :\:\1740 Sensitivity\NN\5651971 to\TO\1740 several\JJ\1740 <e2>convulsion</e2>\NN\14081375 endpoints\NNS\8566028 induced\VBN\1627355 by\IN\1740 nicotine\NN\14712692 ,\,\1740 <e1>carbachol</e1>\NN\1740 ,\,\1740 and\CC\1740 neostigmine\NN\2718084 were\VBD\836236 significantly\RB\1740 greater\JJR\1740 in\IN\13603305 WSR\NN\1740 versus\CC\1740 WSP\NN\1740 mice\NNS\2329401 .\.\1740
D009388_D012640 CID RESULTS\NNS\34213 :\:\1740 Sensitivity\NN\5651971 to\TO\1740 several\JJ\1740 <e2>convulsion</e2>\NN\14081375 endpoints\NNS\8566028 induced\VBN\1627355 by\IN\1740 nicotine\NN\14712692 ,\,\1740 carbachol\NN\1740 ,\,\1740 and\CC\1740 <e1>neostigmine</e1>\NN\2718084 were\VBD\836236 significantly\RB\1740 greater\JJR\1740 in\IN\13603305 WSR\NN\1740 versus\CC\1740 WSP\NN\1740 mice\NNS\2329401 .\.\1740
6518066
D008094_D004437 CID Maternal\JJ\1740 <e1>lithium</e1>\NN\14625458 and\CC\1740 neonatal\JJ\1740 <e2>Ebstein\NNP\1740 's\POS\1740 anomaly</e2>\NN\14501726 :\:\1740 evaluation\NN\874067 with\IN\1740 cross-sectional\JJ\1740 echocardiography\NN\177127 .\.\1740
D008094_D006331 NONE Cross-sectional\JJ\1740 echocardiographic\JJ\1740 screening\NN\6887726 of\IN\1740 newborns\NNS\9827683 exposed\VBN\2110927 to\TO\1740 <e1>lithium</e1>\NN\14625458 during\IN\1740 gestation\NN\15116532 can\MD\3094503 provide\VB\2199590 highly\RB\1740 accurate\JJ\1740 ,\,\1740 noninvasive\JJ\1740 assessment\NN\5732756 of\IN\1740 the\DT\1740 presence\NN\13954253 or\CC\3541091 absence\NN\14449405 of\IN\1740 lithium-induced\JJ\1740 <e2>cardiac\JJ\1740 malformations</e2>\NNS\14213199 .\.\1740
D008094_D006331 NONE Cross-sectional\JJ\1740 echocardiographic\JJ\1740 screening\NN\6887726 of\IN\1740 newborns\NNS\9827683 exposed\VBN\2110927 to\TO\1740 lithium\NN\14625458 during\IN\1740 gestation\NN\15116532 can\MD\3094503 provide\VB\2199590 highly\RB\1740 accurate\JJ\1740 ,\,\1740 noninvasive\JJ\1740 assessment\NN\5732756 of\IN\1740 the\DT\1740 presence\NN\13954253 or\CC\3541091 absence\NN\14449405 of\IN\1740 <e1>lithium-induced</e1>\JJ\1740 <e2>cardiac\JJ\1740 malformations</e2>\NNS\14213199 .\.\1740
10520387
D004809_D007022 NONE We\PRP\1740 investigated\VBD\644583 the\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 adding\VBG\156601 different\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>ephedrine</e1>\NN\14712692 to\TO\1740 propofol\VB\1740 in\IN\13603305 order\NN\7168131 to\TO\1740 obtund\VB\192051 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 response\NN\11410625 .\.\1740
D004809_D007022 NONE The\DT\1740 addition\NN\3081021 of\IN\1740 <e1>ephedrine</e1>\NN\14712692 to\TO\1740 propofol\NN\1740 appears\VBZ\2604760 to\TO\1740 be\VB\836236 an\DT\6697703 effective\JJ\1740 method\NN\5616786 of\IN\1740 obtunding\VBG\192051 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 response\NN\11410625 to\TO\1740 propofol\NN\1740 at\IN\14622893 all\DT\1740 doses\NNS\3740161 used\VBN\1156834 in\IN\13603305 this\DT\1740 study\NN\635850 .\.\1740
D015742_D007022 CID We\PRP\1740 investigated\VBD\644583 the\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 adding\VBG\156601 different\JJ\1740 doses\NNS\3740161 of\IN\1740 ephedrine\NN\14712692 to\TO\1740 <e1>propofol</e1>\VB\1740 in\IN\13603305 order\NN\7168131 to\TO\1740 obtund\VB\192051 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 response\NN\11410625 .\.\1740
D015742_D007022 CID The\DT\1740 addition\NN\3081021 of\IN\1740 ephedrine\NN\14712692 to\TO\1740 <e1>propofol</e1>\NN\1740 appears\VBZ\2604760 to\TO\1740 be\VB\836236 an\DT\6697703 effective\JJ\1740 method\NN\5616786 of\IN\1740 obtunding\VBG\192051 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 response\NN\11410625 to\TO\1740 propofol\NN\1740 at\IN\14622893 all\DT\1740 doses\NNS\3740161 used\VBN\1156834 in\IN\13603305 this\DT\1740 study\NN\635850 .\.\1740
D015742_D007022 CID The\DT\1740 addition\NN\3081021 of\IN\1740 ephedrine\NN\14712692 to\TO\1740 propofol\NN\1740 appears\VBZ\2604760 to\TO\1740 be\VB\836236 an\DT\6697703 effective\JJ\1740 method\NN\5616786 of\IN\1740 obtunding\VBG\192051 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 response\NN\11410625 to\TO\1740 <e1>propofol</e1>\NN\1740 at\IN\14622893 all\DT\1740 doses\NNS\3740161 used\VBN\1156834 in\IN\13603305 this\DT\1740 study\NN\635850 .\.\1740
D004809_D013610 CID However\RB\1740 ,\,\1740 marked\JJ\1740 <e2>tachycardia</e2>\NN\14110674 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>ephedrine</e1>\NN\14712692 in\IN\13603305 combination\NN\7951464 with\IN\1740 propofol\NN\1740 occurred\VBD\2623529 in\IN\13603305 the\DT\1740 majority\NN\5121418 of\IN\1740 patients\NNS\9898892 ,\,\1740 occasionally\RB\1740 reaching\VBG\2005948 high\JJ\1740 levels\NNS\4916342 in\IN\13603305 individual\JJ\1740 patients\NNS\9898892 .\.\1740
D004809_D013610 CID Due\IN\5174653 to\IN\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 this\DT\1740 <e2>tachycardia</e2>\NN\14110674 inducing\VBG\1627355 myocardial\JJ\1740 ischemia\NN\14195315 ,\,\1740 we\PRP\1740 would\MD\1740 not\RB\1740 recommend\VB\875394 the\DT\1740 use\NN\407535 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 of\IN\1740 any\DT\1740 of\IN\1740 the\DT\1740 <e1>ephedrine/propofol/mixtures</e1>\NNS\1740 studied\VBN\630380 .\.\1740
D015742_D013610 CID However\RB\1740 ,\,\1740 marked\JJ\1740 <e2>tachycardia</e2>\NN\14110674 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 ephedrine\NN\14712692 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>propofol</e1>\NN\1740 occurred\VBD\2623529 in\IN\13603305 the\DT\1740 majority\NN\5121418 of\IN\1740 patients\NNS\9898892 ,\,\1740 occasionally\RB\1740 reaching\VBG\2005948 high\JJ\1740 levels\NNS\4916342 in\IN\13603305 individual\JJ\1740 patients\NNS\9898892 .\.\1740
D015742_D013610 CID Due\IN\5174653 to\IN\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 this\DT\1740 <e2>tachycardia</e2>\NN\14110674 inducing\VBG\1627355 myocardial\JJ\1740 ischemia\NN\14195315 ,\,\1740 we\PRP\1740 would\MD\1740 not\RB\1740 recommend\VB\875394 the\DT\1740 use\NN\407535 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 of\IN\1740 any\DT\1740 of\IN\1740 the\DT\1740 <e1>ephedrine/propofol/mixtures</e1>\NNS\1740 studied\VBN\630380 .\.\1740
D004809_D017202 NONE Due\IN\5174653 to\IN\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 this\DT\1740 tachycardia\NN\14110674 inducing\VBG\1627355 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 ,\,\1740 we\PRP\1740 would\MD\1740 not\RB\1740 recommend\VB\875394 the\DT\1740 use\NN\407535 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 of\IN\1740 any\DT\1740 of\IN\1740 the\DT\1740 <e1>ephedrine/propofol/mixtures</e1>\NNS\1740 studied\VBN\630380 .\.\1740
D015742_D017202 NONE Due\IN\5174653 to\IN\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 this\DT\1740 tachycardia\NN\14110674 inducing\VBG\1627355 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 ,\,\1740 we\PRP\1740 would\MD\1740 not\RB\1740 recommend\VB\875394 the\DT\1740 use\NN\407535 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 of\IN\1740 any\DT\1740 of\IN\1740 the\DT\1740 <e1>ephedrine/propofol/mixtures</e1>\NNS\1740 studied\VBN\630380 .\.\1740
6888657
D004967_D010911 NONE Characterization\NN\6724763 of\IN\1740 <e1>estrogen-induced</e1>\JJ\1740 <e2>adenohypophyseal\JJ\1740 tumors</e2>\NNS\14234074 in\IN\13603305 the\DT\1740 Fischer\NNP\1740 344\CD\1740 rat\NN\2329401 .\.\1740
D004054_D010911 CID <e2>Pituitary\JJ\1740 tumors</e2>\NNS\14234074 were\VBD\836236 induced\VBN\1627355 in\IN\13603305 F344\NN\1740 female\JJ\1740 rats\NNS\2329401 by\IN\1740 chronic\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>diethylstilbestrol</e1>\NN\14749794 (\-LRB-\1740 DES\NN\14749794 ,\,\1740 8\CD\13741022 -\SYM\1740 10\CD\13745420 mg\NN\13717155 )\-RRB-\1740 implanted\VBN\1421622 subcutaneously\RB\1740 in\IN\13603305 silastic\JJ\1740 capsules\NNS\3094503 .\.\1740
D004054_D010911 CID <e2>Pituitary\JJ\1740 tumors</e2>\NNS\14234074 were\VBD\836236 induced\VBN\1627355 in\IN\13603305 F344\NN\1740 female\JJ\1740 rats\NNS\2329401 by\IN\1740 chronic\JJ\1740 treatment\NN\654885 with\IN\1740 diethylstilbestrol\NN\14749794 (\-LRB-\1740 <e1>DES</e1>\NN\14749794 ,\,\1740 8\CD\13741022 -\SYM\1740 10\CD\13745420 mg\NN\13717155 )\-RRB-\1740 implanted\VBN\1421622 subcutaneously\RB\1740 in\IN\13603305 silastic\JJ\1740 capsules\NNS\3094503 .\.\1740
D004054_D009369 NONE The\DT\1740 data\NNS\7951464 extend\VBP\153263 the\DT\1740 findings\NNS\7951464 of\IN\1740 other\JJ\1740 investigators\NNS\10560637 ,\,\1740 further\RB\1740 establishing\VBG\2426171 the\DT\1740 <e1>DES-induced</e1>\JJ\1740 <e2>tumor</e2>\NN\14234074 as\IN\14622893 a\DT\13649268 model\NN\5888929 for\IN\1740 study\NN\635850 of\IN\1740 PRL\NN\1740 cellular\JJ\1740 control\NN\5190804 mechanisms\NNS\13446390 .\.\1740
15036754
D010755_D012640 NONE <e1>Organophosphate-induced</e1>\JJ\1740 <e2>convulsions</e2>\NNS\14081375 and\CC\1740 prevention\NN\1073995 of\IN\1740 neuropathological\JJ\1740 damages\NNS\13282550 .\.\1740
D010755_D004194 NONE <e1>Organophosphate-induced</e1>\JJ\1740 convulsions\NNS\14081375 and\CC\1740 prevention\NN\1073995 of\IN\1740 <e2>neuropathological\JJ\1740 damages</e2>\NNS\13282550 .\.\1740
D010755_D064420 NONE The\DT\1740 acute\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 <e1>OPs</e1>\NNS\1740 is\VBZ\836236 the\DT\1740 result\NN\34213 of\IN\1740 their\PRP$\1740 irreversible\JJ\1740 binding\NN\4688246 with\IN\1740 AChEs\NN\14322699 in\IN\13603305 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 (\-LRB-\1740 CNS\NN\5237227 )\-RRB-\1740 ,\,\1740 which\WDT\1740 elevates\VBZ\2391803 acetylcholine\NN\14807558 (\-LRB-\1740 ACh\NN\1740 )\-RRB-\1740 levels\NNS\4916342 .\.\1740
D010755_D064420 NONE The\DT\1740 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 DFP-atropine\NN\1740 showed\VBD\2137132 severe\JJ\1740 typical\JJ\1740 <e1>OP-induced</e1>\JJ\1740 <e2>toxicity</e2>\NN\13576101 signs\NNS\6643763 .\.\1740
D000109_D064420 NONE The\DT\1740 acute\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 OPs\NNS\1740 is\VBZ\836236 the\DT\1740 result\NN\34213 of\IN\1740 their\PRP$\1740 irreversible\JJ\1740 binding\NN\4688246 with\IN\1740 AChEs\NN\14322699 in\IN\13603305 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 (\-LRB-\1740 CNS\NN\5237227 )\-RRB-\1740 ,\,\1740 which\WDT\1740 elevates\VBZ\2391803 <e1>acetylcholine</e1>\NN\14807558 (\-LRB-\1740 ACh\NN\1740 )\-RRB-\1740 levels\NNS\4916342 .\.\1740
D000109_D064420 NONE The\DT\1740 acute\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 OPs\NNS\1740 is\VBZ\836236 the\DT\1740 result\NN\34213 of\IN\1740 their\PRP$\1740 irreversible\JJ\1740 binding\NN\4688246 with\IN\1740 AChEs\NN\14322699 in\IN\13603305 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 (\-LRB-\1740 CNS\NN\5237227 )\-RRB-\1740 ,\,\1740 which\WDT\1740 elevates\VBZ\2391803 acetylcholine\NN\14807558 (\-LRB-\1740 <e1>ACh</e1>\NN\1740 )\-RRB-\1740 levels\NNS\4916342 .\.\1740
D007531_D064420 NONE The\DT\1740 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 <e1>DFP-atropine</e1>\NN\1740 showed\VBD\2137132 severe\JJ\1740 typical\JJ\1740 OP-induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 signs\NNS\6643763 .\.\1740
D007531_D064420 NONE Atropine-MK801\JJ\1740 did\VBD\1640855 not\RB\1740 offer\VB\2327200 any\DT\1740 additional\JJ\1740 protection\NN\407535 against\IN\1740 <e1>DFP</e1>\NN\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D007531_D064420 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 CPA\NN\9761403 ,\,\1740 diazepam\NN\2830852 and\CC\1740 2PAM\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 atropine\NN\14712692 prevented\VBD\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 serious\JJ\1740 signs\NNS\6643763 of\IN\1740 poisoning\NN\14034177 and\CC\1740 thus\RB\1740 reduced\VBD\441445 the\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 <e1>DFP</e1>\NN\1740 in\IN\13603305 rat\NN\2329401 .\.\1740
D001285_D064420 NONE The\DT\1740 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 <e1>DFP-atropine</e1>\NN\1740 showed\VBD\2137132 severe\JJ\1740 typical\JJ\1740 OP-induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 signs\NNS\6643763 .\.\1740
D001285_D064420 NONE <e1>Atropine-MK801</e1>\JJ\1740 did\VBD\1640855 not\RB\1740 offer\VB\2327200 any\DT\1740 additional\JJ\1740 protection\NN\407535 against\IN\1740 DFP\NN\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D001285_D064420 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 CPA\NN\9761403 ,\,\1740 diazepam\NN\2830852 and\CC\1740 2PAM\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>atropine</e1>\NN\14712692 prevented\VBD\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 serious\JJ\1740 signs\NNS\6643763 of\IN\1740 poisoning\NN\14034177 and\CC\1740 thus\RB\1740 reduced\VBD\441445 the\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 DFP\NN\1740 in\IN\13603305 rat\NN\2329401 .\.\1740
C048599_D011041 NONE When\WRB\1740 <e1>CPA</e1>\NN\9761403 ,\,\1740 diazepam\NN\2830852 or\CC\3541091 2PAM\NN\1740 was\VBD\836236 given\VBN\2327200 immediately\RB\1740 after\IN\1740 DFP-atropine\NN\1740 ,\,\1740 these\DT\1740 treatments\NNS\654885 prevented\VBD\1740 ,\,\1740 delayed\VBN\439958 or\CC\3541091 shortened\VBD\429060 the\DT\1740 occurrence\NN\29378 of\IN\1740 serious\JJ\1740 signs\NNS\6643763 of\IN\1740 <e2>poisoning</e2>\NN\14034177 .\.\1740
C048599_D011041 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 <e1>CPA</e1>\NN\9761403 ,\,\1740 diazepam\NN\2830852 and\CC\1740 2PAM\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 atropine\NN\14712692 prevented\VBD\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 serious\JJ\1740 signs\NNS\6643763 of\IN\1740 <e2>poisoning</e2>\NN\14034177 and\CC\1740 thus\RB\1740 reduced\VBD\441445 the\DT\1740 toxicity\NN\13576101 of\IN\1740 DFP\NN\1740 in\IN\13603305 rat\NN\2329401 .\.\1740
D003975_D011041 NONE When\WRB\1740 CPA\NN\9761403 ,\,\1740 <e1>diazepam</e1>\NN\2830852 or\CC\3541091 2PAM\NN\1740 was\VBD\836236 given\VBN\2327200 immediately\RB\1740 after\IN\1740 DFP-atropine\NN\1740 ,\,\1740 these\DT\1740 treatments\NNS\654885 prevented\VBD\1740 ,\,\1740 delayed\VBN\439958 or\CC\3541091 shortened\VBD\429060 the\DT\1740 occurrence\NN\29378 of\IN\1740 serious\JJ\1740 signs\NNS\6643763 of\IN\1740 <e2>poisoning</e2>\NN\14034177 .\.\1740
D003975_D011041 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 CPA\NN\9761403 ,\,\1740 <e1>diazepam</e1>\NN\2830852 and\CC\1740 2PAM\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 atropine\NN\14712692 prevented\VBD\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 serious\JJ\1740 signs\NNS\6643763 of\IN\1740 <e2>poisoning</e2>\NN\14034177 and\CC\1740 thus\RB\1740 reduced\VBD\441445 the\DT\1740 toxicity\NN\13576101 of\IN\1740 DFP\NN\1740 in\IN\13603305 rat\NN\2329401 .\.\1740
D011220_D011041 NONE When\WRB\1740 CPA\NN\9761403 ,\,\1740 diazepam\NN\2830852 or\CC\3541091 <e1>2PAM</e1>\NN\1740 was\VBD\836236 given\VBN\2327200 immediately\RB\1740 after\IN\1740 DFP-atropine\NN\1740 ,\,\1740 these\DT\1740 treatments\NNS\654885 prevented\VBD\1740 ,\,\1740 delayed\VBN\439958 or\CC\3541091 shortened\VBD\429060 the\DT\1740 occurrence\NN\29378 of\IN\1740 serious\JJ\1740 signs\NNS\6643763 of\IN\1740 <e2>poisoning</e2>\NN\14034177 .\.\1740
D011220_D011041 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 CPA\NN\9761403 ,\,\1740 diazepam\NN\2830852 and\CC\1740 <e1>2PAM</e1>\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 atropine\NN\14712692 prevented\VBD\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 serious\JJ\1740 signs\NNS\6643763 of\IN\1740 <e2>poisoning</e2>\NN\14034177 and\CC\1740 thus\RB\1740 reduced\VBD\441445 the\DT\1740 toxicity\NN\13576101 of\IN\1740 DFP\NN\1740 in\IN\13603305 rat\NN\2329401 .\.\1740
D007531_D011041 NONE When\WRB\1740 CPA\NN\9761403 ,\,\1740 diazepam\NN\2830852 or\CC\3541091 2PAM\NN\1740 was\VBD\836236 given\VBN\2327200 immediately\RB\1740 after\IN\1740 <e1>DFP-atropine</e1>\NN\1740 ,\,\1740 these\DT\1740 treatments\NNS\654885 prevented\VBD\1740 ,\,\1740 delayed\VBN\439958 or\CC\3541091 shortened\VBD\429060 the\DT\1740 occurrence\NN\29378 of\IN\1740 serious\JJ\1740 signs\NNS\6643763 of\IN\1740 <e2>poisoning</e2>\NN\14034177 .\.\1740
D007531_D011041 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 CPA\NN\9761403 ,\,\1740 diazepam\NN\2830852 and\CC\1740 2PAM\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 atropine\NN\14712692 prevented\VBD\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 serious\JJ\1740 signs\NNS\6643763 of\IN\1740 <e2>poisoning</e2>\NN\14034177 and\CC\1740 thus\RB\1740 reduced\VBD\441445 the\DT\1740 toxicity\NN\13576101 of\IN\1740 <e1>DFP</e1>\NN\1740 in\IN\13603305 rat\NN\2329401 .\.\1740
D001285_D011041 NONE When\WRB\1740 CPA\NN\9761403 ,\,\1740 diazepam\NN\2830852 or\CC\3541091 2PAM\NN\1740 was\VBD\836236 given\VBN\2327200 immediately\RB\1740 after\IN\1740 <e1>DFP-atropine</e1>\NN\1740 ,\,\1740 these\DT\1740 treatments\NNS\654885 prevented\VBD\1740 ,\,\1740 delayed\VBN\439958 or\CC\3541091 shortened\VBD\429060 the\DT\1740 occurrence\NN\29378 of\IN\1740 serious\JJ\1740 signs\NNS\6643763 of\IN\1740 <e2>poisoning</e2>\NN\14034177 .\.\1740
D001285_D011041 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 CPA\NN\9761403 ,\,\1740 diazepam\NN\2830852 and\CC\1740 2PAM\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>atropine</e1>\NN\14712692 prevented\VBD\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 serious\JJ\1740 signs\NNS\6643763 of\IN\1740 <e2>poisoning</e2>\NN\14034177 and\CC\1740 thus\RB\1740 reduced\VBD\441445 the\DT\1740 toxicity\NN\13576101 of\IN\1740 DFP\NN\1740 in\IN\13603305 rat\NN\2329401 .\.\1740
D016291_D064420 NONE <e1>Atropine-MK801</e1>\JJ\1740 did\VBD\1640855 not\RB\1740 offer\VB\2327200 any\DT\1740 additional\JJ\1740 protection\NN\407535 against\IN\1740 DFP\NN\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
C048599_D064420 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 <e1>CPA</e1>\NN\9761403 ,\,\1740 diazepam\NN\2830852 and\CC\1740 2PAM\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 atropine\NN\14712692 prevented\VBD\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 serious\JJ\1740 signs\NNS\6643763 of\IN\1740 poisoning\NN\14034177 and\CC\1740 thus\RB\1740 reduced\VBD\441445 the\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 DFP\NN\1740 in\IN\13603305 rat\NN\2329401 .\.\1740
D003975_D064420 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 CPA\NN\9761403 ,\,\1740 <e1>diazepam</e1>\NN\2830852 and\CC\1740 2PAM\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 atropine\NN\14712692 prevented\VBD\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 serious\JJ\1740 signs\NNS\6643763 of\IN\1740 poisoning\NN\14034177 and\CC\1740 thus\RB\1740 reduced\VBD\441445 the\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 DFP\NN\1740 in\IN\13603305 rat\NN\2329401 .\.\1740
D011220_D064420 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 CPA\NN\9761403 ,\,\1740 diazepam\NN\2830852 and\CC\1740 <e1>2PAM</e1>\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 atropine\NN\14712692 prevented\VBD\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 serious\JJ\1740 signs\NNS\6643763 of\IN\1740 poisoning\NN\14034177 and\CC\1740 thus\RB\1740 reduced\VBD\441445 the\DT\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 DFP\NN\1740 in\IN\13603305 rat\NN\2329401 .\.\1740
2887062
D004967_D015175 CID Immunohistochemical\JJ\1740 ,\,\1740 electron\NN\9338013 microscopic\JJ\1740 and\CC\1740 morphometric\JJ\1740 studies\NNS\635850 of\IN\1740 <e1>estrogen-induced</e1>\JJ\1740 rat\NN\2329401 <e2>prolactinomas</e2>\NNS\1740 after\IN\1740 bromocriptine\NN\1740 treatment\NN\654885 .\.\1740
D004967_D015175 CID To\TO\1740 clarify\VB\939277 the\DT\1740 effects\NNS\13245626 of\IN\1740 bromocriptine\NN\1740 on\IN\1740 <e2>prolactinoma</e2>\NN\1740 cells\NNS\3080309 in\FW\13603305 vivo\FW\1740 ,\,\1740 immunohistochemical\JJ\1740 ,\,\1740 ultrastructural\JJ\1740 and\CC\1740 morphometrical\JJ\1740 analyses\NNS\633864 were\VBD\836236 applied\VBN\2676054 to\TO\1740 <e1>estrogen-induced</e1>\JJ\1740 rat\NN\2329401 prolactinoma\NN\1740 cells\NNS\3080309 1\CD\13741022 h\NN\14622893 and\CC\1740 6\CD\13741022 h\NN\14622893 after\IN\1740 injection\NN\320852 of\IN\1740 bromocriptine\NN\1740 (\-LRB-\1740 3\CD\13741022 mg/kg\NN\1740 of\IN\1740 body\NN\19128 weight\NN\5009170 )\-RRB-\1740 .\.\1740
D004967_D015175 CID To\TO\1740 clarify\VB\939277 the\DT\1740 effects\NNS\13245626 of\IN\1740 bromocriptine\NN\1740 on\IN\1740 prolactinoma\NN\1740 cells\NNS\3080309 in\FW\13603305 vivo\FW\1740 ,\,\1740 immunohistochemical\JJ\1740 ,\,\1740 ultrastructural\JJ\1740 and\CC\1740 morphometrical\JJ\1740 analyses\NNS\633864 were\VBD\836236 applied\VBN\2676054 to\TO\1740 <e1>estrogen-induced</e1>\JJ\1740 rat\NN\2329401 <e2>prolactinoma</e2>\NN\1740 cells\NNS\3080309 1\CD\13741022 h\NN\14622893 and\CC\1740 6\CD\13741022 h\NN\14622893 after\IN\1740 injection\NN\320852 of\IN\1740 bromocriptine\NN\1740 (\-LRB-\1740 3\CD\13741022 mg/kg\NN\1740 of\IN\1740 body\NN\19128 weight\NN\5009170 )\-RRB-\1740 .\.\1740
D001971_D015175 NONE Immunohistochemical\JJ\1740 ,\,\1740 electron\NN\9338013 microscopic\JJ\1740 and\CC\1740 morphometric\JJ\1740 studies\NNS\635850 of\IN\1740 estrogen-induced\JJ\1740 rat\NN\2329401 <e2>prolactinomas</e2>\NNS\1740 after\IN\1740 <e1>bromocriptine</e1>\NN\1740 treatment\NN\654885 .\.\1740
D001971_D015175 NONE To\TO\1740 clarify\VB\939277 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>bromocriptine</e1>\NN\1740 on\IN\1740 <e2>prolactinoma</e2>\NN\1740 cells\NNS\3080309 in\FW\13603305 vivo\FW\1740 ,\,\1740 immunohistochemical\JJ\1740 ,\,\1740 ultrastructural\JJ\1740 and\CC\1740 morphometrical\JJ\1740 analyses\NNS\633864 were\VBD\836236 applied\VBN\2676054 to\TO\1740 estrogen-induced\JJ\1740 rat\NN\2329401 prolactinoma\NN\1740 cells\NNS\3080309 1\CD\13741022 h\NN\14622893 and\CC\1740 6\CD\13741022 h\NN\14622893 after\IN\1740 injection\NN\320852 of\IN\1740 bromocriptine\NN\1740 (\-LRB-\1740 3\CD\13741022 mg/kg\NN\1740 of\IN\1740 body\NN\19128 weight\NN\5009170 )\-RRB-\1740 .\.\1740
D001971_D015175 NONE To\TO\1740 clarify\VB\939277 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>bromocriptine</e1>\NN\1740 on\IN\1740 prolactinoma\NN\1740 cells\NNS\3080309 in\FW\13603305 vivo\FW\1740 ,\,\1740 immunohistochemical\JJ\1740 ,\,\1740 ultrastructural\JJ\1740 and\CC\1740 morphometrical\JJ\1740 analyses\NNS\633864 were\VBD\836236 applied\VBN\2676054 to\TO\1740 estrogen-induced\JJ\1740 rat\NN\2329401 <e2>prolactinoma</e2>\NN\1740 cells\NNS\3080309 1\CD\13741022 h\NN\14622893 and\CC\1740 6\CD\13741022 h\NN\14622893 after\IN\1740 injection\NN\320852 of\IN\1740 bromocriptine\NN\1740 (\-LRB-\1740 3\CD\13741022 mg/kg\NN\1740 of\IN\1740 body\NN\19128 weight\NN\5009170 )\-RRB-\1740 .\.\1740
D001971_D015175 NONE To\TO\1740 clarify\VB\939277 the\DT\1740 effects\NNS\13245626 of\IN\1740 bromocriptine\NN\1740 on\IN\1740 <e2>prolactinoma</e2>\NN\1740 cells\NNS\3080309 in\FW\13603305 vivo\FW\1740 ,\,\1740 immunohistochemical\JJ\1740 ,\,\1740 ultrastructural\JJ\1740 and\CC\1740 morphometrical\JJ\1740 analyses\NNS\633864 were\VBD\836236 applied\VBN\2676054 to\TO\1740 estrogen-induced\JJ\1740 rat\NN\2329401 prolactinoma\NN\1740 cells\NNS\3080309 1\CD\13741022 h\NN\14622893 and\CC\1740 6\CD\13741022 h\NN\14622893 after\IN\1740 injection\NN\320852 of\IN\1740 <e1>bromocriptine</e1>\NN\1740 (\-LRB-\1740 3\CD\13741022 mg/kg\NN\1740 of\IN\1740 body\NN\19128 weight\NN\5009170 )\-RRB-\1740 .\.\1740
D001971_D015175 NONE To\TO\1740 clarify\VB\939277 the\DT\1740 effects\NNS\13245626 of\IN\1740 bromocriptine\NN\1740 on\IN\1740 prolactinoma\NN\1740 cells\NNS\3080309 in\FW\13603305 vivo\FW\1740 ,\,\1740 immunohistochemical\JJ\1740 ,\,\1740 ultrastructural\JJ\1740 and\CC\1740 morphometrical\JJ\1740 analyses\NNS\633864 were\VBD\836236 applied\VBN\2676054 to\TO\1740 estrogen-induced\JJ\1740 rat\NN\2329401 <e2>prolactinoma</e2>\NN\1740 cells\NNS\3080309 1\CD\13741022 h\NN\14622893 and\CC\1740 6\CD\13741022 h\NN\14622893 after\IN\1740 injection\NN\320852 of\IN\1740 <e1>bromocriptine</e1>\NN\1740 (\-LRB-\1740 3\CD\13741022 mg/kg\NN\1740 of\IN\1740 body\NN\19128 weight\NN\5009170 )\-RRB-\1740 .\.\1740
D001971_D000236 NONE However\RB\1740 ,\,\1740 only\RB\1740 secretory\JJ\1740 granules\NNS\9290777 showed\VBD\2137132 the\DT\1740 positive\JJ\1740 reaction\NN\13446390 products\NNS\3076708 for\IN\1740 prolactin\NN\5410315 6\CD\13741022 h\NN\14622893 after\IN\1740 <e1>bromocriptine</e1>\NN\1740 treatment\NN\654885 of\IN\1740 the\DT\1740 <e2>adenoma</e2>\NN\14236226 cells\NNS\3080309 .\.\1740
10669626
D014859_D061205 CID <e1>Warfarin-induced</e1>\JJ\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 is\VBZ\836236 accelerated\VBN\226566 by\IN\1740 growth\NN\13526110 and\CC\1740 vitamin\NN\7570720 D.\NN\1740
D014859_D061205 CID The\DT\1740 present\JJ\1740 studies\NNS\635850 demonstrate\VBP\2137132 that\IN\1740 growth\NN\13526110 and\CC\1740 vitamin\NN\7570720 D\NN\15089472 treatment\NN\654885 enhance\VBP\227165 the\DT\1740 extent\NN\13939892 of\IN\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 in\IN\13603305 rats\NNS\2329401 given\VBN\2327200 sufficient\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>Warfarin</e1>\NN\2718259 to\TO\1740 inhibit\VB\2510337 gamma-carboxylation\NN\1740 of\IN\1740 matrix\NN\7939382 Gla\NN\1740 protein\NN\14944888 ,\,\1740 a\DT\13649268 calcification\NN\13446390 inhibitor\NN\20090 known\VBN\2110220 to\TO\1740 be\VB\836236 expressed\VBN\928630 by\IN\1740 smooth\JJ\1740 muscle\NN\5289601 cells\NNS\3080309 and\CC\1740 macrophages\NNS\5450888 in\IN\13603305 the\DT\1740 artery\NN\5417975 wall\NN\3894379 .\.\1740
D014859_D061205 CID The\DT\1740 first\JJ\1740 series\NN\8456993 of\IN\1740 experiments\NNS\641820 examined\VBD\789138 the\DT\1740 influence\NN\5190804 of\IN\1740 age\NN\4916342 and\CC\1740 growth\NN\13526110 status\NN\24720 on\IN\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 in\IN\13603305 <e1>Warfarin-treated</e1>\JJ\1740 rats\NNS\2329401 .\.\1740
D014859_D061205 CID Treatment\NN\654885 for\IN\1740 2\CD\13741022 weeks\NNS\15113229 with\IN\1740 <e1>Warfarin</e1>\NNP\2718259 caused\VBD\1617192 massive\JJ\1740 focal\JJ\1740 <e2>calcification\NN\13446390 of\IN\1740 the\DT\1740 artery</e2>\NN\5417975 media\NNS\3575240 in\IN\13603305 20-day-old\JJ\1740 rats\NNS\2329401 and\CC\1740 less\RBR\1740 extensive\JJ\1740 focal\JJ\1740 calcification\NN\13446390 in\IN\13603305 42-day-old\JJ\1740 rats\NNS\2329401 .\.\1740
D014859_D061205 CID In\IN\13603305 contrast\NN\13854649 ,\,\1740 no\DT\7204911 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 could\MD\1740 be\VB\836236 detected\VBN\2163746 in\IN\13603305 10-month-old\JJ\1740 adult\JJ\1740 rats\NNS\2329401 even\RB\1740 after\IN\1740 4\CD\13741022 weeks\NNS\15113229 of\IN\1740 <e1>Warfarin</e1>\NN\2718259 treatment\NN\654885 .\.\1740
D014859_D061205 CID To\TO\1740 directly\RB\1740 examine\VB\789138 the\DT\1740 importance\NN\5138488 of\IN\1740 growth\NN\13526110 to\TO\1740 <e1>Warfarin-induced</e1>\JJ\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 in\IN\13603305 animals\NNS\4475 of\IN\1740 the\DT\1740 same\JJ\1740 age\NN\4916342 ,\,\1740 20-day-old\JJ\1740 rats\NNS\2329401 were\VBD\836236 fed\VBN\1182709 for\IN\1740 2\CD\13741022 weeks\NNS\15113229 either\CC\1740 an\DT\6697703 ad\NN\7247071 libitum\NN\1740 diet\NN\7560652 or\CC\3541091 a\DT\13649268 6-g/d\CD\1740 restricted\JJ\1740 diet\NN\7560652 that\WDT\1740 maintains\VBZ\2202928 weight\NN\5009170 but\CC\1740 prevents\VBZ\1740 growth\NN\13526110 .\.\1740
D014859_D061205 CID Concurrent\JJ\1740 treatment\NN\654885 of\IN\1740 both\CC\1740 dietary\JJ\1740 groups\NNS\2137 with\IN\1740 <e1>Warfarin</e1>\NNP\2718259 produced\VBD\1617192 massive\JJ\1740 focal\JJ\1740 <e2>calcification\NN\13446390 of\IN\1740 the\DT\1740 artery</e2>\NN\5417975 media\NNS\3575240 in\IN\13603305 the\DT\1740 ad\NN\7247071 libitum-fed\JJ\1740 rats\NNS\2329401 but\CC\1740 no\DT\7204911 detectable\JJ\1740 artery\NN\5417975 calcification\NN\13446390 in\IN\13603305 the\DT\1740 restricted-diet\JJ\1740 ,\,\1740 growth-inhibited\JJ\1740 group\NN\2137 .\.\1740
D014859_D061205 CID Concurrent\JJ\1740 treatment\NN\654885 of\IN\1740 both\CC\1740 dietary\JJ\1740 groups\NNS\2137 with\IN\1740 <e1>Warfarin</e1>\NNP\2718259 produced\VBD\1617192 massive\JJ\1740 focal\JJ\1740 calcification\NN\13446390 of\IN\1740 the\DT\1740 artery\NN\5417975 media\NNS\3575240 in\IN\13603305 the\DT\1740 ad\NN\7247071 libitum-fed\JJ\1740 rats\NNS\2329401 but\CC\1740 no\DT\7204911 detectable\JJ\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 in\IN\13603305 the\DT\1740 restricted-diet\JJ\1740 ,\,\1740 growth-inhibited\JJ\1740 group\NN\2137 .\.\1740
D014859_D061205 CID Although\IN\1740 the\DT\1740 explanation\NN\6722453 for\IN\1740 the\DT\1740 association\NN\8008335 between\IN\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 and\CC\1740 growth\NN\13526110 status\NN\24720 can\MD\3094503 not\RB\1740 be\VB\836236 determined\VBN\1645601 from\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 relationship\NN\31921 between\IN\1740 higher\JJR\1740 serum\NN\5397468 phosphate\NN\15010703 and\CC\1740 susceptibility\NN\13920835 to\TO\1740 artery\NN\5417975 calcification\NN\13446390 ,\,\1740 with\IN\1740 30\CD\13745420 %\NN\1740 higher\JJR\1740 levels\NNS\4916342 of\IN\1740 serum\NN\5397468 phosphate\NN\15010703 in\IN\13603305 young\JJ\1740 ,\,\1740 ad\NN\7247071 libitum-fed\JJ\1740 rats\NNS\2329401 compared\VBN\644583 with\IN\1740 either\DT\1740 of\IN\1740 the\DT\1740 groups\NNS\2137 that\WDT\1740 was\VBD\836236 resistant\JJ\1740 to\TO\1740 <e1>Warfarin-induced</e1>\JJ\1740 artery\NN\5417975 calcification\NN\13446390 ,\,\1740 ie\FW\1740 ,\,\1740 the\DT\1740 10-month-old\JJ\1740 rats\NNS\2329401 and\CC\1740 the\DT\1740 restricted-diet\JJ\1740 ,\,\1740 growth-inhibited\JJ\1740 young\JJ\1740 rats\NNS\2329401 .\.\1740
D014859_D061205 CID Although\IN\1740 the\DT\1740 explanation\NN\6722453 for\IN\1740 the\DT\1740 association\NN\8008335 between\IN\1740 artery\NN\5417975 calcification\NN\13446390 and\CC\1740 growth\NN\13526110 status\NN\24720 can\MD\3094503 not\RB\1740 be\VB\836236 determined\VBN\1645601 from\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 relationship\NN\31921 between\IN\1740 higher\JJR\1740 serum\NN\5397468 phosphate\NN\15010703 and\CC\1740 susceptibility\NN\13920835 to\TO\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 ,\,\1740 with\IN\1740 30\CD\13745420 %\NN\1740 higher\JJR\1740 levels\NNS\4916342 of\IN\1740 serum\NN\5397468 phosphate\NN\15010703 in\IN\13603305 young\JJ\1740 ,\,\1740 ad\NN\7247071 libitum-fed\JJ\1740 rats\NNS\2329401 compared\VBN\644583 with\IN\1740 either\DT\1740 of\IN\1740 the\DT\1740 groups\NNS\2137 that\WDT\1740 was\VBD\836236 resistant\JJ\1740 to\TO\1740 <e1>Warfarin-induced</e1>\JJ\1740 artery\NN\5417975 calcification\NN\13446390 ,\,\1740 ie\FW\1740 ,\,\1740 the\DT\1740 10-month-old\JJ\1740 rats\NNS\2329401 and\CC\1740 the\DT\1740 restricted-diet\JJ\1740 ,\,\1740 growth-inhibited\JJ\1740 young\JJ\1740 rats\NNS\2329401 .\.\1740
D014859_D061205 CID Although\IN\1740 the\DT\1740 explanation\NN\6722453 for\IN\1740 the\DT\1740 association\NN\8008335 between\IN\1740 artery\NN\5417975 calcification\NN\13446390 and\CC\1740 growth\NN\13526110 status\NN\24720 can\MD\3094503 not\RB\1740 be\VB\836236 determined\VBN\1645601 from\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 relationship\NN\31921 between\IN\1740 higher\JJR\1740 serum\NN\5397468 phosphate\NN\15010703 and\CC\1740 susceptibility\NN\13920835 to\TO\1740 artery\NN\5417975 calcification\NN\13446390 ,\,\1740 with\IN\1740 30\CD\13745420 %\NN\1740 higher\JJR\1740 levels\NNS\4916342 of\IN\1740 serum\NN\5397468 phosphate\NN\15010703 in\IN\13603305 young\JJ\1740 ,\,\1740 ad\NN\7247071 libitum-fed\JJ\1740 rats\NNS\2329401 compared\VBN\644583 with\IN\1740 either\DT\1740 of\IN\1740 the\DT\1740 groups\NNS\2137 that\WDT\1740 was\VBD\836236 resistant\JJ\1740 to\TO\1740 <e1>Warfarin-induced</e1>\JJ\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 ,\,\1740 ie\FW\1740 ,\,\1740 the\DT\1740 10-month-old\JJ\1740 rats\NNS\2329401 and\CC\1740 the\DT\1740 restricted-diet\JJ\1740 ,\,\1740 growth-inhibited\JJ\1740 young\JJ\1740 rats\NNS\2329401 .\.\1740
D014859_D061205 CID This\DT\1740 observation\NN\996969 suggests\VBZ\1010118 that\IN\1740 increased\VBN\169651 susceptibility\NN\13920835 to\TO\1740 <e1>Warfarin-induced</e1>\JJ\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 could\MD\1740 be\VB\836236 related\JJ\1740 to\TO\1740 higher\JJR\1740 serum\NN\5397468 phosphate\NN\15010703 levels\NNS\4916342 .\.\1740
D014859_D061205 CID The\DT\1740 second\JJ\1740 set\NN\7951464 of\IN\1740 experiments\NNS\641820 examined\VBD\789138 the\DT\1740 possible\JJ\1740 synergy\NN\13518963 between\IN\1740 vitamin\NN\7570720 D\NN\15089472 and\CC\1740 <e1>Warfarin</e1>\NN\2718259 in\IN\13603305 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 .\.\1740
D014859_D061205 CID High\JJ\1740 doses\NNS\3740161 of\IN\1740 the\DT\1740 vitamin\NN\7570720 K\NN\13608598 antagonist\NN\7846 <e1>Warfarin</e1>\NN\2718259 are\VBP\836236 also\RB\1740 known\VBN\2110220 to\TO\1740 cause\VB\1617192 <e2>calcification\NN\13446390 of\IN\1740 the\DT\1740 artery</e2>\NN\5417975 media\NNS\3575240 ,\,\1740 but\CC\1740 at\IN\14622893 treatment\NN\654885 times\NNS\15113229 of\IN\1740 2\CD\13741022 weeks\NNS\15113229 or\CC\3541091 longer\RBR\1740 yet\CC\1740 not\RB\1740 at\IN\14622893 1\CD\13741022 week\NN\15113229 .\.\1740
D014859_D061205 CID High\JJ\1740 levels\NNS\4916342 of\IN\1740 matrix\NN\7939382 Gla\NN\1740 protein\NN\14944888 are\VBP\836236 found\VBN\2426171 at\IN\14622893 sites\NNS\8673395 of\IN\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 in\IN\13603305 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 vitamin\NN\7570720 D\NN\15089472 plus\CC\4723816 <e1>Warfarin</e1>\NN\2718259 ,\,\1740 and\CC\1740 chemical\NN\14580897 analysis\NN\633864 showed\VBD\2137132 that\IN\1740 the\DT\1740 protein\NN\14944888 that\WDT\1740 accumulated\VBN\2281093 was\VBD\836236 indeed\RB\1740 not\RB\1740 gamma-carboxylated\JJ\1740 .\.\1740
D014807_D061205 NONE Warfarin-induced\JJ\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 is\VBZ\836236 accelerated\VBN\226566 by\IN\1740 growth\NN\13526110 and\CC\1740 <e1>vitamin\NN\7570720 D.</e1>\NN\1740
D014807_D061205 NONE The\DT\1740 present\JJ\1740 studies\NNS\635850 demonstrate\VBP\2137132 that\IN\1740 growth\NN\13526110 and\CC\1740 <e1>vitamin\NN\7570720 D</e1>\NN\15089472 treatment\NN\654885 enhance\VBP\227165 the\DT\1740 extent\NN\13939892 of\IN\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 in\IN\13603305 rats\NNS\2329401 given\VBN\2327200 sufficient\JJ\1740 doses\NNS\3740161 of\IN\1740 Warfarin\NN\2718259 to\TO\1740 inhibit\VB\2510337 gamma-carboxylation\NN\1740 of\IN\1740 matrix\NN\7939382 Gla\NN\1740 protein\NN\14944888 ,\,\1740 a\DT\13649268 calcification\NN\13446390 inhibitor\NN\20090 known\VBN\2110220 to\TO\1740 be\VB\836236 expressed\VBN\928630 by\IN\1740 smooth\JJ\1740 muscle\NN\5289601 cells\NNS\3080309 and\CC\1740 macrophages\NNS\5450888 in\IN\13603305 the\DT\1740 artery\NN\5417975 wall\NN\3894379 .\.\1740
D014807_D061205 NONE The\DT\1740 second\JJ\1740 set\NN\7951464 of\IN\1740 experiments\NNS\641820 examined\VBD\789138 the\DT\1740 possible\JJ\1740 synergy\NN\13518963 between\IN\1740 <e1>vitamin\NN\7570720 D</e1>\NN\15089472 and\CC\1740 Warfarin\NN\2718259 in\IN\13603305 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 .\.\1740
D014807_D061205 NONE High\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>vitamin\NN\7570720 D</e1>\NN\15089472 are\VBP\836236 known\VBN\2110220 to\TO\1740 cause\VB\1617192 <e2>calcification\NN\13446390 of\IN\1740 the\DT\1740 artery</e2>\NN\5417975 media\NNS\3575240 in\IN\13603305 as\RB\1740 little\JJ\1740 as\IN\14622893 3\CD\13741022 to\TO\1740 4\CD\13741022 days\NNS\15140892 .\.\1740
D014807_D061205 NONE There\EX\27167 was\VBD\836236 a\DT\13649268 close\JJ\1740 parallel\NN\4743605 between\IN\1740 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>vitamin\NN\7570720 D</e1>\NN\15089472 dose\NN\3740161 on\IN\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 and\CC\1740 the\DT\1740 effect\NN\34213 of\IN\1740 vitamin\NN\7570720 D\NN\15089472 dose\NN\3740161 on\IN\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 serum\NN\5397468 calcium\NN\14625458 ,\,\1740 which\WDT\1740 suggests\VBZ\1010118 that\IN\1740 vitamin\NN\7570720 D\NN\15089472 may\MD\15209706 induce\VB\1627355 artery\NN\5417975 calcification\NN\13446390 through\IN\1740 its\PRP$\6125041 effect\NN\34213 on\IN\1740 serum\NN\5397468 calcium\NN\14625458 .\.\1740
D014807_D061205 NONE There\EX\27167 was\VBD\836236 a\DT\13649268 close\JJ\1740 parallel\NN\4743605 between\IN\1740 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>vitamin\NN\7570720 D</e1>\NN\15089472 dose\NN\3740161 on\IN\1740 artery\NN\5417975 calcification\NN\13446390 and\CC\1740 the\DT\1740 effect\NN\34213 of\IN\1740 vitamin\NN\7570720 D\NN\15089472 dose\NN\3740161 on\IN\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 serum\NN\5397468 calcium\NN\14625458 ,\,\1740 which\WDT\1740 suggests\VBZ\1010118 that\IN\1740 vitamin\NN\7570720 D\NN\15089472 may\MD\15209706 induce\VB\1627355 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 through\IN\1740 its\PRP$\6125041 effect\NN\34213 on\IN\1740 serum\NN\5397468 calcium\NN\14625458 .\.\1740
D014807_D061205 NONE There\EX\27167 was\VBD\836236 a\DT\13649268 close\JJ\1740 parallel\NN\4743605 between\IN\1740 the\DT\1740 effect\NN\34213 of\IN\1740 vitamin\NN\7570720 D\NN\15089472 dose\NN\3740161 on\IN\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 and\CC\1740 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>vitamin\NN\7570720 D</e1>\NN\15089472 dose\NN\3740161 on\IN\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 serum\NN\5397468 calcium\NN\14625458 ,\,\1740 which\WDT\1740 suggests\VBZ\1010118 that\IN\1740 vitamin\NN\7570720 D\NN\15089472 may\MD\15209706 induce\VB\1627355 artery\NN\5417975 calcification\NN\13446390 through\IN\1740 its\PRP$\6125041 effect\NN\34213 on\IN\1740 serum\NN\5397468 calcium\NN\14625458 .\.\1740
D014807_D061205 NONE There\EX\27167 was\VBD\836236 a\DT\13649268 close\JJ\1740 parallel\NN\4743605 between\IN\1740 the\DT\1740 effect\NN\34213 of\IN\1740 vitamin\NN\7570720 D\NN\15089472 dose\NN\3740161 on\IN\1740 artery\NN\5417975 calcification\NN\13446390 and\CC\1740 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>vitamin\NN\7570720 D</e1>\NN\15089472 dose\NN\3740161 on\IN\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 serum\NN\5397468 calcium\NN\14625458 ,\,\1740 which\WDT\1740 suggests\VBZ\1010118 that\IN\1740 vitamin\NN\7570720 D\NN\15089472 may\MD\15209706 induce\VB\1627355 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 through\IN\1740 its\PRP$\6125041 effect\NN\34213 on\IN\1740 serum\NN\5397468 calcium\NN\14625458 .\.\1740
D014807_D061205 NONE There\EX\27167 was\VBD\836236 a\DT\13649268 close\JJ\1740 parallel\NN\4743605 between\IN\1740 the\DT\1740 effect\NN\34213 of\IN\1740 vitamin\NN\7570720 D\NN\15089472 dose\NN\3740161 on\IN\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 and\CC\1740 the\DT\1740 effect\NN\34213 of\IN\1740 vitamin\NN\7570720 D\NN\15089472 dose\NN\3740161 on\IN\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 serum\NN\5397468 calcium\NN\14625458 ,\,\1740 which\WDT\1740 suggests\VBZ\1010118 that\IN\1740 <e1>vitamin\NN\7570720 D</e1>\NN\15089472 may\MD\15209706 induce\VB\1627355 artery\NN\5417975 calcification\NN\13446390 through\IN\1740 its\PRP$\6125041 effect\NN\34213 on\IN\1740 serum\NN\5397468 calcium\NN\14625458 .\.\1740
D014807_D061205 NONE There\EX\27167 was\VBD\836236 a\DT\13649268 close\JJ\1740 parallel\NN\4743605 between\IN\1740 the\DT\1740 effect\NN\34213 of\IN\1740 vitamin\NN\7570720 D\NN\15089472 dose\NN\3740161 on\IN\1740 artery\NN\5417975 calcification\NN\13446390 and\CC\1740 the\DT\1740 effect\NN\34213 of\IN\1740 vitamin\NN\7570720 D\NN\15089472 dose\NN\3740161 on\IN\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 serum\NN\5397468 calcium\NN\14625458 ,\,\1740 which\WDT\1740 suggests\VBZ\1010118 that\IN\1740 <e1>vitamin\NN\7570720 D</e1>\NN\15089472 may\MD\15209706 induce\VB\1627355 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 through\IN\1740 its\PRP$\6125041 effect\NN\34213 on\IN\1740 serum\NN\5397468 calcium\NN\14625458 .\.\1740
D014807_D061205 NONE High\JJ\1740 levels\NNS\4916342 of\IN\1740 matrix\NN\7939382 Gla\NN\1740 protein\NN\14944888 are\VBP\836236 found\VBN\2426171 at\IN\14622893 sites\NNS\8673395 of\IN\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 in\IN\13603305 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 <e1>vitamin\NN\7570720 D</e1>\NN\15089472 plus\CC\4723816 Warfarin\NN\2718259 ,\,\1740 and\CC\1740 chemical\NN\14580897 analysis\NN\633864 showed\VBD\2137132 that\IN\1740 the\DT\1740 protein\NN\14944888 that\WDT\1740 accumulated\VBN\2281093 was\VBD\836236 indeed\RB\1740 not\RB\1740 gamma-carboxylated\JJ\1740 .\.\1740
D014807_D002114 NONE The\DT\1740 present\JJ\1740 studies\NNS\635850 demonstrate\VBP\2137132 that\IN\1740 growth\NN\13526110 and\CC\1740 <e1>vitamin\NN\7570720 D</e1>\NN\15089472 treatment\NN\654885 enhance\VBP\227165 the\DT\1740 extent\NN\13939892 of\IN\1740 artery\NN\5417975 calcification\NN\13446390 in\IN\13603305 rats\NNS\2329401 given\VBN\2327200 sufficient\JJ\1740 doses\NNS\3740161 of\IN\1740 Warfarin\NN\2718259 to\TO\1740 inhibit\VB\2510337 gamma-carboxylation\NN\1740 of\IN\1740 matrix\NN\7939382 Gla\NN\1740 protein\NN\14944888 ,\,\1740 a\DT\13649268 <e2>calcification</e2>\NN\13446390 inhibitor\NN\20090 known\VBN\2110220 to\TO\1740 be\VB\836236 expressed\VBN\928630 by\IN\1740 smooth\JJ\1740 muscle\NN\5289601 cells\NNS\3080309 and\CC\1740 macrophages\NNS\5450888 in\IN\13603305 the\DT\1740 artery\NN\5417975 wall\NN\3894379 .\.\1740
D014807_D002114 NONE In\IN\13603305 the\DT\1740 current\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 investigated\VBD\644583 the\DT\1740 synergy\NN\13518963 between\IN\1740 these\DT\1740 2\CD\13741022 treatments\NNS\654885 and\CC\1740 found\VBD\2426171 that\IN\1740 concurrent\JJ\1740 Warfarin\NNP\2718259 administration\NN\1133281 dramatically\RB\1740 increased\VBD\169651 the\DT\1740 extent\NN\13939892 of\IN\1740 <e2>calcification</e2>\NN\13446390 in\IN\13603305 the\DT\1740 media\NNS\3575240 of\IN\1740 <e1>vitamin\NN\7570720 D-treated</e1>\JJ\1740 rats\NNS\2329401 at\IN\14622893 3\CD\13741022 and\CC\1740 4\CD\13741022 days\NNS\15140892 .\.\1740
D014807_D002114 NONE Because\IN\1740 Warfarin\NN\2718259 treatment\NN\654885 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 the\DT\1740 elevation\NN\7445480 in\IN\13603305 serum\NN\5397468 calcium\NN\14625458 produced\VBN\1617192 by\IN\1740 <e1>vitamin\NN\7570720 D</e1>\NN\15089472 ,\,\1740 the\DT\1740 synergy\NN\13518963 between\IN\1740 Warfarin\NN\2718259 and\CC\1740 vitamin\NN\7570720 D\NN\15089472 is\VBZ\836236 probably\RB\1740 best\RBS\1740 explained\VBN\831651 by\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 Warfarin\NN\2718259 inhibits\VBZ\2510337 the\DT\1740 activity\NN\30358 of\IN\1740 matrix\NN\7939382 Gla\NN\1740 protein\NN\14944888 as\IN\14622893 a\DT\13649268 <e2>calcification</e2>\NN\13446390 inhibitor\NN\20090 .\.\1740
D014807_D002114 NONE Because\IN\1740 Warfarin\NN\2718259 treatment\NN\654885 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 the\DT\1740 elevation\NN\7445480 in\IN\13603305 serum\NN\5397468 calcium\NN\14625458 produced\VBN\1617192 by\IN\1740 vitamin\NN\7570720 D\NN\15089472 ,\,\1740 the\DT\1740 synergy\NN\13518963 between\IN\1740 Warfarin\NN\2718259 and\CC\1740 <e1>vitamin\NN\7570720 D</e1>\NN\15089472 is\VBZ\836236 probably\RB\1740 best\RBS\1740 explained\VBN\831651 by\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 Warfarin\NN\2718259 inhibits\VBZ\2510337 the\DT\1740 activity\NN\30358 of\IN\1740 matrix\NN\7939382 Gla\NN\1740 protein\NN\14944888 as\IN\14622893 a\DT\13649268 <e2>calcification</e2>\NN\13446390 inhibitor\NN\20090 .\.\1740
D014859_D002114 NONE The\DT\1740 present\JJ\1740 studies\NNS\635850 demonstrate\VBP\2137132 that\IN\1740 growth\NN\13526110 and\CC\1740 vitamin\NN\7570720 D\NN\15089472 treatment\NN\654885 enhance\VBP\227165 the\DT\1740 extent\NN\13939892 of\IN\1740 artery\NN\5417975 calcification\NN\13446390 in\IN\13603305 rats\NNS\2329401 given\VBN\2327200 sufficient\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>Warfarin</e1>\NN\2718259 to\TO\1740 inhibit\VB\2510337 gamma-carboxylation\NN\1740 of\IN\1740 matrix\NN\7939382 Gla\NN\1740 protein\NN\14944888 ,\,\1740 a\DT\13649268 <e2>calcification</e2>\NN\13446390 inhibitor\NN\20090 known\VBN\2110220 to\TO\1740 be\VB\836236 expressed\VBN\928630 by\IN\1740 smooth\JJ\1740 muscle\NN\5289601 cells\NNS\3080309 and\CC\1740 macrophages\NNS\5450888 in\IN\13603305 the\DT\1740 artery\NN\5417975 wall\NN\3894379 .\.\1740
D014859_D002114 NONE Treatment\NN\654885 for\IN\1740 2\CD\13741022 weeks\NNS\15113229 with\IN\1740 <e1>Warfarin</e1>\NNP\2718259 caused\VBD\1617192 massive\JJ\1740 focal\JJ\1740 calcification\NN\13446390 of\IN\1740 the\DT\1740 artery\NN\5417975 media\NNS\3575240 in\IN\13603305 20-day-old\JJ\1740 rats\NNS\2329401 and\CC\1740 less\RBR\1740 extensive\JJ\1740 focal\JJ\1740 <e2>calcification</e2>\NN\13446390 in\IN\13603305 42-day-old\JJ\1740 rats\NNS\2329401 .\.\1740
D014859_D002114 NONE In\IN\13603305 the\DT\1740 current\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 investigated\VBD\644583 the\DT\1740 synergy\NN\13518963 between\IN\1740 these\DT\1740 2\CD\13741022 treatments\NNS\654885 and\CC\1740 found\VBD\2426171 that\IN\1740 concurrent\JJ\1740 <e1>Warfarin</e1>\NNP\2718259 administration\NN\1133281 dramatically\RB\1740 increased\VBD\169651 the\DT\1740 extent\NN\13939892 of\IN\1740 <e2>calcification</e2>\NN\13446390 in\IN\13603305 the\DT\1740 media\NNS\3575240 of\IN\1740 vitamin\NN\7570720 D-treated\JJ\1740 rats\NNS\2329401 at\IN\14622893 3\CD\13741022 and\CC\1740 4\CD\13741022 days\NNS\15140892 .\.\1740
D014859_D002114 NONE Because\IN\1740 <e1>Warfarin</e1>\NN\2718259 treatment\NN\654885 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 the\DT\1740 elevation\NN\7445480 in\IN\13603305 serum\NN\5397468 calcium\NN\14625458 produced\VBN\1617192 by\IN\1740 vitamin\NN\7570720 D\NN\15089472 ,\,\1740 the\DT\1740 synergy\NN\13518963 between\IN\1740 Warfarin\NN\2718259 and\CC\1740 vitamin\NN\7570720 D\NN\15089472 is\VBZ\836236 probably\RB\1740 best\RBS\1740 explained\VBN\831651 by\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 Warfarin\NN\2718259 inhibits\VBZ\2510337 the\DT\1740 activity\NN\30358 of\IN\1740 matrix\NN\7939382 Gla\NN\1740 protein\NN\14944888 as\IN\14622893 a\DT\13649268 <e2>calcification</e2>\NN\13446390 inhibitor\NN\20090 .\.\1740
D014859_D002114 NONE Because\IN\1740 Warfarin\NN\2718259 treatment\NN\654885 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 the\DT\1740 elevation\NN\7445480 in\IN\13603305 serum\NN\5397468 calcium\NN\14625458 produced\VBN\1617192 by\IN\1740 vitamin\NN\7570720 D\NN\15089472 ,\,\1740 the\DT\1740 synergy\NN\13518963 between\IN\1740 <e1>Warfarin</e1>\NN\2718259 and\CC\1740 vitamin\NN\7570720 D\NN\15089472 is\VBZ\836236 probably\RB\1740 best\RBS\1740 explained\VBN\831651 by\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 Warfarin\NN\2718259 inhibits\VBZ\2510337 the\DT\1740 activity\NN\30358 of\IN\1740 matrix\NN\7939382 Gla\NN\1740 protein\NN\14944888 as\IN\14622893 a\DT\13649268 <e2>calcification</e2>\NN\13446390 inhibitor\NN\20090 .\.\1740
D014859_D002114 NONE Because\IN\1740 Warfarin\NN\2718259 treatment\NN\654885 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 the\DT\1740 elevation\NN\7445480 in\IN\13603305 serum\NN\5397468 calcium\NN\14625458 produced\VBN\1617192 by\IN\1740 vitamin\NN\7570720 D\NN\15089472 ,\,\1740 the\DT\1740 synergy\NN\13518963 between\IN\1740 Warfarin\NN\2718259 and\CC\1740 vitamin\NN\7570720 D\NN\15089472 is\VBZ\836236 probably\RB\1740 best\RBS\1740 explained\VBN\831651 by\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 <e1>Warfarin</e1>\NN\2718259 inhibits\VBZ\2510337 the\DT\1740 activity\NN\30358 of\IN\1740 matrix\NN\7939382 Gla\NN\1740 protein\NN\14944888 as\IN\14622893 a\DT\13649268 <e2>calcification</e2>\NN\13446390 inhibitor\NN\20090 .\.\1740
D010710_D061205 NONE Although\IN\1740 the\DT\1740 explanation\NN\6722453 for\IN\1740 the\DT\1740 association\NN\8008335 between\IN\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 and\CC\1740 growth\NN\13526110 status\NN\24720 can\MD\3094503 not\RB\1740 be\VB\836236 determined\VBN\1645601 from\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 relationship\NN\31921 between\IN\1740 higher\JJR\1740 serum\NN\5397468 <e1>phosphate</e1>\NN\15010703 and\CC\1740 susceptibility\NN\13920835 to\TO\1740 artery\NN\5417975 calcification\NN\13446390 ,\,\1740 with\IN\1740 30\CD\13745420 %\NN\1740 higher\JJR\1740 levels\NNS\4916342 of\IN\1740 serum\NN\5397468 phosphate\NN\15010703 in\IN\13603305 young\JJ\1740 ,\,\1740 ad\NN\7247071 libitum-fed\JJ\1740 rats\NNS\2329401 compared\VBN\644583 with\IN\1740 either\DT\1740 of\IN\1740 the\DT\1740 groups\NNS\2137 that\WDT\1740 was\VBD\836236 resistant\JJ\1740 to\TO\1740 Warfarin-induced\JJ\1740 artery\NN\5417975 calcification\NN\13446390 ,\,\1740 ie\FW\1740 ,\,\1740 the\DT\1740 10-month-old\JJ\1740 rats\NNS\2329401 and\CC\1740 the\DT\1740 restricted-diet\JJ\1740 ,\,\1740 growth-inhibited\JJ\1740 young\JJ\1740 rats\NNS\2329401 .\.\1740
D010710_D061205 NONE Although\IN\1740 the\DT\1740 explanation\NN\6722453 for\IN\1740 the\DT\1740 association\NN\8008335 between\IN\1740 artery\NN\5417975 calcification\NN\13446390 and\CC\1740 growth\NN\13526110 status\NN\24720 can\MD\3094503 not\RB\1740 be\VB\836236 determined\VBN\1645601 from\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 relationship\NN\31921 between\IN\1740 higher\JJR\1740 serum\NN\5397468 <e1>phosphate</e1>\NN\15010703 and\CC\1740 susceptibility\NN\13920835 to\TO\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 ,\,\1740 with\IN\1740 30\CD\13745420 %\NN\1740 higher\JJR\1740 levels\NNS\4916342 of\IN\1740 serum\NN\5397468 phosphate\NN\15010703 in\IN\13603305 young\JJ\1740 ,\,\1740 ad\NN\7247071 libitum-fed\JJ\1740 rats\NNS\2329401 compared\VBN\644583 with\IN\1740 either\DT\1740 of\IN\1740 the\DT\1740 groups\NNS\2137 that\WDT\1740 was\VBD\836236 resistant\JJ\1740 to\TO\1740 Warfarin-induced\JJ\1740 artery\NN\5417975 calcification\NN\13446390 ,\,\1740 ie\FW\1740 ,\,\1740 the\DT\1740 10-month-old\JJ\1740 rats\NNS\2329401 and\CC\1740 the\DT\1740 restricted-diet\JJ\1740 ,\,\1740 growth-inhibited\JJ\1740 young\JJ\1740 rats\NNS\2329401 .\.\1740
D010710_D061205 NONE Although\IN\1740 the\DT\1740 explanation\NN\6722453 for\IN\1740 the\DT\1740 association\NN\8008335 between\IN\1740 artery\NN\5417975 calcification\NN\13446390 and\CC\1740 growth\NN\13526110 status\NN\24720 can\MD\3094503 not\RB\1740 be\VB\836236 determined\VBN\1645601 from\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 relationship\NN\31921 between\IN\1740 higher\JJR\1740 serum\NN\5397468 <e1>phosphate</e1>\NN\15010703 and\CC\1740 susceptibility\NN\13920835 to\TO\1740 artery\NN\5417975 calcification\NN\13446390 ,\,\1740 with\IN\1740 30\CD\13745420 %\NN\1740 higher\JJR\1740 levels\NNS\4916342 of\IN\1740 serum\NN\5397468 phosphate\NN\15010703 in\IN\13603305 young\JJ\1740 ,\,\1740 ad\NN\7247071 libitum-fed\JJ\1740 rats\NNS\2329401 compared\VBN\644583 with\IN\1740 either\DT\1740 of\IN\1740 the\DT\1740 groups\NNS\2137 that\WDT\1740 was\VBD\836236 resistant\JJ\1740 to\TO\1740 Warfarin-induced\JJ\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 ,\,\1740 ie\FW\1740 ,\,\1740 the\DT\1740 10-month-old\JJ\1740 rats\NNS\2329401 and\CC\1740 the\DT\1740 restricted-diet\JJ\1740 ,\,\1740 growth-inhibited\JJ\1740 young\JJ\1740 rats\NNS\2329401 .\.\1740
D010710_D061205 NONE Although\IN\1740 the\DT\1740 explanation\NN\6722453 for\IN\1740 the\DT\1740 association\NN\8008335 between\IN\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 and\CC\1740 growth\NN\13526110 status\NN\24720 can\MD\3094503 not\RB\1740 be\VB\836236 determined\VBN\1645601 from\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 relationship\NN\31921 between\IN\1740 higher\JJR\1740 serum\NN\5397468 phosphate\NN\15010703 and\CC\1740 susceptibility\NN\13920835 to\TO\1740 artery\NN\5417975 calcification\NN\13446390 ,\,\1740 with\IN\1740 30\CD\13745420 %\NN\1740 higher\JJR\1740 levels\NNS\4916342 of\IN\1740 serum\NN\5397468 <e1>phosphate</e1>\NN\15010703 in\IN\13603305 young\JJ\1740 ,\,\1740 ad\NN\7247071 libitum-fed\JJ\1740 rats\NNS\2329401 compared\VBN\644583 with\IN\1740 either\DT\1740 of\IN\1740 the\DT\1740 groups\NNS\2137 that\WDT\1740 was\VBD\836236 resistant\JJ\1740 to\TO\1740 Warfarin-induced\JJ\1740 artery\NN\5417975 calcification\NN\13446390 ,\,\1740 ie\FW\1740 ,\,\1740 the\DT\1740 10-month-old\JJ\1740 rats\NNS\2329401 and\CC\1740 the\DT\1740 restricted-diet\JJ\1740 ,\,\1740 growth-inhibited\JJ\1740 young\JJ\1740 rats\NNS\2329401 .\.\1740
D010710_D061205 NONE Although\IN\1740 the\DT\1740 explanation\NN\6722453 for\IN\1740 the\DT\1740 association\NN\8008335 between\IN\1740 artery\NN\5417975 calcification\NN\13446390 and\CC\1740 growth\NN\13526110 status\NN\24720 can\MD\3094503 not\RB\1740 be\VB\836236 determined\VBN\1645601 from\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 relationship\NN\31921 between\IN\1740 higher\JJR\1740 serum\NN\5397468 phosphate\NN\15010703 and\CC\1740 susceptibility\NN\13920835 to\TO\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 ,\,\1740 with\IN\1740 30\CD\13745420 %\NN\1740 higher\JJR\1740 levels\NNS\4916342 of\IN\1740 serum\NN\5397468 <e1>phosphate</e1>\NN\15010703 in\IN\13603305 young\JJ\1740 ,\,\1740 ad\NN\7247071 libitum-fed\JJ\1740 rats\NNS\2329401 compared\VBN\644583 with\IN\1740 either\DT\1740 of\IN\1740 the\DT\1740 groups\NNS\2137 that\WDT\1740 was\VBD\836236 resistant\JJ\1740 to\TO\1740 Warfarin-induced\JJ\1740 artery\NN\5417975 calcification\NN\13446390 ,\,\1740 ie\FW\1740 ,\,\1740 the\DT\1740 10-month-old\JJ\1740 rats\NNS\2329401 and\CC\1740 the\DT\1740 restricted-diet\JJ\1740 ,\,\1740 growth-inhibited\JJ\1740 young\JJ\1740 rats\NNS\2329401 .\.\1740
D010710_D061205 NONE Although\IN\1740 the\DT\1740 explanation\NN\6722453 for\IN\1740 the\DT\1740 association\NN\8008335 between\IN\1740 artery\NN\5417975 calcification\NN\13446390 and\CC\1740 growth\NN\13526110 status\NN\24720 can\MD\3094503 not\RB\1740 be\VB\836236 determined\VBN\1645601 from\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 relationship\NN\31921 between\IN\1740 higher\JJR\1740 serum\NN\5397468 phosphate\NN\15010703 and\CC\1740 susceptibility\NN\13920835 to\TO\1740 artery\NN\5417975 calcification\NN\13446390 ,\,\1740 with\IN\1740 30\CD\13745420 %\NN\1740 higher\JJR\1740 levels\NNS\4916342 of\IN\1740 serum\NN\5397468 <e1>phosphate</e1>\NN\15010703 in\IN\13603305 young\JJ\1740 ,\,\1740 ad\NN\7247071 libitum-fed\JJ\1740 rats\NNS\2329401 compared\VBN\644583 with\IN\1740 either\DT\1740 of\IN\1740 the\DT\1740 groups\NNS\2137 that\WDT\1740 was\VBD\836236 resistant\JJ\1740 to\TO\1740 Warfarin-induced\JJ\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 ,\,\1740 ie\FW\1740 ,\,\1740 the\DT\1740 10-month-old\JJ\1740 rats\NNS\2329401 and\CC\1740 the\DT\1740 restricted-diet\JJ\1740 ,\,\1740 growth-inhibited\JJ\1740 young\JJ\1740 rats\NNS\2329401 .\.\1740
D010710_D061205 NONE This\DT\1740 observation\NN\996969 suggests\VBZ\1010118 that\IN\1740 increased\VBN\169651 susceptibility\NN\13920835 to\TO\1740 Warfarin-induced\JJ\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 could\MD\1740 be\VB\836236 related\JJ\1740 to\TO\1740 higher\JJR\1740 serum\NN\5397468 <e1>phosphate</e1>\NN\15010703 levels\NNS\4916342 .\.\1740
D014812_D061205 NONE High\JJ\1740 doses\NNS\3740161 of\IN\1740 the\DT\1740 <e1>vitamin\NN\7570720 K</e1>\NN\13608598 antagonist\NN\7846 Warfarin\NN\2718259 are\VBP\836236 also\RB\1740 known\VBN\2110220 to\TO\1740 cause\VB\1617192 <e2>calcification\NN\13446390 of\IN\1740 the\DT\1740 artery</e2>\NN\5417975 media\NNS\3575240 ,\,\1740 but\CC\1740 at\IN\14622893 treatment\NN\654885 times\NNS\15113229 of\IN\1740 2\CD\13741022 weeks\NNS\15113229 or\CC\3541091 longer\RBR\1740 yet\CC\1740 not\RB\1740 at\IN\14622893 1\CD\13741022 week\NN\15113229 .\.\1740
D002118_D061205 NONE There\EX\27167 was\VBD\836236 a\DT\13649268 close\JJ\1740 parallel\NN\4743605 between\IN\1740 the\DT\1740 effect\NN\34213 of\IN\1740 vitamin\NN\7570720 D\NN\15089472 dose\NN\3740161 on\IN\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 and\CC\1740 the\DT\1740 effect\NN\34213 of\IN\1740 vitamin\NN\7570720 D\NN\15089472 dose\NN\3740161 on\IN\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 serum\NN\5397468 <e1>calcium</e1>\NN\14625458 ,\,\1740 which\WDT\1740 suggests\VBZ\1010118 that\IN\1740 vitamin\NN\7570720 D\NN\15089472 may\MD\15209706 induce\VB\1627355 artery\NN\5417975 calcification\NN\13446390 through\IN\1740 its\PRP$\6125041 effect\NN\34213 on\IN\1740 serum\NN\5397468 calcium\NN\14625458 .\.\1740
D002118_D061205 NONE There\EX\27167 was\VBD\836236 a\DT\13649268 close\JJ\1740 parallel\NN\4743605 between\IN\1740 the\DT\1740 effect\NN\34213 of\IN\1740 vitamin\NN\7570720 D\NN\15089472 dose\NN\3740161 on\IN\1740 artery\NN\5417975 calcification\NN\13446390 and\CC\1740 the\DT\1740 effect\NN\34213 of\IN\1740 vitamin\NN\7570720 D\NN\15089472 dose\NN\3740161 on\IN\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 serum\NN\5397468 <e1>calcium</e1>\NN\14625458 ,\,\1740 which\WDT\1740 suggests\VBZ\1010118 that\IN\1740 vitamin\NN\7570720 D\NN\15089472 may\MD\15209706 induce\VB\1627355 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 through\IN\1740 its\PRP$\6125041 effect\NN\34213 on\IN\1740 serum\NN\5397468 calcium\NN\14625458 .\.\1740
D002118_D061205 NONE There\EX\27167 was\VBD\836236 a\DT\13649268 close\JJ\1740 parallel\NN\4743605 between\IN\1740 the\DT\1740 effect\NN\34213 of\IN\1740 vitamin\NN\7570720 D\NN\15089472 dose\NN\3740161 on\IN\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 and\CC\1740 the\DT\1740 effect\NN\34213 of\IN\1740 vitamin\NN\7570720 D\NN\15089472 dose\NN\3740161 on\IN\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 serum\NN\5397468 calcium\NN\14625458 ,\,\1740 which\WDT\1740 suggests\VBZ\1010118 that\IN\1740 vitamin\NN\7570720 D\NN\15089472 may\MD\15209706 induce\VB\1627355 artery\NN\5417975 calcification\NN\13446390 through\IN\1740 its\PRP$\6125041 effect\NN\34213 on\IN\1740 serum\NN\5397468 <e1>calcium</e1>\NN\14625458 .\.\1740
D002118_D061205 NONE There\EX\27167 was\VBD\836236 a\DT\13649268 close\JJ\1740 parallel\NN\4743605 between\IN\1740 the\DT\1740 effect\NN\34213 of\IN\1740 vitamin\NN\7570720 D\NN\15089472 dose\NN\3740161 on\IN\1740 artery\NN\5417975 calcification\NN\13446390 and\CC\1740 the\DT\1740 effect\NN\34213 of\IN\1740 vitamin\NN\7570720 D\NN\15089472 dose\NN\3740161 on\IN\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 serum\NN\5397468 calcium\NN\14625458 ,\,\1740 which\WDT\1740 suggests\VBZ\1010118 that\IN\1740 vitamin\NN\7570720 D\NN\15089472 may\MD\15209706 induce\VB\1627355 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 through\IN\1740 its\PRP$\6125041 effect\NN\34213 on\IN\1740 serum\NN\5397468 <e1>calcium</e1>\NN\14625458 .\.\1740
D002118_D002114 NONE Because\IN\1740 Warfarin\NN\2718259 treatment\NN\654885 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 the\DT\1740 elevation\NN\7445480 in\IN\13603305 serum\NN\5397468 <e1>calcium</e1>\NN\14625458 produced\VBN\1617192 by\IN\1740 vitamin\NN\7570720 D\NN\15089472 ,\,\1740 the\DT\1740 synergy\NN\13518963 between\IN\1740 Warfarin\NN\2718259 and\CC\1740 vitamin\NN\7570720 D\NN\15089472 is\VBZ\836236 probably\RB\1740 best\RBS\1740 explained\VBN\831651 by\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 Warfarin\NN\2718259 inhibits\VBZ\2510337 the\DT\1740 activity\NN\30358 of\IN\1740 matrix\NN\7939382 Gla\NN\1740 protein\NN\14944888 as\IN\14622893 a\DT\13649268 <e2>calcification</e2>\NN\13446390 inhibitor\NN\20090 .\.\1740
D015055_D061205 NONE High\JJ\1740 levels\NNS\4916342 of\IN\1740 matrix\NN\7939382 Gla\NN\1740 protein\NN\14944888 are\VBP\836236 found\VBN\2426171 at\IN\14622893 sites\NNS\8673395 of\IN\1740 <e2>artery\NN\5417975 calcification</e2>\NN\13446390 in\IN\13603305 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 vitamin\NN\7570720 D\NN\15089472 plus\CC\4723816 Warfarin\NN\2718259 ,\,\1740 and\CC\1740 chemical\NN\14580897 analysis\NN\633864 showed\VBD\2137132 that\IN\1740 the\DT\1740 protein\NN\14944888 that\WDT\1740 accumulated\VBN\2281093 was\VBD\836236 indeed\RB\1740 not\RB\1740 <e1>gamma-carboxylated</e1>\JJ\1740 .\.\1740
D015055_D002114 NONE These\DT\1740 observations\NNS\996969 indicate\VBP\952524 that\IN\1740 although\IN\1740 the\DT\1740 <e1>gamma-carboxyglutamate</e1>\JJ\1740 residues\NNS\20827 of\IN\1740 matrix\NN\7939382 Gla\NN\1740 protein\NN\14944888 are\VBP\836236 apparently\RB\1740 required\VBN\754942 for\IN\1740 its\PRP$\6125041 function\NN\13783581 as\IN\14622893 a\DT\13649268 <e2>calcification</e2>\NN\13446390 inhibitor\NN\20090 ,\,\1740 they\PRP\1740 are\VBP\836236 not\RB\1740 required\VBN\754942 for\IN\1740 its\PRP$\6125041 accumulation\NN\13497135 at\IN\14622893 calcification\NN\13446390 sites\NNS\8673395 .\.\1740
D015055_D002114 NONE These\DT\1740 observations\NNS\996969 indicate\VBP\952524 that\IN\1740 although\IN\1740 the\DT\1740 <e1>gamma-carboxyglutamate</e1>\JJ\1740 residues\NNS\20827 of\IN\1740 matrix\NN\7939382 Gla\NN\1740 protein\NN\14944888 are\VBP\836236 apparently\RB\1740 required\VBN\754942 for\IN\1740 its\PRP$\6125041 function\NN\13783581 as\IN\14622893 a\DT\13649268 calcification\NN\13446390 inhibitor\NN\20090 ,\,\1740 they\PRP\1740 are\VBP\836236 not\RB\1740 required\VBN\754942 for\IN\1740 its\PRP$\6125041 accumulation\NN\13497135 at\IN\14622893 <e2>calcification</e2>\NN\13446390 sites\NNS\8673395 .\.\1740
18004067
D000431_D017114 NONE <e2>Acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 in\IN\13603305 two\CD\13741022 patients\NNS\9898892 with\IN\1740 regular\JJ\1740 <e1>alcohol</e1>\NN\7881800 consumption\NN\13440063 ingesting\VBG\597915 paracetamol\NN\1740 at\IN\14622893 therapeutic\JJ\1740 dosage\NN\13576355 .\.\1740
D000082_D017114 NONE <e2>Acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 in\IN\13603305 two\CD\13741022 patients\NNS\9898892 with\IN\1740 regular\JJ\1740 alcohol\NN\7881800 consumption\NN\13440063 ingesting\VBG\597915 <e1>paracetamol</e1>\NN\1740 at\IN\14622893 therapeutic\JJ\1740 dosage\NN\13576355 .\.\1740
D000431_D056486 NONE BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 possible\JJ\1740 role\NN\719494 of\IN\1740 <e1>alcohol</e1>\NN\7881800 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>hepatotoxicity</e2>\NN\1740 associated\VBN\628491 with\IN\1740 therapeutic\JJ\1740 doses\NNS\3740161 of\IN\1740 paracetamol\NN\1740 (\-LRB-\1740 acetaminophen\RB\1740 )\-RRB-\1740 is\VBZ\836236 currently\RB\1740 debated\VBN\813044 .\.\1740
D000082_D056486 CID BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 possible\JJ\1740 role\NN\719494 of\IN\1740 alcohol\NN\7881800 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>hepatotoxicity</e2>\NN\1740 associated\VBN\628491 with\IN\1740 therapeutic\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>paracetamol</e1>\NN\1740 (\-LRB-\1740 acetaminophen\RB\1740 )\-RRB-\1740 is\VBZ\836236 currently\RB\1740 debated\VBN\813044 .\.\1740
D000082_D056486 CID BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 possible\JJ\1740 role\NN\719494 of\IN\1740 alcohol\NN\7881800 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>hepatotoxicity</e2>\NN\1740 associated\VBN\628491 with\IN\1740 therapeutic\JJ\1740 doses\NNS\3740161 of\IN\1740 paracetamol\NN\1740 (\-LRB-\1740 <e1>acetaminophen</e1>\RB\1740 )\-RRB-\1740 is\VBZ\836236 currently\RB\1740 debated\VBN\813044 .\.\1740
D000082_D056486 CID Possible\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>hepatotoxicity</e2>\NN\1740 in\IN\13603305 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 therapeutic\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>paracetamol</e1>\NN\1740 are\VBP\836236 discussed\VBN\1033527 .\.\1740
D000431_D017093 NONE CASE\NN\7283608 REPORT\NN\6470073 :\:\1740 We\PRP\1740 describe\VBP\1001294 2\CD\13741022 patients\NNS\9898892 who\WP\8299493 were\VBD\836236 regular\JJ\1740 consumers\NNS\10741590 of\IN\1740 <e1>alcohol</e1>\NN\7881800 and\CC\1740 who\WP\8299493 developed\VBD\1753788 <e2>liver\NN\5298729 failure</e2>\NN\66216 within\IN\1740 3\CD\13741022 -\SYM\1740 5\CD\13741022 days\NNS\15140892 after\IN\1740 hospitalization\NN\15113229 and\CC\1740 stopping\VBG\2452885 alcohol\NN\7881800 consumption\NN\13440063 while\IN\15122231 being\VBG\836236 treated\VBN\2376958 with\IN\1740 4\CD\13741022 g\NN\13717155 paracetamol/day\NN\1740 .\.\1740
D000431_D017093 NONE CASE\NN\7283608 REPORT\NN\6470073 :\:\1740 We\PRP\1740 describe\VBP\1001294 2\CD\13741022 patients\NNS\9898892 who\WP\8299493 were\VBD\836236 regular\JJ\1740 consumers\NNS\10741590 of\IN\1740 alcohol\NN\7881800 and\CC\1740 who\WP\8299493 developed\VBD\1753788 <e2>liver\NN\5298729 failure</e2>\NN\66216 within\IN\1740 3\CD\13741022 -\SYM\1740 5\CD\13741022 days\NNS\15140892 after\IN\1740 hospitalization\NN\15113229 and\CC\1740 stopping\VBG\2452885 <e1>alcohol</e1>\NN\7881800 consumption\NN\13440063 while\IN\15122231 being\VBG\836236 treated\VBN\2376958 with\IN\1740 4\CD\13741022 g\NN\13717155 paracetamol/day\NN\1740 .\.\1740
D000431_D017093 NONE CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 patients\NNS\9898892 with\IN\1740 risk\NN\14541044 factors\NNS\7326557 ,\,\1740 e.g.\FW\1740 regular\JJ\1740 consumption\NN\13440063 of\IN\1740 <e1>alcohol</e1>\NN\7881800 ,\,\1740 <e2>liver\NN\5298729 failure</e2>\NN\66216 is\VBZ\836236 possible\JJ\1740 when\WRB\1740 therapeutic\JJ\1740 doses\NNS\3740161 are\VBP\836236 ingested\VBN\597915 .\.\1740
D000082_D017093 CID CASE\NN\7283608 REPORT\NN\6470073 :\:\1740 We\PRP\1740 describe\VBP\1001294 2\CD\13741022 patients\NNS\9898892 who\WP\8299493 were\VBD\836236 regular\JJ\1740 consumers\NNS\10741590 of\IN\1740 alcohol\NN\7881800 and\CC\1740 who\WP\8299493 developed\VBD\1753788 <e2>liver\NN\5298729 failure</e2>\NN\66216 within\IN\1740 3\CD\13741022 -\SYM\1740 5\CD\13741022 days\NNS\15140892 after\IN\1740 hospitalization\NN\15113229 and\CC\1740 stopping\VBG\2452885 alcohol\NN\7881800 consumption\NN\13440063 while\IN\15122231 being\VBG\836236 treated\VBN\2376958 with\IN\1740 4\CD\13741022 g\NN\13717155 <e1>paracetamol/day</e1>\NN\1740 .\.\1740
17439425
D019820_D006973 NONE Role\NN\719494 of\IN\1740 <e1>xanthine</e1>\NN\14727670 oxidase\NN\14732946 in\IN\13603305 dexamethasone-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 rats\NNS\2329401 .\.\1740
D019820_D006973 NONE 2\LS\13741022 .\.\1740 We\PRP\1740 studied\VBD\630380 the\DT\1740 role\NN\719494 of\IN\1740 <e1>xanthine</e1>\NN\14727670 oxidase\NN\14732946 (\-LRB-\1740 XO\NN\1740 )\-RRB-\1740 ,\,\1740 which\WDT\1740 is\VBZ\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 production\NN\30358 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 ,\,\1740 in\IN\13603305 dexamethasone-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 (\-LRB-\1740 dex-HT\NNS\1740 )\-RRB-\1740 .\.\1740
D019820_D006973 NONE 2\LS\13741022 .\.\1740 We\PRP\1740 studied\VBD\630380 the\DT\1740 role\NN\719494 of\IN\1740 <e1>xanthine</e1>\NN\14727670 oxidase\NN\14732946 (\-LRB-\1740 XO\NN\1740 )\-RRB-\1740 ,\,\1740 which\WDT\1740 is\VBZ\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 production\NN\30358 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 ,\,\1740 in\IN\13603305 dexamethasone-induced\JJ\1740 hypertension\NN\14057371 (\-LRB-\1740 <e2>dex-HT</e2>\NNS\1740 )\-RRB-\1740 .\.\1740
D003907_D006973 CID Role\NN\719494 of\IN\1740 xanthine\NN\14727670 oxidase\NN\14732946 in\IN\13603305 <e1>dexamethasone-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 rats\NNS\2329401 .\.\1740
D003907_D006973 CID 2\LS\13741022 .\.\1740 We\PRP\1740 studied\VBD\630380 the\DT\1740 role\NN\719494 of\IN\1740 xanthine\NN\14727670 oxidase\NN\14732946 (\-LRB-\1740 XO\NN\1740 )\-RRB-\1740 ,\,\1740 which\WDT\1740 is\VBZ\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 production\NN\30358 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 ,\,\1740 in\IN\13603305 <e1>dexamethasone-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 (\-LRB-\1740 dex-HT\NNS\1740 )\-RRB-\1740 .\.\1740
D003907_D006973 CID 2\LS\13741022 .\.\1740 We\PRP\1740 studied\VBD\630380 the\DT\1740 role\NN\719494 of\IN\1740 xanthine\NN\14727670 oxidase\NN\14732946 (\-LRB-\1740 XO\NN\1740 )\-RRB-\1740 ,\,\1740 which\WDT\1740 is\VBZ\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 production\NN\30358 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 ,\,\1740 in\IN\13603305 <e1>dexamethasone-induced</e1>\JJ\1740 hypertension\NN\14057371 (\-LRB-\1740 <e2>dex-HT</e2>\NNS\1740 )\-RRB-\1740 .\.\1740
D003907_D006973 CID 2\LS\13741022 .\.\1740 We\PRP\1740 studied\VBD\630380 the\DT\1740 role\NN\719494 of\IN\1740 xanthine\NN\14727670 oxidase\NN\14732946 (\-LRB-\1740 XO\NN\1740 )\-RRB-\1740 ,\,\1740 which\WDT\1740 is\VBZ\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 production\NN\30358 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 ,\,\1740 in\IN\13603305 dexamethasone-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 (\-LRB-\1740 <e1>dex-HT</e1>\NNS\1740 )\-RRB-\1740 .\.\1740
D003907_D006973 CID 2\LS\13741022 .\.\1740 We\PRP\1740 studied\VBD\630380 the\DT\1740 role\NN\719494 of\IN\1740 xanthine\NN\14727670 oxidase\NN\14732946 (\-LRB-\1740 XO\NN\1740 )\-RRB-\1740 ,\,\1740 which\WDT\1740 is\VBZ\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 production\NN\30358 of\IN\1740 reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 ,\,\1740 in\IN\13603305 dexamethasone-induced\JJ\1740 hypertension\NN\14057371 (\-LRB-\1740 <e2><e1>dex-HT</e1></e2>\NNS\1740 )\-RRB-\1740 .\.\1740
D003907_D006973 CID <e1>Dex</e1>\NN\1740 <e2>increased\VBD\169651 SBP</e2>\NN\1740 (\-LRB-\1740 110\CD\1740 +/-\CC\1740 2\CD\13741022 -\SYM\1740 126\CD\1740 +/-\CC\1740 3\CD\13741022 mmHg\NN\1740 ;\:\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 and\CC\1740 decreased\VBN\169651 thymus\NN\11579418 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 and\CC\1740 bodyweights\NNS\1740 (\-LRB-\1740 P\NN\14622893 "\''\1740 <\CD\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
D003907_D006973 CID 6\CD\13741022 .\.\1740 Allopurinol\NN\3740161 did\VBD\1640855 not\RB\1740 prevent\VB\1740 <e2><e1>dex-HT</e1></e2>\JJ\1740 .\.\1740
D009569_D006973 NONE 1\LS\13741022 .\.\1740 Glucocorticoid-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 (\-LRB-\1740 GC-HT\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 is\VBZ\836236 associated\VBN\628491 with\IN\1740 <e1>nitric\JJ\1740 oxide-redox</e1>\NN\1740 imbalance\NN\13934274 .\.\1740
D009569_D006973 NONE 1\LS\13741022 .\.\1740 Glucocorticoid-induced\JJ\1740 hypertension\NN\14057371 (\-LRB-\1740 <e2>GC-HT</e2>\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 is\VBZ\836236 associated\VBN\628491 with\IN\1740 <e1>nitric\JJ\1740 oxide-redox</e1>\NN\1740 imbalance\NN\13934274 .\.\1740
D003907_D015431 CID <e1>Dex</e1>\NN\1740 increased\VBD\169651 SBP\NN\1740 (\-LRB-\1740 110\CD\1740 +/-\CC\1740 2\CD\13741022 -\SYM\1740 126\CD\1740 +/-\CC\1740 3\CD\13741022 mmHg\NN\1740 ;\:\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 and\CC\1740 <e2>decreased\VBN\169651 thymus\NN\11579418 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 and\CC\1740 bodyweights</e2>\NNS\1740 (\-LRB-\1740 P\NN\14622893 "\''\1740 <\CD\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
D000493_D006973 NONE 6\CD\13741022 .\.\1740 <e1>Allopurinol</e1>\NN\3740161 did\VBD\1640855 not\RB\1740 prevent\VB\1740 <e2>dex-HT</e2>\JJ\1740 .\.\1740
D000493_D006973 NONE This\DT\1740 ,\,\1740 together\RB\1740 with\IN\1740 our\PRP$\1740 previous\JJ\1740 findings\NNS\7951464 that\IN\1740 <e1>allopurinol</e1>\NN\3740161 failed\VBD\1798936 to\TO\1740 prevent\VB\1740 adrenocorticotrophic\JJ\1740 hormone\NN\5404728 induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 suggests\VBZ\1010118 that\IN\1740 XO\NN\1740 activity\NN\30358 is\VBZ\836236 not\RB\1740 a\DT\13649268 major\JJ\1740 determinant\NN\5686481 of\IN\1740 GC-HT\NN\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D000493_D006973 NONE This\DT\1740 ,\,\1740 together\RB\1740 with\IN\1740 our\PRP$\1740 previous\JJ\1740 findings\NNS\7951464 that\IN\1740 <e1>allopurinol</e1>\NN\3740161 failed\VBD\1798936 to\TO\1740 prevent\VB\1740 adrenocorticotrophic\JJ\1740 hormone\NN\5404728 induced\JJ\1740 hypertension\NN\14057371 ,\,\1740 suggests\VBZ\1010118 that\IN\1740 XO\NN\1740 activity\NN\30358 is\VBZ\836236 not\RB\1740 a\DT\13649268 major\JJ\1740 determinant\NN\5686481 of\IN\1740 <e2>GC-HT</e2>\NN\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
18996674
D004837_D011317 NONE Intracavernous\JJ\1740 <e1>epinephrine</e1>\NN\14807929 :\:\1740 a\DT\13649268 minimally\RB\1740 invasive\JJ\1740 treatment\NN\654885 for\IN\1740 <e2>priapism</e2>\NN\14204950 in\IN\13603305 the\DT\1740 emergency\NN\7417644 department\NN\8220714 .\.\1740
D003042_D011317 CID A\DT\13649268 45-year-old\JJ\1740 man\NN\9605289 ,\,\1740 an\DT\6697703 admitted\VBN\822367 frequent\JJ\1740 <e1>cocaine</e1>\NN\3492717 user\NN\7846 ,\,\1740 presented\VBN\2137132 to\IN\1740 the\DT\1740 Emergency\NNP\7417644 Department\NNP\8220714 (\-LRB-\1740 ED\NNP\14557898 )\-RRB-\1740 on\IN\1740 two\CD\13741022 separate\JJ\1740 occasions\NNS\5983801 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e2>priapism</e2>\NN\14204950 after\IN\1740 cocaine\NN\3492717 use\NN\407535 .\.\1740
D003042_D011317 CID A\DT\13649268 45-year-old\JJ\1740 man\NN\9605289 ,\,\1740 an\DT\6697703 admitted\VBN\822367 frequent\JJ\1740 cocaine\NN\3492717 user\NN\7846 ,\,\1740 presented\VBN\2137132 to\IN\1740 the\DT\1740 Emergency\NNP\7417644 Department\NNP\8220714 (\-LRB-\1740 ED\NNP\14557898 )\-RRB-\1740 on\IN\1740 two\CD\13741022 separate\JJ\1740 occasions\NNS\5983801 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e2>priapism</e2>\NN\14204950 after\IN\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 .\.\1740
9653867
D013974_D013971 CID <e1>Thyroxine</e1>\JJ\1740 abuse\NN\418025 :\:\1740 an\DT\6697703 unusual\JJ\1740 case\NN\7283608 of\IN\1740 <e2>thyrotoxicosis</e2>\NN\14059928 in\IN\13603305 pregnancy\NN\14034177 .\.\1740
D013974_D013971 CID In\IN\13603305 particular\JJ\1740 it\PRP\6125041 illustrates\VBZ\955601 the\DT\1740 derangements\NNS\14395018 of\IN\1740 thyroid\NN\5329735 function\NN\13783581 seen\VBN\2106506 in\IN\13603305 pregnant\JJ\1740 women\NNS\9605289 with\IN\1740 eating\VBG\1156834 disorders\NNS\14034177 and\CC\1740 reminds\VBZ\831651 us\PRP\14964590 that\IN\1740 when\WRB\1740 a\DT\13649268 cause\NN\7323922 for\IN\1740 <e2>thyrotoxicosis</e2>\NN\14059928 remains\VBZ\2604760 obscure\JJ\1740 ,\,\1740 <e1>thyroxine</e1>\JJ\1740 abuse\NN\418025 should\MD\1740 be\VB\836236 considered\VBN\689344 and\CC\1740 explored\VBN\789138 .\.\1740
D013974_D001068 NONE In\IN\13603305 particular\JJ\1740 it\PRP\6125041 illustrates\VBZ\955601 the\DT\1740 derangements\NNS\14395018 of\IN\1740 thyroid\NN\5329735 function\NN\13783581 seen\VBN\2106506 in\IN\13603305 pregnant\JJ\1740 women\NNS\9605289 with\IN\1740 <e2>eating\VBG\1156834 disorders</e2>\NNS\14034177 and\CC\1740 reminds\VBZ\831651 us\PRP\14964590 that\IN\1740 when\WRB\1740 a\DT\13649268 cause\NN\7323922 for\IN\1740 thyrotoxicosis\NN\14059928 remains\VBZ\2604760 obscure\JJ\1740 ,\,\1740 <e1>thyroxine</e1>\JJ\1740 abuse\NN\418025 should\MD\1740 be\VB\836236 considered\VBN\689344 and\CC\1740 explored\VBN\789138 .\.\1740
2348231
D010431_D006940 NONE <e1>Pentoxifylline</e1>\NN\3247620 (\-LRB-\1740 Trental\JJ\1740 )\-RRB-\1740 does\VBZ\1640855 not\RB\1740 inhibit\VB\2510337 dipyridamole-induced\JJ\1740 coronary\JJ\1740 <e2>hyperemia</e2>\NN\14320394 :\:\1740 implications\NNS\5774614 for\IN\1740 dipyridamole-thallium-201\JJ\1740 myocardial\JJ\1740 imaging\NN\5765159 .\.\1740
D010431_D006940 NONE Pentoxifylline\NN\3247620 (\-LRB-\1740 <e1>Trental</e1>\JJ\1740 )\-RRB-\1740 does\VBZ\1640855 not\RB\1740 inhibit\VB\2510337 dipyridamole-induced\JJ\1740 coronary\JJ\1740 <e2>hyperemia</e2>\NN\14320394 :\:\1740 implications\NNS\5774614 for\IN\1740 dipyridamole-thallium-201\JJ\1740 myocardial\JJ\1740 imaging\NN\5765159 .\.\1740
D010431_D006940 NONE Whether\IN\1740 <e1>pentoxifylline</e1>\NN\3247620 inhibits\VBZ\2510337 dipyridamole-induced\JJ\1740 coronary\JJ\1740 <e2>hyperemia</e2>\NN\14320394 like\IN\5839024 other\JJ\1740 methylxanthines\NNS\1740 such\JJ\1740 as\IN\14622893 theophylline\NN\2905612 and\CC\1740 should\MD\1740 be\VB\836236 stopped\VBN\2452885 prior\RB\1740 to\IN\1740 dipyridamole-thallium-201\NN\1740 imaging\NN\5765159 is\VBZ\836236 unknown\JJ\1740 .\.\1740
D010431_D006940 NONE Neither\DT\1740 dose\NN\3740161 of\IN\1740 <e1>pentoxifylline</e1>\NN\3247620 significantly\RB\1740 decreased\VBD\169651 the\DT\1740 dipyridamole-induced\JJ\1740 <e2>hyperemia</e2>\NN\14320394 ,\,\1740 while\IN\15122231 peak\JJ\1740 coronary\JJ\1740 blood\NN\5397468 flow\NN\7311115 was\VBD\836236 significantly\RB\1740 lower\JJR\1740 after\IN\1740 theophylline\NN\2905612 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
D010431_D006940 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 <e1>pentoxyifylline</e1>\NN\1740 does\VBZ\1640855 not\RB\1740 inhibit\VB\2510337 dipyridamole-induced\JJ\1740 coronary\JJ\1740 <e2>hyperemia</e2>\NN\14320394 even\RB\1740 at\IN\14622893 high\JJ\1740 doses\NNS\3740161 .\.\1740
D004176_D006940 CID Pentoxifylline\NN\3247620 (\-LRB-\1740 Trental\JJ\1740 )\-RRB-\1740 does\VBZ\1640855 not\RB\1740 inhibit\VB\2510337 <e1>dipyridamole-induced</e1>\JJ\1740 coronary\JJ\1740 <e2>hyperemia</e2>\NN\14320394 :\:\1740 implications\NNS\5774614 for\IN\1740 dipyridamole-thallium-201\JJ\1740 myocardial\JJ\1740 imaging\NN\5765159 .\.\1740
D004176_D006940 CID Pentoxifylline\NN\3247620 (\-LRB-\1740 Trental\JJ\1740 )\-RRB-\1740 does\VBZ\1640855 not\RB\1740 inhibit\VB\2510337 dipyridamole-induced\JJ\1740 coronary\JJ\1740 <e2>hyperemia</e2>\NN\14320394 :\:\1740 implications\NNS\5774614 for\IN\1740 <e1>dipyridamole-thallium-201</e1>\JJ\1740 myocardial\JJ\1740 imaging\NN\5765159 .\.\1740
D004176_D006940 CID Whether\IN\1740 pentoxifylline\NN\3247620 inhibits\VBZ\2510337 <e1>dipyridamole-induced</e1>\JJ\1740 coronary\JJ\1740 <e2>hyperemia</e2>\NN\14320394 like\IN\5839024 other\JJ\1740 methylxanthines\NNS\1740 such\JJ\1740 as\IN\14622893 theophylline\NN\2905612 and\CC\1740 should\MD\1740 be\VB\836236 stopped\VBN\2452885 prior\RB\1740 to\IN\1740 dipyridamole-thallium-201\NN\1740 imaging\NN\5765159 is\VBZ\836236 unknown\JJ\1740 .\.\1740
D004176_D006940 CID Whether\IN\1740 pentoxifylline\NN\3247620 inhibits\VBZ\2510337 dipyridamole-induced\JJ\1740 coronary\JJ\1740 <e2>hyperemia</e2>\NN\14320394 like\IN\5839024 other\JJ\1740 methylxanthines\NNS\1740 such\JJ\1740 as\IN\14622893 theophylline\NN\2905612 and\CC\1740 should\MD\1740 be\VB\836236 stopped\VBN\2452885 prior\RB\1740 to\IN\1740 <e1>dipyridamole-thallium-201</e1>\NN\1740 imaging\NN\5765159 is\VBZ\836236 unknown\JJ\1740 .\.\1740
D004176_D006940 CID Neither\DT\1740 dose\NN\3740161 of\IN\1740 pentoxifylline\NN\3247620 significantly\RB\1740 decreased\VBD\169651 the\DT\1740 <e1>dipyridamole-induced</e1>\JJ\1740 <e2>hyperemia</e2>\NN\14320394 ,\,\1740 while\IN\15122231 peak\JJ\1740 coronary\JJ\1740 blood\NN\5397468 flow\NN\7311115 was\VBD\836236 significantly\RB\1740 lower\JJR\1740 after\IN\1740 theophylline\NN\2905612 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
D004176_D006940 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 pentoxyifylline\NN\1740 does\VBZ\1640855 not\RB\1740 inhibit\VB\2510337 <e1>dipyridamole-induced</e1>\JJ\1740 coronary\JJ\1740 <e2>hyperemia</e2>\NN\14320394 even\RB\1740 at\IN\14622893 high\JJ\1740 doses\NNS\3740161 .\.\1740
D013793_D006940 NONE Pentoxifylline\NN\3247620 (\-LRB-\1740 Trental\JJ\1740 )\-RRB-\1740 does\VBZ\1640855 not\RB\1740 inhibit\VB\2510337 dipyridamole-induced\JJ\1740 coronary\JJ\1740 <e2>hyperemia</e2>\NN\14320394 :\:\1740 implications\NNS\5774614 for\IN\1740 <e1>dipyridamole-thallium-201</e1>\JJ\1740 myocardial\JJ\1740 imaging\NN\5765159 .\.\1740
D013793_D006940 NONE Whether\IN\1740 pentoxifylline\NN\3247620 inhibits\VBZ\2510337 dipyridamole-induced\JJ\1740 coronary\JJ\1740 <e2>hyperemia</e2>\NN\14320394 like\IN\5839024 other\JJ\1740 methylxanthines\NNS\1740 such\JJ\1740 as\IN\14622893 theophylline\NN\2905612 and\CC\1740 should\MD\1740 be\VB\836236 stopped\VBN\2452885 prior\RB\1740 to\IN\1740 <e1>dipyridamole-thallium-201</e1>\NN\1740 imaging\NN\5765159 is\VBZ\836236 unknown\JJ\1740 .\.\1740
D004176_D016491 NONE <e1>Dipyridamole-thallium-201</e1>\NN\1740 imaging\NN\5765159 is\VBZ\836236 often\RB\1740 performed\VBN\2367363 in\IN\13603305 patients\NNS\9898892 unable\JJ\1740 to\TO\1740 exercise\VB\1158872 because\IN\1740 of\IN\1740 <e2>peripheral\JJ\1740 vascular\JJ\1740 disease</e2>\NN\14061805 .\.\1740
D013793_D016491 NONE <e1>Dipyridamole-thallium-201</e1>\NN\1740 imaging\NN\5765159 is\VBZ\836236 often\RB\1740 performed\VBN\2367363 in\IN\13603305 patients\NNS\9898892 unable\JJ\1740 to\TO\1740 exercise\VB\1158872 because\IN\1740 of\IN\1740 <e2>peripheral\JJ\1740 vascular\JJ\1740 disease</e2>\NN\14061805 .\.\1740
D010431_D007383 CID Many\JJ\1740 of\IN\1740 these\DT\1740 patients\NNS\9898892 are\VBP\836236 taking\VBG\2367363 <e1>pentoxifylline</e1>\NN\3247620 (\-LRB-\1740 Trental\NNP\3247620 )\-RRB-\1740 ,\,\1740 a\DT\13649268 methylxanthine\NN\1740 derivative\NN\5802185 which\WDT\1740 may\MD\15209706 improve\VB\126264 <e2>intermittent\NN\1740 claudication</e2>\NN\14548913 .\.\1740
D010431_D007383 CID Many\JJ\1740 of\IN\1740 these\DT\1740 patients\NNS\9898892 are\VBP\836236 taking\VBG\2367363 pentoxifylline\NN\3247620 (\-LRB-\1740 <e1>Trental</e1>\NNP\3247620 )\-RRB-\1740 ,\,\1740 a\DT\13649268 methylxanthine\NN\1740 derivative\NN\5802185 which\WDT\1740 may\MD\15209706 improve\VB\126264 <e2>intermittent\NN\1740 claudication</e2>\NN\14548913 .\.\1740
C008514_D007383 NONE Many\JJ\1740 of\IN\1740 these\DT\1740 patients\NNS\9898892 are\VBP\836236 taking\VBG\2367363 pentoxifylline\NN\3247620 (\-LRB-\1740 Trental\NNP\3247620 )\-RRB-\1740 ,\,\1740 a\DT\13649268 <e1>methylxanthine</e1>\NN\1740 derivative\NN\5802185 which\WDT\1740 may\MD\15209706 improve\VB\126264 <e2>intermittent\NN\1740 claudication</e2>\NN\14548913 .\.\1740
C008514_D006940 NONE Whether\IN\1740 pentoxifylline\NN\3247620 inhibits\VBZ\2510337 dipyridamole-induced\JJ\1740 coronary\JJ\1740 <e2>hyperemia</e2>\NN\14320394 like\IN\5839024 other\JJ\1740 <e1>methylxanthines</e1>\NNS\1740 such\JJ\1740 as\IN\14622893 theophylline\NN\2905612 and\CC\1740 should\MD\1740 be\VB\836236 stopped\VBN\2452885 prior\RB\1740 to\IN\1740 dipyridamole-thallium-201\NN\1740 imaging\NN\5765159 is\VBZ\836236 unknown\JJ\1740 .\.\1740
D013806_D006940 NONE Whether\IN\1740 pentoxifylline\NN\3247620 inhibits\VBZ\2510337 dipyridamole-induced\JJ\1740 coronary\JJ\1740 <e2>hyperemia</e2>\NN\14320394 like\IN\5839024 other\JJ\1740 methylxanthines\NNS\1740 such\JJ\1740 as\IN\14622893 <e1>theophylline</e1>\NN\2905612 and\CC\1740 should\MD\1740 be\VB\836236 stopped\VBN\2452885 prior\RB\1740 to\IN\1740 dipyridamole-thallium-201\NN\1740 imaging\NN\5765159 is\VBZ\836236 unknown\JJ\1740 .\.\1740
D013806_D006940 NONE Neither\DT\1740 dose\NN\3740161 of\IN\1740 pentoxifylline\NN\3247620 significantly\RB\1740 decreased\VBD\169651 the\DT\1740 dipyridamole-induced\JJ\1740 <e2>hyperemia</e2>\NN\14320394 ,\,\1740 while\IN\15122231 peak\JJ\1740 coronary\JJ\1740 blood\NN\5397468 flow\NN\7311115 was\VBD\836236 significantly\RB\1740 lower\JJR\1740 after\IN\1740 <e1>theophylline</e1>\NN\2905612 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 .\.\1740
10807237
D003042_D000783 NONE METHODS\NNS\5616786 :\:\1740 A\DT\13649268 review\NN\5733583 of\IN\1740 admissions\NNS\49003 during\IN\1740 a\DT\13649268 6-year\JJ\1740 period\NN\13575869 revealed\VBD\2137132 14\CD\13745420 patients\NNS\9898892 with\IN\1740 <e1>cocaine-related</e1>\JJ\1740 <e2>aneurysms</e2>\NNS\14057371 .\.\1740
D003042_D000783 NONE Hunt\NNP\8227214 and\CC\1740 Hess\NNP\1740 grade\NN\7975026 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.005\CD\1740 )\-RRB-\1740 and\CC\1740 age\NN\4916342 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.007\CD\1740 )\-RRB-\1740 were\VBD\836236 significant\JJ\1740 predictors\NNS\10756433 of\IN\1740 outcome\NN\7291312 for\IN\1740 the\DT\1740 patients\NNS\9898892 with\IN\1740 <e1>cocaine-related</e1>\JJ\1740 <e2>aneurysms</e2>\NNS\14057371 .\.\1740
D003042_D000783 NONE CONCLUSION\NN\5837957 :\:\1740 <e1>Cocaine</e1>\NN\3492717 use\VBP\1156834 predisposed\VBN\680841 aneurysmal\JJ\1740 rupture\NN\14285662 at\IN\14622893 a\DT\13649268 significantly\RB\1740 earlier\JJR\1740 age\NN\4916342 and\CC\1740 in\IN\13603305 much\RB\1740 smaller\JJR\1740 <e2>aneurysms</e2>\NNS\14057371 .\.\1740
D003042_D017542 CID CONCLUSION\NN\5837957 :\:\1740 <e1>Cocaine</e1>\NN\3492717 use\VBP\1156834 predisposed\VBN\680841 <e2>aneurysmal\JJ\1740 rupture</e2>\NN\14285662 at\IN\14622893 a\DT\13649268 significantly\RB\1740 earlier\JJR\1740 age\NN\4916342 and\CC\1740 in\IN\13603305 much\RB\1740 smaller\JJR\1740 aneurysms\NNS\14057371 .\.\1740
3865016
D005047_D054218 NONE A\DT\13649268 synergistic\JJ\1740 effect\NN\34213 of\IN\1740 <e1>etoposide</e1>\NN\1740 and\CC\1740 cyclosporin\NN\1740 A\NN\13649268 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>acute\JJ\1740 T-lymphocytic\JJ\1740 leukemia</e2>\NN\14239918 in\IN\13603305 relapse\NN\66636 .\.\1740
D016572_D054218 NONE A\DT\13649268 synergistic\JJ\1740 effect\NN\34213 of\IN\1740 etoposide\NN\1740 and\CC\1740 <e1>cyclosporin\NN\1740 A</e1>\NN\13649268 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>acute\JJ\1740 T-lymphocytic\JJ\1740 leukemia</e2>\NN\14239918 in\IN\13603305 relapse\NN\66636 .\.\1740
D005047_D017254 NONE The\DT\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>etoposide</e1>\NN\1740 and\CC\1740 cyclosporin\NN\1740 A\NN\13649268 resulted\VBD\2633881 in\IN\13603305 eradication\NN\7334490 of\IN\1740 hitherto\RB\1740 refractory\JJ\1740 <e2>leukemic\JJ\1740 infiltration</e2>\NN\975452 of\IN\1740 bone\NN\5286536 marrow\NN\5286536 .\.\1740
D016572_D017254 NONE The\DT\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 etoposide\NN\1740 and\CC\1740 <e1>cyclosporin\NN\1740 A</e1>\NN\13649268 resulted\VBD\2633881 in\IN\13603305 eradication\NN\7334490 of\IN\1740 hitherto\RB\1740 refractory\JJ\1740 <e2>leukemic\JJ\1740 infiltration</e2>\NN\975452 of\IN\1740 bone\NN\5286536 marrow\NN\5286536 .\.\1740
3192036
10791295
D001058_D010554 CID Development\NN\248977 of\IN\1740 <e1>apomorphine-induced</e1>\JJ\1740 <e2>aggressive\JJ\1740 behavior</e2>\NN\407535 :\:\1740 comparison\NN\635850 of\IN\1740 adult\JJ\1740 male\JJ\1740 and\CC\1740 female\NN\15388 Wistar\NNP\1740 rats\NNS\2329401 .\.\1740
D001058_D010554 CID The\DT\1740 development\NN\248977 of\IN\1740 <e1>apomorphine-induced</e1>\JJ\1740 (\-LRB-\1740 1.0\CD\1740 mg/kg\NN\1740 s.c.\NN\1740 once\RB\1740 daily\RB\1740 )\-RRB-\1740 <e2>aggressive\JJ\1740 behavior</e2>\NN\407535 of\IN\1740 adult\JJ\1740 male\JJ\1740 and\CC\1740 female\NN\15388 Wistar\NNP\1740 rats\NNS\2329401 obtained\VBN\2210855 from\IN\1740 the\DT\1740 same\JJ\1740 breeder\NN\10658501 was\VBD\836236 studied\VBN\630380 in\IN\13603305 two\CD\13741022 consecutive\JJ\1740 sets\NNS\7951464 .\.\1740
D001058_D010554 CID In\IN\13603305 male\JJ\1740 animals\NNS\4475 ,\,\1740 repeated\VBN\952524 <e1>apomorphine</e1>\NN\3786417 treatment\NN\654885 induced\VBD\1627355 a\DT\13649268 gradual\JJ\1740 development\NN\248977 of\IN\1740 <e2>aggressive\JJ\1740 behavior</e2>\NN\407535 as\IN\14622893 evidenced\VBN\1015244 by\IN\1740 the\DT\1740 increased\VBN\169651 intensity\NN\5090441 of\IN\1740 aggressiveness\NN\4835724 and\CC\1740 shortened\VBD\429060 latency\NN\15269513 before\IN\1740 the\DT\1740 first\JJ\1740 attack\NN\955060 toward\IN\1740 the\DT\1740 opponent\NN\9613191 .\.\1740
D001058_D010554 CID In\IN\13603305 male\JJ\1740 animals\NNS\4475 ,\,\1740 repeated\VBN\952524 <e1>apomorphine</e1>\NN\3786417 treatment\NN\654885 induced\VBD\1627355 a\DT\13649268 gradual\JJ\1740 development\NN\248977 of\IN\1740 aggressive\JJ\1740 behavior\NN\407535 as\IN\14622893 evidenced\VBN\1015244 by\IN\1740 the\DT\1740 increased\VBN\169651 intensity\NN\5090441 of\IN\1740 <e2>aggressiveness</e2>\NN\4835724 and\CC\1740 shortened\VBD\429060 latency\NN\15269513 before\IN\1740 the\DT\1740 first\JJ\1740 attack\NN\955060 toward\IN\1740 the\DT\1740 opponent\NN\9613191 .\.\1740
D001058_D010554 CID In\IN\13603305 conclusion\NN\5837957 ,\,\1740 the\DT\1740 present\JJ\1740 study\NN\635850 demonstrates\VBZ\2137132 gender\NN\6309383 differences\NNS\4723816 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 the\DT\1740 <e1>apomorphine-induced</e1>\JJ\1740 <e2>aggressive\JJ\1740 behavior</e2>\NN\407535 and\CC\1740 indicates\VBZ\952524 that\IN\1740 the\DT\1740 female\JJ\1740 rats\NNS\2329401 do\VBP\1640855 not\RB\1740 fill\VB\126264 the\DT\1740 validation\NN\151497 criteria\NNS\13577171 for\IN\1740 use\NN\407535 in\IN\13603305 this\DT\1740 method\NN\5616786 .\.\1740
1992636
D009853_D000743 CID <e2>Hemolytic\JJ\1740 anemia</e2>\NN\14189204 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>omeprazole</e1>\NN\14778019 .\.\1740
D009853_D000743 CID We\PRP\1740 report\VBP\831651 the\DT\1740 first\JJ\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 serious\JJ\1740 short-term\JJ\1740 adverse\JJ\1740 reaction\NN\13446390 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>omeprazole</e1>\NN\14778019 :\:\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 .\.\1740
D009853_D000743 CID The\DT\1740 mechanism\NN\13446390 by\IN\1740 which\WDT\1740 <e1>omeprazole</e1>\NN\14778019 caused\VBD\1617192 the\DT\1740 patient\NN\9898892 's\POS\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 is\VBZ\836236 uncertain\JJ\1740 ,\,\1740 but\CC\1740 physicians\NNS\10305802 should\MD\1740 be\VB\836236 alerted\VBN\870213 to\TO\1740 this\DT\1740 possible\JJ\1740 adverse\JJ\1740 effect\NN\34213 .\.\1740
D009853_D053609 CID The\DT\1740 patient\NN\9898892 developed\VBD\1753788 weakness\NN\14462666 ,\,\1740 <e2>lethargy</e2>\NN\14014621 ,\,\1740 and\CC\1740 shortness\NN\5129201 of\IN\1740 breath\NN\13440063 2\CD\13741022 days\NNS\15140892 after\IN\1740 starting\VBG\2009433 therapy\NN\657604 with\IN\1740 <e1>omeprazole</e1>\NN\14778019 .\.\1740
D009853_D004417 CID The\DT\1740 patient\NN\9898892 developed\VBD\1753788 weakness\NN\14462666 ,\,\1740 lethargy\NN\14014621 ,\,\1740 and\CC\1740 <e2>shortness\NN\5129201 of\IN\1740 breath</e2>\NN\13440063 2\CD\13741022 days\NNS\15140892 after\IN\1740 starting\VBG\2009433 therapy\NN\657604 with\IN\1740 <e1>omeprazole</e1>\NN\14778019 .\.\1740
9660111
D014299_D007035 NONE In\IN\13603305 the\DT\1740 acute\JJ\1740 experiment\NN\641820 <e1>TRI</e1>\NNP\1740 (\-LRB-\1740 given\VBN\2327200 i.p.\RB\1740 )\-RRB-\1740 does\VBZ\1640855 not\RB\1740 antagonize\VB\1787955 the\DT\1740 reserpine\NN\2721160 <e2>hypothermia</e2>\NN\14034177 in\IN\13603305 mice\NNS\2329401 and\CC\1740 does\VBZ\1640855 not\RB\1740 potentiate\VB\229605 the\DT\1740 5-hydroxytryptophan\JJ\1740 head\NN\5225090 twitches\VBZ\10054 in\IN\13603305 rats\NNS\2329401 .\.\1740
D012110_D007035 CID In\IN\13603305 the\DT\1740 acute\JJ\1740 experiment\NN\641820 TRI\NNP\1740 (\-LRB-\1740 given\VBN\2327200 i.p.\RB\1740 )\-RRB-\1740 does\VBZ\1640855 not\RB\1740 antagonize\VB\1787955 the\DT\1740 <e1>reserpine</e1>\NN\2721160 <e2>hypothermia</e2>\NN\14034177 in\IN\13603305 mice\NNS\2329401 and\CC\1740 does\VBZ\1640855 not\RB\1740 potentiate\VB\229605 the\DT\1740 5-hydroxytryptophan\JJ\1740 head\NN\5225090 twitches\VBZ\10054 in\IN\13603305 rats\NNS\2329401 .\.\1740
D006916_D007035 NONE In\IN\13603305 the\DT\1740 acute\JJ\1740 experiment\NN\641820 TRI\NNP\1740 (\-LRB-\1740 given\VBN\2327200 i.p.\RB\1740 )\-RRB-\1740 does\VBZ\1640855 not\RB\1740 antagonize\VB\1787955 the\DT\1740 reserpine\NN\2721160 <e2>hypothermia</e2>\NN\14034177 in\IN\13603305 mice\NNS\2329401 and\CC\1740 does\VBZ\1640855 not\RB\1740 potentiate\VB\229605 the\DT\1740 <e1>5-hydroxytryptophan</e1>\JJ\1740 head\NN\5225090 twitches\VBZ\10054 in\IN\13603305 rats\NNS\2329401 .\.\1740
D014299_D006948 CID <e1>TRI</e1>\NNP\1740 given\VBN\2327200 repeatedly\RB\1740 to\TO\1740 rats\NNS\2329401 increases\VBZ\169651 the\DT\1740 locomotor\NN\1740 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 d-amphetamine\NN\1740 ,\,\1740 quinpirole\NN\1740 and\CC\1740 (+)-7-hydroxy-dipropyloaminotetralin\NN\1740 (\-LRB-\1740 dopamine\NN\14807737 D2\NN\1740 and\CC\1740 D3\NN\1740 effects\NNS\13245626 )\-RRB-\1740 .\.\1740
D003913_D006948 CID TRI\NNP\1740 given\VBN\2327200 repeatedly\RB\1740 to\TO\1740 rats\NNS\2329401 increases\VBZ\169651 the\DT\1740 locomotor\NN\1740 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 <e1>d-amphetamine</e1>\NN\1740 ,\,\1740 quinpirole\NN\1740 and\CC\1740 (+)-7-hydroxy-dipropyloaminotetralin\NN\1740 (\-LRB-\1740 dopamine\NN\14807737 D2\NN\1740 and\CC\1740 D3\NN\1740 effects\NNS\13245626 )\-RRB-\1740 .\.\1740
D019257_D006948 CID TRI\NNP\1740 given\VBN\2327200 repeatedly\RB\1740 to\TO\1740 rats\NNS\2329401 increases\VBZ\169651 the\DT\1740 locomotor\NN\1740 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 d-amphetamine\NN\1740 ,\,\1740 <e1>quinpirole</e1>\NN\1740 and\CC\1740 (+)-7-hydroxy-dipropyloaminotetralin\NN\1740 (\-LRB-\1740 dopamine\NN\14807737 D2\NN\1740 and\CC\1740 D3\NN\1740 effects\NNS\13245626 )\-RRB-\1740 .\.\1740
D004298_D006948 NONE TRI\NNP\1740 given\VBN\2327200 repeatedly\RB\1740 to\TO\1740 rats\NNS\2329401 increases\VBZ\169651 the\DT\1740 locomotor\NN\1740 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 d-amphetamine\NN\1740 ,\,\1740 quinpirole\NN\1740 and\CC\1740 (+)-7-hydroxy-dipropyloaminotetralin\NN\1740 (\-LRB-\1740 <e1>dopamine</e1>\NN\14807737 D2\NN\1740 and\CC\1740 D3\NN\1740 effects\NNS\13245626 )\-RRB-\1740 .\.\1740
D010656_D010554 NONE It\PRP\6125041 increases\VBZ\169651 the\DT\1740 behaviour\NN\14006945 stimulation\NN\242808 evoked\VBN\1617192 by\IN\1740 <e1>phenylephrine</e1>\NN\2682038 (\-LRB-\1740 given\VBN\2327200 intraventricularly\NN\1740 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 ,\,\1740 evaluated\VBN\670261 in\IN\13603305 the\DT\1740 open\JJ\1740 field\NN\8673395 test\NN\5798043 as\RB\1740 well\RB\1740 as\IN\14622893 the\DT\1740 <e2>aggressiveness</e2>\NN\4835724 evoked\VBN\1617192 by\IN\1740 clonidine\NN\2721160 in\IN\13603305 mice\NNS\2329401 ,\,\1740 both\CC\1740 these\DT\1740 effects\NNS\13245626 being\VBG\836236 mediated\VBN\761713 by\IN\1740 an\DT\6697703 alpha1-adrenergic\JJ\1740 receptor\NN\5225602 .\.\1740
D003000_D010554 NONE It\PRP\6125041 increases\VBZ\169651 the\DT\1740 behaviour\NN\14006945 stimulation\NN\242808 evoked\VBN\1617192 by\IN\1740 phenylephrine\NN\2682038 (\-LRB-\1740 given\VBN\2327200 intraventricularly\NN\1740 )\-RRB-\1740 in\IN\13603305 rats\NNS\2329401 ,\,\1740 evaluated\VBN\670261 in\IN\13603305 the\DT\1740 open\JJ\1740 field\NN\8673395 test\NN\5798043 as\RB\1740 well\RB\1740 as\IN\14622893 the\DT\1740 <e2>aggressiveness</e2>\NN\4835724 evoked\VBN\1617192 by\IN\1740 <e1>clonidine</e1>\NN\2721160 in\IN\13603305 mice\NNS\2329401 ,\,\1740 both\CC\1740 these\DT\1740 effects\NNS\13245626 being\VBG\836236 mediated\VBN\761713 by\IN\1740 an\DT\6697703 alpha1-adrenergic\JJ\1740 receptor\NN\5225602 .\.\1740
19211690
D013739_D006973 NONE <e1>Testosterone-dependent</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 and\CC\1740 upregulation\NN\1740 of\IN\1740 intrarenal\JJ\1740 angiotensinogen\NN\1740 in\IN\13603305 Dahl\NN\13112664 salt-sensitive\JJ\1740 rats\NNS\2329401 .\.\1740
D013739_D006973 NONE <e1>Testosterone</e1>\NN\14747587 contributes\VBZ\126264 to\TO\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>hypertension</e2>\NN\14057371 and\CC\1740 renal\JJ\1740 injury\NN\14052046 in\IN\13603305 male\JJ\1740 DS\NN\14622893 rats\NNS\2329401 on\IN\1740 HS\NN\14622893 diet\NN\7560652 possibly\RB\1740 through\IN\1740 upregulation\NN\1740 of\IN\1740 the\DT\1740 intrarenal\JJ\1740 renin-angiotensin\JJ\1740 system\NN\3575240 .\.\1740
D017673_D006973 NONE Testosterone-dependent\JJ\1740 <e2>hypertension</e2>\NN\14057371 and\CC\1740 upregulation\NN\1740 of\IN\1740 intrarenal\JJ\1740 angiotensinogen\NN\1740 in\IN\13603305 Dahl\NN\13112664 <e1>salt-sensitive</e1>\JJ\1740 rats\NNS\2329401 .\.\1740
D013739_D007674 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 the\DT\1740 hypothesis\NN\7162194 was\VBD\836236 tested\VBN\670261 that\IN\1740 there\EX\27167 is\VBZ\836236 a\DT\13649268 sexual\JJ\1740 dimorphism\NN\11492833 in\IN\13603305 HS-induced\JJ\1740 upregulation\NN\1740 of\IN\1740 intrarenal\JJ\1740 angiotensinogen\NN\1740 mediated\VBN\761713 by\IN\1740 <e1>testosterone</e1>\NN\14747587 that\WDT\1740 also\RB\1740 causes\VBZ\1617192 increases\NNS\13576355 in\IN\13603305 BP\NN\1740 and\CC\1740 <e2>renal\JJ\1740 injury</e2>\NN\14052046 .\.\1740
D013739_D007674 NONE <e1>Testosterone</e1>\NN\14747587 replacement\NN\196485 in\IN\13603305 castrated\VBN\224901 DS\NN\14622893 rats\NNS\2329401 increased\VBD\169651 BP\NN\1740 ,\,\1740 <e2>renal\JJ\1740 injury</e2>\NN\14052046 ,\,\1740 and\CC\1740 upregulation\NN\1740 of\IN\1740 renal\JJ\1740 angiotensinogen\NN\1740 associated\VBN\628491 with\IN\1740 HS\NN\14622893 diet\NN\7560652 .\.\1740
D013739_D007674 NONE <e1>Testosterone</e1>\NN\14747587 contributes\VBZ\126264 to\TO\1740 the\DT\1740 development\NN\248977 of\IN\1740 hypertension\NN\14057371 and\CC\1740 <e2>renal\JJ\1740 injury</e2>\NN\14052046 in\IN\13603305 male\JJ\1740 DS\NN\14622893 rats\NNS\2329401 on\IN\1740 HS\NN\14622893 diet\NN\7560652 possibly\RB\1740 through\IN\1740 upregulation\NN\1740 of\IN\1740 the\DT\1740 intrarenal\JJ\1740 renin-angiotensin\JJ\1740 system\NN\3575240 .\.\1740
D000809_D006973 NONE Testosterone\NN\14747587 contributes\VBZ\126264 to\TO\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>hypertension</e2>\NN\14057371 and\CC\1740 renal\JJ\1740 injury\NN\14052046 in\IN\13603305 male\JJ\1740 DS\NN\14622893 rats\NNS\2329401 on\IN\1740 HS\NN\14622893 diet\NN\7560652 possibly\RB\1740 through\IN\1740 upregulation\NN\1740 of\IN\1740 the\DT\1740 intrarenal\JJ\1740 <e1>renin-angiotensin</e1>\JJ\1740 system\NN\3575240 .\.\1740
D000809_D007674 NONE Testosterone\NN\14747587 contributes\VBZ\126264 to\TO\1740 the\DT\1740 development\NN\248977 of\IN\1740 hypertension\NN\14057371 and\CC\1740 <e2>renal\JJ\1740 injury</e2>\NN\14052046 in\IN\13603305 male\JJ\1740 DS\NN\14622893 rats\NNS\2329401 on\IN\1740 HS\NN\14622893 diet\NN\7560652 possibly\RB\1740 through\IN\1740 upregulation\NN\1740 of\IN\1740 the\DT\1740 intrarenal\JJ\1740 <e1>renin-angiotensin</e1>\JJ\1740 system\NN\3575240 .\.\1740
18410508
D008694_D020258 NONE <e1>Methamphetamine-induced</e1>\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 and\CC\1740 microglial\JJ\1740 activation\NN\13561719 are\VBP\836236 not\RB\1740 mediated\VBN\761713 by\IN\1740 fractalkine\NN\1740 receptor\NN\5225602 signaling\NN\33020 .\.\1740
D008694_D020258 NONE Because\IN\1740 the\DT\1740 CNS\NN\5237227 damage\NN\7296428 caused\VBN\1617192 by\IN\1740 <e1>METH</e1>\NN\2704153 and\CC\1740 MPTP\NNP\1740 is\VBZ\836236 highly\RB\1740 selective\JJ\1740 for\IN\1740 the\DT\1740 DA\NN\10484858 neuronal\JJ\1740 system\NN\3575240 in\IN\13603305 mouse\NN\2329401 models\NNS\5888929 of\IN\1740 <e2>neurotoxicity</e2>\NN\1740 ,\,\1740 we\PRP\1740 hypothesized\VBD\719734 that\IN\1740 the\DT\1740 CX3CR1\NNP\1740 plays\VBZ\1072262 a\DT\13649268 role\NN\719494 in\IN\13603305 METH-induced\JJ\1740 neurotoxicity\NN\1740 and\CC\1740 microglial\JJ\1740 activation\NN\13561719 .\.\1740
D008694_D020258 NONE Because\IN\1740 the\DT\1740 CNS\NN\5237227 damage\NN\7296428 caused\VBN\1617192 by\IN\1740 <e1>METH</e1>\NN\2704153 and\CC\1740 MPTP\NNP\1740 is\VBZ\836236 highly\RB\1740 selective\JJ\1740 for\IN\1740 the\DT\1740 DA\NN\10484858 neuronal\JJ\1740 system\NN\3575240 in\IN\13603305 mouse\NN\2329401 models\NNS\5888929 of\IN\1740 neurotoxicity\NN\1740 ,\,\1740 we\PRP\1740 hypothesized\VBD\719734 that\IN\1740 the\DT\1740 CX3CR1\NNP\1740 plays\VBZ\1072262 a\DT\13649268 role\NN\719494 in\IN\13603305 METH-induced\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 and\CC\1740 microglial\JJ\1740 activation\NN\13561719 .\.\1740
D008694_D020258 NONE Because\IN\1740 the\DT\1740 CNS\NN\5237227 damage\NN\7296428 caused\VBN\1617192 by\IN\1740 METH\NN\2704153 and\CC\1740 MPTP\NNP\1740 is\VBZ\836236 highly\RB\1740 selective\JJ\1740 for\IN\1740 the\DT\1740 DA\NN\10484858 neuronal\JJ\1740 system\NN\3575240 in\IN\13603305 mouse\NN\2329401 models\NNS\5888929 of\IN\1740 <e2>neurotoxicity</e2>\NN\1740 ,\,\1740 we\PRP\1740 hypothesized\VBD\719734 that\IN\1740 the\DT\1740 CX3CR1\NNP\1740 plays\VBZ\1072262 a\DT\13649268 role\NN\719494 in\IN\13603305 <e1>METH-induced</e1>\JJ\1740 neurotoxicity\NN\1740 and\CC\1740 microglial\JJ\1740 activation\NN\13561719 .\.\1740
D008694_D020258 NONE Because\IN\1740 the\DT\1740 CNS\NN\5237227 damage\NN\7296428 caused\VBN\1617192 by\IN\1740 METH\NN\2704153 and\CC\1740 MPTP\NNP\1740 is\VBZ\836236 highly\RB\1740 selective\JJ\1740 for\IN\1740 the\DT\1740 DA\NN\10484858 neuronal\JJ\1740 system\NN\3575240 in\IN\13603305 mouse\NN\2329401 models\NNS\5888929 of\IN\1740 neurotoxicity\NN\1740 ,\,\1740 we\PRP\1740 hypothesized\VBD\719734 that\IN\1740 the\DT\1740 CX3CR1\NNP\1740 plays\VBZ\1072262 a\DT\13649268 role\NN\719494 in\IN\13603305 <e1>METH-induced</e1>\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 and\CC\1740 microglial\JJ\1740 activation\NN\13561719 .\.\1740
D008694_D020258 NONE Mice\NNS\2329401 in\IN\13603305 which\WDT\1740 the\DT\1740 CX3CR1\NN\1740 gene\NN\8459252 has\VBZ\2108377 been\VBN\836236 deleted\VBN\173338 and\CC\1740 replaced\VBD\1631072 with\IN\1740 a\DT\13649268 cDNA\NN\14830364 encoding\NN\614489 enhanced\VBD\227165 green\JJ\1740 fluorescent\JJ\1740 protein\NN\14944888 (\-LRB-\1740 eGFP\NN\1740 )\-RRB-\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>METH</e1>\NN\2704153 and\CC\1740 examined\VBN\789138 for\IN\1740 striatal\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D008694_D020258 NONE We\PRP\1740 conclude\VBP\628491 from\IN\1740 these\DT\1740 studies\NNS\635850 that\WDT\1740 CX3CR1\NN\1740 signaling\NN\33020 does\VBZ\1640855 not\RB\1740 modulate\VB\1724459 <e1>METH</e1>\NN\2704153 <e2>neurotoxicity</e2>\NN\1740 or\CC\3541091 microglial\JJ\1740 activation\NN\13561719 .\.\1740
D015632_D009422 CID 9\CD\13741022 (\-LRB-\1740 2006\CD\1740 )\-RRB-\1740 ,\,\1740 917\CD\1740 ]\-RRB-\1740 recently\RB\1740 identified\VBD\699815 the\DT\1740 microglial-specific\JJ\1740 fractalkine\NN\1740 receptor\NN\5225602 (\-LRB-\1740 CX3CR1\NN\1740 )\-RRB-\1740 as\IN\14622893 an\DT\6697703 important\JJ\1740 mediator\NN\10351874 of\IN\1740 <e1>MPTP-induced</e1>\JJ\1740 <e2>neurodegeneration</e2>\NN\1740 of\IN\1740 DA\NN\10484858 neurons\NNS\5430628 .\.\1740
D015632_D009422 CID Because\IN\1740 the\DT\1740 <e2>CNS\NN\5237227 damage</e2>\NN\7296428 caused\VBN\1617192 by\IN\1740 METH\NN\2704153 and\CC\1740 <e1>MPTP</e1>\NNP\1740 is\VBZ\836236 highly\RB\1740 selective\JJ\1740 for\IN\1740 the\DT\1740 DA\NN\10484858 neuronal\JJ\1740 system\NN\3575240 in\IN\13603305 mouse\NN\2329401 models\NNS\5888929 of\IN\1740 neurotoxicity\NN\1740 ,\,\1740 we\PRP\1740 hypothesized\VBD\719734 that\IN\1740 the\DT\1740 CX3CR1\NNP\1740 plays\VBZ\1072262 a\DT\13649268 role\NN\719494 in\IN\13603305 METH-induced\JJ\1740 neurotoxicity\NN\1740 and\CC\1740 microglial\JJ\1740 activation\NN\13561719 .\.\1740
D004298_D009422 NONE 9\CD\13741022 (\-LRB-\1740 2006\CD\1740 )\-RRB-\1740 ,\,\1740 917\CD\1740 ]\-RRB-\1740 recently\RB\1740 identified\VBD\699815 the\DT\1740 microglial-specific\JJ\1740 fractalkine\NN\1740 receptor\NN\5225602 (\-LRB-\1740 CX3CR1\NN\1740 )\-RRB-\1740 as\IN\14622893 an\DT\6697703 important\JJ\1740 mediator\NN\10351874 of\IN\1740 MPTP-induced\JJ\1740 <e2>neurodegeneration</e2>\NN\1740 of\IN\1740 <e1>DA</e1>\NN\10484858 neurons\NNS\5430628 .\.\1740
D004298_D009422 NONE Because\IN\1740 the\DT\1740 <e2>CNS\NN\5237227 damage</e2>\NN\7296428 caused\VBN\1617192 by\IN\1740 METH\NN\2704153 and\CC\1740 MPTP\NNP\1740 is\VBZ\836236 highly\RB\1740 selective\JJ\1740 for\IN\1740 the\DT\1740 <e1>DA</e1>\NN\10484858 neuronal\JJ\1740 system\NN\3575240 in\IN\13603305 mouse\NN\2329401 models\NNS\5888929 of\IN\1740 neurotoxicity\NN\1740 ,\,\1740 we\PRP\1740 hypothesized\VBD\719734 that\IN\1740 the\DT\1740 CX3CR1\NNP\1740 plays\VBZ\1072262 a\DT\13649268 role\NN\719494 in\IN\13603305 METH-induced\JJ\1740 neurotoxicity\NN\1740 and\CC\1740 microglial\JJ\1740 activation\NN\13561719 .\.\1740
D008694_D009422 CID Because\IN\1740 the\DT\1740 <e2>CNS\NN\5237227 damage</e2>\NN\7296428 caused\VBN\1617192 by\IN\1740 <e1>METH</e1>\NN\2704153 and\CC\1740 MPTP\NNP\1740 is\VBZ\836236 highly\RB\1740 selective\JJ\1740 for\IN\1740 the\DT\1740 DA\NN\10484858 neuronal\JJ\1740 system\NN\3575240 in\IN\13603305 mouse\NN\2329401 models\NNS\5888929 of\IN\1740 neurotoxicity\NN\1740 ,\,\1740 we\PRP\1740 hypothesized\VBD\719734 that\IN\1740 the\DT\1740 CX3CR1\NNP\1740 plays\VBZ\1072262 a\DT\13649268 role\NN\719494 in\IN\13603305 METH-induced\JJ\1740 neurotoxicity\NN\1740 and\CC\1740 microglial\JJ\1740 activation\NN\13561719 .\.\1740
D008694_D009422 CID Because\IN\1740 the\DT\1740 <e2>CNS\NN\5237227 damage</e2>\NN\7296428 caused\VBN\1617192 by\IN\1740 METH\NN\2704153 and\CC\1740 MPTP\NNP\1740 is\VBZ\836236 highly\RB\1740 selective\JJ\1740 for\IN\1740 the\DT\1740 DA\NN\10484858 neuronal\JJ\1740 system\NN\3575240 in\IN\13603305 mouse\NN\2329401 models\NNS\5888929 of\IN\1740 neurotoxicity\NN\1740 ,\,\1740 we\PRP\1740 hypothesized\VBD\719734 that\IN\1740 the\DT\1740 CX3CR1\NNP\1740 plays\VBZ\1072262 a\DT\13649268 role\NN\719494 in\IN\13603305 <e1>METH-induced</e1>\JJ\1740 neurotoxicity\NN\1740 and\CC\1740 microglial\JJ\1740 activation\NN\13561719 .\.\1740
D015632_D020258 NONE Because\IN\1740 the\DT\1740 CNS\NN\5237227 damage\NN\7296428 caused\VBN\1617192 by\IN\1740 METH\NN\2704153 and\CC\1740 <e1>MPTP</e1>\NNP\1740 is\VBZ\836236 highly\RB\1740 selective\JJ\1740 for\IN\1740 the\DT\1740 DA\NN\10484858 neuronal\JJ\1740 system\NN\3575240 in\IN\13603305 mouse\NN\2329401 models\NNS\5888929 of\IN\1740 <e2>neurotoxicity</e2>\NN\1740 ,\,\1740 we\PRP\1740 hypothesized\VBD\719734 that\IN\1740 the\DT\1740 CX3CR1\NNP\1740 plays\VBZ\1072262 a\DT\13649268 role\NN\719494 in\IN\13603305 METH-induced\JJ\1740 neurotoxicity\NN\1740 and\CC\1740 microglial\JJ\1740 activation\NN\13561719 .\.\1740
D015632_D020258 NONE Because\IN\1740 the\DT\1740 CNS\NN\5237227 damage\NN\7296428 caused\VBN\1617192 by\IN\1740 METH\NN\2704153 and\CC\1740 <e1>MPTP</e1>\NNP\1740 is\VBZ\836236 highly\RB\1740 selective\JJ\1740 for\IN\1740 the\DT\1740 DA\NN\10484858 neuronal\JJ\1740 system\NN\3575240 in\IN\13603305 mouse\NN\2329401 models\NNS\5888929 of\IN\1740 neurotoxicity\NN\1740 ,\,\1740 we\PRP\1740 hypothesized\VBD\719734 that\IN\1740 the\DT\1740 CX3CR1\NNP\1740 plays\VBZ\1072262 a\DT\13649268 role\NN\719494 in\IN\13603305 METH-induced\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 and\CC\1740 microglial\JJ\1740 activation\NN\13561719 .\.\1740
D004298_D020258 NONE Because\IN\1740 the\DT\1740 CNS\NN\5237227 damage\NN\7296428 caused\VBN\1617192 by\IN\1740 METH\NN\2704153 and\CC\1740 MPTP\NNP\1740 is\VBZ\836236 highly\RB\1740 selective\JJ\1740 for\IN\1740 the\DT\1740 <e1>DA</e1>\NN\10484858 neuronal\JJ\1740 system\NN\3575240 in\IN\13603305 mouse\NN\2329401 models\NNS\5888929 of\IN\1740 <e2>neurotoxicity</e2>\NN\1740 ,\,\1740 we\PRP\1740 hypothesized\VBD\719734 that\IN\1740 the\DT\1740 CX3CR1\NNP\1740 plays\VBZ\1072262 a\DT\13649268 role\NN\719494 in\IN\13603305 METH-induced\JJ\1740 neurotoxicity\NN\1740 and\CC\1740 microglial\JJ\1740 activation\NN\13561719 .\.\1740
D004298_D020258 NONE Because\IN\1740 the\DT\1740 CNS\NN\5237227 damage\NN\7296428 caused\VBN\1617192 by\IN\1740 METH\NN\2704153 and\CC\1740 MPTP\NNP\1740 is\VBZ\836236 highly\RB\1740 selective\JJ\1740 for\IN\1740 the\DT\1740 <e1>DA</e1>\NN\10484858 neuronal\JJ\1740 system\NN\3575240 in\IN\13603305 mouse\NN\2329401 models\NNS\5888929 of\IN\1740 neurotoxicity\NN\1740 ,\,\1740 we\PRP\1740 hypothesized\VBD\719734 that\IN\1740 the\DT\1740 CX3CR1\NNP\1740 plays\VBZ\1072262 a\DT\13649268 role\NN\719494 in\IN\13603305 METH-induced\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 and\CC\1740 microglial\JJ\1740 activation\NN\13561719 .\.\1740
10743446
D007649_D006930 NONE Differential\JJ\1740 effects\NNS\13245626 of\IN\1740 systemically\RB\1740 administered\VBN\2436349 <e1>ketamine</e1>\NN\3054098 and\CC\1740 lidocaine\NN\3681148 on\IN\1740 dynamic\JJ\1740 and\CC\1740 static\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 intradermal\JJ\1740 capsaicin\NN\15032661 in\IN\13603305 humans\NNS\31264 .\.\1740
D007649_D006930 NONE We\PRP\1740 have\VBP\2108377 examined\VBN\789138 the\DT\1740 effect\NN\34213 of\IN\1740 systemic\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>ketamine</e1>\NN\3054098 and\CC\1740 lidocaine\NN\3681148 on\IN\1740 brush-evoked\JJ\1740 (\-LRB-\1740 dynamic\JJ\1740 )\-RRB-\1740 pain\NN\14299637 and\CC\1740 punctate-evoked\JJ\1740 (\-LRB-\1740 static\JJ\1740 )\-RRB-\1740 <e2>hyperalgesia</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 capsaicin\NN\15032661 .\.\1740
D007649_D006930 NONE <e1>Ketamine</e1>\NNP\3054098 reduced\VBD\441445 both\CC\1740 the\DT\1740 area\NN\8630985 of\IN\1740 brush-evoked\JJ\1740 and\CC\1740 punctate-evoked\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 significantly\RB\1740 and\CC\1740 it\PRP\6125041 tended\VBD\2604760 to\TO\1740 reduce\VB\441445 brush-evoked\JJ\1740 pain\NN\14299637 .\.\1740
D007649_D006930 NONE The\DT\1740 differential\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>ketamine</e1>\NN\3054098 and\CC\1740 lidocaine\NN\3681148 on\IN\1740 static\JJ\1740 and\CC\1740 dynamic\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 suggest\VBP\1010118 that\IN\1740 the\DT\1740 two\CD\13741022 types\NNS\5839024 of\IN\1740 hyperalgesia\NN\1740 are\VBP\836236 mediated\VBN\761713 by\IN\1740 separate\JJ\1740 mechanisms\NNS\13446390 and\CC\1740 have\VBP\2108377 a\DT\13649268 distinct\JJ\1740 pharmacology\NN\6043075 .\.\1740
D007649_D006930 NONE The\DT\1740 differential\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>ketamine</e1>\NN\3054098 and\CC\1740 lidocaine\NN\3681148 on\IN\1740 static\JJ\1740 and\CC\1740 dynamic\JJ\1740 hyperalgesia\NN\1740 suggest\VBP\1010118 that\IN\1740 the\DT\1740 two\CD\13741022 types\NNS\5839024 of\IN\1740 <e2>hyperalgesia</e2>\NN\1740 are\VBP\836236 mediated\VBN\761713 by\IN\1740 separate\JJ\1740 mechanisms\NNS\13446390 and\CC\1740 have\VBP\2108377 a\DT\13649268 distinct\JJ\1740 pharmacology\NN\6043075 .\.\1740
D008012_D006930 NONE Differential\JJ\1740 effects\NNS\13245626 of\IN\1740 systemically\RB\1740 administered\VBN\2436349 ketamine\NN\3054098 and\CC\1740 <e1>lidocaine</e1>\NN\3681148 on\IN\1740 dynamic\JJ\1740 and\CC\1740 static\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 intradermal\JJ\1740 capsaicin\NN\15032661 in\IN\13603305 humans\NNS\31264 .\.\1740
D008012_D006930 NONE We\PRP\1740 have\VBP\2108377 examined\VBN\789138 the\DT\1740 effect\NN\34213 of\IN\1740 systemic\JJ\1740 administration\NN\1133281 of\IN\1740 ketamine\NN\3054098 and\CC\1740 <e1>lidocaine</e1>\NN\3681148 on\IN\1740 brush-evoked\JJ\1740 (\-LRB-\1740 dynamic\JJ\1740 )\-RRB-\1740 pain\NN\14299637 and\CC\1740 punctate-evoked\JJ\1740 (\-LRB-\1740 static\JJ\1740 )\-RRB-\1740 <e2>hyperalgesia</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 capsaicin\NN\15032661 .\.\1740
D008012_D006930 NONE <e1>Lidocaine</e1>\NN\3681148 reduced\VBD\441445 the\DT\1740 area\NN\8630985 of\IN\1740 punctate-evoked\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 significantly\RB\1740 .\.\1740
D008012_D006930 NONE The\DT\1740 differential\JJ\1740 effects\NNS\13245626 of\IN\1740 ketamine\NN\3054098 and\CC\1740 <e1>lidocaine</e1>\NN\3681148 on\IN\1740 static\JJ\1740 and\CC\1740 dynamic\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 suggest\VBP\1010118 that\IN\1740 the\DT\1740 two\CD\13741022 types\NNS\5839024 of\IN\1740 hyperalgesia\NN\1740 are\VBP\836236 mediated\VBN\761713 by\IN\1740 separate\JJ\1740 mechanisms\NNS\13446390 and\CC\1740 have\VBP\2108377 a\DT\13649268 distinct\JJ\1740 pharmacology\NN\6043075 .\.\1740
D008012_D006930 NONE The\DT\1740 differential\JJ\1740 effects\NNS\13245626 of\IN\1740 ketamine\NN\3054098 and\CC\1740 <e1>lidocaine</e1>\NN\3681148 on\IN\1740 static\JJ\1740 and\CC\1740 dynamic\JJ\1740 hyperalgesia\NN\1740 suggest\VBP\1010118 that\IN\1740 the\DT\1740 two\CD\13741022 types\NNS\5839024 of\IN\1740 <e2>hyperalgesia</e2>\NN\1740 are\VBP\836236 mediated\VBN\761713 by\IN\1740 separate\JJ\1740 mechanisms\NNS\13446390 and\CC\1740 have\VBP\2108377 a\DT\13649268 distinct\JJ\1740 pharmacology\NN\6043075 .\.\1740
D002211_D006930 CID Differential\JJ\1740 effects\NNS\13245626 of\IN\1740 systemically\RB\1740 administered\VBN\2436349 ketamine\NN\3054098 and\CC\1740 lidocaine\NN\3681148 on\IN\1740 dynamic\JJ\1740 and\CC\1740 static\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 intradermal\JJ\1740 <e1>capsaicin</e1>\NN\15032661 in\IN\13603305 humans\NNS\31264 .\.\1740
D002211_D006930 CID We\PRP\1740 have\VBP\2108377 examined\VBN\789138 the\DT\1740 effect\NN\34213 of\IN\1740 systemic\JJ\1740 administration\NN\1133281 of\IN\1740 ketamine\NN\3054098 and\CC\1740 lidocaine\NN\3681148 on\IN\1740 brush-evoked\JJ\1740 (\-LRB-\1740 dynamic\JJ\1740 )\-RRB-\1740 pain\NN\14299637 and\CC\1740 punctate-evoked\JJ\1740 (\-LRB-\1740 static\JJ\1740 )\-RRB-\1740 <e2>hyperalgesia</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>capsaicin</e1>\NN\15032661 .\.\1740
D007649_D010146 NONE We\PRP\1740 have\VBP\2108377 examined\VBN\789138 the\DT\1740 effect\NN\34213 of\IN\1740 systemic\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>ketamine</e1>\NN\3054098 and\CC\1740 lidocaine\NN\3681148 on\IN\1740 brush-evoked\JJ\1740 (\-LRB-\1740 dynamic\JJ\1740 )\-RRB-\1740 <e2>pain</e2>\NN\14299637 and\CC\1740 punctate-evoked\JJ\1740 (\-LRB-\1740 static\JJ\1740 )\-RRB-\1740 hyperalgesia\NN\1740 induced\VBN\1627355 by\IN\1740 capsaicin\NN\15032661 .\.\1740
D007649_D010146 NONE <e1>Ketamine</e1>\NNP\3054098 reduced\VBD\441445 both\CC\1740 the\DT\1740 area\NN\8630985 of\IN\1740 brush-evoked\JJ\1740 and\CC\1740 punctate-evoked\JJ\1740 hyperalgesia\NN\1740 significantly\RB\1740 and\CC\1740 it\PRP\6125041 tended\VBD\2604760 to\TO\1740 reduce\VB\441445 brush-evoked\JJ\1740 <e2>pain</e2>\NN\14299637 .\.\1740
D008012_D010146 NONE We\PRP\1740 have\VBP\2108377 examined\VBN\789138 the\DT\1740 effect\NN\34213 of\IN\1740 systemic\JJ\1740 administration\NN\1133281 of\IN\1740 ketamine\NN\3054098 and\CC\1740 <e1>lidocaine</e1>\NN\3681148 on\IN\1740 brush-evoked\JJ\1740 (\-LRB-\1740 dynamic\JJ\1740 )\-RRB-\1740 <e2>pain</e2>\NN\14299637 and\CC\1740 punctate-evoked\JJ\1740 (\-LRB-\1740 static\JJ\1740 )\-RRB-\1740 hyperalgesia\NN\1740 induced\VBN\1627355 by\IN\1740 capsaicin\NN\15032661 .\.\1740
D002211_D010146 CID We\PRP\1740 have\VBP\2108377 examined\VBN\789138 the\DT\1740 effect\NN\34213 of\IN\1740 systemic\JJ\1740 administration\NN\1133281 of\IN\1740 ketamine\NN\3054098 and\CC\1740 lidocaine\NN\3681148 on\IN\1740 brush-evoked\JJ\1740 (\-LRB-\1740 dynamic\JJ\1740 )\-RRB-\1740 <e2>pain</e2>\NN\14299637 and\CC\1740 punctate-evoked\JJ\1740 (\-LRB-\1740 static\JJ\1740 )\-RRB-\1740 hyperalgesia\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>capsaicin</e1>\NN\15032661 .\.\1740
18442015
D014700_D006471 NONE Protective\JJ\1740 effect\NN\34213 of\IN\1740 <e1>verapamil</e1>\NN\2938514 on\IN\1740 <e2>gastric\JJ\1740 hemorrhagic</e2>\JJ\1740 ulcers\NNS\14211294 in\IN\13603305 severe\JJ\1740 atherosclerotic\JJ\1740 rats\NNS\2329401 .\.\1740
D014700_D006471 NONE This\DT\1740 <e2>hemorrhagic</e2>\JJ\1740 ulcer\NN\14211294 and\CC\1740 various\JJ\1740 ulcerogenic\JJ\1740 parameters\NNS\5858936 were\VBD\836236 dose-dependently\RB\1740 ameliorated\VBN\126264 by\IN\1740 daily\RB\1740 intragastric\JJ\1740 <e1>verapamil</e1>\RB\1740 .\.\1740
D014700_D006471 NONE Atherosclerosis\NN\14108324 could\MD\1740 produce\VB\1617192 <e2>gastric\JJ\1740 hemorrhagic</e2>\JJ\1740 ulcer\NN\14211294 via\IN\1740 aggravation\NN\7518261 of\IN\1740 gastric\JJ\1740 acid\NN\14818238 back-diffusion\NN\1740 ,\,\1740 LPO\NN\1740 generation\NN\7942152 ,\,\1740 histamine\NN\14739004 release\NN\3748886 and\CC\1740 microvascular\JJ\1740 permeability\NN\4940146 that\WDT\1740 could\MD\1740 be\VB\836236 ameliorated\VBN\126264 by\IN\1740 <e1>verapamil</e1>\NNS\2938514 in\IN\13603305 rats\NNS\2329401 .\.\1740
D014700_D014456 NONE Protective\JJ\1740 effect\NN\34213 of\IN\1740 <e1>verapamil</e1>\NN\2938514 on\IN\1740 gastric\JJ\1740 hemorrhagic\JJ\1740 <e2>ulcers</e2>\NNS\14211294 in\IN\13603305 severe\JJ\1740 atherosclerotic\JJ\1740 rats\NNS\2329401 .\.\1740
D014700_D014456 NONE Additionally\RB\1740 ,\,\1740 the\DT\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 <e1>verapamil</e1>\NN\2938514 on\IN\1740 this\DT\1740 <e2>ulcer</e2>\NN\14211294 model\NN\5888929 was\VBD\836236 evaluated\VBN\670261 .\.\1740
D014700_D014456 NONE This\DT\1740 hemorrhagic\JJ\1740 <e2>ulcer</e2>\NN\14211294 and\CC\1740 various\JJ\1740 ulcerogenic\JJ\1740 parameters\NNS\5858936 were\VBD\836236 dose-dependently\RB\1740 ameliorated\VBN\126264 by\IN\1740 daily\RB\1740 intragastric\JJ\1740 <e1>verapamil</e1>\RB\1740 .\.\1740
D014700_D014456 NONE Atherosclerosis\NN\14108324 could\MD\1740 produce\VB\1617192 gastric\JJ\1740 hemorrhagic\JJ\1740 <e2>ulcer</e2>\NN\14211294 via\IN\1740 aggravation\NN\7518261 of\IN\1740 gastric\JJ\1740 acid\NN\14818238 back-diffusion\NN\1740 ,\,\1740 LPO\NN\1740 generation\NN\7942152 ,\,\1740 histamine\NN\14739004 release\NN\3748886 and\CC\1740 microvascular\JJ\1740 permeability\NN\4940146 that\WDT\1740 could\MD\1740 be\VB\836236 ameliorated\VBN\126264 by\IN\1740 <e1>verapamil</e1>\NNS\2938514 in\IN\13603305 rats\NNS\2329401 .\.\1740
D014700_D050197 NONE Protective\JJ\1740 effect\NN\34213 of\IN\1740 <e1>verapamil</e1>\NN\2938514 on\IN\1740 gastric\JJ\1740 hemorrhagic\JJ\1740 ulcers\NNS\14211294 in\IN\13603305 severe\JJ\1740 <e2>atherosclerotic</e2>\JJ\1740 rats\NNS\2329401 .\.\1740
D014700_D050197 NONE <e2>Atherosclerosis</e2>\NN\14108324 could\MD\1740 produce\VB\1617192 gastric\JJ\1740 hemorrhagic\JJ\1740 ulcer\NN\14211294 via\IN\1740 aggravation\NN\7518261 of\IN\1740 gastric\JJ\1740 acid\NN\14818238 back-diffusion\NN\1740 ,\,\1740 LPO\NN\1740 generation\NN\7942152 ,\,\1740 histamine\NN\14739004 release\NN\3748886 and\CC\1740 microvascular\JJ\1740 permeability\NN\4940146 that\WDT\1740 could\MD\1740 be\VB\836236 ameliorated\VBN\126264 by\IN\1740 <e1>verapamil</e1>\NNS\2938514 in\IN\13603305 rats\NNS\2329401 .\.\1740
D006632_D006471 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 is\VBZ\836236 to\TO\1740 examine\VB\789138 the\DT\1740 role\NN\719494 of\IN\1740 gastric\JJ\1740 acid\NN\14818238 back-diffusion\NN\1740 ,\,\1740 mast\NN\4267577 cell\NN\3080309 <e1>histamine</e1>\NN\14739004 release\NN\3748886 ,\,\1740 lipid\NN\14944888 peroxide\NN\14780040 (\-LRB-\1740 LPO\NN\1740 )\-RRB-\1740 generation\NN\7942152 and\CC\1740 mucosal\JJ\1740 microvascular\JJ\1740 permeability\NN\4940146 in\IN\13603305 modulating\VBG\1724459 <e2>gastric\JJ\1740 hemorrhage</e2>\NN\14285662 and\CC\1740 ulcer\NN\14211294 in\IN\13603305 rats\NNS\2329401 with\IN\1740 atherosclerosis\NN\14108324 induced\VBN\1627355 by\IN\1740 coadministration\NN\1740 of\IN\1740 vitamin\NN\7570720 D2\NN\1740 and\CC\1740 cholesterol\NN\15058310 .\.\1740
D006632_D006471 NONE Moreover\RB\1740 ,\,\1740 a\DT\13649268 positive\JJ\1740 correlation\NN\13841213 of\IN\1740 <e1>histamine</e1>\NN\14739004 to\TO\1740 <e2>gastric\JJ\1740 hemorrhage</e2>\NN\14285662 and\CC\1740 to\TO\1740 ulcer\NN\14211294 was\VBD\836236 found\VBN\2426171 in\IN\13603305 those\DT\1740 atherosclerotic\JJ\1740 rats\NNS\2329401 .\.\1740
D006632_D006471 NONE Atherosclerosis\NN\14108324 could\MD\1740 produce\VB\1617192 <e2>gastric\JJ\1740 hemorrhagic</e2>\JJ\1740 ulcer\NN\14211294 via\IN\1740 aggravation\NN\7518261 of\IN\1740 gastric\JJ\1740 acid\NN\14818238 back-diffusion\NN\1740 ,\,\1740 LPO\NN\1740 generation\NN\7942152 ,\,\1740 <e1>histamine</e1>\NN\14739004 release\NN\3748886 and\CC\1740 microvascular\JJ\1740 permeability\NN\4940146 that\WDT\1740 could\MD\1740 be\VB\836236 ameliorated\VBN\126264 by\IN\1740 verapamil\NNS\2938514 in\IN\13603305 rats\NNS\2329401 .\.\1740
D006632_D014456 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 is\VBZ\836236 to\TO\1740 examine\VB\789138 the\DT\1740 role\NN\719494 of\IN\1740 gastric\JJ\1740 acid\NN\14818238 back-diffusion\NN\1740 ,\,\1740 mast\NN\4267577 cell\NN\3080309 <e1>histamine</e1>\NN\14739004 release\NN\3748886 ,\,\1740 lipid\NN\14944888 peroxide\NN\14780040 (\-LRB-\1740 LPO\NN\1740 )\-RRB-\1740 generation\NN\7942152 and\CC\1740 mucosal\JJ\1740 microvascular\JJ\1740 permeability\NN\4940146 in\IN\13603305 modulating\VBG\1724459 gastric\JJ\1740 hemorrhage\NN\14285662 and\CC\1740 <e2>ulcer</e2>\NN\14211294 in\IN\13603305 rats\NNS\2329401 with\IN\1740 atherosclerosis\NN\14108324 induced\VBN\1627355 by\IN\1740 coadministration\NN\1740 of\IN\1740 vitamin\NN\7570720 D2\NN\1740 and\CC\1740 cholesterol\NN\15058310 .\.\1740
D006632_D014456 NONE Gastric\JJ\1740 acid\NN\14818238 back-diffusion\NN\1740 ,\,\1740 mucosal\JJ\1740 LPO\NN\1740 generation\NN\7942152 ,\,\1740 <e1>histamine</e1>\NN\14739004 concentration\NN\4916342 ,\,\1740 microvascular\JJ\1740 permeability\NN\4940146 ,\,\1740 luminal\JJ\1740 hemoglobin\NN\14888884 content\NN\7951464 and\CC\1740 <e2>ulcer</e2>\NN\14211294 areas\NNS\8630985 were\VBD\836236 determined\VBN\1645601 .\.\1740
D006632_D014456 NONE Severe\JJ\1740 gastric\NN\1740 <e2>ulcers</e2>\NNS\14211294 accompanied\VBN\1835496 with\IN\1740 increased\VBN\169651 ulcerogenic\JJ\1740 factors\NNS\7326557 ,\,\1740 including\VBG\690614 gastric\JJ\1740 acid\NN\14818238 back-diffusion\NN\1740 ,\,\1740 <e1>histamine</e1>\NN\14739004 release\NN\3748886 ,\,\1740 LPO\NN\1740 generation\NN\7942152 and\CC\1740 luminal\JJ\1740 hemoglobin\NN\14888884 content\NN\7951464 were\VBD\836236 also\RB\1740 observed\VBN\2163746 in\IN\13603305 these\DT\1740 rats\NNS\2329401 .\.\1740
D006632_D014456 NONE Moreover\RB\1740 ,\,\1740 a\DT\13649268 positive\JJ\1740 correlation\NN\13841213 of\IN\1740 <e1>histamine</e1>\NN\14739004 to\TO\1740 gastric\JJ\1740 hemorrhage\NN\14285662 and\CC\1740 to\TO\1740 <e2>ulcer</e2>\NN\14211294 was\VBD\836236 found\VBN\2426171 in\IN\13603305 those\DT\1740 atherosclerotic\JJ\1740 rats\NNS\2329401 .\.\1740
D006632_D014456 NONE Atherosclerosis\NN\14108324 could\MD\1740 produce\VB\1617192 gastric\JJ\1740 hemorrhagic\JJ\1740 <e2>ulcer</e2>\NN\14211294 via\IN\1740 aggravation\NN\7518261 of\IN\1740 gastric\JJ\1740 acid\NN\14818238 back-diffusion\NN\1740 ,\,\1740 LPO\NN\1740 generation\NN\7942152 ,\,\1740 <e1>histamine</e1>\NN\14739004 release\NN\3748886 and\CC\1740 microvascular\JJ\1740 permeability\NN\4940146 that\WDT\1740 could\MD\1740 be\VB\836236 ameliorated\VBN\126264 by\IN\1740 verapamil\NNS\2938514 in\IN\13603305 rats\NNS\2329401 .\.\1740
D006632_D050197 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 is\VBZ\836236 to\TO\1740 examine\VB\789138 the\DT\1740 role\NN\719494 of\IN\1740 gastric\JJ\1740 acid\NN\14818238 back-diffusion\NN\1740 ,\,\1740 mast\NN\4267577 cell\NN\3080309 <e1>histamine</e1>\NN\14739004 release\NN\3748886 ,\,\1740 lipid\NN\14944888 peroxide\NN\14780040 (\-LRB-\1740 LPO\NN\1740 )\-RRB-\1740 generation\NN\7942152 and\CC\1740 mucosal\JJ\1740 microvascular\JJ\1740 permeability\NN\4940146 in\IN\13603305 modulating\VBG\1724459 gastric\JJ\1740 hemorrhage\NN\14285662 and\CC\1740 ulcer\NN\14211294 in\IN\13603305 rats\NNS\2329401 with\IN\1740 <e2>atherosclerosis</e2>\NN\14108324 induced\VBN\1627355 by\IN\1740 coadministration\NN\1740 of\IN\1740 vitamin\NN\7570720 D2\NN\1740 and\CC\1740 cholesterol\NN\15058310 .\.\1740
D006632_D050197 NONE Moreover\RB\1740 ,\,\1740 a\DT\13649268 positive\JJ\1740 correlation\NN\13841213 of\IN\1740 <e1>histamine</e1>\NN\14739004 to\TO\1740 gastric\JJ\1740 hemorrhage\NN\14285662 and\CC\1740 to\TO\1740 ulcer\NN\14211294 was\VBD\836236 found\VBN\2426171 in\IN\13603305 those\DT\1740 <e2>atherosclerotic</e2>\JJ\1740 rats\NNS\2329401 .\.\1740
D006632_D050197 NONE <e2>Atherosclerosis</e2>\NN\14108324 could\MD\1740 produce\VB\1617192 gastric\JJ\1740 hemorrhagic\JJ\1740 ulcer\NN\14211294 via\IN\1740 aggravation\NN\7518261 of\IN\1740 gastric\JJ\1740 acid\NN\14818238 back-diffusion\NN\1740 ,\,\1740 LPO\NN\1740 generation\NN\7942152 ,\,\1740 <e1>histamine</e1>\NN\14739004 release\NN\3748886 and\CC\1740 microvascular\JJ\1740 permeability\NN\4940146 that\WDT\1740 could\MD\1740 be\VB\836236 ameliorated\VBN\126264 by\IN\1740 verapamil\NNS\2938514 in\IN\13603305 rats\NNS\2329401 .\.\1740
D004872_D006471 CID The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 is\VBZ\836236 to\TO\1740 examine\VB\789138 the\DT\1740 role\NN\719494 of\IN\1740 gastric\JJ\1740 acid\NN\14818238 back-diffusion\NN\1740 ,\,\1740 mast\NN\4267577 cell\NN\3080309 histamine\NN\14739004 release\NN\3748886 ,\,\1740 lipid\NN\14944888 peroxide\NN\14780040 (\-LRB-\1740 LPO\NN\1740 )\-RRB-\1740 generation\NN\7942152 and\CC\1740 mucosal\JJ\1740 microvascular\JJ\1740 permeability\NN\4940146 in\IN\13603305 modulating\VBG\1724459 <e2>gastric\JJ\1740 hemorrhage</e2>\NN\14285662 and\CC\1740 ulcer\NN\14211294 in\IN\13603305 rats\NNS\2329401 with\IN\1740 atherosclerosis\NN\14108324 induced\VBN\1627355 by\IN\1740 coadministration\NN\1740 of\IN\1740 <e1>vitamin\NN\7570720 D2</e1>\NN\1740 and\CC\1740 cholesterol\NN\15058310 .\.\1740
D004872_D014456 CID The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 is\VBZ\836236 to\TO\1740 examine\VB\789138 the\DT\1740 role\NN\719494 of\IN\1740 gastric\JJ\1740 acid\NN\14818238 back-diffusion\NN\1740 ,\,\1740 mast\NN\4267577 cell\NN\3080309 histamine\NN\14739004 release\NN\3748886 ,\,\1740 lipid\NN\14944888 peroxide\NN\14780040 (\-LRB-\1740 LPO\NN\1740 )\-RRB-\1740 generation\NN\7942152 and\CC\1740 mucosal\JJ\1740 microvascular\JJ\1740 permeability\NN\4940146 in\IN\13603305 modulating\VBG\1724459 gastric\JJ\1740 hemorrhage\NN\14285662 and\CC\1740 <e2>ulcer</e2>\NN\14211294 in\IN\13603305 rats\NNS\2329401 with\IN\1740 atherosclerosis\NN\14108324 induced\VBN\1627355 by\IN\1740 coadministration\NN\1740 of\IN\1740 <e1>vitamin\NN\7570720 D2</e1>\NN\1740 and\CC\1740 cholesterol\NN\15058310 .\.\1740
D004872_D050197 CID The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 is\VBZ\836236 to\TO\1740 examine\VB\789138 the\DT\1740 role\NN\719494 of\IN\1740 gastric\JJ\1740 acid\NN\14818238 back-diffusion\NN\1740 ,\,\1740 mast\NN\4267577 cell\NN\3080309 histamine\NN\14739004 release\NN\3748886 ,\,\1740 lipid\NN\14944888 peroxide\NN\14780040 (\-LRB-\1740 LPO\NN\1740 )\-RRB-\1740 generation\NN\7942152 and\CC\1740 mucosal\JJ\1740 microvascular\JJ\1740 permeability\NN\4940146 in\IN\13603305 modulating\VBG\1724459 gastric\JJ\1740 hemorrhage\NN\14285662 and\CC\1740 ulcer\NN\14211294 in\IN\13603305 rats\NNS\2329401 with\IN\1740 <e2>atherosclerosis</e2>\NN\14108324 induced\VBN\1627355 by\IN\1740 coadministration\NN\1740 of\IN\1740 <e1>vitamin\NN\7570720 D2</e1>\NN\1740 and\CC\1740 cholesterol\NN\15058310 .\.\1740
D004872_D050197 CID Male\NNP\15388 Wistar\NNP\1740 rats\NNS\2329401 were\VBD\836236 challenged\VBN\869596 intragastrically\RB\1740 once\RB\1740 daily\RB\1740 for\IN\1740 9\CD\13741022 days\NNS\15140892 with\IN\1740 1.0\CD\1740 ml/kg\NN\1740 of\IN\1740 corn\NN\12141495 oil\NN\14938907 containing\VBG\2632940 <e1>vitamin\NN\7570720 D2</e1>\NN\1740 and\CC\1740 cholesterol\NN\15058310 to\TO\1740 induce\VB\1627355 <e2>atherosclerosis</e2>\NN\14108324 .\.\1740
D002784_D006471 CID The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 is\VBZ\836236 to\TO\1740 examine\VB\789138 the\DT\1740 role\NN\719494 of\IN\1740 gastric\JJ\1740 acid\NN\14818238 back-diffusion\NN\1740 ,\,\1740 mast\NN\4267577 cell\NN\3080309 histamine\NN\14739004 release\NN\3748886 ,\,\1740 lipid\NN\14944888 peroxide\NN\14780040 (\-LRB-\1740 LPO\NN\1740 )\-RRB-\1740 generation\NN\7942152 and\CC\1740 mucosal\JJ\1740 microvascular\JJ\1740 permeability\NN\4940146 in\IN\13603305 modulating\VBG\1724459 <e2>gastric\JJ\1740 hemorrhage</e2>\NN\14285662 and\CC\1740 ulcer\NN\14211294 in\IN\13603305 rats\NNS\2329401 with\IN\1740 atherosclerosis\NN\14108324 induced\VBN\1627355 by\IN\1740 coadministration\NN\1740 of\IN\1740 vitamin\NN\7570720 D2\NN\1740 and\CC\1740 <e1>cholesterol</e1>\NN\15058310 .\.\1740
D002784_D014456 CID The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 is\VBZ\836236 to\TO\1740 examine\VB\789138 the\DT\1740 role\NN\719494 of\IN\1740 gastric\JJ\1740 acid\NN\14818238 back-diffusion\NN\1740 ,\,\1740 mast\NN\4267577 cell\NN\3080309 histamine\NN\14739004 release\NN\3748886 ,\,\1740 lipid\NN\14944888 peroxide\NN\14780040 (\-LRB-\1740 LPO\NN\1740 )\-RRB-\1740 generation\NN\7942152 and\CC\1740 mucosal\JJ\1740 microvascular\JJ\1740 permeability\NN\4940146 in\IN\13603305 modulating\VBG\1724459 gastric\JJ\1740 hemorrhage\NN\14285662 and\CC\1740 <e2>ulcer</e2>\NN\14211294 in\IN\13603305 rats\NNS\2329401 with\IN\1740 atherosclerosis\NN\14108324 induced\VBN\1627355 by\IN\1740 coadministration\NN\1740 of\IN\1740 vitamin\NN\7570720 D2\NN\1740 and\CC\1740 <e1>cholesterol</e1>\NN\15058310 .\.\1740
D002784_D050197 CID The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 is\VBZ\836236 to\TO\1740 examine\VB\789138 the\DT\1740 role\NN\719494 of\IN\1740 gastric\JJ\1740 acid\NN\14818238 back-diffusion\NN\1740 ,\,\1740 mast\NN\4267577 cell\NN\3080309 histamine\NN\14739004 release\NN\3748886 ,\,\1740 lipid\NN\14944888 peroxide\NN\14780040 (\-LRB-\1740 LPO\NN\1740 )\-RRB-\1740 generation\NN\7942152 and\CC\1740 mucosal\JJ\1740 microvascular\JJ\1740 permeability\NN\4940146 in\IN\13603305 modulating\VBG\1724459 gastric\JJ\1740 hemorrhage\NN\14285662 and\CC\1740 ulcer\NN\14211294 in\IN\13603305 rats\NNS\2329401 with\IN\1740 <e2>atherosclerosis</e2>\NN\14108324 induced\VBN\1627355 by\IN\1740 coadministration\NN\1740 of\IN\1740 vitamin\NN\7570720 D2\NN\1740 and\CC\1740 <e1>cholesterol</e1>\NN\15058310 .\.\1740
D002784_D050197 CID Male\NNP\15388 Wistar\NNP\1740 rats\NNS\2329401 were\VBD\836236 challenged\VBN\869596 intragastrically\RB\1740 once\RB\1740 daily\RB\1740 for\IN\1740 9\CD\13741022 days\NNS\15140892 with\IN\1740 1.0\CD\1740 ml/kg\NN\1740 of\IN\1740 corn\NN\12141495 oil\NN\14938907 containing\VBG\2632940 vitamin\NN\7570720 D2\NN\1740 and\CC\1740 <e1>cholesterol</e1>\NN\15058310 to\TO\1740 induce\VB\1627355 <e2>atherosclerosis</e2>\NN\14108324 .\.\1740
D002784_D050197 CID Elevated\JJ\1740 <e2>atherosclerotic</e2>\JJ\1740 parameters\NNS\5858936 ,\,\1740 such\JJ\1740 as\IN\14622893 serum\NN\5397468 calcium\NN\14625458 ,\,\1740 total\JJ\1740 <e1>cholesterol</e1>\NN\15058310 and\CC\1740 low-density\JJ\1740 lipoprotein\NN\14731135 concentration\NN\4916342 were\VBD\836236 obtained\VBN\2210855 in\IN\13603305 atherosclerotic\JJ\1740 rats\NNS\2329401 .\.\1740
D002784_D050197 CID Elevated\JJ\1740 atherosclerotic\JJ\1740 parameters\NNS\5858936 ,\,\1740 such\JJ\1740 as\IN\14622893 serum\NN\5397468 calcium\NN\14625458 ,\,\1740 total\JJ\1740 <e1>cholesterol</e1>\NN\15058310 and\CC\1740 low-density\JJ\1740 lipoprotein\NN\14731135 concentration\NN\4916342 were\VBD\836236 obtained\VBN\2210855 in\IN\13603305 <e2>atherosclerotic</e2>\JJ\1740 rats\NNS\2329401 .\.\1740
D010634_D014456 NONE Gastric\JJ\1740 acid\NN\14818238 back-diffusion\NN\1740 ,\,\1740 mucosal\JJ\1740 LPO\NN\1740 generation\NN\7942152 ,\,\1740 histamine\NN\14739004 concentration\NN\4916342 ,\,\1740 microvascular\JJ\1740 permeability\NN\4940146 ,\,\1740 <e1>luminal</e1>\JJ\1740 hemoglobin\NN\14888884 content\NN\7951464 and\CC\1740 <e2>ulcer</e2>\NN\14211294 areas\NNS\8630985 were\VBD\836236 determined\VBN\1645601 .\.\1740
D010634_D014456 NONE Severe\JJ\1740 gastric\NN\1740 <e2>ulcers</e2>\NNS\14211294 accompanied\VBN\1835496 with\IN\1740 increased\VBN\169651 ulcerogenic\JJ\1740 factors\NNS\7326557 ,\,\1740 including\VBG\690614 gastric\JJ\1740 acid\NN\14818238 back-diffusion\NN\1740 ,\,\1740 histamine\NN\14739004 release\NN\3748886 ,\,\1740 LPO\NN\1740 generation\NN\7942152 and\CC\1740 <e1>luminal</e1>\JJ\1740 hemoglobin\NN\14888884 content\NN\7951464 were\VBD\836236 also\RB\1740 observed\VBN\2163746 in\IN\13603305 these\DT\1740 rats\NNS\2329401 .\.\1740
D002118_D050197 NONE Elevated\JJ\1740 <e2>atherosclerotic</e2>\JJ\1740 parameters\NNS\5858936 ,\,\1740 such\JJ\1740 as\IN\14622893 serum\NN\5397468 <e1>calcium</e1>\NN\14625458 ,\,\1740 total\JJ\1740 cholesterol\NN\15058310 and\CC\1740 low-density\JJ\1740 lipoprotein\NN\14731135 concentration\NN\4916342 were\VBD\836236 obtained\VBN\2210855 in\IN\13603305 atherosclerotic\JJ\1740 rats\NNS\2329401 .\.\1740
D002118_D050197 NONE Elevated\JJ\1740 atherosclerotic\JJ\1740 parameters\NNS\5858936 ,\,\1740 such\JJ\1740 as\IN\14622893 serum\NN\5397468 <e1>calcium</e1>\NN\14625458 ,\,\1740 total\JJ\1740 cholesterol\NN\15058310 and\CC\1740 low-density\JJ\1740 lipoprotein\NN\14731135 concentration\NN\4916342 were\VBD\836236 obtained\VBN\2210855 in\IN\13603305 <e2>atherosclerotic</e2>\JJ\1740 rats\NNS\2329401 .\.\1740
6286738
D002762_D064420 NONE <e1>Vitamin\NN\7570720 D3</e1>\NN\1740 <e2>toxicity</e2>\NN\13576101 in\IN\13603305 dairy\NN\3322099 cows\NNS\2402010 .\.\1740
D002762_D064420 NONE Signs\NNS\6643763 of\IN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 <e2>toxicity</e2>\NN\13576101 were\VBD\836236 not\RB\1740 observed\VBN\2163746 in\IN\13603305 nonlactating\VBG\1740 nonpregnant\JJ\1740 cows\NNS\2402010 ;\:\1740 however\RB\1740 ,\,\1740 pregnant\JJ\1740 cows\NNS\2402010 commonly\RB\1740 developed\VBD\1753788 severe\JJ\1740 signs\NNS\6643763 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 toxicity\NN\13576101 and\CC\1740 10\CD\13745420 of\IN\1740 17\CD\13745420 cows\NNS\2402010 died\VBD\146138 .\.\1740
D002762_D064420 NONE Signs\NNS\6643763 of\IN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 toxicity\NN\13576101 were\VBD\836236 not\RB\1740 observed\VBN\2163746 in\IN\13603305 nonlactating\VBG\1740 nonpregnant\JJ\1740 cows\NNS\2402010 ;\:\1740 however\RB\1740 ,\,\1740 pregnant\JJ\1740 cows\NNS\2402010 commonly\RB\1740 developed\VBD\1753788 severe\JJ\1740 signs\NNS\6643763 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 <e2>toxicity</e2>\NN\13576101 and\CC\1740 10\CD\13745420 of\IN\1740 17\CD\13745420 cows\NNS\2402010 died\VBD\146138 .\.\1740
D002762_D064420 NONE Signs\NNS\6643763 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 <e2>toxicity</e2>\NN\13576101 were\VBD\836236 not\RB\1740 observed\VBN\2163746 in\IN\13603305 nonlactating\VBG\1740 nonpregnant\JJ\1740 cows\NNS\2402010 ;\:\1740 however\RB\1740 ,\,\1740 pregnant\JJ\1740 cows\NNS\2402010 commonly\RB\1740 developed\VBD\1753788 severe\JJ\1740 signs\NNS\6643763 of\IN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 toxicity\NN\13576101 and\CC\1740 10\CD\13745420 of\IN\1740 17\CD\13745420 cows\NNS\2402010 died\VBD\146138 .\.\1740
D002762_D064420 NONE Signs\NNS\6643763 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 toxicity\NN\13576101 were\VBD\836236 not\RB\1740 observed\VBN\2163746 in\IN\13603305 nonlactating\VBG\1740 nonpregnant\JJ\1740 cows\NNS\2402010 ;\:\1740 however\RB\1740 ,\,\1740 pregnant\JJ\1740 cows\NNS\2402010 commonly\RB\1740 developed\VBD\1753788 severe\JJ\1740 signs\NNS\6643763 of\IN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 <e2>toxicity</e2>\NN\13576101 and\CC\1740 10\CD\13745420 of\IN\1740 17\CD\13745420 cows\NNS\2402010 died\VBD\146138 .\.\1740
D002762_D064420 NONE Because\IN\1740 of\IN\1740 the\DT\1740 extreme\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 in\IN\13603305 pregnant\JJ\1740 Jersey\NNP\8887013 cows\VBZ\1779644 and\CC\1740 the\DT\1740 low\JJ\1740 margin\NN\13903079 of\IN\1740 safety\NN\13920835 between\IN\1740 doses\NNS\3740161 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 that\WDT\1740 prevent\VBP\1740 milk\NN\7881800 fever\NN\14299637 and\CC\1740 doses\NNS\3740161 that\WDT\1740 induce\VBP\1627355 milk\NN\7881800 fever\NN\14299637 ,\,\1740 we\PRP\1740 concluded\VBD\628491 that\IN\1740 vitamin\NN\7570720 D3\NN\1740 can\MD\3094503 not\RB\1740 be\VB\836236 used\VBN\1156834 practically\RB\1740 to\TO\1740 prevent\VB\1740 milk\NN\7881800 fever\NN\14299637 when\WRB\1740 injected\VBN\81072 several\JJ\1740 weeks\NNS\15113229 prepartum\NN\1740 .\.\1740
D002762_D064420 NONE Because\IN\1740 of\IN\1740 the\DT\1740 extreme\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 in\IN\13603305 pregnant\JJ\1740 Jersey\NNP\8887013 cows\VBZ\1779644 and\CC\1740 the\DT\1740 low\JJ\1740 margin\NN\13903079 of\IN\1740 safety\NN\13920835 between\IN\1740 doses\NNS\3740161 of\IN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 that\WDT\1740 prevent\VBP\1740 milk\NN\7881800 fever\NN\14299637 and\CC\1740 doses\NNS\3740161 that\WDT\1740 induce\VBP\1627355 milk\NN\7881800 fever\NN\14299637 ,\,\1740 we\PRP\1740 concluded\VBD\628491 that\IN\1740 vitamin\NN\7570720 D3\NN\1740 can\MD\3094503 not\RB\1740 be\VB\836236 used\VBN\1156834 practically\RB\1740 to\TO\1740 prevent\VB\1740 milk\NN\7881800 fever\NN\14299637 when\WRB\1740 injected\VBN\81072 several\JJ\1740 weeks\NNS\15113229 prepartum\NN\1740 .\.\1740
D002762_D064420 NONE Because\IN\1740 of\IN\1740 the\DT\1740 extreme\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 in\IN\13603305 pregnant\JJ\1740 Jersey\NNP\8887013 cows\VBZ\1779644 and\CC\1740 the\DT\1740 low\JJ\1740 margin\NN\13903079 of\IN\1740 safety\NN\13920835 between\IN\1740 doses\NNS\3740161 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 that\WDT\1740 prevent\VBP\1740 milk\NN\7881800 fever\NN\14299637 and\CC\1740 doses\NNS\3740161 that\WDT\1740 induce\VBP\1627355 milk\NN\7881800 fever\NN\14299637 ,\,\1740 we\PRP\1740 concluded\VBD\628491 that\IN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 can\MD\3094503 not\RB\1740 be\VB\836236 used\VBN\1156834 practically\RB\1740 to\TO\1740 prevent\VB\1740 milk\NN\7881800 fever\NN\14299637 when\WRB\1740 injected\VBN\81072 several\JJ\1740 weeks\NNS\15113229 prepartum\NN\1740 .\.\1740
D002762_D006934 CID Large\JJ\1740 parenteral\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 (\-LRB-\1740 15\CD\13745420 to\TO\1740 17.5\CD\1740 x\NN\13745420 10(6\NN\1740 )\-RRB-\1740 IU\NN\1740 vitamin\NN\7570720 D3\NN\1740 )\-RRB-\1740 were\VBD\836236 associated\VBN\628491 with\IN\1740 prolonged\JJ\1740 <e2>hypercalcemia</e2>\NN\14299637 ,\,\1740 hyperphosphatemia\NN\1740 ,\,\1740 and\CC\1740 large\JJ\1740 increases\NNS\13576355 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 and\CC\1740 its\PRP$\6125041 metabolites\NNS\20090 in\IN\13603305 the\DT\1740 blood\NN\5397468 plasma\NN\5398023 of\IN\1740 nonlactating\VBG\1740 nonpregnant\JJ\1740 and\CC\1740 pregnant\JJ\1740 Jersey\NNP\8887013 cows\VBZ\1779644 .\.\1740
D002762_D006934 CID Large\JJ\1740 parenteral\JJ\1740 doses\NNS\3740161 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 (\-LRB-\1740 15\CD\13745420 to\TO\1740 17.5\CD\1740 x\NN\13745420 10(6\NN\1740 )\-RRB-\1740 IU\NN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 )\-RRB-\1740 were\VBD\836236 associated\VBN\628491 with\IN\1740 prolonged\JJ\1740 <e2>hypercalcemia</e2>\NN\14299637 ,\,\1740 hyperphosphatemia\NN\1740 ,\,\1740 and\CC\1740 large\JJ\1740 increases\NNS\13576355 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 and\CC\1740 its\PRP$\6125041 metabolites\NNS\20090 in\IN\13603305 the\DT\1740 blood\NN\5397468 plasma\NN\5398023 of\IN\1740 nonlactating\VBG\1740 nonpregnant\JJ\1740 and\CC\1740 pregnant\JJ\1740 Jersey\NNP\8887013 cows\VBZ\1779644 .\.\1740
D002762_D006934 CID Large\JJ\1740 parenteral\JJ\1740 doses\NNS\3740161 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 (\-LRB-\1740 15\CD\13745420 to\TO\1740 17.5\CD\1740 x\NN\13745420 10(6\NN\1740 )\-RRB-\1740 IU\NN\1740 vitamin\NN\7570720 D3\NN\1740 )\-RRB-\1740 were\VBD\836236 associated\VBN\628491 with\IN\1740 prolonged\JJ\1740 <e2>hypercalcemia</e2>\NN\14299637 ,\,\1740 hyperphosphatemia\NN\1740 ,\,\1740 and\CC\1740 large\JJ\1740 increases\NNS\13576355 of\IN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 and\CC\1740 its\PRP$\6125041 metabolites\NNS\20090 in\IN\13603305 the\DT\1740 blood\NN\5397468 plasma\NN\5398023 of\IN\1740 nonlactating\VBG\1740 nonpregnant\JJ\1740 and\CC\1740 pregnant\JJ\1740 Jersey\NNP\8887013 cows\VBZ\1779644 .\.\1740
D002762_D054559 CID Large\JJ\1740 parenteral\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 (\-LRB-\1740 15\CD\13745420 to\TO\1740 17.5\CD\1740 x\NN\13745420 10(6\NN\1740 )\-RRB-\1740 IU\NN\1740 vitamin\NN\7570720 D3\NN\1740 )\-RRB-\1740 were\VBD\836236 associated\VBN\628491 with\IN\1740 prolonged\JJ\1740 hypercalcemia\NN\14299637 ,\,\1740 <e2>hyperphosphatemia</e2>\NN\1740 ,\,\1740 and\CC\1740 large\JJ\1740 increases\NNS\13576355 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 and\CC\1740 its\PRP$\6125041 metabolites\NNS\20090 in\IN\13603305 the\DT\1740 blood\NN\5397468 plasma\NN\5398023 of\IN\1740 nonlactating\VBG\1740 nonpregnant\JJ\1740 and\CC\1740 pregnant\JJ\1740 Jersey\NNP\8887013 cows\VBZ\1779644 .\.\1740
D002762_D054559 CID Large\JJ\1740 parenteral\JJ\1740 doses\NNS\3740161 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 (\-LRB-\1740 15\CD\13745420 to\TO\1740 17.5\CD\1740 x\NN\13745420 10(6\NN\1740 )\-RRB-\1740 IU\NN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 )\-RRB-\1740 were\VBD\836236 associated\VBN\628491 with\IN\1740 prolonged\JJ\1740 hypercalcemia\NN\14299637 ,\,\1740 <e2>hyperphosphatemia</e2>\NN\1740 ,\,\1740 and\CC\1740 large\JJ\1740 increases\NNS\13576355 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 and\CC\1740 its\PRP$\6125041 metabolites\NNS\20090 in\IN\13603305 the\DT\1740 blood\NN\5397468 plasma\NN\5398023 of\IN\1740 nonlactating\VBG\1740 nonpregnant\JJ\1740 and\CC\1740 pregnant\JJ\1740 Jersey\NNP\8887013 cows\VBZ\1779644 .\.\1740
D002762_D054559 CID Large\JJ\1740 parenteral\JJ\1740 doses\NNS\3740161 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 (\-LRB-\1740 15\CD\13745420 to\TO\1740 17.5\CD\1740 x\NN\13745420 10(6\NN\1740 )\-RRB-\1740 IU\NN\1740 vitamin\NN\7570720 D3\NN\1740 )\-RRB-\1740 were\VBD\836236 associated\VBN\628491 with\IN\1740 prolonged\JJ\1740 hypercalcemia\NN\14299637 ,\,\1740 <e2>hyperphosphatemia</e2>\NN\1740 ,\,\1740 and\CC\1740 large\JJ\1740 increases\NNS\13576355 of\IN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 and\CC\1740 its\PRP$\6125041 metabolites\NNS\20090 in\IN\13603305 the\DT\1740 blood\NN\5397468 plasma\NN\5398023 of\IN\1740 nonlactating\VBG\1740 nonpregnant\JJ\1740 and\CC\1740 pregnant\JJ\1740 Jersey\NNP\8887013 cows\VBZ\1779644 .\.\1740
D002762_D010319 NONE None\NN\15228378 of\IN\1740 the\DT\1740 cows\NNS\2402010 treated\VBN\2376958 with\IN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 showed\VBD\2137132 signs\NNS\6643763 of\IN\1740 <e2>milk\NN\7881800 fever</e2>\NN\14299637 during\IN\1740 the\DT\1740 peripartal\JJ\1740 period\NN\13575869 ;\:\1740 however\RB\1740 ,\,\1740 22\CD\13745420 %\NN\1740 of\IN\1740 the\DT\1740 control\NN\5190804 cows\NNS\2402010 developed\VBD\1753788 clinical\JJ\1740 signs\NNS\6643763 of\IN\1740 milk\NN\7881800 fever\NN\14299637 during\IN\1740 this\DT\1740 period\NN\13575869 .\.\1740
D002762_D010319 NONE None\NN\15228378 of\IN\1740 the\DT\1740 cows\NNS\2402010 treated\VBN\2376958 with\IN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 showed\VBD\2137132 signs\NNS\6643763 of\IN\1740 milk\NN\7881800 fever\NN\14299637 during\IN\1740 the\DT\1740 peripartal\JJ\1740 period\NN\13575869 ;\:\1740 however\RB\1740 ,\,\1740 22\CD\13745420 %\NN\1740 of\IN\1740 the\DT\1740 control\NN\5190804 cows\NNS\2402010 developed\VBD\1753788 clinical\JJ\1740 signs\NNS\6643763 of\IN\1740 <e2>milk\NN\7881800 fever</e2>\NN\14299637 during\IN\1740 this\DT\1740 period\NN\13575869 .\.\1740
D002762_D010319 NONE Because\IN\1740 of\IN\1740 the\DT\1740 extreme\JJ\1740 toxicity\NN\13576101 of\IN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 in\IN\13603305 pregnant\JJ\1740 Jersey\NNP\8887013 cows\VBZ\1779644 and\CC\1740 the\DT\1740 low\JJ\1740 margin\NN\13903079 of\IN\1740 safety\NN\13920835 between\IN\1740 doses\NNS\3740161 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 that\WDT\1740 prevent\VBP\1740 <e2>milk\NN\7881800 fever</e2>\NN\14299637 and\CC\1740 doses\NNS\3740161 that\WDT\1740 induce\VBP\1627355 milk\NN\7881800 fever\NN\14299637 ,\,\1740 we\PRP\1740 concluded\VBD\628491 that\IN\1740 vitamin\NN\7570720 D3\NN\1740 can\MD\3094503 not\RB\1740 be\VB\836236 used\VBN\1156834 practically\RB\1740 to\TO\1740 prevent\VB\1740 milk\NN\7881800 fever\NN\14299637 when\WRB\1740 injected\VBN\81072 several\JJ\1740 weeks\NNS\15113229 prepartum\NN\1740 .\.\1740
D002762_D010319 NONE Because\IN\1740 of\IN\1740 the\DT\1740 extreme\JJ\1740 toxicity\NN\13576101 of\IN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 in\IN\13603305 pregnant\JJ\1740 Jersey\NNP\8887013 cows\VBZ\1779644 and\CC\1740 the\DT\1740 low\JJ\1740 margin\NN\13903079 of\IN\1740 safety\NN\13920835 between\IN\1740 doses\NNS\3740161 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 that\WDT\1740 prevent\VBP\1740 milk\NN\7881800 fever\NN\14299637 and\CC\1740 doses\NNS\3740161 that\WDT\1740 induce\VBP\1627355 <e2>milk\NN\7881800 fever</e2>\NN\14299637 ,\,\1740 we\PRP\1740 concluded\VBD\628491 that\IN\1740 vitamin\NN\7570720 D3\NN\1740 can\MD\3094503 not\RB\1740 be\VB\836236 used\VBN\1156834 practically\RB\1740 to\TO\1740 prevent\VB\1740 milk\NN\7881800 fever\NN\14299637 when\WRB\1740 injected\VBN\81072 several\JJ\1740 weeks\NNS\15113229 prepartum\NN\1740 .\.\1740
D002762_D010319 NONE Because\IN\1740 of\IN\1740 the\DT\1740 extreme\JJ\1740 toxicity\NN\13576101 of\IN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 in\IN\13603305 pregnant\JJ\1740 Jersey\NNP\8887013 cows\VBZ\1779644 and\CC\1740 the\DT\1740 low\JJ\1740 margin\NN\13903079 of\IN\1740 safety\NN\13920835 between\IN\1740 doses\NNS\3740161 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 that\WDT\1740 prevent\VBP\1740 milk\NN\7881800 fever\NN\14299637 and\CC\1740 doses\NNS\3740161 that\WDT\1740 induce\VBP\1627355 milk\NN\7881800 fever\NN\14299637 ,\,\1740 we\PRP\1740 concluded\VBD\628491 that\IN\1740 vitamin\NN\7570720 D3\NN\1740 can\MD\3094503 not\RB\1740 be\VB\836236 used\VBN\1156834 practically\RB\1740 to\TO\1740 prevent\VB\1740 <e2>milk\NN\7881800 fever</e2>\NN\14299637 when\WRB\1740 injected\VBN\81072 several\JJ\1740 weeks\NNS\15113229 prepartum\NN\1740 .\.\1740
D002762_D010319 NONE Because\IN\1740 of\IN\1740 the\DT\1740 extreme\JJ\1740 toxicity\NN\13576101 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 in\IN\13603305 pregnant\JJ\1740 Jersey\NNP\8887013 cows\VBZ\1779644 and\CC\1740 the\DT\1740 low\JJ\1740 margin\NN\13903079 of\IN\1740 safety\NN\13920835 between\IN\1740 doses\NNS\3740161 of\IN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 that\WDT\1740 prevent\VBP\1740 <e2>milk\NN\7881800 fever</e2>\NN\14299637 and\CC\1740 doses\NNS\3740161 that\WDT\1740 induce\VBP\1627355 milk\NN\7881800 fever\NN\14299637 ,\,\1740 we\PRP\1740 concluded\VBD\628491 that\IN\1740 vitamin\NN\7570720 D3\NN\1740 can\MD\3094503 not\RB\1740 be\VB\836236 used\VBN\1156834 practically\RB\1740 to\TO\1740 prevent\VB\1740 milk\NN\7881800 fever\NN\14299637 when\WRB\1740 injected\VBN\81072 several\JJ\1740 weeks\NNS\15113229 prepartum\NN\1740 .\.\1740
D002762_D010319 NONE Because\IN\1740 of\IN\1740 the\DT\1740 extreme\JJ\1740 toxicity\NN\13576101 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 in\IN\13603305 pregnant\JJ\1740 Jersey\NNP\8887013 cows\VBZ\1779644 and\CC\1740 the\DT\1740 low\JJ\1740 margin\NN\13903079 of\IN\1740 safety\NN\13920835 between\IN\1740 doses\NNS\3740161 of\IN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 that\WDT\1740 prevent\VBP\1740 milk\NN\7881800 fever\NN\14299637 and\CC\1740 doses\NNS\3740161 that\WDT\1740 induce\VBP\1627355 <e2>milk\NN\7881800 fever</e2>\NN\14299637 ,\,\1740 we\PRP\1740 concluded\VBD\628491 that\IN\1740 vitamin\NN\7570720 D3\NN\1740 can\MD\3094503 not\RB\1740 be\VB\836236 used\VBN\1156834 practically\RB\1740 to\TO\1740 prevent\VB\1740 milk\NN\7881800 fever\NN\14299637 when\WRB\1740 injected\VBN\81072 several\JJ\1740 weeks\NNS\15113229 prepartum\NN\1740 .\.\1740
D002762_D010319 NONE Because\IN\1740 of\IN\1740 the\DT\1740 extreme\JJ\1740 toxicity\NN\13576101 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 in\IN\13603305 pregnant\JJ\1740 Jersey\NNP\8887013 cows\VBZ\1779644 and\CC\1740 the\DT\1740 low\JJ\1740 margin\NN\13903079 of\IN\1740 safety\NN\13920835 between\IN\1740 doses\NNS\3740161 of\IN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 that\WDT\1740 prevent\VBP\1740 milk\NN\7881800 fever\NN\14299637 and\CC\1740 doses\NNS\3740161 that\WDT\1740 induce\VBP\1627355 milk\NN\7881800 fever\NN\14299637 ,\,\1740 we\PRP\1740 concluded\VBD\628491 that\IN\1740 vitamin\NN\7570720 D3\NN\1740 can\MD\3094503 not\RB\1740 be\VB\836236 used\VBN\1156834 practically\RB\1740 to\TO\1740 prevent\VB\1740 <e2>milk\NN\7881800 fever</e2>\NN\14299637 when\WRB\1740 injected\VBN\81072 several\JJ\1740 weeks\NNS\15113229 prepartum\NN\1740 .\.\1740
D002762_D010319 NONE Because\IN\1740 of\IN\1740 the\DT\1740 extreme\JJ\1740 toxicity\NN\13576101 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 in\IN\13603305 pregnant\JJ\1740 Jersey\NNP\8887013 cows\VBZ\1779644 and\CC\1740 the\DT\1740 low\JJ\1740 margin\NN\13903079 of\IN\1740 safety\NN\13920835 between\IN\1740 doses\NNS\3740161 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 that\WDT\1740 prevent\VBP\1740 <e2>milk\NN\7881800 fever</e2>\NN\14299637 and\CC\1740 doses\NNS\3740161 that\WDT\1740 induce\VBP\1627355 milk\NN\7881800 fever\NN\14299637 ,\,\1740 we\PRP\1740 concluded\VBD\628491 that\IN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 can\MD\3094503 not\RB\1740 be\VB\836236 used\VBN\1156834 practically\RB\1740 to\TO\1740 prevent\VB\1740 milk\NN\7881800 fever\NN\14299637 when\WRB\1740 injected\VBN\81072 several\JJ\1740 weeks\NNS\15113229 prepartum\NN\1740 .\.\1740
D002762_D010319 NONE Because\IN\1740 of\IN\1740 the\DT\1740 extreme\JJ\1740 toxicity\NN\13576101 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 in\IN\13603305 pregnant\JJ\1740 Jersey\NNP\8887013 cows\VBZ\1779644 and\CC\1740 the\DT\1740 low\JJ\1740 margin\NN\13903079 of\IN\1740 safety\NN\13920835 between\IN\1740 doses\NNS\3740161 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 that\WDT\1740 prevent\VBP\1740 milk\NN\7881800 fever\NN\14299637 and\CC\1740 doses\NNS\3740161 that\WDT\1740 induce\VBP\1627355 <e2>milk\NN\7881800 fever</e2>\NN\14299637 ,\,\1740 we\PRP\1740 concluded\VBD\628491 that\IN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 can\MD\3094503 not\RB\1740 be\VB\836236 used\VBN\1156834 practically\RB\1740 to\TO\1740 prevent\VB\1740 milk\NN\7881800 fever\NN\14299637 when\WRB\1740 injected\VBN\81072 several\JJ\1740 weeks\NNS\15113229 prepartum\NN\1740 .\.\1740
D002762_D010319 NONE Because\IN\1740 of\IN\1740 the\DT\1740 extreme\JJ\1740 toxicity\NN\13576101 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 in\IN\13603305 pregnant\JJ\1740 Jersey\NNP\8887013 cows\VBZ\1779644 and\CC\1740 the\DT\1740 low\JJ\1740 margin\NN\13903079 of\IN\1740 safety\NN\13920835 between\IN\1740 doses\NNS\3740161 of\IN\1740 vitamin\NN\7570720 D3\NN\1740 that\WDT\1740 prevent\VBP\1740 milk\NN\7881800 fever\NN\14299637 and\CC\1740 doses\NNS\3740161 that\WDT\1740 induce\VBP\1627355 milk\NN\7881800 fever\NN\14299637 ,\,\1740 we\PRP\1740 concluded\VBD\628491 that\IN\1740 <e1>vitamin\NN\7570720 D3</e1>\NN\1740 can\MD\3094503 not\RB\1740 be\VB\836236 used\VBN\1156834 practically\RB\1740 to\TO\1740 prevent\VB\1740 <e2>milk\NN\7881800 fever</e2>\NN\14299637 when\WRB\1740 injected\VBN\81072 several\JJ\1740 weeks\NNS\15113229 prepartum\NN\1740 .\.\1740
603022
D005702_D062787 NONE <e1>Galanthamine\NN\1740 hydrobromide</e1>\NN\1740 ,\,\1740 an\DT\6697703 anticholinesterase\NN\3740161 drug\NN\14778436 capable\JJ\1740 of\IN\1740 penetrating\VBG\2016523 the\DT\1740 blood-brain\JJ\1740 barrier\NN\3839993 ,\,\1740 was\VBD\836236 used\VBN\1156834 in\IN\13603305 a\DT\13649268 patient\NN\9898892 demonstrating\VBG\2137132 central\JJ\1740 effects\NNS\13245626 of\IN\1740 scopolamine\NN\14712692 (\-LRB-\1740 hyoscine\NN\14712692 )\-RRB-\1740 <e2>overdosage</e2>\NN\1740 .\.\1740
D012601_D062787 CID Galanthamine\NN\1740 hydrobromide\NN\1740 ,\,\1740 an\DT\6697703 anticholinesterase\NN\3740161 drug\NN\14778436 capable\JJ\1740 of\IN\1740 penetrating\VBG\2016523 the\DT\1740 blood-brain\JJ\1740 barrier\NN\3839993 ,\,\1740 was\VBD\836236 used\VBN\1156834 in\IN\13603305 a\DT\13649268 patient\NN\9898892 demonstrating\VBG\2137132 central\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>scopolamine</e1>\NN\14712692 (\-LRB-\1740 hyoscine\NN\14712692 )\-RRB-\1740 <e2>overdosage</e2>\NN\1740 .\.\1740
D012601_D062787 CID Galanthamine\NN\1740 hydrobromide\NN\1740 ,\,\1740 an\DT\6697703 anticholinesterase\NN\3740161 drug\NN\14778436 capable\JJ\1740 of\IN\1740 penetrating\VBG\2016523 the\DT\1740 blood-brain\JJ\1740 barrier\NN\3839993 ,\,\1740 was\VBD\836236 used\VBN\1156834 in\IN\13603305 a\DT\13649268 patient\NN\9898892 demonstrating\VBG\2137132 central\JJ\1740 effects\NNS\13245626 of\IN\1740 scopolamine\NN\14712692 (\-LRB-\1740 <e1>hyoscine</e1>\NN\14712692 )\-RRB-\1740 <e2>overdosage</e2>\NN\1740 .\.\1740
1601297
D003042_D009202 NONE Electrocardiographic\JJ\1740 evidence\NN\5816287 of\IN\1740 <e2>myocardial\JJ\1740 injury</e2>\NN\14052046 in\IN\13603305 psychiatrically\RB\1740 hospitalized\VBN\2348568 <e1>cocaine</e1>\NN\3492717 abusers\NNS\9633969 .\.\1740
D003042_D009202 NONE Eleven\CD\13745420 of\IN\1740 the\DT\1740 <e1>cocaine</e1>\NN\3492717 abusers\NNS\9633969 and\CC\1740 none\NN\15228378 of\IN\1740 the\DT\1740 controls\NNS\5190804 had\VBD\2108377 ECG\NNP\7000195 evidence\NN\5816287 of\IN\1740 significant\JJ\1740 <e2>myocardial\JJ\1740 injury</e2>\NN\14052046 defined\VBN\2604760 as\IN\14622893 myocardial\JJ\1740 infarction\NN\14204950 ,\,\1740 ischemia\NN\14195315 ,\,\1740 and\CC\1740 bundle\VBP\1482449 branch\NN\8220714 block\NN\21939 .\.\1740
D003042_D012559 NONE The\DT\1740 electrocardiograms\NNS\7000195 (\-LRB-\1740 ECG\NN\7000195 )\-RRB-\1740 of\IN\1740 99\CD\1740 <e1>cocaine-abusing</e1>\JJ\1740 patients\NNS\9898892 were\VBD\836236 compared\VBN\644583 with\IN\1740 the\DT\1740 ECGs\NNS\7000195 of\IN\1740 50\CD\13745420 <e2>schizophrenic</e2>\JJ\1740 controls\NNS\5190804 .\.\1740
D003042_D009203 CID Eleven\CD\13745420 of\IN\1740 the\DT\1740 <e1>cocaine</e1>\NN\3492717 abusers\NNS\9633969 and\CC\1740 none\NN\15228378 of\IN\1740 the\DT\1740 controls\NNS\5190804 had\VBD\2108377 ECG\NNP\7000195 evidence\NN\5816287 of\IN\1740 significant\JJ\1740 myocardial\JJ\1740 injury\NN\14052046 defined\VBN\2604760 as\IN\14622893 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 ,\,\1740 ischemia\NN\14195315 ,\,\1740 and\CC\1740 bundle\VBP\1482449 branch\NN\8220714 block\NN\21939 .\.\1740
D003042_D007511 NONE Eleven\CD\13745420 of\IN\1740 the\DT\1740 <e1>cocaine</e1>\NN\3492717 abusers\NNS\9633969 and\CC\1740 none\NN\15228378 of\IN\1740 the\DT\1740 controls\NNS\5190804 had\VBD\2108377 ECG\NNP\7000195 evidence\NN\5816287 of\IN\1740 significant\JJ\1740 myocardial\JJ\1740 injury\NN\14052046 defined\VBN\2604760 as\IN\14622893 myocardial\JJ\1740 infarction\NN\14204950 ,\,\1740 <e2>ischemia</e2>\NN\14195315 ,\,\1740 and\CC\1740 bundle\VBP\1482449 branch\NN\8220714 block\NN\21939 .\.\1740
D003042_D002037 CID Eleven\CD\13745420 of\IN\1740 the\DT\1740 <e1>cocaine</e1>\NN\3492717 abusers\NNS\9633969 and\CC\1740 none\NN\15228378 of\IN\1740 the\DT\1740 controls\NNS\5190804 had\VBD\2108377 ECG\NNP\7000195 evidence\NN\5816287 of\IN\1740 significant\JJ\1740 myocardial\JJ\1740 injury\NN\14052046 defined\VBN\2604760 as\IN\14622893 myocardial\JJ\1740 infarction\NN\14204950 ,\,\1740 ischemia\NN\14195315 ,\,\1740 and\CC\1740 <e2>bundle\VBP\1482449 branch\NN\8220714 block</e2>\NN\21939 .\.\1740
8643971
D017239_D006258 NONE A\DT\13649268 phase\NN\15113229 I/II\NN\1740 study\NN\635850 of\IN\1740 <e1>paclitaxel</e1>\NN\1740 plus\CC\4723816 cisplatin\NN\1740 as\IN\14622893 first-line\JJ\1740 therapy\NN\657604 for\IN\1740 <e2>head\NN\5225090 and\CC\1740 neck\NN\5225090 cancers</e2>\NNS\14239425 :\:\1740 preliminary\JJ\1740 results\NNS\34213 .\.\1740
D017239_D006258 NONE Preliminary\JJ\1740 results\NNS\34213 of\IN\1740 an\DT\6697703 Eastern\JJ\1740 Cooperative\NNP\8065093 Oncology\NN\6043075 Group\NNP\2137 study\NN\635850 of\IN\1740 single-agent\JJ\1740 <e1>paclitaxel</e1>\NN\1740 (\-LRB-\1740 Taxol\NN\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 reported\VBD\831651 a\DT\13649268 37\CD\1740 %\NN\1740 response\NN\11410625 rate\NN\13815152 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>head\NN\5225090 and\CC\1740 neck\NN\5225090 cancer</e2>\NN\14239425 ,\,\1740 and\CC\1740 the\DT\1740 paclitaxel/cisplatin\NN\1740 combination\NN\7951464 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 successfully\RB\1740 and\CC\1740 has\VBZ\2108377 significantly\RB\1740 improved\VBN\126264 median\JJ\1740 response\NN\11410625 duration\NN\15113229 in\IN\13603305 ovarian\JJ\1740 cancer\NN\14239425 patients\NNS\9898892 .\.\1740
D017239_D006258 NONE Preliminary\JJ\1740 results\NNS\34213 of\IN\1740 an\DT\6697703 Eastern\JJ\1740 Cooperative\NNP\8065093 Oncology\NN\6043075 Group\NNP\2137 study\NN\635850 of\IN\1740 single-agent\JJ\1740 paclitaxel\NN\1740 (\-LRB-\1740 <e1>Taxol</e1>\NN\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 reported\VBD\831651 a\DT\13649268 37\CD\1740 %\NN\1740 response\NN\11410625 rate\NN\13815152 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>head\NN\5225090 and\CC\1740 neck\NN\5225090 cancer</e2>\NN\14239425 ,\,\1740 and\CC\1740 the\DT\1740 paclitaxel/cisplatin\NN\1740 combination\NN\7951464 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 successfully\RB\1740 and\CC\1740 has\VBZ\2108377 significantly\RB\1740 improved\VBN\126264 median\JJ\1740 response\NN\11410625 duration\NN\15113229 in\IN\13603305 ovarian\JJ\1740 cancer\NN\14239425 patients\NNS\9898892 .\.\1740
D017239_D006258 NONE Preliminary\JJ\1740 results\NNS\34213 of\IN\1740 an\DT\6697703 Eastern\JJ\1740 Cooperative\NNP\8065093 Oncology\NN\6043075 Group\NNP\2137 study\NN\635850 of\IN\1740 single-agent\JJ\1740 paclitaxel\NN\1740 (\-LRB-\1740 Taxol\NN\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 reported\VBD\831651 a\DT\13649268 37\CD\1740 %\NN\1740 response\NN\11410625 rate\NN\13815152 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>head\NN\5225090 and\CC\1740 neck\NN\5225090 cancer</e2>\NN\14239425 ,\,\1740 and\CC\1740 the\DT\1740 <e1>paclitaxel/cisplatin</e1>\NN\1740 combination\NN\7951464 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 successfully\RB\1740 and\CC\1740 has\VBZ\2108377 significantly\RB\1740 improved\VBN\126264 median\JJ\1740 response\NN\11410625 duration\NN\15113229 in\IN\13603305 ovarian\JJ\1740 cancer\NN\14239425 patients\NNS\9898892 .\.\1740
D017239_D006258 NONE We\PRP\1740 initiated\VBD\1617192 a\DT\13649268 phase\NN\15113229 I/II\NN\1740 trial\NN\786195 to\TO\1740 determine\VB\1645601 the\DT\1740 response\NN\11410625 and\CC\1740 toxicity\NN\13576101 of\IN\1740 escalating\VBG\153263 <e1>paclitaxel</e1>\NN\1740 doses\NNS\3740161 combined\VBN\2630189 with\IN\1740 fixed-dose\JJ\1740 cisplatin\NN\1740 with\IN\1740 granulocyte\NN\5449959 colony-stimulating\JJ\1740 factor\NN\7326557 support\NN\407535 in\IN\13603305 patients\NNS\9898892 with\IN\1740 untreated\JJ\1740 locally\RB\1740 advanced\VBN\1835496 inoperable\JJ\1740 <e2>head\NN\5225090 and\CC\1740 neck\NN\5225090 carcinoma</e2>\NN\14239918 .\.\1740
D017239_D006258 NONE <e1>Paclitaxel/cisplatin</e1>\NN\1740 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 first-line\JJ\1740 regimen\NN\5898568 for\IN\1740 locoregionally\RB\1740 advanced\JJ\1740 <e2>head\NN\5225090 and\CC\1740 neck\NN\5225090 cancer</e2>\NN\14239425 and\CC\1740 continued\VBN\2367363 study\NN\635850 is\VBZ\836236 warranted\VBN\1012073 .\.\1740
D002945_D006258 NONE A\DT\13649268 phase\NN\15113229 I/II\NN\1740 study\NN\635850 of\IN\1740 paclitaxel\NN\1740 plus\CC\4723816 <e1>cisplatin</e1>\NN\1740 as\IN\14622893 first-line\JJ\1740 therapy\NN\657604 for\IN\1740 <e2>head\NN\5225090 and\CC\1740 neck\NN\5225090 cancers</e2>\NNS\14239425 :\:\1740 preliminary\JJ\1740 results\NNS\34213 .\.\1740
D002945_D006258 NONE Preliminary\JJ\1740 results\NNS\34213 of\IN\1740 an\DT\6697703 Eastern\JJ\1740 Cooperative\NNP\8065093 Oncology\NN\6043075 Group\NNP\2137 study\NN\635850 of\IN\1740 single-agent\JJ\1740 paclitaxel\NN\1740 (\-LRB-\1740 Taxol\NN\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 reported\VBD\831651 a\DT\13649268 37\CD\1740 %\NN\1740 response\NN\11410625 rate\NN\13815152 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>head\NN\5225090 and\CC\1740 neck\NN\5225090 cancer</e2>\NN\14239425 ,\,\1740 and\CC\1740 the\DT\1740 <e1>paclitaxel/cisplatin</e1>\NN\1740 combination\NN\7951464 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 successfully\RB\1740 and\CC\1740 has\VBZ\2108377 significantly\RB\1740 improved\VBN\126264 median\JJ\1740 response\NN\11410625 duration\NN\15113229 in\IN\13603305 ovarian\JJ\1740 cancer\NN\14239425 patients\NNS\9898892 .\.\1740
D002945_D006258 NONE We\PRP\1740 initiated\VBD\1617192 a\DT\13649268 phase\NN\15113229 I/II\NN\1740 trial\NN\786195 to\TO\1740 determine\VB\1645601 the\DT\1740 response\NN\11410625 and\CC\1740 toxicity\NN\13576101 of\IN\1740 escalating\VBG\153263 paclitaxel\NN\1740 doses\NNS\3740161 combined\VBN\2630189 with\IN\1740 fixed-dose\JJ\1740 <e1>cisplatin</e1>\NN\1740 with\IN\1740 granulocyte\NN\5449959 colony-stimulating\JJ\1740 factor\NN\7326557 support\NN\407535 in\IN\13603305 patients\NNS\9898892 with\IN\1740 untreated\JJ\1740 locally\RB\1740 advanced\VBN\1835496 inoperable\JJ\1740 <e2>head\NN\5225090 and\CC\1740 neck\NN\5225090 carcinoma</e2>\NN\14239918 .\.\1740
D002945_D006258 NONE <e1>Paclitaxel/cisplatin</e1>\NN\1740 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 first-line\JJ\1740 regimen\NN\5898568 for\IN\1740 locoregionally\RB\1740 advanced\JJ\1740 <e2>head\NN\5225090 and\CC\1740 neck\NN\5225090 cancer</e2>\NN\14239425 and\CC\1740 continued\VBN\2367363 study\NN\635850 is\VBZ\836236 warranted\VBN\1012073 .\.\1740
D017239_D010051 NONE Preliminary\JJ\1740 results\NNS\34213 of\IN\1740 an\DT\6697703 Eastern\JJ\1740 Cooperative\NNP\8065093 Oncology\NN\6043075 Group\NNP\2137 study\NN\635850 of\IN\1740 single-agent\JJ\1740 <e1>paclitaxel</e1>\NN\1740 (\-LRB-\1740 Taxol\NN\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 reported\VBD\831651 a\DT\13649268 37\CD\1740 %\NN\1740 response\NN\11410625 rate\NN\13815152 in\IN\13603305 patients\NNS\9898892 with\IN\1740 head\NN\5225090 and\CC\1740 neck\NN\5225090 cancer\NN\14239425 ,\,\1740 and\CC\1740 the\DT\1740 paclitaxel/cisplatin\NN\1740 combination\NN\7951464 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 successfully\RB\1740 and\CC\1740 has\VBZ\2108377 significantly\RB\1740 improved\VBN\126264 median\JJ\1740 response\NN\11410625 duration\NN\15113229 in\IN\13603305 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 patients\NNS\9898892 .\.\1740
D017239_D010051 NONE Preliminary\JJ\1740 results\NNS\34213 of\IN\1740 an\DT\6697703 Eastern\JJ\1740 Cooperative\NNP\8065093 Oncology\NN\6043075 Group\NNP\2137 study\NN\635850 of\IN\1740 single-agent\JJ\1740 paclitaxel\NN\1740 (\-LRB-\1740 <e1>Taxol</e1>\NN\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 reported\VBD\831651 a\DT\13649268 37\CD\1740 %\NN\1740 response\NN\11410625 rate\NN\13815152 in\IN\13603305 patients\NNS\9898892 with\IN\1740 head\NN\5225090 and\CC\1740 neck\NN\5225090 cancer\NN\14239425 ,\,\1740 and\CC\1740 the\DT\1740 paclitaxel/cisplatin\NN\1740 combination\NN\7951464 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 successfully\RB\1740 and\CC\1740 has\VBZ\2108377 significantly\RB\1740 improved\VBN\126264 median\JJ\1740 response\NN\11410625 duration\NN\15113229 in\IN\13603305 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 patients\NNS\9898892 .\.\1740
D017239_D010051 NONE Preliminary\JJ\1740 results\NNS\34213 of\IN\1740 an\DT\6697703 Eastern\JJ\1740 Cooperative\NNP\8065093 Oncology\NN\6043075 Group\NNP\2137 study\NN\635850 of\IN\1740 single-agent\JJ\1740 paclitaxel\NN\1740 (\-LRB-\1740 Taxol\NN\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 reported\VBD\831651 a\DT\13649268 37\CD\1740 %\NN\1740 response\NN\11410625 rate\NN\13815152 in\IN\13603305 patients\NNS\9898892 with\IN\1740 head\NN\5225090 and\CC\1740 neck\NN\5225090 cancer\NN\14239425 ,\,\1740 and\CC\1740 the\DT\1740 <e1>paclitaxel/cisplatin</e1>\NN\1740 combination\NN\7951464 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 successfully\RB\1740 and\CC\1740 has\VBZ\2108377 significantly\RB\1740 improved\VBN\126264 median\JJ\1740 response\NN\11410625 duration\NN\15113229 in\IN\13603305 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 patients\NNS\9898892 .\.\1740
D002945_D010051 NONE Preliminary\JJ\1740 results\NNS\34213 of\IN\1740 an\DT\6697703 Eastern\JJ\1740 Cooperative\NNP\8065093 Oncology\NN\6043075 Group\NNP\2137 study\NN\635850 of\IN\1740 single-agent\JJ\1740 paclitaxel\NN\1740 (\-LRB-\1740 Taxol\NN\1740 ;\:\1740 Bristol-Myers\NNP\1740 Squibb\NNP\1740 Company\NNP\8053576 ,\,\1740 Princeton\NNP\1740 ,\,\1740 NJ\NNP\1740 )\-RRB-\1740 reported\VBD\831651 a\DT\13649268 37\CD\1740 %\NN\1740 response\NN\11410625 rate\NN\13815152 in\IN\13603305 patients\NNS\9898892 with\IN\1740 head\NN\5225090 and\CC\1740 neck\NN\5225090 cancer\NN\14239425 ,\,\1740 and\CC\1740 the\DT\1740 <e1>paclitaxel/cisplatin</e1>\NN\1740 combination\NN\7951464 has\VBZ\2108377 been\VBN\836236 used\VBN\1156834 successfully\RB\1740 and\CC\1740 has\VBZ\2108377 significantly\RB\1740 improved\VBN\126264 median\JJ\1740 response\NN\11410625 duration\NN\15113229 in\IN\13603305 <e2>ovarian\JJ\1740 cancer</e2>\NN\14239425 patients\NNS\9898892 .\.\1740
D017239_D064420 NONE We\PRP\1740 initiated\VBD\1617192 a\DT\13649268 phase\NN\15113229 I/II\NN\1740 trial\NN\786195 to\TO\1740 determine\VB\1645601 the\DT\1740 response\NN\11410625 and\CC\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 escalating\VBG\153263 <e1>paclitaxel</e1>\NN\1740 doses\NNS\3740161 combined\VBN\2630189 with\IN\1740 fixed-dose\JJ\1740 cisplatin\NN\1740 with\IN\1740 granulocyte\NN\5449959 colony-stimulating\JJ\1740 factor\NN\7326557 support\NN\407535 in\IN\13603305 patients\NNS\9898892 with\IN\1740 untreated\JJ\1740 locally\RB\1740 advanced\VBN\1835496 inoperable\JJ\1740 head\NN\5225090 and\CC\1740 neck\NN\5225090 carcinoma\NN\14239918 .\.\1740
D017239_D064420 NONE The\DT\1740 dose\NN\3740161 levels\NNS\4916342 incorporate\VBP\1461328 escalating\VBG\153263 <e1>paclitaxel</e1>\NN\1740 doses\NNS\3740161 ,\,\1740 and\CC\1740 intrapatient\JJ\1740 escalations\NNS\363260 within\IN\1740 a\DT\13649268 given\VBN\2327200 dose\NN\3740161 level\NN\4916342 are\VBP\836236 permitted\VBN\797697 if\IN\1740 <e2>toxicity</e2>\NN\13576101 permits\NNS\6479665 .\.\1740
D002945_D064420 NONE We\PRP\1740 initiated\VBD\1617192 a\DT\13649268 phase\NN\15113229 I/II\NN\1740 trial\NN\786195 to\TO\1740 determine\VB\1645601 the\DT\1740 response\NN\11410625 and\CC\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 escalating\VBG\153263 paclitaxel\NN\1740 doses\NNS\3740161 combined\VBN\2630189 with\IN\1740 fixed-dose\JJ\1740 <e1>cisplatin</e1>\NN\1740 with\IN\1740 granulocyte\NN\5449959 colony-stimulating\JJ\1740 factor\NN\7326557 support\NN\407535 in\IN\13603305 patients\NNS\9898892 with\IN\1740 untreated\JJ\1740 locally\RB\1740 advanced\VBN\1835496 inoperable\JJ\1740 head\NN\5225090 and\CC\1740 neck\NN\5225090 carcinoma\NN\14239918 .\.\1740
9523805
D011318_D009422 CID <e2>Transient\JJ\1740 neurologic\JJ\1740 symptoms</e2>\NNS\5823932 after\IN\1740 spinal\JJ\1740 anesthesia\NN\14034177 :\:\1740 a\DT\13649268 lower\JJR\1740 incidence\NN\13821570 with\IN\1740 <e1>prilocaine</e1>\NN\1740 and\CC\1740 bupivacaine\NN\1740 than\IN\1740 with\IN\1740 lidocaine\NN\3681148 .\.\1740
D011318_D009422 CID Accordingly\RB\1740 ,\,\1740 the\DT\1740 present\JJ\1740 ,\,\1740 prospective\JJ\1740 double-blind\JJ\1740 study\NN\635850 compares\VBZ\644583 <e1>prilocaine</e1>\NN\1740 with\IN\1740 lidocaine\NN\3681148 and\CC\1740 bupivacaine\VB\1740 with\IN\1740 respect\NN\5817845 to\TO\1740 duration\NN\15113229 of\IN\1740 action\NN\30358 and\CC\1740 relative\JJ\1740 risk\NN\14541044 of\IN\1740 <e2>TNSs</e2>\NNS\1740 .\.\1740
D011318_D009422 CID RESULTS\NNS\34213 :\:\1740 Nine\CD\13741022 of\IN\1740 30\CD\13745420 patients\NNS\9898892 receiving\VBG\2210855 lidocaine\NN\3681148 experienced\JJ\1740 <e2>TNSs</e2>\NNS\1740 ,\,\1740 1\CD\13741022 of\IN\1740 30\CD\13745420 patients\NNS\9898892 receiving\VBG\2210855 <e1>prilocaine</e1>\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.03\CD\1740 )\-RRB-\1740 had\VBD\2108377 them\PRP\1740 ,\,\1740 and\CC\1740 none\NN\15228378 of\IN\1740 30\CD\13745420 patients\NNS\9898892 receiving\VBG\2210855 bupivacaine\NN\1740 had\VBD\2108377 TNSs\NNS\1740 .\.\1740
D011318_D009422 CID RESULTS\NNS\34213 :\:\1740 Nine\CD\13741022 of\IN\1740 30\CD\13745420 patients\NNS\9898892 receiving\VBG\2210855 lidocaine\NN\3681148 experienced\JJ\1740 TNSs\NNS\1740 ,\,\1740 1\CD\13741022 of\IN\1740 30\CD\13745420 patients\NNS\9898892 receiving\VBG\2210855 <e1>prilocaine</e1>\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.03\CD\1740 )\-RRB-\1740 had\VBD\2108377 them\PRP\1740 ,\,\1740 and\CC\1740 none\NN\15228378 of\IN\1740 30\CD\13745420 patients\NNS\9898892 receiving\VBG\2210855 bupivacaine\NN\1740 had\VBD\2108377 <e2>TNSs</e2>\NNS\1740 .\.\1740
D011318_D009422 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Prilocaine</e1>\NN\1740 may\MD\15209706 be\VB\836236 preferable\JJ\1740 to\TO\1740 lidocaine\NN\3681148 for\IN\1740 short\JJ\1740 surgical\JJ\1740 procedures\NNS\407535 because\IN\1740 it\PRP\6125041 has\VBZ\2108377 a\DT\13649268 similar\JJ\1740 duration\NN\15113229 of\IN\1740 action\NN\30358 but\CC\1740 a\DT\13649268 lower\JJR\1740 incidence\NN\13821570 of\IN\1740 <e2>TNSs</e2>\NNS\1740 .\.\1740
D002045_D009422 NONE <e2>Transient\JJ\1740 neurologic\JJ\1740 symptoms</e2>\NNS\5823932 after\IN\1740 spinal\JJ\1740 anesthesia\NN\14034177 :\:\1740 a\DT\13649268 lower\JJR\1740 incidence\NN\13821570 with\IN\1740 prilocaine\NN\1740 and\CC\1740 <e1>bupivacaine</e1>\NN\1740 than\IN\1740 with\IN\1740 lidocaine\NN\3681148 .\.\1740
D002045_D009422 NONE BACKGROUND\NN\4921011 :\:\1740 Recent\JJ\1740 evidence\NN\5816287 suggests\VBZ\1010118 that\IN\1740 <e2>transient\JJ\1740 neurologic\JJ\1740 symptoms</e2>\NNS\5823932 (\-LRB-\1740 TNSs\NNS\1740 )\-RRB-\1740 frequently\RB\1740 follow\VBP\1835496 lidocaine\NN\3681148 spinal\JJ\1740 anesthesia\NN\14034177 but\CC\1740 are\VBP\836236 infrequent\JJ\1740 with\IN\1740 <e1>bupivacaine</e1>\NN\1740 .\.\1740
D002045_D009422 NONE BACKGROUND\NN\4921011 :\:\1740 Recent\JJ\1740 evidence\NN\5816287 suggests\VBZ\1010118 that\IN\1740 transient\JJ\1740 neurologic\JJ\1740 symptoms\NNS\5823932 (\-LRB-\1740 <e2>TNSs</e2>\NNS\1740 )\-RRB-\1740 frequently\RB\1740 follow\VBP\1835496 lidocaine\NN\3681148 spinal\JJ\1740 anesthesia\NN\14034177 but\CC\1740 are\VBP\836236 infrequent\JJ\1740 with\IN\1740 <e1>bupivacaine</e1>\NN\1740 .\.\1740
D002045_D009422 NONE Accordingly\RB\1740 ,\,\1740 the\DT\1740 present\JJ\1740 ,\,\1740 prospective\JJ\1740 double-blind\JJ\1740 study\NN\635850 compares\VBZ\644583 prilocaine\NN\1740 with\IN\1740 lidocaine\NN\3681148 and\CC\1740 <e1>bupivacaine</e1>\VB\1740 with\IN\1740 respect\NN\5817845 to\TO\1740 duration\NN\15113229 of\IN\1740 action\NN\30358 and\CC\1740 relative\JJ\1740 risk\NN\14541044 of\IN\1740 <e2>TNSs</e2>\NNS\1740 .\.\1740
D002045_D009422 NONE RESULTS\NNS\34213 :\:\1740 Nine\CD\13741022 of\IN\1740 30\CD\13745420 patients\NNS\9898892 receiving\VBG\2210855 lidocaine\NN\3681148 experienced\JJ\1740 <e2>TNSs</e2>\NNS\1740 ,\,\1740 1\CD\13741022 of\IN\1740 30\CD\13745420 patients\NNS\9898892 receiving\VBG\2210855 prilocaine\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.03\CD\1740 )\-RRB-\1740 had\VBD\2108377 them\PRP\1740 ,\,\1740 and\CC\1740 none\NN\15228378 of\IN\1740 30\CD\13745420 patients\NNS\9898892 receiving\VBG\2210855 <e1>bupivacaine</e1>\NN\1740 had\VBD\2108377 TNSs\NNS\1740 .\.\1740
D002045_D009422 NONE RESULTS\NNS\34213 :\:\1740 Nine\CD\13741022 of\IN\1740 30\CD\13745420 patients\NNS\9898892 receiving\VBG\2210855 lidocaine\NN\3681148 experienced\JJ\1740 TNSs\NNS\1740 ,\,\1740 1\CD\13741022 of\IN\1740 30\CD\13745420 patients\NNS\9898892 receiving\VBG\2210855 prilocaine\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.03\CD\1740 )\-RRB-\1740 had\VBD\2108377 them\PRP\1740 ,\,\1740 and\CC\1740 none\NN\15228378 of\IN\1740 30\CD\13745420 patients\NNS\9898892 receiving\VBG\2210855 <e1>bupivacaine</e1>\NN\1740 had\VBD\2108377 <e2>TNSs</e2>\NNS\1740 .\.\1740
D008012_D009422 CID <e2>Transient\JJ\1740 neurologic\JJ\1740 symptoms</e2>\NNS\5823932 after\IN\1740 spinal\JJ\1740 anesthesia\NN\14034177 :\:\1740 a\DT\13649268 lower\JJR\1740 incidence\NN\13821570 with\IN\1740 prilocaine\NN\1740 and\CC\1740 bupivacaine\NN\1740 than\IN\1740 with\IN\1740 <e1>lidocaine</e1>\NN\3681148 .\.\1740
D008012_D009422 CID BACKGROUND\NN\4921011 :\:\1740 Recent\JJ\1740 evidence\NN\5816287 suggests\VBZ\1010118 that\IN\1740 <e2>transient\JJ\1740 neurologic\JJ\1740 symptoms</e2>\NNS\5823932 (\-LRB-\1740 TNSs\NNS\1740 )\-RRB-\1740 frequently\RB\1740 follow\VBP\1835496 <e1>lidocaine</e1>\NN\3681148 spinal\JJ\1740 anesthesia\NN\14034177 but\CC\1740 are\VBP\836236 infrequent\JJ\1740 with\IN\1740 bupivacaine\NN\1740 .\.\1740
D008012_D009422 CID BACKGROUND\NN\4921011 :\:\1740 Recent\JJ\1740 evidence\NN\5816287 suggests\VBZ\1010118 that\IN\1740 transient\JJ\1740 neurologic\JJ\1740 symptoms\NNS\5823932 (\-LRB-\1740 <e2>TNSs</e2>\NNS\1740 )\-RRB-\1740 frequently\RB\1740 follow\VBP\1835496 <e1>lidocaine</e1>\NN\3681148 spinal\JJ\1740 anesthesia\NN\14034177 but\CC\1740 are\VBP\836236 infrequent\JJ\1740 with\IN\1740 bupivacaine\NN\1740 .\.\1740
D008012_D009422 CID Accordingly\RB\1740 ,\,\1740 the\DT\1740 present\JJ\1740 ,\,\1740 prospective\JJ\1740 double-blind\JJ\1740 study\NN\635850 compares\VBZ\644583 prilocaine\NN\1740 with\IN\1740 <e1>lidocaine</e1>\NN\3681148 and\CC\1740 bupivacaine\VB\1740 with\IN\1740 respect\NN\5817845 to\TO\1740 duration\NN\15113229 of\IN\1740 action\NN\30358 and\CC\1740 relative\JJ\1740 risk\NN\14541044 of\IN\1740 <e2>TNSs</e2>\NNS\1740 .\.\1740
D008012_D009422 CID RESULTS\NNS\34213 :\:\1740 Nine\CD\13741022 of\IN\1740 30\CD\13745420 patients\NNS\9898892 receiving\VBG\2210855 <e1>lidocaine</e1>\NN\3681148 experienced\JJ\1740 <e2>TNSs</e2>\NNS\1740 ,\,\1740 1\CD\13741022 of\IN\1740 30\CD\13745420 patients\NNS\9898892 receiving\VBG\2210855 prilocaine\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.03\CD\1740 )\-RRB-\1740 had\VBD\2108377 them\PRP\1740 ,\,\1740 and\CC\1740 none\NN\15228378 of\IN\1740 30\CD\13745420 patients\NNS\9898892 receiving\VBG\2210855 bupivacaine\NN\1740 had\VBD\2108377 TNSs\NNS\1740 .\.\1740
D008012_D009422 CID RESULTS\NNS\34213 :\:\1740 Nine\CD\13741022 of\IN\1740 30\CD\13745420 patients\NNS\9898892 receiving\VBG\2210855 <e1>lidocaine</e1>\NN\3681148 experienced\JJ\1740 TNSs\NNS\1740 ,\,\1740 1\CD\13741022 of\IN\1740 30\CD\13745420 patients\NNS\9898892 receiving\VBG\2210855 prilocaine\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.03\CD\1740 )\-RRB-\1740 had\VBD\2108377 them\PRP\1740 ,\,\1740 and\CC\1740 none\NN\15228378 of\IN\1740 30\CD\13745420 patients\NNS\9898892 receiving\VBG\2210855 bupivacaine\NN\1740 had\VBD\2108377 <e2>TNSs</e2>\NNS\1740 .\.\1740
D008012_D009422 CID CONCLUSIONS\NNS\5837957 :\:\1740 Prilocaine\NN\1740 may\MD\15209706 be\VB\836236 preferable\JJ\1740 to\TO\1740 <e1>lidocaine</e1>\NN\3681148 for\IN\1740 short\JJ\1740 surgical\JJ\1740 procedures\NNS\407535 because\IN\1740 it\PRP\6125041 has\VBZ\2108377 a\DT\13649268 similar\JJ\1740 duration\NN\15113229 of\IN\1740 action\NN\30358 but\CC\1740 a\DT\13649268 lower\JJR\1740 incidence\NN\13821570 of\IN\1740 <e2>TNSs</e2>\NNS\1740 .\.\1740
16167916
D020849_D054556 CID CONCLUSION\NN\5837957 :\:\1740 We\PRP\1740 suggest\VBP\1010118 that\IN\1740 the\DT\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 due\JJ\1740 to\TO\1740 <e1>raloxifene</e1>\NN\1740 treatment\NN\654885 may\MD\15209706 be\VB\836236 related\JJ\1740 to\TO\1740 increased\VBN\169651 tPA\NN\1740 levels\NNS\4916342 ,\,\1740 but\CC\1740 not\RB\1740 TAFI\NN\1740 levels\NNS\4916342 .\.\1740
8092427
D000658_D004342 CID Immediate\JJ\1740 <e2>allergic\JJ\1740 reactions</e2>\NNS\13446390 to\TO\1740 <e1>amoxicillin</e1>\NN\3910033 .\.\1740
D000658_D004342 CID A\DT\13649268 detailed\JJ\1740 clinical\JJ\1740 history\NN\15120823 ,\,\1740 together\RB\1740 with\IN\1740 skin\NN\5237755 tests\NNS\5798043 ,\,\1740 RAST\NN\1740 (\-LRB-\1740 radioallergosorbent\JJ\1740 test\NN\5798043 )\-RRB-\1740 ,\,\1740 and\CC\1740 controlled\VBN\2422663 challenge\NN\13927383 tests\NNS\5798043 ,\,\1740 was\VBD\836236 used\VBN\1156834 to\TO\1740 establish\VB\2426171 whether\IN\1740 patients\NNS\9898892 <e2>allergic</e2>\JJ\1740 to\TO\1740 beta-lactam\JJ\1740 antibiotics\NNS\2716205 had\VBD\2108377 selective\JJ\1740 immediate\JJ\1740 allergic\JJ\1740 responses\NNS\11410625 to\TO\1740 <e1>amoxicillin</e1>\NN\3910033 (\-LRB-\1740 AX\NN\3265032 )\-RRB-\1740 or\CC\3541091 were\VBD\836236 cross-reacting\JJ\1740 with\IN\1740 other\JJ\1740 penicillin\NN\2716866 derivatives\NNS\5802185 .\.\1740
D000658_D004342 CID A\DT\13649268 detailed\JJ\1740 clinical\JJ\1740 history\NN\15120823 ,\,\1740 together\RB\1740 with\IN\1740 skin\NN\5237755 tests\NNS\5798043 ,\,\1740 RAST\NN\1740 (\-LRB-\1740 radioallergosorbent\JJ\1740 test\NN\5798043 )\-RRB-\1740 ,\,\1740 and\CC\1740 controlled\VBN\2422663 challenge\NN\13927383 tests\NNS\5798043 ,\,\1740 was\VBD\836236 used\VBN\1156834 to\TO\1740 establish\VB\2426171 whether\IN\1740 patients\NNS\9898892 allergic\JJ\1740 to\TO\1740 beta-lactam\JJ\1740 antibiotics\NNS\2716205 had\VBD\2108377 selective\JJ\1740 immediate\JJ\1740 <e2>allergic</e2>\JJ\1740 responses\NNS\11410625 to\TO\1740 <e1>amoxicillin</e1>\NN\3910033 (\-LRB-\1740 AX\NN\3265032 )\-RRB-\1740 or\CC\3541091 were\VBD\836236 cross-reacting\JJ\1740 with\IN\1740 other\JJ\1740 penicillin\NN\2716866 derivatives\NNS\5802185 .\.\1740
D000658_D004342 CID A\DT\13649268 detailed\JJ\1740 clinical\JJ\1740 history\NN\15120823 ,\,\1740 together\RB\1740 with\IN\1740 skin\NN\5237755 tests\NNS\5798043 ,\,\1740 RAST\NN\1740 (\-LRB-\1740 radioallergosorbent\JJ\1740 test\NN\5798043 )\-RRB-\1740 ,\,\1740 and\CC\1740 controlled\VBN\2422663 challenge\NN\13927383 tests\NNS\5798043 ,\,\1740 was\VBD\836236 used\VBN\1156834 to\TO\1740 establish\VB\2426171 whether\IN\1740 patients\NNS\9898892 <e2>allergic</e2>\JJ\1740 to\TO\1740 beta-lactam\JJ\1740 antibiotics\NNS\2716205 had\VBD\2108377 selective\JJ\1740 immediate\JJ\1740 allergic\JJ\1740 responses\NNS\11410625 to\TO\1740 amoxicillin\NN\3910033 (\-LRB-\1740 <e1>AX</e1>\NN\3265032 )\-RRB-\1740 or\CC\3541091 were\VBD\836236 cross-reacting\JJ\1740 with\IN\1740 other\JJ\1740 penicillin\NN\2716866 derivatives\NNS\5802185 .\.\1740
D000658_D004342 CID A\DT\13649268 detailed\JJ\1740 clinical\JJ\1740 history\NN\15120823 ,\,\1740 together\RB\1740 with\IN\1740 skin\NN\5237755 tests\NNS\5798043 ,\,\1740 RAST\NN\1740 (\-LRB-\1740 radioallergosorbent\JJ\1740 test\NN\5798043 )\-RRB-\1740 ,\,\1740 and\CC\1740 controlled\VBN\2422663 challenge\NN\13927383 tests\NNS\5798043 ,\,\1740 was\VBD\836236 used\VBN\1156834 to\TO\1740 establish\VB\2426171 whether\IN\1740 patients\NNS\9898892 allergic\JJ\1740 to\TO\1740 beta-lactam\JJ\1740 antibiotics\NNS\2716205 had\VBD\2108377 selective\JJ\1740 immediate\JJ\1740 <e2>allergic</e2>\JJ\1740 responses\NNS\11410625 to\TO\1740 amoxicillin\NN\3910033 (\-LRB-\1740 <e1>AX</e1>\NN\3265032 )\-RRB-\1740 or\CC\3541091 were\VBD\836236 cross-reacting\JJ\1740 with\IN\1740 other\JJ\1740 penicillin\NN\2716866 derivatives\NNS\5802185 .\.\1740
D000658_D004342 CID We\PRP\1740 selected\VBD\697589 the\DT\1740 54\CD\1740 (\-LRB-\1740 30.5\CD\1740 %\NN\1740 )\-RRB-\1740 cases\NNS\7283608 of\IN\1740 immediate\JJ\1740 <e1>AX</e1>\NN\3265032 <e2>allergy</e2>\NN\14533203 with\IN\1740 good\JJ\1740 tolerance\NN\5032565 of\IN\1740 PG\NN\1740 .\.\1740
D000658_D004342 CID Challenge\NN\13927383 tests\NNS\5798043 with\IN\1740 <e1>AX</e1>\NN\3265032 were\VBD\836236 performed\VBN\2367363 in\IN\13603305 23\CD\13745420 subjects\NNS\6598915 (\-LRB-\1740 43\CD\1740 %\NN\1740 )\-RRB-\1740 to\TO\1740 establish\VB\2426171 the\DT\1740 diagnosis\NN\152018 of\IN\1740 immediate\JJ\1740 <e2>allergic\JJ\1740 reaction</e2>\NN\13446390 to\TO\1740 AX\NN\3265032 ,\,\1740 and\CC\1740 in\IN\13603305 15\CD\13745420 cases\NNS\7283608 (\-LRB-\1740 28\CD\13745420 %\NN\1740 )\-RRB-\1740 both\CC\1740 skin\NN\5237755 test\NN\5798043 and\CC\1740 RAST\NN\1740 for\IN\1740 AX\NN\3265032 were\VBD\836236 negative\JJ\1740 .\.\1740
D000658_D004342 CID Challenge\NN\13927383 tests\NNS\5798043 with\IN\1740 AX\NN\3265032 were\VBD\836236 performed\VBN\2367363 in\IN\13603305 23\CD\13745420 subjects\NNS\6598915 (\-LRB-\1740 43\CD\1740 %\NN\1740 )\-RRB-\1740 to\TO\1740 establish\VB\2426171 the\DT\1740 diagnosis\NN\152018 of\IN\1740 immediate\JJ\1740 <e2>allergic\JJ\1740 reaction</e2>\NN\13446390 to\TO\1740 <e1>AX</e1>\NN\3265032 ,\,\1740 and\CC\1740 in\IN\13603305 15\CD\13745420 cases\NNS\7283608 (\-LRB-\1740 28\CD\13745420 %\NN\1740 )\-RRB-\1740 both\CC\1740 skin\NN\5237755 test\NN\5798043 and\CC\1740 RAST\NN\1740 for\IN\1740 AX\NN\3265032 were\VBD\836236 negative\JJ\1740 .\.\1740
D000658_D004342 CID Challenge\NN\13927383 tests\NNS\5798043 with\IN\1740 AX\NN\3265032 were\VBD\836236 performed\VBN\2367363 in\IN\13603305 23\CD\13745420 subjects\NNS\6598915 (\-LRB-\1740 43\CD\1740 %\NN\1740 )\-RRB-\1740 to\TO\1740 establish\VB\2426171 the\DT\1740 diagnosis\NN\152018 of\IN\1740 immediate\JJ\1740 <e2>allergic\JJ\1740 reaction</e2>\NN\13446390 to\TO\1740 AX\NN\3265032 ,\,\1740 and\CC\1740 in\IN\13603305 15\CD\13745420 cases\NNS\7283608 (\-LRB-\1740 28\CD\13745420 %\NN\1740 )\-RRB-\1740 both\CC\1740 skin\NN\5237755 test\NN\5798043 and\CC\1740 RAST\NN\1740 for\IN\1740 <e1>AX</e1>\NN\3265032 were\VBD\836236 negative\JJ\1740 .\.\1740
D000658_D004342 CID We\PRP\1740 describe\VBP\1001294 the\DT\1740 largest\JJS\1740 group\NN\2137 of\IN\1740 <e2><e1>AX-allergic</e1></e2>\JJ\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 tolerated\VBN\802318 PG\NN\1740 reported\VBD\831651 so\RB\1740 far\RB\1740 .\.\1740
D047090_D004342 NONE A\DT\13649268 large\JJ\1740 group\NN\2137 of\IN\1740 patients\NNS\9898892 with\IN\1740 suspected\VBN\916909 <e2>allergic\JJ\1740 reactions</e2>\NNS\13446390 to\TO\1740 <e1>beta-lactam</e1>\NN\1740 antibiotics\NNS\2716205 was\VBD\836236 evaluated\VBN\670261 .\.\1740
D047090_D004342 NONE A\DT\13649268 detailed\JJ\1740 clinical\JJ\1740 history\NN\15120823 ,\,\1740 together\RB\1740 with\IN\1740 skin\NN\5237755 tests\NNS\5798043 ,\,\1740 RAST\NN\1740 (\-LRB-\1740 radioallergosorbent\JJ\1740 test\NN\5798043 )\-RRB-\1740 ,\,\1740 and\CC\1740 controlled\VBN\2422663 challenge\NN\13927383 tests\NNS\5798043 ,\,\1740 was\VBD\836236 used\VBN\1156834 to\TO\1740 establish\VB\2426171 whether\IN\1740 patients\NNS\9898892 <e2>allergic</e2>\JJ\1740 to\TO\1740 <e1>beta-lactam</e1>\JJ\1740 antibiotics\NNS\2716205 had\VBD\2108377 selective\JJ\1740 immediate\JJ\1740 allergic\JJ\1740 responses\NNS\11410625 to\TO\1740 amoxicillin\NN\3910033 (\-LRB-\1740 AX\NN\3265032 )\-RRB-\1740 or\CC\3541091 were\VBD\836236 cross-reacting\JJ\1740 with\IN\1740 other\JJ\1740 penicillin\NN\2716866 derivatives\NNS\5802185 .\.\1740
D047090_D004342 NONE A\DT\13649268 detailed\JJ\1740 clinical\JJ\1740 history\NN\15120823 ,\,\1740 together\RB\1740 with\IN\1740 skin\NN\5237755 tests\NNS\5798043 ,\,\1740 RAST\NN\1740 (\-LRB-\1740 radioallergosorbent\JJ\1740 test\NN\5798043 )\-RRB-\1740 ,\,\1740 and\CC\1740 controlled\VBN\2422663 challenge\NN\13927383 tests\NNS\5798043 ,\,\1740 was\VBD\836236 used\VBN\1156834 to\TO\1740 establish\VB\2426171 whether\IN\1740 patients\NNS\9898892 allergic\JJ\1740 to\TO\1740 <e1>beta-lactam</e1>\JJ\1740 antibiotics\NNS\2716205 had\VBD\2108377 selective\JJ\1740 immediate\JJ\1740 <e2>allergic</e2>\JJ\1740 responses\NNS\11410625 to\TO\1740 amoxicillin\NN\3910033 (\-LRB-\1740 AX\NN\3265032 )\-RRB-\1740 or\CC\3541091 were\VBD\836236 cross-reacting\JJ\1740 with\IN\1740 other\JJ\1740 penicillin\NN\2716866 derivatives\NNS\5802185 .\.\1740
D047090_D004342 NONE A\DT\13649268 total\NN\3553 of\IN\1740 177\CD\1740 patients\NNS\9898892 were\VBD\836236 diagnosed\VBN\644583 as\IN\14622893 <e2>allergic</e2>\JJ\1740 to\TO\1740 <e1>beta-lactam</e1>\JJ\1740 antibiotics\NNS\2716205 .\.\1740
D010406_D004342 NONE A\DT\13649268 detailed\JJ\1740 clinical\JJ\1740 history\NN\15120823 ,\,\1740 together\RB\1740 with\IN\1740 skin\NN\5237755 tests\NNS\5798043 ,\,\1740 RAST\NN\1740 (\-LRB-\1740 radioallergosorbent\JJ\1740 test\NN\5798043 )\-RRB-\1740 ,\,\1740 and\CC\1740 controlled\VBN\2422663 challenge\NN\13927383 tests\NNS\5798043 ,\,\1740 was\VBD\836236 used\VBN\1156834 to\TO\1740 establish\VB\2426171 whether\IN\1740 patients\NNS\9898892 <e2>allergic</e2>\JJ\1740 to\TO\1740 beta-lactam\JJ\1740 antibiotics\NNS\2716205 had\VBD\2108377 selective\JJ\1740 immediate\JJ\1740 allergic\JJ\1740 responses\NNS\11410625 to\TO\1740 amoxicillin\NN\3910033 (\-LRB-\1740 AX\NN\3265032 )\-RRB-\1740 or\CC\3541091 were\VBD\836236 cross-reacting\JJ\1740 with\IN\1740 other\JJ\1740 <e1>penicillin</e1>\NN\2716866 derivatives\NNS\5802185 .\.\1740
D010406_D004342 NONE A\DT\13649268 detailed\JJ\1740 clinical\JJ\1740 history\NN\15120823 ,\,\1740 together\RB\1740 with\IN\1740 skin\NN\5237755 tests\NNS\5798043 ,\,\1740 RAST\NN\1740 (\-LRB-\1740 radioallergosorbent\JJ\1740 test\NN\5798043 )\-RRB-\1740 ,\,\1740 and\CC\1740 controlled\VBN\2422663 challenge\NN\13927383 tests\NNS\5798043 ,\,\1740 was\VBD\836236 used\VBN\1156834 to\TO\1740 establish\VB\2426171 whether\IN\1740 patients\NNS\9898892 allergic\JJ\1740 to\TO\1740 beta-lactam\JJ\1740 antibiotics\NNS\2716205 had\VBD\2108377 selective\JJ\1740 immediate\JJ\1740 <e2>allergic</e2>\JJ\1740 responses\NNS\11410625 to\TO\1740 amoxicillin\NN\3910033 (\-LRB-\1740 AX\NN\3265032 )\-RRB-\1740 or\CC\3541091 were\VBD\836236 cross-reacting\JJ\1740 with\IN\1740 other\JJ\1740 <e1>penicillin</e1>\NN\2716866 derivatives\NNS\5802185 .\.\1740
D010400_D004342 NONE We\PRP\1740 selected\VBD\697589 the\DT\1740 54\CD\1740 (\-LRB-\1740 30.5\CD\1740 %\NN\1740 )\-RRB-\1740 cases\NNS\7283608 of\IN\1740 immediate\JJ\1740 AX\NN\3265032 <e2>allergy</e2>\NN\14533203 with\IN\1740 good\JJ\1740 tolerance\NN\5032565 of\IN\1740 <e1>PG</e1>\NN\1740 .\.\1740
D010400_D004342 NONE We\PRP\1740 describe\VBP\1001294 the\DT\1740 largest\JJS\1740 group\NN\2137 of\IN\1740 <e2>AX-allergic</e2>\JJ\1740 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 tolerated\VBN\802318 <e1>PG</e1>\NN\1740 reported\VBD\831651 so\RB\1740 far\RB\1740 .\.\1740
-1_D007645 NONE All\PDT\1740 the\DT\1740 patients\NNS\9898892 were\VBD\836236 skin\NN\5237755 test\NN\5798043 negative\JJ\1740 to\TO\1740 <e1>BPO</e1>\NN\1740 ;\:\1740 49\CD\1740 of\IN\1740 51\CD\1740 (\-LRB-\1740 96\CD\1740 %\NN\1740 )\-RRB-\1740 were\VBD\836236 also\RB\1740 negative\JJ\1740 to\TO\1740 <e2>MDM</e2>\NN\1740 ,\,\1740 and\CC\1740 44\CD\1740 of\IN\1740 46\CD\1740 (\-LRB-\1740 96\CD\1740 %\NN\1740 )\-RRB-\1740 to\TO\1740 PG\NN\1740 .\.\1740
D010400_D007645 NONE All\PDT\1740 the\DT\1740 patients\NNS\9898892 were\VBD\836236 skin\NN\5237755 test\NN\5798043 negative\JJ\1740 to\TO\1740 BPO\NN\1740 ;\:\1740 49\CD\1740 of\IN\1740 51\CD\1740 (\-LRB-\1740 96\CD\1740 %\NN\1740 )\-RRB-\1740 were\VBD\836236 also\RB\1740 negative\JJ\1740 to\TO\1740 <e2>MDM</e2>\NN\1740 ,\,\1740 and\CC\1740 44\CD\1740 of\IN\1740 46\CD\1740 (\-LRB-\1740 96\CD\1740 %\NN\1740 )\-RRB-\1740 to\TO\1740 <e1>PG</e1>\NN\1740 .\.\1740
11807648
D014148_D004827 NONE <e2>Epileptic\JJ\1740 seizures</e2>\NNS\14081375 following\VBG\1835496 cortical\JJ\1740 application\NN\947128 of\IN\1740 fibrin\NN\14728724 sealants\NNS\14705533 containing\VBG\2632940 <e1>tranexamic\JJ\1740 acid</e1>\NN\14818238 in\IN\13603305 rats\NNS\2329401 .\.\1740
D014148_D004827 NONE However\RB\1740 ,\,\1740 <e1>tAMCA</e1>\NN\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 cause\VB\1617192 <e2>epileptic\JJ\1740 seizures</e2>\NNS\14081375 .\.\1740
D014148_D012640 CID We\PRP\1740 wanted\VBD\2604760 to\TO\1740 study\VB\630380 whether\IN\1740 <e1>tAMCA</e1>\NN\1740 retains\VBZ\2700867 its\PRP$\6125041 <e2>convulsive</e2>\JJ\1740 action\NN\30358 if\IN\1740 incorporated\VBN\1461328 into\IN\1740 a\DT\13649268 FS\NN\13714184 .\.\1740
D014148_D012640 CID FINDINGS\NNS\7951464 :\:\1740 FS\NN\13714184 containing\VBG\2632940 <e1>tAMCA</e1>\NN\1740 caused\VBD\1617192 paroxysmal\JJ\1740 brain\NN\5462674 activity\NN\30358 which\WDT\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 distinct\JJ\1740 <e2>convulsive</e2>\JJ\1740 behaviours\NNS\14006945 .\.\1740
D014148_D012640 CID The\DT\1740 degree\NN\4916342 of\IN\1740 these\DT\1740 <e2>seizures</e2>\NNS\14081375 increased\VBD\169651 with\IN\1740 increasing\VBG\169651 concentration\NN\4916342 of\IN\1740 <e1>tAMCA</e1>\NN\1740 .\.\1740
D014148_D012640 CID Thus\RB\1740 ,\,\1740 FS\NN\13714184 containing\VBG\2632940 47.5\CD\1740 mg/ml\NN\1740 <e1>tAMCA</e1>\NN\1740 evoked\VBD\1617192 <e2>generalized\JJ\1740 seizures</e2>\NNS\14081375 in\IN\13603305 all\DT\1740 tested\VBN\670261 rats\NNS\2329401 (\-LRB-\1740 n=6\NN\1740 )\-RRB-\1740 while\IN\15122231 the\DT\1740 lowest\JJS\1740 concentration\NN\4916342 of\IN\1740 tAMCA\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg/ml\NN\1740 )\-RRB-\1740 only\RB\1740 evoked\VBD\1617192 brief\JJ\1740 episodes\NNS\7283608 of\IN\1740 jerk-correlated\JJ\1740 convulsive\JJ\1740 potentials\NNS\14481929 in\IN\13603305 1\CD\13741022 of\IN\1740 6\CD\13741022 rats\NNS\2329401 .\.\1740
D014148_D012640 CID Thus\RB\1740 ,\,\1740 FS\NN\13714184 containing\VBG\2632940 47.5\CD\1740 mg/ml\NN\1740 <e1>tAMCA</e1>\NN\1740 evoked\VBD\1617192 generalized\JJ\1740 seizures\NNS\14081375 in\IN\13603305 all\DT\1740 tested\VBN\670261 rats\NNS\2329401 (\-LRB-\1740 n=6\NN\1740 )\-RRB-\1740 while\IN\15122231 the\DT\1740 lowest\JJS\1740 concentration\NN\4916342 of\IN\1740 tAMCA\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg/ml\NN\1740 )\-RRB-\1740 only\RB\1740 evoked\VBD\1617192 brief\JJ\1740 episodes\NNS\7283608 of\IN\1740 jerk-correlated\JJ\1740 <e2>convulsive</e2>\JJ\1740 potentials\NNS\14481929 in\IN\13603305 1\CD\13741022 of\IN\1740 6\CD\13741022 rats\NNS\2329401 .\.\1740
D014148_D012640 CID Thus\RB\1740 ,\,\1740 FS\NN\13714184 containing\VBG\2632940 47.5\CD\1740 mg/ml\NN\1740 tAMCA\NN\1740 evoked\VBD\1617192 <e2>generalized\JJ\1740 seizures</e2>\NNS\14081375 in\IN\13603305 all\DT\1740 tested\VBN\670261 rats\NNS\2329401 (\-LRB-\1740 n=6\NN\1740 )\-RRB-\1740 while\IN\15122231 the\DT\1740 lowest\JJS\1740 concentration\NN\4916342 of\IN\1740 <e1>tAMCA</e1>\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg/ml\NN\1740 )\-RRB-\1740 only\RB\1740 evoked\VBD\1617192 brief\JJ\1740 episodes\NNS\7283608 of\IN\1740 jerk-correlated\JJ\1740 convulsive\JJ\1740 potentials\NNS\14481929 in\IN\13603305 1\CD\13741022 of\IN\1740 6\CD\13741022 rats\NNS\2329401 .\.\1740
D014148_D012640 CID Thus\RB\1740 ,\,\1740 FS\NN\13714184 containing\VBG\2632940 47.5\CD\1740 mg/ml\NN\1740 tAMCA\NN\1740 evoked\VBD\1617192 generalized\JJ\1740 seizures\NNS\14081375 in\IN\13603305 all\DT\1740 tested\VBN\670261 rats\NNS\2329401 (\-LRB-\1740 n=6\NN\1740 )\-RRB-\1740 while\IN\15122231 the\DT\1740 lowest\JJS\1740 concentration\NN\4916342 of\IN\1740 <e1>tAMCA</e1>\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg/ml\NN\1740 )\-RRB-\1740 only\RB\1740 evoked\VBD\1617192 brief\JJ\1740 episodes\NNS\7283608 of\IN\1740 jerk-correlated\JJ\1740 <e2>convulsive</e2>\JJ\1740 potentials\NNS\14481929 in\IN\13603305 1\CD\13741022 of\IN\1740 6\CD\13741022 rats\NNS\2329401 .\.\1740
D014148_D012640 CID INTERPRETATION\NN\5926676 :\:\1740 <e1>Tranexamic\JJ\1740 acid</e1>\NN\14818238 retains\VBZ\2700867 its\PRP$\6125041 <e2>convulsive</e2>\JJ\1740 action\NN\30358 within\IN\1740 FS\NN\13714184 .\.\1740
3101906
D007654_D003643 NONE In\IN\13603305 two\CD\13741022 of\IN\1740 the\DT\1740 three\CD\13741022 <e2>deaths</e2>\NNS\7296428 probably\RB\1740 associated\VBN\628491 with\IN\1740 <e1>ketoconazole</e1>\NN\1740 treatment\NN\654885 the\DT\1740 drug\NN\14778436 had\VBD\2108377 been\VBN\836236 continued\VBN\2367363 after\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 jaundice\NN\14299637 and\CC\1740 other\JJ\1740 symptoms\NNS\5823932 of\IN\1740 hepatitis\NN\14127211 .\.\1740
D007654_D007565 CID In\IN\13603305 two\CD\13741022 of\IN\1740 the\DT\1740 three\CD\13741022 deaths\NNS\7296428 probably\RB\1740 associated\VBN\628491 with\IN\1740 <e1>ketoconazole</e1>\NN\1740 treatment\NN\654885 the\DT\1740 drug\NN\14778436 had\VBD\2108377 been\VBN\836236 continued\VBN\2367363 after\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 <e2>jaundice</e2>\NN\14299637 and\CC\1740 other\JJ\1740 symptoms\NNS\5823932 of\IN\1740 hepatitis\NN\14127211 .\.\1740
D007654_D056486 CID In\IN\13603305 two\CD\13741022 of\IN\1740 the\DT\1740 three\CD\13741022 deaths\NNS\7296428 probably\RB\1740 associated\VBN\628491 with\IN\1740 <e1>ketoconazole</e1>\NN\1740 treatment\NN\654885 the\DT\1740 drug\NN\14778436 had\VBD\2108377 been\VBN\836236 continued\VBN\2367363 after\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 jaundice\NN\14299637 and\CC\1740 other\JJ\1740 symptoms\NNS\5823932 of\IN\1740 <e2>hepatitis</e2>\NN\14127211 .\.\1740
D007654_D056486 CID Clinical\JJ\1740 and\CC\1740 biochemical\JJ\1740 monitoring\NN\879759 at\IN\14622893 regular\JJ\1740 intervals\NNS\33615 for\IN\1740 evidence\NN\5816287 of\IN\1740 <e2>hepatitis</e2>\NN\14127211 is\VBZ\836236 advised\VBN\813978 during\IN\1740 long\JJ\1740 term\NN\6286395 treatment\NN\654885 with\IN\1740 <e1>ketoconazole</e1>\NN\1740 to\TO\1740 prevent\VB\1740 possible\JJ\1740 serious\JJ\1740 hepatic\JJ\1740 injury\NN\14052046 .\.\1740
D007654_D056486 CID Clinical\JJ\1740 and\CC\1740 biochemical\JJ\1740 monitoring\NN\879759 at\IN\14622893 regular\JJ\1740 intervals\NNS\33615 for\IN\1740 evidence\NN\5816287 of\IN\1740 hepatitis\NN\14127211 is\VBZ\836236 advised\VBN\813978 during\IN\1740 long\JJ\1740 term\NN\6286395 treatment\NN\654885 with\IN\1740 <e1>ketoconazole</e1>\NN\1740 to\TO\1740 prevent\VB\1740 possible\JJ\1740 serious\JJ\1740 <e2>hepatic\JJ\1740 injury</e2>\NN\14052046 .\.\1740
17244258
D003520_D003556 CID In\FW\13603305 vitro\FW\1740 characterization\NN\6724763 of\IN\1740 parasympathetic\JJ\1740 and\CC\1740 sympathetic\JJ\1740 responses\NNS\11410625 in\IN\13603305 <e1>cyclophosphamide-induced</e1>\JJ\1740 <e2>cystitis</e2>\NN\14566129 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D003520_D003556 CID In\IN\13603305 <e1>cyclophosphamide-induced</e1>\JJ\1740 <e2>cystitis</e2>\NN\14566129 in\IN\13603305 the\DT\1740 rat\NN\2329401 ,\,\1740 detrusor\NN\1740 function\NN\13783581 is\VBZ\836236 impaired\JJ\1740 and\CC\1740 the\DT\1740 expression\NN\4679549 and\CC\1740 effects\NNS\13245626 of\IN\1740 muscarinic\NN\1740 receptors\NNS\5225602 altered\VBN\126264 .\.\1740
26094
D008750_D003866 CID This\DT\1740 was\VBD\836236 accounted\VBN\2604760 for\IN\1740 by\IN\1740 a\DT\13649268 significant\JJ\1740 number\NN\5107765 of\IN\1740 <e2>depressions</e2>\NNS\14373582 occurring\VBG\2623529 in\IN\13603305 <e1>methyl\JJ\1740 dopa</e1>\NN\14601829 treated\VBN\2376958 patients\NNS\9898892 with\IN\1740 psychiatric\JJ\1740 histories\NNS\15120823 .\.\1740
D008750_D001523 NONE This\DT\1740 was\VBD\836236 accounted\VBN\2604760 for\IN\1740 by\IN\1740 a\DT\13649268 significant\JJ\1740 number\NN\5107765 of\IN\1740 depressions\NNS\14373582 occurring\VBG\2623529 in\IN\13603305 <e1>methyl\JJ\1740 dopa</e1>\NN\14601829 treated\VBN\2376958 patients\NNS\9898892 with\IN\1740 <e2>psychiatric</e2>\JJ\1740 histories\NNS\15120823 .\.\1740
1428568
D013999_D005901 NONE Eight\CD\13741022 <e2>glaucomatous</e2>\JJ\1740 patients\NNS\9898892 chronically\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>timolol</e1>\JJ\1740 0.5%/12h\NN\1740 ,\,\1740 suffering\VBG\2110220 from\IN\1740 depression\NN\14373582 diagnosed\VBN\644583 through\IN\1740 DMS-III-R\NN\1740 criteria\NNS\13577171 ,\,\1740 were\VBD\836236 included\VBN\690614 in\IN\13603305 the\DT\1740 study\NN\635850 .\.\1740
D013999_D003866 CID Eight\CD\13741022 glaucomatous\JJ\1740 patients\NNS\9898892 chronically\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>timolol</e1>\JJ\1740 0.5%/12h\NN\1740 ,\,\1740 suffering\VBG\2110220 from\IN\1740 <e2>depression</e2>\NN\14373582 diagnosed\VBN\644583 through\IN\1740 DMS-III-R\NN\1740 criteria\NNS\13577171 ,\,\1740 were\VBD\836236 included\VBN\690614 in\IN\13603305 the\DT\1740 study\NN\635850 .\.\1740
D013999_D003866 CID In\IN\13603305 a\DT\13649268 double\JJ\1740 blind\JJ\1740 cross-over\JJ\1740 study\NN\635850 with\IN\1740 control\NN\5190804 group\NN\2137 ,\,\1740 the\DT\1740 patients\NNS\9898892 under\IN\1740 <e1>timolol</e1>\JJ\1740 treatment\NN\654885 presented\VBD\2137132 higher\JJR\1740 <e2>depression</e2>\NN\14373582 values\NNS\5941423 measured\VBN\697589 through\IN\1740 the\DT\1740 Beck\NNP\6876309 and\CC\1740 the\DT\1740 Zung-Conde\NNP\1740 scales\NNS\7260623 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.001\CD\1740 vs\CC\13634784 control\NN\5190804 )\-RRB-\1740 .\.\1740
D013999_D003866 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 betaxolol\NN\1740 could\MD\1740 be\VB\836236 less\JJR\1740 of\IN\1740 a\DT\13649268 <e2>depression-inducer</e2>\NN\1740 than\IN\1740 <e1>timolol</e1>\CD\2832168 in\IN\13603305 predisposed\JJ\1740 patients\NNS\9898892 .\.\1740
D015784_D003866 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 <e1>betaxolol</e1>\NN\1740 could\MD\1740 be\VB\836236 less\JJR\1740 of\IN\1740 a\DT\13649268 <e2>depression-inducer</e2>\NN\1740 than\IN\1740 timolol\CD\2832168 in\IN\13603305 predisposed\JJ\1740 patients\NNS\9898892 .\.\1740
20722491
-1_D009369 NONE IMPORTANCE\NN\5138488 OF\IN\1740 THE\DT\1740 FIELD\NN\8673395 :\:\1740 <e1>Fluoropyrimidines</e1>\NNS\1740 ,\,\1740 in\IN\13603305 particular\JJ\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 ,\,\1740 have\VBP\2108377 been\VBN\836236 the\DT\1740 mainstay\NN\10677713 of\IN\1740 treatment\NN\654885 for\IN\1740 several\JJ\1740 solid\JJ\1740 <e2>tumors</e2>\NNS\14234074 ,\,\1740 including\VBG\690614 colorectal\JJ\1740 ,\,\1740 breast\NN\5225090 and\CC\1740 head\NN\5225090 and\CC\1740 neck\NN\5225090 cancers\NNS\14239425 ,\,\1740 for\IN\1740 >\NNS\1740 40\CD\13745420 years\NNS\15144371 .\.\1740
-1_D015179 NONE IMPORTANCE\NN\5138488 OF\IN\1740 THE\DT\1740 FIELD\NN\8673395 :\:\1740 <e1>Fluoropyrimidines</e1>\NNS\1740 ,\,\1740 in\IN\13603305 particular\JJ\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 ,\,\1740 have\VBP\2108377 been\VBN\836236 the\DT\1740 mainstay\NN\10677713 of\IN\1740 treatment\NN\654885 for\IN\1740 several\JJ\1740 solid\JJ\1740 tumors\NNS\14234074 ,\,\1740 including\VBG\690614 <e2>colorectal\JJ\1740 ,\,\1740 breast\NN\5225090 and\CC\1740 head\NN\5225090 and\CC\1740 neck\NN\5225090 cancers</e2>\NNS\14239425 ,\,\1740 for\IN\1740 >\NNS\1740 40\CD\13745420 years\NNS\15144371 .\.\1740
-1_D001943 NONE IMPORTANCE\NN\5138488 OF\IN\1740 THE\DT\1740 FIELD\NN\8673395 :\:\1740 <e1>Fluoropyrimidines</e1>\NNS\1740 ,\,\1740 in\IN\13603305 particular\JJ\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 ,\,\1740 have\VBP\2108377 been\VBN\836236 the\DT\1740 mainstay\NN\10677713 of\IN\1740 treatment\NN\654885 for\IN\1740 several\JJ\1740 solid\JJ\1740 tumors\NNS\14234074 ,\,\1740 including\VBG\690614 <e2>colorectal\JJ\1740 ,\,\1740 breast\NN\5225090 and\CC\1740 head\NN\5225090 and\CC\1740 neck\NN\5225090 cancers</e2>\NNS\14239425 ,\,\1740 for\IN\1740 >\NNS\1740 40\CD\13745420 years\NNS\15144371 .\.\1740
-1_D006258 NONE IMPORTANCE\NN\5138488 OF\IN\1740 THE\DT\1740 FIELD\NN\8673395 :\:\1740 <e1>Fluoropyrimidines</e1>\NNS\1740 ,\,\1740 in\IN\13603305 particular\JJ\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 ,\,\1740 have\VBP\2108377 been\VBN\836236 the\DT\1740 mainstay\NN\10677713 of\IN\1740 treatment\NN\654885 for\IN\1740 several\JJ\1740 solid\JJ\1740 tumors\NNS\14234074 ,\,\1740 including\VBG\690614 <e2>colorectal\JJ\1740 ,\,\1740 breast\NN\5225090 and\CC\1740 head\NN\5225090 and\CC\1740 neck\NN\5225090 cancers</e2>\NNS\14239425 ,\,\1740 for\IN\1740 >\NNS\1740 40\CD\13745420 years\NNS\15144371 .\.\1740
D005472_D009369 NONE IMPORTANCE\NN\5138488 OF\IN\1740 THE\DT\1740 FIELD\NN\8673395 :\:\1740 Fluoropyrimidines\NNS\1740 ,\,\1740 in\IN\13603305 particular\JJ\1740 <e1>5-fluorouracil</e1>\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 ,\,\1740 have\VBP\2108377 been\VBN\836236 the\DT\1740 mainstay\NN\10677713 of\IN\1740 treatment\NN\654885 for\IN\1740 several\JJ\1740 solid\JJ\1740 <e2>tumors</e2>\NNS\14234074 ,\,\1740 including\VBG\690614 colorectal\JJ\1740 ,\,\1740 breast\NN\5225090 and\CC\1740 head\NN\5225090 and\CC\1740 neck\NN\5225090 cancers\NNS\14239425 ,\,\1740 for\IN\1740 >\NNS\1740 40\CD\13745420 years\NNS\15144371 .\.\1740
D005472_D009369 NONE IMPORTANCE\NN\5138488 OF\IN\1740 THE\DT\1740 FIELD\NN\8673395 :\:\1740 Fluoropyrimidines\NNS\1740 ,\,\1740 in\IN\13603305 particular\JJ\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 <e1>5-FU</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 have\VBP\2108377 been\VBN\836236 the\DT\1740 mainstay\NN\10677713 of\IN\1740 treatment\NN\654885 for\IN\1740 several\JJ\1740 solid\JJ\1740 <e2>tumors</e2>\NNS\14234074 ,\,\1740 including\VBG\690614 colorectal\JJ\1740 ,\,\1740 breast\NN\5225090 and\CC\1740 head\NN\5225090 and\CC\1740 neck\NN\5225090 cancers\NNS\14239425 ,\,\1740 for\IN\1740 >\NNS\1740 40\CD\13745420 years\NNS\15144371 .\.\1740
D005472_D015179 NONE IMPORTANCE\NN\5138488 OF\IN\1740 THE\DT\1740 FIELD\NN\8673395 :\:\1740 Fluoropyrimidines\NNS\1740 ,\,\1740 in\IN\13603305 particular\JJ\1740 <e1>5-fluorouracil</e1>\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 ,\,\1740 have\VBP\2108377 been\VBN\836236 the\DT\1740 mainstay\NN\10677713 of\IN\1740 treatment\NN\654885 for\IN\1740 several\JJ\1740 solid\JJ\1740 tumors\NNS\14234074 ,\,\1740 including\VBG\690614 <e2>colorectal\JJ\1740 ,\,\1740 breast\NN\5225090 and\CC\1740 head\NN\5225090 and\CC\1740 neck\NN\5225090 cancers</e2>\NNS\14239425 ,\,\1740 for\IN\1740 >\NNS\1740 40\CD\13745420 years\NNS\15144371 .\.\1740
D005472_D015179 NONE IMPORTANCE\NN\5138488 OF\IN\1740 THE\DT\1740 FIELD\NN\8673395 :\:\1740 Fluoropyrimidines\NNS\1740 ,\,\1740 in\IN\13603305 particular\JJ\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 <e1>5-FU</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 have\VBP\2108377 been\VBN\836236 the\DT\1740 mainstay\NN\10677713 of\IN\1740 treatment\NN\654885 for\IN\1740 several\JJ\1740 solid\JJ\1740 tumors\NNS\14234074 ,\,\1740 including\VBG\690614 <e2>colorectal\JJ\1740 ,\,\1740 breast\NN\5225090 and\CC\1740 head\NN\5225090 and\CC\1740 neck\NN\5225090 cancers</e2>\NNS\14239425 ,\,\1740 for\IN\1740 >\NNS\1740 40\CD\13745420 years\NNS\15144371 .\.\1740
D005472_D001943 NONE IMPORTANCE\NN\5138488 OF\IN\1740 THE\DT\1740 FIELD\NN\8673395 :\:\1740 Fluoropyrimidines\NNS\1740 ,\,\1740 in\IN\13603305 particular\JJ\1740 <e1>5-fluorouracil</e1>\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 ,\,\1740 have\VBP\2108377 been\VBN\836236 the\DT\1740 mainstay\NN\10677713 of\IN\1740 treatment\NN\654885 for\IN\1740 several\JJ\1740 solid\JJ\1740 tumors\NNS\14234074 ,\,\1740 including\VBG\690614 <e2>colorectal\JJ\1740 ,\,\1740 breast\NN\5225090 and\CC\1740 head\NN\5225090 and\CC\1740 neck\NN\5225090 cancers</e2>\NNS\14239425 ,\,\1740 for\IN\1740 >\NNS\1740 40\CD\13745420 years\NNS\15144371 .\.\1740
D005472_D001943 NONE IMPORTANCE\NN\5138488 OF\IN\1740 THE\DT\1740 FIELD\NN\8673395 :\:\1740 Fluoropyrimidines\NNS\1740 ,\,\1740 in\IN\13603305 particular\JJ\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 <e1>5-FU</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 have\VBP\2108377 been\VBN\836236 the\DT\1740 mainstay\NN\10677713 of\IN\1740 treatment\NN\654885 for\IN\1740 several\JJ\1740 solid\JJ\1740 tumors\NNS\14234074 ,\,\1740 including\VBG\690614 <e2>colorectal\JJ\1740 ,\,\1740 breast\NN\5225090 and\CC\1740 head\NN\5225090 and\CC\1740 neck\NN\5225090 cancers</e2>\NNS\14239425 ,\,\1740 for\IN\1740 >\NNS\1740 40\CD\13745420 years\NNS\15144371 .\.\1740
D005472_D006258 NONE IMPORTANCE\NN\5138488 OF\IN\1740 THE\DT\1740 FIELD\NN\8673395 :\:\1740 Fluoropyrimidines\NNS\1740 ,\,\1740 in\IN\13603305 particular\JJ\1740 <e1>5-fluorouracil</e1>\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 ,\,\1740 have\VBP\2108377 been\VBN\836236 the\DT\1740 mainstay\NN\10677713 of\IN\1740 treatment\NN\654885 for\IN\1740 several\JJ\1740 solid\JJ\1740 tumors\NNS\14234074 ,\,\1740 including\VBG\690614 <e2>colorectal\JJ\1740 ,\,\1740 breast\NN\5225090 and\CC\1740 head\NN\5225090 and\CC\1740 neck\NN\5225090 cancers</e2>\NNS\14239425 ,\,\1740 for\IN\1740 >\NNS\1740 40\CD\13745420 years\NNS\15144371 .\.\1740
D005472_D006258 NONE IMPORTANCE\NN\5138488 OF\IN\1740 THE\DT\1740 FIELD\NN\8673395 :\:\1740 Fluoropyrimidines\NNS\1740 ,\,\1740 in\IN\13603305 particular\JJ\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 <e1>5-FU</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 have\VBP\2108377 been\VBN\836236 the\DT\1740 mainstay\NN\10677713 of\IN\1740 treatment\NN\654885 for\IN\1740 several\JJ\1740 solid\JJ\1740 tumors\NNS\14234074 ,\,\1740 including\VBG\690614 <e2>colorectal\JJ\1740 ,\,\1740 breast\NN\5225090 and\CC\1740 head\NN\5225090 and\CC\1740 neck\NN\5225090 cancers</e2>\NNS\14239425 ,\,\1740 for\IN\1740 >\NNS\1740 40\CD\13745420 years\NNS\15144371 .\.\1740
C110904_D007674 NONE WHAT\WP\1740 THE\DT\1740 READER\NN\10557854 WILL\NN\5650329 GAIN\NNP\13576355 :\:\1740 The\DT\1740 reader\NN\10557854 will\MD\5650329 gain\VB\2238085 better\JJR\1740 insight\NN\5710020 into\IN\1740 the\DT\1740 safety\NN\13920835 of\IN\1740 <e1>capecitabine</e1>\NN\1740 in\IN\13603305 special\JJ\1740 populations\NNS\7942152 such\JJ\1740 as\IN\14622893 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 age\NN\4916342 ,\,\1740 <e2>renal\JJ\1740 and\CC\1740 kidney\NN\5333259 disease</e2>\NN\14061805 .\.\1740
C110904_D007674 NONE <e1>Capecitabine</e1>\NNP\1740 has\VBZ\2108377 a\DT\13649268 well-established\JJ\1740 safety\NN\13920835 profile\NN\6999802 and\CC\1740 can\MD\3094503 be\VB\836236 given\VBN\2327200 safely\RB\1740 to\TO\1740 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 age\NN\4916342 ,\,\1740 <e2>hepatic\JJ\1740 and\CC\1740 renal\JJ\1740 dysfunctions</e2>\NNS\14204950 .\.\1740
C110904_D003967 CID The\DT\1740 most\RBS\1740 commonly\RB\1740 reported\VBD\831651 toxic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>capecitabine</e1>\NN\1740 are\VBP\836236 <e2>diarrhea</e2>\NN\14299637 ,\,\1740 nausea\NN\14299637 ,\,\1740 vomiting\NN\116687 ,\,\1740 stomatitis\NN\14336539 and\CC\1740 hand-foot\JJ\1740 syndrome\NN\5870365 .\.\1740
C110904_D009325 CID The\DT\1740 most\RBS\1740 commonly\RB\1740 reported\VBD\831651 toxic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>capecitabine</e1>\NN\1740 are\VBP\836236 diarrhea\NN\14299637 ,\,\1740 <e2>nausea</e2>\NN\14299637 ,\,\1740 vomiting\NN\116687 ,\,\1740 stomatitis\NN\14336539 and\CC\1740 hand-foot\JJ\1740 syndrome\NN\5870365 .\.\1740
C110904_D014839 CID The\DT\1740 most\RBS\1740 commonly\RB\1740 reported\VBD\831651 toxic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>capecitabine</e1>\NN\1740 are\VBP\836236 diarrhea\NN\14299637 ,\,\1740 nausea\NN\14299637 ,\,\1740 <e2>vomiting</e2>\NN\116687 ,\,\1740 stomatitis\NN\14336539 and\CC\1740 hand-foot\JJ\1740 syndrome\NN\5870365 .\.\1740
C110904_D013280 CID The\DT\1740 most\RBS\1740 commonly\RB\1740 reported\VBD\831651 toxic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>capecitabine</e1>\NN\1740 are\VBP\836236 diarrhea\NN\14299637 ,\,\1740 nausea\NN\14299637 ,\,\1740 vomiting\NN\116687 ,\,\1740 <e2>stomatitis</e2>\NN\14336539 and\CC\1740 hand-foot\JJ\1740 syndrome\NN\5870365 .\.\1740
C110904_D060831 CID The\DT\1740 most\RBS\1740 commonly\RB\1740 reported\VBD\831651 toxic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>capecitabine</e1>\NN\1740 are\VBP\836236 diarrhea\NN\14299637 ,\,\1740 nausea\NN\14299637 ,\,\1740 vomiting\NN\116687 ,\,\1740 stomatitis\NN\14336539 and\CC\1740 <e2>hand-foot\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
C110904_D008107 NONE <e1>Capecitabine</e1>\NNP\1740 has\VBZ\2108377 a\DT\13649268 well-established\JJ\1740 safety\NN\13920835 profile\NN\6999802 and\CC\1740 can\MD\3094503 be\VB\836236 given\VBN\2327200 safely\RB\1740 to\TO\1740 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 age\NN\4916342 ,\,\1740 <e2>hepatic\JJ\1740 and\CC\1740 renal\JJ\1740 dysfunctions</e2>\NNS\14204950 .\.\1740
9855119
D016559_D005922 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 main\JJ\1740 pathologic\JJ\1740 diagnoses\NNS\152018 (\-LRB-\1740 some\DT\1740 overlap\NN\5926676 )\-RRB-\1740 were\VBD\836236 acute\JJ\1740 rejection\NN\30358 (\-LRB-\1740 AR\NN\14622893 ;\:\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 ,\,\1740 chronic\JJ\1740 rejection\NN\30358 (\-LRB-\1740 CR\NN\14625458 ;\:\1740 n=5\JJ\1740 )\-RRB-\1740 ,\,\1740 AR+CR\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 ,\,\1740 recurrent\JJ\1740 <e2>IgA\NN\15030481 nephropathy</e2>\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 5\CD\13741022 )\-RRB-\1740 ,\,\1740 normal\JJ\1740 findings\NNS\7951464 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 minimal-type\JJ\1740 chronic\JJ\1740 <e1>FK506</e1>\NN\1740 nephropathy\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 mild-type\JJ\1740 FK506\NN\1740 nephropathy\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 11\CD\13745420 )\-RRB-\1740 .\.\1740
D016559_D005922 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 main\JJ\1740 pathologic\JJ\1740 diagnoses\NNS\152018 (\-LRB-\1740 some\DT\1740 overlap\NN\5926676 )\-RRB-\1740 were\VBD\836236 acute\JJ\1740 rejection\NN\30358 (\-LRB-\1740 AR\NN\14622893 ;\:\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 ,\,\1740 chronic\JJ\1740 rejection\NN\30358 (\-LRB-\1740 CR\NN\14625458 ;\:\1740 n=5\JJ\1740 )\-RRB-\1740 ,\,\1740 AR+CR\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 ,\,\1740 recurrent\JJ\1740 <e2>IgA\NN\15030481 nephropathy</e2>\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 5\CD\13741022 )\-RRB-\1740 ,\,\1740 normal\JJ\1740 findings\NNS\7951464 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 minimal-type\JJ\1740 chronic\JJ\1740 FK506\NN\1740 nephropathy\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 mild-type\JJ\1740 <e1>FK506</e1>\NN\1740 nephropathy\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 11\CD\13745420 )\-RRB-\1740 .\.\1740
D016559_D007674 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 main\JJ\1740 pathologic\JJ\1740 diagnoses\NNS\152018 (\-LRB-\1740 some\DT\1740 overlap\NN\5926676 )\-RRB-\1740 were\VBD\836236 acute\JJ\1740 rejection\NN\30358 (\-LRB-\1740 AR\NN\14622893 ;\:\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 ,\,\1740 chronic\JJ\1740 rejection\NN\30358 (\-LRB-\1740 CR\NN\14625458 ;\:\1740 n=5\JJ\1740 )\-RRB-\1740 ,\,\1740 AR+CR\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 ,\,\1740 recurrent\JJ\1740 IgA\NN\15030481 nephropathy\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 5\CD\13741022 )\-RRB-\1740 ,\,\1740 normal\JJ\1740 findings\NNS\7951464 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 minimal-type\JJ\1740 chronic\JJ\1740 <e1>FK506</e1>\NN\1740 <e2>nephropathy</e2>\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 mild-type\JJ\1740 FK506\NN\1740 nephropathy\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 11\CD\13745420 )\-RRB-\1740 .\.\1740
D016559_D007674 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 main\JJ\1740 pathologic\JJ\1740 diagnoses\NNS\152018 (\-LRB-\1740 some\DT\1740 overlap\NN\5926676 )\-RRB-\1740 were\VBD\836236 acute\JJ\1740 rejection\NN\30358 (\-LRB-\1740 AR\NN\14622893 ;\:\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 ,\,\1740 chronic\JJ\1740 rejection\NN\30358 (\-LRB-\1740 CR\NN\14625458 ;\:\1740 n=5\JJ\1740 )\-RRB-\1740 ,\,\1740 AR+CR\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 ,\,\1740 recurrent\JJ\1740 IgA\NN\15030481 nephropathy\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 5\CD\13741022 )\-RRB-\1740 ,\,\1740 normal\JJ\1740 findings\NNS\7951464 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 minimal-type\JJ\1740 chronic\JJ\1740 <e1>FK506</e1>\NN\1740 nephropathy\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 mild-type\JJ\1740 FK506\NN\1740 <e2>nephropathy</e2>\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 11\CD\13745420 )\-RRB-\1740 .\.\1740
D016559_D007674 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 main\JJ\1740 pathologic\JJ\1740 diagnoses\NNS\152018 (\-LRB-\1740 some\DT\1740 overlap\NN\5926676 )\-RRB-\1740 were\VBD\836236 acute\JJ\1740 rejection\NN\30358 (\-LRB-\1740 AR\NN\14622893 ;\:\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 ,\,\1740 chronic\JJ\1740 rejection\NN\30358 (\-LRB-\1740 CR\NN\14625458 ;\:\1740 n=5\JJ\1740 )\-RRB-\1740 ,\,\1740 AR+CR\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 ,\,\1740 recurrent\JJ\1740 IgA\NN\15030481 nephropathy\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 5\CD\13741022 )\-RRB-\1740 ,\,\1740 normal\JJ\1740 findings\NNS\7951464 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 minimal-type\JJ\1740 chronic\JJ\1740 FK506\NN\1740 <e2>nephropathy</e2>\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 mild-type\JJ\1740 <e1>FK506</e1>\NN\1740 nephropathy\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 11\CD\13745420 )\-RRB-\1740 .\.\1740
D016559_D007674 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 main\JJ\1740 pathologic\JJ\1740 diagnoses\NNS\152018 (\-LRB-\1740 some\DT\1740 overlap\NN\5926676 )\-RRB-\1740 were\VBD\836236 acute\JJ\1740 rejection\NN\30358 (\-LRB-\1740 AR\NN\14622893 ;\:\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 ,\,\1740 chronic\JJ\1740 rejection\NN\30358 (\-LRB-\1740 CR\NN\14625458 ;\:\1740 n=5\JJ\1740 )\-RRB-\1740 ,\,\1740 AR+CR\NN\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 4\CD\13741022 )\-RRB-\1740 ,\,\1740 recurrent\JJ\1740 IgA\NN\15030481 nephropathy\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 5\CD\13741022 )\-RRB-\1740 ,\,\1740 normal\JJ\1740 findings\NNS\7951464 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 minimal-type\JJ\1740 chronic\JJ\1740 FK506\NN\1740 nephropathy\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 mild-type\JJ\1740 <e1>FK506</e1>\NN\1740 <e2>nephropathy</e2>\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 11\CD\13745420 )\-RRB-\1740 .\.\1740
D016559_D007674 NONE Of\IN\1740 the\DT\1740 nonepisode\NN\1740 biopsies\NNS\5739043 ,\,\1740 7\CD\13741022 and\CC\1740 4\CD\13741022 biopsies\NNS\5739043 showed\VBD\2137132 minimal-type\JJ\1740 and\CC\1740 mild-type\JJ\1740 chronic\JJ\1740 <e1>FK506</e1>\NN\1740 <e2>nephropathy</e2>\NN\14573196 ,\,\1740 respectively\RB\1740 .\.\1740
D016559_D007674 NONE Chronic\JJ\1740 <e1>FK506</e1>\NN\1740 <e2>nephropathy</e2>\NN\14573196 consisted\VBD\2603699 of\IN\1740 rough\JJ\1740 and\CC\1740 foamy\NN\1740 tubular\JJ\1740 vacuolization\NN\13920835 (\-LRB-\1740 5\CD\13741022 biopsies\NNS\5739043 )\-RRB-\1740 ,\,\1740 arteriolopathy\NN\1740 (\-LRB-\1740 angiodegeneration\NN\1740 of\IN\1740 the\DT\1740 arteriolar\JJ\1740 wall\NN\3894379 ;\:\1740 20\CD\13745420 biopsies\NNS\5739043 )\-RRB-\1740 ,\,\1740 focal\JJ\1740 segmental\JJ\1740 glomerulosclerosis\NN\1740 (\-LRB-\1740 4\CD\13741022 biopsies\NNS\5739043 )\-RRB-\1740 and\CC\1740 the\DT\1740 striped\JJ\1740 form\NN\6286395 of\IN\1740 interstitial\JJ\1740 fibrosis\NN\14204950 (\-LRB-\1740 11\CD\13745420 biopsies\NNS\5739043 )\-RRB-\1740 .\.\1740
D016559_D007674 NONE The\DT\1740 serum\NN\5397468 creatinine\NN\1740 levels\NNS\4916342 of\IN\1740 patients\NNS\9898892 in\IN\13603305 the\DT\1740 mild-type\JJ\1740 chronic\JJ\1740 <e1>FK506</e1>\NN\1740 <e2>nephropathy</e2>\NN\14573196 group\NN\2137 ,\,\1740 which\WDT\1740 included\VBD\690614 7\CD\13741022 episode\NN\7283608 biopsies\NNS\5739043 ,\,\1740 were\VBD\836236 statistically\RB\1740 higher\JJR\1740 than\IN\1740 those\DT\1740 in\IN\13603305 the\DT\1740 minimum-type\JJ\1740 chronic\JJ\1740 FK506-nephropathy\JJ\1740 group\NN\2137 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
D016559_D007674 NONE The\DT\1740 serum\NN\5397468 creatinine\NN\1740 levels\NNS\4916342 of\IN\1740 patients\NNS\9898892 in\IN\13603305 the\DT\1740 mild-type\JJ\1740 chronic\JJ\1740 <e1>FK506</e1>\NN\1740 nephropathy\NN\14573196 group\NN\2137 ,\,\1740 which\WDT\1740 included\VBD\690614 7\CD\13741022 episode\NN\7283608 biopsies\NNS\5739043 ,\,\1740 were\VBD\836236 statistically\RB\1740 higher\JJR\1740 than\IN\1740 those\DT\1740 in\IN\13603305 the\DT\1740 minimum-type\JJ\1740 chronic\JJ\1740 <e2>FK506-nephropathy</e2>\JJ\1740 group\NN\2137 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
D016559_D007674 NONE The\DT\1740 serum\NN\5397468 creatinine\NN\1740 levels\NNS\4916342 of\IN\1740 patients\NNS\9898892 in\IN\13603305 the\DT\1740 mild-type\JJ\1740 chronic\JJ\1740 FK506\NN\1740 <e2>nephropathy</e2>\NN\14573196 group\NN\2137 ,\,\1740 which\WDT\1740 included\VBD\690614 7\CD\13741022 episode\NN\7283608 biopsies\NNS\5739043 ,\,\1740 were\VBD\836236 statistically\RB\1740 higher\JJR\1740 than\IN\1740 those\DT\1740 in\IN\13603305 the\DT\1740 minimum-type\JJ\1740 chronic\JJ\1740 <e1>FK506-nephropathy</e1>\JJ\1740 group\NN\2137 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
D016559_D007674 NONE The\DT\1740 serum\NN\5397468 creatinine\NN\1740 levels\NNS\4916342 of\IN\1740 patients\NNS\9898892 in\IN\13603305 the\DT\1740 mild-type\JJ\1740 chronic\JJ\1740 FK506\NN\1740 nephropathy\NN\14573196 group\NN\2137 ,\,\1740 which\WDT\1740 included\VBD\690614 7\CD\13741022 episode\NN\7283608 biopsies\NNS\5739043 ,\,\1740 were\VBD\836236 statistically\RB\1740 higher\JJR\1740 than\IN\1740 those\DT\1740 in\IN\13603305 the\DT\1740 minimum-type\JJ\1740 chronic\JJ\1740 <e2><e1>FK506-nephropathy</e1></e2>\JJ\1740 group\NN\2137 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
D016559_D007674 NONE CONCLUSIONS\NNS\5837957 :\:\1740 This\DT\1740 study\NN\635850 demonstrates\VBZ\2137132 that\IN\1740 chronic\JJ\1740 <e1>FK506</e1>\NN\1740 <e2>nephropathy</e2>\NN\14573196 consists\VBZ\2603699 primarily\RB\1740 of\IN\1740 arteriolopathy\JJ\1740 manifesting\NN\1740 as\IN\14622893 insudative\JJ\1740 hyalinosis\NN\1740 of\IN\1740 the\DT\1740 arteriolar\JJ\1740 wall\NN\3894379 ,\,\1740 and\CC\1740 suggests\VBZ\1010118 that\IN\1740 mild-type\JJ\1740 chronic\JJ\1740 FK506\NN\1740 nephropathy\NN\14573196 is\VBZ\836236 a\DT\13649268 condition\NN\24720 which\WDT\1740 may\MD\15209706 lead\VB\1752884 to\TO\1740 deterioration\NN\14560612 of\IN\1740 renal\JJ\1740 allograft\NN\5582859 function\NN\13783581 .\.\1740
D016559_D007674 NONE CONCLUSIONS\NNS\5837957 :\:\1740 This\DT\1740 study\NN\635850 demonstrates\VBZ\2137132 that\IN\1740 chronic\JJ\1740 <e1>FK506</e1>\NN\1740 nephropathy\NN\14573196 consists\VBZ\2603699 primarily\RB\1740 of\IN\1740 arteriolopathy\JJ\1740 manifesting\NN\1740 as\IN\14622893 insudative\JJ\1740 hyalinosis\NN\1740 of\IN\1740 the\DT\1740 arteriolar\JJ\1740 wall\NN\3894379 ,\,\1740 and\CC\1740 suggests\VBZ\1010118 that\IN\1740 mild-type\JJ\1740 chronic\JJ\1740 FK506\NN\1740 <e2>nephropathy</e2>\NN\14573196 is\VBZ\836236 a\DT\13649268 condition\NN\24720 which\WDT\1740 may\MD\15209706 lead\VB\1752884 to\TO\1740 deterioration\NN\14560612 of\IN\1740 renal\JJ\1740 allograft\NN\5582859 function\NN\13783581 .\.\1740
D016559_D007674 NONE CONCLUSIONS\NNS\5837957 :\:\1740 This\DT\1740 study\NN\635850 demonstrates\VBZ\2137132 that\IN\1740 chronic\JJ\1740 FK506\NN\1740 <e2>nephropathy</e2>\NN\14573196 consists\VBZ\2603699 primarily\RB\1740 of\IN\1740 arteriolopathy\JJ\1740 manifesting\NN\1740 as\IN\14622893 insudative\JJ\1740 hyalinosis\NN\1740 of\IN\1740 the\DT\1740 arteriolar\JJ\1740 wall\NN\3894379 ,\,\1740 and\CC\1740 suggests\VBZ\1010118 that\IN\1740 mild-type\JJ\1740 chronic\JJ\1740 <e1>FK506</e1>\NN\1740 nephropathy\NN\14573196 is\VBZ\836236 a\DT\13649268 condition\NN\24720 which\WDT\1740 may\MD\15209706 lead\VB\1752884 to\TO\1740 deterioration\NN\14560612 of\IN\1740 renal\JJ\1740 allograft\NN\5582859 function\NN\13783581 .\.\1740
D016559_D007674 NONE CONCLUSIONS\NNS\5837957 :\:\1740 This\DT\1740 study\NN\635850 demonstrates\VBZ\2137132 that\IN\1740 chronic\JJ\1740 FK506\NN\1740 nephropathy\NN\14573196 consists\VBZ\2603699 primarily\RB\1740 of\IN\1740 arteriolopathy\JJ\1740 manifesting\NN\1740 as\IN\14622893 insudative\JJ\1740 hyalinosis\NN\1740 of\IN\1740 the\DT\1740 arteriolar\JJ\1740 wall\NN\3894379 ,\,\1740 and\CC\1740 suggests\VBZ\1010118 that\IN\1740 mild-type\JJ\1740 chronic\JJ\1740 <e1>FK506</e1>\NN\1740 <e2>nephropathy</e2>\NN\14573196 is\VBZ\836236 a\DT\13649268 condition\NN\24720 which\WDT\1740 may\MD\15209706 lead\VB\1752884 to\TO\1740 deterioration\NN\14560612 of\IN\1740 renal\JJ\1740 allograft\NN\5582859 function\NN\13783581 .\.\1740
D016559_D005923 CID Chronic\JJ\1740 <e1>FK506</e1>\NN\1740 nephropathy\NN\14573196 consisted\VBD\2603699 of\IN\1740 rough\JJ\1740 and\CC\1740 foamy\NN\1740 tubular\JJ\1740 vacuolization\NN\13920835 (\-LRB-\1740 5\CD\13741022 biopsies\NNS\5739043 )\-RRB-\1740 ,\,\1740 arteriolopathy\NN\1740 (\-LRB-\1740 angiodegeneration\NN\1740 of\IN\1740 the\DT\1740 arteriolar\JJ\1740 wall\NN\3894379 ;\:\1740 20\CD\13745420 biopsies\NNS\5739043 )\-RRB-\1740 ,\,\1740 <e2>focal\JJ\1740 segmental\JJ\1740 glomerulosclerosis</e2>\NN\1740 (\-LRB-\1740 4\CD\13741022 biopsies\NNS\5739043 )\-RRB-\1740 and\CC\1740 the\DT\1740 striped\JJ\1740 form\NN\6286395 of\IN\1740 interstitial\JJ\1740 fibrosis\NN\14204950 (\-LRB-\1740 11\CD\13745420 biopsies\NNS\5739043 )\-RRB-\1740 .\.\1740
D016559_D005355 NONE Chronic\JJ\1740 <e1>FK506</e1>\NN\1740 nephropathy\NN\14573196 consisted\VBD\2603699 of\IN\1740 rough\JJ\1740 and\CC\1740 foamy\NN\1740 tubular\JJ\1740 vacuolization\NN\13920835 (\-LRB-\1740 5\CD\13741022 biopsies\NNS\5739043 )\-RRB-\1740 ,\,\1740 arteriolopathy\NN\1740 (\-LRB-\1740 angiodegeneration\NN\1740 of\IN\1740 the\DT\1740 arteriolar\JJ\1740 wall\NN\3894379 ;\:\1740 20\CD\13745420 biopsies\NNS\5739043 )\-RRB-\1740 ,\,\1740 focal\JJ\1740 segmental\JJ\1740 glomerulosclerosis\NN\1740 (\-LRB-\1740 4\CD\13741022 biopsies\NNS\5739043 )\-RRB-\1740 and\CC\1740 the\DT\1740 striped\JJ\1740 form\NN\6286395 of\IN\1740 <e2>interstitial\JJ\1740 fibrosis</e2>\NN\14204950 (\-LRB-\1740 11\CD\13745420 biopsies\NNS\5739043 )\-RRB-\1740 .\.\1740
D003404_D007674 NONE The\DT\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 levels\NNS\4916342 of\IN\1740 patients\NNS\9898892 in\IN\13603305 the\DT\1740 mild-type\JJ\1740 chronic\JJ\1740 FK506\NN\1740 <e2>nephropathy</e2>\NN\14573196 group\NN\2137 ,\,\1740 which\WDT\1740 included\VBD\690614 7\CD\13741022 episode\NN\7283608 biopsies\NNS\5739043 ,\,\1740 were\VBD\836236 statistically\RB\1740 higher\JJR\1740 than\IN\1740 those\DT\1740 in\IN\13603305 the\DT\1740 minimum-type\JJ\1740 chronic\JJ\1740 FK506-nephropathy\JJ\1740 group\NN\2137 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
D003404_D007674 NONE The\DT\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 levels\NNS\4916342 of\IN\1740 patients\NNS\9898892 in\IN\13603305 the\DT\1740 mild-type\JJ\1740 chronic\JJ\1740 FK506\NN\1740 nephropathy\NN\14573196 group\NN\2137 ,\,\1740 which\WDT\1740 included\VBD\690614 7\CD\13741022 episode\NN\7283608 biopsies\NNS\5739043 ,\,\1740 were\VBD\836236 statistically\RB\1740 higher\JJR\1740 than\IN\1740 those\DT\1740 in\IN\13603305 the\DT\1740 minimum-type\JJ\1740 chronic\JJ\1740 <e2>FK506-nephropathy</e2>\JJ\1740 group\NN\2137 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
16755009
D003975_D000647 CID <e1>Diazepam-</e1>\NN\1740 ,\,\1740 scopolamine-\NN\1740 and\CC\1740 ageing-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 served\VBD\2669789 as\IN\14622893 the\DT\1740 interoceptive\JJ\1740 behavioral\JJ\1740 models\NNS\5888929 .\.\1740
D003975_D000647 CID Furthermore\RB\1740 ,\,\1740 DCE\NN\1740 reversed\VBD\109660 the\DT\1740 <e2>amnesia</e2>\NN\5669934 induced\VBN\1627355 by\IN\1740 scopolamine\NN\14712692 (\-LRB-\1740 0.4\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 <e1>diazepam</e1>\NN\2830852 (\-LRB-\1740 1\CD\13741022 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
D012601_D000647 CID Diazepam-\NN\1740 ,\,\1740 <e1>scopolamine-</e1>\NN\1740 and\CC\1740 ageing-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 served\VBD\2669789 as\IN\14622893 the\DT\1740 interoceptive\JJ\1740 behavioral\JJ\1740 models\NNS\5888929 .\.\1740
D012601_D000647 CID Furthermore\RB\1740 ,\,\1740 DCE\NN\1740 reversed\VBD\109660 the\DT\1740 <e2>amnesia</e2>\NN\5669934 induced\VBN\1627355 by\IN\1740 <e1>scopolamine</e1>\NN\14712692 (\-LRB-\1740 0.4\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 diazepam\NN\2830852 (\-LRB-\1740 1\CD\13741022 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
D010936_D000647 NONE Furthermore\RB\1740 ,\,\1740 <e1>DCE</e1>\NN\1740 reversed\VBD\109660 the\DT\1740 <e2>amnesia</e2>\NN\5669934 induced\VBN\1627355 by\IN\1740 scopolamine\NN\14712692 (\-LRB-\1740 0.4\CD\1740 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 diazepam\NN\2830852 (\-LRB-\1740 1\CD\13741022 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 .\.\1740
D010936_D003072 NONE Therefore\RB\1740 ,\,\1740 <e1>DCE</e1>\NN\1740 may\MD\15209706 prove\VB\2604760 to\TO\1740 be\VB\836236 a\DT\13649268 useful\JJ\1740 remedy\NN\258854 for\IN\1740 the\DT\1740 management\NN\1123598 of\IN\1740 <e2>cognitive\JJ\1740 dysfunctions</e2>\NNS\14204950 on\IN\1740 account\NN\6647206 of\IN\1740 its\PRP$\6125041 multifarious\JJ\1740 beneficial\JJ\1740 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 ,\,\1740 memory\NN\5926676 improving\VBG\126264 property\NN\32613 ,\,\1740 cholesterol\NN\15058310 lowering\VBG\1850315 property\NN\32613 and\CC\1740 anticholinesterase\NN\3740161 activity\NN\30358 .\.\1740
D002784_D003072 NONE Therefore\RB\1740 ,\,\1740 DCE\NN\1740 may\MD\15209706 prove\VB\2604760 to\TO\1740 be\VB\836236 a\DT\13649268 useful\JJ\1740 remedy\NN\258854 for\IN\1740 the\DT\1740 management\NN\1123598 of\IN\1740 <e2>cognitive\JJ\1740 dysfunctions</e2>\NNS\14204950 on\IN\1740 account\NN\6647206 of\IN\1740 its\PRP$\6125041 multifarious\JJ\1740 beneficial\JJ\1740 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 ,\,\1740 memory\NN\5926676 improving\VBG\126264 property\NN\32613 ,\,\1740 <e1>cholesterol</e1>\NN\15058310 lowering\VBG\1850315 property\NN\32613 and\CC\1740 anticholinesterase\NN\3740161 activity\NN\30358 .\.\1740
19843802
D004837_D006973 CID However\RB\1740 ,\,\1740 a\DT\13649268 bolus\NN\13899404 of\IN\1740 <e1>epinephrine</e1>\NN\14807929 injected\VBN\81072 through\IN\1740 an\DT\6697703 alternative\JJ\1740 catheter\NN\4493505 provoked\VBD\1617192 a\DT\13649268 <e2>hypertensive</e2>\JJ\1740 crisis\NN\14411243 .\.\1740
6534871
D007545_D009203 CID The\DT\1740 effects\NNS\13245626 of\IN\1740 exercise\NN\621627 on\IN\1740 the\DT\1740 severity\NN\5036394 of\IN\1740 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 were\VBD\836236 studied\VBN\630380 in\IN\13603305 female\JJ\1740 albino\NN\9606527 rats\NNS\2329401 of\IN\1740 20,40,60\CD\1740 and\CC\1740 80\CD\13745420 weeks\NNS\15113229 of\IN\1740 age\NN\4916342 .\.\1740
7449470
D004317_D066126 NONE Late\RB\1740 ,\,\1740 late\JJ\1740 <e1>doxorubicin</e1>\NN\2716866 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D004317_D066126 NONE <e2>Cardiac\JJ\1740 toxicity</e2>\NN\13576101 is\VBZ\836236 a\DT\13649268 major\JJ\1740 complication\NN\1073995 which\WDT\1740 limits\VBZ\2510337 the\DT\1740 use\NN\407535 of\IN\1740 <e1>adriamycin</e1>\NN\1740 as\IN\14622893 a\DT\13649268 chemotherapeutic\JJ\1740 agent\NN\7347 .\.\1740
11419773
D002110_D001145 NONE <e1>Caffeine-induced</e1>\JJ\1740 <e2>cardiac\JJ\1740 arrhythmia</e2>\NN\14103288 :\:\1740 an\DT\6697703 unrecognised\JJ\1740 danger\NN\13920835 of\IN\1740 healthfood\NN\1740 products\NNS\3076708 .\.\1740
D002110_D008945 NONE We\PRP\1740 describe\VBP\1001294 a\DT\13649268 25-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 pre-existing\JJ\1740 <e2>mitral\JJ\1740 valve\NN\5225602 prolapse</e2>\NN\14548343 who\WP\8299493 developed\VBD\1753788 intractable\JJ\1740 ventricular\JJ\1740 fibrillation\NN\14361664 after\IN\1740 consuming\VBG\1168468 a\DT\13649268 "\``\1740 natural\JJ\1740 energy\NN\11419404 "\''\1740 guarana\VBZ\1740 health\NN\14447525 drink\VBP\1156834 containing\VBG\2632940 a\DT\13649268 high\JJ\1740 concentration\NN\4916342 of\IN\1740 <e1>caffeine</e1>\NN\14712692 .\.\1740
D002110_D014693 CID We\PRP\1740 describe\VBP\1001294 a\DT\13649268 25-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 pre-existing\JJ\1740 mitral\JJ\1740 valve\NN\5225602 prolapse\NN\14548343 who\WP\8299493 developed\VBD\1753788 intractable\JJ\1740 <e2>ventricular\JJ\1740 fibrillation</e2>\NN\14361664 after\IN\1740 consuming\VBG\1168468 a\DT\13649268 "\``\1740 natural\JJ\1740 energy\NN\11419404 "\''\1740 guarana\VBZ\1740 health\NN\14447525 drink\VBP\1156834 containing\VBG\2632940 a\DT\13649268 high\JJ\1740 concentration\NN\4916342 of\IN\1740 <e1>caffeine</e1>\NN\14712692 .\.\1740
6287825
D013831_D010523 CID <e2>Peripheral\JJ\1740 neuropathy</e2>\NN\14204950 due\JJ\1740 to\TO\1740 nutritional\JJ\1740 deficiency\NN\14449126 of\IN\1740 <e1>thiamine</e1>\NN\15090742 and\CC\1740 riboflavin\NN\15090742 was\VBD\836236 common\JJ\1740 (\-LRB-\1740 10.1\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 presented\VBN\2137132 mainly\RB\1740 as\IN\14622893 sensory\JJ\1740 and\CC\1740 sensori-motor\JJ\1740 neuropathy\JJ\1740 .\.\1740
D013831_D010523 CID Peripheral\JJ\1740 neuropathy\NN\14204950 due\JJ\1740 to\TO\1740 nutritional\JJ\1740 deficiency\NN\14449126 of\IN\1740 <e1>thiamine</e1>\NN\15090742 and\CC\1740 riboflavin\NN\15090742 was\VBD\836236 common\JJ\1740 (\-LRB-\1740 10.1\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 presented\VBN\2137132 mainly\RB\1740 as\IN\14622893 sensory\JJ\1740 and\CC\1740 <e2>sensori-motor\JJ\1740 neuropathy</e2>\JJ\1740 .\.\1740
D013831_D044342 NONE Peripheral\JJ\1740 neuropathy\NN\14204950 due\JJ\1740 to\TO\1740 <e2>nutritional\JJ\1740 deficiency</e2>\NN\14449126 of\IN\1740 <e1>thiamine</e1>\NN\15090742 and\CC\1740 riboflavin\NN\15090742 was\VBD\836236 common\JJ\1740 (\-LRB-\1740 10.1\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 presented\VBN\2137132 mainly\RB\1740 as\IN\14622893 sensory\JJ\1740 and\CC\1740 sensori-motor\JJ\1740 neuropathy\JJ\1740 .\.\1740
D012256_D010523 CID <e2>Peripheral\JJ\1740 neuropathy</e2>\NN\14204950 due\JJ\1740 to\TO\1740 nutritional\JJ\1740 deficiency\NN\14449126 of\IN\1740 thiamine\NN\15090742 and\CC\1740 <e1>riboflavin</e1>\NN\15090742 was\VBD\836236 common\JJ\1740 (\-LRB-\1740 10.1\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 presented\VBN\2137132 mainly\RB\1740 as\IN\14622893 sensory\JJ\1740 and\CC\1740 sensori-motor\JJ\1740 neuropathy\JJ\1740 .\.\1740
D012256_D010523 CID Peripheral\JJ\1740 neuropathy\NN\14204950 due\JJ\1740 to\TO\1740 nutritional\JJ\1740 deficiency\NN\14449126 of\IN\1740 thiamine\NN\15090742 and\CC\1740 <e1>riboflavin</e1>\NN\15090742 was\VBD\836236 common\JJ\1740 (\-LRB-\1740 10.1\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 presented\VBN\2137132 mainly\RB\1740 as\IN\14622893 sensory\JJ\1740 and\CC\1740 <e2>sensori-motor\JJ\1740 neuropathy</e2>\JJ\1740 .\.\1740
D012256_D044342 NONE Peripheral\JJ\1740 neuropathy\NN\14204950 due\JJ\1740 to\TO\1740 <e2>nutritional\JJ\1740 deficiency</e2>\NN\14449126 of\IN\1740 thiamine\NN\15090742 and\CC\1740 <e1>riboflavin</e1>\NN\15090742 was\VBD\836236 common\JJ\1740 (\-LRB-\1740 10.1\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 presented\VBN\2137132 mainly\RB\1740 as\IN\14622893 sensory\JJ\1740 and\CC\1740 sensori-motor\JJ\1740 neuropathy\JJ\1740 .\.\1740
D007538_D009422 NONE <e1>Isoniazid</e1>\NNP\2716205 was\VBD\836236 the\DT\1740 most\RBS\1740 frequent\JJ\1740 agent\NN\7347 in\IN\13603305 drug-induced\JJ\1740 <e2>neuropathy</e2>\JJ\1740 .\.\1740
19820426
C558899_D066126 NONE Twin\JJ\1740 preterm\NN\1740 neonates\NNS\9827683 with\IN\1740 <e2>cardiac\JJ\1740 toxicity</e2>\NN\13576101 related\JJ\1740 to\TO\1740 <e1>lopinavir/ritonavir</e1>\NN\1740 therapy\NN\657604 .\.\1740
C558899_D006327 CID One\CD\13741022 of\IN\1740 the\DT\1740 twins\NNS\14883206 developed\VBD\1753788 complete\JJ\1740 <e2>heart\NN\5919034 block</e2>\NN\21939 and\CC\1740 dilated\VBN\303465 cardiomyopathy\DT\14103288 related\JJ\1740 to\TO\1740 <e1>lopinavir/ritonavir</e1>\NN\1740 therapy\NN\657604 ,\,\1740 a\DT\13649268 boosted\JJ\1740 protease-inhibitor\JJ\1740 agent\NN\7347 ,\,\1740 while\IN\15122231 the\DT\1740 other\JJ\1740 twin\NN\10595164 developed\VBN\1753788 mild\JJ\1740 bradycardia\NN\14110674 .\.\1740
C558899_D002311 CID One\CD\13741022 of\IN\1740 the\DT\1740 twins\NNS\14883206 developed\VBD\1753788 complete\JJ\1740 heart\NN\5919034 block\NN\21939 and\CC\1740 <e2>dilated\VBN\303465 cardiomyopathy</e2>\DT\14103288 related\JJ\1740 to\TO\1740 <e1>lopinavir/ritonavir</e1>\NN\1740 therapy\NN\657604 ,\,\1740 a\DT\13649268 boosted\JJ\1740 protease-inhibitor\JJ\1740 agent\NN\7347 ,\,\1740 while\IN\15122231 the\DT\1740 other\JJ\1740 twin\NN\10595164 developed\VBN\1753788 mild\JJ\1740 bradycardia\NN\14110674 .\.\1740
C558899_D001919 CID One\CD\13741022 of\IN\1740 the\DT\1740 twins\NNS\14883206 developed\VBD\1753788 complete\JJ\1740 heart\NN\5919034 block\NN\21939 and\CC\1740 dilated\VBN\303465 cardiomyopathy\DT\14103288 related\JJ\1740 to\TO\1740 <e1>lopinavir/ritonavir</e1>\NN\1740 therapy\NN\657604 ,\,\1740 a\DT\13649268 boosted\JJ\1740 protease-inhibitor\JJ\1740 agent\NN\7347 ,\,\1740 while\IN\15122231 the\DT\1740 other\JJ\1740 twin\NN\10595164 developed\VBN\1753788 mild\JJ\1740 <e2>bradycardia</e2>\NN\14110674 .\.\1740
9766615
D003024_D001480 NONE The\DT\1740 newer\JJR\1740 atypical\JJ\1740 agents\NNS\7347 have\VBP\2108377 a\DT\13649268 lower\JJR\1740 risk\NN\14541044 of\IN\1740 <e2>EPS</e2>\NN\1740 ,\,\1740 but\CC\1740 are\VBP\836236 associated\VBN\628491 in\IN\13603305 varying\VBG\2666239 degrees\NNS\4916342 with\IN\1740 sedation\NN\14034177 ,\,\1740 cardiovascular\JJ\1740 effects\NNS\13245626 ,\,\1740 anticholinergic\JJ\1740 effects\NNS\13245626 ,\,\1740 weight\NN\5009170 gain\NN\13576355 ,\,\1740 sexual\JJ\1740 dysfunction\NN\14204950 ,\,\1740 hepatic\JJ\1740 effects\NNS\13245626 ,\,\1740 lowered\VBD\1850315 seizure\JJ\1740 threshold\NN\15265518 (\-LRB-\1740 primarily\RB\1740 <e1>clozapine</e1>\NN\3713736 )\-RRB-\1740 ,\,\1740 and\CC\1740 agranulocytosis\NN\14189204 (\-LRB-\1740 clozapine\NN\3713736 only\RB\1740 )\-RRB-\1740 .\.\1740
D003024_D001480 NONE The\DT\1740 newer\JJR\1740 atypical\JJ\1740 agents\NNS\7347 have\VBP\2108377 a\DT\13649268 lower\JJR\1740 risk\NN\14541044 of\IN\1740 <e2>EPS</e2>\NN\1740 ,\,\1740 but\CC\1740 are\VBP\836236 associated\VBN\628491 in\IN\13603305 varying\VBG\2666239 degrees\NNS\4916342 with\IN\1740 sedation\NN\14034177 ,\,\1740 cardiovascular\JJ\1740 effects\NNS\13245626 ,\,\1740 anticholinergic\JJ\1740 effects\NNS\13245626 ,\,\1740 weight\NN\5009170 gain\NN\13576355 ,\,\1740 sexual\JJ\1740 dysfunction\NN\14204950 ,\,\1740 hepatic\JJ\1740 effects\NNS\13245626 ,\,\1740 lowered\VBD\1850315 seizure\JJ\1740 threshold\NN\15265518 (\-LRB-\1740 primarily\RB\1740 clozapine\NN\3713736 )\-RRB-\1740 ,\,\1740 and\CC\1740 agranulocytosis\NN\14189204 (\-LRB-\1740 <e1>clozapine</e1>\NN\3713736 only\RB\1740 )\-RRB-\1740 .\.\1740
D003024_D015430 NONE The\DT\1740 newer\JJR\1740 atypical\JJ\1740 agents\NNS\7347 have\VBP\2108377 a\DT\13649268 lower\JJR\1740 risk\NN\14541044 of\IN\1740 EPS\NN\1740 ,\,\1740 but\CC\1740 are\VBP\836236 associated\VBN\628491 in\IN\13603305 varying\VBG\2666239 degrees\NNS\4916342 with\IN\1740 sedation\NN\14034177 ,\,\1740 cardiovascular\JJ\1740 effects\NNS\13245626 ,\,\1740 anticholinergic\JJ\1740 effects\NNS\13245626 ,\,\1740 <e2>weight\NN\5009170 gain</e2>\NN\13576355 ,\,\1740 sexual\JJ\1740 dysfunction\NN\14204950 ,\,\1740 hepatic\JJ\1740 effects\NNS\13245626 ,\,\1740 lowered\VBD\1850315 seizure\JJ\1740 threshold\NN\15265518 (\-LRB-\1740 primarily\RB\1740 <e1>clozapine</e1>\NN\3713736 )\-RRB-\1740 ,\,\1740 and\CC\1740 agranulocytosis\NN\14189204 (\-LRB-\1740 clozapine\NN\3713736 only\RB\1740 )\-RRB-\1740 .\.\1740
D003024_D015430 NONE The\DT\1740 newer\JJR\1740 atypical\JJ\1740 agents\NNS\7347 have\VBP\2108377 a\DT\13649268 lower\JJR\1740 risk\NN\14541044 of\IN\1740 EPS\NN\1740 ,\,\1740 but\CC\1740 are\VBP\836236 associated\VBN\628491 in\IN\13603305 varying\VBG\2666239 degrees\NNS\4916342 with\IN\1740 sedation\NN\14034177 ,\,\1740 cardiovascular\JJ\1740 effects\NNS\13245626 ,\,\1740 anticholinergic\JJ\1740 effects\NNS\13245626 ,\,\1740 <e2>weight\NN\5009170 gain</e2>\NN\13576355 ,\,\1740 sexual\JJ\1740 dysfunction\NN\14204950 ,\,\1740 hepatic\JJ\1740 effects\NNS\13245626 ,\,\1740 lowered\VBD\1850315 seizure\JJ\1740 threshold\NN\15265518 (\-LRB-\1740 primarily\RB\1740 clozapine\NN\3713736 )\-RRB-\1740 ,\,\1740 and\CC\1740 agranulocytosis\NN\14189204 (\-LRB-\1740 <e1>clozapine</e1>\NN\3713736 only\RB\1740 )\-RRB-\1740 .\.\1740
D003024_D012735 NONE The\DT\1740 newer\JJR\1740 atypical\JJ\1740 agents\NNS\7347 have\VBP\2108377 a\DT\13649268 lower\JJR\1740 risk\NN\14541044 of\IN\1740 EPS\NN\1740 ,\,\1740 but\CC\1740 are\VBP\836236 associated\VBN\628491 in\IN\13603305 varying\VBG\2666239 degrees\NNS\4916342 with\IN\1740 sedation\NN\14034177 ,\,\1740 cardiovascular\JJ\1740 effects\NNS\13245626 ,\,\1740 anticholinergic\JJ\1740 effects\NNS\13245626 ,\,\1740 weight\NN\5009170 gain\NN\13576355 ,\,\1740 <e2>sexual\JJ\1740 dysfunction</e2>\NN\14204950 ,\,\1740 hepatic\JJ\1740 effects\NNS\13245626 ,\,\1740 lowered\VBD\1850315 seizure\JJ\1740 threshold\NN\15265518 (\-LRB-\1740 primarily\RB\1740 <e1>clozapine</e1>\NN\3713736 )\-RRB-\1740 ,\,\1740 and\CC\1740 agranulocytosis\NN\14189204 (\-LRB-\1740 clozapine\NN\3713736 only\RB\1740 )\-RRB-\1740 .\.\1740
D003024_D012735 NONE The\DT\1740 newer\JJR\1740 atypical\JJ\1740 agents\NNS\7347 have\VBP\2108377 a\DT\13649268 lower\JJR\1740 risk\NN\14541044 of\IN\1740 EPS\NN\1740 ,\,\1740 but\CC\1740 are\VBP\836236 associated\VBN\628491 in\IN\13603305 varying\VBG\2666239 degrees\NNS\4916342 with\IN\1740 sedation\NN\14034177 ,\,\1740 cardiovascular\JJ\1740 effects\NNS\13245626 ,\,\1740 anticholinergic\JJ\1740 effects\NNS\13245626 ,\,\1740 weight\NN\5009170 gain\NN\13576355 ,\,\1740 <e2>sexual\JJ\1740 dysfunction</e2>\NN\14204950 ,\,\1740 hepatic\JJ\1740 effects\NNS\13245626 ,\,\1740 lowered\VBD\1850315 seizure\JJ\1740 threshold\NN\15265518 (\-LRB-\1740 primarily\RB\1740 clozapine\NN\3713736 )\-RRB-\1740 ,\,\1740 and\CC\1740 agranulocytosis\NN\14189204 (\-LRB-\1740 <e1>clozapine</e1>\NN\3713736 only\RB\1740 )\-RRB-\1740 .\.\1740
D003024_D012640 NONE The\DT\1740 newer\JJR\1740 atypical\JJ\1740 agents\NNS\7347 have\VBP\2108377 a\DT\13649268 lower\JJR\1740 risk\NN\14541044 of\IN\1740 EPS\NN\1740 ,\,\1740 but\CC\1740 are\VBP\836236 associated\VBN\628491 in\IN\13603305 varying\VBG\2666239 degrees\NNS\4916342 with\IN\1740 sedation\NN\14034177 ,\,\1740 cardiovascular\JJ\1740 effects\NNS\13245626 ,\,\1740 anticholinergic\JJ\1740 effects\NNS\13245626 ,\,\1740 weight\NN\5009170 gain\NN\13576355 ,\,\1740 sexual\JJ\1740 dysfunction\NN\14204950 ,\,\1740 hepatic\JJ\1740 effects\NNS\13245626 ,\,\1740 lowered\VBD\1850315 <e2>seizure</e2>\JJ\1740 threshold\NN\15265518 (\-LRB-\1740 primarily\RB\1740 <e1>clozapine</e1>\NN\3713736 )\-RRB-\1740 ,\,\1740 and\CC\1740 agranulocytosis\NN\14189204 (\-LRB-\1740 clozapine\NN\3713736 only\RB\1740 )\-RRB-\1740 .\.\1740
D003024_D012640 NONE The\DT\1740 newer\JJR\1740 atypical\JJ\1740 agents\NNS\7347 have\VBP\2108377 a\DT\13649268 lower\JJR\1740 risk\NN\14541044 of\IN\1740 EPS\NN\1740 ,\,\1740 but\CC\1740 are\VBP\836236 associated\VBN\628491 in\IN\13603305 varying\VBG\2666239 degrees\NNS\4916342 with\IN\1740 sedation\NN\14034177 ,\,\1740 cardiovascular\JJ\1740 effects\NNS\13245626 ,\,\1740 anticholinergic\JJ\1740 effects\NNS\13245626 ,\,\1740 weight\NN\5009170 gain\NN\13576355 ,\,\1740 sexual\JJ\1740 dysfunction\NN\14204950 ,\,\1740 hepatic\JJ\1740 effects\NNS\13245626 ,\,\1740 lowered\VBD\1850315 <e2>seizure</e2>\JJ\1740 threshold\NN\15265518 (\-LRB-\1740 primarily\RB\1740 clozapine\NN\3713736 )\-RRB-\1740 ,\,\1740 and\CC\1740 agranulocytosis\NN\14189204 (\-LRB-\1740 <e1>clozapine</e1>\NN\3713736 only\RB\1740 )\-RRB-\1740 .\.\1740
D003024_D000380 CID The\DT\1740 newer\JJR\1740 atypical\JJ\1740 agents\NNS\7347 have\VBP\2108377 a\DT\13649268 lower\JJR\1740 risk\NN\14541044 of\IN\1740 EPS\NN\1740 ,\,\1740 but\CC\1740 are\VBP\836236 associated\VBN\628491 in\IN\13603305 varying\VBG\2666239 degrees\NNS\4916342 with\IN\1740 sedation\NN\14034177 ,\,\1740 cardiovascular\JJ\1740 effects\NNS\13245626 ,\,\1740 anticholinergic\JJ\1740 effects\NNS\13245626 ,\,\1740 weight\NN\5009170 gain\NN\13576355 ,\,\1740 sexual\JJ\1740 dysfunction\NN\14204950 ,\,\1740 hepatic\JJ\1740 effects\NNS\13245626 ,\,\1740 lowered\VBD\1850315 seizure\JJ\1740 threshold\NN\15265518 (\-LRB-\1740 primarily\RB\1740 <e1>clozapine</e1>\NN\3713736 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e2>agranulocytosis</e2>\NN\14189204 (\-LRB-\1740 clozapine\NN\3713736 only\RB\1740 )\-RRB-\1740 .\.\1740
D003024_D000380 CID The\DT\1740 newer\JJR\1740 atypical\JJ\1740 agents\NNS\7347 have\VBP\2108377 a\DT\13649268 lower\JJR\1740 risk\NN\14541044 of\IN\1740 EPS\NN\1740 ,\,\1740 but\CC\1740 are\VBP\836236 associated\VBN\628491 in\IN\13603305 varying\VBG\2666239 degrees\NNS\4916342 with\IN\1740 sedation\NN\14034177 ,\,\1740 cardiovascular\JJ\1740 effects\NNS\13245626 ,\,\1740 anticholinergic\JJ\1740 effects\NNS\13245626 ,\,\1740 weight\NN\5009170 gain\NN\13576355 ,\,\1740 sexual\JJ\1740 dysfunction\NN\14204950 ,\,\1740 hepatic\JJ\1740 effects\NNS\13245626 ,\,\1740 lowered\VBD\1850315 seizure\JJ\1740 threshold\NN\15265518 (\-LRB-\1740 primarily\RB\1740 clozapine\NN\3713736 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e2>agranulocytosis</e2>\NN\14189204 (\-LRB-\1740 <e1>clozapine</e1>\NN\3713736 only\RB\1740 )\-RRB-\1740 .\.\1740
16330766
C040029_D009437 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 assess\VB\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>gabapentin</e1>\NN\2718469 ,\,\1740 a\DT\13649268 drug\NN\14778436 effective\JJ\1740 in\IN\13603305 <e2>neuropathic\JJ\1740 pain</e2>\NN\14299637 patients\NNS\9898892 ,\,\1740 on\IN\1740 brain\NN\5462674 processing\NN\29677 of\IN\1740 nociceptive\JJ\1740 information\NN\6598915 in\IN\13603305 normal\JJ\1740 and\CC\1740 central\JJ\1740 sensitization\NN\14531772 states\NNS\8491826 .\.\1740
C040029_D006930 NONE Using\VBG\1156834 functional\JJ\1740 magnetic\JJ\1740 resonance\NN\11419404 imaging\NN\5765159 (\-LRB-\1740 fMRI\NN\902579 )\-RRB-\1740 in\IN\13603305 normal\JJ\1740 volunteers\NNS\10582746 ,\,\1740 we\PRP\1740 studied\VBD\630380 the\DT\1740 <e1>gabapentin-induced</e1>\JJ\1740 modulation\NN\7044917 of\IN\1740 brain\NN\5462674 activity\NN\30358 in\IN\13603305 response\NN\11410625 to\TO\1740 nociceptive\JJ\1740 mechanical\JJ\1740 stimulation\NN\242808 of\IN\1740 normal\JJ\1740 skin\NN\5237755 and\CC\1740 capsaicin-induced\JJ\1740 <e2>secondary\JJ\1740 hyperalgesia</e2>\NN\1740 .\.\1740
D002211_D006930 CID Using\VBG\1156834 functional\JJ\1740 magnetic\JJ\1740 resonance\NN\11419404 imaging\NN\5765159 (\-LRB-\1740 fMRI\NN\902579 )\-RRB-\1740 in\IN\13603305 normal\JJ\1740 volunteers\NNS\10582746 ,\,\1740 we\PRP\1740 studied\VBD\630380 the\DT\1740 gabapentin-induced\JJ\1740 modulation\NN\7044917 of\IN\1740 brain\NN\5462674 activity\NN\30358 in\IN\13603305 response\NN\11410625 to\TO\1740 nociceptive\JJ\1740 mechanical\JJ\1740 stimulation\NN\242808 of\IN\1740 normal\JJ\1740 skin\NN\5237755 and\CC\1740 <e1>capsaicin-induced</e1>\JJ\1740 <e2>secondary\JJ\1740 hyperalgesia</e2>\NN\1740 .\.\1740
6640832
D004317_D001749 NONE Early\JJ\1740 adjuvant\JJ\1740 <e1>adriamycin</e1>\NN\1740 in\IN\13603305 superficial\JJ\1740 <e2>bladder\NN\5515670 carcinoma</e2>\NN\14239918 .\.\1740
D004317_D001749 NONE <e1>Adriamycin</e1>\NN\1740 (\-LRB-\1740 50\CD\13745420 mg/50\NN\1740 ml\NN\13616054 )\-RRB-\1740 was\VBD\836236 administered\VBN\2436349 intravesically\RB\1740 within\IN\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 transurethral\JJ\1740 resection\NN\671351 of\IN\1740 TA-T1\NN\1740 (\-LRB-\1740 O-A\JJ\1740 )\-RRB-\1740 <e2>bladder\NN\5515670 tumors</e2>\NNS\14234074 .\.\1740
D004317_D002277 NONE Early\JJ\1740 adjuvant\JJ\1740 <e1>adriamycin</e1>\NN\1740 in\IN\13603305 superficial\JJ\1740 <e2>bladder\NN\5515670 carcinoma</e2>\NN\14239918 .\.\1740
8421099
D015282_D042882 CID Prospective\JJ\1740 study\NN\635850 of\IN\1740 the\DT\1740 long-term\JJ\1740 effects\NNS\13245626 of\IN\1740 somatostatin\NN\1740 analog\NN\4743605 (\-LRB-\1740 <e1>octreotide</e1>\NN\1740 )\-RRB-\1740 on\IN\1740 gallbladder\NN\5512139 function\NN\13783581 and\CC\1740 <e2>gallstone</e2>\NN\9230768 formation\NN\7938773 in\IN\13603305 Chinese\JJ\1740 acromegalic\JJ\1740 patients\NNS\9898892 .\.\1740
D015282_D042882 CID After\IN\1740 withdrawal\NN\7206096 of\IN\1740 <e1>octreotide</e1>\NN\1740 in\IN\13603305 10\CD\13745420 patients\NNS\9898892 without\IN\1740 <e2>gallstones</e2>\NNS\9230768 ,\,\1740 8\CD\13741022 patients\NNS\9898892 assessed\VBN\670261 had\VBD\2108377 return\NN\6479665 of\IN\1740 normal\JJ\1740 gallbladder\NN\5512139 contractility\NN\5200169 within\IN\1740 1\CD\13741022 month\NN\15113229 .\.\1740
D015282_D042882 CID Our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 the\DT\1740 suppression\NN\13489037 of\IN\1740 gallbladder\NN\5512139 contractility\NN\5200169 is\VBZ\836236 the\DT\1740 cause\NN\7323922 of\IN\1740 the\DT\1740 successive\JJ\1740 formation\NN\7938773 of\IN\1740 bile\NN\5405946 sludge\NN\14591635 ,\,\1740 <e2>gallstones</e2>\NNS\9230768 ,\,\1740 and\CC\1740 cholecystitis\NN\14336539 during\IN\1740 <e1>octreotide</e1>\NN\1740 therapy\NN\657604 in\IN\13603305 Chinese\JJ\1740 acromegalic\JJ\1740 patients\NNS\9898892 .\.\1740
D015282_D000172 NONE Prospective\JJ\1740 study\NN\635850 of\IN\1740 the\DT\1740 long-term\JJ\1740 effects\NNS\13245626 of\IN\1740 somatostatin\NN\1740 analog\NN\4743605 (\-LRB-\1740 <e1>octreotide</e1>\NN\1740 )\-RRB-\1740 on\IN\1740 gallbladder\NN\5512139 function\NN\13783581 and\CC\1740 gallstone\NN\9230768 formation\NN\7938773 in\IN\13603305 Chinese\JJ\1740 <e2>acromegalic</e2>\JJ\1740 patients\NNS\9898892 .\.\1740
D015282_D000172 NONE This\DT\1740 article\NN\6367571 reports\VBZ\831651 the\DT\1740 changes\NNS\7283608 in\IN\13603305 gallbladder\NN\5512139 function\NN\13783581 examined\VBN\789138 by\IN\1740 ultrasonography\NN\901083 in\IN\13603305 20\CD\13745420 Chinese\JJ\1740 patients\NNS\9898892 with\IN\1740 active\JJ\1740 <e2>acromegaly</e2>\NN\14366759 treated\VBN\2376958 with\IN\1740 sc\NN\14625458 injection\NN\320852 of\IN\1740 the\DT\1740 somatostatin\NN\1740 analog\NN\4743605 <e1>octreotide</e1>\NN\1740 in\IN\13603305 dosages\NNS\13576355 of\IN\1740 300\CD\1740 -\SYM\1740 1500\CD\1740 micrograms/day\NN\1740 for\IN\1740 a\DT\13649268 mean\NN\6021761 of\IN\1740 24.2\CD\1740 +/-\CC\1740 13.9\CD\1740 months\NNS\15113229 .\.\1740
D015282_D000172 NONE Our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 the\DT\1740 suppression\NN\13489037 of\IN\1740 gallbladder\NN\5512139 contractility\NN\5200169 is\VBZ\836236 the\DT\1740 cause\NN\7323922 of\IN\1740 the\DT\1740 successive\JJ\1740 formation\NN\7938773 of\IN\1740 bile\NN\5405946 sludge\NN\14591635 ,\,\1740 gallstones\NNS\9230768 ,\,\1740 and\CC\1740 cholecystitis\NN\14336539 during\IN\1740 <e1>octreotide</e1>\NN\1740 therapy\NN\657604 in\IN\13603305 Chinese\JJ\1740 <e2>acromegalic</e2>\JJ\1740 patients\NNS\9898892 .\.\1740
D015282_D000172 NONE It\PRP\6125041 is\VBZ\836236 therefore\RB\1740 very\RB\1740 important\JJ\1740 to\TO\1740 follow\VB\1835496 the\DT\1740 changes\NNS\7283608 of\IN\1740 gallbladder\NN\5512139 function\NN\13783581 during\IN\1740 long-term\JJ\1740 <e1>octreotide</e1>\NN\1740 therapy\NN\657604 of\IN\1740 <e2>acromegalic</e2>\JJ\1740 patients\NNS\9898892 .\.\1740
D015282_D002764 NONE Our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 the\DT\1740 suppression\NN\13489037 of\IN\1740 gallbladder\NN\5512139 contractility\NN\5200169 is\VBZ\836236 the\DT\1740 cause\NN\7323922 of\IN\1740 the\DT\1740 successive\JJ\1740 formation\NN\7938773 of\IN\1740 bile\NN\5405946 sludge\NN\14591635 ,\,\1740 gallstones\NNS\9230768 ,\,\1740 and\CC\1740 <e2>cholecystitis</e2>\NN\14336539 during\IN\1740 <e1>octreotide</e1>\NN\1740 therapy\NN\657604 in\IN\13603305 Chinese\JJ\1740 acromegalic\JJ\1740 patients\NNS\9898892 .\.\1740
7453952
D008094_D003919 CID Attenuation\NN\7427337 of\IN\1740 the\DT\1740 <e1>lithium-induced</e1>\JJ\1740 <e2>diabetes-insipidus-like\JJ\1740 syndrome</e2>\NN\5870365 by\IN\1740 amiloride\NN\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D008094_D003919 CID In\IN\13603305 all\PDT\1740 the\DT\1740 experiments\NNS\641820 ,\,\1740 the\DT\1740 attenuation\NN\7427337 of\IN\1740 the\DT\1740 <e1>lithium-induced</e1>\JJ\1740 <e2>diabetes-insipidus-like\JJ\1740 syndrome</e2>\NN\5870365 by\IN\1740 amiloride\NN\1740 was\VBD\836236 accompanied\VBN\1835496 by\IN\1740 a\DT\13649268 reduction\NN\351485 of\IN\1740 the\DT\1740 ratio\NN\13815152 between\IN\1740 the\DT\1740 lithium\NN\14625458 concentration\NN\4916342 in\IN\13603305 the\DT\1740 renal\JJ\1740 medulla\NN\14864360 and\CC\1740 its\PRP$\6125041 levels\NNS\4916342 in\IN\13603305 the\DT\1740 blood\NN\5397468 and\CC\1740 an\DT\6697703 elevation\NN\7445480 in\IN\13603305 the\DT\1740 plasma\NN\5398023 potassium\NN\14625458 level\NN\4916342 .\.\1740
D008094_D003919 CID In\IN\13603305 all\PDT\1740 the\DT\1740 experiments\NNS\641820 ,\,\1740 the\DT\1740 attenuation\NN\7427337 of\IN\1740 the\DT\1740 lithium-induced\JJ\1740 <e2>diabetes-insipidus-like\JJ\1740 syndrome</e2>\NN\5870365 by\IN\1740 amiloride\NN\1740 was\VBD\836236 accompanied\VBN\1835496 by\IN\1740 a\DT\13649268 reduction\NN\351485 of\IN\1740 the\DT\1740 ratio\NN\13815152 between\IN\1740 the\DT\1740 <e1>lithium</e1>\NN\14625458 concentration\NN\4916342 in\IN\13603305 the\DT\1740 renal\JJ\1740 medulla\NN\14864360 and\CC\1740 its\PRP$\6125041 levels\NNS\4916342 in\IN\13603305 the\DT\1740 blood\NN\5397468 and\CC\1740 an\DT\6697703 elevation\NN\7445480 in\IN\13603305 the\DT\1740 plasma\NN\5398023 potassium\NN\14625458 level\NN\4916342 .\.\1740
D000584_D003919 NONE Attenuation\NN\7427337 of\IN\1740 the\DT\1740 lithium-induced\JJ\1740 <e2>diabetes-insipidus-like\JJ\1740 syndrome</e2>\NN\5870365 by\IN\1740 <e1>amiloride</e1>\NN\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D000584_D003919 NONE In\IN\13603305 all\PDT\1740 the\DT\1740 experiments\NNS\641820 ,\,\1740 the\DT\1740 attenuation\NN\7427337 of\IN\1740 the\DT\1740 lithium-induced\JJ\1740 <e2>diabetes-insipidus-like\JJ\1740 syndrome</e2>\NN\5870365 by\IN\1740 <e1>amiloride</e1>\NN\1740 was\VBD\836236 accompanied\VBN\1835496 by\IN\1740 a\DT\13649268 reduction\NN\351485 of\IN\1740 the\DT\1740 ratio\NN\13815152 between\IN\1740 the\DT\1740 lithium\NN\14625458 concentration\NN\4916342 in\IN\13603305 the\DT\1740 renal\JJ\1740 medulla\NN\14864360 and\CC\1740 its\PRP$\6125041 levels\NNS\4916342 in\IN\13603305 the\DT\1740 blood\NN\5397468 and\CC\1740 an\DT\6697703 elevation\NN\7445480 in\IN\13603305 the\DT\1740 plasma\NN\5398023 potassium\NN\14625458 level\NN\4916342 .\.\1740
D000584_D059606 NONE The\DT\1740 effect\NN\34213 of\IN\1740 <e1>amiloride</e1>\NN\1740 on\IN\1740 lithium-induced\JJ\1740 <e2>polydipsia</e2>\NN\14040660 and\CC\1740 polyuria\NN\14113228 and\CC\1740 on\IN\1740 the\DT\1740 lithium\NN\14625458 concentration\NN\4916342 in\IN\13603305 the\DT\1740 plasma\NN\5398023 ,\,\1740 brain\NN\5462674 ,\,\1740 kidney\NN\5333259 ,\,\1740 thyroid\NN\5329735 and\CC\1740 red\JJ\1740 blood\NN\5397468 cells\NNS\3080309 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 rats\NNS\2329401 ,\,\1740 chronically\RB\1740 treated\VBN\2376958 with\IN\1740 LiCl\NN\1740 .\.\1740
D000584_D059606 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 acute\JJ\1740 <e1>amiloride</e1>\NN\1740 administration\NN\1133281 to\TO\1740 lithium-treated\JJ\1740 patients\NNS\9898892 suffering\VBG\2110220 from\IN\1740 <e2>polydipsia</e2>\NN\14040660 and\CC\1740 polyuria\NN\14113228 might\MD\5029706 relieve\VB\205885 these\DT\1740 patients\NNS\9898892 but\CC\1740 prolonged\JJ\1740 amiloride\NN\1740 supplementation\NN\5108947 would\MD\1740 result\VB\2633881 in\IN\13603305 elevated\JJ\1740 lithium\NN\14625458 levels\NNS\4916342 and\CC\1740 might\MD\5029706 be\VB\836236 hazardous\JJ\1740 .\.\1740
D000584_D059606 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 acute\JJ\1740 amiloride\NN\1740 administration\NN\1133281 to\TO\1740 lithium-treated\JJ\1740 patients\NNS\9898892 suffering\VBG\2110220 from\IN\1740 <e2>polydipsia</e2>\NN\14040660 and\CC\1740 polyuria\NN\14113228 might\MD\5029706 relieve\VB\205885 these\DT\1740 patients\NNS\9898892 but\CC\1740 prolonged\JJ\1740 <e1>amiloride</e1>\NN\1740 supplementation\NN\5108947 would\MD\1740 result\VB\2633881 in\IN\13603305 elevated\JJ\1740 lithium\NN\14625458 levels\NNS\4916342 and\CC\1740 might\MD\5029706 be\VB\836236 hazardous\JJ\1740 .\.\1740
D000584_D011141 NONE The\DT\1740 effect\NN\34213 of\IN\1740 <e1>amiloride</e1>\NN\1740 on\IN\1740 lithium-induced\JJ\1740 polydipsia\NN\14040660 and\CC\1740 <e2>polyuria</e2>\NN\14113228 and\CC\1740 on\IN\1740 the\DT\1740 lithium\NN\14625458 concentration\NN\4916342 in\IN\13603305 the\DT\1740 plasma\NN\5398023 ,\,\1740 brain\NN\5462674 ,\,\1740 kidney\NN\5333259 ,\,\1740 thyroid\NN\5329735 and\CC\1740 red\JJ\1740 blood\NN\5397468 cells\NNS\3080309 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 rats\NNS\2329401 ,\,\1740 chronically\RB\1740 treated\VBN\2376958 with\IN\1740 LiCl\NN\1740 .\.\1740
D000584_D011141 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 acute\JJ\1740 <e1>amiloride</e1>\NN\1740 administration\NN\1133281 to\TO\1740 lithium-treated\JJ\1740 patients\NNS\9898892 suffering\VBG\2110220 from\IN\1740 polydipsia\NN\14040660 and\CC\1740 <e2>polyuria</e2>\NN\14113228 might\MD\5029706 relieve\VB\205885 these\DT\1740 patients\NNS\9898892 but\CC\1740 prolonged\JJ\1740 amiloride\NN\1740 supplementation\NN\5108947 would\MD\1740 result\VB\2633881 in\IN\13603305 elevated\JJ\1740 lithium\NN\14625458 levels\NNS\4916342 and\CC\1740 might\MD\5029706 be\VB\836236 hazardous\JJ\1740 .\.\1740
D000584_D011141 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 acute\JJ\1740 amiloride\NN\1740 administration\NN\1133281 to\TO\1740 lithium-treated\JJ\1740 patients\NNS\9898892 suffering\VBG\2110220 from\IN\1740 polydipsia\NN\14040660 and\CC\1740 <e2>polyuria</e2>\NN\14113228 might\MD\5029706 relieve\VB\205885 these\DT\1740 patients\NNS\9898892 but\CC\1740 prolonged\JJ\1740 <e1>amiloride</e1>\NN\1740 supplementation\NN\5108947 would\MD\1740 result\VB\2633881 in\IN\13603305 elevated\JJ\1740 lithium\NN\14625458 levels\NNS\4916342 and\CC\1740 might\MD\5029706 be\VB\836236 hazardous\JJ\1740 .\.\1740
D008094_D059606 NONE The\DT\1740 effect\NN\34213 of\IN\1740 amiloride\NN\1740 on\IN\1740 <e1>lithium-induced</e1>\JJ\1740 <e2>polydipsia</e2>\NN\14040660 and\CC\1740 polyuria\NN\14113228 and\CC\1740 on\IN\1740 the\DT\1740 lithium\NN\14625458 concentration\NN\4916342 in\IN\13603305 the\DT\1740 plasma\NN\5398023 ,\,\1740 brain\NN\5462674 ,\,\1740 kidney\NN\5333259 ,\,\1740 thyroid\NN\5329735 and\CC\1740 red\JJ\1740 blood\NN\5397468 cells\NNS\3080309 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 rats\NNS\2329401 ,\,\1740 chronically\RB\1740 treated\VBN\2376958 with\IN\1740 LiCl\NN\1740 .\.\1740
D008094_D059606 NONE The\DT\1740 effect\NN\34213 of\IN\1740 amiloride\NN\1740 on\IN\1740 lithium-induced\JJ\1740 <e2>polydipsia</e2>\NN\14040660 and\CC\1740 polyuria\NN\14113228 and\CC\1740 on\IN\1740 the\DT\1740 <e1>lithium</e1>\NN\14625458 concentration\NN\4916342 in\IN\13603305 the\DT\1740 plasma\NN\5398023 ,\,\1740 brain\NN\5462674 ,\,\1740 kidney\NN\5333259 ,\,\1740 thyroid\NN\5329735 and\CC\1740 red\JJ\1740 blood\NN\5397468 cells\NNS\3080309 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 rats\NNS\2329401 ,\,\1740 chronically\RB\1740 treated\VBN\2376958 with\IN\1740 LiCl\NN\1740 .\.\1740
D008094_D059606 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 acute\JJ\1740 amiloride\NN\1740 administration\NN\1133281 to\TO\1740 <e1>lithium-treated</e1>\JJ\1740 patients\NNS\9898892 suffering\VBG\2110220 from\IN\1740 <e2>polydipsia</e2>\NN\14040660 and\CC\1740 polyuria\NN\14113228 might\MD\5029706 relieve\VB\205885 these\DT\1740 patients\NNS\9898892 but\CC\1740 prolonged\JJ\1740 amiloride\NN\1740 supplementation\NN\5108947 would\MD\1740 result\VB\2633881 in\IN\13603305 elevated\JJ\1740 lithium\NN\14625458 levels\NNS\4916342 and\CC\1740 might\MD\5029706 be\VB\836236 hazardous\JJ\1740 .\.\1740
D008094_D059606 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 acute\JJ\1740 amiloride\NN\1740 administration\NN\1133281 to\TO\1740 lithium-treated\JJ\1740 patients\NNS\9898892 suffering\VBG\2110220 from\IN\1740 <e2>polydipsia</e2>\NN\14040660 and\CC\1740 polyuria\NN\14113228 might\MD\5029706 relieve\VB\205885 these\DT\1740 patients\NNS\9898892 but\CC\1740 prolonged\JJ\1740 amiloride\NN\1740 supplementation\NN\5108947 would\MD\1740 result\VB\2633881 in\IN\13603305 elevated\JJ\1740 <e1>lithium</e1>\NN\14625458 levels\NNS\4916342 and\CC\1740 might\MD\5029706 be\VB\836236 hazardous\JJ\1740 .\.\1740
D008094_D011141 NONE The\DT\1740 effect\NN\34213 of\IN\1740 amiloride\NN\1740 on\IN\1740 <e1>lithium-induced</e1>\JJ\1740 polydipsia\NN\14040660 and\CC\1740 <e2>polyuria</e2>\NN\14113228 and\CC\1740 on\IN\1740 the\DT\1740 lithium\NN\14625458 concentration\NN\4916342 in\IN\13603305 the\DT\1740 plasma\NN\5398023 ,\,\1740 brain\NN\5462674 ,\,\1740 kidney\NN\5333259 ,\,\1740 thyroid\NN\5329735 and\CC\1740 red\JJ\1740 blood\NN\5397468 cells\NNS\3080309 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 rats\NNS\2329401 ,\,\1740 chronically\RB\1740 treated\VBN\2376958 with\IN\1740 LiCl\NN\1740 .\.\1740
D008094_D011141 NONE The\DT\1740 effect\NN\34213 of\IN\1740 amiloride\NN\1740 on\IN\1740 lithium-induced\JJ\1740 polydipsia\NN\14040660 and\CC\1740 <e2>polyuria</e2>\NN\14113228 and\CC\1740 on\IN\1740 the\DT\1740 <e1>lithium</e1>\NN\14625458 concentration\NN\4916342 in\IN\13603305 the\DT\1740 plasma\NN\5398023 ,\,\1740 brain\NN\5462674 ,\,\1740 kidney\NN\5333259 ,\,\1740 thyroid\NN\5329735 and\CC\1740 red\JJ\1740 blood\NN\5397468 cells\NNS\3080309 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 rats\NNS\2329401 ,\,\1740 chronically\RB\1740 treated\VBN\2376958 with\IN\1740 LiCl\NN\1740 .\.\1740
D008094_D011141 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 acute\JJ\1740 amiloride\NN\1740 administration\NN\1133281 to\TO\1740 <e1>lithium-treated</e1>\JJ\1740 patients\NNS\9898892 suffering\VBG\2110220 from\IN\1740 polydipsia\NN\14040660 and\CC\1740 <e2>polyuria</e2>\NN\14113228 might\MD\5029706 relieve\VB\205885 these\DT\1740 patients\NNS\9898892 but\CC\1740 prolonged\JJ\1740 amiloride\NN\1740 supplementation\NN\5108947 would\MD\1740 result\VB\2633881 in\IN\13603305 elevated\JJ\1740 lithium\NN\14625458 levels\NNS\4916342 and\CC\1740 might\MD\5029706 be\VB\836236 hazardous\JJ\1740 .\.\1740
D008094_D011141 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 acute\JJ\1740 amiloride\NN\1740 administration\NN\1133281 to\TO\1740 lithium-treated\JJ\1740 patients\NNS\9898892 suffering\VBG\2110220 from\IN\1740 polydipsia\NN\14040660 and\CC\1740 <e2>polyuria</e2>\NN\14113228 might\MD\5029706 relieve\VB\205885 these\DT\1740 patients\NNS\9898892 but\CC\1740 prolonged\JJ\1740 amiloride\NN\1740 supplementation\NN\5108947 would\MD\1740 result\VB\2633881 in\IN\13603305 elevated\JJ\1740 <e1>lithium</e1>\NN\14625458 levels\NNS\4916342 and\CC\1740 might\MD\5029706 be\VB\836236 hazardous\JJ\1740 .\.\1740
D018021_D059606 NONE The\DT\1740 effect\NN\34213 of\IN\1740 amiloride\NN\1740 on\IN\1740 lithium-induced\JJ\1740 <e2>polydipsia</e2>\NN\14040660 and\CC\1740 polyuria\NN\14113228 and\CC\1740 on\IN\1740 the\DT\1740 lithium\NN\14625458 concentration\NN\4916342 in\IN\13603305 the\DT\1740 plasma\NN\5398023 ,\,\1740 brain\NN\5462674 ,\,\1740 kidney\NN\5333259 ,\,\1740 thyroid\NN\5329735 and\CC\1740 red\JJ\1740 blood\NN\5397468 cells\NNS\3080309 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 rats\NNS\2329401 ,\,\1740 chronically\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>LiCl</e1>\NN\1740 .\.\1740
D018021_D011141 NONE The\DT\1740 effect\NN\34213 of\IN\1740 amiloride\NN\1740 on\IN\1740 lithium-induced\JJ\1740 polydipsia\NN\14040660 and\CC\1740 <e2>polyuria</e2>\NN\14113228 and\CC\1740 on\IN\1740 the\DT\1740 lithium\NN\14625458 concentration\NN\4916342 in\IN\13603305 the\DT\1740 plasma\NN\5398023 ,\,\1740 brain\NN\5462674 ,\,\1740 kidney\NN\5333259 ,\,\1740 thyroid\NN\5329735 and\CC\1740 red\JJ\1740 blood\NN\5397468 cells\NNS\3080309 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 rats\NNS\2329401 ,\,\1740 chronically\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>LiCl</e1>\NN\1740 .\.\1740
D011188_D003919 NONE In\IN\13603305 all\PDT\1740 the\DT\1740 experiments\NNS\641820 ,\,\1740 the\DT\1740 attenuation\NN\7427337 of\IN\1740 the\DT\1740 lithium-induced\JJ\1740 <e2>diabetes-insipidus-like\JJ\1740 syndrome</e2>\NN\5870365 by\IN\1740 amiloride\NN\1740 was\VBD\836236 accompanied\VBN\1835496 by\IN\1740 a\DT\13649268 reduction\NN\351485 of\IN\1740 the\DT\1740 ratio\NN\13815152 between\IN\1740 the\DT\1740 lithium\NN\14625458 concentration\NN\4916342 in\IN\13603305 the\DT\1740 renal\JJ\1740 medulla\NN\14864360 and\CC\1740 its\PRP$\6125041 levels\NNS\4916342 in\IN\13603305 the\DT\1740 blood\NN\5397468 and\CC\1740 an\DT\6697703 elevation\NN\7445480 in\IN\13603305 the\DT\1740 plasma\NN\5398023 <e1>potassium</e1>\NN\14625458 level\NN\4916342 .\.\1740
3564823
D008012_D013035 NONE Drug-induced\JJ\1740 arterial\JJ\1740 <e2>spasm</e2>\NN\14299637 relieved\VBN\205885 by\IN\1740 <e1>lidocaine</e1>\NN\3681148 .\.\1740
D013874_D002545 NONE Following\VBG\1835496 major\JJ\1740 intracranial\JJ\1740 surgery\NN\6045562 in\IN\13603305 a\DT\13649268 35-year-old\JJ\1740 man\NN\9605289 ,\,\1740 <e1>sodium\NN\14625458 pentothal</e1>\NN\2792049 was\VBD\836236 intravenously\RB\1740 infused\JJ\1740 to\TO\1740 minimize\VB\441445 <e2>cerebral\JJ\1740 ischaemia</e2>\NN\14195315 .\.\1740
D008012_D020301 NONE Since\IN\1740 the\DT\1740 cranial\JJ\1740 condition\NN\24720 precluded\VBD\2629256 use\NN\407535 of\IN\1740 more\JJR\1740 usual\JJ\1740 methods\NNS\5616786 ,\,\1740 <e1>lidocaine</e1>\NN\3681148 was\VBD\836236 given\VBN\2327200 intra-arterially\RB\1740 ,\,\1740 with\IN\1740 careful\JJ\1740 cardiovascular\JJ\1740 monitoring\NN\879759 ,\,\1740 to\TO\1740 counteract\VB\2367363 the\DT\1740 <e2>vasospasm</e2>\NN\1740 .\.\1740
2304736
D011224_D014550 CID <e1>Prazosin-induced</e1>\JJ\1740 <e2>stress\NN\7083732 incontinence</e2>\NN\13473097 .\.\1740
D011224_D014550 CID A\DT\13649268 case\NN\7283608 of\IN\1740 genuine\JJ\1740 <e2>stress\NN\7083732 incontinence</e2>\NN\13473097 due\JJ\1740 to\IN\1740 <e1>prazosin</e1>\NN\2698769 ,\,\1740 a\DT\13649268 common\JJ\1740 antihypertensive\JJ\1740 drug\NN\14778436 ,\,\1740 is\VBZ\836236 presented\VBN\2137132 .\.\1740
D011224_D014550 CID Patients\NNS\9898892 who\WP\8299493 present\VBP\2137132 with\IN\1740 <e2>stress\NN\7083732 incontinence</e2>\NN\13473097 while\IN\15122231 taking\VBG\2367363 <e1>prazosin</e1>\NN\2698769 should\MD\1740 change\VB\46534 their\PRP$\1740 antihypertensive\JJ\1740 medication\NN\3247620 before\IN\1740 considering\VBG\689344 surgery\NN\6045562 ,\,\1740 because\IN\1740 their\PRP$\1740 incontinence\NN\13473097 may\MD\15209706 resolve\VB\352826 spontaneously\RB\1740 with\IN\1740 a\DT\13649268 change\NN\7283608 in\IN\13603305 drug\NN\14778436 therapy\NN\657604 .\.\1740
D011224_D014549 NONE Patients\NNS\9898892 who\WP\8299493 present\VBP\2137132 with\IN\1740 stress\NN\7083732 incontinence\NN\13473097 while\IN\15122231 taking\VBG\2367363 <e1>prazosin</e1>\NN\2698769 should\MD\1740 change\VB\46534 their\PRP$\1740 antihypertensive\JJ\1740 medication\NN\3247620 before\IN\1740 considering\VBG\689344 surgery\NN\6045562 ,\,\1740 because\IN\1740 their\PRP$\1740 <e2>incontinence</e2>\NN\13473097 may\MD\15209706 resolve\VB\352826 spontaneously\RB\1740 with\IN\1740 a\DT\13649268 change\NN\7283608 in\IN\13603305 drug\NN\14778436 therapy\NN\657604 .\.\1740
4071154
D007213_D051437 NONE <e1>Indomethacin-induced</e1>\JJ\1740 <e2>renal\JJ\1740 insufficiency</e2>\NN\14462946 :\:\1740 recurrence\NN\7342049 on\IN\1740 rechallenge\NN\1740 .\.\1740
D007213_D051437 NONE We\PRP\1740 have\VBP\2108377 reported\VBN\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 oliguric\JJ\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 with\IN\1740 hyperkalemia\NN\14299637 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 cirrhosis\NN\14116321 ,\,\1740 ascites\NNS\14204950 ,\,\1740 and\CC\1740 cor\NN\1740 pulmonale\NN\1740 after\IN\1740 <e1>indomethacin</e1>\NN\3828465 therapy\NN\657604 .\.\1740
D007213_D006947 CID We\PRP\1740 have\VBP\2108377 reported\VBN\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 oliguric\JJ\1740 renal\JJ\1740 failure\NN\66216 with\IN\1740 <e2>hyperkalemia</e2>\NN\14299637 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 cirrhosis\NN\14116321 ,\,\1740 ascites\NNS\14204950 ,\,\1740 and\CC\1740 cor\NN\1740 pulmonale\NN\1740 after\IN\1740 <e1>indomethacin</e1>\NN\3828465 therapy\NN\657604 .\.\1740
D007213_D005355 CID We\PRP\1740 have\VBP\2108377 reported\VBN\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 oliguric\JJ\1740 renal\JJ\1740 failure\NN\66216 with\IN\1740 hyperkalemia\NN\14299637 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>cirrhosis</e2>\NN\14116321 ,\,\1740 ascites\NNS\14204950 ,\,\1740 and\CC\1740 cor\NN\1740 pulmonale\NN\1740 after\IN\1740 <e1>indomethacin</e1>\NN\3828465 therapy\NN\657604 .\.\1740
D007213_D001201 CID We\PRP\1740 have\VBP\2108377 reported\VBN\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 oliguric\JJ\1740 renal\JJ\1740 failure\NN\66216 with\IN\1740 hyperkalemia\NN\14299637 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 cirrhosis\NN\14116321 ,\,\1740 <e2>ascites</e2>\NNS\14204950 ,\,\1740 and\CC\1740 cor\NN\1740 pulmonale\NN\1740 after\IN\1740 <e1>indomethacin</e1>\NN\3828465 therapy\NN\657604 .\.\1740
D007213_D011660 CID We\PRP\1740 have\VBP\2108377 reported\VBN\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 oliguric\JJ\1740 renal\JJ\1740 failure\NN\66216 with\IN\1740 hyperkalemia\NN\14299637 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 cirrhosis\NN\14116321 ,\,\1740 ascites\NNS\14204950 ,\,\1740 and\CC\1740 <e2>cor\NN\1740 pulmonale</e2>\NN\1740 after\IN\1740 <e1>indomethacin</e1>\NN\3828465 therapy\NN\657604 .\.\1740
D007213_D009846 CID Prompt\JJ\1740 restoration\NN\266806 of\IN\1740 renal\JJ\1740 function\NN\13783581 followed\VBD\1835496 drug\NN\14778436 withdrawal\NN\7206096 ,\,\1740 while\IN\15122231 re-exposure\VBP\1740 to\TO\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>indomethacin</e1>\NN\3828465 caused\VBD\1617192 recurrence\NN\7342049 of\IN\1740 acute\JJ\1740 reversible\JJ\1740 <e2>oliguria</e2>\NN\14299637 .\.\1740
3800626
D010423_D009408 CID <e2>Compression\NNS\7413899 neuropathy\JJ\1740 of\IN\1740 the\DT\1740 radial\JJ\1740 nerve</e2>\NN\5475681 due\JJ\1740 to\TO\1740 <e1>pentazocine-induced</e1>\JJ\1740 fibrous\JJ\1740 myopathy\NN\14204950 .\.\1740
D010423_D009408 CID However\RB\1740 ,\,\1740 <e2>compression\NN\7413899 neuropathy</e2>\JJ\1740 due\JJ\1740 to\TO\1740 fibrotic\JJ\1740 muscle\NN\5289601 affected\VBN\126264 by\IN\1740 <e1>pentazocine-induced</e1>\JJ\1740 myopathy\NN\14204950 has\VBZ\2108377 not\RB\1740 previously\RB\1740 been\VBN\836236 reported\VBN\831651 .\.\1740
D010423_D020425 CID <e2>Compression\NNS\7413899 neuropathy\JJ\1740 of\IN\1740 the\DT\1740 radial\JJ\1740 nerve</e2>\NN\5475681 due\JJ\1740 to\TO\1740 <e1>pentazocine-induced</e1>\JJ\1740 fibrous\JJ\1740 myopathy\NN\14204950 .\.\1740
D010423_D005355 CID Compression\NNS\7413899 neuropathy\JJ\1740 of\IN\1740 the\DT\1740 radial\JJ\1740 nerve\NN\5475681 due\JJ\1740 to\TO\1740 <e1>pentazocine-induced</e1>\JJ\1740 <e2>fibrous\JJ\1740 myopathy</e2>\NN\14204950 .\.\1740
D010423_D005355 CID <e2>Fibrous\JJ\1740 myopathy</e2>\NN\14204950 is\VBZ\836236 a\DT\13649268 common\JJ\1740 ,\,\1740 well-known\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 repeated\VBN\952524 <e1>pentazocine</e1>\NN\2707683 injection\NN\320852 .\.\1740
D010423_D005355 CID In\IN\13603305 a\DT\13649268 37-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 documented\VBN\1000214 <e1>pentazocine-induced</e1>\JJ\1740 <e2>fibrous\JJ\1740 myopathy</e2>\NN\14204950 of\IN\1740 triceps\NN\5289861 and\CC\1740 deltoid\JJ\1740 muscles\NNS\5289601 bilaterally\RB\1740 and\CC\1740 a\DT\13649268 three-week\JJ\1740 history\NN\15120823 of\IN\1740 right\JJ\1740 wrist\NN\5578251 drop\NN\13899200 ,\,\1740 electrodiagnostic\JJ\1740 examination\NN\633864 showed\VBD\2137132 a\DT\13649268 severe\JJ\1740 but\CC\1740 partial\JJ\1740 lesion\NN\14204950 of\IN\1740 the\DT\1740 right\JJ\1740 radial\JJ\1740 nerve\NN\5475681 distal\JJ\1740 to\IN\1740 the\DT\1740 branches\NNS\8220714 to\IN\1740 the\DT\1740 triceps\NN\5289861 ,\,\1740 in\IN\13603305 addition\NN\3081021 to\TO\1740 the\DT\1740 fibrous\JJ\1740 myopathy\NN\14204950 .\.\1740
D010423_D005355 CID In\IN\13603305 a\DT\13649268 37-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 documented\VBN\1000214 <e1>pentazocine-induced</e1>\JJ\1740 fibrous\JJ\1740 myopathy\NN\14204950 of\IN\1740 triceps\NN\5289861 and\CC\1740 deltoid\JJ\1740 muscles\NNS\5289601 bilaterally\RB\1740 and\CC\1740 a\DT\13649268 three-week\JJ\1740 history\NN\15120823 of\IN\1740 right\JJ\1740 wrist\NN\5578251 drop\NN\13899200 ,\,\1740 electrodiagnostic\JJ\1740 examination\NN\633864 showed\VBD\2137132 a\DT\13649268 severe\JJ\1740 but\CC\1740 partial\JJ\1740 lesion\NN\14204950 of\IN\1740 the\DT\1740 right\JJ\1740 radial\JJ\1740 nerve\NN\5475681 distal\JJ\1740 to\IN\1740 the\DT\1740 branches\NNS\8220714 to\IN\1740 the\DT\1740 triceps\NN\5289861 ,\,\1740 in\IN\13603305 addition\NN\3081021 to\TO\1740 the\DT\1740 <e2>fibrous\JJ\1740 myopathy</e2>\NN\14204950 .\.\1740
D010423_D009135 CID Compression\NNS\7413899 neuropathy\JJ\1740 of\IN\1740 the\DT\1740 radial\JJ\1740 nerve\NN\5475681 due\JJ\1740 to\TO\1740 <e1>pentazocine-induced</e1>\JJ\1740 <e2>fibrous\JJ\1740 myopathy</e2>\NN\14204950 .\.\1740
D010423_D009135 CID <e2>Fibrous\JJ\1740 myopathy</e2>\NN\14204950 is\VBZ\836236 a\DT\13649268 common\JJ\1740 ,\,\1740 well-known\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 repeated\VBN\952524 <e1>pentazocine</e1>\NN\2707683 injection\NN\320852 .\.\1740
D010423_D009135 CID However\RB\1740 ,\,\1740 compression\NN\7413899 neuropathy\JJ\1740 due\JJ\1740 to\TO\1740 fibrotic\JJ\1740 muscle\NN\5289601 affected\VBN\126264 by\IN\1740 <e1>pentazocine-induced</e1>\JJ\1740 <e2>myopathy</e2>\NN\14204950 has\VBZ\2108377 not\RB\1740 previously\RB\1740 been\VBN\836236 reported\VBN\831651 .\.\1740
D010423_D009135 CID In\IN\13603305 a\DT\13649268 37-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 documented\VBN\1000214 <e1>pentazocine-induced</e1>\JJ\1740 <e2>fibrous\JJ\1740 myopathy</e2>\NN\14204950 of\IN\1740 triceps\NN\5289861 and\CC\1740 deltoid\JJ\1740 muscles\NNS\5289601 bilaterally\RB\1740 and\CC\1740 a\DT\13649268 three-week\JJ\1740 history\NN\15120823 of\IN\1740 right\JJ\1740 wrist\NN\5578251 drop\NN\13899200 ,\,\1740 electrodiagnostic\JJ\1740 examination\NN\633864 showed\VBD\2137132 a\DT\13649268 severe\JJ\1740 but\CC\1740 partial\JJ\1740 lesion\NN\14204950 of\IN\1740 the\DT\1740 right\JJ\1740 radial\JJ\1740 nerve\NN\5475681 distal\JJ\1740 to\IN\1740 the\DT\1740 branches\NNS\8220714 to\IN\1740 the\DT\1740 triceps\NN\5289861 ,\,\1740 in\IN\13603305 addition\NN\3081021 to\TO\1740 the\DT\1740 fibrous\JJ\1740 myopathy\NN\14204950 .\.\1740
D010423_D009135 CID In\IN\13603305 a\DT\13649268 37-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 documented\VBN\1000214 <e1>pentazocine-induced</e1>\JJ\1740 fibrous\JJ\1740 myopathy\NN\14204950 of\IN\1740 triceps\NN\5289861 and\CC\1740 deltoid\JJ\1740 muscles\NNS\5289601 bilaterally\RB\1740 and\CC\1740 a\DT\13649268 three-week\JJ\1740 history\NN\15120823 of\IN\1740 right\JJ\1740 wrist\NN\5578251 drop\NN\13899200 ,\,\1740 electrodiagnostic\JJ\1740 examination\NN\633864 showed\VBD\2137132 a\DT\13649268 severe\JJ\1740 but\CC\1740 partial\JJ\1740 lesion\NN\14204950 of\IN\1740 the\DT\1740 right\JJ\1740 radial\JJ\1740 nerve\NN\5475681 distal\JJ\1740 to\IN\1740 the\DT\1740 branches\NNS\8220714 to\IN\1740 the\DT\1740 triceps\NN\5289861 ,\,\1740 in\IN\13603305 addition\NN\3081021 to\TO\1740 the\DT\1740 <e2>fibrous\JJ\1740 myopathy</e2>\NN\14204950 .\.\1740
15804801
D017239_D003323 CID <e2>Coronary\JJ\1740 aneurysm</e2>\NN\14057371 after\IN\1740 implantation\NN\13526110 of\IN\1740 a\DT\13649268 <e1>paclitaxel-eluting</e1>\JJ\1740 stent\NN\4493505 .\.\1740
D017239_D003323 CID We\PRP\1740 present\VBP\2137132 a\DT\13649268 43-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 developed\VBD\1753788 a\DT\13649268 <e2>coronary\JJ\1740 aneurysm</e2>\NN\14057371 in\IN\13603305 the\DT\1740 right\JJ\1740 coronary\JJ\1740 artery\NN\5417975 6\CD\13741022 months\NNS\15113229 after\IN\1740 receiving\VBG\2210855 a\DT\13649268 <e1>paclitaxel-eluting</e1>\JJ\1740 stent\NN\4493505 .\.\1740
11773892
D016572_D007674 CID BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 calcineurin\NN\1740 inhibitors\NNS\20090 <e1>cyclosporine</e1>\NN\1740 and\CC\1740 tacrolimus\NN\1740 are\VBP\836236 both\CC\1740 known\VBN\2110220 to\TO\1740 be\VB\836236 <e2>nephrotoxic</e2>\JJ\1740 .\.\1740
D016559_D007674 CID BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 calcineurin\NN\1740 inhibitors\NNS\20090 cyclosporine\NN\1740 and\CC\1740 <e1>tacrolimus</e1>\NN\1740 are\VBP\836236 both\CC\1740 known\VBN\2110220 to\TO\1740 be\VB\836236 <e2>nephrotoxic</e2>\JJ\1740 .\.\1740
D003404_D007676 NONE Patients\NNS\9898892 were\VBD\836236 divided\VBN\140123 into\IN\1740 three\CD\13741022 groups\NNS\2137 :\:\1740 Controls\NNS\5190804 ,\,\1740 no\DT\7204911 <e2>CRF</e2>\NN\1740 or\CC\3541091 ESRD\NN\1740 ,\,\1740 n=748\CC\1740 ;\:\1740 CRF\NN\1740 ,\,\1740 sustained\JJ\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 >\NN\1740 2.5\CD\1740 mg/dl\NN\1740 ,\,\1740 n=41\NN\1740 ;\:\1740 and\CC\1740 ESRD\NN\1740 ,\,\1740 n=45\NN\1740 .\.\1740
D003404_D007676 NONE Patients\NNS\9898892 were\VBD\836236 divided\VBN\140123 into\IN\1740 three\CD\13741022 groups\NNS\2137 :\:\1740 Controls\NNS\5190804 ,\,\1740 no\DT\7204911 CRF\NN\1740 or\CC\3541091 <e2>ESRD</e2>\NN\1740 ,\,\1740 n=748\CC\1740 ;\:\1740 CRF\NN\1740 ,\,\1740 sustained\JJ\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 >\NN\1740 2.5\CD\1740 mg/dl\NN\1740 ,\,\1740 n=41\NN\1740 ;\:\1740 and\CC\1740 ESRD\NN\1740 ,\,\1740 n=45\NN\1740 .\.\1740
D003404_D007676 NONE Patients\NNS\9898892 were\VBD\836236 divided\VBN\140123 into\IN\1740 three\CD\13741022 groups\NNS\2137 :\:\1740 Controls\NNS\5190804 ,\,\1740 no\DT\7204911 CRF\NN\1740 or\CC\3541091 ESRD\NN\1740 ,\,\1740 n=748\CC\1740 ;\:\1740 <e2>CRF</e2>\NN\1740 ,\,\1740 sustained\JJ\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 >\NN\1740 2.5\CD\1740 mg/dl\NN\1740 ,\,\1740 n=41\NN\1740 ;\:\1740 and\CC\1740 ESRD\NN\1740 ,\,\1740 n=45\NN\1740 .\.\1740
D003404_D007676 NONE Patients\NNS\9898892 were\VBD\836236 divided\VBN\140123 into\IN\1740 three\CD\13741022 groups\NNS\2137 :\:\1740 Controls\NNS\5190804 ,\,\1740 no\DT\7204911 CRF\NN\1740 or\CC\3541091 ESRD\NN\1740 ,\,\1740 n=748\CC\1740 ;\:\1740 CRF\NN\1740 ,\,\1740 sustained\JJ\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 >\NN\1740 2.5\CD\1740 mg/dl\NN\1740 ,\,\1740 n=41\NN\1740 ;\:\1740 and\CC\1740 <e2>ESRD</e2>\NN\1740 ,\,\1740 n=45\NN\1740 .\.\1740
D003404_D007676 NONE Compared\VBN\644583 with\IN\1740 control\NN\5190804 patients\NNS\9898892 ,\,\1740 <e2>CRF</e2>\NN\1740 and\CC\1740 ESRD\NN\1740 patients\NNS\9898892 had\VBD\2108377 higher\JJR\1740 preoperative\JJ\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 levels\NNS\4916342 ,\,\1740 a\DT\13649268 greater\JJR\1740 percentage\NN\13815742 of\IN\1740 patients\NNS\9898892 with\IN\1740 hepatorenal\JJ\1740 syndrome\NN\5870365 ,\,\1740 higher\JJR\1740 percentage\NN\13815742 requirement\NN\1129920 for\IN\1740 dialysis\NN\646833 in\IN\13603305 the\DT\1740 first\JJ\1740 3\CD\13741022 months\NNS\15113229 postoperatively\RB\1740 ,\,\1740 and\CC\1740 a\DT\13649268 higher\JJR\1740 1-year\JJ\1740 serum\NN\5397468 creatinine\NN\1740 .\.\1740
D003404_D007676 NONE Compared\VBN\644583 with\IN\1740 control\NN\5190804 patients\NNS\9898892 ,\,\1740 CRF\NN\1740 and\CC\1740 <e2>ESRD</e2>\NN\1740 patients\NNS\9898892 had\VBD\2108377 higher\JJR\1740 preoperative\JJ\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 levels\NNS\4916342 ,\,\1740 a\DT\13649268 greater\JJR\1740 percentage\NN\13815742 of\IN\1740 patients\NNS\9898892 with\IN\1740 hepatorenal\JJ\1740 syndrome\NN\5870365 ,\,\1740 higher\JJR\1740 percentage\NN\13815742 requirement\NN\1129920 for\IN\1740 dialysis\NN\646833 in\IN\13603305 the\DT\1740 first\JJ\1740 3\CD\13741022 months\NNS\15113229 postoperatively\RB\1740 ,\,\1740 and\CC\1740 a\DT\13649268 higher\JJR\1740 1-year\JJ\1740 serum\NN\5397468 creatinine\NN\1740 .\.\1740
D003404_D007676 NONE Compared\VBN\644583 with\IN\1740 control\NN\5190804 patients\NNS\9898892 ,\,\1740 <e2>CRF</e2>\NN\1740 and\CC\1740 ESRD\NN\1740 patients\NNS\9898892 had\VBD\2108377 higher\JJR\1740 preoperative\JJ\1740 serum\NN\5397468 creatinine\NN\1740 levels\NNS\4916342 ,\,\1740 a\DT\13649268 greater\JJR\1740 percentage\NN\13815742 of\IN\1740 patients\NNS\9898892 with\IN\1740 hepatorenal\JJ\1740 syndrome\NN\5870365 ,\,\1740 higher\JJR\1740 percentage\NN\13815742 requirement\NN\1129920 for\IN\1740 dialysis\NN\646833 in\IN\13603305 the\DT\1740 first\JJ\1740 3\CD\13741022 months\NNS\15113229 postoperatively\RB\1740 ,\,\1740 and\CC\1740 a\DT\13649268 higher\JJR\1740 1-year\JJ\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 .\.\1740
D003404_D007676 NONE Compared\VBN\644583 with\IN\1740 control\NN\5190804 patients\NNS\9898892 ,\,\1740 CRF\NN\1740 and\CC\1740 <e2>ESRD</e2>\NN\1740 patients\NNS\9898892 had\VBD\2108377 higher\JJR\1740 preoperative\JJ\1740 serum\NN\5397468 creatinine\NN\1740 levels\NNS\4916342 ,\,\1740 a\DT\13649268 greater\JJR\1740 percentage\NN\13815742 of\IN\1740 patients\NNS\9898892 with\IN\1740 hepatorenal\JJ\1740 syndrome\NN\5870365 ,\,\1740 higher\JJR\1740 percentage\NN\13815742 requirement\NN\1129920 for\IN\1740 dialysis\NN\646833 in\IN\13603305 the\DT\1740 first\JJ\1740 3\CD\13741022 months\NNS\15113229 postoperatively\RB\1740 ,\,\1740 and\CC\1740 a\DT\13649268 higher\JJR\1740 1-year\JJ\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 .\.\1740
D003404_D007676 NONE Multivariate\JJ\1740 stepwise\NN\1740 logistic\JJ\1740 regression\NN\14501726 analysis\NN\633864 using\VBG\1156834 preoperative\JJ\1740 and\CC\1740 postoperative\JJ\1740 variables\NNS\2452 identified\VBD\699815 that\IN\1740 an\DT\6697703 increase\NN\13576355 of\IN\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 compared\VBN\644583 with\IN\1740 average\JJ\1740 at\IN\14622893 1\CD\13741022 year\NN\15113229 ,\,\1740 3\CD\13741022 months\NNS\15113229 ,\,\1740 and\CC\1740 4\CD\13741022 weeks\NNS\15113229 postoperatively\RB\1740 were\VBD\836236 independent\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>CRF</e2>\NN\1740 or\CC\3541091 ESRD\NN\1740 with\IN\1740 odds\NNS\4756635 ratios\NNS\13815152 of\IN\1740 2.6\CD\1740 ,\,\1740 2.2\CD\1740 ,\,\1740 and\CC\1740 1.6\CD\1740 ,\,\1740 respectively\RB\1740 .\.\1740
D003404_D007676 NONE Multivariate\JJ\1740 stepwise\NN\1740 logistic\JJ\1740 regression\NN\14501726 analysis\NN\633864 using\VBG\1156834 preoperative\JJ\1740 and\CC\1740 postoperative\JJ\1740 variables\NNS\2452 identified\VBD\699815 that\IN\1740 an\DT\6697703 increase\NN\13576355 of\IN\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 compared\VBN\644583 with\IN\1740 average\JJ\1740 at\IN\14622893 1\CD\13741022 year\NN\15113229 ,\,\1740 3\CD\13741022 months\NNS\15113229 ,\,\1740 and\CC\1740 4\CD\13741022 weeks\NNS\15113229 postoperatively\RB\1740 were\VBD\836236 independent\JJ\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 CRF\NN\1740 or\CC\3541091 <e2>ESRD</e2>\NN\1740 with\IN\1740 odds\NNS\4756635 ratios\NNS\13815152 of\IN\1740 2.6\CD\1740 ,\,\1740 2.2\CD\1740 ,\,\1740 and\CC\1740 1.6\CD\1740 ,\,\1740 respectively\RB\1740 .\.\1740
D003404_D007676 NONE Patients\NNS\9898892 who\WP\8299493 develop\VBP\1753788 <e2>ESRD</e2>\NN\1740 have\VBP\2108377 a\DT\13649268 higher\JJR\1740 preoperative\JJ\1740 and\CC\1740 1-year\JJ\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 and\CC\1740 are\VBP\836236 more\RBR\1740 likely\JJ\1740 to\TO\1740 have\VB\2108377 hepatorenal\JJ\1740 syndrome\NN\5870365 .\.\1740
D003404_D007676 NONE However\RB\1740 ,\,\1740 an\DT\6697703 increase\NN\13576355 of\IN\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 at\IN\14622893 various\JJ\1740 times\NNS\15113229 postoperatively\RB\1740 is\VBZ\836236 more\RBR\1740 predictive\JJ\1740 of\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>CRF</e2>\NN\1740 or\CC\3541091 ESRD\NN\1740 .\.\1740
D003404_D007676 NONE However\RB\1740 ,\,\1740 an\DT\6697703 increase\NN\13576355 of\IN\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 at\IN\14622893 various\JJ\1740 times\NNS\15113229 postoperatively\RB\1740 is\VBZ\836236 more\RBR\1740 predictive\JJ\1740 of\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 CRF\NN\1740 or\CC\3541091 <e2>ESRD</e2>\NN\1740 .\.\1740
D003404_D006530 NONE Compared\VBN\644583 with\IN\1740 control\NN\5190804 patients\NNS\9898892 ,\,\1740 CRF\NN\1740 and\CC\1740 ESRD\NN\1740 patients\NNS\9898892 had\VBD\2108377 higher\JJR\1740 preoperative\JJ\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 levels\NNS\4916342 ,\,\1740 a\DT\13649268 greater\JJR\1740 percentage\NN\13815742 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>hepatorenal\JJ\1740 syndrome</e2>\NN\5870365 ,\,\1740 higher\JJR\1740 percentage\NN\13815742 requirement\NN\1129920 for\IN\1740 dialysis\NN\646833 in\IN\13603305 the\DT\1740 first\JJ\1740 3\CD\13741022 months\NNS\15113229 postoperatively\RB\1740 ,\,\1740 and\CC\1740 a\DT\13649268 higher\JJR\1740 1-year\JJ\1740 serum\NN\5397468 creatinine\NN\1740 .\.\1740
D003404_D006530 NONE Compared\VBN\644583 with\IN\1740 control\NN\5190804 patients\NNS\9898892 ,\,\1740 CRF\NN\1740 and\CC\1740 ESRD\NN\1740 patients\NNS\9898892 had\VBD\2108377 higher\JJR\1740 preoperative\JJ\1740 serum\NN\5397468 creatinine\NN\1740 levels\NNS\4916342 ,\,\1740 a\DT\13649268 greater\JJR\1740 percentage\NN\13815742 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>hepatorenal\JJ\1740 syndrome</e2>\NN\5870365 ,\,\1740 higher\JJR\1740 percentage\NN\13815742 requirement\NN\1129920 for\IN\1740 dialysis\NN\646833 in\IN\13603305 the\DT\1740 first\JJ\1740 3\CD\13741022 months\NNS\15113229 postoperatively\RB\1740 ,\,\1740 and\CC\1740 a\DT\13649268 higher\JJR\1740 1-year\JJ\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 .\.\1740
D003404_D006530 NONE Patients\NNS\9898892 who\WP\8299493 develop\VBP\1753788 ESRD\NN\1740 have\VBP\2108377 a\DT\13649268 higher\JJR\1740 preoperative\JJ\1740 and\CC\1740 1-year\JJ\1740 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 and\CC\1740 are\VBP\836236 more\RBR\1740 likely\JJ\1740 to\TO\1740 have\VB\2108377 <e2>hepatorenal\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
17466854
D008775_D002386 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 assess\VB\670261 the\DT\1740 incidence\NN\13821570 of\IN\1740 postoperative\JJ\1740 emetic\JJ\1740 side\NN\8630039 effects\NNS\13245626 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>methylprednisolone</e1>\NN\1740 and\CC\1740 gentamicin\NN\2716866 into\IN\1740 the\DT\1740 posterior\JJ\1740 sub-Tenon\NNP\1740 's\POS\1740 space\NN\24264 at\IN\14622893 the\DT\1740 end\NN\8568978 of\IN\1740 routine\JJ\1740 <e2>cataract</e2>\JJ\1740 surgery\NN\6045562 .\.\1740
D005839_D002386 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 assess\VB\670261 the\DT\1740 incidence\NN\13821570 of\IN\1740 postoperative\JJ\1740 emetic\JJ\1740 side\NN\8630039 effects\NNS\13245626 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 methylprednisolone\NN\1740 and\CC\1740 <e1>gentamicin</e1>\NN\2716866 into\IN\1740 the\DT\1740 posterior\JJ\1740 sub-Tenon\NNP\1740 's\POS\1740 space\NN\24264 at\IN\14622893 the\DT\1740 end\NN\8568978 of\IN\1740 routine\JJ\1740 <e2>cataract</e2>\JJ\1740 surgery\NN\6045562 .\.\1740
D008775_D020250 CID CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 administration\NN\1133281 of\IN\1740 <e1>methylprednisolone</e1>\NN\1740 and\CC\1740 gentamicin\NN\2716866 in\IN\13603305 the\DT\1740 posterior\JJ\1740 sub-Tenon\NNP\1740 's\POS\1740 space\NN\24264 was\VBD\836236 related\JJ\1740 to\TO\1740 a\DT\13649268 high\JJ\1740 incidence\NN\13821570 of\IN\1740 side\NN\8630039 effects\NNS\13245626 including\VBG\690614 <e2>nausea\NN\14299637 ,\,\1740 vomiting</e2>\NN\116687 ,\,\1740 and\CC\1740 headache\VB\1740 .\.\1740
D008775_D006261 CID CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 administration\NN\1133281 of\IN\1740 <e1>methylprednisolone</e1>\NN\1740 and\CC\1740 gentamicin\NN\2716866 in\IN\13603305 the\DT\1740 posterior\JJ\1740 sub-Tenon\NNP\1740 's\POS\1740 space\NN\24264 was\VBD\836236 related\JJ\1740 to\TO\1740 a\DT\13649268 high\JJ\1740 incidence\NN\13821570 of\IN\1740 side\NN\8630039 effects\NNS\13245626 including\VBG\690614 nausea\NN\14299637 ,\,\1740 vomiting\NN\116687 ,\,\1740 and\CC\1740 <e2>headache</e2>\VB\1740 .\.\1740
D005839_D020250 CID CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 administration\NN\1133281 of\IN\1740 methylprednisolone\NN\1740 and\CC\1740 <e1>gentamicin</e1>\NN\2716866 in\IN\13603305 the\DT\1740 posterior\JJ\1740 sub-Tenon\NNP\1740 's\POS\1740 space\NN\24264 was\VBD\836236 related\JJ\1740 to\TO\1740 a\DT\13649268 high\JJ\1740 incidence\NN\13821570 of\IN\1740 side\NN\8630039 effects\NNS\13245626 including\VBG\690614 <e2>nausea\NN\14299637 ,\,\1740 vomiting</e2>\NN\116687 ,\,\1740 and\CC\1740 headache\VB\1740 .\.\1740
D005839_D006261 CID CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 administration\NN\1133281 of\IN\1740 methylprednisolone\NN\1740 and\CC\1740 <e1>gentamicin</e1>\NN\2716866 in\IN\13603305 the\DT\1740 posterior\JJ\1740 sub-Tenon\NNP\1740 's\POS\1740 space\NN\24264 was\VBD\836236 related\JJ\1740 to\TO\1740 a\DT\13649268 high\JJ\1740 incidence\NN\13821570 of\IN\1740 side\NN\8630039 effects\NNS\13245626 including\VBG\690614 nausea\NN\14299637 ,\,\1740 vomiting\NN\116687 ,\,\1740 and\CC\1740 <e2>headache</e2>\VB\1740 .\.\1740
8590259
C016986_D015814 CID The\DT\1740 <e2>ocular\JJ\1740 hypotensive</e2>\JJ\1740 effects\NNS\13245626 were\VBD\836236 statistically\RB\1740 significant\JJ\1740 for\IN\1740 <e1>apraclonidine-treated</e1>\JJ\1740 eyes\NNS\5945642 throughout\IN\1740 the\DT\1740 study\NN\635850 and\CC\1740 also\RB\1740 statistically\RB\1740 significant\JJ\1740 for\IN\1740 contralateral\JJ\1740 eyes\NNS\5945642 from\IN\1740 three\CD\13741022 hours\NNS\15118228 after\IN\1740 topical\JJ\1740 administration\NN\1133281 of\IN\1740 1\CD\13741022 %\NN\1740 apraclonidine\NN\1740 .\.\1740
C016986_D015814 CID The\DT\1740 <e2>ocular\JJ\1740 hypotensive</e2>\JJ\1740 effects\NNS\13245626 were\VBD\836236 statistically\RB\1740 significant\JJ\1740 for\IN\1740 apraclonidine-treated\JJ\1740 eyes\NNS\5945642 throughout\IN\1740 the\DT\1740 study\NN\635850 and\CC\1740 also\RB\1740 statistically\RB\1740 significant\JJ\1740 for\IN\1740 contralateral\JJ\1740 eyes\NNS\5945642 from\IN\1740 three\CD\13741022 hours\NNS\15118228 after\IN\1740 topical\JJ\1740 administration\NN\1133281 of\IN\1740 1\CD\13741022 %\NN\1740 <e1>apraclonidine</e1>\NN\1740 .\.\1740
14568327
D007980_D004409 CID Development\NN\248977 of\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 in\IN\13603305 parkinsonian\JJ\1740 monkeys\NNS\2469914 may\MD\15209706 depend\VB\2604760 upon\IN\1740 rate\NN\13815152 of\IN\1740 symptom\NN\5823932 onset\NN\7325190 and/or\CC\1740 duration\NN\15113229 of\IN\1740 symptoms\NNS\5823932 .\.\1740
D007980_D004409 CID <e1>Levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 (\-LRB-\1740 LIDs\NNS\5313679 )\-RRB-\1740 present\VBP\2137132 a\DT\13649268 major\JJ\1740 problem\NN\14408086 for\IN\1740 the\DT\1740 long-term\JJ\1740 management\NN\1123598 of\IN\1740 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 patients\NNS\9898892 .\.\1740
D007980_D004409 CID <e1>Levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 (\-LRB-\1740 <e2>LIDs</e2>\NNS\5313679 )\-RRB-\1740 present\VBP\2137132 a\DT\13649268 major\JJ\1740 problem\NN\14408086 for\IN\1740 the\DT\1740 long-term\JJ\1740 management\NN\1123598 of\IN\1740 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 patients\NNS\9898892 .\.\1740
D007980_D004409 CID Using\VBG\1156834 macaque\JJ\1740 monkeys\NNS\2469914 with\IN\1740 different\JJ\1740 types\NNS\5839024 of\IN\1740 MPTP-induced\JJ\1740 parkinsonism\NN\14085708 ,\,\1740 the\DT\1740 current\JJ\1740 study\NN\635850 evaluated\VBD\670261 the\DT\1740 degree\NN\4916342 to\IN\1740 which\WDT\1740 rate\NN\13815152 of\IN\1740 symptom\NN\5823932 progression\NN\8457976 ,\,\1740 symptom\NN\5823932 severity\NN\5036394 ,\,\1740 and\CC\1740 response\NN\11410625 to\TO\1740 and\CC\1740 duration\NN\15113229 of\IN\1740 <e1>levodopa</e1>\NN\14604959 therapy\NN\657604 may\MD\15209706 be\VB\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>LIDs</e2>\NNS\5313679 .\.\1740
D007980_D004409 CID Monkeys\NNS\2469914 with\IN\1740 acute\JJ\1740 (\-LRB-\1740 short-term\JJ\1740 )\-RRB-\1740 MPTP\NN\1740 exposure\NN\5042871 ,\,\1740 rapid\JJ\1740 symptom\NN\5823932 onset\NN\7325190 and\CC\1740 short\JJ\1740 symptom\NN\5823932 duration\NN\15113229 prior\RB\1740 to\TO\1740 initiation\NN\7450842 of\IN\1740 <e1>levodopa</e1>\NN\14604959 therapy\NN\657604 developed\VBD\1753788 <e2>dyskinesia</e2>\NN\14084880 between\IN\1740 11\CD\13745420 and\CC\1740 24\CD\13745420 days\NNS\15140892 of\IN\1740 daily\RB\1740 levodopa\NN\14604959 administration\NN\1133281 .\.\1740
D007980_D004409 CID Monkeys\NNS\2469914 with\IN\1740 acute\JJ\1740 (\-LRB-\1740 short-term\JJ\1740 )\-RRB-\1740 MPTP\NN\1740 exposure\NN\5042871 ,\,\1740 rapid\JJ\1740 symptom\NN\5823932 onset\NN\7325190 and\CC\1740 short\JJ\1740 symptom\NN\5823932 duration\NN\15113229 prior\RB\1740 to\TO\1740 initiation\NN\7450842 of\IN\1740 levodopa\NN\14604959 therapy\NN\657604 developed\VBD\1753788 <e2>dyskinesia</e2>\NN\14084880 between\IN\1740 11\CD\13745420 and\CC\1740 24\CD\13745420 days\NNS\15140892 of\IN\1740 daily\RB\1740 <e1>levodopa</e1>\NN\14604959 administration\NN\1133281 .\.\1740
D007980_D004409 CID In\IN\13603305 contrast\NN\13854649 ,\,\1740 monkeys\NNS\2469914 with\IN\1740 long-term\JJ\1740 MPTP\NN\1740 exposure\NN\5042871 ,\,\1740 slow\JJ\1740 symptom\NN\5823932 progression\NN\8457976 and/or\CC\1740 long\JJ\1740 symptom\NN\5823932 duration\NN\15113229 prior\RB\1740 to\TO\1740 initiation\NN\7450842 of\IN\1740 <e1>levodopa</e1>\NN\14604959 therapy\NN\657604 were\VBD\836236 more\RBR\1740 resistant\JJ\1740 to\TO\1740 developing\VBG\1753788 <e2>LIDs</e2>\NNS\5313679 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dyskinesia\NNP\14084880 developed\VBD\1753788 no\RB\1740 sooner\JJR\1740 than\IN\1740 146\CD\1740 days\NNS\15140892 of\IN\1740 chronic\JJ\1740 levodopa\NN\14604959 administration\NN\1133281 )\-RRB-\1740 .\.\1740
D007980_D004409 CID In\IN\13603305 contrast\NN\13854649 ,\,\1740 monkeys\NNS\2469914 with\IN\1740 long-term\JJ\1740 MPTP\NN\1740 exposure\NN\5042871 ,\,\1740 slow\JJ\1740 symptom\NN\5823932 progression\NN\8457976 and/or\CC\1740 long\JJ\1740 symptom\NN\5823932 duration\NN\15113229 prior\RB\1740 to\TO\1740 initiation\NN\7450842 of\IN\1740 <e1>levodopa</e1>\NN\14604959 therapy\NN\657604 were\VBD\836236 more\RBR\1740 resistant\JJ\1740 to\TO\1740 developing\VBG\1753788 LIDs\NNS\5313679 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 <e2>dyskinesia</e2>\NNP\14084880 developed\VBD\1753788 no\RB\1740 sooner\JJR\1740 than\IN\1740 146\CD\1740 days\NNS\15140892 of\IN\1740 chronic\JJ\1740 levodopa\NN\14604959 administration\NN\1133281 )\-RRB-\1740 .\.\1740
D007980_D004409 CID In\IN\13603305 contrast\NN\13854649 ,\,\1740 monkeys\NNS\2469914 with\IN\1740 long-term\JJ\1740 MPTP\NN\1740 exposure\NN\5042871 ,\,\1740 slow\JJ\1740 symptom\NN\5823932 progression\NN\8457976 and/or\CC\1740 long\JJ\1740 symptom\NN\5823932 duration\NN\15113229 prior\RB\1740 to\TO\1740 initiation\NN\7450842 of\IN\1740 levodopa\NN\14604959 therapy\NN\657604 were\VBD\836236 more\RBR\1740 resistant\JJ\1740 to\TO\1740 developing\VBG\1753788 <e2>LIDs</e2>\NNS\5313679 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dyskinesia\NNP\14084880 developed\VBD\1753788 no\RB\1740 sooner\JJR\1740 than\IN\1740 146\CD\1740 days\NNS\15140892 of\IN\1740 chronic\JJ\1740 <e1>levodopa</e1>\NN\14604959 administration\NN\1133281 )\-RRB-\1740 .\.\1740
D007980_D004409 CID In\IN\13603305 contrast\NN\13854649 ,\,\1740 monkeys\NNS\2469914 with\IN\1740 long-term\JJ\1740 MPTP\NN\1740 exposure\NN\5042871 ,\,\1740 slow\JJ\1740 symptom\NN\5823932 progression\NN\8457976 and/or\CC\1740 long\JJ\1740 symptom\NN\5823932 duration\NN\15113229 prior\RB\1740 to\TO\1740 initiation\NN\7450842 of\IN\1740 levodopa\NN\14604959 therapy\NN\657604 were\VBD\836236 more\RBR\1740 resistant\JJ\1740 to\TO\1740 developing\VBG\1753788 LIDs\NNS\5313679 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 <e2>dyskinesia</e2>\NNP\14084880 developed\VBD\1753788 no\RB\1740 sooner\JJR\1740 than\IN\1740 146\CD\1740 days\NNS\15140892 of\IN\1740 chronic\JJ\1740 <e1>levodopa</e1>\NN\14604959 administration\NN\1133281 )\-RRB-\1740 .\.\1740
D007980_D004409 CID These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 distinct\JJ\1740 differences\NNS\4723816 in\IN\13603305 the\DT\1740 propensity\NN\7498854 to\TO\1740 develop\VB\1753788 <e2>LIDs</e2>\NNS\5313679 in\IN\13603305 monkeys\NNS\2469914 with\IN\1740 different\JJ\1740 rates\NNS\13308999 of\IN\1740 symptom\NN\5823932 progression\NN\8457976 or\CC\3541091 symptom\NN\5823932 durations\NNS\15113229 prior\RB\1740 to\TO\1740 <e1>levodopa</e1>\NN\14604959 and\CC\1740 demonstrate\VBP\2137132 the\DT\1740 value\NN\5856066 of\IN\1740 these\DT\1740 models\NNS\5888929 for\IN\1740 further\RB\1740 studying\VBG\630380 the\DT\1740 pathophysiology\NN\1740 of\IN\1740 LIDs\NNS\5313679 .\.\1740
D007980_D004409 CID These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 distinct\JJ\1740 differences\NNS\4723816 in\IN\13603305 the\DT\1740 propensity\NN\7498854 to\TO\1740 develop\VB\1753788 LIDs\NNS\5313679 in\IN\13603305 monkeys\NNS\2469914 with\IN\1740 different\JJ\1740 rates\NNS\13308999 of\IN\1740 symptom\NN\5823932 progression\NN\8457976 or\CC\3541091 symptom\NN\5823932 durations\NNS\15113229 prior\RB\1740 to\TO\1740 <e1>levodopa</e1>\NN\14604959 and\CC\1740 demonstrate\VBP\2137132 the\DT\1740 value\NN\5856066 of\IN\1740 these\DT\1740 models\NNS\5888929 for\IN\1740 further\RB\1740 studying\VBG\630380 the\DT\1740 pathophysiology\NN\1740 of\IN\1740 <e2>LIDs</e2>\NNS\5313679 .\.\1740
D007980_D010300 NONE Development\NN\248977 of\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 in\IN\13603305 <e2>parkinsonian</e2>\JJ\1740 monkeys\NNS\2469914 may\MD\15209706 depend\VB\2604760 upon\IN\1740 rate\NN\13815152 of\IN\1740 symptom\NN\5823932 onset\NN\7325190 and/or\CC\1740 duration\NN\15113229 of\IN\1740 symptoms\NNS\5823932 .\.\1740
D007980_D010300 NONE <e1>Levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 (\-LRB-\1740 LIDs\NNS\5313679 )\-RRB-\1740 present\VBP\2137132 a\DT\13649268 major\JJ\1740 problem\NN\14408086 for\IN\1740 the\DT\1740 long-term\JJ\1740 management\NN\1123598 of\IN\1740 <e2>Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 patients\NNS\9898892 .\.\1740
D007980_D010300 NONE <e1>Levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 (\-LRB-\1740 LIDs\NNS\5313679 )\-RRB-\1740 present\VBP\2137132 a\DT\13649268 major\JJ\1740 problem\NN\14408086 for\IN\1740 the\DT\1740 long-term\JJ\1740 management\NN\1123598 of\IN\1740 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 <e2>PD</e2>\NN\14625458 )\-RRB-\1740 patients\NNS\9898892 .\.\1740
D015632_D010302 CID Using\VBG\1156834 macaque\JJ\1740 monkeys\NNS\2469914 with\IN\1740 different\JJ\1740 types\NNS\5839024 of\IN\1740 <e1>MPTP-induced</e1>\JJ\1740 <e2>parkinsonism</e2>\NN\14085708 ,\,\1740 the\DT\1740 current\JJ\1740 study\NN\635850 evaluated\VBD\670261 the\DT\1740 degree\NN\4916342 to\IN\1740 which\WDT\1740 rate\NN\13815152 of\IN\1740 symptom\NN\5823932 progression\NN\8457976 ,\,\1740 symptom\NN\5823932 severity\NN\5036394 ,\,\1740 and\CC\1740 response\NN\11410625 to\TO\1740 and\CC\1740 duration\NN\15113229 of\IN\1740 levodopa\NN\14604959 therapy\NN\657604 may\MD\15209706 be\VB\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 LIDs\NNS\5313679 .\.\1740
D015632_D004409 NONE Using\VBG\1156834 macaque\JJ\1740 monkeys\NNS\2469914 with\IN\1740 different\JJ\1740 types\NNS\5839024 of\IN\1740 <e1>MPTP-induced</e1>\JJ\1740 parkinsonism\NN\14085708 ,\,\1740 the\DT\1740 current\JJ\1740 study\NN\635850 evaluated\VBD\670261 the\DT\1740 degree\NN\4916342 to\IN\1740 which\WDT\1740 rate\NN\13815152 of\IN\1740 symptom\NN\5823932 progression\NN\8457976 ,\,\1740 symptom\NN\5823932 severity\NN\5036394 ,\,\1740 and\CC\1740 response\NN\11410625 to\TO\1740 and\CC\1740 duration\NN\15113229 of\IN\1740 levodopa\NN\14604959 therapy\NN\657604 may\MD\15209706 be\VB\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>LIDs</e2>\NNS\5313679 .\.\1740
D015632_D004409 NONE Monkeys\NNS\2469914 with\IN\1740 acute\JJ\1740 (\-LRB-\1740 short-term\JJ\1740 )\-RRB-\1740 <e1>MPTP</e1>\NN\1740 exposure\NN\5042871 ,\,\1740 rapid\JJ\1740 symptom\NN\5823932 onset\NN\7325190 and\CC\1740 short\JJ\1740 symptom\NN\5823932 duration\NN\15113229 prior\RB\1740 to\TO\1740 initiation\NN\7450842 of\IN\1740 levodopa\NN\14604959 therapy\NN\657604 developed\VBD\1753788 <e2>dyskinesia</e2>\NN\14084880 between\IN\1740 11\CD\13745420 and\CC\1740 24\CD\13745420 days\NNS\15140892 of\IN\1740 daily\RB\1740 levodopa\NN\14604959 administration\NN\1133281 .\.\1740
D015632_D004409 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 monkeys\NNS\2469914 with\IN\1740 long-term\JJ\1740 <e1>MPTP</e1>\NN\1740 exposure\NN\5042871 ,\,\1740 slow\JJ\1740 symptom\NN\5823932 progression\NN\8457976 and/or\CC\1740 long\JJ\1740 symptom\NN\5823932 duration\NN\15113229 prior\RB\1740 to\TO\1740 initiation\NN\7450842 of\IN\1740 levodopa\NN\14604959 therapy\NN\657604 were\VBD\836236 more\RBR\1740 resistant\JJ\1740 to\TO\1740 developing\VBG\1753788 <e2>LIDs</e2>\NNS\5313679 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 dyskinesia\NNP\14084880 developed\VBD\1753788 no\RB\1740 sooner\JJR\1740 than\IN\1740 146\CD\1740 days\NNS\15140892 of\IN\1740 chronic\JJ\1740 levodopa\NN\14604959 administration\NN\1133281 )\-RRB-\1740 .\.\1740
D015632_D004409 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 monkeys\NNS\2469914 with\IN\1740 long-term\JJ\1740 <e1>MPTP</e1>\NN\1740 exposure\NN\5042871 ,\,\1740 slow\JJ\1740 symptom\NN\5823932 progression\NN\8457976 and/or\CC\1740 long\JJ\1740 symptom\NN\5823932 duration\NN\15113229 prior\RB\1740 to\TO\1740 initiation\NN\7450842 of\IN\1740 levodopa\NN\14604959 therapy\NN\657604 were\VBD\836236 more\RBR\1740 resistant\JJ\1740 to\TO\1740 developing\VBG\1753788 LIDs\NNS\5313679 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 <e2>dyskinesia</e2>\NNP\14084880 developed\VBD\1753788 no\RB\1740 sooner\JJR\1740 than\IN\1740 146\CD\1740 days\NNS\15140892 of\IN\1740 chronic\JJ\1740 levodopa\NN\14604959 administration\NN\1133281 )\-RRB-\1740 .\.\1740
D007980_D010302 NONE Using\VBG\1156834 macaque\JJ\1740 monkeys\NNS\2469914 with\IN\1740 different\JJ\1740 types\NNS\5839024 of\IN\1740 MPTP-induced\JJ\1740 <e2>parkinsonism</e2>\NN\14085708 ,\,\1740 the\DT\1740 current\JJ\1740 study\NN\635850 evaluated\VBD\670261 the\DT\1740 degree\NN\4916342 to\IN\1740 which\WDT\1740 rate\NN\13815152 of\IN\1740 symptom\NN\5823932 progression\NN\8457976 ,\,\1740 symptom\NN\5823932 severity\NN\5036394 ,\,\1740 and\CC\1740 response\NN\11410625 to\TO\1740 and\CC\1740 duration\NN\15113229 of\IN\1740 <e1>levodopa</e1>\NN\14604959 therapy\NN\657604 may\MD\15209706 be\VB\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 LIDs\NNS\5313679 .\.\1740
9522143
D011318_D034381 CID Patients\NNS\9898892 given\VBN\2327200 <e1>prilocaine</e1>\NN\1740 were\VBD\836236 more\RBR\1740 likely\JJ\1740 to\TO\1740 develop\VB\1753788 <e2>hearing\VBG\2106506 loss</e2>\NN\13252973 (\-LRB-\1740 10\CD\13745420 out\IN\66636 of\IN\1740 22\CD\13745420 )\-RRB-\1740 than\IN\1740 those\DT\1740 given\VBN\2327200 bupivacaine\NN\1740 (\-LRB-\1740 4\CD\13741022 out\IN\66636 of\IN\1740 22\CD\13745420 )\-RRB-\1740 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
D011318_D034381 CID The\DT\1740 average\JJ\1740 <e2>hearing\NN\1184814 loss</e2>\NN\13252973 for\IN\1740 speech\NN\7160883 frequencies\NNS\15286249 was\VBD\836236 about\RB\1740 10\CD\13745420 dB\NN\14622893 after\IN\1740 <e1>prilocaine</e1>\NN\1740 and\CC\1740 15\CD\13745420 dB\NN\14622893 after\IN\1740 bupivacaine\NN\1740 .\.\1740
D002045_D034381 CID Patients\NNS\9898892 given\VBN\2327200 prilocaine\NN\1740 were\VBD\836236 more\RBR\1740 likely\JJ\1740 to\TO\1740 develop\VB\1753788 <e2>hearing\VBG\2106506 loss</e2>\NN\13252973 (\-LRB-\1740 10\CD\13745420 out\IN\66636 of\IN\1740 22\CD\13745420 )\-RRB-\1740 than\IN\1740 those\DT\1740 given\VBN\2327200 <e1>bupivacaine</e1>\NN\1740 (\-LRB-\1740 4\CD\13741022 out\IN\66636 of\IN\1740 22\CD\13745420 )\-RRB-\1740 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
D002045_D034381 CID The\DT\1740 average\JJ\1740 <e2>hearing\NN\1184814 loss</e2>\NN\13252973 for\IN\1740 speech\NN\7160883 frequencies\NNS\15286249 was\VBD\836236 about\RB\1740 10\CD\13745420 dB\NN\14622893 after\IN\1740 prilocaine\NN\1740 and\CC\1740 15\CD\13745420 dB\NN\14622893 after\IN\1740 <e1>bupivacaine</e1>\NN\1740 .\.\1740
15233872
C007145_D009203 NONE Cardioprotective\JJ\1740 effect\NN\34213 of\IN\1740 <e1>tincture\NN\14984973 of\IN\1740 Crataegus</e1>\NN\11585340 on\IN\1740 isoproterenol-induced\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
C007145_D009203 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 done\VBN\1640855 to\TO\1740 investigate\VB\644583 the\DT\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 <e1>TCR</e1>\NN\1740 on\IN\1740 experimentally\RB\1740 induced\VBN\1627355 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
D007545_D009203 CID Cardioprotective\JJ\1740 effect\NN\34213 of\IN\1740 tincture\NN\14984973 of\IN\1740 Crataegus\NN\11585340 on\IN\1740 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
1378968
D008094_D007676 CID Effects\NNS\13245626 of\IN\1740 uninephrectomy\NN\1740 and\CC\1740 high\JJ\1740 protein\NN\14944888 feeding\NN\838098 on\IN\1740 <e1>lithium-induced</e1>\JJ\1740 <e2>chronic\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 in\IN\13603305 rats\NNS\2329401 .\.\1740
D008094_D007674 NONE Rats\NNS\2329401 with\IN\1740 <e1>lithium-induced</e1>\JJ\1740 <e2>nephropathy</e2>\NN\14573196 were\VBD\836236 subjected\VBN\137313 to\TO\1740 high\JJ\1740 protein\NN\14944888 (\-LRB-\1740 HP\NN\13635108 )\-RRB-\1740 feeding\NN\838098 ,\,\1740 uninephrectomy\NN\1740 (\-LRB-\1740 NX\NN\1740 )\-RRB-\1740 or\CC\3541091 a\DT\13649268 combination\NN\7951464 of\IN\1740 these\DT\1740 ,\,\1740 in\IN\13603305 an\DT\6697703 attempt\NN\407535 to\TO\1740 induce\VB\1627355 glomerular\JJ\1740 hyperfiltration\NN\1740 and\CC\1740 further\JJ\1740 progression\NN\8457976 of\IN\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D008094_D007674 NONE The\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 <e1>Li-induced</e1>\JJ\1740 <e2>nephropathy</e2>\NN\14573196 ,\,\1740 even\RB\1740 when\WRB\1740 the\DT\1740 GFR\NN\1740 is\VBZ\836236 only\RB\1740 modestly\RB\1740 reduced\VBN\441445 ,\,\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 proteinuria\NN\14299637 and\CC\1740 arterial\JJ\1740 systolic\JJ\1740 hypertension\NN\14057371 .\.\1740
D008094_D051437 NONE Rats\NNS\2329401 with\IN\1740 <e1>lithium-induced</e1>\JJ\1740 nephropathy\NN\14573196 were\VBD\836236 subjected\VBN\137313 to\TO\1740 high\JJ\1740 protein\NN\14944888 (\-LRB-\1740 HP\NN\13635108 )\-RRB-\1740 feeding\NN\838098 ,\,\1740 uninephrectomy\NN\1740 (\-LRB-\1740 NX\NN\1740 )\-RRB-\1740 or\CC\3541091 a\DT\13649268 combination\NN\7951464 of\IN\1740 these\DT\1740 ,\,\1740 in\IN\13603305 an\DT\6697703 attempt\NN\407535 to\TO\1740 induce\VB\1627355 glomerular\JJ\1740 hyperfiltration\NN\1740 and\CC\1740 further\JJ\1740 progression\NN\8457976 of\IN\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 .\.\1740
D008094_D051437 NONE HP\NN\13635108 failed\VBD\1798936 to\TO\1740 accentuante\VB\1740 progression\NN\8457976 of\IN\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 and\CC\1740 in\IN\13603305 fact\NN\5816287 tended\VBD\2604760 to\TO\1740 increase\VB\169651 GFR\NN\1740 and\CC\1740 decrease\VB\169651 plasma\NN\5398023 creatinine\NN\1740 levels\NNS\4916342 in\IN\13603305 <e1>lithium</e1>\FW\14625458 pretreated\JJ\1740 rats\NNS\2329401 .\.\1740
D008094_D011507 CID <e1>Lithium</e1>\NNP\14625458 also\RB\1740 caused\VBD\1617192 <e2>proteinuria</e2>\NN\14299637 and\CC\1740 systolic\JJ\1740 hypertension\NN\14057371 in\IN\13603305 absence\NN\14449405 of\IN\1740 glomerulosclerosis\NN\1740 .\.\1740
D008094_D011507 CID The\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 <e1>Li-induced</e1>\JJ\1740 nephropathy\NN\14573196 ,\,\1740 even\RB\1740 when\WRB\1740 the\DT\1740 GFR\NN\1740 is\VBZ\836236 only\RB\1740 modestly\RB\1740 reduced\VBN\441445 ,\,\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 <e2>proteinuria</e2>\NN\14299637 and\CC\1740 arterial\JJ\1740 systolic\JJ\1740 hypertension\NN\14057371 .\.\1740
D008094_D006973 CID <e1>Lithium</e1>\NNP\14625458 also\RB\1740 caused\VBD\1617192 proteinuria\NN\14299637 and\CC\1740 systolic\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 absence\NN\14449405 of\IN\1740 glomerulosclerosis\NN\1740 .\.\1740
D008094_D006973 CID The\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 <e1>Li-induced</e1>\JJ\1740 nephropathy\NN\14573196 ,\,\1740 even\RB\1740 when\WRB\1740 the\DT\1740 GFR\NN\1740 is\VBZ\836236 only\RB\1740 modestly\RB\1740 reduced\VBN\441445 ,\,\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 proteinuria\NN\14299637 and\CC\1740 arterial\JJ\1740 systolic\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D008094_D005921 NONE <e1>Lithium</e1>\NNP\14625458 also\RB\1740 caused\VBD\1617192 proteinuria\NN\14299637 and\CC\1740 systolic\JJ\1740 hypertension\NN\14057371 in\IN\13603305 absence\NN\14449405 of\IN\1740 <e2>glomerulosclerosis</e2>\NN\1740 .\.\1740
D003404_D051437 NONE HP\NN\13635108 failed\VBD\1798936 to\TO\1740 accentuante\VB\1740 progression\NN\8457976 of\IN\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 and\CC\1740 in\IN\13603305 fact\NN\5816287 tended\VBD\2604760 to\TO\1740 increase\VB\169651 GFR\NN\1740 and\CC\1740 decrease\VB\169651 plasma\NN\5398023 <e1>creatinine</e1>\NN\1740 levels\NNS\4916342 in\IN\13603305 lithium\FW\14625458 pretreated\JJ\1740 rats\NNS\2329401 .\.\1740
3503576
D003676_D006311 NONE Serial\JJ\1740 studies\NNS\635850 of\IN\1740 <e2>auditory\JJ\1740 neurotoxicity</e2>\NN\1740 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 <e1>deferoxamine</e1>\NN\1740 therapy\NN\657604 .\.\1740
D003676_D006311 NONE <e2>Visual\JJ\1740 and\CC\1740 auditory\JJ\1740 neurotoxicity</e2>\NN\1740 was\VBD\836236 previously\RB\1740 documented\VBN\1000214 in\IN\13603305 42\CD\1740 of\IN\1740 89\CD\1740 patients\NNS\9898892 with\IN\1740 transfusion-dependent\JJ\1740 anemia\NN\14189204 who\WP\8299493 were\VBD\836236 receiving\VBG\2210855 iron\NN\14625458 chelation\NN\29677 therapy\NN\657604 with\IN\1740 daily\RB\1740 subcutaneous\JJ\1740 <e1>deferoxamine</e1>\NN\1740 .\.\1740
D003676_D006311 NONE Since\IN\1740 18\CD\13745420 of\IN\1740 the\DT\1740 22\CD\13745420 patients\NNS\9898892 were\VBD\836236 initially\RB\1740 receiving\VBG\2210855 <e1>deferoxamine</e1>\NN\1740 doses\NNS\3740161 in\IN\13603305 excess\NN\5119367 of\IN\1740 the\DT\1740 commonly\RB\1740 recommended\VBN\875394 50\CD\13745420 mg/kg\NN\1740 per\IN\1740 dose\NN\3740161 ,\,\1740 therapy\NN\657604 was\VBD\836236 restarted\VBN\1857717 with\IN\1740 lower\JJR\1740 doses\NNS\3740161 ,\,\1740 usually\RB\1740 50\CD\13745420 mg/kg\NN\1740 per\IN\1740 dose\NN\3740161 or\CC\3541091 less\RBR\1740 depending\VBG\2604760 on\IN\1740 the\DT\1740 degree\NN\4916342 of\IN\1740 <e2>auditory\JJ\1740 abnormality</e2>\NN\14034177 ,\,\1740 and\CC\1740 with\IN\1740 the\DT\1740 exception\NN\5706954 of\IN\1740 two\CD\13741022 cases\NNS\7283608 no\DT\7204911 further\JJ\1740 toxicity\NN\13576101 was\VBD\836236 demonstrated\VBN\2137132 .\.\1740
D003676_D006311 NONE Auditory\JJ\1740 deterioration\NN\14560612 and\CC\1740 improvement\NN\7359599 ,\,\1740 demonstrated\VBN\2137132 serially\RB\1740 in\IN\13603305 individual\JJ\1740 patients\NNS\9898892 receiving\VBG\2210855 and\CC\1740 not\RB\1740 receiving\VBG\2210855 <e1>deferoxamine</e1>\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 provided\VBN\2199590 convincing\VBG\766418 evidence\NN\5816287 for\IN\1740 a\DT\13649268 cause-and-effect\JJ\1740 relation\NN\2137 between\IN\1740 deferoxamine\NN\1740 administration\NN\1133281 and\CC\1740 <e2>ototoxicity</e2>\NN\1740 .\.\1740
D003676_D006311 NONE Auditory\JJ\1740 deterioration\NN\14560612 and\CC\1740 improvement\NN\7359599 ,\,\1740 demonstrated\VBN\2137132 serially\RB\1740 in\IN\13603305 individual\JJ\1740 patients\NNS\9898892 receiving\VBG\2210855 and\CC\1740 not\RB\1740 receiving\VBG\2210855 deferoxamine\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 provided\VBN\2199590 convincing\VBG\766418 evidence\NN\5816287 for\IN\1740 a\DT\13649268 cause-and-effect\JJ\1740 relation\NN\2137 between\IN\1740 <e1>deferoxamine</e1>\NN\1740 administration\NN\1133281 and\CC\1740 <e2>ototoxicity</e2>\NN\1740 .\.\1740
D007501_D014786 NONE <e2>Visual\JJ\1740 and\CC\1740 auditory\JJ\1740 neurotoxicity</e2>\NN\1740 was\VBD\836236 previously\RB\1740 documented\VBN\1000214 in\IN\13603305 42\CD\1740 of\IN\1740 89\CD\1740 patients\NNS\9898892 with\IN\1740 transfusion-dependent\JJ\1740 anemia\NN\14189204 who\WP\8299493 were\VBD\836236 receiving\VBG\2210855 <e1>iron</e1>\NN\14625458 chelation\NN\29677 therapy\NN\657604 with\IN\1740 daily\RB\1740 subcutaneous\JJ\1740 deferoxamine\NN\1740 .\.\1740
D007501_D006311 NONE <e2>Visual\JJ\1740 and\CC\1740 auditory\JJ\1740 neurotoxicity</e2>\NN\1740 was\VBD\836236 previously\RB\1740 documented\VBN\1000214 in\IN\13603305 42\CD\1740 of\IN\1740 89\CD\1740 patients\NNS\9898892 with\IN\1740 transfusion-dependent\JJ\1740 anemia\NN\14189204 who\WP\8299493 were\VBD\836236 receiving\VBG\2210855 <e1>iron</e1>\NN\14625458 chelation\NN\29677 therapy\NN\657604 with\IN\1740 daily\RB\1740 subcutaneous\JJ\1740 deferoxamine\NN\1740 .\.\1740
D007501_D000740 NONE Visual\JJ\1740 and\CC\1740 auditory\JJ\1740 neurotoxicity\NN\1740 was\VBD\836236 previously\RB\1740 documented\VBN\1000214 in\IN\13603305 42\CD\1740 of\IN\1740 89\CD\1740 patients\NNS\9898892 with\IN\1740 transfusion-dependent\JJ\1740 <e2>anemia</e2>\NN\14189204 who\WP\8299493 were\VBD\836236 receiving\VBG\2210855 <e1>iron</e1>\NN\14625458 chelation\NN\29677 therapy\NN\657604 with\IN\1740 daily\RB\1740 subcutaneous\JJ\1740 deferoxamine\NN\1740 .\.\1740
D003676_D014786 NONE <e2>Visual\JJ\1740 and\CC\1740 auditory\JJ\1740 neurotoxicity</e2>\NN\1740 was\VBD\836236 previously\RB\1740 documented\VBN\1000214 in\IN\13603305 42\CD\1740 of\IN\1740 89\CD\1740 patients\NNS\9898892 with\IN\1740 transfusion-dependent\JJ\1740 anemia\NN\14189204 who\WP\8299493 were\VBD\836236 receiving\VBG\2210855 iron\NN\14625458 chelation\NN\29677 therapy\NN\657604 with\IN\1740 daily\RB\1740 subcutaneous\JJ\1740 <e1>deferoxamine</e1>\NN\1740 .\.\1740
D003676_D000740 NONE Visual\JJ\1740 and\CC\1740 auditory\JJ\1740 neurotoxicity\NN\1740 was\VBD\836236 previously\RB\1740 documented\VBN\1000214 in\IN\13603305 42\CD\1740 of\IN\1740 89\CD\1740 patients\NNS\9898892 with\IN\1740 transfusion-dependent\JJ\1740 <e2>anemia</e2>\NN\14189204 who\WP\8299493 were\VBD\836236 receiving\VBG\2210855 iron\NN\14625458 chelation\NN\29677 therapy\NN\657604 with\IN\1740 daily\RB\1740 subcutaneous\JJ\1740 <e1>deferoxamine</e1>\NN\1740 .\.\1740
D003676_D064420 NONE Since\IN\1740 18\CD\13745420 of\IN\1740 the\DT\1740 22\CD\13745420 patients\NNS\9898892 were\VBD\836236 initially\RB\1740 receiving\VBG\2210855 <e1>deferoxamine</e1>\NN\1740 doses\NNS\3740161 in\IN\13603305 excess\NN\5119367 of\IN\1740 the\DT\1740 commonly\RB\1740 recommended\VBN\875394 50\CD\13745420 mg/kg\NN\1740 per\IN\1740 dose\NN\3740161 ,\,\1740 therapy\NN\657604 was\VBD\836236 restarted\VBN\1857717 with\IN\1740 lower\JJR\1740 doses\NNS\3740161 ,\,\1740 usually\RB\1740 50\CD\13745420 mg/kg\NN\1740 per\IN\1740 dose\NN\3740161 or\CC\3541091 less\RBR\1740 depending\VBG\2604760 on\IN\1740 the\DT\1740 degree\NN\4916342 of\IN\1740 auditory\JJ\1740 abnormality\NN\14034177 ,\,\1740 and\CC\1740 with\IN\1740 the\DT\1740 exception\NN\5706954 of\IN\1740 two\CD\13741022 cases\NNS\7283608 no\DT\7204911 further\JJ\1740 <e2>toxicity</e2>\NN\13576101 was\VBD\836236 demonstrated\VBN\2137132 .\.\1740
7628595
D014805_D064420 NONE Study\NN\635850 of\IN\1740 the\DT\1740 role\NN\719494 of\IN\1740 <e1>vitamin\NN\7570720 B12</e1>\NN\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 supplementation\NN\5108947 in\IN\13603305 preventing\VBG\1740 hematologic\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 zidovudine\NN\3834836 .\.\1740
D002955_D064420 NONE Study\NN\635850 of\IN\1740 the\DT\1740 role\NN\719494 of\IN\1740 vitamin\NN\7570720 B12\NN\1740 and\CC\1740 <e1>folinic\JJ\1740 acid</e1>\NN\14818238 supplementation\NN\5108947 in\IN\13603305 preventing\VBG\1740 hematologic\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 zidovudine\NN\3834836 .\.\1740
D015215_D064420 NONE Study\NN\635850 of\IN\1740 the\DT\1740 role\NN\719494 of\IN\1740 vitamin\NN\7570720 B12\NN\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 supplementation\NN\5108947 in\IN\13603305 preventing\VBG\1740 hematologic\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 <e1>zidovudine</e1>\NN\3834836 .\.\1740
D014805_D001855 NONE A\DT\13649268 prospective\JJ\1740 ,\,\1740 randomized\JJ\1740 study\NN\635850 was\VBD\836236 conducted\VBN\2436349 to\TO\1740 evaluate\VB\670261 the\DT\1740 role\NN\719494 of\IN\1740 <e1>vitamin\NN\7570720 B12</e1>\NN\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 supplementation\NN\5108947 in\IN\13603305 preventing\VBG\1740 zidovudine\NN\3834836 (ZDV)-induced\JJ\1740 <e2>bone\NN\5286536 marrow\NN\5286536 suppression</e2>\NN\13489037 .\.\1740
D014805_D001855 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 correlation\NN\13841213 between\IN\1740 <e1>vitamin\NN\7570720 B12</e1>\NN\1740 or\CC\3541091 folate\VBP\1740 levels\NNS\4916342 and\CC\1740 development\NN\248977 of\IN\1740 <e2>myelosuppression</e2>\NN\1740 .\.\1740
D014805_D001855 NONE <e1>Vitamin\NN\7570720 B12</e1>\NN\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 supplementation\NN\5108947 of\IN\1740 ZDV\NN\3834836 therapy\NN\657604 does\VBZ\1640855 not\RB\1740 seem\VB\2604760 useful\JJ\1740 in\IN\13603305 preventing\VBG\1740 or\CC\3541091 reducing\VBG\441445 ZDV-induced\JJ\1740 <e2>myelotoxicity</e2>\NN\1740 in\IN\13603305 the\DT\1740 overall\JJ\1740 treated\VBN\2376958 population\NN\7942152 ,\,\1740 although\IN\1740 a\DT\13649268 beneficial\JJ\1740 effect\NN\34213 in\IN\13603305 certain\JJ\1740 subgroups\NNS\31264 of\IN\1740 patients\NNS\9898892 can\MD\3094503 not\RB\1740 be\VB\836236 excluded\VBN\471711 .\.\1740
D002955_D001855 NONE A\DT\13649268 prospective\JJ\1740 ,\,\1740 randomized\JJ\1740 study\NN\635850 was\VBD\836236 conducted\VBN\2436349 to\TO\1740 evaluate\VB\670261 the\DT\1740 role\NN\719494 of\IN\1740 vitamin\NN\7570720 B12\NN\1740 and\CC\1740 <e1>folinic\JJ\1740 acid</e1>\NN\14818238 supplementation\NN\5108947 in\IN\13603305 preventing\VBG\1740 zidovudine\NN\3834836 (ZDV)-induced\JJ\1740 <e2>bone\NN\5286536 marrow\NN\5286536 suppression</e2>\NN\13489037 .\.\1740
D002955_D001855 NONE Vitamin\NN\7570720 B12\NN\1740 and\CC\1740 <e1>folinic\JJ\1740 acid</e1>\NN\14818238 supplementation\NN\5108947 of\IN\1740 ZDV\NN\3834836 therapy\NN\657604 does\VBZ\1640855 not\RB\1740 seem\VB\2604760 useful\JJ\1740 in\IN\13603305 preventing\VBG\1740 or\CC\3541091 reducing\VBG\441445 ZDV-induced\JJ\1740 <e2>myelotoxicity</e2>\NN\1740 in\IN\13603305 the\DT\1740 overall\JJ\1740 treated\VBN\2376958 population\NN\7942152 ,\,\1740 although\IN\1740 a\DT\13649268 beneficial\JJ\1740 effect\NN\34213 in\IN\13603305 certain\JJ\1740 subgroups\NNS\31264 of\IN\1740 patients\NNS\9898892 can\MD\3094503 not\RB\1740 be\VB\836236 excluded\VBN\471711 .\.\1740
D015215_D001855 CID A\DT\13649268 prospective\JJ\1740 ,\,\1740 randomized\JJ\1740 study\NN\635850 was\VBD\836236 conducted\VBN\2436349 to\TO\1740 evaluate\VB\670261 the\DT\1740 role\NN\719494 of\IN\1740 vitamin\NN\7570720 B12\NN\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 supplementation\NN\5108947 in\IN\13603305 preventing\VBG\1740 <e1>zidovudine</e1>\NN\3834836 (ZDV)-induced\JJ\1740 <e2>bone\NN\5286536 marrow\NN\5286536 suppression</e2>\NN\13489037 .\.\1740
D015215_D001855 CID A\DT\13649268 prospective\JJ\1740 ,\,\1740 randomized\JJ\1740 study\NN\635850 was\VBD\836236 conducted\VBN\2436349 to\TO\1740 evaluate\VB\670261 the\DT\1740 role\NN\719494 of\IN\1740 vitamin\NN\7570720 B12\NN\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 supplementation\NN\5108947 in\IN\13603305 preventing\VBG\1740 zidovudine\NN\3834836 <e1>(ZDV)-induced</e1>\JJ\1740 <e2>bone\NN\5286536 marrow\NN\5286536 suppression</e2>\NN\13489037 .\.\1740
D015215_D001855 CID Vitamin\NN\7570720 B12\NN\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 supplementation\NN\5108947 of\IN\1740 <e1>ZDV</e1>\NN\3834836 therapy\NN\657604 does\VBZ\1640855 not\RB\1740 seem\VB\2604760 useful\JJ\1740 in\IN\13603305 preventing\VBG\1740 or\CC\3541091 reducing\VBG\441445 ZDV-induced\JJ\1740 <e2>myelotoxicity</e2>\NN\1740 in\IN\13603305 the\DT\1740 overall\JJ\1740 treated\VBN\2376958 population\NN\7942152 ,\,\1740 although\IN\1740 a\DT\13649268 beneficial\JJ\1740 effect\NN\34213 in\IN\13603305 certain\JJ\1740 subgroups\NNS\31264 of\IN\1740 patients\NNS\9898892 can\MD\3094503 not\RB\1740 be\VB\836236 excluded\VBN\471711 .\.\1740
D015215_D001855 CID Vitamin\NN\7570720 B12\NN\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 supplementation\NN\5108947 of\IN\1740 ZDV\NN\3834836 therapy\NN\657604 does\VBZ\1640855 not\RB\1740 seem\VB\2604760 useful\JJ\1740 in\IN\13603305 preventing\VBG\1740 or\CC\3541091 reducing\VBG\441445 <e1>ZDV-induced</e1>\JJ\1740 <e2>myelotoxicity</e2>\NN\1740 in\IN\13603305 the\DT\1740 overall\JJ\1740 treated\VBN\2376958 population\NN\7942152 ,\,\1740 although\IN\1740 a\DT\13649268 beneficial\JJ\1740 effect\NN\34213 in\IN\13603305 certain\JJ\1740 subgroups\NNS\31264 of\IN\1740 patients\NNS\9898892 can\MD\3094503 not\RB\1740 be\VB\836236 excluded\VBN\471711 .\.\1740
D015215_D015658 NONE Seventy-five\JJ\1740 <e2>human\JJ\1740 immunodeficiency\NN\13973990 virus\NN\9312843 (HIV)-infected</e2>\JJ\1740 patients\NNS\9898892 with\IN\1740 CD4\NN\14888310 +\CC\1740 cell\NN\3080309 counts\NNS\13582013 <\NN\1740 500/mm3\NN\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 <e1>ZDV</e1>\NN\3834836 (\-LRB-\1740 500\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 alone\RB\1740 (\-LRB-\1740 group\NN\2137 I\NN\14622893 ,\,\1740 n\NN\14622893 =\JJ\1740 38\CD\1740 )\-RRB-\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 folinic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 15\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 and\CC\1740 intramascular\JJ\1740 vitamin\NN\7570720 B12\NN\1740 (\-LRB-\1740 1000\CD\13745420 micrograms\NNS\13717155 monthly\RB\1740 )\-RRB-\1740 (\-LRB-\1740 group\NN\2137 II\CD\13741022 ,\,\1740 n\NN\14622893 =\JJ\1740 37\CD\1740 )\-RRB-\1740 .\.\1740
D002955_D015658 NONE Seventy-five\JJ\1740 <e2>human\JJ\1740 immunodeficiency\NN\13973990 virus\NN\9312843 (HIV)-infected</e2>\JJ\1740 patients\NNS\9898892 with\IN\1740 CD4\NN\14888310 +\CC\1740 cell\NN\3080309 counts\NNS\13582013 <\NN\1740 500/mm3\NN\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 ZDV\NN\3834836 (\-LRB-\1740 500\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 alone\RB\1740 (\-LRB-\1740 group\NN\2137 I\NN\14622893 ,\,\1740 n\NN\14622893 =\JJ\1740 38\CD\1740 )\-RRB-\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>folinic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 15\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 and\CC\1740 intramascular\JJ\1740 vitamin\NN\7570720 B12\NN\1740 (\-LRB-\1740 1000\CD\13745420 micrograms\NNS\13717155 monthly\RB\1740 )\-RRB-\1740 (\-LRB-\1740 group\NN\2137 II\CD\13741022 ,\,\1740 n\NN\14622893 =\JJ\1740 37\CD\1740 )\-RRB-\1740 .\.\1740
D014805_D015658 NONE Seventy-five\JJ\1740 <e2>human\JJ\1740 immunodeficiency\NN\13973990 virus\NN\9312843 (HIV)-infected</e2>\JJ\1740 patients\NNS\9898892 with\IN\1740 CD4\NN\14888310 +\CC\1740 cell\NN\3080309 counts\NNS\13582013 <\NN\1740 500/mm3\NN\1740 were\VBD\836236 randomized\VBN\278117 to\TO\1740 receive\VB\2210855 either\CC\1740 ZDV\NN\3834836 (\-LRB-\1740 500\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 alone\RB\1740 (\-LRB-\1740 group\NN\2137 I\NN\14622893 ,\,\1740 n\NN\14622893 =\JJ\1740 38\CD\1740 )\-RRB-\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 folinic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 15\CD\13745420 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 and\CC\1740 intramascular\JJ\1740 <e1>vitamin\NN\7570720 B12</e1>\NN\1740 (\-LRB-\1740 1000\CD\13745420 micrograms\NNS\13717155 monthly\RB\1740 )\-RRB-\1740 (\-LRB-\1740 group\NN\2137 II\CD\13741022 ,\,\1740 n\NN\14622893 =\JJ\1740 37\CD\1740 )\-RRB-\1740 .\.\1740
D005492_D001855 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 correlation\NN\13841213 between\IN\1740 vitamin\NN\7570720 B12\NN\1740 or\CC\3541091 <e1>folate</e1>\VBP\1740 levels\NNS\4916342 and\CC\1740 development\NN\248977 of\IN\1740 <e2>myelosuppression</e2>\NN\1740 .\.\1740
16298782
D019331_D006311 NONE <e1>Nitro-L-arginine\NN\1740 methyl\NN\14617189 ester</e1>\NN\14727670 :\:\1740 a\DT\13649268 potential\JJ\1740 protector\NN\10466918 against\IN\1740 gentamicin\NN\2716866 <e2>ototoxicity</e2>\NN\1740 .\.\1740
D005839_D006311 NONE Nitro-L-arginine\NN\1740 methyl\NN\14617189 ester\NN\14727670 :\:\1740 a\DT\13649268 potential\JJ\1740 protector\NN\10466918 against\IN\1740 <e1>gentamicin</e1>\NN\2716866 <e2>ototoxicity</e2>\NN\1740 .\.\1740
D009569_D006316 NONE The\DT\1740 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 inhibitor\NN\20090 nitro-L-arginine\NN\1740 methyl\NN\14617189 ester\NN\14727670 (\-LRB-\1740 L-NAME\NN\1740 )\-RRB-\1740 may\MD\15209706 act\VB\1619354 as\IN\14622893 an\DT\6697703 otoprotectant\NN\1740 against\IN\1740 <e2>high-frequency\NN\1740 hearing\NN\1184814 loss</e2>\NN\13252973 caused\VBN\1617192 by\IN\1740 gentamicin\NN\2716866 ,\,\1740 but\CC\1740 further\JJ\1740 studies\NNS\635850 are\VBP\836236 needed\VBN\2604760 to\TO\1740 confirm\VB\1011725 this\DT\1740 .\.\1740
D009569_D006316 NONE The\DT\1740 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 <e1>NO</e1>\NN\7204911 )\-RRB-\1740 inhibitor\NN\20090 nitro-L-arginine\NN\1740 methyl\NN\14617189 ester\NN\14727670 (\-LRB-\1740 L-NAME\NN\1740 )\-RRB-\1740 may\MD\15209706 act\VB\1619354 as\IN\14622893 an\DT\6697703 otoprotectant\NN\1740 against\IN\1740 <e2>high-frequency\NN\1740 hearing\NN\1184814 loss</e2>\NN\13252973 caused\VBN\1617192 by\IN\1740 gentamicin\NN\2716866 ,\,\1740 but\CC\1740 further\JJ\1740 studies\NNS\635850 are\VBP\836236 needed\VBN\2604760 to\TO\1740 confirm\VB\1011725 this\DT\1740 .\.\1740
D019331_D006316 NONE The\DT\1740 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 inhibitor\NN\20090 <e1>nitro-L-arginine\NN\1740 methyl\NN\14617189 ester</e1>\NN\14727670 (\-LRB-\1740 L-NAME\NN\1740 )\-RRB-\1740 may\MD\15209706 act\VB\1619354 as\IN\14622893 an\DT\6697703 otoprotectant\NN\1740 against\IN\1740 <e2>high-frequency\NN\1740 hearing\NN\1184814 loss</e2>\NN\13252973 caused\VBN\1617192 by\IN\1740 gentamicin\NN\2716866 ,\,\1740 but\CC\1740 further\JJ\1740 studies\NNS\635850 are\VBP\836236 needed\VBN\2604760 to\TO\1740 confirm\VB\1011725 this\DT\1740 .\.\1740
D019331_D006316 NONE The\DT\1740 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 inhibitor\NN\20090 nitro-L-arginine\NN\1740 methyl\NN\14617189 ester\NN\14727670 (\-LRB-\1740 <e1>L-NAME</e1>\NN\1740 )\-RRB-\1740 may\MD\15209706 act\VB\1619354 as\IN\14622893 an\DT\6697703 otoprotectant\NN\1740 against\IN\1740 <e2>high-frequency\NN\1740 hearing\NN\1184814 loss</e2>\NN\13252973 caused\VBN\1617192 by\IN\1740 gentamicin\NN\2716866 ,\,\1740 but\CC\1740 further\JJ\1740 studies\NNS\635850 are\VBP\836236 needed\VBN\2604760 to\TO\1740 confirm\VB\1011725 this\DT\1740 .\.\1740
D005839_D006316 NONE The\DT\1740 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 inhibitor\NN\20090 nitro-L-arginine\NN\1740 methyl\NN\14617189 ester\NN\14727670 (\-LRB-\1740 L-NAME\NN\1740 )\-RRB-\1740 may\MD\15209706 act\VB\1619354 as\IN\14622893 an\DT\6697703 otoprotectant\NN\1740 against\IN\1740 <e2>high-frequency\NN\1740 hearing\NN\1184814 loss</e2>\NN\13252973 caused\VBN\1617192 by\IN\1740 <e1>gentamicin</e1>\NN\2716866 ,\,\1740 but\CC\1740 further\JJ\1740 studies\NNS\635850 are\VBP\836236 needed\VBN\2604760 to\TO\1740 confirm\VB\1011725 this\DT\1740 .\.\1740
D009569_D006311 NONE Their\PRP$\1740 <e2>ototoxicity</e2>\NN\1740 is\VBZ\836236 a\DT\13649268 serious\JJ\1740 health\NN\14447525 problem\NN\14408086 and\CC\1740 ,\,\1740 as\IN\14622893 their\PRP$\1740 ototoxic\JJ\1740 mechanism\NN\13446390 involves\VBZ\2676054 the\DT\1740 production\NN\30358 of\IN\1740 <e1>NO</e1>\NN\7204911 ,\,\1740 we\PRP\1740 need\VBP\2604760 to\TO\1740 assess\VB\670261 the\DT\1740 use\NN\407535 of\IN\1740 NO\DT\7204911 inhibitors\NNS\20090 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 aminoglycoside-induced\JJ\1740 sensorineural\JJ\1740 hearing\NN\1184814 loss\NN\13252973 .\.\1740
D009569_D006311 NONE Their\PRP$\1740 ototoxicity\NN\1740 is\VBZ\836236 a\DT\13649268 serious\JJ\1740 health\NN\14447525 problem\NN\14408086 and\CC\1740 ,\,\1740 as\IN\14622893 their\PRP$\1740 <e2>ototoxic</e2>\JJ\1740 mechanism\NN\13446390 involves\VBZ\2676054 the\DT\1740 production\NN\30358 of\IN\1740 <e1>NO</e1>\NN\7204911 ,\,\1740 we\PRP\1740 need\VBP\2604760 to\TO\1740 assess\VB\670261 the\DT\1740 use\NN\407535 of\IN\1740 NO\DT\7204911 inhibitors\NNS\20090 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 aminoglycoside-induced\JJ\1740 sensorineural\JJ\1740 hearing\NN\1184814 loss\NN\13252973 .\.\1740
D009569_D006311 NONE Their\PRP$\1740 <e2>ototoxicity</e2>\NN\1740 is\VBZ\836236 a\DT\13649268 serious\JJ\1740 health\NN\14447525 problem\NN\14408086 and\CC\1740 ,\,\1740 as\IN\14622893 their\PRP$\1740 ototoxic\JJ\1740 mechanism\NN\13446390 involves\VBZ\2676054 the\DT\1740 production\NN\30358 of\IN\1740 NO\NN\7204911 ,\,\1740 we\PRP\1740 need\VBP\2604760 to\TO\1740 assess\VB\670261 the\DT\1740 use\NN\407535 of\IN\1740 <e1>NO</e1>\DT\7204911 inhibitors\NNS\20090 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 aminoglycoside-induced\JJ\1740 sensorineural\JJ\1740 hearing\NN\1184814 loss\NN\13252973 .\.\1740
D009569_D006311 NONE Their\PRP$\1740 ototoxicity\NN\1740 is\VBZ\836236 a\DT\13649268 serious\JJ\1740 health\NN\14447525 problem\NN\14408086 and\CC\1740 ,\,\1740 as\IN\14622893 their\PRP$\1740 <e2>ototoxic</e2>\JJ\1740 mechanism\NN\13446390 involves\VBZ\2676054 the\DT\1740 production\NN\30358 of\IN\1740 NO\NN\7204911 ,\,\1740 we\PRP\1740 need\VBP\2604760 to\TO\1740 assess\VB\670261 the\DT\1740 use\NN\407535 of\IN\1740 <e1>NO</e1>\DT\7204911 inhibitors\NNS\20090 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 aminoglycoside-induced\JJ\1740 sensorineural\JJ\1740 hearing\NN\1184814 loss\NN\13252973 .\.\1740
D009569_D006319 NONE Their\PRP$\1740 ototoxicity\NN\1740 is\VBZ\836236 a\DT\13649268 serious\JJ\1740 health\NN\14447525 problem\NN\14408086 and\CC\1740 ,\,\1740 as\IN\14622893 their\PRP$\1740 ototoxic\JJ\1740 mechanism\NN\13446390 involves\VBZ\2676054 the\DT\1740 production\NN\30358 of\IN\1740 <e1>NO</e1>\NN\7204911 ,\,\1740 we\PRP\1740 need\VBP\2604760 to\TO\1740 assess\VB\670261 the\DT\1740 use\NN\407535 of\IN\1740 NO\DT\7204911 inhibitors\NNS\20090 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 aminoglycoside-induced\JJ\1740 <e2>sensorineural\JJ\1740 hearing\NN\1184814 loss</e2>\NN\13252973 .\.\1740
D009569_D006319 NONE Their\PRP$\1740 ototoxicity\NN\1740 is\VBZ\836236 a\DT\13649268 serious\JJ\1740 health\NN\14447525 problem\NN\14408086 and\CC\1740 ,\,\1740 as\IN\14622893 their\PRP$\1740 ototoxic\JJ\1740 mechanism\NN\13446390 involves\VBZ\2676054 the\DT\1740 production\NN\30358 of\IN\1740 NO\NN\7204911 ,\,\1740 we\PRP\1740 need\VBP\2604760 to\TO\1740 assess\VB\670261 the\DT\1740 use\NN\407535 of\IN\1740 <e1>NO</e1>\DT\7204911 inhibitors\NNS\20090 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 aminoglycoside-induced\JJ\1740 <e2>sensorineural\JJ\1740 hearing\NN\1184814 loss</e2>\NN\13252973 .\.\1740
D000617_D006311 NONE Their\PRP$\1740 <e2>ototoxicity</e2>\NN\1740 is\VBZ\836236 a\DT\13649268 serious\JJ\1740 health\NN\14447525 problem\NN\14408086 and\CC\1740 ,\,\1740 as\IN\14622893 their\PRP$\1740 ototoxic\JJ\1740 mechanism\NN\13446390 involves\VBZ\2676054 the\DT\1740 production\NN\30358 of\IN\1740 NO\NN\7204911 ,\,\1740 we\PRP\1740 need\VBP\2604760 to\TO\1740 assess\VB\670261 the\DT\1740 use\NN\407535 of\IN\1740 NO\DT\7204911 inhibitors\NNS\20090 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e1>aminoglycoside-induced</e1>\JJ\1740 sensorineural\JJ\1740 hearing\NN\1184814 loss\NN\13252973 .\.\1740
D000617_D006311 NONE Their\PRP$\1740 ototoxicity\NN\1740 is\VBZ\836236 a\DT\13649268 serious\JJ\1740 health\NN\14447525 problem\NN\14408086 and\CC\1740 ,\,\1740 as\IN\14622893 their\PRP$\1740 <e2>ototoxic</e2>\JJ\1740 mechanism\NN\13446390 involves\VBZ\2676054 the\DT\1740 production\NN\30358 of\IN\1740 NO\NN\7204911 ,\,\1740 we\PRP\1740 need\VBP\2604760 to\TO\1740 assess\VB\670261 the\DT\1740 use\NN\407535 of\IN\1740 NO\DT\7204911 inhibitors\NNS\20090 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e1>aminoglycoside-induced</e1>\JJ\1740 sensorineural\JJ\1740 hearing\NN\1184814 loss\NN\13252973 .\.\1740
D000617_D006319 NONE Their\PRP$\1740 ototoxicity\NN\1740 is\VBZ\836236 a\DT\13649268 serious\JJ\1740 health\NN\14447525 problem\NN\14408086 and\CC\1740 ,\,\1740 as\IN\14622893 their\PRP$\1740 ototoxic\JJ\1740 mechanism\NN\13446390 involves\VBZ\2676054 the\DT\1740 production\NN\30358 of\IN\1740 NO\NN\7204911 ,\,\1740 we\PRP\1740 need\VBP\2604760 to\TO\1740 assess\VB\670261 the\DT\1740 use\NN\407535 of\IN\1740 NO\DT\7204911 inhibitors\NNS\20090 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e1>aminoglycoside-induced</e1>\JJ\1740 <e2>sensorineural\JJ\1740 hearing\NN\1184814 loss</e2>\NN\13252973 .\.\1740
D019331_D034381 NONE <e1>L-NAME</e1>\NNP\1740 reduced\VBD\441445 gentamicin-induced\JJ\1740 <e2>hearing\NN\1184814 loss</e2>\NN\13252973 in\IN\13603305 the\DT\1740 high-frequency\NN\1740 range\NN\5123416 ,\,\1740 but\CC\1740 gave\VBD\2327200 no\DT\7204911 protection\NN\407535 in\IN\13603305 the\DT\1740 middle\NN\8497294 or\CC\3541091 low\JJ\1740 frequencies\NNS\15286249 .\.\1740
D005839_D034381 CID L-NAME\NNP\1740 reduced\VBD\441445 <e1>gentamicin-induced</e1>\JJ\1740 <e2>hearing\NN\1184814 loss</e2>\NN\13252973 in\IN\13603305 the\DT\1740 high-frequency\NN\1740 range\NN\5123416 ,\,\1740 but\CC\1740 gave\VBD\2327200 no\DT\7204911 protection\NN\407535 in\IN\13603305 the\DT\1740 middle\NN\8497294 or\CC\3541091 low\JJ\1740 frequencies\NNS\15286249 .\.\1740
6538499
D011092_D064420 NONE Effect\NN\34213 of\IN\1740 <e1>polyethylene\NN\14902141 glycol\NN\14766364 400</e1>\CD\1740 on\IN\1740 adriamycin\NN\1740 <e2>toxicity</e2>\NN\13576101 in\IN\13603305 mice\NNS\2329401 .\.\1740
D004317_D064420 NONE Effect\NN\34213 of\IN\1740 polyethylene\NN\14902141 glycol\NN\14766364 400\CD\1740 on\IN\1740 <e1>adriamycin</e1>\NN\1740 <e2>toxicity</e2>\NN\13576101 in\IN\13603305 mice\NNS\2329401 .\.\1740
D004317_D009202 CID Light\JJ\1740 microscopic\JJ\1740 analysis\NN\633864 showed\VBD\2137132 a\DT\13649268 significant\JJ\1740 protection\NN\407535 against\IN\1740 <e1>ADR-induced</e1>\JJ\1740 <e2>cardiac\JJ\1740 morphological\JJ\1740 alterations</e2>\NNS\7283608 .\.\1740
D004317_D007939 NONE Such\JJ\1740 treatment\NN\654885 did\VBD\1640855 not\RB\1740 diminish\VB\169651 the\DT\1740 <e1>ADR</e1>\NN\1740 antitumor\NN\1740 activity\NN\30358 in\IN\13603305 <e2>L1210\NN\1740 leukemia</e2>\NN\14239918 and\CC\1740 in\IN\13603305 Ehrlich\JJ\1740 ascites\NNS\14204950 tumor\NN\14234074 .\.\1740
D004317_D002286 NONE Such\JJ\1740 treatment\NN\654885 did\VBD\1640855 not\RB\1740 diminish\VB\169651 the\DT\1740 <e1>ADR</e1>\NN\1740 antitumor\NN\1740 activity\NN\30358 in\IN\13603305 L1210\NN\1740 leukemia\NN\14239918 and\CC\1740 in\IN\13603305 <e2>Ehrlich\JJ\1740 ascites\NNS\14204950 tumor</e2>\NN\14234074 .\.\1740
12653683
D012964_D009404 NONE Epithelial\JJ\1740 <e1>sodium</e1>\NN\14625458 channel\NN\6251781 (\-LRB-\1740 ENaC\NN\1740 )\-RRB-\1740 subunit\NN\13604718 mRNA\NN\14832193 and\CC\1740 protein\NN\14944888 expression\NN\4679549 in\IN\13603305 rats\NNS\2329401 with\IN\1740 puromycin\NN\1740 aminonucleoside-induced\JJ\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
D012964_D009404 NONE In\IN\13603305 experimental\JJ\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 ,\,\1740 urinary\JJ\1740 <e1>sodium</e1>\NN\14625458 excretion\NN\13466586 is\VBZ\836236 decreased\VBN\169651 during\IN\1740 the\DT\1740 early\JJ\1740 phase\NN\15113229 of\IN\1740 the\DT\1740 disease\NN\14061805 .\.\1740
D011692_D009404 CID Epithelial\JJ\1740 sodium\NN\14625458 channel\NN\6251781 (\-LRB-\1740 ENaC\NN\1740 )\-RRB-\1740 subunit\NN\13604718 mRNA\NN\14832193 and\CC\1740 protein\NN\14944888 expression\NN\4679549 in\IN\13603305 rats\NNS\2329401 with\IN\1740 <e1>puromycin\NN\1740 aminonucleoside-induced</e1>\JJ\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
D011692_D009404 CID We\PRP\1740 examined\VBD\789138 the\DT\1740 abundance\NN\5108740 of\IN\1740 ENaC\NN\1740 subunit\NN\13604718 mRNAs\NNS\14832193 and\CC\1740 proteins\NNS\14944888 in\IN\13603305 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 (PAN)-induced\JJ\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
D011692_D009404 CID We\PRP\1740 examined\VBD\789138 the\DT\1740 abundance\NN\5108740 of\IN\1740 ENaC\NN\1740 subunit\NN\13604718 mRNAs\NNS\14832193 and\CC\1740 proteins\NNS\14944888 in\IN\13603305 puromycin\NN\1740 aminonucleoside\NN\1740 <e1>(PAN)-induced</e1>\JJ\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
D011692_D009404 CID In\IN\13603305 conclusion\NN\5837957 ,\,\1740 ENaC\NN\1740 mRNA\NN\14832193 expression\NN\4679549 ,\,\1740 especially\RB\1740 alphaENaC\NN\1740 ,\,\1740 is\VBZ\836236 increased\VBN\169651 in\IN\13603305 the\DT\1740 very\RB\1740 early\JJ\1740 phase\NN\15113229 of\IN\1740 the\DT\1740 experimental\JJ\1740 model\NN\5888929 of\IN\1740 <e1>PAN-induced</e1>\JJ\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 in\IN\13603305 rats\NNS\2329401 ,\,\1740 but\CC\1740 appears\VBZ\2604760 to\TO\1740 escape\VB\2075462 from\IN\1740 the\DT\1740 regulation\NN\6652242 by\IN\1740 aldosterone\NN\14751863 after\IN\1740 day\NN\15154774 3\CD\13741022 .\.\1740
D012964_D011507 NONE The\DT\1740 time\NN\7308889 courses\NNS\883297 of\IN\1740 urinary\JJ\1740 <e1>sodium</e1>\NN\14625458 excretion\NN\13466586 ,\,\1740 plasma\NN\5398023 aldosterone\NN\14751863 concentration\NN\4916342 and\CC\1740 <e2>proteinuria</e2>\NN\14299637 were\VBD\836236 studied\VBN\630380 in\IN\13603305 male\JJ\1740 Sprague-Dawley\NN\1740 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 either\CC\1740 PAN\NN\3101986 or\CC\3541091 vehicle\NN\3100490 .\.\1740
D012964_D011507 NONE The\DT\1740 kinetics\NNS\6100236 of\IN\1740 urinary\JJ\1740 <e1>sodium</e1>\NN\14625458 excretion\NN\13466586 and\CC\1740 the\DT\1740 appearance\NN\4723816 of\IN\1740 <e2>proteinuria</e2>\NN\14299637 were\VBD\836236 comparable\JJ\1740 with\IN\1740 those\DT\1740 reported\VBN\831651 previously\RB\1740 .\.\1740
D000450_D011507 NONE The\DT\1740 time\NN\7308889 courses\NNS\883297 of\IN\1740 urinary\JJ\1740 sodium\NN\14625458 excretion\NN\13466586 ,\,\1740 plasma\NN\5398023 <e1>aldosterone</e1>\NN\14751863 concentration\NN\4916342 and\CC\1740 <e2>proteinuria</e2>\NN\14299637 were\VBD\836236 studied\VBN\630380 in\IN\13603305 male\JJ\1740 Sprague-Dawley\NN\1740 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 either\CC\1740 PAN\NN\3101986 or\CC\3541091 vehicle\NN\3100490 .\.\1740
D011692_D011507 CID The\DT\1740 time\NN\7308889 courses\NNS\883297 of\IN\1740 urinary\JJ\1740 sodium\NN\14625458 excretion\NN\13466586 ,\,\1740 plasma\NN\5398023 aldosterone\NN\14751863 concentration\NN\4916342 and\CC\1740 <e2>proteinuria</e2>\NN\14299637 were\VBD\836236 studied\VBN\630380 in\IN\13603305 male\JJ\1740 Sprague-Dawley\NN\1740 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 either\CC\1740 <e1>PAN</e1>\NN\3101986 or\CC\3541091 vehicle\NN\3100490 .\.\1740
D000450_D009404 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 ENaC\NN\1740 mRNA\NN\14832193 expression\NN\4679549 ,\,\1740 especially\RB\1740 alphaENaC\NN\1740 ,\,\1740 is\VBZ\836236 increased\VBN\169651 in\IN\13603305 the\DT\1740 very\RB\1740 early\JJ\1740 phase\NN\15113229 of\IN\1740 the\DT\1740 experimental\JJ\1740 model\NN\5888929 of\IN\1740 PAN-induced\JJ\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 in\IN\13603305 rats\NNS\2329401 ,\,\1740 but\CC\1740 appears\VBZ\2604760 to\TO\1740 escape\VB\2075462 from\IN\1740 the\DT\1740 regulation\NN\6652242 by\IN\1740 <e1>aldosterone</e1>\NN\14751863 after\IN\1740 day\NN\15154774 3\CD\13741022 .\.\1740
3615541
D000661_D006948 CID Regional\JJ\1740 localization\NN\151497 of\IN\1740 the\DT\1740 antagonism\NN\24720 of\IN\1740 <e1>amphetamine-induced</e1>\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 by\IN\1740 intracerebral\JJ\1740 calcitonin\NN\5413241 injections\NNS\320852 .\.\1740
D002116_D006948 NONE Regional\JJ\1740 localization\NN\151497 of\IN\1740 the\DT\1740 antagonism\NN\24720 of\IN\1740 amphetamine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 by\IN\1740 intracerebral\JJ\1740 <e1>calcitonin</e1>\NN\5413241 injections\NNS\320852 .\.\1740
20084309
D008874_D020521 NONE Uni-\NN\1740 and\CC\1740 multivariate\NN\1740 analyses\NNS\633864 were\VBD\836236 used\VBN\1156834 to\TO\1740 test\VB\670261 the\DT\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 clinical\JJ\1740 variables\NNS\2452 :\:\1740 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 <e2>stroke</e2>\NN\556313 ,\,\1740 myocardiopathy\JJ\1740 (\-LRB-\1740 MP\NN\10249459 )\-RRB-\1740 ,\,\1740 duration\NN\15113229 of\IN\1740 the\DT\1740 test\NN\5798043 ,\,\1740 mitral\JJ\1740 regurgitation\NN\7406350 (\-LRB-\1740 MR\NN\6339416 )\-RRB-\1740 and\CC\1740 the\DT\1740 <e1>MZ</e1>\NN\1740 dose\NN\3740161 .\.\1740
D008874_D009202 NONE Uni-\NN\1740 and\CC\1740 multivariate\NN\1740 analyses\NNS\633864 were\VBD\836236 used\VBN\1156834 to\TO\1740 test\VB\670261 the\DT\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 clinical\JJ\1740 variables\NNS\2452 :\:\1740 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 stroke\NN\556313 ,\,\1740 <e2>myocardiopathy</e2>\JJ\1740 (\-LRB-\1740 MP\NN\10249459 )\-RRB-\1740 ,\,\1740 duration\NN\15113229 of\IN\1740 the\DT\1740 test\NN\5798043 ,\,\1740 mitral\JJ\1740 regurgitation\NN\7406350 (\-LRB-\1740 MR\NN\6339416 )\-RRB-\1740 and\CC\1740 the\DT\1740 <e1>MZ</e1>\NN\1740 dose\NN\3740161 .\.\1740
D008874_D009202 NONE Uni-\NN\1740 and\CC\1740 multivariate\NN\1740 analyses\NNS\633864 were\VBD\836236 used\VBN\1156834 to\TO\1740 test\VB\670261 the\DT\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 clinical\JJ\1740 variables\NNS\2452 :\:\1740 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 stroke\NN\556313 ,\,\1740 myocardiopathy\JJ\1740 (\-LRB-\1740 <e2>MP</e2>\NN\10249459 )\-RRB-\1740 ,\,\1740 duration\NN\15113229 of\IN\1740 the\DT\1740 test\NN\5798043 ,\,\1740 mitral\JJ\1740 regurgitation\NN\7406350 (\-LRB-\1740 MR\NN\6339416 )\-RRB-\1740 and\CC\1740 the\DT\1740 <e1>MZ</e1>\NN\1740 dose\NN\3740161 .\.\1740
D008874_D009202 NONE The\DT\1740 multivariate\NN\1740 analysis\NN\633864 showed\VBD\2137132 that\IN\1740 severe\JJ\1740 MR\NN\6339416 ,\,\1740 <e2>MP</e2>\NN\10249459 (\-LRB-\1740 EF<45\NN\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>MZ</e1>\NN\1740 (\-LRB-\1740 >\NNS\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 were\VBD\836236 associated\VBN\628491 with\IN\1740 events\NNS\23100 (\-LRB-\1740 p<0.001\NN\1740 )\-RRB-\1740 .\.\1740
D008874_D008944 NONE Uni-\NN\1740 and\CC\1740 multivariate\NN\1740 analyses\NNS\633864 were\VBD\836236 used\VBN\1156834 to\TO\1740 test\VB\670261 the\DT\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 clinical\JJ\1740 variables\NNS\2452 :\:\1740 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 stroke\NN\556313 ,\,\1740 myocardiopathy\JJ\1740 (\-LRB-\1740 MP\NN\10249459 )\-RRB-\1740 ,\,\1740 duration\NN\15113229 of\IN\1740 the\DT\1740 test\NN\5798043 ,\,\1740 <e2>mitral\JJ\1740 regurgitation</e2>\NN\7406350 (\-LRB-\1740 MR\NN\6339416 )\-RRB-\1740 and\CC\1740 the\DT\1740 <e1>MZ</e1>\NN\1740 dose\NN\3740161 .\.\1740
D008874_D008944 NONE Uni-\NN\1740 and\CC\1740 multivariate\NN\1740 analyses\NNS\633864 were\VBD\836236 used\VBN\1156834 to\TO\1740 test\VB\670261 the\DT\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 clinical\JJ\1740 variables\NNS\2452 :\:\1740 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 stroke\NN\556313 ,\,\1740 myocardiopathy\JJ\1740 (\-LRB-\1740 MP\NN\10249459 )\-RRB-\1740 ,\,\1740 duration\NN\15113229 of\IN\1740 the\DT\1740 test\NN\5798043 ,\,\1740 mitral\JJ\1740 regurgitation\NN\7406350 (\-LRB-\1740 <e2>MR</e2>\NN\6339416 )\-RRB-\1740 and\CC\1740 the\DT\1740 <e1>MZ</e1>\NN\1740 dose\NN\3740161 .\.\1740
D008874_D008944 NONE The\DT\1740 multivariate\NN\1740 analysis\NN\633864 showed\VBD\2137132 that\IN\1740 severe\JJ\1740 <e2>MR</e2>\NN\6339416 ,\,\1740 MP\NN\10249459 (\-LRB-\1740 EF<45\NN\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>MZ</e1>\NN\1740 (\-LRB-\1740 >\NNS\1740 5\CD\13741022 mg\NN\13717155 )\-RRB-\1740 were\VBD\836236 associated\VBN\628491 with\IN\1740 events\NNS\23100 (\-LRB-\1740 p<0.001\NN\1740 )\-RRB-\1740 .\.\1740
D008874_D000860 CID Mild\JJ\1740 <e2>hypoxia</e2>\NN\14035298 (\-LRB-\1740 SO2<90\NN\1740 %\NN\1740 )\-RRB-\1740 was\VBD\836236 the\DT\1740 most\RBS\1740 common\JJ\1740 event\NN\23100 (\-LRB-\1740 11\CD\13745420 patients\NNS\9898892 )\-RRB-\1740 ;\:\1740 3\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 2\CD\13741022 %\NN\1740 )\-RRB-\1740 presented\VBD\2137132 transient\JJ\1740 hypoxia\NN\14035298 due\IN\5174653 to\TO\1740 upper\JJ\1740 airway\NN\3253398 obstruction\NN\4341686 by\IN\1740 probe\NN\5797597 introduction\NN\235435 and\CC\1740 8\CD\13741022 (\-LRB-\1740 5.8\CD\1740 %\NN\1740 )\-RRB-\1740 due\JJ\1740 to\TO\1740 hypoxia\NN\14035298 caused\VBN\1617192 by\IN\1740 <e1>MZ</e1>\JJ\1740 use\NN\407535 .\.\1740
D008874_D000860 CID Mild\JJ\1740 hypoxia\NN\14035298 (\-LRB-\1740 SO2<90\NN\1740 %\NN\1740 )\-RRB-\1740 was\VBD\836236 the\DT\1740 most\RBS\1740 common\JJ\1740 event\NN\23100 (\-LRB-\1740 11\CD\13745420 patients\NNS\9898892 )\-RRB-\1740 ;\:\1740 3\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 2\CD\13741022 %\NN\1740 )\-RRB-\1740 presented\VBD\2137132 transient\JJ\1740 <e2>hypoxia</e2>\NN\14035298 due\IN\5174653 to\TO\1740 upper\JJ\1740 airway\NN\3253398 obstruction\NN\4341686 by\IN\1740 probe\NN\5797597 introduction\NN\235435 and\CC\1740 8\CD\13741022 (\-LRB-\1740 5.8\CD\1740 %\NN\1740 )\-RRB-\1740 due\JJ\1740 to\TO\1740 hypoxia\NN\14035298 caused\VBN\1617192 by\IN\1740 <e1>MZ</e1>\JJ\1740 use\NN\407535 .\.\1740
D008874_D000860 CID Mild\JJ\1740 hypoxia\NN\14035298 (\-LRB-\1740 SO2<90\NN\1740 %\NN\1740 )\-RRB-\1740 was\VBD\836236 the\DT\1740 most\RBS\1740 common\JJ\1740 event\NN\23100 (\-LRB-\1740 11\CD\13745420 patients\NNS\9898892 )\-RRB-\1740 ;\:\1740 3\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 2\CD\13741022 %\NN\1740 )\-RRB-\1740 presented\VBD\2137132 transient\JJ\1740 hypoxia\NN\14035298 due\IN\5174653 to\TO\1740 upper\JJ\1740 airway\NN\3253398 obstruction\NN\4341686 by\IN\1740 probe\NN\5797597 introduction\NN\235435 and\CC\1740 8\CD\13741022 (\-LRB-\1740 5.8\CD\1740 %\NN\1740 )\-RRB-\1740 due\JJ\1740 to\TO\1740 <e2>hypoxia</e2>\NN\14035298 caused\VBN\1617192 by\IN\1740 <e1>MZ</e1>\JJ\1740 use\NN\407535 .\.\1740
D008874_D000402 NONE Mild\JJ\1740 hypoxia\NN\14035298 (\-LRB-\1740 SO2<90\NN\1740 %\NN\1740 )\-RRB-\1740 was\VBD\836236 the\DT\1740 most\RBS\1740 common\JJ\1740 event\NN\23100 (\-LRB-\1740 11\CD\13745420 patients\NNS\9898892 )\-RRB-\1740 ;\:\1740 3\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 2\CD\13741022 %\NN\1740 )\-RRB-\1740 presented\VBD\2137132 transient\JJ\1740 hypoxia\NN\14035298 due\IN\5174653 to\TO\1740 upper\JJ\1740 <e2>airway\NN\3253398 obstruction</e2>\NN\4341686 by\IN\1740 probe\NN\5797597 introduction\NN\235435 and\CC\1740 8\CD\13741022 (\-LRB-\1740 5.8\CD\1740 %\NN\1740 )\-RRB-\1740 due\JJ\1740 to\TO\1740 hypoxia\NN\14035298 caused\VBN\1617192 by\IN\1740 <e1>MZ</e1>\JJ\1740 use\NN\407535 .\.\1740
1786266
D000928_D001480 NONE <e2>Rabbit\NN\2323902 syndrome</e2>\NN\5870365 ,\,\1740 <e1>antidepressant</e1>\JJ\1740 use\NN\407535 ,\,\1740 and\CC\1740 cerebral\JJ\1740 perfusion\NN\320852 SPECT\NN\1740 scan\JJ\1740 findings\NNS\7951464 .\.\1740
15325671
D003520_D066126 NONE <e2>Cardiac\JJ\1740 toxicity</e2>\NN\13576101 observed\VBN\2163746 in\IN\13603305 association\NN\8008335 with\IN\1740 high-dose\JJ\1740 <e1>cyclophosphamide-based</e1>\JJ\1740 chemotherapy\NN\661091 for\IN\1740 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 .\.\1740
D003520_D066126 NONE Incidence\NN\13821570 of\IN\1740 transient\JJ\1740 <e1>cyclophosphamide-related</e1>\JJ\1740 <e2>cardiac\JJ\1740 toxicity</e2>\NN\13576101 (\-LRB-\1740 10\CD\13745420 %\NN\1740 )\-RRB-\1740 is\VBZ\836236 comparable\JJ\1740 to\TO\1740 previous\JJ\1740 recorded\JJ\1740 literature\NN\6362953 .\.\1740
D003520_D001943 NONE Cardiac\JJ\1740 toxicity\NN\13576101 observed\VBN\2163746 in\IN\13603305 association\NN\8008335 with\IN\1740 high-dose\JJ\1740 <e1>cyclophosphamide-based</e1>\JJ\1740 chemotherapy\NN\661091 for\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 .\.\1740
D003520_D001943 NONE STUDY\NN\635850 DESIGN\NN\927261 :\:\1740 We\PRP\1740 combined\VBD\2630189 paclitaxel\NN\1740 ,\,\1740 melphalan\NN\2722458 and\CC\1740 high-dose\JJ\1740 <e1>cyclophosphamide</e1>\NN\1740 ,\,\1740 thiotepa\NN\2722458 ,\,\1740 and\CC\1740 carboplatin\NN\1740 in\IN\13603305 a\DT\13649268 triple\RB\1740 sequential\JJ\1740 high-dose\JJ\1740 regimen\NN\5898568 for\IN\1740 patients\NNS\9898892 with\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 .\.\1740
D003520_D001943 NONE Analysis\NN\633864 was\VBD\836236 performed\VBN\2367363 on\IN\1740 61\CD\1740 women\NNS\9605289 with\IN\1740 chemotherapy-responsive\JJ\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 receiving\VBG\2210855 96-h\JJ\1740 infusional\JJ\1740 <e1>cyclophosphamide</e1>\NN\1740 as\IN\14622893 part\NN\31921 of\IN\1740 a\DT\13649268 triple\RB\1740 sequential\JJ\1740 high-dose\JJ\1740 regimen\NN\5898568 to\TO\1740 assess\VB\670261 association\NN\8008335 between\IN\1740 presence\NN\13954253 of\IN\1740 peritransplant\JJ\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 (\-LRB-\1740 CHF\NN\1740 )\-RRB-\1740 and\CC\1740 the\DT\1740 following\VBG\1835496 pretreatment\NN\1740 characteristics\NNS\5849040 :\:\1740 presence\NN\13954253 of\IN\1740 electrocardiogram\NN\7000195 (\-LRB-\1740 EKG\NN\7000195 )\-RRB-\1740 abnormalities\NNS\14034177 ,\,\1740 age\NN\4916342 ,\,\1740 hypertension\NN\14057371 ,\,\1740 prior\JJ\1740 cardiac\JJ\1740 history\NN\15120823 ,\,\1740 smoking\NN\831191 ,\,\1740 diabetes\NN\14075199 mellitus\NN\1740 ,\,\1740 prior\JJ\1740 use\NN\407535 of\IN\1740 anthracyclines\NNS\1740 ,\,\1740 and\CC\1740 left-sided\JJ\1740 chest\NN\5220461 irradiation\NN\13920835 .\.\1740
D017239_D001943 NONE STUDY\NN\635850 DESIGN\NN\927261 :\:\1740 We\PRP\1740 combined\VBD\2630189 <e1>paclitaxel</e1>\NN\1740 ,\,\1740 melphalan\NN\2722458 and\CC\1740 high-dose\JJ\1740 cyclophosphamide\NN\1740 ,\,\1740 thiotepa\NN\2722458 ,\,\1740 and\CC\1740 carboplatin\NN\1740 in\IN\13603305 a\DT\13649268 triple\RB\1740 sequential\JJ\1740 high-dose\JJ\1740 regimen\NN\5898568 for\IN\1740 patients\NNS\9898892 with\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 .\.\1740
D008558_D001943 NONE STUDY\NN\635850 DESIGN\NN\927261 :\:\1740 We\PRP\1740 combined\VBD\2630189 paclitaxel\NN\1740 ,\,\1740 <e1>melphalan</e1>\NN\2722458 and\CC\1740 high-dose\JJ\1740 cyclophosphamide\NN\1740 ,\,\1740 thiotepa\NN\2722458 ,\,\1740 and\CC\1740 carboplatin\NN\1740 in\IN\13603305 a\DT\13649268 triple\RB\1740 sequential\JJ\1740 high-dose\JJ\1740 regimen\NN\5898568 for\IN\1740 patients\NNS\9898892 with\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 .\.\1740
D013852_D001943 NONE STUDY\NN\635850 DESIGN\NN\927261 :\:\1740 We\PRP\1740 combined\VBD\2630189 paclitaxel\NN\1740 ,\,\1740 melphalan\NN\2722458 and\CC\1740 high-dose\JJ\1740 cyclophosphamide\NN\1740 ,\,\1740 <e1>thiotepa</e1>\NN\2722458 ,\,\1740 and\CC\1740 carboplatin\NN\1740 in\IN\13603305 a\DT\13649268 triple\RB\1740 sequential\JJ\1740 high-dose\JJ\1740 regimen\NN\5898568 for\IN\1740 patients\NNS\9898892 with\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 .\.\1740
D016190_D001943 NONE STUDY\NN\635850 DESIGN\NN\927261 :\:\1740 We\PRP\1740 combined\VBD\2630189 paclitaxel\NN\1740 ,\,\1740 melphalan\NN\2722458 and\CC\1740 high-dose\JJ\1740 cyclophosphamide\NN\1740 ,\,\1740 thiotepa\NN\2722458 ,\,\1740 and\CC\1740 <e1>carboplatin</e1>\NN\1740 in\IN\13603305 a\DT\13649268 triple\RB\1740 sequential\JJ\1740 high-dose\JJ\1740 regimen\NN\5898568 for\IN\1740 patients\NNS\9898892 with\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 .\.\1740
D003520_D006333 CID Analysis\NN\633864 was\VBD\836236 performed\VBN\2367363 on\IN\1740 61\CD\1740 women\NNS\9605289 with\IN\1740 chemotherapy-responsive\JJ\1740 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 receiving\VBG\2210855 96-h\JJ\1740 infusional\JJ\1740 <e1>cyclophosphamide</e1>\NN\1740 as\IN\14622893 part\NN\31921 of\IN\1740 a\DT\13649268 triple\RB\1740 sequential\JJ\1740 high-dose\JJ\1740 regimen\NN\5898568 to\TO\1740 assess\VB\670261 association\NN\8008335 between\IN\1740 presence\NN\13954253 of\IN\1740 peritransplant\JJ\1740 <e2>congestive\JJ\1740 heart\NN\5919034 failure</e2>\NN\66216 (\-LRB-\1740 CHF\NN\1740 )\-RRB-\1740 and\CC\1740 the\DT\1740 following\VBG\1835496 pretreatment\NN\1740 characteristics\NNS\5849040 :\:\1740 presence\NN\13954253 of\IN\1740 electrocardiogram\NN\7000195 (\-LRB-\1740 EKG\NN\7000195 )\-RRB-\1740 abnormalities\NNS\14034177 ,\,\1740 age\NN\4916342 ,\,\1740 hypertension\NN\14057371 ,\,\1740 prior\JJ\1740 cardiac\JJ\1740 history\NN\15120823 ,\,\1740 smoking\NN\831191 ,\,\1740 diabetes\NN\14075199 mellitus\NN\1740 ,\,\1740 prior\JJ\1740 use\NN\407535 of\IN\1740 anthracyclines\NNS\1740 ,\,\1740 and\CC\1740 left-sided\JJ\1740 chest\NN\5220461 irradiation\NN\13920835 .\.\1740
D003520_D006333 CID Analysis\NN\633864 was\VBD\836236 performed\VBN\2367363 on\IN\1740 61\CD\1740 women\NNS\9605289 with\IN\1740 chemotherapy-responsive\JJ\1740 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 receiving\VBG\2210855 96-h\JJ\1740 infusional\JJ\1740 <e1>cyclophosphamide</e1>\NN\1740 as\IN\14622893 part\NN\31921 of\IN\1740 a\DT\13649268 triple\RB\1740 sequential\JJ\1740 high-dose\JJ\1740 regimen\NN\5898568 to\TO\1740 assess\VB\670261 association\NN\8008335 between\IN\1740 presence\NN\13954253 of\IN\1740 peritransplant\JJ\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 (\-LRB-\1740 <e2>CHF</e2>\NN\1740 )\-RRB-\1740 and\CC\1740 the\DT\1740 following\VBG\1835496 pretreatment\NN\1740 characteristics\NNS\5849040 :\:\1740 presence\NN\13954253 of\IN\1740 electrocardiogram\NN\7000195 (\-LRB-\1740 EKG\NN\7000195 )\-RRB-\1740 abnormalities\NNS\14034177 ,\,\1740 age\NN\4916342 ,\,\1740 hypertension\NN\14057371 ,\,\1740 prior\JJ\1740 cardiac\JJ\1740 history\NN\15120823 ,\,\1740 smoking\NN\831191 ,\,\1740 diabetes\NN\14075199 mellitus\NN\1740 ,\,\1740 prior\JJ\1740 use\NN\407535 of\IN\1740 anthracyclines\NNS\1740 ,\,\1740 and\CC\1740 left-sided\JJ\1740 chest\NN\5220461 irradiation\NN\13920835 .\.\1740
D003520_D006333 CID RESULTS\NNS\34213 :\:\1740 Six\CD\13741022 of\IN\1740 61\CD\1740 women\NNS\9605289 (\-LRB-\1740 10\CD\13745420 %\NN\1740 )\-RRB-\1740 developed\VBD\1753788 clinically\RB\1740 reversible\JJ\1740 grade\NN\7975026 3\CD\13741022 <e2>CHF</e2>\NN\1740 following\VBG\1835496 infusional\JJ\1740 <e1>cyclophosphamide</e1>\NN\1740 with\IN\1740 a\DT\13649268 median\JJ\1740 percent\NN\13815742 decline\NN\13458571 in\IN\13603305 ejection\NN\45250 fraction\NN\14806838 of\IN\1740 31\CD\1740 %\NN\1740 .\.\1740
D003520_D006333 CID Routine\JJ\1740 EKG\NN\7000195 monitoring\NN\879759 during\IN\1740 infusional\JJ\1740 <e1>cyclophosphamide</e1>\NN\1740 did\VBD\1640855 not\RB\1740 predict\VB\916909 <e2>CHF</e2>\NN\1740 development\NN\248977 .\.\1740
D003520_D006973 NONE Analysis\NN\633864 was\VBD\836236 performed\VBN\2367363 on\IN\1740 61\CD\1740 women\NNS\9605289 with\IN\1740 chemotherapy-responsive\JJ\1740 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 receiving\VBG\2210855 96-h\JJ\1740 infusional\JJ\1740 <e1>cyclophosphamide</e1>\NN\1740 as\IN\14622893 part\NN\31921 of\IN\1740 a\DT\13649268 triple\RB\1740 sequential\JJ\1740 high-dose\JJ\1740 regimen\NN\5898568 to\TO\1740 assess\VB\670261 association\NN\8008335 between\IN\1740 presence\NN\13954253 of\IN\1740 peritransplant\JJ\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 (\-LRB-\1740 CHF\NN\1740 )\-RRB-\1740 and\CC\1740 the\DT\1740 following\VBG\1835496 pretreatment\NN\1740 characteristics\NNS\5849040 :\:\1740 presence\NN\13954253 of\IN\1740 electrocardiogram\NN\7000195 (\-LRB-\1740 EKG\NN\7000195 )\-RRB-\1740 abnormalities\NNS\14034177 ,\,\1740 age\NN\4916342 ,\,\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 prior\JJ\1740 cardiac\JJ\1740 history\NN\15120823 ,\,\1740 smoking\NN\831191 ,\,\1740 diabetes\NN\14075199 mellitus\NN\1740 ,\,\1740 prior\JJ\1740 use\NN\407535 of\IN\1740 anthracyclines\NNS\1740 ,\,\1740 and\CC\1740 left-sided\JJ\1740 chest\NN\5220461 irradiation\NN\13920835 .\.\1740
D003520_D003920 NONE Analysis\NN\633864 was\VBD\836236 performed\VBN\2367363 on\IN\1740 61\CD\1740 women\NNS\9605289 with\IN\1740 chemotherapy-responsive\JJ\1740 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 receiving\VBG\2210855 96-h\JJ\1740 infusional\JJ\1740 <e1>cyclophosphamide</e1>\NN\1740 as\IN\14622893 part\NN\31921 of\IN\1740 a\DT\13649268 triple\RB\1740 sequential\JJ\1740 high-dose\JJ\1740 regimen\NN\5898568 to\TO\1740 assess\VB\670261 association\NN\8008335 between\IN\1740 presence\NN\13954253 of\IN\1740 peritransplant\JJ\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 (\-LRB-\1740 CHF\NN\1740 )\-RRB-\1740 and\CC\1740 the\DT\1740 following\VBG\1835496 pretreatment\NN\1740 characteristics\NNS\5849040 :\:\1740 presence\NN\13954253 of\IN\1740 electrocardiogram\NN\7000195 (\-LRB-\1740 EKG\NN\7000195 )\-RRB-\1740 abnormalities\NNS\14034177 ,\,\1740 age\NN\4916342 ,\,\1740 hypertension\NN\14057371 ,\,\1740 prior\JJ\1740 cardiac\JJ\1740 history\NN\15120823 ,\,\1740 smoking\NN\831191 ,\,\1740 <e2>diabetes\NN\14075199 mellitus</e2>\NN\1740 ,\,\1740 prior\JJ\1740 use\NN\407535 of\IN\1740 anthracyclines\NNS\1740 ,\,\1740 and\CC\1740 left-sided\JJ\1740 chest\NN\5220461 irradiation\NN\13920835 .\.\1740
D018943_D001943 NONE Analysis\NN\633864 was\VBD\836236 performed\VBN\2367363 on\IN\1740 61\CD\1740 women\NNS\9605289 with\IN\1740 chemotherapy-responsive\JJ\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 receiving\VBG\2210855 96-h\JJ\1740 infusional\JJ\1740 cyclophosphamide\NN\1740 as\IN\14622893 part\NN\31921 of\IN\1740 a\DT\13649268 triple\RB\1740 sequential\JJ\1740 high-dose\JJ\1740 regimen\NN\5898568 to\TO\1740 assess\VB\670261 association\NN\8008335 between\IN\1740 presence\NN\13954253 of\IN\1740 peritransplant\JJ\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 (\-LRB-\1740 CHF\NN\1740 )\-RRB-\1740 and\CC\1740 the\DT\1740 following\VBG\1835496 pretreatment\NN\1740 characteristics\NNS\5849040 :\:\1740 presence\NN\13954253 of\IN\1740 electrocardiogram\NN\7000195 (\-LRB-\1740 EKG\NN\7000195 )\-RRB-\1740 abnormalities\NNS\14034177 ,\,\1740 age\NN\4916342 ,\,\1740 hypertension\NN\14057371 ,\,\1740 prior\JJ\1740 cardiac\JJ\1740 history\NN\15120823 ,\,\1740 smoking\NN\831191 ,\,\1740 diabetes\NN\14075199 mellitus\NN\1740 ,\,\1740 prior\JJ\1740 use\NN\407535 of\IN\1740 <e1>anthracyclines</e1>\NNS\1740 ,\,\1740 and\CC\1740 left-sided\JJ\1740 chest\NN\5220461 irradiation\NN\13920835 .\.\1740
D018943_D006333 NONE Analysis\NN\633864 was\VBD\836236 performed\VBN\2367363 on\IN\1740 61\CD\1740 women\NNS\9605289 with\IN\1740 chemotherapy-responsive\JJ\1740 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 receiving\VBG\2210855 96-h\JJ\1740 infusional\JJ\1740 cyclophosphamide\NN\1740 as\IN\14622893 part\NN\31921 of\IN\1740 a\DT\13649268 triple\RB\1740 sequential\JJ\1740 high-dose\JJ\1740 regimen\NN\5898568 to\TO\1740 assess\VB\670261 association\NN\8008335 between\IN\1740 presence\NN\13954253 of\IN\1740 peritransplant\JJ\1740 <e2>congestive\JJ\1740 heart\NN\5919034 failure</e2>\NN\66216 (\-LRB-\1740 CHF\NN\1740 )\-RRB-\1740 and\CC\1740 the\DT\1740 following\VBG\1835496 pretreatment\NN\1740 characteristics\NNS\5849040 :\:\1740 presence\NN\13954253 of\IN\1740 electrocardiogram\NN\7000195 (\-LRB-\1740 EKG\NN\7000195 )\-RRB-\1740 abnormalities\NNS\14034177 ,\,\1740 age\NN\4916342 ,\,\1740 hypertension\NN\14057371 ,\,\1740 prior\JJ\1740 cardiac\JJ\1740 history\NN\15120823 ,\,\1740 smoking\NN\831191 ,\,\1740 diabetes\NN\14075199 mellitus\NN\1740 ,\,\1740 prior\JJ\1740 use\NN\407535 of\IN\1740 <e1>anthracyclines</e1>\NNS\1740 ,\,\1740 and\CC\1740 left-sided\JJ\1740 chest\NN\5220461 irradiation\NN\13920835 .\.\1740
D018943_D006333 NONE Analysis\NN\633864 was\VBD\836236 performed\VBN\2367363 on\IN\1740 61\CD\1740 women\NNS\9605289 with\IN\1740 chemotherapy-responsive\JJ\1740 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 receiving\VBG\2210855 96-h\JJ\1740 infusional\JJ\1740 cyclophosphamide\NN\1740 as\IN\14622893 part\NN\31921 of\IN\1740 a\DT\13649268 triple\RB\1740 sequential\JJ\1740 high-dose\JJ\1740 regimen\NN\5898568 to\TO\1740 assess\VB\670261 association\NN\8008335 between\IN\1740 presence\NN\13954253 of\IN\1740 peritransplant\JJ\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 (\-LRB-\1740 <e2>CHF</e2>\NN\1740 )\-RRB-\1740 and\CC\1740 the\DT\1740 following\VBG\1835496 pretreatment\NN\1740 characteristics\NNS\5849040 :\:\1740 presence\NN\13954253 of\IN\1740 electrocardiogram\NN\7000195 (\-LRB-\1740 EKG\NN\7000195 )\-RRB-\1740 abnormalities\NNS\14034177 ,\,\1740 age\NN\4916342 ,\,\1740 hypertension\NN\14057371 ,\,\1740 prior\JJ\1740 cardiac\JJ\1740 history\NN\15120823 ,\,\1740 smoking\NN\831191 ,\,\1740 diabetes\NN\14075199 mellitus\NN\1740 ,\,\1740 prior\JJ\1740 use\NN\407535 of\IN\1740 <e1>anthracyclines</e1>\NNS\1740 ,\,\1740 and\CC\1740 left-sided\JJ\1740 chest\NN\5220461 irradiation\NN\13920835 .\.\1740
D018943_D006973 NONE Analysis\NN\633864 was\VBD\836236 performed\VBN\2367363 on\IN\1740 61\CD\1740 women\NNS\9605289 with\IN\1740 chemotherapy-responsive\JJ\1740 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 receiving\VBG\2210855 96-h\JJ\1740 infusional\JJ\1740 cyclophosphamide\NN\1740 as\IN\14622893 part\NN\31921 of\IN\1740 a\DT\13649268 triple\RB\1740 sequential\JJ\1740 high-dose\JJ\1740 regimen\NN\5898568 to\TO\1740 assess\VB\670261 association\NN\8008335 between\IN\1740 presence\NN\13954253 of\IN\1740 peritransplant\JJ\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 (\-LRB-\1740 CHF\NN\1740 )\-RRB-\1740 and\CC\1740 the\DT\1740 following\VBG\1835496 pretreatment\NN\1740 characteristics\NNS\5849040 :\:\1740 presence\NN\13954253 of\IN\1740 electrocardiogram\NN\7000195 (\-LRB-\1740 EKG\NN\7000195 )\-RRB-\1740 abnormalities\NNS\14034177 ,\,\1740 age\NN\4916342 ,\,\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 prior\JJ\1740 cardiac\JJ\1740 history\NN\15120823 ,\,\1740 smoking\NN\831191 ,\,\1740 diabetes\NN\14075199 mellitus\NN\1740 ,\,\1740 prior\JJ\1740 use\NN\407535 of\IN\1740 <e1>anthracyclines</e1>\NNS\1740 ,\,\1740 and\CC\1740 left-sided\JJ\1740 chest\NN\5220461 irradiation\NN\13920835 .\.\1740
D018943_D003920 NONE Analysis\NN\633864 was\VBD\836236 performed\VBN\2367363 on\IN\1740 61\CD\1740 women\NNS\9605289 with\IN\1740 chemotherapy-responsive\JJ\1740 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 receiving\VBG\2210855 96-h\JJ\1740 infusional\JJ\1740 cyclophosphamide\NN\1740 as\IN\14622893 part\NN\31921 of\IN\1740 a\DT\13649268 triple\RB\1740 sequential\JJ\1740 high-dose\JJ\1740 regimen\NN\5898568 to\TO\1740 assess\VB\670261 association\NN\8008335 between\IN\1740 presence\NN\13954253 of\IN\1740 peritransplant\JJ\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 (\-LRB-\1740 CHF\NN\1740 )\-RRB-\1740 and\CC\1740 the\DT\1740 following\VBG\1835496 pretreatment\NN\1740 characteristics\NNS\5849040 :\:\1740 presence\NN\13954253 of\IN\1740 electrocardiogram\NN\7000195 (\-LRB-\1740 EKG\NN\7000195 )\-RRB-\1740 abnormalities\NNS\14034177 ,\,\1740 age\NN\4916342 ,\,\1740 hypertension\NN\14057371 ,\,\1740 prior\JJ\1740 cardiac\JJ\1740 history\NN\15120823 ,\,\1740 smoking\NN\831191 ,\,\1740 <e2>diabetes\NN\14075199 mellitus</e2>\NN\1740 ,\,\1740 prior\JJ\1740 use\NN\407535 of\IN\1740 <e1>anthracyclines</e1>\NNS\1740 ,\,\1740 and\CC\1740 left-sided\JJ\1740 chest\NN\5220461 irradiation\NN\13920835 .\.\1740
2802551
D012964_D007674 NONE <e1>Sodium</e1>\NN\14625458 status\NN\24720 influences\VBZ\137313 chronic\JJ\1740 amphotericin\NN\2716866 B\NN\1355326 <e2>nephrotoxicity</e2>\NN\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D000666_D007674 CID Sodium\NN\14625458 status\NN\24720 influences\VBZ\137313 chronic\JJ\1740 <e1>amphotericin\NN\2716866 B</e1>\NN\1355326 <e2>nephrotoxicity</e2>\NN\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D000666_D007674 CID The\DT\1740 <e2>nephrotoxic</e2>\JJ\1740 potential\NN\14481929 of\IN\1740 <e1>amphotericin\NN\2716866 B</e1>\NN\1355326 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 per\IN\1740 day\NN\15154774 intraperitoneally\RB\1740 for\IN\1740 3\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 investigated\VBN\644583 in\IN\13603305 salt-depleted\JJ\1740 ,\,\1740 normal-salt\JJ\1740 ,\,\1740 and\CC\1740 salt-loaded\JJ\1740 rats\NNS\2329401 .\.\1740
2505783
C004656_D006470 CID Based\VBN\2694933 on\IN\1740 clinical\JJ\1740 data\NNS\7951464 ,\,\1740 indicating\VBG\952524 that\IN\1740 <e1>chloroacetaldehyde</e1>\NN\1740 (\-LRB-\1740 CAA\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 important\JJ\1740 metabolite\NN\20090 of\IN\1740 oxazaphosphorine\NN\1740 cytostatics\NNS\1740 ,\,\1740 an\DT\6697703 experimental\JJ\1740 study\NN\635850 was\VBD\836236 carried\VBN\1850315 out\RP\1740 in\IN\13603305 order\NN\7168131 to\TO\1740 elucidate\VB\939277 the\DT\1740 role\NN\719494 of\IN\1740 CAA\NN\1740 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
C004656_D006470 CID Based\VBN\2694933 on\IN\1740 clinical\JJ\1740 data\NNS\7951464 ,\,\1740 indicating\VBG\952524 that\IN\1740 chloroacetaldehyde\NN\1740 (\-LRB-\1740 <e1>CAA</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 important\JJ\1740 metabolite\NN\20090 of\IN\1740 oxazaphosphorine\NN\1740 cytostatics\NNS\1740 ,\,\1740 an\DT\6697703 experimental\JJ\1740 study\NN\635850 was\VBD\836236 carried\VBN\1850315 out\RP\1740 in\IN\13603305 order\NN\7168131 to\TO\1740 elucidate\VB\939277 the\DT\1740 role\NN\719494 of\IN\1740 CAA\NN\1740 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
C004656_D006470 CID Based\VBN\2694933 on\IN\1740 clinical\JJ\1740 data\NNS\7951464 ,\,\1740 indicating\VBG\952524 that\IN\1740 chloroacetaldehyde\NN\1740 (\-LRB-\1740 CAA\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 important\JJ\1740 metabolite\NN\20090 of\IN\1740 oxazaphosphorine\NN\1740 cytostatics\NNS\1740 ,\,\1740 an\DT\6697703 experimental\JJ\1740 study\NN\635850 was\VBD\836236 carried\VBN\1850315 out\RP\1740 in\IN\13603305 order\NN\7168131 to\TO\1740 elucidate\VB\939277 the\DT\1740 role\NN\719494 of\IN\1740 <e1>CAA</e1>\NN\1740 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
C004656_D003556 CID Based\VBN\2694933 on\IN\1740 clinical\JJ\1740 data\NNS\7951464 ,\,\1740 indicating\VBG\952524 that\IN\1740 <e1>chloroacetaldehyde</e1>\NN\1740 (\-LRB-\1740 CAA\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 important\JJ\1740 metabolite\NN\20090 of\IN\1740 oxazaphosphorine\NN\1740 cytostatics\NNS\1740 ,\,\1740 an\DT\6697703 experimental\JJ\1740 study\NN\635850 was\VBD\836236 carried\VBN\1850315 out\RP\1740 in\IN\13603305 order\NN\7168131 to\TO\1740 elucidate\VB\939277 the\DT\1740 role\NN\719494 of\IN\1740 CAA\NN\1740 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
C004656_D003556 CID Based\VBN\2694933 on\IN\1740 clinical\JJ\1740 data\NNS\7951464 ,\,\1740 indicating\VBG\952524 that\IN\1740 chloroacetaldehyde\NN\1740 (\-LRB-\1740 <e1>CAA</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 important\JJ\1740 metabolite\NN\20090 of\IN\1740 oxazaphosphorine\NN\1740 cytostatics\NNS\1740 ,\,\1740 an\DT\6697703 experimental\JJ\1740 study\NN\635850 was\VBD\836236 carried\VBN\1850315 out\RP\1740 in\IN\13603305 order\NN\7168131 to\TO\1740 elucidate\VB\939277 the\DT\1740 role\NN\719494 of\IN\1740 CAA\NN\1740 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
C004656_D003556 CID Based\VBN\2694933 on\IN\1740 clinical\JJ\1740 data\NNS\7951464 ,\,\1740 indicating\VBG\952524 that\IN\1740 chloroacetaldehyde\NN\1740 (\-LRB-\1740 CAA\NN\1740 )\-RRB-\1740 is\VBZ\836236 an\DT\6697703 important\JJ\1740 metabolite\NN\20090 of\IN\1740 oxazaphosphorine\NN\1740 cytostatics\NNS\1740 ,\,\1740 an\DT\6697703 experimental\JJ\1740 study\NN\635850 was\VBD\836236 carried\VBN\1850315 out\RP\1740 in\IN\13603305 order\NN\7168131 to\TO\1740 elucidate\VB\939277 the\DT\1740 role\NN\719494 of\IN\1740 <e1>CAA</e1>\NN\1740 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
C004656_D001745 NONE The\DT\1740 data\NNS\7951464 demonstrate\VBP\2137132 that\IN\1740 <e1>CAA</e1>\NNP\1740 after\IN\1740 i.v.\NN\1740 administration\NN\1133281 does\VBZ\1640855 not\RB\1740 contribute\VB\126264 to\TO\1740 <e2>bladder\NN\5515670 damage</e2>\NN\7296428 .\.\1740
11532387
D018967_D013375 CID <e2>Withdrawal-emergent\JJ\1740 rabbit\NN\2323902 syndrome</e2>\NN\5870365 during\IN\1740 dose\NN\3740161 reduction\NN\351485 of\IN\1740 <e1>risperidone</e1>\NN\1740 .\.\1740
D018967_D013375 CID The\DT\1740 underlying\VBG\2604760 mechanism\NN\13446390 of\IN\1740 <e2>withdrawal-emergent\JJ\1740 RS</e2>\NN\13635336 in\IN\13603305 the\DT\1740 present\JJ\1740 case\NN\7283608 may\MD\15209706 have\VB\2108377 been\VBN\836236 related\JJ\1740 to\TO\1740 the\DT\1740 pharmacological\JJ\1740 profile\NN\6999802 of\IN\1740 <e1>risperidone</e1>\NN\1740 ,\,\1740 a\DT\13649268 serotonin-dopamine\JJ\1740 antagonist\NN\7846 ,\,\1740 suggesting\VBG\1010118 the\DT\1740 pathophysiologic\JJ\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 serotonin\NN\14807737 system\NN\3575240 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 RS\NN\13635336 .\.\1740
D018967_D001480 CID <e2>Withdrawal-emergent\JJ\1740 rabbit\NN\2323902 syndrome</e2>\NN\5870365 during\IN\1740 dose\NN\3740161 reduction\NN\351485 of\IN\1740 <e1>risperidone</e1>\NN\1740 .\.\1740
D018967_D001480 CID The\DT\1740 patient\NN\9898892 developed\VBD\1753788 <e2>RS</e2>\NN\13635336 during\IN\1740 dose\NN\3740161 reduction\NN\351485 of\IN\1740 <e1>risperidone</e1>\NN\1740 .\.\1740
D018967_D001480 CID The\DT\1740 underlying\VBG\2604760 mechanism\NN\13446390 of\IN\1740 <e2>withdrawal-emergent\JJ\1740 RS</e2>\NN\13635336 in\IN\13603305 the\DT\1740 present\JJ\1740 case\NN\7283608 may\MD\15209706 have\VB\2108377 been\VBN\836236 related\JJ\1740 to\TO\1740 the\DT\1740 pharmacological\JJ\1740 profile\NN\6999802 of\IN\1740 <e1>risperidone</e1>\NN\1740 ,\,\1740 a\DT\13649268 serotonin-dopamine\JJ\1740 antagonist\NN\7846 ,\,\1740 suggesting\VBG\1010118 the\DT\1740 pathophysiologic\JJ\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 serotonin\NN\14807737 system\NN\3575240 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 RS\NN\13635336 .\.\1740
D018967_D001480 CID The\DT\1740 underlying\VBG\2604760 mechanism\NN\13446390 of\IN\1740 withdrawal-emergent\JJ\1740 RS\NN\13635336 in\IN\13603305 the\DT\1740 present\JJ\1740 case\NN\7283608 may\MD\15209706 have\VB\2108377 been\VBN\836236 related\JJ\1740 to\TO\1740 the\DT\1740 pharmacological\JJ\1740 profile\NN\6999802 of\IN\1740 <e1>risperidone</e1>\NN\1740 ,\,\1740 a\DT\13649268 serotonin-dopamine\JJ\1740 antagonist\NN\7846 ,\,\1740 suggesting\VBG\1010118 the\DT\1740 pathophysiologic\JJ\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 serotonin\NN\14807737 system\NN\3575240 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>RS</e2>\NN\13635336 .\.\1740
D012701_D013375 NONE The\DT\1740 underlying\VBG\2604760 mechanism\NN\13446390 of\IN\1740 <e2>withdrawal-emergent\JJ\1740 RS</e2>\NN\13635336 in\IN\13603305 the\DT\1740 present\JJ\1740 case\NN\7283608 may\MD\15209706 have\VB\2108377 been\VBN\836236 related\JJ\1740 to\TO\1740 the\DT\1740 pharmacological\JJ\1740 profile\NN\6999802 of\IN\1740 risperidone\NN\1740 ,\,\1740 a\DT\13649268 <e1>serotonin-dopamine</e1>\JJ\1740 antagonist\NN\7846 ,\,\1740 suggesting\VBG\1010118 the\DT\1740 pathophysiologic\JJ\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 serotonin\NN\14807737 system\NN\3575240 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 RS\NN\13635336 .\.\1740
D012701_D013375 NONE The\DT\1740 underlying\VBG\2604760 mechanism\NN\13446390 of\IN\1740 <e2>withdrawal-emergent\JJ\1740 RS</e2>\NN\13635336 in\IN\13603305 the\DT\1740 present\JJ\1740 case\NN\7283608 may\MD\15209706 have\VB\2108377 been\VBN\836236 related\JJ\1740 to\TO\1740 the\DT\1740 pharmacological\JJ\1740 profile\NN\6999802 of\IN\1740 risperidone\NN\1740 ,\,\1740 a\DT\13649268 serotonin-dopamine\JJ\1740 antagonist\NN\7846 ,\,\1740 suggesting\VBG\1010118 the\DT\1740 pathophysiologic\JJ\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 <e1>serotonin</e1>\NN\14807737 system\NN\3575240 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 RS\NN\13635336 .\.\1740
D012701_D001480 NONE The\DT\1740 underlying\VBG\2604760 mechanism\NN\13446390 of\IN\1740 <e2>withdrawal-emergent\JJ\1740 RS</e2>\NN\13635336 in\IN\13603305 the\DT\1740 present\JJ\1740 case\NN\7283608 may\MD\15209706 have\VB\2108377 been\VBN\836236 related\JJ\1740 to\TO\1740 the\DT\1740 pharmacological\JJ\1740 profile\NN\6999802 of\IN\1740 risperidone\NN\1740 ,\,\1740 a\DT\13649268 <e1>serotonin-dopamine</e1>\JJ\1740 antagonist\NN\7846 ,\,\1740 suggesting\VBG\1010118 the\DT\1740 pathophysiologic\JJ\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 serotonin\NN\14807737 system\NN\3575240 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 RS\NN\13635336 .\.\1740
D012701_D001480 NONE The\DT\1740 underlying\VBG\2604760 mechanism\NN\13446390 of\IN\1740 withdrawal-emergent\JJ\1740 RS\NN\13635336 in\IN\13603305 the\DT\1740 present\JJ\1740 case\NN\7283608 may\MD\15209706 have\VB\2108377 been\VBN\836236 related\JJ\1740 to\TO\1740 the\DT\1740 pharmacological\JJ\1740 profile\NN\6999802 of\IN\1740 risperidone\NN\1740 ,\,\1740 a\DT\13649268 <e1>serotonin-dopamine</e1>\JJ\1740 antagonist\NN\7846 ,\,\1740 suggesting\VBG\1010118 the\DT\1740 pathophysiologic\JJ\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 serotonin\NN\14807737 system\NN\3575240 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>RS</e2>\NN\13635336 .\.\1740
D012701_D001480 NONE The\DT\1740 underlying\VBG\2604760 mechanism\NN\13446390 of\IN\1740 <e2>withdrawal-emergent\JJ\1740 RS</e2>\NN\13635336 in\IN\13603305 the\DT\1740 present\JJ\1740 case\NN\7283608 may\MD\15209706 have\VB\2108377 been\VBN\836236 related\JJ\1740 to\TO\1740 the\DT\1740 pharmacological\JJ\1740 profile\NN\6999802 of\IN\1740 risperidone\NN\1740 ,\,\1740 a\DT\13649268 serotonin-dopamine\JJ\1740 antagonist\NN\7846 ,\,\1740 suggesting\VBG\1010118 the\DT\1740 pathophysiologic\JJ\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 <e1>serotonin</e1>\NN\14807737 system\NN\3575240 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 RS\NN\13635336 .\.\1740
D012701_D001480 NONE The\DT\1740 underlying\VBG\2604760 mechanism\NN\13446390 of\IN\1740 withdrawal-emergent\JJ\1740 RS\NN\13635336 in\IN\13603305 the\DT\1740 present\JJ\1740 case\NN\7283608 may\MD\15209706 have\VB\2108377 been\VBN\836236 related\JJ\1740 to\TO\1740 the\DT\1740 pharmacological\JJ\1740 profile\NN\6999802 of\IN\1740 risperidone\NN\1740 ,\,\1740 a\DT\13649268 serotonin-dopamine\JJ\1740 antagonist\NN\7846 ,\,\1740 suggesting\VBG\1010118 the\DT\1740 pathophysiologic\JJ\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 <e1>serotonin</e1>\NN\14807737 system\NN\3575240 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>RS</e2>\NN\13635336 .\.\1740
D004298_D013375 NONE The\DT\1740 underlying\VBG\2604760 mechanism\NN\13446390 of\IN\1740 <e2>withdrawal-emergent\JJ\1740 RS</e2>\NN\13635336 in\IN\13603305 the\DT\1740 present\JJ\1740 case\NN\7283608 may\MD\15209706 have\VB\2108377 been\VBN\836236 related\JJ\1740 to\TO\1740 the\DT\1740 pharmacological\JJ\1740 profile\NN\6999802 of\IN\1740 risperidone\NN\1740 ,\,\1740 a\DT\13649268 <e1>serotonin-dopamine</e1>\JJ\1740 antagonist\NN\7846 ,\,\1740 suggesting\VBG\1010118 the\DT\1740 pathophysiologic\JJ\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 serotonin\NN\14807737 system\NN\3575240 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 RS\NN\13635336 .\.\1740
D004298_D001480 NONE The\DT\1740 underlying\VBG\2604760 mechanism\NN\13446390 of\IN\1740 <e2>withdrawal-emergent\JJ\1740 RS</e2>\NN\13635336 in\IN\13603305 the\DT\1740 present\JJ\1740 case\NN\7283608 may\MD\15209706 have\VB\2108377 been\VBN\836236 related\JJ\1740 to\TO\1740 the\DT\1740 pharmacological\JJ\1740 profile\NN\6999802 of\IN\1740 risperidone\NN\1740 ,\,\1740 a\DT\13649268 <e1>serotonin-dopamine</e1>\JJ\1740 antagonist\NN\7846 ,\,\1740 suggesting\VBG\1010118 the\DT\1740 pathophysiologic\JJ\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 serotonin\NN\14807737 system\NN\3575240 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 RS\NN\13635336 .\.\1740
D004298_D001480 NONE The\DT\1740 underlying\VBG\2604760 mechanism\NN\13446390 of\IN\1740 withdrawal-emergent\JJ\1740 RS\NN\13635336 in\IN\13603305 the\DT\1740 present\JJ\1740 case\NN\7283608 may\MD\15209706 have\VB\2108377 been\VBN\836236 related\JJ\1740 to\TO\1740 the\DT\1740 pharmacological\JJ\1740 profile\NN\6999802 of\IN\1740 risperidone\NN\1740 ,\,\1740 a\DT\13649268 <e1>serotonin-dopamine</e1>\JJ\1740 antagonist\NN\7846 ,\,\1740 suggesting\VBG\1010118 the\DT\1740 pathophysiologic\JJ\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 serotonin\NN\14807737 system\NN\3575240 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>RS</e2>\NN\13635336 .\.\1740
7420681
D014031_D007674 NONE Clinical\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 of\IN\1740 <e1>tobramycin</e1>\NN\2716866 and\CC\1740 gentamicin\NN\2716866 .\.\1740
D014031_D007674 NONE Gentamicin\NN\2716866 sulfate\NN\15010703 and\CC\1740 <e1>tobramycin\NN\2716866 sulfate</e1>\NN\15010703 continue\VBP\2367363 to\TO\1740 demonstrate\VB\2137132 ototoxicity\NN\1740 and\CC\1740 <e2>nephrotoxicity</e2>\NN\1740 in\IN\13603305 both\CC\1740 animal\NN\4475 and\CC\1740 clinical\JJ\1740 studies\NNS\635850 .\.\1740
D005839_D007674 NONE Clinical\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 of\IN\1740 tobramycin\NN\2716866 and\CC\1740 <e1>gentamicin</e1>\NN\2716866 .\.\1740
D005839_D007674 NONE <e1>Gentamicin\NN\2716866 sulfate</e1>\NN\15010703 and\CC\1740 tobramycin\NN\2716866 sulfate\NN\15010703 continue\VBP\2367363 to\TO\1740 demonstrate\VB\2137132 ototoxicity\NN\1740 and\CC\1740 <e2>nephrotoxicity</e2>\NN\1740 in\IN\13603305 both\CC\1740 animal\NN\4475 and\CC\1740 clinical\JJ\1740 studies\NNS\635850 .\.\1740
D005839_D006311 NONE <e1>Gentamicin\NN\2716866 sulfate</e1>\NN\15010703 and\CC\1740 tobramycin\NN\2716866 sulfate\NN\15010703 continue\VBP\2367363 to\TO\1740 demonstrate\VB\2137132 <e2>ototoxicity</e2>\NN\1740 and\CC\1740 nephrotoxicity\NN\1740 in\IN\13603305 both\CC\1740 animal\NN\4475 and\CC\1740 clinical\JJ\1740 studies\NNS\635850 .\.\1740
D014031_D006311 NONE Gentamicin\NN\2716866 sulfate\NN\15010703 and\CC\1740 <e1>tobramycin\NN\2716866 sulfate</e1>\NN\15010703 continue\VBP\2367363 to\TO\1740 demonstrate\VB\2137132 <e2>ototoxicity</e2>\NN\1740 and\CC\1740 nephrotoxicity\NN\1740 in\IN\13603305 both\CC\1740 animal\NN\4475 and\CC\1740 clinical\JJ\1740 studies\NNS\635850 .\.\1740
D005839_D051437 CID In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 62\CD\1740 patients\NNS\9898892 with\IN\1740 confirmed\VBN\1011725 initial\JJ\1740 normal\JJ\1740 renal\JJ\1740 function\NN\13783581 and\CC\1740 treated\VBN\2376958 with\IN\1740 2\CD\13741022 to\TO\1740 5\CD\13741022 mg/kg/day\NN\1740 of\IN\1740 <e1>gentamicin\NN\2716866 sulfate</e1>\NN\15010703 or\CC\3541091 tobramycin\NN\2716866 sulfate\NN\15010703 for\IN\1740 a\DT\13649268 minimum\NN\13653902 of\IN\1740 seven\CD\13741022 days\NNS\15140892 were\VBD\836236 followed\VBN\1835496 up\RP\1740 prospectively\RB\1740 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 aminoglycoside-related\JJ\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 ,\,\1740 defined\VBN\2604760 as\IN\14622893 at\IN\14622893 least\JJS\1740 a\DT\13649268 one-third\JJ\1740 reduction\NN\351485 in\IN\13603305 renal\JJ\1740 function\NN\13783581 .\.\1740
D005839_D051437 CID Five\CD\13741022 of\IN\1740 33\CD\1740 (\-LRB-\1740 15\CD\13745420 %\NN\1740 )\-RRB-\1740 of\IN\1740 the\DT\1740 tobramycin-treated\JJ\1740 patients\NNS\9898892 and\CC\1740 16\CD\13745420 of\IN\1740 29\CD\13745420 (\-LRB-\1740 55.2\CD\1740 %\NN\1740 )\-RRB-\1740 of\IN\1740 the\DT\1740 <e1>gentamicin-treated</e1>\JJ\1740 patients\NNS\9898892 had\VBD\2108377 <e2>renal\JJ\1740 failure</e2>\NN\66216 .\.\1740
D005839_D051437 CID Thus\RB\1740 ,\,\1740 <e1>gentamicin</e1>\NN\2716866 was\VBD\836236 associated\VBN\628491 with\IN\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 more\JJR\1740 than\IN\1740 three\CD\13741022 times\NNS\15113229 as\RB\1740 often\RB\1740 as\IN\14622893 was\VBD\836236 tobramycin\NN\2716866 .\.\1740
D014031_D051437 CID In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 62\CD\1740 patients\NNS\9898892 with\IN\1740 confirmed\VBN\1011725 initial\JJ\1740 normal\JJ\1740 renal\JJ\1740 function\NN\13783581 and\CC\1740 treated\VBN\2376958 with\IN\1740 2\CD\13741022 to\TO\1740 5\CD\13741022 mg/kg/day\NN\1740 of\IN\1740 gentamicin\NN\2716866 sulfate\NN\15010703 or\CC\3541091 <e1>tobramycin\NN\2716866 sulfate</e1>\NN\15010703 for\IN\1740 a\DT\13649268 minimum\NN\13653902 of\IN\1740 seven\CD\13741022 days\NNS\15140892 were\VBD\836236 followed\VBN\1835496 up\RP\1740 prospectively\RB\1740 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 aminoglycoside-related\JJ\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 ,\,\1740 defined\VBN\2604760 as\IN\14622893 at\IN\14622893 least\JJS\1740 a\DT\13649268 one-third\JJ\1740 reduction\NN\351485 in\IN\13603305 renal\JJ\1740 function\NN\13783581 .\.\1740
D014031_D051437 CID Five\CD\13741022 of\IN\1740 33\CD\1740 (\-LRB-\1740 15\CD\13745420 %\NN\1740 )\-RRB-\1740 of\IN\1740 the\DT\1740 <e1>tobramycin-treated</e1>\JJ\1740 patients\NNS\9898892 and\CC\1740 16\CD\13745420 of\IN\1740 29\CD\13745420 (\-LRB-\1740 55.2\CD\1740 %\NN\1740 )\-RRB-\1740 of\IN\1740 the\DT\1740 gentamicin-treated\JJ\1740 patients\NNS\9898892 had\VBD\2108377 <e2>renal\JJ\1740 failure</e2>\NN\66216 .\.\1740
D014031_D051437 CID Thus\RB\1740 ,\,\1740 gentamicin\NN\2716866 was\VBD\836236 associated\VBN\628491 with\IN\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 more\JJR\1740 than\IN\1740 three\CD\13741022 times\NNS\15113229 as\RB\1740 often\RB\1740 as\IN\14622893 was\VBD\836236 <e1>tobramycin</e1>\NN\2716866 .\.\1740
D000617_D051437 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 62\CD\1740 patients\NNS\9898892 with\IN\1740 confirmed\VBN\1011725 initial\JJ\1740 normal\JJ\1740 renal\JJ\1740 function\NN\13783581 and\CC\1740 treated\VBN\2376958 with\IN\1740 2\CD\13741022 to\TO\1740 5\CD\13741022 mg/kg/day\NN\1740 of\IN\1740 gentamicin\NN\2716866 sulfate\NN\15010703 or\CC\3541091 tobramycin\NN\2716866 sulfate\NN\15010703 for\IN\1740 a\DT\13649268 minimum\NN\13653902 of\IN\1740 seven\CD\13741022 days\NNS\15140892 were\VBD\836236 followed\VBN\1835496 up\RP\1740 prospectively\RB\1740 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e1>aminoglycoside-related</e1>\JJ\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 ,\,\1740 defined\VBN\2604760 as\IN\14622893 at\IN\14622893 least\JJS\1740 a\DT\13649268 one-third\JJ\1740 reduction\NN\351485 in\IN\13603305 renal\JJ\1740 function\NN\13783581 .\.\1740
12905102
D003024_D003693 CID <e2>Delirium</e2>\NN\14391660 during\IN\1740 <e1>clozapine</e1>\NN\3713736 treatment\NN\654885 :\:\1740 incidence\NN\13821570 and\CC\1740 associated\VBN\628491 risk\NN\14541044 factors\NNS\7326557 .\.\1740
D003024_D003693 CID BACKGROUND\NN\4921011 :\:\1740 Incidence\NN\13821570 and\CC\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 <e2>delirium</e2>\NN\14391660 during\IN\1740 <e1>clozapine</e1>\NN\3713736 treatment\NN\654885 require\VBP\754942 further\JJ\1740 clarification\NN\7170753 .\.\1740
D003024_D003693 CID METHODS\NNS\5616786 :\:\1740 We\PRP\1740 used\VBD\1156834 computerized\JJ\1740 pharmacy\NN\6043075 records\NNS\6643408 to\TO\1740 identify\VB\699815 all\DT\1740 adult\JJ\1740 psychiatric\JJ\1740 inpatients\NNS\10405694 treated\VBN\2376958 with\IN\1740 <e1>clozapine</e1>\NN\3713736 (\-LRB-\1740 1995\CD\1740 -\SYM\1740 96\CD\1740 )\-RRB-\1740 ,\,\1740 reviewed\VBD\644583 their\PRP$\1740 medical\JJ\1740 records\NNS\6643408 to\TO\1740 score\VB\1111028 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 <e2>delirium</e2>\NN\14391660 ,\,\1740 and\CC\1740 tested\VBN\670261 associations\NNS\8008335 with\IN\1740 potential\JJ\1740 risk\NN\14541044 factors\NNS\7326557 .\.\1740
D003024_D003693 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e2>Delirium</e2>\NN\14391660 was\VBD\836236 found\VBN\2426171 in\IN\13603305 10\CD\13745420 %\NN\1740 of\IN\1740 <e1>clozapine-treated</e1>\JJ\1740 inpatients\NNS\10405694 ,\,\1740 particularly\RB\1740 in\IN\13603305 older\JJR\1740 patients\NNS\9898892 exposed\VBN\2110927 to\TO\1740 other\JJ\1740 central\JJ\1740 anticholinergics\NNS\3740161 .\.\1740
D003024_D001523 NONE METHODS\NNS\5616786 :\:\1740 We\PRP\1740 used\VBD\1156834 computerized\JJ\1740 pharmacy\NN\6043075 records\NNS\6643408 to\TO\1740 identify\VB\699815 all\DT\1740 adult\JJ\1740 <e2>psychiatric</e2>\JJ\1740 inpatients\NNS\10405694 treated\VBN\2376958 with\IN\1740 <e1>clozapine</e1>\NN\3713736 (\-LRB-\1740 1995\CD\1740 -\SYM\1740 96\CD\1740 )\-RRB-\1740 ,\,\1740 reviewed\VBD\644583 their\PRP$\1740 medical\JJ\1740 records\NNS\6643408 to\TO\1740 score\VB\1111028 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 delirium\NN\14391660 ,\,\1740 and\CC\1740 tested\VBN\670261 associations\NNS\8008335 with\IN\1740 potential\JJ\1740 risk\NN\14541044 factors\NNS\7326557 .\.\1740
8864707
D010672_D004827 NONE Magnetic\JJ\1740 resonance\NN\11419404 volumetry\NN\1740 of\IN\1740 the\DT\1740 cerebellum\NN\5462674 in\IN\13603305 <e2>epileptic</e2>\JJ\1740 patients\NNS\9898892 after\IN\1740 <e1>phenytoin</e1>\NN\3550533 overdosages\NNS\1740 .\.\1740
D010672_D062787 CID Magnetic\JJ\1740 resonance\NN\11419404 volumetry\NN\1740 of\IN\1740 the\DT\1740 cerebellum\NN\5462674 in\IN\13603305 epileptic\JJ\1740 patients\NNS\9898892 after\IN\1740 <e1>phenytoin</e1>\NN\3550533 <e2>overdosages</e2>\NNS\1740 .\.\1740
D010672_D062787 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 <e1>phenytoin</e1>\NN\3550533 <e2>overdosage</e2>\NN\1740 does\VBZ\1640855 not\RB\1740 necessarily\RB\1740 result\VB\2633881 in\IN\13603305 cerebellar\JJ\1740 atrophy\NN\14299637 and\CC\1740 it\PRP\6125041 is\VBZ\836236 unlikely\JJ\1740 that\IN\1740 phenytoin\NN\3550533 medication\NN\3247620 was\VBD\836236 the\DT\1740 only\JJ\1740 cause\NN\7323922 of\IN\1740 cerebellar\JJ\1740 atrophy\NN\14299637 in\IN\13603305 the\DT\1740 remaining\VBG\2604760 patients\NNS\9898892 .\.\1740
D010672_D062787 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 phenytoin\NN\3550533 <e2>overdosage</e2>\NN\1740 does\VBZ\1640855 not\RB\1740 necessarily\RB\1740 result\VB\2633881 in\IN\13603305 cerebellar\JJ\1740 atrophy\NN\14299637 and\CC\1740 it\PRP\6125041 is\VBZ\836236 unlikely\JJ\1740 that\IN\1740 <e1>phenytoin</e1>\NN\3550533 medication\NN\3247620 was\VBD\836236 the\DT\1740 only\JJ\1740 cause\NN\7323922 of\IN\1740 cerebellar\JJ\1740 atrophy\NN\14299637 in\IN\13603305 the\DT\1740 remaining\VBG\2604760 patients\NNS\9898892 .\.\1740
D010672_D002526 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 evaluate\VB\670261 the\DT\1740 relationship\NN\31921 between\IN\1740 <e1>phenytoin</e1>\NN\3550533 medication\NN\3247620 and\CC\1740 <e2>cerebellar\JJ\1740 atrophy</e2>\NN\14299637 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 experienced\VBN\2108377 clinical\JJ\1740 intoxication\NN\14034177 .\.\1740
D010672_D002526 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 <e1>phenytoin</e1>\NN\3550533 overdosage\NN\1740 does\VBZ\1640855 not\RB\1740 necessarily\RB\1740 result\VB\2633881 in\IN\13603305 <e2>cerebellar\JJ\1740 atrophy</e2>\NN\14299637 and\CC\1740 it\PRP\6125041 is\VBZ\836236 unlikely\JJ\1740 that\IN\1740 phenytoin\NN\3550533 medication\NN\3247620 was\VBD\836236 the\DT\1740 only\JJ\1740 cause\NN\7323922 of\IN\1740 cerebellar\JJ\1740 atrophy\NN\14299637 in\IN\13603305 the\DT\1740 remaining\VBG\2604760 patients\NNS\9898892 .\.\1740
D010672_D002526 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 <e1>phenytoin</e1>\NN\3550533 overdosage\NN\1740 does\VBZ\1640855 not\RB\1740 necessarily\RB\1740 result\VB\2633881 in\IN\13603305 cerebellar\JJ\1740 atrophy\NN\14299637 and\CC\1740 it\PRP\6125041 is\VBZ\836236 unlikely\JJ\1740 that\IN\1740 phenytoin\NN\3550533 medication\NN\3247620 was\VBD\836236 the\DT\1740 only\JJ\1740 cause\NN\7323922 of\IN\1740 <e2>cerebellar\JJ\1740 atrophy</e2>\NN\14299637 in\IN\13603305 the\DT\1740 remaining\VBG\2604760 patients\NNS\9898892 .\.\1740
D010672_D002526 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 phenytoin\NN\3550533 overdosage\NN\1740 does\VBZ\1640855 not\RB\1740 necessarily\RB\1740 result\VB\2633881 in\IN\13603305 <e2>cerebellar\JJ\1740 atrophy</e2>\NN\14299637 and\CC\1740 it\PRP\6125041 is\VBZ\836236 unlikely\JJ\1740 that\IN\1740 <e1>phenytoin</e1>\NN\3550533 medication\NN\3247620 was\VBD\836236 the\DT\1740 only\JJ\1740 cause\NN\7323922 of\IN\1740 cerebellar\JJ\1740 atrophy\NN\14299637 in\IN\13603305 the\DT\1740 remaining\VBG\2604760 patients\NNS\9898892 .\.\1740
D010672_D002526 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 phenytoin\NN\3550533 overdosage\NN\1740 does\VBZ\1640855 not\RB\1740 necessarily\RB\1740 result\VB\2633881 in\IN\13603305 cerebellar\JJ\1740 atrophy\NN\14299637 and\CC\1740 it\PRP\6125041 is\VBZ\836236 unlikely\JJ\1740 that\IN\1740 <e1>phenytoin</e1>\NN\3550533 medication\NN\3247620 was\VBD\836236 the\DT\1740 only\JJ\1740 cause\NN\7323922 of\IN\1740 <e2>cerebellar\JJ\1740 atrophy</e2>\NN\14299637 in\IN\13603305 the\DT\1740 remaining\VBG\2604760 patients\NNS\9898892 .\.\1740
D010672_D012640 NONE Using\VBG\1156834 linear\JJ\1740 regression\NN\14501726 we\PRP\1740 found\VBD\2426171 that\IN\1740 no\DT\7204911 correlation\NN\13841213 exists\VBZ\1740 between\IN\1740 <e2>seizure</e2>\JJ\1740 duration\NN\15113229 ,\,\1740 elevation\NN\7445480 of\IN\1740 <e1>phenytoin</e1>\NN\3550533 serum\NN\5397468 levels\NNS\4916342 and\CC\1740 cerebellar\JJ\1740 volume\NN\33615 .\.\1740
8372922
20003049
C031942_D013921 NONE Prolonged\JJ\1740 elevation\NN\7445480 of\IN\1740 plasma\NN\5398023 <e1>argatroban</e1>\NN\1740 in\IN\13603305 a\DT\13649268 cardiac\JJ\1740 transplant\NN\5267548 patient\NN\9898892 with\IN\1740 a\DT\13649268 suspected\VBN\916909 history\NN\15120823 of\IN\1740 heparin-induced\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 with\IN\1740 thrombosis\NN\14100769 .\.\1740
C031942_D013921 NONE In\IN\13603305 the\DT\1740 following\VBG\1835496 report\NN\6470073 ,\,\1740 a\DT\13649268 65-year-old\RB\1740 critically\RB\1740 ill\JJ\1740 patient\NN\9898892 with\IN\1740 a\DT\13649268 suspected\VBN\916909 history\NN\15120823 of\IN\1740 <e2>HITT</e2>\NN\1740 was\VBD\836236 administered\VBN\2436349 <e1>argatroban</e1>\NN\1740 for\IN\1740 anticoagulation\NN\657604 on\IN\1740 bypass\NN\3519981 during\IN\1740 heart\NN\5919034 transplantation\NN\671351 .\.\1740
C031942_D013927 NONE Prolonged\JJ\1740 elevation\NN\7445480 of\IN\1740 plasma\NN\5398023 <e1>argatroban</e1>\NN\1740 in\IN\13603305 a\DT\13649268 cardiac\JJ\1740 transplant\NN\5267548 patient\NN\9898892 with\IN\1740 a\DT\13649268 suspected\VBN\916909 history\NN\15120823 of\IN\1740 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 with\IN\1740 <e2>thrombosis</e2>\NN\14100769 .\.\1740
C031942_D013927 NONE In\IN\13603305 the\DT\1740 following\VBG\1835496 report\NN\6470073 ,\,\1740 a\DT\13649268 65-year-old\RB\1740 critically\RB\1740 ill\JJ\1740 patient\NN\9898892 with\IN\1740 a\DT\13649268 suspected\VBN\916909 history\NN\15120823 of\IN\1740 <e2>HITT</e2>\NN\1740 was\VBD\836236 administered\VBN\2436349 <e1>argatroban</e1>\NN\1740 for\IN\1740 anticoagulation\NN\657604 on\IN\1740 bypass\NN\3519981 during\IN\1740 heart\NN\5919034 transplantation\NN\671351 .\.\1740
D006493_D013921 NONE Prolonged\JJ\1740 elevation\NN\7445480 of\IN\1740 plasma\NN\5398023 argatroban\NN\1740 in\IN\13603305 a\DT\13649268 cardiac\JJ\1740 transplant\NN\5267548 patient\NN\9898892 with\IN\1740 a\DT\13649268 suspected\VBN\916909 history\NN\15120823 of\IN\1740 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 with\IN\1740 thrombosis\NN\14100769 .\.\1740
D006493_D013921 NONE BACKGROUND\NN\4921011 :\:\1740 Direct\JJ\1740 thrombin\NN\14735953 inhibitors\NNS\20090 (\-LRB-\1740 DTIs\NNS\1740 )\-RRB-\1740 provide\VBP\2199590 an\DT\6697703 alternative\JJ\1740 method\NN\5616786 of\IN\1740 anticoagulation\NN\657604 for\IN\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 (\-LRB-\1740 HIT\NN\36762 )\-RRB-\1740 or\CC\3541091 HIT\NN\36762 with\IN\1740 thrombosis\NN\14100769 (\-LRB-\1740 HITT\NN\1740 )\-RRB-\1740 undergoing\VBG\109660 cardiopulmonary\JJ\1740 bypass\NN\3519981 (\-LRB-\1740 CPB\NN\1740 )\-RRB-\1740 .\.\1740
D006493_D013921 NONE BACKGROUND\NN\4921011 :\:\1740 Direct\JJ\1740 thrombin\NN\14735953 inhibitors\NNS\20090 (\-LRB-\1740 DTIs\NNS\1740 )\-RRB-\1740 provide\VBP\2199590 an\DT\6697703 alternative\JJ\1740 method\NN\5616786 of\IN\1740 anticoagulation\NN\657604 for\IN\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 (\-LRB-\1740 <e2>HIT</e2>\NN\36762 )\-RRB-\1740 or\CC\3541091 HIT\NN\36762 with\IN\1740 thrombosis\NN\14100769 (\-LRB-\1740 HITT\NN\1740 )\-RRB-\1740 undergoing\VBG\109660 cardiopulmonary\JJ\1740 bypass\NN\3519981 (\-LRB-\1740 CPB\NN\1740 )\-RRB-\1740 .\.\1740
D006493_D013921 NONE BACKGROUND\NN\4921011 :\:\1740 Direct\JJ\1740 thrombin\NN\14735953 inhibitors\NNS\20090 (\-LRB-\1740 DTIs\NNS\1740 )\-RRB-\1740 provide\VBP\2199590 an\DT\6697703 alternative\JJ\1740 method\NN\5616786 of\IN\1740 anticoagulation\NN\657604 for\IN\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 (\-LRB-\1740 HIT\NN\36762 )\-RRB-\1740 or\CC\3541091 <e2>HIT</e2>\NN\36762 with\IN\1740 thrombosis\NN\14100769 (\-LRB-\1740 HITT\NN\1740 )\-RRB-\1740 undergoing\VBG\109660 cardiopulmonary\JJ\1740 bypass\NN\3519981 (\-LRB-\1740 CPB\NN\1740 )\-RRB-\1740 .\.\1740
D006493_D013921 NONE BACKGROUND\NN\4921011 :\:\1740 Direct\JJ\1740 thrombin\NN\14735953 inhibitors\NNS\20090 (\-LRB-\1740 DTIs\NNS\1740 )\-RRB-\1740 provide\VBP\2199590 an\DT\6697703 alternative\JJ\1740 method\NN\5616786 of\IN\1740 anticoagulation\NN\657604 for\IN\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 (\-LRB-\1740 HIT\NN\36762 )\-RRB-\1740 or\CC\3541091 HIT\NN\36762 with\IN\1740 thrombosis\NN\14100769 (\-LRB-\1740 <e2>HITT</e2>\NN\1740 )\-RRB-\1740 undergoing\VBG\109660 cardiopulmonary\JJ\1740 bypass\NN\3519981 (\-LRB-\1740 CPB\NN\1740 )\-RRB-\1740 .\.\1740
D006493_D013927 NONE Prolonged\JJ\1740 elevation\NN\7445480 of\IN\1740 plasma\NN\5398023 argatroban\NN\1740 in\IN\13603305 a\DT\13649268 cardiac\JJ\1740 transplant\NN\5267548 patient\NN\9898892 with\IN\1740 a\DT\13649268 suspected\VBN\916909 history\NN\15120823 of\IN\1740 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 with\IN\1740 <e2>thrombosis</e2>\NN\14100769 .\.\1740
D006493_D013927 NONE BACKGROUND\NN\4921011 :\:\1740 Direct\JJ\1740 thrombin\NN\14735953 inhibitors\NNS\20090 (\-LRB-\1740 DTIs\NNS\1740 )\-RRB-\1740 provide\VBP\2199590 an\DT\6697703 alternative\JJ\1740 method\NN\5616786 of\IN\1740 anticoagulation\NN\657604 for\IN\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 (\-LRB-\1740 HIT\NN\36762 )\-RRB-\1740 or\CC\3541091 HIT\NN\36762 with\IN\1740 <e2>thrombosis</e2>\NN\14100769 (\-LRB-\1740 HITT\NN\1740 )\-RRB-\1740 undergoing\VBG\109660 cardiopulmonary\JJ\1740 bypass\NN\3519981 (\-LRB-\1740 CPB\NN\1740 )\-RRB-\1740 .\.\1740
D006493_D013927 NONE BACKGROUND\NN\4921011 :\:\1740 Direct\JJ\1740 thrombin\NN\14735953 inhibitors\NNS\20090 (\-LRB-\1740 DTIs\NNS\1740 )\-RRB-\1740 provide\VBP\2199590 an\DT\6697703 alternative\JJ\1740 method\NN\5616786 of\IN\1740 anticoagulation\NN\657604 for\IN\1740 patients\NNS\9898892 with\IN\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 (\-LRB-\1740 HIT\NN\36762 )\-RRB-\1740 or\CC\3541091 HIT\NN\36762 with\IN\1740 thrombosis\NN\14100769 (\-LRB-\1740 <e2>HITT</e2>\NN\1740 )\-RRB-\1740 undergoing\VBG\109660 cardiopulmonary\JJ\1740 bypass\NN\3519981 (\-LRB-\1740 CPB\NN\1740 )\-RRB-\1740 .\.\1740
C031942_D016638 NONE In\IN\13603305 the\DT\1740 following\VBG\1835496 report\NN\6470073 ,\,\1740 a\DT\13649268 65-year-old\RB\1740 <e2>critically\RB\1740 ill</e2>\JJ\1740 patient\NN\9898892 with\IN\1740 a\DT\13649268 suspected\VBN\916909 history\NN\15120823 of\IN\1740 HITT\NN\1740 was\VBD\836236 administered\VBN\2436349 <e1>argatroban</e1>\NN\1740 for\IN\1740 anticoagulation\NN\657604 on\IN\1740 bypass\NN\3519981 during\IN\1740 heart\NN\5919034 transplantation\NN\671351 .\.\1740
C031942_D008107 NONE RESULTS\NNS\34213 :\:\1740 Unexpectedly\RB\1740 high\JJ\1740 concentrations\NNS\4916342 of\IN\1740 <e1>argatroban</e1>\NN\1740 were\VBD\836236 measured\VBN\697589 in\IN\13603305 these\DT\1740 samples\NNS\5820620 (\-LRB-\1740 range\NN\5123416 ,\,\1740 0\CD\13741022 -\SYM\1740 32\CD\1740 microg/mL\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 a\DT\13649268 prolonged\JJ\1740 plasma\NN\5398023 argatroban\NN\1740 half\NN\13732295 life\NN\13954253 (\-LRB-\1740 t(1/2\NN\1740 )\-RRB-\1740 )\-RRB-\1740 of\IN\1740 514\CD\1740 minutes\NNS\6502378 was\VBD\836236 observed\VBN\2163746 (\-LRB-\1740 published\VBN\1621555 elimination\NN\391599 t(1/2\NN\1740 )\-RRB-\1740 is\VBZ\836236 39\CD\1740 -\SYM\1740 51\CD\1740 minutes\NNS\6502378 [\-LRB-\1740 <\XX\1740 or\CC\3541091 =\JJ\1740 181\CD\1740 minutes\NNS\6502378 with\IN\1740 <e2>hepatic\JJ\1740 impairment</e2>\NN\7296428 ]\-RRB-\1740 )\-RRB-\1740 .\.\1740
C031942_D008107 NONE RESULTS\NNS\34213 :\:\1740 Unexpectedly\RB\1740 high\JJ\1740 concentrations\NNS\4916342 of\IN\1740 argatroban\NN\1740 were\VBD\836236 measured\VBN\697589 in\IN\13603305 these\DT\1740 samples\NNS\5820620 (\-LRB-\1740 range\NN\5123416 ,\,\1740 0\CD\13741022 -\SYM\1740 32\CD\1740 microg/mL\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 a\DT\13649268 prolonged\JJ\1740 plasma\NN\5398023 <e1>argatroban</e1>\NN\1740 half\NN\13732295 life\NN\13954253 (\-LRB-\1740 t(1/2\NN\1740 )\-RRB-\1740 )\-RRB-\1740 of\IN\1740 514\CD\1740 minutes\NNS\6502378 was\VBD\836236 observed\VBN\2163746 (\-LRB-\1740 published\VBN\1621555 elimination\NN\391599 t(1/2\NN\1740 )\-RRB-\1740 is\VBZ\836236 39\CD\1740 -\SYM\1740 51\CD\1740 minutes\NNS\6502378 [\-LRB-\1740 <\XX\1740 or\CC\3541091 =\JJ\1740 181\CD\1740 minutes\NNS\6502378 with\IN\1740 <e2>hepatic\JJ\1740 impairment</e2>\NN\7296428 ]\-RRB-\1740 )\-RRB-\1740 .\.\1740
C031942_D001778 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Correlation\NN\13841213 of\IN\1740 plasma\NN\5398023 <e1>argatroban</e1>\NN\1740 concentration\NN\4916342 versus\CC\1740 the\DT\1740 patient\NN\9898892 's\POS\1740 coagulation\NN\13518963 variables\NNS\2452 and\CC\1740 clinical\JJ\1740 course\NN\883297 suggest\VBP\1010118 that\IN\1740 prolonged\JJ\1740 elevated\JJ\1740 levels\NNS\4916342 of\IN\1740 plasma\NN\5398023 argatroban\NN\1740 may\MD\15209706 have\VB\2108377 contributed\VBN\126264 to\IN\1740 the\DT\1740 patient\NN\9898892 's\POS\1740 extended\VBN\153263 <e2>coagulopathy</e2>\JJ\1740 .\.\1740
C031942_D001778 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Correlation\NN\13841213 of\IN\1740 plasma\NN\5398023 argatroban\NN\1740 concentration\NN\4916342 versus\CC\1740 the\DT\1740 patient\NN\9898892 's\POS\1740 coagulation\NN\13518963 variables\NNS\2452 and\CC\1740 clinical\JJ\1740 course\NN\883297 suggest\VBP\1010118 that\IN\1740 prolonged\JJ\1740 elevated\JJ\1740 levels\NNS\4916342 of\IN\1740 plasma\NN\5398023 <e1>argatroban</e1>\NN\1740 may\MD\15209706 have\VB\2108377 contributed\VBN\126264 to\IN\1740 the\DT\1740 patient\NN\9898892 's\POS\1740 extended\VBN\153263 <e2>coagulopathy</e2>\JJ\1740 .\.\1740
C031942_D001778 NONE This\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 report\NN\6470073 to\TO\1740 measure\VB\697589 plasma\NN\5398023 <e1>argatroban</e1>\NN\1740 concentration\NN\4916342 in\IN\13603305 the\DT\1740 context\NN\6284777 of\IN\1740 CPB\NN\1740 and\CC\1740 extended\VBD\153263 <e2>coagulopathy</e2>\RB\1740 .\.\1740
17111419
C102006_D064420 NONE Severe\JJ\1740 <e1>citrate</e1>\NN\14850483 <e2>toxicity</e2>\NN\13576101 complicating\VBG\126264 volunteer\NN\10582746 apheresis\NN\13524399 platelet\NN\5432736 donation\NN\13265011 .\.\1740
C102006_D064420 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 severe\JJ\1740 <e1>citrate</e1>\NN\14850483 <e2>toxicity</e2>\NN\13576101 during\IN\1740 volunteer\NN\10582746 donor\NN\9608709 apheresis\NN\13524399 platelet\NN\5432736 collection\NN\31264 .\.\1740
C102006_D064420 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 careful\JJ\1740 screening\NN\6887726 for\IN\1740 medications\NNS\3247620 and\CC\1740 underlying\VBG\2604760 conditions\NNS\14512817 predisposing\VBG\680841 to\TO\1740 hypocalcemia\NN\14299637 is\VBZ\836236 recommended\VBN\875394 to\TO\1740 help\VB\2556126 prevent\VB\1740 severe\JJ\1740 reactions\NNS\13446390 due\IN\5174653 to\TO\1740 <e1>citrate</e1>\NN\14850483 <e2>toxicity</e2>\NN\13576101 .\.\1740
D002125_C536214 NONE Empirical\JJ\1740 treatment\NN\654885 with\IN\1740 intravenous\JJ\1740 <e1>calcium\NN\14625458 gluconate</e1>\NN\1740 was\VBD\836236 initiated\VBN\1617192 ,\,\1740 and\CC\1740 <e2>muscle\NN\5289601 contractions</e2>\NNS\358931 slowly\RB\1740 subsided\VBD\223500 over\RB\1740 approximately\RB\1740 10\CD\13745420 to\TO\1740 15\CD\13745420 minutes\NNS\6502378 .\.\1740
D002118_D006996 NONE The\DT\1740 events\NNS\23100 are\VBP\836236 consistent\JJ\1740 with\IN\1740 a\DT\13649268 severe\JJ\1740 reaction\NN\13446390 to\TO\1740 <e1>calcium</e1>\NN\14625458 chelation\NN\29677 by\IN\1740 sodium\NN\14625458 citrate\NN\14850483 anticoagulant\NN\3740161 resulting\VBG\2633881 in\IN\13603305 symptomatic\JJ\1740 systemic\JJ\1740 <e2>hypocalcemia</e2>\NN\14299637 .\.\1740
C102006_D006996 CID The\DT\1740 events\NNS\23100 are\VBP\836236 consistent\JJ\1740 with\IN\1740 a\DT\13649268 severe\JJ\1740 reaction\NN\13446390 to\TO\1740 calcium\NN\14625458 chelation\NN\29677 by\IN\1740 <e1>sodium\NN\14625458 citrate</e1>\NN\14850483 anticoagulant\NN\3740161 resulting\VBG\2633881 in\IN\13603305 symptomatic\JJ\1740 systemic\JJ\1740 <e2>hypocalcemia</e2>\NN\14299637 .\.\1740
C102006_D006996 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 careful\JJ\1740 screening\NN\6887726 for\IN\1740 medications\NNS\3247620 and\CC\1740 underlying\VBG\2604760 conditions\NNS\14512817 predisposing\VBG\680841 to\TO\1740 <e2>hypocalcemia</e2>\NN\14299637 is\VBZ\836236 recommended\VBN\875394 to\TO\1740 help\VB\2556126 prevent\VB\1740 severe\JJ\1740 reactions\NNS\13446390 due\IN\5174653 to\TO\1740 <e1>citrate</e1>\NN\14850483 toxicity\NN\13576101 .\.\1740
D002034_D006996 NONE Upon\IN\1740 additional\JJ\1740 retrospective\JJ\1740 analysis\NN\633864 ,\,\1740 it\PRP\6125041 was\VBD\836236 noted\VBN\1009240 that\IN\1740 <e1>bumetanide</e1>\NN\1740 is\VBZ\836236 a\DT\13649268 loop\NN\3323703 diuretic\NN\3247620 that\WDT\1740 may\MD\15209706 cause\VB\1617192 significant\JJ\1740 <e2>hypocalcemia</e2>\NN\14299637 .\.\1740
D049994_D006996 NONE Upon\IN\1740 additional\JJ\1740 retrospective\JJ\1740 analysis\NN\633864 ,\,\1740 it\PRP\6125041 was\VBD\836236 noted\VBN\1009240 that\IN\1740 bumetanide\NN\1740 is\VBZ\836236 a\DT\13649268 <e1>loop\NN\3323703 diuretic</e1>\NN\3247620 that\WDT\1740 may\MD\15209706 cause\VB\1617192 significant\JJ\1740 <e2>hypocalcemia</e2>\NN\14299637 .\.\1740
2070391
D008012_D010146 CID Reduction\NN\351485 in\IN\13603305 injection\NN\320852 <e2>pain</e2>\NN\14299637 using\VBG\1156834 buffered\VBN\169806 <e1>lidocaine</e1>\NN\3681148 as\IN\14622893 a\DT\13649268 local\JJ\1740 anesthetic\JJ\1740 before\IN\1740 cardiac\JJ\1740 catheterization\NN\671351 .\.\1740
D008012_D010146 CID Previous\JJ\1740 reports\NNS\6470073 have\VBP\2108377 suggested\VBN\1010118 that\IN\1740 <e2>pain</e2>\NN\14299637 associated\VBN\628491 with\IN\1740 the\DT\1740 injection\NN\320852 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 is\VBZ\836236 related\JJ\1740 to\TO\1740 the\DT\1740 acidic\JJ\1740 pH\NN\5038959 of\IN\1740 the\DT\1740 solution\NN\14586258 .\.\1740
D008012_D010146 CID To\TO\1740 determine\VB\1645601 if\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 a\DT\13649268 buffering\NN\1740 solution\NN\14586258 to\TO\1740 adjust\VB\126264 the\DT\1740 pH\NN\5038959 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 into\IN\1740 the\DT\1740 physiologic\JJ\1740 range\NN\5123416 would\MD\1740 reduce\VB\441445 <e2>pain</e2>\NN\14299637 during\IN\1740 injection\NN\320852 ,\,\1740 we\PRP\1740 performed\VBD\2367363 a\DT\13649268 blinded\VBN\126264 randomized\JJ\1740 study\NN\635850 in\IN\13603305 patients\NNS\9898892 undergoing\VBG\109660 cardiac\JJ\1740 catheterization\NN\671351 .\.\1740
D008012_D010146 CID Twenty\CD\13745420 patients\NNS\9898892 were\VBD\836236 asked\VBN\740577 to\TO\1740 quantify\VB\947077 the\DT\1740 severity\NN\5036394 of\IN\1740 <e2>pain</e2>\NN\14299637 after\IN\1740 receiving\VBG\2210855 standard\JJ\1740 <e1>lidocaine</e1>\NN\3681148 in\IN\13603305 one\CD\13741022 femoral\JJ\1740 area\NN\8630985 and\CC\1740 buffered\VBD\169806 lidocaine\NN\3681148 in\IN\13603305 the\DT\1740 opposite\JJ\1740 femoral\JJ\1740 area\NN\8630985 .\.\1740
D008012_D010146 CID Twenty\CD\13745420 patients\NNS\9898892 were\VBD\836236 asked\VBN\740577 to\TO\1740 quantify\VB\947077 the\DT\1740 severity\NN\5036394 of\IN\1740 <e2>pain</e2>\NN\14299637 after\IN\1740 receiving\VBG\2210855 standard\JJ\1740 lidocaine\NN\3681148 in\IN\13603305 one\CD\13741022 femoral\JJ\1740 area\NN\8630985 and\CC\1740 buffered\VBD\169806 <e1>lidocaine</e1>\NN\3681148 in\IN\13603305 the\DT\1740 opposite\JJ\1740 femoral\JJ\1740 area\NN\8630985 .\.\1740
D008012_D010146 CID The\DT\1740 mean\NN\6021761 <e2>pain</e2>\NN\14299637 score\NN\5736149 for\IN\1740 buffered\VBN\169806 <e1>lidocaine</e1>\NN\3681148 was\VBD\836236 significantly\RB\1740 lower\JJR\1740 than\IN\1740 the\DT\1740 mean\NN\6021761 score\NN\5736149 for\IN\1740 standard\JJ\1740 lidocaine\NN\3681148 (\-LRB-\1740 2.7\CD\1740 +/-\CC\1740 1.9\CD\1740 vs.\CC\1740 3.8\CD\1740 +/-\CC\1740 2.2\CD\1740 ,\,\1740 P\NN\14622893 =\JJ\1740 0.03\CD\1740 )\-RRB-\1740 .\.\1740
D008012_D010146 CID The\DT\1740 mean\NN\6021761 <e2>pain</e2>\NN\14299637 score\NN\5736149 for\IN\1740 buffered\VBN\169806 lidocaine\NN\3681148 was\VBD\836236 significantly\RB\1740 lower\JJR\1740 than\IN\1740 the\DT\1740 mean\NN\6021761 score\NN\5736149 for\IN\1740 standard\JJ\1740 <e1>lidocaine</e1>\NN\3681148 (\-LRB-\1740 2.7\CD\1740 +/-\CC\1740 1.9\CD\1740 vs.\CC\1740 3.8\CD\1740 +/-\CC\1740 2.2\CD\1740 ,\,\1740 P\NN\14622893 =\JJ\1740 0.03\CD\1740 )\-RRB-\1740 .\.\1740
D008012_D010146 CID The\DT\1740 pH\NN\5038959 adjustment\NN\7357388 of\IN\1740 standard\JJ\1740 <e1>lidocaine</e1>\NN\3681148 can\MD\3094503 be\VB\836236 accomplished\VBN\484166 easily\RB\1740 in\IN\13603305 the\DT\1740 catheterization\NN\671351 laboratory\NN\4602044 before\IN\1740 injection\NN\320852 and\CC\1740 results\VBZ\2633881 in\IN\13603305 a\DT\13649268 reduction\NN\351485 of\IN\1740 the\DT\1740 <e2>pain</e2>\NN\14299637 occurring\VBG\2623529 during\IN\1740 the\DT\1740 infiltration\NN\975452 of\IN\1740 tissues\NNS\5220461 .\.\1740
2611118
D004008_D006521 NONE <e2>Chronic\JJ\1740 active\JJ\1740 hepatitis</e2>\NN\14127211 associated\VBN\628491 with\IN\1740 <e1>diclofenac\JJ\1740 sodium</e1>\NN\14625458 therapy\NN\657604 .\.\1740
D004008_D006521 NONE The\DT\1740 patient\NN\9898892 described\VBD\1001294 developed\VBD\1753788 <e2>chronic\JJ\1740 active\JJ\1740 hepatitis</e2>\NN\14127211 after\IN\1740 six\CD\13741022 months\NNS\15113229 therapy\NN\657604 with\IN\1740 <e1>diclofenac\JJ\1740 sodium</e1>\NN\14625458 which\WDT\1740 progressed\VBD\252019 despite\IN\7501545 the\DT\1740 withdrawal\NN\7206096 of\IN\1740 the\DT\1740 drug\NN\14778436 ,\,\1740 a\DT\13649268 finding\NN\43195 not\RB\1740 previously\RB\1740 reported\VBN\831651 .\.\1740
D004008_D056486 CID Although\IN\1740 generally\RB\1740 well-tolerated\JJ\1740 ,\,\1740 asymptomatic\JJ\1740 <e2>abnormalities\NNS\14034177 of\IN\1740 liver\NN\5298729 function</e2>\NN\13783581 have\VBP\2108377 been\VBN\836236 recorded\VBN\2225492 and\CC\1740 ,\,\1740 less\RBR\1740 commonly\RB\1740 ,\,\1740 severe\JJ\1740 hepatitis\NN\14127211 induced\VBN\1627355 by\IN\1740 <e1>diclofenac</e1>\VBN\1740 .\.\1740
D004008_D056486 CID Although\IN\1740 generally\RB\1740 well-tolerated\JJ\1740 ,\,\1740 asymptomatic\JJ\1740 abnormalities\NNS\14034177 of\IN\1740 liver\NN\5298729 function\NN\13783581 have\VBP\2108377 been\VBN\836236 recorded\VBN\2225492 and\CC\1740 ,\,\1740 less\RBR\1740 commonly\RB\1740 ,\,\1740 severe\JJ\1740 <e2>hepatitis</e2>\NN\14127211 induced\VBN\1627355 by\IN\1740 <e1>diclofenac</e1>\VBN\1740 .\.\1740
2484011
D000547_D003866 NONE The\DT\1740 initial\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>amantadine</e1>\NN\1740 <e2>depressed</e2>\JJ\1740 locomotor\NN\1740 activity\NN\30358 in\IN\13603305 all\DT\1740 mouse\NN\2329401 strains\NNS\7358060 studied\VBN\630380 with\IN\1740 the\DT\1740 BALB/C\NN\1740 mice\NNS\2329401 being\VBG\836236 the\DT\1740 most\RBS\1740 sensitive\JJ\1740 .\.\1740
D000547_D011596 CID Readministration\NN\1740 of\IN\1740 <e1>amantadine</e1>\NN\1740 ,\,\1740 after\IN\1740 a\DT\13649268 drug-free\JJ\1740 overnight\JJ\1740 period\NN\13575869 ,\,\1740 increased\VBN\169651 motility\NN\4773351 from\IN\1740 respective\JJ\1740 saline\NN\14849367 control\NN\5190804 in\IN\13603305 all\DT\1740 strains\NNS\7358060 with\IN\1740 exception\NN\5706954 of\IN\1740 the\DT\1740 BALB/C\NN\1740 mice\NNS\2329401 where\WRB\1740 <e2>suppression\NN\13489037 of\IN\1740 motility</e2>\NN\4773351 occurred\VBD\2623529 .\.\1740
D000547_D011596 CID The\DT\1740 biochemical\JJ\1740 results\NNS\34213 of\IN\1740 brain\NN\5462674 biogenic\JJ\1740 amines\NNS\14951377 of\IN\1740 BALB/C\NN\1740 mouse\NN\2329401 strain\NN\7358060 suggest\VBP\1010118 a\DT\13649268 probable\JJ\1740 decrease\NN\7296428 of\IN\1740 catecholamine\NN\5407119 turnover\NN\13819207 rate\NN\13815152 and/or\CC\1740 metabolism\NN\13526110 by\IN\1740 monoamine\NN\14739004 oxidase\NN\14732946 and\CC\1740 a\DT\13649268 resulting\VBG\2633881 increase\NN\13576355 in\IN\13603305 O-methylation\NN\1740 of\IN\1740 norepinephrine\NN\14807929 which\WDT\1740 may\MD\15209706 account\VB\2604760 for\IN\1740 a\DT\13649268 <e2>behavioral\JJ\1740 depression</e2>\NN\14373582 caused\VBN\1617192 by\IN\1740 <e1>amantadine</e1>\NN\1740 in\IN\13603305 the\DT\1740 BALB/C\NN\1740 mice\NNS\2329401 .\.\1740
D000588_D011596 NONE The\DT\1740 biochemical\JJ\1740 results\NNS\34213 of\IN\1740 brain\NN\5462674 biogenic\JJ\1740 <e1>amines</e1>\NNS\14951377 of\IN\1740 BALB/C\NN\1740 mouse\NN\2329401 strain\NN\7358060 suggest\VBP\1010118 a\DT\13649268 probable\JJ\1740 decrease\NN\7296428 of\IN\1740 catecholamine\NN\5407119 turnover\NN\13819207 rate\NN\13815152 and/or\CC\1740 metabolism\NN\13526110 by\IN\1740 monoamine\NN\14739004 oxidase\NN\14732946 and\CC\1740 a\DT\13649268 resulting\VBG\2633881 increase\NN\13576355 in\IN\13603305 O-methylation\NN\1740 of\IN\1740 norepinephrine\NN\14807929 which\WDT\1740 may\MD\15209706 account\VB\2604760 for\IN\1740 a\DT\13649268 <e2>behavioral\JJ\1740 depression</e2>\NN\14373582 caused\VBN\1617192 by\IN\1740 amantadine\NN\1740 in\IN\13603305 the\DT\1740 BALB/C\NN\1740 mice\NNS\2329401 .\.\1740
D002395_D011596 NONE The\DT\1740 biochemical\JJ\1740 results\NNS\34213 of\IN\1740 brain\NN\5462674 biogenic\JJ\1740 amines\NNS\14951377 of\IN\1740 BALB/C\NN\1740 mouse\NN\2329401 strain\NN\7358060 suggest\VBP\1010118 a\DT\13649268 probable\JJ\1740 decrease\NN\7296428 of\IN\1740 <e1>catecholamine</e1>\NN\5407119 turnover\NN\13819207 rate\NN\13815152 and/or\CC\1740 metabolism\NN\13526110 by\IN\1740 monoamine\NN\14739004 oxidase\NN\14732946 and\CC\1740 a\DT\13649268 resulting\VBG\2633881 increase\NN\13576355 in\IN\13603305 O-methylation\NN\1740 of\IN\1740 norepinephrine\NN\14807929 which\WDT\1740 may\MD\15209706 account\VB\2604760 for\IN\1740 a\DT\13649268 <e2>behavioral\JJ\1740 depression</e2>\NN\14373582 caused\VBN\1617192 by\IN\1740 amantadine\NN\1740 in\IN\13603305 the\DT\1740 BALB/C\NN\1740 mice\NNS\2329401 .\.\1740
D009638_D011596 NONE The\DT\1740 biochemical\JJ\1740 results\NNS\34213 of\IN\1740 brain\NN\5462674 biogenic\JJ\1740 amines\NNS\14951377 of\IN\1740 BALB/C\NN\1740 mouse\NN\2329401 strain\NN\7358060 suggest\VBP\1010118 a\DT\13649268 probable\JJ\1740 decrease\NN\7296428 of\IN\1740 catecholamine\NN\5407119 turnover\NN\13819207 rate\NN\13815152 and/or\CC\1740 metabolism\NN\13526110 by\IN\1740 monoamine\NN\14739004 oxidase\NN\14732946 and\CC\1740 a\DT\13649268 resulting\VBG\2633881 increase\NN\13576355 in\IN\13603305 O-methylation\NN\1740 of\IN\1740 <e1>norepinephrine</e1>\NN\14807929 which\WDT\1740 may\MD\15209706 account\VB\2604760 for\IN\1740 a\DT\13649268 <e2>behavioral\JJ\1740 depression</e2>\NN\14373582 caused\VBN\1617192 by\IN\1740 amantadine\NN\1740 in\IN\13603305 the\DT\1740 BALB/C\NN\1740 mice\NNS\2329401 .\.\1740
9754849
D008691_D002819 CID <e2>Choreoathetoid\NN\1740 movements</e2>\NNS\191142 associated\VBN\628491 with\IN\1740 rapid\JJ\1740 adjustment\NN\7357388 to\IN\1740 <e1>methadone</e1>\NN\3808564 .\.\1740
D008691_D002819 CID This\DT\1740 is\VBZ\836236 a\DT\13649268 case\NN\7283608 report\NN\6470073 of\IN\1740 euphoria\NN\7527656 and\CC\1740 <e2>choreoathetoid\JJ\1740 movements</e2>\NNS\191142 both\CC\1740 transiently\RB\1740 induced\VBN\1627355 by\IN\1740 rapid\JJ\1740 adjustment\NN\7357388 to\IN\1740 the\DT\1740 selective\JJ\1740 mu-opioid\JJ\1740 receptor\NN\5225602 agonist\NN\9613191 <e1>methadone</e1>\NN\3808564 in\IN\13603305 an\DT\6697703 inpatient\JJ\1740 previously\RB\1740 abusing\VBG\2514187 heroine\NN\5929008 and\CC\1740 cocaine\NN\3492717 .\.\1740
D003042_D002819 CID <e2>Choreatiform\NN\1740 hyperkinesias</e2>\NNS\1740 are\VBP\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 occasional\JJ\1740 movement\NN\191142 abnormalities\NNS\14034177 during\IN\1740 intoxications\NNS\14034177 with\IN\1740 <e1>cocaine</e1>\NN\3492717 but\CC\1740 not\RB\1740 opiates\NNS\3808564 .\.\1740
D003042_D002819 CID This\DT\1740 is\VBZ\836236 a\DT\13649268 case\NN\7283608 report\NN\6470073 of\IN\1740 euphoria\NN\7527656 and\CC\1740 <e2>choreoathetoid\JJ\1740 movements</e2>\NNS\191142 both\CC\1740 transiently\RB\1740 induced\VBN\1627355 by\IN\1740 rapid\JJ\1740 adjustment\NN\7357388 to\IN\1740 the\DT\1740 selective\JJ\1740 mu-opioid\JJ\1740 receptor\NN\5225602 agonist\NN\9613191 methadone\NN\3808564 in\IN\13603305 an\DT\6697703 inpatient\JJ\1740 previously\RB\1740 abusing\VBG\2514187 heroine\NN\5929008 and\CC\1740 <e1>cocaine</e1>\NN\3492717 .\.\1740
D003042_D006948 CID <e2>Choreatiform\NN\1740 hyperkinesias</e2>\NNS\1740 are\VBP\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 occasional\JJ\1740 movement\NN\191142 abnormalities\NNS\14034177 during\IN\1740 intoxications\NNS\14034177 with\IN\1740 <e1>cocaine</e1>\NN\3492717 but\CC\1740 not\RB\1740 opiates\NNS\3808564 .\.\1740
D003042_D020820 NONE Choreatiform\NN\1740 hyperkinesias\NNS\1740 are\VBP\836236 known\VBN\2110220 to\TO\1740 be\VB\836236 occasional\JJ\1740 <e2>movement\NN\191142 abnormalities</e2>\NNS\14034177 during\IN\1740 intoxications\NNS\14034177 with\IN\1740 <e1>cocaine</e1>\NN\3492717 but\CC\1740 not\RB\1740 opiates\NNS\3808564 .\.\1740
D003932_D002819 NONE This\DT\1740 is\VBZ\836236 a\DT\13649268 case\NN\7283608 report\NN\6470073 of\IN\1740 euphoria\NN\7527656 and\CC\1740 <e2>choreoathetoid\JJ\1740 movements</e2>\NNS\191142 both\CC\1740 transiently\RB\1740 induced\VBN\1627355 by\IN\1740 rapid\JJ\1740 adjustment\NN\7357388 to\IN\1740 the\DT\1740 selective\JJ\1740 mu-opioid\JJ\1740 receptor\NN\5225602 agonist\NN\9613191 methadone\NN\3808564 in\IN\13603305 an\DT\6697703 inpatient\JJ\1740 previously\RB\1740 abusing\VBG\2514187 <e1>heroine</e1>\NN\5929008 and\CC\1740 cocaine\NN\3492717 .\.\1740
354896
D008012_D006323 CID <e1>Lidocaine-induced</e1>\JJ\1740 <e2>cardiac\JJ\1740 asystole</e2>\NN\14204950 .\.\1740
D008012_D003866 NONE Intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 a\DT\13649268 single\JJ\1740 50-mg\JJ\1740 bolus\NN\13899404 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 in\IN\13603305 a\DT\13649268 67-year-old\JJ\1740 man\NN\9605289 resulted\VBD\2633881 in\IN\13603305 profound\JJ\1740 <e2>depression</e2>\NN\14373582 of\IN\1740 the\DT\1740 activity\NN\30358 of\IN\1740 the\DT\1740 sinoatrial\NN\1740 and\CC\1740 atrioventricular\JJ\1740 nodal\NN\1740 pacemakers\NNS\5925366 .\.\1740
D008012_D001919 NONE The\DT\1740 patient\NN\9898892 had\VBD\2108377 no\DT\7204911 apparent\JJ\1740 associated\VBN\628491 conditions\NNS\14512817 which\WDT\1740 might\MD\5029706 have\VB\2108377 predisposed\VBN\680841 him\PRP\1740 to\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>bradyarrhythmias</e2>\NNS\1740 ;\:\1740 and\CC\1740 ,\,\1740 thus\RB\1740 ,\,\1740 this\DT\1740 probably\RB\1740 represented\VBD\2664769 a\DT\13649268 true\JJ\1740 idiosyncrasy\JJ\1740 to\TO\1740 <e1>lidocaine</e1>\VB\1740 .\.\1740
20619828
D002997_D001008 CID RESULTS\NNS\34213 :\:\1740 <e1>Clomipramine</e1>\NN\4482543 exposure\NN\5042871 in\IN\13603305 immature\JJ\1740 rats\NNS\2329401 produced\VBD\1617192 significant\JJ\1740 behavioral\JJ\1740 and\CC\1740 biochemical\JJ\1740 changes\NNS\7283608 that\WDT\1740 include\VBP\690614 enhanced\VBN\227165 <e2>anxiety</e2>\NN\14373582 (\-LRB-\1740 elevated\JJ\1740 plus\CC\4723816 maze\NN\4377057 and\CC\1740 marble\NN\14696793 burying\NN\1048912 )\-RRB-\1740 ,\,\1740 behavioral\JJ\1740 inflexibility\NN\5023741 (\-LRB-\1740 perseveration\NN\6196584 in\IN\13603305 the\DT\1740 spontaneous\JJ\1740 alternation\NN\1010458 task\NN\575741 and\CC\1740 impaired\JJ\1740 reversal\JJ\1740 learning\NN\5701944 )\-RRB-\1740 ,\,\1740 working\VBG\2524171 memory\NN\5926676 impairment\NN\7296428 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 win-shift\JJ\1740 paradigm\NN\13803782 )\-RRB-\1740 ,\,\1740 hoarding\VBG\2265979 ,\,\1740 and\CC\1740 corticostriatal\JJ\1740 dysfunction\NN\14204950 .\.\1740
D002997_-1 NONE RESULTS\NNS\34213 :\:\1740 <e1>Clomipramine</e1>\NN\4482543 exposure\NN\5042871 in\IN\13603305 immature\JJ\1740 rats\NNS\2329401 produced\VBD\1617192 significant\JJ\1740 behavioral\JJ\1740 and\CC\1740 biochemical\JJ\1740 changes\NNS\7283608 that\WDT\1740 include\VBP\690614 enhanced\VBN\227165 anxiety\NN\14373582 (\-LRB-\1740 elevated\JJ\1740 plus\CC\4723816 maze\NN\4377057 and\CC\1740 marble\NN\14696793 burying\NN\1048912 )\-RRB-\1740 ,\,\1740 <e2>behavioral\JJ\1740 inflexibility</e2>\NN\5023741 (\-LRB-\1740 perseveration\NN\6196584 in\IN\13603305 the\DT\1740 spontaneous\JJ\1740 alternation\NN\1010458 task\NN\575741 and\CC\1740 impaired\JJ\1740 reversal\JJ\1740 learning\NN\5701944 )\-RRB-\1740 ,\,\1740 working\VBG\2524171 memory\NN\5926676 impairment\NN\7296428 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 win-shift\JJ\1740 paradigm\NN\13803782 )\-RRB-\1740 ,\,\1740 hoarding\VBG\2265979 ,\,\1740 and\CC\1740 corticostriatal\JJ\1740 dysfunction\NN\14204950 .\.\1740
D002997_-1 NONE RESULTS\NNS\34213 :\:\1740 <e1>Clomipramine</e1>\NN\4482543 exposure\NN\5042871 in\IN\13603305 immature\JJ\1740 rats\NNS\2329401 produced\VBD\1617192 significant\JJ\1740 behavioral\JJ\1740 and\CC\1740 biochemical\JJ\1740 changes\NNS\7283608 that\WDT\1740 include\VBP\690614 enhanced\VBN\227165 anxiety\NN\14373582 (\-LRB-\1740 elevated\JJ\1740 plus\CC\4723816 maze\NN\4377057 and\CC\1740 marble\NN\14696793 burying\NN\1048912 )\-RRB-\1740 ,\,\1740 behavioral\JJ\1740 inflexibility\NN\5023741 (\-LRB-\1740 perseveration\NN\6196584 in\IN\13603305 the\DT\1740 spontaneous\JJ\1740 alternation\NN\1010458 task\NN\575741 and\CC\1740 impaired\JJ\1740 reversal\JJ\1740 learning\NN\5701944 )\-RRB-\1740 ,\,\1740 working\VBG\2524171 memory\NN\5926676 impairment\NN\7296428 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 win-shift\JJ\1740 paradigm\NN\13803782 )\-RRB-\1740 ,\,\1740 hoarding\VBG\2265979 ,\,\1740 and\CC\1740 <e2>corticostriatal\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D002997_D008569 CID RESULTS\NNS\34213 :\:\1740 <e1>Clomipramine</e1>\NN\4482543 exposure\NN\5042871 in\IN\13603305 immature\JJ\1740 rats\NNS\2329401 produced\VBD\1617192 significant\JJ\1740 behavioral\JJ\1740 and\CC\1740 biochemical\JJ\1740 changes\NNS\7283608 that\WDT\1740 include\VBP\690614 enhanced\VBN\227165 anxiety\NN\14373582 (\-LRB-\1740 elevated\JJ\1740 plus\CC\4723816 maze\NN\4377057 and\CC\1740 marble\NN\14696793 burying\NN\1048912 )\-RRB-\1740 ,\,\1740 behavioral\JJ\1740 inflexibility\NN\5023741 (\-LRB-\1740 perseveration\NN\6196584 in\IN\13603305 the\DT\1740 spontaneous\JJ\1740 alternation\NN\1010458 task\NN\575741 and\CC\1740 impaired\JJ\1740 reversal\JJ\1740 learning\NN\5701944 )\-RRB-\1740 ,\,\1740 working\VBG\2524171 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 win-shift\JJ\1740 paradigm\NN\13803782 )\-RRB-\1740 ,\,\1740 hoarding\VBG\2265979 ,\,\1740 and\CC\1740 corticostriatal\JJ\1740 dysfunction\NN\14204950 .\.\1740
D002997_D060845 CID RESULTS\NNS\34213 :\:\1740 <e1>Clomipramine</e1>\NN\4482543 exposure\NN\5042871 in\IN\13603305 immature\JJ\1740 rats\NNS\2329401 produced\VBD\1617192 significant\JJ\1740 behavioral\JJ\1740 and\CC\1740 biochemical\JJ\1740 changes\NNS\7283608 that\WDT\1740 include\VBP\690614 enhanced\VBN\227165 anxiety\NN\14373582 (\-LRB-\1740 elevated\JJ\1740 plus\CC\4723816 maze\NN\4377057 and\CC\1740 marble\NN\14696793 burying\NN\1048912 )\-RRB-\1740 ,\,\1740 behavioral\JJ\1740 inflexibility\NN\5023741 (\-LRB-\1740 perseveration\NN\6196584 in\IN\13603305 the\DT\1740 spontaneous\JJ\1740 alternation\NN\1010458 task\NN\575741 and\CC\1740 impaired\JJ\1740 reversal\JJ\1740 learning\NN\5701944 )\-RRB-\1740 ,\,\1740 working\VBG\2524171 memory\NN\5926676 impairment\NN\7296428 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 win-shift\JJ\1740 paradigm\NN\13803782 )\-RRB-\1740 ,\,\1740 <e2>hoarding</e2>\VBG\2265979 ,\,\1740 and\CC\1740 corticostriatal\JJ\1740 dysfunction\NN\14204950 .\.\1740
18329269
D006220_D002375 CID SAR\NNP\1740 studies\NNS\635850 led\VBD\1752884 to\TO\1740 compound\VB\156601 14\CD\13745420 with\IN\1740 excellent\JJ\1740 potency\NN\5196375 (\-LRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 0.4\CD\1740 nM\NN\13649268 )\-RRB-\1740 ,\,\1740 selectivity\NN\4916342 (\-LRB-\1740 A(1)/A(2A\NN\1740 )\-RRB-\1740 >\$\1740 100\CD\13745420 )\-RRB-\1740 ,\,\1740 and\CC\1740 efficacy\NN\5199286 (\-LRB-\1740 MED\NN\6700447 10\CD\13745420 mg/kg\NN\1740 p.o.\NN\10360747 )\-RRB-\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 <e1>haloperidol-induced</e1>\JJ\1740 <e2>catalepsy</e2>\NN\14023236 model\NN\5888929 for\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 .\.\1740
D006220_D010300 NONE SAR\NNP\1740 studies\NNS\635850 led\VBD\1752884 to\TO\1740 compound\VB\156601 14\CD\13745420 with\IN\1740 excellent\JJ\1740 potency\NN\5196375 (\-LRB-\1740 K(i\NN\1740 )\-RRB-\1740 =\JJ\1740 0.4\CD\1740 nM\NN\13649268 )\-RRB-\1740 ,\,\1740 selectivity\NN\4916342 (\-LRB-\1740 A(1)/A(2A\NN\1740 )\-RRB-\1740 >\$\1740 100\CD\13745420 )\-RRB-\1740 ,\,\1740 and\CC\1740 efficacy\NN\5199286 (\-LRB-\1740 MED\NN\6700447 10\CD\13745420 mg/kg\NN\1740 p.o.\NN\10360747 )\-RRB-\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 <e1>haloperidol-induced</e1>\JJ\1740 catalepsy\NN\14023236 model\NN\5888929 for\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
18752389
C492458_D017093 NONE <e1>Simvastatin-ezetimibe-induced</e1>\JJ\1740 <e2>hepatic\JJ\1740 failure</e2>\NN\66216 necessitating\NN\1740 liver\NN\5298729 transplantation\NN\671351 .\.\1740
C492458_D017093 NONE To\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 case\NN\7283608 report\NN\6470073 of\IN\1740 <e1>simvastatin-ezetimibe-induced</e1>\JJ\1740 <e2>liver\NN\5298729 failure</e2>\NN\66216 that\WDT\1740 resulted\VBD\2633881 in\IN\13603305 liver\NN\5298729 transplantation\NN\671351 .\.\1740
C108606_D056486 NONE However\RB\1740 ,\,\1740 <e2>hepatotoxic</e2>\JJ\1740 events\NNS\23100 have\VBP\2108377 not\RB\1740 been\VBN\836236 widely\RB\1740 published\VBN\1621555 with\IN\1740 <e1>ezetimibe</e1>\NN\1740 or\CC\3541091 the\DT\1740 combination\NN\7951464 agent\NN\7347 simvastatin-ezetimibe\JJ\1740 .\.\1740
C108606_D056486 NONE <e1>Ezetimibe</e1>\NN\1740 undergoes\VBZ\109660 extensive\JJ\1740 glucuronidation\NN\1740 by\IN\1740 uridine\JJ\1740 diphosphate\NN\1740 glucoronosyltransferases\NNS\1740 (\-LRB-\1740 UGT\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 intestine\NN\5298729 and\CC\1740 liver\NN\5298729 and\CC\1740 may\MD\15209706 have\VB\2108377 inhibited\VBN\2510337 the\DT\1740 glucuronidation\NN\1740 of\IN\1740 simvastatin\JJ\1740 hydroxy\JJ\1740 acid\NN\14818238 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 increased\VBN\169651 simvastatin\NN\3676175 exposure\NN\5042871 and\CC\1740 subsequent\JJ\1740 <e2>hepatotoxicity</e2>\NN\1740 .\.\1740
C108606_D056486 NONE We\PRP\1740 postulate\VBP\756338 that\IN\1740 the\DT\1740 mechanism\NN\13446390 of\IN\1740 the\DT\1740 simvastatinezetimibe-induced\JJ\1740 <e2>hepatotoxicity</e2>\NN\1740 is\VBZ\836236 the\DT\1740 increased\VBN\169651 simvastatin\NN\3676175 exposure\NN\5042871 by\IN\1740 <e1>ezetimibe</e1>\JJ\1740 inhibition\NN\1068773 of\IN\1740 UGT\NN\1740 enzymes\NNS\14723628 .\.\1740
C492458_D056486 CID However\RB\1740 ,\,\1740 <e2>hepatotoxic</e2>\JJ\1740 events\NNS\23100 have\VBP\2108377 not\RB\1740 been\VBN\836236 widely\RB\1740 published\VBN\1621555 with\IN\1740 ezetimibe\NN\1740 or\CC\3541091 the\DT\1740 combination\NN\7951464 agent\NN\7347 <e1>simvastatin-ezetimibe</e1>\JJ\1740 .\.\1740
C492458_D056486 CID <e1>Simvastatinezetimibe</e1>\NN\1740 and\CC\1740 escitalopram\NN\1740 (\-LRB-\1740 which\WDT\1740 she\PRP\1740 was\VBD\836236 taking\VBG\2367363 for\IN\1740 depression\NN\14373582 )\-RRB-\1740 were\VBD\836236 discontinued\VBN\2609764 ,\,\1740 and\CC\1740 other\JJ\1740 potential\JJ\1740 causes\NNS\7323922 of\IN\1740 <e2>hepatotoxicity</e2>\NN\1740 were\VBD\836236 excluded\VBN\471711 .\.\1740
C492458_D056486 CID We\PRP\1740 postulate\VBP\756338 that\IN\1740 the\DT\1740 mechanism\NN\13446390 of\IN\1740 the\DT\1740 <e1>simvastatinezetimibe-induced</e1>\JJ\1740 <e2>hepatotoxicity</e2>\NN\1740 is\VBZ\836236 the\DT\1740 increased\VBN\169651 simvastatin\NN\3676175 exposure\NN\5042871 by\IN\1740 ezetimibe\JJ\1740 inhibition\NN\1068773 of\IN\1740 UGT\NN\1740 enzymes\NNS\14723628 .\.\1740
C492458_D056486 CID Clinicians\NNS\10462860 should\MD\1740 be\VB\836236 aware\JJ\1740 of\IN\1740 potential\JJ\1740 <e2>hepatotoxicity</e2>\NN\1740 with\IN\1740 <e1>simvastatin-ezetimibe</e1>\NN\1740 especially\RB\1740 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 and\CC\1740 should\MD\1740 carefully\RB\1740 monitor\VB\2169352 serum\NN\5397468 aminotransferase\NN\15077571 levels\NNS\4916342 when\WRB\1740 starting\VBG\2009433 therapy\NN\657604 and\CC\1740 titrating\VBG\489837 the\DT\1740 dosage\NN\13576355 .\.\1740
D019821_D017114 NONE We\PRP\1740 describe\VBP\1001294 a\DT\13649268 70-year-old\JJ\1740 Hispanic\JJ\1740 woman\NN\9605289 who\WP\8299493 developed\VBD\1753788 <e2>fulminant\JJ\1740 hepatic\JJ\1740 failure</e2>\NN\66216 necessitating\NN\1740 liver\NN\5298729 transplantation\NN\671351 10\CD\13745420 weeks\NNS\15113229 after\IN\1740 conversion\NN\7359599 from\IN\1740 <e1>simvastatin</e1>\NN\3676175 40\CD\13745420 mg/day\NN\1740 to\TO\1740 simvastatin\NN\3676175 10\CD\13745420 mg-ezetimibe\NNS\1740 40\CD\13745420 mg/day\NN\1740 .\.\1740
C492458_D017114 CID We\PRP\1740 describe\VBP\1001294 a\DT\13649268 70-year-old\JJ\1740 Hispanic\JJ\1740 woman\NN\9605289 who\WP\8299493 developed\VBD\1753788 <e2>fulminant\JJ\1740 hepatic\JJ\1740 failure</e2>\NN\66216 necessitating\NN\1740 liver\NN\5298729 transplantation\NN\671351 10\CD\13745420 weeks\NNS\15113229 after\IN\1740 conversion\NN\7359599 from\IN\1740 simvastatin\NN\3676175 40\CD\13745420 mg/day\NN\1740 to\TO\1740 <e1>simvastatin\NN\3676175 10\CD\13745420 mg-ezetimibe\NNS\1740 40\CD\13745420 mg/day</e1>\NN\1740 .\.\1740
D019821_D056486 NONE The\DT\1740 patient\NN\9898892 's\POS\1740 lipid\NN\14944888 panel\NN\4188643 had\VBD\2108377 been\VBN\836236 maintained\VBN\2202928 with\IN\1740 <e1>simvastatin</e1>\NN\3676175 for\IN\1740 18\CD\13745420 months\NNS\15113229 before\IN\1740 the\DT\1740 conversion\NN\7359599 without\IN\1740 evidence\NN\5816287 of\IN\1740 <e2>hepatotoxicity</e2>\NN\1740 .\.\1740
D019821_D056486 NONE Ezetimibe\NN\1740 undergoes\VBZ\109660 extensive\JJ\1740 glucuronidation\NN\1740 by\IN\1740 uridine\JJ\1740 diphosphate\NN\1740 glucoronosyltransferases\NNS\1740 (\-LRB-\1740 UGT\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 intestine\NN\5298729 and\CC\1740 liver\NN\5298729 and\CC\1740 may\MD\15209706 have\VB\2108377 inhibited\VBN\2510337 the\DT\1740 glucuronidation\NN\1740 of\IN\1740 simvastatin\JJ\1740 hydroxy\JJ\1740 acid\NN\14818238 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 increased\VBN\169651 <e1>simvastatin</e1>\NN\3676175 exposure\NN\5042871 and\CC\1740 subsequent\JJ\1740 <e2>hepatotoxicity</e2>\NN\1740 .\.\1740
D019821_D056486 NONE We\PRP\1740 postulate\VBP\756338 that\IN\1740 the\DT\1740 mechanism\NN\13446390 of\IN\1740 the\DT\1740 simvastatinezetimibe-induced\JJ\1740 <e2>hepatotoxicity</e2>\NN\1740 is\VBZ\836236 the\DT\1740 increased\VBN\169651 <e1>simvastatin</e1>\NN\3676175 exposure\NN\5042871 by\IN\1740 ezetimibe\JJ\1740 inhibition\NN\1068773 of\IN\1740 UGT\NN\1740 enzymes\NNS\14723628 .\.\1740
C492458_D003866 NONE <e1>Simvastatinezetimibe</e1>\NN\1740 and\CC\1740 escitalopram\NN\1740 (\-LRB-\1740 which\WDT\1740 she\PRP\1740 was\VBD\836236 taking\VBG\2367363 for\IN\1740 <e2>depression</e2>\NN\14373582 )\-RRB-\1740 were\VBD\836236 discontinued\VBN\2609764 ,\,\1740 and\CC\1740 other\JJ\1740 potential\JJ\1740 causes\NNS\7323922 of\IN\1740 hepatotoxicity\NN\1740 were\VBD\836236 excluded\VBN\471711 .\.\1740
D015283_D003866 NONE Simvastatinezetimibe\NN\1740 and\CC\1740 <e1>escitalopram</e1>\NN\1740 (\-LRB-\1740 which\WDT\1740 she\PRP\1740 was\VBD\836236 taking\VBG\2367363 for\IN\1740 <e2>depression</e2>\NN\14373582 )\-RRB-\1740 were\VBD\836236 discontinued\VBN\2609764 ,\,\1740 and\CC\1740 other\JJ\1740 potential\JJ\1740 causes\NNS\7323922 of\IN\1740 hepatotoxicity\NN\1740 were\VBD\836236 excluded\VBN\471711 .\.\1740
D015283_D056486 NONE Simvastatinezetimibe\NN\1740 and\CC\1740 <e1>escitalopram</e1>\NN\1740 (\-LRB-\1740 which\WDT\1740 she\PRP\1740 was\VBD\836236 taking\VBG\2367363 for\IN\1740 depression\NN\14373582 )\-RRB-\1740 were\VBD\836236 discontinued\VBN\2609764 ,\,\1740 and\CC\1740 other\JJ\1740 potential\JJ\1740 causes\NNS\7323922 of\IN\1740 <e2>hepatotoxicity</e2>\NN\1740 were\VBD\836236 excluded\VBN\471711 .\.\1740
D014530_D056486 NONE Ezetimibe\NN\1740 undergoes\VBZ\109660 extensive\JJ\1740 glucuronidation\NN\1740 by\IN\1740 <e1>uridine\JJ\1740 diphosphate</e1>\NN\1740 glucoronosyltransferases\NNS\1740 (\-LRB-\1740 UGT\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 intestine\NN\5298729 and\CC\1740 liver\NN\5298729 and\CC\1740 may\MD\15209706 have\VB\2108377 inhibited\VBN\2510337 the\DT\1740 glucuronidation\NN\1740 of\IN\1740 simvastatin\JJ\1740 hydroxy\JJ\1740 acid\NN\14818238 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 increased\VBN\169651 simvastatin\NN\3676175 exposure\NN\5042871 and\CC\1740 subsequent\JJ\1740 <e2>hepatotoxicity</e2>\NN\1740 .\.\1740
C532833_D056486 NONE Ezetimibe\NN\1740 undergoes\VBZ\109660 extensive\JJ\1740 glucuronidation\NN\1740 by\IN\1740 uridine\JJ\1740 diphosphate\NN\1740 glucoronosyltransferases\NNS\1740 (\-LRB-\1740 UGT\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 intestine\NN\5298729 and\CC\1740 liver\NN\5298729 and\CC\1740 may\MD\15209706 have\VB\2108377 inhibited\VBN\2510337 the\DT\1740 glucuronidation\NN\1740 of\IN\1740 <e1>simvastatin\JJ\1740 hydroxy\JJ\1740 acid</e1>\NN\14818238 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 increased\VBN\169651 simvastatin\NN\3676175 exposure\NN\5042871 and\CC\1740 subsequent\JJ\1740 <e2>hepatotoxicity</e2>\NN\1740 .\.\1740
8996652
D000617_D006311 NONE <e2>Ototoxicity</e2>\NN\1740 appeared\VBD\2604760 closely\RB\1740 related\JJ\1740 to\TO\1740 a\DT\13649268 prolonged\JJ\1740 administration\NN\1133281 and\CC\1740 higher\JJR\1740 total\JJ\1740 dose\NN\3740161 of\IN\1740 ototoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 particularly\RB\1740 <e1>aminoglycosides</e1>\NNS\1740 and\CC\1740 furosemide\NN\3214670 .\.\1740
D000617_D006311 NONE Ototoxicity\NN\1740 appeared\VBD\2604760 closely\RB\1740 related\JJ\1740 to\TO\1740 a\DT\13649268 prolonged\JJ\1740 administration\NN\1133281 and\CC\1740 higher\JJR\1740 total\JJ\1740 dose\NN\3740161 of\IN\1740 <e2>ototoxic</e2>\JJ\1740 drugs\NNS\14778436 ,\,\1740 particularly\RB\1740 <e1>aminoglycosides</e1>\NNS\1740 and\CC\1740 furosemide\NN\3214670 .\.\1740
D005665_D006311 NONE <e2>Ototoxicity</e2>\NN\1740 appeared\VBD\2604760 closely\RB\1740 related\JJ\1740 to\TO\1740 a\DT\13649268 prolonged\JJ\1740 administration\NN\1133281 and\CC\1740 higher\JJR\1740 total\JJ\1740 dose\NN\3740161 of\IN\1740 ototoxic\JJ\1740 drugs\NNS\14778436 ,\,\1740 particularly\RB\1740 aminoglycosides\NNS\1740 and\CC\1740 <e1>furosemide</e1>\NN\3214670 .\.\1740
D005665_D006311 NONE Ototoxicity\NN\1740 appeared\VBD\2604760 closely\RB\1740 related\JJ\1740 to\TO\1740 a\DT\13649268 prolonged\JJ\1740 administration\NN\1133281 and\CC\1740 higher\JJR\1740 total\JJ\1740 dose\NN\3740161 of\IN\1740 <e2>ototoxic</e2>\JJ\1740 drugs\NNS\14778436 ,\,\1740 particularly\RB\1740 aminoglycosides\NNS\1740 and\CC\1740 <e1>furosemide</e1>\NN\3214670 .\.\1740
19759529
D004298_D012559 NONE <e2>Schizophrenia</e2>\NNP\14398067 has\VBZ\2108377 been\VBN\836236 initially\RB\1740 associated\VBN\628491 with\IN\1740 dysfunction\NN\14204950 in\IN\13603305 <e1>dopamine</e1>\NN\14807737 neurotransmission\NN\1740 .\.\1740
D018698_D012559 NONE However\RB\1740 ,\,\1740 the\DT\1740 observation\NN\996969 that\IN\1740 antagonists\NNS\7846 of\IN\1740 the\DT\1740 <e1>glutamate</e1>\JJ\1740 N-methyl-D-aspartate\NN\1740 (\-LRB-\1740 NMDA\NN\1740 )\-RRB-\1740 receptor\NN\5225602 produce\VBP\1617192 <e2>schizophrenic-like</e2>\JJ\1740 symptoms\NNS\5823932 in\IN\13603305 humans\NNS\31264 has\VBZ\2108377 led\VBN\1752884 to\IN\1740 the\DT\1740 idea\NN\5809192 of\IN\1740 a\DT\13649268 dysfunctioning\NN\1740 of\IN\1740 the\DT\1740 glutamatergic\JJ\1740 system\NN\3575240 via\IN\1740 its\PRP$\6125041 NMDA\NN\1740 receptor\NN\5225602 .\.\1740
D016202_D012559 NONE However\RB\1740 ,\,\1740 the\DT\1740 observation\NN\996969 that\IN\1740 antagonists\NNS\7846 of\IN\1740 the\DT\1740 glutamate\JJ\1740 <e1>N-methyl-D-aspartate</e1>\NN\1740 (\-LRB-\1740 NMDA\NN\1740 )\-RRB-\1740 receptor\NN\5225602 produce\VBP\1617192 <e2>schizophrenic-like</e2>\JJ\1740 symptoms\NNS\5823932 in\IN\13603305 humans\NNS\31264 has\VBZ\2108377 led\VBN\1752884 to\IN\1740 the\DT\1740 idea\NN\5809192 of\IN\1740 a\DT\13649268 dysfunctioning\NN\1740 of\IN\1740 the\DT\1740 glutamatergic\JJ\1740 system\NN\3575240 via\IN\1740 its\PRP$\6125041 NMDA\NN\1740 receptor\NN\5225602 .\.\1740
D016202_D012559 NONE However\RB\1740 ,\,\1740 the\DT\1740 observation\NN\996969 that\IN\1740 antagonists\NNS\7846 of\IN\1740 the\DT\1740 glutamate\JJ\1740 N-methyl-D-aspartate\NN\1740 (\-LRB-\1740 <e1>NMDA</e1>\NN\1740 )\-RRB-\1740 receptor\NN\5225602 produce\VBP\1617192 <e2>schizophrenic-like</e2>\JJ\1740 symptoms\NNS\5823932 in\IN\13603305 humans\NNS\31264 has\VBZ\2108377 led\VBN\1752884 to\IN\1740 the\DT\1740 idea\NN\5809192 of\IN\1740 a\DT\13649268 dysfunctioning\NN\1740 of\IN\1740 the\DT\1740 glutamatergic\JJ\1740 system\NN\3575240 via\IN\1740 its\PRP$\6125041 NMDA\NN\1740 receptor\NN\5225602 .\.\1740
D016202_D012559 NONE However\RB\1740 ,\,\1740 the\DT\1740 observation\NN\996969 that\IN\1740 antagonists\NNS\7846 of\IN\1740 the\DT\1740 glutamate\JJ\1740 N-methyl-D-aspartate\NN\1740 (\-LRB-\1740 NMDA\NN\1740 )\-RRB-\1740 receptor\NN\5225602 produce\VBP\1617192 <e2>schizophrenic-like</e2>\JJ\1740 symptoms\NNS\5823932 in\IN\13603305 humans\NNS\31264 has\VBZ\2108377 led\VBN\1752884 to\IN\1740 the\DT\1740 idea\NN\5809192 of\IN\1740 a\DT\13649268 dysfunctioning\NN\1740 of\IN\1740 the\DT\1740 glutamatergic\JJ\1740 system\NN\3575240 via\IN\1740 its\PRP$\6125041 <e1>NMDA</e1>\NN\1740 receptor\NN\5225602 .\.\1740
-1_D006948 NONE This\DT\1740 study\NN\635850 aimed\VBN\1987160 at\IN\14622893 investigating\VBG\644583 the\DT\1740 potential\JJ\1740 antipsychotic-like\JJ\1740 properties\NNS\32613 of\IN\1740 <e1>SSR103800</e1>\NN\1740 ,\,\1740 with\IN\1740 a\DT\13649268 particular\JJ\1740 focus\NN\5704266 on\IN\1740 models\NNS\5888929 of\IN\1740 <e2>hyperactivity</e2>\NN\14052403 ,\,\1740 involving\VBG\2676054 either\DT\1740 drug\NN\14778436 challenge\NN\13927383 (\-LRB-\1740 ie\FW\1740 ,\,\1740 amphetamine\NN\3248958 and\CC\1740 MK-801\NN\1740 )\-RRB-\1740 or\CC\3541091 transgenic\JJ\1740 mice\NNS\2329401 (\-LRB-\1740 ie\FW\1740 ,\,\1740 NMDA\NN\1740 Nr1(neo-/-\NN\1740 )\-RRB-\1740 and\CC\1740 DAT(-/-\NN\1740 )\-RRB-\1740 )\-RRB-\1740 .\.\1740
-1_D006948 NONE Results\NNS\34213 showed\VBD\2137132 that\IN\1740 <e1>SSR103800</e1>\NN\1740 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 30\CD\13745420 mg/kg\NN\1740 p.o.\NN\10360747 )\-RRB-\1740 blocked\VBD\1476483 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 the\DT\1740 non-competitive\JJ\1740 NMDA\NN\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 MK-801\NN\1740 and\CC\1740 partially\RB\1740 reversed\VBN\109660 spontaneous\JJ\1740 hyperactivity\NN\14052403 of\IN\1740 NMDA\NN\1740 Nr1(neo-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 .\.\1740
-1_D006948 NONE Results\NNS\34213 showed\VBD\2137132 that\IN\1740 <e1>SSR103800</e1>\NN\1740 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 30\CD\13745420 mg/kg\NN\1740 p.o.\NN\10360747 )\-RRB-\1740 blocked\VBD\1476483 hyperactivity\NN\14052403 induced\VBN\1627355 by\IN\1740 the\DT\1740 non-competitive\JJ\1740 NMDA\NN\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 MK-801\NN\1740 and\CC\1740 partially\RB\1740 reversed\VBN\109660 spontaneous\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 of\IN\1740 NMDA\NN\1740 Nr1(neo-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 .\.\1740
-1_D006948 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 <e1>SSR103800</e1>\NN\1740 failed\VBD\1798936 to\TO\1740 affect\VB\126264 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 amphetamine\NN\3248958 or\CC\3541091 naturally\RB\1740 observed\VBN\2163746 in\IN\13603305 dopamine\NN\14807737 transporter\NN\4490091 (\-LRB-\1740 DAT(-/-\NN\1740 )\-RRB-\1740 )\-RRB-\1740 knockout\JJ\1740 mice\NNS\2329401 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 30\CD\13745420 mg/kg\NN\1740 p.o.\NN\10360747 )\-RRB-\1740 .\.\1740
D000661_D006948 CID This\DT\1740 study\NN\635850 aimed\VBN\1987160 at\IN\14622893 investigating\VBG\644583 the\DT\1740 potential\JJ\1740 antipsychotic-like\JJ\1740 properties\NNS\32613 of\IN\1740 SSR103800\NN\1740 ,\,\1740 with\IN\1740 a\DT\13649268 particular\JJ\1740 focus\NN\5704266 on\IN\1740 models\NNS\5888929 of\IN\1740 <e2>hyperactivity</e2>\NN\14052403 ,\,\1740 involving\VBG\2676054 either\DT\1740 drug\NN\14778436 challenge\NN\13927383 (\-LRB-\1740 ie\FW\1740 ,\,\1740 <e1>amphetamine</e1>\NN\3248958 and\CC\1740 MK-801\NN\1740 )\-RRB-\1740 or\CC\3541091 transgenic\JJ\1740 mice\NNS\2329401 (\-LRB-\1740 ie\FW\1740 ,\,\1740 NMDA\NN\1740 Nr1(neo-/-\NN\1740 )\-RRB-\1740 and\CC\1740 DAT(-/-\NN\1740 )\-RRB-\1740 )\-RRB-\1740 .\.\1740
D000661_D006948 CID In\IN\13603305 contrast\NN\13854649 ,\,\1740 SSR103800\NN\1740 failed\VBD\1798936 to\TO\1740 affect\VB\126264 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 <e1>amphetamine</e1>\NN\3248958 or\CC\3541091 naturally\RB\1740 observed\VBN\2163746 in\IN\13603305 dopamine\NN\14807737 transporter\NN\4490091 (\-LRB-\1740 DAT(-/-\NN\1740 )\-RRB-\1740 )\-RRB-\1740 knockout\JJ\1740 mice\NNS\2329401 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 30\CD\13745420 mg/kg\NN\1740 p.o.\NN\10360747 )\-RRB-\1740 .\.\1740
D016291_D006948 CID This\DT\1740 study\NN\635850 aimed\VBN\1987160 at\IN\14622893 investigating\VBG\644583 the\DT\1740 potential\JJ\1740 antipsychotic-like\JJ\1740 properties\NNS\32613 of\IN\1740 SSR103800\NN\1740 ,\,\1740 with\IN\1740 a\DT\13649268 particular\JJ\1740 focus\NN\5704266 on\IN\1740 models\NNS\5888929 of\IN\1740 <e2>hyperactivity</e2>\NN\14052403 ,\,\1740 involving\VBG\2676054 either\DT\1740 drug\NN\14778436 challenge\NN\13927383 (\-LRB-\1740 ie\FW\1740 ,\,\1740 amphetamine\NN\3248958 and\CC\1740 <e1>MK-801</e1>\NN\1740 )\-RRB-\1740 or\CC\3541091 transgenic\JJ\1740 mice\NNS\2329401 (\-LRB-\1740 ie\FW\1740 ,\,\1740 NMDA\NN\1740 Nr1(neo-/-\NN\1740 )\-RRB-\1740 and\CC\1740 DAT(-/-\NN\1740 )\-RRB-\1740 )\-RRB-\1740 .\.\1740
D016291_D006948 CID Results\NNS\34213 showed\VBD\2137132 that\IN\1740 SSR103800\NN\1740 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 30\CD\13745420 mg/kg\NN\1740 p.o.\NN\10360747 )\-RRB-\1740 blocked\VBD\1476483 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 the\DT\1740 non-competitive\JJ\1740 NMDA\NN\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 <e1>MK-801</e1>\NN\1740 and\CC\1740 partially\RB\1740 reversed\VBN\109660 spontaneous\JJ\1740 hyperactivity\NN\14052403 of\IN\1740 NMDA\NN\1740 Nr1(neo-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 .\.\1740
D016291_D006948 CID Results\NNS\34213 showed\VBD\2137132 that\IN\1740 SSR103800\NN\1740 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 30\CD\13745420 mg/kg\NN\1740 p.o.\NN\10360747 )\-RRB-\1740 blocked\VBD\1476483 hyperactivity\NN\14052403 induced\VBN\1627355 by\IN\1740 the\DT\1740 non-competitive\JJ\1740 NMDA\NN\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 <e1>MK-801</e1>\NN\1740 and\CC\1740 partially\RB\1740 reversed\VBN\109660 spontaneous\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 of\IN\1740 NMDA\NN\1740 Nr1(neo-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 .\.\1740
D016202_D006948 NONE This\DT\1740 study\NN\635850 aimed\VBN\1987160 at\IN\14622893 investigating\VBG\644583 the\DT\1740 potential\JJ\1740 antipsychotic-like\JJ\1740 properties\NNS\32613 of\IN\1740 SSR103800\NN\1740 ,\,\1740 with\IN\1740 a\DT\13649268 particular\JJ\1740 focus\NN\5704266 on\IN\1740 models\NNS\5888929 of\IN\1740 <e2>hyperactivity</e2>\NN\14052403 ,\,\1740 involving\VBG\2676054 either\DT\1740 drug\NN\14778436 challenge\NN\13927383 (\-LRB-\1740 ie\FW\1740 ,\,\1740 amphetamine\NN\3248958 and\CC\1740 MK-801\NN\1740 )\-RRB-\1740 or\CC\3541091 transgenic\JJ\1740 mice\NNS\2329401 (\-LRB-\1740 ie\FW\1740 ,\,\1740 <e1>NMDA</e1>\NN\1740 Nr1(neo-/-\NN\1740 )\-RRB-\1740 and\CC\1740 DAT(-/-\NN\1740 )\-RRB-\1740 )\-RRB-\1740 .\.\1740
D016202_D006948 NONE Results\NNS\34213 showed\VBD\2137132 that\IN\1740 SSR103800\NN\1740 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 30\CD\13745420 mg/kg\NN\1740 p.o.\NN\10360747 )\-RRB-\1740 blocked\VBD\1476483 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 the\DT\1740 non-competitive\JJ\1740 <e1>NMDA</e1>\NN\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 MK-801\NN\1740 and\CC\1740 partially\RB\1740 reversed\VBN\109660 spontaneous\JJ\1740 hyperactivity\NN\14052403 of\IN\1740 NMDA\NN\1740 Nr1(neo-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 .\.\1740
D016202_D006948 NONE Results\NNS\34213 showed\VBD\2137132 that\IN\1740 SSR103800\NN\1740 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 30\CD\13745420 mg/kg\NN\1740 p.o.\NN\10360747 )\-RRB-\1740 blocked\VBD\1476483 hyperactivity\NN\14052403 induced\VBN\1627355 by\IN\1740 the\DT\1740 non-competitive\JJ\1740 <e1>NMDA</e1>\NN\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 MK-801\NN\1740 and\CC\1740 partially\RB\1740 reversed\VBN\109660 spontaneous\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 of\IN\1740 NMDA\NN\1740 Nr1(neo-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 .\.\1740
D016202_D006948 NONE Results\NNS\34213 showed\VBD\2137132 that\IN\1740 SSR103800\NN\1740 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 30\CD\13745420 mg/kg\NN\1740 p.o.\NN\10360747 )\-RRB-\1740 blocked\VBD\1476483 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 the\DT\1740 non-competitive\JJ\1740 NMDA\NN\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 MK-801\NN\1740 and\CC\1740 partially\RB\1740 reversed\VBN\109660 spontaneous\JJ\1740 hyperactivity\NN\14052403 of\IN\1740 <e1>NMDA</e1>\NN\1740 Nr1(neo-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 .\.\1740
D016202_D006948 NONE Results\NNS\34213 showed\VBD\2137132 that\IN\1740 SSR103800\NN\1740 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 30\CD\13745420 mg/kg\NN\1740 p.o.\NN\10360747 )\-RRB-\1740 blocked\VBD\1476483 hyperactivity\NN\14052403 induced\VBN\1627355 by\IN\1740 the\DT\1740 non-competitive\JJ\1740 NMDA\NN\1740 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 MK-801\NN\1740 and\CC\1740 partially\RB\1740 reversed\VBN\109660 spontaneous\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 of\IN\1740 <e1>NMDA</e1>\NN\1740 Nr1(neo-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 .\.\1740
D004298_D006948 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 SSR103800\NN\1740 failed\VBD\1798936 to\TO\1740 affect\VB\126264 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 amphetamine\NN\3248958 or\CC\3541091 naturally\RB\1740 observed\VBN\2163746 in\IN\13603305 <e1>dopamine</e1>\NN\14807737 transporter\NN\4490091 (\-LRB-\1740 DAT(-/-\NN\1740 )\-RRB-\1740 )\-RRB-\1740 knockout\JJ\1740 mice\NNS\2329401 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 30\CD\13745420 mg/kg\NN\1740 p.o.\NN\10360747 )\-RRB-\1740 .\.\1740
D006220_D006948 NONE Importantly\RB\1740 ,\,\1740 both\CC\1740 classical\JJ\1740 (\-LRB-\1740 <e1>haloperidol</e1>\NN\3713736 )\-RRB-\1740 and\CC\1740 atypical\JJ\1740 (\-LRB-\1740 olanzapine\NN\1740 ,\,\1740 clozapine\NN\3713736 and\CC\1740 aripiprazole\NN\1740 )\-RRB-\1740 antipsychotics\NNS\4470232 were\VBD\836236 effective\JJ\1740 in\IN\13603305 all\PDT\1740 these\DT\1740 models\NNS\5888929 of\IN\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
C076029_D006948 NONE Importantly\RB\1740 ,\,\1740 both\CC\1740 classical\JJ\1740 (\-LRB-\1740 haloperidol\NN\3713736 )\-RRB-\1740 and\CC\1740 atypical\JJ\1740 (\-LRB-\1740 <e1>olanzapine</e1>\NN\1740 ,\,\1740 clozapine\NN\3713736 and\CC\1740 aripiprazole\NN\1740 )\-RRB-\1740 antipsychotics\NNS\4470232 were\VBD\836236 effective\JJ\1740 in\IN\13603305 all\PDT\1740 these\DT\1740 models\NNS\5888929 of\IN\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
D003024_D006948 NONE Importantly\RB\1740 ,\,\1740 both\CC\1740 classical\JJ\1740 (\-LRB-\1740 haloperidol\NN\3713736 )\-RRB-\1740 and\CC\1740 atypical\JJ\1740 (\-LRB-\1740 olanzapine\NN\1740 ,\,\1740 <e1>clozapine</e1>\NN\3713736 and\CC\1740 aripiprazole\NN\1740 )\-RRB-\1740 antipsychotics\NNS\4470232 were\VBD\836236 effective\JJ\1740 in\IN\13603305 all\PDT\1740 these\DT\1740 models\NNS\5888929 of\IN\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
C094645_D006948 NONE Importantly\RB\1740 ,\,\1740 both\CC\1740 classical\JJ\1740 (\-LRB-\1740 haloperidol\NN\3713736 )\-RRB-\1740 and\CC\1740 atypical\JJ\1740 (\-LRB-\1740 olanzapine\NN\1740 ,\,\1740 clozapine\NN\3713736 and\CC\1740 <e1>aripiprazole</e1>\NN\1740 )\-RRB-\1740 antipsychotics\NNS\4470232 were\VBD\836236 effective\JJ\1740 in\IN\13603305 all\PDT\1740 these\DT\1740 models\NNS\5888929 of\IN\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
-1_D002375 NONE However\RB\1740 ,\,\1740 unlike\IN\1740 these\DT\1740 latter\JJ\1740 ,\,\1740 <e1>SSR103800</e1>\NN\1740 did\VBD\1640855 not\RB\1740 produce\VB\1617192 <e2>catalepsy</e2>\NN\14023236 (\-LRB-\1740 retention\NN\809465 on\IN\1740 the\DT\1740 bar\NN\4105893 test\NN\5798043 )\-RRB-\1740 up\IN\1740 to\TO\1740 30\CD\13745420 mg/kg\NN\1740 p.o.\NN\10360747 Together\RB\1740 these\DT\1740 findings\NNS\7951464 show\VBP\2137132 that\IN\1740 the\DT\1740 GlyT1\NN\1740 inhibitor\NN\20090 ,\,\1740 SSR103800\NN\1740 ,\,\1740 produces\VBZ\1617192 antipsychotic-like\JJ\1740 effects\NNS\13245626 ,\,\1740 which\WDT\1740 differ\VBP\1740 from\IN\1740 those\DT\1740 observed\VBN\2163746 with\IN\1740 compounds\NNS\5869584 primarily\RB\1740 targeting\VBG\1151110 the\DT\1740 dopaminergic\JJ\1740 system\NN\3575240 ,\,\1740 and\CC\1740 has\VBZ\2108377 a\DT\13649268 reduced\VBN\441445 side-effect\JJ\1740 potential\NN\14481929 as\IN\14622893 compared\VBN\644583 with\IN\1740 these\DT\1740 latter\JJ\1740 drugs\NNS\14778436 .\.\1740
-1_D002375 NONE However\RB\1740 ,\,\1740 unlike\IN\1740 these\DT\1740 latter\JJ\1740 ,\,\1740 SSR103800\NN\1740 did\VBD\1640855 not\RB\1740 produce\VB\1617192 <e2>catalepsy</e2>\NN\14023236 (\-LRB-\1740 retention\NN\809465 on\IN\1740 the\DT\1740 bar\NN\4105893 test\NN\5798043 )\-RRB-\1740 up\IN\1740 to\TO\1740 30\CD\13745420 mg/kg\NN\1740 p.o.\NN\10360747 Together\RB\1740 these\DT\1740 findings\NNS\7951464 show\VBP\2137132 that\IN\1740 the\DT\1740 GlyT1\NN\1740 inhibitor\NN\20090 ,\,\1740 <e1>SSR103800</e1>\NN\1740 ,\,\1740 produces\VBZ\1617192 antipsychotic-like\JJ\1740 effects\NNS\13245626 ,\,\1740 which\WDT\1740 differ\VBP\1740 from\IN\1740 those\DT\1740 observed\VBN\2163746 with\IN\1740 compounds\NNS\5869584 primarily\RB\1740 targeting\VBG\1151110 the\DT\1740 dopaminergic\JJ\1740 system\NN\3575240 ,\,\1740 and\CC\1740 has\VBZ\2108377 a\DT\13649268 reduced\VBN\441445 side-effect\JJ\1740 potential\NN\14481929 as\IN\14622893 compared\VBN\644583 with\IN\1740 these\DT\1740 latter\JJ\1740 drugs\NNS\14778436 .\.\1740
8170551
D000086_D053040 NONE <e1>Acetazolamide-induced</e1>\JJ\1740 <e2>nephrolithiasis</e2>\NN\14115914 :\:\1740 implications\NNS\5774614 for\IN\1740 treatment\NN\654885 of\IN\1740 neuromuscular\JJ\1740 disorders\NNS\14034177 .\.\1740
D000086_D053040 NONE <e2>Nephrolithiasis</e2>\NN\14115914 is\VBZ\836236 a\DT\13649268 complication\NN\1073995 of\IN\1740 <e1>acetazolamide</e1>\NN\1740 but\CC\1740 does\VBZ\1640855 not\RB\1740 preclude\VB\2629256 its\PRP$\6125041 use\NN\407535 .\.\1740
D000086_D009468 NONE <e1>Acetazolamide-induced</e1>\JJ\1740 nephrolithiasis\NN\14115914 :\:\1740 implications\NNS\5774614 for\IN\1740 treatment\NN\654885 of\IN\1740 <e2>neuromuscular\JJ\1740 disorders</e2>\NNS\14034177 .\.\1740
D000086_D007669 CID Three\CD\13741022 patients\NNS\9898892 on\IN\1740 <e1>acetazolamide</e1>\NN\1740 (\-LRB-\1740 15\CD\13745420 %\NN\1740 )\-RRB-\1740 developed\VBD\1753788 <e2>renal\JJ\1740 calculi</e2>\NNS\9416076 .\.\1740
10342929
D000806_D000799 CID <e2>Angioedema</e2>\NNP\14316714 due\JJ\1740 to\TO\1740 <e1>ACE\NN\13741022 inhibitors</e1>\NNS\20090 :\:\1740 common\JJ\1740 and\CC\1740 inadequately\RB\1740 diagnosed\VBN\644583 .\.\1740
D000806_D000799 CID The\DT\1740 estimated\VBN\637259 incidence\NN\13821570 of\IN\1740 <e2>angioedema</e2>\NN\14316714 during\IN\1740 <e1>angiotensin-converting\JJ\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitor</e1>\NN\20090 treatment\NN\654885 is\VBZ\836236 between\IN\1740 1\CD\13741022 and\CC\1740 7\CD\13741022 per\IN\1740 thousand\CD\13745420 patients\NNS\9898892 .\.\1740
15275829
D000109_D012640 NONE The\DT\1740 alpha3\NN\1740 and\CC\1740 beta4\NN\1740 nicotinic\JJ\1740 <e1>acetylcholine</e1>\NN\14807558 receptor\NN\5225602 subunits\NNS\13604718 are\VBP\836236 necessary\JJ\1740 for\IN\1740 nicotine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 hypolocomotion\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D000109_D012640 NONE Binding\NN\4688246 of\IN\1740 nicotine\NN\14712692 to\TO\1740 nicotinic\JJ\1740 <e1>acetylcholine</e1>\NN\14807558 receptors\NNS\5225602 (\-LRB-\1740 nAChRs\NNS\1740 )\-RRB-\1740 elicits\VBZ\1617192 a\DT\13649268 series\NN\8456993 of\IN\1740 dose-dependent\JJ\1740 behaviors\NNS\407535 that\WDT\1740 go\VBP\2367363 from\IN\1740 altered\JJ\1740 exploration\NN\309647 ,\,\1740 sedation\NN\14034177 ,\,\1740 and\CC\1740 tremors\NNS\345926 ,\,\1740 to\IN\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 death\NN\7296428 .\.\1740
D000109_D006948 NONE The\DT\1740 alpha3\NN\1740 and\CC\1740 beta4\NN\1740 nicotinic\JJ\1740 <e1>acetylcholine</e1>\NN\14807558 receptor\NN\5225602 subunits\NNS\13604718 are\VBP\836236 necessary\JJ\1740 for\IN\1740 nicotine-induced\JJ\1740 seizures\NNS\14081375 and\CC\1740 <e2>hypolocomotion</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D009538_D012640 CID The\DT\1740 alpha3\NN\1740 and\CC\1740 beta4\NN\1740 nicotinic\JJ\1740 acetylcholine\NN\14807558 receptor\NN\5225602 subunits\NNS\13604718 are\VBP\836236 necessary\JJ\1740 for\IN\1740 <e1>nicotine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 hypolocomotion\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D009538_D012640 CID Binding\NN\4688246 of\IN\1740 <e1>nicotine</e1>\NN\14712692 to\TO\1740 nicotinic\JJ\1740 acetylcholine\NN\14807558 receptors\NNS\5225602 (\-LRB-\1740 nAChRs\NNS\1740 )\-RRB-\1740 elicits\VBZ\1617192 a\DT\13649268 series\NN\8456993 of\IN\1740 dose-dependent\JJ\1740 behaviors\NNS\407535 that\WDT\1740 go\VBP\2367363 from\IN\1740 altered\JJ\1740 exploration\NN\309647 ,\,\1740 sedation\NN\14034177 ,\,\1740 and\CC\1740 tremors\NNS\345926 ,\,\1740 to\IN\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 death\NN\7296428 .\.\1740
D009538_D012640 CID We\PRP\1740 examined\VBD\789138 the\DT\1740 role\NN\719494 of\IN\1740 the\DT\1740 beta4\CD\1740 subunits\NNS\13604718 in\IN\13603305 <e1>nicotine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 hypolocomotion\NN\1740 in\IN\13603305 beta4\CD\1740 homozygous\JJ\1740 null\NN\13576982 (\-LRB-\1740 beta4\CD\1740 -/-\NN\1740 )\-RRB-\1740 and\CC\1740 alpha3\NN\1740 heterozygous\JJ\1740 (\-LRB-\1740 +/-\CC\1740 )\-RRB-\1740 mice\NNS\2329401 .\.\1740
D009538_D012640 CID beta4\NN\1740 -/-\JJ\1740 mice\NNS\2329401 were\VBD\836236 less\RBR\1740 sensitive\JJ\1740 to\TO\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>nicotine</e1>\NN\14712692 both\CC\1740 at\IN\14622893 low\JJ\1740 doses\NNS\3740161 ,\,\1740 measured\VBN\697589 as\IN\14622893 decreased\VBN\169651 exploration\NN\309647 in\IN\13603305 an\DT\6697703 open\JJ\1740 field\NN\8673395 ,\,\1740 and\CC\1740 at\IN\14622893 high\JJ\1740 doses\NNS\3740161 ,\,\1740 measured\VBN\697589 as\IN\14622893 sensitivity\NN\5651971 to\TO\1740 nicotine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D009538_D012640 CID beta4\NN\1740 -/-\JJ\1740 mice\NNS\2329401 were\VBD\836236 less\RBR\1740 sensitive\JJ\1740 to\TO\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 nicotine\NN\14712692 both\CC\1740 at\IN\14622893 low\JJ\1740 doses\NNS\3740161 ,\,\1740 measured\VBN\697589 as\IN\14622893 decreased\VBN\169651 exploration\NN\309647 in\IN\13603305 an\DT\6697703 open\JJ\1740 field\NN\8673395 ,\,\1740 and\CC\1740 at\IN\14622893 high\JJ\1740 doses\NNS\3740161 ,\,\1740 measured\VBN\697589 as\IN\14622893 sensitivity\NN\5651971 to\TO\1740 <e1>nicotine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D009538_D012640 CID alpha3\NN\1740 +/-\CC\1740 mice\NNS\2329401 were\VBD\836236 partially\RB\1740 resistant\JJ\1740 to\TO\1740 <e1>nicotine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 when\WRB\1740 compared\VBN\644583 to\TO\1740 wild-type\JJ\1740 littermates\NNS\1740 .\.\1740
D009538_D012640 CID Together\RB\1740 ,\,\1740 these\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 the\DT\1740 beta4\NN\1740 and\CC\1740 the\DT\1740 alpha3\NN\1740 subunits\NNS\13604718 are\VBP\836236 mediators\NNS\10351874 of\IN\1740 <e1>nicotine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 hypolocomotion\NN\1740 .\.\1740
D009538_D006948 NONE The\DT\1740 alpha3\NN\1740 and\CC\1740 beta4\NN\1740 nicotinic\JJ\1740 acetylcholine\NN\14807558 receptor\NN\5225602 subunits\NNS\13604718 are\VBP\836236 necessary\JJ\1740 for\IN\1740 <e1>nicotine-induced</e1>\JJ\1740 seizures\NNS\14081375 and\CC\1740 <e2>hypolocomotion</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D009538_D006948 NONE We\PRP\1740 examined\VBD\789138 the\DT\1740 role\NN\719494 of\IN\1740 the\DT\1740 beta4\CD\1740 subunits\NNS\13604718 in\IN\13603305 <e1>nicotine-induced</e1>\JJ\1740 seizures\NNS\14081375 and\CC\1740 <e2>hypolocomotion</e2>\NN\1740 in\IN\13603305 beta4\CD\1740 homozygous\JJ\1740 null\NN\13576982 (\-LRB-\1740 beta4\CD\1740 -/-\NN\1740 )\-RRB-\1740 and\CC\1740 alpha3\NN\1740 heterozygous\JJ\1740 (\-LRB-\1740 +/-\CC\1740 )\-RRB-\1740 mice\NNS\2329401 .\.\1740
D009538_D006948 NONE Together\RB\1740 ,\,\1740 these\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 the\DT\1740 beta4\NN\1740 and\CC\1740 the\DT\1740 alpha3\NN\1740 subunits\NNS\13604718 are\VBP\836236 mediators\NNS\10351874 of\IN\1740 <e1>nicotine-induced</e1>\JJ\1740 seizures\NNS\14081375 and\CC\1740 <e2>hypolocomotion</e2>\NN\1740 .\.\1740
D009538_D014202 NONE Binding\NN\4688246 of\IN\1740 <e1>nicotine</e1>\NN\14712692 to\TO\1740 nicotinic\JJ\1740 acetylcholine\NN\14807558 receptors\NNS\5225602 (\-LRB-\1740 nAChRs\NNS\1740 )\-RRB-\1740 elicits\VBZ\1617192 a\DT\13649268 series\NN\8456993 of\IN\1740 dose-dependent\JJ\1740 behaviors\NNS\407535 that\WDT\1740 go\VBP\2367363 from\IN\1740 altered\JJ\1740 exploration\NN\309647 ,\,\1740 sedation\NN\14034177 ,\,\1740 and\CC\1740 <e2>tremors</e2>\NNS\345926 ,\,\1740 to\IN\1740 seizures\NNS\14081375 and\CC\1740 death\NN\7296428 .\.\1740
D009538_D003643 NONE Binding\NN\4688246 of\IN\1740 <e1>nicotine</e1>\NN\14712692 to\TO\1740 nicotinic\JJ\1740 acetylcholine\NN\14807558 receptors\NNS\5225602 (\-LRB-\1740 nAChRs\NNS\1740 )\-RRB-\1740 elicits\VBZ\1617192 a\DT\13649268 series\NN\8456993 of\IN\1740 dose-dependent\JJ\1740 behaviors\NNS\407535 that\WDT\1740 go\VBP\2367363 from\IN\1740 altered\JJ\1740 exploration\NN\309647 ,\,\1740 sedation\NN\14034177 ,\,\1740 and\CC\1740 tremors\NNS\345926 ,\,\1740 to\IN\1740 seizures\NNS\14081375 and\CC\1740 <e2>death</e2>\NN\7296428 .\.\1740
D000109_D014202 NONE Binding\NN\4688246 of\IN\1740 nicotine\NN\14712692 to\TO\1740 nicotinic\JJ\1740 <e1>acetylcholine</e1>\NN\14807558 receptors\NNS\5225602 (\-LRB-\1740 nAChRs\NNS\1740 )\-RRB-\1740 elicits\VBZ\1617192 a\DT\13649268 series\NN\8456993 of\IN\1740 dose-dependent\JJ\1740 behaviors\NNS\407535 that\WDT\1740 go\VBP\2367363 from\IN\1740 altered\JJ\1740 exploration\NN\309647 ,\,\1740 sedation\NN\14034177 ,\,\1740 and\CC\1740 <e2>tremors</e2>\NNS\345926 ,\,\1740 to\IN\1740 seizures\NNS\14081375 and\CC\1740 death\NN\7296428 .\.\1740
D000109_D003643 NONE Binding\NN\4688246 of\IN\1740 nicotine\NN\14712692 to\TO\1740 nicotinic\JJ\1740 <e1>acetylcholine</e1>\NN\14807558 receptors\NNS\5225602 (\-LRB-\1740 nAChRs\NNS\1740 )\-RRB-\1740 elicits\VBZ\1617192 a\DT\13649268 series\NN\8456993 of\IN\1740 dose-dependent\JJ\1740 behaviors\NNS\407535 that\WDT\1740 go\VBP\2367363 from\IN\1740 altered\JJ\1740 exploration\NN\309647 ,\,\1740 sedation\NN\14034177 ,\,\1740 and\CC\1740 tremors\NNS\345926 ,\,\1740 to\IN\1740 seizures\NNS\14081375 and\CC\1740 <e2>death</e2>\NN\7296428 .\.\1740
9812111
D006220_D011618 NONE A\DT\13649268 randomized\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 dose-comparison\JJ\1740 trial\NN\786195 of\IN\1740 <e1>haloperidol</e1>\NN\3713736 for\IN\1740 <e2>psychosis</e2>\NN\14380140 and\CC\1740 disruptive\JJ\1740 behaviors\NNS\407535 in\IN\13603305 Alzheimer\NN\1740 's\POS\1740 disease\NN\14061805 .\.\1740
D006220_D011618 NONE OBJECTIVE\NN\5980875 :\:\1740 The\DT\1740 goal\NN\5809192 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 compare\VB\644583 the\DT\1740 efficacy\NN\5199286 and\CC\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 two\CD\13741022 doses\NNS\3740161 of\IN\1740 <e1>haloperidol</e1>\NN\3713736 and\CC\1740 placebo\VB\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>psychosis</e2>\NN\14380140 and\CC\1740 disruptive\JJ\1740 behaviors\NNS\407535 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Alzheimer\NN\1740 's\POS\1740 disease\NN\14061805 .\.\1740
D006220_D011618 NONE RESULTS\NNS\34213 :\:\1740 For\IN\1740 the\DT\1740 60\CD\13745420 patients\NNS\9898892 who\WP\8299493 completed\VBD\352826 phase\NN\15113229 A\NN\13649268 ,\,\1740 standard-dose\JJ\1740 <e1>haloperidol</e1>\NN\3713736 was\VBD\836236 efficacious\JJ\1740 and\CC\1740 superior\JJ\1740 to\TO\1740 both\CC\1740 low-dose\JJ\1740 haloperidol\NN\3713736 and\CC\1740 placebo\NN\3740161 for\IN\1740 scores\NNS\13757724 on\IN\1740 the\DT\1740 Brief\NNP\6479665 Psychiatric\NNP\1740 Rating\NNP\5733583 Scale\NN\7260623 <e2>psychosis</e2>\NN\14380140 factor\NN\7326557 and\CC\1740 on\IN\1740 psychomotor\NN\1740 agitation\NN\14373582 .\.\1740
D006220_D011618 NONE RESULTS\NNS\34213 :\:\1740 For\IN\1740 the\DT\1740 60\CD\13745420 patients\NNS\9898892 who\WP\8299493 completed\VBD\352826 phase\NN\15113229 A\NN\13649268 ,\,\1740 standard-dose\JJ\1740 haloperidol\NN\3713736 was\VBD\836236 efficacious\JJ\1740 and\CC\1740 superior\JJ\1740 to\TO\1740 both\CC\1740 low-dose\JJ\1740 <e1>haloperidol</e1>\NN\3713736 and\CC\1740 placebo\NN\3740161 for\IN\1740 scores\NNS\13757724 on\IN\1740 the\DT\1740 Brief\NNP\6479665 Psychiatric\NNP\1740 Rating\NNP\5733583 Scale\NN\7260623 <e2>psychosis</e2>\NN\14380140 factor\NN\7326557 and\CC\1740 on\IN\1740 psychomotor\NN\1740 agitation\NN\14373582 .\.\1740
D006220_D011618 NONE The\DT\1740 narrow\JJ\1740 therapeutic\JJ\1740 window\NN\3391770 observed\VBN\2163746 with\IN\1740 <e1>haloperidol</e1>\NN\3713736 may\MD\15209706 also\RB\1740 apply\VB\2676054 to\IN\1740 other\JJ\1740 neuroleptics\NNS\4470232 used\VBN\1156834 in\IN\13603305 Alzheimer\NN\1740 's\POS\1740 disease\NN\14061805 patients\NNS\9898892 with\IN\1740 <e2>psychosis</e2>\NN\14380140 and\CC\1740 disruptive\JJ\1740 behaviors\NNS\407535 .\.\1740
D006220_D019958 NONE A\DT\13649268 randomized\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 dose-comparison\JJ\1740 trial\NN\786195 of\IN\1740 <e1>haloperidol</e1>\NN\3713736 for\IN\1740 psychosis\NN\14380140 and\CC\1740 <e2>disruptive\JJ\1740 behaviors</e2>\NNS\407535 in\IN\13603305 Alzheimer\NN\1740 's\POS\1740 disease\NN\14061805 .\.\1740
D006220_D019958 NONE OBJECTIVE\NN\5980875 :\:\1740 The\DT\1740 goal\NN\5809192 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 compare\VB\644583 the\DT\1740 efficacy\NN\5199286 and\CC\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 two\CD\13741022 doses\NNS\3740161 of\IN\1740 <e1>haloperidol</e1>\NN\3713736 and\CC\1740 placebo\VB\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 psychosis\NN\14380140 and\CC\1740 <e2>disruptive\JJ\1740 behaviors</e2>\NNS\407535 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Alzheimer\NN\1740 's\POS\1740 disease\NN\14061805 .\.\1740
D006220_D019958 NONE The\DT\1740 narrow\JJ\1740 therapeutic\JJ\1740 window\NN\3391770 observed\VBN\2163746 with\IN\1740 <e1>haloperidol</e1>\NN\3713736 may\MD\15209706 also\RB\1740 apply\VB\2676054 to\IN\1740 other\JJ\1740 neuroleptics\NNS\4470232 used\VBN\1156834 in\IN\13603305 Alzheimer\NN\1740 's\POS\1740 disease\NN\14061805 patients\NNS\9898892 with\IN\1740 psychosis\NN\14380140 and\CC\1740 <e2>disruptive\JJ\1740 behaviors</e2>\NNS\407535 .\.\1740
D006220_D000544 NONE A\DT\13649268 randomized\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 dose-comparison\JJ\1740 trial\NN\786195 of\IN\1740 <e1>haloperidol</e1>\NN\3713736 for\IN\1740 psychosis\NN\14380140 and\CC\1740 disruptive\JJ\1740 behaviors\NNS\407535 in\IN\13603305 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D006220_D000544 NONE OBJECTIVE\NN\5980875 :\:\1740 The\DT\1740 goal\NN\5809192 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 compare\VB\644583 the\DT\1740 efficacy\NN\5199286 and\CC\1740 side\JJ\1740 effects\NNS\13245626 of\IN\1740 two\CD\13741022 doses\NNS\3740161 of\IN\1740 <e1>haloperidol</e1>\NN\3713736 and\CC\1740 placebo\VB\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 psychosis\NN\14380140 and\CC\1740 disruptive\JJ\1740 behaviors\NNS\407535 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D006220_D000544 NONE METHOD\NNP\5616786 :\:\1740 In\IN\13603305 a\DT\13649268 6-week\JJ\1740 random-assignment\JJ\1740 ,\,\1740 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 trial\NN\786195 (\-LRB-\1740 phase\NN\15113229 A\NN\13649268 )\-RRB-\1740 ,\,\1740 <e1>haloperidol</e1>\NN\3713736 ,\,\1740 2\CD\13741022 -\SYM\1740 3\CD\13741022 mg/day\NN\1740 (\-LRB-\1740 standard\JJ\1740 dose\NN\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 haloperidol\VB\1740 ,\,\1740 0.50\CD\1740 -\HYPH\1740 0.75\CD\1740 mg/day\NN\1740 (\-LRB-\1740 low\JJ\1740 dose\NN\3740161 )\-RRB-\1740 ,\,\1740 were\VBD\836236 compared\VBN\644583 in\IN\13603305 71\CD\1740 outpatients\NNS\10405694 with\IN\1740 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D006220_D000544 NONE METHOD\NNP\5616786 :\:\1740 In\IN\13603305 a\DT\13649268 6-week\JJ\1740 random-assignment\JJ\1740 ,\,\1740 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 trial\NN\786195 (\-LRB-\1740 phase\NN\15113229 A\NN\13649268 )\-RRB-\1740 ,\,\1740 haloperidol\NN\3713736 ,\,\1740 2\CD\13741022 -\SYM\1740 3\CD\13741022 mg/day\NN\1740 (\-LRB-\1740 standard\JJ\1740 dose\NN\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e1>haloperidol</e1>\VB\1740 ,\,\1740 0.50\CD\1740 -\HYPH\1740 0.75\CD\1740 mg/day\NN\1740 (\-LRB-\1740 low\JJ\1740 dose\NN\3740161 )\-RRB-\1740 ,\,\1740 were\VBD\836236 compared\VBN\644583 in\IN\13603305 71\CD\1740 outpatients\NNS\10405694 with\IN\1740 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D006220_D000544 NONE The\DT\1740 narrow\JJ\1740 therapeutic\JJ\1740 window\NN\3391770 observed\VBN\2163746 with\IN\1740 <e1>haloperidol</e1>\NN\3713736 may\MD\15209706 also\RB\1740 apply\VB\2676054 to\IN\1740 other\JJ\1740 neuroleptics\NNS\4470232 used\VBN\1156834 in\IN\13603305 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 patients\NNS\9898892 with\IN\1740 psychosis\NN\14380140 and\CC\1740 disruptive\JJ\1740 behaviors\NNS\407535 .\.\1740
D006220_D011595 NONE RESULTS\NNS\34213 :\:\1740 For\IN\1740 the\DT\1740 60\CD\13745420 patients\NNS\9898892 who\WP\8299493 completed\VBD\352826 phase\NN\15113229 A\NN\13649268 ,\,\1740 standard-dose\JJ\1740 <e1>haloperidol</e1>\NN\3713736 was\VBD\836236 efficacious\JJ\1740 and\CC\1740 superior\JJ\1740 to\TO\1740 both\CC\1740 low-dose\JJ\1740 haloperidol\NN\3713736 and\CC\1740 placebo\NN\3740161 for\IN\1740 scores\NNS\13757724 on\IN\1740 the\DT\1740 Brief\NNP\6479665 Psychiatric\NNP\1740 Rating\NNP\5733583 Scale\NN\7260623 psychosis\NN\14380140 factor\NN\7326557 and\CC\1740 on\IN\1740 <e2>psychomotor\NN\1740 agitation</e2>\NN\14373582 .\.\1740
D006220_D011595 NONE RESULTS\NNS\34213 :\:\1740 For\IN\1740 the\DT\1740 60\CD\13745420 patients\NNS\9898892 who\WP\8299493 completed\VBD\352826 phase\NN\15113229 A\NN\13649268 ,\,\1740 standard-dose\JJ\1740 haloperidol\NN\3713736 was\VBD\836236 efficacious\JJ\1740 and\CC\1740 superior\JJ\1740 to\TO\1740 both\CC\1740 low-dose\JJ\1740 <e1>haloperidol</e1>\NN\3713736 and\CC\1740 placebo\NN\3740161 for\IN\1740 scores\NNS\13757724 on\IN\1740 the\DT\1740 Brief\NNP\6479665 Psychiatric\NNP\1740 Rating\NNP\5733583 Scale\NN\7260623 psychosis\NN\14380140 factor\NN\7326557 and\CC\1740 on\IN\1740 <e2>psychomotor\NN\1740 agitation</e2>\NN\14373582 .\.\1740
D006220_D001480 CID CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 results\NNS\34213 indicated\VBD\952524 a\DT\13649268 favorable\JJ\1740 therapeutic\JJ\1740 profile\NN\6999802 for\IN\1740 <e1>haloperidol</e1>\NN\3713736 in\IN\13603305 doses\NNS\3740161 of\IN\1740 2\CD\13741022 -\SYM\1740 3\CD\13741022 mg/day\NN\1740 ,\,\1740 although\IN\1740 a\DT\13649268 subgroup\NN\31264 developed\VBD\1753788 moderate\JJ\1740 to\TO\1740 severe\JJ\1740 <e2>extrapyramidal\JJ\1740 signs</e2>\NNS\6643763 .\.\1740
9351491
D018967_D011618 NONE Previous\JJ\1740 clinical\JJ\1740 studies\NNS\635850 have\VBP\2108377 proposed\VBN\1010118 that\IN\1740 <e1>risperidone</e1>\NN\1740 's\POS\1740 pharmacologic\JJ\1740 profile\NN\6999802 may\MD\15209706 produce\VB\1617192 improved\VBN\126264 efficacy\NN\5199286 for\IN\1740 negative\JJ\1740 <e2>psychotic\JJ\1740 symptoms</e2>\NNS\5823932 and\CC\1740 decreased\VBD\169651 propensity\NN\7498854 for\IN\1740 extrapyramidal\JJ\1740 side\NN\8630039 effects\NNS\13245626 ;\:\1740 features\NNS\5849040 shared\VBN\2660631 by\IN\1740 so-called\JJ\1740 '\``\1740 atypical\JJ\1740 '\''\1740 neuroleptics\NNS\4470232 .\.\1740
D018967_D010302 CID <e2>Drug-induced\JJ\1740 parkinsonism</e2>\NN\14085708 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 subjects\NNS\6598915 treated\VBN\2376958 with\IN\1740 <e1>risperidone</e1>\NN\1740 (\-LRB-\1740 42\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 haloperidol\NN\3713736 (\-LRB-\1740 29\CD\13745420 %\NN\1740 )\-RRB-\1740 and\CC\1740 was\VBD\836236 observed\VBN\2163746 at\IN\14622893 occupancy\NN\1053920 levels\NNS\4916342 above\IN\6392001 60\CD\13745420 %\NN\1740 .\.\1740
D006220_D010302 CID <e2>Drug-induced\JJ\1740 parkinsonism</e2>\NN\14085708 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 subjects\NNS\6598915 treated\VBN\2376958 with\IN\1740 risperidone\NN\1740 (\-LRB-\1740 42\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>haloperidol</e1>\NN\3713736 (\-LRB-\1740 29\CD\13745420 %\NN\1740 )\-RRB-\1740 and\CC\1740 was\VBD\836236 observed\VBN\2163746 at\IN\14622893 occupancy\NN\1053920 levels\NNS\4916342 above\IN\6392001 60\CD\13745420 %\NN\1740 .\.\1740
8829025
D016559_D006973 CID Two\CD\13741022 groups\NNS\2137 of\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 <e1>tacrolimus</e1>\NN\1740 were\VBD\836236 compared\VBN\644583 over\IN\5867413 a\DT\13649268 period\NN\13575869 of\IN\1740 1\CD\13741022 year\NN\15113229 ,\,\1740 one\CD\13741022 group\NN\2137 comprising\VBG\2604760 <e2>hypertensive</e2>\JJ\1740 patients\NNS\9898892 who\WP\8299493 were\VBD\836236 receiving\VBG\2210855 nifedipine\NN\2938514 ,\,\1740 and\CC\1740 the\DT\1740 other\JJ\1740 comprising\VBG\2604760 nonhypertensive\JJ\1740 patients\NNS\9898892 not\RB\1740 receiving\VBG\2210855 nifedipine\NN\2938514 .\.\1740
D016559_D006973 CID The\DT\1740 observed\VBN\2163746 positive\JJ\1740 impact\NN\7339329 of\IN\1740 nifedipine\NN\2938514 on\IN\1740 reducing\VBG\441445 the\DT\1740 nephrotoxicity\NN\1740 associated\VBN\628491 with\IN\1740 <e1>tacrolimus</e1>\NN\1740 in\IN\13603305 liver\NN\5298729 transplant\NN\5267548 recipients\NNS\9764201 should\MD\1740 be\VB\836236 an\DT\6697703 important\JJ\1740 factor\NN\7326557 in\IN\13603305 selecting\VBG\697589 an\DT\6697703 agent\NN\7347 to\TO\1740 treat\VB\2376958 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 this\DT\1740 population\NN\7942152 .\.\1740
D009543_D006973 NONE Two\CD\13741022 groups\NNS\2137 of\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 tacrolimus\NN\1740 were\VBD\836236 compared\VBN\644583 over\IN\5867413 a\DT\13649268 period\NN\13575869 of\IN\1740 1\CD\13741022 year\NN\15113229 ,\,\1740 one\CD\13741022 group\NN\2137 comprising\VBG\2604760 <e2>hypertensive</e2>\JJ\1740 patients\NNS\9898892 who\WP\8299493 were\VBD\836236 receiving\VBG\2210855 <e1>nifedipine</e1>\NN\2938514 ,\,\1740 and\CC\1740 the\DT\1740 other\JJ\1740 comprising\VBG\2604760 nonhypertensive\JJ\1740 patients\NNS\9898892 not\RB\1740 receiving\VBG\2210855 nifedipine\NN\2938514 .\.\1740
D009543_D006973 NONE Two\CD\13741022 groups\NNS\2137 of\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 tacrolimus\NN\1740 were\VBD\836236 compared\VBN\644583 over\IN\5867413 a\DT\13649268 period\NN\13575869 of\IN\1740 1\CD\13741022 year\NN\15113229 ,\,\1740 one\CD\13741022 group\NN\2137 comprising\VBG\2604760 <e2>hypertensive</e2>\JJ\1740 patients\NNS\9898892 who\WP\8299493 were\VBD\836236 receiving\VBG\2210855 nifedipine\NN\2938514 ,\,\1740 and\CC\1740 the\DT\1740 other\JJ\1740 comprising\VBG\2604760 nonhypertensive\JJ\1740 patients\NNS\9898892 not\RB\1740 receiving\VBG\2210855 <e1>nifedipine</e1>\NN\2938514 .\.\1740
D009543_D006973 NONE The\DT\1740 observed\VBN\2163746 positive\JJ\1740 impact\NN\7339329 of\IN\1740 <e1>nifedipine</e1>\NN\2938514 on\IN\1740 reducing\VBG\441445 the\DT\1740 nephrotoxicity\NN\1740 associated\VBN\628491 with\IN\1740 tacrolimus\NN\1740 in\IN\13603305 liver\NN\5298729 transplant\NN\5267548 recipients\NNS\9764201 should\MD\1740 be\VB\836236 an\DT\6697703 important\JJ\1740 factor\NN\7326557 in\IN\13603305 selecting\VBG\697589 an\DT\6697703 agent\NN\7347 to\TO\1740 treat\VB\2376958 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 this\DT\1740 population\NN\7942152 .\.\1740
D009543_D007674 NONE The\DT\1740 observed\VBN\2163746 positive\JJ\1740 impact\NN\7339329 of\IN\1740 <e1>nifedipine</e1>\NN\2938514 on\IN\1740 reducing\VBG\441445 the\DT\1740 <e2>nephrotoxicity</e2>\NN\1740 associated\VBN\628491 with\IN\1740 tacrolimus\NN\1740 in\IN\13603305 liver\NN\5298729 transplant\NN\5267548 recipients\NNS\9764201 should\MD\1740 be\VB\836236 an\DT\6697703 important\JJ\1740 factor\NN\7326557 in\IN\13603305 selecting\VBG\697589 an\DT\6697703 agent\NN\7347 to\TO\1740 treat\VB\2376958 hypertension\NN\14057371 in\IN\13603305 this\DT\1740 population\NN\7942152 .\.\1740
D016559_D007674 NONE The\DT\1740 observed\VBN\2163746 positive\JJ\1740 impact\NN\7339329 of\IN\1740 nifedipine\NN\2938514 on\IN\1740 reducing\VBG\441445 the\DT\1740 <e2>nephrotoxicity</e2>\NN\1740 associated\VBN\628491 with\IN\1740 <e1>tacrolimus</e1>\NN\1740 in\IN\13603305 liver\NN\5298729 transplant\NN\5267548 recipients\NNS\9764201 should\MD\1740 be\VB\836236 an\DT\6697703 important\JJ\1740 factor\NN\7326557 in\IN\13603305 selecting\VBG\697589 an\DT\6697703 agent\NN\7347 to\TO\1740 treat\VB\2376958 hypertension\NN\14057371 in\IN\13603305 this\DT\1740 population\NN\7942152 .\.\1740
2670794
D000809_D011665 NONE Effects\NNS\13245626 of\IN\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 <e1>angiotensin</e1>\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 Captopril\NNP\2673637 )\-RRB-\1740 on\IN\1740 <e2>pulmonary\JJ\1740 and\CC\1740 renal\JJ\1740 insufficiency</e2>\NN\14462946 due\IN\5174653 to\TO\1740 intravascular\JJ\1740 coagulation\NN\13518963 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D000809_D011665 NONE Injection\NN\320852 of\IN\1740 Captopril\NNP\2673637 (\-LRB-\1740 1\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 <e1>angiotensin</e1>\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 ,\,\1740 reduced\VBD\441445 both\CC\1740 <e2>pulmonary\JJ\1740 and\CC\1740 renal\JJ\1740 insufficiency</e2>\NN\14462946 in\IN\13603305 this\DT\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D000809_D051437 NONE Effects\NNS\13245626 of\IN\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 <e1>angiotensin</e1>\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 Captopril\NNP\2673637 )\-RRB-\1740 on\IN\1740 <e2>pulmonary\JJ\1740 and\CC\1740 renal\JJ\1740 insufficiency</e2>\NN\14462946 due\IN\5174653 to\TO\1740 intravascular\JJ\1740 coagulation\NN\13518963 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D000809_D051437 NONE Injection\NN\320852 of\IN\1740 Captopril\NNP\2673637 (\-LRB-\1740 1\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 <e1>angiotensin</e1>\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 ,\,\1740 reduced\VBD\441445 both\CC\1740 <e2>pulmonary\JJ\1740 and\CC\1740 renal\JJ\1740 insufficiency</e2>\NN\14462946 in\IN\13603305 this\DT\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D000809_D004211 NONE Effects\NNS\13245626 of\IN\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 <e1>angiotensin</e1>\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 Captopril\NNP\2673637 )\-RRB-\1740 on\IN\1740 pulmonary\JJ\1740 and\CC\1740 renal\JJ\1740 insufficiency\NN\14462946 due\IN\5174653 to\TO\1740 <e2>intravascular\JJ\1740 coagulation</e2>\NN\13518963 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D002216_D011665 NONE Effects\NNS\13245626 of\IN\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 <e1>Captopril</e1>\NNP\2673637 )\-RRB-\1740 on\IN\1740 <e2>pulmonary\JJ\1740 and\CC\1740 renal\JJ\1740 insufficiency</e2>\NN\14462946 due\IN\5174653 to\TO\1740 intravascular\JJ\1740 coagulation\NN\13518963 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D002216_D011665 NONE Injection\NN\320852 of\IN\1740 <e1>Captopril</e1>\NNP\2673637 (\-LRB-\1740 1\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 ,\,\1740 reduced\VBD\441445 both\CC\1740 <e2>pulmonary\JJ\1740 and\CC\1740 renal\JJ\1740 insufficiency</e2>\NN\14462946 in\IN\13603305 this\DT\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D002216_D051437 NONE Effects\NNS\13245626 of\IN\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 <e1>Captopril</e1>\NNP\2673637 )\-RRB-\1740 on\IN\1740 <e2>pulmonary\JJ\1740 and\CC\1740 renal\JJ\1740 insufficiency</e2>\NN\14462946 due\IN\5174653 to\TO\1740 intravascular\JJ\1740 coagulation\NN\13518963 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D002216_D051437 NONE Injection\NN\320852 of\IN\1740 <e1>Captopril</e1>\NNP\2673637 (\-LRB-\1740 1\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 ,\,\1740 reduced\VBD\441445 both\CC\1740 <e2>pulmonary\JJ\1740 and\CC\1740 renal\JJ\1740 insufficiency</e2>\NN\14462946 in\IN\13603305 this\DT\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D002216_D004211 NONE Effects\NNS\13245626 of\IN\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 <e1>Captopril</e1>\NNP\2673637 )\-RRB-\1740 on\IN\1740 pulmonary\JJ\1740 and\CC\1740 renal\JJ\1740 insufficiency\NN\14462946 due\IN\5174653 to\TO\1740 <e2>intravascular\JJ\1740 coagulation</e2>\NN\13518963 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D014148_D004211 CID Induction\NN\7450842 of\IN\1740 <e2>intravascular\JJ\1740 coagulation</e2>\NN\13518963 and\CC\1740 inhibition\NN\1068773 of\IN\1740 fibrinolysis\NN\13467916 by\IN\1740 injection\NN\320852 of\IN\1740 thrombin\NN\14735953 and\CC\1740 <e1>tranexamic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 AMCA\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 gives\VBZ\2327200 rise\NN\7324673 to\TO\1740 pulmonary\JJ\1740 and\CC\1740 renal\JJ\1740 insufficiency\NN\14462946 resembling\VBG\2657219 that\DT\1740 occurring\VBG\2623529 after\IN\1740 trauma\NN\14052046 or\CC\3541091 sepsis\NN\14174549 in\IN\13603305 man\NN\9605289 .\.\1740
D014148_D004211 CID Induction\NN\7450842 of\IN\1740 <e2>intravascular\JJ\1740 coagulation</e2>\NN\13518963 and\CC\1740 inhibition\NN\1068773 of\IN\1740 fibrinolysis\NN\13467916 by\IN\1740 injection\NN\320852 of\IN\1740 thrombin\NN\14735953 and\CC\1740 tranexamic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>AMCA</e1>\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 gives\VBZ\2327200 rise\NN\7324673 to\TO\1740 pulmonary\JJ\1740 and\CC\1740 renal\JJ\1740 insufficiency\NN\14462946 resembling\VBG\2657219 that\DT\1740 occurring\VBG\2623529 after\IN\1740 trauma\NN\14052046 or\CC\3541091 sepsis\NN\14174549 in\IN\13603305 man\NN\9605289 .\.\1740
D014148_D011665 NONE Induction\NN\7450842 of\IN\1740 intravascular\JJ\1740 coagulation\NN\13518963 and\CC\1740 inhibition\NN\1068773 of\IN\1740 fibrinolysis\NN\13467916 by\IN\1740 injection\NN\320852 of\IN\1740 thrombin\NN\14735953 and\CC\1740 <e1>tranexamic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 AMCA\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 gives\VBZ\2327200 rise\NN\7324673 to\TO\1740 <e2>pulmonary\JJ\1740 and\CC\1740 renal\JJ\1740 insufficiency</e2>\NN\14462946 resembling\VBG\2657219 that\DT\1740 occurring\VBG\2623529 after\IN\1740 trauma\NN\14052046 or\CC\3541091 sepsis\NN\14174549 in\IN\13603305 man\NN\9605289 .\.\1740
D014148_D011665 NONE Induction\NN\7450842 of\IN\1740 intravascular\JJ\1740 coagulation\NN\13518963 and\CC\1740 inhibition\NN\1068773 of\IN\1740 fibrinolysis\NN\13467916 by\IN\1740 injection\NN\320852 of\IN\1740 thrombin\NN\14735953 and\CC\1740 tranexamic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>AMCA</e1>\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 gives\VBZ\2327200 rise\NN\7324673 to\TO\1740 <e2>pulmonary\JJ\1740 and\CC\1740 renal\JJ\1740 insufficiency</e2>\NN\14462946 resembling\VBG\2657219 that\DT\1740 occurring\VBG\2623529 after\IN\1740 trauma\NN\14052046 or\CC\3541091 sepsis\NN\14174549 in\IN\13603305 man\NN\9605289 .\.\1740
D014148_D051437 NONE Induction\NN\7450842 of\IN\1740 intravascular\JJ\1740 coagulation\NN\13518963 and\CC\1740 inhibition\NN\1068773 of\IN\1740 fibrinolysis\NN\13467916 by\IN\1740 injection\NN\320852 of\IN\1740 thrombin\NN\14735953 and\CC\1740 <e1>tranexamic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 AMCA\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 gives\VBZ\2327200 rise\NN\7324673 to\TO\1740 <e2>pulmonary\JJ\1740 and\CC\1740 renal\JJ\1740 insufficiency</e2>\NN\14462946 resembling\VBG\2657219 that\DT\1740 occurring\VBG\2623529 after\IN\1740 trauma\NN\14052046 or\CC\3541091 sepsis\NN\14174549 in\IN\13603305 man\NN\9605289 .\.\1740
D014148_D051437 NONE Induction\NN\7450842 of\IN\1740 intravascular\JJ\1740 coagulation\NN\13518963 and\CC\1740 inhibition\NN\1068773 of\IN\1740 fibrinolysis\NN\13467916 by\IN\1740 injection\NN\320852 of\IN\1740 thrombin\NN\14735953 and\CC\1740 tranexamic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>AMCA</e1>\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 gives\VBZ\2327200 rise\NN\7324673 to\TO\1740 <e2>pulmonary\JJ\1740 and\CC\1740 renal\JJ\1740 insufficiency</e2>\NN\14462946 resembling\VBG\2657219 that\DT\1740 occurring\VBG\2623529 after\IN\1740 trauma\NN\14052046 or\CC\3541091 sepsis\NN\14174549 in\IN\13603305 man\NN\9605289 .\.\1740
D014148_D014947 NONE Induction\NN\7450842 of\IN\1740 intravascular\JJ\1740 coagulation\NN\13518963 and\CC\1740 inhibition\NN\1068773 of\IN\1740 fibrinolysis\NN\13467916 by\IN\1740 injection\NN\320852 of\IN\1740 thrombin\NN\14735953 and\CC\1740 <e1>tranexamic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 AMCA\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 gives\VBZ\2327200 rise\NN\7324673 to\TO\1740 pulmonary\JJ\1740 and\CC\1740 renal\JJ\1740 insufficiency\NN\14462946 resembling\VBG\2657219 that\DT\1740 occurring\VBG\2623529 after\IN\1740 <e2>trauma</e2>\NN\14052046 or\CC\3541091 sepsis\NN\14174549 in\IN\13603305 man\NN\9605289 .\.\1740
D014148_D014947 NONE Induction\NN\7450842 of\IN\1740 intravascular\JJ\1740 coagulation\NN\13518963 and\CC\1740 inhibition\NN\1068773 of\IN\1740 fibrinolysis\NN\13467916 by\IN\1740 injection\NN\320852 of\IN\1740 thrombin\NN\14735953 and\CC\1740 tranexamic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>AMCA</e1>\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 gives\VBZ\2327200 rise\NN\7324673 to\TO\1740 pulmonary\JJ\1740 and\CC\1740 renal\JJ\1740 insufficiency\NN\14462946 resembling\VBG\2657219 that\DT\1740 occurring\VBG\2623529 after\IN\1740 <e2>trauma</e2>\NN\14052046 or\CC\3541091 sepsis\NN\14174549 in\IN\13603305 man\NN\9605289 .\.\1740
D014148_D018805 NONE Induction\NN\7450842 of\IN\1740 intravascular\JJ\1740 coagulation\NN\13518963 and\CC\1740 inhibition\NN\1068773 of\IN\1740 fibrinolysis\NN\13467916 by\IN\1740 injection\NN\320852 of\IN\1740 thrombin\NN\14735953 and\CC\1740 <e1>tranexamic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 AMCA\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 gives\VBZ\2327200 rise\NN\7324673 to\TO\1740 pulmonary\JJ\1740 and\CC\1740 renal\JJ\1740 insufficiency\NN\14462946 resembling\VBG\2657219 that\DT\1740 occurring\VBG\2623529 after\IN\1740 trauma\NN\14052046 or\CC\3541091 <e2>sepsis</e2>\NN\14174549 in\IN\13603305 man\NN\9605289 .\.\1740
D014148_D018805 NONE Induction\NN\7450842 of\IN\1740 intravascular\JJ\1740 coagulation\NN\13518963 and\CC\1740 inhibition\NN\1068773 of\IN\1740 fibrinolysis\NN\13467916 by\IN\1740 injection\NN\320852 of\IN\1740 thrombin\NN\14735953 and\CC\1740 tranexamic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>AMCA</e1>\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 rat\NN\2329401 gives\VBZ\2327200 rise\NN\7324673 to\TO\1740 pulmonary\JJ\1740 and\CC\1740 renal\JJ\1740 insufficiency\NN\14462946 resembling\VBG\2657219 that\DT\1740 occurring\VBG\2623529 after\IN\1740 trauma\NN\14052046 or\CC\3541091 <e2>sepsis</e2>\NN\14174549 in\IN\13603305 man\NN\9605289 .\.\1740
D014508_D007674 NONE <e2>Renal\JJ\1740 damage</e2>\NN\7296428 as\IN\14622893 reflected\VBN\923793 by\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 serum\NN\5397468 <e1>urea</e1>\NN\14727670 and\CC\1740 in\IN\13603305 kidney\NN\5333259 weight\NN\5009170 was\VBD\836236 prevented\VBN\1740 by\IN\1740 Captopril\NNP\2673637 .\.\1740
D002216_D007674 NONE <e2>Renal\JJ\1740 damage</e2>\NN\7296428 as\IN\14622893 reflected\VBN\923793 by\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 serum\NN\5397468 urea\NN\14727670 and\CC\1740 in\IN\13603305 kidney\NN\5333259 weight\NN\5009170 was\VBD\836236 prevented\VBN\1740 by\IN\1740 <e1>Captopril</e1>\NNP\2673637 .\.\1740
D002216_D007674 NONE <e1>Captopril</e1>\NNP\2673637 may\MD\15209706 ,\,\1740 by\IN\1740 the\DT\1740 same\JJ\1740 mechanism\NN\13446390 ,\,\1740 reduce\VB\441445 the\DT\1740 increase\NN\13576355 in\IN\13603305 glomerular\JJ\1740 filtration\NN\13518963 that\WDT\1740 is\VBZ\836236 known\VBN\2110220 to\TO\1740 occur\VB\2623529 after\IN\1740 an\DT\6697703 injection\NN\320852 of\IN\1740 thrombin\NN\14735953 ,\,\1740 thereby\RB\1740 diminishing\VBG\169651 the\DT\1740 aggregation\NN\31264 of\IN\1740 fibrin\NN\14728724 monomers\NNS\14818238 in\IN\13603305 the\DT\1740 glomeruli\NNS\5425910 ,\,\1740 with\IN\1740 the\DT\1740 result\NN\34213 that\IN\1740 less\JJR\1740 fibrin\NN\14728724 will\MD\5650329 be\VB\836236 deposited\VBN\1340439 and\CC\1740 thus\RB\1740 less\JJR\1740 <e2>kidney\NN\5333259 damage</e2>\NN\7296428 will\MD\5650329 be\VB\836236 produced\VBN\1617192 .\.\1740
1728522
D019980_D006099 CID <e2>Granulomatous\JJ\1740 hepatitis</e2>\NN\14127211 due\IN\5174653 to\TO\1740 <e1>combination\NN\7951464 of\IN\1740 amoxicillin\NN\3910033 and\CC\1740 clavulanic\JJ\1740 acid</e1>\NN\14818238 .\.\1740
D019980_D006099 CID We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e1>amoxicillin-clavulanic\JJ\1740 acid-induced</e1>\JJ\1740 hepatitis\NN\14127211 with\IN\1740 histologic\JJ\1740 multiple\JJ\1740 <e2>granulomas</e2>\NNS\14235200 .\.\1740
D019980_D056486 CID <e2>Granulomatous\JJ\1740 hepatitis</e2>\NN\14127211 due\IN\5174653 to\TO\1740 <e1>combination\NN\7951464 of\IN\1740 amoxicillin\NN\3910033 and\CC\1740 clavulanic\JJ\1740 acid</e1>\NN\14818238 .\.\1740
D019980_D056486 CID We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e1>amoxicillin-clavulanic\JJ\1740 acid-induced</e1>\JJ\1740 <e2>hepatitis</e2>\NN\14127211 with\IN\1740 histologic\JJ\1740 multiple\JJ\1740 granulomas\NNS\14235200 .\.\1740
7890216
D015282_D042882 CID Composition\NN\5075602 of\IN\1740 <e2>gall\NN\14253124 bladder\NN\5515670 stones</e2>\NNS\19128 associated\VBN\628491 with\IN\1740 <e1>octreotide</e1>\NN\1740 :\:\1740 response\NN\11410625 to\TO\1740 oral\JJ\1740 ursodeoxycholic\JJ\1740 acid\NN\14818238 .\.\1740
D015282_D042882 CID <e1>Octreotide</e1>\NNP\1740 ,\,\1740 an\DT\6697703 effective\JJ\1740 treatment\NN\654885 for\IN\1740 acromegaly\NN\14366759 ,\,\1740 induces\VBZ\1627355 <e2>gall\NN\14253124 bladder\NN\5515670 stones</e2>\NNS\19128 in\IN\13603305 13\CD\13745420 -\SYM\1740 60\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 .\.\1740
D015282_D042882 CID Because\IN\1740 knowledge\NN\23100 of\IN\1740 stone\NN\19128 composition\NN\5075602 is\VBZ\836236 essential\JJ\1740 for\IN\1740 studies\NNS\635850 of\IN\1740 their\PRP$\1740 pathogenesis\NN\13533470 ,\,\1740 treatment\NN\654885 ,\,\1740 and\CC\1740 prevention\NN\1073995 ,\,\1740 this\DT\1740 was\VBD\836236 investigated\VBN\644583 by\IN\1740 direct\JJ\1740 and\CC\1740 indirect\JJ\1740 methods\NNS\5616786 in\IN\13603305 14\CD\13745420 <e1>octreotide</e1>\NN\1740 treated\VBN\2376958 acromegalic\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>gall\NN\14253124 stones</e2>\NNS\19128 .\.\1740
D015282_D042882 CID In\IN\13603305 conclusion\NN\5837957 ,\,\1740 <e1>octreotide</e1>\NN\1740 induced\VBD\1627355 <e2>gall\NN\14253124 stones</e2>\NNS\19128 are\VBP\836236 generally\RB\1740 small\JJ\1740 ,\,\1740 multiple\JJ\1740 ,\,\1740 and\CC\1740 cholesterol\NN\15058310 rich\JJ\1740 although\IN\1740 ,\,\1740 in\IN\13603305 common\JJ\1740 with\IN\1740 spontaneous\JJ\1740 gall\NN\14253124 stone\NN\19128 disease\NN\14061805 ,\,\1740 at\IN\14622893 presentation\NN\1027379 some\DT\1740 patients\NNS\9898892 will\MD\5650329 have\VB\2108377 a\DT\13649268 blocked\VBN\1476483 cystic\JJ\1740 duct\NN\5248181 and\CC\1740 some\DT\1740 gall\NN\14253124 stones\NNS\19128 containing\VBG\2632940 calcium\NN\14625458 .\.\1740
D015282_D042882 CID In\IN\13603305 conclusion\NN\5837957 ,\,\1740 <e1>octreotide</e1>\NN\1740 induced\VBD\1627355 gall\NN\14253124 stones\NNS\19128 are\VBP\836236 generally\RB\1740 small\JJ\1740 ,\,\1740 multiple\JJ\1740 ,\,\1740 and\CC\1740 cholesterol\NN\15058310 rich\JJ\1740 although\IN\1740 ,\,\1740 in\IN\13603305 common\JJ\1740 with\IN\1740 spontaneous\JJ\1740 <e2>gall\NN\14253124 stone\NN\19128 disease</e2>\NN\14061805 ,\,\1740 at\IN\14622893 presentation\NN\1027379 some\DT\1740 patients\NNS\9898892 will\MD\5650329 have\VB\2108377 a\DT\13649268 blocked\VBN\1476483 cystic\JJ\1740 duct\NN\5248181 and\CC\1740 some\DT\1740 gall\NN\14253124 stones\NNS\19128 containing\VBG\2632940 calcium\NN\14625458 .\.\1740
D015282_D042882 CID In\IN\13603305 conclusion\NN\5837957 ,\,\1740 <e1>octreotide</e1>\NN\1740 induced\VBD\1627355 gall\NN\14253124 stones\NNS\19128 are\VBP\836236 generally\RB\1740 small\JJ\1740 ,\,\1740 multiple\JJ\1740 ,\,\1740 and\CC\1740 cholesterol\NN\15058310 rich\JJ\1740 although\IN\1740 ,\,\1740 in\IN\13603305 common\JJ\1740 with\IN\1740 spontaneous\JJ\1740 gall\NN\14253124 stone\NN\19128 disease\NN\14061805 ,\,\1740 at\IN\14622893 presentation\NN\1027379 some\DT\1740 patients\NNS\9898892 will\MD\5650329 have\VB\2108377 a\DT\13649268 blocked\VBN\1476483 cystic\JJ\1740 duct\NN\5248181 and\CC\1740 some\DT\1740 <e2>gall\NN\14253124 stones</e2>\NNS\19128 containing\VBG\2632940 calcium\NN\14625458 .\.\1740
D014580_D042882 NONE Composition\NN\5075602 of\IN\1740 <e2>gall\NN\14253124 bladder\NN\5515670 stones</e2>\NNS\19128 associated\VBN\628491 with\IN\1740 octreotide\NN\1740 :\:\1740 response\NN\11410625 to\TO\1740 oral\JJ\1740 <e1>ursodeoxycholic\JJ\1740 acid</e1>\NN\14818238 .\.\1740
D015282_D000172 NONE <e1>Octreotide</e1>\NNP\1740 ,\,\1740 an\DT\6697703 effective\JJ\1740 treatment\NN\654885 for\IN\1740 <e2>acromegaly</e2>\NN\14366759 ,\,\1740 induces\VBZ\1627355 gall\NN\14253124 bladder\NN\5515670 stones\NNS\19128 in\IN\13603305 13\CD\13745420 -\SYM\1740 60\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 .\.\1740
D015282_D000172 NONE Because\IN\1740 knowledge\NN\23100 of\IN\1740 stone\NN\19128 composition\NN\5075602 is\VBZ\836236 essential\JJ\1740 for\IN\1740 studies\NNS\635850 of\IN\1740 their\PRP$\1740 pathogenesis\NN\13533470 ,\,\1740 treatment\NN\654885 ,\,\1740 and\CC\1740 prevention\NN\1073995 ,\,\1740 this\DT\1740 was\VBD\836236 investigated\VBN\644583 by\IN\1740 direct\JJ\1740 and\CC\1740 indirect\JJ\1740 methods\NNS\5616786 in\IN\13603305 14\CD\13745420 <e1>octreotide</e1>\NN\1740 treated\VBN\2376958 <e2>acromegalic</e2>\JJ\1740 patients\NNS\9898892 with\IN\1740 gall\NN\14253124 stones\NNS\19128 .\.\1740
D002784_D042882 NONE Chemical\JJ\1740 analysis\NN\633864 of\IN\1740 <e2>gall\NN\14253124 stones</e2>\NNS\19128 retrieved\VBN\2210855 at\IN\14622893 cholecystectomy\NN\393369 from\IN\1740 two\CD\13741022 patients\NNS\9898892 ,\,\1740 showed\VBD\2137132 that\IN\1740 they\PRP\1740 contained\VBD\2632940 71\CD\1740 %\NN\1740 and\CC\1740 87\CD\1740 %\NN\1740 <e1>cholesterol</e1>\NN\15058310 by\IN\1740 weight\NN\5009170 .\.\1740
D002784_D042882 NONE After\IN\1740 one\CD\13741022 year\NN\15113229 of\IN\1740 treatment\NN\654885 ,\,\1740 five\CD\13741022 of\IN\1740 the\DT\1740 remaining\VBG\2604760 nine\CD\13741022 patients\NNS\9898892 showed\VBD\2137132 either\CC\1740 partial\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 3\CD\13741022 )\-RRB-\1740 or\CC\3541091 complete\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 <e2>gall\VBP\63291 stone</e2>\NN\19128 dissolution\NN\13518963 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 their\PRP$\1740 stones\NNS\19128 were\VBD\836236 <e1>cholesterol</e1>\NN\15058310 rich\JJ\1740 .\.\1740
D002784_D042882 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 octreotide\NN\1740 induced\VBD\1627355 <e2>gall\NN\14253124 stones</e2>\NNS\19128 are\VBP\836236 generally\RB\1740 small\JJ\1740 ,\,\1740 multiple\JJ\1740 ,\,\1740 and\CC\1740 <e1>cholesterol</e1>\NN\15058310 rich\JJ\1740 although\IN\1740 ,\,\1740 in\IN\13603305 common\JJ\1740 with\IN\1740 spontaneous\JJ\1740 gall\NN\14253124 stone\NN\19128 disease\NN\14061805 ,\,\1740 at\IN\14622893 presentation\NN\1027379 some\DT\1740 patients\NNS\9898892 will\MD\5650329 have\VB\2108377 a\DT\13649268 blocked\VBN\1476483 cystic\JJ\1740 duct\NN\5248181 and\CC\1740 some\DT\1740 gall\NN\14253124 stones\NNS\19128 containing\VBG\2632940 calcium\NN\14625458 .\.\1740
D002784_D042882 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 octreotide\NN\1740 induced\VBD\1627355 gall\NN\14253124 stones\NNS\19128 are\VBP\836236 generally\RB\1740 small\JJ\1740 ,\,\1740 multiple\JJ\1740 ,\,\1740 and\CC\1740 <e1>cholesterol</e1>\NN\15058310 rich\JJ\1740 although\IN\1740 ,\,\1740 in\IN\13603305 common\JJ\1740 with\IN\1740 spontaneous\JJ\1740 <e2>gall\NN\14253124 stone\NN\19128 disease</e2>\NN\14061805 ,\,\1740 at\IN\14622893 presentation\NN\1027379 some\DT\1740 patients\NNS\9898892 will\MD\5650329 have\VB\2108377 a\DT\13649268 blocked\VBN\1476483 cystic\JJ\1740 duct\NN\5248181 and\CC\1740 some\DT\1740 gall\NN\14253124 stones\NNS\19128 containing\VBG\2632940 calcium\NN\14625458 .\.\1740
D002784_D042882 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 octreotide\NN\1740 induced\VBD\1627355 gall\NN\14253124 stones\NNS\19128 are\VBP\836236 generally\RB\1740 small\JJ\1740 ,\,\1740 multiple\JJ\1740 ,\,\1740 and\CC\1740 <e1>cholesterol</e1>\NN\15058310 rich\JJ\1740 although\IN\1740 ,\,\1740 in\IN\13603305 common\JJ\1740 with\IN\1740 spontaneous\JJ\1740 gall\NN\14253124 stone\NN\19128 disease\NN\14061805 ,\,\1740 at\IN\14622893 presentation\NN\1027379 some\DT\1740 patients\NNS\9898892 will\MD\5650329 have\VB\2108377 a\DT\13649268 blocked\VBN\1476483 cystic\JJ\1740 duct\NN\5248181 and\CC\1740 some\DT\1740 <e2>gall\NN\14253124 stones</e2>\NNS\19128 containing\VBG\2632940 calcium\NN\14625458 .\.\1740
D002118_D042882 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 octreotide\NN\1740 induced\VBD\1627355 <e2>gall\NN\14253124 stones</e2>\NNS\19128 are\VBP\836236 generally\RB\1740 small\JJ\1740 ,\,\1740 multiple\JJ\1740 ,\,\1740 and\CC\1740 cholesterol\NN\15058310 rich\JJ\1740 although\IN\1740 ,\,\1740 in\IN\13603305 common\JJ\1740 with\IN\1740 spontaneous\JJ\1740 gall\NN\14253124 stone\NN\19128 disease\NN\14061805 ,\,\1740 at\IN\14622893 presentation\NN\1027379 some\DT\1740 patients\NNS\9898892 will\MD\5650329 have\VB\2108377 a\DT\13649268 blocked\VBN\1476483 cystic\JJ\1740 duct\NN\5248181 and\CC\1740 some\DT\1740 gall\NN\14253124 stones\NNS\19128 containing\VBG\2632940 <e1>calcium</e1>\NN\14625458 .\.\1740
D002118_D042882 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 octreotide\NN\1740 induced\VBD\1627355 gall\NN\14253124 stones\NNS\19128 are\VBP\836236 generally\RB\1740 small\JJ\1740 ,\,\1740 multiple\JJ\1740 ,\,\1740 and\CC\1740 cholesterol\NN\15058310 rich\JJ\1740 although\IN\1740 ,\,\1740 in\IN\13603305 common\JJ\1740 with\IN\1740 spontaneous\JJ\1740 <e2>gall\NN\14253124 stone\NN\19128 disease</e2>\NN\14061805 ,\,\1740 at\IN\14622893 presentation\NN\1027379 some\DT\1740 patients\NNS\9898892 will\MD\5650329 have\VB\2108377 a\DT\13649268 blocked\VBN\1476483 cystic\JJ\1740 duct\NN\5248181 and\CC\1740 some\DT\1740 gall\NN\14253124 stones\NNS\19128 containing\VBG\2632940 <e1>calcium</e1>\NN\14625458 .\.\1740
D002118_D042882 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 octreotide\NN\1740 induced\VBD\1627355 gall\NN\14253124 stones\NNS\19128 are\VBP\836236 generally\RB\1740 small\JJ\1740 ,\,\1740 multiple\JJ\1740 ,\,\1740 and\CC\1740 cholesterol\NN\15058310 rich\JJ\1740 although\IN\1740 ,\,\1740 in\IN\13603305 common\JJ\1740 with\IN\1740 spontaneous\JJ\1740 gall\NN\14253124 stone\NN\19128 disease\NN\14061805 ,\,\1740 at\IN\14622893 presentation\NN\1027379 some\DT\1740 patients\NNS\9898892 will\MD\5650329 have\VB\2108377 a\DT\13649268 blocked\VBN\1476483 cystic\JJ\1740 duct\NN\5248181 and\CC\1740 some\DT\1740 <e2>gall\NN\14253124 stones</e2>\NNS\19128 containing\VBG\2632940 <e1>calcium</e1>\NN\14625458 .\.\1740
9390208
D008942_D001943 NONE Treatment\NN\654885 of\IN\1740 previously\RB\1740 treated\VBN\2376958 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 by\IN\1740 <e1>mitoxantrone</e1>\NN\1740 and\CC\1740 48-hour\JJ\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 high-dose\JJ\1740 5-FU\NN\1740 and\CC\1740 leucovorin\NN\1740 (\-LRB-\1740 MFL\NN\1740 ):\-RRB-\1740 low\JJ\1740 palliative\JJ\1740 benefit\NN\13278375 and\CC\1740 high\JJ\1740 treatment-related\JJ\1740 toxicity\NN\13576101 .\.\1740
D008942_D001943 NONE From\IN\1740 October\NNP\15209706 1993\CD\1740 to\IN\1740 November\NNP\15209706 1995\CD\1740 ,\,\1740 we\PRP\1740 treated\VBD\2376958 13\CD\13745420 patients\NNS\9898892 with\IN\1740 previously\RB\1740 chemotherapy-treated\JJ\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 by\IN\1740 <e1>mitoxantrone</e1>\NN\1740 ,\,\1740 12\CD\13745420 mg/m2\NN\1740 ,\,\1740 on\IN\1740 day\NN\15154774 1\CD\13741022 and\CC\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 5-FU\NN\1740 ,\,\1740 3000\CD\1740 mg/m2\NN\1740 ,\,\1740 together\RB\1740 with\IN\1740 leucovorin\NN\1740 ,\,\1740 300\CD\1740 mg/m2\NN\1740 ,\,\1740 for\IN\1740 48\CD\1740 h\NN\14622893 from\IN\1740 day\NN\15154774 1\CD\13741022 to\TO\1740 2\CD\13741022 .\.\1740
D008942_D064420 NONE Treatment\NN\654885 of\IN\1740 previously\RB\1740 treated\VBN\2376958 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 by\IN\1740 <e1>mitoxantrone</e1>\NN\1740 and\CC\1740 48-hour\JJ\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 high-dose\JJ\1740 5-FU\NN\1740 and\CC\1740 leucovorin\NN\1740 (\-LRB-\1740 MFL\NN\1740 ):\-RRB-\1740 low\JJ\1740 palliative\JJ\1740 benefit\NN\13278375 and\CC\1740 high\JJ\1740 treatment-related\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D005472_D001943 NONE Treatment\NN\654885 of\IN\1740 previously\RB\1740 treated\VBN\2376958 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 by\IN\1740 mitoxantrone\NN\1740 and\CC\1740 48-hour\JJ\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 high-dose\JJ\1740 <e1>5-FU</e1>\NN\1740 and\CC\1740 leucovorin\NN\1740 (\-LRB-\1740 MFL\NN\1740 ):\-RRB-\1740 low\JJ\1740 palliative\JJ\1740 benefit\NN\13278375 and\CC\1740 high\JJ\1740 treatment-related\JJ\1740 toxicity\NN\13576101 .\.\1740
D005472_D001943 NONE From\IN\1740 October\NNP\15209706 1993\CD\1740 to\IN\1740 November\NNP\15209706 1995\CD\1740 ,\,\1740 we\PRP\1740 treated\VBD\2376958 13\CD\13745420 patients\NNS\9898892 with\IN\1740 previously\RB\1740 chemotherapy-treated\JJ\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 by\IN\1740 mitoxantrone\NN\1740 ,\,\1740 12\CD\13745420 mg/m2\NN\1740 ,\,\1740 on\IN\1740 day\NN\15154774 1\CD\13741022 and\CC\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>5-FU</e1>\NN\1740 ,\,\1740 3000\CD\1740 mg/m2\NN\1740 ,\,\1740 together\RB\1740 with\IN\1740 leucovorin\NN\1740 ,\,\1740 300\CD\1740 mg/m2\NN\1740 ,\,\1740 for\IN\1740 48\CD\1740 h\NN\14622893 from\IN\1740 day\NN\15154774 1\CD\13741022 to\TO\1740 2\CD\13741022 .\.\1740
D005472_D064420 NONE Treatment\NN\654885 of\IN\1740 previously\RB\1740 treated\VBN\2376958 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 by\IN\1740 mitoxantrone\NN\1740 and\CC\1740 48-hour\JJ\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 high-dose\JJ\1740 <e1>5-FU</e1>\NN\1740 and\CC\1740 leucovorin\NN\1740 (\-LRB-\1740 MFL\NN\1740 ):\-RRB-\1740 low\JJ\1740 palliative\JJ\1740 benefit\NN\13278375 and\CC\1740 high\JJ\1740 treatment-related\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D002955_D001943 NONE Treatment\NN\654885 of\IN\1740 previously\RB\1740 treated\VBN\2376958 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 by\IN\1740 mitoxantrone\NN\1740 and\CC\1740 48-hour\JJ\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 high-dose\JJ\1740 5-FU\NN\1740 and\CC\1740 <e1>leucovorin</e1>\NN\1740 (\-LRB-\1740 MFL\NN\1740 ):\-RRB-\1740 low\JJ\1740 palliative\JJ\1740 benefit\NN\13278375 and\CC\1740 high\JJ\1740 treatment-related\JJ\1740 toxicity\NN\13576101 .\.\1740
D002955_D001943 NONE From\IN\1740 October\NNP\15209706 1993\CD\1740 to\IN\1740 November\NNP\15209706 1995\CD\1740 ,\,\1740 we\PRP\1740 treated\VBD\2376958 13\CD\13745420 patients\NNS\9898892 with\IN\1740 previously\RB\1740 chemotherapy-treated\JJ\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 by\IN\1740 mitoxantrone\NN\1740 ,\,\1740 12\CD\13745420 mg/m2\NN\1740 ,\,\1740 on\IN\1740 day\NN\15154774 1\CD\13741022 and\CC\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 5-FU\NN\1740 ,\,\1740 3000\CD\1740 mg/m2\NN\1740 ,\,\1740 together\RB\1740 with\IN\1740 <e1>leucovorin</e1>\NN\1740 ,\,\1740 300\CD\1740 mg/m2\NN\1740 ,\,\1740 for\IN\1740 48\CD\1740 h\NN\14622893 from\IN\1740 day\NN\15154774 1\CD\13741022 to\TO\1740 2\CD\13741022 .\.\1740
D002955_D064420 NONE Treatment\NN\654885 of\IN\1740 previously\RB\1740 treated\VBN\2376958 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 by\IN\1740 mitoxantrone\NN\1740 and\CC\1740 48-hour\JJ\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 high-dose\JJ\1740 5-FU\NN\1740 and\CC\1740 <e1>leucovorin</e1>\NN\1740 (\-LRB-\1740 MFL\NN\1740 ):\-RRB-\1740 low\JJ\1740 palliative\JJ\1740 benefit\NN\13278375 and\CC\1740 high\JJ\1740 treatment-related\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
C085788_D001943 NONE Treatment\NN\654885 of\IN\1740 previously\RB\1740 treated\VBN\2376958 metastatic\JJ\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 by\IN\1740 mitoxantrone\NN\1740 and\CC\1740 48-hour\JJ\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 high-dose\JJ\1740 5-FU\NN\1740 and\CC\1740 leucovorin\NN\1740 (\-LRB-\1740 <e1>MFL</e1>\NN\1740 ):\-RRB-\1740 low\JJ\1740 palliative\JJ\1740 benefit\NN\13278375 and\CC\1740 high\JJ\1740 treatment-related\JJ\1740 toxicity\NN\13576101 .\.\1740
C085788_D064420 NONE Treatment\NN\654885 of\IN\1740 previously\RB\1740 treated\VBN\2376958 metastatic\JJ\1740 breast\NN\5225090 cancer\NN\14239425 by\IN\1740 mitoxantrone\NN\1740 and\CC\1740 48-hour\JJ\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 high-dose\JJ\1740 5-FU\NN\1740 and\CC\1740 leucovorin\NN\1740 (\-LRB-\1740 <e1>MFL</e1>\NN\1740 ):\-RRB-\1740 low\JJ\1740 palliative\JJ\1740 benefit\NN\13278375 and\CC\1740 high\JJ\1740 treatment-related\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
C085788_D064420 NONE The\DT\1740 <e1>MFL\NNP\1740 regimen</e1>\NN\5898568 achieves\VBZ\2524171 little\JJ\1740 palliative\JJ\1740 benefit\NN\13278375 and\CC\1740 induces\VBZ\1627355 severe\JJ\1740 <e2>toxicity</e2>\NN\13576101 at\IN\14622893 a\DT\13649268 fairly\RB\1740 high\JJ\1740 rate\NN\13815152 .\.\1740
7088431
D004054_D018262 CID Development\NN\248977 of\IN\1740 <e2>clear\JJ\1740 cell\NN\3080309 adenocarcinoma</e2>\NN\14242337 in\IN\13603305 <e1>DES-exposed</e1>\JJ\1740 offspring\NN\10235549 under\IN\1740 observation\NN\996969 .\.\1740
D004054_D018262 CID Two\CD\13741022 cases\NNS\7283608 of\IN\1740 <e2>clear\JJ\1740 cell\NN\3080309 adenocarcinoma\NN\14242337 of\IN\1740 the\DT\1740 vagina</e2>\NN\5250659 detected\VBN\2163746 at\IN\14622893 follow-up\NN\4599396 in\IN\13603305 young\JJ\1740 women\NNS\9605289 exposed\VBN\2110927 in\IN\13603305 utero\NN\1740 to\TO\1740 <e1>diethylstilbestrol</e1>\NN\14749794 are\VBP\836236 reported\VBN\831651 .\.\1740
D004054_D014625 CID Two\CD\13741022 cases\NNS\7283608 of\IN\1740 <e2>clear\JJ\1740 cell\NN\3080309 adenocarcinoma\NN\14242337 of\IN\1740 the\DT\1740 vagina</e2>\NN\5250659 detected\VBN\2163746 at\IN\14622893 follow-up\NN\4599396 in\IN\13603305 young\JJ\1740 women\NNS\9605289 exposed\VBN\2110927 in\IN\13603305 utero\NN\1740 to\TO\1740 <e1>diethylstilbestrol</e1>\NN\14749794 are\VBP\836236 reported\VBN\831651 .\.\1740
18417364
D009538_D009759 CID <e1>Nicotine-induced</e1>\JJ\1740 <e2>nystagmus</e2>\NN\337486 correlates\VBZ\2657219 with\IN\1740 midpontine\NN\1740 activation\NN\13561719 .\.\1740
D009538_D009759 CID The\DT\1740 pathomechanism\NN\1740 of\IN\1740 <e1>nicotine-induced</e1>\JJ\1740 <e2>nystagmus</e2>\NN\337486 (\-LRB-\1740 NIN\NN\1740 )\-RRB-\1740 is\VBZ\836236 unknown\JJ\1740 .\.\1740
D009538_D009759 CID The\DT\1740 pathomechanism\NN\1740 of\IN\1740 <e1>nicotine-induced</e1>\JJ\1740 nystagmus\NN\337486 (\-LRB-\1740 <e2>NIN</e2>\NN\1740 )\-RRB-\1740 is\VBZ\836236 unknown\JJ\1740 .\.\1740
D010100_D009759 NONE <e2>NIN</e2>\NN\1740 correlated\VBD\2657219 with\IN\1740 blood\NN\5397468 <e1>oxygen</e1>\NN\14622893 level-dependent\JJ\1740 (\-LRB-\1740 BOLD\NN\6825399 )\-RRB-\1740 activity\NN\30358 levels\NNS\4916342 in\IN\13603305 a\DT\13649268 midpontine\NN\1740 site\NN\8673395 in\IN\13603305 the\DT\1740 posterior\JJ\1740 basis\NN\13790712 pontis\NN\1740 .\.\1740
9869257
C087567_D000647 NONE In\IN\13603305 the\DT\1740 mouse\NN\2329401 passive-avoidance\NN\1740 test\NN\5798043 ,\,\1740 <e1>PG-9</e1>\NN\1740 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 30\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 administered\VBN\2436349 20\CD\13745420 min\NN\15154774 before\IN\1740 the\DT\1740 training\NN\407535 session\NN\7142566 ,\,\1740 prevented\VBD\1740 <e2>amnesia</e2>\NN\5669934 induced\VBN\1627355 by\IN\1740 both\CC\1740 the\DT\1740 non\RB\1740 selective\JJ\1740 antimuscarinic\JJ\1740 drug\NN\14778436 scopolamine\NN\14712692 and\CC\1740 the\DT\1740 M1-selective\JJ\1740 antagonist\NN\7846 S-(-)-ET-126\NNS\1740 .\.\1740
C087567_D000647 NONE In\IN\13603305 the\DT\1740 same\JJ\1740 experimental\JJ\1740 conditions\NNS\14512817 ,\,\1740 <e1>PG-9</e1>\NN\1740 (\-LRB-\1740 5\CD\13741022 -\SYM\1740 20\CD\13745420 microg\NN\1740 per\IN\1740 mouse\NN\2329401 ,\,\1740 i.c.v.\NN\1740 )\-RRB-\1740 was\VBD\836236 also\RB\1740 able\JJ\1740 to\TO\1740 prevent\VB\1740 antimuscarine-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 ,\,\1740 demonstrating\VBG\2137132 a\DT\13649268 central\JJ\1740 localization\NN\151497 of\IN\1740 the\DT\1740 activity\NN\30358 .\.\1740
D012601_D000647 CID In\IN\13603305 the\DT\1740 mouse\NN\2329401 passive-avoidance\NN\1740 test\NN\5798043 ,\,\1740 PG-9\NN\1740 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 30\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 administered\VBN\2436349 20\CD\13745420 min\NN\15154774 before\IN\1740 the\DT\1740 training\NN\407535 session\NN\7142566 ,\,\1740 prevented\VBD\1740 <e2>amnesia</e2>\NN\5669934 induced\VBN\1627355 by\IN\1740 both\CC\1740 the\DT\1740 non\RB\1740 selective\JJ\1740 antimuscarinic\JJ\1740 drug\NN\14778436 <e1>scopolamine</e1>\NN\14712692 and\CC\1740 the\DT\1740 M1-selective\JJ\1740 antagonist\NN\7846 S-(-)-ET-126\NNS\1740 .\.\1740
C098725_D000647 CID In\IN\13603305 the\DT\1740 mouse\NN\2329401 passive-avoidance\NN\1740 test\NN\5798043 ,\,\1740 PG-9\NN\1740 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 30\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 administered\VBN\2436349 20\CD\13745420 min\NN\15154774 before\IN\1740 the\DT\1740 training\NN\407535 session\NN\7142566 ,\,\1740 prevented\VBD\1740 <e2>amnesia</e2>\NN\5669934 induced\VBN\1627355 by\IN\1740 both\CC\1740 the\DT\1740 non\RB\1740 selective\JJ\1740 antimuscarinic\JJ\1740 drug\NN\14778436 scopolamine\NN\14712692 and\CC\1740 the\DT\1740 M1-selective\JJ\1740 antagonist\NN\7846 <e1>S-(-)-ET-126</e1>\NNS\1740 .\.\1740
3015567
D009599_D007022 CID <e1>Nitroprusside-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 evokes\VBZ\1617192 ACTH\NN\5407119 secretion\NN\13526110 which\WDT\1740 is\VBZ\836236 primarily\RB\1740 mediated\VBN\761713 by\IN\1740 enhanced\VBN\227165 secretion\NN\13526110 of\IN\1740 immunoreactive\JJ\1740 corticotropin-releasing\JJ\1740 factor\NN\7326557 (\-LRB-\1740 irCRF\NN\1740 )\-RRB-\1740 into\IN\1740 the\DT\1740 hypophysial-portal\JJ\1740 circulation\NN\6253140 .\.\1740
D009599_D007022 CID Suppression\NN\13489037 of\IN\1740 irCRF\NN\1740 secretion\NN\13526110 in\IN\13603305 response\NN\11410625 to\TO\1740 <e1>nitroprusside-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 is\VBZ\836236 observed\VBN\2163746 and\CC\1740 occurs\VBZ\2623529 at\IN\14622893 a\DT\13649268 plasma\NN\5398023 corticosterone\NN\14752057 level\NN\4916342 between\IN\1740 8\CD\13741022 -\SYM\1740 12\CD\13745420 micrograms/dl\NN\1740 .\.\1740
D003345_D007022 NONE Suppression\NN\13489037 of\IN\1740 irCRF\NN\1740 secretion\NN\13526110 in\IN\13603305 response\NN\11410625 to\TO\1740 nitroprusside-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 is\VBZ\836236 observed\VBN\2163746 and\CC\1740 occurs\VBZ\2623529 at\IN\14622893 a\DT\13649268 plasma\NN\5398023 <e1>corticosterone</e1>\NN\14752057 level\NN\4916342 between\IN\1740 8\CD\13741022 -\SYM\1740 12\CD\13745420 micrograms/dl\NN\1740 .\.\1740
8739323
D008466_D007674 NONE The\DT\1740 <e2>nephrotoxic</e2>\JJ\1740 action\NN\30358 of\IN\1740 anticancer\NN\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 <e1>nitrogranulogen</e1>\NN\1740 (\-LRB-\1740 NG\NN\13717155 )\-RRB-\1740 ,\,\1740 methotrexate\VBP\1740 (\-LRB-\1740 MTX\NN\1740 )\-RRB-\1740 ,\,\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 CY\NN\1740 )\-RRB-\1740 administered\VBN\2436349 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 [\-LRB-\1740 MTX\NN\1740 +\CC\1740 5-FU\NN\1740 +\CC\1740 CY\NN\1740 (\-LRB-\1740 CMF\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 experiments\NNS\641820 on\IN\1740 Wistar\NNP\1740 rats\NNS\2329401 .\.\1740
D008466_D007674 NONE The\DT\1740 <e2>nephrotoxic</e2>\JJ\1740 action\NN\30358 of\IN\1740 anticancer\NN\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 nitrogranulogen\NN\1740 (\-LRB-\1740 <e1>NG</e1>\NN\13717155 )\-RRB-\1740 ,\,\1740 methotrexate\VBP\1740 (\-LRB-\1740 MTX\NN\1740 )\-RRB-\1740 ,\,\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 CY\NN\1740 )\-RRB-\1740 administered\VBN\2436349 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 [\-LRB-\1740 MTX\NN\1740 +\CC\1740 5-FU\NN\1740 +\CC\1740 CY\NN\1740 (\-LRB-\1740 CMF\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 experiments\NNS\641820 on\IN\1740 Wistar\NNP\1740 rats\NNS\2329401 .\.\1740
D008727_D007674 NONE The\DT\1740 <e2>nephrotoxic</e2>\JJ\1740 action\NN\30358 of\IN\1740 anticancer\NN\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 nitrogranulogen\NN\1740 (\-LRB-\1740 NG\NN\13717155 )\-RRB-\1740 ,\,\1740 <e1>methotrexate</e1>\VBP\1740 (\-LRB-\1740 MTX\NN\1740 )\-RRB-\1740 ,\,\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 CY\NN\1740 )\-RRB-\1740 administered\VBN\2436349 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 [\-LRB-\1740 MTX\NN\1740 +\CC\1740 5-FU\NN\1740 +\CC\1740 CY\NN\1740 (\-LRB-\1740 CMF\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 experiments\NNS\641820 on\IN\1740 Wistar\NNP\1740 rats\NNS\2329401 .\.\1740
D008727_D007674 NONE The\DT\1740 <e2>nephrotoxic</e2>\JJ\1740 action\NN\30358 of\IN\1740 anticancer\NN\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 nitrogranulogen\NN\1740 (\-LRB-\1740 NG\NN\13717155 )\-RRB-\1740 ,\,\1740 methotrexate\VBP\1740 (\-LRB-\1740 <e1>MTX</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 CY\NN\1740 )\-RRB-\1740 administered\VBN\2436349 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 [\-LRB-\1740 MTX\NN\1740 +\CC\1740 5-FU\NN\1740 +\CC\1740 CY\NN\1740 (\-LRB-\1740 CMF\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 experiments\NNS\641820 on\IN\1740 Wistar\NNP\1740 rats\NNS\2329401 .\.\1740
D008727_D007674 NONE The\DT\1740 <e2>nephrotoxic</e2>\JJ\1740 action\NN\30358 of\IN\1740 anticancer\NN\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 nitrogranulogen\NN\1740 (\-LRB-\1740 NG\NN\13717155 )\-RRB-\1740 ,\,\1740 methotrexate\VBP\1740 (\-LRB-\1740 MTX\NN\1740 )\-RRB-\1740 ,\,\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 CY\NN\1740 )\-RRB-\1740 administered\VBN\2436349 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 [\-LRB-\1740 <e1>MTX</e1>\NN\1740 +\CC\1740 5-FU\NN\1740 +\CC\1740 CY\NN\1740 (\-LRB-\1740 CMF\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 experiments\NNS\641820 on\IN\1740 Wistar\NNP\1740 rats\NNS\2329401 .\.\1740
D008727_D007674 NONE Our\PRP$\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 <e2>nephrotoxicity</e2>\NN\1740 of\IN\1740 <e1>MTX</e1>\NN\1740 +\CC\1740 5-FU\NN\1740 +\CC\1740 CY\NN\1740 administered\VBN\2436349 jointly\RB\1740 is\VBZ\836236 lower\JJR\1740 than\IN\1740 in\IN\13603305 monotherapy\NN\1740 .\.\1740
D005472_D007674 NONE The\DT\1740 <e2>nephrotoxic</e2>\JJ\1740 action\NN\30358 of\IN\1740 anticancer\NN\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 nitrogranulogen\NN\1740 (\-LRB-\1740 NG\NN\13717155 )\-RRB-\1740 ,\,\1740 methotrexate\VBP\1740 (\-LRB-\1740 MTX\NN\1740 )\-RRB-\1740 ,\,\1740 <e1>5-fluorouracil</e1>\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 CY\NN\1740 )\-RRB-\1740 administered\VBN\2436349 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 [\-LRB-\1740 MTX\NN\1740 +\CC\1740 5-FU\NN\1740 +\CC\1740 CY\NN\1740 (\-LRB-\1740 CMF\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 experiments\NNS\641820 on\IN\1740 Wistar\NNP\1740 rats\NNS\2329401 .\.\1740
D005472_D007674 NONE The\DT\1740 <e2>nephrotoxic</e2>\JJ\1740 action\NN\30358 of\IN\1740 anticancer\NN\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 nitrogranulogen\NN\1740 (\-LRB-\1740 NG\NN\13717155 )\-RRB-\1740 ,\,\1740 methotrexate\VBP\1740 (\-LRB-\1740 MTX\NN\1740 )\-RRB-\1740 ,\,\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 <e1>5-FU</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 CY\NN\1740 )\-RRB-\1740 administered\VBN\2436349 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 [\-LRB-\1740 MTX\NN\1740 +\CC\1740 5-FU\NN\1740 +\CC\1740 CY\NN\1740 (\-LRB-\1740 CMF\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 experiments\NNS\641820 on\IN\1740 Wistar\NNP\1740 rats\NNS\2329401 .\.\1740
D005472_D007674 NONE The\DT\1740 <e2>nephrotoxic</e2>\JJ\1740 action\NN\30358 of\IN\1740 anticancer\NN\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 nitrogranulogen\NN\1740 (\-LRB-\1740 NG\NN\13717155 )\-RRB-\1740 ,\,\1740 methotrexate\VBP\1740 (\-LRB-\1740 MTX\NN\1740 )\-RRB-\1740 ,\,\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 CY\NN\1740 )\-RRB-\1740 administered\VBN\2436349 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 [\-LRB-\1740 MTX\NN\1740 +\CC\1740 <e1>5-FU</e1>\NN\1740 +\CC\1740 CY\NN\1740 (\-LRB-\1740 CMF\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 experiments\NNS\641820 on\IN\1740 Wistar\NNP\1740 rats\NNS\2329401 .\.\1740
D005472_D007674 NONE Our\PRP$\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 <e2>nephrotoxicity</e2>\NN\1740 of\IN\1740 MTX\NN\1740 +\CC\1740 <e1>5-FU</e1>\NN\1740 +\CC\1740 CY\NN\1740 administered\VBN\2436349 jointly\RB\1740 is\VBZ\836236 lower\JJR\1740 than\IN\1740 in\IN\13603305 monotherapy\NN\1740 .\.\1740
D003520_D007674 NONE The\DT\1740 <e2>nephrotoxic</e2>\JJ\1740 action\NN\30358 of\IN\1740 anticancer\NN\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 nitrogranulogen\NN\1740 (\-LRB-\1740 NG\NN\13717155 )\-RRB-\1740 ,\,\1740 methotrexate\VBP\1740 (\-LRB-\1740 MTX\NN\1740 )\-RRB-\1740 ,\,\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>cyclophosphamide</e1>\NN\1740 (\-LRB-\1740 CY\NN\1740 )\-RRB-\1740 administered\VBN\2436349 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 [\-LRB-\1740 MTX\NN\1740 +\CC\1740 5-FU\NN\1740 +\CC\1740 CY\NN\1740 (\-LRB-\1740 CMF\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 experiments\NNS\641820 on\IN\1740 Wistar\NNP\1740 rats\NNS\2329401 .\.\1740
D003520_D007674 NONE The\DT\1740 <e2>nephrotoxic</e2>\JJ\1740 action\NN\30358 of\IN\1740 anticancer\NN\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 nitrogranulogen\NN\1740 (\-LRB-\1740 NG\NN\13717155 )\-RRB-\1740 ,\,\1740 methotrexate\VBP\1740 (\-LRB-\1740 MTX\NN\1740 )\-RRB-\1740 ,\,\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 <e1>CY</e1>\NN\1740 )\-RRB-\1740 administered\VBN\2436349 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 [\-LRB-\1740 MTX\NN\1740 +\CC\1740 5-FU\NN\1740 +\CC\1740 CY\NN\1740 (\-LRB-\1740 CMF\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 experiments\NNS\641820 on\IN\1740 Wistar\NNP\1740 rats\NNS\2329401 .\.\1740
D003520_D007674 NONE The\DT\1740 <e2>nephrotoxic</e2>\JJ\1740 action\NN\30358 of\IN\1740 anticancer\NN\1740 drugs\NNS\14778436 such\JJ\1740 as\IN\14622893 nitrogranulogen\NN\1740 (\-LRB-\1740 NG\NN\13717155 )\-RRB-\1740 ,\,\1740 methotrexate\VBP\1740 (\-LRB-\1740 MTX\NN\1740 )\-RRB-\1740 ,\,\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 5-FU\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 CY\NN\1740 )\-RRB-\1740 administered\VBN\2436349 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 [\-LRB-\1740 MTX\NN\1740 +\CC\1740 5-FU\NN\1740 +\CC\1740 <e1>CY</e1>\NN\1740 (\-LRB-\1740 CMF\NN\1740 )\-RRB-\1740 ]\-RRB-\1740 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 experiments\NNS\641820 on\IN\1740 Wistar\NNP\1740 rats\NNS\2329401 .\.\1740
D003520_D007674 NONE Our\PRP$\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 <e2>nephrotoxicity</e2>\NN\1740 of\IN\1740 MTX\NN\1740 +\CC\1740 5-FU\NN\1740 +\CC\1740 <e1>CY</e1>\NN\1740 administered\VBN\2436349 jointly\RB\1740 is\VBZ\836236 lower\JJR\1740 than\IN\1740 in\IN\13603305 monotherapy\NN\1740 .\.\1740
D003520_D006470 CID <e1>CY</e1>\NNP\1740 caused\VBD\1617192 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 in\IN\13603305 40\CD\13745420 %\NN\1740 of\IN\1740 rats\NNS\2329401 ,\,\1740 but\CC\1740 it\PRP\6125041 did\VBD\1640855 not\RB\1740 cause\VB\1617192 this\DT\1740 complication\NN\1073995 when\WRB\1740 combined\VBN\2630189 with\IN\1740 5-FU\NN\1740 and\CC\1740 MTX\NN\1740 .\.\1740
D003520_D003556 CID <e1>CY</e1>\NNP\1740 caused\VBD\1617192 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 in\IN\13603305 40\CD\13745420 %\NN\1740 of\IN\1740 rats\NNS\2329401 ,\,\1740 but\CC\1740 it\PRP\6125041 did\VBD\1640855 not\RB\1740 cause\VB\1617192 this\DT\1740 complication\NN\1073995 when\WRB\1740 combined\VBN\2630189 with\IN\1740 5-FU\NN\1740 and\CC\1740 MTX\NN\1740 .\.\1740
D005472_D006470 NONE CY\NNP\1740 caused\VBD\1617192 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 in\IN\13603305 40\CD\13745420 %\NN\1740 of\IN\1740 rats\NNS\2329401 ,\,\1740 but\CC\1740 it\PRP\6125041 did\VBD\1640855 not\RB\1740 cause\VB\1617192 this\DT\1740 complication\NN\1073995 when\WRB\1740 combined\VBN\2630189 with\IN\1740 <e1>5-FU</e1>\NN\1740 and\CC\1740 MTX\NN\1740 .\.\1740
D005472_D003556 NONE CY\NNP\1740 caused\VBD\1617192 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 in\IN\13603305 40\CD\13745420 %\NN\1740 of\IN\1740 rats\NNS\2329401 ,\,\1740 but\CC\1740 it\PRP\6125041 did\VBD\1640855 not\RB\1740 cause\VB\1617192 this\DT\1740 complication\NN\1073995 when\WRB\1740 combined\VBN\2630189 with\IN\1740 <e1>5-FU</e1>\NN\1740 and\CC\1740 MTX\NN\1740 .\.\1740
D008727_D006470 NONE CY\NNP\1740 caused\VBD\1617192 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 in\IN\13603305 40\CD\13745420 %\NN\1740 of\IN\1740 rats\NNS\2329401 ,\,\1740 but\CC\1740 it\PRP\6125041 did\VBD\1640855 not\RB\1740 cause\VB\1617192 this\DT\1740 complication\NN\1073995 when\WRB\1740 combined\VBN\2630189 with\IN\1740 5-FU\NN\1740 and\CC\1740 <e1>MTX</e1>\NN\1740 .\.\1740
D008727_D003556 NONE CY\NNP\1740 caused\VBD\1617192 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 in\IN\13603305 40\CD\13745420 %\NN\1740 of\IN\1740 rats\NNS\2329401 ,\,\1740 but\CC\1740 it\PRP\6125041 did\VBD\1640855 not\RB\1740 cause\VB\1617192 this\DT\1740 complication\NN\1073995 when\WRB\1740 combined\VBN\2630189 with\IN\1740 5-FU\NN\1740 and\CC\1740 <e1>MTX</e1>\NN\1740 .\.\1740
20880751
D007980_D004409 CID <e1>Levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 :\:\1740 filling\VBG\126264 the\DT\1740 bench-to-bedside\JJ\1740 gap\NN\4752530 .\.\1740
D007980_D004409 CID Although\IN\1740 preclinical\JJ\1740 and\CC\1740 clinical\JJ\1740 findings\NNS\7951464 suggest\VBP\1010118 pulsatile\JJ\1740 stimulation\NN\242808 of\IN\1740 striatal\JJ\1740 postsynaptic\JJ\1740 receptors\NNS\5225602 as\IN\14622893 a\DT\13649268 key\JJ\1740 mechanism\NN\13446390 underlying\VBG\2604760 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 ,\,\1740 their\PRP$\1740 pathogenesis\NN\13533470 is\VBZ\836236 still\RB\1740 unclear\JJ\1740 .\.\1740
D007980_D004409 CID Recent\JJ\1740 preclinical\JJ\1740 and\CC\1740 clinical\JJ\1740 data\NNS\7951464 from\IN\1740 promising\JJ\1740 lines\NNS\8426461 of\IN\1740 research\NN\633864 focus\NN\5704266 on\IN\1740 the\DT\1740 differential\JJ\1740 role\NN\719494 of\IN\1740 presynaptic\JJ\1740 versus\CC\1740 postsynaptic\JJ\1740 mechanisms\NNS\13446390 ,\,\1740 dopamine\NN\14807737 receptor\NN\5225602 subtypes\NNS\1740 ,\,\1740 ionotropic\JJ\1740 and\CC\1740 metabotropic\NN\1740 glutamate\NN\15010703 receptors\NNS\5225602 ,\,\1740 and\CC\1740 non-dopaminergic\JJ\1740 neurotransmitter\NN\14807410 systems\NNS\3575240 in\IN\13603305 the\DT\1740 pathophysiology\NN\1740 of\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 .\.\1740
D007980_D010300 NONE <e1>Levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 :\:\1740 filling\VBG\126264 the\DT\1740 bench-to-bedside\JJ\1740 gap\NN\4752530 .\.\1740
D007980_D010300 NONE <e1>Levodopa</e1>\NN\14604959 is\VBZ\836236 the\DT\1740 most\RBS\1740 effective\JJ\1740 drug\NN\14778436 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D004298_D004409 NONE However\RB\1740 ,\,\1740 the\DT\1740 long-term\JJ\1740 use\NN\407535 of\IN\1740 this\DT\1740 <e1>dopamine</e1>\NN\14807737 precursor\NN\14580897 is\VBZ\836236 complicated\VBN\126264 by\IN\1740 highly\RB\1740 disabling\VBG\126264 fluctuations\NNS\7345593 and\CC\1740 <e2>dyskinesias</e2>\NNS\14084880 .\.\1740
D004298_D004409 NONE Recent\JJ\1740 preclinical\JJ\1740 and\CC\1740 clinical\JJ\1740 data\NNS\7951464 from\IN\1740 promising\JJ\1740 lines\NNS\8426461 of\IN\1740 research\NN\633864 focus\NN\5704266 on\IN\1740 the\DT\1740 differential\JJ\1740 role\NN\719494 of\IN\1740 presynaptic\JJ\1740 versus\CC\1740 postsynaptic\JJ\1740 mechanisms\NNS\13446390 ,\,\1740 <e1>dopamine</e1>\NN\14807737 receptor\NN\5225602 subtypes\NNS\1740 ,\,\1740 ionotropic\JJ\1740 and\CC\1740 metabotropic\NN\1740 glutamate\NN\15010703 receptors\NNS\5225602 ,\,\1740 and\CC\1740 non-dopaminergic\JJ\1740 neurotransmitter\NN\14807410 systems\NNS\3575240 in\IN\13603305 the\DT\1740 pathophysiology\NN\1740 of\IN\1740 levodopa-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 .\.\1740
D018698_D004409 NONE Recent\JJ\1740 preclinical\JJ\1740 and\CC\1740 clinical\JJ\1740 data\NNS\7951464 from\IN\1740 promising\JJ\1740 lines\NNS\8426461 of\IN\1740 research\NN\633864 focus\NN\5704266 on\IN\1740 the\DT\1740 differential\JJ\1740 role\NN\719494 of\IN\1740 presynaptic\JJ\1740 versus\CC\1740 postsynaptic\JJ\1740 mechanisms\NNS\13446390 ,\,\1740 dopamine\NN\14807737 receptor\NN\5225602 subtypes\NNS\1740 ,\,\1740 ionotropic\JJ\1740 and\CC\1740 metabotropic\NN\1740 <e1>glutamate</e1>\NN\15010703 receptors\NNS\5225602 ,\,\1740 and\CC\1740 non-dopaminergic\JJ\1740 neurotransmitter\NN\14807410 systems\NNS\3575240 in\IN\13603305 the\DT\1740 pathophysiology\NN\1740 of\IN\1740 levodopa-induced\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 .\.\1740
20098969
D008694_D001145 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Methamphetamine</e1>\NNP\2704153 is\VBZ\836236 a\DT\13649268 very\RB\1740 addictive\JJ\1740 ,\,\1740 powerful\JJ\1740 stimulant\NN\5816287 that\WDT\1740 increases\VBZ\169651 wakefulness\NN\14034177 and\CC\1740 physical\JJ\1740 activity\NN\30358 and\CC\1740 can\MD\3094503 produce\VB\1617192 other\JJ\1740 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 <e2>cardiac\JJ\1740 dysrhythmias</e2>\NNS\1740 ,\,\1740 hypertension\NN\14057371 ,\,\1740 hallucinations\NNS\14376855 ,\,\1740 and\CC\1740 violent\JJ\1740 behavior\NN\407535 .\.\1740
D008694_D006973 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Methamphetamine</e1>\NNP\2704153 is\VBZ\836236 a\DT\13649268 very\RB\1740 addictive\JJ\1740 ,\,\1740 powerful\JJ\1740 stimulant\NN\5816287 that\WDT\1740 increases\VBZ\169651 wakefulness\NN\14034177 and\CC\1740 physical\JJ\1740 activity\NN\30358 and\CC\1740 can\MD\3094503 produce\VB\1617192 other\JJ\1740 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 cardiac\JJ\1740 dysrhythmias\NNS\1740 ,\,\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 hallucinations\NNS\14376855 ,\,\1740 and\CC\1740 violent\JJ\1740 behavior\NN\407535 .\.\1740
D008694_D006212 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Methamphetamine</e1>\NNP\2704153 is\VBZ\836236 a\DT\13649268 very\RB\1740 addictive\JJ\1740 ,\,\1740 powerful\JJ\1740 stimulant\NN\5816287 that\WDT\1740 increases\VBZ\169651 wakefulness\NN\14034177 and\CC\1740 physical\JJ\1740 activity\NN\30358 and\CC\1740 can\MD\3094503 produce\VB\1617192 other\JJ\1740 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 cardiac\JJ\1740 dysrhythmias\NNS\1740 ,\,\1740 hypertension\NN\14057371 ,\,\1740 <e2>hallucinations</e2>\NNS\14376855 ,\,\1740 and\CC\1740 violent\JJ\1740 behavior\NN\407535 .\.\1740
D008694_D001523 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Methamphetamine</e1>\NNP\2704153 is\VBZ\836236 a\DT\13649268 very\RB\1740 addictive\JJ\1740 ,\,\1740 powerful\JJ\1740 stimulant\NN\5816287 that\WDT\1740 increases\VBZ\169651 wakefulness\NN\14034177 and\CC\1740 physical\JJ\1740 activity\NN\30358 and\CC\1740 can\MD\3094503 produce\VB\1617192 other\JJ\1740 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 cardiac\JJ\1740 dysrhythmias\NNS\1740 ,\,\1740 hypertension\NN\14057371 ,\,\1740 hallucinations\NNS\14376855 ,\,\1740 and\CC\1740 <e2>violent\JJ\1740 behavior</e2>\NN\407535 .\.\1740
D008694_D014987 NONE Dental\JJ\1740 patients\NNS\9898892 abusing\VBG\2514187 <e1>methamphetamine</e1>\NN\2704153 can\MD\3094503 present\VB\2137132 with\IN\1740 poor\JJ\1740 oral\JJ\1740 hygiene\NN\14494893 ,\,\1740 <e2>xerostomia</e2>\NN\14536438 ,\,\1740 rampant\JJ\1740 caries\NNS\13456715 (\-LRB-\1740 "\``\1740 meth\NN\2704153 mouth\NN\5610008 "\''\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 excessive\JJ\1740 tooth\NN\5269901 wear\NN\14561618 .\.\1740
D008694_D003731 CID Dental\JJ\1740 patients\NNS\9898892 abusing\VBG\2514187 <e1>methamphetamine</e1>\NN\2704153 can\MD\3094503 present\VB\2137132 with\IN\1740 poor\JJ\1740 oral\JJ\1740 hygiene\NN\14494893 ,\,\1740 xerostomia\NN\14536438 ,\,\1740 rampant\JJ\1740 <e2>caries</e2>\NNS\13456715 (\-LRB-\1740 "\``\1740 meth\NN\2704153 mouth\NN\5610008 "\''\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 excessive\JJ\1740 tooth\NN\5269901 wear\NN\14561618 .\.\1740
D008694_D003731 CID She\PRP\1740 reported\VBD\831651 her\PRP$\1740 use\NN\407535 of\IN\1740 <e1>methamphetamine</e1>\NN\2704153 for\IN\1740 five\CD\13741022 years\NNS\15144371 and\CC\1740 had\VBD\2108377 not\RB\1740 experienced\VBN\2108377 any\DT\1740 major\JJ\1740 <e2>carious\JJ\1740 episodes</e2>\NNS\7283608 before\IN\1740 she\PRP\1740 started\VBD\2009433 using\VBG\1156834 the\DT\1740 drug\NN\14778436 .\.\1740
D008694_-1 NONE Dental\JJ\1740 patients\NNS\9898892 abusing\VBG\2514187 <e1>methamphetamine</e1>\NN\2704153 can\MD\3094503 present\VB\2137132 with\IN\1740 poor\JJ\1740 oral\JJ\1740 hygiene\NN\14494893 ,\,\1740 xerostomia\NN\14536438 ,\,\1740 rampant\JJ\1740 caries\NNS\13456715 (\-LRB-\1740 "\``\1740 <e2>meth\NN\2704153 mouth</e2>\NN\5610008 "\''\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 excessive\JJ\1740 tooth\NN\5269901 wear\NN\14561618 .\.\1740
D008694_-1 NONE CLINICAL\NN\1740 SIGNIFICANCE\NN\5168261 :\:\1740 This\DT\1740 clinical\JJ\1740 case\NN\7283608 showing\VBG\2137132 oral\JJ\1740 manifestations\NNS\7321772 of\IN\1740 <e2>meth\NN\2704153 mouth</e2>\NN\5610008 was\VBD\836236 presented\VBN\2137132 to\TO\1740 help\VB\2556126 dental\JJ\1740 practitioners\NNS\10480253 recognize\VBP\686447 and\CC\1740 manage\VBP\2524171 patients\NNS\9898892 who\WP\8299493 may\MD\15209706 be\VB\836236 abusing\VBG\2514187 <e1>methamphetamines</e1>\NNS\2704153 .\.\1740
D008694_D057085 NONE Dental\JJ\1740 patients\NNS\9898892 abusing\VBG\2514187 <e1>methamphetamine</e1>\NN\2704153 can\MD\3094503 present\VB\2137132 with\IN\1740 poor\JJ\1740 oral\JJ\1740 hygiene\NN\14494893 ,\,\1740 xerostomia\NN\14536438 ,\,\1740 rampant\JJ\1740 caries\NNS\13456715 (\-LRB-\1740 "\``\1740 meth\NN\2704153 mouth\NN\5610008 "\''\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 excessive\JJ\1740 <e2>tooth\NN\5269901 wear</e2>\NN\14561618 .\.\1740
16428221
D008774_D020293 CID <e2>Cerebral\JJ\1740 vasculitis</e2>\NN\14336539 following\VBG\1835496 oral\JJ\1740 <e1>methylphenidate</e1>\NN\4320126 intake\NN\13440063 in\IN\13603305 an\DT\6697703 adult\NN\7846 :\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 .\.\1740
D008774_D020293 CID <e2>Cerebral\JJ\1740 vasculitis</e2>\NN\14336539 associated\VBN\628491 with\IN\1740 amphetamine\NN\3248958 abuse\NN\418025 is\VBZ\836236 well\RB\1740 documented\VBN\1000214 ,\,\1740 and\CC\1740 in\IN\13603305 rare\JJ\1740 cases\NNS\7283608 ischaemic\JJ\1740 stroke\NN\556313 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 after\IN\1740 <e1>methylphenidate</e1>\JJ\1740 intake\NN\13440063 in\IN\13603305 children\NNS\9622049 .\.\1740
D008774_D019969 NONE Cerebral\JJ\1740 vasculitis\NN\14336539 associated\VBN\628491 with\IN\1740 <e2>amphetamine\NN\3248958 abuse</e2>\NN\418025 is\VBZ\836236 well\RB\1740 documented\VBN\1000214 ,\,\1740 and\CC\1740 in\IN\13603305 rare\JJ\1740 cases\NNS\7283608 ischaemic\JJ\1740 stroke\NN\556313 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 after\IN\1740 <e1>methylphenidate</e1>\JJ\1740 intake\NN\13440063 in\IN\13603305 children\NNS\9622049 .\.\1740
D008774_D002544 NONE Cerebral\JJ\1740 vasculitis\NN\14336539 associated\VBN\628491 with\IN\1740 amphetamine\NN\3248958 abuse\NN\418025 is\VBZ\836236 well\RB\1740 documented\VBN\1000214 ,\,\1740 and\CC\1740 in\IN\13603305 rare\JJ\1740 cases\NNS\7283608 <e2>ischaemic\JJ\1740 stroke</e2>\NN\556313 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 after\IN\1740 <e1>methylphenidate</e1>\JJ\1740 intake\NN\13440063 in\IN\13603305 children\NNS\9622049 .\.\1740
D008774_D002544 NONE We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 63-year-old\JJ\1740 female\NN\15388 who\WP\8299493 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>methylphenidate</e1>\NN\4320126 due\IN\5174653 to\TO\1740 hyperactivity\NN\14052403 and\CC\1740 suffered\VBN\2110220 from\IN\1740 multiple\JJ\1740 <e2>ischaemic\JJ\1740 strokes</e2>\NNS\556313 .\.\1740
D008774_D006948 NONE We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 63-year-old\JJ\1740 female\NN\15388 who\WP\8299493 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>methylphenidate</e1>\NN\4320126 due\IN\5174653 to\TO\1740 <e2>hyperactivity</e2>\NN\14052403 and\CC\1740 suffered\VBN\2110220 from\IN\1740 multiple\JJ\1740 ischaemic\JJ\1740 strokes\NNS\556313 .\.\1740
D008774_D014657 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 <e1>methylphenidate</e1>\VB\1740 mediated\JJ\1740 <e2>vasculitis</e2>\NN\14336539 should\MD\1740 be\VB\836236 considered\VBN\689344 in\IN\13603305 patients\NNS\9898892 with\IN\1740 neurological\JJ\1740 symptoms\NNS\5823932 and\CC\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 methylphenidate\NN\4320126 therapy\NN\657604 .\.\1740
D008774_D014657 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 methylphenidate\VB\1740 mediated\JJ\1740 <e2>vasculitis</e2>\NN\14336539 should\MD\1740 be\VB\836236 considered\VBN\689344 in\IN\13603305 patients\NNS\9898892 with\IN\1740 neurological\JJ\1740 symptoms\NNS\5823932 and\CC\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 <e1>methylphenidate</e1>\NN\4320126 therapy\NN\657604 .\.\1740
220563
C023470_D010523 CID <e1>Perhexiline\NN\1740 maleate</e1>\NN\2718811 and\CC\1740 <e2>peripheral\JJ\1740 neuropathy</e2>\NN\14204950 .\.\1740
C023470_D010523 CID <e2>Peripheral\JJ\1740 neuropathy</e2>\NN\14204950 has\VBZ\2108377 been\VBN\836236 noted\VBN\1009240 as\IN\14622893 a\DT\13649268 complication\NN\1073995 of\IN\1740 therapy\NN\657604 with\IN\1740 <e1>perhexiline\NN\1740 maleate</e1>\NN\2718811 ,\,\1740 a\DT\13649268 drug\NN\14778436 widely\RB\1740 used\VBN\1156834 in\IN\13603305 France\NNP\1740 (\-LRB-\1740 and\CC\1740 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 in\IN\13603305 the\DT\1740 United\NNP\1740 States\NNP\8491826 )\-RRB-\1740 for\IN\1740 the\DT\1740 prophylactic\JJ\1740 treatment\NN\654885 of\IN\1740 angina\JJ\1740 pectoris\NN\1740 .\.\1740
C023470_D000787 NONE Peripheral\JJ\1740 neuropathy\NN\14204950 has\VBZ\2108377 been\VBN\836236 noted\VBN\1009240 as\IN\14622893 a\DT\13649268 complication\NN\1073995 of\IN\1740 therapy\NN\657604 with\IN\1740 <e1>perhexiline\NN\1740 maleate</e1>\NN\2718811 ,\,\1740 a\DT\13649268 drug\NN\14778436 widely\RB\1740 used\VBN\1156834 in\IN\13603305 France\NNP\1740 (\-LRB-\1740 and\CC\1740 in\IN\13603305 clinical\JJ\1740 trials\NNS\786195 in\IN\13603305 the\DT\1740 United\NNP\1740 States\NNP\8491826 )\-RRB-\1740 for\IN\1740 the\DT\1740 prophylactic\JJ\1740 treatment\NN\654885 of\IN\1740 <e2>angina\JJ\1740 pectoris</e2>\NN\1740 .\.\1740
9721172
D007052_D001649 NONE A\DT\13649268 previously\RB\1740 healthy\JJ\1740 child\NN\9622049 who\WP\8299493 developed\VBD\1753788 acute\JJ\1740 ,\,\1740 severe\JJ\1740 ,\,\1740 rapidly\RB\1740 progressive\JJ\1740 <e2>vanishing\NN\7335716 bile\NN\5405946 duct\NN\5248181 syndrome</e2>\NN\5870365 shortly\RB\1740 after\IN\1740 Stevens-Johnson\NN\1740 syndrome\NN\5870365 is\VBZ\836236 described\VBN\1001294 ;\:\1740 this\DT\1740 was\VBD\836236 temporally\RB\1740 associated\VBN\628491 with\IN\1740 <e1>ibuprofen</e1>\NN\3828465 use\NN\407535 .\.\1740
D007052_D013262 CID A\DT\13649268 previously\RB\1740 healthy\JJ\1740 child\NN\9622049 who\WP\8299493 developed\VBD\1753788 acute\JJ\1740 ,\,\1740 severe\JJ\1740 ,\,\1740 rapidly\RB\1740 progressive\JJ\1740 vanishing\NN\7335716 bile\NN\5405946 duct\NN\5248181 syndrome\NN\5870365 shortly\RB\1740 after\IN\1740 <e2>Stevens-Johnson\NN\1740 syndrome</e2>\NN\5870365 is\VBZ\836236 described\VBN\1001294 ;\:\1740 this\DT\1740 was\VBD\836236 temporally\RB\1740 associated\VBN\628491 with\IN\1740 <e1>ibuprofen</e1>\NN\3828465 use\NN\407535 .\.\1740
D014580_D002779 NONE Despite\IN\7501545 therapy\NN\657604 with\IN\1740 <e1>ursodeoxycholic\JJ\1740 acid</e1>\NN\14818238 ,\,\1740 prednisone\NN\2721538 ,\,\1740 and\CC\1740 then\RB\1740 tacrolimus\NN\1740 ,\,\1740 her\PRP$\1740 <e2>cholestatic\JJ\1740 disease</e2>\NN\14061805 was\VBD\836236 unrelenting\VBG\1740 ,\,\1740 with\IN\1740 cirrhosis\NN\14116321 shown\VBN\2137132 by\IN\1740 biopsy\NN\5739043 6\CD\13741022 months\NNS\15113229 after\IN\1740 presentation\NN\1027379 .\.\1740
D014580_D005355 NONE Despite\IN\7501545 therapy\NN\657604 with\IN\1740 <e1>ursodeoxycholic\JJ\1740 acid</e1>\NN\14818238 ,\,\1740 prednisone\NN\2721538 ,\,\1740 and\CC\1740 then\RB\1740 tacrolimus\NN\1740 ,\,\1740 her\PRP$\1740 cholestatic\JJ\1740 disease\NN\14061805 was\VBD\836236 unrelenting\VBG\1740 ,\,\1740 with\IN\1740 <e2>cirrhosis</e2>\NN\14116321 shown\VBN\2137132 by\IN\1740 biopsy\NN\5739043 6\CD\13741022 months\NNS\15113229 after\IN\1740 presentation\NN\1027379 .\.\1740
D011241_D002779 NONE Despite\IN\7501545 therapy\NN\657604 with\IN\1740 ursodeoxycholic\JJ\1740 acid\NN\14818238 ,\,\1740 <e1>prednisone</e1>\NN\2721538 ,\,\1740 and\CC\1740 then\RB\1740 tacrolimus\NN\1740 ,\,\1740 her\PRP$\1740 <e2>cholestatic\JJ\1740 disease</e2>\NN\14061805 was\VBD\836236 unrelenting\VBG\1740 ,\,\1740 with\IN\1740 cirrhosis\NN\14116321 shown\VBN\2137132 by\IN\1740 biopsy\NN\5739043 6\CD\13741022 months\NNS\15113229 after\IN\1740 presentation\NN\1027379 .\.\1740
D011241_D005355 NONE Despite\IN\7501545 therapy\NN\657604 with\IN\1740 ursodeoxycholic\JJ\1740 acid\NN\14818238 ,\,\1740 <e1>prednisone</e1>\NN\2721538 ,\,\1740 and\CC\1740 then\RB\1740 tacrolimus\NN\1740 ,\,\1740 her\PRP$\1740 cholestatic\JJ\1740 disease\NN\14061805 was\VBD\836236 unrelenting\VBG\1740 ,\,\1740 with\IN\1740 <e2>cirrhosis</e2>\NN\14116321 shown\VBN\2137132 by\IN\1740 biopsy\NN\5739043 6\CD\13741022 months\NNS\15113229 after\IN\1740 presentation\NN\1027379 .\.\1740
D016559_D002779 NONE Despite\IN\7501545 therapy\NN\657604 with\IN\1740 ursodeoxycholic\JJ\1740 acid\NN\14818238 ,\,\1740 prednisone\NN\2721538 ,\,\1740 and\CC\1740 then\RB\1740 <e1>tacrolimus</e1>\NN\1740 ,\,\1740 her\PRP$\1740 <e2>cholestatic\JJ\1740 disease</e2>\NN\14061805 was\VBD\836236 unrelenting\VBG\1740 ,\,\1740 with\IN\1740 cirrhosis\NN\14116321 shown\VBN\2137132 by\IN\1740 biopsy\NN\5739043 6\CD\13741022 months\NNS\15113229 after\IN\1740 presentation\NN\1027379 .\.\1740
D016559_D005355 NONE Despite\IN\7501545 therapy\NN\657604 with\IN\1740 ursodeoxycholic\JJ\1740 acid\NN\14818238 ,\,\1740 prednisone\NN\2721538 ,\,\1740 and\CC\1740 then\RB\1740 <e1>tacrolimus</e1>\NN\1740 ,\,\1740 her\PRP$\1740 cholestatic\JJ\1740 disease\NN\14061805 was\VBD\836236 unrelenting\VBG\1740 ,\,\1740 with\IN\1740 <e2>cirrhosis</e2>\NN\14116321 shown\VBN\2137132 by\IN\1740 biopsy\NN\5739043 6\CD\13741022 months\NNS\15113229 after\IN\1740 presentation\NN\1027379 .\.\1740
7919560
D000667_D004892 CID <e2>Erythema\NNP\14227218 multiforme</e2>\VBD\1740 and\CC\1740 hypersensitivity\NN\14531772 myocarditis\NN\14338942 caused\VBN\1617192 by\IN\1740 <e1>ampicillin</e1>\NN\3910033 .\.\1740
D000667_D004892 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 <e2>erythema\NN\14227218 multiforme</e2>\JJ\1740 and\CC\1740 hypersensitivity\NN\14531772 myocarditis\NN\14338942 caused\VBN\1617192 by\IN\1740 <e1>ampicillin</e1>\NN\3910033 .\.\1740
D000667_D009205 CID Erythema\NNP\14227218 multiforme\VBD\1740 and\CC\1740 <e2>hypersensitivity\NN\14531772 myocarditis</e2>\NN\14338942 caused\VBN\1617192 by\IN\1740 <e1>ampicillin</e1>\NN\3910033 .\.\1740
D000667_D009205 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 erythema\NN\14227218 multiforme\JJ\1740 and\CC\1740 <e2>hypersensitivity\NN\14531772 myocarditis</e2>\NN\14338942 caused\VBN\1617192 by\IN\1740 <e1>ampicillin</e1>\NN\3910033 .\.\1740
D000667_D018805 NONE CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 13-year-old\JJ\1740 boy\NN\9624168 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>ampicillin</e1>\NN\3910033 and\CC\1740 gentamicin\NN\2716866 because\IN\1740 of\IN\1740 suspected\VBN\916909 <e2>septicemia</e2>\NN\14189204 .\.\1740
D005839_D018805 NONE CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 13-year-old\JJ\1740 boy\NN\9624168 was\VBD\836236 treated\VBN\2376958 with\IN\1740 ampicillin\NN\3910033 and\CC\1740 <e1>gentamicin</e1>\NN\2716866 because\IN\1740 of\IN\1740 suspected\VBN\916909 <e2>septicemia</e2>\NN\14189204 .\.\1740
D010406_D009205 NONE CONCLUSIONS\NNS\5837957 :\:\1740 <e2>Hypersensitivity\NN\14531772 myocarditis</e2>\NN\14338942 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 and\CC\1740 dangerous\JJ\1740 manifestation\NN\7321772 of\IN\1740 allergy\NN\14533203 to\TO\1740 <e1>penicillins</e1>\NNS\2716866 .\.\1740
D010406_D004342 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Hypersensitivity\NN\14531772 myocarditis\NN\14338942 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 and\CC\1740 dangerous\JJ\1740 manifestation\NN\7321772 of\IN\1740 <e2>allergy</e2>\NN\14533203 to\TO\1740 <e1>penicillins</e1>\NNS\2716866 .\.\1740
2425813
D011239_D006529 CID <e2>Liver\NN\5298729 enlargement</e2>\NN\363260 and\CC\1740 muscle\NN\5289601 wastage\NN\13458571 occurred\VBD\2623529 in\IN\13603305 Wistar\NNP\1740 rats\NNS\2329401 following\VBG\1835496 the\DT\1740 subcutaneous\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>prednisolone</e1>\NN\2721538 .\.\1740
D011239_D009133 CID Liver\NN\5298729 enlargement\NN\363260 and\CC\1740 <e2>muscle\NN\5289601 wastage</e2>\NN\13458571 occurred\VBD\2623529 in\IN\13603305 Wistar\NNP\1740 rats\NNS\2329401 following\VBG\1835496 the\DT\1740 subcutaneous\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>prednisolone</e1>\NN\2721538 .\.\1740
12695819
D016559_D020258 NONE MR\NN\6339416 imaging\NN\5765159 with\IN\1740 quantitative\JJ\1740 diffusion\NN\13518963 mapping\NN\13783581 of\IN\1740 <e1>tacrolimus-induced</e1>\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 in\IN\13603305 organ\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 .\.\1740
D016559_D020258 NONE Diffusion-weighted\JJ\1740 imaging\NN\5765159 may\MD\15209706 be\VB\836236 useful\JJ\1740 in\IN\13603305 predicting\VBG\916909 the\DT\1740 outcomes\NNS\7291312 of\IN\1740 the\DT\1740 lesions\NNS\14204950 of\IN\1740 <e1>tacrolimus-induced</e1>\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D016559_D009422 NONE Brain\NN\5462674 MR\NN\6339416 studies\NNS\635850 ,\,\1740 including\VBG\690614 DW\NN\1740 imaging\NN\5765159 ,\,\1740 were\VBD\836236 prospectively\RB\1740 performed\VBN\2367363 in\IN\13603305 14\CD\13745420 organ\NN\5220461 transplant\NN\5267548 patients\NNS\9898892 receiving\VBG\2210855 <e1>tacrolimus</e1>\NN\1740 who\WP\8299493 developed\VBD\1753788 <e2>neurologic\JJ\1740 complications</e2>\NNS\1073995 .\.\1740
6133211
D012460_D015212 NONE Three\CD\13741022 infants\NNS\9918248 ,\,\1740 born\VBN\2630189 of\IN\1740 two\CD\13741022 mothers\NNS\10399491 with\IN\1740 <e2>inflammatory\JJ\1740 bowel\NN\5298729 disease</e2>\NN\14061805 who\WP\8299493 received\VBD\2210855 treatment\NN\654885 with\IN\1740 <e1>sulphasalazine</e1>\NN\1740 throughout\IN\1740 pregnancy\NN\14034177 ,\,\1740 were\VBD\836236 found\VBN\2426171 to\TO\1740 have\VB\2108377 major\JJ\1740 congenital\JJ\1740 anomalies\NNS\14501726 .\.\1740
D012460_D000013 NONE Three\CD\13741022 infants\NNS\9918248 ,\,\1740 born\VBN\2630189 of\IN\1740 two\CD\13741022 mothers\NNS\10399491 with\IN\1740 inflammatory\JJ\1740 bowel\NN\5298729 disease\NN\14061805 who\WP\8299493 received\VBD\2210855 treatment\NN\654885 with\IN\1740 <e1>sulphasalazine</e1>\NN\1740 throughout\IN\1740 pregnancy\NN\14034177 ,\,\1740 were\VBD\836236 found\VBN\2426171 to\TO\1740 have\VB\2108377 major\JJ\1740 <e2>congenital\JJ\1740 anomalies</e2>\NNS\14501726 .\.\1740
2355241
D007980_D002543 NONE The\DT\1740 low\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>cerebral\JJ\1740 haemorrhage</e2>\NN\14285662 as\IN\14622893 a\DT\13649268 cause\NN\7323922 of\IN\1740 death\NN\7296428 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 may\MD\15209706 reflect\VB\923793 the\DT\1740 hypotensive\JJ\1740 effect\NN\34213 of\IN\1740 <e1>levodopa</e1>\NN\14604959 and\CC\1740 a\DT\13649268 hypotensive\JJ\1740 mechanism\NN\13446390 due\IN\5174653 to\TO\1740 reduced\VBN\441445 noradrenaline\JJ\1740 levels\NNS\4916342 in\IN\13603305 the\DT\1740 parkinsonian\JJ\1740 brain\NN\5462674 .\.\1740
D007980_D003643 NONE The\DT\1740 low\JJ\1740 incidence\NN\13821570 of\IN\1740 cerebral\JJ\1740 haemorrhage\NN\14285662 as\IN\14622893 a\DT\13649268 cause\NN\7323922 of\IN\1740 <e2>death</e2>\NN\7296428 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 may\MD\15209706 reflect\VB\923793 the\DT\1740 hypotensive\JJ\1740 effect\NN\34213 of\IN\1740 <e1>levodopa</e1>\NN\14604959 and\CC\1740 a\DT\13649268 hypotensive\JJ\1740 mechanism\NN\13446390 due\IN\5174653 to\TO\1740 reduced\VBN\441445 noradrenaline\JJ\1740 levels\NNS\4916342 in\IN\13603305 the\DT\1740 parkinsonian\JJ\1740 brain\NN\5462674 .\.\1740
D007980_D010300 NONE The\DT\1740 low\JJ\1740 incidence\NN\13821570 of\IN\1740 cerebral\JJ\1740 haemorrhage\NN\14285662 as\IN\14622893 a\DT\13649268 cause\NN\7323922 of\IN\1740 death\NN\7296428 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 may\MD\15209706 reflect\VB\923793 the\DT\1740 hypotensive\JJ\1740 effect\NN\34213 of\IN\1740 <e1>levodopa</e1>\NN\14604959 and\CC\1740 a\DT\13649268 hypotensive\JJ\1740 mechanism\NN\13446390 due\IN\5174653 to\TO\1740 reduced\VBN\441445 noradrenaline\JJ\1740 levels\NNS\4916342 in\IN\13603305 the\DT\1740 parkinsonian\JJ\1740 brain\NN\5462674 .\.\1740
D007980_D010300 NONE The\DT\1740 low\JJ\1740 incidence\NN\13821570 of\IN\1740 cerebral\JJ\1740 haemorrhage\NN\14285662 as\IN\14622893 a\DT\13649268 cause\NN\7323922 of\IN\1740 death\NN\7296428 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 may\MD\15209706 reflect\VB\923793 the\DT\1740 hypotensive\JJ\1740 effect\NN\34213 of\IN\1740 <e1>levodopa</e1>\NN\14604959 and\CC\1740 a\DT\13649268 hypotensive\JJ\1740 mechanism\NN\13446390 due\IN\5174653 to\TO\1740 reduced\VBN\441445 noradrenaline\JJ\1740 levels\NNS\4916342 in\IN\13603305 the\DT\1740 <e2>parkinsonian</e2>\JJ\1740 brain\NN\5462674 .\.\1740
D007980_D007022 CID The\DT\1740 low\JJ\1740 incidence\NN\13821570 of\IN\1740 cerebral\JJ\1740 haemorrhage\NN\14285662 as\IN\14622893 a\DT\13649268 cause\NN\7323922 of\IN\1740 death\NN\7296428 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 may\MD\15209706 reflect\VB\923793 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 effect\NN\34213 of\IN\1740 <e1>levodopa</e1>\NN\14604959 and\CC\1740 a\DT\13649268 hypotensive\JJ\1740 mechanism\NN\13446390 due\IN\5174653 to\TO\1740 reduced\VBN\441445 noradrenaline\JJ\1740 levels\NNS\4916342 in\IN\13603305 the\DT\1740 parkinsonian\JJ\1740 brain\NN\5462674 .\.\1740
D007980_D007022 CID The\DT\1740 low\JJ\1740 incidence\NN\13821570 of\IN\1740 cerebral\JJ\1740 haemorrhage\NN\14285662 as\IN\14622893 a\DT\13649268 cause\NN\7323922 of\IN\1740 death\NN\7296428 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 may\MD\15209706 reflect\VB\923793 the\DT\1740 hypotensive\JJ\1740 effect\NN\34213 of\IN\1740 <e1>levodopa</e1>\NN\14604959 and\CC\1740 a\DT\13649268 <e2>hypotensive</e2>\JJ\1740 mechanism\NN\13446390 due\IN\5174653 to\TO\1740 reduced\VBN\441445 noradrenaline\JJ\1740 levels\NNS\4916342 in\IN\13603305 the\DT\1740 parkinsonian\JJ\1740 brain\NN\5462674 .\.\1740
D009638_D002543 NONE The\DT\1740 low\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>cerebral\JJ\1740 haemorrhage</e2>\NN\14285662 as\IN\14622893 a\DT\13649268 cause\NN\7323922 of\IN\1740 death\NN\7296428 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 may\MD\15209706 reflect\VB\923793 the\DT\1740 hypotensive\JJ\1740 effect\NN\34213 of\IN\1740 levodopa\NN\14604959 and\CC\1740 a\DT\13649268 hypotensive\JJ\1740 mechanism\NN\13446390 due\IN\5174653 to\TO\1740 reduced\VBN\441445 <e1>noradrenaline</e1>\JJ\1740 levels\NNS\4916342 in\IN\13603305 the\DT\1740 parkinsonian\JJ\1740 brain\NN\5462674 .\.\1740
D009638_D003643 NONE The\DT\1740 low\JJ\1740 incidence\NN\13821570 of\IN\1740 cerebral\JJ\1740 haemorrhage\NN\14285662 as\IN\14622893 a\DT\13649268 cause\NN\7323922 of\IN\1740 <e2>death</e2>\NN\7296428 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 may\MD\15209706 reflect\VB\923793 the\DT\1740 hypotensive\JJ\1740 effect\NN\34213 of\IN\1740 levodopa\NN\14604959 and\CC\1740 a\DT\13649268 hypotensive\JJ\1740 mechanism\NN\13446390 due\IN\5174653 to\TO\1740 reduced\VBN\441445 <e1>noradrenaline</e1>\JJ\1740 levels\NNS\4916342 in\IN\13603305 the\DT\1740 parkinsonian\JJ\1740 brain\NN\5462674 .\.\1740
D009638_D010300 NONE The\DT\1740 low\JJ\1740 incidence\NN\13821570 of\IN\1740 cerebral\JJ\1740 haemorrhage\NN\14285662 as\IN\14622893 a\DT\13649268 cause\NN\7323922 of\IN\1740 death\NN\7296428 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 may\MD\15209706 reflect\VB\923793 the\DT\1740 hypotensive\JJ\1740 effect\NN\34213 of\IN\1740 levodopa\NN\14604959 and\CC\1740 a\DT\13649268 hypotensive\JJ\1740 mechanism\NN\13446390 due\IN\5174653 to\TO\1740 reduced\VBN\441445 <e1>noradrenaline</e1>\JJ\1740 levels\NNS\4916342 in\IN\13603305 the\DT\1740 parkinsonian\JJ\1740 brain\NN\5462674 .\.\1740
D009638_D010300 NONE The\DT\1740 low\JJ\1740 incidence\NN\13821570 of\IN\1740 cerebral\JJ\1740 haemorrhage\NN\14285662 as\IN\14622893 a\DT\13649268 cause\NN\7323922 of\IN\1740 death\NN\7296428 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 may\MD\15209706 reflect\VB\923793 the\DT\1740 hypotensive\JJ\1740 effect\NN\34213 of\IN\1740 levodopa\NN\14604959 and\CC\1740 a\DT\13649268 hypotensive\JJ\1740 mechanism\NN\13446390 due\IN\5174653 to\TO\1740 reduced\VBN\441445 <e1>noradrenaline</e1>\JJ\1740 levels\NNS\4916342 in\IN\13603305 the\DT\1740 <e2>parkinsonian</e2>\JJ\1740 brain\NN\5462674 .\.\1740
D009638_D007022 NONE The\DT\1740 low\JJ\1740 incidence\NN\13821570 of\IN\1740 cerebral\JJ\1740 haemorrhage\NN\14285662 as\IN\14622893 a\DT\13649268 cause\NN\7323922 of\IN\1740 death\NN\7296428 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 may\MD\15209706 reflect\VB\923793 the\DT\1740 <e2>hypotensive</e2>\JJ\1740 effect\NN\34213 of\IN\1740 levodopa\NN\14604959 and\CC\1740 a\DT\13649268 hypotensive\JJ\1740 mechanism\NN\13446390 due\IN\5174653 to\TO\1740 reduced\VBN\441445 <e1>noradrenaline</e1>\JJ\1740 levels\NNS\4916342 in\IN\13603305 the\DT\1740 parkinsonian\JJ\1740 brain\NN\5462674 .\.\1740
D009638_D007022 NONE The\DT\1740 low\JJ\1740 incidence\NN\13821570 of\IN\1740 cerebral\JJ\1740 haemorrhage\NN\14285662 as\IN\14622893 a\DT\13649268 cause\NN\7323922 of\IN\1740 death\NN\7296428 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 may\MD\15209706 reflect\VB\923793 the\DT\1740 hypotensive\JJ\1740 effect\NN\34213 of\IN\1740 levodopa\NN\14604959 and\CC\1740 a\DT\13649268 <e2>hypotensive</e2>\JJ\1740 mechanism\NN\13446390 due\IN\5174653 to\TO\1740 reduced\VBN\441445 <e1>noradrenaline</e1>\JJ\1740 levels\NNS\4916342 in\IN\13603305 the\DT\1740 parkinsonian\JJ\1740 brain\NN\5462674 .\.\1740
17608141
D008694_D020258 NONE Attenuation\NN\7427337 of\IN\1740 <e1>methamphetamine-induced</e1>\JJ\1740 nigrostriatal\JJ\1740 dopaminergic\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 by\IN\1740 lipopolysaccharide\NN\1740 pretreatment\NN\1740 .\.\1740
D008694_D020258 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 examined\VBD\789138 the\DT\1740 roles\NNS\719494 of\IN\1740 lipopolysaccharide\NN\1740 ,\,\1740 a\DT\13649268 pro-inflammatory\JJ\1740 and\CC\1740 inflammatory\JJ\1740 factor\NN\7326557 ,\,\1740 treatment\NN\654885 in\IN\13603305 modulating\VBG\1724459 the\DT\1740 <e1>methamphetamine-induced</e1>\JJ\1740 nigrostriatal\JJ\1740 dopamine\NN\14807737 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D008694_D020258 NONE We\PRP\1740 concluded\VBD\628491 a\DT\13649268 critical\JJ\1740 time\NN\7308889 window\NN\3391770 for\IN\1740 systemic\JJ\1740 lipopolysaccharide\NN\1740 pretreatment\NN\1740 in\IN\13603305 exerting\VBG\1158872 effective\JJ\1740 protection\NN\407535 against\IN\1740 <e1>methamphetamine-induced</e1>\JJ\1740 nigrostriatal\JJ\1740 dopamine\NN\14807737 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D008070_D020258 NONE Attenuation\NN\7427337 of\IN\1740 methamphetamine-induced\JJ\1740 nigrostriatal\JJ\1740 dopaminergic\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 by\IN\1740 <e1>lipopolysaccharide</e1>\NN\1740 pretreatment\NN\1740 .\.\1740
D008070_D020258 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 examined\VBD\789138 the\DT\1740 roles\NNS\719494 of\IN\1740 <e1>lipopolysaccharide</e1>\NN\1740 ,\,\1740 a\DT\13649268 pro-inflammatory\JJ\1740 and\CC\1740 inflammatory\JJ\1740 factor\NN\7326557 ,\,\1740 treatment\NN\654885 in\IN\13603305 modulating\VBG\1724459 the\DT\1740 methamphetamine-induced\JJ\1740 nigrostriatal\JJ\1740 dopamine\NN\14807737 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D008070_D020258 NONE We\PRP\1740 concluded\VBD\628491 a\DT\13649268 critical\JJ\1740 time\NN\7308889 window\NN\3391770 for\IN\1740 systemic\JJ\1740 <e1>lipopolysaccharide</e1>\NN\1740 pretreatment\NN\1740 in\IN\13603305 exerting\VBG\1158872 effective\JJ\1740 protection\NN\407535 against\IN\1740 methamphetamine-induced\JJ\1740 nigrostriatal\JJ\1740 dopamine\NN\14807737 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D008694_D009422 NONE Immunological\JJ\1740 activation\NN\13561719 has\VBZ\2108377 been\VBN\836236 proposed\VBN\1010118 to\TO\1740 play\VB\1072262 a\DT\13649268 role\NN\719494 in\IN\13603305 <e1>methamphetamine-induced</e1>\JJ\1740 <e2>dopaminergic\JJ\1740 terminal\JJ\1740 damage</e2>\NN\7296428 .\.\1740
D004298_D020258 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 examined\VBD\789138 the\DT\1740 roles\NNS\719494 of\IN\1740 lipopolysaccharide\NN\1740 ,\,\1740 a\DT\13649268 pro-inflammatory\JJ\1740 and\CC\1740 inflammatory\JJ\1740 factor\NN\7326557 ,\,\1740 treatment\NN\654885 in\IN\13603305 modulating\VBG\1724459 the\DT\1740 methamphetamine-induced\JJ\1740 nigrostriatal\JJ\1740 <e1>dopamine</e1>\NN\14807737 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D004298_D020258 NONE We\PRP\1740 concluded\VBD\628491 a\DT\13649268 critical\JJ\1740 time\NN\7308889 window\NN\3391770 for\IN\1740 systemic\JJ\1740 lipopolysaccharide\NN\1740 pretreatment\NN\1740 in\IN\13603305 exerting\VBG\1158872 effective\JJ\1740 protection\NN\407535 against\IN\1740 methamphetamine-induced\JJ\1740 nigrostriatal\JJ\1740 <e1>dopamine</e1>\NN\14807737 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D008070_D005334 NONE <e1>Lipopolysaccharide</e1>\NN\1740 pretreatment\NN\1740 did\VBD\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 basal\JJ\1740 body\NN\19128 temperature\NN\13575869 or\CC\3541091 methamphetamine-elicited\JJ\1740 <e2>hyperthermia</e2>\NN\14034177 three\CD\13741022 days\NNS\15140892 later\RB\1740 .\.\1740
D008694_D005334 CID Lipopolysaccharide\NN\1740 pretreatment\NN\1740 did\VBD\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 basal\JJ\1740 body\NN\19128 temperature\NN\13575869 or\CC\3541091 <e1>methamphetamine-elicited</e1>\JJ\1740 <e2>hyperthermia</e2>\NN\14034177 three\CD\13741022 days\NNS\15140892 later\RB\1740 .\.\1740
1130930
D002512_D007674 NONE <e2>Nephrotoxicity</e2>\NN\1740 of\IN\1740 combined\JJ\1740 <e1>cephalothin-gentamicin</e1>\JJ\1740 regimen\NN\5898568 .\.\1740
D005839_D007674 NONE <e2>Nephrotoxicity</e2>\NN\1740 of\IN\1740 combined\JJ\1740 <e1>cephalothin-gentamicin</e1>\JJ\1740 regimen\NN\5898568 .\.\1740
D002512_D007683 CID Two\CD\13741022 patients\NNS\9898892 developed\VBD\1753788 <e2>acute\JJ\1740 tubular\JJ\1740 necrosis</e2>\NN\11444117 ,\,\1740 characterized\VBN\609683 clinically\RB\1740 by\IN\1740 acute\JJ\1740 oliguric\JJ\1740 renal\JJ\1740 failure\NN\66216 ,\,\1740 while\IN\15122231 they\PRP\1740 were\VBD\836236 receiving\VBG\2210855 a\DT\13649268 combination\NN\7951464 of\IN\1740 <e1>cephalothin\JJ\1740 sodium</e1>\NN\14625458 and\CC\1740 gentamicin\NN\2716866 sulfate\NN\15010703 therapy\NN\657604 .\.\1740
D002512_D009846 NONE Two\CD\13741022 patients\NNS\9898892 developed\VBD\1753788 acute\JJ\1740 tubular\JJ\1740 necrosis\NN\11444117 ,\,\1740 characterized\VBN\609683 clinically\RB\1740 by\IN\1740 acute\JJ\1740 <e2>oliguric\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 ,\,\1740 while\IN\15122231 they\PRP\1740 were\VBD\836236 receiving\VBG\2210855 a\DT\13649268 combination\NN\7951464 of\IN\1740 <e1>cephalothin\JJ\1740 sodium</e1>\NN\14625458 and\CC\1740 gentamicin\NN\2716866 sulfate\NN\15010703 therapy\NN\657604 .\.\1740
D002512_D051437 NONE Two\CD\13741022 patients\NNS\9898892 developed\VBD\1753788 acute\JJ\1740 tubular\JJ\1740 necrosis\NN\11444117 ,\,\1740 characterized\VBN\609683 clinically\RB\1740 by\IN\1740 acute\JJ\1740 <e2>oliguric\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 ,\,\1740 while\IN\15122231 they\PRP\1740 were\VBD\836236 receiving\VBG\2210855 a\DT\13649268 combination\NN\7951464 of\IN\1740 <e1>cephalothin\JJ\1740 sodium</e1>\NN\14625458 and\CC\1740 gentamicin\NN\2716866 sulfate\NN\15010703 therapy\NN\657604 .\.\1740
D005839_D007683 CID Two\CD\13741022 patients\NNS\9898892 developed\VBD\1753788 <e2>acute\JJ\1740 tubular\JJ\1740 necrosis</e2>\NN\11444117 ,\,\1740 characterized\VBN\609683 clinically\RB\1740 by\IN\1740 acute\JJ\1740 oliguric\JJ\1740 renal\JJ\1740 failure\NN\66216 ,\,\1740 while\IN\15122231 they\PRP\1740 were\VBD\836236 receiving\VBG\2210855 a\DT\13649268 combination\NN\7951464 of\IN\1740 cephalothin\JJ\1740 sodium\NN\14625458 and\CC\1740 <e1>gentamicin\NN\2716866 sulfate</e1>\NN\15010703 therapy\NN\657604 .\.\1740
D005839_D009846 NONE Two\CD\13741022 patients\NNS\9898892 developed\VBD\1753788 acute\JJ\1740 tubular\JJ\1740 necrosis\NN\11444117 ,\,\1740 characterized\VBN\609683 clinically\RB\1740 by\IN\1740 acute\JJ\1740 <e2>oliguric\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 ,\,\1740 while\IN\15122231 they\PRP\1740 were\VBD\836236 receiving\VBG\2210855 a\DT\13649268 combination\NN\7951464 of\IN\1740 cephalothin\JJ\1740 sodium\NN\14625458 and\CC\1740 <e1>gentamicin\NN\2716866 sulfate</e1>\NN\15010703 therapy\NN\657604 .\.\1740
D005839_D051437 NONE Two\CD\13741022 patients\NNS\9898892 developed\VBD\1753788 acute\JJ\1740 tubular\JJ\1740 necrosis\NN\11444117 ,\,\1740 characterized\VBN\609683 clinically\RB\1740 by\IN\1740 acute\JJ\1740 <e2>oliguric\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 ,\,\1740 while\IN\15122231 they\PRP\1740 were\VBD\836236 receiving\VBG\2210855 a\DT\13649268 combination\NN\7951464 of\IN\1740 cephalothin\JJ\1740 sodium\NN\14625458 and\CC\1740 <e1>gentamicin\NN\2716866 sulfate</e1>\NN\15010703 therapy\NN\657604 .\.\1740
8649546
D007980_D004409 CID Improvement\NN\7359599 of\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesia</e2>\NN\14084880 by\IN\1740 propranolol\NN\1740 in\IN\13603305 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 .\.\1740
D007980_D004409 CID This\DT\1740 study\NN\635850 suggests\VBZ\1010118 that\IN\1740 administration\NN\1133281 of\IN\1740 low\JJ\1740 doses\NNS\3740161 of\IN\1740 beta-blockers\NNS\1740 may\MD\15209706 improve\VB\126264 <e1>levodopa-induced</e1>\JJ\1740 ballistic\JJ\1740 and\CC\1740 choreic\JJ\1740 <e2>dyskinesia</e2>\NN\14084880 in\IN\13603305 PD\NN\14625458 .\.\1740
D007980_D010300 NONE Improvement\NN\7359599 of\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesia\NN\14084880 by\IN\1740 propranolol\NN\1740 in\IN\13603305 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D007980_D010300 NONE This\DT\1740 study\NN\635850 suggests\VBZ\1010118 that\IN\1740 administration\NN\1133281 of\IN\1740 low\JJ\1740 doses\NNS\3740161 of\IN\1740 beta-blockers\NNS\1740 may\MD\15209706 improve\VB\126264 <e1>levodopa-induced</e1>\JJ\1740 ballistic\JJ\1740 and\CC\1740 choreic\JJ\1740 dyskinesia\NN\14084880 in\IN\13603305 <e2>PD</e2>\NN\14625458 .\.\1740
D011433_D004409 NONE Improvement\NN\7359599 of\IN\1740 levodopa-induced\JJ\1740 <e2>dyskinesia</e2>\NN\14084880 by\IN\1740 <e1>propranolol</e1>\NN\1740 in\IN\13603305 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 .\.\1740
D011433_D004409 NONE Seven\CD\13741022 patients\NNS\9898892 suffering\VBG\2110220 from\IN\1740 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 with\IN\1740 severely\RB\1740 disabling\VBG\126264 <e2>dyskinesia</e2>\NN\14084880 received\VBD\2210855 low-dose\JJ\1740 <e1>propranolol</e1>\NN\1740 as\IN\14622893 an\DT\6697703 adjunct\NN\9312645 to\TO\1740 the\DT\1740 currently\RB\1740 used\VBN\1156834 medical\JJ\1740 treatment\NN\654885 .\.\1740
D011433_D010300 NONE Improvement\NN\7359599 of\IN\1740 levodopa-induced\JJ\1740 dyskinesia\NN\14084880 by\IN\1740 <e1>propranolol</e1>\NN\1740 in\IN\13603305 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
D011433_D010300 NONE Seven\CD\13741022 patients\NNS\9898892 suffering\VBG\2110220 from\IN\1740 <e2>Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 with\IN\1740 severely\RB\1740 disabling\VBG\126264 dyskinesia\NN\14084880 received\VBD\2210855 low-dose\JJ\1740 <e1>propranolol</e1>\NN\1740 as\IN\14622893 an\DT\6697703 adjunct\NN\9312645 to\TO\1740 the\DT\1740 currently\RB\1740 used\VBN\1156834 medical\JJ\1740 treatment\NN\654885 .\.\1740
D011433_D010300 NONE Seven\CD\13741022 patients\NNS\9898892 suffering\VBG\2110220 from\IN\1740 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 <e2>PD</e2>\NN\14625458 )\-RRB-\1740 with\IN\1740 severely\RB\1740 disabling\VBG\126264 dyskinesia\NN\14084880 received\VBD\2210855 low-dose\JJ\1740 <e1>propranolol</e1>\NN\1740 as\IN\14622893 an\DT\6697703 adjunct\NN\9312645 to\TO\1740 the\DT\1740 currently\RB\1740 used\VBN\1156834 medical\JJ\1740 treatment\NN\654885 .\.\1740
9406968
D014667_D003919 NONE Upregulation\NN\1740 of\IN\1740 the\DT\1740 expression\NN\4679549 of\IN\1740 <e1>vasopressin</e1>\NN\5407119 gene\NN\8459252 in\IN\13603305 the\DT\1740 paraventricular\JJ\1740 and\CC\1740 supraoptic\JJ\1740 nuclei\NNS\5445668 of\IN\1740 the\DT\1740 lithium-induced\JJ\1740 <e2>diabetes\NN\14075199 insipidus</e2>\NN\1740 rat\NN\2329401 .\.\1740
D008094_D003919 NONE Upregulation\NN\1740 of\IN\1740 the\DT\1740 expression\NN\4679549 of\IN\1740 vasopressin\NN\5407119 gene\NN\8459252 in\IN\13603305 the\DT\1740 paraventricular\JJ\1740 and\CC\1740 supraoptic\JJ\1740 nuclei\NNS\5445668 of\IN\1740 the\DT\1740 <e1>lithium-induced</e1>\JJ\1740 <e2>diabetes\NN\14075199 insipidus</e2>\NN\1740 rat\NN\2329401 .\.\1740
D008094_D003919 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 dehydration\NN\14536438 and/or\CC\1740 the\DT\1740 activation\NN\13561719 of\IN\1740 visceral\JJ\1740 afferent\JJ\1740 inputs\NNS\6791372 may\MD\15209706 contribute\VB\126264 to\TO\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 plasma\NN\5398023 AVP\NN\1740 and\CC\1740 the\DT\1740 upregulation\NN\1740 of\IN\1740 AVP\NN\1740 gene\NN\8459252 expression\NN\4679549 in\IN\13603305 the\DT\1740 PVN\NN\1740 and\CC\1740 the\DT\1740 SON\NN\10285938 of\IN\1740 the\DT\1740 <e1>Li-induced</e1>\JJ\1740 <e2>diabetes\NNS\14075199 insipidus</e2>\NN\1740 rat\NN\2329401 .\.\1740
D001127_D011141 NONE The\DT\1740 expression\NN\4679549 of\IN\1740 <e1>arginine\NN\14605787 vasopressin</e1>\NN\5407119 (\-LRB-\1740 AVP\NN\1740 )\-RRB-\1740 gene\NN\8459252 in\IN\13603305 the\DT\1740 paraventricular\NN\1740 (\-LRB-\1740 PVN\NN\1740 )\-RRB-\1740 and\CC\1740 supraoptic\JJ\1740 nuclei\NNS\5445668 (\-LRB-\1740 SON\NN\10285938 )\-RRB-\1740 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 rats\NNS\2329401 with\IN\1740 lithium\NN\14625458 (Li)-induced\JJ\1740 <e2>polyuria</e2>\NN\14113228 ,\,\1740 using\VBG\1156834 in\FW\13603305 situ\FW\1740 hybridization\NN\847340 histochemistry\NN\1740 and\CC\1740 radioimmunoassay\JJ\1740 .\.\1740
D001127_D011141 NONE The\DT\1740 expression\NN\4679549 of\IN\1740 arginine\NN\14605787 vasopressin\NN\5407119 (\-LRB-\1740 <e1>AVP</e1>\NN\1740 )\-RRB-\1740 gene\NN\8459252 in\IN\13603305 the\DT\1740 paraventricular\NN\1740 (\-LRB-\1740 PVN\NN\1740 )\-RRB-\1740 and\CC\1740 supraoptic\JJ\1740 nuclei\NNS\5445668 (\-LRB-\1740 SON\NN\10285938 )\-RRB-\1740 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 rats\NNS\2329401 with\IN\1740 lithium\NN\14625458 (Li)-induced\JJ\1740 <e2>polyuria</e2>\NN\14113228 ,\,\1740 using\VBG\1156834 in\FW\13603305 situ\FW\1740 hybridization\NN\847340 histochemistry\NN\1740 and\CC\1740 radioimmunoassay\JJ\1740 .\.\1740
D008094_D011141 NONE The\DT\1740 expression\NN\4679549 of\IN\1740 arginine\NN\14605787 vasopressin\NN\5407119 (\-LRB-\1740 AVP\NN\1740 )\-RRB-\1740 gene\NN\8459252 in\IN\13603305 the\DT\1740 paraventricular\NN\1740 (\-LRB-\1740 PVN\NN\1740 )\-RRB-\1740 and\CC\1740 supraoptic\JJ\1740 nuclei\NNS\5445668 (\-LRB-\1740 SON\NN\10285938 )\-RRB-\1740 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 rats\NNS\2329401 with\IN\1740 <e1>lithium</e1>\NN\14625458 (Li)-induced\JJ\1740 <e2>polyuria</e2>\NN\14113228 ,\,\1740 using\VBG\1156834 in\FW\13603305 situ\FW\1740 hybridization\NN\847340 histochemistry\NN\1740 and\CC\1740 radioimmunoassay\JJ\1740 .\.\1740
D008094_D011141 NONE The\DT\1740 expression\NN\4679549 of\IN\1740 arginine\NN\14605787 vasopressin\NN\5407119 (\-LRB-\1740 AVP\NN\1740 )\-RRB-\1740 gene\NN\8459252 in\IN\13603305 the\DT\1740 paraventricular\NN\1740 (\-LRB-\1740 PVN\NN\1740 )\-RRB-\1740 and\CC\1740 supraoptic\JJ\1740 nuclei\NNS\5445668 (\-LRB-\1740 SON\NN\10285938 )\-RRB-\1740 was\VBD\836236 investigated\VBN\644583 in\IN\13603305 rats\NNS\2329401 with\IN\1740 lithium\NN\14625458 <e1>(Li)-induced</e1>\JJ\1740 <e2>polyuria</e2>\NN\14113228 ,\,\1740 using\VBG\1156834 in\FW\13603305 situ\FW\1740 hybridization\NN\847340 histochemistry\NN\1740 and\CC\1740 radioimmunoassay\JJ\1740 .\.\1740
D018021_D011141 CID The\DT\1740 male\JJ\1740 Wistar\NNP\1740 rats\NNS\2329401 consuming\VBG\1168468 a\DT\13649268 diet\NN\7560652 that\WDT\1740 contained\VBD\2632940 <e1>LiCl</e1>\NN\1740 (\-LRB-\1740 60\CD\13745420 mmol/kg\NNS\1740 )\-RRB-\1740 for\IN\1740 4\CD\13741022 weeks\NNS\15113229 developed\VBD\1753788 marked\JJ\1740 <e2>polyuria</e2>\NN\14113228 .\.\1740
D001127_D003681 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 <e2>dehydration</e2>\NN\14536438 and/or\CC\1740 the\DT\1740 activation\NN\13561719 of\IN\1740 visceral\JJ\1740 afferent\JJ\1740 inputs\NNS\6791372 may\MD\15209706 contribute\VB\126264 to\TO\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 plasma\NN\5398023 <e1>AVP</e1>\NN\1740 and\CC\1740 the\DT\1740 upregulation\NN\1740 of\IN\1740 AVP\NN\1740 gene\NN\8459252 expression\NN\4679549 in\IN\13603305 the\DT\1740 PVN\NN\1740 and\CC\1740 the\DT\1740 SON\NN\10285938 of\IN\1740 the\DT\1740 Li-induced\JJ\1740 diabetes\NNS\14075199 insipidus\NN\1740 rat\NN\2329401 .\.\1740
D001127_D003681 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 <e2>dehydration</e2>\NN\14536438 and/or\CC\1740 the\DT\1740 activation\NN\13561719 of\IN\1740 visceral\JJ\1740 afferent\JJ\1740 inputs\NNS\6791372 may\MD\15209706 contribute\VB\126264 to\TO\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 plasma\NN\5398023 AVP\NN\1740 and\CC\1740 the\DT\1740 upregulation\NN\1740 of\IN\1740 <e1>AVP</e1>\NN\1740 gene\NN\8459252 expression\NN\4679549 in\IN\13603305 the\DT\1740 PVN\NN\1740 and\CC\1740 the\DT\1740 SON\NN\10285938 of\IN\1740 the\DT\1740 Li-induced\JJ\1740 diabetes\NNS\14075199 insipidus\NN\1740 rat\NN\2329401 .\.\1740
D001127_D003919 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 dehydration\NN\14536438 and/or\CC\1740 the\DT\1740 activation\NN\13561719 of\IN\1740 visceral\JJ\1740 afferent\JJ\1740 inputs\NNS\6791372 may\MD\15209706 contribute\VB\126264 to\TO\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 plasma\NN\5398023 <e1>AVP</e1>\NN\1740 and\CC\1740 the\DT\1740 upregulation\NN\1740 of\IN\1740 AVP\NN\1740 gene\NN\8459252 expression\NN\4679549 in\IN\13603305 the\DT\1740 PVN\NN\1740 and\CC\1740 the\DT\1740 SON\NN\10285938 of\IN\1740 the\DT\1740 Li-induced\JJ\1740 <e2>diabetes\NNS\14075199 insipidus</e2>\NN\1740 rat\NN\2329401 .\.\1740
D001127_D003919 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 dehydration\NN\14536438 and/or\CC\1740 the\DT\1740 activation\NN\13561719 of\IN\1740 visceral\JJ\1740 afferent\JJ\1740 inputs\NNS\6791372 may\MD\15209706 contribute\VB\126264 to\TO\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 plasma\NN\5398023 AVP\NN\1740 and\CC\1740 the\DT\1740 upregulation\NN\1740 of\IN\1740 <e1>AVP</e1>\NN\1740 gene\NN\8459252 expression\NN\4679549 in\IN\13603305 the\DT\1740 PVN\NN\1740 and\CC\1740 the\DT\1740 SON\NN\10285938 of\IN\1740 the\DT\1740 Li-induced\JJ\1740 <e2>diabetes\NNS\14075199 insipidus</e2>\NN\1740 rat\NN\2329401 .\.\1740
D008094_D003681 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 <e2>dehydration</e2>\NN\14536438 and/or\CC\1740 the\DT\1740 activation\NN\13561719 of\IN\1740 visceral\JJ\1740 afferent\JJ\1740 inputs\NNS\6791372 may\MD\15209706 contribute\VB\126264 to\TO\1740 the\DT\1740 elevation\NN\7445480 of\IN\1740 plasma\NN\5398023 AVP\NN\1740 and\CC\1740 the\DT\1740 upregulation\NN\1740 of\IN\1740 AVP\NN\1740 gene\NN\8459252 expression\NN\4679549 in\IN\13603305 the\DT\1740 PVN\NN\1740 and\CC\1740 the\DT\1740 SON\NN\10285938 of\IN\1740 the\DT\1740 <e1>Li-induced</e1>\JJ\1740 diabetes\NNS\14075199 insipidus\NN\1740 rat\NN\2329401 .\.\1740
3187073
D005472_D002637 CID It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 patients\NNS\9898892 on\IN\1740 <e1>5-FU</e1>\NN\1740 treatment\NN\654885 should\MD\1740 be\VB\836236 under\IN\1740 close\JJ\1740 supervision\NN\1133281 and\CC\1740 that\IN\1740 the\DT\1740 treatment\NN\654885 should\MD\1740 be\VB\836236 discontinued\VBN\2609764 if\IN\1740 <e2>chest\JJ\1740 pain</e2>\NN\14299637 or\CC\3541091 tachyarrhythmia\NN\1740 is\VBZ\836236 observed\VBN\2163746 .\.\1740
D005472_D013610 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 patients\NNS\9898892 on\IN\1740 <e1>5-FU</e1>\NN\1740 treatment\NN\654885 should\MD\1740 be\VB\836236 under\IN\1740 close\JJ\1740 supervision\NN\1133281 and\CC\1740 that\IN\1740 the\DT\1740 treatment\NN\654885 should\MD\1740 be\VB\836236 discontinued\VBN\2609764 if\IN\1740 chest\JJ\1740 pain\NN\14299637 or\CC\3541091 <e2>tachyarrhythmia</e2>\NN\1740 is\VBZ\836236 observed\VBN\2163746 .\.\1740
17400887
D013726_D020078 NONE <e2>Neuroinflammation</e2>\NN\1740 and\CC\1740 behavioral\JJ\1740 abnormalities\NNS\14034177 after\IN\1740 neonatal\JJ\1740 <e1>terbutaline</e1>\NN\1740 treatment\NN\654885 in\IN\13603305 rats\NNS\2329401 :\:\1740 implications\NNS\5774614 for\IN\1740 autism\NN\14304060 .\.\1740
D013726_D001523 NONE Neuroinflammation\NN\1740 and\CC\1740 <e2>behavioral\JJ\1740 abnormalities</e2>\NNS\14034177 after\IN\1740 neonatal\JJ\1740 <e1>terbutaline</e1>\NN\1740 treatment\NN\654885 in\IN\13603305 rats\NNS\2329401 :\:\1740 implications\NNS\5774614 for\IN\1740 autism\NN\14304060 .\.\1740
D013726_D001321 CID Neuroinflammation\NN\1740 and\CC\1740 behavioral\JJ\1740 abnormalities\NNS\14034177 after\IN\1740 neonatal\JJ\1740 <e1>terbutaline</e1>\NN\1740 treatment\NN\654885 in\IN\13603305 rats\NNS\2329401 :\:\1740 implications\NNS\5774614 for\IN\1740 <e2>autism</e2>\NN\14304060 .\.\1740
D013726_D001321 CID <e1>Terbutaline</e1>\NNP\1740 ,\,\1740 a\DT\13649268 beta2-adrenoceptor\NN\1740 agonist\NN\9613191 used\VBN\1156834 to\TO\1740 arrest\VB\1212572 preterm\NN\1740 labor\NN\7974025 ,\,\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 increased\VBN\169651 concordance\NN\13968547 for\IN\1740 <e2>autism</e2>\NN\14304060 in\IN\13603305 dizygotic\JJ\1740 twins\NNS\14883206 .\.\1740
D013726_D007752 NONE <e1>Terbutaline</e1>\NNP\1740 ,\,\1740 a\DT\13649268 beta2-adrenoceptor\NN\1740 agonist\NN\9613191 used\VBN\1156834 to\TO\1740 arrest\VB\1212572 <e2>preterm\NN\1740 labor</e2>\NN\7974025 ,\,\1740 has\VBZ\2108377 been\VBN\836236 associated\VBN\628491 with\IN\1740 increased\VBN\169651 concordance\NN\13968547 for\IN\1740 autism\NN\14304060 in\IN\13603305 dizygotic\JJ\1740 twins\NNS\14883206 .\.\1740
9522152
D002045_D009461 NONE A\DT\13649268 transient\JJ\1740 <e2>neurological\JJ\1740 deficit</e2>\NN\5113133 following\VBG\1835496 intrathecal\JJ\1740 injection\NN\320852 of\IN\1740 1\CD\13741022 %\NN\1740 hyperbaric\JJ\1740 <e1>bupivacaine</e1>\NN\1740 for\IN\1740 unilateral\JJ\1740 spinal\JJ\1740 anaesthesia\NN\14034177 .\.\1740
D002045_D009461 NONE We\PRP\1740 describe\VBP\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 transient\JJ\1740 <e2>neurological\JJ\1740 deficit</e2>\NN\5113133 that\WDT\1740 occurred\VBD\2623529 after\IN\1740 unilateral\JJ\1740 spinal\JJ\1740 anaesthesia\NN\14034177 with\IN\1740 8\CD\13741022 mg\NN\13717155 of\IN\1740 1\CD\13741022 %\NN\1740 hyperbaric\NN\1740 <e1>bupivacaine</e1>\NN\1740 slowly\RB\1740 injected\VBN\81072 through\IN\1740 a\DT\13649268 25-gauge\JJ\1740 pencil-point\JJ\1740 spinal\JJ\1740 needle\NN\13156083 .\.\1740
17562951
D007479_D051436 NONE METHODS\NNS\5616786 AND\CC\1740 RESULTS\NNS\34213 :\:\1740 The\DT\1740 present\JJ\1740 study\NN\635850 is\VBZ\836236 a\DT\13649268 multicenter\NN\1740 ,\,\1740 randomized\VBN\278117 ,\,\1740 double-blind\JJ\1740 comparison\NN\635850 of\IN\1740 <e1>iopamidol</e1>\NN\1740 and\CC\1740 iodixanol\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>chronic\JJ\1740 kidney\NN\5333259 disease</e2>\NN\14061805 (\-LRB-\1740 estimated\VBN\637259 glomerular\JJ\1740 filtration\NN\13518963 rate\NN\13815152 ,\,\1740 20\CD\13745420 to\TO\1740 59\CD\1740 mL/min\NN\1740 )\-RRB-\1740 who\WP\8299493 underwent\VBD\109660 cardiac\JJ\1740 angiography\NN\904623 or\CC\3541091 percutaneous\JJ\1740 coronary\JJ\1740 interventions\NNS\1239064 .\.\1740
C044834_D051436 NONE METHODS\NNS\5616786 AND\CC\1740 RESULTS\NNS\34213 :\:\1740 The\DT\1740 present\JJ\1740 study\NN\635850 is\VBZ\836236 a\DT\13649268 multicenter\NN\1740 ,\,\1740 randomized\VBN\278117 ,\,\1740 double-blind\JJ\1740 comparison\NN\635850 of\IN\1740 iopamidol\NN\1740 and\CC\1740 <e1>iodixanol</e1>\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>chronic\JJ\1740 kidney\NN\5333259 disease</e2>\NN\14061805 (\-LRB-\1740 estimated\VBN\637259 glomerular\JJ\1740 filtration\NN\13518963 rate\NN\13815152 ,\,\1740 20\CD\13745420 to\TO\1740 59\CD\1740 mL/min\NN\1740 )\-RRB-\1740 who\WP\8299493 underwent\VBD\109660 cardiac\JJ\1740 angiography\NN\904623 or\CC\3541091 percutaneous\JJ\1740 coronary\JJ\1740 interventions\NNS\1239064 .\.\1740
D000111_D003920 NONE In\IN\13603305 414\CD\1740 patients\NNS\9898892 ,\,\1740 contrast\VBP\650353 volume\NN\33615 ,\,\1740 presence\NN\13954253 of\IN\1740 <e2>diabetes\NN\14075199 mellitus</e2>\NN\1740 ,\,\1740 use\NN\407535 of\IN\1740 <e1>N-acetylcysteine</e1>\NN\1740 ,\,\1740 mean\VBP\928630 baseline\NN\7260623 SCr\NNS\1740 ,\,\1740 and\CC\1740 estimated\VBD\637259 glomerular\JJ\1740 filtration\NN\13518963 rate\NN\13815152 were\VBD\836236 comparable\JJ\1740 in\IN\13603305 the\DT\1740 2\CD\13741022 groups\NNS\2137 .\.\1740
D007479_D003920 NONE In\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>diabetes</e2>\NNS\14075199 ,\,\1740 SCr\NNS\1740 increases\VBZ\169651 >\NN\1740 or\CC\3541091 =\JJ\1740 0.5\CD\1740 mg/dL\NN\1740 were\VBD\836236 5.1\CD\1740 %\NN\1740 (\-LRB-\1740 4\CD\13741022 of\IN\1740 78\CD\13745420 patients\NNS\9898892 )\-RRB-\1740 with\IN\1740 <e1>iopamidol</e1>\NN\1740 and\CC\1740 13.0\CD\1740 %\NN\1740 (\-LRB-\1740 12\CD\13745420 of\IN\1740 92\CD\1740 patients\NNS\9898892 )\-RRB-\1740 with\IN\1740 iodixanol\NN\1740 (\-LRB-\1740 P=0.11\NNS\1740 )\-RRB-\1740 ,\,\1740 whereas\IN\1740 SCr\NN\1740 increases\VBZ\169651 >\NN\1740 or\CC\3541091 =\JJ\1740 25\CD\13745420 %\NN\1740 were\VBD\836236 10.3\CD\1740 %\NN\1740 and\CC\1740 15.2\CD\1740 %\NN\1740 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 P=0.37\NN\1740 )\-RRB-\1740 .\.\1740
D007479_D003920 NONE Mean\NN\6021761 post-SCr\NN\1740 increases\NNS\13576355 were\VBD\836236 significantly\RB\1740 less\JJR\1740 with\IN\1740 <e1>iopamidol</e1>\NN\1740 (\-LRB-\1740 all\DT\1740 patients\NNS\9898892 :\:\1740 0.07\CD\1740 versus\CC\1740 0.12\CD\1740 mg/dL\NN\1740 ,\,\1740 6.2\CD\1740 versus\CC\1740 10.6\CD\1740 micromol/L\NN\1740 ,\,\1740 P=0.03\JJ\1740 ;\:\1740 patients\NNS\9898892 with\IN\1740 <e2>diabetes</e2>\NNS\14075199 :\:\1740 0.07\CD\1740 versus\CC\1740 0.16\CD\1740 mg/dL\NN\1740 ,\,\1740 6.2\CD\1740 versus\CC\1740 14.1\CD\1740 micromol/L\NN\1740 ,\,\1740 P=0.01\NN\1740 )\-RRB-\1740 .\.\1740
D007479_D003920 NONE CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 rate\NN\13815152 of\IN\1740 contrast-induced\JJ\1740 nephropathy\NN\14573196 ,\,\1740 defined\VBN\2604760 by\IN\1740 multiple\JJ\1740 end\NN\8568978 points\NNS\5868954 ,\,\1740 is\VBZ\836236 not\RB\1740 statistically\RB\1740 different\JJ\1740 after\IN\1740 the\DT\1740 intraarterial\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>iopamidol</e1>\NN\1740 or\CC\3541091 iodixanol\NN\1740 to\TO\1740 high-risk\JJ\1740 patients\NNS\9898892 ,\,\1740 with\IN\1740 or\CC\3541091 without\IN\1740 <e2>diabetes\NN\14075199 mellitus</e2>\NN\1740 .\.\1740
C044834_D003920 NONE In\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>diabetes</e2>\NNS\14075199 ,\,\1740 SCr\NNS\1740 increases\VBZ\169651 >\NN\1740 or\CC\3541091 =\JJ\1740 0.5\CD\1740 mg/dL\NN\1740 were\VBD\836236 5.1\CD\1740 %\NN\1740 (\-LRB-\1740 4\CD\13741022 of\IN\1740 78\CD\13745420 patients\NNS\9898892 )\-RRB-\1740 with\IN\1740 iopamidol\NN\1740 and\CC\1740 13.0\CD\1740 %\NN\1740 (\-LRB-\1740 12\CD\13745420 of\IN\1740 92\CD\1740 patients\NNS\9898892 )\-RRB-\1740 with\IN\1740 <e1>iodixanol</e1>\NN\1740 (\-LRB-\1740 P=0.11\NNS\1740 )\-RRB-\1740 ,\,\1740 whereas\IN\1740 SCr\NN\1740 increases\VBZ\169651 >\NN\1740 or\CC\3541091 =\JJ\1740 25\CD\13745420 %\NN\1740 were\VBD\836236 10.3\CD\1740 %\NN\1740 and\CC\1740 15.2\CD\1740 %\NN\1740 ,\,\1740 respectively\RB\1740 (\-LRB-\1740 P=0.37\NN\1740 )\-RRB-\1740 .\.\1740
C044834_D003920 NONE CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 rate\NN\13815152 of\IN\1740 contrast-induced\JJ\1740 nephropathy\NN\14573196 ,\,\1740 defined\VBN\2604760 by\IN\1740 multiple\JJ\1740 end\NN\8568978 points\NNS\5868954 ,\,\1740 is\VBZ\836236 not\RB\1740 statistically\RB\1740 different\JJ\1740 after\IN\1740 the\DT\1740 intraarterial\JJ\1740 administration\NN\1133281 of\IN\1740 iopamidol\NN\1740 or\CC\3541091 <e1>iodixanol</e1>\NN\1740 to\TO\1740 high-risk\JJ\1740 patients\NNS\9898892 ,\,\1740 with\IN\1740 or\CC\3541091 without\IN\1740 <e2>diabetes\NN\14075199 mellitus</e2>\NN\1740 .\.\1740
D007479_D007674 CID CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 rate\NN\13815152 of\IN\1740 contrast-induced\JJ\1740 <e2>nephropathy</e2>\NN\14573196 ,\,\1740 defined\VBN\2604760 by\IN\1740 multiple\JJ\1740 end\NN\8568978 points\NNS\5868954 ,\,\1740 is\VBZ\836236 not\RB\1740 statistically\RB\1740 different\JJ\1740 after\IN\1740 the\DT\1740 intraarterial\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>iopamidol</e1>\NN\1740 or\CC\3541091 iodixanol\NN\1740 to\TO\1740 high-risk\JJ\1740 patients\NNS\9898892 ,\,\1740 with\IN\1740 or\CC\3541091 without\IN\1740 diabetes\NN\14075199 mellitus\NN\1740 .\.\1740
C044834_D007674 CID CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 rate\NN\13815152 of\IN\1740 contrast-induced\JJ\1740 <e2>nephropathy</e2>\NN\14573196 ,\,\1740 defined\VBN\2604760 by\IN\1740 multiple\JJ\1740 end\NN\8568978 points\NNS\5868954 ,\,\1740 is\VBZ\836236 not\RB\1740 statistically\RB\1740 different\JJ\1740 after\IN\1740 the\DT\1740 intraarterial\JJ\1740 administration\NN\1133281 of\IN\1740 iopamidol\NN\1740 or\CC\3541091 <e1>iodixanol</e1>\NN\1740 to\TO\1740 high-risk\JJ\1740 patients\NNS\9898892 ,\,\1740 with\IN\1740 or\CC\3541091 without\IN\1740 diabetes\NN\14075199 mellitus\NN\1740 .\.\1740
12574103
D003907_D006973 CID Prenatal\JJ\1740 <e1>dexamethasone</e1>\NN\2721538 programs\NNS\5833840 <e2>hypertension</e2>\NN\14057371 and\CC\1740 renal\JJ\1740 injury\NN\14052046 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D003907_D006973 CID The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 if\IN\1740 prenatal\JJ\1740 <e1>dexamethasone</e1>\NN\2721538 programmed\VBD\794981 a\DT\13649268 progressive\JJ\1740 <e2>increase\NN\13576355 in\IN\13603305 blood\NN\5397468 pressure</e2>\NN\11419404 and\CC\1740 renal\JJ\1740 injury\NN\14052046 in\IN\13603305 rats\NNS\2329401 .\.\1740
D003907_D006973 CID Male\JJ\1740 rats\NNS\2329401 that\WDT\1740 received\VBD\2210855 prenatal\JJ\1740 <e1>dexamethasone</e1>\NN\2721538 on\IN\1740 days\NNS\15140892 15\CD\13745420 and\CC\1740 16\CD\13745420 ,\,\1740 17\CD\13745420 and\CC\1740 18\CD\13745420 ,\,\1740 and\CC\1740 13\CD\13745420 and\CC\1740 14\CD\13745420 of\IN\1740 gestation\NN\15116532 had\VBD\2108377 <e2>elevated\JJ\1740 blood\NN\5397468 pressures</e2>\NNS\11419404 at\IN\14622893 6\CD\13741022 months\NNS\15113229 of\IN\1740 age\NN\4916342 ;\:\1740 the\DT\1740 latter\JJ\1740 group\NN\2137 did\VBD\1640855 not\RB\1740 have\VB\2108377 a\DT\13649268 reduction\NN\351485 in\IN\13603305 glomerular\JJ\1740 number\NN\5107765 .\.\1740
D003907_D006973 CID This\DT\1740 study\NN\635850 shows\VBZ\2137132 that\IN\1740 prenatal\JJ\1740 <e1>dexamethasone</e1>\NN\2721538 in\IN\13603305 rats\NNS\2329401 results\VBZ\2633881 in\IN\13603305 a\DT\13649268 reduction\NN\351485 in\IN\13603305 glomerular\JJ\1740 number\NN\5107765 ,\,\1740 glomerulosclerosis\NN\1740 ,\,\1740 and\CC\1740 <e2>hypertension</e2>\NN\14057371 when\WRB\1740 administered\VBN\2436349 at\IN\14622893 specific\JJ\1740 points\NNS\5868954 during\IN\1740 gestation\NN\15116532 .\.\1740
D003907_D007674 CID Prenatal\JJ\1740 <e1>dexamethasone</e1>\NN\2721538 programs\NNS\5833840 hypertension\NN\14057371 and\CC\1740 <e2>renal\JJ\1740 injury</e2>\NN\14052046 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D003907_D007674 CID The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 if\IN\1740 prenatal\JJ\1740 <e1>dexamethasone</e1>\NN\2721538 programmed\VBD\794981 a\DT\13649268 progressive\JJ\1740 increase\NN\13576355 in\IN\13603305 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 <e2>renal\JJ\1740 injury</e2>\NN\14052046 in\IN\13603305 rats\NNS\2329401 .\.\1740
D003907_D007674 CID Offspring\NN\10235549 of\IN\1740 rats\NNS\2329401 administered\VBN\2436349 <e1>dexamethasone</e1>\NN\2721538 on\IN\1740 days\NNS\15140892 15\CD\13745420 and\CC\1740 16\CD\13745420 gestation\NN\15116532 had\VBD\2108377 a\DT\13649268 20\CD\13745420 %\NN\1740 <e2>reduction\NN\351485 in\IN\13603305 glomerular\JJ\1740 number</e2>\NN\5107765 compared\VBN\644583 with\IN\1740 control\NN\5190804 at\IN\14622893 6\CD\13741022 to\TO\1740 9\CD\13741022 months\NNS\15113229 of\IN\1740 age\NN\4916342 (\-LRB-\1740 22\CD\13745420 527+/-509\CD\1740 versus\CC\1740 28\CD\13745420 050+/-561\CD\1740 ,\,\1740 P<0.05\CD\1740 )\-RRB-\1740 ,\,\1740 which\WDT\1740 was\VBD\836236 comparable\JJ\1740 to\TO\1740 the\DT\1740 percent\NN\13815742 reduction\NN\351485 in\IN\13603305 glomeruli\NNS\5425910 measured\VBN\697589 at\IN\14622893 3\CD\13741022 weeks\NNS\15113229 of\IN\1740 age\NN\4916342 .\.\1740
D003907_D007674 CID Male\JJ\1740 rats\NNS\2329401 that\WDT\1740 received\VBD\2210855 prenatal\JJ\1740 <e1>dexamethasone</e1>\NN\2721538 on\IN\1740 days\NNS\15140892 15\CD\13745420 and\CC\1740 16\CD\13745420 ,\,\1740 17\CD\13745420 and\CC\1740 18\CD\13745420 ,\,\1740 and\CC\1740 13\CD\13745420 and\CC\1740 14\CD\13745420 of\IN\1740 gestation\NN\15116532 had\VBD\2108377 elevated\JJ\1740 blood\NN\5397468 pressures\NNS\11419404 at\IN\14622893 6\CD\13741022 months\NNS\15113229 of\IN\1740 age\NN\4916342 ;\:\1740 the\DT\1740 latter\JJ\1740 group\NN\2137 did\VBD\1640855 not\RB\1740 have\VB\2108377 a\DT\13649268 <e2>reduction\NN\351485 in\IN\13603305 glomerular\JJ\1740 number</e2>\NN\5107765 .\.\1740
D003907_D007674 CID This\DT\1740 study\NN\635850 shows\VBZ\2137132 that\IN\1740 prenatal\JJ\1740 <e1>dexamethasone</e1>\NN\2721538 in\IN\13603305 rats\NNS\2329401 results\VBZ\2633881 in\IN\13603305 a\DT\13649268 <e2>reduction\NN\351485 in\IN\13603305 glomerular\JJ\1740 number</e2>\NN\5107765 ,\,\1740 glomerulosclerosis\NN\1740 ,\,\1740 and\CC\1740 hypertension\NN\14057371 when\WRB\1740 administered\VBN\2436349 at\IN\14622893 specific\JJ\1740 points\NNS\5868954 during\IN\1740 gestation\NN\15116532 .\.\1740
D003907_D005921 NONE Adult\JJ\1740 rats\NNS\2329401 given\VBD\2327200 <e1>dexamethasone</e1>\NN\2721538 on\IN\1740 days\NNS\15140892 15\CD\13745420 and\CC\1740 16\CD\13745420 of\IN\1740 gestation\NN\15116532 had\VBD\2108377 more\JJR\1740 glomeruli\NNS\5425910 with\IN\1740 <e2>glomerulosclerosis</e2>\NN\1740 than\IN\1740 control\NN\5190804 rats\NNS\2329401 .\.\1740
D003907_D005921 NONE This\DT\1740 study\NN\635850 shows\VBZ\2137132 that\IN\1740 prenatal\JJ\1740 <e1>dexamethasone</e1>\NN\2721538 in\IN\13603305 rats\NNS\2329401 results\VBZ\2633881 in\IN\13603305 a\DT\13649268 reduction\NN\351485 in\IN\13603305 glomerular\JJ\1740 number\NN\5107765 ,\,\1740 <e2>glomerulosclerosis</e2>\NN\1740 ,\,\1740 and\CC\1740 hypertension\NN\14057371 when\WRB\1740 administered\VBN\2436349 at\IN\14622893 specific\JJ\1740 points\NNS\5868954 during\IN\1740 gestation\NN\15116532 .\.\1740
18023325
D004221_D014826 CID Acute\JJ\1740 <e2>vocal\JJ\1740 fold\JJ\1740 palsy</e2>\NN\14557898 after\IN\1740 acute\JJ\1740 <e1>disulfiram</e1>\NN\3740161 intoxication\NN\14034177 .\.\1740
D004221_D014826 CID Acute\JJ\1740 peripheral\JJ\1740 neuropathy\NN\14204950 caused\VBN\1617192 by\IN\1740 a\DT\13649268 <e1>disulfiram</e1>\NN\3740161 overdose\NN\1740 is\VBZ\836236 very\RB\1740 rare\JJ\1740 and\CC\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 report\NN\6470073 of\IN\1740 it\PRP\6125041 leading\VBG\1752884 to\TO\1740 <e2>vocal\JJ\1740 fold\JJ\1740 palsy</e2>\NN\14557898 .\.\1740
D004221_D010523 CID Acute\JJ\1740 <e2>peripheral\JJ\1740 neuropathy</e2>\NN\14204950 caused\VBN\1617192 by\IN\1740 a\DT\13649268 <e1>disulfiram</e1>\NN\3740161 overdose\NN\1740 is\VBZ\836236 very\RB\1740 rare\JJ\1740 and\CC\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 report\NN\6470073 of\IN\1740 it\PRP\6125041 leading\VBG\1752884 to\TO\1740 vocal\JJ\1740 fold\JJ\1740 palsy\NN\14557898 .\.\1740
D004221_D062787 NONE Acute\JJ\1740 peripheral\JJ\1740 neuropathy\NN\14204950 caused\VBN\1617192 by\IN\1740 a\DT\13649268 <e1>disulfiram</e1>\NN\3740161 <e2>overdose</e2>\NN\1740 is\VBZ\836236 very\RB\1740 rare\JJ\1740 and\CC\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 report\NN\6470073 of\IN\1740 it\PRP\6125041 leading\VBG\1752884 to\TO\1740 vocal\JJ\1740 fold\JJ\1740 palsy\NN\14557898 .\.\1740
D004221_D010243 NONE This\DT\1740 was\VBD\836236 a\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 <e2>palsy</e2>\NN\14557898 of\IN\1740 the\DT\1740 recurrent\JJ\1740 laryngeal\JJ\1740 nerve\NN\5475681 and\CC\1740 superimposed\VBD\1494310 severe\JJ\1740 acute\JJ\1740 sensorimotor\NN\1740 axonal\JJ\1740 polyneuropathy\NN\1740 caused\VBN\1617192 by\IN\1740 high-dose\JJ\1740 <e1>disulfiram</e1>\NN\3740161 intoxication\NN\14034177 .\.\1740
D004221_D011115 NONE This\DT\1740 was\VBD\836236 a\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 palsy\NN\14557898 of\IN\1740 the\DT\1740 recurrent\JJ\1740 laryngeal\JJ\1740 nerve\NN\5475681 and\CC\1740 superimposed\VBD\1494310 severe\JJ\1740 acute\JJ\1740 sensorimotor\NN\1740 axonal\JJ\1740 <e2>polyneuropathy</e2>\NN\1740 caused\VBN\1617192 by\IN\1740 high-dose\JJ\1740 <e1>disulfiram</e1>\NN\3740161 intoxication\NN\14034177 .\.\1740
12369736
D003042_D009069 CID Effects\NNS\13245626 of\IN\1740 5-HT1B\NN\1740 receptor\NN\5225602 ligands\NNS\20090 microinjected\VBN\1740 into\IN\1740 the\DT\1740 accumbal\JJ\1740 shell\NN\2703275 or\CC\3541091 core\NN\7996689 on\IN\1740 the\DT\1740 <e1>cocaine-induced</e1>\JJ\1740 <e2>locomotor\NN\1740 hyperactivity</e2>\NN\14052403 in\IN\13603305 rats\NNS\2329401 .\.\1740
D003042_D009069 CID The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 examine\VB\789138 the\DT\1740 effect\NN\34213 of\IN\1740 5-HT1B\NN\1740 receptor\NN\5225602 ligands\NNS\20090 microinjected\VBN\1740 into\IN\1740 the\DT\1740 subregions\NNS\1740 of\IN\1740 the\DT\1740 nucleus\NN\5445668 accumbens\NNS\1740 (\-LRB-\1740 the\DT\1740 shell\NN\2703275 and\CC\1740 the\DT\1740 core\NN\7996689 )\-RRB-\1740 on\IN\1740 the\DT\1740 <e2>locomotor\NN\1740 hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 <e1>cocaine</e1>\NN\3492717 in\IN\13603305 rats\NNS\2329401 .\.\1740
D003042_D009069 CID GR\NN\1740 55562\CD\1740 (\-LRB-\1740 0.1\CD\1740 -\SYM\1740 10\CD\13745420 microg/side\NN\1740 )\-RRB-\1740 ,\,\1740 administered\VBN\2436349 intra-accumbens\NNS\1740 shell\NN\2703275 prior\JJ\1740 to\TO\1740 <e1>cocaine</e1>\NN\3492717 ,\,\1740 dose-dependently\RB\1740 attenuated\VBD\224901 the\DT\1740 psychostimulant-induced\JJ\1740 <e2>locomotor\NN\1740 hyperactivity</e2>\NN\14052403 .\.\1740
D003042_D009069 CID Our\PRP$\1740 findings\NNS\7951464 indicate\VBP\952524 that\IN\1740 <e1>cocaine</e1>\NN\3492717 induced\VBD\1627355 <e2>hyperlocomotion</e2>\NN\1740 is\VBZ\836236 modified\VBN\109660 by\IN\1740 5-HT1B\NN\1740 receptor\NN\5225602 ligands\NNS\20090 microinjected\VBN\1740 into\IN\1740 the\DT\1740 accumbens\NNS\1740 shell\NN\2703275 ,\,\1740 but\CC\1740 not\RB\1740 core\NN\7996689 ,\,\1740 this\DT\1740 modification\NN\191142 consisting\VBG\2603699 in\IN\13603305 inhibitory\JJ\1740 and\CC\1740 facilitatory\JJ\1740 effects\NNS\13245626 of\IN\1740 the\DT\1740 5-HT1B\NN\1740 receptor\NN\5225602 antagonist\NN\7846 (\-LRB-\1740 GR\NN\1740 55562\CD\1740 )\-RRB-\1740 and\CC\1740 agonist\NN\9613191 (\-LRB-\1740 CP\NN\1740 93129\CD\1740 )\-RRB-\1740 ,\,\1740 respectively\RB\1740 .\.\1740
C103477_D009069 NONE <e1>GR\NN\1740 55562</e1>\CD\1740 (\-LRB-\1740 0.1\CD\1740 -\SYM\1740 10\CD\13745420 microg/side\NN\1740 )\-RRB-\1740 ,\,\1740 administered\VBN\2436349 intra-accumbens\NNS\1740 shell\NN\2703275 prior\JJ\1740 to\TO\1740 cocaine\NN\3492717 ,\,\1740 dose-dependently\RB\1740 attenuated\VBD\224901 the\DT\1740 psychostimulant-induced\JJ\1740 <e2>locomotor\NN\1740 hyperactivity</e2>\NN\14052403 .\.\1740
C103477_D009069 NONE Our\PRP$\1740 findings\NNS\7951464 indicate\VBP\952524 that\IN\1740 cocaine\NN\3492717 induced\VBD\1627355 <e2>hyperlocomotion</e2>\NN\1740 is\VBZ\836236 modified\VBN\109660 by\IN\1740 5-HT1B\NN\1740 receptor\NN\5225602 ligands\NNS\20090 microinjected\VBN\1740 into\IN\1740 the\DT\1740 accumbens\NNS\1740 shell\NN\2703275 ,\,\1740 but\CC\1740 not\RB\1740 core\NN\7996689 ,\,\1740 this\DT\1740 modification\NN\191142 consisting\VBG\2603699 in\IN\13603305 inhibitory\JJ\1740 and\CC\1740 facilitatory\JJ\1740 effects\NNS\13245626 of\IN\1740 the\DT\1740 5-HT1B\NN\1740 receptor\NN\5225602 antagonist\NN\7846 (\-LRB-\1740 <e1>GR\NN\1740 55562</e1>\CD\1740 )\-RRB-\1740 and\CC\1740 agonist\NN\9613191 (\-LRB-\1740 CP\NN\1740 93129\CD\1740 )\-RRB-\1740 ,\,\1740 respectively\RB\1740 .\.\1740
C065046_D009069 CID Our\PRP$\1740 findings\NNS\7951464 indicate\VBP\952524 that\IN\1740 cocaine\NN\3492717 induced\VBD\1627355 <e2>hyperlocomotion</e2>\NN\1740 is\VBZ\836236 modified\VBN\109660 by\IN\1740 5-HT1B\NN\1740 receptor\NN\5225602 ligands\NNS\20090 microinjected\VBN\1740 into\IN\1740 the\DT\1740 accumbens\NNS\1740 shell\NN\2703275 ,\,\1740 but\CC\1740 not\RB\1740 core\NN\7996689 ,\,\1740 this\DT\1740 modification\NN\191142 consisting\VBG\2603699 in\IN\13603305 inhibitory\JJ\1740 and\CC\1740 facilitatory\JJ\1740 effects\NNS\13245626 of\IN\1740 the\DT\1740 5-HT1B\NN\1740 receptor\NN\5225602 antagonist\NN\7846 (\-LRB-\1740 GR\NN\1740 55562\CD\1740 )\-RRB-\1740 and\CC\1740 agonist\NN\9613191 (\-LRB-\1740 <e1>CP\NN\1740 93129</e1>\CD\1740 )\-RRB-\1740 ,\,\1740 respectively\RB\1740 .\.\1740
8953972
D004837_D013345 CID Fatal\JJ\1740 <e2>intracranial\JJ\1740 bleeding</e2>\NN\14285662 associated\VBN\628491 with\IN\1740 prehospital\JJ\1740 use\NN\407535 of\IN\1740 <e1>epinephrine</e1>\NN\14807929 .\.\1740
D004837_D012128 NONE The\DT\1740 sudden\JJ\1740 onset\NN\7325190 of\IN\1740 <e2>respiratory\JJ\1740 distress</e2>\NN\7494363 ,\,\1740 rash\NN\14321469 ,\,\1740 and\CC\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 a\DT\13649268 new\JJ\1740 medicine\NN\6045562 led\VBD\1752884 the\DT\1740 two\CD\13741022 paramedics\NNS\10398624 on\IN\1740 the\DT\1740 scene\NN\8497294 to\TO\1740 administer\VB\2436349 subcutaneous\JJ\1740 <e1>epinephrine</e1>\NN\14807929 .\.\1740
D004837_D005076 NONE The\DT\1740 sudden\JJ\1740 onset\NN\7325190 of\IN\1740 respiratory\JJ\1740 distress\NN\7494363 ,\,\1740 <e2>rash</e2>\NN\14321469 ,\,\1740 and\CC\1740 a\DT\13649268 history\NN\15120823 of\IN\1740 a\DT\13649268 new\JJ\1740 medicine\NN\6045562 led\VBD\1752884 the\DT\1740 two\CD\13741022 paramedics\NNS\10398624 on\IN\1740 the\DT\1740 scene\NN\8497294 to\TO\1740 administer\VB\2436349 subcutaneous\JJ\1740 <e1>epinephrine</e1>\NN\14807929 .\.\1740
D004837_D006323 CID <e1>Epinephrine</e1>\NN\14807929 has\VBZ\2108377 a\DT\13649268 proven\VBN\2604760 role\NN\719494 in\IN\13603305 <e2>cardiac\JJ\1740 arrest</e2>\NN\88481 in\IN\13603305 prehospital\JJ\1740 care\NN\575741 ;\:\1740 however\RB\1740 ,\,\1740 use\NN\407535 by\IN\1740 paramedics\NNS\10398624 in\IN\13603305 patients\NNS\9898892 with\IN\1740 suspected\VBN\916909 allergic\JJ\1740 reaction\NN\13446390 and\CC\1740 severe\JJ\1740 hypertension\NN\14057371 should\MD\1740 be\VB\836236 viewed\VBN\689344 with\IN\1740 caution\NN\4662951 .\.\1740
D004837_D004342 NONE <e1>Epinephrine</e1>\NN\14807929 has\VBZ\2108377 a\DT\13649268 proven\VBN\2604760 role\NN\719494 in\IN\13603305 cardiac\JJ\1740 arrest\NN\88481 in\IN\13603305 prehospital\JJ\1740 care\NN\575741 ;\:\1740 however\RB\1740 ,\,\1740 use\NN\407535 by\IN\1740 paramedics\NNS\10398624 in\IN\13603305 patients\NNS\9898892 with\IN\1740 suspected\VBN\916909 <e2>allergic\JJ\1740 reaction</e2>\NN\13446390 and\CC\1740 severe\JJ\1740 hypertension\NN\14057371 should\MD\1740 be\VB\836236 viewed\VBN\689344 with\IN\1740 caution\NN\4662951 .\.\1740
D004837_D006973 NONE <e1>Epinephrine</e1>\NN\14807929 has\VBZ\2108377 a\DT\13649268 proven\VBN\2604760 role\NN\719494 in\IN\13603305 cardiac\JJ\1740 arrest\NN\88481 in\IN\13603305 prehospital\JJ\1740 care\NN\575741 ;\:\1740 however\RB\1740 ,\,\1740 use\NN\407535 by\IN\1740 paramedics\NNS\10398624 in\IN\13603305 patients\NNS\9898892 with\IN\1740 suspected\VBN\916909 allergic\JJ\1740 reaction\NN\13446390 and\CC\1740 severe\JJ\1740 <e2>hypertension</e2>\NN\14057371 should\MD\1740 be\VB\836236 viewed\VBN\689344 with\IN\1740 caution\NN\4662951 .\.\1740
20588063
D011692_D009401 CID Permeability\NN\4940146 ,\,\1740 ultrastructural\JJ\1740 changes\NNS\7283608 ,\,\1740 and\CC\1740 distribution\NN\5726596 of\IN\1740 novel\JJ\1740 proteins\NNS\14944888 in\IN\13603305 the\DT\1740 glomerular\JJ\1740 barrier\NN\3839993 in\IN\13603305 early\JJ\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 <e2>nephrosis</e2>\NN\14304060 .\.\1740
D011692_D009401 CID Using\VBG\1156834 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 <e2>nephrosis</e2>\NN\14304060 (\-LRB-\1740 PAN\NN\3101986 )\-RRB-\1740 rats\NNS\2329401 ,\,\1740 we\PRP\1740 studied\VBD\630380 early\JJ\1740 ultrastructural\JJ\1740 and\CC\1740 permeability\NN\4940146 changes\NNS\7283608 in\IN\13603305 relation\NN\2137 to\TO\1740 the\DT\1740 expression\NN\4679549 of\IN\1740 the\DT\1740 podocyte-associated\JJ\1740 molecules\NNS\9465459 nephrin\NN\1740 ,\,\1740 a-actinin\NN\1740 ,\,\1740 dendrin\NN\1740 ,\,\1740 and\CC\1740 plekhh2\NN\1740 ,\,\1740 the\DT\1740 last\JJ\1740 two\CD\13741022 of\IN\1740 which\WDT\1740 were\VBD\836236 only\RB\1740 recently\RB\1740 discovered\VBN\2163746 in\IN\13603305 podocytes\NNS\1740 .\.\1740
9293063
D003613_D001650 CID <e2>Bile\NN\5405946 duct\NN\5248181 hamartoma</e2>\NN\14234074 occurring\VBG\2623529 in\IN\13603305 association\NN\8008335 with\IN\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>danazol</e1>\NN\1740 .\.\1740
D003613_D001650 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 <e2>bile\NN\5405946 duct\NN\5248181 hamartoma</e2>\NN\14234074 which\WDT\1740 developed\VBD\1753788 in\IN\13603305 a\DT\13649268 patient\NN\9898892 who\WP\8299493 had\VBD\2108377 been\VBN\836236 on\IN\1740 long-term\JJ\1740 <e1>danazol</e1>\NN\1740 treatment\NN\654885 .\.\1740
D003613_D006222 CID <e2>Bile\NN\5405946 duct\NN\5248181 hamartoma</e2>\NN\14234074 occurring\VBG\2623529 in\IN\13603305 association\NN\8008335 with\IN\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>danazol</e1>\NN\1740 .\.\1740
D003613_D006222 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 <e2>bile\NN\5405946 duct\NN\5248181 hamartoma</e2>\NN\14234074 which\WDT\1740 developed\VBD\1753788 in\IN\13603305 a\DT\13649268 patient\NN\9898892 who\WP\8299493 had\VBD\2108377 been\VBN\836236 on\IN\1740 long-term\JJ\1740 <e1>danazol</e1>\NN\1740 treatment\NN\654885 .\.\1740
6634932
C002616_D017180 NONE <e1>UM-272</e1>\NN\1740 (\-LRB-\1740 N\NN\14622893 ,\,\1740 N-dimethylpropranolol\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 quaternary\JJ\1740 antiarrhythmic\JJ\1740 agent\NN\7347 ,\,\1740 was\VBD\836236 administered\VBN\2436349 sublingually\RB\1740 to\IN\1740 dogs\NNS\2083346 with\IN\1740 ouabain-induced\JJ\1740 <e2>ventricular\JJ\1740 tachycardias</e2>\NNS\14110674 .\.\1740
C002616_D017180 NONE UM-272\NN\1740 (\-LRB-\1740 <e1>N\NN\14622893 ,\,\1740 N-dimethylpropranolol</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 quaternary\JJ\1740 antiarrhythmic\JJ\1740 agent\NN\7347 ,\,\1740 was\VBD\836236 administered\VBN\2436349 sublingually\RB\1740 to\IN\1740 dogs\NNS\2083346 with\IN\1740 ouabain-induced\JJ\1740 <e2>ventricular\JJ\1740 tachycardias</e2>\NNS\14110674 .\.\1740
C002616_D017180 NONE Sublingual\JJ\1740 <e1>UM-272</e1>\NN\1740 converted\VBD\126264 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 to\TO\1740 sinus\NN\5248181 rhythm\NN\15122011 in\IN\13603305 all\DT\1740 5\CD\13741022 dogs\NNS\2083346 .\.\1740
D010042_D017180 CID UM-272\NN\1740 (\-LRB-\1740 N\NN\14622893 ,\,\1740 N-dimethylpropranolol\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 quaternary\JJ\1740 antiarrhythmic\JJ\1740 agent\NN\7347 ,\,\1740 was\VBD\836236 administered\VBN\2436349 sublingually\RB\1740 to\IN\1740 dogs\NNS\2083346 with\IN\1740 <e1>ouabain-induced</e1>\JJ\1740 <e2>ventricular\JJ\1740 tachycardias</e2>\NNS\14110674 .\.\1740
15602202
D017963_D009395 CID Recurrent\JJ\1740 acute\JJ\1740 <e2>interstitial\JJ\1740 nephritis</e2>\NN\14113228 induced\VBN\1627355 by\IN\1740 <e1>azithromycin</e1>\NN\2716205 .\.\1740
D017963_D009395 CID A\DT\13649268 14-year-old\JJ\1740 girl\NN\10787470 is\VBZ\836236 reported\VBN\831651 with\IN\1740 recurrent\JJ\1740 ,\,\1740 <e1>azithromycin-induced</e1>\JJ\1740 ,\,\1740 acute\JJ\1740 <e2>interstitial\JJ\1740 nephritis</e2>\NN\14113228 .\.\1740
8638206
D001279_D010243 CID Persistent\JJ\1740 <e2>paralysis</e2>\NN\14557898 after\IN\1740 prolonged\JJ\1740 use\NN\407535 of\IN\1740 <e1>atracurium</e1>\NN\1740 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 corticosteroids\NNS\14745635 .\.\1740
D001279_D010243 CID <e1>Atracurium\NN\1740 besylate</e1>\VBP\1740 ,\,\1740 a\DT\13649268 short-acting\JJ\1740 benzylisoquinolinium\NN\1740 NMBA\NN\1740 that\WDT\1740 is\VBZ\836236 eliminated\VBN\1619929 independently\RB\1740 of\IN\1740 renal\JJ\1740 or\CC\3541091 hepatic\JJ\1740 function\NN\13783581 ,\,\1740 has\VBZ\2108377 also\RB\1740 been\VBN\836236 associated\VBN\628491 with\IN\1740 persistent\JJ\1740 <e2>paralysis</e2>\NN\14557898 ,\,\1740 but\CC\1740 only\RB\1740 when\WRB\1740 used\VBN\1156834 with\IN\1740 corticosteroids\NNS\14745635 .\.\1740
D001279_D010243 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 <e1>atracurium-related</e1>\JJ\1740 <e2>paralysis</e2>\NN\14557898 persisting\VBG\118523 for\IN\1740 approximately\RB\1740 50\CD\13745420 hours\NNS\15118228 in\IN\13603305 a\DT\13649268 patient\NN\9898892 who\WP\8299493 was\VBD\836236 not\RB\1740 treated\VBN\2376958 with\IN\1740 corticosteroids\NNS\14745635 .\.\1740
D014673_D010243 CID Reports\NNS\6470073 of\IN\1740 persistent\JJ\1740 <e2>paralysis</e2>\NN\14557898 after\IN\1740 the\DT\1740 discontinuance\NN\209943 of\IN\1740 these\DT\1740 drugs\NNS\14778436 have\VBP\2108377 most\RBS\1740 often\RB\1740 involved\VBN\2676054 aminosteroid-based\JJ\1740 NMBAs\NN\1740 such\JJ\1740 as\IN\14622893 <e1>vecuronium\NN\1740 bromide</e1>\NN\14904359 ,\,\1740 especially\RB\1740 when\WRB\1740 used\VBN\1156834 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 corticosteroids\NNS\14745635 .\.\1740
-1_D010243 NONE Atracurium\NN\1740 besylate\VBP\1740 ,\,\1740 a\DT\13649268 short-acting\JJ\1740 <e1>benzylisoquinolinium</e1>\NN\1740 NMBA\NN\1740 that\WDT\1740 is\VBZ\836236 eliminated\VBN\1619929 independently\RB\1740 of\IN\1740 renal\JJ\1740 or\CC\3541091 hepatic\JJ\1740 function\NN\13783581 ,\,\1740 has\VBZ\2108377 also\RB\1740 been\VBN\836236 associated\VBN\628491 with\IN\1740 persistent\JJ\1740 <e2>paralysis</e2>\NN\14557898 ,\,\1740 but\CC\1740 only\RB\1740 when\WRB\1740 used\VBN\1156834 with\IN\1740 corticosteroids\NNS\14745635 .\.\1740
15632880
D013148_D051437 CID <e1>Spironolactone-induced</e1>\JJ\1740 <e2>renal\JJ\1740 insufficiency</e2>\NN\14462946 and\CC\1740 hyperkalemia\NN\14299637 in\IN\13603305 patients\NNS\9898892 with\IN\1740 heart\NN\5919034 failure\NN\66216 .\.\1740
D013148_D051437 CID BACKGROUND\NN\4921011 :\:\1740 A\DT\13649268 previous\JJ\1740 randomized\NN\1740 controlled\JJ\1740 trial\NN\786195 evaluating\VBG\670261 the\DT\1740 use\NN\407535 of\IN\1740 <e1>spironolactone</e1>\NN\2721160 in\IN\13603305 heart\NN\5919034 failure\NN\66216 patients\NNS\9898892 reported\VBD\831651 a\DT\13649268 low\JJ\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 (\-LRB-\1740 2\CD\13741022 %\NN\1740 )\-RRB-\1740 and\CC\1740 <e2>renal\JJ\1740 insufficiency</e2>\NN\14462946 (\-LRB-\1740 0\CD\13741022 %\NN\1740 )\-RRB-\1740 .\.\1740
D013148_D051437 CID We\PRP\1740 therefore\RB\1740 sought\VBD\1825237 to\TO\1740 determine\VB\1645601 the\DT\1740 prevalence\NN\4764412 and\CC\1740 clinical\JJ\1740 associations\NNS\8008335 of\IN\1740 hyperkalemia\NN\14299637 and\CC\1740 <e2>renal\JJ\1740 insufficiency</e2>\NN\14462946 in\IN\13603305 heart\NN\5919034 failure\NN\66216 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>spironolactone</e1>\NN\2721160 .\.\1740
D013148_D051437 CID RESULTS\NNS\34213 :\:\1740 Sixty-seven\CD\1740 of\IN\1740 926\CD\1740 patients\NNS\9898892 (\-LRB-\1740 7.2\CD\1740 %\NN\1740 )\-RRB-\1740 required\VBD\754942 discontinuation\NN\209943 of\IN\1740 <e1>spironolactone</e1>\NN\2721160 due\JJ\1740 to\TO\1740 hyperkalemia\NN\14299637 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 33\CD\1740 )\-RRB-\1740 or\CC\3541091 <e2>renal\JJ\1740 failure</e2>\NN\66216 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 34\CD\1740 )\-RRB-\1740 .\.\1740
D013148_D051437 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Spironolactone-induced</e1>\JJ\1740 hyperkalemia\NN\14299637 and\CC\1740 <e2>renal\JJ\1740 insufficiency</e2>\NN\14462946 are\VBP\836236 more\RBR\1740 common\JJ\1740 in\IN\13603305 our\PRP$\1740 clinical\JJ\1740 experience\NN\5984287 than\IN\1740 reported\VBN\831651 previously\RB\1740 .\.\1740
D013148_D006947 CID <e1>Spironolactone-induced</e1>\JJ\1740 renal\JJ\1740 insufficiency\NN\14462946 and\CC\1740 <e2>hyperkalemia</e2>\NN\14299637 in\IN\13603305 patients\NNS\9898892 with\IN\1740 heart\NN\5919034 failure\NN\66216 .\.\1740
D013148_D006947 CID BACKGROUND\NN\4921011 :\:\1740 A\DT\13649268 previous\JJ\1740 randomized\NN\1740 controlled\JJ\1740 trial\NN\786195 evaluating\VBG\670261 the\DT\1740 use\NN\407535 of\IN\1740 <e1>spironolactone</e1>\NN\2721160 in\IN\13603305 heart\NN\5919034 failure\NN\66216 patients\NNS\9898892 reported\VBD\831651 a\DT\13649268 low\JJ\1740 risk\NN\14541044 of\IN\1740 <e2>hyperkalemia</e2>\NN\14299637 (\-LRB-\1740 2\CD\13741022 %\NN\1740 )\-RRB-\1740 and\CC\1740 renal\JJ\1740 insufficiency\NN\14462946 (\-LRB-\1740 0\CD\13741022 %\NN\1740 )\-RRB-\1740 .\.\1740
D013148_D006947 CID We\PRP\1740 therefore\RB\1740 sought\VBD\1825237 to\TO\1740 determine\VB\1645601 the\DT\1740 prevalence\NN\4764412 and\CC\1740 clinical\JJ\1740 associations\NNS\8008335 of\IN\1740 <e2>hyperkalemia</e2>\NN\14299637 and\CC\1740 renal\JJ\1740 insufficiency\NN\14462946 in\IN\13603305 heart\NN\5919034 failure\NN\66216 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>spironolactone</e1>\NN\2721160 .\.\1740
D013148_D006947 CID RESULTS\NNS\34213 :\:\1740 Sixty-seven\CD\1740 of\IN\1740 926\CD\1740 patients\NNS\9898892 (\-LRB-\1740 7.2\CD\1740 %\NN\1740 )\-RRB-\1740 required\VBD\754942 discontinuation\NN\209943 of\IN\1740 <e1>spironolactone</e1>\NN\2721160 due\JJ\1740 to\TO\1740 <e2>hyperkalemia</e2>\NN\14299637 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 33\CD\1740 )\-RRB-\1740 or\CC\3541091 renal\JJ\1740 failure\NN\66216 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 34\CD\1740 )\-RRB-\1740 .\.\1740
D013148_D006947 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Spironolactone-induced</e1>\JJ\1740 <e2>hyperkalemia</e2>\NN\14299637 and\CC\1740 renal\JJ\1740 insufficiency\NN\14462946 are\VBP\836236 more\RBR\1740 common\JJ\1740 in\IN\13603305 our\PRP$\1740 clinical\JJ\1740 experience\NN\5984287 than\IN\1740 reported\VBN\831651 previously\RB\1740 .\.\1740
D013148_D006333 NONE <e1>Spironolactone-induced</e1>\JJ\1740 renal\JJ\1740 insufficiency\NN\14462946 and\CC\1740 hyperkalemia\NN\14299637 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 .\.\1740
D013148_D006333 NONE BACKGROUND\NN\4921011 :\:\1740 A\DT\13649268 previous\JJ\1740 randomized\NN\1740 controlled\JJ\1740 trial\NN\786195 evaluating\VBG\670261 the\DT\1740 use\NN\407535 of\IN\1740 <e1>spironolactone</e1>\NN\2721160 in\IN\13603305 <e2>heart\NN\5919034 failure</e2>\NN\66216 patients\NNS\9898892 reported\VBD\831651 a\DT\13649268 low\JJ\1740 risk\NN\14541044 of\IN\1740 hyperkalemia\NN\14299637 (\-LRB-\1740 2\CD\13741022 %\NN\1740 )\-RRB-\1740 and\CC\1740 renal\JJ\1740 insufficiency\NN\14462946 (\-LRB-\1740 0\CD\13741022 %\NN\1740 )\-RRB-\1740 .\.\1740
D013148_D006333 NONE Because\IN\1740 treatments\NNS\654885 for\IN\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 have\VBP\2108377 changed\VBN\46534 since\IN\1740 the\DT\1740 benefits\NNS\13278375 of\IN\1740 <e1>spironolactone</e1>\NN\2721160 were\VBD\836236 reported\VBN\831651 ,\,\1740 the\DT\1740 prevalence\NN\4764412 of\IN\1740 these\DT\1740 complications\NNS\1073995 may\MD\15209706 differ\VB\1740 in\IN\13603305 current\JJ\1740 clinical\JJ\1740 practice\NN\407535 .\.\1740
D013148_D006333 NONE We\PRP\1740 therefore\RB\1740 sought\VBD\1825237 to\TO\1740 determine\VB\1645601 the\DT\1740 prevalence\NN\4764412 and\CC\1740 clinical\JJ\1740 associations\NNS\8008335 of\IN\1740 hyperkalemia\NN\14299637 and\CC\1740 renal\JJ\1740 insufficiency\NN\14462946 in\IN\13603305 <e2>heart\NN\5919034 failure</e2>\NN\66216 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>spironolactone</e1>\NN\2721160 .\.\1740
D013148_D006333 NONE METHODS\NNS\5616786 :\:\1740 We\PRP\1740 performed\VBD\2367363 a\DT\13649268 case\NN\7283608 control\NN\5190804 study\NN\635850 of\IN\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>spironolactone</e1>\NN\2721160 in\IN\13603305 our\PRP$\1740 clinical\JJ\1740 practice\NN\407535 .\.\1740
D011188_D006947 NONE Cases\NNS\7283608 were\VBD\836236 patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 <e2>hyperkalemia</e2>\NN\14299637 (\-LRB-\1740 <e1>K(+</e1>\NNS\1740 )\-RRB-\1740 >\NN\1740 5.0\CD\1740 mEq/L\NN\1740 )\-RRB-\1740 or\CC\3541091 renal\JJ\1740 insufficiency\NN\14462946 (\-LRB-\1740 Cr\NN\14625458 >\NN\1740 or=2.5\NN\1740 mg/dL\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 they\PRP\1740 were\VBD\836236 compared\VBN\644583 to\TO\1740 2\CD\13741022 randomly\RB\1740 selected\VBD\697589 controls\NNS\5190804 per\IN\1740 case\NN\7283608 .\.\1740
D011188_D006947 NONE Patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 <e2>hyperkalemia</e2>\NN\14299637 were\VBD\836236 older\JJR\1740 and\CC\1740 more\RBR\1740 likely\JJ\1740 to\TO\1740 have\VB\2108377 diabetes\NNS\14075199 ,\,\1740 had\VBD\2108377 higher\JJR\1740 baseline\NN\7260623 serum\NN\5397468 <e1>potassium</e1>\NN\14625458 levels\NNS\4916342 and\CC\1740 lower\JJR\1740 baseline\NN\7260623 potassium\NN\14625458 supplement\NN\6365467 doses\NNS\3740161 ,\,\1740 and\CC\1740 were\VBD\836236 more\RBR\1740 likely\JJ\1740 to\TO\1740 be\VB\836236 treated\VBN\2376958 with\IN\1740 beta-blockers\NNS\1740 than\IN\1740 controls\NNS\5190804 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 134\CD\1740 )\-RRB-\1740 .\.\1740
D011188_D006947 NONE Patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 <e2>hyperkalemia</e2>\NN\14299637 were\VBD\836236 older\JJR\1740 and\CC\1740 more\RBR\1740 likely\JJ\1740 to\TO\1740 have\VB\2108377 diabetes\NNS\14075199 ,\,\1740 had\VBD\2108377 higher\JJR\1740 baseline\NN\7260623 serum\NN\5397468 potassium\NN\14625458 levels\NNS\4916342 and\CC\1740 lower\JJR\1740 baseline\NN\7260623 <e1>potassium</e1>\NN\14625458 supplement\NN\6365467 doses\NNS\3740161 ,\,\1740 and\CC\1740 were\VBD\836236 more\RBR\1740 likely\JJ\1740 to\TO\1740 be\VB\836236 treated\VBN\2376958 with\IN\1740 beta-blockers\NNS\1740 than\IN\1740 controls\NNS\5190804 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 134\CD\1740 )\-RRB-\1740 .\.\1740
D011188_D051437 NONE Cases\NNS\7283608 were\VBD\836236 patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 hyperkalemia\NN\14299637 (\-LRB-\1740 <e1>K(+</e1>\NNS\1740 )\-RRB-\1740 >\NN\1740 5.0\CD\1740 mEq/L\NN\1740 )\-RRB-\1740 or\CC\3541091 <e2>renal\JJ\1740 insufficiency</e2>\NN\14462946 (\-LRB-\1740 Cr\NN\14625458 >\NN\1740 or=2.5\NN\1740 mg/dL\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 they\PRP\1740 were\VBD\836236 compared\VBN\644583 to\TO\1740 2\CD\13741022 randomly\RB\1740 selected\VBD\697589 controls\NNS\5190804 per\IN\1740 case\NN\7283608 .\.\1740
D002857_D006947 NONE Cases\NNS\7283608 were\VBD\836236 patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 <e2>hyperkalemia</e2>\NN\14299637 (\-LRB-\1740 K(+\NNS\1740 )\-RRB-\1740 >\NN\1740 5.0\CD\1740 mEq/L\NN\1740 )\-RRB-\1740 or\CC\3541091 renal\JJ\1740 insufficiency\NN\14462946 (\-LRB-\1740 <e1>Cr</e1>\NN\14625458 >\NN\1740 or=2.5\NN\1740 mg/dL\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 they\PRP\1740 were\VBD\836236 compared\VBN\644583 to\TO\1740 2\CD\13741022 randomly\RB\1740 selected\VBD\697589 controls\NNS\5190804 per\IN\1740 case\NN\7283608 .\.\1740
D002857_D051437 NONE Cases\NNS\7283608 were\VBD\836236 patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 hyperkalemia\NN\14299637 (\-LRB-\1740 K(+\NNS\1740 )\-RRB-\1740 >\NN\1740 5.0\CD\1740 mEq/L\NN\1740 )\-RRB-\1740 or\CC\3541091 <e2>renal\JJ\1740 insufficiency</e2>\NN\14462946 (\-LRB-\1740 <e1>Cr</e1>\NN\14625458 >\NN\1740 or=2.5\NN\1740 mg/dL\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 they\PRP\1740 were\VBD\836236 compared\VBN\644583 to\TO\1740 2\CD\13741022 randomly\RB\1740 selected\VBD\697589 controls\NNS\5190804 per\IN\1740 case\NN\7283608 .\.\1740
D011188_D003920 NONE Patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 hyperkalemia\NN\14299637 were\VBD\836236 older\JJR\1740 and\CC\1740 more\RBR\1740 likely\JJ\1740 to\TO\1740 have\VB\2108377 <e2>diabetes</e2>\NNS\14075199 ,\,\1740 had\VBD\2108377 higher\JJR\1740 baseline\NN\7260623 serum\NN\5397468 <e1>potassium</e1>\NN\14625458 levels\NNS\4916342 and\CC\1740 lower\JJR\1740 baseline\NN\7260623 potassium\NN\14625458 supplement\NN\6365467 doses\NNS\3740161 ,\,\1740 and\CC\1740 were\VBD\836236 more\RBR\1740 likely\JJ\1740 to\TO\1740 be\VB\836236 treated\VBN\2376958 with\IN\1740 beta-blockers\NNS\1740 than\IN\1740 controls\NNS\5190804 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 134\CD\1740 )\-RRB-\1740 .\.\1740
D011188_D003920 NONE Patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 hyperkalemia\NN\14299637 were\VBD\836236 older\JJR\1740 and\CC\1740 more\RBR\1740 likely\JJ\1740 to\TO\1740 have\VB\2108377 <e2>diabetes</e2>\NNS\14075199 ,\,\1740 had\VBD\2108377 higher\JJR\1740 baseline\NN\7260623 serum\NN\5397468 potassium\NN\14625458 levels\NNS\4916342 and\CC\1740 lower\JJR\1740 baseline\NN\7260623 <e1>potassium</e1>\NN\14625458 supplement\NN\6365467 doses\NNS\3740161 ,\,\1740 and\CC\1740 were\VBD\836236 more\RBR\1740 likely\JJ\1740 to\TO\1740 be\VB\836236 treated\VBN\2376958 with\IN\1740 beta-blockers\NNS\1740 than\IN\1740 controls\NNS\5190804 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 134\CD\1740 )\-RRB-\1740 .\.\1740
D003404_D051437 NONE Patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 <e2>renal\JJ\1740 insufficiency</e2>\NN\14462946 had\VBD\2108377 lower\JJR\1740 baseline\NN\7260623 body\NN\19128 weight\NN\5009170 and\CC\1740 higher\JJR\1740 baseline\NN\7260623 serum\NN\5397468 <e1>creatinine</e1>\NN\1740 ,\,\1740 required\VBD\754942 higher\JJR\1740 doses\NNS\3740161 of\IN\1740 loop\NN\3323703 diuretics\NNS\3247620 ,\,\1740 and\CC\1740 were\VBD\836236 more\RBR\1740 likely\JJ\1740 to\TO\1740 be\VB\836236 treated\VBN\2376958 with\IN\1740 thiazide\NN\3214670 diuretics\NNS\3247620 than\IN\1740 controls\NNS\5190804 .\.\1740
D049971_D051437 NONE Patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 <e2>renal\JJ\1740 insufficiency</e2>\NN\14462946 had\VBD\2108377 lower\JJR\1740 baseline\NN\7260623 body\NN\19128 weight\NN\5009170 and\CC\1740 higher\JJR\1740 baseline\NN\7260623 serum\NN\5397468 creatinine\NN\1740 ,\,\1740 required\VBD\754942 higher\JJR\1740 doses\NNS\3740161 of\IN\1740 loop\NN\3323703 diuretics\NNS\3247620 ,\,\1740 and\CC\1740 were\VBD\836236 more\RBR\1740 likely\JJ\1740 to\TO\1740 be\VB\836236 treated\VBN\2376958 with\IN\1740 <e1>thiazide</e1>\NN\3214670 diuretics\NNS\3247620 than\IN\1740 controls\NNS\5190804 .\.\1740
6386793
D004308_D003866 NONE A\DT\13649268 double-blind\JJ\1740 study\NN\635850 of\IN\1740 the\DT\1740 efficacy\NN\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 <e1>dothiepin\NN\1740 hydrochloride</e1>\NN\14817592 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 major\JJ\1740 <e2>depressive\JJ\1740 disorder</e2>\NN\14034177 .\.\1740
D004308_D003866 NONE In\IN\13603305 a\DT\13649268 6-week\JJ\1740 double-blind\JJ\1740 parallel\NN\4743605 treatment\NN\654885 study\NN\635850 ,\,\1740 <e1>dothiepin</e1>\NN\1740 and\CC\1740 amitriptyline\NN\4482543 were\VBD\836236 compared\VBN\644583 to\TO\1740 placebo\VB\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 33\CD\1740 <e2>depressed</e2>\JJ\1740 outpatients\NNS\10405694 .\.\1740
D004308_D003866 NONE <e1>Dothiepin</e1>\NN\1740 and\CC\1740 amitriptyline\NN\4482543 were\VBD\836236 equally\RB\1740 effective\JJ\1740 in\IN\13603305 alleviating\VBG\205885 the\DT\1740 symptoms\NNS\5823932 of\IN\1740 <e2>depressive\JJ\1740 illness</e2>\NN\14052046 ,\,\1740 and\CC\1740 both\DT\1740 were\VBD\836236 significantly\RB\1740 superior\JJ\1740 to\TO\1740 placebo\NN\3740161 .\.\1740
D004308_D003866 NONE <e1>Dothiepin</e1>\NNP\1740 thus\RB\1740 was\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 an\DT\6697703 effective\JJ\1740 antidepressant\JJ\1740 drug\NN\14778436 associated\VBN\628491 with\IN\1740 fewer\JJR\1740 side\JJ\1740 effects\NNS\13245626 than\IN\1740 amitriptyline\NN\4482543 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>depressed</e2>\JJ\1740 outpatients\NNS\10405694 .\.\1740
D000639_D003866 NONE In\IN\13603305 a\DT\13649268 6-week\JJ\1740 double-blind\JJ\1740 parallel\NN\4743605 treatment\NN\654885 study\NN\635850 ,\,\1740 dothiepin\NN\1740 and\CC\1740 <e1>amitriptyline</e1>\NN\4482543 were\VBD\836236 compared\VBN\644583 to\TO\1740 placebo\VB\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 33\CD\1740 <e2>depressed</e2>\JJ\1740 outpatients\NNS\10405694 .\.\1740
D000639_D003866 NONE Dothiepin\NN\1740 and\CC\1740 <e1>amitriptyline</e1>\NN\4482543 were\VBD\836236 equally\RB\1740 effective\JJ\1740 in\IN\13603305 alleviating\VBG\205885 the\DT\1740 symptoms\NNS\5823932 of\IN\1740 <e2>depressive\JJ\1740 illness</e2>\NN\14052046 ,\,\1740 and\CC\1740 both\DT\1740 were\VBD\836236 significantly\RB\1740 superior\JJ\1740 to\TO\1740 placebo\NN\3740161 .\.\1740
D000639_D003866 NONE Dothiepin\NNP\1740 thus\RB\1740 was\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 an\DT\6697703 effective\JJ\1740 antidepressant\JJ\1740 drug\NN\14778436 associated\VBN\628491 with\IN\1740 fewer\JJR\1740 side\JJ\1740 effects\NNS\13245626 than\IN\1740 <e1>amitriptyline</e1>\NN\4482543 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>depressed</e2>\JJ\1740 outpatients\NNS\10405694 .\.\1740
D004308_D014786 NONE The\DT\1740 overall\JJ\1740 incidence\NN\13821570 of\IN\1740 side\NN\8630039 effects\NNS\13245626 and\CC\1740 the\DT\1740 frequency\NN\15286249 and\CC\1740 severity\NN\5036394 of\IN\1740 <e2>blurred\JJ\1740 vision</e2>\NN\5767733 ,\,\1740 dry\JJ\1740 mouth\NN\5610008 ,\,\1740 and\CC\1740 drowsiness\VBD\1740 were\VBD\836236 significantly\RB\1740 less\JJR\1740 with\IN\1740 <e1>dothiepin</e1>\NN\1740 than\IN\1740 with\IN\1740 amitriptyline\NN\4482543 .\.\1740
D004308_D014987 NONE The\DT\1740 overall\JJ\1740 incidence\NN\13821570 of\IN\1740 side\NN\8630039 effects\NNS\13245626 and\CC\1740 the\DT\1740 frequency\NN\15286249 and\CC\1740 severity\NN\5036394 of\IN\1740 blurred\JJ\1740 vision\NN\5767733 ,\,\1740 <e2>dry\JJ\1740 mouth</e2>\NN\5610008 ,\,\1740 and\CC\1740 drowsiness\VBD\1740 were\VBD\836236 significantly\RB\1740 less\JJR\1740 with\IN\1740 <e1>dothiepin</e1>\NN\1740 than\IN\1740 with\IN\1740 amitriptyline\NN\4482543 .\.\1740
D000639_D014786 CID The\DT\1740 overall\JJ\1740 incidence\NN\13821570 of\IN\1740 side\NN\8630039 effects\NNS\13245626 and\CC\1740 the\DT\1740 frequency\NN\15286249 and\CC\1740 severity\NN\5036394 of\IN\1740 <e2>blurred\JJ\1740 vision</e2>\NN\5767733 ,\,\1740 dry\JJ\1740 mouth\NN\5610008 ,\,\1740 and\CC\1740 drowsiness\VBD\1740 were\VBD\836236 significantly\RB\1740 less\JJR\1740 with\IN\1740 dothiepin\NN\1740 than\IN\1740 with\IN\1740 <e1>amitriptyline</e1>\NN\4482543 .\.\1740
D000639_D014987 CID The\DT\1740 overall\JJ\1740 incidence\NN\13821570 of\IN\1740 side\NN\8630039 effects\NNS\13245626 and\CC\1740 the\DT\1740 frequency\NN\15286249 and\CC\1740 severity\NN\5036394 of\IN\1740 blurred\JJ\1740 vision\NN\5767733 ,\,\1740 <e2>dry\JJ\1740 mouth</e2>\NN\5610008 ,\,\1740 and\CC\1740 drowsiness\VBD\1740 were\VBD\836236 significantly\RB\1740 less\JJR\1740 with\IN\1740 dothiepin\NN\1740 than\IN\1740 with\IN\1740 <e1>amitriptyline</e1>\NN\4482543 .\.\1740
D000928_D003866 NONE Dothiepin\NNP\1740 thus\RB\1740 was\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 an\DT\6697703 effective\JJ\1740 <e1>antidepressant</e1>\JJ\1740 drug\NN\14778436 associated\VBN\628491 with\IN\1740 fewer\JJR\1740 side\JJ\1740 effects\NNS\13245626 than\IN\1740 amitriptyline\NN\4482543 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>depressed</e2>\JJ\1740 outpatients\NNS\10405694 .\.\1740
2673163
D003042_D020521 NONE <e2>Stroke</e2>\NNP\556313 associated\VBN\628491 with\IN\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 .\.\1740
D003042_D020521 NONE We\PRP\1740 describe\VBP\1001294 eight\CD\13741022 patients\NNS\9898892 in\IN\13603305 whom\WP\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 was\VBD\836236 related\JJ\1740 to\TO\1740 <e2>stroke</e2>\VB\1206218 and\CC\1740 review\VB\644583 39\CD\1740 cases\NNS\7283608 from\IN\1740 the\DT\1740 literature\NN\6362953 .\.\1740
D003042_D020521 NONE <e2>Stroke</e2>\NN\556313 followed\VBD\1835496 <e1>cocaine</e1>\NN\3492717 use\NN\407535 by\IN\1740 inhalation\NN\835032 ,\,\1740 intranasal\JJ\1740 ,\,\1740 intravenous\JJ\1740 ,\,\1740 and\CC\1740 intramuscular\JJ\1740 routes\NNS\8593262 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>stroke</e2>\NN\556313 related\JJ\1740 to\TO\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 <e2>stroke</e2>\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 <e2>stroke</e2>\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 <e2>stroke</e2>\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 <e2>stroke</e2>\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>stroke</e2>\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 <e1>cocaine-associated</e1>\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 <e1>cocaine-associated</e1>\JJ\1740 <e2>stroke</e2>\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 <e1>cocaine-associated</e1>\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 <e2>stroke</e2>\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 <e1>cocaine-associated</e1>\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 <e2>stroke</e2>\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 <e1>cocaine-associated</e1>\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 <e2>stroke</e2>\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>stroke</e2>\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 <e1>cocaine</e1>\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 <e2>stroke</e2>\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 <e1>cocaine</e1>\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 <e2>stroke</e2>\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 <e1>cocaine</e1>\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 <e1>cocaine</e1>\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 <e2>stroke</e2>\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 <e1>cocaine</e1>\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 <e2>stroke</e2>\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>stroke</e2>\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 <e2>stroke</e2>\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 <e2>stroke</e2>\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 <e2>stroke</e2>\NN\556313 after\IN\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 <e2>stroke</e2>\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>stroke</e2>\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 <e1>cocaine-associated</e1>\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 <e2>stroke</e2>\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 <e1>cocaine-associated</e1>\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 <e2>stroke</e2>\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 <e1>cocaine-associated</e1>\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 <e2>stroke</e2>\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 <e1>cocaine-associated</e1>\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020521 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 <e1>cocaine-associated</e1>\JJ\1740 <e2>stroke</e2>\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D002532 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 <e2>intracranial\JJ\1740 aneurysms</e2>\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D002532 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 <e1>cocaine-associated</e1>\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 <e2>intracranial\JJ\1740 aneurysms</e2>\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D002532 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 <e1>cocaine</e1>\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 <e2>intracranial\JJ\1740 aneurysms</e2>\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D002532 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 <e2>intracranial\JJ\1740 aneurysms</e2>\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D002532 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 <e2>intracranial\JJ\1740 aneurysms</e2>\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 <e1>cocaine-associated</e1>\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D001165 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 <e2>arteriovenous\JJ\1740 malformations</e2>\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D001165 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 <e1>cocaine-associated</e1>\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 <e2>arteriovenous\JJ\1740 malformations</e2>\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D001165 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 <e1>cocaine</e1>\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 <e2>arteriovenous\JJ\1740 malformations</e2>\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D001165 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 <e2>arteriovenous\JJ\1740 malformations</e2>\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D001165 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 <e2>arteriovenous\JJ\1740 malformations</e2>\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 <e1>cocaine-associated</e1>\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020300 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 <e2>intracranial\JJ\1740 hemorrhage</e2>\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020300 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 <e1>cocaine-associated</e1>\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 <e2>intracranial\JJ\1740 hemorrhage</e2>\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020300 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 <e1>cocaine</e1>\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 <e2>intracranial\JJ\1740 hemorrhage</e2>\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020300 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 <e2>intracranial\JJ\1740 hemorrhage</e2>\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D020300 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 <e1>cocaine-associated</e1>\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 <e2>intracranial\JJ\1740 hemorrhage</e2>\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 cerebral\JJ\1740 infarction\NN\14204950 .\.\1740
D003042_D002544 CID These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 <e2>cerebral\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D003042_D002544 CID These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 <e1>cocaine-associated</e1>\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 <e2>cerebral\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D003042_D002544 CID These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 <e1>cocaine</e1>\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 <e2>cerebral\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D003042_D002544 CID These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 cocaine-associated\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 <e2>cerebral\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D003042_D002544 CID These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 (\-LRB-\1740 1\LS\13741022 )\-RRB-\1740 the\DT\1740 apparent\JJ\1740 incidence\NN\13821570 of\IN\1740 stroke\NN\556313 related\JJ\1740 to\TO\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 increasing\VBG\169651 ;\:\1740 (\-LRB-\1740 2\LS\13741022 )\-RRB-\1740 cocaine-associated\JJ\1740 stroke\NN\556313 occurs\VBZ\2623529 primarily\RB\1740 in\IN\13603305 young\JJ\1740 adults\NNS\7846 ;\:\1740 (\-LRB-\1740 3\LS\13741022 )\-RRB-\1740 stroke\NN\556313 may\MD\15209706 follow\VB\1835496 any\DT\1740 route\NN\8593262 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 ;\:\1740 (\-LRB-\1740 4\LS\13741022 )\-RRB-\1740 stroke\NN\556313 after\IN\1740 cocaine\NN\3492717 use\NN\407535 is\VBZ\836236 frequently\RB\1740 associated\VBN\628491 with\IN\1740 intracranial\JJ\1740 aneurysms\NNS\14057371 and\CC\1740 arteriovenous\JJ\1740 malformations\NNS\14213199 ;\:\1740 and\CC\1740 (\-LRB-\1740 5\LS\13741022 )\-RRB-\1740 in\IN\13603305 <e1>cocaine-associated</e1>\JJ\1740 stroke\NN\556313 ,\,\1740 the\DT\1740 frequency\NN\15286249 of\IN\1740 intracranial\JJ\1740 hemorrhage\NN\14285662 exceeds\NNS\1740 that\DT\1740 of\IN\1740 <e2>cerebral\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
19803309
D013390_D009224 NONE We\PRP\1740 report\VBP\831651 an\DT\6697703 undiagnosed\JJ\1740 case\NN\7283608 of\IN\1740 <e2>myotonia\NN\14544672 congenita</e2>\NN\1740 in\IN\13603305 a\DT\13649268 24-year-old\JJ\1740 previously\RB\1740 healthy\JJ\1740 primigravida\NN\10144838 ,\,\1740 who\WP\8299493 developed\VBD\1753788 life\NN\13954253 threatening\VBG\2603699 masseter\NN\5602132 spasm\NN\14299637 following\VBG\1835496 a\DT\13649268 standard\JJ\1740 dose\NN\3740161 of\IN\1740 intravenous\JJ\1740 <e1>suxamethonium</e1>\NN\1740 for\IN\1740 induction\NN\7450842 of\IN\1740 anaesthesia\NN\14034177 .\.\1740
D013390_D014313 CID We\PRP\1740 report\VBP\831651 an\DT\6697703 undiagnosed\JJ\1740 case\NN\7283608 of\IN\1740 myotonia\NN\14544672 congenita\NN\1740 in\IN\13603305 a\DT\13649268 24-year-old\JJ\1740 previously\RB\1740 healthy\JJ\1740 primigravida\NN\10144838 ,\,\1740 who\WP\8299493 developed\VBD\1753788 life\NN\13954253 threatening\VBG\2603699 <e2>masseter\NN\5602132 spasm</e2>\NN\14299637 following\VBG\1835496 a\DT\13649268 standard\JJ\1740 dose\NN\3740161 of\IN\1740 intravenous\JJ\1740 <e1>suxamethonium</e1>\NN\1740 for\IN\1740 induction\NN\7450842 of\IN\1740 anaesthesia\NN\14034177 .\.\1740
234669
D000628_D014693 CID Effects\NNS\13245626 of\IN\1740 <e1>aminophylline</e1>\NN\2905612 on\IN\1740 the\DT\1740 threshold\NN\15265518 for\IN\1740 initiating\VBG\1617192 <e2>ventricular\JJ\1740 fibrillation</e2>\NN\14361664 during\IN\1740 respiratory\JJ\1740 failure\NN\66216 .\.\1740
D000628_D014693 CID The\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>aminophylline</e1>\NN\2905612 on\IN\1740 the\DT\1740 <e2>ventricular\JJ\1740 fibrillation</e2>\NN\14361664 threshold\NN\15265518 during\IN\1740 normal\JJ\1740 acid-base\JJ\1740 conditions\NNS\14512817 and\CC\1740 during\IN\1740 respiratory\JJ\1740 failure\NN\66216 were\VBD\836236 studied\VBN\630380 in\IN\13603305 anesthetized\JJ\1740 open\JJ\1740 chest\JJS\1740 dogs\NNS\2083346 .\.\1740
D000628_D014693 CID During\IN\1740 the\DT\1740 infusion\NN\14589223 of\IN\1740 <e1>aminophylline</e1>\NN\2905612 ,\,\1740 the\DT\1740 <e2>ventricular\JJ\1740 fibrillation</e2>\NN\14361664 threshold\NN\15265518 was\VBD\836236 reduced\VBN\441445 by\IN\1740 30\CD\13745420 to\TO\1740 40\CD\13745420 percent\NN\13815742 of\IN\1740 the\DT\1740 control\NN\5190804 when\WRB\1740 pH\NN\5038959 and\CC\1740 partial\JJ\1740 pressures\NNS\11419404 of\IN\1740 oxygen\NN\14622893 (\-LRB-\1740 PO2\NN\1740 )\-RRB-\1740 and\CC\1740 carbon\NN\14622893 dioxide\NN\14971519 (\-LRB-\1740 CO2\NN\14836127 )\-RRB-\1740 were\VBD\836236 kept\VBN\2367363 within\IN\1740 normal\JJ\1740 limits\NNS\5123416 .\.\1740
D000628_D014693 CID When\WRB\1740 respiratory\JJ\1740 failure\NN\66216 was\VBD\836236 produced\VBN\1617192 by\IN\1740 hypoventilation\NN\1740 (\-LRB-\1740 pH\NN\5038959 7.05\CD\1740 to\TO\1740 7.25\CD\1740 ;\:\1740 PC02\NN\1740 70\CD\13745420 to\TO\1740 100\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 :\:\1740 P02\NN\1740 20\CD\13745420 to\TO\1740 40\CD\13745420 mm\NN\13649268 Hg\NN\14625458 )\-RRB-\1740 ,\,\1740 infusion\NN\14589223 of\IN\1740 <e1>aminophylline</e1>\NN\2905612 resulted\VBD\2633881 in\IN\13603305 an\DT\6697703 even\RB\1740 greater\JJR\1740 decrease\NN\7296428 in\IN\13603305 <e2>ventricular\JJ\1740 fibrillation</e2>\NN\14361664 threshold\NN\15265518 to\IN\1740 60\CD\13745420 percent\NN\13815742 of\IN\1740 the\DT\1740 control\NN\5190804 level\NN\4916342 .\.\1740
D000628_D012131 NONE Effects\NNS\13245626 of\IN\1740 <e1>aminophylline</e1>\NN\2905612 on\IN\1740 the\DT\1740 threshold\NN\15265518 for\IN\1740 initiating\VBG\1617192 ventricular\JJ\1740 fibrillation\NN\14361664 during\IN\1740 <e2>respiratory\JJ\1740 failure</e2>\NN\66216 .\.\1740
D000628_D012131 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>aminophylline</e1>\NN\2905612 on\IN\1740 the\DT\1740 ventricular\JJ\1740 fibrillation\NN\14361664 threshold\NN\15265518 during\IN\1740 normal\JJ\1740 acid-base\JJ\1740 conditions\NNS\14512817 and\CC\1740 during\IN\1740 <e2>respiratory\JJ\1740 failure</e2>\NN\66216 were\VBD\836236 studied\VBN\630380 in\IN\13603305 anesthetized\JJ\1740 open\JJ\1740 chest\JJS\1740 dogs\NNS\2083346 .\.\1740
D000628_D012131 NONE When\WRB\1740 <e2>respiratory\JJ\1740 failure</e2>\NN\66216 was\VBD\836236 produced\VBN\1617192 by\IN\1740 hypoventilation\NN\1740 (\-LRB-\1740 pH\NN\5038959 7.05\CD\1740 to\TO\1740 7.25\CD\1740 ;\:\1740 PC02\NN\1740 70\CD\13745420 to\TO\1740 100\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 :\:\1740 P02\NN\1740 20\CD\13745420 to\TO\1740 40\CD\13745420 mm\NN\13649268 Hg\NN\14625458 )\-RRB-\1740 ,\,\1740 infusion\NN\14589223 of\IN\1740 <e1>aminophylline</e1>\NN\2905612 resulted\VBD\2633881 in\IN\13603305 an\DT\6697703 even\RB\1740 greater\JJR\1740 decrease\NN\7296428 in\IN\13603305 ventricular\JJ\1740 fibrillation\NN\14361664 threshold\NN\15265518 to\IN\1740 60\CD\13745420 percent\NN\13815742 of\IN\1740 the\DT\1740 control\NN\5190804 level\NN\4916342 .\.\1740
D000628_D012131 NONE These\DT\1740 experiments\NNS\641820 suggest\VBP\1010118 that\IN\1740 although\IN\1740 many\JJ\1740 factors\NNS\7326557 may\MD\15209706 contribute\VB\126264 to\TO\1740 the\DT\1740 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 ventricular\JJ\1740 arrhythmias\NNS\14103288 in\IN\13603305 <e2>respiratory\JJ\1740 failure</e2>\NN\66216 ,\,\1740 pharmacologic\JJ\1740 agents\NNS\7347 ,\,\1740 particularly\RB\1740 <e1>aminophylline</e1>\NN\2905612 ,\,\1740 may\MD\15209706 play\VB\1072262 a\DT\13649268 significant\JJ\1740 role\NN\719494 .\.\1740
D010100_D014693 NONE During\IN\1740 the\DT\1740 infusion\NN\14589223 of\IN\1740 aminophylline\NN\2905612 ,\,\1740 the\DT\1740 <e2>ventricular\JJ\1740 fibrillation</e2>\NN\14361664 threshold\NN\15265518 was\VBD\836236 reduced\VBN\441445 by\IN\1740 30\CD\13745420 to\TO\1740 40\CD\13745420 percent\NN\13815742 of\IN\1740 the\DT\1740 control\NN\5190804 when\WRB\1740 pH\NN\5038959 and\CC\1740 partial\JJ\1740 pressures\NNS\11419404 of\IN\1740 <e1>oxygen</e1>\NN\14622893 (\-LRB-\1740 PO2\NN\1740 )\-RRB-\1740 and\CC\1740 carbon\NN\14622893 dioxide\NN\14971519 (\-LRB-\1740 CO2\NN\14836127 )\-RRB-\1740 were\VBD\836236 kept\VBN\2367363 within\IN\1740 normal\JJ\1740 limits\NNS\5123416 .\.\1740
C093415_D014693 NONE During\IN\1740 the\DT\1740 infusion\NN\14589223 of\IN\1740 aminophylline\NN\2905612 ,\,\1740 the\DT\1740 <e2>ventricular\JJ\1740 fibrillation</e2>\NN\14361664 threshold\NN\15265518 was\VBD\836236 reduced\VBN\441445 by\IN\1740 30\CD\13745420 to\TO\1740 40\CD\13745420 percent\NN\13815742 of\IN\1740 the\DT\1740 control\NN\5190804 when\WRB\1740 pH\NN\5038959 and\CC\1740 partial\JJ\1740 pressures\NNS\11419404 of\IN\1740 oxygen\NN\14622893 (\-LRB-\1740 <e1>PO2</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 carbon\NN\14622893 dioxide\NN\14971519 (\-LRB-\1740 CO2\NN\14836127 )\-RRB-\1740 were\VBD\836236 kept\VBN\2367363 within\IN\1740 normal\JJ\1740 limits\NNS\5123416 .\.\1740
D002245_D014693 NONE During\IN\1740 the\DT\1740 infusion\NN\14589223 of\IN\1740 aminophylline\NN\2905612 ,\,\1740 the\DT\1740 <e2>ventricular\JJ\1740 fibrillation</e2>\NN\14361664 threshold\NN\15265518 was\VBD\836236 reduced\VBN\441445 by\IN\1740 30\CD\13745420 to\TO\1740 40\CD\13745420 percent\NN\13815742 of\IN\1740 the\DT\1740 control\NN\5190804 when\WRB\1740 pH\NN\5038959 and\CC\1740 partial\JJ\1740 pressures\NNS\11419404 of\IN\1740 oxygen\NN\14622893 (\-LRB-\1740 PO2\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>carbon\NN\14622893 dioxide</e1>\NN\14971519 (\-LRB-\1740 CO2\NN\14836127 )\-RRB-\1740 were\VBD\836236 kept\VBN\2367363 within\IN\1740 normal\JJ\1740 limits\NNS\5123416 .\.\1740
D002245_D014693 NONE During\IN\1740 the\DT\1740 infusion\NN\14589223 of\IN\1740 aminophylline\NN\2905612 ,\,\1740 the\DT\1740 <e2>ventricular\JJ\1740 fibrillation</e2>\NN\14361664 threshold\NN\15265518 was\VBD\836236 reduced\VBN\441445 by\IN\1740 30\CD\13745420 to\TO\1740 40\CD\13745420 percent\NN\13815742 of\IN\1740 the\DT\1740 control\NN\5190804 when\WRB\1740 pH\NN\5038959 and\CC\1740 partial\JJ\1740 pressures\NNS\11419404 of\IN\1740 oxygen\NN\14622893 (\-LRB-\1740 PO2\NN\1740 )\-RRB-\1740 and\CC\1740 carbon\NN\14622893 dioxide\NN\14971519 (\-LRB-\1740 <e1>CO2</e1>\NN\14836127 )\-RRB-\1740 were\VBD\836236 kept\VBN\2367363 within\IN\1740 normal\JJ\1740 limits\NNS\5123416 .\.\1740
D000628_D007040 NONE When\WRB\1740 respiratory\JJ\1740 failure\NN\66216 was\VBD\836236 produced\VBN\1617192 by\IN\1740 <e2>hypoventilation</e2>\NN\1740 (\-LRB-\1740 pH\NN\5038959 7.05\CD\1740 to\TO\1740 7.25\CD\1740 ;\:\1740 PC02\NN\1740 70\CD\13745420 to\TO\1740 100\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 :\:\1740 P02\NN\1740 20\CD\13745420 to\TO\1740 40\CD\13745420 mm\NN\13649268 Hg\NN\14625458 )\-RRB-\1740 ,\,\1740 infusion\NN\14589223 of\IN\1740 <e1>aminophylline</e1>\NN\2905612 resulted\VBD\2633881 in\IN\13603305 an\DT\6697703 even\RB\1740 greater\JJR\1740 decrease\NN\7296428 in\IN\13603305 ventricular\JJ\1740 fibrillation\NN\14361664 threshold\NN\15265518 to\IN\1740 60\CD\13745420 percent\NN\13815742 of\IN\1740 the\DT\1740 control\NN\5190804 level\NN\4916342 .\.\1740
D000628_D001145 NONE These\DT\1740 experiments\NNS\641820 suggest\VBP\1010118 that\IN\1740 although\IN\1740 many\JJ\1740 factors\NNS\7326557 may\MD\15209706 contribute\VB\126264 to\TO\1740 the\DT\1740 increased\VBN\169651 incidence\NN\13821570 of\IN\1740 <e2>ventricular\JJ\1740 arrhythmias</e2>\NNS\14103288 in\IN\13603305 respiratory\JJ\1740 failure\NN\66216 ,\,\1740 pharmacologic\JJ\1740 agents\NNS\7347 ,\,\1740 particularly\RB\1740 <e1>aminophylline</e1>\NN\2905612 ,\,\1740 may\MD\15209706 play\VB\1072262 a\DT\13649268 significant\JJ\1740 role\NN\719494 .\.\1740
3985451
D014859_D006470 NONE <e1>Warfarin-induced</e1>\JJ\1740 iliopsoas\NN\1740 <e2>hemorrhage</e2>\NN\14285662 with\IN\1740 subsequent\JJ\1740 femoral\JJ\1740 nerve\NN\5475681 palsy\NN\14557898 .\.\1740
D014859_D020428 CID <e1>Warfarin-induced</e1>\JJ\1740 iliopsoas\NN\1740 hemorrhage\NN\14285662 with\IN\1740 subsequent\JJ\1740 <e2>femoral\JJ\1740 nerve\NN\5475681 palsy</e2>\NN\14557898 .\.\1740
D014859_D020428 CID Anticoagulant-induced\JJ\1740 <e2>femoral\JJ\1740 nerve\NN\5475681 palsy</e2>\NN\14557898 represents\VBZ\2664769 the\DT\1740 most\RBS\1740 common\JJ\1740 form\NN\6286395 of\IN\1740 <e1>warfarin-induced</e1>\JJ\1740 peripheral\JJ\1740 neuropathy\NN\14204950 ;\:\1740 it\PRP\6125041 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 severe\JJ\1740 pain\NN\14299637 in\IN\13603305 the\DT\1740 inguinal\JJ\1740 region\NN\27167 ,\,\1740 varying\VBG\2666239 degrees\NNS\4916342 of\IN\1740 motor\NN\3699975 and\CC\1740 sensory\JJ\1740 impairment\NN\7296428 ,\,\1740 and\CC\1740 flexure\JJ\1740 contracture\NN\369802 of\IN\1740 the\DT\1740 involved\JJ\1740 extremity\NN\5225090 .\.\1740
D014859_D009135 CID We\PRP\1740 present\VBP\2137132 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 28-year-old\JJ\1740 man\NN\9605289 on\IN\1740 chronic\JJ\1740 <e1>warfarin</e1>\NN\2718259 therapy\NN\657604 who\WP\8299493 sustained\VBD\2679899 a\DT\13649268 minor\JJ\1740 <e2>muscle\NN\5289601 tear</e2>\NN\13771404 and\CC\1740 developed\VBD\1753788 increasing\VBG\169651 pain\NN\14299637 and\CC\1740 a\DT\13649268 flexure\JJ\1740 contracture\NN\369802 of\IN\1740 the\DT\1740 right\JJ\1740 hip\NN\5220461 .\.\1740
D014859_D010146 NONE We\PRP\1740 present\VBP\2137132 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 28-year-old\JJ\1740 man\NN\9605289 on\IN\1740 chronic\JJ\1740 <e1>warfarin</e1>\NN\2718259 therapy\NN\657604 who\WP\8299493 sustained\VBD\2679899 a\DT\13649268 minor\JJ\1740 muscle\NN\5289601 tear\NN\13771404 and\CC\1740 developed\VBD\1753788 increasing\VBG\169651 <e2>pain</e2>\NN\14299637 and\CC\1740 a\DT\13649268 flexure\JJ\1740 contracture\NN\369802 of\IN\1740 the\DT\1740 right\JJ\1740 hip\NN\5220461 .\.\1740
D014859_D010146 NONE Anticoagulant-induced\JJ\1740 femoral\JJ\1740 nerve\NN\5475681 palsy\NN\14557898 represents\VBZ\2664769 the\DT\1740 most\RBS\1740 common\JJ\1740 form\NN\6286395 of\IN\1740 <e1>warfarin-induced</e1>\JJ\1740 peripheral\JJ\1740 neuropathy\NN\14204950 ;\:\1740 it\PRP\6125041 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 severe\JJ\1740 <e2>pain</e2>\NN\14299637 in\IN\13603305 the\DT\1740 inguinal\JJ\1740 region\NN\27167 ,\,\1740 varying\VBG\2666239 degrees\NNS\4916342 of\IN\1740 motor\NN\3699975 and\CC\1740 sensory\JJ\1740 impairment\NN\7296428 ,\,\1740 and\CC\1740 flexure\JJ\1740 contracture\NN\369802 of\IN\1740 the\DT\1740 involved\JJ\1740 extremity\NN\5225090 .\.\1740
D014859_D003286 NONE We\PRP\1740 present\VBP\2137132 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 28-year-old\JJ\1740 man\NN\9605289 on\IN\1740 chronic\JJ\1740 <e1>warfarin</e1>\NN\2718259 therapy\NN\657604 who\WP\8299493 sustained\VBD\2679899 a\DT\13649268 minor\JJ\1740 muscle\NN\5289601 tear\NN\13771404 and\CC\1740 developed\VBD\1753788 increasing\VBG\169651 pain\NN\14299637 and\CC\1740 a\DT\13649268 flexure\JJ\1740 <e2>contracture</e2>\NN\369802 of\IN\1740 the\DT\1740 right\JJ\1740 hip\NN\5220461 .\.\1740
D014859_D003286 NONE Anticoagulant-induced\JJ\1740 femoral\JJ\1740 nerve\NN\5475681 palsy\NN\14557898 represents\VBZ\2664769 the\DT\1740 most\RBS\1740 common\JJ\1740 form\NN\6286395 of\IN\1740 <e1>warfarin-induced</e1>\JJ\1740 peripheral\JJ\1740 neuropathy\NN\14204950 ;\:\1740 it\PRP\6125041 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 severe\JJ\1740 pain\NN\14299637 in\IN\13603305 the\DT\1740 inguinal\JJ\1740 region\NN\27167 ,\,\1740 varying\VBG\2666239 degrees\NNS\4916342 of\IN\1740 motor\NN\3699975 and\CC\1740 sensory\JJ\1740 impairment\NN\7296428 ,\,\1740 and\CC\1740 flexure\JJ\1740 <e2>contracture</e2>\NN\369802 of\IN\1740 the\DT\1740 involved\JJ\1740 extremity\NN\5225090 .\.\1740
D014859_D010523 NONE Anticoagulant-induced\JJ\1740 femoral\JJ\1740 nerve\NN\5475681 palsy\NN\14557898 represents\VBZ\2664769 the\DT\1740 most\RBS\1740 common\JJ\1740 form\NN\6286395 of\IN\1740 <e1>warfarin-induced</e1>\JJ\1740 <e2>peripheral\JJ\1740 neuropathy</e2>\NN\14204950 ;\:\1740 it\PRP\6125041 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 severe\JJ\1740 pain\NN\14299637 in\IN\13603305 the\DT\1740 inguinal\JJ\1740 region\NN\27167 ,\,\1740 varying\VBG\2666239 degrees\NNS\4916342 of\IN\1740 motor\NN\3699975 and\CC\1740 sensory\JJ\1740 impairment\NN\7296428 ,\,\1740 and\CC\1740 flexure\JJ\1740 contracture\NN\369802 of\IN\1740 the\DT\1740 involved\JJ\1740 extremity\NN\5225090 .\.\1740
D014859_D015417 NONE Anticoagulant-induced\JJ\1740 femoral\JJ\1740 nerve\NN\5475681 palsy\NN\14557898 represents\VBZ\2664769 the\DT\1740 most\RBS\1740 common\JJ\1740 form\NN\6286395 of\IN\1740 <e1>warfarin-induced</e1>\JJ\1740 peripheral\JJ\1740 neuropathy\NN\14204950 ;\:\1740 it\PRP\6125041 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 severe\JJ\1740 pain\NN\14299637 in\IN\13603305 the\DT\1740 inguinal\JJ\1740 region\NN\27167 ,\,\1740 varying\VBG\2666239 degrees\NNS\4916342 of\IN\1740 <e2>motor\NN\3699975 and\CC\1740 sensory\JJ\1740 impairment</e2>\NN\7296428 ,\,\1740 and\CC\1740 flexure\JJ\1740 contracture\NN\369802 of\IN\1740 the\DT\1740 involved\JJ\1740 extremity\NN\5225090 .\.\1740
19356053
D020123_D011507 CID Clinically\RB\1740 significant\JJ\1740 <e2>proteinuria</e2>\NN\14299637 following\VBG\1835496 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>sirolimus</e1>\NN\1740 to\TO\1740 renal\JJ\1740 transplant\NN\5267548 recipients\NNS\9764201 .\.\1740
D020123_D011507 CID To\IN\1740 date\NN\15155220 there\EX\27167 has\VBZ\2108377 been\VBN\836236 little\JJ\1740 documentation\NN\6650070 of\IN\1740 clinically\RB\1740 significant\JJ\1740 <e2>proteinuria</e2>\NN\14299637 linked\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>sirolimus</e1>\NN\1740 .\.\1740
D020123_D011507 CID We\PRP\1740 have\VBP\2108377 encountered\VBN\2604760 several\JJ\1740 patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 substantial\JJ\1740 <e2>proteinuria</e2>\NN\14299637 associated\VBN\628491 with\IN\1740 <e1>sirolimus</e1>\NN\1740 use\NN\407535 .\.\1740
D020123_D011507 CID In\IN\13603305 each\DT\1740 patient\NN\9898892 ,\,\1740 the\DT\1740 close\JJ\1740 temporal\JJ\1740 association\NN\8008335 between\IN\1740 the\DT\1740 commencement\NN\15180528 of\IN\1740 <e1>sirolimus</e1>\NN\1740 therapy\NN\657604 and\CC\1740 <e2>proteinuria</e2>\NN\14299637 implicated\VBD\2677097 sirolimus\NN\1740 as\IN\14622893 the\DT\1740 most\RBS\1740 likely\JJ\1740 etiology\NN\7326557 of\IN\1740 the\DT\1740 proteinuria\NN\14299637 .\.\1740
D020123_D011507 CID In\IN\13603305 each\DT\1740 patient\NN\9898892 ,\,\1740 the\DT\1740 close\JJ\1740 temporal\JJ\1740 association\NN\8008335 between\IN\1740 the\DT\1740 commencement\NN\15180528 of\IN\1740 <e1>sirolimus</e1>\NN\1740 therapy\NN\657604 and\CC\1740 proteinuria\NN\14299637 implicated\VBD\2677097 sirolimus\NN\1740 as\IN\14622893 the\DT\1740 most\RBS\1740 likely\JJ\1740 etiology\NN\7326557 of\IN\1740 the\DT\1740 <e2>proteinuria</e2>\NN\14299637 .\.\1740
D020123_D011507 CID In\IN\13603305 each\DT\1740 patient\NN\9898892 ,\,\1740 the\DT\1740 close\JJ\1740 temporal\JJ\1740 association\NN\8008335 between\IN\1740 the\DT\1740 commencement\NN\15180528 of\IN\1740 sirolimus\NN\1740 therapy\NN\657604 and\CC\1740 <e2>proteinuria</e2>\NN\14299637 implicated\VBD\2677097 <e1>sirolimus</e1>\NN\1740 as\IN\14622893 the\DT\1740 most\RBS\1740 likely\JJ\1740 etiology\NN\7326557 of\IN\1740 the\DT\1740 proteinuria\NN\14299637 .\.\1740
D020123_D011507 CID In\IN\13603305 each\DT\1740 patient\NN\9898892 ,\,\1740 the\DT\1740 close\JJ\1740 temporal\JJ\1740 association\NN\8008335 between\IN\1740 the\DT\1740 commencement\NN\15180528 of\IN\1740 sirolimus\NN\1740 therapy\NN\657604 and\CC\1740 proteinuria\NN\14299637 implicated\VBD\2677097 <e1>sirolimus</e1>\NN\1740 as\IN\14622893 the\DT\1740 most\RBS\1740 likely\JJ\1740 etiology\NN\7326557 of\IN\1740 the\DT\1740 <e2>proteinuria</e2>\NN\14299637 .\.\1740
D020123_D011507 CID In\IN\13603305 7\CD\13741022 of\IN\1740 the\DT\1740 28\CD\13745420 patients\NNS\9898892 there\EX\27167 was\VBD\836236 a\DT\13649268 striking\JJ\1740 temporal\JJ\1740 association\NN\8008335 between\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 <e1>sirolimus</e1>\NN\1740 and\CC\1740 the\DT\1740 development\NN\248977 of\IN\1740 nephrotic-range\JJ\1740 <e2>proteinuria</e2>\NN\14299637 .\.\1740
D020123_D011507 CID <e2>Proteinuria</e2>\NNP\14299637 correlated\VBD\2657219 most\RBS\1740 strongly\RB\1740 with\IN\1740 <e1>sirolimus</e1>\NN\1740 therapy\NN\657604 when\WRB\1740 compared\VBN\644583 to\TO\1740 other\JJ\1740 demographic\NN\6021499 and\CC\1740 clinical\JJ\1740 variables\NNS\2452 .\.\1740
D020123_D011507 CID In\IN\13603305 most\JJS\1740 patients\NNS\9898892 ,\,\1740 discontinuation\NN\209943 of\IN\1740 <e1>sirolimus</e1>\NN\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 decrease\NN\7296428 ,\,\1740 but\CC\1740 not\RB\1740 resolution\NN\6470073 ,\,\1740 of\IN\1740 <e2>proteinuria</e2>\NN\14299637 .\.\1740
D020123_D011507 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Sirolimus</e1>\NN\1740 induces\VBZ\1627355 or\CC\3541091 aggravates\VBZ\126264 pre-existing\JJ\1740 <e2>proteinuria</e2>\NN\14299637 in\IN\13603305 an\DT\6697703 unpredictable\JJ\1740 subset\NN\7999699 of\IN\1740 renal\JJ\1740 allograft\NN\5582859 recipients\NNS\9764201 .\.\1740
D020123_D011507 CID <e2>Proteinuria</e2>\NNP\14299637 may\MD\15209706 improve\VB\126264 ,\,\1740 but\CC\1740 does\VBZ\1640855 not\RB\1740 resolve\VB\352826 ,\,\1740 when\WRB\1740 <e1>sirolimus</e1>\NN\1740 is\VBZ\836236 withdrawn\VBN\1835496 .\.\1740
D020123_D007674 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Sirolimus</e1>\NN\1740 is\VBZ\836236 the\DT\1740 latest\JJS\1740 immunosuppressive\JJ\1740 agent\NN\7347 used\VBN\1156834 to\TO\1740 prevent\VB\1740 rejection\NN\30358 ,\,\1740 and\CC\1740 may\MD\15209706 have\VB\2108377 less\JJR\1740 <e2>nephrotoxicity</e2>\NN\1740 than\IN\1740 calcineurin\NN\1740 inhibitor\NN\20090 (CNI)-based\VBN\1740 regimens\NNS\5898568 .\.\1740
D003404_D011507 NONE In\IN\13603305 these\DT\1740 patients\NNS\9898892 ,\,\1740 the\DT\1740 magnitude\NN\4916342 of\IN\1740 <e2>proteinuria</e2>\NN\14299637 was\VBD\836236 assessed\VBN\670261 on\IN\1740 morning\NN\15113229 urine\NN\14853947 samples\NNS\5820620 by\IN\1740 turbidometric\JJ\1740 measurement\NN\407535 or\CC\3541091 random\JJ\1740 urine\NN\14853947 protein\NN\14944888 :\:\1740 <e1>creatinine</e1>\NN\1740 ratios\NNS\13815152 ,\,\1740 an\DT\6697703 estimate\NN\5802185 of\IN\1740 grams\NNS\13717155 of\IN\1740 proteinuria/day\NN\1740 .\.\1740
D003404_D011507 NONE In\IN\13603305 these\DT\1740 patients\NNS\9898892 ,\,\1740 the\DT\1740 magnitude\NN\4916342 of\IN\1740 proteinuria\NN\14299637 was\VBD\836236 assessed\VBN\670261 on\IN\1740 morning\NN\15113229 urine\NN\14853947 samples\NNS\5820620 by\IN\1740 turbidometric\JJ\1740 measurement\NN\407535 or\CC\3541091 random\JJ\1740 urine\NN\14853947 protein\NN\14944888 :\:\1740 <e1>creatinine</e1>\NN\1740 ratios\NNS\13815152 ,\,\1740 an\DT\6697703 estimate\NN\5802185 of\IN\1740 grams\NNS\13717155 of\IN\1740 <e2>proteinuria/day</e2>\NN\1740 .\.\1740
D020123_D009404 NONE In\IN\13603305 7\CD\13741022 of\IN\1740 the\DT\1740 28\CD\13745420 patients\NNS\9898892 there\EX\27167 was\VBD\836236 a\DT\13649268 striking\JJ\1740 temporal\JJ\1740 association\NN\8008335 between\IN\1740 the\DT\1740 initiation\NN\7450842 of\IN\1740 <e1>sirolimus</e1>\NN\1740 and\CC\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>nephrotic-range</e2>\JJ\1740 proteinuria\NN\14299637 .\.\1740
7802851
D000525_D016584 NONE The\DT\1740 efficacy\NN\5199286 of\IN\1740 <e1>alprazolam</e1>\NNS\2830852 and\CC\1740 placebo\NN\3740161 in\IN\13603305 <e2>panic\JJ\1740 disorder</e2>\NN\14034177 with\IN\1740 agoraphobia\NN\14381416 ,\,\1740 and\CC\1740 the\DT\1740 side-effect\JJ\1740 and\CC\1740 adverse\JJ\1740 effect\NN\34213 profiles\NNS\6999802 of\IN\1740 both\DT\1740 drug\NN\14778436 groups\NNS\2137 were\VBD\836236 measured\VBN\697589 .\.\1740
D000525_D016584 NONE METHOD\NNP\5616786 :\:\1740 In\IN\13603305 London\NNP\1740 and\CC\1740 Toronto\NNP\1740 154\CD\1740 patients\NNS\9898892 who\WP\8299493 met\VBD\1182709 DSM-III\NN\1740 criteria\NNS\13577171 for\IN\1740 <e2>panic\JJ\1740 disorder</e2>\NN\14034177 with\IN\1740 agoraphobia\NN\14381416 were\VBD\836236 randomised\VBN\278117 to\TO\1740 <e1>alprazolam</e1>\NNS\2830852 or\CC\3541091 placebo\NN\3740161 .\.\1740
D000525_D000379 NONE The\DT\1740 efficacy\NN\5199286 of\IN\1740 <e1>alprazolam</e1>\NNS\2830852 and\CC\1740 placebo\NN\3740161 in\IN\13603305 panic\JJ\1740 disorder\NN\14034177 with\IN\1740 <e2>agoraphobia</e2>\NN\14381416 ,\,\1740 and\CC\1740 the\DT\1740 side-effect\JJ\1740 and\CC\1740 adverse\JJ\1740 effect\NN\34213 profiles\NNS\6999802 of\IN\1740 both\DT\1740 drug\NN\14778436 groups\NNS\2137 were\VBD\836236 measured\VBN\697589 .\.\1740
D000525_D000379 NONE METHOD\NNP\5616786 :\:\1740 In\IN\13603305 London\NNP\1740 and\CC\1740 Toronto\NNP\1740 154\CD\1740 patients\NNS\9898892 who\WP\8299493 met\VBD\1182709 DSM-III\NN\1740 criteria\NNS\13577171 for\IN\1740 panic\JJ\1740 disorder\NN\14034177 with\IN\1740 <e2>agoraphobia</e2>\NN\14381416 were\VBD\836236 randomised\VBN\278117 to\TO\1740 <e1>alprazolam</e1>\NNS\2830852 or\CC\3541091 placebo\NN\3740161 .\.\1740
D000525_D003866 CID Compared\VBN\644583 with\IN\1740 placebo\JJ\1740 subjects\NNS\6598915 ,\,\1740 <e1>alprazolam</e1>\NN\2830852 patients\NNS\9898892 developed\VBD\1753788 more\JJR\1740 adverse\JJ\1740 reactions\NNS\13446390 (\-LRB-\1740 21\CD\13745420 %\NN\1740 v.\NN\1740 0\CD\13741022 %\NN\1740 )\-RRB-\1740 of\IN\1740 <e2>depression</e2>\NN\14373582 ,\,\1740 enuresis\NN\13496972 ,\,\1740 disinhibition\NN\1740 and\CC\1740 aggression\NN\4657876 ;\:\1740 and\CC\1740 more\JJR\1740 side-effects\NNS\1740 ,\,\1740 particularly\RB\1740 sedation\NN\14034177 ,\,\1740 irritability\NN\7552087 ,\,\1740 impaired\JJ\1740 memory\NN\5926676 ,\,\1740 weight\NN\5009170 loss\NN\13252973 and\CC\1740 ataxia\NN\14084880 .\.\1740
D000525_D004775 CID Compared\VBN\644583 with\IN\1740 placebo\JJ\1740 subjects\NNS\6598915 ,\,\1740 <e1>alprazolam</e1>\NN\2830852 patients\NNS\9898892 developed\VBD\1753788 more\JJR\1740 adverse\JJ\1740 reactions\NNS\13446390 (\-LRB-\1740 21\CD\13745420 %\NN\1740 v.\NN\1740 0\CD\13741022 %\NN\1740 )\-RRB-\1740 of\IN\1740 depression\NN\14373582 ,\,\1740 <e2>enuresis</e2>\NN\13496972 ,\,\1740 disinhibition\NN\1740 and\CC\1740 aggression\NN\4657876 ;\:\1740 and\CC\1740 more\JJR\1740 side-effects\NNS\1740 ,\,\1740 particularly\RB\1740 sedation\NN\14034177 ,\,\1740 irritability\NN\7552087 ,\,\1740 impaired\JJ\1740 memory\NN\5926676 ,\,\1740 weight\NN\5009170 loss\NN\13252973 and\CC\1740 ataxia\NN\14084880 .\.\1740
D000525_D001523 NONE Compared\VBN\644583 with\IN\1740 placebo\JJ\1740 subjects\NNS\6598915 ,\,\1740 <e1>alprazolam</e1>\NN\2830852 patients\NNS\9898892 developed\VBD\1753788 more\JJR\1740 adverse\JJ\1740 reactions\NNS\13446390 (\-LRB-\1740 21\CD\13745420 %\NN\1740 v.\NN\1740 0\CD\13741022 %\NN\1740 )\-RRB-\1740 of\IN\1740 depression\NN\14373582 ,\,\1740 enuresis\NN\13496972 ,\,\1740 disinhibition\NN\1740 and\CC\1740 <e2>aggression</e2>\NN\4657876 ;\:\1740 and\CC\1740 more\JJR\1740 side-effects\NNS\1740 ,\,\1740 particularly\RB\1740 sedation\NN\14034177 ,\,\1740 irritability\NN\7552087 ,\,\1740 impaired\JJ\1740 memory\NN\5926676 ,\,\1740 weight\NN\5009170 loss\NN\13252973 and\CC\1740 ataxia\NN\14084880 .\.\1740
D000525_D001523 NONE Compared\VBN\644583 with\IN\1740 placebo\JJ\1740 subjects\NNS\6598915 ,\,\1740 <e1>alprazolam</e1>\NN\2830852 patients\NNS\9898892 developed\VBD\1753788 more\JJR\1740 adverse\JJ\1740 reactions\NNS\13446390 (\-LRB-\1740 21\CD\13745420 %\NN\1740 v.\NN\1740 0\CD\13741022 %\NN\1740 )\-RRB-\1740 of\IN\1740 depression\NN\14373582 ,\,\1740 enuresis\NN\13496972 ,\,\1740 disinhibition\NN\1740 and\CC\1740 aggression\NN\4657876 ;\:\1740 and\CC\1740 more\JJR\1740 side-effects\NNS\1740 ,\,\1740 particularly\RB\1740 sedation\NN\14034177 ,\,\1740 <e2>irritability</e2>\NN\7552087 ,\,\1740 impaired\JJ\1740 memory\NN\5926676 ,\,\1740 weight\NN\5009170 loss\NN\13252973 and\CC\1740 ataxia\NN\14084880 .\.\1740
D000525_D008569 CID Compared\VBN\644583 with\IN\1740 placebo\JJ\1740 subjects\NNS\6598915 ,\,\1740 <e1>alprazolam</e1>\NN\2830852 patients\NNS\9898892 developed\VBD\1753788 more\JJR\1740 adverse\JJ\1740 reactions\NNS\13446390 (\-LRB-\1740 21\CD\13745420 %\NN\1740 v.\NN\1740 0\CD\13741022 %\NN\1740 )\-RRB-\1740 of\IN\1740 depression\NN\14373582 ,\,\1740 enuresis\NN\13496972 ,\,\1740 disinhibition\NN\1740 and\CC\1740 aggression\NN\4657876 ;\:\1740 and\CC\1740 more\JJR\1740 side-effects\NNS\1740 ,\,\1740 particularly\RB\1740 sedation\NN\14034177 ,\,\1740 irritability\NN\7552087 ,\,\1740 <e2>impaired\JJ\1740 memory</e2>\NN\5926676 ,\,\1740 weight\NN\5009170 loss\NN\13252973 and\CC\1740 ataxia\NN\14084880 .\.\1740
D000525_D015431 CID Compared\VBN\644583 with\IN\1740 placebo\JJ\1740 subjects\NNS\6598915 ,\,\1740 <e1>alprazolam</e1>\NN\2830852 patients\NNS\9898892 developed\VBD\1753788 more\JJR\1740 adverse\JJ\1740 reactions\NNS\13446390 (\-LRB-\1740 21\CD\13745420 %\NN\1740 v.\NN\1740 0\CD\13741022 %\NN\1740 )\-RRB-\1740 of\IN\1740 depression\NN\14373582 ,\,\1740 enuresis\NN\13496972 ,\,\1740 disinhibition\NN\1740 and\CC\1740 aggression\NN\4657876 ;\:\1740 and\CC\1740 more\JJR\1740 side-effects\NNS\1740 ,\,\1740 particularly\RB\1740 sedation\NN\14034177 ,\,\1740 irritability\NN\7552087 ,\,\1740 impaired\JJ\1740 memory\NN\5926676 ,\,\1740 <e2>weight\NN\5009170 loss</e2>\NN\13252973 and\CC\1740 ataxia\NN\14084880 .\.\1740
D000525_D001259 CID Compared\VBN\644583 with\IN\1740 placebo\JJ\1740 subjects\NNS\6598915 ,\,\1740 <e1>alprazolam</e1>\NN\2830852 patients\NNS\9898892 developed\VBD\1753788 more\JJR\1740 adverse\JJ\1740 reactions\NNS\13446390 (\-LRB-\1740 21\CD\13745420 %\NN\1740 v.\NN\1740 0\CD\13741022 %\NN\1740 )\-RRB-\1740 of\IN\1740 depression\NN\14373582 ,\,\1740 enuresis\NN\13496972 ,\,\1740 disinhibition\NN\1740 and\CC\1740 aggression\NN\4657876 ;\:\1740 and\CC\1740 more\JJR\1740 side-effects\NNS\1740 ,\,\1740 particularly\RB\1740 sedation\NN\14034177 ,\,\1740 irritability\NN\7552087 ,\,\1740 impaired\JJ\1740 memory\NN\5926676 ,\,\1740 weight\NN\5009170 loss\NN\13252973 and\CC\1740 <e2>ataxia</e2>\NN\14084880 .\.\1740
6503301
D003606_D006504 CID <e2>Veno-occlusive\JJ\1740 liver\NN\5298729 disease</e2>\NN\14061805 after\IN\1740 <e1>dacarbazine</e1>\NN\1740 therapy\NN\657604 (\-LRB-\1740 DTIC\NN\8337324 )\-RRB-\1740 for\IN\1740 melanoma\NN\14252320 .\.\1740
D003606_D006504 CID <e2>Veno-occlusive\JJ\1740 liver\NN\5298729 disease</e2>\NN\14061805 after\IN\1740 dacarbazine\NN\1740 therapy\NN\657604 (\-LRB-\1740 <e1>DTIC</e1>\NN\8337324 )\-RRB-\1740 for\IN\1740 melanoma\NN\14252320 .\.\1740
D003606_D006504 CID A\DT\13649268 case\NN\7283608 of\IN\1740 <e2>veno-occlusive\JJ\1740 disease\NN\14061805 of\IN\1740 the\DT\1740 liver</e2>\NN\5298729 with\IN\1740 fatal\JJ\1740 outcome\NN\7291312 after\IN\1740 <e1>dacarbazine</e1>\NN\1740 (\-LRB-\1740 DTIC\NN\8337324 )\-RRB-\1740 therapy\NN\657604 for\IN\1740 melanoma\NN\14252320 is\VBZ\836236 reported\VBN\831651 .\.\1740
D003606_D006504 CID A\DT\13649268 case\NN\7283608 of\IN\1740 <e2>veno-occlusive\JJ\1740 disease\NN\14061805 of\IN\1740 the\DT\1740 liver</e2>\NN\5298729 with\IN\1740 fatal\JJ\1740 outcome\NN\7291312 after\IN\1740 dacarbazine\NN\1740 (\-LRB-\1740 <e1>DTIC</e1>\NN\8337324 )\-RRB-\1740 therapy\NN\657604 for\IN\1740 melanoma\NN\14252320 is\VBZ\836236 reported\VBN\831651 .\.\1740
D003606_D008545 NONE Veno-occlusive\JJ\1740 liver\NN\5298729 disease\NN\14061805 after\IN\1740 <e1>dacarbazine</e1>\NN\1740 therapy\NN\657604 (\-LRB-\1740 DTIC\NN\8337324 )\-RRB-\1740 for\IN\1740 <e2>melanoma</e2>\NN\14252320 .\.\1740
D003606_D008545 NONE Veno-occlusive\JJ\1740 liver\NN\5298729 disease\NN\14061805 after\IN\1740 dacarbazine\NN\1740 therapy\NN\657604 (\-LRB-\1740 <e1>DTIC</e1>\NN\8337324 )\-RRB-\1740 for\IN\1740 <e2>melanoma</e2>\NN\14252320 .\.\1740
D003606_D008545 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 veno-occlusive\JJ\1740 disease\NN\14061805 of\IN\1740 the\DT\1740 liver\NN\5298729 with\IN\1740 fatal\JJ\1740 outcome\NN\7291312 after\IN\1740 <e1>dacarbazine</e1>\NN\1740 (\-LRB-\1740 DTIC\NN\8337324 )\-RRB-\1740 therapy\NN\657604 for\IN\1740 <e2>melanoma</e2>\NN\14252320 is\VBZ\836236 reported\VBN\831651 .\.\1740
D003606_D008545 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 veno-occlusive\JJ\1740 disease\NN\14061805 of\IN\1740 the\DT\1740 liver\NN\5298729 with\IN\1740 fatal\JJ\1740 outcome\NN\7291312 after\IN\1740 dacarbazine\NN\1740 (\-LRB-\1740 <e1>DTIC</e1>\NN\8337324 )\-RRB-\1740 therapy\NN\657604 for\IN\1740 <e2>melanoma</e2>\NN\14252320 is\VBZ\836236 reported\VBN\831651 .\.\1740
3714122
C005238_D020258 NONE The\DT\1740 correlation\NN\13841213 between\IN\1740 <e2>neurotoxic</e2>\JJ\1740 esterase\NN\1740 inhibition\NN\1068773 and\CC\1740 <e1>mipafox-induced</e1>\JJ\1740 neuropathic\JJ\1740 damage\NN\7296428 in\IN\13603305 rats\NNS\2329401 .\.\1740
C005238_D020258 NONE The\DT\1740 correlation\NN\13841213 between\IN\1740 neuropathic\JJ\1740 damage\NN\7296428 and\CC\1740 inhibition\NN\1068773 of\IN\1740 <e2>neurotoxic</e2>\JJ\1740 esterase\NN\1740 or\CC\3541091 neuropathy\JJ\1740 target\NN\7258332 enzyme\NN\14723628 (\-LRB-\1740 NTE\NN\1740 )\-RRB-\1740 was\VBD\836236 examined\VBN\789138 in\IN\13603305 rats\NNS\2329401 acutely\RB\1740 exposed\VBN\2110927 to\IN\1740 <e1>Mipafox</e1>\NNP\1740 (\-LRB-\1740 N\NN\14622893 ,\,\1740 N'-diisopropylphosphorodiamidofluoridate\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 neurotoxic\JJ\1740 organophosphate\NN\14919948 .\.\1740
C005238_D020258 NONE The\DT\1740 correlation\NN\13841213 between\IN\1740 neuropathic\JJ\1740 damage\NN\7296428 and\CC\1740 inhibition\NN\1068773 of\IN\1740 neurotoxic\JJ\1740 esterase\NN\1740 or\CC\3541091 neuropathy\JJ\1740 target\NN\7258332 enzyme\NN\14723628 (\-LRB-\1740 NTE\NN\1740 )\-RRB-\1740 was\VBD\836236 examined\VBN\789138 in\IN\13603305 rats\NNS\2329401 acutely\RB\1740 exposed\VBN\2110927 to\IN\1740 <e1>Mipafox</e1>\NNP\1740 (\-LRB-\1740 N\NN\14622893 ,\,\1740 N'-diisopropylphosphorodiamidofluoridate\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 <e2>neurotoxic</e2>\JJ\1740 organophosphate\NN\14919948 .\.\1740
C005238_D020258 NONE The\DT\1740 correlation\NN\13841213 between\IN\1740 neuropathic\JJ\1740 damage\NN\7296428 and\CC\1740 inhibition\NN\1068773 of\IN\1740 <e2>neurotoxic</e2>\JJ\1740 esterase\NN\1740 or\CC\3541091 neuropathy\JJ\1740 target\NN\7258332 enzyme\NN\14723628 (\-LRB-\1740 NTE\NN\1740 )\-RRB-\1740 was\VBD\836236 examined\VBN\789138 in\IN\13603305 rats\NNS\2329401 acutely\RB\1740 exposed\VBN\2110927 to\IN\1740 Mipafox\NNP\1740 (\-LRB-\1740 <e1>N\NN\14622893 ,\,\1740 N'-diisopropylphosphorodiamidofluoridate</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 neurotoxic\JJ\1740 organophosphate\NN\14919948 .\.\1740
C005238_D020258 NONE The\DT\1740 correlation\NN\13841213 between\IN\1740 neuropathic\JJ\1740 damage\NN\7296428 and\CC\1740 inhibition\NN\1068773 of\IN\1740 neurotoxic\JJ\1740 esterase\NN\1740 or\CC\3541091 neuropathy\JJ\1740 target\NN\7258332 enzyme\NN\14723628 (\-LRB-\1740 NTE\NN\1740 )\-RRB-\1740 was\VBD\836236 examined\VBN\789138 in\IN\13603305 rats\NNS\2329401 acutely\RB\1740 exposed\VBN\2110927 to\IN\1740 Mipafox\NNP\1740 (\-LRB-\1740 <e1>N\NN\14622893 ,\,\1740 N'-diisopropylphosphorodiamidofluoridate</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 <e2>neurotoxic</e2>\JJ\1740 organophosphate\NN\14919948 .\.\1740
C005238_D009422 NONE The\DT\1740 correlation\NN\13841213 between\IN\1740 neurotoxic\JJ\1740 esterase\NN\1740 inhibition\NN\1068773 and\CC\1740 <e1>mipafox-induced</e1>\JJ\1740 <e2>neuropathic\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 rats\NNS\2329401 .\.\1740
C005238_D009422 NONE The\DT\1740 correlation\NN\13841213 between\IN\1740 <e2>neuropathic\JJ\1740 damage</e2>\NN\7296428 and\CC\1740 inhibition\NN\1068773 of\IN\1740 neurotoxic\JJ\1740 esterase\NN\1740 or\CC\3541091 neuropathy\JJ\1740 target\NN\7258332 enzyme\NN\14723628 (\-LRB-\1740 NTE\NN\1740 )\-RRB-\1740 was\VBD\836236 examined\VBN\789138 in\IN\13603305 rats\NNS\2329401 acutely\RB\1740 exposed\VBN\2110927 to\IN\1740 <e1>Mipafox</e1>\NNP\1740 (\-LRB-\1740 N\NN\14622893 ,\,\1740 N'-diisopropylphosphorodiamidofluoridate\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 neurotoxic\JJ\1740 organophosphate\NN\14919948 .\.\1740
C005238_D009422 NONE The\DT\1740 correlation\NN\13841213 between\IN\1740 neuropathic\JJ\1740 damage\NN\7296428 and\CC\1740 inhibition\NN\1068773 of\IN\1740 neurotoxic\JJ\1740 esterase\NN\1740 or\CC\3541091 <e2>neuropathy</e2>\JJ\1740 target\NN\7258332 enzyme\NN\14723628 (\-LRB-\1740 NTE\NN\1740 )\-RRB-\1740 was\VBD\836236 examined\VBN\789138 in\IN\13603305 rats\NNS\2329401 acutely\RB\1740 exposed\VBN\2110927 to\IN\1740 <e1>Mipafox</e1>\NNP\1740 (\-LRB-\1740 N\NN\14622893 ,\,\1740 N'-diisopropylphosphorodiamidofluoridate\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 neurotoxic\JJ\1740 organophosphate\NN\14919948 .\.\1740
C005238_D009422 NONE The\DT\1740 correlation\NN\13841213 between\IN\1740 <e2>neuropathic\JJ\1740 damage</e2>\NN\7296428 and\CC\1740 inhibition\NN\1068773 of\IN\1740 neurotoxic\JJ\1740 esterase\NN\1740 or\CC\3541091 neuropathy\JJ\1740 target\NN\7258332 enzyme\NN\14723628 (\-LRB-\1740 NTE\NN\1740 )\-RRB-\1740 was\VBD\836236 examined\VBN\789138 in\IN\13603305 rats\NNS\2329401 acutely\RB\1740 exposed\VBN\2110927 to\IN\1740 Mipafox\NNP\1740 (\-LRB-\1740 <e1>N\NN\14622893 ,\,\1740 N'-diisopropylphosphorodiamidofluoridate</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 neurotoxic\JJ\1740 organophosphate\NN\14919948 .\.\1740
C005238_D009422 NONE The\DT\1740 correlation\NN\13841213 between\IN\1740 neuropathic\JJ\1740 damage\NN\7296428 and\CC\1740 inhibition\NN\1068773 of\IN\1740 neurotoxic\JJ\1740 esterase\NN\1740 or\CC\3541091 <e2>neuropathy</e2>\JJ\1740 target\NN\7258332 enzyme\NN\14723628 (\-LRB-\1740 NTE\NN\1740 )\-RRB-\1740 was\VBD\836236 examined\VBN\789138 in\IN\13603305 rats\NNS\2329401 acutely\RB\1740 exposed\VBN\2110927 to\IN\1740 Mipafox\NNP\1740 (\-LRB-\1740 <e1>N\NN\14622893 ,\,\1740 N'-diisopropylphosphorodiamidofluoridate</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 neurotoxic\JJ\1740 organophosphate\NN\14919948 .\.\1740
C005238_D009422 NONE These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 a\DT\13649268 critical\JJ\1740 percentage\NN\13815742 of\IN\1740 NTE\NN\1740 inhibition\NN\1068773 in\IN\13603305 brain\NN\5462674 and\CC\1740 spinal\JJ\1740 cord\NN\3670849 sampled\VBN\1156834 shortly\RB\1740 after\IN\1740 <e1>Mipafox</e1>\NNP\1740 exposure\NN\5042871 can\MD\3094503 predict\VB\916909 <e2>neuropathic\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 rats\NNS\2329401 several\JJ\1740 weeks\NNS\15113229 later\RB\1740 .\.\1740
D010755_D009422 NONE The\DT\1740 correlation\NN\13841213 between\IN\1740 <e2>neuropathic\JJ\1740 damage</e2>\NN\7296428 and\CC\1740 inhibition\NN\1068773 of\IN\1740 neurotoxic\JJ\1740 esterase\NN\1740 or\CC\3541091 neuropathy\JJ\1740 target\NN\7258332 enzyme\NN\14723628 (\-LRB-\1740 NTE\NN\1740 )\-RRB-\1740 was\VBD\836236 examined\VBN\789138 in\IN\13603305 rats\NNS\2329401 acutely\RB\1740 exposed\VBN\2110927 to\IN\1740 Mipafox\NNP\1740 (\-LRB-\1740 N\NN\14622893 ,\,\1740 N'-diisopropylphosphorodiamidofluoridate\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 neurotoxic\JJ\1740 <e1>organophosphate</e1>\NN\14919948 .\.\1740
D010755_D009422 NONE The\DT\1740 correlation\NN\13841213 between\IN\1740 neuropathic\JJ\1740 damage\NN\7296428 and\CC\1740 inhibition\NN\1068773 of\IN\1740 neurotoxic\JJ\1740 esterase\NN\1740 or\CC\3541091 <e2>neuropathy</e2>\JJ\1740 target\NN\7258332 enzyme\NN\14723628 (\-LRB-\1740 NTE\NN\1740 )\-RRB-\1740 was\VBD\836236 examined\VBN\789138 in\IN\13603305 rats\NNS\2329401 acutely\RB\1740 exposed\VBN\2110927 to\IN\1740 Mipafox\NNP\1740 (\-LRB-\1740 N\NN\14622893 ,\,\1740 N'-diisopropylphosphorodiamidofluoridate\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 neurotoxic\JJ\1740 <e1>organophosphate</e1>\NN\14919948 .\.\1740
D010755_D020258 NONE The\DT\1740 correlation\NN\13841213 between\IN\1740 neuropathic\JJ\1740 damage\NN\7296428 and\CC\1740 inhibition\NN\1068773 of\IN\1740 <e2>neurotoxic</e2>\JJ\1740 esterase\NN\1740 or\CC\3541091 neuropathy\JJ\1740 target\NN\7258332 enzyme\NN\14723628 (\-LRB-\1740 NTE\NN\1740 )\-RRB-\1740 was\VBD\836236 examined\VBN\789138 in\IN\13603305 rats\NNS\2329401 acutely\RB\1740 exposed\VBN\2110927 to\IN\1740 Mipafox\NNP\1740 (\-LRB-\1740 N\NN\14622893 ,\,\1740 N'-diisopropylphosphorodiamidofluoridate\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 neurotoxic\JJ\1740 <e1>organophosphate</e1>\NN\14919948 .\.\1740
D010755_D020258 NONE The\DT\1740 correlation\NN\13841213 between\IN\1740 neuropathic\JJ\1740 damage\NN\7296428 and\CC\1740 inhibition\NN\1068773 of\IN\1740 neurotoxic\JJ\1740 esterase\NN\1740 or\CC\3541091 neuropathy\JJ\1740 target\NN\7258332 enzyme\NN\14723628 (\-LRB-\1740 NTE\NN\1740 )\-RRB-\1740 was\VBD\836236 examined\VBN\789138 in\IN\13603305 rats\NNS\2329401 acutely\RB\1740 exposed\VBN\2110927 to\IN\1740 Mipafox\NNP\1740 (\-LRB-\1740 N\NN\14622893 ,\,\1740 N'-diisopropylphosphorodiamidofluoridate\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 <e2>neurotoxic</e2>\JJ\1740 <e1>organophosphate</e1>\NN\14919948 .\.\1740
C005238_D013118 CID In\IN\13603305 contrast\NN\13854649 ,\,\1740 dosages\NNS\13576355 of\IN\1740 <e1>Mipafox</e1>\NNP\1740 (\-LRB-\1740 less\JJR\1740 than\IN\1740 or\CC\3541091 equal\JJ\1740 to\TO\1740 5\CD\13741022 mg/kg\NN\1740 )\-RRB-\1740 which\WDT\1740 inhibited\VBD\2510337 mean\NN\6021761 NTE\NN\1740 activity\NN\30358 in\IN\13603305 spinal\JJ\1740 cord\NN\3670849 less\JJR\1740 than\IN\1740 or\CC\3541091 equal\JJ\1740 to\TO\1740 61\CD\1740 %\NN\1740 and\CC\1740 brain\NN\5462674 less\JJR\1740 than\IN\1740 or\CC\3541091 equal\JJ\1740 to\TO\1740 60\CD\13745420 %\NN\1740 produced\VBD\1617192 this\DT\1740 degree\NN\4916342 of\IN\1740 <e2>cord\NN\3670849 damage</e2>\NN\7296428 in\IN\13603305 only\RB\1740 9\CD\13741022 %\NN\1740 of\IN\1740 the\DT\1740 animals\NNS\4475 .\.\1740
2559236
D004317_D007674 NONE Effect\NN\34213 of\IN\1740 converting\VBG\126264 enzyme\NN\14723628 inhibition\NN\1068773 on\IN\1740 the\DT\1740 course\NN\883297 of\IN\1740 <e1>adriamycin-induced</e1>\JJ\1740 <e2>nephropathy</e2>\NN\14573196 .\.\1740
D004317_D007674 NONE Groups\NNS\2137 3\CD\13741022 and\CC\1740 4\CD\13741022 were\VBD\836236 studied\VBN\630380 at\IN\14622893 four\CD\13741022 and\CC\1740 at\IN\14622893 six\CD\13741022 months\NNS\15113229 to\TO\1740 assess\VB\670261 the\DT\1740 effect\NN\34213 of\IN\1740 enalapril\NN\2673637 on\IN\1740 progression\NN\8457976 of\IN\1740 <e2>renal\JJ\1740 injury</e2>\NN\14052046 in\IN\13603305 <e1>adriamycin</e1>\NN\1740 nephrosis\NN\14304060 .\.\1740
D004656_D009401 NONE The\DT\1740 effect\NN\34213 of\IN\1740 the\DT\1740 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 (\-LRB-\1740 CEI\NN\1740 )\-RRB-\1740 <e1>enalapril</e1>\NN\2673637 was\VBD\836236 assessed\VBN\670261 in\IN\13603305 Munich-Wistar\JJ\1740 rats\NNS\2329401 with\IN\1740 established\JJ\1740 adriamycin\NN\1740 <e2>nephrosis</e2>\NN\14304060 .\.\1740
D004656_D009401 NONE Groups\NNS\2137 3\CD\13741022 and\CC\1740 4\CD\13741022 were\VBD\836236 studied\VBN\630380 at\IN\14622893 four\CD\13741022 and\CC\1740 at\IN\14622893 six\CD\13741022 months\NNS\15113229 to\TO\1740 assess\VB\670261 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>enalapril</e1>\NN\2673637 on\IN\1740 progression\NN\8457976 of\IN\1740 renal\JJ\1740 injury\NN\14052046 in\IN\13603305 adriamycin\NN\1740 <e2>nephrosis</e2>\NN\14304060 .\.\1740
D004317_D009401 CID The\DT\1740 effect\NN\34213 of\IN\1740 the\DT\1740 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 (\-LRB-\1740 CEI\NN\1740 )\-RRB-\1740 enalapril\NN\2673637 was\VBD\836236 assessed\VBN\670261 in\IN\13603305 Munich-Wistar\JJ\1740 rats\NNS\2329401 with\IN\1740 established\JJ\1740 <e1>adriamycin</e1>\NN\1740 <e2>nephrosis</e2>\NN\14304060 .\.\1740
D004317_D009401 CID Groups\NNS\2137 3\CD\13741022 and\CC\1740 4\CD\13741022 were\VBD\836236 studied\VBN\630380 at\IN\14622893 four\CD\13741022 and\CC\1740 at\IN\14622893 six\CD\13741022 months\NNS\15113229 to\TO\1740 assess\VB\670261 the\DT\1740 effect\NN\34213 of\IN\1740 enalapril\NN\2673637 on\IN\1740 progression\NN\8457976 of\IN\1740 renal\JJ\1740 injury\NN\14052046 in\IN\13603305 <e1>adriamycin</e1>\NN\1740 <e2>nephrosis</e2>\NN\14304060 .\.\1740
D004317_D000419 CID Rats\NNS\2329401 were\VBD\836236 given\VBN\2327200 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>adriamycin</e1>\NN\1740 and\CC\1740 one\CD\13741022 month\NN\15113229 later\RB\1740 divided\VBD\140123 into\IN\1740 four\CD\13741022 groups\NNS\2137 matched\VBN\2664769 for\IN\1740 <e2>albuminuria</e2>\NN\14299637 ,\,\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 and\CC\1740 plasma\NN\5398023 albumin\NN\14736972 concentration\NN\4916342 .\.\1740
D004656_D000419 NONE These\DT\1740 short-term\JJ\1740 studies\NNS\635850 showed\VBD\2137132 that\IN\1740 <e1>enalapril</e1>\NN\2673637 reduced\VBD\441445 arterial\JJ\1740 blood\NN\5397468 pressure\NN\11419404 (\-LRB-\1740 101\CD\1740 +/-\CC\1740 2\CD\13741022 vs.\CC\1740 124\CD\1740 +/-\CC\1740 3\CD\13741022 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 group\NN\2137 2\CD\13741022 vs.\CC\1740 1\CD\13741022 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 and\CC\1740 glomerular\JJ\1740 capillary\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 54\CD\1740 +/-\CC\1740 1\CD\13741022 vs.\CC\1740 61\CD\1740 +/-\CC\1740 2\CD\13741022 mm\NN\13649268 Hg\NNP\14625458 ,\,\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 without\IN\1740 reducing\VBG\441445 <e2>albuminuria</e2>\NN\14299637 (\-LRB-\1740 617\CD\1740 +/-\CC\1740 50\CD\13745420 vs.\CC\1740 570\CD\1740 +/-\CC\1740 47\CD\1740 mg/day\NN\1740 )\-RRB-\1740 or\CC\3541091 GFR\NN\1740 (\-LRB-\1740 1.03\CD\1740 +/-\CC\1740 0.04\CD\1740 vs.\CC\1740 1.04\CD\1740 +/-\CC\1740 0.11\CD\1740 ml/min\NN\1740 )\-RRB-\1740 .\.\1740
D004656_D000419 NONE Chronic\JJ\1740 <e1>enalapril</e1>\NN\2673637 treatment\NN\654885 reduced\VBD\441445 blood\NN\5397468 pressure\NN\11419404 without\IN\1740 reducing\VBG\441445 <e2>albuminuria</e2>\NN\14299637 in\IN\13603305 group\NN\2137 4\CD\13741022 .\.\1740
D004656_D007674 NONE Groups\NNS\2137 3\CD\13741022 and\CC\1740 4\CD\13741022 were\VBD\836236 studied\VBN\630380 at\IN\14622893 four\CD\13741022 and\CC\1740 at\IN\14622893 six\CD\13741022 months\NNS\15113229 to\TO\1740 assess\VB\670261 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>enalapril</e1>\NN\2673637 on\IN\1740 progression\NN\8457976 of\IN\1740 <e2>renal\JJ\1740 injury</e2>\NN\14052046 in\IN\13603305 adriamycin\NN\1740 nephrosis\NN\14304060 .\.\1740
10739826
D003276_D054556 CID Recurrent\JJ\1740 use\NN\407535 of\IN\1740 newer\JJR\1740 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 and\CC\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 .\.\1740
D003276_D054556 CID The\DT\1740 epidemiological\JJ\1740 studies\NNS\635850 that\WDT\1740 assessed\VBD\670261 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 newer\JJR\1740 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 (\-LRB-\1740 OC\NNP\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 distinguish\VB\618878 between\IN\1740 patterns\NNS\5726345 of\IN\1740 OC\NN\1740 use\NN\407535 ,\,\1740 namely\RB\1740 first-time\JJ\1740 users\NNS\7846 ,\,\1740 repeaters\NNS\7846 and\CC\1740 switchers\NNS\10379758 .\.\1740
D003276_D054556 CID The\DT\1740 epidemiological\JJ\1740 studies\NNS\635850 that\WDT\1740 assessed\VBD\670261 the\DT\1740 risk\NN\14541044 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 <e2>VTE</e2>\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 newer\JJR\1740 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 (\-LRB-\1740 OC\NNP\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 distinguish\VB\618878 between\IN\1740 patterns\NNS\5726345 of\IN\1740 OC\NN\1740 use\NN\407535 ,\,\1740 namely\RB\1740 first-time\JJ\1740 users\NNS\7846 ,\,\1740 repeaters\NNS\7846 and\CC\1740 switchers\NNS\10379758 .\.\1740
D003276_D054556 CID The\DT\1740 epidemiological\JJ\1740 studies\NNS\635850 that\WDT\1740 assessed\VBD\670261 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 newer\JJR\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 <e1>OC</e1>\NNP\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 distinguish\VB\618878 between\IN\1740 patterns\NNS\5726345 of\IN\1740 OC\NN\1740 use\NN\407535 ,\,\1740 namely\RB\1740 first-time\JJ\1740 users\NNS\7846 ,\,\1740 repeaters\NNS\7846 and\CC\1740 switchers\NNS\10379758 .\.\1740
D003276_D054556 CID The\DT\1740 epidemiological\JJ\1740 studies\NNS\635850 that\WDT\1740 assessed\VBD\670261 the\DT\1740 risk\NN\14541044 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 <e2>VTE</e2>\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 newer\JJR\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 <e1>OC</e1>\NNP\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 distinguish\VB\618878 between\IN\1740 patterns\NNS\5726345 of\IN\1740 OC\NN\1740 use\NN\407535 ,\,\1740 namely\RB\1740 first-time\JJ\1740 users\NNS\7846 ,\,\1740 repeaters\NNS\7846 and\CC\1740 switchers\NNS\10379758 .\.\1740
D003276_D054556 CID The\DT\1740 epidemiological\JJ\1740 studies\NNS\635850 that\WDT\1740 assessed\VBD\670261 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 newer\JJR\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 OC\NNP\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 distinguish\VB\618878 between\IN\1740 patterns\NNS\5726345 of\IN\1740 <e1>OC</e1>\NN\1740 use\NN\407535 ,\,\1740 namely\RB\1740 first-time\JJ\1740 users\NNS\7846 ,\,\1740 repeaters\NNS\7846 and\CC\1740 switchers\NNS\10379758 .\.\1740
D003276_D054556 CID The\DT\1740 epidemiological\JJ\1740 studies\NNS\635850 that\WDT\1740 assessed\VBD\670261 the\DT\1740 risk\NN\14541044 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 <e2>VTE</e2>\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 newer\JJR\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 OC\NNP\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 distinguish\VB\618878 between\IN\1740 patterns\NNS\5726345 of\IN\1740 <e1>OC</e1>\NN\1740 use\NN\407535 ,\,\1740 namely\RB\1740 first-time\JJ\1740 users\NNS\7846 ,\,\1740 repeaters\NNS\7846 and\CC\1740 switchers\NNS\10379758 .\.\1740
D003276_D054556 CID The\DT\1740 adjusted\VBN\126264 rate\NN\13815152 ratio\NN\13815152 of\IN\1740 <e2>VTE</e2>\NN\1740 for\IN\1740 repeat\NN\7296190 users\NNS\7846 of\IN\1740 third\JJ\1740 generation\NN\7942152 <e1>OC</e1>\NNP\1740 was\VBD\836236 0.6\CD\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI:0.3\JJ\1740 -\HYPH\1740 1.2\CD\1740 )\-RRB-\1740 relative\JJ\1740 to\TO\1740 repeat\NN\7296190 users\NNS\7846 of\IN\1740 second\JJ\1740 generation\NN\7942152 pills\NNS\4424218 ,\,\1740 whereas\IN\1740 it\PRP\6125041 was\VBD\836236 1.3\CD\1740 (\-LRB-\1740 95\CD\1740 %\NN\1740 CI:0.7\NN\1740 -\HYPH\1740 2.4\CD\1740 )\-RRB-\1740 for\IN\1740 switchers\NNS\10379758 from\IN\1740 second\JJ\1740 to\TO\1740 third\JJ\1740 generation\NN\7942152 pills\NNS\4424218 relative\JJ\1740 to\TO\1740 switchers\NNS\10379758 from\IN\1740 third\JJ\1740 to\TO\1740 second\JJ\1740 generation\NN\7942152 pills\NNS\4424218 .\.\1740
12627929
C067311_D054556 CID Increased\VBN\169651 frequency\NN\15286249 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 with\IN\1740 the\DT\1740 combination\NN\7951464 of\IN\1740 <e1>docetaxel</e1>\NN\1740 and\CC\1740 thalidomide\VBP\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 metastatic\JJ\1740 androgen-independent\JJ\1740 prostate\NN\5329735 cancer\NN\14239425 .\.\1740
C067311_D054556 CID STUDY\VB\630380 OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 frequency\NN\15286249 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 androgen-independent\JJ\1740 prostate\NN\5329735 cancer\NN\14239425 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>docetaxel</e1>\NN\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 thalidomide\NN\4166841 .\.\1740
C067311_D054556 CID STUDY\VB\630380 OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 frequency\NN\15286249 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 <e2>VTE</e2>\NN\1740 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 androgen-independent\JJ\1740 prostate\NN\5329735 cancer\NN\14239425 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>docetaxel</e1>\NN\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 thalidomide\NN\4166841 .\.\1740
C067311_D054556 CID MEASUREMENTS\NNS\407535 AND\CC\1740 MAIN\JJ\1740 RESULTS\NNS\34213 :\:\1740 None\NN\15228378 of\IN\1740 23\CD\13745420 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 <e1>docetaxel</e1>\NN\1740 alone\RB\1740 developed\VBD\1753788 <e2>VTE</e2>\NN\1740 ,\,\1740 whereas\IN\1740 9\CD\13741022 of\IN\1740 47\CD\1740 patients\NNS\9898892 (\-LRB-\1740 19\CD\13745420 %\NN\1740 )\-RRB-\1740 who\WP\8299493 received\VBD\2210855 docetaxel\NN\1740 plus\CC\4723816 thalidomide\NN\4166841 developed\VBD\1753788 VTE\NN\1740 (\-LRB-\1740 p=0.025\NNP\1740 )\-RRB-\1740 .\.\1740
C067311_D054556 CID MEASUREMENTS\NNS\407535 AND\CC\1740 MAIN\JJ\1740 RESULTS\NNS\34213 :\:\1740 None\NN\15228378 of\IN\1740 23\CD\13745420 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 <e1>docetaxel</e1>\NN\1740 alone\RB\1740 developed\VBD\1753788 VTE\NN\1740 ,\,\1740 whereas\IN\1740 9\CD\13741022 of\IN\1740 47\CD\1740 patients\NNS\9898892 (\-LRB-\1740 19\CD\13745420 %\NN\1740 )\-RRB-\1740 who\WP\8299493 received\VBD\2210855 docetaxel\NN\1740 plus\CC\4723816 thalidomide\NN\4166841 developed\VBD\1753788 <e2>VTE</e2>\NN\1740 (\-LRB-\1740 p=0.025\NNP\1740 )\-RRB-\1740 .\.\1740
C067311_D054556 CID MEASUREMENTS\NNS\407535 AND\CC\1740 MAIN\JJ\1740 RESULTS\NNS\34213 :\:\1740 None\NN\15228378 of\IN\1740 23\CD\13745420 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 docetaxel\NN\1740 alone\RB\1740 developed\VBD\1753788 <e2>VTE</e2>\NN\1740 ,\,\1740 whereas\IN\1740 9\CD\13741022 of\IN\1740 47\CD\1740 patients\NNS\9898892 (\-LRB-\1740 19\CD\13745420 %\NN\1740 )\-RRB-\1740 who\WP\8299493 received\VBD\2210855 <e1>docetaxel</e1>\NN\1740 plus\CC\4723816 thalidomide\NN\4166841 developed\VBD\1753788 VTE\NN\1740 (\-LRB-\1740 p=0.025\NNP\1740 )\-RRB-\1740 .\.\1740
C067311_D054556 CID MEASUREMENTS\NNS\407535 AND\CC\1740 MAIN\JJ\1740 RESULTS\NNS\34213 :\:\1740 None\NN\15228378 of\IN\1740 23\CD\13745420 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 docetaxel\NN\1740 alone\RB\1740 developed\VBD\1753788 VTE\NN\1740 ,\,\1740 whereas\IN\1740 9\CD\13741022 of\IN\1740 47\CD\1740 patients\NNS\9898892 (\-LRB-\1740 19\CD\13745420 %\NN\1740 )\-RRB-\1740 who\WP\8299493 received\VBD\2210855 <e1>docetaxel</e1>\NN\1740 plus\CC\4723816 thalidomide\NN\4166841 developed\VBD\1753788 <e2>VTE</e2>\NN\1740 (\-LRB-\1740 p=0.025\NNP\1740 )\-RRB-\1740 .\.\1740
C067311_D054556 CID CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 addition\NN\3081021 of\IN\1740 thalidomide\NN\4166841 to\TO\1740 <e1>docetaxel</e1>\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 prostate\NN\5329735 cancer\NN\14239425 significantly\RB\1740 increases\VBZ\169651 the\DT\1740 frequency\NN\15286249 of\IN\1740 <e2>VTE</e2>\NN\1740 .\.\1740
C067311_D011471 NONE Increased\VBN\169651 frequency\NN\15286249 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 with\IN\1740 the\DT\1740 combination\NN\7951464 of\IN\1740 <e1>docetaxel</e1>\NN\1740 and\CC\1740 thalidomide\VBP\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 metastatic\JJ\1740 androgen-independent\JJ\1740 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 .\.\1740
C067311_D011471 NONE STUDY\VB\630380 OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 frequency\NN\15286249 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 androgen-independent\JJ\1740 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>docetaxel</e1>\NN\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 thalidomide\NN\4166841 .\.\1740
C067311_D011471 NONE CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 addition\NN\3081021 of\IN\1740 thalidomide\NN\4166841 to\TO\1740 <e1>docetaxel</e1>\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 significantly\RB\1740 increases\VBZ\169651 the\DT\1740 frequency\NN\15286249 of\IN\1740 VTE\NN\1740 .\.\1740
D013792_D054556 CID Increased\VBN\169651 frequency\NN\15286249 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 with\IN\1740 the\DT\1740 combination\NN\7951464 of\IN\1740 docetaxel\NN\1740 and\CC\1740 <e1>thalidomide</e1>\VBP\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 metastatic\JJ\1740 androgen-independent\JJ\1740 prostate\NN\5329735 cancer\NN\14239425 .\.\1740
D013792_D054556 CID STUDY\VB\630380 OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 frequency\NN\15286249 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 androgen-independent\JJ\1740 prostate\NN\5329735 cancer\NN\14239425 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 docetaxel\NN\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>thalidomide</e1>\NN\4166841 .\.\1740
D013792_D054556 CID STUDY\VB\630380 OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 frequency\NN\15286249 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 <e2>VTE</e2>\NN\1740 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 androgen-independent\JJ\1740 prostate\NN\5329735 cancer\NN\14239425 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 docetaxel\NN\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>thalidomide</e1>\NN\4166841 .\.\1740
D013792_D054556 CID MEASUREMENTS\NNS\407535 AND\CC\1740 MAIN\JJ\1740 RESULTS\NNS\34213 :\:\1740 None\NN\15228378 of\IN\1740 23\CD\13745420 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 docetaxel\NN\1740 alone\RB\1740 developed\VBD\1753788 <e2>VTE</e2>\NN\1740 ,\,\1740 whereas\IN\1740 9\CD\13741022 of\IN\1740 47\CD\1740 patients\NNS\9898892 (\-LRB-\1740 19\CD\13745420 %\NN\1740 )\-RRB-\1740 who\WP\8299493 received\VBD\2210855 docetaxel\NN\1740 plus\CC\4723816 <e1>thalidomide</e1>\NN\4166841 developed\VBD\1753788 VTE\NN\1740 (\-LRB-\1740 p=0.025\NNP\1740 )\-RRB-\1740 .\.\1740
D013792_D054556 CID MEASUREMENTS\NNS\407535 AND\CC\1740 MAIN\JJ\1740 RESULTS\NNS\34213 :\:\1740 None\NN\15228378 of\IN\1740 23\CD\13745420 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 docetaxel\NN\1740 alone\RB\1740 developed\VBD\1753788 VTE\NN\1740 ,\,\1740 whereas\IN\1740 9\CD\13741022 of\IN\1740 47\CD\1740 patients\NNS\9898892 (\-LRB-\1740 19\CD\13745420 %\NN\1740 )\-RRB-\1740 who\WP\8299493 received\VBD\2210855 docetaxel\NN\1740 plus\CC\4723816 <e1>thalidomide</e1>\NN\4166841 developed\VBD\1753788 <e2>VTE</e2>\NN\1740 (\-LRB-\1740 p=0.025\NNP\1740 )\-RRB-\1740 .\.\1740
D013792_D054556 CID CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 addition\NN\3081021 of\IN\1740 <e1>thalidomide</e1>\NN\4166841 to\TO\1740 docetaxel\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 prostate\NN\5329735 cancer\NN\14239425 significantly\RB\1740 increases\VBZ\169651 the\DT\1740 frequency\NN\15286249 of\IN\1740 <e2>VTE</e2>\NN\1740 .\.\1740
D013792_D011471 NONE Increased\VBN\169651 frequency\NN\15286249 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 with\IN\1740 the\DT\1740 combination\NN\7951464 of\IN\1740 docetaxel\NN\1740 and\CC\1740 <e1>thalidomide</e1>\VBP\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 metastatic\JJ\1740 androgen-independent\JJ\1740 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 .\.\1740
D013792_D011471 NONE STUDY\VB\630380 OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 frequency\NN\15286249 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 androgen-independent\JJ\1740 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 docetaxel\NN\1740 alone\RB\1740 or\CC\3541091 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>thalidomide</e1>\NN\4166841 .\.\1740
D013792_D011471 NONE CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 addition\NN\3081021 of\IN\1740 <e1>thalidomide</e1>\NN\4166841 to\TO\1740 docetaxel\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>prostate\NN\5329735 cancer</e2>\NN\14239425 significantly\RB\1740 increases\VBZ\169651 the\DT\1740 frequency\NN\15286249 of\IN\1740 VTE\NN\1740 .\.\1740
8919272
D014635_D001927 CID Morphological\JJ\1740 features\NNS\5849040 of\IN\1740 <e2>encephalopathy</e2>\JJ\1740 after\IN\1740 chronic\JJ\1740 administration\NN\1133281 of\IN\1740 the\DT\1740 antiepileptic\JJ\1740 drug\NN\14778436 <e1>valproate</e1>\VBP\1740 to\IN\1740 rats\NNS\2329401 .\.\1740
D014635_D001927 CID Long-term\JJ\1740 intragastric\JJ\1740 application\NN\947128 of\IN\1740 the\DT\1740 antiepileptic\JJ\1740 drug\NN\14778436 <e1>sodium\NN\14625458 valproate</e1>\NN\1740 (\-LRB-\1740 Vupral\NNP\1740 "\``\1740 Polfa\NNP\1740 "\''\1740 )\-RRB-\1740 at\IN\14622893 the\DT\1740 effective\JJ\1740 dose\NN\3740161 of\IN\1740 200\CD\1740 mg/kg\NN\1740 b.\NN\1740 w.\NN\1740 once\RB\1740 daily\RB\1740 to\TO\1740 rats\NNS\2329401 for\IN\1740 1\CD\13741022 ,\,\1740 3\CD\13741022 ,\,\1740 6\CD\13741022 ,\,\1740 9\CD\13741022 and\CC\1740 12\CD\13745420 months\NNS\15113229 revealed\VBD\2137132 neurological\JJ\1740 disorders\NNS\14034177 indicating\VBG\952524 cerebellum\NN\5462674 damage\NN\7296428 (\-LRB-\1740 "\``\1740 valproate\VB\1740 <e2>encephalopathy</e2>\RB\1740 "\''\1740 )\-RRB-\1740 .\.\1740
D014635_D001927 CID Long-term\JJ\1740 intragastric\JJ\1740 application\NN\947128 of\IN\1740 the\DT\1740 antiepileptic\JJ\1740 drug\NN\14778436 sodium\NN\14625458 valproate\NN\1740 (\-LRB-\1740 Vupral\NNP\1740 "\``\1740 Polfa\NNP\1740 "\''\1740 )\-RRB-\1740 at\IN\14622893 the\DT\1740 effective\JJ\1740 dose\NN\3740161 of\IN\1740 200\CD\1740 mg/kg\NN\1740 b.\NN\1740 w.\NN\1740 once\RB\1740 daily\RB\1740 to\TO\1740 rats\NNS\2329401 for\IN\1740 1\CD\13741022 ,\,\1740 3\CD\13741022 ,\,\1740 6\CD\13741022 ,\,\1740 9\CD\13741022 and\CC\1740 12\CD\13745420 months\NNS\15113229 revealed\VBD\2137132 neurological\JJ\1740 disorders\NNS\14034177 indicating\VBG\952524 cerebellum\NN\5462674 damage\NN\7296428 (\-LRB-\1740 "\``\1740 <e1>valproate</e1>\VB\1740 <e2>encephalopathy</e2>\RB\1740 "\''\1740 )\-RRB-\1740 .\.\1740
D014635_D001927 CID The\DT\1740 possible\JJ\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 hepatic\JJ\1740 damage\NN\7296428 ,\,\1740 mainly\RB\1740 hyperammonemia\NN\1740 ,\,\1740 upon\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e1>valproate</e1>\NN\1740 <e2>encephalopathy</e2>\NN\14084880 is\VBZ\836236 discussed\VBN\1033527 .\.\1740
D014635_D009422 NONE Long-term\JJ\1740 intragastric\JJ\1740 application\NN\947128 of\IN\1740 the\DT\1740 antiepileptic\JJ\1740 drug\NN\14778436 <e1>sodium\NN\14625458 valproate</e1>\NN\1740 (\-LRB-\1740 Vupral\NNP\1740 "\``\1740 Polfa\NNP\1740 "\''\1740 )\-RRB-\1740 at\IN\14622893 the\DT\1740 effective\JJ\1740 dose\NN\3740161 of\IN\1740 200\CD\1740 mg/kg\NN\1740 b.\NN\1740 w.\NN\1740 once\RB\1740 daily\RB\1740 to\TO\1740 rats\NNS\2329401 for\IN\1740 1\CD\13741022 ,\,\1740 3\CD\13741022 ,\,\1740 6\CD\13741022 ,\,\1740 9\CD\13741022 and\CC\1740 12\CD\13745420 months\NNS\15113229 revealed\VBD\2137132 <e2>neurological\JJ\1740 disorders</e2>\NNS\14034177 indicating\VBG\952524 cerebellum\NN\5462674 damage\NN\7296428 (\-LRB-\1740 "\``\1740 valproate\VB\1740 encephalopathy\RB\1740 "\''\1740 )\-RRB-\1740 .\.\1740
D014635_D009422 NONE Long-term\JJ\1740 intragastric\JJ\1740 application\NN\947128 of\IN\1740 the\DT\1740 antiepileptic\JJ\1740 drug\NN\14778436 sodium\NN\14625458 valproate\NN\1740 (\-LRB-\1740 Vupral\NNP\1740 "\``\1740 Polfa\NNP\1740 "\''\1740 )\-RRB-\1740 at\IN\14622893 the\DT\1740 effective\JJ\1740 dose\NN\3740161 of\IN\1740 200\CD\1740 mg/kg\NN\1740 b.\NN\1740 w.\NN\1740 once\RB\1740 daily\RB\1740 to\TO\1740 rats\NNS\2329401 for\IN\1740 1\CD\13741022 ,\,\1740 3\CD\13741022 ,\,\1740 6\CD\13741022 ,\,\1740 9\CD\13741022 and\CC\1740 12\CD\13745420 months\NNS\15113229 revealed\VBD\2137132 <e2>neurological\JJ\1740 disorders</e2>\NNS\14034177 indicating\VBG\952524 cerebellum\NN\5462674 damage\NN\7296428 (\-LRB-\1740 "\``\1740 <e1>valproate</e1>\VB\1740 encephalopathy\RB\1740 "\''\1740 )\-RRB-\1740 .\.\1740
D014635_D002526 NONE Long-term\JJ\1740 intragastric\JJ\1740 application\NN\947128 of\IN\1740 the\DT\1740 antiepileptic\JJ\1740 drug\NN\14778436 <e1>sodium\NN\14625458 valproate</e1>\NN\1740 (\-LRB-\1740 Vupral\NNP\1740 "\``\1740 Polfa\NNP\1740 "\''\1740 )\-RRB-\1740 at\IN\14622893 the\DT\1740 effective\JJ\1740 dose\NN\3740161 of\IN\1740 200\CD\1740 mg/kg\NN\1740 b.\NN\1740 w.\NN\1740 once\RB\1740 daily\RB\1740 to\TO\1740 rats\NNS\2329401 for\IN\1740 1\CD\13741022 ,\,\1740 3\CD\13741022 ,\,\1740 6\CD\13741022 ,\,\1740 9\CD\13741022 and\CC\1740 12\CD\13745420 months\NNS\15113229 revealed\VBD\2137132 neurological\JJ\1740 disorders\NNS\14034177 indicating\VBG\952524 <e2>cerebellum\NN\5462674 damage</e2>\NN\7296428 (\-LRB-\1740 "\``\1740 valproate\VB\1740 encephalopathy\RB\1740 "\''\1740 )\-RRB-\1740 .\.\1740
D014635_D002526 NONE Long-term\JJ\1740 intragastric\JJ\1740 application\NN\947128 of\IN\1740 the\DT\1740 antiepileptic\JJ\1740 drug\NN\14778436 sodium\NN\14625458 valproate\NN\1740 (\-LRB-\1740 Vupral\NNP\1740 "\``\1740 Polfa\NNP\1740 "\''\1740 )\-RRB-\1740 at\IN\14622893 the\DT\1740 effective\JJ\1740 dose\NN\3740161 of\IN\1740 200\CD\1740 mg/kg\NN\1740 b.\NN\1740 w.\NN\1740 once\RB\1740 daily\RB\1740 to\TO\1740 rats\NNS\2329401 for\IN\1740 1\CD\13741022 ,\,\1740 3\CD\13741022 ,\,\1740 6\CD\13741022 ,\,\1740 9\CD\13741022 and\CC\1740 12\CD\13745420 months\NNS\15113229 revealed\VBD\2137132 neurological\JJ\1740 disorders\NNS\14034177 indicating\VBG\952524 <e2>cerebellum\NN\5462674 damage</e2>\NN\7296428 (\-LRB-\1740 "\``\1740 <e1>valproate</e1>\VB\1740 encephalopathy\RB\1740 "\''\1740 )\-RRB-\1740 .\.\1740
D014635_D056486 NONE The\DT\1740 possible\JJ\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 <e2>hepatic\JJ\1740 damage</e2>\NN\7296428 ,\,\1740 mainly\RB\1740 hyperammonemia\NN\1740 ,\,\1740 upon\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e1>valproate</e1>\NN\1740 encephalopathy\NN\14084880 is\VBZ\836236 discussed\VBN\1033527 .\.\1740
D014635_D022124 NONE The\DT\1740 possible\JJ\1740 influence\NN\5190804 of\IN\1740 the\DT\1740 hepatic\JJ\1740 damage\NN\7296428 ,\,\1740 mainly\RB\1740 <e2>hyperammonemia</e2>\NN\1740 ,\,\1740 upon\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e1>valproate</e1>\NN\1740 encephalopathy\NN\14084880 is\VBZ\836236 discussed\VBN\1033527 .\.\1740
18439803
C108761_D012640 NONE Acute\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>N-(2-propylpentanoyl)urea</e1>\NN\1740 on\IN\1740 hippocampal\NN\1740 amino\NN\14621446 acid\NN\14818238 neurotransmitters\NNS\14807410 in\IN\13603305 pilocarpine-induced\JJ\1740 <e2>seizure</e2>\NN\14081375 in\IN\13603305 rats\NNS\2329401 .\.\1740
C108761_D012640 NONE <e1>VPU</e1>\NNP\1740 was\VBD\836236 more\RBR\1740 potent\JJ\1740 than\IN\1740 VPA\NN\1740 ,\,\1740 exhibiting\VBG\2632167 the\DT\1740 median\JJ\1740 effective\JJ\1740 dose\NN\3740161 (\-LRB-\1740 ED(50\NN\1740 )\-RRB-\1740 )\-RRB-\1740 of\IN\1740 49\CD\1740 mg/kg\NN\1740 in\IN\13603305 protecting\VBG\1127795 rats\NNS\2329401 against\IN\1740 pilocarpine-induced\JJ\1740 <e2>seizure</e2>\NN\14081375 whereas\IN\1740 the\DT\1740 corresponding\JJ\1740 value\NN\5856066 for\IN\1740 VPA\NN\1740 was\VBD\836236 322\CD\1740 mg/kg\NN\1740 .\.\1740
C108761_D012640 NONE Based\VBN\2694933 on\IN\1740 the\DT\1740 finding\NN\43195 that\IN\1740 <e1>VPU</e1>\NNP\1740 and\CC\1740 VPA\NN\1740 could\MD\1740 protect\VB\1127795 the\DT\1740 animals\NNS\4475 against\IN\1740 pilocarpine-induced\JJ\1740 <e2>seizure</e2>\JJ\1740 it\PRP\6125041 is\VBZ\836236 suggested\VBN\1010118 that\IN\1740 the\DT\1740 reduction\NN\351485 of\IN\1740 inhibitory\JJ\1740 amino\NN\14621446 acid\NN\14818238 neurotransmitters\NNS\14807410 was\VBD\836236 comparatively\RB\1740 minor\JJ\1740 and\CC\1740 offset\VB\2673134 by\IN\1740 a\DT\13649268 pronounced\JJ\1740 reduction\NN\351485 of\IN\1740 glutamate\NN\15010703 and\CC\1740 aspartate\VBP\1740 .\.\1740
C108761_D012640 NONE Therefore\RB\1740 ,\,\1740 like\IN\5839024 VPA\NN\1740 ,\,\1740 the\DT\1740 finding\NN\43195 that\IN\1740 <e1>VPU</e1>\NNP\1740 could\MD\1740 drastically\RB\1740 reduce\VB\441445 pilocarpine-induced\JJ\1740 increases\NNS\13576355 in\IN\13603305 glutamate\NN\15010703 and\CC\1740 aspartate\NN\1740 should\MD\1740 account\VB\2604760 ,\,\1740 at\IN\14622893 least\JJS\1740 partly\RB\1740 ,\,\1740 for\IN\1740 its\PRP$\6125041 anticonvulsant\JJ\1740 activity\NN\30358 observed\VBN\2163746 in\IN\13603305 pilocarpine-induced\JJ\1740 <e2>seizure</e2>\NN\14081375 in\IN\13603305 experimental\JJ\1740 animals\NNS\4475 .\.\1740
D000596_D012640 NONE Acute\JJ\1740 effects\NNS\13245626 of\IN\1740 N-(2-propylpentanoyl)urea\NN\1740 on\IN\1740 hippocampal\NN\1740 <e1>amino\NN\14621446 acid</e1>\NN\14818238 neurotransmitters\NNS\14807410 in\IN\13603305 pilocarpine-induced\JJ\1740 <e2>seizure</e2>\NN\14081375 in\IN\13603305 rats\NNS\2329401 .\.\1740
D000596_D012640 NONE Based\VBN\2694933 on\IN\1740 the\DT\1740 finding\NN\43195 that\IN\1740 VPU\NNP\1740 and\CC\1740 VPA\NN\1740 could\MD\1740 protect\VB\1127795 the\DT\1740 animals\NNS\4475 against\IN\1740 pilocarpine-induced\JJ\1740 <e2>seizure</e2>\JJ\1740 it\PRP\6125041 is\VBZ\836236 suggested\VBN\1010118 that\IN\1740 the\DT\1740 reduction\NN\351485 of\IN\1740 inhibitory\JJ\1740 <e1>amino\NN\14621446 acid</e1>\NN\14818238 neurotransmitters\NNS\14807410 was\VBD\836236 comparatively\RB\1740 minor\JJ\1740 and\CC\1740 offset\VB\2673134 by\IN\1740 a\DT\13649268 pronounced\JJ\1740 reduction\NN\351485 of\IN\1740 glutamate\NN\15010703 and\CC\1740 aspartate\VBP\1740 .\.\1740
D010862_D012640 CID Acute\JJ\1740 effects\NNS\13245626 of\IN\1740 N-(2-propylpentanoyl)urea\NN\1740 on\IN\1740 hippocampal\NN\1740 amino\NN\14621446 acid\NN\14818238 neurotransmitters\NNS\14807410 in\IN\13603305 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>seizure</e2>\NN\14081375 in\IN\13603305 rats\NNS\2329401 .\.\1740
D010862_D012640 CID VPU\NNP\1740 was\VBD\836236 more\RBR\1740 potent\JJ\1740 than\IN\1740 VPA\NN\1740 ,\,\1740 exhibiting\VBG\2632167 the\DT\1740 median\JJ\1740 effective\JJ\1740 dose\NN\3740161 (\-LRB-\1740 ED(50\NN\1740 )\-RRB-\1740 )\-RRB-\1740 of\IN\1740 49\CD\1740 mg/kg\NN\1740 in\IN\13603305 protecting\VBG\1127795 rats\NNS\2329401 against\IN\1740 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>seizure</e2>\NN\14081375 whereas\IN\1740 the\DT\1740 corresponding\JJ\1740 value\NN\5856066 for\IN\1740 VPA\NN\1740 was\VBD\836236 322\CD\1740 mg/kg\NN\1740 .\.\1740
D010862_D012640 CID Based\VBN\2694933 on\IN\1740 the\DT\1740 finding\NN\43195 that\IN\1740 VPU\NNP\1740 and\CC\1740 VPA\NN\1740 could\MD\1740 protect\VB\1127795 the\DT\1740 animals\NNS\4475 against\IN\1740 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>seizure</e2>\JJ\1740 it\PRP\6125041 is\VBZ\836236 suggested\VBN\1010118 that\IN\1740 the\DT\1740 reduction\NN\351485 of\IN\1740 inhibitory\JJ\1740 amino\NN\14621446 acid\NN\14818238 neurotransmitters\NNS\14807410 was\VBD\836236 comparatively\RB\1740 minor\JJ\1740 and\CC\1740 offset\VB\2673134 by\IN\1740 a\DT\13649268 pronounced\JJ\1740 reduction\NN\351485 of\IN\1740 glutamate\NN\15010703 and\CC\1740 aspartate\VBP\1740 .\.\1740
D010862_D012640 CID Therefore\RB\1740 ,\,\1740 like\IN\5839024 VPA\NN\1740 ,\,\1740 the\DT\1740 finding\NN\43195 that\IN\1740 VPU\NNP\1740 could\MD\1740 drastically\RB\1740 reduce\VB\441445 <e1>pilocarpine-induced</e1>\JJ\1740 increases\NNS\13576355 in\IN\13603305 glutamate\NN\15010703 and\CC\1740 aspartate\NN\1740 should\MD\1740 account\VB\2604760 ,\,\1740 at\IN\14622893 least\JJS\1740 partly\RB\1740 ,\,\1740 for\IN\1740 its\PRP$\6125041 anticonvulsant\JJ\1740 activity\NN\30358 observed\VBN\2163746 in\IN\13603305 pilocarpine-induced\JJ\1740 <e2>seizure</e2>\NN\14081375 in\IN\13603305 experimental\JJ\1740 animals\NNS\4475 .\.\1740
D010862_D012640 CID Therefore\RB\1740 ,\,\1740 like\IN\5839024 VPA\NN\1740 ,\,\1740 the\DT\1740 finding\NN\43195 that\IN\1740 VPU\NNP\1740 could\MD\1740 drastically\RB\1740 reduce\VB\441445 pilocarpine-induced\JJ\1740 increases\NNS\13576355 in\IN\13603305 glutamate\NN\15010703 and\CC\1740 aspartate\NN\1740 should\MD\1740 account\VB\2604760 ,\,\1740 at\IN\14622893 least\JJS\1740 partly\RB\1740 ,\,\1740 for\IN\1740 its\PRP$\6125041 anticonvulsant\JJ\1740 activity\NN\30358 observed\VBN\2163746 in\IN\13603305 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>seizure</e2>\NN\14081375 in\IN\13603305 experimental\JJ\1740 animals\NNS\4475 .\.\1740
D014635_D012640 NONE VPU\NNP\1740 was\VBD\836236 more\RBR\1740 potent\JJ\1740 than\IN\1740 <e1>VPA</e1>\NN\1740 ,\,\1740 exhibiting\VBG\2632167 the\DT\1740 median\JJ\1740 effective\JJ\1740 dose\NN\3740161 (\-LRB-\1740 ED(50\NN\1740 )\-RRB-\1740 )\-RRB-\1740 of\IN\1740 49\CD\1740 mg/kg\NN\1740 in\IN\13603305 protecting\VBG\1127795 rats\NNS\2329401 against\IN\1740 pilocarpine-induced\JJ\1740 <e2>seizure</e2>\NN\14081375 whereas\IN\1740 the\DT\1740 corresponding\JJ\1740 value\NN\5856066 for\IN\1740 VPA\NN\1740 was\VBD\836236 322\CD\1740 mg/kg\NN\1740 .\.\1740
D014635_D012640 NONE VPU\NNP\1740 was\VBD\836236 more\RBR\1740 potent\JJ\1740 than\IN\1740 VPA\NN\1740 ,\,\1740 exhibiting\VBG\2632167 the\DT\1740 median\JJ\1740 effective\JJ\1740 dose\NN\3740161 (\-LRB-\1740 ED(50\NN\1740 )\-RRB-\1740 )\-RRB-\1740 of\IN\1740 49\CD\1740 mg/kg\NN\1740 in\IN\13603305 protecting\VBG\1127795 rats\NNS\2329401 against\IN\1740 pilocarpine-induced\JJ\1740 <e2>seizure</e2>\NN\14081375 whereas\IN\1740 the\DT\1740 corresponding\JJ\1740 value\NN\5856066 for\IN\1740 <e1>VPA</e1>\NN\1740 was\VBD\836236 322\CD\1740 mg/kg\NN\1740 .\.\1740
D014635_D012640 NONE Based\VBN\2694933 on\IN\1740 the\DT\1740 finding\NN\43195 that\IN\1740 VPU\NNP\1740 and\CC\1740 <e1>VPA</e1>\NN\1740 could\MD\1740 protect\VB\1127795 the\DT\1740 animals\NNS\4475 against\IN\1740 pilocarpine-induced\JJ\1740 <e2>seizure</e2>\JJ\1740 it\PRP\6125041 is\VBZ\836236 suggested\VBN\1010118 that\IN\1740 the\DT\1740 reduction\NN\351485 of\IN\1740 inhibitory\JJ\1740 amino\NN\14621446 acid\NN\14818238 neurotransmitters\NNS\14807410 was\VBD\836236 comparatively\RB\1740 minor\JJ\1740 and\CC\1740 offset\VB\2673134 by\IN\1740 a\DT\13649268 pronounced\JJ\1740 reduction\NN\351485 of\IN\1740 glutamate\NN\15010703 and\CC\1740 aspartate\VBP\1740 .\.\1740
D014635_D012640 NONE Therefore\RB\1740 ,\,\1740 like\IN\5839024 <e1>VPA</e1>\NN\1740 ,\,\1740 the\DT\1740 finding\NN\43195 that\IN\1740 VPU\NNP\1740 could\MD\1740 drastically\RB\1740 reduce\VB\441445 pilocarpine-induced\JJ\1740 increases\NNS\13576355 in\IN\13603305 glutamate\NN\15010703 and\CC\1740 aspartate\NN\1740 should\MD\1740 account\VB\2604760 ,\,\1740 at\IN\14622893 least\JJS\1740 partly\RB\1740 ,\,\1740 for\IN\1740 its\PRP$\6125041 anticonvulsant\JJ\1740 activity\NN\30358 observed\VBN\2163746 in\IN\13603305 pilocarpine-induced\JJ\1740 <e2>seizure</e2>\NN\14081375 in\IN\13603305 experimental\JJ\1740 animals\NNS\4475 .\.\1740
D018698_D012640 NONE Based\VBN\2694933 on\IN\1740 the\DT\1740 finding\NN\43195 that\IN\1740 VPU\NNP\1740 and\CC\1740 VPA\NN\1740 could\MD\1740 protect\VB\1127795 the\DT\1740 animals\NNS\4475 against\IN\1740 pilocarpine-induced\JJ\1740 <e2>seizure</e2>\JJ\1740 it\PRP\6125041 is\VBZ\836236 suggested\VBN\1010118 that\IN\1740 the\DT\1740 reduction\NN\351485 of\IN\1740 inhibitory\JJ\1740 amino\NN\14621446 acid\NN\14818238 neurotransmitters\NNS\14807410 was\VBD\836236 comparatively\RB\1740 minor\JJ\1740 and\CC\1740 offset\VB\2673134 by\IN\1740 a\DT\13649268 pronounced\JJ\1740 reduction\NN\351485 of\IN\1740 <e1>glutamate</e1>\NN\15010703 and\CC\1740 aspartate\VBP\1740 .\.\1740
D018698_D012640 NONE Therefore\RB\1740 ,\,\1740 like\IN\5839024 VPA\NN\1740 ,\,\1740 the\DT\1740 finding\NN\43195 that\IN\1740 VPU\NNP\1740 could\MD\1740 drastically\RB\1740 reduce\VB\441445 pilocarpine-induced\JJ\1740 increases\NNS\13576355 in\IN\13603305 <e1>glutamate</e1>\NN\15010703 and\CC\1740 aspartate\NN\1740 should\MD\1740 account\VB\2604760 ,\,\1740 at\IN\14622893 least\JJS\1740 partly\RB\1740 ,\,\1740 for\IN\1740 its\PRP$\6125041 anticonvulsant\JJ\1740 activity\NN\30358 observed\VBN\2163746 in\IN\13603305 pilocarpine-induced\JJ\1740 <e2>seizure</e2>\NN\14081375 in\IN\13603305 experimental\JJ\1740 animals\NNS\4475 .\.\1740
D001224_D012640 NONE Based\VBN\2694933 on\IN\1740 the\DT\1740 finding\NN\43195 that\IN\1740 VPU\NNP\1740 and\CC\1740 VPA\NN\1740 could\MD\1740 protect\VB\1127795 the\DT\1740 animals\NNS\4475 against\IN\1740 pilocarpine-induced\JJ\1740 <e2>seizure</e2>\JJ\1740 it\PRP\6125041 is\VBZ\836236 suggested\VBN\1010118 that\IN\1740 the\DT\1740 reduction\NN\351485 of\IN\1740 inhibitory\JJ\1740 amino\NN\14621446 acid\NN\14818238 neurotransmitters\NNS\14807410 was\VBD\836236 comparatively\RB\1740 minor\JJ\1740 and\CC\1740 offset\VB\2673134 by\IN\1740 a\DT\13649268 pronounced\JJ\1740 reduction\NN\351485 of\IN\1740 glutamate\NN\15010703 and\CC\1740 <e1>aspartate</e1>\VBP\1740 .\.\1740
D001224_D012640 NONE Therefore\RB\1740 ,\,\1740 like\IN\5839024 VPA\NN\1740 ,\,\1740 the\DT\1740 finding\NN\43195 that\IN\1740 VPU\NNP\1740 could\MD\1740 drastically\RB\1740 reduce\VB\441445 pilocarpine-induced\JJ\1740 increases\NNS\13576355 in\IN\13603305 glutamate\NN\15010703 and\CC\1740 <e1>aspartate</e1>\NN\1740 should\MD\1740 account\VB\2604760 ,\,\1740 at\IN\14622893 least\JJS\1740 partly\RB\1740 ,\,\1740 for\IN\1740 its\PRP$\6125041 anticonvulsant\JJ\1740 activity\NN\30358 observed\VBN\2163746 in\IN\13603305 pilocarpine-induced\JJ\1740 <e2>seizure</e2>\NN\14081375 in\IN\13603305 experimental\JJ\1740 animals\NNS\4475 .\.\1740
1720453
D007069_D007674 CID Long-term\JJ\1740 follow-up\NN\4599396 of\IN\1740 <e1>ifosfamide</e1>\NN\1740 <e2>renal\JJ\1740 toxicity</e2>\NN\13576101 in\IN\13603305 children\NNS\9622049 treated\VBN\2376958 for\IN\1740 malignant\JJ\1740 mesenchymal\JJ\1740 tumors\NNS\14234074 :\:\1740 an\DT\6697703 International\NNP\8366202 Society\NNP\7950920 of\IN\1740 Pediatric\NNP\1740 Oncology\NNP\6043075 report\NN\6470073 .\.\1740
D007069_C535700 NONE Long-term\JJ\1740 follow-up\NN\4599396 of\IN\1740 <e1>ifosfamide</e1>\NN\1740 renal\JJ\1740 toxicity\NN\13576101 in\IN\13603305 children\NNS\9622049 treated\VBN\2376958 for\IN\1740 <e2>malignant\JJ\1740 mesenchymal\JJ\1740 tumors</e2>\NNS\14234074 :\:\1740 an\DT\6697703 International\NNP\8366202 Society\NNP\7950920 of\IN\1740 Pediatric\NNP\1740 Oncology\NNP\6043075 report\NN\6470073 .\.\1740
D007069_C535700 NONE The\DT\1740 renal\JJ\1740 function\NN\13783581 of\IN\1740 74\CD\1740 children\NNS\9622049 with\IN\1740 <e2>malignant\JJ\1740 mesenchymal\JJ\1740 tumors</e2>\NNS\14234074 in\IN\13603305 complete\JJ\1740 remission\NN\7368256 and\CC\1740 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 the\DT\1740 same\JJ\1740 <e1>ifosfamide</e1>\NN\1740 chemotherapy\NN\661091 protocol\NN\6652242 (\-LRB-\1740 International\NNP\8366202 Society\NNP\7950920 of\IN\1740 Pediatric\NNP\1740 Oncology\NNP\6043075 Malignant\NNP\1740 Mesenchymal\NNP\1740 Tumor\NNP\14234074 Study\NN\635850 84\CD\1740 [\-LRB-\1740 SIOP\NN\1740 MMT\NN\1740 84\CD\1740 ]\-RRB-\1740 )\-RRB-\1740 were\VBD\836236 studied\VBN\630380 1\CD\13741022 year\NN\15113229 after\IN\1740 the\DT\1740 completion\NN\556313 of\IN\1740 treatment\NN\654885 .\.\1740
D007069_C535700 NONE The\DT\1740 renal\JJ\1740 function\NN\13783581 of\IN\1740 74\CD\1740 children\NNS\9622049 with\IN\1740 malignant\JJ\1740 mesenchymal\JJ\1740 tumors\NNS\14234074 in\IN\13603305 complete\JJ\1740 remission\NN\7368256 and\CC\1740 who\WP\8299493 have\VBP\2108377 received\VBN\2210855 the\DT\1740 same\JJ\1740 <e1>ifosfamide</e1>\NN\1740 chemotherapy\NN\661091 protocol\NN\6652242 (\-LRB-\1740 International\NNP\8366202 Society\NNP\7950920 of\IN\1740 Pediatric\NNP\1740 Oncology\NNP\6043075 <e2>Malignant\NNP\1740 Mesenchymal\NNP\1740 Tumor</e2>\NNP\14234074 Study\NN\635850 84\CD\1740 [\-LRB-\1740 SIOP\NN\1740 MMT\NN\1740 84\CD\1740 ]\-RRB-\1740 )\-RRB-\1740 were\VBD\836236 studied\VBN\630380 1\CD\13741022 year\NN\15113229 after\IN\1740 the\DT\1740 completion\NN\556313 of\IN\1740 treatment\NN\654885 .\.\1740
D007069_C535700 NONE This\DT\1740 low\JJ\1740 percentage\NN\13815742 (\-LRB-\1740 5\CD\13741022 %\NN\1740 )\-RRB-\1740 of\IN\1740 TDFS\NN\1740 must\MD\9367203 be\VB\836236 evaluated\VBN\670261 with\IN\1740 respect\NN\5817845 to\TO\1740 the\DT\1740 efficacy\NN\5199286 of\IN\1740 <e1>ifosfamide</e1>\NN\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>mesenchymal\JJ\1740 tumors</e2>\NNS\14234074 in\IN\13603305 children\NNS\9622049 .\.\1740
D003404_D006030 NONE Renal\JJ\1740 function\NN\13783581 was\VBD\836236 investigated\VBN\644583 by\IN\1740 measuring\VBG\697589 plasma\NN\5398023 and\CC\1740 urinary\JJ\1740 electrolytes\NNS\14589223 ,\,\1740 <e2>glucosuria</e2>\NNS\14267841 ,\,\1740 proteinuria\NN\14299637 ,\,\1740 aminoaciduria\NN\14299637 ,\,\1740 urinary\JJ\1740 pH\NN\5038959 ,\,\1740 osmolarity\NN\1740 ,\,\1740 <e1>creatinine</e1>\NN\1740 clearance\NN\5089947 ,\,\1740 phosphate\NN\15010703 tubular\JJ\1740 reabsorption\NN\13526110 ,\,\1740 beta\NN\6828818 2\CD\13741022 microglobulinuria\NN\1740 ,\,\1740 and\CC\1740 lysozymuria\NNS\1740 .\.\1740
D003404_D011507 NONE Renal\JJ\1740 function\NN\13783581 was\VBD\836236 investigated\VBN\644583 by\IN\1740 measuring\VBG\697589 plasma\NN\5398023 and\CC\1740 urinary\JJ\1740 electrolytes\NNS\14589223 ,\,\1740 glucosuria\NNS\14267841 ,\,\1740 <e2>proteinuria</e2>\NN\14299637 ,\,\1740 aminoaciduria\NN\14299637 ,\,\1740 urinary\JJ\1740 pH\NN\5038959 ,\,\1740 osmolarity\NN\1740 ,\,\1740 <e1>creatinine</e1>\NN\1740 clearance\NN\5089947 ,\,\1740 phosphate\NN\15010703 tubular\JJ\1740 reabsorption\NN\13526110 ,\,\1740 beta\NN\6828818 2\CD\13741022 microglobulinuria\NN\1740 ,\,\1740 and\CC\1740 lysozymuria\NNS\1740 .\.\1740
D003404_D000608 NONE Renal\JJ\1740 function\NN\13783581 was\VBD\836236 investigated\VBN\644583 by\IN\1740 measuring\VBG\697589 plasma\NN\5398023 and\CC\1740 urinary\JJ\1740 electrolytes\NNS\14589223 ,\,\1740 glucosuria\NNS\14267841 ,\,\1740 proteinuria\NN\14299637 ,\,\1740 <e2>aminoaciduria</e2>\NN\14299637 ,\,\1740 urinary\JJ\1740 pH\NN\5038959 ,\,\1740 osmolarity\NN\1740 ,\,\1740 <e1>creatinine</e1>\NN\1740 clearance\NN\5089947 ,\,\1740 phosphate\NN\15010703 tubular\JJ\1740 reabsorption\NN\13526110 ,\,\1740 beta\NN\6828818 2\CD\13741022 microglobulinuria\NN\1740 ,\,\1740 and\CC\1740 lysozymuria\NNS\1740 .\.\1740
D010710_D006030 NONE Renal\JJ\1740 function\NN\13783581 was\VBD\836236 investigated\VBN\644583 by\IN\1740 measuring\VBG\697589 plasma\NN\5398023 and\CC\1740 urinary\JJ\1740 electrolytes\NNS\14589223 ,\,\1740 <e2>glucosuria</e2>\NNS\14267841 ,\,\1740 proteinuria\NN\14299637 ,\,\1740 aminoaciduria\NN\14299637 ,\,\1740 urinary\JJ\1740 pH\NN\5038959 ,\,\1740 osmolarity\NN\1740 ,\,\1740 creatinine\NN\1740 clearance\NN\5089947 ,\,\1740 <e1>phosphate</e1>\NN\15010703 tubular\JJ\1740 reabsorption\NN\13526110 ,\,\1740 beta\NN\6828818 2\CD\13741022 microglobulinuria\NN\1740 ,\,\1740 and\CC\1740 lysozymuria\NNS\1740 .\.\1740
D010710_D011507 NONE Renal\JJ\1740 function\NN\13783581 was\VBD\836236 investigated\VBN\644583 by\IN\1740 measuring\VBG\697589 plasma\NN\5398023 and\CC\1740 urinary\JJ\1740 electrolytes\NNS\14589223 ,\,\1740 glucosuria\NNS\14267841 ,\,\1740 <e2>proteinuria</e2>\NN\14299637 ,\,\1740 aminoaciduria\NN\14299637 ,\,\1740 urinary\JJ\1740 pH\NN\5038959 ,\,\1740 osmolarity\NN\1740 ,\,\1740 creatinine\NN\1740 clearance\NN\5089947 ,\,\1740 <e1>phosphate</e1>\NN\15010703 tubular\JJ\1740 reabsorption\NN\13526110 ,\,\1740 beta\NN\6828818 2\CD\13741022 microglobulinuria\NN\1740 ,\,\1740 and\CC\1740 lysozymuria\NNS\1740 .\.\1740
D010710_D000608 NONE Renal\JJ\1740 function\NN\13783581 was\VBD\836236 investigated\VBN\644583 by\IN\1740 measuring\VBG\697589 plasma\NN\5398023 and\CC\1740 urinary\JJ\1740 electrolytes\NNS\14589223 ,\,\1740 glucosuria\NNS\14267841 ,\,\1740 proteinuria\NN\14299637 ,\,\1740 <e2>aminoaciduria</e2>\NN\14299637 ,\,\1740 urinary\JJ\1740 pH\NN\5038959 ,\,\1740 osmolarity\NN\1740 ,\,\1740 creatinine\NN\1740 clearance\NN\5089947 ,\,\1740 <e1>phosphate</e1>\NN\15010703 tubular\JJ\1740 reabsorption\NN\13526110 ,\,\1740 beta\NN\6828818 2\CD\13741022 microglobulinuria\NN\1740 ,\,\1740 and\CC\1740 lysozymuria\NNS\1740 .\.\1740
D010710_D064420 NONE Two\CD\13741022 subsets\NNS\7999699 of\IN\1740 patients\NNS\9898892 were\VBD\836236 identified\VBN\699815 from\IN\1740 this\DT\1740 latter\JJ\1740 group\NN\2137 :\:\1740 the\DT\1740 first\RB\1740 included\VBN\690614 four\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 5\CD\13741022 %\NN\1740 of\IN\1740 the\DT\1740 total\JJ\1740 population\NN\7942152 )\-RRB-\1740 who\WP\8299493 developed\VBD\1753788 major\JJ\1740 <e2>toxicity</e2>\NN\13576101 resulting\VBG\2633881 in\IN\13603305 Fanconi\NNP\1740 's\POS\1740 syndrome\NN\5870365 (\-LRB-\1740 TDFS\NN\1740 )\-RRB-\1740 ;\:\1740 and\CC\1740 the\DT\1740 second\JJ\1740 group\NN\2137 included\VBD\690614 five\CD\13741022 patients\NNS\9898892 with\IN\1740 elevated\JJ\1740 beta\NN\6828818 2\CD\13741022 microglobulinuria\NN\1740 and\CC\1740 low\JJ\1740 <e1>phosphate</e1>\NN\15010703 reabsorption\NN\13526110 .\.\1740
D010710_D005198 NONE Two\CD\13741022 subsets\NNS\7999699 of\IN\1740 patients\NNS\9898892 were\VBD\836236 identified\VBN\699815 from\IN\1740 this\DT\1740 latter\JJ\1740 group\NN\2137 :\:\1740 the\DT\1740 first\RB\1740 included\VBN\690614 four\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 5\CD\13741022 %\NN\1740 of\IN\1740 the\DT\1740 total\JJ\1740 population\NN\7942152 )\-RRB-\1740 who\WP\8299493 developed\VBD\1753788 major\JJ\1740 toxicity\NN\13576101 resulting\VBG\2633881 in\IN\13603305 <e2>Fanconi\NNP\1740 's\POS\1740 syndrome</e2>\NN\5870365 (\-LRB-\1740 TDFS\NN\1740 )\-RRB-\1740 ;\:\1740 and\CC\1740 the\DT\1740 second\JJ\1740 group\NN\2137 included\VBD\690614 five\CD\13741022 patients\NNS\9898892 with\IN\1740 elevated\JJ\1740 beta\NN\6828818 2\CD\13741022 microglobulinuria\NN\1740 and\CC\1740 low\JJ\1740 <e1>phosphate</e1>\NN\15010703 reabsorption\NN\13526110 .\.\1740
D010710_D005198 NONE Two\CD\13741022 subsets\NNS\7999699 of\IN\1740 patients\NNS\9898892 were\VBD\836236 identified\VBN\699815 from\IN\1740 this\DT\1740 latter\JJ\1740 group\NN\2137 :\:\1740 the\DT\1740 first\RB\1740 included\VBN\690614 four\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 5\CD\13741022 %\NN\1740 of\IN\1740 the\DT\1740 total\JJ\1740 population\NN\7942152 )\-RRB-\1740 who\WP\8299493 developed\VBD\1753788 major\JJ\1740 toxicity\NN\13576101 resulting\VBG\2633881 in\IN\13603305 Fanconi\NNP\1740 's\POS\1740 syndrome\NN\5870365 (\-LRB-\1740 <e2>TDFS</e2>\NN\1740 )\-RRB-\1740 ;\:\1740 and\CC\1740 the\DT\1740 second\JJ\1740 group\NN\2137 included\VBD\690614 five\CD\13741022 patients\NNS\9898892 with\IN\1740 elevated\JJ\1740 beta\NN\6828818 2\CD\13741022 microglobulinuria\NN\1740 and\CC\1740 low\JJ\1740 <e1>phosphate</e1>\NN\15010703 reabsorption\NN\13526110 .\.\1740
D007069_D064420 NONE Severe\JJ\1740 <e2>toxicity</e2>\NN\13576101 was\VBD\836236 correlated\VBN\2657219 with\IN\1740 the\DT\1740 higher\JJR\1740 cumulative\JJ\1740 dose\NN\3740161 of\IN\1740 60\CD\13745420 g/m2\NN\1740 of\IN\1740 <e1>ifosfamide</e1>\NN\1740 ,\,\1740 a\DT\13649268 younger\JJR\1740 age\NN\4916342 (\-LRB-\1740 less\JJR\1740 than\IN\1740 2\CD\13741022 1/2\CD\1740 years\NNS\15144371 old\JJ\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 a\DT\13649268 predominance\NN\14441825 of\IN\1740 vesicoprostatic\JJ\1740 tumor\NN\14234074 involvement\NN\1080366 .\.\1740
D007069_D009369 NONE Severe\JJ\1740 toxicity\NN\13576101 was\VBD\836236 correlated\VBN\2657219 with\IN\1740 the\DT\1740 higher\JJR\1740 cumulative\JJ\1740 dose\NN\3740161 of\IN\1740 60\CD\13745420 g/m2\NN\1740 of\IN\1740 <e1>ifosfamide</e1>\NN\1740 ,\,\1740 a\DT\13649268 younger\JJR\1740 age\NN\4916342 (\-LRB-\1740 less\JJR\1740 than\IN\1740 2\CD\13741022 1/2\CD\1740 years\NNS\15144371 old\JJ\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 a\DT\13649268 predominance\NN\14441825 of\IN\1740 vesicoprostatic\JJ\1740 <e2>tumor</e2>\NN\14234074 involvement\NN\1080366 .\.\1740
9245658
D009538_D002318 CID The\DT\1740 role\NN\719494 of\IN\1740 <e1>nicotine</e1>\NN\14712692 in\IN\13603305 smoking-related\JJ\1740 <e2>cardiovascular\JJ\1740 disease</e2>\NN\14061805 .\.\1740
D009538_D002318 CID <e1>Nicotine</e1>\NN\14712692 activates\VBZ\1641914 the\DT\1740 sympathetic\JJ\1740 nervous\JJ\1740 system\NN\3575240 and\CC\1740 in\IN\13603305 this\DT\1740 way\NN\4916342 could\MD\1740 contribute\VB\126264 to\TO\1740 <e2>cardiovascular\JJ\1740 disease</e2>\NN\14061805 .\.\1740
D009538_D050197 CID Animal\JJ\1740 studies\NNS\635850 and\CC\1740 mechanistic\JJ\1740 studies\NNS\635850 indicate\VBP\952524 that\IN\1740 <e1>nicotine</e1>\NN\14712692 could\MD\1740 play\VB\1072262 a\DT\13649268 role\NN\719494 in\IN\13603305 accelerating\VBG\226566 <e2>atherosclerosis</e2>\NN\14108324 ,\,\1740 but\CC\1740 evidence\NN\5816287 among\IN\1740 humans\NNS\31264 is\VBZ\836236 too\RB\1740 inadequate\JJ\1740 to\TO\1740 be\VB\836236 definitive\JJ\1740 about\IN\1740 such\PDT\1740 an\DT\6697703 effect\NN\34213 .\.\1740
D009538_D013927 NONE <e1>Nicotine</e1>\NN\14712692 does\VBZ\1640855 not\RB\1740 appear\VB\2604760 to\TO\1740 enhance\VB\227165 <e2>thrombosis</e2>\NN\14100769 among\IN\1740 humans\NNS\31264 .\.\1740
9746003
D002220_D004832 CID Inappropriate\JJ\1740 use\NN\407535 of\IN\1740 <e1>carbamazepine</e1>\NN\1740 and\CC\1740 vigabatrin\NN\1740 in\IN\13603305 typical\JJ\1740 <e2>absence\NN\14449405 seizures</e2>\NNS\14081375 .\.\1740
D002220_D004832 CID <e1>Carbamazepine</e1>\NNP\1740 and\CC\1740 vigabatrin\NN\1740 are\VBP\836236 contraindicated\VBN\872886 in\IN\13603305 typical\JJ\1740 <e2>absence\NN\14449405 seizures</e2>\NNS\14081375 .\.\1740
D020888_D004832 CID Inappropriate\JJ\1740 use\NN\407535 of\IN\1740 carbamazepine\NN\1740 and\CC\1740 <e1>vigabatrin</e1>\NN\1740 in\IN\13603305 typical\JJ\1740 <e2>absence\NN\14449405 seizures</e2>\NNS\14081375 .\.\1740
D020888_D004832 CID Carbamazepine\NNP\1740 and\CC\1740 <e1>vigabatrin</e1>\NN\1740 are\VBP\836236 contraindicated\VBN\872886 in\IN\13603305 typical\JJ\1740 <e2>absence\NN\14449405 seizures</e2>\NNS\14081375 .\.\1740
D002220_D009207 CID Frequency\NN\15286249 of\IN\1740 absences\NNS\14449405 increased\VBD\169651 in\IN\13603305 four\CD\13741022 children\NNS\9622049 treated\VBN\2376958 with\IN\1740 <e1>carbamazepine</e1>\NN\1740 and\CC\1740 two\CD\13741022 of\IN\1740 these\DT\1740 developed\VBN\1753788 <e2>myoclonic\JJ\1740 jerks</e2>\NNS\10322238 ,\,\1740 which\WDT\1740 resolved\VBD\352826 on\IN\1740 withdrawal\NN\7206096 of\IN\1740 carbamazepine\NN\1740 .\.\1740
D002220_D009207 CID Frequency\NN\15286249 of\IN\1740 absences\NNS\14449405 increased\VBD\169651 in\IN\13603305 four\CD\13741022 children\NNS\9622049 treated\VBN\2376958 with\IN\1740 carbamazepine\NN\1740 and\CC\1740 two\CD\13741022 of\IN\1740 these\DT\1740 developed\VBN\1753788 <e2>myoclonic\JJ\1740 jerks</e2>\NNS\10322238 ,\,\1740 which\WDT\1740 resolved\VBD\352826 on\IN\1740 withdrawal\NN\7206096 of\IN\1740 <e1>carbamazepine</e1>\NN\1740 .\.\1740
18081909
C026098_D001927 CID <e2>Encephalopathy</e2>\NNP\14084880 induced\VBN\1627355 by\IN\1740 <e1>levetiracetam</e1>\NN\1740 added\VBN\156601 to\TO\1740 valproate\VB\1740 .\.\1740
C026098_D001927 CID BACKGROUND\NN\4921011 :\:\1740 We\PRP\1740 report\VBP\831651 on\IN\1740 the\DT\1740 manifestation\NN\7321772 of\IN\1740 a\DT\13649268 <e1>levetiracetam</e1>\NN\1740 (LEV)-induced\NN\1740 <e2>encephalopathy</e2>\JJ\1740 .\.\1740
C026098_D001927 CID BACKGROUND\NN\4921011 :\:\1740 We\PRP\1740 report\VBP\831651 on\IN\1740 the\DT\1740 manifestation\NN\7321772 of\IN\1740 a\DT\13649268 levetiracetam\NN\1740 <e1>(LEV)-induced</e1>\NN\1740 <e2>encephalopathy</e2>\JJ\1740 .\.\1740
D014635_D001927 CID <e2>Encephalopathy</e2>\NNP\14084880 induced\VBN\1627355 by\IN\1740 levetiracetam\NN\1740 added\VBN\156601 to\TO\1740 <e1>valproate</e1>\VB\1740 .\.\1740
C026098_C562694 NONE FINDINGS\NNS\7951464 :\:\1740 A\DT\13649268 28-year-old\JJ\1740 man\NN\9605289 suffering\VBG\2110220 from\IN\1740 <e2>idiopathic\JJ\1740 epilepsy</e2>\NN\14085708 with\IN\1740 generalized\JJ\1740 seizures\NNS\14081375 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>LEV</e1>\NN\13685678 (\-LRB-\1740 3000\CD\1740 mg\NN\13717155 )\-RRB-\1740 added\VBN\156601 to\TO\1740 valproate\VB\1740 (\-LRB-\1740 VPA\NN\1740 )\-RRB-\1740 (\-LRB-\1740 2000\CD\1740 mg\NN\13717155 )\-RRB-\1740 .\.\1740
C026098_D012640 NONE FINDINGS\NNS\7951464 :\:\1740 A\DT\13649268 28-year-old\JJ\1740 man\NN\9605289 suffering\VBG\2110220 from\IN\1740 idiopathic\JJ\1740 epilepsy\NN\14085708 with\IN\1740 generalized\JJ\1740 <e2>seizures</e2>\NNS\14081375 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>LEV</e1>\NN\13685678 (\-LRB-\1740 3000\CD\1740 mg\NN\13717155 )\-RRB-\1740 added\VBN\156601 to\TO\1740 valproate\VB\1740 (\-LRB-\1740 VPA\NN\1740 )\-RRB-\1740 (\-LRB-\1740 2000\CD\1740 mg\NN\13717155 )\-RRB-\1740 .\.\1740
C026098_D012640 NONE OUTCOME\NN\7291312 :\:\1740 Following\VBG\1835496 discontinuation\NN\209943 of\IN\1740 <e1>LEV</e1>\NN\13685678 ,\,\1740 EEG\NN\7000195 and\CC\1740 neuropsychological\JJ\1740 findings\NNS\7951464 improved\VBD\126264 and\CC\1740 <e2>seizure</e2>\JJ\1740 frequency\NN\15286249 decreased\VBD\169651 .\.\1740
D014635_C562694 NONE FINDINGS\NNS\7951464 :\:\1740 A\DT\13649268 28-year-old\JJ\1740 man\NN\9605289 suffering\VBG\2110220 from\IN\1740 <e2>idiopathic\JJ\1740 epilepsy</e2>\NN\14085708 with\IN\1740 generalized\JJ\1740 seizures\NNS\14081375 was\VBD\836236 treated\VBN\2376958 with\IN\1740 LEV\NN\13685678 (\-LRB-\1740 3000\CD\1740 mg\NN\13717155 )\-RRB-\1740 added\VBN\156601 to\TO\1740 <e1>valproate</e1>\VB\1740 (\-LRB-\1740 VPA\NN\1740 )\-RRB-\1740 (\-LRB-\1740 2000\CD\1740 mg\NN\13717155 )\-RRB-\1740 .\.\1740
D014635_C562694 NONE FINDINGS\NNS\7951464 :\:\1740 A\DT\13649268 28-year-old\JJ\1740 man\NN\9605289 suffering\VBG\2110220 from\IN\1740 <e2>idiopathic\JJ\1740 epilepsy</e2>\NN\14085708 with\IN\1740 generalized\JJ\1740 seizures\NNS\14081375 was\VBD\836236 treated\VBN\2376958 with\IN\1740 LEV\NN\13685678 (\-LRB-\1740 3000\CD\1740 mg\NN\13717155 )\-RRB-\1740 added\VBN\156601 to\TO\1740 valproate\VB\1740 (\-LRB-\1740 <e1>VPA</e1>\NN\1740 )\-RRB-\1740 (\-LRB-\1740 2000\CD\1740 mg\NN\13717155 )\-RRB-\1740 .\.\1740
D014635_D012640 NONE FINDINGS\NNS\7951464 :\:\1740 A\DT\13649268 28-year-old\JJ\1740 man\NN\9605289 suffering\VBG\2110220 from\IN\1740 idiopathic\JJ\1740 epilepsy\NN\14085708 with\IN\1740 generalized\JJ\1740 <e2>seizures</e2>\NNS\14081375 was\VBD\836236 treated\VBN\2376958 with\IN\1740 LEV\NN\13685678 (\-LRB-\1740 3000\CD\1740 mg\NN\13717155 )\-RRB-\1740 added\VBN\156601 to\TO\1740 <e1>valproate</e1>\VB\1740 (\-LRB-\1740 VPA\NN\1740 )\-RRB-\1740 (\-LRB-\1740 2000\CD\1740 mg\NN\13717155 )\-RRB-\1740 .\.\1740
D014635_D012640 NONE FINDINGS\NNS\7951464 :\:\1740 A\DT\13649268 28-year-old\JJ\1740 man\NN\9605289 suffering\VBG\2110220 from\IN\1740 idiopathic\JJ\1740 epilepsy\NN\14085708 with\IN\1740 generalized\JJ\1740 <e2>seizures</e2>\NNS\14081375 was\VBD\836236 treated\VBN\2376958 with\IN\1740 LEV\NN\13685678 (\-LRB-\1740 3000\CD\1740 mg\NN\13717155 )\-RRB-\1740 added\VBN\156601 to\TO\1740 valproate\VB\1740 (\-LRB-\1740 <e1>VPA</e1>\NN\1740 )\-RRB-\1740 (\-LRB-\1740 2000\CD\1740 mg\NN\13717155 )\-RRB-\1740 .\.\1740
20520283
C522667_D012559 NONE Efficacy\NNP\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 <e1>asenapine</e1>\NN\1740 in\IN\13603305 a\DT\13649268 placebo-\NN\1740 and\CC\1740 haloperidol-controlled\JJ\1740 trial\NN\786195 in\IN\13603305 patients\NNS\9898892 with\IN\1740 acute\JJ\1740 exacerbation\NN\374224 of\IN\1740 <e2>schizophrenia</e2>\NN\14398067 .\.\1740
C522667_D012559 NONE <e1>Asenapine</e1>\NNP\1740 is\VBZ\836236 approved\VBN\803325 by\IN\1740 the\DT\1740 Food\NNP\20090 and\CC\1740 Drugs\NNP\14778436 Administration\NNP\1133281 in\IN\13603305 adults\NNS\7846 for\IN\1740 acute\JJ\1740 treatment\NN\654885 of\IN\1740 <e2>schizophrenia</e2>\NN\14398067 or\CC\3541091 of\IN\1740 manic\JJ\1740 or\CC\3541091 mixed\JJ\1740 episodes\NNS\7283608 associated\VBN\628491 with\IN\1740 bipolar\JJ\1740 I\CD\14622893 disorder\NN\14034177 with\IN\1740 or\CC\3541091 without\IN\1740 psychotic\JJ\1740 features\NNS\5849040 .\.\1740
C522667_D012559 NONE In\IN\13603305 a\DT\13649268 double-blind\JJ\1740 6-week\JJ\1740 trial\NN\786195 ,\,\1740 458\CD\1740 patients\NNS\9898892 with\IN\1740 acute\JJ\1740 <e2>schizophrenia</e2>\NN\14398067 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 fixed-dose\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>asenapine</e1>\NN\1740 at\IN\14622893 5\CD\13741022 mg\NN\13717155 twice\RB\1740 daily\RB\1740 (\-LRB-\1740 BID\NN\7160883 )\-RRB-\1740 ,\,\1740 asenapine\NN\1740 at\IN\14622893 10\CD\13745420 mg\NN\13717155 BID\NN\7160883 ,\,\1740 placebo\NN\3740161 ,\,\1740 or\CC\3541091 haloperidol\VB\1740 at\IN\14622893 4\CD\13741022 mg\NN\13717155 BID\NN\7160883 (\-LRB-\1740 to\TO\1740 verify\VB\665886 assay\NN\5733583 sensitivity\NN\5651971 )\-RRB-\1740 .\.\1740
C522667_D012559 NONE In\IN\13603305 a\DT\13649268 double-blind\JJ\1740 6-week\JJ\1740 trial\NN\786195 ,\,\1740 458\CD\1740 patients\NNS\9898892 with\IN\1740 acute\JJ\1740 <e2>schizophrenia</e2>\NN\14398067 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 fixed-dose\JJ\1740 treatment\NN\654885 with\IN\1740 asenapine\NN\1740 at\IN\14622893 5\CD\13741022 mg\NN\13717155 twice\RB\1740 daily\RB\1740 (\-LRB-\1740 BID\NN\7160883 )\-RRB-\1740 ,\,\1740 <e1>asenapine</e1>\NN\1740 at\IN\14622893 10\CD\13745420 mg\NN\13717155 BID\NN\7160883 ,\,\1740 placebo\NN\3740161 ,\,\1740 or\CC\3541091 haloperidol\VB\1740 at\IN\14622893 4\CD\13741022 mg\NN\13717155 BID\NN\7160883 (\-LRB-\1740 to\TO\1740 verify\VB\665886 assay\NN\5733583 sensitivity\NN\5651971 )\-RRB-\1740 .\.\1740
D006220_D012559 NONE Efficacy\NNP\5199286 and\CC\1740 safety\NN\13920835 of\IN\1740 asenapine\NN\1740 in\IN\13603305 a\DT\13649268 placebo-\NN\1740 and\CC\1740 <e1>haloperidol-controlled</e1>\JJ\1740 trial\NN\786195 in\IN\13603305 patients\NNS\9898892 with\IN\1740 acute\JJ\1740 exacerbation\NN\374224 of\IN\1740 <e2>schizophrenia</e2>\NN\14398067 .\.\1740
D006220_D012559 NONE In\IN\13603305 a\DT\13649268 double-blind\JJ\1740 6-week\JJ\1740 trial\NN\786195 ,\,\1740 458\CD\1740 patients\NNS\9898892 with\IN\1740 acute\JJ\1740 <e2>schizophrenia</e2>\NN\14398067 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 fixed-dose\JJ\1740 treatment\NN\654885 with\IN\1740 asenapine\NN\1740 at\IN\14622893 5\CD\13741022 mg\NN\13717155 twice\RB\1740 daily\RB\1740 (\-LRB-\1740 BID\NN\7160883 )\-RRB-\1740 ,\,\1740 asenapine\NN\1740 at\IN\14622893 10\CD\13745420 mg\NN\13717155 BID\NN\7160883 ,\,\1740 placebo\NN\3740161 ,\,\1740 or\CC\3541091 <e1>haloperidol</e1>\VB\1740 at\IN\14622893 4\CD\13741022 mg\NN\13717155 BID\NN\7160883 (\-LRB-\1740 to\TO\1740 verify\VB\665886 assay\NN\5733583 sensitivity\NN\5651971 )\-RRB-\1740 .\.\1740
C522667_D001714 NONE <e1>Asenapine</e1>\NNP\1740 is\VBZ\836236 approved\VBN\803325 by\IN\1740 the\DT\1740 Food\NNP\20090 and\CC\1740 Drugs\NNP\14778436 Administration\NNP\1133281 in\IN\13603305 adults\NNS\7846 for\IN\1740 acute\JJ\1740 treatment\NN\654885 of\IN\1740 schizophrenia\NN\14398067 or\CC\3541091 of\IN\1740 <e2>manic</e2>\JJ\1740 or\CC\3541091 mixed\JJ\1740 episodes\NNS\7283608 associated\VBN\628491 with\IN\1740 bipolar\JJ\1740 I\CD\14622893 disorder\NN\14034177 with\IN\1740 or\CC\3541091 without\IN\1740 psychotic\JJ\1740 features\NNS\5849040 .\.\1740
C522667_D001714 NONE <e1>Asenapine</e1>\NNP\1740 is\VBZ\836236 approved\VBN\803325 by\IN\1740 the\DT\1740 Food\NNP\20090 and\CC\1740 Drugs\NNP\14778436 Administration\NNP\1133281 in\IN\13603305 adults\NNS\7846 for\IN\1740 acute\JJ\1740 treatment\NN\654885 of\IN\1740 schizophrenia\NN\14398067 or\CC\3541091 of\IN\1740 manic\JJ\1740 or\CC\3541091 mixed\JJ\1740 episodes\NNS\7283608 associated\VBN\628491 with\IN\1740 <e2>bipolar\JJ\1740 I\CD\14622893 disorder</e2>\NN\14034177 with\IN\1740 or\CC\3541091 without\IN\1740 psychotic\JJ\1740 features\NNS\5849040 .\.\1740
C522667_D011618 NONE <e1>Asenapine</e1>\NNP\1740 is\VBZ\836236 approved\VBN\803325 by\IN\1740 the\DT\1740 Food\NNP\20090 and\CC\1740 Drugs\NNP\14778436 Administration\NNP\1133281 in\IN\13603305 adults\NNS\7846 for\IN\1740 acute\JJ\1740 treatment\NN\654885 of\IN\1740 schizophrenia\NN\14398067 or\CC\3541091 of\IN\1740 manic\JJ\1740 or\CC\3541091 mixed\JJ\1740 episodes\NNS\7283608 associated\VBN\628491 with\IN\1740 bipolar\JJ\1740 I\CD\14622893 disorder\NN\14034177 with\IN\1740 or\CC\3541091 without\IN\1740 <e2>psychotic</e2>\JJ\1740 features\NNS\5849040 .\.\1740
C522667_D001480 CID <e2>Extrapyramidal\JJ\1740 symptoms</e2>\NNS\5823932 reported\VBN\831651 as\IN\14622893 AEs\NN\1740 occurred\VBD\2623529 in\IN\13603305 15\CD\13745420 %\NN\1740 and\CC\1740 18\CD\13745420 %\NN\1740 ,\,\1740 34\CD\1740 %\NN\1740 ,\,\1740 and\CC\1740 10\CD\13745420 %\NN\1740 of\IN\1740 the\DT\1740 <e1>asenapine</e1>\NN\1740 at\IN\14622893 5\CD\13741022 and\CC\1740 10\CD\13745420 mg\NN\13717155 BID\NN\7160883 ,\,\1740 haloperidol\VB\1740 ,\,\1740 and\CC\1740 placebo\JJ\1740 groups\NNS\2137 ,\,\1740 respectively\RB\1740 .\.\1740
C522667_D001480 CID Post\NN\8621598 hoc\NN\1740 analyses\NNS\633864 indicated\VBD\952524 that\IN\1740 efficacy\NN\5199286 was\VBD\836236 similar\JJ\1740 with\IN\1740 <e1>asenapine</e1>\NN\1740 and\CC\1740 haloperidol\VB\1740 ;\:\1740 greater\JJR\1740 contrasts\NNS\13854649 were\VBD\836236 seen\VBN\2106506 in\IN\13603305 AEs\NNS\1740 ,\,\1740 especially\RB\1740 <e2>extrapyramidal\JJ\1740 symptoms</e2>\NNS\5823932 .\.\1740
D006220_D001480 CID <e2>Extrapyramidal\JJ\1740 symptoms</e2>\NNS\5823932 reported\VBN\831651 as\IN\14622893 AEs\NN\1740 occurred\VBD\2623529 in\IN\13603305 15\CD\13745420 %\NN\1740 and\CC\1740 18\CD\13745420 %\NN\1740 ,\,\1740 34\CD\1740 %\NN\1740 ,\,\1740 and\CC\1740 10\CD\13745420 %\NN\1740 of\IN\1740 the\DT\1740 asenapine\NN\1740 at\IN\14622893 5\CD\13741022 and\CC\1740 10\CD\13745420 mg\NN\13717155 BID\NN\7160883 ,\,\1740 <e1>haloperidol</e1>\VB\1740 ,\,\1740 and\CC\1740 placebo\JJ\1740 groups\NNS\2137 ,\,\1740 respectively\RB\1740 .\.\1740
D006220_D001480 CID Post\NN\8621598 hoc\NN\1740 analyses\NNS\633864 indicated\VBD\952524 that\IN\1740 efficacy\NN\5199286 was\VBD\836236 similar\JJ\1740 with\IN\1740 asenapine\NN\1740 and\CC\1740 <e1>haloperidol</e1>\VB\1740 ;\:\1740 greater\JJR\1740 contrasts\NNS\13854649 were\VBD\836236 seen\VBN\2106506 in\IN\13603305 AEs\NNS\1740 ,\,\1740 especially\RB\1740 <e2>extrapyramidal\JJ\1740 symptoms</e2>\NNS\5823932 .\.\1740
7504976
D002231_D056486 CID <e2>Toxic\JJ\1740 hepatitis</e2>\NN\14127211 induced\VBN\1627355 by\IN\1740 antithyroid\NN\1740 drugs\NNS\14778436 :\:\1740 four\CD\13741022 cases\NNS\7283608 including\VBG\690614 one\CD\13741022 with\IN\1740 cross-reactivity\NN\1740 between\IN\1740 <e1>carbimazole</e1>\NN\1740 and\CC\1740 benzylthiouracil\NN\1740 .\.\1740
D002231_D056486 CID Two\CD\13741022 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 induced\VBN\1627355 by\IN\1740 <e1>carbimazole</e1>\NN\1740 (\-LRB-\1740 N\NN\14622893 omercazole\NN\1740 )\-RRB-\1740 .\.\1740
D002231_D056486 CID Two\CD\13741022 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 induced\VBN\1627355 by\IN\1740 carbimazole\NN\1740 (\-LRB-\1740 <e1>N\NN\14622893 omercazole</e1>\NN\1740 )\-RRB-\1740 .\.\1740
D002231_D056486 CID Two\CD\13741022 others\NNS\1740 had\VBD\2108377 a\DT\13649268 mixed\JJ\1740 (\-LRB-\1740 cholestatic\JJ\1740 and\CC\1740 cytolytic\JJ\1740 )\-RRB-\1740 <e2>hepatitis</e2>\NN\14127211 following\VBG\1835496 <e1>carbimazole</e1>\NN\1740 .\.\1740
D002231_D056486 CID One\CD\13741022 of\IN\1740 the\DT\1740 latter\JJ\1740 two\CD\13741022 patients\NNS\9898892 further\RB\1740 experienced\VBD\2108377 a\DT\13649268 cytolytic\JJ\1740 <e2>hepatitis</e2>\NN\14127211 which\WDT\1740 appeared\VBD\2604760 after\IN\1740 Benzylthiouracil\NNP\1740 (\-LRB-\1740 Basd\NNP\1740 ne\NN\14622893 )\-RRB-\1740 had\VBD\2108377 replaced\VBN\1631072 <e1>carbimazole</e1>\NN\1740 .\.\1740
C019269_D056486 NONE <e2>Toxic\JJ\1740 hepatitis</e2>\NN\14127211 induced\VBN\1627355 by\IN\1740 antithyroid\NN\1740 drugs\NNS\14778436 :\:\1740 four\CD\13741022 cases\NNS\7283608 including\VBG\690614 one\CD\13741022 with\IN\1740 cross-reactivity\NN\1740 between\IN\1740 carbimazole\NN\1740 and\CC\1740 <e1>benzylthiouracil</e1>\NN\1740 .\.\1740
C019269_D056486 NONE One\CD\13741022 of\IN\1740 the\DT\1740 latter\JJ\1740 two\CD\13741022 patients\NNS\9898892 further\RB\1740 experienced\VBD\2108377 a\DT\13649268 cytolytic\JJ\1740 <e2>hepatitis</e2>\NN\14127211 which\WDT\1740 appeared\VBD\2604760 after\IN\1740 <e1>Benzylthiouracil</e1>\NNP\1740 (\-LRB-\1740 Basd\NNP\1740 ne\NN\14622893 )\-RRB-\1740 had\VBD\2108377 replaced\VBN\1631072 carbimazole\NN\1740 .\.\1740
C019269_D056486 NONE One\CD\13741022 of\IN\1740 the\DT\1740 latter\JJ\1740 two\CD\13741022 patients\NNS\9898892 further\RB\1740 experienced\VBD\2108377 a\DT\13649268 cytolytic\JJ\1740 <e2>hepatitis</e2>\NN\14127211 which\WDT\1740 appeared\VBD\2604760 after\IN\1740 Benzylthiouracil\NNP\1740 (\-LRB-\1740 <e1>Basd\NNP\1740 ne</e1>\NN\14622893 )\-RRB-\1740 had\VBD\2108377 replaced\VBN\1631072 carbimazole\NN\1740 .\.\1740
D002231_D002779 CID Two\CD\13741022 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 induced\VBN\1627355 by\IN\1740 <e1>carbimazole</e1>\NN\1740 (\-LRB-\1740 N\NN\14622893 omercazole\NN\1740 )\-RRB-\1740 .\.\1740
D002231_D002779 CID Two\CD\13741022 patients\NNS\9898892 had\VBD\2108377 a\DT\13649268 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 induced\VBN\1627355 by\IN\1740 carbimazole\NN\1740 (\-LRB-\1740 <e1>N\NN\14622893 omercazole</e1>\NN\1740 )\-RRB-\1740 .\.\1740
D002231_D002779 CID Two\CD\13741022 others\NNS\1740 had\VBD\2108377 a\DT\13649268 mixed\JJ\1740 (\-LRB-\1740 <e2>cholestatic</e2>\JJ\1740 and\CC\1740 cytolytic\JJ\1740 )\-RRB-\1740 hepatitis\NN\14127211 following\VBG\1835496 <e1>carbimazole</e1>\NN\1740 .\.\1740
11007689
D016572_D057049 CID <e1>Cyclosporine</e1>\NN\1740 and\CC\1740 tacrolimus-associated\JJ\1740 <e2>thrombotic\JJ\1740 microangiopathy</e2>\NN\1740 .\.\1740
D016572_D057049 CID The\DT\1740 development\NN\248977 of\IN\1740 <e2>thrombotic\JJ\1740 microangiopathy</e2>\NN\1740 (\-LRB-\1740 TMA\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>cyclosporine</e1>\NN\1740 has\VBZ\2108377 been\VBN\836236 well\RB\1740 documented\VBN\1000214 .\.\1740
D016572_D057049 CID The\DT\1740 development\NN\248977 of\IN\1740 thrombotic\JJ\1740 microangiopathy\NN\1740 (\-LRB-\1740 <e2>TMA</e2>\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>cyclosporine</e1>\NN\1740 has\VBZ\2108377 been\VBN\836236 well\RB\1740 documented\VBN\1000214 .\.\1740
D016572_D057049 CID As\IN\14622893 a\DT\13649268 result\NN\34213 ,\,\1740 switching\NN\191142 to\TO\1740 tacrolimus\NN\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 be\VB\836236 a\DT\13649268 viable\JJ\1740 therapeutic\JJ\1740 option\NN\6480506 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 <e1>cyclosporine-induced</e1>\JJ\1740 <e2>TMA</e2>\NN\1740 .\.\1740
D016572_D057049 CID However\RB\1740 ,\,\1740 literature\NN\6362953 regarding\VBG\689344 the\DT\1740 incidence\NN\13821570 of\IN\1740 the\DT\1740 recurrence\NN\7342049 of\IN\1740 <e2>TMA</e2>\NN\1740 in\IN\13603305 patients\NNS\9898892 exposed\VBN\2110927 sequentially\RB\1740 to\TO\1740 <e1>cyclosporine</e1>\NN\1740 and\CC\1740 tacrolimus\NN\1740 is\VBZ\836236 limited\JJ\1740 .\.\1740
D016572_D057049 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 living\VBG\2655135 donor\NN\9608709 renal\JJ\1740 transplant\NN\5267548 recipient\NN\9764201 who\WP\8299493 developed\VBD\1753788 <e1>cyclosporine-induced</e1>\JJ\1740 <e2>TMA</e2>\NN\1740 that\WDT\1740 responded\VBD\2367363 to\IN\1740 the\DT\1740 withdrawal\NN\7206096 of\IN\1740 cyclosporine\NN\1740 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 plasmapheresis\NN\649992 and\CC\1740 fresh\JJ\1740 frozen\JJ\1740 plasma\NN\5398023 replacement\NN\196485 therapy\NN\657604 .\.\1740
D016572_D057049 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 living\VBG\2655135 donor\NN\9608709 renal\JJ\1740 transplant\NN\5267548 recipient\NN\9764201 who\WP\8299493 developed\VBD\1753788 cyclosporine-induced\JJ\1740 <e2>TMA</e2>\NN\1740 that\WDT\1740 responded\VBD\2367363 to\IN\1740 the\DT\1740 withdrawal\NN\7206096 of\IN\1740 <e1>cyclosporine</e1>\NN\1740 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 plasmapheresis\NN\649992 and\CC\1740 fresh\JJ\1740 frozen\JJ\1740 plasma\NN\5398023 replacement\NN\196485 therapy\NN\657604 .\.\1740
D016572_D057049 CID Patients\NNS\9898892 who\WP\8299493 are\VBP\836236 switched\VBN\138508 from\IN\1740 <e1>cyclosporine</e1>\NN\1740 to\TO\1740 tacrolimus\NN\1740 or\CC\3541091 vice\RB\1740 versa\RB\1740 should\MD\1740 be\VB\836236 closely\RB\1740 monitored\VBN\2169352 for\IN\1740 the\DT\1740 signs\NNS\6643763 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 recurrent\JJ\1740 <e2>TMA</e2>\NN\1740 .\.\1740
D016559_D057049 CID Cyclosporine\NN\1740 and\CC\1740 <e1>tacrolimus-associated</e1>\JJ\1740 <e2>thrombotic\JJ\1740 microangiopathy</e2>\NN\1740 .\.\1740
D016559_D057049 CID As\IN\14622893 a\DT\13649268 result\NN\34213 ,\,\1740 switching\NN\191142 to\TO\1740 <e1>tacrolimus</e1>\NN\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 be\VB\836236 a\DT\13649268 viable\JJ\1740 therapeutic\JJ\1740 option\NN\6480506 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 cyclosporine-induced\JJ\1740 <e2>TMA</e2>\NN\1740 .\.\1740
D016559_D057049 CID With\IN\1740 the\DT\1740 more\RBR\1740 widespread\JJ\1740 application\NN\947128 of\IN\1740 <e1>tacrolimus</e1>\NN\1740 in\IN\13603305 organ\NN\5220461 transplantation\NN\671351 ,\,\1740 tacrolimus-associated\JJ\1740 <e2>TMA</e2>\NN\1740 has\VBZ\2108377 also\RB\1740 been\VBN\836236 recognized\VBN\686447 .\.\1740
D016559_D057049 CID With\IN\1740 the\DT\1740 more\RBR\1740 widespread\JJ\1740 application\NN\947128 of\IN\1740 tacrolimus\NN\1740 in\IN\13603305 organ\NN\5220461 transplantation\NN\671351 ,\,\1740 <e1>tacrolimus-associated</e1>\JJ\1740 <e2>TMA</e2>\NN\1740 has\VBZ\2108377 also\RB\1740 been\VBN\836236 recognized\VBN\686447 .\.\1740
D016559_D057049 CID However\RB\1740 ,\,\1740 literature\NN\6362953 regarding\VBG\689344 the\DT\1740 incidence\NN\13821570 of\IN\1740 the\DT\1740 recurrence\NN\7342049 of\IN\1740 <e2>TMA</e2>\NN\1740 in\IN\13603305 patients\NNS\9898892 exposed\VBN\2110927 sequentially\RB\1740 to\TO\1740 cyclosporine\NN\1740 and\CC\1740 <e1>tacrolimus</e1>\NN\1740 is\VBZ\836236 limited\JJ\1740 .\.\1740
D016559_D057049 CID Introduction\NN\235435 of\IN\1740 <e1>tacrolimus</e1>\NN\1740 as\IN\14622893 an\DT\6697703 alternative\JJ\1740 immunosuppressive\JJ\1740 agent\NN\7347 resulted\VBD\2633881 in\IN\13603305 the\DT\1740 recurrence\NN\7342049 of\IN\1740 <e2>TMA</e2>\NN\1740 and\CC\1740 the\DT\1740 subsequent\JJ\1740 loss\NN\13252973 of\IN\1740 the\DT\1740 renal\JJ\1740 allograft\NN\5582859 .\.\1740
D016559_D057049 CID Patients\NNS\9898892 who\WP\8299493 are\VBP\836236 switched\VBN\138508 from\IN\1740 cyclosporine\NN\1740 to\TO\1740 <e1>tacrolimus</e1>\NN\1740 or\CC\3541091 vice\RB\1740 versa\RB\1740 should\MD\1740 be\VB\836236 closely\RB\1740 monitored\VBN\2169352 for\IN\1740 the\DT\1740 signs\NNS\6643763 and\CC\1740 symptoms\NNS\5823932 of\IN\1740 recurrent\JJ\1740 <e2>TMA</e2>\NN\1740 .\.\1740
8682684
D000082_D007022 CID <e1>Acetaminophen-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D000082_D007022 CID However\RB\1740 ,\,\1740 <e1>acetaminophen</e1>\RB\1740 has\VBZ\2108377 been\VBN\836236 demonstrated\VBN\2137132 to\TO\1740 produce\VB\1617192 symptoms\NNS\5823932 of\IN\1740 anaphylaxis\NN\14533203 ,\,\1740 including\VBG\690614 <e2>hypotension</e2>\NN\14057371 ,\,\1740 in\IN\13603305 sensitive\JJ\1740 individuals\NNS\7347 .\.\1740
D000082_D007022 CID This\DT\1740 article\NN\6367571 describes\VBZ\1001294 two\CD\13741022 critically\RB\1740 ill\JJ\1740 patients\NNS\9898892 in\IN\13603305 whom\WP\1740 transient\JJ\1740 episodes\NNS\7283608 of\IN\1740 <e2>hypotension</e2>\NN\14057371 reproducibly\RB\1740 developed\VBD\1753788 after\IN\1740 administration\NN\1133281 of\IN\1740 <e1>acetaminophen</e1>\NN\2707683 .\.\1740
D000082_D007022 CID The\DT\1740 reports\NNS\6470073 illustrate\VBP\955601 the\DT\1740 need\NN\13920835 for\IN\1740 clinicians\NNS\10462860 to\TO\1740 consider\VB\689344 <e1>acetaminophen</e1>\NN\2707683 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>hypotension</e2>\NN\14057371 of\IN\1740 unknown\JJ\1740 origin\NN\8620061 .\.\1740
D000082_D002318 NONE The\DT\1740 potential\NN\14481929 for\IN\1740 <e1>acetaminophen</e1>\NN\2707683 to\TO\1740 produce\VB\1617192 <e2>cardiovascular\JJ\1740 toxicities</e2>\NNS\13576101 is\VBZ\836236 very\RB\1740 low\JJ\1740 .\.\1740
D000082_D000707 NONE However\RB\1740 ,\,\1740 <e1>acetaminophen</e1>\RB\1740 has\VBZ\2108377 been\VBN\836236 demonstrated\VBN\2137132 to\TO\1740 produce\VB\1617192 symptoms\NNS\5823932 of\IN\1740 <e2>anaphylaxis</e2>\NN\14533203 ,\,\1740 including\VBG\690614 hypotension\NN\14057371 ,\,\1740 in\IN\13603305 sensitive\JJ\1740 individuals\NNS\7347 .\.\1740
D000082_D016638 NONE This\DT\1740 article\NN\6367571 describes\VBZ\1001294 two\CD\13741022 <e2>critically\RB\1740 ill</e2>\JJ\1740 patients\NNS\9898892 in\IN\13603305 whom\WP\1740 transient\JJ\1740 episodes\NNS\7283608 of\IN\1740 hypotension\NN\14057371 reproducibly\RB\1740 developed\VBD\1753788 after\IN\1740 administration\NN\1133281 of\IN\1740 <e1>acetaminophen</e1>\NN\2707683 .\.\1740
15737522
D002443_D001660 CID <e1>Ceftriaxone-associated</e1>\JJ\1740 <e2>biliary\JJ\1740 pseudolithiasis</e2>\NN\1740 in\IN\13603305 paediatric\JJ\1740 surgical\JJ\1740 patients\NNS\9898892 .\.\1740
D002443_D001660 CID It\PRP\6125041 is\VBZ\836236 well\RB\1740 known\VBN\2110220 that\IN\1740 <e1>ceftriaxone</e1>\NN\2996840 leads\VBZ\1752884 to\TO\1740 <e2>pseudolithiasis</e2>\NN\1740 in\IN\13603305 some\DT\1740 patients\NNS\9898892 .\.\1740
D002443_D001660 CID In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 prospectively\RB\1740 evaluated\VBD\670261 the\DT\1740 incidence\NN\13821570 and\CC\1740 clinical\JJ\1740 importance\NN\5138488 of\IN\1740 <e2>pseudolithiasis</e2>\NN\1740 in\IN\13603305 paediatric\JJ\1740 surgical\JJ\1740 patients\NNS\9898892 receiving\VBG\2210855 <e1>ceftriaxone</e1>\NN\2996840 treatment\NN\654885 ,\,\1740 who\WP\8299493 often\RB\1740 had\VBD\2108377 to\TO\1740 fast\VB\1196037 in\IN\13603305 the\DT\1740 post-operative\JJ\1740 period\NN\13575869 .\.\1740
19767176
C020972_D013226 NONE <e1>Pyrrolidine\NNP\1740 dithiocarbamate</e1>\NN\1740 protects\VBZ\1127795 the\DT\1740 piriform\NN\1740 cortex\NN\5462674 in\IN\13603305 the\DT\1740 pilocarpine\NN\14712692 <e2>status\NN\24720 epilepticus</e2>\NN\1740 model\NN\5888929 .\.\1740
C020972_D013226 NONE The\DT\1740 effect\NN\34213 of\IN\1740 <e1>PDTC</e1>\NN\1740 on\IN\1740 <e2>status\NN\24720 epilepticus-associated</e2>\JJ\1740 cell\NN\3080309 loss\NN\13252973 in\IN\13603305 the\DT\1740 hippocampus\NN\5462674 and\CC\1740 piriform\NN\1740 cortex\NN\5462674 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 the\DT\1740 rat\NN\2329401 fractionated\VBD\1458973 pilocarpine\NN\14712692 model\NN\5888929 .\.\1740
C020972_D013226 NONE Treatment\NN\654885 with\IN\1740 150\CD\1740 mg/kg\NN\1740 <e1>PDTC</e1>\NN\1740 before\IN\1740 and\CC\1740 following\VBG\1835496 <e2>status\NN\24720 epilepticus</e2>\NN\1740 significantly\RB\1740 increased\VBD\169651 the\DT\1740 mortality\NN\5054863 rate\NN\13815152 to\IN\1740 100\CD\13745420 %\NN\1740 .\.\1740
C020972_D013226 NONE Administration\NN\1133281 of\IN\1740 50\CD\13745420 mg/kg\NN\1740 <e1>PDTC</e1>\NN\1740 (\-LRB-\1740 low-dose\JJ\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 exert\VB\1158872 major\JJ\1740 effects\NNS\13245626 on\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 a\DT\13649268 <e2>status\NN\24720 epilepticus</e2>\NN\1740 or\CC\3541091 the\DT\1740 mortality\NN\5054863 rate\NN\13815152 .\.\1740
C020972_D013226 NONE A\DT\13649268 significant\JJ\1740 decrease\NN\7296428 in\IN\13603305 neuronal\JJ\1740 density\NN\4941325 of\IN\1740 the\DT\1740 hippocampal\NN\1740 hilar\JJ\1740 formation\NN\7938773 was\VBD\836236 identified\VBN\699815 in\IN\13603305 vehicle-\NN\1740 and\CC\1740 <e1>PDTC-treated</e1>\JJ\1740 rats\NNS\2329401 following\VBG\1835496 <e2>status\NN\24720 epilepticus</e2>\NN\1740 .\.\1740
D010862_D013226 CID Pyrrolidine\NNP\1740 dithiocarbamate\NN\1740 protects\VBZ\1127795 the\DT\1740 piriform\NN\1740 cortex\NN\5462674 in\IN\13603305 the\DT\1740 <e1>pilocarpine</e1>\NN\14712692 <e2>status\NN\24720 epilepticus</e2>\NN\1740 model\NN\5888929 .\.\1740
D010862_D013226 CID The\DT\1740 effect\NN\34213 of\IN\1740 PDTC\NN\1740 on\IN\1740 <e2>status\NN\24720 epilepticus-associated</e2>\JJ\1740 cell\NN\3080309 loss\NN\13252973 in\IN\13603305 the\DT\1740 hippocampus\NN\5462674 and\CC\1740 piriform\NN\1740 cortex\NN\5462674 was\VBD\836236 evaluated\VBN\670261 in\IN\13603305 the\DT\1740 rat\NN\2329401 fractionated\VBD\1458973 <e1>pilocarpine</e1>\NN\14712692 model\NN\5888929 .\.\1740
D010100_D009410 NONE Both\DT\1740 ,\,\1740 production\NN\30358 of\IN\1740 reactive\JJ\1740 <e1>oxygen</e1>\NN\14622893 species\NNS\7992450 as\RB\1740 well\RB\1740 as\IN\14622893 activation\NN\13561719 of\IN\1740 NF-kappaB\NN\1740 have\VBP\2108377 been\VBN\836236 implicated\VBN\2677097 in\IN\13603305 severe\JJ\1740 <e2>neuronal\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 different\JJ\1740 sub-regions\NNS\1740 of\IN\1740 the\DT\1740 hippocampus\NN\5462674 as\RB\1740 well\RB\1740 as\IN\14622893 in\IN\13603305 the\DT\1740 surrounding\VBG\1205696 cortices\NNS\5462674 .\.\1740
D010100_D009410 NONE These\DT\1740 data\NNS\7951464 might\MD\5029706 indicate\VB\952524 that\IN\1740 the\DT\1740 generation\NN\7942152 of\IN\1740 reactive\JJ\1740 <e1>oxygen</e1>\NN\14622893 species\NNS\7992450 and\CC\1740 activation\NN\13561719 of\IN\1740 NF-kappaB\NN\1740 plays\VBZ\1072262 a\DT\13649268 more\RBR\1740 central\JJ\1740 role\NN\719494 in\IN\13603305 seizure-associated\JJ\1740 <e2>neuronal\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 the\DT\1740 temporal\JJ\1740 cortex\NN\5462674 as\IN\14622893 compared\VBN\644583 to\IN\1740 the\DT\1740 hippocampal\NN\1740 hilus\NN\5223370 .\.\1740
C020972_D009410 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 the\DT\1740 NF-kappaB\NN\1740 inhibitor\NN\20090 and\CC\1740 antioxidant\JJ\1740 <e1>PDTC</e1>\NN\1740 protected\VBD\1127795 the\DT\1740 piriform\NN\1740 cortex\NN\5462674 ,\,\1740 whereas\IN\1740 it\PRP\6125041 did\VBD\1640855 not\RB\1740 affect\VB\126264 hilar\JJ\1740 <e2>neuronal\JJ\1740 loss</e2>\NN\13252973 .\.\1740
D010100_D012640 NONE These\DT\1740 data\NNS\7951464 might\MD\5029706 indicate\VB\952524 that\IN\1740 the\DT\1740 generation\NN\7942152 of\IN\1740 reactive\JJ\1740 <e1>oxygen</e1>\NN\14622893 species\NNS\7992450 and\CC\1740 activation\NN\13561719 of\IN\1740 NF-kappaB\NN\1740 plays\VBZ\1072262 a\DT\13649268 more\RBR\1740 central\JJ\1740 role\NN\719494 in\IN\13603305 <e2>seizure-associated</e2>\JJ\1740 neuronal\JJ\1740 damage\NN\7296428 in\IN\13603305 the\DT\1740 temporal\JJ\1740 cortex\NN\5462674 as\IN\14622893 compared\VBN\644583 to\IN\1740 the\DT\1740 hippocampal\NN\1740 hilus\NN\5223370 .\.\1740
10193204
C009438_D013927 NONE Effects\NNS\13245626 of\IN\1740 <e1>tetrandrine</e1>\NN\1740 and\CC\1740 fangchinoline\NN\1740 on\IN\1740 experimental\JJ\1740 <e2>thrombosis</e2>\NN\14100769 in\IN\13603305 mice\NNS\2329401 and\CC\1740 human\JJ\1740 platelet\NN\5432736 aggregation\NN\31264 .\.\1740
C009438_D013927 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>TET</e1>\NN\15157225 and\CC\1740 FAN\NN\3183080 on\IN\1740 the\DT\1740 experimental\JJ\1740 <e2>thrombosis</e2>\NN\14100769 induced\VBN\1627355 by\IN\1740 collagen\NN\15026716 plus\CC\4723816 epinephrine\NN\14807929 (\-LRB-\1740 EP\NN\1740 )\-RRB-\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 and\CC\1740 platelet\NN\5432736 aggregation\NN\31264 and\CC\1740 blood\NN\5397468 coagulation\NN\13518963 in\FW\13603305 vitro\FW\1740 .\.\1740
C009438_D013927 NONE In\IN\13603305 the\DT\1740 in\FW\13603305 vivo\FW\1740 study\NN\635850 ,\,\1740 the\DT\1740 administration\NN\1133281 (\-LRB-\1740 50\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 of\IN\1740 <e1>TET</e1>\NN\15157225 and\CC\1740 FAN\NN\3183080 in\IN\13603305 mice\NNS\2329401 showed\VBD\2137132 the\DT\1740 inhibition\NN\1068773 of\IN\1740 <e2>thrombosis</e2>\NN\14100769 by\IN\1740 55\CD\1740 %\NN\1740 and\CC\1740 35\CD\1740 %\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 acetylsalicylic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 ASA\NN\1740 ,\,\1740 50\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 positive\JJ\1740 control\NN\5190804 ,\,\1740 showed\VBD\2137132 only\RB\1740 30\CD\13745420 %\NN\1740 inhibition\NN\1068773 .\.\1740
C009438_D001791 NONE Effects\NNS\13245626 of\IN\1740 <e1>tetrandrine</e1>\NN\1740 and\CC\1740 fangchinoline\NN\1740 on\IN\1740 experimental\JJ\1740 thrombosis\NN\14100769 in\IN\13603305 mice\NNS\2329401 and\CC\1740 human\JJ\1740 <e2>platelet\NN\5432736 aggregation</e2>\NN\31264 .\.\1740
C009438_D001791 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>TET</e1>\NN\15157225 and\CC\1740 FAN\NN\3183080 on\IN\1740 the\DT\1740 experimental\JJ\1740 thrombosis\NN\14100769 induced\VBN\1627355 by\IN\1740 collagen\NN\15026716 plus\CC\4723816 epinephrine\NN\14807929 (\-LRB-\1740 EP\NN\1740 )\-RRB-\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 and\CC\1740 <e2>platelet\NN\5432736 aggregation</e2>\NN\31264 and\CC\1740 blood\NN\5397468 coagulation\NN\13518963 in\FW\13603305 vitro\FW\1740 .\.\1740
C009438_D001791 NONE In\IN\13603305 the\DT\1740 vitro\FW\1740 human\JJ\1740 <e2>platelet\NN\5432736 aggregations</e2>\NNS\31264 induced\VBN\1627355 by\IN\1740 the\DT\1740 agonists\NNS\9613191 used\VBN\1156834 in\IN\13603305 tests\NNS\5798043 ,\,\1740 <e1>TET</e1>\NN\15157225 and\CC\1740 FAN\NN\3183080 showed\VBD\2137132 the\DT\1740 inhibitions\NN\1068773 dose\NN\3740161 dependently\RB\1740 .\.\1740
C060802_D013927 NONE Effects\NNS\13245626 of\IN\1740 tetrandrine\NN\1740 and\CC\1740 <e1>fangchinoline</e1>\NN\1740 on\IN\1740 experimental\JJ\1740 <e2>thrombosis</e2>\NN\14100769 in\IN\13603305 mice\NNS\2329401 and\CC\1740 human\JJ\1740 platelet\NN\5432736 aggregation\NN\31264 .\.\1740
C060802_D013927 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 TET\NN\15157225 and\CC\1740 <e1>FAN</e1>\NN\3183080 on\IN\1740 the\DT\1740 experimental\JJ\1740 <e2>thrombosis</e2>\NN\14100769 induced\VBN\1627355 by\IN\1740 collagen\NN\15026716 plus\CC\4723816 epinephrine\NN\14807929 (\-LRB-\1740 EP\NN\1740 )\-RRB-\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 and\CC\1740 platelet\NN\5432736 aggregation\NN\31264 and\CC\1740 blood\NN\5397468 coagulation\NN\13518963 in\FW\13603305 vitro\FW\1740 .\.\1740
C060802_D013927 NONE In\IN\13603305 the\DT\1740 in\FW\13603305 vivo\FW\1740 study\NN\635850 ,\,\1740 the\DT\1740 administration\NN\1133281 (\-LRB-\1740 50\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 of\IN\1740 TET\NN\15157225 and\CC\1740 <e1>FAN</e1>\NN\3183080 in\IN\13603305 mice\NNS\2329401 showed\VBD\2137132 the\DT\1740 inhibition\NN\1068773 of\IN\1740 <e2>thrombosis</e2>\NN\14100769 by\IN\1740 55\CD\1740 %\NN\1740 and\CC\1740 35\CD\1740 %\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 acetylsalicylic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 ASA\NN\1740 ,\,\1740 50\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 positive\JJ\1740 control\NN\5190804 ,\,\1740 showed\VBD\2137132 only\RB\1740 30\CD\13745420 %\NN\1740 inhibition\NN\1068773 .\.\1740
C060802_D001791 NONE Effects\NNS\13245626 of\IN\1740 tetrandrine\NN\1740 and\CC\1740 <e1>fangchinoline</e1>\NN\1740 on\IN\1740 experimental\JJ\1740 thrombosis\NN\14100769 in\IN\13603305 mice\NNS\2329401 and\CC\1740 human\JJ\1740 <e2>platelet\NN\5432736 aggregation</e2>\NN\31264 .\.\1740
C060802_D001791 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 TET\NN\15157225 and\CC\1740 <e1>FAN</e1>\NN\3183080 on\IN\1740 the\DT\1740 experimental\JJ\1740 thrombosis\NN\14100769 induced\VBN\1627355 by\IN\1740 collagen\NN\15026716 plus\CC\4723816 epinephrine\NN\14807929 (\-LRB-\1740 EP\NN\1740 )\-RRB-\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 and\CC\1740 <e2>platelet\NN\5432736 aggregation</e2>\NN\31264 and\CC\1740 blood\NN\5397468 coagulation\NN\13518963 in\FW\13603305 vitro\FW\1740 .\.\1740
C060802_D001791 NONE In\IN\13603305 the\DT\1740 vitro\FW\1740 human\JJ\1740 <e2>platelet\NN\5432736 aggregations</e2>\NNS\31264 induced\VBN\1627355 by\IN\1740 the\DT\1740 agonists\NNS\9613191 used\VBN\1156834 in\IN\13603305 tests\NNS\5798043 ,\,\1740 TET\NN\15157225 and\CC\1740 <e1>FAN</e1>\NN\3183080 showed\VBD\2137132 the\DT\1740 inhibitions\NN\1068773 dose\NN\3740161 dependently\RB\1740 .\.\1740
C009438_D001778 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>TET</e1>\NN\15157225 and\CC\1740 FAN\NN\3183080 on\IN\1740 the\DT\1740 experimental\JJ\1740 thrombosis\NN\14100769 induced\VBN\1627355 by\IN\1740 collagen\NN\15026716 plus\CC\4723816 epinephrine\NN\14807929 (\-LRB-\1740 EP\NN\1740 )\-RRB-\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 and\CC\1740 platelet\NN\5432736 aggregation\NN\31264 and\CC\1740 <e2>blood\NN\5397468 coagulation</e2>\NN\13518963 in\FW\13603305 vitro\FW\1740 .\.\1740
C060802_D001778 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 TET\NN\15157225 and\CC\1740 <e1>FAN</e1>\NN\3183080 on\IN\1740 the\DT\1740 experimental\JJ\1740 thrombosis\NN\14100769 induced\VBN\1627355 by\IN\1740 collagen\NN\15026716 plus\CC\4723816 epinephrine\NN\14807929 (\-LRB-\1740 EP\NN\1740 )\-RRB-\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 and\CC\1740 platelet\NN\5432736 aggregation\NN\31264 and\CC\1740 <e2>blood\NN\5397468 coagulation</e2>\NN\13518963 in\FW\13603305 vitro\FW\1740 .\.\1740
D004837_D013927 CID The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 TET\NN\15157225 and\CC\1740 FAN\NN\3183080 on\IN\1740 the\DT\1740 experimental\JJ\1740 <e2>thrombosis</e2>\NN\14100769 induced\VBN\1627355 by\IN\1740 collagen\NN\15026716 plus\CC\4723816 <e1>epinephrine</e1>\NN\14807929 (\-LRB-\1740 EP\NN\1740 )\-RRB-\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 and\CC\1740 platelet\NN\5432736 aggregation\NN\31264 and\CC\1740 blood\NN\5397468 coagulation\NN\13518963 in\FW\13603305 vitro\FW\1740 .\.\1740
D004837_D013927 CID The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 TET\NN\15157225 and\CC\1740 FAN\NN\3183080 on\IN\1740 the\DT\1740 experimental\JJ\1740 <e2>thrombosis</e2>\NN\14100769 induced\VBN\1627355 by\IN\1740 collagen\NN\15026716 plus\CC\4723816 epinephrine\NN\14807929 (\-LRB-\1740 <e1>EP</e1>\NN\1740 )\-RRB-\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 and\CC\1740 platelet\NN\5432736 aggregation\NN\31264 and\CC\1740 blood\NN\5397468 coagulation\NN\13518963 in\FW\13603305 vitro\FW\1740 .\.\1740
D004837_D001791 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 TET\NN\15157225 and\CC\1740 FAN\NN\3183080 on\IN\1740 the\DT\1740 experimental\JJ\1740 thrombosis\NN\14100769 induced\VBN\1627355 by\IN\1740 collagen\NN\15026716 plus\CC\4723816 <e1>epinephrine</e1>\NN\14807929 (\-LRB-\1740 EP\NN\1740 )\-RRB-\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 and\CC\1740 <e2>platelet\NN\5432736 aggregation</e2>\NN\31264 and\CC\1740 blood\NN\5397468 coagulation\NN\13518963 in\FW\13603305 vitro\FW\1740 .\.\1740
D004837_D001791 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 TET\NN\15157225 and\CC\1740 FAN\NN\3183080 on\IN\1740 the\DT\1740 experimental\JJ\1740 thrombosis\NN\14100769 induced\VBN\1627355 by\IN\1740 collagen\NN\15026716 plus\CC\4723816 epinephrine\NN\14807929 (\-LRB-\1740 <e1>EP</e1>\NN\1740 )\-RRB-\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 and\CC\1740 <e2>platelet\NN\5432736 aggregation</e2>\NN\31264 and\CC\1740 blood\NN\5397468 coagulation\NN\13518963 in\FW\13603305 vitro\FW\1740 .\.\1740
D004837_D001778 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 TET\NN\15157225 and\CC\1740 FAN\NN\3183080 on\IN\1740 the\DT\1740 experimental\JJ\1740 thrombosis\NN\14100769 induced\VBN\1627355 by\IN\1740 collagen\NN\15026716 plus\CC\4723816 <e1>epinephrine</e1>\NN\14807929 (\-LRB-\1740 EP\NN\1740 )\-RRB-\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 and\CC\1740 platelet\NN\5432736 aggregation\NN\31264 and\CC\1740 <e2>blood\NN\5397468 coagulation</e2>\NN\13518963 in\FW\13603305 vitro\FW\1740 .\.\1740
D004837_D001778 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 TET\NN\15157225 and\CC\1740 FAN\NN\3183080 on\IN\1740 the\DT\1740 experimental\JJ\1740 thrombosis\NN\14100769 induced\VBN\1627355 by\IN\1740 collagen\NN\15026716 plus\CC\4723816 epinephrine\NN\14807929 (\-LRB-\1740 <e1>EP</e1>\NN\1740 )\-RRB-\1740 in\IN\13603305 mice\NNS\2329401 ,\,\1740 and\CC\1740 platelet\NN\5432736 aggregation\NN\31264 and\CC\1740 <e2>blood\NN\5397468 coagulation</e2>\NN\13518963 in\FW\13603305 vitro\FW\1740 .\.\1740
D001241_D013927 NONE In\IN\13603305 the\DT\1740 in\FW\13603305 vivo\FW\1740 study\NN\635850 ,\,\1740 the\DT\1740 administration\NN\1133281 (\-LRB-\1740 50\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 of\IN\1740 TET\NN\15157225 and\CC\1740 FAN\NN\3183080 in\IN\13603305 mice\NNS\2329401 showed\VBD\2137132 the\DT\1740 inhibition\NN\1068773 of\IN\1740 <e2>thrombosis</e2>\NN\14100769 by\IN\1740 55\CD\1740 %\NN\1740 and\CC\1740 35\CD\1740 %\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 <e1>acetylsalicylic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 ASA\NN\1740 ,\,\1740 50\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 positive\JJ\1740 control\NN\5190804 ,\,\1740 showed\VBD\2137132 only\RB\1740 30\CD\13745420 %\NN\1740 inhibition\NN\1068773 .\.\1740
D001241_D013927 NONE In\IN\13603305 the\DT\1740 in\FW\13603305 vivo\FW\1740 study\NN\635850 ,\,\1740 the\DT\1740 administration\NN\1133281 (\-LRB-\1740 50\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 of\IN\1740 TET\NN\15157225 and\CC\1740 FAN\NN\3183080 in\IN\13603305 mice\NNS\2329401 showed\VBD\2137132 the\DT\1740 inhibition\NN\1068773 of\IN\1740 <e2>thrombosis</e2>\NN\14100769 by\IN\1740 55\CD\1740 %\NN\1740 and\CC\1740 35\CD\1740 %\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 acetylsalicylic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>ASA</e1>\NN\1740 ,\,\1740 50\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 positive\JJ\1740 control\NN\5190804 ,\,\1740 showed\VBD\2137132 only\RB\1740 30\CD\13745420 %\NN\1740 inhibition\NN\1068773 .\.\1740
7083920
D000638_D006327 CID A\DT\13649268 case\NN\7283608 is\VBZ\836236 presented\VBN\2137132 of\IN\1740 a\DT\13649268 reversible\JJ\1740 <e2>intra-Hisian\JJ\1740 block</e2>\NN\21939 occurring\VBG\2623529 under\IN\1740 <e1>amiodarone</e1>\JJ\1740 treatment\NN\654885 for\IN\1740 atrial\JJ\1740 tachycardia\NN\14110674 in\IN\13603305 a\DT\13649268 patient\NN\9898892 without\IN\1740 clear\JJ\1740 intraventricular\JJ\1740 conduction\NN\11419404 abnormalities\NNS\14034177 .\.\1740
D000638_D013617 NONE A\DT\13649268 case\NN\7283608 is\VBZ\836236 presented\VBN\2137132 of\IN\1740 a\DT\13649268 reversible\JJ\1740 intra-Hisian\JJ\1740 block\NN\21939 occurring\VBG\2623529 under\IN\1740 <e1>amiodarone</e1>\JJ\1740 treatment\NN\654885 for\IN\1740 <e2>atrial\JJ\1740 tachycardia</e2>\NN\14110674 in\IN\13603305 a\DT\13649268 patient\NN\9898892 without\IN\1740 clear\JJ\1740 intraventricular\JJ\1740 conduction\NN\11419404 abnormalities\NNS\14034177 .\.\1740
D000638_D006345 NONE A\DT\13649268 case\NN\7283608 is\VBZ\836236 presented\VBN\2137132 of\IN\1740 a\DT\13649268 reversible\JJ\1740 intra-Hisian\JJ\1740 block\NN\21939 occurring\VBG\2623529 under\IN\1740 <e1>amiodarone</e1>\JJ\1740 treatment\NN\654885 for\IN\1740 atrial\JJ\1740 tachycardia\NN\14110674 in\IN\13603305 a\DT\13649268 patient\NN\9898892 without\IN\1740 clear\JJ\1740 <e2>intraventricular\JJ\1740 conduction\NN\11419404 abnormalities</e2>\NNS\14034177 .\.\1740
D000638_D001282 NONE Thirty\CD\13745420 days\NNS\15140892 after\IN\1740 <e1>amiodarone</e1>\JJ\1740 discontinuation\NN\209943 ,\,\1740 His\PRP$\1740 bundle\NN\7951464 electrograms\NNS\1740 showed\VBD\2137132 <e2>atrial\JJ\1740 flutter</e2>\NN\331950 without\IN\1740 intra-Hisian\JJ\1740 or\CC\3541091 infra-Hisian\JJ\1740 delay\NN\15271008 .\.\1740
8558192
C030852_C562729 NONE Phase\NN\15113229 II\CD\13741022 trial\NN\786195 of\IN\1740 <e1>vinorelbine</e1>\NN\1740 in\IN\13603305 metastatic\JJ\1740 <e2>squamous\JJ\1740 cell\NN\3080309 esophageal\NN\1740 carcinoma</e2>\NN\14239918 .\.\1740
C030852_C562729 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 response\NN\11410625 rate\NN\13815152 and\CC\1740 toxic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>vinorelbine</e1>\NN\1740 (\-LRB-\1740 VNB\NN\1740 )\-RRB-\1740 administered\VBN\2436349 as\IN\14622893 a\DT\13649268 single\JJ\1740 agent\NN\7347 in\IN\13603305 metastatic\JJ\1740 <e2>squamous\JJ\1740 cell\NN\3080309 esophageal\NN\1740 carcinoma</e2>\NN\14239918 .\.\1740
C030852_C562729 NONE PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 response\NN\11410625 rate\NN\13815152 and\CC\1740 toxic\JJ\1740 effects\NNS\13245626 of\IN\1740 vinorelbine\NN\1740 (\-LRB-\1740 <e1>VNB</e1>\NN\1740 )\-RRB-\1740 administered\VBN\2436349 as\IN\14622893 a\DT\13649268 single\JJ\1740 agent\NN\7347 in\IN\13603305 metastatic\JJ\1740 <e2>squamous\JJ\1740 cell\NN\3080309 esophageal\NN\1740 carcinoma</e2>\NN\14239918 .\.\1740
C030852_C562729 NONE CONCLUSION\NN\5837957 :\:\1740 These\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 <e1>VNB</e1>\NNP\1740 is\VBZ\836236 an\DT\6697703 active\JJ\1740 agent\NN\7347 in\IN\13603305 metastatic\JJ\1740 <e2>esophageal\NN\1740 squamous\JJ\1740 cell\NN\3080309 carcinoma</e2>\NN\14239918 .\.\1740
D002945_D064420 NONE Thirty\CD\13745420 patients\NNS\9898892 without\IN\1740 prior\JJ\1740 chemotherapy\NN\661091 and\CC\1740 16\CD\13745420 pretreated\JJ\1740 with\IN\1740 <e1>cisplatin-based</e1>\JJ\1740 chemotherapy\NN\661091 were\VBD\836236 assessable\JJ\1740 for\IN\1740 <e2>toxicity</e2>\NN\13576101 and\CC\1740 response\NN\11410625 .\.\1740
C030852_D064420 NONE <e1>VNB</e1>\NNP\1740 was\VBD\836236 well\RB\1740 tolerated\VBN\802318 and\CC\1740 zero\CD\13576982 instances\NNS\7283608 of\IN\1740 WHO\WP\8299493 grade\NN\7975026 4\CD\13741022 nonhematologic\JJ\1740 <e2>toxicity</e2>\NN\13576101 occurred\VBD\2623529 .\.\1740
C030852_D064420 NONE Given\VBN\2327200 its\PRP$\6125041 excellent\JJ\1740 tolerance\NN\5032565 profile\NN\6999802 and\CC\1740 low\JJ\1740 <e2>toxicity</e2>\NN\13576101 ,\,\1740 further\JJ\1740 evaluation\NN\874067 of\IN\1740 <e1>VNB</e1>\NN\1740 in\IN\13603305 combination\NN\7951464 therapy\NN\657604 is\VBZ\836236 warranted\VBN\1012073 .\.\1740
19299179
D015662_D002779 NONE Severe\JJ\1740 and\CC\1740 long\JJ\1740 lasting\VBG\2704349 <e2>cholestasis</e2>\NN\14052403 after\IN\1740 high-dose\JJ\1740 <e1>co-trimoxazole</e1>\NN\1740 treatment\NN\654885 for\IN\1740 Pneumocystis\NN\1740 pneumonia\NN\14145095 in\IN\13603305 HIV-infected\JJ\1740 patients\NNS\9898892 --\:\1740 a\DT\13649268 report\NN\6470073 of\IN\1740 two\CD\13741022 cases\NNS\7283608 .\.\1740
D015662_D011020 NONE Severe\JJ\1740 and\CC\1740 long\JJ\1740 lasting\VBG\2704349 cholestasis\NN\14052403 after\IN\1740 high-dose\JJ\1740 <e1>co-trimoxazole</e1>\NN\1740 treatment\NN\654885 for\IN\1740 <e2>Pneumocystis\NN\1740 pneumonia</e2>\NN\14145095 in\IN\13603305 HIV-infected\JJ\1740 patients\NNS\9898892 --\:\1740 a\DT\13649268 report\NN\6470073 of\IN\1740 two\CD\13741022 cases\NNS\7283608 .\.\1740
D015662_D011020 NONE <e2>Pneumocystis\NN\1740 pneumonia</e2>\NN\14145095 (\-LRB-\1740 PCP\NN\10480253 )\-RRB-\1740 ,\,\1740 a\DT\13649268 common\JJ\1740 opportunistic\JJ\1740 infection\NN\14052046 in\IN\13603305 HIV-infected\JJ\1740 individuals\NNS\7347 ,\,\1740 is\VBZ\836236 generally\RB\1740 treated\VBN\2376958 with\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>co-trimoxazole</e1>\NN\1740 .\.\1740
D015662_D011020 NONE Pneumocystis\NN\1740 pneumonia\NN\14145095 (\-LRB-\1740 <e2>PCP</e2>\NN\10480253 )\-RRB-\1740 ,\,\1740 a\DT\13649268 common\JJ\1740 opportunistic\JJ\1740 infection\NN\14052046 in\IN\13603305 HIV-infected\JJ\1740 individuals\NNS\7347 ,\,\1740 is\VBZ\836236 generally\RB\1740 treated\VBN\2376958 with\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>co-trimoxazole</e1>\NN\1740 .\.\1740
D015662_D011020 NONE Here\RB\1740 ,\,\1740 we\PRP\1740 report\VBP\831651 two\CD\13741022 cases\NNS\7283608 of\IN\1740 severely\RB\1740 immunocompromised\VBN\1740 HIV-infected\JJ\1740 patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 severe\JJ\1740 intrahepatic\JJ\1740 cholestasis\NN\14052403 ,\,\1740 and\CC\1740 in\IN\13603305 one\CD\13741022 patient\NN\9898892 lesions\NNS\14204950 mimicking\VBG\1742886 liver\NN\5298729 abscess\NN\14299637 formation\NN\7938773 on\IN\1740 radiologic\JJ\1740 exams\NNS\6252138 ,\,\1740 during\IN\1740 <e1>co-trimoxazole</e1>\NN\1740 treatment\NN\654885 for\IN\1740 <e2>PCP</e2>\NN\10480253 .\.\1740
D015662_D015658 NONE Severe\JJ\1740 and\CC\1740 long\JJ\1740 lasting\VBG\2704349 cholestasis\NN\14052403 after\IN\1740 high-dose\JJ\1740 <e1>co-trimoxazole</e1>\NN\1740 treatment\NN\654885 for\IN\1740 Pneumocystis\NN\1740 pneumonia\NN\14145095 in\IN\13603305 <e2>HIV-infected</e2>\JJ\1740 patients\NNS\9898892 --\:\1740 a\DT\13649268 report\NN\6470073 of\IN\1740 two\CD\13741022 cases\NNS\7283608 .\.\1740
D015662_D015658 NONE Pneumocystis\NN\1740 pneumonia\NN\14145095 (\-LRB-\1740 PCP\NN\10480253 )\-RRB-\1740 ,\,\1740 a\DT\13649268 common\JJ\1740 opportunistic\JJ\1740 infection\NN\14052046 in\IN\13603305 <e2>HIV-infected</e2>\JJ\1740 individuals\NNS\7347 ,\,\1740 is\VBZ\836236 generally\RB\1740 treated\VBN\2376958 with\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>co-trimoxazole</e1>\NN\1740 .\.\1740
D015662_D015658 NONE Here\RB\1740 ,\,\1740 we\PRP\1740 report\VBP\831651 two\CD\13741022 cases\NNS\7283608 of\IN\1740 severely\RB\1740 immunocompromised\VBN\1740 <e2>HIV-infected</e2>\JJ\1740 patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 severe\JJ\1740 intrahepatic\JJ\1740 cholestasis\NN\14052403 ,\,\1740 and\CC\1740 in\IN\13603305 one\CD\13741022 patient\NN\9898892 lesions\NNS\14204950 mimicking\VBG\1742886 liver\NN\5298729 abscess\NN\14299637 formation\NN\7938773 on\IN\1740 radiologic\JJ\1740 exams\NNS\6252138 ,\,\1740 during\IN\1740 <e1>co-trimoxazole</e1>\NN\1740 treatment\NN\654885 for\IN\1740 PCP\NN\10480253 .\.\1740
D015662_D009894 NONE Pneumocystis\NN\1740 pneumonia\NN\14145095 (\-LRB-\1740 PCP\NN\10480253 )\-RRB-\1740 ,\,\1740 a\DT\13649268 common\JJ\1740 <e2>opportunistic\JJ\1740 infection</e2>\NN\14052046 in\IN\13603305 HIV-infected\JJ\1740 individuals\NNS\7347 ,\,\1740 is\VBZ\836236 generally\RB\1740 treated\VBN\2376958 with\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>co-trimoxazole</e1>\NN\1740 .\.\1740
D015662_D002780 CID Here\RB\1740 ,\,\1740 we\PRP\1740 report\VBP\831651 two\CD\13741022 cases\NNS\7283608 of\IN\1740 severely\RB\1740 immunocompromised\VBN\1740 HIV-infected\JJ\1740 patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 severe\JJ\1740 <e2>intrahepatic\JJ\1740 cholestasis</e2>\NN\14052403 ,\,\1740 and\CC\1740 in\IN\13603305 one\CD\13741022 patient\NN\9898892 lesions\NNS\14204950 mimicking\VBG\1742886 liver\NN\5298729 abscess\NN\14299637 formation\NN\7938773 on\IN\1740 radiologic\JJ\1740 exams\NNS\6252138 ,\,\1740 during\IN\1740 <e1>co-trimoxazole</e1>\NN\1740 treatment\NN\654885 for\IN\1740 PCP\NN\10480253 .\.\1740
D015662_D008100 NONE Here\RB\1740 ,\,\1740 we\PRP\1740 report\VBP\831651 two\CD\13741022 cases\NNS\7283608 of\IN\1740 severely\RB\1740 immunocompromised\VBN\1740 HIV-infected\JJ\1740 patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 severe\JJ\1740 intrahepatic\JJ\1740 cholestasis\NN\14052403 ,\,\1740 and\CC\1740 in\IN\13603305 one\CD\13741022 patient\NN\9898892 lesions\NNS\14204950 mimicking\VBG\1742886 <e2>liver\NN\5298729 abscess</e2>\NN\14299637 formation\NN\7938773 on\IN\1740 radiologic\JJ\1740 exams\NNS\6252138 ,\,\1740 during\IN\1740 <e1>co-trimoxazole</e1>\NN\1740 treatment\NN\654885 for\IN\1740 PCP\NN\10480253 .\.\1740
19889778
12639165
D013988_D002779 CID <e1>Ticlopidine-induced</e1>\JJ\1740 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 .\.\1740
D013988_D002779 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 2\CD\13741022 cases\NNS\7283608 of\IN\1740 <e1>ticlopidine-induced</e1>\JJ\1740 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 ,\,\1740 investigate\VBP\644583 its\PRP$\6125041 mechanism\NN\13446390 ,\,\1740 and\CC\1740 compare\VB\644583 the\DT\1740 observed\VBN\2163746 main\JJ\1740 characteristics\NNS\5849040 with\IN\1740 those\DT\1740 of\IN\1740 the\DT\1740 published\VBN\1621555 cases\NNS\7283608 .\.\1740
D013988_D002779 CID CASE\NN\7283608 SUMMARIES\NN\6722453 :\:\1740 Two\CD\13741022 patients\NNS\9898892 developed\VBD\1753788 prolonged\JJ\1740 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 after\IN\1740 receiving\VBG\2210855 <e1>ticlopidine</e1>\NN\1740 following\VBG\1835496 percutaneous\JJ\1740 coronary\JJ\1740 angioplasty\NN\671351 ,\,\1740 with\IN\1740 complete\JJ\1740 remission\NN\7368256 during\IN\1740 the\DT\1740 follow-up\JJ\1740 period\NN\13575869 .\.\1740
D013988_D002779 CID DISCUSSION\NN\6252138 :\:\1740 <e2>Cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 complication\NN\1073995 of\IN\1740 the\DT\1740 antiplatelet\NN\1740 agent\NN\7347 <e1>ticlopidine</e1>\NN\1740 ;\:\1740 several\JJ\1740 cases\NNS\7283608 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 but\CC\1740 few\JJ\1740 in\IN\13603305 the\DT\1740 English\NNP\6946823 literature\NN\6362953 .\.\1740
D013988_D002779 CID Our\PRP$\1740 patients\NNS\9898892 developed\VBD\1753788 jaundice\NN\14299637 following\VBG\1835496 treatment\NN\654885 with\IN\1740 <e1>ticlopidine</e1>\NN\1740 and\CC\1740 showed\VBD\2137132 the\DT\1740 clinical\JJ\1740 and\CC\1740 laboratory\JJ\1740 characteristics\NNS\5849040 of\IN\1740 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 ,\,\1740 which\WDT\1740 resolved\VBD\352826 after\IN\1740 discontinuation\NN\209943 of\IN\1740 the\DT\1740 drug\NN\14778436 .\.\1740
D013988_D002779 CID The\DT\1740 mechanisms\NNS\13446390 of\IN\1740 this\DT\1740 <e1>ticlopidine-induced</e1>\JJ\1740 <e2>cholestasis</e2>\NN\14052403 are\VBP\836236 unclear\JJ\1740 .\.\1740
D013988_D002779 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e2>Cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 adverse\JJ\1740 effect\NN\34213 of\IN\1740 <e1>ticlopidine</e1>\NN\1740 that\WDT\1740 may\MD\15209706 be\VB\836236 immune\JJ\1740 mediated\JJ\1740 .\.\1740
D013988_D056486 CID <e1>Ticlopidine-induced</e1>\JJ\1740 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 .\.\1740
D013988_D056486 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 2\CD\13741022 cases\NNS\7283608 of\IN\1740 <e1>ticlopidine-induced</e1>\JJ\1740 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 ,\,\1740 investigate\VBP\644583 its\PRP$\6125041 mechanism\NN\13446390 ,\,\1740 and\CC\1740 compare\VB\644583 the\DT\1740 observed\VBN\2163746 main\JJ\1740 characteristics\NNS\5849040 with\IN\1740 those\DT\1740 of\IN\1740 the\DT\1740 published\VBN\1621555 cases\NNS\7283608 .\.\1740
D013988_D056486 CID CASE\NN\7283608 SUMMARIES\NN\6722453 :\:\1740 Two\CD\13741022 patients\NNS\9898892 developed\VBD\1753788 prolonged\JJ\1740 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 after\IN\1740 receiving\VBG\2210855 <e1>ticlopidine</e1>\NN\1740 following\VBG\1835496 percutaneous\JJ\1740 coronary\JJ\1740 angioplasty\NN\671351 ,\,\1740 with\IN\1740 complete\JJ\1740 remission\NN\7368256 during\IN\1740 the\DT\1740 follow-up\JJ\1740 period\NN\13575869 .\.\1740
D013988_D056486 CID DISCUSSION\NN\6252138 :\:\1740 <e2>Cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 complication\NN\1073995 of\IN\1740 the\DT\1740 antiplatelet\NN\1740 agent\NN\7347 <e1>ticlopidine</e1>\NN\1740 ;\:\1740 several\JJ\1740 cases\NNS\7283608 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 but\CC\1740 few\JJ\1740 in\IN\13603305 the\DT\1740 English\NNP\6946823 literature\NN\6362953 .\.\1740
D013988_D056486 CID Our\PRP$\1740 patients\NNS\9898892 developed\VBD\1753788 jaundice\NN\14299637 following\VBG\1835496 treatment\NN\654885 with\IN\1740 <e1>ticlopidine</e1>\NN\1740 and\CC\1740 showed\VBD\2137132 the\DT\1740 clinical\JJ\1740 and\CC\1740 laboratory\JJ\1740 characteristics\NNS\5849040 of\IN\1740 <e2>cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 ,\,\1740 which\WDT\1740 resolved\VBD\352826 after\IN\1740 discontinuation\NN\209943 of\IN\1740 the\DT\1740 drug\NN\14778436 .\.\1740
D013988_D056486 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e2>Cholestatic\JJ\1740 hepatitis</e2>\NN\14127211 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 adverse\JJ\1740 effect\NN\34213 of\IN\1740 <e1>ticlopidine</e1>\NN\1740 that\WDT\1740 may\MD\15209706 be\VB\836236 immune\JJ\1740 mediated\JJ\1740 .\.\1740
D013988_D007565 CID Our\PRP$\1740 patients\NNS\9898892 developed\VBD\1753788 <e2>jaundice</e2>\NN\14299637 following\VBG\1835496 treatment\NN\654885 with\IN\1740 <e1>ticlopidine</e1>\NN\1740 and\CC\1740 showed\VBD\2137132 the\DT\1740 clinical\JJ\1740 and\CC\1740 laboratory\JJ\1740 characteristics\NNS\5849040 of\IN\1740 cholestatic\JJ\1740 hepatitis\NN\14127211 ,\,\1740 which\WDT\1740 resolved\VBD\352826 after\IN\1740 discontinuation\NN\209943 of\IN\1740 the\DT\1740 drug\NN\14778436 .\.\1740
12063090
D004177_D003248 NONE <e1>Metamizol</e1>\JJ\1740 potentiates\VBZ\229605 morphine\JJ\1740 antinociception\NN\1740 but\CC\1740 not\RB\1740 <e2>constipation</e2>\NN\14299637 after\IN\1740 chronic\JJ\1740 treatment\NN\654885 .\.\1740
D004177_D003248 NONE This\DT\1740 work\NN\407535 evaluates\VBZ\670261 the\DT\1740 antinociceptive\JJ\1740 and\CC\1740 <e2>constipating</e2>\VBG\440786 effects\NNS\13245626 of\IN\1740 the\DT\1740 combination\NN\7951464 of\IN\1740 3.2\CD\1740 mg/kg\NN\1740 s.c.\NN\1740 morphine\NN\2707683 with\IN\1740 177.8\CD\1740 mg/kg\NN\1740 s.c.\NN\1740 <e1>metamizol</e1>\NN\1740 in\IN\13603305 acutely\RB\1740 and\CC\1740 chronically\RB\1740 treated\VBN\2376958 (\-LRB-\1740 once\RB\1740 a\DT\13649268 day\NN\15154774 for\IN\1740 12\CD\13745420 days\NNS\15140892 )\-RRB-\1740 rats\NNS\2329401 .\.\1740
D004177_D003248 NONE The\DT\1740 combination\NN\7951464 inhibited\VBD\2510337 intestinal\JJ\1740 transit\NN\4365484 similar\JJ\1740 to\TO\1740 that\DT\1740 produced\VBN\1617192 by\IN\1740 morphine\NN\2707683 regardless\RB\1740 of\IN\1740 the\DT\1740 time\NN\7308889 of\IN\1740 treatment\NN\654885 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 <e1>metamizol</e1>\NN\1740 did\VBD\1640855 not\RB\1740 potentiate\VB\229605 morphine-induced\JJ\1740 <e2>constipation</e2>\NN\14299637 .\.\1740
D009020_D003248 CID Metamizol\JJ\1740 potentiates\VBZ\229605 <e1>morphine</e1>\JJ\1740 antinociception\NN\1740 but\CC\1740 not\RB\1740 <e2>constipation</e2>\NN\14299637 after\IN\1740 chronic\JJ\1740 treatment\NN\654885 .\.\1740
D009020_D003248 CID This\DT\1740 work\NN\407535 evaluates\VBZ\670261 the\DT\1740 antinociceptive\JJ\1740 and\CC\1740 <e2>constipating</e2>\VBG\440786 effects\NNS\13245626 of\IN\1740 the\DT\1740 combination\NN\7951464 of\IN\1740 3.2\CD\1740 mg/kg\NN\1740 s.c.\NN\1740 <e1>morphine</e1>\NN\2707683 with\IN\1740 177.8\CD\1740 mg/kg\NN\1740 s.c.\NN\1740 metamizol\NN\1740 in\IN\13603305 acutely\RB\1740 and\CC\1740 chronically\RB\1740 treated\VBN\2376958 (\-LRB-\1740 once\RB\1740 a\DT\13649268 day\NN\15154774 for\IN\1740 12\CD\13745420 days\NNS\15140892 )\-RRB-\1740 rats\NNS\2329401 .\.\1740
D009020_D003248 CID In\IN\13603305 independent\JJ\1740 groups\NNS\2137 ,\,\1740 <e1>morphine</e1>\NN\2707683 inhibited\VBD\2510337 the\DT\1740 intestinal\JJ\1740 transit\NN\4365484 in\IN\13603305 48+/-4\CD\1740 %\NN\1740 and\CC\1740 38+/-4\CD\1740 %\NN\1740 after\IN\1740 acute\JJ\1740 and\CC\1740 chronic\JJ\1740 treatment\NN\654885 ,\,\1740 respectively\RB\1740 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 tolerance\NN\5032565 did\VBD\1640855 not\RB\1740 develop\VB\1753788 to\IN\1740 the\DT\1740 <e2>constipating</e2>\VBG\440786 effects\NNS\13245626 .\.\1740
D009020_D003248 CID The\DT\1740 combination\NN\7951464 inhibited\VBD\2510337 intestinal\JJ\1740 transit\NN\4365484 similar\JJ\1740 to\TO\1740 that\DT\1740 produced\VBN\1617192 by\IN\1740 <e1>morphine</e1>\NN\2707683 regardless\RB\1740 of\IN\1740 the\DT\1740 time\NN\7308889 of\IN\1740 treatment\NN\654885 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 metamizol\NN\1740 did\VBD\1640855 not\RB\1740 potentiate\VB\229605 morphine-induced\JJ\1740 <e2>constipation</e2>\NN\14299637 .\.\1740
D009020_D003248 CID The\DT\1740 combination\NN\7951464 inhibited\VBD\2510337 intestinal\JJ\1740 transit\NN\4365484 similar\JJ\1740 to\TO\1740 that\DT\1740 produced\VBN\1617192 by\IN\1740 morphine\NN\2707683 regardless\RB\1740 of\IN\1740 the\DT\1740 time\NN\7308889 of\IN\1740 treatment\NN\654885 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 metamizol\NN\1740 did\VBD\1640855 not\RB\1740 potentiate\VB\229605 <e1>morphine-induced</e1>\JJ\1740 <e2>constipation</e2>\NN\14299637 .\.\1740
D002606_D010146 NONE On\IN\1740 the\DT\1740 13th\NN\1740 day\NN\15154774 ,\,\1740 antinociceptive\JJ\1740 effects\NNS\13245626 were\VBD\836236 assessed\VBN\670261 using\VBG\1156834 a\DT\13649268 model\NN\5888929 of\IN\1740 inflammatory\JJ\1740 nociception\NN\1740 ,\,\1740 <e2>pain-induced</e2>\JJ\1740 functional\JJ\1740 impairment\NN\7296428 model\NN\5888929 ,\,\1740 and\CC\1740 the\DT\1740 <e1>charcoal</e1>\NN\14633206 meal\NN\7570720 test\NN\5798043 was\VBD\836236 used\VBN\1156834 to\TO\1740 evaluate\VB\670261 the\DT\1740 intestinal\JJ\1740 transit\NN\4365484 .\.\1740
D009020_D059350 NONE These\DT\1740 findings\NNS\7951464 show\VBP\2137132 a\DT\13649268 significant\JJ\1740 interaction\NN\37396 between\IN\1740 <e1>morphine</e1>\NN\2707683 and\CC\1740 metamizol\JJ\1740 in\IN\13603305 chronically\RB\1740 treated\VBN\2376958 rats\NNS\2329401 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 this\DT\1740 combination\NN\7951464 could\MD\1740 be\VB\836236 useful\JJ\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>chronic\JJ\1740 pain</e2>\NN\14299637 .\.\1740
D004177_D059350 NONE These\DT\1740 findings\NNS\7951464 show\VBP\2137132 a\DT\13649268 significant\JJ\1740 interaction\NN\37396 between\IN\1740 morphine\NN\2707683 and\CC\1740 <e1>metamizol</e1>\JJ\1740 in\IN\13603305 chronically\RB\1740 treated\VBN\2376958 rats\NNS\2329401 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 this\DT\1740 combination\NN\7951464 could\MD\1740 be\VB\836236 useful\JJ\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>chronic\JJ\1740 pain</e2>\NN\14299637 .\.\1740
9672936
D008614_D012640 CID <e1>Pethidine-associated</e1>\JJ\1740 <e2>seizure</e2>\NN\14081375 in\IN\13603305 a\DT\13649268 healthy\JJ\1740 adolescent\JJ\1740 receiving\NN\1740 pethidine\NN\1740 for\IN\1740 postoperative\JJ\1740 pain\NN\14299637 control\NN\5190804 .\.\1740
D008614_D012640 CID Pethidine-associated\JJ\1740 <e2>seizure</e2>\NN\14081375 in\IN\13603305 a\DT\13649268 healthy\JJ\1740 adolescent\JJ\1740 receiving\NN\1740 <e1>pethidine</e1>\NN\1740 for\IN\1740 postoperative\JJ\1740 pain\NN\14299637 control\NN\5190804 .\.\1740
D008614_D010149 NONE <e1>Pethidine-associated</e1>\JJ\1740 seizure\NN\14081375 in\IN\13603305 a\DT\13649268 healthy\JJ\1740 adolescent\JJ\1740 receiving\NN\1740 pethidine\NN\1740 for\IN\1740 <e2>postoperative\JJ\1740 pain</e2>\NN\14299637 control\NN\5190804 .\.\1740
D008614_D010149 NONE Pethidine-associated\JJ\1740 seizure\NN\14081375 in\IN\13603305 a\DT\13649268 healthy\JJ\1740 adolescent\JJ\1740 receiving\NN\1740 <e1>pethidine</e1>\NN\1740 for\IN\1740 <e2>postoperative\JJ\1740 pain</e2>\NN\14299637 control\NN\5190804 .\.\1740
D008614_D010149 NONE A\DT\13649268 healthy\JJ\1740 17-year-old\JJ\1740 male\JJ\1740 received\VBD\2210855 standard\JJ\1740 intermittent\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>pethidine</e1>\NN\1740 via\IN\1740 a\DT\13649268 patient-controlled\JJ\1740 analgesia\NN\14034177 (\-LRB-\1740 PCA\NN\1740 )\-RRB-\1740 pump\VBP\1224415 for\IN\1740 management\NN\1123598 of\IN\1740 <e2>postoperative\JJ\1740 pain</e2>\NN\14299637 control\NN\5190804 .\.\1740
1749407
D003042_D009203 CID <e1>Cocaine-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 :\:\1740 clinical\JJ\1740 observations\NNS\996969 and\CC\1740 pathogenetic\JJ\1740 considerations\NNS\5770926 .\.\1740
D003042_D009203 CID Clinical\JJ\1740 and\CC\1740 experimental\JJ\1740 data\NNS\7951464 published\VBN\1621555 to\TO\1740 date\NN\15155220 suggest\VBP\1010118 several\JJ\1740 possible\JJ\1740 mechanisms\NNS\13446390 by\IN\1740 which\WDT\1740 <e1>cocaine</e1>\NN\3492717 may\MD\15209706 result\VB\2633881 in\IN\13603305 <e2>acute\JJ\1740 myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D003042_D009203 CID In\IN\13603305 individuals\NNS\7347 with\IN\1740 preexisting\JJ\1740 ,\,\1740 high-grade\JJ\1740 coronary\JJ\1740 arterial\JJ\1740 narrowing\NN\5064037 ,\,\1740 <e2>acute\JJ\1740 myocardial\JJ\1740 infarction</e2>\NN\14204950 may\MD\15209706 result\VB\2633881 from\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 myocardial\JJ\1740 oxygen\NN\14622893 demand\NN\6513366 associated\VBN\628491 with\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 increase\NN\13576355 in\IN\13603305 rate-pressure\JJ\1740 product\NN\3076708 .\.\1740
D010100_D009203 NONE In\IN\13603305 individuals\NNS\7347 with\IN\1740 preexisting\JJ\1740 ,\,\1740 high-grade\JJ\1740 coronary\JJ\1740 arterial\JJ\1740 narrowing\NN\5064037 ,\,\1740 <e2>acute\JJ\1740 myocardial\JJ\1740 infarction</e2>\NN\14204950 may\MD\15209706 result\VB\2633881 from\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 myocardial\JJ\1740 <e1>oxygen</e1>\NN\14622893 demand\NN\6513366 associated\VBN\628491 with\IN\1740 cocaine-induced\JJ\1740 increase\NN\13576355 in\IN\13603305 rate-pressure\JJ\1740 product\NN\3076708 .\.\1740
D003042_D013035 NONE With\IN\1740 regard\NN\5817845 to\TO\1740 <e2>spasm</e2>\NN\14299637 ,\,\1740 the\DT\1740 clinical\JJ\1740 findings\NNS\7951464 are\VBP\836236 largely\RB\1740 circumstantial\JJ\1740 ,\,\1740 and\CC\1740 the\DT\1740 locus\NN\8645963 of\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 vasoconstriction\NN\1149911 remains\VBZ\2604760 speculative\JJ\1740 .\.\1740
D003042_D013927 NONE Finally\RB\1740 ,\,\1740 the\DT\1740 contribution\NN\786195 of\IN\1740 a\DT\13649268 primary\JJ\1740 ,\,\1740 <e2>thrombotic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 <e1>cocaine</e1>\NN\3492717 has\VBZ\2108377 not\RB\1740 been\VBN\836236 excluded\VBN\471711 .\.\1740
4812392
D001379_D011565 NONE Treatment\NN\654885 of\IN\1740 <e2>psoriasis</e2>\NN\14219661 with\IN\1740 <e1>azathioprine</e1>\NN\3740161 .\.\1740
D001379_D011565 NONE <e1>Azathioprine</e1>\NN\3740161 treatment\NN\654885 benefited\VBD\2210855 19\CD\13745420 (\-LRB-\1740 66\CD\1740 %\NN\1740 )\-RRB-\1740 out\IN\66636 of\IN\1740 29\CD\13745420 patients\NNS\9898892 suffering\VBG\2110220 from\IN\1740 severe\JJ\1740 <e2>psoriasis</e2>\NN\14219661 .\.\1740
D001379_D056486 NONE Liver\NN\5298729 biopsies\NNS\5739043 should\MD\1740 be\VB\836236 undertaken\VBN\1641914 at\IN\14622893 regular\JJ\1740 intervals\NNS\33615 if\IN\1740 <e1>azathioprine</e1>\NN\3740161 therapy\NN\657604 is\VBZ\836236 continued\VBN\2367363 so\RB\1740 that\IN\1740 structural\JJ\1740 <e2>liver\NN\5298729 damage</e2>\NN\7296428 may\MD\15209706 be\VB\836236 detected\VBN\2163746 at\IN\14622893 an\DT\6697703 early\JJ\1740 and\CC\1740 reversible\JJ\1740 stage\NN\15113229 .\.\1740
18343374
D002996_D012170 CID Central\JJ\1740 <e2>retinal\JJ\1740 vein\NN\5417975 occlusion</e2>\NN\14081375 associated\VBN\628491 with\IN\1740 <e1>clomiphene-induced</e1>\JJ\1740 ovulation\NN\13526110 .\.\1740
D002996_D012170 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 central\JJ\1740 <e2>retinal\JJ\1740 vein\NN\5417975 occlusion</e2>\NN\14081375 associated\VBN\628491 with\IN\1740 <e1>clomiphene\NN\3329880 citrate</e1>\NN\14850483 (\-LRB-\1740 CC\NN\13616054 )\-RRB-\1740 .\.\1740
D002996_D012170 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 central\JJ\1740 <e2>retinal\JJ\1740 vein\NN\5417975 occlusion</e2>\NN\14081375 associated\VBN\628491 with\IN\1740 clomiphene\NN\3329880 citrate\NN\14850483 (\-LRB-\1740 <e1>CC</e1>\NN\13616054 )\-RRB-\1740 .\.\1740
D002996_D012170 CID MAIN\NNP\9225146 OUTCOME\NN\7291312 MEASURE(S\NNP\1740 ):\-RRB-\1740 Central\JJ\1740 <e2>retinal\JJ\1740 vein\NN\5417975 occlusion</e2>\NN\14081375 after\IN\1740 ovulation\NN\13526110 induction\NN\7450842 with\IN\1740 <e1>CC</e1>\NN\13616054 .\.\1740
D002996_D012170 CID RESULT(S\NN\1740 ):\NN\1740 A\NN\13649268 36-year-old\JJ\1740 Chinese\JJ\1740 woman\NN\9605289 developed\VBD\1753788 central\JJ\1740 <e2>retinal\JJ\1740 vein\NN\5417975 occlusion</e2>\NN\14081375 after\IN\1740 eight\CD\13741022 courses\NNS\883297 of\IN\1740 <e1>CC</e1>\NNP\13616054 .\.\1740
D002996_D012170 CID CONCLUSION(S\NN\1740 ):\NFP\1740 This\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 reported\VBN\831651 case\NN\7283608 of\IN\1740 central\JJ\1740 <e2>retinal\JJ\1740 vein\NN\5417975 occlusion</e2>\NN\14081375 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>CC</e1>\NN\13616054 .\.\1740
D002996_D013923 NONE A\DT\13649268 search\NN\407535 of\IN\1740 the\DT\1740 literature\NN\6362953 on\IN\1740 the\DT\1740 <e2>thromboembolic</e2>\JJ\1740 complications\NNS\1073995 of\IN\1740 <e1>CC</e1>\NN\13616054 does\VBZ\1640855 not\RB\1740 include\VB\690614 this\DT\1740 severe\JJ\1740 ophthalmic\JJ\1740 complication\NN\1073995 ,\,\1740 although\IN\1740 mild\JJ\1740 visual\JJ\1740 disturbance\NN\407535 after\IN\1740 CC\NNP\13616054 intake\NN\13440063 is\VBZ\836236 not\RB\1740 uncommon\JJ\1740 .\.\1740
D002996_D013923 NONE A\DT\13649268 search\NN\407535 of\IN\1740 the\DT\1740 literature\NN\6362953 on\IN\1740 the\DT\1740 <e2>thromboembolic</e2>\JJ\1740 complications\NNS\1073995 of\IN\1740 CC\NN\13616054 does\VBZ\1640855 not\RB\1740 include\VB\690614 this\DT\1740 severe\JJ\1740 ophthalmic\JJ\1740 complication\NN\1073995 ,\,\1740 although\IN\1740 mild\JJ\1740 visual\JJ\1740 disturbance\NN\407535 after\IN\1740 <e1>CC</e1>\NNP\13616054 intake\NN\13440063 is\VBZ\836236 not\RB\1740 uncommon\JJ\1740 .\.\1740
D002996_D014786 CID A\DT\13649268 search\NN\407535 of\IN\1740 the\DT\1740 literature\NN\6362953 on\IN\1740 the\DT\1740 thromboembolic\JJ\1740 complications\NNS\1073995 of\IN\1740 <e1>CC</e1>\NN\13616054 does\VBZ\1640855 not\RB\1740 include\VB\690614 this\DT\1740 severe\JJ\1740 ophthalmic\JJ\1740 complication\NN\1073995 ,\,\1740 although\IN\1740 mild\JJ\1740 <e2>visual\JJ\1740 disturbance</e2>\NN\407535 after\IN\1740 CC\NNP\13616054 intake\NN\13440063 is\VBZ\836236 not\RB\1740 uncommon\JJ\1740 .\.\1740
D002996_D014786 CID A\DT\13649268 search\NN\407535 of\IN\1740 the\DT\1740 literature\NN\6362953 on\IN\1740 the\DT\1740 thromboembolic\JJ\1740 complications\NNS\1073995 of\IN\1740 CC\NN\13616054 does\VBZ\1640855 not\RB\1740 include\VB\690614 this\DT\1740 severe\JJ\1740 ophthalmic\JJ\1740 complication\NN\1073995 ,\,\1740 although\IN\1740 mild\JJ\1740 <e2>visual\JJ\1740 disturbance</e2>\NN\407535 after\IN\1740 <e1>CC</e1>\NNP\13616054 intake\NN\13440063 is\VBZ\836236 not\RB\1740 uncommon\JJ\1740 .\.\1740
D002996_D007247 NONE Extra\JJ\1740 caution\NN\4662951 is\VBZ\836236 warranted\VBN\1012073 in\IN\13603305 treating\VBG\2376958 <e2>infertility</e2>\NN\14034177 patients\NNS\9898892 with\IN\1740 <e1>CC</e1>\NN\13616054 ,\,\1740 and\CC\1740 patients\NNS\9898892 should\MD\1740 be\VB\836236 well\RB\1740 informed\JJ\1740 of\IN\1740 this\DT\1740 side\NN\8630039 effect\NN\34213 before\IN\1740 commencement\NN\15180528 of\IN\1740 therapy\NN\657604 .\.\1740
6203452
D002945_D002277 NONE Five\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>carcinoma</e2>\NN\14239918 developed\VBD\1753788 thrombotic\JJ\1740 microangiopathy\NN\1740 (\-LRB-\1740 characterized\VBN\609683 by\IN\1740 renal\JJ\1740 insufficiency\NN\14462946 ,\,\1740 microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 ,\,\1740 and\CC\1740 usually\RB\1740 thrombocytopenia\NN\14189204 )\-RRB-\1740 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>cisplatin</e1>\NN\1740 ,\,\1740 bleomycin\NN\1740 ,\,\1740 and\CC\1740 a\DT\13649268 vinca\JJ\1740 alkaloid\NN\14727670 .\.\1740
D002945_D057049 NONE Five\CD\13741022 patients\NNS\9898892 with\IN\1740 carcinoma\NN\14239918 developed\VBD\1753788 <e2>thrombotic\JJ\1740 microangiopathy</e2>\NN\1740 (\-LRB-\1740 characterized\VBN\609683 by\IN\1740 renal\JJ\1740 insufficiency\NN\14462946 ,\,\1740 microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 ,\,\1740 and\CC\1740 usually\RB\1740 thrombocytopenia\NN\14189204 )\-RRB-\1740 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>cisplatin</e1>\NN\1740 ,\,\1740 bleomycin\NN\1740 ,\,\1740 and\CC\1740 a\DT\13649268 vinca\JJ\1740 alkaloid\NN\14727670 .\.\1740
D002945_D051437 NONE Five\CD\13741022 patients\NNS\9898892 with\IN\1740 carcinoma\NN\14239918 developed\VBD\1753788 thrombotic\JJ\1740 microangiopathy\NN\1740 (\-LRB-\1740 characterized\VBN\609683 by\IN\1740 <e2>renal\JJ\1740 insufficiency</e2>\NN\14462946 ,\,\1740 microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 ,\,\1740 and\CC\1740 usually\RB\1740 thrombocytopenia\NN\14189204 )\-RRB-\1740 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>cisplatin</e1>\NN\1740 ,\,\1740 bleomycin\NN\1740 ,\,\1740 and\CC\1740 a\DT\13649268 vinca\JJ\1740 alkaloid\NN\14727670 .\.\1740
D002945_D051437 NONE Diagnosis\NN\152018 of\IN\1740 this\DT\1740 potentially\RB\1740 fatal\JJ\1740 complication\NN\1073995 may\MD\15209706 be\VB\836236 delayed\VBN\439958 or\CC\3541091 missed\VBN\1825237 if\IN\1740 renal\JJ\1740 tissue\NN\5220461 or\CC\3541091 the\DT\1740 peripheral\JJ\1740 blood\NN\5397468 smear\NN\6719579 is\VBZ\836236 not\RB\1740 examined\VBN\789138 ,\,\1740 because\IN\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 may\MD\15209706 be\VB\836236 ascribed\VBN\670261 to\TO\1740 <e1>cisplatin</e1>\NN\1740 nephrotoxicity\NN\1740 and\CC\1740 the\DT\1740 anemia\NN\14189204 and\CC\1740 thrombocytopenia\NN\14189204 to\TO\1740 drug-induced\JJ\1740 bone\NN\5286536 marrow\NN\5286536 suppression\NN\13489037 .\.\1740
D002945_D000743 NONE Five\CD\13741022 patients\NNS\9898892 with\IN\1740 carcinoma\NN\14239918 developed\VBD\1753788 thrombotic\JJ\1740 microangiopathy\NN\1740 (\-LRB-\1740 characterized\VBN\609683 by\IN\1740 renal\JJ\1740 insufficiency\NN\14462946 ,\,\1740 <e2>microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia</e2>\NN\14189204 ,\,\1740 and\CC\1740 usually\RB\1740 thrombocytopenia\NN\14189204 )\-RRB-\1740 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>cisplatin</e1>\NN\1740 ,\,\1740 bleomycin\NN\1740 ,\,\1740 and\CC\1740 a\DT\13649268 vinca\JJ\1740 alkaloid\NN\14727670 .\.\1740
D002945_D013921 NONE Five\CD\13741022 patients\NNS\9898892 with\IN\1740 carcinoma\NN\14239918 developed\VBD\1753788 thrombotic\JJ\1740 microangiopathy\NN\1740 (\-LRB-\1740 characterized\VBN\609683 by\IN\1740 renal\JJ\1740 insufficiency\NN\14462946 ,\,\1740 microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 ,\,\1740 and\CC\1740 usually\RB\1740 <e2>thrombocytopenia</e2>\NN\14189204 )\-RRB-\1740 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>cisplatin</e1>\NN\1740 ,\,\1740 bleomycin\NN\1740 ,\,\1740 and\CC\1740 a\DT\13649268 vinca\JJ\1740 alkaloid\NN\14727670 .\.\1740
D002945_D013921 NONE Diagnosis\NN\152018 of\IN\1740 this\DT\1740 potentially\RB\1740 fatal\JJ\1740 complication\NN\1073995 may\MD\15209706 be\VB\836236 delayed\VBN\439958 or\CC\3541091 missed\VBN\1825237 if\IN\1740 renal\JJ\1740 tissue\NN\5220461 or\CC\3541091 the\DT\1740 peripheral\JJ\1740 blood\NN\5397468 smear\NN\6719579 is\VBZ\836236 not\RB\1740 examined\VBN\789138 ,\,\1740 because\IN\1740 renal\JJ\1740 failure\NN\66216 may\MD\15209706 be\VB\836236 ascribed\VBN\670261 to\TO\1740 <e1>cisplatin</e1>\NN\1740 nephrotoxicity\NN\1740 and\CC\1740 the\DT\1740 anemia\NN\14189204 and\CC\1740 <e2>thrombocytopenia</e2>\NN\14189204 to\TO\1740 drug-induced\JJ\1740 bone\NN\5286536 marrow\NN\5286536 suppression\NN\13489037 .\.\1740
D001761_D002277 NONE Five\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>carcinoma</e2>\NN\14239918 developed\VBD\1753788 thrombotic\JJ\1740 microangiopathy\NN\1740 (\-LRB-\1740 characterized\VBN\609683 by\IN\1740 renal\JJ\1740 insufficiency\NN\14462946 ,\,\1740 microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 ,\,\1740 and\CC\1740 usually\RB\1740 thrombocytopenia\NN\14189204 )\-RRB-\1740 after\IN\1740 treatment\NN\654885 with\IN\1740 cisplatin\NN\1740 ,\,\1740 <e1>bleomycin</e1>\NN\1740 ,\,\1740 and\CC\1740 a\DT\13649268 vinca\JJ\1740 alkaloid\NN\14727670 .\.\1740
D001761_D057049 NONE Five\CD\13741022 patients\NNS\9898892 with\IN\1740 carcinoma\NN\14239918 developed\VBD\1753788 <e2>thrombotic\JJ\1740 microangiopathy</e2>\NN\1740 (\-LRB-\1740 characterized\VBN\609683 by\IN\1740 renal\JJ\1740 insufficiency\NN\14462946 ,\,\1740 microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 ,\,\1740 and\CC\1740 usually\RB\1740 thrombocytopenia\NN\14189204 )\-RRB-\1740 after\IN\1740 treatment\NN\654885 with\IN\1740 cisplatin\NN\1740 ,\,\1740 <e1>bleomycin</e1>\NN\1740 ,\,\1740 and\CC\1740 a\DT\13649268 vinca\JJ\1740 alkaloid\NN\14727670 .\.\1740
D001761_D051437 NONE Five\CD\13741022 patients\NNS\9898892 with\IN\1740 carcinoma\NN\14239918 developed\VBD\1753788 thrombotic\JJ\1740 microangiopathy\NN\1740 (\-LRB-\1740 characterized\VBN\609683 by\IN\1740 <e2>renal\JJ\1740 insufficiency</e2>\NN\14462946 ,\,\1740 microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 ,\,\1740 and\CC\1740 usually\RB\1740 thrombocytopenia\NN\14189204 )\-RRB-\1740 after\IN\1740 treatment\NN\654885 with\IN\1740 cisplatin\NN\1740 ,\,\1740 <e1>bleomycin</e1>\NN\1740 ,\,\1740 and\CC\1740 a\DT\13649268 vinca\JJ\1740 alkaloid\NN\14727670 .\.\1740
D001761_D000743 NONE Five\CD\13741022 patients\NNS\9898892 with\IN\1740 carcinoma\NN\14239918 developed\VBD\1753788 thrombotic\JJ\1740 microangiopathy\NN\1740 (\-LRB-\1740 characterized\VBN\609683 by\IN\1740 renal\JJ\1740 insufficiency\NN\14462946 ,\,\1740 <e2>microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia</e2>\NN\14189204 ,\,\1740 and\CC\1740 usually\RB\1740 thrombocytopenia\NN\14189204 )\-RRB-\1740 after\IN\1740 treatment\NN\654885 with\IN\1740 cisplatin\NN\1740 ,\,\1740 <e1>bleomycin</e1>\NN\1740 ,\,\1740 and\CC\1740 a\DT\13649268 vinca\JJ\1740 alkaloid\NN\14727670 .\.\1740
D001761_D013921 NONE Five\CD\13741022 patients\NNS\9898892 with\IN\1740 carcinoma\NN\14239918 developed\VBD\1753788 thrombotic\JJ\1740 microangiopathy\NN\1740 (\-LRB-\1740 characterized\VBN\609683 by\IN\1740 renal\JJ\1740 insufficiency\NN\14462946 ,\,\1740 microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 ,\,\1740 and\CC\1740 usually\RB\1740 <e2>thrombocytopenia</e2>\NN\14189204 )\-RRB-\1740 after\IN\1740 treatment\NN\654885 with\IN\1740 cisplatin\NN\1740 ,\,\1740 <e1>bleomycin</e1>\NN\1740 ,\,\1740 and\CC\1740 a\DT\13649268 vinca\JJ\1740 alkaloid\NN\14727670 .\.\1740
D014748_D002277 NONE Five\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>carcinoma</e2>\NN\14239918 developed\VBD\1753788 thrombotic\JJ\1740 microangiopathy\NN\1740 (\-LRB-\1740 characterized\VBN\609683 by\IN\1740 renal\JJ\1740 insufficiency\NN\14462946 ,\,\1740 microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 ,\,\1740 and\CC\1740 usually\RB\1740 thrombocytopenia\NN\14189204 )\-RRB-\1740 after\IN\1740 treatment\NN\654885 with\IN\1740 cisplatin\NN\1740 ,\,\1740 bleomycin\NN\1740 ,\,\1740 and\CC\1740 a\DT\13649268 <e1>vinca\JJ\1740 alkaloid</e1>\NN\14727670 .\.\1740
D014748_D057049 NONE Five\CD\13741022 patients\NNS\9898892 with\IN\1740 carcinoma\NN\14239918 developed\VBD\1753788 <e2>thrombotic\JJ\1740 microangiopathy</e2>\NN\1740 (\-LRB-\1740 characterized\VBN\609683 by\IN\1740 renal\JJ\1740 insufficiency\NN\14462946 ,\,\1740 microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 ,\,\1740 and\CC\1740 usually\RB\1740 thrombocytopenia\NN\14189204 )\-RRB-\1740 after\IN\1740 treatment\NN\654885 with\IN\1740 cisplatin\NN\1740 ,\,\1740 bleomycin\NN\1740 ,\,\1740 and\CC\1740 a\DT\13649268 <e1>vinca\JJ\1740 alkaloid</e1>\NN\14727670 .\.\1740
D014748_D051437 NONE Five\CD\13741022 patients\NNS\9898892 with\IN\1740 carcinoma\NN\14239918 developed\VBD\1753788 thrombotic\JJ\1740 microangiopathy\NN\1740 (\-LRB-\1740 characterized\VBN\609683 by\IN\1740 <e2>renal\JJ\1740 insufficiency</e2>\NN\14462946 ,\,\1740 microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 ,\,\1740 and\CC\1740 usually\RB\1740 thrombocytopenia\NN\14189204 )\-RRB-\1740 after\IN\1740 treatment\NN\654885 with\IN\1740 cisplatin\NN\1740 ,\,\1740 bleomycin\NN\1740 ,\,\1740 and\CC\1740 a\DT\13649268 <e1>vinca\JJ\1740 alkaloid</e1>\NN\14727670 .\.\1740
D014748_D000743 NONE Five\CD\13741022 patients\NNS\9898892 with\IN\1740 carcinoma\NN\14239918 developed\VBD\1753788 thrombotic\JJ\1740 microangiopathy\NN\1740 (\-LRB-\1740 characterized\VBN\609683 by\IN\1740 renal\JJ\1740 insufficiency\NN\14462946 ,\,\1740 <e2>microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia</e2>\NN\14189204 ,\,\1740 and\CC\1740 usually\RB\1740 thrombocytopenia\NN\14189204 )\-RRB-\1740 after\IN\1740 treatment\NN\654885 with\IN\1740 cisplatin\NN\1740 ,\,\1740 bleomycin\NN\1740 ,\,\1740 and\CC\1740 a\DT\13649268 <e1>vinca\JJ\1740 alkaloid</e1>\NN\14727670 .\.\1740
D014748_D013921 NONE Five\CD\13741022 patients\NNS\9898892 with\IN\1740 carcinoma\NN\14239918 developed\VBD\1753788 thrombotic\JJ\1740 microangiopathy\NN\1740 (\-LRB-\1740 characterized\VBN\609683 by\IN\1740 renal\JJ\1740 insufficiency\NN\14462946 ,\,\1740 microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 ,\,\1740 and\CC\1740 usually\RB\1740 <e2>thrombocytopenia</e2>\NN\14189204 )\-RRB-\1740 after\IN\1740 treatment\NN\654885 with\IN\1740 cisplatin\NN\1740 ,\,\1740 bleomycin\NN\1740 ,\,\1740 and\CC\1740 a\DT\13649268 <e1>vinca\JJ\1740 alkaloid</e1>\NN\14727670 .\.\1740
D002945_D007674 CID Diagnosis\NN\152018 of\IN\1740 this\DT\1740 potentially\RB\1740 fatal\JJ\1740 complication\NN\1073995 may\MD\15209706 be\VB\836236 delayed\VBN\439958 or\CC\3541091 missed\VBN\1825237 if\IN\1740 renal\JJ\1740 tissue\NN\5220461 or\CC\3541091 the\DT\1740 peripheral\JJ\1740 blood\NN\5397468 smear\NN\6719579 is\VBZ\836236 not\RB\1740 examined\VBN\789138 ,\,\1740 because\IN\1740 renal\JJ\1740 failure\NN\66216 may\MD\15209706 be\VB\836236 ascribed\VBN\670261 to\TO\1740 <e1>cisplatin</e1>\NN\1740 <e2>nephrotoxicity</e2>\NN\1740 and\CC\1740 the\DT\1740 anemia\NN\14189204 and\CC\1740 thrombocytopenia\NN\14189204 to\TO\1740 drug-induced\JJ\1740 bone\NN\5286536 marrow\NN\5286536 suppression\NN\13489037 .\.\1740
D002945_D000740 NONE Diagnosis\NN\152018 of\IN\1740 this\DT\1740 potentially\RB\1740 fatal\JJ\1740 complication\NN\1073995 may\MD\15209706 be\VB\836236 delayed\VBN\439958 or\CC\3541091 missed\VBN\1825237 if\IN\1740 renal\JJ\1740 tissue\NN\5220461 or\CC\3541091 the\DT\1740 peripheral\JJ\1740 blood\NN\5397468 smear\NN\6719579 is\VBZ\836236 not\RB\1740 examined\VBN\789138 ,\,\1740 because\IN\1740 renal\JJ\1740 failure\NN\66216 may\MD\15209706 be\VB\836236 ascribed\VBN\670261 to\TO\1740 <e1>cisplatin</e1>\NN\1740 nephrotoxicity\NN\1740 and\CC\1740 the\DT\1740 <e2>anemia</e2>\NN\14189204 and\CC\1740 thrombocytopenia\NN\14189204 to\TO\1740 drug-induced\JJ\1740 bone\NN\5286536 marrow\NN\5286536 suppression\NN\13489037 .\.\1740
D002945_D001855 NONE Diagnosis\NN\152018 of\IN\1740 this\DT\1740 potentially\RB\1740 fatal\JJ\1740 complication\NN\1073995 may\MD\15209706 be\VB\836236 delayed\VBN\439958 or\CC\3541091 missed\VBN\1825237 if\IN\1740 renal\JJ\1740 tissue\NN\5220461 or\CC\3541091 the\DT\1740 peripheral\JJ\1740 blood\NN\5397468 smear\NN\6719579 is\VBZ\836236 not\RB\1740 examined\VBN\789138 ,\,\1740 because\IN\1740 renal\JJ\1740 failure\NN\66216 may\MD\15209706 be\VB\836236 ascribed\VBN\670261 to\TO\1740 <e1>cisplatin</e1>\NN\1740 nephrotoxicity\NN\1740 and\CC\1740 the\DT\1740 anemia\NN\14189204 and\CC\1740 thrombocytopenia\NN\14189204 to\TO\1740 drug-induced\JJ\1740 <e2>bone\NN\5286536 marrow\NN\5286536 suppression</e2>\NN\13489037 .\.\1740
11279304
D018943_D066126 NONE Brain\NN\5462674 natriuretic\JJ\1740 peptide\NN\14724264 is\VBZ\836236 a\DT\13649268 predictor\NN\10756433 of\IN\1740 <e1>anthracycline-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D018943_D066126 NONE <e1>Anthracyclines</e1>\NNS\1740 are\VBP\836236 effective\JJ\1740 antineoplastic\JJ\1740 drugs\NNS\14778436 ,\,\1740 but\CC\1740 they\PRP\1740 frequently\RB\1740 cause\VBP\1617192 dose-related\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D018943_D066126 NONE The\DT\1740 <e2>cardiotoxicity</e2>\NN\1740 of\IN\1740 conventional\JJ\1740 <e1>anthracycline</e1>\NN\1740 therapy\NN\657604 highlights\VBZ\514463 a\DT\13649268 need\NN\13920835 to\TO\1740 search\VB\2131279 for\IN\1740 methods\NNS\5616786 that\WDT\1740 are\VBP\836236 highly\RB\1740 sensitive\JJ\1740 and\CC\1740 capable\JJ\1740 of\IN\1740 predicting\VBG\916909 cardiac\JJ\1740 dysfunction\NN\14204950 .\.\1740
D018943_D066126 NONE We\PRP\1740 measured\VBD\697589 the\DT\1740 plasma\NN\5398023 level\NN\4916342 of\IN\1740 brain\NN\5462674 natriuretic\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 BNP\NN\1740 )\-RRB-\1740 to\TO\1740 determine\VB\1645601 whether\IN\1740 BNP\NN\1740 might\MD\5029706 serve\VB\2669789 as\IN\14622893 a\DT\13649268 simple\JJ\1740 diagnostic\JJ\1740 indicator\NN\6636259 of\IN\1740 <e1>anthracycline-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 acute\JJ\1740 leukemia\NN\14239918 treated\VBN\2376958 with\IN\1740 a\DT\13649268 daunorubicin\NN\1740 (DNR)-containing\NN\1740 regimen\NN\5898568 .\.\1740
D018943_D066126 NONE These\DT\1740 preliminary\JJ\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 BNP\NN\1740 may\MD\15209706 be\VB\836236 useful\JJ\1740 as\IN\14622893 an\DT\6697703 early\JJ\1740 and\CC\1740 sensitive\JJ\1740 indicator\NN\6636259 of\IN\1740 <e1>anthracycline-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D018943_D006331 NONE The\DT\1740 cardiotoxicity\NN\1740 of\IN\1740 conventional\JJ\1740 <e1>anthracycline</e1>\NN\1740 therapy\NN\657604 highlights\VBZ\514463 a\DT\13649268 need\NN\13920835 to\TO\1740 search\VB\2131279 for\IN\1740 methods\NNS\5616786 that\WDT\1740 are\VBP\836236 highly\RB\1740 sensitive\JJ\1740 and\CC\1740 capable\JJ\1740 of\IN\1740 predicting\VBG\916909 <e2>cardiac\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D018943_D015470 NONE We\PRP\1740 measured\VBD\697589 the\DT\1740 plasma\NN\5398023 level\NN\4916342 of\IN\1740 brain\NN\5462674 natriuretic\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 BNP\NN\1740 )\-RRB-\1740 to\TO\1740 determine\VB\1645601 whether\IN\1740 BNP\NN\1740 might\MD\5029706 serve\VB\2669789 as\IN\14622893 a\DT\13649268 simple\JJ\1740 diagnostic\JJ\1740 indicator\NN\6636259 of\IN\1740 <e1>anthracycline-induced</e1>\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>acute\JJ\1740 leukemia</e2>\NN\14239918 treated\VBN\2376958 with\IN\1740 a\DT\13649268 daunorubicin\NN\1740 (DNR)-containing\NN\1740 regimen\NN\5898568 .\.\1740
D003630_D066126 NONE We\PRP\1740 measured\VBD\697589 the\DT\1740 plasma\NN\5398023 level\NN\4916342 of\IN\1740 brain\NN\5462674 natriuretic\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 BNP\NN\1740 )\-RRB-\1740 to\TO\1740 determine\VB\1645601 whether\IN\1740 BNP\NN\1740 might\MD\5029706 serve\VB\2669789 as\IN\14622893 a\DT\13649268 simple\JJ\1740 diagnostic\JJ\1740 indicator\NN\6636259 of\IN\1740 anthracycline-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 acute\JJ\1740 leukemia\NN\14239918 treated\VBN\2376958 with\IN\1740 a\DT\13649268 <e1>daunorubicin</e1>\NN\1740 (DNR)-containing\NN\1740 regimen\NN\5898568 .\.\1740
D003630_D066126 NONE We\PRP\1740 measured\VBD\697589 the\DT\1740 plasma\NN\5398023 level\NN\4916342 of\IN\1740 brain\NN\5462674 natriuretic\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 BNP\NN\1740 )\-RRB-\1740 to\TO\1740 determine\VB\1645601 whether\IN\1740 BNP\NN\1740 might\MD\5029706 serve\VB\2669789 as\IN\14622893 a\DT\13649268 simple\JJ\1740 diagnostic\JJ\1740 indicator\NN\6636259 of\IN\1740 anthracycline-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 acute\JJ\1740 leukemia\NN\14239918 treated\VBN\2376958 with\IN\1740 a\DT\13649268 daunorubicin\NN\1740 <e1>(DNR)-containing</e1>\NN\1740 regimen\NN\5898568 .\.\1740
D003630_D015470 NONE We\PRP\1740 measured\VBD\697589 the\DT\1740 plasma\NN\5398023 level\NN\4916342 of\IN\1740 brain\NN\5462674 natriuretic\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 BNP\NN\1740 )\-RRB-\1740 to\TO\1740 determine\VB\1645601 whether\IN\1740 BNP\NN\1740 might\MD\5029706 serve\VB\2669789 as\IN\14622893 a\DT\13649268 simple\JJ\1740 diagnostic\JJ\1740 indicator\NN\6636259 of\IN\1740 anthracycline-induced\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>acute\JJ\1740 leukemia</e2>\NN\14239918 treated\VBN\2376958 with\IN\1740 a\DT\13649268 <e1>daunorubicin</e1>\NN\1740 (DNR)-containing\NN\1740 regimen\NN\5898568 .\.\1740
D003630_D015470 NONE We\PRP\1740 measured\VBD\697589 the\DT\1740 plasma\NN\5398023 level\NN\4916342 of\IN\1740 brain\NN\5462674 natriuretic\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 BNP\NN\1740 )\-RRB-\1740 to\TO\1740 determine\VB\1645601 whether\IN\1740 BNP\NN\1740 might\MD\5029706 serve\VB\2669789 as\IN\14622893 a\DT\13649268 simple\JJ\1740 diagnostic\JJ\1740 indicator\NN\6636259 of\IN\1740 anthracycline-induced\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>acute\JJ\1740 leukemia</e2>\NN\14239918 treated\VBN\2376958 with\IN\1740 a\DT\13649268 daunorubicin\NN\1740 <e1>(DNR)-containing</e1>\NN\1740 regimen\NN\5898568 .\.\1740
D003630_D015470 NONE Thirteen\CD\13745420 patients\NNS\9898892 with\IN\1740 <e2>acute\JJ\1740 leukemia</e2>\NN\14239918 were\VBD\836236 treated\VBN\2376958 with\IN\1740 a\DT\13649268 <e1>DNR-containing</e1>\JJ\1740 regimen\NN\5898568 .\.\1740
D003630_D006333 CID On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 BNP\NN\1740 did\VBD\1640855 not\RB\1740 increase\VB\169651 in\IN\13603305 the\DT\1740 patients\NNS\9898892 without\IN\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 given\VBN\2327200 <e1>DNR</e1>\NN\1740 ,\,\1740 even\RB\1740 at\IN\14622893 more\JJR\1740 than\IN\1740 700\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 .\.\1740
20067456
D016642_D012735 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 the\DT\1740 adjunctive\JJ\1740 <e1>bupropion</e1>\NN\1740 on\IN\1740 male\JJ\1740 <e2>sexual\JJ\1740 dysfunction</e2>\NN\14204950 induced\VBN\1627355 by\IN\1740 a\DT\13649268 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitor\NN\20090 :\:\1740 a\DT\13649268 double-blind\JJ\1740 placebo-controlled\JJ\1740 and\CC\1740 randomized\JJ\1740 study\NN\635850 .\.\1740
D016642_D012735 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 adjunctive\JJ\1740 <e1>bupropion</e1>\NN\1740 sustained-release\NN\1740 (\-LRB-\1740 SR\NN\14625458 )\-RRB-\1740 on\IN\1740 male\JJ\1740 <e2>sexual\JJ\1740 dysfunction</e2>\NN\14204950 (\-LRB-\1740 SD\NN\1740 )\-RRB-\1740 induced\VBN\1627355 by\IN\1740 a\DT\13649268 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitor\NN\20090 (\-LRB-\1740 SSRI\NN\2718811 )\-RRB-\1740 ,\,\1740 as\IN\14622893 SD\NN\1740 is\VBZ\836236 a\DT\13649268 common\JJ\1740 side-effect\NN\1740 of\IN\1740 SSRIs\NNP\2718811 and\CC\1740 the\DT\1740 most\RBS\1740 effective\JJ\1740 treatments\NNS\654885 have\VBP\2108377 yet\RB\1740 to\TO\1740 be\VB\836236 determined\VBN\1645601 .\.\1740
D016642_D012735 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 adjunctive\JJ\1740 <e1>bupropion</e1>\NN\1740 sustained-release\NN\1740 (\-LRB-\1740 SR\NN\14625458 )\-RRB-\1740 on\IN\1740 male\JJ\1740 sexual\JJ\1740 dysfunction\NN\14204950 (\-LRB-\1740 <e2>SD</e2>\NN\1740 )\-RRB-\1740 induced\VBN\1627355 by\IN\1740 a\DT\13649268 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitor\NN\20090 (\-LRB-\1740 SSRI\NN\2718811 )\-RRB-\1740 ,\,\1740 as\IN\14622893 SD\NN\1740 is\VBZ\836236 a\DT\13649268 common\JJ\1740 side-effect\NN\1740 of\IN\1740 SSRIs\NNP\2718811 and\CC\1740 the\DT\1740 most\RBS\1740 effective\JJ\1740 treatments\NNS\654885 have\VBP\2108377 yet\RB\1740 to\TO\1740 be\VB\836236 determined\VBN\1645601 .\.\1740
D016642_D012735 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 adjunctive\JJ\1740 <e1>bupropion</e1>\NN\1740 sustained-release\NN\1740 (\-LRB-\1740 SR\NN\14625458 )\-RRB-\1740 on\IN\1740 male\JJ\1740 sexual\JJ\1740 dysfunction\NN\14204950 (\-LRB-\1740 SD\NN\1740 )\-RRB-\1740 induced\VBN\1627355 by\IN\1740 a\DT\13649268 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitor\NN\20090 (\-LRB-\1740 SSRI\NN\2718811 )\-RRB-\1740 ,\,\1740 as\IN\14622893 <e2>SD</e2>\NN\1740 is\VBZ\836236 a\DT\13649268 common\JJ\1740 side-effect\NN\1740 of\IN\1740 SSRIs\NNP\2718811 and\CC\1740 the\DT\1740 most\RBS\1740 effective\JJ\1740 treatments\NNS\654885 have\VBP\2108377 yet\RB\1740 to\TO\1740 be\VB\836236 determined\VBN\1645601 .\.\1740
D016642_D012735 NONE CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Bupropion</e1>\NN\1740 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 treatment\NN\654885 for\IN\1740 male\JJ\1740 <e2>SD</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 SSRIs\NNP\2718811 .\.\1740
D017367_D012735 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 the\DT\1740 adjunctive\JJ\1740 bupropion\NN\1740 on\IN\1740 male\JJ\1740 <e2>sexual\JJ\1740 dysfunction</e2>\NN\14204950 induced\VBN\1627355 by\IN\1740 a\DT\13649268 <e1>selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitor</e1>\NN\20090 :\:\1740 a\DT\13649268 double-blind\JJ\1740 placebo-controlled\JJ\1740 and\CC\1740 randomized\JJ\1740 study\NN\635850 .\.\1740
D017367_D012735 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 adjunctive\JJ\1740 bupropion\NN\1740 sustained-release\NN\1740 (\-LRB-\1740 SR\NN\14625458 )\-RRB-\1740 on\IN\1740 male\JJ\1740 <e2>sexual\JJ\1740 dysfunction</e2>\NN\14204950 (\-LRB-\1740 SD\NN\1740 )\-RRB-\1740 induced\VBN\1627355 by\IN\1740 a\DT\13649268 <e1>selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitor</e1>\NN\20090 (\-LRB-\1740 SSRI\NN\2718811 )\-RRB-\1740 ,\,\1740 as\IN\14622893 SD\NN\1740 is\VBZ\836236 a\DT\13649268 common\JJ\1740 side-effect\NN\1740 of\IN\1740 SSRIs\NNP\2718811 and\CC\1740 the\DT\1740 most\RBS\1740 effective\JJ\1740 treatments\NNS\654885 have\VBP\2108377 yet\RB\1740 to\TO\1740 be\VB\836236 determined\VBN\1645601 .\.\1740
D017367_D012735 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 adjunctive\JJ\1740 bupropion\NN\1740 sustained-release\NN\1740 (\-LRB-\1740 SR\NN\14625458 )\-RRB-\1740 on\IN\1740 male\JJ\1740 sexual\JJ\1740 dysfunction\NN\14204950 (\-LRB-\1740 <e2>SD</e2>\NN\1740 )\-RRB-\1740 induced\VBN\1627355 by\IN\1740 a\DT\13649268 <e1>selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitor</e1>\NN\20090 (\-LRB-\1740 SSRI\NN\2718811 )\-RRB-\1740 ,\,\1740 as\IN\14622893 SD\NN\1740 is\VBZ\836236 a\DT\13649268 common\JJ\1740 side-effect\NN\1740 of\IN\1740 SSRIs\NNP\2718811 and\CC\1740 the\DT\1740 most\RBS\1740 effective\JJ\1740 treatments\NNS\654885 have\VBP\2108377 yet\RB\1740 to\TO\1740 be\VB\836236 determined\VBN\1645601 .\.\1740
D017367_D012735 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 adjunctive\JJ\1740 bupropion\NN\1740 sustained-release\NN\1740 (\-LRB-\1740 SR\NN\14625458 )\-RRB-\1740 on\IN\1740 male\JJ\1740 sexual\JJ\1740 dysfunction\NN\14204950 (\-LRB-\1740 SD\NN\1740 )\-RRB-\1740 induced\VBN\1627355 by\IN\1740 a\DT\13649268 <e1>selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitor</e1>\NN\20090 (\-LRB-\1740 SSRI\NN\2718811 )\-RRB-\1740 ,\,\1740 as\IN\14622893 <e2>SD</e2>\NN\1740 is\VBZ\836236 a\DT\13649268 common\JJ\1740 side-effect\NN\1740 of\IN\1740 SSRIs\NNP\2718811 and\CC\1740 the\DT\1740 most\RBS\1740 effective\JJ\1740 treatments\NNS\654885 have\VBP\2108377 yet\RB\1740 to\TO\1740 be\VB\836236 determined\VBN\1645601 .\.\1740
D017367_D012735 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 adjunctive\JJ\1740 bupropion\NN\1740 sustained-release\NN\1740 (\-LRB-\1740 SR\NN\14625458 )\-RRB-\1740 on\IN\1740 male\JJ\1740 <e2>sexual\JJ\1740 dysfunction</e2>\NN\14204950 (\-LRB-\1740 SD\NN\1740 )\-RRB-\1740 induced\VBN\1627355 by\IN\1740 a\DT\13649268 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitor\NN\20090 (\-LRB-\1740 <e1>SSRI</e1>\NN\2718811 )\-RRB-\1740 ,\,\1740 as\IN\14622893 SD\NN\1740 is\VBZ\836236 a\DT\13649268 common\JJ\1740 side-effect\NN\1740 of\IN\1740 SSRIs\NNP\2718811 and\CC\1740 the\DT\1740 most\RBS\1740 effective\JJ\1740 treatments\NNS\654885 have\VBP\2108377 yet\RB\1740 to\TO\1740 be\VB\836236 determined\VBN\1645601 .\.\1740
D017367_D012735 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 adjunctive\JJ\1740 bupropion\NN\1740 sustained-release\NN\1740 (\-LRB-\1740 SR\NN\14625458 )\-RRB-\1740 on\IN\1740 male\JJ\1740 sexual\JJ\1740 dysfunction\NN\14204950 (\-LRB-\1740 <e2>SD</e2>\NN\1740 )\-RRB-\1740 induced\VBN\1627355 by\IN\1740 a\DT\13649268 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitor\NN\20090 (\-LRB-\1740 <e1>SSRI</e1>\NN\2718811 )\-RRB-\1740 ,\,\1740 as\IN\14622893 SD\NN\1740 is\VBZ\836236 a\DT\13649268 common\JJ\1740 side-effect\NN\1740 of\IN\1740 SSRIs\NNP\2718811 and\CC\1740 the\DT\1740 most\RBS\1740 effective\JJ\1740 treatments\NNS\654885 have\VBP\2108377 yet\RB\1740 to\TO\1740 be\VB\836236 determined\VBN\1645601 .\.\1740
D017367_D012735 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 adjunctive\JJ\1740 bupropion\NN\1740 sustained-release\NN\1740 (\-LRB-\1740 SR\NN\14625458 )\-RRB-\1740 on\IN\1740 male\JJ\1740 sexual\JJ\1740 dysfunction\NN\14204950 (\-LRB-\1740 SD\NN\1740 )\-RRB-\1740 induced\VBN\1627355 by\IN\1740 a\DT\13649268 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitor\NN\20090 (\-LRB-\1740 <e1>SSRI</e1>\NN\2718811 )\-RRB-\1740 ,\,\1740 as\IN\14622893 <e2>SD</e2>\NN\1740 is\VBZ\836236 a\DT\13649268 common\JJ\1740 side-effect\NN\1740 of\IN\1740 SSRIs\NNP\2718811 and\CC\1740 the\DT\1740 most\RBS\1740 effective\JJ\1740 treatments\NNS\654885 have\VBP\2108377 yet\RB\1740 to\TO\1740 be\VB\836236 determined\VBN\1645601 .\.\1740
D017367_D012735 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 adjunctive\JJ\1740 bupropion\NN\1740 sustained-release\NN\1740 (\-LRB-\1740 SR\NN\14625458 )\-RRB-\1740 on\IN\1740 male\JJ\1740 <e2>sexual\JJ\1740 dysfunction</e2>\NN\14204950 (\-LRB-\1740 SD\NN\1740 )\-RRB-\1740 induced\VBN\1627355 by\IN\1740 a\DT\13649268 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitor\NN\20090 (\-LRB-\1740 SSRI\NN\2718811 )\-RRB-\1740 ,\,\1740 as\IN\14622893 SD\NN\1740 is\VBZ\836236 a\DT\13649268 common\JJ\1740 side-effect\NN\1740 of\IN\1740 <e1>SSRIs</e1>\NNP\2718811 and\CC\1740 the\DT\1740 most\RBS\1740 effective\JJ\1740 treatments\NNS\654885 have\VBP\2108377 yet\RB\1740 to\TO\1740 be\VB\836236 determined\VBN\1645601 .\.\1740
D017367_D012735 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 adjunctive\JJ\1740 bupropion\NN\1740 sustained-release\NN\1740 (\-LRB-\1740 SR\NN\14625458 )\-RRB-\1740 on\IN\1740 male\JJ\1740 sexual\JJ\1740 dysfunction\NN\14204950 (\-LRB-\1740 <e2>SD</e2>\NN\1740 )\-RRB-\1740 induced\VBN\1627355 by\IN\1740 a\DT\13649268 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitor\NN\20090 (\-LRB-\1740 SSRI\NN\2718811 )\-RRB-\1740 ,\,\1740 as\IN\14622893 SD\NN\1740 is\VBZ\836236 a\DT\13649268 common\JJ\1740 side-effect\NN\1740 of\IN\1740 <e1>SSRIs</e1>\NNP\2718811 and\CC\1740 the\DT\1740 most\RBS\1740 effective\JJ\1740 treatments\NNS\654885 have\VBP\2108377 yet\RB\1740 to\TO\1740 be\VB\836236 determined\VBN\1645601 .\.\1740
D017367_D012735 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 determine\VB\1645601 the\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 adjunctive\JJ\1740 bupropion\NN\1740 sustained-release\NN\1740 (\-LRB-\1740 SR\NN\14625458 )\-RRB-\1740 on\IN\1740 male\JJ\1740 sexual\JJ\1740 dysfunction\NN\14204950 (\-LRB-\1740 SD\NN\1740 )\-RRB-\1740 induced\VBN\1627355 by\IN\1740 a\DT\13649268 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitor\NN\20090 (\-LRB-\1740 SSRI\NN\2718811 )\-RRB-\1740 ,\,\1740 as\IN\14622893 <e2>SD</e2>\NN\1740 is\VBZ\836236 a\DT\13649268 common\JJ\1740 side-effect\NN\1740 of\IN\1740 <e1>SSRIs</e1>\NNP\2718811 and\CC\1740 the\DT\1740 most\RBS\1740 effective\JJ\1740 treatments\NNS\654885 have\VBP\2108377 yet\RB\1740 to\TO\1740 be\VB\836236 determined\VBN\1645601 .\.\1740
D017367_D012735 NONE In\IN\13603305 linear\JJ\1740 regression\NN\14501726 analyses\VBZ\78760 the\DT\1740 CGI-SF\NN\1740 score\NN\5736149 was\VBD\836236 not\RB\1740 affected\VBN\126264 significantly\RB\1740 by\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 <e2>SD</e2>\NN\1740 ,\,\1740 type\NN\5839024 of\IN\1740 <e1>SSRI</e1>\NN\2718811 used\VBN\1156834 and\CC\1740 age\NN\4916342 .\.\1740
D017367_D012735 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Bupropion\NN\1740 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 treatment\NN\654885 for\IN\1740 male\JJ\1740 <e2>SD</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>SSRIs</e1>\NNP\2718811 .\.\1740
8231633
D002118_D064420 NONE Effects\NNS\13245626 of\IN\1740 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 on\IN\1740 bupivacaine-induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D002118_D064420 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 the\DT\1740 influence\NN\5190804 of\IN\1740 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 on\IN\1740 bupivacaine-induced\JJ\1740 acute\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D002045_D064420 NONE Effects\NNS\13245626 of\IN\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 on\IN\1740 <e1>bupivacaine-induced</e1>\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D002045_D064420 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 the\DT\1740 influence\NN\5190804 of\IN\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 on\IN\1740 <e1>bupivacaine-induced</e1>\JJ\1740 acute\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D002045_D012640 CID The\DT\1740 convulsant\JJ\1740 activity\NN\30358 of\IN\1740 <e1>bupivacaine</e1>\NN\1740 was\VBD\836236 not\RB\1740 significantly\RB\1740 modified\VBN\109660 but\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 decreased\VBD\169651 the\DT\1740 time\NN\7308889 of\IN\1740 latency\NN\15269513 to\TO\1740 obtain\VB\2210855 bupivacaine-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 ;\:\1740 this\DT\1740 effect\NN\34213 was\VBD\836236 less\RBR\1740 pronounced\JJ\1740 with\IN\1740 bepridil\NN\1740 .\.\1740
D002045_D012640 CID The\DT\1740 convulsant\JJ\1740 activity\NN\30358 of\IN\1740 bupivacaine\NN\1740 was\VBD\836236 not\RB\1740 significantly\RB\1740 modified\VBN\109660 but\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 decreased\VBD\169651 the\DT\1740 time\NN\7308889 of\IN\1740 latency\NN\15269513 to\TO\1740 obtain\VB\2210855 <e1>bupivacaine-induced</e1>\JJ\1740 <e2>convulsions</e2>\NNS\14081375 ;\:\1740 this\DT\1740 effect\NN\34213 was\VBD\836236 less\RBR\1740 pronounced\JJ\1740 with\IN\1740 bepridil\NN\1740 .\.\1740
D002118_D012640 NONE The\DT\1740 convulsant\JJ\1740 activity\NN\30358 of\IN\1740 bupivacaine\NN\1740 was\VBD\836236 not\RB\1740 significantly\RB\1740 modified\VBN\109660 but\CC\1740 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 decreased\VBD\169651 the\DT\1740 time\NN\7308889 of\IN\1740 latency\NN\15269513 to\TO\1740 obtain\VB\2210855 bupivacaine-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 ;\:\1740 this\DT\1740 effect\NN\34213 was\VBD\836236 less\RBR\1740 pronounced\JJ\1740 with\IN\1740 bepridil\NN\1740 .\.\1740
D015764_D012640 NONE The\DT\1740 convulsant\JJ\1740 activity\NN\30358 of\IN\1740 bupivacaine\NN\1740 was\VBD\836236 not\RB\1740 significantly\RB\1740 modified\VBN\109660 but\CC\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 decreased\VBD\169651 the\DT\1740 time\NN\7308889 of\IN\1740 latency\NN\15269513 to\TO\1740 obtain\VB\2210855 bupivacaine-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 ;\:\1740 this\DT\1740 effect\NN\34213 was\VBD\836236 less\RBR\1740 pronounced\JJ\1740 with\IN\1740 <e1>bepridil</e1>\NN\1740 .\.\1740
2549018
D005473_D017109 CID <e1>Fluoxetine-induced</e1>\JJ\1740 <e2>akathisia</e2>\NN\1740 :\:\1740 clinical\JJ\1740 and\CC\1740 theoretical\JJ\1740 implications\NNS\5774614 .\.\1740
D005473_D017109 CID Five\CD\13741022 patients\NNS\9898892 receiving\VBG\2210855 <e1>fluoxetine</e1>\NN\4169152 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 obsessive\JJ\1740 compulsive\JJ\1740 disorder\NN\14034177 or\CC\3541091 major\JJ\1740 depression\NN\14373582 developed\VBD\1753788 <e2>akathisia</e2>\NN\1740 .\.\1740
D005473_D017109 CID The\DT\1740 typical\JJ\1740 <e1>fluoxetine-induced</e1>\JJ\1740 symptoms\NNS\5823932 of\IN\1740 restlessness\NN\4773351 ,\,\1740 constant\JJ\1740 pacing\NN\15122011 ,\,\1740 purposeless\NN\1740 movements\NNS\191142 of\IN\1740 the\DT\1740 feet\NNS\5563034 and\CC\1740 legs\NNS\5032918 ,\,\1740 and\CC\1740 marked\JJ\1740 anxiety\NN\14373582 were\VBD\836236 indistinguishable\JJ\1740 from\IN\1740 those\DT\1740 of\IN\1740 neuroleptic-induced\JJ\1740 <e2>akathisia</e2>\NN\1740 .\.\1740
D005473_D017109 CID Three\CD\13741022 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 experienced\VBN\2108377 neuroleptic-induced\JJ\1740 <e2>akathisia</e2>\NN\1740 in\IN\13603305 the\DT\1740 past\NN\28270 reported\VBD\831651 that\IN\1740 the\DT\1740 symptoms\NNS\5823932 of\IN\1740 <e1>fluoxetine-induced</e1>\JJ\1740 akathisia\NN\1740 were\VBD\836236 identical\JJ\1740 ,\,\1740 although\IN\1740 somewhat\RB\1740 milder\NN\1740 .\.\1740
D005473_D017109 CID Three\CD\13741022 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 experienced\VBN\2108377 neuroleptic-induced\JJ\1740 akathisia\NN\1740 in\IN\13603305 the\DT\1740 past\NN\28270 reported\VBD\831651 that\IN\1740 the\DT\1740 symptoms\NNS\5823932 of\IN\1740 <e1>fluoxetine-induced</e1>\JJ\1740 <e2>akathisia</e2>\NN\1740 were\VBD\836236 identical\JJ\1740 ,\,\1740 although\IN\1740 somewhat\RB\1740 milder\NN\1740 .\.\1740
D005473_D017109 CID <e2>Akathisia</e2>\NNP\1740 appeared\VBD\2604760 to\TO\1740 be\VB\836236 a\DT\13649268 common\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 <e1>fluoxetine</e1>\NN\4169152 and\CC\1740 generally\RB\1740 responded\VBD\2367363 well\RB\1740 to\IN\1740 treatment\NN\654885 with\IN\1740 the\DT\1740 beta-adrenergic\JJ\1740 antagonist\NN\7846 propranolol\NN\1740 ,\,\1740 dose\NN\3740161 reduction\NN\351485 ,\,\1740 or\CC\3541091 both\DT\1740 .\.\1740
D005473_D017109 CID The\DT\1740 authors\NNS\9610660 suggest\VBP\1010118 that\IN\1740 <e1>fluoxetine-induced</e1>\JJ\1740 <e2>akathisia</e2>\NN\1740 may\MD\15209706 be\VB\836236 caused\VBN\1617192 by\IN\1740 serotonergically\RB\1740 mediated\VBN\761713 inhibition\NN\1068773 of\IN\1740 dopaminergic\JJ\1740 neurotransmission\NN\1740 and\CC\1740 that\IN\1740 the\DT\1740 pathophysiology\NN\1740 of\IN\1740 fluoxetine-induced\JJ\1740 akathisia\NN\1740 and\CC\1740 tricyclic\JJ\1740 antidepressant-induced\JJ\1740 "\``\1740 jitteriness\NN\7523905 "\''\1740 may\MD\15209706 be\VB\836236 identical\JJ\1740 .\.\1740
D005473_D017109 CID The\DT\1740 authors\NNS\9610660 suggest\VBP\1010118 that\IN\1740 <e1>fluoxetine-induced</e1>\JJ\1740 akathisia\NN\1740 may\MD\15209706 be\VB\836236 caused\VBN\1617192 by\IN\1740 serotonergically\RB\1740 mediated\VBN\761713 inhibition\NN\1068773 of\IN\1740 dopaminergic\JJ\1740 neurotransmission\NN\1740 and\CC\1740 that\IN\1740 the\DT\1740 pathophysiology\NN\1740 of\IN\1740 fluoxetine-induced\JJ\1740 <e2>akathisia</e2>\NN\1740 and\CC\1740 tricyclic\JJ\1740 antidepressant-induced\JJ\1740 "\``\1740 jitteriness\NN\7523905 "\''\1740 may\MD\15209706 be\VB\836236 identical\JJ\1740 .\.\1740
D005473_D017109 CID The\DT\1740 authors\NNS\9610660 suggest\VBP\1010118 that\IN\1740 fluoxetine-induced\JJ\1740 <e2>akathisia</e2>\NN\1740 may\MD\15209706 be\VB\836236 caused\VBN\1617192 by\IN\1740 serotonergically\RB\1740 mediated\VBN\761713 inhibition\NN\1068773 of\IN\1740 dopaminergic\JJ\1740 neurotransmission\NN\1740 and\CC\1740 that\IN\1740 the\DT\1740 pathophysiology\NN\1740 of\IN\1740 <e1>fluoxetine-induced</e1>\JJ\1740 akathisia\NN\1740 and\CC\1740 tricyclic\JJ\1740 antidepressant-induced\JJ\1740 "\``\1740 jitteriness\NN\7523905 "\''\1740 may\MD\15209706 be\VB\836236 identical\JJ\1740 .\.\1740
D005473_D017109 CID The\DT\1740 authors\NNS\9610660 suggest\VBP\1010118 that\IN\1740 fluoxetine-induced\JJ\1740 akathisia\NN\1740 may\MD\15209706 be\VB\836236 caused\VBN\1617192 by\IN\1740 serotonergically\RB\1740 mediated\VBN\761713 inhibition\NN\1068773 of\IN\1740 dopaminergic\JJ\1740 neurotransmission\NN\1740 and\CC\1740 that\IN\1740 the\DT\1740 pathophysiology\NN\1740 of\IN\1740 <e1>fluoxetine-induced</e1>\JJ\1740 <e2>akathisia</e2>\NN\1740 and\CC\1740 tricyclic\JJ\1740 antidepressant-induced\JJ\1740 "\``\1740 jitteriness\NN\7523905 "\''\1740 may\MD\15209706 be\VB\836236 identical\JJ\1740 .\.\1740
D005473_D009771 NONE Five\CD\13741022 patients\NNS\9898892 receiving\VBG\2210855 <e1>fluoxetine</e1>\NN\4169152 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>obsessive\JJ\1740 compulsive\JJ\1740 disorder</e2>\NN\14034177 or\CC\3541091 major\JJ\1740 depression\NN\14373582 developed\VBD\1753788 akathisia\NN\1740 .\.\1740
D005473_D003865 NONE Five\CD\13741022 patients\NNS\9898892 receiving\VBG\2210855 <e1>fluoxetine</e1>\NN\4169152 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 obsessive\JJ\1740 compulsive\JJ\1740 disorder\NN\14034177 or\CC\3541091 <e2>major\JJ\1740 depression</e2>\NN\14373582 developed\VBD\1753788 akathisia\NN\1740 .\.\1740
D005473_D001008 NONE The\DT\1740 typical\JJ\1740 <e1>fluoxetine-induced</e1>\JJ\1740 symptoms\NNS\5823932 of\IN\1740 restlessness\NN\4773351 ,\,\1740 constant\JJ\1740 pacing\NN\15122011 ,\,\1740 purposeless\NN\1740 movements\NNS\191142 of\IN\1740 the\DT\1740 feet\NNS\5563034 and\CC\1740 legs\NNS\5032918 ,\,\1740 and\CC\1740 marked\JJ\1740 <e2>anxiety</e2>\NN\14373582 were\VBD\836236 indistinguishable\JJ\1740 from\IN\1740 those\DT\1740 of\IN\1740 neuroleptic-induced\JJ\1740 akathisia\NN\1740 .\.\1740
D011433_D017109 NONE <e2>Akathisia</e2>\NNP\1740 appeared\VBD\2604760 to\TO\1740 be\VB\836236 a\DT\13649268 common\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 fluoxetine\NN\4169152 and\CC\1740 generally\RB\1740 responded\VBD\2367363 well\RB\1740 to\IN\1740 treatment\NN\654885 with\IN\1740 the\DT\1740 beta-adrenergic\JJ\1740 antagonist\NN\7846 <e1>propranolol</e1>\NN\1740 ,\,\1740 dose\NN\3740161 reduction\NN\351485 ,\,\1740 or\CC\3541091 both\DT\1740 .\.\1740
D000928_D017109 NONE The\DT\1740 authors\NNS\9610660 suggest\VBP\1010118 that\IN\1740 fluoxetine-induced\JJ\1740 <e2>akathisia</e2>\NN\1740 may\MD\15209706 be\VB\836236 caused\VBN\1617192 by\IN\1740 serotonergically\RB\1740 mediated\VBN\761713 inhibition\NN\1068773 of\IN\1740 dopaminergic\JJ\1740 neurotransmission\NN\1740 and\CC\1740 that\IN\1740 the\DT\1740 pathophysiology\NN\1740 of\IN\1740 fluoxetine-induced\JJ\1740 akathisia\NN\1740 and\CC\1740 tricyclic\JJ\1740 <e1>antidepressant-induced</e1>\JJ\1740 "\``\1740 jitteriness\NN\7523905 "\''\1740 may\MD\15209706 be\VB\836236 identical\JJ\1740 .\.\1740
D000928_D017109 NONE The\DT\1740 authors\NNS\9610660 suggest\VBP\1010118 that\IN\1740 fluoxetine-induced\JJ\1740 akathisia\NN\1740 may\MD\15209706 be\VB\836236 caused\VBN\1617192 by\IN\1740 serotonergically\RB\1740 mediated\VBN\761713 inhibition\NN\1068773 of\IN\1740 dopaminergic\JJ\1740 neurotransmission\NN\1740 and\CC\1740 that\IN\1740 the\DT\1740 pathophysiology\NN\1740 of\IN\1740 fluoxetine-induced\JJ\1740 <e2>akathisia</e2>\NN\1740 and\CC\1740 tricyclic\JJ\1740 <e1>antidepressant-induced</e1>\JJ\1740 "\``\1740 jitteriness\NN\7523905 "\''\1740 may\MD\15209706 be\VB\836236 identical\JJ\1740 .\.\1740
3997294
D000638_D010996 CID Pneumonitis\NN\14336539 with\IN\1740 <e2>pleural\JJ\1740 and\CC\1740 pericardial\JJ\1740 effusion</e2>\NN\6880249 and\CC\1740 neuropathy\JJ\1740 during\IN\1740 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 .\.\1740
D000638_D010490 CID Pneumonitis\NN\14336539 with\IN\1740 <e2>pleural\JJ\1740 and\CC\1740 pericardial\JJ\1740 effusion</e2>\NN\6880249 and\CC\1740 neuropathy\JJ\1740 during\IN\1740 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 .\.\1740
D000638_D009422 NONE Pneumonitis\NN\14336539 with\IN\1740 pleural\JJ\1740 and\CC\1740 pericardial\JJ\1740 effusion\NN\6880249 and\CC\1740 <e2>neuropathy</e2>\JJ\1740 during\IN\1740 <e1>amiodarone</e1>\NN\2715941 therapy\NN\657604 .\.\1740
D000638_D002318 NONE A\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>sinuatrial\JJ\1740 disease</e2>\NN\14061805 and\CC\1740 implanted\JJ\1740 pacemaker\NN\5925366 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>amiodarone</e1>\NN\2715941 (\-LRB-\1740 maximum\NN\13653902 dose\NN\3740161 1000\CD\13745420 mg\NN\13717155 ,\,\1740 maintenance\NN\266806 dose\NN\3740161 800\CD\1740 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 for\IN\1740 10\CD\13745420 months\NNS\15113229 ,\,\1740 for\IN\1740 control\NN\5190804 of\IN\1740 supraventricular\JJ\1740 tachyarrhythmias\NNS\1740 .\.\1740
D000638_D013617 NONE A\DT\13649268 patient\NN\9898892 with\IN\1740 sinuatrial\JJ\1740 disease\NN\14061805 and\CC\1740 implanted\JJ\1740 pacemaker\NN\5925366 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>amiodarone</e1>\NN\2715941 (\-LRB-\1740 maximum\NN\13653902 dose\NN\3740161 1000\CD\13745420 mg\NN\13717155 ,\,\1740 maintenance\NN\266806 dose\NN\3740161 800\CD\1740 mg\NN\13717155 daily\RB\1740 )\-RRB-\1740 for\IN\1740 10\CD\13745420 months\NNS\15113229 ,\,\1740 for\IN\1740 control\NN\5190804 of\IN\1740 <e2>supraventricular\JJ\1740 tachyarrhythmias</e2>\NNS\1740 .\.\1740
D000638_D011014 CID Review\NN\5733583 of\IN\1740 this\DT\1740 and\CC\1740 previously\RB\1740 reported\VBN\831651 cases\NNS\7283608 indicates\VBZ\952524 the\DT\1740 need\NN\13920835 for\IN\1740 early\JJ\1740 diagnosis\NN\152018 of\IN\1740 <e1>amiodarone</e1>\JJ\1740 <e2>pneumonitis</e2>\NN\14336539 ,\,\1740 immediate\JJ\1740 withdrawal\NN\7206096 of\IN\1740 amiodarone\NN\2715941 ,\,\1740 and\CC\1740 prompt\NN\7011209 but\CC\1740 continued\JJ\1740 steroid\NN\14727670 therapy\NN\657604 to\TO\1740 ensure\VB\664483 full\JJ\1740 recovery\NN\7357388 .\.\1740
D000638_D011014 CID Review\NN\5733583 of\IN\1740 this\DT\1740 and\CC\1740 previously\RB\1740 reported\VBN\831651 cases\NNS\7283608 indicates\VBZ\952524 the\DT\1740 need\NN\13920835 for\IN\1740 early\JJ\1740 diagnosis\NN\152018 of\IN\1740 amiodarone\JJ\1740 <e2>pneumonitis</e2>\NN\14336539 ,\,\1740 immediate\JJ\1740 withdrawal\NN\7206096 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 ,\,\1740 and\CC\1740 prompt\NN\7011209 but\CC\1740 continued\JJ\1740 steroid\NN\14727670 therapy\NN\657604 to\TO\1740 ensure\VB\664483 full\JJ\1740 recovery\NN\7357388 .\.\1740
D013256_D011014 NONE Review\NN\5733583 of\IN\1740 this\DT\1740 and\CC\1740 previously\RB\1740 reported\VBN\831651 cases\NNS\7283608 indicates\VBZ\952524 the\DT\1740 need\NN\13920835 for\IN\1740 early\JJ\1740 diagnosis\NN\152018 of\IN\1740 amiodarone\JJ\1740 <e2>pneumonitis</e2>\NN\14336539 ,\,\1740 immediate\JJ\1740 withdrawal\NN\7206096 of\IN\1740 amiodarone\NN\2715941 ,\,\1740 and\CC\1740 prompt\NN\7011209 but\CC\1740 continued\JJ\1740 <e1>steroid</e1>\NN\14727670 therapy\NN\657604 to\TO\1740 ensure\VB\664483 full\JJ\1740 recovery\NN\7357388 .\.\1740
2265898
C009265_D004827 CID Serial\JJ\1740 <e2>epilepsy</e2>\NN\14085708 caused\VBN\1617192 by\IN\1740 <e1>levodopa/carbidopa</e1>\JJ\1740 administration\NN\1133281 in\IN\13603305 two\CD\13741022 patients\NNS\9898892 on\IN\1740 hemodialysis\NN\649760 .\.\1740
C009265_D007676 NONE Two\CD\13741022 patients\NNS\9898892 with\IN\1740 similar\JJ\1740 clinical\JJ\1740 features\NNS\5849040 are\VBP\836236 presented\VBN\2137132 :\:\1740 both\DT\1740 patients\NNS\9898892 had\VBD\2108377 <e2>chronic\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 ,\,\1740 on\IN\1740 hemodialysis\NN\649760 for\IN\1740 many\JJ\1740 years\NNS\15144371 but\CC\1740 recently\RB\1740 begun\VBN\941990 on\IN\1740 a\DT\13649268 high-flux\JJ\1740 dialyzer\NN\3739693 ;\:\1740 both\DT\1740 had\VBD\2108377 been\VBN\836236 receiving\VBG\2210855 a\DT\13649268 <e1>carbidopa/levodopa</e1>\NN\1740 preparation\NN\407535 ;\:\1740 and\CC\1740 both\DT\1740 had\VBD\2108377 the\DT\1740 onset\NN\7325190 of\IN\1740 hallucinosis\NN\14373582 and\CC\1740 recurrent\JJ\1740 seizures\NNS\14081375 ,\,\1740 which\WDT\1740 were\VBD\836236 refractory\JJ\1740 to\TO\1740 anticonvulsants\NNS\3740161 .\.\1740
C009265_D001523 NONE Two\CD\13741022 patients\NNS\9898892 with\IN\1740 similar\JJ\1740 clinical\JJ\1740 features\NNS\5849040 are\VBP\836236 presented\VBN\2137132 :\:\1740 both\DT\1740 patients\NNS\9898892 had\VBD\2108377 chronic\JJ\1740 renal\JJ\1740 failure\NN\66216 ,\,\1740 on\IN\1740 hemodialysis\NN\649760 for\IN\1740 many\JJ\1740 years\NNS\15144371 but\CC\1740 recently\RB\1740 begun\VBN\941990 on\IN\1740 a\DT\13649268 high-flux\JJ\1740 dialyzer\NN\3739693 ;\:\1740 both\DT\1740 had\VBD\2108377 been\VBN\836236 receiving\VBG\2210855 a\DT\13649268 <e1>carbidopa/levodopa</e1>\NN\1740 preparation\NN\407535 ;\:\1740 and\CC\1740 both\DT\1740 had\VBD\2108377 the\DT\1740 onset\NN\7325190 of\IN\1740 <e2>hallucinosis</e2>\NN\14373582 and\CC\1740 recurrent\JJ\1740 seizures\NNS\14081375 ,\,\1740 which\WDT\1740 were\VBD\836236 refractory\JJ\1740 to\TO\1740 anticonvulsants\NNS\3740161 .\.\1740
C009265_D012640 NONE Two\CD\13741022 patients\NNS\9898892 with\IN\1740 similar\JJ\1740 clinical\JJ\1740 features\NNS\5849040 are\VBP\836236 presented\VBN\2137132 :\:\1740 both\DT\1740 patients\NNS\9898892 had\VBD\2108377 chronic\JJ\1740 renal\JJ\1740 failure\NN\66216 ,\,\1740 on\IN\1740 hemodialysis\NN\649760 for\IN\1740 many\JJ\1740 years\NNS\15144371 but\CC\1740 recently\RB\1740 begun\VBN\941990 on\IN\1740 a\DT\13649268 high-flux\JJ\1740 dialyzer\NN\3739693 ;\:\1740 both\DT\1740 had\VBD\2108377 been\VBN\836236 receiving\VBG\2210855 a\DT\13649268 <e1>carbidopa/levodopa</e1>\NN\1740 preparation\NN\407535 ;\:\1740 and\CC\1740 both\DT\1740 had\VBD\2108377 the\DT\1740 onset\NN\7325190 of\IN\1740 hallucinosis\NN\14373582 and\CC\1740 recurrent\JJ\1740 <e2>seizures</e2>\NNS\14081375 ,\,\1740 which\WDT\1740 were\VBD\836236 refractory\JJ\1740 to\TO\1740 anticonvulsants\NNS\3740161 .\.\1740
1147734
D011441_D008107 NONE <e2>Liver\NN\5298729 disease</e2>\NN\14061805 caused\VBN\1617192 by\IN\1740 <e1>propylthiouracil</e1>\NN\14727670 .\.\1740
D011441_D006521 CID This\DT\1740 report\NN\6470073 presents\VBZ\2137132 the\DT\1740 clinical\JJ\1740 ,\,\1740 laboratory\NN\4602044 ,\,\1740 and\CC\1740 light\NN\11421401 and\CC\1740 electron\NN\9338013 microscopic\JJ\1740 observations\NNS\996969 on\IN\1740 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>chronic\JJ\1740 active\JJ\1740 (\-LRB-\1740 aggressive\JJ\1740 )\-RRB-\1740 hepatitis</e2>\NN\14127211 caused\VBN\1617192 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>propylthiouracil</e1>\NN\14727670 .\.\1740
14659530
D009569_D008881 NONE <e1>NO-induced</e1>\JJ\1740 <e2>migraine</e2>\NN\14326607 attack\NN\955060 :\:\1740 strong\JJ\1740 increase\NN\13576355 in\IN\13603305 plasma\NN\5398023 calcitonin\NN\5413241 gene-related\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 CGRP\NN\1740 )\-RRB-\1740 concentration\NN\4916342 and\CC\1740 negative\JJ\1740 correlation\NN\13841213 with\IN\1740 platelet\NN\5432736 serotonin\NN\14807737 release\NN\3748886 .\.\1740
D015740_D008881 NONE NO-induced\JJ\1740 <e2>migraine</e2>\NN\14326607 attack\NN\955060 :\:\1740 strong\JJ\1740 increase\NN\13576355 in\IN\13603305 plasma\NN\5398023 <e1>calcitonin\NN\5413241 gene-related\JJ\1740 peptide</e1>\NN\14724264 (\-LRB-\1740 CGRP\NN\1740 )\-RRB-\1740 concentration\NN\4916342 and\CC\1740 negative\JJ\1740 correlation\NN\13841213 with\IN\1740 platelet\NN\5432736 serotonin\NN\14807737 release\NN\3748886 .\.\1740
D015740_D008881 NONE NO-induced\JJ\1740 <e2>migraine</e2>\NN\14326607 attack\NN\955060 :\:\1740 strong\JJ\1740 increase\NN\13576355 in\IN\13603305 plasma\NN\5398023 calcitonin\NN\5413241 gene-related\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 <e1>CGRP</e1>\NN\1740 )\-RRB-\1740 concentration\NN\4916342 and\CC\1740 negative\JJ\1740 correlation\NN\13841213 with\IN\1740 platelet\NN\5432736 serotonin\NN\14807737 release\NN\3748886 .\.\1740
D015740_D008881 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 changes\NNS\7283608 in\IN\13603305 the\DT\1740 plasma\NN\5398023 <e1>calcitonin\NN\5413241 gene-related\JJ\1740 peptide</e1>\NN\14724264 (\-LRB-\1740 CGRP\NN\1740 )\-RRB-\1740 concentration\NN\4916342 and\CC\1740 platelet\NN\5432736 serotonin\NN\14807737 (\-LRB-\1740 5-hydroxytriptamine\NN\1740 ,\,\1740 5-HT\NN\1740 )\-RRB-\1740 content\NN\7951464 during\IN\1740 the\DT\1740 immediate\JJ\1740 headache\NN\5829480 and\CC\1740 the\DT\1740 delayed\VBN\439958 genuine\NN\1740 <e2>migraine</e2>\NN\14326607 attack\NN\955060 provoked\VBN\1617192 by\IN\1740 nitroglycerin\NN\15015501 .\.\1740
D015740_D008881 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 changes\NNS\7283608 in\IN\13603305 the\DT\1740 plasma\NN\5398023 calcitonin\NN\5413241 gene-related\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 <e1>CGRP</e1>\NN\1740 )\-RRB-\1740 concentration\NN\4916342 and\CC\1740 platelet\NN\5432736 serotonin\NN\14807737 (\-LRB-\1740 5-hydroxytriptamine\NN\1740 ,\,\1740 5-HT\NN\1740 )\-RRB-\1740 content\NN\7951464 during\IN\1740 the\DT\1740 immediate\JJ\1740 headache\NN\5829480 and\CC\1740 the\DT\1740 delayed\VBN\439958 genuine\NN\1740 <e2>migraine</e2>\NN\14326607 attack\NN\955060 provoked\VBN\1617192 by\IN\1740 nitroglycerin\NN\15015501 .\.\1740
D015740_D008881 NONE Plasma\NN\5398023 <e1>CGRP</e1>\NN\1740 concentration\NN\4916342 increased\VBD\169651 significantly\RB\1740 (\-LRB-\1740 P<0.01\NN\1740 )\-RRB-\1740 during\IN\1740 the\DT\1740 <e2>migraine</e2>\NN\14326607 attack\NN\955060 and\CC\1740 returned\VBD\1835496 to\TO\1740 baseline\NN\7260623 after\IN\1740 the\DT\1740 cessation\NN\7365849 of\IN\1740 the\DT\1740 migraine\NN\14326607 .\.\1740
D015740_D008881 NONE Plasma\NN\5398023 <e1>CGRP</e1>\NN\1740 concentration\NN\4916342 increased\VBD\169651 significantly\RB\1740 (\-LRB-\1740 P<0.01\NN\1740 )\-RRB-\1740 during\IN\1740 the\DT\1740 migraine\NN\14326607 attack\NN\955060 and\CC\1740 returned\VBD\1835496 to\TO\1740 baseline\NN\7260623 after\IN\1740 the\DT\1740 cessation\NN\7365849 of\IN\1740 the\DT\1740 <e2>migraine</e2>\NN\14326607 .\.\1740
D015740_D008881 NONE However\RB\1740 ,\,\1740 plasma\NN\5398023 <e1>CGRP</e1>\NN\1740 concentrations\NNS\4916342 failed\VBD\1798936 to\TO\1740 change\VB\46534 during\IN\1740 immediate\JJ\1740 headache\NN\5829480 and\CC\1740 in\IN\13603305 the\DT\1740 subjects\NNS\6598915 with\IN\1740 no\DT\7204911 <e2>migraine</e2>\NN\14326607 attack\NN\955060 .\.\1740
D015740_D008881 NONE Basal\JJ\1740 <e1>CGRP</e1>\NN\1740 concentration\NN\4916342 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 and\CC\1740 platelet\NN\5432736 5-HT\NN\1740 content\NN\7951464 tended\VBD\2604760 to\TO\1740 be\VB\836236 lower\JJR\1740 in\IN\13603305 subjects\NNS\6598915 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 <e2>migraine</e2>\NN\14326607 attack\NN\955060 .\.\1740
D015740_D008881 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 the\DT\1740 fact\NN\5816287 that\IN\1740 plasma\NN\5398023 <e1>CGRP</e1>\NN\1740 concentration\NN\4916342 correlates\VBZ\2657219 with\IN\1740 the\DT\1740 timing\NN\5044673 and\CC\1740 severity\NN\5036394 of\IN\1740 a\DT\13649268 <e2>migraine</e2>\NN\14326607 headache\NN\5829480 suggests\VBZ\1010118 a\DT\13649268 direct\JJ\1740 relationship\NN\31921 between\IN\1740 CGRP\NN\1740 and\CC\1740 migraine\NN\14326607 .\.\1740
D015740_D008881 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 the\DT\1740 fact\NN\5816287 that\IN\1740 plasma\NN\5398023 <e1>CGRP</e1>\NN\1740 concentration\NN\4916342 correlates\VBZ\2657219 with\IN\1740 the\DT\1740 timing\NN\5044673 and\CC\1740 severity\NN\5036394 of\IN\1740 a\DT\13649268 migraine\NN\14326607 headache\NN\5829480 suggests\VBZ\1010118 a\DT\13649268 direct\JJ\1740 relationship\NN\31921 between\IN\1740 CGRP\NN\1740 and\CC\1740 <e2>migraine</e2>\NN\14326607 .\.\1740
D015740_D008881 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 the\DT\1740 fact\NN\5816287 that\IN\1740 plasma\NN\5398023 CGRP\NN\1740 concentration\NN\4916342 correlates\VBZ\2657219 with\IN\1740 the\DT\1740 timing\NN\5044673 and\CC\1740 severity\NN\5036394 of\IN\1740 a\DT\13649268 <e2>migraine</e2>\NN\14326607 headache\NN\5829480 suggests\VBZ\1010118 a\DT\13649268 direct\JJ\1740 relationship\NN\31921 between\IN\1740 <e1>CGRP</e1>\NN\1740 and\CC\1740 migraine\NN\14326607 .\.\1740
D015740_D008881 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 the\DT\1740 fact\NN\5816287 that\IN\1740 plasma\NN\5398023 CGRP\NN\1740 concentration\NN\4916342 correlates\VBZ\2657219 with\IN\1740 the\DT\1740 timing\NN\5044673 and\CC\1740 severity\NN\5036394 of\IN\1740 a\DT\13649268 migraine\NN\14326607 headache\NN\5829480 suggests\VBZ\1010118 a\DT\13649268 direct\JJ\1740 relationship\NN\31921 between\IN\1740 <e1>CGRP</e1>\NN\1740 and\CC\1740 <e2>migraine</e2>\NN\14326607 .\.\1740
D015740_D008881 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 serotonin\NN\14807737 release\NN\3748886 from\IN\1740 platelets\NNS\5432736 does\VBZ\1640855 not\RB\1740 provoke\VB\1617192 <e2>migraine</e2>\NN\14326607 ,\,\1740 it\PRP\6125041 may\MD\15209706 even\RB\1740 counteract\VB\2367363 the\DT\1740 headache\NN\5829480 and\CC\1740 the\DT\1740 concomitant\JJ\1740 <e1>CGRP</e1>\NN\1740 release\NN\3748886 in\IN\13603305 this\DT\1740 model\NN\5888929 .\.\1740
D012701_D008881 NONE NO-induced\JJ\1740 <e2>migraine</e2>\NN\14326607 attack\NN\955060 :\:\1740 strong\JJ\1740 increase\NN\13576355 in\IN\13603305 plasma\NN\5398023 calcitonin\NN\5413241 gene-related\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 CGRP\NN\1740 )\-RRB-\1740 concentration\NN\4916342 and\CC\1740 negative\JJ\1740 correlation\NN\13841213 with\IN\1740 platelet\NN\5432736 <e1>serotonin</e1>\NN\14807737 release\NN\3748886 .\.\1740
D012701_D008881 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 changes\NNS\7283608 in\IN\13603305 the\DT\1740 plasma\NN\5398023 calcitonin\NN\5413241 gene-related\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 CGRP\NN\1740 )\-RRB-\1740 concentration\NN\4916342 and\CC\1740 platelet\NN\5432736 <e1>serotonin</e1>\NN\14807737 (\-LRB-\1740 5-hydroxytriptamine\NN\1740 ,\,\1740 5-HT\NN\1740 )\-RRB-\1740 content\NN\7951464 during\IN\1740 the\DT\1740 immediate\JJ\1740 headache\NN\5829480 and\CC\1740 the\DT\1740 delayed\VBN\439958 genuine\NN\1740 <e2>migraine</e2>\NN\14326607 attack\NN\955060 provoked\VBN\1617192 by\IN\1740 nitroglycerin\NN\15015501 .\.\1740
D012701_D008881 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 changes\NNS\7283608 in\IN\13603305 the\DT\1740 plasma\NN\5398023 calcitonin\NN\5413241 gene-related\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 CGRP\NN\1740 )\-RRB-\1740 concentration\NN\4916342 and\CC\1740 platelet\NN\5432736 serotonin\NN\14807737 (\-LRB-\1740 <e1>5-hydroxytriptamine</e1>\NN\1740 ,\,\1740 5-HT\NN\1740 )\-RRB-\1740 content\NN\7951464 during\IN\1740 the\DT\1740 immediate\JJ\1740 headache\NN\5829480 and\CC\1740 the\DT\1740 delayed\VBN\439958 genuine\NN\1740 <e2>migraine</e2>\NN\14326607 attack\NN\955060 provoked\VBN\1617192 by\IN\1740 nitroglycerin\NN\15015501 .\.\1740
D012701_D008881 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 changes\NNS\7283608 in\IN\13603305 the\DT\1740 plasma\NN\5398023 calcitonin\NN\5413241 gene-related\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 CGRP\NN\1740 )\-RRB-\1740 concentration\NN\4916342 and\CC\1740 platelet\NN\5432736 serotonin\NN\14807737 (\-LRB-\1740 5-hydroxytriptamine\NN\1740 ,\,\1740 <e1>5-HT</e1>\NN\1740 )\-RRB-\1740 content\NN\7951464 during\IN\1740 the\DT\1740 immediate\JJ\1740 headache\NN\5829480 and\CC\1740 the\DT\1740 delayed\VBN\439958 genuine\NN\1740 <e2>migraine</e2>\NN\14326607 attack\NN\955060 provoked\VBN\1617192 by\IN\1740 nitroglycerin\NN\15015501 .\.\1740
D012701_D008881 NONE Basal\JJ\1740 CGRP\NN\1740 concentration\NN\4916342 was\VBD\836236 significantly\RB\1740 higher\JJR\1740 and\CC\1740 platelet\NN\5432736 <e1>5-HT</e1>\NN\1740 content\NN\7951464 tended\VBD\2604760 to\TO\1740 be\VB\836236 lower\JJR\1740 in\IN\13603305 subjects\NNS\6598915 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 <e2>migraine</e2>\NN\14326607 attack\NN\955060 .\.\1740
D012701_D008881 NONE Platelet\NN\5432736 <e1>serotonin</e1>\NN\14807737 content\NN\7951464 decreased\VBD\169651 significantly\RB\1740 (\-LRB-\1740 P<0.01\NN\1740 )\-RRB-\1740 after\IN\1740 nitroglycerin\NN\15015501 in\IN\13603305 subjects\NNS\6598915 with\IN\1740 no\DT\7204911 <e2>migraine</e2>\NN\14326607 attack\NN\955060 but\CC\1740 no\DT\7204911 consistent\JJ\1740 change\NN\7283608 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 patients\NNS\9898892 with\IN\1740 migraine\NN\14326607 attack\NN\955060 .\.\1740
D012701_D008881 NONE Platelet\NN\5432736 <e1>serotonin</e1>\NN\14807737 content\NN\7951464 decreased\VBD\169651 significantly\RB\1740 (\-LRB-\1740 P<0.01\NN\1740 )\-RRB-\1740 after\IN\1740 nitroglycerin\NN\15015501 in\IN\13603305 subjects\NNS\6598915 with\IN\1740 no\DT\7204911 migraine\NN\14326607 attack\NN\955060 but\CC\1740 no\DT\7204911 consistent\JJ\1740 change\NN\7283608 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>migraine</e2>\NN\14326607 attack\NN\955060 .\.\1740
D012701_D008881 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 <e1>serotonin</e1>\NN\14807737 release\NN\3748886 from\IN\1740 platelets\NNS\5432736 does\VBZ\1640855 not\RB\1740 provoke\VB\1617192 <e2>migraine</e2>\NN\14326607 ,\,\1740 it\PRP\6125041 may\MD\15209706 even\RB\1740 counteract\VB\2367363 the\DT\1740 headache\NN\5829480 and\CC\1740 the\DT\1740 concomitant\JJ\1740 CGRP\NN\1740 release\NN\3748886 in\IN\13603305 this\DT\1740 model\NN\5888929 .\.\1740
D015740_D006261 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 changes\NNS\7283608 in\IN\13603305 the\DT\1740 plasma\NN\5398023 <e1>calcitonin\NN\5413241 gene-related\JJ\1740 peptide</e1>\NN\14724264 (\-LRB-\1740 CGRP\NN\1740 )\-RRB-\1740 concentration\NN\4916342 and\CC\1740 platelet\NN\5432736 serotonin\NN\14807737 (\-LRB-\1740 5-hydroxytriptamine\NN\1740 ,\,\1740 5-HT\NN\1740 )\-RRB-\1740 content\NN\7951464 during\IN\1740 the\DT\1740 immediate\JJ\1740 <e2>headache</e2>\NN\5829480 and\CC\1740 the\DT\1740 delayed\VBN\439958 genuine\NN\1740 migraine\NN\14326607 attack\NN\955060 provoked\VBN\1617192 by\IN\1740 nitroglycerin\NN\15015501 .\.\1740
D015740_D006261 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 changes\NNS\7283608 in\IN\13603305 the\DT\1740 plasma\NN\5398023 calcitonin\NN\5413241 gene-related\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 <e1>CGRP</e1>\NN\1740 )\-RRB-\1740 concentration\NN\4916342 and\CC\1740 platelet\NN\5432736 serotonin\NN\14807737 (\-LRB-\1740 5-hydroxytriptamine\NN\1740 ,\,\1740 5-HT\NN\1740 )\-RRB-\1740 content\NN\7951464 during\IN\1740 the\DT\1740 immediate\JJ\1740 <e2>headache</e2>\NN\5829480 and\CC\1740 the\DT\1740 delayed\VBN\439958 genuine\NN\1740 migraine\NN\14326607 attack\NN\955060 provoked\VBN\1617192 by\IN\1740 nitroglycerin\NN\15015501 .\.\1740
D015740_D006261 NONE However\RB\1740 ,\,\1740 plasma\NN\5398023 <e1>CGRP</e1>\NN\1740 concentrations\NNS\4916342 failed\VBD\1798936 to\TO\1740 change\VB\46534 during\IN\1740 immediate\JJ\1740 <e2>headache</e2>\NN\5829480 and\CC\1740 in\IN\13603305 the\DT\1740 subjects\NNS\6598915 with\IN\1740 no\DT\7204911 migraine\NN\14326607 attack\NN\955060 .\.\1740
D015740_D006261 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 the\DT\1740 fact\NN\5816287 that\IN\1740 plasma\NN\5398023 <e1>CGRP</e1>\NN\1740 concentration\NN\4916342 correlates\VBZ\2657219 with\IN\1740 the\DT\1740 timing\NN\5044673 and\CC\1740 severity\NN\5036394 of\IN\1740 a\DT\13649268 migraine\NN\14326607 <e2>headache</e2>\NN\5829480 suggests\VBZ\1010118 a\DT\13649268 direct\JJ\1740 relationship\NN\31921 between\IN\1740 CGRP\NN\1740 and\CC\1740 migraine\NN\14326607 .\.\1740
D015740_D006261 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 the\DT\1740 fact\NN\5816287 that\IN\1740 plasma\NN\5398023 CGRP\NN\1740 concentration\NN\4916342 correlates\VBZ\2657219 with\IN\1740 the\DT\1740 timing\NN\5044673 and\CC\1740 severity\NN\5036394 of\IN\1740 a\DT\13649268 migraine\NN\14326607 <e2>headache</e2>\NN\5829480 suggests\VBZ\1010118 a\DT\13649268 direct\JJ\1740 relationship\NN\31921 between\IN\1740 <e1>CGRP</e1>\NN\1740 and\CC\1740 migraine\NN\14326607 .\.\1740
D015740_D006261 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 serotonin\NN\14807737 release\NN\3748886 from\IN\1740 platelets\NNS\5432736 does\VBZ\1640855 not\RB\1740 provoke\VB\1617192 migraine\NN\14326607 ,\,\1740 it\PRP\6125041 may\MD\15209706 even\RB\1740 counteract\VB\2367363 the\DT\1740 <e2>headache</e2>\NN\5829480 and\CC\1740 the\DT\1740 concomitant\JJ\1740 <e1>CGRP</e1>\NN\1740 release\NN\3748886 in\IN\13603305 this\DT\1740 model\NN\5888929 .\.\1740
D012701_D006261 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 changes\NNS\7283608 in\IN\13603305 the\DT\1740 plasma\NN\5398023 calcitonin\NN\5413241 gene-related\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 CGRP\NN\1740 )\-RRB-\1740 concentration\NN\4916342 and\CC\1740 platelet\NN\5432736 <e1>serotonin</e1>\NN\14807737 (\-LRB-\1740 5-hydroxytriptamine\NN\1740 ,\,\1740 5-HT\NN\1740 )\-RRB-\1740 content\NN\7951464 during\IN\1740 the\DT\1740 immediate\JJ\1740 <e2>headache</e2>\NN\5829480 and\CC\1740 the\DT\1740 delayed\VBN\439958 genuine\NN\1740 migraine\NN\14326607 attack\NN\955060 provoked\VBN\1617192 by\IN\1740 nitroglycerin\NN\15015501 .\.\1740
D012701_D006261 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 changes\NNS\7283608 in\IN\13603305 the\DT\1740 plasma\NN\5398023 calcitonin\NN\5413241 gene-related\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 CGRP\NN\1740 )\-RRB-\1740 concentration\NN\4916342 and\CC\1740 platelet\NN\5432736 serotonin\NN\14807737 (\-LRB-\1740 <e1>5-hydroxytriptamine</e1>\NN\1740 ,\,\1740 5-HT\NN\1740 )\-RRB-\1740 content\NN\7951464 during\IN\1740 the\DT\1740 immediate\JJ\1740 <e2>headache</e2>\NN\5829480 and\CC\1740 the\DT\1740 delayed\VBN\439958 genuine\NN\1740 migraine\NN\14326607 attack\NN\955060 provoked\VBN\1617192 by\IN\1740 nitroglycerin\NN\15015501 .\.\1740
D012701_D006261 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 changes\NNS\7283608 in\IN\13603305 the\DT\1740 plasma\NN\5398023 calcitonin\NN\5413241 gene-related\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 CGRP\NN\1740 )\-RRB-\1740 concentration\NN\4916342 and\CC\1740 platelet\NN\5432736 serotonin\NN\14807737 (\-LRB-\1740 5-hydroxytriptamine\NN\1740 ,\,\1740 <e1>5-HT</e1>\NN\1740 )\-RRB-\1740 content\NN\7951464 during\IN\1740 the\DT\1740 immediate\JJ\1740 <e2>headache</e2>\NN\5829480 and\CC\1740 the\DT\1740 delayed\VBN\439958 genuine\NN\1740 migraine\NN\14326607 attack\NN\955060 provoked\VBN\1617192 by\IN\1740 nitroglycerin\NN\15015501 .\.\1740
D012701_D006261 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 <e1>serotonin</e1>\NN\14807737 release\NN\3748886 from\IN\1740 platelets\NNS\5432736 does\VBZ\1640855 not\RB\1740 provoke\VB\1617192 migraine\NN\14326607 ,\,\1740 it\PRP\6125041 may\MD\15209706 even\RB\1740 counteract\VB\2367363 the\DT\1740 <e2>headache</e2>\NN\5829480 and\CC\1740 the\DT\1740 concomitant\JJ\1740 CGRP\NN\1740 release\NN\3748886 in\IN\13603305 this\DT\1740 model\NN\5888929 .\.\1740
D005996_D006261 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 changes\NNS\7283608 in\IN\13603305 the\DT\1740 plasma\NN\5398023 calcitonin\NN\5413241 gene-related\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 CGRP\NN\1740 )\-RRB-\1740 concentration\NN\4916342 and\CC\1740 platelet\NN\5432736 serotonin\NN\14807737 (\-LRB-\1740 5-hydroxytriptamine\NN\1740 ,\,\1740 5-HT\NN\1740 )\-RRB-\1740 content\NN\7951464 during\IN\1740 the\DT\1740 immediate\JJ\1740 <e2>headache</e2>\NN\5829480 and\CC\1740 the\DT\1740 delayed\VBN\439958 genuine\NN\1740 migraine\NN\14326607 attack\NN\955060 provoked\VBN\1617192 by\IN\1740 <e1>nitroglycerin</e1>\NN\15015501 .\.\1740
D005996_D008881 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 changes\NNS\7283608 in\IN\13603305 the\DT\1740 plasma\NN\5398023 calcitonin\NN\5413241 gene-related\JJ\1740 peptide\NN\14724264 (\-LRB-\1740 CGRP\NN\1740 )\-RRB-\1740 concentration\NN\4916342 and\CC\1740 platelet\NN\5432736 serotonin\NN\14807737 (\-LRB-\1740 5-hydroxytriptamine\NN\1740 ,\,\1740 5-HT\NN\1740 )\-RRB-\1740 content\NN\7951464 during\IN\1740 the\DT\1740 immediate\JJ\1740 headache\NN\5829480 and\CC\1740 the\DT\1740 delayed\VBN\439958 genuine\NN\1740 <e2>migraine</e2>\NN\14326607 attack\NN\955060 provoked\VBN\1617192 by\IN\1740 <e1>nitroglycerin</e1>\NN\15015501 .\.\1740
D005996_D008881 NONE Blood\NNP\5397468 was\VBD\836236 collected\VBN\2281093 from\IN\1740 the\DT\1740 antecubital\JJ\1740 vein\NN\5417975 four\CD\13741022 times\NNS\15113229 :\:\1740 60\CD\13745420 min\NN\15154774 before\RB\1740 and\CC\1740 after\IN\1740 the\DT\1740 <e1>nitroglycerin</e1>\NN\15015501 application\NN\947128 ,\,\1740 and\CC\1740 60\CD\13745420 and\CC\1740 120\CD\13745420 min\NN\15154774 after\IN\1740 the\DT\1740 beginning\NN\7283608 of\IN\1740 the\DT\1740 <e2>migraine</e2>\NN\14326607 attack\NN\955060 (\-LRB-\1740 mean\NN\6021761 344\CD\1740 and\CC\1740 404\CD\1740 min\NN\15154774 ;\:\1740 12\CD\13745420 subjects\NNS\6598915 )\-RRB-\1740 .\.\1740
D005996_D008881 NONE Platelet\NN\5432736 serotonin\NN\14807737 content\NN\7951464 decreased\VBD\169651 significantly\RB\1740 (\-LRB-\1740 P<0.01\NN\1740 )\-RRB-\1740 after\IN\1740 <e1>nitroglycerin</e1>\NN\15015501 in\IN\13603305 subjects\NNS\6598915 with\IN\1740 no\DT\7204911 <e2>migraine</e2>\NN\14326607 attack\NN\955060 but\CC\1740 no\DT\7204911 consistent\JJ\1740 change\NN\7283608 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 patients\NNS\9898892 with\IN\1740 migraine\NN\14326607 attack\NN\955060 .\.\1740
D005996_D008881 NONE Platelet\NN\5432736 serotonin\NN\14807737 content\NN\7951464 decreased\VBD\169651 significantly\RB\1740 (\-LRB-\1740 P<0.01\NN\1740 )\-RRB-\1740 after\IN\1740 <e1>nitroglycerin</e1>\NN\15015501 in\IN\13603305 subjects\NNS\6598915 with\IN\1740 no\DT\7204911 migraine\NN\14326607 attack\NN\955060 but\CC\1740 no\DT\7204911 consistent\JJ\1740 change\NN\7283608 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>migraine</e2>\NN\14326607 attack\NN\955060 .\.\1740
9034419
C047426_D012640 CID <e2>Seizure</e2>\NNP\14081375 resulting\VBG\2633881 from\IN\1740 a\DT\13649268 <e1>venlafaxine</e1>\NN\1740 overdose\NN\1740 .\.\1740
C047426_D012640 CID After\IN\1740 the\DT\1740 ingestion\NN\13440063 of\IN\1740 26\CD\13745420 <e1>venlafaxine</e1>\NN\1740 50-mg\JJ\1740 tablets\NNS\4233405 ,\,\1740 the\DT\1740 patient\NN\9898892 experienced\VBD\2108377 a\DT\13649268 witnessed\VBN\2150510 generalized\VBN\634472 <e2>seizure</e2>\JJ\1740 .\.\1740
C047426_D012640 CID DISCUSSION\NN\6252138 :\:\1740 To\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 reported\VBN\831651 case\NN\7283608 of\IN\1740 <e1>venlafaxine</e1>\NN\1740 overdose\NN\1740 that\WDT\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 generalized\JJ\1740 <e2>seizure</e2>\NN\14081375 .\.\1740
C047426_D012640 CID CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 <e1>venlafaxine</e1>\NN\1740 overdose\NN\1740 in\IN\13603305 our\PRP$\1740 patient\NN\9898892 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 single\JJ\1740 episode\NN\7283608 of\IN\1740 generalized\VBN\634472 <e2>seizure</e2>\NN\14081375 but\CC\1740 elicited\VBD\1617192 no\DT\7204911 further\RB\1740 sequelae\JJ\1740 .\.\1740
C047426_D062787 CID Seizure\NNP\14081375 resulting\VBG\2633881 from\IN\1740 a\DT\13649268 <e1>venlafaxine</e1>\NN\1740 <e2>overdose</e2>\NN\1740 .\.\1740
C047426_D062787 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 <e1>venlafaxine</e1>\NN\1740 <e2>overdose</e2>\NN\1740 .\.\1740
C047426_D062787 CID CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 40-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 major\JJ\1740 depression\NN\14373582 took\VBD\2367363 an\DT\6697703 <e2>overdose</e2>\NN\1740 of\IN\1740 <e1>venlafaxine</e1>\NN\1740 in\IN\13603305 an\DT\6697703 apparent\JJ\1740 suicide\NN\219012 attempt\NN\407535 .\.\1740
C047426_D062787 CID DISCUSSION\NN\6252138 :\:\1740 To\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 reported\VBN\831651 case\NN\7283608 of\IN\1740 <e1>venlafaxine</e1>\NN\1740 <e2>overdose</e2>\NN\1740 that\WDT\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 generalized\JJ\1740 seizure\NN\14081375 .\.\1740
C047426_D062787 CID CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 <e1>venlafaxine</e1>\NN\1740 <e2>overdose</e2>\NN\1740 in\IN\13603305 our\PRP$\1740 patient\NN\9898892 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 single\JJ\1740 episode\NN\7283608 of\IN\1740 generalized\VBN\634472 seizure\NN\14081375 but\CC\1740 elicited\VBD\1617192 no\DT\7204911 further\RB\1740 sequelae\JJ\1740 .\.\1740
C047426_D003865 NONE CASE\NN\7283608 SUMMARY\NN\6722453 :\:\1740 A\DT\13649268 40-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 <e2>major\JJ\1740 depression</e2>\NN\14373582 took\VBD\2367363 an\DT\6697703 overdose\NN\1740 of\IN\1740 <e1>venlafaxine</e1>\NN\1740 in\IN\13603305 an\DT\6697703 apparent\JJ\1740 suicide\NN\219012 attempt\NN\407535 .\.\1740
18560792
D010479_D006349 NONE <e2>Valvular\JJ\1740 heart\NN\5919034 disease</e2>\NN\14061805 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 treated\VBN\2376958 with\IN\1740 <e1>pergolide</e1>\NN\1740 .\.\1740
D010479_D006349 NONE <e2>Valvular\JJ\1740 heart\NN\5919034 abnormalities</e2>\NNS\14034177 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 <e1>pergolide</e1>\NN\1740 .\.\1740
D010479_D006349 NONE A\DT\13649268 restrictive\JJ\1740 pattern\NN\5726345 of\IN\1740 <e2>valvular\JJ\1740 regurgitation</e2>\NN\7406350 ,\,\1740 suggestive\JJ\1740 of\IN\1740 the\DT\1740 role\NN\719494 of\IN\1740 <e1>pergolide</e1>\NN\1740 ,\,\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 12/30\CD\1740 (\-LRB-\1740 40\CD\13745420 %\NN\1740 )\-RRB-\1740 patients\NNS\9898892 including\VBG\690614 two\CD\13741022 with\IN\1740 heart\NN\5919034 failure\NN\66216 .\.\1740
D010479_D006349 NONE <e1>Pergolide</e1>\NN\1740 was\VBD\836236 discontinued\VBN\2609764 in\IN\13603305 10\CD\13745420 patients\NNS\9898892 with\IN\1740 <e2>valvular\JJ\1740 heart\NN\5919034 disease</e2>\NN\14061805 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 a\DT\13649268 lower\JJR\1740 regurgitation\NN\7406350 grade\NN\7975026 (\-LRB-\1740 p=0.01\NN\1740 )\-RRB-\1740 at\IN\14622893 the\DT\1740 second\JJ\1740 transthoracic\NN\1740 echocardiography\NN\177127 and\CC\1740 the\DT\1740 two\CD\13741022 patients\NNS\9898892 with\IN\1740 heart\NN\5919034 failure\NN\66216 returned\VBD\1835496 to\TO\1740 nearly\RB\1740 normal\JJ\1740 clinical\JJ\1740 examination\NN\633864 .\.\1740
D010479_D006349 NONE This\DT\1740 study\NN\635850 supports\VBZ\2199590 the\DT\1740 high\JJ\1740 frequency\NN\15286249 of\IN\1740 restrictive\JJ\1740 <e2>valve\NN\5225602 regurgitation</e2>\NN\7406350 in\IN\13603305 PD\NN\14625458 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>pergolide</e1>\NN\1740 and\CC\1740 reveals\VBZ\2137132 that\IN\1740 a\DT\13649268 significant\JJ\1740 improvement\NN\7359599 is\VBZ\836236 usual\JJ\1740 when\WRB\1740 the\DT\1740 treatment\NN\654885 is\VBZ\836236 converted\VBN\126264 to\TO\1740 non-ergot\JJ\1740 dopamine\NN\14807737 agonists\NNS\9613191 .\.\1740
D010479_D010300 NONE Valvular\JJ\1740 heart\NN\5919034 disease\NN\14061805 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 treated\VBN\2376958 with\IN\1740 <e1>pergolide</e1>\NN\1740 .\.\1740
D010479_D010300 NONE Valvular\JJ\1740 heart\NN\5919034 abnormalities\NNS\14034177 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 <e1>pergolide</e1>\NN\1740 .\.\1740
D010479_D010300 NONE Valvular\JJ\1740 heart\NN\5919034 abnormalities\NNS\14034177 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 <e2>PD</e2>\NN\14625458 )\-RRB-\1740 treated\VBN\2376958 with\IN\1740 <e1>pergolide</e1>\NN\1740 .\.\1740
D010479_D010300 NONE METHODS\NNS\5616786 :\:\1740 All\DT\1740 <e2>PD</e2>\NN\14625458 patients\NNS\9898892 in\IN\13603305 the\DT\1740 Amiens\NNPS\1740 area\NN\8630985 treated\VBN\2376958 with\IN\1740 <e1>pergolide</e1>\NN\1740 were\VBD\836236 invited\VBN\1759326 to\TO\1740 attend\VB\2655135 a\DT\13649268 cardiologic\JJ\1740 assessment\NN\5732756 including\VBG\690614 transthoracic\JJ\1740 echocardiography\NN\177127 .\.\1740
D010479_D010300 NONE This\DT\1740 study\NN\635850 supports\VBZ\2199590 the\DT\1740 high\JJ\1740 frequency\NN\15286249 of\IN\1740 restrictive\JJ\1740 valve\NN\5225602 regurgitation\NN\7406350 in\IN\13603305 <e2>PD</e2>\NN\14625458 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>pergolide</e1>\NN\1740 and\CC\1740 reveals\VBZ\2137132 that\IN\1740 a\DT\13649268 significant\JJ\1740 improvement\NN\7359599 is\VBZ\836236 usual\JJ\1740 when\WRB\1740 the\DT\1740 treatment\NN\654885 is\VBZ\836236 converted\VBN\126264 to\TO\1740 non-ergot\JJ\1740 dopamine\NN\14807737 agonists\NNS\9613191 .\.\1740
D010479_D006333 NONE A\DT\13649268 restrictive\JJ\1740 pattern\NN\5726345 of\IN\1740 valvular\JJ\1740 regurgitation\NN\7406350 ,\,\1740 suggestive\JJ\1740 of\IN\1740 the\DT\1740 role\NN\719494 of\IN\1740 <e1>pergolide</e1>\NN\1740 ,\,\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 12/30\CD\1740 (\-LRB-\1740 40\CD\13745420 %\NN\1740 )\-RRB-\1740 patients\NNS\9898892 including\VBG\690614 two\CD\13741022 with\IN\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 .\.\1740
D010479_D006333 NONE <e1>Pergolide</e1>\NN\1740 was\VBD\836236 discontinued\VBN\2609764 in\IN\13603305 10\CD\13745420 patients\NNS\9898892 with\IN\1740 valvular\JJ\1740 heart\NN\5919034 disease\NN\14061805 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 a\DT\13649268 lower\JJR\1740 regurgitation\NN\7406350 grade\NN\7975026 (\-LRB-\1740 p=0.01\NN\1740 )\-RRB-\1740 at\IN\14622893 the\DT\1740 second\JJ\1740 transthoracic\NN\1740 echocardiography\NN\177127 and\CC\1740 the\DT\1740 two\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 returned\VBD\1835496 to\TO\1740 nearly\RB\1740 normal\JJ\1740 clinical\JJ\1740 examination\NN\633864 .\.\1740
D004298_D006349 NONE This\DT\1740 study\NN\635850 supports\VBZ\2199590 the\DT\1740 high\JJ\1740 frequency\NN\15286249 of\IN\1740 restrictive\JJ\1740 <e2>valve\NN\5225602 regurgitation</e2>\NN\7406350 in\IN\13603305 PD\NN\14625458 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 pergolide\NN\1740 and\CC\1740 reveals\VBZ\2137132 that\IN\1740 a\DT\13649268 significant\JJ\1740 improvement\NN\7359599 is\VBZ\836236 usual\JJ\1740 when\WRB\1740 the\DT\1740 treatment\NN\654885 is\VBZ\836236 converted\VBN\126264 to\TO\1740 non-ergot\JJ\1740 <e1>dopamine</e1>\NN\14807737 agonists\NNS\9613191 .\.\1740
D004298_D010300 NONE This\DT\1740 study\NN\635850 supports\VBZ\2199590 the\DT\1740 high\JJ\1740 frequency\NN\15286249 of\IN\1740 restrictive\JJ\1740 valve\NN\5225602 regurgitation\NN\7406350 in\IN\13603305 <e2>PD</e2>\NN\14625458 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 pergolide\NN\1740 and\CC\1740 reveals\VBZ\2137132 that\IN\1740 a\DT\13649268 significant\JJ\1740 improvement\NN\7359599 is\VBZ\836236 usual\JJ\1740 when\WRB\1740 the\DT\1740 treatment\NN\654885 is\VBZ\836236 converted\VBN\126264 to\TO\1740 non-ergot\JJ\1740 <e1>dopamine</e1>\NN\14807737 agonists\NNS\9613191 .\.\1740
16181582
D014635_D001927 CID <e1>Valproate-induced</e1>\JJ\1740 <e2>encephalopathy</e2>\RB\1740 .\.\1740
D014635_D001927 CID <e1>Valproate-induced</e1>\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 syndrome\NN\5870365 that\WDT\1740 may\MD\15209706 manifest\VB\1015244 in\IN\13603305 otherwise\JJ\1740 normal\JJ\1740 epileptic\JJ\1740 individuals\NNS\7347 .\.\1740
D014635_D001927 CID A\DT\13649268 case\NN\7283608 of\IN\1740 <e1>valproate-induced</e1>\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 is\VBZ\836236 presented\VBN\2137132 .\.\1740
D014635_D004827 NONE <e1>Valproate-induced</e1>\JJ\1740 encephalopathy\JJ\1740 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 syndrome\NN\5870365 that\WDT\1740 may\MD\15209706 manifest\VB\1015244 in\IN\13603305 otherwise\JJ\1740 normal\JJ\1740 <e2>epileptic</e2>\JJ\1740 individuals\NNS\7347 .\.\1740
869641
D007980_D001919 NONE Mediation\NN\7148192 of\IN\1740 enhanced\VBN\227165 reflex\JJ\1740 vagal\NN\1740 <e2>bradycardia</e2>\NN\14110674 by\IN\1740 <e1>L-dopa</e1>\NN\14604959 via\IN\1740 central\JJ\1740 dopamine\NN\14807737 formation\NN\7938773 in\IN\13603305 dogs\NNS\2083346 .\.\1740
D007980_D001919 NONE In\IN\13603305 addition\NN\3081021 ,\,\1740 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 caused\VBN\1617192 by\IN\1740 injected\VBN\81072 norepinephrine\NN\14807929 was\VBD\836236 significantly\RB\1740 enhanced\VBN\227165 by\IN\1740 <e1>L-dopa</e1>\JJ\1740 ,\,\1740 DL-Threo-dihydroxyphenylserine\NN\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 heart\NN\5919034 rate\NN\13815152 or\CC\3541091 reflex\JJ\1740 responses\NNS\11410625 to\TO\1740 norepinephrine\NN\14807929 .\.\1740
D007980_D001919 NONE FLA-63\NN\1740 ,\,\1740 a\DT\13649268 dopamine-beta-oxidase\NN\1740 inhibitor\NN\20090 ,\,\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 any\DT\1740 effect\NN\34213 on\IN\1740 the\DT\1740 hypotension\NN\14057371 ,\,\1740 <e2>bradycardia</e2>\NN\14110674 or\CC\3541091 reflex-enhancing\JJ\1740 effect\NN\34213 of\IN\1740 <e1>L-dopa</e1>\JJ\1740 .\.\1740
D007980_D001919 NONE However\RB\1740 ,\,\1740 <e1>L-dopa</e1>\NN\14604959 restored\VBD\1631072 the\DT\1740 <e2>bradycardia</e2>\NN\14110674 caused\VBN\1617192 by\IN\1740 norepinephrine\NN\14807929 in\IN\13603305 addition\NN\3081021 to\TO\1740 decreasing\VBG\169651 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 heart\NN\5919034 rate\NN\13815152 .\.\1740
D007980_D001919 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 <e1>L-dopa</e1>\NN\14604959 enhances\VBZ\227165 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 through\IN\1740 central\JJ\1740 alpha-receptor\NN\1740 stimulation\NN\242808 .\.\1740
D004298_D001919 NONE Mediation\NN\7148192 of\IN\1740 enhanced\VBN\227165 reflex\JJ\1740 vagal\NN\1740 <e2>bradycardia</e2>\NN\14110674 by\IN\1740 L-dopa\NN\14604959 via\IN\1740 central\JJ\1740 <e1>dopamine</e1>\NN\14807737 formation\NN\7938773 in\IN\13603305 dogs\NNS\2083346 .\.\1740
D004298_D001919 NONE FLA-63\NN\1740 ,\,\1740 a\DT\13649268 <e1>dopamine-beta-oxidase</e1>\NN\1740 inhibitor\NN\20090 ,\,\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 any\DT\1740 effect\NN\34213 on\IN\1740 the\DT\1740 hypotension\NN\14057371 ,\,\1740 <e2>bradycardia</e2>\NN\14110674 or\CC\3541091 reflex-enhancing\JJ\1740 effect\NN\34213 of\IN\1740 L-dopa\JJ\1740 .\.\1740
D009638_D001919 CID In\IN\13603305 addition\NN\3081021 ,\,\1740 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 caused\VBN\1617192 by\IN\1740 injected\VBN\81072 <e1>norepinephrine</e1>\NN\14807929 was\VBD\836236 significantly\RB\1740 enhanced\VBN\227165 by\IN\1740 L-dopa\JJ\1740 ,\,\1740 DL-Threo-dihydroxyphenylserine\NN\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 heart\NN\5919034 rate\NN\13815152 or\CC\3541091 reflex\JJ\1740 responses\NNS\11410625 to\TO\1740 norepinephrine\NN\14807929 .\.\1740
D009638_D001919 CID In\IN\13603305 addition\NN\3081021 ,\,\1740 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 caused\VBN\1617192 by\IN\1740 injected\VBN\81072 norepinephrine\NN\14807929 was\VBD\836236 significantly\RB\1740 enhanced\VBN\227165 by\IN\1740 L-dopa\JJ\1740 ,\,\1740 DL-Threo-dihydroxyphenylserine\NN\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 heart\NN\5919034 rate\NN\13815152 or\CC\3541091 reflex\JJ\1740 responses\NNS\11410625 to\TO\1740 <e1>norepinephrine</e1>\NN\14807929 .\.\1740
D009638_D001919 CID However\RB\1740 ,\,\1740 L-dopa\NN\14604959 restored\VBD\1631072 the\DT\1740 <e2>bradycardia</e2>\NN\14110674 caused\VBN\1617192 by\IN\1740 <e1>norepinephrine</e1>\NN\14807929 in\IN\13603305 addition\NN\3081021 to\TO\1740 decreasing\VBG\169651 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 heart\NN\5919034 rate\NN\13815152 .\.\1740
D009638_D001919 CID 5-HTP\NN\1740 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 decreased\VBN\169651 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 heart\NN\5919034 rate\NN\13815152 and\CC\1740 decreased\VBD\169651 the\DT\1740 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 to\TO\1740 <e1>norepinephrine</e1>\NN\14807929 .\.\1740
D015103_D001919 NONE In\IN\13603305 addition\NN\3081021 ,\,\1740 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 caused\VBN\1617192 by\IN\1740 injected\VBN\81072 norepinephrine\NN\14807929 was\VBD\836236 significantly\RB\1740 enhanced\VBN\227165 by\IN\1740 L-dopa\JJ\1740 ,\,\1740 <e1>DL-Threo-dihydroxyphenylserine</e1>\NN\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 heart\NN\5919034 rate\NN\13815152 or\CC\3541091 reflex\JJ\1740 responses\NNS\11410625 to\TO\1740 norepinephrine\NN\14807929 .\.\1740
D005406_D007022 NONE <e1>FLA-63</e1>\NN\1740 ,\,\1740 a\DT\13649268 dopamine-beta-oxidase\NN\1740 inhibitor\NN\20090 ,\,\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 any\DT\1740 effect\NN\34213 on\IN\1740 the\DT\1740 <e2>hypotension</e2>\NN\14057371 ,\,\1740 bradycardia\NN\14110674 or\CC\3541091 reflex-enhancing\JJ\1740 effect\NN\34213 of\IN\1740 L-dopa\JJ\1740 .\.\1740
D005406_D001919 NONE <e1>FLA-63</e1>\NN\1740 ,\,\1740 a\DT\13649268 dopamine-beta-oxidase\NN\1740 inhibitor\NN\20090 ,\,\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 any\DT\1740 effect\NN\34213 on\IN\1740 the\DT\1740 hypotension\NN\14057371 ,\,\1740 <e2>bradycardia</e2>\NN\14110674 or\CC\3541091 reflex-enhancing\JJ\1740 effect\NN\34213 of\IN\1740 L-dopa\JJ\1740 .\.\1740
D004298_D007022 NONE FLA-63\NN\1740 ,\,\1740 a\DT\13649268 <e1>dopamine-beta-oxidase</e1>\NN\1740 inhibitor\NN\20090 ,\,\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 any\DT\1740 effect\NN\34213 on\IN\1740 the\DT\1740 <e2>hypotension</e2>\NN\14057371 ,\,\1740 bradycardia\NN\14110674 or\CC\3541091 reflex-enhancing\JJ\1740 effect\NN\34213 of\IN\1740 L-dopa\JJ\1740 .\.\1740
D007980_D007022 NONE FLA-63\NN\1740 ,\,\1740 a\DT\13649268 dopamine-beta-oxidase\NN\1740 inhibitor\NN\20090 ,\,\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 any\DT\1740 effect\NN\34213 on\IN\1740 the\DT\1740 <e2>hypotension</e2>\NN\14057371 ,\,\1740 bradycardia\NN\14110674 or\CC\3541091 reflex-enhancing\JJ\1740 effect\NN\34213 of\IN\1740 <e1>L-dopa</e1>\JJ\1740 .\.\1740
D006916_D001919 NONE <e1>5-HTP</e1>\NN\1740 (\-LRB-\1740 5\CD\13741022 mg/kg\NN\1740 i.v.\NN\1740 )\-RRB-\1740 decreased\VBN\169651 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 heart\NN\5919034 rate\NN\13815152 and\CC\1740 decreased\VBD\169651 the\DT\1740 reflex\JJ\1740 <e2>bradycardia</e2>\NN\14110674 to\TO\1740 norepinephrine\NN\14807929 .\.\1740
7423039
D004317_D066126 CID Metabolic\JJ\1740 involvement\NN\1080366 in\IN\13603305 <e1>adriamycin</e1>\NN\1740 <e2>cardiotoxicity</e2>\NN\1740 .\.\1740
D004317_D066126 CID The\DT\1740 <e2>cardiotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>adriamycin</e1>\NN\1740 were\VBD\836236 studied\VBN\630380 in\IN\13603305 mammalian\JJ\1740 myocardial\JJ\1740 cells\NNS\3080309 in\IN\13603305 culture\NN\7966140 as\IN\14622893 a\DT\13649268 model\NN\5888929 system\NN\3575240 .\.\1740
8386779
D017693_D004414 NONE <e1>Sodium\NN\14625458 bicarbonate</e1>\NN\14798450 alleviates\VBZ\205885 <e2>penile\JJ\1740 pain</e2>\NN\14299637 induced\VBN\1627355 by\IN\1740 intracavernous\JJ\1740 injections\NNS\320852 for\IN\1740 erectile\JJ\1740 dysfunction\NN\14204950 .\.\1740
D017693_D004414 NONE In\IN\13603305 an\DT\6697703 attempt\NN\407535 to\TO\1740 determine\VB\1645601 whether\IN\1740 <e2>penile\NN\1740 pain</e2>\NN\14299637 associated\VBN\628491 with\IN\1740 intracorporeal\JJ\1740 injections\NNS\320852 could\MD\1740 be\VB\836236 due\JJ\1740 to\TO\1740 the\DT\1740 acidity\NN\4992163 of\IN\1740 the\DT\1740 medication\NN\3247620 ,\,\1740 we\PRP\1740 performed\VBD\2367363 a\DT\13649268 randomized\JJ\1740 study\NN\635850 comparing\VBG\644583 the\DT\1740 incidence\NN\13821570 of\IN\1740 penile\NN\1740 pain\NN\14299637 following\VBG\1835496 intracorporeal\JJ\1740 injections\NNS\320852 with\IN\1740 or\CC\3541091 without\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 <e1>sodium\NN\14625458 bicarbonate</e1>\NN\14798450 to\IN\1740 the\DT\1740 intracorporeal\NN\1740 medications.\NN\1740 A\NN\13649268 total\NN\3553 of\IN\1740 38\CD\1740 consecutive\JJ\1740 patients\NNS\9898892 who\WP\8299493 presented\VBD\2137132 to\TO\1740 our\PRP$\1740 clinic\NN\8053905 with\IN\1740 impotence\NN\4723816 received\VBD\2210855 0.2\CD\1740 ml.\NN\1740 of\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 3\CD\13741022 drugs\NNS\14778436 :\:\1740 6\CD\13741022 mg.\NN\1740 papaverine\JJ\1740 ,\,\1740 100\CD\13745420 micrograms\NNS\13717155 .\.\1740
D017693_D004414 NONE In\IN\13603305 an\DT\6697703 attempt\NN\407535 to\TO\1740 determine\VB\1645601 whether\IN\1740 penile\NN\1740 pain\NN\14299637 associated\VBN\628491 with\IN\1740 intracorporeal\JJ\1740 injections\NNS\320852 could\MD\1740 be\VB\836236 due\JJ\1740 to\TO\1740 the\DT\1740 acidity\NN\4992163 of\IN\1740 the\DT\1740 medication\NN\3247620 ,\,\1740 we\PRP\1740 performed\VBD\2367363 a\DT\13649268 randomized\JJ\1740 study\NN\635850 comparing\VBG\644583 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>penile\NN\1740 pain</e2>\NN\14299637 following\VBG\1835496 intracorporeal\JJ\1740 injections\NNS\320852 with\IN\1740 or\CC\3541091 without\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 <e1>sodium\NN\14625458 bicarbonate</e1>\NN\14798450 to\IN\1740 the\DT\1740 intracorporeal\NN\1740 medications.\NN\1740 A\NN\13649268 total\NN\3553 of\IN\1740 38\CD\1740 consecutive\JJ\1740 patients\NNS\9898892 who\WP\8299493 presented\VBD\2137132 to\TO\1740 our\PRP$\1740 clinic\NN\8053905 with\IN\1740 impotence\NN\4723816 received\VBD\2210855 0.2\CD\1740 ml.\NN\1740 of\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 3\CD\13741022 drugs\NNS\14778436 :\:\1740 6\CD\13741022 mg.\NN\1740 papaverine\JJ\1740 ,\,\1740 100\CD\13745420 micrograms\NNS\13717155 .\.\1740
D017693_D004414 NONE Of\IN\1740 the\DT\1740 19\CD\13745420 patients\NNS\9898892 without\IN\1740 <e1>sodium\NN\14625458 bicarbonate</e1>\NN\14798450 added\VBN\156601 to\IN\1740 the\DT\1740 medication\NN\3247620 11\CD\13745420 (\-LRB-\1740 58\CD\1740 %\NN\1740 )\-RRB-\1740 complained\VBD\843959 of\IN\1740 <e2>penile\NN\1740 pain</e2>\NN\14299637 due\JJ\1740 to\IN\1740 the\DT\1740 medication\NN\3247620 ,\,\1740 while\IN\15122231 only\RB\1740 1\CD\13741022 of\IN\1740 the\DT\1740 19\CD\13745420 men\NNS\8208016 (\-LRB-\1740 5\CD\13741022 %\NN\1740 )\-RRB-\1740 who\WP\8299493 received\VBD\2210855 sodium\NN\14625458 bicarbonate\NN\14798450 complained\VBD\843959 of\IN\1740 penile\NN\1740 pain\NN\14299637 .\.\1740
D017693_D004414 NONE Of\IN\1740 the\DT\1740 19\CD\13745420 patients\NNS\9898892 without\IN\1740 <e1>sodium\NN\14625458 bicarbonate</e1>\NN\14798450 added\VBN\156601 to\IN\1740 the\DT\1740 medication\NN\3247620 11\CD\13745420 (\-LRB-\1740 58\CD\1740 %\NN\1740 )\-RRB-\1740 complained\VBD\843959 of\IN\1740 penile\NN\1740 pain\NN\14299637 due\JJ\1740 to\IN\1740 the\DT\1740 medication\NN\3247620 ,\,\1740 while\IN\15122231 only\RB\1740 1\CD\13741022 of\IN\1740 the\DT\1740 19\CD\13745420 men\NNS\8208016 (\-LRB-\1740 5\CD\13741022 %\NN\1740 )\-RRB-\1740 who\WP\8299493 received\VBD\2210855 sodium\NN\14625458 bicarbonate\NN\14798450 complained\VBD\843959 of\IN\1740 <e2>penile\NN\1740 pain</e2>\NN\14299637 .\.\1740
D017693_D004414 NONE Of\IN\1740 the\DT\1740 19\CD\13745420 patients\NNS\9898892 without\IN\1740 sodium\NN\14625458 bicarbonate\NN\14798450 added\VBN\156601 to\IN\1740 the\DT\1740 medication\NN\3247620 11\CD\13745420 (\-LRB-\1740 58\CD\1740 %\NN\1740 )\-RRB-\1740 complained\VBD\843959 of\IN\1740 <e2>penile\NN\1740 pain</e2>\NN\14299637 due\JJ\1740 to\IN\1740 the\DT\1740 medication\NN\3247620 ,\,\1740 while\IN\15122231 only\RB\1740 1\CD\13741022 of\IN\1740 the\DT\1740 19\CD\13745420 men\NNS\8208016 (\-LRB-\1740 5\CD\13741022 %\NN\1740 )\-RRB-\1740 who\WP\8299493 received\VBD\2210855 <e1>sodium\NN\14625458 bicarbonate</e1>\NN\14798450 complained\VBD\843959 of\IN\1740 penile\NN\1740 pain\NN\14299637 .\.\1740
D017693_D004414 NONE Of\IN\1740 the\DT\1740 19\CD\13745420 patients\NNS\9898892 without\IN\1740 sodium\NN\14625458 bicarbonate\NN\14798450 added\VBN\156601 to\IN\1740 the\DT\1740 medication\NN\3247620 11\CD\13745420 (\-LRB-\1740 58\CD\1740 %\NN\1740 )\-RRB-\1740 complained\VBD\843959 of\IN\1740 penile\NN\1740 pain\NN\14299637 due\JJ\1740 to\IN\1740 the\DT\1740 medication\NN\3247620 ,\,\1740 while\IN\15122231 only\RB\1740 1\CD\13741022 of\IN\1740 the\DT\1740 19\CD\13745420 men\NNS\8208016 (\-LRB-\1740 5\CD\13741022 %\NN\1740 )\-RRB-\1740 who\WP\8299493 received\VBD\2210855 <e1>sodium\NN\14625458 bicarbonate</e1>\NN\14798450 complained\VBD\843959 of\IN\1740 <e2>penile\NN\1740 pain</e2>\NN\14299637 .\.\1740
D017693_D007172 NONE <e1>Sodium\NN\14625458 bicarbonate</e1>\NN\14798450 alleviates\VBZ\205885 penile\JJ\1740 pain\NN\14299637 induced\VBN\1627355 by\IN\1740 intracavernous\JJ\1740 injections\NNS\320852 for\IN\1740 <e2>erectile\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D017693_D007172 NONE In\IN\13603305 an\DT\6697703 attempt\NN\407535 to\TO\1740 determine\VB\1645601 whether\IN\1740 penile\NN\1740 pain\NN\14299637 associated\VBN\628491 with\IN\1740 intracorporeal\JJ\1740 injections\NNS\320852 could\MD\1740 be\VB\836236 due\JJ\1740 to\TO\1740 the\DT\1740 acidity\NN\4992163 of\IN\1740 the\DT\1740 medication\NN\3247620 ,\,\1740 we\PRP\1740 performed\VBD\2367363 a\DT\13649268 randomized\JJ\1740 study\NN\635850 comparing\VBG\644583 the\DT\1740 incidence\NN\13821570 of\IN\1740 penile\NN\1740 pain\NN\14299637 following\VBG\1835496 intracorporeal\JJ\1740 injections\NNS\320852 with\IN\1740 or\CC\3541091 without\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 <e1>sodium\NN\14625458 bicarbonate</e1>\NN\14798450 to\IN\1740 the\DT\1740 intracorporeal\NN\1740 medications.\NN\1740 A\NN\13649268 total\NN\3553 of\IN\1740 38\CD\1740 consecutive\JJ\1740 patients\NNS\9898892 who\WP\8299493 presented\VBD\2137132 to\TO\1740 our\PRP$\1740 clinic\NN\8053905 with\IN\1740 <e2>impotence</e2>\NN\4723816 received\VBD\2210855 0.2\CD\1740 ml.\NN\1740 of\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 3\CD\13741022 drugs\NNS\14778436 :\:\1740 6\CD\13741022 mg.\NN\1740 papaverine\JJ\1740 ,\,\1740 100\CD\13745420 micrograms\NNS\13717155 .\.\1740
D010208_D004414 NONE In\IN\13603305 an\DT\6697703 attempt\NN\407535 to\TO\1740 determine\VB\1645601 whether\IN\1740 <e2>penile\NN\1740 pain</e2>\NN\14299637 associated\VBN\628491 with\IN\1740 intracorporeal\JJ\1740 injections\NNS\320852 could\MD\1740 be\VB\836236 due\JJ\1740 to\TO\1740 the\DT\1740 acidity\NN\4992163 of\IN\1740 the\DT\1740 medication\NN\3247620 ,\,\1740 we\PRP\1740 performed\VBD\2367363 a\DT\13649268 randomized\JJ\1740 study\NN\635850 comparing\VBG\644583 the\DT\1740 incidence\NN\13821570 of\IN\1740 penile\NN\1740 pain\NN\14299637 following\VBG\1835496 intracorporeal\JJ\1740 injections\NNS\320852 with\IN\1740 or\CC\3541091 without\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 sodium\NN\14625458 bicarbonate\NN\14798450 to\IN\1740 the\DT\1740 intracorporeal\NN\1740 medications.\NN\1740 A\NN\13649268 total\NN\3553 of\IN\1740 38\CD\1740 consecutive\JJ\1740 patients\NNS\9898892 who\WP\8299493 presented\VBD\2137132 to\TO\1740 our\PRP$\1740 clinic\NN\8053905 with\IN\1740 impotence\NN\4723816 received\VBD\2210855 0.2\CD\1740 ml.\NN\1740 of\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 3\CD\13741022 drugs\NNS\14778436 :\:\1740 6\CD\13741022 mg.\NN\1740 <e1>papaverine</e1>\JJ\1740 ,\,\1740 100\CD\13745420 micrograms\NNS\13717155 .\.\1740
D010208_D004414 NONE In\IN\13603305 an\DT\6697703 attempt\NN\407535 to\TO\1740 determine\VB\1645601 whether\IN\1740 penile\NN\1740 pain\NN\14299637 associated\VBN\628491 with\IN\1740 intracorporeal\JJ\1740 injections\NNS\320852 could\MD\1740 be\VB\836236 due\JJ\1740 to\TO\1740 the\DT\1740 acidity\NN\4992163 of\IN\1740 the\DT\1740 medication\NN\3247620 ,\,\1740 we\PRP\1740 performed\VBD\2367363 a\DT\13649268 randomized\JJ\1740 study\NN\635850 comparing\VBG\644583 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>penile\NN\1740 pain</e2>\NN\14299637 following\VBG\1835496 intracorporeal\JJ\1740 injections\NNS\320852 with\IN\1740 or\CC\3541091 without\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 sodium\NN\14625458 bicarbonate\NN\14798450 to\IN\1740 the\DT\1740 intracorporeal\NN\1740 medications.\NN\1740 A\NN\13649268 total\NN\3553 of\IN\1740 38\CD\1740 consecutive\JJ\1740 patients\NNS\9898892 who\WP\8299493 presented\VBD\2137132 to\TO\1740 our\PRP$\1740 clinic\NN\8053905 with\IN\1740 impotence\NN\4723816 received\VBD\2210855 0.2\CD\1740 ml.\NN\1740 of\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 3\CD\13741022 drugs\NNS\14778436 :\:\1740 6\CD\13741022 mg.\NN\1740 <e1>papaverine</e1>\JJ\1740 ,\,\1740 100\CD\13745420 micrograms\NNS\13717155 .\.\1740
D010208_D007172 NONE In\IN\13603305 an\DT\6697703 attempt\NN\407535 to\TO\1740 determine\VB\1645601 whether\IN\1740 penile\NN\1740 pain\NN\14299637 associated\VBN\628491 with\IN\1740 intracorporeal\JJ\1740 injections\NNS\320852 could\MD\1740 be\VB\836236 due\JJ\1740 to\TO\1740 the\DT\1740 acidity\NN\4992163 of\IN\1740 the\DT\1740 medication\NN\3247620 ,\,\1740 we\PRP\1740 performed\VBD\2367363 a\DT\13649268 randomized\JJ\1740 study\NN\635850 comparing\VBG\644583 the\DT\1740 incidence\NN\13821570 of\IN\1740 penile\NN\1740 pain\NN\14299637 following\VBG\1835496 intracorporeal\JJ\1740 injections\NNS\320852 with\IN\1740 or\CC\3541091 without\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 sodium\NN\14625458 bicarbonate\NN\14798450 to\IN\1740 the\DT\1740 intracorporeal\NN\1740 medications.\NN\1740 A\NN\13649268 total\NN\3553 of\IN\1740 38\CD\1740 consecutive\JJ\1740 patients\NNS\9898892 who\WP\8299493 presented\VBD\2137132 to\TO\1740 our\PRP$\1740 clinic\NN\8053905 with\IN\1740 <e2>impotence</e2>\NN\4723816 received\VBD\2210855 0.2\CD\1740 ml.\NN\1740 of\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 3\CD\13741022 drugs\NNS\14778436 :\:\1740 6\CD\13741022 mg.\NN\1740 <e1>papaverine</e1>\JJ\1740 ,\,\1740 100\CD\13745420 micrograms\NNS\13717155 .\.\1740
11569530
D016593_D016171 CID <e2>TDP</e2>\NN\1740 is\VBZ\836236 a\DT\13649268 side-effect\NN\1740 that\WDT\1740 has\VBZ\2108377 led\VBN\1752884 to\IN\1740 withdrawal\NN\7206096 of\IN\1740 several\JJ\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 market\NN\407535 (\-LRB-\1740 e.g.\FW\1740 <e1>terfenadine</e1>\NN\1740 and\CC\1740 terodiline\NN\1740 )\-RRB-\1740 .\.\1740
D016593_D016171 CID Four\CD\13741022 compounds\NNS\5869584 known\VBN\2110220 to\TO\1740 increase\VB\169651 QT\NN\1740 interval\NN\33615 and\CC\1740 cause\VB\1617192 <e2>TDP</e2>\NN\1740 were\VBD\836236 investigated\VBN\644583 :\:\1740 <e1>terfenadine</e1>\NN\1740 ,\,\1740 terodiline\NN\1740 ,\,\1740 cisapride\NN\1740 and\CC\1740 E4031\NN\1740 .\.\1740
D016593_D016171 CID For\IN\1740 compounds\NNS\5869584 that\WDT\1740 have\VBP\2108377 shown\VBN\2137132 <e2>TDP</e2>\NN\1740 in\IN\13603305 the\DT\1740 clinic\NN\8053905 (\-LRB-\1740 <e1>terfenadine</e1>\NN\1740 ,\,\1740 terodiline\NN\1740 ,\,\1740 cisapride\NN\1740 )\-RRB-\1740 there\EX\27167 is\VBZ\836236 little\JJ\1740 differentiation\NN\5748054 between\IN\1740 the\DT\1740 dog\NN\2083346 ED50\NN\1740 and\CC\1740 the\DT\1740 efficacious\JJ\1740 free\JJ\1740 plasma\NN\5398023 concentrations\NNS\4916342 in\IN\13603305 man\NN\9605289 (\-LRB-\1740 <\XX\1740 10-fold\RB\1740 )\-RRB-\1740 reflecting\VBG\923793 their\PRP$\1740 limited\JJ\1740 safety\NN\13920835 margins\NNS\13903079 .\.\1740
C010637_D016171 CID <e2>TDP</e2>\NN\1740 is\VBZ\836236 a\DT\13649268 side-effect\NN\1740 that\WDT\1740 has\VBZ\2108377 led\VBN\1752884 to\IN\1740 withdrawal\NN\7206096 of\IN\1740 several\JJ\1740 drugs\NNS\14778436 from\IN\1740 the\DT\1740 market\NN\407535 (\-LRB-\1740 e.g.\FW\1740 terfenadine\NN\1740 and\CC\1740 <e1>terodiline</e1>\NN\1740 )\-RRB-\1740 .\.\1740
C010637_D016171 CID Four\CD\13741022 compounds\NNS\5869584 known\VBN\2110220 to\TO\1740 increase\VB\169651 QT\NN\1740 interval\NN\33615 and\CC\1740 cause\VB\1617192 <e2>TDP</e2>\NN\1740 were\VBD\836236 investigated\VBN\644583 :\:\1740 terfenadine\NN\1740 ,\,\1740 <e1>terodiline</e1>\NN\1740 ,\,\1740 cisapride\NN\1740 and\CC\1740 E4031\NN\1740 .\.\1740
C010637_D016171 CID For\IN\1740 compounds\NNS\5869584 that\WDT\1740 have\VBP\2108377 shown\VBN\2137132 <e2>TDP</e2>\NN\1740 in\IN\13603305 the\DT\1740 clinic\NN\8053905 (\-LRB-\1740 terfenadine\NN\1740 ,\,\1740 <e1>terodiline</e1>\NN\1740 ,\,\1740 cisapride\NN\1740 )\-RRB-\1740 there\EX\27167 is\VBZ\836236 little\JJ\1740 differentiation\NN\5748054 between\IN\1740 the\DT\1740 dog\NN\2083346 ED50\NN\1740 and\CC\1740 the\DT\1740 efficacious\JJ\1740 free\JJ\1740 plasma\NN\5398023 concentrations\NNS\4916342 in\IN\13603305 man\NN\9605289 (\-LRB-\1740 <\XX\1740 10-fold\RB\1740 )\-RRB-\1740 reflecting\VBG\923793 their\PRP$\1740 limited\JJ\1740 safety\NN\13920835 margins\NNS\13903079 .\.\1740
D020117_D016171 CID Four\CD\13741022 compounds\NNS\5869584 known\VBN\2110220 to\TO\1740 increase\VB\169651 QT\NN\1740 interval\NN\33615 and\CC\1740 cause\VB\1617192 <e2>TDP</e2>\NN\1740 were\VBD\836236 investigated\VBN\644583 :\:\1740 terfenadine\NN\1740 ,\,\1740 terodiline\NN\1740 ,\,\1740 <e1>cisapride</e1>\NN\1740 and\CC\1740 E4031\NN\1740 .\.\1740
D020117_D016171 CID For\IN\1740 compounds\NNS\5869584 that\WDT\1740 have\VBP\2108377 shown\VBN\2137132 <e2>TDP</e2>\NN\1740 in\IN\13603305 the\DT\1740 clinic\NN\8053905 (\-LRB-\1740 terfenadine\NN\1740 ,\,\1740 terodiline\NN\1740 ,\,\1740 <e1>cisapride</e1>\NN\1740 )\-RRB-\1740 there\EX\27167 is\VBZ\836236 little\JJ\1740 differentiation\NN\5748054 between\IN\1740 the\DT\1740 dog\NN\2083346 ED50\NN\1740 and\CC\1740 the\DT\1740 efficacious\JJ\1740 free\JJ\1740 plasma\NN\5398023 concentrations\NNS\4916342 in\IN\13603305 man\NN\9605289 (\-LRB-\1740 <\XX\1740 10-fold\RB\1740 )\-RRB-\1740 reflecting\VBG\923793 their\PRP$\1740 limited\JJ\1740 safety\NN\13920835 margins\NNS\13903079 .\.\1740
C063968_D016171 NONE Four\CD\13741022 compounds\NNS\5869584 known\VBN\2110220 to\TO\1740 increase\VB\169651 QT\NN\1740 interval\NN\33615 and\CC\1740 cause\VB\1617192 <e2>TDP</e2>\NN\1740 were\VBD\836236 investigated\VBN\644583 :\:\1740 terfenadine\NN\1740 ,\,\1740 terodiline\NN\1740 ,\,\1740 cisapride\NN\1740 and\CC\1740 <e1>E4031</e1>\NN\1740 .\.\1740
6308277
D002110_D064420 NONE Reduction\NN\351485 in\IN\13603305 <e1>caffeine</e1>\NN\14712692 <e2>toxicity</e2>\NN\13576101 by\IN\1740 acetaminophen\RB\1740 .\.\1740
D002110_D064420 NONE Because\IN\1740 salicylates\NNS\3828465 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 augment\VB\153263 the\DT\1740 stimulatory\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>caffeine</e1>\NN\14712692 on\IN\1740 the\DT\1740 CNS\NN\5237227 ,\,\1740 attention\NN\5701944 was\VBD\836236 focused\VBN\628491 on\IN\1740 the\DT\1740 possibility\NN\5944958 that\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 acetaminophen\NN\2707683 (\-LRB-\1740 52\CD\1740 micrograms/mL\NNS\1740 )\-RRB-\1740 reduced\VBD\441445 the\DT\1740 CNS\NN\5237227 <e2>toxicity</e2>\NN\13576101 of\IN\1740 caffeine\NN\14712692 .\.\1740
D002110_D064420 NONE Because\IN\1740 salicylates\NNS\3828465 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 augment\VB\153263 the\DT\1740 stimulatory\JJ\1740 effects\NNS\13245626 of\IN\1740 caffeine\NN\14712692 on\IN\1740 the\DT\1740 CNS\NN\5237227 ,\,\1740 attention\NN\5701944 was\VBD\836236 focused\VBN\628491 on\IN\1740 the\DT\1740 possibility\NN\5944958 that\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 acetaminophen\NN\2707683 (\-LRB-\1740 52\CD\1740 micrograms/mL\NNS\1740 )\-RRB-\1740 reduced\VBD\441445 the\DT\1740 CNS\NN\5237227 <e2>toxicity</e2>\NN\13576101 of\IN\1740 <e1>caffeine</e1>\NN\14712692 .\.\1740
D000082_D064420 NONE Reduction\NN\351485 in\IN\13603305 caffeine\NN\14712692 <e2>toxicity</e2>\NN\13576101 by\IN\1740 <e1>acetaminophen</e1>\RB\1740 .\.\1740
D000082_D064420 NONE Because\IN\1740 salicylates\NNS\3828465 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 augment\VB\153263 the\DT\1740 stimulatory\JJ\1740 effects\NNS\13245626 of\IN\1740 caffeine\NN\14712692 on\IN\1740 the\DT\1740 CNS\NN\5237227 ,\,\1740 attention\NN\5701944 was\VBD\836236 focused\VBN\628491 on\IN\1740 the\DT\1740 possibility\NN\5944958 that\IN\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 <e1>acetaminophen</e1>\NN\2707683 (\-LRB-\1740 52\CD\1740 micrograms/mL\NNS\1740 )\-RRB-\1740 reduced\VBD\441445 the\DT\1740 CNS\NN\5237227 <e2>toxicity</e2>\NN\13576101 of\IN\1740 caffeine\NN\14712692 .\.\1740
D000082_D012640 NONE Studies\NNS\635850 in\IN\13603305 DBA/2J\NN\1740 mice\NNS\2329401 showed\VBD\2137132 that\IN\1740 :\:\1740 1\LS\13741022 )\-RRB-\1740 pretreatment\NN\1740 with\IN\1740 <e1>acetaminophen</e1>\NN\2707683 (\-LRB-\1740 100\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 interval\NN\33615 between\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 caffeine\NN\14712692 (\-LRB-\1740 300\CD\1740 to\TO\1740 450\CD\1740 mg/kg\NN\1740 IP\NN\5999797 )\-RRB-\1740 and\CC\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 fatal\JJ\1740 <e2>convulsions</e2>\NNS\14081375 by\IN\1740 a\DT\13649268 factor\NN\7326557 of\IN\1740 about\RB\1740 two\CD\13741022 ;\:\1740 and\CC\1740 2\LS\13741022 )\-RRB-\1740 pretreatment\NN\1740 with\IN\1740 acetaminophen\NN\2707683 (\-LRB-\1740 75\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 reduced\VBD\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 audiogenic\JJ\1740 seizures\NNS\14081375 produced\VBN\1617192 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 caffeine\NN\14712692 (\-LRB-\1740 12.5\CD\1740 to\TO\1740 75\CD\1740 mg/kg\NN\1740 IP\NN\5999797 )\-RRB-\1740 .\.\1740
D000082_D012640 NONE Studies\NNS\635850 in\IN\13603305 DBA/2J\NN\1740 mice\NNS\2329401 showed\VBD\2137132 that\IN\1740 :\:\1740 1\LS\13741022 )\-RRB-\1740 pretreatment\NN\1740 with\IN\1740 <e1>acetaminophen</e1>\NN\2707683 (\-LRB-\1740 100\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 interval\NN\33615 between\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 caffeine\NN\14712692 (\-LRB-\1740 300\CD\1740 to\TO\1740 450\CD\1740 mg/kg\NN\1740 IP\NN\5999797 )\-RRB-\1740 and\CC\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 fatal\JJ\1740 convulsions\NNS\14081375 by\IN\1740 a\DT\13649268 factor\NN\7326557 of\IN\1740 about\RB\1740 two\CD\13741022 ;\:\1740 and\CC\1740 2\LS\13741022 )\-RRB-\1740 pretreatment\NN\1740 with\IN\1740 acetaminophen\NN\2707683 (\-LRB-\1740 75\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 reduced\VBD\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 audiogenic\JJ\1740 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 caffeine\NN\14712692 (\-LRB-\1740 12.5\CD\1740 to\TO\1740 75\CD\1740 mg/kg\NN\1740 IP\NN\5999797 )\-RRB-\1740 .\.\1740
D000082_D012640 NONE Studies\NNS\635850 in\IN\13603305 DBA/2J\NN\1740 mice\NNS\2329401 showed\VBD\2137132 that\IN\1740 :\:\1740 1\LS\13741022 )\-RRB-\1740 pretreatment\NN\1740 with\IN\1740 acetaminophen\NN\2707683 (\-LRB-\1740 100\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 interval\NN\33615 between\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 caffeine\NN\14712692 (\-LRB-\1740 300\CD\1740 to\TO\1740 450\CD\1740 mg/kg\NN\1740 IP\NN\5999797 )\-RRB-\1740 and\CC\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 fatal\JJ\1740 <e2>convulsions</e2>\NNS\14081375 by\IN\1740 a\DT\13649268 factor\NN\7326557 of\IN\1740 about\RB\1740 two\CD\13741022 ;\:\1740 and\CC\1740 2\LS\13741022 )\-RRB-\1740 pretreatment\NN\1740 with\IN\1740 <e1>acetaminophen</e1>\NN\2707683 (\-LRB-\1740 75\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 reduced\VBD\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 audiogenic\JJ\1740 seizures\NNS\14081375 produced\VBN\1617192 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 caffeine\NN\14712692 (\-LRB-\1740 12.5\CD\1740 to\TO\1740 75\CD\1740 mg/kg\NN\1740 IP\NN\5999797 )\-RRB-\1740 .\.\1740
D000082_D012640 NONE Studies\NNS\635850 in\IN\13603305 DBA/2J\NN\1740 mice\NNS\2329401 showed\VBD\2137132 that\IN\1740 :\:\1740 1\LS\13741022 )\-RRB-\1740 pretreatment\NN\1740 with\IN\1740 acetaminophen\NN\2707683 (\-LRB-\1740 100\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 interval\NN\33615 between\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 caffeine\NN\14712692 (\-LRB-\1740 300\CD\1740 to\TO\1740 450\CD\1740 mg/kg\NN\1740 IP\NN\5999797 )\-RRB-\1740 and\CC\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 fatal\JJ\1740 convulsions\NNS\14081375 by\IN\1740 a\DT\13649268 factor\NN\7326557 of\IN\1740 about\RB\1740 two\CD\13741022 ;\:\1740 and\CC\1740 2\LS\13741022 )\-RRB-\1740 pretreatment\NN\1740 with\IN\1740 <e1>acetaminophen</e1>\NN\2707683 (\-LRB-\1740 75\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 reduced\VBD\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 audiogenic\JJ\1740 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 caffeine\NN\14712692 (\-LRB-\1740 12.5\CD\1740 to\TO\1740 75\CD\1740 mg/kg\NN\1740 IP\NN\5999797 )\-RRB-\1740 .\.\1740
D000082_D012640 NONE The\DT\1740 frequency\NN\15286249 of\IN\1740 sound-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 after\IN\1740 12.5\CD\1740 or\CC\3541091 25\CD\13745420 mg/kg\NN\1740 caffeine\NN\14712692 was\VBD\836236 reduced\VBN\441445 from\IN\1740 50\CD\13745420 to\TO\1740 5\CD\13741022 %\NN\1740 by\IN\1740 <e1>acetaminophen</e1>\RB\1740 .\.\1740
D000082_D012640 NONE In\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 caffeine\NN\14712692 ,\,\1740 <e1>acetaminophen</e1>\RB\1740 (\-LRB-\1740 up\RB\1740 to\TO\1740 300\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 modify\VB\109660 the\DT\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 maximal\JJ\1740 electroshock\NN\662681 and\CC\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 convulsant\JJ\1740 dose\NN\3740161 of\IN\1740 pentylenetetrezol\NN\1740 in\IN\13603305 mice\NNS\2329401 (\-LRB-\1740 tests\NNS\5798043 performed\VBN\2367363 by\IN\1740 the\DT\1740 Anticonvulsant\NNP\3740161 Screening\NNP\6887726 Project\NNP\575741 of\IN\1740 NINCDS\NNP\1740 )\-RRB-\1740 .\.\1740
D002110_D012640 CID Studies\NNS\635850 in\IN\13603305 DBA/2J\NN\1740 mice\NNS\2329401 showed\VBD\2137132 that\IN\1740 :\:\1740 1\LS\13741022 )\-RRB-\1740 pretreatment\NN\1740 with\IN\1740 acetaminophen\NN\2707683 (\-LRB-\1740 100\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 interval\NN\33615 between\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>caffeine</e1>\NN\14712692 (\-LRB-\1740 300\CD\1740 to\TO\1740 450\CD\1740 mg/kg\NN\1740 IP\NN\5999797 )\-RRB-\1740 and\CC\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 fatal\JJ\1740 <e2>convulsions</e2>\NNS\14081375 by\IN\1740 a\DT\13649268 factor\NN\7326557 of\IN\1740 about\RB\1740 two\CD\13741022 ;\:\1740 and\CC\1740 2\LS\13741022 )\-RRB-\1740 pretreatment\NN\1740 with\IN\1740 acetaminophen\NN\2707683 (\-LRB-\1740 75\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 reduced\VBD\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 audiogenic\JJ\1740 seizures\NNS\14081375 produced\VBN\1617192 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 caffeine\NN\14712692 (\-LRB-\1740 12.5\CD\1740 to\TO\1740 75\CD\1740 mg/kg\NN\1740 IP\NN\5999797 )\-RRB-\1740 .\.\1740
D002110_D012640 CID Studies\NNS\635850 in\IN\13603305 DBA/2J\NN\1740 mice\NNS\2329401 showed\VBD\2137132 that\IN\1740 :\:\1740 1\LS\13741022 )\-RRB-\1740 pretreatment\NN\1740 with\IN\1740 acetaminophen\NN\2707683 (\-LRB-\1740 100\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 interval\NN\33615 between\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>caffeine</e1>\NN\14712692 (\-LRB-\1740 300\CD\1740 to\TO\1740 450\CD\1740 mg/kg\NN\1740 IP\NN\5999797 )\-RRB-\1740 and\CC\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 fatal\JJ\1740 convulsions\NNS\14081375 by\IN\1740 a\DT\13649268 factor\NN\7326557 of\IN\1740 about\RB\1740 two\CD\13741022 ;\:\1740 and\CC\1740 2\LS\13741022 )\-RRB-\1740 pretreatment\NN\1740 with\IN\1740 acetaminophen\NN\2707683 (\-LRB-\1740 75\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 reduced\VBD\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 audiogenic\JJ\1740 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 caffeine\NN\14712692 (\-LRB-\1740 12.5\CD\1740 to\TO\1740 75\CD\1740 mg/kg\NN\1740 IP\NN\5999797 )\-RRB-\1740 .\.\1740
D002110_D012640 CID Studies\NNS\635850 in\IN\13603305 DBA/2J\NN\1740 mice\NNS\2329401 showed\VBD\2137132 that\IN\1740 :\:\1740 1\LS\13741022 )\-RRB-\1740 pretreatment\NN\1740 with\IN\1740 acetaminophen\NN\2707683 (\-LRB-\1740 100\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 interval\NN\33615 between\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 caffeine\NN\14712692 (\-LRB-\1740 300\CD\1740 to\TO\1740 450\CD\1740 mg/kg\NN\1740 IP\NN\5999797 )\-RRB-\1740 and\CC\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 fatal\JJ\1740 <e2>convulsions</e2>\NNS\14081375 by\IN\1740 a\DT\13649268 factor\NN\7326557 of\IN\1740 about\RB\1740 two\CD\13741022 ;\:\1740 and\CC\1740 2\LS\13741022 )\-RRB-\1740 pretreatment\NN\1740 with\IN\1740 acetaminophen\NN\2707683 (\-LRB-\1740 75\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 reduced\VBD\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 audiogenic\JJ\1740 seizures\NNS\14081375 produced\VBN\1617192 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 <e1>caffeine</e1>\NN\14712692 (\-LRB-\1740 12.5\CD\1740 to\TO\1740 75\CD\1740 mg/kg\NN\1740 IP\NN\5999797 )\-RRB-\1740 .\.\1740
D002110_D012640 CID Studies\NNS\635850 in\IN\13603305 DBA/2J\NN\1740 mice\NNS\2329401 showed\VBD\2137132 that\IN\1740 :\:\1740 1\LS\13741022 )\-RRB-\1740 pretreatment\NN\1740 with\IN\1740 acetaminophen\NN\2707683 (\-LRB-\1740 100\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 increased\VBD\169651 the\DT\1740 interval\NN\33615 between\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 caffeine\NN\14712692 (\-LRB-\1740 300\CD\1740 to\TO\1740 450\CD\1740 mg/kg\NN\1740 IP\NN\5999797 )\-RRB-\1740 and\CC\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 fatal\JJ\1740 convulsions\NNS\14081375 by\IN\1740 a\DT\13649268 factor\NN\7326557 of\IN\1740 about\RB\1740 two\CD\13741022 ;\:\1740 and\CC\1740 2\LS\13741022 )\-RRB-\1740 pretreatment\NN\1740 with\IN\1740 acetaminophen\NN\2707683 (\-LRB-\1740 75\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 reduced\VBD\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 audiogenic\JJ\1740 <e2>seizures</e2>\NNS\14081375 produced\VBN\1617192 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 <e1>caffeine</e1>\NN\14712692 (\-LRB-\1740 12.5\CD\1740 to\TO\1740 75\CD\1740 mg/kg\NN\1740 IP\NN\5999797 )\-RRB-\1740 .\.\1740
D002110_D012640 CID The\DT\1740 frequency\NN\15286249 of\IN\1740 sound-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 after\IN\1740 12.5\CD\1740 or\CC\3541091 25\CD\13745420 mg/kg\NN\1740 <e1>caffeine</e1>\NN\14712692 was\VBD\836236 reduced\VBN\441445 from\IN\1740 50\CD\13745420 to\TO\1740 5\CD\13741022 %\NN\1740 by\IN\1740 acetaminophen\RB\1740 .\.\1740
D002110_D012640 CID In\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 <e1>caffeine</e1>\NN\14712692 ,\,\1740 acetaminophen\RB\1740 (\-LRB-\1740 up\RB\1740 to\TO\1740 300\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 modify\VB\109660 the\DT\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 maximal\JJ\1740 electroshock\NN\662681 and\CC\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 convulsant\JJ\1740 dose\NN\3740161 of\IN\1740 pentylenetetrezol\NN\1740 in\IN\13603305 mice\NNS\2329401 (\-LRB-\1740 tests\NNS\5798043 performed\VBN\2367363 by\IN\1740 the\DT\1740 Anticonvulsant\NNP\3740161 Screening\NNP\6887726 Project\NNP\575741 of\IN\1740 NINCDS\NNP\1740 )\-RRB-\1740 .\.\1740
D010433_D012640 CID In\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 caffeine\NN\14712692 ,\,\1740 acetaminophen\RB\1740 (\-LRB-\1740 up\RB\1740 to\TO\1740 300\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 did\VBD\1640855 not\RB\1740 modify\VB\109660 the\DT\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 maximal\JJ\1740 electroshock\NN\662681 and\CC\1740 did\VBD\1640855 not\RB\1740 alter\VB\126264 the\DT\1740 convulsant\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>pentylenetetrezol</e1>\NN\1740 in\IN\13603305 mice\NNS\2329401 (\-LRB-\1740 tests\NNS\5798043 performed\VBN\2367363 by\IN\1740 the\DT\1740 Anticonvulsant\NNP\3740161 Screening\NNP\6887726 Project\NNP\575741 of\IN\1740 NINCDS\NNP\1740 )\-RRB-\1740 .\.\1740
16574712
D018817_D003072 CID <e1>MDMA</e1>\NN\3054098 polydrug\NN\1740 users\NNS\7846 show\VBP\2137132 process-specific\JJ\1740 central\JJ\1740 executive\JJ\1740 impairments\NNS\7296428 coupled\VBN\1295275 with\IN\1740 <e2>impaired\JJ\1740 social\JJ\1740 and\CC\1740 emotional\JJ\1740 judgement\NN\6479665 processes</e2>\NNS\407535 .\.\1740
D018817_D008569 NONE In\IN\13603305 recent\JJ\1740 years\NNS\15144371 working\VBG\2524171 <e2>memory\NN\5926676 deficits</e2>\NNS\5113133 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 users\NNS\7846 of\IN\1740 <e1>MDMA</e1>\NN\3054098 (\-LRB-\1740 3,4-methylenedioxymethamphetamine\NN\1740 ,\,\1740 ecstasy\NN\13985818 )\-RRB-\1740 .\.\1740
D018817_D008569 NONE In\IN\13603305 recent\JJ\1740 years\NNS\15144371 working\VBG\2524171 <e2>memory\NN\5926676 deficits</e2>\NNS\5113133 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 users\NNS\7846 of\IN\1740 MDMA\NN\3054098 (\-LRB-\1740 <e1>3,4-methylenedioxymethamphetamine</e1>\NN\1740 ,\,\1740 ecstasy\NN\13985818 )\-RRB-\1740 .\.\1740
D018817_D008569 NONE In\IN\13603305 recent\JJ\1740 years\NNS\15144371 working\VBG\2524171 <e2>memory\NN\5926676 deficits</e2>\NNS\5113133 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 in\IN\13603305 users\NNS\7846 of\IN\1740 MDMA\NN\3054098 (\-LRB-\1740 3,4-methylenedioxymethamphetamine\NN\1740 ,\,\1740 <e1>ecstasy</e1>\NN\13985818 )\-RRB-\1740 .\.\1740
6773726
D005996_D007022 CID Provocation\NN\1221611 of\IN\1740 postural\JJ\1740 <e2>hypotension</e2>\NN\14057371 by\IN\1740 <e1>nitroglycerin</e1>\NN\15015501 in\IN\13603305 diabetic\JJ\1740 autonomic\JJ\1740 neuropathy\JJ\1740 ?\.\1740
D005996_D003929 NONE Provocation\NN\1221611 of\IN\1740 postural\JJ\1740 hypotension\NN\14057371 by\IN\1740 <e1>nitroglycerin</e1>\NN\15015501 in\IN\13603305 <e2>diabetic\JJ\1740 autonomic\JJ\1740 neuropathy</e2>\JJ\1740 ?\.\1740
D005996_D003920 NONE The\DT\1740 effect\NN\34213 of\IN\1740 <e1>nitroglycerin</e1>\NN\15015501 on\IN\1740 heart\NN\5919034 rate\NN\13815152 and\CC\1740 systolic\JJ\1740 blood\NN\5397468 pressure\NN\11419404 was\VBD\836236 compared\VBN\644583 in\IN\13603305 5\CD\13741022 normal\JJ\1740 subjects\NNS\6598915 ,\,\1740 12\CD\13745420 <e2>diabetic</e2>\JJ\1740 subjects\NNS\6598915 without\IN\1740 autonomic\JJ\1740 neuropathy\RB\1740 ,\,\1740 and\CC\1740 5\CD\13741022 diabetic\JJ\1740 subjects\NNS\6598915 with\IN\1740 autonomic\JJ\1740 neuropathy\NN\14204950 .\.\1740
D005996_D003920 NONE The\DT\1740 effect\NN\34213 of\IN\1740 <e1>nitroglycerin</e1>\NN\15015501 on\IN\1740 heart\NN\5919034 rate\NN\13815152 and\CC\1740 systolic\JJ\1740 blood\NN\5397468 pressure\NN\11419404 was\VBD\836236 compared\VBN\644583 in\IN\13603305 5\CD\13741022 normal\JJ\1740 subjects\NNS\6598915 ,\,\1740 12\CD\13745420 diabetic\JJ\1740 subjects\NNS\6598915 without\IN\1740 autonomic\JJ\1740 neuropathy\RB\1740 ,\,\1740 and\CC\1740 5\CD\13741022 <e2>diabetic</e2>\JJ\1740 subjects\NNS\6598915 with\IN\1740 autonomic\JJ\1740 neuropathy\NN\14204950 .\.\1740
D005996_D003920 NONE The\DT\1740 magnitude\NN\4916342 and\CC\1740 time\NN\7308889 course\NN\883297 of\IN\1740 the\DT\1740 increase\NN\13576355 in\IN\13603305 heart\NN\5919034 rate\NN\13815152 and\CC\1740 the\DT\1740 decrease\NN\7296428 in\IN\13603305 systolic\JJ\1740 blood\NN\5397468 pressure\NN\11419404 after\IN\1740 <e1>nitroglycerin</e1>\NN\15015501 were\VBD\836236 similar\JJ\1740 in\IN\13603305 the\DT\1740 normal\JJ\1740 and\CC\1740 <e2>diabetic</e2>\JJ\1740 subjects\NNS\6598915 without\IN\1740 autonomic\JJ\1740 neuropathy\JJ\1740 ,\,\1740 whereas\IN\1740 a\DT\13649268 lesser\JJR\1740 increase\NN\13576355 in\IN\13603305 heart\NN\5919034 rate\NN\13815152 and\CC\1740 a\DT\13649268 greater\JJR\1740 decrease\NN\7296428 in\IN\13603305 systolic\JJ\1740 blood\NN\5397468 pressure\NN\11419404 occurred\VBD\2623529 in\IN\13603305 the\DT\1740 diabetic\JJ\1740 subjects\NNS\6598915 with\IN\1740 autonomic\JJ\1740 neuropathy\NN\14204950 .\.\1740
D005996_D003920 NONE The\DT\1740 magnitude\NN\4916342 and\CC\1740 time\NN\7308889 course\NN\883297 of\IN\1740 the\DT\1740 increase\NN\13576355 in\IN\13603305 heart\NN\5919034 rate\NN\13815152 and\CC\1740 the\DT\1740 decrease\NN\7296428 in\IN\13603305 systolic\JJ\1740 blood\NN\5397468 pressure\NN\11419404 after\IN\1740 <e1>nitroglycerin</e1>\NN\15015501 were\VBD\836236 similar\JJ\1740 in\IN\13603305 the\DT\1740 normal\JJ\1740 and\CC\1740 diabetic\JJ\1740 subjects\NNS\6598915 without\IN\1740 autonomic\JJ\1740 neuropathy\JJ\1740 ,\,\1740 whereas\IN\1740 a\DT\13649268 lesser\JJR\1740 increase\NN\13576355 in\IN\13603305 heart\NN\5919034 rate\NN\13815152 and\CC\1740 a\DT\13649268 greater\JJR\1740 decrease\NN\7296428 in\IN\13603305 systolic\JJ\1740 blood\NN\5397468 pressure\NN\11419404 occurred\VBD\2623529 in\IN\13603305 the\DT\1740 <e2>diabetic</e2>\JJ\1740 subjects\NNS\6598915 with\IN\1740 autonomic\JJ\1740 neuropathy\NN\14204950 .\.\1740
D005996_D009422 NONE The\DT\1740 effect\NN\34213 of\IN\1740 <e1>nitroglycerin</e1>\NN\15015501 on\IN\1740 heart\NN\5919034 rate\NN\13815152 and\CC\1740 systolic\JJ\1740 blood\NN\5397468 pressure\NN\11419404 was\VBD\836236 compared\VBN\644583 in\IN\13603305 5\CD\13741022 normal\JJ\1740 subjects\NNS\6598915 ,\,\1740 12\CD\13745420 diabetic\JJ\1740 subjects\NNS\6598915 without\IN\1740 <e2>autonomic\JJ\1740 neuropathy</e2>\RB\1740 ,\,\1740 and\CC\1740 5\CD\13741022 diabetic\JJ\1740 subjects\NNS\6598915 with\IN\1740 autonomic\JJ\1740 neuropathy\NN\14204950 .\.\1740
D005996_D009422 NONE The\DT\1740 effect\NN\34213 of\IN\1740 <e1>nitroglycerin</e1>\NN\15015501 on\IN\1740 heart\NN\5919034 rate\NN\13815152 and\CC\1740 systolic\JJ\1740 blood\NN\5397468 pressure\NN\11419404 was\VBD\836236 compared\VBN\644583 in\IN\13603305 5\CD\13741022 normal\JJ\1740 subjects\NNS\6598915 ,\,\1740 12\CD\13745420 diabetic\JJ\1740 subjects\NNS\6598915 without\IN\1740 autonomic\JJ\1740 neuropathy\RB\1740 ,\,\1740 and\CC\1740 5\CD\13741022 diabetic\JJ\1740 subjects\NNS\6598915 with\IN\1740 <e2>autonomic\JJ\1740 neuropathy</e2>\NN\14204950 .\.\1740
D005996_D009422 NONE The\DT\1740 magnitude\NN\4916342 and\CC\1740 time\NN\7308889 course\NN\883297 of\IN\1740 the\DT\1740 increase\NN\13576355 in\IN\13603305 heart\NN\5919034 rate\NN\13815152 and\CC\1740 the\DT\1740 decrease\NN\7296428 in\IN\13603305 systolic\JJ\1740 blood\NN\5397468 pressure\NN\11419404 after\IN\1740 <e1>nitroglycerin</e1>\NN\15015501 were\VBD\836236 similar\JJ\1740 in\IN\13603305 the\DT\1740 normal\JJ\1740 and\CC\1740 diabetic\JJ\1740 subjects\NNS\6598915 without\IN\1740 <e2>autonomic\JJ\1740 neuropathy</e2>\JJ\1740 ,\,\1740 whereas\IN\1740 a\DT\13649268 lesser\JJR\1740 increase\NN\13576355 in\IN\13603305 heart\NN\5919034 rate\NN\13815152 and\CC\1740 a\DT\13649268 greater\JJR\1740 decrease\NN\7296428 in\IN\13603305 systolic\JJ\1740 blood\NN\5397468 pressure\NN\11419404 occurred\VBD\2623529 in\IN\13603305 the\DT\1740 diabetic\JJ\1740 subjects\NNS\6598915 with\IN\1740 autonomic\JJ\1740 neuropathy\NN\14204950 .\.\1740
D005996_D009422 NONE The\DT\1740 magnitude\NN\4916342 and\CC\1740 time\NN\7308889 course\NN\883297 of\IN\1740 the\DT\1740 increase\NN\13576355 in\IN\13603305 heart\NN\5919034 rate\NN\13815152 and\CC\1740 the\DT\1740 decrease\NN\7296428 in\IN\13603305 systolic\JJ\1740 blood\NN\5397468 pressure\NN\11419404 after\IN\1740 <e1>nitroglycerin</e1>\NN\15015501 were\VBD\836236 similar\JJ\1740 in\IN\13603305 the\DT\1740 normal\JJ\1740 and\CC\1740 diabetic\JJ\1740 subjects\NNS\6598915 without\IN\1740 autonomic\JJ\1740 neuropathy\JJ\1740 ,\,\1740 whereas\IN\1740 a\DT\13649268 lesser\JJR\1740 increase\NN\13576355 in\IN\13603305 heart\NN\5919034 rate\NN\13815152 and\CC\1740 a\DT\13649268 greater\JJR\1740 decrease\NN\7296428 in\IN\13603305 systolic\JJ\1740 blood\NN\5397468 pressure\NN\11419404 occurred\VBD\2623529 in\IN\13603305 the\DT\1740 diabetic\JJ\1740 subjects\NNS\6598915 with\IN\1740 <e2>autonomic\JJ\1740 neuropathy</e2>\NN\14204950 .\.\1740
15130900
D003520_D001749 CID <e2>Urinary\JJ\1740 bladder\NN\5515670 cancer</e2>\NN\14239425 in\IN\13603305 Wegener\NNP\1740 's\POS\1740 granulomatosis\NN\1740 :\:\1740 risks\NNS\14541044 and\CC\1740 relation\NN\2137 to\TO\1740 <e1>cyclophosphamide</e1>\NN\1740 .\.\1740
D003520_D001749 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 assess\VB\670261 and\CC\1740 characterise\VB\651991 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>bladder\NN\5515670 cancer</e2>\NN\14239425 ,\,\1740 and\CC\1740 its\PRP$\6125041 relation\NN\2137 to\TO\1740 <e1>cyclophosphamide</e1>\NN\1740 ,\,\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Wegener\NNP\1740 's\POS\1740 granulomatosis\NN\1740 .\.\1740
D003520_D001749 CID Nested\VBN\2649830 within\IN\1740 the\DT\1740 cohort\NN\8184861 ,\,\1740 a\DT\13649268 matched\VBN\2664769 case-control\JJ\1740 study\NN\635850 was\VBD\836236 performed\VBN\2367363 to\TO\1740 estimate\VB\637259 the\DT\1740 association\NN\8008335 between\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 and\CC\1740 <e2>bladder\NN\5515670 cancer</e2>\NN\14239425 using\VBG\1156834 odds\NNS\4756635 ratios\NNS\13815152 (\-LRB-\1740 ORs\NNS\3541091 )\-RRB-\1740 as\IN\14622893 relative\JJ\1740 risk\NN\14541044 .\.\1740
D003520_D001749 CID The\DT\1740 risk\NN\14541044 of\IN\1740 <e2>bladder\NN\5515670 cancer</e2>\NN\14239425 doubled\VBN\247390 for\IN\1740 every\DT\1740 10\CD\13745420 g\NN\13717155 increment\NN\29677 in\IN\13603305 <e1>cyclophosphamide</e1>\NN\1740 (\-LRB-\1740 OR\NN\3541091 =\JJ\1740 2.0\CD\1740 ,\,\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 (\-LRB-\1740 CI\NN\13635336 )\-RRB-\1740 0.8\CD\1740 to\TO\1740 4.9\CD\1740 )\-RRB-\1740 .\.\1740
D003520_D001749 CID CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 results\NNS\34213 indicate\VBP\952524 a\DT\13649268 dose-response\JJ\1740 relationship\NN\31921 between\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 and\CC\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>bladder\NN\5515670 cancer</e2>\NN\14239425 ,\,\1740 high\JJ\1740 cumulative\JJ\1740 risks\NNS\14541044 in\IN\13603305 the\DT\1740 entire\JJ\1740 cohort\NN\8184861 ,\,\1740 and\CC\1740 also\RB\1740 the\DT\1740 possibility\NN\5944958 of\IN\1740 risk\NN\14541044 factors\NNS\7326557 operating\VBG\2439501 even\RB\1740 before\IN\1740 Wegener\NNP\1740 's\POS\1740 granulomatosis\NN\1740 .\.\1740
D003520_D014890 NONE Urinary\JJ\1740 bladder\NN\5515670 cancer\NN\14239425 in\IN\13603305 <e2>Wegener\NNP\1740 's\POS\1740 granulomatosis</e2>\NN\1740 :\:\1740 risks\NNS\14541044 and\CC\1740 relation\NN\2137 to\TO\1740 <e1>cyclophosphamide</e1>\NN\1740 .\.\1740
D003520_D014890 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 assess\VB\670261 and\CC\1740 characterise\VB\651991 the\DT\1740 risk\NN\14541044 of\IN\1740 bladder\NN\5515670 cancer\NN\14239425 ,\,\1740 and\CC\1740 its\PRP$\6125041 relation\NN\2137 to\TO\1740 <e1>cyclophosphamide</e1>\NN\1740 ,\,\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>Wegener\NNP\1740 's\POS\1740 granulomatosis</e2>\NN\1740 .\.\1740
D003520_D014890 NONE CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 results\NNS\34213 indicate\VBP\952524 a\DT\13649268 dose-response\JJ\1740 relationship\NN\31921 between\IN\1740 <e1>cyclophosphamide</e1>\NN\1740 and\CC\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 bladder\NN\5515670 cancer\NN\14239425 ,\,\1740 high\JJ\1740 cumulative\JJ\1740 risks\NNS\14541044 in\IN\13603305 the\DT\1740 entire\JJ\1740 cohort\NN\8184861 ,\,\1740 and\CC\1740 also\RB\1740 the\DT\1740 possibility\NN\5944958 of\IN\1740 risk\NN\14541044 factors\NNS\7326557 operating\VBG\2439501 even\RB\1740 before\IN\1740 <e2>Wegener\NNP\1740 's\POS\1740 granulomatosis</e2>\NN\1740 .\.\1740
150790
D011736_D002653 NONE A\DT\13649268 <e1>pyridoxine-dependent</e1>\JJ\1740 <e2>behavioral\JJ\1740 disorder</e2>\NN\14034177 unmasked\VBN\853195 by\IN\1740 isoniazid\NNS\2716205 .\.\1740
D007538_D002653 CID A\DT\13649268 pyridoxine-dependent\JJ\1740 <e2>behavioral\JJ\1740 disorder</e2>\NN\14034177 unmasked\VBN\853195 by\IN\1740 <e1>isoniazid</e1>\NNS\2716205 .\.\1740
D007538_D002653 CID A\DT\13649268 3-year-old\JJ\1740 girl\NN\10787470 had\VBD\2108377 <e2>behavioral\JJ\1740 deterioration</e2>\NN\14560612 ,\,\1740 with\IN\1740 hyperkinesis\NN\1740 ,\,\1740 irritability\NN\7552087 ,\,\1740 and\CC\1740 sleeping\VBG\14405 difficulties\NNS\621627 after\IN\1740 the\DT\1740 therapeutic\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>isoniazid</e1>\NN\2716205 .\.\1740
D007538_D006948 CID A\DT\13649268 3-year-old\JJ\1740 girl\NN\10787470 had\VBD\2108377 behavioral\JJ\1740 deterioration\NN\14560612 ,\,\1740 with\IN\1740 <e2>hyperkinesis</e2>\NN\1740 ,\,\1740 irritability\NN\7552087 ,\,\1740 and\CC\1740 sleeping\VBG\14405 difficulties\NNS\621627 after\IN\1740 the\DT\1740 therapeutic\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>isoniazid</e1>\NN\2716205 .\.\1740
D007538_D001523 NONE A\DT\13649268 3-year-old\JJ\1740 girl\NN\10787470 had\VBD\2108377 behavioral\JJ\1740 deterioration\NN\14560612 ,\,\1740 with\IN\1740 hyperkinesis\NN\1740 ,\,\1740 <e2>irritability</e2>\NN\7552087 ,\,\1740 and\CC\1740 sleeping\VBG\14405 difficulties\NNS\621627 after\IN\1740 the\DT\1740 therapeutic\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>isoniazid</e1>\NN\2716205 .\.\1740
D007538_D012893 NONE A\DT\13649268 3-year-old\JJ\1740 girl\NN\10787470 had\VBD\2108377 behavioral\JJ\1740 deterioration\NN\14560612 ,\,\1740 with\IN\1740 hyperkinesis\NN\1740 ,\,\1740 irritability\NN\7552087 ,\,\1740 and\CC\1740 <e2>sleeping\VBG\14405 difficulties</e2>\NNS\621627 after\IN\1740 the\DT\1740 therapeutic\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>isoniazid</e1>\NN\2716205 .\.\1740
D011736_D006948 NONE Periodic\JJ\1740 withdrawal\NN\7206096 of\IN\1740 <e1>pyridoxine</e1>\NN\15090742 was\VBD\836236 associated\VBN\628491 with\IN\1740 return\NN\6479665 of\IN\1740 the\DT\1740 <e2>hyperkinesis</e2>\NN\1740 .\.\1740
3719553
D005472_D004342 NONE <e2>Allergic\JJ\1740 reaction</e2>\NN\13446390 to\TO\1740 <e1>5-fluorouracil</e1>\NN\1740 infusion\NN\14589223 .\.\1740
D005472_D004342 NONE An\DT\6697703 <e2>allergic\JJ\1740 reaction</e2>\NN\13446390 consisting\VBG\2603699 of\IN\1740 angioneurotic\JJ\1740 edema\NN\14315192 secondary\JJ\1740 to\TO\1740 continuous\JJ\1740 infusion\NN\14589223 <e1>5-fluorouracil</e1>\NN\1740 occurred\VBD\2623529 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 recurrent\JJ\1740 carcinoma\NN\14239918 of\IN\1740 the\DT\1740 oral\JJ\1740 cavity\NN\9304750 ,\,\1740 cirrhosis\NN\14116321 ,\,\1740 and\CC\1740 cisplatin-induced\JJ\1740 impaired\JJ\1740 renal\JJ\1740 function\NN\13783581 .\.\1740
D005472_D000799 CID An\DT\6697703 allergic\JJ\1740 reaction\NN\13446390 consisting\VBG\2603699 of\IN\1740 <e2>angioneurotic\JJ\1740 edema</e2>\NN\14315192 secondary\JJ\1740 to\TO\1740 continuous\JJ\1740 infusion\NN\14589223 <e1>5-fluorouracil</e1>\NN\1740 occurred\VBD\2623529 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 recurrent\JJ\1740 carcinoma\NN\14239918 of\IN\1740 the\DT\1740 oral\JJ\1740 cavity\NN\9304750 ,\,\1740 cirrhosis\NN\14116321 ,\,\1740 and\CC\1740 cisplatin-induced\JJ\1740 impaired\JJ\1740 renal\JJ\1740 function\NN\13783581 .\.\1740
D005472_D009062 NONE An\DT\6697703 allergic\JJ\1740 reaction\NN\13446390 consisting\VBG\2603699 of\IN\1740 angioneurotic\JJ\1740 edema\NN\14315192 secondary\JJ\1740 to\TO\1740 continuous\JJ\1740 infusion\NN\14589223 <e1>5-fluorouracil</e1>\NN\1740 occurred\VBD\2623529 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 recurrent\JJ\1740 <e2>carcinoma\NN\14239918 of\IN\1740 the\DT\1740 oral\JJ\1740 cavity</e2>\NN\9304750 ,\,\1740 cirrhosis\NN\14116321 ,\,\1740 and\CC\1740 cisplatin-induced\JJ\1740 impaired\JJ\1740 renal\JJ\1740 function\NN\13783581 .\.\1740
D005472_D005355 NONE An\DT\6697703 allergic\JJ\1740 reaction\NN\13446390 consisting\VBG\2603699 of\IN\1740 angioneurotic\JJ\1740 edema\NN\14315192 secondary\JJ\1740 to\TO\1740 continuous\JJ\1740 infusion\NN\14589223 <e1>5-fluorouracil</e1>\NN\1740 occurred\VBD\2623529 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 recurrent\JJ\1740 carcinoma\NN\14239918 of\IN\1740 the\DT\1740 oral\JJ\1740 cavity\NN\9304750 ,\,\1740 <e2>cirrhosis</e2>\NN\14116321 ,\,\1740 and\CC\1740 cisplatin-induced\JJ\1740 impaired\JJ\1740 renal\JJ\1740 function\NN\13783581 .\.\1740
D005472_D007674 NONE An\DT\6697703 allergic\JJ\1740 reaction\NN\13446390 consisting\VBG\2603699 of\IN\1740 angioneurotic\JJ\1740 edema\NN\14315192 secondary\JJ\1740 to\TO\1740 continuous\JJ\1740 infusion\NN\14589223 <e1>5-fluorouracil</e1>\NN\1740 occurred\VBD\2623529 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 recurrent\JJ\1740 carcinoma\NN\14239918 of\IN\1740 the\DT\1740 oral\JJ\1740 cavity\NN\9304750 ,\,\1740 cirrhosis\NN\14116321 ,\,\1740 and\CC\1740 cisplatin-induced\JJ\1740 <e2>impaired\JJ\1740 renal\JJ\1740 function</e2>\NN\13783581 .\.\1740
D002945_D004342 NONE An\DT\6697703 <e2>allergic\JJ\1740 reaction</e2>\NN\13446390 consisting\VBG\2603699 of\IN\1740 angioneurotic\JJ\1740 edema\NN\14315192 secondary\JJ\1740 to\TO\1740 continuous\JJ\1740 infusion\NN\14589223 5-fluorouracil\NN\1740 occurred\VBD\2623529 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 recurrent\JJ\1740 carcinoma\NN\14239918 of\IN\1740 the\DT\1740 oral\JJ\1740 cavity\NN\9304750 ,\,\1740 cirrhosis\NN\14116321 ,\,\1740 and\CC\1740 <e1>cisplatin-induced</e1>\JJ\1740 impaired\JJ\1740 renal\JJ\1740 function\NN\13783581 .\.\1740
D002945_D000799 NONE An\DT\6697703 allergic\JJ\1740 reaction\NN\13446390 consisting\VBG\2603699 of\IN\1740 <e2>angioneurotic\JJ\1740 edema</e2>\NN\14315192 secondary\JJ\1740 to\TO\1740 continuous\JJ\1740 infusion\NN\14589223 5-fluorouracil\NN\1740 occurred\VBD\2623529 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 recurrent\JJ\1740 carcinoma\NN\14239918 of\IN\1740 the\DT\1740 oral\JJ\1740 cavity\NN\9304750 ,\,\1740 cirrhosis\NN\14116321 ,\,\1740 and\CC\1740 <e1>cisplatin-induced</e1>\JJ\1740 impaired\JJ\1740 renal\JJ\1740 function\NN\13783581 .\.\1740
D002945_D009062 NONE An\DT\6697703 allergic\JJ\1740 reaction\NN\13446390 consisting\VBG\2603699 of\IN\1740 angioneurotic\JJ\1740 edema\NN\14315192 secondary\JJ\1740 to\TO\1740 continuous\JJ\1740 infusion\NN\14589223 5-fluorouracil\NN\1740 occurred\VBD\2623529 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 recurrent\JJ\1740 <e2>carcinoma\NN\14239918 of\IN\1740 the\DT\1740 oral\JJ\1740 cavity</e2>\NN\9304750 ,\,\1740 cirrhosis\NN\14116321 ,\,\1740 and\CC\1740 <e1>cisplatin-induced</e1>\JJ\1740 impaired\JJ\1740 renal\JJ\1740 function\NN\13783581 .\.\1740
D002945_D005355 NONE An\DT\6697703 allergic\JJ\1740 reaction\NN\13446390 consisting\VBG\2603699 of\IN\1740 angioneurotic\JJ\1740 edema\NN\14315192 secondary\JJ\1740 to\TO\1740 continuous\JJ\1740 infusion\NN\14589223 5-fluorouracil\NN\1740 occurred\VBD\2623529 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 recurrent\JJ\1740 carcinoma\NN\14239918 of\IN\1740 the\DT\1740 oral\JJ\1740 cavity\NN\9304750 ,\,\1740 <e2>cirrhosis</e2>\NN\14116321 ,\,\1740 and\CC\1740 <e1>cisplatin-induced</e1>\JJ\1740 impaired\JJ\1740 renal\JJ\1740 function\NN\13783581 .\.\1740
D002945_D007674 NONE An\DT\6697703 allergic\JJ\1740 reaction\NN\13446390 consisting\VBG\2603699 of\IN\1740 angioneurotic\JJ\1740 edema\NN\14315192 secondary\JJ\1740 to\TO\1740 continuous\JJ\1740 infusion\NN\14589223 5-fluorouracil\NN\1740 occurred\VBD\2623529 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 recurrent\JJ\1740 carcinoma\NN\14239918 of\IN\1740 the\DT\1740 oral\JJ\1740 cavity\NN\9304750 ,\,\1740 cirrhosis\NN\14116321 ,\,\1740 and\CC\1740 <e1>cisplatin-induced</e1>\JJ\1740 <e2>impaired\JJ\1740 renal\JJ\1740 function</e2>\NN\13783581 .\.\1740
D004155_D004342 NONE Oral\JJ\1740 <e1>diphenhydramine</e1>\NN\2720725 and\CC\1740 prednisone\NN\2721538 were\VBD\836236 ineffective\JJ\1740 in\IN\13603305 preventing\VBG\1740 the\DT\1740 recurrence\NN\7342049 of\IN\1740 the\DT\1740 <e2>allergic\JJ\1740 reaction</e2>\NN\13446390 .\.\1740
D011241_D004342 NONE Oral\JJ\1740 diphenhydramine\NN\2720725 and\CC\1740 <e1>prednisone</e1>\NN\2721538 were\VBD\836236 ineffective\JJ\1740 in\IN\13603305 preventing\VBG\1740 the\DT\1740 recurrence\NN\7342049 of\IN\1740 the\DT\1740 <e2>allergic\JJ\1740 reaction</e2>\NN\13446390 .\.\1740
12090760
D015215_D000740 CID Antagonism\NN\24720 between\IN\1740 interleukin\NN\14943950 3\CD\13741022 and\CC\1740 erythropoietin\NN\14888310 in\IN\13603305 mice\NNS\2329401 with\IN\1740 <e1>azidothymidine-induced</e1>\JJ\1740 <e2>anemia</e2>\NN\14189204 and\CC\1740 in\IN\13603305 bone\NN\5286536 marrow\NN\5286536 endothelial\JJ\1740 cells\NNS\3080309 .\.\1740
D015215_D000740 CID <e1>Azidothymidine</e1>\NN\1740 (AZT)-induced\JJ\1740 <e2>anemia</e2>\NN\14189204 in\IN\13603305 mice\NNS\2329401 can\MD\3094503 be\VB\836236 reversed\VBN\109660 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 IGF-IL-3\NN\1740 (\-LRB-\1740 fusion\NN\7373277 protein\NN\14944888 of\IN\1740 insulin-like\JJ\1740 growth\NN\13526110 factor\NN\7326557 II\CD\13741022 (\-LRB-\1740 IGF\NN\1740 II\CD\13741022 )\-RRB-\1740 and\CC\1740 interleukin\NN\14943950 3\CD\13741022 )\-RRB-\1740 .\.\1740
D015215_D000740 CID Azidothymidine\NN\1740 <e1>(AZT)-induced</e1>\JJ\1740 <e2>anemia</e2>\NN\14189204 in\IN\13603305 mice\NNS\2329401 can\MD\3094503 be\VB\836236 reversed\VBN\109660 by\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 IGF-IL-3\NN\1740 (\-LRB-\1740 fusion\NN\7373277 protein\NN\14944888 of\IN\1740 insulin-like\JJ\1740 growth\NN\13526110 factor\NN\7326557 II\CD\13741022 (\-LRB-\1740 IGF\NN\1740 II\CD\13741022 )\-RRB-\1740 and\CC\1740 interleukin\NN\14943950 3\CD\13741022 )\-RRB-\1740 .\.\1740
15120741
D010862_D013226 CID Similar\JJ\1740 to\TO\1740 rats\NNS\2329401 ,\,\1740 systemic\JJ\1740 <e1>pilocarpine</e1>\NN\14712692 injection\NN\320852 causes\VBZ\1617192 <e2>status\NN\24720 epilepticus</e2>\NN\1740 (\-LRB-\1740 SE\NN\14724645 )\-RRB-\1740 and\CC\1740 the\DT\1740 eventual\JJ\1740 development\NN\248977 of\IN\1740 spontaneous\JJ\1740 seizures\NNS\14081375 and\CC\1740 mossy\NN\1740 fiber\NN\14580897 sprouting\VBG\231557 in\IN\13603305 C57BL/6\NN\1740 and\CC\1740 CD1\NN\1740 mice\NNS\2329401 ,\,\1740 but\CC\1740 the\DT\1740 physiological\JJ\1740 correlates\NNS\5857459 of\IN\1740 these\DT\1740 events\NNS\23100 have\VBP\2108377 not\RB\1740 been\VBN\836236 identified\VBN\699815 in\IN\13603305 mice\NNS\2329401 .\.\1740
D010862_D013226 CID Similar\JJ\1740 to\TO\1740 rats\NNS\2329401 ,\,\1740 systemic\JJ\1740 <e1>pilocarpine</e1>\NN\14712692 injection\NN\320852 causes\VBZ\1617192 status\NN\24720 epilepticus\NN\1740 (\-LRB-\1740 <e2>SE</e2>\NN\14724645 )\-RRB-\1740 and\CC\1740 the\DT\1740 eventual\JJ\1740 development\NN\248977 of\IN\1740 spontaneous\JJ\1740 seizures\NNS\14081375 and\CC\1740 mossy\NN\1740 fiber\NN\14580897 sprouting\VBG\231557 in\IN\13603305 C57BL/6\NN\1740 and\CC\1740 CD1\NN\1740 mice\NNS\2329401 ,\,\1740 but\CC\1740 the\DT\1740 physiological\JJ\1740 correlates\NNS\5857459 of\IN\1740 these\DT\1740 events\NNS\23100 have\VBP\2108377 not\RB\1740 been\VBN\836236 identified\VBN\699815 in\IN\13603305 mice\NNS\2329401 .\.\1740
D010862_D013226 CID In\IN\13603305 Mg(2+)-free\NN\1740 bathing\NN\426928 medium\NN\3575240 containing\VBG\2632940 bicuculline\NN\1740 ,\,\1740 conditions\NNS\14512817 designed\VBN\1631534 to\TO\1740 increase\VB\169651 excitability\NN\5653575 in\IN\13603305 the\DT\1740 slices\NNS\13285176 ,\,\1740 electrical\JJ\1740 stimulation\NN\242808 of\IN\1740 the\DT\1740 hilus\NN\5223370 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 single\JJ\1740 population\NN\7942152 spike\JJ\1740 in\IN\13603305 granule\NN\9290777 cells\NNS\3080309 from\IN\1740 control\NN\5190804 mice\NNS\2329401 and\CC\1740 <e1>pilocarpine-treated</e1>\JJ\1740 mice\NNS\2329401 that\WDT\1740 did\VBD\1640855 not\RB\1740 experience\VB\2108377 <e2>SE</e2>\NN\14724645 .\.\1740
D010862_D012640 CID Similar\JJ\1740 to\TO\1740 rats\NNS\2329401 ,\,\1740 systemic\JJ\1740 <e1>pilocarpine</e1>\NN\14712692 injection\NN\320852 causes\VBZ\1617192 status\NN\24720 epilepticus\NN\1740 (\-LRB-\1740 SE\NN\14724645 )\-RRB-\1740 and\CC\1740 the\DT\1740 eventual\JJ\1740 development\NN\248977 of\IN\1740 spontaneous\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 mossy\NN\1740 fiber\NN\14580897 sprouting\VBG\231557 in\IN\13603305 C57BL/6\NN\1740 and\CC\1740 CD1\NN\1740 mice\NNS\2329401 ,\,\1740 but\CC\1740 the\DT\1740 physiological\JJ\1740 correlates\NNS\5857459 of\IN\1740 these\DT\1740 events\NNS\23100 have\VBP\2108377 not\RB\1740 been\VBN\836236 identified\VBN\699815 in\IN\13603305 mice\NNS\2329401 .\.\1740
D008274_D013226 NONE In\IN\13603305 <e1>Mg(2+)-free</e1>\NN\1740 bathing\NN\426928 medium\NN\3575240 containing\VBG\2632940 bicuculline\NN\1740 ,\,\1740 conditions\NNS\14512817 designed\VBN\1631534 to\TO\1740 increase\VB\169651 excitability\NN\5653575 in\IN\13603305 the\DT\1740 slices\NNS\13285176 ,\,\1740 electrical\JJ\1740 stimulation\NN\242808 of\IN\1740 the\DT\1740 hilus\NN\5223370 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 single\JJ\1740 population\NN\7942152 spike\JJ\1740 in\IN\13603305 granule\NN\9290777 cells\NNS\3080309 from\IN\1740 control\NN\5190804 mice\NNS\2329401 and\CC\1740 pilocarpine-treated\JJ\1740 mice\NNS\2329401 that\WDT\1740 did\VBD\1640855 not\RB\1740 experience\VB\2108377 <e2>SE</e2>\NN\14724645 .\.\1740
D001640_D013226 NONE In\IN\13603305 Mg(2+)-free\NN\1740 bathing\NN\426928 medium\NN\3575240 containing\VBG\2632940 <e1>bicuculline</e1>\NN\1740 ,\,\1740 conditions\NNS\14512817 designed\VBN\1631534 to\TO\1740 increase\VB\169651 excitability\NN\5653575 in\IN\13603305 the\DT\1740 slices\NNS\13285176 ,\,\1740 electrical\JJ\1740 stimulation\NN\242808 of\IN\1740 the\DT\1740 hilus\NN\5223370 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 single\JJ\1740 population\NN\7942152 spike\JJ\1740 in\IN\13603305 granule\NN\9290777 cells\NNS\3080309 from\IN\1740 control\NN\5190804 mice\NNS\2329401 and\CC\1740 pilocarpine-treated\JJ\1740 mice\NNS\2329401 that\WDT\1740 did\VBD\1640855 not\RB\1740 experience\VB\2108377 <e2>SE</e2>\NN\14724645 .\.\1740
D018698_D013226 NONE In\IN\13603305 <e2>SE</e2>\NN\14724645 survivors\NNS\9630641 ,\,\1740 similar\JJ\1740 stimulation\NN\242808 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 population\NN\7942152 spike\NN\7307895 followed\VBD\1835496 ,\,\1740 at\IN\14622893 a\DT\13649268 variable\JJ\1740 latency\NN\15269513 ,\,\1740 by\IN\1740 negative\JJ\1740 DC\NN\11450566 shifts\NNS\7446404 and\CC\1740 repetitive\JJ\1740 afterdischarges\NNS\1740 of\IN\1740 3\CD\13741022 -\SYM\1740 60\CD\13745420 s\NN\15154774 duration\NN\15113229 ,\,\1740 which\WDT\1740 were\VBD\836236 blocked\VBN\1476483 by\IN\1740 ionotropic\JJ\1740 <e1>glutamate</e1>\JJ\1740 receptor\NN\5225602 antagonists\NNS\7846 .\.\1740
D018698_D013226 NONE Focal\JJ\1740 <e1>glutamate</e1>\JJ\1740 photostimulation\NN\1740 of\IN\1740 the\DT\1740 granule\NN\9290777 cell\NN\3080309 layer\NN\21939 at\IN\14622893 sites\NNS\8673395 distant\JJ\1740 from\IN\1740 the\DT\1740 recording\NN\6791372 pipette\NN\3733925 resulted\VBD\2633881 in\IN\13603305 population\NN\7942152 responses\NNS\11410625 of\IN\1740 1\CD\13741022 -\SYM\1740 30\CD\13745420 s\NN\15154774 duration\NN\15113229 in\IN\13603305 slices\NNS\13285176 from\IN\1740 <e2>SE</e2>\NN\14724645 survivors\NNS\9630641 but\CC\1740 not\RB\1740 other\JJ\1740 groups\NNS\2137 .\.\1740
14765563
D011803_D020922 NONE Although\IN\1740 the\DT\1740 United\NNP\1740 States\NNP\8491826 Food\NNP\20090 and\CC\1740 Drug\NNP\14778436 Administration\NNP\1133281 banned\VBD\2480923 its\PRP$\6125041 use\NN\407535 for\IN\1740 <e2>nocturnal\JJ\1740 leg\NN\5560244 cramps</e2>\NNS\14299637 due\JJ\1740 to\TO\1740 lack\NN\14449126 of\IN\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 ,\,\1740 <e1>quinine</e1>\NN\2721948 is\VBZ\836236 widely\RB\1740 available\JJ\1740 in\IN\13603305 beverages\NNS\21265 including\VBG\690614 tonic\JJ\1740 water\NN\14618834 and\CC\1740 bitter\JJ\1740 lemon\RB\1740 .\.\1740
D011803_D002493 NONE Numerous\JJ\1740 anecdotal\JJ\1740 reports\NNS\6470073 suggest\VBP\1010118 that\IN\1740 products\NNS\3076708 containing\VBG\2632940 <e1>quinine</e1>\NN\2721948 may\MD\15209706 produce\VB\1617192 <e2>neurological\JJ\1740 complications</e2>\NNS\1073995 ,\,\1740 including\VBG\690614 confusion\NN\13972797 ,\,\1740 altered\JJ\1740 mental\JJ\1740 status\NN\24720 ,\,\1740 seizures\NNS\14081375 ,\,\1740 and\CC\1740 coma\NN\5678932 ,\,\1740 particularly\RB\1740 in\IN\13603305 older\JJR\1740 women\NNS\9605289 .\.\1740
D011803_D003221 CID Numerous\JJ\1740 anecdotal\JJ\1740 reports\NNS\6470073 suggest\VBP\1010118 that\IN\1740 products\NNS\3076708 containing\VBG\2632940 <e1>quinine</e1>\NN\2721948 may\MD\15209706 produce\VB\1617192 neurological\JJ\1740 complications\NNS\1073995 ,\,\1740 including\VBG\690614 <e2>confusion</e2>\NN\13972797 ,\,\1740 altered\JJ\1740 mental\JJ\1740 status\NN\24720 ,\,\1740 seizures\NNS\14081375 ,\,\1740 and\CC\1740 coma\NN\5678932 ,\,\1740 particularly\RB\1740 in\IN\13603305 older\JJR\1740 women\NNS\9605289 .\.\1740
D011803_D012640 CID Numerous\JJ\1740 anecdotal\JJ\1740 reports\NNS\6470073 suggest\VBP\1010118 that\IN\1740 products\NNS\3076708 containing\VBG\2632940 <e1>quinine</e1>\NN\2721948 may\MD\15209706 produce\VB\1617192 neurological\JJ\1740 complications\NNS\1073995 ,\,\1740 including\VBG\690614 confusion\NN\13972797 ,\,\1740 altered\JJ\1740 mental\JJ\1740 status\NN\24720 ,\,\1740 <e2>seizures</e2>\NNS\14081375 ,\,\1740 and\CC\1740 coma\NN\5678932 ,\,\1740 particularly\RB\1740 in\IN\13603305 older\JJR\1740 women\NNS\9605289 .\.\1740
D011803_D003128 CID Numerous\JJ\1740 anecdotal\JJ\1740 reports\NNS\6470073 suggest\VBP\1010118 that\IN\1740 products\NNS\3076708 containing\VBG\2632940 <e1>quinine</e1>\NN\2721948 may\MD\15209706 produce\VB\1617192 neurological\JJ\1740 complications\NNS\1073995 ,\,\1740 including\VBG\690614 confusion\NN\13972797 ,\,\1740 altered\JJ\1740 mental\JJ\1740 status\NN\24720 ,\,\1740 seizures\NNS\14081375 ,\,\1740 and\CC\1740 <e2>coma</e2>\NN\5678932 ,\,\1740 particularly\RB\1740 in\IN\13603305 older\JJR\1740 women\NNS\9605289 .\.\1740
10835440
D009553_D020521 NONE Effect\NN\34213 of\IN\1740 intravenous\JJ\1740 <e1>nimodipine</e1>\NN\1740 on\IN\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 outcome\VB\1740 after\IN\1740 <e2>acute\JJ\1740 stroke</e2>\NN\556313 .\.\1740
D009553_D020521 NONE BACKGROUND\NN\4921011 AND\CC\1740 PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 Intravenous\NNP\1740 <e1>Nimodipine</e1>\NNP\1740 West\NNP\13831000 European\NNP\9620078 <e2>Stroke</e2>\NNP\556313 Trial\NNP\786195 (\-LRB-\1740 INWEST\NN\1740 )\-RRB-\1740 found\VBD\2426171 a\DT\13649268 correlation\NN\13841213 between\IN\1740 nimodipine-induced\JJ\1740 reduction\NN\351485 in\IN\13603305 blood\NN\5397468 pressure\NN\11419404 (\-LRB-\1740 BP\NN\1740 )\-RRB-\1740 and\CC\1740 an\DT\6697703 unfavorable\JJ\1740 outcome\NN\7291312 in\IN\13603305 acute\JJ\1740 stroke\NN\556313 .\.\1740
D009553_D020521 NONE BACKGROUND\NN\4921011 AND\CC\1740 PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 Intravenous\NNP\1740 <e1>Nimodipine</e1>\NNP\1740 West\NNP\13831000 European\NNP\9620078 Stroke\NNP\556313 Trial\NNP\786195 (\-LRB-\1740 INWEST\NN\1740 )\-RRB-\1740 found\VBD\2426171 a\DT\13649268 correlation\NN\13841213 between\IN\1740 nimodipine-induced\JJ\1740 reduction\NN\351485 in\IN\13603305 blood\NN\5397468 pressure\NN\11419404 (\-LRB-\1740 BP\NN\1740 )\-RRB-\1740 and\CC\1740 an\DT\6697703 unfavorable\JJ\1740 outcome\NN\7291312 in\IN\13603305 <e2>acute\JJ\1740 stroke</e2>\NN\556313 .\.\1740
D009553_D020521 NONE BACKGROUND\NN\4921011 AND\CC\1740 PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 Intravenous\NNP\1740 Nimodipine\NNP\1740 West\NNP\13831000 European\NNP\9620078 <e2>Stroke</e2>\NNP\556313 Trial\NNP\786195 (\-LRB-\1740 INWEST\NN\1740 )\-RRB-\1740 found\VBD\2426171 a\DT\13649268 correlation\NN\13841213 between\IN\1740 <e1>nimodipine-induced</e1>\JJ\1740 reduction\NN\351485 in\IN\13603305 blood\NN\5397468 pressure\NN\11419404 (\-LRB-\1740 BP\NN\1740 )\-RRB-\1740 and\CC\1740 an\DT\6697703 unfavorable\JJ\1740 outcome\NN\7291312 in\IN\13603305 acute\JJ\1740 stroke\NN\556313 .\.\1740
D009553_D020521 NONE BACKGROUND\NN\4921011 AND\CC\1740 PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 Intravenous\NNP\1740 Nimodipine\NNP\1740 West\NNP\13831000 European\NNP\9620078 Stroke\NNP\556313 Trial\NNP\786195 (\-LRB-\1740 INWEST\NN\1740 )\-RRB-\1740 found\VBD\2426171 a\DT\13649268 correlation\NN\13841213 between\IN\1740 <e1>nimodipine-induced</e1>\JJ\1740 reduction\NN\351485 in\IN\13603305 blood\NN\5397468 pressure\NN\11419404 (\-LRB-\1740 BP\NN\1740 )\-RRB-\1740 and\CC\1740 an\DT\6697703 unfavorable\JJ\1740 outcome\NN\7291312 in\IN\13603305 <e2>acute\JJ\1740 stroke</e2>\NN\556313 .\.\1740
D009553_D020521 NONE CONCLUSIONS\NNS\5837957 :\:\1740 DBP\NN\1740 ,\,\1740 but\CC\1740 not\RB\1740 SBP\NN\1740 ,\,\1740 reduction\NN\351485 was\VBD\836236 associated\VBN\628491 with\IN\1740 neurological\JJ\1740 worsening\NN\13457378 after\IN\1740 the\DT\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 high-dose\JJ\1740 <e1>nimodipine</e1>\NN\1740 after\IN\1740 <e2>acute\JJ\1740 stroke</e2>\NN\556313 .\.\1740
D009553_D007022 CID BACKGROUND\NN\4921011 AND\CC\1740 PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 Intravenous\NNP\1740 <e1>Nimodipine</e1>\NNP\1740 West\NNP\13831000 European\NNP\9620078 Stroke\NNP\556313 Trial\NNP\786195 (\-LRB-\1740 INWEST\NN\1740 )\-RRB-\1740 found\VBD\2426171 a\DT\13649268 correlation\NN\13841213 between\IN\1740 nimodipine-induced\JJ\1740 <e2>reduction\NN\351485 in\IN\13603305 blood\NN\5397468 pressure</e2>\NN\11419404 (\-LRB-\1740 BP\NN\1740 )\-RRB-\1740 and\CC\1740 an\DT\6697703 unfavorable\JJ\1740 outcome\NN\7291312 in\IN\13603305 acute\JJ\1740 stroke\NN\556313 .\.\1740
D009553_D007022 CID BACKGROUND\NN\4921011 AND\CC\1740 PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 Intravenous\NNP\1740 Nimodipine\NNP\1740 West\NNP\13831000 European\NNP\9620078 Stroke\NNP\556313 Trial\NNP\786195 (\-LRB-\1740 INWEST\NN\1740 )\-RRB-\1740 found\VBD\2426171 a\DT\13649268 correlation\NN\13841213 between\IN\1740 <e1>nimodipine-induced</e1>\JJ\1740 <e2>reduction\NN\351485 in\IN\13603305 blood\NN\5397468 pressure</e2>\NN\11419404 (\-LRB-\1740 BP\NN\1740 )\-RRB-\1740 and\CC\1740 an\DT\6697703 unfavorable\JJ\1740 outcome\NN\7291312 in\IN\13603305 acute\JJ\1740 stroke\NN\556313 .\.\1740
D009553_D007022 CID <e1>Nimodipine</e1>\NN\1740 treatment\NN\654885 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 statistically\RB\1740 significant\JJ\1740 <e2>reduction\NN\351485 in\IN\13603305 systolic\JJ\1740 BP</e2>\NN\1740 (\-LRB-\1740 SBP\NN\1740 )\-RRB-\1740 and\CC\1740 diastolic\JJ\1740 BP\NN\1740 (\-LRB-\1740 DBP\NN\1740 )\-RRB-\1740 from\IN\1740 baseline\NN\7260623 compared\VBN\644583 with\IN\1740 placebo\NN\3740161 during\IN\1740 the\DT\1740 first\JJ\1740 few\JJ\1740 days\NNS\15140892 .\.\1740
D009553_D002544 NONE METHODS\NNS\5616786 :\:\1740 Patients\NNS\9898892 with\IN\1740 a\DT\13649268 clinical\JJ\1740 diagnosis\NN\152018 of\IN\1740 <e2>ischemic\JJ\1740 stroke</e2>\NN\556313 (\-LRB-\1740 within\IN\1740 24\CD\13745420 hours\NNS\15118228 )\-RRB-\1740 were\VBD\836236 consecutively\RB\1740 allocated\VBN\2228698 to\TO\1740 receive\VB\2210855 placebo\NN\3740161 (\-LRB-\1740 n=100\NN\1740 )\-RRB-\1740 ,\,\1740 1\CD\13741022 mg/h\NN\1740 (\-LRB-\1740 low-dose\JJ\1740 )\-RRB-\1740 <e1>nimodipine</e1>\NN\1740 (\-LRB-\1740 n=101\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 2\CD\13741022 mg/h\NNS\1740 (\-LRB-\1740 high-dose\JJ\1740 )\-RRB-\1740 nimodipine\NN\1740 (\-LRB-\1740 n=94\NN\1740 )\-RRB-\1740 .\.\1740
D009553_D002544 NONE METHODS\NNS\5616786 :\:\1740 Patients\NNS\9898892 with\IN\1740 a\DT\13649268 clinical\JJ\1740 diagnosis\NN\152018 of\IN\1740 <e2>ischemic\JJ\1740 stroke</e2>\NN\556313 (\-LRB-\1740 within\IN\1740 24\CD\13745420 hours\NNS\15118228 )\-RRB-\1740 were\VBD\836236 consecutively\RB\1740 allocated\VBN\2228698 to\TO\1740 receive\VB\2210855 placebo\NN\3740161 (\-LRB-\1740 n=100\NN\1740 )\-RRB-\1740 ,\,\1740 1\CD\13741022 mg/h\NN\1740 (\-LRB-\1740 low-dose\JJ\1740 )\-RRB-\1740 nimodipine\NN\1740 (\-LRB-\1740 n=101\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 2\CD\13741022 mg/h\NNS\1740 (\-LRB-\1740 high-dose\JJ\1740 )\-RRB-\1740 <e1>nimodipine</e1>\NN\1740 (\-LRB-\1740 n=94\NN\1740 )\-RRB-\1740 .\.\1740
18464113
D019259_D006509 NONE <e1>Lamivudine</e1>\NN\3834836 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 virus\NN\9312843 reactivation\NN\1740 in\IN\13603305 hepatitis-B\NN\1740 surface\NN\21939 antigen\NN\20090 (\-LRB-\1740 HBSAG\NN\1740 )\-RRB-\1740 seropositive\JJ\1740 cancer\NN\14239425 patients\NNS\9898892 undergoing\VBG\109660 cytotoxic\JJ\1740 chemotherapy\NN\661091 .\.\1740
D019259_D006509 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 cancer\NN\14239425 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 solid\JJ\1740 and\CC\1740 hematological\JJ\1740 malignancies\NNS\14070360 with\IN\1740 chronic\JJ\1740 <e2>HBV\NN\1740 infection</e2>\NN\14052046 received\VBD\2210855 the\DT\1740 antiviral\JJ\1740 agent\NN\7347 <e1>lamivudine</e1>\NN\3834836 prior\RB\1740 and\CC\1740 during\IN\1740 CT\NN\901316 compared\VBN\644583 with\IN\1740 historical\JJ\1740 control\NN\5190804 group\NN\2137 who\WP\8299493 did\VBD\1640855 not\RB\1740 receive\VB\2210855 lamivudine\NN\3834836 .\.\1740
D019259_D006509 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 cancer\NN\14239425 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 solid\JJ\1740 and\CC\1740 hematological\JJ\1740 malignancies\NNS\14070360 with\IN\1740 chronic\JJ\1740 <e2>HBV\NN\1740 infection</e2>\NN\14052046 received\VBD\2210855 the\DT\1740 antiviral\JJ\1740 agent\NN\7347 lamivudine\NN\3834836 prior\RB\1740 and\CC\1740 during\IN\1740 CT\NN\901316 compared\VBN\644583 with\IN\1740 historical\JJ\1740 control\NN\5190804 group\NN\2137 who\WP\8299493 did\VBD\1640855 not\RB\1740 receive\VB\2210855 <e1>lamivudine</e1>\NN\3834836 .\.\1740
D019259_D009369 NONE <e1>Lamivudine</e1>\NN\3834836 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 hepatitis\NN\14127211 B\NN\1355326 virus\NN\9312843 reactivation\NN\1740 in\IN\13603305 hepatitis-B\NN\1740 surface\NN\21939 antigen\NN\20090 (\-LRB-\1740 HBSAG\NN\1740 )\-RRB-\1740 seropositive\JJ\1740 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 undergoing\VBG\109660 cytotoxic\JJ\1740 chemotherapy\NN\661091 .\.\1740
D019259_D009369 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 solid\JJ\1740 and\CC\1740 hematological\JJ\1740 malignancies\NNS\14070360 with\IN\1740 chronic\JJ\1740 HBV\NN\1740 infection\NN\14052046 received\VBD\2210855 the\DT\1740 antiviral\JJ\1740 agent\NN\7347 <e1>lamivudine</e1>\NN\3834836 prior\RB\1740 and\CC\1740 during\IN\1740 CT\NN\901316 compared\VBN\644583 with\IN\1740 historical\JJ\1740 control\NN\5190804 group\NN\2137 who\WP\8299493 did\VBD\1640855 not\RB\1740 receive\VB\2210855 lamivudine\NN\3834836 .\.\1740
D019259_D009369 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 solid\JJ\1740 and\CC\1740 hematological\JJ\1740 malignancies\NNS\14070360 with\IN\1740 chronic\JJ\1740 HBV\NN\1740 infection\NN\14052046 received\VBD\2210855 the\DT\1740 antiviral\JJ\1740 agent\NN\7347 lamivudine\NN\3834836 prior\RB\1740 and\CC\1740 during\IN\1740 CT\NN\901316 compared\VBN\644583 with\IN\1740 historical\JJ\1740 control\NN\5190804 group\NN\2137 who\WP\8299493 did\VBD\1640855 not\RB\1740 receive\VB\2210855 <e1>lamivudine</e1>\NN\3834836 .\.\1740
D019259_D009369 NONE Our\PRP$\1740 study\NN\635850 suggests\VBZ\1010118 that\IN\1740 prophylactic\JJ\1740 <e1>lamivudine</e1>\NN\3834836 significantly\RB\1740 decreases\VBZ\169651 the\DT\1740 incidence\NN\13821570 of\IN\1740 HBV\NN\1740 reactivation\NN\1740 and\CC\1740 overall\JJ\1740 morbidity\NN\13826959 in\IN\13603305 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 during\IN\1740 and\CC\1740 after\IN\1740 immunosuppressive\JJ\1740 therapy\NN\657604 .\.\1740
D006514_D006509 CID Lamivudine\NN\3834836 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 virus\NN\9312843 reactivation\NN\1740 in\IN\13603305 <e1>hepatitis-B\NN\1740 surface\NN\21939 antigen</e1>\NN\20090 (\-LRB-\1740 HBSAG\NN\1740 )\-RRB-\1740 seropositive\JJ\1740 cancer\NN\14239425 patients\NNS\9898892 undergoing\VBG\109660 cytotoxic\JJ\1740 chemotherapy\NN\661091 .\.\1740
D006514_D006509 CID Lamivudine\NN\3834836 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 virus\NN\9312843 reactivation\NN\1740 in\IN\13603305 hepatitis-B\NN\1740 surface\NN\21939 antigen\NN\20090 (\-LRB-\1740 <e1>HBSAG</e1>\NN\1740 )\-RRB-\1740 seropositive\JJ\1740 cancer\NN\14239425 patients\NNS\9898892 undergoing\VBG\109660 cytotoxic\JJ\1740 chemotherapy\NN\661091 .\.\1740
D006514_D009369 NONE Lamivudine\NN\3834836 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 hepatitis\NN\14127211 B\NN\1355326 virus\NN\9312843 reactivation\NN\1740 in\IN\13603305 <e1>hepatitis-B\NN\1740 surface\NN\21939 antigen</e1>\NN\20090 (\-LRB-\1740 HBSAG\NN\1740 )\-RRB-\1740 seropositive\JJ\1740 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 undergoing\VBG\109660 cytotoxic\JJ\1740 chemotherapy\NN\661091 .\.\1740
D006514_D009369 NONE Lamivudine\NN\3834836 for\IN\1740 the\DT\1740 prevention\NN\1073995 of\IN\1740 hepatitis\NN\14127211 B\NN\1355326 virus\NN\9312843 reactivation\NN\1740 in\IN\13603305 hepatitis-B\NN\1740 surface\NN\21939 antigen\NN\20090 (\-LRB-\1740 <e1>HBSAG</e1>\NN\1740 )\-RRB-\1740 seropositive\JJ\1740 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 undergoing\VBG\109660 cytotoxic\JJ\1740 chemotherapy\NN\661091 .\.\1740
D019259_D019337 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 cancer\NN\14239425 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 solid\JJ\1740 and\CC\1740 <e2>hematological\JJ\1740 malignancies</e2>\NNS\14070360 with\IN\1740 chronic\JJ\1740 HBV\NN\1740 infection\NN\14052046 received\VBD\2210855 the\DT\1740 antiviral\JJ\1740 agent\NN\7347 <e1>lamivudine</e1>\NN\3834836 prior\RB\1740 and\CC\1740 during\IN\1740 CT\NN\901316 compared\VBN\644583 with\IN\1740 historical\JJ\1740 control\NN\5190804 group\NN\2137 who\WP\8299493 did\VBD\1640855 not\RB\1740 receive\VB\2210855 lamivudine\NN\3834836 .\.\1740
D019259_D019337 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 cancer\NN\14239425 patients\NNS\9898892 who\WP\8299493 have\VBP\2108377 solid\JJ\1740 and\CC\1740 <e2>hematological\JJ\1740 malignancies</e2>\NNS\14070360 with\IN\1740 chronic\JJ\1740 HBV\NN\1740 infection\NN\14052046 received\VBD\2210855 the\DT\1740 antiviral\JJ\1740 agent\NN\7347 lamivudine\NN\3834836 prior\RB\1740 and\CC\1740 during\IN\1740 CT\NN\901316 compared\VBN\644583 with\IN\1740 historical\JJ\1740 control\NN\5190804 group\NN\2137 who\WP\8299493 did\VBD\1640855 not\RB\1740 receive\VB\2210855 <e1>lamivudine</e1>\NN\3834836 .\.\1740
D019259_D056486 NONE In\IN\13603305 the\DT\1740 prophylactic\JJ\1740 <e1>lamivudine</e1>\NN\3834836 group\NN\2137 severe\JJ\1740 <e2>hepatitis</e2>\NN\14127211 were\VBD\836236 observed\VBN\2163746 only\RB\1740 in\IN\13603305 1\CD\13741022 patient\NN\9898892 (\-LRB-\1740 2.7\CD\1740 %\NN\1740 )\-RRB-\1740 of\IN\1740 37\CD\1740 patients\NNS\9898892 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.006\CD\1740 )\-RRB-\1740 .\.\1740
2924746
D002220_D064420 NONE Chronic\JJ\1740 <e1>carbamazepine</e1>\NN\1740 treatment\NN\654885 in\IN\13603305 the\DT\1740 rat\NN\2329401 :\:\1740 efficacy\NN\5199286 ,\,\1740 <e2>toxicity</e2>\NN\13576101 ,\,\1740 and\CC\1740 effect\NN\34213 on\IN\1740 plasma\NN\5398023 and\CC\1740 tissue\NN\5220461 folate\NN\15090742 concentrations\NNS\4916342 .\.\1740
D005492_D064420 NONE Chronic\JJ\1740 carbamazepine\NN\1740 treatment\NN\654885 in\IN\13603305 the\DT\1740 rat\NN\2329401 :\:\1740 efficacy\NN\5199286 ,\,\1740 <e2>toxicity</e2>\NN\13576101 ,\,\1740 and\CC\1740 effect\NN\34213 on\IN\1740 plasma\NN\5398023 and\CC\1740 tissue\NN\5220461 <e1>folate</e1>\NN\15090742 concentrations\NNS\4916342 .\.\1740
D019946_D012640 NONE In\IN\13603305 the\DT\1740 course\NN\883297 of\IN\1740 developing\VBG\1753788 this\DT\1740 model\NN\5888929 ,\,\1740 a\DT\13649268 common\JJ\1740 vehicle\NN\3100490 ,\,\1740 <e1>propylene\NN\14877585 glycol</e1>\NN\14766364 ,\,\1740 by\IN\1740 itself\PRP\1740 in\IN\13603305 high\JJ\1740 doses\NNS\3740161 ,\,\1740 was\VBD\836236 found\VBN\2426171 to\TO\1740 exhibit\VB\2632167 protective\JJ\1740 properties\NNS\32613 against\IN\1740 induced\VBN\1627355 <e2>seizures</e2>\NNS\14081375 and\CC\1740 inhibited\VBD\2510337 weight\NN\5009170 gain\NN\13576355 .\.\1740
D019946_D015430 NONE In\IN\13603305 the\DT\1740 course\NN\883297 of\IN\1740 developing\VBG\1753788 this\DT\1740 model\NN\5888929 ,\,\1740 a\DT\13649268 common\JJ\1740 vehicle\NN\3100490 ,\,\1740 <e1>propylene\NN\14877585 glycol</e1>\NN\14766364 ,\,\1740 by\IN\1740 itself\PRP\1740 in\IN\13603305 high\JJ\1740 doses\NNS\3740161 ,\,\1740 was\VBD\836236 found\VBN\2426171 to\TO\1740 exhibit\VB\2632167 protective\JJ\1740 properties\NNS\32613 against\IN\1740 induced\VBN\1627355 seizures\NNS\14081375 and\CC\1740 inhibited\VBD\2510337 <e2>weight\NN\5009170 gain</e2>\NN\13576355 .\.\1740
D005481_D012640 CID <e2>Seizures</e2>\NNP\14081375 induced\VBN\1627355 by\IN\1740 <e1>hexafluorodiethyl\JJ\1740 ether</e1>\NN\14840755 (\-LRB-\1740 HFDE\NN\1740 )\-RRB-\1740 were\VBD\836236 also\RB\1740 found\VBN\2426171 to\TO\1740 be\VB\836236 a\DT\13649268 more\RBR\1740 sensitive\JJ\1740 measure\NN\168237 of\IN\1740 protection\NN\407535 by\IN\1740 CBZ\NN\1740 than\IN\1740 seizures\NNS\14081375 induced\VBN\1627355 by\IN\1740 maximal\JJ\1740 electroshock\NN\662681 (\-LRB-\1740 MES\NN\1740 )\-RRB-\1740 .\.\1740
D005481_D012640 CID Seizures\NNP\14081375 induced\VBN\1627355 by\IN\1740 <e1>hexafluorodiethyl\JJ\1740 ether</e1>\NN\14840755 (\-LRB-\1740 HFDE\NN\1740 )\-RRB-\1740 were\VBD\836236 also\RB\1740 found\VBN\2426171 to\TO\1740 be\VB\836236 a\DT\13649268 more\RBR\1740 sensitive\JJ\1740 measure\NN\168237 of\IN\1740 protection\NN\407535 by\IN\1740 CBZ\NN\1740 than\IN\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 maximal\JJ\1740 electroshock\NN\662681 (\-LRB-\1740 MES\NN\1740 )\-RRB-\1740 .\.\1740
D005481_D012640 CID <e2>Seizures</e2>\NNP\14081375 induced\VBN\1627355 by\IN\1740 hexafluorodiethyl\JJ\1740 ether\NN\14840755 (\-LRB-\1740 <e1>HFDE</e1>\NN\1740 )\-RRB-\1740 were\VBD\836236 also\RB\1740 found\VBN\2426171 to\TO\1740 be\VB\836236 a\DT\13649268 more\RBR\1740 sensitive\JJ\1740 measure\NN\168237 of\IN\1740 protection\NN\407535 by\IN\1740 CBZ\NN\1740 than\IN\1740 seizures\NNS\14081375 induced\VBN\1627355 by\IN\1740 maximal\JJ\1740 electroshock\NN\662681 (\-LRB-\1740 MES\NN\1740 )\-RRB-\1740 .\.\1740
D005481_D012640 CID Seizures\NNP\14081375 induced\VBN\1627355 by\IN\1740 hexafluorodiethyl\JJ\1740 ether\NN\14840755 (\-LRB-\1740 <e1>HFDE</e1>\NN\1740 )\-RRB-\1740 were\VBD\836236 also\RB\1740 found\VBN\2426171 to\TO\1740 be\VB\836236 a\DT\13649268 more\RBR\1740 sensitive\JJ\1740 measure\NN\168237 of\IN\1740 protection\NN\407535 by\IN\1740 CBZ\NN\1740 than\IN\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 maximal\JJ\1740 electroshock\NN\662681 (\-LRB-\1740 MES\NN\1740 )\-RRB-\1740 .\.\1740
D005481_D012640 CID Oral\JJ\1740 administration\NN\1133281 of\IN\1740 CBZ\NN\1740 as\IN\14622893 an\DT\6697703 aqueous\JJ\1740 suspension\NN\14586258 every\DT\1740 8\CD\13741022 h\NN\14622893 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 250\CD\1740 mg/kg\NN\1740 was\VBD\836236 continuously\RB\1740 protective\JJ\1740 against\IN\1740 <e1>HFDE-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 was\VBD\836236 minimally\RB\1740 toxic\JJ\1740 as\IN\14622893 measured\VBN\697589 by\IN\1740 weight\NN\5009170 gain\NN\13576355 over\IN\5867413 8\CD\13741022 weeks\NNS\15113229 of\IN\1740 treatment\NN\654885 .\.\1740
D002220_D012640 NONE <e2>Seizures</e2>\NNP\14081375 induced\VBN\1627355 by\IN\1740 hexafluorodiethyl\JJ\1740 ether\NN\14840755 (\-LRB-\1740 HFDE\NN\1740 )\-RRB-\1740 were\VBD\836236 also\RB\1740 found\VBN\2426171 to\TO\1740 be\VB\836236 a\DT\13649268 more\RBR\1740 sensitive\JJ\1740 measure\NN\168237 of\IN\1740 protection\NN\407535 by\IN\1740 <e1>CBZ</e1>\NN\1740 than\IN\1740 seizures\NNS\14081375 induced\VBN\1627355 by\IN\1740 maximal\JJ\1740 electroshock\NN\662681 (\-LRB-\1740 MES\NN\1740 )\-RRB-\1740 .\.\1740
D002220_D012640 NONE Seizures\NNP\14081375 induced\VBN\1627355 by\IN\1740 hexafluorodiethyl\JJ\1740 ether\NN\14840755 (\-LRB-\1740 HFDE\NN\1740 )\-RRB-\1740 were\VBD\836236 also\RB\1740 found\VBN\2426171 to\TO\1740 be\VB\836236 a\DT\13649268 more\RBR\1740 sensitive\JJ\1740 measure\NN\168237 of\IN\1740 protection\NN\407535 by\IN\1740 <e1>CBZ</e1>\NN\1740 than\IN\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 maximal\JJ\1740 electroshock\NN\662681 (\-LRB-\1740 MES\NN\1740 )\-RRB-\1740 .\.\1740
D002220_D012640 NONE Oral\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>CBZ</e1>\NN\1740 as\IN\14622893 an\DT\6697703 aqueous\JJ\1740 suspension\NN\14586258 every\DT\1740 8\CD\13741022 h\NN\14622893 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 250\CD\1740 mg/kg\NN\1740 was\VBD\836236 continuously\RB\1740 protective\JJ\1740 against\IN\1740 HFDE-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 was\VBD\836236 minimally\RB\1740 toxic\JJ\1740 as\IN\14622893 measured\VBN\697589 by\IN\1740 weight\NN\5009170 gain\NN\13576355 over\IN\5867413 8\CD\13741022 weeks\NNS\15113229 of\IN\1740 treatment\NN\654885 .\.\1740
D002220_D015430 NONE Oral\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>CBZ</e1>\NN\1740 as\IN\14622893 an\DT\6697703 aqueous\JJ\1740 suspension\NN\14586258 every\DT\1740 8\CD\13741022 h\NN\14622893 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 250\CD\1740 mg/kg\NN\1740 was\VBD\836236 continuously\RB\1740 protective\JJ\1740 against\IN\1740 HFDE-induced\JJ\1740 seizures\NNS\14081375 and\CC\1740 was\VBD\836236 minimally\RB\1740 toxic\JJ\1740 as\IN\14622893 measured\VBN\697589 by\IN\1740 <e2>weight\NN\5009170 gain</e2>\NN\13576355 over\IN\5867413 8\CD\13741022 weeks\NNS\15113229 of\IN\1740 treatment\NN\654885 .\.\1740
D005481_D015430 NONE Oral\JJ\1740 administration\NN\1133281 of\IN\1740 CBZ\NN\1740 as\IN\14622893 an\DT\6697703 aqueous\JJ\1740 suspension\NN\14586258 every\DT\1740 8\CD\13741022 h\NN\14622893 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 250\CD\1740 mg/kg\NN\1740 was\VBD\836236 continuously\RB\1740 protective\JJ\1740 against\IN\1740 <e1>HFDE-induced</e1>\JJ\1740 seizures\NNS\14081375 and\CC\1740 was\VBD\836236 minimally\RB\1740 toxic\JJ\1740 as\IN\14622893 measured\VBN\697589 by\IN\1740 <e2>weight\NN\5009170 gain</e2>\NN\13576355 over\IN\5867413 8\CD\13741022 weeks\NNS\15113229 of\IN\1740 treatment\NN\654885 .\.\1740
2224762
C027260_D009369 NONE A\DT\13649268 Phase\NN\15113229 I\CD\14622893 study\NN\635850 of\IN\1740 intravenous\JJ\1740 (\-LRB-\1740 IV\CD\13741022 )\-RRB-\1740 bolus\NN\13899404 <e1>4'-0-tetrahydropyranyladriamycin</e1>\CD\1740 (\-LRB-\1740 Pirarubicin\NN\1740 )\-RRB-\1740 was\VBD\836236 done\VBN\1640855 in\IN\13603305 55\CD\1740 patients\NNS\9898892 in\IN\13603305 good\JJ\1740 performance\NN\6619065 status\NN\24720 with\IN\1740 refractory\JJ\1740 <e2>tumors</e2>\NNS\14234074 .\.\1740
C027260_D009369 NONE A\DT\13649268 Phase\NN\15113229 I\CD\14622893 study\NN\635850 of\IN\1740 intravenous\JJ\1740 (\-LRB-\1740 IV\CD\13741022 )\-RRB-\1740 bolus\NN\13899404 4'-0-tetrahydropyranyladriamycin\CD\1740 (\-LRB-\1740 <e1>Pirarubicin</e1>\NN\1740 )\-RRB-\1740 was\VBD\836236 done\VBN\1640855 in\IN\13603305 55\CD\1740 patients\NNS\9898892 in\IN\13603305 good\JJ\1740 performance\NN\6619065 status\NN\24720 with\IN\1740 refractory\JJ\1740 <e2>tumors</e2>\NNS\14234074 .\.\1740
10721819
D007545_D013610 NONE Effects\NNS\13245626 of\IN\1740 long-term\JJ\1740 pretreatment\NN\1740 with\IN\1740 <e1>isoproterenol</e1>\NN\3740161 on\IN\1740 bromocriptine-induced\JJ\1740 <e2>tachycardia</e2>\NN\14110674 in\IN\13603305 conscious\JJ\1740 rats\NNS\2329401 .\.\1740
D007545_D013610 NONE It\PRP\6125041 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 that\IN\1740 bromocriptine-induced\JJ\1740 <e2>tachycardia</e2>\NN\14110674 ,\,\1740 which\WDT\1740 persisted\VBD\118523 after\IN\1740 adrenalectomy\NN\393369 ,\,\1740 is\VBZ\836236 (\-LRB-\1740 i\LS\14622893 )\-RRB-\1740 mediated\VBN\761713 by\IN\1740 central\JJ\1740 dopamine\NN\14807737 D2\NN\1740 receptor\NN\5225602 activation\NN\13561719 and\CC\1740 (\-LRB-\1740 ii\LS\13741022 )\-RRB-\1740 reduced\VBN\441445 by\IN\1740 5-day\JJ\1740 <e1>isoproterenol</e1>\NN\3740161 pretreatment\NN\1740 ,\,\1740 supporting\VBG\2199590 therefore\RB\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 this\DT\1740 effect\NN\34213 is\VBZ\836236 dependent\JJ\1740 on\IN\1740 sympathetic\JJ\1740 outflow\NN\7407777 to\IN\1740 the\DT\1740 heart\NN\5919034 .\.\1740
D007545_D013610 NONE This\DT\1740 study\NN\635850 was\VBD\836236 conducted\VBN\2436349 to\TO\1740 examine\VB\789138 whether\IN\1740 prolonged\JJ\1740 pretreatment\NN\1740 with\IN\1740 <e1>isoproterenol</e1>\NN\3740161 could\MD\1740 abolish\VB\1740 bromocriptine-induced\JJ\1740 <e2>tachycardia</e2>\NN\14110674 in\IN\13603305 conscious\JJ\1740 rats\NNS\2329401 .\.\1740
D007545_D013610 NONE Bromocriptine-induced\JJ\1740 hypotension\NN\14057371 was\VBD\836236 unaffected\JJ\1740 by\IN\1740 <e1>isoproterenol</e1>\NN\3740161 pretreatment\NN\1740 ,\,\1740 while\IN\15122231 <e2>tachycardia</e2>\NN\14110674 was\VBD\836236 reversed\VBN\109660 to\TO\1740 significant\JJ\1740 bradycardia\NN\14110674 ,\,\1740 an\DT\6697703 effect\NN\34213 that\WDT\1740 was\VBD\836236 partly\RB\1740 reduced\VBN\441445 by\IN\1740 i.v.\NN\1740 domperidone\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 .\.\1740
D007545_D013610 NONE These\DT\1740 results\NNS\34213 show\VBP\2137132 that\IN\1740 15-day\JJ\1740 <e1>isoproterenol</e1>\NN\3740161 pretreatment\NN\1740 not\RB\1740 only\RB\1740 abolished\VBD\1740 but\CC\1740 reversed\VBN\109660 bromocriptine-induced\JJ\1740 <e2>tachycardia</e2>\NN\14110674 to\TO\1740 bradycardia\NN\14110674 ,\,\1740 an\DT\6697703 effect\NN\34213 that\WDT\1740 is\VBZ\836236 mainly\RB\1740 related\JJ\1740 to\TO\1740 further\RB\1740 cardiac\JJ\1740 beta-adrenoceptor\NN\5608868 desensitization\NN\13458571 rather\RB\1740 than\IN\1740 to\TO\1740 impairment\NN\7296428 of\IN\1740 autonomic\JJ\1740 regulation\NN\6652242 of\IN\1740 the\DT\1740 heart\NN\5919034 .\.\1740
D001971_D013610 CID Effects\NNS\13245626 of\IN\1740 long-term\JJ\1740 pretreatment\NN\1740 with\IN\1740 isoproterenol\NN\3740161 on\IN\1740 <e1>bromocriptine-induced</e1>\JJ\1740 <e2>tachycardia</e2>\NN\14110674 in\IN\13603305 conscious\JJ\1740 rats\NNS\2329401 .\.\1740
D001971_D013610 CID It\PRP\6125041 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 that\IN\1740 <e1>bromocriptine-induced</e1>\JJ\1740 <e2>tachycardia</e2>\NN\14110674 ,\,\1740 which\WDT\1740 persisted\VBD\118523 after\IN\1740 adrenalectomy\NN\393369 ,\,\1740 is\VBZ\836236 (\-LRB-\1740 i\LS\14622893 )\-RRB-\1740 mediated\VBN\761713 by\IN\1740 central\JJ\1740 dopamine\NN\14807737 D2\NN\1740 receptor\NN\5225602 activation\NN\13561719 and\CC\1740 (\-LRB-\1740 ii\LS\13741022 )\-RRB-\1740 reduced\VBN\441445 by\IN\1740 5-day\JJ\1740 isoproterenol\NN\3740161 pretreatment\NN\1740 ,\,\1740 supporting\VBG\2199590 therefore\RB\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 this\DT\1740 effect\NN\34213 is\VBZ\836236 dependent\JJ\1740 on\IN\1740 sympathetic\JJ\1740 outflow\NN\7407777 to\IN\1740 the\DT\1740 heart\NN\5919034 .\.\1740
D001971_D013610 CID This\DT\1740 study\NN\635850 was\VBD\836236 conducted\VBN\2436349 to\TO\1740 examine\VB\789138 whether\IN\1740 prolonged\JJ\1740 pretreatment\NN\1740 with\IN\1740 isoproterenol\NN\3740161 could\MD\1740 abolish\VB\1740 <e1>bromocriptine-induced</e1>\JJ\1740 <e2>tachycardia</e2>\NN\14110674 in\IN\13603305 conscious\JJ\1740 rats\NNS\2329401 .\.\1740
D001971_D013610 CID In\IN\13603305 control\JJ\1740 rats\NNS\2329401 ,\,\1740 intravenous\JJ\1740 <e1>bromocriptine</e1>\NN\1740 (\-LRB-\1740 150\CD\1740 microg/kg\NNS\1740 )\-RRB-\1740 induced\VBD\1627355 significant\JJ\1740 hypotension\NN\14057371 and\CC\1740 <e2>tachycardia</e2>\NN\14110674 .\.\1740
D001971_D013610 CID <e1>Bromocriptine-induced</e1>\JJ\1740 hypotension\NN\14057371 was\VBD\836236 unaffected\JJ\1740 by\IN\1740 isoproterenol\NN\3740161 pretreatment\NN\1740 ,\,\1740 while\IN\15122231 <e2>tachycardia</e2>\NN\14110674 was\VBD\836236 reversed\VBN\109660 to\TO\1740 significant\JJ\1740 bradycardia\NN\14110674 ,\,\1740 an\DT\6697703 effect\NN\34213 that\WDT\1740 was\VBD\836236 partly\RB\1740 reduced\VBN\441445 by\IN\1740 i.v.\NN\1740 domperidone\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 .\.\1740
D001971_D013610 CID These\DT\1740 results\NNS\34213 show\VBP\2137132 that\IN\1740 15-day\JJ\1740 isoproterenol\NN\3740161 pretreatment\NN\1740 not\RB\1740 only\RB\1740 abolished\VBD\1740 but\CC\1740 reversed\VBN\109660 <e1>bromocriptine-induced</e1>\JJ\1740 <e2>tachycardia</e2>\NN\14110674 to\TO\1740 bradycardia\NN\14110674 ,\,\1740 an\DT\6697703 effect\NN\34213 that\WDT\1740 is\VBZ\836236 mainly\RB\1740 related\JJ\1740 to\TO\1740 further\RB\1740 cardiac\JJ\1740 beta-adrenoceptor\NN\5608868 desensitization\NN\13458571 rather\RB\1740 than\IN\1740 to\TO\1740 impairment\NN\7296428 of\IN\1740 autonomic\JJ\1740 regulation\NN\6652242 of\IN\1740 the\DT\1740 heart\NN\5919034 .\.\1740
D001971_D013610 CID They\PRP\1740 suggest\VBP\1010118 that\IN\1740 ,\,\1740 in\IN\13603305 normal\JJ\1740 conscious\JJ\1740 rats\NNS\2329401 ,\,\1740 the\DT\1740 central\JJ\1740 <e2>tachycardia</e2>\NN\14110674 of\IN\1740 <e1>bromocriptine</e1>\NN\1740 appears\VBZ\2604760 to\TO\1740 predominate\VB\2696801 and\CC\1740 to\TO\1740 mask\VB\2158587 the\DT\1740 bradycardia\NN\14110674 of\IN\1740 this\DT\1740 agonist\NN\9613191 at\IN\14622893 peripheral\JJ\1740 dopamine\NN\14807737 D2\NN\1740 receptors\NNS\5225602 .\.\1740
D004298_D013610 NONE It\PRP\6125041 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 that\IN\1740 bromocriptine-induced\JJ\1740 <e2>tachycardia</e2>\NN\14110674 ,\,\1740 which\WDT\1740 persisted\VBD\118523 after\IN\1740 adrenalectomy\NN\393369 ,\,\1740 is\VBZ\836236 (\-LRB-\1740 i\LS\14622893 )\-RRB-\1740 mediated\VBN\761713 by\IN\1740 central\JJ\1740 <e1>dopamine</e1>\NN\14807737 D2\NN\1740 receptor\NN\5225602 activation\NN\13561719 and\CC\1740 (\-LRB-\1740 ii\LS\13741022 )\-RRB-\1740 reduced\VBN\441445 by\IN\1740 5-day\JJ\1740 isoproterenol\NN\3740161 pretreatment\NN\1740 ,\,\1740 supporting\VBG\2199590 therefore\RB\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 this\DT\1740 effect\NN\34213 is\VBZ\836236 dependent\JJ\1740 on\IN\1740 sympathetic\JJ\1740 outflow\NN\7407777 to\IN\1740 the\DT\1740 heart\NN\5919034 .\.\1740
D004298_D013610 NONE They\PRP\1740 suggest\VBP\1010118 that\IN\1740 ,\,\1740 in\IN\13603305 normal\JJ\1740 conscious\JJ\1740 rats\NNS\2329401 ,\,\1740 the\DT\1740 central\JJ\1740 <e2>tachycardia</e2>\NN\14110674 of\IN\1740 bromocriptine\NN\1740 appears\VBZ\2604760 to\TO\1740 predominate\VB\2696801 and\CC\1740 to\TO\1740 mask\VB\2158587 the\DT\1740 bradycardia\NN\14110674 of\IN\1740 this\DT\1740 agonist\NN\9613191 at\IN\14622893 peripheral\JJ\1740 <e1>dopamine</e1>\NN\14807737 D2\NN\1740 receptors\NNS\5225602 .\.\1740
D007545_D006332 CID <e1>Isoproterenol</e1>\NN\3740161 pretreatment\NN\1740 for\IN\1740 15\CD\13745420 days\NNS\15140892 caused\VBD\1617192 <e2>cardiac\JJ\1740 hypertrophy</e2>\NN\14365950 without\IN\1740 affecting\VBG\126264 baseline\NN\7260623 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 heart\NN\5919034 rate\NN\13815152 .\.\1740
D001971_D007022 CID In\IN\13603305 control\JJ\1740 rats\NNS\2329401 ,\,\1740 intravenous\JJ\1740 <e1>bromocriptine</e1>\NN\1740 (\-LRB-\1740 150\CD\1740 microg/kg\NNS\1740 )\-RRB-\1740 induced\VBD\1627355 significant\JJ\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 tachycardia\NN\14110674 .\.\1740
D001971_D007022 CID <e1>Bromocriptine-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 was\VBD\836236 unaffected\JJ\1740 by\IN\1740 isoproterenol\NN\3740161 pretreatment\NN\1740 ,\,\1740 while\IN\15122231 tachycardia\NN\14110674 was\VBD\836236 reversed\VBN\109660 to\TO\1740 significant\JJ\1740 bradycardia\NN\14110674 ,\,\1740 an\DT\6697703 effect\NN\34213 that\WDT\1740 was\VBD\836236 partly\RB\1740 reduced\VBN\441445 by\IN\1740 i.v.\NN\1740 domperidone\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 .\.\1740
D001971_D001919 NONE <e1>Bromocriptine-induced</e1>\JJ\1740 hypotension\NN\14057371 was\VBD\836236 unaffected\JJ\1740 by\IN\1740 isoproterenol\NN\3740161 pretreatment\NN\1740 ,\,\1740 while\IN\15122231 tachycardia\NN\14110674 was\VBD\836236 reversed\VBN\109660 to\TO\1740 significant\JJ\1740 <e2>bradycardia</e2>\NN\14110674 ,\,\1740 an\DT\6697703 effect\NN\34213 that\WDT\1740 was\VBD\836236 partly\RB\1740 reduced\VBN\441445 by\IN\1740 i.v.\NN\1740 domperidone\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 .\.\1740
D001971_D001919 NONE These\DT\1740 results\NNS\34213 show\VBP\2137132 that\IN\1740 15-day\JJ\1740 isoproterenol\NN\3740161 pretreatment\NN\1740 not\RB\1740 only\RB\1740 abolished\VBD\1740 but\CC\1740 reversed\VBN\109660 <e1>bromocriptine-induced</e1>\JJ\1740 tachycardia\NN\14110674 to\TO\1740 <e2>bradycardia</e2>\NN\14110674 ,\,\1740 an\DT\6697703 effect\NN\34213 that\WDT\1740 is\VBZ\836236 mainly\RB\1740 related\JJ\1740 to\TO\1740 further\RB\1740 cardiac\JJ\1740 beta-adrenoceptor\NN\5608868 desensitization\NN\13458571 rather\RB\1740 than\IN\1740 to\TO\1740 impairment\NN\7296428 of\IN\1740 autonomic\JJ\1740 regulation\NN\6652242 of\IN\1740 the\DT\1740 heart\NN\5919034 .\.\1740
D001971_D001919 NONE They\PRP\1740 suggest\VBP\1010118 that\IN\1740 ,\,\1740 in\IN\13603305 normal\JJ\1740 conscious\JJ\1740 rats\NNS\2329401 ,\,\1740 the\DT\1740 central\JJ\1740 tachycardia\NN\14110674 of\IN\1740 <e1>bromocriptine</e1>\NN\1740 appears\VBZ\2604760 to\TO\1740 predominate\VB\2696801 and\CC\1740 to\TO\1740 mask\VB\2158587 the\DT\1740 <e2>bradycardia</e2>\NN\14110674 of\IN\1740 this\DT\1740 agonist\NN\9613191 at\IN\14622893 peripheral\JJ\1740 dopamine\NN\14807737 D2\NN\1740 receptors\NNS\5225602 .\.\1740
D007545_D007022 NONE Bromocriptine-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 was\VBD\836236 unaffected\JJ\1740 by\IN\1740 <e1>isoproterenol</e1>\NN\3740161 pretreatment\NN\1740 ,\,\1740 while\IN\15122231 tachycardia\NN\14110674 was\VBD\836236 reversed\VBN\109660 to\TO\1740 significant\JJ\1740 bradycardia\NN\14110674 ,\,\1740 an\DT\6697703 effect\NN\34213 that\WDT\1740 was\VBD\836236 partly\RB\1740 reduced\VBN\441445 by\IN\1740 i.v.\NN\1740 domperidone\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 .\.\1740
D007545_D001919 CID Bromocriptine-induced\JJ\1740 hypotension\NN\14057371 was\VBD\836236 unaffected\JJ\1740 by\IN\1740 <e1>isoproterenol</e1>\NN\3740161 pretreatment\NN\1740 ,\,\1740 while\IN\15122231 tachycardia\NN\14110674 was\VBD\836236 reversed\VBN\109660 to\TO\1740 significant\JJ\1740 <e2>bradycardia</e2>\NN\14110674 ,\,\1740 an\DT\6697703 effect\NN\34213 that\WDT\1740 was\VBD\836236 partly\RB\1740 reduced\VBN\441445 by\IN\1740 i.v.\NN\1740 domperidone\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 .\.\1740
D007545_D001919 CID These\DT\1740 results\NNS\34213 show\VBP\2137132 that\IN\1740 15-day\JJ\1740 <e1>isoproterenol</e1>\NN\3740161 pretreatment\NN\1740 not\RB\1740 only\RB\1740 abolished\VBD\1740 but\CC\1740 reversed\VBN\109660 bromocriptine-induced\JJ\1740 tachycardia\NN\14110674 to\TO\1740 <e2>bradycardia</e2>\NN\14110674 ,\,\1740 an\DT\6697703 effect\NN\34213 that\WDT\1740 is\VBZ\836236 mainly\RB\1740 related\JJ\1740 to\TO\1740 further\RB\1740 cardiac\JJ\1740 beta-adrenoceptor\NN\5608868 desensitization\NN\13458571 rather\RB\1740 than\IN\1740 to\TO\1740 impairment\NN\7296428 of\IN\1740 autonomic\JJ\1740 regulation\NN\6652242 of\IN\1740 the\DT\1740 heart\NN\5919034 .\.\1740
D004294_D007022 NONE Bromocriptine-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 was\VBD\836236 unaffected\JJ\1740 by\IN\1740 isoproterenol\NN\3740161 pretreatment\NN\1740 ,\,\1740 while\IN\15122231 tachycardia\NN\14110674 was\VBD\836236 reversed\VBN\109660 to\TO\1740 significant\JJ\1740 bradycardia\NN\14110674 ,\,\1740 an\DT\6697703 effect\NN\34213 that\WDT\1740 was\VBD\836236 partly\RB\1740 reduced\VBN\441445 by\IN\1740 i.v.\NN\1740 <e1>domperidone</e1>\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 .\.\1740
D004294_D013610 NONE Bromocriptine-induced\JJ\1740 hypotension\NN\14057371 was\VBD\836236 unaffected\JJ\1740 by\IN\1740 isoproterenol\NN\3740161 pretreatment\NN\1740 ,\,\1740 while\IN\15122231 <e2>tachycardia</e2>\NN\14110674 was\VBD\836236 reversed\VBN\109660 to\TO\1740 significant\JJ\1740 bradycardia\NN\14110674 ,\,\1740 an\DT\6697703 effect\NN\34213 that\WDT\1740 was\VBD\836236 partly\RB\1740 reduced\VBN\441445 by\IN\1740 i.v.\NN\1740 <e1>domperidone</e1>\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 .\.\1740
D004294_D001919 CID Bromocriptine-induced\JJ\1740 hypotension\NN\14057371 was\VBD\836236 unaffected\JJ\1740 by\IN\1740 isoproterenol\NN\3740161 pretreatment\NN\1740 ,\,\1740 while\IN\15122231 tachycardia\NN\14110674 was\VBD\836236 reversed\VBN\109660 to\TO\1740 significant\JJ\1740 <e2>bradycardia</e2>\NN\14110674 ,\,\1740 an\DT\6697703 effect\NN\34213 that\WDT\1740 was\VBD\836236 partly\RB\1740 reduced\VBN\441445 by\IN\1740 i.v.\NN\1740 <e1>domperidone</e1>\NN\1740 (\-LRB-\1740 0.5\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 .\.\1740
D004298_D001919 NONE They\PRP\1740 suggest\VBP\1010118 that\IN\1740 ,\,\1740 in\IN\13603305 normal\JJ\1740 conscious\JJ\1740 rats\NNS\2329401 ,\,\1740 the\DT\1740 central\JJ\1740 tachycardia\NN\14110674 of\IN\1740 bromocriptine\NN\1740 appears\VBZ\2604760 to\TO\1740 predominate\VB\2696801 and\CC\1740 to\TO\1740 mask\VB\2158587 the\DT\1740 <e2>bradycardia</e2>\NN\14110674 of\IN\1740 this\DT\1740 agonist\NN\9613191 at\IN\14622893 peripheral\JJ\1740 <e1>dopamine</e1>\NN\14807737 D2\NN\1740 receptors\NNS\5225602 .\.\1740
18754075
D004164_D011507 NONE Massive\JJ\1740 <e2>proteinuria</e2>\NN\14299637 and\CC\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 after\IN\1740 oral\JJ\1740 <e1>bisphosphonate</e1>\NN\1740 (\-LRB-\1740 alendronate\NN\3740161 )\-RRB-\1740 administration\NN\1133281 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 focal\JJ\1740 segmental\JJ\1740 glomerulosclerosis\NN\1740 .\.\1740
D004164_D011507 NONE This\DT\1740 report\NN\6470073 demonstrates\VBZ\2137132 that\IN\1740 not\RB\1740 only\RB\1740 intravenous\JJ\1740 ,\,\1740 but\CC\1740 also\RB\1740 oral\JJ\1740 <e1>bisphosphonates</e1>\NNS\1740 can\MD\3094503 aggravate\VB\126264 <e2>proteinuria</e2>\NN\14299637 and\CC\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D004164_D058186 NONE Massive\JJ\1740 proteinuria\NN\14299637 and\CC\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 after\IN\1740 oral\JJ\1740 <e1>bisphosphonate</e1>\NN\1740 (\-LRB-\1740 alendronate\NN\3740161 )\-RRB-\1740 administration\NN\1133281 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 focal\JJ\1740 segmental\JJ\1740 glomerulosclerosis\NN\1740 .\.\1740
D004164_D058186 NONE The\DT\1740 amount\NN\13329641 of\IN\1740 daily\JJ\1740 urinary\JJ\1740 protein\NN\14944888 decreased\VBD\169651 from\IN\1740 15.6\CD\1740 to\TO\1740 2.8\CD\1740 g.\NN\1740 Within\IN\1740 14\CD\13745420 days\NNS\15140892 of\IN\1740 the\DT\1740 oral\JJ\1740 <e1>bisphosphonate</e1>\NN\1740 (\-LRB-\1740 alendronate\NN\3740161 sodium\NN\14625458 )\-RRB-\1740 administration\NN\1133281 ,\,\1740 the\DT\1740 amount\NN\13329641 of\IN\1740 daily\JJ\1740 urinary\JJ\1740 protein\NN\14944888 increased\VBD\169651 rapidly\RB\1740 up\RB\1740 to\TO\1740 12.8\CD\1740 g\NN\13717155 with\IN\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 .\.\1740
D004164_D058186 NONE This\DT\1740 report\NN\6470073 demonstrates\VBZ\2137132 that\IN\1740 not\RB\1740 only\RB\1740 intravenous\JJ\1740 ,\,\1740 but\CC\1740 also\RB\1740 oral\JJ\1740 <e1>bisphosphonates</e1>\NNS\1740 can\MD\3094503 aggravate\VB\126264 proteinuria\NN\14299637 and\CC\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 .\.\1740
D004164_D005923 NONE Massive\JJ\1740 proteinuria\NN\14299637 and\CC\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 after\IN\1740 oral\JJ\1740 <e1>bisphosphonate</e1>\NN\1740 (\-LRB-\1740 alendronate\NN\3740161 )\-RRB-\1740 administration\NN\1133281 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>focal\JJ\1740 segmental\JJ\1740 glomerulosclerosis</e2>\NN\1740 .\.\1740
D019386_D011507 CID Massive\JJ\1740 <e2>proteinuria</e2>\NN\14299637 and\CC\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 after\IN\1740 oral\JJ\1740 bisphosphonate\NN\1740 (\-LRB-\1740 <e1>alendronate</e1>\NN\3740161 )\-RRB-\1740 administration\NN\1133281 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 focal\JJ\1740 segmental\JJ\1740 glomerulosclerosis\NN\1740 .\.\1740
D019386_D058186 CID Massive\JJ\1740 proteinuria\NN\14299637 and\CC\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 after\IN\1740 oral\JJ\1740 bisphosphonate\NN\1740 (\-LRB-\1740 <e1>alendronate</e1>\NN\3740161 )\-RRB-\1740 administration\NN\1133281 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 focal\JJ\1740 segmental\JJ\1740 glomerulosclerosis\NN\1740 .\.\1740
D019386_D058186 CID The\DT\1740 amount\NN\13329641 of\IN\1740 daily\JJ\1740 urinary\JJ\1740 protein\NN\14944888 decreased\VBD\169651 from\IN\1740 15.6\CD\1740 to\TO\1740 2.8\CD\1740 g.\NN\1740 Within\IN\1740 14\CD\13745420 days\NNS\15140892 of\IN\1740 the\DT\1740 oral\JJ\1740 bisphosphonate\NN\1740 (\-LRB-\1740 <e1>alendronate\NN\3740161 sodium</e1>\NN\14625458 )\-RRB-\1740 administration\NN\1133281 ,\,\1740 the\DT\1740 amount\NN\13329641 of\IN\1740 daily\JJ\1740 urinary\JJ\1740 protein\NN\14944888 increased\VBD\169651 rapidly\RB\1740 up\RB\1740 to\TO\1740 12.8\CD\1740 g\NN\13717155 with\IN\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 .\.\1740
D019386_D005923 NONE Massive\JJ\1740 proteinuria\NN\14299637 and\CC\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 after\IN\1740 oral\JJ\1740 bisphosphonate\NN\1740 (\-LRB-\1740 <e1>alendronate</e1>\NN\3740161 )\-RRB-\1740 administration\NN\1133281 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>focal\JJ\1740 segmental\JJ\1740 glomerulosclerosis</e2>\NN\1740 .\.\1740
D013256_D009404 NONE A\DT\13649268 61-year-old\JJ\1740 Japanese\JJ\1740 man\NN\9605289 with\IN\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 due\JJ\1740 to\TO\1740 focal\JJ\1740 segmental\JJ\1740 glomerulosclerosis\NN\1740 was\VBD\836236 initially\RB\1740 responding\VBG\2367363 well\RB\1740 to\TO\1740 <e1>steroid</e1>\NN\14727670 therapy\NN\657604 .\.\1740
D013256_D005923 NONE A\DT\13649268 61-year-old\JJ\1740 Japanese\JJ\1740 man\NN\9605289 with\IN\1740 nephrotic\JJ\1740 syndrome\NN\5870365 due\JJ\1740 to\TO\1740 <e2>focal\JJ\1740 segmental\JJ\1740 glomerulosclerosis</e2>\NN\1740 was\VBD\836236 initially\RB\1740 responding\VBG\2367363 well\RB\1740 to\TO\1740 <e1>steroid</e1>\NN\14727670 therapy\NN\657604 .\.\1740
6747681
D002330_D005910 NONE Intra-arterial\JJ\1740 <e1>BCNU</e1>\NNS\1740 chemotherapy\NN\661091 for\IN\1740 treatment\NN\654885 of\IN\1740 <e2>malignant\JJ\1740 gliomas</e2>\NNS\14236743 of\IN\1740 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 .\.\1740
D002330_D005910 NONE Because\IN\1740 of\IN\1740 the\DT\1740 rapid\JJ\1740 systemic\JJ\1740 clearance\NN\5089947 of\IN\1740 <e1>BCNU</e1>\NN\1740 (\-LRB-\1740 1,3-bis-(2-chloroethyl)-1-nitrosourea\NN\1740 )\-RRB-\1740 ,\,\1740 intra-arterial\JJ\1740 administration\NN\1133281 should\MD\1740 provide\VB\2199590 a\DT\13649268 substantial\JJ\1740 advantage\NN\5154517 over\IN\5867413 intravenous\JJ\1740 administration\NN\1133281 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>malignant\JJ\1740 gliomas</e2>\NNS\14236743 .\.\1740
D002330_D005910 NONE Because\IN\1740 of\IN\1740 the\DT\1740 rapid\JJ\1740 systemic\JJ\1740 clearance\NN\5089947 of\IN\1740 BCNU\NN\1740 (\-LRB-\1740 <e1>1,3-bis-(2-chloroethyl)-1-nitrosourea</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 intra-arterial\JJ\1740 administration\NN\1133281 should\MD\1740 provide\VB\2199590 a\DT\13649268 substantial\JJ\1740 advantage\NN\5154517 over\IN\5867413 intravenous\JJ\1740 administration\NN\1133281 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>malignant\JJ\1740 gliomas</e2>\NNS\14236743 .\.\1740
D002330_D001254 NONE Twenty-four\CD\13745420 patients\NNS\9898892 with\IN\1740 recurrent\JJ\1740 Grade\NNP\7975026 I\CD\14622893 to\TO\1740 IV\CD\13741022 <e2>astrocytomas</e2>\NNS\1740 ,\,\1740 whose\WP$\1740 resection\NN\671351 and\CC\1740 irradiation\NN\13920835 therapy\NN\657604 had\VBD\2108377 failed\VBN\1798936 ,\,\1740 received\VBD\2210855 two\CD\13741022 to\TO\1740 eight\CD\13741022 courses\NNS\883297 of\IN\1740 intra-arterial\JJ\1740 <e1>BCNU</e1>\NN\1740 therapy\NN\657604 .\.\1740
D000431_D014786 NONE The\DT\1740 frequency\NN\15286249 of\IN\1740 <e2>visual\JJ\1740 loss</e2>\NN\13252973 decreased\VBD\169651 after\IN\1740 the\DT\1740 concentration\NN\4916342 of\IN\1740 the\DT\1740 <e1>ethanol</e1>\NN\14708720 diluent\NN\14778436 was\VBD\836236 lowered\VBN\1850315 .\.\1740
2522601
D002220_D004342 CID <e2>Hypersensitivity</e2>\NN\14531772 to\TO\1740 <e1>carbamazepine</e1>\VB\1740 presenting\NN\1740 with\IN\1740 a\DT\13649268 leukemoid\JJ\1740 reaction\NN\13446390 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 erythroderma\NN\14219661 ,\,\1740 and\CC\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D002220_D004342 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 patient\NN\9898892 in\IN\13603305 whom\WP\1740 <e2>hypersensitivity</e2>\NN\14531772 to\TO\1740 <e1>carbamazepine</e1>\NN\1740 presented\VBN\2137132 with\IN\1740 generalized\JJ\1740 erythroderma\NN\14219661 ,\,\1740 a\DT\13649268 severe\JJ\1740 leukemoid\JJ\1740 reaction\NN\13446390 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 hyponatremia\NN\14299637 ,\,\1740 and\CC\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D002220_D007955 CID Hypersensitivity\NN\14531772 to\TO\1740 <e1>carbamazepine</e1>\VB\1740 presenting\NN\1740 with\IN\1740 a\DT\13649268 <e2>leukemoid\JJ\1740 reaction</e2>\NN\13446390 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 erythroderma\NN\14219661 ,\,\1740 and\CC\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D002220_D007955 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 patient\NN\9898892 in\IN\13603305 whom\WP\1740 hypersensitivity\NN\14531772 to\TO\1740 <e1>carbamazepine</e1>\NN\1740 presented\VBN\2137132 with\IN\1740 generalized\JJ\1740 erythroderma\NN\14219661 ,\,\1740 a\DT\13649268 severe\JJ\1740 <e2>leukemoid\JJ\1740 reaction</e2>\NN\13446390 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 hyponatremia\NN\14299637 ,\,\1740 and\CC\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D002220_D004802 NONE Hypersensitivity\NN\14531772 to\TO\1740 <e1>carbamazepine</e1>\VB\1740 presenting\NN\1740 with\IN\1740 a\DT\13649268 leukemoid\JJ\1740 reaction\NN\13446390 ,\,\1740 <e2>eosinophilia</e2>\NN\14299637 ,\,\1740 erythroderma\NN\14219661 ,\,\1740 and\CC\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D002220_D004802 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 patient\NN\9898892 in\IN\13603305 whom\WP\1740 hypersensitivity\NN\14531772 to\TO\1740 <e1>carbamazepine</e1>\NN\1740 presented\VBN\2137132 with\IN\1740 generalized\JJ\1740 erythroderma\NN\14219661 ,\,\1740 a\DT\13649268 severe\JJ\1740 leukemoid\JJ\1740 reaction\NN\13446390 ,\,\1740 <e2>eosinophilia</e2>\NN\14299637 ,\,\1740 hyponatremia\NN\14299637 ,\,\1740 and\CC\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D002220_D003873 CID Hypersensitivity\NN\14531772 to\TO\1740 <e1>carbamazepine</e1>\VB\1740 presenting\NN\1740 with\IN\1740 a\DT\13649268 leukemoid\JJ\1740 reaction\NN\13446390 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 <e2>erythroderma</e2>\NN\14219661 ,\,\1740 and\CC\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D002220_D003873 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 patient\NN\9898892 in\IN\13603305 whom\WP\1740 hypersensitivity\NN\14531772 to\TO\1740 <e1>carbamazepine</e1>\NN\1740 presented\VBN\2137132 with\IN\1740 generalized\JJ\1740 <e2>erythroderma</e2>\NN\14219661 ,\,\1740 a\DT\13649268 severe\JJ\1740 leukemoid\JJ\1740 reaction\NN\13446390 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 hyponatremia\NN\14299637 ,\,\1740 and\CC\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D002220_D051437 CID Hypersensitivity\NN\14531772 to\TO\1740 <e1>carbamazepine</e1>\VB\1740 presenting\NN\1740 with\IN\1740 a\DT\13649268 leukemoid\JJ\1740 reaction\NN\13446390 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 erythroderma\NN\14219661 ,\,\1740 and\CC\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 .\.\1740
D002220_D051437 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 patient\NN\9898892 in\IN\13603305 whom\WP\1740 hypersensitivity\NN\14531772 to\TO\1740 <e1>carbamazepine</e1>\NN\1740 presented\VBN\2137132 with\IN\1740 generalized\JJ\1740 erythroderma\NN\14219661 ,\,\1740 a\DT\13649268 severe\JJ\1740 leukemoid\JJ\1740 reaction\NN\13446390 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 hyponatremia\NN\14299637 ,\,\1740 and\CC\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 .\.\1740
D002220_D007010 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 patient\NN\9898892 in\IN\13603305 whom\WP\1740 hypersensitivity\NN\14531772 to\TO\1740 <e1>carbamazepine</e1>\NN\1740 presented\VBN\2137132 with\IN\1740 generalized\JJ\1740 erythroderma\NN\14219661 ,\,\1740 a\DT\13649268 severe\JJ\1740 leukemoid\JJ\1740 reaction\NN\13446390 ,\,\1740 eosinophilia\NN\14299637 ,\,\1740 <e2>hyponatremia</e2>\NN\14299637 ,\,\1740 and\CC\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
11426838
-1_D012640 NONE In\IN\13603305 behavioral\JJ\1740 studies\NNS\635850 ,\,\1740 pre-treatment\NN\1740 of\IN\1740 mice\NNS\2329401 with\IN\1740 <e1>BD1018</e1>\NN\1740 ,\,\1740 BD1063\NN\1740 ,\,\1740 or\CC\3541091 LR132\NN\1740 significantly\RB\1740 attenuated\VBD\224901 cocaine-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 and\CC\1740 lethality\NN\4790449 .\.\1740
-1_D012640 NONE In\IN\13603305 behavioral\JJ\1740 studies\NNS\635850 ,\,\1740 pre-treatment\NN\1740 of\IN\1740 mice\NNS\2329401 with\IN\1740 BD1018\NN\1740 ,\,\1740 BD1063\NN\1740 ,\,\1740 or\CC\3541091 <e1>LR132</e1>\NN\1740 significantly\RB\1740 attenuated\VBD\224901 cocaine-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 and\CC\1740 lethality\NN\4790449 .\.\1740
C093337_D012640 NONE In\IN\13603305 behavioral\JJ\1740 studies\NNS\635850 ,\,\1740 pre-treatment\NN\1740 of\IN\1740 mice\NNS\2329401 with\IN\1740 BD1018\NN\1740 ,\,\1740 <e1>BD1063</e1>\NN\1740 ,\,\1740 or\CC\3541091 LR132\NN\1740 significantly\RB\1740 attenuated\VBD\224901 cocaine-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 and\CC\1740 lethality\NN\4790449 .\.\1740
D003042_D012640 CID In\IN\13603305 behavioral\JJ\1740 studies\NNS\635850 ,\,\1740 pre-treatment\NN\1740 of\IN\1740 mice\NNS\2329401 with\IN\1740 BD1018\NN\1740 ,\,\1740 BD1063\NN\1740 ,\,\1740 or\CC\3541091 LR132\NN\1740 significantly\RB\1740 attenuated\VBD\224901 <e1>cocaine-induced</e1>\JJ\1740 <e2>convulsions</e2>\NNS\14081375 and\CC\1740 lethality\NN\4790449 .\.\1740
D003042_D012640 CID To\TO\1740 further\RB\1740 validate\VB\803325 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 the\DT\1740 <e1>anti-cocaine</e1>\JJ\1740 effects\NNS\13245626 of\IN\1740 the\DT\1740 novel\JJ\1740 ligands\NNS\20090 involved\VBD\2676054 antagonism\NN\24720 of\IN\1740 sigma\NN\6828818 receptors\NNS\5225602 ,\,\1740 an\DT\6697703 antisense\JJ\1740 oligodeoxynucleotide\NN\1740 against\IN\1740 sigma1\CD\1740 receptors\NNS\5225602 was\VBD\836236 also\RB\1740 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 attenuate\VB\224901 the\DT\1740 <e2>convulsive</e2>\JJ\1740 and\CC\1740 locomotor\NN\1740 stimulatory\JJ\1740 effects\NNS\13245626 of\IN\1740 cocaine\NN\3492717 .\.\1740
D003042_D012640 CID To\TO\1740 further\RB\1740 validate\VB\803325 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 the\DT\1740 anti-cocaine\JJ\1740 effects\NNS\13245626 of\IN\1740 the\DT\1740 novel\JJ\1740 ligands\NNS\20090 involved\VBD\2676054 antagonism\NN\24720 of\IN\1740 sigma\NN\6828818 receptors\NNS\5225602 ,\,\1740 an\DT\6697703 antisense\JJ\1740 oligodeoxynucleotide\NN\1740 against\IN\1740 sigma1\CD\1740 receptors\NNS\5225602 was\VBD\836236 also\RB\1740 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 attenuate\VB\224901 the\DT\1740 <e2>convulsive</e2>\JJ\1740 and\CC\1740 locomotor\NN\1740 stimulatory\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>cocaine</e1>\NN\3492717 .\.\1740
C050232_D064420 NONE In\IN\13603305 contrast\NN\13854649 to\TO\1740 the\DT\1740 protection\NN\407535 provided\VBN\2199590 by\IN\1740 the\DT\1740 putative\JJ\1740 antagonists\NNS\7846 ,\,\1740 the\DT\1740 well-characterized\JJ\1740 sigma\NN\6828818 receptor\NN\5225602 agonist\NN\9613191 <e1>di-o-tolylguanidine</e1>\NN\1740 (\-LRB-\1740 DTG\NN\1740 )\-RRB-\1740 and\CC\1740 the\DT\1740 novel\JJ\1740 sigma\NN\6828818 receptor\NN\5225602 agonist\NN\9613191 BD1031\NN\1740 (\-LRB-\1740 3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane\NN\1740 )\-RRB-\1740 each\DT\1740 worsened\VBD\146138 the\DT\1740 behavioral\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 cocaine\NN\3492717 .\.\1740
C050232_D064420 NONE In\IN\13603305 contrast\NN\13854649 to\TO\1740 the\DT\1740 protection\NN\407535 provided\VBN\2199590 by\IN\1740 the\DT\1740 putative\JJ\1740 antagonists\NNS\7846 ,\,\1740 the\DT\1740 well-characterized\JJ\1740 sigma\NN\6828818 receptor\NN\5225602 agonist\NN\9613191 di-o-tolylguanidine\NN\1740 (\-LRB-\1740 <e1>DTG</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 the\DT\1740 novel\JJ\1740 sigma\NN\6828818 receptor\NN\5225602 agonist\NN\9613191 BD1031\NN\1740 (\-LRB-\1740 3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane\NN\1740 )\-RRB-\1740 each\DT\1740 worsened\VBD\146138 the\DT\1740 behavioral\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 cocaine\NN\3492717 .\.\1740
-1_D064420 NONE In\IN\13603305 contrast\NN\13854649 to\TO\1740 the\DT\1740 protection\NN\407535 provided\VBN\2199590 by\IN\1740 the\DT\1740 putative\JJ\1740 antagonists\NNS\7846 ,\,\1740 the\DT\1740 well-characterized\JJ\1740 sigma\NN\6828818 receptor\NN\5225602 agonist\NN\9613191 di-o-tolylguanidine\NN\1740 (\-LRB-\1740 DTG\NN\1740 )\-RRB-\1740 and\CC\1740 the\DT\1740 novel\JJ\1740 sigma\NN\6828818 receptor\NN\5225602 agonist\NN\9613191 <e1>BD1031</e1>\NN\1740 (\-LRB-\1740 3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane\NN\1740 )\-RRB-\1740 each\DT\1740 worsened\VBD\146138 the\DT\1740 behavioral\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 cocaine\NN\3492717 .\.\1740
-1_D064420 NONE In\IN\13603305 contrast\NN\13854649 to\TO\1740 the\DT\1740 protection\NN\407535 provided\VBN\2199590 by\IN\1740 the\DT\1740 putative\JJ\1740 antagonists\NNS\7846 ,\,\1740 the\DT\1740 well-characterized\JJ\1740 sigma\NN\6828818 receptor\NN\5225602 agonist\NN\9613191 di-o-tolylguanidine\NN\1740 (\-LRB-\1740 DTG\NN\1740 )\-RRB-\1740 and\CC\1740 the\DT\1740 novel\JJ\1740 sigma\NN\6828818 receptor\NN\5225602 agonist\NN\9613191 BD1031\NN\1740 (\-LRB-\1740 <e1>3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane</e1>\NN\1740 )\-RRB-\1740 each\DT\1740 worsened\VBD\146138 the\DT\1740 behavioral\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 cocaine\NN\3492717 .\.\1740
D003042_D064420 NONE In\IN\13603305 contrast\NN\13854649 to\TO\1740 the\DT\1740 protection\NN\407535 provided\VBN\2199590 by\IN\1740 the\DT\1740 putative\JJ\1740 antagonists\NNS\7846 ,\,\1740 the\DT\1740 well-characterized\JJ\1740 sigma\NN\6828818 receptor\NN\5225602 agonist\NN\9613191 di-o-tolylguanidine\NN\1740 (\-LRB-\1740 DTG\NN\1740 )\-RRB-\1740 and\CC\1740 the\DT\1740 novel\JJ\1740 sigma\NN\6828818 receptor\NN\5225602 agonist\NN\9613191 BD1031\NN\1740 (\-LRB-\1740 3R-1-[2-(3,4-dichlorophenyl)ethyl]-1,4-diazabicyclo[4.3.0]nonane\NN\1740 )\-RRB-\1740 each\DT\1740 worsened\VBD\146138 the\DT\1740 behavioral\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 <e1>cocaine</e1>\NN\3492717 .\.\1740
D009838_D012640 NONE To\TO\1740 further\RB\1740 validate\VB\803325 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 the\DT\1740 anti-cocaine\JJ\1740 effects\NNS\13245626 of\IN\1740 the\DT\1740 novel\JJ\1740 ligands\NNS\20090 involved\VBD\2676054 antagonism\NN\24720 of\IN\1740 sigma\NN\6828818 receptors\NNS\5225602 ,\,\1740 an\DT\6697703 antisense\JJ\1740 <e1>oligodeoxynucleotide</e1>\NN\1740 against\IN\1740 sigma1\CD\1740 receptors\NNS\5225602 was\VBD\836236 also\RB\1740 shown\VBN\2137132 to\TO\1740 significantly\RB\1740 attenuate\VB\224901 the\DT\1740 <e2>convulsive</e2>\JJ\1740 and\CC\1740 locomotor\NN\1740 stimulatory\JJ\1740 effects\NNS\13245626 of\IN\1740 cocaine\NN\3492717 .\.\1740
19957053
D010656_D002534 CID <e1>Phenylephrine</e1>\NNP\2682038 but\CC\1740 not\RB\1740 ephedrine\NN\14712692 <e2>reduces\VBZ\441445 frontal\JJ\1740 lobe\JJ\1740 oxygenation</e2>\NN\13518963 following\VBG\1835496 anesthesia-induced\JJ\1740 hypotension\NN\14057371 .\.\1740
D010656_D007022 NONE <e1>Phenylephrine</e1>\NNP\2682038 but\CC\1740 not\RB\1740 ephedrine\NN\14712692 reduces\VBZ\441445 frontal\JJ\1740 lobe\JJ\1740 oxygenation\NN\13518963 following\VBG\1835496 anesthesia-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D010656_D007022 NONE We\PRP\1740 describe\VBP\1001294 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>phenylephrine</e1>\NN\2682038 and\CC\1740 ephedrine\NN\14712692 on\IN\1740 frontal\JJ\1740 lobe\JJ\1740 oxygenation\NN\13518963 (\-LRB-\1740 S(c)O(2\NN\1740 )\-RRB-\1740 )\-RRB-\1740 following\VBG\1835496 anesthesia-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D010656_D007022 NONE CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 utilization\NN\407535 of\IN\1740 <e1>phenylephrine</e1>\NN\2682038 to\TO\1740 correct\VB\138508 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 anesthesia\NN\14034177 has\VBZ\2108377 a\DT\13649268 negative\JJ\1740 impact\NN\7339329 on\IN\1740 S(c)O(2\NN\1740 )\-RRB-\1740 while\IN\15122231 ephedrine\NN\14712692 maintains\VBZ\2202928 frontal\JJ\1740 lobe\VBD\1740 oxygenation\NN\13518963 potentially\RB\1740 related\JJ\1740 to\TO\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 CO\NN\14954601 .\.\1740
D004809_D002534 NONE Phenylephrine\NNP\2682038 but\CC\1740 not\RB\1740 <e1>ephedrine</e1>\NN\14712692 <e2>reduces\VBZ\441445 frontal\JJ\1740 lobe\JJ\1740 oxygenation</e2>\NN\13518963 following\VBG\1835496 anesthesia-induced\JJ\1740 hypotension\NN\14057371 .\.\1740
D004809_D007022 NONE Phenylephrine\NNP\2682038 but\CC\1740 not\RB\1740 <e1>ephedrine</e1>\NN\14712692 reduces\VBZ\441445 frontal\JJ\1740 lobe\JJ\1740 oxygenation\NN\13518963 following\VBG\1835496 anesthesia-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D004809_D007022 NONE We\PRP\1740 describe\VBP\1001294 the\DT\1740 effect\NN\34213 of\IN\1740 phenylephrine\NN\2682038 and\CC\1740 <e1>ephedrine</e1>\NN\14712692 on\IN\1740 frontal\JJ\1740 lobe\JJ\1740 oxygenation\NN\13518963 (\-LRB-\1740 S(c)O(2\NN\1740 )\-RRB-\1740 )\-RRB-\1740 following\VBG\1835496 anesthesia-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D004809_D007022 NONE CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 utilization\NN\407535 of\IN\1740 phenylephrine\NN\2682038 to\TO\1740 correct\VB\138508 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 anesthesia\NN\14034177 has\VBZ\2108377 a\DT\13649268 negative\JJ\1740 impact\NN\7339329 on\IN\1740 S(c)O(2\NN\1740 )\-RRB-\1740 while\IN\15122231 <e1>ephedrine</e1>\NN\14712692 maintains\VBZ\2202928 frontal\JJ\1740 lobe\VBD\1740 oxygenation\NN\13518963 potentially\RB\1740 related\JJ\1740 to\TO\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 CO\NN\14954601 .\.\1740
12684739
D020888_D019966 NONE OBJECTIVES\NNS\5980875 :\:\1740 Given\VBN\2327200 its\PRP$\6125041 preclinical\JJ\1740 success\NN\7283608 for\IN\1740 treating\VBG\2376958 <e2>substance\NN\20827 abuse</e2>\NN\418025 and\CC\1740 the\DT\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 visual\JJ\1740 field\NN\8673395 defects\NNS\14462666 (\-LRB-\1740 VFD\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 cumulative\JJ\1740 lifetime\NN\15113229 exposure\NN\5042871 ,\,\1740 we\PRP\1740 explored\VBD\789138 the\DT\1740 effects\NNS\13245626 of\IN\1740 sub-chronic\JJ\1740 low\JJ\1740 dose\NN\3740161 <e1>GVG</e1>\NN\1740 on\IN\1740 cocaine-induced\JJ\1740 increases\NNS\13576355 in\IN\13603305 nucleus\NN\5445668 accumbens\NNS\1740 (\-LRB-\1740 NAcc\NN\1740 )\-RRB-\1740 dopamine\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 .\.\1740
D020888_D005128 CID OBJECTIVES\NNS\5980875 :\:\1740 Given\VBN\2327200 its\PRP$\6125041 preclinical\JJ\1740 success\NN\7283608 for\IN\1740 treating\VBG\2376958 substance\NN\20827 abuse\NN\418025 and\CC\1740 the\DT\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>visual\JJ\1740 field\NN\8673395 defects</e2>\NNS\14462666 (\-LRB-\1740 VFD\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 cumulative\JJ\1740 lifetime\NN\15113229 exposure\NN\5042871 ,\,\1740 we\PRP\1740 explored\VBD\789138 the\DT\1740 effects\NNS\13245626 of\IN\1740 sub-chronic\JJ\1740 low\JJ\1740 dose\NN\3740161 <e1>GVG</e1>\NN\1740 on\IN\1740 cocaine-induced\JJ\1740 increases\NNS\13576355 in\IN\13603305 nucleus\NN\5445668 accumbens\NNS\1740 (\-LRB-\1740 NAcc\NN\1740 )\-RRB-\1740 dopamine\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 .\.\1740
D020888_D005128 CID OBJECTIVES\NNS\5980875 :\:\1740 Given\VBN\2327200 its\PRP$\6125041 preclinical\JJ\1740 success\NN\7283608 for\IN\1740 treating\VBG\2376958 substance\NN\20827 abuse\NN\418025 and\CC\1740 the\DT\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 visual\JJ\1740 field\NN\8673395 defects\NNS\14462666 (\-LRB-\1740 <e2>VFD</e2>\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 cumulative\JJ\1740 lifetime\NN\15113229 exposure\NN\5042871 ,\,\1740 we\PRP\1740 explored\VBD\789138 the\DT\1740 effects\NNS\13245626 of\IN\1740 sub-chronic\JJ\1740 low\JJ\1740 dose\NN\3740161 <e1>GVG</e1>\NN\1740 on\IN\1740 cocaine-induced\JJ\1740 increases\NNS\13576355 in\IN\13603305 nucleus\NN\5445668 accumbens\NNS\1740 (\-LRB-\1740 NAcc\NN\1740 )\-RRB-\1740 dopamine\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 .\.\1740
D003042_D019966 NONE OBJECTIVES\NNS\5980875 :\:\1740 Given\VBN\2327200 its\PRP$\6125041 preclinical\JJ\1740 success\NN\7283608 for\IN\1740 treating\VBG\2376958 <e2>substance\NN\20827 abuse</e2>\NN\418025 and\CC\1740 the\DT\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 visual\JJ\1740 field\NN\8673395 defects\NNS\14462666 (\-LRB-\1740 VFD\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 cumulative\JJ\1740 lifetime\NN\15113229 exposure\NN\5042871 ,\,\1740 we\PRP\1740 explored\VBD\789138 the\DT\1740 effects\NNS\13245626 of\IN\1740 sub-chronic\JJ\1740 low\JJ\1740 dose\NN\3740161 GVG\NN\1740 on\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 increases\NNS\13576355 in\IN\13603305 nucleus\NN\5445668 accumbens\NNS\1740 (\-LRB-\1740 NAcc\NN\1740 )\-RRB-\1740 dopamine\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 .\.\1740
D003042_D005128 NONE OBJECTIVES\NNS\5980875 :\:\1740 Given\VBN\2327200 its\PRP$\6125041 preclinical\JJ\1740 success\NN\7283608 for\IN\1740 treating\VBG\2376958 substance\NN\20827 abuse\NN\418025 and\CC\1740 the\DT\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>visual\JJ\1740 field\NN\8673395 defects</e2>\NNS\14462666 (\-LRB-\1740 VFD\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 cumulative\JJ\1740 lifetime\NN\15113229 exposure\NN\5042871 ,\,\1740 we\PRP\1740 explored\VBD\789138 the\DT\1740 effects\NNS\13245626 of\IN\1740 sub-chronic\JJ\1740 low\JJ\1740 dose\NN\3740161 GVG\NN\1740 on\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 increases\NNS\13576355 in\IN\13603305 nucleus\NN\5445668 accumbens\NNS\1740 (\-LRB-\1740 NAcc\NN\1740 )\-RRB-\1740 dopamine\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 .\.\1740
D003042_D005128 NONE OBJECTIVES\NNS\5980875 :\:\1740 Given\VBN\2327200 its\PRP$\6125041 preclinical\JJ\1740 success\NN\7283608 for\IN\1740 treating\VBG\2376958 substance\NN\20827 abuse\NN\418025 and\CC\1740 the\DT\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 visual\JJ\1740 field\NN\8673395 defects\NNS\14462666 (\-LRB-\1740 <e2>VFD</e2>\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 cumulative\JJ\1740 lifetime\NN\15113229 exposure\NN\5042871 ,\,\1740 we\PRP\1740 explored\VBD\789138 the\DT\1740 effects\NNS\13245626 of\IN\1740 sub-chronic\JJ\1740 low\JJ\1740 dose\NN\3740161 GVG\NN\1740 on\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 increases\NNS\13576355 in\IN\13603305 nucleus\NN\5445668 accumbens\NNS\1740 (\-LRB-\1740 NAcc\NN\1740 )\-RRB-\1740 dopamine\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 .\.\1740
D004298_D019966 NONE OBJECTIVES\NNS\5980875 :\:\1740 Given\VBN\2327200 its\PRP$\6125041 preclinical\JJ\1740 success\NN\7283608 for\IN\1740 treating\VBG\2376958 <e2>substance\NN\20827 abuse</e2>\NN\418025 and\CC\1740 the\DT\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 visual\JJ\1740 field\NN\8673395 defects\NNS\14462666 (\-LRB-\1740 VFD\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 cumulative\JJ\1740 lifetime\NN\15113229 exposure\NN\5042871 ,\,\1740 we\PRP\1740 explored\VBD\789138 the\DT\1740 effects\NNS\13245626 of\IN\1740 sub-chronic\JJ\1740 low\JJ\1740 dose\NN\3740161 GVG\NN\1740 on\IN\1740 cocaine-induced\JJ\1740 increases\NNS\13576355 in\IN\13603305 nucleus\NN\5445668 accumbens\NNS\1740 (\-LRB-\1740 NAcc\NN\1740 )\-RRB-\1740 <e1>dopamine</e1>\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 .\.\1740
D004298_D019966 NONE OBJECTIVES\NNS\5980875 :\:\1740 Given\VBN\2327200 its\PRP$\6125041 preclinical\JJ\1740 success\NN\7283608 for\IN\1740 treating\VBG\2376958 <e2>substance\NN\20827 abuse</e2>\NN\418025 and\CC\1740 the\DT\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 visual\JJ\1740 field\NN\8673395 defects\NNS\14462666 (\-LRB-\1740 VFD\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 cumulative\JJ\1740 lifetime\NN\15113229 exposure\NN\5042871 ,\,\1740 we\PRP\1740 explored\VBD\789138 the\DT\1740 effects\NNS\13245626 of\IN\1740 sub-chronic\JJ\1740 low\JJ\1740 dose\NN\3740161 GVG\NN\1740 on\IN\1740 cocaine-induced\JJ\1740 increases\NNS\13576355 in\IN\13603305 nucleus\NN\5445668 accumbens\NNS\1740 (\-LRB-\1740 NAcc\NN\1740 )\-RRB-\1740 dopamine\NN\14807737 (\-LRB-\1740 <e1>DA</e1>\NN\10484858 )\-RRB-\1740 .\.\1740
D004298_D005128 NONE OBJECTIVES\NNS\5980875 :\:\1740 Given\VBN\2327200 its\PRP$\6125041 preclinical\JJ\1740 success\NN\7283608 for\IN\1740 treating\VBG\2376958 substance\NN\20827 abuse\NN\418025 and\CC\1740 the\DT\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>visual\JJ\1740 field\NN\8673395 defects</e2>\NNS\14462666 (\-LRB-\1740 VFD\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 cumulative\JJ\1740 lifetime\NN\15113229 exposure\NN\5042871 ,\,\1740 we\PRP\1740 explored\VBD\789138 the\DT\1740 effects\NNS\13245626 of\IN\1740 sub-chronic\JJ\1740 low\JJ\1740 dose\NN\3740161 GVG\NN\1740 on\IN\1740 cocaine-induced\JJ\1740 increases\NNS\13576355 in\IN\13603305 nucleus\NN\5445668 accumbens\NNS\1740 (\-LRB-\1740 NAcc\NN\1740 )\-RRB-\1740 <e1>dopamine</e1>\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 .\.\1740
D004298_D005128 NONE OBJECTIVES\NNS\5980875 :\:\1740 Given\VBN\2327200 its\PRP$\6125041 preclinical\JJ\1740 success\NN\7283608 for\IN\1740 treating\VBG\2376958 substance\NN\20827 abuse\NN\418025 and\CC\1740 the\DT\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 visual\JJ\1740 field\NN\8673395 defects\NNS\14462666 (\-LRB-\1740 <e2>VFD</e2>\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 cumulative\JJ\1740 lifetime\NN\15113229 exposure\NN\5042871 ,\,\1740 we\PRP\1740 explored\VBD\789138 the\DT\1740 effects\NNS\13245626 of\IN\1740 sub-chronic\JJ\1740 low\JJ\1740 dose\NN\3740161 GVG\NN\1740 on\IN\1740 cocaine-induced\JJ\1740 increases\NNS\13576355 in\IN\13603305 nucleus\NN\5445668 accumbens\NNS\1740 (\-LRB-\1740 NAcc\NN\1740 )\-RRB-\1740 <e1>dopamine</e1>\NN\14807737 (\-LRB-\1740 DA\NN\10484858 )\-RRB-\1740 .\.\1740
D004298_D005128 NONE OBJECTIVES\NNS\5980875 :\:\1740 Given\VBN\2327200 its\PRP$\6125041 preclinical\JJ\1740 success\NN\7283608 for\IN\1740 treating\VBG\2376958 substance\NN\20827 abuse\NN\418025 and\CC\1740 the\DT\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>visual\JJ\1740 field\NN\8673395 defects</e2>\NNS\14462666 (\-LRB-\1740 VFD\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 cumulative\JJ\1740 lifetime\NN\15113229 exposure\NN\5042871 ,\,\1740 we\PRP\1740 explored\VBD\789138 the\DT\1740 effects\NNS\13245626 of\IN\1740 sub-chronic\JJ\1740 low\JJ\1740 dose\NN\3740161 GVG\NN\1740 on\IN\1740 cocaine-induced\JJ\1740 increases\NNS\13576355 in\IN\13603305 nucleus\NN\5445668 accumbens\NNS\1740 (\-LRB-\1740 NAcc\NN\1740 )\-RRB-\1740 dopamine\NN\14807737 (\-LRB-\1740 <e1>DA</e1>\NN\10484858 )\-RRB-\1740 .\.\1740
D004298_D005128 NONE OBJECTIVES\NNS\5980875 :\:\1740 Given\VBN\2327200 its\PRP$\6125041 preclinical\JJ\1740 success\NN\7283608 for\IN\1740 treating\VBG\2376958 substance\NN\20827 abuse\NN\418025 and\CC\1740 the\DT\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 visual\JJ\1740 field\NN\8673395 defects\NNS\14462666 (\-LRB-\1740 <e2>VFD</e2>\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 cumulative\JJ\1740 lifetime\NN\15113229 exposure\NN\5042871 ,\,\1740 we\PRP\1740 explored\VBD\789138 the\DT\1740 effects\NNS\13245626 of\IN\1740 sub-chronic\JJ\1740 low\JJ\1740 dose\NN\3740161 GVG\NN\1740 on\IN\1740 cocaine-induced\JJ\1740 increases\NNS\13576355 in\IN\13603305 nucleus\NN\5445668 accumbens\NNS\1740 (\-LRB-\1740 NAcc\NN\1740 )\-RRB-\1740 dopamine\NN\14807737 (\-LRB-\1740 <e1>DA</e1>\NN\10484858 )\-RRB-\1740 .\.\1740
17919553
C106791_D056486 CID Acute\JJ\1740 <e2>hepatitis</e2>\NN\14127211 attack\NN\955060 after\IN\1740 exposure\NN\5042871 to\TO\1740 <e1>telithromycin</e1>\NN\1740 .\.\1740
C106791_D056486 CID The\DT\1740 patient\NN\9898892 had\VBD\2108377 suffered\VBN\2110220 a\DT\13649268 previous\JJ\1740 episode\NN\7283608 of\IN\1740 "\``\1740 acute\JJ\1740 <e2>hepatitis</e2>\NN\14127211 of\IN\1740 unknown\JJ\1740 origin\NN\8620061 ,\,\1740 "\''\1740 that\WDT\1740 occurred\VBD\2623529 after\IN\1740 <e1>telithromycin</e1>\NN\1740 usage\NN\407535 .\.\1740
C106791_D056486 CID Based\VBN\2694933 on\IN\1740 a\DT\13649268 score\NN\5736149 of\IN\1740 8\CD\13741022 on\IN\1740 the\DT\1740 Naranjo\NNP\1740 adverse\JJ\1740 drug\NN\14778436 reaction\NN\13446390 probability\NN\33615 scale\NN\7260623 ,\,\1740 <e1>telithromycin</e1>\NN\1740 was\VBD\836236 the\DT\1740 probable\JJ\1740 cause\NN\7323922 of\IN\1740 acute\JJ\1740 <e2>hepatitis</e2>\NN\14127211 in\IN\13603305 this\DT\1740 patient\NN\9898892 ,\,\1740 and\CC\1740 pathological\JJ\1740 findings\NNS\7951464 suggested\VBD\1010118 drug-induced\JJ\1740 toxic\JJ\1740 hepatitis\NN\14127211 .\.\1740
C106791_D056486 CID Based\VBN\2694933 on\IN\1740 a\DT\13649268 score\NN\5736149 of\IN\1740 8\CD\13741022 on\IN\1740 the\DT\1740 Naranjo\NNP\1740 adverse\JJ\1740 drug\NN\14778436 reaction\NN\13446390 probability\NN\33615 scale\NN\7260623 ,\,\1740 <e1>telithromycin</e1>\NN\1740 was\VBD\836236 the\DT\1740 probable\JJ\1740 cause\NN\7323922 of\IN\1740 acute\JJ\1740 hepatitis\NN\14127211 in\IN\13603305 this\DT\1740 patient\NN\9898892 ,\,\1740 and\CC\1740 pathological\JJ\1740 findings\NNS\7951464 suggested\VBD\1010118 drug-induced\JJ\1740 <e2>toxic\JJ\1740 hepatitis</e2>\NN\14127211 .\.\1740
C106791_D056486 CID Recurrence\NN\7342049 of\IN\1740 <e2>hepatitis</e2>\NN\14127211 attack\NN\955060 might\MD\5029706 have\VB\2108377 been\VBN\836236 avoided\VBN\2452885 if\IN\1740 the\DT\1740 initial\JJ\1740 incident\NN\7283608 had\VBD\2108377 been\VBN\836236 communicated\VBN\2231661 to\IN\1740 the\DT\1740 attending\VBG\2655135 physician\NN\10305802 who\WP\8299493 prescribed\VBD\748282 <e1>telithromycin</e1>\NN\1740 the\DT\1740 second\JJ\1740 time\NN\7308889 .\.\1740
C106791_D056486 CID CONCLUSION\NN\5837957 :\:\1740 Here\RB\1740 we\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 <e2>hepatitis</e2>\NN\14127211 probably\RB\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>telithromycin</e1>\NN\1740 .\.\1740
C106791_D012141 NONE He\PRP\14622893 had\VBD\2108377 been\VBN\836236 prescribed\VBN\748282 <e1>telithromycin</e1>\NN\1740 400\CD\1740 mg/d\NN\1740 PO\NN\14625458 to\TO\1740 treat\VB\2376958 an\DT\6697703 <e2>upper\JJ\1740 respiratory\JJ\1740 tract\NN\8574314 infection</e2>\NN\14052046 7\CD\13741022 days\NNS\15140892 prior\RB\1740 .\.\1740
C106791_D064420 NONE Based\VBN\2694933 on\IN\1740 a\DT\13649268 score\NN\5736149 of\IN\1740 8\CD\13741022 on\IN\1740 the\DT\1740 Naranjo\NNP\1740 <e2>adverse\JJ\1740 drug\NN\14778436 reaction</e2>\NN\13446390 probability\NN\33615 scale\NN\7260623 ,\,\1740 <e1>telithromycin</e1>\NN\1740 was\VBD\836236 the\DT\1740 probable\JJ\1740 cause\NN\7323922 of\IN\1740 acute\JJ\1740 hepatitis\NN\14127211 in\IN\13603305 this\DT\1740 patient\NN\9898892 ,\,\1740 and\CC\1740 pathological\JJ\1740 findings\NNS\7951464 suggested\VBD\1010118 drug-induced\JJ\1740 toxic\JJ\1740 hepatitis\NN\14127211 .\.\1740
7248170
D010634_D006529 CID <e1>Phenobarbitone-induced</e1>\JJ\1740 <e2>enlargement\NN\363260 of\IN\1740 the\DT\1740 liver</e2>\NN\5298729 in\IN\13603305 the\DT\1740 rat\NN\2329401 :\:\1740 its\PRP$\6125041 relationship\NN\31921 to\TO\1740 carbon\NN\14622893 tetrachloride-induced\JJ\1740 cirrhosis\NN\14116321 .\.\1740
D010634_D006529 CID The\DT\1740 yield\NN\913705 of\IN\1740 severe\JJ\1740 cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver\NN\5298729 (\-LRB-\1740 defined\VBN\2604760 as\IN\14622893 a\DT\13649268 shrunken\JJ\1740 finely\RB\1740 nodular\JJ\1740 liver\NN\5298729 with\IN\1740 micronodular\JJ\1740 histology\NN\6060049 ,\,\1740 ascites\NNS\14204950 greater\JJR\1740 than\IN\1740 30\CD\13745420 ml\NN\13616054 ,\,\1740 plasma\NN\5398023 albumin\NN\14736972 less\JJR\1740 than\IN\1740 2.2\CD\1740 g/dl\NN\1740 ,\,\1740 splenomegaly\NN\14366759 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 normal\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 atrophy\NN\14299637 approximately\RB\1740 half\NN\13732295 normal\JJ\1740 weight\NN\5009170 )\-RRB-\1740 after\IN\1740 12\CD\13745420 doses\NNS\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 given\VBN\2327200 intragastrically\RB\1740 in\IN\13603305 the\DT\1740 <e1>phenobarbitone-primed</e1>\JJ\1740 rat\NN\2329401 was\VBD\836236 increased\VBN\169651 from\IN\1740 25\CD\13745420 %\NN\1740 to\TO\1740 56\CD\1740 %\NN\1740 by\IN\1740 giving\VBG\2327200 the\DT\1740 initial\JJ\1740 "\``\1740 calibrating\VBG\296178 "\``\1740 dose\NN\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 at\IN\14622893 the\DT\1740 peak\NN\13758296 of\IN\1740 the\DT\1740 phenobarbitone-induced\JJ\1740 <e2>enlargement\NN\363260 of\IN\1740 the\DT\1740 liver</e2>\NN\5298729 .\.\1740
D010634_D006529 CID The\DT\1740 yield\NN\913705 of\IN\1740 severe\JJ\1740 cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver\NN\5298729 (\-LRB-\1740 defined\VBN\2604760 as\IN\14622893 a\DT\13649268 shrunken\JJ\1740 finely\RB\1740 nodular\JJ\1740 liver\NN\5298729 with\IN\1740 micronodular\JJ\1740 histology\NN\6060049 ,\,\1740 ascites\NNS\14204950 greater\JJR\1740 than\IN\1740 30\CD\13745420 ml\NN\13616054 ,\,\1740 plasma\NN\5398023 albumin\NN\14736972 less\JJR\1740 than\IN\1740 2.2\CD\1740 g/dl\NN\1740 ,\,\1740 splenomegaly\NN\14366759 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 normal\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 atrophy\NN\14299637 approximately\RB\1740 half\NN\13732295 normal\JJ\1740 weight\NN\5009170 )\-RRB-\1740 after\IN\1740 12\CD\13745420 doses\NNS\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 given\VBN\2327200 intragastrically\RB\1740 in\IN\13603305 the\DT\1740 phenobarbitone-primed\JJ\1740 rat\NN\2329401 was\VBD\836236 increased\VBN\169651 from\IN\1740 25\CD\13745420 %\NN\1740 to\TO\1740 56\CD\1740 %\NN\1740 by\IN\1740 giving\VBG\2327200 the\DT\1740 initial\JJ\1740 "\``\1740 calibrating\VBG\296178 "\``\1740 dose\NN\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 at\IN\14622893 the\DT\1740 peak\NN\13758296 of\IN\1740 the\DT\1740 <e1>phenobarbitone-induced</e1>\JJ\1740 <e2>enlargement\NN\363260 of\IN\1740 the\DT\1740 liver</e2>\NN\5298729 .\.\1740
D010634_D005355 NONE <e1>Phenobarbitone-induced</e1>\JJ\1740 enlargement\NN\363260 of\IN\1740 the\DT\1740 liver\NN\5298729 in\IN\13603305 the\DT\1740 rat\NN\2329401 :\:\1740 its\PRP$\6125041 relationship\NN\31921 to\TO\1740 carbon\NN\14622893 tetrachloride-induced\JJ\1740 <e2>cirrhosis</e2>\NN\14116321 .\.\1740
D002251_D006529 NONE Phenobarbitone-induced\JJ\1740 <e2>enlargement\NN\363260 of\IN\1740 the\DT\1740 liver</e2>\NN\5298729 in\IN\13603305 the\DT\1740 rat\NN\2329401 :\:\1740 its\PRP$\6125041 relationship\NN\31921 to\TO\1740 <e1>carbon\NN\14622893 tetrachloride-induced</e1>\JJ\1740 cirrhosis\NN\14116321 .\.\1740
D002251_D006529 NONE The\DT\1740 yield\NN\913705 of\IN\1740 severe\JJ\1740 cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver\NN\5298729 (\-LRB-\1740 defined\VBN\2604760 as\IN\14622893 a\DT\13649268 shrunken\JJ\1740 finely\RB\1740 nodular\JJ\1740 liver\NN\5298729 with\IN\1740 micronodular\JJ\1740 histology\NN\6060049 ,\,\1740 ascites\NNS\14204950 greater\JJR\1740 than\IN\1740 30\CD\13745420 ml\NN\13616054 ,\,\1740 plasma\NN\5398023 albumin\NN\14736972 less\JJR\1740 than\IN\1740 2.2\CD\1740 g/dl\NN\1740 ,\,\1740 splenomegaly\NN\14366759 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 normal\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 atrophy\NN\14299637 approximately\RB\1740 half\NN\13732295 normal\JJ\1740 weight\NN\5009170 )\-RRB-\1740 after\IN\1740 12\CD\13745420 doses\NNS\3740161 of\IN\1740 <e1>carbon\NN\14622893 tetrachloride</e1>\NN\14818238 given\VBN\2327200 intragastrically\RB\1740 in\IN\13603305 the\DT\1740 phenobarbitone-primed\JJ\1740 rat\NN\2329401 was\VBD\836236 increased\VBN\169651 from\IN\1740 25\CD\13745420 %\NN\1740 to\TO\1740 56\CD\1740 %\NN\1740 by\IN\1740 giving\VBG\2327200 the\DT\1740 initial\JJ\1740 "\``\1740 calibrating\VBG\296178 "\``\1740 dose\NN\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 at\IN\14622893 the\DT\1740 peak\NN\13758296 of\IN\1740 the\DT\1740 phenobarbitone-induced\JJ\1740 <e2>enlargement\NN\363260 of\IN\1740 the\DT\1740 liver</e2>\NN\5298729 .\.\1740
D002251_D006529 NONE The\DT\1740 yield\NN\913705 of\IN\1740 severe\JJ\1740 cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver\NN\5298729 (\-LRB-\1740 defined\VBN\2604760 as\IN\14622893 a\DT\13649268 shrunken\JJ\1740 finely\RB\1740 nodular\JJ\1740 liver\NN\5298729 with\IN\1740 micronodular\JJ\1740 histology\NN\6060049 ,\,\1740 ascites\NNS\14204950 greater\JJR\1740 than\IN\1740 30\CD\13745420 ml\NN\13616054 ,\,\1740 plasma\NN\5398023 albumin\NN\14736972 less\JJR\1740 than\IN\1740 2.2\CD\1740 g/dl\NN\1740 ,\,\1740 splenomegaly\NN\14366759 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 normal\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 atrophy\NN\14299637 approximately\RB\1740 half\NN\13732295 normal\JJ\1740 weight\NN\5009170 )\-RRB-\1740 after\IN\1740 12\CD\13745420 doses\NNS\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 given\VBN\2327200 intragastrically\RB\1740 in\IN\13603305 the\DT\1740 phenobarbitone-primed\JJ\1740 rat\NN\2329401 was\VBD\836236 increased\VBN\169651 from\IN\1740 25\CD\13745420 %\NN\1740 to\TO\1740 56\CD\1740 %\NN\1740 by\IN\1740 giving\VBG\2327200 the\DT\1740 initial\JJ\1740 "\``\1740 calibrating\VBG\296178 "\``\1740 dose\NN\3740161 of\IN\1740 <e1>carbon\NN\14622893 tetrachloride</e1>\NN\14818238 at\IN\14622893 the\DT\1740 peak\NN\13758296 of\IN\1740 the\DT\1740 phenobarbitone-induced\JJ\1740 <e2>enlargement\NN\363260 of\IN\1740 the\DT\1740 liver</e2>\NN\5298729 .\.\1740
D002251_D005355 NONE Phenobarbitone-induced\JJ\1740 enlargement\NN\363260 of\IN\1740 the\DT\1740 liver\NN\5298729 in\IN\13603305 the\DT\1740 rat\NN\2329401 :\:\1740 its\PRP$\6125041 relationship\NN\31921 to\TO\1740 <e1>carbon\NN\14622893 tetrachloride-induced</e1>\JJ\1740 <e2>cirrhosis</e2>\NN\14116321 .\.\1740
D002251_D008103 CID The\DT\1740 yield\NN\913705 of\IN\1740 severe\JJ\1740 <e2>cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver</e2>\NN\5298729 (\-LRB-\1740 defined\VBN\2604760 as\IN\14622893 a\DT\13649268 shrunken\JJ\1740 finely\RB\1740 nodular\JJ\1740 liver\NN\5298729 with\IN\1740 micronodular\JJ\1740 histology\NN\6060049 ,\,\1740 ascites\NNS\14204950 greater\JJR\1740 than\IN\1740 30\CD\13745420 ml\NN\13616054 ,\,\1740 plasma\NN\5398023 albumin\NN\14736972 less\JJR\1740 than\IN\1740 2.2\CD\1740 g/dl\NN\1740 ,\,\1740 splenomegaly\NN\14366759 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 normal\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 atrophy\NN\14299637 approximately\RB\1740 half\NN\13732295 normal\JJ\1740 weight\NN\5009170 )\-RRB-\1740 after\IN\1740 12\CD\13745420 doses\NNS\3740161 of\IN\1740 <e1>carbon\NN\14622893 tetrachloride</e1>\NN\14818238 given\VBN\2327200 intragastrically\RB\1740 in\IN\13603305 the\DT\1740 phenobarbitone-primed\JJ\1740 rat\NN\2329401 was\VBD\836236 increased\VBN\169651 from\IN\1740 25\CD\13745420 %\NN\1740 to\TO\1740 56\CD\1740 %\NN\1740 by\IN\1740 giving\VBG\2327200 the\DT\1740 initial\JJ\1740 "\``\1740 calibrating\VBG\296178 "\``\1740 dose\NN\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 at\IN\14622893 the\DT\1740 peak\NN\13758296 of\IN\1740 the\DT\1740 phenobarbitone-induced\JJ\1740 enlargement\NN\363260 of\IN\1740 the\DT\1740 liver\NN\5298729 .\.\1740
D002251_D008103 CID The\DT\1740 yield\NN\913705 of\IN\1740 severe\JJ\1740 <e2>cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver</e2>\NN\5298729 (\-LRB-\1740 defined\VBN\2604760 as\IN\14622893 a\DT\13649268 shrunken\JJ\1740 finely\RB\1740 nodular\JJ\1740 liver\NN\5298729 with\IN\1740 micronodular\JJ\1740 histology\NN\6060049 ,\,\1740 ascites\NNS\14204950 greater\JJR\1740 than\IN\1740 30\CD\13745420 ml\NN\13616054 ,\,\1740 plasma\NN\5398023 albumin\NN\14736972 less\JJR\1740 than\IN\1740 2.2\CD\1740 g/dl\NN\1740 ,\,\1740 splenomegaly\NN\14366759 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 normal\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 atrophy\NN\14299637 approximately\RB\1740 half\NN\13732295 normal\JJ\1740 weight\NN\5009170 )\-RRB-\1740 after\IN\1740 12\CD\13745420 doses\NNS\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 given\VBN\2327200 intragastrically\RB\1740 in\IN\13603305 the\DT\1740 phenobarbitone-primed\JJ\1740 rat\NN\2329401 was\VBD\836236 increased\VBN\169651 from\IN\1740 25\CD\13745420 %\NN\1740 to\TO\1740 56\CD\1740 %\NN\1740 by\IN\1740 giving\VBG\2327200 the\DT\1740 initial\JJ\1740 "\``\1740 calibrating\VBG\296178 "\``\1740 dose\NN\3740161 of\IN\1740 <e1>carbon\NN\14622893 tetrachloride</e1>\NN\14818238 at\IN\14622893 the\DT\1740 peak\NN\13758296 of\IN\1740 the\DT\1740 phenobarbitone-induced\JJ\1740 enlargement\NN\363260 of\IN\1740 the\DT\1740 liver\NN\5298729 .\.\1740
D002251_D001201 NONE The\DT\1740 yield\NN\913705 of\IN\1740 severe\JJ\1740 cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver\NN\5298729 (\-LRB-\1740 defined\VBN\2604760 as\IN\14622893 a\DT\13649268 shrunken\JJ\1740 finely\RB\1740 nodular\JJ\1740 liver\NN\5298729 with\IN\1740 micronodular\JJ\1740 histology\NN\6060049 ,\,\1740 <e2>ascites</e2>\NNS\14204950 greater\JJR\1740 than\IN\1740 30\CD\13745420 ml\NN\13616054 ,\,\1740 plasma\NN\5398023 albumin\NN\14736972 less\JJR\1740 than\IN\1740 2.2\CD\1740 g/dl\NN\1740 ,\,\1740 splenomegaly\NN\14366759 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 normal\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 atrophy\NN\14299637 approximately\RB\1740 half\NN\13732295 normal\JJ\1740 weight\NN\5009170 )\-RRB-\1740 after\IN\1740 12\CD\13745420 doses\NNS\3740161 of\IN\1740 <e1>carbon\NN\14622893 tetrachloride</e1>\NN\14818238 given\VBN\2327200 intragastrically\RB\1740 in\IN\13603305 the\DT\1740 phenobarbitone-primed\JJ\1740 rat\NN\2329401 was\VBD\836236 increased\VBN\169651 from\IN\1740 25\CD\13745420 %\NN\1740 to\TO\1740 56\CD\1740 %\NN\1740 by\IN\1740 giving\VBG\2327200 the\DT\1740 initial\JJ\1740 "\``\1740 calibrating\VBG\296178 "\``\1740 dose\NN\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 at\IN\14622893 the\DT\1740 peak\NN\13758296 of\IN\1740 the\DT\1740 phenobarbitone-induced\JJ\1740 enlargement\NN\363260 of\IN\1740 the\DT\1740 liver\NN\5298729 .\.\1740
D002251_D001201 NONE The\DT\1740 yield\NN\913705 of\IN\1740 severe\JJ\1740 cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver\NN\5298729 (\-LRB-\1740 defined\VBN\2604760 as\IN\14622893 a\DT\13649268 shrunken\JJ\1740 finely\RB\1740 nodular\JJ\1740 liver\NN\5298729 with\IN\1740 micronodular\JJ\1740 histology\NN\6060049 ,\,\1740 <e2>ascites</e2>\NNS\14204950 greater\JJR\1740 than\IN\1740 30\CD\13745420 ml\NN\13616054 ,\,\1740 plasma\NN\5398023 albumin\NN\14736972 less\JJR\1740 than\IN\1740 2.2\CD\1740 g/dl\NN\1740 ,\,\1740 splenomegaly\NN\14366759 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 normal\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 atrophy\NN\14299637 approximately\RB\1740 half\NN\13732295 normal\JJ\1740 weight\NN\5009170 )\-RRB-\1740 after\IN\1740 12\CD\13745420 doses\NNS\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 given\VBN\2327200 intragastrically\RB\1740 in\IN\13603305 the\DT\1740 phenobarbitone-primed\JJ\1740 rat\NN\2329401 was\VBD\836236 increased\VBN\169651 from\IN\1740 25\CD\13745420 %\NN\1740 to\TO\1740 56\CD\1740 %\NN\1740 by\IN\1740 giving\VBG\2327200 the\DT\1740 initial\JJ\1740 "\``\1740 calibrating\VBG\296178 "\``\1740 dose\NN\3740161 of\IN\1740 <e1>carbon\NN\14622893 tetrachloride</e1>\NN\14818238 at\IN\14622893 the\DT\1740 peak\NN\13758296 of\IN\1740 the\DT\1740 phenobarbitone-induced\JJ\1740 enlargement\NN\363260 of\IN\1740 the\DT\1740 liver\NN\5298729 .\.\1740
D002251_D013163 NONE The\DT\1740 yield\NN\913705 of\IN\1740 severe\JJ\1740 cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver\NN\5298729 (\-LRB-\1740 defined\VBN\2604760 as\IN\14622893 a\DT\13649268 shrunken\JJ\1740 finely\RB\1740 nodular\JJ\1740 liver\NN\5298729 with\IN\1740 micronodular\JJ\1740 histology\NN\6060049 ,\,\1740 ascites\NNS\14204950 greater\JJR\1740 than\IN\1740 30\CD\13745420 ml\NN\13616054 ,\,\1740 plasma\NN\5398023 albumin\NN\14736972 less\JJR\1740 than\IN\1740 2.2\CD\1740 g/dl\NN\1740 ,\,\1740 <e2>splenomegaly</e2>\NN\14366759 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 normal\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 atrophy\NN\14299637 approximately\RB\1740 half\NN\13732295 normal\JJ\1740 weight\NN\5009170 )\-RRB-\1740 after\IN\1740 12\CD\13745420 doses\NNS\3740161 of\IN\1740 <e1>carbon\NN\14622893 tetrachloride</e1>\NN\14818238 given\VBN\2327200 intragastrically\RB\1740 in\IN\13603305 the\DT\1740 phenobarbitone-primed\JJ\1740 rat\NN\2329401 was\VBD\836236 increased\VBN\169651 from\IN\1740 25\CD\13745420 %\NN\1740 to\TO\1740 56\CD\1740 %\NN\1740 by\IN\1740 giving\VBG\2327200 the\DT\1740 initial\JJ\1740 "\``\1740 calibrating\VBG\296178 "\``\1740 dose\NN\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 at\IN\14622893 the\DT\1740 peak\NN\13758296 of\IN\1740 the\DT\1740 phenobarbitone-induced\JJ\1740 enlargement\NN\363260 of\IN\1740 the\DT\1740 liver\NN\5298729 .\.\1740
D002251_D013163 NONE The\DT\1740 yield\NN\913705 of\IN\1740 severe\JJ\1740 cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver\NN\5298729 (\-LRB-\1740 defined\VBN\2604760 as\IN\14622893 a\DT\13649268 shrunken\JJ\1740 finely\RB\1740 nodular\JJ\1740 liver\NN\5298729 with\IN\1740 micronodular\JJ\1740 histology\NN\6060049 ,\,\1740 ascites\NNS\14204950 greater\JJR\1740 than\IN\1740 30\CD\13745420 ml\NN\13616054 ,\,\1740 plasma\NN\5398023 albumin\NN\14736972 less\JJR\1740 than\IN\1740 2.2\CD\1740 g/dl\NN\1740 ,\,\1740 <e2>splenomegaly</e2>\NN\14366759 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 normal\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 atrophy\NN\14299637 approximately\RB\1740 half\NN\13732295 normal\JJ\1740 weight\NN\5009170 )\-RRB-\1740 after\IN\1740 12\CD\13745420 doses\NNS\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 given\VBN\2327200 intragastrically\RB\1740 in\IN\13603305 the\DT\1740 phenobarbitone-primed\JJ\1740 rat\NN\2329401 was\VBD\836236 increased\VBN\169651 from\IN\1740 25\CD\13745420 %\NN\1740 to\TO\1740 56\CD\1740 %\NN\1740 by\IN\1740 giving\VBG\2327200 the\DT\1740 initial\JJ\1740 "\``\1740 calibrating\VBG\296178 "\``\1740 dose\NN\3740161 of\IN\1740 <e1>carbon\NN\14622893 tetrachloride</e1>\NN\14818238 at\IN\14622893 the\DT\1740 peak\NN\13758296 of\IN\1740 the\DT\1740 phenobarbitone-induced\JJ\1740 enlargement\NN\363260 of\IN\1740 the\DT\1740 liver\NN\5298729 .\.\1740
D002251_D001284 NONE The\DT\1740 yield\NN\913705 of\IN\1740 severe\JJ\1740 cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver\NN\5298729 (\-LRB-\1740 defined\VBN\2604760 as\IN\14622893 a\DT\13649268 shrunken\JJ\1740 finely\RB\1740 nodular\JJ\1740 liver\NN\5298729 with\IN\1740 micronodular\JJ\1740 histology\NN\6060049 ,\,\1740 ascites\NNS\14204950 greater\JJR\1740 than\IN\1740 30\CD\13745420 ml\NN\13616054 ,\,\1740 plasma\NN\5398023 albumin\NN\14736972 less\JJR\1740 than\IN\1740 2.2\CD\1740 g/dl\NN\1740 ,\,\1740 splenomegaly\NN\14366759 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 normal\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 <e2>atrophy</e2>\NN\14299637 approximately\RB\1740 half\NN\13732295 normal\JJ\1740 weight\NN\5009170 )\-RRB-\1740 after\IN\1740 12\CD\13745420 doses\NNS\3740161 of\IN\1740 <e1>carbon\NN\14622893 tetrachloride</e1>\NN\14818238 given\VBN\2327200 intragastrically\RB\1740 in\IN\13603305 the\DT\1740 phenobarbitone-primed\JJ\1740 rat\NN\2329401 was\VBD\836236 increased\VBN\169651 from\IN\1740 25\CD\13745420 %\NN\1740 to\TO\1740 56\CD\1740 %\NN\1740 by\IN\1740 giving\VBG\2327200 the\DT\1740 initial\JJ\1740 "\``\1740 calibrating\VBG\296178 "\``\1740 dose\NN\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 at\IN\14622893 the\DT\1740 peak\NN\13758296 of\IN\1740 the\DT\1740 phenobarbitone-induced\JJ\1740 enlargement\NN\363260 of\IN\1740 the\DT\1740 liver\NN\5298729 .\.\1740
D002251_D001284 NONE The\DT\1740 yield\NN\913705 of\IN\1740 severe\JJ\1740 cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver\NN\5298729 (\-LRB-\1740 defined\VBN\2604760 as\IN\14622893 a\DT\13649268 shrunken\JJ\1740 finely\RB\1740 nodular\JJ\1740 liver\NN\5298729 with\IN\1740 micronodular\JJ\1740 histology\NN\6060049 ,\,\1740 ascites\NNS\14204950 greater\JJR\1740 than\IN\1740 30\CD\13745420 ml\NN\13616054 ,\,\1740 plasma\NN\5398023 albumin\NN\14736972 less\JJR\1740 than\IN\1740 2.2\CD\1740 g/dl\NN\1740 ,\,\1740 splenomegaly\NN\14366759 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 normal\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 <e2>atrophy</e2>\NN\14299637 approximately\RB\1740 half\NN\13732295 normal\JJ\1740 weight\NN\5009170 )\-RRB-\1740 after\IN\1740 12\CD\13745420 doses\NNS\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 given\VBN\2327200 intragastrically\RB\1740 in\IN\13603305 the\DT\1740 phenobarbitone-primed\JJ\1740 rat\NN\2329401 was\VBD\836236 increased\VBN\169651 from\IN\1740 25\CD\13745420 %\NN\1740 to\TO\1740 56\CD\1740 %\NN\1740 by\IN\1740 giving\VBG\2327200 the\DT\1740 initial\JJ\1740 "\``\1740 calibrating\VBG\296178 "\``\1740 dose\NN\3740161 of\IN\1740 <e1>carbon\NN\14622893 tetrachloride</e1>\NN\14818238 at\IN\14622893 the\DT\1740 peak\NN\13758296 of\IN\1740 the\DT\1740 phenobarbitone-induced\JJ\1740 enlargement\NN\363260 of\IN\1740 the\DT\1740 liver\NN\5298729 .\.\1740
D010634_D008103 CID The\DT\1740 yield\NN\913705 of\IN\1740 severe\JJ\1740 <e2>cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver</e2>\NN\5298729 (\-LRB-\1740 defined\VBN\2604760 as\IN\14622893 a\DT\13649268 shrunken\JJ\1740 finely\RB\1740 nodular\JJ\1740 liver\NN\5298729 with\IN\1740 micronodular\JJ\1740 histology\NN\6060049 ,\,\1740 ascites\NNS\14204950 greater\JJR\1740 than\IN\1740 30\CD\13745420 ml\NN\13616054 ,\,\1740 plasma\NN\5398023 albumin\NN\14736972 less\JJR\1740 than\IN\1740 2.2\CD\1740 g/dl\NN\1740 ,\,\1740 splenomegaly\NN\14366759 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 normal\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 atrophy\NN\14299637 approximately\RB\1740 half\NN\13732295 normal\JJ\1740 weight\NN\5009170 )\-RRB-\1740 after\IN\1740 12\CD\13745420 doses\NNS\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 given\VBN\2327200 intragastrically\RB\1740 in\IN\13603305 the\DT\1740 <e1>phenobarbitone-primed</e1>\JJ\1740 rat\NN\2329401 was\VBD\836236 increased\VBN\169651 from\IN\1740 25\CD\13745420 %\NN\1740 to\TO\1740 56\CD\1740 %\NN\1740 by\IN\1740 giving\VBG\2327200 the\DT\1740 initial\JJ\1740 "\``\1740 calibrating\VBG\296178 "\``\1740 dose\NN\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 at\IN\14622893 the\DT\1740 peak\NN\13758296 of\IN\1740 the\DT\1740 phenobarbitone-induced\JJ\1740 enlargement\NN\363260 of\IN\1740 the\DT\1740 liver\NN\5298729 .\.\1740
D010634_D008103 CID The\DT\1740 yield\NN\913705 of\IN\1740 severe\JJ\1740 <e2>cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver</e2>\NN\5298729 (\-LRB-\1740 defined\VBN\2604760 as\IN\14622893 a\DT\13649268 shrunken\JJ\1740 finely\RB\1740 nodular\JJ\1740 liver\NN\5298729 with\IN\1740 micronodular\JJ\1740 histology\NN\6060049 ,\,\1740 ascites\NNS\14204950 greater\JJR\1740 than\IN\1740 30\CD\13745420 ml\NN\13616054 ,\,\1740 plasma\NN\5398023 albumin\NN\14736972 less\JJR\1740 than\IN\1740 2.2\CD\1740 g/dl\NN\1740 ,\,\1740 splenomegaly\NN\14366759 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 normal\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 atrophy\NN\14299637 approximately\RB\1740 half\NN\13732295 normal\JJ\1740 weight\NN\5009170 )\-RRB-\1740 after\IN\1740 12\CD\13745420 doses\NNS\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 given\VBN\2327200 intragastrically\RB\1740 in\IN\13603305 the\DT\1740 phenobarbitone-primed\JJ\1740 rat\NN\2329401 was\VBD\836236 increased\VBN\169651 from\IN\1740 25\CD\13745420 %\NN\1740 to\TO\1740 56\CD\1740 %\NN\1740 by\IN\1740 giving\VBG\2327200 the\DT\1740 initial\JJ\1740 "\``\1740 calibrating\VBG\296178 "\``\1740 dose\NN\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 at\IN\14622893 the\DT\1740 peak\NN\13758296 of\IN\1740 the\DT\1740 <e1>phenobarbitone-induced</e1>\JJ\1740 enlargement\NN\363260 of\IN\1740 the\DT\1740 liver\NN\5298729 .\.\1740
D010634_D001201 NONE The\DT\1740 yield\NN\913705 of\IN\1740 severe\JJ\1740 cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver\NN\5298729 (\-LRB-\1740 defined\VBN\2604760 as\IN\14622893 a\DT\13649268 shrunken\JJ\1740 finely\RB\1740 nodular\JJ\1740 liver\NN\5298729 with\IN\1740 micronodular\JJ\1740 histology\NN\6060049 ,\,\1740 <e2>ascites</e2>\NNS\14204950 greater\JJR\1740 than\IN\1740 30\CD\13745420 ml\NN\13616054 ,\,\1740 plasma\NN\5398023 albumin\NN\14736972 less\JJR\1740 than\IN\1740 2.2\CD\1740 g/dl\NN\1740 ,\,\1740 splenomegaly\NN\14366759 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 normal\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 atrophy\NN\14299637 approximately\RB\1740 half\NN\13732295 normal\JJ\1740 weight\NN\5009170 )\-RRB-\1740 after\IN\1740 12\CD\13745420 doses\NNS\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 given\VBN\2327200 intragastrically\RB\1740 in\IN\13603305 the\DT\1740 <e1>phenobarbitone-primed</e1>\JJ\1740 rat\NN\2329401 was\VBD\836236 increased\VBN\169651 from\IN\1740 25\CD\13745420 %\NN\1740 to\TO\1740 56\CD\1740 %\NN\1740 by\IN\1740 giving\VBG\2327200 the\DT\1740 initial\JJ\1740 "\``\1740 calibrating\VBG\296178 "\``\1740 dose\NN\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 at\IN\14622893 the\DT\1740 peak\NN\13758296 of\IN\1740 the\DT\1740 phenobarbitone-induced\JJ\1740 enlargement\NN\363260 of\IN\1740 the\DT\1740 liver\NN\5298729 .\.\1740
D010634_D001201 NONE The\DT\1740 yield\NN\913705 of\IN\1740 severe\JJ\1740 cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver\NN\5298729 (\-LRB-\1740 defined\VBN\2604760 as\IN\14622893 a\DT\13649268 shrunken\JJ\1740 finely\RB\1740 nodular\JJ\1740 liver\NN\5298729 with\IN\1740 micronodular\JJ\1740 histology\NN\6060049 ,\,\1740 <e2>ascites</e2>\NNS\14204950 greater\JJR\1740 than\IN\1740 30\CD\13745420 ml\NN\13616054 ,\,\1740 plasma\NN\5398023 albumin\NN\14736972 less\JJR\1740 than\IN\1740 2.2\CD\1740 g/dl\NN\1740 ,\,\1740 splenomegaly\NN\14366759 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 normal\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 atrophy\NN\14299637 approximately\RB\1740 half\NN\13732295 normal\JJ\1740 weight\NN\5009170 )\-RRB-\1740 after\IN\1740 12\CD\13745420 doses\NNS\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 given\VBN\2327200 intragastrically\RB\1740 in\IN\13603305 the\DT\1740 phenobarbitone-primed\JJ\1740 rat\NN\2329401 was\VBD\836236 increased\VBN\169651 from\IN\1740 25\CD\13745420 %\NN\1740 to\TO\1740 56\CD\1740 %\NN\1740 by\IN\1740 giving\VBG\2327200 the\DT\1740 initial\JJ\1740 "\``\1740 calibrating\VBG\296178 "\``\1740 dose\NN\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 at\IN\14622893 the\DT\1740 peak\NN\13758296 of\IN\1740 the\DT\1740 <e1>phenobarbitone-induced</e1>\JJ\1740 enlargement\NN\363260 of\IN\1740 the\DT\1740 liver\NN\5298729 .\.\1740
D010634_D013163 NONE The\DT\1740 yield\NN\913705 of\IN\1740 severe\JJ\1740 cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver\NN\5298729 (\-LRB-\1740 defined\VBN\2604760 as\IN\14622893 a\DT\13649268 shrunken\JJ\1740 finely\RB\1740 nodular\JJ\1740 liver\NN\5298729 with\IN\1740 micronodular\JJ\1740 histology\NN\6060049 ,\,\1740 ascites\NNS\14204950 greater\JJR\1740 than\IN\1740 30\CD\13745420 ml\NN\13616054 ,\,\1740 plasma\NN\5398023 albumin\NN\14736972 less\JJR\1740 than\IN\1740 2.2\CD\1740 g/dl\NN\1740 ,\,\1740 <e2>splenomegaly</e2>\NN\14366759 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 normal\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 atrophy\NN\14299637 approximately\RB\1740 half\NN\13732295 normal\JJ\1740 weight\NN\5009170 )\-RRB-\1740 after\IN\1740 12\CD\13745420 doses\NNS\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 given\VBN\2327200 intragastrically\RB\1740 in\IN\13603305 the\DT\1740 <e1>phenobarbitone-primed</e1>\JJ\1740 rat\NN\2329401 was\VBD\836236 increased\VBN\169651 from\IN\1740 25\CD\13745420 %\NN\1740 to\TO\1740 56\CD\1740 %\NN\1740 by\IN\1740 giving\VBG\2327200 the\DT\1740 initial\JJ\1740 "\``\1740 calibrating\VBG\296178 "\``\1740 dose\NN\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 at\IN\14622893 the\DT\1740 peak\NN\13758296 of\IN\1740 the\DT\1740 phenobarbitone-induced\JJ\1740 enlargement\NN\363260 of\IN\1740 the\DT\1740 liver\NN\5298729 .\.\1740
D010634_D013163 NONE The\DT\1740 yield\NN\913705 of\IN\1740 severe\JJ\1740 cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver\NN\5298729 (\-LRB-\1740 defined\VBN\2604760 as\IN\14622893 a\DT\13649268 shrunken\JJ\1740 finely\RB\1740 nodular\JJ\1740 liver\NN\5298729 with\IN\1740 micronodular\JJ\1740 histology\NN\6060049 ,\,\1740 ascites\NNS\14204950 greater\JJR\1740 than\IN\1740 30\CD\13745420 ml\NN\13616054 ,\,\1740 plasma\NN\5398023 albumin\NN\14736972 less\JJR\1740 than\IN\1740 2.2\CD\1740 g/dl\NN\1740 ,\,\1740 <e2>splenomegaly</e2>\NN\14366759 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 normal\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 atrophy\NN\14299637 approximately\RB\1740 half\NN\13732295 normal\JJ\1740 weight\NN\5009170 )\-RRB-\1740 after\IN\1740 12\CD\13745420 doses\NNS\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 given\VBN\2327200 intragastrically\RB\1740 in\IN\13603305 the\DT\1740 phenobarbitone-primed\JJ\1740 rat\NN\2329401 was\VBD\836236 increased\VBN\169651 from\IN\1740 25\CD\13745420 %\NN\1740 to\TO\1740 56\CD\1740 %\NN\1740 by\IN\1740 giving\VBG\2327200 the\DT\1740 initial\JJ\1740 "\``\1740 calibrating\VBG\296178 "\``\1740 dose\NN\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 at\IN\14622893 the\DT\1740 peak\NN\13758296 of\IN\1740 the\DT\1740 <e1>phenobarbitone-induced</e1>\JJ\1740 enlargement\NN\363260 of\IN\1740 the\DT\1740 liver\NN\5298729 .\.\1740
D010634_D001284 NONE The\DT\1740 yield\NN\913705 of\IN\1740 severe\JJ\1740 cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver\NN\5298729 (\-LRB-\1740 defined\VBN\2604760 as\IN\14622893 a\DT\13649268 shrunken\JJ\1740 finely\RB\1740 nodular\JJ\1740 liver\NN\5298729 with\IN\1740 micronodular\JJ\1740 histology\NN\6060049 ,\,\1740 ascites\NNS\14204950 greater\JJR\1740 than\IN\1740 30\CD\13745420 ml\NN\13616054 ,\,\1740 plasma\NN\5398023 albumin\NN\14736972 less\JJR\1740 than\IN\1740 2.2\CD\1740 g/dl\NN\1740 ,\,\1740 splenomegaly\NN\14366759 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 normal\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 <e2>atrophy</e2>\NN\14299637 approximately\RB\1740 half\NN\13732295 normal\JJ\1740 weight\NN\5009170 )\-RRB-\1740 after\IN\1740 12\CD\13745420 doses\NNS\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 given\VBN\2327200 intragastrically\RB\1740 in\IN\13603305 the\DT\1740 <e1>phenobarbitone-primed</e1>\JJ\1740 rat\NN\2329401 was\VBD\836236 increased\VBN\169651 from\IN\1740 25\CD\13745420 %\NN\1740 to\TO\1740 56\CD\1740 %\NN\1740 by\IN\1740 giving\VBG\2327200 the\DT\1740 initial\JJ\1740 "\``\1740 calibrating\VBG\296178 "\``\1740 dose\NN\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 at\IN\14622893 the\DT\1740 peak\NN\13758296 of\IN\1740 the\DT\1740 phenobarbitone-induced\JJ\1740 enlargement\NN\363260 of\IN\1740 the\DT\1740 liver\NN\5298729 .\.\1740
D010634_D001284 NONE The\DT\1740 yield\NN\913705 of\IN\1740 severe\JJ\1740 cirrhosis\NN\14116321 of\IN\1740 the\DT\1740 liver\NN\5298729 (\-LRB-\1740 defined\VBN\2604760 as\IN\14622893 a\DT\13649268 shrunken\JJ\1740 finely\RB\1740 nodular\JJ\1740 liver\NN\5298729 with\IN\1740 micronodular\JJ\1740 histology\NN\6060049 ,\,\1740 ascites\NNS\14204950 greater\JJR\1740 than\IN\1740 30\CD\13745420 ml\NN\13616054 ,\,\1740 plasma\NN\5398023 albumin\NN\14736972 less\JJR\1740 than\IN\1740 2.2\CD\1740 g/dl\NN\1740 ,\,\1740 splenomegaly\NN\14366759 2\CD\13741022 -\SYM\1740 3\CD\13741022 times\NNS\15113229 normal\JJ\1740 ,\,\1740 and\CC\1740 testicular\JJ\1740 <e2>atrophy</e2>\NN\14299637 approximately\RB\1740 half\NN\13732295 normal\JJ\1740 weight\NN\5009170 )\-RRB-\1740 after\IN\1740 12\CD\13745420 doses\NNS\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 given\VBN\2327200 intragastrically\RB\1740 in\IN\13603305 the\DT\1740 phenobarbitone-primed\JJ\1740 rat\NN\2329401 was\VBD\836236 increased\VBN\169651 from\IN\1740 25\CD\13745420 %\NN\1740 to\TO\1740 56\CD\1740 %\NN\1740 by\IN\1740 giving\VBG\2327200 the\DT\1740 initial\JJ\1740 "\``\1740 calibrating\VBG\296178 "\``\1740 dose\NN\3740161 of\IN\1740 carbon\NN\14622893 tetrachloride\NN\14818238 at\IN\14622893 the\DT\1740 peak\NN\13758296 of\IN\1740 the\DT\1740 <e1>phenobarbitone-induced</e1>\JJ\1740 enlargement\NN\363260 of\IN\1740 the\DT\1740 liver\NN\5298729 .\.\1740
17242861
D010862_D012640 NONE QTLs\NNS\1740 for\IN\1740 susceptibility\NN\13920835 to\TO\1740 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 ,\,\1740 a\DT\13649268 model\NN\5888929 of\IN\1740 temporal\JJ\1740 lobe\JJ\1740 epilepsy\NN\14085708 ,\,\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 reported\VBN\831651 ,\,\1740 and\CC\1740 CSS\NN\14625458 have\VBP\2108377 not\RB\1740 previously\RB\1740 been\VBN\836236 used\VBN\1156834 to\TO\1740 localize\VB\2694933 seizure\JJ\1740 susceptibility\NN\13920835 genes\NNS\8459252 .\.\1740
D010862_D012640 NONE QTLs\NNS\1740 for\IN\1740 susceptibility\NN\13920835 to\TO\1740 <e1>pilocarpine-induced</e1>\JJ\1740 seizures\NNS\14081375 ,\,\1740 a\DT\13649268 model\NN\5888929 of\IN\1740 temporal\JJ\1740 lobe\JJ\1740 epilepsy\NN\14085708 ,\,\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 reported\VBN\831651 ,\,\1740 and\CC\1740 CSS\NN\14625458 have\VBP\2108377 not\RB\1740 previously\RB\1740 been\VBN\836236 used\VBN\1156834 to\TO\1740 localize\VB\2694933 <e2>seizure</e2>\JJ\1740 susceptibility\NN\13920835 genes\NNS\8459252 .\.\1740
D010862_D012640 NONE We\PRP\1740 report\VBP\831651 QTLs\NNS\1740 identified\VBN\699815 using\VBG\1156834 a\DT\13649268 B6\NN\1740 (\-LRB-\1740 host\NN\9605289 )\-RRB-\1740 x\CC\13745420 A/J\NN\1740 (\-LRB-\1740 donor\NN\9608709 )\-RRB-\1740 CSS\NN\14625458 panel\NN\4188643 to\TO\1740 localize\VB\2694933 genes\NNS\8459252 involved\VBN\2676054 in\IN\13603305 susceptibility\NN\13920835 to\TO\1740 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D010862_D012640 NONE Three\CD\13741022 hundred\CD\13745420 fifty-five\JJ\1740 adult\JJ\1740 male\JJ\1740 CSS\NN\14625458 mice\NNS\2329401 ,\,\1740 58\CD\1740 B6\NN\1740 ,\,\1740 and\CC\1740 39\CD\1740 A/J\NN\1740 were\VBD\836236 tested\VBN\670261 for\IN\1740 susceptibility\NN\13920835 to\TO\1740 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D010862_D004833 CID QTLs\NNS\1740 for\IN\1740 susceptibility\NN\13920835 to\TO\1740 <e1>pilocarpine-induced</e1>\JJ\1740 seizures\NNS\14081375 ,\,\1740 a\DT\13649268 model\NN\5888929 of\IN\1740 <e2>temporal\JJ\1740 lobe\JJ\1740 epilepsy</e2>\NN\14085708 ,\,\1740 have\VBP\2108377 not\RB\1740 been\VBN\836236 reported\VBN\831651 ,\,\1740 and\CC\1740 CSS\NN\14625458 have\VBP\2108377 not\RB\1740 previously\RB\1740 been\VBN\836236 used\VBN\1156834 to\TO\1740 localize\VB\2694933 seizure\JJ\1740 susceptibility\NN\13920835 genes\NNS\8459252 .\.\1740
15278670
C009250_D012640 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>sevoflurane</e1>\NN\1740 on\IN\1740 lidocaine-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
C009250_D012640 NONE The\DT\1740 influence\NN\5190804 of\IN\1740 <e1>sevoflurane</e1>\NN\1740 on\IN\1740 lidocaine-induced\JJ\1740 <e2>convulsions</e2>\NNS\14081375 was\VBD\836236 studied\VBN\630380 in\IN\13603305 cats\NNS\2120997 .\.\1740
C009250_D012640 NONE The\DT\1740 <e2>convulsive</e2>\JJ\1740 threshold\NN\15265518 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 SD\NN\1740 )\-RRB-\1740 was\VBD\836236 41.4\CD\1740 +/-\CC\1740 6.5\CD\1740 mg.\NN\1740 l(-1\NN\1740 )\-RRB-\1740 with\IN\1740 lidocaine\NN\3681148 infusion\NN\14589223 (\-LRB-\1740 6\CD\13741022 mg.kg(-1).min(-1\NN\1740 )\-RRB-\1740 )\-RRB-\1740 ,\,\1740 increasing\VBG\169651 significantly\RB\1740 to\TO\1740 66.6\CD\1740 +/-\CC\1740 10.9\CD\1740 mg.\NN\1740 l(-1\NN\1740 )\-RRB-\1740 when\WRB\1740 the\DT\1740 end-tidal\JJ\1740 concentration\NN\4916342 of\IN\1740 <e1>sevoflurane</e1>\NN\1740 was\VBD\836236 0.8\CD\1740 %\NN\1740 .\.\1740
C009250_D012640 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 the\DT\1740 <e2>convulsive</e2>\JJ\1740 threshold\NN\15265518 between\IN\1740 <e1>sevoflurane</e1>\NN\1740 and\CC\1740 enflurane\NN\3299929 .\.\1740
C009250_D012640 NONE The\DT\1740 rise\NN\7324673 in\IN\13603305 blood\NN\5397468 pressure\NN\11419404 became\VBD\146138 less\RBR\1740 marked\JJ\1740 when\WRB\1740 higher\JJR\1740 concentrations\NNS\4916342 of\IN\1740 <e1>sevoflurane</e1>\NN\1740 or\CC\3541091 enflurane\NN\3299929 were\VBD\836236 administered\VBN\2436349 and\CC\1740 the\DT\1740 blood\NN\5397468 pressure\NN\11419404 at\IN\14622893 <e2>convulsions</e2>\NNS\14081375 decreased\VBD\169651 significantly\RB\1740 in\IN\13603305 1.6\CD\1740 %\NN\1740 sevoflurane\NN\1740 ,\,\1740 and\CC\1740 in\IN\13603305 0.8\CD\1740 %\NN\1740 and\CC\1740 1.6\CD\1740 %\NN\1740 enflurane\NN\3299929 .\.\1740
C009250_D012640 NONE The\DT\1740 rise\NN\7324673 in\IN\13603305 blood\NN\5397468 pressure\NN\11419404 became\VBD\146138 less\RBR\1740 marked\JJ\1740 when\WRB\1740 higher\JJR\1740 concentrations\NNS\4916342 of\IN\1740 sevoflurane\NN\1740 or\CC\3541091 enflurane\NN\3299929 were\VBD\836236 administered\VBN\2436349 and\CC\1740 the\DT\1740 blood\NN\5397468 pressure\NN\11419404 at\IN\14622893 <e2>convulsions</e2>\NNS\14081375 decreased\VBD\169651 significantly\RB\1740 in\IN\13603305 1.6\CD\1740 %\NN\1740 <e1>sevoflurane</e1>\NN\1740 ,\,\1740 and\CC\1740 in\IN\13603305 0.8\CD\1740 %\NN\1740 and\CC\1740 1.6\CD\1740 %\NN\1740 enflurane\NN\3299929 .\.\1740
C009250_D012640 NONE It\PRP\6125041 is\VBZ\836236 suggested\VBN\1010118 that\IN\1740 <e1>sevoflurane</e1>\NN\1740 reduces\VBZ\441445 the\DT\1740 <e2>convulsive</e2>\JJ\1740 effect\NN\34213 of\IN\1740 lidocaine\NN\3681148 toxicity\NN\13576101 but\CC\1740 carries\VBZ\1850315 some\DT\1740 risk\NN\14541044 due\IN\5174653 to\IN\1740 circulatory\JJ\1740 depression\NN\14373582 .\.\1740
D008012_D012640 CID The\DT\1740 effects\NNS\13245626 of\IN\1740 sevoflurane\NN\1740 on\IN\1740 <e1>lidocaine-induced</e1>\JJ\1740 <e2>convulsions</e2>\NNS\14081375 .\.\1740
D008012_D012640 CID The\DT\1740 influence\NN\5190804 of\IN\1740 sevoflurane\NN\1740 on\IN\1740 <e1>lidocaine-induced</e1>\JJ\1740 <e2>convulsions</e2>\NNS\14081375 was\VBD\836236 studied\VBN\630380 in\IN\13603305 cats\NNS\2120997 .\.\1740
D008012_D012640 CID The\DT\1740 <e2>convulsive</e2>\JJ\1740 threshold\NN\15265518 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 SD\NN\1740 )\-RRB-\1740 was\VBD\836236 41.4\CD\1740 +/-\CC\1740 6.5\CD\1740 mg.\NN\1740 l(-1\NN\1740 )\-RRB-\1740 with\IN\1740 <e1>lidocaine</e1>\NN\3681148 infusion\NN\14589223 (\-LRB-\1740 6\CD\13741022 mg.kg(-1).min(-1\NN\1740 )\-RRB-\1740 )\-RRB-\1740 ,\,\1740 increasing\VBG\169651 significantly\RB\1740 to\TO\1740 66.6\CD\1740 +/-\CC\1740 10.9\CD\1740 mg.\NN\1740 l(-1\NN\1740 )\-RRB-\1740 when\WRB\1740 the\DT\1740 end-tidal\JJ\1740 concentration\NN\4916342 of\IN\1740 sevoflurane\NN\1740 was\VBD\836236 0.8\CD\1740 %\NN\1740 .\.\1740
D008012_D012640 CID It\PRP\6125041 is\VBZ\836236 suggested\VBN\1010118 that\IN\1740 sevoflurane\NN\1740 reduces\VBZ\441445 the\DT\1740 <e2>convulsive</e2>\JJ\1740 effect\NN\34213 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 toxicity\NN\13576101 but\CC\1740 carries\VBZ\1850315 some\DT\1740 risk\NN\14541044 due\IN\5174653 to\IN\1740 circulatory\JJ\1740 depression\NN\14373582 .\.\1740
D004737_D012640 NONE There\EX\27167 was\VBD\836236 no\DT\7204911 significant\JJ\1740 difference\NN\4723816 in\IN\13603305 the\DT\1740 <e2>convulsive</e2>\JJ\1740 threshold\NN\15265518 between\IN\1740 sevoflurane\NN\1740 and\CC\1740 <e1>enflurane</e1>\NN\3299929 .\.\1740
D004737_D012640 NONE The\DT\1740 rise\NN\7324673 in\IN\13603305 blood\NN\5397468 pressure\NN\11419404 became\VBD\146138 less\RBR\1740 marked\JJ\1740 when\WRB\1740 higher\JJR\1740 concentrations\NNS\4916342 of\IN\1740 sevoflurane\NN\1740 or\CC\3541091 <e1>enflurane</e1>\NN\3299929 were\VBD\836236 administered\VBN\2436349 and\CC\1740 the\DT\1740 blood\NN\5397468 pressure\NN\11419404 at\IN\14622893 <e2>convulsions</e2>\NNS\14081375 decreased\VBD\169651 significantly\RB\1740 in\IN\13603305 1.6\CD\1740 %\NN\1740 sevoflurane\NN\1740 ,\,\1740 and\CC\1740 in\IN\13603305 0.8\CD\1740 %\NN\1740 and\CC\1740 1.6\CD\1740 %\NN\1740 enflurane\NN\3299929 .\.\1740
D004737_D012640 NONE The\DT\1740 rise\NN\7324673 in\IN\13603305 blood\NN\5397468 pressure\NN\11419404 became\VBD\146138 less\RBR\1740 marked\JJ\1740 when\WRB\1740 higher\JJR\1740 concentrations\NNS\4916342 of\IN\1740 sevoflurane\NN\1740 or\CC\3541091 enflurane\NN\3299929 were\VBD\836236 administered\VBN\2436349 and\CC\1740 the\DT\1740 blood\NN\5397468 pressure\NN\11419404 at\IN\14622893 <e2>convulsions</e2>\NNS\14081375 decreased\VBD\169651 significantly\RB\1740 in\IN\13603305 1.6\CD\1740 %\NN\1740 sevoflurane\NN\1740 ,\,\1740 and\CC\1740 in\IN\13603305 0.8\CD\1740 %\NN\1740 and\CC\1740 1.6\CD\1740 %\NN\1740 <e1>enflurane</e1>\NN\3299929 .\.\1740
D001030_D012640 NONE <e1>Apamin</e1>\NN\1740 (\-LRB-\1740 10\CD\13745420 ng\NN\13717155 )\-RRB-\1740 had\VBD\2108377 a\DT\13649268 tendency\NN\6193203 to\TO\1740 decrease\VB\169651 the\DT\1740 <e2>convulsive</e2>\JJ\1740 threshold\NN\15265518 (\-LRB-\1740 21.6\CD\1740 +/-\CC\1740 2.2\CD\1740 to\IN\1740 19.9\CD\1740 +/-\CC\1740 2.5\CD\1740 mg.\NN\1740 l(-1\NN\1740 )\-RRB-\1740 )\-RRB-\1740 but\CC\1740 this\DT\1740 was\VBD\836236 not\RB\1740 statistically\RB\1740 significant\JJ\1740 .\.\1740
C009250_D064420 NONE It\PRP\6125041 is\VBZ\836236 suggested\VBN\1010118 that\IN\1740 <e1>sevoflurane</e1>\NN\1740 reduces\VBZ\441445 the\DT\1740 convulsive\JJ\1740 effect\NN\34213 of\IN\1740 lidocaine\NN\3681148 <e2>toxicity</e2>\NN\13576101 but\CC\1740 carries\VBZ\1850315 some\DT\1740 risk\NN\14541044 due\IN\5174653 to\IN\1740 circulatory\JJ\1740 depression\NN\14373582 .\.\1740
C009250_D003866 NONE It\PRP\6125041 is\VBZ\836236 suggested\VBN\1010118 that\IN\1740 <e1>sevoflurane</e1>\NN\1740 reduces\VBZ\441445 the\DT\1740 convulsive\JJ\1740 effect\NN\34213 of\IN\1740 lidocaine\NN\3681148 toxicity\NN\13576101 but\CC\1740 carries\VBZ\1850315 some\DT\1740 risk\NN\14541044 due\IN\5174653 to\IN\1740 circulatory\JJ\1740 <e2>depression</e2>\NN\14373582 .\.\1740
D008012_D064420 NONE It\PRP\6125041 is\VBZ\836236 suggested\VBN\1010118 that\IN\1740 sevoflurane\NN\1740 reduces\VBZ\441445 the\DT\1740 convulsive\JJ\1740 effect\NN\34213 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 <e2>toxicity</e2>\NN\13576101 but\CC\1740 carries\VBZ\1850315 some\DT\1740 risk\NN\14541044 due\IN\5174653 to\IN\1740 circulatory\JJ\1740 depression\NN\14373582 .\.\1740
D008012_D003866 NONE It\PRP\6125041 is\VBZ\836236 suggested\VBN\1010118 that\IN\1740 sevoflurane\NN\1740 reduces\VBZ\441445 the\DT\1740 convulsive\JJ\1740 effect\NN\34213 of\IN\1740 <e1>lidocaine</e1>\NN\3681148 toxicity\NN\13576101 but\CC\1740 carries\VBZ\1850315 some\DT\1740 risk\NN\14541044 due\IN\5174653 to\IN\1740 circulatory\JJ\1740 <e2>depression</e2>\NN\14373582 .\.\1740
3856631
D008727_D008577 NONE Remission\NN\7368256 induction\NN\7450842 of\IN\1740 <e2>meningeal\NN\1740 leukemia</e2>\NN\14239918 with\IN\1740 high-dose\JJ\1740 intravenous\JJ\1740 <e1>methotrexate</e1>\NN\2722166 .\.\1740
D008727_D054198 NONE Twenty\CD\13745420 children\NNS\9622049 with\IN\1740 <e2>acute\JJ\1740 lymphoblastic\JJ\1740 leukemia</e2>\NN\14239918 who\WP\8299493 developed\VBD\1753788 meningeal\NN\1740 disease\NN\14061805 were\VBD\836236 treated\VBN\2376958 with\IN\1740 a\DT\13649268 high-dose\JJ\1740 intravenous\JJ\1740 <e1>methotrexate</e1>\VBP\1740 regimen\NN\5898568 that\WDT\1740 was\VBD\836236 designed\VBN\1631534 to\TO\1740 achieve\VB\2524171 and\CC\1740 maintain\VB\2202928 CSF\NN\1740 methotrexate\VBP\1740 concentrations\NNS\4916342 of\IN\1740 10(-5\NN\1740 )\-RRB-\1740 mol/L\NN\1740 without\IN\1740 the\DT\1740 need\NN\13920835 for\IN\1740 concomitant\JJ\1740 intrathecal\JJ\1740 dosing\NN\1740 .\.\1740
D008727_D054198 NONE Twenty\CD\13745420 children\NNS\9622049 with\IN\1740 <e2>acute\JJ\1740 lymphoblastic\JJ\1740 leukemia</e2>\NN\14239918 who\WP\8299493 developed\VBD\1753788 meningeal\NN\1740 disease\NN\14061805 were\VBD\836236 treated\VBN\2376958 with\IN\1740 a\DT\13649268 high-dose\JJ\1740 intravenous\JJ\1740 methotrexate\VBP\1740 regimen\NN\5898568 that\WDT\1740 was\VBD\836236 designed\VBN\1631534 to\TO\1740 achieve\VB\2524171 and\CC\1740 maintain\VB\2202928 CSF\NN\1740 <e1>methotrexate</e1>\VBP\1740 concentrations\NNS\4916342 of\IN\1740 10(-5\NN\1740 )\-RRB-\1740 mol/L\NN\1740 without\IN\1740 the\DT\1740 need\NN\13920835 for\IN\1740 concomitant\JJ\1740 intrathecal\JJ\1740 dosing\NN\1740 .\.\1740
D008727_D054198 NONE High-dose\JJ\1740 intravenous\JJ\1740 <e1>methotrexate</e1>\NN\2722166 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 treatment\NN\654885 for\IN\1740 the\DT\1740 induction\NN\7450842 of\IN\1740 remission\NN\7368256 after\IN\1740 meningeal\NN\1740 relapse\NN\66636 in\IN\13603305 <e2>acute\JJ\1740 lymphoblastic\JJ\1740 leukemia</e2>\NN\14239918 .\.\1740
D008727_D002493 NONE Twenty\CD\13745420 children\NNS\9622049 with\IN\1740 acute\JJ\1740 lymphoblastic\JJ\1740 leukemia\NN\14239918 who\WP\8299493 developed\VBD\1753788 <e2>meningeal\NN\1740 disease</e2>\NN\14061805 were\VBD\836236 treated\VBN\2376958 with\IN\1740 a\DT\13649268 high-dose\JJ\1740 intravenous\JJ\1740 <e1>methotrexate</e1>\VBP\1740 regimen\NN\5898568 that\WDT\1740 was\VBD\836236 designed\VBN\1631534 to\TO\1740 achieve\VB\2524171 and\CC\1740 maintain\VB\2202928 CSF\NN\1740 methotrexate\VBP\1740 concentrations\NNS\4916342 of\IN\1740 10(-5\NN\1740 )\-RRB-\1740 mol/L\NN\1740 without\IN\1740 the\DT\1740 need\NN\13920835 for\IN\1740 concomitant\JJ\1740 intrathecal\JJ\1740 dosing\NN\1740 .\.\1740
D008727_D002493 NONE Twenty\CD\13745420 children\NNS\9622049 with\IN\1740 acute\JJ\1740 lymphoblastic\JJ\1740 leukemia\NN\14239918 who\WP\8299493 developed\VBD\1753788 <e2>meningeal\NN\1740 disease</e2>\NN\14061805 were\VBD\836236 treated\VBN\2376958 with\IN\1740 a\DT\13649268 high-dose\JJ\1740 intravenous\JJ\1740 methotrexate\VBP\1740 regimen\NN\5898568 that\WDT\1740 was\VBD\836236 designed\VBN\1631534 to\TO\1740 achieve\VB\2524171 and\CC\1740 maintain\VB\2202928 CSF\NN\1740 <e1>methotrexate</e1>\VBP\1740 concentrations\NNS\4916342 of\IN\1740 10(-5\NN\1740 )\-RRB-\1740 mol/L\NN\1740 without\IN\1740 the\DT\1740 need\NN\13920835 for\IN\1740 concomitant\JJ\1740 intrathecal\JJ\1740 dosing\NN\1740 .\.\1740
D001663_D064420 NONE The\DT\1740 most\RBS\1740 common\JJ\1740 <e2>toxicities</e2>\NNS\13576101 encountered\VBN\2604760 were\VBD\836236 transient\JJ\1740 serum\NN\5397468 transaminase\NN\15077571 and\CC\1740 <e1>bilirubin</e1>\NN\14756039 elevations\NNS\7445480 ,\,\1740 neutropenia\NN\14196405 ,\,\1740 and\CC\1740 mucositis\NN\1740 .\.\1740
D001663_D009503 NONE The\DT\1740 most\RBS\1740 common\JJ\1740 toxicities\NNS\13576101 encountered\VBN\2604760 were\VBD\836236 transient\JJ\1740 serum\NN\5397468 transaminase\NN\15077571 and\CC\1740 <e1>bilirubin</e1>\NN\14756039 elevations\NNS\7445480 ,\,\1740 <e2>neutropenia</e2>\NN\14196405 ,\,\1740 and\CC\1740 mucositis\NN\1740 .\.\1740
D001663_D052016 NONE The\DT\1740 most\RBS\1740 common\JJ\1740 toxicities\NNS\13576101 encountered\VBN\2604760 were\VBD\836236 transient\JJ\1740 serum\NN\5397468 transaminase\NN\15077571 and\CC\1740 <e1>bilirubin</e1>\NN\14756039 elevations\NNS\7445480 ,\,\1740 neutropenia\NN\14196405 ,\,\1740 and\CC\1740 <e2>mucositis</e2>\NN\1740 .\.\1740
15957009
C507242_D008569 NONE The\DT\1740 selective\JJ\1740 5-HT6\NN\1740 receptor\NN\5225602 antagonist\NN\7846 <e1>Ro4368554</e1>\NNS\1740 restores\VBZ\1631072 memory\NN\5926676 performance\NN\6619065 in\IN\13603305 cholinergic\JJ\1740 and\CC\1740 serotonergic\JJ\1740 models\NNS\5888929 of\IN\1740 <e2>memory\NN\5926676 deficiency</e2>\NN\14449126 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
C507242_D008569 NONE Both\DT\1740 ,\,\1740 <e1>Ro4368554</e1>\NNP\1740 (\-LRB-\1740 3\CD\13741022 and\CC\1740 10\CD\13745420 mg/kg\NN\1740 ,\,\1740 intraperitoneally\RB\1740 (\-LRB-\1740 i.p.\RB\1740 )\-RRB-\1740 )\-RRB-\1740 and\CC\1740 metrifonate\NN\1740 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 reversed\VBN\109660 <e2>memory\NN\5926676 deficits</e2>\NNS\5113133 induced\VBN\1627355 by\IN\1740 scopolamine\NN\14712692 and\CC\1740 TRP\NN\1740 depletion\NN\351638 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 ,\,\1740 and\CC\1740 3\CD\13741022 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 .\.\1740
C507242_D008569 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 although\IN\1740 <e1>Ro4368554</e1>\NNS\1740 did\VBD\1640855 not\RB\1740 improve\VB\126264 a\DT\13649268 time-related\JJ\1740 retention\NN\809465 deficit\NN\5113133 ,\,\1740 it\PRP\6125041 reversed\VBD\109660 a\DT\13649268 cholinergic\NN\1740 and\CC\1740 a\DT\13649268 serotonergic\JJ\1740 <e2>memory\NN\5926676 deficit</e2>\NN\5113133 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 both\DT\1740 mechanisms\NNS\13446390 may\MD\15209706 be\VB\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 facilitation\NN\13920835 of\IN\1740 object\NN\1930 memory\NN\5926676 by\IN\1740 Ro4368554\NNS\1740 and\CC\1740 ,\,\1740 possibly\RB\1740 ,\,\1740 other\JJ\1740 5-HT(6\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonists\NNS\7846 .\.\1740
C507242_D008569 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 although\IN\1740 Ro4368554\NNS\1740 did\VBD\1640855 not\RB\1740 improve\VB\126264 a\DT\13649268 time-related\JJ\1740 retention\NN\809465 deficit\NN\5113133 ,\,\1740 it\PRP\6125041 reversed\VBD\109660 a\DT\13649268 cholinergic\NN\1740 and\CC\1740 a\DT\13649268 serotonergic\JJ\1740 <e2>memory\NN\5926676 deficit</e2>\NN\5113133 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 both\DT\1740 mechanisms\NNS\13446390 may\MD\15209706 be\VB\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 facilitation\NN\13920835 of\IN\1740 object\NN\1930 memory\NN\5926676 by\IN\1740 <e1>Ro4368554</e1>\NNS\1740 and\CC\1740 ,\,\1740 possibly\RB\1740 ,\,\1740 other\JJ\1740 5-HT(6\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonists\NNS\7846 .\.\1740
D014236_D008569 NONE Both\DT\1740 ,\,\1740 Ro4368554\NNP\1740 (\-LRB-\1740 3\CD\13741022 and\CC\1740 10\CD\13745420 mg/kg\NN\1740 ,\,\1740 intraperitoneally\RB\1740 (\-LRB-\1740 i.p.\RB\1740 )\-RRB-\1740 )\-RRB-\1740 and\CC\1740 <e1>metrifonate</e1>\NN\1740 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 reversed\VBN\109660 <e2>memory\NN\5926676 deficits</e2>\NNS\5113133 induced\VBN\1627355 by\IN\1740 scopolamine\NN\14712692 and\CC\1740 TRP\NN\1740 depletion\NN\351638 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 ,\,\1740 and\CC\1740 3\CD\13741022 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 .\.\1740
D012601_D008569 CID Both\DT\1740 ,\,\1740 Ro4368554\NNP\1740 (\-LRB-\1740 3\CD\13741022 and\CC\1740 10\CD\13745420 mg/kg\NN\1740 ,\,\1740 intraperitoneally\RB\1740 (\-LRB-\1740 i.p.\RB\1740 )\-RRB-\1740 )\-RRB-\1740 and\CC\1740 metrifonate\NN\1740 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 reversed\VBN\109660 <e2>memory\NN\5926676 deficits</e2>\NNS\5113133 induced\VBN\1627355 by\IN\1740 <e1>scopolamine</e1>\NN\14712692 and\CC\1740 TRP\NN\1740 depletion\NN\351638 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 ,\,\1740 and\CC\1740 3\CD\13741022 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 .\.\1740
D014364_D008569 NONE Both\DT\1740 ,\,\1740 Ro4368554\NNP\1740 (\-LRB-\1740 3\CD\13741022 and\CC\1740 10\CD\13745420 mg/kg\NN\1740 ,\,\1740 intraperitoneally\RB\1740 (\-LRB-\1740 i.p.\RB\1740 )\-RRB-\1740 )\-RRB-\1740 and\CC\1740 metrifonate\NN\1740 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 reversed\VBN\109660 <e2>memory\NN\5926676 deficits</e2>\NNS\5113133 induced\VBN\1627355 by\IN\1740 scopolamine\NN\14712692 and\CC\1740 <e1>TRP</e1>\NN\1740 depletion\NN\351638 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 ,\,\1740 i.p.\RB\1740 ,\,\1740 and\CC\1740 3\CD\13741022 mg/kg\NN\1740 ,\,\1740 p.o.\NN\10360747 ,\,\1740 respectively\RB\1740 )\-RRB-\1740 .\.\1740
D012701_D008569 NONE In\IN\13603305 conclusion\NN\5837957 ,\,\1740 although\IN\1740 Ro4368554\NNS\1740 did\VBD\1640855 not\RB\1740 improve\VB\126264 a\DT\13649268 time-related\JJ\1740 retention\NN\809465 deficit\NN\5113133 ,\,\1740 it\PRP\6125041 reversed\VBD\109660 a\DT\13649268 cholinergic\NN\1740 and\CC\1740 a\DT\13649268 serotonergic\JJ\1740 <e2>memory\NN\5926676 deficit</e2>\NN\5113133 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 both\DT\1740 mechanisms\NNS\13446390 may\MD\15209706 be\VB\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 facilitation\NN\13920835 of\IN\1740 object\NN\1930 memory\NN\5926676 by\IN\1740 Ro4368554\NNS\1740 and\CC\1740 ,\,\1740 possibly\RB\1740 ,\,\1740 other\JJ\1740 <e1>5-HT(6</e1>\NN\1740 )\-RRB-\1740 receptor\NN\5225602 antagonists\NNS\7846 .\.\1740
15188772
D004837_D018487 NONE Severe\JJ\1740 reversible\JJ\1740 <e2>left\VBD\120316 ventricular\JJ\1740 systolic\NN\1740 and\CC\1740 diastolic\JJ\1740 dysfunction</e2>\NN\14204950 due\IN\5174653 to\TO\1740 accidental\JJ\1740 iatrogenic\JJ\1740 <e1>epinephrine</e1>\NN\14807929 overdose\NN\1740 .\.\1740
D004837_D018487 NONE A\DT\13649268 35-year-old\JJ\1740 woman\NN\9605289 whose\WP$\1740 cervix\NN\5225090 uteri\NN\5514717 was\VBD\836236 inadvertently\RB\1740 injected\VBN\81072 with\IN\1740 8\CD\13741022 mg\NN\13717155 of\IN\1740 <e1>epinephrine</e1>\NN\14807929 developed\VBD\1753788 myocardial\JJ\1740 stunning\NN\1740 that\WDT\1740 was\VBD\836236 characterized\VBN\609683 by\IN\1740 severe\JJ\1740 hemodynamic\JJ\1740 compromise\NN\1202904 ,\,\1740 profound\JJ\1740 ,\,\1740 albeit\IN\1740 transient\JJ\1740 ,\,\1740 <e2>left\VBD\120316 ventricular\JJ\1740 systolic\NN\1740 and\CC\1740 diastolic\JJ\1740 dysfunction</e2>\NN\14204950 ,\,\1740 and\CC\1740 only\RB\1740 modestly\RB\1740 elevated\JJ\1740 biochemical\JJ\1740 markers\NNS\21939 of\IN\1740 myocardial\JJ\1740 necrosis\NN\11444117 .\.\1740
D004837_D062787 NONE Severe\JJ\1740 reversible\JJ\1740 left\VBD\120316 ventricular\JJ\1740 systolic\NN\1740 and\CC\1740 diastolic\JJ\1740 dysfunction\NN\14204950 due\IN\5174653 to\TO\1740 accidental\JJ\1740 iatrogenic\JJ\1740 <e1>epinephrine</e1>\NN\14807929 <e2>overdose</e2>\NN\1740 .\.\1740
D002395_D009202 NONE <e1>Catecholamine-induced</e1>\JJ\1740 <e2>cardiomyopathy</e2>\NN\14103288 due\JJ\1740 to\TO\1740 chronic\JJ\1740 excess\NN\5119367 of\IN\1740 endogenous\JJ\1740 catecholamines\NNS\5407119 has\VBZ\2108377 been\VBN\836236 recognized\VBN\686447 for\IN\1740 decades\NNS\15113229 as\IN\14622893 a\DT\13649268 clinical\JJ\1740 phenomenon\NN\29677 .\.\1740
D002395_D009202 NONE Catecholamine-induced\JJ\1740 <e2>cardiomyopathy</e2>\NN\14103288 due\JJ\1740 to\TO\1740 chronic\JJ\1740 excess\NN\5119367 of\IN\1740 endogenous\JJ\1740 <e1>catecholamines</e1>\NNS\5407119 has\VBZ\2108377 been\VBN\836236 recognized\VBN\686447 for\IN\1740 decades\NNS\15113229 as\IN\14622893 a\DT\13649268 clinical\JJ\1740 phenomenon\NN\29677 .\.\1740
D004837_D017682 CID A\DT\13649268 35-year-old\JJ\1740 woman\NN\9605289 whose\WP$\1740 cervix\NN\5225090 uteri\NN\5514717 was\VBD\836236 inadvertently\RB\1740 injected\VBN\81072 with\IN\1740 8\CD\13741022 mg\NN\13717155 of\IN\1740 <e1>epinephrine</e1>\NN\14807929 developed\VBD\1753788 <e2>myocardial\JJ\1740 stunning</e2>\NN\1740 that\WDT\1740 was\VBD\836236 characterized\VBN\609683 by\IN\1740 severe\JJ\1740 hemodynamic\JJ\1740 compromise\NN\1202904 ,\,\1740 profound\JJ\1740 ,\,\1740 albeit\IN\1740 transient\JJ\1740 ,\,\1740 left\VBD\120316 ventricular\JJ\1740 systolic\NN\1740 and\CC\1740 diastolic\JJ\1740 dysfunction\NN\14204950 ,\,\1740 and\CC\1740 only\RB\1740 modestly\RB\1740 elevated\JJ\1740 biochemical\JJ\1740 markers\NNS\21939 of\IN\1740 myocardial\JJ\1740 necrosis\NN\11444117 .\.\1740
D004837_D009202 NONE A\DT\13649268 35-year-old\JJ\1740 woman\NN\9605289 whose\WP$\1740 cervix\NN\5225090 uteri\NN\5514717 was\VBD\836236 inadvertently\RB\1740 injected\VBN\81072 with\IN\1740 8\CD\13741022 mg\NN\13717155 of\IN\1740 <e1>epinephrine</e1>\NN\14807929 developed\VBD\1753788 myocardial\JJ\1740 stunning\NN\1740 that\WDT\1740 was\VBD\836236 characterized\VBN\609683 by\IN\1740 severe\JJ\1740 hemodynamic\JJ\1740 compromise\NN\1202904 ,\,\1740 profound\JJ\1740 ,\,\1740 albeit\IN\1740 transient\JJ\1740 ,\,\1740 left\VBD\120316 ventricular\JJ\1740 systolic\NN\1740 and\CC\1740 diastolic\JJ\1740 dysfunction\NN\14204950 ,\,\1740 and\CC\1740 only\RB\1740 modestly\RB\1740 elevated\JJ\1740 biochemical\JJ\1740 markers\NNS\21939 of\IN\1740 <e2>myocardial\JJ\1740 necrosis</e2>\NN\11444117 .\.\1740
17615423
D019821_D012206 CID Severe\JJ\1740 <e2>rhabdomyolysis</e2>\NN\1740 and\CC\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 secondary\JJ\1740 to\TO\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 <e1>simvastatin</e1>\NN\3676175 ,\,\1740 amiodarone\RB\1740 ,\,\1740 and\CC\1740 atazanavir\NN\1740 .\.\1740
D019821_D012206 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 severe\JJ\1740 interaction\NN\37396 between\IN\1740 <e1>simvastatin</e1>\NN\3676175 ,\,\1740 amiodarone\RB\1740 ,\,\1740 and\CC\1740 atazanavir\NN\1740 resulting\VBG\2633881 in\IN\13603305 <e2>rhabdomyolysis</e2>\NN\1740 and\CC\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D019821_D012206 CID DISCUSSION\NN\6252138 :\:\1740 The\DT\1740 risk\NN\14541044 of\IN\1740 <e2>rhabdomyolysis</e2>\NN\1740 is\VBZ\836236 increased\VBN\169651 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 concomitant\JJ\1740 drugs\NNS\14778436 that\WDT\1740 inhibit\VBP\2510337 <e1>simvastatin</e1>\NN\3676175 metabolism\NN\13526110 .\.\1740
D019821_D058186 CID Severe\JJ\1740 rhabdomyolysis\NN\1740 and\CC\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 secondary\JJ\1740 to\TO\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 <e1>simvastatin</e1>\NN\3676175 ,\,\1740 amiodarone\RB\1740 ,\,\1740 and\CC\1740 atazanavir\NN\1740 .\.\1740
D019821_D058186 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 severe\JJ\1740 interaction\NN\37396 between\IN\1740 <e1>simvastatin</e1>\NN\3676175 ,\,\1740 amiodarone\RB\1740 ,\,\1740 and\CC\1740 atazanavir\NN\1740 resulting\VBG\2633881 in\IN\13603305 rhabdomyolysis\NN\1740 and\CC\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 .\.\1740
D000638_D012206 CID Severe\JJ\1740 <e2>rhabdomyolysis</e2>\NN\1740 and\CC\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 secondary\JJ\1740 to\TO\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 simvastatin\NN\3676175 ,\,\1740 <e1>amiodarone</e1>\RB\1740 ,\,\1740 and\CC\1740 atazanavir\NN\1740 .\.\1740
D000638_D012206 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 severe\JJ\1740 interaction\NN\37396 between\IN\1740 simvastatin\NN\3676175 ,\,\1740 <e1>amiodarone</e1>\RB\1740 ,\,\1740 and\CC\1740 atazanavir\NN\1740 resulting\VBG\2633881 in\IN\13603305 <e2>rhabdomyolysis</e2>\NN\1740 and\CC\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D000638_D058186 CID Severe\JJ\1740 rhabdomyolysis\NN\1740 and\CC\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 secondary\JJ\1740 to\TO\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 simvastatin\NN\3676175 ,\,\1740 <e1>amiodarone</e1>\RB\1740 ,\,\1740 and\CC\1740 atazanavir\NN\1740 .\.\1740
D000638_D058186 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 severe\JJ\1740 interaction\NN\37396 between\IN\1740 simvastatin\NN\3676175 ,\,\1740 <e1>amiodarone</e1>\RB\1740 ,\,\1740 and\CC\1740 atazanavir\NN\1740 resulting\VBG\2633881 in\IN\13603305 rhabdomyolysis\NN\1740 and\CC\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 .\.\1740
C413408_D012206 CID Severe\JJ\1740 <e2>rhabdomyolysis</e2>\NN\1740 and\CC\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 secondary\JJ\1740 to\TO\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 simvastatin\NN\3676175 ,\,\1740 amiodarone\RB\1740 ,\,\1740 and\CC\1740 <e1>atazanavir</e1>\NN\1740 .\.\1740
C413408_D012206 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 severe\JJ\1740 interaction\NN\37396 between\IN\1740 simvastatin\NN\3676175 ,\,\1740 amiodarone\RB\1740 ,\,\1740 and\CC\1740 <e1>atazanavir</e1>\NN\1740 resulting\VBG\2633881 in\IN\13603305 <e2>rhabdomyolysis</e2>\NN\1740 and\CC\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
C413408_D058186 CID Severe\JJ\1740 rhabdomyolysis\NN\1740 and\CC\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 secondary\JJ\1740 to\TO\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 simvastatin\NN\3676175 ,\,\1740 amiodarone\RB\1740 ,\,\1740 and\CC\1740 <e1>atazanavir</e1>\NN\1740 .\.\1740
C413408_D058186 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 report\VB\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 severe\JJ\1740 interaction\NN\37396 between\IN\1740 simvastatin\NN\3676175 ,\,\1740 amiodarone\RB\1740 ,\,\1740 and\CC\1740 <e1>atazanavir</e1>\NN\1740 resulting\VBG\2633881 in\IN\13603305 rhabdomyolysis\NN\1740 and\CC\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 .\.\1740
D019821_D015658 NONE <e1>Simvastatin</e1>\NN\3676175 ,\,\1740 amiodarone\RB\1740 ,\,\1740 and\CC\1740 the\DT\1740 patient\NN\9898892 's\POS\1740 <e2>human\JJ\1740 immunodeficiency\NN\13973990 virus</e2>\NN\9312843 medications\NNS\3247620 were\VBD\836236 all\DT\1740 temporarily\RB\1740 discontinued\VBN\2609764 and\CC\1740 the\DT\1740 patient\NN\9898892 was\VBD\836236 given\VBN\2327200 forced\VBN\2506546 alkaline\NN\1740 diuresis\NN\14299637 and\CC\1740 started\VBD\2009433 on\IN\1740 dialysis\NN\646833 .\.\1740
D000638_D015658 NONE Simvastatin\NN\3676175 ,\,\1740 <e1>amiodarone</e1>\RB\1740 ,\,\1740 and\CC\1740 the\DT\1740 patient\NN\9898892 's\POS\1740 <e2>human\JJ\1740 immunodeficiency\NN\13973990 virus</e2>\NN\9312843 medications\NNS\3247620 were\VBD\836236 all\DT\1740 temporarily\RB\1740 discontinued\VBN\2609764 and\CC\1740 the\DT\1740 patient\NN\9898892 was\VBD\836236 given\VBN\2327200 forced\VBN\2506546 alkaline\NN\1740 diuresis\NN\14299637 and\CC\1740 started\VBD\2009433 on\IN\1740 dialysis\NN\646833 .\.\1740
12584269
D020123_D007674 CID These\DT\1740 are\VBP\836236 <e2>nephrotoxic</e2>\JJ\1740 ,\,\1740 but\CC\1740 <e1>SRL</e1>\NN\1740 seems\VBZ\2604760 to\TO\1740 act\VB\1619354 differently\RB\1740 displaying\VBG\2137132 only\RB\1740 minor\JJ\1740 nephrotoxic\JJ\1740 effects\NNS\13245626 ,\,\1740 although\IN\1740 this\DT\1740 question\NN\7193184 is\VBZ\836236 still\RB\1740 open\JJ\1740 .\.\1740
D020123_D007674 CID These\DT\1740 are\VBP\836236 nephrotoxic\JJ\1740 ,\,\1740 but\CC\1740 <e1>SRL</e1>\NN\1740 seems\VBZ\2604760 to\TO\1740 act\VB\1619354 differently\RB\1740 displaying\VBG\2137132 only\RB\1740 minor\JJ\1740 <e2>nephrotoxic</e2>\JJ\1740 effects\NNS\13245626 ,\,\1740 although\IN\1740 this\DT\1740 question\NN\7193184 is\VBZ\836236 still\RB\1740 open\JJ\1740 .\.\1740
D020123_D007674 CID In\IN\13603305 a\DT\13649268 number\NN\5107765 of\IN\1740 treatment\NN\654885 protocols\NNS\6652242 where\WRB\1740 <e1>SRL</e1>\NN\1740 was\VBD\836236 combined\VBN\2630189 with\IN\1740 a\DT\13649268 calcineurin\NN\1740 inhibitor\NN\20090 indications\NNS\33020 of\IN\1740 a\DT\13649268 synergistic\JJ\1740 <e2>nephrotoxic</e2>\JJ\1740 effect\NN\34213 were\VBD\836236 described\VBN\1001294 .\.\1740
D020123_D007674 CID CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 rat\NN\2329401 study\NN\635850 demonstrated\VBD\2137132 a\DT\13649268 synergistic\JJ\1740 <e2>nephrotoxic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 CsA\NN\1740 plus\CC\4723816 <e1>SRL</e1>\NN\1740 ,\,\1740 whereas\IN\1740 FK506\NN\1740 plus\CC\4723816 SRL\NN\1740 was\VBD\836236 better\RBR\1740 tolerated\VBN\802318 .\.\1740
D020123_D007674 CID CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 rat\NN\2329401 study\NN\635850 demonstrated\VBD\2137132 a\DT\13649268 synergistic\JJ\1740 <e2>nephrotoxic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 CsA\NN\1740 plus\CC\4723816 SRL\NN\1740 ,\,\1740 whereas\IN\1740 FK506\NN\1740 plus\CC\4723816 <e1>SRL</e1>\NN\1740 was\VBD\836236 better\RBR\1740 tolerated\VBN\802318 .\.\1740
D016572_D005355 NONE The\DT\1740 semi-quantitative\JJ\1740 scoring\NN\874806 was\VBD\836236 significantly\RB\1740 worst\VBN\1101913 in\IN\13603305 the\DT\1740 group\NN\2137 treated\VBN\2376958 with\IN\1740 <e1>CsA</e1>\NN\1740 plus\CC\4723816 SRL\NN\1740 (\-LRB-\1740 P<0.001\NN\1740 compared\VBN\644583 with\IN\1740 controls\NNS\5190804 )\-RRB-\1740 and\CC\1740 the\DT\1740 analysis\NN\633864 of\IN\1740 the\DT\1740 total\JJ\1740 grade\NN\7975026 of\IN\1740 <e2>fibrosis</e2>\NN\14204950 also\RB\1740 showed\VBD\2137132 the\DT\1740 highest\JJS\1740 proportion\NN\13824815 in\IN\13603305 the\DT\1740 same\JJ\1740 group\NN\2137 and\CC\1740 was\VBD\836236 significantly\RB\1740 different\JJ\1740 from\IN\1740 controls\NNS\5190804 (\-LRB-\1740 P<0.02\NN\1740 )\-RRB-\1740 .\.\1740
D020123_D005355 NONE The\DT\1740 semi-quantitative\JJ\1740 scoring\NN\874806 was\VBD\836236 significantly\RB\1740 worst\VBN\1101913 in\IN\13603305 the\DT\1740 group\NN\2137 treated\VBN\2376958 with\IN\1740 CsA\NN\1740 plus\CC\4723816 <e1>SRL</e1>\NN\1740 (\-LRB-\1740 P<0.001\NN\1740 compared\VBN\644583 with\IN\1740 controls\NNS\5190804 )\-RRB-\1740 and\CC\1740 the\DT\1740 analysis\NN\633864 of\IN\1740 the\DT\1740 total\JJ\1740 grade\NN\7975026 of\IN\1740 <e2>fibrosis</e2>\NN\14204950 also\RB\1740 showed\VBD\2137132 the\DT\1740 highest\JJS\1740 proportion\NN\13824815 in\IN\13603305 the\DT\1740 same\JJ\1740 group\NN\2137 and\CC\1740 was\VBD\836236 significantly\RB\1740 different\JJ\1740 from\IN\1740 controls\NNS\5190804 (\-LRB-\1740 P<0.02\NN\1740 )\-RRB-\1740 .\.\1740
D020123_D005355 NONE The\DT\1740 FK506\NN\1740 plus\CC\4723816 <e1>SRL</e1>\NN\1740 combination\NN\7951464 showed\VBD\2137132 only\RB\1740 a\DT\13649268 marginally\RB\1740 higher\JJR\1740 degree\NN\4916342 of\IN\1740 <e2>fibrosis</e2>\NN\14204950 as\IN\14622893 compared\VBN\644583 with\IN\1740 controls\NNS\5190804 (\-LRB-\1740 P=0.05\NN\1740 )\-RRB-\1740 .\.\1740
D016559_D005355 NONE The\DT\1740 <e1>FK506</e1>\NN\1740 plus\CC\4723816 SRL\NN\1740 combination\NN\7951464 showed\VBD\2137132 only\RB\1740 a\DT\13649268 marginally\RB\1740 higher\JJR\1740 degree\NN\4916342 of\IN\1740 <e2>fibrosis</e2>\NN\14204950 as\IN\14622893 compared\VBN\644583 with\IN\1740 controls\NNS\5190804 (\-LRB-\1740 P=0.05\NN\1740 )\-RRB-\1740 .\.\1740
D016572_D007674 CID CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 rat\NN\2329401 study\NN\635850 demonstrated\VBD\2137132 a\DT\13649268 synergistic\JJ\1740 <e2>nephrotoxic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 <e1>CsA</e1>\NN\1740 plus\CC\4723816 SRL\NN\1740 ,\,\1740 whereas\IN\1740 FK506\NN\1740 plus\CC\4723816 SRL\NN\1740 was\VBD\836236 better\RBR\1740 tolerated\VBN\802318 .\.\1740
D016559_D007674 CID CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 rat\NN\2329401 study\NN\635850 demonstrated\VBD\2137132 a\DT\13649268 synergistic\JJ\1740 <e2>nephrotoxic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 CsA\NN\1740 plus\CC\4723816 SRL\NN\1740 ,\,\1740 whereas\IN\1740 <e1>FK506</e1>\NN\1740 plus\CC\4723816 SRL\NN\1740 was\VBD\836236 better\RBR\1740 tolerated\VBN\802318 .\.\1740
14976857
D011405_-1 NONE Transient\JJ\1740 <e2>platypnea-orthodeoxia-like\JJ\1740 syndrome</e2>\NN\5870365 induced\VBN\1627355 by\IN\1740 <e1>propafenone</e1>\NN\1740 overdose\NN\1740 in\IN\13603305 a\DT\13649268 young\JJ\1740 woman\NN\9605289 with\IN\1740 Ebstein\NNP\1740 's\POS\1740 anomaly\NN\14501726 .\.\1740
D011405_D062787 NONE Transient\JJ\1740 platypnea-orthodeoxia-like\JJ\1740 syndrome\NN\5870365 induced\VBN\1627355 by\IN\1740 <e1>propafenone</e1>\NN\1740 <e2>overdose</e2>\NN\1740 in\IN\13603305 a\DT\13649268 young\JJ\1740 woman\NN\9605289 with\IN\1740 Ebstein\NNP\1740 's\POS\1740 anomaly\NN\14501726 .\.\1740
D011405_D062787 NONE This\DT\1740 shunt\NN\5248181 of\IN\1740 blood\NN\5397468 via\IN\1740 a\DT\13649268 patent\NN\6470073 foramen\NN\9379111 ovale\NN\1740 occurred\VBD\2623529 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 a\DT\13649268 normal\JJ\1740 pulmonary\JJ\1740 artery\NN\5417975 pressure\NN\11419404 ,\,\1740 and\CC\1740 was\VBD\836236 probably\RB\1740 precipitated\VBN\1642924 by\IN\1740 a\DT\13649268 <e1>propafenone</e1>\NN\1740 <e2>overdose</e2>\NN\1740 .\.\1740
D011405_D004437 NONE Transient\JJ\1740 platypnea-orthodeoxia-like\JJ\1740 syndrome\NN\5870365 induced\VBN\1627355 by\IN\1740 <e1>propafenone</e1>\NN\1740 overdose\NN\1740 in\IN\13603305 a\DT\13649268 young\JJ\1740 woman\NN\9605289 with\IN\1740 <e2>Ebstein\NNP\1740 's\POS\1740 anomaly</e2>\NN\14501726 .\.\1740
D011405_D054092 NONE This\DT\1740 shunt\NN\5248181 of\IN\1740 blood\NN\5397468 via\IN\1740 a\DT\13649268 <e2>patent\NN\6470073 foramen\NN\9379111 ovale</e2>\NN\1740 occurred\VBD\2623529 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 a\DT\13649268 normal\JJ\1740 pulmonary\JJ\1740 artery\NN\5417975 pressure\NN\11419404 ,\,\1740 and\CC\1740 was\VBD\836236 probably\RB\1740 precipitated\VBN\1642924 by\IN\1740 a\DT\13649268 <e1>propafenone</e1>\NN\1740 overdose\NN\1740 .\.\1740
11166519
D003042_D012640 CID Acute\JJ\1740 <e1>cocaine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 :\:\1740 differential\JJ\1740 sensitivity\NN\5651971 of\IN\1740 six\CD\13741022 inbred\JJ\1740 mouse\NN\2329401 strains\NNS\7358060 .\.\1740
D003042_D012640 CID Mature\JJ\1740 male\JJ\1740 and\CC\1740 female\JJ\1740 mice\NNS\2329401 from\IN\1740 six\CD\13741022 inbred\VBN\1740 stains\NNS\4673965 were\VBD\836236 tested\VBN\670261 for\IN\1740 susceptibility\NN\13920835 to\TO\1740 behavioral\JJ\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 a\DT\13649268 single\JJ\1740 injection\NN\320852 of\IN\1740 <e1>cocaine</e1>\NN\3492717 .\.\1740
D003042_D012640 CID Additional\JJ\1740 studies\NNS\635850 of\IN\1740 these\DT\1740 murine\JJ\1740 strains\NNS\7358060 may\MD\15209706 be\VB\836236 useful\JJ\1740 for\IN\1740 investigating\VBG\644583 genetic\JJ\1740 influences\NNS\5190804 on\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
6209318
D008801_D001145 NONE International\JJ\1740 <e1>mexiletine</e1>\NN\2715941 and\CC\1740 placebo\JJ\1740 antiarrhythmic\JJ\1740 coronary\JJ\1740 trial\NN\786195 :\:\1740 I.\NNP\1740 Report\NNP\6470073 on\IN\1740 <e2>arrhythmia</e2>\NN\14103288 and\CC\1740 other\JJ\1740 findings\NNS\7951464 .\.\1740
D008801_D009203 NONE The\DT\1740 antiarrhythmic\JJ\1740 effects\NNS\13245626 of\IN\1740 the\DT\1740 sustained\JJ\1740 release\NN\3748886 form\NN\6286395 of\IN\1740 <e1>mexiletine</e1>\NN\2715941 (\-LRB-\1740 Mexitil-Perlongets\NNS\1740 )\-RRB-\1740 were\VBD\836236 evaluated\VBN\670261 in\IN\13603305 a\DT\13649268 double-blind\JJ\1740 placebo\NN\3740161 trial\NN\786195 in\IN\13603305 630\CD\1740 patients\NNS\9898892 with\IN\1740 recent\JJ\1740 documented\VBN\1000214 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D008801_D009203 NONE The\DT\1740 antiarrhythmic\JJ\1740 effects\NNS\13245626 of\IN\1740 the\DT\1740 sustained\JJ\1740 release\NN\3748886 form\NN\6286395 of\IN\1740 mexiletine\NN\2715941 (\-LRB-\1740 <e1>Mexitil-Perlongets</e1>\NNS\1740 )\-RRB-\1740 were\VBD\836236 evaluated\VBN\670261 in\IN\13603305 a\DT\13649268 double-blind\JJ\1740 placebo\NN\3740161 trial\NN\786195 in\IN\13603305 630\CD\1740 patients\NNS\9898892 with\IN\1740 recent\JJ\1740 documented\VBN\1000214 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D008801_D003643 NONE There\EX\27167 were\VBD\836236 more\JJR\1740 <e2>deaths</e2>\NNS\7296428 in\IN\13603305 the\DT\1740 <e1>mexiletine</e1>\NN\2715941 group\NN\2137 (\-LRB-\1740 7.6\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 in\IN\13603305 the\DT\1740 placebo\NN\3740161 group\NN\2137 (\-LRB-\1740 4.8\CD\1740 %\NN\1740 )\-RRB-\1740 ;\:\1740 the\DT\1740 difference\NN\4723816 was\VBD\836236 not\RB\1740 statistically\RB\1740 significant\JJ\1740 .\.\1740
D008801_D014202 CID Previously\RB\1740 recognized\VBN\686447 side\NN\8630039 effects\NNS\13245626 ,\,\1740 particularly\RB\1740 <e2>tremor</e2>\NN\345926 and\CC\1740 gastrointestinal\JJ\1740 problems\NNS\14408086 ,\,\1740 were\VBD\836236 more\RBR\1740 frequent\JJ\1740 in\IN\13603305 the\DT\1740 <e1>mexiletine</e1>\NN\2715941 group\NN\2137 than\IN\1740 in\IN\13603305 the\DT\1740 placebo\NN\3740161 group\NN\2137 .\.\1740
D008801_D012817 CID Previously\RB\1740 recognized\VBN\686447 side\NN\8630039 effects\NNS\13245626 ,\,\1740 particularly\RB\1740 tremor\NN\345926 and\CC\1740 <e2>gastrointestinal\JJ\1740 problems</e2>\NNS\14408086 ,\,\1740 were\VBD\836236 more\RBR\1740 frequent\JJ\1740 in\IN\13603305 the\DT\1740 <e1>mexiletine</e1>\NN\2715941 group\NN\2137 than\IN\1740 in\IN\13603305 the\DT\1740 placebo\NN\3740161 group\NN\2137 .\.\1740
20196116
D000995_D017114 CID <e1>Antituberculosis</e1>\NN\1740 therapy-induced\JJ\1740 <e2>acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 :\:\1740 magnitude\NN\4916342 ,\,\1740 profile\NN\6999802 ,\,\1740 prognosis\NN\6748969 ,\,\1740 and\CC\1740 predictors\NNS\10756433 of\IN\1740 outcome\NN\7291312 .\.\1740
D000995_D017114 CID <e1>Antituberculosis</e1>\NN\1740 therapy\NN\657604 (ATT)-associated\VBD\1740 <e2>acute\JJ\1740 liver\NN\5298729 failure</e2>\NN\66216 (\-LRB-\1740 ATT-ALF\NN\1740 )\-RRB-\1740 is\VBZ\836236 the\DT\1740 commonest\NN\1740 drug-induced\JJ\1740 ALF\NN\1740 in\IN\13603305 South\NNP\13831000 Asia\NNP\7951464 .\.\1740
D000995_D017114 CID <e1>Antituberculosis</e1>\NN\1740 therapy\NN\657604 (ATT)-associated\VBD\1740 acute\JJ\1740 liver\NN\5298729 failure\NN\66216 (\-LRB-\1740 <e2>ATT-ALF</e2>\NN\1740 )\-RRB-\1740 is\VBZ\836236 the\DT\1740 commonest\NN\1740 drug-induced\JJ\1740 ALF\NN\1740 in\IN\13603305 South\NNP\13831000 Asia\NNP\7951464 .\.\1740
D000995_D017114 CID <e1>Antituberculosis</e1>\NN\1740 therapy\NN\657604 (ATT)-associated\VBD\1740 acute\JJ\1740 liver\NN\5298729 failure\NN\66216 (\-LRB-\1740 ATT-ALF\NN\1740 )\-RRB-\1740 is\VBZ\836236 the\DT\1740 commonest\NN\1740 drug-induced\JJ\1740 <e2>ALF</e2>\NN\1740 in\IN\13603305 South\NNP\13831000 Asia\NNP\7951464 .\.\1740
D001663_D001927 NONE In\IN\13603305 multivariate\JJ\1740 analysis\NN\633864 ,\,\1740 three\CD\13741022 factors\NNS\7326557 independently\RB\1740 predicted\VBD\916909 mortality\NN\5054863 :\:\1740 serum\NN\5397468 <e1>bilirubin</e1>\NN\14756039 (\-LRB-\1740 >\NN\1740 or=10.8\NN\1740 mg/dL\NN\1740 )\-RRB-\1740 ,\,\1740 prothrombin\NN\15022776 time\NN\7308889 (\-LRB-\1740 PT\NN\14627081 )\-RRB-\1740 prolongation\NN\1017987 (\-LRB-\1740 >\NNS\1740 or=26\NN\1740 seconds\NNS\15154774 )\-RRB-\1740 ,\,\1740 and\CC\1740 grade\NN\7975026 III/IV\NN\1740 <e2>encephalopathy</e2>\JJ\1740 at\IN\14622893 presentation\NN\1027379 .\.\1740
20477932
D003042_D008569 CID <e1>Cocaine</e1>\NN\3492717 causes\VBZ\1617192 <e2>memory\NN\5926676 and\CC\1740 learning\NN\5701944 impairments</e2>\NNS\7296428 in\IN\13603305 rats\NNS\2329401 :\:\1740 involvement\NN\1080366 of\IN\1740 nuclear\JJ\1740 factor\NN\7326557 kappa\NN\6828818 B\NN\1355326 and\CC\1740 oxidative\JJ\1740 stress\NN\7083732 ,\,\1740 and\CC\1740 prevention\NN\1073995 by\IN\1740 topiramate\NN\1740 .\.\1740
D003042_D007859 CID <e1>Cocaine</e1>\NN\3492717 causes\VBZ\1617192 <e2>memory\NN\5926676 and\CC\1740 learning\NN\5701944 impairments</e2>\NNS\7296428 in\IN\13603305 rats\NNS\2329401 :\:\1740 involvement\NN\1080366 of\IN\1740 nuclear\JJ\1740 factor\NN\7326557 kappa\NN\6828818 B\NN\1355326 and\CC\1740 oxidative\JJ\1740 stress\NN\7083732 ,\,\1740 and\CC\1740 prevention\NN\1073995 by\IN\1740 topiramate\NN\1740 .\.\1740
C052342_D008569 NONE Cocaine\NN\3492717 causes\VBZ\1617192 <e2>memory\NN\5926676 and\CC\1740 learning\NN\5701944 impairments</e2>\NNS\7296428 in\IN\13603305 rats\NNS\2329401 :\:\1740 involvement\NN\1080366 of\IN\1740 nuclear\JJ\1740 factor\NN\7326557 kappa\NN\6828818 B\NN\1355326 and\CC\1740 oxidative\JJ\1740 stress\NN\7083732 ,\,\1740 and\CC\1740 prevention\NN\1073995 by\IN\1740 <e1>topiramate</e1>\NN\1740 .\.\1740
C052342_D007859 NONE Cocaine\NN\3492717 causes\VBZ\1617192 <e2>memory\NN\5926676 and\CC\1740 learning\NN\5701944 impairments</e2>\NNS\7296428 in\IN\13603305 rats\NNS\2329401 :\:\1740 involvement\NN\1080366 of\IN\1740 nuclear\JJ\1740 factor\NN\7326557 kappa\NN\6828818 B\NN\1355326 and\CC\1740 oxidative\JJ\1740 stress\NN\7083732 ,\,\1740 and\CC\1740 prevention\NN\1073995 by\IN\1740 <e1>topiramate</e1>\NN\1740 .\.\1740
D003042_D064420 NONE Different\JJ\1740 mechanisms\NNS\13446390 have\VBP\2108377 been\VBN\836236 suggested\VBN\1010118 for\IN\1740 <e1>cocaine</e1>\NN\3492717 <e2>toxicity</e2>\NN\13576101 including\VBG\690614 an\DT\6697703 increase\NN\13576355 in\IN\13603305 oxidative\JJ\1740 stress\NN\7083732 but\CC\1740 the\DT\1740 association\NN\8008335 between\IN\1740 oxidative\JJ\1740 status\NN\24720 in\IN\13603305 the\DT\1740 brain\NN\5462674 and\CC\1740 cocaine\NN\3492717 induced-behaviour\NN\1740 is\VBZ\836236 poorly\RB\1740 understood\VBN\588888 .\.\1740
D003042_D064420 NONE Different\JJ\1740 mechanisms\NNS\13446390 have\VBP\2108377 been\VBN\836236 suggested\VBN\1010118 for\IN\1740 cocaine\NN\3492717 <e2>toxicity</e2>\NN\13576101 including\VBG\690614 an\DT\6697703 increase\NN\13576355 in\IN\13603305 oxidative\JJ\1740 stress\NN\7083732 but\CC\1740 the\DT\1740 association\NN\8008335 between\IN\1740 oxidative\JJ\1740 status\NN\24720 in\IN\13603305 the\DT\1740 brain\NN\5462674 and\CC\1740 <e1>cocaine</e1>\NN\3492717 induced-behaviour\NN\1740 is\VBZ\836236 poorly\RB\1740 understood\VBN\588888 .\.\1740
D009569_D019970 NONE Therefore\RB\1740 NFkappaB\NN\1740 activity\NN\30358 ,\,\1740 oxidative\JJ\1740 stress\NN\7083732 ,\,\1740 neuronal\JJ\1740 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 synthase\NN\1740 (\-LRB-\1740 nNOS\NN\1740 )\-RRB-\1740 activity\NN\30358 ,\,\1740 spatial\JJ\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 as\RB\1740 well\RB\1740 as\IN\14622893 the\DT\1740 effect\NN\34213 of\IN\1740 topiramate\NN\1740 ,\,\1740 a\DT\13649268 previously\RB\1740 proposed\VBN\1010118 therapy\NN\657604 for\IN\1740 <e2>cocaine\NN\3492717 addiction</e2>\NN\14034177 ,\,\1740 were\VBD\836236 evaluated\VBN\670261 in\IN\13603305 an\DT\6697703 experimental\JJ\1740 model\NN\5888929 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 in\IN\13603305 rats\NNS\2329401 .\.\1740
C052342_D019970 NONE Therefore\RB\1740 NFkappaB\NN\1740 activity\NN\30358 ,\,\1740 oxidative\JJ\1740 stress\NN\7083732 ,\,\1740 neuronal\JJ\1740 nitric\JJ\1740 oxide\NN\14818238 synthase\NN\1740 (\-LRB-\1740 nNOS\NN\1740 )\-RRB-\1740 activity\NN\30358 ,\,\1740 spatial\JJ\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 as\RB\1740 well\RB\1740 as\IN\14622893 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>topiramate</e1>\NN\1740 ,\,\1740 a\DT\13649268 previously\RB\1740 proposed\VBN\1010118 therapy\NN\657604 for\IN\1740 <e2>cocaine\NN\3492717 addiction</e2>\NN\14034177 ,\,\1740 were\VBD\836236 evaluated\VBN\670261 in\IN\13603305 an\DT\6697703 experimental\JJ\1740 model\NN\5888929 of\IN\1740 cocaine\NN\3492717 administration\NN\1133281 in\IN\13603305 rats\NNS\2329401 .\.\1740
D003042_D019970 NONE Therefore\RB\1740 NFkappaB\NN\1740 activity\NN\30358 ,\,\1740 oxidative\JJ\1740 stress\NN\7083732 ,\,\1740 neuronal\JJ\1740 nitric\JJ\1740 oxide\NN\14818238 synthase\NN\1740 (\-LRB-\1740 nNOS\NN\1740 )\-RRB-\1740 activity\NN\30358 ,\,\1740 spatial\JJ\1740 learning\NN\5701944 and\CC\1740 memory\NN\5926676 as\RB\1740 well\RB\1740 as\IN\14622893 the\DT\1740 effect\NN\34213 of\IN\1740 topiramate\NN\1740 ,\,\1740 a\DT\13649268 previously\RB\1740 proposed\VBN\1010118 therapy\NN\657604 for\IN\1740 <e2>cocaine\NN\3492717 addiction</e2>\NN\14034177 ,\,\1740 were\VBD\836236 evaluated\VBN\670261 in\IN\13603305 an\DT\6697703 experimental\JJ\1740 model\NN\5888929 of\IN\1740 <e1>cocaine</e1>\NN\3492717 administration\NN\1133281 in\IN\13603305 rats\NNS\2329401 .\.\1740
7265370
D014223_D053040 CID <e1>Triamterene</e1>\NN\1740 <e2>nephrolithiasis</e2>\NN\14115914 complicating\VBG\126264 dyazide\NN\1740 therapy\NN\657604 .\.\1740
D014223_D053040 CID A\DT\13649268 case\NN\7283608 of\IN\1740 <e1>triamterene</e1>\JJ\1740 <e2>nephrolithiasis</e2>\NN\14115914 is\VBZ\836236 reported\VBN\831651 in\IN\13603305 a\DT\13649268 man\NN\9605289 after\IN\1740 4\CD\13741022 years\NNS\15144371 of\IN\1740 hydrochlorothiazide-triamterene\NN\1740 therapy\NN\657604 for\IN\1740 hypertension\NN\14057371 .\.\1740
D014223_D053040 CID Factors\NNS\7326557 affecting\VBG\126264 <e1>triamterene</e1>\JJ\1740 <e2>nephrolithiasis</e2>\NN\14115914 are\VBP\836236 discussed\VBN\1033527 and\CC\1740 2\CD\13741022 previously\RB\1740 reported\VBN\831651 cases\NNS\7283608 are\VBP\836236 reviewed\VBN\644583 .\.\1740
C020743_D053040 NONE Triamterene\NN\1740 <e2>nephrolithiasis</e2>\NN\14115914 complicating\VBG\126264 <e1>dyazide</e1>\NN\1740 therapy\NN\657604 .\.\1740
C020743_D053040 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 triamterene\JJ\1740 <e2>nephrolithiasis</e2>\NN\14115914 is\VBZ\836236 reported\VBN\831651 in\IN\13603305 a\DT\13649268 man\NN\9605289 after\IN\1740 4\CD\13741022 years\NNS\15144371 of\IN\1740 <e1>hydrochlorothiazide-triamterene</e1>\NN\1740 therapy\NN\657604 for\IN\1740 hypertension\NN\14057371 .\.\1740
D014223_D006973 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 <e1>triamterene</e1>\JJ\1740 nephrolithiasis\NN\14115914 is\VBZ\836236 reported\VBN\831651 in\IN\13603305 a\DT\13649268 man\NN\9605289 after\IN\1740 4\CD\13741022 years\NNS\15144371 of\IN\1740 hydrochlorothiazide-triamterene\NN\1740 therapy\NN\657604 for\IN\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
C020743_D006973 NONE A\DT\13649268 case\NN\7283608 of\IN\1740 triamterene\JJ\1740 nephrolithiasis\NN\14115914 is\VBZ\836236 reported\VBN\831651 in\IN\13603305 a\DT\13649268 man\NN\9605289 after\IN\1740 4\CD\13741022 years\NNS\15144371 of\IN\1740 <e1>hydrochlorothiazide-triamterene</e1>\NN\1740 therapy\NN\657604 for\IN\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
424937
D008750_D056486 CID Patterns\NNS\5726345 of\IN\1740 <e2>hepatic\JJ\1740 injury</e2>\NN\14052046 induced\VBN\1627355 by\IN\1740 <e1>methyldopa</e1>\NN\2721160 .\.\1740
D008750_D056486 CID The\DT\1740 remaining\VBG\2604760 patient\NN\9898892 in\IN\13603305 the\DT\1740 series\NN\8456993 developed\VBD\1753788 fulminant\JJ\1740 hepatitis\NN\14127211 when\WRB\1740 the\DT\1740 drug\NN\14778436 was\VBD\836236 accidentally\RB\1740 recommenced\VBN\348746 1\CD\13741022 year\NN\15113229 after\IN\1740 a\DT\13649268 prior\JJ\1740 episode\NN\7283608 of\IN\1740 <e1>methyldopa-induced</e1>\JJ\1740 <e2>hepatitis</e2>\NN\14127211 .\.\1740
D008750_D056486 CID In\IN\13603305 this\DT\1740 latter\JJ\1740 patient\NN\9898892 ,\,\1740 and\CC\1740 in\IN\13603305 2\CD\13741022 others\NNS\1740 ,\,\1740 the\DT\1740 causal\JJ\1740 relationship\NN\31921 between\IN\1740 <e1>methyldopa</e1>\JJ\1740 and\CC\1740 hepatic\JJ\1740 dysfunction\NN\14204950 was\VBD\836236 proved\VBN\2604760 with\IN\1740 the\DT\1740 recurrence\NN\7342049 of\IN\1740 <e2>hepatitis</e2>\NN\14127211 within\IN\1740 2\CD\13741022 weeks\NNS\15113229 of\IN\1740 re-exposure\NN\1740 to\IN\1740 the\DT\1740 drug\NN\14778436 .\.\1740
D008750_D008107 NONE Twelve\CD\13745420 patients\NNS\9898892 with\IN\1740 <e2>liver\NN\5298729 disease</e2>\NN\14061805 related\JJ\1740 to\TO\1740 <e1>methyldopa</e1>\NN\2721160 were\VBD\836236 seen\VBN\2106506 between\IN\1740 1967\CD\1740 and\CC\1740 1977\CD\1740 .\.\1740
D008750_D008107 NONE In\IN\13603305 this\DT\1740 latter\JJ\1740 patient\NN\9898892 ,\,\1740 and\CC\1740 in\IN\13603305 2\CD\13741022 others\NNS\1740 ,\,\1740 the\DT\1740 causal\JJ\1740 relationship\NN\31921 between\IN\1740 <e1>methyldopa</e1>\JJ\1740 and\CC\1740 <e2>hepatic\JJ\1740 dysfunction</e2>\NN\14204950 was\VBD\836236 proved\VBN\2604760 with\IN\1740 the\DT\1740 recurrence\NN\7342049 of\IN\1740 hepatitis\NN\14127211 within\IN\1740 2\CD\13741022 weeks\NNS\15113229 of\IN\1740 re-exposure\NN\1740 to\IN\1740 the\DT\1740 drug\NN\14778436 .\.\1740
D008750_D017093 NONE One\CD\13741022 patient\NN\9898892 died\VBD\146138 ,\,\1740 having\VBG\2108377 presented\VBN\2137132 in\IN\13603305 <e2>hepatic\JJ\1740 failure</e2>\NN\66216 ,\,\1740 and\CC\1740 another\DT\1740 ,\,\1740 who\WP\8299493 had\VBD\2108377 been\VBN\836236 taking\VBG\2367363 <e1>methyldopa</e1>\JJ\1740 for\IN\1740 7\CD\13741022 years\NNS\15144371 ,\,\1740 showed\VBD\2137132 slower\JJR\1740 clinical\JJ\1740 and\CC\1740 biochemical\JJ\1740 resolution\NN\6470073 over\IN\5867413 a\DT\13649268 period\NN\13575869 of\IN\1740 several\JJ\1740 months\NNS\15113229 .\.\1740
D008750_D017114 NONE The\DT\1740 remaining\VBG\2604760 patient\NN\9898892 in\IN\13603305 the\DT\1740 series\NN\8456993 developed\VBD\1753788 <e2>fulminant\JJ\1740 hepatitis</e2>\NN\14127211 when\WRB\1740 the\DT\1740 drug\NN\14778436 was\VBD\836236 accidentally\RB\1740 recommenced\VBN\348746 1\CD\13741022 year\NN\15113229 after\IN\1740 a\DT\13649268 prior\JJ\1740 episode\NN\7283608 of\IN\1740 <e1>methyldopa-induced</e1>\JJ\1740 hepatitis\NN\14127211 .\.\1740
20470218
D008727_D056784 NONE CNS\NN\5237227 complications\NNS\1073995 included\VBD\690614 posterior\JJ\1740 reversible\JJ\1740 <e2>leukoencephalopathy</e2>\NN\1740 syndrome\NN\5870365 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 10\CD\13745420 )\-RRB-\1740 ,\,\1740 stroke\NN\556313 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 5\CD\13741022 )\-RRB-\1740 ,\,\1740 temporal\JJ\1740 lobe\VBD\1740 epilepsy\NN\14085708 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 high-dose\NN\1740 <e1>methotrexate</e1>\VBP\1740 toxicity\NN\13576101 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 syndrome\NN\5870365 of\IN\1740 inappropriate\JJ\1740 antidiuretic\JJ\1740 hormone\NN\5404728 secretion\NN\13526110 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 1\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 other\JJ\1740 unclassified\JJ\1740 events\NNS\23100 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 .\.\1740
D008727_D020521 NONE CNS\NN\5237227 complications\NNS\1073995 included\VBD\690614 posterior\JJ\1740 reversible\JJ\1740 leukoencephalopathy\NN\1740 syndrome\NN\5870365 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 10\CD\13745420 )\-RRB-\1740 ,\,\1740 <e2>stroke</e2>\NN\556313 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 5\CD\13741022 )\-RRB-\1740 ,\,\1740 temporal\JJ\1740 lobe\VBD\1740 epilepsy\NN\14085708 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 high-dose\NN\1740 <e1>methotrexate</e1>\VBP\1740 toxicity\NN\13576101 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 syndrome\NN\5870365 of\IN\1740 inappropriate\JJ\1740 antidiuretic\JJ\1740 hormone\NN\5404728 secretion\NN\13526110 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 1\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 other\JJ\1740 unclassified\JJ\1740 events\NNS\23100 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 .\.\1740
D008727_D004833 NONE CNS\NN\5237227 complications\NNS\1073995 included\VBD\690614 posterior\JJ\1740 reversible\JJ\1740 leukoencephalopathy\NN\1740 syndrome\NN\5870365 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 10\CD\13745420 )\-RRB-\1740 ,\,\1740 stroke\NN\556313 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 5\CD\13741022 )\-RRB-\1740 ,\,\1740 <e2>temporal\JJ\1740 lobe\VBD\1740 epilepsy</e2>\NN\14085708 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 high-dose\NN\1740 <e1>methotrexate</e1>\VBP\1740 toxicity\NN\13576101 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 syndrome\NN\5870365 of\IN\1740 inappropriate\JJ\1740 antidiuretic\JJ\1740 hormone\NN\5404728 secretion\NN\13526110 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 1\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 other\JJ\1740 unclassified\JJ\1740 events\NNS\23100 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 .\.\1740
D008727_D064420 NONE CNS\NN\5237227 complications\NNS\1073995 included\VBD\690614 posterior\JJ\1740 reversible\JJ\1740 leukoencephalopathy\NN\1740 syndrome\NN\5870365 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 10\CD\13745420 )\-RRB-\1740 ,\,\1740 stroke\NN\556313 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 5\CD\13741022 )\-RRB-\1740 ,\,\1740 temporal\JJ\1740 lobe\VBD\1740 epilepsy\NN\14085708 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 high-dose\NN\1740 <e1>methotrexate</e1>\VBP\1740 <e2>toxicity</e2>\NN\13576101 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 syndrome\NN\5870365 of\IN\1740 inappropriate\JJ\1740 antidiuretic\JJ\1740 hormone\NN\5404728 secretion\NN\13526110 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 1\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 other\JJ\1740 unclassified\JJ\1740 events\NNS\23100 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 .\.\1740
D008727_D007177 NONE CNS\NN\5237227 complications\NNS\1073995 included\VBD\690614 posterior\JJ\1740 reversible\JJ\1740 leukoencephalopathy\NN\1740 syndrome\NN\5870365 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 10\CD\13745420 )\-RRB-\1740 ,\,\1740 stroke\NN\556313 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 5\CD\13741022 )\-RRB-\1740 ,\,\1740 temporal\JJ\1740 lobe\VBD\1740 epilepsy\NN\14085708 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 high-dose\NN\1740 <e1>methotrexate</e1>\VBP\1740 toxicity\NN\13576101 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 ,\,\1740 syndrome\NN\5870365 of\IN\1740 <e2>inappropriate\JJ\1740 antidiuretic\JJ\1740 hormone\NN\5404728 secretion</e2>\NN\13526110 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 1\CD\13741022 )\-RRB-\1740 ,\,\1740 and\CC\1740 other\JJ\1740 unclassified\JJ\1740 events\NNS\23100 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 .\.\1740
15572383
D004317_D007674 NONE Individual\JJ\1740 differences\NNS\4723816 in\IN\13603305 renal\JJ\1740 ACE\NN\13741022 activity\NN\30358 in\IN\13603305 healthy\JJ\1740 rats\NNS\2329401 predict\VBP\916909 susceptibility\NN\13920835 to\TO\1740 <e1>adriamycin-induced</e1>\JJ\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 .\.\1740
D004317_D007674 NONE Therefore\RB\1740 ,\,\1740 we\PRP\1740 studied\VBD\630380 the\DT\1740 predictive\JJ\1740 effect\NN\34213 of\IN\1740 renal\JJ\1740 ACE\NN\13741022 activity\NN\30358 for\IN\1740 the\DT\1740 severity\NN\5036394 of\IN\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 induced\VBN\1627355 by\IN\1740 a\DT\13649268 single\JJ\1740 injection\NN\320852 of\IN\1740 <e1>adriamycin</e1>\NN\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D004317_D007674 NONE RESULTS\NNS\34213 :\:\1740 As\IN\14622893 anticipated\VBN\670261 ,\,\1740 <e1>adriamycin</e1>\NN\1740 elicited\VBD\1617192 nephrotic\JJ\1740 range\NN\5123416 proteinuria\NN\14299637 ,\,\1740 <e2>renal\JJ\1740 interstitial\JJ\1740 damage</e2>\NN\7296428 and\CC\1740 mild\JJ\1740 focal\JJ\1740 glomerulosclerosis\NN\1740 .\.\1740
D004317_D007674 NONE CONCLUSION\NN\5837957 :\:\1740 Individual\JJ\1740 differences\NNS\4723816 in\IN\13603305 renal\JJ\1740 ACE\NN\13741022 activity\NN\30358 predict\VBP\916909 the\DT\1740 severity\NN\5036394 of\IN\1740 <e1>adriamycin-induced</e1>\JJ\1740 <e2>renal\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 this\DT\1740 outbred\JJ\1740 rat\NN\2329401 strain\NN\7358060 .\.\1740
D004317_D011507 CID After\IN\1740 1\CD\13741022 week\NN\15113229 of\IN\1740 recovery\NN\7357388 ,\,\1740 <e2>proteinuria</e2>\NN\14299637 was\VBD\836236 induced\VBN\1627355 by\IN\1740 <e1>adriamycin</e1>\NN\1740 [\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 intravenously\RB\1740 (\-LRB-\1740 i.v.\NN\1740 )\-RRB-\1740 n\NN\14622893 =\JJ\1740 18\CD\13745420 ;\:\1740 controls\NNS\5190804 ,\,\1740 saline\NN\14849367 i.v.\NN\1740 n\NN\14622893 =\JJ\1740 9\CD\13741022 ]\-RRB-\1740 .\.\1740
D004317_D011507 CID RESULTS\NNS\34213 :\:\1740 As\IN\14622893 anticipated\VBN\670261 ,\,\1740 <e1>adriamycin</e1>\NN\1740 elicited\VBD\1617192 nephrotic\JJ\1740 range\NN\5123416 <e2>proteinuria</e2>\NN\14299637 ,\,\1740 renal\JJ\1740 interstitial\JJ\1740 damage\NN\7296428 and\CC\1740 mild\JJ\1740 focal\JJ\1740 glomerulosclerosis\NN\1740 .\.\1740
D004317_D011507 CID Baseline\NN\7260623 renal\JJ\1740 ACE\NN\13741022 positively\RB\1740 correlated\VBD\2657219 with\IN\1740 the\DT\1740 relative\JJ\1740 rise\NN\7324673 in\IN\13603305 <e2>proteinuria</e2>\NN\14299637 after\IN\1740 <e1>adriamycin</e1>\NN\1740 (\-LRB-\1740 r\NN\13635336 =\JJ\1740 0.62\CD\1740 ,\,\1740 P<0.01\NN\1740 )\-RRB-\1740 ,\,\1740 renal\JJ\1740 interstitial\JJ\1740 alpha-smooth\NN\1740 muscle\NN\5289601 actin\NN\14736972 (\-LRB-\1740 r\NN\13635336 =\JJ\1740 0.49\CD\1740 ,\,\1740 P<0.05\CD\1740 )\-RRB-\1740 ,\,\1740 interstitial\JJ\1740 macrophage\NN\5450888 influx\NN\13482330 (\-LRB-\1740 r\NN\13635336 =\JJ\1740 0.56\CD\1740 ,\,\1740 P<0.05\CD\1740 )\-RRB-\1740 ,\,\1740 interstitial\JJ\1740 collagen\NN\15026716 III\CD\13741022 (\-LRB-\1740 r\NN\13635336 =\JJ\1740 0.53\CD\1740 ,\,\1740 P<0.05\CD\1740 )\-RRB-\1740 ,\,\1740 glomerular\JJ\1740 alpha-smooth\JJ\1740 muscle\NN\5289601 actin\NN\14736972 (\-LRB-\1740 r\NN\13635336 =\JJ\1740 0.74\CD\1740 ,\,\1740 P<0.01\NN\1740 )\-RRB-\1740 and\CC\1740 glomerular\JJ\1740 desmin\NN\1740 (\-LRB-\1740 r\NN\13635336 =\JJ\1740 0.48\CD\1740 ,\,\1740 P<0.05\CD\1740 )\-RRB-\1740 .\.\1740
D004317_D009404 NONE RESULTS\NNS\34213 :\:\1740 As\IN\14622893 anticipated\VBN\670261 ,\,\1740 <e1>adriamycin</e1>\NN\1740 elicited\VBD\1617192 <e2>nephrotic</e2>\JJ\1740 range\NN\5123416 proteinuria\NN\14299637 ,\,\1740 renal\JJ\1740 interstitial\JJ\1740 damage\NN\7296428 and\CC\1740 mild\JJ\1740 focal\JJ\1740 glomerulosclerosis\NN\1740 .\.\1740
D004317_D005923 NONE RESULTS\NNS\34213 :\:\1740 As\IN\14622893 anticipated\VBN\670261 ,\,\1740 <e1>adriamycin</e1>\NN\1740 elicited\VBD\1617192 nephrotic\JJ\1740 range\NN\5123416 proteinuria\NN\14299637 ,\,\1740 renal\JJ\1740 interstitial\JJ\1740 damage\NN\7296428 and\CC\1740 mild\JJ\1740 <e2>focal\JJ\1740 glomerulosclerosis</e2>\NN\1740 .\.\1740
7582165
D000305_D004342 NONE <e2>Pseudo-allergic\JJ\1740 reactions</e2>\NNS\13446390 to\TO\1740 <e1>corticosteroids</e1>\NNS\14745635 :\:\1740 diagnosis\NN\152018 and\CC\1740 alternatives\NNS\5788149 .\.\1740
D010248_D004342 NONE Corticosteroids\NNS\14745635 different\JJ\1740 from\IN\1740 <e1>paramethasone</e1>\NN\1740 also\RB\1740 produced\VBD\1617192 <e2>hypersensitivity</e2>\NN\14531772 reactions\NNS\13446390 in\IN\13603305 these\DT\1740 patients\NNS\9898892 ;\:\1740 however\RB\1740 ,\,\1740 a\DT\13649268 few\JJ\1740 of\IN\1740 them\PRP\1740 were\VBD\836236 tolerated\VBN\802318 .\.\1740
D010248_D004342 NONE To\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 report\NN\6470073 of\IN\1740 a\DT\13649268 <e2>pseudo-allergy</e2>\NN\1740 caused\VBN\1617192 by\IN\1740 <e1>paramethasone</e1>\NN\1740 .\.\1740
18208574
D006493_D013927 CID Higher\JJR\1740 optical\JJ\1740 density\NN\4941325 of\IN\1740 an\DT\6697703 antigen\NN\20090 assay\NN\5733583 predicts\VBZ\916909 <e2>thrombosis</e2>\NN\14100769 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 .\.\1740
D006493_D013927 CID OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 correlate\VB\2657219 optical\JJ\1740 density\NN\4941325 and\CC\1740 percent\NN\13815742 inhibition\NN\1068773 of\IN\1740 a\DT\13649268 two-step\JJ\1740 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 (\-LRB-\1740 HIT\NN\36762 )\-RRB-\1740 antigen\NN\20090 assay\NN\5733583 with\IN\1740 <e2>thrombosis</e2>\NN\14100769 ;\:\1740 the\DT\1740 assay\NN\5733583 utilizes\VBZ\161225 reaction\NN\13446390 inhibition\NN\1068773 characteristics\NNS\5849040 of\IN\1740 a\DT\13649268 high\JJ\1740 heparin\NN\2718259 concentration\NN\4916342 .\.\1740
D006493_D013927 CID OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 correlate\VB\2657219 optical\JJ\1740 density\NN\4941325 and\CC\1740 percent\NN\13815742 inhibition\NN\1068773 of\IN\1740 a\DT\13649268 two-step\JJ\1740 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 (\-LRB-\1740 HIT\NN\36762 )\-RRB-\1740 antigen\NN\20090 assay\NN\5733583 with\IN\1740 <e2>thrombosis</e2>\NN\14100769 ;\:\1740 the\DT\1740 assay\NN\5733583 utilizes\VBZ\161225 reaction\NN\13446390 inhibition\NN\1068773 characteristics\NNS\5849040 of\IN\1740 a\DT\13649268 high\JJ\1740 <e1>heparin</e1>\NN\2718259 concentration\NN\4916342 .\.\1740
D006493_D013921 CID Higher\JJR\1740 optical\JJ\1740 density\NN\4941325 of\IN\1740 an\DT\6697703 antigen\NN\20090 assay\NN\5733583 predicts\VBZ\916909 thrombosis\NN\14100769 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 .\.\1740
D006493_D013921 CID OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 correlate\VB\2657219 optical\JJ\1740 density\NN\4941325 and\CC\1740 percent\NN\13815742 inhibition\NN\1068773 of\IN\1740 a\DT\13649268 two-step\JJ\1740 <e1>heparin-induced</e1>\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 (\-LRB-\1740 HIT\NN\36762 )\-RRB-\1740 antigen\NN\20090 assay\NN\5733583 with\IN\1740 thrombosis\NN\14100769 ;\:\1740 the\DT\1740 assay\NN\5733583 utilizes\VBZ\161225 reaction\NN\13446390 inhibition\NN\1068773 characteristics\NNS\5849040 of\IN\1740 a\DT\13649268 high\JJ\1740 heparin\NN\2718259 concentration\NN\4916342 .\.\1740
D006493_D013921 CID OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 correlate\VB\2657219 optical\JJ\1740 density\NN\4941325 and\CC\1740 percent\NN\13815742 inhibition\NN\1068773 of\IN\1740 a\DT\13649268 two-step\JJ\1740 <e1>heparin-induced</e1>\JJ\1740 thrombocytopenia\NN\14189204 (\-LRB-\1740 <e2>HIT</e2>\NN\36762 )\-RRB-\1740 antigen\NN\20090 assay\NN\5733583 with\IN\1740 thrombosis\NN\14100769 ;\:\1740 the\DT\1740 assay\NN\5733583 utilizes\VBZ\161225 reaction\NN\13446390 inhibition\NN\1068773 characteristics\NNS\5849040 of\IN\1740 a\DT\13649268 high\JJ\1740 heparin\NN\2718259 concentration\NN\4916342 .\.\1740
D006493_D013921 CID OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 correlate\VB\2657219 optical\JJ\1740 density\NN\4941325 and\CC\1740 percent\NN\13815742 inhibition\NN\1068773 of\IN\1740 a\DT\13649268 two-step\JJ\1740 heparin-induced\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 (\-LRB-\1740 HIT\NN\36762 )\-RRB-\1740 antigen\NN\20090 assay\NN\5733583 with\IN\1740 thrombosis\NN\14100769 ;\:\1740 the\DT\1740 assay\NN\5733583 utilizes\VBZ\161225 reaction\NN\13446390 inhibition\NN\1068773 characteristics\NNS\5849040 of\IN\1740 a\DT\13649268 high\JJ\1740 <e1>heparin</e1>\NN\2718259 concentration\NN\4916342 .\.\1740
D006493_D013921 CID OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 correlate\VB\2657219 optical\JJ\1740 density\NN\4941325 and\CC\1740 percent\NN\13815742 inhibition\NN\1068773 of\IN\1740 a\DT\13649268 two-step\JJ\1740 heparin-induced\JJ\1740 thrombocytopenia\NN\14189204 (\-LRB-\1740 <e2>HIT</e2>\NN\36762 )\-RRB-\1740 antigen\NN\20090 assay\NN\5733583 with\IN\1740 thrombosis\NN\14100769 ;\:\1740 the\DT\1740 assay\NN\5733583 utilizes\VBZ\161225 reaction\NN\13446390 inhibition\NN\1068773 characteristics\NNS\5849040 of\IN\1740 a\DT\13649268 high\JJ\1740 <e1>heparin</e1>\NN\2718259 concentration\NN\4916342 .\.\1740
D006493_D013921 CID PATIENTS\NNS\9898892 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 Patients\NNS\9898892 with\IN\1740 more\JJR\1740 than\IN\1740 50\CD\13745420 %\NN\1740 decrease\NN\7296428 in\IN\13603305 platelet\NN\5432736 count\NN\13582013 or\CC\3541091 <e2>thrombocytopenia</e2>\NN\14189204 (\-LRB-\1740 <\XX\1740 150\CD\1740 x\CC\13745420 10(9)/L\CD\1740 )\-RRB-\1740 after\IN\1740 exposure\NN\5042871 to\TO\1740 <e1>heparin</e1>\NN\2718259 ,\,\1740 who\WP\8299493 had\VBD\2108377 a\DT\13649268 positive\JJ\1740 two-step\JJ\1740 antigen\NN\20090 assay\NN\5733583 [\-LRB-\1740 optical\JJ\1740 density\NN\4941325 (\-LRB-\1740 OD\NN\6702458 )\-RRB-\1740 >\NN\1740 0.4\CD\1740 and\CC\1740 >\NN\1740 50\CD\13745420 inhibition\NN\1068773 with\IN\1740 high\JJ\1740 concentration\NN\4916342 of\IN\1740 heparin\NN\2718259 ]\-RRB-\1740 were\VBD\836236 included\VBN\690614 in\IN\13603305 the\DT\1740 study\NN\635850 .\.\1740
D006493_D013921 CID PATIENTS\NNS\9898892 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 Patients\NNS\9898892 with\IN\1740 more\JJR\1740 than\IN\1740 50\CD\13745420 %\NN\1740 decrease\NN\7296428 in\IN\13603305 platelet\NN\5432736 count\NN\13582013 or\CC\3541091 <e2>thrombocytopenia</e2>\NN\14189204 (\-LRB-\1740 <\XX\1740 150\CD\1740 x\CC\13745420 10(9)/L\CD\1740 )\-RRB-\1740 after\IN\1740 exposure\NN\5042871 to\TO\1740 heparin\NN\2718259 ,\,\1740 who\WP\8299493 had\VBD\2108377 a\DT\13649268 positive\JJ\1740 two-step\JJ\1740 antigen\NN\20090 assay\NN\5733583 [\-LRB-\1740 optical\JJ\1740 density\NN\4941325 (\-LRB-\1740 OD\NN\6702458 )\-RRB-\1740 >\NN\1740 0.4\CD\1740 and\CC\1740 >\NN\1740 50\CD\13745420 inhibition\NN\1068773 with\IN\1740 high\JJ\1740 concentration\NN\4916342 of\IN\1740 <e1>heparin</e1>\NN\2718259 ]\-RRB-\1740 were\VBD\836236 included\VBN\690614 in\IN\13603305 the\DT\1740 study\NN\635850 .\.\1740
19884587
D013449_D000757 CID <e1>Sulfonamides</e1>\NNS\2716205 were\VBD\836236 associated\VBN\628491 with\IN\1740 <e2>anencephaly</e2>\NN\14465048 (\-LRB-\1740 adjusted\VBN\126264 OR\NN\3541091 [\-LRB-\1740 AOR\NN\1740 ]\-RRB-\1740 =\JJ\1740 3.4\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 [\-LRB-\1740 CI\NNP\13635336 ]\-RRB-\1740 ,\,\1740 1.3\CD\1740 -\SYM\1740 8.8\CD\1740 )\-RRB-\1740 ,\,\1740 hypoplastic\JJ\1740 left\VBD\120316 heart\NN\5919034 syndrome\NN\5870365 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 3.2\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.3\CD\1740 -\SYM\1740 7.6\CD\1740 )\-RRB-\1740 ,\,\1740 coarctation\NN\7313241 of\IN\1740 the\DT\1740 aorta\NN\5333777 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.7\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.3\CD\1740 -\SYM\1740 5.6\CD\1740 )\-RRB-\1740 ,\,\1740 choanal\JJ\1740 atresia\NN\14501726 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 8.0\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 2.7\CD\1740 -\SYM\1740 23.5\CD\1740 )\-RRB-\1740 ,\,\1740 transverse\JJ\1740 limb\JJ\1740 deficiency\NN\14449126 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.5\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.0\CD\1740 -\SYM\1740 5.9\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 diaphragmatic\JJ\1740 hernia\NN\14295248 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.4\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.1\CD\1740 -\SYM\1740 5.4\CD\1740 )\-RRB-\1740 .\.\1740
D013449_D018636 CID <e1>Sulfonamides</e1>\NNS\2716205 were\VBD\836236 associated\VBN\628491 with\IN\1740 anencephaly\NN\14465048 (\-LRB-\1740 adjusted\VBN\126264 OR\NN\3541091 [\-LRB-\1740 AOR\NN\1740 ]\-RRB-\1740 =\JJ\1740 3.4\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 [\-LRB-\1740 CI\NNP\13635336 ]\-RRB-\1740 ,\,\1740 1.3\CD\1740 -\SYM\1740 8.8\CD\1740 )\-RRB-\1740 ,\,\1740 <e2>hypoplastic\JJ\1740 left\VBD\120316 heart\NN\5919034 syndrome</e2>\NN\5870365 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 3.2\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.3\CD\1740 -\SYM\1740 7.6\CD\1740 )\-RRB-\1740 ,\,\1740 coarctation\NN\7313241 of\IN\1740 the\DT\1740 aorta\NN\5333777 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.7\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.3\CD\1740 -\SYM\1740 5.6\CD\1740 )\-RRB-\1740 ,\,\1740 choanal\JJ\1740 atresia\NN\14501726 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 8.0\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 2.7\CD\1740 -\SYM\1740 23.5\CD\1740 )\-RRB-\1740 ,\,\1740 transverse\JJ\1740 limb\JJ\1740 deficiency\NN\14449126 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.5\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.0\CD\1740 -\SYM\1740 5.9\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 diaphragmatic\JJ\1740 hernia\NN\14295248 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.4\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.1\CD\1740 -\SYM\1740 5.4\CD\1740 )\-RRB-\1740 .\.\1740
D013449_D001017 CID <e1>Sulfonamides</e1>\NNS\2716205 were\VBD\836236 associated\VBN\628491 with\IN\1740 anencephaly\NN\14465048 (\-LRB-\1740 adjusted\VBN\126264 OR\NN\3541091 [\-LRB-\1740 AOR\NN\1740 ]\-RRB-\1740 =\JJ\1740 3.4\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 [\-LRB-\1740 CI\NNP\13635336 ]\-RRB-\1740 ,\,\1740 1.3\CD\1740 -\SYM\1740 8.8\CD\1740 )\-RRB-\1740 ,\,\1740 hypoplastic\JJ\1740 left\VBD\120316 heart\NN\5919034 syndrome\NN\5870365 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 3.2\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.3\CD\1740 -\SYM\1740 7.6\CD\1740 )\-RRB-\1740 ,\,\1740 <e2>coarctation\NN\7313241 of\IN\1740 the\DT\1740 aorta</e2>\NN\5333777 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.7\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.3\CD\1740 -\SYM\1740 5.6\CD\1740 )\-RRB-\1740 ,\,\1740 choanal\JJ\1740 atresia\NN\14501726 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 8.0\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 2.7\CD\1740 -\SYM\1740 23.5\CD\1740 )\-RRB-\1740 ,\,\1740 transverse\JJ\1740 limb\JJ\1740 deficiency\NN\14449126 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.5\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.0\CD\1740 -\SYM\1740 5.9\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 diaphragmatic\JJ\1740 hernia\NN\14295248 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.4\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.1\CD\1740 -\SYM\1740 5.4\CD\1740 )\-RRB-\1740 .\.\1740
D013449_D002754 CID <e1>Sulfonamides</e1>\NNS\2716205 were\VBD\836236 associated\VBN\628491 with\IN\1740 anencephaly\NN\14465048 (\-LRB-\1740 adjusted\VBN\126264 OR\NN\3541091 [\-LRB-\1740 AOR\NN\1740 ]\-RRB-\1740 =\JJ\1740 3.4\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 [\-LRB-\1740 CI\NNP\13635336 ]\-RRB-\1740 ,\,\1740 1.3\CD\1740 -\SYM\1740 8.8\CD\1740 )\-RRB-\1740 ,\,\1740 hypoplastic\JJ\1740 left\VBD\120316 heart\NN\5919034 syndrome\NN\5870365 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 3.2\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.3\CD\1740 -\SYM\1740 7.6\CD\1740 )\-RRB-\1740 ,\,\1740 coarctation\NN\7313241 of\IN\1740 the\DT\1740 aorta\NN\5333777 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.7\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.3\CD\1740 -\SYM\1740 5.6\CD\1740 )\-RRB-\1740 ,\,\1740 <e2>choanal\JJ\1740 atresia</e2>\NN\14501726 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 8.0\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 2.7\CD\1740 -\SYM\1740 23.5\CD\1740 )\-RRB-\1740 ,\,\1740 transverse\JJ\1740 limb\JJ\1740 deficiency\NN\14449126 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.5\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.0\CD\1740 -\SYM\1740 5.9\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 diaphragmatic\JJ\1740 hernia\NN\14295248 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.4\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.1\CD\1740 -\SYM\1740 5.4\CD\1740 )\-RRB-\1740 .\.\1740
D013449_D017880 CID <e1>Sulfonamides</e1>\NNS\2716205 were\VBD\836236 associated\VBN\628491 with\IN\1740 anencephaly\NN\14465048 (\-LRB-\1740 adjusted\VBN\126264 OR\NN\3541091 [\-LRB-\1740 AOR\NN\1740 ]\-RRB-\1740 =\JJ\1740 3.4\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 [\-LRB-\1740 CI\NNP\13635336 ]\-RRB-\1740 ,\,\1740 1.3\CD\1740 -\SYM\1740 8.8\CD\1740 )\-RRB-\1740 ,\,\1740 hypoplastic\JJ\1740 left\VBD\120316 heart\NN\5919034 syndrome\NN\5870365 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 3.2\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.3\CD\1740 -\SYM\1740 7.6\CD\1740 )\-RRB-\1740 ,\,\1740 coarctation\NN\7313241 of\IN\1740 the\DT\1740 aorta\NN\5333777 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.7\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.3\CD\1740 -\SYM\1740 5.6\CD\1740 )\-RRB-\1740 ,\,\1740 choanal\JJ\1740 atresia\NN\14501726 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 8.0\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 2.7\CD\1740 -\SYM\1740 23.5\CD\1740 )\-RRB-\1740 ,\,\1740 <e2>transverse\JJ\1740 limb\JJ\1740 deficiency</e2>\NN\14449126 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.5\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.0\CD\1740 -\SYM\1740 5.9\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 diaphragmatic\JJ\1740 hernia\NN\14295248 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.4\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.1\CD\1740 -\SYM\1740 5.4\CD\1740 )\-RRB-\1740 .\.\1740
D013449_D006548 CID <e1>Sulfonamides</e1>\NNS\2716205 were\VBD\836236 associated\VBN\628491 with\IN\1740 anencephaly\NN\14465048 (\-LRB-\1740 adjusted\VBN\126264 OR\NN\3541091 [\-LRB-\1740 AOR\NN\1740 ]\-RRB-\1740 =\JJ\1740 3.4\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 [\-LRB-\1740 CI\NNP\13635336 ]\-RRB-\1740 ,\,\1740 1.3\CD\1740 -\SYM\1740 8.8\CD\1740 )\-RRB-\1740 ,\,\1740 hypoplastic\JJ\1740 left\VBD\120316 heart\NN\5919034 syndrome\NN\5870365 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 3.2\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.3\CD\1740 -\SYM\1740 7.6\CD\1740 )\-RRB-\1740 ,\,\1740 coarctation\NN\7313241 of\IN\1740 the\DT\1740 aorta\NN\5333777 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.7\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.3\CD\1740 -\SYM\1740 5.6\CD\1740 )\-RRB-\1740 ,\,\1740 choanal\JJ\1740 atresia\NN\14501726 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 8.0\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 2.7\CD\1740 -\SYM\1740 23.5\CD\1740 )\-RRB-\1740 ,\,\1740 transverse\JJ\1740 limb\JJ\1740 deficiency\NN\14449126 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.5\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.0\CD\1740 -\SYM\1740 5.9\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e2>diaphragmatic\JJ\1740 hernia</e2>\NN\14295248 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.4\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.1\CD\1740 -\SYM\1740 5.4\CD\1740 )\-RRB-\1740 .\.\1740
D009582_D000853 CID <e1>Nitrofurantoins</e1>\NNS\2716205 were\VBD\836236 associated\VBN\628491 with\IN\1740 <e2>anophthalmia</e2>\NN\1740 or\CC\3541091 microphthalmos\NN\1740 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 3.7\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.1\CD\1740 -\SYM\1740 12.2\CD\1740 )\-RRB-\1740 ,\,\1740 hypoplastic\JJ\1740 left\VBD\120316 heart\NN\5919034 syndrome\NN\5870365 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 4.2\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.9\CD\1740 -\SYM\1740 9.1\CD\1740 )\-RRB-\1740 ,\,\1740 atrial\JJ\1740 septal\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 1.9\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.1\CD\1740 -\SYM\1740 3.4\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 cleft\VBD\1556346 lip\NN\5301392 with\IN\1740 cleft\NN\13908021 palate\NN\8660339 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.1\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.2\CD\1740 -\SYM\1740 3.9\CD\1740 )\-RRB-\1740 .\.\1740
D009582_D008850 CID <e1>Nitrofurantoins</e1>\NNS\2716205 were\VBD\836236 associated\VBN\628491 with\IN\1740 anophthalmia\NN\1740 or\CC\3541091 <e2>microphthalmos</e2>\NN\1740 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 3.7\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.1\CD\1740 -\SYM\1740 12.2\CD\1740 )\-RRB-\1740 ,\,\1740 hypoplastic\JJ\1740 left\VBD\120316 heart\NN\5919034 syndrome\NN\5870365 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 4.2\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.9\CD\1740 -\SYM\1740 9.1\CD\1740 )\-RRB-\1740 ,\,\1740 atrial\JJ\1740 septal\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 1.9\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.1\CD\1740 -\SYM\1740 3.4\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 cleft\VBD\1556346 lip\NN\5301392 with\IN\1740 cleft\NN\13908021 palate\NN\8660339 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.1\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.2\CD\1740 -\SYM\1740 3.9\CD\1740 )\-RRB-\1740 .\.\1740
D009582_D018636 CID <e1>Nitrofurantoins</e1>\NNS\2716205 were\VBD\836236 associated\VBN\628491 with\IN\1740 anophthalmia\NN\1740 or\CC\3541091 microphthalmos\NN\1740 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 3.7\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.1\CD\1740 -\SYM\1740 12.2\CD\1740 )\-RRB-\1740 ,\,\1740 <e2>hypoplastic\JJ\1740 left\VBD\120316 heart\NN\5919034 syndrome</e2>\NN\5870365 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 4.2\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.9\CD\1740 -\SYM\1740 9.1\CD\1740 )\-RRB-\1740 ,\,\1740 atrial\JJ\1740 septal\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 1.9\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.1\CD\1740 -\SYM\1740 3.4\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 cleft\VBD\1556346 lip\NN\5301392 with\IN\1740 cleft\NN\13908021 palate\NN\8660339 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.1\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.2\CD\1740 -\SYM\1740 3.9\CD\1740 )\-RRB-\1740 .\.\1740
D009582_D006344 CID <e1>Nitrofurantoins</e1>\NNS\2716205 were\VBD\836236 associated\VBN\628491 with\IN\1740 anophthalmia\NN\1740 or\CC\3541091 microphthalmos\NN\1740 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 3.7\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.1\CD\1740 -\SYM\1740 12.2\CD\1740 )\-RRB-\1740 ,\,\1740 hypoplastic\JJ\1740 left\VBD\120316 heart\NN\5919034 syndrome\NN\5870365 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 4.2\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.9\CD\1740 -\SYM\1740 9.1\CD\1740 )\-RRB-\1740 ,\,\1740 <e2>atrial\JJ\1740 septal\JJ\1740 defects</e2>\NNS\14462666 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 1.9\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.1\CD\1740 -\SYM\1740 3.4\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 cleft\VBD\1556346 lip\NN\5301392 with\IN\1740 cleft\NN\13908021 palate\NN\8660339 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.1\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.2\CD\1740 -\SYM\1740 3.9\CD\1740 )\-RRB-\1740 .\.\1740
D009582_D002971 CID <e1>Nitrofurantoins</e1>\NNS\2716205 were\VBD\836236 associated\VBN\628491 with\IN\1740 anophthalmia\NN\1740 or\CC\3541091 microphthalmos\NN\1740 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 3.7\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.1\CD\1740 -\SYM\1740 12.2\CD\1740 )\-RRB-\1740 ,\,\1740 hypoplastic\JJ\1740 left\VBD\120316 heart\NN\5919034 syndrome\NN\5870365 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 4.2\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.9\CD\1740 -\SYM\1740 9.1\CD\1740 )\-RRB-\1740 ,\,\1740 atrial\JJ\1740 septal\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 1.9\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.1\CD\1740 -\SYM\1740 3.4\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e2>cleft\VBD\1556346 lip</e2>\NN\5301392 with\IN\1740 cleft\NN\13908021 palate\NN\8660339 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.1\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.2\CD\1740 -\SYM\1740 3.9\CD\1740 )\-RRB-\1740 .\.\1740
D009582_D002972 CID <e1>Nitrofurantoins</e1>\NNS\2716205 were\VBD\836236 associated\VBN\628491 with\IN\1740 anophthalmia\NN\1740 or\CC\3541091 microphthalmos\NN\1740 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 3.7\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.1\CD\1740 -\SYM\1740 12.2\CD\1740 )\-RRB-\1740 ,\,\1740 hypoplastic\JJ\1740 left\VBD\120316 heart\NN\5919034 syndrome\NN\5870365 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 4.2\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.9\CD\1740 -\SYM\1740 9.1\CD\1740 )\-RRB-\1740 ,\,\1740 atrial\JJ\1740 septal\JJ\1740 defects\NNS\14462666 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 1.9\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.1\CD\1740 -\SYM\1740 3.4\CD\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 cleft\VBD\1556346 lip\NN\5301392 with\IN\1740 <e2>cleft\NN\13908021 palate</e2>\NN\8660339 (\-LRB-\1740 AOR\NN\1740 =\JJ\1740 2.1\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 ,\,\1740 1.2\CD\1740 -\SYM\1740 3.9\CD\1740 )\-RRB-\1740 .\.\1740
D010406_D000014 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Reassuringly\RB\1740 ,\,\1740 <e1>penicillins</e1>\NNS\2716866 ,\,\1740 erythromycins\NNS\2716866 ,\,\1740 and\CC\1740 cephalosporins\NNS\2716866 ,\,\1740 although\IN\1740 used\VBN\1156834 commonly\RB\1740 by\IN\1740 pregnant\JJ\1740 women\NNS\9605289 ,\,\1740 were\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 many\JJ\1740 <e2>birth\NN\15265518 defects</e2>\NNS\14462666 .\.\1740
D004917_D000014 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Reassuringly\RB\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 <e1>erythromycins</e1>\NNS\2716866 ,\,\1740 and\CC\1740 cephalosporins\NNS\2716866 ,\,\1740 although\IN\1740 used\VBN\1156834 commonly\RB\1740 by\IN\1740 pregnant\JJ\1740 women\NNS\9605289 ,\,\1740 were\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 many\JJ\1740 <e2>birth\NN\15265518 defects</e2>\NNS\14462666 .\.\1740
D002511_D000014 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Reassuringly\RB\1740 ,\,\1740 penicillins\NNS\2716866 ,\,\1740 erythromycins\NNS\2716866 ,\,\1740 and\CC\1740 <e1>cephalosporins</e1>\NNS\2716866 ,\,\1740 although\IN\1740 used\VBN\1156834 commonly\RB\1740 by\IN\1740 pregnant\JJ\1740 women\NNS\9605289 ,\,\1740 were\VBD\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 many\JJ\1740 <e2>birth\NN\15265518 defects</e2>\NNS\14462666 .\.\1740
D013449_D000014 CID <e1>Sulfonamides</e1>\NNS\2716205 and\CC\1740 nitrofurantoins\NNS\2716205 were\VBD\836236 associated\VBN\628491 with\IN\1740 several\JJ\1740 <e2>birth\NN\15265518 defects</e2>\NNS\14462666 ,\,\1740 indicating\VBG\952524 a\DT\13649268 need\NN\13920835 for\IN\1740 additional\JJ\1740 scrutiny\NN\633864 .\.\1740
D009582_D000014 CID Sulfonamides\NNS\2716205 and\CC\1740 <e1>nitrofurantoins</e1>\NNS\2716205 were\VBD\836236 associated\VBN\628491 with\IN\1740 several\JJ\1740 <e2>birth\NN\15265518 defects</e2>\NNS\14462666 ,\,\1740 indicating\VBG\952524 a\DT\13649268 need\NN\13920835 for\IN\1740 additional\JJ\1740 scrutiny\NN\633864 .\.\1740
17343925
D012906_D034381 CID The\DT\1740 influence\NN\5190804 of\IN\1740 <e1>smoking</e1>\VBG\1156834 during\IN\1740 pregnancy\NN\14034177 on\IN\1740 the\DT\1740 developing\VBG\1753788 cochlea\NN\5246511 has\VBZ\2108377 not\RB\1740 been\VBN\836236 estimated\VBN\637259 ,\,\1740 although\IN\1740 smoking\NN\831191 has\VBZ\2108377 been\VBN\836236 positively\RB\1740 associated\VBN\628491 with\IN\1740 <e2>hearing\VBG\2106506 loss</e2>\NN\13252973 in\IN\13603305 adults\NNS\7846 .\.\1740
D012906_D034381 CID The\DT\1740 influence\NN\5190804 of\IN\1740 smoking\VBG\1156834 during\IN\1740 pregnancy\NN\14034177 on\IN\1740 the\DT\1740 developing\VBG\1753788 cochlea\NN\5246511 has\VBZ\2108377 not\RB\1740 been\VBN\836236 estimated\VBN\637259 ,\,\1740 although\IN\1740 <e1>smoking</e1>\NN\831191 has\VBZ\2108377 been\VBN\836236 positively\RB\1740 associated\VBN\628491 with\IN\1740 <e2>hearing\VBG\2106506 loss</e2>\NN\13252973 in\IN\13603305 adults\NNS\7846 .\.\1740
8387218
D016049_D064420 NONE The\DT\1740 use\NN\407535 and\CC\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 <e1>didanosine</e1>\NN\2725367 (\-LRB-\1740 ddI\NN\2725367 )\-RRB-\1740 in\IN\13603305 HIV\NN\14186340 antibody-positive\JJ\1740 individuals\NNS\7347 intolerant\JJ\1740 to\TO\1740 zidovudine\NN\3834836 (\-LRB-\1740 AZT\NN\3834836 )\-RRB-\1740
D016049_D064420 NONE The\DT\1740 use\NN\407535 and\CC\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 didanosine\NN\2725367 (\-LRB-\1740 <e1>ddI</e1>\NN\2725367 )\-RRB-\1740 in\IN\13603305 HIV\NN\14186340 antibody-positive\JJ\1740 individuals\NNS\7347 intolerant\JJ\1740 to\TO\1740 zidovudine\NN\3834836 (\-LRB-\1740 AZT\NN\3834836 )\-RRB-\1740
D016049_D015658 NONE The\DT\1740 use\NN\407535 and\CC\1740 toxicity\NN\13576101 of\IN\1740 <e1>didanosine</e1>\NN\2725367 (\-LRB-\1740 ddI\NN\2725367 )\-RRB-\1740 in\IN\13603305 <e2>HIV\NN\14186340 antibody-positive</e2>\JJ\1740 individuals\NNS\7347 intolerant\JJ\1740 to\TO\1740 zidovudine\NN\3834836 (\-LRB-\1740 AZT\NN\3834836 )\-RRB-\1740
D016049_D015658 NONE The\DT\1740 use\NN\407535 and\CC\1740 toxicity\NN\13576101 of\IN\1740 didanosine\NN\2725367 (\-LRB-\1740 <e1>ddI</e1>\NN\2725367 )\-RRB-\1740 in\IN\13603305 <e2>HIV\NN\14186340 antibody-positive</e2>\JJ\1740 individuals\NNS\7347 intolerant\JJ\1740 to\TO\1740 zidovudine\NN\3834836 (\-LRB-\1740 AZT\NN\3834836 )\-RRB-\1740
D015215_D064420 NONE The\DT\1740 use\NN\407535 and\CC\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 didanosine\NN\2725367 (\-LRB-\1740 ddI\NN\2725367 )\-RRB-\1740 in\IN\13603305 HIV\NN\14186340 antibody-positive\JJ\1740 individuals\NNS\7347 intolerant\JJ\1740 to\TO\1740 <e1>zidovudine</e1>\NN\3834836 (\-LRB-\1740 AZT\NN\3834836 )\-RRB-\1740
D015215_D064420 NONE The\DT\1740 use\NN\407535 and\CC\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 didanosine\NN\2725367 (\-LRB-\1740 ddI\NN\2725367 )\-RRB-\1740 in\IN\13603305 HIV\NN\14186340 antibody-positive\JJ\1740 individuals\NNS\7347 intolerant\JJ\1740 to\TO\1740 zidovudine\NN\3834836 (\-LRB-\1740 <e1>AZT</e1>\NN\3834836 )\-RRB-\1740
D015215_D015658 NONE The\DT\1740 use\NN\407535 and\CC\1740 toxicity\NN\13576101 of\IN\1740 didanosine\NN\2725367 (\-LRB-\1740 ddI\NN\2725367 )\-RRB-\1740 in\IN\13603305 <e2>HIV\NN\14186340 antibody-positive</e2>\JJ\1740 individuals\NNS\7347 intolerant\JJ\1740 to\TO\1740 <e1>zidovudine</e1>\NN\3834836 (\-LRB-\1740 AZT\NN\3834836 )\-RRB-\1740
D015215_D015658 NONE The\DT\1740 use\NN\407535 and\CC\1740 toxicity\NN\13576101 of\IN\1740 didanosine\NN\2725367 (\-LRB-\1740 ddI\NN\2725367 )\-RRB-\1740 in\IN\13603305 <e2>HIV\NN\14186340 antibody-positive</e2>\JJ\1740 individuals\NNS\7347 intolerant\JJ\1740 to\TO\1740 zidovudine\NN\3834836 (\-LRB-\1740 <e1>AZT</e1>\NN\3834836 )\-RRB-\1740
D016049_D018149 CID Seven\CD\13741022 patients\NNS\9898892 developed\VBD\1753788 <e2>glucose\NN\14710501 tolerance\NN\5032565 curves</e2>\NNS\13863771 characteristic\JJ\1740 of\IN\1740 diabetes\NNS\14075199 but\CC\1740 these\DT\1740 were\VBD\836236 mild\JJ\1740 ,\,\1740 did\VBD\1640855 not\RB\1740 require\VB\754942 treatment\NN\654885 and\CC\1740 returned\VBD\1835496 to\IN\1740 normal\JJ\1740 on\IN\1740 ceasing\VBG\1740 <e1>didanosine</e1>\NN\2725367 .\.\1740
D016049_D003920 NONE Seven\CD\13741022 patients\NNS\9898892 developed\VBD\1753788 glucose\NN\14710501 tolerance\NN\5032565 curves\NNS\13863771 characteristic\JJ\1740 of\IN\1740 <e2>diabetes</e2>\NNS\14075199 but\CC\1740 these\DT\1740 were\VBD\836236 mild\JJ\1740 ,\,\1740 did\VBD\1640855 not\RB\1740 require\VB\754942 treatment\NN\654885 and\CC\1740 returned\VBD\1835496 to\IN\1740 normal\JJ\1740 on\IN\1740 ceasing\VBG\1740 <e1>didanosine</e1>\NN\2725367 .\.\1740
1639466
D002118_D009400 NONE Adverse\JJ\1740 effect\NN\34213 of\IN\1740 the\DT\1740 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 blocker\NN\10101634 nitrendipine\NN\1740 on\IN\1740 <e2>nephrosclerosis</e2>\NN\14113228 in\IN\13603305 rats\NNS\2329401 with\IN\1740 renovascular\JJ\1740 hypertension\NN\14057371 .\.\1740
D002118_D006978 NONE Adverse\JJ\1740 effect\NN\34213 of\IN\1740 the\DT\1740 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 blocker\NN\10101634 nitrendipine\NN\1740 on\IN\1740 nephrosclerosis\NN\14113228 in\IN\13603305 rats\NNS\2329401 with\IN\1740 <e2>renovascular\JJ\1740 hypertension</e2>\NN\14057371 .\.\1740
D002118_D006978 NONE The\DT\1740 effect\NN\34213 of\IN\1740 a\DT\13649268 6-week\JJ\1740 treatment\NN\654885 with\IN\1740 the\DT\1740 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 blocker\NN\10101634 nitrendipine\NN\1740 or\CC\3541091 the\DT\1740 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 enalapril\NN\2673637 on\IN\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 albuminuria\NN\14299637 ,\,\1740 renal\JJ\1740 hemodynamics\NNS\6080522 ,\,\1740 and\CC\1740 morphology\NN\6037666 of\IN\1740 the\DT\1740 nonclipped\JJ\1740 kidney\NN\5333259 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 with\IN\1740 two-kidney\NN\1740 ,\,\1740 one\CD\13741022 clip\NN\4359335 <e2>renovascular\JJ\1740 hypertension</e2>\NN\14057371 .\.\1740
D009568_D009400 CID Adverse\JJ\1740 effect\NN\34213 of\IN\1740 the\DT\1740 calcium\NN\14625458 channel\NN\6251781 blocker\NN\10101634 <e1>nitrendipine</e1>\NN\1740 on\IN\1740 <e2>nephrosclerosis</e2>\NN\14113228 in\IN\13603305 rats\NNS\2329401 with\IN\1740 renovascular\JJ\1740 hypertension\NN\14057371 .\.\1740
D009568_D006978 NONE Adverse\JJ\1740 effect\NN\34213 of\IN\1740 the\DT\1740 calcium\NN\14625458 channel\NN\6251781 blocker\NN\10101634 <e1>nitrendipine</e1>\NN\1740 on\IN\1740 nephrosclerosis\NN\14113228 in\IN\13603305 rats\NNS\2329401 with\IN\1740 <e2>renovascular\JJ\1740 hypertension</e2>\NN\14057371 .\.\1740
D009568_D006978 NONE The\DT\1740 effect\NN\34213 of\IN\1740 a\DT\13649268 6-week\JJ\1740 treatment\NN\654885 with\IN\1740 the\DT\1740 calcium\NN\14625458 channel\NN\6251781 blocker\NN\10101634 <e1>nitrendipine</e1>\NN\1740 or\CC\3541091 the\DT\1740 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 enalapril\NN\2673637 on\IN\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 albuminuria\NN\14299637 ,\,\1740 renal\JJ\1740 hemodynamics\NNS\6080522 ,\,\1740 and\CC\1740 morphology\NN\6037666 of\IN\1740 the\DT\1740 nonclipped\JJ\1740 kidney\NN\5333259 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 with\IN\1740 two-kidney\NN\1740 ,\,\1740 one\CD\13741022 clip\NN\4359335 <e2>renovascular\JJ\1740 hypertension</e2>\NN\14057371 .\.\1740
D002118_D000419 NONE The\DT\1740 effect\NN\34213 of\IN\1740 a\DT\13649268 6-week\JJ\1740 treatment\NN\654885 with\IN\1740 the\DT\1740 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 blocker\NN\10101634 nitrendipine\NN\1740 or\CC\3541091 the\DT\1740 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 enalapril\NN\2673637 on\IN\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 <e2>albuminuria</e2>\NN\14299637 ,\,\1740 renal\JJ\1740 hemodynamics\NNS\6080522 ,\,\1740 and\CC\1740 morphology\NN\6037666 of\IN\1740 the\DT\1740 nonclipped\JJ\1740 kidney\NN\5333259 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 with\IN\1740 two-kidney\NN\1740 ,\,\1740 one\CD\13741022 clip\NN\4359335 renovascular\JJ\1740 hypertension\NN\14057371 .\.\1740
D009568_D000419 CID The\DT\1740 effect\NN\34213 of\IN\1740 a\DT\13649268 6-week\JJ\1740 treatment\NN\654885 with\IN\1740 the\DT\1740 calcium\NN\14625458 channel\NN\6251781 blocker\NN\10101634 <e1>nitrendipine</e1>\NN\1740 or\CC\3541091 the\DT\1740 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 enalapril\NN\2673637 on\IN\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 <e2>albuminuria</e2>\NN\14299637 ,\,\1740 renal\JJ\1740 hemodynamics\NNS\6080522 ,\,\1740 and\CC\1740 morphology\NN\6037666 of\IN\1740 the\DT\1740 nonclipped\JJ\1740 kidney\NN\5333259 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 with\IN\1740 two-kidney\NN\1740 ,\,\1740 one\CD\13741022 clip\NN\4359335 renovascular\JJ\1740 hypertension\NN\14057371 .\.\1740
D009568_D000419 CID In\IN\13603305 contrast\NN\13854649 ,\,\1740 in\IN\13603305 the\DT\1740 <e1>nitrendipine-treated</e1>\JJ\1740 group\NN\2137 <e2>albuminuria</e2>\NN\14299637 increased\VBD\169651 from\IN\1740 12.8\CD\1740 +/-\CC\1740 2\CD\13741022 progressively\RB\1740 to\TO\1740 163\CD\1740 +/-\CC\1740 55\CD\1740 compared\VBN\644583 with\IN\1740 19.2\CD\1740 +/-\CC\1740 9\CD\13741022 mg/24\NNS\1740 hr\NN\15154774 in\IN\13603305 the\DT\1740 hypertensive\JJ\1740 controls\NNS\5190804 .\.\1740
D000809_D000419 NONE The\DT\1740 effect\NN\34213 of\IN\1740 a\DT\13649268 6-week\JJ\1740 treatment\NN\654885 with\IN\1740 the\DT\1740 calcium\NN\14625458 channel\NN\6251781 blocker\NN\10101634 nitrendipine\NN\1740 or\CC\3541091 the\DT\1740 <e1>angiotensin</e1>\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 enalapril\NN\2673637 on\IN\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 <e2>albuminuria</e2>\NN\14299637 ,\,\1740 renal\JJ\1740 hemodynamics\NNS\6080522 ,\,\1740 and\CC\1740 morphology\NN\6037666 of\IN\1740 the\DT\1740 nonclipped\JJ\1740 kidney\NN\5333259 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 with\IN\1740 two-kidney\NN\1740 ,\,\1740 one\CD\13741022 clip\NN\4359335 renovascular\JJ\1740 hypertension\NN\14057371 .\.\1740
D000809_D006978 NONE The\DT\1740 effect\NN\34213 of\IN\1740 a\DT\13649268 6-week\JJ\1740 treatment\NN\654885 with\IN\1740 the\DT\1740 calcium\NN\14625458 channel\NN\6251781 blocker\NN\10101634 nitrendipine\NN\1740 or\CC\3541091 the\DT\1740 <e1>angiotensin</e1>\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 enalapril\NN\2673637 on\IN\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 albuminuria\NN\14299637 ,\,\1740 renal\JJ\1740 hemodynamics\NNS\6080522 ,\,\1740 and\CC\1740 morphology\NN\6037666 of\IN\1740 the\DT\1740 nonclipped\JJ\1740 kidney\NN\5333259 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 with\IN\1740 two-kidney\NN\1740 ,\,\1740 one\CD\13741022 clip\NN\4359335 <e2>renovascular\JJ\1740 hypertension</e2>\NN\14057371 .\.\1740
D004656_D000419 NONE The\DT\1740 effect\NN\34213 of\IN\1740 a\DT\13649268 6-week\JJ\1740 treatment\NN\654885 with\IN\1740 the\DT\1740 calcium\NN\14625458 channel\NN\6251781 blocker\NN\10101634 nitrendipine\NN\1740 or\CC\3541091 the\DT\1740 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 <e1>enalapril</e1>\NN\2673637 on\IN\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 <e2>albuminuria</e2>\NN\14299637 ,\,\1740 renal\JJ\1740 hemodynamics\NNS\6080522 ,\,\1740 and\CC\1740 morphology\NN\6037666 of\IN\1740 the\DT\1740 nonclipped\JJ\1740 kidney\NN\5333259 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 with\IN\1740 two-kidney\NN\1740 ,\,\1740 one\CD\13741022 clip\NN\4359335 renovascular\JJ\1740 hypertension\NN\14057371 .\.\1740
D004656_D006978 NONE The\DT\1740 effect\NN\34213 of\IN\1740 a\DT\13649268 6-week\JJ\1740 treatment\NN\654885 with\IN\1740 the\DT\1740 calcium\NN\14625458 channel\NN\6251781 blocker\NN\10101634 nitrendipine\NN\1740 or\CC\3541091 the\DT\1740 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 <e1>enalapril</e1>\NN\2673637 on\IN\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 albuminuria\NN\14299637 ,\,\1740 renal\JJ\1740 hemodynamics\NNS\6080522 ,\,\1740 and\CC\1740 morphology\NN\6037666 of\IN\1740 the\DT\1740 nonclipped\JJ\1740 kidney\NN\5333259 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 with\IN\1740 two-kidney\NN\1740 ,\,\1740 one\CD\13741022 clip\NN\4359335 <e2>renovascular\JJ\1740 hypertension</e2>\NN\14057371 .\.\1740
D004656_D006973 NONE Six\CD\13741022 weeks\NNS\15113229 after\IN\1740 clipping\VBG\1552519 of\IN\1740 one\CD\13741022 renal\JJ\1740 artery\NN\5417975 ,\,\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 178\CD\1740 +/-\CC\1740 4\CD\13741022 mm\NN\13649268 Hg\NN\14625458 )\-RRB-\1740 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 three\CD\13741022 groups\NNS\2137 :\:\1740 untreated\JJ\1740 hypertensive\JJ\1740 controls\NNS\5190804 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 8)\CD\1740 ,\,\1740 <e1>enalapril-treated</e1>\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 8)\CD\1740 ,\,\1740 or\CC\3541091 nitrendipine-treated\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 10\CD\13745420 )\-RRB-\1740 .\.\1740
D004656_D006973 NONE Six\CD\13741022 weeks\NNS\15113229 after\IN\1740 clipping\VBG\1552519 of\IN\1740 one\CD\13741022 renal\JJ\1740 artery\NN\5417975 ,\,\1740 hypertensive\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 178\CD\1740 +/-\CC\1740 4\CD\13741022 mm\NN\13649268 Hg\NN\14625458 )\-RRB-\1740 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 three\CD\13741022 groups\NNS\2137 :\:\1740 untreated\JJ\1740 <e2>hypertensive</e2>\JJ\1740 controls\NNS\5190804 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 8)\CD\1740 ,\,\1740 <e1>enalapril-treated</e1>\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 8)\CD\1740 ,\,\1740 or\CC\3541091 nitrendipine-treated\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 10\CD\13745420 )\-RRB-\1740 .\.\1740
D004656_D006973 NONE In\IN\13603305 addition\NN\3081021 ,\,\1740 glomerular\JJ\1740 size\NN\5090441 was\VBD\836236 higher\JJR\1740 in\IN\13603305 the\DT\1740 nitrendipine-treated\JJ\1740 group\NN\2137 (\-LRB-\1740 14.9\CD\1740 +/-\CC\1740 0.17\CD\1740 10(-3\NN\1740 )\-RRB-\1740 mm2\CD\1740 )\-RRB-\1740 but\CC\1740 lower\JJR\1740 in\IN\13603305 the\DT\1740 <e1>enalapril-treated</e1>\JJ\1740 group\NN\2137 (\-LRB-\1740 11.5\CD\1740 +/-\CC\1740 0.15\CD\1740 10(-3\NN\1740 )\-RRB-\1740 mm2\CD\1740 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 the\DT\1740 <e2>hypertensive</e2>\JJ\1740 controls\NNS\5190804 (\-LRB-\1740 12.1\CD\1740 +/-\CC\1740 0.17\CD\1740 10(-3\NN\1740 )\-RRB-\1740 mm2\CD\1740 )\-RRB-\1740 .\.\1740
D009568_D006973 NONE Six\CD\13741022 weeks\NNS\15113229 after\IN\1740 clipping\VBG\1552519 of\IN\1740 one\CD\13741022 renal\JJ\1740 artery\NN\5417975 ,\,\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 178\CD\1740 +/-\CC\1740 4\CD\13741022 mm\NN\13649268 Hg\NN\14625458 )\-RRB-\1740 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 three\CD\13741022 groups\NNS\2137 :\:\1740 untreated\JJ\1740 hypertensive\JJ\1740 controls\NNS\5190804 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 8)\CD\1740 ,\,\1740 enalapril-treated\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 8)\CD\1740 ,\,\1740 or\CC\3541091 <e1>nitrendipine-treated</e1>\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 10\CD\13745420 )\-RRB-\1740 .\.\1740
D009568_D006973 NONE Six\CD\13741022 weeks\NNS\15113229 after\IN\1740 clipping\VBG\1552519 of\IN\1740 one\CD\13741022 renal\JJ\1740 artery\NN\5417975 ,\,\1740 hypertensive\JJ\1740 rats\NNS\2329401 (\-LRB-\1740 178\CD\1740 +/-\CC\1740 4\CD\13741022 mm\NN\13649268 Hg\NN\14625458 )\-RRB-\1740 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 three\CD\13741022 groups\NNS\2137 :\:\1740 untreated\JJ\1740 <e2>hypertensive</e2>\JJ\1740 controls\NNS\5190804 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 8)\CD\1740 ,\,\1740 enalapril-treated\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 8)\CD\1740 ,\,\1740 or\CC\3541091 <e1>nitrendipine-treated</e1>\JJ\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 10\CD\13745420 )\-RRB-\1740 .\.\1740
D009568_D006973 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 in\IN\13603305 the\DT\1740 <e1>nitrendipine-treated</e1>\JJ\1740 group\NN\2137 albuminuria\NN\14299637 increased\VBD\169651 from\IN\1740 12.8\CD\1740 +/-\CC\1740 2\CD\13741022 progressively\RB\1740 to\TO\1740 163\CD\1740 +/-\CC\1740 55\CD\1740 compared\VBN\644583 with\IN\1740 19.2\CD\1740 +/-\CC\1740 9\CD\13741022 mg/24\NNS\1740 hr\NN\15154774 in\IN\13603305 the\DT\1740 <e2>hypertensive</e2>\JJ\1740 controls\NNS\5190804 .\.\1740
D009568_D006973 NONE Furthermore\RB\1740 ,\,\1740 glomerulosclerosis\NN\1740 index\NN\13850304 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 in\IN\13603305 the\DT\1740 <e1>nitrendipine-treated</e1>\JJ\1740 group\NN\2137 compared\VBN\644583 with\IN\1740 the\DT\1740 <e2>hypertensive</e2>\JJ\1740 controls\NNS\5190804 (\-LRB-\1740 0.38\CD\1740 +/-\CC\1740 0.1\CD\1740 versus\CC\1740 0.13\CD\1740 +/-\CC\1740 0.04\CD\1740 )\-RRB-\1740 .\.\1740
D009568_D006973 NONE In\IN\13603305 addition\NN\3081021 ,\,\1740 glomerular\JJ\1740 size\NN\5090441 was\VBD\836236 higher\JJR\1740 in\IN\13603305 the\DT\1740 <e1>nitrendipine-treated</e1>\JJ\1740 group\NN\2137 (\-LRB-\1740 14.9\CD\1740 +/-\CC\1740 0.17\CD\1740 10(-3\NN\1740 )\-RRB-\1740 mm2\CD\1740 )\-RRB-\1740 but\CC\1740 lower\JJR\1740 in\IN\13603305 the\DT\1740 enalapril-treated\JJ\1740 group\NN\2137 (\-LRB-\1740 11.5\CD\1740 +/-\CC\1740 0.15\CD\1740 10(-3\NN\1740 )\-RRB-\1740 mm2\CD\1740 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 the\DT\1740 <e2>hypertensive</e2>\JJ\1740 controls\NNS\5190804 (\-LRB-\1740 12.1\CD\1740 +/-\CC\1740 0.17\CD\1740 10(-3\NN\1740 )\-RRB-\1740 mm2\CD\1740 )\-RRB-\1740 .\.\1740
D004656_D005921 NONE Renal\JJ\1740 plasma\NN\5398023 flow\NN\7311115 increased\VBD\169651 ,\,\1740 but\CC\1740 albumin\NN\14736972 excretion\NN\13466586 and\CC\1740 <e2>glomerulosclerosis</e2>\NN\1740 did\VBD\1640855 not\RB\1740 change\VB\46534 after\IN\1740 <e1>enalapril</e1>\JJ\1740 treatment\NN\654885 .\.\1740
D009568_D005921 NONE Furthermore\RB\1740 ,\,\1740 <e2>glomerulosclerosis</e2>\NN\1740 index\NN\13850304 was\VBD\836236 significantly\RB\1740 increased\VBN\169651 in\IN\13603305 the\DT\1740 <e1>nitrendipine-treated</e1>\JJ\1740 group\NN\2137 compared\VBN\644583 with\IN\1740 the\DT\1740 hypertensive\JJ\1740 controls\NNS\5190804 (\-LRB-\1740 0.38\CD\1740 +/-\CC\1740 0.1\CD\1740 versus\CC\1740 0.13\CD\1740 +/-\CC\1740 0.04\CD\1740 )\-RRB-\1740 .\.\1740
16858720
D014859_D002543 CID <e2>Cerebral\JJ\1740 haemorrhage</e2>\NN\14285662 induced\VBN\1627355 by\IN\1740 <e1>warfarin</e1>\NN\2718259 -\:\1740 the\DT\1740 influence\NN\5190804 of\IN\1740 drug-drug\JJ\1740 interactions\NNS\37396 .\.\1740
D014859_D002543 CID PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 frequency\NN\15286249 ,\,\1740 severity\NN\5036394 and\CC\1740 preventability\NN\1740 of\IN\1740 <e1>warfarin-induced</e1>\JJ\1740 <e2>cerebral\JJ\1740 haemorrhages</e2>\NNS\14285662 due\JJ\1740 to\TO\1740 warfarin\NN\2718259 and\CC\1740 warfarin-drug\JJ\1740 interactions\NNS\37396 in\IN\13603305 patients\NNS\9898892 living\VBG\2655135 in\IN\13603305 the\DT\1740 county\NN\8630039 of\IN\1740 Osterg\NNP\1740 tland\NN\1740 ,\,\1740 Sweden\NNP\1740 .\.\1740
D014859_D002543 CID PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 frequency\NN\15286249 ,\,\1740 severity\NN\5036394 and\CC\1740 preventability\NN\1740 of\IN\1740 warfarin-induced\JJ\1740 <e2>cerebral\JJ\1740 haemorrhages</e2>\NNS\14285662 due\JJ\1740 to\TO\1740 <e1>warfarin</e1>\NN\2718259 and\CC\1740 warfarin-drug\JJ\1740 interactions\NNS\37396 in\IN\13603305 patients\NNS\9898892 living\VBG\2655135 in\IN\13603305 the\DT\1740 county\NN\8630039 of\IN\1740 Osterg\NNP\1740 tland\NN\1740 ,\,\1740 Sweden\NNP\1740 .\.\1740
D014859_D002543 CID PURPOSE\NNP\5980875 :\:\1740 To\TO\1740 evaluate\VB\670261 the\DT\1740 frequency\NN\15286249 ,\,\1740 severity\NN\5036394 and\CC\1740 preventability\NN\1740 of\IN\1740 warfarin-induced\JJ\1740 <e2>cerebral\JJ\1740 haemorrhages</e2>\NNS\14285662 due\JJ\1740 to\TO\1740 warfarin\NN\2718259 and\CC\1740 <e1>warfarin-drug</e1>\JJ\1740 interactions\NNS\37396 in\IN\13603305 patients\NNS\9898892 living\VBG\2655135 in\IN\13603305 the\DT\1740 county\NN\8630039 of\IN\1740 Osterg\NNP\1740 tland\NN\1740 ,\,\1740 Sweden\NNP\1740 .\.\1740
D014859_D002543 CID Medical\JJ\1740 records\NNS\6643408 were\VBD\836236 studied\VBN\630380 retrospectively\RB\1740 to\TO\1740 evaluate\VB\670261 whether\IN\1740 <e1>warfarin</e1>\NN\2718259 and\CC\1740 warfarin-drug\JJ\1740 interactions\NNS\37396 could\MD\1740 have\VB\2108377 caused\VBN\1617192 the\DT\1740 <e2>cerebral\JJ\1740 haemorrhage</e2>\NN\14285662 .\.\1740
D014859_D002543 CID Medical\JJ\1740 records\NNS\6643408 were\VBD\836236 studied\VBN\630380 retrospectively\RB\1740 to\TO\1740 evaluate\VB\670261 whether\IN\1740 warfarin\NN\2718259 and\CC\1740 <e1>warfarin-drug</e1>\JJ\1740 interactions\NNS\37396 could\MD\1740 have\VB\2108377 caused\VBN\1617192 the\DT\1740 <e2>cerebral\JJ\1740 haemorrhage</e2>\NN\14285662 .\.\1740
D014859_D002543 CID RESULTS\NNS\34213 :\:\1740 Among\IN\1740 593\CD\1740 patients\NNS\9898892 with\IN\1740 <e2>cerebral\JJ\1740 haemorrhage</e2>\NN\14285662 ,\,\1740 59\CD\1740 (\-LRB-\1740 10\CD\13745420 %\NN\1740 )\-RRB-\1740 were\VBD\836236 assessed\VBN\670261 as\IN\14622893 related\JJ\1740 to\TO\1740 <e1>warfarin</e1>\NN\2718259 treatment\NN\654885 .\.\1740
D014859_D002543 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Warfarin-induced</e1>\JJ\1740 <e2>cerebral\JJ\1740 haemorrhages</e2>\NNS\14285662 are\VBP\836236 a\DT\13649268 major\JJ\1740 clinical\JJ\1740 problem\NN\14408086 with\IN\1740 a\DT\13649268 high\JJ\1740 fatality\NN\7355491 rate\NN\13815152 .\.\1740
D014859_D002543 CID A\DT\13649268 significant\JJ\1740 proportion\NN\13824815 of\IN\1740 <e1>warfarin-related</e1>\JJ\1740 <e2>cerebral\JJ\1740 haemorrhages</e2>\NNS\14285662 might\MD\5029706 have\VB\2108377 been\VBN\836236 prevented\VBN\1740 if\IN\1740 greater\JJR\1740 caution\NN\4662951 had\VBD\2108377 been\VBN\836236 taken\VBN\2367363 when\WRB\1740 prescribing\VBG\748282 drugs\NNS\14778436 known\VBN\2110220 to\TO\1740 interact\VB\2367363 with\IN\1740 warfarin\NN\2718259 .\.\1740
D014859_D002543 CID A\DT\13649268 significant\JJ\1740 proportion\NN\13824815 of\IN\1740 warfarin-related\JJ\1740 <e2>cerebral\JJ\1740 haemorrhages</e2>\NNS\14285662 might\MD\5029706 have\VB\2108377 been\VBN\836236 prevented\VBN\1740 if\IN\1740 greater\JJR\1740 caution\NN\4662951 had\VBD\2108377 been\VBN\836236 taken\VBN\2367363 when\WRB\1740 prescribing\VBG\748282 drugs\NNS\14778436 known\VBN\2110220 to\TO\1740 interact\VB\2367363 with\IN\1740 <e1>warfarin</e1>\NN\2718259 .\.\1740
D014859_D006470 NONE A\DT\13649268 <e1>warfarin-drug</e1>\JJ\1740 interaction\NN\37396 could\MD\1740 have\VB\2108377 contributed\VBN\126264 to\IN\1740 the\DT\1740 <e2>haemorrhage</e2>\NN\14285662 in\IN\13603305 24\CD\13745420 (\-LRB-\1740 41\CD\1740 %\NN\1740 )\-RRB-\1740 of\IN\1740 the\DT\1740 warfarin\NN\2718259 patients\NNS\9898892 and\CC\1740 in\IN\13603305 7\CD\13741022 of\IN\1740 these\DT\1740 (\-LRB-\1740 12\CD\13745420 %\NN\1740 )\-RRB-\1740 the\DT\1740 bleeding\VBG\104868 complication\NN\1073995 was\VBD\836236 considered\VBN\689344 being\VBG\836236 possible\JJ\1740 to\TO\1740 avoid\VB\2452885 .\.\1740
D014859_D006470 NONE A\DT\13649268 <e1>warfarin-drug</e1>\JJ\1740 interaction\NN\37396 could\MD\1740 have\VB\2108377 contributed\VBN\126264 to\IN\1740 the\DT\1740 haemorrhage\NN\14285662 in\IN\13603305 24\CD\13745420 (\-LRB-\1740 41\CD\1740 %\NN\1740 )\-RRB-\1740 of\IN\1740 the\DT\1740 warfarin\NN\2718259 patients\NNS\9898892 and\CC\1740 in\IN\13603305 7\CD\13741022 of\IN\1740 these\DT\1740 (\-LRB-\1740 12\CD\13745420 %\NN\1740 )\-RRB-\1740 the\DT\1740 <e2>bleeding</e2>\VBG\104868 complication\NN\1073995 was\VBD\836236 considered\VBN\689344 being\VBG\836236 possible\JJ\1740 to\TO\1740 avoid\VB\2452885 .\.\1740
D014859_D006470 NONE A\DT\13649268 warfarin-drug\JJ\1740 interaction\NN\37396 could\MD\1740 have\VB\2108377 contributed\VBN\126264 to\IN\1740 the\DT\1740 <e2>haemorrhage</e2>\NN\14285662 in\IN\13603305 24\CD\13745420 (\-LRB-\1740 41\CD\1740 %\NN\1740 )\-RRB-\1740 of\IN\1740 the\DT\1740 <e1>warfarin</e1>\NN\2718259 patients\NNS\9898892 and\CC\1740 in\IN\13603305 7\CD\13741022 of\IN\1740 these\DT\1740 (\-LRB-\1740 12\CD\13745420 %\NN\1740 )\-RRB-\1740 the\DT\1740 bleeding\VBG\104868 complication\NN\1073995 was\VBD\836236 considered\VBN\689344 being\VBG\836236 possible\JJ\1740 to\TO\1740 avoid\VB\2452885 .\.\1740
D014859_D006470 NONE A\DT\13649268 warfarin-drug\JJ\1740 interaction\NN\37396 could\MD\1740 have\VB\2108377 contributed\VBN\126264 to\IN\1740 the\DT\1740 haemorrhage\NN\14285662 in\IN\13603305 24\CD\13745420 (\-LRB-\1740 41\CD\1740 %\NN\1740 )\-RRB-\1740 of\IN\1740 the\DT\1740 <e1>warfarin</e1>\NN\2718259 patients\NNS\9898892 and\CC\1740 in\IN\13603305 7\CD\13741022 of\IN\1740 these\DT\1740 (\-LRB-\1740 12\CD\13745420 %\NN\1740 )\-RRB-\1740 the\DT\1740 <e2>bleeding</e2>\VBG\104868 complication\NN\1073995 was\VBD\836236 considered\VBN\689344 being\VBG\836236 possible\JJ\1740 to\TO\1740 avoid\VB\2452885 .\.\1740
3173179
D014700_D009203 CID <e1>Verapamil</e1>\NN\2938514 withdrawal\NN\7206096 as\IN\14622893 a\DT\13649268 possible\JJ\1740 cause\NN\7323922 of\IN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 a\DT\13649268 hypertensive\JJ\1740 woman\NN\9605289 with\IN\1740 a\DT\13649268 normal\JJ\1740 coronary\JJ\1740 angiogram\NN\4100620 .\.\1740
D014700_D009203 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 in\IN\13603305 which\WDT\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 coincided\VBD\2604477 with\IN\1740 the\DT\1740 introduction\NN\235435 of\IN\1740 captopril\NN\2673637 and\CC\1740 the\DT\1740 withdrawal\NN\7206096 of\IN\1740 <e1>verapamil</e1>\NN\2938514 in\IN\13603305 a\DT\13649268 previously\RB\1740 asymptomatic\JJ\1740 woman\NN\9605289 with\IN\1740 severe\JJ\1740 hypertension\NN\14057371 .\.\1740
D014700_D006973 NONE <e1>Verapamil</e1>\NN\2938514 withdrawal\NN\7206096 as\IN\14622893 a\DT\13649268 possible\JJ\1740 cause\NN\7323922 of\IN\1740 myocardial\JJ\1740 infarction\NN\14204950 in\IN\13603305 a\DT\13649268 <e2>hypertensive</e2>\JJ\1740 woman\NN\9605289 with\IN\1740 a\DT\13649268 normal\JJ\1740 coronary\JJ\1740 angiogram\NN\4100620 .\.\1740
D014700_D006973 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 in\IN\13603305 which\WDT\1740 myocardial\JJ\1740 infarction\NN\14204950 coincided\VBD\2604477 with\IN\1740 the\DT\1740 introduction\NN\235435 of\IN\1740 captopril\NN\2673637 and\CC\1740 the\DT\1740 withdrawal\NN\7206096 of\IN\1740 <e1>verapamil</e1>\NN\2938514 in\IN\13603305 a\DT\13649268 previously\RB\1740 asymptomatic\JJ\1740 woman\NN\9605289 with\IN\1740 severe\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D002216_D009203 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 in\IN\13603305 which\WDT\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 coincided\VBD\2604477 with\IN\1740 the\DT\1740 introduction\NN\235435 of\IN\1740 <e1>captopril</e1>\NN\2673637 and\CC\1740 the\DT\1740 withdrawal\NN\7206096 of\IN\1740 verapamil\NN\2938514 in\IN\13603305 a\DT\13649268 previously\RB\1740 asymptomatic\JJ\1740 woman\NN\9605289 with\IN\1740 severe\JJ\1740 hypertension\NN\14057371 .\.\1740
D002216_D006973 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 in\IN\13603305 which\WDT\1740 myocardial\JJ\1740 infarction\NN\14204950 coincided\VBD\2604477 with\IN\1740 the\DT\1740 introduction\NN\235435 of\IN\1740 <e1>captopril</e1>\NN\2673637 and\CC\1740 the\DT\1740 withdrawal\NN\7206096 of\IN\1740 verapamil\NN\2938514 in\IN\13603305 a\DT\13649268 previously\RB\1740 asymptomatic\JJ\1740 woman\NN\9605289 with\IN\1740 severe\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
12202650
D002211_D063806 NONE <e1>Capsaicin-induced</e1>\JJ\1740 <e2>muscle\NN\5289601 pain</e2>\NN\14299637 alters\VBZ\126264 the\DT\1740 excitability\NN\5653575 of\IN\1740 the\DT\1740 human\JJ\1740 jaw-stretch\JJ\1740 reflex\NN\859001 .\.\1740
D002211_D010146 CID <e1>Capsaicin</e1>\NN\15032661 (\-LRB-\1740 10\CD\13745420 micro\JJ\1740 g\NN\13717155 )\-RRB-\1740 was\VBD\836236 injected\VBN\81072 into\IN\1740 the\DT\1740 masseter\NN\5602132 muscle\NN\5289601 to\TO\1740 induce\VB\1627355 <e2>pain</e2>\NN\14299637 in\IN\13603305 11\CD\13745420 healthy\JJ\1740 volunteers\NNS\10582746 .\.\1740
1833784
D004298_D006948 NONE Evidence\NN\5816287 for\IN\1740 an\DT\6697703 involvement\NN\1080366 of\IN\1740 D1\NN\1740 and\CC\1740 D2\NN\1740 <e1>dopamine</e1>\NN\14807737 receptors\NNS\5225602 in\IN\13603305 mediating\VBG\761713 nicotine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 in\IN\13603305 rats\NNS\2329401 .\.\1740
D009538_D006948 CID Evidence\NN\5816287 for\IN\1740 an\DT\6697703 involvement\NN\1080366 of\IN\1740 D1\NN\1740 and\CC\1740 D2\NN\1740 dopamine\NN\14807737 receptors\NNS\5225602 in\IN\13603305 mediating\VBG\761713 <e1>nicotine-induced</e1>\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 in\IN\13603305 rats\NNS\2329401 .\.\1740
D009538_D006948 CID <e1>Nicotine</e1>\NN\14712692 (\-LRB-\1740 1.0\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 caused\VBD\1617192 a\DT\13649268 significant\JJ\1740 <e2>increase\NN\13576355 in\IN\13603305 locomotor\NN\1740 activity</e2>\NN\30358 in\IN\13603305 rats\NNS\2329401 that\WDT\1740 were\VBD\836236 habituated\VBN\1156834 to\IN\1740 the\DT\1740 test\NN\5798043 environment\NN\13927383 ,\,\1740 but\CC\1740 had\VBD\2108377 only\RB\1740 a\DT\13649268 weak\JJ\1740 and\CC\1740 delayed\VBN\439958 stimulant\JJ\1740 action\NN\30358 in\IN\13603305 rats\NNS\2329401 that\WDT\1740 were\VBD\836236 unfamiliar\JJ\1740 with\IN\1740 the\DT\1740 test\NN\5798043 environment\NN\13927383 .\.\1740
D009538_D006948 CID <e1>Nicotine-induced</e1>\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 the\DT\1740 selective\JJ\1740 D1\NN\1740 antagonist\NN\7846 SCH\NN\1740 23390\CD\1740 ,\,\1740 the\DT\1740 selective\JJ\1740 D2\NN\1740 antagonist\NN\7846 raclopride\NN\1740 and\CC\1740 the\DT\1740 D1/D2\NN\1740 antagonist\NN\7846 fluphenazine\NN\3713736 .\.\1740
D009538_D006948 CID Pretreatment\NN\1740 with\IN\1740 the\DT\1740 D2\NN\1740 agonist\NN\9613191 PHNO\NN\1740 enhanced\VBD\227165 <e1>nicotine-induced</e1>\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 ,\,\1740 whereas\IN\1740 the\DT\1740 D1\NN\1740 agonist\NN\9613191 SKF\NN\1740 38393\CD\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 .\.\1740
D009538_D006948 CID The\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 acute\JJ\1740 <e1>nicotine</e1>\NN\14712692 injection\NN\320852 induces\VBZ\1627355 a\DT\13649268 pronounced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 in\IN\13603305 rats\NNS\2329401 habituated\VBN\1156834 to\IN\1740 the\DT\1740 test\NN\5798043 environment\NN\13927383 .\.\1740
C534628_D006948 NONE Nicotine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 the\DT\1740 selective\JJ\1740 D1\NN\1740 antagonist\NN\7846 <e1>SCH\NN\1740 23390</e1>\CD\1740 ,\,\1740 the\DT\1740 selective\JJ\1740 D2\NN\1740 antagonist\NN\7846 raclopride\NN\1740 and\CC\1740 the\DT\1740 D1/D2\NN\1740 antagonist\NN\7846 fluphenazine\NN\3713736 .\.\1740
D020891_D006948 NONE Nicotine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 the\DT\1740 selective\JJ\1740 D1\NN\1740 antagonist\NN\7846 SCH\NN\1740 23390\CD\1740 ,\,\1740 the\DT\1740 selective\JJ\1740 D2\NN\1740 antagonist\NN\7846 <e1>raclopride</e1>\NN\1740 and\CC\1740 the\DT\1740 D1/D2\NN\1740 antagonist\NN\7846 fluphenazine\NN\3713736 .\.\1740
D005476_D006948 NONE Nicotine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 was\VBD\836236 blocked\VBN\1476483 by\IN\1740 the\DT\1740 selective\JJ\1740 D1\NN\1740 antagonist\NN\7846 SCH\NN\1740 23390\CD\1740 ,\,\1740 the\DT\1740 selective\JJ\1740 D2\NN\1740 antagonist\NN\7846 raclopride\NN\1740 and\CC\1740 the\DT\1740 D1/D2\NN\1740 antagonist\NN\7846 <e1>fluphenazine</e1>\NN\3713736 .\.\1740
-1_D006948 NONE Pretreatment\NN\1740 with\IN\1740 the\DT\1740 D2\NN\1740 agonist\NN\9613191 <e1>PHNO</e1>\NN\1740 enhanced\VBD\227165 nicotine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 ,\,\1740 whereas\IN\1740 the\DT\1740 D1\NN\1740 agonist\NN\9613191 SKF\NN\1740 38393\CD\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 .\.\1740
D015647_D006948 NONE Pretreatment\NN\1740 with\IN\1740 the\DT\1740 D2\NN\1740 agonist\NN\9613191 PHNO\NN\1740 enhanced\VBD\227165 nicotine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 ,\,\1740 whereas\IN\1740 the\DT\1740 D1\NN\1740 agonist\NN\9613191 <e1>SKF\NN\1740 38393</e1>\CD\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 .\.\1740
3371379
D014700_D020258 CID <e1>Verapamil-induced</e1>\JJ\1740 carbamazepine\NN\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D014700_D020258 CID Two\CD\13741022 patients\NNS\9898892 with\IN\1740 signs\NNS\6643763 of\IN\1740 carbamazepine\NN\1740 <e2>neurotoxicity</e2>\NN\1740 after\IN\1740 combined\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>verapamil</e1>\NNS\2938514 showed\VBD\2137132 complete\JJ\1740 recovery\NN\7357388 after\IN\1740 discontinuation\NN\209943 of\IN\1740 the\DT\1740 calcium\NN\14625458 entry\NN\6502378 blocker\NN\10101634 .\.\1740
D002220_D020258 CID Verapamil-induced\JJ\1740 <e1>carbamazepine</e1>\NN\1740 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D002220_D020258 CID Two\CD\13741022 patients\NNS\9898892 with\IN\1740 signs\NNS\6643763 of\IN\1740 <e1>carbamazepine</e1>\NN\1740 <e2>neurotoxicity</e2>\NN\1740 after\IN\1740 combined\JJ\1740 treatment\NN\654885 with\IN\1740 verapamil\NNS\2938514 showed\VBD\2137132 complete\JJ\1740 recovery\NN\7357388 after\IN\1740 discontinuation\NN\209943 of\IN\1740 the\DT\1740 calcium\NN\14625458 entry\NN\6502378 blocker\NN\10101634 .\.\1740
D002118_D020258 NONE Two\CD\13741022 patients\NNS\9898892 with\IN\1740 signs\NNS\6643763 of\IN\1740 carbamazepine\NN\1740 <e2>neurotoxicity</e2>\NN\1740 after\IN\1740 combined\JJ\1740 treatment\NN\654885 with\IN\1740 verapamil\NNS\2938514 showed\VBD\2137132 complete\JJ\1740 recovery\NN\7357388 after\IN\1740 discontinuation\NN\209943 of\IN\1740 the\DT\1740 <e1>calcium</e1>\NN\14625458 entry\NN\6502378 blocker\NN\10101634 .\.\1740
20080419
D010862_D004827 CID In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 investigated\VBD\644583 the\DT\1740 therapeutic\JJ\1740 potential\NN\14481929 of\IN\1740 bone\NN\5286536 marrow\NN\5286536 mononuclear\JJ\1740 cells\NNS\3080309 (\-LRB-\1740 BMCs\NNS\1740 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 model\NN\5888929 of\IN\1740 <e2>epilepsy</e2>\NN\14085708 induced\VBN\1627355 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 in\IN\13603305 rats\NNS\2329401 .\.\1740
10457883
16938416
D013739_D050197 CID High-dose\JJ\1740 <e1>testosterone</e1>\NN\14747587 is\VBZ\836236 associated\VBN\628491 with\IN\1740 <e2>atherosclerosis</e2>\NN\14108324 in\IN\13603305 postmenopausal\JJ\1740 women\NNS\9605289 .\.\1740
D013739_D050197 CID METHODS\NNS\5616786 :\:\1740 In\IN\13603305 a\DT\13649268 population-based\JJ\1740 study\NN\635850 in\IN\13603305 513\CD\1740 naturally\RB\1740 postmenopausal\JJ\1740 women\NNS\9605289 aged\JJ\1740 54\CD\1740 -\SYM\1740 67\CD\1740 years\NNS\15144371 ,\,\1740 we\PRP\1740 studied\VBD\630380 the\DT\1740 association\NN\8008335 between\IN\1740 self-reported\JJ\1740 intramuscularly\RB\1740 administered\VBN\2436349 high-dose\JJ\1740 <e1>estrogen-testosterone</e1>\JJ\1740 therapy\NN\657604 (\-LRB-\1740 estradiol-\NN\1740 and\CC\1740 testosterone\NN\14747587 esters\NNS\14727670 )\-RRB-\1740 and\CC\1740 aortic\JJ\1740 <e2>atherosclerosis</e2>\NN\14108324 .\.\1740
D013739_D050197 CID CONCLUSION\NN\5837957 :\:\1740 Our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 high-dose\JJ\1740 <e1>testosterone</e1>\NN\14747587 therapy\NN\657604 may\MD\15209706 adversely\RB\1740 affect\VB\126264 <e2>atherosclerosis</e2>\NN\14108324 in\IN\13603305 postmenopausal\JJ\1740 women\NNS\9605289 and\CC\1740 indicate\VBP\952524 that\IN\1740 androgen\NN\14745635 replacement\NN\196485 in\IN\13603305 these\DT\1740 women\NNS\9605289 may\MD\15209706 not\RB\1740 be\VB\836236 harmless\NN\1740 .\.\1740
D004967_D050197 NONE METHODS\NNS\5616786 :\:\1740 In\IN\13603305 a\DT\13649268 population-based\JJ\1740 study\NN\635850 in\IN\13603305 513\CD\1740 naturally\RB\1740 postmenopausal\JJ\1740 women\NNS\9605289 aged\JJ\1740 54\CD\1740 -\SYM\1740 67\CD\1740 years\NNS\15144371 ,\,\1740 we\PRP\1740 studied\VBD\630380 the\DT\1740 association\NN\8008335 between\IN\1740 self-reported\JJ\1740 intramuscularly\RB\1740 administered\VBN\2436349 high-dose\JJ\1740 <e1>estrogen-testosterone</e1>\JJ\1740 therapy\NN\657604 (\-LRB-\1740 estradiol-\NN\1740 and\CC\1740 testosterone\NN\14747587 esters\NNS\14727670 )\-RRB-\1740 and\CC\1740 aortic\JJ\1740 <e2>atherosclerosis</e2>\NN\14108324 .\.\1740
C032109_D050197 NONE METHODS\NNS\5616786 :\:\1740 In\IN\13603305 a\DT\13649268 population-based\JJ\1740 study\NN\635850 in\IN\13603305 513\CD\1740 naturally\RB\1740 postmenopausal\JJ\1740 women\NNS\9605289 aged\JJ\1740 54\CD\1740 -\SYM\1740 67\CD\1740 years\NNS\15144371 ,\,\1740 we\PRP\1740 studied\VBD\630380 the\DT\1740 association\NN\8008335 between\IN\1740 self-reported\JJ\1740 intramuscularly\RB\1740 administered\VBN\2436349 high-dose\JJ\1740 estrogen-testosterone\JJ\1740 therapy\NN\657604 (\-LRB-\1740 <e1>estradiol-\NN\1740 and\CC\1740 testosterone\NN\14747587 esters</e1>\NNS\14727670 )\-RRB-\1740 and\CC\1740 aortic\JJ\1740 <e2>atherosclerosis</e2>\NN\14108324 .\.\1740
D002784_D003920 NONE The\DT\1740 association\NN\8008335 remained\VBD\2604760 after\IN\1740 additional\JJ\1740 adjustment\NN\7357388 for\IN\1740 <e2>diabetes</e2>\NNS\14075199 ,\,\1740 <e1>cholesterol</e1>\NN\15058310 level\NN\4916342 ,\,\1740 systolic\JJ\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 or\CC\3541091 alcohol\NN\7881800 use\NN\407535 .\.\1740
D000431_D003920 NONE The\DT\1740 association\NN\8008335 remained\VBD\2604760 after\IN\1740 additional\JJ\1740 adjustment\NN\7357388 for\IN\1740 <e2>diabetes</e2>\NNS\14075199 ,\,\1740 cholesterol\NN\15058310 level\NN\4916342 ,\,\1740 systolic\JJ\1740 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 or\CC\3541091 <e1>alcohol</e1>\NN\7881800 use\NN\407535 .\.\1740
17612891
D003024_D009205 CID Acute\JJ\1740 <e2>myocarditis</e2>\NN\14338942 associated\VBN\628491 with\IN\1740 <e1>clozapine</e1>\NN\3713736 .\.\1740
D003024_D009205 CID OBJECTIVE\NN\5980875 :\:\1740 A\DT\13649268 case\NN\7283608 of\IN\1740 acute\JJ\1740 <e2>myocarditis</e2>\NN\14338942 associated\VBN\628491 with\IN\1740 the\DT\1740 commencement\NN\15180528 of\IN\1740 <e1>clozapine</e1>\NN\3713736 is\VBZ\836236 described\VBN\1001294 ,\,\1740 highlighting\VBG\514463 the\DT\1740 onset\NN\7325190 ,\,\1740 course\NN\883297 and\CC\1740 possible\JJ\1740 contributing\VBG\126264 factors\NNS\7326557 .\.\1740
D003024_D009205 CID RESULTS\NNS\34213 :\:\1740 A\DT\13649268 20-year-old\NN\1740 male\JJ\1740 with\IN\1740 schizophrenia\NN\14398067 developed\VBD\1753788 a\DT\13649268 sudden\JJ\1740 onset\NN\7325190 of\IN\1740 <e2>myocarditis</e2>\NN\14338942 after\IN\1740 commencement\NN\15180528 of\IN\1740 <e1>clozapine</e1>\NN\3713736 .\.\1740
D003024_D009205 CID CONCLUSIONS\NNS\5837957 :\:\1740 <e2>Myocarditis</e2>\NNP\14338942 is\VBZ\836236 an\DT\6697703 increasingly\RB\1740 recognized\VBN\686447 complication\NN\1073995 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>clozapine</e1>\NN\3713736 .\.\1740
D003024_D012559 NONE RESULTS\NNS\34213 :\:\1740 A\DT\13649268 20-year-old\NN\1740 male\JJ\1740 with\IN\1740 <e2>schizophrenia</e2>\NN\14398067 developed\VBD\1753788 a\DT\13649268 sudden\JJ\1740 onset\NN\7325190 of\IN\1740 myocarditis\NN\14338942 after\IN\1740 commencement\NN\15180528 of\IN\1740 <e1>clozapine</e1>\NN\3713736 .\.\1740
D003024_D011618 NONE Considering\VBG\689344 that\DT\1740 <e1>clozapine</e1>\NN\3713736 remains\VBZ\2604760 the\DT\1740 gold\NN\13371489 standard\JJ\1740 in\IN\13603305 treatment\NN\654885 of\IN\1740 resistant\JJ\1740 <e2>psychosis</e2>\NN\14380140 ,\,\1740 there\EX\27167 is\VBZ\836236 an\DT\6697703 urgent\JJ\1740 need\NN\13920835 to\TO\1740 raise\VB\153263 awareness\NN\5804793 among\IN\1740 medical\JJ\1740 and\CC\1740 paramedical\JJ\1740 staff\NN\8208016 involved\VBN\2676054 in\IN\13603305 the\DT\1740 care\NN\575741 of\IN\1740 these\DT\1740 patients\NNS\9898892 .\.\1740
12716030
D006493_D002543 NONE In\IN\13603305 <e2>ICH</e2>\NN\1740 induction\NN\7450842 using\VBG\1156834 0.014-unit\NN\1740 collagenase\NN\14732946 ,\,\1740 <e1>heparin</e1>\NN\2718259 enhanced\VBD\227165 the\DT\1740 hematoma\NN\14317720 volume\NN\33615 3.4-fold\RB\1740 over\IN\5867413 that\DT\1740 seen\VBN\2106506 in\IN\13603305 control\NN\5190804 ICH\NN\1740 animals\NNS\4475 and\CC\1740 the\DT\1740 bleeding\NN\14285662 7.6-fold\RB\1740 .\.\1740
D006493_D002543 NONE In\IN\13603305 ICH\NN\1740 induction\NN\7450842 using\VBG\1156834 0.014-unit\NN\1740 collagenase\NN\14732946 ,\,\1740 <e1>heparin</e1>\NN\2718259 enhanced\VBD\227165 the\DT\1740 hematoma\NN\14317720 volume\NN\33615 3.4-fold\RB\1740 over\IN\5867413 that\DT\1740 seen\VBN\2106506 in\IN\13603305 control\NN\5190804 <e2>ICH</e2>\NN\1740 animals\NNS\4475 and\CC\1740 the\DT\1740 bleeding\NN\14285662 7.6-fold\RB\1740 .\.\1740
D006493_D006406 CID In\IN\13603305 ICH\NN\1740 induction\NN\7450842 using\VBG\1156834 0.014-unit\NN\1740 collagenase\NN\14732946 ,\,\1740 <e1>heparin</e1>\NN\2718259 enhanced\VBD\227165 the\DT\1740 <e2>hematoma</e2>\NN\14317720 volume\NN\33615 3.4-fold\RB\1740 over\IN\5867413 that\DT\1740 seen\VBN\2106506 in\IN\13603305 control\NN\5190804 ICH\NN\1740 animals\NNS\4475 and\CC\1740 the\DT\1740 bleeding\NN\14285662 7.6-fold\RB\1740 .\.\1740
D006493_D006470 NONE In\IN\13603305 ICH\NN\1740 induction\NN\7450842 using\VBG\1156834 0.014-unit\NN\1740 collagenase\NN\14732946 ,\,\1740 <e1>heparin</e1>\NN\2718259 enhanced\VBD\227165 the\DT\1740 hematoma\NN\14317720 volume\NN\33615 3.4-fold\RB\1740 over\IN\5867413 that\DT\1740 seen\VBN\2106506 in\IN\13603305 control\NN\5190804 ICH\NN\1740 animals\NNS\4475 and\CC\1740 the\DT\1740 <e2>bleeding</e2>\NN\14285662 7.6-fold\RB\1740 .\.\1740
16274958
D017255_D055154 CID Recurrent\JJ\1740 <e2>dysphonia</e2>\NN\14400677 and\CC\1740 <e1>acitretin</e1>\NN\1740 .\.\1740
D017255_D055154 CID We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 woman\NN\9605289 complaining\NN\1740 of\IN\1740 <e2>dysphonia</e2>\NN\14400677 while\IN\15122231 she\PRP\1740 was\VBD\836236 treated\VBN\2376958 by\IN\1740 <e1>acitretin</e1>\NN\1740 .\.\1740
D017255_D055154 CID To\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 case\NN\7283608 of\IN\1740 <e1>acitretin-induced</e1>\JJ\1740 <e2>dysphonia</e2>\NN\14400677 .\.\1740
19631624
D018817_D007859 CID <e2>Learning\NN\5701944 and\CC\1740 memory\NN\5926676 deficits</e2>\NNS\5113133 in\IN\13603305 <e1>ecstasy</e1>\NN\13985818 users\NNS\7846 and\CC\1740 their\PRP$\1740 neural\JJ\1740 correlates\VBZ\2657219 during\IN\1740 a\DT\13649268 face-learning\JJ\1740 task\NN\575741 .\.\1740
D018817_D007859 CID It\PRP\6125041 has\VBZ\2108377 been\VBN\836236 consistently\RB\1740 shown\VBN\2137132 that\IN\1740 <e1>ecstasy</e1>\NN\13985818 users\NNS\7846 display\VBP\2137132 <e2>impairments\NNS\7296428 in\IN\13603305 learning\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 performance\NN\6619065 .\.\1740
D018817_D008569 CID <e2>Learning\NN\5701944 and\CC\1740 memory\NN\5926676 deficits</e2>\NNS\5113133 in\IN\13603305 <e1>ecstasy</e1>\NN\13985818 users\NNS\7846 and\CC\1740 their\PRP$\1740 neural\JJ\1740 correlates\VBZ\2657219 during\IN\1740 a\DT\13649268 face-learning\JJ\1740 task\NN\575741 .\.\1740
D018817_D008569 CID It\PRP\6125041 has\VBZ\2108377 been\VBN\836236 consistently\RB\1740 shown\VBN\2137132 that\IN\1740 <e1>ecstasy</e1>\NN\13985818 users\NNS\7846 display\VBP\2137132 <e2>impairments\NNS\7296428 in\IN\13603305 learning\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 performance\NN\6619065 .\.\1740
D002188_D007859 NONE <e2>Deficits\NNS\5113133 in\IN\13603305 learning\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 :\:\1740 parahippocampal\JJ\1740 hyperactivity\NN\14052403 and\CC\1740 frontocortical\JJ\1740 hypoactivity\NN\1740 in\IN\13603305 <e1>cannabis</e1>\NN\13112664 users\NNS\7846 .\.\1740
D002188_D008569 NONE <e2>Deficits\NNS\5113133 in\IN\13603305 learning\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 :\:\1740 parahippocampal\JJ\1740 hyperactivity\NN\14052403 and\CC\1740 frontocortical\JJ\1740 hypoactivity\NN\1740 in\IN\13603305 <e1>cannabis</e1>\NN\13112664 users\NNS\7846 .\.\1740
D002188_D006948 NONE Deficits\NNS\5113133 in\IN\13603305 learning\NN\5701944 and\CC\1740 memory\NN\5926676 :\:\1740 parahippocampal\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 and\CC\1740 frontocortical\JJ\1740 hypoactivity\NN\1740 in\IN\13603305 <e1>cannabis</e1>\NN\13112664 users\NNS\7846 .\.\1740
D018817_D006948 NONE A\DT\13649268 conjunction\NN\5048123 analysis\NN\633864 of\IN\1740 the\DT\1740 encode\NN\1740 and\CC\1740 recall\VB\931467 phases\NNS\15113229 of\IN\1740 the\DT\1740 task\NN\575741 revealed\VBD\2137132 <e1>ecstasy-specific</e1>\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 in\IN\13603305 bilateral\JJ\1740 frontal\JJ\1740 regions\NNS\27167 ,\,\1740 left\VBD\120316 temporal\JJ\1740 ,\,\1740 right\JJ\1740 parietal\JJ\1740 ,\,\1740 bilateral\JJ\1740 temporal\JJ\1740 ,\,\1740 and\CC\1740 bilateral\JJ\1740 occipital\NN\1740 brain\NN\5462674 regions\NNS\27167 .\.\1740
D018817_D020258 NONE These\DT\1740 <e1>ecstasy-specific</e1>\JJ\1740 effects\NNS\13245626 may\MD\15209706 be\VB\836236 related\JJ\1740 to\TO\1740 the\DT\1740 vulnerability\NN\14540765 of\IN\1740 isocortical\JJ\1740 and\CC\1740 allocortical\JJ\1740 regions\NNS\27167 to\TO\1740 the\DT\1740 <e2>neurotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 ecstasy\NN\13985818 .\.\1740
D018817_D020258 NONE These\DT\1740 ecstasy-specific\JJ\1740 effects\NNS\13245626 may\MD\15209706 be\VB\836236 related\JJ\1740 to\TO\1740 the\DT\1740 vulnerability\NN\14540765 of\IN\1740 isocortical\JJ\1740 and\CC\1740 allocortical\JJ\1740 regions\NNS\27167 to\TO\1740 the\DT\1740 <e2>neurotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>ecstasy</e1>\NN\13985818 .\.\1740
1732369
D004280_D009369 NONE <e1>Dobutamine</e1>\JJ\1740 stress\NN\7083732 echocardiography\NN\177127 :\:\1740 a\DT\13649268 sensitive\JJ\1740 indicator\NN\6636259 of\IN\1740 diminished\VBN\169651 myocardial\JJ\1740 function\NN\13783581 in\IN\13603305 asymptomatic\JJ\1740 doxorubicin-treated\JJ\1740 long-term\JJ\1740 survivors\NNS\9630641 of\IN\1740 childhood\NN\15144371 <e2>cancer</e2>\NN\14239425 .\.\1740
D004280_D009369 NONE To\TO\1740 develop\VB\1753788 a\DT\13649268 more\RBR\1740 sensitive\JJ\1740 echocardiographic\JJ\1740 screening\NN\6887726 test\NN\5798043 for\IN\1740 cardiac\JJ\1740 damage\NN\7296428 due\IN\5174653 to\IN\1740 doxorubicin\NN\2716866 ,\,\1740 a\DT\13649268 cohort\NN\8184861 study\NN\635850 was\VBD\836236 performed\VBN\2367363 using\VBG\1156834 <e1>dobutamine</e1>\NN\1740 infusion\NN\14589223 to\TO\1740 differentiate\VB\618878 asymptomatic\JJ\1740 long-term\JJ\1740 survivors\NNS\9630641 of\IN\1740 childhood\NN\15144371 <e2>cancer</e2>\NN\14239425 treated\VBN\2376958 with\IN\1740 doxorubicin\NN\2716866 from\IN\1740 healthy\JJ\1740 control\NN\5190804 subjects\NNS\6598915 .\.\1740
D004317_D009369 NONE Dobutamine\JJ\1740 stress\NN\7083732 echocardiography\NN\177127 :\:\1740 a\DT\13649268 sensitive\JJ\1740 indicator\NN\6636259 of\IN\1740 diminished\VBN\169651 myocardial\JJ\1740 function\NN\13783581 in\IN\13603305 asymptomatic\JJ\1740 <e1>doxorubicin-treated</e1>\JJ\1740 long-term\JJ\1740 survivors\NNS\9630641 of\IN\1740 childhood\NN\15144371 <e2>cancer</e2>\NN\14239425 .\.\1740
D004317_D009369 NONE To\TO\1740 develop\VB\1753788 a\DT\13649268 more\RBR\1740 sensitive\JJ\1740 echocardiographic\JJ\1740 screening\NN\6887726 test\NN\5798043 for\IN\1740 cardiac\JJ\1740 damage\NN\7296428 due\IN\5174653 to\IN\1740 <e1>doxorubicin</e1>\NN\2716866 ,\,\1740 a\DT\13649268 cohort\NN\8184861 study\NN\635850 was\VBD\836236 performed\VBN\2367363 using\VBG\1156834 dobutamine\NN\1740 infusion\NN\14589223 to\TO\1740 differentiate\VB\618878 asymptomatic\JJ\1740 long-term\JJ\1740 survivors\NNS\9630641 of\IN\1740 childhood\NN\15144371 <e2>cancer</e2>\NN\14239425 treated\VBN\2376958 with\IN\1740 doxorubicin\NN\2716866 from\IN\1740 healthy\JJ\1740 control\NN\5190804 subjects\NNS\6598915 .\.\1740
D004317_D009369 NONE To\TO\1740 develop\VB\1753788 a\DT\13649268 more\RBR\1740 sensitive\JJ\1740 echocardiographic\JJ\1740 screening\NN\6887726 test\NN\5798043 for\IN\1740 cardiac\JJ\1740 damage\NN\7296428 due\IN\5174653 to\IN\1740 doxorubicin\NN\2716866 ,\,\1740 a\DT\13649268 cohort\NN\8184861 study\NN\635850 was\VBD\836236 performed\VBN\2367363 using\VBG\1156834 dobutamine\NN\1740 infusion\NN\14589223 to\TO\1740 differentiate\VB\618878 asymptomatic\JJ\1740 long-term\JJ\1740 survivors\NNS\9630641 of\IN\1740 childhood\NN\15144371 <e2>cancer</e2>\NN\14239425 treated\VBN\2376958 with\IN\1740 <e1>doxorubicin</e1>\NN\2716866 from\IN\1740 healthy\JJ\1740 control\NN\5190804 subjects\NNS\6598915 .\.\1740
D004317_D009202 CID <e1>Doxorubicin</e1>\NNP\2716866 is\VBZ\836236 an\DT\6697703 effective\JJ\1740 anticancer\NN\1740 chemotherapeutic\NN\1740 agent\NN\7347 known\VBN\2110220 to\TO\1740 cause\VB\1617192 acute\JJ\1740 and\CC\1740 chronic\JJ\1740 <e2>cardiomyopathy</e2>\JJ\1740 .\.\1740
D004317_D006331 NONE To\TO\1740 develop\VB\1753788 a\DT\13649268 more\RBR\1740 sensitive\JJ\1740 echocardiographic\JJ\1740 screening\NN\6887726 test\NN\5798043 for\IN\1740 <e2>cardiac\JJ\1740 damage</e2>\NN\7296428 due\IN\5174653 to\IN\1740 <e1>doxorubicin</e1>\NN\2716866 ,\,\1740 a\DT\13649268 cohort\NN\8184861 study\NN\635850 was\VBD\836236 performed\VBN\2367363 using\VBG\1156834 dobutamine\NN\1740 infusion\NN\14589223 to\TO\1740 differentiate\VB\618878 asymptomatic\JJ\1740 long-term\JJ\1740 survivors\NNS\9630641 of\IN\1740 childhood\NN\15144371 cancer\NN\14239425 treated\VBN\2376958 with\IN\1740 doxorubicin\NN\2716866 from\IN\1740 healthy\JJ\1740 control\NN\5190804 subjects\NNS\6598915 .\.\1740
D004317_D006331 NONE To\TO\1740 develop\VB\1753788 a\DT\13649268 more\RBR\1740 sensitive\JJ\1740 echocardiographic\JJ\1740 screening\NN\6887726 test\NN\5798043 for\IN\1740 <e2>cardiac\JJ\1740 damage</e2>\NN\7296428 due\IN\5174653 to\IN\1740 doxorubicin\NN\2716866 ,\,\1740 a\DT\13649268 cohort\NN\8184861 study\NN\635850 was\VBD\836236 performed\VBN\2367363 using\VBG\1156834 dobutamine\NN\1740 infusion\NN\14589223 to\TO\1740 differentiate\VB\618878 asymptomatic\JJ\1740 long-term\JJ\1740 survivors\NNS\9630641 of\IN\1740 childhood\NN\15144371 cancer\NN\14239425 treated\VBN\2376958 with\IN\1740 <e1>doxorubicin</e1>\NN\2716866 from\IN\1740 healthy\JJ\1740 control\NN\5190804 subjects\NNS\6598915 .\.\1740
D004280_D006331 NONE To\TO\1740 develop\VB\1753788 a\DT\13649268 more\RBR\1740 sensitive\JJ\1740 echocardiographic\JJ\1740 screening\NN\6887726 test\NN\5798043 for\IN\1740 <e2>cardiac\JJ\1740 damage</e2>\NN\7296428 due\IN\5174653 to\IN\1740 doxorubicin\NN\2716866 ,\,\1740 a\DT\13649268 cohort\NN\8184861 study\NN\635850 was\VBD\836236 performed\VBN\2367363 using\VBG\1156834 <e1>dobutamine</e1>\NN\1740 infusion\NN\14589223 to\TO\1740 differentiate\VB\618878 asymptomatic\JJ\1740 long-term\JJ\1740 survivors\NNS\9630641 of\IN\1740 childhood\NN\15144371 cancer\NN\14239425 treated\VBN\2376958 with\IN\1740 doxorubicin\NN\2716866 from\IN\1740 healthy\JJ\1740 control\NN\5190804 subjects\NNS\6598915 .\.\1740
3629586
D015790_D006402 NONE The\DT\1740 hematologic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>cefonicid</e1>\NN\1740 and\CC\1740 cefazedone\NN\1740 in\IN\13603305 the\DT\1740 dog\NN\2083346 :\:\1740 a\DT\13649268 potential\JJ\1740 model\NN\5888929 of\IN\1740 cephalosporin\NN\2716866 <e2>hematotoxicity</e2>\NN\1740 in\IN\13603305 man\NN\9605289 .\.\1740
D015790_D006402 NONE A\DT\13649268 nonregenerative\JJ\1740 anemia\NN\14189204 was\VBD\836236 the\DT\1740 most\RBS\1740 compromising\VBG\1035530 of\IN\1740 the\DT\1740 <e2>cytopenias</e2>\NNS\14189204 and\CC\1740 occurred\VBD\2623529 in\IN\13603305 approximately\RB\1740 50\CD\13745420 %\NN\1740 of\IN\1740 dogs\NNS\2083346 receiving\VBG\2210855 400\CD\1740 -\SYM\1740 500\CD\13745420 mg/kg\NN\1740 <e1>cefonicid</e1>\NN\1740 or\CC\3541091 540\CD\1740 -\SYM\1740 840\CD\1740 mg/kg\NN\1740 cefazedone\NN\1740 .\.\1740
D015790_D006402 NONE Upon\IN\1740 rechallenge\NN\1740 with\IN\1740 either\CC\1740 cephalosporin\NN\2716866 ,\,\1740 the\DT\1740 <e2>hematologic\JJ\1740 syndrome</e2>\NN\5870365 was\VBD\836236 reproduced\VBN\1621555 in\IN\13603305 most\JJS\1740 dogs\NNS\2083346 tested\VBN\670261 ;\:\1740 <e1>cefonicid</e1>\NN\1740 (\-LRB-\1740 but\CC\1740 not\RB\1740 cefazedone)-treated\VBN\1740 dogs\NNS\2083346 showed\VBD\2137132 a\DT\13649268 substantially\RB\1740 reduced\VBN\441445 induction\NN\7450842 period\NN\13575869 (\-LRB-\1740 15\CD\13745420 +/-\CC\1740 5\CD\13741022 days\NNS\15140892 )\-RRB-\1740 compared\VBN\644583 to\TO\1740 that\DT\1740 of\IN\1740 the\DT\1740 first\JJ\1740 exposure\NN\5042871 to\TO\1740 the\DT\1740 drug\NN\14778436 (\-LRB-\1740 61\CD\1740 +/-\CC\1740 24\CD\13745420 days\NNS\15140892 )\-RRB-\1740 .\.\1740
D015790_D006402 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>cefonicid</e1>\NN\1740 or\CC\3541091 cefazedone\NN\1740 to\IN\1740 dogs\NNS\2083346 can\MD\3094503 induce\VB\1627355 <e2>hematotoxicity</e2>\NN\1740 similar\JJ\1740 to\TO\1740 the\DT\1740 cephalosporin-induced\JJ\1740 blood\NN\5397468 dyscrasias\NN\14052046 described\VBN\1001294 in\IN\13603305 man\NN\9605289 and\CC\1740 thus\RB\1740 provides\VBZ\2199590 a\DT\13649268 useful\JJ\1740 model\NN\5888929 for\IN\1740 studying\VBG\630380 the\DT\1740 mechanisms\NNS\13446390 of\IN\1740 these\DT\1740 disorders\NNS\14034177 .\.\1740
D015790_D006402 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>cefonicid</e1>\NN\1740 or\CC\3541091 cefazedone\NN\1740 to\IN\1740 dogs\NNS\2083346 can\MD\3094503 induce\VB\1627355 hematotoxicity\NN\1740 similar\JJ\1740 to\TO\1740 the\DT\1740 cephalosporin-induced\JJ\1740 <e2>blood\NN\5397468 dyscrasias</e2>\NN\14052046 described\VBN\1001294 in\IN\13603305 man\NN\9605289 and\CC\1740 thus\RB\1740 provides\VBZ\2199590 a\DT\13649268 useful\JJ\1740 model\NN\5888929 for\IN\1740 studying\VBG\630380 the\DT\1740 mechanisms\NNS\13446390 of\IN\1740 these\DT\1740 disorders\NNS\14034177 .\.\1740
C021341_D006402 NONE The\DT\1740 hematologic\JJ\1740 effects\NNS\13245626 of\IN\1740 cefonicid\NN\1740 and\CC\1740 <e1>cefazedone</e1>\NN\1740 in\IN\13603305 the\DT\1740 dog\NN\2083346 :\:\1740 a\DT\13649268 potential\JJ\1740 model\NN\5888929 of\IN\1740 cephalosporin\NN\2716866 <e2>hematotoxicity</e2>\NN\1740 in\IN\13603305 man\NN\9605289 .\.\1740
C021341_D006402 NONE A\DT\13649268 nonregenerative\JJ\1740 anemia\NN\14189204 was\VBD\836236 the\DT\1740 most\RBS\1740 compromising\VBG\1035530 of\IN\1740 the\DT\1740 <e2>cytopenias</e2>\NNS\14189204 and\CC\1740 occurred\VBD\2623529 in\IN\13603305 approximately\RB\1740 50\CD\13745420 %\NN\1740 of\IN\1740 dogs\NNS\2083346 receiving\VBG\2210855 400\CD\1740 -\SYM\1740 500\CD\13745420 mg/kg\NN\1740 cefonicid\NN\1740 or\CC\3541091 540\CD\1740 -\SYM\1740 840\CD\1740 mg/kg\NN\1740 <e1>cefazedone</e1>\NN\1740 .\.\1740
C021341_D006402 NONE Upon\IN\1740 rechallenge\NN\1740 with\IN\1740 either\CC\1740 cephalosporin\NN\2716866 ,\,\1740 the\DT\1740 <e2>hematologic\JJ\1740 syndrome</e2>\NN\5870365 was\VBD\836236 reproduced\VBN\1621555 in\IN\13603305 most\JJS\1740 dogs\NNS\2083346 tested\VBN\670261 ;\:\1740 cefonicid\NN\1740 (\-LRB-\1740 but\CC\1740 not\RB\1740 <e1>cefazedone)-treated</e1>\VBN\1740 dogs\NNS\2083346 showed\VBD\2137132 a\DT\13649268 substantially\RB\1740 reduced\VBN\441445 induction\NN\7450842 period\NN\13575869 (\-LRB-\1740 15\CD\13745420 +/-\CC\1740 5\CD\13741022 days\NNS\15140892 )\-RRB-\1740 compared\VBN\644583 to\TO\1740 that\DT\1740 of\IN\1740 the\DT\1740 first\JJ\1740 exposure\NN\5042871 to\TO\1740 the\DT\1740 drug\NN\14778436 (\-LRB-\1740 61\CD\1740 +/-\CC\1740 24\CD\13745420 days\NNS\15140892 )\-RRB-\1740 .\.\1740
C021341_D006402 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 cefonicid\NN\1740 or\CC\3541091 <e1>cefazedone</e1>\NN\1740 to\IN\1740 dogs\NNS\2083346 can\MD\3094503 induce\VB\1627355 <e2>hematotoxicity</e2>\NN\1740 similar\JJ\1740 to\TO\1740 the\DT\1740 cephalosporin-induced\JJ\1740 blood\NN\5397468 dyscrasias\NN\14052046 described\VBN\1001294 in\IN\13603305 man\NN\9605289 and\CC\1740 thus\RB\1740 provides\VBZ\2199590 a\DT\13649268 useful\JJ\1740 model\NN\5888929 for\IN\1740 studying\VBG\630380 the\DT\1740 mechanisms\NNS\13446390 of\IN\1740 these\DT\1740 disorders\NNS\14034177 .\.\1740
C021341_D006402 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 cefonicid\NN\1740 or\CC\3541091 <e1>cefazedone</e1>\NN\1740 to\IN\1740 dogs\NNS\2083346 can\MD\3094503 induce\VB\1627355 hematotoxicity\NN\1740 similar\JJ\1740 to\TO\1740 the\DT\1740 cephalosporin-induced\JJ\1740 <e2>blood\NN\5397468 dyscrasias</e2>\NN\14052046 described\VBN\1001294 in\IN\13603305 man\NN\9605289 and\CC\1740 thus\RB\1740 provides\VBZ\2199590 a\DT\13649268 useful\JJ\1740 model\NN\5888929 for\IN\1740 studying\VBG\630380 the\DT\1740 mechanisms\NNS\13446390 of\IN\1740 these\DT\1740 disorders\NNS\14034177 .\.\1740
D002511_D006402 NONE The\DT\1740 hematologic\JJ\1740 effects\NNS\13245626 of\IN\1740 cefonicid\NN\1740 and\CC\1740 cefazedone\NN\1740 in\IN\13603305 the\DT\1740 dog\NN\2083346 :\:\1740 a\DT\13649268 potential\JJ\1740 model\NN\5888929 of\IN\1740 <e1>cephalosporin</e1>\NN\2716866 <e2>hematotoxicity</e2>\NN\1740 in\IN\13603305 man\NN\9605289 .\.\1740
D002511_D006402 NONE <e1>Cephalosporin</e1>\NN\2716866 antibiotics\NNS\2716205 cause\VBP\1617192 a\DT\13649268 variety\NN\7951464 of\IN\1740 <e2>hematologic\JJ\1740 disturbances</e2>\NNS\407535 in\IN\13603305 man\NN\9605289 ,\,\1740 the\DT\1740 pathogeneses\NNS\1740 and\CC\1740 hematopathology\NN\1740 of\IN\1740 which\WDT\1740 remain\VBP\2604760 poorly\RB\1740 characterized\VBN\609683 .\.\1740
D002511_D006402 NONE Upon\IN\1740 rechallenge\NN\1740 with\IN\1740 either\CC\1740 <e1>cephalosporin</e1>\NN\2716866 ,\,\1740 the\DT\1740 <e2>hematologic\JJ\1740 syndrome</e2>\NN\5870365 was\VBD\836236 reproduced\VBN\1621555 in\IN\13603305 most\JJS\1740 dogs\NNS\2083346 tested\VBN\670261 ;\:\1740 cefonicid\NN\1740 (\-LRB-\1740 but\CC\1740 not\RB\1740 cefazedone)-treated\VBN\1740 dogs\NNS\2083346 showed\VBD\2137132 a\DT\13649268 substantially\RB\1740 reduced\VBN\441445 induction\NN\7450842 period\NN\13575869 (\-LRB-\1740 15\CD\13745420 +/-\CC\1740 5\CD\13741022 days\NNS\15140892 )\-RRB-\1740 compared\VBN\644583 to\TO\1740 that\DT\1740 of\IN\1740 the\DT\1740 first\JJ\1740 exposure\NN\5042871 to\TO\1740 the\DT\1740 drug\NN\14778436 (\-LRB-\1740 61\CD\1740 +/-\CC\1740 24\CD\13745420 days\NNS\15140892 )\-RRB-\1740 .\.\1740
D002511_D006402 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 cefonicid\NN\1740 or\CC\3541091 cefazedone\NN\1740 to\IN\1740 dogs\NNS\2083346 can\MD\3094503 induce\VB\1627355 <e2>hematotoxicity</e2>\NN\1740 similar\JJ\1740 to\TO\1740 the\DT\1740 <e1>cephalosporin-induced</e1>\JJ\1740 blood\NN\5397468 dyscrasias\NN\14052046 described\VBN\1001294 in\IN\13603305 man\NN\9605289 and\CC\1740 thus\RB\1740 provides\VBZ\2199590 a\DT\13649268 useful\JJ\1740 model\NN\5888929 for\IN\1740 studying\VBG\630380 the\DT\1740 mechanisms\NNS\13446390 of\IN\1740 these\DT\1740 disorders\NNS\14034177 .\.\1740
D002511_D006402 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 cefonicid\NN\1740 or\CC\3541091 cefazedone\NN\1740 to\IN\1740 dogs\NNS\2083346 can\MD\3094503 induce\VB\1627355 hematotoxicity\NN\1740 similar\JJ\1740 to\TO\1740 the\DT\1740 <e1>cephalosporin-induced</e1>\JJ\1740 <e2>blood\NN\5397468 dyscrasias</e2>\NN\14052046 described\VBN\1001294 in\IN\13603305 man\NN\9605289 and\CC\1740 thus\RB\1740 provides\VBZ\2199590 a\DT\13649268 useful\JJ\1740 model\NN\5888929 for\IN\1740 studying\VBG\630380 the\DT\1740 mechanisms\NNS\13446390 of\IN\1740 these\DT\1740 disorders\NNS\14034177 .\.\1740
D015790_D064420 NONE In\IN\13603305 four\CD\13741022 subacute\NN\1740 <e2>toxicity</e2>\NN\13576101 studies\NNS\635850 ,\,\1740 the\DT\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>cefonicid</e1>\NN\1740 or\CC\3541091 cefazedone\NN\1740 to\TO\1740 beagle\VB\1740 dogs\NNS\2083346 caused\VBD\1617192 a\DT\13649268 dose-dependent\JJ\1740 incidence\NN\13821570 of\IN\1740 anemia\NN\14189204 ,\,\1740 neutropenia\NN\14196405 ,\,\1740 and\CC\1740 thrombocytopenia\NN\14189204 after\IN\1740 1\CD\13741022 -\SYM\1740 3\CD\13741022 months\NNS\15113229 of\IN\1740 treatment\NN\654885 .\.\1740
D015790_D000740 CID In\IN\13603305 four\CD\13741022 subacute\NN\1740 toxicity\NN\13576101 studies\NNS\635850 ,\,\1740 the\DT\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>cefonicid</e1>\NN\1740 or\CC\3541091 cefazedone\NN\1740 to\TO\1740 beagle\VB\1740 dogs\NNS\2083346 caused\VBD\1617192 a\DT\13649268 dose-dependent\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>anemia</e2>\NN\14189204 ,\,\1740 neutropenia\NN\14196405 ,\,\1740 and\CC\1740 thrombocytopenia\NN\14189204 after\IN\1740 1\CD\13741022 -\SYM\1740 3\CD\13741022 months\NNS\15113229 of\IN\1740 treatment\NN\654885 .\.\1740
D015790_D000740 CID A\DT\13649268 nonregenerative\JJ\1740 <e2>anemia</e2>\NN\14189204 was\VBD\836236 the\DT\1740 most\RBS\1740 compromising\VBG\1035530 of\IN\1740 the\DT\1740 cytopenias\NNS\14189204 and\CC\1740 occurred\VBD\2623529 in\IN\13603305 approximately\RB\1740 50\CD\13745420 %\NN\1740 of\IN\1740 dogs\NNS\2083346 receiving\VBG\2210855 400\CD\1740 -\SYM\1740 500\CD\13745420 mg/kg\NN\1740 <e1>cefonicid</e1>\NN\1740 or\CC\3541091 540\CD\1740 -\SYM\1740 840\CD\1740 mg/kg\NN\1740 cefazedone\NN\1740 .\.\1740
D015790_D009503 CID In\IN\13603305 four\CD\13741022 subacute\NN\1740 toxicity\NN\13576101 studies\NNS\635850 ,\,\1740 the\DT\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>cefonicid</e1>\NN\1740 or\CC\3541091 cefazedone\NN\1740 to\TO\1740 beagle\VB\1740 dogs\NNS\2083346 caused\VBD\1617192 a\DT\13649268 dose-dependent\JJ\1740 incidence\NN\13821570 of\IN\1740 anemia\NN\14189204 ,\,\1740 <e2>neutropenia</e2>\NN\14196405 ,\,\1740 and\CC\1740 thrombocytopenia\NN\14189204 after\IN\1740 1\CD\13741022 -\SYM\1740 3\CD\13741022 months\NNS\15113229 of\IN\1740 treatment\NN\654885 .\.\1740
D015790_D013921 CID In\IN\13603305 four\CD\13741022 subacute\NN\1740 toxicity\NN\13576101 studies\NNS\635850 ,\,\1740 the\DT\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>cefonicid</e1>\NN\1740 or\CC\3541091 cefazedone\NN\1740 to\TO\1740 beagle\VB\1740 dogs\NNS\2083346 caused\VBD\1617192 a\DT\13649268 dose-dependent\JJ\1740 incidence\NN\13821570 of\IN\1740 anemia\NN\14189204 ,\,\1740 neutropenia\NN\14196405 ,\,\1740 and\CC\1740 <e2>thrombocytopenia</e2>\NN\14189204 after\IN\1740 1\CD\13741022 -\SYM\1740 3\CD\13741022 months\NNS\15113229 of\IN\1740 treatment\NN\654885 .\.\1740
C021341_D064420 NONE In\IN\13603305 four\CD\13741022 subacute\NN\1740 <e2>toxicity</e2>\NN\13576101 studies\NNS\635850 ,\,\1740 the\DT\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 cefonicid\NN\1740 or\CC\3541091 <e1>cefazedone</e1>\NN\1740 to\TO\1740 beagle\VB\1740 dogs\NNS\2083346 caused\VBD\1617192 a\DT\13649268 dose-dependent\JJ\1740 incidence\NN\13821570 of\IN\1740 anemia\NN\14189204 ,\,\1740 neutropenia\NN\14196405 ,\,\1740 and\CC\1740 thrombocytopenia\NN\14189204 after\IN\1740 1\CD\13741022 -\SYM\1740 3\CD\13741022 months\NNS\15113229 of\IN\1740 treatment\NN\654885 .\.\1740
C021341_D000740 CID In\IN\13603305 four\CD\13741022 subacute\NN\1740 toxicity\NN\13576101 studies\NNS\635850 ,\,\1740 the\DT\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 cefonicid\NN\1740 or\CC\3541091 <e1>cefazedone</e1>\NN\1740 to\TO\1740 beagle\VB\1740 dogs\NNS\2083346 caused\VBD\1617192 a\DT\13649268 dose-dependent\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>anemia</e2>\NN\14189204 ,\,\1740 neutropenia\NN\14196405 ,\,\1740 and\CC\1740 thrombocytopenia\NN\14189204 after\IN\1740 1\CD\13741022 -\SYM\1740 3\CD\13741022 months\NNS\15113229 of\IN\1740 treatment\NN\654885 .\.\1740
C021341_D000740 CID A\DT\13649268 nonregenerative\JJ\1740 <e2>anemia</e2>\NN\14189204 was\VBD\836236 the\DT\1740 most\RBS\1740 compromising\VBG\1035530 of\IN\1740 the\DT\1740 cytopenias\NNS\14189204 and\CC\1740 occurred\VBD\2623529 in\IN\13603305 approximately\RB\1740 50\CD\13745420 %\NN\1740 of\IN\1740 dogs\NNS\2083346 receiving\VBG\2210855 400\CD\1740 -\SYM\1740 500\CD\13745420 mg/kg\NN\1740 cefonicid\NN\1740 or\CC\3541091 540\CD\1740 -\SYM\1740 840\CD\1740 mg/kg\NN\1740 <e1>cefazedone</e1>\NN\1740 .\.\1740
C021341_D009503 CID In\IN\13603305 four\CD\13741022 subacute\NN\1740 toxicity\NN\13576101 studies\NNS\635850 ,\,\1740 the\DT\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 cefonicid\NN\1740 or\CC\3541091 <e1>cefazedone</e1>\NN\1740 to\TO\1740 beagle\VB\1740 dogs\NNS\2083346 caused\VBD\1617192 a\DT\13649268 dose-dependent\JJ\1740 incidence\NN\13821570 of\IN\1740 anemia\NN\14189204 ,\,\1740 <e2>neutropenia</e2>\NN\14196405 ,\,\1740 and\CC\1740 thrombocytopenia\NN\14189204 after\IN\1740 1\CD\13741022 -\SYM\1740 3\CD\13741022 months\NNS\15113229 of\IN\1740 treatment\NN\654885 .\.\1740
C021341_D013921 CID In\IN\13603305 four\CD\13741022 subacute\NN\1740 toxicity\NN\13576101 studies\NNS\635850 ,\,\1740 the\DT\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 cefonicid\NN\1740 or\CC\3541091 <e1>cefazedone</e1>\NN\1740 to\TO\1740 beagle\VB\1740 dogs\NNS\2083346 caused\VBD\1617192 a\DT\13649268 dose-dependent\JJ\1740 incidence\NN\13821570 of\IN\1740 anemia\NN\14189204 ,\,\1740 neutropenia\NN\14196405 ,\,\1740 and\CC\1740 <e2>thrombocytopenia</e2>\NN\14189204 after\IN\1740 1\CD\13741022 -\SYM\1740 3\CD\13741022 months\NNS\15113229 of\IN\1740 treatment\NN\654885 .\.\1740
14698717
D010672_D011605 NONE <e2>Acute\JJ\1740 psychosis</e2>\NN\14380140 due\IN\5174653 to\TO\1740 treatment\NN\654885 with\IN\1740 <e1>phenytoin</e1>\NN\3550533 in\IN\13603305 a\DT\13649268 nonepileptic\JJ\1740 patient\NN\9898892 .\.\1740
D010672_D011605 NONE The\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 nonepileptic\JJ\1740 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 <e2>psychosis</e2>\NN\14380140 following\VBG\1835496 <e1>phenytoin</e1>\NN\3550533 treatment\NN\654885 for\IN\1740 trigeminal\JJ\1740 neuralgia\NN\14322699 is\VBZ\836236 described\VBN\1001294 .\.\1740
D010672_D011605 NONE This\DT\1740 case\NN\7283608 suggests\VBZ\1010118 that\IN\1740 the\DT\1740 <e2>psychotic\JJ\1740 symptoms</e2>\NNS\5823932 that\WDT\1740 occur\VBP\2623529 following\VBG\1835496 <e1>phenytoin</e1>\NN\3550533 treatment\NN\654885 in\IN\13603305 some\DT\1740 epileptic\JJ\1740 patients\NNS\9898892 may\MD\15209706 be\VB\836236 the\DT\1740 direct\JJ\1740 result\NN\34213 of\IN\1740 medication\NN\3247620 ,\,\1740 unrelated\JJ\1740 to\IN\1740 seizures\NNS\14081375 .\.\1740
D010672_D014277 NONE The\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 nonepileptic\JJ\1740 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 psychosis\NN\14380140 following\VBG\1835496 <e1>phenytoin</e1>\NN\3550533 treatment\NN\654885 for\IN\1740 <e2>trigeminal\JJ\1740 neuralgia</e2>\NN\14322699 is\VBZ\836236 described\VBN\1001294 .\.\1740
D010672_D004827 NONE This\DT\1740 case\NN\7283608 suggests\VBZ\1010118 that\IN\1740 the\DT\1740 psychotic\JJ\1740 symptoms\NNS\5823932 that\WDT\1740 occur\VBP\2623529 following\VBG\1835496 <e1>phenytoin</e1>\NN\3550533 treatment\NN\654885 in\IN\13603305 some\DT\1740 <e2>epileptic</e2>\JJ\1740 patients\NNS\9898892 may\MD\15209706 be\VB\836236 the\DT\1740 direct\JJ\1740 result\NN\34213 of\IN\1740 medication\NN\3247620 ,\,\1740 unrelated\JJ\1740 to\IN\1740 seizures\NNS\14081375 .\.\1740
D010672_D012640 NONE This\DT\1740 case\NN\7283608 suggests\VBZ\1010118 that\IN\1740 the\DT\1740 psychotic\JJ\1740 symptoms\NNS\5823932 that\WDT\1740 occur\VBP\2623529 following\VBG\1835496 <e1>phenytoin</e1>\NN\3550533 treatment\NN\654885 in\IN\13603305 some\DT\1740 epileptic\JJ\1740 patients\NNS\9898892 may\MD\15209706 be\VB\836236 the\DT\1740 direct\JJ\1740 result\NN\34213 of\IN\1740 medication\NN\3247620 ,\,\1740 unrelated\JJ\1740 to\IN\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
17931375
D006493_D003288 CID A\DT\13649268 study\NN\635850 on\IN\1740 the\DT\1740 effect\NN\34213 of\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 subcutaneous\JJ\1740 <e1>heparin</e1>\NN\2718259 injection\NN\320852 on\IN\1740 <e2>bruising</e2>\NN\1740 and\CC\1740 pain\NN\14299637 .\.\1740
D006493_D003288 CID AIM\NN\5980875 :\:\1740 This\DT\1740 study\NN\635850 was\VBD\836236 carried\VBN\1850315 out\RP\1740 to\TO\1740 determine\VB\1645601 the\DT\1740 effect\NN\34213 of\IN\1740 injection\NN\320852 duration\NN\15113229 on\IN\1740 <e2>bruising</e2>\NN\1740 and\CC\1740 pain\NN\14299637 following\VBG\1835496 the\DT\1740 administration\NN\1133281 of\IN\1740 the\DT\1740 subcutaneous\JJ\1740 injection\NN\320852 of\IN\1740 <e1>heparin</e1>\NN\2718259 .\.\1740
D006493_D003288 CID BACKGROUND\NN\4921011 :\:\1740 Although\IN\1740 different\JJ\1740 methods\NNS\5616786 to\TO\1740 prevent\VB\1740 <e2>bruising</e2>\NN\1740 and\CC\1740 pain\NN\14299637 following\VBG\1835496 the\DT\1740 subcutaneous\JJ\1740 injection\NN\320852 of\IN\1740 <e1>heparin</e1>\NN\2718259 have\VBP\2108377 been\VBN\836236 widely\RB\1740 studied\VBN\630380 and\CC\1740 described\VBN\1001294 ,\,\1740 the\DT\1740 effect\NN\34213 of\IN\1740 injection\NN\320852 duration\NN\15113229 on\IN\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 bruising\NN\1740 and\CC\1740 pain\NN\14299637 is\VBZ\836236 little\RB\1740 documented\VBN\1000214 .\.\1740
D006493_D003288 CID BACKGROUND\NN\4921011 :\:\1740 Although\IN\1740 different\JJ\1740 methods\NNS\5616786 to\TO\1740 prevent\VB\1740 bruising\NN\1740 and\CC\1740 pain\NN\14299637 following\VBG\1835496 the\DT\1740 subcutaneous\JJ\1740 injection\NN\320852 of\IN\1740 <e1>heparin</e1>\NN\2718259 have\VBP\2108377 been\VBN\836236 widely\RB\1740 studied\VBN\630380 and\CC\1740 described\VBN\1001294 ,\,\1740 the\DT\1740 effect\NN\34213 of\IN\1740 injection\NN\320852 duration\NN\15113229 on\IN\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 <e2>bruising</e2>\NN\1740 and\CC\1740 pain\NN\14299637 is\VBZ\836236 little\RB\1740 documented\VBN\1000214 .\.\1740
D006493_D003288 CID Dimensions\NNS\5090441 of\IN\1740 the\DT\1740 <e2>bruising</e2>\NN\1740 on\IN\1740 the\DT\1740 <e1>heparin</e1>\NN\2718259 applied\JJ\1740 areas\NNS\8630985 were\VBD\836236 measured\VBN\697589 using\VBG\1156834 transparent\JJ\1740 millimetric\JJ\1740 measuring\NN\407535 paper\NN\14580897 .\.\1740
D006493_D003288 CID CONCLUSIONS\NNS\5837957 :\:\1740 It\PRP\6125041 was\VBD\836236 determined\VBN\1645601 that\IN\1740 injection\NN\320852 duration\NN\15113229 had\VBD\2108377 an\DT\6697703 effect\NN\34213 on\IN\1740 <e2>bruising</e2>\NN\1740 and\CC\1740 pain\NN\14299637 following\VBG\1835496 the\DT\1740 subcutaneous\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>heparin</e1>\NN\2718259 .\.\1740
D006493_D010146 CID A\DT\13649268 study\NN\635850 on\IN\1740 the\DT\1740 effect\NN\34213 of\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 subcutaneous\JJ\1740 <e1>heparin</e1>\NN\2718259 injection\NN\320852 on\IN\1740 bruising\NN\1740 and\CC\1740 <e2>pain</e2>\NN\14299637 .\.\1740
D006493_D010146 CID AIM\NN\5980875 :\:\1740 This\DT\1740 study\NN\635850 was\VBD\836236 carried\VBN\1850315 out\RP\1740 to\TO\1740 determine\VB\1645601 the\DT\1740 effect\NN\34213 of\IN\1740 injection\NN\320852 duration\NN\15113229 on\IN\1740 bruising\NN\1740 and\CC\1740 <e2>pain</e2>\NN\14299637 following\VBG\1835496 the\DT\1740 administration\NN\1133281 of\IN\1740 the\DT\1740 subcutaneous\JJ\1740 injection\NN\320852 of\IN\1740 <e1>heparin</e1>\NN\2718259 .\.\1740
D006493_D010146 CID BACKGROUND\NN\4921011 :\:\1740 Although\IN\1740 different\JJ\1740 methods\NNS\5616786 to\TO\1740 prevent\VB\1740 bruising\NN\1740 and\CC\1740 <e2>pain</e2>\NN\14299637 following\VBG\1835496 the\DT\1740 subcutaneous\JJ\1740 injection\NN\320852 of\IN\1740 <e1>heparin</e1>\NN\2718259 have\VBP\2108377 been\VBN\836236 widely\RB\1740 studied\VBN\630380 and\CC\1740 described\VBN\1001294 ,\,\1740 the\DT\1740 effect\NN\34213 of\IN\1740 injection\NN\320852 duration\NN\15113229 on\IN\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 bruising\NN\1740 and\CC\1740 pain\NN\14299637 is\VBZ\836236 little\RB\1740 documented\VBN\1000214 .\.\1740
D006493_D010146 CID BACKGROUND\NN\4921011 :\:\1740 Although\IN\1740 different\JJ\1740 methods\NNS\5616786 to\TO\1740 prevent\VB\1740 bruising\NN\1740 and\CC\1740 pain\NN\14299637 following\VBG\1835496 the\DT\1740 subcutaneous\JJ\1740 injection\NN\320852 of\IN\1740 <e1>heparin</e1>\NN\2718259 have\VBP\2108377 been\VBN\836236 widely\RB\1740 studied\VBN\630380 and\CC\1740 described\VBN\1001294 ,\,\1740 the\DT\1740 effect\NN\34213 of\IN\1740 injection\NN\320852 duration\NN\15113229 on\IN\1740 the\DT\1740 occurrence\NN\29378 of\IN\1740 bruising\NN\1740 and\CC\1740 <e2>pain</e2>\NN\14299637 is\VBZ\836236 little\RB\1740 documented\VBN\1000214 .\.\1740
D006493_D010146 CID CONCLUSIONS\NNS\5837957 :\:\1740 It\PRP\6125041 was\VBD\836236 determined\VBN\1645601 that\IN\1740 injection\NN\320852 duration\NN\15113229 had\VBD\2108377 an\DT\6697703 effect\NN\34213 on\IN\1740 bruising\NN\1740 and\CC\1740 <e2>pain</e2>\NN\14299637 following\VBG\1835496 the\DT\1740 subcutaneous\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>heparin</e1>\NN\2718259 .\.\1740
2696505
D007741_D007022 CID A\DT\13649268 randomized\JJ\1740 comparison\NN\635850 of\IN\1740 <e1>labetalol</e1>\NN\2721160 and\CC\1740 nitroprusside\NN\1740 for\IN\1740 induced\VBN\1627355 <e2>hypotension</e2>\NN\14057371 .\.\1740
D007741_D007022 CID In\IN\13603305 a\DT\13649268 randomized\JJ\1740 study\NN\635850 ,\,\1740 <e1>labetalol-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 nitroprusside-induced\JJ\1740 hypotension\NN\14057371 were\VBD\836236 compared\VBN\644583 in\IN\13603305 20\CD\13745420 patients\NNS\9898892 (\-LRB-\1740 10\CD\13745420 in\IN\13603305 each\DT\1740 group\NN\2137 )\-RRB-\1740 scheduled\VBN\704690 for\IN\1740 major\JJ\1740 orthopedic\JJ\1740 procedures\NNS\407535 .\.\1740
D007741_D007022 CID In\IN\13603305 a\DT\13649268 randomized\JJ\1740 study\NN\635850 ,\,\1740 <e1>labetalol-induced</e1>\JJ\1740 hypotension\NN\14057371 and\CC\1740 nitroprusside-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 were\VBD\836236 compared\VBN\644583 in\IN\13603305 20\CD\13745420 patients\NNS\9898892 (\-LRB-\1740 10\CD\13745420 in\IN\13603305 each\DT\1740 group\NN\2137 )\-RRB-\1740 scheduled\VBN\704690 for\IN\1740 major\JJ\1740 orthopedic\JJ\1740 procedures\NNS\407535 .\.\1740
D009599_D007022 CID A\DT\13649268 randomized\JJ\1740 comparison\NN\635850 of\IN\1740 labetalol\NN\2721160 and\CC\1740 <e1>nitroprusside</e1>\NN\1740 for\IN\1740 induced\VBN\1627355 <e2>hypotension</e2>\NN\14057371 .\.\1740
D009599_D007022 CID In\IN\13603305 a\DT\13649268 randomized\JJ\1740 study\NN\635850 ,\,\1740 labetalol-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 <e1>nitroprusside-induced</e1>\JJ\1740 hypotension\NN\14057371 were\VBD\836236 compared\VBN\644583 in\IN\13603305 20\CD\13745420 patients\NNS\9898892 (\-LRB-\1740 10\CD\13745420 in\IN\13603305 each\DT\1740 group\NN\2137 )\-RRB-\1740 scheduled\VBN\704690 for\IN\1740 major\JJ\1740 orthopedic\JJ\1740 procedures\NNS\407535 .\.\1740
D009599_D007022 CID In\IN\13603305 a\DT\13649268 randomized\JJ\1740 study\NN\635850 ,\,\1740 labetalol-induced\JJ\1740 hypotension\NN\14057371 and\CC\1740 <e1>nitroprusside-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 were\VBD\836236 compared\VBN\644583 in\IN\13603305 20\CD\13745420 patients\NNS\9898892 (\-LRB-\1740 10\CD\13745420 in\IN\13603305 each\DT\1740 group\NN\2137 )\-RRB-\1740 scheduled\VBN\704690 for\IN\1740 major\JJ\1740 orthopedic\JJ\1740 procedures\NNS\407535 .\.\1740
D009599_D016534 CID Nitroprusside\NN\1740 infusion\NN\14589223 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significant\JJ\1740 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 <e2>increase\NN\13576355 in\IN\13603305 heart\NN\5919034 rate\NN\13815152 and\CC\1740 cardiac\JJ\1740 output</e2>\NN\4007894 ;\:\1740 rebound\NN\7309781 hypertension\NN\14057371 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 three\CD\13741022 patients\NNS\9898892 after\IN\1740 discontinuation\NN\209943 of\IN\1740 <e1>nitroprusside</e1>\NN\1740 .\.\1740
D009599_D006973 NONE Nitroprusside\NN\1740 infusion\NN\14589223 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significant\JJ\1740 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 increase\NN\13576355 in\IN\13603305 heart\NN\5919034 rate\NN\13815152 and\CC\1740 cardiac\JJ\1740 output\NN\4007894 ;\:\1740 rebound\NN\7309781 <e2>hypertension</e2>\NN\14057371 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 three\CD\13741022 patients\NNS\9898892 after\IN\1740 discontinuation\NN\209943 of\IN\1740 <e1>nitroprusside</e1>\NN\1740 .\.\1740
10579464
C121249_D006948 NONE <e1>NRA0160</e1>\NN\1740 and\CC\1740 clozapine\NN\3713736 antagonized\JJ\1740 locomotor\NN\1740 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 methamphetamine\NN\2704153 (\-LRB-\1740 MAP\NN\4076846 )\-RRB-\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D003024_D006948 NONE NRA0160\NN\1740 and\CC\1740 <e1>clozapine</e1>\NN\3713736 antagonized\JJ\1740 locomotor\NN\1740 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 methamphetamine\NN\2704153 (\-LRB-\1740 MAP\NN\4076846 )\-RRB-\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D008694_D006948 CID NRA0160\NN\1740 and\CC\1740 clozapine\NN\3713736 antagonized\JJ\1740 locomotor\NN\1740 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 <e1>methamphetamine</e1>\NN\2704153 (\-LRB-\1740 MAP\NN\4076846 )\-RRB-\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D008694_D006948 CID NRA0160\NN\1740 and\CC\1740 clozapine\NN\3713736 antagonized\JJ\1740 locomotor\NN\1740 <e2>hyperactivity</e2>\NN\14052403 induced\VBN\1627355 by\IN\1740 methamphetamine\NN\2704153 (\-LRB-\1740 <e1>MAP</e1>\NN\4076846 )\-RRB-\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
C121249_D002375 CID <e1>NRA0160</e1>\NN\1740 and\CC\1740 clozapine\NN\3713736 significantly\RB\1740 induced\VBD\1627355 <e2>catalepsy</e2>\NN\14023236 in\IN\13603305 rats\NNS\2329401 ,\,\1740 although\IN\1740 their\PRP$\1740 effects\NNS\13245626 did\VBD\1640855 not\RB\1740 exceed\VB\2673965 50\CD\13745420 %\NN\1740 induction\NN\7450842 even\RB\1740 at\IN\14622893 the\DT\1740 highest\JJS\1740 dose\NN\3740161 given\VBN\2327200 .\.\1740
D003024_D002375 CID NRA0160\NN\1740 and\CC\1740 <e1>clozapine</e1>\NN\3713736 significantly\RB\1740 induced\VBD\1627355 <e2>catalepsy</e2>\NN\14023236 in\IN\13603305 rats\NNS\2329401 ,\,\1740 although\IN\1740 their\PRP$\1740 effects\NNS\13245626 did\VBD\1640855 not\RB\1740 exceed\VB\2673965 50\CD\13745420 %\NN\1740 induction\NN\7450842 even\RB\1740 at\IN\14622893 the\DT\1740 highest\JJS\1740 dose\NN\3740161 given\VBN\2327200 .\.\1740
19356307
D012601_D003704 NONE Components\NNS\5867413 of\IN\1740 lemon\JJ\1740 essential\JJ\1740 oil\NN\14938907 attenuate\NN\1740 <e2>dementia</e2>\NN\14395018 induced\VBN\1627355 by\IN\1740 <e1>scopolamine</e1>\NN\14712692 .\.\1740
C008281_D003704 NONE The\DT\1740 <e2>anti-dementia</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>s-limonene</e1>\NN\1740 and\CC\1740 s-perillyl\JJ\1740 alcohol\NN\7881800 were\VBD\836236 observed\VBN\2163746 using\VBG\1156834 the\DT\1740 passive\JJ\1740 avoidance\NN\203342 test\NN\5798043 (\-LRB-\1740 PA\NN\10080869 )\-RRB-\1740 and\CC\1740 the\DT\1740 open\JJ\1740 field\NN\8673395 habituation\NN\14034177 test\NN\5798043 (\-LRB-\1740 OFH\NN\1740 )\-RRB-\1740 .\.\1740
C032208_D003704 NONE The\DT\1740 <e2>anti-dementia</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 s-limonene\NN\1740 and\CC\1740 <e1>s-perillyl\JJ\1740 alcohol</e1>\NN\7881800 were\VBD\836236 observed\VBN\2163746 using\VBG\1156834 the\DT\1740 passive\JJ\1740 avoidance\NN\203342 test\NN\5798043 (\-LRB-\1740 PA\NN\10080869 )\-RRB-\1740 and\CC\1740 the\DT\1740 open\JJ\1740 field\NN\8673395 habituation\NN\14034177 test\NN\5798043 (\-LRB-\1740 OFH\NN\1740 )\-RRB-\1740 .\.\1740
D012601_D008569 CID These\DT\1740 lemon\JJ\1740 essential\JJ\1740 oils\NNS\14938907 showed\VBD\2137132 strong\JJ\1740 ability\NN\4723816 to\TO\1740 improve\VB\126264 <e2>memory\NN\5926676 impaired</e2>\VBN\258857 by\IN\1740 <e1>scopolamine</e1>\NN\14712692 ;\:\1740 however\RB\1740 ,\,\1740 s-perillyl\NN\1740 alcohol\NN\7881800 relieved\VBD\205885 the\DT\1740 deficit\NN\5113133 of\IN\1740 associative\JJ\1740 memory\NN\5926676 in\IN\13603305 PA\NN\10080869 only\RB\1740 ,\,\1740 and\CC\1740 did\VBD\1640855 not\RB\1740 improve\VB\126264 non-associative\JJ\1740 memory\NN\5926676 significantly\RB\1740 in\IN\13603305 OFH\NN\1740 .\.\1740
D012601_D008569 CID These\DT\1740 lemon\JJ\1740 essential\JJ\1740 oils\NNS\14938907 showed\VBD\2137132 strong\JJ\1740 ability\NN\4723816 to\TO\1740 improve\VB\126264 memory\NN\5926676 impaired\VBN\258857 by\IN\1740 <e1>scopolamine</e1>\NN\14712692 ;\:\1740 however\RB\1740 ,\,\1740 s-perillyl\NN\1740 alcohol\NN\7881800 relieved\VBD\205885 the\DT\1740 <e2>deficit\NN\5113133 of\IN\1740 associative\JJ\1740 memory</e2>\NN\5926676 in\IN\13603305 PA\NN\10080869 only\RB\1740 ,\,\1740 and\CC\1740 did\VBD\1640855 not\RB\1740 improve\VB\126264 non-associative\JJ\1740 memory\NN\5926676 significantly\RB\1740 in\IN\13603305 OFH\NN\1740 .\.\1740
C032208_D008569 NONE These\DT\1740 lemon\JJ\1740 essential\JJ\1740 oils\NNS\14938907 showed\VBD\2137132 strong\JJ\1740 ability\NN\4723816 to\TO\1740 improve\VB\126264 <e2>memory\NN\5926676 impaired</e2>\VBN\258857 by\IN\1740 scopolamine\NN\14712692 ;\:\1740 however\RB\1740 ,\,\1740 <e1>s-perillyl\NN\1740 alcohol</e1>\NN\7881800 relieved\VBD\205885 the\DT\1740 deficit\NN\5113133 of\IN\1740 associative\JJ\1740 memory\NN\5926676 in\IN\13603305 PA\NN\10080869 only\RB\1740 ,\,\1740 and\CC\1740 did\VBD\1640855 not\RB\1740 improve\VB\126264 non-associative\JJ\1740 memory\NN\5926676 significantly\RB\1740 in\IN\13603305 OFH\NN\1740 .\.\1740
C032208_D008569 NONE These\DT\1740 lemon\JJ\1740 essential\JJ\1740 oils\NNS\14938907 showed\VBD\2137132 strong\JJ\1740 ability\NN\4723816 to\TO\1740 improve\VB\126264 memory\NN\5926676 impaired\VBN\258857 by\IN\1740 scopolamine\NN\14712692 ;\:\1740 however\RB\1740 ,\,\1740 <e1>s-perillyl\NN\1740 alcohol</e1>\NN\7881800 relieved\VBD\205885 the\DT\1740 <e2>deficit\NN\5113133 of\IN\1740 associative\JJ\1740 memory</e2>\NN\5926676 in\IN\13603305 PA\NN\10080869 only\RB\1740 ,\,\1740 and\CC\1740 did\VBD\1640855 not\RB\1740 improve\VB\126264 non-associative\JJ\1740 memory\NN\5926676 significantly\RB\1740 in\IN\13603305 OFH\NN\1740 .\.\1740
2273650
D012601_D000647 CID <e2>Amnesia</e2>\NNP\5669934 produced\VBN\1617192 by\IN\1740 <e1>scopolamine</e1>\NN\14712692 and\CC\1740 cycloheximide\NN\1740 were\VBD\836236 reversed\VBN\109660 by\IN\1740 morphine\NN\2707683 given\VBN\2327200 30\CD\13745420 min\NN\15154774 before\IN\1740 the\DT\1740 test\NN\5798043 trial\NN\786195 (\-LRB-\1740 pre-test\JJ\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 pre-test\JJ\1740 morphine\NN\2707683 also\RB\1740 facilitated\VBD\2547586 the\DT\1740 memory\NN\5926676 retrieval\NN\13450862 in\IN\13603305 the\DT\1740 animals\NNS\4475 administered\VBN\2436349 naloxone\NN\3808977 during\IN\1740 the\DT\1740 training\NN\407535 trial\NN\786195 .\.\1740
D012601_D000647 CID Similarly\RB\1740 ,\,\1740 pre-test\JJ\1740 <e1>scopolamine</e1>\NN\14712692 partially\RB\1740 reversed\VBD\109660 the\DT\1740 scopolamine-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 ,\,\1740 but\CC\1740 not\RB\1740 significantly\RB\1740 ;\:\1740 and\CC\1740 pre-test\JJ\1740 cycloheximide\NN\1740 failed\VBD\1798936 to\TO\1740 reverse\VB\109660 the\DT\1740 cycloheximide-induced\JJ\1740 amnesia\NN\5669934 .\.\1740
D012601_D000647 CID Similarly\RB\1740 ,\,\1740 pre-test\JJ\1740 <e1>scopolamine</e1>\NN\14712692 partially\RB\1740 reversed\VBD\109660 the\DT\1740 scopolamine-induced\JJ\1740 amnesia\NN\5669934 ,\,\1740 but\CC\1740 not\RB\1740 significantly\RB\1740 ;\:\1740 and\CC\1740 pre-test\JJ\1740 cycloheximide\NN\1740 failed\VBD\1798936 to\TO\1740 reverse\VB\109660 the\DT\1740 cycloheximide-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 .\.\1740
D012601_D000647 CID Similarly\RB\1740 ,\,\1740 pre-test\JJ\1740 scopolamine\NN\14712692 partially\RB\1740 reversed\VBD\109660 the\DT\1740 <e1>scopolamine-induced</e1>\JJ\1740 <e2>amnesia</e2>\NN\5669934 ,\,\1740 but\CC\1740 not\RB\1740 significantly\RB\1740 ;\:\1740 and\CC\1740 pre-test\JJ\1740 cycloheximide\NN\1740 failed\VBD\1798936 to\TO\1740 reverse\VB\109660 the\DT\1740 cycloheximide-induced\JJ\1740 amnesia\NN\5669934 .\.\1740
D012601_D000647 CID Similarly\RB\1740 ,\,\1740 pre-test\JJ\1740 scopolamine\NN\14712692 partially\RB\1740 reversed\VBD\109660 the\DT\1740 <e1>scopolamine-induced</e1>\JJ\1740 amnesia\NN\5669934 ,\,\1740 but\CC\1740 not\RB\1740 significantly\RB\1740 ;\:\1740 and\CC\1740 pre-test\JJ\1740 cycloheximide\NN\1740 failed\VBD\1798936 to\TO\1740 reverse\VB\109660 the\DT\1740 cycloheximide-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 .\.\1740
D003513_D000647 CID <e2>Amnesia</e2>\NNP\5669934 produced\VBN\1617192 by\IN\1740 scopolamine\NN\14712692 and\CC\1740 <e1>cycloheximide</e1>\NN\1740 were\VBD\836236 reversed\VBN\109660 by\IN\1740 morphine\NN\2707683 given\VBN\2327200 30\CD\13745420 min\NN\15154774 before\IN\1740 the\DT\1740 test\NN\5798043 trial\NN\786195 (\-LRB-\1740 pre-test\JJ\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 pre-test\JJ\1740 morphine\NN\2707683 also\RB\1740 facilitated\VBD\2547586 the\DT\1740 memory\NN\5926676 retrieval\NN\13450862 in\IN\13603305 the\DT\1740 animals\NNS\4475 administered\VBN\2436349 naloxone\NN\3808977 during\IN\1740 the\DT\1740 training\NN\407535 trial\NN\786195 .\.\1740
D003513_D000647 CID Similarly\RB\1740 ,\,\1740 pre-test\JJ\1740 scopolamine\NN\14712692 partially\RB\1740 reversed\VBD\109660 the\DT\1740 scopolamine-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 ,\,\1740 but\CC\1740 not\RB\1740 significantly\RB\1740 ;\:\1740 and\CC\1740 pre-test\JJ\1740 <e1>cycloheximide</e1>\NN\1740 failed\VBD\1798936 to\TO\1740 reverse\VB\109660 the\DT\1740 cycloheximide-induced\JJ\1740 amnesia\NN\5669934 .\.\1740
D003513_D000647 CID Similarly\RB\1740 ,\,\1740 pre-test\JJ\1740 scopolamine\NN\14712692 partially\RB\1740 reversed\VBD\109660 the\DT\1740 scopolamine-induced\JJ\1740 amnesia\NN\5669934 ,\,\1740 but\CC\1740 not\RB\1740 significantly\RB\1740 ;\:\1740 and\CC\1740 pre-test\JJ\1740 <e1>cycloheximide</e1>\NN\1740 failed\VBD\1798936 to\TO\1740 reverse\VB\109660 the\DT\1740 cycloheximide-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 .\.\1740
D003513_D000647 CID Similarly\RB\1740 ,\,\1740 pre-test\JJ\1740 scopolamine\NN\14712692 partially\RB\1740 reversed\VBD\109660 the\DT\1740 scopolamine-induced\JJ\1740 <e2>amnesia</e2>\NN\5669934 ,\,\1740 but\CC\1740 not\RB\1740 significantly\RB\1740 ;\:\1740 and\CC\1740 pre-test\JJ\1740 cycloheximide\NN\1740 failed\VBD\1798936 to\TO\1740 reverse\VB\109660 the\DT\1740 <e1>cycloheximide-induced</e1>\JJ\1740 amnesia\NN\5669934 .\.\1740
D003513_D000647 CID Similarly\RB\1740 ,\,\1740 pre-test\JJ\1740 scopolamine\NN\14712692 partially\RB\1740 reversed\VBD\109660 the\DT\1740 scopolamine-induced\JJ\1740 amnesia\NN\5669934 ,\,\1740 but\CC\1740 not\RB\1740 significantly\RB\1740 ;\:\1740 and\CC\1740 pre-test\JJ\1740 cycloheximide\NN\1740 failed\VBD\1798936 to\TO\1740 reverse\VB\109660 the\DT\1740 <e1>cycloheximide-induced</e1>\JJ\1740 <e2>amnesia</e2>\NN\5669934 .\.\1740
D009020_D000647 NONE <e2>Amnesia</e2>\NNP\5669934 produced\VBN\1617192 by\IN\1740 scopolamine\NN\14712692 and\CC\1740 cycloheximide\NN\1740 were\VBD\836236 reversed\VBN\109660 by\IN\1740 <e1>morphine</e1>\NN\2707683 given\VBN\2327200 30\CD\13745420 min\NN\15154774 before\IN\1740 the\DT\1740 test\NN\5798043 trial\NN\786195 (\-LRB-\1740 pre-test\JJ\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 pre-test\JJ\1740 morphine\NN\2707683 also\RB\1740 facilitated\VBD\2547586 the\DT\1740 memory\NN\5926676 retrieval\NN\13450862 in\IN\13603305 the\DT\1740 animals\NNS\4475 administered\VBN\2436349 naloxone\NN\3808977 during\IN\1740 the\DT\1740 training\NN\407535 trial\NN\786195 .\.\1740
D009020_D000647 NONE <e2>Amnesia</e2>\NNP\5669934 produced\VBN\1617192 by\IN\1740 scopolamine\NN\14712692 and\CC\1740 cycloheximide\NN\1740 were\VBD\836236 reversed\VBN\109660 by\IN\1740 morphine\NN\2707683 given\VBN\2327200 30\CD\13745420 min\NN\15154774 before\IN\1740 the\DT\1740 test\NN\5798043 trial\NN\786195 (\-LRB-\1740 pre-test\JJ\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 pre-test\JJ\1740 <e1>morphine</e1>\NN\2707683 also\RB\1740 facilitated\VBD\2547586 the\DT\1740 memory\NN\5926676 retrieval\NN\13450862 in\IN\13603305 the\DT\1740 animals\NNS\4475 administered\VBN\2436349 naloxone\NN\3808977 during\IN\1740 the\DT\1740 training\NN\407535 trial\NN\786195 .\.\1740
D009270_D000647 NONE <e2>Amnesia</e2>\NNP\5669934 produced\VBN\1617192 by\IN\1740 scopolamine\NN\14712692 and\CC\1740 cycloheximide\NN\1740 were\VBD\836236 reversed\VBN\109660 by\IN\1740 morphine\NN\2707683 given\VBN\2327200 30\CD\13745420 min\NN\15154774 before\IN\1740 the\DT\1740 test\NN\5798043 trial\NN\786195 (\-LRB-\1740 pre-test\JJ\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 pre-test\JJ\1740 morphine\NN\2707683 also\RB\1740 facilitated\VBD\2547586 the\DT\1740 memory\NN\5926676 retrieval\NN\13450862 in\IN\13603305 the\DT\1740 animals\NNS\4475 administered\VBN\2436349 <e1>naloxone</e1>\NN\3808977 during\IN\1740 the\DT\1740 training\NN\407535 trial\NN\786195 .\.\1740
18217897
D013792_D008228 NONE <e1>Thalidomide</e1>\NN\4166841 has\VBZ\2108377 limited\VBN\2510337 single-agent\JJ\1740 activity\NN\30358 in\IN\13603305 relapsed\JJ\1740 or\CC\3541091 refractory\JJ\1740 indolent\JJ\1740 <e2>non-Hodgkin\JJ\1740 lymphomas</e2>\NNS\14239918 :\:\1740 a\DT\13649268 phase\NN\15113229 II\CD\13741022 trial\NN\786195 of\IN\1740 the\DT\1740 Cancer\NN\14239425 and\CC\1740 Leukemia\NNP\14239918 Group\NNP\2137 B.\NNP\1740
D013792_D009369 NONE <e1>Thalidomide</e1>\NN\4166841 has\VBZ\2108377 limited\VBN\2510337 single-agent\JJ\1740 activity\NN\30358 in\IN\13603305 relapsed\JJ\1740 or\CC\3541091 refractory\JJ\1740 indolent\JJ\1740 non-Hodgkin\JJ\1740 lymphomas\NNS\14239918 :\:\1740 a\DT\13649268 phase\NN\15113229 II\CD\13741022 trial\NN\786195 of\IN\1740 the\DT\1740 <e2>Cancer</e2>\NN\14239425 and\CC\1740 Leukemia\NNP\14239918 Group\NNP\2137 B.\NNP\1740
D013792_D007938 NONE <e1>Thalidomide</e1>\NN\4166841 has\VBZ\2108377 limited\VBN\2510337 single-agent\JJ\1740 activity\NN\30358 in\IN\13603305 relapsed\JJ\1740 or\CC\3541091 refractory\JJ\1740 indolent\JJ\1740 non-Hodgkin\JJ\1740 lymphomas\NNS\14239918 :\:\1740 a\DT\13649268 phase\NN\15113229 II\CD\13741022 trial\NN\786195 of\IN\1740 the\DT\1740 Cancer\NN\14239425 and\CC\1740 <e2>Leukemia</e2>\NNP\14239918 Group\NNP\2137 B.\NNP\1740
D013792_D009101 NONE <e1>Thalidomide</e1>\NN\4166841 is\VBZ\836236 an\DT\6697703 immunomodulatory\JJ\1740 agent\NN\7347 with\IN\1740 demonstrated\VBN\2137132 activity\NN\30358 in\IN\13603305 <e2>multiple\JJ\1740 myeloma</e2>\NN\14239425 ,\,\1740 mantle\NN\6806469 cell\NN\3080309 lymphoma\NN\14239918 and\CC\1740 lymphoplasmacytic\JJ\1740 lymphoma\NN\14239918 .\.\1740
D013792_D020522 NONE <e1>Thalidomide</e1>\NN\4166841 is\VBZ\836236 an\DT\6697703 immunomodulatory\JJ\1740 agent\NN\7347 with\IN\1740 demonstrated\VBN\2137132 activity\NN\30358 in\IN\13603305 multiple\JJ\1740 myeloma\NN\14239425 ,\,\1740 <e2>mantle\NN\6806469 cell\NN\3080309 lymphoma</e2>\NN\14239918 and\CC\1740 lymphoplasmacytic\JJ\1740 lymphoma\NN\14239918 .\.\1740
D013792_D008223 NONE <e1>Thalidomide</e1>\NN\4166841 is\VBZ\836236 an\DT\6697703 immunomodulatory\JJ\1740 agent\NN\7347 with\IN\1740 demonstrated\VBN\2137132 activity\NN\30358 in\IN\13603305 multiple\JJ\1740 myeloma\NN\14239425 ,\,\1740 mantle\NN\6806469 cell\NN\3080309 lymphoma\NN\14239918 and\CC\1740 <e2>lymphoplasmacytic\JJ\1740 lymphoma</e2>\NN\14239918 .\.\1740
D013792_D008223 NONE Between\IN\1740 July\NNP\15209706 2001\CD\1740 and\CC\1740 April\NNP\15209706 2004\CD\1740 ,\,\1740 24\CD\13745420 patients\NNS\9898892 with\IN\1740 relapsed/refractory\JJ\1740 indolent\JJ\1740 <e2>lymphomas</e2>\NNS\14239918 received\VBD\2210855 <e1>thalidomide</e1>\NN\4166841 200\CD\1740 mg\NN\13717155 daily\RB\1740 with\IN\1740 escalation\NN\363260 by\IN\1740 100\CD\13745420 mg\NN\13717155 daily\RB\1740 every\DT\1740 1\CD\13741022 -\SYM\1740 2\CD\13741022 weeks\NNS\15113229 as\IN\14622893 tolerated\VBN\802318 ,\,\1740 up\RB\1740 to\TO\1740 a\DT\13649268 maximum\NN\13653902 of\IN\1740 800\CD\1740 mg\NN\13717155 daily\RB\1740 .\.\1740
D013792_D008223 NONE Our\PRP$\1740 results\NNS\34213 failed\VBD\1798936 to\TO\1740 demonstrate\VB\2137132 an\DT\6697703 important\JJ\1740 response\NN\11410625 rate\NN\13815152 to\IN\1740 single\JJ\1740 agent\NN\7347 <e1>thalidomide</e1>\NN\4166841 in\IN\13603305 indolent\JJ\1740 <e2>lymphomas</e2>\NNS\14239918 and\CC\1740 contrast\VB\650353 with\IN\1740 the\DT\1740 higher\JJR\1740 activity\NN\30358 level\NN\4916342 reported\VBN\831651 with\IN\1740 the\DT\1740 second\JJ\1740 generation\NN\7942152 immunomodulatory\JJ\1740 agent\NN\7347 ,\,\1740 lenalidomide\NN\1740 .\.\1740
C467567_D008223 NONE Our\PRP$\1740 results\NNS\34213 failed\VBD\1798936 to\TO\1740 demonstrate\VB\2137132 an\DT\6697703 important\JJ\1740 response\NN\11410625 rate\NN\13815152 to\IN\1740 single\JJ\1740 agent\NN\7347 thalidomide\NN\4166841 in\IN\13603305 indolent\JJ\1740 <e2>lymphomas</e2>\NNS\14239918 and\CC\1740 contrast\VB\650353 with\IN\1740 the\DT\1740 higher\JJR\1740 activity\NN\30358 level\NN\4916342 reported\VBN\831651 with\IN\1740 the\DT\1740 second\JJ\1740 generation\NN\7942152 immunomodulatory\JJ\1740 agent\NN\7347 ,\,\1740 <e1>lenalidomide</e1>\NN\1740 .\.\1740
3070035
D002216_D051437 NONE Reversibility\NN\4733640 of\IN\1740 <e1>captopril-induced</e1>\JJ\1740 <e2>renal\JJ\1740 insufficiency</e2>\NN\14462946 after\IN\1740 prolonged\JJ\1740 use\NN\407535 in\IN\13603305 an\DT\6697703 unusual\JJ\1740 case\NN\7283608 of\IN\1740 renovascular\JJ\1740 hypertension\NN\14057371 .\.\1740
D002216_D051437 NONE This\DT\1740 indicates\VBZ\952524 reversibility\NN\4733640 in\IN\13603305 <e1>captopril-induced</e1>\JJ\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 even\RB\1740 after\IN\1740 its\PRP$\6125041 prolonged\JJ\1740 use\NN\407535 and\CC\1740 suggests\VBZ\1010118 that\IN\1740 no\DT\7204911 organic\JJ\1740 damage\NN\7296428 occurs\VBZ\2623529 to\TO\1740 glomerular\JJ\1740 arterioles\NNS\5333777 following\VBG\1835496 chronic\JJ\1740 ACE\NN\13741022 inhibition\NN\1068773 .\.\1740
D002216_D006978 NONE Reversibility\NN\4733640 of\IN\1740 <e1>captopril-induced</e1>\JJ\1740 renal\JJ\1740 insufficiency\NN\14462946 after\IN\1740 prolonged\JJ\1740 use\NN\407535 in\IN\13603305 an\DT\6697703 unusual\JJ\1740 case\NN\7283608 of\IN\1740 <e2>renovascular\JJ\1740 hypertension</e2>\NN\14057371 .\.\1740
D002216_D006973 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 severe\JJ\1740 <e2>hypertension</e2>\NN\14057371 with\IN\1740 an\DT\6697703 occluded\VBN\2451370 renal\JJ\1740 artery\NN\5417975 to\TO\1740 a\DT\13649268 solitary\JJ\1740 kidney\NN\5333259 ,\,\1740 who\WP\8299493 developed\VBD\1753788 sudden\JJ\1740 deterioration\NN\14560612 of\IN\1740 renal\JJ\1740 function\NN\13783581 following\VBG\1835496 treatment\NN\654885 with\IN\1740 <e1>captopril</e1>\NN\2673637 .\.\1740
D002216_D058186 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 severe\JJ\1740 hypertension\NN\14057371 with\IN\1740 an\DT\6697703 occluded\VBN\2451370 renal\JJ\1740 artery\NN\5417975 to\TO\1740 a\DT\13649268 solitary\JJ\1740 kidney\NN\5333259 ,\,\1740 who\WP\8299493 developed\VBD\1753788 <e2>sudden\JJ\1740 deterioration\NN\14560612 of\IN\1740 renal\JJ\1740 function</e2>\NN\13783581 following\VBG\1835496 treatment\NN\654885 with\IN\1740 <e1>captopril</e1>\NN\2673637 .\.\1740
1987816
D008094_D011141 CID <e1>Lithium-induced</e1>\JJ\1740 <e2>polyuria</e2>\NN\14113228 seems\VBZ\2604760 to\TO\1740 be\VB\836236 related\JJ\1740 to\TO\1740 extrarenal\JJ\1740 as\RB\1740 well\RB\1740 as\IN\14622893 to\TO\1740 renal\JJ\1740 effects\NNS\13245626 .\.\1740
4008111
D000638_D012848 CID <e1>Amiodarone-induced</e1>\JJ\1740 <e2>sinoatrial\NN\1740 block</e2>\NN\21939 .\.\1740
D000638_D012848 CID We\PRP\1740 observed\VBD\2163746 <e2>sinoatrial\JJ\1740 block</e2>\NN\21939 due\JJ\1740 to\TO\1740 chronic\JJ\1740 <e1>amiodarone</e1>\NN\2715941 administration\NN\1133281 in\IN\13603305 a\DT\13649268 5-year-old\JJ\1740 boy\NN\9624168 with\IN\1740 primary\JJ\1740 cardiomyopathy\JJ\1740 ,\,\1740 Wolff-Parkinson-White\JJ\1740 syndrome\NN\5870365 and\CC\1740 supraventricular\JJ\1740 tachycardia\NN\14110674 .\.\1740
D000638_D012848 CID Reduction\NN\351485 in\IN\13603305 the\DT\1740 dosage\NN\13576355 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 resulted\VBD\2633881 in\IN\13603305 the\DT\1740 disappearance\NN\42757 of\IN\1740 the\DT\1740 <e2>sinoatrial\JJ\1740 block</e2>\NN\21939 and\CC\1740 the\DT\1740 persistence\NN\5053688 of\IN\1740 asymptomatic\JJ\1740 sinus\NN\5248181 bradycardia\NN\14110674 .\.\1740
D000638_D009202 NONE We\PRP\1740 observed\VBD\2163746 sinoatrial\JJ\1740 block\NN\21939 due\JJ\1740 to\TO\1740 chronic\JJ\1740 <e1>amiodarone</e1>\NN\2715941 administration\NN\1133281 in\IN\13603305 a\DT\13649268 5-year-old\JJ\1740 boy\NN\9624168 with\IN\1740 <e2>primary\JJ\1740 cardiomyopathy</e2>\JJ\1740 ,\,\1740 Wolff-Parkinson-White\JJ\1740 syndrome\NN\5870365 and\CC\1740 supraventricular\JJ\1740 tachycardia\NN\14110674 .\.\1740
D000638_D014927 NONE We\PRP\1740 observed\VBD\2163746 sinoatrial\JJ\1740 block\NN\21939 due\JJ\1740 to\TO\1740 chronic\JJ\1740 <e1>amiodarone</e1>\NN\2715941 administration\NN\1133281 in\IN\13603305 a\DT\13649268 5-year-old\JJ\1740 boy\NN\9624168 with\IN\1740 primary\JJ\1740 cardiomyopathy\JJ\1740 ,\,\1740 <e2>Wolff-Parkinson-White\JJ\1740 syndrome</e2>\NN\5870365 and\CC\1740 supraventricular\JJ\1740 tachycardia\NN\14110674 .\.\1740
D000638_D013617 NONE We\PRP\1740 observed\VBD\2163746 sinoatrial\JJ\1740 block\NN\21939 due\JJ\1740 to\TO\1740 chronic\JJ\1740 <e1>amiodarone</e1>\NN\2715941 administration\NN\1133281 in\IN\13603305 a\DT\13649268 5-year-old\JJ\1740 boy\NN\9624168 with\IN\1740 primary\JJ\1740 cardiomyopathy\JJ\1740 ,\,\1740 Wolff-Parkinson-White\JJ\1740 syndrome\NN\5870365 and\CC\1740 <e2>supraventricular\JJ\1740 tachycardia</e2>\NN\14110674 .\.\1740
D000638_D012804 NONE Reduction\NN\351485 in\IN\13603305 the\DT\1740 dosage\NN\13576355 of\IN\1740 <e1>amiodarone</e1>\NN\2715941 resulted\VBD\2633881 in\IN\13603305 the\DT\1740 disappearance\NN\42757 of\IN\1740 the\DT\1740 sinoatrial\JJ\1740 block\NN\21939 and\CC\1740 the\DT\1740 persistence\NN\5053688 of\IN\1740 asymptomatic\JJ\1740 <e2>sinus\NN\5248181 bradycardia</e2>\NN\14110674 .\.\1740
3425586
D003622_D000743 CID <e1>Dapsone-associated</e1>\JJ\1740 Heinz\NNP\1740 body\NN\19128 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 in\IN\13603305 a\DT\13649268 Cambodian\JJ\1740 woman\NN\9605289 with\IN\1740 hemoglobin\NN\14888884 E\NN\14724645 trait\NN\24264 .\.\1740
D003622_D000743 CID A\DT\13649268 Cambodian\JJ\1740 woman\NN\9605289 with\IN\1740 hemoglobin\NN\14888884 E\NN\14724645 trait\NN\24264 (\-LRB-\1740 AE\NN\1740 )\-RRB-\1740 and\CC\1740 leprosy\NN\14127211 developed\VBD\1753788 a\DT\13649268 Heinz\NNP\1740 body\NN\19128 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 while\IN\15122231 taking\VBG\2367363 a\DT\13649268 dose\NN\3740161 of\IN\1740 <e1>dapsone</e1>\NN\2716205 (\-LRB-\1740 50\CD\13745420 mg/day\NN\1740 )\-RRB-\1740 not\RB\1740 usually\RB\1740 associated\VBN\628491 with\IN\1740 clinical\JJ\1740 hemolysis\NN\13509528 .\.\1740
D003622_D000743 CID Thus\RB\1740 ,\,\1740 AE\NN\1740 RBCs\NNS\5449268 appear\VBP\2604760 to\TO\1740 have\VB\2108377 an\DT\6697703 increased\VBN\169651 sensitivity\NN\5651971 to\TO\1740 oxidant\JJ\1740 stress\NN\7083732 both\CC\1740 in\FW\13603305 vitro\FW\1740 and\CC\1740 in\FW\13603305 vivo\FW\1740 ,\,\1740 since\IN\1740 <e1>dapsone</e1>\NN\2716205 does\VBZ\1640855 not\RB\1740 cause\VB\1617192 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 at\IN\14622893 this\DT\1740 dose\NN\3740161 in\IN\13603305 hematologically\RB\1740 normal\JJ\1740 individuals\NNS\7347 .\.\1740
D003622_D007918 NONE A\DT\13649268 Cambodian\JJ\1740 woman\NN\9605289 with\IN\1740 hemoglobin\NN\14888884 E\NN\14724645 trait\NN\24264 (\-LRB-\1740 AE\NN\1740 )\-RRB-\1740 and\CC\1740 <e2>leprosy</e2>\NN\14127211 developed\VBD\1753788 a\DT\13649268 Heinz\NNP\1740 body\NN\19128 hemolytic\JJ\1740 anemia\NN\14189204 while\IN\15122231 taking\VBG\2367363 a\DT\13649268 dose\NN\3740161 of\IN\1740 <e1>dapsone</e1>\NN\2716205 (\-LRB-\1740 50\CD\13745420 mg/day\NN\1740 )\-RRB-\1740 not\RB\1740 usually\RB\1740 associated\VBN\628491 with\IN\1740 clinical\JJ\1740 hemolysis\NN\13509528 .\.\1740
D003622_D006461 NONE A\DT\13649268 Cambodian\JJ\1740 woman\NN\9605289 with\IN\1740 hemoglobin\NN\14888884 E\NN\14724645 trait\NN\24264 (\-LRB-\1740 AE\NN\1740 )\-RRB-\1740 and\CC\1740 leprosy\NN\14127211 developed\VBD\1753788 a\DT\13649268 Heinz\NNP\1740 body\NN\19128 hemolytic\JJ\1740 anemia\NN\14189204 while\IN\15122231 taking\VBG\2367363 a\DT\13649268 dose\NN\3740161 of\IN\1740 <e1>dapsone</e1>\NN\2716205 (\-LRB-\1740 50\CD\13745420 mg/day\NN\1740 )\-RRB-\1740 not\RB\1740 usually\RB\1740 associated\VBN\628491 with\IN\1740 clinical\JJ\1740 <e2>hemolysis</e2>\NN\13509528 .\.\1740
15338796
D000420_D014202 CID <e2>Tremor</e2>\NN\345926 side\NN\8630039 effects\NNS\13245626 of\IN\1740 <e1>salbutamol</e1>\NN\1740 ,\,\1740 quantified\VBN\947077 by\IN\1740 a\DT\13649268 laser\NN\3851341 pointer\NN\6817782 technique\NN\5660268 .\.\1740
D000420_D014202 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 study\VB\630380 <e2>tremor</e2>\NN\345926 side\NN\8630039 effects\NNS\13245626 of\IN\1740 <e1>salbutamol</e1>\JJ\1740 an\DT\6697703 easily\RB\1740 applicable\JJ\1740 ,\,\1740 quick\JJ\1740 and\CC\1740 low-priced\JJ\1740 method\NN\5616786 is\VBZ\836236 needed\VBN\2604760 .\.\1740
D000420_D014202 CID To\TO\1740 determine\VB\1645601 sensitivity\NN\5651971 we\PRP\1740 assessed\VBD\670261 <e2>tremor</e2>\NN\345926 in\IN\13603305 44\CD\1740 patients\NNS\9898892 with\IN\1740 obstructive\JJ\1740 lung\NN\5528060 disease\NN\14061805 after\IN\1740 administration\NN\1133281 of\IN\1740 cumulative\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>salbutamol</e1>\NN\1740 .\.\1740
D000420_D014202 CID RESULTS\NNS\34213 :\:\1740 <e1>Salbutamol</e1>\NN\1740 significantly\RB\1740 increased\VBD\169651 <e2>tremor</e2>\NN\345926 severity\NN\5036394 in\IN\13603305 patients\NNS\9898892 in\IN\13603305 a\DT\13649268 dose-dependent\JJ\1740 way\NN\4916342 .\.\1740
D000420_D008173 NONE To\TO\1740 determine\VB\1645601 sensitivity\NN\5651971 we\PRP\1740 assessed\VBD\670261 tremor\NN\345926 in\IN\13603305 44\CD\1740 patients\NNS\9898892 with\IN\1740 <e2>obstructive\JJ\1740 lung\NN\5528060 disease</e2>\NN\14061805 after\IN\1740 administration\NN\1133281 of\IN\1740 cumulative\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>salbutamol</e1>\NN\1740 .\.\1740
3358181
D012312_D014693 CID <e2>Ventricular\JJ\1740 tachyarrhythmias</e2>\NNS\1740 during\IN\1740 cesarean\JJ\1740 section\NN\7020895 after\IN\1740 <e1>ritodrine</e1>\NN\1740 therapy\NN\657604 :\:\1740 interaction\NN\37396 with\IN\1740 anesthetics\NNS\3247620 .\.\1740
D012312_D007752 NONE This\DT\1740 case\NN\7283608 illustrates\VBZ\955601 that\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 <e1>ritodrine</e1>\NN\1740 for\IN\1740 <e2>preterm\NN\1740 labor</e2>\NN\7974025 may\MD\15209706 risk\VB\2530167 interactions\NNS\37396 between\IN\1740 the\DT\1740 residual\JJ\1740 betamimetic\JJ\1740 effects\NNS\13245626 of\IN\1740 ritodrine\NN\1740 and\CC\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 anesthetics\NNS\3247620 during\IN\1740 cesarean\JJ\1740 section\NN\7020895 .\.\1740
D012312_D007752 NONE This\DT\1740 case\NN\7283608 illustrates\VBZ\955601 that\IN\1740 patients\NNS\9898892 receiving\VBG\2210855 ritodrine\NN\1740 for\IN\1740 <e2>preterm\NN\1740 labor</e2>\NN\7974025 may\MD\15209706 risk\VB\2530167 interactions\NNS\37396 between\IN\1740 the\DT\1740 residual\JJ\1740 betamimetic\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>ritodrine</e1>\NN\1740 and\CC\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 anesthetics\NNS\3247620 during\IN\1740 cesarean\JJ\1740 section\NN\7020895 .\.\1740
D012312_D002318 NONE Such\JJ\1740 interactions\NNS\37396 may\MD\15209706 result\VB\2633881 in\IN\13603305 serious\JJ\1740 <e2>cardiovascular\JJ\1740 complications</e2>\NNS\1073995 even\RB\1740 after\IN\1740 cessation\NN\7365849 of\IN\1740 an\DT\6697703 infusion\NN\14589223 of\IN\1740 <e1>ritodrine</e1>\NN\1740 .\.\1740
D010656_D007022 NONE After\IN\1740 delivery\NN\315986 of\IN\1740 the\DT\1740 infant\NN\9918248 ,\,\1740 there\EX\27167 should\MD\1740 be\VB\836236 no\DT\7204911 contraindication\NN\5819149 to\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 an\DT\6697703 alpha-adrenergic\JJ\1740 vasopressor\NN\4522421 such\JJ\1740 as\IN\14622893 <e1>phenylephrine</e1>\NN\2682038 to\TO\1740 treat\VB\2376958 <e2>hypotensive</e2>\JJ\1740 patients\NNS\9898892 with\IN\1740 tachycardia\NN\14110674 .\.\1740
D010656_D013610 NONE After\IN\1740 delivery\NN\315986 of\IN\1740 the\DT\1740 infant\NN\9918248 ,\,\1740 there\EX\27167 should\MD\1740 be\VB\836236 no\DT\7204911 contraindication\NN\5819149 to\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 an\DT\6697703 alpha-adrenergic\JJ\1740 vasopressor\NN\4522421 such\JJ\1740 as\IN\14622893 <e1>phenylephrine</e1>\NN\2682038 to\TO\1740 treat\VB\2376958 hypotensive\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>tachycardia</e2>\NN\14110674 .\.\1740
19581773
C417083_D009157 CID Development\NN\248977 of\IN\1740 <e2>ocular\JJ\1740 myasthenia</e2>\NN\14187378 during\IN\1740 <e1>pegylated\JJ\1740 interferon</e1>\NN\2725367 and\CC\1740 ribavirin\NN\2725367 treatment\NN\654885 for\IN\1740 chronic\JJ\1740 hepatitis\NN\14127211 C.\NN\1740
C417083_D009157 CID The\DT\1740 <e2>ocular\JJ\1740 myasthenia</e2>\NN\14187378 associated\VBN\628491 with\IN\1740 combination\NN\7951464 therapy\NN\657604 of\IN\1740 <e1>pegylated\JJ\1740 IFN\NN\1740 alpha-2b</e1>\NN\1740 and\CC\1740 ribavirin\NN\2725367 for\IN\1740 CHC\NN\1740 is\VBZ\836236 very\RB\1740 rarely\RB\1740 reported\VBN\831651 ;\:\1740 therefore\RB\1740 ,\,\1740 we\PRP\1740 present\VBP\2137132 this\DT\1740 case\NN\7283608 with\IN\1740 a\DT\13649268 review\NN\5733583 of\IN\1740 the\DT\1740 various\JJ\1740 eye\NN\5299178 complications\NNS\1073995 of\IN\1740 IFN\NN\1740 therapy\NN\657604 .\.\1740
C417083_D009157 CID The\DT\1740 <e2>ocular\JJ\1740 myasthenia</e2>\NN\14187378 associated\VBN\628491 with\IN\1740 combination\NN\7951464 therapy\NN\657604 of\IN\1740 pegylated\JJ\1740 IFN\NN\1740 alpha-2b\NN\1740 and\CC\1740 ribavirin\NN\2725367 for\IN\1740 CHC\NN\1740 is\VBZ\836236 very\RB\1740 rarely\RB\1740 reported\VBN\831651 ;\:\1740 therefore\RB\1740 ,\,\1740 we\PRP\1740 present\VBP\2137132 this\DT\1740 case\NN\7283608 with\IN\1740 a\DT\13649268 review\NN\5733583 of\IN\1740 the\DT\1740 various\JJ\1740 eye\NN\5299178 complications\NNS\1073995 of\IN\1740 <e1>IFN</e1>\NN\1740 therapy\NN\657604 .\.\1740
C417083_D019698 NONE Development\NN\248977 of\IN\1740 ocular\JJ\1740 myasthenia\NN\14187378 during\IN\1740 <e1>pegylated\JJ\1740 interferon</e1>\NN\2725367 and\CC\1740 ribavirin\NN\2725367 treatment\NN\654885 for\IN\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 C.</e2>\NN\1740
C417083_D019698 NONE A\DT\13649268 63-year-old\JJ\1740 male\JJ\1740 experienced\VBD\2108377 sudden\JJ\1740 diplopia\NN\14552802 after\IN\1740 9\CD\13741022 weeks\NNS\15113229 of\IN\1740 administration\NN\1133281 of\IN\1740 <e1>pegylated\JJ\1740 interferon\NN\2725367 (\-LRB-\1740 IFN\NN\1740 )\-RRB-\1740 alpha-2b</e1>\NN\1740 and\CC\1740 ribavirin\NN\2725367 for\IN\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 C</e2>\NN\13714184 (\-LRB-\1740 CHC\NN\1740 )\-RRB-\1740 .\.\1740
C417083_D019698 NONE A\DT\13649268 63-year-old\JJ\1740 male\JJ\1740 experienced\VBD\2108377 sudden\JJ\1740 diplopia\NN\14552802 after\IN\1740 9\CD\13741022 weeks\NNS\15113229 of\IN\1740 administration\NN\1133281 of\IN\1740 <e1>pegylated\JJ\1740 interferon\NN\2725367 (\-LRB-\1740 IFN\NN\1740 )\-RRB-\1740 alpha-2b</e1>\NN\1740 and\CC\1740 ribavirin\NN\2725367 for\IN\1740 chronic\JJ\1740 hepatitis\NN\14127211 C\NN\13714184 (\-LRB-\1740 <e2>CHC</e2>\NN\1740 )\-RRB-\1740 .\.\1740
C417083_D019698 NONE The\DT\1740 ocular\JJ\1740 myasthenia\NN\14187378 associated\VBN\628491 with\IN\1740 combination\NN\7951464 therapy\NN\657604 of\IN\1740 <e1>pegylated\JJ\1740 IFN\NN\1740 alpha-2b</e1>\NN\1740 and\CC\1740 ribavirin\NN\2725367 for\IN\1740 <e2>CHC</e2>\NN\1740 is\VBZ\836236 very\RB\1740 rarely\RB\1740 reported\VBN\831651 ;\:\1740 therefore\RB\1740 ,\,\1740 we\PRP\1740 present\VBP\2137132 this\DT\1740 case\NN\7283608 with\IN\1740 a\DT\13649268 review\NN\5733583 of\IN\1740 the\DT\1740 various\JJ\1740 eye\NN\5299178 complications\NNS\1073995 of\IN\1740 IFN\NN\1740 therapy\NN\657604 .\.\1740
C417083_D019698 NONE The\DT\1740 ocular\JJ\1740 myasthenia\NN\14187378 associated\VBN\628491 with\IN\1740 combination\NN\7951464 therapy\NN\657604 of\IN\1740 pegylated\JJ\1740 IFN\NN\1740 alpha-2b\NN\1740 and\CC\1740 ribavirin\NN\2725367 for\IN\1740 <e2>CHC</e2>\NN\1740 is\VBZ\836236 very\RB\1740 rarely\RB\1740 reported\VBN\831651 ;\:\1740 therefore\RB\1740 ,\,\1740 we\PRP\1740 present\VBP\2137132 this\DT\1740 case\NN\7283608 with\IN\1740 a\DT\13649268 review\NN\5733583 of\IN\1740 the\DT\1740 various\JJ\1740 eye\NN\5299178 complications\NNS\1073995 of\IN\1740 <e1>IFN</e1>\NN\1740 therapy\NN\657604 .\.\1740
D012254_D009157 CID Development\NN\248977 of\IN\1740 <e2>ocular\JJ\1740 myasthenia</e2>\NN\14187378 during\IN\1740 pegylated\JJ\1740 interferon\NN\2725367 and\CC\1740 <e1>ribavirin</e1>\NN\2725367 treatment\NN\654885 for\IN\1740 chronic\JJ\1740 hepatitis\NN\14127211 C.\NN\1740
D012254_D009157 CID The\DT\1740 <e2>ocular\JJ\1740 myasthenia</e2>\NN\14187378 associated\VBN\628491 with\IN\1740 combination\NN\7951464 therapy\NN\657604 of\IN\1740 pegylated\JJ\1740 IFN\NN\1740 alpha-2b\NN\1740 and\CC\1740 <e1>ribavirin</e1>\NN\2725367 for\IN\1740 CHC\NN\1740 is\VBZ\836236 very\RB\1740 rarely\RB\1740 reported\VBN\831651 ;\:\1740 therefore\RB\1740 ,\,\1740 we\PRP\1740 present\VBP\2137132 this\DT\1740 case\NN\7283608 with\IN\1740 a\DT\13649268 review\NN\5733583 of\IN\1740 the\DT\1740 various\JJ\1740 eye\NN\5299178 complications\NNS\1073995 of\IN\1740 IFN\NN\1740 therapy\NN\657604 .\.\1740
D012254_D019698 NONE Development\NN\248977 of\IN\1740 ocular\JJ\1740 myasthenia\NN\14187378 during\IN\1740 pegylated\JJ\1740 interferon\NN\2725367 and\CC\1740 <e1>ribavirin</e1>\NN\2725367 treatment\NN\654885 for\IN\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 C.</e2>\NN\1740
D012254_D019698 NONE A\DT\13649268 63-year-old\JJ\1740 male\JJ\1740 experienced\VBD\2108377 sudden\JJ\1740 diplopia\NN\14552802 after\IN\1740 9\CD\13741022 weeks\NNS\15113229 of\IN\1740 administration\NN\1133281 of\IN\1740 pegylated\JJ\1740 interferon\NN\2725367 (\-LRB-\1740 IFN\NN\1740 )\-RRB-\1740 alpha-2b\NN\1740 and\CC\1740 <e1>ribavirin</e1>\NN\2725367 for\IN\1740 <e2>chronic\JJ\1740 hepatitis\NN\14127211 C</e2>\NN\13714184 (\-LRB-\1740 CHC\NN\1740 )\-RRB-\1740 .\.\1740
D012254_D019698 NONE A\DT\13649268 63-year-old\JJ\1740 male\JJ\1740 experienced\VBD\2108377 sudden\JJ\1740 diplopia\NN\14552802 after\IN\1740 9\CD\13741022 weeks\NNS\15113229 of\IN\1740 administration\NN\1133281 of\IN\1740 pegylated\JJ\1740 interferon\NN\2725367 (\-LRB-\1740 IFN\NN\1740 )\-RRB-\1740 alpha-2b\NN\1740 and\CC\1740 <e1>ribavirin</e1>\NN\2725367 for\IN\1740 chronic\JJ\1740 hepatitis\NN\14127211 C\NN\13714184 (\-LRB-\1740 <e2>CHC</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D012254_D019698 NONE The\DT\1740 ocular\JJ\1740 myasthenia\NN\14187378 associated\VBN\628491 with\IN\1740 combination\NN\7951464 therapy\NN\657604 of\IN\1740 pegylated\JJ\1740 IFN\NN\1740 alpha-2b\NN\1740 and\CC\1740 <e1>ribavirin</e1>\NN\2725367 for\IN\1740 <e2>CHC</e2>\NN\1740 is\VBZ\836236 very\RB\1740 rarely\RB\1740 reported\VBN\831651 ;\:\1740 therefore\RB\1740 ,\,\1740 we\PRP\1740 present\VBP\2137132 this\DT\1740 case\NN\7283608 with\IN\1740 a\DT\13649268 review\NN\5733583 of\IN\1740 the\DT\1740 various\JJ\1740 eye\NN\5299178 complications\NNS\1073995 of\IN\1740 IFN\NN\1740 therapy\NN\657604 .\.\1740
C417083_D004172 NONE A\DT\13649268 63-year-old\JJ\1740 male\JJ\1740 experienced\VBD\2108377 sudden\JJ\1740 <e2>diplopia</e2>\NN\14552802 after\IN\1740 9\CD\13741022 weeks\NNS\15113229 of\IN\1740 administration\NN\1133281 of\IN\1740 <e1>pegylated\JJ\1740 interferon\NN\2725367 (\-LRB-\1740 IFN\NN\1740 )\-RRB-\1740 alpha-2b</e1>\NN\1740 and\CC\1740 ribavirin\NN\2725367 for\IN\1740 chronic\JJ\1740 hepatitis\NN\14127211 C\NN\13714184 (\-LRB-\1740 CHC\NN\1740 )\-RRB-\1740 .\.\1740
D012254_D004172 NONE A\DT\13649268 63-year-old\JJ\1740 male\JJ\1740 experienced\VBD\2108377 sudden\JJ\1740 <e2>diplopia</e2>\NN\14552802 after\IN\1740 9\CD\13741022 weeks\NNS\15113229 of\IN\1740 administration\NN\1133281 of\IN\1740 pegylated\JJ\1740 interferon\NN\2725367 (\-LRB-\1740 IFN\NN\1740 )\-RRB-\1740 alpha-2b\NN\1740 and\CC\1740 <e1>ribavirin</e1>\NN\2725367 for\IN\1740 chronic\JJ\1740 hepatitis\NN\14127211 C\NN\13714184 (\-LRB-\1740 CHC\NN\1740 )\-RRB-\1740 .\.\1740
9088814
D000527_D007022 CID Combined\JJ\1740 effects\NNS\13245626 of\IN\1740 prolonged\JJ\1740 <e1>prostaglandin\NN\5414534 E1-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 haemodilution\NN\1740 on\IN\1740 human\JJ\1740 hepatic\JJ\1740 function\NN\13783581 .\.\1740
D000527_D007022 CID Combined\JJ\1740 effects\NNS\13245626 of\IN\1740 prolonged\JJ\1740 <e1>prostaglandin\NN\5414534 E1</e1>\NN\1740 (PGE1)-induced\VBD\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 haemodilution\NN\1740 on\IN\1740 hepatic\JJ\1740 function\NN\13783581 were\VBD\836236 studied\VBN\630380 in\IN\13603305 30\CD\13745420 patients\NNS\9898892 undergoing\VBG\109660 hip\NN\5220461 surgery\NN\6045562 .\.\1740
D000527_D007022 CID Combined\JJ\1740 effects\NNS\13245626 of\IN\1740 prolonged\JJ\1740 prostaglandin\NN\5414534 E1\NN\1740 <e1>(PGE1)-induced</e1>\VBD\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 haemodilution\NN\1740 on\IN\1740 hepatic\JJ\1740 function\NN\13783581 were\VBD\836236 studied\VBN\630380 in\IN\13603305 30\CD\13745420 patients\NNS\9898892 undergoing\VBG\109660 hip\NN\5220461 surgery\NN\6045562 .\.\1740
D000527_D007022 CID Controlled\VBN\2422663 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 groups\NNS\2137 A\NN\13649268 and\CC\1740 C\NN\13714184 was\VBD\836236 induced\VBN\1627355 with\IN\1740 <e1>PGE1</e1>\NN\1740 to\TO\1740 maintain\VB\2202928 mean\VB\928630 arterial\JJ\1740 blood\NN\5397468 pressure\NN\11419404 at\IN\14622893 55\CD\1740 mmHg\NN\1740 for\IN\1740 180\CD\1740 min\NN\15154774 .\.\1740
D000527_D007022 CID The\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 a\DT\13649268 prolonged\JJ\1740 combination\NN\7951464 of\IN\1740 more\JJR\1740 than\IN\1740 120\CD\13745420 min\NN\15154774 of\IN\1740 <e1>PGE1-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 moderate\JJ\1740 haemodilution\NN\1740 would\MD\1740 cause\VB\1617192 impairment\NN\7296428 of\IN\1740 hepatic\JJ\1740 function\NN\13783581 .\.\1740
D000527_D020141 NONE Combined\JJ\1740 effects\NNS\13245626 of\IN\1740 prolonged\JJ\1740 <e1>prostaglandin\NN\5414534 E1-induced</e1>\JJ\1740 hypotension\NN\14057371 and\CC\1740 <e2>haemodilution</e2>\NN\1740 on\IN\1740 human\JJ\1740 hepatic\JJ\1740 function\NN\13783581 .\.\1740
D000527_D020141 NONE Combined\JJ\1740 effects\NNS\13245626 of\IN\1740 prolonged\JJ\1740 <e1>prostaglandin\NN\5414534 E1</e1>\NN\1740 (PGE1)-induced\VBD\1740 hypotension\NN\14057371 and\CC\1740 <e2>haemodilution</e2>\NN\1740 on\IN\1740 hepatic\JJ\1740 function\NN\13783581 were\VBD\836236 studied\VBN\630380 in\IN\13603305 30\CD\13745420 patients\NNS\9898892 undergoing\VBG\109660 hip\NN\5220461 surgery\NN\6045562 .\.\1740
D000527_D020141 NONE Combined\JJ\1740 effects\NNS\13245626 of\IN\1740 prolonged\JJ\1740 prostaglandin\NN\5414534 E1\NN\1740 <e1>(PGE1)-induced</e1>\VBD\1740 hypotension\NN\14057371 and\CC\1740 <e2>haemodilution</e2>\NN\1740 on\IN\1740 hepatic\JJ\1740 function\NN\13783581 were\VBD\836236 studied\VBN\630380 in\IN\13603305 30\CD\13745420 patients\NNS\9898892 undergoing\VBG\109660 hip\NN\5220461 surgery\NN\6045562 .\.\1740
D000527_D020141 NONE The\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 a\DT\13649268 prolonged\JJ\1740 combination\NN\7951464 of\IN\1740 more\JJR\1740 than\IN\1740 120\CD\13745420 min\NN\15154774 of\IN\1740 <e1>PGE1-induced</e1>\JJ\1740 hypotension\NN\14057371 and\CC\1740 moderate\JJ\1740 <e2>haemodilution</e2>\NN\1740 would\MD\1740 cause\VB\1617192 impairment\NN\7296428 of\IN\1740 hepatic\JJ\1740 function\NN\13783581 .\.\1740
D003911_D020141 NONE <e2>Haemodilution</e2>\NN\1740 in\IN\13603305 groups\NNS\2137 B\NN\1355326 and\CC\1740 C\NN\13714184 was\VBD\836236 produced\VBN\1617192 by\IN\1740 withdrawing\VBG\1835496 approximately\RB\1740 1000\CD\13745420 mL\NN\13616054 of\IN\1740 blood\NN\5397468 and\CC\1740 replacing\VBG\1631072 it\PRP\6125041 with\IN\1740 the\DT\1740 same\JJ\1740 amount\NN\13329641 of\IN\1740 <e1>dextran</e1>\NN\1740 solution\NN\14586258 ,\,\1740 and\CC\1740 final\JJ\1740 haematocrit\NN\13819207 values\NNS\5941423 were\VBD\836236 21\CD\13745420 or\CC\3541091 22\CD\13745420 %\NN\1740 .\.\1740
D001663_D007022 NONE AKBR\NN\1740 and\CC\1740 biological\JJ\1740 hepatic\JJ\1740 function\NN\13783581 tests\NNS\5798043 showed\VBD\2137132 no\DT\7204911 change\NN\7283608 throughout\IN\1740 the\DT\1740 time\NN\7308889 course\NN\883297 in\IN\13603305 groups\NNS\2137 A\NN\13649268 and\CC\1740 B.\NN\1740 In\IN\13603305 group\NN\2137 C\NN\13714184 ,\,\1740 AKBR\NN\1740 showed\VBD\2137132 a\DT\13649268 significant\JJ\1740 decrease\NN\7296428 at\IN\14622893 120\CD\13745420 min\NN\15154774 (\-LRB-\1740 -40\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 at\IN\14622893 180\CD\1740 min\NN\15154774 (\-LRB-\1740 -49\CD\1740 %\NN\1740 )\-RRB-\1740 after\IN\1740 the\DT\1740 start\NN\7290905 of\IN\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 at\IN\14622893 60\CD\13745420 min\NN\15154774 (\-LRB-\1740 -32\CD\1740 %\NN\1740 )\-RRB-\1740 after\IN\1740 recovery\NN\7357388 of\IN\1740 normotension\NN\1740 ,\,\1740 and\CC\1740 SGOT\NNS\1740 ,\,\1740 SGPT\NN\1740 ,\,\1740 LDH\NN\1740 and\CC\1740 total\JJ\1740 <e1>bilirubin</e1>\NN\14756039 showed\VBD\2137132 significant\JJ\1740 increases\NNS\13576355 after\IN\1740 operation\NN\14006945 .\.\1740
D000527_D008107 CID The\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 a\DT\13649268 prolonged\JJ\1740 combination\NN\7951464 of\IN\1740 more\JJR\1740 than\IN\1740 120\CD\13745420 min\NN\15154774 of\IN\1740 <e1>PGE1-induced</e1>\JJ\1740 hypotension\NN\14057371 and\CC\1740 moderate\JJ\1740 haemodilution\NN\1740 would\MD\1740 cause\VB\1617192 <e2>impairment\NN\7296428 of\IN\1740 hepatic\JJ\1740 function</e2>\NN\13783581 .\.\1740
18726058
D010208_D020301 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Papaverine\NNP\3800001 hydrochloride</e1>\NN\14817592 is\VBZ\836236 a\DT\13649268 direct-acting\JJ\1740 vasodilator\NN\3198383 used\VBN\1156834 to\TO\1740 manage\VB\2524171 <e2>vasospasm</e2>\NN\1740 during\IN\1740 various\JJ\1740 neurosurgical\JJ\1740 operations\NNS\1106808 .\.\1740
D010208_D020301 NONE METHODS\NNS\5616786 :\:\1740 We\PRP\1740 conducted\VBD\2436349 a\DT\13649268 retrospective\JJ\1740 review\NN\5733583 of\IN\1740 70\CD\13745420 consecutive\JJ\1740 microvascular\JJ\1740 decompression\NN\617059 operations\NNS\1106808 and\CC\1740 studied\VBD\630380 those\DT\1740 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 topical\JJ\1740 <e1>papaverine</e1>\NN\3800001 for\IN\1740 <e2>vasospasm</e2>\NN\1740 .\.\1740
D010208_D020301 NONE Topical\JJ\1740 <e1>papaverine</e1>\NN\3800001 was\VBD\836236 used\VBN\1156834 as\IN\14622893 a\DT\13649268 direct\JJ\1740 therapeutic\JJ\1740 action\NN\30358 to\TO\1740 manage\VB\2524171 <e2>vasospasm</e2>\NN\1740 in\IN\13603305 a\DT\13649268 total\NN\3553 of\IN\1740 11\CD\13745420 patients\NNS\9898892 .\.\1740
D010208_D020301 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Topical\JJ\1740 <e1>papaverine</e1>\NN\3800001 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>vasospasm</e2>\NN\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 a\DT\13649268 transient\JJ\1740 disturbance\NN\407535 in\IN\13603305 neurophysiological\JJ\1740 function\NN\13783581 of\IN\1740 the\DT\1740 ascending\VBG\1835496 auditory\JJ\1740 brainstem\NN\5462674 pathway\NN\5483677 .\.\1740
D010208_D003389 NONE Transient\JJ\1740 <e2>cranial\JJ\1740 nerve\NN\5475681 dysfunction</e2>\NN\14204950 has\VBZ\2108377 been\VBN\836236 described\VBN\1001294 in\IN\13603305 a\DT\13649268 few\JJ\1740 cases\NNS\7283608 with\IN\1740 topical\JJ\1740 <e1>papaverine</e1>\NN\3800001 .\.\1740
D010208_D003389 NONE Recommendations\NNS\6671484 to\TO\1740 avoid\VB\2452885 potential\JJ\1740 <e2>cranial\JJ\1740 nerve\NN\5475681 deficits</e2>\NNS\5113133 from\IN\1740 <e1>papaverine</e1>\NN\3800001 are\VBP\836236 provided\VBN\2199590 .\.\1740
17639754
D014859_D006470 CID We\PRP\1740 report\VBP\831651 3\CD\13741022 cases\NNS\7283608 of\IN\1740 serious\JJ\1740 <e2>bleeding</e2>\VBG\104868 complications\NNS\1073995 that\WDT\1740 appear\VBP\2604760 to\TO\1740 be\VB\836236 the\DT\1740 result\NN\34213 of\IN\1740 the\DT\1740 interaction\NN\37396 between\IN\1740 <e1>warfarin</e1>\NN\2718259 and\CC\1740 levofloxacin\NN\1740 .\.\1740
D064704_D006470 CID We\PRP\1740 report\VBP\831651 3\CD\13741022 cases\NNS\7283608 of\IN\1740 serious\JJ\1740 <e2>bleeding</e2>\VBG\104868 complications\NNS\1073995 that\WDT\1740 appear\VBP\2604760 to\TO\1740 be\VB\836236 the\DT\1740 result\NN\34213 of\IN\1740 the\DT\1740 interaction\NN\37396 between\IN\1740 warfarin\NN\2718259 and\CC\1740 <e1>levofloxacin</e1>\NN\1740 .\.\1740
19473225
D018698_D010523 NONE Long-term\JJ\1740 <e1>glutamate</e1>\JJ\1740 supplementation\NN\5108947 failed\VBD\1798936 to\TO\1740 protect\VB\1127795 against\IN\1740 <e2>peripheral\JJ\1740 neurotoxicity</e2>\NN\1740 of\IN\1740 paclitaxel\NN\1740 .\.\1740
D018698_D010523 NONE Toxic\JJ\1740 <e2>peripheral\JJ\1740 neuropathy</e2>\NN\14204950 is\VBZ\836236 still\RB\1740 a\DT\13649268 significant\JJ\1740 limiting\NN\13796779 factor\NN\7326557 for\IN\1740 chemotherapy\NN\661091 with\IN\1740 paclitaxel\NN\1740 (\-LRB-\1740 PAC\NN\8324514 )\-RRB-\1740 ,\,\1740 although\IN\1740 <e1>glutamate</e1>\NN\15010703 and\CC\1740 its\PRP$\6125041 closely\RB\1740 related\JJ\1740 amino\NN\14621446 acid\NN\14818238 glutamine\NN\14601829 were\VBD\836236 claimed\VBN\1011725 to\TO\1740 ameliorate\VB\126264 PAC\NN\8324514 neurotoxicity\NN\1740 .\.\1740
D018698_D010523 NONE Toxic\JJ\1740 <e2>peripheral\JJ\1740 neuropathy</e2>\NN\14204950 is\VBZ\836236 still\RB\1740 a\DT\13649268 significant\JJ\1740 limiting\NN\13796779 factor\NN\7326557 for\IN\1740 chemotherapy\NN\661091 with\IN\1740 paclitaxel\NN\1740 (\-LRB-\1740 PAC\NN\8324514 )\-RRB-\1740 ,\,\1740 although\IN\1740 glutamate\NN\15010703 and\CC\1740 its\PRP$\6125041 closely\RB\1740 related\JJ\1740 amino\NN\14621446 acid\NN\14818238 <e1>glutamine</e1>\NN\14601829 were\VBD\836236 claimed\VBN\1011725 to\TO\1740 ameliorate\VB\126264 PAC\NN\8324514 neurotoxicity\NN\1740 .\.\1740
D018698_D010523 NONE This\DT\1740 pilot\NN\9826204 trial\NN\786195 aimed\VBN\1987160 to\TO\1740 evaluate\VB\670261 the\DT\1740 role\NN\719494 of\IN\1740 <e1>glutamate</e1>\JJ\1740 supplementation\NN\5108947 for\IN\1740 preventing\VBG\1740 PAC-induced\JJ\1740 <e2>peripheral\JJ\1740 neuropathy</e2>\NN\14204950 in\IN\13603305 a\DT\13649268 randomized\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 ,\,\1740 double-blinded\JJ\1740 clinical\JJ\1740 and\CC\1740 electro-diagnostic\JJ\1740 study\NN\635850 .\.\1740
D018698_D010523 NONE This\DT\1740 pilot\NN\9826204 study\NN\635850 leads\VBZ\1752884 to\TO\1740 the\DT\1740 conclusion\NN\5837957 that\WDT\1740 <e1>glutamate</e1>\VBP\1740 supplementation\NN\5108947 at\IN\14622893 the\DT\1740 chosen\VBN\697589 regimen\NN\5898568 fails\VBZ\1798936 to\TO\1740 protect\VB\1127795 against\IN\1740 <e2>peripheral\JJ\1740 neurotoxicity</e2>\NN\1740 of\IN\1740 PAC\NN\8324514 .\.\1740
D017239_D010523 CID Long-term\JJ\1740 glutamate\JJ\1740 supplementation\NN\5108947 failed\VBD\1798936 to\TO\1740 protect\VB\1127795 against\IN\1740 <e2>peripheral\JJ\1740 neurotoxicity</e2>\NN\1740 of\IN\1740 <e1>paclitaxel</e1>\NN\1740 .\.\1740
D017239_D010523 CID Toxic\JJ\1740 <e2>peripheral\JJ\1740 neuropathy</e2>\NN\14204950 is\VBZ\836236 still\RB\1740 a\DT\13649268 significant\JJ\1740 limiting\NN\13796779 factor\NN\7326557 for\IN\1740 chemotherapy\NN\661091 with\IN\1740 <e1>paclitaxel</e1>\NN\1740 (\-LRB-\1740 PAC\NN\8324514 )\-RRB-\1740 ,\,\1740 although\IN\1740 glutamate\NN\15010703 and\CC\1740 its\PRP$\6125041 closely\RB\1740 related\JJ\1740 amino\NN\14621446 acid\NN\14818238 glutamine\NN\14601829 were\VBD\836236 claimed\VBN\1011725 to\TO\1740 ameliorate\VB\126264 PAC\NN\8324514 neurotoxicity\NN\1740 .\.\1740
D017239_D010523 CID Toxic\JJ\1740 <e2>peripheral\JJ\1740 neuropathy</e2>\NN\14204950 is\VBZ\836236 still\RB\1740 a\DT\13649268 significant\JJ\1740 limiting\NN\13796779 factor\NN\7326557 for\IN\1740 chemotherapy\NN\661091 with\IN\1740 paclitaxel\NN\1740 (\-LRB-\1740 <e1>PAC</e1>\NN\8324514 )\-RRB-\1740 ,\,\1740 although\IN\1740 glutamate\NN\15010703 and\CC\1740 its\PRP$\6125041 closely\RB\1740 related\JJ\1740 amino\NN\14621446 acid\NN\14818238 glutamine\NN\14601829 were\VBD\836236 claimed\VBN\1011725 to\TO\1740 ameliorate\VB\126264 PAC\NN\8324514 neurotoxicity\NN\1740 .\.\1740
D017239_D010523 CID Toxic\JJ\1740 <e2>peripheral\JJ\1740 neuropathy</e2>\NN\14204950 is\VBZ\836236 still\RB\1740 a\DT\13649268 significant\JJ\1740 limiting\NN\13796779 factor\NN\7326557 for\IN\1740 chemotherapy\NN\661091 with\IN\1740 paclitaxel\NN\1740 (\-LRB-\1740 PAC\NN\8324514 )\-RRB-\1740 ,\,\1740 although\IN\1740 glutamate\NN\15010703 and\CC\1740 its\PRP$\6125041 closely\RB\1740 related\JJ\1740 amino\NN\14621446 acid\NN\14818238 glutamine\NN\14601829 were\VBD\836236 claimed\VBN\1011725 to\TO\1740 ameliorate\VB\126264 <e1>PAC</e1>\NN\8324514 neurotoxicity\NN\1740 .\.\1740
D017239_D010523 CID This\DT\1740 pilot\NN\9826204 trial\NN\786195 aimed\VBN\1987160 to\TO\1740 evaluate\VB\670261 the\DT\1740 role\NN\719494 of\IN\1740 glutamate\JJ\1740 supplementation\NN\5108947 for\IN\1740 preventing\VBG\1740 <e1>PAC-induced</e1>\JJ\1740 <e2>peripheral\JJ\1740 neuropathy</e2>\NN\14204950 in\IN\13603305 a\DT\13649268 randomized\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 ,\,\1740 double-blinded\JJ\1740 clinical\JJ\1740 and\CC\1740 electro-diagnostic\JJ\1740 study\NN\635850 .\.\1740
D017239_D010523 CID This\DT\1740 pilot\NN\9826204 study\NN\635850 leads\VBZ\1752884 to\TO\1740 the\DT\1740 conclusion\NN\5837957 that\WDT\1740 glutamate\VBP\1740 supplementation\NN\5108947 at\IN\14622893 the\DT\1740 chosen\VBN\697589 regimen\NN\5898568 fails\VBZ\1798936 to\TO\1740 protect\VB\1127795 against\IN\1740 <e2>peripheral\JJ\1740 neurotoxicity</e2>\NN\1740 of\IN\1740 <e1>PAC</e1>\NN\8324514 .\.\1740
D017239_D020258 NONE Toxic\JJ\1740 peripheral\JJ\1740 neuropathy\NN\14204950 is\VBZ\836236 still\RB\1740 a\DT\13649268 significant\JJ\1740 limiting\NN\13796779 factor\NN\7326557 for\IN\1740 chemotherapy\NN\661091 with\IN\1740 <e1>paclitaxel</e1>\NN\1740 (\-LRB-\1740 PAC\NN\8324514 )\-RRB-\1740 ,\,\1740 although\IN\1740 glutamate\NN\15010703 and\CC\1740 its\PRP$\6125041 closely\RB\1740 related\JJ\1740 amino\NN\14621446 acid\NN\14818238 glutamine\NN\14601829 were\VBD\836236 claimed\VBN\1011725 to\TO\1740 ameliorate\VB\126264 PAC\NN\8324514 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D017239_D020258 NONE Toxic\JJ\1740 peripheral\JJ\1740 neuropathy\NN\14204950 is\VBZ\836236 still\RB\1740 a\DT\13649268 significant\JJ\1740 limiting\NN\13796779 factor\NN\7326557 for\IN\1740 chemotherapy\NN\661091 with\IN\1740 paclitaxel\NN\1740 (\-LRB-\1740 <e1>PAC</e1>\NN\8324514 )\-RRB-\1740 ,\,\1740 although\IN\1740 glutamate\NN\15010703 and\CC\1740 its\PRP$\6125041 closely\RB\1740 related\JJ\1740 amino\NN\14621446 acid\NN\14818238 glutamine\NN\14601829 were\VBD\836236 claimed\VBN\1011725 to\TO\1740 ameliorate\VB\126264 PAC\NN\8324514 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D017239_D020258 NONE Toxic\JJ\1740 peripheral\JJ\1740 neuropathy\NN\14204950 is\VBZ\836236 still\RB\1740 a\DT\13649268 significant\JJ\1740 limiting\NN\13796779 factor\NN\7326557 for\IN\1740 chemotherapy\NN\661091 with\IN\1740 paclitaxel\NN\1740 (\-LRB-\1740 PAC\NN\8324514 )\-RRB-\1740 ,\,\1740 although\IN\1740 glutamate\NN\15010703 and\CC\1740 its\PRP$\6125041 closely\RB\1740 related\JJ\1740 amino\NN\14621446 acid\NN\14818238 glutamine\NN\14601829 were\VBD\836236 claimed\VBN\1011725 to\TO\1740 ameliorate\VB\126264 <e1>PAC</e1>\NN\8324514 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D018698_D020258 NONE Toxic\JJ\1740 peripheral\JJ\1740 neuropathy\NN\14204950 is\VBZ\836236 still\RB\1740 a\DT\13649268 significant\JJ\1740 limiting\NN\13796779 factor\NN\7326557 for\IN\1740 chemotherapy\NN\661091 with\IN\1740 paclitaxel\NN\1740 (\-LRB-\1740 PAC\NN\8324514 )\-RRB-\1740 ,\,\1740 although\IN\1740 <e1>glutamate</e1>\NN\15010703 and\CC\1740 its\PRP$\6125041 closely\RB\1740 related\JJ\1740 amino\NN\14621446 acid\NN\14818238 glutamine\NN\14601829 were\VBD\836236 claimed\VBN\1011725 to\TO\1740 ameliorate\VB\126264 PAC\NN\8324514 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D018698_D020258 NONE Toxic\JJ\1740 peripheral\JJ\1740 neuropathy\NN\14204950 is\VBZ\836236 still\RB\1740 a\DT\13649268 significant\JJ\1740 limiting\NN\13796779 factor\NN\7326557 for\IN\1740 chemotherapy\NN\661091 with\IN\1740 paclitaxel\NN\1740 (\-LRB-\1740 PAC\NN\8324514 )\-RRB-\1740 ,\,\1740 although\IN\1740 glutamate\NN\15010703 and\CC\1740 its\PRP$\6125041 closely\RB\1740 related\JJ\1740 amino\NN\14621446 acid\NN\14818238 <e1>glutamine</e1>\NN\14601829 were\VBD\836236 claimed\VBN\1011725 to\TO\1740 ameliorate\VB\126264 PAC\NN\8324514 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D000596_D010523 NONE Toxic\JJ\1740 <e2>peripheral\JJ\1740 neuropathy</e2>\NN\14204950 is\VBZ\836236 still\RB\1740 a\DT\13649268 significant\JJ\1740 limiting\NN\13796779 factor\NN\7326557 for\IN\1740 chemotherapy\NN\661091 with\IN\1740 paclitaxel\NN\1740 (\-LRB-\1740 PAC\NN\8324514 )\-RRB-\1740 ,\,\1740 although\IN\1740 glutamate\NN\15010703 and\CC\1740 its\PRP$\6125041 closely\RB\1740 related\JJ\1740 <e1>amino\NN\14621446 acid</e1>\NN\14818238 glutamine\NN\14601829 were\VBD\836236 claimed\VBN\1011725 to\TO\1740 ameliorate\VB\126264 PAC\NN\8324514 neurotoxicity\NN\1740 .\.\1740
D000596_D020258 NONE Toxic\JJ\1740 peripheral\JJ\1740 neuropathy\NN\14204950 is\VBZ\836236 still\RB\1740 a\DT\13649268 significant\JJ\1740 limiting\NN\13796779 factor\NN\7326557 for\IN\1740 chemotherapy\NN\661091 with\IN\1740 paclitaxel\NN\1740 (\-LRB-\1740 PAC\NN\8324514 )\-RRB-\1740 ,\,\1740 although\IN\1740 glutamate\NN\15010703 and\CC\1740 its\PRP$\6125041 closely\RB\1740 related\JJ\1740 <e1>amino\NN\14621446 acid</e1>\NN\14818238 glutamine\NN\14601829 were\VBD\836236 claimed\VBN\1011725 to\TO\1740 ameliorate\VB\126264 PAC\NN\8324514 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D017239_D010051 NONE Forty-three\JJ\1740 <e2>ovarian\NN\1740 cancer</e2>\NN\14239425 patients\NNS\9898892 were\VBD\836236 available\JJ\1740 for\IN\1740 analysis\NN\633864 following\VBG\1835496 six\CD\13741022 cycles\NNS\15269513 of\IN\1740 the\DT\1740 same\JJ\1740 <e1>PAC-containing</e1>\JJ\1740 regimen\NNS\5898568 :\:\1740 23\CD\13745420 had\VBD\2108377 been\VBN\836236 supplemented\VBN\182406 by\IN\1740 glutamate\NN\15010703 all\RB\1740 along\IN\1740 the\DT\1740 treatment\NN\654885 period\NN\13575869 ,\,\1740 at\IN\14622893 a\DT\13649268 daily\JJ\1740 dose\NN\3740161 of\IN\1740 three\CD\13741022 times\NNS\15113229 500\CD\13745420 mg\NN\13717155 (\-LRB-\1740 group\NN\2137 G\NN\13717155 )\-RRB-\1740 ,\,\1740 and\CC\1740 20\CD\13745420 had\VBD\2108377 received\VBN\2210855 a\DT\13649268 placebo\NN\3740161 (\-LRB-\1740 group\NN\2137 P\NN\14622893 )\-RRB-\1740 .\.\1740
D018698_D010051 NONE Forty-three\JJ\1740 <e2>ovarian\NN\1740 cancer</e2>\NN\14239425 patients\NNS\9898892 were\VBD\836236 available\JJ\1740 for\IN\1740 analysis\NN\633864 following\VBG\1835496 six\CD\13741022 cycles\NNS\15269513 of\IN\1740 the\DT\1740 same\JJ\1740 PAC-containing\JJ\1740 regimen\NNS\5898568 :\:\1740 23\CD\13745420 had\VBD\2108377 been\VBN\836236 supplemented\VBN\182406 by\IN\1740 <e1>glutamate</e1>\NN\15010703 all\RB\1740 along\IN\1740 the\DT\1740 treatment\NN\654885 period\NN\13575869 ,\,\1740 at\IN\14622893 a\DT\13649268 daily\JJ\1740 dose\NN\3740161 of\IN\1740 three\CD\13741022 times\NNS\15113229 500\CD\13745420 mg\NN\13717155 (\-LRB-\1740 group\NN\2137 G\NN\13717155 )\-RRB-\1740 ,\,\1740 and\CC\1740 20\CD\13745420 had\VBD\2108377 received\VBN\2210855 a\DT\13649268 placebo\NN\3740161 (\-LRB-\1740 group\NN\2137 P\NN\14622893 )\-RRB-\1740 .\.\1740
435349
D013390_D005207 CID <e1>Suxamethonium</e1>\NN\1740 infusion\NN\14589223 rate\NN\13815152 and\CC\1740 observed\VBN\2163746 <e2>fasciculations</e2>\NNS\14361664 .\.\1740
D013390_D013746 NONE The\DT\1740 infusion\NN\14589223 was\VBD\836236 discontinued\VBN\2609764 either\CC\1740 when\WRB\1740 there\EX\27167 was\VBD\836236 no\DT\7204911 muscular\JJ\1740 response\NN\11410625 to\TO\1740 <e2>tetanic</e2>\JJ\1740 stimulation\NN\242808 of\IN\1740 the\DT\1740 ulnar\JJ\1740 nerve\NN\5475681 or\CC\3541091 when\WRB\1740 <e1>Sch</e1>\NN\1740 120\CD\13745420 mg\NN\13717155 was\VBD\836236 exceeded\VBN\2673965 .\.\1740
3827439
D000666_D058186 CID Recurrent\JJ\1740 reversible\JJ\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 from\IN\1740 <e1>amphotericin</e1>\NN\2716866 .\.\1740
D000666_D058186 CID A\DT\13649268 patient\NN\9898892 with\IN\1740 cryptogenic\JJ\1740 cirrhosis\NN\14116321 and\CC\1740 disseminated\JJ\1740 sporotrichosis\NN\14176895 developed\VBD\1753788 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 immediately\RB\1740 following\VBG\1835496 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>amphotericin\NN\2716866 B</e1>\NN\1355326 on\IN\1740 four\CD\13741022 separate\JJ\1740 occasions\NNS\5983801 .\.\1740
D000666_D058186 CID We\PRP\1740 propose\VBP\1010118 that\IN\1740 <e1>amphotericin</e1>\NN\2716866 ,\,\1740 in\IN\13603305 the\DT\1740 setting\NN\8567235 of\IN\1740 reduced\VBN\441445 effective\JJ\1740 arterial\JJ\1740 volume\NN\33615 ,\,\1740 may\MD\15209706 activate\VB\1641914 tubuloglomerular\JJ\1740 feedback\NN\13518963 ,\,\1740 thereby\RB\1740 contributing\VBG\126264 to\TO\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 .\.\1740
D000666_D005355 NONE A\DT\13649268 patient\NN\9898892 with\IN\1740 cryptogenic\JJ\1740 <e2>cirrhosis</e2>\NN\14116321 and\CC\1740 disseminated\JJ\1740 sporotrichosis\NN\14176895 developed\VBD\1753788 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 immediately\RB\1740 following\VBG\1835496 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>amphotericin\NN\2716866 B</e1>\NN\1355326 on\IN\1740 four\CD\13741022 separate\JJ\1740 occasions\NNS\5983801 .\.\1740
D000666_D013174 NONE A\DT\13649268 patient\NN\9898892 with\IN\1740 cryptogenic\JJ\1740 cirrhosis\NN\14116321 and\CC\1740 disseminated\JJ\1740 <e2>sporotrichosis</e2>\NN\14176895 developed\VBD\1753788 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 immediately\RB\1740 following\VBG\1835496 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>amphotericin\NN\2716866 B</e1>\NN\1355326 on\IN\1740 four\CD\13741022 separate\JJ\1740 occasions\NNS\5983801 .\.\1740
20667451
D003474_D003072 NONE <e1>Curcumin</e1>\NN\1740 ameliorates\VBZ\126264 <e2>cognitive\JJ\1740 dysfunction</e2>\NN\14204950 and\CC\1740 oxidative\JJ\1740 damage\NN\7296428 in\IN\13603305 phenobarbitone\NN\2792049 and\CC\1740 carbamazepine\NN\1740 administered\JJ\1740 rats\NNS\2329401 .\.\1740
D003474_D003072 NONE Therefore\RB\1740 ,\,\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 carried\VBN\1850315 out\RP\1740 to\TO\1740 investigate\VB\644583 the\DT\1740 effect\NN\34213 of\IN\1740 chronic\JJ\1740 <e1>curcumin</e1>\NN\1740 administration\NN\1133281 on\IN\1740 phenobarbitone-\NN\1740 and\CC\1740 carbamazepine-induced\JJ\1740 <e2>cognitive\JJ\1740 impairment</e2>\NN\7296428 and\CC\1740 oxidative\JJ\1740 stress\NN\7083732 in\IN\13603305 rats\NNS\2329401 .\.\1740
D003474_D003072 NONE Concomitant\JJ\1740 <e1>curcumin</e1>\NN\1740 administration\NN\1133281 prevented\VBD\1740 the\DT\1740 <e2>cognitive\JJ\1740 impairment</e2>\NN\7296428 and\CC\1740 decreased\VBD\169651 the\DT\1740 increased\VBN\169651 oxidative\JJ\1740 stress\NN\7083732 induced\VBN\1627355 by\IN\1740 these\DT\1740 antiepileptic\JJ\1740 drugs\NNS\14778436 .\.\1740
D003474_D003072 NONE These\DT\1740 results\NNS\34213 show\VBP\2137132 that\IN\1740 <e1>curcumin</e1>\NN\1740 has\VBZ\2108377 beneficial\JJ\1740 effect\NN\34213 in\IN\13603305 mitigating\VBG\894738 the\DT\1740 <e2>deterioration\NN\14560612 of\IN\1740 cognitive\JJ\1740 functions</e2>\NNS\13783581 and\CC\1740 oxidative\JJ\1740 damage\NN\7296428 in\IN\13603305 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 phenobarbitone\NN\2792049 and\CC\1740 carbamazepine\NN\1740 without\IN\1740 significantly\RB\1740 altering\VBG\126264 their\PRP$\1740 serum\NN\5397468 concentrations\NNS\4916342 .\.\1740
D003474_D003072 NONE The\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 <e1>curcumin</e1>\NN\1740 can\MD\3094503 be\VB\836236 considered\VBN\689344 as\IN\14622893 a\DT\13649268 potential\JJ\1740 safe\JJ\1740 and\CC\1740 effective\JJ\1740 adjuvant\JJ\1740 to\TO\1740 phenobarbitone\NN\2792049 and\CC\1740 carbamazepine\NN\1740 therapy\NN\657604 in\IN\13603305 preventing\VBG\1740 <e2>cognitive\JJ\1740 impairment</e2>\NN\7296428 associated\VBN\628491 with\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D010634_D003072 CID Curcumin\NN\1740 ameliorates\VBZ\126264 <e2>cognitive\JJ\1740 dysfunction</e2>\NN\14204950 and\CC\1740 oxidative\JJ\1740 damage\NN\7296428 in\IN\13603305 <e1>phenobarbitone</e1>\NN\2792049 and\CC\1740 carbamazepine\NN\1740 administered\JJ\1740 rats\NNS\2329401 .\.\1740
D010634_D003072 CID The\DT\1740 antiepileptic\JJ\1740 drugs\NNS\14778436 ,\,\1740 <e1>phenobarbitone</e1>\NN\2792049 and\CC\1740 carbamazepine\NN\1740 are\VBP\836236 well\RB\1740 known\VBN\2110220 to\TO\1740 cause\VB\1617192 <e2>cognitive\JJ\1740 impairment</e2>\NN\7296428 on\IN\1740 chronic\JJ\1740 use\NN\407535 .\.\1740
D010634_D003072 CID Therefore\RB\1740 ,\,\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 carried\VBN\1850315 out\RP\1740 to\TO\1740 investigate\VB\644583 the\DT\1740 effect\NN\34213 of\IN\1740 chronic\JJ\1740 curcumin\NN\1740 administration\NN\1133281 on\IN\1740 <e1>phenobarbitone-</e1>\NN\1740 and\CC\1740 carbamazepine-induced\JJ\1740 <e2>cognitive\JJ\1740 impairment</e2>\NN\7296428 and\CC\1740 oxidative\JJ\1740 stress\NN\7083732 in\IN\13603305 rats\NNS\2329401 .\.\1740
D010634_D003072 CID The\DT\1740 administration\NN\1133281 of\IN\1740 <e1>phenobarbitone</e1>\NN\2792049 and\CC\1740 carbamazepine\NN\1740 for\IN\1740 21days\NNS\1740 caused\VBD\1617192 a\DT\13649268 significant\JJ\1740 <e2>impairment\NN\7296428 of\IN\1740 learning\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 as\RB\1740 well\RB\1740 as\IN\14622893 an\DT\6697703 increased\VBN\169651 oxidative\JJ\1740 stress\NN\7083732 .\.\1740
D010634_D003072 CID These\DT\1740 results\NNS\34213 show\VBP\2137132 that\IN\1740 curcumin\NN\1740 has\VBZ\2108377 beneficial\JJ\1740 effect\NN\34213 in\IN\13603305 mitigating\VBG\894738 the\DT\1740 <e2>deterioration\NN\14560612 of\IN\1740 cognitive\JJ\1740 functions</e2>\NNS\13783581 and\CC\1740 oxidative\JJ\1740 damage\NN\7296428 in\IN\13603305 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 <e1>phenobarbitone</e1>\NN\2792049 and\CC\1740 carbamazepine\NN\1740 without\IN\1740 significantly\RB\1740 altering\VBG\126264 their\PRP$\1740 serum\NN\5397468 concentrations\NNS\4916342 .\.\1740
D010634_D003072 CID The\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 curcumin\NN\1740 can\MD\3094503 be\VB\836236 considered\VBN\689344 as\IN\14622893 a\DT\13649268 potential\JJ\1740 safe\JJ\1740 and\CC\1740 effective\JJ\1740 adjuvant\JJ\1740 to\TO\1740 <e1>phenobarbitone</e1>\NN\2792049 and\CC\1740 carbamazepine\NN\1740 therapy\NN\657604 in\IN\13603305 preventing\VBG\1740 <e2>cognitive\JJ\1740 impairment</e2>\NN\7296428 associated\VBN\628491 with\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
D002220_D003072 CID Curcumin\NN\1740 ameliorates\VBZ\126264 <e2>cognitive\JJ\1740 dysfunction</e2>\NN\14204950 and\CC\1740 oxidative\JJ\1740 damage\NN\7296428 in\IN\13603305 phenobarbitone\NN\2792049 and\CC\1740 <e1>carbamazepine</e1>\NN\1740 administered\JJ\1740 rats\NNS\2329401 .\.\1740
D002220_D003072 CID The\DT\1740 antiepileptic\JJ\1740 drugs\NNS\14778436 ,\,\1740 phenobarbitone\NN\2792049 and\CC\1740 <e1>carbamazepine</e1>\NN\1740 are\VBP\836236 well\RB\1740 known\VBN\2110220 to\TO\1740 cause\VB\1617192 <e2>cognitive\JJ\1740 impairment</e2>\NN\7296428 on\IN\1740 chronic\JJ\1740 use\NN\407535 .\.\1740
D002220_D003072 CID Therefore\RB\1740 ,\,\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 carried\VBN\1850315 out\RP\1740 to\TO\1740 investigate\VB\644583 the\DT\1740 effect\NN\34213 of\IN\1740 chronic\JJ\1740 curcumin\NN\1740 administration\NN\1133281 on\IN\1740 phenobarbitone-\NN\1740 and\CC\1740 <e1>carbamazepine-induced</e1>\JJ\1740 <e2>cognitive\JJ\1740 impairment</e2>\NN\7296428 and\CC\1740 oxidative\JJ\1740 stress\NN\7083732 in\IN\13603305 rats\NNS\2329401 .\.\1740
D002220_D003072 CID The\DT\1740 administration\NN\1133281 of\IN\1740 phenobarbitone\NN\2792049 and\CC\1740 <e1>carbamazepine</e1>\NN\1740 for\IN\1740 21days\NNS\1740 caused\VBD\1617192 a\DT\13649268 significant\JJ\1740 <e2>impairment\NN\7296428 of\IN\1740 learning\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 as\RB\1740 well\RB\1740 as\IN\14622893 an\DT\6697703 increased\VBN\169651 oxidative\JJ\1740 stress\NN\7083732 .\.\1740
D002220_D003072 CID These\DT\1740 results\NNS\34213 show\VBP\2137132 that\IN\1740 curcumin\NN\1740 has\VBZ\2108377 beneficial\JJ\1740 effect\NN\34213 in\IN\13603305 mitigating\VBG\894738 the\DT\1740 <e2>deterioration\NN\14560612 of\IN\1740 cognitive\JJ\1740 functions</e2>\NNS\13783581 and\CC\1740 oxidative\JJ\1740 damage\NN\7296428 in\IN\13603305 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 phenobarbitone\NN\2792049 and\CC\1740 <e1>carbamazepine</e1>\NN\1740 without\IN\1740 significantly\RB\1740 altering\VBG\126264 their\PRP$\1740 serum\NN\5397468 concentrations\NNS\4916342 .\.\1740
D002220_D003072 CID The\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 curcumin\NN\1740 can\MD\3094503 be\VB\836236 considered\VBN\689344 as\IN\14622893 a\DT\13649268 potential\JJ\1740 safe\JJ\1740 and\CC\1740 effective\JJ\1740 adjuvant\JJ\1740 to\TO\1740 phenobarbitone\NN\2792049 and\CC\1740 <e1>carbamazepine</e1>\NN\1740 therapy\NN\657604 in\IN\13603305 preventing\VBG\1740 <e2>cognitive\JJ\1740 impairment</e2>\NN\7296428 associated\VBN\628491 with\IN\1740 these\DT\1740 drugs\NNS\14778436 .\.\1740
12907309
C121465_D020258 NONE Neuroprotective\JJ\1740 action\NN\30358 of\IN\1740 <e1>MPEP</e1>\NN\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 mGluR5\NN\1740 antagonist\NN\7846 ,\,\1740 in\IN\13603305 methamphetamine-induced\JJ\1740 dopaminergic\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 dopamine\NN\14807737 outflow\NN\7407777 and\CC\1740 inhibition\NN\1068773 of\IN\1740 hyperthermia\NN\14034177 in\IN\13603305 rats\NNS\2329401 .\.\1740
C121465_D005334 NONE Neuroprotective\JJ\1740 action\NN\30358 of\IN\1740 <e1>MPEP</e1>\NN\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 mGluR5\NN\1740 antagonist\NN\7846 ,\,\1740 in\IN\13603305 methamphetamine-induced\JJ\1740 dopaminergic\JJ\1740 neurotoxicity\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 dopamine\NN\14807737 outflow\NN\7407777 and\CC\1740 inhibition\NN\1068773 of\IN\1740 <e2>hyperthermia</e2>\NN\14034177 in\IN\13603305 rats\NNS\2329401 .\.\1740
C121465_D005334 NONE Neuroprotection\NN\1740 rendered\VBN\120316 by\IN\1740 <e1>MPEP</e1>\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 reduction\NN\351485 of\IN\1740 the\DT\1740 methamphetamine-induced\JJ\1740 dopamine\NN\14807737 efflux\NN\13482330 in\IN\13603305 the\DT\1740 striatum\NN\5497363 due\JJ\1740 to\TO\1740 the\DT\1740 blockade\NN\952963 of\IN\1740 extrastriatal\JJ\1740 mGluR5\NN\1740 ,\,\1740 and\CC\1740 with\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 <e2>hyperthermia</e2>\NN\14034177 .\.\1740
D008694_D020258 NONE Neuroprotective\JJ\1740 action\NN\30358 of\IN\1740 MPEP\NN\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 mGluR5\NN\1740 antagonist\NN\7846 ,\,\1740 in\IN\13603305 <e1>methamphetamine-induced</e1>\JJ\1740 dopaminergic\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 dopamine\NN\14807737 outflow\NN\7407777 and\CC\1740 inhibition\NN\1068773 of\IN\1740 hyperthermia\NN\14034177 in\IN\13603305 rats\NNS\2329401 .\.\1740
D008694_D005334 CID Neuroprotective\JJ\1740 action\NN\30358 of\IN\1740 MPEP\NN\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 mGluR5\NN\1740 antagonist\NN\7846 ,\,\1740 in\IN\13603305 <e1>methamphetamine-induced</e1>\JJ\1740 dopaminergic\JJ\1740 neurotoxicity\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 dopamine\NN\14807737 outflow\NN\7407777 and\CC\1740 inhibition\NN\1068773 of\IN\1740 <e2>hyperthermia</e2>\NN\14034177 in\IN\13603305 rats\NNS\2329401 .\.\1740
D008694_D005334 CID Moreover\RB\1740 ,\,\1740 it\PRP\6125041 transiently\RB\1740 diminished\VBD\169651 the\DT\1740 <e1>methamphetamine</e1>\NN\2704153 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 sc)-induced\JJ\1740 <e2>hyperthermia</e2>\NN\14034177 and\CC\1740 reduced\VBN\441445 basal\JJ\1740 body\NN\19128 temperature\NN\13575869 .\.\1740
D008694_D005334 CID Neuroprotection\NN\1740 rendered\VBN\120316 by\IN\1740 MPEP\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 reduction\NN\351485 of\IN\1740 the\DT\1740 <e1>methamphetamine-induced</e1>\JJ\1740 dopamine\NN\14807737 efflux\NN\13482330 in\IN\13603305 the\DT\1740 striatum\NN\5497363 due\JJ\1740 to\TO\1740 the\DT\1740 blockade\NN\952963 of\IN\1740 extrastriatal\JJ\1740 mGluR5\NN\1740 ,\,\1740 and\CC\1740 with\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 <e2>hyperthermia</e2>\NN\14034177 .\.\1740
D004298_D020258 NONE Neuroprotective\JJ\1740 action\NN\30358 of\IN\1740 MPEP\NN\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 mGluR5\NN\1740 antagonist\NN\7846 ,\,\1740 in\IN\13603305 methamphetamine-induced\JJ\1740 dopaminergic\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 <e1>dopamine</e1>\NN\14807737 outflow\NN\7407777 and\CC\1740 inhibition\NN\1068773 of\IN\1740 hyperthermia\NN\14034177 in\IN\13603305 rats\NNS\2329401 .\.\1740
D004298_D005334 NONE Neuroprotective\JJ\1740 action\NN\30358 of\IN\1740 MPEP\NN\1740 ,\,\1740 a\DT\13649268 selective\JJ\1740 mGluR5\NN\1740 antagonist\NN\7846 ,\,\1740 in\IN\13603305 methamphetamine-induced\JJ\1740 dopaminergic\JJ\1740 neurotoxicity\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 <e1>dopamine</e1>\NN\14807737 outflow\NN\7407777 and\CC\1740 inhibition\NN\1068773 of\IN\1740 <e2>hyperthermia</e2>\NN\14034177 in\IN\13603305 rats\NNS\2329401 .\.\1740
D004298_D005334 NONE Neuroprotection\NN\1740 rendered\VBN\120316 by\IN\1740 MPEP\NN\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 reduction\NN\351485 of\IN\1740 the\DT\1740 methamphetamine-induced\JJ\1740 <e1>dopamine</e1>\NN\14807737 efflux\NN\13482330 in\IN\13603305 the\DT\1740 striatum\NN\5497363 due\JJ\1740 to\TO\1740 the\DT\1740 blockade\NN\952963 of\IN\1740 extrastriatal\JJ\1740 mGluR5\NN\1740 ,\,\1740 and\CC\1740 with\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 <e2>hyperthermia</e2>\NN\14034177 .\.\1740
C121465_D064420 NONE The\DT\1740 results\NNS\34213 of\IN\1740 this\DT\1740 study\NN\635850 suggest\VBP\1010118 that\IN\1740 the\DT\1740 blockade\NN\952963 of\IN\1740 mGluR5\NN\1740 by\IN\1740 <e1>MPEP</e1>\NN\1740 may\MD\15209706 protect\VB\1127795 dopaminergic\JJ\1740 neurones\NNS\1740 against\IN\1740 methamphetamine-induced\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D008694_D064420 NONE The\DT\1740 results\NNS\34213 of\IN\1740 this\DT\1740 study\NN\635850 suggest\VBP\1010118 that\IN\1740 the\DT\1740 blockade\NN\952963 of\IN\1740 mGluR5\NN\1740 by\IN\1740 MPEP\NN\1740 may\MD\15209706 protect\VB\1127795 dopaminergic\JJ\1740 neurones\NNS\1740 against\IN\1740 <e1>methamphetamine-induced</e1>\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
11391224
D003042_D006974 NONE These\DT\1740 13\CD\13745420 included\VBD\690614 cases\NNS\7283608 of\IN\1740 <e2>malignant\JJ\1740 hypertension</e2>\NN\14057371 ,\,\1740 thrombotic\JJ\1740 microangiopathy\NN\1740 ,\,\1740 lupus\NN\14219661 nephritis\NN\14113228 ,\,\1740 Henoch-Schonlein\NN\1740 nephritis\NN\14113228 ,\,\1740 crescentic\JJ\1740 glomerulonephritis\NN\14113798 ,\,\1740 and\CC\1740 <e1>cocaine-related</e1>\JJ\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D003042_D057049 NONE These\DT\1740 13\CD\13745420 included\VBD\690614 cases\NNS\7283608 of\IN\1740 malignant\JJ\1740 hypertension\NN\14057371 ,\,\1740 <e2>thrombotic\JJ\1740 microangiopathy</e2>\NN\1740 ,\,\1740 lupus\NN\14219661 nephritis\NN\14113228 ,\,\1740 Henoch-Schonlein\NN\1740 nephritis\NN\14113228 ,\,\1740 crescentic\JJ\1740 glomerulonephritis\NN\14113798 ,\,\1740 and\CC\1740 <e1>cocaine-related</e1>\JJ\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D003042_D008181 NONE These\DT\1740 13\CD\13745420 included\VBD\690614 cases\NNS\7283608 of\IN\1740 malignant\JJ\1740 hypertension\NN\14057371 ,\,\1740 thrombotic\JJ\1740 microangiopathy\NN\1740 ,\,\1740 <e2>lupus\NN\14219661 nephritis</e2>\NN\14113228 ,\,\1740 Henoch-Schonlein\NN\1740 nephritis\NN\14113228 ,\,\1740 crescentic\JJ\1740 glomerulonephritis\NN\14113798 ,\,\1740 and\CC\1740 <e1>cocaine-related</e1>\JJ\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D003042_D011695 NONE These\DT\1740 13\CD\13745420 included\VBD\690614 cases\NNS\7283608 of\IN\1740 malignant\JJ\1740 hypertension\NN\14057371 ,\,\1740 thrombotic\JJ\1740 microangiopathy\NN\1740 ,\,\1740 lupus\NN\14219661 nephritis\NN\14113228 ,\,\1740 <e2>Henoch-Schonlein\NN\1740 nephritis</e2>\NN\14113228 ,\,\1740 crescentic\JJ\1740 glomerulonephritis\NN\14113798 ,\,\1740 and\CC\1740 <e1>cocaine-related</e1>\JJ\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D003042_D005921 NONE These\DT\1740 13\CD\13745420 included\VBD\690614 cases\NNS\7283608 of\IN\1740 malignant\JJ\1740 hypertension\NN\14057371 ,\,\1740 thrombotic\JJ\1740 microangiopathy\NN\1740 ,\,\1740 lupus\NN\14219661 nephritis\NN\14113228 ,\,\1740 Henoch-Schonlein\NN\1740 nephritis\NN\14113228 ,\,\1740 crescentic\JJ\1740 <e2>glomerulonephritis</e2>\NN\14113798 ,\,\1740 and\CC\1740 <e1>cocaine-related</e1>\JJ\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 .\.\1740
D003042_D058186 CID These\DT\1740 13\CD\13745420 included\VBD\690614 cases\NNS\7283608 of\IN\1740 malignant\JJ\1740 hypertension\NN\14057371 ,\,\1740 thrombotic\JJ\1740 microangiopathy\NN\1740 ,\,\1740 lupus\NN\14219661 nephritis\NN\14113228 ,\,\1740 Henoch-Schonlein\NN\1740 nephritis\NN\14113228 ,\,\1740 crescentic\JJ\1740 glomerulonephritis\NN\14113798 ,\,\1740 and\CC\1740 <e1>cocaine-related</e1>\JJ\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 .\.\1740
14596845
D000661_D019966 NONE A\DT\13649268 diet\NN\7560652 promoting\VBG\2556126 <e2>sugar\NN\7858595 dependency</e2>\NN\24720 causes\VBZ\1617192 behavioral\JJ\1740 cross-sensitization\NN\1740 to\TO\1740 a\DT\13649268 low\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>amphetamine</e1>\NN\3248958 .\.\1740
D000661_D006948 CID A\DT\13649268 diet\NN\7560652 promoting\VBG\2556126 sugar\NN\7858595 dependency\NN\24720 causes\VBZ\1617192 <e2>behavioral\JJ\1740 cross-sensitization</e2>\NN\1740 to\TO\1740 a\DT\13649268 low\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>amphetamine</e1>\NN\3248958 .\.\1740
D000661_D006948 CID The\DT\1740 present\JJ\1740 study\NN\635850 examined\VBD\789138 whether\IN\1740 female\JJ\1740 rats\NNS\2329401 on\IN\1740 various\JJ\1740 regimens\NNS\5898568 of\IN\1740 sugar\NN\7858595 access\NN\5174653 would\MD\1740 show\VB\2137132 <e2>behavioral\JJ\1740 cross-sensitization</e2>\NN\1740 to\TO\1740 a\DT\13649268 low\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>amphetamine</e1>\NN\3248958 .\.\1740
D000661_D006948 CID The\DT\1740 animals\NNS\4475 that\WDT\1740 had\VBD\2108377 experienced\VBN\2108377 cyclic\JJ\1740 sucrose\NN\14836642 and\CC\1740 chow\VB\1740 were\VBD\836236 <e2>hyperactive</e2>\JJ\1740 in\IN\13603305 response\NN\11410625 to\TO\1740 <e1>amphetamine</e1>\NN\3248958 compared\VBN\644583 with\IN\1740 four\CD\13741022 control\NN\5190804 groups\NNS\2137 (\-LRB-\1740 ad\NN\7247071 libitum\NN\1740 10\CD\13745420 %\NN\1740 sucrose\NN\14836642 and\CC\1740 chow\VB\1740 followed\VBN\1835496 by\IN\1740 amphetamine\NN\3248958 injection\NN\320852 ,\,\1740 cyclic\JJ\1740 chow\NN\7971582 followed\VBN\1835496 by\IN\1740 amphetamine\NN\3248958 injection\NN\320852 ,\,\1740 ad\NN\7247071 libitum\NN\1740 chow\VBP\1740 with\IN\1740 amphetamine\NN\3248958 ,\,\1740 or\CC\3541091 cyclic\JJ\1740 10\CD\13745420 %\NN\1740 sucrose\NN\14836642 and\CC\1740 chow\VB\1740 with\IN\1740 a\DT\13649268 saline\NN\14849367 injection\NN\320852 )\-RRB-\1740 .\.\1740
D000661_D006948 CID The\DT\1740 animals\NNS\4475 that\WDT\1740 had\VBD\2108377 experienced\VBN\2108377 cyclic\JJ\1740 sucrose\NN\14836642 and\CC\1740 chow\VB\1740 were\VBD\836236 <e2>hyperactive</e2>\JJ\1740 in\IN\13603305 response\NN\11410625 to\TO\1740 amphetamine\NN\3248958 compared\VBN\644583 with\IN\1740 four\CD\13741022 control\NN\5190804 groups\NNS\2137 (\-LRB-\1740 ad\NN\7247071 libitum\NN\1740 10\CD\13745420 %\NN\1740 sucrose\NN\14836642 and\CC\1740 chow\VB\1740 followed\VBN\1835496 by\IN\1740 <e1>amphetamine</e1>\NN\3248958 injection\NN\320852 ,\,\1740 cyclic\JJ\1740 chow\NN\7971582 followed\VBN\1835496 by\IN\1740 amphetamine\NN\3248958 injection\NN\320852 ,\,\1740 ad\NN\7247071 libitum\NN\1740 chow\VBP\1740 with\IN\1740 amphetamine\NN\3248958 ,\,\1740 or\CC\3541091 cyclic\JJ\1740 10\CD\13745420 %\NN\1740 sucrose\NN\14836642 and\CC\1740 chow\VB\1740 with\IN\1740 a\DT\13649268 saline\NN\14849367 injection\NN\320852 )\-RRB-\1740 .\.\1740
D000661_D006948 CID The\DT\1740 animals\NNS\4475 that\WDT\1740 had\VBD\2108377 experienced\VBN\2108377 cyclic\JJ\1740 sucrose\NN\14836642 and\CC\1740 chow\VB\1740 were\VBD\836236 <e2>hyperactive</e2>\JJ\1740 in\IN\13603305 response\NN\11410625 to\TO\1740 amphetamine\NN\3248958 compared\VBN\644583 with\IN\1740 four\CD\13741022 control\NN\5190804 groups\NNS\2137 (\-LRB-\1740 ad\NN\7247071 libitum\NN\1740 10\CD\13745420 %\NN\1740 sucrose\NN\14836642 and\CC\1740 chow\VB\1740 followed\VBN\1835496 by\IN\1740 amphetamine\NN\3248958 injection\NN\320852 ,\,\1740 cyclic\JJ\1740 chow\NN\7971582 followed\VBN\1835496 by\IN\1740 <e1>amphetamine</e1>\NN\3248958 injection\NN\320852 ,\,\1740 ad\NN\7247071 libitum\NN\1740 chow\VBP\1740 with\IN\1740 amphetamine\NN\3248958 ,\,\1740 or\CC\3541091 cyclic\JJ\1740 10\CD\13745420 %\NN\1740 sucrose\NN\14836642 and\CC\1740 chow\VB\1740 with\IN\1740 a\DT\13649268 saline\NN\14849367 injection\NN\320852 )\-RRB-\1740 .\.\1740
D000661_D006948 CID The\DT\1740 animals\NNS\4475 that\WDT\1740 had\VBD\2108377 experienced\VBN\2108377 cyclic\JJ\1740 sucrose\NN\14836642 and\CC\1740 chow\VB\1740 were\VBD\836236 <e2>hyperactive</e2>\JJ\1740 in\IN\13603305 response\NN\11410625 to\TO\1740 amphetamine\NN\3248958 compared\VBN\644583 with\IN\1740 four\CD\13741022 control\NN\5190804 groups\NNS\2137 (\-LRB-\1740 ad\NN\7247071 libitum\NN\1740 10\CD\13745420 %\NN\1740 sucrose\NN\14836642 and\CC\1740 chow\VB\1740 followed\VBN\1835496 by\IN\1740 amphetamine\NN\3248958 injection\NN\320852 ,\,\1740 cyclic\JJ\1740 chow\NN\7971582 followed\VBN\1835496 by\IN\1740 amphetamine\NN\3248958 injection\NN\320852 ,\,\1740 ad\NN\7247071 libitum\NN\1740 chow\VBP\1740 with\IN\1740 <e1>amphetamine</e1>\NN\3248958 ,\,\1740 or\CC\3541091 cyclic\JJ\1740 10\CD\13745420 %\NN\1740 sucrose\NN\14836642 and\CC\1740 chow\VB\1740 with\IN\1740 a\DT\13649268 saline\NN\14849367 injection\NN\320852 )\-RRB-\1740 .\.\1740
D013395_D006948 CID The\DT\1740 animals\NNS\4475 that\WDT\1740 had\VBD\2108377 experienced\VBN\2108377 cyclic\JJ\1740 <e1>sucrose</e1>\NN\14836642 and\CC\1740 chow\VB\1740 were\VBD\836236 <e2>hyperactive</e2>\JJ\1740 in\IN\13603305 response\NN\11410625 to\TO\1740 amphetamine\NN\3248958 compared\VBN\644583 with\IN\1740 four\CD\13741022 control\NN\5190804 groups\NNS\2137 (\-LRB-\1740 ad\NN\7247071 libitum\NN\1740 10\CD\13745420 %\NN\1740 sucrose\NN\14836642 and\CC\1740 chow\VB\1740 followed\VBN\1835496 by\IN\1740 amphetamine\NN\3248958 injection\NN\320852 ,\,\1740 cyclic\JJ\1740 chow\NN\7971582 followed\VBN\1835496 by\IN\1740 amphetamine\NN\3248958 injection\NN\320852 ,\,\1740 ad\NN\7247071 libitum\NN\1740 chow\VBP\1740 with\IN\1740 amphetamine\NN\3248958 ,\,\1740 or\CC\3541091 cyclic\JJ\1740 10\CD\13745420 %\NN\1740 sucrose\NN\14836642 and\CC\1740 chow\VB\1740 with\IN\1740 a\DT\13649268 saline\NN\14849367 injection\NN\320852 )\-RRB-\1740 .\.\1740
D013395_D006948 CID The\DT\1740 animals\NNS\4475 that\WDT\1740 had\VBD\2108377 experienced\VBN\2108377 cyclic\JJ\1740 sucrose\NN\14836642 and\CC\1740 chow\VB\1740 were\VBD\836236 <e2>hyperactive</e2>\JJ\1740 in\IN\13603305 response\NN\11410625 to\TO\1740 amphetamine\NN\3248958 compared\VBN\644583 with\IN\1740 four\CD\13741022 control\NN\5190804 groups\NNS\2137 (\-LRB-\1740 ad\NN\7247071 libitum\NN\1740 10\CD\13745420 %\NN\1740 <e1>sucrose</e1>\NN\14836642 and\CC\1740 chow\VB\1740 followed\VBN\1835496 by\IN\1740 amphetamine\NN\3248958 injection\NN\320852 ,\,\1740 cyclic\JJ\1740 chow\NN\7971582 followed\VBN\1835496 by\IN\1740 amphetamine\NN\3248958 injection\NN\320852 ,\,\1740 ad\NN\7247071 libitum\NN\1740 chow\VBP\1740 with\IN\1740 amphetamine\NN\3248958 ,\,\1740 or\CC\3541091 cyclic\JJ\1740 10\CD\13745420 %\NN\1740 sucrose\NN\14836642 and\CC\1740 chow\VB\1740 with\IN\1740 a\DT\13649268 saline\NN\14849367 injection\NN\320852 )\-RRB-\1740 .\.\1740
D013395_D006948 CID The\DT\1740 animals\NNS\4475 that\WDT\1740 had\VBD\2108377 experienced\VBN\2108377 cyclic\JJ\1740 sucrose\NN\14836642 and\CC\1740 chow\VB\1740 were\VBD\836236 <e2>hyperactive</e2>\JJ\1740 in\IN\13603305 response\NN\11410625 to\TO\1740 amphetamine\NN\3248958 compared\VBN\644583 with\IN\1740 four\CD\13741022 control\NN\5190804 groups\NNS\2137 (\-LRB-\1740 ad\NN\7247071 libitum\NN\1740 10\CD\13745420 %\NN\1740 sucrose\NN\14836642 and\CC\1740 chow\VB\1740 followed\VBN\1835496 by\IN\1740 amphetamine\NN\3248958 injection\NN\320852 ,\,\1740 cyclic\JJ\1740 chow\NN\7971582 followed\VBN\1835496 by\IN\1740 amphetamine\NN\3248958 injection\NN\320852 ,\,\1740 ad\NN\7247071 libitum\NN\1740 chow\VBP\1740 with\IN\1740 amphetamine\NN\3248958 ,\,\1740 or\CC\3541091 cyclic\JJ\1740 10\CD\13745420 %\NN\1740 <e1>sucrose</e1>\NN\14836642 and\CC\1740 chow\VB\1740 with\IN\1740 a\DT\13649268 saline\NN\14849367 injection\NN\320852 )\-RRB-\1740 .\.\1740
19445921
C066201_D009203 NONE Cardioprotective\JJ\1740 effect\NN\34213 of\IN\1740 <e1>salvianolic\JJ\1740 acid\NN\14818238 A</e1>\NN\13649268 on\IN\1740 isoproterenol-induced\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
C066201_D009203 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 evaluate\VB\670261 the\DT\1740 cardioprotective\JJ\1740 potential\NN\14481929 of\IN\1740 <e1>salvianolic\JJ\1740 acid\NN\14818238 A</e1>\NN\13649268 on\IN\1740 isoproterenol-induced\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
C066201_D009203 NONE The\DT\1740 results\NNS\34213 of\IN\1740 our\PRP$\1740 study\NN\635850 suggest\VBP\1010118 that\IN\1740 <e1>salvianolic\JJ\1740 acid\NN\14818238 A</e1>\NN\13649268 possessing\VBG\2630189 antioxidant\JJ\1740 activity\NN\30358 has\VBZ\2108377 a\DT\13649268 significant\JJ\1740 protective\JJ\1740 effect\NN\34213 against\IN\1740 isoproterenol-induced\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D007545_D009203 CID Cardioprotective\JJ\1740 effect\NN\34213 of\IN\1740 salvianolic\JJ\1740 acid\NN\14818238 A\NN\13649268 on\IN\1740 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
D007545_D009203 CID The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 evaluate\VB\670261 the\DT\1740 cardioprotective\JJ\1740 potential\NN\14481929 of\IN\1740 salvianolic\JJ\1740 acid\NN\14818238 A\NN\13649268 on\IN\1740 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
D007545_D009203 CID The\DT\1740 results\NNS\34213 of\IN\1740 our\PRP$\1740 study\NN\635850 suggest\VBP\1010118 that\IN\1740 salvianolic\JJ\1740 acid\NN\14818238 A\NN\13649268 possessing\VBG\2630189 antioxidant\JJ\1740 activity\NN\30358 has\VBZ\2108377 a\DT\13649268 significant\JJ\1740 protective\JJ\1740 effect\NN\34213 against\IN\1740 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D000244_D012131 NONE In\IN\13603305 addition\NN\3081021 ,\,\1740 mitochondrial\JJ\1740 <e2>respiratory\JJ\1740 dysfunction</e2>\NN\14204950 characterized\VBN\609683 by\IN\1740 decreased\VBN\169651 respiratory\JJ\1740 control\NN\5190804 ratio\NN\13815152 and\CC\1740 <e1>ADP/O</e1>\NN\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 isoproterenol-treated\JJ\1740 rats\NNS\2329401 .\.\1740
D007545_D012131 NONE In\IN\13603305 addition\NN\3081021 ,\,\1740 mitochondrial\JJ\1740 <e2>respiratory\JJ\1740 dysfunction</e2>\NN\14204950 characterized\VBN\609683 by\IN\1740 decreased\VBN\169651 respiratory\JJ\1740 control\NN\5190804 ratio\NN\13815152 and\CC\1740 ADP/O\NN\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 <e1>isoproterenol-treated</e1>\JJ\1740 rats\NNS\2329401 .\.\1740
C066201_D006331 NONE Administration\NN\1133281 of\IN\1740 <e1>salvianolic\JJ\1740 acid\NN\14818238 A</e1>\NN\13649268 for\IN\1740 a\DT\13649268 period\NN\13575869 of\IN\1740 8\CD\13741022 days\NNS\15140892 significantly\RB\1740 attenuated\VBD\224901 isoproterenol-induced\JJ\1740 <e2>cardiac\JJ\1740 dysfunction</e2>\NN\14204950 and\CC\1740 myocardial\JJ\1740 injury\NN\14052046 and\CC\1740 improved\VBD\126264 mitochondrial\JJ\1740 respiratory\JJ\1740 function\NN\13783581 .\.\1740
C066201_D009202 NONE Administration\NN\1133281 of\IN\1740 <e1>salvianolic\JJ\1740 acid\NN\14818238 A</e1>\NN\13649268 for\IN\1740 a\DT\13649268 period\NN\13575869 of\IN\1740 8\CD\13741022 days\NNS\15140892 significantly\RB\1740 attenuated\VBD\224901 isoproterenol-induced\JJ\1740 cardiac\JJ\1740 dysfunction\NN\14204950 and\CC\1740 <e2>myocardial\JJ\1740 injury</e2>\NN\14052046 and\CC\1740 improved\VBD\126264 mitochondrial\JJ\1740 respiratory\JJ\1740 function\NN\13783581 .\.\1740
C066201_D009202 NONE The\DT\1740 protective\JJ\1740 role\NN\719494 of\IN\1740 <e1>salvianolic\JJ\1740 acid\NN\14818238 A</e1>\NN\13649268 against\IN\1740 isoproterenol-induced\JJ\1740 <e2>myocardial\JJ\1740 damage</e2>\NN\7296428 was\VBD\836236 further\RB\1740 confirmed\VBN\1011725 by\IN\1740 histopathological\JJ\1740 examination\NN\633864 .\.\1740
D007545_D006331 NONE Administration\NN\1133281 of\IN\1740 salvianolic\JJ\1740 acid\NN\14818238 A\NN\13649268 for\IN\1740 a\DT\13649268 period\NN\13575869 of\IN\1740 8\CD\13741022 days\NNS\15140892 significantly\RB\1740 attenuated\VBD\224901 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>cardiac\JJ\1740 dysfunction</e2>\NN\14204950 and\CC\1740 myocardial\JJ\1740 injury\NN\14052046 and\CC\1740 improved\VBD\126264 mitochondrial\JJ\1740 respiratory\JJ\1740 function\NN\13783581 .\.\1740
D007545_D009202 NONE Administration\NN\1133281 of\IN\1740 salvianolic\JJ\1740 acid\NN\14818238 A\NN\13649268 for\IN\1740 a\DT\13649268 period\NN\13575869 of\IN\1740 8\CD\13741022 days\NNS\15140892 significantly\RB\1740 attenuated\VBD\224901 <e1>isoproterenol-induced</e1>\JJ\1740 cardiac\JJ\1740 dysfunction\NN\14204950 and\CC\1740 <e2>myocardial\JJ\1740 injury</e2>\NN\14052046 and\CC\1740 improved\VBD\126264 mitochondrial\JJ\1740 respiratory\JJ\1740 function\NN\13783581 .\.\1740
D007545_D009202 NONE The\DT\1740 protective\JJ\1740 role\NN\719494 of\IN\1740 salvianolic\JJ\1740 acid\NN\14818238 A\NN\13649268 against\IN\1740 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 damage</e2>\NN\7296428 was\VBD\836236 further\RB\1740 confirmed\VBN\1011725 by\IN\1740 histopathological\JJ\1740 examination\NN\633864 .\.\1740
7930386
D002997_D012893 CID <e1>Clomipramine-induced</e1>\JJ\1740 <e2>sleep\NN\14034177 disturbance</e2>\NN\407535 does\VBZ\1640855 not\RB\1740 impair\VB\258857 its\PRP$\6125041 prolactin-releasing\JJ\1740 action\NN\30358 .\.\1740
D002997_D012893 CID The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 examine\VB\789138 the\DT\1740 role\NN\719494 of\IN\1740 <e2>sleep\NN\14034177 disturbance</e2>\NN\407535 ,\,\1740 induced\VBN\1627355 by\IN\1740 <e1>clomipramine</e1>\NN\4482543 administration\NN\1133281 ,\,\1740 on\IN\1740 the\DT\1740 secretory\JJ\1740 rate\NN\13815152 of\IN\1740 prolactin\NN\5410315 (\-LRB-\1740 PRL\NN\1740 )\-RRB-\1740 in\IN\13603305 addition\NN\3081021 to\TO\1740 the\DT\1740 direct\JJ\1740 drug\NN\14778436 effect\NN\34213 .\.\1740
9587734
D013390_D006323 CID <e1>Suxamethonium-induced</e1>\JJ\1740 <e2>cardiac\JJ\1740 arrest</e2>\NN\88481 and\CC\1740 death\NN\7296428 following\VBG\1835496 5\CD\13741022 days\NNS\15140892 of\IN\1740 immobilization\NN\819024 .\.\1740
D013390_D006323 CID The\DT\1740 present\JJ\1740 report\NN\6470073 describes\VBZ\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 <e2>cardiac\JJ\1740 arrest</e2>\NN\88481 and\CC\1740 subsequent\JJ\1740 death\NN\7296428 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 hyperkalaemia\NN\1740 following\VBG\1835496 the\DT\1740 use\NN\407535 of\IN\1740 <e1>suxamethonium</e1>\NN\1740 in\IN\13603305 a\DT\13649268 23-year-old\JJ\1740 Malawian\JJ\1740 woman\NN\9605289 .\.\1740
D013390_D006323 CID Forty\CD\13745420 seconds\NNS\15154774 after\IN\1740 injection\NN\320852 of\IN\1740 <e1>suxamethonium</e1>\NN\1740 ,\,\1740 bradycardia\NN\14110674 and\CC\1740 <e2>cardiac\JJ\1740 arrest</e2>\NN\88481 occurred\VBD\2623529 .\.\1740
D013390_D003643 NONE <e1>Suxamethonium-induced</e1>\JJ\1740 cardiac\JJ\1740 arrest\NN\88481 and\CC\1740 <e2>death</e2>\NN\7296428 following\VBG\1835496 5\CD\13741022 days\NNS\15140892 of\IN\1740 immobilization\NN\819024 .\.\1740
D013390_D003643 NONE The\DT\1740 present\JJ\1740 report\NN\6470073 describes\VBZ\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 cardiac\JJ\1740 arrest\NN\88481 and\CC\1740 subsequent\JJ\1740 <e2>death</e2>\NN\7296428 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 hyperkalaemia\NN\1740 following\VBG\1835496 the\DT\1740 use\NN\407535 of\IN\1740 <e1>suxamethonium</e1>\NN\1740 in\IN\13603305 a\DT\13649268 23-year-old\JJ\1740 Malawian\JJ\1740 woman\NN\9605289 .\.\1740
D013390_D003643 NONE It\PRP\6125041 is\VBZ\836236 postulated\VBN\756338 that\IN\1740 her\PRP$\1740 <e2>death</e2>\NN\7296428 was\VBD\836236 caused\VBN\1617192 by\IN\1740 hypersensitivity\NN\14531772 to\TO\1740 <e1>suxamethonium</e1>\NN\1740 ,\,\1740 associated\VBN\628491 with\IN\1740 her\PRP$\1740 5-day\JJ\1740 immobilization\NN\819024 .\.\1740
D013390_D006947 CID The\DT\1740 present\JJ\1740 report\NN\6470073 describes\VBZ\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 cardiac\JJ\1740 arrest\NN\88481 and\CC\1740 subsequent\JJ\1740 death\NN\7296428 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 <e2>hyperkalaemia</e2>\NN\1740 following\VBG\1835496 the\DT\1740 use\NN\407535 of\IN\1740 <e1>suxamethonium</e1>\NN\1740 in\IN\13603305 a\DT\13649268 23-year-old\JJ\1740 Malawian\JJ\1740 woman\NN\9605289 .\.\1740
D013390_D006947 CID Apart\RB\1740 from\IN\1740 the\DT\1740 reduction\NN\351485 in\IN\13603305 the\DT\1740 patient\NN\9898892 's\POS\1740 level\NN\4916342 of\IN\1740 consciousness\NN\5669934 ,\,\1740 there\EX\27167 were\VBD\836236 no\DT\7204911 signs\NNS\6643763 of\IN\1740 motor\NN\3699975 neurone\NN\1740 damage\NN\7296428 or\CC\3541091 of\IN\1740 any\DT\1740 of\IN\1740 the\DT\1740 other\JJ\1740 known\JJ\1740 predisposing\VBG\680841 conditions\NNS\14512817 for\IN\1740 <e2>hyperkalaemia</e2>\NN\1740 following\VBG\1835496 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>suxamethonium</e1>\NN\1740 .\.\1740
D013390_D001919 CID Forty\CD\13745420 seconds\NNS\15154774 after\IN\1740 injection\NN\320852 of\IN\1740 <e1>suxamethonium</e1>\NN\1740 ,\,\1740 <e2>bradycardia</e2>\NN\14110674 and\CC\1740 cardiac\JJ\1740 arrest\NN\88481 occurred\VBD\2623529 .\.\1740
D013390_D004342 CID It\PRP\6125041 is\VBZ\836236 postulated\VBN\756338 that\IN\1740 her\PRP$\1740 death\NN\7296428 was\VBD\836236 caused\VBN\1617192 by\IN\1740 <e2>hypersensitivity</e2>\NN\14531772 to\TO\1740 <e1>suxamethonium</e1>\NN\1740 ,\,\1740 associated\VBN\628491 with\IN\1740 her\PRP$\1740 5-day\JJ\1740 immobilization\NN\819024 .\.\1740
11752354
D003276_D009203 CID <e1>Oral\JJ\1740 contraceptives</e1>\NNS\3183080 and\CC\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D003276_D009203 CID BACKGROUND\NN\4921011 :\:\1740 An\DT\6697703 association\NN\8008335 between\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 and\CC\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 has\VBZ\2108377 been\VBN\836236 found\VBN\2426171 in\IN\13603305 some\DT\1740 ,\,\1740 but\CC\1740 not\RB\1740 all\DT\1740 ,\,\1740 studies\NNS\635850 .\.\1740
D003276_D009203 CID We\PRP\1740 investigated\VBD\644583 this\DT\1740 association\NN\8008335 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 type\NN\5839024 of\IN\1740 progestagen\NN\1740 included\VBN\690614 in\IN\13603305 third-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 desogestrel\NN\1740 or\CC\3541091 gestodene\NN\1740 )\-RRB-\1740 and\CC\1740 second-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 levonorgestrel\NN\1740 )\-RRB-\1740 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 ,\,\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 estrogen\NN\14745635 ,\,\1740 and\CC\1740 the\DT\1740 presence\NN\13954253 or\CC\3541091 absence\NN\14449405 of\IN\1740 prothrombotic\JJ\1740 mutations\NNS\4475 METHODS\NNS\5616786 :\:\1740 In\IN\13603305 a\DT\13649268 nationwide\JJ\1740 ,\,\1740 population-based\JJ\1740 ,\,\1740 case-control\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 identified\VBD\699815 and\CC\1740 enrolled\VBD\2471690 248\CD\1740 women\NNS\9605289 18\CD\13745420 through\IN\1740 49\CD\1740 years\NNS\15144371 of\IN\1740 age\NN\4916342 who\WP\8299493 had\VBD\2108377 had\VBN\2108377 a\DT\13649268 first\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 between\IN\1740 1990\CD\1740 and\CC\1740 1995\CD\1740 and\CC\1740 925\CD\1740 control\NN\5190804 women\NNS\9605289 who\WP\8299493 had\VBD\2108377 not\RB\1740 had\VBN\2108377 a\DT\13649268 myocardial\JJ\1740 infarction\NN\14204950 and\CC\1740 who\WP\8299493 were\VBD\836236 matched\VBN\2664769 for\IN\1740 age\NN\4916342 ,\,\1740 calendar\NN\5726596 year\NN\15113229 of\IN\1740 the\DT\1740 index\NN\13850304 event\NN\23100 ,\,\1740 and\CC\1740 area\NN\8630985 of\IN\1740 residence\NN\8491027 .\.\1740
D003276_D009203 CID We\PRP\1740 investigated\VBD\644583 this\DT\1740 association\NN\8008335 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 type\NN\5839024 of\IN\1740 progestagen\NN\1740 included\VBN\690614 in\IN\13603305 third-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 desogestrel\NN\1740 or\CC\3541091 gestodene\NN\1740 )\-RRB-\1740 and\CC\1740 second-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 levonorgestrel\NN\1740 )\-RRB-\1740 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 ,\,\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 estrogen\NN\14745635 ,\,\1740 and\CC\1740 the\DT\1740 presence\NN\13954253 or\CC\3541091 absence\NN\14449405 of\IN\1740 prothrombotic\JJ\1740 mutations\NNS\4475 METHODS\NNS\5616786 :\:\1740 In\IN\13603305 a\DT\13649268 nationwide\JJ\1740 ,\,\1740 population-based\JJ\1740 ,\,\1740 case-control\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 identified\VBD\699815 and\CC\1740 enrolled\VBD\2471690 248\CD\1740 women\NNS\9605289 18\CD\13745420 through\IN\1740 49\CD\1740 years\NNS\15144371 of\IN\1740 age\NN\4916342 who\WP\8299493 had\VBD\2108377 had\VBN\2108377 a\DT\13649268 first\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 between\IN\1740 1990\CD\1740 and\CC\1740 1995\CD\1740 and\CC\1740 925\CD\1740 control\NN\5190804 women\NNS\9605289 who\WP\8299493 had\VBD\2108377 not\RB\1740 had\VBN\2108377 a\DT\13649268 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 and\CC\1740 who\WP\8299493 were\VBD\836236 matched\VBN\2664769 for\IN\1740 age\NN\4916342 ,\,\1740 calendar\NN\5726596 year\NN\15113229 of\IN\1740 the\DT\1740 index\NN\13850304 event\NN\23100 ,\,\1740 and\CC\1740 area\NN\8630985 of\IN\1740 residence\NN\8491027 .\.\1740
D003276_D009203 CID An\DT\6697703 analysis\NN\633864 for\IN\1740 factor\NN\7326557 V\NN\13634784 Leiden\NNP\1740 and\CC\1740 the\DT\1740 G20210A\NN\1740 mutation\NN\4475 in\IN\13603305 the\DT\1740 prothrombin\NN\15022776 gene\NN\8459252 was\VBD\836236 conducted\VBN\2436349 in\IN\13603305 217\CD\1740 patients\NNS\9898892 and\CC\1740 763\CD\1740 controls\NNS\5190804 RESULTS\NNS\34213 :\:\1740 The\DT\1740 odds\NNS\4756635 ratio\NN\13815152 for\IN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 among\IN\1740 women\NNS\9605289 who\WP\8299493 used\VBD\1156834 any\DT\1740 type\NN\5839024 of\IN\1740 combined\JJ\1740 <e1>oral\JJ\1740 contraceptive</e1>\NN\3183080 ,\,\1740 as\IN\14622893 compared\VBN\644583 with\IN\1740 nonusers\NNS\1740 ,\,\1740 was\VBD\836236 2.0\CD\1740 (\-LRB-\1740 95\CD\1740 percent\NN\13815742 confidence\NN\5697135 interval\NN\33615 ,\,\1740 1.5\CD\1740 to\TO\1740 2.8\CD\1740 )\-RRB-\1740 .\.\1740
D003276_D009203 CID Among\IN\1740 women\NNS\9605289 who\WP\8299493 used\VBD\1156834 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 ,\,\1740 the\DT\1740 odds\NNS\4756635 ratio\NN\13815152 was\VBD\836236 2.1\CD\1740 (\-LRB-\1740 95\CD\1740 percent\NN\13815742 confidence\NN\5697135 interval\NN\33615 ,\,\1740 1.5\CD\1740 to\TO\1740 3.0\CD\1740 )\-RRB-\1740 for\IN\1740 those\DT\1740 without\IN\1740 a\DT\13649268 prothrombotic\JJ\1740 mutation\NN\4475 and\CC\1740 1.9\CD\1740 (\-LRB-\1740 95\CD\1740 percent\NN\13815742 confidence\NN\5697135 interval\NN\33615 ,\,\1740 0.6\CD\1740 to\TO\1740 5.5\CD\1740 )\-RRB-\1740 for\IN\1740 those\DT\1740 with\IN\1740 a\DT\13649268 mutation\NN\4475 CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 risk\NN\14541044 of\IN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 was\VBD\836236 increased\VBN\169651 among\IN\1740 women\NNS\9605289 who\WP\8299493 used\VBD\1156834 second-generation\JJ\1740 oral\JJ\1740 contraceptives\NNS\3183080 .\.\1740
D003276_D009203 CID Among\IN\1740 women\NNS\9605289 who\WP\8299493 used\VBD\1156834 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 the\DT\1740 odds\NNS\4756635 ratio\NN\13815152 was\VBD\836236 2.1\CD\1740 (\-LRB-\1740 95\CD\1740 percent\NN\13815742 confidence\NN\5697135 interval\NN\33615 ,\,\1740 1.5\CD\1740 to\TO\1740 3.0\CD\1740 )\-RRB-\1740 for\IN\1740 those\DT\1740 without\IN\1740 a\DT\13649268 prothrombotic\JJ\1740 mutation\NN\4475 and\CC\1740 1.9\CD\1740 (\-LRB-\1740 95\CD\1740 percent\NN\13815742 confidence\NN\5697135 interval\NN\33615 ,\,\1740 0.6\CD\1740 to\TO\1740 5.5\CD\1740 )\-RRB-\1740 for\IN\1740 those\DT\1740 with\IN\1740 a\DT\13649268 mutation\NN\4475 CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 risk\NN\14541044 of\IN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 was\VBD\836236 increased\VBN\169651 among\IN\1740 women\NNS\9605289 who\WP\8299493 used\VBD\1156834 second-generation\JJ\1740 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 .\.\1740
D003276_D009203 CID The\DT\1740 risk\NN\14541044 of\IN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 was\VBD\836236 similar\JJ\1740 among\IN\1740 women\NNS\9605289 who\WP\8299493 used\VBD\1156834 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 whether\IN\1740 or\CC\3541091 not\RB\1740 they\PRP\1740 had\VBD\2108377 a\DT\13649268 prothrombotic\JJ\1740 mutation\NN\4475 .\.\1740
D011372_D009203 NONE We\PRP\1740 investigated\VBD\644583 this\DT\1740 association\NN\8008335 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 type\NN\5839024 of\IN\1740 <e1>progestagen</e1>\NN\1740 included\VBN\690614 in\IN\13603305 third-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 desogestrel\NN\1740 or\CC\3541091 gestodene\NN\1740 )\-RRB-\1740 and\CC\1740 second-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 levonorgestrel\NN\1740 )\-RRB-\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 estrogen\NN\14745635 ,\,\1740 and\CC\1740 the\DT\1740 presence\NN\13954253 or\CC\3541091 absence\NN\14449405 of\IN\1740 prothrombotic\JJ\1740 mutations\NNS\4475 METHODS\NNS\5616786 :\:\1740 In\IN\13603305 a\DT\13649268 nationwide\JJ\1740 ,\,\1740 population-based\JJ\1740 ,\,\1740 case-control\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 identified\VBD\699815 and\CC\1740 enrolled\VBD\2471690 248\CD\1740 women\NNS\9605289 18\CD\13745420 through\IN\1740 49\CD\1740 years\NNS\15144371 of\IN\1740 age\NN\4916342 who\WP\8299493 had\VBD\2108377 had\VBN\2108377 a\DT\13649268 first\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 between\IN\1740 1990\CD\1740 and\CC\1740 1995\CD\1740 and\CC\1740 925\CD\1740 control\NN\5190804 women\NNS\9605289 who\WP\8299493 had\VBD\2108377 not\RB\1740 had\VBN\2108377 a\DT\13649268 myocardial\JJ\1740 infarction\NN\14204950 and\CC\1740 who\WP\8299493 were\VBD\836236 matched\VBN\2664769 for\IN\1740 age\NN\4916342 ,\,\1740 calendar\NN\5726596 year\NN\15113229 of\IN\1740 the\DT\1740 index\NN\13850304 event\NN\23100 ,\,\1740 and\CC\1740 area\NN\8630985 of\IN\1740 residence\NN\8491027 .\.\1740
D011372_D009203 NONE We\PRP\1740 investigated\VBD\644583 this\DT\1740 association\NN\8008335 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 type\NN\5839024 of\IN\1740 <e1>progestagen</e1>\NN\1740 included\VBN\690614 in\IN\13603305 third-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 desogestrel\NN\1740 or\CC\3541091 gestodene\NN\1740 )\-RRB-\1740 and\CC\1740 second-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 levonorgestrel\NN\1740 )\-RRB-\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 estrogen\NN\14745635 ,\,\1740 and\CC\1740 the\DT\1740 presence\NN\13954253 or\CC\3541091 absence\NN\14449405 of\IN\1740 prothrombotic\JJ\1740 mutations\NNS\4475 METHODS\NNS\5616786 :\:\1740 In\IN\13603305 a\DT\13649268 nationwide\JJ\1740 ,\,\1740 population-based\JJ\1740 ,\,\1740 case-control\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 identified\VBD\699815 and\CC\1740 enrolled\VBD\2471690 248\CD\1740 women\NNS\9605289 18\CD\13745420 through\IN\1740 49\CD\1740 years\NNS\15144371 of\IN\1740 age\NN\4916342 who\WP\8299493 had\VBD\2108377 had\VBN\2108377 a\DT\13649268 first\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 between\IN\1740 1990\CD\1740 and\CC\1740 1995\CD\1740 and\CC\1740 925\CD\1740 control\NN\5190804 women\NNS\9605289 who\WP\8299493 had\VBD\2108377 not\RB\1740 had\VBN\2108377 a\DT\13649268 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 and\CC\1740 who\WP\8299493 were\VBD\836236 matched\VBN\2664769 for\IN\1740 age\NN\4916342 ,\,\1740 calendar\NN\5726596 year\NN\15113229 of\IN\1740 the\DT\1740 index\NN\13850304 event\NN\23100 ,\,\1740 and\CC\1740 area\NN\8630985 of\IN\1740 residence\NN\8491027 .\.\1740
D017135_D009203 NONE We\PRP\1740 investigated\VBD\644583 this\DT\1740 association\NN\8008335 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 type\NN\5839024 of\IN\1740 progestagen\NN\1740 included\VBN\690614 in\IN\13603305 third-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 <e1>desogestrel</e1>\NN\1740 or\CC\3541091 gestodene\NN\1740 )\-RRB-\1740 and\CC\1740 second-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 levonorgestrel\NN\1740 )\-RRB-\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 estrogen\NN\14745635 ,\,\1740 and\CC\1740 the\DT\1740 presence\NN\13954253 or\CC\3541091 absence\NN\14449405 of\IN\1740 prothrombotic\JJ\1740 mutations\NNS\4475 METHODS\NNS\5616786 :\:\1740 In\IN\13603305 a\DT\13649268 nationwide\JJ\1740 ,\,\1740 population-based\JJ\1740 ,\,\1740 case-control\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 identified\VBD\699815 and\CC\1740 enrolled\VBD\2471690 248\CD\1740 women\NNS\9605289 18\CD\13745420 through\IN\1740 49\CD\1740 years\NNS\15144371 of\IN\1740 age\NN\4916342 who\WP\8299493 had\VBD\2108377 had\VBN\2108377 a\DT\13649268 first\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 between\IN\1740 1990\CD\1740 and\CC\1740 1995\CD\1740 and\CC\1740 925\CD\1740 control\NN\5190804 women\NNS\9605289 who\WP\8299493 had\VBD\2108377 not\RB\1740 had\VBN\2108377 a\DT\13649268 myocardial\JJ\1740 infarction\NN\14204950 and\CC\1740 who\WP\8299493 were\VBD\836236 matched\VBN\2664769 for\IN\1740 age\NN\4916342 ,\,\1740 calendar\NN\5726596 year\NN\15113229 of\IN\1740 the\DT\1740 index\NN\13850304 event\NN\23100 ,\,\1740 and\CC\1740 area\NN\8630985 of\IN\1740 residence\NN\8491027 .\.\1740
D017135_D009203 NONE We\PRP\1740 investigated\VBD\644583 this\DT\1740 association\NN\8008335 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 type\NN\5839024 of\IN\1740 progestagen\NN\1740 included\VBN\690614 in\IN\13603305 third-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 <e1>desogestrel</e1>\NN\1740 or\CC\3541091 gestodene\NN\1740 )\-RRB-\1740 and\CC\1740 second-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 levonorgestrel\NN\1740 )\-RRB-\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 estrogen\NN\14745635 ,\,\1740 and\CC\1740 the\DT\1740 presence\NN\13954253 or\CC\3541091 absence\NN\14449405 of\IN\1740 prothrombotic\JJ\1740 mutations\NNS\4475 METHODS\NNS\5616786 :\:\1740 In\IN\13603305 a\DT\13649268 nationwide\JJ\1740 ,\,\1740 population-based\JJ\1740 ,\,\1740 case-control\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 identified\VBD\699815 and\CC\1740 enrolled\VBD\2471690 248\CD\1740 women\NNS\9605289 18\CD\13745420 through\IN\1740 49\CD\1740 years\NNS\15144371 of\IN\1740 age\NN\4916342 who\WP\8299493 had\VBD\2108377 had\VBN\2108377 a\DT\13649268 first\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 between\IN\1740 1990\CD\1740 and\CC\1740 1995\CD\1740 and\CC\1740 925\CD\1740 control\NN\5190804 women\NNS\9605289 who\WP\8299493 had\VBD\2108377 not\RB\1740 had\VBN\2108377 a\DT\13649268 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 and\CC\1740 who\WP\8299493 were\VBD\836236 matched\VBN\2664769 for\IN\1740 age\NN\4916342 ,\,\1740 calendar\NN\5726596 year\NN\15113229 of\IN\1740 the\DT\1740 index\NN\13850304 event\NN\23100 ,\,\1740 and\CC\1740 area\NN\8630985 of\IN\1740 residence\NN\8491027 .\.\1740
C033273_D009203 NONE We\PRP\1740 investigated\VBD\644583 this\DT\1740 association\NN\8008335 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 type\NN\5839024 of\IN\1740 progestagen\NN\1740 included\VBN\690614 in\IN\13603305 third-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 desogestrel\NN\1740 or\CC\3541091 <e1>gestodene</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 second-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 levonorgestrel\NN\1740 )\-RRB-\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 estrogen\NN\14745635 ,\,\1740 and\CC\1740 the\DT\1740 presence\NN\13954253 or\CC\3541091 absence\NN\14449405 of\IN\1740 prothrombotic\JJ\1740 mutations\NNS\4475 METHODS\NNS\5616786 :\:\1740 In\IN\13603305 a\DT\13649268 nationwide\JJ\1740 ,\,\1740 population-based\JJ\1740 ,\,\1740 case-control\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 identified\VBD\699815 and\CC\1740 enrolled\VBD\2471690 248\CD\1740 women\NNS\9605289 18\CD\13745420 through\IN\1740 49\CD\1740 years\NNS\15144371 of\IN\1740 age\NN\4916342 who\WP\8299493 had\VBD\2108377 had\VBN\2108377 a\DT\13649268 first\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 between\IN\1740 1990\CD\1740 and\CC\1740 1995\CD\1740 and\CC\1740 925\CD\1740 control\NN\5190804 women\NNS\9605289 who\WP\8299493 had\VBD\2108377 not\RB\1740 had\VBN\2108377 a\DT\13649268 myocardial\JJ\1740 infarction\NN\14204950 and\CC\1740 who\WP\8299493 were\VBD\836236 matched\VBN\2664769 for\IN\1740 age\NN\4916342 ,\,\1740 calendar\NN\5726596 year\NN\15113229 of\IN\1740 the\DT\1740 index\NN\13850304 event\NN\23100 ,\,\1740 and\CC\1740 area\NN\8630985 of\IN\1740 residence\NN\8491027 .\.\1740
C033273_D009203 NONE We\PRP\1740 investigated\VBD\644583 this\DT\1740 association\NN\8008335 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 type\NN\5839024 of\IN\1740 progestagen\NN\1740 included\VBN\690614 in\IN\13603305 third-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 desogestrel\NN\1740 or\CC\3541091 <e1>gestodene</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 second-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 levonorgestrel\NN\1740 )\-RRB-\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 estrogen\NN\14745635 ,\,\1740 and\CC\1740 the\DT\1740 presence\NN\13954253 or\CC\3541091 absence\NN\14449405 of\IN\1740 prothrombotic\JJ\1740 mutations\NNS\4475 METHODS\NNS\5616786 :\:\1740 In\IN\13603305 a\DT\13649268 nationwide\JJ\1740 ,\,\1740 population-based\JJ\1740 ,\,\1740 case-control\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 identified\VBD\699815 and\CC\1740 enrolled\VBD\2471690 248\CD\1740 women\NNS\9605289 18\CD\13745420 through\IN\1740 49\CD\1740 years\NNS\15144371 of\IN\1740 age\NN\4916342 who\WP\8299493 had\VBD\2108377 had\VBN\2108377 a\DT\13649268 first\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 between\IN\1740 1990\CD\1740 and\CC\1740 1995\CD\1740 and\CC\1740 925\CD\1740 control\NN\5190804 women\NNS\9605289 who\WP\8299493 had\VBD\2108377 not\RB\1740 had\VBN\2108377 a\DT\13649268 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 and\CC\1740 who\WP\8299493 were\VBD\836236 matched\VBN\2664769 for\IN\1740 age\NN\4916342 ,\,\1740 calendar\NN\5726596 year\NN\15113229 of\IN\1740 the\DT\1740 index\NN\13850304 event\NN\23100 ,\,\1740 and\CC\1740 area\NN\8630985 of\IN\1740 residence\NN\8491027 .\.\1740
D016912_D009203 NONE We\PRP\1740 investigated\VBD\644583 this\DT\1740 association\NN\8008335 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 type\NN\5839024 of\IN\1740 progestagen\NN\1740 included\VBN\690614 in\IN\13603305 third-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 desogestrel\NN\1740 or\CC\3541091 gestodene\NN\1740 )\-RRB-\1740 and\CC\1740 second-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 <e1>levonorgestrel</e1>\NN\1740 )\-RRB-\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 estrogen\NN\14745635 ,\,\1740 and\CC\1740 the\DT\1740 presence\NN\13954253 or\CC\3541091 absence\NN\14449405 of\IN\1740 prothrombotic\JJ\1740 mutations\NNS\4475 METHODS\NNS\5616786 :\:\1740 In\IN\13603305 a\DT\13649268 nationwide\JJ\1740 ,\,\1740 population-based\JJ\1740 ,\,\1740 case-control\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 identified\VBD\699815 and\CC\1740 enrolled\VBD\2471690 248\CD\1740 women\NNS\9605289 18\CD\13745420 through\IN\1740 49\CD\1740 years\NNS\15144371 of\IN\1740 age\NN\4916342 who\WP\8299493 had\VBD\2108377 had\VBN\2108377 a\DT\13649268 first\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 between\IN\1740 1990\CD\1740 and\CC\1740 1995\CD\1740 and\CC\1740 925\CD\1740 control\NN\5190804 women\NNS\9605289 who\WP\8299493 had\VBD\2108377 not\RB\1740 had\VBN\2108377 a\DT\13649268 myocardial\JJ\1740 infarction\NN\14204950 and\CC\1740 who\WP\8299493 were\VBD\836236 matched\VBN\2664769 for\IN\1740 age\NN\4916342 ,\,\1740 calendar\NN\5726596 year\NN\15113229 of\IN\1740 the\DT\1740 index\NN\13850304 event\NN\23100 ,\,\1740 and\CC\1740 area\NN\8630985 of\IN\1740 residence\NN\8491027 .\.\1740
D016912_D009203 NONE We\PRP\1740 investigated\VBD\644583 this\DT\1740 association\NN\8008335 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 type\NN\5839024 of\IN\1740 progestagen\NN\1740 included\VBN\690614 in\IN\13603305 third-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 desogestrel\NN\1740 or\CC\3541091 gestodene\NN\1740 )\-RRB-\1740 and\CC\1740 second-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 <e1>levonorgestrel</e1>\NN\1740 )\-RRB-\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 estrogen\NN\14745635 ,\,\1740 and\CC\1740 the\DT\1740 presence\NN\13954253 or\CC\3541091 absence\NN\14449405 of\IN\1740 prothrombotic\JJ\1740 mutations\NNS\4475 METHODS\NNS\5616786 :\:\1740 In\IN\13603305 a\DT\13649268 nationwide\JJ\1740 ,\,\1740 population-based\JJ\1740 ,\,\1740 case-control\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 identified\VBD\699815 and\CC\1740 enrolled\VBD\2471690 248\CD\1740 women\NNS\9605289 18\CD\13745420 through\IN\1740 49\CD\1740 years\NNS\15144371 of\IN\1740 age\NN\4916342 who\WP\8299493 had\VBD\2108377 had\VBN\2108377 a\DT\13649268 first\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 between\IN\1740 1990\CD\1740 and\CC\1740 1995\CD\1740 and\CC\1740 925\CD\1740 control\NN\5190804 women\NNS\9605289 who\WP\8299493 had\VBD\2108377 not\RB\1740 had\VBN\2108377 a\DT\13649268 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 and\CC\1740 who\WP\8299493 were\VBD\836236 matched\VBN\2664769 for\IN\1740 age\NN\4916342 ,\,\1740 calendar\NN\5726596 year\NN\15113229 of\IN\1740 the\DT\1740 index\NN\13850304 event\NN\23100 ,\,\1740 and\CC\1740 area\NN\8630985 of\IN\1740 residence\NN\8491027 .\.\1740
D004967_D009203 NONE We\PRP\1740 investigated\VBD\644583 this\DT\1740 association\NN\8008335 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 type\NN\5839024 of\IN\1740 progestagen\NN\1740 included\VBN\690614 in\IN\13603305 third-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 desogestrel\NN\1740 or\CC\3541091 gestodene\NN\1740 )\-RRB-\1740 and\CC\1740 second-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 levonorgestrel\NN\1740 )\-RRB-\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 <e1>estrogen</e1>\NN\14745635 ,\,\1740 and\CC\1740 the\DT\1740 presence\NN\13954253 or\CC\3541091 absence\NN\14449405 of\IN\1740 prothrombotic\JJ\1740 mutations\NNS\4475 METHODS\NNS\5616786 :\:\1740 In\IN\13603305 a\DT\13649268 nationwide\JJ\1740 ,\,\1740 population-based\JJ\1740 ,\,\1740 case-control\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 identified\VBD\699815 and\CC\1740 enrolled\VBD\2471690 248\CD\1740 women\NNS\9605289 18\CD\13745420 through\IN\1740 49\CD\1740 years\NNS\15144371 of\IN\1740 age\NN\4916342 who\WP\8299493 had\VBD\2108377 had\VBN\2108377 a\DT\13649268 first\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 between\IN\1740 1990\CD\1740 and\CC\1740 1995\CD\1740 and\CC\1740 925\CD\1740 control\NN\5190804 women\NNS\9605289 who\WP\8299493 had\VBD\2108377 not\RB\1740 had\VBN\2108377 a\DT\13649268 myocardial\JJ\1740 infarction\NN\14204950 and\CC\1740 who\WP\8299493 were\VBD\836236 matched\VBN\2664769 for\IN\1740 age\NN\4916342 ,\,\1740 calendar\NN\5726596 year\NN\15113229 of\IN\1740 the\DT\1740 index\NN\13850304 event\NN\23100 ,\,\1740 and\CC\1740 area\NN\8630985 of\IN\1740 residence\NN\8491027 .\.\1740
D004967_D009203 NONE We\PRP\1740 investigated\VBD\644583 this\DT\1740 association\NN\8008335 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 type\NN\5839024 of\IN\1740 progestagen\NN\1740 included\VBN\690614 in\IN\13603305 third-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 desogestrel\NN\1740 or\CC\3541091 gestodene\NN\1740 )\-RRB-\1740 and\CC\1740 second-generation\NN\1740 (\-LRB-\1740 i.e.\FW\1740 ,\,\1740 levonorgestrel\NN\1740 )\-RRB-\1740 oral\JJ\1740 contraceptives\NNS\3183080 ,\,\1740 the\DT\1740 dose\NN\3740161 of\IN\1740 <e1>estrogen</e1>\NN\14745635 ,\,\1740 and\CC\1740 the\DT\1740 presence\NN\13954253 or\CC\3541091 absence\NN\14449405 of\IN\1740 prothrombotic\JJ\1740 mutations\NNS\4475 METHODS\NNS\5616786 :\:\1740 In\IN\13603305 a\DT\13649268 nationwide\JJ\1740 ,\,\1740 population-based\JJ\1740 ,\,\1740 case-control\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 identified\VBD\699815 and\CC\1740 enrolled\VBD\2471690 248\CD\1740 women\NNS\9605289 18\CD\13745420 through\IN\1740 49\CD\1740 years\NNS\15144371 of\IN\1740 age\NN\4916342 who\WP\8299493 had\VBD\2108377 had\VBN\2108377 a\DT\13649268 first\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 between\IN\1740 1990\CD\1740 and\CC\1740 1995\CD\1740 and\CC\1740 925\CD\1740 control\NN\5190804 women\NNS\9605289 who\WP\8299493 had\VBD\2108377 not\RB\1740 had\VBN\2108377 a\DT\13649268 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 and\CC\1740 who\WP\8299493 were\VBD\836236 matched\VBN\2664769 for\IN\1740 age\NN\4916342 ,\,\1740 calendar\NN\5726596 year\NN\15113229 of\IN\1740 the\DT\1740 index\NN\13850304 event\NN\23100 ,\,\1740 and\CC\1740 area\NN\8630985 of\IN\1740 residence\NN\8491027 .\.\1740
7444978
D013307_D020258 NONE Age-dependent\JJ\1740 sensitivity\NN\5651971 of\IN\1740 the\DT\1740 rat\NN\2329401 to\TO\1740 <e2>neurotoxic</e2>\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>streptomycin</e1>\NN\2716866 .\.\1740
D013307_D004409 CID <e2>Abnormal\JJ\1740 movements</e2>\NNS\191142 and\CC\1740 deafness\VBP\1740 occurred\VBD\2623529 only\RB\1740 in\IN\13603305 rats\NNS\2329401 treated\VBN\2376958 during\IN\1740 the\DT\1740 preweaning\VBG\1740 period\NN\13575869 ;\:\1740 within\IN\1740 this\DT\1740 period\NN\13575869 the\DT\1740 greatest\JJS\1740 sensitivities\NNS\5651971 for\IN\1740 these\DT\1740 abnormalities\NNS\14034177 occurred\VBD\2623529 from\IN\1740 2\CD\13741022 to\TO\1740 11\CD\13745420 -\SYM\1740 17\CD\13745420 and\CC\1740 5\CD\13741022 to\TO\1740 11\CD\13745420 days\NNS\15140892 of\IN\1740 age\NN\4916342 ,\,\1740 respectively\RB\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 the\DT\1740 cochlea\NN\5246511 is\VBZ\836236 more\RBR\1740 sensitive\JJ\1740 to\TO\1740 <e1>streptomycin</e1>\NN\2716866 than\IN\1740 the\DT\1740 site\NN\8673395 (\-LRB-\1740 vestibular\JJ\1740 or\CC\3541091 central\JJ\1740 )\-RRB-\1740 responsible\JJ\1740 for\IN\1740 the\DT\1740 dyskinesias\NNS\14084880 .\.\1740
D013307_D004409 CID Abnormal\JJ\1740 movements\NNS\191142 and\CC\1740 deafness\VBP\1740 occurred\VBD\2623529 only\RB\1740 in\IN\13603305 rats\NNS\2329401 treated\VBN\2376958 during\IN\1740 the\DT\1740 preweaning\VBG\1740 period\NN\13575869 ;\:\1740 within\IN\1740 this\DT\1740 period\NN\13575869 the\DT\1740 greatest\JJS\1740 sensitivities\NNS\5651971 for\IN\1740 these\DT\1740 abnormalities\NNS\14034177 occurred\VBD\2623529 from\IN\1740 2\CD\13741022 to\TO\1740 11\CD\13745420 -\SYM\1740 17\CD\13745420 and\CC\1740 5\CD\13741022 to\TO\1740 11\CD\13745420 days\NNS\15140892 of\IN\1740 age\NN\4916342 ,\,\1740 respectively\RB\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 the\DT\1740 cochlea\NN\5246511 is\VBZ\836236 more\RBR\1740 sensitive\JJ\1740 to\TO\1740 <e1>streptomycin</e1>\NN\2716866 than\IN\1740 the\DT\1740 site\NN\8673395 (\-LRB-\1740 vestibular\JJ\1740 or\CC\3541091 central\JJ\1740 )\-RRB-\1740 responsible\JJ\1740 for\IN\1740 the\DT\1740 <e2>dyskinesias</e2>\NNS\14084880 .\.\1740
D013307_D003638 CID Abnormal\JJ\1740 movements\NNS\191142 and\CC\1740 <e2>deafness</e2>\VBP\1740 occurred\VBD\2623529 only\RB\1740 in\IN\13603305 rats\NNS\2329401 treated\VBN\2376958 during\IN\1740 the\DT\1740 preweaning\VBG\1740 period\NN\13575869 ;\:\1740 within\IN\1740 this\DT\1740 period\NN\13575869 the\DT\1740 greatest\JJS\1740 sensitivities\NNS\5651971 for\IN\1740 these\DT\1740 abnormalities\NNS\14034177 occurred\VBD\2623529 from\IN\1740 2\CD\13741022 to\TO\1740 11\CD\13745420 -\SYM\1740 17\CD\13745420 and\CC\1740 5\CD\13741022 to\TO\1740 11\CD\13745420 days\NNS\15140892 of\IN\1740 age\NN\4916342 ,\,\1740 respectively\RB\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 the\DT\1740 cochlea\NN\5246511 is\VBZ\836236 more\RBR\1740 sensitive\JJ\1740 to\TO\1740 <e1>streptomycin</e1>\NN\2716866 than\IN\1740 the\DT\1740 site\NN\8673395 (\-LRB-\1740 vestibular\JJ\1740 or\CC\3541091 central\JJ\1740 )\-RRB-\1740 responsible\JJ\1740 for\IN\1740 the\DT\1740 dyskinesias\NNS\14084880 .\.\1740
18544179
D005283_D009325 NONE Omitting\VBG\471711 <e1>fentanyl</e1>\NN\2707683 reduces\VBZ\441445 <e2>nausea</e2>\NN\14299637 and\CC\1740 vomiting\NN\116687 ,\,\1740 without\IN\1740 increasing\VBG\169651 pain\NN\14299637 ,\,\1740 after\IN\1740 sevoflurane\NN\1740 for\IN\1740 day\NN\15154774 surgery\NN\6045562 .\.\1740
D005283_D009325 NONE RESULTS\NNS\34213 :\:\1740 Omission\NN\70965 of\IN\1740 <e1>fentanyl</e1>\NN\2707683 did\VBD\1640855 not\RB\1740 reduce\VB\441445 the\DT\1740 overall\JJ\1740 incidence\NN\13821570 of\IN\1740 postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 ,\,\1740 but\CC\1740 did\VBD\1640855 reduce\VB\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 vomiting\NN\116687 and/or\CC\1740 moderate\JJ\1740 to\IN\1740 severe\JJ\1740 <e2>nausea</e2>\NN\14299637 prior\RB\1740 to\TO\1740 discharge\VB\1640855 from\IN\1740 20\CD\13745420 %\NN\1740 and\CC\1740 17\CD\13745420 %\NN\1740 with\IN\1740 fentanyl\NN\2707683 and\CC\1740 fentanyl-dexamethasone\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 to\TO\1740 5\CD\13741022 %\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.013\CD\1740 )\-RRB-\1740 .\.\1740
D005283_D009325 NONE RESULTS\NNS\34213 :\:\1740 Omission\NN\70965 of\IN\1740 fentanyl\NN\2707683 did\VBD\1640855 not\RB\1740 reduce\VB\441445 the\DT\1740 overall\JJ\1740 incidence\NN\13821570 of\IN\1740 postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 ,\,\1740 but\CC\1740 did\VBD\1640855 reduce\VB\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 vomiting\NN\116687 and/or\CC\1740 moderate\JJ\1740 to\IN\1740 severe\JJ\1740 <e2>nausea</e2>\NN\14299637 prior\RB\1740 to\TO\1740 discharge\VB\1640855 from\IN\1740 20\CD\13745420 %\NN\1740 and\CC\1740 17\CD\13745420 %\NN\1740 with\IN\1740 <e1>fentanyl</e1>\NN\2707683 and\CC\1740 fentanyl-dexamethasone\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 to\TO\1740 5\CD\13741022 %\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.013\CD\1740 )\-RRB-\1740 .\.\1740
D005283_D009325 NONE RESULTS\NNS\34213 :\:\1740 Omission\NN\70965 of\IN\1740 fentanyl\NN\2707683 did\VBD\1640855 not\RB\1740 reduce\VB\441445 the\DT\1740 overall\JJ\1740 incidence\NN\13821570 of\IN\1740 postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 ,\,\1740 but\CC\1740 did\VBD\1640855 reduce\VB\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 vomiting\NN\116687 and/or\CC\1740 moderate\JJ\1740 to\IN\1740 severe\JJ\1740 <e2>nausea</e2>\NN\14299637 prior\RB\1740 to\TO\1740 discharge\VB\1640855 from\IN\1740 20\CD\13745420 %\NN\1740 and\CC\1740 17\CD\13745420 %\NN\1740 with\IN\1740 fentanyl\NN\2707683 and\CC\1740 <e1>fentanyl-dexamethasone</e1>\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 to\TO\1740 5\CD\13741022 %\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.013\CD\1740 )\-RRB-\1740 .\.\1740
D005283_D009325 NONE Combining\VBG\2630189 the\DT\1740 two\CD\13741022 <e1>fentanyl</e1>\JJ\1740 groups\NNS\2137 revealed\VBD\2137132 further\RB\1740 significant\JJ\1740 benefits\NNS\13278375 from\IN\1740 the\DT\1740 avoidance\NN\203342 of\IN\1740 opioids\NNS\1740 ,\,\1740 reducing\VBG\441445 postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 and\CC\1740 <e2>nausea</e2>\NN\14299637 prior\RB\1740 to\TO\1740 discharge\VB\1640855 from\IN\1740 35\CD\1740 %\NN\1740 and\CC\1740 33\CD\1740 %\NN\1740 to\TO\1740 22\CD\13745420 %\NN\1740 and\CC\1740 19\CD\13745420 %\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.049\CD\1740 and\CC\1740 P\NN\14622893 =\JJ\1740 0.035\CD\1740 )\-RRB-\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 nausea\NN\14299637 in\IN\13603305 the\DT\1740 first\JJ\1740 24\CD\13745420 h\NN\14622893 was\VBD\836236 decreased\VBN\169651 from\IN\1740 42\CD\1740 %\NN\1740 to\TO\1740 27\CD\13745420 %\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.034\CD\1740 )\-RRB-\1740 .\.\1740
D005283_D009325 NONE Combining\VBG\2630189 the\DT\1740 two\CD\13741022 <e1>fentanyl</e1>\JJ\1740 groups\NNS\2137 revealed\VBD\2137132 further\RB\1740 significant\JJ\1740 benefits\NNS\13278375 from\IN\1740 the\DT\1740 avoidance\NN\203342 of\IN\1740 opioids\NNS\1740 ,\,\1740 reducing\VBG\441445 postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 and\CC\1740 nausea\NN\14299637 prior\RB\1740 to\TO\1740 discharge\VB\1640855 from\IN\1740 35\CD\1740 %\NN\1740 and\CC\1740 33\CD\1740 %\NN\1740 to\TO\1740 22\CD\13745420 %\NN\1740 and\CC\1740 19\CD\13745420 %\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.049\CD\1740 and\CC\1740 P\NN\14622893 =\JJ\1740 0.035\CD\1740 )\-RRB-\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 <e2>nausea</e2>\NN\14299637 in\IN\13603305 the\DT\1740 first\JJ\1740 24\CD\13745420 h\NN\14622893 was\VBD\836236 decreased\VBN\169651 from\IN\1740 42\CD\1740 %\NN\1740 to\TO\1740 27\CD\13745420 %\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.034\CD\1740 )\-RRB-\1740 .\.\1740
D005283_D014839 NONE Omitting\VBG\471711 <e1>fentanyl</e1>\NN\2707683 reduces\VBZ\441445 nausea\NN\14299637 and\CC\1740 <e2>vomiting</e2>\NN\116687 ,\,\1740 without\IN\1740 increasing\VBG\169651 pain\NN\14299637 ,\,\1740 after\IN\1740 sevoflurane\NN\1740 for\IN\1740 day\NN\15154774 surgery\NN\6045562 .\.\1740
D005283_D014839 NONE RESULTS\NNS\34213 :\:\1740 Omission\NN\70965 of\IN\1740 <e1>fentanyl</e1>\NN\2707683 did\VBD\1640855 not\RB\1740 reduce\VB\441445 the\DT\1740 overall\JJ\1740 incidence\NN\13821570 of\IN\1740 postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 ,\,\1740 but\CC\1740 did\VBD\1640855 reduce\VB\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>vomiting</e2>\NN\116687 and/or\CC\1740 moderate\JJ\1740 to\IN\1740 severe\JJ\1740 nausea\NN\14299637 prior\RB\1740 to\TO\1740 discharge\VB\1640855 from\IN\1740 20\CD\13745420 %\NN\1740 and\CC\1740 17\CD\13745420 %\NN\1740 with\IN\1740 fentanyl\NN\2707683 and\CC\1740 fentanyl-dexamethasone\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 to\TO\1740 5\CD\13741022 %\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.013\CD\1740 )\-RRB-\1740 .\.\1740
D005283_D014839 NONE RESULTS\NNS\34213 :\:\1740 Omission\NN\70965 of\IN\1740 fentanyl\NN\2707683 did\VBD\1640855 not\RB\1740 reduce\VB\441445 the\DT\1740 overall\JJ\1740 incidence\NN\13821570 of\IN\1740 postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 ,\,\1740 but\CC\1740 did\VBD\1640855 reduce\VB\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>vomiting</e2>\NN\116687 and/or\CC\1740 moderate\JJ\1740 to\IN\1740 severe\JJ\1740 nausea\NN\14299637 prior\RB\1740 to\TO\1740 discharge\VB\1640855 from\IN\1740 20\CD\13745420 %\NN\1740 and\CC\1740 17\CD\13745420 %\NN\1740 with\IN\1740 <e1>fentanyl</e1>\NN\2707683 and\CC\1740 fentanyl-dexamethasone\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 to\TO\1740 5\CD\13741022 %\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.013\CD\1740 )\-RRB-\1740 .\.\1740
D005283_D014839 NONE RESULTS\NNS\34213 :\:\1740 Omission\NN\70965 of\IN\1740 fentanyl\NN\2707683 did\VBD\1640855 not\RB\1740 reduce\VB\441445 the\DT\1740 overall\JJ\1740 incidence\NN\13821570 of\IN\1740 postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 ,\,\1740 but\CC\1740 did\VBD\1640855 reduce\VB\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>vomiting</e2>\NN\116687 and/or\CC\1740 moderate\JJ\1740 to\IN\1740 severe\JJ\1740 nausea\NN\14299637 prior\RB\1740 to\TO\1740 discharge\VB\1640855 from\IN\1740 20\CD\13745420 %\NN\1740 and\CC\1740 17\CD\13745420 %\NN\1740 with\IN\1740 fentanyl\NN\2707683 and\CC\1740 <e1>fentanyl-dexamethasone</e1>\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 to\TO\1740 5\CD\13741022 %\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.013\CD\1740 )\-RRB-\1740 .\.\1740
D005283_D010146 NONE Omitting\VBG\471711 <e1>fentanyl</e1>\NN\2707683 reduces\VBZ\441445 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 ,\,\1740 without\IN\1740 increasing\VBG\169651 <e2>pain</e2>\NN\14299637 ,\,\1740 after\IN\1740 sevoflurane\NN\1740 for\IN\1740 day\NN\15154774 surgery\NN\6045562 .\.\1740
D005283_D010146 NONE <e2>Pain</e2>\NN\14299637 severity\NN\5036394 and\CC\1740 analgesic\NN\3740161 requirements\NNS\1129920 were\VBD\836236 unaffected\JJ\1740 by\IN\1740 the\DT\1740 omission\NN\70965 of\IN\1740 <e1>fentanyl</e1>\NN\2707683 .\.\1740
C009250_D009325 NONE Omitting\VBG\471711 fentanyl\NN\2707683 reduces\VBZ\441445 <e2>nausea</e2>\NN\14299637 and\CC\1740 vomiting\NN\116687 ,\,\1740 without\IN\1740 increasing\VBG\169651 pain\NN\14299637 ,\,\1740 after\IN\1740 <e1>sevoflurane</e1>\NN\1740 for\IN\1740 day\NN\15154774 surgery\NN\6045562 .\.\1740
C009250_D014839 NONE Omitting\VBG\471711 fentanyl\NN\2707683 reduces\VBZ\441445 nausea\NN\14299637 and\CC\1740 <e2>vomiting</e2>\NN\116687 ,\,\1740 without\IN\1740 increasing\VBG\169651 pain\NN\14299637 ,\,\1740 after\IN\1740 <e1>sevoflurane</e1>\NN\1740 for\IN\1740 day\NN\15154774 surgery\NN\6045562 .\.\1740
C009250_D010146 NONE Omitting\VBG\471711 fentanyl\NN\2707683 reduces\VBZ\441445 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 ,\,\1740 without\IN\1740 increasing\VBG\169651 <e2>pain</e2>\NN\14299637 ,\,\1740 after\IN\1740 <e1>sevoflurane</e1>\NN\1740 for\IN\1740 day\NN\15154774 surgery\NN\6045562 .\.\1740
C009250_D010146 NONE METHODS\NNS\5616786 :\:\1740 This\DT\1740 double-blind\JJ\1740 study\NN\635850 examined\VBD\789138 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 and\CC\1740 <e2>pain</e2>\NN\14299637 in\IN\13603305 the\DT\1740 first\JJ\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 <e1>sevoflurane</e1>\NN\1740 anaesthesia\NN\14034177 in\IN\13603305 216\CD\1740 adult\JJ\1740 day\NN\15154774 surgery\NN\6045562 patients\NNS\9898892 .\.\1740
C009250_D020250 NONE BACKGROUND\NN\4921011 AND\CC\1740 OBJECTIVE\NN\5980875 :\:\1740 Despite\IN\7501545 advantages\NNS\5154517 of\IN\1740 induction\NN\7450842 and\CC\1740 maintenance\NN\266806 of\IN\1740 anaesthesia\NN\14034177 with\IN\1740 <e1>sevoflurane</e1>\NN\1740 ,\,\1740 <e2>postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting</e2>\NN\116687 occurs\VBZ\2623529 frequently\RB\1740 .\.\1740
C009250_D020250 NONE METHODS\NNS\5616786 :\:\1740 This\DT\1740 double-blind\JJ\1740 study\NN\635850 examined\VBD\789138 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 <e2>postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting</e2>\NN\116687 and\CC\1740 pain\NN\14299637 in\IN\13603305 the\DT\1740 first\JJ\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 <e1>sevoflurane</e1>\NN\1740 anaesthesia\NN\14034177 in\IN\13603305 216\CD\1740 adult\JJ\1740 day\NN\15154774 surgery\NN\6045562 patients\NNS\9898892 .\.\1740
C009250_D020250 NONE CONCLUSION\NN\5837957 :\:\1740 As\IN\14622893 fentanyl\JJ\1740 exacerbated\JJ\1740 <e2>postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting</e2>\NN\116687 without\IN\1740 an\DT\6697703 improvement\NN\7359599 in\IN\13603305 postoperative\JJ\1740 pain\NN\14299637 and\CC\1740 also\RB\1740 had\VBD\2108377 adverse\JJ\1740 cardiorespiratory\JJ\1740 effects\NNS\13245626 ,\,\1740 it\PRP\6125041 appears\VBZ\2604760 to\TO\1740 be\VB\836236 an\DT\6697703 unnecessary\JJ\1740 and\CC\1740 possibly\RB\1740 detrimental\VB\1740 supplement\NN\6365467 to\TO\1740 <e1>sevoflurane</e1>\NN\1740 in\IN\13603305 day\NN\15154774 surgery\NN\6045562 .\.\1740
D005283_D020250 CID RESULTS\NNS\34213 :\:\1740 Omission\NN\70965 of\IN\1740 <e1>fentanyl</e1>\NN\2707683 did\VBD\1640855 not\RB\1740 reduce\VB\441445 the\DT\1740 overall\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting</e2>\NN\116687 ,\,\1740 but\CC\1740 did\VBD\1640855 reduce\VB\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 vomiting\NN\116687 and/or\CC\1740 moderate\JJ\1740 to\IN\1740 severe\JJ\1740 nausea\NN\14299637 prior\RB\1740 to\TO\1740 discharge\VB\1640855 from\IN\1740 20\CD\13745420 %\NN\1740 and\CC\1740 17\CD\13745420 %\NN\1740 with\IN\1740 fentanyl\NN\2707683 and\CC\1740 fentanyl-dexamethasone\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 to\TO\1740 5\CD\13741022 %\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.013\CD\1740 )\-RRB-\1740 .\.\1740
D005283_D020250 CID RESULTS\NNS\34213 :\:\1740 Omission\NN\70965 of\IN\1740 fentanyl\NN\2707683 did\VBD\1640855 not\RB\1740 reduce\VB\441445 the\DT\1740 overall\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting</e2>\NN\116687 ,\,\1740 but\CC\1740 did\VBD\1640855 reduce\VB\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 vomiting\NN\116687 and/or\CC\1740 moderate\JJ\1740 to\IN\1740 severe\JJ\1740 nausea\NN\14299637 prior\RB\1740 to\TO\1740 discharge\VB\1640855 from\IN\1740 20\CD\13745420 %\NN\1740 and\CC\1740 17\CD\13745420 %\NN\1740 with\IN\1740 <e1>fentanyl</e1>\NN\2707683 and\CC\1740 fentanyl-dexamethasone\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 to\TO\1740 5\CD\13741022 %\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.013\CD\1740 )\-RRB-\1740 .\.\1740
D005283_D020250 CID RESULTS\NNS\34213 :\:\1740 Omission\NN\70965 of\IN\1740 fentanyl\NN\2707683 did\VBD\1640855 not\RB\1740 reduce\VB\441445 the\DT\1740 overall\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting</e2>\NN\116687 ,\,\1740 but\CC\1740 did\VBD\1640855 reduce\VB\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 vomiting\NN\116687 and/or\CC\1740 moderate\JJ\1740 to\IN\1740 severe\JJ\1740 nausea\NN\14299637 prior\RB\1740 to\TO\1740 discharge\VB\1640855 from\IN\1740 20\CD\13745420 %\NN\1740 and\CC\1740 17\CD\13745420 %\NN\1740 with\IN\1740 fentanyl\NN\2707683 and\CC\1740 <e1>fentanyl-dexamethasone</e1>\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 to\TO\1740 5\CD\13741022 %\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.013\CD\1740 )\-RRB-\1740 .\.\1740
D005283_D020250 CID Combining\VBG\2630189 the\DT\1740 two\CD\13741022 <e1>fentanyl</e1>\JJ\1740 groups\NNS\2137 revealed\VBD\2137132 further\RB\1740 significant\JJ\1740 benefits\NNS\13278375 from\IN\1740 the\DT\1740 avoidance\NN\203342 of\IN\1740 opioids\NNS\1740 ,\,\1740 reducing\VBG\441445 <e2>postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting</e2>\NN\116687 and\CC\1740 nausea\NN\14299637 prior\RB\1740 to\TO\1740 discharge\VB\1640855 from\IN\1740 35\CD\1740 %\NN\1740 and\CC\1740 33\CD\1740 %\NN\1740 to\TO\1740 22\CD\13745420 %\NN\1740 and\CC\1740 19\CD\13745420 %\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.049\CD\1740 and\CC\1740 P\NN\14622893 =\JJ\1740 0.035\CD\1740 )\-RRB-\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 while\IN\15122231 nausea\NN\14299637 in\IN\13603305 the\DT\1740 first\JJ\1740 24\CD\13745420 h\NN\14622893 was\VBD\836236 decreased\VBN\169651 from\IN\1740 42\CD\1740 %\NN\1740 to\TO\1740 27\CD\13745420 %\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.034\CD\1740 )\-RRB-\1740 .\.\1740
D005283_D020250 CID CONCLUSION\NN\5837957 :\:\1740 As\IN\14622893 <e1>fentanyl</e1>\JJ\1740 exacerbated\JJ\1740 <e2>postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting</e2>\NN\116687 without\IN\1740 an\DT\6697703 improvement\NN\7359599 in\IN\13603305 postoperative\JJ\1740 pain\NN\14299637 and\CC\1740 also\RB\1740 had\VBD\2108377 adverse\JJ\1740 cardiorespiratory\JJ\1740 effects\NNS\13245626 ,\,\1740 it\PRP\6125041 appears\VBZ\2604760 to\TO\1740 be\VB\836236 an\DT\6697703 unnecessary\JJ\1740 and\CC\1740 possibly\RB\1740 detrimental\VB\1740 supplement\NN\6365467 to\TO\1740 sevoflurane\NN\1740 in\IN\13603305 day\NN\15154774 surgery\NN\6045562 .\.\1740
D003907_D020250 NONE RESULTS\NNS\34213 :\:\1740 Omission\NN\70965 of\IN\1740 fentanyl\NN\2707683 did\VBD\1640855 not\RB\1740 reduce\VB\441445 the\DT\1740 overall\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting</e2>\NN\116687 ,\,\1740 but\CC\1740 did\VBD\1640855 reduce\VB\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 vomiting\NN\116687 and/or\CC\1740 moderate\JJ\1740 to\IN\1740 severe\JJ\1740 nausea\NN\14299637 prior\RB\1740 to\TO\1740 discharge\VB\1640855 from\IN\1740 20\CD\13745420 %\NN\1740 and\CC\1740 17\CD\13745420 %\NN\1740 with\IN\1740 fentanyl\NN\2707683 and\CC\1740 <e1>fentanyl-dexamethasone</e1>\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 to\TO\1740 5\CD\13741022 %\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.013\CD\1740 )\-RRB-\1740 .\.\1740
D003907_D020250 NONE <e1>Dexamethasone</e1>\NN\2721538 had\VBD\2108377 no\DT\7204911 significant\JJ\1740 effect\NN\34213 on\IN\1740 the\DT\1740 incidence\NN\13821570 or\CC\3541091 severity\NN\5036394 of\IN\1740 <e2>postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting</e2>\NN\116687 .\.\1740
D003907_D014839 NONE RESULTS\NNS\34213 :\:\1740 Omission\NN\70965 of\IN\1740 fentanyl\NN\2707683 did\VBD\1640855 not\RB\1740 reduce\VB\441445 the\DT\1740 overall\JJ\1740 incidence\NN\13821570 of\IN\1740 postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 ,\,\1740 but\CC\1740 did\VBD\1640855 reduce\VB\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>vomiting</e2>\NN\116687 and/or\CC\1740 moderate\JJ\1740 to\IN\1740 severe\JJ\1740 nausea\NN\14299637 prior\RB\1740 to\TO\1740 discharge\VB\1640855 from\IN\1740 20\CD\13745420 %\NN\1740 and\CC\1740 17\CD\13745420 %\NN\1740 with\IN\1740 fentanyl\NN\2707683 and\CC\1740 <e1>fentanyl-dexamethasone</e1>\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 to\TO\1740 5\CD\13741022 %\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.013\CD\1740 )\-RRB-\1740 .\.\1740
D003907_D009325 NONE RESULTS\NNS\34213 :\:\1740 Omission\NN\70965 of\IN\1740 fentanyl\NN\2707683 did\VBD\1640855 not\RB\1740 reduce\VB\441445 the\DT\1740 overall\JJ\1740 incidence\NN\13821570 of\IN\1740 postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 ,\,\1740 but\CC\1740 did\VBD\1640855 reduce\VB\441445 the\DT\1740 incidence\NN\13821570 of\IN\1740 vomiting\NN\116687 and/or\CC\1740 moderate\JJ\1740 to\IN\1740 severe\JJ\1740 <e2>nausea</e2>\NN\14299637 prior\RB\1740 to\TO\1740 discharge\VB\1640855 from\IN\1740 20\CD\13745420 %\NN\1740 and\CC\1740 17\CD\13745420 %\NN\1740 with\IN\1740 fentanyl\NN\2707683 and\CC\1740 <e1>fentanyl-dexamethasone</e1>\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 to\TO\1740 5\CD\13741022 %\NN\1740 (\-LRB-\1740 P\NN\14622893 =\JJ\1740 0.013\CD\1740 )\-RRB-\1740 .\.\1740
D005283_D012131 CID <e1>Fentanyl</e1>\NNP\2707683 did\VBD\1640855 reduce\VB\441445 minor\JJ\1740 intraoperative\JJ\1740 movement\NN\191142 but\CC\1740 had\VBD\2108377 no\DT\7204911 sevoflurane-sparing\JJ\1740 effect\NN\34213 and\CC\1740 increased\VBN\169651 <e2>respiratory\JJ\1740 depression</e2>\NN\14373582 ,\,\1740 hypotension\NN\14057371 and\CC\1740 bradycardia\NN\14110674 .\.\1740
D005283_D007022 CID <e1>Fentanyl</e1>\NNP\2707683 did\VBD\1640855 reduce\VB\441445 minor\JJ\1740 intraoperative\JJ\1740 movement\NN\191142 but\CC\1740 had\VBD\2108377 no\DT\7204911 sevoflurane-sparing\JJ\1740 effect\NN\34213 and\CC\1740 increased\VBN\169651 respiratory\JJ\1740 depression\NN\14373582 ,\,\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 bradycardia\NN\14110674 .\.\1740
D005283_D001919 CID <e1>Fentanyl</e1>\NNP\2707683 did\VBD\1640855 reduce\VB\441445 minor\JJ\1740 intraoperative\JJ\1740 movement\NN\191142 but\CC\1740 had\VBD\2108377 no\DT\7204911 sevoflurane-sparing\JJ\1740 effect\NN\34213 and\CC\1740 increased\VBN\169651 respiratory\JJ\1740 depression\NN\14373582 ,\,\1740 hypotension\NN\14057371 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 .\.\1740
C009250_D012131 NONE Fentanyl\NNP\2707683 did\VBD\1640855 reduce\VB\441445 minor\JJ\1740 intraoperative\JJ\1740 movement\NN\191142 but\CC\1740 had\VBD\2108377 no\DT\7204911 <e1>sevoflurane-sparing</e1>\JJ\1740 effect\NN\34213 and\CC\1740 increased\VBN\169651 <e2>respiratory\JJ\1740 depression</e2>\NN\14373582 ,\,\1740 hypotension\NN\14057371 and\CC\1740 bradycardia\NN\14110674 .\.\1740
C009250_D007022 NONE Fentanyl\NNP\2707683 did\VBD\1640855 reduce\VB\441445 minor\JJ\1740 intraoperative\JJ\1740 movement\NN\191142 but\CC\1740 had\VBD\2108377 no\DT\7204911 <e1>sevoflurane-sparing</e1>\JJ\1740 effect\NN\34213 and\CC\1740 increased\VBN\169651 respiratory\JJ\1740 depression\NN\14373582 ,\,\1740 <e2>hypotension</e2>\NN\14057371 and\CC\1740 bradycardia\NN\14110674 .\.\1740
C009250_D001919 NONE Fentanyl\NNP\2707683 did\VBD\1640855 reduce\VB\441445 minor\JJ\1740 intraoperative\JJ\1740 movement\NN\191142 but\CC\1740 had\VBD\2108377 no\DT\7204911 <e1>sevoflurane-sparing</e1>\JJ\1740 effect\NN\34213 and\CC\1740 increased\VBN\169651 respiratory\JJ\1740 depression\NN\14373582 ,\,\1740 hypotension\NN\14057371 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 .\.\1740
D005283_D010149 NONE CONCLUSION\NN\5837957 :\:\1740 As\IN\14622893 <e1>fentanyl</e1>\JJ\1740 exacerbated\JJ\1740 postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 without\IN\1740 an\DT\6697703 improvement\NN\7359599 in\IN\13603305 <e2>postoperative\JJ\1740 pain</e2>\NN\14299637 and\CC\1740 also\RB\1740 had\VBD\2108377 adverse\JJ\1740 cardiorespiratory\JJ\1740 effects\NNS\13245626 ,\,\1740 it\PRP\6125041 appears\VBZ\2604760 to\TO\1740 be\VB\836236 an\DT\6697703 unnecessary\JJ\1740 and\CC\1740 possibly\RB\1740 detrimental\VB\1740 supplement\NN\6365467 to\TO\1740 sevoflurane\NN\1740 in\IN\13603305 day\NN\15154774 surgery\NN\6045562 .\.\1740
C009250_D010149 NONE CONCLUSION\NN\5837957 :\:\1740 As\IN\14622893 fentanyl\JJ\1740 exacerbated\JJ\1740 postoperative\JJ\1740 nausea\NN\14299637 and\CC\1740 vomiting\NN\116687 without\IN\1740 an\DT\6697703 improvement\NN\7359599 in\IN\13603305 <e2>postoperative\JJ\1740 pain</e2>\NN\14299637 and\CC\1740 also\RB\1740 had\VBD\2108377 adverse\JJ\1740 cardiorespiratory\JJ\1740 effects\NNS\13245626 ,\,\1740 it\PRP\6125041 appears\VBZ\2604760 to\TO\1740 be\VB\836236 an\DT\6697703 unnecessary\JJ\1740 and\CC\1740 possibly\RB\1740 detrimental\VB\1740 supplement\NN\6365467 to\TO\1740 <e1>sevoflurane</e1>\NN\1740 in\IN\13603305 day\NN\15154774 surgery\NN\6045562 .\.\1740
17241784
D019821_D009135 CID Progressive\JJ\1740 <e2>myopathy</e2>\NN\14204950 with\IN\1740 up-regulation\NN\1740 of\IN\1740 MHC-I\NN\1740 associated\VBN\628491 with\IN\1740 <e1>statin</e1>\NN\3740161 therapy\NN\657604 .\.\1740
D019821_D009135 CID <e1>Statins</e1>\NNS\3740161 can\MD\3094503 cause\VB\1617192 a\DT\13649268 necrotizing\NN\1740 <e2>myopathy</e2>\NN\14204950 and\CC\1740 hyperCKaemia\NN\1740 which\WDT\1740 is\VBZ\836236 reversible\JJ\1740 on\IN\1740 cessation\NN\7365849 of\IN\1740 the\DT\1740 drug\NN\14778436 .\.\1740
D019821_D009135 CID What\WP\1740 is\VBZ\836236 less\RBR\1740 well\RB\1740 known\JJ\1740 is\VBZ\836236 a\DT\13649268 phenomenon\NN\29677 whereby\WRB\1740 <e1>statins</e1>\NNS\3740161 may\MD\15209706 induce\VB\1627355 a\DT\13649268 <e2>myopathy</e2>\JJ\1740 ,\,\1740 which\WDT\1740 persists\VBZ\118523 or\CC\3541091 may\MD\15209706 progress\VB\252019 after\IN\1740 stopping\VBG\2452885 the\DT\1740 drug\NN\14778436 .\.\1740
D019821_D009135 CID These\DT\1740 observations\NNS\996969 suggest\VBP\1010118 that\IN\1740 <e1>statins</e1>\NNS\3740161 may\MD\15209706 initiate\VB\1617192 an\DT\6697703 immune-mediated\JJ\1740 <e2>myopathy</e2>\NN\14204950 that\WDT\1740 persists\VBZ\118523 after\IN\1740 withdrawal\NN\7206096 of\IN\1740 the\DT\1740 drug\NN\14778436 and\CC\1740 responds\VBZ\2367363 to\TO\1740 immunosuppressive\JJ\1740 therapy\NN\657604 .\.\1740
D019821_D009135 CID The\DT\1740 mechanism\NN\13446390 of\IN\1740 this\DT\1740 <e2>myopathy</e2>\NN\14204950 is\VBZ\836236 uncertain\JJ\1740 but\CC\1740 may\MD\15209706 involve\VB\2676054 the\DT\1740 induction\NN\7450842 by\IN\1740 <e1>statins</e1>\NNS\3740161 of\IN\1740 an\DT\6697703 endoplasmic\JJ\1740 reticulum\NN\8434259 stress\NN\7083732 response\NN\11410625 with\IN\1740 associated\VBN\628491 up-regulation\NN\1740 of\IN\1740 MHC-I\NN\1740 expression\NN\4679549 and\CC\1740 antigen\NN\20090 presentation\NN\1027379 by\IN\1740 muscle\NN\5289601 fibres\NNS\14580897 .\.\1740
D019821_-1 NONE <e1>Statins</e1>\NNS\3740161 can\MD\3094503 cause\VB\1617192 a\DT\13649268 necrotizing\NN\1740 myopathy\NN\14204950 and\CC\1740 <e2>hyperCKaemia</e2>\NN\1740 which\WDT\1740 is\VBZ\836236 reversible\JJ\1740 on\IN\1740 cessation\NN\7365849 of\IN\1740 the\DT\1740 drug\NN\14778436 .\.\1740
19308880
D014635_D003221 CID <e2>Confusion</e2>\NN\13972797 ,\,\1740 a\DT\13649268 rather\RB\1740 serious\JJ\1740 adverse\JJ\1740 drug\NN\14778436 reaction\NN\13446390 with\IN\1740 <e1>valproic\JJ\1740 acid</e1>\NN\14818238 :\:\1740 a\DT\13649268 review\NN\5733583 of\IN\1740 the\DT\1740 French\JJ\1740 Pharmacovigilance\NN\1740 database\NN\6634376 .\.\1740
D014635_D003221 CID INTRODUCTION\NNP\235435 :\:\1740 <e2>Confusion</e2>\NN\13972797 is\VBZ\836236 an\DT\6697703 adverse\JJ\1740 drug\NN\14778436 reaction\NN\13446390 frequently\RB\1740 observed\VBN\2163746 with\IN\1740 <e1>valproic\JJ\1740 acid</e1>\NN\14818238 .\.\1740
D014635_D003221 CID METHODS\NNS\5616786 :\:\1740 Using\VBG\1156834 the\DT\1740 French\JJ\1740 Pharmacovigilance\NN\1740 database\NN\6634376 ,\,\1740 we\PRP\1740 selected\VBD\697589 the\DT\1740 cases\NNS\7283608 of\IN\1740 <e2>confusion</e2>\NN\13972797 reported\VBN\831651 since\IN\1740 1985\CD\1740 with\IN\1740 <e1>valproic\JJ\1740 acid</e1>\NN\14818238 .\.\1740
D014635_D003221 CID RESULTS\NNS\34213 :\:\1740 272\CD\1740 cases\NNS\7283608 of\IN\1740 <e2>confusion</e2>\NN\13972797 were\VBD\836236 reported\VBN\831651 with\IN\1740 <e1>valproic\JJ\1740 acid</e1>\NN\14818238 :\:\1740 153\CD\1740 women\NNS\9605289 and\CC\1740 119\CD\1740 men\NNS\8208016 .\.\1740
D014635_D003221 CID <e2>Confusion</e2>\NN\13972797 mostly\RB\1740 occurred\VBD\2623529 during\IN\1740 the\DT\1740 two\CD\13741022 first\JJ\1740 weeks\NNS\15113229 following\VBG\1835496 <e1>valproic\JJ\1740 acid</e1>\NN\14818238 exposure\NN\5042871 (\-LRB-\1740 39.7\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D014635_D003221 CID CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 work\NN\407535 shows\VBZ\2137132 that\IN\1740 <e2>confusion</e2>\NN\13972797 with\IN\1740 <e1>valproic\JJ\1740 acid</e1>\NN\14818238 is\VBZ\836236 a\DT\13649268 serious\JJ\1740 ,\,\1740 rather\RB\1740 frequent\JJ\1740 but\CC\1740 reversible\JJ\1740 adverse\JJ\1740 drug\NN\14778436 reaction\NN\13446390 .\.\1740
18182964
D003000_D001289 NONE <e1>Clonidine</e1>\NN\2721160 for\IN\1740 <e2>attention-deficit/hyperactivity\JJ\1740 disorder</e2>\NN\14034177 :\:\1740 II\CD\13741022 .\.\1740
D003000_D001289 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 examine\VB\789138 the\DT\1740 safety\NN\13920835 and\CC\1740 tolerability\NN\1740 of\IN\1740 <e1>clonidine</e1>\NN\2721160 used\VBN\1156834 alone\RB\1740 or\CC\3541091 with\IN\1740 methylphenidate\NN\4320126 in\IN\13603305 children\NNS\9622049 with\IN\1740 <e2>attention-deficit/hyperactivity\NN\1740 disorder</e2>\NN\14034177 (\-LRB-\1740 ADHD\NN\14304060 )\-RRB-\1740 .\.\1740
D003000_D001289 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 examine\VB\789138 the\DT\1740 safety\NN\13920835 and\CC\1740 tolerability\NN\1740 of\IN\1740 <e1>clonidine</e1>\NN\2721160 used\VBN\1156834 alone\RB\1740 or\CC\3541091 with\IN\1740 methylphenidate\NN\4320126 in\IN\13603305 children\NNS\9622049 with\IN\1740 attention-deficit/hyperactivity\NN\1740 disorder\NN\14034177 (\-LRB-\1740 <e2>ADHD</e2>\NN\14304060 )\-RRB-\1740 .\.\1740
D003000_D001289 NONE METHOD\NNP\5616786 :\:\1740 In\IN\13603305 a\DT\13649268 16-week\NN\1740 multicenter\NN\1740 ,\,\1740 double-blind\JJ\1740 trial\NN\786195 ,\,\1740 122\CD\1740 children\NNS\9622049 with\IN\1740 <e2>ADHD</e2>\NN\14304060 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 <e1>clonidine</e1>\NN\2721160 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 31\CD\1740 )\-RRB-\1740 ,\,\1740 methylphenidate\NN\4320126 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 29\CD\13745420 )\-RRB-\1740 ,\,\1740 clonidine\NN\2721160 and\CC\1740 methylphenidate\NN\4320126 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 32\CD\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 placebo\NN\3740161 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 30\CD\13745420 )\-RRB-\1740 .\.\1740
D003000_D001289 NONE METHOD\NNP\5616786 :\:\1740 In\IN\13603305 a\DT\13649268 16-week\NN\1740 multicenter\NN\1740 ,\,\1740 double-blind\JJ\1740 trial\NN\786195 ,\,\1740 122\CD\1740 children\NNS\9622049 with\IN\1740 <e2>ADHD</e2>\NN\14304060 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 clonidine\NN\2721160 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 31\CD\1740 )\-RRB-\1740 ,\,\1740 methylphenidate\NN\4320126 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 29\CD\13745420 )\-RRB-\1740 ,\,\1740 <e1>clonidine</e1>\NN\2721160 and\CC\1740 methylphenidate\NN\4320126 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 32\CD\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 placebo\NN\3740161 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 30\CD\13745420 )\-RRB-\1740 .\.\1740
D003000_D001289 NONE CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Clonidine</e1>\NNP\2721160 ,\,\1740 used\VBN\1156834 alone\RB\1740 or\CC\3541091 with\IN\1740 methylphenidate\NN\4320126 ,\,\1740 appears\VBZ\2604760 safe\JJ\1740 and\CC\1740 well\RB\1740 tolerated\VBN\802318 in\IN\13603305 childhood\NN\15144371 <e2>ADHD</e2>\NN\14304060 .\.\1740
D008774_D001289 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 examine\VB\789138 the\DT\1740 safety\NN\13920835 and\CC\1740 tolerability\NN\1740 of\IN\1740 clonidine\NN\2721160 used\VBN\1156834 alone\RB\1740 or\CC\3541091 with\IN\1740 <e1>methylphenidate</e1>\NN\4320126 in\IN\13603305 children\NNS\9622049 with\IN\1740 <e2>attention-deficit/hyperactivity\NN\1740 disorder</e2>\NN\14034177 (\-LRB-\1740 ADHD\NN\14304060 )\-RRB-\1740 .\.\1740
D008774_D001289 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 examine\VB\789138 the\DT\1740 safety\NN\13920835 and\CC\1740 tolerability\NN\1740 of\IN\1740 clonidine\NN\2721160 used\VBN\1156834 alone\RB\1740 or\CC\3541091 with\IN\1740 <e1>methylphenidate</e1>\NN\4320126 in\IN\13603305 children\NNS\9622049 with\IN\1740 attention-deficit/hyperactivity\NN\1740 disorder\NN\14034177 (\-LRB-\1740 <e2>ADHD</e2>\NN\14304060 )\-RRB-\1740 .\.\1740
D008774_D001289 NONE METHOD\NNP\5616786 :\:\1740 In\IN\13603305 a\DT\13649268 16-week\NN\1740 multicenter\NN\1740 ,\,\1740 double-blind\JJ\1740 trial\NN\786195 ,\,\1740 122\CD\1740 children\NNS\9622049 with\IN\1740 <e2>ADHD</e2>\NN\14304060 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 clonidine\NN\2721160 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 31\CD\1740 )\-RRB-\1740 ,\,\1740 <e1>methylphenidate</e1>\NN\4320126 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 29\CD\13745420 )\-RRB-\1740 ,\,\1740 clonidine\NN\2721160 and\CC\1740 methylphenidate\NN\4320126 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 32\CD\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 placebo\NN\3740161 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 30\CD\13745420 )\-RRB-\1740 .\.\1740
D008774_D001289 NONE METHOD\NNP\5616786 :\:\1740 In\IN\13603305 a\DT\13649268 16-week\NN\1740 multicenter\NN\1740 ,\,\1740 double-blind\JJ\1740 trial\NN\786195 ,\,\1740 122\CD\1740 children\NNS\9622049 with\IN\1740 <e2>ADHD</e2>\NN\14304060 were\VBD\836236 randomly\RB\1740 assigned\VBN\2475922 to\TO\1740 clonidine\NN\2721160 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 31\CD\1740 )\-RRB-\1740 ,\,\1740 methylphenidate\NN\4320126 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 29\CD\13745420 )\-RRB-\1740 ,\,\1740 clonidine\NN\2721160 and\CC\1740 <e1>methylphenidate</e1>\NN\4320126 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 32\CD\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 placebo\NN\3740161 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 30\CD\13745420 )\-RRB-\1740 .\.\1740
D008774_D001289 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Clonidine\NNP\2721160 ,\,\1740 used\VBN\1156834 alone\RB\1740 or\CC\3541091 with\IN\1740 <e1>methylphenidate</e1>\NN\4320126 ,\,\1740 appears\VBZ\2604760 safe\JJ\1740 and\CC\1740 well\RB\1740 tolerated\VBN\802318 in\IN\13603305 childhood\NN\15144371 <e2>ADHD</e2>\NN\14304060 .\.\1740
D003000_D001919 CID RESULTS\NNS\34213 :\:\1740 There\EX\27167 were\VBD\836236 more\JJR\1740 incidents\NNS\7283608 of\IN\1740 <e2>bradycardia</e2>\NN\14110674 in\IN\13603305 subjects\NNS\6598915 treated\VBN\2376958 with\IN\1740 <e1>clonidine</e1>\NN\2721160 compared\VBN\644583 with\IN\1740 those\DT\1740 not\RB\1740 treated\VBN\2376958 with\IN\1740 clonidine\NN\2721160 (\-LRB-\1740 17.5\CD\1740 %\NN\1740 versus\CC\1740 3.4\CD\1740 %\NN\1740 ;\:\1740 p\NN\14622893 =\JJ\1740 .02\CD\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 no\DT\7204911 other\JJ\1740 significant\JJ\1740 group\NN\2137 differences\NNS\4723816 regarding\VBG\689344 electrocardiogram\NN\7000195 and\CC\1740 other\JJ\1740 cardiovascular\JJ\1740 outcomes\NNS\7291312 .\.\1740
D003000_D001919 CID RESULTS\NNS\34213 :\:\1740 There\EX\27167 were\VBD\836236 more\JJR\1740 incidents\NNS\7283608 of\IN\1740 <e2>bradycardia</e2>\NN\14110674 in\IN\13603305 subjects\NNS\6598915 treated\VBN\2376958 with\IN\1740 clonidine\NN\2721160 compared\VBN\644583 with\IN\1740 those\DT\1740 not\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>clonidine</e1>\NN\2721160 (\-LRB-\1740 17.5\CD\1740 %\NN\1740 versus\CC\1740 3.4\CD\1740 %\NN\1740 ;\:\1740 p\NN\14622893 =\JJ\1740 .02\CD\1740 )\-RRB-\1740 ,\,\1740 but\CC\1740 no\DT\7204911 other\JJ\1740 significant\JJ\1740 group\NN\2137 differences\NNS\4723816 regarding\VBG\689344 electrocardiogram\NN\7000195 and\CC\1740 other\JJ\1740 cardiovascular\JJ\1740 outcomes\NNS\7291312 .\.\1740
D003000_D001919 CID Physicians\NNS\10305802 prescribing\NN\1740 <e1>clonidine</e1>\NN\2721160 should\MD\1740 monitor\VB\2169352 for\IN\1740 <e2>bradycardia</e2>\NN\14110674 and\CC\1740 advise\VB\813978 patients\NNS\9898892 about\IN\1740 the\DT\1740 high\JJ\1740 likelihood\NN\4756172 of\IN\1740 initial\JJ\1740 drowsiness\NN\14015731 .\.\1740
D003000_D006970 NONE <e2>Drowsiness</e2>\NNP\14015731 was\VBD\836236 common\JJ\1740 on\IN\1740 <e1>clonidine</e1>\NN\2721160 ,\,\1740 but\CC\1740 generally\RB\1740 resolved\VBN\352826 by\IN\1740 6\CD\13741022 to\TO\1740 8\CD\13741022 weeks\NNS\15113229 .\.\1740
D003000_D006970 NONE Physicians\NNS\10305802 prescribing\NN\1740 <e1>clonidine</e1>\NN\2721160 should\MD\1740 monitor\VB\2169352 for\IN\1740 bradycardia\NN\14110674 and\CC\1740 advise\VB\813978 patients\NNS\9898892 about\IN\1740 the\DT\1740 high\JJ\1740 likelihood\NN\4756172 of\IN\1740 initial\JJ\1740 <e2>drowsiness</e2>\NN\14015731 .\.\1740
20528871
C104457_D015458 NONE Salvage\NN\3076708 therapy\NN\657604 with\IN\1740 <e1>nelarabine</e1>\NN\1740 ,\,\1740 etoposide\NN\1740 ,\,\1740 and\CC\1740 cyclophosphamide\NN\1740 in\IN\13603305 relapsed/refractory\JJ\1740 paediatric\JJ\1740 <e2>T-cell\NN\1740 lymphoblastic\JJ\1740 leukaemia\NN\14239918 and\CC\1740 lymphoma</e2>\NN\14239918 .\.\1740
C104457_D015458 NONE A\DT\13649268 combination\NN\7951464 of\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 <e1>nelarabine</e1>\NN\1740 (\-LRB-\1740 AraG\NN\1740 )\-RRB-\1740 with\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 etoposide\NN\1740 (\-LRB-\1740 VP\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 CPM\NN\1740 )\-RRB-\1740 and\CC\1740 prophylactic\JJ\1740 intrathecal\JJ\1740 chemotherapy\NN\661091 was\VBD\836236 used\VBN\1156834 as\IN\14622893 salvage\NN\3076708 therapy\NN\657604 in\IN\13603305 seven\CD\13741022 children\NNS\9622049 with\IN\1740 refractory\JJ\1740 or\CC\3541091 relapsed\JJ\1740 <e2>T-cell\NN\1740 leukaemia\NN\14239918 or\CC\3541091 lymphoma</e2>\NN\14239918 .\.\1740
C104457_D015458 NONE A\DT\13649268 combination\NN\7951464 of\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 nelarabine\NN\1740 (\-LRB-\1740 <e1>AraG</e1>\NN\1740 )\-RRB-\1740 with\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 etoposide\NN\1740 (\-LRB-\1740 VP\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 CPM\NN\1740 )\-RRB-\1740 and\CC\1740 prophylactic\JJ\1740 intrathecal\JJ\1740 chemotherapy\NN\661091 was\VBD\836236 used\VBN\1156834 as\IN\14622893 salvage\NN\3076708 therapy\NN\657604 in\IN\13603305 seven\CD\13741022 children\NNS\9622049 with\IN\1740 refractory\JJ\1740 or\CC\3541091 relapsed\JJ\1740 <e2>T-cell\NN\1740 leukaemia\NN\14239918 or\CC\3541091 lymphoma</e2>\NN\14239918 .\.\1740
C104457_D016399 NONE Salvage\NN\3076708 therapy\NN\657604 with\IN\1740 <e1>nelarabine</e1>\NN\1740 ,\,\1740 etoposide\NN\1740 ,\,\1740 and\CC\1740 cyclophosphamide\NN\1740 in\IN\13603305 relapsed/refractory\JJ\1740 paediatric\JJ\1740 <e2>T-cell\NN\1740 lymphoblastic\JJ\1740 leukaemia\NN\14239918 and\CC\1740 lymphoma</e2>\NN\14239918 .\.\1740
C104457_D016399 NONE A\DT\13649268 combination\NN\7951464 of\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 <e1>nelarabine</e1>\NN\1740 (\-LRB-\1740 AraG\NN\1740 )\-RRB-\1740 with\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 etoposide\NN\1740 (\-LRB-\1740 VP\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 CPM\NN\1740 )\-RRB-\1740 and\CC\1740 prophylactic\JJ\1740 intrathecal\JJ\1740 chemotherapy\NN\661091 was\VBD\836236 used\VBN\1156834 as\IN\14622893 salvage\NN\3076708 therapy\NN\657604 in\IN\13603305 seven\CD\13741022 children\NNS\9622049 with\IN\1740 refractory\JJ\1740 or\CC\3541091 relapsed\JJ\1740 <e2>T-cell\NN\1740 leukaemia\NN\14239918 or\CC\3541091 lymphoma</e2>\NN\14239918 .\.\1740
C104457_D016399 NONE A\DT\13649268 combination\NN\7951464 of\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 nelarabine\NN\1740 (\-LRB-\1740 <e1>AraG</e1>\NN\1740 )\-RRB-\1740 with\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 etoposide\NN\1740 (\-LRB-\1740 VP\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 CPM\NN\1740 )\-RRB-\1740 and\CC\1740 prophylactic\JJ\1740 intrathecal\JJ\1740 chemotherapy\NN\661091 was\VBD\836236 used\VBN\1156834 as\IN\14622893 salvage\NN\3076708 therapy\NN\657604 in\IN\13603305 seven\CD\13741022 children\NNS\9622049 with\IN\1740 refractory\JJ\1740 or\CC\3541091 relapsed\JJ\1740 <e2>T-cell\NN\1740 leukaemia\NN\14239918 or\CC\3541091 lymphoma</e2>\NN\14239918 .\.\1740
D005047_D015458 NONE Salvage\NN\3076708 therapy\NN\657604 with\IN\1740 nelarabine\NN\1740 ,\,\1740 <e1>etoposide</e1>\NN\1740 ,\,\1740 and\CC\1740 cyclophosphamide\NN\1740 in\IN\13603305 relapsed/refractory\JJ\1740 paediatric\JJ\1740 <e2>T-cell\NN\1740 lymphoblastic\JJ\1740 leukaemia\NN\14239918 and\CC\1740 lymphoma</e2>\NN\14239918 .\.\1740
D005047_D015458 NONE A\DT\13649268 combination\NN\7951464 of\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 nelarabine\NN\1740 (\-LRB-\1740 AraG\NN\1740 )\-RRB-\1740 with\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 <e1>etoposide</e1>\NN\1740 (\-LRB-\1740 VP\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 CPM\NN\1740 )\-RRB-\1740 and\CC\1740 prophylactic\JJ\1740 intrathecal\JJ\1740 chemotherapy\NN\661091 was\VBD\836236 used\VBN\1156834 as\IN\14622893 salvage\NN\3076708 therapy\NN\657604 in\IN\13603305 seven\CD\13741022 children\NNS\9622049 with\IN\1740 refractory\JJ\1740 or\CC\3541091 relapsed\JJ\1740 <e2>T-cell\NN\1740 leukaemia\NN\14239918 or\CC\3541091 lymphoma</e2>\NN\14239918 .\.\1740
D005047_D015458 NONE A\DT\13649268 combination\NN\7951464 of\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 nelarabine\NN\1740 (\-LRB-\1740 AraG\NN\1740 )\-RRB-\1740 with\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 etoposide\NN\1740 (\-LRB-\1740 <e1>VP</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 CPM\NN\1740 )\-RRB-\1740 and\CC\1740 prophylactic\JJ\1740 intrathecal\JJ\1740 chemotherapy\NN\661091 was\VBD\836236 used\VBN\1156834 as\IN\14622893 salvage\NN\3076708 therapy\NN\657604 in\IN\13603305 seven\CD\13741022 children\NNS\9622049 with\IN\1740 refractory\JJ\1740 or\CC\3541091 relapsed\JJ\1740 <e2>T-cell\NN\1740 leukaemia\NN\14239918 or\CC\3541091 lymphoma</e2>\NN\14239918 .\.\1740
D005047_D016399 NONE Salvage\NN\3076708 therapy\NN\657604 with\IN\1740 nelarabine\NN\1740 ,\,\1740 <e1>etoposide</e1>\NN\1740 ,\,\1740 and\CC\1740 cyclophosphamide\NN\1740 in\IN\13603305 relapsed/refractory\JJ\1740 paediatric\JJ\1740 <e2>T-cell\NN\1740 lymphoblastic\JJ\1740 leukaemia\NN\14239918 and\CC\1740 lymphoma</e2>\NN\14239918 .\.\1740
D005047_D016399 NONE A\DT\13649268 combination\NN\7951464 of\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 nelarabine\NN\1740 (\-LRB-\1740 AraG\NN\1740 )\-RRB-\1740 with\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 <e1>etoposide</e1>\NN\1740 (\-LRB-\1740 VP\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 CPM\NN\1740 )\-RRB-\1740 and\CC\1740 prophylactic\JJ\1740 intrathecal\JJ\1740 chemotherapy\NN\661091 was\VBD\836236 used\VBN\1156834 as\IN\14622893 salvage\NN\3076708 therapy\NN\657604 in\IN\13603305 seven\CD\13741022 children\NNS\9622049 with\IN\1740 refractory\JJ\1740 or\CC\3541091 relapsed\JJ\1740 <e2>T-cell\NN\1740 leukaemia\NN\14239918 or\CC\3541091 lymphoma</e2>\NN\14239918 .\.\1740
D005047_D016399 NONE A\DT\13649268 combination\NN\7951464 of\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 nelarabine\NN\1740 (\-LRB-\1740 AraG\NN\1740 )\-RRB-\1740 with\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 etoposide\NN\1740 (\-LRB-\1740 <e1>VP</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 CPM\NN\1740 )\-RRB-\1740 and\CC\1740 prophylactic\JJ\1740 intrathecal\JJ\1740 chemotherapy\NN\661091 was\VBD\836236 used\VBN\1156834 as\IN\14622893 salvage\NN\3076708 therapy\NN\657604 in\IN\13603305 seven\CD\13741022 children\NNS\9622049 with\IN\1740 refractory\JJ\1740 or\CC\3541091 relapsed\JJ\1740 <e2>T-cell\NN\1740 leukaemia\NN\14239918 or\CC\3541091 lymphoma</e2>\NN\14239918 .\.\1740
D003520_D015458 NONE Salvage\NN\3076708 therapy\NN\657604 with\IN\1740 nelarabine\NN\1740 ,\,\1740 etoposide\NN\1740 ,\,\1740 and\CC\1740 <e1>cyclophosphamide</e1>\NN\1740 in\IN\13603305 relapsed/refractory\JJ\1740 paediatric\JJ\1740 <e2>T-cell\NN\1740 lymphoblastic\JJ\1740 leukaemia\NN\14239918 and\CC\1740 lymphoma</e2>\NN\14239918 .\.\1740
D003520_D015458 NONE A\DT\13649268 combination\NN\7951464 of\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 nelarabine\NN\1740 (\-LRB-\1740 AraG\NN\1740 )\-RRB-\1740 with\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 etoposide\NN\1740 (\-LRB-\1740 VP\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>cyclophosphamide</e1>\NN\1740 (\-LRB-\1740 CPM\NN\1740 )\-RRB-\1740 and\CC\1740 prophylactic\JJ\1740 intrathecal\JJ\1740 chemotherapy\NN\661091 was\VBD\836236 used\VBN\1156834 as\IN\14622893 salvage\NN\3076708 therapy\NN\657604 in\IN\13603305 seven\CD\13741022 children\NNS\9622049 with\IN\1740 refractory\JJ\1740 or\CC\3541091 relapsed\JJ\1740 <e2>T-cell\NN\1740 leukaemia\NN\14239918 or\CC\3541091 lymphoma</e2>\NN\14239918 .\.\1740
D003520_D015458 NONE A\DT\13649268 combination\NN\7951464 of\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 nelarabine\NN\1740 (\-LRB-\1740 AraG\NN\1740 )\-RRB-\1740 with\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 etoposide\NN\1740 (\-LRB-\1740 VP\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 <e1>CPM</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 prophylactic\JJ\1740 intrathecal\JJ\1740 chemotherapy\NN\661091 was\VBD\836236 used\VBN\1156834 as\IN\14622893 salvage\NN\3076708 therapy\NN\657604 in\IN\13603305 seven\CD\13741022 children\NNS\9622049 with\IN\1740 refractory\JJ\1740 or\CC\3541091 relapsed\JJ\1740 <e2>T-cell\NN\1740 leukaemia\NN\14239918 or\CC\3541091 lymphoma</e2>\NN\14239918 .\.\1740
D003520_D016399 NONE Salvage\NN\3076708 therapy\NN\657604 with\IN\1740 nelarabine\NN\1740 ,\,\1740 etoposide\NN\1740 ,\,\1740 and\CC\1740 <e1>cyclophosphamide</e1>\NN\1740 in\IN\13603305 relapsed/refractory\JJ\1740 paediatric\JJ\1740 <e2>T-cell\NN\1740 lymphoblastic\JJ\1740 leukaemia\NN\14239918 and\CC\1740 lymphoma</e2>\NN\14239918 .\.\1740
D003520_D016399 NONE A\DT\13649268 combination\NN\7951464 of\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 nelarabine\NN\1740 (\-LRB-\1740 AraG\NN\1740 )\-RRB-\1740 with\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 etoposide\NN\1740 (\-LRB-\1740 VP\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>cyclophosphamide</e1>\NN\1740 (\-LRB-\1740 CPM\NN\1740 )\-RRB-\1740 and\CC\1740 prophylactic\JJ\1740 intrathecal\JJ\1740 chemotherapy\NN\661091 was\VBD\836236 used\VBN\1156834 as\IN\14622893 salvage\NN\3076708 therapy\NN\657604 in\IN\13603305 seven\CD\13741022 children\NNS\9622049 with\IN\1740 refractory\JJ\1740 or\CC\3541091 relapsed\JJ\1740 <e2>T-cell\NN\1740 leukaemia\NN\14239918 or\CC\3541091 lymphoma</e2>\NN\14239918 .\.\1740
D003520_D016399 NONE A\DT\13649268 combination\NN\7951464 of\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 nelarabine\NN\1740 (\-LRB-\1740 AraG\NN\1740 )\-RRB-\1740 with\IN\1740 5\CD\13741022 d\NN\15089472 of\IN\1740 etoposide\NN\1740 (\-LRB-\1740 VP\NN\1740 )\-RRB-\1740 and\CC\1740 cyclophosphamide\NN\1740 (\-LRB-\1740 <e1>CPM</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 prophylactic\JJ\1740 intrathecal\JJ\1740 chemotherapy\NN\661091 was\VBD\836236 used\VBN\1156834 as\IN\14622893 salvage\NN\3076708 therapy\NN\657604 in\IN\13603305 seven\CD\13741022 children\NNS\9622049 with\IN\1740 refractory\JJ\1740 or\CC\3541091 relapsed\JJ\1740 <e2>T-cell\NN\1740 leukaemia\NN\14239918 or\CC\3541091 lymphoma</e2>\NN\14239918 .\.\1740
C104457_D009422 CID The\DT\1740 most\RBS\1740 common\JJ\1740 side\NN\8630039 effects\NNS\13245626 attributable\JJ\1740 to\TO\1740 the\DT\1740 <e1>AraG</e1>\NN\1740 included\VBD\690614 Grade\NNP\7975026 2\CD\13741022 and\CC\1740 3\CD\13741022 sensory\JJ\1740 and\CC\1740 motor\NN\3699975 <e2>neuropathy</e2>\JJ\1740 and\CC\1740 musculoskeletal\JJ\1740 pain\NN\14299637 .\.\1740
C104457_D009422 CID Our\PRP$\1740 experience\NN\5984287 supports\VBZ\2199590 the\DT\1740 safety\NN\13920835 of\IN\1740 giving\VBG\2327200 <e1>AraG</e1>\NN\1740 as\IN\14622893 salvage\NN\3076708 therapy\NN\657604 in\IN\13603305 synchrony\NN\13844690 with\IN\1740 etoposide\NN\1740 and\CC\1740 cyclophosphamide\NN\1740 ,\,\1740 although\IN\1740 <e2>neurological\JJ\1740 toxicity</e2>\NN\13576101 must\MD\9367203 be\VB\836236 closely\RB\1740 monitored\VBN\2169352 .\.\1740
C104457_D059352 CID The\DT\1740 most\RBS\1740 common\JJ\1740 side\NN\8630039 effects\NNS\13245626 attributable\JJ\1740 to\TO\1740 the\DT\1740 <e1>AraG</e1>\NN\1740 included\VBD\690614 Grade\NNP\7975026 2\CD\13741022 and\CC\1740 3\CD\13741022 sensory\JJ\1740 and\CC\1740 motor\NN\3699975 neuropathy\JJ\1740 and\CC\1740 <e2>musculoskeletal\JJ\1740 pain</e2>\NN\14299637 .\.\1740
C104457_D006402 CID <e2>Haematological\JJ\1740 toxicity</e2>\NN\13576101 was\VBD\836236 greater\JJR\1740 for\IN\1740 the\DT\1740 combination\NN\7951464 than\IN\1740 <e1>AraG</e1>\NN\1740 alone\RB\1740 ,\,\1740 although\IN\1740 median\JJ\1740 time\NN\7308889 to\IN\1740 neutrophil\NN\5449959 and\CC\1740 platelet\NN\5432736 recovery\NN\7357388 was\VBD\836236 consistent\JJ\1740 with\IN\1740 other\JJ\1740 salvage\NN\3076708 therapies\NNS\657604 .\.\1740
D005047_D009422 NONE Our\PRP$\1740 experience\NN\5984287 supports\VBZ\2199590 the\DT\1740 safety\NN\13920835 of\IN\1740 giving\VBG\2327200 AraG\NN\1740 as\IN\14622893 salvage\NN\3076708 therapy\NN\657604 in\IN\13603305 synchrony\NN\13844690 with\IN\1740 <e1>etoposide</e1>\NN\1740 and\CC\1740 cyclophosphamide\NN\1740 ,\,\1740 although\IN\1740 <e2>neurological\JJ\1740 toxicity</e2>\NN\13576101 must\MD\9367203 be\VB\836236 closely\RB\1740 monitored\VBN\2169352 .\.\1740
D003520_D009422 NONE Our\PRP$\1740 experience\NN\5984287 supports\VBZ\2199590 the\DT\1740 safety\NN\13920835 of\IN\1740 giving\VBG\2327200 AraG\NN\1740 as\IN\14622893 salvage\NN\3076708 therapy\NN\657604 in\IN\13603305 synchrony\NN\13844690 with\IN\1740 etoposide\NN\1740 and\CC\1740 <e1>cyclophosphamide</e1>\NN\1740 ,\,\1740 although\IN\1740 <e2>neurological\JJ\1740 toxicity</e2>\NN\13576101 must\MD\9367203 be\VB\836236 closely\RB\1740 monitored\VBN\2169352 .\.\1740
10704919
D013629_D006461 CID <e2>Hemolysis</e2>\NN\13509528 of\IN\1740 human\JJ\1740 erythrocytes\NNS\5449268 induced\VBN\1627355 by\IN\1740 <e1>tamoxifen</e1>\NN\2714883 is\VBZ\836236 related\JJ\1740 to\TO\1740 disruption\NN\1066163 of\IN\1740 membrane\NN\4188643 structure\NN\21939 .\.\1740
D013629_D006461 CID <e1>TAM</e1>\NN\2954340 induces\VBZ\1627355 <e2>hemolysis</e2>\NN\13509528 of\IN\1740 erythrocytes\NNS\5449268 as\IN\14622893 a\DT\13649268 function\NN\13783581 of\IN\1740 concentration\NN\4916342 .\.\1740
D013629_D006461 CID The\DT\1740 extension\NN\15272029 of\IN\1740 <e2>hemolysis</e2>\NN\13509528 is\VBZ\836236 variable\JJ\1740 with\IN\1740 erythrocyte\NN\5449268 samples\NNS\5820620 ,\,\1740 but\CC\1740 12.5\CD\1740 microM\NN\1740 <e1>TAM</e1>\NN\2954340 induces\VBZ\1627355 total\JJ\1740 hemolysis\NN\13509528 of\IN\1740 all\DT\1740 tested\VBN\670261 suspensions\NNS\14586258 .\.\1740
D013629_D006461 CID The\DT\1740 extension\NN\15272029 of\IN\1740 hemolysis\NN\13509528 is\VBZ\836236 variable\JJ\1740 with\IN\1740 erythrocyte\NN\5449268 samples\NNS\5820620 ,\,\1740 but\CC\1740 12.5\CD\1740 microM\NN\1740 <e1>TAM</e1>\NN\2954340 induces\VBZ\1627355 total\JJ\1740 <e2>hemolysis</e2>\NN\13509528 of\IN\1740 all\DT\1740 tested\VBN\670261 suspensions\NNS\14586258 .\.\1740
D013629_D006461 CID The\DT\1740 <e2>hemolytic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 <e1>TAM</e1>\NN\2954340 is\VBZ\836236 prevented\VBN\1740 by\IN\1740 low\JJ\1740 concentrations\NNS\4916342 of\IN\1740 alpha-tocopherol\NN\1740 (\-LRB-\1740 alpha-T\NN\1740 )\-RRB-\1740 and\CC\1740 alpha-tocopherol\NN\1740 acetate\NN\15010703 (\-LRB-\1740 alpha-TAc\NN\1740 )\-RRB-\1740 (\-LRB-\1740 inactivated\VBD\1097743 functional\JJ\1740 hydroxyl\NN\14621446 )\-RRB-\1740 indicating\VBG\952524 that\IN\1740 TAM-induced\JJ\1740 hemolysis\NN\13509528 is\VBZ\836236 not\RB\1740 related\JJ\1740 to\TO\1740 oxidative\JJ\1740 membrane\NN\4188643 damage\NN\7296428 .\.\1740
D013629_D006461 CID The\DT\1740 hemolytic\JJ\1740 effect\NN\34213 of\IN\1740 <e1>TAM</e1>\NN\2954340 is\VBZ\836236 prevented\VBN\1740 by\IN\1740 low\JJ\1740 concentrations\NNS\4916342 of\IN\1740 alpha-tocopherol\NN\1740 (\-LRB-\1740 alpha-T\NN\1740 )\-RRB-\1740 and\CC\1740 alpha-tocopherol\NN\1740 acetate\NN\15010703 (\-LRB-\1740 alpha-TAc\NN\1740 )\-RRB-\1740 (\-LRB-\1740 inactivated\VBD\1097743 functional\JJ\1740 hydroxyl\NN\14621446 )\-RRB-\1740 indicating\VBG\952524 that\IN\1740 TAM-induced\JJ\1740 <e2>hemolysis</e2>\NN\13509528 is\VBZ\836236 not\RB\1740 related\JJ\1740 to\TO\1740 oxidative\JJ\1740 membrane\NN\4188643 damage\NN\7296428 .\.\1740
D013629_D006461 CID The\DT\1740 <e2>hemolytic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 TAM\NN\2954340 is\VBZ\836236 prevented\VBN\1740 by\IN\1740 low\JJ\1740 concentrations\NNS\4916342 of\IN\1740 alpha-tocopherol\NN\1740 (\-LRB-\1740 alpha-T\NN\1740 )\-RRB-\1740 and\CC\1740 alpha-tocopherol\NN\1740 acetate\NN\15010703 (\-LRB-\1740 alpha-TAc\NN\1740 )\-RRB-\1740 (\-LRB-\1740 inactivated\VBD\1097743 functional\JJ\1740 hydroxyl\NN\14621446 )\-RRB-\1740 indicating\VBG\952524 that\IN\1740 <e1>TAM-induced</e1>\JJ\1740 hemolysis\NN\13509528 is\VBZ\836236 not\RB\1740 related\JJ\1740 to\TO\1740 oxidative\JJ\1740 membrane\NN\4188643 damage\NN\7296428 .\.\1740
D013629_D006461 CID The\DT\1740 hemolytic\JJ\1740 effect\NN\34213 of\IN\1740 TAM\NN\2954340 is\VBZ\836236 prevented\VBN\1740 by\IN\1740 low\JJ\1740 concentrations\NNS\4916342 of\IN\1740 alpha-tocopherol\NN\1740 (\-LRB-\1740 alpha-T\NN\1740 )\-RRB-\1740 and\CC\1740 alpha-tocopherol\NN\1740 acetate\NN\15010703 (\-LRB-\1740 alpha-TAc\NN\1740 )\-RRB-\1740 (\-LRB-\1740 inactivated\VBD\1097743 functional\JJ\1740 hydroxyl\NN\14621446 )\-RRB-\1740 indicating\VBG\952524 that\IN\1740 <e1>TAM-induced</e1>\JJ\1740 <e2>hemolysis</e2>\NN\13509528 is\VBZ\836236 not\RB\1740 related\JJ\1740 to\TO\1740 oxidative\JJ\1740 membrane\NN\4188643 damage\NN\7296428 .\.\1740
D013629_D006461 CID This\DT\1740 was\VBD\836236 further\RB\1740 evidenced\VBN\1015244 by\IN\1740 absence\NN\14449405 of\IN\1740 oxygen\NN\14622893 consumption\NN\13440063 and\CC\1740 hemoglobin\NN\14888884 oxidation\NN\13447361 both\CC\1740 determined\VBN\1645601 in\IN\13603305 parallel\NN\4743605 with\IN\1740 <e1>TAM-induced</e1>\JJ\1740 <e2>hemolysis</e2>\NN\13509528 .\.\1740
D013629_D006461 CID <e2>Hemolysis</e2>\NN\13509528 caused\VBN\1617192 by\IN\1740 <e1>TAM</e1>\NN\2954340 was\VBD\836236 not\RB\1740 preceded\VBN\2690708 by\IN\1740 the\DT\1740 leakage\NN\7407777 of\IN\1740 K(+\NN\1740 )\-RRB-\1740 from\IN\1740 the\DT\1740 cells\NNS\3080309 ,\,\1740 also\RB\1740 excluding\VBG\471711 a\DT\13649268 colloid-osmotic\JJ\1740 type\NN\5839024 mechanism\NN\13446390 of\IN\1740 hemolysis\NN\13509528 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 effects\NNS\13245626 on\IN\1740 osmotic\JJ\1740 fragility\NN\5042871 curves\NNS\13863771 .\.\1740
D013629_D006461 CID Hemolysis\NN\13509528 caused\VBN\1617192 by\IN\1740 <e1>TAM</e1>\NN\2954340 was\VBD\836236 not\RB\1740 preceded\VBN\2690708 by\IN\1740 the\DT\1740 leakage\NN\7407777 of\IN\1740 K(+\NN\1740 )\-RRB-\1740 from\IN\1740 the\DT\1740 cells\NNS\3080309 ,\,\1740 also\RB\1740 excluding\VBG\471711 a\DT\13649268 colloid-osmotic\JJ\1740 type\NN\5839024 mechanism\NN\13446390 of\IN\1740 <e2>hemolysis</e2>\NN\13509528 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 effects\NNS\13245626 on\IN\1740 osmotic\JJ\1740 fragility\NN\5042871 curves\NNS\13863771 .\.\1740
D013629_D006461 CID These\DT\1740 effects\NNS\13245626 suggest\VBP\1010118 that\IN\1740 the\DT\1740 protection\NN\407535 from\IN\1740 <e2>hemolysis</e2>\NN\13509528 by\IN\1740 tocopherols\NNS\14724645 is\VBZ\836236 related\JJ\1740 to\TO\1740 a\DT\13649268 decreased\VBN\169651 <e1>TAM</e1>\NN\2954340 incorporation\NN\1237415 in\IN\13603305 condensed\VBN\443984 membranes\NNS\4188643 and\CC\1740 the\DT\1740 structural\JJ\1740 damage\NN\7296428 of\IN\1740 the\DT\1740 erythrocyte\NN\5449268 membrane\NN\4188643 is\VBZ\836236 consequently\RB\1740 avoided\VBN\2452885 .\.\1740
D013629_D006461 CID Therefore\RB\1740 ,\,\1740 <e1>TAM-induced</e1>\JJ\1740 <e2>hemolysis</e2>\NN\13509528 results\VBZ\2633881 from\IN\1740 a\DT\13649268 structural\JJ\1740 perturbation\NN\14403107 of\IN\1740 red\JJ\1740 cell\NN\3080309 membrane\NN\4188643 ,\,\1740 leading\VBG\1752884 to\TO\1740 changes\NNS\7283608 in\IN\13603305 the\DT\1740 framework\NN\5888929 of\IN\1740 the\DT\1740 erythrocyte\NN\5449268 membrane\NN\4188643 and\CC\1740 its\PRP$\6125041 cytoskeleton\NN\5225602 caused\VBN\1617192 by\IN\1740 its\PRP$\6125041 high\JJ\1740 partition\NN\4341686 in\IN\13603305 the\DT\1740 membrane\NN\4188643 .\.\1740
D013629_D001943 NONE <e1>Tamoxifen</e1>\NN\2714883 (\-LRB-\1740 TAM\NNP\2954340 )\-RRB-\1740 ,\,\1740 the\DT\1740 antiestrogenic\JJ\1740 drug\NN\14778436 most\RBS\1740 widely\RB\1740 prescribed\VBN\748282 in\IN\13603305 the\DT\1740 chemotherapy\NN\661091 of\IN\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 ,\,\1740 induces\VBZ\1627355 changes\NNS\7283608 in\IN\13603305 normal\JJ\1740 discoid\JJ\1740 shape\NN\5062748 of\IN\1740 erythrocytes\NNS\5449268 and\CC\1740 hemolytic\JJ\1740 anemia\NN\14189204 .\.\1740
D013629_D001943 NONE Tamoxifen\NN\2714883 (\-LRB-\1740 <e1>TAM</e1>\NNP\2954340 )\-RRB-\1740 ,\,\1740 the\DT\1740 antiestrogenic\JJ\1740 drug\NN\14778436 most\RBS\1740 widely\RB\1740 prescribed\VBN\748282 in\IN\13603305 the\DT\1740 chemotherapy\NN\661091 of\IN\1740 <e2>breast\NN\5225090 cancer</e2>\NN\14239425 ,\,\1740 induces\VBZ\1627355 changes\NNS\7283608 in\IN\13603305 normal\JJ\1740 discoid\JJ\1740 shape\NN\5062748 of\IN\1740 erythrocytes\NNS\5449268 and\CC\1740 hemolytic\JJ\1740 anemia\NN\14189204 .\.\1740
D013629_D000743 CID <e1>Tamoxifen</e1>\NN\2714883 (\-LRB-\1740 TAM\NNP\2954340 )\-RRB-\1740 ,\,\1740 the\DT\1740 antiestrogenic\JJ\1740 drug\NN\14778436 most\RBS\1740 widely\RB\1740 prescribed\VBN\748282 in\IN\13603305 the\DT\1740 chemotherapy\NN\661091 of\IN\1740 breast\NN\5225090 cancer\NN\14239425 ,\,\1740 induces\VBZ\1627355 changes\NNS\7283608 in\IN\13603305 normal\JJ\1740 discoid\JJ\1740 shape\NN\5062748 of\IN\1740 erythrocytes\NNS\5449268 and\CC\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 .\.\1740
D013629_D000743 CID Tamoxifen\NN\2714883 (\-LRB-\1740 <e1>TAM</e1>\NNP\2954340 )\-RRB-\1740 ,\,\1740 the\DT\1740 antiestrogenic\JJ\1740 drug\NN\14778436 most\RBS\1740 widely\RB\1740 prescribed\VBN\748282 in\IN\13603305 the\DT\1740 chemotherapy\NN\661091 of\IN\1740 breast\NN\5225090 cancer\NN\14239425 ,\,\1740 induces\VBZ\1627355 changes\NNS\7283608 in\IN\13603305 normal\JJ\1740 discoid\JJ\1740 shape\NN\5062748 of\IN\1740 erythrocytes\NNS\5449268 and\CC\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 .\.\1740
D013629_D000743 CID This\DT\1740 work\NN\407535 evaluates\VBZ\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>TAM</e1>\NN\2954340 on\IN\1740 isolated\VBN\2512305 human\JJ\1740 erythrocytes\NNS\5449268 ,\,\1740 attempting\VBG\2367363 to\TO\1740 identify\VB\699815 the\DT\1740 underlying\VBG\2604760 mechanisms\NNS\13446390 on\IN\1740 TAM-induced\JJ\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 and\CC\1740 the\DT\1740 involvement\NN\1080366 of\IN\1740 biomembranes\NNS\1740 in\IN\13603305 its\PRP$\6125041 cytostatic\JJ\1740 action\NN\30358 mechanisms\NNS\13446390 .\.\1740
D013629_D000743 CID This\DT\1740 work\NN\407535 evaluates\VBZ\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 TAM\NN\2954340 on\IN\1740 isolated\VBN\2512305 human\JJ\1740 erythrocytes\NNS\5449268 ,\,\1740 attempting\VBG\2367363 to\TO\1740 identify\VB\699815 the\DT\1740 underlying\VBG\2604760 mechanisms\NNS\13446390 on\IN\1740 <e1>TAM-induced</e1>\JJ\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 and\CC\1740 the\DT\1740 involvement\NN\1080366 of\IN\1740 biomembranes\NNS\1740 in\IN\13603305 its\PRP$\6125041 cytostatic\JJ\1740 action\NN\30358 mechanisms\NNS\13446390 .\.\1740
D013629_D000743 CID These\DT\1740 defects\NNS\14462666 explain\VBP\831651 the\DT\1740 abnormal\JJ\1740 erythrocyte\NN\5449268 shape\NN\5062748 and\CC\1740 decreased\VBD\169651 mechanical\JJ\1740 stability\NN\4777852 promoted\VBN\2556126 by\IN\1740 <e1>TAM</e1>\NN\2954340 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 .\.\1740
D024502_D006461 NONE The\DT\1740 <e2>hemolytic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 TAM\NN\2954340 is\VBZ\836236 prevented\VBN\1740 by\IN\1740 low\JJ\1740 concentrations\NNS\4916342 of\IN\1740 <e1>alpha-tocopherol</e1>\NN\1740 (\-LRB-\1740 alpha-T\NN\1740 )\-RRB-\1740 and\CC\1740 alpha-tocopherol\NN\1740 acetate\NN\15010703 (\-LRB-\1740 alpha-TAc\NN\1740 )\-RRB-\1740 (\-LRB-\1740 inactivated\VBD\1097743 functional\JJ\1740 hydroxyl\NN\14621446 )\-RRB-\1740 indicating\VBG\952524 that\IN\1740 TAM-induced\JJ\1740 hemolysis\NN\13509528 is\VBZ\836236 not\RB\1740 related\JJ\1740 to\TO\1740 oxidative\JJ\1740 membrane\NN\4188643 damage\NN\7296428 .\.\1740
D024502_D006461 NONE The\DT\1740 hemolytic\JJ\1740 effect\NN\34213 of\IN\1740 TAM\NN\2954340 is\VBZ\836236 prevented\VBN\1740 by\IN\1740 low\JJ\1740 concentrations\NNS\4916342 of\IN\1740 <e1>alpha-tocopherol</e1>\NN\1740 (\-LRB-\1740 alpha-T\NN\1740 )\-RRB-\1740 and\CC\1740 alpha-tocopherol\NN\1740 acetate\NN\15010703 (\-LRB-\1740 alpha-TAc\NN\1740 )\-RRB-\1740 (\-LRB-\1740 inactivated\VBD\1097743 functional\JJ\1740 hydroxyl\NN\14621446 )\-RRB-\1740 indicating\VBG\952524 that\IN\1740 TAM-induced\JJ\1740 <e2>hemolysis</e2>\NN\13509528 is\VBZ\836236 not\RB\1740 related\JJ\1740 to\TO\1740 oxidative\JJ\1740 membrane\NN\4188643 damage\NN\7296428 .\.\1740
D024502_D006461 NONE The\DT\1740 <e2>hemolytic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 TAM\NN\2954340 is\VBZ\836236 prevented\VBN\1740 by\IN\1740 low\JJ\1740 concentrations\NNS\4916342 of\IN\1740 alpha-tocopherol\NN\1740 (\-LRB-\1740 <e1>alpha-T</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 alpha-tocopherol\NN\1740 acetate\NN\15010703 (\-LRB-\1740 alpha-TAc\NN\1740 )\-RRB-\1740 (\-LRB-\1740 inactivated\VBD\1097743 functional\JJ\1740 hydroxyl\NN\14621446 )\-RRB-\1740 indicating\VBG\952524 that\IN\1740 TAM-induced\JJ\1740 hemolysis\NN\13509528 is\VBZ\836236 not\RB\1740 related\JJ\1740 to\TO\1740 oxidative\JJ\1740 membrane\NN\4188643 damage\NN\7296428 .\.\1740
D024502_D006461 NONE The\DT\1740 hemolytic\JJ\1740 effect\NN\34213 of\IN\1740 TAM\NN\2954340 is\VBZ\836236 prevented\VBN\1740 by\IN\1740 low\JJ\1740 concentrations\NNS\4916342 of\IN\1740 alpha-tocopherol\NN\1740 (\-LRB-\1740 <e1>alpha-T</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 alpha-tocopherol\NN\1740 acetate\NN\15010703 (\-LRB-\1740 alpha-TAc\NN\1740 )\-RRB-\1740 (\-LRB-\1740 inactivated\VBD\1097743 functional\JJ\1740 hydroxyl\NN\14621446 )\-RRB-\1740 indicating\VBG\952524 that\IN\1740 TAM-induced\JJ\1740 <e2>hemolysis</e2>\NN\13509528 is\VBZ\836236 not\RB\1740 related\JJ\1740 to\TO\1740 oxidative\JJ\1740 membrane\NN\4188643 damage\NN\7296428 .\.\1740
D024502_D006461 NONE The\DT\1740 <e2>hemolytic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 TAM\NN\2954340 is\VBZ\836236 prevented\VBN\1740 by\IN\1740 low\JJ\1740 concentrations\NNS\4916342 of\IN\1740 alpha-tocopherol\NN\1740 (\-LRB-\1740 alpha-T\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>alpha-tocopherol\NN\1740 acetate</e1>\NN\15010703 (\-LRB-\1740 alpha-TAc\NN\1740 )\-RRB-\1740 (\-LRB-\1740 inactivated\VBD\1097743 functional\JJ\1740 hydroxyl\NN\14621446 )\-RRB-\1740 indicating\VBG\952524 that\IN\1740 TAM-induced\JJ\1740 hemolysis\NN\13509528 is\VBZ\836236 not\RB\1740 related\JJ\1740 to\TO\1740 oxidative\JJ\1740 membrane\NN\4188643 damage\NN\7296428 .\.\1740
D024502_D006461 NONE The\DT\1740 hemolytic\JJ\1740 effect\NN\34213 of\IN\1740 TAM\NN\2954340 is\VBZ\836236 prevented\VBN\1740 by\IN\1740 low\JJ\1740 concentrations\NNS\4916342 of\IN\1740 alpha-tocopherol\NN\1740 (\-LRB-\1740 alpha-T\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>alpha-tocopherol\NN\1740 acetate</e1>\NN\15010703 (\-LRB-\1740 alpha-TAc\NN\1740 )\-RRB-\1740 (\-LRB-\1740 inactivated\VBD\1097743 functional\JJ\1740 hydroxyl\NN\14621446 )\-RRB-\1740 indicating\VBG\952524 that\IN\1740 TAM-induced\JJ\1740 <e2>hemolysis</e2>\NN\13509528 is\VBZ\836236 not\RB\1740 related\JJ\1740 to\TO\1740 oxidative\JJ\1740 membrane\NN\4188643 damage\NN\7296428 .\.\1740
D024502_D006461 NONE The\DT\1740 <e2>hemolytic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 TAM\NN\2954340 is\VBZ\836236 prevented\VBN\1740 by\IN\1740 low\JJ\1740 concentrations\NNS\4916342 of\IN\1740 alpha-tocopherol\NN\1740 (\-LRB-\1740 alpha-T\NN\1740 )\-RRB-\1740 and\CC\1740 alpha-tocopherol\NN\1740 acetate\NN\15010703 (\-LRB-\1740 <e1>alpha-TAc</e1>\NN\1740 )\-RRB-\1740 (\-LRB-\1740 inactivated\VBD\1097743 functional\JJ\1740 hydroxyl\NN\14621446 )\-RRB-\1740 indicating\VBG\952524 that\IN\1740 TAM-induced\JJ\1740 hemolysis\NN\13509528 is\VBZ\836236 not\RB\1740 related\JJ\1740 to\TO\1740 oxidative\JJ\1740 membrane\NN\4188643 damage\NN\7296428 .\.\1740
D024502_D006461 NONE The\DT\1740 hemolytic\JJ\1740 effect\NN\34213 of\IN\1740 TAM\NN\2954340 is\VBZ\836236 prevented\VBN\1740 by\IN\1740 low\JJ\1740 concentrations\NNS\4916342 of\IN\1740 alpha-tocopherol\NN\1740 (\-LRB-\1740 alpha-T\NN\1740 )\-RRB-\1740 and\CC\1740 alpha-tocopherol\NN\1740 acetate\NN\15010703 (\-LRB-\1740 <e1>alpha-TAc</e1>\NN\1740 )\-RRB-\1740 (\-LRB-\1740 inactivated\VBD\1097743 functional\JJ\1740 hydroxyl\NN\14621446 )\-RRB-\1740 indicating\VBG\952524 that\IN\1740 TAM-induced\JJ\1740 <e2>hemolysis</e2>\NN\13509528 is\VBZ\836236 not\RB\1740 related\JJ\1740 to\TO\1740 oxidative\JJ\1740 membrane\NN\4188643 damage\NN\7296428 .\.\1740
D017665_D006461 NONE The\DT\1740 <e2>hemolytic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 TAM\NN\2954340 is\VBZ\836236 prevented\VBN\1740 by\IN\1740 low\JJ\1740 concentrations\NNS\4916342 of\IN\1740 alpha-tocopherol\NN\1740 (\-LRB-\1740 alpha-T\NN\1740 )\-RRB-\1740 and\CC\1740 alpha-tocopherol\NN\1740 acetate\NN\15010703 (\-LRB-\1740 alpha-TAc\NN\1740 )\-RRB-\1740 (\-LRB-\1740 inactivated\VBD\1097743 functional\JJ\1740 <e1>hydroxyl</e1>\NN\14621446 )\-RRB-\1740 indicating\VBG\952524 that\IN\1740 TAM-induced\JJ\1740 hemolysis\NN\13509528 is\VBZ\836236 not\RB\1740 related\JJ\1740 to\TO\1740 oxidative\JJ\1740 membrane\NN\4188643 damage\NN\7296428 .\.\1740
D017665_D006461 NONE The\DT\1740 hemolytic\JJ\1740 effect\NN\34213 of\IN\1740 TAM\NN\2954340 is\VBZ\836236 prevented\VBN\1740 by\IN\1740 low\JJ\1740 concentrations\NNS\4916342 of\IN\1740 alpha-tocopherol\NN\1740 (\-LRB-\1740 alpha-T\NN\1740 )\-RRB-\1740 and\CC\1740 alpha-tocopherol\NN\1740 acetate\NN\15010703 (\-LRB-\1740 alpha-TAc\NN\1740 )\-RRB-\1740 (\-LRB-\1740 inactivated\VBD\1097743 functional\JJ\1740 <e1>hydroxyl</e1>\NN\14621446 )\-RRB-\1740 indicating\VBG\952524 that\IN\1740 TAM-induced\JJ\1740 <e2>hemolysis</e2>\NN\13509528 is\VBZ\836236 not\RB\1740 related\JJ\1740 to\TO\1740 oxidative\JJ\1740 membrane\NN\4188643 damage\NN\7296428 .\.\1740
D010100_D006461 NONE This\DT\1740 was\VBD\836236 further\RB\1740 evidenced\VBN\1015244 by\IN\1740 absence\NN\14449405 of\IN\1740 <e1>oxygen</e1>\NN\14622893 consumption\NN\13440063 and\CC\1740 hemoglobin\NN\14888884 oxidation\NN\13447361 both\CC\1740 determined\VBN\1645601 in\IN\13603305 parallel\NN\4743605 with\IN\1740 TAM-induced\JJ\1740 <e2>hemolysis</e2>\NN\13509528 .\.\1740
D011188_D006461 NONE <e2>Hemolysis</e2>\NN\13509528 caused\VBN\1617192 by\IN\1740 TAM\NN\2954340 was\VBD\836236 not\RB\1740 preceded\VBN\2690708 by\IN\1740 the\DT\1740 leakage\NN\7407777 of\IN\1740 <e1>K(+</e1>\NN\1740 )\-RRB-\1740 from\IN\1740 the\DT\1740 cells\NNS\3080309 ,\,\1740 also\RB\1740 excluding\VBG\471711 a\DT\13649268 colloid-osmotic\JJ\1740 type\NN\5839024 mechanism\NN\13446390 of\IN\1740 hemolysis\NN\13509528 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 effects\NNS\13245626 on\IN\1740 osmotic\JJ\1740 fragility\NN\5042871 curves\NNS\13863771 .\.\1740
D011188_D006461 NONE Hemolysis\NN\13509528 caused\VBN\1617192 by\IN\1740 TAM\NN\2954340 was\VBD\836236 not\RB\1740 preceded\VBN\2690708 by\IN\1740 the\DT\1740 leakage\NN\7407777 of\IN\1740 <e1>K(+</e1>\NN\1740 )\-RRB-\1740 from\IN\1740 the\DT\1740 cells\NNS\3080309 ,\,\1740 also\RB\1740 excluding\VBG\471711 a\DT\13649268 colloid-osmotic\JJ\1740 type\NN\5839024 mechanism\NN\13446390 of\IN\1740 <e2>hemolysis</e2>\NN\13509528 ,\,\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 effects\NNS\13245626 on\IN\1740 osmotic\JJ\1740 fragility\NN\5042871 curves\NNS\13863771 .\.\1740
D024505_D006461 NONE These\DT\1740 effects\NNS\13245626 suggest\VBP\1010118 that\IN\1740 the\DT\1740 protection\NN\407535 from\IN\1740 <e2>hemolysis</e2>\NN\13509528 by\IN\1740 <e1>tocopherols</e1>\NNS\14724645 is\VBZ\836236 related\JJ\1740 to\TO\1740 a\DT\13649268 decreased\VBN\169651 TAM\NN\2954340 incorporation\NN\1237415 in\IN\13603305 condensed\VBN\443984 membranes\NNS\4188643 and\CC\1740 the\DT\1740 structural\JJ\1740 damage\NN\7296428 of\IN\1740 the\DT\1740 erythrocyte\NN\5449268 membrane\NN\4188643 is\VBZ\836236 consequently\RB\1740 avoided\VBN\2452885 .\.\1740
10683478
D001058_D007035 CID <e1>Apomorphine</e1>\NNP\3786417 ,\,\1740 a\DT\13649268 nonselective\JJ\1740 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 was\VBD\836236 selected\VBN\697589 due\IN\5174653 to\TO\1740 its\PRP$\6125041 biphasic\JJ\1740 behavioral\JJ\1740 effects\NNS\13245626 ,\,\1740 its\PRP$\6125041 ability\NN\4723816 to\TO\1740 induce\VB\1627355 <e2>hypothermia</e2>\NN\14034177 ,\,\1740 and\CC\1740 to\TO\1740 produce\VB\1617192 distinct\JJ\1740 changes\NNS\7283608 to\TO\1740 dopamine\NN\14807737 turnover\NN\13819207 in\IN\13603305 the\DT\1740 rodent\JJ\1740 brain\NN\5462674 .\.\1740
D001058_D007035 CID Moreover\RB\1740 ,\,\1740 test\NN\5798043 conditions\NNS\14512817 can\MD\3094503 impact\VB\1527271 upon\IN\1740 other\JJ\1740 physiological\JJ\1740 responses\NNS\11410625 to\TO\1740 <e1>apomorphine</e1>\VB\1740 such\JJ\1740 as\IN\14622893 drug-induced\JJ\1740 <e2>hypothermia</e2>\NN\14034177 .\.\1740
D018491_D007035 NONE Apomorphine\NNP\3786417 ,\,\1740 a\DT\13649268 nonselective\JJ\1740 <e1>dopamine\NN\14807737 agonist</e1>\NN\9613191 ,\,\1740 was\VBD\836236 selected\VBN\697589 due\IN\5174653 to\TO\1740 its\PRP$\6125041 biphasic\JJ\1740 behavioral\JJ\1740 effects\NNS\13245626 ,\,\1740 its\PRP$\6125041 ability\NN\4723816 to\TO\1740 induce\VB\1627355 <e2>hypothermia</e2>\NN\14034177 ,\,\1740 and\CC\1740 to\TO\1740 produce\VB\1617192 distinct\JJ\1740 changes\NNS\7283608 to\TO\1740 dopamine\NN\14807737 turnover\NN\13819207 in\IN\13603305 the\DT\1740 rodent\JJ\1740 brain\NN\5462674 .\.\1740
D004298_D007035 NONE Apomorphine\NNP\3786417 ,\,\1740 a\DT\13649268 nonselective\JJ\1740 dopamine\NN\14807737 agonist\NN\9613191 ,\,\1740 was\VBD\836236 selected\VBN\697589 due\IN\5174653 to\TO\1740 its\PRP$\6125041 biphasic\JJ\1740 behavioral\JJ\1740 effects\NNS\13245626 ,\,\1740 its\PRP$\6125041 ability\NN\4723816 to\TO\1740 induce\VB\1627355 <e2>hypothermia</e2>\NN\14034177 ,\,\1740 and\CC\1740 to\TO\1740 produce\VB\1617192 distinct\JJ\1740 changes\NNS\7283608 to\TO\1740 <e1>dopamine</e1>\NN\14807737 turnover\NN\13819207 in\IN\13603305 the\DT\1740 rodent\JJ\1740 brain\NN\5462674 .\.\1740
D001058_D006948 CID In\IN\13603305 rats\NNS\2329401 ,\,\1740 detection\NN\5708432 of\IN\1740 <e1>apomorphine-induced</e1>\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 was\VBD\836236 facilitated\VBN\2547586 by\IN\1740 a\DT\13649268 period\NN\13575869 of\IN\1740 acclimatization\NN\13427078 to\IN\1740 the\DT\1740 test\NN\5798043 conditions\NNS\14512817 .\.\1740
12041669
D000961_D000741 NONE <e1>Antithymocyte\NNP\1740 globulin</e1>\NN\14736972 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 D-penicillamine-induced\JJ\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 .\.\1740
D000961_D000741 NONE A\DT\13649268 patient\NN\9898892 who\WP\8299493 received\VBD\2210855 <e1>antithymocyte\NN\1740 globulin</e1>\NN\14736972 therapy\NN\657604 for\IN\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 due\IN\5174653 to\TO\1740 D-penicillamine\NN\1740 therapy\NN\657604 is\VBZ\836236 described\VBN\1001294 .\.\1740
D000961_D000741 NONE Use\NN\407535 of\IN\1740 <e1>antithymocyte\NN\1740 globulin</e1>\NN\14736972 may\MD\15209706 be\VB\836236 the\DT\1740 optimal\JJ\1740 treatment\NN\654885 of\IN\1740 D-penicillamine-induced\JJ\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 .\.\1740
D010396_D000741 CID Antithymocyte\NNP\1740 globulin\NN\14736972 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e1>D-penicillamine-induced</e1>\JJ\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 .\.\1740
D010396_D000741 CID A\DT\13649268 patient\NN\9898892 who\WP\8299493 received\VBD\2210855 antithymocyte\NN\1740 globulin\NN\14736972 therapy\NN\657604 for\IN\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 due\IN\5174653 to\TO\1740 <e1>D-penicillamine</e1>\NN\1740 therapy\NN\657604 is\VBZ\836236 described\VBN\1001294 .\.\1740
D010396_D000741 CID Use\NN\407535 of\IN\1740 antithymocyte\NN\1740 globulin\NN\14736972 may\MD\15209706 be\VB\836236 the\DT\1740 optimal\JJ\1740 treatment\NN\654885 of\IN\1740 <e1>D-penicillamine-induced</e1>\JJ\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 .\.\1740
12536034
D002220_D004832 CID The\DT\1740 authors\NNS\9610660 present\VBP\2137132 three\CD\13741022 patients\NNS\9898892 with\IN\1740 de\FW\1740 novo\FW\1740 <e2>absence\NN\14449405 epilepsy</e2>\NN\14085708 after\IN\1740 administration\NN\1133281 of\IN\1740 <e1>carbamazepine</e1>\NN\1740 and\CC\1740 vigabatrin\NN\1740 .\.\1740
D020888_D004832 CID The\DT\1740 authors\NNS\9610660 present\VBP\2137132 three\CD\13741022 patients\NNS\9898892 with\IN\1740 de\FW\1740 novo\FW\1740 <e2>absence\NN\14449405 epilepsy</e2>\NN\14085708 after\IN\1740 administration\NN\1133281 of\IN\1740 carbamazepine\NN\1740 and\CC\1740 <e1>vigabatrin</e1>\NN\1740 .\.\1740
D005680_D004832 NONE The\DT\1740 <e1>gamma-aminobutyric\JJ\1740 acid-transmitted</e1>\JJ\1740 thalamocortical\JJ\1740 circuitry\NN\3278248 accounts\NNS\6647206 for\IN\1740 a\DT\13649268 major\JJ\1740 part\NN\31921 of\IN\1740 the\DT\1740 underlying\VBG\2604760 neurophysiology\NN\6081833 of\IN\1740 the\DT\1740 <e2>absence\NN\14449405 epilepsy</e2>\NN\14085708 .\.\1740
10365197
D003042_D019964 CID <e1>Cocaine-induced</e1>\JJ\1740 <e2>mood\NN\26192 disorder</e2>\NN\14034177 :\:\1740 prevalence\NN\4764412 rates\NNS\13308999 and\CC\1740 psychiatric\JJ\1740 symptoms\NNS\5823932 in\IN\13603305 an\DT\6697703 outpatient\JJ\1740 cocaine-dependent\JJ\1740 sample\NN\5820620 .\.\1740
D003042_D019964 CID Cocaine-induced\JJ\1740 <e2>mood\NN\26192 disorder</e2>\NN\14034177 :\:\1740 prevalence\NN\4764412 rates\NNS\13308999 and\CC\1740 psychiatric\JJ\1740 symptoms\NNS\5823932 in\IN\13603305 an\DT\6697703 outpatient\JJ\1740 <e1>cocaine-dependent</e1>\JJ\1740 sample\NN\5820620 .\.\1740
D003042_D019964 CID 243\CD\1740 <e1>cocaine-dependent</e1>\JJ\1740 outpatients\NNS\10405694 with\IN\1740 cocaine-induced\JJ\1740 <e2>mood\NN\26192 disorder</e2>\NN\14034177 (\-LRB-\1740 CIMD\NN\1740 )\-RRB-\1740 ,\,\1740 other\JJ\1740 mood\NN\26192 disorders\NNS\14034177 ,\,\1740 or\CC\3541091 no\DT\7204911 mood\NN\26192 disorder\NN\14034177 were\VBD\836236 compared\VBN\644583 on\IN\1740 measures\NNS\168237 of\IN\1740 psychiatric\JJ\1740 symptoms\NNS\5823932 .\.\1740
D003042_D019964 CID 243\CD\1740 <e1>cocaine-dependent</e1>\JJ\1740 outpatients\NNS\10405694 with\IN\1740 cocaine-induced\JJ\1740 mood\NN\26192 disorder\NN\14034177 (\-LRB-\1740 CIMD\NN\1740 )\-RRB-\1740 ,\,\1740 other\JJ\1740 <e2>mood\NN\26192 disorders</e2>\NNS\14034177 ,\,\1740 or\CC\3541091 no\DT\7204911 mood\NN\26192 disorder\NN\14034177 were\VBD\836236 compared\VBN\644583 on\IN\1740 measures\NNS\168237 of\IN\1740 psychiatric\JJ\1740 symptoms\NNS\5823932 .\.\1740
D003042_D019964 CID 243\CD\1740 <e1>cocaine-dependent</e1>\JJ\1740 outpatients\NNS\10405694 with\IN\1740 cocaine-induced\JJ\1740 mood\NN\26192 disorder\NN\14034177 (\-LRB-\1740 CIMD\NN\1740 )\-RRB-\1740 ,\,\1740 other\JJ\1740 mood\NN\26192 disorders\NNS\14034177 ,\,\1740 or\CC\3541091 no\DT\7204911 <e2>mood\NN\26192 disorder</e2>\NN\14034177 were\VBD\836236 compared\VBN\644583 on\IN\1740 measures\NNS\168237 of\IN\1740 psychiatric\JJ\1740 symptoms\NNS\5823932 .\.\1740
D003042_D019964 CID 243\CD\1740 cocaine-dependent\JJ\1740 outpatients\NNS\10405694 with\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 <e2>mood\NN\26192 disorder</e2>\NN\14034177 (\-LRB-\1740 CIMD\NN\1740 )\-RRB-\1740 ,\,\1740 other\JJ\1740 mood\NN\26192 disorders\NNS\14034177 ,\,\1740 or\CC\3541091 no\DT\7204911 mood\NN\26192 disorder\NN\14034177 were\VBD\836236 compared\VBN\644583 on\IN\1740 measures\NNS\168237 of\IN\1740 psychiatric\JJ\1740 symptoms\NNS\5823932 .\.\1740
D003042_D019964 CID 243\CD\1740 cocaine-dependent\JJ\1740 outpatients\NNS\10405694 with\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 mood\NN\26192 disorder\NN\14034177 (\-LRB-\1740 CIMD\NN\1740 )\-RRB-\1740 ,\,\1740 other\JJ\1740 <e2>mood\NN\26192 disorders</e2>\NNS\14034177 ,\,\1740 or\CC\3541091 no\DT\7204911 mood\NN\26192 disorder\NN\14034177 were\VBD\836236 compared\VBN\644583 on\IN\1740 measures\NNS\168237 of\IN\1740 psychiatric\JJ\1740 symptoms\NNS\5823932 .\.\1740
D003042_D019964 CID 243\CD\1740 cocaine-dependent\JJ\1740 outpatients\NNS\10405694 with\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 mood\NN\26192 disorder\NN\14034177 (\-LRB-\1740 CIMD\NN\1740 )\-RRB-\1740 ,\,\1740 other\JJ\1740 mood\NN\26192 disorders\NNS\14034177 ,\,\1740 or\CC\3541091 no\DT\7204911 <e2>mood\NN\26192 disorder</e2>\NN\14034177 were\VBD\836236 compared\VBN\644583 on\IN\1740 measures\NNS\168237 of\IN\1740 psychiatric\JJ\1740 symptoms\NNS\5823932 .\.\1740
D003042_D001523 NONE <e1>Cocaine-induced</e1>\JJ\1740 mood\NN\26192 disorder\NN\14034177 :\:\1740 prevalence\NN\4764412 rates\NNS\13308999 and\CC\1740 <e2>psychiatric</e2>\JJ\1740 symptoms\NNS\5823932 in\IN\13603305 an\DT\6697703 outpatient\JJ\1740 cocaine-dependent\JJ\1740 sample\NN\5820620 .\.\1740
D003042_D001523 NONE Cocaine-induced\JJ\1740 mood\NN\26192 disorder\NN\14034177 :\:\1740 prevalence\NN\4764412 rates\NNS\13308999 and\CC\1740 <e2>psychiatric</e2>\JJ\1740 symptoms\NNS\5823932 in\IN\13603305 an\DT\6697703 outpatient\JJ\1740 <e1>cocaine-dependent</e1>\JJ\1740 sample\NN\5820620 .\.\1740
D003042_D001523 NONE 243\CD\1740 <e1>cocaine-dependent</e1>\JJ\1740 outpatients\NNS\10405694 with\IN\1740 cocaine-induced\JJ\1740 mood\NN\26192 disorder\NN\14034177 (\-LRB-\1740 CIMD\NN\1740 )\-RRB-\1740 ,\,\1740 other\JJ\1740 mood\NN\26192 disorders\NNS\14034177 ,\,\1740 or\CC\3541091 no\DT\7204911 mood\NN\26192 disorder\NN\14034177 were\VBD\836236 compared\VBN\644583 on\IN\1740 measures\NNS\168237 of\IN\1740 <e2>psychiatric</e2>\JJ\1740 symptoms\NNS\5823932 .\.\1740
D003042_D001523 NONE 243\CD\1740 cocaine-dependent\JJ\1740 outpatients\NNS\10405694 with\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 mood\NN\26192 disorder\NN\14034177 (\-LRB-\1740 CIMD\NN\1740 )\-RRB-\1740 ,\,\1740 other\JJ\1740 mood\NN\26192 disorders\NNS\14034177 ,\,\1740 or\CC\3541091 no\DT\7204911 mood\NN\26192 disorder\NN\14034177 were\VBD\836236 compared\VBN\644583 on\IN\1740 measures\NNS\168237 of\IN\1740 <e2>psychiatric</e2>\JJ\1740 symptoms\NNS\5823932 .\.\1740
D003042_D019970 NONE 243\CD\1740 <e1>cocaine-dependent</e1>\JJ\1740 outpatients\NNS\10405694 with\IN\1740 cocaine-induced\JJ\1740 mood\NN\26192 disorder\NN\14034177 (\-LRB-\1740 <e2>CIMD</e2>\NN\1740 )\-RRB-\1740 ,\,\1740 other\JJ\1740 mood\NN\26192 disorders\NNS\14034177 ,\,\1740 or\CC\3541091 no\DT\7204911 mood\NN\26192 disorder\NN\14034177 were\VBD\836236 compared\VBN\644583 on\IN\1740 measures\NNS\168237 of\IN\1740 psychiatric\JJ\1740 symptoms\NNS\5823932 .\.\1740
D003042_D019970 NONE 243\CD\1740 cocaine-dependent\JJ\1740 outpatients\NNS\10405694 with\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 mood\NN\26192 disorder\NN\14034177 (\-LRB-\1740 <e2>CIMD</e2>\NN\1740 )\-RRB-\1740 ,\,\1740 other\JJ\1740 mood\NN\26192 disorders\NNS\14034177 ,\,\1740 or\CC\3541091 no\DT\7204911 mood\NN\26192 disorder\NN\14034177 were\VBD\836236 compared\VBN\644583 on\IN\1740 measures\NNS\168237 of\IN\1740 psychiatric\JJ\1740 symptoms\NNS\5823932 .\.\1740
16160878
D014579_D006973 NONE Intracerebroventricular\JJ\1740 (\-LRB-\1740 i.c.v.\NN\1740 )\-RRB-\1740 injection\NN\320852 of\IN\1740 <e1>U-II</e1>\NN\1740 causes\VBZ\1617192 <e2>hypertension</e2>\NN\14057371 and\CC\1740 bradycardia\NN\14110674 and\CC\1740 stimulates\VBZ\137313 prolactin\NN\5410315 and\CC\1740 thyrotropin\NN\5407119 secretion\NN\13526110 .\.\1740
D014579_D001919 NONE Intracerebroventricular\JJ\1740 (\-LRB-\1740 i.c.v.\NN\1740 )\-RRB-\1740 injection\NN\320852 of\IN\1740 <e1>U-II</e1>\NN\1740 causes\VBZ\1617192 hypertension\NN\14057371 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 and\CC\1740 stimulates\VBZ\137313 prolactin\NN\5410315 and\CC\1740 thyrotropin\NN\5407119 secretion\NN\13526110 .\.\1740
D014579_D010409 NONE Whatever\WP\1740 was\VBD\836236 the\DT\1740 dose\NN\3740161 ,\,\1740 the\DT\1740 central\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>U-II</e1>\NN\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 body\NN\19128 temperature\NN\13575869 ,\,\1740 nociception\NN\1740 ,\,\1740 apomorphine-induced\JJ\1740 <e2>penile\NN\1740 erection</e2>\NN\14037619 and\CC\1740 climbing\NN\7445480 behavior\NN\407535 ,\,\1740 and\CC\1740 stress-induced\JJ\1740 plasma\NN\5398023 corticosterone\NN\14752057 level\NN\4916342 .\.\1740
D001058_D010409 CID Whatever\WP\1740 was\VBD\836236 the\DT\1740 dose\NN\3740161 ,\,\1740 the\DT\1740 central\JJ\1740 administration\NN\1133281 of\IN\1740 U-II\NN\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 body\NN\19128 temperature\NN\13575869 ,\,\1740 nociception\NN\1740 ,\,\1740 <e1>apomorphine-induced</e1>\JJ\1740 <e2>penile\NN\1740 erection</e2>\NN\14037619 and\CC\1740 climbing\NN\7445480 behavior\NN\407535 ,\,\1740 and\CC\1740 stress-induced\JJ\1740 plasma\NN\5398023 corticosterone\NN\14752057 level\NN\4916342 .\.\1740
D003345_D010409 NONE Whatever\WP\1740 was\VBD\836236 the\DT\1740 dose\NN\3740161 ,\,\1740 the\DT\1740 central\JJ\1740 administration\NN\1133281 of\IN\1740 U-II\NN\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 body\NN\19128 temperature\NN\13575869 ,\,\1740 nociception\NN\1740 ,\,\1740 apomorphine-induced\JJ\1740 <e2>penile\NN\1740 erection</e2>\NN\14037619 and\CC\1740 climbing\NN\7445480 behavior\NN\407535 ,\,\1740 and\CC\1740 stress-induced\JJ\1740 plasma\NN\5398023 <e1>corticosterone</e1>\NN\14752057 level\NN\4916342 .\.\1740
D014579_D001523 NONE These\DT\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 <e1>U-II</e1>\NN\1740 may\MD\15209706 be\VB\836236 involved\VBN\2676054 in\IN\13603305 some\DT\1740 aspects\NNS\5849789 of\IN\1740 <e2>psychiatric\JJ\1740 disorders</e2>\NNS\14034177 .\.\1740
2385256
D008274_D009157 CID <e2>Myasthenia\NNP\14187378 gravis</e2>\NN\1740 presenting\VBG\2137132 as\IN\14622893 weakness\NN\14462666 after\IN\1740 <e1>magnesium</e1>\NN\14625458 administration\NN\1133281 .\.\1740
D008274_D009157 CID Although\IN\1740 paralysis\NN\14557898 after\IN\1740 <e1>magnesium</e1>\NN\14625458 administration\NN\1133281 has\VBZ\2108377 been\VBN\836236 described\VBN\1001294 in\IN\13603305 patients\NNS\9898892 with\IN\1740 known\JJ\1740 <e2>myasthenia\NN\14187378 gravis</e2>\NN\1740 ,\,\1740 it\PRP\6125041 has\VBZ\2108377 not\RB\1740 previously\RB\1740 been\VBN\836236 reported\VBN\831651 to\TO\1740 be\VB\836236 the\DT\1740 initial\JJ\1740 or\CC\3541091 only\JJ\1740 manifestation\NN\7321772 of\IN\1740 the\DT\1740 disease\NN\14061805 .\.\1740
D008274_D009468 NONE We\PRP\1740 studied\VBD\630380 a\DT\13649268 patient\NN\9898892 with\IN\1740 no\DT\7204911 prior\JJ\1740 history\NN\15120823 of\IN\1740 <e2>neuromuscular\JJ\1740 disease</e2>\NN\14061805 who\WP\8299493 became\VBD\146138 virtually\RB\1740 quadriplegic\JJ\1740 after\IN\1740 parenteral\JJ\1740 <e1>magnesium</e1>\NN\14625458 administration\NN\1133281 for\IN\1740 preeclampsia\NN\14191037 .\.\1740
D008274_D011782 NONE We\PRP\1740 studied\VBD\630380 a\DT\13649268 patient\NN\9898892 with\IN\1740 no\DT\7204911 prior\JJ\1740 history\NN\15120823 of\IN\1740 neuromuscular\JJ\1740 disease\NN\14061805 who\WP\8299493 became\VBD\146138 virtually\RB\1740 <e2>quadriplegic</e2>\JJ\1740 after\IN\1740 parenteral\JJ\1740 <e1>magnesium</e1>\NN\14625458 administration\NN\1133281 for\IN\1740 preeclampsia\NN\14191037 .\.\1740
D008274_D011225 NONE We\PRP\1740 studied\VBD\630380 a\DT\13649268 patient\NN\9898892 with\IN\1740 no\DT\7204911 prior\JJ\1740 history\NN\15120823 of\IN\1740 neuromuscular\JJ\1740 disease\NN\14061805 who\WP\8299493 became\VBD\146138 virtually\RB\1740 quadriplegic\JJ\1740 after\IN\1740 parenteral\JJ\1740 <e1>magnesium</e1>\NN\14625458 administration\NN\1133281 for\IN\1740 <e2>preeclampsia</e2>\NN\14191037 .\.\1740
D008274_D010243 NONE Although\IN\1740 <e2>paralysis</e2>\NN\14557898 after\IN\1740 <e1>magnesium</e1>\NN\14625458 administration\NN\1133281 has\VBZ\2108377 been\VBN\836236 described\VBN\1001294 in\IN\13603305 patients\NNS\9898892 with\IN\1740 known\JJ\1740 myasthenia\NN\14187378 gravis\NN\1740 ,\,\1740 it\PRP\6125041 has\VBZ\2108377 not\RB\1740 previously\RB\1740 been\VBN\836236 reported\VBN\831651 to\TO\1740 be\VB\836236 the\DT\1740 initial\JJ\1740 or\CC\3541091 only\JJ\1740 manifestation\NN\7321772 of\IN\1740 the\DT\1740 disease\NN\14061805 .\.\1740
D008274_D020511 NONE Patients\NNS\9898892 who\WP\8299493 are\VBP\836236 unusually\RB\1740 sensitive\JJ\1740 to\TO\1740 the\DT\1740 neuromuscular\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>magnesium</e1>\NN\14625458 should\MD\1740 be\VB\836236 suspected\VBN\916909 of\IN\1740 having\VBG\2108377 an\DT\6697703 underlying\VBG\2604760 <e2>disorder\NN\14034177 of\IN\1740 neuromuscular\JJ\1740 transmission</e2>\NN\121166 .\.\1740
3076126
D008148_D009135 NONE <e2>Myopathy</e2>\NNP\14204950 ,\,\1740 associated\VBN\628491 in\IN\13603305 some\DT\1740 cases\NNS\7283608 with\IN\1740 myoglobinuria\NNS\14299637 ,\,\1740 and\CC\1740 in\IN\13603305 2\CD\13741022 cases\NNS\7283608 with\IN\1740 transient\JJ\1740 renal\JJ\1740 failure\NN\66216 ,\,\1740 has\VBZ\2108377 been\VBN\836236 rarely\RB\1740 reported\VBN\831651 with\IN\1740 <e1>lovastatin</e1>\NN\3676175 ,\,\1740 especially\RB\1740 in\IN\13603305 patients\NNS\9898892 concomitantly\RB\1740 treated\VBN\2376958 with\IN\1740 cyclosporin\NN\1740 ,\,\1740 gemfibrozil\NN\3740161 or\CC\3541091 niacin\NN\15090742 .\.\1740
D008148_D009212 CID Myopathy\NNP\14204950 ,\,\1740 associated\VBN\628491 in\IN\13603305 some\DT\1740 cases\NNS\7283608 with\IN\1740 <e2>myoglobinuria</e2>\NNS\14299637 ,\,\1740 and\CC\1740 in\IN\13603305 2\CD\13741022 cases\NNS\7283608 with\IN\1740 transient\JJ\1740 renal\JJ\1740 failure\NN\66216 ,\,\1740 has\VBZ\2108377 been\VBN\836236 rarely\RB\1740 reported\VBN\831651 with\IN\1740 <e1>lovastatin</e1>\NN\3676175 ,\,\1740 especially\RB\1740 in\IN\13603305 patients\NNS\9898892 concomitantly\RB\1740 treated\VBN\2376958 with\IN\1740 cyclosporin\NN\1740 ,\,\1740 gemfibrozil\NN\3740161 or\CC\3541091 niacin\NN\15090742 .\.\1740
D008148_D051437 CID Myopathy\NNP\14204950 ,\,\1740 associated\VBN\628491 in\IN\13603305 some\DT\1740 cases\NNS\7283608 with\IN\1740 myoglobinuria\NNS\14299637 ,\,\1740 and\CC\1740 in\IN\13603305 2\CD\13741022 cases\NNS\7283608 with\IN\1740 transient\JJ\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 ,\,\1740 has\VBZ\2108377 been\VBN\836236 rarely\RB\1740 reported\VBN\831651 with\IN\1740 <e1>lovastatin</e1>\NN\3676175 ,\,\1740 especially\RB\1740 in\IN\13603305 patients\NNS\9898892 concomitantly\RB\1740 treated\VBN\2376958 with\IN\1740 cyclosporin\NN\1740 ,\,\1740 gemfibrozil\NN\3740161 or\CC\3541091 niacin\NN\15090742 .\.\1740
D016572_D009135 CID <e2>Myopathy</e2>\NNP\14204950 ,\,\1740 associated\VBN\628491 in\IN\13603305 some\DT\1740 cases\NNS\7283608 with\IN\1740 myoglobinuria\NNS\14299637 ,\,\1740 and\CC\1740 in\IN\13603305 2\CD\13741022 cases\NNS\7283608 with\IN\1740 transient\JJ\1740 renal\JJ\1740 failure\NN\66216 ,\,\1740 has\VBZ\2108377 been\VBN\836236 rarely\RB\1740 reported\VBN\831651 with\IN\1740 lovastatin\NN\3676175 ,\,\1740 especially\RB\1740 in\IN\13603305 patients\NNS\9898892 concomitantly\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>cyclosporin</e1>\NN\1740 ,\,\1740 gemfibrozil\NN\3740161 or\CC\3541091 niacin\NN\15090742 .\.\1740
D016572_D009212 NONE Myopathy\NNP\14204950 ,\,\1740 associated\VBN\628491 in\IN\13603305 some\DT\1740 cases\NNS\7283608 with\IN\1740 <e2>myoglobinuria</e2>\NNS\14299637 ,\,\1740 and\CC\1740 in\IN\13603305 2\CD\13741022 cases\NNS\7283608 with\IN\1740 transient\JJ\1740 renal\JJ\1740 failure\NN\66216 ,\,\1740 has\VBZ\2108377 been\VBN\836236 rarely\RB\1740 reported\VBN\831651 with\IN\1740 lovastatin\NN\3676175 ,\,\1740 especially\RB\1740 in\IN\13603305 patients\NNS\9898892 concomitantly\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>cyclosporin</e1>\NN\1740 ,\,\1740 gemfibrozil\NN\3740161 or\CC\3541091 niacin\NN\15090742 .\.\1740
D016572_D051437 NONE Myopathy\NNP\14204950 ,\,\1740 associated\VBN\628491 in\IN\13603305 some\DT\1740 cases\NNS\7283608 with\IN\1740 myoglobinuria\NNS\14299637 ,\,\1740 and\CC\1740 in\IN\13603305 2\CD\13741022 cases\NNS\7283608 with\IN\1740 transient\JJ\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 ,\,\1740 has\VBZ\2108377 been\VBN\836236 rarely\RB\1740 reported\VBN\831651 with\IN\1740 lovastatin\NN\3676175 ,\,\1740 especially\RB\1740 in\IN\13603305 patients\NNS\9898892 concomitantly\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>cyclosporin</e1>\NN\1740 ,\,\1740 gemfibrozil\NN\3740161 or\CC\3541091 niacin\NN\15090742 .\.\1740
D015248_D009135 CID <e2>Myopathy</e2>\NNP\14204950 ,\,\1740 associated\VBN\628491 in\IN\13603305 some\DT\1740 cases\NNS\7283608 with\IN\1740 myoglobinuria\NNS\14299637 ,\,\1740 and\CC\1740 in\IN\13603305 2\CD\13741022 cases\NNS\7283608 with\IN\1740 transient\JJ\1740 renal\JJ\1740 failure\NN\66216 ,\,\1740 has\VBZ\2108377 been\VBN\836236 rarely\RB\1740 reported\VBN\831651 with\IN\1740 lovastatin\NN\3676175 ,\,\1740 especially\RB\1740 in\IN\13603305 patients\NNS\9898892 concomitantly\RB\1740 treated\VBN\2376958 with\IN\1740 cyclosporin\NN\1740 ,\,\1740 <e1>gemfibrozil</e1>\NN\3740161 or\CC\3541091 niacin\NN\15090742 .\.\1740
D015248_D009212 NONE Myopathy\NNP\14204950 ,\,\1740 associated\VBN\628491 in\IN\13603305 some\DT\1740 cases\NNS\7283608 with\IN\1740 <e2>myoglobinuria</e2>\NNS\14299637 ,\,\1740 and\CC\1740 in\IN\13603305 2\CD\13741022 cases\NNS\7283608 with\IN\1740 transient\JJ\1740 renal\JJ\1740 failure\NN\66216 ,\,\1740 has\VBZ\2108377 been\VBN\836236 rarely\RB\1740 reported\VBN\831651 with\IN\1740 lovastatin\NN\3676175 ,\,\1740 especially\RB\1740 in\IN\13603305 patients\NNS\9898892 concomitantly\RB\1740 treated\VBN\2376958 with\IN\1740 cyclosporin\NN\1740 ,\,\1740 <e1>gemfibrozil</e1>\NN\3740161 or\CC\3541091 niacin\NN\15090742 .\.\1740
D015248_D051437 NONE Myopathy\NNP\14204950 ,\,\1740 associated\VBN\628491 in\IN\13603305 some\DT\1740 cases\NNS\7283608 with\IN\1740 myoglobinuria\NNS\14299637 ,\,\1740 and\CC\1740 in\IN\13603305 2\CD\13741022 cases\NNS\7283608 with\IN\1740 transient\JJ\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 ,\,\1740 has\VBZ\2108377 been\VBN\836236 rarely\RB\1740 reported\VBN\831651 with\IN\1740 lovastatin\NN\3676175 ,\,\1740 especially\RB\1740 in\IN\13603305 patients\NNS\9898892 concomitantly\RB\1740 treated\VBN\2376958 with\IN\1740 cyclosporin\NN\1740 ,\,\1740 <e1>gemfibrozil</e1>\NN\3740161 or\CC\3541091 niacin\NN\15090742 .\.\1740
D009525_D009135 CID <e2>Myopathy</e2>\NNP\14204950 ,\,\1740 associated\VBN\628491 in\IN\13603305 some\DT\1740 cases\NNS\7283608 with\IN\1740 myoglobinuria\NNS\14299637 ,\,\1740 and\CC\1740 in\IN\13603305 2\CD\13741022 cases\NNS\7283608 with\IN\1740 transient\JJ\1740 renal\JJ\1740 failure\NN\66216 ,\,\1740 has\VBZ\2108377 been\VBN\836236 rarely\RB\1740 reported\VBN\831651 with\IN\1740 lovastatin\NN\3676175 ,\,\1740 especially\RB\1740 in\IN\13603305 patients\NNS\9898892 concomitantly\RB\1740 treated\VBN\2376958 with\IN\1740 cyclosporin\NN\1740 ,\,\1740 gemfibrozil\NN\3740161 or\CC\3541091 <e1>niacin</e1>\NN\15090742 .\.\1740
D009525_D009212 NONE Myopathy\NNP\14204950 ,\,\1740 associated\VBN\628491 in\IN\13603305 some\DT\1740 cases\NNS\7283608 with\IN\1740 <e2>myoglobinuria</e2>\NNS\14299637 ,\,\1740 and\CC\1740 in\IN\13603305 2\CD\13741022 cases\NNS\7283608 with\IN\1740 transient\JJ\1740 renal\JJ\1740 failure\NN\66216 ,\,\1740 has\VBZ\2108377 been\VBN\836236 rarely\RB\1740 reported\VBN\831651 with\IN\1740 lovastatin\NN\3676175 ,\,\1740 especially\RB\1740 in\IN\13603305 patients\NNS\9898892 concomitantly\RB\1740 treated\VBN\2376958 with\IN\1740 cyclosporin\NN\1740 ,\,\1740 gemfibrozil\NN\3740161 or\CC\3541091 <e1>niacin</e1>\NN\15090742 .\.\1740
D009525_D051437 NONE Myopathy\NNP\14204950 ,\,\1740 associated\VBN\628491 in\IN\13603305 some\DT\1740 cases\NNS\7283608 with\IN\1740 myoglobinuria\NNS\14299637 ,\,\1740 and\CC\1740 in\IN\13603305 2\CD\13741022 cases\NNS\7283608 with\IN\1740 transient\JJ\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 ,\,\1740 has\VBZ\2108377 been\VBN\836236 rarely\RB\1740 reported\VBN\831651 with\IN\1740 lovastatin\NN\3676175 ,\,\1740 especially\RB\1740 in\IN\13603305 patients\NNS\9898892 concomitantly\RB\1740 treated\VBN\2376958 with\IN\1740 cyclosporin\NN\1740 ,\,\1740 gemfibrozil\NN\3740161 or\CC\3541091 <e1>niacin</e1>\NN\15090742 .\.\1740
1592014
D003042_D012640 CID <e2>Seizures</e2>\NNP\14081375 induced\VBN\1627355 by\IN\1740 the\DT\1740 <e1>cocaine</e1>\NN\3492717 metabolite\NN\20090 benzoylecgonine\NN\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
D003042_D012640 CID The\DT\1740 half-life\NN\15113229 (\-LRB-\1740 t1/2\NN\1740 )\-RRB-\1740 of\IN\1740 <e1>cocaine</e1>\NN\3492717 is\VBZ\836236 relatively\RB\1740 short\JJ\1740 ,\,\1740 but\CC\1740 some\DT\1740 of\IN\1740 the\DT\1740 consequences\NNS\34213 of\IN\1740 its\PRP$\6125041 use\NN\407535 ,\,\1740 such\JJ\1740 as\IN\14622893 <e2>seizures</e2>\NNS\14081375 and\CC\1740 strokes\NNS\556313 ,\,\1740 can\MD\3094503 occur\VB\2623529 hours\NNS\15118228 after\IN\1740 exposure\NN\5042871 .\.\1740
D003042_D012640 CID We\PRP\1740 evaluated\VBD\670261 the\DT\1740 potential\NN\14481929 of\IN\1740 the\DT\1740 major\JJ\1740 metabolite\NN\20090 of\IN\1740 <e1>cocaine</e1>\NN\3492717 ,\,\1740 benzoylecgonine\NN\1740 (\-LRB-\1740 BE\NN\14625458 )\-RRB-\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 <e2>seizures</e2>\NNS\14081375 .\.\1740
D003042_D012640 CID BE-Induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 occurred\VBD\2623529 more\RBR\1740 frequently\RB\1740 and\CC\1740 had\VBD\2108377 significantly\RB\1740 longer\JJR\1740 latencies\NNS\15269513 than\IN\1740 those\DT\1740 induced\VBN\1627355 by\IN\1740 equimolar\JJ\1740 amounts\NNS\13329641 of\IN\1740 <e1>cocaine</e1>\NN\3492717 .\.\1740
D003042_D012640 CID Whereas\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 were\VBD\836236 best\RBS\1740 characterized\VBN\609683 as\IN\14622893 brief\JJ\1740 ,\,\1740 generalized\VBN\634472 ,\,\1740 and\CC\1740 tonic\JJ\1740 and\CC\1740 resulted\VBD\2633881 in\IN\13603305 death\NN\7296428 ,\,\1740 those\DT\1740 induced\VBN\1627355 by\IN\1740 BE\NN\14625458 were\VBD\836236 prolonged\JJ\1740 ,\,\1740 often\RB\1740 multiple\JJ\1740 and\CC\1740 mixed\JJ\1740 in\IN\13603305 type\NN\5839024 ,\,\1740 and\CC\1740 rarely\RB\1740 resulted\VBD\2633881 in\IN\13603305 death\NN\7296428 .\.\1740
D003042_D012640 CID BE-Injected\JJ\1740 rats\NNS\2329401 that\WDT\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 <e2>seizures</e2>\NNS\14081375 had\VBD\2108377 significantly\RB\1740 more\JJR\1740 locomotor\NN\1740 activity\NN\30358 than\IN\1740 <e1>cocaine-injected</e1>\JJ\1740 animals\NNS\4475 without\IN\1740 seizures\NNS\14081375 .\.\1740
D003042_D012640 CID BE-Injected\JJ\1740 rats\NNS\2329401 that\WDT\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 seizures\NNS\14081375 had\VBD\2108377 significantly\RB\1740 more\JJR\1740 locomotor\NN\1740 activity\NN\30358 than\IN\1740 <e1>cocaine-injected</e1>\JJ\1740 animals\NNS\4475 without\IN\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D003042_D012640 CID The\DT\1740 finding\NN\43195 that\IN\1740 <e1>cocaine-</e1>\NN\1740 and\CC\1740 BE-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 differ\VBP\1740 in\IN\13603305 several\JJ\1740 respects\NNS\6598915 suggests\VBZ\1010118 more\JJR\1740 than\IN\1740 one\CD\13741022 mechanism\NN\13446390 for\IN\1740 cocaine-induced\JJ\1740 seizures\NNS\14081375 and\CC\1740 emphasizes\VBZ\943837 the\DT\1740 importance\NN\5138488 of\IN\1740 a\DT\13649268 cocaine\NN\3492717 metabolite\NN\20090 ,\,\1740 BE\NN\14625458 .\.\1740
D003042_D012640 CID The\DT\1740 finding\NN\43195 that\IN\1740 <e1>cocaine-</e1>\NN\1740 and\CC\1740 BE-induced\JJ\1740 seizures\NNS\14081375 differ\VBP\1740 in\IN\13603305 several\JJ\1740 respects\NNS\6598915 suggests\VBZ\1010118 more\JJR\1740 than\IN\1740 one\CD\13741022 mechanism\NN\13446390 for\IN\1740 cocaine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 emphasizes\VBZ\943837 the\DT\1740 importance\NN\5138488 of\IN\1740 a\DT\13649268 cocaine\NN\3492717 metabolite\NN\20090 ,\,\1740 BE\NN\14625458 .\.\1740
D003042_D012640 CID The\DT\1740 finding\NN\43195 that\IN\1740 cocaine-\NN\1740 and\CC\1740 BE-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 differ\VBP\1740 in\IN\13603305 several\JJ\1740 respects\NNS\6598915 suggests\VBZ\1010118 more\JJR\1740 than\IN\1740 one\CD\13741022 mechanism\NN\13446390 for\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 seizures\NNS\14081375 and\CC\1740 emphasizes\VBZ\943837 the\DT\1740 importance\NN\5138488 of\IN\1740 a\DT\13649268 cocaine\NN\3492717 metabolite\NN\20090 ,\,\1740 BE\NN\14625458 .\.\1740
D003042_D012640 CID The\DT\1740 finding\NN\43195 that\IN\1740 cocaine-\NN\1740 and\CC\1740 BE-induced\JJ\1740 seizures\NNS\14081375 differ\VBP\1740 in\IN\13603305 several\JJ\1740 respects\NNS\6598915 suggests\VBZ\1010118 more\JJR\1740 than\IN\1740 one\CD\13741022 mechanism\NN\13446390 for\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 emphasizes\VBZ\943837 the\DT\1740 importance\NN\5138488 of\IN\1740 a\DT\13649268 cocaine\NN\3492717 metabolite\NN\20090 ,\,\1740 BE\NN\14625458 .\.\1740
D003042_D012640 CID The\DT\1740 finding\NN\43195 that\IN\1740 cocaine-\NN\1740 and\CC\1740 BE-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 differ\VBP\1740 in\IN\13603305 several\JJ\1740 respects\NNS\6598915 suggests\VBZ\1010118 more\JJR\1740 than\IN\1740 one\CD\13741022 mechanism\NN\13446390 for\IN\1740 cocaine-induced\JJ\1740 seizures\NNS\14081375 and\CC\1740 emphasizes\VBZ\943837 the\DT\1740 importance\NN\5138488 of\IN\1740 a\DT\13649268 <e1>cocaine</e1>\NN\3492717 metabolite\NN\20090 ,\,\1740 BE\NN\14625458 .\.\1740
D003042_D012640 CID The\DT\1740 finding\NN\43195 that\IN\1740 cocaine-\NN\1740 and\CC\1740 BE-induced\JJ\1740 seizures\NNS\14081375 differ\VBP\1740 in\IN\13603305 several\JJ\1740 respects\NNS\6598915 suggests\VBZ\1010118 more\JJR\1740 than\IN\1740 one\CD\13741022 mechanism\NN\13446390 for\IN\1740 cocaine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 emphasizes\VBZ\943837 the\DT\1740 importance\NN\5138488 of\IN\1740 a\DT\13649268 <e1>cocaine</e1>\NN\3492717 metabolite\NN\20090 ,\,\1740 BE\NN\14625458 .\.\1740
C005618_D012640 CID <e2>Seizures</e2>\NNP\14081375 induced\VBN\1627355 by\IN\1740 the\DT\1740 cocaine\NN\3492717 metabolite\NN\20090 <e1>benzoylecgonine</e1>\NN\1740 in\IN\13603305 rats\NNS\2329401 .\.\1740
C005618_D012640 CID We\PRP\1740 evaluated\VBD\670261 the\DT\1740 potential\NN\14481929 of\IN\1740 the\DT\1740 major\JJ\1740 metabolite\NN\20090 of\IN\1740 cocaine\NN\3492717 ,\,\1740 <e1>benzoylecgonine</e1>\NN\1740 (\-LRB-\1740 BE\NN\14625458 )\-RRB-\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 <e2>seizures</e2>\NNS\14081375 .\.\1740
C005618_D012640 CID We\PRP\1740 evaluated\VBD\670261 the\DT\1740 potential\NN\14481929 of\IN\1740 the\DT\1740 major\JJ\1740 metabolite\NN\20090 of\IN\1740 cocaine\NN\3492717 ,\,\1740 benzoylecgonine\NN\1740 (\-LRB-\1740 <e1>BE</e1>\NN\14625458 )\-RRB-\1740 ,\,\1740 to\TO\1740 cause\VB\1617192 <e2>seizures</e2>\NNS\14081375 .\.\1740
C005618_D012640 CID <e1>BE-Induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 occurred\VBD\2623529 more\RBR\1740 frequently\RB\1740 and\CC\1740 had\VBD\2108377 significantly\RB\1740 longer\JJR\1740 latencies\NNS\15269513 than\IN\1740 those\DT\1740 induced\VBN\1627355 by\IN\1740 equimolar\JJ\1740 amounts\NNS\13329641 of\IN\1740 cocaine\NN\3492717 .\.\1740
C005618_D012640 CID Whereas\IN\1740 cocaine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 were\VBD\836236 best\RBS\1740 characterized\VBN\609683 as\IN\14622893 brief\JJ\1740 ,\,\1740 generalized\VBN\634472 ,\,\1740 and\CC\1740 tonic\JJ\1740 and\CC\1740 resulted\VBD\2633881 in\IN\13603305 death\NN\7296428 ,\,\1740 those\DT\1740 induced\VBN\1627355 by\IN\1740 <e1>BE</e1>\NN\14625458 were\VBD\836236 prolonged\JJ\1740 ,\,\1740 often\RB\1740 multiple\JJ\1740 and\CC\1740 mixed\JJ\1740 in\IN\13603305 type\NN\5839024 ,\,\1740 and\CC\1740 rarely\RB\1740 resulted\VBD\2633881 in\IN\13603305 death\NN\7296428 .\.\1740
C005618_D012640 CID <e1>BE-Injected</e1>\JJ\1740 rats\NNS\2329401 that\WDT\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 <e2>seizures</e2>\NNS\14081375 had\VBD\2108377 significantly\RB\1740 more\JJR\1740 locomotor\NN\1740 activity\NN\30358 than\IN\1740 cocaine-injected\JJ\1740 animals\NNS\4475 without\IN\1740 seizures\NNS\14081375 .\.\1740
C005618_D012640 CID <e1>BE-Injected</e1>\JJ\1740 rats\NNS\2329401 that\WDT\1740 did\VBD\1640855 not\RB\1740 have\VB\2108377 seizures\NNS\14081375 had\VBD\2108377 significantly\RB\1740 more\JJR\1740 locomotor\NN\1740 activity\NN\30358 than\IN\1740 cocaine-injected\JJ\1740 animals\NNS\4475 without\IN\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
C005618_D012640 CID The\DT\1740 finding\NN\43195 that\IN\1740 cocaine-\NN\1740 and\CC\1740 <e1>BE-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 differ\VBP\1740 in\IN\13603305 several\JJ\1740 respects\NNS\6598915 suggests\VBZ\1010118 more\JJR\1740 than\IN\1740 one\CD\13741022 mechanism\NN\13446390 for\IN\1740 cocaine-induced\JJ\1740 seizures\NNS\14081375 and\CC\1740 emphasizes\VBZ\943837 the\DT\1740 importance\NN\5138488 of\IN\1740 a\DT\13649268 cocaine\NN\3492717 metabolite\NN\20090 ,\,\1740 BE\NN\14625458 .\.\1740
C005618_D012640 CID The\DT\1740 finding\NN\43195 that\IN\1740 cocaine-\NN\1740 and\CC\1740 <e1>BE-induced</e1>\JJ\1740 seizures\NNS\14081375 differ\VBP\1740 in\IN\13603305 several\JJ\1740 respects\NNS\6598915 suggests\VBZ\1010118 more\JJR\1740 than\IN\1740 one\CD\13741022 mechanism\NN\13446390 for\IN\1740 cocaine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 emphasizes\VBZ\943837 the\DT\1740 importance\NN\5138488 of\IN\1740 a\DT\13649268 cocaine\NN\3492717 metabolite\NN\20090 ,\,\1740 BE\NN\14625458 .\.\1740
C005618_D012640 CID The\DT\1740 finding\NN\43195 that\IN\1740 cocaine-\NN\1740 and\CC\1740 BE-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 differ\VBP\1740 in\IN\13603305 several\JJ\1740 respects\NNS\6598915 suggests\VBZ\1010118 more\JJR\1740 than\IN\1740 one\CD\13741022 mechanism\NN\13446390 for\IN\1740 cocaine-induced\JJ\1740 seizures\NNS\14081375 and\CC\1740 emphasizes\VBZ\943837 the\DT\1740 importance\NN\5138488 of\IN\1740 a\DT\13649268 cocaine\NN\3492717 metabolite\NN\20090 ,\,\1740 <e1>BE</e1>\NN\14625458 .\.\1740
C005618_D012640 CID The\DT\1740 finding\NN\43195 that\IN\1740 cocaine-\NN\1740 and\CC\1740 BE-induced\JJ\1740 seizures\NNS\14081375 differ\VBP\1740 in\IN\13603305 several\JJ\1740 respects\NNS\6598915 suggests\VBZ\1010118 more\JJR\1740 than\IN\1740 one\CD\13741022 mechanism\NN\13446390 for\IN\1740 cocaine-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 and\CC\1740 emphasizes\VBZ\943837 the\DT\1740 importance\NN\5138488 of\IN\1740 a\DT\13649268 cocaine\NN\3492717 metabolite\NN\20090 ,\,\1740 <e1>BE</e1>\NN\14625458 .\.\1740
D003042_D020521 NONE The\DT\1740 half-life\NN\15113229 (\-LRB-\1740 t1/2\NN\1740 )\-RRB-\1740 of\IN\1740 <e1>cocaine</e1>\NN\3492717 is\VBZ\836236 relatively\RB\1740 short\JJ\1740 ,\,\1740 but\CC\1740 some\DT\1740 of\IN\1740 the\DT\1740 consequences\NNS\34213 of\IN\1740 its\PRP$\6125041 use\NN\407535 ,\,\1740 such\JJ\1740 as\IN\14622893 seizures\NNS\14081375 and\CC\1740 <e2>strokes</e2>\NNS\556313 ,\,\1740 can\MD\3094503 occur\VB\2623529 hours\NNS\15118228 after\IN\1740 exposure\NN\5042871 .\.\1740
D003042_D003643 NONE Whereas\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 seizures\NNS\14081375 were\VBD\836236 best\RBS\1740 characterized\VBN\609683 as\IN\14622893 brief\JJ\1740 ,\,\1740 generalized\VBN\634472 ,\,\1740 and\CC\1740 tonic\JJ\1740 and\CC\1740 resulted\VBD\2633881 in\IN\13603305 <e2>death</e2>\NN\7296428 ,\,\1740 those\DT\1740 induced\VBN\1627355 by\IN\1740 BE\NN\14625458 were\VBD\836236 prolonged\JJ\1740 ,\,\1740 often\RB\1740 multiple\JJ\1740 and\CC\1740 mixed\JJ\1740 in\IN\13603305 type\NN\5839024 ,\,\1740 and\CC\1740 rarely\RB\1740 resulted\VBD\2633881 in\IN\13603305 death\NN\7296428 .\.\1740
D003042_D003643 NONE Whereas\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 seizures\NNS\14081375 were\VBD\836236 best\RBS\1740 characterized\VBN\609683 as\IN\14622893 brief\JJ\1740 ,\,\1740 generalized\VBN\634472 ,\,\1740 and\CC\1740 tonic\JJ\1740 and\CC\1740 resulted\VBD\2633881 in\IN\13603305 death\NN\7296428 ,\,\1740 those\DT\1740 induced\VBN\1627355 by\IN\1740 BE\NN\14625458 were\VBD\836236 prolonged\JJ\1740 ,\,\1740 often\RB\1740 multiple\JJ\1740 and\CC\1740 mixed\JJ\1740 in\IN\13603305 type\NN\5839024 ,\,\1740 and\CC\1740 rarely\RB\1740 resulted\VBD\2633881 in\IN\13603305 <e2>death</e2>\NN\7296428 .\.\1740
C005618_D003643 NONE Whereas\IN\1740 cocaine-induced\JJ\1740 seizures\NNS\14081375 were\VBD\836236 best\RBS\1740 characterized\VBN\609683 as\IN\14622893 brief\JJ\1740 ,\,\1740 generalized\VBN\634472 ,\,\1740 and\CC\1740 tonic\JJ\1740 and\CC\1740 resulted\VBD\2633881 in\IN\13603305 <e2>death</e2>\NN\7296428 ,\,\1740 those\DT\1740 induced\VBN\1627355 by\IN\1740 <e1>BE</e1>\NN\14625458 were\VBD\836236 prolonged\JJ\1740 ,\,\1740 often\RB\1740 multiple\JJ\1740 and\CC\1740 mixed\JJ\1740 in\IN\13603305 type\NN\5839024 ,\,\1740 and\CC\1740 rarely\RB\1740 resulted\VBD\2633881 in\IN\13603305 death\NN\7296428 .\.\1740
C005618_D003643 NONE Whereas\IN\1740 cocaine-induced\JJ\1740 seizures\NNS\14081375 were\VBD\836236 best\RBS\1740 characterized\VBN\609683 as\IN\14622893 brief\JJ\1740 ,\,\1740 generalized\VBN\634472 ,\,\1740 and\CC\1740 tonic\JJ\1740 and\CC\1740 resulted\VBD\2633881 in\IN\13603305 death\NN\7296428 ,\,\1740 those\DT\1740 induced\VBN\1627355 by\IN\1740 <e1>BE</e1>\NN\14625458 were\VBD\836236 prolonged\JJ\1740 ,\,\1740 often\RB\1740 multiple\JJ\1740 and\CC\1740 mixed\JJ\1740 in\IN\13603305 type\NN\5839024 ,\,\1740 and\CC\1740 rarely\RB\1740 resulted\VBD\2633881 in\IN\13603305 <e2>death</e2>\NN\7296428 .\.\1740
1867351
D015767_D008288 NONE Therefore\RB\1740 ,\,\1740 certain\JJ\1740 limitations\NNS\5846054 for\IN\1740 <e2>malaria</e2>\NN\14178913 prophylaxis\NN\1077350 and\CC\1740 treatment\NN\654885 with\IN\1740 <e1>mefloquine</e1>\NN\2721948 are\VBP\836236 recommended\VBN\875394 .\.\1740
21029050
D013390_D001049 CID Butyrylcholinesterase\NN\1740 gene\NN\8459252 mutations\NNS\4475 in\IN\13603305 patients\NNS\9898892 with\IN\1740 prolonged\JJ\1740 <e2>apnea</e2>\NN\14299637 after\IN\1740 <e1>succinylcholine</e1>\NN\3800001 for\IN\1740 electroconvulsive\JJ\1740 therapy\NN\657604 .\.\1740
D013390_D001049 CID CONCLUSION\NN\5837957 :\:\1740 eleven\CD\13745420 of\IN\1740 13\CD\13745420 patients\NNS\9898892 with\IN\1740 a\DT\13649268 prolonged\JJ\1740 duration\NN\15113229 of\IN\1740 action\NN\30358 of\IN\1740 <e1>succinylcholine</e1>\NN\3800001 had\VBD\2108377 mutations\NNS\4475 in\IN\13603305 BCHE\NN\1740 ,\,\1740 indicating\VBG\952524 that\IN\1740 this\DT\1740 is\VBZ\836236 the\DT\1740 possible\JJ\1740 reason\NN\9178821 for\IN\1740 a\DT\13649268 prolonged\JJ\1740 period\NN\13575869 of\IN\1740 <e2>apnea</e2>\NN\14299637 .\.\1740
322550
D009599_D007022 CID Pulmonary\JJ\1740 shunt\NN\5248181 and\CC\1740 cardiovascular\JJ\1740 responses\NNS\11410625 to\TO\1740 CPAP\NN\1740 during\IN\1740 <e1>nitroprusside-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D009599_D007022 CID Ten\CD\13745420 cm\NNS\13649268 H2O\NN\14618834 CPAP\NN\1740 before\IN\1740 <e1>nitroprusside</e1>\NN\1740 infusion\NN\14589223 produced\VBD\1617192 a\DT\13649268 further\JJ\1740 <e2>decrease\NN\7296428 in\IN\13603305 arterial\JJ\1740 blood\NN\5397468 pressure</e2>\NN\11419404 and\CC\1740 significantly\RB\1740 increased\VBD\169651 heart\NN\5919034 rate\NN\13815152 and\CC\1740 decreased\VBD\169651 cardiac\JJ\1740 output\NN\4007894 and\CC\1740 QS/QT\NN\1740 .\.\1740
D009599_D007022 CID <e1>Nitroprusside</e1>\NNP\1740 caused\VBD\1617192 significant\JJ\1740 <e2>decreases\NNS\7296428 in\IN\13603305 arterial\JJ\1740 blood\NN\5397468 pressure</e2>\NN\11419404 and\CC\1740 systemic\JJ\1740 vascular\JJ\1740 resistance\NN\37396 and\CC\1740 increases\VBZ\169651 in\IN\13603305 heart\NN\5919034 rate\NN\13815152 ,\,\1740 but\CC\1740 did\VBD\1640855 not\RB\1740 change\VB\46534 cardiac\JJ\1740 output\NN\4007894 or\CC\3541091 QS/QT\NN\1740 .\.\1740
D009599_D007022 NONE During\IN\1740 <e1>nitroprusside</e1>\NN\1740 infusion\NN\14589223 low\JJ\1740 levels\NNS\4916342 of\IN\1740 CPAP\NN\1740 do\VBP\1640855 not\RB\1740 markedly\RB\1740 alter\VB\126264 cardiovascular\JJ\1740 dynamics\NNS\6100236 ,\,\1740 but\CC\1740 high\JJ\1740 levels\NNS\4916342 of\IN\1740 CPAP\NN\1740 (\-LRB-\1740 10\CD\13745420 cm\NNS\13649268 H2O\NN\14618834 )\-RRB-\1740 ,\,\1740 while\IN\15122231 decreasing\VBG\169651 QS/QT\NN\1740 ,\,\1740 produce\VB\1617192 marked\JJ\1740 <e2>decreases\NNS\7296428 in\IN\13603305 arterial\JJ\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 cardiac\JJ\1740 output</e2>\NN\4007894 .\.\1740
D014867_D007022 NONE Ten\CD\13745420 cm\NNS\13649268 <e1>H2O</e1>\NN\14618834 CPAP\NN\1740 before\IN\1740 nitroprusside\NN\1740 infusion\NN\14589223 produced\VBD\1617192 a\DT\13649268 further\JJ\1740 <e2>decrease\NN\7296428 in\IN\13603305 arterial\JJ\1740 blood\NN\5397468 pressure</e2>\NN\11419404 and\CC\1740 significantly\RB\1740 increased\VBD\169651 heart\NN\5919034 rate\NN\13815152 and\CC\1740 decreased\VBD\169651 cardiac\JJ\1740 output\NN\4007894 and\CC\1740 QS/QT\NN\1740 .\.\1740
D014867_D007022 NONE During\IN\1740 nitroprusside\NN\1740 infusion\NN\14589223 low\JJ\1740 levels\NNS\4916342 of\IN\1740 CPAP\NN\1740 do\VBP\1640855 not\RB\1740 markedly\RB\1740 alter\VB\126264 cardiovascular\JJ\1740 dynamics\NNS\6100236 ,\,\1740 but\CC\1740 high\JJ\1740 levels\NNS\4916342 of\IN\1740 CPAP\NN\1740 (\-LRB-\1740 10\CD\13745420 cm\NNS\13649268 <e1>H2O</e1>\NN\14618834 )\-RRB-\1740 ,\,\1740 while\IN\15122231 decreasing\VBG\169651 QS/QT\NN\1740 ,\,\1740 produce\VB\1617192 marked\JJ\1740 <e2>decreases\NNS\7296428 in\IN\13603305 arterial\JJ\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 cardiac\JJ\1740 output</e2>\NN\4007894 .\.\1740
D014867_D002303 NONE Ten\CD\13745420 cm\NNS\13649268 <e1>H2O</e1>\NN\14618834 CPAP\NN\1740 before\IN\1740 nitroprusside\NN\1740 infusion\NN\14589223 produced\VBD\1617192 a\DT\13649268 further\JJ\1740 decrease\NN\7296428 in\IN\13603305 arterial\JJ\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 significantly\RB\1740 increased\VBD\169651 heart\NN\5919034 rate\NN\13815152 and\CC\1740 <e2>decreased\VBD\169651 cardiac\JJ\1740 output</e2>\NN\4007894 and\CC\1740 QS/QT\NN\1740 .\.\1740
D014867_D002303 NONE During\IN\1740 nitroprusside\NN\1740 infusion\NN\14589223 low\JJ\1740 levels\NNS\4916342 of\IN\1740 CPAP\NN\1740 do\VBP\1640855 not\RB\1740 markedly\RB\1740 alter\VB\126264 cardiovascular\JJ\1740 dynamics\NNS\6100236 ,\,\1740 but\CC\1740 high\JJ\1740 levels\NNS\4916342 of\IN\1740 CPAP\NN\1740 (\-LRB-\1740 10\CD\13745420 cm\NNS\13649268 <e1>H2O</e1>\NN\14618834 )\-RRB-\1740 ,\,\1740 while\IN\15122231 decreasing\VBG\169651 QS/QT\NN\1740 ,\,\1740 produce\VB\1617192 marked\JJ\1740 <e2>decreases\NNS\7296428 in\IN\13603305 arterial\JJ\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 cardiac\JJ\1740 output</e2>\NN\4007894 .\.\1740
D009599_D002303 NONE Ten\CD\13745420 cm\NNS\13649268 H2O\NN\14618834 CPAP\NN\1740 before\IN\1740 <e1>nitroprusside</e1>\NN\1740 infusion\NN\14589223 produced\VBD\1617192 a\DT\13649268 further\JJ\1740 decrease\NN\7296428 in\IN\13603305 arterial\JJ\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 significantly\RB\1740 increased\VBD\169651 heart\NN\5919034 rate\NN\13815152 and\CC\1740 <e2>decreased\VBD\169651 cardiac\JJ\1740 output</e2>\NN\4007894 and\CC\1740 QS/QT\NN\1740 .\.\1740
D009599_D002303 NONE During\IN\1740 <e1>nitroprusside</e1>\NN\1740 infusion\NN\14589223 low\JJ\1740 levels\NNS\4916342 of\IN\1740 CPAP\NN\1740 do\VBP\1640855 not\RB\1740 markedly\RB\1740 alter\VB\126264 cardiovascular\JJ\1740 dynamics\NNS\6100236 ,\,\1740 but\CC\1740 high\JJ\1740 levels\NNS\4916342 of\IN\1740 CPAP\NN\1740 (\-LRB-\1740 10\CD\13745420 cm\NNS\13649268 H2O\NN\14618834 )\-RRB-\1740 ,\,\1740 while\IN\15122231 decreasing\VBG\169651 QS/QT\NN\1740 ,\,\1740 produce\VB\1617192 marked\JJ\1740 <e2>decreases\NNS\7296428 in\IN\13603305 arterial\JJ\1740 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 cardiac\JJ\1740 output</e2>\NN\4007894 .\.\1740
3031535
D013759_D002375 CID Noradrenergic\JJ\1740 involvement\NN\1080366 in\IN\13603305 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 <e1>delta\NN\9193282 9-tetrahydrocannabinol</e1>\NN\1740 .\.\1740
D013759_D002375 CID These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 noradrenergic\JJ\1740 neurons\NNS\5430628 have\VBP\2108377 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 manifestation\NN\7321772 of\IN\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 <e1>THC</e1>\NN\4017137 ,\,\1740 whereas\IN\1740 dopaminergic\JJ\1740 neurons\NNS\5430628 are\VBP\836236 important\JJ\1740 in\IN\13603305 catalepsy\NN\14023236 induced\VBN\1627355 by\IN\1740 haloperidol\NN\3713736 .\.\1740
D013759_D002375 CID These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 noradrenergic\JJ\1740 neurons\NNS\5430628 have\VBP\2108377 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 manifestation\NN\7321772 of\IN\1740 catalepsy\NN\14023236 induced\VBN\1627355 by\IN\1740 <e1>THC</e1>\NN\4017137 ,\,\1740 whereas\IN\1740 dopaminergic\JJ\1740 neurons\NNS\5430628 are\VBP\836236 important\JJ\1740 in\IN\13603305 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 haloperidol\NN\3713736 .\.\1740
D006220_D002375 CID These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 noradrenergic\JJ\1740 neurons\NNS\5430628 have\VBP\2108377 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 manifestation\NN\7321772 of\IN\1740 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 THC\NN\4017137 ,\,\1740 whereas\IN\1740 dopaminergic\JJ\1740 neurons\NNS\5430628 are\VBP\836236 important\JJ\1740 in\IN\13603305 catalepsy\NN\14023236 induced\VBN\1627355 by\IN\1740 <e1>haloperidol</e1>\NN\3713736 .\.\1740
D006220_D002375 CID These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 noradrenergic\JJ\1740 neurons\NNS\5430628 have\VBP\2108377 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 manifestation\NN\7321772 of\IN\1740 catalepsy\NN\14023236 induced\VBN\1627355 by\IN\1740 THC\NN\4017137 ,\,\1740 whereas\IN\1740 dopaminergic\JJ\1740 neurons\NNS\5430628 are\VBP\836236 important\JJ\1740 in\IN\13603305 <e2>catalepsy</e2>\NN\14023236 induced\VBN\1627355 by\IN\1740 <e1>haloperidol</e1>\NN\3713736 .\.\1740
9284778
-1_D008107 NONE Epidemic\NN\7435273 of\IN\1740 <e2>liver\NN\5298729 disease</e2>\NN\14061805 caused\VBN\1617192 by\IN\1740 <e1>hydrochlorofluorocarbons</e1>\NNS\14603497 used\VBN\1156834 as\IN\14622893 ozone-sparing\JJ\1740 substitutes\NNS\5695554 of\IN\1740 chlorofluorocarbons\NNS\14871968 .\.\1740
D010126_D008107 NONE Epidemic\NN\7435273 of\IN\1740 <e2>liver\NN\5298729 disease</e2>\NN\14061805 caused\VBN\1617192 by\IN\1740 hydrochlorofluorocarbons\NNS\14603497 used\VBN\1156834 as\IN\14622893 <e1>ozone-sparing</e1>\JJ\1740 substitutes\NNS\5695554 of\IN\1740 chlorofluorocarbons\NNS\14871968 .\.\1740
D017402_D008107 NONE Epidemic\NN\7435273 of\IN\1740 <e2>liver\NN\5298729 disease</e2>\NN\14061805 caused\VBN\1617192 by\IN\1740 hydrochlorofluorocarbons\NNS\14603497 used\VBN\1156834 as\IN\14622893 ozone-sparing\JJ\1740 substitutes\NNS\5695554 of\IN\1740 <e1>chlorofluorocarbons</e1>\NNS\14871968 .\.\1740
C067411_D008107 CID We\PRP\1740 investigated\VBD\644583 an\DT\6697703 epidemic\NN\7435273 of\IN\1740 <e2>liver\NN\5298729 disease</e2>\NN\14061805 in\IN\13603305 nine\CD\13741022 industrial\JJ\1740 workers\NNS\7846 who\WP\8299493 had\VBD\2108377 had\VBN\2108377 repeated\VBN\952524 accidental\JJ\1740 exposure\NN\5042871 to\TO\1740 a\DT\13649268 mixture\NN\19613 of\IN\1740 <e1>1,1-dichloro-2,2,2-trifluoroethane</e1>\NN\1740 (\-LRB-\1740 HCFC\NN\14603497 123\CD\1740 )\-RRB-\1740 and\CC\1740 1-chloro-1,2,2,2-tetrafluoroethane\NN\1740 (\-LRB-\1740 HCFC\NN\14603497 124\CD\1740 )\-RRB-\1740 .\.\1740
C067411_D008107 CID We\PRP\1740 investigated\VBD\644583 an\DT\6697703 epidemic\NN\7435273 of\IN\1740 <e2>liver\NN\5298729 disease</e2>\NN\14061805 in\IN\13603305 nine\CD\13741022 industrial\JJ\1740 workers\NNS\7846 who\WP\8299493 had\VBD\2108377 had\VBN\2108377 repeated\VBN\952524 accidental\JJ\1740 exposure\NN\5042871 to\TO\1740 a\DT\13649268 mixture\NN\19613 of\IN\1740 1,1-dichloro-2,2,2-trifluoroethane\NN\1740 (\-LRB-\1740 <e1>HCFC\NN\14603497 123</e1>\CD\1740 )\-RRB-\1740 and\CC\1740 1-chloro-1,2,2,2-tetrafluoroethane\NN\1740 (\-LRB-\1740 HCFC\NN\14603497 124\CD\1740 )\-RRB-\1740 .\.\1740
C067411_D008107 CID We\PRP\1740 aimed\VBD\1987160 to\TO\1740 test\VB\670261 whether\IN\1740 <e1>HCFCs\NNS\14603497 123\CD\1740 and\CC\1740 124</e1>\CD\1740 can\MD\3094503 result\VB\2633881 in\IN\13603305 serious\JJ\1740 <e2>liver\NN\5298729 disease</e2>\NN\14061805 .\.\1740
C072959_D008107 CID We\PRP\1740 investigated\VBD\644583 an\DT\6697703 epidemic\NN\7435273 of\IN\1740 <e2>liver\NN\5298729 disease</e2>\NN\14061805 in\IN\13603305 nine\CD\13741022 industrial\JJ\1740 workers\NNS\7846 who\WP\8299493 had\VBD\2108377 had\VBN\2108377 repeated\VBN\952524 accidental\JJ\1740 exposure\NN\5042871 to\TO\1740 a\DT\13649268 mixture\NN\19613 of\IN\1740 1,1-dichloro-2,2,2-trifluoroethane\NN\1740 (\-LRB-\1740 HCFC\NN\14603497 123\CD\1740 )\-RRB-\1740 and\CC\1740 <e1>1-chloro-1,2,2,2-tetrafluoroethane</e1>\NN\1740 (\-LRB-\1740 HCFC\NN\14603497 124\CD\1740 )\-RRB-\1740 .\.\1740
C072959_D008107 CID We\PRP\1740 investigated\VBD\644583 an\DT\6697703 epidemic\NN\7435273 of\IN\1740 <e2>liver\NN\5298729 disease</e2>\NN\14061805 in\IN\13603305 nine\CD\13741022 industrial\JJ\1740 workers\NNS\7846 who\WP\8299493 had\VBD\2108377 had\VBN\2108377 repeated\VBN\952524 accidental\JJ\1740 exposure\NN\5042871 to\TO\1740 a\DT\13649268 mixture\NN\19613 of\IN\1740 1,1-dichloro-2,2,2-trifluoroethane\NN\1740 (\-LRB-\1740 HCFC\NN\14603497 123\CD\1740 )\-RRB-\1740 and\CC\1740 1-chloro-1,2,2,2-tetrafluoroethane\NN\1740 (\-LRB-\1740 <e1>HCFC\NN\14603497 124</e1>\CD\1740 )\-RRB-\1740 .\.\1740
C072959_D008107 CID We\PRP\1740 aimed\VBD\1987160 to\TO\1740 test\VB\670261 whether\IN\1740 <e1>HCFCs\NNS\14603497 123\CD\1740 and\CC\1740 124</e1>\CD\1740 can\MD\3094503 result\VB\2633881 in\IN\13603305 serious\JJ\1740 <e2>liver\NN\5298729 disease</e2>\NN\14061805 .\.\1740
D006221_D056486 NONE Both\DT\1740 compounds\NNS\5869584 are\VBP\836236 metabolised\VBN\1740 in\IN\13603305 the\DT\1740 same\JJ\1740 way\NN\4916342 as\IN\14622893 <e1>1-bromo-1-chloro-2,2,2-trifluoroethane</e1>\NN\1740 (\-LRB-\1740 halothane\NN\3570838 )\-RRB-\1740 to\TO\1740 form\VB\1617192 reactive\JJ\1740 trifluoroacetyl\NN\1740 halide\NN\15010703 intermediates\NNS\14806838 ,\,\1740 which\WDT\1740 have\VBP\2108377 been\VBN\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 <e2>hepatotoxicity</e2>\NN\1740 of\IN\1740 halothane\NN\3570838 .\.\1740
D006221_D056486 NONE Both\DT\1740 compounds\NNS\5869584 are\VBP\836236 metabolised\VBN\1740 in\IN\13603305 the\DT\1740 same\JJ\1740 way\NN\4916342 as\IN\14622893 1-bromo-1-chloro-2,2,2-trifluoroethane\NN\1740 (\-LRB-\1740 <e1>halothane</e1>\NN\3570838 )\-RRB-\1740 to\TO\1740 form\VB\1617192 reactive\JJ\1740 trifluoroacetyl\NN\1740 halide\NN\15010703 intermediates\NNS\14806838 ,\,\1740 which\WDT\1740 have\VBP\2108377 been\VBN\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 <e2>hepatotoxicity</e2>\NN\1740 of\IN\1740 halothane\NN\3570838 .\.\1740
D006221_D056486 NONE Both\DT\1740 compounds\NNS\5869584 are\VBP\836236 metabolised\VBN\1740 in\IN\13603305 the\DT\1740 same\JJ\1740 way\NN\4916342 as\IN\14622893 1-bromo-1-chloro-2,2,2-trifluoroethane\NN\1740 (\-LRB-\1740 halothane\NN\3570838 )\-RRB-\1740 to\TO\1740 form\VB\1617192 reactive\JJ\1740 trifluoroacetyl\NN\1740 halide\NN\15010703 intermediates\NNS\14806838 ,\,\1740 which\WDT\1740 have\VBP\2108377 been\VBN\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 <e2>hepatotoxicity</e2>\NN\1740 of\IN\1740 <e1>halothane</e1>\NN\3570838 .\.\1740
D014269_D056486 NONE Both\DT\1740 compounds\NNS\5869584 are\VBP\836236 metabolised\VBN\1740 in\IN\13603305 the\DT\1740 same\JJ\1740 way\NN\4916342 as\IN\14622893 1-bromo-1-chloro-2,2,2-trifluoroethane\NN\1740 (\-LRB-\1740 halothane\NN\3570838 )\-RRB-\1740 to\TO\1740 form\VB\1617192 reactive\JJ\1740 <e1>trifluoroacetyl</e1>\NN\1740 halide\NN\15010703 intermediates\NNS\14806838 ,\,\1740 which\WDT\1740 have\VBP\2108377 been\VBN\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 <e2>hepatotoxicity</e2>\NN\1740 of\IN\1740 halothane\NN\3570838 .\.\1740
D014269_D056486 NONE Although\IN\1740 the\DT\1740 exact\JJ\1740 mechanism\NN\13446390 of\IN\1740 <e2>hepatotoxicity</e2>\NN\1740 of\IN\1740 these\DT\1740 agents\NNS\7347 is\VBZ\836236 not\RB\1740 known\VBN\2110220 ,\,\1740 the\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 <e1>trifluoroacetyl-altered</e1>\JJ\1740 liver\NN\5298729 proteins\NNS\14944888 are\VBP\836236 involved\VBN\2676054 .\.\1740
C067411_D056486 NONE INTERPRETATION\NN\5926676 :\:\1740 Repeated\VBN\952524 exposure\NN\5042871 of\IN\1740 human\JJ\1740 beings\NNS\24720 to\IN\1740 <e1>HCFCs\NNS\14603497 123\CD\1740 and\CC\1740 124</e1>\CD\1740 can\MD\3094503 result\VB\2633881 in\IN\13603305 serious\JJ\1740 <e2>liver\NN\5298729 injury</e2>\NN\14052046 in\IN\13603305 a\DT\13649268 large\JJ\1740 proportion\NN\13824815 of\IN\1740 the\DT\1740 exposed\VBN\2110927 population\NN\7942152 .\.\1740
C072959_D056486 NONE INTERPRETATION\NN\5926676 :\:\1740 Repeated\VBN\952524 exposure\NN\5042871 of\IN\1740 human\JJ\1740 beings\NNS\24720 to\IN\1740 <e1>HCFCs\NNS\14603497 123\CD\1740 and\CC\1740 124</e1>\CD\1740 can\MD\3094503 result\VB\2633881 in\IN\13603305 serious\JJ\1740 <e2>liver\NN\5298729 injury</e2>\NN\14052046 in\IN\13603305 a\DT\13649268 large\JJ\1740 proportion\NN\13824815 of\IN\1740 the\DT\1740 exposed\VBN\2110927 population\NN\7942152 .\.\1740
8752018
D008094_D003072 CID <e1>Lithium-associated</e1>\JJ\1740 <e2>cognitive\JJ\1740 and\CC\1740 functional\JJ\1740 deficits</e2>\NNS\5113133 reduced\VBN\441445 by\IN\1740 a\DT\13649268 switch\NN\3096960 to\TO\1740 divalproex\NN\1740 sodium\NN\14625458 :\:\1740 a\DT\13649268 case\NN\7283608 series\NN\8456993 .\.\1740
D008094_D003072 CID Although\IN\1740 much\JJ\1740 has\VBZ\2108377 been\VBN\836236 written\VBN\1697816 about\IN\1740 the\DT\1740 management\NN\1123598 of\IN\1740 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>lithium</e1>\NN\14625458 ,\,\1740 such\JJ\1740 as\IN\14622893 polyuria\NN\14113228 and\CC\1740 tremor\NN\345926 ,\,\1740 more\RBR\1740 subtle\JJ\1740 lithium\NN\14625458 side\NN\8630039 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 <e2>cognitive\JJ\1740 deficits</e2>\NNS\5113133 ,\,\1740 loss\NN\13252973 of\IN\1740 creativity\NN\5616246 ,\,\1740 and\CC\1740 functional\JJ\1740 impairments\NNS\7296428 remain\VBP\2604760 understudied\JJ\1740 .\.\1740
D008094_D003072 CID Although\IN\1740 much\JJ\1740 has\VBZ\2108377 been\VBN\836236 written\VBN\1697816 about\IN\1740 the\DT\1740 management\NN\1123598 of\IN\1740 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>lithium</e1>\NN\14625458 ,\,\1740 such\JJ\1740 as\IN\14622893 polyuria\NN\14113228 and\CC\1740 tremor\NN\345926 ,\,\1740 more\RBR\1740 subtle\JJ\1740 lithium\NN\14625458 side\NN\8630039 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 cognitive\JJ\1740 deficits\NNS\5113133 ,\,\1740 <e2>loss\NN\13252973 of\IN\1740 creativity</e2>\NN\5616246 ,\,\1740 and\CC\1740 functional\JJ\1740 impairments\NNS\7296428 remain\VBP\2604760 understudied\JJ\1740 .\.\1740
D008094_D003072 CID Although\IN\1740 much\JJ\1740 has\VBZ\2108377 been\VBN\836236 written\VBN\1697816 about\IN\1740 the\DT\1740 management\NN\1123598 of\IN\1740 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>lithium</e1>\NN\14625458 ,\,\1740 such\JJ\1740 as\IN\14622893 polyuria\NN\14113228 and\CC\1740 tremor\NN\345926 ,\,\1740 more\RBR\1740 subtle\JJ\1740 lithium\NN\14625458 side\NN\8630039 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 cognitive\JJ\1740 deficits\NNS\5113133 ,\,\1740 loss\NN\13252973 of\IN\1740 creativity\NN\5616246 ,\,\1740 and\CC\1740 <e2>functional\JJ\1740 impairments</e2>\NNS\7296428 remain\VBP\2604760 understudied\JJ\1740 .\.\1740
D008094_D003072 CID Although\IN\1740 much\JJ\1740 has\VBZ\2108377 been\VBN\836236 written\VBN\1697816 about\IN\1740 the\DT\1740 management\NN\1123598 of\IN\1740 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 of\IN\1740 lithium\NN\14625458 ,\,\1740 such\JJ\1740 as\IN\14622893 polyuria\NN\14113228 and\CC\1740 tremor\NN\345926 ,\,\1740 more\RBR\1740 subtle\JJ\1740 <e1>lithium</e1>\NN\14625458 side\NN\8630039 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 <e2>cognitive\JJ\1740 deficits</e2>\NNS\5113133 ,\,\1740 loss\NN\13252973 of\IN\1740 creativity\NN\5616246 ,\,\1740 and\CC\1740 functional\JJ\1740 impairments\NNS\7296428 remain\VBP\2604760 understudied\JJ\1740 .\.\1740
D008094_D003072 CID Although\IN\1740 much\JJ\1740 has\VBZ\2108377 been\VBN\836236 written\VBN\1697816 about\IN\1740 the\DT\1740 management\NN\1123598 of\IN\1740 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 of\IN\1740 lithium\NN\14625458 ,\,\1740 such\JJ\1740 as\IN\14622893 polyuria\NN\14113228 and\CC\1740 tremor\NN\345926 ,\,\1740 more\RBR\1740 subtle\JJ\1740 <e1>lithium</e1>\NN\14625458 side\NN\8630039 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 cognitive\JJ\1740 deficits\NNS\5113133 ,\,\1740 <e2>loss\NN\13252973 of\IN\1740 creativity</e2>\NN\5616246 ,\,\1740 and\CC\1740 functional\JJ\1740 impairments\NNS\7296428 remain\VBP\2604760 understudied\JJ\1740 .\.\1740
D008094_D003072 CID Although\IN\1740 much\JJ\1740 has\VBZ\2108377 been\VBN\836236 written\VBN\1697816 about\IN\1740 the\DT\1740 management\NN\1123598 of\IN\1740 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 of\IN\1740 lithium\NN\14625458 ,\,\1740 such\JJ\1740 as\IN\14622893 polyuria\NN\14113228 and\CC\1740 tremor\NN\345926 ,\,\1740 more\RBR\1740 subtle\JJ\1740 <e1>lithium</e1>\NN\14625458 side\NN\8630039 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 cognitive\JJ\1740 deficits\NNS\5113133 ,\,\1740 loss\NN\13252973 of\IN\1740 creativity\NN\5616246 ,\,\1740 and\CC\1740 <e2>functional\JJ\1740 impairments</e2>\NNS\7296428 remain\VBP\2604760 understudied\JJ\1740 .\.\1740
D008094_D003072 CID This\DT\1740 report\NN\6470073 summarizes\VBZ\958334 our\PRP$\1740 experience\NN\5984287 in\IN\13603305 switching\VBG\138508 bipolar\JJ\1740 patients\NNS\9898892 from\IN\1740 <e1>lithium</e1>\NN\14625458 to\TO\1740 divalproex\JJ\1740 sodium\NN\14625458 to\TO\1740 alleviate\VB\205885 such\JJ\1740 <e2>cognitive\JJ\1740 and\CC\1740 functional\JJ\1740 impairments</e2>\NNS\7296428 .\.\1740
D008094_D003072 CID RESULTS\NNS\34213 :\:\1740 We\PRP\1740 report\VBP\831651 seven\CD\13741022 cases\NNS\7283608 where\WRB\1740 substitution\NN\7337390 of\IN\1740 <e1>lithium</e1>\NN\14625458 ,\,\1740 either\CC\1740 fully\RB\1740 or\CC\3541091 partially\RB\1740 ,\,\1740 with\IN\1740 divalproex\NN\1740 sodium\NN\14625458 was\VBD\836236 extremely\RB\1740 helpful\JJ\1740 in\IN\13603305 reducing\VBG\441445 the\DT\1740 <e2>cognitive\JJ\1740 ,\,\1740 motivational\JJ\1740 ,\,\1740 or\CC\3541091 creative\JJ\1740 deficits</e2>\NNS\5113133 attributed\VBN\670261 to\TO\1740 lithium\NN\14625458 in\IN\13603305 our\PRP$\1740 bipolar\JJ\1740 patients\NNS\9898892 .\.\1740
D008094_D003072 CID RESULTS\NNS\34213 :\:\1740 We\PRP\1740 report\VBP\831651 seven\CD\13741022 cases\NNS\7283608 where\WRB\1740 substitution\NN\7337390 of\IN\1740 lithium\NN\14625458 ,\,\1740 either\CC\1740 fully\RB\1740 or\CC\3541091 partially\RB\1740 ,\,\1740 with\IN\1740 divalproex\NN\1740 sodium\NN\14625458 was\VBD\836236 extremely\RB\1740 helpful\JJ\1740 in\IN\13603305 reducing\VBG\441445 the\DT\1740 <e2>cognitive\JJ\1740 ,\,\1740 motivational\JJ\1740 ,\,\1740 or\CC\3541091 creative\JJ\1740 deficits</e2>\NNS\5113133 attributed\VBN\670261 to\TO\1740 <e1>lithium</e1>\NN\14625458 in\IN\13603305 our\PRP$\1740 bipolar\JJ\1740 patients\NNS\9898892 .\.\1740
D008094_D003072 CID CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 this\DT\1740 preliminary\JJ\1740 report\NN\6470073 ,\,\1740 divalproex\NN\1740 sodium\NN\14625458 was\VBD\836236 a\DT\13649268 superior\JJ\1740 alternative\NN\5788149 to\TO\1740 <e1>lithium</e1>\NN\14625458 in\IN\13603305 bipolar\JJ\1740 patients\NNS\9898892 experiencing\VBG\2108377 <e2>cognitive\JJ\1740 deficits</e2>\NNS\5113133 ,\,\1740 loss\NN\13252973 of\IN\1740 creativity\NN\5616246 ,\,\1740 and\CC\1740 functional\JJ\1740 impairments\NNS\7296428 .\.\1740
D008094_D003072 CID CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 this\DT\1740 preliminary\JJ\1740 report\NN\6470073 ,\,\1740 divalproex\NN\1740 sodium\NN\14625458 was\VBD\836236 a\DT\13649268 superior\JJ\1740 alternative\NN\5788149 to\TO\1740 <e1>lithium</e1>\NN\14625458 in\IN\13603305 bipolar\JJ\1740 patients\NNS\9898892 experiencing\VBG\2108377 cognitive\JJ\1740 deficits\NNS\5113133 ,\,\1740 <e2>loss\NN\13252973 of\IN\1740 creativity</e2>\NN\5616246 ,\,\1740 and\CC\1740 functional\JJ\1740 impairments\NNS\7296428 .\.\1740
D008094_D003072 CID CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 this\DT\1740 preliminary\JJ\1740 report\NN\6470073 ,\,\1740 divalproex\NN\1740 sodium\NN\14625458 was\VBD\836236 a\DT\13649268 superior\JJ\1740 alternative\NN\5788149 to\TO\1740 <e1>lithium</e1>\NN\14625458 in\IN\13603305 bipolar\JJ\1740 patients\NNS\9898892 experiencing\VBG\2108377 cognitive\JJ\1740 deficits\NNS\5113133 ,\,\1740 loss\NN\13252973 of\IN\1740 creativity\NN\5616246 ,\,\1740 and\CC\1740 <e2>functional\JJ\1740 impairments</e2>\NNS\7296428 .\.\1740
D014635_D003072 NONE Lithium-associated\JJ\1740 <e2>cognitive\JJ\1740 and\CC\1740 functional\JJ\1740 deficits</e2>\NNS\5113133 reduced\VBN\441445 by\IN\1740 a\DT\13649268 switch\NN\3096960 to\TO\1740 <e1>divalproex\NN\1740 sodium</e1>\NN\14625458 :\:\1740 a\DT\13649268 case\NN\7283608 series\NN\8456993 .\.\1740
D014635_D003072 NONE This\DT\1740 report\NN\6470073 summarizes\VBZ\958334 our\PRP$\1740 experience\NN\5984287 in\IN\13603305 switching\VBG\138508 bipolar\JJ\1740 patients\NNS\9898892 from\IN\1740 lithium\NN\14625458 to\TO\1740 <e1>divalproex\JJ\1740 sodium</e1>\NN\14625458 to\TO\1740 alleviate\VB\205885 such\JJ\1740 <e2>cognitive\JJ\1740 and\CC\1740 functional\JJ\1740 impairments</e2>\NNS\7296428 .\.\1740
D014635_D003072 NONE RESULTS\NNS\34213 :\:\1740 We\PRP\1740 report\VBP\831651 seven\CD\13741022 cases\NNS\7283608 where\WRB\1740 substitution\NN\7337390 of\IN\1740 lithium\NN\14625458 ,\,\1740 either\CC\1740 fully\RB\1740 or\CC\3541091 partially\RB\1740 ,\,\1740 with\IN\1740 <e1>divalproex\NN\1740 sodium</e1>\NN\14625458 was\VBD\836236 extremely\RB\1740 helpful\JJ\1740 in\IN\13603305 reducing\VBG\441445 the\DT\1740 <e2>cognitive\JJ\1740 ,\,\1740 motivational\JJ\1740 ,\,\1740 or\CC\3541091 creative\JJ\1740 deficits</e2>\NNS\5113133 attributed\VBN\670261 to\TO\1740 lithium\NN\14625458 in\IN\13603305 our\PRP$\1740 bipolar\JJ\1740 patients\NNS\9898892 .\.\1740
D014635_D003072 NONE CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 this\DT\1740 preliminary\JJ\1740 report\NN\6470073 ,\,\1740 <e1>divalproex\NN\1740 sodium</e1>\NN\14625458 was\VBD\836236 a\DT\13649268 superior\JJ\1740 alternative\NN\5788149 to\TO\1740 lithium\NN\14625458 in\IN\13603305 bipolar\JJ\1740 patients\NNS\9898892 experiencing\VBG\2108377 <e2>cognitive\JJ\1740 deficits</e2>\NNS\5113133 ,\,\1740 loss\NN\13252973 of\IN\1740 creativity\NN\5616246 ,\,\1740 and\CC\1740 functional\JJ\1740 impairments\NNS\7296428 .\.\1740
D014635_D003072 NONE CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 this\DT\1740 preliminary\JJ\1740 report\NN\6470073 ,\,\1740 <e1>divalproex\NN\1740 sodium</e1>\NN\14625458 was\VBD\836236 a\DT\13649268 superior\JJ\1740 alternative\NN\5788149 to\TO\1740 lithium\NN\14625458 in\IN\13603305 bipolar\JJ\1740 patients\NNS\9898892 experiencing\VBG\2108377 cognitive\JJ\1740 deficits\NNS\5113133 ,\,\1740 <e2>loss\NN\13252973 of\IN\1740 creativity</e2>\NN\5616246 ,\,\1740 and\CC\1740 functional\JJ\1740 impairments\NNS\7296428 .\.\1740
D014635_D003072 NONE CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 this\DT\1740 preliminary\JJ\1740 report\NN\6470073 ,\,\1740 <e1>divalproex\NN\1740 sodium</e1>\NN\14625458 was\VBD\836236 a\DT\13649268 superior\JJ\1740 alternative\NN\5788149 to\TO\1740 lithium\NN\14625458 in\IN\13603305 bipolar\JJ\1740 patients\NNS\9898892 experiencing\VBG\2108377 cognitive\JJ\1740 deficits\NNS\5113133 ,\,\1740 loss\NN\13252973 of\IN\1740 creativity\NN\5616246 ,\,\1740 and\CC\1740 <e2>functional\JJ\1740 impairments</e2>\NNS\7296428 .\.\1740
D008094_D001714 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Lithium</e1>\NNP\14625458 remains\VBZ\2604760 a\DT\13649268 first-line\JJ\1740 treatment\NN\654885 for\IN\1740 the\DT\1740 acute\JJ\1740 and\CC\1740 maintenance\NN\266806 treatment\NN\654885 of\IN\1740 <e2>bipolar\JJ\1740 disorder</e2>\NN\14034177 .\.\1740
D008094_D001714 NONE This\DT\1740 report\NN\6470073 summarizes\VBZ\958334 our\PRP$\1740 experience\NN\5984287 in\IN\13603305 switching\VBG\138508 <e2>bipolar</e2>\JJ\1740 patients\NNS\9898892 from\IN\1740 <e1>lithium</e1>\NN\14625458 to\TO\1740 divalproex\JJ\1740 sodium\NN\14625458 to\TO\1740 alleviate\VB\205885 such\JJ\1740 cognitive\JJ\1740 and\CC\1740 functional\JJ\1740 impairments\NNS\7296428 .\.\1740
D008094_D001714 NONE RESULTS\NNS\34213 :\:\1740 We\PRP\1740 report\VBP\831651 seven\CD\13741022 cases\NNS\7283608 where\WRB\1740 substitution\NN\7337390 of\IN\1740 <e1>lithium</e1>\NN\14625458 ,\,\1740 either\CC\1740 fully\RB\1740 or\CC\3541091 partially\RB\1740 ,\,\1740 with\IN\1740 divalproex\NN\1740 sodium\NN\14625458 was\VBD\836236 extremely\RB\1740 helpful\JJ\1740 in\IN\13603305 reducing\VBG\441445 the\DT\1740 cognitive\JJ\1740 ,\,\1740 motivational\JJ\1740 ,\,\1740 or\CC\3541091 creative\JJ\1740 deficits\NNS\5113133 attributed\VBN\670261 to\TO\1740 lithium\NN\14625458 in\IN\13603305 our\PRP$\1740 <e2>bipolar</e2>\JJ\1740 patients\NNS\9898892 .\.\1740
D008094_D001714 NONE RESULTS\NNS\34213 :\:\1740 We\PRP\1740 report\VBP\831651 seven\CD\13741022 cases\NNS\7283608 where\WRB\1740 substitution\NN\7337390 of\IN\1740 lithium\NN\14625458 ,\,\1740 either\CC\1740 fully\RB\1740 or\CC\3541091 partially\RB\1740 ,\,\1740 with\IN\1740 divalproex\NN\1740 sodium\NN\14625458 was\VBD\836236 extremely\RB\1740 helpful\JJ\1740 in\IN\13603305 reducing\VBG\441445 the\DT\1740 cognitive\JJ\1740 ,\,\1740 motivational\JJ\1740 ,\,\1740 or\CC\3541091 creative\JJ\1740 deficits\NNS\5113133 attributed\VBN\670261 to\TO\1740 <e1>lithium</e1>\NN\14625458 in\IN\13603305 our\PRP$\1740 <e2>bipolar</e2>\JJ\1740 patients\NNS\9898892 .\.\1740
D008094_D001714 NONE CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 this\DT\1740 preliminary\JJ\1740 report\NN\6470073 ,\,\1740 divalproex\NN\1740 sodium\NN\14625458 was\VBD\836236 a\DT\13649268 superior\JJ\1740 alternative\NN\5788149 to\TO\1740 <e1>lithium</e1>\NN\14625458 in\IN\13603305 <e2>bipolar</e2>\JJ\1740 patients\NNS\9898892 experiencing\VBG\2108377 cognitive\JJ\1740 deficits\NNS\5113133 ,\,\1740 loss\NN\13252973 of\IN\1740 creativity\NN\5616246 ,\,\1740 and\CC\1740 functional\JJ\1740 impairments\NNS\7296428 .\.\1740
D008094_D011141 NONE Although\IN\1740 much\JJ\1740 has\VBZ\2108377 been\VBN\836236 written\VBN\1697816 about\IN\1740 the\DT\1740 management\NN\1123598 of\IN\1740 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>lithium</e1>\NN\14625458 ,\,\1740 such\JJ\1740 as\IN\14622893 <e2>polyuria</e2>\NN\14113228 and\CC\1740 tremor\NN\345926 ,\,\1740 more\RBR\1740 subtle\JJ\1740 lithium\NN\14625458 side\NN\8630039 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 cognitive\JJ\1740 deficits\NNS\5113133 ,\,\1740 loss\NN\13252973 of\IN\1740 creativity\NN\5616246 ,\,\1740 and\CC\1740 functional\JJ\1740 impairments\NNS\7296428 remain\VBP\2604760 understudied\JJ\1740 .\.\1740
D008094_D011141 NONE Although\IN\1740 much\JJ\1740 has\VBZ\2108377 been\VBN\836236 written\VBN\1697816 about\IN\1740 the\DT\1740 management\NN\1123598 of\IN\1740 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 of\IN\1740 lithium\NN\14625458 ,\,\1740 such\JJ\1740 as\IN\14622893 <e2>polyuria</e2>\NN\14113228 and\CC\1740 tremor\NN\345926 ,\,\1740 more\RBR\1740 subtle\JJ\1740 <e1>lithium</e1>\NN\14625458 side\NN\8630039 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 cognitive\JJ\1740 deficits\NNS\5113133 ,\,\1740 loss\NN\13252973 of\IN\1740 creativity\NN\5616246 ,\,\1740 and\CC\1740 functional\JJ\1740 impairments\NNS\7296428 remain\VBP\2604760 understudied\JJ\1740 .\.\1740
D008094_D014202 NONE Although\IN\1740 much\JJ\1740 has\VBZ\2108377 been\VBN\836236 written\VBN\1697816 about\IN\1740 the\DT\1740 management\NN\1123598 of\IN\1740 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>lithium</e1>\NN\14625458 ,\,\1740 such\JJ\1740 as\IN\14622893 polyuria\NN\14113228 and\CC\1740 <e2>tremor</e2>\NN\345926 ,\,\1740 more\RBR\1740 subtle\JJ\1740 lithium\NN\14625458 side\NN\8630039 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 cognitive\JJ\1740 deficits\NNS\5113133 ,\,\1740 loss\NN\13252973 of\IN\1740 creativity\NN\5616246 ,\,\1740 and\CC\1740 functional\JJ\1740 impairments\NNS\7296428 remain\VBP\2604760 understudied\JJ\1740 .\.\1740
D008094_D014202 NONE Although\IN\1740 much\JJ\1740 has\VBZ\2108377 been\VBN\836236 written\VBN\1697816 about\IN\1740 the\DT\1740 management\NN\1123598 of\IN\1740 the\DT\1740 more\RBR\1740 common\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 of\IN\1740 lithium\NN\14625458 ,\,\1740 such\JJ\1740 as\IN\14622893 polyuria\NN\14113228 and\CC\1740 <e2>tremor</e2>\NN\345926 ,\,\1740 more\RBR\1740 subtle\JJ\1740 <e1>lithium</e1>\NN\14625458 side\NN\8630039 effects\NNS\13245626 such\JJ\1740 as\IN\14622893 cognitive\JJ\1740 deficits\NNS\5113133 ,\,\1740 loss\NN\13252973 of\IN\1740 creativity\NN\5616246 ,\,\1740 and\CC\1740 functional\JJ\1740 impairments\NNS\7296428 remain\VBP\2604760 understudied\JJ\1740 .\.\1740
D014635_D001714 NONE This\DT\1740 report\NN\6470073 summarizes\VBZ\958334 our\PRP$\1740 experience\NN\5984287 in\IN\13603305 switching\VBG\138508 <e2>bipolar</e2>\JJ\1740 patients\NNS\9898892 from\IN\1740 lithium\NN\14625458 to\TO\1740 <e1>divalproex\JJ\1740 sodium</e1>\NN\14625458 to\TO\1740 alleviate\VB\205885 such\JJ\1740 cognitive\JJ\1740 and\CC\1740 functional\JJ\1740 impairments\NNS\7296428 .\.\1740
D014635_D001714 NONE RESULTS\NNS\34213 :\:\1740 We\PRP\1740 report\VBP\831651 seven\CD\13741022 cases\NNS\7283608 where\WRB\1740 substitution\NN\7337390 of\IN\1740 lithium\NN\14625458 ,\,\1740 either\CC\1740 fully\RB\1740 or\CC\3541091 partially\RB\1740 ,\,\1740 with\IN\1740 <e1>divalproex\NN\1740 sodium</e1>\NN\14625458 was\VBD\836236 extremely\RB\1740 helpful\JJ\1740 in\IN\13603305 reducing\VBG\441445 the\DT\1740 cognitive\JJ\1740 ,\,\1740 motivational\JJ\1740 ,\,\1740 or\CC\3541091 creative\JJ\1740 deficits\NNS\5113133 attributed\VBN\670261 to\TO\1740 lithium\NN\14625458 in\IN\13603305 our\PRP$\1740 <e2>bipolar</e2>\JJ\1740 patients\NNS\9898892 .\.\1740
D014635_D001714 NONE CONCLUSION\NN\5837957 :\:\1740 In\IN\13603305 this\DT\1740 preliminary\JJ\1740 report\NN\6470073 ,\,\1740 <e1>divalproex\NN\1740 sodium</e1>\NN\14625458 was\VBD\836236 a\DT\13649268 superior\JJ\1740 alternative\NN\5788149 to\TO\1740 lithium\NN\14625458 in\IN\13603305 <e2>bipolar</e2>\JJ\1740 patients\NNS\9898892 experiencing\VBG\2108377 cognitive\JJ\1740 deficits\NNS\5113133 ,\,\1740 loss\NN\13252973 of\IN\1740 creativity\NN\5616246 ,\,\1740 and\CC\1740 functional\JJ\1740 impairments\NNS\7296428 .\.\1740
7516729
D014700_D001919 CID Dose-dependent\JJ\1740 <e2>bradycardia</e2>\NN\14110674 induced\VBN\1627355 by\IN\1740 <e1>verapamil</e1>\NN\2938514 was\VBD\836236 potentiated\VBN\229605 by\IN\1740 LNa\NNS\1740 ,\,\1740 LCa\NNS\1740 ,\,\1740 and\CC\1740 HCa\NN\1740 .\.\1740
6727060
D008787_D004409 CID A\DT\13649268 case\NN\7283608 of\IN\1740 <e2>tardive\JJ\1740 dyskinesia</e2>\NN\14084880 caused\VBN\1617192 by\IN\1740 <e1>metoclopramide</e1>\NN\1740 .\.\1740
D008787_D004409 CID <e2>Abnormal\JJ\1740 involuntary\JJ\1740 movements</e2>\NNS\191142 appeared\VBD\2604760 in\IN\13603305 the\DT\1740 mouth\NN\5610008 ,\,\1740 tongue\NN\5301392 ,\,\1740 neck\NN\5225090 and\CC\1740 abdomen\NNS\5220461 of\IN\1740 a\DT\13649268 64-year-old\JJ\1740 male\JJ\1740 patient\NN\9898892 after\IN\1740 he\PRP\14622893 took\VBD\2367363 <e1>metoclopramide</e1>\NN\1740 for\IN\1740 gastrointestinal\JJ\1740 disorder\NN\14034177 in\IN\13603305 a\DT\13649268 regimen\NN\5898568 of\IN\1740 30\CD\13745420 mg\NN\13717155 per\IN\1740 day\NN\15154774 for\IN\1740 a\DT\13649268 total\NN\3553 of\IN\1740 about\RB\1740 260\CD\1740 days\NNS\15140892 .\.\1740
D008787_D004409 CID When\WRB\1740 the\DT\1740 <e1>metoclopramide</e1>\NN\1740 administration\NN\1133281 was\VBD\836236 discontinued\VBN\2609764 ,\,\1740 the\DT\1740 <e2>abnormal\JJ\1740 movements</e2>\NNS\191142 gradually\RB\1740 improved\VBD\126264 to\TO\1740 a\DT\13649268 considerable\JJ\1740 extent\NN\13939892 .\.\1740
D008787_D005767 NONE Abnormal\JJ\1740 involuntary\JJ\1740 movements\NNS\191142 appeared\VBD\2604760 in\IN\13603305 the\DT\1740 mouth\NN\5610008 ,\,\1740 tongue\NN\5301392 ,\,\1740 neck\NN\5225090 and\CC\1740 abdomen\NNS\5220461 of\IN\1740 a\DT\13649268 64-year-old\JJ\1740 male\JJ\1740 patient\NN\9898892 after\IN\1740 he\PRP\14622893 took\VBD\2367363 <e1>metoclopramide</e1>\NN\1740 for\IN\1740 <e2>gastrointestinal\JJ\1740 disorder</e2>\NN\14034177 in\IN\13603305 a\DT\13649268 regimen\NN\5898568 of\IN\1740 30\CD\13745420 mg\NN\13717155 per\IN\1740 day\NN\15154774 for\IN\1740 a\DT\13649268 total\NN\3553 of\IN\1740 about\RB\1740 260\CD\1740 days\NNS\15140892 .\.\1740
983936
D001241_D009202 NONE Effects\NNS\13245626 of\IN\1740 <e1>acetylsalicylic\JJ\1740 acid</e1>\NN\14818238 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 hydrocortisone\NN\14751417 on\IN\1740 epinephrine-induced\JJ\1740 <e2>myocardial\JJ\1740 injury</e2>\NN\14052046 in\IN\13603305 dogs\NNS\2083346 .\.\1740
D004176_D009202 NONE Effects\NNS\13245626 of\IN\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 <e1>dipyridamole</e1>\NN\1740 ,\,\1740 and\CC\1740 hydrocortisone\NN\14751417 on\IN\1740 epinephrine-induced\JJ\1740 <e2>myocardial\JJ\1740 injury</e2>\NN\14052046 in\IN\13603305 dogs\NNS\2083346 .\.\1740
D006854_D009202 NONE Effects\NNS\13245626 of\IN\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 <e1>hydrocortisone</e1>\NN\14751417 on\IN\1740 epinephrine-induced\JJ\1740 <e2>myocardial\JJ\1740 injury</e2>\NN\14052046 in\IN\13603305 dogs\NNS\2083346 .\.\1740
D004837_D009202 CID Effects\NNS\13245626 of\IN\1740 acetylsalicylic\JJ\1740 acid\NN\14818238 ,\,\1740 dipyridamole\NN\1740 ,\,\1740 and\CC\1740 hydrocortisone\NN\14751417 on\IN\1740 <e1>epinephrine-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 injury</e2>\NN\14052046 in\IN\13603305 dogs\NNS\2083346 .\.\1740
D004837_D009202 CID A\DT\13649268 reproducible\JJ\1740 model\NN\5888929 for\IN\1740 producing\VBG\1617192 diffuse\JJ\1740 <e2>myocardial\JJ\1740 injury</e2>\NN\14052046 (\-LRB-\1740 <e1>epinephrine</e1>\NN\14807929 infusion\NN\14589223 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 developed\VBN\1753788 to\TO\1740 study\VB\630380 the\DT\1740 cardioprotective\JJ\1740 effects\NNS\13245626 of\IN\1740 agents\NNS\7347 or\CC\3541091 maneuvers\NNS\955060 which\WDT\1740 might\MD\5029706 alter\VB\126264 the\DT\1740 evolution\NN\29677 of\IN\1740 acute\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 .\.\1740
D004837_D009203 NONE A\DT\13649268 reproducible\JJ\1740 model\NN\5888929 for\IN\1740 producing\VBG\1617192 diffuse\JJ\1740 myocardial\JJ\1740 injury\NN\14052046 (\-LRB-\1740 <e1>epinephrine</e1>\NN\14807929 infusion\NN\14589223 )\-RRB-\1740 has\VBZ\2108377 been\VBN\836236 developed\VBN\1753788 to\TO\1740 study\VB\630380 the\DT\1740 cardioprotective\JJ\1740 effects\NNS\13245626 of\IN\1740 agents\NNS\7347 or\CC\3541091 maneuvers\NNS\955060 which\WDT\1740 might\MD\5029706 alter\VB\126264 the\DT\1740 evolution\NN\29677 of\IN\1740 acute\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
11431197
D011899_D009395 CID <e1>Ranitidine-induced</e1>\JJ\1740 acute\JJ\1740 <e2>interstitial\JJ\1740 nephritis</e2>\NN\14113228 in\IN\13603305 a\DT\13649268 cadaveric\JJ\1740 renal\JJ\1740 allograft\NN\5582859 .\.\1740
D011899_D009395 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 <e1>ranitidine-induced</e1>\JJ\1740 acute\JJ\1740 <e2>interstitial\JJ\1740 nephritis</e2>\NN\14113228 in\IN\13603305 a\DT\13649268 recipient\NN\9764201 of\IN\1740 a\DT\13649268 cadaveric\JJ\1740 renal\JJ\1740 allograft\NN\5582859 presenting\VBG\2137132 with\IN\1740 acute\JJ\1740 allograft\NN\5582859 dysfunction\NN\14204950 within\IN\1740 48\CD\1740 hours\NNS\15118228 of\IN\1740 exposure\NN\5042871 to\TO\1740 the\DT\1740 drug\NN\14778436 .\.\1740
12757899
D004958_D012640 NONE <e1>Estradiol</e1>\NN\14749794 reduces\VBZ\441445 <e2>seizure-induced</e2>\JJ\1740 hippocampal\NN\1740 injury\NN\14052046 in\IN\13603305 ovariectomized\JJ\1740 female\NN\15388 but\CC\1740 not\RB\1740 in\IN\13603305 male\JJ\1740 rats\NNS\2329401 .\.\1740
D004958_D012640 NONE These\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>estradiol</e1>\NN\14749794 on\IN\1740 <e2>seizure</e2>\JJ\1740 threshold\NN\15265518 and\CC\1740 damage\NN\7296428 may\MD\15209706 be\VB\836236 altered\VBN\126264 by\IN\1740 sex-related\JJ\1740 differences\NNS\4723816 in\IN\13603305 the\DT\1740 hormonal\JJ\1740 environment\NN\13927383 .\.\1740
D004958_D001930 NONE <e1>Estradiol</e1>\NN\14749794 reduces\VBZ\441445 seizure-induced\JJ\1740 <e2>hippocampal\NN\1740 injury</e2>\NN\14052046 in\IN\13603305 ovariectomized\JJ\1740 female\NN\15388 but\CC\1740 not\RB\1740 in\IN\13603305 male\JJ\1740 rats\NNS\2329401 .\.\1740
D007608_D001930 NONE Estrogens\NNS\14745635 protect\VBP\1127795 ovariectomized\JJ\1740 rats\NNS\2329401 from\IN\1740 <e2>hippocampal\NN\1740 injury</e2>\NN\14052046 induced\VBN\1627355 by\IN\1740 <e1>kainic\JJ\1740 acid-induced</e1>\JJ\1740 status\NN\24720 epilepticus\NN\1740 (\-LRB-\1740 SE\NN\14724645 )\-RRB-\1740 .\.\1740
D007608_D013226 NONE Estrogens\NNS\14745635 protect\VBP\1127795 ovariectomized\JJ\1740 rats\NNS\2329401 from\IN\1740 hippocampal\NN\1740 injury\NN\14052046 induced\VBN\1627355 by\IN\1740 <e1>kainic\JJ\1740 acid-induced</e1>\JJ\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 (\-LRB-\1740 SE\NN\14724645 )\-RRB-\1740 .\.\1740
D007608_D013226 NONE Estrogens\NNS\14745635 protect\VBP\1127795 ovariectomized\JJ\1740 rats\NNS\2329401 from\IN\1740 hippocampal\NN\1740 injury\NN\14052046 induced\VBN\1627355 by\IN\1740 <e1>kainic\JJ\1740 acid-induced</e1>\JJ\1740 status\NN\24720 epilepticus\NN\1740 (\-LRB-\1740 <e2>SE</e2>\NN\14724645 )\-RRB-\1740 .\.\1740
D004958_D013226 NONE We\PRP\1740 compared\VBD\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>17beta-estradiol</e1>\NN\1740 in\IN\13603305 adult\JJ\1740 male\JJ\1740 and\CC\1740 ovariectomized\JJ\1740 female\JJ\1740 rats\NNS\2329401 subjected\VBN\137313 to\TO\1740 lithium-pilocarpine-induced\JJ\1740 <e2>SE</e2>\NN\14724645 .\.\1740
D008094_D013226 CID We\PRP\1740 compared\VBD\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 17beta-estradiol\NN\1740 in\IN\13603305 adult\JJ\1740 male\JJ\1740 and\CC\1740 ovariectomized\JJ\1740 female\JJ\1740 rats\NNS\2329401 subjected\VBN\137313 to\TO\1740 <e1>lithium-pilocarpine-induced</e1>\JJ\1740 <e2>SE</e2>\NN\14724645 .\.\1740
D010862_D013226 CID We\PRP\1740 compared\VBD\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 17beta-estradiol\NN\1740 in\IN\13603305 adult\JJ\1740 male\JJ\1740 and\CC\1740 ovariectomized\JJ\1740 female\JJ\1740 rats\NNS\2329401 subjected\VBN\137313 to\TO\1740 <e1>lithium-pilocarpine-induced</e1>\JJ\1740 <e2>SE</e2>\NN\14724645 .\.\1740
D012834_D013226 NONE The\DT\1740 extent\NN\13939892 of\IN\1740 <e1>silver-stained</e1>\JJ\1740 CA3\NN\1740 and\CC\1740 CA1\NN\1740 hippocampal\NN\1740 neurons\NNS\5430628 was\VBD\836236 evaluated\VBN\670261 2\CD\13741022 days\NNS\15140892 after\IN\1740 <e2>SE</e2>\NNP\14724645 .\.\1740
8073369
C007112_D001176 CID However\RB\1740 ,\,\1740 <e1>coniine</e1>\NN\1740 has\VBZ\2108377 failed\VBN\1798936 to\TO\1740 produce\VB\1617192 <e2>arthrogryposis</e2>\NN\1740 in\IN\13603305 rats\NNS\2329401 or\CC\3541091 mice\NNS\2329401 and\CC\1740 is\VBZ\836236 only\RB\1740 weakly\RB\1740 teratogenic\JJ\1740 in\IN\13603305 rabbits\NNS\2323902 .\.\1740
C007112_D001176 CID In\IN\13603305 summary\NN\6722453 ,\,\1740 the\DT\1740 chick\JJ\1740 embryo\NN\17222 provides\VBZ\2199590 a\DT\13649268 reliable\JJ\1740 and\CC\1740 simple\JJ\1740 experimental\JJ\1740 animal\JJ\1740 model\NN\5888929 of\IN\1740 <e1>coniine-induced</e1>\JJ\1740 <e2>arthrogryposis</e2>\NN\1740 .\.\1740
C007112_D009140 NONE The\DT\1740 <e2>deformations</e2>\NNS\7420770 caused\VBN\1617192 by\IN\1740 both\CC\1740 <e1>coniine</e1>\NN\1740 and\CC\1740 nicotine\NN\14712692 sulfate\NN\15010703 were\VBD\836236 excessive\JJ\1740 flexion\NN\14034177 or\CC\3541091 extension\NN\15272029 of\IN\1740 one\CD\13741022 or\CC\3541091 more\JJR\1740 toes\NNS\5566097 .\.\1740
C007112_D009140 NONE The\DT\1740 deformations\NNS\7420770 caused\VBN\1617192 by\IN\1740 both\CC\1740 <e1>coniine</e1>\NN\1740 and\CC\1740 nicotine\NN\14712692 sulfate\NN\15010703 were\VBD\836236 <e2>excessive\JJ\1740 flexion\NN\14034177 or\CC\3541091 extension\NN\15272029 of\IN\1740 one\CD\13741022 or\CC\3541091 more\JJR\1740 toes</e2>\NNS\5566097 .\.\1740
D009538_D009140 NONE The\DT\1740 <e2>deformations</e2>\NNS\7420770 caused\VBN\1617192 by\IN\1740 both\CC\1740 coniine\NN\1740 and\CC\1740 <e1>nicotine</e1>\NN\14712692 sulfate\NN\15010703 were\VBD\836236 excessive\JJ\1740 flexion\NN\14034177 or\CC\3541091 extension\NN\15272029 of\IN\1740 one\CD\13741022 or\CC\3541091 more\JJR\1740 toes\NNS\5566097 .\.\1740
D009538_D009140 NONE The\DT\1740 deformations\NNS\7420770 caused\VBN\1617192 by\IN\1740 both\CC\1740 coniine\NN\1740 and\CC\1740 <e1>nicotine</e1>\NN\14712692 sulfate\NN\15010703 were\VBD\836236 <e2>excessive\JJ\1740 flexion\NN\14034177 or\CC\3541091 extension\NN\15272029 of\IN\1740 one\CD\13741022 or\CC\3541091 more\JJR\1740 toes</e2>\NNS\5566097 .\.\1740
D009538_D002543 CID No\DT\7204911 histopathological\JJ\1740 alterations\NNS\7283608 or\CC\3541091 differences\NNS\4723816 in\IN\13603305 bone\NN\5286536 formation\NN\7938773 were\VBD\836236 seen\VBN\2106506 in\IN\13603305 the\DT\1740 limbs\NNS\5559908 or\CC\3541091 toes\NNS\5566097 of\IN\1740 any\DT\1740 chicks\NNS\1791625 from\IN\1740 any\DT\1740 group\NN\2137 ;\:\1740 however\RB\1740 ,\,\1740 extensive\JJ\1740 <e2>cranial\JJ\1740 hemorrhage</e2>\NN\14285662 occurred\VBD\2623529 in\IN\13603305 all\DT\1740 <e1>nicotine</e1>\NN\14712692 sulfate-treated\JJ\1740 chicks\NNS\1791625 .\.\1740
15863244
C106876_D064420 NONE Comparison\NN\635850 of\IN\1740 developmental\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 selective\JJ\1740 and\CC\1740 non-selective\JJ\1740 cyclooxygenase-2\NN\14737847 inhibitors\NNS\20090 in\IN\13603305 CRL:(WI)WUBR\NN\1740 Wistar\NNP\1740 rats\NNS\2329401 --\:\1740 <e1>DFU</e1>\NN\1740 and\CC\1740 piroxicam\NN\3828465 study\NN\635850 .\.\1740
C106876_D064420 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 experiment\NN\641820 was\VBD\836236 to\TO\1740 evaluate\VB\670261 the\DT\1740 developmental\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 the\DT\1740 non-selective\JJ\1740 (\-LRB-\1740 piroxicam\NNS\3828465 )\-RRB-\1740 and\CC\1740 selective\JJ\1740 (\-LRB-\1740 <e1>DFU</e1>\NN\1740 ;\:\1740 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl\NN\1740 )\-RRB-\1740 phenyl-2(5H)-furanon\NN\1740 )\-RRB-\1740 COX-2\NN\14737847 inhibitors\NNS\20090 .\.\1740
C106876_D064420 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 experiment\NN\641820 was\VBD\836236 to\TO\1740 evaluate\VB\670261 the\DT\1740 developmental\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 the\DT\1740 non-selective\JJ\1740 (\-LRB-\1740 piroxicam\NNS\3828465 )\-RRB-\1740 and\CC\1740 selective\JJ\1740 (\-LRB-\1740 DFU\NN\1740 ;\:\1740 <e1>5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl\NN\1740 )\-RRB-\1740 phenyl-2(5H)-furanon</e1>\NN\1740 )\-RRB-\1740 COX-2\NN\14737847 inhibitors\NNS\20090 .\.\1740
C106876_D064420 NONE Decrease\NN\7296428 of\IN\1740 fetal\JJ\1740 length\NN\5093581 was\VBD\836236 the\DT\1740 only\JJ\1740 signs\NNS\6643763 of\IN\1740 the\DT\1740 <e1>DFU</e1>\NN\1740 developmental\JJ\1740 <e2>toxicity</e2>\NN\13576101 observed\VBN\2163746 in\IN\13603305 pups\NNS\1321854 exposed\VBN\2110927 to\TO\1740 the\DT\1740 highest\JJS\1740 compound\NN\5869584 dose\NN\3740161 .\.\1740
D010894_D064420 NONE Comparison\NN\635850 of\IN\1740 developmental\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 selective\JJ\1740 and\CC\1740 non-selective\JJ\1740 cyclooxygenase-2\NN\14737847 inhibitors\NNS\20090 in\IN\13603305 CRL:(WI)WUBR\NN\1740 Wistar\NNP\1740 rats\NNS\2329401 --\:\1740 DFU\NN\1740 and\CC\1740 <e1>piroxicam</e1>\NN\3828465 study\NN\635850 .\.\1740
D010894_D064420 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 the\DT\1740 experiment\NN\641820 was\VBD\836236 to\TO\1740 evaluate\VB\670261 the\DT\1740 developmental\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 the\DT\1740 non-selective\JJ\1740 (\-LRB-\1740 <e1>piroxicam</e1>\NNS\3828465 )\-RRB-\1740 and\CC\1740 selective\JJ\1740 (\-LRB-\1740 DFU\NN\1740 ;\:\1740 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulphonyl\NN\1740 )\-RRB-\1740 phenyl-2(5H)-furanon\NN\1740 )\-RRB-\1740 COX-2\NN\14737847 inhibitors\NNS\20090 .\.\1740
D010894_D064420 NONE RESULTS\NNS\34213 :\:\1740 Maternal\JJ\1740 <e2>toxicity</e2>\NN\13576101 ,\,\1740 intrauterine\NN\1740 growth\NN\13526110 retardation\NN\7296428 ,\,\1740 and\CC\1740 increase\NN\13576355 of\IN\1740 external\JJ\1740 and\CC\1740 skeletal\JJ\1740 variations\NNS\7296428 were\VBD\836236 found\VBN\2426171 in\IN\13603305 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 the\DT\1740 highest\JJS\1740 dose\NN\3740161 of\IN\1740 <e1>piroxicam</e1>\NN\3828465 .\.\1740
D010894_D006345 NONE The\DT\1740 pooled\VBN\2295550 statistical\JJ\1740 analysis\NN\633864 for\IN\1740 <e2>ventricular\JJ\1740 septal\NN\1740 (\-LRB-\1740 VSD\NN\1740 )\-RRB-\1740 and\CC\1740 midline\NN\13861050 (\-LRB-\1740 MD\NN\14622893 )\-RRB-\1740 defects</e2>\NNS\14462666 was\VBD\836236 performed\VBN\2367363 for\IN\1740 rat\NN\2329401 fetuses\NNS\1471682 exposed\VBN\2110927 to\TO\1740 <e1>piroxicam</e1>\VB\1740 ,\,\1740 selective\JJ\1740 and\CC\1740 non-selective\JJ\1740 COX-2\NN\14737847 inhibitor\NN\20090 based\VBN\2694933 on\IN\1740 present\JJ\1740 and\CC\1740 historic\JJ\1740 data\NNS\7951464 .\.\1740
D010894_D009436 NONE The\DT\1740 pooled\VBN\2295550 statistical\JJ\1740 analysis\NN\633864 for\IN\1740 <e2>ventricular\JJ\1740 septal\NN\1740 (\-LRB-\1740 VSD\NN\1740 )\-RRB-\1740 and\CC\1740 midline\NN\13861050 (\-LRB-\1740 MD\NN\14622893 )\-RRB-\1740 defects</e2>\NNS\14462666 was\VBD\836236 performed\VBN\2367363 for\IN\1740 rat\NN\2329401 fetuses\NNS\1471682 exposed\VBN\2110927 to\TO\1740 <e1>piroxicam</e1>\VB\1740 ,\,\1740 selective\JJ\1740 and\CC\1740 non-selective\JJ\1740 COX-2\NN\14737847 inhibitor\NN\20090 based\VBN\2694933 on\IN\1740 present\JJ\1740 and\CC\1740 historic\JJ\1740 data\NNS\7951464 .\.\1740
D010894_D005317 CID RESULTS\NNS\34213 :\:\1740 Maternal\JJ\1740 toxicity\NN\13576101 ,\,\1740 <e2>intrauterine\NN\1740 growth\NN\13526110 retardation</e2>\NN\7296428 ,\,\1740 and\CC\1740 increase\NN\13576355 of\IN\1740 external\JJ\1740 and\CC\1740 skeletal\JJ\1740 variations\NNS\7296428 were\VBD\836236 found\VBN\2426171 in\IN\13603305 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 the\DT\1740 highest\JJS\1740 dose\NN\3740161 of\IN\1740 <e1>piroxicam</e1>\NN\3828465 .\.\1740
D010894_D009139 CID RESULTS\NNS\34213 :\:\1740 Maternal\JJ\1740 toxicity\NN\13576101 ,\,\1740 intrauterine\NN\1740 growth\NN\13526110 retardation\NN\7296428 ,\,\1740 and\CC\1740 <e2>increase\NN\13576355 of\IN\1740 external\JJ\1740 and\CC\1740 skeletal\JJ\1740 variations</e2>\NNS\7296428 were\VBD\836236 found\VBN\2426171 in\IN\13603305 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 the\DT\1740 highest\JJS\1740 dose\NN\3740161 of\IN\1740 <e1>piroxicam</e1>\NN\3828465 .\.\1740
9495837
C087567_D000647 NONE <e1>(+/-)-PG-9</e1>\NN\1740 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 40\CD\13745420 mg\NN\13717155 kg-1\NN\1740 i.p.\RB\1740 )\-RRB-\1740 was\VBD\836236 able\JJ\1740 to\TO\1740 prevent\VB\1740 <e2>amnesia</e2>\NN\5669934 induced\VBN\1627355 by\IN\1740 scopolamine\NN\14712692 (\-LRB-\1740 1\CD\13741022 mg\NN\13717155 kg-1\NN\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 dicyclomine\NN\1740 (\-LRB-\1740 2\CD\13741022 mg\NN\13717155 kg-1\NN\1740 i.p.\RB\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 mouse\NN\2329401 passive-avoidance\NN\1740 test\NN\5798043 .\.\1740
C087567_D000647 NONE Affinity\NN\11426530 profiles\NNS\6999802 of\IN\1740 <e1>(+/-)-PG-9</e1>\NN\1740 for\IN\1740 muscarinic\JJ\1740 receptor\NN\5225602 subtypes\NNS\1740 ,\,\1740 determined\VBN\1645601 by\IN\1740 functional\JJ\1740 studies\NNS\635850 (\-LRB-\1740 rabbit\NN\2323902 vas\NN\5246511 deferens\NNS\1740 for\IN\1740 M1\NN\13357178 ,\,\1740 guinea\NN\13388245 pig\NN\2395003 atrium\NN\5392744 for\IN\1740 M2\NN\13357178 ,\,\1740 guinea\NN\13388245 pig\NN\2395003 ileum\NN\5534712 for\IN\1740 M3\NN\13357178 and\CC\1740 immature\JJ\1740 guinea\NN\13388245 pig\NN\2395003 uterus\NN\5514717 for\IN\1740 putative\JJ\1740 M4\NN\1740 )\-RRB-\1740 ,\,\1740 have\VBP\2108377 shown\VBN\2137132 an\DT\6697703 M4/M1\NN\1740 selectivity\NN\4916342 ratio\NN\13815152 of\IN\1740 10.2\CD\1740 that\WDT\1740 might\MD\5029706 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 antinociception\NN\1740 and\CC\1740 the\DT\1740 <e2>anti-amnesic</e2>\JJ\1740 effect\NN\34213 induced\VBN\1627355 by\IN\1740 (+/-)-PG-9\NN\1740 through\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 acetylcholine\NN\14807558 extracellular\JJ\1740 levels\NNS\4916342 .\.\1740
C087567_D000647 NONE Affinity\NN\11426530 profiles\NNS\6999802 of\IN\1740 (+/-)-PG-9\NN\1740 for\IN\1740 muscarinic\JJ\1740 receptor\NN\5225602 subtypes\NNS\1740 ,\,\1740 determined\VBN\1645601 by\IN\1740 functional\JJ\1740 studies\NNS\635850 (\-LRB-\1740 rabbit\NN\2323902 vas\NN\5246511 deferens\NNS\1740 for\IN\1740 M1\NN\13357178 ,\,\1740 guinea\NN\13388245 pig\NN\2395003 atrium\NN\5392744 for\IN\1740 M2\NN\13357178 ,\,\1740 guinea\NN\13388245 pig\NN\2395003 ileum\NN\5534712 for\IN\1740 M3\NN\13357178 and\CC\1740 immature\JJ\1740 guinea\NN\13388245 pig\NN\2395003 uterus\NN\5514717 for\IN\1740 putative\JJ\1740 M4\NN\1740 )\-RRB-\1740 ,\,\1740 have\VBP\2108377 shown\VBN\2137132 an\DT\6697703 M4/M1\NN\1740 selectivity\NN\4916342 ratio\NN\13815152 of\IN\1740 10.2\CD\1740 that\WDT\1740 might\MD\5029706 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 antinociception\NN\1740 and\CC\1740 the\DT\1740 <e2>anti-amnesic</e2>\JJ\1740 effect\NN\34213 induced\VBN\1627355 by\IN\1740 <e1>(+/-)-PG-9</e1>\NN\1740 through\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 acetylcholine\NN\14807558 extracellular\JJ\1740 levels\NNS\4916342 .\.\1740
D012601_D000647 CID (+/-)-PG-9\NN\1740 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 40\CD\13745420 mg\NN\13717155 kg-1\NN\1740 i.p.\RB\1740 )\-RRB-\1740 was\VBD\836236 able\JJ\1740 to\TO\1740 prevent\VB\1740 <e2>amnesia</e2>\NN\5669934 induced\VBN\1627355 by\IN\1740 <e1>scopolamine</e1>\NN\14712692 (\-LRB-\1740 1\CD\13741022 mg\NN\13717155 kg-1\NN\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 dicyclomine\NN\1740 (\-LRB-\1740 2\CD\13741022 mg\NN\13717155 kg-1\NN\1740 i.p.\RB\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 mouse\NN\2329401 passive-avoidance\NN\1740 test\NN\5798043 .\.\1740
D004025_D000647 CID (+/-)-PG-9\NN\1740 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 40\CD\13745420 mg\NN\13717155 kg-1\NN\1740 i.p.\RB\1740 )\-RRB-\1740 was\VBD\836236 able\JJ\1740 to\TO\1740 prevent\VB\1740 <e2>amnesia</e2>\NN\5669934 induced\VBN\1627355 by\IN\1740 scopolamine\NN\14712692 (\-LRB-\1740 1\CD\13741022 mg\NN\13717155 kg-1\NN\1740 i.p.\RB\1740 )\-RRB-\1740 and\CC\1740 <e1>dicyclomine</e1>\NN\1740 (\-LRB-\1740 2\CD\13741022 mg\NN\13717155 kg-1\NN\1740 i.p.\RB\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 mouse\NN\2329401 passive-avoidance\NN\1740 test\NN\5798043 .\.\1740
D000109_D000647 NONE Affinity\NN\11426530 profiles\NNS\6999802 of\IN\1740 (+/-)-PG-9\NN\1740 for\IN\1740 muscarinic\JJ\1740 receptor\NN\5225602 subtypes\NNS\1740 ,\,\1740 determined\VBN\1645601 by\IN\1740 functional\JJ\1740 studies\NNS\635850 (\-LRB-\1740 rabbit\NN\2323902 vas\NN\5246511 deferens\NNS\1740 for\IN\1740 M1\NN\13357178 ,\,\1740 guinea\NN\13388245 pig\NN\2395003 atrium\NN\5392744 for\IN\1740 M2\NN\13357178 ,\,\1740 guinea\NN\13388245 pig\NN\2395003 ileum\NN\5534712 for\IN\1740 M3\NN\13357178 and\CC\1740 immature\JJ\1740 guinea\NN\13388245 pig\NN\2395003 uterus\NN\5514717 for\IN\1740 putative\JJ\1740 M4\NN\1740 )\-RRB-\1740 ,\,\1740 have\VBP\2108377 shown\VBN\2137132 an\DT\6697703 M4/M1\NN\1740 selectivity\NN\4916342 ratio\NN\13815152 of\IN\1740 10.2\CD\1740 that\WDT\1740 might\MD\5029706 be\VB\836236 responsible\JJ\1740 for\IN\1740 the\DT\1740 antinociception\NN\1740 and\CC\1740 the\DT\1740 <e2>anti-amnesic</e2>\JJ\1740 effect\NN\34213 induced\VBN\1627355 by\IN\1740 (+/-)-PG-9\NN\1740 through\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 <e1>acetylcholine</e1>\NN\14807558 extracellular\JJ\1740 levels\NNS\4916342 .\.\1740
11875660
D001374_D009436 NONE We\PRP\1740 observed\VBD\2163746 the\DT\1740 <e2>exencephaly</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>5-azacytidine</e1>\NN\1740 at\IN\14622893 embryonic\JJ\1740 day\NN\15154774 13.5\CD\1740 (\-LRB-\1740 E13.5\NN\1740 )\-RRB-\1740 ,\,\1740 let\VB\770437 the\DT\1740 embryos\NNS\17222 develop\VBP\1753788 exo\NN\1740 utero\NN\1740 until\IN\1740 E18.5\NNP\1740 ,\,\1740 and\CC\1740 re-observed\VBD\1740 the\DT\1740 same\JJ\1740 embryos\NNS\17222 at\IN\14622893 E18.5\NN\1740 .\.\1740
17532790
D007980_D004409 CID Proteomic\JJ\1740 analysis\NN\633864 of\IN\1740 striatal\JJ\1740 proteins\NNS\14944888 in\IN\13603305 the\DT\1740 rat\NN\2329401 model\NN\5888929 of\IN\1740 <e1>L-DOPA-induced</e1>\JJ\1740 <e2>dyskinesia</e2>\NN\14084880 .\.\1740
D007980_D004409 CID <e1>L-DOPA-induced</e1>\VBN\1740 <e2>dyskinesia</e2>\NN\14084880 (\-LRB-\1740 LID\NN\5313679 )\-RRB-\1740 is\VBZ\836236 among\IN\1740 the\DT\1740 motor\NN\3699975 complications\NNS\1073995 that\WDT\1740 arise\VBP\2623529 in\IN\13603305 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 patients\NNS\9898892 after\IN\1740 a\DT\13649268 prolonged\JJ\1740 treatment\NN\654885 with\IN\1740 L-DOPA\NN\14604959 .\.\1740
D007980_D004409 CID <e1>L-DOPA-induced</e1>\VBN\1740 dyskinesia\NN\14084880 (\-LRB-\1740 <e2>LID</e2>\NN\5313679 )\-RRB-\1740 is\VBZ\836236 among\IN\1740 the\DT\1740 motor\NN\3699975 complications\NNS\1073995 that\WDT\1740 arise\VBP\2623529 in\IN\13603305 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 patients\NNS\9898892 after\IN\1740 a\DT\13649268 prolonged\JJ\1740 treatment\NN\654885 with\IN\1740 L-DOPA\NN\14604959 .\.\1740
D007980_D004409 CID L-DOPA-induced\VBN\1740 <e2>dyskinesia</e2>\NN\14084880 (\-LRB-\1740 LID\NN\5313679 )\-RRB-\1740 is\VBZ\836236 among\IN\1740 the\DT\1740 motor\NN\3699975 complications\NNS\1073995 that\WDT\1740 arise\VBP\2623529 in\IN\13603305 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 patients\NNS\9898892 after\IN\1740 a\DT\13649268 prolonged\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>L-DOPA</e1>\NN\14604959 .\.\1740
D007980_D004409 CID L-DOPA-induced\VBN\1740 dyskinesia\NN\14084880 (\-LRB-\1740 <e2>LID</e2>\NN\5313679 )\-RRB-\1740 is\VBZ\836236 among\IN\1740 the\DT\1740 motor\NN\3699975 complications\NNS\1073995 that\WDT\1740 arise\VBP\2623529 in\IN\13603305 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 patients\NNS\9898892 after\IN\1740 a\DT\13649268 prolonged\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>L-DOPA</e1>\NN\14604959 .\.\1740
D007980_D004409 CID Rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 <e1>L-DOPA</e1>\NN\14604959 were\VBD\836236 allocated\VBN\2228698 to\TO\1740 two\CD\13741022 groups\NNS\2137 based\VBN\2694933 on\IN\1740 the\DT\1740 presence\NN\13954253 or\CC\3541091 absence\NN\14449405 of\IN\1740 <e2>LID</e2>\NN\5313679 .\.\1740
D007980_D010300 NONE <e1>L-DOPA-induced</e1>\VBN\1740 dyskinesia\NN\14084880 (\-LRB-\1740 LID\NN\5313679 )\-RRB-\1740 is\VBZ\836236 among\IN\1740 the\DT\1740 motor\NN\3699975 complications\NNS\1073995 that\WDT\1740 arise\VBP\2623529 in\IN\13603305 <e2>Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 patients\NNS\9898892 after\IN\1740 a\DT\13649268 prolonged\JJ\1740 treatment\NN\654885 with\IN\1740 L-DOPA\NN\14604959 .\.\1740
D007980_D010300 NONE <e1>L-DOPA-induced</e1>\VBN\1740 dyskinesia\NN\14084880 (\-LRB-\1740 LID\NN\5313679 )\-RRB-\1740 is\VBZ\836236 among\IN\1740 the\DT\1740 motor\NN\3699975 complications\NNS\1073995 that\WDT\1740 arise\VBP\2623529 in\IN\13603305 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 <e2>PD</e2>\NN\14625458 )\-RRB-\1740 patients\NNS\9898892 after\IN\1740 a\DT\13649268 prolonged\JJ\1740 treatment\NN\654885 with\IN\1740 L-DOPA\NN\14604959 .\.\1740
D007980_D010300 NONE L-DOPA-induced\VBN\1740 dyskinesia\NN\14084880 (\-LRB-\1740 LID\NN\5313679 )\-RRB-\1740 is\VBZ\836236 among\IN\1740 the\DT\1740 motor\NN\3699975 complications\NNS\1073995 that\WDT\1740 arise\VBP\2623529 in\IN\13603305 <e2>Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 patients\NNS\9898892 after\IN\1740 a\DT\13649268 prolonged\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>L-DOPA</e1>\NN\14604959 .\.\1740
D007980_D010300 NONE L-DOPA-induced\VBN\1740 dyskinesia\NN\14084880 (\-LRB-\1740 LID\NN\5313679 )\-RRB-\1740 is\VBZ\836236 among\IN\1740 the\DT\1740 motor\NN\3699975 complications\NNS\1073995 that\WDT\1740 arise\VBP\2623529 in\IN\13603305 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 <e2>PD</e2>\NN\14625458 )\-RRB-\1740 patients\NNS\9898892 after\IN\1740 a\DT\13649268 prolonged\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>L-DOPA</e1>\NN\14604959 .\.\1740
D007980_D010300 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 investigated\VBD\644583 the\DT\1740 changes\NNS\7283608 occurring\VBG\2623529 at\IN\14622893 the\DT\1740 protein\NN\14944888 level\NN\4916342 in\IN\13603305 striatal\JJ\1740 samples\NNS\5820620 obtained\VBN\2210855 from\IN\1740 the\DT\1740 unilaterally\RB\1740 6-hydroxydopamine-lesion\NN\1740 rat\NN\2329401 model\NN\5888929 of\IN\1740 <e2>PD</e2>\NN\14625458 treated\VBN\2376958 with\IN\1740 saline\NN\14849367 ,\,\1740 <e1>L-DOPA</e1>\NN\14604959 or\CC\3541091 bromocriptine\NN\1740 using\VBG\1156834 two-dimensional\JJ\1740 difference\NN\4723816 gel\NN\14588219 electrophoresis\NN\13518963 and\CC\1740 mass\JJ\1740 spectrometry\NN\646833 (\-LRB-\1740 MS\NN\14187378 )\-RRB-\1740 .\.\1740
D016627_D010300 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 investigated\VBD\644583 the\DT\1740 changes\NNS\7283608 occurring\VBG\2623529 at\IN\14622893 the\DT\1740 protein\NN\14944888 level\NN\4916342 in\IN\13603305 striatal\JJ\1740 samples\NNS\5820620 obtained\VBN\2210855 from\IN\1740 the\DT\1740 unilaterally\RB\1740 <e1>6-hydroxydopamine-lesion</e1>\NN\1740 rat\NN\2329401 model\NN\5888929 of\IN\1740 <e2>PD</e2>\NN\14625458 treated\VBN\2376958 with\IN\1740 saline\NN\14849367 ,\,\1740 L-DOPA\NN\14604959 or\CC\3541091 bromocriptine\NN\1740 using\VBG\1156834 two-dimensional\JJ\1740 difference\NN\4723816 gel\NN\14588219 electrophoresis\NN\13518963 and\CC\1740 mass\JJ\1740 spectrometry\NN\646833 (\-LRB-\1740 MS\NN\14187378 )\-RRB-\1740 .\.\1740
D001971_D010300 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 investigated\VBD\644583 the\DT\1740 changes\NNS\7283608 occurring\VBG\2623529 at\IN\14622893 the\DT\1740 protein\NN\14944888 level\NN\4916342 in\IN\13603305 striatal\JJ\1740 samples\NNS\5820620 obtained\VBN\2210855 from\IN\1740 the\DT\1740 unilaterally\RB\1740 6-hydroxydopamine-lesion\NN\1740 rat\NN\2329401 model\NN\5888929 of\IN\1740 <e2>PD</e2>\NN\14625458 treated\VBN\2376958 with\IN\1740 saline\NN\14849367 ,\,\1740 L-DOPA\NN\14604959 or\CC\3541091 <e1>bromocriptine</e1>\NN\1740 using\VBG\1156834 two-dimensional\JJ\1740 difference\NN\4723816 gel\NN\14588219 electrophoresis\NN\13518963 and\CC\1740 mass\JJ\1740 spectrometry\NN\646833 (\-LRB-\1740 MS\NN\14187378 )\-RRB-\1740 .\.\1740
11198499
C023754_D007022 CID <e2>Hypotension</e2>\NN\14057371 following\VBG\1835496 the\DT\1740 initiation\NN\7450842 of\IN\1740 <e1>tizanidine</e1>\NN\1740 in\IN\13603305 a\DT\13649268 patient\NN\9898892 treated\VBN\2376958 with\IN\1740 an\DT\6697703 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 for\IN\1740 chronic\JJ\1740 hypertension\NN\14057371 .\.\1740
C023754_D007022 CID The\DT\1740 authors\NNS\9610660 present\VBP\2137132 a\DT\13649268 10-year-old\JJ\1740 boy\NN\9624168 chronically\RB\1740 treated\VBN\2376958 with\IN\1740 lisinopril\NN\2673637 ,\,\1740 an\DT\6697703 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 ,\,\1740 to\TO\1740 control\VB\2422663 hypertension\NN\14057371 who\WP\8299493 developed\VBD\1753788 <e2>hypotension</e2>\NN\14057371 following\VBG\1835496 the\DT\1740 addition\NN\3081021 of\IN\1740 <e1>tizanidine</e1>\NN\1740 ,\,\1740 an\DT\6697703 alpha-2\NN\1740 agonist\NN\9613191 ,\,\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 spasticity\NN\4770535 .\.\1740
C023754_D006973 NONE Hypotension\NN\14057371 following\VBG\1835496 the\DT\1740 initiation\NN\7450842 of\IN\1740 <e1>tizanidine</e1>\NN\1740 in\IN\13603305 a\DT\13649268 patient\NN\9898892 treated\VBN\2376958 with\IN\1740 an\DT\6697703 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 for\IN\1740 chronic\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
C023754_D006973 NONE The\DT\1740 authors\NNS\9610660 present\VBP\2137132 a\DT\13649268 10-year-old\JJ\1740 boy\NN\9624168 chronically\RB\1740 treated\VBN\2376958 with\IN\1740 lisinopril\NN\2673637 ,\,\1740 an\DT\6697703 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 ,\,\1740 to\TO\1740 control\VB\2422663 <e2>hypertension</e2>\NN\14057371 who\WP\8299493 developed\VBD\1753788 hypotension\NN\14057371 following\VBG\1835496 the\DT\1740 addition\NN\3081021 of\IN\1740 <e1>tizanidine</e1>\NN\1740 ,\,\1740 an\DT\6697703 alpha-2\NN\1740 agonist\NN\9613191 ,\,\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 spasticity\NN\4770535 .\.\1740
C023754_D006973 NONE The\DT\1740 possible\JJ\1740 interaction\NN\37396 of\IN\1740 <e1>tizanidine</e1>\NN\1740 and\CC\1740 other\JJ\1740 antihypertensive\JJ\1740 agents\NNS\7347 should\MD\1740 be\VB\836236 kept\VBN\2367363 in\IN\13603305 mind\NN\23271 when\WRB\1740 prescribing\NN\1740 therapy\NN\657604 to\TO\1740 treat\VB\2376958 either\CC\1740 <e2>hypertension</e2>\NN\14057371 or\CC\3541091 spasticity\NN\4770535 in\IN\13603305 such\JJ\1740 patients\NNS\9898892 .\.\1740
D000809_D007022 NONE <e2>Hypotension</e2>\NN\14057371 following\VBG\1835496 the\DT\1740 initiation\NN\7450842 of\IN\1740 tizanidine\NN\1740 in\IN\13603305 a\DT\13649268 patient\NN\9898892 treated\VBN\2376958 with\IN\1740 an\DT\6697703 <e1>angiotensin</e1>\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 for\IN\1740 chronic\JJ\1740 hypertension\NN\14057371 .\.\1740
D000809_D007022 NONE Adults\NNS\7846 chronically\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>angiotensin</e1>\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitors\NNS\20090 may\MD\15209706 have\VB\2108377 a\DT\13649268 limited\JJ\1740 ability\NN\4723816 to\TO\1740 respond\VB\2367363 to\TO\1740 <e2>hypotension</e2>\NN\14057371 when\WRB\1740 the\DT\1740 sympathetic\JJ\1740 response\NN\11410625 is\VBZ\836236 simultaneously\RB\1740 blocked\VBN\1476483 .\.\1740
D000809_D007022 NONE The\DT\1740 authors\NNS\9610660 present\VBP\2137132 a\DT\13649268 10-year-old\JJ\1740 boy\NN\9624168 chronically\RB\1740 treated\VBN\2376958 with\IN\1740 lisinopril\NN\2673637 ,\,\1740 an\DT\6697703 <e1>angiotensin</e1>\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 ,\,\1740 to\TO\1740 control\VB\2422663 hypertension\NN\14057371 who\WP\8299493 developed\VBD\1753788 <e2>hypotension</e2>\NN\14057371 following\VBG\1835496 the\DT\1740 addition\NN\3081021 of\IN\1740 tizanidine\NN\1740 ,\,\1740 an\DT\6697703 alpha-2\NN\1740 agonist\NN\9613191 ,\,\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 spasticity\NN\4770535 .\.\1740
D000809_D006973 NONE Hypotension\NN\14057371 following\VBG\1835496 the\DT\1740 initiation\NN\7450842 of\IN\1740 tizanidine\NN\1740 in\IN\13603305 a\DT\13649268 patient\NN\9898892 treated\VBN\2376958 with\IN\1740 an\DT\6697703 <e1>angiotensin</e1>\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 for\IN\1740 chronic\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D000809_D006973 NONE The\DT\1740 authors\NNS\9610660 present\VBP\2137132 a\DT\13649268 10-year-old\JJ\1740 boy\NN\9624168 chronically\RB\1740 treated\VBN\2376958 with\IN\1740 lisinopril\NN\2673637 ,\,\1740 an\DT\6697703 <e1>angiotensin</e1>\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 ,\,\1740 to\TO\1740 control\VB\2422663 <e2>hypertension</e2>\NN\14057371 who\WP\8299493 developed\VBD\1753788 hypotension\NN\14057371 following\VBG\1835496 the\DT\1740 addition\NN\3081021 of\IN\1740 tizanidine\NN\1740 ,\,\1740 an\DT\6697703 alpha-2\NN\1740 agonist\NN\9613191 ,\,\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 spasticity\NN\4770535 .\.\1740
D017706_D006973 NONE The\DT\1740 authors\NNS\9610660 present\VBP\2137132 a\DT\13649268 10-year-old\JJ\1740 boy\NN\9624168 chronically\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>lisinopril</e1>\NN\2673637 ,\,\1740 an\DT\6697703 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 ,\,\1740 to\TO\1740 control\VB\2422663 <e2>hypertension</e2>\NN\14057371 who\WP\8299493 developed\VBD\1753788 hypotension\NN\14057371 following\VBG\1835496 the\DT\1740 addition\NN\3081021 of\IN\1740 tizanidine\NN\1740 ,\,\1740 an\DT\6697703 alpha-2\NN\1740 agonist\NN\9613191 ,\,\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 spasticity\NN\4770535 .\.\1740
D017706_D007022 CID The\DT\1740 authors\NNS\9610660 present\VBP\2137132 a\DT\13649268 10-year-old\JJ\1740 boy\NN\9624168 chronically\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>lisinopril</e1>\NN\2673637 ,\,\1740 an\DT\6697703 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 ,\,\1740 to\TO\1740 control\VB\2422663 hypertension\NN\14057371 who\WP\8299493 developed\VBD\1753788 <e2>hypotension</e2>\NN\14057371 following\VBG\1835496 the\DT\1740 addition\NN\3081021 of\IN\1740 tizanidine\NN\1740 ,\,\1740 an\DT\6697703 alpha-2\NN\1740 agonist\NN\9613191 ,\,\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 spasticity\NN\4770535 .\.\1740
D017706_D009128 NONE The\DT\1740 authors\NNS\9610660 present\VBP\2137132 a\DT\13649268 10-year-old\JJ\1740 boy\NN\9624168 chronically\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>lisinopril</e1>\NN\2673637 ,\,\1740 an\DT\6697703 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 ,\,\1740 to\TO\1740 control\VB\2422663 hypertension\NN\14057371 who\WP\8299493 developed\VBD\1753788 hypotension\NN\14057371 following\VBG\1835496 the\DT\1740 addition\NN\3081021 of\IN\1740 tizanidine\NN\1740 ,\,\1740 an\DT\6697703 alpha-2\NN\1740 agonist\NN\9613191 ,\,\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>spasticity</e2>\NN\4770535 .\.\1740
D000809_D009128 NONE The\DT\1740 authors\NNS\9610660 present\VBP\2137132 a\DT\13649268 10-year-old\JJ\1740 boy\NN\9624168 chronically\RB\1740 treated\VBN\2376958 with\IN\1740 lisinopril\NN\2673637 ,\,\1740 an\DT\6697703 <e1>angiotensin</e1>\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 ,\,\1740 to\TO\1740 control\VB\2422663 hypertension\NN\14057371 who\WP\8299493 developed\VBD\1753788 hypotension\NN\14057371 following\VBG\1835496 the\DT\1740 addition\NN\3081021 of\IN\1740 tizanidine\NN\1740 ,\,\1740 an\DT\6697703 alpha-2\NN\1740 agonist\NN\9613191 ,\,\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>spasticity</e2>\NN\4770535 .\.\1740
C023754_D009128 NONE The\DT\1740 authors\NNS\9610660 present\VBP\2137132 a\DT\13649268 10-year-old\JJ\1740 boy\NN\9624168 chronically\RB\1740 treated\VBN\2376958 with\IN\1740 lisinopril\NN\2673637 ,\,\1740 an\DT\6697703 angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 inhibitor\NN\20090 ,\,\1740 to\TO\1740 control\VB\2422663 hypertension\NN\14057371 who\WP\8299493 developed\VBD\1753788 hypotension\NN\14057371 following\VBG\1835496 the\DT\1740 addition\NN\3081021 of\IN\1740 <e1>tizanidine</e1>\NN\1740 ,\,\1740 an\DT\6697703 alpha-2\NN\1740 agonist\NN\9613191 ,\,\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>spasticity</e2>\NN\4770535 .\.\1740
C023754_D009128 NONE The\DT\1740 possible\JJ\1740 interaction\NN\37396 of\IN\1740 <e1>tizanidine</e1>\NN\1740 and\CC\1740 other\JJ\1740 antihypertensive\JJ\1740 agents\NNS\7347 should\MD\1740 be\VB\836236 kept\VBN\2367363 in\IN\13603305 mind\NN\23271 when\WRB\1740 prescribing\NN\1740 therapy\NN\657604 to\TO\1740 treat\VB\2376958 either\CC\1740 hypertension\NN\14057371 or\CC\3541091 <e2>spasticity</e2>\NN\4770535 in\IN\13603305 such\JJ\1740 patients\NNS\9898892 .\.\1740
8423889
D005473_D009069 CID Increase\NN\13576355 of\IN\1740 <e2>Parkinson\NN\1740 disability</e2>\NN\14547369 after\IN\1740 <e1>fluoxetine</e1>\NN\4169152 medication\NN\3247620 .\.\1740
D005473_D009069 CID We\PRP\1740 report\VBP\831651 the\DT\1740 increased\VBN\169651 amount\NN\13329641 of\IN\1740 <e2>motor\NN\3699975 disability</e2>\NN\14547369 in\IN\13603305 four\CD\13741022 patients\NNS\9898892 with\IN\1740 idiopathic\JJ\1740 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 after\IN\1740 exposure\NN\5042871 to\TO\1740 the\DT\1740 antidepressant\JJ\1740 <e1>fluoxetine</e1>\NN\4169152 .\.\1740
D000928_D009069 NONE We\PRP\1740 report\VBP\831651 the\DT\1740 increased\VBN\169651 amount\NN\13329641 of\IN\1740 <e2>motor\NN\3699975 disability</e2>\NN\14547369 in\IN\13603305 four\CD\13741022 patients\NNS\9898892 with\IN\1740 idiopathic\JJ\1740 Parkinson\NNP\1740 's\POS\1740 disease\NN\14061805 after\IN\1740 exposure\NN\5042871 to\TO\1740 the\DT\1740 <e1>antidepressant</e1>\JJ\1740 fluoxetine\NN\4169152 .\.\1740
D000928_D010300 NONE We\PRP\1740 report\VBP\831651 the\DT\1740 increased\VBN\169651 amount\NN\13329641 of\IN\1740 motor\NN\3699975 disability\NN\14547369 in\IN\13603305 four\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>idiopathic\JJ\1740 Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 after\IN\1740 exposure\NN\5042871 to\TO\1740 the\DT\1740 <e1>antidepressant</e1>\JJ\1740 fluoxetine\NN\4169152 .\.\1740
D005473_D010300 NONE We\PRP\1740 report\VBP\831651 the\DT\1740 increased\VBN\169651 amount\NN\13329641 of\IN\1740 motor\NN\3699975 disability\NN\14547369 in\IN\13603305 four\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>idiopathic\JJ\1740 Parkinson\NNP\1740 's\POS\1740 disease</e2>\NN\14061805 after\IN\1740 exposure\NN\5042871 to\TO\1740 the\DT\1740 antidepressant\JJ\1740 <e1>fluoxetine</e1>\NN\4169152 .\.\1740
D005473_D010300 NONE The\DT\1740 possibility\NN\5944958 of\IN\1740 a\DT\13649268 clinically\RB\1740 relevant\JJ\1740 dopamine-antagonistic\JJ\1740 capacity\NN\5202497 of\IN\1740 <e1>fluoxetine</e1>\NN\4169152 in\IN\13603305 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 patients\NNS\9898892 must\MD\9367203 be\VB\836236 considered\VBN\689344 .\.\1740
D004298_D010300 NONE The\DT\1740 possibility\NN\5944958 of\IN\1740 a\DT\13649268 clinically\RB\1740 relevant\JJ\1740 <e1>dopamine-antagonistic</e1>\JJ\1740 capacity\NN\5202497 of\IN\1740 fluoxetine\NN\4169152 in\IN\13603305 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 patients\NNS\9898892 must\MD\9367203 be\VB\836236 considered\VBN\689344 .\.\1740
1420741
D005672_D003424 NONE Treatment\NN\654885 of\IN\1740 <e2>Crohn\NN\1740 's\POS\1740 disease</e2>\NN\14061805 with\IN\1740 <e1>fusidic\JJ\1740 acid</e1>\NN\14818238 :\:\1740 an\DT\6697703 antibiotic\NN\2716205 with\IN\1740 immunosuppressive\JJ\1740 properties\NNS\32613 similar\JJ\1740 to\TO\1740 cyclosporin\NN\1740 .\.\1740
D005672_D003424 NONE Because\IN\1740 of\IN\1740 the\DT\1740 need\NN\13920835 for\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 new\JJ\1740 treatments\NNS\654885 for\IN\1740 <e2>Crohn\NN\1740 's\POS\1740 disease</e2>\NN\14061805 ,\,\1740 a\DT\13649268 pilot\NN\9826204 study\NN\635850 was\VBD\836236 undertaken\VBN\1641914 to\TO\1740 estimate\VB\637259 the\DT\1740 pharmacodynamics\NNS\1740 and\CC\1740 tolerability\NN\1740 of\IN\1740 <e1>fusidic\JJ\1740 acid</e1>\NN\14818238 treatment\NN\654885 in\IN\13603305 chronic\JJ\1740 active\JJ\1740 ,\,\1740 therapy-resistant\JJ\1740 patients\NNS\9898892 .\.\1740
D005672_D003424 NONE The\DT\1740 results\NNS\34213 of\IN\1740 this\DT\1740 pilot\NN\9826204 study\NN\635850 suggest\VBP\1010118 that\IN\1740 <e1>fusidic\JJ\1740 acid</e1>\NN\14818238 may\MD\15209706 be\VB\836236 of\IN\1740 benefit\NN\13278375 in\IN\13603305 selected\VBN\697589 chronic\JJ\1740 active\JJ\1740 <e2>Crohn\NN\1740 's\POS\1740 disease</e2>\NN\14061805 patients\NNS\9898892 in\IN\13603305 whom\WP\1740 conventional\JJ\1740 treatment\NN\654885 is\VBZ\836236 ineffective\JJ\1740 .\.\1740
D016572_D003424 NONE Treatment\NN\654885 of\IN\1740 <e2>Crohn\NN\1740 's\POS\1740 disease</e2>\NN\14061805 with\IN\1740 fusidic\JJ\1740 acid\NN\14818238 :\:\1740 an\DT\6697703 antibiotic\NN\2716205 with\IN\1740 immunosuppressive\JJ\1740 properties\NNS\32613 similar\JJ\1740 to\TO\1740 <e1>cyclosporin</e1>\NN\1740 .\.\1740
D005672_D015212 NONE Because\IN\1740 there\EX\27167 seems\VBZ\2604760 to\TO\1740 exist\VB\1740 a\DT\13649268 scientific\JJ\1740 rationale\NN\5793000 for\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>fusidic\JJ\1740 acid</e1>\NN\14818238 at\IN\14622893 the\DT\1740 cytokine\NN\14728724 level\NN\4916342 in\IN\13603305 <e2>inflammatory\JJ\1740 bowel\NN\5298729 disease</e2>\NN\14061805 ,\,\1740 we\PRP\1740 suggest\VBP\1010118 that\IN\1740 the\DT\1740 role\NN\719494 of\IN\1740 this\DT\1740 treatment\NN\654885 should\MD\1740 be\VB\836236 further\RB\1740 investigated\VBN\644583 .\.\1740
18703024
D006220_D002375 CID No\DT\7204911 changes\NNS\7283608 in\IN\13603305 <e1>haloperidol-induced</e1>\JJ\1740 <e2>catalepsy</e2>\NN\14023236 or\CC\3541091 MK-801-induced\JJ\1740 locomotion\NN\4773351 were\VBD\836236 seen\VBN\2106506 following\VBG\1835496 PD\NN\14625458 .\.\1740
D016291_D002375 NONE No\DT\7204911 changes\NNS\7283608 in\IN\13603305 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 or\CC\3541091 <e1>MK-801-induced</e1>\JJ\1740 locomotion\NN\4773351 were\VBD\836236 seen\VBN\2106506 following\VBG\1835496 PD\NN\14625458 .\.\1740
11679859
D011346_D017109 CID Intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>prochlorperazine</e1>\NN\2719750 by\IN\1740 15-minute\JJ\1740 infusion\NN\14589223 versus\CC\1740 2-minute\JJ\1740 bolus\NN\13899404 does\VBZ\1640855 not\RB\1740 affect\VB\126264 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>akathisia</e2>\NN\1740 :\:\1740 a\DT\13649268 prospective\JJ\1740 ,\,\1740 randomized\JJ\1740 ,\,\1740 controlled\VBN\2422663 trial\NN\786195 .\.\1740
D011346_D017109 CID STUDY\VB\630380 OBJECTIVE\NN\5980875 :\:\1740 We\PRP\1740 sought\VBD\1825237 to\TO\1740 compare\VB\644583 the\DT\1740 rate\NN\13815152 of\IN\1740 <e2>akathisia</e2>\NN\1740 after\IN\1740 administration\NN\1133281 of\IN\1740 intravenous\JJ\1740 <e1>prochlorperazine</e1>\NN\2719750 as\IN\14622893 a\DT\13649268 2-minute\JJ\1740 bolus\NN\13899404 or\CC\3541091 15-minute\JJ\1740 infusion\NN\14589223 .\.\1740
D011346_D017109 CID CONCLUSION\NN\5837957 :\:\1740 A\DT\13649268 50\CD\13745420 %\NN\1740 reduction\NN\351485 in\IN\13603305 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>akathisia</e2>\NN\1740 when\WRB\1740 <e1>prochlorperazine</e1>\NN\2719750 was\VBD\836236 administered\VBN\2436349 by\IN\1740 means\NNS\44150 of\IN\1740 15-minute\JJ\1740 intravenous\JJ\1740 infusion\NN\14589223 versus\CC\1740 a\DT\13649268 2-minute\JJ\1740 intravenous\JJ\1740 push\NN\45250 was\VBD\836236 not\RB\1740 detected\VBN\2163746 .\.\1740
D011346_D006261 NONE Patients\NNS\9898892 aged\JJ\1740 18\CD\13745420 years\NNS\15144371 or\CC\3541091 older\JJR\1740 treated\VBN\2376958 with\IN\1740 <e1>prochlorperazine</e1>\NN\2719750 for\IN\1740 <e2>headache</e2>\NN\5829480 ,\,\1740 nausea\NN\14299637 ,\,\1740 or\CC\3541091 vomiting\NN\116687 were\VBD\836236 eligible\JJ\1740 for\IN\1740 inclusion\NN\13927383 .\.\1740
D011346_D006261 NONE The\DT\1740 efficacy\NN\5199286 of\IN\1740 <e1>prochlorperazine</e1>\NN\2719750 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>headache</e2>\NN\5829480 and\CC\1740 nausea\NN\14299637 likewise\RB\1740 did\VBD\1640855 not\RB\1740 appear\VB\2604760 to\TO\1740 be\VB\836236 affected\VBN\126264 by\IN\1740 the\DT\1740 rate\NN\13815152 of\IN\1740 administration\NN\1133281 ,\,\1740 although\IN\1740 no\DT\7204911 formal\JJ\1740 statistical\JJ\1740 comparisons\NNS\635850 were\VBD\836236 made\VBN\126264 .\.\1740
D011346_D009325 NONE Patients\NNS\9898892 aged\JJ\1740 18\CD\13745420 years\NNS\15144371 or\CC\3541091 older\JJR\1740 treated\VBN\2376958 with\IN\1740 <e1>prochlorperazine</e1>\NN\2719750 for\IN\1740 headache\NN\5829480 ,\,\1740 <e2>nausea</e2>\NN\14299637 ,\,\1740 or\CC\3541091 vomiting\NN\116687 were\VBD\836236 eligible\JJ\1740 for\IN\1740 inclusion\NN\13927383 .\.\1740
D011346_D009325 NONE The\DT\1740 efficacy\NN\5199286 of\IN\1740 <e1>prochlorperazine</e1>\NN\2719750 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 headache\NN\5829480 and\CC\1740 <e2>nausea</e2>\NN\14299637 likewise\RB\1740 did\VBD\1640855 not\RB\1740 appear\VB\2604760 to\TO\1740 be\VB\836236 affected\VBN\126264 by\IN\1740 the\DT\1740 rate\NN\13815152 of\IN\1740 administration\NN\1133281 ,\,\1740 although\IN\1740 no\DT\7204911 formal\JJ\1740 statistical\JJ\1740 comparisons\NNS\635850 were\VBD\836236 made\VBN\126264 .\.\1740
D011346_D014839 NONE Patients\NNS\9898892 aged\JJ\1740 18\CD\13745420 years\NNS\15144371 or\CC\3541091 older\JJR\1740 treated\VBN\2376958 with\IN\1740 <e1>prochlorperazine</e1>\NN\2719750 for\IN\1740 headache\NN\5829480 ,\,\1740 nausea\NN\14299637 ,\,\1740 or\CC\3541091 <e2>vomiting</e2>\NN\116687 were\VBD\836236 eligible\JJ\1740 for\IN\1740 inclusion\NN\13927383 .\.\1740
3828020
D010665_D002544 CID <e2>Cerebral\JJ\1740 infarction</e2>\NN\14204950 with\IN\1740 a\DT\13649268 single\JJ\1740 oral\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>phenylpropanolamine</e1>\NN\2682038 .\.\1740
D010665_D002544 CID We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 young\JJ\1740 woman\NN\9605289 who\WP\8299493 suffered\VBD\2110220 a\DT\13649268 <e2>cerebral\JJ\1740 infarction</e2>\NN\14204950 after\IN\1740 taking\VBG\2367363 a\DT\13649268 single\JJ\1740 oral\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>PPA</e1>\NN\1740 .\.\1740
2396046
D002794_D006528 CID No\DT\7204911 hepatic\JJ\1740 preneoplastic\JJ\1740 nodules\NNS\5264913 or\CC\3541091 <e2>hepatocellular\JJ\1740 carcinomas</e2>\NNS\14239918 developed\VBN\1753788 in\IN\13603305 rats\NNS\2329401 fed\VBD\1182709 the\DT\1740 plain\JJ\1740 <e1>choline-supplemented</e1>\JJ\1740 diet\NN\7560652 ,\,\1740 while\IN\15122231 one\CD\13741022 preneoplastic\JJ\1740 nodule\NN\5264913 and\CC\1740 one\CD\13741022 hepatocellular\JJ\1740 carcinoma\NN\14239918 developed\VBD\1753788 in\IN\13603305 two\CD\13741022 rats\NNS\2329401 fed\VBD\1182709 the\DT\1740 same\JJ\1740 diet\NN\7560652 containing\VBG\2632940 phenobarbital\JJ\1740 .\.\1740
D002794_D006528 CID No\DT\7204911 hepatic\JJ\1740 preneoplastic\JJ\1740 nodules\NNS\5264913 or\CC\3541091 hepatocellular\JJ\1740 carcinomas\NNS\14239918 developed\VBN\1753788 in\IN\13603305 rats\NNS\2329401 fed\VBD\1182709 the\DT\1740 plain\JJ\1740 <e1>choline-supplemented</e1>\JJ\1740 diet\NN\7560652 ,\,\1740 while\IN\15122231 one\CD\13741022 preneoplastic\JJ\1740 nodule\NN\5264913 and\CC\1740 one\CD\13741022 <e2>hepatocellular\JJ\1740 carcinoma</e2>\NN\14239918 developed\VBD\1753788 in\IN\13603305 two\CD\13741022 rats\NNS\2329401 fed\VBD\1182709 the\DT\1740 same\JJ\1740 diet\NN\7560652 containing\VBG\2632940 phenobarbital\JJ\1740 .\.\1740
D002794_D006528 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 preneoplastic\JJ\1740 nodules\NNS\5264913 and\CC\1740 of\IN\1740 <e2>hepatocellular\JJ\1740 carcinomas</e2>\NNS\14239918 was\VBD\836236 10\CD\13745420 %\NN\1740 and\CC\1740 37\CD\1740 %\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 in\IN\13603305 rats\NNS\2329401 fed\VBD\1182709 the\DT\1740 plain\JJ\1740 <e1>choline-devoid</e1>\JJ\1740 diet\NN\7560652 ,\,\1740 and\CC\1740 17\CD\13745420 %\NN\1740 and\CC\1740 30\CD\13745420 %\NN\1740 ,\,\1740 in\IN\13603305 rats\NNS\2329401 fed\VBD\1182709 the\DT\1740 phenobarbital-containing\JJ\1740 choline-devoid\JJ\1740 diet\NN\7560652 .\.\1740
D002794_D006528 CID The\DT\1740 incidence\NN\13821570 of\IN\1740 preneoplastic\JJ\1740 nodules\NNS\5264913 and\CC\1740 of\IN\1740 <e2>hepatocellular\JJ\1740 carcinomas</e2>\NNS\14239918 was\VBD\836236 10\CD\13745420 %\NN\1740 and\CC\1740 37\CD\1740 %\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 in\IN\13603305 rats\NNS\2329401 fed\VBD\1182709 the\DT\1740 plain\JJ\1740 choline-devoid\JJ\1740 diet\NN\7560652 ,\,\1740 and\CC\1740 17\CD\13745420 %\NN\1740 and\CC\1740 30\CD\13745420 %\NN\1740 ,\,\1740 in\IN\13603305 rats\NNS\2329401 fed\VBD\1182709 the\DT\1740 phenobarbital-containing\JJ\1740 <e1>choline-devoid</e1>\JJ\1740 diet\NN\7560652 .\.\1740
D010634_D006528 NONE No\DT\7204911 hepatic\JJ\1740 preneoplastic\JJ\1740 nodules\NNS\5264913 or\CC\3541091 <e2>hepatocellular\JJ\1740 carcinomas</e2>\NNS\14239918 developed\VBN\1753788 in\IN\13603305 rats\NNS\2329401 fed\VBD\1182709 the\DT\1740 plain\JJ\1740 choline-supplemented\JJ\1740 diet\NN\7560652 ,\,\1740 while\IN\15122231 one\CD\13741022 preneoplastic\JJ\1740 nodule\NN\5264913 and\CC\1740 one\CD\13741022 hepatocellular\JJ\1740 carcinoma\NN\14239918 developed\VBD\1753788 in\IN\13603305 two\CD\13741022 rats\NNS\2329401 fed\VBD\1182709 the\DT\1740 same\JJ\1740 diet\NN\7560652 containing\VBG\2632940 <e1>phenobarbital</e1>\JJ\1740 .\.\1740
D010634_D006528 NONE No\DT\7204911 hepatic\JJ\1740 preneoplastic\JJ\1740 nodules\NNS\5264913 or\CC\3541091 hepatocellular\JJ\1740 carcinomas\NNS\14239918 developed\VBN\1753788 in\IN\13603305 rats\NNS\2329401 fed\VBD\1182709 the\DT\1740 plain\JJ\1740 choline-supplemented\JJ\1740 diet\NN\7560652 ,\,\1740 while\IN\15122231 one\CD\13741022 preneoplastic\JJ\1740 nodule\NN\5264913 and\CC\1740 one\CD\13741022 <e2>hepatocellular\JJ\1740 carcinoma</e2>\NN\14239918 developed\VBD\1753788 in\IN\13603305 two\CD\13741022 rats\NNS\2329401 fed\VBD\1182709 the\DT\1740 same\JJ\1740 diet\NN\7560652 containing\VBG\2632940 <e1>phenobarbital</e1>\JJ\1740 .\.\1740
D010634_D006528 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 preneoplastic\JJ\1740 nodules\NNS\5264913 and\CC\1740 of\IN\1740 <e2>hepatocellular\JJ\1740 carcinomas</e2>\NNS\14239918 was\VBD\836236 10\CD\13745420 %\NN\1740 and\CC\1740 37\CD\1740 %\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 in\IN\13603305 rats\NNS\2329401 fed\VBD\1182709 the\DT\1740 plain\JJ\1740 choline-devoid\JJ\1740 diet\NN\7560652 ,\,\1740 and\CC\1740 17\CD\13745420 %\NN\1740 and\CC\1740 30\CD\13745420 %\NN\1740 ,\,\1740 in\IN\13603305 rats\NNS\2329401 fed\VBD\1182709 the\DT\1740 <e1>phenobarbital-containing</e1>\JJ\1740 choline-devoid\JJ\1740 diet\NN\7560652 .\.\1740
9698967
D008619_D006973 CID An\DT\6697703 <e2>increase\NN\13576355 in\IN\13603305 blood\NN\5397468 pressure</e2>\NN\11419404 ,\,\1740 accompanied\VBN\1835496 by\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 ,\,\1740 agitation\NN\14373582 ,\,\1740 incomprehensible\JJ\1740 shouts\NNS\7109847 and\CC\1740 loss\NN\13252973 of\IN\1740 consciousness\NN\5669934 ,\,\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 ,\,\1740 ASA\NN\1740 classification\NN\1012360 group\NN\2137 II\CD\13741022 ,\,\1740 cardiovascularly\RB\1740 medicated\VBD\497705 male\JJ\1740 ,\,\1740 12\CD\13745420 min\NN\15154774 after\IN\1740 performance\NN\6619065 of\IN\1740 axillary\JJ\1740 block\NN\21939 with\IN\1740 <e1>mepivacaine</e1>\NN\1740 850\CD\1740 mg\NN\13717155 containing\VBG\2632940 adrenaline\NN\14807929 0.225\CD\1740 mg\NN\13717155 ,\,\1740 for\IN\1740 correction\NN\248977 of\IN\1740 Dupuytren\NN\1740 's\POS\1740 contracture\NN\369802 .\.\1740
D008619_D001281 CID An\DT\6697703 increase\NN\13576355 in\IN\13603305 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 accompanied\VBN\1835496 by\IN\1740 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 ,\,\1740 agitation\NN\14373582 ,\,\1740 incomprehensible\JJ\1740 shouts\NNS\7109847 and\CC\1740 loss\NN\13252973 of\IN\1740 consciousness\NN\5669934 ,\,\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 ,\,\1740 ASA\NN\1740 classification\NN\1012360 group\NN\2137 II\CD\13741022 ,\,\1740 cardiovascularly\RB\1740 medicated\VBD\497705 male\JJ\1740 ,\,\1740 12\CD\13745420 min\NN\15154774 after\IN\1740 performance\NN\6619065 of\IN\1740 axillary\JJ\1740 block\NN\21939 with\IN\1740 <e1>mepivacaine</e1>\NN\1740 850\CD\1740 mg\NN\13717155 containing\VBG\2632940 adrenaline\NN\14807929 0.225\CD\1740 mg\NN\13717155 ,\,\1740 for\IN\1740 correction\NN\248977 of\IN\1740 Dupuytren\NN\1740 's\POS\1740 contracture\NN\369802 .\.\1740
D008619_D011595 NONE An\DT\6697703 increase\NN\13576355 in\IN\13603305 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 accompanied\VBN\1835496 by\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 ,\,\1740 <e2>agitation</e2>\NN\14373582 ,\,\1740 incomprehensible\JJ\1740 shouts\NNS\7109847 and\CC\1740 loss\NN\13252973 of\IN\1740 consciousness\NN\5669934 ,\,\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 ,\,\1740 ASA\NN\1740 classification\NN\1012360 group\NN\2137 II\CD\13741022 ,\,\1740 cardiovascularly\RB\1740 medicated\VBD\497705 male\JJ\1740 ,\,\1740 12\CD\13745420 min\NN\15154774 after\IN\1740 performance\NN\6619065 of\IN\1740 axillary\JJ\1740 block\NN\21939 with\IN\1740 <e1>mepivacaine</e1>\NN\1740 850\CD\1740 mg\NN\13717155 containing\VBG\2632940 adrenaline\NN\14807929 0.225\CD\1740 mg\NN\13717155 ,\,\1740 for\IN\1740 correction\NN\248977 of\IN\1740 Dupuytren\NN\1740 's\POS\1740 contracture\NN\369802 .\.\1740
D008619_D019954 NONE An\DT\6697703 increase\NN\13576355 in\IN\13603305 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 accompanied\VBN\1835496 by\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 ,\,\1740 agitation\NN\14373582 ,\,\1740 <e2>incomprehensible\JJ\1740 shouts</e2>\NNS\7109847 and\CC\1740 loss\NN\13252973 of\IN\1740 consciousness\NN\5669934 ,\,\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 ,\,\1740 ASA\NN\1740 classification\NN\1012360 group\NN\2137 II\CD\13741022 ,\,\1740 cardiovascularly\RB\1740 medicated\VBD\497705 male\JJ\1740 ,\,\1740 12\CD\13745420 min\NN\15154774 after\IN\1740 performance\NN\6619065 of\IN\1740 axillary\JJ\1740 block\NN\21939 with\IN\1740 <e1>mepivacaine</e1>\NN\1740 850\CD\1740 mg\NN\13717155 containing\VBG\2632940 adrenaline\NN\14807929 0.225\CD\1740 mg\NN\13717155 ,\,\1740 for\IN\1740 correction\NN\248977 of\IN\1740 Dupuytren\NN\1740 's\POS\1740 contracture\NN\369802 .\.\1740
D008619_D014474 NONE An\DT\6697703 increase\NN\13576355 in\IN\13603305 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 accompanied\VBN\1835496 by\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 ,\,\1740 agitation\NN\14373582 ,\,\1740 incomprehensible\JJ\1740 shouts\NNS\7109847 and\CC\1740 <e2>loss\NN\13252973 of\IN\1740 consciousness</e2>\NN\5669934 ,\,\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 ,\,\1740 ASA\NN\1740 classification\NN\1012360 group\NN\2137 II\CD\13741022 ,\,\1740 cardiovascularly\RB\1740 medicated\VBD\497705 male\JJ\1740 ,\,\1740 12\CD\13745420 min\NN\15154774 after\IN\1740 performance\NN\6619065 of\IN\1740 axillary\JJ\1740 block\NN\21939 with\IN\1740 <e1>mepivacaine</e1>\NN\1740 850\CD\1740 mg\NN\13717155 containing\VBG\2632940 adrenaline\NN\14807929 0.225\CD\1740 mg\NN\13717155 ,\,\1740 for\IN\1740 correction\NN\248977 of\IN\1740 Dupuytren\NN\1740 's\POS\1740 contracture\NN\369802 .\.\1740
D008619_D004387 NONE An\DT\6697703 increase\NN\13576355 in\IN\13603305 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 accompanied\VBN\1835496 by\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 ,\,\1740 agitation\NN\14373582 ,\,\1740 incomprehensible\JJ\1740 shouts\NNS\7109847 and\CC\1740 loss\NN\13252973 of\IN\1740 consciousness\NN\5669934 ,\,\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 ,\,\1740 ASA\NN\1740 classification\NN\1012360 group\NN\2137 II\CD\13741022 ,\,\1740 cardiovascularly\RB\1740 medicated\VBD\497705 male\JJ\1740 ,\,\1740 12\CD\13745420 min\NN\15154774 after\IN\1740 performance\NN\6619065 of\IN\1740 axillary\JJ\1740 block\NN\21939 with\IN\1740 <e1>mepivacaine</e1>\NN\1740 850\CD\1740 mg\NN\13717155 containing\VBG\2632940 adrenaline\NN\14807929 0.225\CD\1740 mg\NN\13717155 ,\,\1740 for\IN\1740 correction\NN\248977 of\IN\1740 <e2>Dupuytren\NN\1740 's\POS\1740 contracture</e2>\NN\369802 .\.\1740
D004837_D006973 CID An\DT\6697703 <e2>increase\NN\13576355 in\IN\13603305 blood\NN\5397468 pressure</e2>\NN\11419404 ,\,\1740 accompanied\VBN\1835496 by\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 ,\,\1740 agitation\NN\14373582 ,\,\1740 incomprehensible\JJ\1740 shouts\NNS\7109847 and\CC\1740 loss\NN\13252973 of\IN\1740 consciousness\NN\5669934 ,\,\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 ,\,\1740 ASA\NN\1740 classification\NN\1012360 group\NN\2137 II\CD\13741022 ,\,\1740 cardiovascularly\RB\1740 medicated\VBD\497705 male\JJ\1740 ,\,\1740 12\CD\13745420 min\NN\15154774 after\IN\1740 performance\NN\6619065 of\IN\1740 axillary\JJ\1740 block\NN\21939 with\IN\1740 mepivacaine\NN\1740 850\CD\1740 mg\NN\13717155 containing\VBG\2632940 <e1>adrenaline</e1>\NN\14807929 0.225\CD\1740 mg\NN\13717155 ,\,\1740 for\IN\1740 correction\NN\248977 of\IN\1740 Dupuytren\NN\1740 's\POS\1740 contracture\NN\369802 .\.\1740
D004837_D001281 CID An\DT\6697703 increase\NN\13576355 in\IN\13603305 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 accompanied\VBN\1835496 by\IN\1740 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 ,\,\1740 agitation\NN\14373582 ,\,\1740 incomprehensible\JJ\1740 shouts\NNS\7109847 and\CC\1740 loss\NN\13252973 of\IN\1740 consciousness\NN\5669934 ,\,\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 ,\,\1740 ASA\NN\1740 classification\NN\1012360 group\NN\2137 II\CD\13741022 ,\,\1740 cardiovascularly\RB\1740 medicated\VBD\497705 male\JJ\1740 ,\,\1740 12\CD\13745420 min\NN\15154774 after\IN\1740 performance\NN\6619065 of\IN\1740 axillary\JJ\1740 block\NN\21939 with\IN\1740 mepivacaine\NN\1740 850\CD\1740 mg\NN\13717155 containing\VBG\2632940 <e1>adrenaline</e1>\NN\14807929 0.225\CD\1740 mg\NN\13717155 ,\,\1740 for\IN\1740 correction\NN\248977 of\IN\1740 Dupuytren\NN\1740 's\POS\1740 contracture\NN\369802 .\.\1740
D004837_D011595 NONE An\DT\6697703 increase\NN\13576355 in\IN\13603305 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 accompanied\VBN\1835496 by\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 ,\,\1740 <e2>agitation</e2>\NN\14373582 ,\,\1740 incomprehensible\JJ\1740 shouts\NNS\7109847 and\CC\1740 loss\NN\13252973 of\IN\1740 consciousness\NN\5669934 ,\,\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 ,\,\1740 ASA\NN\1740 classification\NN\1012360 group\NN\2137 II\CD\13741022 ,\,\1740 cardiovascularly\RB\1740 medicated\VBD\497705 male\JJ\1740 ,\,\1740 12\CD\13745420 min\NN\15154774 after\IN\1740 performance\NN\6619065 of\IN\1740 axillary\JJ\1740 block\NN\21939 with\IN\1740 mepivacaine\NN\1740 850\CD\1740 mg\NN\13717155 containing\VBG\2632940 <e1>adrenaline</e1>\NN\14807929 0.225\CD\1740 mg\NN\13717155 ,\,\1740 for\IN\1740 correction\NN\248977 of\IN\1740 Dupuytren\NN\1740 's\POS\1740 contracture\NN\369802 .\.\1740
D004837_D019954 NONE An\DT\6697703 increase\NN\13576355 in\IN\13603305 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 accompanied\VBN\1835496 by\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 ,\,\1740 agitation\NN\14373582 ,\,\1740 <e2>incomprehensible\JJ\1740 shouts</e2>\NNS\7109847 and\CC\1740 loss\NN\13252973 of\IN\1740 consciousness\NN\5669934 ,\,\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 ,\,\1740 ASA\NN\1740 classification\NN\1012360 group\NN\2137 II\CD\13741022 ,\,\1740 cardiovascularly\RB\1740 medicated\VBD\497705 male\JJ\1740 ,\,\1740 12\CD\13745420 min\NN\15154774 after\IN\1740 performance\NN\6619065 of\IN\1740 axillary\JJ\1740 block\NN\21939 with\IN\1740 mepivacaine\NN\1740 850\CD\1740 mg\NN\13717155 containing\VBG\2632940 <e1>adrenaline</e1>\NN\14807929 0.225\CD\1740 mg\NN\13717155 ,\,\1740 for\IN\1740 correction\NN\248977 of\IN\1740 Dupuytren\NN\1740 's\POS\1740 contracture\NN\369802 .\.\1740
D004837_D014474 NONE An\DT\6697703 increase\NN\13576355 in\IN\13603305 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 accompanied\VBN\1835496 by\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 ,\,\1740 agitation\NN\14373582 ,\,\1740 incomprehensible\JJ\1740 shouts\NNS\7109847 and\CC\1740 <e2>loss\NN\13252973 of\IN\1740 consciousness</e2>\NN\5669934 ,\,\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 ,\,\1740 ASA\NN\1740 classification\NN\1012360 group\NN\2137 II\CD\13741022 ,\,\1740 cardiovascularly\RB\1740 medicated\VBD\497705 male\JJ\1740 ,\,\1740 12\CD\13745420 min\NN\15154774 after\IN\1740 performance\NN\6619065 of\IN\1740 axillary\JJ\1740 block\NN\21939 with\IN\1740 mepivacaine\NN\1740 850\CD\1740 mg\NN\13717155 containing\VBG\2632940 <e1>adrenaline</e1>\NN\14807929 0.225\CD\1740 mg\NN\13717155 ,\,\1740 for\IN\1740 correction\NN\248977 of\IN\1740 Dupuytren\NN\1740 's\POS\1740 contracture\NN\369802 .\.\1740
D004837_D004387 NONE An\DT\6697703 increase\NN\13576355 in\IN\13603305 blood\NN\5397468 pressure\NN\11419404 ,\,\1740 accompanied\VBN\1835496 by\IN\1740 atrial\JJ\1740 fibrillation\NN\14361664 ,\,\1740 agitation\NN\14373582 ,\,\1740 incomprehensible\JJ\1740 shouts\NNS\7109847 and\CC\1740 loss\NN\13252973 of\IN\1740 consciousness\NN\5669934 ,\,\1740 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 an\DT\6697703 elderly\JJ\1740 ,\,\1740 ASA\NN\1740 classification\NN\1012360 group\NN\2137 II\CD\13741022 ,\,\1740 cardiovascularly\RB\1740 medicated\VBD\497705 male\JJ\1740 ,\,\1740 12\CD\13745420 min\NN\15154774 after\IN\1740 performance\NN\6619065 of\IN\1740 axillary\JJ\1740 block\NN\21939 with\IN\1740 mepivacaine\NN\1740 850\CD\1740 mg\NN\13717155 containing\VBG\2632940 <e1>adrenaline</e1>\NN\14807929 0.225\CD\1740 mg\NN\13717155 ,\,\1740 for\IN\1740 correction\NN\248977 of\IN\1740 <e2>Dupuytren\NN\1740 's\POS\1740 contracture</e2>\NN\369802 .\.\1740
1616457
D010424_D000647 CID Learning\NN\5701944 of\IN\1740 rats\NNS\2329401 under\IN\1740 <e2>amnesia</e2>\NN\5669934 caused\VBN\1617192 by\IN\1740 <e1>pentobarbital</e1>\JJ\1740 .\.\1740
D010424_D000647 CID Dissociated\VBN\2431320 learning\NN\5701944 of\IN\1740 rats\NNS\2329401 in\IN\13603305 the\DT\1740 normal\JJ\1740 state\NN\8491826 and\CC\1740 the\DT\1740 state\NN\8491826 of\IN\1740 <e2>amnesia</e2>\NN\5669934 produced\VBN\1617192 by\IN\1740 <e1>pentobarbital</e1>\JJ\1740 (\-LRB-\1740 15\CD\13745420 mg/kg\NN\1740 ,\,\1740 ip\FW\5999797 )\-RRB-\1740 was\VBD\836236 carried\VBN\1850315 out\RP\1740 .\.\1740
12589964
D004317_D009202 CID Evaluation\NN\874067 of\IN\1740 cardiac\JJ\1740 troponin\NN\1740 I\CD\14622893 and\CC\1740 T\NN\14999913 levels\NNS\4916342 as\IN\14622893 markers\NNS\21939 of\IN\1740 <e2>myocardial\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 <e1>doxorubicin-induced</e1>\JJ\1740 cardiomyopathy\JJ\1740 rats\NNS\2329401 ,\,\1740 and\CC\1740 their\PRP$\1740 relationship\NN\31921 with\IN\1740 echocardiographic\JJ\1740 and\CC\1740 histological\JJ\1740 findings\NNS\7951464 .\.\1740
D004317_D009202 CID Evaluation\NN\874067 of\IN\1740 cardiac\JJ\1740 troponin\NN\1740 I\CD\14622893 and\CC\1740 T\NN\14999913 levels\NNS\4916342 as\IN\14622893 markers\NNS\21939 of\IN\1740 myocardial\JJ\1740 damage\NN\7296428 in\IN\13603305 <e1>doxorubicin-induced</e1>\JJ\1740 <e2>cardiomyopathy</e2>\JJ\1740 rats\NNS\2329401 ,\,\1740 and\CC\1740 their\PRP$\1740 relationship\NN\31921 with\IN\1740 echocardiographic\JJ\1740 and\CC\1740 histological\JJ\1740 findings\NNS\7951464 .\.\1740
D004317_D009202 CID We\PRP\1740 investigated\VBD\644583 the\DT\1740 diagnostic\JJ\1740 value\NN\5856066 of\IN\1740 cTnI\NN\1740 and\CC\1740 cTnT\NN\1740 for\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 <e2>myocardial\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 (DOX)-induced\NN\1740 cardiomyopathy\JJ\1740 ,\,\1740 and\CC\1740 we\PRP\1740 examined\VBD\789138 the\DT\1740 relationship\NN\31921 between\IN\1740 serial\JJ\1740 cTnI\NN\1740 and\CC\1740 cTnT\NN\1740 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 cardiac\JJ\1740 disorders\NNS\14034177 monitored\VBN\2169352 by\IN\1740 echocardiography\NN\177127 and\CC\1740 histological\JJ\1740 examinations\NNS\633864 in\IN\13603305 this\DT\1740 model\NN\5888929 .\.\1740
D004317_D009202 CID We\PRP\1740 investigated\VBD\644583 the\DT\1740 diagnostic\JJ\1740 value\NN\5856066 of\IN\1740 cTnI\NN\1740 and\CC\1740 cTnT\NN\1740 for\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 myocardial\JJ\1740 damage\NN\7296428 in\IN\13603305 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 (DOX)-induced\NN\1740 <e2>cardiomyopathy</e2>\JJ\1740 ,\,\1740 and\CC\1740 we\PRP\1740 examined\VBD\789138 the\DT\1740 relationship\NN\31921 between\IN\1740 serial\JJ\1740 cTnI\NN\1740 and\CC\1740 cTnT\NN\1740 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 cardiac\JJ\1740 disorders\NNS\14034177 monitored\VBN\2169352 by\IN\1740 echocardiography\NN\177127 and\CC\1740 histological\JJ\1740 examinations\NNS\633864 in\IN\13603305 this\DT\1740 model\NN\5888929 .\.\1740
D004317_D009202 CID We\PRP\1740 investigated\VBD\644583 the\DT\1740 diagnostic\JJ\1740 value\NN\5856066 of\IN\1740 cTnI\NN\1740 and\CC\1740 cTnT\NN\1740 for\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 <e2>myocardial\JJ\1740 damage</e2>\NN\7296428 in\IN\13603305 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 doxorubicin\NN\2716866 <e1>(DOX)-induced</e1>\NN\1740 cardiomyopathy\JJ\1740 ,\,\1740 and\CC\1740 we\PRP\1740 examined\VBD\789138 the\DT\1740 relationship\NN\31921 between\IN\1740 serial\JJ\1740 cTnI\NN\1740 and\CC\1740 cTnT\NN\1740 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 cardiac\JJ\1740 disorders\NNS\14034177 monitored\VBN\2169352 by\IN\1740 echocardiography\NN\177127 and\CC\1740 histological\JJ\1740 examinations\NNS\633864 in\IN\13603305 this\DT\1740 model\NN\5888929 .\.\1740
D004317_D009202 CID We\PRP\1740 investigated\VBD\644583 the\DT\1740 diagnostic\JJ\1740 value\NN\5856066 of\IN\1740 cTnI\NN\1740 and\CC\1740 cTnT\NN\1740 for\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 myocardial\JJ\1740 damage\NN\7296428 in\IN\13603305 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 doxorubicin\NN\2716866 <e1>(DOX)-induced</e1>\NN\1740 <e2>cardiomyopathy</e2>\JJ\1740 ,\,\1740 and\CC\1740 we\PRP\1740 examined\VBD\789138 the\DT\1740 relationship\NN\31921 between\IN\1740 serial\JJ\1740 cTnI\NN\1740 and\CC\1740 cTnT\NN\1740 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 cardiac\JJ\1740 disorders\NNS\14034177 monitored\VBN\2169352 by\IN\1740 echocardiography\NN\177127 and\CC\1740 histological\JJ\1740 examinations\NNS\633864 in\IN\13603305 this\DT\1740 model\NN\5888929 .\.\1740
D004317_D009202 CID CONCLUSIONS\NNS\5837957 :\:\1740 Among\IN\1740 markers\NNS\21939 of\IN\1740 ischemic\JJ\1740 injury\NN\14052046 after\IN\1740 <e1>DOX</e1>\NN\1740 in\IN\13603305 rats\NNS\2329401 ,\,\1740 cTnT\NN\1740 showed\VBD\2137132 the\DT\1740 greatest\JJS\1740 ability\NN\4723816 to\TO\1740 detect\VB\2163746 <e2>myocardial\JJ\1740 damage</e2>\NN\7296428 assessed\VBN\670261 by\IN\1740 echocardiographic\JJ\1740 detection\NN\5708432 and\CC\1740 histological\JJ\1740 changes\NNS\7283608 .\.\1740
D004317_D006331 NONE We\PRP\1740 investigated\VBD\644583 the\DT\1740 diagnostic\JJ\1740 value\NN\5856066 of\IN\1740 cTnI\NN\1740 and\CC\1740 cTnT\NN\1740 for\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 myocardial\JJ\1740 damage\NN\7296428 in\IN\13603305 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 <e1>doxorubicin</e1>\NN\2716866 (DOX)-induced\NN\1740 cardiomyopathy\JJ\1740 ,\,\1740 and\CC\1740 we\PRP\1740 examined\VBD\789138 the\DT\1740 relationship\NN\31921 between\IN\1740 serial\JJ\1740 cTnI\NN\1740 and\CC\1740 cTnT\NN\1740 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>cardiac\JJ\1740 disorders</e2>\NNS\14034177 monitored\VBN\2169352 by\IN\1740 echocardiography\NN\177127 and\CC\1740 histological\JJ\1740 examinations\NNS\633864 in\IN\13603305 this\DT\1740 model\NN\5888929 .\.\1740
D004317_D006331 NONE We\PRP\1740 investigated\VBD\644583 the\DT\1740 diagnostic\JJ\1740 value\NN\5856066 of\IN\1740 cTnI\NN\1740 and\CC\1740 cTnT\NN\1740 for\IN\1740 the\DT\1740 diagnosis\NN\152018 of\IN\1740 myocardial\JJ\1740 damage\NN\7296428 in\IN\13603305 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 doxorubicin\NN\2716866 <e1>(DOX)-induced</e1>\NN\1740 cardiomyopathy\JJ\1740 ,\,\1740 and\CC\1740 we\PRP\1740 examined\VBD\789138 the\DT\1740 relationship\NN\31921 between\IN\1740 serial\JJ\1740 cTnI\NN\1740 and\CC\1740 cTnT\NN\1740 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>cardiac\JJ\1740 disorders</e2>\NNS\14034177 monitored\VBN\2169352 by\IN\1740 echocardiography\NN\177127 and\CC\1740 histological\JJ\1740 examinations\NNS\633864 in\IN\13603305 this\DT\1740 model\NN\5888929 .\.\1740
D004317_D064420 NONE RESULTS\NNS\34213 :\:\1740 Eighteen\CD\13745420 of\IN\1740 the\DT\1740 <e1>DOX</e1>\NN\1740 rats\NNS\2329401 died\VBD\146138 prematurely\RB\1740 of\IN\1740 general\JJ\1740 <e2>toxicity</e2>\NN\13576101 during\IN\1740 the\DT\1740 9-week\JJ\1740 period\NN\13575869 .\.\1740
D004317_D005355 NONE Histological\JJ\1740 evaluation\NN\874067 of\IN\1740 hearts\NNS\496167 from\IN\1740 all\DT\1740 rats\NNS\2329401 given\VBN\2327200 <e1>DOX</e1>\NN\1740 revealed\VBD\2137132 significant\JJ\1740 slight\JJ\1740 degrees\NNS\4916342 of\IN\1740 perivascular\JJ\1740 and\CC\1740 interstitial\JJ\1740 <e2>fibrosis</e2>\NN\14204950 .\.\1740
D004317_D017202 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Among\IN\1740 markers\NNS\21939 of\IN\1740 <e2>ischemic\JJ\1740 injury</e2>\NN\14052046 after\IN\1740 <e1>DOX</e1>\NN\1740 in\IN\13603305 rats\NNS\2329401 ,\,\1740 cTnT\NN\1740 showed\VBD\2137132 the\DT\1740 greatest\JJS\1740 ability\NN\4723816 to\TO\1740 detect\VB\2163746 myocardial\JJ\1740 damage\NN\7296428 assessed\VBN\670261 by\IN\1740 echocardiographic\JJ\1740 detection\NN\5708432 and\CC\1740 histological\JJ\1740 changes\NNS\7283608 .\.\1740
D004317_D066126 NONE Although\IN\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 discrepancy\NN\4748836 between\IN\1740 the\DT\1740 amount\NN\13329641 of\IN\1740 cTnI\NN\1740 and\CC\1740 cTnT\NN\1740 after\IN\1740 <e1>DOX</e1>\NN\1740 ,\,\1740 probably\RB\1740 due\JJ\1740 to\TO\1740 heterogeneity\NN\4750940 in\IN\13603305 cross-reactivities\NNS\1740 of\IN\1740 mAbs\NNS\1740 to\TO\1740 various\JJ\1740 cTnI\NN\1740 and\CC\1740 cTnT\NN\1740 forms\NNS\6286395 ,\,\1740 it\PRP\6125041 is\VBZ\836236 likely\JJ\1740 that\IN\1740 cTnT\NN\1740 in\IN\13603305 rats\NNS\2329401 after\IN\1740 DOX\NN\1740 indicates\VBZ\952524 cell\NN\3080309 damage\NN\7296428 determined\VBN\1645601 by\IN\1740 the\DT\1740 magnitude\NN\4916342 of\IN\1740 injury\NN\14052046 induced\VBN\1627355 and\CC\1740 that\IN\1740 cTnT\NN\1740 should\MD\1740 be\VB\836236 a\DT\13649268 useful\JJ\1740 marker\NN\21939 for\IN\1740 the\DT\1740 prediction\NN\5772356 of\IN\1740 experimentally\RB\1740 induced\VBN\1627355 <e2>cardiotoxicity</e2>\NN\1740 and\CC\1740 possibly\RB\1740 for\IN\1740 cardioprotective\JJ\1740 experiments\NNS\641820 .\.\1740
D004317_D066126 NONE Although\IN\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 discrepancy\NN\4748836 between\IN\1740 the\DT\1740 amount\NN\13329641 of\IN\1740 cTnI\NN\1740 and\CC\1740 cTnT\NN\1740 after\IN\1740 DOX\NN\1740 ,\,\1740 probably\RB\1740 due\JJ\1740 to\TO\1740 heterogeneity\NN\4750940 in\IN\13603305 cross-reactivities\NNS\1740 of\IN\1740 mAbs\NNS\1740 to\TO\1740 various\JJ\1740 cTnI\NN\1740 and\CC\1740 cTnT\NN\1740 forms\NNS\6286395 ,\,\1740 it\PRP\6125041 is\VBZ\836236 likely\JJ\1740 that\IN\1740 cTnT\NN\1740 in\IN\13603305 rats\NNS\2329401 after\IN\1740 <e1>DOX</e1>\NN\1740 indicates\VBZ\952524 cell\NN\3080309 damage\NN\7296428 determined\VBN\1645601 by\IN\1740 the\DT\1740 magnitude\NN\4916342 of\IN\1740 injury\NN\14052046 induced\VBN\1627355 and\CC\1740 that\IN\1740 cTnT\NN\1740 should\MD\1740 be\VB\836236 a\DT\13649268 useful\JJ\1740 marker\NN\21939 for\IN\1740 the\DT\1740 prediction\NN\5772356 of\IN\1740 experimentally\RB\1740 induced\VBN\1627355 <e2>cardiotoxicity</e2>\NN\1740 and\CC\1740 possibly\RB\1740 for\IN\1740 cardioprotective\JJ\1740 experiments\NNS\641820 .\.\1740
11379838
D000928_D001714 CID <e1>Antidepressant-induced</e1>\JJ\1740 <e2>mania</e2>\NN\9180259 in\IN\13603305 bipolar\JJ\1740 patients\NNS\9898892 :\:\1740 identification\NN\151497 of\IN\1740 risk\NN\14541044 factors\NNS\7326557 .\.\1740
D000928_D001714 CID <e1>Antidepressant-induced</e1>\JJ\1740 mania\NN\9180259 in\IN\13603305 <e2>bipolar</e2>\JJ\1740 patients\NNS\9898892 :\:\1740 identification\NN\151497 of\IN\1740 risk\NN\14541044 factors\NNS\7326557 .\.\1740
D000928_D001714 CID BACKGROUND\NN\4921011 :\:\1740 Concerns\NNS\5682950 about\IN\1740 possible\JJ\1740 risks\NNS\14541044 of\IN\1740 switching\NN\191142 to\TO\1740 <e2>mania</e2>\NN\9180259 associated\VBN\628491 with\IN\1740 <e1>antidepressants</e1>\NNS\3740161 continue\VBP\2367363 to\TO\1740 interfere\VB\2451370 with\IN\1740 the\DT\1740 establishment\NN\235435 of\IN\1740 an\DT\6697703 optimal\JJ\1740 treatment\NN\654885 paradigm\NN\13803782 for\IN\1740 bipolar\JJ\1740 depression\NN\14373582 .\.\1740
D000928_D001714 CID BACKGROUND\NN\4921011 :\:\1740 Concerns\NNS\5682950 about\IN\1740 possible\JJ\1740 risks\NNS\14541044 of\IN\1740 switching\NN\191142 to\TO\1740 mania\NN\9180259 associated\VBN\628491 with\IN\1740 <e1>antidepressants</e1>\NNS\3740161 continue\VBP\2367363 to\TO\1740 interfere\VB\2451370 with\IN\1740 the\DT\1740 establishment\NN\235435 of\IN\1740 an\DT\6697703 optimal\JJ\1740 treatment\NN\654885 paradigm\NN\13803782 for\IN\1740 <e2>bipolar\JJ\1740 depression</e2>\NN\14373582 .\.\1740
D000928_D001714 CID Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 <e2>manic</e2>\JJ\1740 or\CC\3541091 hypomanic\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 DSM-IV\NN\1740 bipolar\NN\1740 I\CD\14622893 vs.\CC\1740 bipolar\NN\1740 II\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 <e1>antidepressant</e1>\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 antidepressant\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 [\-LRB-\1740 SSRIs\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 lithium\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D000928_D001714 CID Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 manic\JJ\1740 or\CC\3541091 <e2>hypomanic</e2>\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 DSM-IV\NN\1740 bipolar\NN\1740 I\CD\14622893 vs.\CC\1740 bipolar\NN\1740 II\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 <e1>antidepressant</e1>\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 antidepressant\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 [\-LRB-\1740 SSRIs\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 lithium\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D000928_D001714 CID Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 manic\JJ\1740 or\CC\3541091 hypomanic\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 <e2>DSM-IV\NN\1740 bipolar\NN\1740 I</e2>\CD\14622893 vs.\CC\1740 bipolar\NN\1740 II\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 <e1>antidepressant</e1>\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 antidepressant\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 [\-LRB-\1740 SSRIs\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 lithium\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D000928_D001714 CID Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 manic\JJ\1740 or\CC\3541091 hypomanic\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 DSM-IV\NN\1740 bipolar\NN\1740 I\CD\14622893 vs.\CC\1740 <e2>bipolar\NN\1740 II</e2>\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 <e1>antidepressant</e1>\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 antidepressant\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 [\-LRB-\1740 SSRIs\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 lithium\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D000928_D001714 CID Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 manic\JJ\1740 or\CC\3541091 hypomanic\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 DSM-IV\NN\1740 bipolar\NN\1740 I\CD\14622893 vs.\CC\1740 bipolar\NN\1740 II\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 <e2>manic</e2>\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 <e1>antidepressant</e1>\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 antidepressant\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 [\-LRB-\1740 SSRIs\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 lithium\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D000928_D001714 CID Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 <e2>manic</e2>\JJ\1740 or\CC\3541091 hypomanic\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 DSM-IV\NN\1740 bipolar\NN\1740 I\CD\14622893 vs.\CC\1740 bipolar\NN\1740 II\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 antidepressant\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 <e1>antidepressant</e1>\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 [\-LRB-\1740 SSRIs\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 lithium\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D000928_D001714 CID Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 manic\JJ\1740 or\CC\3541091 <e2>hypomanic</e2>\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 DSM-IV\NN\1740 bipolar\NN\1740 I\CD\14622893 vs.\CC\1740 bipolar\NN\1740 II\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 antidepressant\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 <e1>antidepressant</e1>\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 [\-LRB-\1740 SSRIs\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 lithium\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D000928_D001714 CID Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 manic\JJ\1740 or\CC\3541091 hypomanic\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 <e2>DSM-IV\NN\1740 bipolar\NN\1740 I</e2>\CD\14622893 vs.\CC\1740 bipolar\NN\1740 II\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 antidepressant\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 <e1>antidepressant</e1>\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 [\-LRB-\1740 SSRIs\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 lithium\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D000928_D001714 CID Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 manic\JJ\1740 or\CC\3541091 hypomanic\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 DSM-IV\NN\1740 bipolar\NN\1740 I\CD\14622893 vs.\CC\1740 <e2>bipolar\NN\1740 II</e2>\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 antidepressant\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 <e1>antidepressant</e1>\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 [\-LRB-\1740 SSRIs\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 lithium\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D000928_D001714 CID Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 manic\JJ\1740 or\CC\3541091 hypomanic\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 DSM-IV\NN\1740 bipolar\NN\1740 I\CD\14622893 vs.\CC\1740 bipolar\NN\1740 II\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 <e2>manic</e2>\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 antidepressant\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 <e1>antidepressant</e1>\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 [\-LRB-\1740 SSRIs\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 lithium\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D017367_D001714 CID Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 <e2>manic</e2>\JJ\1740 or\CC\3541091 hypomanic\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 DSM-IV\NN\1740 bipolar\NN\1740 I\CD\14622893 vs.\CC\1740 bipolar\NN\1740 II\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 antidepressant\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 antidepressant\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 <e1>serotonin\NN\14807737 reuptake\NN\13571580 inhibitors</e1>\NNS\20090 [\-LRB-\1740 SSRIs\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 lithium\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D017367_D001714 CID Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 manic\JJ\1740 or\CC\3541091 <e2>hypomanic</e2>\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 DSM-IV\NN\1740 bipolar\NN\1740 I\CD\14622893 vs.\CC\1740 bipolar\NN\1740 II\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 antidepressant\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 antidepressant\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 <e1>serotonin\NN\14807737 reuptake\NN\13571580 inhibitors</e1>\NNS\20090 [\-LRB-\1740 SSRIs\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 lithium\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D017367_D001714 CID Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 manic\JJ\1740 or\CC\3541091 hypomanic\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 <e2>DSM-IV\NN\1740 bipolar\NN\1740 I</e2>\CD\14622893 vs.\CC\1740 bipolar\NN\1740 II\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 antidepressant\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 antidepressant\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 <e1>serotonin\NN\14807737 reuptake\NN\13571580 inhibitors</e1>\NNS\20090 [\-LRB-\1740 SSRIs\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 lithium\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D017367_D001714 CID Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 manic\JJ\1740 or\CC\3541091 hypomanic\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 DSM-IV\NN\1740 bipolar\NN\1740 I\CD\14622893 vs.\CC\1740 <e2>bipolar\NN\1740 II</e2>\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 antidepressant\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 antidepressant\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 <e1>serotonin\NN\14807737 reuptake\NN\13571580 inhibitors</e1>\NNS\20090 [\-LRB-\1740 SSRIs\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 lithium\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D017367_D001714 CID Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 manic\JJ\1740 or\CC\3541091 hypomanic\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 DSM-IV\NN\1740 bipolar\NN\1740 I\CD\14622893 vs.\CC\1740 bipolar\NN\1740 II\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 <e2>manic</e2>\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 antidepressant\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 antidepressant\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 <e1>serotonin\NN\14807737 reuptake\NN\13571580 inhibitors</e1>\NNS\20090 [\-LRB-\1740 SSRIs\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 lithium\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D017367_D001714 CID Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 <e2>manic</e2>\JJ\1740 or\CC\3541091 hypomanic\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 DSM-IV\NN\1740 bipolar\NN\1740 I\CD\14622893 vs.\CC\1740 bipolar\NN\1740 II\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 antidepressant\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 antidepressant\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 [\-LRB-\1740 <e1>SSRIs</e1>\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 lithium\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D017367_D001714 CID Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 manic\JJ\1740 or\CC\3541091 <e2>hypomanic</e2>\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 DSM-IV\NN\1740 bipolar\NN\1740 I\CD\14622893 vs.\CC\1740 bipolar\NN\1740 II\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 antidepressant\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 antidepressant\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 [\-LRB-\1740 <e1>SSRIs</e1>\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 lithium\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D017367_D001714 CID Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 manic\JJ\1740 or\CC\3541091 hypomanic\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 <e2>DSM-IV\NN\1740 bipolar\NN\1740 I</e2>\CD\14622893 vs.\CC\1740 bipolar\NN\1740 II\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 antidepressant\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 antidepressant\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 [\-LRB-\1740 <e1>SSRIs</e1>\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 lithium\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D017367_D001714 CID Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 manic\JJ\1740 or\CC\3541091 hypomanic\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 DSM-IV\NN\1740 bipolar\NN\1740 I\CD\14622893 vs.\CC\1740 <e2>bipolar\NN\1740 II</e2>\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 antidepressant\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 antidepressant\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 [\-LRB-\1740 <e1>SSRIs</e1>\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 lithium\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D017367_D001714 CID Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 manic\JJ\1740 or\CC\3541091 hypomanic\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 DSM-IV\NN\1740 bipolar\NN\1740 I\CD\14622893 vs.\CC\1740 bipolar\NN\1740 II\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 <e2>manic</e2>\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 antidepressant\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 antidepressant\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 [\-LRB-\1740 <e1>SSRIs</e1>\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 lithium\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D017367_D001714 CID RESULTS\NNS\34213 :\:\1740 Switches\NNS\3096960 to\TO\1740 <e2>hypomania</e2>\NN\1740 or\CC\3541091 mania\NN\9180259 occurred\VBD\2623529 in\IN\13603305 27\CD\13745420 %\NN\1740 of\IN\1740 all\DT\1740 patients\NNS\9898892 (\-LRB-\1740 N\NN\14622893 =\JJ\1740 12\CD\13745420 )\-RRB-\1740 (\-LRB-\1740 and\CC\1740 in\IN\13603305 24\CD\13745420 %\NN\1740 of\IN\1740 the\DT\1740 subgroup\NN\31264 of\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>SSRIs</e1>\NN\2718811 [\-LRB-\1740 8/33\CD\1740 ]\-RRB-\1740 )\-RRB-\1740 ;\:\1740 16\CD\13745420 %\NN\1740 (\-LRB-\1740 N\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 experienced\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 and\CC\1740 11\CD\13745420 %\NN\1740 (\-LRB-\1740 N\NN\14622893 =\JJ\1740 5\CD\13741022 )\-RRB-\1740 experienced\JJ\1740 hypomanic\JJ\1740 episodes\NNS\7283608 .\.\1740
D017367_D001714 CID RESULTS\NNS\34213 :\:\1740 Switches\NNS\3096960 to\TO\1740 hypomania\NN\1740 or\CC\3541091 <e2>mania</e2>\NN\9180259 occurred\VBD\2623529 in\IN\13603305 27\CD\13745420 %\NN\1740 of\IN\1740 all\DT\1740 patients\NNS\9898892 (\-LRB-\1740 N\NN\14622893 =\JJ\1740 12\CD\13745420 )\-RRB-\1740 (\-LRB-\1740 and\CC\1740 in\IN\13603305 24\CD\13745420 %\NN\1740 of\IN\1740 the\DT\1740 subgroup\NN\31264 of\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>SSRIs</e1>\NN\2718811 [\-LRB-\1740 8/33\CD\1740 ]\-RRB-\1740 )\-RRB-\1740 ;\:\1740 16\CD\13745420 %\NN\1740 (\-LRB-\1740 N\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 experienced\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 and\CC\1740 11\CD\13745420 %\NN\1740 (\-LRB-\1740 N\NN\14622893 =\JJ\1740 5\CD\13741022 )\-RRB-\1740 experienced\JJ\1740 hypomanic\JJ\1740 episodes\NNS\7283608 .\.\1740
D017367_D001714 CID RESULTS\NNS\34213 :\:\1740 Switches\NNS\3096960 to\TO\1740 hypomania\NN\1740 or\CC\3541091 mania\NN\9180259 occurred\VBD\2623529 in\IN\13603305 27\CD\13745420 %\NN\1740 of\IN\1740 all\DT\1740 patients\NNS\9898892 (\-LRB-\1740 N\NN\14622893 =\JJ\1740 12\CD\13745420 )\-RRB-\1740 (\-LRB-\1740 and\CC\1740 in\IN\13603305 24\CD\13745420 %\NN\1740 of\IN\1740 the\DT\1740 subgroup\NN\31264 of\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>SSRIs</e1>\NN\2718811 [\-LRB-\1740 8/33\CD\1740 ]\-RRB-\1740 )\-RRB-\1740 ;\:\1740 16\CD\13745420 %\NN\1740 (\-LRB-\1740 N\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 experienced\JJ\1740 <e2>manic</e2>\JJ\1740 episodes\NNS\7283608 ,\,\1740 and\CC\1740 11\CD\13745420 %\NN\1740 (\-LRB-\1740 N\NN\14622893 =\JJ\1740 5\CD\13741022 )\-RRB-\1740 experienced\JJ\1740 hypomanic\JJ\1740 episodes\NNS\7283608 .\.\1740
D017367_D001714 CID RESULTS\NNS\34213 :\:\1740 Switches\NNS\3096960 to\TO\1740 hypomania\NN\1740 or\CC\3541091 mania\NN\9180259 occurred\VBD\2623529 in\IN\13603305 27\CD\13745420 %\NN\1740 of\IN\1740 all\DT\1740 patients\NNS\9898892 (\-LRB-\1740 N\NN\14622893 =\JJ\1740 12\CD\13745420 )\-RRB-\1740 (\-LRB-\1740 and\CC\1740 in\IN\13603305 24\CD\13745420 %\NN\1740 of\IN\1740 the\DT\1740 subgroup\NN\31264 of\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>SSRIs</e1>\NN\2718811 [\-LRB-\1740 8/33\CD\1740 ]\-RRB-\1740 )\-RRB-\1740 ;\:\1740 16\CD\13745420 %\NN\1740 (\-LRB-\1740 N\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 experienced\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 and\CC\1740 11\CD\13745420 %\NN\1740 (\-LRB-\1740 N\NN\14622893 =\JJ\1740 5\CD\13741022 )\-RRB-\1740 experienced\JJ\1740 <e2>hypomanic</e2>\JJ\1740 episodes\NNS\7283608 .\.\1740
D008094_D001714 NONE Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 <e2>manic</e2>\JJ\1740 or\CC\3541091 hypomanic\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 DSM-IV\NN\1740 bipolar\NN\1740 I\CD\14622893 vs.\CC\1740 bipolar\NN\1740 II\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 antidepressant\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 antidepressant\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 [\-LRB-\1740 SSRIs\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 <e1>lithium</e1>\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D008094_D001714 NONE Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 manic\JJ\1740 or\CC\3541091 <e2>hypomanic</e2>\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 DSM-IV\NN\1740 bipolar\NN\1740 I\CD\14622893 vs.\CC\1740 bipolar\NN\1740 II\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 antidepressant\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 antidepressant\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 [\-LRB-\1740 SSRIs\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 <e1>lithium</e1>\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D008094_D001714 NONE Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 manic\JJ\1740 or\CC\3541091 hypomanic\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 <e2>DSM-IV\NN\1740 bipolar\NN\1740 I</e2>\CD\14622893 vs.\CC\1740 bipolar\NN\1740 II\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 antidepressant\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 antidepressant\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 [\-LRB-\1740 SSRIs\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 <e1>lithium</e1>\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D008094_D001714 NONE Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 manic\JJ\1740 or\CC\3541091 hypomanic\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 DSM-IV\NN\1740 bipolar\NN\1740 I\CD\14622893 vs.\CC\1740 <e2>bipolar\NN\1740 II</e2>\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 manic\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 antidepressant\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 antidepressant\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 [\-LRB-\1740 SSRIs\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 <e1>lithium</e1>\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
D008094_D001714 NONE Patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 a\DT\13649268 manic\JJ\1740 or\CC\3541091 hypomanic\JJ\1740 switch\NN\3096960 were\VBD\836236 compared\VBN\644583 with\IN\1740 those\DT\1740 who\WP\8299493 did\VBD\1640855 not\RB\1740 on\IN\1740 several\JJ\1740 variables\NNS\2452 including\VBG\690614 age\NN\4916342 ,\,\1740 sex\NN\13440063 ,\,\1740 diagnosis\NN\152018 (\-LRB-\1740 DSM-IV\NN\1740 bipolar\NN\1740 I\CD\14622893 vs.\CC\1740 bipolar\NN\1740 II\CD\13741022 )\-RRB-\1740 ,\,\1740 number\NN\5107765 of\IN\1740 previous\JJ\1740 <e2>manic</e2>\JJ\1740 episodes\NNS\7283608 ,\,\1740 type\NN\5839024 of\IN\1740 antidepressant\JJ\1740 therapy\NN\657604 used\VBN\1156834 (\-LRB-\1740 electroconvulsive\JJ\1740 therapy\NN\657604 vs.\CC\1740 antidepressant\JJ\1740 drugs\NNS\14778436 and\CC\1740 ,\,\1740 more\RBR\1740 particularly\RB\1740 ,\,\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 [\-LRB-\1740 SSRIs\NNP\2718811 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 use\NN\407535 and\CC\1740 type\NN\5839024 of\IN\1740 mood\NN\26192 stabilizers\NNS\14806838 (\-LRB-\1740 <e1>lithium</e1>\NN\14625458 vs.\FW\1740 anticonvulsants\NNS\3740161 )\-RRB-\1740 ,\,\1740 and\CC\1740 temperament\NN\4623113 of\IN\1740 the\DT\1740 patient\NN\9898892 ,\,\1740 assessed\VBN\670261 during\IN\1740 a\DT\13649268 normothymic\JJ\1740 period\NN\13575869 using\VBG\1156834 the\DT\1740 hyperthymia\JJ\1740 component\NN\5867413 of\IN\1740 the\DT\1740 Semi-structured\JJ\1740 Affective\JJ\1740 Temperament\NNP\4623113 Interview\NNP\7193958 .\.\1740
7977601
11206082
C036150_D012640 CID Two\CD\13741022 mouse\NN\2329401 lines\NNS\8426461 selected\VBN\697589 for\IN\1740 differential\JJ\1740 sensitivities\NNS\5651971 to\TO\1740 <e1>beta-carboline-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 are\VBP\836236 also\RB\1740 differentially\RB\1740 sensitive\JJ\1740 to\TO\1740 various\JJ\1740 pharmacological\JJ\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 GABA(A\NN\1740 )\-RRB-\1740 receptor\NN\5225602 ligands\NNS\20090 .\.\1740
C036150_D012640 CID Two\CD\13741022 mouse\NN\2329401 lines\NNS\8426461 were\VBD\836236 selectively\RB\1740 bred\VBN\1645601 according\VBG\2657219 to\IN\1740 their\PRP$\1740 sensitivity\NN\5651971 (\-LRB-\1740 BS\NN\6698252 line\NN\8426461 )\-RRB-\1740 or\CC\3541091 resistance\NN\37396 (\-LRB-\1740 BR\NN\14622893 line\NN\8426461 )\-RRB-\1740 to\TO\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 a\DT\13649268 single\JJ\1740 i.p.\RB\1740 injection\NN\320852 of\IN\1740 <e1>methyl\JJ\1740 beta-carboline-3-carboxylate</e1>\NN\1740 (\-LRB-\1740 beta-CCM\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inverse\JJ\1740 agonist\NN\9613191 of\IN\1740 the\DT\1740 GABA(A\NN\1740 )\-RRB-\1740 receptor\NN\5225602 benzodiazepine\NN\3771443 site\NN\8673395 .\.\1740
C036150_D012640 CID Two\CD\13741022 mouse\NN\2329401 lines\NNS\8426461 were\VBD\836236 selectively\RB\1740 bred\VBN\1645601 according\VBG\2657219 to\IN\1740 their\PRP$\1740 sensitivity\NN\5651971 (\-LRB-\1740 BS\NN\6698252 line\NN\8426461 )\-RRB-\1740 or\CC\3541091 resistance\NN\37396 (\-LRB-\1740 BR\NN\14622893 line\NN\8426461 )\-RRB-\1740 to\TO\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 a\DT\13649268 single\JJ\1740 i.p.\RB\1740 injection\NN\320852 of\IN\1740 methyl\JJ\1740 beta-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 <e1>beta-CCM</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inverse\JJ\1740 agonist\NN\9613191 of\IN\1740 the\DT\1740 GABA(A\NN\1740 )\-RRB-\1740 receptor\NN\5225602 benzodiazepine\NN\3771443 site\NN\8673395 .\.\1740
D005680_D012640 NONE Two\CD\13741022 mouse\NN\2329401 lines\NNS\8426461 selected\VBN\697589 for\IN\1740 differential\JJ\1740 sensitivities\NNS\5651971 to\TO\1740 beta-carboline-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 are\VBP\836236 also\RB\1740 differentially\RB\1740 sensitive\JJ\1740 to\TO\1740 various\JJ\1740 pharmacological\JJ\1740 effects\NNS\13245626 of\IN\1740 other\JJ\1740 <e1>GABA(A</e1>\NN\1740 )\-RRB-\1740 receptor\NN\5225602 ligands\NNS\20090 .\.\1740
D005680_D012640 NONE Two\CD\13741022 mouse\NN\2329401 lines\NNS\8426461 were\VBD\836236 selectively\RB\1740 bred\VBN\1645601 according\VBG\2657219 to\IN\1740 their\PRP$\1740 sensitivity\NN\5651971 (\-LRB-\1740 BS\NN\6698252 line\NN\8426461 )\-RRB-\1740 or\CC\3541091 resistance\NN\37396 (\-LRB-\1740 BR\NN\14622893 line\NN\8426461 )\-RRB-\1740 to\TO\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 a\DT\13649268 single\JJ\1740 i.p.\RB\1740 injection\NN\320852 of\IN\1740 methyl\JJ\1740 beta-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 beta-CCM\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inverse\JJ\1740 agonist\NN\9613191 of\IN\1740 the\DT\1740 <e1>GABA(A</e1>\NN\1740 )\-RRB-\1740 receptor\NN\5225602 benzodiazepine\NN\3771443 site\NN\8673395 .\.\1740
D001569_D012640 NONE Two\CD\13741022 mouse\NN\2329401 lines\NNS\8426461 were\VBD\836236 selectively\RB\1740 bred\VBN\1645601 according\VBG\2657219 to\IN\1740 their\PRP$\1740 sensitivity\NN\5651971 (\-LRB-\1740 BS\NN\6698252 line\NN\8426461 )\-RRB-\1740 or\CC\3541091 resistance\NN\37396 (\-LRB-\1740 BR\NN\14622893 line\NN\8426461 )\-RRB-\1740 to\TO\1740 <e2>seizures</e2>\NNS\14081375 induced\VBN\1627355 by\IN\1740 a\DT\13649268 single\JJ\1740 i.p.\RB\1740 injection\NN\320852 of\IN\1740 methyl\JJ\1740 beta-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 beta-CCM\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inverse\JJ\1740 agonist\NN\9613191 of\IN\1740 the\DT\1740 GABA(A\NN\1740 )\-RRB-\1740 receptor\NN\5225602 <e1>benzodiazepine</e1>\NN\3771443 site\NN\8673395 .\.\1740
D003975_D012640 NONE We\PRP\1740 measured\VBD\697589 <e1>diazepam-induced</e1>\JJ\1740 anxiolysis\NN\1740 with\IN\1740 the\DT\1740 elevated\JJ\1740 plus-maze\JJ\1740 test\NN\5798043 ,\,\1740 diazepam-induced\JJ\1740 sedation\NN\14034177 by\IN\1740 recording\VBG\2225492 the\DT\1740 vigilance\NN\5650579 states\NNS\8491826 ,\,\1740 and\CC\1740 picrotoxin-\NN\1740 and\CC\1740 pentylenetetrazol-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 after\IN\1740 i.p.\RB\1740 injections\NNS\320852 .\.\1740
D003975_D012640 NONE We\PRP\1740 measured\VBD\697589 diazepam-induced\JJ\1740 anxiolysis\NN\1740 with\IN\1740 the\DT\1740 elevated\JJ\1740 plus-maze\JJ\1740 test\NN\5798043 ,\,\1740 <e1>diazepam-induced</e1>\JJ\1740 sedation\NN\14034177 by\IN\1740 recording\VBG\2225492 the\DT\1740 vigilance\NN\5650579 states\NNS\8491826 ,\,\1740 and\CC\1740 picrotoxin-\NN\1740 and\CC\1740 pentylenetetrazol-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 after\IN\1740 i.p.\RB\1740 injections\NNS\320852 .\.\1740
D010852_D012640 CID We\PRP\1740 measured\VBD\697589 diazepam-induced\JJ\1740 anxiolysis\NN\1740 with\IN\1740 the\DT\1740 elevated\JJ\1740 plus-maze\JJ\1740 test\NN\5798043 ,\,\1740 diazepam-induced\JJ\1740 sedation\NN\14034177 by\IN\1740 recording\VBG\2225492 the\DT\1740 vigilance\NN\5650579 states\NNS\8491826 ,\,\1740 and\CC\1740 <e1>picrotoxin-</e1>\NN\1740 and\CC\1740 pentylenetetrazol-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 after\IN\1740 i.p.\RB\1740 injections\NNS\320852 .\.\1740
D010433_D012640 CID We\PRP\1740 measured\VBD\697589 diazepam-induced\JJ\1740 anxiolysis\NN\1740 with\IN\1740 the\DT\1740 elevated\JJ\1740 plus-maze\JJ\1740 test\NN\5798043 ,\,\1740 diazepam-induced\JJ\1740 sedation\NN\14034177 by\IN\1740 recording\VBG\2225492 the\DT\1740 vigilance\NN\5650579 states\NNS\8491826 ,\,\1740 and\CC\1740 picrotoxin-\NN\1740 and\CC\1740 <e1>pentylenetetrazol-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 after\IN\1740 i.p.\RB\1740 injections\NNS\320852 .\.\1740
18951540
D007980_D004409 CID Repetitive\JJ\1740 transcranial\JJ\1740 magnetic\JJ\1740 stimulation\NN\242808 for\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 <e2>dyskinesias</e2>\NNS\14084880 in\IN\13603305 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 .\.\1740
D007980_D010300 NONE Repetitive\JJ\1740 transcranial\JJ\1740 magnetic\JJ\1740 stimulation\NN\242808 for\IN\1740 <e1>levodopa-induced</e1>\JJ\1740 dyskinesias\NNS\14084880 in\IN\13603305 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 .\.\1740
17879945
D019438_D050197 CID We\PRP\1740 have\VBP\2108377 previously\RB\1740 demonstrated\VBN\2137132 that\IN\1740 <e1>ritonavir</e1>\NN\4013993 treatment\NN\654885 increases\VBZ\169651 <e2>atherosclerotic\JJ\1740 lesion</e2>\NN\14204950 formation\NN\7938773 in\IN\13603305 male\JJ\1740 mice\NNS\2329401 to\TO\1740 a\DT\13649268 greater\JJR\1740 extent\NN\13939892 than\IN\1740 in\IN\13603305 female\JJ\1740 mice\NNS\2329401 .\.\1740
4027862
D003891_D003693 CID <e1>Desipramine-induced</e1>\JJ\1740 <e2>delirium</e2>\NN\14391660 at\IN\14622893 "\``\1740 subtherapeutic\JJ\1740 "\''\1740 concentrations\NNS\4916342 :\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 .\.\1740
D003891_D003693 CID An\DT\6697703 elderly\JJ\1740 patient\NN\9898892 treated\VBN\2376958 with\IN\1740 low\JJ\1740 dose\NN\3740161 <e1>Desipramine</e1>\NN\4482543 developed\VBD\1753788 a\DT\13649268 <e2>delirium</e2>\NN\14391660 while\IN\15122231 her\PRP$\1740 plasma\NN\5398023 level\NN\4916342 was\VBD\836236 in\IN\13603305 the\DT\1740 "\``\1740 subtherapeutic\JJ\1740 "\''\1740 range\NN\5123416 .\.\1740
7862923
D002220_D012559 NONE <e1>Carbamazepine</e1>\NNP\1740 was\VBD\836236 switched\VBN\138508 to\TO\1740 its\PRP$\6125041 10-keto\NN\1740 analogue\NN\4743605 oxcarbazepine\NN\1740 among\IN\1740 six\CD\13741022 difficult-to-treat\JJ\1740 <e2>schizophrenic</e2>\NN\10490141 or\CC\3541091 organic\JJ\1740 psychotic\JJ\1740 patients\NNS\9898892 using\VBG\1156834 concomitantly\RB\1740 haloperidol\JJ\1740 ,\,\1740 chlorpromazine\NN\3713736 or\CC\3541091 clozapine\NN\3713736 .\.\1740
D002220_D019965 NONE <e1>Carbamazepine</e1>\NNP\1740 was\VBD\836236 switched\VBN\138508 to\TO\1740 its\PRP$\6125041 10-keto\NN\1740 analogue\NN\4743605 oxcarbazepine\NN\1740 among\IN\1740 six\CD\13741022 difficult-to-treat\JJ\1740 schizophrenic\NN\10490141 or\CC\3541091 <e2>organic\JJ\1740 psychotic</e2>\JJ\1740 patients\NNS\9898892 using\VBG\1156834 concomitantly\RB\1740 haloperidol\JJ\1740 ,\,\1740 chlorpromazine\NN\3713736 or\CC\3541091 clozapine\NN\3713736 .\.\1740
C036006_D012559 NONE Carbamazepine\NNP\1740 was\VBD\836236 switched\VBN\138508 to\TO\1740 its\PRP$\6125041 10-keto\NN\1740 analogue\NN\4743605 <e1>oxcarbazepine</e1>\NN\1740 among\IN\1740 six\CD\13741022 difficult-to-treat\JJ\1740 <e2>schizophrenic</e2>\NN\10490141 or\CC\3541091 organic\JJ\1740 psychotic\JJ\1740 patients\NNS\9898892 using\VBG\1156834 concomitantly\RB\1740 haloperidol\JJ\1740 ,\,\1740 chlorpromazine\NN\3713736 or\CC\3541091 clozapine\NN\3713736 .\.\1740
C036006_D019965 NONE Carbamazepine\NNP\1740 was\VBD\836236 switched\VBN\138508 to\TO\1740 its\PRP$\6125041 10-keto\NN\1740 analogue\NN\4743605 <e1>oxcarbazepine</e1>\NN\1740 among\IN\1740 six\CD\13741022 difficult-to-treat\JJ\1740 schizophrenic\NN\10490141 or\CC\3541091 <e2>organic\JJ\1740 psychotic</e2>\JJ\1740 patients\NNS\9898892 using\VBG\1156834 concomitantly\RB\1740 haloperidol\JJ\1740 ,\,\1740 chlorpromazine\NN\3713736 or\CC\3541091 clozapine\NN\3713736 .\.\1740
D006220_D012559 NONE Carbamazepine\NNP\1740 was\VBD\836236 switched\VBN\138508 to\TO\1740 its\PRP$\6125041 10-keto\NN\1740 analogue\NN\4743605 oxcarbazepine\NN\1740 among\IN\1740 six\CD\13741022 difficult-to-treat\JJ\1740 <e2>schizophrenic</e2>\NN\10490141 or\CC\3541091 organic\JJ\1740 psychotic\JJ\1740 patients\NNS\9898892 using\VBG\1156834 concomitantly\RB\1740 <e1>haloperidol</e1>\JJ\1740 ,\,\1740 chlorpromazine\NN\3713736 or\CC\3541091 clozapine\NN\3713736 .\.\1740
D006220_D019965 NONE Carbamazepine\NNP\1740 was\VBD\836236 switched\VBN\138508 to\TO\1740 its\PRP$\6125041 10-keto\NN\1740 analogue\NN\4743605 oxcarbazepine\NN\1740 among\IN\1740 six\CD\13741022 difficult-to-treat\JJ\1740 schizophrenic\NN\10490141 or\CC\3541091 <e2>organic\JJ\1740 psychotic</e2>\JJ\1740 patients\NNS\9898892 using\VBG\1156834 concomitantly\RB\1740 <e1>haloperidol</e1>\JJ\1740 ,\,\1740 chlorpromazine\NN\3713736 or\CC\3541091 clozapine\NN\3713736 .\.\1740
D002746_D012559 NONE Carbamazepine\NNP\1740 was\VBD\836236 switched\VBN\138508 to\TO\1740 its\PRP$\6125041 10-keto\NN\1740 analogue\NN\4743605 oxcarbazepine\NN\1740 among\IN\1740 six\CD\13741022 difficult-to-treat\JJ\1740 <e2>schizophrenic</e2>\NN\10490141 or\CC\3541091 organic\JJ\1740 psychotic\JJ\1740 patients\NNS\9898892 using\VBG\1156834 concomitantly\RB\1740 haloperidol\JJ\1740 ,\,\1740 <e1>chlorpromazine</e1>\NN\3713736 or\CC\3541091 clozapine\NN\3713736 .\.\1740
D002746_D019965 NONE Carbamazepine\NNP\1740 was\VBD\836236 switched\VBN\138508 to\TO\1740 its\PRP$\6125041 10-keto\NN\1740 analogue\NN\4743605 oxcarbazepine\NN\1740 among\IN\1740 six\CD\13741022 difficult-to-treat\JJ\1740 schizophrenic\NN\10490141 or\CC\3541091 <e2>organic\JJ\1740 psychotic</e2>\JJ\1740 patients\NNS\9898892 using\VBG\1156834 concomitantly\RB\1740 haloperidol\JJ\1740 ,\,\1740 <e1>chlorpromazine</e1>\NN\3713736 or\CC\3541091 clozapine\NN\3713736 .\.\1740
D003024_D012559 NONE Carbamazepine\NNP\1740 was\VBD\836236 switched\VBN\138508 to\TO\1740 its\PRP$\6125041 10-keto\NN\1740 analogue\NN\4743605 oxcarbazepine\NN\1740 among\IN\1740 six\CD\13741022 difficult-to-treat\JJ\1740 <e2>schizophrenic</e2>\NN\10490141 or\CC\3541091 organic\JJ\1740 psychotic\JJ\1740 patients\NNS\9898892 using\VBG\1156834 concomitantly\RB\1740 haloperidol\JJ\1740 ,\,\1740 chlorpromazine\NN\3713736 or\CC\3541091 <e1>clozapine</e1>\NN\3713736 .\.\1740
D003024_D019965 NONE Carbamazepine\NNP\1740 was\VBD\836236 switched\VBN\138508 to\TO\1740 its\PRP$\6125041 10-keto\NN\1740 analogue\NN\4743605 oxcarbazepine\NN\1740 among\IN\1740 six\CD\13741022 difficult-to-treat\JJ\1740 schizophrenic\NN\10490141 or\CC\3541091 <e2>organic\JJ\1740 psychotic</e2>\JJ\1740 patients\NNS\9898892 using\VBG\1156834 concomitantly\RB\1740 haloperidol\JJ\1740 ,\,\1740 chlorpromazine\NN\3713736 or\CC\3541091 <e1>clozapine</e1>\NN\3713736 .\.\1740
18221780
D016202_D010146 NONE Sex\NN\13440063 differences\NNS\4723816 in\IN\13603305 <e1>NMDA</e1>\NN\1740 antagonist\NN\7846 enhancement\NN\248977 of\IN\1740 morphine\NN\2707683 antihyperalgesia\NN\1740 in\IN\13603305 a\DT\13649268 capsaicin\NN\15032661 model\NN\5888929 of\IN\1740 persistent\JJ\1740 <e2>pain</e2>\NN\14299637 :\:\1740 comparisons\NNS\635850 to\TO\1740 two\CD\13741022 models\NNS\5888929 of\IN\1740 acute\JJ\1740 pain\NN\14299637 .\.\1740
D016202_D010146 NONE These\DT\1740 findings\NNS\7951464 demonstrate\VBP\2137132 a\DT\13649268 sexually-dimorphic\JJ\1740 interaction\NN\37396 between\IN\1740 <e1>NMDA</e1>\NN\1740 antagonists\NNS\7846 and\CC\1740 morphine\NN\2707683 in\IN\13603305 a\DT\13649268 persistent\JJ\1740 <e2>pain</e2>\NN\14299637 model\NN\5888929 that\WDT\1740 can\MD\3094503 be\VB\836236 distinguished\VBN\618878 from\IN\1740 those\DT\1740 observed\VBN\2163746 in\IN\13603305 acute\JJ\1740 pain\NN\14299637 models\NNS\5888929 .\.\1740
D016202_D059787 NONE Sex\NN\13440063 differences\NNS\4723816 in\IN\13603305 <e1>NMDA</e1>\NN\1740 antagonist\NN\7846 enhancement\NN\248977 of\IN\1740 morphine\NN\2707683 antihyperalgesia\NN\1740 in\IN\13603305 a\DT\13649268 capsaicin\NN\15032661 model\NN\5888929 of\IN\1740 persistent\JJ\1740 pain\NN\14299637 :\:\1740 comparisons\NNS\635850 to\TO\1740 two\CD\13741022 models\NNS\5888929 of\IN\1740 <e2>acute\JJ\1740 pain</e2>\NN\14299637 .\.\1740
D016202_D059787 NONE In\IN\13603305 <e2>acute\JJ\1740 pain</e2>\NN\14299637 models\NNS\5888929 ,\,\1740 <e1>N-methyl-D-aspartate</e1>\NN\1740 (\-LRB-\1740 NMDA\NN\1740 )\-RRB-\1740 antagonists\NNS\7846 enhance\VBP\227165 the\DT\1740 antinociceptive\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 to\TO\1740 a\DT\13649268 greater\JJR\1740 extent\NN\13939892 in\IN\13603305 males\NNS\15388 than\IN\1740 females\NNS\15388 .\.\1740
D016202_D059787 NONE In\IN\13603305 <e2>acute\JJ\1740 pain</e2>\NN\14299637 models\NNS\5888929 ,\,\1740 N-methyl-D-aspartate\NN\1740 (\-LRB-\1740 <e1>NMDA</e1>\NN\1740 )\-RRB-\1740 antagonists\NNS\7846 enhance\VBP\227165 the\DT\1740 antinociceptive\JJ\1740 effects\NNS\13245626 of\IN\1740 morphine\NN\2707683 to\TO\1740 a\DT\13649268 greater\JJR\1740 extent\NN\13939892 in\IN\13603305 males\NNS\15388 than\IN\1740 females\NNS\15388 .\.\1740
D016202_D059787 NONE These\DT\1740 findings\NNS\7951464 demonstrate\VBP\2137132 a\DT\13649268 sexually-dimorphic\JJ\1740 interaction\NN\37396 between\IN\1740 <e1>NMDA</e1>\NN\1740 antagonists\NNS\7846 and\CC\1740 morphine\NN\2707683 in\IN\13603305 a\DT\13649268 persistent\JJ\1740 pain\NN\14299637 model\NN\5888929 that\WDT\1740 can\MD\3094503 be\VB\836236 distinguished\VBN\618878 from\IN\1740 those\DT\1740 observed\VBN\2163746 in\IN\13603305 <e2>acute\JJ\1740 pain</e2>\NN\14299637 models\NNS\5888929 .\.\1740
D009020_D010146 NONE Sex\NN\13440063 differences\NNS\4723816 in\IN\13603305 NMDA\NN\1740 antagonist\NN\7846 enhancement\NN\248977 of\IN\1740 <e1>morphine</e1>\NN\2707683 antihyperalgesia\NN\1740 in\IN\13603305 a\DT\13649268 capsaicin\NN\15032661 model\NN\5888929 of\IN\1740 persistent\JJ\1740 <e2>pain</e2>\NN\14299637 :\:\1740 comparisons\NNS\635850 to\TO\1740 two\CD\13741022 models\NNS\5888929 of\IN\1740 acute\JJ\1740 pain\NN\14299637 .\.\1740
D009020_D010146 NONE These\DT\1740 findings\NNS\7951464 demonstrate\VBP\2137132 a\DT\13649268 sexually-dimorphic\JJ\1740 interaction\NN\37396 between\IN\1740 NMDA\NN\1740 antagonists\NNS\7846 and\CC\1740 <e1>morphine</e1>\NN\2707683 in\IN\13603305 a\DT\13649268 persistent\JJ\1740 <e2>pain</e2>\NN\14299637 model\NN\5888929 that\WDT\1740 can\MD\3094503 be\VB\836236 distinguished\VBN\618878 from\IN\1740 those\DT\1740 observed\VBN\2163746 in\IN\13603305 acute\JJ\1740 pain\NN\14299637 models\NNS\5888929 .\.\1740
D009020_D059787 NONE Sex\NN\13440063 differences\NNS\4723816 in\IN\13603305 NMDA\NN\1740 antagonist\NN\7846 enhancement\NN\248977 of\IN\1740 <e1>morphine</e1>\NN\2707683 antihyperalgesia\NN\1740 in\IN\13603305 a\DT\13649268 capsaicin\NN\15032661 model\NN\5888929 of\IN\1740 persistent\JJ\1740 pain\NN\14299637 :\:\1740 comparisons\NNS\635850 to\TO\1740 two\CD\13741022 models\NNS\5888929 of\IN\1740 <e2>acute\JJ\1740 pain</e2>\NN\14299637 .\.\1740
D009020_D059787 NONE In\IN\13603305 <e2>acute\JJ\1740 pain</e2>\NN\14299637 models\NNS\5888929 ,\,\1740 N-methyl-D-aspartate\NN\1740 (\-LRB-\1740 NMDA\NN\1740 )\-RRB-\1740 antagonists\NNS\7846 enhance\VBP\227165 the\DT\1740 antinociceptive\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>morphine</e1>\NN\2707683 to\TO\1740 a\DT\13649268 greater\JJR\1740 extent\NN\13939892 in\IN\13603305 males\NNS\15388 than\IN\1740 females\NNS\15388 .\.\1740
D009020_D059787 NONE Enhancement\NN\248977 of\IN\1740 <e1>morphine</e1>\NN\2707683 antinociception\NN\1740 by\IN\1740 dextromethorphan\NN\1740 was\VBD\836236 seen\VBN\2106506 in\IN\13603305 both\DT\1740 males\NNS\15388 and\CC\1740 females\NNS\15388 in\IN\13603305 the\DT\1740 <e2>acute\JJ\1740 pain</e2>\NN\14299637 models\NNS\5888929 ,\,\1740 with\IN\1740 the\DT\1740 magnitude\NN\4916342 of\IN\1740 this\DT\1740 effect\NN\34213 being\VBG\836236 greater\JJR\1740 in\IN\13603305 males\NNS\15388 .\.\1740
D009020_D059787 NONE These\DT\1740 findings\NNS\7951464 demonstrate\VBP\2137132 a\DT\13649268 sexually-dimorphic\JJ\1740 interaction\NN\37396 between\IN\1740 NMDA\NN\1740 antagonists\NNS\7846 and\CC\1740 <e1>morphine</e1>\NN\2707683 in\IN\13603305 a\DT\13649268 persistent\JJ\1740 pain\NN\14299637 model\NN\5888929 that\WDT\1740 can\MD\3094503 be\VB\836236 distinguished\VBN\618878 from\IN\1740 those\DT\1740 observed\VBN\2163746 in\IN\13603305 <e2>acute\JJ\1740 pain</e2>\NN\14299637 models\NNS\5888929 .\.\1740
D002211_D010146 NONE Sex\NN\13440063 differences\NNS\4723816 in\IN\13603305 NMDA\NN\1740 antagonist\NN\7846 enhancement\NN\248977 of\IN\1740 morphine\NN\2707683 antihyperalgesia\NN\1740 in\IN\13603305 a\DT\13649268 <e1>capsaicin</e1>\NN\15032661 model\NN\5888929 of\IN\1740 persistent\JJ\1740 <e2>pain</e2>\NN\14299637 :\:\1740 comparisons\NNS\635850 to\TO\1740 two\CD\13741022 models\NNS\5888929 of\IN\1740 acute\JJ\1740 pain\NN\14299637 .\.\1740
D002211_D059787 NONE Sex\NN\13440063 differences\NNS\4723816 in\IN\13603305 NMDA\NN\1740 antagonist\NN\7846 enhancement\NN\248977 of\IN\1740 morphine\NN\2707683 antihyperalgesia\NN\1740 in\IN\13603305 a\DT\13649268 <e1>capsaicin</e1>\NN\15032661 model\NN\5888929 of\IN\1740 persistent\JJ\1740 pain\NN\14299637 :\:\1740 comparisons\NNS\635850 to\TO\1740 two\CD\13741022 models\NNS\5888929 of\IN\1740 <e2>acute\JJ\1740 pain</e2>\NN\14299637 .\.\1740
D002211_D006930 CID To\IN\1740 this\DT\1740 end\NN\8568978 ,\,\1740 persistent\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 was\VBD\836236 induced\VBN\1627355 by\IN\1740 administration\NN\1133281 of\IN\1740 <e1>capsaicin</e1>\NN\15032661 in\IN\13603305 the\DT\1740 tail\NN\5470189 of\IN\1740 gonadally\RB\1740 intact\JJ\1740 F344\NN\1740 rats\NNS\2329401 ,\,\1740 following\VBG\1835496 which\WDT\1740 the\DT\1740 tail\NN\5470189 was\VBD\836236 immersed\VBN\1227675 in\IN\13603305 a\DT\13649268 mildly\RB\1740 noxious\JJ\1740 thermal\JJ\1740 stimulus\NN\5816287 ,\,\1740 and\CC\1740 tail-withdrawal\JJ\1740 latencies\NNS\15269513 measured\VBN\697589 .\.\1740
D003915_D059787 NONE Enhancement\NN\248977 of\IN\1740 morphine\NN\2707683 antinociception\NN\1740 by\IN\1740 <e1>dextromethorphan</e1>\NN\1740 was\VBD\836236 seen\VBN\2106506 in\IN\13603305 both\DT\1740 males\NNS\15388 and\CC\1740 females\NNS\15388 in\IN\13603305 the\DT\1740 <e2>acute\JJ\1740 pain</e2>\NN\14299637 models\NNS\5888929 ,\,\1740 with\IN\1740 the\DT\1740 magnitude\NN\4916342 of\IN\1740 this\DT\1740 effect\NN\34213 being\VBG\836236 greater\JJR\1740 in\IN\13603305 males\NNS\15388 .\.\1740
17261653
D003000_D001919 CID <e1>Clonidine-induced</e1>\JJ\1740 <e2>bradycardia</e2>\NN\14110674 in\IN\13603305 conscious\JJ\1740 alpha2ABC-/-\JJ\1740 mice\NNS\2329401 was\VBD\836236 32.3\CD\1740 %\NN\1740 (\-LRB-\1740 10\CD\13745420 microg/kg\NNS\1740 )\-RRB-\1740 and\CC\1740 26.6\CD\1740 %\NN\1740 (\-LRB-\1740 100\CD\13745420 microg/kg\NNS\1740 )\-RRB-\1740 of\IN\1740 the\DT\1740 effect\NN\34213 in\IN\13603305 wild-type\JJ\1740 mice\NNS\2329401 .\.\1740
7858459
D005472_D003221 CID Acute\JJ\1740 <e2>confusion</e2>\NN\13972797 induced\VBN\1627355 by\IN\1740 a\DT\13649268 high-dose\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 .\.\1740
D005472_D003221 CID He\PRP\14622893 developed\VBD\1753788 acute\JJ\1740 neurologic\JJ\1740 symptoms\NNS\5823932 of\IN\1740 mental\JJ\1740 <e2>confusion</e2>\NN\13972797 ,\,\1740 disorientation\NN\5896733 and\CC\1740 irritability\NN\7552087 ,\,\1740 and\CC\1740 then\RB\1740 lapsed\VBN\124442 into\IN\1740 a\DT\13649268 deep\JJ\1740 coma\NN\5678932 ,\,\1740 lasting\VBG\2704349 for\IN\1740 approximately\RB\1740 40\CD\13745420 hours\NNS\15118228 during\IN\1740 the\DT\1740 first\JJ\1740 dose\NN\3740161 (\-LRB-\1740 day\NN\15154774 2\CD\13741022 )\-RRB-\1740 of\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 infusion\NN\14589223 .\.\1740
D005472_D003221 CID He\PRP\14622893 developed\VBD\1753788 acute\JJ\1740 neurologic\JJ\1740 symptoms\NNS\5823932 of\IN\1740 mental\JJ\1740 confusion\NN\13972797 ,\,\1740 <e2>disorientation</e2>\NN\5896733 and\CC\1740 irritability\NN\7552087 ,\,\1740 and\CC\1740 then\RB\1740 lapsed\VBN\124442 into\IN\1740 a\DT\13649268 deep\JJ\1740 coma\NN\5678932 ,\,\1740 lasting\VBG\2704349 for\IN\1740 approximately\RB\1740 40\CD\13745420 hours\NNS\15118228 during\IN\1740 the\DT\1740 first\JJ\1740 dose\NN\3740161 (\-LRB-\1740 day\NN\15154774 2\CD\13741022 )\-RRB-\1740 of\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 infusion\NN\14589223 .\.\1740
D002955_D003221 CID Acute\JJ\1740 <e2>confusion</e2>\NN\13972797 induced\VBN\1627355 by\IN\1740 a\DT\13649268 high-dose\JJ\1740 infusion\NN\14589223 of\IN\1740 5-fluorouracil\NN\1740 and\CC\1740 <e1>folinic\JJ\1740 acid</e1>\NN\14818238 .\.\1740
D002955_D003221 CID He\PRP\14622893 developed\VBD\1753788 acute\JJ\1740 neurologic\JJ\1740 symptoms\NNS\5823932 of\IN\1740 mental\JJ\1740 <e2>confusion</e2>\NN\13972797 ,\,\1740 disorientation\NN\5896733 and\CC\1740 irritability\NN\7552087 ,\,\1740 and\CC\1740 then\RB\1740 lapsed\VBN\124442 into\IN\1740 a\DT\13649268 deep\JJ\1740 coma\NN\5678932 ,\,\1740 lasting\VBG\2704349 for\IN\1740 approximately\RB\1740 40\CD\13745420 hours\NNS\15118228 during\IN\1740 the\DT\1740 first\JJ\1740 dose\NN\3740161 (\-LRB-\1740 day\NN\15154774 2\CD\13741022 )\-RRB-\1740 of\IN\1740 5-fluorouracil\NN\1740 and\CC\1740 <e1>folinic\JJ\1740 acid</e1>\NN\14818238 infusion\NN\14589223 .\.\1740
D002955_D003221 CID He\PRP\14622893 developed\VBD\1753788 acute\JJ\1740 neurologic\JJ\1740 symptoms\NNS\5823932 of\IN\1740 mental\JJ\1740 confusion\NN\13972797 ,\,\1740 <e2>disorientation</e2>\NN\5896733 and\CC\1740 irritability\NN\7552087 ,\,\1740 and\CC\1740 then\RB\1740 lapsed\VBN\124442 into\IN\1740 a\DT\13649268 deep\JJ\1740 coma\NN\5678932 ,\,\1740 lasting\VBG\2704349 for\IN\1740 approximately\RB\1740 40\CD\13745420 hours\NNS\15118228 during\IN\1740 the\DT\1740 first\JJ\1740 dose\NN\3740161 (\-LRB-\1740 day\NN\15154774 2\CD\13741022 )\-RRB-\1740 of\IN\1740 5-fluorouracil\NN\1740 and\CC\1740 <e1>folinic\JJ\1740 acid</e1>\NN\14818238 infusion\NN\14589223 .\.\1740
D002945_D013274 NONE A\DT\13649268 61-year-old\JJ\1740 man\NN\9605289 was\VBD\836236 treated\VBN\2376958 with\IN\1740 combination\NN\7951464 chemotherapy\NN\661091 incorporating\VBG\1461328 <e1>cisplatinum</e1>\NN\1740 ,\,\1740 etoposide\NN\1740 ,\,\1740 high-dose\NN\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 2,250\CD\1740 mg/m2/24\NNS\1740 hours\NNS\15118228 )\-RRB-\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 for\IN\1740 an\DT\6697703 inoperable\JJ\1740 <e2>gastric\JJ\1740 adenocarcinoma</e2>\NN\14242337 .\.\1740
D005047_D013274 NONE A\DT\13649268 61-year-old\JJ\1740 man\NN\9605289 was\VBD\836236 treated\VBN\2376958 with\IN\1740 combination\NN\7951464 chemotherapy\NN\661091 incorporating\VBG\1461328 cisplatinum\NN\1740 ,\,\1740 <e1>etoposide</e1>\NN\1740 ,\,\1740 high-dose\NN\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 2,250\CD\1740 mg/m2/24\NNS\1740 hours\NNS\15118228 )\-RRB-\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 for\IN\1740 an\DT\6697703 inoperable\JJ\1740 <e2>gastric\JJ\1740 adenocarcinoma</e2>\NN\14242337 .\.\1740
D005472_D013274 NONE A\DT\13649268 61-year-old\JJ\1740 man\NN\9605289 was\VBD\836236 treated\VBN\2376958 with\IN\1740 combination\NN\7951464 chemotherapy\NN\661091 incorporating\VBG\1461328 cisplatinum\NN\1740 ,\,\1740 etoposide\NN\1740 ,\,\1740 high-dose\NN\1740 <e1>5-fluorouracil</e1>\NN\1740 (\-LRB-\1740 2,250\CD\1740 mg/m2/24\NNS\1740 hours\NNS\15118228 )\-RRB-\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 for\IN\1740 an\DT\6697703 inoperable\JJ\1740 <e2>gastric\JJ\1740 adenocarcinoma</e2>\NN\14242337 .\.\1740
D002955_D013274 NONE A\DT\13649268 61-year-old\JJ\1740 man\NN\9605289 was\VBD\836236 treated\VBN\2376958 with\IN\1740 combination\NN\7951464 chemotherapy\NN\661091 incorporating\VBG\1461328 cisplatinum\NN\1740 ,\,\1740 etoposide\NN\1740 ,\,\1740 high-dose\NN\1740 5-fluorouracil\NN\1740 (\-LRB-\1740 2,250\CD\1740 mg/m2/24\NNS\1740 hours\NNS\15118228 )\-RRB-\1740 and\CC\1740 <e1>folinic\JJ\1740 acid</e1>\NN\14818238 for\IN\1740 an\DT\6697703 inoperable\JJ\1740 <e2>gastric\JJ\1740 adenocarcinoma</e2>\NN\14242337 .\.\1740
D005472_D001523 NONE He\PRP\14622893 developed\VBD\1753788 acute\JJ\1740 neurologic\JJ\1740 symptoms\NNS\5823932 of\IN\1740 mental\JJ\1740 confusion\NN\13972797 ,\,\1740 disorientation\NN\5896733 and\CC\1740 <e2>irritability</e2>\NN\7552087 ,\,\1740 and\CC\1740 then\RB\1740 lapsed\VBN\124442 into\IN\1740 a\DT\13649268 deep\JJ\1740 coma\NN\5678932 ,\,\1740 lasting\VBG\2704349 for\IN\1740 approximately\RB\1740 40\CD\13745420 hours\NNS\15118228 during\IN\1740 the\DT\1740 first\JJ\1740 dose\NN\3740161 (\-LRB-\1740 day\NN\15154774 2\CD\13741022 )\-RRB-\1740 of\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 infusion\NN\14589223 .\.\1740
D005472_D003128 CID He\PRP\14622893 developed\VBD\1753788 acute\JJ\1740 neurologic\JJ\1740 symptoms\NNS\5823932 of\IN\1740 mental\JJ\1740 confusion\NN\13972797 ,\,\1740 disorientation\NN\5896733 and\CC\1740 irritability\NN\7552087 ,\,\1740 and\CC\1740 then\RB\1740 lapsed\VBN\124442 into\IN\1740 a\DT\13649268 deep\JJ\1740 <e2>coma</e2>\NN\5678932 ,\,\1740 lasting\VBG\2704349 for\IN\1740 approximately\RB\1740 40\CD\13745420 hours\NNS\15118228 during\IN\1740 the\DT\1740 first\JJ\1740 dose\NN\3740161 (\-LRB-\1740 day\NN\15154774 2\CD\13741022 )\-RRB-\1740 of\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 and\CC\1740 folinic\JJ\1740 acid\NN\14818238 infusion\NN\14589223 .\.\1740
D002955_D001523 NONE He\PRP\14622893 developed\VBD\1753788 acute\JJ\1740 neurologic\JJ\1740 symptoms\NNS\5823932 of\IN\1740 mental\JJ\1740 confusion\NN\13972797 ,\,\1740 disorientation\NN\5896733 and\CC\1740 <e2>irritability</e2>\NN\7552087 ,\,\1740 and\CC\1740 then\RB\1740 lapsed\VBN\124442 into\IN\1740 a\DT\13649268 deep\JJ\1740 coma\NN\5678932 ,\,\1740 lasting\VBG\2704349 for\IN\1740 approximately\RB\1740 40\CD\13745420 hours\NNS\15118228 during\IN\1740 the\DT\1740 first\JJ\1740 dose\NN\3740161 (\-LRB-\1740 day\NN\15154774 2\CD\13741022 )\-RRB-\1740 of\IN\1740 5-fluorouracil\NN\1740 and\CC\1740 <e1>folinic\JJ\1740 acid</e1>\NN\14818238 infusion\NN\14589223 .\.\1740
D002955_D003128 CID He\PRP\14622893 developed\VBD\1753788 acute\JJ\1740 neurologic\JJ\1740 symptoms\NNS\5823932 of\IN\1740 mental\JJ\1740 confusion\NN\13972797 ,\,\1740 disorientation\NN\5896733 and\CC\1740 irritability\NN\7552087 ,\,\1740 and\CC\1740 then\RB\1740 lapsed\VBN\124442 into\IN\1740 a\DT\13649268 deep\JJ\1740 <e2>coma</e2>\NN\5678932 ,\,\1740 lasting\VBG\2704349 for\IN\1740 approximately\RB\1740 40\CD\13745420 hours\NNS\15118228 during\IN\1740 the\DT\1740 first\JJ\1740 dose\NN\3740161 (\-LRB-\1740 day\NN\15154774 2\CD\13741022 )\-RRB-\1740 of\IN\1740 5-fluorouracil\NN\1740 and\CC\1740 <e1>folinic\JJ\1740 acid</e1>\NN\14818238 infusion\NN\14589223 .\.\1740
D002955_D020258 NONE Because\IN\1740 <e1>folinic\JJ\1740 acid</e1>\NN\14818238 was\VBD\836236 unlikely\JJ\1740 to\TO\1740 be\VB\836236 associated\VBN\628491 with\IN\1740 this\DT\1740 condition\NN\24720 ,\,\1740 <e2>neurotoxicity</e2>\NN\1740 due\JJ\1740 to\TO\1740 high-dose\JJ\1740 5-fluorouracil\NN\1740 was\VBD\836236 highly\RB\1740 suspected\VBN\916909 .\.\1740
D005472_D020258 NONE Because\IN\1740 folinic\JJ\1740 acid\NN\14818238 was\VBD\836236 unlikely\JJ\1740 to\TO\1740 be\VB\836236 associated\VBN\628491 with\IN\1740 this\DT\1740 condition\NN\24720 ,\,\1740 <e2>neurotoxicity</e2>\NN\1740 due\JJ\1740 to\TO\1740 high-dose\JJ\1740 <e1>5-fluorouracil</e1>\NN\1740 was\VBD\836236 highly\RB\1740 suspected\VBN\916909 .\.\1740
D005472_D020258 NONE The\DT\1740 pathogenesis\NN\13533470 of\IN\1740 <e1>5-fluorouracil</e1>\NN\1740 <e2>neurotoxicity</e2>\NN\1740 may\MD\15209706 be\VB\836236 due\JJ\1740 to\TO\1740 a\DT\13649268 Krebs\NN\1740 cycle\NN\15269513 blockade\NN\952963 by\IN\1740 fluoroacetate\NN\1740 and\CC\1740 fluorocitrate\VB\1740 ,\,\1740 thiamine\NN\15090742 deficiency\NN\14449126 ,\,\1740 or\CC\3541091 dihydrouracil\NN\1740 dehydrogenase\NN\1740 deficiency\NN\14449126 .\.\1740
D005463_D020258 NONE The\DT\1740 pathogenesis\NN\13533470 of\IN\1740 5-fluorouracil\NN\1740 <e2>neurotoxicity</e2>\NN\1740 may\MD\15209706 be\VB\836236 due\JJ\1740 to\TO\1740 a\DT\13649268 Krebs\NN\1740 cycle\NN\15269513 blockade\NN\952963 by\IN\1740 <e1>fluoroacetate</e1>\NN\1740 and\CC\1740 fluorocitrate\VB\1740 ,\,\1740 thiamine\NN\15090742 deficiency\NN\14449126 ,\,\1740 or\CC\3541091 dihydrouracil\NN\1740 dehydrogenase\NN\1740 deficiency\NN\14449126 .\.\1740
C007744_D020258 NONE The\DT\1740 pathogenesis\NN\13533470 of\IN\1740 5-fluorouracil\NN\1740 <e2>neurotoxicity</e2>\NN\1740 may\MD\15209706 be\VB\836236 due\JJ\1740 to\TO\1740 a\DT\13649268 Krebs\NN\1740 cycle\NN\15269513 blockade\NN\952963 by\IN\1740 fluoroacetate\NN\1740 and\CC\1740 <e1>fluorocitrate</e1>\VB\1740 ,\,\1740 thiamine\NN\15090742 deficiency\NN\14449126 ,\,\1740 or\CC\3541091 dihydrouracil\NN\1740 dehydrogenase\NN\1740 deficiency\NN\14449126 .\.\1740
D013831_D020258 NONE The\DT\1740 pathogenesis\NN\13533470 of\IN\1740 5-fluorouracil\NN\1740 <e2>neurotoxicity</e2>\NN\1740 may\MD\15209706 be\VB\836236 due\JJ\1740 to\TO\1740 a\DT\13649268 Krebs\NN\1740 cycle\NN\15269513 blockade\NN\952963 by\IN\1740 fluoroacetate\NN\1740 and\CC\1740 fluorocitrate\VB\1740 ,\,\1740 <e1>thiamine</e1>\NN\15090742 deficiency\NN\14449126 ,\,\1740 or\CC\3541091 dihydrouracil\NN\1740 dehydrogenase\NN\1740 deficiency\NN\14449126 .\.\1740
C007419_D020258 NONE The\DT\1740 pathogenesis\NN\13533470 of\IN\1740 5-fluorouracil\NN\1740 <e2>neurotoxicity</e2>\NN\1740 may\MD\15209706 be\VB\836236 due\JJ\1740 to\TO\1740 a\DT\13649268 Krebs\NN\1740 cycle\NN\15269513 blockade\NN\952963 by\IN\1740 fluoroacetate\NN\1740 and\CC\1740 fluorocitrate\VB\1740 ,\,\1740 thiamine\NN\15090742 deficiency\NN\14449126 ,\,\1740 or\CC\3541091 <e1>dihydrouracil</e1>\NN\1740 dehydrogenase\NN\1740 deficiency\NN\14449126 .\.\1740
D005472_D009369 NONE High-dose\JJ\1740 <e1>5-fluorouracil/folinic</e1>\NN\1740 acid\NN\14818238 infusion\NN\14589223 therapy\NN\657604 has\VBZ\2108377 recently\RB\1740 become\VBN\146138 a\DT\13649268 popular\JJ\1740 regimen\NN\5898568 for\IN\1740 various\JJ\1740 <e2>cancers</e2>\NNS\14239425 .\.\1740
D002955_D009369 NONE High-dose\JJ\1740 <e1>5-fluorouracil/folinic\NN\1740 acid</e1>\NN\14818238 infusion\NN\14589223 therapy\NN\657604 has\VBZ\2108377 recently\RB\1740 become\VBN\146138 a\DT\13649268 popular\JJ\1740 regimen\NN\5898568 for\IN\1740 various\JJ\1740 <e2>cancers</e2>\NNS\14239425 .\.\1740
2234245
D003676_D014786 NONE <e2>Ocular\JJ\1740 and\CC\1740 auditory\JJ\1740 toxicity</e2>\NN\13576101 in\IN\13603305 hemodialyzed\VBN\1740 patients\NNS\9898892 receiving\VBG\2210855 <e1>desferrioxamine</e1>\NN\1740 .\.\1740
D003676_D014786 NONE During\IN\1740 an\DT\6697703 18-month\JJ\1740 period\NN\13575869 of\IN\1740 study\NN\635850 41\CD\1740 hemodialyzed\VBD\1740 patients\NNS\9898892 receiving\VBG\2210855 <e1>desferrioxamine</e1>\NN\1740 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 40\CD\13745420 mg/kg\NN\1740 BW/3\NN\1740 times\NNS\15113229 weekly\RB\1740 )\-RRB-\1740 for\IN\1740 the\DT\1740 first\JJ\1740 time\NN\7308889 were\VBD\836236 monitored\VBN\2169352 for\IN\1740 detection\NN\5708432 of\IN\1740 <e2>audiovisual\JJ\1740 toxicity</e2>\NN\13576101 .\.\1740
D003676_D014786 NONE The\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 <e2>audiovisual\JJ\1740 toxicity</e2>\NN\13576101 is\VBZ\836236 not\RB\1740 an\DT\6697703 infrequent\JJ\1740 complication\NN\1073995 in\IN\13603305 hemodialyzed\VBN\1740 patients\NNS\9898892 receiving\VBG\2210855 <e1>desferrioxamine</e1>\NN\1740 .\.\1740
D003676_D006311 NONE <e2>Ocular\JJ\1740 and\CC\1740 auditory\JJ\1740 toxicity</e2>\NN\13576101 in\IN\13603305 hemodialyzed\VBN\1740 patients\NNS\9898892 receiving\VBG\2210855 <e1>desferrioxamine</e1>\NN\1740 .\.\1740
D003676_D006311 NONE During\IN\1740 an\DT\6697703 18-month\JJ\1740 period\NN\13575869 of\IN\1740 study\NN\635850 41\CD\1740 hemodialyzed\VBD\1740 patients\NNS\9898892 receiving\VBG\2210855 <e1>desferrioxamine</e1>\NN\1740 (\-LRB-\1740 10\CD\13745420 -\SYM\1740 40\CD\13745420 mg/kg\NN\1740 BW/3\NN\1740 times\NNS\15113229 weekly\RB\1740 )\-RRB-\1740 for\IN\1740 the\DT\1740 first\JJ\1740 time\NN\7308889 were\VBD\836236 monitored\VBN\2169352 for\IN\1740 detection\NN\5708432 of\IN\1740 <e2>audiovisual\JJ\1740 toxicity</e2>\NN\13576101 .\.\1740
D003676_D006311 NONE The\DT\1740 data\NNS\7951464 indicate\VBP\952524 that\IN\1740 <e2>audiovisual\JJ\1740 toxicity</e2>\NN\13576101 is\VBZ\836236 not\RB\1740 an\DT\6697703 infrequent\JJ\1740 complication\NN\1073995 in\IN\13603305 hemodialyzed\VBN\1740 patients\NNS\9898892 receiving\VBG\2210855 <e1>desferrioxamine</e1>\NN\1740 .\.\1740
D003676_D034381 NONE <e1>Desferrioxamine</e1>\NN\1740 withdrawal\NN\7206096 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 complete\JJ\1740 recovery\NN\7357388 of\IN\1740 visual\JJ\1740 function\NN\13783581 in\IN\13603305 1\CD\13741022 patient\NN\9898892 and\CC\1740 partial\JJ\1740 recovery\NN\7357388 in\IN\13603305 3\CD\13741022 ,\,\1740 and\CC\1740 a\DT\13649268 complete\JJ\1740 reversal\NN\199130 of\IN\1740 <e2>hearing\VBG\2106506 loss</e2>\NN\13252973 in\IN\13603305 3\CD\13741022 patients\NNS\9898892 and\CC\1740 partial\JJ\1740 recovery\NN\7357388 in\IN\13603305 3\CD\13741022 .\.\1740
D003676_D064420 NONE This\DT\1740 <e2>toxicity</e2>\NN\13576101 appeared\VBD\2604760 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 the\DT\1740 higher\JJR\1740 doses\NNS\3740161 of\IN\1740 <e1>desferrioxamine</e1>\NN\1740 or\CC\3541091 coincided\VBD\2604477 with\IN\1740 the\DT\1740 normalization\NN\1123598 of\IN\1740 ferritin\NN\14728724 or\CC\3541091 aluminium\NN\14625458 serum\NN\5397468 levels\NNS\4916342 .\.\1740
-1_D064420 NONE This\DT\1740 <e2>toxicity</e2>\NN\13576101 appeared\VBD\2604760 in\IN\13603305 patients\NNS\9898892 receiving\VBG\2210855 the\DT\1740 higher\JJR\1740 doses\NNS\3740161 of\IN\1740 desferrioxamine\NN\1740 or\CC\3541091 coincided\VBD\2604477 with\IN\1740 the\DT\1740 normalization\NN\1123598 of\IN\1740 ferritin\NN\14728724 or\CC\3541091 <e1>aluminium</e1>\NN\14625458 serum\NN\5397468 levels\NNS\4916342 .\.\1740
17437408
D010862_D012640 CID A\DT\13649268 comparable\JJ\1740 overexpression\NN\1740 of\IN\1740 Pgp\NN\1740 in\IN\13603305 the\DT\1740 BBB\NN\1740 was\VBD\836236 obtained\VBN\2210855 after\IN\1740 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 wild-type\JJ\1740 Wistar\NNP\1740 rats\NNS\2329401 .\.\1740
18020536
D001569_D004244 CID However\RB\1740 ,\,\1740 use\NN\407535 of\IN\1740 <e1>BZDs/RDs</e1>\NN\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 <e2>dizziness</e2>\NN\14299637 ,\,\1740 inability\NN\23271 to\TO\1740 sleep\VB\14405 after\IN\1740 awaking\VBG\146138 at\IN\14622893 night\NN\15113229 and\CC\1740 tiredness\VB\1740 in\IN\13603305 the\DT\1740 mornings\NNS\15113229 during\IN\1740 the\DT\1740 week\NN\15113229 prior\RB\1740 to\IN\1740 admission\NN\49003 and\CC\1740 with\IN\1740 stronger\JJR\1740 depressive\JJ\1740 symptoms\NNS\5823932 measured\VBN\697589 at\IN\14622893 the\DT\1740 beginning\NN\7283608 of\IN\1740 the\DT\1740 hospital\NN\3739518 stay\VBP\2604760 .\.\1740
D001569_D007319 CID However\RB\1740 ,\,\1740 use\NN\407535 of\IN\1740 <e1>BZDs/RDs</e1>\NN\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 dizziness\NN\14299637 ,\,\1740 <e2>inability\NN\23271 to\TO\1740 sleep</e2>\VB\14405 after\IN\1740 awaking\VBG\146138 at\IN\14622893 night\NN\15113229 and\CC\1740 tiredness\VB\1740 in\IN\13603305 the\DT\1740 mornings\NNS\15113229 during\IN\1740 the\DT\1740 week\NN\15113229 prior\RB\1740 to\IN\1740 admission\NN\49003 and\CC\1740 with\IN\1740 stronger\JJR\1740 depressive\JJ\1740 symptoms\NNS\5823932 measured\VBN\697589 at\IN\14622893 the\DT\1740 beginning\NN\7283608 of\IN\1740 the\DT\1740 hospital\NN\3739518 stay\VBP\2604760 .\.\1740
D001569_D005221 CID However\RB\1740 ,\,\1740 use\NN\407535 of\IN\1740 <e1>BZDs/RDs</e1>\NN\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 dizziness\NN\14299637 ,\,\1740 inability\NN\23271 to\TO\1740 sleep\VB\14405 after\IN\1740 awaking\VBG\146138 at\IN\14622893 night\NN\15113229 and\CC\1740 <e2>tiredness</e2>\VB\1740 in\IN\13603305 the\DT\1740 mornings\NNS\15113229 during\IN\1740 the\DT\1740 week\NN\15113229 prior\RB\1740 to\IN\1740 admission\NN\49003 and\CC\1740 with\IN\1740 stronger\JJR\1740 depressive\JJ\1740 symptoms\NNS\5823932 measured\VBN\697589 at\IN\14622893 the\DT\1740 beginning\NN\7283608 of\IN\1740 the\DT\1740 hospital\NN\3739518 stay\VBP\2604760 .\.\1740
D001569_D003866 CID However\RB\1740 ,\,\1740 use\NN\407535 of\IN\1740 <e1>BZDs/RDs</e1>\NN\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 dizziness\NN\14299637 ,\,\1740 inability\NN\23271 to\TO\1740 sleep\VB\14405 after\IN\1740 awaking\VBG\146138 at\IN\14622893 night\NN\15113229 and\CC\1740 tiredness\VB\1740 in\IN\13603305 the\DT\1740 mornings\NNS\15113229 during\IN\1740 the\DT\1740 week\NN\15113229 prior\RB\1740 to\IN\1740 admission\NN\49003 and\CC\1740 with\IN\1740 stronger\JJR\1740 <e2>depressive\JJ\1740 symptoms</e2>\NNS\5823932 measured\VBN\697589 at\IN\14622893 the\DT\1740 beginning\NN\7283608 of\IN\1740 the\DT\1740 hospital\NN\3739518 stay\VBP\2604760 .\.\1740
9625142
D002443_D056486 CID Acute\JJ\1740 <e2>hepatitis</e2>\NN\14127211 ,\,\1740 autoimmune\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 ,\,\1740 and\CC\1740 erythroblastocytopenia\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>ceftriaxone</e1>\NN\2996840 .\.\1740
D002443_D056486 CID An\DT\6697703 80-yr-old\NN\1740 man\NN\9605289 developed\VBD\1753788 acute\JJ\1740 <e2>hepatitis</e2>\NN\14127211 shortly\RB\1740 after\IN\1740 ingesting\VBG\597915 oral\JJ\1740 <e1>ceftriaxone</e1>\NN\2996840 .\.\1740
D002443_D000744 CID Acute\JJ\1740 hepatitis\NN\14127211 ,\,\1740 <e2>autoimmune\JJ\1740 hemolytic\JJ\1740 anemia</e2>\NN\14189204 ,\,\1740 and\CC\1740 erythroblastocytopenia\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>ceftriaxone</e1>\NN\2996840 .\.\1740
D002443_-1 NONE Acute\JJ\1740 hepatitis\NN\14127211 ,\,\1740 autoimmune\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 ,\,\1740 and\CC\1740 <e2>erythroblastocytopenia</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 <e1>ceftriaxone</e1>\NN\2996840 .\.\1740
D047090_D000744 NONE Although\IN\1740 the\DT\1740 transaminases\NNS\15077571 gradually\RB\1740 returned\VBD\1835496 to\TO\1740 baseline\NN\7260623 after\IN\1740 withholding\VBG\2212825 the\DT\1740 <e1>beta\NN\6828818 lactam</e1>\NN\1740 antibiotic\NN\2716205 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 gradual\JJ\1740 increase\NN\13576355 in\IN\13603305 serum\NN\5397468 bilirubin\NN\14756039 and\CC\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 hemoglobin\NN\14888884 concentration\NN\4916342 caused\VBN\1617192 by\IN\1740 an\DT\6697703 <e2>autoimmune\JJ\1740 hemolytic\JJ\1740 anemia</e2>\NN\14189204 and\CC\1740 erythroblastocytopenia\NN\1740 .\.\1740
D047090_-1 NONE Although\IN\1740 the\DT\1740 transaminases\NNS\15077571 gradually\RB\1740 returned\VBD\1835496 to\TO\1740 baseline\NN\7260623 after\IN\1740 withholding\VBG\2212825 the\DT\1740 <e1>beta\NN\6828818 lactam</e1>\NN\1740 antibiotic\NN\2716205 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 gradual\JJ\1740 increase\NN\13576355 in\IN\13603305 serum\NN\5397468 bilirubin\NN\14756039 and\CC\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 hemoglobin\NN\14888884 concentration\NN\4916342 caused\VBN\1617192 by\IN\1740 an\DT\6697703 autoimmune\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 and\CC\1740 <e2>erythroblastocytopenia</e2>\NN\1740 .\.\1740
D001663_D000744 NONE Although\IN\1740 the\DT\1740 transaminases\NNS\15077571 gradually\RB\1740 returned\VBD\1835496 to\TO\1740 baseline\NN\7260623 after\IN\1740 withholding\VBG\2212825 the\DT\1740 beta\NN\6828818 lactam\NN\1740 antibiotic\NN\2716205 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 gradual\JJ\1740 increase\NN\13576355 in\IN\13603305 serum\NN\5397468 <e1>bilirubin</e1>\NN\14756039 and\CC\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 hemoglobin\NN\14888884 concentration\NN\4916342 caused\VBN\1617192 by\IN\1740 an\DT\6697703 <e2>autoimmune\JJ\1740 hemolytic\JJ\1740 anemia</e2>\NN\14189204 and\CC\1740 erythroblastocytopenia\NN\1740 .\.\1740
D001663_-1 NONE Although\IN\1740 the\DT\1740 transaminases\NNS\15077571 gradually\RB\1740 returned\VBD\1835496 to\TO\1740 baseline\NN\7260623 after\IN\1740 withholding\VBG\2212825 the\DT\1740 beta\NN\6828818 lactam\NN\1740 antibiotic\NN\2716205 ,\,\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 gradual\JJ\1740 increase\NN\13576355 in\IN\13603305 serum\NN\5397468 <e1>bilirubin</e1>\NN\14756039 and\CC\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 hemoglobin\NN\14888884 concentration\NN\4916342 caused\VBN\1617192 by\IN\1740 an\DT\6697703 autoimmune\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 and\CC\1740 <e2>erythroblastocytopenia</e2>\NN\1740 .\.\1740
16403073
D007654_D016171 CID <e1>Ketoconazole</e1>\NNP\1740 induced\VBD\1627355 <e2>torsades\NNS\1740 de\IN\1740 pointes</e2>\NNS\1740 without\IN\1740 concomitant\JJ\1740 use\NN\407535 of\IN\1740 QT\NN\1740 interval-prolonging\JJ\1740 drug\NN\14778436 .\.\1740
D007654_D016171 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 woman\NN\9605289 with\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 who\WP\8299493 developed\VBD\1753788 a\DT\13649268 markedly\RB\1740 prolonged\JJ\1740 QT\NN\1740 interval\NN\33615 and\CC\1740 <e2>torsades\NNS\1740 de\IN\1740 pointes</e2>\NNS\1740 (\-LRB-\1740 TdP\NN\1740 )\-RRB-\1740 after\IN\1740 taking\VBG\2367363 <e1>ketoconazole</e1>\NN\1740 for\IN\1740 treatment\NN\654885 of\IN\1740 fungal\JJ\1740 infection\NN\14052046 .\.\1740
D007654_D016171 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 woman\NN\9605289 with\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 who\WP\8299493 developed\VBD\1753788 a\DT\13649268 markedly\RB\1740 prolonged\JJ\1740 QT\NN\1740 interval\NN\33615 and\CC\1740 torsades\NNS\1740 de\IN\1740 pointes\NNS\1740 (\-LRB-\1740 <e2>TdP</e2>\NN\1740 )\-RRB-\1740 after\IN\1740 taking\VBG\2367363 <e1>ketoconazole</e1>\NN\1740 for\IN\1740 treatment\NN\654885 of\IN\1740 fungal\JJ\1740 infection\NN\14052046 .\.\1740
D007654_D016171 CID We\PRP\1740 postulate\VBP\756338 that\IN\1740 by\IN\1740 virtue\NN\4849241 of\IN\1740 its\PRP$\6125041 direct\JJ\1740 blocking\NN\562280 action\NN\30358 on\IN\1740 IKr\NN\1740 ,\,\1740 <e1>ketoconazole</e1>\NN\1740 alone\RB\1740 may\MD\15209706 prolong\VB\317700 QT\NN\1740 interval\NN\33615 and\CC\1740 induce\VBP\1627355 <e2>TdP.</e2>\NN\1740 This\DT\1740 calls\VBZ\1029852 for\IN\1740 attention\NN\5701944 when\WRB\1740 ketoconazole\NN\1740 is\VBZ\836236 administered\VBN\2436349 to\TO\1740 patients\NNS\9898892 with\IN\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 acquired\VBN\109660 long\JJ\1740 QT\NN\1740 syndrome\NN\5870365 .\.\1740
D007654_D016171 CID We\PRP\1740 postulate\VBP\756338 that\IN\1740 by\IN\1740 virtue\NN\4849241 of\IN\1740 its\PRP$\6125041 direct\JJ\1740 blocking\NN\562280 action\NN\30358 on\IN\1740 IKr\NN\1740 ,\,\1740 ketoconazole\NN\1740 alone\RB\1740 may\MD\15209706 prolong\VB\317700 QT\NN\1740 interval\NN\33615 and\CC\1740 induce\VBP\1627355 <e2>TdP.</e2>\NN\1740 This\DT\1740 calls\VBZ\1029852 for\IN\1740 attention\NN\5701944 when\WRB\1740 <e1>ketoconazole</e1>\NN\1740 is\VBZ\836236 administered\VBN\2436349 to\TO\1740 patients\NNS\9898892 with\IN\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 acquired\VBN\109660 long\JJ\1740 QT\NN\1740 syndrome\NN\5870365 .\.\1740
D007654_D003324 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 woman\NN\9605289 with\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 who\WP\8299493 developed\VBD\1753788 a\DT\13649268 markedly\RB\1740 prolonged\JJ\1740 QT\NN\1740 interval\NN\33615 and\CC\1740 torsades\NNS\1740 de\IN\1740 pointes\NNS\1740 (\-LRB-\1740 TdP\NN\1740 )\-RRB-\1740 after\IN\1740 taking\VBG\2367363 <e1>ketoconazole</e1>\NN\1740 for\IN\1740 treatment\NN\654885 of\IN\1740 fungal\JJ\1740 infection\NN\14052046 .\.\1740
D007654_D008133 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 woman\NN\9605289 with\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 who\WP\8299493 developed\VBD\1753788 a\DT\13649268 markedly\RB\1740 <e2>prolonged\JJ\1740 QT\NN\1740 interval</e2>\NN\33615 and\CC\1740 torsades\NNS\1740 de\IN\1740 pointes\NNS\1740 (\-LRB-\1740 TdP\NN\1740 )\-RRB-\1740 after\IN\1740 taking\VBG\2367363 <e1>ketoconazole</e1>\NN\1740 for\IN\1740 treatment\NN\654885 of\IN\1740 fungal\JJ\1740 infection\NN\14052046 .\.\1740
D007654_D008133 CID We\PRP\1740 postulate\VBP\756338 that\IN\1740 by\IN\1740 virtue\NN\4849241 of\IN\1740 its\PRP$\6125041 direct\JJ\1740 blocking\NN\562280 action\NN\30358 on\IN\1740 IKr\NN\1740 ,\,\1740 <e1>ketoconazole</e1>\NN\1740 alone\RB\1740 may\MD\15209706 prolong\VB\317700 QT\NN\1740 interval\NN\33615 and\CC\1740 induce\VBP\1627355 TdP.\NN\1740 This\DT\1740 calls\VBZ\1029852 for\IN\1740 attention\NN\5701944 when\WRB\1740 ketoconazole\NN\1740 is\VBZ\836236 administered\VBN\2436349 to\TO\1740 patients\NNS\9898892 with\IN\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 acquired\VBN\109660 <e2>long\JJ\1740 QT\NN\1740 syndrome</e2>\NN\5870365 .\.\1740
D007654_D008133 CID We\PRP\1740 postulate\VBP\756338 that\IN\1740 by\IN\1740 virtue\NN\4849241 of\IN\1740 its\PRP$\6125041 direct\JJ\1740 blocking\NN\562280 action\NN\30358 on\IN\1740 IKr\NN\1740 ,\,\1740 ketoconazole\NN\1740 alone\RB\1740 may\MD\15209706 prolong\VB\317700 QT\NN\1740 interval\NN\33615 and\CC\1740 induce\VBP\1627355 TdP.\NN\1740 This\DT\1740 calls\VBZ\1029852 for\IN\1740 attention\NN\5701944 when\WRB\1740 <e1>ketoconazole</e1>\NN\1740 is\VBZ\836236 administered\VBN\2436349 to\TO\1740 patients\NNS\9898892 with\IN\1740 risk\NN\14541044 factors\NNS\7326557 for\IN\1740 acquired\VBN\109660 <e2>long\JJ\1740 QT\NN\1740 syndrome</e2>\NN\5870365 .\.\1740
D007654_D009181 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 woman\NN\9605289 with\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 who\WP\8299493 developed\VBD\1753788 a\DT\13649268 markedly\RB\1740 prolonged\JJ\1740 QT\NN\1740 interval\NN\33615 and\CC\1740 torsades\NNS\1740 de\IN\1740 pointes\NNS\1740 (\-LRB-\1740 TdP\NN\1740 )\-RRB-\1740 after\IN\1740 taking\VBG\2367363 <e1>ketoconazole</e1>\NN\1740 for\IN\1740 treatment\NN\654885 of\IN\1740 <e2>fungal\JJ\1740 infection</e2>\NN\14052046 .\.\1740
3341566
D009599_D006470 NONE Systolic\JJ\1740 pressure\NN\11419404 variation\NN\7296428 is\VBZ\836236 greater\JJR\1740 during\IN\1740 <e2>hemorrhage</e2>\NN\14285662 than\IN\1740 during\IN\1740 <e1>sodium\NN\14625458 nitroprusside-induced</e1>\JJ\1740 hypotension\NN\14057371 in\IN\13603305 ventilated\VBN\164444 dogs\NNS\2083346 .\.\1740
D009599_D006470 NONE Mean\VB\928630 arterial\JJ\1740 pressure\NN\11419404 was\VBD\836236 decreased\VBN\169651 to\TO\1740 50\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 for\IN\1740 30\CD\13745420 minutes\NNS\6502378 either\CC\1740 by\IN\1740 <e2>hemorrhage</e2>\NN\14285662 (\-LRB-\1740 HEM\NN\3264542 ,\,\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 or\CC\3541091 by\IN\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>sodium\NN\14625458 nitroprusside</e1>\NN\1740 (\-LRB-\1740 SNP\NN\11493266 ,\,\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 .\.\1740
D009599_D006470 NONE Mean\VB\928630 arterial\JJ\1740 pressure\NN\11419404 was\VBD\836236 decreased\VBN\169651 to\TO\1740 50\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 for\IN\1740 30\CD\13745420 minutes\NNS\6502378 either\CC\1740 by\IN\1740 hemorrhage\NN\14285662 (\-LRB-\1740 <e2>HEM</e2>\NN\3264542 ,\,\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 or\CC\3541091 by\IN\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>sodium\NN\14625458 nitroprusside</e1>\NN\1740 (\-LRB-\1740 SNP\NN\11493266 ,\,\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 .\.\1740
D009599_D006470 NONE Mean\VB\928630 arterial\JJ\1740 pressure\NN\11419404 was\VBD\836236 decreased\VBN\169651 to\TO\1740 50\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 for\IN\1740 30\CD\13745420 minutes\NNS\6502378 either\CC\1740 by\IN\1740 <e2>hemorrhage</e2>\NN\14285662 (\-LRB-\1740 HEM\NN\3264542 ,\,\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 or\CC\3541091 by\IN\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 sodium\NN\14625458 nitroprusside\NN\1740 (\-LRB-\1740 <e1>SNP</e1>\NN\11493266 ,\,\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 .\.\1740
D009599_D006470 NONE Mean\VB\928630 arterial\JJ\1740 pressure\NN\11419404 was\VBD\836236 decreased\VBN\169651 to\TO\1740 50\CD\13745420 mm\NN\13649268 Hg\NNP\14625458 for\IN\1740 30\CD\13745420 minutes\NNS\6502378 either\CC\1740 by\IN\1740 hemorrhage\NN\14285662 (\-LRB-\1740 <e2>HEM</e2>\NN\3264542 ,\,\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 or\CC\3541091 by\IN\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 sodium\NN\14625458 nitroprusside\NN\1740 (\-LRB-\1740 <e1>SNP</e1>\NN\11493266 ,\,\1740 n\NN\14622893 =\JJ\1740 7\CD\13741022 )\-RRB-\1740 .\.\1740
D009599_D006470 NONE During\IN\1740 <e2>HEM-induced</e2>\JJ\1740 hypotension\NN\14057371 the\DT\1740 cardiac\JJ\1740 output\NN\4007894 was\VBD\836236 significantly\RB\1740 lower\JJR\1740 and\CC\1740 systemic\JJ\1740 vascular\JJ\1740 resistance\NN\37396 higher\JJR\1740 compared\VBN\644583 with\IN\1740 that\DT\1740 in\IN\13603305 the\DT\1740 <e1>SNP</e1>\NN\11493266 group\NN\2137 .\.\1740
D009599_D006470 NONE The\DT\1740 SPV\NN\1740 during\IN\1740 hypotension\NN\14057371 was\VBD\836236 15.7\CD\1740 +/-\CC\1740 6.7\CD\1740 mm\NN\13649268 Hg\NNP\14625458 in\IN\13603305 the\DT\1740 <e2>HEM</e2>\NN\3264542 group\NN\2137 ,\,\1740 compared\VBN\644583 with\IN\1740 9.1\CD\1740 +/-\CC\1740 2.0\CD\1740 mm\NN\13649268 Hg\NNP\14625458 in\IN\13603305 the\DT\1740 <e1>SNP</e1>\NN\11493266 group\NN\2137 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.02\CD\1740 )\-RRB-\1740 .\.\1740
D009599_D006470 NONE The\DT\1740 delta\NN\9193282 down\RP\1740 ,\,\1740 which\WDT\1740 is\VBZ\836236 the\DT\1740 measure\NN\168237 of\IN\1740 decrease\NN\7296428 of\IN\1740 SBP\NN\1740 after\IN\1740 a\DT\13649268 mechanical\JJ\1740 breath\NN\13440063 ,\,\1740 was\VBD\836236 20.3\CD\1740 +/-\CC\1740 8.4\CD\1740 and\CC\1740 10.1\CD\1740 +/-\CC\1740 3.8\CD\1740 mm\NN\13649268 Hg\NNP\14625458 in\IN\13603305 the\DT\1740 <e2>HEM</e2>\NN\3264542 and\CC\1740 <e1>SNP</e1>\NN\11493266 groups\NNS\2137 ,\,\1740 respectively\RB\1740 ,\,\1740 during\IN\1740 hypotension\NN\14057371 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.02\CD\1740 )\-RRB-\1740 .\.\1740
D009599_D007022 CID Systolic\JJ\1740 pressure\NN\11419404 variation\NN\7296428 is\VBZ\836236 greater\JJR\1740 during\IN\1740 hemorrhage\NN\14285662 than\IN\1740 during\IN\1740 <e1>sodium\NN\14625458 nitroprusside-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 ventilated\VBN\164444 dogs\NNS\2083346 .\.\1740
D009599_D007022 CID During\IN\1740 HEM-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 the\DT\1740 cardiac\JJ\1740 output\NN\4007894 was\VBD\836236 significantly\RB\1740 lower\JJR\1740 and\CC\1740 systemic\JJ\1740 vascular\JJ\1740 resistance\NN\37396 higher\JJR\1740 compared\VBN\644583 with\IN\1740 that\DT\1740 in\IN\13603305 the\DT\1740 <e1>SNP</e1>\NN\11493266 group\NN\2137 .\.\1740
D009599_D007022 CID The\DT\1740 SPV\NN\1740 during\IN\1740 <e2>hypotension</e2>\NN\14057371 was\VBD\836236 15.7\CD\1740 +/-\CC\1740 6.7\CD\1740 mm\NN\13649268 Hg\NNP\14625458 in\IN\13603305 the\DT\1740 HEM\NN\3264542 group\NN\2137 ,\,\1740 compared\VBN\644583 with\IN\1740 9.1\CD\1740 +/-\CC\1740 2.0\CD\1740 mm\NN\13649268 Hg\NNP\14625458 in\IN\13603305 the\DT\1740 <e1>SNP</e1>\NN\11493266 group\NN\2137 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.02\CD\1740 )\-RRB-\1740 .\.\1740
D009599_D007022 CID The\DT\1740 delta\NN\9193282 down\RP\1740 ,\,\1740 which\WDT\1740 is\VBZ\836236 the\DT\1740 measure\NN\168237 of\IN\1740 decrease\NN\7296428 of\IN\1740 SBP\NN\1740 after\IN\1740 a\DT\13649268 mechanical\JJ\1740 breath\NN\13440063 ,\,\1740 was\VBD\836236 20.3\CD\1740 +/-\CC\1740 8.4\CD\1740 and\CC\1740 10.1\CD\1740 +/-\CC\1740 3.8\CD\1740 mm\NN\13649268 Hg\NNP\14625458 in\IN\13603305 the\DT\1740 HEM\NN\3264542 and\CC\1740 <e1>SNP</e1>\NN\11493266 groups\NNS\2137 ,\,\1740 respectively\RB\1740 ,\,\1740 during\IN\1740 <e2>hypotension</e2>\NN\14057371 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.02\CD\1740 )\-RRB-\1740 .\.\1740
15009014
D002211_D006940 CID <e1>Capsaicin</e1>\NN\15032661 (\-LRB-\1740 0.01\CD\1740 -\SYM\1740 1\CD\13741022 mm\NN\13649268 )\-RRB-\1740 applied\VBD\2676054 to\TO\1740 oral\JJ\1740 or\CC\3541091 nasal\JJ\1740 mucosa\NN\5426243 induced\VBN\1627355 <e2>increases\NNS\13576355 in\IN\13603305 dural\JJ\1740 and\CC\1740 cortical\JJ\1740 blood\NN\5397468 flow</e2>\NN\7311115 and\CC\1740 provoked\VBD\1617192 lacrimation\NN\13440063 .\.\1740
D001285_D006940 NONE The\DT\1740 evoked\VBN\1617192 <e2>increases\NNS\13576355 in\IN\13603305 dural\JJ\1740 blood\NN\5397468 flow</e2>\NN\7311115 were\VBD\836236 also\RB\1740 abolished\VBN\1740 by\IN\1740 topical\JJ\1740 pre-administration\NN\1740 of\IN\1740 <e1>atropine</e1>\NN\14712692 (\-LRB-\1740 1\CD\13741022 mm\NN\13649268 )\-RRB-\1740 and\CC\1740 [\-LRB-\1740 Lys1\NN\1740 ,\,\1740 Pro2,5\NN\1740 ,\,\1740 Arg3,4\NN\1740 ,\,\1740 Tyr6]-VIP\NN\1740 (\-LRB-\1740 0.1\CD\1740 mm\NN\13649268 )\-RRB-\1740 ,\,\1740 a\DT\13649268 vasoactive\JJ\1740 intestinal\JJ\1740 polypeptide\NN\14743046 (\-LRB-\1740 VIP\NN\10200781 )\-RRB-\1740 antagonist\NN\7846 ,\,\1740 onto\IN\1740 the\DT\1740 exposed\VBN\2110927 dura\JJ\1740 mater\NN\10332385 .\.\1740
19058010
D010936_D009203 NONE Effect\NN\34213 of\IN\1740 <e1>green\JJ\1740 tea</e1>\NN\7881800 and\CC\1740 vitamin\NN\7570720 E\NN\14724645 combination\NN\7951464 in\IN\13603305 isoproterenol\NN\3740161 induced\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
D010936_D009203 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 aimed\VBN\1987160 to\TO\1740 investigate\VB\644583 the\DT\1740 combined\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>green\JJ\1740 tea</e1>\NN\7881800 and\CC\1740 vitamin\NN\7570720 E\NN\14724645 on\IN\1740 heart\NN\5919034 weight\NN\5009170 ,\,\1740 body\NN\19128 weight\NN\5009170 ,\,\1740 serum\NN\5397468 marker\NN\21939 enzymes\NNS\14723628 ,\,\1740 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 endogenous\JJ\1740 antioxidants\NNS\14724436 and\CC\1740 membrane\NN\4188643 bound\VBD\1831531 ATPases\NNS\1740 in\IN\13603305 isoproterenol\NN\3740161 (ISO)-induced\VBN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
D010936_D009203 NONE These\DT\1740 findings\NNS\7951464 indicate\VBP\952524 the\DT\1740 synergistic\JJ\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 <e1>green\JJ\1740 tea</e1>\NN\7881800 and\CC\1740 vitamin\NN\7570720 E\NN\14724645 during\IN\1740 ISO\NN\1740 induced\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
D014810_D009203 NONE Effect\NN\34213 of\IN\1740 green\JJ\1740 tea\NN\7881800 and\CC\1740 <e1>vitamin\NN\7570720 E</e1>\NN\14724645 combination\NN\7951464 in\IN\13603305 isoproterenol\NN\3740161 induced\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
D014810_D009203 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 aimed\VBN\1987160 to\TO\1740 investigate\VB\644583 the\DT\1740 combined\JJ\1740 effects\NNS\13245626 of\IN\1740 green\JJ\1740 tea\NN\7881800 and\CC\1740 <e1>vitamin\NN\7570720 E</e1>\NN\14724645 on\IN\1740 heart\NN\5919034 weight\NN\5009170 ,\,\1740 body\NN\19128 weight\NN\5009170 ,\,\1740 serum\NN\5397468 marker\NN\21939 enzymes\NNS\14723628 ,\,\1740 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 endogenous\JJ\1740 antioxidants\NNS\14724436 and\CC\1740 membrane\NN\4188643 bound\VBD\1831531 ATPases\NNS\1740 in\IN\13603305 isoproterenol\NN\3740161 (ISO)-induced\VBN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
D014810_D009203 NONE These\DT\1740 findings\NNS\7951464 indicate\VBP\952524 the\DT\1740 synergistic\JJ\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 green\JJ\1740 tea\NN\7881800 and\CC\1740 <e1>vitamin\NN\7570720 E</e1>\NN\14724645 during\IN\1740 ISO\NN\1740 induced\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
D007545_D009203 CID Effect\NN\34213 of\IN\1740 green\JJ\1740 tea\NN\7881800 and\CC\1740 vitamin\NN\7570720 E\NN\14724645 combination\NN\7951464 in\IN\13603305 <e1>isoproterenol</e1>\NN\3740161 induced\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
D007545_D009203 CID The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 aimed\VBN\1987160 to\TO\1740 investigate\VB\644583 the\DT\1740 combined\JJ\1740 effects\NNS\13245626 of\IN\1740 green\JJ\1740 tea\NN\7881800 and\CC\1740 vitamin\NN\7570720 E\NN\14724645 on\IN\1740 heart\NN\5919034 weight\NN\5009170 ,\,\1740 body\NN\19128 weight\NN\5009170 ,\,\1740 serum\NN\5397468 marker\NN\21939 enzymes\NNS\14723628 ,\,\1740 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 endogenous\JJ\1740 antioxidants\NNS\14724436 and\CC\1740 membrane\NN\4188643 bound\VBD\1831531 ATPases\NNS\1740 in\IN\13603305 <e1>isoproterenol</e1>\NN\3740161 (ISO)-induced\VBN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
D007545_D009203 CID The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 aimed\VBN\1987160 to\TO\1740 investigate\VB\644583 the\DT\1740 combined\JJ\1740 effects\NNS\13245626 of\IN\1740 green\JJ\1740 tea\NN\7881800 and\CC\1740 vitamin\NN\7570720 E\NN\14724645 on\IN\1740 heart\NN\5919034 weight\NN\5009170 ,\,\1740 body\NN\19128 weight\NN\5009170 ,\,\1740 serum\NN\5397468 marker\NN\21939 enzymes\NNS\14723628 ,\,\1740 lipid\NN\14944888 peroxidation\NN\1740 ,\,\1740 endogenous\JJ\1740 antioxidants\NNS\14724436 and\CC\1740 membrane\NN\4188643 bound\VBD\1831531 ATPases\NNS\1740 in\IN\13603305 isoproterenol\NN\3740161 <e1>(ISO)-induced</e1>\VBN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
D007545_D009203 CID These\DT\1740 findings\NNS\7951464 indicate\VBP\952524 the\DT\1740 synergistic\JJ\1740 protective\JJ\1740 effect\NN\34213 of\IN\1740 green\JJ\1740 tea\NN\7881800 and\CC\1740 vitamin\NN\7570720 E\NN\14724645 during\IN\1740 <e1>ISO</e1>\NN\1740 induced\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
2096243
C017367_D019965 CID <e1>Carmofur-induced</e1>\JJ\1740 <e2>organic\JJ\1740 mental\JJ\1740 disorders</e2>\NNS\14034177 .\.\1740
C017367_D019965 CID <e2>Organic\JJ\1740 mental\JJ\1740 disorder</e2>\NN\14034177 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 a\DT\13649268 29-year-old\JJ\1740 female\NN\15388 in\IN\13603305 the\DT\1740 prognostic\JJ\1740 period\NN\13575869 after\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 <e1>carmofur-induced</e1>\JJ\1740 leukoencephalopathy\NN\1740 .\.\1740
C017367_D056784 CID Organic\JJ\1740 mental\JJ\1740 disorder\NN\14034177 was\VBD\836236 observed\VBN\2163746 in\IN\13603305 a\DT\13649268 29-year-old\JJ\1740 female\NN\15388 in\IN\13603305 the\DT\1740 prognostic\JJ\1740 period\NN\13575869 after\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 <e1>carmofur-induced</e1>\JJ\1740 <e2>leukoencephalopathy</e2>\NN\1740 .\.\1740
C017367_D056784 CID Consequently\RB\1740 ,\,\1740 <e1>carmofur-induced</e1>\JJ\1740 <e2>leukoencephalopathy</e2>\NN\1740 may\MD\15209706 uncommonly\RB\1740 result\VB\2633881 in\IN\13603305 organic\JJ\1740 personality\NN\24264 syndrome\NN\5870365 in\IN\13603305 the\DT\1740 residual\JJ\1740 state\NN\8491826 .\.\1740
C017367_D010554 NONE Consequently\RB\1740 ,\,\1740 <e1>carmofur-induced</e1>\JJ\1740 leukoencephalopathy\NN\1740 may\MD\15209706 uncommonly\RB\1740 result\VB\2633881 in\IN\13603305 <e2>organic\JJ\1740 personality\NN\24264 syndrome</e2>\NN\5870365 in\IN\13603305 the\DT\1740 residual\JJ\1740 state\NN\8491826 .\.\1740
3676049
D007530_D007022 CID Cerebral\JJ\1740 blood\NN\5397468 flow\NN\7311115 and\CC\1740 metabolism\NN\13526110 during\IN\1740 <e1>isoflurane-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 patients\NNS\9898892 subjected\VBN\137313 to\TO\1740 surgery\NN\6045562 for\IN\1740 cerebral\JJ\1740 aneurysms\NNS\14057371 .\.\1740
D007530_D007022 CID Cerebral\JJ\1740 blood\NN\5397468 flow\NN\7311115 and\CC\1740 cerebral\JJ\1740 metabolic\JJ\1740 rate\NN\13815152 for\IN\1740 oxygen\NN\14622893 were\VBD\836236 measured\VBN\697589 during\IN\1740 <e1>isoflurane-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 10\CD\13745420 patients\NNS\9898892 subjected\VBN\137313 to\TO\1740 craniotomy\VB\1740 for\IN\1740 clipping\VBG\1552519 of\IN\1740 a\DT\13649268 cerebral\JJ\1740 aneurysm\NN\14057371 .\.\1740
D007530_D007022 CID Controlled\VBN\2422663 <e2>hypotension</e2>\NN\14057371 to\TO\1740 an\DT\6697703 average\JJ\1740 MAP\NN\4076846 of\IN\1740 50\CD\13745420 -\SYM\1740 55\CD\1740 mm\NNS\13649268 Hg\NNP\14625458 was\VBD\836236 induced\VBN\1627355 by\IN\1740 increasing\VBG\169651 the\DT\1740 dose\NN\3740161 of\IN\1740 <e1>isoflurane</e1>\NN\3570838 ,\,\1740 and\CC\1740 maintained\VBN\2202928 at\IN\14622893 an\DT\6697703 inspired\JJ\1740 concentration\NN\4916342 of\IN\1740 2.2\CD\1740 +/-\CC\1740 0.2\CD\1740 %\NN\1740 .\.\1740
D007530_D002532 NONE Cerebral\JJ\1740 blood\NN\5397468 flow\NN\7311115 and\CC\1740 metabolism\NN\13526110 during\IN\1740 <e1>isoflurane-induced</e1>\JJ\1740 hypotension\NN\14057371 in\IN\13603305 patients\NNS\9898892 subjected\VBN\137313 to\TO\1740 surgery\NN\6045562 for\IN\1740 <e2>cerebral\JJ\1740 aneurysms</e2>\NNS\14057371 .\.\1740
D007530_D002532 NONE Cerebral\JJ\1740 blood\NN\5397468 flow\NN\7311115 and\CC\1740 cerebral\JJ\1740 metabolic\JJ\1740 rate\NN\13815152 for\IN\1740 oxygen\NN\14622893 were\VBD\836236 measured\VBN\697589 during\IN\1740 <e1>isoflurane-induced</e1>\JJ\1740 hypotension\NN\14057371 in\IN\13603305 10\CD\13745420 patients\NNS\9898892 subjected\VBN\137313 to\TO\1740 craniotomy\VB\1740 for\IN\1740 clipping\VBG\1552519 of\IN\1740 a\DT\13649268 <e2>cerebral\JJ\1740 aneurysm</e2>\NN\14057371 .\.\1740
D010100_D007022 NONE Cerebral\JJ\1740 blood\NN\5397468 flow\NN\7311115 and\CC\1740 cerebral\JJ\1740 metabolic\JJ\1740 rate\NN\13815152 for\IN\1740 <e1>oxygen</e1>\NN\14622893 were\VBD\836236 measured\VBN\697589 during\IN\1740 isoflurane-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 in\IN\13603305 10\CD\13745420 patients\NNS\9898892 subjected\VBN\137313 to\TO\1740 craniotomy\VB\1740 for\IN\1740 clipping\VBG\1552519 of\IN\1740 a\DT\13649268 cerebral\JJ\1740 aneurysm\NN\14057371 .\.\1740
D010100_D002532 NONE Cerebral\JJ\1740 blood\NN\5397468 flow\NN\7311115 and\CC\1740 cerebral\JJ\1740 metabolic\JJ\1740 rate\NN\13815152 for\IN\1740 <e1>oxygen</e1>\NN\14622893 were\VBD\836236 measured\VBN\697589 during\IN\1740 isoflurane-induced\JJ\1740 hypotension\NN\14057371 in\IN\13603305 10\CD\13745420 patients\NNS\9898892 subjected\VBN\137313 to\TO\1740 craniotomy\VB\1740 for\IN\1740 clipping\VBG\1552519 of\IN\1740 a\DT\13649268 <e2>cerebral\JJ\1740 aneurysm</e2>\NN\14057371 .\.\1740
D014978_D013345 NONE Flow\NN\7311115 and\CC\1740 metabolism\NN\13526110 were\VBD\836236 measured\VBN\697589 5\CD\13741022 -\SYM\1740 13\CD\13745420 days\NNS\15140892 after\IN\1740 the\DT\1740 <e2>subarachnoid\JJ\1740 haemorrhage</e2>\NN\14285662 by\IN\1740 a\DT\13649268 modification\NN\191142 of\IN\1740 the\DT\1740 classical\JJ\1740 Kety-Schmidt\JJ\1740 technique\NN\5660268 using\VBG\1156834 <e1>xenon-133</e1>\NN\1740 i.v.\NN\1740 Anaesthesia\NNP\14034177 was\VBD\836236 maintained\VBN\2202928 with\IN\1740 an\DT\6697703 inspired\JJ\1740 isoflurane\NN\3570838 concentration\NN\4916342 of\IN\1740 0.75\CD\1740 %\NN\1740 (\-LRB-\1740 plus\CC\4723816 67\CD\1740 %\NN\1740 nitrous\JJ\1740 oxide\NN\14818238 in\IN\13603305 oxygen\NN\14622893 )\-RRB-\1740 ,\,\1740 during\IN\1740 which\WDT\1740 CBF\NN\1740 and\CC\1740 CMRO2\NN\1740 were\VBD\836236 34.3\CD\1740 +/-\CC\1740 2.1\CD\1740 ml/100\CD\1740 g\NN\13717155 min-1\NN\1740 and\CC\1740 2.32\CD\1740 +/-\CC\1740 0.16\CD\1740 ml/100\CD\1740 g\NN\13717155 min-1\NN\1740 at\IN\14622893 PaCO2\NN\1740 4.1\CD\1740 +/-\CC\1740 0.1\CD\1740 kPa\NN\1740 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 SEM\NN\1740 )\-RRB-\1740 .\.\1740
D007530_D013345 NONE Flow\NN\7311115 and\CC\1740 metabolism\NN\13526110 were\VBD\836236 measured\VBN\697589 5\CD\13741022 -\SYM\1740 13\CD\13745420 days\NNS\15140892 after\IN\1740 the\DT\1740 <e2>subarachnoid\JJ\1740 haemorrhage</e2>\NN\14285662 by\IN\1740 a\DT\13649268 modification\NN\191142 of\IN\1740 the\DT\1740 classical\JJ\1740 Kety-Schmidt\JJ\1740 technique\NN\5660268 using\VBG\1156834 xenon-133\NN\1740 i.v.\NN\1740 Anaesthesia\NNP\14034177 was\VBD\836236 maintained\VBN\2202928 with\IN\1740 an\DT\6697703 inspired\JJ\1740 <e1>isoflurane</e1>\NN\3570838 concentration\NN\4916342 of\IN\1740 0.75\CD\1740 %\NN\1740 (\-LRB-\1740 plus\CC\4723816 67\CD\1740 %\NN\1740 nitrous\JJ\1740 oxide\NN\14818238 in\IN\13603305 oxygen\NN\14622893 )\-RRB-\1740 ,\,\1740 during\IN\1740 which\WDT\1740 CBF\NN\1740 and\CC\1740 CMRO2\NN\1740 were\VBD\836236 34.3\CD\1740 +/-\CC\1740 2.1\CD\1740 ml/100\CD\1740 g\NN\13717155 min-1\NN\1740 and\CC\1740 2.32\CD\1740 +/-\CC\1740 0.16\CD\1740 ml/100\CD\1740 g\NN\13717155 min-1\NN\1740 at\IN\14622893 PaCO2\NN\1740 4.1\CD\1740 +/-\CC\1740 0.1\CD\1740 kPa\NN\1740 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 SEM\NN\1740 )\-RRB-\1740 .\.\1740
D009609_D013345 NONE Flow\NN\7311115 and\CC\1740 metabolism\NN\13526110 were\VBD\836236 measured\VBN\697589 5\CD\13741022 -\SYM\1740 13\CD\13745420 days\NNS\15140892 after\IN\1740 the\DT\1740 <e2>subarachnoid\JJ\1740 haemorrhage</e2>\NN\14285662 by\IN\1740 a\DT\13649268 modification\NN\191142 of\IN\1740 the\DT\1740 classical\JJ\1740 Kety-Schmidt\JJ\1740 technique\NN\5660268 using\VBG\1156834 xenon-133\NN\1740 i.v.\NN\1740 Anaesthesia\NNP\14034177 was\VBD\836236 maintained\VBN\2202928 with\IN\1740 an\DT\6697703 inspired\JJ\1740 isoflurane\NN\3570838 concentration\NN\4916342 of\IN\1740 0.75\CD\1740 %\NN\1740 (\-LRB-\1740 plus\CC\4723816 67\CD\1740 %\NN\1740 <e1>nitrous\JJ\1740 oxide</e1>\NN\14818238 in\IN\13603305 oxygen\NN\14622893 )\-RRB-\1740 ,\,\1740 during\IN\1740 which\WDT\1740 CBF\NN\1740 and\CC\1740 CMRO2\NN\1740 were\VBD\836236 34.3\CD\1740 +/-\CC\1740 2.1\CD\1740 ml/100\CD\1740 g\NN\13717155 min-1\NN\1740 and\CC\1740 2.32\CD\1740 +/-\CC\1740 0.16\CD\1740 ml/100\CD\1740 g\NN\13717155 min-1\NN\1740 at\IN\14622893 PaCO2\NN\1740 4.1\CD\1740 +/-\CC\1740 0.1\CD\1740 kPa\NN\1740 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 SEM\NN\1740 )\-RRB-\1740 .\.\1740
D010100_D013345 NONE Flow\NN\7311115 and\CC\1740 metabolism\NN\13526110 were\VBD\836236 measured\VBN\697589 5\CD\13741022 -\SYM\1740 13\CD\13745420 days\NNS\15140892 after\IN\1740 the\DT\1740 <e2>subarachnoid\JJ\1740 haemorrhage</e2>\NN\14285662 by\IN\1740 a\DT\13649268 modification\NN\191142 of\IN\1740 the\DT\1740 classical\JJ\1740 Kety-Schmidt\JJ\1740 technique\NN\5660268 using\VBG\1156834 xenon-133\NN\1740 i.v.\NN\1740 Anaesthesia\NNP\14034177 was\VBD\836236 maintained\VBN\2202928 with\IN\1740 an\DT\6697703 inspired\JJ\1740 isoflurane\NN\3570838 concentration\NN\4916342 of\IN\1740 0.75\CD\1740 %\NN\1740 (\-LRB-\1740 plus\CC\4723816 67\CD\1740 %\NN\1740 nitrous\JJ\1740 oxide\NN\14818238 in\IN\13603305 <e1>oxygen</e1>\NN\14622893 )\-RRB-\1740 ,\,\1740 during\IN\1740 which\WDT\1740 CBF\NN\1740 and\CC\1740 CMRO2\NN\1740 were\VBD\836236 34.3\CD\1740 +/-\CC\1740 2.1\CD\1740 ml/100\CD\1740 g\NN\13717155 min-1\NN\1740 and\CC\1740 2.32\CD\1740 +/-\CC\1740 0.16\CD\1740 ml/100\CD\1740 g\NN\13717155 min-1\NN\1740 at\IN\14622893 PaCO2\NN\1740 4.1\CD\1740 +/-\CC\1740 0.1\CD\1740 kPa\NN\1740 (\-LRB-\1740 mean\NN\6021761 +/-\CC\1740 SEM\NN\1740 )\-RRB-\1740 .\.\1740
D008628_D007022 NONE Controlled\VBN\2422663 <e2>hypotension</e2>\NN\14057371 to\TO\1740 an\DT\6697703 average\JJ\1740 MAP\NN\4076846 of\IN\1740 50\CD\13745420 -\SYM\1740 55\CD\1740 mm\NNS\13649268 <e1>Hg</e1>\NNP\14625458 was\VBD\836236 induced\VBN\1627355 by\IN\1740 increasing\VBG\169651 the\DT\1740 dose\NN\3740161 of\IN\1740 isoflurane\NN\3570838 ,\,\1740 and\CC\1740 maintained\VBN\2202928 at\IN\14622893 an\DT\6697703 inspired\JJ\1740 concentration\NN\4916342 of\IN\1740 2.2\CD\1740 +/-\CC\1740 0.2\CD\1740 %\NN\1740 .\.\1740
D007530_D000783 NONE After\IN\1740 the\DT\1740 clipping\NN\6400510 of\IN\1740 the\DT\1740 <e2>aneurysm</e2>\NN\14057371 the\DT\1740 <e1>isoflurane</e1>\NN\3570838 concentration\NN\4916342 was\VBD\836236 reduced\VBN\441445 to\TO\1740 0.75\CD\1740 %\NN\1740 .\.\1740
10706004
D012964_D006973 NONE Changes\NNS\7283608 of\IN\1740 <e1>sodium</e1>\NN\14625458 and\CC\1740 ATP\NN\14964590 affinities\NNS\11426530 of\IN\1740 the\DT\1740 cardiac\JJ\1740 (Na\NN\1740 ,\,\1740 K)-ATPase\NN\1740 during\IN\1740 and\CC\1740 after\IN\1740 nitric\JJ\1740 oxide\NN\14818238 deficient\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D012964_D006973 NONE Changes\NNS\7283608 of\IN\1740 sodium\NN\14625458 and\CC\1740 ATP\NN\14964590 affinities\NNS\11426530 of\IN\1740 the\DT\1740 cardiac\JJ\1740 <e1>(Na</e1>\NN\1740 ,\,\1740 K)-ATPase\NN\1740 during\IN\1740 and\CC\1740 after\IN\1740 nitric\JJ\1740 oxide\NN\14818238 deficient\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D012964_D006973 NONE In\IN\13603305 several\JJ\1740 models\NNS\5888929 of\IN\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 elevation\NN\7445480 of\IN\1740 intracellular\JJ\1740 <e1>sodium</e1>\NN\14625458 level\NN\4916342 was\VBD\836236 documented\VBN\1000214 in\IN\13603305 cardiac\JJ\1740 tissue\NN\5220461 .\.\1740
D012964_D006973 NONE To\TO\1740 assess\VB\670261 the\DT\1740 molecular\JJ\1740 basis\NN\13790712 of\IN\1740 disturbances\NNS\407535 in\IN\13603305 transmembraneous\JJ\1740 transport\NN\3575240 of\IN\1740 <e1>Na+</e1>\NN\1740 ,\,\1740 we\PRP\1740 studied\VBD\630380 the\DT\1740 response\NN\11410625 of\IN\1740 cardiac\JJ\1740 (Na\NN\1740 ,\,\1740 K)-ATPase\NN\1740 to\TO\1740 NO-deficient\JJ\1740 <e2>hypertension</e2>\NN\14057371 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 NO-synthase\NN\1740 inhibition\NN\1068773 with\IN\1740 40\CD\13745420 mg/kg/day\NN\1740 N(G)-nitro-L-arginine\NN\1740 methyl\NN\14617189 ester\NN\14727670 (\-LRB-\1740 L-NAME\NN\1740 )\-RRB-\1740 for\IN\1740 4\CD\13741022 four\CD\13741022 weeks\NNS\15113229 .\.\1740
D012964_D006973 NONE To\TO\1740 assess\VB\670261 the\DT\1740 molecular\JJ\1740 basis\NN\13790712 of\IN\1740 disturbances\NNS\407535 in\IN\13603305 transmembraneous\JJ\1740 transport\NN\3575240 of\IN\1740 Na+\NN\1740 ,\,\1740 we\PRP\1740 studied\VBD\630380 the\DT\1740 response\NN\11410625 of\IN\1740 cardiac\JJ\1740 <e1>(Na</e1>\NN\1740 ,\,\1740 K)-ATPase\NN\1740 to\TO\1740 NO-deficient\JJ\1740 <e2>hypertension</e2>\NN\14057371 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 NO-synthase\NN\1740 inhibition\NN\1068773 with\IN\1740 40\CD\13745420 mg/kg/day\NN\1740 N(G)-nitro-L-arginine\NN\1740 methyl\NN\14617189 ester\NN\14727670 (\-LRB-\1740 L-NAME\NN\1740 )\-RRB-\1740 for\IN\1740 4\CD\13741022 four\CD\13741022 weeks\NNS\15113229 .\.\1740
D012964_D006973 NONE After\IN\1740 recovery\NN\7357388 from\IN\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 the\DT\1740 activity\NN\30358 of\IN\1740 <e1>(Na</e1>\NN\1740 ,\,\1740 K)-ATPase\NN\1740 increased\VBD\169651 ,\,\1740 due\JJ\1740 to\TO\1740 higher\JJR\1740 affinity\NN\11426530 of\IN\1740 the\DT\1740 ATP-binding\JJ\1740 site\NN\8673395 ,\,\1740 as\IN\14622893 revealed\VBN\2137132 from\IN\1740 the\DT\1740 lowered\JJ\1740 Km\NN\13649268 value\NN\5856066 for\IN\1740 ATP\NN\14964590 .\.\1740
D012964_D006973 NONE Inhibition\NN\1068773 of\IN\1740 NO-synthase\NN\1740 induced\VBD\1627355 a\DT\13649268 reversible\JJ\1740 <e2>hypertension</e2>\NN\14057371 accompanied\VBN\1835496 by\IN\1740 depressed\JJ\1740 <e1>Na+-extrusion</e1>\NN\1740 from\IN\1740 cardiac\JJ\1740 cells\NNS\3080309 as\IN\14622893 a\DT\13649268 consequence\NN\34213 of\IN\1740 deteriorated\VBN\208836 Na+-binding\NN\1740 properties\NNS\32613 of\IN\1740 the\DT\1740 (Na\NN\1740 ,\,\1740 K)-ATPase\NN\1740 .\.\1740
D012964_D006973 NONE Inhibition\NN\1068773 of\IN\1740 NO-synthase\NN\1740 induced\VBD\1627355 a\DT\13649268 reversible\JJ\1740 <e2>hypertension</e2>\NN\14057371 accompanied\VBN\1835496 by\IN\1740 depressed\JJ\1740 Na+-extrusion\NN\1740 from\IN\1740 cardiac\JJ\1740 cells\NNS\3080309 as\IN\14622893 a\DT\13649268 consequence\NN\34213 of\IN\1740 deteriorated\VBN\208836 <e1>Na+-binding</e1>\NN\1740 properties\NNS\32613 of\IN\1740 the\DT\1740 (Na\NN\1740 ,\,\1740 K)-ATPase\NN\1740 .\.\1740
D012964_D006973 NONE Inhibition\NN\1068773 of\IN\1740 NO-synthase\NN\1740 induced\VBD\1627355 a\DT\13649268 reversible\JJ\1740 <e2>hypertension</e2>\NN\14057371 accompanied\VBN\1835496 by\IN\1740 depressed\JJ\1740 Na+-extrusion\NN\1740 from\IN\1740 cardiac\JJ\1740 cells\NNS\3080309 as\IN\14622893 a\DT\13649268 consequence\NN\34213 of\IN\1740 deteriorated\VBN\208836 Na+-binding\NN\1740 properties\NNS\32613 of\IN\1740 the\DT\1740 <e1>(Na</e1>\NN\1740 ,\,\1740 K)-ATPase\NN\1740 .\.\1740
D000255_D006973 NONE Changes\NNS\7283608 of\IN\1740 sodium\NN\14625458 and\CC\1740 <e1>ATP</e1>\NN\14964590 affinities\NNS\11426530 of\IN\1740 the\DT\1740 cardiac\JJ\1740 (Na\NN\1740 ,\,\1740 K)-ATPase\NN\1740 during\IN\1740 and\CC\1740 after\IN\1740 nitric\JJ\1740 oxide\NN\14818238 deficient\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D000255_D006973 NONE After\IN\1740 recovery\NN\7357388 from\IN\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 the\DT\1740 activity\NN\30358 of\IN\1740 (Na\NN\1740 ,\,\1740 K)-ATPase\NN\1740 increased\VBD\169651 ,\,\1740 due\JJ\1740 to\TO\1740 higher\JJR\1740 affinity\NN\11426530 of\IN\1740 the\DT\1740 <e1>ATP-binding</e1>\JJ\1740 site\NN\8673395 ,\,\1740 as\IN\14622893 revealed\VBN\2137132 from\IN\1740 the\DT\1740 lowered\JJ\1740 Km\NN\13649268 value\NN\5856066 for\IN\1740 ATP\NN\14964590 .\.\1740
D000255_D006973 NONE After\IN\1740 recovery\NN\7357388 from\IN\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 the\DT\1740 activity\NN\30358 of\IN\1740 (Na\NN\1740 ,\,\1740 K)-ATPase\NN\1740 increased\VBD\169651 ,\,\1740 due\JJ\1740 to\TO\1740 higher\JJR\1740 affinity\NN\11426530 of\IN\1740 the\DT\1740 ATP-binding\JJ\1740 site\NN\8673395 ,\,\1740 as\IN\14622893 revealed\VBN\2137132 from\IN\1740 the\DT\1740 lowered\JJ\1740 Km\NN\13649268 value\NN\5856066 for\IN\1740 <e1>ATP</e1>\NN\14964590 .\.\1740
D011188_D006973 NONE Changes\NNS\7283608 of\IN\1740 sodium\NN\14625458 and\CC\1740 ATP\NN\14964590 affinities\NNS\11426530 of\IN\1740 the\DT\1740 cardiac\JJ\1740 (Na\NN\1740 ,\,\1740 <e1>K)-ATPase</e1>\NN\1740 during\IN\1740 and\CC\1740 after\IN\1740 nitric\JJ\1740 oxide\NN\14818238 deficient\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D011188_D006973 NONE To\TO\1740 assess\VB\670261 the\DT\1740 molecular\JJ\1740 basis\NN\13790712 of\IN\1740 disturbances\NNS\407535 in\IN\13603305 transmembraneous\JJ\1740 transport\NN\3575240 of\IN\1740 Na+\NN\1740 ,\,\1740 we\PRP\1740 studied\VBD\630380 the\DT\1740 response\NN\11410625 of\IN\1740 cardiac\JJ\1740 (Na\NN\1740 ,\,\1740 <e1>K)-ATPase</e1>\NN\1740 to\TO\1740 NO-deficient\JJ\1740 <e2>hypertension</e2>\NN\14057371 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 NO-synthase\NN\1740 inhibition\NN\1068773 with\IN\1740 40\CD\13745420 mg/kg/day\NN\1740 N(G)-nitro-L-arginine\NN\1740 methyl\NN\14617189 ester\NN\14727670 (\-LRB-\1740 L-NAME\NN\1740 )\-RRB-\1740 for\IN\1740 4\CD\13741022 four\CD\13741022 weeks\NNS\15113229 .\.\1740
D011188_D006973 NONE After\IN\1740 recovery\NN\7357388 from\IN\1740 <e2>hypertension</e2>\NN\14057371 ,\,\1740 the\DT\1740 activity\NN\30358 of\IN\1740 (Na\NN\1740 ,\,\1740 <e1>K)-ATPase</e1>\NN\1740 increased\VBD\169651 ,\,\1740 due\JJ\1740 to\TO\1740 higher\JJR\1740 affinity\NN\11426530 of\IN\1740 the\DT\1740 ATP-binding\JJ\1740 site\NN\8673395 ,\,\1740 as\IN\14622893 revealed\VBN\2137132 from\IN\1740 the\DT\1740 lowered\JJ\1740 Km\NN\13649268 value\NN\5856066 for\IN\1740 ATP\NN\14964590 .\.\1740
D011188_D006973 NONE Inhibition\NN\1068773 of\IN\1740 NO-synthase\NN\1740 induced\VBD\1627355 a\DT\13649268 reversible\JJ\1740 <e2>hypertension</e2>\NN\14057371 accompanied\VBN\1835496 by\IN\1740 depressed\JJ\1740 Na+-extrusion\NN\1740 from\IN\1740 cardiac\JJ\1740 cells\NNS\3080309 as\IN\14622893 a\DT\13649268 consequence\NN\34213 of\IN\1740 deteriorated\VBN\208836 Na+-binding\NN\1740 properties\NNS\32613 of\IN\1740 the\DT\1740 (Na\NN\1740 ,\,\1740 <e1>K)-ATPase</e1>\NN\1740 .\.\1740
D009569_D006973 CID Changes\NNS\7283608 of\IN\1740 sodium\NN\14625458 and\CC\1740 ATP\NN\14964590 affinities\NNS\11426530 of\IN\1740 the\DT\1740 cardiac\JJ\1740 (Na\NN\1740 ,\,\1740 K)-ATPase\NN\1740 during\IN\1740 and\CC\1740 after\IN\1740 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 deficient\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D009569_D006973 CID Inhibition\NN\1068773 of\IN\1740 <e1>NO</e1>\NN\7204911 synthesis\NN\13446390 induces\VBZ\1627355 sustained\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D009569_D006973 CID To\TO\1740 assess\VB\670261 the\DT\1740 molecular\JJ\1740 basis\NN\13790712 of\IN\1740 disturbances\NNS\407535 in\IN\13603305 transmembraneous\JJ\1740 transport\NN\3575240 of\IN\1740 Na+\NN\1740 ,\,\1740 we\PRP\1740 studied\VBD\630380 the\DT\1740 response\NN\11410625 of\IN\1740 cardiac\JJ\1740 (Na\NN\1740 ,\,\1740 K)-ATPase\NN\1740 to\TO\1740 <e1>NO-deficient</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 NO-synthase\NN\1740 inhibition\NN\1068773 with\IN\1740 40\CD\13745420 mg/kg/day\NN\1740 N(G)-nitro-L-arginine\NN\1740 methyl\NN\14617189 ester\NN\14727670 (\-LRB-\1740 L-NAME\NN\1740 )\-RRB-\1740 for\IN\1740 4\CD\13741022 four\CD\13741022 weeks\NNS\15113229 .\.\1740
D009569_D006973 CID To\TO\1740 assess\VB\670261 the\DT\1740 molecular\JJ\1740 basis\NN\13790712 of\IN\1740 disturbances\NNS\407535 in\IN\13603305 transmembraneous\JJ\1740 transport\NN\3575240 of\IN\1740 Na+\NN\1740 ,\,\1740 we\PRP\1740 studied\VBD\630380 the\DT\1740 response\NN\11410625 of\IN\1740 cardiac\JJ\1740 (Na\NN\1740 ,\,\1740 K)-ATPase\NN\1740 to\TO\1740 NO-deficient\JJ\1740 <e2>hypertension</e2>\NN\14057371 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 <e1>NO-synthase</e1>\NN\1740 inhibition\NN\1068773 with\IN\1740 40\CD\13745420 mg/kg/day\NN\1740 N(G)-nitro-L-arginine\NN\1740 methyl\NN\14617189 ester\NN\14727670 (\-LRB-\1740 L-NAME\NN\1740 )\-RRB-\1740 for\IN\1740 4\CD\13741022 four\CD\13741022 weeks\NNS\15113229 .\.\1740
D009569_D006973 CID Inhibition\NN\1068773 of\IN\1740 <e1>NO-synthase</e1>\NN\1740 induced\VBD\1627355 a\DT\13649268 reversible\JJ\1740 <e2>hypertension</e2>\NN\14057371 accompanied\VBN\1835496 by\IN\1740 depressed\JJ\1740 Na+-extrusion\NN\1740 from\IN\1740 cardiac\JJ\1740 cells\NNS\3080309 as\IN\14622893 a\DT\13649268 consequence\NN\34213 of\IN\1740 deteriorated\VBN\208836 Na+-binding\NN\1740 properties\NNS\32613 of\IN\1740 the\DT\1740 (Na\NN\1740 ,\,\1740 K)-ATPase\NN\1740 .\.\1740
D019331_D006973 NONE To\TO\1740 assess\VB\670261 the\DT\1740 molecular\JJ\1740 basis\NN\13790712 of\IN\1740 disturbances\NNS\407535 in\IN\13603305 transmembraneous\JJ\1740 transport\NN\3575240 of\IN\1740 Na+\NN\1740 ,\,\1740 we\PRP\1740 studied\VBD\630380 the\DT\1740 response\NN\11410625 of\IN\1740 cardiac\JJ\1740 (Na\NN\1740 ,\,\1740 K)-ATPase\NN\1740 to\TO\1740 NO-deficient\JJ\1740 <e2>hypertension</e2>\NN\14057371 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 NO-synthase\NN\1740 inhibition\NN\1068773 with\IN\1740 40\CD\13745420 mg/kg/day\NN\1740 <e1>N(G)-nitro-L-arginine\NN\1740 methyl\NN\14617189 ester</e1>\NN\14727670 (\-LRB-\1740 L-NAME\NN\1740 )\-RRB-\1740 for\IN\1740 4\CD\13741022 four\CD\13741022 weeks\NNS\15113229 .\.\1740
D019331_D006973 NONE To\TO\1740 assess\VB\670261 the\DT\1740 molecular\JJ\1740 basis\NN\13790712 of\IN\1740 disturbances\NNS\407535 in\IN\13603305 transmembraneous\JJ\1740 transport\NN\3575240 of\IN\1740 Na+\NN\1740 ,\,\1740 we\PRP\1740 studied\VBD\630380 the\DT\1740 response\NN\11410625 of\IN\1740 cardiac\JJ\1740 (Na\NN\1740 ,\,\1740 K)-ATPase\NN\1740 to\TO\1740 NO-deficient\JJ\1740 <e2>hypertension</e2>\NN\14057371 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 NO-synthase\NN\1740 inhibition\NN\1068773 with\IN\1740 40\CD\13745420 mg/kg/day\NN\1740 N(G)-nitro-L-arginine\NN\1740 methyl\NN\14617189 ester\NN\14727670 (\-LRB-\1740 <e1>L-NAME</e1>\NN\1740 )\-RRB-\1740 for\IN\1740 4\CD\13741022 four\CD\13741022 weeks\NNS\15113229 .\.\1740
D009569_D003866 NONE Inhibition\NN\1068773 of\IN\1740 <e1>NO-synthase</e1>\NN\1740 induced\VBD\1627355 a\DT\13649268 reversible\JJ\1740 hypertension\NN\14057371 accompanied\VBN\1835496 by\IN\1740 <e2>depressed</e2>\JJ\1740 Na+-extrusion\NN\1740 from\IN\1740 cardiac\JJ\1740 cells\NNS\3080309 as\IN\14622893 a\DT\13649268 consequence\NN\34213 of\IN\1740 deteriorated\VBN\208836 Na+-binding\NN\1740 properties\NNS\32613 of\IN\1740 the\DT\1740 (Na\NN\1740 ,\,\1740 K)-ATPase\NN\1740 .\.\1740
D012964_D003866 NONE Inhibition\NN\1068773 of\IN\1740 NO-synthase\NN\1740 induced\VBD\1627355 a\DT\13649268 reversible\JJ\1740 hypertension\NN\14057371 accompanied\VBN\1835496 by\IN\1740 <e2>depressed</e2>\JJ\1740 <e1>Na+-extrusion</e1>\NN\1740 from\IN\1740 cardiac\JJ\1740 cells\NNS\3080309 as\IN\14622893 a\DT\13649268 consequence\NN\34213 of\IN\1740 deteriorated\VBN\208836 Na+-binding\NN\1740 properties\NNS\32613 of\IN\1740 the\DT\1740 (Na\NN\1740 ,\,\1740 K)-ATPase\NN\1740 .\.\1740
D012964_D003866 NONE Inhibition\NN\1068773 of\IN\1740 NO-synthase\NN\1740 induced\VBD\1627355 a\DT\13649268 reversible\JJ\1740 hypertension\NN\14057371 accompanied\VBN\1835496 by\IN\1740 <e2>depressed</e2>\JJ\1740 Na+-extrusion\NN\1740 from\IN\1740 cardiac\JJ\1740 cells\NNS\3080309 as\IN\14622893 a\DT\13649268 consequence\NN\34213 of\IN\1740 deteriorated\VBN\208836 <e1>Na+-binding</e1>\NN\1740 properties\NNS\32613 of\IN\1740 the\DT\1740 (Na\NN\1740 ,\,\1740 K)-ATPase\NN\1740 .\.\1740
D012964_D003866 NONE Inhibition\NN\1068773 of\IN\1740 NO-synthase\NN\1740 induced\VBD\1627355 a\DT\13649268 reversible\JJ\1740 hypertension\NN\14057371 accompanied\VBN\1835496 by\IN\1740 <e2>depressed</e2>\JJ\1740 Na+-extrusion\NN\1740 from\IN\1740 cardiac\JJ\1740 cells\NNS\3080309 as\IN\14622893 a\DT\13649268 consequence\NN\34213 of\IN\1740 deteriorated\VBN\208836 Na+-binding\NN\1740 properties\NNS\32613 of\IN\1740 the\DT\1740 <e1>(Na</e1>\NN\1740 ,\,\1740 K)-ATPase\NN\1740 .\.\1740
D011188_D003866 NONE Inhibition\NN\1068773 of\IN\1740 NO-synthase\NN\1740 induced\VBD\1627355 a\DT\13649268 reversible\JJ\1740 hypertension\NN\14057371 accompanied\VBN\1835496 by\IN\1740 <e2>depressed</e2>\JJ\1740 Na+-extrusion\NN\1740 from\IN\1740 cardiac\JJ\1740 cells\NNS\3080309 as\IN\14622893 a\DT\13649268 consequence\NN\34213 of\IN\1740 deteriorated\VBN\208836 Na+-binding\NN\1740 properties\NNS\32613 of\IN\1740 the\DT\1740 (Na\NN\1740 ,\,\1740 <e1>K)-ATPase</e1>\NN\1740 .\.\1740
10737864
D003000_D001919 CID Given\VBN\2327200 that\DT\1740 sympathetic\JJ\1740 neural\JJ\1740 dominance\NN\4997988 exhibits\VBZ\2632167 a\DT\13649268 similar\JJ\1740 developmental\JJ\1740 pattern\NN\5726345 ,\,\1740 and\CC\1740 given\VBN\2327200 that\DT\1740 <e1>clonidine</e1>\NN\2721160 induces\VBZ\1627355 sympathetic\JJ\1740 withdrawal\NN\7206096 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 ,\,\1740 we\PRP\1740 hypothesized\VBD\719734 that\IN\1740 clonidine\NN\2721160 's\POS\1740 developmental\JJ\1740 effects\NNS\13245626 on\IN\1740 cardiac\JJ\1740 rate\NN\13815152 and\CC\1740 ultrasound\NN\11480930 production\NN\30358 would\MD\1740 mirror\VB\2136271 each\DT\1740 other\JJ\1740 .\.\1740
D003000_D001919 CID Given\VBN\2327200 that\DT\1740 sympathetic\JJ\1740 neural\JJ\1740 dominance\NN\4997988 exhibits\VBZ\2632167 a\DT\13649268 similar\JJ\1740 developmental\JJ\1740 pattern\NN\5726345 ,\,\1740 and\CC\1740 given\VBN\2327200 that\DT\1740 clonidine\NN\2721160 induces\VBZ\1627355 sympathetic\JJ\1740 withdrawal\NN\7206096 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 ,\,\1740 we\PRP\1740 hypothesized\VBD\719734 that\IN\1740 <e1>clonidine</e1>\NN\2721160 's\POS\1740 developmental\JJ\1740 effects\NNS\13245626 on\IN\1740 cardiac\JJ\1740 rate\NN\13815152 and\CC\1740 ultrasound\NN\11480930 production\NN\30358 would\MD\1740 mirror\VB\2136271 each\DT\1740 other\JJ\1740 .\.\1740
D003000_D001919 CID Age-related\JJ\1740 changes\NNS\7283608 in\IN\13603305 ultrasound\JJ\1740 production\NN\30358 corresponded\VBD\2664769 with\IN\1740 changes\NNS\7283608 in\IN\13603305 cardiovascular\JJ\1740 variables\NNS\2452 ,\,\1740 including\VBG\690614 baseline\NN\7260623 cardiac\JJ\1740 rate\NN\13815152 and\CC\1740 <e1>clonidine-induced</e1>\JJ\1740 <e2>bradycardia</e2>\NN\14110674 .\.\1740
12617329
D006170_D007674 NONE The\DT\1740 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 <e1>gum\JJ\1740 Arabic</e1>\NNP\6986894 on\IN\1740 gentamicin\NN\2716866 <e2>nephrotoxicity</e2>\NN\1740 in\IN\13603305 rats\NNS\2329401 :\:\1740 a\DT\13649268 preliminary\JJ\1740 study\NN\635850 .\.\1740
D006170_D007674 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 work\NN\407535 we\PRP\1740 assessed\VBD\670261 the\DT\1740 effect\NN\34213 of\IN\1740 treatment\NN\654885 of\IN\1740 rats\NNS\2329401 with\IN\1740 <e1>gum\JJ\1740 Arabic</e1>\NNP\6986894 on\IN\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 induced\VBN\1627355 by\IN\1740 gentamicin\NN\2716866 (\-LRB-\1740 GM\NN\13717155 )\-RRB-\1740 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
D006170_D007674 NONE It\PRP\6125041 could\MD\1740 be\VB\836236 inferred\VBN\634472 that\IN\1740 <e1>gum\NN\7596684 Arabic</e1>\NNP\6986894 treatment\NN\654885 has\VBZ\2108377 induced\VBN\1627355 a\DT\13649268 modest\JJ\1740 amelioration\NN\248977 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 histological\JJ\1740 and\CC\1740 biochemical\JJ\1740 indices\NNS\13850304 of\IN\1740 GM\NNP\13717155 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
D005839_D007674 NONE The\DT\1740 effect\NN\34213 of\IN\1740 treatment\NN\654885 with\IN\1740 gum\JJ\1740 Arabic\NNP\6986894 on\IN\1740 <e1>gentamicin</e1>\NN\2716866 <e2>nephrotoxicity</e2>\NN\1740 in\IN\13603305 rats\NNS\2329401 :\:\1740 a\DT\13649268 preliminary\JJ\1740 study\NN\635850 .\.\1740
D005839_D007674 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 work\NN\407535 we\PRP\1740 assessed\VBD\670261 the\DT\1740 effect\NN\34213 of\IN\1740 treatment\NN\654885 of\IN\1740 rats\NNS\2329401 with\IN\1740 gum\JJ\1740 Arabic\NNP\6986894 on\IN\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 induced\VBN\1627355 by\IN\1740 <e1>gentamicin</e1>\NN\2716866 (\-LRB-\1740 GM\NN\13717155 )\-RRB-\1740 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
D005839_D007674 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 work\NN\407535 we\PRP\1740 assessed\VBD\670261 the\DT\1740 effect\NN\34213 of\IN\1740 treatment\NN\654885 of\IN\1740 rats\NNS\2329401 with\IN\1740 gum\JJ\1740 Arabic\NNP\6986894 on\IN\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 induced\VBN\1627355 by\IN\1740 gentamicin\NN\2716866 (\-LRB-\1740 <e1>GM</e1>\NN\13717155 )\-RRB-\1740 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
D005839_D007674 NONE It\PRP\6125041 could\MD\1740 be\VB\836236 inferred\VBN\634472 that\IN\1740 gum\NN\7596684 Arabic\NNP\6986894 treatment\NN\654885 has\VBZ\2108377 induced\VBN\1627355 a\DT\13649268 modest\JJ\1740 amelioration\NN\248977 of\IN\1740 some\DT\1740 of\IN\1740 the\DT\1740 histological\JJ\1740 and\CC\1740 biochemical\JJ\1740 indices\NNS\13850304 of\IN\1740 <e1>GM</e1>\NNP\13717155 <e2>nephrotoxicity</e2>\NN\1740 .\.\1740
D006170_D058186 CID In\IN\13603305 the\DT\1740 present\JJ\1740 work\NN\407535 we\PRP\1740 assessed\VBD\670261 the\DT\1740 effect\NN\34213 of\IN\1740 treatment\NN\654885 of\IN\1740 rats\NNS\2329401 with\IN\1740 <e1>gum\JJ\1740 Arabic</e1>\NNP\6986894 on\IN\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 induced\VBN\1627355 by\IN\1740 gentamicin\NN\2716866 (\-LRB-\1740 GM\NN\13717155 )\-RRB-\1740 nephrotoxicity\NN\1740 .\.\1740
D005839_D058186 CID In\IN\13603305 the\DT\1740 present\JJ\1740 work\NN\407535 we\PRP\1740 assessed\VBD\670261 the\DT\1740 effect\NN\34213 of\IN\1740 treatment\NN\654885 of\IN\1740 rats\NNS\2329401 with\IN\1740 gum\JJ\1740 Arabic\NNP\6986894 on\IN\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 induced\VBN\1627355 by\IN\1740 <e1>gentamicin</e1>\NN\2716866 (\-LRB-\1740 GM\NN\13717155 )\-RRB-\1740 nephrotoxicity\NN\1740 .\.\1740
D005839_D058186 CID In\IN\13603305 the\DT\1740 present\JJ\1740 work\NN\407535 we\PRP\1740 assessed\VBD\670261 the\DT\1740 effect\NN\34213 of\IN\1740 treatment\NN\654885 of\IN\1740 rats\NNS\2329401 with\IN\1740 gum\JJ\1740 Arabic\NNP\6986894 on\IN\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 induced\VBN\1627355 by\IN\1740 gentamicin\NN\2716866 (\-LRB-\1740 <e1>GM</e1>\NN\13717155 )\-RRB-\1740 nephrotoxicity\NN\1740 .\.\1740
D003404_D007674 NONE <e2>Nephrotoxicity</e2>\NN\1740 was\VBD\836236 assessed\VBN\670261 by\IN\1740 measuring\VBG\697589 the\DT\1740 concentrations\NNS\4916342 of\IN\1740 <e1>creatinine</e1>\NN\1740 and\CC\1740 urea\NN\14727670 in\IN\13603305 the\DT\1740 plasma\NN\5398023 and\CC\1740 reduced\VBN\441445 glutathione\NN\1740 (\-LRB-\1740 GSH\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 kidney\NN\5333259 cortex\NN\5462674 ,\,\1740 and\CC\1740 by\IN\1740 light\JJ\1740 microscopic\JJ\1740 examination\NN\633864 of\IN\1740 kidney\NN\5333259 sections\NNS\7020895 .\.\1740
D014508_D007674 NONE <e2>Nephrotoxicity</e2>\NN\1740 was\VBD\836236 assessed\VBN\670261 by\IN\1740 measuring\VBG\697589 the\DT\1740 concentrations\NNS\4916342 of\IN\1740 creatinine\NN\1740 and\CC\1740 <e1>urea</e1>\NN\14727670 in\IN\13603305 the\DT\1740 plasma\NN\5398023 and\CC\1740 reduced\VBN\441445 glutathione\NN\1740 (\-LRB-\1740 GSH\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 kidney\NN\5333259 cortex\NN\5462674 ,\,\1740 and\CC\1740 by\IN\1740 light\JJ\1740 microscopic\JJ\1740 examination\NN\633864 of\IN\1740 kidney\NN\5333259 sections\NNS\7020895 .\.\1740
D005978_D007674 NONE <e2>Nephrotoxicity</e2>\NN\1740 was\VBD\836236 assessed\VBN\670261 by\IN\1740 measuring\VBG\697589 the\DT\1740 concentrations\NNS\4916342 of\IN\1740 creatinine\NN\1740 and\CC\1740 urea\NN\14727670 in\IN\13603305 the\DT\1740 plasma\NN\5398023 and\CC\1740 reduced\VBN\441445 <e1>glutathione</e1>\NN\1740 (\-LRB-\1740 GSH\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 kidney\NN\5333259 cortex\NN\5462674 ,\,\1740 and\CC\1740 by\IN\1740 light\JJ\1740 microscopic\JJ\1740 examination\NN\633864 of\IN\1740 kidney\NN\5333259 sections\NNS\7020895 .\.\1740
D005978_D007674 NONE <e2>Nephrotoxicity</e2>\NN\1740 was\VBD\836236 assessed\VBN\670261 by\IN\1740 measuring\VBG\697589 the\DT\1740 concentrations\NNS\4916342 of\IN\1740 creatinine\NN\1740 and\CC\1740 urea\NN\14727670 in\IN\13603305 the\DT\1740 plasma\NN\5398023 and\CC\1740 reduced\VBN\441445 glutathione\NN\1740 (\-LRB-\1740 <e1>GSH</e1>\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 kidney\NN\5333259 cortex\NN\5462674 ,\,\1740 and\CC\1740 by\IN\1740 light\JJ\1740 microscopic\JJ\1740 examination\NN\633864 of\IN\1740 kidney\NN\5333259 sections\NNS\7020895 .\.\1740
D005839_D007683 NONE The\DT\1740 <e1>GM-induced</e1>\JJ\1740 proximal\JJ\1740 <e2>tubular\JJ\1740 necrosis</e2>\NN\11444117 appeared\VBD\2604760 to\TO\1740 be\VB\836236 slightly\RB\1740 less\RBR\1740 severe\JJ\1740 in\IN\13603305 rats\NNS\2329401 given\VBN\2327200 GM\NNP\13717155 together\RB\1740 with\IN\1740 gum\NN\7596684 Arabic\NNP\6986894 than\IN\1740 in\IN\13603305 those\DT\1740 given\VBN\2327200 GM\NNP\13717155 and\CC\1740 cellulose\VB\1740 .\.\1740
D005839_D007683 NONE The\DT\1740 GM-induced\JJ\1740 proximal\JJ\1740 <e2>tubular\JJ\1740 necrosis</e2>\NN\11444117 appeared\VBD\2604760 to\TO\1740 be\VB\836236 slightly\RB\1740 less\RBR\1740 severe\JJ\1740 in\IN\13603305 rats\NNS\2329401 given\VBN\2327200 <e1>GM</e1>\NNP\13717155 together\RB\1740 with\IN\1740 gum\NN\7596684 Arabic\NNP\6986894 than\IN\1740 in\IN\13603305 those\DT\1740 given\VBN\2327200 GM\NNP\13717155 and\CC\1740 cellulose\VB\1740 .\.\1740
D005839_D007683 NONE The\DT\1740 GM-induced\JJ\1740 proximal\JJ\1740 <e2>tubular\JJ\1740 necrosis</e2>\NN\11444117 appeared\VBD\2604760 to\TO\1740 be\VB\836236 slightly\RB\1740 less\RBR\1740 severe\JJ\1740 in\IN\13603305 rats\NNS\2329401 given\VBN\2327200 GM\NNP\13717155 together\RB\1740 with\IN\1740 gum\NN\7596684 Arabic\NNP\6986894 than\IN\1740 in\IN\13603305 those\DT\1740 given\VBN\2327200 <e1>GM</e1>\NNP\13717155 and\CC\1740 cellulose\VB\1740 .\.\1740
D006170_D007683 NONE The\DT\1740 GM-induced\JJ\1740 proximal\JJ\1740 <e2>tubular\JJ\1740 necrosis</e2>\NN\11444117 appeared\VBD\2604760 to\TO\1740 be\VB\836236 slightly\RB\1740 less\RBR\1740 severe\JJ\1740 in\IN\13603305 rats\NNS\2329401 given\VBN\2327200 GM\NNP\13717155 together\RB\1740 with\IN\1740 <e1>gum\NN\7596684 Arabic</e1>\NNP\6986894 than\IN\1740 in\IN\13603305 those\DT\1740 given\VBN\2327200 GM\NNP\13717155 and\CC\1740 cellulose\VB\1740 .\.\1740
6466532
D006024_D001919 NONE Comparison\NN\635850 of\IN\1740 i.v.\NN\1740 <e1>glycopyrrolate</e1>\NN\1740 and\CC\1740 atropine\NN\14712692 in\IN\13603305 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e2>bradycardia</e2>\NN\14110674 and\CC\1740 arrhythmias\VBZ\1740 following\VBG\1835496 repeated\VBN\952524 doses\NNS\3740161 of\IN\1740 suxamethonium\NN\1740 in\IN\13603305 children\NNS\9622049 .\.\1740
D006024_D001919 NONE The\DT\1740 effectiveness\NN\5190804 of\IN\1740 administration\NN\1133281 of\IN\1740 <e1>glycopyrrolate</e1>\NN\1740 5\CD\13741022 and\CC\1740 10\CD\13745420 micrograms\NNS\13717155 kg-1\NN\1740 and\CC\1740 atropine\NN\14712692 10\CD\13745420 and\CC\1740 20\CD\13745420 micrograms\NNS\13717155 kg-1\NN\1740 i.v.\RBR\1740 immediately\RB\1740 before\IN\1740 the\DT\1740 induction\NN\7450842 of\IN\1740 anaesthesia\NN\14034177 ,\,\1740 to\TO\1740 prevent\VB\1740 arrhythmia\NN\14103288 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 following\VBG\1835496 repeated\VBN\952524 doses\NNS\3740161 of\IN\1740 suxamethonium\NN\1740 in\IN\13603305 children\NNS\9622049 ,\,\1740 was\VBD\836236 studied\VBN\630380 .\.\1740
D006024_D001145 NONE Comparison\NN\635850 of\IN\1740 i.v.\NN\1740 <e1>glycopyrrolate</e1>\NN\1740 and\CC\1740 atropine\NN\14712692 in\IN\13603305 the\DT\1740 prevention\NN\1073995 of\IN\1740 bradycardia\NN\14110674 and\CC\1740 <e2>arrhythmias</e2>\VBZ\1740 following\VBG\1835496 repeated\VBN\952524 doses\NNS\3740161 of\IN\1740 suxamethonium\NN\1740 in\IN\13603305 children\NNS\9622049 .\.\1740
D006024_D001145 NONE The\DT\1740 effectiveness\NN\5190804 of\IN\1740 administration\NN\1133281 of\IN\1740 <e1>glycopyrrolate</e1>\NN\1740 5\CD\13741022 and\CC\1740 10\CD\13745420 micrograms\NNS\13717155 kg-1\NN\1740 and\CC\1740 atropine\NN\14712692 10\CD\13745420 and\CC\1740 20\CD\13745420 micrograms\NNS\13717155 kg-1\NN\1740 i.v.\RBR\1740 immediately\RB\1740 before\IN\1740 the\DT\1740 induction\NN\7450842 of\IN\1740 anaesthesia\NN\14034177 ,\,\1740 to\TO\1740 prevent\VB\1740 <e2>arrhythmia</e2>\NN\14103288 and\CC\1740 bradycardia\NN\14110674 following\VBG\1835496 repeated\VBN\952524 doses\NNS\3740161 of\IN\1740 suxamethonium\NN\1740 in\IN\13603305 children\NNS\9622049 ,\,\1740 was\VBD\836236 studied\VBN\630380 .\.\1740
D001285_D001919 NONE Comparison\NN\635850 of\IN\1740 i.v.\NN\1740 glycopyrrolate\NN\1740 and\CC\1740 <e1>atropine</e1>\NN\14712692 in\IN\13603305 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e2>bradycardia</e2>\NN\14110674 and\CC\1740 arrhythmias\VBZ\1740 following\VBG\1835496 repeated\VBN\952524 doses\NNS\3740161 of\IN\1740 suxamethonium\NN\1740 in\IN\13603305 children\NNS\9622049 .\.\1740
D001285_D001919 NONE The\DT\1740 effectiveness\NN\5190804 of\IN\1740 administration\NN\1133281 of\IN\1740 glycopyrrolate\NN\1740 5\CD\13741022 and\CC\1740 10\CD\13745420 micrograms\NNS\13717155 kg-1\NN\1740 and\CC\1740 <e1>atropine</e1>\NN\14712692 10\CD\13745420 and\CC\1740 20\CD\13745420 micrograms\NNS\13717155 kg-1\NN\1740 i.v.\RBR\1740 immediately\RB\1740 before\IN\1740 the\DT\1740 induction\NN\7450842 of\IN\1740 anaesthesia\NN\14034177 ,\,\1740 to\TO\1740 prevent\VB\1740 arrhythmia\NN\14103288 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 following\VBG\1835496 repeated\VBN\952524 doses\NNS\3740161 of\IN\1740 suxamethonium\NN\1740 in\IN\13603305 children\NNS\9622049 ,\,\1740 was\VBD\836236 studied\VBN\630380 .\.\1740
D001285_D001145 NONE Comparison\NN\635850 of\IN\1740 i.v.\NN\1740 glycopyrrolate\NN\1740 and\CC\1740 <e1>atropine</e1>\NN\14712692 in\IN\13603305 the\DT\1740 prevention\NN\1073995 of\IN\1740 bradycardia\NN\14110674 and\CC\1740 <e2>arrhythmias</e2>\VBZ\1740 following\VBG\1835496 repeated\VBN\952524 doses\NNS\3740161 of\IN\1740 suxamethonium\NN\1740 in\IN\13603305 children\NNS\9622049 .\.\1740
D001285_D001145 NONE The\DT\1740 effectiveness\NN\5190804 of\IN\1740 administration\NN\1133281 of\IN\1740 glycopyrrolate\NN\1740 5\CD\13741022 and\CC\1740 10\CD\13745420 micrograms\NNS\13717155 kg-1\NN\1740 and\CC\1740 <e1>atropine</e1>\NN\14712692 10\CD\13745420 and\CC\1740 20\CD\13745420 micrograms\NNS\13717155 kg-1\NN\1740 i.v.\RBR\1740 immediately\RB\1740 before\IN\1740 the\DT\1740 induction\NN\7450842 of\IN\1740 anaesthesia\NN\14034177 ,\,\1740 to\TO\1740 prevent\VB\1740 <e2>arrhythmia</e2>\NN\14103288 and\CC\1740 bradycardia\NN\14110674 following\VBG\1835496 repeated\VBN\952524 doses\NNS\3740161 of\IN\1740 suxamethonium\NN\1740 in\IN\13603305 children\NNS\9622049 ,\,\1740 was\VBD\836236 studied\VBN\630380 .\.\1740
D013390_D001919 CID Comparison\NN\635850 of\IN\1740 i.v.\NN\1740 glycopyrrolate\NN\1740 and\CC\1740 atropine\NN\14712692 in\IN\13603305 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e2>bradycardia</e2>\NN\14110674 and\CC\1740 arrhythmias\VBZ\1740 following\VBG\1835496 repeated\VBN\952524 doses\NNS\3740161 of\IN\1740 <e1>suxamethonium</e1>\NN\1740 in\IN\13603305 children\NNS\9622049 .\.\1740
D013390_D001919 CID The\DT\1740 effectiveness\NN\5190804 of\IN\1740 administration\NN\1133281 of\IN\1740 glycopyrrolate\NN\1740 5\CD\13741022 and\CC\1740 10\CD\13745420 micrograms\NNS\13717155 kg-1\NN\1740 and\CC\1740 atropine\NN\14712692 10\CD\13745420 and\CC\1740 20\CD\13745420 micrograms\NNS\13717155 kg-1\NN\1740 i.v.\RBR\1740 immediately\RB\1740 before\IN\1740 the\DT\1740 induction\NN\7450842 of\IN\1740 anaesthesia\NN\14034177 ,\,\1740 to\TO\1740 prevent\VB\1740 arrhythmia\NN\14103288 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 following\VBG\1835496 repeated\VBN\952524 doses\NNS\3740161 of\IN\1740 <e1>suxamethonium</e1>\NN\1740 in\IN\13603305 children\NNS\9622049 ,\,\1740 was\VBD\836236 studied\VBN\630380 .\.\1740
D013390_D001145 NONE Comparison\NN\635850 of\IN\1740 i.v.\NN\1740 glycopyrrolate\NN\1740 and\CC\1740 atropine\NN\14712692 in\IN\13603305 the\DT\1740 prevention\NN\1073995 of\IN\1740 bradycardia\NN\14110674 and\CC\1740 <e2>arrhythmias</e2>\VBZ\1740 following\VBG\1835496 repeated\VBN\952524 doses\NNS\3740161 of\IN\1740 <e1>suxamethonium</e1>\NN\1740 in\IN\13603305 children\NNS\9622049 .\.\1740
D013390_D001145 NONE The\DT\1740 effectiveness\NN\5190804 of\IN\1740 administration\NN\1133281 of\IN\1740 glycopyrrolate\NN\1740 5\CD\13741022 and\CC\1740 10\CD\13745420 micrograms\NNS\13717155 kg-1\NN\1740 and\CC\1740 atropine\NN\14712692 10\CD\13745420 and\CC\1740 20\CD\13745420 micrograms\NNS\13717155 kg-1\NN\1740 i.v.\RBR\1740 immediately\RB\1740 before\IN\1740 the\DT\1740 induction\NN\7450842 of\IN\1740 anaesthesia\NN\14034177 ,\,\1740 to\TO\1740 prevent\VB\1740 <e2>arrhythmia</e2>\NN\14103288 and\CC\1740 bradycardia\NN\14110674 following\VBG\1835496 repeated\VBN\952524 doses\NNS\3740161 of\IN\1740 <e1>suxamethonium</e1>\NN\1740 in\IN\13603305 children\NNS\9622049 ,\,\1740 was\VBD\836236 studied\VBN\630380 .\.\1740
9199746
D000583_D064420 NONE Macula\CD\4682462 <e2>toxicity</e2>\NN\13576101 after\IN\1740 intravitreal\JJ\1740 <e1>amikacin</e1>\NN\1740 .\.\1740
D000617_D009877 NONE BACKGROUND\NN\4921011 :\:\1740 Although\IN\1740 intravitreal\NN\1740 <e1>aminoglycosides</e1>\NNS\1740 have\VBP\2108377 substantially\RB\1740 improved\VBN\126264 visual\JJ\1740 prognosis\NN\6748969 in\IN\13603305 <e2>endophthalmitis</e2>\NN\1740 ,\,\1740 macular\JJ\1740 infarction\NN\14204950 may\MD\15209706 impair\VB\258857 full\JJ\1740 visual\JJ\1740 recovery\NN\7357388 .\.\1740
D000617_D007238 NONE BACKGROUND\NN\4921011 :\:\1740 Although\IN\1740 intravitreal\NN\1740 <e1>aminoglycosides</e1>\NNS\1740 have\VBP\2108377 substantially\RB\1740 improved\VBN\126264 visual\JJ\1740 prognosis\NN\6748969 in\IN\13603305 endophthalmitis\NN\1740 ,\,\1740 macular\JJ\1740 <e2>infarction</e2>\NN\14204950 may\MD\15209706 impair\VB\258857 full\JJ\1740 visual\JJ\1740 recovery\NN\7357388 .\.\1740
D000583_D012164 CID METHODS\NNS\5616786 :\:\1740 We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 presumed\VBN\719734 <e1>amikacin</e1>\NN\1740 <e2>retinal\JJ\1740 toxicity</e2>\NN\13576101 following\VBG\1835496 treatment\NN\654885 with\IN\1740 amikacin\NN\1740 and\CC\1740 vancomycin\NN\2716866 for\IN\1740 alpha-haemolytic\JJ\1740 streptococcal\JJ\1740 endophthalmitis\NN\1740 .\.\1740
D000583_D012164 CID METHODS\NNS\5616786 :\:\1740 We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 presumed\VBN\719734 amikacin\NN\1740 <e2>retinal\JJ\1740 toxicity</e2>\NN\13576101 following\VBG\1835496 treatment\NN\654885 with\IN\1740 <e1>amikacin</e1>\NN\1740 and\CC\1740 vancomycin\NN\2716866 for\IN\1740 alpha-haemolytic\JJ\1740 streptococcal\JJ\1740 endophthalmitis\NN\1740 .\.\1740
D000583_D013290 NONE METHODS\NNS\5616786 :\:\1740 We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 presumed\VBN\719734 <e1>amikacin</e1>\NN\1740 retinal\JJ\1740 toxicity\NN\13576101 following\VBG\1835496 treatment\NN\654885 with\IN\1740 amikacin\NN\1740 and\CC\1740 vancomycin\NN\2716866 for\IN\1740 alpha-haemolytic\JJ\1740 <e2>streptococcal\JJ\1740 endophthalmitis</e2>\NN\1740 .\.\1740
D000583_D013290 NONE METHODS\NNS\5616786 :\:\1740 We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 presumed\VBN\719734 amikacin\NN\1740 retinal\JJ\1740 toxicity\NN\13576101 following\VBG\1835496 treatment\NN\654885 with\IN\1740 <e1>amikacin</e1>\NN\1740 and\CC\1740 vancomycin\NN\2716866 for\IN\1740 alpha-haemolytic\JJ\1740 <e2>streptococcal\JJ\1740 endophthalmitis</e2>\NN\1740 .\.\1740
D014640_D012164 NONE METHODS\NNS\5616786 :\:\1740 We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 presumed\VBN\719734 amikacin\NN\1740 <e2>retinal\JJ\1740 toxicity</e2>\NN\13576101 following\VBG\1835496 treatment\NN\654885 with\IN\1740 amikacin\NN\1740 and\CC\1740 <e1>vancomycin</e1>\NN\2716866 for\IN\1740 alpha-haemolytic\JJ\1740 streptococcal\JJ\1740 endophthalmitis\NN\1740 .\.\1740
D014640_D013290 NONE METHODS\NNS\5616786 :\:\1740 We\PRP\1740 present\VBP\2137132 a\DT\13649268 case\NN\7283608 of\IN\1740 presumed\VBN\719734 amikacin\NN\1740 retinal\JJ\1740 toxicity\NN\13576101 following\VBG\1835496 treatment\NN\654885 with\IN\1740 amikacin\NN\1740 and\CC\1740 <e1>vancomycin</e1>\NN\2716866 for\IN\1740 alpha-haemolytic\JJ\1740 <e2>streptococcal\JJ\1740 endophthalmitis</e2>\NN\1740 .\.\1740
D019793_D013684 NONE Fundus\NN\5225602 <e1>fluorescein</e1>\NN\14598383 angiography\NN\904623 confirmed\VBD\1011725 macular\JJ\1740 capillary\JJ\1740 closure\NN\280853 and\CC\1740 <e2>telangiectasis</e2>\NN\1740 .\.\1740
17175308
D020123_D011507 CID <e2>Proteinuria</e2>\NNP\14299637 after\IN\1740 conversion\NN\7359599 to\TO\1740 <e1>sirolimus</e1>\NN\1740 in\IN\13603305 renal\JJ\1740 transplant\NN\5267548 recipients\NNS\9764201 .\.\1740
D020123_D011507 CID More\RBR\1740 recently\RB\1740 ,\,\1740 <e2>proteinuria</e2>\NN\14299637 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 as\IN\14622893 a\DT\13649268 consequence\NN\34213 of\IN\1740 <e1>sirolimus</e1>\NN\1740 therapy\NN\657604 ,\,\1740 although\IN\1740 the\DT\1740 mechanism\NN\13446390 has\VBZ\2108377 remained\VBN\2604760 unclear\JJ\1740 .\.\1740
D020123_D011507 CID We\PRP\1740 retrospectively\RB\1740 examined\VBD\789138 the\DT\1740 records\NNS\6643408 of\IN\1740 25\CD\13745420 renal\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 ,\,\1740 who\WP\8299493 developed\VBD\1753788 or\CC\3541091 displayed\VBD\2137132 increased\VBN\169651 <e2>proteinuria</e2>\NN\14299637 after\IN\1740 <e1>SRL</e1>\NN\1740 conversion\NN\7359599 .\.\1740
D020123_D011507 CID Heavy\JJ\1740 <e2>proteinuria</e2>\NN\14299637 was\VBD\836236 common\JJ\1740 after\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>SRL</e1>\NN\1740 as\IN\14622893 rescue\NN\45907 therapy\NN\657604 for\IN\1740 renal\JJ\1740 transplantation\NN\671351 .\.\1740
D020123_D051436 NONE The\DT\1740 patient\NN\9898892 cohort\NN\8184861 (\-LRB-\1740 14\CD\13745420 men\NNS\8208016 ,\,\1740 11\CD\13745420 women\NNS\9605289 )\-RRB-\1740 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>SRL</e1>\NN\1740 as\IN\14622893 conversion\NN\7359599 therapy\NN\657604 ,\,\1740 due\JJ\1740 to\TO\1740 <e2>chronic\JJ\1740 allograft\NN\5582859 nephropathy</e2>\NN\14573196 (\-LRB-\1740 CAN\NN\3094503 )\-RRB-\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 15\CD\13745420 )\-RRB-\1740 neoplasia\NN\13533470 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 8)\CD\1740 ;\:\1740 Kaposi\NN\1740 's\POS\1740 sarcoma\NN\14239918 ,\,\1740 Four\CD\13741022 skin\NN\5237755 cancers\NNS\14239425 ,\,\1740 One\CD\13741022 intestinal\JJ\1740 tumors\NNS\14234074 ,\,\1740 One\CD\13741022 renal\JJ\1740 cell\NN\3080309 carsinom\NN\1740 )\-RRB-\1740 or\CC\3541091 BK\NN\14625458 virus\NN\9312843 nephropathy\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 .\.\1740
D020123_D007674 NONE The\DT\1740 patient\NN\9898892 cohort\NN\8184861 (\-LRB-\1740 14\CD\13745420 men\NNS\8208016 ,\,\1740 11\CD\13745420 women\NNS\9605289 )\-RRB-\1740 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>SRL</e1>\NN\1740 as\IN\14622893 conversion\NN\7359599 therapy\NN\657604 ,\,\1740 due\JJ\1740 to\TO\1740 chronic\JJ\1740 allograft\NN\5582859 nephropathy\NN\14573196 (\-LRB-\1740 <e2>CAN</e2>\NN\3094503 )\-RRB-\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 15\CD\13745420 )\-RRB-\1740 neoplasia\NN\13533470 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 8)\CD\1740 ;\:\1740 Kaposi\NN\1740 's\POS\1740 sarcoma\NN\14239918 ,\,\1740 Four\CD\13741022 skin\NN\5237755 cancers\NNS\14239425 ,\,\1740 One\CD\13741022 intestinal\JJ\1740 tumors\NNS\14234074 ,\,\1740 One\CD\13741022 renal\JJ\1740 cell\NN\3080309 carsinom\NN\1740 )\-RRB-\1740 or\CC\3541091 BK\NN\14625458 virus\NN\9312843 nephropathy\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 .\.\1740
D020123_D007674 NONE The\DT\1740 patient\NN\9898892 cohort\NN\8184861 (\-LRB-\1740 14\CD\13745420 men\NNS\8208016 ,\,\1740 11\CD\13745420 women\NNS\9605289 )\-RRB-\1740 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>SRL</e1>\NN\1740 as\IN\14622893 conversion\NN\7359599 therapy\NN\657604 ,\,\1740 due\JJ\1740 to\TO\1740 chronic\JJ\1740 allograft\NN\5582859 nephropathy\NN\14573196 (\-LRB-\1740 CAN\NN\3094503 )\-RRB-\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 15\CD\13745420 )\-RRB-\1740 neoplasia\NN\13533470 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 8)\CD\1740 ;\:\1740 Kaposi\NN\1740 's\POS\1740 sarcoma\NN\14239918 ,\,\1740 Four\CD\13741022 skin\NN\5237755 cancers\NNS\14239425 ,\,\1740 One\CD\13741022 intestinal\JJ\1740 tumors\NNS\14234074 ,\,\1740 One\CD\13741022 renal\JJ\1740 cell\NN\3080309 carsinom\NN\1740 )\-RRB-\1740 or\CC\3541091 BK\NN\14625458 virus\NN\9312843 <e2>nephropathy</e2>\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 .\.\1740
D020123_D009369 NONE The\DT\1740 patient\NN\9898892 cohort\NN\8184861 (\-LRB-\1740 14\CD\13745420 men\NNS\8208016 ,\,\1740 11\CD\13745420 women\NNS\9605289 )\-RRB-\1740 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>SRL</e1>\NN\1740 as\IN\14622893 conversion\NN\7359599 therapy\NN\657604 ,\,\1740 due\JJ\1740 to\TO\1740 chronic\JJ\1740 allograft\NN\5582859 nephropathy\NN\14573196 (\-LRB-\1740 CAN\NN\3094503 )\-RRB-\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 15\CD\13745420 )\-RRB-\1740 <e2>neoplasia</e2>\NN\13533470 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 8)\CD\1740 ;\:\1740 Kaposi\NN\1740 's\POS\1740 sarcoma\NN\14239918 ,\,\1740 Four\CD\13741022 skin\NN\5237755 cancers\NNS\14239425 ,\,\1740 One\CD\13741022 intestinal\JJ\1740 tumors\NNS\14234074 ,\,\1740 One\CD\13741022 renal\JJ\1740 cell\NN\3080309 carsinom\NN\1740 )\-RRB-\1740 or\CC\3541091 BK\NN\14625458 virus\NN\9312843 nephropathy\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 .\.\1740
D020123_D012514 NONE The\DT\1740 patient\NN\9898892 cohort\NN\8184861 (\-LRB-\1740 14\CD\13745420 men\NNS\8208016 ,\,\1740 11\CD\13745420 women\NNS\9605289 )\-RRB-\1740 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>SRL</e1>\NN\1740 as\IN\14622893 conversion\NN\7359599 therapy\NN\657604 ,\,\1740 due\JJ\1740 to\TO\1740 chronic\JJ\1740 allograft\NN\5582859 nephropathy\NN\14573196 (\-LRB-\1740 CAN\NN\3094503 )\-RRB-\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 15\CD\13745420 )\-RRB-\1740 neoplasia\NN\13533470 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 8)\CD\1740 ;\:\1740 <e2>Kaposi\NN\1740 's\POS\1740 sarcoma</e2>\NN\14239918 ,\,\1740 Four\CD\13741022 skin\NN\5237755 cancers\NNS\14239425 ,\,\1740 One\CD\13741022 intestinal\JJ\1740 tumors\NNS\14234074 ,\,\1740 One\CD\13741022 renal\JJ\1740 cell\NN\3080309 carsinom\NN\1740 )\-RRB-\1740 or\CC\3541091 BK\NN\14625458 virus\NN\9312843 nephropathy\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 .\.\1740
D020123_D012878 NONE The\DT\1740 patient\NN\9898892 cohort\NN\8184861 (\-LRB-\1740 14\CD\13745420 men\NNS\8208016 ,\,\1740 11\CD\13745420 women\NNS\9605289 )\-RRB-\1740 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>SRL</e1>\NN\1740 as\IN\14622893 conversion\NN\7359599 therapy\NN\657604 ,\,\1740 due\JJ\1740 to\TO\1740 chronic\JJ\1740 allograft\NN\5582859 nephropathy\NN\14573196 (\-LRB-\1740 CAN\NN\3094503 )\-RRB-\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 15\CD\13745420 )\-RRB-\1740 neoplasia\NN\13533470 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 8)\CD\1740 ;\:\1740 Kaposi\NN\1740 's\POS\1740 sarcoma\NN\14239918 ,\,\1740 Four\CD\13741022 <e2>skin\NN\5237755 cancers</e2>\NNS\14239425 ,\,\1740 One\CD\13741022 intestinal\JJ\1740 tumors\NNS\14234074 ,\,\1740 One\CD\13741022 renal\JJ\1740 cell\NN\3080309 carsinom\NN\1740 )\-RRB-\1740 or\CC\3541091 BK\NN\14625458 virus\NN\9312843 nephropathy\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 .\.\1740
D020123_D007414 NONE The\DT\1740 patient\NN\9898892 cohort\NN\8184861 (\-LRB-\1740 14\CD\13745420 men\NNS\8208016 ,\,\1740 11\CD\13745420 women\NNS\9605289 )\-RRB-\1740 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>SRL</e1>\NN\1740 as\IN\14622893 conversion\NN\7359599 therapy\NN\657604 ,\,\1740 due\JJ\1740 to\TO\1740 chronic\JJ\1740 allograft\NN\5582859 nephropathy\NN\14573196 (\-LRB-\1740 CAN\NN\3094503 )\-RRB-\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 15\CD\13745420 )\-RRB-\1740 neoplasia\NN\13533470 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 8)\CD\1740 ;\:\1740 Kaposi\NN\1740 's\POS\1740 sarcoma\NN\14239918 ,\,\1740 Four\CD\13741022 skin\NN\5237755 cancers\NNS\14239425 ,\,\1740 One\CD\13741022 <e2>intestinal\JJ\1740 tumors</e2>\NNS\14234074 ,\,\1740 One\CD\13741022 renal\JJ\1740 cell\NN\3080309 carsinom\NN\1740 )\-RRB-\1740 or\CC\3541091 BK\NN\14625458 virus\NN\9312843 nephropathy\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 .\.\1740
D020123_D002292 NONE The\DT\1740 patient\NN\9898892 cohort\NN\8184861 (\-LRB-\1740 14\CD\13745420 men\NNS\8208016 ,\,\1740 11\CD\13745420 women\NNS\9605289 )\-RRB-\1740 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>SRL</e1>\NN\1740 as\IN\14622893 conversion\NN\7359599 therapy\NN\657604 ,\,\1740 due\JJ\1740 to\TO\1740 chronic\JJ\1740 allograft\NN\5582859 nephropathy\NN\14573196 (\-LRB-\1740 CAN\NN\3094503 )\-RRB-\1740 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 15\CD\13745420 )\-RRB-\1740 neoplasia\NN\13533470 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 8)\CD\1740 ;\:\1740 Kaposi\NN\1740 's\POS\1740 sarcoma\NN\14239918 ,\,\1740 Four\CD\13741022 skin\NN\5237755 cancers\NNS\14239425 ,\,\1740 One\CD\13741022 intestinal\JJ\1740 tumors\NNS\14234074 ,\,\1740 One\CD\13741022 <e2>renal\JJ\1740 cell\NN\3080309 carsinom</e2>\NN\1740 )\-RRB-\1740 or\CC\3541091 BK\NN\14625458 virus\NN\9312843 nephropathy\NN\14573196 (\-LRB-\1740 n\NN\14622893 =\JJ\1740 2\CD\13741022 )\-RRB-\1740 .\.\1740
3750012
D010396_D009157 CID <e2>Myasthenia\NNP\14187378 gravis</e2>\NN\1740 caused\VBN\1617192 by\IN\1740 <e1>penicillamine</e1>\NN\3740161 and\CC\1740 chloroquine\NN\2721948 therapy\NN\657604 for\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 .\.\1740
D010396_D009157 CID We\PRP\1740 have\VBP\2108377 described\VBN\1001294 a\DT\13649268 unique\JJ\1740 patient\NN\9898892 who\WP\8299493 had\VBD\2108377 reversible\JJ\1740 and\CC\1740 dose-related\JJ\1740 <e2>myasthenia\NN\14187378 gravis</e2>\NN\1740 after\IN\1740 <e1>penicillamine</e1>\NN\3740161 and\CC\1740 chloroquine\NN\2721948 therapy\NN\657604 for\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 .\.\1740
D010396_D001172 NONE Myasthenia\NNP\14187378 gravis\NN\1740 caused\VBN\1617192 by\IN\1740 <e1>penicillamine</e1>\NN\3740161 and\CC\1740 chloroquine\NN\2721948 therapy\NN\657604 for\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 .\.\1740
D010396_D001172 NONE We\PRP\1740 have\VBP\2108377 described\VBN\1001294 a\DT\13649268 unique\JJ\1740 patient\NN\9898892 who\WP\8299493 had\VBD\2108377 reversible\JJ\1740 and\CC\1740 dose-related\JJ\1740 myasthenia\NN\14187378 gravis\NN\1740 after\IN\1740 <e1>penicillamine</e1>\NN\3740161 and\CC\1740 chloroquine\NN\2721948 therapy\NN\657604 for\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 .\.\1740
D002738_D009157 CID <e2>Myasthenia\NNP\14187378 gravis</e2>\NN\1740 caused\VBN\1617192 by\IN\1740 penicillamine\NN\3740161 and\CC\1740 <e1>chloroquine</e1>\NN\2721948 therapy\NN\657604 for\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 .\.\1740
D002738_D009157 CID We\PRP\1740 have\VBP\2108377 described\VBN\1001294 a\DT\13649268 unique\JJ\1740 patient\NN\9898892 who\WP\8299493 had\VBD\2108377 reversible\JJ\1740 and\CC\1740 dose-related\JJ\1740 <e2>myasthenia\NN\14187378 gravis</e2>\NN\1740 after\IN\1740 penicillamine\NN\3740161 and\CC\1740 <e1>chloroquine</e1>\NN\2721948 therapy\NN\657604 for\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 .\.\1740
D002738_D001172 NONE Myasthenia\NNP\14187378 gravis\NN\1740 caused\VBN\1617192 by\IN\1740 penicillamine\NN\3740161 and\CC\1740 <e1>chloroquine</e1>\NN\2721948 therapy\NN\657604 for\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 .\.\1740
D002738_D001172 NONE We\PRP\1740 have\VBP\2108377 described\VBN\1001294 a\DT\13649268 unique\JJ\1740 patient\NN\9898892 who\WP\8299493 had\VBD\2108377 reversible\JJ\1740 and\CC\1740 dose-related\JJ\1740 myasthenia\NN\14187378 gravis\NN\1740 after\IN\1740 penicillamine\NN\3740161 and\CC\1740 <e1>chloroquine</e1>\NN\2721948 therapy\NN\657604 for\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 .\.\1740
18186898
D019259_D006509 NONE <e1>Lamivudine</e1>\NNP\3834836 was\VBD\836236 added\VBN\156601 because\IN\1740 of\IN\1740 de\FW\1740 nova\JJ\1740 <e2>hepatitis\NN\14127211 B\NN\1355326 infection</e2>\NN\14052046 during\IN\1740 her\PRP$\1740 follow-up\NN\4599396 .\.\1740
D016559_D000138 NONE Although\IN\1740 <e1>tacrolimus</e1>\NN\1740 was\VBD\836236 suspected\VBN\916909 to\TO\1740 be\VB\836236 the\DT\1740 cause\NN\7323922 of\IN\1740 late\JJ\1740 post-transplant\JJ\1740 renal\JJ\1740 <e2>acidosis</e2>\NN\14204950 and\CC\1740 was\VBD\836236 replaced\VBN\1631072 by\IN\1740 sirolimus\NN\1740 ,\,\1740 acidosis\NN\14204950 ,\,\1740 and\CC\1740 electrolyte\NN\14589223 imbalance\NN\13934274 got\VBD\146138 worse\JJR\1740 .\.\1740
D016559_D000138 NONE Although\IN\1740 <e1>tacrolimus</e1>\NN\1740 was\VBD\836236 suspected\VBN\916909 to\TO\1740 be\VB\836236 the\DT\1740 cause\NN\7323922 of\IN\1740 late\JJ\1740 post-transplant\JJ\1740 renal\JJ\1740 acidosis\NN\14204950 and\CC\1740 was\VBD\836236 replaced\VBN\1631072 by\IN\1740 sirolimus\NN\1740 ,\,\1740 <e2>acidosis</e2>\NN\14204950 ,\,\1740 and\CC\1740 electrolyte\NN\14589223 imbalance\NN\13934274 got\VBD\146138 worse\JJR\1740 .\.\1740
D020123_D000138 NONE Although\IN\1740 tacrolimus\NN\1740 was\VBD\836236 suspected\VBN\916909 to\TO\1740 be\VB\836236 the\DT\1740 cause\NN\7323922 of\IN\1740 late\JJ\1740 post-transplant\JJ\1740 renal\JJ\1740 <e2>acidosis</e2>\NN\14204950 and\CC\1740 was\VBD\836236 replaced\VBN\1631072 by\IN\1740 <e1>sirolimus</e1>\NN\1740 ,\,\1740 acidosis\NN\14204950 ,\,\1740 and\CC\1740 electrolyte\NN\14589223 imbalance\NN\13934274 got\VBD\146138 worse\JJR\1740 .\.\1740
D020123_D000138 NONE Although\IN\1740 tacrolimus\NN\1740 was\VBD\836236 suspected\VBN\916909 to\TO\1740 be\VB\836236 the\DT\1740 cause\NN\7323922 of\IN\1740 late\JJ\1740 post-transplant\JJ\1740 renal\JJ\1740 acidosis\NN\14204950 and\CC\1740 was\VBD\836236 replaced\VBN\1631072 by\IN\1740 <e1>sirolimus</e1>\NN\1740 ,\,\1740 <e2>acidosis</e2>\NN\14204950 ,\,\1740 and\CC\1740 electrolyte\NN\14589223 imbalance\NN\13934274 got\VBD\146138 worse\JJR\1740 .\.\1740
D016559_D005198 CID We\PRP\1740 suggest\VBP\1010118 that\IN\1740 our\PRP$\1740 patient\NN\9898892 's\POS\1740 <e2>tubular\JJ\1740 dysfunction</e2>\NN\14204950 and\CC\1740 myopathy\NN\14204950 may\MD\15209706 have\VB\2108377 resulted\VBN\2633881 from\IN\1740 mitochondrial\JJ\1740 dysfunction\NN\14204950 which\WDT\1740 is\VBZ\836236 triggered\VBN\1641914 by\IN\1740 <e1>tacrolimus</e1>\NN\1740 and\CC\1740 augmented\VBN\153263 by\IN\1740 lamivudine\NN\3834836 .\.\1740
D016559_D009135 CID We\PRP\1740 suggest\VBP\1010118 that\IN\1740 our\PRP$\1740 patient\NN\9898892 's\POS\1740 tubular\JJ\1740 dysfunction\NN\14204950 and\CC\1740 <e2>myopathy</e2>\NN\14204950 may\MD\15209706 have\VB\2108377 resulted\VBN\2633881 from\IN\1740 mitochondrial\JJ\1740 dysfunction\NN\14204950 which\WDT\1740 is\VBZ\836236 triggered\VBN\1641914 by\IN\1740 <e1>tacrolimus</e1>\NN\1740 and\CC\1740 augmented\VBN\153263 by\IN\1740 lamivudine\NN\3834836 .\.\1740
D016559_D028361 NONE We\PRP\1740 suggest\VBP\1010118 that\IN\1740 our\PRP$\1740 patient\NN\9898892 's\POS\1740 tubular\JJ\1740 dysfunction\NN\14204950 and\CC\1740 myopathy\NN\14204950 may\MD\15209706 have\VB\2108377 resulted\VBN\2633881 from\IN\1740 <e2>mitochondrial\JJ\1740 dysfunction</e2>\NN\14204950 which\WDT\1740 is\VBZ\836236 triggered\VBN\1641914 by\IN\1740 <e1>tacrolimus</e1>\NN\1740 and\CC\1740 augmented\VBN\153263 by\IN\1740 lamivudine\NN\3834836 .\.\1740
D019259_D005198 CID We\PRP\1740 suggest\VBP\1010118 that\IN\1740 our\PRP$\1740 patient\NN\9898892 's\POS\1740 <e2>tubular\JJ\1740 dysfunction</e2>\NN\14204950 and\CC\1740 myopathy\NN\14204950 may\MD\15209706 have\VB\2108377 resulted\VBN\2633881 from\IN\1740 mitochondrial\JJ\1740 dysfunction\NN\14204950 which\WDT\1740 is\VBZ\836236 triggered\VBN\1641914 by\IN\1740 tacrolimus\NN\1740 and\CC\1740 augmented\VBN\153263 by\IN\1740 <e1>lamivudine</e1>\NN\3834836 .\.\1740
D019259_D009135 CID We\PRP\1740 suggest\VBP\1010118 that\IN\1740 our\PRP$\1740 patient\NN\9898892 's\POS\1740 tubular\JJ\1740 dysfunction\NN\14204950 and\CC\1740 <e2>myopathy</e2>\NN\14204950 may\MD\15209706 have\VB\2108377 resulted\VBN\2633881 from\IN\1740 mitochondrial\JJ\1740 dysfunction\NN\14204950 which\WDT\1740 is\VBZ\836236 triggered\VBN\1641914 by\IN\1740 tacrolimus\NN\1740 and\CC\1740 augmented\VBN\153263 by\IN\1740 <e1>lamivudine</e1>\NN\3834836 .\.\1740
D019259_D028361 NONE We\PRP\1740 suggest\VBP\1010118 that\IN\1740 our\PRP$\1740 patient\NN\9898892 's\POS\1740 tubular\JJ\1740 dysfunction\NN\14204950 and\CC\1740 myopathy\NN\14204950 may\MD\15209706 have\VB\2108377 resulted\VBN\2633881 from\IN\1740 <e2>mitochondrial\JJ\1740 dysfunction</e2>\NN\14204950 which\WDT\1740 is\VBZ\836236 triggered\VBN\1641914 by\IN\1740 tacrolimus\NN\1740 and\CC\1740 augmented\VBN\153263 by\IN\1740 <e1>lamivudine</e1>\NN\3834836 .\.\1740
16330293
12084448
D007069_D001927 CID <e1>Ifosfamide</e1>\NN\1740 <e2>encephalopathy</e2>\JJ\1740 presenting\VBG\2137132 with\IN\1740 asterixis\NN\1740 .\.\1740
D007069_D020820 NONE <e1>Ifosfamide</e1>\NN\1740 encephalopathy\JJ\1740 presenting\VBG\2137132 with\IN\1740 <e2>asterixis</e2>\NN\1740 .\.\1740
D007069_D020820 NONE The\DT\1740 administration\NN\1133281 of\IN\1740 <e1>ifosfamide</e1>\NN\1740 was\VBD\836236 discontinued\VBN\2609764 and\CC\1740 within\IN\1740 12\CD\13745420 h\NN\14622893 the\DT\1740 <e2>asterixis</e2>\NN\1740 resolved\VBN\352826 completely\RB\1740 .\.\1740
D007069_D020820 NONE In\IN\13603305 the\DT\1740 patient\NN\9898892 described\VBN\1001294 ,\,\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 <e2>asterixis</e2>\NN\1740 during\IN\1740 infusion\NN\14589223 of\IN\1740 <e1>ifosfamide</e1>\NN\1740 ,\,\1740 normal\JJ\1740 laboratory\NN\4602044 findings\NNS\7951464 and\CC\1740 imaging\NN\5765159 studies\NNS\635850 and\CC\1740 the\DT\1740 resolution\NN\6470073 of\IN\1740 symptoms\NNS\5823932 following\VBG\1835496 the\DT\1740 discontinuation\NN\209943 of\IN\1740 the\DT\1740 drug\NN\14778436 suggest\VBP\1010118 that\IN\1740 negative\JJ\1740 myoclonus\NN\14360459 is\VBZ\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 IFX\NN\1740 .\.\1740
D007069_D020820 NONE In\IN\13603305 the\DT\1740 patient\NN\9898892 described\VBN\1001294 ,\,\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 <e2>asterixis</e2>\NN\1740 during\IN\1740 infusion\NN\14589223 of\IN\1740 ifosfamide\NN\1740 ,\,\1740 normal\JJ\1740 laboratory\NN\4602044 findings\NNS\7951464 and\CC\1740 imaging\NN\5765159 studies\NNS\635850 and\CC\1740 the\DT\1740 resolution\NN\6470073 of\IN\1740 symptoms\NNS\5823932 following\VBG\1835496 the\DT\1740 discontinuation\NN\209943 of\IN\1740 the\DT\1740 drug\NN\14778436 suggest\VBP\1010118 that\IN\1740 negative\JJ\1740 myoclonus\NN\14360459 is\VBZ\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>IFX</e1>\NN\1740 .\.\1740
D007069_D009207 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 51-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 developed\VBD\1753788 severe\JJ\1740 ,\,\1740 disabling\VBG\126264 negative\JJ\1740 <e2>myoclonus</e2>\NN\14360459 of\IN\1740 the\DT\1740 upper\JJ\1740 and\CC\1740 lower\JJR\1740 extremities\NNS\5225090 after\IN\1740 the\DT\1740 infusion\NN\14589223 of\IN\1740 <e1>ifosfamide</e1>\NN\1740 for\IN\1740 plasmacytoma\NN\14235200 .\.\1740
D007069_D009207 CID In\IN\13603305 the\DT\1740 patient\NN\9898892 described\VBN\1001294 ,\,\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 asterixis\NN\1740 during\IN\1740 infusion\NN\14589223 of\IN\1740 <e1>ifosfamide</e1>\NN\1740 ,\,\1740 normal\JJ\1740 laboratory\NN\4602044 findings\NNS\7951464 and\CC\1740 imaging\NN\5765159 studies\NNS\635850 and\CC\1740 the\DT\1740 resolution\NN\6470073 of\IN\1740 symptoms\NNS\5823932 following\VBG\1835496 the\DT\1740 discontinuation\NN\209943 of\IN\1740 the\DT\1740 drug\NN\14778436 suggest\VBP\1010118 that\IN\1740 negative\JJ\1740 <e2>myoclonus</e2>\NN\14360459 is\VBZ\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 IFX\NN\1740 .\.\1740
D007069_D009207 CID In\IN\13603305 the\DT\1740 patient\NN\9898892 described\VBN\1001294 ,\,\1740 the\DT\1740 presence\NN\13954253 of\IN\1740 asterixis\NN\1740 during\IN\1740 infusion\NN\14589223 of\IN\1740 ifosfamide\NN\1740 ,\,\1740 normal\JJ\1740 laboratory\NN\4602044 findings\NNS\7951464 and\CC\1740 imaging\NN\5765159 studies\NNS\635850 and\CC\1740 the\DT\1740 resolution\NN\6470073 of\IN\1740 symptoms\NNS\5823932 following\VBG\1835496 the\DT\1740 discontinuation\NN\209943 of\IN\1740 the\DT\1740 drug\NN\14778436 suggest\VBP\1010118 that\IN\1740 negative\JJ\1740 <e2>myoclonus</e2>\NN\14360459 is\VBZ\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>IFX</e1>\NN\1740 .\.\1740
D007069_D010954 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 51-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 developed\VBD\1753788 severe\JJ\1740 ,\,\1740 disabling\VBG\126264 negative\JJ\1740 myoclonus\NN\14360459 of\IN\1740 the\DT\1740 upper\JJ\1740 and\CC\1740 lower\JJR\1740 extremities\NNS\5225090 after\IN\1740 the\DT\1740 infusion\NN\14589223 of\IN\1740 <e1>ifosfamide</e1>\NN\1740 for\IN\1740 <e2>plasmacytoma</e2>\NN\14235200 .\.\1740
15458908
D020849_D010024 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 Multiple\JJ\1740 Outcomes\NNPS\7291312 of\IN\1740 <e1>Raloxifene</e1>\NNP\1740 Evaluation\NNP\874067 ,\,\1740 a\DT\13649268 multicenter\NN\1740 ,\,\1740 randomized\VBN\278117 ,\,\1740 double-blind\JJ\1740 trial\NN\786195 ,\,\1740 enrolled\VBD\2471690 7,705\CD\1740 postmenopausal\JJ\1740 women\NNS\9605289 with\IN\1740 <e2>osteoporosis</e2>\NN\14204950 .\.\1740
D020849_D054556 CID RESULTS\NNS\34213 :\:\1740 During\IN\1740 a\DT\13649268 mean\NN\6021761 follow-up\NN\4599396 of\IN\1740 3.3\CD\1740 years\NNS\15144371 ,\,\1740 <e1>raloxifene</e1>\NN\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 for\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 (\-LRB-\1740 relative\JJ\1740 risk\NN\14541044 [\-LRB-\1740 RR\NN\1740 ]\-RRB-\1740 2.1\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 confidence\NN\5697135 interval\NN\33615 [\-LRB-\1740 CI\NNP\13635336 ]\-RRB-\1740 1.2\CD\1740 -\SYM\1740 3.8\CD\1740 )\-RRB-\1740 .\.\1740
D020849_D054556 CID CONCLUSION\NN\5837957 :\:\1740 <e1>Raloxifene</e1>\NNP\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 for\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 ,\,\1740 but\CC\1740 there\EX\27167 was\VBD\836236 no\DT\7204911 increased\VBN\169651 risk\NN\14541044 for\IN\1740 cataracts\NNS\14252864 ,\,\1740 gallbladder\NN\5512139 disease\NN\14061805 ,\,\1740 endometrial\JJ\1740 hyperplasia\NN\14365950 ,\,\1740 or\CC\3541091 endometrial\JJ\1740 cancer\NN\14239425 .\.\1740
D020849_D002386 NONE <e1>Raloxifene</e1>\NN\1740 did\VBD\1640855 not\RB\1740 increase\VB\169651 risk\NN\14541044 for\IN\1740 <e2>cataracts</e2>\NNS\14252864 (\-LRB-\1740 RR\NN\1740 0.9\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.8\CD\1740 -\SYM\1740 1.1\CD\1740 )\-RRB-\1740 ,\,\1740 gallbladder\NN\5512139 disease\NN\14061805 (\-LRB-\1740 RR\NN\1740 1.0\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.7\CD\1740 -\SYM\1740 1.3\CD\1740 )\-RRB-\1740 ,\,\1740 endometrial\JJ\1740 hyperplasia\NN\14365950 (\-LRB-\1740 RR\NN\1740 1.3\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.4\CD\1740 -\SYM\1740 5.1\CD\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 endometrial\JJ\1740 cancer\NN\14239425 (\-LRB-\1740 RR\NN\1740 0.9\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.3\CD\1740 -\SYM\1740 2.7\CD\1740 )\-RRB-\1740 .\.\1740
D020849_D002386 NONE CONCLUSION\NN\5837957 :\:\1740 <e1>Raloxifene</e1>\NNP\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 for\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 ,\,\1740 but\CC\1740 there\EX\27167 was\VBD\836236 no\DT\7204911 increased\VBN\169651 risk\NN\14541044 for\IN\1740 <e2>cataracts</e2>\NNS\14252864 ,\,\1740 gallbladder\NN\5512139 disease\NN\14061805 ,\,\1740 endometrial\JJ\1740 hyperplasia\NN\14365950 ,\,\1740 or\CC\3541091 endometrial\JJ\1740 cancer\NN\14239425 .\.\1740
D020849_D005705 NONE <e1>Raloxifene</e1>\NN\1740 did\VBD\1640855 not\RB\1740 increase\VB\169651 risk\NN\14541044 for\IN\1740 cataracts\NNS\14252864 (\-LRB-\1740 RR\NN\1740 0.9\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.8\CD\1740 -\SYM\1740 1.1\CD\1740 )\-RRB-\1740 ,\,\1740 <e2>gallbladder\NN\5512139 disease</e2>\NN\14061805 (\-LRB-\1740 RR\NN\1740 1.0\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.7\CD\1740 -\SYM\1740 1.3\CD\1740 )\-RRB-\1740 ,\,\1740 endometrial\JJ\1740 hyperplasia\NN\14365950 (\-LRB-\1740 RR\NN\1740 1.3\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.4\CD\1740 -\SYM\1740 5.1\CD\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 endometrial\JJ\1740 cancer\NN\14239425 (\-LRB-\1740 RR\NN\1740 0.9\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.3\CD\1740 -\SYM\1740 2.7\CD\1740 )\-RRB-\1740 .\.\1740
D020849_D005705 NONE CONCLUSION\NN\5837957 :\:\1740 <e1>Raloxifene</e1>\NNP\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 for\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 ,\,\1740 but\CC\1740 there\EX\27167 was\VBD\836236 no\DT\7204911 increased\VBN\169651 risk\NN\14541044 for\IN\1740 cataracts\NNS\14252864 ,\,\1740 <e2>gallbladder\NN\5512139 disease</e2>\NN\14061805 ,\,\1740 endometrial\JJ\1740 hyperplasia\NN\14365950 ,\,\1740 or\CC\3541091 endometrial\JJ\1740 cancer\NN\14239425 .\.\1740
D020849_D004714 NONE <e1>Raloxifene</e1>\NN\1740 did\VBD\1640855 not\RB\1740 increase\VB\169651 risk\NN\14541044 for\IN\1740 cataracts\NNS\14252864 (\-LRB-\1740 RR\NN\1740 0.9\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.8\CD\1740 -\SYM\1740 1.1\CD\1740 )\-RRB-\1740 ,\,\1740 gallbladder\NN\5512139 disease\NN\14061805 (\-LRB-\1740 RR\NN\1740 1.0\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.7\CD\1740 -\SYM\1740 1.3\CD\1740 )\-RRB-\1740 ,\,\1740 <e2>endometrial\JJ\1740 hyperplasia</e2>\NN\14365950 (\-LRB-\1740 RR\NN\1740 1.3\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.4\CD\1740 -\SYM\1740 5.1\CD\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 endometrial\JJ\1740 cancer\NN\14239425 (\-LRB-\1740 RR\NN\1740 0.9\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.3\CD\1740 -\SYM\1740 2.7\CD\1740 )\-RRB-\1740 .\.\1740
D020849_D004714 NONE CONCLUSION\NN\5837957 :\:\1740 <e1>Raloxifene</e1>\NNP\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 for\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 ,\,\1740 but\CC\1740 there\EX\27167 was\VBD\836236 no\DT\7204911 increased\VBN\169651 risk\NN\14541044 for\IN\1740 cataracts\NNS\14252864 ,\,\1740 gallbladder\NN\5512139 disease\NN\14061805 ,\,\1740 <e2>endometrial\JJ\1740 hyperplasia</e2>\NN\14365950 ,\,\1740 or\CC\3541091 endometrial\JJ\1740 cancer\NN\14239425 .\.\1740
D020849_D016889 NONE <e1>Raloxifene</e1>\NN\1740 did\VBD\1640855 not\RB\1740 increase\VB\169651 risk\NN\14541044 for\IN\1740 cataracts\NNS\14252864 (\-LRB-\1740 RR\NN\1740 0.9\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.8\CD\1740 -\SYM\1740 1.1\CD\1740 )\-RRB-\1740 ,\,\1740 gallbladder\NN\5512139 disease\NN\14061805 (\-LRB-\1740 RR\NN\1740 1.0\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.7\CD\1740 -\SYM\1740 1.3\CD\1740 )\-RRB-\1740 ,\,\1740 endometrial\JJ\1740 hyperplasia\NN\14365950 (\-LRB-\1740 RR\NN\1740 1.3\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.4\CD\1740 -\SYM\1740 5.1\CD\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 <e2>endometrial\JJ\1740 cancer</e2>\NN\14239425 (\-LRB-\1740 RR\NN\1740 0.9\CD\1740 ;\:\1740 95\CD\1740 %\NN\1740 CI\NN\13635336 0.3\CD\1740 -\SYM\1740 2.7\CD\1740 )\-RRB-\1740 .\.\1740
D020849_D016889 NONE CONCLUSION\NN\5837957 :\:\1740 <e1>Raloxifene</e1>\NNP\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 for\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 ,\,\1740 but\CC\1740 there\EX\27167 was\VBD\836236 no\DT\7204911 increased\VBN\169651 risk\NN\14541044 for\IN\1740 cataracts\NNS\14252864 ,\,\1740 gallbladder\NN\5512139 disease\NN\14061805 ,\,\1740 endometrial\JJ\1740 hyperplasia\NN\14365950 ,\,\1740 or\CC\3541091 <e2>endometrial\JJ\1740 cancer</e2>\NN\14239425 .\.\1740
17491223
D004280_D017202 CID Assessment\NN\5732756 of\IN\1740 a\DT\13649268 new\JJ\1740 non-invasive\JJ\1740 index\NN\13850304 of\IN\1740 cardiac\JJ\1740 performance\NN\6619065 for\IN\1740 detection\NN\5708432 of\IN\1740 <e1>dobutamine-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 .\.\1740
D004280_D017202 CID BACKGROUND\NN\4921011 :\:\1740 Electrocardiography\NN\177127 has\VBZ\2108377 a\DT\13649268 very\RB\1740 low\JJ\1740 sensitivity\NN\5651971 in\IN\13603305 detecting\VBG\2163746 <e1>dobutamine-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 .\.\1740
D004280_D017202 CID OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 assess\VB\670261 the\DT\1740 added\VBN\156601 diagnostic\JJ\1740 value\NN\5856066 of\IN\1740 a\DT\13649268 new\JJ\1740 cardiac\JJ\1740 performance\NN\6619065 index\NN\13850304 (\-LRB-\1740 dP/dtejc\NN\1740 )\-RRB-\1740 measurement\NN\407535 ,\,\1740 based\VBN\2694933 on\IN\1740 brachial\JJ\1740 artery\NN\5417975 flow\NN\7311115 changes\NNS\7283608 ,\,\1740 as\IN\14622893 compared\VBN\644583 to\TO\1740 standard\JJ\1740 12-lead\JJ\1740 ECG\NNP\7000195 ,\,\1740 for\IN\1740 detecting\VBG\2163746 <e1>dobutamine-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 ,\,\1740 using\VBG\1156834 Tc99m-Sestamibi\NN\1740 single-photon\NN\1740 emission\NN\44455 computed\VBD\632627 tomography\NN\900375 as\IN\14622893 the\DT\1740 gold\NN\13371489 standard\NN\13577171 of\IN\1740 comparison\NN\635850 to\TO\1740 assess\VB\670261 the\DT\1740 presence\NN\13954253 or\CC\3541091 absence\NN\14449405 of\IN\1740 ischemia\NN\14195315 .\.\1740
D004280_D007511 NONE OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 assess\VB\670261 the\DT\1740 added\VBN\156601 diagnostic\JJ\1740 value\NN\5856066 of\IN\1740 a\DT\13649268 new\JJ\1740 cardiac\JJ\1740 performance\NN\6619065 index\NN\13850304 (\-LRB-\1740 dP/dtejc\NN\1740 )\-RRB-\1740 measurement\NN\407535 ,\,\1740 based\VBN\2694933 on\IN\1740 brachial\JJ\1740 artery\NN\5417975 flow\NN\7311115 changes\NNS\7283608 ,\,\1740 as\IN\14622893 compared\VBN\644583 to\TO\1740 standard\JJ\1740 12-lead\JJ\1740 ECG\NNP\7000195 ,\,\1740 for\IN\1740 detecting\VBG\2163746 <e1>dobutamine-induced</e1>\JJ\1740 myocardial\JJ\1740 ischemia\NN\14195315 ,\,\1740 using\VBG\1156834 Tc99m-Sestamibi\NN\1740 single-photon\NN\1740 emission\NN\44455 computed\VBD\632627 tomography\NN\900375 as\IN\14622893 the\DT\1740 gold\NN\13371489 standard\NN\13577171 of\IN\1740 comparison\NN\635850 to\TO\1740 assess\VB\670261 the\DT\1740 presence\NN\13954253 or\CC\3541091 absence\NN\14449405 of\IN\1740 <e2>ischemia</e2>\NN\14195315 .\.\1740
D017256_D017202 NONE OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 assess\VB\670261 the\DT\1740 added\VBN\156601 diagnostic\JJ\1740 value\NN\5856066 of\IN\1740 a\DT\13649268 new\JJ\1740 cardiac\JJ\1740 performance\NN\6619065 index\NN\13850304 (\-LRB-\1740 dP/dtejc\NN\1740 )\-RRB-\1740 measurement\NN\407535 ,\,\1740 based\VBN\2694933 on\IN\1740 brachial\JJ\1740 artery\NN\5417975 flow\NN\7311115 changes\NNS\7283608 ,\,\1740 as\IN\14622893 compared\VBN\644583 to\TO\1740 standard\JJ\1740 12-lead\JJ\1740 ECG\NNP\7000195 ,\,\1740 for\IN\1740 detecting\VBG\2163746 dobutamine-induced\JJ\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 ,\,\1740 using\VBG\1156834 <e1>Tc99m-Sestamibi</e1>\NN\1740 single-photon\NN\1740 emission\NN\44455 computed\VBD\632627 tomography\NN\900375 as\IN\14622893 the\DT\1740 gold\NN\13371489 standard\NN\13577171 of\IN\1740 comparison\NN\635850 to\TO\1740 assess\VB\670261 the\DT\1740 presence\NN\13954253 or\CC\3541091 absence\NN\14449405 of\IN\1740 ischemia\NN\14195315 .\.\1740
D017256_D007511 NONE OBJECTIVES\NNS\5980875 :\:\1740 To\TO\1740 assess\VB\670261 the\DT\1740 added\VBN\156601 diagnostic\JJ\1740 value\NN\5856066 of\IN\1740 a\DT\13649268 new\JJ\1740 cardiac\JJ\1740 performance\NN\6619065 index\NN\13850304 (\-LRB-\1740 dP/dtejc\NN\1740 )\-RRB-\1740 measurement\NN\407535 ,\,\1740 based\VBN\2694933 on\IN\1740 brachial\JJ\1740 artery\NN\5417975 flow\NN\7311115 changes\NNS\7283608 ,\,\1740 as\IN\14622893 compared\VBN\644583 to\TO\1740 standard\JJ\1740 12-lead\JJ\1740 ECG\NNP\7000195 ,\,\1740 for\IN\1740 detecting\VBG\2163746 dobutamine-induced\JJ\1740 myocardial\JJ\1740 ischemia\NN\14195315 ,\,\1740 using\VBG\1156834 <e1>Tc99m-Sestamibi</e1>\NN\1740 single-photon\NN\1740 emission\NN\44455 computed\VBD\632627 tomography\NN\900375 as\IN\14622893 the\DT\1740 gold\NN\13371489 standard\NN\13577171 of\IN\1740 comparison\NN\635850 to\TO\1740 assess\VB\670261 the\DT\1740 presence\NN\13954253 or\CC\3541091 absence\NN\14449405 of\IN\1740 <e2>ischemia</e2>\NN\14195315 .\.\1740
10091617
D012642_D007024 CID <e1>Selegiline-induced</e1>\JJ\1740 <e2>postural\JJ\1740 hypotension</e2>\NN\14057371 in\IN\13603305 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 :\:\1740 a\DT\13649268 longitudinal\JJ\1740 study\NN\635850 on\IN\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 drug\NN\14778436 withdrawal\NN\7206096 .\.\1740
D012642_D007024 CID Recently\RB\1740 ,\,\1740 we\PRP\1740 found\VBD\2426171 that\IN\1740 therapy\NN\657604 with\IN\1740 <e1>selegiline</e1>\NN\1740 and\CC\1740 L-dopa\NN\14604959 was\VBD\836236 associated\VBN\628491 with\IN\1740 selective\JJ\1740 <e2>systolic\NN\1740 orthostatic\JJ\1740 hypotension</e2>\NN\14057371 which\WDT\1740 was\VBD\836236 abolished\VBN\1740 by\IN\1740 withdrawal\NN\7206096 of\IN\1740 selegiline\NN\1740 .\.\1740
D012642_D007024 CID Recently\RB\1740 ,\,\1740 we\PRP\1740 found\VBD\2426171 that\IN\1740 therapy\NN\657604 with\IN\1740 selegiline\NN\1740 and\CC\1740 L-dopa\NN\14604959 was\VBD\836236 associated\VBN\628491 with\IN\1740 selective\JJ\1740 <e2>systolic\NN\1740 orthostatic\JJ\1740 hypotension</e2>\NN\14057371 which\WDT\1740 was\VBD\836236 abolished\VBN\1740 by\IN\1740 withdrawal\NN\7206096 of\IN\1740 <e1>selegiline</e1>\NN\1740 .\.\1740
D012642_D007024 CID The\DT\1740 aims\NNS\5980875 of\IN\1740 this\DT\1740 study\NN\635850 were\VBD\836236 to\TO\1740 confirm\VB\1011725 our\PRP$\1740 previous\JJ\1740 findings\NNS\7951464 in\IN\13603305 a\DT\13649268 separate\JJ\1740 cohort\NN\8184861 of\IN\1740 patients\NNS\9898892 and\CC\1740 to\TO\1740 determine\VB\1645601 the\DT\1740 time\NN\7308889 course\NN\883297 of\IN\1740 the\DT\1740 cardiovascular\JJ\1740 consequences\NNS\34213 of\IN\1740 stopping\VBG\2452885 <e1>selegiline</e1>\NN\1740 in\IN\13603305 the\DT\1740 expectation\NN\5941423 that\IN\1740 this\DT\1740 might\MD\5029706 shed\VB\173338 light\NN\11421401 on\IN\1740 the\DT\1740 mechanisms\NNS\13446390 by\IN\1740 which\WDT\1740 the\DT\1740 drug\NN\14778436 causes\VBZ\1617192 <e2>orthostatic\JJ\1740 hypotension</e2>\NN\14057371 .\.\1740
D012642_D007024 CID RESULTS\NNS\34213 :\:\1740 Head-up\NN\1740 tilt\NN\788973 caused\VBD\1617192 <e2>systolic\JJ\1740 orthostatic\JJ\1740 hypotension</e2>\NN\14057371 which\WDT\1740 was\VBD\836236 marked\VBN\1296462 in\IN\13603305 six\CD\13741022 of\IN\1740 20\CD\13745420 PD\NN\14625458 patients\NNS\9898892 on\IN\1740 <e1>selegiline</e1>\NN\1740 ,\,\1740 one\CD\13741022 of\IN\1740 whom\WP\1740 lost\VBD\1794668 consciousness\NN\5669934 with\IN\1740 unrecordable\JJ\1740 blood\NN\5397468 pressures\NNS\11419404 .\.\1740
D012642_D007024 CID <e2>Orthostatic\JJ\1740 hypotension</e2>\NN\14057371 was\VBD\836236 ameliorated\VBN\126264 4\CD\13741022 days\NNS\15140892 after\IN\1740 withdrawal\NN\7206096 of\IN\1740 <e1>selegiline</e1>\NN\1740 and\CC\1740 totally\RB\1740 abolished\VBD\1740 7\CD\13741022 days\NNS\15140892 after\IN\1740 discontinuation\NN\209943 of\IN\1740 the\DT\1740 drug\NN\14778436 .\.\1740
D012642_D007024 CID Stopping\VBG\2452885 <e1>selegiline</e1>\NN\1740 also\RB\1740 significantly\RB\1740 <e2>reduced\VBD\441445 the\DT\1740 supine\JJ\1740 systolic\NN\1740 and\CC\1740 diastolic\JJ\1740 blood\NN\5397468 pressures</e2>\NNS\11419404 consistent\JJ\1740 with\IN\1740 a\DT\13649268 previously\RB\1740 undescribed\JJ\1740 supine\NN\1740 pressor\NN\9190918 action\NN\30358 .\.\1740
D012642_D007024 CID CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 study\NN\635850 confirms\VBZ\1011725 our\PRP$\1740 previous\JJ\1740 finding\NN\43195 that\IN\1740 <e1>selegiline</e1>\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 L-dopa\NN\14604959 is\VBZ\836236 associated\VBN\628491 with\IN\1740 selective\JJ\1740 <e2>orthostatic\JJ\1740 hypotension</e2>\NN\14057371 .\.\1740
D012642_D010300 NONE <e1>Selegiline-induced</e1>\JJ\1740 postural\JJ\1740 hypotension\NN\14057371 in\IN\13603305 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 :\:\1740 a\DT\13649268 longitudinal\JJ\1740 study\NN\635850 on\IN\1740 the\DT\1740 effects\NNS\13245626 of\IN\1740 drug\NN\14778436 withdrawal\NN\7206096 .\.\1740
D012642_D010300 NONE OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 United\NNP\1740 Kingdom\NNP\14514039 <e2>Parkinson\NNP\1740 's\POS\1740 Disease</e2>\NNP\14061805 Research\NNP\633864 Group\NNP\2137 (\-LRB-\1740 UKPDRG\NN\1740 )\-RRB-\1740 trial\NN\786195 found\VBD\2426171 an\DT\6697703 increased\VBN\169651 mortality\NN\5054863 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 randomized\VBD\278117 to\TO\1740 receive\VB\2210855 10\CD\13745420 mg\NN\13717155 <e1>selegiline</e1>\NN\1740 per\IN\1740 day\NN\15154774 and\CC\1740 L-dopa\JJ\1740 compared\VBN\644583 with\IN\1740 those\DT\1740 taking\VBG\2367363 L-dopa\NN\14604959 alone\RB\1740 .\.\1740
D012642_D010300 NONE OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 United\NNP\1740 Kingdom\NNP\14514039 Parkinson\NNP\1740 's\POS\1740 Disease\NNP\14061805 Research\NNP\633864 Group\NNP\2137 (\-LRB-\1740 UKPDRG\NN\1740 )\-RRB-\1740 trial\NN\786195 found\VBD\2426171 an\DT\6697703 increased\VBN\169651 mortality\NN\5054863 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 randomized\VBD\278117 to\TO\1740 receive\VB\2210855 10\CD\13745420 mg\NN\13717155 <e1>selegiline</e1>\NN\1740 per\IN\1740 day\NN\15154774 and\CC\1740 L-dopa\JJ\1740 compared\VBN\644583 with\IN\1740 those\DT\1740 taking\VBG\2367363 L-dopa\NN\14604959 alone\RB\1740 .\.\1740
D012642_D010300 NONE OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 United\NNP\1740 Kingdom\NNP\14514039 Parkinson\NNP\1740 's\POS\1740 Disease\NNP\14061805 Research\NNP\633864 Group\NNP\2137 (\-LRB-\1740 UKPDRG\NN\1740 )\-RRB-\1740 trial\NN\786195 found\VBD\2426171 an\DT\6697703 increased\VBN\169651 mortality\NN\5054863 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 <e2>PD</e2>\NN\14625458 )\-RRB-\1740 randomized\VBD\278117 to\TO\1740 receive\VB\2210855 10\CD\13745420 mg\NN\13717155 <e1>selegiline</e1>\NN\1740 per\IN\1740 day\NN\15154774 and\CC\1740 L-dopa\JJ\1740 compared\VBN\644583 with\IN\1740 those\DT\1740 taking\VBG\2367363 L-dopa\NN\14604959 alone\RB\1740 .\.\1740
D012642_D010300 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 cardiovascular\JJ\1740 responses\NNS\11410625 to\TO\1740 standing\NN\13945919 and\CC\1740 head-up\JJ\1740 tilt\NN\788973 were\VBD\836236 studied\VBN\630380 repeatedly\RB\1740 in\IN\13603305 <e2>PD</e2>\NN\14625458 patients\NNS\9898892 receiving\VBG\2210855 <e1>selegiline</e1>\NN\1740 and\CC\1740 as\IN\14622893 the\DT\1740 drug\NN\14778436 was\VBD\836236 withdrawn\VBN\1835496 .\.\1740
D012642_D010300 NONE RESULTS\NNS\34213 :\:\1740 Head-up\NN\1740 tilt\NN\788973 caused\VBD\1617192 systolic\JJ\1740 orthostatic\JJ\1740 hypotension\NN\14057371 which\WDT\1740 was\VBD\836236 marked\VBN\1296462 in\IN\13603305 six\CD\13741022 of\IN\1740 20\CD\13745420 <e2>PD</e2>\NN\14625458 patients\NNS\9898892 on\IN\1740 <e1>selegiline</e1>\NN\1740 ,\,\1740 one\CD\13741022 of\IN\1740 whom\WP\1740 lost\VBD\1794668 consciousness\NN\5669934 with\IN\1740 unrecordable\JJ\1740 blood\NN\5397468 pressures\NNS\11419404 .\.\1740
D007980_D010300 NONE OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 United\NNP\1740 Kingdom\NNP\14514039 <e2>Parkinson\NNP\1740 's\POS\1740 Disease</e2>\NNP\14061805 Research\NNP\633864 Group\NNP\2137 (\-LRB-\1740 UKPDRG\NN\1740 )\-RRB-\1740 trial\NN\786195 found\VBD\2426171 an\DT\6697703 increased\VBN\169651 mortality\NN\5054863 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 randomized\VBD\278117 to\TO\1740 receive\VB\2210855 10\CD\13745420 mg\NN\13717155 selegiline\NN\1740 per\IN\1740 day\NN\15154774 and\CC\1740 <e1>L-dopa</e1>\JJ\1740 compared\VBN\644583 with\IN\1740 those\DT\1740 taking\VBG\2367363 L-dopa\NN\14604959 alone\RB\1740 .\.\1740
D007980_D010300 NONE OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 United\NNP\1740 Kingdom\NNP\14514039 Parkinson\NNP\1740 's\POS\1740 Disease\NNP\14061805 Research\NNP\633864 Group\NNP\2137 (\-LRB-\1740 UKPDRG\NN\1740 )\-RRB-\1740 trial\NN\786195 found\VBD\2426171 an\DT\6697703 increased\VBN\169651 mortality\NN\5054863 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 randomized\VBD\278117 to\TO\1740 receive\VB\2210855 10\CD\13745420 mg\NN\13717155 selegiline\NN\1740 per\IN\1740 day\NN\15154774 and\CC\1740 <e1>L-dopa</e1>\JJ\1740 compared\VBN\644583 with\IN\1740 those\DT\1740 taking\VBG\2367363 L-dopa\NN\14604959 alone\RB\1740 .\.\1740
D007980_D010300 NONE OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 United\NNP\1740 Kingdom\NNP\14514039 Parkinson\NNP\1740 's\POS\1740 Disease\NNP\14061805 Research\NNP\633864 Group\NNP\2137 (\-LRB-\1740 UKPDRG\NN\1740 )\-RRB-\1740 trial\NN\786195 found\VBD\2426171 an\DT\6697703 increased\VBN\169651 mortality\NN\5054863 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 <e2>PD</e2>\NN\14625458 )\-RRB-\1740 randomized\VBD\278117 to\TO\1740 receive\VB\2210855 10\CD\13745420 mg\NN\13717155 selegiline\NN\1740 per\IN\1740 day\NN\15154774 and\CC\1740 <e1>L-dopa</e1>\JJ\1740 compared\VBN\644583 with\IN\1740 those\DT\1740 taking\VBG\2367363 L-dopa\NN\14604959 alone\RB\1740 .\.\1740
D007980_D010300 NONE OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 United\NNP\1740 Kingdom\NNP\14514039 <e2>Parkinson\NNP\1740 's\POS\1740 Disease</e2>\NNP\14061805 Research\NNP\633864 Group\NNP\2137 (\-LRB-\1740 UKPDRG\NN\1740 )\-RRB-\1740 trial\NN\786195 found\VBD\2426171 an\DT\6697703 increased\VBN\169651 mortality\NN\5054863 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 randomized\VBD\278117 to\TO\1740 receive\VB\2210855 10\CD\13745420 mg\NN\13717155 selegiline\NN\1740 per\IN\1740 day\NN\15154774 and\CC\1740 L-dopa\JJ\1740 compared\VBN\644583 with\IN\1740 those\DT\1740 taking\VBG\2367363 <e1>L-dopa</e1>\NN\14604959 alone\RB\1740 .\.\1740
D007980_D010300 NONE OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 United\NNP\1740 Kingdom\NNP\14514039 Parkinson\NNP\1740 's\POS\1740 Disease\NNP\14061805 Research\NNP\633864 Group\NNP\2137 (\-LRB-\1740 UKPDRG\NN\1740 )\-RRB-\1740 trial\NN\786195 found\VBD\2426171 an\DT\6697703 increased\VBN\169651 mortality\NN\5054863 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>Parkinson\NN\1740 's\POS\1740 disease</e2>\NN\14061805 (\-LRB-\1740 PD\NN\14625458 )\-RRB-\1740 randomized\VBD\278117 to\TO\1740 receive\VB\2210855 10\CD\13745420 mg\NN\13717155 selegiline\NN\1740 per\IN\1740 day\NN\15154774 and\CC\1740 L-dopa\JJ\1740 compared\VBN\644583 with\IN\1740 those\DT\1740 taking\VBG\2367363 <e1>L-dopa</e1>\NN\14604959 alone\RB\1740 .\.\1740
D007980_D010300 NONE OBJECTIVES\NNS\5980875 :\:\1740 The\DT\1740 United\NNP\1740 Kingdom\NNP\14514039 Parkinson\NNP\1740 's\POS\1740 Disease\NNP\14061805 Research\NNP\633864 Group\NNP\2137 (\-LRB-\1740 UKPDRG\NN\1740 )\-RRB-\1740 trial\NN\786195 found\VBD\2426171 an\DT\6697703 increased\VBN\169651 mortality\NN\5054863 in\IN\13603305 patients\NNS\9898892 with\IN\1740 Parkinson\NN\1740 's\POS\1740 disease\NN\14061805 (\-LRB-\1740 <e2>PD</e2>\NN\14625458 )\-RRB-\1740 randomized\VBD\278117 to\TO\1740 receive\VB\2210855 10\CD\13745420 mg\NN\13717155 selegiline\NN\1740 per\IN\1740 day\NN\15154774 and\CC\1740 L-dopa\JJ\1740 compared\VBN\644583 with\IN\1740 those\DT\1740 taking\VBG\2367363 <e1>L-dopa</e1>\NN\14604959 alone\RB\1740 .\.\1740
D007980_D007024 NONE Recently\RB\1740 ,\,\1740 we\PRP\1740 found\VBD\2426171 that\IN\1740 therapy\NN\657604 with\IN\1740 selegiline\NN\1740 and\CC\1740 <e1>L-dopa</e1>\NN\14604959 was\VBD\836236 associated\VBN\628491 with\IN\1740 selective\JJ\1740 <e2>systolic\NN\1740 orthostatic\JJ\1740 hypotension</e2>\NN\14057371 which\WDT\1740 was\VBD\836236 abolished\VBN\1740 by\IN\1740 withdrawal\NN\7206096 of\IN\1740 selegiline\NN\1740 .\.\1740
D007980_D007024 NONE CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 study\NN\635850 confirms\VBZ\1011725 our\PRP$\1740 previous\JJ\1740 finding\NN\43195 that\IN\1740 selegiline\NN\1740 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>L-dopa</e1>\NN\14604959 is\VBZ\836236 associated\VBN\628491 with\IN\1740 selective\JJ\1740 <e2>orthostatic\JJ\1740 hypotension</e2>\NN\14057371 .\.\1740
2951327
D009638_D013610 NONE Mean\VB\928630 arterial\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 as\IN\14622893 a\DT\13649268 percentage\NN\13815742 of\IN\1740 control\NN\5190804 +/-\CC\1740 SEM\NN\1740 )\-RRB-\1740 during\IN\1740 randomized\JJ\1740 infusions\NNS\14589223 of\IN\1740 0.03\CD\1740 ,\,\1740 0.1\CD\1740 ,\,\1740 0.3\CD\1740 ,\,\1740 or\CC\3541091 1.0\CD\1740 microgram/kg/min\NN\1740 was\VBD\836236 99\CD\1740 +/-\CC\1740 1\CD\13741022 ,\,\1740 95\CD\1740 +/-\CC\1740 1\CD\13741022 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 ,\,\1740 93\CD\1740 +/-\CC\1740 1\CD\13741022 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 79\CD\1740 +/-\CC\1740 6\CD\13741022 %\NN\1740 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 but\CC\1740 no\DT\7204911 <e2>tachycardia</e2>\NN\14110674 and\CC\1740 no\DT\7204911 augmentation\NN\7356676 of\IN\1740 the\DT\1740 <e1>norepinephrine</e1>\NN\14807929 release\NN\3748886 rate\NN\13815152 (\-LRB-\1740 up\RB\1740 to\TO\1740 0.3\CD\1740 microgram/kg/min\NN\1740 )\-RRB-\1740 were\VBD\836236 observed\VBN\2163746 ,\,\1740 which\WDT\1740 is\VBZ\836236 in\IN\13603305 contrast\NN\13854649 to\TO\1740 comparable\JJ\1740 hypotension\NN\14057371 induced\VBN\1627355 by\IN\1740 hydralazine\NN\2721160 or\CC\3541091 nitroglycerin\NN\15015501 .\.\1740
D009638_D007022 NONE Mean\VB\928630 arterial\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 as\IN\14622893 a\DT\13649268 percentage\NN\13815742 of\IN\1740 control\NN\5190804 +/-\CC\1740 SEM\NN\1740 )\-RRB-\1740 during\IN\1740 randomized\JJ\1740 infusions\NNS\14589223 of\IN\1740 0.03\CD\1740 ,\,\1740 0.1\CD\1740 ,\,\1740 0.3\CD\1740 ,\,\1740 or\CC\3541091 1.0\CD\1740 microgram/kg/min\NN\1740 was\VBD\836236 99\CD\1740 +/-\CC\1740 1\CD\13741022 ,\,\1740 95\CD\1740 +/-\CC\1740 1\CD\13741022 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 ,\,\1740 93\CD\1740 +/-\CC\1740 1\CD\13741022 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 79\CD\1740 +/-\CC\1740 6\CD\13741022 %\NN\1740 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 but\CC\1740 no\DT\7204911 tachycardia\NN\14110674 and\CC\1740 no\DT\7204911 augmentation\NN\7356676 of\IN\1740 the\DT\1740 <e1>norepinephrine</e1>\NN\14807929 release\NN\3748886 rate\NN\13815152 (\-LRB-\1740 up\RB\1740 to\TO\1740 0.3\CD\1740 microgram/kg/min\NN\1740 )\-RRB-\1740 were\VBD\836236 observed\VBN\2163746 ,\,\1740 which\WDT\1740 is\VBZ\836236 in\IN\13603305 contrast\NN\13854649 to\TO\1740 comparable\JJ\1740 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 hydralazine\NN\2721160 or\CC\3541091 nitroglycerin\NN\15015501 .\.\1740
D006830_D013610 NONE Mean\VB\928630 arterial\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 as\IN\14622893 a\DT\13649268 percentage\NN\13815742 of\IN\1740 control\NN\5190804 +/-\CC\1740 SEM\NN\1740 )\-RRB-\1740 during\IN\1740 randomized\JJ\1740 infusions\NNS\14589223 of\IN\1740 0.03\CD\1740 ,\,\1740 0.1\CD\1740 ,\,\1740 0.3\CD\1740 ,\,\1740 or\CC\3541091 1.0\CD\1740 microgram/kg/min\NN\1740 was\VBD\836236 99\CD\1740 +/-\CC\1740 1\CD\13741022 ,\,\1740 95\CD\1740 +/-\CC\1740 1\CD\13741022 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 ,\,\1740 93\CD\1740 +/-\CC\1740 1\CD\13741022 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 79\CD\1740 +/-\CC\1740 6\CD\13741022 %\NN\1740 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 but\CC\1740 no\DT\7204911 <e2>tachycardia</e2>\NN\14110674 and\CC\1740 no\DT\7204911 augmentation\NN\7356676 of\IN\1740 the\DT\1740 norepinephrine\NN\14807929 release\NN\3748886 rate\NN\13815152 (\-LRB-\1740 up\RB\1740 to\TO\1740 0.3\CD\1740 microgram/kg/min\NN\1740 )\-RRB-\1740 were\VBD\836236 observed\VBN\2163746 ,\,\1740 which\WDT\1740 is\VBZ\836236 in\IN\13603305 contrast\NN\13854649 to\TO\1740 comparable\JJ\1740 hypotension\NN\14057371 induced\VBN\1627355 by\IN\1740 <e1>hydralazine</e1>\NN\2721160 or\CC\3541091 nitroglycerin\NN\15015501 .\.\1740
D006830_D007022 CID Mean\VB\928630 arterial\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 as\IN\14622893 a\DT\13649268 percentage\NN\13815742 of\IN\1740 control\NN\5190804 +/-\CC\1740 SEM\NN\1740 )\-RRB-\1740 during\IN\1740 randomized\JJ\1740 infusions\NNS\14589223 of\IN\1740 0.03\CD\1740 ,\,\1740 0.1\CD\1740 ,\,\1740 0.3\CD\1740 ,\,\1740 or\CC\3541091 1.0\CD\1740 microgram/kg/min\NN\1740 was\VBD\836236 99\CD\1740 +/-\CC\1740 1\CD\13741022 ,\,\1740 95\CD\1740 +/-\CC\1740 1\CD\13741022 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 ,\,\1740 93\CD\1740 +/-\CC\1740 1\CD\13741022 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 79\CD\1740 +/-\CC\1740 6\CD\13741022 %\NN\1740 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 but\CC\1740 no\DT\7204911 tachycardia\NN\14110674 and\CC\1740 no\DT\7204911 augmentation\NN\7356676 of\IN\1740 the\DT\1740 norepinephrine\NN\14807929 release\NN\3748886 rate\NN\13815152 (\-LRB-\1740 up\RB\1740 to\TO\1740 0.3\CD\1740 microgram/kg/min\NN\1740 )\-RRB-\1740 were\VBD\836236 observed\VBN\2163746 ,\,\1740 which\WDT\1740 is\VBZ\836236 in\IN\13603305 contrast\NN\13854649 to\TO\1740 comparable\JJ\1740 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 <e1>hydralazine</e1>\NN\2721160 or\CC\3541091 nitroglycerin\NN\15015501 .\.\1740
D005996_D013610 NONE Mean\VB\928630 arterial\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 as\IN\14622893 a\DT\13649268 percentage\NN\13815742 of\IN\1740 control\NN\5190804 +/-\CC\1740 SEM\NN\1740 )\-RRB-\1740 during\IN\1740 randomized\JJ\1740 infusions\NNS\14589223 of\IN\1740 0.03\CD\1740 ,\,\1740 0.1\CD\1740 ,\,\1740 0.3\CD\1740 ,\,\1740 or\CC\3541091 1.0\CD\1740 microgram/kg/min\NN\1740 was\VBD\836236 99\CD\1740 +/-\CC\1740 1\CD\13741022 ,\,\1740 95\CD\1740 +/-\CC\1740 1\CD\13741022 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 ,\,\1740 93\CD\1740 +/-\CC\1740 1\CD\13741022 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 79\CD\1740 +/-\CC\1740 6\CD\13741022 %\NN\1740 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 but\CC\1740 no\DT\7204911 <e2>tachycardia</e2>\NN\14110674 and\CC\1740 no\DT\7204911 augmentation\NN\7356676 of\IN\1740 the\DT\1740 norepinephrine\NN\14807929 release\NN\3748886 rate\NN\13815152 (\-LRB-\1740 up\RB\1740 to\TO\1740 0.3\CD\1740 microgram/kg/min\NN\1740 )\-RRB-\1740 were\VBD\836236 observed\VBN\2163746 ,\,\1740 which\WDT\1740 is\VBZ\836236 in\IN\13603305 contrast\NN\13854649 to\TO\1740 comparable\JJ\1740 hypotension\NN\14057371 induced\VBN\1627355 by\IN\1740 hydralazine\NN\2721160 or\CC\3541091 <e1>nitroglycerin</e1>\NN\15015501 .\.\1740
D005996_D007022 CID Mean\VB\928630 arterial\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 as\IN\14622893 a\DT\13649268 percentage\NN\13815742 of\IN\1740 control\NN\5190804 +/-\CC\1740 SEM\NN\1740 )\-RRB-\1740 during\IN\1740 randomized\JJ\1740 infusions\NNS\14589223 of\IN\1740 0.03\CD\1740 ,\,\1740 0.1\CD\1740 ,\,\1740 0.3\CD\1740 ,\,\1740 or\CC\3541091 1.0\CD\1740 microgram/kg/min\NN\1740 was\VBD\836236 99\CD\1740 +/-\CC\1740 1\CD\13741022 ,\,\1740 95\CD\1740 +/-\CC\1740 1\CD\13741022 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 ,\,\1740 93\CD\1740 +/-\CC\1740 1\CD\13741022 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.01\CD\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 79\CD\1740 +/-\CC\1740 6\CD\13741022 %\NN\1740 (\-LRB-\1740 p\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 but\CC\1740 no\DT\7204911 tachycardia\NN\14110674 and\CC\1740 no\DT\7204911 augmentation\NN\7356676 of\IN\1740 the\DT\1740 norepinephrine\NN\14807929 release\NN\3748886 rate\NN\13815152 (\-LRB-\1740 up\RB\1740 to\TO\1740 0.3\CD\1740 microgram/kg/min\NN\1740 )\-RRB-\1740 were\VBD\836236 observed\VBN\2163746 ,\,\1740 which\WDT\1740 is\VBZ\836236 in\IN\13603305 contrast\NN\13854649 to\TO\1740 comparable\JJ\1740 <e2>hypotension</e2>\NN\14057371 induced\VBN\1627355 by\IN\1740 hydralazine\NN\2721160 or\CC\3541091 <e1>nitroglycerin</e1>\NN\15015501 .\.\1740
19657887
D000431_D005483 CID In\IN\13603305 less\JJR\1740 than\IN\1740 1\CD\13741022 hour\NN\15154774 after\IN\1740 the\DT\1740 ingestion\NN\13440063 of\IN\1740 <e1>alcohol</e1>\NN\7881800 ,\,\1740 he\PRP\14622893 developed\VBD\1753788 malaise\NN\14446652 with\IN\1740 <e2>flushing\NN\1740 of\IN\1740 the\DT\1740 face</e2>\NN\5225090 ,\,\1740 tachycardia\NN\14110674 ,\,\1740 and\CC\1740 dyspnea\VB\1740 .\.\1740
D000431_D013610 CID In\IN\13603305 less\JJR\1740 than\IN\1740 1\CD\13741022 hour\NN\15154774 after\IN\1740 the\DT\1740 ingestion\NN\13440063 of\IN\1740 <e1>alcohol</e1>\NN\7881800 ,\,\1740 he\PRP\14622893 developed\VBD\1753788 malaise\NN\14446652 with\IN\1740 flushing\NN\1740 of\IN\1740 the\DT\1740 face\NN\5225090 ,\,\1740 <e2>tachycardia</e2>\NN\14110674 ,\,\1740 and\CC\1740 dyspnea\VB\1740 .\.\1740
D000431_D004417 CID In\IN\13603305 less\JJR\1740 than\IN\1740 1\CD\13741022 hour\NN\15154774 after\IN\1740 the\DT\1740 ingestion\NN\13440063 of\IN\1740 <e1>alcohol</e1>\NN\7881800 ,\,\1740 he\PRP\14622893 developed\VBD\1753788 malaise\NN\14446652 with\IN\1740 flushing\NN\1740 of\IN\1740 the\DT\1740 face\NN\5225090 ,\,\1740 tachycardia\NN\14110674 ,\,\1740 and\CC\1740 <e2>dyspnea</e2>\VB\1740 .\.\1740
D004221_D005483 NONE Five\CD\13741022 hours\NNS\15118228 after\IN\1740 exposure\NN\5042871 ,\,\1740 he\PRP\14622893 developed\VBD\1753788 <e1>disulfiram-like</e1>\JJ\1740 syndrome\NN\5870365 with\IN\1740 <e2>flushing</e2>\NN\1740 ,\,\1740 tachycardia\NN\14110674 ,\,\1740 and\CC\1740 arterial\JJ\1740 hypotension\NN\14057371 after\IN\1740 consuming\VBG\1168468 three\CD\13741022 glasses\NNS\3852280 of\IN\1740 wine\NN\7884567 .\.\1740
D004221_D013610 NONE Five\CD\13741022 hours\NNS\15118228 after\IN\1740 exposure\NN\5042871 ,\,\1740 he\PRP\14622893 developed\VBD\1753788 <e1>disulfiram-like</e1>\JJ\1740 syndrome\NN\5870365 with\IN\1740 flushing\NN\1740 ,\,\1740 <e2>tachycardia</e2>\NN\14110674 ,\,\1740 and\CC\1740 arterial\JJ\1740 hypotension\NN\14057371 after\IN\1740 consuming\VBG\1168468 three\CD\13741022 glasses\NNS\3852280 of\IN\1740 wine\NN\7884567 .\.\1740
D004221_D007022 NONE Five\CD\13741022 hours\NNS\15118228 after\IN\1740 exposure\NN\5042871 ,\,\1740 he\PRP\14622893 developed\VBD\1753788 <e1>disulfiram-like</e1>\JJ\1740 syndrome\NN\5870365 with\IN\1740 flushing\NN\1740 ,\,\1740 tachycardia\NN\14110674 ,\,\1740 and\CC\1740 <e2>arterial\JJ\1740 hypotension</e2>\NN\14057371 after\IN\1740 consuming\VBG\1168468 three\CD\13741022 glasses\NNS\3852280 of\IN\1740 wine\NN\7884567 .\.\1740
2071257
D005997_D000647 NONE Effect\NN\34213 of\IN\1740 <e1>L-alpha-glyceryl-phosphorylcholine</e1>\NN\1740 on\IN\1740 <e2>amnesia</e2>\NN\5669934 caused\VBN\1617192 by\IN\1740 scopolamine\NN\14712692 .\.\1740
D012601_D000647 NONE Effect\NN\34213 of\IN\1740 L-alpha-glyceryl-phosphorylcholine\NN\1740 on\IN\1740 <e2>amnesia</e2>\NN\5669934 caused\VBN\1617192 by\IN\1740 <e1>scopolamine</e1>\NN\14712692 .\.\1740
D005997_D008569 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 carried\VBN\1850315 out\RP\1740 to\TO\1740 test\VB\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 <e1>L-alpha-glycerylphosphorylcholine</e1>\NN\1740 (\-LRB-\1740 L-alpha-GFC\NN\1740 )\-RRB-\1740 on\IN\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 induced\VBN\1627355 by\IN\1740 scopolamine\NN\14712692 in\IN\13603305 man\NN\9605289 .\.\1740
D005997_D008569 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 carried\VBN\1850315 out\RP\1740 to\TO\1740 test\VB\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 L-alpha-glycerylphosphorylcholine\NN\1740 (\-LRB-\1740 <e1>L-alpha-GFC</e1>\NN\1740 )\-RRB-\1740 on\IN\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 induced\VBN\1627355 by\IN\1740 scopolamine\NN\14712692 in\IN\13603305 man\NN\9605289 .\.\1740
D012601_D008569 CID The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 carried\VBN\1850315 out\RP\1740 to\TO\1740 test\VB\670261 the\DT\1740 effects\NNS\13245626 of\IN\1740 L-alpha-glycerylphosphorylcholine\NN\1740 (\-LRB-\1740 L-alpha-GFC\NN\1740 )\-RRB-\1740 on\IN\1740 <e2>memory\NN\5926676 impairment</e2>\NN\7296428 induced\VBN\1627355 by\IN\1740 <e1>scopolamine</e1>\NN\14712692 in\IN\13603305 man\NN\9605289 .\.\1740
D012601_D008569 CID The\DT\1740 findings\NNS\7951464 of\IN\1740 this\DT\1740 study\NN\635850 indicate\VBP\952524 that\IN\1740 the\DT\1740 drug\NN\14778436 is\VBZ\836236 able\JJ\1740 to\TO\1740 antagonize\VB\1787955 <e2>impairment\NN\7296428 of\IN\1740 attention\NN\5701944 and\CC\1740 memory</e2>\NN\5926676 induced\VBN\1627355 by\IN\1740 <e1>scopolamine</e1>\NN\14712692 .\.\1740
2375138
D008874_D006323 CID Possible\JJ\1740 intramuscular\JJ\1740 <e1>midazolam-associated</e1>\JJ\1740 <e2>cardiorespiratory\JJ\1740 arrest</e2>\NN\88481 and\CC\1740 death\NN\7296428 .\.\1740
D008874_D006323 CID This\DT\1740 report\NN\6470073 describes\VBZ\1001294 the\DT\1740 first\JJ\1740 published\VBN\1621555 case\NN\7283608 of\IN\1740 <e2>cardiorespiratory\JJ\1740 arrest</e2>\NN\88481 and\CC\1740 death\NN\7296428 associated\VBN\628491 with\IN\1740 intramuscular\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>midazolam</e1>\NN\2830852 .\.\1740
D008874_D003643 NONE Possible\JJ\1740 intramuscular\JJ\1740 <e1>midazolam-associated</e1>\JJ\1740 cardiorespiratory\JJ\1740 arrest\NN\88481 and\CC\1740 <e2>death</e2>\NN\7296428 .\.\1740
D008874_D003643 NONE This\DT\1740 report\NN\6470073 describes\VBZ\1001294 the\DT\1740 first\JJ\1740 published\VBN\1621555 case\NN\7283608 of\IN\1740 cardiorespiratory\JJ\1740 arrest\NN\88481 and\CC\1740 <e2>death</e2>\NN\7296428 associated\VBN\628491 with\IN\1740 intramuscular\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>midazolam</e1>\NN\2830852 .\.\1740
1436384
D000661_D020258 CID Protection\NN\407535 against\IN\1740 <e1>amphetamine-induced</e1>\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 toward\IN\1740 striatal\JJ\1740 dopamine\NN\14807737 neurons\NNS\5430628 in\IN\13603305 rodents\NNS\1886756 by\IN\1740 LY274614\NN\1740 ,\,\1740 an\DT\6697703 excitatory\JJ\1740 amino\NN\14621446 acid\NN\14818238 antagonist\NN\7846 .\.\1740
D000661_D020258 CID The\DT\1740 data\NNS\7951464 strengthen\VBP\126264 the\DT\1740 evidence\NN\5816287 that\IN\1740 the\DT\1740 <e2>neurotoxic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 <e1>amphetamine</e1>\NN\3248958 and\CC\1740 related\JJ\1740 compounds\NNS\5869584 toward\IN\1740 nigrostriatal\JJ\1740 dopamine\NN\14807737 neurons\NNS\5430628 involves\VBZ\2676054 NMDA\NN\1740 receptors\NNS\5225602 and\CC\1740 that\IN\1740 LY274614\NN\1740 is\VBZ\836236 an\DT\6697703 NMDA\NN\1740 receptor\NN\5225602 antagonist\NN\7846 with\IN\1740 long-lasting\JJ\1740 in\FW\13603305 vivo\FW\1740 effects\NNS\13245626 in\IN\13603305 rats\NNS\2329401 .\.\1740
D004298_D020258 NONE Protection\NN\407535 against\IN\1740 amphetamine-induced\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 toward\IN\1740 striatal\JJ\1740 <e1>dopamine</e1>\NN\14807737 neurons\NNS\5430628 in\IN\13603305 rodents\NNS\1886756 by\IN\1740 LY274614\NN\1740 ,\,\1740 an\DT\6697703 excitatory\JJ\1740 amino\NN\14621446 acid\NN\14818238 antagonist\NN\7846 .\.\1740
D004298_D020258 NONE The\DT\1740 data\NNS\7951464 strengthen\VBP\126264 the\DT\1740 evidence\NN\5816287 that\IN\1740 the\DT\1740 <e2>neurotoxic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 amphetamine\NN\3248958 and\CC\1740 related\JJ\1740 compounds\NNS\5869584 toward\IN\1740 nigrostriatal\JJ\1740 <e1>dopamine</e1>\NN\14807737 neurons\NNS\5430628 involves\VBZ\2676054 NMDA\NN\1740 receptors\NNS\5225602 and\CC\1740 that\IN\1740 LY274614\NN\1740 is\VBZ\836236 an\DT\6697703 NMDA\NN\1740 receptor\NN\5225602 antagonist\NN\7846 with\IN\1740 long-lasting\JJ\1740 in\FW\13603305 vivo\FW\1740 effects\NNS\13245626 in\IN\13603305 rats\NNS\2329401 .\.\1740
C070935_D020258 NONE Protection\NN\407535 against\IN\1740 amphetamine-induced\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 toward\IN\1740 striatal\JJ\1740 dopamine\NN\14807737 neurons\NNS\5430628 in\IN\13603305 rodents\NNS\1886756 by\IN\1740 <e1>LY274614</e1>\NN\1740 ,\,\1740 an\DT\6697703 excitatory\JJ\1740 amino\NN\14621446 acid\NN\14818238 antagonist\NN\7846 .\.\1740
C070935_D020258 NONE The\DT\1740 data\NNS\7951464 strengthen\VBP\126264 the\DT\1740 evidence\NN\5816287 that\IN\1740 the\DT\1740 <e2>neurotoxic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 amphetamine\NN\3248958 and\CC\1740 related\JJ\1740 compounds\NNS\5869584 toward\IN\1740 nigrostriatal\JJ\1740 dopamine\NN\14807737 neurons\NNS\5430628 involves\VBZ\2676054 NMDA\NN\1740 receptors\NNS\5225602 and\CC\1740 that\IN\1740 <e1>LY274614</e1>\NN\1740 is\VBZ\836236 an\DT\6697703 NMDA\NN\1740 receptor\NN\5225602 antagonist\NN\7846 with\IN\1740 long-lasting\JJ\1740 in\FW\13603305 vivo\FW\1740 effects\NNS\13245626 in\IN\13603305 rats\NNS\2329401 .\.\1740
D000596_D020258 NONE Protection\NN\407535 against\IN\1740 amphetamine-induced\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 toward\IN\1740 striatal\JJ\1740 dopamine\NN\14807737 neurons\NNS\5430628 in\IN\13603305 rodents\NNS\1886756 by\IN\1740 LY274614\NN\1740 ,\,\1740 an\DT\6697703 excitatory\JJ\1740 <e1>amino\NN\14621446 acid</e1>\NN\14818238 antagonist\NN\7846 .\.\1740
D016202_D020258 NONE The\DT\1740 data\NNS\7951464 strengthen\VBP\126264 the\DT\1740 evidence\NN\5816287 that\IN\1740 the\DT\1740 <e2>neurotoxic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 amphetamine\NN\3248958 and\CC\1740 related\JJ\1740 compounds\NNS\5869584 toward\IN\1740 nigrostriatal\JJ\1740 dopamine\NN\14807737 neurons\NNS\5430628 involves\VBZ\2676054 <e1>NMDA</e1>\NN\1740 receptors\NNS\5225602 and\CC\1740 that\IN\1740 LY274614\NN\1740 is\VBZ\836236 an\DT\6697703 NMDA\NN\1740 receptor\NN\5225602 antagonist\NN\7846 with\IN\1740 long-lasting\JJ\1740 in\FW\13603305 vivo\FW\1740 effects\NNS\13245626 in\IN\13603305 rats\NNS\2329401 .\.\1740
D016202_D020258 NONE The\DT\1740 data\NNS\7951464 strengthen\VBP\126264 the\DT\1740 evidence\NN\5816287 that\IN\1740 the\DT\1740 <e2>neurotoxic</e2>\JJ\1740 effect\NN\34213 of\IN\1740 amphetamine\NN\3248958 and\CC\1740 related\JJ\1740 compounds\NNS\5869584 toward\IN\1740 nigrostriatal\JJ\1740 dopamine\NN\14807737 neurons\NNS\5430628 involves\VBZ\2676054 NMDA\NN\1740 receptors\NNS\5225602 and\CC\1740 that\IN\1740 LY274614\NN\1740 is\VBZ\836236 an\DT\6697703 <e1>NMDA</e1>\NN\1740 receptor\NN\5225602 antagonist\NN\7846 with\IN\1740 long-lasting\JJ\1740 in\FW\13603305 vivo\FW\1740 effects\NNS\13245626 in\IN\13603305 rats\NNS\2329401 .\.\1740
12443032
D003042_D002637 CID <e1>Cocaine</e1>\NN\3492717 related\JJ\1740 <e2>chest\JJS\1740 pain</e2>\NN\14299637 :\:\1740 are\VBP\836236 we\PRP\1740 seeing\VBG\2106506 the\DT\1740 tip\NN\8566028 of\IN\1740 an\DT\6697703 iceberg\NN\9281777 ?\.\1740
D003042_D002637 CID In\IN\13603305 particular\JJ\1740 ,\,\1740 the\DT\1740 tendency\NN\6193203 of\IN\1740 <e1>cocaine</e1>\NN\3492717 to\TO\1740 produce\VB\1617192 <e2>chest\JJ\1740 pain</e2>\NN\14299637 ought\MD\1740 to\TO\1740 be\VB\836236 in\IN\13603305 the\DT\1740 mind\NN\23271 of\IN\1740 the\DT\1740 emergency\NN\7417644 nurse\NN\10165109 when\WRB\1740 faced\VBN\2439281 with\IN\1740 a\DT\13649268 young\JJ\1740 victim\NN\9630641 of\IN\1740 chest\JJ\1740 pain\NN\14299637 who\WP\8299493 is\VBZ\836236 otherwise\RB\1740 at\IN\14622893 low\JJ\1740 risk\NN\14541044 .\.\1740
D003042_D002637 CID In\IN\13603305 particular\JJ\1740 ,\,\1740 the\DT\1740 tendency\NN\6193203 of\IN\1740 <e1>cocaine</e1>\NN\3492717 to\TO\1740 produce\VB\1617192 chest\JJ\1740 pain\NN\14299637 ought\MD\1740 to\TO\1740 be\VB\836236 in\IN\13603305 the\DT\1740 mind\NN\23271 of\IN\1740 the\DT\1740 emergency\NN\7417644 nurse\NN\10165109 when\WRB\1740 faced\VBN\2439281 with\IN\1740 a\DT\13649268 young\JJ\1740 victim\NN\9630641 of\IN\1740 <e2>chest\JJ\1740 pain</e2>\NN\14299637 who\WP\8299493 is\VBZ\836236 otherwise\RB\1740 at\IN\14622893 low\JJ\1740 risk\NN\14541044 .\.\1740
D003042_D002637 CID The\DT\1740 mechanism\NN\13446390 of\IN\1740 <e2>chest\JJ\1740 pain</e2>\NN\14299637 related\JJ\1740 to\TO\1740 <e1>cocaine</e1>\NN\3492717 use\NN\407535 is\VBZ\836236 discussed\VBN\1033527 and\CC\1740 treatment\NN\654885 dilemmas\NNS\5685363 are\VBP\836236 discussed\VBN\1033527 .\.\1740
11135224
D017239_D002289 NONE <e1>Paclitaxel</e1>\NNP\1740 ,\,\1740 cisplatin\NN\1740 ,\,\1740 and\CC\1740 gemcitabine\NN\1740 combination\NN\7951464 chemotherapy\NN\661091 within\IN\1740 a\DT\13649268 multidisciplinary\JJ\1740 therapeutic\JJ\1740 approach\NN\940842 in\IN\13603305 metastatic\JJ\1740 <e2>nonsmall\NN\1740 cell\NN\3080309 lung\NN\5528060 carcinoma</e2>\NN\14239918 .\.\1740
D017239_D002289 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 objective\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 the\DT\1740 feasibility\NN\5152150 ,\,\1740 response\NN\11410625 rate\NN\13815152 ,\,\1740 and\CC\1740 toxicity\NN\13576101 of\IN\1740 a\DT\13649268 <e1>paclitaxel</e1>\NN\1740 ,\,\1740 cisplatin\NN\1740 ,\,\1740 and\CC\1740 gemcitabine\NN\1740 combination\NN\7951464 to\TO\1740 treat\VB\2376958 metastatic\JJ\1740 <e2>NSCLC</e2>\NN\1740 .\.\1740
D017239_D002289 NONE Thirty-five\JJ\1740 consecutive\JJ\1740 chemotherapy-naive\JJ\1740 patients\NNS\9898892 with\IN\1740 Stage\NN\15113229 IV\CD\13741022 <e2>NSCLC</e2>\NN\1740 and\CC\1740 an\DT\6697703 Eastern\JJ\1740 Cooperative\NNP\8065093 Oncology\NNP\6043075 Group\NNP\2137 performance\NN\6619065 status\NN\24720 of\IN\1740 0\CD\13741022 -\SYM\1740 2\CD\13741022 were\VBD\836236 treated\VBN\2376958 with\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 <e1>paclitaxel</e1>\NN\1740 (\-LRB-\1740 135\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 given\VBN\2327200 intravenously\RB\1740 in\IN\13603305 3\CD\13741022 hours\NNS\15118228 )\-RRB-\1740 on\IN\1740 Day\NN\15154774 1\CD\13741022 ,\,\1740 cisplatin\NN\1740 (\-LRB-\1740 120\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 given\VBN\2327200 intravenously\RB\1740 in\IN\13603305 6\CD\13741022 hours\NNS\15118228 )\-RRB-\1740 on\IN\1740 Day\NN\15154774 1\CD\13741022 ,\,\1740 and\CC\1740 gemcitabine\NN\1740 (\-LRB-\1740 800\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 given\VBN\2327200 intravenously\RB\1740 in\IN\13603305 30\CD\13745420 minutes\NNS\6502378 )\-RRB-\1740 on\IN\1740 Days\NNS\15140892 1\CD\13741022 and\CC\1740 8\CD\13741022 ,\,\1740 every\DT\1740 4\CD\13741022 weeks\NNS\15113229 .\.\1740
D017239_D002289 NONE CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 combination\NN\7951464 of\IN\1740 <e1>paclitaxel</e1>\NN\1740 ,\,\1740 cisplatin\NN\1740 ,\,\1740 and\CC\1740 gemcitabine\NN\1740 is\VBZ\836236 well\RB\1740 tolerated\VBN\802318 and\CC\1740 shows\VBZ\2137132 high\JJ\1740 activity\NN\30358 in\IN\13603305 metastatic\JJ\1740 <e2>NSCLC</e2>\NN\1740 .\.\1740
D002945_D002289 NONE Paclitaxel\NNP\1740 ,\,\1740 <e1>cisplatin</e1>\NN\1740 ,\,\1740 and\CC\1740 gemcitabine\NN\1740 combination\NN\7951464 chemotherapy\NN\661091 within\IN\1740 a\DT\13649268 multidisciplinary\JJ\1740 therapeutic\JJ\1740 approach\NN\940842 in\IN\13603305 metastatic\JJ\1740 <e2>nonsmall\NN\1740 cell\NN\3080309 lung\NN\5528060 carcinoma</e2>\NN\14239918 .\.\1740
D002945_D002289 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Cisplatin-based</e1>\JJ\1740 chemotherapy\NN\661091 combinations\NNS\7951464 improve\VBP\126264 quality\NN\24264 of\IN\1740 life\NN\13954253 and\CC\1740 survival\NN\13961642 in\IN\13603305 advanced\JJ\1740 <e2>nonsmall\NN\1740 cell\NN\3080309 lung\NN\5528060 carcinoma</e2>\NN\14239918 (\-LRB-\1740 NSCLC\NN\1740 )\-RRB-\1740 .\.\1740
D002945_D002289 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Cisplatin-based</e1>\JJ\1740 chemotherapy\NN\661091 combinations\NNS\7951464 improve\VBP\126264 quality\NN\24264 of\IN\1740 life\NN\13954253 and\CC\1740 survival\NN\13961642 in\IN\13603305 advanced\JJ\1740 nonsmall\NN\1740 cell\NN\3080309 lung\NN\5528060 carcinoma\NN\14239918 (\-LRB-\1740 <e2>NSCLC</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D002945_D002289 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 objective\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 the\DT\1740 feasibility\NN\5152150 ,\,\1740 response\NN\11410625 rate\NN\13815152 ,\,\1740 and\CC\1740 toxicity\NN\13576101 of\IN\1740 a\DT\13649268 paclitaxel\NN\1740 ,\,\1740 <e1>cisplatin</e1>\NN\1740 ,\,\1740 and\CC\1740 gemcitabine\NN\1740 combination\NN\7951464 to\TO\1740 treat\VB\2376958 metastatic\JJ\1740 <e2>NSCLC</e2>\NN\1740 .\.\1740
D002945_D002289 NONE Thirty-five\JJ\1740 consecutive\JJ\1740 chemotherapy-naive\JJ\1740 patients\NNS\9898892 with\IN\1740 Stage\NN\15113229 IV\CD\13741022 <e2>NSCLC</e2>\NN\1740 and\CC\1740 an\DT\6697703 Eastern\JJ\1740 Cooperative\NNP\8065093 Oncology\NNP\6043075 Group\NNP\2137 performance\NN\6619065 status\NN\24720 of\IN\1740 0\CD\13741022 -\SYM\1740 2\CD\13741022 were\VBD\836236 treated\VBN\2376958 with\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 paclitaxel\NN\1740 (\-LRB-\1740 135\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 given\VBN\2327200 intravenously\RB\1740 in\IN\13603305 3\CD\13741022 hours\NNS\15118228 )\-RRB-\1740 on\IN\1740 Day\NN\15154774 1\CD\13741022 ,\,\1740 <e1>cisplatin</e1>\NN\1740 (\-LRB-\1740 120\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 given\VBN\2327200 intravenously\RB\1740 in\IN\13603305 6\CD\13741022 hours\NNS\15118228 )\-RRB-\1740 on\IN\1740 Day\NN\15154774 1\CD\13741022 ,\,\1740 and\CC\1740 gemcitabine\NN\1740 (\-LRB-\1740 800\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 given\VBN\2327200 intravenously\RB\1740 in\IN\13603305 30\CD\13745420 minutes\NNS\6502378 )\-RRB-\1740 on\IN\1740 Days\NNS\15140892 1\CD\13741022 and\CC\1740 8\CD\13741022 ,\,\1740 every\DT\1740 4\CD\13741022 weeks\NNS\15113229 .\.\1740
D002945_D002289 NONE CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 combination\NN\7951464 of\IN\1740 paclitaxel\NN\1740 ,\,\1740 <e1>cisplatin</e1>\NN\1740 ,\,\1740 and\CC\1740 gemcitabine\NN\1740 is\VBZ\836236 well\RB\1740 tolerated\VBN\802318 and\CC\1740 shows\VBZ\2137132 high\JJ\1740 activity\NN\30358 in\IN\13603305 metastatic\JJ\1740 <e2>NSCLC</e2>\NN\1740 .\.\1740
C056507_D002289 NONE Paclitaxel\NNP\1740 ,\,\1740 cisplatin\NN\1740 ,\,\1740 and\CC\1740 <e1>gemcitabine</e1>\NN\1740 combination\NN\7951464 chemotherapy\NN\661091 within\IN\1740 a\DT\13649268 multidisciplinary\JJ\1740 therapeutic\JJ\1740 approach\NN\940842 in\IN\13603305 metastatic\JJ\1740 <e2>nonsmall\NN\1740 cell\NN\3080309 lung\NN\5528060 carcinoma</e2>\NN\14239918 .\.\1740
C056507_D002289 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 objective\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 the\DT\1740 feasibility\NN\5152150 ,\,\1740 response\NN\11410625 rate\NN\13815152 ,\,\1740 and\CC\1740 toxicity\NN\13576101 of\IN\1740 a\DT\13649268 paclitaxel\NN\1740 ,\,\1740 cisplatin\NN\1740 ,\,\1740 and\CC\1740 <e1>gemcitabine</e1>\NN\1740 combination\NN\7951464 to\TO\1740 treat\VB\2376958 metastatic\JJ\1740 <e2>NSCLC</e2>\NN\1740 .\.\1740
C056507_D002289 NONE Thirty-five\JJ\1740 consecutive\JJ\1740 chemotherapy-naive\JJ\1740 patients\NNS\9898892 with\IN\1740 Stage\NN\15113229 IV\CD\13741022 <e2>NSCLC</e2>\NN\1740 and\CC\1740 an\DT\6697703 Eastern\JJ\1740 Cooperative\NNP\8065093 Oncology\NNP\6043075 Group\NNP\2137 performance\NN\6619065 status\NN\24720 of\IN\1740 0\CD\13741022 -\SYM\1740 2\CD\13741022 were\VBD\836236 treated\VBN\2376958 with\IN\1740 a\DT\13649268 combination\NN\7951464 of\IN\1740 paclitaxel\NN\1740 (\-LRB-\1740 135\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 given\VBN\2327200 intravenously\RB\1740 in\IN\13603305 3\CD\13741022 hours\NNS\15118228 )\-RRB-\1740 on\IN\1740 Day\NN\15154774 1\CD\13741022 ,\,\1740 cisplatin\NN\1740 (\-LRB-\1740 120\CD\13745420 mg/m(2\NN\1740 )\-RRB-\1740 given\VBN\2327200 intravenously\RB\1740 in\IN\13603305 6\CD\13741022 hours\NNS\15118228 )\-RRB-\1740 on\IN\1740 Day\NN\15154774 1\CD\13741022 ,\,\1740 and\CC\1740 <e1>gemcitabine</e1>\NN\1740 (\-LRB-\1740 800\CD\1740 mg/m(2\NN\1740 )\-RRB-\1740 given\VBN\2327200 intravenously\RB\1740 in\IN\13603305 30\CD\13745420 minutes\NNS\6502378 )\-RRB-\1740 on\IN\1740 Days\NNS\15140892 1\CD\13741022 and\CC\1740 8\CD\13741022 ,\,\1740 every\DT\1740 4\CD\13741022 weeks\NNS\15113229 .\.\1740
C056507_D002289 NONE CONCLUSIONS\NNS\5837957 :\:\1740 The\DT\1740 combination\NN\7951464 of\IN\1740 paclitaxel\NN\1740 ,\,\1740 cisplatin\NN\1740 ,\,\1740 and\CC\1740 <e1>gemcitabine</e1>\NN\1740 is\VBZ\836236 well\RB\1740 tolerated\VBN\802318 and\CC\1740 shows\VBZ\2137132 high\JJ\1740 activity\NN\30358 in\IN\13603305 metastatic\JJ\1740 <e2>NSCLC</e2>\NN\1740 .\.\1740
D017239_D064420 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 objective\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 the\DT\1740 feasibility\NN\5152150 ,\,\1740 response\NN\11410625 rate\NN\13815152 ,\,\1740 and\CC\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 a\DT\13649268 <e1>paclitaxel</e1>\NN\1740 ,\,\1740 cisplatin\NN\1740 ,\,\1740 and\CC\1740 gemcitabine\NN\1740 combination\NN\7951464 to\TO\1740 treat\VB\2376958 metastatic\JJ\1740 NSCLC\NN\1740 .\.\1740
D002945_D064420 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 objective\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 the\DT\1740 feasibility\NN\5152150 ,\,\1740 response\NN\11410625 rate\NN\13815152 ,\,\1740 and\CC\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 a\DT\13649268 paclitaxel\NN\1740 ,\,\1740 <e1>cisplatin</e1>\NN\1740 ,\,\1740 and\CC\1740 gemcitabine\NN\1740 combination\NN\7951464 to\TO\1740 treat\VB\2376958 metastatic\JJ\1740 NSCLC\NN\1740 .\.\1740
C056507_D064420 NONE METHODS\NNS\5616786 :\:\1740 The\DT\1740 objective\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 the\DT\1740 feasibility\NN\5152150 ,\,\1740 response\NN\11410625 rate\NN\13815152 ,\,\1740 and\CC\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 a\DT\13649268 paclitaxel\NN\1740 ,\,\1740 cisplatin\NN\1740 ,\,\1740 and\CC\1740 <e1>gemcitabine</e1>\NN\1740 combination\NN\7951464 to\TO\1740 treat\VB\2376958 metastatic\JJ\1740 NSCLC\NN\1740 .\.\1740
3403780
D000082_D003128 NONE <e1>Paracetamol-associated</e1>\JJ\1740 <e2>coma</e2>\NN\5678932 ,\,\1740 metabolic\JJ\1740 acidosis\NN\14204950 ,\,\1740 renal\JJ\1740 and\CC\1740 hepatic\JJ\1740 failure\NN\66216 .\.\1740
D000082_D000138 CID <e1>Paracetamol-associated</e1>\JJ\1740 coma\NN\5678932 ,\,\1740 <e2>metabolic\JJ\1740 acidosis</e2>\NN\14204950 ,\,\1740 renal\JJ\1740 and\CC\1740 hepatic\JJ\1740 failure\NN\66216 .\.\1740
D000082_D000138 CID A\DT\13649268 case\NN\7283608 of\IN\1740 <e2>metabolic\JJ\1740 acidosis</e2>\NN\14204950 ,\,\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 and\CC\1740 hepatic\JJ\1740 failure\NN\66216 following\VBG\1835496 <e1>paracetamol</e1>\NN\1740 ingestion\NN\13440063 is\VBZ\836236 presented\VBN\2137132 .\.\1740
D000082_D058186 CID A\DT\13649268 case\NN\7283608 of\IN\1740 metabolic\JJ\1740 acidosis\NN\14204950 ,\,\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure\NN\66216 and\CC\1740 hepatic\JJ\1740 failure</e2>\NN\66216 following\VBG\1835496 <e1>paracetamol</e1>\NN\1740 ingestion\NN\13440063 is\VBZ\836236 presented\VBN\2137132 .\.\1740
D000082_D058186 NONE <e1>Paracetamol-associated</e1>\JJ\1740 coma\NN\5678932 ,\,\1740 metabolic\JJ\1740 acidosis\NN\14204950 ,\,\1740 <e2>renal\JJ\1740 and\CC\1740 hepatic\JJ\1740 failure</e2>\NN\66216 .\.\1740
D000082_D017093 NONE <e1>Paracetamol-associated</e1>\JJ\1740 coma\NN\5678932 ,\,\1740 metabolic\JJ\1740 acidosis\NN\14204950 ,\,\1740 <e2>renal\JJ\1740 and\CC\1740 hepatic\JJ\1740 failure</e2>\NN\66216 .\.\1740
D000082_D017114 CID A\DT\13649268 case\NN\7283608 of\IN\1740 metabolic\JJ\1740 acidosis\NN\14204950 ,\,\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure\NN\66216 and\CC\1740 hepatic\JJ\1740 failure</e2>\NN\66216 following\VBG\1835496 <e1>paracetamol</e1>\NN\1740 ingestion\NN\13440063 is\VBZ\836236 presented\VBN\2137132 .\.\1740
2632720
D007654_D006973 CID Arterial\JJ\1740 <e2>hypertension</e2>\NN\14057371 as\IN\14622893 a\DT\13649268 complication\NN\1073995 of\IN\1740 prolonged\JJ\1740 <e1>ketoconazole</e1>\NN\1740 treatment\NN\654885 .\.\1740
D007654_D006973 CID Two\CD\13741022 of\IN\1740 14\CD\13745420 patients\NNS\9898892 with\IN\1740 Cushing\NN\1740 's\POS\1740 syndrome\NN\5870365 treated\VBN\2376958 on\IN\1740 a\DT\13649268 long-term\JJ\1740 basis\NN\13790712 with\IN\1740 <e1>ketoconazole</e1>\NN\1740 developed\VBD\1753788 sustained\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D007654_D006973 CID In\IN\13603305 both\DT\1740 cases\NNS\7283608 normal\JJ\1740 plasma\NN\5398023 and\CC\1740 urinary\JJ\1740 free\JJ\1740 cortisol\NN\14751417 levels\NNS\4916342 had\VBD\2108377 been\VBN\836236 achieved\VBN\2524171 following\VBG\1835496 <e1>ketoconazole</e1>\NN\1740 therapy\NN\657604 ,\,\1740 yet\RB\1740 continuous\JJ\1740 blood\NN\5397468 pressure\NN\11419404 monitoring\NN\879759 demonstrated\VBD\2137132 <e2>hypertension</e2>\NN\14057371 31\CD\1740 (\-LRB-\1740 patient\NN\9898892 1\CD\13741022 )\-RRB-\1740 and\CC\1740 52\CD\1740 weeks\NNS\15113229 (\-LRB-\1740 patient\NN\9898892 2\CD\13741022 )\-RRB-\1740 after\IN\1740 treatment\NN\654885 .\.\1740
D007654_D006973 CID Our\PRP$\1740 findings\NNS\7951464 show\VBP\2137132 that\IN\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>ketoconazole</e1>\NN\1740 may\MD\15209706 induce\VB\1627355 enzyme\NN\14723628 blockade\NN\952963 leading\VBG\1752884 to\TO\1740 mineralocorticoid-related\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D007654_D003480 NONE Two\CD\13741022 of\IN\1740 14\CD\13745420 patients\NNS\9898892 with\IN\1740 <e2>Cushing\NN\1740 's\POS\1740 syndrome</e2>\NN\5870365 treated\VBN\2376958 on\IN\1740 a\DT\13649268 long-term\JJ\1740 basis\NN\13790712 with\IN\1740 <e1>ketoconazole</e1>\NN\1740 developed\VBD\1753788 sustained\JJ\1740 hypertension\NN\14057371 .\.\1740
D006854_D006973 NONE In\IN\13603305 both\DT\1740 cases\NNS\7283608 normal\JJ\1740 plasma\NN\5398023 and\CC\1740 urinary\JJ\1740 free\JJ\1740 <e1>cortisol</e1>\NN\14751417 levels\NNS\4916342 had\VBD\2108377 been\VBN\836236 achieved\VBN\2524171 following\VBG\1835496 ketoconazole\NN\1740 therapy\NN\657604 ,\,\1740 yet\RB\1740 continuous\JJ\1740 blood\NN\5397468 pressure\NN\11419404 monitoring\NN\879759 demonstrated\VBD\2137132 <e2>hypertension</e2>\NN\14057371 31\CD\1740 (\-LRB-\1740 patient\NN\9898892 1\CD\13741022 )\-RRB-\1740 and\CC\1740 52\CD\1740 weeks\NNS\15113229 (\-LRB-\1740 patient\NN\9898892 2\CD\13741022 )\-RRB-\1740 after\IN\1740 treatment\NN\654885 .\.\1740
17042910
C065179_D006973 NONE Anti-oxidant\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>atorvastatin</e1>\NN\3676175 in\IN\13603305 dexamethasone-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
C065179_D006973 NONE <e1>Atorvastatin</e1>\NN\3676175 (\-LRB-\1740 Ato\NN\1740 )\-RRB-\1740 possesses\VBZ\2630189 pleiotropic\JJ\1740 properties\NNS\32613 that\WDT\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 improve\VB\126264 endothelial\JJ\1740 function\NN\13783581 through\IN\1740 increased\VBN\169651 availability\NN\4718563 of\IN\1740 NO\NN\7204911 and\CC\1740 reduced\VBD\441445 O2-\NN\1740 production\NN\30358 in\IN\13603305 various\JJ\1740 forms\NNS\6286395 of\IN\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
C065179_D006973 NONE Atorvastatin\NN\3676175 (\-LRB-\1740 <e1>Ato</e1>\NN\1740 )\-RRB-\1740 possesses\VBZ\2630189 pleiotropic\JJ\1740 properties\NNS\32613 that\WDT\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 improve\VB\126264 endothelial\JJ\1740 function\NN\13783581 through\IN\1740 increased\VBN\169651 availability\NN\4718563 of\IN\1740 NO\NN\7204911 and\CC\1740 reduced\VBD\441445 O2-\NN\1740 production\NN\30358 in\IN\13603305 various\JJ\1740 forms\NNS\6286395 of\IN\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D003907_D006973 CID Anti-oxidant\JJ\1740 effects\NNS\13245626 of\IN\1740 atorvastatin\NN\3676175 in\IN\13603305 <e1>dexamethasone-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 the\DT\1740 rat\NN\2329401 .\.\1740
D003907_D006973 CID 1\LS\13741022 .\.\1740 <e1>Dexamethasone</e1>\NN\2721538 (Dex)-induced\VBD\1740 <e2>hypertension</e2>\NN\14057371 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 endothelial\JJ\1740 dysfunction\NN\14204950 associated\VBN\628491 with\IN\1740 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 deficiency\NN\14449126 and\CC\1740 increased\VBN\169651 superoxide\NN\14971519 (\-LRB-\1740 O2-\NN\1740 )\-RRB-\1740 production\NN\30358 .\.\1740
D003907_D006973 CID 1\LS\13741022 .\.\1740 Dexamethasone\NN\2721538 <e1>(Dex)-induced</e1>\VBD\1740 <e2>hypertension</e2>\NN\14057371 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 endothelial\JJ\1740 dysfunction\NN\14204950 associated\VBN\628491 with\IN\1740 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 deficiency\NN\14449126 and\CC\1740 increased\VBN\169651 superoxide\NN\14971519 (\-LRB-\1740 O2-\NN\1740 )\-RRB-\1740 production\NN\30358 .\.\1740
D009569_D006973 NONE 1\LS\13741022 .\.\1740 Dexamethasone\NN\2721538 (Dex)-induced\VBD\1740 <e2>hypertension</e2>\NN\14057371 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 endothelial\JJ\1740 dysfunction\NN\14204950 associated\VBN\628491 with\IN\1740 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 deficiency\NN\14449126 and\CC\1740 increased\VBN\169651 superoxide\NN\14971519 (\-LRB-\1740 O2-\NN\1740 )\-RRB-\1740 production\NN\30358 .\.\1740
D009569_D006973 NONE 1\LS\13741022 .\.\1740 Dexamethasone\NN\2721538 (Dex)-induced\VBD\1740 <e2>hypertension</e2>\NN\14057371 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 endothelial\JJ\1740 dysfunction\NN\14204950 associated\VBN\628491 with\IN\1740 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 <e1>NO</e1>\NN\7204911 )\-RRB-\1740 deficiency\NN\14449126 and\CC\1740 increased\VBN\169651 superoxide\NN\14971519 (\-LRB-\1740 O2-\NN\1740 )\-RRB-\1740 production\NN\30358 .\.\1740
D009569_D006973 NONE Atorvastatin\NN\3676175 (\-LRB-\1740 Ato\NN\1740 )\-RRB-\1740 possesses\VBZ\2630189 pleiotropic\JJ\1740 properties\NNS\32613 that\WDT\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 improve\VB\126264 endothelial\JJ\1740 function\NN\13783581 through\IN\1740 increased\VBN\169651 availability\NN\4718563 of\IN\1740 <e1>NO</e1>\NN\7204911 and\CC\1740 reduced\VBD\441445 O2-\NN\1740 production\NN\30358 in\IN\13603305 various\JJ\1740 forms\NNS\6286395 of\IN\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D013481_D006973 NONE 1\LS\13741022 .\.\1740 Dexamethasone\NN\2721538 (Dex)-induced\VBD\1740 <e2>hypertension</e2>\NN\14057371 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 endothelial\JJ\1740 dysfunction\NN\14204950 associated\VBN\628491 with\IN\1740 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 deficiency\NN\14449126 and\CC\1740 increased\VBN\169651 <e1>superoxide</e1>\NN\14971519 (\-LRB-\1740 O2-\NN\1740 )\-RRB-\1740 production\NN\30358 .\.\1740
D013481_D006973 NONE 1\LS\13741022 .\.\1740 Dexamethasone\NN\2721538 (Dex)-induced\VBD\1740 <e2>hypertension</e2>\NN\14057371 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 endothelial\JJ\1740 dysfunction\NN\14204950 associated\VBN\628491 with\IN\1740 nitric\JJ\1740 oxide\NN\14818238 (\-LRB-\1740 NO\NN\7204911 )\-RRB-\1740 deficiency\NN\14449126 and\CC\1740 increased\VBN\169651 superoxide\NN\14971519 (\-LRB-\1740 <e1>O2-</e1>\NN\1740 )\-RRB-\1740 production\NN\30358 .\.\1740
D013481_D006973 NONE Atorvastatin\NN\3676175 (\-LRB-\1740 Ato\NN\1740 )\-RRB-\1740 possesses\VBZ\2630189 pleiotropic\JJ\1740 properties\NNS\32613 that\WDT\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 improve\VB\126264 endothelial\JJ\1740 function\NN\13783581 through\IN\1740 increased\VBN\169651 availability\NN\4718563 of\IN\1740 NO\NN\7204911 and\CC\1740 reduced\VBD\441445 <e1>O2-</e1>\NN\1740 production\NN\30358 in\IN\13603305 various\JJ\1740 forms\NNS\6286395 of\IN\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
3780846
D009020_D009127 CID On\IN\1740 the\DT\1740 mechanisms\NNS\13446390 of\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 tolerance\NN\5032565 to\TO\1740 the\DT\1740 <e2>muscular\JJ\1740 rigidity</e2>\NN\5023233 produced\VBN\1617192 by\IN\1740 <e1>morphine</e1>\NN\2707683 in\IN\13603305 rats\NNS\2329401 .\.\1740
D009020_D009127 CID The\DT\1740 development\NN\248977 of\IN\1740 tolerance\NN\5032565 to\TO\1740 the\DT\1740 <e2>muscular\JJ\1740 rigidity</e2>\NN\5023233 produced\VBN\1617192 by\IN\1740 <e1>morphine</e1>\NN\2707683 was\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 .\.\1740
D009020_D009127 CID Saline-pretreated\JJ\1740 controls\NNS\5190804 given\VBN\2327200 a\DT\13649268 test\NN\5798043 dose\NN\3740161 of\IN\1740 <e1>morphine</e1>\NN\2707683 (\-LRB-\1740 20\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 showed\VBD\2137132 a\DT\13649268 pronounced\JJ\1740 <e2>rigidity</e2>\NN\5023233 recorded\VBN\2225492 as\IN\14622893 tonic\JJ\1740 activity\NN\30358 in\IN\13603305 the\DT\1740 electromyogram\NN\7005158 .\.\1740
D009020_D009127 CID Rats\NNS\2329401 treated\VBN\2376958 for\IN\1740 11\CD\13745420 days\NNS\15140892 with\IN\1740 <e1>morphine</e1>\NN\2707683 and\CC\1740 withdrawn\VBN\1835496 for\IN\1740 36\CD\1740 -\SYM\1740 40\CD\13745420 h\NN\14622893 showed\VBD\2137132 differences\NNS\4723816 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 tolerance\NN\5032565 :\:\1740 about\RB\1740 half\NN\13732295 of\IN\1740 the\DT\1740 animals\NNS\4475 showed\VBD\2137132 a\DT\13649268 <e2>rigidity</e2>\NN\5023233 after\IN\1740 the\DT\1740 test\NN\5798043 dose\NN\3740161 of\IN\1740 morphine\NN\2707683 that\WDT\1740 was\VBD\836236 not\RB\1740 significantly\RB\1740 less\JJR\1740 than\IN\1740 in\IN\13603305 the\DT\1740 controls\NNS\5190804 and\CC\1740 were\VBD\836236 akinetic\JJ\1740 (\-LRB-\1740 A\NN\13649268 group\NN\2137 )\-RRB-\1740 .\.\1740
D009020_D009127 CID Rats\NNS\2329401 treated\VBN\2376958 for\IN\1740 11\CD\13745420 days\NNS\15140892 with\IN\1740 morphine\NN\2707683 and\CC\1740 withdrawn\VBN\1835496 for\IN\1740 36\CD\1740 -\SYM\1740 40\CD\13745420 h\NN\14622893 showed\VBD\2137132 differences\NNS\4723816 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 tolerance\NN\5032565 :\:\1740 about\RB\1740 half\NN\13732295 of\IN\1740 the\DT\1740 animals\NNS\4475 showed\VBD\2137132 a\DT\13649268 <e2>rigidity</e2>\NN\5023233 after\IN\1740 the\DT\1740 test\NN\5798043 dose\NN\3740161 of\IN\1740 <e1>morphine</e1>\NN\2707683 that\WDT\1740 was\VBD\836236 not\RB\1740 significantly\RB\1740 less\JJR\1740 than\IN\1740 in\IN\13603305 the\DT\1740 controls\NNS\5190804 and\CC\1740 were\VBD\836236 akinetic\JJ\1740 (\-LRB-\1740 A\NN\13649268 group\NN\2137 )\-RRB-\1740 .\.\1740
D009020_D009127 CID The\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 <e2>rigidity</e2>\NN\5023233 ,\,\1740 which\WDT\1740 is\VBZ\836236 assumed\VBN\719734 to\TO\1740 be\VB\836236 due\JJ\1740 to\TO\1740 an\DT\6697703 action\NN\30358 of\IN\1740 <e1>morphine</e1>\NN\2707683 in\IN\13603305 the\DT\1740 striatum\NN\5497363 ,\,\1740 can\MD\3094503 be\VB\836236 antagonized\VBN\1787955 by\IN\1740 another\DT\1740 process\NN\407535 leading\VBG\1752884 to\TO\1740 dopaminergic\JJ\1740 activation\NN\13561719 in\IN\13603305 the\DT\1740 striatum\NN\5497363 .\.\1740
D009020_D018476 CID Rats\NNS\2329401 treated\VBN\2376958 for\IN\1740 11\CD\13745420 days\NNS\15140892 with\IN\1740 <e1>morphine</e1>\NN\2707683 and\CC\1740 withdrawn\VBN\1835496 for\IN\1740 36\CD\1740 -\SYM\1740 40\CD\13745420 h\NN\14622893 showed\VBD\2137132 differences\NNS\4723816 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 tolerance\NN\5032565 :\:\1740 about\RB\1740 half\NN\13732295 of\IN\1740 the\DT\1740 animals\NNS\4475 showed\VBD\2137132 a\DT\13649268 rigidity\NN\5023233 after\IN\1740 the\DT\1740 test\NN\5798043 dose\NN\3740161 of\IN\1740 morphine\NN\2707683 that\WDT\1740 was\VBD\836236 not\RB\1740 significantly\RB\1740 less\JJR\1740 than\IN\1740 in\IN\13603305 the\DT\1740 controls\NNS\5190804 and\CC\1740 were\VBD\836236 <e2>akinetic</e2>\JJ\1740 (\-LRB-\1740 A\NN\13649268 group\NN\2137 )\-RRB-\1740 .\.\1740
D009020_D018476 CID Rats\NNS\2329401 treated\VBN\2376958 for\IN\1740 11\CD\13745420 days\NNS\15140892 with\IN\1740 morphine\NN\2707683 and\CC\1740 withdrawn\VBN\1835496 for\IN\1740 36\CD\1740 -\SYM\1740 40\CD\13745420 h\NN\14622893 showed\VBD\2137132 differences\NNS\4723816 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 tolerance\NN\5032565 :\:\1740 about\RB\1740 half\NN\13732295 of\IN\1740 the\DT\1740 animals\NNS\4475 showed\VBD\2137132 a\DT\13649268 rigidity\NN\5023233 after\IN\1740 the\DT\1740 test\NN\5798043 dose\NN\3740161 of\IN\1740 <e1>morphine</e1>\NN\2707683 that\WDT\1740 was\VBD\836236 not\RB\1740 significantly\RB\1740 less\JJR\1740 than\IN\1740 in\IN\13603305 the\DT\1740 controls\NNS\5190804 and\CC\1740 were\VBD\836236 <e2>akinetic</e2>\JJ\1740 (\-LRB-\1740 A\NN\13649268 group\NN\2137 )\-RRB-\1740 .\.\1740
D006220_D009127 CID In\IN\13603305 a\DT\13649268 further\JJ\1740 series\NN\8456993 of\IN\1740 experiments\NNS\641820 ,\,\1740 <e1>haloperidol</e1>\NN\3713736 (\-LRB-\1740 0.2\CD\1740 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 was\VBD\836236 used\VBN\1156834 in\IN\13603305 order\NN\7168131 to\TO\1740 block\VB\1476483 the\DT\1740 dopaminergic\JJ\1740 activation\NN\13561719 and\CC\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 real\JJ\1740 degree\NN\4916342 of\IN\1740 the\DT\1740 tolerance\NN\5032565 to\TO\1740 the\DT\1740 <e2>rigidity</e2>\NN\5023233 without\IN\1740 any\DT\1740 dopaminergic\JJ\1740 interference\NN\6660942 .\.\1740
D006220_D009127 CID <e1>Haloperidol</e1>\NNP\3713736 enhanced\VBD\227165 the\DT\1740 <e2>rigidity</e2>\NN\5023233 in\IN\13603305 the\DT\1740 A\NN\13649268 group\NN\2137 .\.\1740
3693336
D014229_D001714 CID <e1>Triazolam-induced</e1>\JJ\1740 brief\JJ\1740 episodes\NNS\7283608 of\IN\1740 secondary\JJ\1740 <e2>mania</e2>\NN\9180259 in\IN\13603305 a\DT\13649268 depressed\JJ\1740 patient\NN\9898892 .\.\1740
D014229_D001714 CID Large\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>triazolam</e1>\NNS\2830852 repeatedly\RB\1740 induced\VBD\1627355 brief\JJ\1740 episodes\NNS\7283608 of\IN\1740 <e2>mania</e2>\NN\9180259 in\IN\13603305 a\DT\13649268 depressed\JJ\1740 elderly\JJ\1740 woman\NN\9605289 .\.\1740
D014229_D001714 CID <e2>Manic</e2>\JJ\1740 excitement\NN\7527352 was\VBD\836236 coincident\JJ\1740 with\IN\1740 the\DT\1740 duration\NN\15113229 of\IN\1740 action\NN\30358 of\IN\1740 <e1>triazolam</e1>\NNS\2830852 .\.\1740
D014229_D003866 NONE <e1>Triazolam-induced</e1>\JJ\1740 brief\JJ\1740 episodes\NNS\7283608 of\IN\1740 secondary\JJ\1740 mania\NN\9180259 in\IN\13603305 a\DT\13649268 <e2>depressed</e2>\JJ\1740 patient\NN\9898892 .\.\1740
D014229_D003866 NONE Large\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>triazolam</e1>\NNS\2830852 repeatedly\RB\1740 induced\VBD\1627355 brief\JJ\1740 episodes\NNS\7283608 of\IN\1740 mania\NN\9180259 in\IN\13603305 a\DT\13649268 <e2>depressed</e2>\JJ\1740 elderly\JJ\1740 woman\NN\9605289 .\.\1740
12523465
C022189_D006212 CID <e2>Visual\JJ\1740 hallucinations</e2>\NNS\14376855 associated\VBN\628491 with\IN\1740 <e1>zonisamide</e1>\NN\1740 .\.\1740
C022189_D006212 CID Although\IN\1740 <e2>visual\JJ\1740 hallucinations</e2>\NNS\14376855 have\VBP\2108377 not\RB\1740 been\VBN\836236 reported\VBN\831651 as\IN\14622893 an\DT\6697703 adverse\JJ\1740 effect\NN\34213 of\IN\1740 this\DT\1740 agent\NN\7347 ,\,\1740 we\PRP\1740 describe\VBP\1001294 three\CD\13741022 patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 complex\JJ\1740 visual\JJ\1740 hallucinations\NNS\14376855 and\CC\1740 altered\JJ\1740 mental\JJ\1740 status\NN\24720 after\IN\1740 <e1>zonisamide</e1>\NN\1740 treatment\NN\654885 was\VBD\836236 begun\VBN\941990 or\CC\3541091 its\PRP$\6125041 dosage\NN\13576355 increased\VBD\169651 .\.\1740
C022189_D006212 CID Although\IN\1740 visual\JJ\1740 hallucinations\NNS\14376855 have\VBP\2108377 not\RB\1740 been\VBN\836236 reported\VBN\831651 as\IN\14622893 an\DT\6697703 adverse\JJ\1740 effect\NN\34213 of\IN\1740 this\DT\1740 agent\NN\7347 ,\,\1740 we\PRP\1740 describe\VBP\1001294 three\CD\13741022 patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 complex\JJ\1740 <e2>visual\JJ\1740 hallucinations</e2>\NNS\14376855 and\CC\1740 altered\JJ\1740 mental\JJ\1740 status\NN\24720 after\IN\1740 <e1>zonisamide</e1>\NN\1740 treatment\NN\654885 was\VBD\836236 begun\VBN\941990 or\CC\3541091 its\PRP$\6125041 dosage\NN\13576355 increased\VBD\169651 .\.\1740
C022189_D012640 NONE <e1>Zonisamide</e1>\NNP\1740 is\VBZ\836236 a\DT\13649268 broad-spectrum\NN\1740 antiepileptic\JJ\1740 drug\NN\14778436 used\VBN\1156834 to\TO\1740 treat\VB\2376958 various\JJ\1740 types\NNS\5839024 of\IN\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
15649445
D012110_D004409 CID Acute\JJ\1740 <e1>reserpine</e1>\NN\2721160 and\CC\1740 subchronic\JJ\1740 haloperidol\NN\3713736 treatments\NNS\654885 change\VBP\46534 synaptosomal\JJ\1740 brain\NN\5462674 glutamate\NN\15010703 uptake\NN\13440063 and\CC\1740 elicit\VB\1617192 <e2>orofacial\JJ\1740 dyskinesia</e2>\NN\14084880 in\IN\13603305 rats\NNS\2329401 .\.\1740
D012110_D004409 CID <e1>Reserpine-</e1>\NN\1740 and\CC\1740 haloperidol-induced\JJ\1740 <e2>orofacial\JJ\1740 dyskinesia</e2>\NN\14084880 are\VBP\836236 putative\JJ\1740 animal\NN\4475 models\NNS\5888929 of\IN\1740 tardive\JJ\1740 dyskinesia\NN\14084880 (\-LRB-\1740 TD\NN\1740 )\-RRB-\1740 whose\WP$\1740 pathophysiology\NN\1740 has\VBZ\2108377 been\VBN\836236 related\JJ\1740 to\TO\1740 free\JJ\1740 radical\JJ\1740 generation\NN\7942152 and\CC\1740 oxidative\JJ\1740 stress\NN\7083732 .\.\1740
D012110_D004409 CID <e1>Reserpine-</e1>\NN\1740 and\CC\1740 haloperidol-induced\JJ\1740 orofacial\JJ\1740 dyskinesia\NN\14084880 are\VBP\836236 putative\JJ\1740 animal\NN\4475 models\NNS\5888929 of\IN\1740 <e2>tardive\JJ\1740 dyskinesia</e2>\NN\14084880 (\-LRB-\1740 TD\NN\1740 )\-RRB-\1740 whose\WP$\1740 pathophysiology\NN\1740 has\VBZ\2108377 been\VBN\836236 related\JJ\1740 to\TO\1740 free\JJ\1740 radical\JJ\1740 generation\NN\7942152 and\CC\1740 oxidative\JJ\1740 stress\NN\7083732 .\.\1740
D012110_D004409 CID <e1>Reserpine-</e1>\NN\1740 and\CC\1740 haloperidol-induced\JJ\1740 orofacial\JJ\1740 dyskinesia\NN\14084880 are\VBP\836236 putative\JJ\1740 animal\NN\4475 models\NNS\5888929 of\IN\1740 tardive\JJ\1740 dyskinesia\NN\14084880 (\-LRB-\1740 <e2>TD</e2>\NN\1740 )\-RRB-\1740 whose\WP$\1740 pathophysiology\NN\1740 has\VBZ\2108377 been\VBN\836236 related\JJ\1740 to\TO\1740 free\JJ\1740 radical\JJ\1740 generation\NN\7942152 and\CC\1740 oxidative\JJ\1740 stress\NN\7083732 .\.\1740
D012110_D004409 CID In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 the\DT\1740 authors\NNS\9610660 induced\VBD\1627355 <e2>orofacial\JJ\1740 dyskinesia</e2>\NN\14084880 by\IN\1740 acute\JJ\1740 <e1>reserpine</e1>\NN\2721160 and\CC\1740 subchronic\JJ\1740 haloperidol\NN\3713736 administration\NN\1133281 to\TO\1740 rats\NNS\2329401 .\.\1740
D006220_D004409 CID Acute\JJ\1740 reserpine\NN\2721160 and\CC\1740 subchronic\JJ\1740 <e1>haloperidol</e1>\NN\3713736 treatments\NNS\654885 change\VBP\46534 synaptosomal\JJ\1740 brain\NN\5462674 glutamate\NN\15010703 uptake\NN\13440063 and\CC\1740 elicit\VB\1617192 <e2>orofacial\JJ\1740 dyskinesia</e2>\NN\14084880 in\IN\13603305 rats\NNS\2329401 .\.\1740
D006220_D004409 CID Reserpine-\NN\1740 and\CC\1740 <e1>haloperidol-induced</e1>\JJ\1740 <e2>orofacial\JJ\1740 dyskinesia</e2>\NN\14084880 are\VBP\836236 putative\JJ\1740 animal\NN\4475 models\NNS\5888929 of\IN\1740 tardive\JJ\1740 dyskinesia\NN\14084880 (\-LRB-\1740 TD\NN\1740 )\-RRB-\1740 whose\WP$\1740 pathophysiology\NN\1740 has\VBZ\2108377 been\VBN\836236 related\JJ\1740 to\TO\1740 free\JJ\1740 radical\JJ\1740 generation\NN\7942152 and\CC\1740 oxidative\JJ\1740 stress\NN\7083732 .\.\1740
D006220_D004409 CID Reserpine-\NN\1740 and\CC\1740 <e1>haloperidol-induced</e1>\JJ\1740 orofacial\JJ\1740 dyskinesia\NN\14084880 are\VBP\836236 putative\JJ\1740 animal\NN\4475 models\NNS\5888929 of\IN\1740 <e2>tardive\JJ\1740 dyskinesia</e2>\NN\14084880 (\-LRB-\1740 TD\NN\1740 )\-RRB-\1740 whose\WP$\1740 pathophysiology\NN\1740 has\VBZ\2108377 been\VBN\836236 related\JJ\1740 to\TO\1740 free\JJ\1740 radical\JJ\1740 generation\NN\7942152 and\CC\1740 oxidative\JJ\1740 stress\NN\7083732 .\.\1740
D006220_D004409 CID Reserpine-\NN\1740 and\CC\1740 <e1>haloperidol-induced</e1>\JJ\1740 orofacial\JJ\1740 dyskinesia\NN\14084880 are\VBP\836236 putative\JJ\1740 animal\NN\4475 models\NNS\5888929 of\IN\1740 tardive\JJ\1740 dyskinesia\NN\14084880 (\-LRB-\1740 <e2>TD</e2>\NN\1740 )\-RRB-\1740 whose\WP$\1740 pathophysiology\NN\1740 has\VBZ\2108377 been\VBN\836236 related\JJ\1740 to\TO\1740 free\JJ\1740 radical\JJ\1740 generation\NN\7942152 and\CC\1740 oxidative\JJ\1740 stress\NN\7083732 .\.\1740
D006220_D004409 CID In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 the\DT\1740 authors\NNS\9610660 induced\VBD\1627355 <e2>orofacial\JJ\1740 dyskinesia</e2>\NN\14084880 by\IN\1740 acute\JJ\1740 reserpine\NN\2721160 and\CC\1740 subchronic\JJ\1740 <e1>haloperidol</e1>\NN\3713736 administration\NN\1133281 to\TO\1740 rats\NNS\2329401 .\.\1740
D018698_D004409 NONE Acute\JJ\1740 reserpine\NN\2721160 and\CC\1740 subchronic\JJ\1740 haloperidol\NN\3713736 treatments\NNS\654885 change\VBP\46534 synaptosomal\JJ\1740 brain\NN\5462674 <e1>glutamate</e1>\NN\15010703 uptake\NN\13440063 and\CC\1740 elicit\VB\1617192 <e2>orofacial\JJ\1740 dyskinesia</e2>\NN\14084880 in\IN\13603305 rats\NNS\2329401 .\.\1740
D018698_D004409 NONE Importantly\RB\1740 ,\,\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 <e1>glutamate</e1>\JJ\1740 uptake\NN\13440063 correlates\VBZ\2657219 negatively\RB\1740 with\IN\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>orofacial\JJ\1740 diskinesia</e2>\NN\1740 .\.\1740
18631865
D020123_D051436 NONE Massive\JJ\1740 urinary\JJ\1740 protein\NN\14944888 excretion\NN\13466586 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 after\IN\1740 conversion\NN\7359599 from\IN\1740 calcineurin\NN\1740 inhibitors\NNS\20090 to\TO\1740 mammalian\JJ\1740 target\NN\7258332 of\IN\1740 <e1>rapamycin</e1>\NN\1740 (\-LRB-\1740 mToR\NN\1740 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 especially\RB\1740 sirolimus\NN\1740 ,\,\1740 in\IN\13603305 renal\JJ\1740 transplant\NN\5267548 recipients\NNS\9764201 with\IN\1740 <e2>chronic\JJ\1740 allograft\NN\5582859 nephropathy</e2>\NN\14573196 .\.\1740
D020123_D051436 NONE Massive\JJ\1740 urinary\JJ\1740 protein\NN\14944888 excretion\NN\13466586 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 after\IN\1740 conversion\NN\7359599 from\IN\1740 calcineurin\NN\1740 inhibitors\NNS\20090 to\TO\1740 mammalian\JJ\1740 target\NN\7258332 of\IN\1740 rapamycin\NN\1740 (\-LRB-\1740 mToR\NN\1740 )\-RRB-\1740 inhibitors\NNS\20090 ,\,\1740 especially\RB\1740 <e1>sirolimus</e1>\NN\1740 ,\,\1740 in\IN\13603305 renal\JJ\1740 transplant\NN\5267548 recipients\NNS\9764201 with\IN\1740 <e2>chronic\JJ\1740 allograft\NN\5582859 nephropathy</e2>\NN\14573196 .\.\1740
D020123_D011507 CID Whether\IN\1740 <e2>proteinuria</e2>\NN\14299637 was\VBD\836236 due\JJ\1740 to\TO\1740 <e1>sirolimus</e1>\NN\1740 or\CC\3541091 only\RB\1740 a\DT\13649268 consequence\NN\34213 of\IN\1740 calcineurin\NN\1740 inhibitors\NNS\20090 withdrawal\NN\7206096 remained\VBD\2604760 unsolved\JJ\1740 until\IN\1740 high\JJ\1740 range\NN\5123416 proteinuria\NN\14299637 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 during\IN\1740 sirolimus\NN\1740 therapy\NN\657604 in\IN\13603305 islet\NN\1740 transplantation\NN\671351 and\CC\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 sirolimus\NN\1740 de\FW\1740 novo\FW\1740 .\.\1740
D020123_D011507 CID Whether\IN\1740 proteinuria\NN\14299637 was\VBD\836236 due\JJ\1740 to\TO\1740 <e1>sirolimus</e1>\NN\1740 or\CC\3541091 only\RB\1740 a\DT\13649268 consequence\NN\34213 of\IN\1740 calcineurin\NN\1740 inhibitors\NNS\20090 withdrawal\NN\7206096 remained\VBD\2604760 unsolved\JJ\1740 until\IN\1740 high\JJ\1740 range\NN\5123416 <e2>proteinuria</e2>\NN\14299637 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 during\IN\1740 sirolimus\NN\1740 therapy\NN\657604 in\IN\13603305 islet\NN\1740 transplantation\NN\671351 and\CC\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 sirolimus\NN\1740 de\FW\1740 novo\FW\1740 .\.\1740
D020123_D011507 CID Whether\IN\1740 <e2>proteinuria</e2>\NN\14299637 was\VBD\836236 due\JJ\1740 to\TO\1740 sirolimus\NN\1740 or\CC\3541091 only\RB\1740 a\DT\13649268 consequence\NN\34213 of\IN\1740 calcineurin\NN\1740 inhibitors\NNS\20090 withdrawal\NN\7206096 remained\VBD\2604760 unsolved\JJ\1740 until\IN\1740 high\JJ\1740 range\NN\5123416 proteinuria\NN\14299637 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 during\IN\1740 <e1>sirolimus</e1>\NN\1740 therapy\NN\657604 in\IN\13603305 islet\NN\1740 transplantation\NN\671351 and\CC\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 sirolimus\NN\1740 de\FW\1740 novo\FW\1740 .\.\1740
D020123_D011507 CID Whether\IN\1740 proteinuria\NN\14299637 was\VBD\836236 due\JJ\1740 to\TO\1740 sirolimus\NN\1740 or\CC\3541091 only\RB\1740 a\DT\13649268 consequence\NN\34213 of\IN\1740 calcineurin\NN\1740 inhibitors\NNS\20090 withdrawal\NN\7206096 remained\VBD\2604760 unsolved\JJ\1740 until\IN\1740 high\JJ\1740 range\NN\5123416 <e2>proteinuria</e2>\NN\14299637 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 during\IN\1740 <e1>sirolimus</e1>\NN\1740 therapy\NN\657604 in\IN\13603305 islet\NN\1740 transplantation\NN\671351 and\CC\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 sirolimus\NN\1740 de\FW\1740 novo\FW\1740 .\.\1740
D020123_D011507 CID Whether\IN\1740 <e2>proteinuria</e2>\NN\14299637 was\VBD\836236 due\JJ\1740 to\TO\1740 sirolimus\NN\1740 or\CC\3541091 only\RB\1740 a\DT\13649268 consequence\NN\34213 of\IN\1740 calcineurin\NN\1740 inhibitors\NNS\20090 withdrawal\NN\7206096 remained\VBD\2604760 unsolved\JJ\1740 until\IN\1740 high\JJ\1740 range\NN\5123416 proteinuria\NN\14299637 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 during\IN\1740 sirolimus\NN\1740 therapy\NN\657604 in\IN\13603305 islet\NN\1740 transplantation\NN\671351 and\CC\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 <e1>sirolimus</e1>\NN\1740 de\FW\1740 novo\FW\1740 .\.\1740
D020123_D011507 CID Whether\IN\1740 proteinuria\NN\14299637 was\VBD\836236 due\JJ\1740 to\TO\1740 sirolimus\NN\1740 or\CC\3541091 only\RB\1740 a\DT\13649268 consequence\NN\34213 of\IN\1740 calcineurin\NN\1740 inhibitors\NNS\20090 withdrawal\NN\7206096 remained\VBD\2604760 unsolved\JJ\1740 until\IN\1740 high\JJ\1740 range\NN\5123416 <e2>proteinuria</e2>\NN\14299637 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 during\IN\1740 sirolimus\NN\1740 therapy\NN\657604 in\IN\13603305 islet\NN\1740 transplantation\NN\671351 and\CC\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 <e1>sirolimus</e1>\NN\1740 de\FW\1740 novo\FW\1740 .\.\1740
1085609
D011736_D012640 NONE Neonatal\JJ\1740 <e1>pyridoxine</e1>\NN\15090742 responsive\JJ\1740 <e2>convulsions</e2>\NNS\14081375 due\JJ\1740 to\IN\1740 isoniazid\NN\2716205 therapy\NN\657604 .\.\1740
D011736_D012640 NONE The\DT\1740 <e2>fits</e2>\NNS\7518132 ceased\VBD\1740 within\IN\1740 4\CD\13741022 hours\NNS\15118228 of\IN\1740 administering\VBG\2436349 intramuscular\JJ\1740 <e1>pyridoxine</e1>\NN\15090742 ,\,\1740 suggesting\VBG\1010118 an\DT\6697703 aetiology\NN\7326557 of\IN\1740 pyridoxine\NN\15090742 deficiency\NN\14449126 secondary\JJ\1740 to\IN\1740 isoniazid\NN\2716205 medication\NN\3247620 .\.\1740
D011736_D012640 NONE The\DT\1740 <e2>fits</e2>\NNS\7518132 ceased\VBD\1740 within\IN\1740 4\CD\13741022 hours\NNS\15118228 of\IN\1740 administering\VBG\2436349 intramuscular\JJ\1740 pyridoxine\NN\15090742 ,\,\1740 suggesting\VBG\1010118 an\DT\6697703 aetiology\NN\7326557 of\IN\1740 <e1>pyridoxine</e1>\NN\15090742 deficiency\NN\14449126 secondary\JJ\1740 to\IN\1740 isoniazid\NN\2716205 medication\NN\3247620 .\.\1740
D007538_D012640 CID Neonatal\JJ\1740 pyridoxine\NN\15090742 responsive\JJ\1740 <e2>convulsions</e2>\NNS\14081375 due\JJ\1740 to\IN\1740 <e1>isoniazid</e1>\NN\2716205 therapy\NN\657604 .\.\1740
D007538_D012640 CID A\DT\13649268 17-day-old\JJ\1740 infant\NN\9918248 on\IN\1740 <e1>isoniazid</e1>\NN\2716205 therapy\NN\657604 13\CD\13745420 mg/kg\NN\1740 daily\RB\1740 from\IN\1740 birth\NN\15265518 because\IN\1740 of\IN\1740 maternal\JJ\1740 tuberculosis\NN\14127211 was\VBD\836236 admitted\VBN\822367 after\IN\1740 4\CD\13741022 days\NNS\15140892 of\IN\1740 <e2>clonic\JJ\1740 fits</e2>\NNS\7518132 .\.\1740
D007538_D012640 CID The\DT\1740 <e2>fits</e2>\NNS\7518132 ceased\VBD\1740 within\IN\1740 4\CD\13741022 hours\NNS\15118228 of\IN\1740 administering\VBG\2436349 intramuscular\JJ\1740 pyridoxine\NN\15090742 ,\,\1740 suggesting\VBG\1010118 an\DT\6697703 aetiology\NN\7326557 of\IN\1740 pyridoxine\NN\15090742 deficiency\NN\14449126 secondary\JJ\1740 to\IN\1740 <e1>isoniazid</e1>\NN\2716205 medication\NN\3247620 .\.\1740
D007538_D014376 NONE A\DT\13649268 17-day-old\JJ\1740 infant\NN\9918248 on\IN\1740 <e1>isoniazid</e1>\NN\2716205 therapy\NN\657604 13\CD\13745420 mg/kg\NN\1740 daily\RB\1740 from\IN\1740 birth\NN\15265518 because\IN\1740 of\IN\1740 maternal\JJ\1740 <e2>tuberculosis</e2>\NN\14127211 was\VBD\836236 admitted\VBN\822367 after\IN\1740 4\CD\13741022 days\NNS\15140892 of\IN\1740 clonic\JJ\1740 fits\NNS\7518132 .\.\1740
891050
D003276_D006463 CID A\DT\13649268 case\NN\7283608 is\VBZ\836236 reported\VBN\831651 of\IN\1740 the\DT\1740 <e2>hemolytic\JJ\1740 uremic\JJ\1740 syndrome</e2>\NN\5870365 (\-LRB-\1740 HUS\NN\1740 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 woman\NN\9605289 taking\VBG\2367363 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 .\.\1740
D003276_D006463 CID A\DT\13649268 case\NN\7283608 is\VBZ\836236 reported\VBN\831651 of\IN\1740 the\DT\1740 hemolytic\JJ\1740 uremic\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 <e2>HUS</e2>\NN\1740 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 woman\NN\9605289 taking\VBG\2367363 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 .\.\1740
D006493_D001002 NONE She\PRP\1740 was\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>heparin</e1>\NN\2718259 ,\,\1740 dipyridamole\NN\1740 and\CC\1740 hemodialysis\NN\649760 ;\:\1740 and\CC\1740 after\IN\1740 more\JJR\1740 than\IN\1740 three\CD\13741022 months\NNS\15113229 ,\,\1740 her\PRP$\1740 urinary\JJ\1740 output\NN\4007894 rose\VBD\1835496 above\IN\6392001 500\CD\13745420 ml\NN\13616054 ;\:\1740 and\CC\1740 six\CD\13741022 months\NNS\15113229 after\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 <e2>anuria</e2>\NN\14061805 ,\,\1740 dialysis\NN\646833 treatment\NN\654885 was\VBD\836236 stopped\VBN\2452885 .\.\1740
D004176_D001002 NONE She\PRP\1740 was\VBD\836236 treated\VBN\2376958 with\IN\1740 heparin\NN\2718259 ,\,\1740 <e1>dipyridamole</e1>\NN\1740 and\CC\1740 hemodialysis\NN\649760 ;\:\1740 and\CC\1740 after\IN\1740 more\JJR\1740 than\IN\1740 three\CD\13741022 months\NNS\15113229 ,\,\1740 her\PRP$\1740 urinary\JJ\1740 output\NN\4007894 rose\VBD\1835496 above\IN\6392001 500\CD\13745420 ml\NN\13616054 ;\:\1740 and\CC\1740 six\CD\13741022 months\NNS\15113229 after\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 <e2>anuria</e2>\NN\14061805 ,\,\1740 dialysis\NN\646833 treatment\NN\654885 was\VBD\836236 stopped\VBN\2452885 .\.\1740
7199841
C004616_D010243 CID Of\IN\1740 the\DT\1740 20\CD\13745420 animals\NNS\4475 that\WDT\1740 received\VBD\2210855 subarachnoid\JJ\1740 injection\NN\320852 of\IN\1740 <e1>2-chloroprocaine-CE</e1>\CD\1740 seven\CD\13741022 (\-LRB-\1740 35\CD\1740 %\NN\1740 )\-RRB-\1740 developed\VBD\1753788 hind-limb\JJ\1740 <e2>paralysis</e2>\NN\14557898 .\.\1740
D002045_D010243 NONE None\NN\15228378 of\IN\1740 the\DT\1740 animals\NNS\4475 that\WDT\1740 received\VBD\2210855 <e1>bupivacaine</e1>\NN\1740 ,\,\1740 normal\JJ\1740 saline\NN\14849367 ,\,\1740 or\CC\3541091 normal\JJ\1740 saline\NN\14849367 titrated\VBN\489837 to\TO\1740 a\DT\13649268 pH\NN\5038959 3.0\CD\1740 developed\VBD\1753788 hind-limb\JJ\1740 <e2>paralysis</e2>\NN\14557898 .\.\1740
C004616_D013118 CID Of\IN\1740 the\DT\1740 15\CD\13745420 spinal\JJ\1740 cords\NNS\4489008 of\IN\1740 the\DT\1740 animals\NNS\4475 that\WDT\1740 received\VBD\2210855 <e1>2-chloroprocaine-CE</e1>\CD\1740 ,\,\1740 13\CD\13745420 showed\VBD\2137132 <e2>subpial\JJ\1740 necrosis</e2>\NN\11444117 ;\:\1740 the\DT\1740 nerve\NN\5475681 roots\NNS\13920429 and\CC\1740 subarachnoid\JJ\1740 vessels\NNS\5246511 were\VBD\836236 normal\JJ\1740 .\.\1740
11256525
D019808_D001002 CID Repeated\VBN\952524 transient\JJ\1740 <e2>anuria</e2>\NN\14061805 following\VBG\1835496 <e1>losartan</e1>\JJ\1740 administration\NN\1133281 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 a\DT\13649268 solitary\JJ\1740 kidney\NN\5333259 .\.\1740
D019808_D001002 CID We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 70-year-old\JJ\1740 hypertensive\JJ\1740 man\NN\9605289 with\IN\1740 a\DT\13649268 solitary\JJ\1740 kidney\NN\5333259 and\CC\1740 chronic\JJ\1740 renal\JJ\1740 insufficiency\NN\14462946 who\WP\8299493 developed\VBD\1753788 two\CD\13741022 episodes\NNS\7283608 of\IN\1740 transient\JJ\1740 <e2>anuria</e2>\NN\14061805 after\IN\1740 <e1>losartan</e1>\JJ\1740 administration\NN\1133281 .\.\1740
D019808_D001002 CID Surprisingly\RB\1740 ,\,\1740 the\DT\1740 first\JJ\1740 dose\NN\3740161 of\IN\1740 50\CD\13745420 mg\NN\13717155 of\IN\1740 <e1>losartan</e1>\NN\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 sudden\JJ\1740 <e2>anuria</e2>\NN\14061805 ,\,\1740 which\WDT\1740 lasted\VBD\2704349 eight\CD\13741022 hours\NNS\15118228 despite\IN\7501545 high-dose\JJ\1740 furosemide\NN\3214670 and\CC\1740 amine\NN\14951377 infusion\NN\14589223 .\.\1740
D019808_D001002 CID One\CD\13741022 week\NN\15113229 later\RB\1740 ,\,\1740 by\IN\1740 mistake\NN\66216 ,\,\1740 <e1>losartan</e1>\NN\1740 was\VBD\836236 prescribed\VBN\748282 again\RB\1740 and\CC\1740 after\IN\1740 the\DT\1740 second\JJ\1740 dose\NN\3740161 of\IN\1740 50\CD\13745420 mg\NN\13717155 ,\,\1740 the\DT\1740 patient\NN\9898892 developed\VBD\1753788 a\DT\13649268 second\JJ\1740 episode\NN\7283608 of\IN\1740 transient\JJ\1740 <e2>anuria</e2>\NN\14061805 lasting\VBG\2704349 10\CD\13745420 hours\NNS\15118228 .\.\1740
D019808_D006973 NONE We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 70-year-old\JJ\1740 <e2>hypertensive</e2>\JJ\1740 man\NN\9605289 with\IN\1740 a\DT\13649268 solitary\JJ\1740 kidney\NN\5333259 and\CC\1740 chronic\JJ\1740 renal\JJ\1740 insufficiency\NN\14462946 who\WP\8299493 developed\VBD\1753788 two\CD\13741022 episodes\NNS\7283608 of\IN\1740 transient\JJ\1740 anuria\NN\14061805 after\IN\1740 <e1>losartan</e1>\JJ\1740 administration\NN\1133281 .\.\1740
D019808_D051436 NONE We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 70-year-old\JJ\1740 hypertensive\JJ\1740 man\NN\9605289 with\IN\1740 a\DT\13649268 solitary\JJ\1740 kidney\NN\5333259 and\CC\1740 <e2>chronic\JJ\1740 renal\JJ\1740 insufficiency</e2>\NN\14462946 who\WP\8299493 developed\VBD\1753788 two\CD\13741022 episodes\NNS\7283608 of\IN\1740 transient\JJ\1740 anuria\NN\14061805 after\IN\1740 <e1>losartan</e1>\JJ\1740 administration\NN\1133281 .\.\1740
D019808_D006331 NONE Due\IN\5174653 to\TO\1740 severe\JJ\1740 <e2>systolic\JJ\1740 dysfunction</e2>\NN\14204950 <e1>losartan</e1>\NN\1740 was\VBD\836236 prescribed\VBN\748282 .\.\1740
D005665_D001002 NONE Surprisingly\RB\1740 ,\,\1740 the\DT\1740 first\JJ\1740 dose\NN\3740161 of\IN\1740 50\CD\13745420 mg\NN\13717155 of\IN\1740 losartan\NN\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 sudden\JJ\1740 <e2>anuria</e2>\NN\14061805 ,\,\1740 which\WDT\1740 lasted\VBD\2704349 eight\CD\13741022 hours\NNS\15118228 despite\IN\7501545 high-dose\JJ\1740 <e1>furosemide</e1>\NN\3214670 and\CC\1740 amine\NN\14951377 infusion\NN\14589223 .\.\1740
D000588_D001002 NONE Surprisingly\RB\1740 ,\,\1740 the\DT\1740 first\JJ\1740 dose\NN\3740161 of\IN\1740 50\CD\13745420 mg\NN\13717155 of\IN\1740 losartan\NN\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 sudden\JJ\1740 <e2>anuria</e2>\NN\14061805 ,\,\1740 which\WDT\1740 lasted\VBD\2704349 eight\CD\13741022 hours\NNS\15118228 despite\IN\7501545 high-dose\JJ\1740 furosemide\NN\3214670 and\CC\1740 <e1>amine</e1>\NN\14951377 infusion\NN\14589223 .\.\1740
D000809_D012078 NONE In\IN\13603305 this\DT\1740 patient\NN\9898892 ,\,\1740 <e2>renal\JJ\1740 artery\NN\5417975 stenosis</e2>\NN\14204950 combined\VBN\2630189 with\IN\1740 heart\NN\5919034 failure\NN\66216 and\CC\1740 diuretic\NN\3247620 therapy\NN\657604 certainly\RB\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 strong\JJ\1740 activation\NN\13561719 of\IN\1740 the\DT\1740 <e1>renin-angiotensin</e1>\JJ\1740 system\NN\3575240 (\-LRB-\1740 RAS\NN\5501711 )\-RRB-\1740 .\.\1740
D000809_D006333 NONE In\IN\13603305 this\DT\1740 patient\NN\9898892 ,\,\1740 renal\JJ\1740 artery\NN\5417975 stenosis\NN\14204950 combined\VBN\2630189 with\IN\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 and\CC\1740 diuretic\NN\3247620 therapy\NN\657604 certainly\RB\1740 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 strong\JJ\1740 activation\NN\13561719 of\IN\1740 the\DT\1740 <e1>renin-angiotensin</e1>\JJ\1740 system\NN\3575240 (\-LRB-\1740 RAS\NN\5501711 )\-RRB-\1740 .\.\1740
D000804_D014652 NONE This\DT\1740 case\NN\7283608 report\NN\6470073 highlights\VBZ\514463 the\DT\1740 fact\NN\5816287 that\IN\1740 the\DT\1740 <e1>angiotensin\NN\4522421 II</e1>\CD\13741022 receptor\NN\5225602 antagonist\NN\7846 losartan\NN\1740 can\MD\3094503 cause\VB\1617192 serious\JJ\1740 unexpected\JJ\1740 complications\NNS\1073995 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>renovascular\JJ\1740 disease</e2>\NN\14061805 and\CC\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 extreme\JJ\1740 caution\NN\4662951 in\IN\13603305 this\DT\1740 setting\NN\8567235 .\.\1740
D019808_D014652 NONE This\DT\1740 case\NN\7283608 report\NN\6470073 highlights\VBZ\514463 the\DT\1740 fact\NN\5816287 that\IN\1740 the\DT\1740 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 antagonist\NN\7846 <e1>losartan</e1>\NN\1740 can\MD\3094503 cause\VB\1617192 serious\JJ\1740 unexpected\JJ\1740 complications\NNS\1073995 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>renovascular\JJ\1740 disease</e2>\NN\14061805 and\CC\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 extreme\JJ\1740 caution\NN\4662951 in\IN\13603305 this\DT\1740 setting\NN\8567235 .\.\1740
3412544
D000082_D014523 NONE Does\VBZ\1640855 <e1>paracetamol</e1>\NN\1740 cause\VB\1617192 <e2>urothelial\JJ\1740 cancer</e2>\NN\14239425 or\CC\3541091 renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 ?\.\1740
D000082_D007681 NONE Does\VBZ\1640855 <e1>paracetamol</e1>\NN\1740 cause\VB\1617192 urothelial\JJ\1740 cancer\NN\14239425 or\CC\3541091 <e2>renal\JJ\1740 papillary\NN\1740 necrosis</e2>\NN\11444117 ?\.\1740
D000082_D007681 NONE The\DT\1740 risk\NN\14541044 of\IN\1740 developing\VBG\1753788 <e2>renal\JJ\1740 papillary\NN\1740 necrosis</e2>\NN\11444117 or\CC\3541091 cancer\NN\14239425 of\IN\1740 the\DT\1740 renal\JJ\1740 pelvis\NNS\5578911 ,\,\1740 ureter\NN\5250659 or\CC\3541091 bladder\NN\5515670 associated\VBN\628491 with\IN\1740 consumption\NN\13440063 of\IN\1740 either\CC\1740 phenacetin\NN\2707683 or\CC\3541091 <e1>paracetamol</e1>\NN\1740 was\VBD\836236 calculated\VBN\632627 from\IN\1740 data\NNS\7951464 acquired\VBN\109660 by\IN\1740 questionnaire\NN\6473563 from\IN\1740 381\CD\1740 cases\NNS\7283608 and\CC\1740 808\CD\1740 controls\NNS\5190804 .\.\1740
D000082_D007681 NONE By\IN\1740 contrast\NN\13854649 ,\,\1740 we\PRP\1740 were\VBD\836236 unable\JJ\1740 to\TO\1740 substantiate\VB\2604760 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 from\IN\1740 <e1>paracetamol</e1>\NN\1740 consumption\NN\13440063 for\IN\1740 <e2>renal\JJ\1740 papillary\NN\1740 necrosis</e2>\NN\11444117 or\CC\3541091 any\DT\1740 of\IN\1740 these\DT\1740 cancers\NNS\14239425 although\IN\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 suggestion\NN\5833840 of\IN\1740 an\DT\6697703 association\NN\8008335 with\IN\1740 cancer\NN\14239425 of\IN\1740 the\DT\1740 ureter\NN\5250659 .\.\1740
D010615_D007681 CID The\DT\1740 risk\NN\14541044 of\IN\1740 developing\VBG\1753788 <e2>renal\JJ\1740 papillary\NN\1740 necrosis</e2>\NN\11444117 or\CC\3541091 cancer\NN\14239425 of\IN\1740 the\DT\1740 renal\JJ\1740 pelvis\NNS\5578911 ,\,\1740 ureter\NN\5250659 or\CC\3541091 bladder\NN\5515670 associated\VBN\628491 with\IN\1740 consumption\NN\13440063 of\IN\1740 either\CC\1740 <e1>phenacetin</e1>\NN\2707683 or\CC\3541091 paracetamol\NN\1740 was\VBD\836236 calculated\VBN\632627 from\IN\1740 data\NNS\7951464 acquired\VBN\109660 by\IN\1740 questionnaire\NN\6473563 from\IN\1740 381\CD\1740 cases\NNS\7283608 and\CC\1740 808\CD\1740 controls\NNS\5190804 .\.\1740
D010615_D007681 CID The\DT\1740 risk\NN\14541044 of\IN\1740 <e2>renal\JJ\1740 papillary\NN\1740 necrosis</e2>\NN\11444117 was\VBD\836236 increased\VBN\169651 nearly\RB\1740 20-fold\RB\1740 by\IN\1740 consumption\NN\13440063 of\IN\1740 <e1>phenacetin</e1>\NN\2707683 ,\,\1740 which\WDT\1740 also\RB\1740 increased\VBD\169651 the\DT\1740 risk\NN\14541044 for\IN\1740 cancer\NN\14239425 of\IN\1740 the\DT\1740 renal\JJ\1740 pelvis\NN\5578911 and\CC\1740 bladder\NN\5515670 but\CC\1740 not\RB\1740 for\IN\1740 ureteric\JJ\1740 cancer\NN\14239425 .\.\1740
D010615_D007680 CID The\DT\1740 risk\NN\14541044 of\IN\1740 renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 was\VBD\836236 increased\VBN\169651 nearly\RB\1740 20-fold\RB\1740 by\IN\1740 consumption\NN\13440063 of\IN\1740 <e1>phenacetin</e1>\NN\2707683 ,\,\1740 which\WDT\1740 also\RB\1740 increased\VBD\169651 the\DT\1740 risk\NN\14541044 for\IN\1740 <e2>cancer\NN\14239425 of\IN\1740 the\DT\1740 renal\JJ\1740 pelvis\NN\5578911 and\CC\1740 bladder</e2>\NN\5515670 but\CC\1740 not\RB\1740 for\IN\1740 ureteric\JJ\1740 cancer\NN\14239425 .\.\1740
D010615_D007680 NONE The\DT\1740 risk\NN\14541044 of\IN\1740 developing\VBG\1753788 renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 or\CC\3541091 <e2>cancer\NN\14239425 of\IN\1740 the\DT\1740 renal\JJ\1740 pelvis\NNS\5578911 ,\,\1740 ureter\NN\5250659 or\CC\3541091 bladder</e2>\NN\5515670 associated\VBN\628491 with\IN\1740 consumption\NN\13440063 of\IN\1740 either\CC\1740 <e1>phenacetin</e1>\NN\2707683 or\CC\3541091 paracetamol\NN\1740 was\VBD\836236 calculated\VBN\632627 from\IN\1740 data\NNS\7951464 acquired\VBN\109660 by\IN\1740 questionnaire\NN\6473563 from\IN\1740 381\CD\1740 cases\NNS\7283608 and\CC\1740 808\CD\1740 controls\NNS\5190804 .\.\1740
D010615_D014516 NONE The\DT\1740 risk\NN\14541044 of\IN\1740 developing\VBG\1753788 renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 or\CC\3541091 <e2>cancer\NN\14239425 of\IN\1740 the\DT\1740 renal\JJ\1740 pelvis\NNS\5578911 ,\,\1740 ureter\NN\5250659 or\CC\3541091 bladder</e2>\NN\5515670 associated\VBN\628491 with\IN\1740 consumption\NN\13440063 of\IN\1740 either\CC\1740 <e1>phenacetin</e1>\NN\2707683 or\CC\3541091 paracetamol\NN\1740 was\VBD\836236 calculated\VBN\632627 from\IN\1740 data\NNS\7951464 acquired\VBN\109660 by\IN\1740 questionnaire\NN\6473563 from\IN\1740 381\CD\1740 cases\NNS\7283608 and\CC\1740 808\CD\1740 controls\NNS\5190804 .\.\1740
D010615_D014516 NONE The\DT\1740 risk\NN\14541044 of\IN\1740 renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 was\VBD\836236 increased\VBN\169651 nearly\RB\1740 20-fold\RB\1740 by\IN\1740 consumption\NN\13440063 of\IN\1740 <e1>phenacetin</e1>\NN\2707683 ,\,\1740 which\WDT\1740 also\RB\1740 increased\VBD\169651 the\DT\1740 risk\NN\14541044 for\IN\1740 cancer\NN\14239425 of\IN\1740 the\DT\1740 renal\JJ\1740 pelvis\NN\5578911 and\CC\1740 bladder\NN\5515670 but\CC\1740 not\RB\1740 for\IN\1740 <e2>ureteric\JJ\1740 cancer</e2>\NN\14239425 .\.\1740
D010615_D001749 CID The\DT\1740 risk\NN\14541044 of\IN\1740 renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 was\VBD\836236 increased\VBN\169651 nearly\RB\1740 20-fold\RB\1740 by\IN\1740 consumption\NN\13440063 of\IN\1740 <e1>phenacetin</e1>\NN\2707683 ,\,\1740 which\WDT\1740 also\RB\1740 increased\VBD\169651 the\DT\1740 risk\NN\14541044 for\IN\1740 <e2>cancer\NN\14239425 of\IN\1740 the\DT\1740 renal\JJ\1740 pelvis\NN\5578911 and\CC\1740 bladder</e2>\NN\5515670 but\CC\1740 not\RB\1740 for\IN\1740 ureteric\JJ\1740 cancer\NN\14239425 .\.\1740
D010615_D001749 NONE The\DT\1740 risk\NN\14541044 of\IN\1740 developing\VBG\1753788 renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 or\CC\3541091 <e2>cancer\NN\14239425 of\IN\1740 the\DT\1740 renal\JJ\1740 pelvis\NNS\5578911 ,\,\1740 ureter\NN\5250659 or\CC\3541091 bladder</e2>\NN\5515670 associated\VBN\628491 with\IN\1740 consumption\NN\13440063 of\IN\1740 either\CC\1740 <e1>phenacetin</e1>\NN\2707683 or\CC\3541091 paracetamol\NN\1740 was\VBD\836236 calculated\VBN\632627 from\IN\1740 data\NNS\7951464 acquired\VBN\109660 by\IN\1740 questionnaire\NN\6473563 from\IN\1740 381\CD\1740 cases\NNS\7283608 and\CC\1740 808\CD\1740 controls\NNS\5190804 .\.\1740
D000082_D007680 NONE The\DT\1740 risk\NN\14541044 of\IN\1740 developing\VBG\1753788 renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 or\CC\3541091 <e2>cancer\NN\14239425 of\IN\1740 the\DT\1740 renal\JJ\1740 pelvis\NNS\5578911 ,\,\1740 ureter\NN\5250659 or\CC\3541091 bladder</e2>\NN\5515670 associated\VBN\628491 with\IN\1740 consumption\NN\13440063 of\IN\1740 either\CC\1740 phenacetin\NN\2707683 or\CC\3541091 <e1>paracetamol</e1>\NN\1740 was\VBD\836236 calculated\VBN\632627 from\IN\1740 data\NNS\7951464 acquired\VBN\109660 by\IN\1740 questionnaire\NN\6473563 from\IN\1740 381\CD\1740 cases\NNS\7283608 and\CC\1740 808\CD\1740 controls\NNS\5190804 .\.\1740
D000082_D014516 NONE The\DT\1740 risk\NN\14541044 of\IN\1740 developing\VBG\1753788 renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 or\CC\3541091 <e2>cancer\NN\14239425 of\IN\1740 the\DT\1740 renal\JJ\1740 pelvis\NNS\5578911 ,\,\1740 ureter\NN\5250659 or\CC\3541091 bladder</e2>\NN\5515670 associated\VBN\628491 with\IN\1740 consumption\NN\13440063 of\IN\1740 either\CC\1740 phenacetin\NN\2707683 or\CC\3541091 <e1>paracetamol</e1>\NN\1740 was\VBD\836236 calculated\VBN\632627 from\IN\1740 data\NNS\7951464 acquired\VBN\109660 by\IN\1740 questionnaire\NN\6473563 from\IN\1740 381\CD\1740 cases\NNS\7283608 and\CC\1740 808\CD\1740 controls\NNS\5190804 .\.\1740
D000082_D014516 NONE By\IN\1740 contrast\NN\13854649 ,\,\1740 we\PRP\1740 were\VBD\836236 unable\JJ\1740 to\TO\1740 substantiate\VB\2604760 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 from\IN\1740 <e1>paracetamol</e1>\NN\1740 consumption\NN\13440063 for\IN\1740 renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 or\CC\3541091 any\DT\1740 of\IN\1740 these\DT\1740 cancers\NNS\14239425 although\IN\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 suggestion\NN\5833840 of\IN\1740 an\DT\6697703 association\NN\8008335 with\IN\1740 <e2>cancer\NN\14239425 of\IN\1740 the\DT\1740 ureter</e2>\NN\5250659 .\.\1740
D000082_D001749 NONE The\DT\1740 risk\NN\14541044 of\IN\1740 developing\VBG\1753788 renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 or\CC\3541091 <e2>cancer\NN\14239425 of\IN\1740 the\DT\1740 renal\JJ\1740 pelvis\NNS\5578911 ,\,\1740 ureter\NN\5250659 or\CC\3541091 bladder</e2>\NN\5515670 associated\VBN\628491 with\IN\1740 consumption\NN\13440063 of\IN\1740 either\CC\1740 phenacetin\NN\2707683 or\CC\3541091 <e1>paracetamol</e1>\NN\1740 was\VBD\836236 calculated\VBN\632627 from\IN\1740 data\NNS\7951464 acquired\VBN\109660 by\IN\1740 questionnaire\NN\6473563 from\IN\1740 381\CD\1740 cases\NNS\7283608 and\CC\1740 808\CD\1740 controls\NNS\5190804 .\.\1740
D000082_D009369 NONE By\IN\1740 contrast\NN\13854649 ,\,\1740 we\PRP\1740 were\VBD\836236 unable\JJ\1740 to\TO\1740 substantiate\VB\2604760 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 from\IN\1740 <e1>paracetamol</e1>\NN\1740 consumption\NN\13440063 for\IN\1740 renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 or\CC\3541091 any\DT\1740 of\IN\1740 these\DT\1740 <e2>cancers</e2>\NNS\14239425 although\IN\1740 there\EX\27167 was\VBD\836236 a\DT\13649268 suggestion\NN\5833840 of\IN\1740 an\DT\6697703 association\NN\8008335 with\IN\1740 cancer\NN\14239425 of\IN\1740 the\DT\1740 ureter\NN\5250659 .\.\1740
9862868
D004997_D002780 CID We\PRP\1740 used\VBD\1156834 rat\NN\2329401 models\NNS\5888929 of\IN\1740 <e2>intrahepatic\JJ\1740 cholestasis</e2>\NN\14052403 by\IN\1740 <e1>ethinyl\JJ\1740 estradiol</e1>\NN\14749794 (\-LRB-\1740 EE\NN\6125041 )\-RRB-\1740 treatment\NN\654885 and\CC\1740 extrahepatic\JJ\1740 cholestasis\NN\14052403 by\IN\1740 bile\NN\5405946 duct\NN\5248181 ligation\NN\149084 (\-LRB-\1740 BDL\NN\1740 )\-RRB-\1740 to\TO\1740 precisely\RB\1740 determine\VB\1645601 the\DT\1740 site\NN\8673395 of\IN\1740 TJ\NN\1740 damage\NN\7296428 .\.\1740
D004997_D002780 CID We\PRP\1740 used\VBD\1156834 rat\NN\2329401 models\NNS\5888929 of\IN\1740 <e2>intrahepatic\JJ\1740 cholestasis</e2>\NN\14052403 by\IN\1740 ethinyl\JJ\1740 estradiol\NN\14749794 (\-LRB-\1740 <e1>EE</e1>\NN\6125041 )\-RRB-\1740 treatment\NN\654885 and\CC\1740 extrahepatic\JJ\1740 cholestasis\NN\14052403 by\IN\1740 bile\NN\5405946 duct\NN\5248181 ligation\NN\149084 (\-LRB-\1740 BDL\NN\1740 )\-RRB-\1740 to\TO\1740 precisely\RB\1740 determine\VB\1645601 the\DT\1740 site\NN\8673395 of\IN\1740 TJ\NN\1740 damage\NN\7296428 .\.\1740
D004997_D001651 NONE We\PRP\1740 used\VBD\1156834 rat\NN\2329401 models\NNS\5888929 of\IN\1740 intrahepatic\JJ\1740 cholestasis\NN\14052403 by\IN\1740 <e1>ethinyl\JJ\1740 estradiol</e1>\NN\14749794 (\-LRB-\1740 EE\NN\6125041 )\-RRB-\1740 treatment\NN\654885 and\CC\1740 <e2>extrahepatic\JJ\1740 cholestasis</e2>\NN\14052403 by\IN\1740 bile\NN\5405946 duct\NN\5248181 ligation\NN\149084 (\-LRB-\1740 BDL\NN\1740 )\-RRB-\1740 to\TO\1740 precisely\RB\1740 determine\VB\1645601 the\DT\1740 site\NN\8673395 of\IN\1740 TJ\NN\1740 damage\NN\7296428 .\.\1740
D004997_D001651 NONE We\PRP\1740 used\VBD\1156834 rat\NN\2329401 models\NNS\5888929 of\IN\1740 intrahepatic\JJ\1740 cholestasis\NN\14052403 by\IN\1740 ethinyl\JJ\1740 estradiol\NN\14749794 (\-LRB-\1740 <e1>EE</e1>\NN\6125041 )\-RRB-\1740 treatment\NN\654885 and\CC\1740 <e2>extrahepatic\JJ\1740 cholestasis</e2>\NN\14052403 by\IN\1740 bile\NN\5405946 duct\NN\5248181 ligation\NN\149084 (\-LRB-\1740 BDL\NN\1740 )\-RRB-\1740 to\TO\1740 precisely\RB\1740 determine\VB\1645601 the\DT\1740 site\NN\8673395 of\IN\1740 TJ\NN\1740 damage\NN\7296428 .\.\1740
2008831
D008755_D000788 NONE Effect\NN\34213 of\IN\1740 direct\JJ\1740 intracoronary\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>methylergonovine</e1>\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 and\CC\1740 without\IN\1740 <e2>variant\JJ\1740 angina</e2>\NN\14171682 .\.\1740
D008755_D000788 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 intracoronary\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>methylergonovine</e1>\NN\1740 were\VBD\836236 studied\VBN\630380 in\IN\13603305 21\CD\13745420 patients\NNS\9898892 with\IN\1740 <e2>variant\JJ\1740 angina</e2>\NN\14171682 and\CC\1740 22\CD\13745420 patients\NNS\9898892 with\IN\1740 atypical\JJ\1740 chest\NN\5220461 pain\NN\14299637 and\CC\1740 in\IN\13603305 others\NNS\1740 without\IN\1740 angina\JJ\1740 pectoris\NN\1740 (\-LRB-\1740 control\NN\5190804 group\NN\2137 )\-RRB-\1740 .\.\1740
D008755_D000788 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 spasm\NN\14299637 provocation\NN\1221611 tests\NNS\5798043 ,\,\1740 which\WDT\1740 use\VBP\1156834 an\DT\6697703 intracoronary\JJ\1740 injection\NN\320852 of\IN\1740 a\DT\13649268 relatively\RB\1740 low\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>methylergonovine</e1>\NN\1740 ,\,\1740 have\VBP\2108377 a\DT\13649268 high\JJ\1740 sensitivity\NN\5651971 in\IN\13603305 <e2>variant\JJ\1740 angina</e2>\NN\14171682 and\CC\1740 the\DT\1740 vasoreactivity\NN\1740 of\IN\1740 the\DT\1740 right\JJ\1740 coronary\JJ\1740 artery\NN\5417975 may\MD\15209706 be\VB\836236 greater\JJR\1740 than\IN\1740 that\DT\1740 of\IN\1740 the\DT\1740 other\JJ\1740 coronary\JJ\1740 arteries\NNS\5417975 .\.\1740
D008755_D002637 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 intracoronary\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>methylergonovine</e1>\NN\1740 were\VBD\836236 studied\VBN\630380 in\IN\13603305 21\CD\13745420 patients\NNS\9898892 with\IN\1740 variant\JJ\1740 angina\NN\14171682 and\CC\1740 22\CD\13745420 patients\NNS\9898892 with\IN\1740 atypical\JJ\1740 <e2>chest\NN\5220461 pain</e2>\NN\14299637 and\CC\1740 in\IN\13603305 others\NNS\1740 without\IN\1740 angina\JJ\1740 pectoris\NN\1740 (\-LRB-\1740 control\NN\5190804 group\NN\2137 )\-RRB-\1740 .\.\1740
D008755_D000787 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 intracoronary\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>methylergonovine</e1>\NN\1740 were\VBD\836236 studied\VBN\630380 in\IN\13603305 21\CD\13745420 patients\NNS\9898892 with\IN\1740 variant\JJ\1740 angina\NN\14171682 and\CC\1740 22\CD\13745420 patients\NNS\9898892 with\IN\1740 atypical\JJ\1740 chest\NN\5220461 pain\NN\14299637 and\CC\1740 in\IN\13603305 others\NNS\1740 without\IN\1740 <e2>angina\JJ\1740 pectoris</e2>\NN\1740 (\-LRB-\1740 control\NN\5190804 group\NN\2137 )\-RRB-\1740 .\.\1740
D008755_D013035 NONE These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 <e2>spasm</e2>\NN\14299637 provocation\NN\1221611 tests\NNS\5798043 ,\,\1740 which\WDT\1740 use\VBP\1156834 an\DT\6697703 intracoronary\JJ\1740 injection\NN\320852 of\IN\1740 a\DT\13649268 relatively\RB\1740 low\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>methylergonovine</e1>\NN\1740 ,\,\1740 have\VBP\2108377 a\DT\13649268 high\JJ\1740 sensitivity\NN\5651971 in\IN\13603305 variant\JJ\1740 angina\NN\14171682 and\CC\1740 the\DT\1740 vasoreactivity\NN\1740 of\IN\1740 the\DT\1740 right\JJ\1740 coronary\JJ\1740 artery\NN\5417975 may\MD\15209706 be\VB\836236 greater\JJR\1740 than\IN\1740 that\DT\1740 of\IN\1740 the\DT\1740 other\JJ\1740 coronary\JJ\1740 arteries\NNS\5417975 .\.\1740
17020434
D014859_D020521 NONE Pooled\JJ\1740 data\NNS\7951464 from\IN\1740 trials\NNS\786195 comparing\VBG\644583 antithrombotic\JJ\1740 treatment\NN\654885 with\IN\1740 placebo\NN\3740161 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 <e1>warfarin</e1>\NN\2718259 reduces\VBZ\441445 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>stroke</e2>\NN\556313 by\IN\1740 62\CD\1740 %\NN\1740 ,\,\1740 and\CC\1740 that\IN\1740 aspirin\NN\2707683 alone\RB\1740 reduces\VBZ\441445 the\DT\1740 risk\NN\14541044 by\IN\1740 22\CD\13745420 %\NN\1740 .\.\1740
D014859_D020521 NONE Overall\RB\1740 ,\,\1740 in\IN\13603305 high-risk\JJ\1740 patients\NNS\9898892 ,\,\1740 <e1>warfarin</e1>\NN\2718259 is\VBZ\836236 superior\JJ\1740 to\TO\1740 aspirin\NN\2707683 in\IN\13603305 preventing\VBG\1740 <e2>strokes</e2>\NNS\556313 ,\,\1740 with\IN\1740 a\DT\13649268 relative\JJ\1740 risk\NN\14541044 reduction\NN\351485 of\IN\1740 36\CD\1740 %\NN\1740 .\.\1740
D001241_D020521 NONE Pooled\JJ\1740 data\NNS\7951464 from\IN\1740 trials\NNS\786195 comparing\VBG\644583 antithrombotic\JJ\1740 treatment\NN\654885 with\IN\1740 placebo\NN\3740161 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 warfarin\NN\2718259 reduces\VBZ\441445 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>stroke</e2>\NN\556313 by\IN\1740 62\CD\1740 %\NN\1740 ,\,\1740 and\CC\1740 that\IN\1740 <e1>aspirin</e1>\NN\2707683 alone\RB\1740 reduces\VBZ\441445 the\DT\1740 risk\NN\14541044 by\IN\1740 22\CD\13745420 %\NN\1740 .\.\1740
D001241_D020521 NONE Overall\RB\1740 ,\,\1740 in\IN\13603305 high-risk\JJ\1740 patients\NNS\9898892 ,\,\1740 warfarin\NN\2718259 is\VBZ\836236 superior\JJ\1740 to\TO\1740 <e1>aspirin</e1>\NN\2707683 in\IN\13603305 preventing\VBG\1740 <e2>strokes</e2>\NNS\556313 ,\,\1740 with\IN\1740 a\DT\13649268 relative\JJ\1740 risk\NN\14541044 reduction\NN\351485 of\IN\1740 36\CD\1740 %\NN\1740 .\.\1740
C426686_D004617 NONE <e1>Ximelagatran</e1>\NNP\1740 ,\,\1740 an\DT\6697703 oral\JJ\1740 direct\JJ\1740 thrombin\NN\14735953 inhibitor\NN\20090 ,\,\1740 was\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 as\RB\1740 efficient\JJ\1740 as\IN\14622893 vitamin\NN\7570720 K\NN\13608598 antagonist\NN\7846 drugs\NNS\14778436 in\IN\13603305 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e2>embolic\JJ\1740 events</e2>\NNS\23100 ,\,\1740 but\CC\1740 has\VBZ\2108377 been\VBN\836236 recently\RB\1740 withdrawn\VBN\1835496 because\IN\1740 of\IN\1740 abnormal\JJ\1740 liver\NN\5298729 function\NN\13783581 tests\NNS\5798043 .\.\1740
C426686_D056486 CID <e1>Ximelagatran</e1>\NNP\1740 ,\,\1740 an\DT\6697703 oral\JJ\1740 direct\JJ\1740 thrombin\NN\14735953 inhibitor\NN\20090 ,\,\1740 was\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 as\RB\1740 efficient\JJ\1740 as\IN\14622893 vitamin\NN\7570720 K\NN\13608598 antagonist\NN\7846 drugs\NNS\14778436 in\IN\13603305 the\DT\1740 prevention\NN\1073995 of\IN\1740 embolic\JJ\1740 events\NNS\23100 ,\,\1740 but\CC\1740 has\VBZ\2108377 been\VBN\836236 recently\RB\1740 withdrawn\VBN\1835496 because\IN\1740 of\IN\1740 <e2>abnormal\JJ\1740 liver\NN\5298729 function</e2>\NN\13783581 tests\NNS\5798043 .\.\1740
D014812_D004617 NONE Ximelagatran\NNP\1740 ,\,\1740 an\DT\6697703 oral\JJ\1740 direct\JJ\1740 thrombin\NN\14735953 inhibitor\NN\20090 ,\,\1740 was\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 as\RB\1740 efficient\JJ\1740 as\IN\14622893 <e1>vitamin\NN\7570720 K</e1>\NN\13608598 antagonist\NN\7846 drugs\NNS\14778436 in\IN\13603305 the\DT\1740 prevention\NN\1073995 of\IN\1740 <e2>embolic\JJ\1740 events</e2>\NNS\23100 ,\,\1740 but\CC\1740 has\VBZ\2108377 been\VBN\836236 recently\RB\1740 withdrawn\VBN\1835496 because\IN\1740 of\IN\1740 abnormal\JJ\1740 liver\NN\5298729 function\NN\13783581 tests\NNS\5798043 .\.\1740
D014812_D056486 NONE Ximelagatran\NNP\1740 ,\,\1740 an\DT\6697703 oral\JJ\1740 direct\JJ\1740 thrombin\NN\14735953 inhibitor\NN\20090 ,\,\1740 was\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 as\RB\1740 efficient\JJ\1740 as\IN\14622893 <e1>vitamin\NN\7570720 K</e1>\NN\13608598 antagonist\NN\7846 drugs\NNS\14778436 in\IN\13603305 the\DT\1740 prevention\NN\1073995 of\IN\1740 embolic\JJ\1740 events\NNS\23100 ,\,\1740 but\CC\1740 has\VBZ\2108377 been\VBN\836236 recently\RB\1740 withdrawn\VBN\1835496 because\IN\1740 of\IN\1740 <e2>abnormal\JJ\1740 liver\NN\5298729 function</e2>\NN\13783581 tests\NNS\5798043 .\.\1740
C055162_D001281 NONE The\DT\1740 ACTIVE-W\NN\1740 (\-LRB-\1740 <e2>Atrial\NNP\1740 Fibrillation</e2>\NNP\14361664 <e1>Clopidogrel</e1>\NNP\1740 Trial\NNP\786195 with\IN\1740 Irbesartan\NNP\1740 for\IN\1740 Prevention\NN\1073995 of\IN\1740 Vascular\NNP\1740 Events\NNPS\23100 )\-RRB-\1740 study\NN\635850 has\VBZ\2108377 demonstrated\VBN\2137132 that\IN\1740 warfarin\NN\2718259 is\VBZ\836236 superior\JJ\1740 to\TO\1740 platelet\NN\5432736 therapy\NN\657604 (\-LRB-\1740 clopidogrel\NN\1740 plus\CC\4723816 aspirin\NN\2707683 )\-RRB-\1740 in\IN\13603305 the\DT\1740 prevention\NN\1073995 af\IN\1740 embolic\JJ\1740 events\NNS\23100 .\.\1740
C055162_D001281 NONE The\DT\1740 ACTIVE-W\NN\1740 (\-LRB-\1740 <e2>Atrial\NNP\1740 Fibrillation</e2>\NNP\14361664 Clopidogrel\NNP\1740 Trial\NNP\786195 with\IN\1740 Irbesartan\NNP\1740 for\IN\1740 Prevention\NN\1073995 of\IN\1740 Vascular\NNP\1740 Events\NNPS\23100 )\-RRB-\1740 study\NN\635850 has\VBZ\2108377 demonstrated\VBN\2137132 that\IN\1740 warfarin\NN\2718259 is\VBZ\836236 superior\JJ\1740 to\TO\1740 platelet\NN\5432736 therapy\NN\657604 (\-LRB-\1740 <e1>clopidogrel</e1>\NN\1740 plus\CC\4723816 aspirin\NN\2707683 )\-RRB-\1740 in\IN\13603305 the\DT\1740 prevention\NN\1073995 af\IN\1740 embolic\JJ\1740 events\NNS\23100 .\.\1740
C055162_D004617 NONE The\DT\1740 ACTIVE-W\NN\1740 (\-LRB-\1740 Atrial\NNP\1740 Fibrillation\NNP\14361664 <e1>Clopidogrel</e1>\NNP\1740 Trial\NNP\786195 with\IN\1740 Irbesartan\NNP\1740 for\IN\1740 Prevention\NN\1073995 of\IN\1740 Vascular\NNP\1740 Events\NNPS\23100 )\-RRB-\1740 study\NN\635850 has\VBZ\2108377 demonstrated\VBN\2137132 that\IN\1740 warfarin\NN\2718259 is\VBZ\836236 superior\JJ\1740 to\TO\1740 platelet\NN\5432736 therapy\NN\657604 (\-LRB-\1740 clopidogrel\NN\1740 plus\CC\4723816 aspirin\NN\2707683 )\-RRB-\1740 in\IN\13603305 the\DT\1740 prevention\NN\1073995 af\IN\1740 <e2>embolic\JJ\1740 events</e2>\NNS\23100 .\.\1740
C055162_D004617 NONE The\DT\1740 ACTIVE-W\NN\1740 (\-LRB-\1740 Atrial\NNP\1740 Fibrillation\NNP\14361664 Clopidogrel\NNP\1740 Trial\NNP\786195 with\IN\1740 Irbesartan\NNP\1740 for\IN\1740 Prevention\NN\1073995 of\IN\1740 Vascular\NNP\1740 Events\NNPS\23100 )\-RRB-\1740 study\NN\635850 has\VBZ\2108377 demonstrated\VBN\2137132 that\IN\1740 warfarin\NN\2718259 is\VBZ\836236 superior\JJ\1740 to\TO\1740 platelet\NN\5432736 therapy\NN\657604 (\-LRB-\1740 <e1>clopidogrel</e1>\NN\1740 plus\CC\4723816 aspirin\NN\2707683 )\-RRB-\1740 in\IN\13603305 the\DT\1740 prevention\NN\1073995 af\IN\1740 <e2>embolic\JJ\1740 events</e2>\NNS\23100 .\.\1740
C081309_D001281 NONE The\DT\1740 ACTIVE-W\NN\1740 (\-LRB-\1740 <e2>Atrial\NNP\1740 Fibrillation</e2>\NNP\14361664 Clopidogrel\NNP\1740 Trial\NNP\786195 with\IN\1740 <e1>Irbesartan</e1>\NNP\1740 for\IN\1740 Prevention\NN\1073995 of\IN\1740 Vascular\NNP\1740 Events\NNPS\23100 )\-RRB-\1740 study\NN\635850 has\VBZ\2108377 demonstrated\VBN\2137132 that\IN\1740 warfarin\NN\2718259 is\VBZ\836236 superior\JJ\1740 to\TO\1740 platelet\NN\5432736 therapy\NN\657604 (\-LRB-\1740 clopidogrel\NN\1740 plus\CC\4723816 aspirin\NN\2707683 )\-RRB-\1740 in\IN\13603305 the\DT\1740 prevention\NN\1073995 af\IN\1740 embolic\JJ\1740 events\NNS\23100 .\.\1740
C081309_D004617 NONE The\DT\1740 ACTIVE-W\NN\1740 (\-LRB-\1740 Atrial\NNP\1740 Fibrillation\NNP\14361664 Clopidogrel\NNP\1740 Trial\NNP\786195 with\IN\1740 <e1>Irbesartan</e1>\NNP\1740 for\IN\1740 Prevention\NN\1073995 of\IN\1740 Vascular\NNP\1740 Events\NNPS\23100 )\-RRB-\1740 study\NN\635850 has\VBZ\2108377 demonstrated\VBN\2137132 that\IN\1740 warfarin\NN\2718259 is\VBZ\836236 superior\JJ\1740 to\TO\1740 platelet\NN\5432736 therapy\NN\657604 (\-LRB-\1740 clopidogrel\NN\1740 plus\CC\4723816 aspirin\NN\2707683 )\-RRB-\1740 in\IN\13603305 the\DT\1740 prevention\NN\1073995 af\IN\1740 <e2>embolic\JJ\1740 events</e2>\NNS\23100 .\.\1740
D014859_D001281 NONE The\DT\1740 ACTIVE-W\NN\1740 (\-LRB-\1740 <e2>Atrial\NNP\1740 Fibrillation</e2>\NNP\14361664 Clopidogrel\NNP\1740 Trial\NNP\786195 with\IN\1740 Irbesartan\NNP\1740 for\IN\1740 Prevention\NN\1073995 of\IN\1740 Vascular\NNP\1740 Events\NNPS\23100 )\-RRB-\1740 study\NN\635850 has\VBZ\2108377 demonstrated\VBN\2137132 that\IN\1740 <e1>warfarin</e1>\NN\2718259 is\VBZ\836236 superior\JJ\1740 to\TO\1740 platelet\NN\5432736 therapy\NN\657604 (\-LRB-\1740 clopidogrel\NN\1740 plus\CC\4723816 aspirin\NN\2707683 )\-RRB-\1740 in\IN\13603305 the\DT\1740 prevention\NN\1073995 af\IN\1740 embolic\JJ\1740 events\NNS\23100 .\.\1740
D014859_D004617 NONE The\DT\1740 ACTIVE-W\NN\1740 (\-LRB-\1740 Atrial\NNP\1740 Fibrillation\NNP\14361664 Clopidogrel\NNP\1740 Trial\NNP\786195 with\IN\1740 Irbesartan\NNP\1740 for\IN\1740 Prevention\NN\1073995 of\IN\1740 Vascular\NNP\1740 Events\NNPS\23100 )\-RRB-\1740 study\NN\635850 has\VBZ\2108377 demonstrated\VBN\2137132 that\IN\1740 <e1>warfarin</e1>\NN\2718259 is\VBZ\836236 superior\JJ\1740 to\TO\1740 platelet\NN\5432736 therapy\NN\657604 (\-LRB-\1740 clopidogrel\NN\1740 plus\CC\4723816 aspirin\NN\2707683 )\-RRB-\1740 in\IN\13603305 the\DT\1740 prevention\NN\1073995 af\IN\1740 <e2>embolic\JJ\1740 events</e2>\NNS\23100 .\.\1740
D001241_D001281 NONE The\DT\1740 ACTIVE-W\NN\1740 (\-LRB-\1740 <e2>Atrial\NNP\1740 Fibrillation</e2>\NNP\14361664 Clopidogrel\NNP\1740 Trial\NNP\786195 with\IN\1740 Irbesartan\NNP\1740 for\IN\1740 Prevention\NN\1073995 of\IN\1740 Vascular\NNP\1740 Events\NNPS\23100 )\-RRB-\1740 study\NN\635850 has\VBZ\2108377 demonstrated\VBN\2137132 that\IN\1740 warfarin\NN\2718259 is\VBZ\836236 superior\JJ\1740 to\TO\1740 platelet\NN\5432736 therapy\NN\657604 (\-LRB-\1740 clopidogrel\NN\1740 plus\CC\4723816 <e1>aspirin</e1>\NN\2707683 )\-RRB-\1740 in\IN\13603305 the\DT\1740 prevention\NN\1073995 af\IN\1740 embolic\JJ\1740 events\NNS\23100 .\.\1740
D001241_D004617 NONE The\DT\1740 ACTIVE-W\NN\1740 (\-LRB-\1740 Atrial\NNP\1740 Fibrillation\NNP\14361664 Clopidogrel\NNP\1740 Trial\NNP\786195 with\IN\1740 Irbesartan\NNP\1740 for\IN\1740 Prevention\NN\1073995 of\IN\1740 Vascular\NNP\1740 Events\NNPS\23100 )\-RRB-\1740 study\NN\635850 has\VBZ\2108377 demonstrated\VBN\2137132 that\IN\1740 warfarin\NN\2718259 is\VBZ\836236 superior\JJ\1740 to\TO\1740 platelet\NN\5432736 therapy\NN\657604 (\-LRB-\1740 clopidogrel\NN\1740 plus\CC\4723816 <e1>aspirin</e1>\NN\2707683 )\-RRB-\1740 in\IN\13603305 the\DT\1740 prevention\NN\1073995 af\IN\1740 <e2>embolic\JJ\1740 events</e2>\NNS\23100 .\.\1740
C479958_D001281 NONE <e1>Idraparinux</e1>\NNP\1740 ,\,\1740 a\DT\13649268 Factor\NN\7326557 Xa\NN\1740 inhibitor\NN\20090 ,\,\1740 is\VBZ\836236 being\VBG\836236 evaluated\VBN\670261 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 .\.\1740
D000809_D001281 NONE <e1>Angiotensin-converting</e1>\JJ\1740 enzyme\NN\14723628 inhibitors\NNS\20090 and\CC\1740 angiotensin\NN\4522421 II\CD\13741022 receptor-blocking\JJ\1740 drugs\NNS\14778436 hold\VBP\2439501 promise\NN\6684383 in\IN\13603305 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 through\IN\1740 cardiac\JJ\1740 remodelling\NN\1740 .\.\1740
D000809_D020257 NONE <e1>Angiotensin-converting</e1>\JJ\1740 enzyme\NN\14723628 inhibitors\NNS\20090 and\CC\1740 angiotensin\NN\4522421 II\CD\13741022 receptor-blocking\JJ\1740 drugs\NNS\14778436 hold\VBP\2439501 promise\NN\6684383 in\IN\13603305 atrial\JJ\1740 fibrillation\NN\14361664 through\IN\1740 <e2>cardiac\JJ\1740 remodelling</e2>\NN\1740 .\.\1740
D000804_D001281 NONE Angiotensin-converting\JJ\1740 enzyme\NN\14723628 inhibitors\NNS\20090 and\CC\1740 <e1>angiotensin\NN\4522421 II</e1>\CD\13741022 receptor-blocking\JJ\1740 drugs\NNS\14778436 hold\VBP\2439501 promise\NN\6684383 in\IN\13603305 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 through\IN\1740 cardiac\JJ\1740 remodelling\NN\1740 .\.\1740
D000804_D020257 NONE Angiotensin-converting\JJ\1740 enzyme\NN\14723628 inhibitors\NNS\20090 and\CC\1740 <e1>angiotensin\NN\4522421 II</e1>\CD\13741022 receptor-blocking\JJ\1740 drugs\NNS\14778436 hold\VBP\2439501 promise\NN\6684383 in\IN\13603305 atrial\JJ\1740 fibrillation\NN\14361664 through\IN\1740 <e2>cardiac\JJ\1740 remodelling</e2>\NN\1740 .\.\1740
11745184
D002945_D001943 NONE A\DT\13649268 Phase\NN\15113229 II\CD\13741022 trial\NN\786195 of\IN\1740 <e1>cisplatin</e1>\NN\1740 plus\CC\4723816 WR-2721\JJ\1740 (\-LRB-\1740 amifostine\NN\1740 )\-RRB-\1740 for\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 carcinoma</e2>\NN\14239918 :\:\1740 an\DT\6697703 Eastern\JJ\1740 Cooperative\JJ\1740 Oncology\NN\6043075 Group\NNP\2137 Study\NN\635850 (\-LRB-\1740 E8188\NN\1740 )\-RRB-\1740 .\.\1740
D002945_D001943 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Cisplatin</e1>\NNP\1740 has\VBZ\2108377 minimal\JJ\1740 antitumor\NN\1740 activity\NN\30358 when\WRB\1740 used\VBN\1156834 as\IN\14622893 second-\NN\1740 or\CC\3541091 third-line\JJ\1740 treatment\NN\654885 of\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 carcinoma</e2>\NN\14239918 .\.\1740
D002945_D001943 NONE Although\IN\1740 a\DT\13649268 dose-response\JJ\1740 effect\NN\34213 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 with\IN\1740 <e1>cisplatin</e1>\NN\1740 ,\,\1740 the\DT\1740 dose-limiting\JJ\1740 toxicities\NNS\13576101 associated\VBN\628491 with\IN\1740 cisplatin\NN\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 nephrotoxicity\NN\1740 ,\,\1740 ototoxicity\NN\1740 ,\,\1740 and\CC\1740 neurotoxicity\NN\1740 )\-RRB-\1740 have\VBP\2108377 limited\VBN\2510337 its\PRP$\6125041 use\NN\407535 as\IN\14622893 a\DT\13649268 treatment\NN\654885 for\IN\1740 <e2>breast\NN\5225090 carcinoma</e2>\NN\14239918 .\.\1740
D002945_D001943 NONE Although\IN\1740 a\DT\13649268 dose-response\JJ\1740 effect\NN\34213 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 with\IN\1740 cisplatin\NN\1740 ,\,\1740 the\DT\1740 dose-limiting\JJ\1740 toxicities\NNS\13576101 associated\VBN\628491 with\IN\1740 <e1>cisplatin</e1>\NN\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 nephrotoxicity\NN\1740 ,\,\1740 ototoxicity\NN\1740 ,\,\1740 and\CC\1740 neurotoxicity\NN\1740 )\-RRB-\1740 have\VBP\2108377 limited\VBN\2510337 its\PRP$\6125041 use\NN\407535 as\IN\14622893 a\DT\13649268 treatment\NN\654885 for\IN\1740 <e2>breast\NN\5225090 carcinoma</e2>\NN\14239918 .\.\1740
D002945_D001943 NONE METHODS\NNS\5616786 :\:\1740 A\DT\13649268 Phase\NN\15113229 II\CD\13741022 study\NN\635850 of\IN\1740 the\DT\1740 combination\NN\7951464 of\IN\1740 <e1>cisplatin</e1>\NN\1740 plus\CC\4723816 amifostine\NN\1740 was\VBD\836236 conducted\VBN\2436349 in\IN\13603305 patients\NNS\9898892 with\IN\1740 progressive\JJ\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 carcinoma</e2>\NN\14239918 who\WP\8299493 had\VBD\2108377 received\VBN\2210855 one\CD\13741022 ,\,\1740 but\CC\1740 not\RB\1740 more\JJR\1740 than\IN\1740 one\CD\13741022 ,\,\1740 chemotherapy\NN\661091 regimen\NNS\5898568 for\IN\1740 metastatic\JJ\1740 disease\NN\14061805 .\.\1740
D004999_D001943 NONE A\DT\13649268 Phase\NN\15113229 II\CD\13741022 trial\NN\786195 of\IN\1740 cisplatin\NN\1740 plus\CC\4723816 <e1>WR-2721</e1>\JJ\1740 (\-LRB-\1740 amifostine\NN\1740 )\-RRB-\1740 for\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 carcinoma</e2>\NN\14239918 :\:\1740 an\DT\6697703 Eastern\JJ\1740 Cooperative\JJ\1740 Oncology\NN\6043075 Group\NNP\2137 Study\NN\635850 (\-LRB-\1740 E8188\NN\1740 )\-RRB-\1740 .\.\1740
D004999_D001943 NONE A\DT\13649268 Phase\NN\15113229 II\CD\13741022 trial\NN\786195 of\IN\1740 cisplatin\NN\1740 plus\CC\4723816 WR-2721\JJ\1740 (\-LRB-\1740 <e1>amifostine</e1>\NN\1740 )\-RRB-\1740 for\IN\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 carcinoma</e2>\NN\14239918 :\:\1740 an\DT\6697703 Eastern\JJ\1740 Cooperative\JJ\1740 Oncology\NN\6043075 Group\NNP\2137 Study\NN\635850 (\-LRB-\1740 E8188\NN\1740 )\-RRB-\1740 .\.\1740
D004999_D001943 NONE METHODS\NNS\5616786 :\:\1740 A\DT\13649268 Phase\NN\15113229 II\CD\13741022 study\NN\635850 of\IN\1740 the\DT\1740 combination\NN\7951464 of\IN\1740 cisplatin\NN\1740 plus\CC\4723816 <e1>amifostine</e1>\NN\1740 was\VBD\836236 conducted\VBN\2436349 in\IN\13603305 patients\NNS\9898892 with\IN\1740 progressive\JJ\1740 metastatic\JJ\1740 <e2>breast\NN\5225090 carcinoma</e2>\NN\14239918 who\WP\8299493 had\VBD\2108377 received\VBN\2210855 one\CD\13741022 ,\,\1740 but\CC\1740 not\RB\1740 more\JJR\1740 than\IN\1740 one\CD\13741022 ,\,\1740 chemotherapy\NN\661091 regimen\NNS\5898568 for\IN\1740 metastatic\JJ\1740 disease\NN\14061805 .\.\1740
D002945_D064420 NONE Although\IN\1740 a\DT\13649268 dose-response\JJ\1740 effect\NN\34213 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 with\IN\1740 <e1>cisplatin</e1>\NN\1740 ,\,\1740 the\DT\1740 dose-limiting\JJ\1740 <e2>toxicities</e2>\NNS\13576101 associated\VBN\628491 with\IN\1740 cisplatin\NN\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 nephrotoxicity\NN\1740 ,\,\1740 ototoxicity\NN\1740 ,\,\1740 and\CC\1740 neurotoxicity\NN\1740 )\-RRB-\1740 have\VBP\2108377 limited\VBN\2510337 its\PRP$\6125041 use\NN\407535 as\IN\14622893 a\DT\13649268 treatment\NN\654885 for\IN\1740 breast\NN\5225090 carcinoma\NN\14239918 .\.\1740
D002945_D064420 NONE Although\IN\1740 a\DT\13649268 dose-response\JJ\1740 effect\NN\34213 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 with\IN\1740 cisplatin\NN\1740 ,\,\1740 the\DT\1740 dose-limiting\JJ\1740 <e2>toxicities</e2>\NNS\13576101 associated\VBN\628491 with\IN\1740 <e1>cisplatin</e1>\NN\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 nephrotoxicity\NN\1740 ,\,\1740 ototoxicity\NN\1740 ,\,\1740 and\CC\1740 neurotoxicity\NN\1740 )\-RRB-\1740 have\VBP\2108377 limited\VBN\2510337 its\PRP$\6125041 use\NN\407535 as\IN\14622893 a\DT\13649268 treatment\NN\654885 for\IN\1740 breast\NN\5225090 carcinoma\NN\14239918 .\.\1740
D002945_D064420 NONE Neither\CC\1740 a\DT\13649268 tumor-protective\JJ\1740 effect\NN\34213 nor\CC\1740 reduced\VBN\441445 <e2>toxicity</e2>\NN\13576101 to\TO\1740 normal\JJ\1740 tissues\NNS\5220461 was\VBD\836236 observed\VBN\2163746 with\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 amifostine\NN\1740 to\TO\1740 <e1>cisplatin</e1>\NN\1740 in\IN\13603305 this\DT\1740 trial\NN\786195 .\.\1740
D002945_D007674 CID Although\IN\1740 a\DT\13649268 dose-response\JJ\1740 effect\NN\34213 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 with\IN\1740 <e1>cisplatin</e1>\NN\1740 ,\,\1740 the\DT\1740 dose-limiting\JJ\1740 toxicities\NNS\13576101 associated\VBN\628491 with\IN\1740 cisplatin\NN\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 <e2>nephrotoxicity</e2>\NN\1740 ,\,\1740 ototoxicity\NN\1740 ,\,\1740 and\CC\1740 neurotoxicity\NN\1740 )\-RRB-\1740 have\VBP\2108377 limited\VBN\2510337 its\PRP$\6125041 use\NN\407535 as\IN\14622893 a\DT\13649268 treatment\NN\654885 for\IN\1740 breast\NN\5225090 carcinoma\NN\14239918 .\.\1740
D002945_D007674 CID Although\IN\1740 a\DT\13649268 dose-response\JJ\1740 effect\NN\34213 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 with\IN\1740 cisplatin\NN\1740 ,\,\1740 the\DT\1740 dose-limiting\JJ\1740 toxicities\NNS\13576101 associated\VBN\628491 with\IN\1740 <e1>cisplatin</e1>\NN\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 <e2>nephrotoxicity</e2>\NN\1740 ,\,\1740 ototoxicity\NN\1740 ,\,\1740 and\CC\1740 neurotoxicity\NN\1740 )\-RRB-\1740 have\VBP\2108377 limited\VBN\2510337 its\PRP$\6125041 use\NN\407535 as\IN\14622893 a\DT\13649268 treatment\NN\654885 for\IN\1740 breast\NN\5225090 carcinoma\NN\14239918 .\.\1740
D002945_D007674 CID Early\JJ\1740 trials\NNS\786195 of\IN\1740 <e1>cisplatin</e1>\NN\1740 and\CC\1740 amifostine\NN\1740 also\RB\1740 suggested\VBD\1010118 that\IN\1740 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 cisplatin-induced\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 ,\,\1740 ototoxicity\NN\1740 ,\,\1740 and\CC\1740 neuropathy\RB\1740 were\VBD\836236 reduced\VBN\441445 .\.\1740
D002945_D007674 CID Early\JJ\1740 trials\NNS\786195 of\IN\1740 cisplatin\NN\1740 and\CC\1740 amifostine\NN\1740 also\RB\1740 suggested\VBD\1010118 that\IN\1740 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 <e1>cisplatin-induced</e1>\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 ,\,\1740 ototoxicity\NN\1740 ,\,\1740 and\CC\1740 neuropathy\RB\1740 were\VBD\836236 reduced\VBN\441445 .\.\1740
D002945_D006311 CID Although\IN\1740 a\DT\13649268 dose-response\JJ\1740 effect\NN\34213 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 with\IN\1740 <e1>cisplatin</e1>\NN\1740 ,\,\1740 the\DT\1740 dose-limiting\JJ\1740 toxicities\NNS\13576101 associated\VBN\628491 with\IN\1740 cisplatin\NN\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 nephrotoxicity\NN\1740 ,\,\1740 <e2>ototoxicity</e2>\NN\1740 ,\,\1740 and\CC\1740 neurotoxicity\NN\1740 )\-RRB-\1740 have\VBP\2108377 limited\VBN\2510337 its\PRP$\6125041 use\NN\407535 as\IN\14622893 a\DT\13649268 treatment\NN\654885 for\IN\1740 breast\NN\5225090 carcinoma\NN\14239918 .\.\1740
D002945_D006311 CID Although\IN\1740 a\DT\13649268 dose-response\JJ\1740 effect\NN\34213 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 with\IN\1740 cisplatin\NN\1740 ,\,\1740 the\DT\1740 dose-limiting\JJ\1740 toxicities\NNS\13576101 associated\VBN\628491 with\IN\1740 <e1>cisplatin</e1>\NN\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 nephrotoxicity\NN\1740 ,\,\1740 <e2>ototoxicity</e2>\NN\1740 ,\,\1740 and\CC\1740 neurotoxicity\NN\1740 )\-RRB-\1740 have\VBP\2108377 limited\VBN\2510337 its\PRP$\6125041 use\NN\407535 as\IN\14622893 a\DT\13649268 treatment\NN\654885 for\IN\1740 breast\NN\5225090 carcinoma\NN\14239918 .\.\1740
D002945_D006311 CID Early\JJ\1740 trials\NNS\786195 of\IN\1740 <e1>cisplatin</e1>\NN\1740 and\CC\1740 amifostine\NN\1740 also\RB\1740 suggested\VBD\1010118 that\IN\1740 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 cisplatin-induced\JJ\1740 nephrotoxicity\NN\1740 ,\,\1740 <e2>ototoxicity</e2>\NN\1740 ,\,\1740 and\CC\1740 neuropathy\RB\1740 were\VBD\836236 reduced\VBN\441445 .\.\1740
D002945_D006311 CID Early\JJ\1740 trials\NNS\786195 of\IN\1740 cisplatin\NN\1740 and\CC\1740 amifostine\NN\1740 also\RB\1740 suggested\VBD\1010118 that\IN\1740 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 <e1>cisplatin-induced</e1>\JJ\1740 nephrotoxicity\NN\1740 ,\,\1740 <e2>ototoxicity</e2>\NN\1740 ,\,\1740 and\CC\1740 neuropathy\RB\1740 were\VBD\836236 reduced\VBN\441445 .\.\1740
D002945_D020258 NONE Although\IN\1740 a\DT\13649268 dose-response\JJ\1740 effect\NN\34213 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 with\IN\1740 <e1>cisplatin</e1>\NN\1740 ,\,\1740 the\DT\1740 dose-limiting\JJ\1740 toxicities\NNS\13576101 associated\VBN\628491 with\IN\1740 cisplatin\NN\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 nephrotoxicity\NN\1740 ,\,\1740 ototoxicity\NN\1740 ,\,\1740 and\CC\1740 <e2>neurotoxicity</e2>\NN\1740 )\-RRB-\1740 have\VBP\2108377 limited\VBN\2510337 its\PRP$\6125041 use\NN\407535 as\IN\14622893 a\DT\13649268 treatment\NN\654885 for\IN\1740 breast\NN\5225090 carcinoma\NN\14239918 .\.\1740
D002945_D020258 NONE Although\IN\1740 a\DT\13649268 dose-response\JJ\1740 effect\NN\34213 has\VBZ\2108377 been\VBN\836236 observed\VBN\2163746 with\IN\1740 cisplatin\NN\1740 ,\,\1740 the\DT\1740 dose-limiting\JJ\1740 toxicities\NNS\13576101 associated\VBN\628491 with\IN\1740 <e1>cisplatin</e1>\NN\1740 (\-LRB-\1740 e.g.\FW\1740 ,\,\1740 nephrotoxicity\NN\1740 ,\,\1740 ototoxicity\NN\1740 ,\,\1740 and\CC\1740 <e2>neurotoxicity</e2>\NN\1740 )\-RRB-\1740 have\VBP\2108377 limited\VBN\2510337 its\PRP$\6125041 use\NN\407535 as\IN\14622893 a\DT\13649268 treatment\NN\654885 for\IN\1740 breast\NN\5225090 carcinoma\NN\14239918 .\.\1740
D002945_D009422 CID Early\JJ\1740 trials\NNS\786195 of\IN\1740 <e1>cisplatin</e1>\NN\1740 and\CC\1740 amifostine\NN\1740 also\RB\1740 suggested\VBD\1010118 that\IN\1740 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 cisplatin-induced\JJ\1740 nephrotoxicity\NN\1740 ,\,\1740 ototoxicity\NN\1740 ,\,\1740 and\CC\1740 <e2>neuropathy</e2>\RB\1740 were\VBD\836236 reduced\VBN\441445 .\.\1740
D002945_D009422 CID Early\JJ\1740 trials\NNS\786195 of\IN\1740 cisplatin\NN\1740 and\CC\1740 amifostine\NN\1740 also\RB\1740 suggested\VBD\1010118 that\IN\1740 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 <e1>cisplatin-induced</e1>\JJ\1740 nephrotoxicity\NN\1740 ,\,\1740 ototoxicity\NN\1740 ,\,\1740 and\CC\1740 <e2>neuropathy</e2>\RB\1740 were\VBD\836236 reduced\VBN\441445 .\.\1740
D004999_D007674 NONE Early\JJ\1740 trials\NNS\786195 of\IN\1740 cisplatin\NN\1740 and\CC\1740 <e1>amifostine</e1>\NN\1740 also\RB\1740 suggested\VBD\1010118 that\IN\1740 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 cisplatin-induced\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 ,\,\1740 ototoxicity\NN\1740 ,\,\1740 and\CC\1740 neuropathy\RB\1740 were\VBD\836236 reduced\VBN\441445 .\.\1740
D004999_D006311 NONE Early\JJ\1740 trials\NNS\786195 of\IN\1740 cisplatin\NN\1740 and\CC\1740 <e1>amifostine</e1>\NN\1740 also\RB\1740 suggested\VBD\1010118 that\IN\1740 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 cisplatin-induced\JJ\1740 nephrotoxicity\NN\1740 ,\,\1740 <e2>ototoxicity</e2>\NN\1740 ,\,\1740 and\CC\1740 neuropathy\RB\1740 were\VBD\836236 reduced\VBN\441445 .\.\1740
D004999_D009422 NONE Early\JJ\1740 trials\NNS\786195 of\IN\1740 cisplatin\NN\1740 and\CC\1740 <e1>amifostine</e1>\NN\1740 also\RB\1740 suggested\VBD\1010118 that\IN\1740 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 cisplatin-induced\JJ\1740 nephrotoxicity\NN\1740 ,\,\1740 ototoxicity\NN\1740 ,\,\1740 and\CC\1740 <e2>neuropathy</e2>\RB\1740 were\VBD\836236 reduced\VBN\441445 .\.\1740
D004999_D009369 NONE Neither\CC\1740 a\DT\13649268 <e2>tumor-protective</e2>\JJ\1740 effect\NN\34213 nor\CC\1740 reduced\VBN\441445 toxicity\NN\13576101 to\TO\1740 normal\JJ\1740 tissues\NNS\5220461 was\VBD\836236 observed\VBN\2163746 with\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 <e1>amifostine</e1>\NN\1740 to\TO\1740 cisplatin\NN\1740 in\IN\13603305 this\DT\1740 trial\NN\786195 .\.\1740
D004999_D064420 NONE Neither\CC\1740 a\DT\13649268 tumor-protective\JJ\1740 effect\NN\34213 nor\CC\1740 reduced\VBN\441445 <e2>toxicity</e2>\NN\13576101 to\TO\1740 normal\JJ\1740 tissues\NNS\5220461 was\VBD\836236 observed\VBN\2163746 with\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 <e1>amifostine</e1>\NN\1740 to\TO\1740 cisplatin\NN\1740 in\IN\13603305 this\DT\1740 trial\NN\786195 .\.\1740
D002945_D009369 NONE Neither\CC\1740 a\DT\13649268 <e2>tumor-protective</e2>\JJ\1740 effect\NN\34213 nor\CC\1740 reduced\VBN\441445 toxicity\NN\13576101 to\TO\1740 normal\JJ\1740 tissues\NNS\5220461 was\VBD\836236 observed\VBN\2163746 with\IN\1740 the\DT\1740 addition\NN\3081021 of\IN\1740 amifostine\NN\1740 to\TO\1740 <e1>cisplatin</e1>\NN\1740 in\IN\13603305 this\DT\1740 trial\NN\786195 .\.\1740
8410052
D019344_D001480 NONE Focal\JJ\1740 <e2>injury\NN\14052046 in\IN\13603305 the\DT\1740 cortex</e2>\NN\5462674 was\VBD\836236 produced\VBN\1617192 by\IN\1740 infusion\NN\14589223 of\IN\1740 <e1>lactate</e1>\NN\14850483 at\IN\14622893 acid\NN\14818238 pH\NN\5038959 or\CC\3541091 by\IN\1740 stab\JJ\1740 caused\VBN\1617192 by\IN\1740 needle\NN\13156083 insertion\NN\6598915 .\.\1740
D010862_D002544 CID <e2>Infarcts\NNS\14204950 in\IN\13603305 substantia\RB\1740 nigra\JJ\1740 pars\NNS\13594585 reticulata</e2>\NNS\1740 were\VBD\836236 evoked\VBN\1617192 by\IN\1740 prolonged\JJ\1740 <e1>pilocarpine-induced</e1>\JJ\1740 status\NN\24720 epilepticus\NN\1740 .\.\1740
D010862_D013226 CID Infarcts\NNS\14204950 in\IN\13603305 substantia\RB\1740 nigra\JJ\1740 pars\NNS\13594585 reticulata\NNS\1740 were\VBD\836236 evoked\VBN\1617192 by\IN\1740 prolonged\JJ\1740 <e1>pilocarpine-induced</e1>\JJ\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 .\.\1740
14657095
D000666_D002311 CID Reversible\JJ\1740 <e2>dilated\VBD\303465 cardiomyopathy</e2>\DT\14103288 related\JJ\1740 to\TO\1740 <e1>amphotericin\NN\2716866 B</e1>\NN\1355326 therapy\NN\657604 .\.\1740
D000666_D002311 CID We\PRP\1740 describe\VBP\1001294 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 <e2>dilated\VBN\303465 cardiomyopathy</e2>\JJ\1740 and\CC\1740 clinical\JJ\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 after\IN\1740 2\CD\13741022 months\NNS\15113229 of\IN\1740 therapy\NN\657604 with\IN\1740 <e1>amphotericin\NN\2716866 B</e1>\NN\1355326 (\-LRB-\1740 AmB\NN\1740 )\-RRB-\1740 for\IN\1740 disseminated\VBN\954608 coccidioidomycosis\NN\14176895 .\.\1740
D000666_D002311 CID We\PRP\1740 describe\VBP\1001294 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 <e2>dilated\VBN\303465 cardiomyopathy</e2>\JJ\1740 and\CC\1740 clinical\JJ\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 after\IN\1740 2\CD\13741022 months\NNS\15113229 of\IN\1740 therapy\NN\657604 with\IN\1740 amphotericin\NN\2716866 B\NN\1355326 (\-LRB-\1740 <e1>AmB</e1>\NN\1740 )\-RRB-\1740 for\IN\1740 disseminated\VBN\954608 coccidioidomycosis\NN\14176895 .\.\1740
D000666_D006333 CID We\PRP\1740 describe\VBP\1001294 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 dilated\VBN\303465 cardiomyopathy\JJ\1740 and\CC\1740 clinical\JJ\1740 congestive\JJ\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 after\IN\1740 2\CD\13741022 months\NNS\15113229 of\IN\1740 therapy\NN\657604 with\IN\1740 <e1>amphotericin\NN\2716866 B</e1>\NN\1355326 (\-LRB-\1740 AmB\NN\1740 )\-RRB-\1740 for\IN\1740 disseminated\VBN\954608 coccidioidomycosis\NN\14176895 .\.\1740
D000666_D006333 CID We\PRP\1740 describe\VBP\1001294 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 dilated\VBN\303465 cardiomyopathy\JJ\1740 and\CC\1740 clinical\JJ\1740 congestive\JJ\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 after\IN\1740 2\CD\13741022 months\NNS\15113229 of\IN\1740 therapy\NN\657604 with\IN\1740 amphotericin\NN\2716866 B\NN\1355326 (\-LRB-\1740 <e1>AmB</e1>\NN\1740 )\-RRB-\1740 for\IN\1740 disseminated\VBN\954608 coccidioidomycosis\NN\14176895 .\.\1740
D000666_D006333 CID His\PRP$\1740 echocardiographic\JJ\1740 abnormalities\NNS\14034177 and\CC\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 resolved\VBN\352826 after\IN\1740 posaconazole\NN\1740 was\VBD\836236 substituted\VBN\126264 for\IN\1740 <e1>AmB.</e1>\NN\1740 It\PRP\6125041 is\VBZ\836236 important\JJ\1740 to\TO\1740 recognize\VB\686447 the\DT\1740 rare\JJ\1740 and\CC\1740 potentially\RB\1740 reversible\JJ\1740 toxicity\NN\13576101 of\IN\1740 AmB.\NN\1740
D000666_D006333 CID His\PRP$\1740 echocardiographic\JJ\1740 abnormalities\NNS\14034177 and\CC\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 resolved\VBN\352826 after\IN\1740 posaconazole\NN\1740 was\VBD\836236 substituted\VBN\126264 for\IN\1740 AmB.\NN\1740 It\PRP\6125041 is\VBZ\836236 important\JJ\1740 to\TO\1740 recognize\VB\686447 the\DT\1740 rare\JJ\1740 and\CC\1740 potentially\RB\1740 reversible\JJ\1740 toxicity\NN\13576101 of\IN\1740 <e1>AmB.</e1>\NN\1740
D000666_D003047 NONE We\PRP\1740 describe\VBP\1001294 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 dilated\VBN\303465 cardiomyopathy\JJ\1740 and\CC\1740 clinical\JJ\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 after\IN\1740 2\CD\13741022 months\NNS\15113229 of\IN\1740 therapy\NN\657604 with\IN\1740 <e1>amphotericin\NN\2716866 B</e1>\NN\1355326 (\-LRB-\1740 AmB\NN\1740 )\-RRB-\1740 for\IN\1740 disseminated\VBN\954608 <e2>coccidioidomycosis</e2>\NN\14176895 .\.\1740
D000666_D003047 NONE We\PRP\1740 describe\VBP\1001294 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 dilated\VBN\303465 cardiomyopathy\JJ\1740 and\CC\1740 clinical\JJ\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 after\IN\1740 2\CD\13741022 months\NNS\15113229 of\IN\1740 therapy\NN\657604 with\IN\1740 amphotericin\NN\2716866 B\NN\1355326 (\-LRB-\1740 <e1>AmB</e1>\NN\1740 )\-RRB-\1740 for\IN\1740 disseminated\VBN\954608 <e2>coccidioidomycosis</e2>\NN\14176895 .\.\1740
C101425_D006333 NONE His\PRP$\1740 echocardiographic\JJ\1740 abnormalities\NNS\14034177 and\CC\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 resolved\VBN\352826 after\IN\1740 <e1>posaconazole</e1>\NN\1740 was\VBD\836236 substituted\VBN\126264 for\IN\1740 AmB.\NN\1740 It\PRP\6125041 is\VBZ\836236 important\JJ\1740 to\TO\1740 recognize\VB\686447 the\DT\1740 rare\JJ\1740 and\CC\1740 potentially\RB\1740 reversible\JJ\1740 toxicity\NN\13576101 of\IN\1740 AmB.\NN\1740
C101425_D064420 NONE His\PRP$\1740 echocardiographic\JJ\1740 abnormalities\NNS\14034177 and\CC\1740 heart\NN\5919034 failure\NN\66216 resolved\VBN\352826 after\IN\1740 <e1>posaconazole</e1>\NN\1740 was\VBD\836236 substituted\VBN\126264 for\IN\1740 AmB.\NN\1740 It\PRP\6125041 is\VBZ\836236 important\JJ\1740 to\TO\1740 recognize\VB\686447 the\DT\1740 rare\JJ\1740 and\CC\1740 potentially\RB\1740 reversible\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 AmB.\NN\1740
D000666_D064420 NONE His\PRP$\1740 echocardiographic\JJ\1740 abnormalities\NNS\14034177 and\CC\1740 heart\NN\5919034 failure\NN\66216 resolved\VBN\352826 after\IN\1740 posaconazole\NN\1740 was\VBD\836236 substituted\VBN\126264 for\IN\1740 <e1>AmB.</e1>\NN\1740 It\PRP\6125041 is\VBZ\836236 important\JJ\1740 to\TO\1740 recognize\VB\686447 the\DT\1740 rare\JJ\1740 and\CC\1740 potentially\RB\1740 reversible\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 AmB.\NN\1740
D000666_D064420 NONE His\PRP$\1740 echocardiographic\JJ\1740 abnormalities\NNS\14034177 and\CC\1740 heart\NN\5919034 failure\NN\66216 resolved\VBN\352826 after\IN\1740 posaconazole\NN\1740 was\VBD\836236 substituted\VBN\126264 for\IN\1740 AmB.\NN\1740 It\PRP\6125041 is\VBZ\836236 important\JJ\1740 to\TO\1740 recognize\VB\686447 the\DT\1740 rare\JJ\1740 and\CC\1740 potentially\RB\1740 reversible\JJ\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 <e1>AmB.</e1>\NN\1740
2334618
D009020_D001049 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 postoperative\JJ\1740 respiratory\JJ\1740 <e2>apnoea</e2>\NN\1740 was\VBD\836236 compared\VBN\644583 between\IN\1740 five\CD\13741022 patients\NNS\9898892 receiving\VBG\2210855 a\DT\13649268 continuous\JJ\1740 i.v.\NN\1740 infusion\NN\14589223 of\IN\1740 <e1>morphine</e1>\NN\2707683 (\-LRB-\1740 mean\NN\6021761 73.6\CD\1740 mg\NN\13717155 )\-RRB-\1740 and\CC\1740 five\CD\13741022 patients\NNS\9898892 receiving\VBG\2210855 a\DT\13649268 continuous\JJ\1740 extradural\JJ\1740 infusion\NN\14589223 of\IN\1740 0.25\CD\1740 %\NN\1740 bupivacaine\NN\1740 (\-LRB-\1740 mean\NN\6021761 192\CD\1740 mg\NN\13717155 )\-RRB-\1740 in\IN\13603305 the\DT\1740 24-h\JJ\1740 period\NN\13575869 following\VBG\1835496 upper\JJ\1740 abdominal\JJ\1740 surgery\NN\6045562 .\.\1740
D002045_D001049 NONE The\DT\1740 incidence\NN\13821570 of\IN\1740 postoperative\JJ\1740 respiratory\JJ\1740 <e2>apnoea</e2>\NN\1740 was\VBD\836236 compared\VBN\644583 between\IN\1740 five\CD\13741022 patients\NNS\9898892 receiving\VBG\2210855 a\DT\13649268 continuous\JJ\1740 i.v.\NN\1740 infusion\NN\14589223 of\IN\1740 morphine\NN\2707683 (\-LRB-\1740 mean\NN\6021761 73.6\CD\1740 mg\NN\13717155 )\-RRB-\1740 and\CC\1740 five\CD\13741022 patients\NNS\9898892 receiving\VBG\2210855 a\DT\13649268 continuous\JJ\1740 extradural\JJ\1740 infusion\NN\14589223 of\IN\1740 0.25\CD\1740 %\NN\1740 <e1>bupivacaine</e1>\NN\1740 (\-LRB-\1740 mean\NN\6021761 192\CD\1740 mg\NN\13717155 )\-RRB-\1740 in\IN\13603305 the\DT\1740 24-h\JJ\1740 period\NN\13575869 following\VBG\1835496 upper\JJ\1740 abdominal\JJ\1740 surgery\NN\6045562 .\.\1740
D009020_D020181 CID Both\CC\1740 <e2>obstructive\JJ\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 and\CC\1740 central\JJ\1740 apnoea</e2>\NN\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 occurred\VBD\2623529 more\RBR\1740 frequently\RB\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 a\DT\13649268 <e1>morphine</e1>\NN\2707683 infusion\NN\14589223 .\.\1740
D009020_D020182 CID Both\CC\1740 <e2>obstructive\JJ\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 and\CC\1740 central\JJ\1740 apnoea</e2>\NN\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 occurred\VBD\2623529 more\RBR\1740 frequently\RB\1740 in\IN\13603305 patients\NNS\9898892 who\WP\8299493 had\VBD\2108377 a\DT\13649268 <e1>morphine</e1>\NN\2707683 infusion\NN\14589223 .\.\1740
D009020_D013610 NONE There\EX\27167 was\VBD\836236 also\RB\1740 a\DT\13649268 higher\JJR\1740 incidence\NN\13821570 of\IN\1740 <e2>tachyarrhythmias</e2>\NNS\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 and\CC\1740 ventricular\JJ\1740 ectopic\JJ\1740 beats\NNS\8289449 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 <e1>morphine</e1>\NN\2707683 infusion\NN\14589223 group\NN\2137 .\.\1740
D009020_D018879 CID There\EX\27167 was\VBD\836236 also\RB\1740 a\DT\13649268 higher\JJR\1740 incidence\NN\13821570 of\IN\1740 tachyarrhythmias\NNS\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 and\CC\1740 <e2>ventricular\JJ\1740 ectopic\JJ\1740 beats</e2>\NNS\8289449 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 <e1>morphine</e1>\NN\2707683 infusion\NN\14589223 group\NN\2137 .\.\1740
8437969
D002927_D054138 CID <e2>Sinus\NN\5248181 arrest</e2>\NN\88481 associated\VBN\628491 with\IN\1740 continuous-infusion\JJ\1740 <e1>cimetidine</e1>\NN\14778019 .\.\1740
D002927_D054138 CID A\DT\13649268 40-year-old\JJ\1740 man\NN\9605289 with\IN\1740 leukemia\NN\14239918 and\CC\1740 no\DT\7204911 history\NN\15120823 of\IN\1740 cardiac\JJ\1740 disease\NN\14061805 developed\VBD\1753788 recurrent\JJ\1740 ,\,\1740 brief\JJ\1740 episodes\NNS\7283608 of\IN\1740 apparent\JJ\1740 <e2>sinus\NN\5248181 arrest</e2>\NN\88481 while\IN\15122231 receiving\VBG\2210855 continuous-infusion\JJ\1740 <e1>cimetidine</e1>\NN\14778019 50\CD\13745420 mg/hour\NN\1740 .\.\1740
D002927_D054138 CID This\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 reported\VBN\831651 case\NN\7283608 of\IN\1740 <e2>sinus\NN\5248181 arrest</e2>\NN\88481 associated\VBN\628491 with\IN\1740 continuous-infusion\JJ\1740 <e1>cimetidine</e1>\NN\14778019 .\.\1740
D002927_D001919 CID The\DT\1740 administration\NN\1133281 of\IN\1740 intermittent\JJ\1740 intravenous\JJ\1740 infusions\NNS\14589223 of\IN\1740 <e1>cimetidine</e1>\NN\14778019 is\VBZ\836236 infrequently\RB\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>bradyarrhythmias</e2>\NNS\1740 .\.\1740
D002927_D007938 NONE A\DT\13649268 40-year-old\JJ\1740 man\NN\9605289 with\IN\1740 <e2>leukemia</e2>\NN\14239918 and\CC\1740 no\DT\7204911 history\NN\15120823 of\IN\1740 cardiac\JJ\1740 disease\NN\14061805 developed\VBD\1753788 recurrent\JJ\1740 ,\,\1740 brief\JJ\1740 episodes\NNS\7283608 of\IN\1740 apparent\JJ\1740 sinus\NN\5248181 arrest\NN\88481 while\IN\15122231 receiving\VBG\2210855 continuous-infusion\JJ\1740 <e1>cimetidine</e1>\NN\14778019 50\CD\13745420 mg/hour\NN\1740 .\.\1740
D002927_D006331 NONE A\DT\13649268 40-year-old\JJ\1740 man\NN\9605289 with\IN\1740 leukemia\NN\14239918 and\CC\1740 no\DT\7204911 history\NN\15120823 of\IN\1740 <e2>cardiac\JJ\1740 disease</e2>\NN\14061805 developed\VBD\1753788 recurrent\JJ\1740 ,\,\1740 brief\JJ\1740 episodes\NNS\7283608 of\IN\1740 apparent\JJ\1740 sinus\NN\5248181 arrest\NN\88481 while\IN\15122231 receiving\VBG\2210855 continuous-infusion\JJ\1740 <e1>cimetidine</e1>\NN\14778019 50\CD\13745420 mg/hour\NN\1740 .\.\1740
D002927_D001145 NONE The\DT\1740 <e2>arrhythmias</e2>\NNS\14103288 were\VBD\836236 temporally\RB\1740 related\JJ\1740 to\TO\1740 <e1>cimetidine</e1>\NN\14778019 administration\NN\1133281 ,\,\1740 disappeared\VBD\2609764 after\IN\1740 dechallenge\NN\1740 ,\,\1740 and\CC\1740 did\VBD\1640855 not\RB\1740 recur\VB\339934 during\IN\1740 ranitidine\NN\14778019 treatment\NN\654885 .\.\1740
D011899_D001145 NONE The\DT\1740 <e2>arrhythmias</e2>\NNS\14103288 were\VBD\836236 temporally\RB\1740 related\JJ\1740 to\TO\1740 cimetidine\NN\14778019 administration\NN\1133281 ,\,\1740 disappeared\VBD\2609764 after\IN\1740 dechallenge\NN\1740 ,\,\1740 and\CC\1740 did\VBD\1640855 not\RB\1740 recur\VB\339934 during\IN\1740 <e1>ranitidine</e1>\NN\14778019 treatment\NN\654885 .\.\1740
2870085
C047847_D013610 NONE <e1>Flestolol</e1>\NNP\1740 produced\VBD\1617192 a\DT\13649268 dose-dependent\JJ\1740 attenuation\NN\7427337 of\IN\1740 isoproterenol-induced\JJ\1740 <e2>tachycardia</e2>\NN\14110674 .\.\1740
D007545_D013610 CID Flestolol\NNP\1740 produced\VBD\1617192 a\DT\13649268 dose-dependent\JJ\1740 attenuation\NN\7427337 of\IN\1740 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>tachycardia</e2>\NN\14110674 .\.\1740
C047847_D013617 NONE <e1>Flestolol</e1>\NNP\1740 effectively\RB\1740 reduced\VBD\441445 heart\NN\5919034 rate\NN\13815152 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>supraventricular\JJ\1740 tachyarrhythmia</e2>\NN\1740 .\.\1740
C047847_D000789 NONE In\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>unstable\JJ\1740 angina</e2>\NN\14171682 ,\,\1740 <e1>flestolol</e1>\NN\1740 infusion\NN\14589223 was\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 safe\JJ\1740 and\CC\1740 effective\JJ\1740 in\IN\13603305 controlling\VBG\2422663 chest\JJ\1740 pain\NN\14299637 .\.\1740
C047847_D002637 NONE In\IN\13603305 patients\NNS\9898892 with\IN\1740 unstable\JJ\1740 angina\NN\14171682 ,\,\1740 <e1>flestolol</e1>\NN\1740 infusion\NN\14589223 was\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 safe\JJ\1740 and\CC\1740 effective\JJ\1740 in\IN\13603305 controlling\VBG\2422663 <e2>chest\JJ\1740 pain</e2>\NN\14299637 .\.\1740
7053303
D002927_D003704 CID There\EX\27167 was\VBD\836236 only\RB\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 <e2>dementia</e2>\NN\14395018 possibly\RB\1740 due\JJ\1740 to\TO\1740 <e1>cimetidine</e1>\NN\14778019 (\-LRB-\1740 with\IN\1740 a\DT\13649268 drug\NN\14778436 level\NN\4916342 of\IN\1740 1.9\CD\1740 microgram/ml\NN\1740 6\CD\13741022 hr\NN\15154774 after\IN\1740 a\DT\13649268 dose\NN\3740161 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 13\CD\13745420 patients\NNS\9898892 without\IN\1740 liver\NN\5298729 or\CC\3541091 kidney\NN\5333259 disease\NN\14061805 who\WP\8299493 had\VBD\2108377 cimetidine\NN\14778019 levels\NNS\4916342 above\IN\6392001 1.25\CD\1740 microgram/ml\NN\1740 .\.\1740
D002927_D003704 CID There\EX\27167 was\VBD\836236 only\RB\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 <e2>dementia</e2>\NN\14395018 possibly\RB\1740 due\JJ\1740 to\TO\1740 cimetidine\NN\14778019 (\-LRB-\1740 with\IN\1740 a\DT\13649268 drug\NN\14778436 level\NN\4916342 of\IN\1740 1.9\CD\1740 microgram/ml\NN\1740 6\CD\13741022 hr\NN\15154774 after\IN\1740 a\DT\13649268 dose\NN\3740161 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 13\CD\13745420 patients\NNS\9898892 without\IN\1740 liver\NN\5298729 or\CC\3541091 kidney\NN\5333259 disease\NN\14061805 who\WP\8299493 had\VBD\2108377 <e1>cimetidine</e1>\NN\14778019 levels\NNS\4916342 above\IN\6392001 1.25\CD\1740 microgram/ml\NN\1740 .\.\1740
D002927_D003704 CID Thus\RB\1740 ,\,\1740 high\JJ\1740 <e1>cimetidine</e1>\NN\14778019 levels\NNS\4916342 alone\RB\1740 do\VBP\1640855 not\RB\1740 always\RB\1740 induce\VB\1627355 <e2>dementia</e2>\NN\14395018 .\.\1740
D002927_D008107 NONE There\EX\27167 was\VBD\836236 only\RB\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 dementia\NN\14395018 possibly\RB\1740 due\JJ\1740 to\TO\1740 <e1>cimetidine</e1>\NN\14778019 (\-LRB-\1740 with\IN\1740 a\DT\13649268 drug\NN\14778436 level\NN\4916342 of\IN\1740 1.9\CD\1740 microgram/ml\NN\1740 6\CD\13741022 hr\NN\15154774 after\IN\1740 a\DT\13649268 dose\NN\3740161 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 13\CD\13745420 patients\NNS\9898892 without\IN\1740 <e2>liver\NN\5298729 or\CC\3541091 kidney\NN\5333259 disease</e2>\NN\14061805 who\WP\8299493 had\VBD\2108377 cimetidine\NN\14778019 levels\NNS\4916342 above\IN\6392001 1.25\CD\1740 microgram/ml\NN\1740 .\.\1740
D002927_D008107 NONE There\EX\27167 was\VBD\836236 only\RB\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 dementia\NN\14395018 possibly\RB\1740 due\JJ\1740 to\TO\1740 cimetidine\NN\14778019 (\-LRB-\1740 with\IN\1740 a\DT\13649268 drug\NN\14778436 level\NN\4916342 of\IN\1740 1.9\CD\1740 microgram/ml\NN\1740 6\CD\13741022 hr\NN\15154774 after\IN\1740 a\DT\13649268 dose\NN\3740161 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 13\CD\13745420 patients\NNS\9898892 without\IN\1740 <e2>liver\NN\5298729 or\CC\3541091 kidney\NN\5333259 disease</e2>\NN\14061805 who\WP\8299493 had\VBD\2108377 <e1>cimetidine</e1>\NN\14778019 levels\NNS\4916342 above\IN\6392001 1.25\CD\1740 microgram/ml\NN\1740 .\.\1740
D002927_D007674 NONE There\EX\27167 was\VBD\836236 only\RB\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 dementia\NN\14395018 possibly\RB\1740 due\JJ\1740 to\TO\1740 <e1>cimetidine</e1>\NN\14778019 (\-LRB-\1740 with\IN\1740 a\DT\13649268 drug\NN\14778436 level\NN\4916342 of\IN\1740 1.9\CD\1740 microgram/ml\NN\1740 6\CD\13741022 hr\NN\15154774 after\IN\1740 a\DT\13649268 dose\NN\3740161 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 13\CD\13745420 patients\NNS\9898892 without\IN\1740 <e2>liver\NN\5298729 or\CC\3541091 kidney\NN\5333259 disease</e2>\NN\14061805 who\WP\8299493 had\VBD\2108377 cimetidine\NN\14778019 levels\NNS\4916342 above\IN\6392001 1.25\CD\1740 microgram/ml\NN\1740 .\.\1740
D002927_D007674 NONE There\EX\27167 was\VBD\836236 only\RB\1740 one\CD\13741022 case\NN\7283608 of\IN\1740 dementia\NN\14395018 possibly\RB\1740 due\JJ\1740 to\TO\1740 cimetidine\NN\14778019 (\-LRB-\1740 with\IN\1740 a\DT\13649268 drug\NN\14778436 level\NN\4916342 of\IN\1740 1.9\CD\1740 microgram/ml\NN\1740 6\CD\13741022 hr\NN\15154774 after\IN\1740 a\DT\13649268 dose\NN\3740161 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 group\NN\2137 of\IN\1740 13\CD\13745420 patients\NNS\9898892 without\IN\1740 <e2>liver\NN\5298729 or\CC\3541091 kidney\NN\5333259 disease</e2>\NN\14061805 who\WP\8299493 had\VBD\2108377 <e1>cimetidine</e1>\NN\14778019 levels\NNS\4916342 above\IN\6392001 1.25\CD\1740 microgram/ml\NN\1740 .\.\1740
12921865
D013256_D012640 NONE Protective\JJ\1740 efficacy\NN\5199286 of\IN\1740 neuroactive\JJ\1740 <e1>steroids</e1>\NNS\14727670 against\IN\1740 cocaine\NN\3492717 <e2>kindled-seizures</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D013256_D012640 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 evaluate\VB\670261 two\CD\13741022 endogenous\JJ\1740 and\CC\1740 one\CD\13741022 synthetic\JJ\1740 neuroactive\JJ\1740 <e1>steroid</e1>\NN\14727670 that\WDT\1740 positively\RB\1740 modulate\VBP\1724459 the\DT\1740 gamma-aminobutyric\JJ\1740 acid\NN\14818238 (\-LRB-\1740 GABA(A\NN\1740 )\-RRB-\1740 )\-RRB-\1740 receptor\NN\5225602 against\IN\1740 the\DT\1740 increase\NN\13576355 in\IN\13603305 sensitivity\NN\5651971 to\TO\1740 the\DT\1740 convulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 cocaine\NN\3492717 engendered\VBN\1645601 by\IN\1740 repeated\VBN\952524 cocaine\NN\3492717 administration\NN\1133281 (\-LRB-\1740 <e2>seizure</e2>\JJ\1740 kindling\NN\15101361 )\-RRB-\1740 .\.\1740
D003042_D012640 CID Protective\JJ\1740 efficacy\NN\5199286 of\IN\1740 neuroactive\JJ\1740 steroids\NNS\14727670 against\IN\1740 <e1>cocaine</e1>\NN\3492717 <e2>kindled-seizures</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D003042_D012640 CID The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 evaluate\VB\670261 two\CD\13741022 endogenous\JJ\1740 and\CC\1740 one\CD\13741022 synthetic\JJ\1740 neuroactive\JJ\1740 steroid\NN\14727670 that\WDT\1740 positively\RB\1740 modulate\VBP\1724459 the\DT\1740 gamma-aminobutyric\JJ\1740 acid\NN\14818238 (\-LRB-\1740 GABA(A\NN\1740 )\-RRB-\1740 )\-RRB-\1740 receptor\NN\5225602 against\IN\1740 the\DT\1740 increase\NN\13576355 in\IN\13603305 sensitivity\NN\5651971 to\TO\1740 the\DT\1740 convulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>cocaine</e1>\NN\3492717 engendered\VBN\1645601 by\IN\1740 repeated\VBN\952524 cocaine\NN\3492717 administration\NN\1133281 (\-LRB-\1740 <e2>seizure</e2>\JJ\1740 kindling\NN\15101361 )\-RRB-\1740 .\.\1740
D003042_D012640 CID The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 evaluate\VB\670261 two\CD\13741022 endogenous\JJ\1740 and\CC\1740 one\CD\13741022 synthetic\JJ\1740 neuroactive\JJ\1740 steroid\NN\14727670 that\WDT\1740 positively\RB\1740 modulate\VBP\1724459 the\DT\1740 gamma-aminobutyric\JJ\1740 acid\NN\14818238 (\-LRB-\1740 GABA(A\NN\1740 )\-RRB-\1740 )\-RRB-\1740 receptor\NN\5225602 against\IN\1740 the\DT\1740 increase\NN\13576355 in\IN\13603305 sensitivity\NN\5651971 to\TO\1740 the\DT\1740 convulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 cocaine\NN\3492717 engendered\VBN\1645601 by\IN\1740 repeated\VBN\952524 <e1>cocaine</e1>\NN\3492717 administration\NN\1133281 (\-LRB-\1740 <e2>seizure</e2>\JJ\1740 kindling\NN\15101361 )\-RRB-\1740 .\.\1740
D003042_D012640 CID Allopregnanolone\NN\1740 (\-LRB-\1740 3alpha-hydroxy-5alpha-pregnan-20-one\NN\1740 )\-RRB-\1740 ,\,\1740 pregnanolone\NN\1740 (\-LRB-\1740 3alpha-hydroxy-5beta-pregnan-20-one\NN\1740 )\-RRB-\1740 and\CC\1740 ganaxolone\NN\1740 (\-LRB-\1740 a\DT\13649268 synthetic\JJ\1740 derivative\NN\5802185 of\IN\1740 allopregnanolone\NN\1740 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one\CD\1740 )\-RRB-\1740 were\VBD\836236 tested\VBN\670261 for\IN\1740 their\PRP$\1740 ability\NN\4723816 to\TO\1740 suppress\VB\2510337 the\DT\1740 expression\NN\4679549 (\-LRB-\1740 anticonvulsant\JJ\1740 effect\NN\34213 )\-RRB-\1740 and\CC\1740 development\NN\248977 (\-LRB-\1740 antiepileptogenic\JJ\1740 effect\NN\34213 )\-RRB-\1740 of\IN\1740 <e1>cocaine-kindled</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 male\JJ\1740 ,\,\1740 Swiss-Webster\NN\1740 mice\NNS\2329401 .\.\1740
D003042_D012640 CID Kindled\JJ\1740 <e2>seizures</e2>\NNS\14081375 were\VBD\836236 induced\VBN\1627355 by\IN\1740 daily\JJ\1740 administration\NN\1133281 of\IN\1740 60\CD\13745420 mg/kg\NN\1740 <e1>cocaine</e1>\NN\3492717 for\IN\1740 5\CD\13741022 days\NNS\15140892 .\.\1740
D013256_D009422 NONE Neuroactive\JJ\1740 <e1>steroids</e1>\NNS\14727670 demonstrate\VBP\2137132 pharmacological\JJ\1740 actions\NNS\30358 that\WDT\1740 have\VBP\2108377 relevance\NN\13791389 for\IN\1740 a\DT\13649268 host\NN\9605289 of\IN\1740 <e2>neurological\JJ\1740 and\CC\1740 psychiatric\JJ\1740 disorders</e2>\NNS\14034177 .\.\1740
D013256_D001523 NONE Neuroactive\JJ\1740 <e1>steroids</e1>\NNS\14727670 demonstrate\VBP\2137132 pharmacological\JJ\1740 actions\NNS\30358 that\WDT\1740 have\VBP\2108377 relevance\NN\13791389 for\IN\1740 a\DT\13649268 host\NN\9605289 of\IN\1740 <e2>neurological\JJ\1740 and\CC\1740 psychiatric\JJ\1740 disorders</e2>\NNS\14034177 .\.\1740
D005680_D012640 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 evaluate\VB\670261 two\CD\13741022 endogenous\JJ\1740 and\CC\1740 one\CD\13741022 synthetic\JJ\1740 neuroactive\JJ\1740 steroid\NN\14727670 that\WDT\1740 positively\RB\1740 modulate\VBP\1724459 the\DT\1740 <e1>gamma-aminobutyric\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 GABA(A\NN\1740 )\-RRB-\1740 )\-RRB-\1740 receptor\NN\5225602 against\IN\1740 the\DT\1740 increase\NN\13576355 in\IN\13603305 sensitivity\NN\5651971 to\TO\1740 the\DT\1740 convulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 cocaine\NN\3492717 engendered\VBN\1645601 by\IN\1740 repeated\VBN\952524 cocaine\NN\3492717 administration\NN\1133281 (\-LRB-\1740 <e2>seizure</e2>\JJ\1740 kindling\NN\15101361 )\-RRB-\1740 .\.\1740
D005680_D012640 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 evaluate\VB\670261 two\CD\13741022 endogenous\JJ\1740 and\CC\1740 one\CD\13741022 synthetic\JJ\1740 neuroactive\JJ\1740 steroid\NN\14727670 that\WDT\1740 positively\RB\1740 modulate\VBP\1724459 the\DT\1740 gamma-aminobutyric\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>GABA(A</e1>\NN\1740 )\-RRB-\1740 )\-RRB-\1740 receptor\NN\5225602 against\IN\1740 the\DT\1740 increase\NN\13576355 in\IN\13603305 sensitivity\NN\5651971 to\TO\1740 the\DT\1740 convulsant\JJ\1740 effects\NNS\13245626 of\IN\1740 cocaine\NN\3492717 engendered\VBN\1645601 by\IN\1740 repeated\VBN\952524 cocaine\NN\3492717 administration\NN\1133281 (\-LRB-\1740 <e2>seizure</e2>\JJ\1740 kindling\NN\15101361 )\-RRB-\1740 .\.\1740
D005680_D012640 NONE All\DT\1740 of\IN\1740 these\DT\1740 positive\JJ\1740 <e1>GABA(A</e1>\NN\1740 )\-RRB-\1740 modulators\NNS\1740 suppressed\VBD\2510337 the\DT\1740 expression\NN\4679549 of\IN\1740 kindled\VBN\2764245 <e2>seizures</e2>\NNS\14081375 ,\,\1740 whereas\IN\1740 only\RB\1740 allopregnanolone\NN\1740 and\CC\1740 ganaxolone\NN\1740 inhibited\VBD\2510337 the\DT\1740 development\NN\248977 of\IN\1740 kindling\NN\15101361 .\.\1740
D011280_D012640 NONE <e1>Allopregnanolone</e1>\NN\1740 (\-LRB-\1740 3alpha-hydroxy-5alpha-pregnan-20-one\NN\1740 )\-RRB-\1740 ,\,\1740 pregnanolone\NN\1740 (\-LRB-\1740 3alpha-hydroxy-5beta-pregnan-20-one\NN\1740 )\-RRB-\1740 and\CC\1740 ganaxolone\NN\1740 (\-LRB-\1740 a\DT\13649268 synthetic\JJ\1740 derivative\NN\5802185 of\IN\1740 allopregnanolone\NN\1740 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one\CD\1740 )\-RRB-\1740 were\VBD\836236 tested\VBN\670261 for\IN\1740 their\PRP$\1740 ability\NN\4723816 to\TO\1740 suppress\VB\2510337 the\DT\1740 expression\NN\4679549 (\-LRB-\1740 anticonvulsant\JJ\1740 effect\NN\34213 )\-RRB-\1740 and\CC\1740 development\NN\248977 (\-LRB-\1740 antiepileptogenic\JJ\1740 effect\NN\34213 )\-RRB-\1740 of\IN\1740 cocaine-kindled\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 male\JJ\1740 ,\,\1740 Swiss-Webster\NN\1740 mice\NNS\2329401 .\.\1740
D011280_D012640 NONE Allopregnanolone\NN\1740 (\-LRB-\1740 <e1>3alpha-hydroxy-5alpha-pregnan-20-one</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 pregnanolone\NN\1740 (\-LRB-\1740 3alpha-hydroxy-5beta-pregnan-20-one\NN\1740 )\-RRB-\1740 and\CC\1740 ganaxolone\NN\1740 (\-LRB-\1740 a\DT\13649268 synthetic\JJ\1740 derivative\NN\5802185 of\IN\1740 allopregnanolone\NN\1740 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one\CD\1740 )\-RRB-\1740 were\VBD\836236 tested\VBN\670261 for\IN\1740 their\PRP$\1740 ability\NN\4723816 to\TO\1740 suppress\VB\2510337 the\DT\1740 expression\NN\4679549 (\-LRB-\1740 anticonvulsant\JJ\1740 effect\NN\34213 )\-RRB-\1740 and\CC\1740 development\NN\248977 (\-LRB-\1740 antiepileptogenic\JJ\1740 effect\NN\34213 )\-RRB-\1740 of\IN\1740 cocaine-kindled\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 male\JJ\1740 ,\,\1740 Swiss-Webster\NN\1740 mice\NNS\2329401 .\.\1740
D011280_D012640 NONE Allopregnanolone\NN\1740 (\-LRB-\1740 3alpha-hydroxy-5alpha-pregnan-20-one\NN\1740 )\-RRB-\1740 ,\,\1740 <e1>pregnanolone</e1>\NN\1740 (\-LRB-\1740 3alpha-hydroxy-5beta-pregnan-20-one\NN\1740 )\-RRB-\1740 and\CC\1740 ganaxolone\NN\1740 (\-LRB-\1740 a\DT\13649268 synthetic\JJ\1740 derivative\NN\5802185 of\IN\1740 allopregnanolone\NN\1740 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one\CD\1740 )\-RRB-\1740 were\VBD\836236 tested\VBN\670261 for\IN\1740 their\PRP$\1740 ability\NN\4723816 to\TO\1740 suppress\VB\2510337 the\DT\1740 expression\NN\4679549 (\-LRB-\1740 anticonvulsant\JJ\1740 effect\NN\34213 )\-RRB-\1740 and\CC\1740 development\NN\248977 (\-LRB-\1740 antiepileptogenic\JJ\1740 effect\NN\34213 )\-RRB-\1740 of\IN\1740 cocaine-kindled\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 male\JJ\1740 ,\,\1740 Swiss-Webster\NN\1740 mice\NNS\2329401 .\.\1740
D011280_D012640 NONE Allopregnanolone\NN\1740 (\-LRB-\1740 3alpha-hydroxy-5alpha-pregnan-20-one\NN\1740 )\-RRB-\1740 ,\,\1740 pregnanolone\NN\1740 (\-LRB-\1740 <e1>3alpha-hydroxy-5beta-pregnan-20-one</e1>\NN\1740 )\-RRB-\1740 and\CC\1740 ganaxolone\NN\1740 (\-LRB-\1740 a\DT\13649268 synthetic\JJ\1740 derivative\NN\5802185 of\IN\1740 allopregnanolone\NN\1740 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one\CD\1740 )\-RRB-\1740 were\VBD\836236 tested\VBN\670261 for\IN\1740 their\PRP$\1740 ability\NN\4723816 to\TO\1740 suppress\VB\2510337 the\DT\1740 expression\NN\4679549 (\-LRB-\1740 anticonvulsant\JJ\1740 effect\NN\34213 )\-RRB-\1740 and\CC\1740 development\NN\248977 (\-LRB-\1740 antiepileptogenic\JJ\1740 effect\NN\34213 )\-RRB-\1740 of\IN\1740 cocaine-kindled\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 male\JJ\1740 ,\,\1740 Swiss-Webster\NN\1740 mice\NNS\2329401 .\.\1740
D011280_D012640 NONE Allopregnanolone\NN\1740 (\-LRB-\1740 3alpha-hydroxy-5alpha-pregnan-20-one\NN\1740 )\-RRB-\1740 ,\,\1740 pregnanolone\NN\1740 (\-LRB-\1740 3alpha-hydroxy-5beta-pregnan-20-one\NN\1740 )\-RRB-\1740 and\CC\1740 ganaxolone\NN\1740 (\-LRB-\1740 a\DT\13649268 synthetic\JJ\1740 derivative\NN\5802185 of\IN\1740 <e1>allopregnanolone</e1>\NN\1740 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one\CD\1740 )\-RRB-\1740 were\VBD\836236 tested\VBN\670261 for\IN\1740 their\PRP$\1740 ability\NN\4723816 to\TO\1740 suppress\VB\2510337 the\DT\1740 expression\NN\4679549 (\-LRB-\1740 anticonvulsant\JJ\1740 effect\NN\34213 )\-RRB-\1740 and\CC\1740 development\NN\248977 (\-LRB-\1740 antiepileptogenic\JJ\1740 effect\NN\34213 )\-RRB-\1740 of\IN\1740 cocaine-kindled\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 male\JJ\1740 ,\,\1740 Swiss-Webster\NN\1740 mice\NNS\2329401 .\.\1740
D011280_D012640 NONE All\DT\1740 of\IN\1740 these\DT\1740 positive\JJ\1740 GABA(A\NN\1740 )\-RRB-\1740 modulators\NNS\1740 suppressed\VBD\2510337 the\DT\1740 expression\NN\4679549 of\IN\1740 kindled\VBN\2764245 <e2>seizures</e2>\NNS\14081375 ,\,\1740 whereas\IN\1740 only\RB\1740 <e1>allopregnanolone</e1>\NN\1740 and\CC\1740 ganaxolone\NN\1740 inhibited\VBD\2510337 the\DT\1740 development\NN\248977 of\IN\1740 kindling\NN\15101361 .\.\1740
C105051_D012640 NONE Allopregnanolone\NN\1740 (\-LRB-\1740 3alpha-hydroxy-5alpha-pregnan-20-one\NN\1740 )\-RRB-\1740 ,\,\1740 pregnanolone\NN\1740 (\-LRB-\1740 3alpha-hydroxy-5beta-pregnan-20-one\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>ganaxolone</e1>\NN\1740 (\-LRB-\1740 a\DT\13649268 synthetic\JJ\1740 derivative\NN\5802185 of\IN\1740 allopregnanolone\NN\1740 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one\CD\1740 )\-RRB-\1740 were\VBD\836236 tested\VBN\670261 for\IN\1740 their\PRP$\1740 ability\NN\4723816 to\TO\1740 suppress\VB\2510337 the\DT\1740 expression\NN\4679549 (\-LRB-\1740 anticonvulsant\JJ\1740 effect\NN\34213 )\-RRB-\1740 and\CC\1740 development\NN\248977 (\-LRB-\1740 antiepileptogenic\JJ\1740 effect\NN\34213 )\-RRB-\1740 of\IN\1740 cocaine-kindled\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 male\JJ\1740 ,\,\1740 Swiss-Webster\NN\1740 mice\NNS\2329401 .\.\1740
C105051_D012640 NONE Allopregnanolone\NN\1740 (\-LRB-\1740 3alpha-hydroxy-5alpha-pregnan-20-one\NN\1740 )\-RRB-\1740 ,\,\1740 pregnanolone\NN\1740 (\-LRB-\1740 3alpha-hydroxy-5beta-pregnan-20-one\NN\1740 )\-RRB-\1740 and\CC\1740 ganaxolone\NN\1740 (\-LRB-\1740 a\DT\13649268 synthetic\JJ\1740 derivative\NN\5802185 of\IN\1740 allopregnanolone\NN\1740 <e1>3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one</e1>\CD\1740 )\-RRB-\1740 were\VBD\836236 tested\VBN\670261 for\IN\1740 their\PRP$\1740 ability\NN\4723816 to\TO\1740 suppress\VB\2510337 the\DT\1740 expression\NN\4679549 (\-LRB-\1740 anticonvulsant\JJ\1740 effect\NN\34213 )\-RRB-\1740 and\CC\1740 development\NN\248977 (\-LRB-\1740 antiepileptogenic\JJ\1740 effect\NN\34213 )\-RRB-\1740 of\IN\1740 cocaine-kindled\JJ\1740 <e2>seizures</e2>\NNS\14081375 in\IN\13603305 male\JJ\1740 ,\,\1740 Swiss-Webster\NN\1740 mice\NNS\2329401 .\.\1740
C105051_D012640 NONE All\DT\1740 of\IN\1740 these\DT\1740 positive\JJ\1740 GABA(A\NN\1740 )\-RRB-\1740 modulators\NNS\1740 suppressed\VBD\2510337 the\DT\1740 expression\NN\4679549 of\IN\1740 kindled\VBN\2764245 <e2>seizures</e2>\NNS\14081375 ,\,\1740 whereas\IN\1740 only\RB\1740 allopregnanolone\NN\1740 and\CC\1740 <e1>ganaxolone</e1>\NN\1740 inhibited\VBD\2510337 the\DT\1740 development\NN\248977 of\IN\1740 kindling\NN\15101361 .\.\1740
16904497
D013256_D011128 NONE <e2>Cauda\JJ\1740 equina\NN\1740 syndrome</e2>\NN\5870365 after\IN\1740 epidural\JJ\1740 <e1>steroid</e1>\NN\14727670 injection\NN\320852 :\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 .\.\1740
D013256_D011843 NONE OBJECTIVE\NN\5980875 :\:\1740 Conventional\JJ\1740 treatment\NN\654885 methods\NNS\5616786 of\IN\1740 lumbusacral\JJ\1740 <e2>radiculopathy</e2>\NN\1740 are\VBP\836236 physical\JJ\1740 therapy\NN\657604 ,\,\1740 epidural\JJ\1740 <e1>steroid</e1>\NN\14727670 injections\NNS\320852 ,\,\1740 oral\JJ\1740 medications\NNS\3247620 ,\,\1740 and\CC\1740 spinal\JJ\1740 manipulative\NN\1740 therapy\NN\657604 .\.\1740
D014221_D011128 NONE The\DT\1740 following\VBG\1835496 case\NN\7283608 is\VBZ\836236 a\DT\13649268 report\NN\6470073 of\IN\1740 <e2>cauda\JJ\1740 equina\NN\1740 syndrome</e2>\NN\5870365 possibly\RB\1740 caused\VBN\1617192 by\IN\1740 epidural\JJ\1740 injection\NN\320852 of\IN\1740 <e1>triamcinolone</e1>\NN\14751417 and\CC\1740 bupivacaine\NN\1740 .\.\1740
D002045_D011128 CID The\DT\1740 following\VBG\1835496 case\NN\7283608 is\VBZ\836236 a\DT\13649268 report\NN\6470073 of\IN\1740 <e2>cauda\JJ\1740 equina\NN\1740 syndrome</e2>\NN\5870365 possibly\RB\1740 caused\VBN\1617192 by\IN\1740 epidural\JJ\1740 injection\NN\320852 of\IN\1740 triamcinolone\NN\14751417 and\CC\1740 <e1>bupivacaine</e1>\NN\1740 .\.\1740
D013256_D017116 NONE CLINICAL\NN\1740 FEATURES\NN\5849040 :\:\1740 A\DT\13649268 50-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 <e2>low\JJ\1740 back\NN\5220461 and\CC\1740 right\JJ\1740 leg\NN\5560244 pain</e2>\NN\14299637 was\VBD\836236 scheduled\VBN\704690 for\IN\1740 epidural\JJ\1740 <e1>steroid</e1>\NN\14727670 injection\NN\320852 .\.\1740
D013256_D010146 NONE CLINICAL\NN\1740 FEATURES\NN\5849040 :\:\1740 A\DT\13649268 50-year-old\JJ\1740 woman\NN\9605289 with\IN\1740 <e2>low\JJ\1740 back\NN\5220461 and\CC\1740 right\JJ\1740 leg\NN\5560244 pain</e2>\NN\14299637 was\VBD\836236 scheduled\VBN\704690 for\IN\1740 epidural\JJ\1740 <e1>steroid</e1>\NN\14727670 injection\NN\320852 .\.\1740
D013256_D009422 NONE Clinical\JJ\1740 examination\NN\633864 and\CC\1740 continued\VBD\2367363 vigilance\NN\5650579 for\IN\1740 <e2>neurologic\JJ\1740 deterioration</e2>\NN\14560612 after\IN\1740 epidural\JJ\1740 <e1>steroid</e1>\NN\14727670 injections\NNS\320852 is\VBZ\836236 important\JJ\1740 .\.\1740
12596116
D015282_D000860 NONE <e1>Octreotide-induced</e1>\JJ\1740 <e2>hypoxemia</e2>\NN\1740 and\CC\1740 pulmonary\JJ\1740 hypertension\NN\14057371 in\IN\13603305 premature\JJ\1740 neonates\NNS\9827683 .\.\1740
D015282_D006976 CID <e1>Octreotide-induced</e1>\JJ\1740 hypoxemia\NN\1740 and\CC\1740 <e2>pulmonary\JJ\1740 hypertension</e2>\NN\14057371 in\IN\13603305 premature\JJ\1740 neonates\NNS\9827683 .\.\1740
D015282_D006976 CID <e2>Pulmonary\JJ\1740 hypertension</e2>\NN\14057371 developed\VBD\1753788 after\IN\1740 administration\NN\1133281 of\IN\1740 a\DT\13649268 somatostatin\NN\1740 analogue\NN\4743605 ,\,\1740 <e1>octreotide</e1>\NN\1740 ,\,\1740 to\TO\1740 enhance\VB\227165 resolution\NN\6470073 of\IN\1740 the\DT\1740 fistula\NN\14253124 .\.\1740
D015282_D005402 NONE Pulmonary\JJ\1740 hypertension\NN\14057371 developed\VBD\1753788 after\IN\1740 administration\NN\1133281 of\IN\1740 a\DT\13649268 somatostatin\NN\1740 analogue\NN\4743605 ,\,\1740 <e1>octreotide</e1>\NN\1740 ,\,\1740 to\TO\1740 enhance\VB\227165 resolution\NN\6470073 of\IN\1740 the\DT\1740 <e2>fistula</e2>\NN\14253124 .\.\1740
16337777
D010862_D004827 NONE Investigation\NN\5797597 of\IN\1740 mitochondrial\JJ\1740 involvement\NN\1080366 in\IN\13603305 the\DT\1740 experimental\JJ\1740 model\NN\5888929 of\IN\1740 <e2>epilepsy</e2>\NN\14085708 induced\VBN\1627355 by\IN\1740 <e1>pilocarpine</e1>\NN\14712692 .\.\1740
D010862_D013226 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 investigated\VBD\644583 whether\IN\1740 increased\VBN\169651 generation\NN\7942152 of\IN\1740 FR\NN\14625458 during\IN\1740 <e2>status\NN\24720 epilepticus</e2>\NN\1740 would\MD\1740 be\VB\836236 sufficient\JJ\1740 to\TO\1740 provoke\VB\1617192 abnormalities\NNS\14034177 in\IN\13603305 mtDNA\NN\1740 and\CC\1740 in\IN\13603305 the\DT\1740 expression\NN\4679549 and\CC\1740 activity\NN\30358 of\IN\1740 cytochrome\NN\14888884 c\NN\13714184 oxidase\NN\14732946 (\-LRB-\1740 CCO\NN\1740 )\-RRB-\1740 ,\,\1740 complex\NN\5869584 IV\CD\13741022 of\IN\1740 the\DT\1740 respiratory\JJ\1740 chain\NN\8457976 ,\,\1740 in\IN\13603305 the\DT\1740 chronic\JJ\1740 phase\NN\15113229 of\IN\1740 the\DT\1740 <e1>pilocarpine</e1>\NN\14712692 model\NN\5888929 of\IN\1740 temporal\JJ\1740 lobe\JJ\1740 epilepsy\NN\14085708 .\.\1740
D010862_D004833 CID In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 investigated\VBD\644583 whether\IN\1740 increased\VBN\169651 generation\NN\7942152 of\IN\1740 FR\NN\14625458 during\IN\1740 status\NN\24720 epilepticus\NN\1740 would\MD\1740 be\VB\836236 sufficient\JJ\1740 to\TO\1740 provoke\VB\1617192 abnormalities\NNS\14034177 in\IN\13603305 mtDNA\NN\1740 and\CC\1740 in\IN\13603305 the\DT\1740 expression\NN\4679549 and\CC\1740 activity\NN\30358 of\IN\1740 cytochrome\NN\14888884 c\NN\13714184 oxidase\NN\14732946 (\-LRB-\1740 CCO\NN\1740 )\-RRB-\1740 ,\,\1740 complex\NN\5869584 IV\CD\13741022 of\IN\1740 the\DT\1740 respiratory\JJ\1740 chain\NN\8457976 ,\,\1740 in\IN\13603305 the\DT\1740 chronic\JJ\1740 phase\NN\15113229 of\IN\1740 the\DT\1740 <e1>pilocarpine</e1>\NN\14712692 model\NN\5888929 of\IN\1740 <e2>temporal\JJ\1740 lobe\JJ\1740 epilepsy</e2>\NN\14085708 .\.\1740
18503483
D016559_D020968 CID Recovery\NN\7357388 of\IN\1740 <e1>tacrolimus-associated</e1>\JJ\1740 <e2>brachial\JJ\1740 neuritis</e2>\NN\14336539 after\IN\1740 conversion\NN\7359599 to\TO\1740 everolimus\NN\1740 in\IN\13603305 a\DT\13649268 pediatric\JJ\1740 renal\JJ\1740 transplant\NN\5267548 recipient\NN\9764201 --\:\1740 case\NN\7283608 report\NN\6470073 and\CC\1740 review\NN\5733583 of\IN\1740 the\DT\1740 literature\NN\6362953 .\.\1740
C107135_D020968 NONE Recovery\NN\7357388 of\IN\1740 tacrolimus-associated\JJ\1740 <e2>brachial\JJ\1740 neuritis</e2>\NN\14336539 after\IN\1740 conversion\NN\7359599 to\TO\1740 <e1>everolimus</e1>\NN\1740 in\IN\13603305 a\DT\13649268 pediatric\JJ\1740 renal\JJ\1740 transplant\NN\5267548 recipient\NN\9764201 --\:\1740 case\NN\7283608 report\NN\6470073 and\CC\1740 review\NN\5733583 of\IN\1740 the\DT\1740 literature\NN\6362953 .\.\1740
11334364
D000082_D009336 CID In\FW\13603305 vivo\FW\1740 protection\NN\407535 of\IN\1740 dna\JJ\1740 damage\NN\7296428 associated\VBN\628491 apoptotic\JJ\1740 and\CC\1740 <e2>necrotic</e2>\JJ\1740 cell\NN\3080309 deaths\NNS\7296428 during\IN\1740 <e1>acetaminophen-induced</e1>\JJ\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone-induced\JJ\1740 lung\NN\5528060 toxicity\NN\13576101 and\CC\1740 doxorubicin-induced\JJ\1740 cardiotoxicity\NN\1740 by\IN\1740 a\DT\13649268 novel\JJ\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 .\.\1740
D000082_D009336 CID Interestingly\RB\1740 ,\,\1740 all\PDT\1740 the\DT\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 ,\,\1740 <e1>AAP</e1>\NNP\1740 ,\,\1740 AMI\NN\1740 and\CC\1740 DOX\NN\1740 induced\VBD\1627355 apoptotic\JJ\1740 death\NN\7296428 in\IN\13603305 addition\NN\3081021 to\TO\1740 <e2>necrosis</e2>\NN\11444117 in\IN\13603305 the\DT\1740 respective\JJ\1740 organs\NNS\7649854 which\WDT\1740 was\VBD\836236 very\RB\1740 effectively\RB\1740 blocked\VBN\1476483 by\IN\1740 GSPE\NN\1740 .\.\1740
D000082_D007674 CID In\FW\13603305 vivo\FW\1740 protection\NN\407535 of\IN\1740 dna\JJ\1740 damage\NN\7296428 associated\VBN\628491 apoptotic\JJ\1740 and\CC\1740 necrotic\JJ\1740 cell\NN\3080309 deaths\NNS\7296428 during\IN\1740 <e1>acetaminophen-induced</e1>\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 ,\,\1740 amiodarone-induced\JJ\1740 lung\NN\5528060 toxicity\NN\13576101 and\CC\1740 doxorubicin-induced\JJ\1740 cardiotoxicity\NN\1740 by\IN\1740 a\DT\13649268 novel\JJ\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 .\.\1740
D000082_D007674 CID This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 (\-LRB-\1740 GSPE\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 <e1>acetaminophen</e1>\RB\1740 (AAP)-induced\VBN\1740 <e2>nephrotoxicity</e2>\NN\1740 ,\,\1740 amiodarone\JJ\1740 (AMI)-induced\VBN\1740 lung\NN\5528060 toxicity\NN\13576101 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 (DOX)-induced\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D000082_D007674 CID This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 (\-LRB-\1740 GSPE\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 acetaminophen\RB\1740 <e1>(AAP)-induced</e1>\VBN\1740 <e2>nephrotoxicity</e2>\NN\1740 ,\,\1740 amiodarone\JJ\1740 (AMI)-induced\VBN\1740 lung\NN\5528060 toxicity\NN\13576101 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 (DOX)-induced\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D000082_D008171 NONE In\FW\13603305 vivo\FW\1740 protection\NN\407535 of\IN\1740 dna\JJ\1740 damage\NN\7296428 associated\VBN\628491 apoptotic\JJ\1740 and\CC\1740 necrotic\JJ\1740 cell\NN\3080309 deaths\NNS\7296428 during\IN\1740 <e1>acetaminophen-induced</e1>\JJ\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone-induced\JJ\1740 <e2>lung\NN\5528060 toxicity</e2>\NN\13576101 and\CC\1740 doxorubicin-induced\JJ\1740 cardiotoxicity\NN\1740 by\IN\1740 a\DT\13649268 novel\JJ\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 .\.\1740
D000082_D008171 NONE This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 (\-LRB-\1740 GSPE\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 <e1>acetaminophen</e1>\RB\1740 (AAP)-induced\VBN\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone\JJ\1740 (AMI)-induced\VBN\1740 <e2>lung\NN\5528060 toxicity</e2>\NN\13576101 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 (DOX)-induced\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D000082_D008171 NONE This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 (\-LRB-\1740 GSPE\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 acetaminophen\RB\1740 <e1>(AAP)-induced</e1>\VBN\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone\JJ\1740 (AMI)-induced\VBN\1740 <e2>lung\NN\5528060 toxicity</e2>\NN\13576101 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 (DOX)-induced\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D000082_D066126 NONE In\FW\13603305 vivo\FW\1740 protection\NN\407535 of\IN\1740 dna\JJ\1740 damage\NN\7296428 associated\VBN\628491 apoptotic\JJ\1740 and\CC\1740 necrotic\JJ\1740 cell\NN\3080309 deaths\NNS\7296428 during\IN\1740 <e1>acetaminophen-induced</e1>\JJ\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone-induced\JJ\1740 lung\NN\5528060 toxicity\NN\13576101 and\CC\1740 doxorubicin-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 by\IN\1740 a\DT\13649268 novel\JJ\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 .\.\1740
D000082_D066126 NONE This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 (\-LRB-\1740 GSPE\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 <e1>acetaminophen</e1>\RB\1740 (AAP)-induced\VBN\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone\JJ\1740 (AMI)-induced\VBN\1740 lung\NN\5528060 toxicity\NN\13576101 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 (DOX)-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D000082_D066126 NONE This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 (\-LRB-\1740 GSPE\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 acetaminophen\RB\1740 <e1>(AAP)-induced</e1>\VBN\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone\JJ\1740 (AMI)-induced\VBN\1740 lung\NN\5528060 toxicity\NN\13576101 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 (DOX)-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D000638_D009336 CID In\FW\13603305 vivo\FW\1740 protection\NN\407535 of\IN\1740 dna\JJ\1740 damage\NN\7296428 associated\VBN\628491 apoptotic\JJ\1740 and\CC\1740 <e2>necrotic</e2>\JJ\1740 cell\NN\3080309 deaths\NNS\7296428 during\IN\1740 acetaminophen-induced\JJ\1740 nephrotoxicity\NN\1740 ,\,\1740 <e1>amiodarone-induced</e1>\JJ\1740 lung\NN\5528060 toxicity\NN\13576101 and\CC\1740 doxorubicin-induced\JJ\1740 cardiotoxicity\NN\1740 by\IN\1740 a\DT\13649268 novel\JJ\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 .\.\1740
D000638_D009336 CID Interestingly\RB\1740 ,\,\1740 all\PDT\1740 the\DT\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 ,\,\1740 AAP\NNP\1740 ,\,\1740 <e1>AMI</e1>\NN\1740 and\CC\1740 DOX\NN\1740 induced\VBD\1627355 apoptotic\JJ\1740 death\NN\7296428 in\IN\13603305 addition\NN\3081021 to\TO\1740 <e2>necrosis</e2>\NN\11444117 in\IN\13603305 the\DT\1740 respective\JJ\1740 organs\NNS\7649854 which\WDT\1740 was\VBD\836236 very\RB\1740 effectively\RB\1740 blocked\VBN\1476483 by\IN\1740 GSPE\NN\1740 .\.\1740
D000638_D007674 NONE In\FW\13603305 vivo\FW\1740 protection\NN\407535 of\IN\1740 dna\JJ\1740 damage\NN\7296428 associated\VBN\628491 apoptotic\JJ\1740 and\CC\1740 necrotic\JJ\1740 cell\NN\3080309 deaths\NNS\7296428 during\IN\1740 acetaminophen-induced\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 ,\,\1740 <e1>amiodarone-induced</e1>\JJ\1740 lung\NN\5528060 toxicity\NN\13576101 and\CC\1740 doxorubicin-induced\JJ\1740 cardiotoxicity\NN\1740 by\IN\1740 a\DT\13649268 novel\JJ\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 .\.\1740
D000638_D007674 NONE This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 (\-LRB-\1740 GSPE\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 acetaminophen\RB\1740 (AAP)-induced\VBN\1740 <e2>nephrotoxicity</e2>\NN\1740 ,\,\1740 <e1>amiodarone</e1>\JJ\1740 (AMI)-induced\VBN\1740 lung\NN\5528060 toxicity\NN\13576101 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 (DOX)-induced\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D000638_D007674 NONE This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 (\-LRB-\1740 GSPE\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 acetaminophen\RB\1740 (AAP)-induced\VBN\1740 <e2>nephrotoxicity</e2>\NN\1740 ,\,\1740 amiodarone\JJ\1740 <e1>(AMI)-induced</e1>\VBN\1740 lung\NN\5528060 toxicity\NN\13576101 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 (DOX)-induced\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D000638_D008171 CID In\FW\13603305 vivo\FW\1740 protection\NN\407535 of\IN\1740 dna\JJ\1740 damage\NN\7296428 associated\VBN\628491 apoptotic\JJ\1740 and\CC\1740 necrotic\JJ\1740 cell\NN\3080309 deaths\NNS\7296428 during\IN\1740 acetaminophen-induced\JJ\1740 nephrotoxicity\NN\1740 ,\,\1740 <e1>amiodarone-induced</e1>\JJ\1740 <e2>lung\NN\5528060 toxicity</e2>\NN\13576101 and\CC\1740 doxorubicin-induced\JJ\1740 cardiotoxicity\NN\1740 by\IN\1740 a\DT\13649268 novel\JJ\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 .\.\1740
D000638_D008171 CID This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 (\-LRB-\1740 GSPE\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 acetaminophen\RB\1740 (AAP)-induced\VBN\1740 nephrotoxicity\NN\1740 ,\,\1740 <e1>amiodarone</e1>\JJ\1740 (AMI)-induced\VBN\1740 <e2>lung\NN\5528060 toxicity</e2>\NN\13576101 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 (DOX)-induced\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D000638_D008171 CID This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 (\-LRB-\1740 GSPE\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 acetaminophen\RB\1740 (AAP)-induced\VBN\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone\JJ\1740 <e1>(AMI)-induced</e1>\VBN\1740 <e2>lung\NN\5528060 toxicity</e2>\NN\13576101 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 (DOX)-induced\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D000638_D066126 NONE In\FW\13603305 vivo\FW\1740 protection\NN\407535 of\IN\1740 dna\JJ\1740 damage\NN\7296428 associated\VBN\628491 apoptotic\JJ\1740 and\CC\1740 necrotic\JJ\1740 cell\NN\3080309 deaths\NNS\7296428 during\IN\1740 acetaminophen-induced\JJ\1740 nephrotoxicity\NN\1740 ,\,\1740 <e1>amiodarone-induced</e1>\JJ\1740 lung\NN\5528060 toxicity\NN\13576101 and\CC\1740 doxorubicin-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 by\IN\1740 a\DT\13649268 novel\JJ\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 .\.\1740
D000638_D066126 NONE This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 (\-LRB-\1740 GSPE\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 acetaminophen\RB\1740 (AAP)-induced\VBN\1740 nephrotoxicity\NN\1740 ,\,\1740 <e1>amiodarone</e1>\JJ\1740 (AMI)-induced\VBN\1740 lung\NN\5528060 toxicity\NN\13576101 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 (DOX)-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D000638_D066126 NONE This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 (\-LRB-\1740 GSPE\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 acetaminophen\RB\1740 (AAP)-induced\VBN\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone\JJ\1740 <e1>(AMI)-induced</e1>\VBN\1740 lung\NN\5528060 toxicity\NN\13576101 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 (DOX)-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D004317_D009336 CID In\FW\13603305 vivo\FW\1740 protection\NN\407535 of\IN\1740 dna\JJ\1740 damage\NN\7296428 associated\VBN\628491 apoptotic\JJ\1740 and\CC\1740 <e2>necrotic</e2>\JJ\1740 cell\NN\3080309 deaths\NNS\7296428 during\IN\1740 acetaminophen-induced\JJ\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone-induced\JJ\1740 lung\NN\5528060 toxicity\NN\13576101 and\CC\1740 <e1>doxorubicin-induced</e1>\JJ\1740 cardiotoxicity\NN\1740 by\IN\1740 a\DT\13649268 novel\JJ\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 .\.\1740
D004317_D009336 CID Interestingly\RB\1740 ,\,\1740 all\PDT\1740 the\DT\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 ,\,\1740 AAP\NNP\1740 ,\,\1740 AMI\NN\1740 and\CC\1740 <e1>DOX</e1>\NN\1740 induced\VBD\1627355 apoptotic\JJ\1740 death\NN\7296428 in\IN\13603305 addition\NN\3081021 to\TO\1740 <e2>necrosis</e2>\NN\11444117 in\IN\13603305 the\DT\1740 respective\JJ\1740 organs\NNS\7649854 which\WDT\1740 was\VBD\836236 very\RB\1740 effectively\RB\1740 blocked\VBN\1476483 by\IN\1740 GSPE\NN\1740 .\.\1740
D004317_D007674 NONE In\FW\13603305 vivo\FW\1740 protection\NN\407535 of\IN\1740 dna\JJ\1740 damage\NN\7296428 associated\VBN\628491 apoptotic\JJ\1740 and\CC\1740 necrotic\JJ\1740 cell\NN\3080309 deaths\NNS\7296428 during\IN\1740 acetaminophen-induced\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 ,\,\1740 amiodarone-induced\JJ\1740 lung\NN\5528060 toxicity\NN\13576101 and\CC\1740 <e1>doxorubicin-induced</e1>\JJ\1740 cardiotoxicity\NN\1740 by\IN\1740 a\DT\13649268 novel\JJ\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 .\.\1740
D004317_D007674 NONE This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 (\-LRB-\1740 GSPE\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 acetaminophen\RB\1740 (AAP)-induced\VBN\1740 <e2>nephrotoxicity</e2>\NN\1740 ,\,\1740 amiodarone\JJ\1740 (AMI)-induced\VBN\1740 lung\NN\5528060 toxicity\NN\13576101 ,\,\1740 and\CC\1740 <e1>doxorubicin</e1>\NN\2716866 (DOX)-induced\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D004317_D007674 NONE This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 (\-LRB-\1740 GSPE\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 acetaminophen\RB\1740 (AAP)-induced\VBN\1740 <e2>nephrotoxicity</e2>\NN\1740 ,\,\1740 amiodarone\JJ\1740 (AMI)-induced\VBN\1740 lung\NN\5528060 toxicity\NN\13576101 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 <e1>(DOX)-induced</e1>\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D004317_D008171 NONE In\FW\13603305 vivo\FW\1740 protection\NN\407535 of\IN\1740 dna\JJ\1740 damage\NN\7296428 associated\VBN\628491 apoptotic\JJ\1740 and\CC\1740 necrotic\JJ\1740 cell\NN\3080309 deaths\NNS\7296428 during\IN\1740 acetaminophen-induced\JJ\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone-induced\JJ\1740 <e2>lung\NN\5528060 toxicity</e2>\NN\13576101 and\CC\1740 <e1>doxorubicin-induced</e1>\JJ\1740 cardiotoxicity\NN\1740 by\IN\1740 a\DT\13649268 novel\JJ\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 .\.\1740
D004317_D008171 NONE This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 (\-LRB-\1740 GSPE\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 acetaminophen\RB\1740 (AAP)-induced\VBN\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone\JJ\1740 (AMI)-induced\VBN\1740 <e2>lung\NN\5528060 toxicity</e2>\NN\13576101 ,\,\1740 and\CC\1740 <e1>doxorubicin</e1>\NN\2716866 (DOX)-induced\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D004317_D008171 NONE This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 (\-LRB-\1740 GSPE\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 acetaminophen\RB\1740 (AAP)-induced\VBN\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone\JJ\1740 (AMI)-induced\VBN\1740 <e2>lung\NN\5528060 toxicity</e2>\NN\13576101 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 <e1>(DOX)-induced</e1>\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D004317_D066126 CID In\FW\13603305 vivo\FW\1740 protection\NN\407535 of\IN\1740 dna\JJ\1740 damage\NN\7296428 associated\VBN\628491 apoptotic\JJ\1740 and\CC\1740 necrotic\JJ\1740 cell\NN\3080309 deaths\NNS\7296428 during\IN\1740 acetaminophen-induced\JJ\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone-induced\JJ\1740 lung\NN\5528060 toxicity\NN\13576101 and\CC\1740 <e1>doxorubicin-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 by\IN\1740 a\DT\13649268 novel\JJ\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 .\.\1740
D004317_D066126 CID This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 (\-LRB-\1740 GSPE\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 acetaminophen\RB\1740 (AAP)-induced\VBN\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone\JJ\1740 (AMI)-induced\VBN\1740 lung\NN\5528060 toxicity\NN\13576101 ,\,\1740 and\CC\1740 <e1>doxorubicin</e1>\NN\2716866 (DOX)-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
D004317_D066126 CID This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 (\-LRB-\1740 GSPE\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 acetaminophen\RB\1740 (AAP)-induced\VBN\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone\JJ\1740 (AMI)-induced\VBN\1740 lung\NN\5528060 toxicity\NN\13576101 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 <e1>(DOX)-induced</e1>\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
C511402_D009336 NONE In\FW\13603305 vivo\FW\1740 protection\NN\407535 of\IN\1740 dna\JJ\1740 damage\NN\7296428 associated\VBN\628491 apoptotic\JJ\1740 and\CC\1740 <e2>necrotic</e2>\JJ\1740 cell\NN\3080309 deaths\NNS\7296428 during\IN\1740 acetaminophen-induced\JJ\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone-induced\JJ\1740 lung\NN\5528060 toxicity\NN\13576101 and\CC\1740 doxorubicin-induced\JJ\1740 cardiotoxicity\NN\1740 by\IN\1740 a\DT\13649268 novel\JJ\1740 <e1>IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract</e1>\NN\14589223 .\.\1740
C511402_D009336 NONE Interestingly\RB\1740 ,\,\1740 all\PDT\1740 the\DT\1740 drugs\NNS\14778436 ,\,\1740 such\JJ\1740 as\IN\14622893 ,\,\1740 AAP\NNP\1740 ,\,\1740 AMI\NN\1740 and\CC\1740 DOX\NN\1740 induced\VBD\1627355 apoptotic\JJ\1740 death\NN\7296428 in\IN\13603305 addition\NN\3081021 to\TO\1740 <e2>necrosis</e2>\NN\11444117 in\IN\13603305 the\DT\1740 respective\JJ\1740 organs\NNS\7649854 which\WDT\1740 was\VBD\836236 very\RB\1740 effectively\RB\1740 blocked\VBN\1476483 by\IN\1740 <e1>GSPE</e1>\NN\1740 .\.\1740
C511402_D007674 NONE In\FW\13603305 vivo\FW\1740 protection\NN\407535 of\IN\1740 dna\JJ\1740 damage\NN\7296428 associated\VBN\628491 apoptotic\JJ\1740 and\CC\1740 necrotic\JJ\1740 cell\NN\3080309 deaths\NNS\7296428 during\IN\1740 acetaminophen-induced\JJ\1740 <e2>nephrotoxicity</e2>\NN\1740 ,\,\1740 amiodarone-induced\JJ\1740 lung\NN\5528060 toxicity\NN\13576101 and\CC\1740 doxorubicin-induced\JJ\1740 cardiotoxicity\NN\1740 by\IN\1740 a\DT\13649268 novel\JJ\1740 <e1>IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract</e1>\NN\14589223 .\.\1740
C511402_D007674 NONE This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 <e1>IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract</e1>\NN\14589223 (\-LRB-\1740 GSPE\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 acetaminophen\RB\1740 (AAP)-induced\VBN\1740 <e2>nephrotoxicity</e2>\NN\1740 ,\,\1740 amiodarone\JJ\1740 (AMI)-induced\VBN\1740 lung\NN\5528060 toxicity\NN\13576101 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 (DOX)-induced\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
C511402_D007674 NONE This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 (\-LRB-\1740 <e1>GSPE</e1>\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 acetaminophen\RB\1740 (AAP)-induced\VBN\1740 <e2>nephrotoxicity</e2>\NN\1740 ,\,\1740 amiodarone\JJ\1740 (AMI)-induced\VBN\1740 lung\NN\5528060 toxicity\NN\13576101 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 (DOX)-induced\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
C511402_D008171 NONE In\FW\13603305 vivo\FW\1740 protection\NN\407535 of\IN\1740 dna\JJ\1740 damage\NN\7296428 associated\VBN\628491 apoptotic\JJ\1740 and\CC\1740 necrotic\JJ\1740 cell\NN\3080309 deaths\NNS\7296428 during\IN\1740 acetaminophen-induced\JJ\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone-induced\JJ\1740 <e2>lung\NN\5528060 toxicity</e2>\NN\13576101 and\CC\1740 doxorubicin-induced\JJ\1740 cardiotoxicity\NN\1740 by\IN\1740 a\DT\13649268 novel\JJ\1740 <e1>IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract</e1>\NN\14589223 .\.\1740
C511402_D008171 NONE This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 <e1>IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract</e1>\NN\14589223 (\-LRB-\1740 GSPE\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 acetaminophen\RB\1740 (AAP)-induced\VBN\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone\JJ\1740 (AMI)-induced\VBN\1740 <e2>lung\NN\5528060 toxicity</e2>\NN\13576101 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 (DOX)-induced\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
C511402_D008171 NONE This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 (\-LRB-\1740 <e1>GSPE</e1>\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 acetaminophen\RB\1740 (AAP)-induced\VBN\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone\JJ\1740 (AMI)-induced\VBN\1740 <e2>lung\NN\5528060 toxicity</e2>\NN\13576101 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 (DOX)-induced\JJ\1740 cardiotoxicity\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
C511402_D066126 NONE In\FW\13603305 vivo\FW\1740 protection\NN\407535 of\IN\1740 dna\JJ\1740 damage\NN\7296428 associated\VBN\628491 apoptotic\JJ\1740 and\CC\1740 necrotic\JJ\1740 cell\NN\3080309 deaths\NNS\7296428 during\IN\1740 acetaminophen-induced\JJ\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone-induced\JJ\1740 lung\NN\5528060 toxicity\NN\13576101 and\CC\1740 doxorubicin-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 by\IN\1740 a\DT\13649268 novel\JJ\1740 <e1>IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract</e1>\NN\14589223 .\.\1740
C511402_D066126 NONE This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 <e1>IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract</e1>\NN\14589223 (\-LRB-\1740 GSPE\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 acetaminophen\RB\1740 (AAP)-induced\VBN\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone\JJ\1740 (AMI)-induced\VBN\1740 lung\NN\5528060 toxicity\NN\13576101 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 (DOX)-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
C511402_D066126 NONE This\DT\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 ability\NN\4723816 of\IN\1740 IH636\NN\1740 grape\NN\7705931 seed\NN\13134947 proanthocyanidin\NN\1740 extract\NN\14589223 (\-LRB-\1740 <e1>GSPE</e1>\NN\1740 )\-RRB-\1740 to\TO\1740 prevent\VB\1740 acetaminophen\RB\1740 (AAP)-induced\VBN\1740 nephrotoxicity\NN\1740 ,\,\1740 amiodarone\JJ\1740 (AMI)-induced\VBN\1740 lung\NN\5528060 toxicity\NN\13576101 ,\,\1740 and\CC\1740 doxorubicin\NN\2716866 (DOX)-induced\JJ\1740 <e2>cardiotoxicity</e2>\NN\1740 in\IN\13603305 mice\NNS\2329401 .\.\1740
C511402_D017695 NONE Histopathological\JJ\1740 examination\NN\633864 of\IN\1740 kidney\NN\5333259 ,\,\1740 heart\NN\5919034 and\CC\1740 lung\NN\5528060 sections\NNS\7020895 revealed\VBD\2137132 moderate\JJ\1740 to\TO\1740 massive\JJ\1740 <e2>tissue\NN\5220461 damage</e2>\NN\7296428 with\IN\1740 a\DT\13649268 variety\NN\7951464 of\IN\1740 morphological\JJ\1740 aberrations\NNS\14501726 by\IN\1740 all\PDT\1740 the\DT\1740 three\CD\13741022 drugs\NNS\14778436 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 <e1>GSPE</e1>\NN\1740 preexposure\NN\1740 than\IN\1740 in\IN\13603305 its\PRP$\6125041 presence\NN\13954253 .\.\1740
19346865
D008795_D001927 CID Reversible\JJ\1740 <e2>inferior\JJ\1740 colliculus\NN\1740 lesion</e2>\NN\14204950 in\IN\13603305 <e1>metronidazole-induced</e1>\JJ\1740 encephalopathy\JJ\1740 :\:\1740 magnetic\JJ\1740 resonance\NN\11419404 findings\NNS\7951464 on\IN\1740 diffusion-weighted\JJ\1740 and\CC\1740 fluid\NN\19613 attenuated\VBN\224901 inversion\NN\11425580 recovery\NN\7357388 imaging\NN\5765159 .\.\1740
D008795_D001927 CID Reversible\JJ\1740 inferior\JJ\1740 colliculus\NN\1740 lesion\NN\14204950 in\IN\13603305 <e1>metronidazole-induced</e1>\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 :\:\1740 magnetic\JJ\1740 resonance\NN\11419404 findings\NNS\7951464 on\IN\1740 diffusion-weighted\JJ\1740 and\CC\1740 fluid\NN\19613 attenuated\VBN\224901 inversion\NN\11425580 recovery\NN\7357388 imaging\NN\5765159 .\.\1740
D008795_D001927 CID OBJECTIVE\NN\5980875 :\:\1740 This\DT\1740 is\VBZ\836236 to\TO\1740 present\VB\2137132 reversible\JJ\1740 <e2>inferior\JJ\1740 colliculus\NN\1740 lesions</e2>\NNS\14204950 in\IN\13603305 <e1>metronidazole-induced</e1>\JJ\1740 encephalopathy\JJ\1740 ,\,\1740 to\TO\1740 focus\VB\628491 on\IN\1740 the\DT\1740 diffusion-weighted\JJ\1740 imaging\NN\5765159 (\-LRB-\1740 DWI\NN\1740 )\-RRB-\1740 and\CC\1740 fluid\NN\19613 attenuated\VBN\224901 inversion\NN\11425580 recovery\NN\7357388 (\-LRB-\1740 FLAIR\NN\5624042 )\-RRB-\1740 imaging\NN\5765159 .\.\1740
D008795_D001927 CID OBJECTIVE\NN\5980875 :\:\1740 This\DT\1740 is\VBZ\836236 to\TO\1740 present\VB\2137132 reversible\JJ\1740 inferior\JJ\1740 colliculus\NN\1740 lesions\NNS\14204950 in\IN\13603305 <e1>metronidazole-induced</e1>\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 ,\,\1740 to\TO\1740 focus\VB\628491 on\IN\1740 the\DT\1740 diffusion-weighted\JJ\1740 imaging\NN\5765159 (\-LRB-\1740 DWI\NN\1740 )\-RRB-\1740 and\CC\1740 fluid\NN\19613 attenuated\VBN\224901 inversion\NN\11425580 recovery\NN\7357388 (\-LRB-\1740 FLAIR\NN\5624042 )\-RRB-\1740 imaging\NN\5765159 .\.\1740
D008795_D001927 CID MATERIALS\NNS\19613 AND\CC\1740 METHODS\NNS\5616786 :\:\1740 From\IN\1740 November\NNP\15209706 2005\CD\1740 to\IN\1740 September\NNP\15209706 2007\CD\1740 ,\,\1740 8\CD\13741022 patients\NNS\9898892 (\-LRB-\1740 5\CD\13741022 men\NNS\8208016 and\CC\1740 3\CD\13741022 women\NNS\9605289 )\-RRB-\1740 were\VBD\836236 diagnosed\VBN\644583 as\IN\14622893 having\VBG\2108377 <e1>metronidazole-induced</e1>\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 (\-LRB-\1740 age\NN\4916342 range\NN\5123416 ;\:\1740 43\CD\1740 -\SYM\1740 78\CD\13745420 years\NNS\15144371 )\-RRB-\1740 .\.\1740
D008795_D001927 CID CONCLUSIONS\NNS\5837957 :\:\1740 Reversible\JJ\1740 <e2>inferior\JJ\1740 colliculus\NN\1740 lesions</e2>\NNS\14204950 could\MD\1740 be\VB\836236 considered\VBN\689344 as\IN\14622893 the\DT\1740 characteristic\NN\5849040 for\IN\1740 <e1>metronidazole-induced</e1>\JJ\1740 encephalopathy\JJ\1740 ,\,\1740 next\RB\1740 to\IN\1740 the\DT\1740 dentate\NN\1740 nucleus\NN\5445668 involvement\NN\1080366 .\.\1740
D008795_D001927 CID CONCLUSIONS\NNS\5837957 :\:\1740 Reversible\JJ\1740 inferior\JJ\1740 colliculus\NN\1740 lesions\NNS\14204950 could\MD\1740 be\VB\836236 considered\VBN\689344 as\IN\14622893 the\DT\1740 characteristic\NN\5849040 for\IN\1740 <e1>metronidazole-induced</e1>\JJ\1740 <e2>encephalopathy</e2>\JJ\1740 ,\,\1740 next\RB\1740 to\IN\1740 the\DT\1740 dentate\NN\1740 nucleus\NN\5445668 involvement\NN\1080366 .\.\1740
D008795_D007239 NONE They\PRP\1740 had\VBD\2108377 been\VBN\836236 taking\VBG\2367363 <e1>metronidazole</e1>\NN\2723292 (\-LRB-\1740 total\JJ\1740 dosage\NN\13576355 ,\,\1740 45\CD\1740 -\SYM\1740 120\CD\13745420 g\NN\13717155 ;\:\1740 duration\NN\15113229 ,\,\1740 30\CD\13745420 days\NNS\15140892 to\IN\1740 2\CD\13741022 months\NNS\15113229 )\-RRB-\1740 to\TO\1740 treat\VB\2376958 the\DT\1740 <e2>infection</e2>\NN\14052046 in\IN\13603305 various\JJ\1740 organs\NNS\7649854 .\.\1740
3970039
D000477_D015470 CID Patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>alkylating\VBG\1740 agents</e1>\NNS\7347 have\VBP\2108377 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 development\NN\248977 of\IN\1740 <e2>acute\JJ\1740 nonlymphocytic\JJ\1740 leukemia</e2>\NN\14239918 ,\,\1740 and\CC\1740 both\DT\1740 alkylating\VBG\1740 agents\NNS\7347 and\CC\1740 azathioprine\NN\3740161 are\VBP\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 non-Hodgkin\JJ\1740 's\POS\1740 lymphoma\NN\14239918 .\.\1740
D000477_D015470 CID Patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 alkylating\VBG\1740 agents\NNS\7347 have\VBP\2108377 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 development\NN\248977 of\IN\1740 <e2>acute\JJ\1740 nonlymphocytic\JJ\1740 leukemia</e2>\NN\14239918 ,\,\1740 and\CC\1740 both\DT\1740 <e1>alkylating\VBG\1740 agents</e1>\NNS\7347 and\CC\1740 azathioprine\NN\3740161 are\VBP\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 non-Hodgkin\JJ\1740 's\POS\1740 lymphoma\NN\14239918 .\.\1740
D000477_D008228 CID Patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>alkylating\VBG\1740 agents</e1>\NNS\7347 have\VBP\2108377 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 development\NN\248977 of\IN\1740 acute\JJ\1740 nonlymphocytic\JJ\1740 leukemia\NN\14239918 ,\,\1740 and\CC\1740 both\DT\1740 alkylating\VBG\1740 agents\NNS\7347 and\CC\1740 azathioprine\NN\3740161 are\VBP\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>non-Hodgkin\JJ\1740 's\POS\1740 lymphoma</e2>\NN\14239918 .\.\1740
D000477_D008228 CID Patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 alkylating\VBG\1740 agents\NNS\7347 have\VBP\2108377 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 development\NN\248977 of\IN\1740 acute\JJ\1740 nonlymphocytic\JJ\1740 leukemia\NN\14239918 ,\,\1740 and\CC\1740 both\DT\1740 <e1>alkylating\VBG\1740 agents</e1>\NNS\7347 and\CC\1740 azathioprine\NN\3740161 are\VBP\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>non-Hodgkin\JJ\1740 's\POS\1740 lymphoma</e2>\NN\14239918 .\.\1740
D001379_D015470 NONE Patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 alkylating\VBG\1740 agents\NNS\7347 have\VBP\2108377 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 development\NN\248977 of\IN\1740 <e2>acute\JJ\1740 nonlymphocytic\JJ\1740 leukemia</e2>\NN\14239918 ,\,\1740 and\CC\1740 both\DT\1740 alkylating\VBG\1740 agents\NNS\7347 and\CC\1740 <e1>azathioprine</e1>\NN\3740161 are\VBP\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 non-Hodgkin\JJ\1740 's\POS\1740 lymphoma\NN\14239918 .\.\1740
D001379_D008228 CID Patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 alkylating\VBG\1740 agents\NNS\7347 have\VBP\2108377 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 development\NN\248977 of\IN\1740 acute\JJ\1740 nonlymphocytic\JJ\1740 leukemia\NN\14239918 ,\,\1740 and\CC\1740 both\DT\1740 alkylating\VBG\1740 agents\NNS\7347 and\CC\1740 <e1>azathioprine</e1>\NN\3740161 are\VBP\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>non-Hodgkin\JJ\1740 's\POS\1740 lymphoma</e2>\NN\14239918 .\.\1740
D003520_D001749 CID <e1>Cyclophosphamide</e1>\NN\1740 therapy\NN\657604 increases\VBZ\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>carcinoma\NN\14239918 of\IN\1740 the\DT\1740 bladder</e2>\NN\5515670 .\.\1740
D003520_D002277 CID <e1>Cyclophosphamide</e1>\NN\1740 therapy\NN\657604 increases\VBZ\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>carcinoma\NN\14239918 of\IN\1740 the\DT\1740 bladder</e2>\NN\5515670 .\.\1740
D001379_D001172 NONE There\EX\27167 have\VBP\2108377 been\VBN\836236 several\JJ\1740 long-term\JJ\1740 studies\NNS\635850 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 treated\VBN\2376958 with\IN\1740 <e1>azathioprine</e1>\NN\3740161 and\CC\1740 cyclophosphamide\NN\1740 and\CC\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 most\JJS\1740 of\IN\1740 the\DT\1740 common\JJ\1740 cancers\NNS\14239425 is\VBZ\836236 not\RB\1740 increased\VBN\169651 .\.\1740
D001379_D009369 NONE There\EX\27167 have\VBP\2108377 been\VBN\836236 several\JJ\1740 long-term\JJ\1740 studies\NNS\635850 of\IN\1740 patients\NNS\9898892 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 treated\VBN\2376958 with\IN\1740 <e1>azathioprine</e1>\NN\3740161 and\CC\1740 cyclophosphamide\NN\1740 and\CC\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 most\JJS\1740 of\IN\1740 the\DT\1740 common\JJ\1740 <e2>cancers</e2>\NNS\14239425 is\VBZ\836236 not\RB\1740 increased\VBN\169651 .\.\1740
D003520_D001172 NONE There\EX\27167 have\VBP\2108377 been\VBN\836236 several\JJ\1740 long-term\JJ\1740 studies\NNS\635850 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 treated\VBN\2376958 with\IN\1740 azathioprine\NN\3740161 and\CC\1740 <e1>cyclophosphamide</e1>\NN\1740 and\CC\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 most\JJS\1740 of\IN\1740 the\DT\1740 common\JJ\1740 cancers\NNS\14239425 is\VBZ\836236 not\RB\1740 increased\VBN\169651 .\.\1740
D003520_D009369 NONE There\EX\27167 have\VBP\2108377 been\VBN\836236 several\JJ\1740 long-term\JJ\1740 studies\NNS\635850 of\IN\1740 patients\NNS\9898892 with\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 treated\VBN\2376958 with\IN\1740 azathioprine\NN\3740161 and\CC\1740 <e1>cyclophosphamide</e1>\NN\1740 and\CC\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 most\JJS\1740 of\IN\1740 the\DT\1740 common\JJ\1740 <e2>cancers</e2>\NNS\14239425 is\VBZ\836236 not\RB\1740 increased\VBN\169651 .\.\1740
D000477_D009369 NONE Data\NNS\7951464 on\IN\1740 the\DT\1740 possible\JJ\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>malignancy</e2>\NN\14070360 in\IN\13603305 rheumatoid\JJ\1740 arthritis\NN\14171682 are\VBP\836236 still\RB\1740 being\VBG\836236 collected\VBN\2281093 ,\,\1740 and\CC\1740 until\IN\1740 further\JJ\1740 information\NN\6598915 is\VBZ\836236 available\JJ\1740 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 immunosuppressive\JJ\1740 drugs\NNS\14778436 ,\,\1740 particularly\RB\1740 <e1>alkylating\VBG\1740 agents</e1>\NNS\7347 ,\,\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 should\MD\1740 be\VB\836236 reserved\VBN\2213690 for\IN\1740 patients\NNS\9898892 with\IN\1740 severe\JJ\1740 progressive\JJ\1740 disease\NN\14061805 or\CC\3541091 life-threatening\JJ\1740 complications\NNS\1073995 .\.\1740
D000477_D001172 NONE Data\NNS\7951464 on\IN\1740 the\DT\1740 possible\JJ\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 malignancy\NN\14070360 in\IN\13603305 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 are\VBP\836236 still\RB\1740 being\VBG\836236 collected\VBN\2281093 ,\,\1740 and\CC\1740 until\IN\1740 further\JJ\1740 information\NN\6598915 is\VBZ\836236 available\JJ\1740 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 immunosuppressive\JJ\1740 drugs\NNS\14778436 ,\,\1740 particularly\RB\1740 <e1>alkylating\VBG\1740 agents</e1>\NNS\7347 ,\,\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 rheumatoid\JJ\1740 arthritis\NN\14171682 should\MD\1740 be\VB\836236 reserved\VBN\2213690 for\IN\1740 patients\NNS\9898892 with\IN\1740 severe\JJ\1740 progressive\JJ\1740 disease\NN\14061805 or\CC\3541091 life-threatening\JJ\1740 complications\NNS\1073995 .\.\1740
D000477_D001172 NONE Data\NNS\7951464 on\IN\1740 the\DT\1740 possible\JJ\1740 increased\VBN\169651 risk\NN\14541044 of\IN\1740 malignancy\NN\14070360 in\IN\13603305 rheumatoid\JJ\1740 arthritis\NN\14171682 are\VBP\836236 still\RB\1740 being\VBG\836236 collected\VBN\2281093 ,\,\1740 and\CC\1740 until\IN\1740 further\JJ\1740 information\NN\6598915 is\VBZ\836236 available\JJ\1740 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 immunosuppressive\JJ\1740 drugs\NNS\14778436 ,\,\1740 particularly\RB\1740 <e1>alkylating\VBG\1740 agents</e1>\NNS\7347 ,\,\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 should\MD\1740 be\VB\836236 reserved\VBN\2213690 for\IN\1740 patients\NNS\9898892 with\IN\1740 severe\JJ\1740 progressive\JJ\1740 disease\NN\14061805 or\CC\3541091 life-threatening\JJ\1740 complications\NNS\1073995 .\.\1740
2266990
D008454_D020388 NONE Randomized\JJ\1740 ,\,\1740 double-blind\JJ\1740 trial\NN\786195 of\IN\1740 <e1>mazindol</e1>\NN\1740 in\IN\13603305 <e2>Duchenne\NNP\1740 dystrophy</e2>\NN\14151139 .\.\1740
D008454_D020388 NONE We\PRP\1740 conducted\VBD\2436349 a\DT\13649268 12-month\NN\1740 controlled\VBN\2422663 trial\NN\786195 of\IN\1740 <e1>mazindol</e1>\NN\1740 ,\,\1740 a\DT\13649268 putative\JJ\1740 growth\NN\13526110 hormone\NN\5404728 secretion\NN\13526110 inhibitor\NN\20090 ,\,\1740 in\IN\13603305 83\CD\1740 boys\NNS\9624168 with\IN\1740 <e2>Duchenne\NNP\1740 dystrophy</e2>\NN\14151139 .\.\1740
D008454_D020388 NONE <e1>Mazindol</e1>\NN\1740 doses\NNS\3740161 not\RB\1740 slow\VB\151689 the\DT\1740 progression\NN\8457976 of\IN\1740 weakness\NN\14462666 in\IN\13603305 <e2>Duchenne\NNP\1740 dystrophy</e2>\NN\14151139 .\.\1740
D008454_D001068 CID Side\JJ\1740 effects\NNS\13245626 attributable\JJ\1740 to\TO\1740 <e1>mazindol</e1>\NN\1740 included\VBN\690614 <e2>decreased\VBN\169651 appetite</e2>\NN\7485475 (\-LRB-\1740 36\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 dry\JJ\1740 mouth\NN\5610008 (\-LRB-\1740 10\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 behavioral\JJ\1740 change\NN\7283608 (\-LRB-\1740 22\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 gastrointestinal\JJ\1740 symptoms\NNS\5823932 (\-LRB-\1740 18\CD\13745420 %\NN\1740 )\-RRB-\1740 ;\:\1740 mazindol\NN\1740 dosage\NN\13576355 was\VBD\836236 reduced\VBN\441445 in\IN\13603305 43\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 .\.\1740
D008454_D001068 CID Side\JJ\1740 effects\NNS\13245626 attributable\JJ\1740 to\TO\1740 mazindol\NN\1740 included\VBN\690614 <e2>decreased\VBN\169651 appetite</e2>\NN\7485475 (\-LRB-\1740 36\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 dry\JJ\1740 mouth\NN\5610008 (\-LRB-\1740 10\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 behavioral\JJ\1740 change\NN\7283608 (\-LRB-\1740 22\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 gastrointestinal\JJ\1740 symptoms\NNS\5823932 (\-LRB-\1740 18\CD\13745420 %\NN\1740 )\-RRB-\1740 ;\:\1740 <e1>mazindol</e1>\NN\1740 dosage\NN\13576355 was\VBD\836236 reduced\VBN\441445 in\IN\13603305 43\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 .\.\1740
D008454_D014987 CID Side\JJ\1740 effects\NNS\13245626 attributable\JJ\1740 to\TO\1740 <e1>mazindol</e1>\NN\1740 included\VBN\690614 decreased\VBN\169651 appetite\NN\7485475 (\-LRB-\1740 36\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 <e2>dry\JJ\1740 mouth</e2>\NN\5610008 (\-LRB-\1740 10\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 behavioral\JJ\1740 change\NN\7283608 (\-LRB-\1740 22\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 gastrointestinal\JJ\1740 symptoms\NNS\5823932 (\-LRB-\1740 18\CD\13745420 %\NN\1740 )\-RRB-\1740 ;\:\1740 mazindol\NN\1740 dosage\NN\13576355 was\VBD\836236 reduced\VBN\441445 in\IN\13603305 43\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 .\.\1740
D008454_D014987 CID Side\JJ\1740 effects\NNS\13245626 attributable\JJ\1740 to\TO\1740 mazindol\NN\1740 included\VBN\690614 decreased\VBN\169651 appetite\NN\7485475 (\-LRB-\1740 36\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 <e2>dry\JJ\1740 mouth</e2>\NN\5610008 (\-LRB-\1740 10\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 behavioral\JJ\1740 change\NN\7283608 (\-LRB-\1740 22\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 gastrointestinal\JJ\1740 symptoms\NNS\5823932 (\-LRB-\1740 18\CD\13745420 %\NN\1740 )\-RRB-\1740 ;\:\1740 <e1>mazindol</e1>\NN\1740 dosage\NN\13576355 was\VBD\836236 reduced\VBN\441445 in\IN\13603305 43\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 .\.\1740
D008454_D012817 CID Side\JJ\1740 effects\NNS\13245626 attributable\JJ\1740 to\TO\1740 <e1>mazindol</e1>\NN\1740 included\VBN\690614 decreased\VBN\169651 appetite\NN\7485475 (\-LRB-\1740 36\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 dry\JJ\1740 mouth\NN\5610008 (\-LRB-\1740 10\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 behavioral\JJ\1740 change\NN\7283608 (\-LRB-\1740 22\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e2>gastrointestinal\JJ\1740 symptoms</e2>\NNS\5823932 (\-LRB-\1740 18\CD\13745420 %\NN\1740 )\-RRB-\1740 ;\:\1740 mazindol\NN\1740 dosage\NN\13576355 was\VBD\836236 reduced\VBN\441445 in\IN\13603305 43\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 .\.\1740
D008454_D012817 CID Side\JJ\1740 effects\NNS\13245626 attributable\JJ\1740 to\TO\1740 mazindol\NN\1740 included\VBN\690614 decreased\VBN\169651 appetite\NN\7485475 (\-LRB-\1740 36\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 dry\JJ\1740 mouth\NN\5610008 (\-LRB-\1740 10\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 behavioral\JJ\1740 change\NN\7283608 (\-LRB-\1740 22\CD\13745420 %\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e2>gastrointestinal\JJ\1740 symptoms</e2>\NNS\5823932 (\-LRB-\1740 18\CD\13745420 %\NN\1740 )\-RRB-\1740 ;\:\1740 <e1>mazindol</e1>\NN\1740 dosage\NN\13576355 was\VBD\836236 reduced\VBN\441445 in\IN\13603305 43\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 .\.\1740
D008454_D018908 NONE <e1>Mazindol</e1>\NN\1740 doses\NNS\3740161 not\RB\1740 slow\VB\151689 the\DT\1740 progression\NN\8457976 of\IN\1740 <e2>weakness</e2>\NN\14462666 in\IN\13603305 Duchenne\NNP\1740 dystrophy\NN\14151139 .\.\1740
6861444
D009638_D006973 CID Intrarenal\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>noradrenaline</e1>\NN\14807929 caused\VBD\1617192 <e2>hypertension</e2>\NN\14057371 at\IN\14622893 doses\NNS\3740161 which\WDT\1740 did\VBD\1640855 not\RB\1740 do\VB\1640855 so\RB\1740 when\WRB\1740 infused\VBN\606335 intravenously\RB\1740 .\.\1740
D009638_D006973 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 <e2>hypertension</e2>\NN\14057371 after\IN\1740 chronic\JJ\1740 intrarenal\JJ\1740 <e1>noradrenaline</e1>\NN\14807929 infusion\NN\14589223 is\VBZ\836236 produced\VBN\1617192 by\IN\1740 relatively\RB\1740 higher\JJR\1740 levels\NNS\4916342 of\IN\1740 circulating\VBG\1835496 noradrenaline\NN\14807929 and\CC\1740 by\IN\1740 triggering\NN\1740 of\IN\1740 an\DT\6697703 additional\JJ\1740 intrarenal\JJ\1740 pressor\NN\9190918 mechanism\NN\13446390 .\.\1740
D009638_D006973 CID These\DT\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 <e2>hypertension</e2>\NN\14057371 after\IN\1740 chronic\JJ\1740 intrarenal\JJ\1740 noradrenaline\NN\14807929 infusion\NN\14589223 is\VBZ\836236 produced\VBN\1617192 by\IN\1740 relatively\RB\1740 higher\JJR\1740 levels\NNS\4916342 of\IN\1740 circulating\VBG\1835496 <e1>noradrenaline</e1>\NN\14807929 and\CC\1740 by\IN\1740 triggering\NN\1740 of\IN\1740 an\DT\6697703 additional\JJ\1740 intrarenal\JJ\1740 pressor\NN\9190918 mechanism\NN\13446390 .\.\1740
137340
D009020_D006948 CID Effect\NN\34213 of\IN\1740 humoral\JJ\1740 modulators\NNS\1740 of\IN\1740 <e1>morphine-induced</e1>\JJ\1740 <e2>increase\NN\13576355 in\IN\13603305 locomotor\NN\1740 activity</e2>\NN\30358 of\IN\1740 mice\NNS\2329401 .\.\1740
D009020_D006948 CID The\DT\1740 effect\NN\34213 of\IN\1740 humoral\JJ\1740 modulators\NNS\1740 on\IN\1740 the\DT\1740 <e1>morphine-induced</e1>\JJ\1740 <e2>increase\NN\13576355 in\IN\13603305 locomotor\NN\1740 activity</e2>\NN\30358 of\IN\1740 mice\NNS\2329401 was\VBD\836236 studied\VBN\630380 .\.\1740
D009020_D006948 CID The\DT\1740 subcutaneous\JJ\1740 administration\NN\1133281 of\IN\1740 10\CD\13745420 mg/kg\NN\1740 of\IN\1740 <e1>morphine-HC1</e1>\NN\1740 produced\VBD\1617192 a\DT\13649268 marked\JJ\1740 <e2>increase\NN\13576355 in\IN\13603305 locomotor\NN\1740 activity</e2>\NN\30358 in\IN\13603305 mice\NNS\2329401 .\.\1740
D009020_D006948 CID The\DT\1740 <e1>morphine-induced</e1>\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 was\VBD\836236 potentiated\VBN\229605 by\IN\1740 scopolamine\NN\14712692 and\CC\1740 attenuated\VBN\224901 by\IN\1740 physostigmine\NN\14712692 .\.\1740
D009020_D006948 CID In\IN\13603305 contrast\NN\13854649 ,\,\1740 both\CC\1740 methscopolamine\NN\1740 and\CC\1740 neostigmine\NN\2718084 ,\,\1740 which\WDT\1740 do\VBP\1640855 not\RB\1740 penetrate\VB\2016523 the\DT\1740 blood-brain\JJ\1740 barrier\NN\3839993 ,\,\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 the\DT\1740 <e2>hyperactivity</e2>\NN\14052403 produced\VBN\1617192 by\IN\1740 <e1>morphine</e1>\NN\2707683 .\.\1740
D012601_D006948 CID The\DT\1740 morphine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 was\VBD\836236 potentiated\VBN\229605 by\IN\1740 <e1>scopolamine</e1>\NN\14712692 and\CC\1740 attenuated\VBN\224901 by\IN\1740 physostigmine\NN\14712692 .\.\1740
D010830_D006948 NONE The\DT\1740 morphine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 was\VBD\836236 potentiated\VBN\229605 by\IN\1740 scopolamine\NN\14712692 and\CC\1740 attenuated\VBN\224901 by\IN\1740 <e1>physostigmine</e1>\NN\14712692 .\.\1740
D019832_D006948 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 both\CC\1740 <e1>methscopolamine</e1>\NN\1740 and\CC\1740 neostigmine\NN\2718084 ,\,\1740 which\WDT\1740 do\VBP\1640855 not\RB\1740 penetrate\VB\2016523 the\DT\1740 blood-brain\JJ\1740 barrier\NN\3839993 ,\,\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 the\DT\1740 <e2>hyperactivity</e2>\NN\14052403 produced\VBN\1617192 by\IN\1740 morphine\NN\2707683 .\.\1740
D009388_D006948 NONE In\IN\13603305 contrast\NN\13854649 ,\,\1740 both\CC\1740 methscopolamine\NN\1740 and\CC\1740 <e1>neostigmine</e1>\NN\2718084 ,\,\1740 which\WDT\1740 do\VBP\1640855 not\RB\1740 penetrate\VB\2016523 the\DT\1740 blood-brain\JJ\1740 barrier\NN\3839993 ,\,\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 on\IN\1740 the\DT\1740 <e2>hyperactivity</e2>\NN\14052403 produced\VBN\1617192 by\IN\1740 morphine\NN\2707683 .\.\1740
D010134_D006948 NONE On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 pretreatment\NN\1740 with\IN\1740 <e1>p-chlorophenylalamine</e1>\NN\1740 (\-LRB-\1740 3\CD\13741022 X\NN\13745420 320\CD\1740 mg/kg\NN\1740 i.p.\RB\1740 ,\,\1740 24\CD\13745420 hr\NN\15154774 )\-RRB-\1740 ,\,\1740 a\DT\13649268 serotonin\NN\14807737 depletor\NN\1740 ,\,\1740 caused\VBD\1617192 no\DT\7204911 significant\JJ\1740 change\NN\7283608 in\IN\13603305 the\DT\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
D012701_D006948 NONE On\IN\1740 the\DT\1740 other\JJ\1740 hand\NN\5566919 ,\,\1740 pretreatment\NN\1740 with\IN\1740 p-chlorophenylalamine\NN\1740 (\-LRB-\1740 3\CD\13741022 X\NN\13745420 320\CD\1740 mg/kg\NN\1740 i.p.\RB\1740 ,\,\1740 24\CD\13745420 hr\NN\15154774 )\-RRB-\1740 ,\,\1740 a\DT\13649268 <e1>serotonin</e1>\NN\14807737 depletor\NN\1740 ,\,\1740 caused\VBD\1617192 no\DT\7204911 significant\JJ\1740 change\NN\7283608 in\IN\13603305 the\DT\1740 <e2>hyperactivity</e2>\NN\14052403 .\.\1740
227508
D003000_D006973 NONE In\IN\13603305 unanesthetized\VBN\1740 ,\,\1740 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\VBZ\2584097 the\DT\1740 decrease\NN\7296428 in\IN\13603305 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 heart\NN\5919034 rate\NN\13815152 produced\VBN\1617192 by\IN\1740 intravenous\JJ\1740 <e1>clonidine</e1>\NN\2721160 ,\,\1740 5\CD\13741022 to\TO\1740 20\CD\13745420 micrograms/kg\NNS\1740 ,\,\1740 was\VBD\836236 inhibited\VBN\2510337 or\CC\3541091 reversed\VBN\109660 by\IN\1740 nalozone\NN\1740 ,\,\1740 0.2\CD\1740 to\TO\1740 2\CD\13741022 mg/kg\NN\1740 .\.\1740
D003000_D006973 NONE In\IN\13603305 brain\NN\5462674 membranes\NNS\4188643 from\IN\1740 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 <e1>clonidine</e1>\NN\2721160 ,\,\1740 10(-8\NN\1740 )\-RRB-\1740 to\TO\1740 10(-5\NN\1740 )\-RRB-\1740 M\NN\13649268 ,\,\1740 did\VBD\1640855 not\RB\1740 influence\VB\137313 stereoselective\JJ\1740 binding\NN\4688246 of\IN\1740 [3H]-naloxone\XX\1740 (\-LRB-\1740 8\CD\13741022 nM\NN\13649268 )\-RRB-\1740 ,\,\1740 and\CC\1740 naloxone\NN\3808977 ,\,\1740 10(-8\NN\1740 )\-RRB-\1740 to\TO\1740 10(-4\NN\1740 )\-RRB-\1740 M\NN\13649268 ,\,\1740 did\VBD\1640855 not\RB\1740 influence\VB\137313 clonidine-suppressible\JJ\1740 binding\NN\4688246 of\IN\1740 [3H]-dihydroergocryptine\XX\1740 (\-LRB-\1740 1\CD\13741022 nM\NN\13649268 )\-RRB-\1740 .\.\1740
D003000_D006973 NONE In\IN\13603305 brain\NN\5462674 membranes\NNS\4188643 from\IN\1740 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 clonidine\NN\2721160 ,\,\1740 10(-8\NN\1740 )\-RRB-\1740 to\TO\1740 10(-5\NN\1740 )\-RRB-\1740 M\NN\13649268 ,\,\1740 did\VBD\1640855 not\RB\1740 influence\VB\137313 stereoselective\JJ\1740 binding\NN\4688246 of\IN\1740 [3H]-naloxone\XX\1740 (\-LRB-\1740 8\CD\13741022 nM\NN\13649268 )\-RRB-\1740 ,\,\1740 and\CC\1740 naloxone\NN\3808977 ,\,\1740 10(-8\NN\1740 )\-RRB-\1740 to\TO\1740 10(-4\NN\1740 )\-RRB-\1740 M\NN\13649268 ,\,\1740 did\VBD\1640855 not\RB\1740 influence\VB\137313 <e1>clonidine-suppressible</e1>\JJ\1740 binding\NN\4688246 of\IN\1740 [3H]-dihydroergocryptine\XX\1740 (\-LRB-\1740 1\CD\13741022 nM\NN\13649268 )\-RRB-\1740 .\.\1740
-1_D006973 NONE In\IN\13603305 unanesthetized\VBN\1740 ,\,\1740 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\VBZ\2584097 the\DT\1740 decrease\NN\7296428 in\IN\13603305 blood\NN\5397468 pressure\NN\11419404 and\CC\1740 heart\NN\5919034 rate\NN\13815152 produced\VBN\1617192 by\IN\1740 intravenous\JJ\1740 clonidine\NN\2721160 ,\,\1740 5\CD\13741022 to\TO\1740 20\CD\13745420 micrograms/kg\NNS\1740 ,\,\1740 was\VBD\836236 inhibited\VBN\2510337 or\CC\3541091 reversed\VBN\109660 by\IN\1740 <e1>nalozone</e1>\NN\1740 ,\,\1740 0.2\CD\1740 to\TO\1740 2\CD\13741022 mg/kg\NN\1740 .\.\1740
-1_D006973 NONE In\IN\13603305 brain\NN\5462674 membranes\NNS\4188643 from\IN\1740 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 clonidine\NN\2721160 ,\,\1740 10(-8\NN\1740 )\-RRB-\1740 to\TO\1740 10(-5\NN\1740 )\-RRB-\1740 M\NN\13649268 ,\,\1740 did\VBD\1640855 not\RB\1740 influence\VB\137313 stereoselective\JJ\1740 binding\NN\4688246 of\IN\1740 <e1>[3H]-naloxone</e1>\XX\1740 (\-LRB-\1740 8\CD\13741022 nM\NN\13649268 )\-RRB-\1740 ,\,\1740 and\CC\1740 naloxone\NN\3808977 ,\,\1740 10(-8\NN\1740 )\-RRB-\1740 to\TO\1740 10(-4\NN\1740 )\-RRB-\1740 M\NN\13649268 ,\,\1740 did\VBD\1640855 not\RB\1740 influence\VB\137313 clonidine-suppressible\JJ\1740 binding\NN\4688246 of\IN\1740 [3H]-dihydroergocryptine\XX\1740 (\-LRB-\1740 1\CD\13741022 nM\NN\13649268 )\-RRB-\1740 .\.\1740
-1_D006973 NONE In\IN\13603305 brain\NN\5462674 membranes\NNS\4188643 from\IN\1740 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 clonidine\NN\2721160 ,\,\1740 10(-8\NN\1740 )\-RRB-\1740 to\TO\1740 10(-5\NN\1740 )\-RRB-\1740 M\NN\13649268 ,\,\1740 did\VBD\1640855 not\RB\1740 influence\VB\137313 stereoselective\JJ\1740 binding\NN\4688246 of\IN\1740 [3H]-naloxone\XX\1740 (\-LRB-\1740 8\CD\13741022 nM\NN\13649268 )\-RRB-\1740 ,\,\1740 and\CC\1740 naloxone\NN\3808977 ,\,\1740 10(-8\NN\1740 )\-RRB-\1740 to\TO\1740 10(-4\NN\1740 )\-RRB-\1740 M\NN\13649268 ,\,\1740 did\VBD\1640855 not\RB\1740 influence\VB\137313 clonidine-suppressible\JJ\1740 binding\NN\4688246 of\IN\1740 <e1>[3H]-dihydroergocryptine</e1>\XX\1740 (\-LRB-\1740 1\CD\13741022 nM\NN\13649268 )\-RRB-\1740 .\.\1740
D008750_D007022 CID The\DT\1740 <e2>hypotensive</e2>\JJ\1740 effect\NN\34213 of\IN\1740 100\CD\13745420 mg/kg\NN\1740 <e1>alpha-methyldopa</e1>\NN\1740 was\VBD\836236 also\RB\1740 partially\RB\1740 reversed\VBN\109660 by\IN\1740 naloxone\NN\3808977 .\.\1740
D009270_D007022 NONE The\DT\1740 <e2>hypotensive</e2>\JJ\1740 effect\NN\34213 of\IN\1740 100\CD\13745420 mg/kg\NN\1740 alpha-methyldopa\NN\1740 was\VBD\836236 also\RB\1740 partially\RB\1740 reversed\VBN\109660 by\IN\1740 <e1>naloxone</e1>\NN\3808977 .\.\1740
D009270_D006973 NONE In\IN\13603305 brain\NN\5462674 membranes\NNS\4188643 from\IN\1740 spontaneously\JJ\1740 <e2>hypertensive</e2>\JJ\1740 rats\NNS\2329401 clonidine\NN\2721160 ,\,\1740 10(-8\NN\1740 )\-RRB-\1740 to\TO\1740 10(-5\NN\1740 )\-RRB-\1740 M\NN\13649268 ,\,\1740 did\VBD\1640855 not\RB\1740 influence\VB\137313 stereoselective\JJ\1740 binding\NN\4688246 of\IN\1740 [3H]-naloxone\XX\1740 (\-LRB-\1740 8\CD\13741022 nM\NN\13649268 )\-RRB-\1740 ,\,\1740 and\CC\1740 <e1>naloxone</e1>\NN\3808977 ,\,\1740 10(-8\NN\1740 )\-RRB-\1740 to\TO\1740 10(-4\NN\1740 )\-RRB-\1740 M\NN\13649268 ,\,\1740 did\VBD\1640855 not\RB\1740 influence\VB\137313 clonidine-suppressible\JJ\1740 binding\NN\4688246 of\IN\1740 [3H]-dihydroergocryptine\XX\1740 (\-LRB-\1740 1\CD\13741022 nM\NN\13649268 )\-RRB-\1740 .\.\1740
16680561
D003891_D009325 CID Fewer\JJR\1740 subjects\NNS\6598915 reported\VBD\831651 adverse\JJ\1740 events\NNS\23100 following\VBG\1835496 treatment\NN\654885 with\IN\1740 <e1>desipramine</e1>\NN\4482543 alone\RB\1740 than\IN\1740 when\WRB\1740 receiving\VBG\2210855 desipramine\NN\4482543 with\IN\1740 cinacalcet\NN\1740 (\-LRB-\1740 33\CD\1740 versus\CC\1740 86\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 most\RBS\1740 frequent\JJ\1740 of\IN\1740 which\WDT\1740 (\-LRB-\1740 <e2>nausea</e2>\NN\14299637 and\CC\1740 headache\NN\5829480 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 for\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 either\CC\1740 desipramine\NN\4482543 or\CC\3541091 cinacalcet\NN\1740 .\.\1740
D003891_D009325 CID Fewer\JJR\1740 subjects\NNS\6598915 reported\VBD\831651 adverse\JJ\1740 events\NNS\23100 following\VBG\1835496 treatment\NN\654885 with\IN\1740 desipramine\NN\4482543 alone\RB\1740 than\IN\1740 when\WRB\1740 receiving\VBG\2210855 <e1>desipramine</e1>\NN\4482543 with\IN\1740 cinacalcet\NN\1740 (\-LRB-\1740 33\CD\1740 versus\CC\1740 86\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 most\RBS\1740 frequent\JJ\1740 of\IN\1740 which\WDT\1740 (\-LRB-\1740 <e2>nausea</e2>\NN\14299637 and\CC\1740 headache\NN\5829480 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 for\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 either\CC\1740 desipramine\NN\4482543 or\CC\3541091 cinacalcet\NN\1740 .\.\1740
D003891_D009325 CID Fewer\JJR\1740 subjects\NNS\6598915 reported\VBD\831651 adverse\JJ\1740 events\NNS\23100 following\VBG\1835496 treatment\NN\654885 with\IN\1740 desipramine\NN\4482543 alone\RB\1740 than\IN\1740 when\WRB\1740 receiving\VBG\2210855 desipramine\NN\4482543 with\IN\1740 cinacalcet\NN\1740 (\-LRB-\1740 33\CD\1740 versus\CC\1740 86\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 most\RBS\1740 frequent\JJ\1740 of\IN\1740 which\WDT\1740 (\-LRB-\1740 <e2>nausea</e2>\NN\14299637 and\CC\1740 headache\NN\5829480 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 for\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 either\CC\1740 <e1>desipramine</e1>\NN\4482543 or\CC\3541091 cinacalcet\NN\1740 .\.\1740
D003891_D006261 CID Fewer\JJR\1740 subjects\NNS\6598915 reported\VBD\831651 adverse\JJ\1740 events\NNS\23100 following\VBG\1835496 treatment\NN\654885 with\IN\1740 <e1>desipramine</e1>\NN\4482543 alone\RB\1740 than\IN\1740 when\WRB\1740 receiving\VBG\2210855 desipramine\NN\4482543 with\IN\1740 cinacalcet\NN\1740 (\-LRB-\1740 33\CD\1740 versus\CC\1740 86\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 most\RBS\1740 frequent\JJ\1740 of\IN\1740 which\WDT\1740 (\-LRB-\1740 nausea\NN\14299637 and\CC\1740 <e2>headache</e2>\NN\5829480 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 for\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 either\CC\1740 desipramine\NN\4482543 or\CC\3541091 cinacalcet\NN\1740 .\.\1740
D003891_D006261 CID Fewer\JJR\1740 subjects\NNS\6598915 reported\VBD\831651 adverse\JJ\1740 events\NNS\23100 following\VBG\1835496 treatment\NN\654885 with\IN\1740 desipramine\NN\4482543 alone\RB\1740 than\IN\1740 when\WRB\1740 receiving\VBG\2210855 <e1>desipramine</e1>\NN\4482543 with\IN\1740 cinacalcet\NN\1740 (\-LRB-\1740 33\CD\1740 versus\CC\1740 86\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 most\RBS\1740 frequent\JJ\1740 of\IN\1740 which\WDT\1740 (\-LRB-\1740 nausea\NN\14299637 and\CC\1740 <e2>headache</e2>\NN\5829480 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 for\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 either\CC\1740 desipramine\NN\4482543 or\CC\3541091 cinacalcet\NN\1740 .\.\1740
D003891_D006261 CID Fewer\JJR\1740 subjects\NNS\6598915 reported\VBD\831651 adverse\JJ\1740 events\NNS\23100 following\VBG\1835496 treatment\NN\654885 with\IN\1740 desipramine\NN\4482543 alone\RB\1740 than\IN\1740 when\WRB\1740 receiving\VBG\2210855 desipramine\NN\4482543 with\IN\1740 cinacalcet\NN\1740 (\-LRB-\1740 33\CD\1740 versus\CC\1740 86\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 most\RBS\1740 frequent\JJ\1740 of\IN\1740 which\WDT\1740 (\-LRB-\1740 nausea\NN\14299637 and\CC\1740 <e2>headache</e2>\NN\5829480 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 for\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 either\CC\1740 <e1>desipramine</e1>\NN\4482543 or\CC\3541091 cinacalcet\NN\1740 .\.\1740
C476217_D009325 CID Fewer\JJR\1740 subjects\NNS\6598915 reported\VBD\831651 adverse\JJ\1740 events\NNS\23100 following\VBG\1835496 treatment\NN\654885 with\IN\1740 desipramine\NN\4482543 alone\RB\1740 than\IN\1740 when\WRB\1740 receiving\VBG\2210855 desipramine\NN\4482543 with\IN\1740 <e1>cinacalcet</e1>\NN\1740 (\-LRB-\1740 33\CD\1740 versus\CC\1740 86\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 most\RBS\1740 frequent\JJ\1740 of\IN\1740 which\WDT\1740 (\-LRB-\1740 <e2>nausea</e2>\NN\14299637 and\CC\1740 headache\NN\5829480 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 for\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 either\CC\1740 desipramine\NN\4482543 or\CC\3541091 cinacalcet\NN\1740 .\.\1740
C476217_D009325 CID Fewer\JJR\1740 subjects\NNS\6598915 reported\VBD\831651 adverse\JJ\1740 events\NNS\23100 following\VBG\1835496 treatment\NN\654885 with\IN\1740 desipramine\NN\4482543 alone\RB\1740 than\IN\1740 when\WRB\1740 receiving\VBG\2210855 desipramine\NN\4482543 with\IN\1740 cinacalcet\NN\1740 (\-LRB-\1740 33\CD\1740 versus\CC\1740 86\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 most\RBS\1740 frequent\JJ\1740 of\IN\1740 which\WDT\1740 (\-LRB-\1740 <e2>nausea</e2>\NN\14299637 and\CC\1740 headache\NN\5829480 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 for\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 either\CC\1740 desipramine\NN\4482543 or\CC\3541091 <e1>cinacalcet</e1>\NN\1740 .\.\1740
C476217_D006261 CID Fewer\JJR\1740 subjects\NNS\6598915 reported\VBD\831651 adverse\JJ\1740 events\NNS\23100 following\VBG\1835496 treatment\NN\654885 with\IN\1740 desipramine\NN\4482543 alone\RB\1740 than\IN\1740 when\WRB\1740 receiving\VBG\2210855 desipramine\NN\4482543 with\IN\1740 <e1>cinacalcet</e1>\NN\1740 (\-LRB-\1740 33\CD\1740 versus\CC\1740 86\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 most\RBS\1740 frequent\JJ\1740 of\IN\1740 which\WDT\1740 (\-LRB-\1740 nausea\NN\14299637 and\CC\1740 <e2>headache</e2>\NN\5829480 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 for\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 either\CC\1740 desipramine\NN\4482543 or\CC\3541091 cinacalcet\NN\1740 .\.\1740
C476217_D006261 CID Fewer\JJR\1740 subjects\NNS\6598915 reported\VBD\831651 adverse\JJ\1740 events\NNS\23100 following\VBG\1835496 treatment\NN\654885 with\IN\1740 desipramine\NN\4482543 alone\RB\1740 than\IN\1740 when\WRB\1740 receiving\VBG\2210855 desipramine\NN\4482543 with\IN\1740 cinacalcet\NN\1740 (\-LRB-\1740 33\CD\1740 versus\CC\1740 86\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 most\RBS\1740 frequent\JJ\1740 of\IN\1740 which\WDT\1740 (\-LRB-\1740 nausea\NN\14299637 and\CC\1740 <e2>headache</e2>\NN\5829480 )\-RRB-\1740 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 for\IN\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 either\CC\1740 desipramine\NN\4482543 or\CC\3541091 <e1>cinacalcet</e1>\NN\1740 .\.\1740
7881871
D011692_D007674 CID Time\NN\7308889 course\NN\883297 of\IN\1740 lipid\NN\14944888 peroxidation\NN\1740 in\IN\13603305 <e1>puromycin\NN\1740 aminonucleoside-induced</e1>\JJ\1740 <e2>nephropathy</e2>\NN\14573196 .\.\1740
D011692_D007674 CID Reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 have\VBP\2108377 been\VBN\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 acute\JJ\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 (PAN)-induced\VBN\1740 <e2>nephropathy</e2>\NN\14573196 ,\,\1740 with\IN\1740 antioxidants\NNS\14724436 significantly\RB\1740 reducing\VBG\441445 the\DT\1740 proteinuria\NN\14299637 .\.\1740
D011692_D007674 CID Reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 have\VBP\2108377 been\VBN\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 acute\JJ\1740 puromycin\NN\1740 aminonucleoside\NN\1740 <e1>(PAN)-induced</e1>\VBN\1740 <e2>nephropathy</e2>\NN\14573196 ,\,\1740 with\IN\1740 antioxidants\NNS\14724436 significantly\RB\1740 reducing\VBG\441445 the\DT\1740 proteinuria\NN\14299637 .\.\1740
D011692_D007674 CID This\DT\1740 study\NN\635850 supports\VBZ\2199590 the\DT\1740 role\NN\719494 of\IN\1740 lipid\NN\14944888 peroxidation\NN\1740 in\IN\13603305 mediating\VBG\761713 the\DT\1740 proteinuric\JJ\1740 injury\NN\14052046 in\IN\13603305 <e1>PAN</e1>\NN\3101986 <e2>nephropathy</e2>\NN\14573196 .\.\1740
D010100_D007674 NONE Reactive\JJ\1740 <e1>oxygen</e1>\NN\14622893 species\NNS\7992450 have\VBP\2108377 been\VBN\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 acute\JJ\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (PAN)-induced\VBN\1740 <e2>nephropathy</e2>\NN\14573196 ,\,\1740 with\IN\1740 antioxidants\NNS\14724436 significantly\RB\1740 reducing\VBG\441445 the\DT\1740 proteinuria\NN\14299637 .\.\1740
D010100_D011507 NONE Reactive\JJ\1740 <e1>oxygen</e1>\NN\14622893 species\NNS\7992450 have\VBP\2108377 been\VBN\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 acute\JJ\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (PAN)-induced\VBN\1740 nephropathy\NN\14573196 ,\,\1740 with\IN\1740 antioxidants\NNS\14724436 significantly\RB\1740 reducing\VBG\441445 the\DT\1740 <e2>proteinuria</e2>\NN\14299637 .\.\1740
D011692_D011507 CID Reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 have\VBP\2108377 been\VBN\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 acute\JJ\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 (PAN)-induced\VBN\1740 nephropathy\NN\14573196 ,\,\1740 with\IN\1740 antioxidants\NNS\14724436 significantly\RB\1740 reducing\VBG\441445 the\DT\1740 <e2>proteinuria</e2>\NN\14299637 .\.\1740
D011692_D011507 CID Reactive\JJ\1740 oxygen\NN\14622893 species\NNS\7992450 have\VBP\2108377 been\VBN\836236 implicated\VBN\2677097 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 acute\JJ\1740 puromycin\NN\1740 aminonucleoside\NN\1740 <e1>(PAN)-induced</e1>\VBN\1740 nephropathy\NN\14573196 ,\,\1740 with\IN\1740 antioxidants\NNS\14724436 significantly\RB\1740 reducing\VBG\441445 the\DT\1740 <e2>proteinuria</e2>\NN\14299637 .\.\1740
D011692_D011507 CID This\DT\1740 study\NN\635850 supports\VBZ\2199590 the\DT\1740 role\NN\719494 of\IN\1740 lipid\NN\14944888 peroxidation\NN\1740 in\IN\13603305 mediating\VBG\761713 the\DT\1740 <e2>proteinuric\JJ\1740 injury</e2>\NN\14052046 in\IN\13603305 <e1>PAN</e1>\NN\3101986 nephropathy\NN\14573196 .\.\1740
16740173
6666578
D010396_D001018 CID <e1>D-penicillamine-induced</e1>\JJ\1740 <e2>angiopathy</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
9249847
D014700_D013611 CID Iatrogenically\RB\1740 induced\VBN\1627355 intractable\JJ\1740 <e2>atrioventricular\JJ\1740 reentrant\JJ\1740 tachycardia</e2>\NN\14110674 after\IN\1740 <e1>verapamil</e1>\NN\2938514 and\CC\1740 catheter\NN\4493505 ablation\NN\671351 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 Wolff-Parkinson-White\JJ\1740 syndrome\NN\5870365 and\CC\1740 idiopathic\JJ\1740 dilated\VBN\303465 cardiomyopathy\JJ\1740 .\.\1740
D014700_D013611 CID QRS\NN\1740 without\IN\1740 preexcitation\NN\1740 ,\,\1740 caused\VBN\1617192 by\IN\1740 junctional\JJ\1740 escape\NN\46177 beats\VBZ\1108148 after\IN\1740 <e1>verapamil</e1>\NN\2938514 or\CC\3541091 unidirectional\JJ\1740 antegrade\NN\1740 block\NN\21939 of\IN\1740 accessory\NN\3051540 pathway\NN\5483677 after\IN\1740 catheter\NN\4493505 ablation\NN\671351 ,\,\1740 established\JJ\1740 frequent\JJ\1740 <e2>AVRT</e2>\NN\1740 attack\NN\955060 .\.\1740
D014700_D014927 NONE Iatrogenically\RB\1740 induced\VBN\1627355 intractable\JJ\1740 atrioventricular\JJ\1740 reentrant\JJ\1740 tachycardia\NN\14110674 after\IN\1740 <e1>verapamil</e1>\NN\2938514 and\CC\1740 catheter\NN\4493505 ablation\NN\671351 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 <e2>Wolff-Parkinson-White\JJ\1740 syndrome</e2>\NN\5870365 and\CC\1740 idiopathic\JJ\1740 dilated\VBN\303465 cardiomyopathy\JJ\1740 .\.\1740
D014700_D002311 NONE Iatrogenically\RB\1740 induced\VBN\1627355 intractable\JJ\1740 atrioventricular\JJ\1740 reentrant\JJ\1740 tachycardia\NN\14110674 after\IN\1740 <e1>verapamil</e1>\NN\2938514 and\CC\1740 catheter\NN\4493505 ablation\NN\671351 in\IN\13603305 a\DT\13649268 patient\NN\9898892 with\IN\1740 Wolff-Parkinson-White\JJ\1740 syndrome\NN\5870365 and\CC\1740 <e2>idiopathic\JJ\1740 dilated\VBN\303465 cardiomyopathy</e2>\JJ\1740 .\.\1740
3107448
D005905_D056486 CID <e1>Glyburide-induced</e1>\JJ\1740 <e2>hepatitis</e2>\NN\14127211 .\.\1740
D005905_D056486 CID For\IN\1740 <e1>glyburide</e1>\VB\1740 ,\,\1740 a\DT\13649268 second-generation\JJ\1740 sulfonylurea\NN\2719105 ,\,\1740 only\RB\1740 two\CD\13741022 brief\JJ\1740 reports\NNS\6470073 of\IN\1740 <e2>hepatotoxicity</e2>\NN\1740 exist\NN\1740 .\.\1740
D005905_D056486 CID Two\CD\13741022 patients\NNS\9898892 with\IN\1740 type\NN\5839024 II\CD\13741022 diabetes\NN\14075199 mellitus\NN\1740 developed\VBD\1753788 an\DT\6697703 <e2>acute\JJ\1740 hepatitis-like\JJ\1740 syndrome</e2>\NN\5870365 soon\RB\1740 after\IN\1740 initiation\NN\7450842 of\IN\1740 <e1>glyburide</e1>\NN\2719105 therapy\NN\657604 .\.\1740
D005905_D056486 CID <e1>Glyburide</e1>\NNP\2719105 can\MD\3094503 produce\VB\1617192 an\DT\6697703 <e2>acute\JJ\1740 hepatitis-like\JJ\1740 illness</e2>\NN\14052046 in\IN\13603305 some\DT\1740 persons\NNS\7347 .\.\1740
D013453_D056486 NONE Drug-induced\JJ\1740 <e2>hepatotoxicity</e2>\NN\1740 ,\,\1740 although\IN\1740 common\JJ\1740 ,\,\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 only\RB\1740 infrequently\RB\1740 with\IN\1740 <e1>sulfonylureas</e1>\NNS\2719105 .\.\1740
D013453_D056486 NONE For\IN\1740 glyburide\VB\1740 ,\,\1740 a\DT\13649268 second-generation\JJ\1740 <e1>sulfonylurea</e1>\NN\2719105 ,\,\1740 only\RB\1740 two\CD\13741022 brief\JJ\1740 reports\NNS\6470073 of\IN\1740 <e2>hepatotoxicity</e2>\NN\1740 exist\NN\1740 .\.\1740
D005905_D003924 NONE Two\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>type\NN\5839024 II\CD\13741022 diabetes\NN\14075199 mellitus</e2>\NN\1740 developed\VBD\1753788 an\DT\6697703 acute\JJ\1740 hepatitis-like\JJ\1740 syndrome\NN\5870365 soon\RB\1740 after\IN\1740 initiation\NN\7450842 of\IN\1740 <e1>glyburide</e1>\NN\2719105 therapy\NN\657604 .\.\1740
6387529
D003975_D016584 NONE Behavioral\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>diazepam</e1>\NN\2830852 and\CC\1740 propranolol\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>panic\JJ\1740 disorder</e2>\NN\14034177 and\CC\1740 agoraphobia\NN\14381416 .\.\1740
D003975_D016584 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 oral\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>diazepam</e1>\NN\2830852 (\-LRB-\1740 single\JJ\1740 dose\NN\3740161 of\IN\1740 10\CD\13745420 mg\NN\13717155 and\CC\1740 a\DT\13649268 median\JJ\1740 dose\NN\3740161 of\IN\1740 30\CD\13745420 mg/day\NN\1740 for\IN\1740 2\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 and\CC\1740 propranolol\NN\1740 (\-LRB-\1740 single\JJ\1740 dose\NN\3740161 of\IN\1740 80\CD\13745420 mg\NN\13717155 and\CC\1740 a\DT\13649268 median\JJ\1740 dose\NN\3740161 of\IN\1740 240\CD\1740 mg/day\NN\1740 for\IN\1740 2\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 on\IN\1740 psychological\JJ\1740 performance\NN\6619065 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>panic\NN\7519253 disorders</e2>\NNS\14034177 and\CC\1740 agoraphobia\NN\14381416 were\VBD\836236 investigated\VBN\644583 in\IN\13603305 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 randomized\JJ\1740 and\CC\1740 crossover\NN\13526110 design\NN\927261 .\.\1740
D003975_D000379 NONE Behavioral\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>diazepam</e1>\NN\2830852 and\CC\1740 propranolol\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 panic\JJ\1740 disorder\NN\14034177 and\CC\1740 <e2>agoraphobia</e2>\NN\14381416 .\.\1740
D003975_D000379 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 oral\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>diazepam</e1>\NN\2830852 (\-LRB-\1740 single\JJ\1740 dose\NN\3740161 of\IN\1740 10\CD\13745420 mg\NN\13717155 and\CC\1740 a\DT\13649268 median\JJ\1740 dose\NN\3740161 of\IN\1740 30\CD\13745420 mg/day\NN\1740 for\IN\1740 2\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 and\CC\1740 propranolol\NN\1740 (\-LRB-\1740 single\JJ\1740 dose\NN\3740161 of\IN\1740 80\CD\13745420 mg\NN\13717155 and\CC\1740 a\DT\13649268 median\JJ\1740 dose\NN\3740161 of\IN\1740 240\CD\1740 mg/day\NN\1740 for\IN\1740 2\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 on\IN\1740 psychological\JJ\1740 performance\NN\6619065 of\IN\1740 patients\NNS\9898892 with\IN\1740 panic\NN\7519253 disorders\NNS\14034177 and\CC\1740 <e2>agoraphobia</e2>\NN\14381416 were\VBD\836236 investigated\VBN\644583 in\IN\13603305 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 randomized\JJ\1740 and\CC\1740 crossover\NN\13526110 design\NN\927261 .\.\1740
D011433_D016584 NONE Behavioral\JJ\1740 effects\NNS\13245626 of\IN\1740 diazepam\NN\2830852 and\CC\1740 <e1>propranolol</e1>\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>panic\JJ\1740 disorder</e2>\NN\14034177 and\CC\1740 agoraphobia\NN\14381416 .\.\1740
D011433_D016584 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 oral\JJ\1740 doses\NNS\3740161 of\IN\1740 diazepam\NN\2830852 (\-LRB-\1740 single\JJ\1740 dose\NN\3740161 of\IN\1740 10\CD\13745420 mg\NN\13717155 and\CC\1740 a\DT\13649268 median\JJ\1740 dose\NN\3740161 of\IN\1740 30\CD\13745420 mg/day\NN\1740 for\IN\1740 2\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 and\CC\1740 <e1>propranolol</e1>\NN\1740 (\-LRB-\1740 single\JJ\1740 dose\NN\3740161 of\IN\1740 80\CD\13745420 mg\NN\13717155 and\CC\1740 a\DT\13649268 median\JJ\1740 dose\NN\3740161 of\IN\1740 240\CD\1740 mg/day\NN\1740 for\IN\1740 2\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 on\IN\1740 psychological\JJ\1740 performance\NN\6619065 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>panic\NN\7519253 disorders</e2>\NNS\14034177 and\CC\1740 agoraphobia\NN\14381416 were\VBD\836236 investigated\VBN\644583 in\IN\13603305 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 randomized\JJ\1740 and\CC\1740 crossover\NN\13526110 design\NN\927261 .\.\1740
D011433_D000379 NONE Behavioral\JJ\1740 effects\NNS\13245626 of\IN\1740 diazepam\NN\2830852 and\CC\1740 <e1>propranolol</e1>\NN\1740 in\IN\13603305 patients\NNS\9898892 with\IN\1740 panic\JJ\1740 disorder\NN\14034177 and\CC\1740 <e2>agoraphobia</e2>\NN\14381416 .\.\1740
D011433_D000379 NONE The\DT\1740 effects\NNS\13245626 of\IN\1740 oral\JJ\1740 doses\NNS\3740161 of\IN\1740 diazepam\NN\2830852 (\-LRB-\1740 single\JJ\1740 dose\NN\3740161 of\IN\1740 10\CD\13745420 mg\NN\13717155 and\CC\1740 a\DT\13649268 median\JJ\1740 dose\NN\3740161 of\IN\1740 30\CD\13745420 mg/day\NN\1740 for\IN\1740 2\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 and\CC\1740 <e1>propranolol</e1>\NN\1740 (\-LRB-\1740 single\JJ\1740 dose\NN\3740161 of\IN\1740 80\CD\13745420 mg\NN\13717155 and\CC\1740 a\DT\13649268 median\JJ\1740 dose\NN\3740161 of\IN\1740 240\CD\1740 mg/day\NN\1740 for\IN\1740 2\CD\13741022 weeks\NNS\15113229 )\-RRB-\1740 on\IN\1740 psychological\JJ\1740 performance\NN\6619065 of\IN\1740 patients\NNS\9898892 with\IN\1740 panic\NN\7519253 disorders\NNS\14034177 and\CC\1740 <e2>agoraphobia</e2>\NN\14381416 were\VBD\836236 investigated\VBN\644583 in\IN\13603305 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 randomized\JJ\1740 and\CC\1740 crossover\NN\13526110 design\NN\927261 .\.\1740
D003975_D008569 CID Both\DT\1740 drugs\NNS\14778436 <e2>impaired\VBD\258857 immediate\JJ\1740 free\JJ\1740 recall</e2>\NN\7185325 but\CC\1740 the\DT\1740 decrease\NN\7296428 was\VBD\836236 greater\JJR\1740 for\IN\1740 <e1>diazepam</e1>\NN\2830852 than\IN\1740 propranolol\NN\1740 .\.\1740
D011433_D008569 CID Both\DT\1740 drugs\NNS\14778436 <e2>impaired\VBD\258857 immediate\JJ\1740 free\JJ\1740 recall</e2>\NN\7185325 but\CC\1740 the\DT\1740 decrease\NN\7296428 was\VBD\836236 greater\JJR\1740 for\IN\1740 diazepam\NN\2830852 than\IN\1740 <e1>propranolol</e1>\NN\1740 .\.\1740
18083142
D009638_D001008 NONE <e1>Norepinephrine</e1>\NN\14807929 signaling\NN\33020 through\IN\1740 beta-adrenergic\JJ\1740 receptors\NNS\5225602 is\VBZ\836236 critical\JJ\1740 for\IN\1740 expression\NN\4679549 of\IN\1740 cocaine-induced\JJ\1740 <e2>anxiety</e2>\NN\14373582 .\.\1740
D009638_D001008 NONE METHODS\NNS\5616786 :\:\1740 In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 evaluated\VBD\670261 the\DT\1740 performance\NN\6619065 of\IN\1740 dopamine\NN\14807737 beta-hydroxylase\NN\1740 knockout\NN\10787470 (\-LRB-\1740 Dbh\NN\1740 -/-\JJ\1740 )\-RRB-\1740 mice\NNS\2329401 ,\,\1740 which\WDT\1740 lack\VBP\1740 <e1>norepinephrine</e1>\NN\14807929 (\-LRB-\1740 NE\NN\14622893 )\-RRB-\1740 ,\,\1740 in\IN\13603305 the\DT\1740 elevated\JJ\1740 plus\CC\4723816 maze\NN\4377057 (\-LRB-\1740 EPM\NN\1740 )\-RRB-\1740 to\TO\1740 examine\VB\789138 the\DT\1740 contribution\NN\786195 of\IN\1740 noradrenergic\JJ\1740 signaling\NN\33020 to\TO\1740 cocaine-induced\JJ\1740 <e2>anxiety</e2>\NN\14373582 .\.\1740
D009638_D001008 NONE METHODS\NNS\5616786 :\:\1740 In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 evaluated\VBD\670261 the\DT\1740 performance\NN\6619065 of\IN\1740 dopamine\NN\14807737 beta-hydroxylase\NN\1740 knockout\NN\10787470 (\-LRB-\1740 Dbh\NN\1740 -/-\JJ\1740 )\-RRB-\1740 mice\NNS\2329401 ,\,\1740 which\WDT\1740 lack\VBP\1740 norepinephrine\NN\14807929 (\-LRB-\1740 <e1>NE</e1>\NN\14622893 )\-RRB-\1740 ,\,\1740 in\IN\13603305 the\DT\1740 elevated\JJ\1740 plus\CC\4723816 maze\NN\4377057 (\-LRB-\1740 EPM\NN\1740 )\-RRB-\1740 to\TO\1740 examine\VB\789138 the\DT\1740 contribution\NN\786195 of\IN\1740 noradrenergic\JJ\1740 signaling\NN\33020 to\TO\1740 cocaine-induced\JJ\1740 <e2>anxiety</e2>\NN\14373582 .\.\1740
D003042_D001008 CID Norepinephrine\NN\14807929 signaling\NN\33020 through\IN\1740 beta-adrenergic\JJ\1740 receptors\NNS\5225602 is\VBZ\836236 critical\JJ\1740 for\IN\1740 expression\NN\4679549 of\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 <e2>anxiety</e2>\NN\14373582 .\.\1740
D003042_D001008 CID While\IN\15122231 the\DT\1740 mechanisms\NNS\13446390 underlying\VBG\2604760 <e1>cocaine</e1>\NN\3492717 's\POS\1740 rewarding\VBG\2546467 effects\NNS\13245626 have\VBP\2108377 been\VBN\836236 studied\VBN\630380 extensively\RB\1740 ,\,\1740 less\JJR\1740 attention\NN\5701944 has\VBZ\2108377 been\VBN\836236 paid\VBN\2199590 to\IN\1740 the\DT\1740 unpleasant\JJ\1740 behavioral\JJ\1740 states\NNS\8491826 induced\VBN\1627355 by\IN\1740 cocaine\NN\3492717 ,\,\1740 such\JJ\1740 as\IN\14622893 <e2>anxiety</e2>\NN\14373582 .\.\1740
D003042_D001008 CID While\IN\15122231 the\DT\1740 mechanisms\NNS\13446390 underlying\VBG\2604760 cocaine\NN\3492717 's\POS\1740 rewarding\VBG\2546467 effects\NNS\13245626 have\VBP\2108377 been\VBN\836236 studied\VBN\630380 extensively\RB\1740 ,\,\1740 less\JJR\1740 attention\NN\5701944 has\VBZ\2108377 been\VBN\836236 paid\VBN\2199590 to\IN\1740 the\DT\1740 unpleasant\JJ\1740 behavioral\JJ\1740 states\NNS\8491826 induced\VBN\1627355 by\IN\1740 <e1>cocaine</e1>\NN\3492717 ,\,\1740 such\JJ\1740 as\IN\14622893 <e2>anxiety</e2>\NN\14373582 .\.\1740
D003042_D001008 CID METHODS\NNS\5616786 :\:\1740 In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 evaluated\VBD\670261 the\DT\1740 performance\NN\6619065 of\IN\1740 dopamine\NN\14807737 beta-hydroxylase\NN\1740 knockout\NN\10787470 (\-LRB-\1740 Dbh\NN\1740 -/-\JJ\1740 )\-RRB-\1740 mice\NNS\2329401 ,\,\1740 which\WDT\1740 lack\VBP\1740 norepinephrine\NN\14807929 (\-LRB-\1740 NE\NN\14622893 )\-RRB-\1740 ,\,\1740 in\IN\13603305 the\DT\1740 elevated\JJ\1740 plus\CC\4723816 maze\NN\4377057 (\-LRB-\1740 EPM\NN\1740 )\-RRB-\1740 to\TO\1740 examine\VB\789138 the\DT\1740 contribution\NN\786195 of\IN\1740 noradrenergic\JJ\1740 signaling\NN\33020 to\TO\1740 <e1>cocaine-induced</e1>\JJ\1740 <e2>anxiety</e2>\NN\14373582 .\.\1740
D003042_D001008 CID RESULTS\NNS\34213 :\:\1740 We\PRP\1740 found\VBD\2426171 that\IN\1740 <e1>cocaine</e1>\NN\3492717 dose-dependently\RB\1740 increased\VBD\169651 <e2>anxiety-like</e2>\JJ\1740 behavior\NN\407535 in\IN\13603305 control\NN\5190804 (\-LRB-\1740 Dbh\NN\1740 +/-\CC\1740 )\-RRB-\1740 mice\NNS\2329401 ,\,\1740 as\IN\14622893 measured\VBN\697589 by\IN\1740 a\DT\13649268 decrease\NN\7296428 in\IN\13603305 open\JJ\1740 arm\NN\5560244 exploration\NN\309647 .\.\1740
D003042_D001008 CID <e1>Cocaine-induced</e1>\JJ\1740 <e2>anxiety</e2>\NN\14373582 was\VBD\836236 also\RB\1740 attenuated\VBN\224901 in\IN\13603305 Dbh\NNP\1740 +/-\CC\1740 mice\NNS\2329401 following\VBG\1835496 administration\NN\1133281 of\IN\1740 disulfiram\NN\3740161 ,\,\1740 a\DT\13649268 dopamine\NN\14807737 beta-hydroxylase\NN\1740 (\-LRB-\1740 DBH\NN\1740 )\-RRB-\1740 inhibitor\NN\20090 .\.\1740
D003042_D001008 CID In\IN\13603305 experiments\NNS\641820 using\VBG\1156834 specific\JJ\1740 adrenergic\JJ\1740 antagonists\NNS\7846 ,\,\1740 we\PRP\1740 found\VBD\2426171 that\IN\1740 pretreatment\NN\1740 with\IN\1740 the\DT\1740 beta-adrenergic\JJ\1740 receptor\NN\5225602 antagonist\NN\7846 propranolol\NN\1740 blocked\VBD\1476483 <e1>cocaine-induced</e1>\JJ\1740 <e2>anxiety-like</e2>\JJ\1740 behavior\NN\407535 in\IN\13603305 Dbh\NNP\1740 +/-\CC\1740 and\CC\1740 wild-type\JJ\1740 C57BL6/J\NN\1740 mice\NNS\2329401 ,\,\1740 while\IN\15122231 the\DT\1740 alpha(1\NN\1740 )\-RRB-\1740 antagonist\NN\7846 prazosin\NN\2698769 and\CC\1740 the\DT\1740 alpha(2\NN\1740 )\-RRB-\1740 antagonist\NN\7846 yohimbine\NN\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 .\.\1740
D003042_D001008 CID CONCLUSIONS\NNS\5837957 :\:\1740 These\DT\1740 results\NNS\34213 indicate\VBP\952524 that\IN\1740 noradrenergic\JJ\1740 signaling\NN\33020 via\IN\1740 beta-adrenergic\JJ\1740 receptors\NNS\5225602 is\VBZ\836236 required\VBN\754942 for\IN\1740 <e1>cocaine-induced</e1>\JJ\1740 <e2>anxiety</e2>\NN\14373582 in\IN\13603305 mice\NNS\2329401 .\.\1740
D004298_D001008 NONE METHODS\NNS\5616786 :\:\1740 In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 we\PRP\1740 evaluated\VBD\670261 the\DT\1740 performance\NN\6619065 of\IN\1740 <e1>dopamine</e1>\NN\14807737 beta-hydroxylase\NN\1740 knockout\NN\10787470 (\-LRB-\1740 Dbh\NN\1740 -/-\JJ\1740 )\-RRB-\1740 mice\NNS\2329401 ,\,\1740 which\WDT\1740 lack\VBP\1740 norepinephrine\NN\14807929 (\-LRB-\1740 NE\NN\14622893 )\-RRB-\1740 ,\,\1740 in\IN\13603305 the\DT\1740 elevated\JJ\1740 plus\CC\4723816 maze\NN\4377057 (\-LRB-\1740 EPM\NN\1740 )\-RRB-\1740 to\TO\1740 examine\VB\789138 the\DT\1740 contribution\NN\786195 of\IN\1740 noradrenergic\JJ\1740 signaling\NN\33020 to\TO\1740 cocaine-induced\JJ\1740 <e2>anxiety</e2>\NN\14373582 .\.\1740
D004298_D001008 NONE Cocaine-induced\JJ\1740 <e2>anxiety</e2>\NN\14373582 was\VBD\836236 also\RB\1740 attenuated\VBN\224901 in\IN\13603305 Dbh\NNP\1740 +/-\CC\1740 mice\NNS\2329401 following\VBG\1835496 administration\NN\1133281 of\IN\1740 disulfiram\NN\3740161 ,\,\1740 a\DT\13649268 <e1>dopamine</e1>\NN\14807737 beta-hydroxylase\NN\1740 (\-LRB-\1740 DBH\NN\1740 )\-RRB-\1740 inhibitor\NN\20090 .\.\1740
D004221_D001008 NONE Cocaine-induced\JJ\1740 <e2>anxiety</e2>\NN\14373582 was\VBD\836236 also\RB\1740 attenuated\VBN\224901 in\IN\13603305 Dbh\NNP\1740 +/-\CC\1740 mice\NNS\2329401 following\VBG\1835496 administration\NN\1133281 of\IN\1740 <e1>disulfiram</e1>\NN\3740161 ,\,\1740 a\DT\13649268 dopamine\NN\14807737 beta-hydroxylase\NN\1740 (\-LRB-\1740 DBH\NN\1740 )\-RRB-\1740 inhibitor\NN\20090 .\.\1740
D011433_D001008 NONE In\IN\13603305 experiments\NNS\641820 using\VBG\1156834 specific\JJ\1740 adrenergic\JJ\1740 antagonists\NNS\7846 ,\,\1740 we\PRP\1740 found\VBD\2426171 that\IN\1740 pretreatment\NN\1740 with\IN\1740 the\DT\1740 beta-adrenergic\JJ\1740 receptor\NN\5225602 antagonist\NN\7846 <e1>propranolol</e1>\NN\1740 blocked\VBD\1476483 cocaine-induced\JJ\1740 <e2>anxiety-like</e2>\JJ\1740 behavior\NN\407535 in\IN\13603305 Dbh\NNP\1740 +/-\CC\1740 and\CC\1740 wild-type\JJ\1740 C57BL6/J\NN\1740 mice\NNS\2329401 ,\,\1740 while\IN\15122231 the\DT\1740 alpha(1\NN\1740 )\-RRB-\1740 antagonist\NN\7846 prazosin\NN\2698769 and\CC\1740 the\DT\1740 alpha(2\NN\1740 )\-RRB-\1740 antagonist\NN\7846 yohimbine\NN\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 .\.\1740
D011224_D001008 NONE In\IN\13603305 experiments\NNS\641820 using\VBG\1156834 specific\JJ\1740 adrenergic\JJ\1740 antagonists\NNS\7846 ,\,\1740 we\PRP\1740 found\VBD\2426171 that\IN\1740 pretreatment\NN\1740 with\IN\1740 the\DT\1740 beta-adrenergic\JJ\1740 receptor\NN\5225602 antagonist\NN\7846 propranolol\NN\1740 blocked\VBD\1476483 cocaine-induced\JJ\1740 <e2>anxiety-like</e2>\JJ\1740 behavior\NN\407535 in\IN\13603305 Dbh\NNP\1740 +/-\CC\1740 and\CC\1740 wild-type\JJ\1740 C57BL6/J\NN\1740 mice\NNS\2329401 ,\,\1740 while\IN\15122231 the\DT\1740 alpha(1\NN\1740 )\-RRB-\1740 antagonist\NN\7846 <e1>prazosin</e1>\NN\2698769 and\CC\1740 the\DT\1740 alpha(2\NN\1740 )\-RRB-\1740 antagonist\NN\7846 yohimbine\NN\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 .\.\1740
D015016_D001008 NONE In\IN\13603305 experiments\NNS\641820 using\VBG\1156834 specific\JJ\1740 adrenergic\JJ\1740 antagonists\NNS\7846 ,\,\1740 we\PRP\1740 found\VBD\2426171 that\IN\1740 pretreatment\NN\1740 with\IN\1740 the\DT\1740 beta-adrenergic\JJ\1740 receptor\NN\5225602 antagonist\NN\7846 propranolol\NN\1740 blocked\VBD\1476483 cocaine-induced\JJ\1740 <e2>anxiety-like</e2>\JJ\1740 behavior\NN\407535 in\IN\13603305 Dbh\NNP\1740 +/-\CC\1740 and\CC\1740 wild-type\JJ\1740 C57BL6/J\NN\1740 mice\NNS\2329401 ,\,\1740 while\IN\15122231 the\DT\1740 alpha(1\NN\1740 )\-RRB-\1740 antagonist\NN\7846 prazosin\NN\2698769 and\CC\1740 the\DT\1740 alpha(2\NN\1740 )\-RRB-\1740 antagonist\NN\7846 <e1>yohimbine</e1>\NN\1740 had\VBD\2108377 no\DT\7204911 effect\NN\34213 .\.\1740
3173180
D008795_D006463 CID <e2>Haemolytic-uraemic\JJ\1740 syndrome</e2>\NN\5870365 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>metronidazole</e1>\NN\2723292 .\.\1740
D008795_D006463 CID This\DT\1740 paper\NN\14580897 describes\VBZ\1001294 the\DT\1740 clinical\JJ\1740 features\NNS\5849040 of\IN\1740 six\CD\13741022 children\NNS\9622049 who\WP\8299493 developed\VBD\1753788 the\DT\1740 <e2>haemolytic-uraemic\JJ\1740 syndrome</e2>\NN\5870365 after\IN\1740 treatment\NN\654885 with\IN\1740 <e1>metronidazole</e1>\NN\2723292 .\.\1740
D008795_D006463 CID While\IN\15122231 the\DT\1740 involvement\NN\1080366 of\IN\1740 <e1>metronidazole</e1>\NN\2723292 in\IN\13603305 the\DT\1740 aetiology\NN\7326557 of\IN\1740 the\DT\1740 <e2>haemolytic-uraemic\JJ\1740 syndrome</e2>\NN\5870365 is\VBZ\836236 not\RB\1740 established\VBN\2426171 firmly\RB\1740 ,\,\1740 the\DT\1740 action\NN\30358 of\IN\1740 this\DT\1740 drug\NN\14778436 in\IN\13603305 sensitizing\VBG\126264 tissues\NNS\5220461 to\IN\1740 oxidation\NN\13447361 injury\NN\14052046 and\CC\1740 the\DT\1740 reported\VBN\831651 evidence\NN\5816287 of\IN\1740 oxidation\NN\13447361 changes\NNS\7283608 in\IN\13603305 the\DT\1740 haemolytic-uraemic\JJ\1740 syndrome\NN\5870365 suggest\VBP\1010118 a\DT\13649268 possible\JJ\1740 link\NN\13792579 between\IN\1740 metronidazole\NN\2723292 treatment\NN\654885 and\CC\1740 some\DT\1740 cases\NNS\7283608 of\IN\1740 the\DT\1740 haemolytic-uraemic\JJ\1740 syndrome\NN\5870365 .\.\1740
D008795_D006463 CID While\IN\15122231 the\DT\1740 involvement\NN\1080366 of\IN\1740 <e1>metronidazole</e1>\NN\2723292 in\IN\13603305 the\DT\1740 aetiology\NN\7326557 of\IN\1740 the\DT\1740 haemolytic-uraemic\JJ\1740 syndrome\NN\5870365 is\VBZ\836236 not\RB\1740 established\VBN\2426171 firmly\RB\1740 ,\,\1740 the\DT\1740 action\NN\30358 of\IN\1740 this\DT\1740 drug\NN\14778436 in\IN\13603305 sensitizing\VBG\126264 tissues\NNS\5220461 to\IN\1740 oxidation\NN\13447361 injury\NN\14052046 and\CC\1740 the\DT\1740 reported\VBN\831651 evidence\NN\5816287 of\IN\1740 oxidation\NN\13447361 changes\NNS\7283608 in\IN\13603305 the\DT\1740 <e2>haemolytic-uraemic\JJ\1740 syndrome</e2>\NN\5870365 suggest\VBP\1010118 a\DT\13649268 possible\JJ\1740 link\NN\13792579 between\IN\1740 metronidazole\NN\2723292 treatment\NN\654885 and\CC\1740 some\DT\1740 cases\NNS\7283608 of\IN\1740 the\DT\1740 haemolytic-uraemic\JJ\1740 syndrome\NN\5870365 .\.\1740
D008795_D006463 CID While\IN\15122231 the\DT\1740 involvement\NN\1080366 of\IN\1740 <e1>metronidazole</e1>\NN\2723292 in\IN\13603305 the\DT\1740 aetiology\NN\7326557 of\IN\1740 the\DT\1740 haemolytic-uraemic\JJ\1740 syndrome\NN\5870365 is\VBZ\836236 not\RB\1740 established\VBN\2426171 firmly\RB\1740 ,\,\1740 the\DT\1740 action\NN\30358 of\IN\1740 this\DT\1740 drug\NN\14778436 in\IN\13603305 sensitizing\VBG\126264 tissues\NNS\5220461 to\IN\1740 oxidation\NN\13447361 injury\NN\14052046 and\CC\1740 the\DT\1740 reported\VBN\831651 evidence\NN\5816287 of\IN\1740 oxidation\NN\13447361 changes\NNS\7283608 in\IN\13603305 the\DT\1740 haemolytic-uraemic\JJ\1740 syndrome\NN\5870365 suggest\VBP\1010118 a\DT\13649268 possible\JJ\1740 link\NN\13792579 between\IN\1740 metronidazole\NN\2723292 treatment\NN\654885 and\CC\1740 some\DT\1740 cases\NNS\7283608 of\IN\1740 the\DT\1740 <e2>haemolytic-uraemic\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
D008795_D006463 CID While\IN\15122231 the\DT\1740 involvement\NN\1080366 of\IN\1740 metronidazole\NN\2723292 in\IN\13603305 the\DT\1740 aetiology\NN\7326557 of\IN\1740 the\DT\1740 <e2>haemolytic-uraemic\JJ\1740 syndrome</e2>\NN\5870365 is\VBZ\836236 not\RB\1740 established\VBN\2426171 firmly\RB\1740 ,\,\1740 the\DT\1740 action\NN\30358 of\IN\1740 this\DT\1740 drug\NN\14778436 in\IN\13603305 sensitizing\VBG\126264 tissues\NNS\5220461 to\IN\1740 oxidation\NN\13447361 injury\NN\14052046 and\CC\1740 the\DT\1740 reported\VBN\831651 evidence\NN\5816287 of\IN\1740 oxidation\NN\13447361 changes\NNS\7283608 in\IN\13603305 the\DT\1740 haemolytic-uraemic\JJ\1740 syndrome\NN\5870365 suggest\VBP\1010118 a\DT\13649268 possible\JJ\1740 link\NN\13792579 between\IN\1740 <e1>metronidazole</e1>\NN\2723292 treatment\NN\654885 and\CC\1740 some\DT\1740 cases\NNS\7283608 of\IN\1740 the\DT\1740 haemolytic-uraemic\JJ\1740 syndrome\NN\5870365 .\.\1740
D008795_D006463 CID While\IN\15122231 the\DT\1740 involvement\NN\1080366 of\IN\1740 metronidazole\NN\2723292 in\IN\13603305 the\DT\1740 aetiology\NN\7326557 of\IN\1740 the\DT\1740 haemolytic-uraemic\JJ\1740 syndrome\NN\5870365 is\VBZ\836236 not\RB\1740 established\VBN\2426171 firmly\RB\1740 ,\,\1740 the\DT\1740 action\NN\30358 of\IN\1740 this\DT\1740 drug\NN\14778436 in\IN\13603305 sensitizing\VBG\126264 tissues\NNS\5220461 to\IN\1740 oxidation\NN\13447361 injury\NN\14052046 and\CC\1740 the\DT\1740 reported\VBN\831651 evidence\NN\5816287 of\IN\1740 oxidation\NN\13447361 changes\NNS\7283608 in\IN\13603305 the\DT\1740 <e2>haemolytic-uraemic\JJ\1740 syndrome</e2>\NN\5870365 suggest\VBP\1010118 a\DT\13649268 possible\JJ\1740 link\NN\13792579 between\IN\1740 <e1>metronidazole</e1>\NN\2723292 treatment\NN\654885 and\CC\1740 some\DT\1740 cases\NNS\7283608 of\IN\1740 the\DT\1740 haemolytic-uraemic\JJ\1740 syndrome\NN\5870365 .\.\1740
D008795_D006463 CID While\IN\15122231 the\DT\1740 involvement\NN\1080366 of\IN\1740 metronidazole\NN\2723292 in\IN\13603305 the\DT\1740 aetiology\NN\7326557 of\IN\1740 the\DT\1740 haemolytic-uraemic\JJ\1740 syndrome\NN\5870365 is\VBZ\836236 not\RB\1740 established\VBN\2426171 firmly\RB\1740 ,\,\1740 the\DT\1740 action\NN\30358 of\IN\1740 this\DT\1740 drug\NN\14778436 in\IN\13603305 sensitizing\VBG\126264 tissues\NNS\5220461 to\IN\1740 oxidation\NN\13447361 injury\NN\14052046 and\CC\1740 the\DT\1740 reported\VBN\831651 evidence\NN\5816287 of\IN\1740 oxidation\NN\13447361 changes\NNS\7283608 in\IN\13603305 the\DT\1740 haemolytic-uraemic\JJ\1740 syndrome\NN\5870365 suggest\VBP\1010118 a\DT\13649268 possible\JJ\1740 link\NN\13792579 between\IN\1740 <e1>metronidazole</e1>\NN\2723292 treatment\NN\654885 and\CC\1740 some\DT\1740 cases\NNS\7283608 of\IN\1740 the\DT\1740 <e2>haemolytic-uraemic\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
2578334
D001374_D011230 CID <e1>5-azacytidine</e1>\NN\1740 potentiates\VBZ\229605 <e2>initiation\NN\7450842 induced\VBN\1627355 by\IN\1740 carcinogens</e2>\NNS\20090 in\IN\13603305 rat\NN\2329401 liver\NN\5298729 .\.\1740
D001374_D011230 CID To\TO\1740 test\VB\670261 the\DT\1740 validity\NN\4782878 of\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 hypomethylation\NN\1740 of\IN\1740 DNA\NN\14994328 plays\VBZ\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 <e2>initiation\NN\7450842 of\IN\1740 carcinogenic\JJ\1740 process</e2>\NN\407535 ,\,\1740 <e1>5-azacytidine</e1>\NN\1740 (\-LRB-\1740 5-AzC\NN\1740 )\-RRB-\1740 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 DNA\NN\14994328 methylation\NN\1740 ,\,\1740 was\VBD\836236 given\VBN\2327200 to\TO\1740 rats\NNS\2329401 during\IN\1740 the\DT\1740 phase\NN\15113229 of\IN\1740 repair\NN\248977 synthesis\NN\13446390 induced\VBN\1627355 by\IN\1740 the\DT\1740 three\CD\13741022 carcinogens\NNS\20090 ,\,\1740 benzo[a]-pyrene\NN\1740 (\-LRB-\1740 200\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 N-methyl-N-nitrosourea\NN\1740 (\-LRB-\1740 60\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 and\CC\1740 1,2-dimethylhydrazine\NN\1740 (\-LRB-\1740 1,2-DMH\CD\1740 )\-RRB-\1740 (\-LRB-\1740 100\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 .\.\1740
D001374_D011230 CID To\TO\1740 test\VB\670261 the\DT\1740 validity\NN\4782878 of\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 hypomethylation\NN\1740 of\IN\1740 DNA\NN\14994328 plays\VBZ\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 <e2>initiation\NN\7450842 of\IN\1740 carcinogenic\JJ\1740 process</e2>\NN\407535 ,\,\1740 5-azacytidine\NN\1740 (\-LRB-\1740 <e1>5-AzC</e1>\NN\1740 )\-RRB-\1740 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 DNA\NN\14994328 methylation\NN\1740 ,\,\1740 was\VBD\836236 given\VBN\2327200 to\TO\1740 rats\NNS\2329401 during\IN\1740 the\DT\1740 phase\NN\15113229 of\IN\1740 repair\NN\248977 synthesis\NN\13446390 induced\VBN\1627355 by\IN\1740 the\DT\1740 three\CD\13741022 carcinogens\NNS\20090 ,\,\1740 benzo[a]-pyrene\NN\1740 (\-LRB-\1740 200\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 N-methyl-N-nitrosourea\NN\1740 (\-LRB-\1740 60\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 and\CC\1740 1,2-dimethylhydrazine\NN\1740 (\-LRB-\1740 1,2-DMH\CD\1740 )\-RRB-\1740 (\-LRB-\1740 100\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 .\.\1740
D001564_D011230 CID To\TO\1740 test\VB\670261 the\DT\1740 validity\NN\4782878 of\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 hypomethylation\NN\1740 of\IN\1740 DNA\NN\14994328 plays\VBZ\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 <e2>initiation\NN\7450842 of\IN\1740 carcinogenic\JJ\1740 process</e2>\NN\407535 ,\,\1740 5-azacytidine\NN\1740 (\-LRB-\1740 5-AzC\NN\1740 )\-RRB-\1740 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 DNA\NN\14994328 methylation\NN\1740 ,\,\1740 was\VBD\836236 given\VBN\2327200 to\TO\1740 rats\NNS\2329401 during\IN\1740 the\DT\1740 phase\NN\15113229 of\IN\1740 repair\NN\248977 synthesis\NN\13446390 induced\VBN\1627355 by\IN\1740 the\DT\1740 three\CD\13741022 carcinogens\NNS\20090 ,\,\1740 <e1>benzo[a]-pyrene</e1>\NN\1740 (\-LRB-\1740 200\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 N-methyl-N-nitrosourea\NN\1740 (\-LRB-\1740 60\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 and\CC\1740 1,2-dimethylhydrazine\NN\1740 (\-LRB-\1740 1,2-DMH\CD\1740 )\-RRB-\1740 (\-LRB-\1740 100\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 .\.\1740
D008770_D011230 CID To\TO\1740 test\VB\670261 the\DT\1740 validity\NN\4782878 of\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 hypomethylation\NN\1740 of\IN\1740 DNA\NN\14994328 plays\VBZ\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 <e2>initiation\NN\7450842 of\IN\1740 carcinogenic\JJ\1740 process</e2>\NN\407535 ,\,\1740 5-azacytidine\NN\1740 (\-LRB-\1740 5-AzC\NN\1740 )\-RRB-\1740 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 DNA\NN\14994328 methylation\NN\1740 ,\,\1740 was\VBD\836236 given\VBN\2327200 to\TO\1740 rats\NNS\2329401 during\IN\1740 the\DT\1740 phase\NN\15113229 of\IN\1740 repair\NN\248977 synthesis\NN\13446390 induced\VBN\1627355 by\IN\1740 the\DT\1740 three\CD\13741022 carcinogens\NNS\20090 ,\,\1740 benzo[a]-pyrene\NN\1740 (\-LRB-\1740 200\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 <e1>N-methyl-N-nitrosourea</e1>\NN\1740 (\-LRB-\1740 60\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 and\CC\1740 1,2-dimethylhydrazine\NN\1740 (\-LRB-\1740 1,2-DMH\CD\1740 )\-RRB-\1740 (\-LRB-\1740 100\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 .\.\1740
D019813_D011230 CID To\TO\1740 test\VB\670261 the\DT\1740 validity\NN\4782878 of\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 hypomethylation\NN\1740 of\IN\1740 DNA\NN\14994328 plays\VBZ\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 <e2>initiation\NN\7450842 of\IN\1740 carcinogenic\JJ\1740 process</e2>\NN\407535 ,\,\1740 5-azacytidine\NN\1740 (\-LRB-\1740 5-AzC\NN\1740 )\-RRB-\1740 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 DNA\NN\14994328 methylation\NN\1740 ,\,\1740 was\VBD\836236 given\VBN\2327200 to\TO\1740 rats\NNS\2329401 during\IN\1740 the\DT\1740 phase\NN\15113229 of\IN\1740 repair\NN\248977 synthesis\NN\13446390 induced\VBN\1627355 by\IN\1740 the\DT\1740 three\CD\13741022 carcinogens\NNS\20090 ,\,\1740 benzo[a]-pyrene\NN\1740 (\-LRB-\1740 200\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 N-methyl-N-nitrosourea\NN\1740 (\-LRB-\1740 60\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>1,2-dimethylhydrazine</e1>\NN\1740 (\-LRB-\1740 1,2-DMH\CD\1740 )\-RRB-\1740 (\-LRB-\1740 100\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 .\.\1740
D019813_D011230 CID To\TO\1740 test\VB\670261 the\DT\1740 validity\NN\4782878 of\IN\1740 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 hypomethylation\NN\1740 of\IN\1740 DNA\NN\14994328 plays\VBZ\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 <e2>initiation\NN\7450842 of\IN\1740 carcinogenic\JJ\1740 process</e2>\NN\407535 ,\,\1740 5-azacytidine\NN\1740 (\-LRB-\1740 5-AzC\NN\1740 )\-RRB-\1740 (\-LRB-\1740 10\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 inhibitor\NN\20090 of\IN\1740 DNA\NN\14994328 methylation\NN\1740 ,\,\1740 was\VBD\836236 given\VBN\2327200 to\TO\1740 rats\NNS\2329401 during\IN\1740 the\DT\1740 phase\NN\15113229 of\IN\1740 repair\NN\248977 synthesis\NN\13446390 induced\VBN\1627355 by\IN\1740 the\DT\1740 three\CD\13741022 carcinogens\NNS\20090 ,\,\1740 benzo[a]-pyrene\NN\1740 (\-LRB-\1740 200\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 N-methyl-N-nitrosourea\NN\1740 (\-LRB-\1740 60\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 and\CC\1740 1,2-dimethylhydrazine\NN\1740 (\-LRB-\1740 <e1>1,2-DMH</e1>\CD\1740 )\-RRB-\1740 (\-LRB-\1740 100\CD\13745420 mg/kg\NN\1740 )\-RRB-\1740 .\.\1740
8669433
D000082_D007676 NONE Habitual\JJ\1740 use\NN\407535 of\IN\1740 <e1>acetaminophen</e1>\NN\2707683 as\IN\14622893 a\DT\13649268 risk\NN\14541044 factor\NN\7326557 for\IN\1740 <e2>chronic\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 :\:\1740 a\DT\13649268 comparison\NN\635850 with\IN\1740 phenacetin\NN\2707683 .\.\1740
D000082_D007676 NONE However\RB\1740 ,\,\1740 three\CD\13741022 case\NN\7283608 control\NN\5190804 studies\NNS\635850 ,\,\1740 one\CD\13741022 each\DT\1740 in\IN\13603305 North\NNP\13831000 Carolina\NNP\1740 ,\,\1740 northern\JJ\1740 Maryland\NNP\1740 ,\,\1740 and\CC\1740 West\NNP\13831000 Berlin\NNP\3670208 ,\,\1740 Germany\NNP\1740 ,\,\1740 showed\VBD\2137132 that\IN\1740 habitual\JJ\1740 use\NN\407535 of\IN\1740 <e1>acetaminophen</e1>\NN\2707683 is\VBZ\836236 also\RB\1740 associated\VBN\628491 with\IN\1740 <e2>chronic\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 and\CC\1740 ESRD\NN\1740 ,\,\1740 with\IN\1740 a\DT\13649268 relative\JJ\1740 risk\NN\14541044 in\IN\13603305 the\DT\1740 range\NN\5123416 of\IN\1740 2\CD\13741022 to\TO\1740 4\CD\13741022 .\.\1740
D000082_D007676 NONE However\RB\1740 ,\,\1740 three\CD\13741022 case\NN\7283608 control\NN\5190804 studies\NNS\635850 ,\,\1740 one\CD\13741022 each\DT\1740 in\IN\13603305 North\NNP\13831000 Carolina\NNP\1740 ,\,\1740 northern\JJ\1740 Maryland\NNP\1740 ,\,\1740 and\CC\1740 West\NNP\13831000 Berlin\NNP\3670208 ,\,\1740 Germany\NNP\1740 ,\,\1740 showed\VBD\2137132 that\IN\1740 habitual\JJ\1740 use\NN\407535 of\IN\1740 <e1>acetaminophen</e1>\NN\2707683 is\VBZ\836236 also\RB\1740 associated\VBN\628491 with\IN\1740 chronic\JJ\1740 renal\JJ\1740 failure\NN\66216 and\CC\1740 <e2>ESRD</e2>\NN\1740 ,\,\1740 with\IN\1740 a\DT\13649268 relative\JJ\1740 risk\NN\14541044 in\IN\13603305 the\DT\1740 range\NN\5123416 of\IN\1740 2\CD\13741022 to\TO\1740 4\CD\13741022 .\.\1740
D000082_D007676 NONE These\DT\1740 studies\NNS\635850 suggest\VBP\1010118 that\IN\1740 both\CC\1740 phenacetin\NN\2707683 and\CC\1740 <e1>acetaminophen</e1>\NN\2707683 may\MD\15209706 contribute\VB\126264 to\TO\1740 the\DT\1740 burden\NN\5832264 of\IN\1740 <e2>ESRD</e2>\NN\1740 ,\,\1740 with\IN\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 the\DT\1740 latter\NN\13846546 being\VBG\836236 somewhat\RB\1740 less\JJR\1740 than\IN\1740 that\DT\1740 of\IN\1740 the\DT\1740 former\JJ\1740 .\.\1740
D000082_D007676 NONE The\DT\1740 possibility\NN\5944958 that\IN\1740 habitual\JJ\1740 use\NN\407535 of\IN\1740 <e1>acetaminophen</e1>\NN\2707683 alone\RB\1740 increases\VBZ\169651 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>ESRD</e2>\NN\1740 has\VBZ\2108377 not\RB\1740 been\VBN\836236 clearly\RB\1740 demonstrated\VBN\2137132 ,\,\1740 but\CC\1740 can\MD\3094503 not\RB\1740 be\VB\836236 dismissed\VBN\685683 .\.\1740
D010615_D007676 CID Habitual\JJ\1740 use\NN\407535 of\IN\1740 acetaminophen\NN\2707683 as\IN\14622893 a\DT\13649268 risk\NN\14541044 factor\NN\7326557 for\IN\1740 <e2>chronic\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 :\:\1740 a\DT\13649268 comparison\NN\635850 with\IN\1740 <e1>phenacetin</e1>\NN\2707683 .\.\1740
D010615_D007676 CID Six\CD\13741022 epidemiologic\JJ\1740 studies\NNS\635850 in\IN\13603305 the\DT\1740 United\NNP\1740 States\NNP\8491826 and\CC\1740 Europe\NNP\8294696 indicate\VBP\952524 that\IN\1740 habitual\JJ\1740 use\NN\407535 of\IN\1740 <e1>phenacetin</e1>\NN\2707683 is\VBZ\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>chronic\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 and\CC\1740 end-stage\JJ\1740 renal\JJ\1740 disease\NN\14061805 (\-LRB-\1740 ESRD\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 a\DT\13649268 relative\JJ\1740 risk\NN\14541044 in\IN\13603305 the\DT\1740 range\NN\5123416 of\IN\1740 4\CD\13741022 to\TO\1740 19\CD\13745420 .\.\1740
D010615_D007676 CID Six\CD\13741022 epidemiologic\JJ\1740 studies\NNS\635850 in\IN\13603305 the\DT\1740 United\NNP\1740 States\NNP\8491826 and\CC\1740 Europe\NNP\8294696 indicate\VBP\952524 that\IN\1740 habitual\JJ\1740 use\NN\407535 of\IN\1740 <e1>phenacetin</e1>\NN\2707683 is\VBZ\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 chronic\JJ\1740 renal\JJ\1740 failure\NN\66216 and\CC\1740 <e2>end-stage\JJ\1740 renal\JJ\1740 disease</e2>\NN\14061805 (\-LRB-\1740 ESRD\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 a\DT\13649268 relative\JJ\1740 risk\NN\14541044 in\IN\13603305 the\DT\1740 range\NN\5123416 of\IN\1740 4\CD\13741022 to\TO\1740 19\CD\13745420 .\.\1740
D010615_D007676 CID Six\CD\13741022 epidemiologic\JJ\1740 studies\NNS\635850 in\IN\13603305 the\DT\1740 United\NNP\1740 States\NNP\8491826 and\CC\1740 Europe\NNP\8294696 indicate\VBP\952524 that\IN\1740 habitual\JJ\1740 use\NN\407535 of\IN\1740 <e1>phenacetin</e1>\NN\2707683 is\VBZ\836236 associated\VBN\628491 with\IN\1740 the\DT\1740 development\NN\248977 of\IN\1740 chronic\JJ\1740 renal\JJ\1740 failure\NN\66216 and\CC\1740 end-stage\JJ\1740 renal\JJ\1740 disease\NN\14061805 (\-LRB-\1740 <e2>ESRD</e2>\NN\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 a\DT\13649268 relative\JJ\1740 risk\NN\14541044 in\IN\13603305 the\DT\1740 range\NN\5123416 of\IN\1740 4\CD\13741022 to\TO\1740 19\CD\13745420 .\.\1740
D010615_D007676 CID These\DT\1740 studies\NNS\635850 suggest\VBP\1010118 that\IN\1740 both\CC\1740 <e1>phenacetin</e1>\NN\2707683 and\CC\1740 acetaminophen\NN\2707683 may\MD\15209706 contribute\VB\126264 to\TO\1740 the\DT\1740 burden\NN\5832264 of\IN\1740 <e2>ESRD</e2>\NN\1740 ,\,\1740 with\IN\1740 the\DT\1740 risk\NN\14541044 of\IN\1740 the\DT\1740 latter\NN\13846546 being\VBG\836236 somewhat\RB\1740 less\JJR\1740 than\IN\1740 that\DT\1740 of\IN\1740 the\DT\1740 former\JJ\1740 .\.\1740
8741744
D009538_D009069 NONE Compared\VBN\644583 with\IN\1740 sham-operated\JJ\1740 controls\NNS\5190804 ,\,\1740 lesions\NNS\14204950 significantly\RB\1740 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.25\CD\1740 )\-RRB-\1740 blunted\VBD\224901 the\DT\1740 early\JJ\1740 (\-LRB-\1740 <\XX\1740 60\CD\13745420 min\NN\15154774 )\-RRB-\1740 free-field\JJ\1740 <e2>locomotor\NN\1740 hypoactivity</e2>\NN\1740 caused\VBN\1617192 by\IN\1740 <e1>nicotine</e1>\NN\14712692 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 kg(-1\NN\1740 )\-RRB-\1740 ,\,\1740 i.m.\RB\1740 )\-RRB-\1740 ,\,\1740 enhanced\VBD\227165 the\DT\1740 later\JJR\1740 (\-LRB-\1740 60\CD\13745420 -\SYM\1740 120\CD\13745420 min\NN\15154774 )\-RRB-\1740 nicotine-induced\JJ\1740 hyperactivity\NN\14052403 ,\,\1740 and\CC\1740 raised\VBD\153263 spontaneous\JJ\1740 nocturnal\JJ\1740 activity\NN\30358 .\.\1740
D009538_D009069 NONE Compared\VBN\644583 with\IN\1740 sham-operated\JJ\1740 controls\NNS\5190804 ,\,\1740 lesions\NNS\14204950 significantly\RB\1740 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.25\CD\1740 )\-RRB-\1740 blunted\VBD\224901 the\DT\1740 early\JJ\1740 (\-LRB-\1740 <\XX\1740 60\CD\13745420 min\NN\15154774 )\-RRB-\1740 free-field\JJ\1740 <e2>locomotor\NN\1740 hypoactivity</e2>\NN\1740 caused\VBN\1617192 by\IN\1740 nicotine\NN\14712692 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 kg(-1\NN\1740 )\-RRB-\1740 ,\,\1740 i.m.\RB\1740 )\-RRB-\1740 ,\,\1740 enhanced\VBD\227165 the\DT\1740 later\JJR\1740 (\-LRB-\1740 60\CD\13745420 -\SYM\1740 120\CD\13745420 min\NN\15154774 )\-RRB-\1740 <e1>nicotine-induced</e1>\JJ\1740 hyperactivity\NN\14052403 ,\,\1740 and\CC\1740 raised\VBD\153263 spontaneous\JJ\1740 nocturnal\JJ\1740 activity\NN\30358 .\.\1740
D009538_D006948 CID Compared\VBN\644583 with\IN\1740 sham-operated\JJ\1740 controls\NNS\5190804 ,\,\1740 lesions\NNS\14204950 significantly\RB\1740 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.25\CD\1740 )\-RRB-\1740 blunted\VBD\224901 the\DT\1740 early\JJ\1740 (\-LRB-\1740 <\XX\1740 60\CD\13745420 min\NN\15154774 )\-RRB-\1740 free-field\JJ\1740 locomotor\NN\1740 hypoactivity\NN\1740 caused\VBN\1617192 by\IN\1740 <e1>nicotine</e1>\NN\14712692 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 kg(-1\NN\1740 )\-RRB-\1740 ,\,\1740 i.m.\RB\1740 )\-RRB-\1740 ,\,\1740 enhanced\VBD\227165 the\DT\1740 later\JJR\1740 (\-LRB-\1740 60\CD\13745420 -\SYM\1740 120\CD\13745420 min\NN\15154774 )\-RRB-\1740 nicotine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 ,\,\1740 and\CC\1740 raised\VBD\153263 spontaneous\JJ\1740 nocturnal\JJ\1740 activity\NN\30358 .\.\1740
D009538_D006948 CID Compared\VBN\644583 with\IN\1740 sham-operated\JJ\1740 controls\NNS\5190804 ,\,\1740 lesions\NNS\14204950 significantly\RB\1740 (\-LRB-\1740 p\NN\14622893 <\XX\1740 0.25\CD\1740 )\-RRB-\1740 blunted\VBD\224901 the\DT\1740 early\JJ\1740 (\-LRB-\1740 <\XX\1740 60\CD\13745420 min\NN\15154774 )\-RRB-\1740 free-field\JJ\1740 locomotor\NN\1740 hypoactivity\NN\1740 caused\VBN\1617192 by\IN\1740 nicotine\NN\14712692 (\-LRB-\1740 0.5\CD\1740 mg\NN\13717155 kg(-1\NN\1740 )\-RRB-\1740 ,\,\1740 i.m.\RB\1740 )\-RRB-\1740 ,\,\1740 enhanced\VBD\227165 the\DT\1740 later\JJR\1740 (\-LRB-\1740 60\CD\13745420 -\SYM\1740 120\CD\13745420 min\NN\15154774 )\-RRB-\1740 <e1>nicotine-induced</e1>\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 ,\,\1740 and\CC\1740 raised\VBD\153263 spontaneous\JJ\1740 nocturnal\JJ\1740 activity\NN\30358 .\.\1740
2894766
D012460_D008180 CID <e1>Sulfasalazine-induced</e1>\JJ\1740 <e2>lupus\NN\14219661 erythematosus</e2>\NN\1740 .\.\1740
D012460_D008180 CID It\PRP\6125041 is\VBZ\836236 suggested\VBN\1010118 that\IN\1740 the\DT\1740 patient\NN\9898892 had\VBD\2108377 <e1>sulfasalazine-induced</e1>\JJ\1740 <e2>lupus</e2>\NN\14219661 ,\,\1740 which\WDT\1740 manifested\VBD\1015244 with\IN\1740 serositis\NN\1740 and\CC\1740 pulmonary\JJ\1740 parenchymal\JJ\1740 involvement\NN\1080366 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 joint\JJ\1740 symptoms\NNS\5823932 .\.\1740
D012460_D008180 CID Physicians\NNS\10305802 who\WP\8299493 use\VBP\1156834 <e1>sulfasalazine</e1>\NN\1740 to\TO\1740 treat\VB\2376958 patients\NNS\9898892 with\IN\1740 inflammatory\JJ\1740 bowel\NN\5298729 disease\NN\14061805 should\MD\1740 be\VB\836236 aware\JJ\1740 of\IN\1740 the\DT\1740 signs\NNS\6643763 of\IN\1740 sulfasalazine-induced\JJ\1740 <e2>lupus\NN\14219661 syndrome</e2>\NN\5870365 .\.\1740
D012460_D008180 CID Physicians\NNS\10305802 who\WP\8299493 use\VBP\1156834 sulfasalazine\NN\1740 to\TO\1740 treat\VB\2376958 patients\NNS\9898892 with\IN\1740 inflammatory\JJ\1740 bowel\NN\5298729 disease\NN\14061805 should\MD\1740 be\VB\836236 aware\JJ\1740 of\IN\1740 the\DT\1740 signs\NNS\6643763 of\IN\1740 <e1>sulfasalazine-induced</e1>\JJ\1740 <e2>lupus\NN\14219661 syndrome</e2>\NN\5870365 .\.\1740
D012460_D011014 CID <e2>Pneumonitis</e2>\NN\14336539 ,\,\1740 bilateral\JJ\1740 pleural\JJ\1740 effusions\NNS\6880249 ,\,\1740 echocardiographic\JJ\1740 evidence\NN\5816287 of\IN\1740 cardiac\JJ\1740 tamponade\NN\14507951 ,\,\1740 and\CC\1740 positive\JJ\1740 autoantibodies\NNS\15027189 developed\VBD\1753788 in\IN\13603305 a\DT\13649268 43-year-old\JJ\1740 man\NN\9605289 ,\,\1740 who\WP\8299493 was\VBD\836236 receiving\VBG\2210855 long-term\JJ\1740 <e1>sulfasalazine</e1>\NN\1740 therapy\NN\657604 for\IN\1740 chronic\JJ\1740 ulcerative\JJ\1740 colitis\NN\14336539 .\.\1740
D012460_D010996 CID Pneumonitis\NN\14336539 ,\,\1740 bilateral\JJ\1740 <e2>pleural\JJ\1740 effusions</e2>\NNS\6880249 ,\,\1740 echocardiographic\JJ\1740 evidence\NN\5816287 of\IN\1740 cardiac\JJ\1740 tamponade\NN\14507951 ,\,\1740 and\CC\1740 positive\JJ\1740 autoantibodies\NNS\15027189 developed\VBD\1753788 in\IN\13603305 a\DT\13649268 43-year-old\JJ\1740 man\NN\9605289 ,\,\1740 who\WP\8299493 was\VBD\836236 receiving\VBG\2210855 long-term\JJ\1740 <e1>sulfasalazine</e1>\NN\1740 therapy\NN\657604 for\IN\1740 chronic\JJ\1740 ulcerative\JJ\1740 colitis\NN\14336539 .\.\1740
D012460_D002305 CID Pneumonitis\NN\14336539 ,\,\1740 bilateral\JJ\1740 pleural\JJ\1740 effusions\NNS\6880249 ,\,\1740 echocardiographic\JJ\1740 evidence\NN\5816287 of\IN\1740 <e2>cardiac\JJ\1740 tamponade</e2>\NN\14507951 ,\,\1740 and\CC\1740 positive\JJ\1740 autoantibodies\NNS\15027189 developed\VBD\1753788 in\IN\13603305 a\DT\13649268 43-year-old\JJ\1740 man\NN\9605289 ,\,\1740 who\WP\8299493 was\VBD\836236 receiving\VBG\2210855 long-term\JJ\1740 <e1>sulfasalazine</e1>\NN\1740 therapy\NN\657604 for\IN\1740 chronic\JJ\1740 ulcerative\JJ\1740 colitis\NN\14336539 .\.\1740
D012460_D003093 NONE Pneumonitis\NN\14336539 ,\,\1740 bilateral\JJ\1740 pleural\JJ\1740 effusions\NNS\6880249 ,\,\1740 echocardiographic\JJ\1740 evidence\NN\5816287 of\IN\1740 cardiac\JJ\1740 tamponade\NN\14507951 ,\,\1740 and\CC\1740 positive\JJ\1740 autoantibodies\NNS\15027189 developed\VBD\1753788 in\IN\13603305 a\DT\13649268 43-year-old\JJ\1740 man\NN\9605289 ,\,\1740 who\WP\8299493 was\VBD\836236 receiving\VBG\2210855 long-term\JJ\1740 <e1>sulfasalazine</e1>\NN\1740 therapy\NN\657604 for\IN\1740 chronic\JJ\1740 <e2>ulcerative\JJ\1740 colitis</e2>\NN\14336539 .\.\1740
D012460_D012700 NONE It\PRP\6125041 is\VBZ\836236 suggested\VBN\1010118 that\IN\1740 the\DT\1740 patient\NN\9898892 had\VBD\2108377 <e1>sulfasalazine-induced</e1>\JJ\1740 lupus\NN\14219661 ,\,\1740 which\WDT\1740 manifested\VBD\1015244 with\IN\1740 <e2>serositis</e2>\NN\1740 and\CC\1740 pulmonary\JJ\1740 parenchymal\JJ\1740 involvement\NN\1080366 in\IN\13603305 the\DT\1740 absence\NN\14449405 of\IN\1740 joint\JJ\1740 symptoms\NNS\5823932 .\.\1740
D012460_D015212 NONE Physicians\NNS\10305802 who\WP\8299493 use\VBP\1156834 <e1>sulfasalazine</e1>\NN\1740 to\TO\1740 treat\VB\2376958 patients\NNS\9898892 with\IN\1740 <e2>inflammatory\JJ\1740 bowel\NN\5298729 disease</e2>\NN\14061805 should\MD\1740 be\VB\836236 aware\JJ\1740 of\IN\1740 the\DT\1740 signs\NNS\6643763 of\IN\1740 sulfasalazine-induced\JJ\1740 lupus\NN\14219661 syndrome\NN\5870365 .\.\1740
D012460_D015212 NONE Physicians\NNS\10305802 who\WP\8299493 use\VBP\1156834 sulfasalazine\NN\1740 to\TO\1740 treat\VB\2376958 patients\NNS\9898892 with\IN\1740 <e2>inflammatory\JJ\1740 bowel\NN\5298729 disease</e2>\NN\14061805 should\MD\1740 be\VB\836236 aware\JJ\1740 of\IN\1740 the\DT\1740 signs\NNS\6643763 of\IN\1740 <e1>sulfasalazine-induced</e1>\JJ\1740 lupus\NN\14219661 syndrome\NN\5870365 .\.\1740
19729346
D010098_D010146 NONE This\DT\1740 study\NN\635850 measured\VBD\697589 the\DT\1740 objective\JJ\1740 and\CC\1740 subjective\JJ\1740 neurocognitive\JJ\1740 effects\NNS\13245626 of\IN\1740 a\DT\13649268 single\JJ\1740 10-mg\JJ\1740 dose\NN\3740161 of\IN\1740 immediate-release\NN\1740 <e1>oxycodone</e1>\NN\1740 in\IN\13603305 healthy\JJ\1740 ,\,\1740 older\JJR\1740 (\-LRB-\1740 >\NNS\1740 65\CD\1740 years\NNS\15144371 )\-RRB-\1740 ,\,\1740 and\CC\1740 middle-aged\JJ\1740 (\-LRB-\1740 35\CD\1740 to\TO\1740 55\CD\1740 years\NNS\15144371 )\-RRB-\1740 adults\NNS\7846 who\WP\8299493 were\VBD\836236 not\RB\1740 suffering\VBG\2110220 from\IN\1740 chronic\JJ\1740 or\CC\3541091 significant\JJ\1740 daily\NN\6267145 <e2>pain</e2>\NN\14299637 .\.\1740
D010098_D059350 NONE This\DT\1740 study\NN\635850 suggests\VBZ\1010118 that\IN\1740 for\IN\1740 healthy\JJ\1740 older\JJR\1740 adults\NNS\7846 who\WP\8299493 are\VBP\836236 not\RB\1740 suffering\VBG\2110220 from\IN\1740 <e2>chronic\JJ\1740 pain</e2>\NN\14299637 ,\,\1740 neurocognitive\JJ\1740 and\CC\1740 pharmacodynamic\JJ\1740 changes\NNS\7283608 in\IN\13603305 response\NN\11410625 to\TO\1740 a\DT\13649268 10-mg\JJ\1740 dose\NN\3740161 of\IN\1740 immediate-release\NN\1740 <e1>oxycodone</e1>\NN\1740 are\VBP\836236 similar\JJ\1740 to\TO\1740 those\DT\1740 observed\VBN\2163746 for\IN\1740 middle-aged\JJ\1740 adults\NNS\7846 .\.\1740
14513889
D007654_D009422 NONE <e1>Ketoconazole-induced</e1>\JJ\1740 <e2>neurologic\JJ\1740 sequelae</e2>\NN\14501726 .\.\1740
D007654_D018908 CID A\DT\13649268 77-y-old\JJ\1740 patient\NN\9898892 developed\VBD\1753788 <e2>weakness\NN\14462666 of\IN\1740 extremities</e2>\NNS\5225090 ,\,\1740 legs\NNS\5032918 paralysis\NN\14557898 ,\,\1740 dysarthria\NN\14400677 and\CC\1740 tremor\NN\345926 1\CD\13741022 h\NN\14622893 after\IN\1740 ingestion\NN\13440063 of\IN\1740 200\CD\1740 mg\NN\13717155 <e1>ketoconazole</e1>\NN\1740 for\IN\1740 the\DT\1740 first\JJ\1740 time\NN\7308889 in\IN\13603305 his\PRP$\1740 life\NN\13954253 .\.\1740
D007654_D010243 CID A\DT\13649268 77-y-old\JJ\1740 patient\NN\9898892 developed\VBD\1753788 weakness\NN\14462666 of\IN\1740 extremities\NNS\5225090 ,\,\1740 <e2>legs\NNS\5032918 paralysis</e2>\NN\14557898 ,\,\1740 dysarthria\NN\14400677 and\CC\1740 tremor\NN\345926 1\CD\13741022 h\NN\14622893 after\IN\1740 ingestion\NN\13440063 of\IN\1740 200\CD\1740 mg\NN\13717155 <e1>ketoconazole</e1>\NN\1740 for\IN\1740 the\DT\1740 first\JJ\1740 time\NN\7308889 in\IN\13603305 his\PRP$\1740 life\NN\13954253 .\.\1740
D007654_D004401 CID A\DT\13649268 77-y-old\JJ\1740 patient\NN\9898892 developed\VBD\1753788 weakness\NN\14462666 of\IN\1740 extremities\NNS\5225090 ,\,\1740 legs\NNS\5032918 paralysis\NN\14557898 ,\,\1740 <e2>dysarthria</e2>\NN\14400677 and\CC\1740 tremor\NN\345926 1\CD\13741022 h\NN\14622893 after\IN\1740 ingestion\NN\13440063 of\IN\1740 200\CD\1740 mg\NN\13717155 <e1>ketoconazole</e1>\NN\1740 for\IN\1740 the\DT\1740 first\JJ\1740 time\NN\7308889 in\IN\13603305 his\PRP$\1740 life\NN\13954253 .\.\1740
D007654_D014202 CID A\DT\13649268 77-y-old\JJ\1740 patient\NN\9898892 developed\VBD\1753788 weakness\NN\14462666 of\IN\1740 extremities\NNS\5225090 ,\,\1740 legs\NNS\5032918 paralysis\NN\14557898 ,\,\1740 dysarthria\NN\14400677 and\CC\1740 <e2>tremor</e2>\NN\345926 1\CD\13741022 h\NN\14622893 after\IN\1740 ingestion\NN\13440063 of\IN\1740 200\CD\1740 mg\NN\13717155 <e1>ketoconazole</e1>\NN\1740 for\IN\1740 the\DT\1740 first\JJ\1740 time\NN\7308889 in\IN\13603305 his\PRP$\1740 life\NN\13954253 .\.\1740
20633755
D013390_D001049 CID <e1>Suxamethonium</e1>\NNP\1740 induced\VBD\1627355 prolonged\JJ\1740 <e2>apnea</e2>\NN\14299637 in\IN\13603305 a\DT\13649268 patient\NN\9898892 receiving\VBG\2210855 electroconvulsive\JJ\1740 therapy\NN\657604 .\.\1740
D013390_D001049 CID <e1>Suxamethonium</e1>\NNP\1740 causes\VBZ\1617192 prolonged\JJ\1740 <e2>apnea</e2>\NN\14299637 in\IN\13603305 patients\NNS\9898892 in\IN\13603305 whom\WP\1740 pseudocholinesterase\NN\1740 enzyme\NN\14723628 gets\VBZ\146138 deactivated\VBN\1097743 by\IN\1740 organophosphorus\NN\1740 (\-LRB-\1740 OP\NN\1740 )\-RRB-\1740 poisons\NNS\20090 .\.\1740
D009943_D001049 CID Suxamethonium\NNP\1740 causes\VBZ\1617192 prolonged\JJ\1740 <e2>apnea</e2>\NN\14299637 in\IN\13603305 patients\NNS\9898892 in\IN\13603305 whom\WP\1740 pseudocholinesterase\NN\1740 enzyme\NN\14723628 gets\VBZ\146138 deactivated\VBN\1097743 by\IN\1740 <e1>organophosphorus\NN\1740 (\-LRB-\1740 OP\NN\1740 )\-RRB-\1740 poisons</e1>\NNS\20090 .\.\1740
D009943_D001049 CID Prolonged\JJ\1740 <e2>apnea</e2>\NN\14299637 in\IN\13603305 our\PRP$\1740 case\NN\7283608 ensued\VBN\2633881 because\IN\1740 the\DT\1740 information\NN\6598915 about\IN\1740 suicidal\JJ\1740 attempt\NN\407535 by\IN\1740 <e1>OP\NN\1740 compound</e1>\NN\5869584 was\VBD\836236 concealed\VBN\1740 from\IN\1740 the\DT\1740 treating\NN\1740 team\NN\8189659 .\.\1740
8319760
D019808_D009401 NONE <e1>Dup\NN\1740 753</e1>\CD\1740 prevents\VBZ\1740 the\DT\1740 development\NN\248977 of\IN\1740 puromycin\NN\1740 aminonucleoside-induced\JJ\1740 <e2>nephrosis</e2>\NN\14304060 .\.\1740
D011692_D009401 NONE Dup\NN\1740 753\CD\1740 prevents\VBZ\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e1>puromycin\NN\1740 aminonucleoside-induced</e1>\JJ\1740 <e2>nephrosis</e2>\NN\14304060 .\.\1740
D011692_D009401 NONE The\DT\1740 results\NNS\34213 suggest\VBP\1010118 a\DT\13649268 possible\JJ\1740 involvement\NN\1080366 of\IN\1740 the\DT\1740 renin-angiotensin\JJ\1740 system\NN\3575240 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e1>puromycin\NN\1740 aminonucleoside-induced</e1>\JJ\1740 <e2>nephrosis</e2>\NN\14304060 .\.\1740
D001806_D009404 NONE The\DT\1740 appearance\NN\4723816 of\IN\1740 <e2>nephrotic\JJ\1740 syndromes</e2>\NNS\5870365 such\JJ\1740 as\IN\14622893 proteinuria\NN\14299637 ,\,\1740 hypoalbuminemia\NN\1740 ,\,\1740 hypercholesterolemia\NN\14299637 and\CC\1740 increase\VB\169651 in\IN\13603305 <e1>blood\NN\5397468 nitrogen\NN\14622893 urea</e1>\NN\14727670 ,\,\1740 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 injection\NN\320852 of\IN\1740 puromycin\NN\1740 aminonucleoside\NN\1740 was\VBD\836236 markedly\RB\1740 inhibited\VBN\2510337 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 Dup\NN\1740 753\CD\1740 (\-LRB-\1740 losartan\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 1\CD\13741022 or\CC\3541091 2\CD\13741022 mg/kg\NN\1740 per\IN\1740 day\NN\15154774 .\.\1740
D001806_D011507 NONE The\DT\1740 appearance\NN\4723816 of\IN\1740 nephrotic\JJ\1740 syndromes\NNS\5870365 such\JJ\1740 as\IN\14622893 <e2>proteinuria</e2>\NN\14299637 ,\,\1740 hypoalbuminemia\NN\1740 ,\,\1740 hypercholesterolemia\NN\14299637 and\CC\1740 increase\VB\169651 in\IN\13603305 <e1>blood\NN\5397468 nitrogen\NN\14622893 urea</e1>\NN\14727670 ,\,\1740 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 injection\NN\320852 of\IN\1740 puromycin\NN\1740 aminonucleoside\NN\1740 was\VBD\836236 markedly\RB\1740 inhibited\VBN\2510337 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 Dup\NN\1740 753\CD\1740 (\-LRB-\1740 losartan\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 1\CD\13741022 or\CC\3541091 2\CD\13741022 mg/kg\NN\1740 per\IN\1740 day\NN\15154774 .\.\1740
D001806_D034141 NONE The\DT\1740 appearance\NN\4723816 of\IN\1740 nephrotic\JJ\1740 syndromes\NNS\5870365 such\JJ\1740 as\IN\14622893 proteinuria\NN\14299637 ,\,\1740 <e2>hypoalbuminemia</e2>\NN\1740 ,\,\1740 hypercholesterolemia\NN\14299637 and\CC\1740 increase\VB\169651 in\IN\13603305 <e1>blood\NN\5397468 nitrogen\NN\14622893 urea</e1>\NN\14727670 ,\,\1740 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 injection\NN\320852 of\IN\1740 puromycin\NN\1740 aminonucleoside\NN\1740 was\VBD\836236 markedly\RB\1740 inhibited\VBN\2510337 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 Dup\NN\1740 753\CD\1740 (\-LRB-\1740 losartan\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 1\CD\13741022 or\CC\3541091 2\CD\13741022 mg/kg\NN\1740 per\IN\1740 day\NN\15154774 .\.\1740
D001806_D006937 NONE The\DT\1740 appearance\NN\4723816 of\IN\1740 nephrotic\JJ\1740 syndromes\NNS\5870365 such\JJ\1740 as\IN\14622893 proteinuria\NN\14299637 ,\,\1740 hypoalbuminemia\NN\1740 ,\,\1740 <e2>hypercholesterolemia</e2>\NN\14299637 and\CC\1740 increase\VB\169651 in\IN\13603305 <e1>blood\NN\5397468 nitrogen\NN\14622893 urea</e1>\NN\14727670 ,\,\1740 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 injection\NN\320852 of\IN\1740 puromycin\NN\1740 aminonucleoside\NN\1740 was\VBD\836236 markedly\RB\1740 inhibited\VBN\2510337 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 Dup\NN\1740 753\CD\1740 (\-LRB-\1740 losartan\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 1\CD\13741022 or\CC\3541091 2\CD\13741022 mg/kg\NN\1740 per\IN\1740 day\NN\15154774 .\.\1740
D011692_D009404 CID The\DT\1740 appearance\NN\4723816 of\IN\1740 <e2>nephrotic\JJ\1740 syndromes</e2>\NNS\5870365 such\JJ\1740 as\IN\14622893 proteinuria\NN\14299637 ,\,\1740 hypoalbuminemia\NN\1740 ,\,\1740 hypercholesterolemia\NN\14299637 and\CC\1740 increase\VB\169651 in\IN\13603305 blood\NN\5397468 nitrogen\NN\14622893 urea\NN\14727670 ,\,\1740 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 injection\NN\320852 of\IN\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 was\VBD\836236 markedly\RB\1740 inhibited\VBN\2510337 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 Dup\NN\1740 753\CD\1740 (\-LRB-\1740 losartan\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 1\CD\13741022 or\CC\3541091 2\CD\13741022 mg/kg\NN\1740 per\IN\1740 day\NN\15154774 .\.\1740
D011692_D011507 CID The\DT\1740 appearance\NN\4723816 of\IN\1740 nephrotic\JJ\1740 syndromes\NNS\5870365 such\JJ\1740 as\IN\14622893 <e2>proteinuria</e2>\NN\14299637 ,\,\1740 hypoalbuminemia\NN\1740 ,\,\1740 hypercholesterolemia\NN\14299637 and\CC\1740 increase\VB\169651 in\IN\13603305 blood\NN\5397468 nitrogen\NN\14622893 urea\NN\14727670 ,\,\1740 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 injection\NN\320852 of\IN\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 was\VBD\836236 markedly\RB\1740 inhibited\VBN\2510337 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 Dup\NN\1740 753\CD\1740 (\-LRB-\1740 losartan\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 1\CD\13741022 or\CC\3541091 2\CD\13741022 mg/kg\NN\1740 per\IN\1740 day\NN\15154774 .\.\1740
D011692_D034141 CID The\DT\1740 appearance\NN\4723816 of\IN\1740 nephrotic\JJ\1740 syndromes\NNS\5870365 such\JJ\1740 as\IN\14622893 proteinuria\NN\14299637 ,\,\1740 <e2>hypoalbuminemia</e2>\NN\1740 ,\,\1740 hypercholesterolemia\NN\14299637 and\CC\1740 increase\VB\169651 in\IN\13603305 blood\NN\5397468 nitrogen\NN\14622893 urea\NN\14727670 ,\,\1740 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 injection\NN\320852 of\IN\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 was\VBD\836236 markedly\RB\1740 inhibited\VBN\2510337 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 Dup\NN\1740 753\CD\1740 (\-LRB-\1740 losartan\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 1\CD\13741022 or\CC\3541091 2\CD\13741022 mg/kg\NN\1740 per\IN\1740 day\NN\15154774 .\.\1740
D011692_D006937 CID The\DT\1740 appearance\NN\4723816 of\IN\1740 nephrotic\JJ\1740 syndromes\NNS\5870365 such\JJ\1740 as\IN\14622893 proteinuria\NN\14299637 ,\,\1740 hypoalbuminemia\NN\1740 ,\,\1740 <e2>hypercholesterolemia</e2>\NN\14299637 and\CC\1740 increase\VB\169651 in\IN\13603305 blood\NN\5397468 nitrogen\NN\14622893 urea\NN\14727670 ,\,\1740 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 injection\NN\320852 of\IN\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 was\VBD\836236 markedly\RB\1740 inhibited\VBN\2510337 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 Dup\NN\1740 753\CD\1740 (\-LRB-\1740 losartan\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 1\CD\13741022 or\CC\3541091 2\CD\13741022 mg/kg\NN\1740 per\IN\1740 day\NN\15154774 .\.\1740
D019808_D009404 NONE The\DT\1740 appearance\NN\4723816 of\IN\1740 <e2>nephrotic\JJ\1740 syndromes</e2>\NNS\5870365 such\JJ\1740 as\IN\14622893 proteinuria\NN\14299637 ,\,\1740 hypoalbuminemia\NN\1740 ,\,\1740 hypercholesterolemia\NN\14299637 and\CC\1740 increase\VB\169651 in\IN\13603305 blood\NN\5397468 nitrogen\NN\14622893 urea\NN\14727670 ,\,\1740 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 injection\NN\320852 of\IN\1740 puromycin\NN\1740 aminonucleoside\NN\1740 was\VBD\836236 markedly\RB\1740 inhibited\VBN\2510337 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>Dup\NN\1740 753</e1>\CD\1740 (\-LRB-\1740 losartan\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 1\CD\13741022 or\CC\3541091 2\CD\13741022 mg/kg\NN\1740 per\IN\1740 day\NN\15154774 .\.\1740
D019808_D009404 NONE The\DT\1740 appearance\NN\4723816 of\IN\1740 <e2>nephrotic\JJ\1740 syndromes</e2>\NNS\5870365 such\JJ\1740 as\IN\14622893 proteinuria\NN\14299637 ,\,\1740 hypoalbuminemia\NN\1740 ,\,\1740 hypercholesterolemia\NN\14299637 and\CC\1740 increase\VB\169651 in\IN\13603305 blood\NN\5397468 nitrogen\NN\14622893 urea\NN\14727670 ,\,\1740 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 injection\NN\320852 of\IN\1740 puromycin\NN\1740 aminonucleoside\NN\1740 was\VBD\836236 markedly\RB\1740 inhibited\VBN\2510337 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 Dup\NN\1740 753\CD\1740 (\-LRB-\1740 <e1>losartan</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 1\CD\13741022 or\CC\3541091 2\CD\13741022 mg/kg\NN\1740 per\IN\1740 day\NN\15154774 .\.\1740
D019808_D011507 NONE The\DT\1740 appearance\NN\4723816 of\IN\1740 nephrotic\JJ\1740 syndromes\NNS\5870365 such\JJ\1740 as\IN\14622893 <e2>proteinuria</e2>\NN\14299637 ,\,\1740 hypoalbuminemia\NN\1740 ,\,\1740 hypercholesterolemia\NN\14299637 and\CC\1740 increase\VB\169651 in\IN\13603305 blood\NN\5397468 nitrogen\NN\14622893 urea\NN\14727670 ,\,\1740 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 injection\NN\320852 of\IN\1740 puromycin\NN\1740 aminonucleoside\NN\1740 was\VBD\836236 markedly\RB\1740 inhibited\VBN\2510337 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>Dup\NN\1740 753</e1>\CD\1740 (\-LRB-\1740 losartan\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 1\CD\13741022 or\CC\3541091 2\CD\13741022 mg/kg\NN\1740 per\IN\1740 day\NN\15154774 .\.\1740
D019808_D011507 NONE The\DT\1740 appearance\NN\4723816 of\IN\1740 nephrotic\JJ\1740 syndromes\NNS\5870365 such\JJ\1740 as\IN\14622893 <e2>proteinuria</e2>\NN\14299637 ,\,\1740 hypoalbuminemia\NN\1740 ,\,\1740 hypercholesterolemia\NN\14299637 and\CC\1740 increase\VB\169651 in\IN\13603305 blood\NN\5397468 nitrogen\NN\14622893 urea\NN\14727670 ,\,\1740 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 injection\NN\320852 of\IN\1740 puromycin\NN\1740 aminonucleoside\NN\1740 was\VBD\836236 markedly\RB\1740 inhibited\VBN\2510337 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 Dup\NN\1740 753\CD\1740 (\-LRB-\1740 <e1>losartan</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 1\CD\13741022 or\CC\3541091 2\CD\13741022 mg/kg\NN\1740 per\IN\1740 day\NN\15154774 .\.\1740
D019808_D034141 NONE The\DT\1740 appearance\NN\4723816 of\IN\1740 nephrotic\JJ\1740 syndromes\NNS\5870365 such\JJ\1740 as\IN\14622893 proteinuria\NN\14299637 ,\,\1740 <e2>hypoalbuminemia</e2>\NN\1740 ,\,\1740 hypercholesterolemia\NN\14299637 and\CC\1740 increase\VB\169651 in\IN\13603305 blood\NN\5397468 nitrogen\NN\14622893 urea\NN\14727670 ,\,\1740 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 injection\NN\320852 of\IN\1740 puromycin\NN\1740 aminonucleoside\NN\1740 was\VBD\836236 markedly\RB\1740 inhibited\VBN\2510337 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>Dup\NN\1740 753</e1>\CD\1740 (\-LRB-\1740 losartan\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 1\CD\13741022 or\CC\3541091 2\CD\13741022 mg/kg\NN\1740 per\IN\1740 day\NN\15154774 .\.\1740
D019808_D034141 NONE The\DT\1740 appearance\NN\4723816 of\IN\1740 nephrotic\JJ\1740 syndromes\NNS\5870365 such\JJ\1740 as\IN\14622893 proteinuria\NN\14299637 ,\,\1740 <e2>hypoalbuminemia</e2>\NN\1740 ,\,\1740 hypercholesterolemia\NN\14299637 and\CC\1740 increase\VB\169651 in\IN\13603305 blood\NN\5397468 nitrogen\NN\14622893 urea\NN\14727670 ,\,\1740 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 injection\NN\320852 of\IN\1740 puromycin\NN\1740 aminonucleoside\NN\1740 was\VBD\836236 markedly\RB\1740 inhibited\VBN\2510337 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 Dup\NN\1740 753\CD\1740 (\-LRB-\1740 <e1>losartan</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 1\CD\13741022 or\CC\3541091 2\CD\13741022 mg/kg\NN\1740 per\IN\1740 day\NN\15154774 .\.\1740
D019808_D006937 NONE The\DT\1740 appearance\NN\4723816 of\IN\1740 nephrotic\JJ\1740 syndromes\NNS\5870365 such\JJ\1740 as\IN\14622893 proteinuria\NN\14299637 ,\,\1740 hypoalbuminemia\NN\1740 ,\,\1740 <e2>hypercholesterolemia</e2>\NN\14299637 and\CC\1740 increase\VB\169651 in\IN\13603305 blood\NN\5397468 nitrogen\NN\14622893 urea\NN\14727670 ,\,\1740 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 injection\NN\320852 of\IN\1740 puromycin\NN\1740 aminonucleoside\NN\1740 was\VBD\836236 markedly\RB\1740 inhibited\VBN\2510337 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>Dup\NN\1740 753</e1>\CD\1740 (\-LRB-\1740 losartan\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 1\CD\13741022 or\CC\3541091 2\CD\13741022 mg/kg\NN\1740 per\IN\1740 day\NN\15154774 .\.\1740
D019808_D006937 NONE The\DT\1740 appearance\NN\4723816 of\IN\1740 nephrotic\JJ\1740 syndromes\NNS\5870365 such\JJ\1740 as\IN\14622893 proteinuria\NN\14299637 ,\,\1740 hypoalbuminemia\NN\1740 ,\,\1740 <e2>hypercholesterolemia</e2>\NN\14299637 and\CC\1740 increase\VB\169651 in\IN\13603305 blood\NN\5397468 nitrogen\NN\14622893 urea\NN\14727670 ,\,\1740 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 injection\NN\320852 of\IN\1740 puromycin\NN\1740 aminonucleoside\NN\1740 was\VBD\836236 markedly\RB\1740 inhibited\VBN\2510337 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 Dup\NN\1740 753\CD\1740 (\-LRB-\1740 <e1>losartan</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 1\CD\13741022 or\CC\3541091 2\CD\13741022 mg/kg\NN\1740 per\IN\1740 day\NN\15154774 .\.\1740
D000804_D009404 NONE The\DT\1740 appearance\NN\4723816 of\IN\1740 <e2>nephrotic\JJ\1740 syndromes</e2>\NNS\5870365 such\JJ\1740 as\IN\14622893 proteinuria\NN\14299637 ,\,\1740 hypoalbuminemia\NN\1740 ,\,\1740 hypercholesterolemia\NN\14299637 and\CC\1740 increase\VB\169651 in\IN\13603305 blood\NN\5397468 nitrogen\NN\14622893 urea\NN\14727670 ,\,\1740 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 injection\NN\320852 of\IN\1740 puromycin\NN\1740 aminonucleoside\NN\1740 was\VBD\836236 markedly\RB\1740 inhibited\VBN\2510337 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 Dup\NN\1740 753\CD\1740 (\-LRB-\1740 losartan\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 <e1>angiotensin\NN\4522421 II</e1>\CD\13741022 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 1\CD\13741022 or\CC\3541091 2\CD\13741022 mg/kg\NN\1740 per\IN\1740 day\NN\15154774 .\.\1740
D000804_D011507 NONE The\DT\1740 appearance\NN\4723816 of\IN\1740 nephrotic\JJ\1740 syndromes\NNS\5870365 such\JJ\1740 as\IN\14622893 <e2>proteinuria</e2>\NN\14299637 ,\,\1740 hypoalbuminemia\NN\1740 ,\,\1740 hypercholesterolemia\NN\14299637 and\CC\1740 increase\VB\169651 in\IN\13603305 blood\NN\5397468 nitrogen\NN\14622893 urea\NN\14727670 ,\,\1740 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 injection\NN\320852 of\IN\1740 puromycin\NN\1740 aminonucleoside\NN\1740 was\VBD\836236 markedly\RB\1740 inhibited\VBN\2510337 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 Dup\NN\1740 753\CD\1740 (\-LRB-\1740 losartan\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 <e1>angiotensin\NN\4522421 II</e1>\CD\13741022 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 1\CD\13741022 or\CC\3541091 2\CD\13741022 mg/kg\NN\1740 per\IN\1740 day\NN\15154774 .\.\1740
D000804_D034141 NONE The\DT\1740 appearance\NN\4723816 of\IN\1740 nephrotic\JJ\1740 syndromes\NNS\5870365 such\JJ\1740 as\IN\14622893 proteinuria\NN\14299637 ,\,\1740 <e2>hypoalbuminemia</e2>\NN\1740 ,\,\1740 hypercholesterolemia\NN\14299637 and\CC\1740 increase\VB\169651 in\IN\13603305 blood\NN\5397468 nitrogen\NN\14622893 urea\NN\14727670 ,\,\1740 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 injection\NN\320852 of\IN\1740 puromycin\NN\1740 aminonucleoside\NN\1740 was\VBD\836236 markedly\RB\1740 inhibited\VBN\2510337 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 Dup\NN\1740 753\CD\1740 (\-LRB-\1740 losartan\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 <e1>angiotensin\NN\4522421 II</e1>\CD\13741022 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 1\CD\13741022 or\CC\3541091 2\CD\13741022 mg/kg\NN\1740 per\IN\1740 day\NN\15154774 .\.\1740
D000804_D006937 NONE The\DT\1740 appearance\NN\4723816 of\IN\1740 nephrotic\JJ\1740 syndromes\NNS\5870365 such\JJ\1740 as\IN\14622893 proteinuria\NN\14299637 ,\,\1740 hypoalbuminemia\NN\1740 ,\,\1740 <e2>hypercholesterolemia</e2>\NN\14299637 and\CC\1740 increase\VB\169651 in\IN\13603305 blood\NN\5397468 nitrogen\NN\14622893 urea\NN\14727670 ,\,\1740 induced\VBN\1627355 in\IN\13603305 rats\NNS\2329401 by\IN\1740 injection\NN\320852 of\IN\1740 puromycin\NN\1740 aminonucleoside\NN\1740 was\VBD\836236 markedly\RB\1740 inhibited\VBN\2510337 by\IN\1740 oral\JJ\1740 administration\NN\1133281 of\IN\1740 Dup\NN\1740 753\CD\1740 (\-LRB-\1740 losartan\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 novel\JJ\1740 <e1>angiotensin\NN\4522421 II</e1>\CD\13741022 receptor\NN\5225602 antagonist\NN\7846 ,\,\1740 at\IN\14622893 a\DT\13649268 dose\NN\3740161 of\IN\1740 1\CD\13741022 or\CC\3541091 2\CD\13741022 mg/kg\NN\1740 per\IN\1740 day\NN\15154774 .\.\1740
D000809_D009401 NONE The\DT\1740 results\NNS\34213 suggest\VBP\1010118 a\DT\13649268 possible\JJ\1740 involvement\NN\1080366 of\IN\1740 the\DT\1740 <e1>renin-angiotensin</e1>\JJ\1740 system\NN\3575240 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 puromycin\NN\1740 aminonucleoside-induced\JJ\1740 <e2>nephrosis</e2>\NN\14304060 .\.\1740
11147747
D018490_D014549 CID <e1>Serotonergic\JJ\1740 antidepressants</e1>\NNS\3740161 and\CC\1740 <e2>urinary\JJ\1740 incontinence</e2>\NN\13473097 .\.\1740
D018490_D014549 CID Animal\JJ\1740 studies\NNS\635850 suggest\VBP\1010118 that\IN\1740 <e2>incontinence</e2>\NN\13473097 secondary\JJ\1740 to\TO\1740 <e1>serotonergic\JJ\1740 antidepressants</e1>\NNS\3740161 could\MD\1740 be\VB\836236 mediated\VBN\761713 by\IN\1740 the\DT\1740 5HT4\NN\1740 receptors\NNS\5225602 found\VBN\2426171 on\IN\1740 the\DT\1740 bladder\NN\5515670 .\.\1740
C047426_D014549 CID This\DT\1740 concerns\NNS\5682950 2\CD\13741022 male\JJ\1740 patients\NNS\9898892 who\WP\8299493 experienced\VBD\2108377 <e2>incontinence</e2>\NN\13473097 while\IN\15122231 taking\VBG\2367363 <e1>venlafaxine</e1>\NN\1740 .\.\1740
C047426_D014549 CID In\IN\13603305 the\DT\1740 present\JJ\1740 paper\NN\14580897 the\DT\1740 authors\NNS\9610660 describe\VBP\1001294 2\CD\13741022 female\JJ\1740 patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 <e2>incontinence</e2>\NN\13473097 secondary\JJ\1740 to\TO\1740 the\DT\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 paroxetine\NN\1740 and\CC\1740 sertraline\NN\4169152 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 a\DT\13649268 third\NN\13732295 who\WP\8299493 developed\VBD\1753788 this\DT\1740 side\NN\8630039 effect\NN\34213 on\IN\1740 <e1>venlafaxine</e1>\NN\1740 .\.\1740
D012701_D014549 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 paper\NN\14580897 the\DT\1740 authors\NNS\9610660 describe\VBP\1001294 2\CD\13741022 female\JJ\1740 patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 <e2>incontinence</e2>\NN\13473097 secondary\JJ\1740 to\TO\1740 the\DT\1740 selective\JJ\1740 <e1>serotonin</e1>\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 paroxetine\NN\1740 and\CC\1740 sertraline\NN\4169152 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 a\DT\13649268 third\NN\13732295 who\WP\8299493 developed\VBD\1753788 this\DT\1740 side\NN\8630039 effect\NN\34213 on\IN\1740 venlafaxine\NN\1740 .\.\1740
D017374_D014549 CID In\IN\13603305 the\DT\1740 present\JJ\1740 paper\NN\14580897 the\DT\1740 authors\NNS\9610660 describe\VBP\1001294 2\CD\13741022 female\JJ\1740 patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 <e2>incontinence</e2>\NN\13473097 secondary\JJ\1740 to\TO\1740 the\DT\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 <e1>paroxetine</e1>\NN\1740 and\CC\1740 sertraline\NN\4169152 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 a\DT\13649268 third\NN\13732295 who\WP\8299493 developed\VBD\1753788 this\DT\1740 side\NN\8630039 effect\NN\34213 on\IN\1740 venlafaxine\NN\1740 .\.\1740
D020280_D014549 CID In\IN\13603305 the\DT\1740 present\JJ\1740 paper\NN\14580897 the\DT\1740 authors\NNS\9610660 describe\VBP\1001294 2\CD\13741022 female\JJ\1740 patients\NNS\9898892 who\WP\8299493 developed\VBD\1753788 <e2>incontinence</e2>\NN\13473097 secondary\JJ\1740 to\TO\1740 the\DT\1740 selective\JJ\1740 serotonin\NN\14807737 reuptake\NN\13571580 inhibitors\NNS\20090 paroxetine\NN\1740 and\CC\1740 <e1>sertraline</e1>\NN\4169152 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 a\DT\13649268 third\NN\13732295 who\WP\8299493 developed\VBD\1753788 this\DT\1740 side\NN\8630039 effect\NN\34213 on\IN\1740 venlafaxine\NN\1740 .\.\1740
D016651_D014549 CID In\IN\13603305 2\CD\13741022 of\IN\1740 the\DT\1740 3\CD\13741022 cases\NNS\7283608 the\DT\1740 patients\NNS\9898892 were\VBD\836236 also\RB\1740 taking\VBG\2367363 <e1>lithium\NN\14625458 carbonate</e1>\NN\15010703 and\CC\1740 beta-blockers\NNS\1740 ,\,\1740 both\DT\1740 of\IN\1740 which\WDT\1740 could\MD\1740 have\VB\2108377 contributed\VBN\126264 to\IN\1740 the\DT\1740 <e2>incontinence</e2>\NN\13473097 .\.\1740
20882060
D009496_D002375 NONE Effects\NNS\13245626 of\IN\1740 pallidal\JJ\1740 <e1>neurotensin</e1>\NN\1740 on\IN\1740 haloperidol-induced\JJ\1740 <e2>parkinsonian\JJ\1740 catalepsy</e2>\NN\14023236 :\:\1740 behavioral\JJ\1740 and\CC\1740 electrophysiological\JJ\1740 studies\NNS\635850 .\.\1740
D009496_D002375 NONE RESULTS\NNS\34213 :\:\1740 Bilateral\JJ\1740 infusions\NNS\14589223 of\IN\1740 <e1>neurotensin</e1>\NN\1740 into\IN\1740 the\DT\1740 globus\NN\1740 pallidus\NN\1740 reversed\VBN\109660 haloperidol-induced\JJ\1740 <e2>parkinsonian\JJ\1740 catalepsy</e2>\NN\14023236 in\IN\13603305 rats\NNS\2329401 .\.\1740
D006220_D002375 CID Effects\NNS\13245626 of\IN\1740 pallidal\JJ\1740 neurotensin\NN\1740 on\IN\1740 <e1>haloperidol-induced</e1>\JJ\1740 <e2>parkinsonian\JJ\1740 catalepsy</e2>\NN\14023236 :\:\1740 behavioral\JJ\1740 and\CC\1740 electrophysiological\JJ\1740 studies\NNS\635850 .\.\1740
D006220_D002375 CID RESULTS\NNS\34213 :\:\1740 Bilateral\JJ\1740 infusions\NNS\14589223 of\IN\1740 neurotensin\NN\1740 into\IN\1740 the\DT\1740 globus\NN\1740 pallidus\NN\1740 reversed\VBN\109660 <e1>haloperidol-induced</e1>\JJ\1740 <e2>parkinsonian\JJ\1740 catalepsy</e2>\NN\14023236 in\IN\13603305 rats\NNS\2329401 .\.\1740
D009496_D010302 NONE The\DT\1740 present\JJ\1740 study\NN\635850 aimed\VBN\1987160 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 pallidal\JJ\1740 <e1>neurotensin</e1>\NN\1740 on\IN\1740 haloperidol-induced\JJ\1740 <e2>parkinsonian\JJ\1740 symptoms</e2>\NNS\5823932 .\.\1740
D006220_D010302 NONE The\DT\1740 present\JJ\1740 study\NN\635850 aimed\VBN\1987160 to\TO\1740 investigate\VB\644583 the\DT\1740 effects\NNS\13245626 of\IN\1740 pallidal\JJ\1740 neurotensin\NN\1740 on\IN\1740 <e1>haloperidol-induced</e1>\JJ\1740 <e2>parkinsonian\JJ\1740 symptoms</e2>\NNS\5823932 .\.\1740
3496378
D014217_D002779 CID Prolonged\JJ\1740 <e2>cholestasis</e2>\NN\14052403 after\IN\1740 <e1>troleandomycin-induced</e1>\JJ\1740 acute\JJ\1740 hepatitis\NN\14127211 .\.\1740
D014217_D002779 CID We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 in\IN\13603305 whom\WP\1740 <e1>troleandomycin-induced</e1>\JJ\1740 hepatitis\NN\14127211 was\VBD\836236 followed\VBN\1835496 by\IN\1740 prolonged\JJ\1740 anicteric\JJ\1740 <e2>cholestasis</e2>\NN\14052403 .\.\1740
D014217_D002779 CID This\DT\1740 observation\NN\996969 demonstrates\VBZ\2137132 that\IN\1740 prolonged\JJ\1740 <e2>cholestasis</e2>\NN\14052403 can\MD\3094503 follow\VB\1835496 <e1>troleandomycin-induced</e1>\JJ\1740 acute\JJ\1740 hepatitis\NN\14127211 .\.\1740
D014217_D056486 CID Prolonged\JJ\1740 cholestasis\NN\14052403 after\IN\1740 <e1>troleandomycin-induced</e1>\JJ\1740 acute\JJ\1740 <e2>hepatitis</e2>\NN\14127211 .\.\1740
D014217_D056486 CID We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 in\IN\13603305 whom\WP\1740 <e1>troleandomycin-induced</e1>\JJ\1740 <e2>hepatitis</e2>\NN\14127211 was\VBD\836236 followed\VBN\1835496 by\IN\1740 prolonged\JJ\1740 anicteric\JJ\1740 cholestasis\NN\14052403 .\.\1740
D014217_D056486 CID This\DT\1740 observation\NN\996969 demonstrates\VBZ\2137132 that\IN\1740 prolonged\JJ\1740 cholestasis\NN\14052403 can\MD\3094503 follow\VB\1835496 <e1>troleandomycin-induced</e1>\JJ\1740 acute\JJ\1740 <e2>hepatitis</e2>\NN\14127211 .\.\1740
D014217_D007565 CID <e2>Jaundice</e2>\NNP\14299637 occurred\VBD\2623529 after\IN\1740 administration\NN\1133281 of\IN\1740 <e1>troleandomycin</e1>\NN\1740 for\IN\1740 7\CD\13741022 days\NNS\15140892 and\CC\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 hypereosinophilia\NN\1740 .\.\1740
D014217_D004802 CID Jaundice\NNP\14299637 occurred\VBD\2623529 after\IN\1740 administration\NN\1133281 of\IN\1740 <e1>troleandomycin</e1>\NN\1740 for\IN\1740 7\CD\13741022 days\NNS\15140892 and\CC\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 <e2>hypereosinophilia</e2>\NN\1740 .\.\1740
16005948
-1_D062787 NONE Evaluation\NN\874067 of\IN\1740 the\DT\1740 anticocaine\JJ\1740 monoclonal\JJ\1740 antibody\NN\14728724 <e1>GNC92H2</e1>\NN\1740 as\IN\14622893 an\DT\6697703 immunotherapy\NN\661091 for\IN\1740 <e2>cocaine\NN\3492717 overdose</e2>\NN\1740 .\.\1740
-1_D062787 NONE The\DT\1740 therapeutic\JJ\1740 potential\NN\14481929 of\IN\1740 the\DT\1740 anticocaine\JJ\1740 antibody\NN\14728724 <e1>GNC92H2</e1>\NN\1740 was\VBD\836236 examined\VBN\789138 using\VBG\1156834 a\DT\13649268 model\NN\5888929 of\IN\1740 <e2>cocaine\NN\3492717 overdose</e2>\NN\1740 .\.\1740
-1_D062787 NONE The\DT\1740 results\NNS\34213 support\VBP\2199590 the\DT\1740 important\JJ\1740 potential\NN\14481929 of\IN\1740 <e1>GNC92H2</e1>\NN\1740 as\IN\14622893 a\DT\13649268 therapeutic\JJ\1740 tool\NN\3563967 against\IN\1740 <e2>cocaine\NN\3492717 overdose</e2>\NN\1740 .\.\1740
D003042_D062787 NONE The\DT\1740 illicit\NN\1740 use\NN\407535 of\IN\1740 <e1>cocaine</e1>\NN\3492717 continues\VBZ\2367363 in\IN\13603305 epidemic\JJ\1740 proportions\NNS\13824815 and\CC\1740 treatment\NN\654885 for\IN\1740 <e2>cocaine\NN\3492717 overdose</e2>\NN\1740 remains\VBZ\2604760 elusive\JJ\1740 .\.\1740
D003042_D064420 NONE Significant\JJ\1740 blockade\NN\952963 of\IN\1740 <e1>cocaine</e1>\NN\3492717 <e2>toxicity</e2>\NN\13576101 was\VBD\836236 observed\VBN\2163746 with\IN\1740 the\DT\1740 higher\JJR\1740 dose\NN\3740161 of\IN\1740 GNC92H2\NN\1740 (\-LRB-\1740 190\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 where\WRB\1740 premorbid\JJ\1740 behaviors\NNS\407535 were\VBD\836236 reduced\VBN\441445 up\RB\1740 to\TO\1740 40\CD\13745420 %\NN\1740 ,\,\1740 seizures\VBZ\1740 up\RP\1740 to\TO\1740 77\CD\1740 %\NN\1740 and\CC\1740 death\NN\7296428 by\IN\1740 72\CD\1740 %\NN\1740 .\.\1740
D003042_D012640 CID Significant\JJ\1740 blockade\NN\952963 of\IN\1740 <e1>cocaine</e1>\NN\3492717 toxicity\NN\13576101 was\VBD\836236 observed\VBN\2163746 with\IN\1740 the\DT\1740 higher\JJR\1740 dose\NN\3740161 of\IN\1740 GNC92H2\NN\1740 (\-LRB-\1740 190\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 where\WRB\1740 premorbid\JJ\1740 behaviors\NNS\407535 were\VBD\836236 reduced\VBN\441445 up\RB\1740 to\TO\1740 40\CD\13745420 %\NN\1740 ,\,\1740 <e2>seizures</e2>\VBZ\1740 up\RP\1740 to\TO\1740 77\CD\1740 %\NN\1740 and\CC\1740 death\NN\7296428 by\IN\1740 72\CD\1740 %\NN\1740 .\.\1740
D003042_D003643 NONE Significant\JJ\1740 blockade\NN\952963 of\IN\1740 <e1>cocaine</e1>\NN\3492717 toxicity\NN\13576101 was\VBD\836236 observed\VBN\2163746 with\IN\1740 the\DT\1740 higher\JJR\1740 dose\NN\3740161 of\IN\1740 GNC92H2\NN\1740 (\-LRB-\1740 190\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 where\WRB\1740 premorbid\JJ\1740 behaviors\NNS\407535 were\VBD\836236 reduced\VBN\441445 up\RB\1740 to\TO\1740 40\CD\13745420 %\NN\1740 ,\,\1740 seizures\VBZ\1740 up\RP\1740 to\TO\1740 77\CD\1740 %\NN\1740 and\CC\1740 <e2>death</e2>\NN\7296428 by\IN\1740 72\CD\1740 %\NN\1740 .\.\1740
D003042_D003643 NONE Importantly\RB\1740 ,\,\1740 GNC92H2\NNP\1740 prevented\VBD\1740 <e2>death</e2>\NN\7296428 even\RB\1740 <e1>post-cocaine</e1>\JJ\1740 injection\NN\320852 .\.\1740
-1_D064420 NONE Significant\JJ\1740 blockade\NN\952963 of\IN\1740 cocaine\NN\3492717 <e2>toxicity</e2>\NN\13576101 was\VBD\836236 observed\VBN\2163746 with\IN\1740 the\DT\1740 higher\JJR\1740 dose\NN\3740161 of\IN\1740 <e1>GNC92H2</e1>\NN\1740 (\-LRB-\1740 190\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 where\WRB\1740 premorbid\JJ\1740 behaviors\NNS\407535 were\VBD\836236 reduced\VBN\441445 up\RB\1740 to\TO\1740 40\CD\13745420 %\NN\1740 ,\,\1740 seizures\VBZ\1740 up\RP\1740 to\TO\1740 77\CD\1740 %\NN\1740 and\CC\1740 death\NN\7296428 by\IN\1740 72\CD\1740 %\NN\1740 .\.\1740
-1_D012640 NONE Significant\JJ\1740 blockade\NN\952963 of\IN\1740 cocaine\NN\3492717 toxicity\NN\13576101 was\VBD\836236 observed\VBN\2163746 with\IN\1740 the\DT\1740 higher\JJR\1740 dose\NN\3740161 of\IN\1740 <e1>GNC92H2</e1>\NN\1740 (\-LRB-\1740 190\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 where\WRB\1740 premorbid\JJ\1740 behaviors\NNS\407535 were\VBD\836236 reduced\VBN\441445 up\RB\1740 to\TO\1740 40\CD\13745420 %\NN\1740 ,\,\1740 <e2>seizures</e2>\VBZ\1740 up\RP\1740 to\TO\1740 77\CD\1740 %\NN\1740 and\CC\1740 death\NN\7296428 by\IN\1740 72\CD\1740 %\NN\1740 .\.\1740
-1_D003643 NONE Significant\JJ\1740 blockade\NN\952963 of\IN\1740 cocaine\NN\3492717 toxicity\NN\13576101 was\VBD\836236 observed\VBN\2163746 with\IN\1740 the\DT\1740 higher\JJR\1740 dose\NN\3740161 of\IN\1740 <e1>GNC92H2</e1>\NN\1740 (\-LRB-\1740 190\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 where\WRB\1740 premorbid\JJ\1740 behaviors\NNS\407535 were\VBD\836236 reduced\VBN\441445 up\RB\1740 to\TO\1740 40\CD\13745420 %\NN\1740 ,\,\1740 seizures\VBZ\1740 up\RP\1740 to\TO\1740 77\CD\1740 %\NN\1740 and\CC\1740 <e2>death</e2>\NN\7296428 by\IN\1740 72\CD\1740 %\NN\1740 .\.\1740
-1_D003643 NONE Importantly\RB\1740 ,\,\1740 <e1>GNC92H2</e1>\NNP\1740 prevented\VBD\1740 <e2>death</e2>\NN\7296428 even\RB\1740 post-cocaine\JJ\1740 injection\NN\320852 .\.\1740
11897407
C067171_D009203 NONE <e1>99mTc-glucarate</e1>\NN\1740 for\IN\1740 detection\NN\5708432 of\IN\1740 isoproterenol-induced\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
C067171_D009203 NONE <e1>99mTc-glucarate</e1>\NN\1740 was\VBD\836236 easy\JJ\1740 to\TO\1740 prepare\VB\126264 ,\,\1740 stable\JJ\1740 for\IN\1740 96\CD\1740 h\NN\14622893 and\CC\1740 was\VBD\836236 used\VBN\1156834 to\TO\1740 study\VB\630380 its\PRP$\6125041 biodistribution\NN\1740 in\IN\13603305 rats\NNS\2329401 with\IN\1740 isoproterenol-induced\JJ\1740 acute\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D007545_D009203 CID 99mTc-glucarate\NN\1740 for\IN\1740 detection\NN\5708432 of\IN\1740 <e1>isoproterenol-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 in\IN\13603305 rats\NNS\2329401 .\.\1740
D007545_D009203 CID 99mTc-glucarate\NN\1740 was\VBD\836236 easy\JJ\1740 to\TO\1740 prepare\VB\126264 ,\,\1740 stable\JJ\1740 for\IN\1740 96\CD\1740 h\NN\14622893 and\CC\1740 was\VBD\836236 used\VBN\1156834 to\TO\1740 study\VB\630380 its\PRP$\6125041 biodistribution\NN\1740 in\IN\13603305 rats\NNS\2329401 with\IN\1740 <e1>isoproterenol-induced</e1>\JJ\1740 acute\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D007545_D007238 NONE The\DT\1740 animal\NN\4475 model\NN\5888929 used\VBN\1156834 to\TO\1740 produce\VB\1617192 <e2>infarction</e2>\NN\14204950 implies\VBZ\943837 artery\NN\5417975 ligation\NN\149084 but\CC\1740 chemical\NN\14580897 induction\NN\7450842 can\MD\3094503 be\VB\836236 easily\RB\1740 obtained\VBN\2210855 with\IN\1740 <e1>isoproterenol</e1>\NN\3740161 .\.\1740
D007545_D007238 NONE Histological\JJ\1740 studies\NNS\635850 demonstrated\VBD\2137132 that\IN\1740 the\DT\1740 rats\NNS\2329401 developed\VBD\1753788 an\DT\6697703 <e2>infarct</e2>\NN\14204950 18\CD\13745420 h\NN\14622893 after\IN\1740 <e1>isoproterenol</e1>\JJ\1740 administration\NN\1133281 .\.\1740
D005937_D007238 NONE A\DT\13649268 new\JJ\1740 <e2>infarct-avid</e2>\JJ\1740 radiopharmaceutical\JJ\1740 based\VBN\2694933 on\IN\1740 <e1>glucaric\JJ\1740 acid</e1>\NN\14818238 was\VBD\836236 prepared\VBN\126264 in\IN\13603305 the\DT\1740 hospital\NN\3739518 radiopharmacy\NN\1740 of\IN\1740 the\DT\1740 INCMNSZ\NN\1740 .\.\1740
567256
D004054_D006394 CID <e2>Angiosarcoma\NN\14239425 of\IN\1740 the\DT\1740 liver</e2>\NN\5298729 associated\VBN\628491 with\IN\1740 <e1>diethylstilbestrol</e1>\NN\14749794 .\.\1740
D004054_D006394 CID <e2>Angiosarcoma\NN\14239425 of\IN\1740 the\DT\1740 liver</e2>\NN\5298729 occurred\VBD\2623529 in\IN\13603305 a\DT\13649268 76-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 had\VBD\2108377 been\VBN\836236 treated\VBN\2376958 for\IN\1740 a\DT\13649268 well-differentiated\JJ\1740 adenocarcinoma\NN\14242337 of\IN\1740 the\DT\1740 liver\NN\5298729 with\IN\1740 <e1>diethylstilbestrol</e1>\NN\14749794 for\IN\1740 13\CD\13745420 years\NNS\15144371 .\.\1740
D004054_D008113 CID <e2>Angiosarcoma\NN\14239425 of\IN\1740 the\DT\1740 liver</e2>\NN\5298729 associated\VBN\628491 with\IN\1740 <e1>diethylstilbestrol</e1>\NN\14749794 .\.\1740
D004054_D008113 CID <e2>Angiosarcoma\NN\14239425 of\IN\1740 the\DT\1740 liver</e2>\NN\5298729 occurred\VBD\2623529 in\IN\13603305 a\DT\13649268 76-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 had\VBD\2108377 been\VBN\836236 treated\VBN\2376958 for\IN\1740 a\DT\13649268 well-differentiated\JJ\1740 adenocarcinoma\NN\14242337 of\IN\1740 the\DT\1740 liver\NN\5298729 with\IN\1740 <e1>diethylstilbestrol</e1>\NN\14749794 for\IN\1740 13\CD\13745420 years\NNS\15144371 .\.\1740
D004054_D008113 NONE Angiosarcoma\NN\14239425 of\IN\1740 the\DT\1740 liver\NN\5298729 occurred\VBD\2623529 in\IN\13603305 a\DT\13649268 76-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 had\VBD\2108377 been\VBN\836236 treated\VBN\2376958 for\IN\1740 a\DT\13649268 well-differentiated\JJ\1740 <e2>adenocarcinoma\NN\14242337 of\IN\1740 the\DT\1740 liver</e2>\NN\5298729 with\IN\1740 <e1>diethylstilbestrol</e1>\NN\14749794 for\IN\1740 13\CD\13745420 years\NNS\15144371 .\.\1740
D004054_D000230 NONE Angiosarcoma\NN\14239425 of\IN\1740 the\DT\1740 liver\NN\5298729 occurred\VBD\2623529 in\IN\13603305 a\DT\13649268 76-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 had\VBD\2108377 been\VBN\836236 treated\VBN\2376958 for\IN\1740 a\DT\13649268 well-differentiated\JJ\1740 <e2>adenocarcinoma\NN\14242337 of\IN\1740 the\DT\1740 liver</e2>\NN\5298729 with\IN\1740 <e1>diethylstilbestrol</e1>\NN\14749794 for\IN\1740 13\CD\13745420 years\NNS\15144371 .\.\1740
15515654
D003676_D006311 NONE No\DT\7204911 <e2>ototoxic</e2>\JJ\1740 factor\NN\7326557 ,\,\1740 other\JJ\1740 than\IN\1740 <e1>DFO</e1>\NNP\1740 ,\,\1740 was\VBD\836236 present\JJ\1740 in\IN\13603305 any\DT\1740 of\IN\1740 the\DT\1740 patients\NNS\9898892 .\.\1740
D003676_D006319 CID Subjects\NNS\6598915 with\IN\1740 <e2>SNHL</e2>\NN\1740 were\VBD\836236 submitted\VBN\1952898 to\TO\1740 <e1>DFO</e1>\NN\1740 reduction\NN\351485 or\CC\3541091 temporary\JJ\1740 withdrawal\NN\7206096 .\.\1740
D003676_D034381 NONE CONCLUSION\NN\5837957 :\:\1740 The\DT\1740 findings\NNS\7951464 are\VBP\836236 indicative\JJ\1740 of\IN\1740 <e1>DFO</e1>\NN\1740 's\POS\1740 contributing\VBG\126264 role\NN\719494 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 <e2>hearing\NN\1184814 impairment</e2>\NN\7296428 .\.\1740
18162529
D012313_D006966 NONE Hypothalamic\JJ\1740 prolactin\NN\5410315 receptor\NN\5225602 messenger\NN\9629752 <e1>ribonucleic\JJ\1740 acid</e1>\NN\14818238 levels\NNS\4916342 ,\,\1740 prolactin\NN\5410315 signaling\NN\33020 ,\,\1740 and\CC\1740 <e2>hyperprolactinemic</e2>\JJ\1740 inhibition\NN\1068773 of\IN\1740 pulsatile\JJ\1740 luteinizing\NN\1740 hormone\NN\5404728 secretion\NN\13526110 are\VBP\836236 dependent\JJ\1740 on\IN\1740 estradiol\NN\14749794 .\.\1740
D004958_D006966 NONE Hypothalamic\JJ\1740 prolactin\NN\5410315 receptor\NN\5225602 messenger\NN\9629752 ribonucleic\JJ\1740 acid\NN\14818238 levels\NNS\4916342 ,\,\1740 prolactin\NN\5410315 signaling\NN\33020 ,\,\1740 and\CC\1740 <e2>hyperprolactinemic</e2>\JJ\1740 inhibition\NN\1068773 of\IN\1740 pulsatile\JJ\1740 luteinizing\NN\1740 hormone\NN\5404728 secretion\NN\13526110 are\VBP\836236 dependent\JJ\1740 on\IN\1740 <e1>estradiol</e1>\NN\14749794 .\.\1740
D004958_D006966 NONE Chronic\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 the\DT\1740 dopamine\NN\14807737 antagonist\NN\7846 sulpiride\NN\1740 caused\VBD\1617192 a\DT\13649268 40\CD\13745420 %\NN\1740 reduction\NN\351485 LH\NN\5410315 pulse\NN\7345593 frequency\NN\15286249 in\IN\13603305 ovariectomized\JJ\1740 rats\NNS\2329401 ,\,\1740 but\CC\1740 only\RB\1740 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 chronic\JJ\1740 low\JJ\1740 levels\NNS\4916342 of\IN\1740 <e1>estradiol</e1>\NN\14749794 .\.\1740
D004967_D006966 NONE We\PRP\1740 first\RB\1740 tested\VBD\670261 whether\IN\1740 chronic\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 inhibited\VBD\2510337 two\CD\13741022 neuroendocrine\JJ\1740 parameters\NNS\5858936 necessary\JJ\1740 for\IN\1740 female\JJ\1740 fertility\NN\15286249 :\:\1740 pulsatile\VB\1740 LH\NN\5410315 secretion\NN\13526110 and\CC\1740 the\DT\1740 <e1>estrogen-induced</e1>\JJ\1740 LH\NN\5410315 surge\VBP\264034 .\.\1740
D004298_D006966 NONE Chronic\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 the\DT\1740 <e1>dopamine</e1>\NN\14807737 antagonist\NN\7846 sulpiride\NN\1740 caused\VBD\1617192 a\DT\13649268 40\CD\13745420 %\NN\1740 reduction\NN\351485 LH\NN\5410315 pulse\NN\7345593 frequency\NN\15286249 in\IN\13603305 ovariectomized\JJ\1740 rats\NNS\2329401 ,\,\1740 but\CC\1740 only\RB\1740 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 chronic\JJ\1740 low\JJ\1740 levels\NNS\4916342 of\IN\1740 estradiol\NN\14749794 .\.\1740
D013469_D006966 CID Chronic\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 induced\VBN\1627355 by\IN\1740 the\DT\1740 dopamine\NN\14807737 antagonist\NN\7846 <e1>sulpiride</e1>\NN\1740 caused\VBD\1617192 a\DT\13649268 40\CD\13745420 %\NN\1740 reduction\NN\351485 LH\NN\5410315 pulse\NN\7345593 frequency\NN\15286249 in\IN\13603305 ovariectomized\JJ\1740 rats\NNS\2329401 ,\,\1740 but\CC\1740 only\RB\1740 in\IN\13603305 the\DT\1740 presence\NN\13954253 of\IN\1740 chronic\JJ\1740 low\JJ\1740 levels\NNS\4916342 of\IN\1740 estradiol\NN\14749794 .\.\1740
D013256_D006966 NONE These\DT\1740 data\NNS\7951464 show\VBP\2137132 that\IN\1740 GnRH\NN\1740 pulse\NN\7345593 frequency\NN\15286249 is\VBZ\836236 inhibited\VBN\2510337 by\IN\1740 chronic\JJ\1740 <e2>hyperprolactinemia</e2>\NN\1740 in\IN\13603305 a\DT\13649268 <e1>steroid-dependent</e1>\JJ\1740 manner\NN\4916342 .\.\1740
11587867
D014750_D001927 NONE Fatal\JJ\1740 <e2>myeloencephalopathy</e2>\NN\1740 due\JJ\1740 to\TO\1740 accidental\JJ\1740 intrathecal\JJ\1740 <e1>vincristin</e1>\NN\1740 administration\NN\1133281 :\:\1740 a\DT\13649268 report\NN\6470073 of\IN\1740 two\CD\13741022 cases\NNS\7283608 .\.\1740
D014750_D054198 NONE We\PRP\1740 report\VBP\831651 on\IN\1740 two\CD\13741022 fatal\JJ\1740 cases\NNS\7283608 of\IN\1740 accidental\JJ\1740 intrathecal\JJ\1740 <e1>vincristine</e1>\NN\3917455 instillation\NN\320852 in\IN\13603305 a\DT\13649268 5-year\JJ\1740 old\JJ\1740 girl\NN\10787470 with\IN\1740 recurrent\JJ\1740 <e2>acute\JJ\1740 lymphoblastic\JJ\1740 leucemia</e2>\NN\1740 and\CC\1740 a\DT\13649268 57-year\JJ\1740 old\JJ\1740 man\NN\9605289 with\IN\1740 lymphoblastic\JJ\1740 lymphoma\NN\14239918 .\.\1740
D014750_D054198 NONE We\PRP\1740 report\VBP\831651 on\IN\1740 two\CD\13741022 fatal\JJ\1740 cases\NNS\7283608 of\IN\1740 accidental\JJ\1740 intrathecal\JJ\1740 <e1>vincristine</e1>\NN\3917455 instillation\NN\320852 in\IN\13603305 a\DT\13649268 5-year\JJ\1740 old\JJ\1740 girl\NN\10787470 with\IN\1740 recurrent\JJ\1740 acute\JJ\1740 lymphoblastic\JJ\1740 leucemia\NN\1740 and\CC\1740 a\DT\13649268 57-year\JJ\1740 old\JJ\1740 man\NN\9605289 with\IN\1740 <e2>lymphoblastic\JJ\1740 lymphoma</e2>\NN\14239918 .\.\1740
D014750_D003711 CID Histological\JJ\1740 and\CC\1740 immunohistochemical\JJ\1740 investigations\NNS\5797597 (\-LRB-\1740 HE-LFB\NN\1740 ,\,\1740 CD-68\NN\1740 ,\,\1740 Neurofilament\NN\1740 )\-RRB-\1740 revealed\VBD\2137132 <e2>degeneration\NN\29677 of\IN\1740 myelin\NN\14864360 and\CC\1740 axons</e2>\NNS\5464104 as\RB\1740 well\RB\1740 as\IN\14622893 pseudocystic\JJ\1740 transformation\NN\7296428 in\IN\13603305 areas\NNS\8630985 exposed\VBN\2110927 to\TO\1740 <e1>vincristine</e1>\NN\3917455 ,\,\1740 accompanied\VBN\1835496 by\IN\1740 secondary\JJ\1740 changes\NNS\7283608 with\IN\1740 numerous\JJ\1740 prominent\JJ\1740 macrophages\NNS\5450888 .\.\1740
D014750_D009410 CID Histological\JJ\1740 and\CC\1740 immunohistochemical\JJ\1740 investigations\NNS\5797597 (\-LRB-\1740 HE-LFB\NN\1740 ,\,\1740 CD-68\NN\1740 ,\,\1740 Neurofilament\NN\1740 )\-RRB-\1740 revealed\VBD\2137132 <e2>degeneration\NN\29677 of\IN\1740 myelin\NN\14864360 and\CC\1740 axons</e2>\NNS\5464104 as\RB\1740 well\RB\1740 as\IN\14622893 pseudocystic\JJ\1740 transformation\NN\7296428 in\IN\13603305 areas\NNS\8630985 exposed\VBN\2110927 to\TO\1740 <e1>vincristine</e1>\NN\3917455 ,\,\1740 accompanied\VBN\1835496 by\IN\1740 secondary\JJ\1740 changes\NNS\7283608 with\IN\1740 numerous\JJ\1740 prominent\JJ\1740 macrophages\NNS\5450888 .\.\1740
D014750_-1 NONE Histological\JJ\1740 and\CC\1740 immunohistochemical\JJ\1740 investigations\NNS\5797597 (\-LRB-\1740 HE-LFB\NN\1740 ,\,\1740 CD-68\NN\1740 ,\,\1740 Neurofilament\NN\1740 )\-RRB-\1740 revealed\VBD\2137132 degeneration\NN\29677 of\IN\1740 myelin\NN\14864360 and\CC\1740 axons\NNS\5464104 as\RB\1740 well\RB\1740 as\IN\14622893 <e2>pseudocystic\JJ\1740 transformation</e2>\NN\7296428 in\IN\13603305 areas\NNS\8630985 exposed\VBN\2110927 to\TO\1740 <e1>vincristine</e1>\NN\3917455 ,\,\1740 accompanied\VBN\1835496 by\IN\1740 secondary\JJ\1740 changes\NNS\7283608 with\IN\1740 numerous\JJ\1740 prominent\JJ\1740 macrophages\NNS\5450888 .\.\1740
2312209
D007548_D009203 CID <e2>Myocardial\JJ\1740 infarction</e2>\NN\14204950 following\VBG\1835496 sublingual\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>isosorbide\JJ\1740 dinitrate</e1>\NN\1740 .\.\1740
D007548_D009203 CID A\DT\13649268 78-year-old\RB\1740 with\IN\1740 healed\VBN\205046 septal\JJ\1740 necrosis\NN\11444117 suffered\VBD\2110220 a\DT\13649268 recurrent\JJ\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 of\IN\1740 the\DT\1740 anterior\JJ\1740 wall\NN\3894379 following\VBG\1835496 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>isosorbide\JJ\1740 dinitrate</e1>\NN\1740 5\CD\13741022 mg\NN\13717155 sublingually\RB\1740 .\.\1740
D007548_D009336 NONE A\DT\13649268 78-year-old\RB\1740 with\IN\1740 healed\VBN\205046 septal\JJ\1740 <e2>necrosis</e2>\NN\11444117 suffered\VBD\2110220 a\DT\13649268 recurrent\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 of\IN\1740 the\DT\1740 anterior\JJ\1740 wall\NN\3894379 following\VBG\1835496 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>isosorbide\JJ\1740 dinitrate</e1>\NN\1740 5\CD\13741022 mg\NN\13717155 sublingually\RB\1740 .\.\1740
6229975
D013999_D009203 NONE Changes\NNS\7283608 in\IN\13603305 heart\NN\5919034 size\NN\5090441 during\IN\1740 long-term\JJ\1740 <e1>timolol</e1>\NN\2832168 treatment\NN\654885 after\IN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D013999_D009203 NONE The\DT\1740 effect\NN\34213 of\IN\1740 long-term\JJ\1740 <e1>timolol</e1>\CD\2832168 treatment\NN\654885 on\IN\1740 heart\NN\5919034 size\NN\5090441 after\IN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 was\VBD\836236 evaluated\VBN\670261 by\IN\1740 X-ray\NN\11450869 in\IN\13603305 a\DT\13649268 double-blind\JJ\1740 study\NN\635850 including\VBG\690614 241\CD\1740 patients\NNS\9898892 (\-LRB-\1740 placebo\NN\3740161 126\CD\1740 ,\,\1740 timolol\NN\2832168 115\CD\1740 )\-RRB-\1740 .\.\1740
D013999_D009203 NONE The\DT\1740 effect\NN\34213 of\IN\1740 long-term\JJ\1740 timolol\CD\2832168 treatment\NN\654885 on\IN\1740 heart\NN\5919034 size\NN\5090441 after\IN\1740 <e2>myocardial\JJ\1740 infarction</e2>\NN\14204950 was\VBD\836236 evaluated\VBN\670261 by\IN\1740 X-ray\NN\11450869 in\IN\13603305 a\DT\13649268 double-blind\JJ\1740 study\NN\635850 including\VBG\690614 241\CD\1740 patients\NNS\9898892 (\-LRB-\1740 placebo\NN\3740161 126\CD\1740 ,\,\1740 <e1>timolol</e1>\NN\2832168 115\CD\1740 )\-RRB-\1740 .\.\1740
D013999_D001919 NONE These\DT\1740 differences\NNS\4723816 may\MD\15209706 be\VB\836236 caused\VBN\1617192 by\IN\1740 <e1>timolol-induced</e1>\JJ\1740 <e2>bradycardia</e2>\NN\14110674 and\CC\1740 a\DT\13649268 compensatory\JJ\1740 increase\NN\13576355 in\IN\13603305 end-diastolic\JJ\1740 volume\NN\33615 .\.\1740
D013999_D007238 NONE After\IN\1740 <e2>re-infarction</e2>\NN\1740 ,\,\1740 heart\NN\5919034 size\NN\5090441 increased\VBD\169651 in\IN\13603305 the\DT\1740 placebo\NN\3740161 group\NN\2137 and\CC\1740 remained\VBD\2604760 unchanged\JJ\1740 in\IN\13603305 the\DT\1740 <e1>timolol</e1>\CD\2832168 group\NN\2137 .\.\1740
10901305
D007649_D050723 NONE <e1>Ketamine</e1>\NNP\3054098 sedation\NN\14034177 for\IN\1740 the\DT\1740 reduction\NN\351485 of\IN\1740 children\NNS\9622049 's\POS\1740 <e2>fractures</e2>\NNS\14285662 in\IN\13603305 the\DT\1740 emergency\NN\7417644 department\NN\8220714 .\.\1740
D007649_D050723 NONE The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 examine\VB\789138 the\DT\1740 safety\NN\13920835 and\CC\1740 efficacy\NN\5199286 of\IN\1740 <e1>ketamine</e1>\NN\3054098 for\IN\1740 sedation\NN\14034177 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 children\NNS\9622049 's\POS\1740 <e2>fractures</e2>\NNS\14285662 in\IN\13603305 the\DT\1740 emergency\NN\7417644 department\NN\8220714 .\.\1740
D007649_D050723 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 average\JJ\1740 time\NN\7308889 from\IN\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>ketamine</e1>\NN\3054098 to\TO\1740 manipulation\NN\157081 of\IN\1740 the\DT\1740 <e2>fracture</e2>\NN\14285662 or\CC\3541091 dislocation\NN\7367812 was\VBD\836236 one\CD\13741022 minute\NN\15154774 and\CC\1740 thirty-six\CD\1740 seconds\NNS\15154774 (\-LRB-\1740 range\NN\5123416 ,\,\1740 twenty\CD\13745420 seconds\NNS\15154774 to\IN\1740 five\CD\13741022 minutes\NNS\6502378 )\-RRB-\1740 ,\,\1740 and\CC\1740 the\DT\1740 average\JJ\1740 time\NN\7308889 from\IN\1740 intramuscular\JJ\1740 administration\NN\1133281 to\TO\1740 manipulation\NN\157081 was\VBD\836236 four\CD\13741022 minutes\NNS\6502378 and\CC\1740 forty-two\JJ\1740 seconds\NNS\15154774 (\-LRB-\1740 range\NN\5123416 ,\,\1740 sixty\CD\13745420 seconds\NNS\15154774 to\IN\1740 fifteen\CD\13745420 minutes\NNS\6502378 )\-RRB-\1740 .\.\1740
D007649_D050723 NONE CONCLUSIONS\NNS\5837957 :\:\1740 <e1>Ketamine</e1>\NNP\3054098 reliably\RB\1740 ,\,\1740 safely\RB\1740 ,\,\1740 and\CC\1740 quickly\RB\1740 provided\VBD\2199590 adequate\JJ\1740 sedation\NN\14034177 to\TO\1740 effectively\RB\1740 facilitate\VB\2547586 the\DT\1740 reduction\NN\351485 of\IN\1740 children\NNS\9622049 's\POS\1740 <e2>fractures</e2>\NNS\14285662 in\IN\13603305 the\DT\1740 emergency\NN\7417644 department\NN\8220714 at\IN\14622893 our\PRP$\1740 institution\NN\8008335 .\.\1740
D007649_D004204 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 average\JJ\1740 time\NN\7308889 from\IN\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>ketamine</e1>\NN\3054098 to\TO\1740 manipulation\NN\157081 of\IN\1740 the\DT\1740 fracture\NN\14285662 or\CC\3541091 <e2>dislocation</e2>\NN\7367812 was\VBD\836236 one\CD\13741022 minute\NN\15154774 and\CC\1740 thirty-six\CD\1740 seconds\NNS\15154774 (\-LRB-\1740 range\NN\5123416 ,\,\1740 twenty\CD\13745420 seconds\NNS\15154774 to\IN\1740 five\CD\13741022 minutes\NNS\6502378 )\-RRB-\1740 ,\,\1740 and\CC\1740 the\DT\1740 average\JJ\1740 time\NN\7308889 from\IN\1740 intramuscular\JJ\1740 administration\NN\1133281 to\TO\1740 manipulation\NN\157081 was\VBD\836236 four\CD\13741022 minutes\NNS\6502378 and\CC\1740 forty-two\JJ\1740 seconds\NNS\15154774 (\-LRB-\1740 range\NN\5123416 ,\,\1740 sixty\CD\13745420 seconds\NNS\15154774 to\IN\1740 fifteen\CD\13745420 minutes\NNS\6502378 )\-RRB-\1740 .\.\1740
7988234
D008790_D000799 CID <e2>Angioedema</e2>\NNP\14316714 following\VBG\1835496 the\DT\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>metoprolol</e1>\NN\2832168 .\.\1740
D008790_D000799 CID During\IN\1740 the\DT\1740 first\JJ\1740 day\NN\15154774 of\IN\1740 hospitalization\NN\15113229 (\-LRB-\1740 while\IN\15122231 intubated\JJ\1740 )\-RRB-\1740 ,\,\1740 intravenous\JJ\1740 <e1>metoprolol</e1>\NN\2832168 was\VBD\836236 given\VBN\2327200 ,\,\1740 resulting\VBG\2633881 in\IN\13603305 severe\JJ\1740 <e2>angioedema</e2>\NN\14316714 .\.\1740
D017706_D000799 CID A\DT\13649268 history\NN\15120823 of\IN\1740 <e2>angioedema</e2>\NN\14316714 secondary\JJ\1740 to\TO\1740 <e1>lisinopril</e1>\NN\2673637 therapy\NN\657604 was\VBD\836236 elicited\VBN\1617192 .\.\1740
D013256_D000799 NONE The\DT\1740 <e2>angioedema</e2>\NN\14316714 resolved\VBN\352826 after\IN\1740 therapy\NN\657604 with\IN\1740 intravenous\JJ\1740 <e1>steroids</e1>\NNS\14727670 and\CC\1740 diphenhydramine\NN\2720725 hydrochloride\NN\14817592 .\.\1740
D004155_D000799 NONE The\DT\1740 <e2>angioedema</e2>\NN\14316714 resolved\VBN\352826 after\IN\1740 therapy\NN\657604 with\IN\1740 intravenous\JJ\1740 steroids\NNS\14727670 and\CC\1740 <e1>diphenhydramine</e1>\NN\2720725 hydrochloride\NN\14817592 .\.\1740
2054792
D004317_D005334 NONE Effect\NN\34213 of\IN\1740 <e1>adriamycin</e1>\NN\1740 combined\VBN\2630189 with\IN\1740 whole\JJ\1740 body\NN\19128 <e2>hyperthermia</e2>\NN\14034177 on\IN\1740 tumor\NN\14234074 and\CC\1740 normal\JJ\1740 tissues\NNS\5220461 .\.\1740
D004317_D005334 NONE Thermal\JJ\1740 enhancement\NN\248977 of\IN\1740 <e1>Adriamycin-mediated</e1>\JJ\1740 antitumor\NN\1740 activity\NN\30358 and\CC\1740 normal\JJ\1740 tissue\NN\5220461 toxicities\NNS\13576101 by\IN\1740 whole\JJ\1740 body\NN\19128 <e2>hyperthermia</e2>\NN\14034177 were\VBD\836236 compared\VBN\644583 using\VBG\1156834 a\DT\13649268 F344\NN\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D004317_D005334 NONE Whole\NN\5835747 body\NN\19128 <e2>hyperthermia</e2>\NN\14034177 (\-LRB-\1740 120\CD\13745420 min\NN\15154774 at\IN\14622893 41.5\CD\1740 degrees\NNS\4916342 C\NN\13714184 )\-RRB-\1740 enhanced\VBD\227165 both\CC\1740 <e1>Adriamycin-mediated</e1>\JJ\1740 antitumor\NN\1740 activity\NN\30358 and\CC\1740 toxic\JJ\1740 side\NN\8630039 effects\NNS\13245626 .\.\1740
D004317_D005334 NONE Thus\RB\1740 ,\,\1740 while\IN\15122231 whole\JJ\1740 body\NN\19128 <e2>hyperthermia</e2>\NN\14034177 enhances\VBZ\227165 <e1>Adriamycin-mediated</e1>\JJ\1740 antitumor\NN\1740 effect\NN\34213 ,\,\1740 normal\JJ\1740 tissue\NN\5220461 toxicity\NN\13576101 is\VBZ\836236 also\RB\1740 increased\VBN\169651 ,\,\1740 and\CC\1740 the\DT\1740 potential\JJ\1740 therapeutic\JJ\1740 gain\NN\13576355 of\IN\1740 the\DT\1740 combined\JJ\1740 modality\NN\13783038 treatment\NN\654885 is\VBZ\836236 eroded\VBN\208836 .\.\1740
D004317_D009369 NONE Effect\NN\34213 of\IN\1740 <e1>adriamycin</e1>\NN\1740 combined\VBN\2630189 with\IN\1740 whole\JJ\1740 body\NN\19128 hyperthermia\NN\14034177 on\IN\1740 <e2>tumor</e2>\NN\14234074 and\CC\1740 normal\JJ\1740 tissues\NNS\5220461 .\.\1740
D004317_D064420 NONE Thermal\JJ\1740 enhancement\NN\248977 of\IN\1740 <e1>Adriamycin-mediated</e1>\JJ\1740 antitumor\NN\1740 activity\NN\30358 and\CC\1740 normal\JJ\1740 tissue\NN\5220461 <e2>toxicities</e2>\NNS\13576101 by\IN\1740 whole\JJ\1740 body\NN\19128 hyperthermia\NN\14034177 were\VBD\836236 compared\VBN\644583 using\VBG\1156834 a\DT\13649268 F344\NN\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D004317_D064420 NONE Thus\RB\1740 ,\,\1740 while\IN\15122231 whole\JJ\1740 body\NN\19128 hyperthermia\NN\14034177 enhances\VBZ\227165 <e1>Adriamycin-mediated</e1>\JJ\1740 antitumor\NN\1740 effect\NN\34213 ,\,\1740 normal\JJ\1740 tissue\NN\5220461 <e2>toxicity</e2>\NN\13576101 is\VBZ\836236 also\RB\1740 increased\VBN\169651 ,\,\1740 and\CC\1740 the\DT\1740 potential\JJ\1740 therapeutic\JJ\1740 gain\NN\13576355 of\IN\1740 the\DT\1740 combined\JJ\1740 modality\NN\13783038 treatment\NN\654885 is\VBZ\836236 eroded\VBN\208836 .\.\1740
20621845
D002122_D017545 CID Elevation\NN\7445480 of\IN\1740 ADAM10\NN\1740 ,\,\1740 ADAM17\NN\1740 ,\,\1740 MMP-2\NN\1740 and\CC\1740 MMP-9\NN\1740 expression\NN\4679549 with\IN\1740 media\NN\3575240 degeneration\NN\29677 features\NNS\5849040 <e1>CaCl2-induced</e1>\JJ\1740 <e2>thoracic\NN\1740 aortic\JJ\1740 aneurysm</e2>\NN\14057371 in\IN\13603305 a\DT\13649268 rat\NN\2329401 model\NN\5888929 .\.\1740
D002122_D017545 CID PURPOSE\NN\5980875 :\:\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 establish\VB\2426171 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 <e2>thoracic\NN\1740 aortic\JJ\1740 aneurysm</e2>\NN\14057371 (\-LRB-\1740 TAA\NN\1740 )\-RRB-\1740 by\IN\1740 <e1>calcium\NN\14625458 chloride</e1>\NN\14818238 (\-LRB-\1740 CaCl(2))-induced\JJ\1740 arterial\JJ\1740 injury\NN\14052046 and\CC\1740 to\TO\1740 explore\VB\789138 the\DT\1740 potential\JJ\1740 role\NN\719494 of\IN\1740 a\DT\13649268 disintegrin\NN\1740 and\CC\1740 metalloproteinase\NN\1740 (\-LRB-\1740 ADAM\NN\3756184 )\-RRB-\1740 ,\,\1740 matrix\NN\7939382 metalloproteinases\NNS\1740 (\-LRB-\1740 MMPs\NNS\1740 )\-RRB-\1740 and\CC\1740 their\PRP$\1740 endogenous\JJ\1740 inhibitors\NNS\20090 (\-LRB-\1740 TIMPs\NNS\1740 )\-RRB-\1740 in\IN\13603305 TAA\NN\1740 formation\NN\7938773 .\.\1740
D002122_D017545 CID PURPOSE\NN\5980875 :\:\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 establish\VB\2426171 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 thoracic\NN\1740 aortic\JJ\1740 aneurysm\NN\14057371 (\-LRB-\1740 <e2>TAA</e2>\NN\1740 )\-RRB-\1740 by\IN\1740 <e1>calcium\NN\14625458 chloride</e1>\NN\14818238 (\-LRB-\1740 CaCl(2))-induced\JJ\1740 arterial\JJ\1740 injury\NN\14052046 and\CC\1740 to\TO\1740 explore\VB\789138 the\DT\1740 potential\JJ\1740 role\NN\719494 of\IN\1740 a\DT\13649268 disintegrin\NN\1740 and\CC\1740 metalloproteinase\NN\1740 (\-LRB-\1740 ADAM\NN\3756184 )\-RRB-\1740 ,\,\1740 matrix\NN\7939382 metalloproteinases\NNS\1740 (\-LRB-\1740 MMPs\NNS\1740 )\-RRB-\1740 and\CC\1740 their\PRP$\1740 endogenous\JJ\1740 inhibitors\NNS\20090 (\-LRB-\1740 TIMPs\NNS\1740 )\-RRB-\1740 in\IN\13603305 TAA\NN\1740 formation\NN\7938773 .\.\1740
D002122_D017545 CID PURPOSE\NN\5980875 :\:\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 establish\VB\2426171 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 thoracic\NN\1740 aortic\JJ\1740 aneurysm\NN\14057371 (\-LRB-\1740 TAA\NN\1740 )\-RRB-\1740 by\IN\1740 <e1>calcium\NN\14625458 chloride</e1>\NN\14818238 (\-LRB-\1740 CaCl(2))-induced\JJ\1740 arterial\JJ\1740 injury\NN\14052046 and\CC\1740 to\TO\1740 explore\VB\789138 the\DT\1740 potential\JJ\1740 role\NN\719494 of\IN\1740 a\DT\13649268 disintegrin\NN\1740 and\CC\1740 metalloproteinase\NN\1740 (\-LRB-\1740 ADAM\NN\3756184 )\-RRB-\1740 ,\,\1740 matrix\NN\7939382 metalloproteinases\NNS\1740 (\-LRB-\1740 MMPs\NNS\1740 )\-RRB-\1740 and\CC\1740 their\PRP$\1740 endogenous\JJ\1740 inhibitors\NNS\20090 (\-LRB-\1740 TIMPs\NNS\1740 )\-RRB-\1740 in\IN\13603305 <e2>TAA</e2>\NN\1740 formation\NN\7938773 .\.\1740
D002122_D017545 CID PURPOSE\NN\5980875 :\:\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 establish\VB\2426171 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 <e2>thoracic\NN\1740 aortic\JJ\1740 aneurysm</e2>\NN\14057371 (\-LRB-\1740 TAA\NN\1740 )\-RRB-\1740 by\IN\1740 calcium\NN\14625458 chloride\NN\14818238 (\-LRB-\1740 <e1>CaCl(2))-induced</e1>\JJ\1740 arterial\JJ\1740 injury\NN\14052046 and\CC\1740 to\TO\1740 explore\VB\789138 the\DT\1740 potential\JJ\1740 role\NN\719494 of\IN\1740 a\DT\13649268 disintegrin\NN\1740 and\CC\1740 metalloproteinase\NN\1740 (\-LRB-\1740 ADAM\NN\3756184 )\-RRB-\1740 ,\,\1740 matrix\NN\7939382 metalloproteinases\NNS\1740 (\-LRB-\1740 MMPs\NNS\1740 )\-RRB-\1740 and\CC\1740 their\PRP$\1740 endogenous\JJ\1740 inhibitors\NNS\20090 (\-LRB-\1740 TIMPs\NNS\1740 )\-RRB-\1740 in\IN\13603305 TAA\NN\1740 formation\NN\7938773 .\.\1740
D002122_D017545 CID PURPOSE\NN\5980875 :\:\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 establish\VB\2426171 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 thoracic\NN\1740 aortic\JJ\1740 aneurysm\NN\14057371 (\-LRB-\1740 <e2>TAA</e2>\NN\1740 )\-RRB-\1740 by\IN\1740 calcium\NN\14625458 chloride\NN\14818238 (\-LRB-\1740 <e1>CaCl(2))-induced</e1>\JJ\1740 arterial\JJ\1740 injury\NN\14052046 and\CC\1740 to\TO\1740 explore\VB\789138 the\DT\1740 potential\JJ\1740 role\NN\719494 of\IN\1740 a\DT\13649268 disintegrin\NN\1740 and\CC\1740 metalloproteinase\NN\1740 (\-LRB-\1740 ADAM\NN\3756184 )\-RRB-\1740 ,\,\1740 matrix\NN\7939382 metalloproteinases\NNS\1740 (\-LRB-\1740 MMPs\NNS\1740 )\-RRB-\1740 and\CC\1740 their\PRP$\1740 endogenous\JJ\1740 inhibitors\NNS\20090 (\-LRB-\1740 TIMPs\NNS\1740 )\-RRB-\1740 in\IN\13603305 TAA\NN\1740 formation\NN\7938773 .\.\1740
D002122_D017545 CID PURPOSE\NN\5980875 :\:\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 establish\VB\2426171 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 thoracic\NN\1740 aortic\JJ\1740 aneurysm\NN\14057371 (\-LRB-\1740 TAA\NN\1740 )\-RRB-\1740 by\IN\1740 calcium\NN\14625458 chloride\NN\14818238 (\-LRB-\1740 <e1>CaCl(2))-induced</e1>\JJ\1740 arterial\JJ\1740 injury\NN\14052046 and\CC\1740 to\TO\1740 explore\VB\789138 the\DT\1740 potential\JJ\1740 role\NN\719494 of\IN\1740 a\DT\13649268 disintegrin\NN\1740 and\CC\1740 metalloproteinase\NN\1740 (\-LRB-\1740 ADAM\NN\3756184 )\-RRB-\1740 ,\,\1740 matrix\NN\7939382 metalloproteinases\NNS\1740 (\-LRB-\1740 MMPs\NNS\1740 )\-RRB-\1740 and\CC\1740 their\PRP$\1740 endogenous\JJ\1740 inhibitors\NNS\20090 (\-LRB-\1740 TIMPs\NNS\1740 )\-RRB-\1740 in\IN\13603305 <e2>TAA</e2>\NN\1740 formation\NN\7938773 .\.\1740
D002122_D017545 CID CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 study\NN\635850 establishes\VBZ\2426171 a\DT\13649268 <e2>TAA</e2>\NN\1740 model\NN\5888929 by\IN\1740 periarterial\JJ\1740 <e1>CaCl(2\NNS\1740 )</e1>\-RRB-\1740 exposure\NN\5042871 in\IN\13603305 rats\NNS\2329401 ,\,\1740 and\CC\1740 demonstrates\VBZ\2137132 a\DT\13649268 significant\JJ\1740 elevation\NN\7445480 of\IN\1740 expression\NN\4679549 of\IN\1740 MMP-2\NN\1740 ,\,\1740 MMP-9\NN\1740 ,\,\1740 ADAM10\NN\1740 and\CC\1740 ADAM17\NN\1740 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 vascular\JJ\1740 remodeling\NN\1740 .\.\1740
D002122_D014652 NONE PURPOSE\NN\5980875 :\:\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 establish\VB\2426171 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 thoracic\NN\1740 aortic\JJ\1740 aneurysm\NN\14057371 (\-LRB-\1740 TAA\NN\1740 )\-RRB-\1740 by\IN\1740 <e1>calcium\NN\14625458 chloride</e1>\NN\14818238 (\-LRB-\1740 CaCl(2))-induced\JJ\1740 <e2>arterial\JJ\1740 injury</e2>\NN\14052046 and\CC\1740 to\TO\1740 explore\VB\789138 the\DT\1740 potential\JJ\1740 role\NN\719494 of\IN\1740 a\DT\13649268 disintegrin\NN\1740 and\CC\1740 metalloproteinase\NN\1740 (\-LRB-\1740 ADAM\NN\3756184 )\-RRB-\1740 ,\,\1740 matrix\NN\7939382 metalloproteinases\NNS\1740 (\-LRB-\1740 MMPs\NNS\1740 )\-RRB-\1740 and\CC\1740 their\PRP$\1740 endogenous\JJ\1740 inhibitors\NNS\20090 (\-LRB-\1740 TIMPs\NNS\1740 )\-RRB-\1740 in\IN\13603305 TAA\NN\1740 formation\NN\7938773 .\.\1740
D002122_D014652 NONE PURPOSE\NN\5980875 :\:\1740 This\DT\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 establish\VB\2426171 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 thoracic\NN\1740 aortic\JJ\1740 aneurysm\NN\14057371 (\-LRB-\1740 TAA\NN\1740 )\-RRB-\1740 by\IN\1740 calcium\NN\14625458 chloride\NN\14818238 (\-LRB-\1740 <e1>CaCl(2))-induced</e1>\JJ\1740 <e2>arterial\JJ\1740 injury</e2>\NN\14052046 and\CC\1740 to\TO\1740 explore\VB\789138 the\DT\1740 potential\JJ\1740 role\NN\719494 of\IN\1740 a\DT\13649268 disintegrin\NN\1740 and\CC\1740 metalloproteinase\NN\1740 (\-LRB-\1740 ADAM\NN\3756184 )\-RRB-\1740 ,\,\1740 matrix\NN\7939382 metalloproteinases\NNS\1740 (\-LRB-\1740 MMPs\NNS\1740 )\-RRB-\1740 and\CC\1740 their\PRP$\1740 endogenous\JJ\1740 inhibitors\NNS\20090 (\-LRB-\1740 TIMPs\NNS\1740 )\-RRB-\1740 in\IN\13603305 TAA\NN\1740 formation\NN\7938773 .\.\1740
1835291
D009241_D029424 NONE Acute\JJ\1740 bronchodilating\NN\1740 effects\NNS\13245626 of\IN\1740 <e1>ipratropium\NN\1740 bromide</e1>\NN\14904359 and\CC\1740 theophylline\NN\2905612 in\IN\13603305 <e2>chronic\JJ\1740 obstructive\JJ\1740 pulmonary\JJ\1740 disease</e2>\NN\14061805 .\.\1740
D009241_D029424 NONE The\DT\1740 bronchodilator\NN\3740161 effects\NNS\13245626 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 <e1>ipratropium\NN\1740 bromide</e1>\NN\14904359 aerosol\NN\11439690 (\-LRB-\1740 36\CD\1740 micrograms\NNS\13717155 )\-RRB-\1740 and\CC\1740 short-acting\JJ\1740 theophylline\NN\2905612 tablets\NNS\4233405 (\-LRB-\1740 dose\NN\3740161 titrated\VBN\489837 to\TO\1740 produce\VB\1617192 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 10\CD\13745420 -\SYM\1740 20\CD\13745420 micrograms/mL\NNS\1740 )\-RRB-\1740 were\VBD\836236 compared\VBN\644583 in\IN\13603305 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 crossover\NN\13526110 study\VBP\630380 in\IN\13603305 21\CD\13745420 patients\NNS\9898892 with\IN\1740 stable\JJ\1740 ,\,\1740 <e2>chronic\JJ\1740 obstructive\JJ\1740 pulmonary\JJ\1740 disease</e2>\NN\14061805 .\.\1740
D009241_D029424 NONE These\DT\1740 results\NNS\34213 show\VBP\2137132 that\IN\1740 <e1>ipratropium</e1>\NN\1740 is\VBZ\836236 a\DT\13649268 more\RBR\1740 potent\JJ\1740 bronchodilator\NN\3740161 than\IN\1740 oral\JJ\1740 theophylline\NN\2905612 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>chronic\JJ\1740 airflow\NN\7405893 obstruction</e2>\NN\4341686 .\.\1740
D013806_D029424 NONE Acute\JJ\1740 bronchodilating\NN\1740 effects\NNS\13245626 of\IN\1740 ipratropium\NN\1740 bromide\NN\14904359 and\CC\1740 <e1>theophylline</e1>\NN\2905612 in\IN\13603305 <e2>chronic\JJ\1740 obstructive\JJ\1740 pulmonary\JJ\1740 disease</e2>\NN\14061805 .\.\1740
D013806_D029424 NONE The\DT\1740 bronchodilator\NN\3740161 effects\NNS\13245626 of\IN\1740 a\DT\13649268 single\JJ\1740 dose\NN\3740161 of\IN\1740 ipratropium\NN\1740 bromide\NN\14904359 aerosol\NN\11439690 (\-LRB-\1740 36\CD\1740 micrograms\NNS\13717155 )\-RRB-\1740 and\CC\1740 short-acting\JJ\1740 <e1>theophylline</e1>\NN\2905612 tablets\NNS\4233405 (\-LRB-\1740 dose\NN\3740161 titrated\VBN\489837 to\TO\1740 produce\VB\1617192 serum\NN\5397468 levels\NNS\4916342 of\IN\1740 10\CD\13745420 -\SYM\1740 20\CD\13745420 micrograms/mL\NNS\1740 )\-RRB-\1740 were\VBD\836236 compared\VBN\644583 in\IN\13603305 a\DT\13649268 double-blind\JJ\1740 ,\,\1740 placebo-controlled\JJ\1740 crossover\NN\13526110 study\VBP\630380 in\IN\13603305 21\CD\13745420 patients\NNS\9898892 with\IN\1740 stable\JJ\1740 ,\,\1740 <e2>chronic\JJ\1740 obstructive\JJ\1740 pulmonary\JJ\1740 disease</e2>\NN\14061805 .\.\1740
D013806_D029424 NONE These\DT\1740 results\NNS\34213 show\VBP\2137132 that\IN\1740 ipratropium\NN\1740 is\VBZ\836236 a\DT\13649268 more\RBR\1740 potent\JJ\1740 bronchodilator\NN\3740161 than\IN\1740 oral\JJ\1740 <e1>theophylline</e1>\NN\2905612 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>chronic\JJ\1740 airflow\NN\7405893 obstruction</e2>\NN\4341686 .\.\1740
D013806_D002318 CID While\IN\15122231 side\NN\8630039 effects\NNS\13245626 were\VBD\836236 rare\JJ\1740 ,\,\1740 those\DT\1740 experienced\VBN\2108377 after\IN\1740 <e1>theophylline</e1>\NN\2905612 use\NN\407535 did\VBD\1640855 involve\VB\2676054 the\DT\1740 <e2>cardiovascular\JJ\1740 and\CC\1740 gastrointestinal\JJ\1740 systems</e2>\NNS\3575240 .\.\1740
D013806_D005767 CID While\IN\15122231 side\NN\8630039 effects\NNS\13245626 were\VBD\836236 rare\JJ\1740 ,\,\1740 those\DT\1740 experienced\VBN\2108377 after\IN\1740 <e1>theophylline</e1>\NN\2905612 use\NN\407535 did\VBD\1640855 involve\VB\2676054 the\DT\1740 <e2>cardiovascular\JJ\1740 and\CC\1740 gastrointestinal\JJ\1740 systems</e2>\NNS\3575240 .\.\1740
347884
D006220_D019967 NONE In\IN\13603305 the\DT\1740 double\JJ\1740 blind\NN\7942152 study\NN\635850 with\IN\1740 <e1>haloperidol</e1>\NN\3713736 ,\,\1740 both\DT\1740 substances\NNS\20827 were\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 highly\RB\1740 effective\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>psychotic\JJ\1740 syndromes\NNS\5870365 belonging\VBG\2604760 predominantly\RB\1740 to\IN\1740 the\DT\1740 schizophrenia\NN\14398067 group</e2>\NN\2137 .\.\1740
2445283
D012254_D006478 NONE Tolerance\NN\5032565 and\CC\1740 antiviral\JJ\1740 effect\NN\34213 of\IN\1740 <e1>ribavirin</e1>\NN\2725367 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>Argentine\JJ\1740 hemorrhagic\JJ\1740 fever</e2>\NN\14299637 .\.\1740
D012254_D006478 NONE Tolerance\NN\5032565 and\CC\1740 antiviral\JJ\1740 effect\NN\34213 of\IN\1740 <e1>ribavirin</e1>\NN\2725367 was\VBD\836236 studied\VBN\630380 in\IN\13603305 6\CD\13741022 patients\NNS\9898892 with\IN\1740 <e2>Argentine\JJ\1740 hemorrhagic\JJ\1740 fever</e2>\NN\14299637 (\-LRB-\1740 AHF\NN\1740 )\-RRB-\1740 of\IN\1740 more\JJR\1740 than\IN\1740 8\CD\13741022 days\NNS\15140892 of\IN\1740 evolution\NN\29677 .\.\1740
D012254_D006478 NONE Tolerance\NN\5032565 and\CC\1740 antiviral\JJ\1740 effect\NN\34213 of\IN\1740 <e1>ribavirin</e1>\NN\2725367 was\VBD\836236 studied\VBN\630380 in\IN\13603305 6\CD\13741022 patients\NNS\9898892 with\IN\1740 Argentine\JJ\1740 hemorrhagic\JJ\1740 fever\NN\14299637 (\-LRB-\1740 <e2>AHF</e2>\NN\1740 )\-RRB-\1740 of\IN\1740 more\JJR\1740 than\IN\1740 8\CD\13741022 days\NNS\15140892 of\IN\1740 evolution\NN\29677 .\.\1740
D012254_D006478 NONE From\IN\1740 these\DT\1740 results\NNS\34213 ,\,\1740 we\PRP\1740 conclude\VBP\628491 that\IN\1740 <e1>ribavirin</e1>\NN\2725367 has\VBZ\2108377 an\DT\6697703 antiviral\JJ\1740 effect\NN\34213 in\IN\13603305 advanced\JJ\1740 cases\NNS\7283608 of\IN\1740 <e2>AHF</e2>\NN\1740 ,\,\1740 and\CC\1740 that\DT\1740 anemia\NN\14189204 ,\,\1740 the\DT\1740 only\JJ\1740 secondary\JJ\1740 reaction\NN\13446390 observed\VBN\2163746 ,\,\1740 can\MD\3094503 be\VB\836236 easily\RB\1740 managed\VBN\2524171 .\.\1740
D012254_D006478 NONE The\DT\1740 possible\JJ\1740 beneficial\JJ\1740 effect\NN\34213 of\IN\1740 <e1>ribavirin</e1>\NN\2725367 during\IN\1740 the\DT\1740 initial\JJ\1740 days\NNS\15140892 of\IN\1740 <e2>AHF</e2>\NN\1740 is\VBZ\836236 discussed\VBN\1033527 .\.\1740
D012254_D014766 NONE Administration\NN\1133281 of\IN\1740 <e1>ribavirin</e1>\NN\2725367 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 neutralization\NN\231567 of\IN\1740 <e2>viremia</e2>\NN\14204950 and\CC\1740 a\DT\13649268 drop\NN\13899200 of\IN\1740 endogenous\JJ\1740 interferon\NN\2725367 titers\NNS\5038593 .\.\1740
D012254_D000740 CID From\IN\1740 these\DT\1740 results\NNS\34213 ,\,\1740 we\PRP\1740 conclude\VBP\628491 that\IN\1740 <e1>ribavirin</e1>\NN\2725367 has\VBZ\2108377 an\DT\6697703 antiviral\JJ\1740 effect\NN\34213 in\IN\13603305 advanced\JJ\1740 cases\NNS\7283608 of\IN\1740 AHF\NN\1740 ,\,\1740 and\CC\1740 that\DT\1740 <e2>anemia</e2>\NN\14189204 ,\,\1740 the\DT\1740 only\JJ\1740 secondary\JJ\1740 reaction\NN\13446390 observed\VBN\2163746 ,\,\1740 can\MD\3094503 be\VB\836236 easily\RB\1740 managed\VBN\2524171 .\.\1740
17854040
D019259_D006509 NONE Mutations\NNS\4475 associated\VBN\628491 with\IN\1740 <e1>lamivudine-resistance</e1>\NN\1740 in\IN\13603305 therapy-na\JJ\1740 ve\NN\1740 <e2>hepatitis\NN\14127211 B\NN\1355326 virus\NN\9312843 (\-LRB-\1740 HBV\NN\1740 )\-RRB-\1740 infected</e2>\JJ\1740 patients\NNS\9898892 with\IN\1740 and\CC\1740 without\IN\1740 HIV\NN\14186340 co-infection\NN\1740 :\:\1740 implications\NNS\5774614 for\IN\1740 antiretroviral\JJ\1740 therapy\NN\657604 in\IN\13603305 HBV\NN\1740 and\CC\1740 HIV\NN\14186340 co-infected\VBD\1740 South\JJ\1740 African\JJ\1740 patients\NNS\9898892 .\.\1740
D019259_D006509 NONE Mutations\NNS\4475 associated\VBN\628491 with\IN\1740 <e1>lamivudine-resistance</e1>\NN\1740 in\IN\13603305 therapy-na\JJ\1740 ve\NN\1740 hepatitis\NN\14127211 B\NN\1355326 virus\NN\9312843 (\-LRB-\1740 HBV\NN\1740 )\-RRB-\1740 infected\JJ\1740 patients\NNS\9898892 with\IN\1740 and\CC\1740 without\IN\1740 HIV\NN\14186340 co-infection\NN\1740 :\:\1740 implications\NNS\5774614 for\IN\1740 antiretroviral\JJ\1740 therapy\NN\657604 in\IN\13603305 <e2>HBV\NN\1740 and\CC\1740 HIV\NN\14186340 co-infected</e2>\VBD\1740 South\JJ\1740 African\JJ\1740 patients\NNS\9898892 .\.\1740
D019259_D006509 NONE This\DT\1740 was\VBD\836236 an\DT\6697703 exploratory\JJ\1740 study\NN\635850 to\TO\1740 investigate\VB\644583 <e1>lamivudine-resistant</e1>\JJ\1740 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 virus\NN\9312843 (\-LRB-\1740 HBV\NN\1740 )\-RRB-\1740 strains\NNS\7358060 in\IN\13603305 selected\VBN\697589 lamivudine-na\JJ\1740 ve\NN\1740 HBV\NN\1740 carriers\NNS\9629752 with\IN\1740 and\CC\1740 without\IN\1740 human\JJ\1740 immunodeficiency\NN\13973990 virus\NN\9312843 (\-LRB-\1740 HIV\NN\14186340 )\-RRB-\1740 co-infection\NN\1740 in\IN\13603305 South\JJ\1740 African\JJ\1740 patients\NNS\9898892 .\.\1740
D019259_D006509 NONE This\DT\1740 was\VBD\836236 an\DT\6697703 exploratory\JJ\1740 study\NN\635850 to\TO\1740 investigate\VB\644583 lamivudine-resistant\JJ\1740 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 virus\NN\9312843 (\-LRB-\1740 HBV\NN\1740 )\-RRB-\1740 strains\NNS\7358060 in\IN\13603305 selected\VBN\697589 <e1>lamivudine-na</e1>\JJ\1740 ve\NN\1740 HBV\NN\1740 carriers\NNS\9629752 with\IN\1740 and\CC\1740 without\IN\1740 human\JJ\1740 immunodeficiency\NN\13973990 virus\NN\9312843 (\-LRB-\1740 HIV\NN\14186340 )\-RRB-\1740 co-infection\NN\1740 in\IN\13603305 South\JJ\1740 African\JJ\1740 patients\NNS\9898892 .\.\1740
D019259_D006509 NONE Thirty-five\JJ\1740 <e1>lamivudine-na</e1>\NN\1740 ve\NN\1740 <e2>HBV\NN\1740 infected</e2>\JJ\1740 patients\NNS\9898892 with\IN\1740 or\CC\3541091 without\IN\1740 HIV\NN\14186340 co-infection\NN\1740 were\VBD\836236 studied\VBN\630380 :\:\1740 15\CD\13745420 chronic\JJ\1740 HBV\NN\1740 mono-infected\JJ\1740 patients\NNS\9898892 and\CC\1740 20\CD\13745420 HBV-HIV\NN\1740 co-infected\VBD\1740 patients\NNS\9898892 .\.\1740
D019259_D006509 NONE Thirty-five\JJ\1740 <e1>lamivudine-na</e1>\NN\1740 ve\NN\1740 HBV\NN\1740 infected\JJ\1740 patients\NNS\9898892 with\IN\1740 or\CC\3541091 without\IN\1740 HIV\NN\14186340 co-infection\NN\1740 were\VBD\836236 studied\VBN\630380 :\:\1740 15\CD\13745420 chronic\JJ\1740 <e2>HBV\NN\1740 mono-infected</e2>\JJ\1740 patients\NNS\9898892 and\CC\1740 20\CD\13745420 HBV-HIV\NN\1740 co-infected\VBD\1740 patients\NNS\9898892 .\.\1740
D019259_D006509 NONE Thirty-five\JJ\1740 <e1>lamivudine-na</e1>\NN\1740 ve\NN\1740 HBV\NN\1740 infected\JJ\1740 patients\NNS\9898892 with\IN\1740 or\CC\3541091 without\IN\1740 HIV\NN\14186340 co-infection\NN\1740 were\VBD\836236 studied\VBN\630380 :\:\1740 15\CD\13745420 chronic\JJ\1740 HBV\NN\1740 mono-infected\JJ\1740 patients\NNS\9898892 and\CC\1740 20\CD\13745420 <e2>HBV-HIV\NN\1740 co-infected</e2>\VBD\1740 patients\NNS\9898892 .\.\1740
D019259_D006509 NONE HBV\NN\1740 <e1>lamivudine-resistant</e1>\JJ\1740 strains\NNS\7358060 were\VBD\836236 detected\VBN\2163746 in\IN\13603305 3\CD\13741022 of\IN\1740 15\CD\13745420 mono-infected\JJ\1740 chronic\JJ\1740 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 patients\NNS\9898892 and\CC\1740 10\CD\13745420 of\IN\1740 20\CD\13745420 HBV-HIV\NN\1740 co-infected\VBD\1740 patients\NNS\9898892 .\.\1740
D019259_D006509 NONE HBV\NN\1740 <e1>lamivudine-resistant</e1>\JJ\1740 strains\NNS\7358060 were\VBD\836236 detected\VBN\2163746 in\IN\13603305 3\CD\13741022 of\IN\1740 15\CD\13745420 mono-infected\JJ\1740 chronic\JJ\1740 hepatitis\NN\14127211 B\NN\1355326 patients\NNS\9898892 and\CC\1740 10\CD\13745420 of\IN\1740 20\CD\13745420 <e2>HBV-HIV\NN\1740 co-infected</e2>\VBD\1740 patients\NNS\9898892 .\.\1740
D019259_D006509 NONE To\IN\1740 the\DT\1740 best\JJS\1740 of\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 this\DT\1740 constitutes\VBZ\1647229 the\DT\1740 first\JJ\1740 report\NN\6470073 of\IN\1740 HBV\NN\1740 <e1>lamivudine-resistant</e1>\JJ\1740 strains\NNS\7358060 in\IN\13603305 therapy-na\NN\1740 ve\NN\1740 <e2>HBV-HIV\NN\1740 co-infected</e2>\VBD\1740 patients\NNS\9898892 .\.\1740
D019259_D006509 NONE It\PRP\6125041 remains\VBZ\2604760 to\TO\1740 be\VB\836236 seen\VBN\2106506 whether\IN\1740 such\JJ\1740 pre-existing\JJ\1740 antiviral\JJ\1740 mutations\NNS\4475 could\MD\1740 result\VB\2633881 in\IN\13603305 widespread\JJ\1740 emergence\NN\7290905 of\IN\1740 HBV\NN\1740 resistant\JJ\1740 strains\NNS\7358060 when\WRB\1740 <e1>lamivudine-containing</e1>\JJ\1740 highly\RB\1740 active\JJ\1740 antiretroviral\JJ\1740 (\-LRB-\1740 ARV\NN\1740 )\-RRB-\1740 treatment\NN\654885 (\-LRB-\1740 HAART\NN\3740161 )\-RRB-\1740 regimens\NNS\5898568 become\VBP\146138 widely\RB\1740 applied\VBN\2676054 in\IN\13603305 South\NNP\13831000 Africa\NNP\1740 ,\,\1740 as\IN\14622893 this\DT\1740 is\VBZ\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 potential\JJ\1740 implications\NNS\5774614 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 <e2>HBV-HIV\NN\1740 co-infected</e2>\VBD\1740 patients\NNS\9898892 .\.\1740
D019259_D015658 NONE Mutations\NNS\4475 associated\VBN\628491 with\IN\1740 <e1>lamivudine-resistance</e1>\NN\1740 in\IN\13603305 therapy-na\JJ\1740 ve\NN\1740 hepatitis\NN\14127211 B\NN\1355326 virus\NN\9312843 (\-LRB-\1740 HBV\NN\1740 )\-RRB-\1740 infected\JJ\1740 patients\NNS\9898892 with\IN\1740 and\CC\1740 without\IN\1740 <e2>HIV\NN\14186340 co-infection</e2>\NN\1740 :\:\1740 implications\NNS\5774614 for\IN\1740 antiretroviral\JJ\1740 therapy\NN\657604 in\IN\13603305 HBV\NN\1740 and\CC\1740 HIV\NN\14186340 co-infected\VBD\1740 South\JJ\1740 African\JJ\1740 patients\NNS\9898892 .\.\1740
D019259_D015658 NONE Mutations\NNS\4475 associated\VBN\628491 with\IN\1740 <e1>lamivudine-resistance</e1>\NN\1740 in\IN\13603305 therapy-na\JJ\1740 ve\NN\1740 hepatitis\NN\14127211 B\NN\1355326 virus\NN\9312843 (\-LRB-\1740 HBV\NN\1740 )\-RRB-\1740 infected\JJ\1740 patients\NNS\9898892 with\IN\1740 and\CC\1740 without\IN\1740 HIV\NN\14186340 co-infection\NN\1740 :\:\1740 implications\NNS\5774614 for\IN\1740 antiretroviral\JJ\1740 therapy\NN\657604 in\IN\13603305 <e2>HBV\NN\1740 and\CC\1740 HIV\NN\14186340 co-infected</e2>\VBD\1740 South\JJ\1740 African\JJ\1740 patients\NNS\9898892 .\.\1740
D019259_D015658 NONE This\DT\1740 was\VBD\836236 an\DT\6697703 exploratory\JJ\1740 study\NN\635850 to\TO\1740 investigate\VB\644583 <e1>lamivudine-resistant</e1>\JJ\1740 hepatitis\NN\14127211 B\NN\1355326 virus\NN\9312843 (\-LRB-\1740 HBV\NN\1740 )\-RRB-\1740 strains\NNS\7358060 in\IN\13603305 selected\VBN\697589 lamivudine-na\JJ\1740 ve\NN\1740 HBV\NN\1740 carriers\NNS\9629752 with\IN\1740 and\CC\1740 without\IN\1740 <e2>human\JJ\1740 immunodeficiency\NN\13973990 virus\NN\9312843 (\-LRB-\1740 HIV\NN\14186340 )\-RRB-\1740 co-infection</e2>\NN\1740 in\IN\13603305 South\JJ\1740 African\JJ\1740 patients\NNS\9898892 .\.\1740
D019259_D015658 NONE This\DT\1740 was\VBD\836236 an\DT\6697703 exploratory\JJ\1740 study\NN\635850 to\TO\1740 investigate\VB\644583 lamivudine-resistant\JJ\1740 hepatitis\NN\14127211 B\NN\1355326 virus\NN\9312843 (\-LRB-\1740 HBV\NN\1740 )\-RRB-\1740 strains\NNS\7358060 in\IN\13603305 selected\VBN\697589 <e1>lamivudine-na</e1>\JJ\1740 ve\NN\1740 HBV\NN\1740 carriers\NNS\9629752 with\IN\1740 and\CC\1740 without\IN\1740 <e2>human\JJ\1740 immunodeficiency\NN\13973990 virus\NN\9312843 (\-LRB-\1740 HIV\NN\14186340 )\-RRB-\1740 co-infection</e2>\NN\1740 in\IN\13603305 South\JJ\1740 African\JJ\1740 patients\NNS\9898892 .\.\1740
D019259_D015658 NONE Thirty-five\JJ\1740 <e1>lamivudine-na</e1>\NN\1740 ve\NN\1740 HBV\NN\1740 infected\JJ\1740 patients\NNS\9898892 with\IN\1740 or\CC\3541091 without\IN\1740 <e2>HIV\NN\14186340 co-infection</e2>\NN\1740 were\VBD\836236 studied\VBN\630380 :\:\1740 15\CD\13745420 chronic\JJ\1740 HBV\NN\1740 mono-infected\JJ\1740 patients\NNS\9898892 and\CC\1740 20\CD\13745420 HBV-HIV\NN\1740 co-infected\VBD\1740 patients\NNS\9898892 .\.\1740
D019259_D015658 NONE Thirty-five\JJ\1740 <e1>lamivudine-na</e1>\NN\1740 ve\NN\1740 HBV\NN\1740 infected\JJ\1740 patients\NNS\9898892 with\IN\1740 or\CC\3541091 without\IN\1740 HIV\NN\14186340 co-infection\NN\1740 were\VBD\836236 studied\VBN\630380 :\:\1740 15\CD\13745420 chronic\JJ\1740 HBV\NN\1740 mono-infected\JJ\1740 patients\NNS\9898892 and\CC\1740 20\CD\13745420 <e2>HBV-HIV\NN\1740 co-infected</e2>\VBD\1740 patients\NNS\9898892 .\.\1740
D019259_D015658 NONE HBV\NN\1740 <e1>lamivudine-resistant</e1>\JJ\1740 strains\NNS\7358060 were\VBD\836236 detected\VBN\2163746 in\IN\13603305 3\CD\13741022 of\IN\1740 15\CD\13745420 mono-infected\JJ\1740 chronic\JJ\1740 hepatitis\NN\14127211 B\NN\1355326 patients\NNS\9898892 and\CC\1740 10\CD\13745420 of\IN\1740 20\CD\13745420 <e2>HBV-HIV\NN\1740 co-infected</e2>\VBD\1740 patients\NNS\9898892 .\.\1740
D019259_D015658 NONE To\IN\1740 the\DT\1740 best\JJS\1740 of\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 this\DT\1740 constitutes\VBZ\1647229 the\DT\1740 first\JJ\1740 report\NN\6470073 of\IN\1740 HBV\NN\1740 <e1>lamivudine-resistant</e1>\JJ\1740 strains\NNS\7358060 in\IN\13603305 therapy-na\NN\1740 ve\NN\1740 <e2>HBV-HIV\NN\1740 co-infected</e2>\VBD\1740 patients\NNS\9898892 .\.\1740
D019259_D015658 NONE It\PRP\6125041 remains\VBZ\2604760 to\TO\1740 be\VB\836236 seen\VBN\2106506 whether\IN\1740 such\JJ\1740 pre-existing\JJ\1740 antiviral\JJ\1740 mutations\NNS\4475 could\MD\1740 result\VB\2633881 in\IN\13603305 widespread\JJ\1740 emergence\NN\7290905 of\IN\1740 HBV\NN\1740 resistant\JJ\1740 strains\NNS\7358060 when\WRB\1740 <e1>lamivudine-containing</e1>\JJ\1740 highly\RB\1740 active\JJ\1740 antiretroviral\JJ\1740 (\-LRB-\1740 ARV\NN\1740 )\-RRB-\1740 treatment\NN\654885 (\-LRB-\1740 HAART\NN\3740161 )\-RRB-\1740 regimens\NNS\5898568 become\VBP\146138 widely\RB\1740 applied\VBN\2676054 in\IN\13603305 South\NNP\13831000 Africa\NNP\1740 ,\,\1740 as\IN\14622893 this\DT\1740 is\VBZ\836236 likely\JJ\1740 to\TO\1740 have\VB\2108377 potential\JJ\1740 implications\NNS\5774614 in\IN\13603305 the\DT\1740 management\NN\1123598 of\IN\1740 <e2>HBV-HIV\NN\1740 co-infected</e2>\VBD\1740 patients\NNS\9898892 .\.\1740
D012964_D006509 NONE Mutations\NNS\4475 associated\VBN\628491 with\IN\1740 lamivudine-resistance\NN\1740 in\IN\13603305 <e1>therapy-na</e1>\JJ\1740 ve\NN\1740 <e2>hepatitis\NN\14127211 B\NN\1355326 virus\NN\9312843 (\-LRB-\1740 HBV\NN\1740 )\-RRB-\1740 infected</e2>\JJ\1740 patients\NNS\9898892 with\IN\1740 and\CC\1740 without\IN\1740 HIV\NN\14186340 co-infection\NN\1740 :\:\1740 implications\NNS\5774614 for\IN\1740 antiretroviral\JJ\1740 therapy\NN\657604 in\IN\13603305 HBV\NN\1740 and\CC\1740 HIV\NN\14186340 co-infected\VBD\1740 South\JJ\1740 African\JJ\1740 patients\NNS\9898892 .\.\1740
D012964_D006509 NONE Mutations\NNS\4475 associated\VBN\628491 with\IN\1740 lamivudine-resistance\NN\1740 in\IN\13603305 <e1>therapy-na</e1>\JJ\1740 ve\NN\1740 hepatitis\NN\14127211 B\NN\1355326 virus\NN\9312843 (\-LRB-\1740 HBV\NN\1740 )\-RRB-\1740 infected\JJ\1740 patients\NNS\9898892 with\IN\1740 and\CC\1740 without\IN\1740 HIV\NN\14186340 co-infection\NN\1740 :\:\1740 implications\NNS\5774614 for\IN\1740 antiretroviral\JJ\1740 therapy\NN\657604 in\IN\13603305 <e2>HBV\NN\1740 and\CC\1740 HIV\NN\14186340 co-infected</e2>\VBD\1740 South\JJ\1740 African\JJ\1740 patients\NNS\9898892 .\.\1740
D012964_D006509 NONE This\DT\1740 was\VBD\836236 an\DT\6697703 exploratory\JJ\1740 study\NN\635850 to\TO\1740 investigate\VB\644583 lamivudine-resistant\JJ\1740 <e2>hepatitis\NN\14127211 B</e2>\NN\1355326 virus\NN\9312843 (\-LRB-\1740 HBV\NN\1740 )\-RRB-\1740 strains\NNS\7358060 in\IN\13603305 selected\VBN\697589 <e1>lamivudine-na</e1>\JJ\1740 ve\NN\1740 HBV\NN\1740 carriers\NNS\9629752 with\IN\1740 and\CC\1740 without\IN\1740 human\JJ\1740 immunodeficiency\NN\13973990 virus\NN\9312843 (\-LRB-\1740 HIV\NN\14186340 )\-RRB-\1740 co-infection\NN\1740 in\IN\13603305 South\JJ\1740 African\JJ\1740 patients\NNS\9898892 .\.\1740
D012964_D006509 NONE Thirty-five\JJ\1740 <e1>lamivudine-na</e1>\NN\1740 ve\NN\1740 <e2>HBV\NN\1740 infected</e2>\JJ\1740 patients\NNS\9898892 with\IN\1740 or\CC\3541091 without\IN\1740 HIV\NN\14186340 co-infection\NN\1740 were\VBD\836236 studied\VBN\630380 :\:\1740 15\CD\13745420 chronic\JJ\1740 HBV\NN\1740 mono-infected\JJ\1740 patients\NNS\9898892 and\CC\1740 20\CD\13745420 HBV-HIV\NN\1740 co-infected\VBD\1740 patients\NNS\9898892 .\.\1740
D012964_D006509 NONE Thirty-five\JJ\1740 <e1>lamivudine-na</e1>\NN\1740 ve\NN\1740 HBV\NN\1740 infected\JJ\1740 patients\NNS\9898892 with\IN\1740 or\CC\3541091 without\IN\1740 HIV\NN\14186340 co-infection\NN\1740 were\VBD\836236 studied\VBN\630380 :\:\1740 15\CD\13745420 chronic\JJ\1740 <e2>HBV\NN\1740 mono-infected</e2>\JJ\1740 patients\NNS\9898892 and\CC\1740 20\CD\13745420 HBV-HIV\NN\1740 co-infected\VBD\1740 patients\NNS\9898892 .\.\1740
D012964_D006509 NONE Thirty-five\JJ\1740 <e1>lamivudine-na</e1>\NN\1740 ve\NN\1740 HBV\NN\1740 infected\JJ\1740 patients\NNS\9898892 with\IN\1740 or\CC\3541091 without\IN\1740 HIV\NN\14186340 co-infection\NN\1740 were\VBD\836236 studied\VBN\630380 :\:\1740 15\CD\13745420 chronic\JJ\1740 HBV\NN\1740 mono-infected\JJ\1740 patients\NNS\9898892 and\CC\1740 20\CD\13745420 <e2>HBV-HIV\NN\1740 co-infected</e2>\VBD\1740 patients\NNS\9898892 .\.\1740
D012964_D006509 NONE To\IN\1740 the\DT\1740 best\JJS\1740 of\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 this\DT\1740 constitutes\VBZ\1647229 the\DT\1740 first\JJ\1740 report\NN\6470073 of\IN\1740 HBV\NN\1740 lamivudine-resistant\JJ\1740 strains\NNS\7358060 in\IN\13603305 <e1>therapy-na</e1>\NN\1740 ve\NN\1740 <e2>HBV-HIV\NN\1740 co-infected</e2>\VBD\1740 patients\NNS\9898892 .\.\1740
D012964_D015658 NONE Mutations\NNS\4475 associated\VBN\628491 with\IN\1740 lamivudine-resistance\NN\1740 in\IN\13603305 <e1>therapy-na</e1>\JJ\1740 ve\NN\1740 hepatitis\NN\14127211 B\NN\1355326 virus\NN\9312843 (\-LRB-\1740 HBV\NN\1740 )\-RRB-\1740 infected\JJ\1740 patients\NNS\9898892 with\IN\1740 and\CC\1740 without\IN\1740 <e2>HIV\NN\14186340 co-infection</e2>\NN\1740 :\:\1740 implications\NNS\5774614 for\IN\1740 antiretroviral\JJ\1740 therapy\NN\657604 in\IN\13603305 HBV\NN\1740 and\CC\1740 HIV\NN\14186340 co-infected\VBD\1740 South\JJ\1740 African\JJ\1740 patients\NNS\9898892 .\.\1740
D012964_D015658 NONE Mutations\NNS\4475 associated\VBN\628491 with\IN\1740 lamivudine-resistance\NN\1740 in\IN\13603305 <e1>therapy-na</e1>\JJ\1740 ve\NN\1740 hepatitis\NN\14127211 B\NN\1355326 virus\NN\9312843 (\-LRB-\1740 HBV\NN\1740 )\-RRB-\1740 infected\JJ\1740 patients\NNS\9898892 with\IN\1740 and\CC\1740 without\IN\1740 HIV\NN\14186340 co-infection\NN\1740 :\:\1740 implications\NNS\5774614 for\IN\1740 antiretroviral\JJ\1740 therapy\NN\657604 in\IN\13603305 <e2>HBV\NN\1740 and\CC\1740 HIV\NN\14186340 co-infected</e2>\VBD\1740 South\JJ\1740 African\JJ\1740 patients\NNS\9898892 .\.\1740
D012964_D015658 NONE This\DT\1740 was\VBD\836236 an\DT\6697703 exploratory\JJ\1740 study\NN\635850 to\TO\1740 investigate\VB\644583 lamivudine-resistant\JJ\1740 hepatitis\NN\14127211 B\NN\1355326 virus\NN\9312843 (\-LRB-\1740 HBV\NN\1740 )\-RRB-\1740 strains\NNS\7358060 in\IN\13603305 selected\VBN\697589 <e1>lamivudine-na</e1>\JJ\1740 ve\NN\1740 HBV\NN\1740 carriers\NNS\9629752 with\IN\1740 and\CC\1740 without\IN\1740 <e2>human\JJ\1740 immunodeficiency\NN\13973990 virus\NN\9312843 (\-LRB-\1740 HIV\NN\14186340 )\-RRB-\1740 co-infection</e2>\NN\1740 in\IN\13603305 South\JJ\1740 African\JJ\1740 patients\NNS\9898892 .\.\1740
D012964_D015658 NONE Thirty-five\JJ\1740 <e1>lamivudine-na</e1>\NN\1740 ve\NN\1740 HBV\NN\1740 infected\JJ\1740 patients\NNS\9898892 with\IN\1740 or\CC\3541091 without\IN\1740 <e2>HIV\NN\14186340 co-infection</e2>\NN\1740 were\VBD\836236 studied\VBN\630380 :\:\1740 15\CD\13745420 chronic\JJ\1740 HBV\NN\1740 mono-infected\JJ\1740 patients\NNS\9898892 and\CC\1740 20\CD\13745420 HBV-HIV\NN\1740 co-infected\VBD\1740 patients\NNS\9898892 .\.\1740
D012964_D015658 NONE Thirty-five\JJ\1740 <e1>lamivudine-na</e1>\NN\1740 ve\NN\1740 HBV\NN\1740 infected\JJ\1740 patients\NNS\9898892 with\IN\1740 or\CC\3541091 without\IN\1740 HIV\NN\14186340 co-infection\NN\1740 were\VBD\836236 studied\VBN\630380 :\:\1740 15\CD\13745420 chronic\JJ\1740 HBV\NN\1740 mono-infected\JJ\1740 patients\NNS\9898892 and\CC\1740 20\CD\13745420 <e2>HBV-HIV\NN\1740 co-infected</e2>\VBD\1740 patients\NNS\9898892 .\.\1740
D012964_D015658 NONE To\IN\1740 the\DT\1740 best\JJS\1740 of\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 this\DT\1740 constitutes\VBZ\1647229 the\DT\1740 first\JJ\1740 report\NN\6470073 of\IN\1740 HBV\NN\1740 lamivudine-resistant\JJ\1740 strains\NNS\7358060 in\IN\13603305 <e1>therapy-na</e1>\NN\1740 ve\NN\1740 <e2>HBV-HIV\NN\1740 co-infected</e2>\VBD\1740 patients\NNS\9898892 .\.\1740
7468724
D013726_D002318 CID <e2>Cardiovascular\JJ\1740 complications</e2>\NNS\1073995 associated\VBN\628491 with\IN\1740 <e1>terbutaline</e1>\NN\1740 treatment\NN\654885 for\IN\1740 preterm\NN\1740 labor\NN\7974025 .\.\1740
D013726_D002318 CID Severe\JJ\1740 <e2>cardiovascular\JJ\1740 complications</e2>\NNS\1073995 occurred\VBD\2623529 in\IN\13603305 eight\CD\13741022 of\IN\1740 160\CD\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>terbutaline</e1>\NN\1740 for\IN\1740 preterm\NN\1740 labor\NN\7974025 .\.\1740
D013726_D007752 NONE Cardiovascular\JJ\1740 complications\NNS\1073995 associated\VBN\628491 with\IN\1740 <e1>terbutaline</e1>\NN\1740 treatment\NN\654885 for\IN\1740 <e2>preterm\NN\1740 labor</e2>\NN\7974025 .\.\1740
D013726_D007752 NONE Severe\JJ\1740 cardiovascular\JJ\1740 complications\NNS\1073995 occurred\VBD\2623529 in\IN\13603305 eight\CD\13741022 of\IN\1740 160\CD\1740 patients\NNS\9898892 treated\VBN\2376958 with\IN\1740 <e1>terbutaline</e1>\NN\1740 for\IN\1740 <e2>preterm\NN\1740 labor</e2>\NN\7974025 .\.\1740
7269015
D002066_D006470 CID <e1>Busulfan-induced</e1>\JJ\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
D002066_D006470 CID A\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 <e1>busulfan-induced</e1>\JJ\1740 <e2>hemorrhage\NN\14285662 cystitis</e2>\NN\14566129 is\VBZ\836236 reported\VBN\831651 .\.\1740
D002066_D003556 CID <e1>Busulfan-induced</e1>\JJ\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
D002066_D003556 CID A\DT\13649268 case\NN\7283608 of\IN\1740 a\DT\13649268 <e1>busulfan-induced</e1>\JJ\1740 <e2>hemorrhage\NN\14285662 cystitis</e2>\NN\14566129 is\VBZ\836236 reported\VBN\831651 .\.\1740
D002066_D003556 CID The\DT\1740 similarity\NN\4742535 between\IN\1740 the\DT\1740 histologic\JJ\1740 appearances\NNS\4723816 of\IN\1740 <e1>busulfan</e1>\NNS\1740 <e2>cystitis</e2>\NN\14566129 and\CC\1740 both\DT\1740 radiation\NN\11452218 and\CC\1740 cyclophosphamide-induced\JJ\1740 cystitis\NN\14566129 is\VBZ\836236 discussed\VBN\1033527 and\CC\1740 the\DT\1740 world\NN\19128 literature\NN\6362953 reviewed\VBN\644583 .\.\1740
D002066_D003556 CID The\DT\1740 similarity\NN\4742535 between\IN\1740 the\DT\1740 histologic\JJ\1740 appearances\NNS\4723816 of\IN\1740 <e1>busulfan</e1>\NNS\1740 cystitis\NN\14566129 and\CC\1740 both\DT\1740 radiation\NN\11452218 and\CC\1740 cyclophosphamide-induced\JJ\1740 <e2>cystitis</e2>\NN\14566129 is\VBZ\836236 discussed\VBN\1033527 and\CC\1740 the\DT\1740 world\NN\19128 literature\NN\6362953 reviewed\VBN\644583 .\.\1740
D003520_D003556 NONE The\DT\1740 similarity\NN\4742535 between\IN\1740 the\DT\1740 histologic\JJ\1740 appearances\NNS\4723816 of\IN\1740 busulfan\NNS\1740 <e2>cystitis</e2>\NN\14566129 and\CC\1740 both\DT\1740 radiation\NN\11452218 and\CC\1740 <e1>cyclophosphamide-induced</e1>\JJ\1740 cystitis\NN\14566129 is\VBZ\836236 discussed\VBN\1033527 and\CC\1740 the\DT\1740 world\NN\19128 literature\NN\6362953 reviewed\VBN\644583 .\.\1740
D003520_D003556 NONE The\DT\1740 similarity\NN\4742535 between\IN\1740 the\DT\1740 histologic\JJ\1740 appearances\NNS\4723816 of\IN\1740 busulfan\NNS\1740 cystitis\NN\14566129 and\CC\1740 both\DT\1740 radiation\NN\11452218 and\CC\1740 <e1>cyclophosphamide-induced</e1>\JJ\1740 <e2>cystitis</e2>\NN\14566129 is\VBZ\836236 discussed\VBN\1033527 and\CC\1740 the\DT\1740 world\NN\19128 literature\NN\6362953 reviewed\VBN\644583 .\.\1740
D002066_D002277 NONE In\IN\13603305 view\NN\6208021 of\IN\1740 the\DT\1740 known\JJ\1740 tendency\NN\6193203 of\IN\1740 <e1>busulfan</e1>\NNS\1740 to\TO\1740 induce\VB\1627355 cellular\JJ\1740 atypia\NN\1740 and\CC\1740 <e2>carcinoma</e2>\NN\14239918 in\IN\13603305 other\JJ\1740 sites\NNS\8673395 ,\,\1740 periodic\JJ\1740 urinary\JJ\1740 cytology\NN\6037666 is\VBZ\836236 suggested\VBN\1010118 in\IN\13603305 patients\NNS\9898892 on\IN\1740 long-term\JJ\1740 therapy\NN\657604 .\.\1740
15899738
D003401_D001281 CID Lone\JJ\1740 <e2>atrial\JJ\1740 fibrillation</e2>\NN\14361664 associated\VBN\628491 with\IN\1740 <e1>creatine</e1>\NN\14601829 monohydrate\NN\14910440 supplementation\NN\5108947 .\.\1740
D003401_D001145 NONE Previous\JJ\1740 anecdotal\JJ\1740 reports\NNS\6470073 have\VBP\2108377 linked\VBN\628491 <e1>creatine</e1>\NN\14601829 to\TO\1740 the\DT\1740 development\NN\248977 of\IN\1740 <e2>arrhythmia</e2>\NN\14103288 .\.\1740
12615818
D017373_D054556 CID The\DT\1740 risk\NN\14541044 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 in\IN\13603305 women\NNS\9605289 prescribed\VBD\748282 <e1>cyproterone\NN\1740 acetate</e1>\NN\15010703 in\IN\13603305 combination\NN\7951464 with\IN\1740 ethinyl\JJ\1740 estradiol\NN\14749794 :\:\1740 a\DT\13649268 nested\JJ\1740 cohort\NN\8184861 analysis\NN\633864 and\CC\1740 case-control\JJ\1740 study\NN\635850 .\.\1740
D017373_D054556 CID Previous\JJ\1740 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 <e1>CPA/EE</e1>\NN\1740 compared\VBN\644583 with\IN\1740 conventional\JJ\1740 combined\JJ\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 COCs\NNS\1740 )\-RRB-\1740 .\.\1740
D017373_D054556 CID Previous\JJ\1740 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 <e2>VTE</e2>\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 <e1>CPA/EE</e1>\NN\1740 compared\VBN\644583 with\IN\1740 conventional\JJ\1740 combined\JJ\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 COCs\NNS\1740 )\-RRB-\1740 .\.\1740
D017373_D054556 CID METHODS\NNS\5616786 :\:\1740 Using\VBG\1156834 the\DT\1740 General\NNP\10125786 Practice\NNP\407535 Research\NNP\633864 Database\NNP\6634376 we\PRP\1740 conducted\VBD\2436349 a\DT\13649268 cohort\NN\8184861 analysis\NN\633864 and\CC\1740 case-control\JJ\1740 study\NN\635850 nested\VBN\2649830 within\IN\1740 a\DT\13649268 population\NN\7942152 of\IN\1740 women\NNS\9605289 aged\JJ\1740 between\IN\1740 15\CD\13745420 and\CC\1740 39\CD\1740 years\NNS\15144371 with\IN\1740 acne\NN\14171682 ,\,\1740 hirsutism\NN\4683453 or\CC\3541091 PCOS\NN\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>VTE</e2>\NN\1740 associated\VBN\628491 with\IN\1740 <e1>CPA/EE</e1>\NN\1740 .\.\1740
D017373_D054556 CID CONCLUSIONS\NNS\5837957 :\:\1740 We\PRP\1740 have\VBP\2108377 demonstrated\VBN\2137132 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>VTE</e2>\NN\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>CPA/EE</e1>\NN\1740 in\IN\13603305 women\NNS\9605289 with\IN\1740 acne\NN\14171682 ,\,\1740 hirsutism\NN\4683453 or\CC\3541091 PCOS\NN\1740 although\IN\1740 residual\JJ\1740 confounding\NN\1740 by\IN\1740 indication\NN\33020 can\MD\3094503 not\RB\1740 be\VB\836236 excluded\VBN\471711 .\.\1740
D004997_D054556 CID The\DT\1740 risk\NN\14541044 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 in\IN\13603305 women\NNS\9605289 prescribed\VBD\748282 cyproterone\NN\1740 acetate\NN\15010703 in\IN\13603305 combination\NN\7951464 with\IN\1740 <e1>ethinyl\JJ\1740 estradiol</e1>\NN\14749794 :\:\1740 a\DT\13649268 nested\JJ\1740 cohort\NN\8184861 analysis\NN\633864 and\CC\1740 case-control\JJ\1740 study\NN\635850 .\.\1740
D004997_D054556 CID Previous\JJ\1740 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 <e1>CPA/EE</e1>\NN\1740 compared\VBN\644583 with\IN\1740 conventional\JJ\1740 combined\JJ\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 COCs\NNS\1740 )\-RRB-\1740 .\.\1740
D004997_D054556 CID Previous\JJ\1740 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 <e2>VTE</e2>\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 <e1>CPA/EE</e1>\NN\1740 compared\VBN\644583 with\IN\1740 conventional\JJ\1740 combined\JJ\1740 oral\JJ\1740 contraceptives\NNS\3183080 (\-LRB-\1740 COCs\NNS\1740 )\-RRB-\1740 .\.\1740
D004997_D054556 CID METHODS\NNS\5616786 :\:\1740 Using\VBG\1156834 the\DT\1740 General\NNP\10125786 Practice\NNP\407535 Research\NNP\633864 Database\NNP\6634376 we\PRP\1740 conducted\VBD\2436349 a\DT\13649268 cohort\NN\8184861 analysis\NN\633864 and\CC\1740 case-control\JJ\1740 study\NN\635850 nested\VBN\2649830 within\IN\1740 a\DT\13649268 population\NN\7942152 of\IN\1740 women\NNS\9605289 aged\JJ\1740 between\IN\1740 15\CD\13745420 and\CC\1740 39\CD\1740 years\NNS\15144371 with\IN\1740 acne\NN\14171682 ,\,\1740 hirsutism\NN\4683453 or\CC\3541091 PCOS\NN\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 <e2>VTE</e2>\NN\1740 associated\VBN\628491 with\IN\1740 <e1>CPA/EE</e1>\NN\1740 .\.\1740
D004997_D054556 CID CONCLUSIONS\NNS\5837957 :\:\1740 We\PRP\1740 have\VBP\2108377 demonstrated\VBN\2137132 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>VTE</e2>\NN\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>CPA/EE</e1>\NN\1740 in\IN\13603305 women\NNS\9605289 with\IN\1740 acne\NN\14171682 ,\,\1740 hirsutism\NN\4683453 or\CC\3541091 PCOS\NN\1740 although\IN\1740 residual\JJ\1740 confounding\NN\1740 by\IN\1740 indication\NN\33020 can\MD\3094503 not\RB\1740 be\VB\836236 excluded\VBN\471711 .\.\1740
D017373_D000152 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Cyproterone\NN\1740 acetate</e1>\NN\15010703 combined\VBN\2630189 with\IN\1740 ethinyl\JJ\1740 estradiol\NN\14749794 (\-LRB-\1740 CPA/EE\NN\1740 )\-RRB-\1740 is\VBZ\836236 licensed\VBN\803325 in\IN\13603305 the\DT\1740 UK\NNP\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 women\NNS\9605289 with\IN\1740 <e2>acne</e2>\NN\14171682 and\CC\1740 hirsutism\NN\4683453 and\CC\1740 is\VBZ\836236 also\RB\1740 a\DT\13649268 treatment\NN\654885 option\NN\6480506 for\IN\1740 polycystic\JJ\1740 ovary\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 PCOS\NN\1740 )\-RRB-\1740 .\.\1740
D017373_D000152 NONE BACKGROUND\NN\4921011 :\:\1740 Cyproterone\NN\1740 acetate\NN\15010703 combined\VBN\2630189 with\IN\1740 ethinyl\JJ\1740 estradiol\NN\14749794 (\-LRB-\1740 <e1>CPA/EE</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 licensed\VBN\803325 in\IN\13603305 the\DT\1740 UK\NNP\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 women\NNS\9605289 with\IN\1740 <e2>acne</e2>\NN\14171682 and\CC\1740 hirsutism\NN\4683453 and\CC\1740 is\VBZ\836236 also\RB\1740 a\DT\13649268 treatment\NN\654885 option\NN\6480506 for\IN\1740 polycystic\JJ\1740 ovary\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 PCOS\NN\1740 )\-RRB-\1740 .\.\1740
D017373_D000152 NONE METHODS\NNS\5616786 :\:\1740 Using\VBG\1156834 the\DT\1740 General\NNP\10125786 Practice\NNP\407535 Research\NNP\633864 Database\NNP\6634376 we\PRP\1740 conducted\VBD\2436349 a\DT\13649268 cohort\NN\8184861 analysis\NN\633864 and\CC\1740 case-control\JJ\1740 study\NN\635850 nested\VBN\2649830 within\IN\1740 a\DT\13649268 population\NN\7942152 of\IN\1740 women\NNS\9605289 aged\JJ\1740 between\IN\1740 15\CD\13745420 and\CC\1740 39\CD\1740 years\NNS\15144371 with\IN\1740 <e2>acne</e2>\NN\14171682 ,\,\1740 hirsutism\NN\4683453 or\CC\3541091 PCOS\NN\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 VTE\NN\1740 associated\VBN\628491 with\IN\1740 <e1>CPA/EE</e1>\NN\1740 .\.\1740
D017373_D000152 NONE CONCLUSIONS\NNS\5837957 :\:\1740 We\PRP\1740 have\VBP\2108377 demonstrated\VBN\2137132 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 VTE\NN\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>CPA/EE</e1>\NN\1740 in\IN\13603305 women\NNS\9605289 with\IN\1740 <e2>acne</e2>\NN\14171682 ,\,\1740 hirsutism\NN\4683453 or\CC\3541091 PCOS\NN\1740 although\IN\1740 residual\JJ\1740 confounding\NN\1740 by\IN\1740 indication\NN\33020 can\MD\3094503 not\RB\1740 be\VB\836236 excluded\VBN\471711 .\.\1740
D017373_D006628 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Cyproterone\NN\1740 acetate</e1>\NN\15010703 combined\VBN\2630189 with\IN\1740 ethinyl\JJ\1740 estradiol\NN\14749794 (\-LRB-\1740 CPA/EE\NN\1740 )\-RRB-\1740 is\VBZ\836236 licensed\VBN\803325 in\IN\13603305 the\DT\1740 UK\NNP\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 women\NNS\9605289 with\IN\1740 acne\NN\14171682 and\CC\1740 <e2>hirsutism</e2>\NN\4683453 and\CC\1740 is\VBZ\836236 also\RB\1740 a\DT\13649268 treatment\NN\654885 option\NN\6480506 for\IN\1740 polycystic\JJ\1740 ovary\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 PCOS\NN\1740 )\-RRB-\1740 .\.\1740
D017373_D006628 NONE BACKGROUND\NN\4921011 :\:\1740 Cyproterone\NN\1740 acetate\NN\15010703 combined\VBN\2630189 with\IN\1740 ethinyl\JJ\1740 estradiol\NN\14749794 (\-LRB-\1740 <e1>CPA/EE</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 licensed\VBN\803325 in\IN\13603305 the\DT\1740 UK\NNP\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 women\NNS\9605289 with\IN\1740 acne\NN\14171682 and\CC\1740 <e2>hirsutism</e2>\NN\4683453 and\CC\1740 is\VBZ\836236 also\RB\1740 a\DT\13649268 treatment\NN\654885 option\NN\6480506 for\IN\1740 polycystic\JJ\1740 ovary\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 PCOS\NN\1740 )\-RRB-\1740 .\.\1740
D017373_D006628 NONE METHODS\NNS\5616786 :\:\1740 Using\VBG\1156834 the\DT\1740 General\NNP\10125786 Practice\NNP\407535 Research\NNP\633864 Database\NNP\6634376 we\PRP\1740 conducted\VBD\2436349 a\DT\13649268 cohort\NN\8184861 analysis\NN\633864 and\CC\1740 case-control\JJ\1740 study\NN\635850 nested\VBN\2649830 within\IN\1740 a\DT\13649268 population\NN\7942152 of\IN\1740 women\NNS\9605289 aged\JJ\1740 between\IN\1740 15\CD\13745420 and\CC\1740 39\CD\1740 years\NNS\15144371 with\IN\1740 acne\NN\14171682 ,\,\1740 <e2>hirsutism</e2>\NN\4683453 or\CC\3541091 PCOS\NN\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 VTE\NN\1740 associated\VBN\628491 with\IN\1740 <e1>CPA/EE</e1>\NN\1740 .\.\1740
D017373_D006628 NONE CONCLUSIONS\NNS\5837957 :\:\1740 We\PRP\1740 have\VBP\2108377 demonstrated\VBN\2137132 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 VTE\NN\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>CPA/EE</e1>\NN\1740 in\IN\13603305 women\NNS\9605289 with\IN\1740 acne\NN\14171682 ,\,\1740 <e2>hirsutism</e2>\NN\4683453 or\CC\3541091 PCOS\NN\1740 although\IN\1740 residual\JJ\1740 confounding\NN\1740 by\IN\1740 indication\NN\33020 can\MD\3094503 not\RB\1740 be\VB\836236 excluded\VBN\471711 .\.\1740
D017373_D011085 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Cyproterone\NN\1740 acetate</e1>\NN\15010703 combined\VBN\2630189 with\IN\1740 ethinyl\JJ\1740 estradiol\NN\14749794 (\-LRB-\1740 CPA/EE\NN\1740 )\-RRB-\1740 is\VBZ\836236 licensed\VBN\803325 in\IN\13603305 the\DT\1740 UK\NNP\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 women\NNS\9605289 with\IN\1740 acne\NN\14171682 and\CC\1740 hirsutism\NN\4683453 and\CC\1740 is\VBZ\836236 also\RB\1740 a\DT\13649268 treatment\NN\654885 option\NN\6480506 for\IN\1740 <e2>polycystic\JJ\1740 ovary\JJ\1740 syndrome</e2>\NN\5870365 (\-LRB-\1740 PCOS\NN\1740 )\-RRB-\1740 .\.\1740
D017373_D011085 NONE BACKGROUND\NN\4921011 :\:\1740 <e1>Cyproterone\NN\1740 acetate</e1>\NN\15010703 combined\VBN\2630189 with\IN\1740 ethinyl\JJ\1740 estradiol\NN\14749794 (\-LRB-\1740 CPA/EE\NN\1740 )\-RRB-\1740 is\VBZ\836236 licensed\VBN\803325 in\IN\13603305 the\DT\1740 UK\NNP\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 women\NNS\9605289 with\IN\1740 acne\NN\14171682 and\CC\1740 hirsutism\NN\4683453 and\CC\1740 is\VBZ\836236 also\RB\1740 a\DT\13649268 treatment\NN\654885 option\NN\6480506 for\IN\1740 polycystic\JJ\1740 ovary\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 <e2>PCOS</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D017373_D011085 NONE BACKGROUND\NN\4921011 :\:\1740 Cyproterone\NN\1740 acetate\NN\15010703 combined\VBN\2630189 with\IN\1740 ethinyl\JJ\1740 estradiol\NN\14749794 (\-LRB-\1740 <e1>CPA/EE</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 licensed\VBN\803325 in\IN\13603305 the\DT\1740 UK\NNP\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 women\NNS\9605289 with\IN\1740 acne\NN\14171682 and\CC\1740 hirsutism\NN\4683453 and\CC\1740 is\VBZ\836236 also\RB\1740 a\DT\13649268 treatment\NN\654885 option\NN\6480506 for\IN\1740 <e2>polycystic\JJ\1740 ovary\JJ\1740 syndrome</e2>\NN\5870365 (\-LRB-\1740 PCOS\NN\1740 )\-RRB-\1740 .\.\1740
D017373_D011085 NONE BACKGROUND\NN\4921011 :\:\1740 Cyproterone\NN\1740 acetate\NN\15010703 combined\VBN\2630189 with\IN\1740 ethinyl\JJ\1740 estradiol\NN\14749794 (\-LRB-\1740 <e1>CPA/EE</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 licensed\VBN\803325 in\IN\13603305 the\DT\1740 UK\NNP\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 women\NNS\9605289 with\IN\1740 acne\NN\14171682 and\CC\1740 hirsutism\NN\4683453 and\CC\1740 is\VBZ\836236 also\RB\1740 a\DT\13649268 treatment\NN\654885 option\NN\6480506 for\IN\1740 polycystic\JJ\1740 ovary\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 <e2>PCOS</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D017373_D011085 NONE METHODS\NNS\5616786 :\:\1740 Using\VBG\1156834 the\DT\1740 General\NNP\10125786 Practice\NNP\407535 Research\NNP\633864 Database\NNP\6634376 we\PRP\1740 conducted\VBD\2436349 a\DT\13649268 cohort\NN\8184861 analysis\NN\633864 and\CC\1740 case-control\JJ\1740 study\NN\635850 nested\VBN\2649830 within\IN\1740 a\DT\13649268 population\NN\7942152 of\IN\1740 women\NNS\9605289 aged\JJ\1740 between\IN\1740 15\CD\13745420 and\CC\1740 39\CD\1740 years\NNS\15144371 with\IN\1740 acne\NN\14171682 ,\,\1740 hirsutism\NN\4683453 or\CC\3541091 <e2>PCOS</e2>\NN\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 VTE\NN\1740 associated\VBN\628491 with\IN\1740 <e1>CPA/EE</e1>\NN\1740 .\.\1740
D017373_D011085 NONE CONCLUSIONS\NNS\5837957 :\:\1740 We\PRP\1740 have\VBP\2108377 demonstrated\VBN\2137132 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 VTE\NN\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>CPA/EE</e1>\NN\1740 in\IN\13603305 women\NNS\9605289 with\IN\1740 acne\NN\14171682 ,\,\1740 hirsutism\NN\4683453 or\CC\3541091 <e2>PCOS</e2>\NN\1740 although\IN\1740 residual\JJ\1740 confounding\NN\1740 by\IN\1740 indication\NN\33020 can\MD\3094503 not\RB\1740 be\VB\836236 excluded\VBN\471711 .\.\1740
D004997_D000152 NONE BACKGROUND\NN\4921011 :\:\1740 Cyproterone\NN\1740 acetate\NN\15010703 combined\VBN\2630189 with\IN\1740 <e1>ethinyl\JJ\1740 estradiol</e1>\NN\14749794 (\-LRB-\1740 CPA/EE\NN\1740 )\-RRB-\1740 is\VBZ\836236 licensed\VBN\803325 in\IN\13603305 the\DT\1740 UK\NNP\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 women\NNS\9605289 with\IN\1740 <e2>acne</e2>\NN\14171682 and\CC\1740 hirsutism\NN\4683453 and\CC\1740 is\VBZ\836236 also\RB\1740 a\DT\13649268 treatment\NN\654885 option\NN\6480506 for\IN\1740 polycystic\JJ\1740 ovary\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 PCOS\NN\1740 )\-RRB-\1740 .\.\1740
D004997_D000152 NONE BACKGROUND\NN\4921011 :\:\1740 Cyproterone\NN\1740 acetate\NN\15010703 combined\VBN\2630189 with\IN\1740 ethinyl\JJ\1740 estradiol\NN\14749794 (\-LRB-\1740 <e1>CPA/EE</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 licensed\VBN\803325 in\IN\13603305 the\DT\1740 UK\NNP\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 women\NNS\9605289 with\IN\1740 <e2>acne</e2>\NN\14171682 and\CC\1740 hirsutism\NN\4683453 and\CC\1740 is\VBZ\836236 also\RB\1740 a\DT\13649268 treatment\NN\654885 option\NN\6480506 for\IN\1740 polycystic\JJ\1740 ovary\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 PCOS\NN\1740 )\-RRB-\1740 .\.\1740
D004997_D000152 NONE METHODS\NNS\5616786 :\:\1740 Using\VBG\1156834 the\DT\1740 General\NNP\10125786 Practice\NNP\407535 Research\NNP\633864 Database\NNP\6634376 we\PRP\1740 conducted\VBD\2436349 a\DT\13649268 cohort\NN\8184861 analysis\NN\633864 and\CC\1740 case-control\JJ\1740 study\NN\635850 nested\VBN\2649830 within\IN\1740 a\DT\13649268 population\NN\7942152 of\IN\1740 women\NNS\9605289 aged\JJ\1740 between\IN\1740 15\CD\13745420 and\CC\1740 39\CD\1740 years\NNS\15144371 with\IN\1740 <e2>acne</e2>\NN\14171682 ,\,\1740 hirsutism\NN\4683453 or\CC\3541091 PCOS\NN\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 VTE\NN\1740 associated\VBN\628491 with\IN\1740 <e1>CPA/EE</e1>\NN\1740 .\.\1740
D004997_D000152 NONE CONCLUSIONS\NNS\5837957 :\:\1740 We\PRP\1740 have\VBP\2108377 demonstrated\VBN\2137132 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 VTE\NN\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>CPA/EE</e1>\NN\1740 in\IN\13603305 women\NNS\9605289 with\IN\1740 <e2>acne</e2>\NN\14171682 ,\,\1740 hirsutism\NN\4683453 or\CC\3541091 PCOS\NN\1740 although\IN\1740 residual\JJ\1740 confounding\NN\1740 by\IN\1740 indication\NN\33020 can\MD\3094503 not\RB\1740 be\VB\836236 excluded\VBN\471711 .\.\1740
D004997_D006628 NONE BACKGROUND\NN\4921011 :\:\1740 Cyproterone\NN\1740 acetate\NN\15010703 combined\VBN\2630189 with\IN\1740 <e1>ethinyl\JJ\1740 estradiol</e1>\NN\14749794 (\-LRB-\1740 CPA/EE\NN\1740 )\-RRB-\1740 is\VBZ\836236 licensed\VBN\803325 in\IN\13603305 the\DT\1740 UK\NNP\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 women\NNS\9605289 with\IN\1740 acne\NN\14171682 and\CC\1740 <e2>hirsutism</e2>\NN\4683453 and\CC\1740 is\VBZ\836236 also\RB\1740 a\DT\13649268 treatment\NN\654885 option\NN\6480506 for\IN\1740 polycystic\JJ\1740 ovary\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 PCOS\NN\1740 )\-RRB-\1740 .\.\1740
D004997_D006628 NONE BACKGROUND\NN\4921011 :\:\1740 Cyproterone\NN\1740 acetate\NN\15010703 combined\VBN\2630189 with\IN\1740 ethinyl\JJ\1740 estradiol\NN\14749794 (\-LRB-\1740 <e1>CPA/EE</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 licensed\VBN\803325 in\IN\13603305 the\DT\1740 UK\NNP\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 women\NNS\9605289 with\IN\1740 acne\NN\14171682 and\CC\1740 <e2>hirsutism</e2>\NN\4683453 and\CC\1740 is\VBZ\836236 also\RB\1740 a\DT\13649268 treatment\NN\654885 option\NN\6480506 for\IN\1740 polycystic\JJ\1740 ovary\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 PCOS\NN\1740 )\-RRB-\1740 .\.\1740
D004997_D006628 NONE METHODS\NNS\5616786 :\:\1740 Using\VBG\1156834 the\DT\1740 General\NNP\10125786 Practice\NNP\407535 Research\NNP\633864 Database\NNP\6634376 we\PRP\1740 conducted\VBD\2436349 a\DT\13649268 cohort\NN\8184861 analysis\NN\633864 and\CC\1740 case-control\JJ\1740 study\NN\635850 nested\VBN\2649830 within\IN\1740 a\DT\13649268 population\NN\7942152 of\IN\1740 women\NNS\9605289 aged\JJ\1740 between\IN\1740 15\CD\13745420 and\CC\1740 39\CD\1740 years\NNS\15144371 with\IN\1740 acne\NN\14171682 ,\,\1740 <e2>hirsutism</e2>\NN\4683453 or\CC\3541091 PCOS\NN\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 VTE\NN\1740 associated\VBN\628491 with\IN\1740 <e1>CPA/EE</e1>\NN\1740 .\.\1740
D004997_D006628 NONE CONCLUSIONS\NNS\5837957 :\:\1740 We\PRP\1740 have\VBP\2108377 demonstrated\VBN\2137132 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 VTE\NN\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>CPA/EE</e1>\NN\1740 in\IN\13603305 women\NNS\9605289 with\IN\1740 acne\NN\14171682 ,\,\1740 <e2>hirsutism</e2>\NN\4683453 or\CC\3541091 PCOS\NN\1740 although\IN\1740 residual\JJ\1740 confounding\NN\1740 by\IN\1740 indication\NN\33020 can\MD\3094503 not\RB\1740 be\VB\836236 excluded\VBN\471711 .\.\1740
D004997_D011085 NONE BACKGROUND\NN\4921011 :\:\1740 Cyproterone\NN\1740 acetate\NN\15010703 combined\VBN\2630189 with\IN\1740 <e1>ethinyl\JJ\1740 estradiol</e1>\NN\14749794 (\-LRB-\1740 CPA/EE\NN\1740 )\-RRB-\1740 is\VBZ\836236 licensed\VBN\803325 in\IN\13603305 the\DT\1740 UK\NNP\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 women\NNS\9605289 with\IN\1740 acne\NN\14171682 and\CC\1740 hirsutism\NN\4683453 and\CC\1740 is\VBZ\836236 also\RB\1740 a\DT\13649268 treatment\NN\654885 option\NN\6480506 for\IN\1740 <e2>polycystic\JJ\1740 ovary\JJ\1740 syndrome</e2>\NN\5870365 (\-LRB-\1740 PCOS\NN\1740 )\-RRB-\1740 .\.\1740
D004997_D011085 NONE BACKGROUND\NN\4921011 :\:\1740 Cyproterone\NN\1740 acetate\NN\15010703 combined\VBN\2630189 with\IN\1740 <e1>ethinyl\JJ\1740 estradiol</e1>\NN\14749794 (\-LRB-\1740 CPA/EE\NN\1740 )\-RRB-\1740 is\VBZ\836236 licensed\VBN\803325 in\IN\13603305 the\DT\1740 UK\NNP\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 women\NNS\9605289 with\IN\1740 acne\NN\14171682 and\CC\1740 hirsutism\NN\4683453 and\CC\1740 is\VBZ\836236 also\RB\1740 a\DT\13649268 treatment\NN\654885 option\NN\6480506 for\IN\1740 polycystic\JJ\1740 ovary\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 <e2>PCOS</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D004997_D011085 NONE BACKGROUND\NN\4921011 :\:\1740 Cyproterone\NN\1740 acetate\NN\15010703 combined\VBN\2630189 with\IN\1740 ethinyl\JJ\1740 estradiol\NN\14749794 (\-LRB-\1740 <e1>CPA/EE</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 licensed\VBN\803325 in\IN\13603305 the\DT\1740 UK\NNP\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 women\NNS\9605289 with\IN\1740 acne\NN\14171682 and\CC\1740 hirsutism\NN\4683453 and\CC\1740 is\VBZ\836236 also\RB\1740 a\DT\13649268 treatment\NN\654885 option\NN\6480506 for\IN\1740 <e2>polycystic\JJ\1740 ovary\JJ\1740 syndrome</e2>\NN\5870365 (\-LRB-\1740 PCOS\NN\1740 )\-RRB-\1740 .\.\1740
D004997_D011085 NONE BACKGROUND\NN\4921011 :\:\1740 Cyproterone\NN\1740 acetate\NN\15010703 combined\VBN\2630189 with\IN\1740 ethinyl\JJ\1740 estradiol\NN\14749794 (\-LRB-\1740 <e1>CPA/EE</e1>\NN\1740 )\-RRB-\1740 is\VBZ\836236 licensed\VBN\803325 in\IN\13603305 the\DT\1740 UK\NNP\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 women\NNS\9605289 with\IN\1740 acne\NN\14171682 and\CC\1740 hirsutism\NN\4683453 and\CC\1740 is\VBZ\836236 also\RB\1740 a\DT\13649268 treatment\NN\654885 option\NN\6480506 for\IN\1740 polycystic\JJ\1740 ovary\JJ\1740 syndrome\NN\5870365 (\-LRB-\1740 <e2>PCOS</e2>\NN\1740 )\-RRB-\1740 .\.\1740
D004997_D011085 NONE METHODS\NNS\5616786 :\:\1740 Using\VBG\1156834 the\DT\1740 General\NNP\10125786 Practice\NNP\407535 Research\NNP\633864 Database\NNP\6634376 we\PRP\1740 conducted\VBD\2436349 a\DT\13649268 cohort\NN\8184861 analysis\NN\633864 and\CC\1740 case-control\JJ\1740 study\NN\635850 nested\VBN\2649830 within\IN\1740 a\DT\13649268 population\NN\7942152 of\IN\1740 women\NNS\9605289 aged\JJ\1740 between\IN\1740 15\CD\13745420 and\CC\1740 39\CD\1740 years\NNS\15144371 with\IN\1740 acne\NN\14171682 ,\,\1740 hirsutism\NN\4683453 or\CC\3541091 <e2>PCOS</e2>\NN\1740 to\TO\1740 estimate\VB\637259 the\DT\1740 risk\NN\14541044 of\IN\1740 VTE\NN\1740 associated\VBN\628491 with\IN\1740 <e1>CPA/EE</e1>\NN\1740 .\.\1740
D004997_D011085 NONE CONCLUSIONS\NNS\5837957 :\:\1740 We\PRP\1740 have\VBP\2108377 demonstrated\VBN\2137132 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 VTE\NN\1740 associated\VBN\628491 with\IN\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>CPA/EE</e1>\NN\1740 in\IN\13603305 women\NNS\9605289 with\IN\1740 acne\NN\14171682 ,\,\1740 hirsutism\NN\4683453 or\CC\3541091 <e2>PCOS</e2>\NN\1740 although\IN\1740 residual\JJ\1740 confounding\NN\1740 by\IN\1740 indication\NN\33020 can\MD\3094503 not\RB\1740 be\VB\836236 excluded\VBN\471711 .\.\1740
D003276_D054556 NONE Previous\JJ\1740 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 <e2>venous\JJ\1740 thromboembolism</e2>\NN\14100769 (\-LRB-\1740 VTE\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 CPA/EE\NN\1740 compared\VBN\644583 with\IN\1740 conventional\JJ\1740 combined\JJ\1740 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 (\-LRB-\1740 COCs\NNS\1740 )\-RRB-\1740 .\.\1740
D003276_D054556 NONE Previous\JJ\1740 studies\NNS\635850 have\VBP\2108377 demonstrated\VBN\2137132 an\DT\6697703 increased\VBN\169651 risk\NN\14541044 of\IN\1740 venous\JJ\1740 thromboembolism\NN\14100769 (\-LRB-\1740 <e2>VTE</e2>\NN\1740 )\-RRB-\1740 associated\VBN\628491 with\IN\1740 CPA/EE\NN\1740 compared\VBN\644583 with\IN\1740 conventional\JJ\1740 combined\JJ\1740 <e1>oral\JJ\1740 contraceptives</e1>\NNS\3183080 (\-LRB-\1740 COCs\NNS\1740 )\-RRB-\1740 .\.\1740
12483326
D016190_D005128 NONE Severe\JJ\1740 <e2>ocular\JJ\1740 and\CC\1740 orbital\JJ\1740 toxicity</e2>\NN\13576101 after\IN\1740 intracarotid\NN\1740 injection\NN\320852 of\IN\1740 <e1>carboplatin</e1>\NN\1740 for\IN\1740 recurrent\JJ\1740 glioblastomas\NNS\14236743 .\.\1740
D016190_D005128 NONE Generally\RB\1740 ,\,\1740 <e1>carboplatin</e1>\NN\1740 is\VBZ\836236 said\VBN\940384 to\TO\1740 have\VB\2108377 milder\NN\1740 side\NN\8630039 effects\NNS\13245626 than\IN\1740 cisplatin\NN\1740 ,\,\1740 whose\WP$\1740 <e2>ocular\JJ\1740 and\CC\1740 orbital\JJ\1740 toxicity</e2>\NN\13576101 are\VBP\836236 well\RB\1740 known\JJ\1740 .\.\1740
D016190_D005128 NONE However\RB\1740 ,\,\1740 we\PRP\1740 experienced\VBD\2108377 a\DT\13649268 case\NN\7283608 of\IN\1740 severe\JJ\1740 <e2>ocular\JJ\1740 and\CC\1740 orbital\JJ\1740 toxicity</e2>\NN\13576101 after\IN\1740 intracarotid\NN\1740 injection\NN\320852 of\IN\1740 <e1>carboplatin</e1>\NN\1740 ,\,\1740 which\WDT\1740 is\VBZ\836236 infrequently\RB\1740 reported\VBN\831651 .\.\1740
D016190_D005128 NONE CONCLUSION\NN\5837957 :\:\1740 When\WRB\1740 performing\VBG\2367363 intracarotid\NN\1740 injection\NN\320852 of\IN\1740 <e1>carboplatin</e1>\NN\1740 ,\,\1740 we\PRP\1740 must\MD\9367203 be\VB\836236 aware\JJ\1740 of\IN\1740 its\PRP$\6125041 potentially\RB\1740 blinding\VBG\126264 <e2>ocular\JJ\1740 toxicity</e2>\NN\13576101 .\.\1740
D016190_D009916 NONE Severe\JJ\1740 <e2>ocular\JJ\1740 and\CC\1740 orbital\JJ\1740 toxicity</e2>\NN\13576101 after\IN\1740 intracarotid\NN\1740 injection\NN\320852 of\IN\1740 <e1>carboplatin</e1>\NN\1740 for\IN\1740 recurrent\JJ\1740 glioblastomas\NNS\14236743 .\.\1740
D016190_D009916 NONE Generally\RB\1740 ,\,\1740 <e1>carboplatin</e1>\NN\1740 is\VBZ\836236 said\VBN\940384 to\TO\1740 have\VB\2108377 milder\NN\1740 side\NN\8630039 effects\NNS\13245626 than\IN\1740 cisplatin\NN\1740 ,\,\1740 whose\WP$\1740 <e2>ocular\JJ\1740 and\CC\1740 orbital\JJ\1740 toxicity</e2>\NN\13576101 are\VBP\836236 well\RB\1740 known\JJ\1740 .\.\1740
D016190_D009916 NONE However\RB\1740 ,\,\1740 we\PRP\1740 experienced\VBD\2108377 a\DT\13649268 case\NN\7283608 of\IN\1740 severe\JJ\1740 <e2>ocular\JJ\1740 and\CC\1740 orbital\JJ\1740 toxicity</e2>\NN\13576101 after\IN\1740 intracarotid\NN\1740 injection\NN\320852 of\IN\1740 <e1>carboplatin</e1>\NN\1740 ,\,\1740 which\WDT\1740 is\VBZ\836236 infrequently\RB\1740 reported\VBN\831651 .\.\1740
D016190_D005909 NONE Severe\JJ\1740 ocular\JJ\1740 and\CC\1740 orbital\JJ\1740 toxicity\NN\13576101 after\IN\1740 intracarotid\NN\1740 injection\NN\320852 of\IN\1740 <e1>carboplatin</e1>\NN\1740 for\IN\1740 recurrent\JJ\1740 <e2>glioblastomas</e2>\NNS\14236743 .\.\1740
D016190_D005909 NONE CASE\NN\7283608 :\:\1740 A\DT\13649268 58-year-old\JJ\1740 man\NN\9605289 received\VBD\2210855 an\DT\6697703 intracarotid\NN\1740 injection\NN\320852 of\IN\1740 <e1>carboplatin</e1>\NN\1740 for\IN\1740 recurrent\JJ\1740 <e2>glioblastomas</e2>\NNS\14236743 in\IN\13603305 his\PRP$\1740 left\JJ\1740 temporal\JJ\1740 lobe\NN\5220461 .\.\1740
D002945_D005128 NONE Generally\RB\1740 ,\,\1740 carboplatin\NN\1740 is\VBZ\836236 said\VBN\940384 to\TO\1740 have\VB\2108377 milder\NN\1740 side\NN\8630039 effects\NNS\13245626 than\IN\1740 <e1>cisplatin</e1>\NN\1740 ,\,\1740 whose\WP$\1740 <e2>ocular\JJ\1740 and\CC\1740 orbital\JJ\1740 toxicity</e2>\NN\13576101 are\VBP\836236 well\RB\1740 known\JJ\1740 .\.\1740
D002945_D009916 NONE Generally\RB\1740 ,\,\1740 carboplatin\NN\1740 is\VBZ\836236 said\VBN\940384 to\TO\1740 have\VB\2108377 milder\NN\1740 side\NN\8630039 effects\NNS\13245626 than\IN\1740 <e1>cisplatin</e1>\NN\1740 ,\,\1740 whose\WP$\1740 <e2>ocular\JJ\1740 and\CC\1740 orbital\JJ\1740 toxicity</e2>\NN\13576101 are\VBP\836236 well\RB\1740 known\JJ\1740 .\.\1740
D016190_D064420 NONE Various\JJ\1740 ocular\JJ\1740 symptoms\NNS\5823932 and\CC\1740 findings\NNS\7951464 caused\VBN\1617192 by\IN\1740 <e1>carboplatin</e1>\NN\1740 <e2>toxicity</e2>\NN\13576101 were\VBD\836236 seen\VBN\2106506 .\.\1740
7292072
D003891_D017180 CID Variant\JJ\1740 <e2>ventricular\NN\1740 tachycardia</e2>\NN\14110674 in\IN\13603305 <e1>desipramine</e1>\NN\4482543 toxicity\NN\13576101 .\.\1740
D003891_D017180 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 variant\JJ\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 induced\VBN\1627355 by\IN\1740 <e1>desipramine</e1>\NN\4482543 toxicity\NN\13576101 .\.\1740
D003891_D064420 NONE Variant\JJ\1740 ventricular\NN\1740 tachycardia\NN\14110674 in\IN\13603305 <e1>desipramine</e1>\NN\4482543 <e2>toxicity</e2>\NN\13576101 .\.\1740
D003891_D064420 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 variant\JJ\1740 ventricular\JJ\1740 tachycardia\NN\14110674 induced\VBN\1627355 by\IN\1740 <e1>desipramine</e1>\NN\4482543 <e2>toxicity</e2>\NN\13576101 .\.\1740
9401499
D013988_D000741 CID <e1>Ticlopidine-induced</e1>\JJ\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 :\:\1740 report\NN\6470073 of\IN\1740 three\CD\13741022 Chinese\JJ\1740 patients\NNS\9898892 and\CC\1740 review\NN\5733583 of\IN\1740 the\DT\1740 literature\NN\6362953 .\.\1740
D013988_D000741 CID In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 three\CD\13741022 Chinese\JJ\1740 patients\NNS\9898892 with\IN\1740 <e1>ticlopidine-induced</e1>\JJ\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 were\VBD\836236 reported\VBN\831651 and\CC\1740 another\DT\1740 13\CD\13745420 patients\NNS\9898892 in\IN\13603305 the\DT\1740 English\NNP\6946823 literature\NN\6362953 were\VBD\836236 reviewed\VBN\644583 .\.\1740
D013988_D000741 CID Treatment\NN\654885 for\IN\1740 <e1>ticlopidine-induced</e1>\JJ\1740 <e2>aplastic\JJ\1740 anemia</e2>\NN\14189204 with\IN\1740 colony-stimulating\JJ\1740 factors\NNS\7326557 seemed\VBD\2604760 to\TO\1740 have\VB\2108377 little\JJ\1740 effect\NN\34213 .\.\1740
D013988_D000380 CID <e2>Agranulocytosis</e2>\NN\14189204 occurred\VBD\2623529 3\CD\13741022 -\SYM\1740 20\CD\13745420 weeks\NNS\15113229 after\IN\1740 initiation\NN\7450842 of\IN\1740 <e1>ticlopidine</e1>\NN\1740 ,\,\1740 so\RB\1740 frequent\JJ\1740 examination\NN\633864 of\IN\1740 white\JJ\1740 cell\NN\3080309 count\NN\13582013 during\IN\1740 treatment\NN\654885 is\VBZ\836236 recommended\VBN\875394 .\.\1740
9195768
D018170_D010292 CID <e2>Atypical\JJ\1740 sensations</e2>\NNS\5708432 following\VBG\1835496 the\DT\1740 use\NN\407535 of\IN\1740 subcutaneous\JJ\1740 <e1>sumatriptan</e1>\NN\1740 are\VBP\836236 common\JJ\1740 ,\,\1740 but\CC\1740 of\IN\1740 uncertain\JJ\1740 origin\NN\8620061 .\.\1740
17147461
D020123_D011507 CID <e1>Sirolimus-associated</e1>\JJ\1740 <e2>proteinuria</e2>\NN\14299637 and\CC\1740 renal\JJ\1740 dysfunction\NN\14204950 .\.\1740
D020123_D011507 CID However\RB\1740 ,\,\1740 clinical\JJ\1740 reports\NNS\6470073 suggest\VBP\1010118 that\IN\1740 ,\,\1740 under\IN\1740 some\DT\1740 circumstances\NNS\13920429 ,\,\1740 <e1>sirolimus</e1>\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 <e2>proteinuria</e2>\NN\14299637 and\CC\1740 acute\JJ\1740 renal\JJ\1740 dysfunction\NN\14204950 .\.\1740
D020123_D011507 CID The\DT\1740 mechanisms\NNS\13446390 of\IN\1740 <e1>sirolimus-associated</e1>\JJ\1740 <e2>proteinuria</e2>\NN\14299637 are\VBP\836236 multifactorial\JJ\1740 and\CC\1740 may\MD\15209706 be\VB\836236 due\JJ\1740 to\TO\1740 an\DT\6697703 increase\NN\13576355 in\IN\13603305 glomerular\JJ\1740 capillary\JJ\1740 pressure\NN\11419404 following\VBG\1835496 calcineurin\NN\1740 inhibitor\NN\20090 withdrawal\NN\7206096 .\.\1740
D020123_D011507 CID Although\IN\1740 these\DT\1740 adverse\JJ\1740 effects\NNS\13245626 occur\VBP\2623529 in\IN\13603305 some\DT\1740 patients\NNS\9898892 ,\,\1740 their\PRP$\1740 occurrence\NN\29378 could\MD\1740 be\VB\836236 minimised\VBN\831651 by\IN\1740 knowledge\NN\23100 of\IN\1740 the\DT\1740 molecular\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>sirolimus</e1>\NN\1740 on\IN\1740 the\DT\1740 kidney\NN\5333259 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 sirolimus\NN\1740 in\IN\13603305 appropriate\JJ\1740 patient\NN\9898892 populations\NNS\7942152 ,\,\1740 close\JJ\1740 monitoring\NN\879759 of\IN\1740 <e2>proteinuria</e2>\NN\14299637 and\CC\1740 renal\JJ\1740 function\NN\13783581 ,\,\1740 use\NN\407535 of\IN\1740 angiotensin-converting\JJ\1740 enzyme\NN\14723628 inhibitors\NNS\20090 or\CC\3541091 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 blockers\NNS\10101634 if\IN\1740 proteinuria\NN\14299637 occurs\VBZ\2623529 and\CC\1740 withdrawal\NN\7206096 if\IN\1740 needed\VBN\2604760 .\.\1740
D020123_D011507 CID Although\IN\1740 these\DT\1740 adverse\JJ\1740 effects\NNS\13245626 occur\VBP\2623529 in\IN\13603305 some\DT\1740 patients\NNS\9898892 ,\,\1740 their\PRP$\1740 occurrence\NN\29378 could\MD\1740 be\VB\836236 minimised\VBN\831651 by\IN\1740 knowledge\NN\23100 of\IN\1740 the\DT\1740 molecular\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>sirolimus</e1>\NN\1740 on\IN\1740 the\DT\1740 kidney\NN\5333259 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 sirolimus\NN\1740 in\IN\13603305 appropriate\JJ\1740 patient\NN\9898892 populations\NNS\7942152 ,\,\1740 close\JJ\1740 monitoring\NN\879759 of\IN\1740 proteinuria\NN\14299637 and\CC\1740 renal\JJ\1740 function\NN\13783581 ,\,\1740 use\NN\407535 of\IN\1740 angiotensin-converting\JJ\1740 enzyme\NN\14723628 inhibitors\NNS\20090 or\CC\3541091 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 blockers\NNS\10101634 if\IN\1740 <e2>proteinuria</e2>\NN\14299637 occurs\VBZ\2623529 and\CC\1740 withdrawal\NN\7206096 if\IN\1740 needed\VBN\2604760 .\.\1740
D020123_D011507 CID Although\IN\1740 these\DT\1740 adverse\JJ\1740 effects\NNS\13245626 occur\VBP\2623529 in\IN\13603305 some\DT\1740 patients\NNS\9898892 ,\,\1740 their\PRP$\1740 occurrence\NN\29378 could\MD\1740 be\VB\836236 minimised\VBN\831651 by\IN\1740 knowledge\NN\23100 of\IN\1740 the\DT\1740 molecular\JJ\1740 effects\NNS\13245626 of\IN\1740 sirolimus\NN\1740 on\IN\1740 the\DT\1740 kidney\NN\5333259 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>sirolimus</e1>\NN\1740 in\IN\13603305 appropriate\JJ\1740 patient\NN\9898892 populations\NNS\7942152 ,\,\1740 close\JJ\1740 monitoring\NN\879759 of\IN\1740 <e2>proteinuria</e2>\NN\14299637 and\CC\1740 renal\JJ\1740 function\NN\13783581 ,\,\1740 use\NN\407535 of\IN\1740 angiotensin-converting\JJ\1740 enzyme\NN\14723628 inhibitors\NNS\20090 or\CC\3541091 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 blockers\NNS\10101634 if\IN\1740 proteinuria\NN\14299637 occurs\VBZ\2623529 and\CC\1740 withdrawal\NN\7206096 if\IN\1740 needed\VBN\2604760 .\.\1740
D020123_D011507 CID Although\IN\1740 these\DT\1740 adverse\JJ\1740 effects\NNS\13245626 occur\VBP\2623529 in\IN\13603305 some\DT\1740 patients\NNS\9898892 ,\,\1740 their\PRP$\1740 occurrence\NN\29378 could\MD\1740 be\VB\836236 minimised\VBN\831651 by\IN\1740 knowledge\NN\23100 of\IN\1740 the\DT\1740 molecular\JJ\1740 effects\NNS\13245626 of\IN\1740 sirolimus\NN\1740 on\IN\1740 the\DT\1740 kidney\NN\5333259 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 <e1>sirolimus</e1>\NN\1740 in\IN\13603305 appropriate\JJ\1740 patient\NN\9898892 populations\NNS\7942152 ,\,\1740 close\JJ\1740 monitoring\NN\879759 of\IN\1740 proteinuria\NN\14299637 and\CC\1740 renal\JJ\1740 function\NN\13783581 ,\,\1740 use\NN\407535 of\IN\1740 angiotensin-converting\JJ\1740 enzyme\NN\14723628 inhibitors\NNS\20090 or\CC\3541091 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 blockers\NNS\10101634 if\IN\1740 <e2>proteinuria</e2>\NN\14299637 occurs\VBZ\2623529 and\CC\1740 withdrawal\NN\7206096 if\IN\1740 needed\VBN\2604760 .\.\1740
D020123_D007674 CID <e1>Sirolimus-associated</e1>\JJ\1740 proteinuria\NN\14299637 and\CC\1740 <e2>renal\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D020123_D007674 CID <e1>Sirolimus</e1>\NN\1740 represents\VBZ\2664769 a\DT\13649268 major\JJ\1740 therapeutic\JJ\1740 advance\NN\7311115 in\IN\13603305 the\DT\1740 prevention\NN\1073995 of\IN\1740 acute\JJ\1740 renal\JJ\1740 allograft\NN\5582859 rejection\NN\30358 and\CC\1740 chronic\JJ\1740 allograft\NN\5582859 <e2>nephropathy</e2>\RB\1740 .\.\1740
D020123_D007674 CID Because\IN\1740 <e1>sirolimus</e1>\NN\1740 does\VBZ\1640855 not\RB\1740 share\VB\2660631 the\DT\1740 vasomotor\NN\1740 renal\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 exhibited\VBN\2632167 by\IN\1740 calcineurin\NN\1740 inhibitors\NNS\20090 ,\,\1740 it\PRP\6125041 has\VBZ\2108377 been\VBN\836236 designated\VBN\2475922 a\DT\13649268 '\``\1740 <e2>non-nephrotoxic</e2>\JJ\1740 drug\NN\14778436 '\''\1740 .\.\1740
D020123_D058186 NONE However\RB\1740 ,\,\1740 clinical\JJ\1740 reports\NNS\6470073 suggest\VBP\1010118 that\IN\1740 ,\,\1740 under\IN\1740 some\DT\1740 circumstances\NNS\13920429 ,\,\1740 <e1>sirolimus</e1>\NN\1740 is\VBZ\836236 associated\VBN\628491 with\IN\1740 proteinuria\NN\14299637 and\CC\1740 <e2>acute\JJ\1740 renal\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D020123_D058186 NONE The\DT\1740 <e2>acute\JJ\1740 renal\JJ\1740 dysfunction</e2>\NN\14204950 associated\VBN\628491 with\IN\1740 <e1>sirolimus</e1>\NN\1740 (\-LRB-\1740 such\JJ\1740 as\IN\14622893 in\IN\13603305 delayed\VBN\439958 graft\NN\5267548 function\NN\13783581 )\-RRB-\1740 may\MD\15209706 be\VB\836236 due\JJ\1740 to\TO\1740 suppression\NN\13489037 of\IN\1740 compensatory\JJ\1740 renal\JJ\1740 cell\NN\3080309 proliferation\NN\13489037 and\CC\1740 survival/repair\JJ\1740 processes\NNS\407535 .\.\1740
D000809_D011507 NONE Although\IN\1740 these\DT\1740 adverse\JJ\1740 effects\NNS\13245626 occur\VBP\2623529 in\IN\13603305 some\DT\1740 patients\NNS\9898892 ,\,\1740 their\PRP$\1740 occurrence\NN\29378 could\MD\1740 be\VB\836236 minimised\VBN\831651 by\IN\1740 knowledge\NN\23100 of\IN\1740 the\DT\1740 molecular\JJ\1740 effects\NNS\13245626 of\IN\1740 sirolimus\NN\1740 on\IN\1740 the\DT\1740 kidney\NN\5333259 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 sirolimus\NN\1740 in\IN\13603305 appropriate\JJ\1740 patient\NN\9898892 populations\NNS\7942152 ,\,\1740 close\JJ\1740 monitoring\NN\879759 of\IN\1740 <e2>proteinuria</e2>\NN\14299637 and\CC\1740 renal\JJ\1740 function\NN\13783581 ,\,\1740 use\NN\407535 of\IN\1740 <e1>angiotensin-converting</e1>\JJ\1740 enzyme\NN\14723628 inhibitors\NNS\20090 or\CC\3541091 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 blockers\NNS\10101634 if\IN\1740 proteinuria\NN\14299637 occurs\VBZ\2623529 and\CC\1740 withdrawal\NN\7206096 if\IN\1740 needed\VBN\2604760 .\.\1740
D000809_D011507 NONE Although\IN\1740 these\DT\1740 adverse\JJ\1740 effects\NNS\13245626 occur\VBP\2623529 in\IN\13603305 some\DT\1740 patients\NNS\9898892 ,\,\1740 their\PRP$\1740 occurrence\NN\29378 could\MD\1740 be\VB\836236 minimised\VBN\831651 by\IN\1740 knowledge\NN\23100 of\IN\1740 the\DT\1740 molecular\JJ\1740 effects\NNS\13245626 of\IN\1740 sirolimus\NN\1740 on\IN\1740 the\DT\1740 kidney\NN\5333259 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 sirolimus\NN\1740 in\IN\13603305 appropriate\JJ\1740 patient\NN\9898892 populations\NNS\7942152 ,\,\1740 close\JJ\1740 monitoring\NN\879759 of\IN\1740 proteinuria\NN\14299637 and\CC\1740 renal\JJ\1740 function\NN\13783581 ,\,\1740 use\NN\407535 of\IN\1740 <e1>angiotensin-converting</e1>\JJ\1740 enzyme\NN\14723628 inhibitors\NNS\20090 or\CC\3541091 angiotensin\NN\4522421 II\CD\13741022 receptor\NN\5225602 blockers\NNS\10101634 if\IN\1740 <e2>proteinuria</e2>\NN\14299637 occurs\VBZ\2623529 and\CC\1740 withdrawal\NN\7206096 if\IN\1740 needed\VBN\2604760 .\.\1740
D000804_D011507 NONE Although\IN\1740 these\DT\1740 adverse\JJ\1740 effects\NNS\13245626 occur\VBP\2623529 in\IN\13603305 some\DT\1740 patients\NNS\9898892 ,\,\1740 their\PRP$\1740 occurrence\NN\29378 could\MD\1740 be\VB\836236 minimised\VBN\831651 by\IN\1740 knowledge\NN\23100 of\IN\1740 the\DT\1740 molecular\JJ\1740 effects\NNS\13245626 of\IN\1740 sirolimus\NN\1740 on\IN\1740 the\DT\1740 kidney\NN\5333259 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 sirolimus\NN\1740 in\IN\13603305 appropriate\JJ\1740 patient\NN\9898892 populations\NNS\7942152 ,\,\1740 close\JJ\1740 monitoring\NN\879759 of\IN\1740 <e2>proteinuria</e2>\NN\14299637 and\CC\1740 renal\JJ\1740 function\NN\13783581 ,\,\1740 use\NN\407535 of\IN\1740 angiotensin-converting\JJ\1740 enzyme\NN\14723628 inhibitors\NNS\20090 or\CC\3541091 <e1>angiotensin\NN\4522421 II</e1>\CD\13741022 receptor\NN\5225602 blockers\NNS\10101634 if\IN\1740 proteinuria\NN\14299637 occurs\VBZ\2623529 and\CC\1740 withdrawal\NN\7206096 if\IN\1740 needed\VBN\2604760 .\.\1740
D000804_D011507 NONE Although\IN\1740 these\DT\1740 adverse\JJ\1740 effects\NNS\13245626 occur\VBP\2623529 in\IN\13603305 some\DT\1740 patients\NNS\9898892 ,\,\1740 their\PRP$\1740 occurrence\NN\29378 could\MD\1740 be\VB\836236 minimised\VBN\831651 by\IN\1740 knowledge\NN\23100 of\IN\1740 the\DT\1740 molecular\JJ\1740 effects\NNS\13245626 of\IN\1740 sirolimus\NN\1740 on\IN\1740 the\DT\1740 kidney\NN\5333259 ,\,\1740 the\DT\1740 use\NN\407535 of\IN\1740 sirolimus\NN\1740 in\IN\13603305 appropriate\JJ\1740 patient\NN\9898892 populations\NNS\7942152 ,\,\1740 close\JJ\1740 monitoring\NN\879759 of\IN\1740 proteinuria\NN\14299637 and\CC\1740 renal\JJ\1740 function\NN\13783581 ,\,\1740 use\NN\407535 of\IN\1740 angiotensin-converting\JJ\1740 enzyme\NN\14723628 inhibitors\NNS\20090 or\CC\3541091 <e1>angiotensin\NN\4522421 II</e1>\CD\13741022 receptor\NN\5225602 blockers\NNS\10101634 if\IN\1740 <e2>proteinuria</e2>\NN\14299637 occurs\VBZ\2623529 and\CC\1740 withdrawal\NN\7206096 if\IN\1740 needed\VBN\2604760 .\.\1740
12464714
C093622_D008881 NONE Crossover\NN\13526110 comparison\NN\635850 of\IN\1740 efficacy\NN\5199286 and\CC\1740 preference\NN\7497473 for\IN\1740 <e1>rizatriptan</e1>\JJ\1740 10\CD\13745420 mg\NN\13717155 versus\CC\1740 ergotamine/caffeine\NN\1740 in\IN\13603305 <e2>migraine</e2>\NN\14326607 .\.\1740
C093622_D008881 NONE <e1>Rizatriptan</e1>\NNP\1740 is\VBZ\836236 a\DT\13649268 selective\JJ\1740 5-HT(1B/1D\NN\1740 )\-RRB-\1740 receptor\NN\5225602 agonist\NN\9613191 with\IN\1740 rapid\JJ\1740 oral\JJ\1740 absorption\NN\13558490 and\CC\1740 early\JJ\1740 onset\NN\7325190 of\IN\1740 action\NN\30358 in\IN\13603305 the\DT\1740 acute\JJ\1740 treatment\NN\654885 of\IN\1740 <e2>migraine</e2>\NN\14326607 .\.\1740
C093622_D008881 NONE This\DT\1740 randomized\JJ\1740 double-\NN\1740 blind\JJ\1740 crossover\NN\13526110 outpatient\JJ\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 preference\NN\7497473 for\IN\1740 1\CD\13741022 <e1>rizatriptan</e1>\JJ\1740 10\CD\13745420 mg\NN\13717155 tablet\NN\4233405 to\TO\1740 2\CD\13741022 ergotamine\NN\14712692 1\CD\13741022 mg/caffeine\NN\1740 100\CD\13745420 mg\NN\13717155 tablets\NNS\4233405 in\IN\13603305 439\CD\1740 patients\NNS\9898892 treating\VBG\2376958 a\DT\13649268 single\JJ\1740 <e2>migraine</e2>\NN\14326607 attack\NN\955060 with\IN\1740 each\DT\1740 therapy\NN\657604 .\.\1740
D004878_D008881 NONE Crossover\NN\13526110 comparison\NN\635850 of\IN\1740 efficacy\NN\5199286 and\CC\1740 preference\NN\7497473 for\IN\1740 rizatriptan\JJ\1740 10\CD\13745420 mg\NN\13717155 versus\CC\1740 <e1>ergotamine/caffeine</e1>\NN\1740 in\IN\13603305 <e2>migraine</e2>\NN\14326607 .\.\1740
D004878_D008881 NONE This\DT\1740 randomized\JJ\1740 double-\NN\1740 blind\JJ\1740 crossover\NN\13526110 outpatient\JJ\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 preference\NN\7497473 for\IN\1740 1\CD\13741022 rizatriptan\JJ\1740 10\CD\13745420 mg\NN\13717155 tablet\NN\4233405 to\TO\1740 2\CD\13741022 <e1>ergotamine</e1>\NN\14712692 1\CD\13741022 mg/caffeine\NN\1740 100\CD\13745420 mg\NN\13717155 tablets\NNS\4233405 in\IN\13603305 439\CD\1740 patients\NNS\9898892 treating\VBG\2376958 a\DT\13649268 single\JJ\1740 <e2>migraine</e2>\NN\14326607 attack\NN\955060 with\IN\1740 each\DT\1740 therapy\NN\657604 .\.\1740
D002110_D008881 NONE Crossover\NN\13526110 comparison\NN\635850 of\IN\1740 efficacy\NN\5199286 and\CC\1740 preference\NN\7497473 for\IN\1740 rizatriptan\JJ\1740 10\CD\13745420 mg\NN\13717155 versus\CC\1740 <e1>ergotamine/caffeine</e1>\NN\1740 in\IN\13603305 <e2>migraine</e2>\NN\14326607 .\.\1740
D002110_D008881 NONE This\DT\1740 randomized\JJ\1740 double-\NN\1740 blind\JJ\1740 crossover\NN\13526110 outpatient\JJ\1740 study\NN\635850 assessed\VBD\670261 the\DT\1740 preference\NN\7497473 for\IN\1740 1\CD\13741022 rizatriptan\JJ\1740 10\CD\13745420 mg\NN\13717155 tablet\NN\4233405 to\TO\1740 2\CD\13741022 ergotamine\NN\14712692 1\CD\13741022 <e1>mg/caffeine</e1>\NN\1740 100\CD\13745420 mg\NN\13717155 tablets\NNS\4233405 in\IN\13603305 439\CD\1740 patients\NNS\9898892 treating\VBG\2376958 a\DT\13649268 single\JJ\1740 <e2>migraine</e2>\NN\14326607 attack\NN\955060 with\IN\1740 each\DT\1740 therapy\NN\657604 .\.\1740
D012701_D008881 NONE Rizatriptan\NNP\1740 is\VBZ\836236 a\DT\13649268 selective\JJ\1740 <e1>5-HT(1B/1D</e1>\NN\1740 )\-RRB-\1740 receptor\NN\5225602 agonist\NN\9613191 with\IN\1740 rapid\JJ\1740 oral\JJ\1740 absorption\NN\13558490 and\CC\1740 early\JJ\1740 onset\NN\7325190 of\IN\1740 action\NN\30358 in\IN\13603305 the\DT\1740 acute\JJ\1740 treatment\NN\654885 of\IN\1740 <e2>migraine</e2>\NN\14326607 .\.\1740
C093622_D006261 NONE Faster\JJR\1740 relief\NN\7492516 of\IN\1740 <e2>headache</e2>\NN\5829480 was\VBD\836236 the\DT\1740 most\RBS\1740 important\JJ\1740 reason\NN\9178821 for\IN\1740 preference\NN\7497473 ,\,\1740 cited\VBN\730052 by\IN\1740 67.3\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 preferring\VBG\1777210 <e1>rizatriptan</e1>\JJ\1740 and\CC\1740 54.2\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 who\WP\8299493 preferred\VBD\1777210 ergotamine/caffeine\NN\1740 .\.\1740
C093622_D006261 NONE <e2>Headache</e2>\NNP\5829480 relief\NN\7492516 at\IN\14622893 2\CD\13741022 h\NN\14622893 was\VBD\836236 75.9\CD\1740 %\NN\1740 for\IN\1740 <e1>rizatriptan</e1>\NN\1740 and\CC\1740 47.3\CD\1740 %\NN\1740 for\IN\1740 ergotamine/caffeine\NN\1740 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 rizatriptan\NN\1740 being\VBG\836236 superior\JJ\1740 to\TO\1740 ergotamine/caffeine\NN\1740 within\IN\1740 30\CD\13745420 min\NN\15154774 of\IN\1740 dosing\NN\1740 .\.\1740
C093622_D006261 NONE <e2>Headache</e2>\NNP\5829480 relief\NN\7492516 at\IN\14622893 2\CD\13741022 h\NN\14622893 was\VBD\836236 75.9\CD\1740 %\NN\1740 for\IN\1740 rizatriptan\NN\1740 and\CC\1740 47.3\CD\1740 %\NN\1740 for\IN\1740 ergotamine/caffeine\NN\1740 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 <e1>rizatriptan</e1>\NN\1740 being\VBG\836236 superior\JJ\1740 to\TO\1740 ergotamine/caffeine\NN\1740 within\IN\1740 30\CD\13745420 min\NN\15154774 of\IN\1740 dosing\NN\1740 .\.\1740
D004878_D006261 NONE Faster\JJR\1740 relief\NN\7492516 of\IN\1740 <e2>headache</e2>\NN\5829480 was\VBD\836236 the\DT\1740 most\RBS\1740 important\JJ\1740 reason\NN\9178821 for\IN\1740 preference\NN\7497473 ,\,\1740 cited\VBN\730052 by\IN\1740 67.3\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 preferring\VBG\1777210 rizatriptan\JJ\1740 and\CC\1740 54.2\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 who\WP\8299493 preferred\VBD\1777210 <e1>ergotamine/caffeine</e1>\NN\1740 .\.\1740
D004878_D006261 NONE <e2>Headache</e2>\NNP\5829480 relief\NN\7492516 at\IN\14622893 2\CD\13741022 h\NN\14622893 was\VBD\836236 75.9\CD\1740 %\NN\1740 for\IN\1740 rizatriptan\NN\1740 and\CC\1740 47.3\CD\1740 %\NN\1740 for\IN\1740 <e1>ergotamine/caffeine</e1>\NN\1740 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 rizatriptan\NN\1740 being\VBG\836236 superior\JJ\1740 to\TO\1740 ergotamine/caffeine\NN\1740 within\IN\1740 30\CD\13745420 min\NN\15154774 of\IN\1740 dosing\NN\1740 .\.\1740
D004878_D006261 NONE <e2>Headache</e2>\NNP\5829480 relief\NN\7492516 at\IN\14622893 2\CD\13741022 h\NN\14622893 was\VBD\836236 75.9\CD\1740 %\NN\1740 for\IN\1740 rizatriptan\NN\1740 and\CC\1740 47.3\CD\1740 %\NN\1740 for\IN\1740 ergotamine/caffeine\NN\1740 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 rizatriptan\NN\1740 being\VBG\836236 superior\JJ\1740 to\TO\1740 <e1>ergotamine/caffeine</e1>\NN\1740 within\IN\1740 30\CD\13745420 min\NN\15154774 of\IN\1740 dosing\NN\1740 .\.\1740
D002110_D006261 NONE Faster\JJR\1740 relief\NN\7492516 of\IN\1740 <e2>headache</e2>\NN\5829480 was\VBD\836236 the\DT\1740 most\RBS\1740 important\JJ\1740 reason\NN\9178821 for\IN\1740 preference\NN\7497473 ,\,\1740 cited\VBN\730052 by\IN\1740 67.3\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 preferring\VBG\1777210 rizatriptan\JJ\1740 and\CC\1740 54.2\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 who\WP\8299493 preferred\VBD\1777210 <e1>ergotamine/caffeine</e1>\NN\1740 .\.\1740
D002110_D006261 NONE <e2>Headache</e2>\NNP\5829480 relief\NN\7492516 at\IN\14622893 2\CD\13741022 h\NN\14622893 was\VBD\836236 75.9\CD\1740 %\NN\1740 for\IN\1740 rizatriptan\NN\1740 and\CC\1740 47.3\CD\1740 %\NN\1740 for\IN\1740 <e1>ergotamine/caffeine</e1>\NN\1740 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 rizatriptan\NN\1740 being\VBG\836236 superior\JJ\1740 to\TO\1740 ergotamine/caffeine\NN\1740 within\IN\1740 30\CD\13745420 min\NN\15154774 of\IN\1740 dosing\NN\1740 .\.\1740
D002110_D006261 NONE <e2>Headache</e2>\NNP\5829480 relief\NN\7492516 at\IN\14622893 2\CD\13741022 h\NN\14622893 was\VBD\836236 75.9\CD\1740 %\NN\1740 for\IN\1740 rizatriptan\NN\1740 and\CC\1740 47.3\CD\1740 %\NN\1740 for\IN\1740 ergotamine/caffeine\NN\1740 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 with\IN\1740 rizatriptan\NN\1740 being\VBG\836236 superior\JJ\1740 to\TO\1740 <e1>ergotamine/caffeine</e1>\NN\1740 within\IN\1740 30\CD\13745420 min\NN\15154774 of\IN\1740 dosing\NN\1740 .\.\1740
C093622_D010146 NONE The\DT\1740 co-primary\JJ\1740 endpoint\NN\8566028 of\IN\1740 being\VBG\836236 <e2>pain</e2>\NN\14299637 free\JJ\1740 at\IN\14622893 2\CD\13741022 h\NN\14622893 was\VBD\836236 also\RB\1740 in\IN\13603305 favor\NN\34574 of\IN\1740 <e1>rizatriptan</e1>\NN\1740 .\.\1740
C093622_D010146 NONE Forty-nine\JJ\1740 percent\NN\13815742 of\IN\1740 patients\NNS\9898892 were\VBD\836236 <e2>pain</e2>\NN\14299637 free\JJ\1740 2\CD\13741022 h\NN\14622893 after\IN\1740 <e1>rizatriptan</e1>\NN\1740 ,\,\1740 compared\VBN\644583 with\IN\1740 24.3\CD\1740 %\NN\1740 treated\VBN\2376958 with\IN\1740 ergotamine/caffeine\NN\1740 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 rizatriptan\NN\1740 being\VBG\836236 superior\JJ\1740 within\IN\1740 1\CD\13741022 h\NN\14622893 of\IN\1740 treatment\NN\654885 .\.\1740
C093622_D010146 NONE Forty-nine\JJ\1740 percent\NN\13815742 of\IN\1740 patients\NNS\9898892 were\VBD\836236 <e2>pain</e2>\NN\14299637 free\JJ\1740 2\CD\13741022 h\NN\14622893 after\IN\1740 rizatriptan\NN\1740 ,\,\1740 compared\VBN\644583 with\IN\1740 24.3\CD\1740 %\NN\1740 treated\VBN\2376958 with\IN\1740 ergotamine/caffeine\NN\1740 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 <e1>rizatriptan</e1>\NN\1740 being\VBG\836236 superior\JJ\1740 within\IN\1740 1\CD\13741022 h\NN\14622893 of\IN\1740 treatment\NN\654885 .\.\1740
C093622_D010146 NONE Almost\RB\1740 36\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 taking\VBG\2367363 <e1>rizatriptan</e1>\NN\1740 were\VBD\836236 <e2>pain</e2>\NN\14299637 free\JJ\1740 at\IN\14622893 2\CD\13741022 h\NN\14622893 and\CC\1740 had\VBD\2108377 no\DT\7204911 recurrence\NN\7342049 or\CC\3541091 need\VBP\2604760 for\IN\1740 additional\JJ\1740 medication\NN\3247620 within\IN\1740 24\CD\13745420 h\NN\14622893 ,\,\1740 compared\VBN\644583 to\TO\1740 20\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 on\IN\1740 ergotamine/caffeine\NN\1740 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
D004878_D010146 NONE Forty-nine\JJ\1740 percent\NN\13815742 of\IN\1740 patients\NNS\9898892 were\VBD\836236 <e2>pain</e2>\NN\14299637 free\JJ\1740 2\CD\13741022 h\NN\14622893 after\IN\1740 rizatriptan\NN\1740 ,\,\1740 compared\VBN\644583 with\IN\1740 24.3\CD\1740 %\NN\1740 treated\VBN\2376958 with\IN\1740 <e1>ergotamine/caffeine</e1>\NN\1740 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 rizatriptan\NN\1740 being\VBG\836236 superior\JJ\1740 within\IN\1740 1\CD\13741022 h\NN\14622893 of\IN\1740 treatment\NN\654885 .\.\1740
D004878_D010146 NONE Almost\RB\1740 36\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 taking\VBG\2367363 rizatriptan\NN\1740 were\VBD\836236 <e2>pain</e2>\NN\14299637 free\JJ\1740 at\IN\14622893 2\CD\13741022 h\NN\14622893 and\CC\1740 had\VBD\2108377 no\DT\7204911 recurrence\NN\7342049 or\CC\3541091 need\VBP\2604760 for\IN\1740 additional\JJ\1740 medication\NN\3247620 within\IN\1740 24\CD\13745420 h\NN\14622893 ,\,\1740 compared\VBN\644583 to\TO\1740 20\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 on\IN\1740 <e1>ergotamine/caffeine</e1>\NN\1740 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
D002110_D010146 NONE Forty-nine\JJ\1740 percent\NN\13815742 of\IN\1740 patients\NNS\9898892 were\VBD\836236 <e2>pain</e2>\NN\14299637 free\JJ\1740 2\CD\13741022 h\NN\14622893 after\IN\1740 rizatriptan\NN\1740 ,\,\1740 compared\VBN\644583 with\IN\1740 24.3\CD\1740 %\NN\1740 treated\VBN\2376958 with\IN\1740 <e1>ergotamine/caffeine</e1>\NN\1740 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 rizatriptan\NN\1740 being\VBG\836236 superior\JJ\1740 within\IN\1740 1\CD\13741022 h\NN\14622893 of\IN\1740 treatment\NN\654885 .\.\1740
D002110_D010146 NONE Almost\RB\1740 36\CD\1740 %\NN\1740 of\IN\1740 patients\NNS\9898892 taking\VBG\2367363 rizatriptan\NN\1740 were\VBD\836236 <e2>pain</e2>\NN\14299637 free\JJ\1740 at\IN\14622893 2\CD\13741022 h\NN\14622893 and\CC\1740 had\VBD\2108377 no\DT\7204911 recurrence\NN\7342049 or\CC\3541091 need\VBP\2604760 for\IN\1740 additional\JJ\1740 medication\NN\3247620 within\IN\1740 24\CD\13745420 h\NN\14622893 ,\,\1740 compared\VBN\644583 to\TO\1740 20\CD\13745420 %\NN\1740 of\IN\1740 patients\NNS\9898892 on\IN\1740 <e1>ergotamine/caffeine</e1>\NN\1740 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
C093622_D009325 CID <e1>Rizatriptan</e1>\NNP\1740 was\VBD\836236 also\RB\1740 superior\JJ\1740 to\TO\1740 ergotamine/caffeine\NN\1740 in\IN\13603305 the\DT\1740 proportions\NNS\13824815 of\IN\1740 patients\NNS\9898892 with\IN\1740 no\DT\7204911 <e2>nausea</e2>\NN\14299637 ,\,\1740 vomiting\NN\116687 ,\,\1740 phonophobia\NN\14382238 or\CC\3541091 photophobia\NN\14382238 and\CC\1740 for\IN\1740 patients\NNS\9898892 with\IN\1740 normal\JJ\1740 function\NN\13783581 2\CD\13741022 h\NN\14622893 after\IN\1740 drug\NN\14778436 intake\NN\13440063 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
C093622_D009325 CID The\DT\1740 most\RBS\1740 common\JJ\1740 adverse\JJ\1740 events\NNS\23100 (\-LRB-\1740 incidence\VBP\1740 >\NN\1740 or\CC\3541091 =\JJ\1740 5\CD\13741022 %\NN\1740 in\IN\13603305 one\CD\13741022 group\NN\2137 )\-RRB-\1740 after\IN\1740 <e1>rizatriptan</e1>\JJ\1740 and\CC\1740 ergotamine/caffeine\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 were\VBD\836236 dizziness\JJ\1740 (\-LRB-\1740 6.7\CD\1740 and\CC\1740 5.3\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 <e2>nausea</e2>\NN\14299637 (\-LRB-\1740 4.2\CD\1740 and\CC\1740 8.5\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 somnolence\NN\14015731 (\-LRB-\1740 5.5\CD\1740 and\CC\1740 2.3\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C093622_D014839 NONE <e1>Rizatriptan</e1>\NNP\1740 was\VBD\836236 also\RB\1740 superior\JJ\1740 to\TO\1740 ergotamine/caffeine\NN\1740 in\IN\13603305 the\DT\1740 proportions\NNS\13824815 of\IN\1740 patients\NNS\9898892 with\IN\1740 no\DT\7204911 nausea\NN\14299637 ,\,\1740 <e2>vomiting</e2>\NN\116687 ,\,\1740 phonophobia\NN\14382238 or\CC\3541091 photophobia\NN\14382238 and\CC\1740 for\IN\1740 patients\NNS\9898892 with\IN\1740 normal\JJ\1740 function\NN\13783581 2\CD\13741022 h\NN\14622893 after\IN\1740 drug\NN\14778436 intake\NN\13440063 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
C093622_D012001 NONE <e1>Rizatriptan</e1>\NNP\1740 was\VBD\836236 also\RB\1740 superior\JJ\1740 to\TO\1740 ergotamine/caffeine\NN\1740 in\IN\13603305 the\DT\1740 proportions\NNS\13824815 of\IN\1740 patients\NNS\9898892 with\IN\1740 no\DT\7204911 nausea\NN\14299637 ,\,\1740 vomiting\NN\116687 ,\,\1740 <e2>phonophobia</e2>\NN\14382238 or\CC\3541091 photophobia\NN\14382238 and\CC\1740 for\IN\1740 patients\NNS\9898892 with\IN\1740 normal\JJ\1740 function\NN\13783581 2\CD\13741022 h\NN\14622893 after\IN\1740 drug\NN\14778436 intake\NN\13440063 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
C093622_D020795 NONE <e1>Rizatriptan</e1>\NNP\1740 was\VBD\836236 also\RB\1740 superior\JJ\1740 to\TO\1740 ergotamine/caffeine\NN\1740 in\IN\13603305 the\DT\1740 proportions\NNS\13824815 of\IN\1740 patients\NNS\9898892 with\IN\1740 no\DT\7204911 nausea\NN\14299637 ,\,\1740 vomiting\NN\116687 ,\,\1740 phonophobia\NN\14382238 or\CC\3541091 <e2>photophobia</e2>\NN\14382238 and\CC\1740 for\IN\1740 patients\NNS\9898892 with\IN\1740 normal\JJ\1740 function\NN\13783581 2\CD\13741022 h\NN\14622893 after\IN\1740 drug\NN\14778436 intake\NN\13440063 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
D004878_D009325 NONE Rizatriptan\NNP\1740 was\VBD\836236 also\RB\1740 superior\JJ\1740 to\TO\1740 <e1>ergotamine/caffeine</e1>\NN\1740 in\IN\13603305 the\DT\1740 proportions\NNS\13824815 of\IN\1740 patients\NNS\9898892 with\IN\1740 no\DT\7204911 <e2>nausea</e2>\NN\14299637 ,\,\1740 vomiting\NN\116687 ,\,\1740 phonophobia\NN\14382238 or\CC\3541091 photophobia\NN\14382238 and\CC\1740 for\IN\1740 patients\NNS\9898892 with\IN\1740 normal\JJ\1740 function\NN\13783581 2\CD\13741022 h\NN\14622893 after\IN\1740 drug\NN\14778436 intake\NN\13440063 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
D004878_D009325 NONE The\DT\1740 most\RBS\1740 common\JJ\1740 adverse\JJ\1740 events\NNS\23100 (\-LRB-\1740 incidence\VBP\1740 >\NN\1740 or\CC\3541091 =\JJ\1740 5\CD\13741022 %\NN\1740 in\IN\13603305 one\CD\13741022 group\NN\2137 )\-RRB-\1740 after\IN\1740 rizatriptan\JJ\1740 and\CC\1740 <e1>ergotamine/caffeine</e1>\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 were\VBD\836236 dizziness\JJ\1740 (\-LRB-\1740 6.7\CD\1740 and\CC\1740 5.3\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 <e2>nausea</e2>\NN\14299637 (\-LRB-\1740 4.2\CD\1740 and\CC\1740 8.5\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 somnolence\NN\14015731 (\-LRB-\1740 5.5\CD\1740 and\CC\1740 2.3\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D004878_D014839 NONE Rizatriptan\NNP\1740 was\VBD\836236 also\RB\1740 superior\JJ\1740 to\TO\1740 <e1>ergotamine/caffeine</e1>\NN\1740 in\IN\13603305 the\DT\1740 proportions\NNS\13824815 of\IN\1740 patients\NNS\9898892 with\IN\1740 no\DT\7204911 nausea\NN\14299637 ,\,\1740 <e2>vomiting</e2>\NN\116687 ,\,\1740 phonophobia\NN\14382238 or\CC\3541091 photophobia\NN\14382238 and\CC\1740 for\IN\1740 patients\NNS\9898892 with\IN\1740 normal\JJ\1740 function\NN\13783581 2\CD\13741022 h\NN\14622893 after\IN\1740 drug\NN\14778436 intake\NN\13440063 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
D004878_D012001 NONE Rizatriptan\NNP\1740 was\VBD\836236 also\RB\1740 superior\JJ\1740 to\TO\1740 <e1>ergotamine/caffeine</e1>\NN\1740 in\IN\13603305 the\DT\1740 proportions\NNS\13824815 of\IN\1740 patients\NNS\9898892 with\IN\1740 no\DT\7204911 nausea\NN\14299637 ,\,\1740 vomiting\NN\116687 ,\,\1740 <e2>phonophobia</e2>\NN\14382238 or\CC\3541091 photophobia\NN\14382238 and\CC\1740 for\IN\1740 patients\NNS\9898892 with\IN\1740 normal\JJ\1740 function\NN\13783581 2\CD\13741022 h\NN\14622893 after\IN\1740 drug\NN\14778436 intake\NN\13440063 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
D004878_D020795 NONE Rizatriptan\NNP\1740 was\VBD\836236 also\RB\1740 superior\JJ\1740 to\TO\1740 <e1>ergotamine/caffeine</e1>\NN\1740 in\IN\13603305 the\DT\1740 proportions\NNS\13824815 of\IN\1740 patients\NNS\9898892 with\IN\1740 no\DT\7204911 nausea\NN\14299637 ,\,\1740 vomiting\NN\116687 ,\,\1740 phonophobia\NN\14382238 or\CC\3541091 <e2>photophobia</e2>\NN\14382238 and\CC\1740 for\IN\1740 patients\NNS\9898892 with\IN\1740 normal\JJ\1740 function\NN\13783581 2\CD\13741022 h\NN\14622893 after\IN\1740 drug\NN\14778436 intake\NN\13440063 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
D002110_D009325 NONE Rizatriptan\NNP\1740 was\VBD\836236 also\RB\1740 superior\JJ\1740 to\TO\1740 <e1>ergotamine/caffeine</e1>\NN\1740 in\IN\13603305 the\DT\1740 proportions\NNS\13824815 of\IN\1740 patients\NNS\9898892 with\IN\1740 no\DT\7204911 <e2>nausea</e2>\NN\14299637 ,\,\1740 vomiting\NN\116687 ,\,\1740 phonophobia\NN\14382238 or\CC\3541091 photophobia\NN\14382238 and\CC\1740 for\IN\1740 patients\NNS\9898892 with\IN\1740 normal\JJ\1740 function\NN\13783581 2\CD\13741022 h\NN\14622893 after\IN\1740 drug\NN\14778436 intake\NN\13440063 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
D002110_D009325 NONE The\DT\1740 most\RBS\1740 common\JJ\1740 adverse\JJ\1740 events\NNS\23100 (\-LRB-\1740 incidence\VBP\1740 >\NN\1740 or\CC\3541091 =\JJ\1740 5\CD\13741022 %\NN\1740 in\IN\13603305 one\CD\13741022 group\NN\2137 )\-RRB-\1740 after\IN\1740 rizatriptan\JJ\1740 and\CC\1740 <e1>ergotamine/caffeine</e1>\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 were\VBD\836236 dizziness\JJ\1740 (\-LRB-\1740 6.7\CD\1740 and\CC\1740 5.3\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 <e2>nausea</e2>\NN\14299637 (\-LRB-\1740 4.2\CD\1740 and\CC\1740 8.5\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 somnolence\NN\14015731 (\-LRB-\1740 5.5\CD\1740 and\CC\1740 2.3\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D002110_D014839 NONE Rizatriptan\NNP\1740 was\VBD\836236 also\RB\1740 superior\JJ\1740 to\TO\1740 <e1>ergotamine/caffeine</e1>\NN\1740 in\IN\13603305 the\DT\1740 proportions\NNS\13824815 of\IN\1740 patients\NNS\9898892 with\IN\1740 no\DT\7204911 nausea\NN\14299637 ,\,\1740 <e2>vomiting</e2>\NN\116687 ,\,\1740 phonophobia\NN\14382238 or\CC\3541091 photophobia\NN\14382238 and\CC\1740 for\IN\1740 patients\NNS\9898892 with\IN\1740 normal\JJ\1740 function\NN\13783581 2\CD\13741022 h\NN\14622893 after\IN\1740 drug\NN\14778436 intake\NN\13440063 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
D002110_D012001 NONE Rizatriptan\NNP\1740 was\VBD\836236 also\RB\1740 superior\JJ\1740 to\TO\1740 <e1>ergotamine/caffeine</e1>\NN\1740 in\IN\13603305 the\DT\1740 proportions\NNS\13824815 of\IN\1740 patients\NNS\9898892 with\IN\1740 no\DT\7204911 nausea\NN\14299637 ,\,\1740 vomiting\NN\116687 ,\,\1740 <e2>phonophobia</e2>\NN\14382238 or\CC\3541091 photophobia\NN\14382238 and\CC\1740 for\IN\1740 patients\NNS\9898892 with\IN\1740 normal\JJ\1740 function\NN\13783581 2\CD\13741022 h\NN\14622893 after\IN\1740 drug\NN\14778436 intake\NN\13440063 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
D002110_D020795 NONE Rizatriptan\NNP\1740 was\VBD\836236 also\RB\1740 superior\JJ\1740 to\TO\1740 <e1>ergotamine/caffeine</e1>\NN\1740 in\IN\13603305 the\DT\1740 proportions\NNS\13824815 of\IN\1740 patients\NNS\9898892 with\IN\1740 no\DT\7204911 nausea\NN\14299637 ,\,\1740 vomiting\NN\116687 ,\,\1740 phonophobia\NN\14382238 or\CC\3541091 <e2>photophobia</e2>\NN\14382238 and\CC\1740 for\IN\1740 patients\NNS\9898892 with\IN\1740 normal\JJ\1740 function\NN\13783581 2\CD\13741022 h\NN\14622893 after\IN\1740 drug\NN\14778436 intake\NN\13440063 (\-LRB-\1740 p\NN\14622893 <\XX\1740 or\CC\3541091 =\JJ\1740 0.001\CD\1740 )\-RRB-\1740 .\.\1740
C093622_D004244 CID The\DT\1740 most\RBS\1740 common\JJ\1740 adverse\JJ\1740 events\NNS\23100 (\-LRB-\1740 incidence\VBP\1740 >\NN\1740 or\CC\3541091 =\JJ\1740 5\CD\13741022 %\NN\1740 in\IN\13603305 one\CD\13741022 group\NN\2137 )\-RRB-\1740 after\IN\1740 <e1>rizatriptan</e1>\JJ\1740 and\CC\1740 ergotamine/caffeine\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 were\VBD\836236 <e2>dizziness</e2>\JJ\1740 (\-LRB-\1740 6.7\CD\1740 and\CC\1740 5.3\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 nausea\NN\14299637 (\-LRB-\1740 4.2\CD\1740 and\CC\1740 8.5\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 somnolence\NN\14015731 (\-LRB-\1740 5.5\CD\1740 and\CC\1740 2.3\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
C093622_D006970 NONE The\DT\1740 most\RBS\1740 common\JJ\1740 adverse\JJ\1740 events\NNS\23100 (\-LRB-\1740 incidence\VBP\1740 >\NN\1740 or\CC\3541091 =\JJ\1740 5\CD\13741022 %\NN\1740 in\IN\13603305 one\CD\13741022 group\NN\2137 )\-RRB-\1740 after\IN\1740 <e1>rizatriptan</e1>\JJ\1740 and\CC\1740 ergotamine/caffeine\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 were\VBD\836236 dizziness\JJ\1740 (\-LRB-\1740 6.7\CD\1740 and\CC\1740 5.3\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 nausea\NN\14299637 (\-LRB-\1740 4.2\CD\1740 and\CC\1740 8.5\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 <e2>somnolence</e2>\NN\14015731 (\-LRB-\1740 5.5\CD\1740 and\CC\1740 2.3\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D004878_D004244 NONE The\DT\1740 most\RBS\1740 common\JJ\1740 adverse\JJ\1740 events\NNS\23100 (\-LRB-\1740 incidence\VBP\1740 >\NN\1740 or\CC\3541091 =\JJ\1740 5\CD\13741022 %\NN\1740 in\IN\13603305 one\CD\13741022 group\NN\2137 )\-RRB-\1740 after\IN\1740 rizatriptan\JJ\1740 and\CC\1740 <e1>ergotamine/caffeine</e1>\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 were\VBD\836236 <e2>dizziness</e2>\JJ\1740 (\-LRB-\1740 6.7\CD\1740 and\CC\1740 5.3\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 nausea\NN\14299637 (\-LRB-\1740 4.2\CD\1740 and\CC\1740 8.5\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 somnolence\NN\14015731 (\-LRB-\1740 5.5\CD\1740 and\CC\1740 2.3\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D004878_D006970 NONE The\DT\1740 most\RBS\1740 common\JJ\1740 adverse\JJ\1740 events\NNS\23100 (\-LRB-\1740 incidence\VBP\1740 >\NN\1740 or\CC\3541091 =\JJ\1740 5\CD\13741022 %\NN\1740 in\IN\13603305 one\CD\13741022 group\NN\2137 )\-RRB-\1740 after\IN\1740 rizatriptan\JJ\1740 and\CC\1740 <e1>ergotamine/caffeine</e1>\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 were\VBD\836236 dizziness\JJ\1740 (\-LRB-\1740 6.7\CD\1740 and\CC\1740 5.3\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 nausea\NN\14299637 (\-LRB-\1740 4.2\CD\1740 and\CC\1740 8.5\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 <e2>somnolence</e2>\NN\14015731 (\-LRB-\1740 5.5\CD\1740 and\CC\1740 2.3\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D002110_D004244 NONE The\DT\1740 most\RBS\1740 common\JJ\1740 adverse\JJ\1740 events\NNS\23100 (\-LRB-\1740 incidence\VBP\1740 >\NN\1740 or\CC\3541091 =\JJ\1740 5\CD\13741022 %\NN\1740 in\IN\13603305 one\CD\13741022 group\NN\2137 )\-RRB-\1740 after\IN\1740 rizatriptan\JJ\1740 and\CC\1740 <e1>ergotamine/caffeine</e1>\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 were\VBD\836236 <e2>dizziness</e2>\JJ\1740 (\-LRB-\1740 6.7\CD\1740 and\CC\1740 5.3\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 nausea\NN\14299637 (\-LRB-\1740 4.2\CD\1740 and\CC\1740 8.5\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 somnolence\NN\14015731 (\-LRB-\1740 5.5\CD\1740 and\CC\1740 2.3\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D002110_D006970 NONE The\DT\1740 most\RBS\1740 common\JJ\1740 adverse\JJ\1740 events\NNS\23100 (\-LRB-\1740 incidence\VBP\1740 >\NN\1740 or\CC\3541091 =\JJ\1740 5\CD\13741022 %\NN\1740 in\IN\13603305 one\CD\13741022 group\NN\2137 )\-RRB-\1740 after\IN\1740 rizatriptan\JJ\1740 and\CC\1740 <e1>ergotamine/caffeine</e1>\NN\1740 ,\,\1740 respectively\RB\1740 ,\,\1740 were\VBD\836236 dizziness\JJ\1740 (\-LRB-\1740 6.7\CD\1740 and\CC\1740 5.3\CD\1740 %\NN\1740 )\-RRB-\1740 ,\,\1740 nausea\NN\14299637 (\-LRB-\1740 4.2\CD\1740 and\CC\1740 8.5\CD\1740 %\NN\1740 )\-RRB-\1740 and\CC\1740 <e2>somnolence</e2>\NN\14015731 (\-LRB-\1740 5.5\CD\1740 and\CC\1740 2.3\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
18619688
D004317_D003643 NONE <e1>Adriamycin-induced</e1>\JJ\1740 autophagic\JJ\1740 cardiomyocyte\NN\1740 <e2>death</e2>\NN\7296428 plays\VBZ\1072262 a\DT\13649268 pathogenic\JJ\1740 role\NN\719494 in\IN\13603305 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 heart\NN\5919034 failure\NN\66216 .\.\1740
D004317_D003643 NONE CONCLUSION\NN\5837957 :\:\1740 Autophagic\JJ\1740 cardiomyocyte\NN\1740 <e2>death</e2>\NN\7296428 plays\VBZ\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 heart\NN\5919034 failure\NN\66216 in\IN\13603305 rats\NNS\2329401 induced\VBN\1627355 by\IN\1740 <e1>adriamycin</e1>\NN\1740 .\.\1740
D004317_D006333 CID <e1>Adriamycin-induced</e1>\JJ\1740 autophagic\JJ\1740 cardiomyocyte\NN\1740 death\NN\7296428 plays\VBZ\1072262 a\DT\13649268 pathogenic\JJ\1740 role\NN\719494 in\IN\13603305 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 .\.\1740
D004317_D006333 CID BACKGROUND\NN\4921011 :\:\1740 The\DT\1740 mechanisms\NNS\13446390 underlying\VBG\2604760 <e2>heart\NN\5919034 failure</e2>\NN\66216 induced\VBN\1627355 by\IN\1740 <e1>adriamycin</e1>\NN\1740 are\VBP\836236 very\RB\1740 complicated\JJ\1740 and\CC\1740 still\RB\1740 unclear\JJ\1740 .\.\1740
D004317_D006333 CID The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 whether\IN\1740 autophagy\NN\1740 was\VBD\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 progression\NN\8457976 of\IN\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 induced\VBN\1627355 by\IN\1740 <e1>adriamycin</e1>\NN\1740 ,\,\1740 so\IN\6868043 that\IN\1740 we\PRP\1740 can\MD\3094503 develop\VB\1753788 a\DT\13649268 novel\JJ\1740 treatment\NN\654885 strategy\NN\5902545 for\IN\1740 heart\NN\5919034 failure\NN\66216 .\.\1740
D004317_D006333 CID The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 whether\IN\1740 autophagy\NN\1740 was\VBD\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 progression\NN\8457976 of\IN\1740 heart\NN\5919034 failure\NN\66216 induced\VBN\1627355 by\IN\1740 <e1>adriamycin</e1>\NN\1740 ,\,\1740 so\IN\6868043 that\IN\1740 we\PRP\1740 can\MD\3094503 develop\VB\1753788 a\DT\13649268 novel\JJ\1740 treatment\NN\654885 strategy\NN\5902545 for\IN\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 .\.\1740
D004317_D006333 CID METHODS\NNS\5616786 :\:\1740 3-methyladenine\NN\1740 (\-LRB-\1740 3MA\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 specific\JJ\1740 inhibitor\NN\20090 on\IN\1740 autophagy\NN\1740 was\VBD\836236 used\VBN\1156834 in\IN\13603305 a\DT\13649268 <e2>heart\NN\5919034 failure</e2>\NN\66216 model\NN\5888929 of\IN\1740 rats\NNS\2329401 induced\VBN\1627355 by\IN\1740 <e1>adriamycin</e1>\NN\1740 .\.\1740
D004317_D006333 CID CONCLUSION\NN\5837957 :\:\1740 Autophagic\JJ\1740 cardiomyocyte\NN\1740 death\NN\7296428 plays\VBZ\1072262 an\DT\6697703 important\JJ\1740 role\NN\719494 in\IN\13603305 the\DT\1740 pathogenesis\NN\13533470 of\IN\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 in\IN\13603305 rats\NNS\2329401 induced\VBN\1627355 by\IN\1740 <e1>adriamycin</e1>\NN\1740 .\.\1740
D004317_D006333 CID Mitochondrial\JJ\1740 injury\NN\14052046 may\MD\15209706 be\VB\836236 involved\VBN\2676054 in\IN\13603305 the\DT\1740 progression\NN\8457976 of\IN\1740 <e2>heart\NN\5919034 failure</e2>\NN\66216 caused\VBN\1617192 by\IN\1740 <e1>adriamycin</e1>\NN\1740 via\IN\1740 the\DT\1740 autophagy\NN\1740 pathway\NN\5483677 .\.\1740
C025946_D006333 NONE METHODS\NNS\5616786 :\:\1740 <e1>3-methyladenine</e1>\NN\1740 (\-LRB-\1740 3MA\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 specific\JJ\1740 inhibitor\NN\20090 on\IN\1740 autophagy\NN\1740 was\VBD\836236 used\VBN\1156834 in\IN\13603305 a\DT\13649268 <e2>heart\NN\5919034 failure</e2>\NN\66216 model\NN\5888929 of\IN\1740 rats\NNS\2329401 induced\VBN\1627355 by\IN\1740 adriamycin\NN\1740 .\.\1740
C025946_D006333 NONE METHODS\NNS\5616786 :\:\1740 3-methyladenine\NN\1740 (\-LRB-\1740 <e1>3MA</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 a\DT\13649268 specific\JJ\1740 inhibitor\NN\20090 on\IN\1740 autophagy\NN\1740 was\VBD\836236 used\VBN\1156834 in\IN\13603305 a\DT\13649268 <e2>heart\NN\5919034 failure</e2>\NN\66216 model\NN\5888929 of\IN\1740 rats\NNS\2329401 induced\VBN\1627355 by\IN\1740 adriamycin\NN\1740 .\.\1740
11250767
D011441_D014657 NONE <e1>Propylthiouracil-induced</e1>\JJ\1740 perinuclear-staining\JJ\1740 antineutrophil\NN\1740 cytoplasmic\JJ\1740 autoantibody-positive\JJ\1740 <e2>vasculitis</e2>\NN\14336539 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 pericarditis\NN\14338942 .\.\1740
D011441_D014657 NONE OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 describe\VB\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 <e1>propylthiouracil-induced</e1>\JJ\1740 <e2>vasculitis</e2>\NN\14336539 manifesting\NN\1740 with\IN\1740 pericarditis\NN\14338942 .\.\1740
D011441_D014657 NONE A\DT\13649268 literature\NN\6362953 review\NN\5733583 revealed\VBD\2137132 no\DT\7204911 prior\JJ\1740 reports\NNS\6470073 of\IN\1740 pericarditis\NN\14338942 in\IN\13603305 anti-MPO\NN\1740 pANCA-positive\NN\1740 <e2>vasculitis</e2>\NN\14336539 associated\VBN\628491 with\IN\1740 <e1>propylthio-\JJ\1740 uracil</e1>\NN\14964590 therapy\NN\657604 .\.\1740
D011441_D014657 NONE CONCLUSION\NN\5837957 :\:\1740 Pericarditis\NNP\14338942 may\MD\15209706 be\VB\836236 the\DT\1740 initial\JJ\1740 manifestation\NN\7321772 of\IN\1740 drug-induced\JJ\1740 <e2>vasculitis</e2>\NN\14336539 attributable\JJ\1740 to\TO\1740 <e1>propylthio-\JJ\1740 uracil</e1>\NN\14964590 therapy\NN\657604 .\.\1740
D011441_D010493 CID <e1>Propylthiouracil-induced</e1>\JJ\1740 perinuclear-staining\JJ\1740 antineutrophil\NN\1740 cytoplasmic\JJ\1740 autoantibody-positive\JJ\1740 vasculitis\NN\14336539 in\IN\13603305 conjunction\NN\5048123 with\IN\1740 <e2>pericarditis</e2>\NN\14338942 .\.\1740
D011441_D010493 CID OBJECTIVE\NN\5980875 :\:\1740 To\TO\1740 describe\VB\1001294 a\DT\13649268 case\NN\7283608 of\IN\1740 <e1>propylthiouracil-induced</e1>\JJ\1740 vasculitis\NN\14336539 manifesting\NN\1740 with\IN\1740 <e2>pericarditis</e2>\NN\14338942 .\.\1740
D011441_D010493 CID METHODS\NNS\5616786 :\:\1740 We\PRP\1740 present\VBP\2137132 the\DT\1740 first\JJ\1740 case\NN\7283608 report\NN\6470073 of\IN\1740 a\DT\13649268 woman\NN\9605289 with\IN\1740 hyperthyroidism\NN\14059928 treated\VBN\2376958 with\IN\1740 <e1>propylthiouracil</e1>\NN\14727670 in\IN\13603305 whom\WP\1740 a\DT\13649268 syndrome\NN\5870365 of\IN\1740 <e2>pericarditis</e2>\NN\14338942 ,\,\1740 fever\NN\14299637 ,\,\1740 and\CC\1740 glomerulonephritis\NN\14113798 developed\VBD\1753788 .\.\1740
D011441_D010493 CID A\DT\13649268 literature\NN\6362953 review\NN\5733583 revealed\VBD\2137132 no\DT\7204911 prior\JJ\1740 reports\NNS\6470073 of\IN\1740 <e2>pericarditis</e2>\NN\14338942 in\IN\13603305 anti-MPO\NN\1740 pANCA-positive\NN\1740 vasculitis\NN\14336539 associated\VBN\628491 with\IN\1740 <e1>propylthio-\JJ\1740 uracil</e1>\NN\14964590 therapy\NN\657604 .\.\1740
D011441_D010493 CID CONCLUSION\NN\5837957 :\:\1740 <e2>Pericarditis</e2>\NNP\14338942 may\MD\15209706 be\VB\836236 the\DT\1740 initial\JJ\1740 manifestation\NN\7321772 of\IN\1740 drug-induced\JJ\1740 vasculitis\NN\14336539 attributable\JJ\1740 to\TO\1740 <e1>propylthio-\JJ\1740 uracil</e1>\NN\14964590 therapy\NN\657604 .\.\1740
D011441_D006980 NONE METHODS\NNS\5616786 :\:\1740 We\PRP\1740 present\VBP\2137132 the\DT\1740 first\JJ\1740 case\NN\7283608 report\NN\6470073 of\IN\1740 a\DT\13649268 woman\NN\9605289 with\IN\1740 <e2>hyperthyroidism</e2>\NN\14059928 treated\VBN\2376958 with\IN\1740 <e1>propylthiouracil</e1>\NN\14727670 in\IN\13603305 whom\WP\1740 a\DT\13649268 syndrome\NN\5870365 of\IN\1740 pericarditis\NN\14338942 ,\,\1740 fever\NN\14299637 ,\,\1740 and\CC\1740 glomerulonephritis\NN\14113798 developed\VBD\1753788 .\.\1740
D011441_D005334 CID METHODS\NNS\5616786 :\:\1740 We\PRP\1740 present\VBP\2137132 the\DT\1740 first\JJ\1740 case\NN\7283608 report\NN\6470073 of\IN\1740 a\DT\13649268 woman\NN\9605289 with\IN\1740 hyperthyroidism\NN\14059928 treated\VBN\2376958 with\IN\1740 <e1>propylthiouracil</e1>\NN\14727670 in\IN\13603305 whom\WP\1740 a\DT\13649268 syndrome\NN\5870365 of\IN\1740 pericarditis\NN\14338942 ,\,\1740 <e2>fever</e2>\NN\14299637 ,\,\1740 and\CC\1740 glomerulonephritis\NN\14113798 developed\VBD\1753788 .\.\1740
D011441_D005921 CID METHODS\NNS\5616786 :\:\1740 We\PRP\1740 present\VBP\2137132 the\DT\1740 first\JJ\1740 case\NN\7283608 report\NN\6470073 of\IN\1740 a\DT\13649268 woman\NN\9605289 with\IN\1740 hyperthyroidism\NN\14059928 treated\VBN\2376958 with\IN\1740 <e1>propylthiouracil</e1>\NN\14727670 in\IN\13603305 whom\WP\1740 a\DT\13649268 syndrome\NN\5870365 of\IN\1740 pericarditis\NN\14338942 ,\,\1740 fever\NN\14299637 ,\,\1740 and\CC\1740 <e2>glomerulonephritis</e2>\NN\14113798 developed\VBD\1753788 .\.\1740
11706060
D019344_D009202 NONE Combined\JJ\1740 antiretroviral\JJ\1740 therapy\NN\657604 causes\VBZ\1617192 <e2>cardiomyopathy</e2>\JJ\1740 and\CC\1740 elevates\VBZ\2391803 plasma\NN\5398023 <e1>lactate</e1>\NN\14850483 in\IN\13603305 transgenic\JJ\1740 AIDS\NN\13974317 mice\NNS\2329401 .\.\1740
D019344_D009202 NONE Highly\RB\1740 active\JJ\1740 antiretroviral\JJ\1740 therapy\NN\657604 (\-LRB-\1740 HAART\NN\3740161 )\-RRB-\1740 is\VBZ\836236 implicated\VBN\2677097 in\IN\13603305 <e2>cardiomyopathy</e2>\JJ\1740 (\-LRB-\1740 CM\NN\13649268 )\-RRB-\1740 and\CC\1740 in\IN\13603305 elevated\JJ\1740 plasma\NN\5398023 <e1>lactate</e1>\NN\14850483 (\-LRB-\1740 LA\NN\14625458 )\-RRB-\1740 in\IN\13603305 AIDS\NN\13974317 through\IN\1740 mechanisms\NNS\13446390 of\IN\1740 mitochondrial\JJ\1740 dysfunction\NN\14204950 .\.\1740
D019344_D009202 NONE Highly\RB\1740 active\JJ\1740 antiretroviral\JJ\1740 therapy\NN\657604 (\-LRB-\1740 HAART\NN\3740161 )\-RRB-\1740 is\VBZ\836236 implicated\VBN\2677097 in\IN\13603305 cardiomyopathy\JJ\1740 (\-LRB-\1740 <e2>CM</e2>\NN\13649268 )\-RRB-\1740 and\CC\1740 in\IN\13603305 elevated\JJ\1740 plasma\NN\5398023 <e1>lactate</e1>\NN\14850483 (\-LRB-\1740 LA\NN\14625458 )\-RRB-\1740 in\IN\13603305 AIDS\NN\13974317 through\IN\1740 mechanisms\NNS\13446390 of\IN\1740 mitochondrial\JJ\1740 dysfunction\NN\14204950 .\.\1740
D019344_D009202 NONE Highly\RB\1740 active\JJ\1740 antiretroviral\JJ\1740 therapy\NN\657604 (\-LRB-\1740 HAART\NN\3740161 )\-RRB-\1740 is\VBZ\836236 implicated\VBN\2677097 in\IN\13603305 <e2>cardiomyopathy</e2>\JJ\1740 (\-LRB-\1740 CM\NN\13649268 )\-RRB-\1740 and\CC\1740 in\IN\13603305 elevated\JJ\1740 plasma\NN\5398023 lactate\NN\14850483 (\-LRB-\1740 <e1>LA</e1>\NN\14625458 )\-RRB-\1740 in\IN\13603305 AIDS\NN\13974317 through\IN\1740 mechanisms\NNS\13446390 of\IN\1740 mitochondrial\JJ\1740 dysfunction\NN\14204950 .\.\1740
D019344_D009202 NONE Highly\RB\1740 active\JJ\1740 antiretroviral\JJ\1740 therapy\NN\657604 (\-LRB-\1740 HAART\NN\3740161 )\-RRB-\1740 is\VBZ\836236 implicated\VBN\2677097 in\IN\13603305 cardiomyopathy\JJ\1740 (\-LRB-\1740 <e2>CM</e2>\NN\13649268 )\-RRB-\1740 and\CC\1740 in\IN\13603305 elevated\JJ\1740 plasma\NN\5398023 lactate\NN\14850483 (\-LRB-\1740 <e1>LA</e1>\NN\14625458 )\-RRB-\1740 in\IN\13603305 AIDS\NN\13974317 through\IN\1740 mechanisms\NNS\13446390 of\IN\1740 mitochondrial\JJ\1740 dysfunction\NN\14204950 .\.\1740
D019344_D009202 NONE At\IN\14622893 termination\NN\15266911 of\IN\1740 the\DT\1740 experiments\NNS\641820 ,\,\1740 mice\NNS\2329401 underwent\VBD\109660 echocardiography\NN\177127 ,\,\1740 quantitation\NN\1740 of\IN\1740 abundance\NN\5108740 of\IN\1740 molecular\JJ\1740 markers\NNS\21939 of\IN\1740 <e2>CM</e2>\NN\13649268 (\-LRB-\1740 ventricular\JJ\1740 mRNA\NN\14832193 encoding\VBG\115157 atrial\JJ\1740 natriuretic\JJ\1740 factor\NN\7326557 [\-LRB-\1740 ANF\NN\1740 ]\-RRB-\1740 and\CC\1740 sarcoplasmic\JJ\1740 calcium\NN\14625458 ATPase\NN\1740 [\-LRB-\1740 SERCA2\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 determination\NN\43195 of\IN\1740 plasma\NN\5398023 <e1>LA</e1>\NNP\14625458 .\.\1740
D019344_D009202 NONE Results\NNS\34213 show\VBP\2137132 that\IN\1740 cumulative\JJ\1740 HAART\NN\3740161 caused\VBD\1617192 mitochondrial\JJ\1740 <e2>CM</e2>\NN\13649268 with\IN\1740 elevated\JJ\1740 <e1>LA</e1>\NN\14625458 in\IN\13603305 AIDS\NN\13974317 transgenic\JJ\1740 mice\NNS\2329401 .\.\1740
D019344_D000163 NONE Combined\JJ\1740 antiretroviral\JJ\1740 therapy\NN\657604 causes\VBZ\1617192 cardiomyopathy\JJ\1740 and\CC\1740 elevates\VBZ\2391803 plasma\NN\5398023 <e1>lactate</e1>\NN\14850483 in\IN\13603305 transgenic\JJ\1740 <e2>AIDS</e2>\NN\13974317 mice\NNS\2329401 .\.\1740
D019344_D000163 NONE Highly\RB\1740 active\JJ\1740 antiretroviral\JJ\1740 therapy\NN\657604 (\-LRB-\1740 HAART\NN\3740161 )\-RRB-\1740 is\VBZ\836236 implicated\VBN\2677097 in\IN\13603305 cardiomyopathy\JJ\1740 (\-LRB-\1740 CM\NN\13649268 )\-RRB-\1740 and\CC\1740 in\IN\13603305 elevated\JJ\1740 plasma\NN\5398023 <e1>lactate</e1>\NN\14850483 (\-LRB-\1740 LA\NN\14625458 )\-RRB-\1740 in\IN\13603305 <e2>AIDS</e2>\NN\13974317 through\IN\1740 mechanisms\NNS\13446390 of\IN\1740 mitochondrial\JJ\1740 dysfunction\NN\14204950 .\.\1740
D019344_D000163 NONE Highly\RB\1740 active\JJ\1740 antiretroviral\JJ\1740 therapy\NN\657604 (\-LRB-\1740 HAART\NN\3740161 )\-RRB-\1740 is\VBZ\836236 implicated\VBN\2677097 in\IN\13603305 cardiomyopathy\JJ\1740 (\-LRB-\1740 CM\NN\13649268 )\-RRB-\1740 and\CC\1740 in\IN\13603305 elevated\JJ\1740 plasma\NN\5398023 lactate\NN\14850483 (\-LRB-\1740 <e1>LA</e1>\NN\14625458 )\-RRB-\1740 in\IN\13603305 <e2>AIDS</e2>\NN\13974317 through\IN\1740 mechanisms\NNS\13446390 of\IN\1740 mitochondrial\JJ\1740 dysfunction\NN\14204950 .\.\1740
D019344_D000163 NONE Results\NNS\34213 show\VBP\2137132 that\IN\1740 cumulative\JJ\1740 HAART\NN\3740161 caused\VBD\1617192 mitochondrial\JJ\1740 CM\NN\13649268 with\IN\1740 elevated\JJ\1740 <e1>LA</e1>\NN\14625458 in\IN\13603305 <e2>AIDS</e2>\NN\13974317 transgenic\JJ\1740 mice\NNS\2329401 .\.\1740
D019344_D028361 NONE Highly\RB\1740 active\JJ\1740 antiretroviral\JJ\1740 therapy\NN\657604 (\-LRB-\1740 HAART\NN\3740161 )\-RRB-\1740 is\VBZ\836236 implicated\VBN\2677097 in\IN\13603305 cardiomyopathy\JJ\1740 (\-LRB-\1740 CM\NN\13649268 )\-RRB-\1740 and\CC\1740 in\IN\13603305 elevated\JJ\1740 plasma\NN\5398023 <e1>lactate</e1>\NN\14850483 (\-LRB-\1740 LA\NN\14625458 )\-RRB-\1740 in\IN\13603305 AIDS\NN\13974317 through\IN\1740 mechanisms\NNS\13446390 of\IN\1740 <e2>mitochondrial\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D019344_D028361 NONE Highly\RB\1740 active\JJ\1740 antiretroviral\JJ\1740 therapy\NN\657604 (\-LRB-\1740 HAART\NN\3740161 )\-RRB-\1740 is\VBZ\836236 implicated\VBN\2677097 in\IN\13603305 cardiomyopathy\JJ\1740 (\-LRB-\1740 CM\NN\13649268 )\-RRB-\1740 and\CC\1740 in\IN\13603305 elevated\JJ\1740 plasma\NN\5398023 lactate\NN\14850483 (\-LRB-\1740 <e1>LA</e1>\NN\14625458 )\-RRB-\1740 in\IN\13603305 AIDS\NN\13974317 through\IN\1740 mechanisms\NNS\13446390 of\IN\1740 <e2>mitochondrial\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D015215_D000163 NONE To\TO\1740 determine\VB\1645601 mitochondrial\JJ\1740 events\NNS\23100 from\IN\1740 HAART\NN\3740161 in\FW\13603305 vivo\FW\1740 ,\,\1740 8-week-old\JJ\1740 hemizygous\JJ\1740 transgenic\JJ\1740 <e2>AIDS</e2>\NN\13974317 mice\NNS\2329401 (\-LRB-\1740 NL4\NN\1740 -\HYPH\1740 3Delta\NN\1740 gag/pol\NN\1740 ;\:\1740 TG\NN\1740 )\-RRB-\1740 and\CC\1740 wild-type\JJ\1740 FVB/n\NN\1740 littermates\NNS\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 the\DT\1740 HAART\NN\3740161 combination\NN\7951464 of\IN\1740 <e1>zidovudine</e1>\NN\3834836 ,\,\1740 lamivudine\NN\3834836 ,\,\1740 and\CC\1740 indinavir\NN\4013993 or\CC\3541091 vehicle\NN\3100490 control\NN\5190804 for\IN\1740 10\CD\13745420 days\NNS\15140892 or\CC\3541091 35\CD\1740 days\NNS\15140892 .\.\1740
D019259_D000163 NONE To\TO\1740 determine\VB\1645601 mitochondrial\JJ\1740 events\NNS\23100 from\IN\1740 HAART\NN\3740161 in\FW\13603305 vivo\FW\1740 ,\,\1740 8-week-old\JJ\1740 hemizygous\JJ\1740 transgenic\JJ\1740 <e2>AIDS</e2>\NN\13974317 mice\NNS\2329401 (\-LRB-\1740 NL4\NN\1740 -\HYPH\1740 3Delta\NN\1740 gag/pol\NN\1740 ;\:\1740 TG\NN\1740 )\-RRB-\1740 and\CC\1740 wild-type\JJ\1740 FVB/n\NN\1740 littermates\NNS\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 the\DT\1740 HAART\NN\3740161 combination\NN\7951464 of\IN\1740 zidovudine\NN\3834836 ,\,\1740 <e1>lamivudine</e1>\NN\3834836 ,\,\1740 and\CC\1740 indinavir\NN\4013993 or\CC\3541091 vehicle\NN\3100490 control\NN\5190804 for\IN\1740 10\CD\13745420 days\NNS\15140892 or\CC\3541091 35\CD\1740 days\NNS\15140892 .\.\1740
D019469_D000163 NONE To\TO\1740 determine\VB\1645601 mitochondrial\JJ\1740 events\NNS\23100 from\IN\1740 HAART\NN\3740161 in\FW\13603305 vivo\FW\1740 ,\,\1740 8-week-old\JJ\1740 hemizygous\JJ\1740 transgenic\JJ\1740 <e2>AIDS</e2>\NN\13974317 mice\NNS\2329401 (\-LRB-\1740 NL4\NN\1740 -\HYPH\1740 3Delta\NN\1740 gag/pol\NN\1740 ;\:\1740 TG\NN\1740 )\-RRB-\1740 and\CC\1740 wild-type\JJ\1740 FVB/n\NN\1740 littermates\NNS\1740 were\VBD\836236 treated\VBN\2376958 with\IN\1740 the\DT\1740 HAART\NN\3740161 combination\NN\7951464 of\IN\1740 zidovudine\NN\3834836 ,\,\1740 lamivudine\NN\3834836 ,\,\1740 and\CC\1740 <e1>indinavir</e1>\NN\4013993 or\CC\3541091 vehicle\NN\3100490 control\NN\5190804 for\IN\1740 10\CD\13745420 days\NNS\15140892 or\CC\3541091 35\CD\1740 days\NNS\15140892 .\.\1740
D002118_D009202 NONE At\IN\14622893 termination\NN\15266911 of\IN\1740 the\DT\1740 experiments\NNS\641820 ,\,\1740 mice\NNS\2329401 underwent\VBD\109660 echocardiography\NN\177127 ,\,\1740 quantitation\NN\1740 of\IN\1740 abundance\NN\5108740 of\IN\1740 molecular\JJ\1740 markers\NNS\21939 of\IN\1740 <e2>CM</e2>\NN\13649268 (\-LRB-\1740 ventricular\JJ\1740 mRNA\NN\14832193 encoding\VBG\115157 atrial\JJ\1740 natriuretic\JJ\1740 factor\NN\7326557 [\-LRB-\1740 ANF\NN\1740 ]\-RRB-\1740 and\CC\1740 sarcoplasmic\JJ\1740 <e1>calcium</e1>\NN\14625458 ATPase\NN\1740 [\-LRB-\1740 SERCA2\NN\1740 ]\-RRB-\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 determination\NN\43195 of\IN\1740 plasma\NN\5398023 LA\NNP\14625458 .\.\1740
9100294
D002118_D018376 NONE <e2>Cardiovascular\JJ\1740 alterations</e2>\NNS\7283608 in\IN\13603305 rat\NN\2329401 fetuses\NNS\1471682 exposed\VBN\2110927 to\TO\1740 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 .\.\1740
D002118_D018376 NONE Preclinical\JJ\1740 toxicologic\JJ\1740 investigation\NN\5797597 suggested\VBD\1010118 that\IN\1740 a\DT\13649268 new\JJ\1740 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 blocker\NN\10101634 ,\,\1740 Ro\NN\6894544 40\CD\13745420 -\SYM\1740 5967\CD\1740 ,\,\1740 induced\VBN\1627355 <e2>cardiovascular\JJ\1740 alterations</e2>\NNS\7283608 in\IN\13603305 rat\NN\2329401 fetuses\NNS\1471682 exposed\VBN\2110927 to\TO\1740 this\DT\1740 agent\NN\7347 during\IN\1740 organogenesis\NN\1740 .\.\1740
D002118_D018376 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 investigate\VB\644583 the\DT\1740 hypothesis\NN\7162194 that\IN\1740 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 in\IN\13603305 general\JJ\1740 induce\VBP\1627355 <e2>cardiovascular\JJ\1740 malformations</e2>\NNS\14213199 indicating\VBG\952524 a\DT\13649268 pharmacologic\JJ\1740 class\NN\7951464 effect\NN\34213 .\.\1740
D002118_D018376 NONE Pregnant\JJ\1740 rats\NNS\2329401 were\VBD\836236 administered\VBN\2436349 one\CD\13741022 of\IN\1740 these\DT\1740 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 during\IN\1740 the\DT\1740 period\NN\13575869 of\IN\1740 cardiac\JJ\1740 morphogenesis\NN\13489037 and\CC\1740 the\DT\1740 offspring\NN\10235549 examined\VBN\789138 on\IN\1740 day\NN\15154774 20\CD\13745420 of\IN\1740 gestation\NN\15116532 for\IN\1740 <e2>cardiovascular\JJ\1740 malformations</e2>\NNS\14213199 .\.\1740
D002118_D018376 NONE A\DT\13649268 low\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>cardiovascular\JJ\1740 malformations</e2>\NNS\14213199 was\VBD\836236 observed\VBN\2163746 after\IN\1740 exposure\NN\5042871 to\TO\1740 each\DT\1740 of\IN\1740 the\DT\1740 four\CD\13741022 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 ,\,\1740 but\CC\1740 this\DT\1740 incidence\NN\13821570 was\VBD\836236 statistically\RB\1740 significant\JJ\1740 only\RB\1740 for\IN\1740 verapamil\NN\2938514 and\CC\1740 nifedipine\NN\2938514 .\.\1740
D020748_D018376 CID Preclinical\JJ\1740 toxicologic\JJ\1740 investigation\NN\5797597 suggested\VBD\1010118 that\IN\1740 a\DT\13649268 new\JJ\1740 calcium\NN\14625458 channel\NN\6251781 blocker\NN\10101634 ,\,\1740 <e1>Ro\NN\6894544 40\CD\13745420 -\SYM\1740 5967</e1>\CD\1740 ,\,\1740 induced\VBN\1627355 <e2>cardiovascular\JJ\1740 alterations</e2>\NNS\7283608 in\IN\13603305 rat\NN\2329401 fetuses\NNS\1471682 exposed\VBN\2110927 to\TO\1740 this\DT\1740 agent\NN\7347 during\IN\1740 organogenesis\NN\1740 .\.\1740
D014700_D018376 CID A\DT\13649268 low\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>cardiovascular\JJ\1740 malformations</e2>\NNS\14213199 was\VBD\836236 observed\VBN\2163746 after\IN\1740 exposure\NN\5042871 to\TO\1740 each\DT\1740 of\IN\1740 the\DT\1740 four\CD\13741022 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 ,\,\1740 but\CC\1740 this\DT\1740 incidence\NN\13821570 was\VBD\836236 statistically\RB\1740 significant\JJ\1740 only\RB\1740 for\IN\1740 <e1>verapamil</e1>\NN\2938514 and\CC\1740 nifedipine\NN\2938514 .\.\1740
D009543_D018376 CID A\DT\13649268 low\JJ\1740 incidence\NN\13821570 of\IN\1740 <e2>cardiovascular\JJ\1740 malformations</e2>\NNS\14213199 was\VBD\836236 observed\VBN\2163746 after\IN\1740 exposure\NN\5042871 to\TO\1740 each\DT\1740 of\IN\1740 the\DT\1740 four\CD\13741022 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 ,\,\1740 but\CC\1740 this\DT\1740 incidence\NN\13821570 was\VBD\836236 statistically\RB\1740 significant\JJ\1740 only\RB\1740 for\IN\1740 verapamil\NN\2938514 and\CC\1740 <e1>nifedipine</e1>\NN\2938514 .\.\1740
16867021
D006632_D002375 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 study\VB\630380 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>histamine</e1>\NN\14739004 H(3)-receptor\NN\1740 ligands\NNS\20090 on\IN\1740 neuroleptic-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 apomorphine-induced\JJ\1740 climbing\NN\7445480 behavior\NN\407535 and\CC\1740 amphetamine-induced\JJ\1740 locomotor\NN\1740 activities\NNS\30358 in\IN\13603305 mice\NNS\2329401 .\.\1740
D001058_D002375 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 study\VB\630380 the\DT\1740 effect\NN\34213 of\IN\1740 histamine\NN\14739004 H(3)-receptor\NN\1740 ligands\NNS\20090 on\IN\1740 neuroleptic-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 <e1>apomorphine-induced</e1>\JJ\1740 climbing\NN\7445480 behavior\NN\407535 and\CC\1740 amphetamine-induced\JJ\1740 locomotor\NN\1740 activities\NNS\30358 in\IN\13603305 mice\NNS\2329401 .\.\1740
D001058_D002375 NONE <e2>Catalepsy</e2>\NNP\14023236 was\VBD\836236 induced\VBN\1627355 by\IN\1740 haloperidol\NN\3713736 (\-LRB-\1740 2\CD\13741022 mg/kg\NN\1740 p.o.\NN\10360747 )\-RRB-\1740 ,\,\1740 while\IN\15122231 <e1>apomorphine</e1>\NN\3786417 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 s.c.\NN\1740 )\-RRB-\1740 and\CC\1740 amphetamine\NN\3248958 (\-LRB-\1740 2\CD\13741022 mg/kg\NN\1740 s.c.\NN\1740 )\-RRB-\1740 were\VBD\836236 used\VBN\1156834 for\IN\1740 studying\VBG\630380 climbing\NN\7445480 behavior\NN\407535 and\CC\1740 locomotor\NN\1740 activities\NNS\30358 ,\,\1740 respectively\RB\1740 .\.\1740
D001058_D002375 NONE THP\NN\1740 exhibited\VBD\2632167 an\DT\6697703 antipsychotic-like\JJ\1740 profile\NN\6999802 by\IN\1740 potentiating\VBG\229605 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 reducing\VBG\441445 amphetamine-induced\JJ\1740 hyperactivity\NN\14052403 and\CC\1740 reducing\VBG\441445 <e1>apomorphine-induced</e1>\JJ\1740 climbing\NN\7445480 in\IN\13603305 mice\NNS\2329401 .\.\1740
D000661_D002375 NONE The\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 designed\VBN\1631534 to\TO\1740 study\VB\630380 the\DT\1740 effect\NN\34213 of\IN\1740 histamine\NN\14739004 H(3)-receptor\NN\1740 ligands\NNS\20090 on\IN\1740 neuroleptic-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 apomorphine-induced\JJ\1740 climbing\NN\7445480 behavior\NN\407535 and\CC\1740 <e1>amphetamine-induced</e1>\JJ\1740 locomotor\NN\1740 activities\NNS\30358 in\IN\13603305 mice\NNS\2329401 .\.\1740
D000661_D002375 NONE <e2>Catalepsy</e2>\NNP\14023236 was\VBD\836236 induced\VBN\1627355 by\IN\1740 haloperidol\NN\3713736 (\-LRB-\1740 2\CD\13741022 mg/kg\NN\1740 p.o.\NN\10360747 )\-RRB-\1740 ,\,\1740 while\IN\15122231 apomorphine\NN\3786417 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 s.c.\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>amphetamine</e1>\NN\3248958 (\-LRB-\1740 2\CD\13741022 mg/kg\NN\1740 s.c.\NN\1740 )\-RRB-\1740 were\VBD\836236 used\VBN\1156834 for\IN\1740 studying\VBG\630380 climbing\NN\7445480 behavior\NN\407535 and\CC\1740 locomotor\NN\1740 activities\NNS\30358 ,\,\1740 respectively\RB\1740 .\.\1740
D000661_D002375 NONE THP\NN\1740 exhibited\VBD\2632167 an\DT\6697703 antipsychotic-like\JJ\1740 profile\NN\6999802 by\IN\1740 potentiating\VBG\229605 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 reducing\VBG\441445 <e1>amphetamine-induced</e1>\JJ\1740 hyperactivity\NN\14052403 and\CC\1740 reducing\VBG\441445 apomorphine-induced\JJ\1740 climbing\NN\7445480 in\IN\13603305 mice\NNS\2329401 .\.\1740
D006220_D002375 CID <e2>Catalepsy</e2>\NNP\14023236 was\VBD\836236 induced\VBN\1627355 by\IN\1740 <e1>haloperidol</e1>\NN\3713736 (\-LRB-\1740 2\CD\13741022 mg/kg\NN\1740 p.o.\NN\10360747 )\-RRB-\1740 ,\,\1740 while\IN\15122231 apomorphine\NN\3786417 (\-LRB-\1740 1.5\CD\1740 mg/kg\NN\1740 s.c.\NN\1740 )\-RRB-\1740 and\CC\1740 amphetamine\NN\3248958 (\-LRB-\1740 2\CD\13741022 mg/kg\NN\1740 s.c.\NN\1740 )\-RRB-\1740 were\VBD\836236 used\VBN\1156834 for\IN\1740 studying\VBG\630380 climbing\NN\7445480 behavior\NN\407535 and\CC\1740 locomotor\NN\1740 activities\NNS\30358 ,\,\1740 respectively\RB\1740 .\.\1740
D006220_D002375 CID Administration\NN\1133281 of\IN\1740 THP\NN\1740 (\-LRB-\1740 3.75\CD\1740 ,\,\1740 7.5\CD\1740 and\CC\1740 15\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 1\CD\13741022 h\NN\14622893 prior\RB\1740 to\TO\1740 <e1>haloperidol</e1>\NN\3713736 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 dose-dependent\JJ\1740 increase\NN\13576355 in\IN\13603305 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 times\NNS\15113229 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
D006220_D002375 CID THP\NN\1740 exhibited\VBD\2632167 an\DT\6697703 antipsychotic-like\JJ\1740 profile\NN\6999802 by\IN\1740 potentiating\VBG\229605 <e1>haloperidol-induced</e1>\JJ\1740 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 reducing\VBG\441445 amphetamine-induced\JJ\1740 hyperactivity\NN\14052403 and\CC\1740 reducing\VBG\441445 apomorphine-induced\JJ\1740 climbing\NN\7445480 in\IN\13603305 mice\NNS\2329401 .\.\1740
C069357_D002375 NONE <e1>(R)-alpha-methylhistamine</e1>\NN\1740 (\-LRB-\1740 RAMH\NN\1740 )\-RRB-\1740 (\-LRB-\1740 5\CD\13741022 microg\NN\1740 i.c.v.\NN\1740 )\-RRB-\1740 and\CC\1740 thioperamide\NN\1740 (\-LRB-\1740 THP\NN\1740 )\-RRB-\1740 (\-LRB-\1740 15\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 per\FW\1740 se\FW\14724645 did\VBD\1640855 not\RB\1740 cause\VB\1617192 <e2>catalepsy</e2>\NN\14023236 .\.\1740
C069357_D002375 NONE (R)-alpha-methylhistamine\NN\1740 (\-LRB-\1740 <e1>RAMH</e1>\NN\1740 )\-RRB-\1740 (\-LRB-\1740 5\CD\13741022 microg\NN\1740 i.c.v.\NN\1740 )\-RRB-\1740 and\CC\1740 thioperamide\NN\1740 (\-LRB-\1740 THP\NN\1740 )\-RRB-\1740 (\-LRB-\1740 15\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 per\FW\1740 se\FW\14724645 did\VBD\1640855 not\RB\1740 cause\VB\1617192 <e2>catalepsy</e2>\NN\14023236 .\.\1740
C052075_D002375 CID (R)-alpha-methylhistamine\NN\1740 (\-LRB-\1740 RAMH\NN\1740 )\-RRB-\1740 (\-LRB-\1740 5\CD\13741022 microg\NN\1740 i.c.v.\NN\1740 )\-RRB-\1740 and\CC\1740 <e1>thioperamide</e1>\NN\1740 (\-LRB-\1740 THP\NN\1740 )\-RRB-\1740 (\-LRB-\1740 15\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 per\FW\1740 se\FW\14724645 did\VBD\1640855 not\RB\1740 cause\VB\1617192 <e2>catalepsy</e2>\NN\14023236 .\.\1740
C052075_D002375 CID (R)-alpha-methylhistamine\NN\1740 (\-LRB-\1740 RAMH\NN\1740 )\-RRB-\1740 (\-LRB-\1740 5\CD\13741022 microg\NN\1740 i.c.v.\NN\1740 )\-RRB-\1740 and\CC\1740 thioperamide\NN\1740 (\-LRB-\1740 <e1>THP</e1>\NN\1740 )\-RRB-\1740 (\-LRB-\1740 15\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 ,\,\1740 per\FW\1740 se\FW\14724645 did\VBD\1640855 not\RB\1740 cause\VB\1617192 <e2>catalepsy</e2>\NN\14023236 .\.\1740
C052075_D002375 CID Administration\NN\1133281 of\IN\1740 <e1>THP</e1>\NN\1740 (\-LRB-\1740 3.75\CD\1740 ,\,\1740 7.5\CD\1740 and\CC\1740 15\CD\13745420 mg/kg\NN\1740 i.p.\RB\1740 )\-RRB-\1740 1\CD\13741022 h\NN\14622893 prior\RB\1740 to\TO\1740 haloperidol\NN\3713736 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 dose-dependent\JJ\1740 increase\NN\13576355 in\IN\13603305 the\DT\1740 <e2>catalepsy</e2>\NN\14023236 times\NNS\15113229 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
C052075_D002375 CID <e1>THP</e1>\NN\1740 exhibited\VBD\2632167 an\DT\6697703 antipsychotic-like\JJ\1740 profile\NN\6999802 by\IN\1740 potentiating\VBG\229605 haloperidol-induced\JJ\1740 <e2>catalepsy</e2>\NN\14023236 ,\,\1740 reducing\VBG\441445 amphetamine-induced\JJ\1740 hyperactivity\NN\14052403 and\CC\1740 reducing\VBG\441445 apomorphine-induced\JJ\1740 climbing\NN\7445480 in\IN\13603305 mice\NNS\2329401 .\.\1740
D000661_D006948 CID On\IN\1740 <e1>amphetamine-induced</e1>\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 ,\,\1740 THP\NN\1740 (\-LRB-\1740 3.75\CD\1740 and\CC\1740 7.5\CD\1740 mg/kg\NN\1740 i.p.\FW\1740 )\-RRB-\1740 reduced\VBN\441445 locomotor\NN\1740 time\NN\7308889 ,\,\1740 distance\NN\5083328 traveled\VBN\1843055 and\CC\1740 average\JJ\1740 speed\NN\15286249 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
D000661_D006948 CID THP\NN\1740 exhibited\VBD\2632167 an\DT\6697703 antipsychotic-like\JJ\1740 profile\NN\6999802 by\IN\1740 potentiating\VBG\229605 haloperidol-induced\JJ\1740 catalepsy\NN\14023236 ,\,\1740 reducing\VBG\441445 <e1>amphetamine-induced</e1>\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 and\CC\1740 reducing\VBG\441445 apomorphine-induced\JJ\1740 climbing\NN\7445480 in\IN\13603305 mice\NNS\2329401 .\.\1740
C052075_D006948 NONE On\IN\1740 amphetamine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 ,\,\1740 <e1>THP</e1>\NN\1740 (\-LRB-\1740 3.75\CD\1740 and\CC\1740 7.5\CD\1740 mg/kg\NN\1740 i.p.\FW\1740 )\-RRB-\1740 reduced\VBN\441445 locomotor\NN\1740 time\NN\7308889 ,\,\1740 distance\NN\5083328 traveled\VBN\1843055 and\CC\1740 average\JJ\1740 speed\NN\15286249 (\-LRB-\1740 P\NN\14622893 <\XX\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
C052075_D006948 NONE <e1>THP</e1>\NN\1740 exhibited\VBD\2632167 an\DT\6697703 antipsychotic-like\JJ\1740 profile\NN\6999802 by\IN\1740 potentiating\VBG\229605 haloperidol-induced\JJ\1740 catalepsy\NN\14023236 ,\,\1740 reducing\VBG\441445 amphetamine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 and\CC\1740 reducing\VBG\441445 apomorphine-induced\JJ\1740 climbing\NN\7445480 in\IN\13603305 mice\NNS\2329401 .\.\1740
D006220_D006948 NONE THP\NN\1740 exhibited\VBD\2632167 an\DT\6697703 antipsychotic-like\JJ\1740 profile\NN\6999802 by\IN\1740 potentiating\VBG\229605 <e1>haloperidol-induced</e1>\JJ\1740 catalepsy\NN\14023236 ,\,\1740 reducing\VBG\441445 amphetamine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 and\CC\1740 reducing\VBG\441445 apomorphine-induced\JJ\1740 climbing\NN\7445480 in\IN\13603305 mice\NNS\2329401 .\.\1740
D001058_D006948 NONE THP\NN\1740 exhibited\VBD\2632167 an\DT\6697703 antipsychotic-like\JJ\1740 profile\NN\6999802 by\IN\1740 potentiating\VBG\229605 haloperidol-induced\JJ\1740 catalepsy\NN\14023236 ,\,\1740 reducing\VBG\441445 amphetamine-induced\JJ\1740 <e2>hyperactivity</e2>\NN\14052403 and\CC\1740 reducing\VBG\441445 <e1>apomorphine-induced</e1>\JJ\1740 climbing\NN\7445480 in\IN\13603305 mice\NNS\2329401 .\.\1740
19269743
D002211_D010146 CID Explicit\NN\1740 episodic\JJ\1740 memory\NN\5926676 for\IN\1740 sensory-discriminative\JJ\1740 components\NNS\5867413 of\IN\1740 <e1>capsaicin-induced</e1>\JJ\1740 <e2>pain</e2>\NN\14299637 :\:\1740 immediate\JJ\1740 and\CC\1740 delayed\VBN\439958 ratings\NNS\5733583 .\.\1740
D002211_D010146 CID In\IN\13603305 order\NN\7168131 to\TO\1740 address\VB\740577 long-term\JJ\1740 <e2>pain</e2>\NN\14299637 memory\NN\5926676 ,\,\1740 nine\CD\13741022 healthy\JJ\1740 male\JJ\1740 volunteers\NNS\10582746 received\VBD\2210855 intradermal\JJ\1740 injections\NNS\320852 of\IN\1740 three\CD\13741022 doses\NNS\3740161 of\IN\1740 <e1>capsaicin</e1>\NN\15032661 (\-LRB-\1740 0.05\CD\1740 ,\,\1740 1\CD\13741022 and\CC\1740 20\CD\13745420 microg\NN\1740 ,\,\1740 separated\VBN\1850315 by\IN\1740 15\CD\13745420 min\NN\15154774 breaks\NNS\7283608 )\-RRB-\1740 ,\,\1740 each\DT\1740 given\VBN\2327200 three\CD\13741022 times\NNS\15113229 in\IN\13603305 a\DT\13649268 balanced\JJ\1740 design\NN\927261 across\IN\1740 three\CD\13741022 sessions\NNS\7142566 at\IN\14622893 one\CD\13741022 week\NN\15113229 intervals\NNS\33615 .\.\1740
D002211_D010146 CID Subjects\NNS\6598915 were\VBD\836236 able\JJ\1740 to\TO\1740 reliably\RB\1740 discriminate\VB\650353 <e2>pain</e2>\NN\14299637 magnitude\NN\4916342 and\CC\1740 duration\NN\15113229 across\IN\1740 <e1>capsaicin</e1>\NN\15032661 doses\NNS\3740161 (\-LRB-\1740 both\CC\1740 p<0.001\NN\1740 )\-RRB-\1740 ,\,\1740 regardless\RB\1740 of\IN\1740 whether\IN\1740 first-time\JJ\1740 ratings\NNS\5733583 were\VBD\836236 requested\VBN\742320 immediately\RB\1740 ,\,\1740 after\IN\1740 one\CD\13741022 hour\NN\15154774 or\CC\3541091 after\IN\1740 one\CD\13741022 day\NN\15154774 .\.\1740
84204
D002927_D003221 CID Pharmacokinetic\JJ\1740 and\CC\1740 clinical\JJ\1740 studies\NNS\635850 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e1>cimetidine-associated</e1>\JJ\1740 mental\JJ\1740 <e2>confusion</e2>\NN\13972797 .\.\1740
D002927_D003221 CID 15\CD\13745420 cases\NNS\7283608 of\IN\1740 <e1>cimetidine-associated</e1>\JJ\1740 mental\JJ\1740 <e2>confusion</e2>\NN\13972797 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 .\.\1740
D002927_D051437 NONE These\DT\1740 6\CD\13741022 patients\NNS\9898892 had\VBD\2108377 both\CC\1740 <e2>renal\JJ\1740 and\CC\1740 liver\NN\5298729 dysfunction</e2>\NN\14204950 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 <e1>cimetidine</e1>\NN\14778019 trough-concentrations\NNS\1740 of\IN\1740 more\JJR\1740 than\IN\1740 1.25\CD\1740 microgram/ml\NN\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
D002927_D008107 NONE These\DT\1740 6\CD\13741022 patients\NNS\9898892 had\VBD\2108377 both\CC\1740 <e2>renal\JJ\1740 and\CC\1740 liver\NN\5298729 dysfunction</e2>\NN\14204950 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 ,\,\1740 as\RB\1740 well\RB\1740 as\IN\14622893 <e1>cimetidine</e1>\NN\14778019 trough-concentrations\NNS\1740 of\IN\1740 more\JJR\1740 than\IN\1740 1.25\CD\1740 microgram/ml\NN\1740 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.05\CD\1740 )\-RRB-\1740 .\.\1740
11027905
D007649_D009369 NONE Analgesic\JJ\1740 effect\NN\34213 of\IN\1740 intravenous\JJ\1740 <e1>ketamine</e1>\NN\3054098 in\IN\13603305 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 on\IN\1740 morphine\NN\2707683 therapy\NN\657604 :\:\1740 a\DT\13649268 randomized\VBN\278117 ,\,\1740 controlled\VBN\2422663 ,\,\1740 double-blind\JJ\1740 ,\,\1740 crossover\NN\13526110 ,\,\1740 double-dose\JJ\1740 study\NN\635850 .\.\1740
D007649_D009369 NONE A\DT\13649268 slow\JJ\1740 bolus\NN\13899404 of\IN\1740 subhypnotic\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>ketamine</e1>\NN\3054098 (\-LRB-\1740 0.25\CD\1740 mg/kg\NN\1740 or\CC\3541091 0.50\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 was\VBD\836236 given\VBN\2327200 to\TO\1740 10\CD\13745420 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 whose\WP$\1740 pain\NN\14299637 was\VBD\836236 unrelieved\VBN\1740 by\IN\1740 morphine\NN\2707683 in\IN\13603305 a\DT\13649268 randomized\JJ\1740 ,\,\1740 double-blind\JJ\1740 ,\,\1740 crossover\NN\13526110 ,\,\1740 double-dose\JJ\1740 study\NN\635850 .\.\1740
D009020_D009369 NONE Analgesic\JJ\1740 effect\NN\34213 of\IN\1740 intravenous\JJ\1740 ketamine\NN\3054098 in\IN\13603305 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 on\IN\1740 <e1>morphine</e1>\NN\2707683 therapy\NN\657604 :\:\1740 a\DT\13649268 randomized\VBN\278117 ,\,\1740 controlled\VBN\2422663 ,\,\1740 double-blind\JJ\1740 ,\,\1740 crossover\NN\13526110 ,\,\1740 double-dose\JJ\1740 study\NN\635850 .\.\1740
D009020_D009369 NONE A\DT\13649268 slow\JJ\1740 bolus\NN\13899404 of\IN\1740 subhypnotic\JJ\1740 doses\NNS\3740161 of\IN\1740 ketamine\NN\3054098 (\-LRB-\1740 0.25\CD\1740 mg/kg\NN\1740 or\CC\3541091 0.50\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 was\VBD\836236 given\VBN\2327200 to\TO\1740 10\CD\13745420 <e2>cancer</e2>\NN\14239425 patients\NNS\9898892 whose\WP$\1740 pain\NN\14299637 was\VBD\836236 unrelieved\VBN\1740 by\IN\1740 <e1>morphine</e1>\NN\2707683 in\IN\13603305 a\DT\13649268 randomized\JJ\1740 ,\,\1740 double-blind\JJ\1740 ,\,\1740 crossover\NN\13526110 ,\,\1740 double-dose\JJ\1740 study\NN\635850 .\.\1740
D009020_D010146 NONE <e2>Pain</e2>\NN\14299637 not\RB\1740 responsive\JJ\1740 to\TO\1740 <e1>morphine</e1>\NN\2707683 is\VBZ\836236 often\RB\1740 problematic\JJ\1740 .\.\1740
D009020_D010146 NONE A\DT\13649268 slow\JJ\1740 bolus\NN\13899404 of\IN\1740 subhypnotic\JJ\1740 doses\NNS\3740161 of\IN\1740 ketamine\NN\3054098 (\-LRB-\1740 0.25\CD\1740 mg/kg\NN\1740 or\CC\3541091 0.50\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 was\VBD\836236 given\VBN\2327200 to\TO\1740 10\CD\13745420 cancer\NN\14239425 patients\NNS\9898892 whose\WP$\1740 <e2>pain</e2>\NN\14299637 was\VBD\836236 unrelieved\VBN\1740 by\IN\1740 <e1>morphine</e1>\NN\2707683 in\IN\13603305 a\DT\13649268 randomized\JJ\1740 ,\,\1740 double-blind\JJ\1740 ,\,\1740 crossover\NN\13526110 ,\,\1740 double-dose\JJ\1740 study\NN\635850 .\.\1740
D009020_D010146 NONE Ketamine\NNP\3054098 can\MD\3094503 improve\VB\126264 <e1>morphine</e1>\NN\2707683 analgesia\NN\14034177 in\IN\13603305 difficult\JJ\1740 <e2>pain</e2>\NN\14299637 syndromes\NNS\5870365 ,\,\1740 such\JJ\1740 as\IN\14622893 neuropathic\JJ\1740 pain\NN\14299637 .\.\1740
D016202_D010146 NONE Animal\NN\4475 and\CC\1740 clinical\JJ\1740 studies\NNS\635850 have\VBP\2108377 suggested\VBN\1010118 that\IN\1740 <e1>N-methyl-D-aspartate</e1>\NN\1740 (\-LRB-\1740 NMDA\NN\1740 )\-RRB-\1740 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 ketamine\NN\3054098 ,\,\1740 may\MD\15209706 be\VB\836236 effective\JJ\1740 in\IN\13603305 improving\VBG\126264 opioid\JJ\1740 analgesia\NN\14034177 in\IN\13603305 difficult\JJ\1740 <e2>pain</e2>\NN\14299637 syndromes\NNS\5870365 ,\,\1740 such\JJ\1740 as\IN\14622893 neuropathic\JJ\1740 pain\NN\14299637 .\.\1740
D016202_D010146 NONE Animal\NN\4475 and\CC\1740 clinical\JJ\1740 studies\NNS\635850 have\VBP\2108377 suggested\VBN\1010118 that\IN\1740 N-methyl-D-aspartate\NN\1740 (\-LRB-\1740 <e1>NMDA</e1>\NN\1740 )\-RRB-\1740 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 ketamine\NN\3054098 ,\,\1740 may\MD\15209706 be\VB\836236 effective\JJ\1740 in\IN\13603305 improving\VBG\126264 opioid\JJ\1740 analgesia\NN\14034177 in\IN\13603305 difficult\JJ\1740 <e2>pain</e2>\NN\14299637 syndromes\NNS\5870365 ,\,\1740 such\JJ\1740 as\IN\14622893 neuropathic\JJ\1740 pain\NN\14299637 .\.\1740
D016202_D009437 NONE Animal\NN\4475 and\CC\1740 clinical\JJ\1740 studies\NNS\635850 have\VBP\2108377 suggested\VBN\1010118 that\IN\1740 <e1>N-methyl-D-aspartate</e1>\NN\1740 (\-LRB-\1740 NMDA\NN\1740 )\-RRB-\1740 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 ketamine\NN\3054098 ,\,\1740 may\MD\15209706 be\VB\836236 effective\JJ\1740 in\IN\13603305 improving\VBG\126264 opioid\JJ\1740 analgesia\NN\14034177 in\IN\13603305 difficult\JJ\1740 pain\NN\14299637 syndromes\NNS\5870365 ,\,\1740 such\JJ\1740 as\IN\14622893 <e2>neuropathic\JJ\1740 pain</e2>\NN\14299637 .\.\1740
D016202_D009437 NONE Animal\NN\4475 and\CC\1740 clinical\JJ\1740 studies\NNS\635850 have\VBP\2108377 suggested\VBN\1010118 that\IN\1740 N-methyl-D-aspartate\NN\1740 (\-LRB-\1740 <e1>NMDA</e1>\NN\1740 )\-RRB-\1740 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 ketamine\NN\3054098 ,\,\1740 may\MD\15209706 be\VB\836236 effective\JJ\1740 in\IN\13603305 improving\VBG\126264 opioid\JJ\1740 analgesia\NN\14034177 in\IN\13603305 difficult\JJ\1740 pain\NN\14299637 syndromes\NNS\5870365 ,\,\1740 such\JJ\1740 as\IN\14622893 <e2>neuropathic\JJ\1740 pain</e2>\NN\14299637 .\.\1740
D007649_D010146 NONE Animal\NN\4475 and\CC\1740 clinical\JJ\1740 studies\NNS\635850 have\VBP\2108377 suggested\VBN\1010118 that\IN\1740 N-methyl-D-aspartate\NN\1740 (\-LRB-\1740 NMDA\NN\1740 )\-RRB-\1740 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 <e1>ketamine</e1>\NN\3054098 ,\,\1740 may\MD\15209706 be\VB\836236 effective\JJ\1740 in\IN\13603305 improving\VBG\126264 opioid\JJ\1740 analgesia\NN\14034177 in\IN\13603305 difficult\JJ\1740 <e2>pain</e2>\NN\14299637 syndromes\NNS\5870365 ,\,\1740 such\JJ\1740 as\IN\14622893 neuropathic\JJ\1740 pain\NN\14299637 .\.\1740
D007649_D010146 NONE A\DT\13649268 slow\JJ\1740 bolus\NN\13899404 of\IN\1740 subhypnotic\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>ketamine</e1>\NN\3054098 (\-LRB-\1740 0.25\CD\1740 mg/kg\NN\1740 or\CC\3541091 0.50\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 was\VBD\836236 given\VBN\2327200 to\TO\1740 10\CD\13745420 cancer\NN\14239425 patients\NNS\9898892 whose\WP$\1740 <e2>pain</e2>\NN\14299637 was\VBD\836236 unrelieved\VBN\1740 by\IN\1740 morphine\NN\2707683 in\IN\13603305 a\DT\13649268 randomized\JJ\1740 ,\,\1740 double-blind\JJ\1740 ,\,\1740 crossover\NN\13526110 ,\,\1740 double-dose\JJ\1740 study\NN\635850 .\.\1740
D007649_D010146 NONE <e1>Ketamine</e1>\NNP\3054098 ,\,\1740 but\CC\1740 not\RB\1740 saline\NN\14849367 solution\NN\14586258 ,\,\1740 significantly\RB\1740 reduced\VBD\441445 the\DT\1740 <e2>pain</e2>\NN\14299637 intensity\NN\5090441 in\IN\13603305 almost\RB\1740 all\PDT\1740 the\DT\1740 patients\NNS\9898892 at\IN\14622893 both\DT\1740 doses\NNS\3740161 .\.\1740
D007649_D010146 NONE <e1>Ketamine</e1>\NNP\3054098 can\MD\3094503 improve\VB\126264 morphine\NN\2707683 analgesia\NN\14034177 in\IN\13603305 difficult\JJ\1740 <e2>pain</e2>\NN\14299637 syndromes\NNS\5870365 ,\,\1740 such\JJ\1740 as\IN\14622893 neuropathic\JJ\1740 pain\NN\14299637 .\.\1740
D007649_D009437 NONE Animal\NN\4475 and\CC\1740 clinical\JJ\1740 studies\NNS\635850 have\VBP\2108377 suggested\VBN\1010118 that\IN\1740 N-methyl-D-aspartate\NN\1740 (\-LRB-\1740 NMDA\NN\1740 )\-RRB-\1740 antagonists\NNS\7846 ,\,\1740 such\JJ\1740 as\IN\14622893 <e1>ketamine</e1>\NN\3054098 ,\,\1740 may\MD\15209706 be\VB\836236 effective\JJ\1740 in\IN\13603305 improving\VBG\126264 opioid\JJ\1740 analgesia\NN\14034177 in\IN\13603305 difficult\JJ\1740 pain\NN\14299637 syndromes\NNS\5870365 ,\,\1740 such\JJ\1740 as\IN\14622893 <e2>neuropathic\JJ\1740 pain</e2>\NN\14299637 .\.\1740
D007649_D009437 NONE <e1>Ketamine</e1>\NNP\3054098 can\MD\3094503 improve\VB\126264 morphine\NN\2707683 analgesia\NN\14034177 in\IN\13603305 difficult\JJ\1740 pain\NN\14299637 syndromes\NNS\5870365 ,\,\1740 such\JJ\1740 as\IN\14622893 <e2>neuropathic\JJ\1740 pain</e2>\NN\14299637 .\.\1740
D009020_D009437 NONE Ketamine\NNP\3054098 can\MD\3094503 improve\VB\126264 <e1>morphine</e1>\NN\2707683 analgesia\NN\14034177 in\IN\13603305 difficult\JJ\1740 pain\NN\14299637 syndromes\NNS\5870365 ,\,\1740 such\JJ\1740 as\IN\14622893 <e2>neuropathic\JJ\1740 pain</e2>\NN\14299637 .\.\1740
3409645
D008727_D007172 CID <e2>Impotence</e2>\NN\4723816 was\VBD\836236 more\RBR\1740 common\JJ\1740 among\IN\1740 male\JJ\1740 patients\NNS\9898892 than\IN\1740 controls\NNS\5190804 and\CC\1740 was\VBD\836236 found\VBN\2426171 to\TO\1740 be\VB\836236 associated\VBN\628491 with\IN\1740 co-morbidity\NN\1740 and\CC\1740 the\DT\1740 taking\NN\37396 of\IN\1740 <e1>methotrexate</e1>\NN\2722166 .\.\1740
7234705
D011342_D017180 CID <e1>Procainamide-induced</e1>\JJ\1740 polymorphous\JJ\1740 <e2>ventricular\NN\1740 tachycardia</e2>\NN\14110674 .\.\1740
D011342_D017180 CID Seven\CD\13741022 cases\NNS\7283608 of\IN\1740 <e1>procainamide-induced</e1>\JJ\1740 polymorphous\JJ\1740 <e2>ventricular\NN\1740 tachycardia</e2>\NN\14110674 are\VBP\836236 presented\VBN\2137132 .\.\1740
D011342_D017180 CID In\IN\13603305 four\CD\13741022 patients\NNS\9898892 ,\,\1740 polymorphous\JJ\1740 <e2>ventricular\NN\1740 tachycardia</e2>\NN\14110674 appeared\VBD\2604760 after\IN\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 200\CD\1740 to\TO\1740 400\CD\1740 mg\NN\13717155 of\IN\1740 <e1>procainamide</e1>\NN\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 sustained\JJ\1740 ventricular\JJ\1740 tachycardia\NN\14110674 .\.\1740
D011342_D017180 CID In\IN\13603305 four\CD\13741022 patients\NNS\9898892 ,\,\1740 polymorphous\JJ\1740 ventricular\NN\1740 tachycardia\NN\14110674 appeared\VBD\2604760 after\IN\1740 intravenous\JJ\1740 administration\NN\1133281 of\IN\1740 200\CD\1740 to\TO\1740 400\CD\1740 mg\NN\13717155 of\IN\1740 <e1>procainamide</e1>\NN\1740 for\IN\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 sustained\JJ\1740 <e2>ventricular\JJ\1740 tachycardia</e2>\NN\14110674 .\.\1740
D011342_D017180 CID In\IN\13603305 the\DT\1740 seventh\JJ\1740 patient\NN\9898892 ,\,\1740 a\DT\13649268 permanent\JJ\1740 ventricular\NN\1740 pacemaker\NN\5925366 was\VBD\836236 inserted\VBN\1296462 and\CC\1740 ,\,\1740 despite\IN\7501545 continuation\NN\407535 of\IN\1740 <e1>procainamide</e1>\NN\1740 therapy\NN\657604 ,\,\1740 polymorphous\JJ\1740 <e2>ventricular\NN\1740 tachycardia</e2>\NN\14110674 did\VBD\1640855 not\RB\1740 reoccur\VB\1740 .\.\1740
D011342_D017180 CID These\DT\1740 seven\CD\13741022 cases\NNS\7283608 demonstrate\VBP\2137132 that\IN\1740 <e1>procainamide</e1>\NN\1740 can\MD\3094503 produce\VB\1617192 an\DT\6697703 acquired\VBN\109660 prolonged\JJ\1740 Q-T\NN\1740 syndrome\NN\5870365 with\IN\1740 polymorphous\JJ\1740 <e2>ventricular\NN\1740 tachycardia</e2>\NN\14110674 .\.\1740
D011342_D018879 NONE In\IN\13603305 the\DT\1740 remaining\VBG\2604760 three\CD\13741022 patients\NNS\9898892 ,\,\1740 <e1>procainamide</e1>\NN\1740 was\VBD\836236 administered\VBN\2436349 orally\RB\1740 for\IN\1740 treatment\NN\654885 of\IN\1740 chronic\JJ\1740 <e2>premature\JJ\1740 ventricular\JJ\1740 contractions</e2>\NNS\358931 or\CC\3541091 atrial\JJ\1740 flutter\NN\331950 .\.\1740
D011342_D001282 NONE In\IN\13603305 the\DT\1740 remaining\VBG\2604760 three\CD\13741022 patients\NNS\9898892 ,\,\1740 <e1>procainamide</e1>\NN\1740 was\VBD\836236 administered\VBN\2436349 orally\RB\1740 for\IN\1740 treatment\NN\654885 of\IN\1740 chronic\JJ\1740 premature\JJ\1740 ventricular\JJ\1740 contractions\NNS\358931 or\CC\3541091 <e2>atrial\JJ\1740 flutter</e2>\NN\331950 .\.\1740
D011342_D008133 NONE These\DT\1740 seven\CD\13741022 cases\NNS\7283608 demonstrate\VBP\2137132 that\IN\1740 <e1>procainamide</e1>\NN\1740 can\MD\3094503 produce\VB\1617192 an\DT\6697703 acquired\VBN\109660 <e2>prolonged\JJ\1740 Q-T\NN\1740 syndrome</e2>\NN\5870365 with\IN\1740 polymorphous\JJ\1740 ventricular\NN\1740 tachycardia\NN\14110674 .\.\1740
1549199
D007980_D064420 NONE While\IN\15122231 there\EX\27167 is\VBZ\836236 no\DT\7204911 single\JJ\1740 correct\JJ\1740 starting\VBG\2009433 dose\NN\3740161 for\IN\1740 <e1>levodopa</e1>\NN\14604959 therapy\NN\657604 ,\,\1740 many\JJ\1740 individuals\NNS\7347 can\MD\3094503 be\VB\836236 started\VBN\2009433 on\IN\1740 either\CC\1740 the\DT\1740 25/100\CD\1740 or\CC\3541091 controlled-release\NN\1740 formula\NN\6732169 ,\,\1740 following\VBG\1835496 the\DT\1740 general\JJ\1740 rule\NN\5835747 not\RB\1740 to\TO\1740 attempt\VB\2367363 to\TO\1740 titrate\VB\489837 carbidopa-levodopa\JJ\1740 to\TO\1740 the\DT\1740 point\NN\5868954 of\IN\1740 "\``\1740 normality\NN\13920835 ,\,\1740 "\''\1740 which\WDT\1740 can\MD\3094503 lead\VB\1752884 to\IN\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D007980_D064420 NONE While\IN\15122231 there\EX\27167 is\VBZ\836236 no\DT\7204911 single\JJ\1740 correct\JJ\1740 starting\VBG\2009433 dose\NN\3740161 for\IN\1740 levodopa\NN\14604959 therapy\NN\657604 ,\,\1740 many\JJ\1740 individuals\NNS\7347 can\MD\3094503 be\VB\836236 started\VBN\2009433 on\IN\1740 either\CC\1740 the\DT\1740 25/100\CD\1740 or\CC\3541091 controlled-release\NN\1740 formula\NN\6732169 ,\,\1740 following\VBG\1835496 the\DT\1740 general\JJ\1740 rule\NN\5835747 not\RB\1740 to\TO\1740 attempt\VB\2367363 to\TO\1740 titrate\VB\489837 <e1>carbidopa-levodopa</e1>\JJ\1740 to\TO\1740 the\DT\1740 point\NN\5868954 of\IN\1740 "\``\1740 normality\NN\13920835 ,\,\1740 "\''\1740 which\WDT\1740 can\MD\3094503 lead\VB\1752884 to\IN\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D002230_D064420 NONE While\IN\15122231 there\EX\27167 is\VBZ\836236 no\DT\7204911 single\JJ\1740 correct\JJ\1740 starting\VBG\2009433 dose\NN\3740161 for\IN\1740 levodopa\NN\14604959 therapy\NN\657604 ,\,\1740 many\JJ\1740 individuals\NNS\7347 can\MD\3094503 be\VB\836236 started\VBN\2009433 on\IN\1740 either\CC\1740 the\DT\1740 25/100\CD\1740 or\CC\3541091 controlled-release\NN\1740 formula\NN\6732169 ,\,\1740 following\VBG\1835496 the\DT\1740 general\JJ\1740 rule\NN\5835747 not\RB\1740 to\TO\1740 attempt\VB\2367363 to\TO\1740 titrate\VB\489837 <e1>carbidopa-levodopa</e1>\JJ\1740 to\TO\1740 the\DT\1740 point\NN\5868954 of\IN\1740 "\``\1740 normality\NN\13920835 ,\,\1740 "\''\1740 which\WDT\1740 can\MD\3094503 lead\VB\1752884 to\IN\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D007980_D005767 CID Other\JJ\1740 possible\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 --\:\1740 such\JJ\1740 as\IN\14622893 <e2>gastrointestinal\JJ\1740 disorders</e2>\NNS\14034177 ,\,\1740 orthostatic\JJ\1740 hypotension\NN\14057371 ,\,\1740 <e1>levodopa-induced</e1>\JJ\1740 psychosis\NN\14380140 ,\,\1740 sleep\NN\14034177 disturbances\NNS\407535 or\CC\3541091 parasomnias\NNS\1740 ,\,\1740 or\CC\3541091 drug\NN\14778436 interactions\NNS\37396 --\:\1740 also\RB\1740 require\VBP\754942 carefully\RB\1740 monitored\VBN\2169352 individual\JJ\1740 treatment\NN\654885 .\.\1740
D007980_D007024 CID Other\JJ\1740 possible\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 --\:\1740 such\JJ\1740 as\IN\14622893 gastrointestinal\JJ\1740 disorders\NNS\14034177 ,\,\1740 <e2>orthostatic\JJ\1740 hypotension</e2>\NN\14057371 ,\,\1740 <e1>levodopa-induced</e1>\JJ\1740 psychosis\NN\14380140 ,\,\1740 sleep\NN\14034177 disturbances\NNS\407535 or\CC\3541091 parasomnias\NNS\1740 ,\,\1740 or\CC\3541091 drug\NN\14778436 interactions\NNS\37396 --\:\1740 also\RB\1740 require\VBP\754942 carefully\RB\1740 monitored\VBN\2169352 individual\JJ\1740 treatment\NN\654885 .\.\1740
D007980_D011618 NONE Other\JJ\1740 possible\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 --\:\1740 such\JJ\1740 as\IN\14622893 gastrointestinal\JJ\1740 disorders\NNS\14034177 ,\,\1740 orthostatic\JJ\1740 hypotension\NN\14057371 ,\,\1740 <e1>levodopa-induced</e1>\JJ\1740 <e2>psychosis</e2>\NN\14380140 ,\,\1740 sleep\NN\14034177 disturbances\NNS\407535 or\CC\3541091 parasomnias\NNS\1740 ,\,\1740 or\CC\3541091 drug\NN\14778436 interactions\NNS\37396 --\:\1740 also\RB\1740 require\VBP\754942 carefully\RB\1740 monitored\VBN\2169352 individual\JJ\1740 treatment\NN\654885 .\.\1740
D007980_D012893 NONE Other\JJ\1740 possible\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 --\:\1740 such\JJ\1740 as\IN\14622893 gastrointestinal\JJ\1740 disorders\NNS\14034177 ,\,\1740 orthostatic\JJ\1740 hypotension\NN\14057371 ,\,\1740 <e1>levodopa-induced</e1>\JJ\1740 psychosis\NN\14380140 ,\,\1740 <e2>sleep\NN\14034177 disturbances</e2>\NNS\407535 or\CC\3541091 parasomnias\NNS\1740 ,\,\1740 or\CC\3541091 drug\NN\14778436 interactions\NNS\37396 --\:\1740 also\RB\1740 require\VBP\754942 carefully\RB\1740 monitored\VBN\2169352 individual\JJ\1740 treatment\NN\654885 .\.\1740
D007980_D020447 CID Other\JJ\1740 possible\JJ\1740 adverse\JJ\1740 effects\NNS\13245626 --\:\1740 such\JJ\1740 as\IN\14622893 gastrointestinal\JJ\1740 disorders\NNS\14034177 ,\,\1740 orthostatic\JJ\1740 hypotension\NN\14057371 ,\,\1740 <e1>levodopa-induced</e1>\JJ\1740 psychosis\NN\14380140 ,\,\1740 sleep\NN\14034177 disturbances\NNS\407535 or\CC\3541091 <e2>parasomnias</e2>\NNS\1740 ,\,\1740 or\CC\3541091 drug\NN\14778436 interactions\NNS\37396 --\:\1740 also\RB\1740 require\VBP\754942 carefully\RB\1740 monitored\VBN\2169352 individual\JJ\1740 treatment\NN\654885 .\.\1740
18308784
C035054_D007859 NONE <e1>Ginsenoside\NN\1740 Rg1</e1>\NN\1740 restores\VBZ\1631072 the\DT\1740 <e2>impairment\NN\7296428 of\IN\1740 learning</e2>\NN\5701944 induced\VBN\1627355 by\IN\1740 chronic\JJ\1740 morphine\NN\2707683 administration\NN\1133281 in\IN\13603305 rats\NNS\2329401 .\.\1740
C035054_D007859 NONE <e1>Rg1</e1>\NN\1740 ,\,\1740 as\IN\14622893 a\DT\13649268 ginsenoside\NN\1740 extracted\VBN\173338 from\IN\1740 Panax\NNP\11585340 ginseng\NNP\13125117 ,\,\1740 could\MD\1740 ameliorate\VB\126264 spatial\JJ\1740 <e2>learning\NN\5701944 impairment</e2>\NN\7296428 .\.\1740
C035054_D007859 NONE The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 the\DT\1740 effect\NN\34213 of\IN\1740 <e1>Rg1</e1>\NN\1740 on\IN\1740 <e2>learning\NN\5701944 impairment</e2>\NN\7296428 by\IN\1740 chronic\JJ\1740 morphine\NN\2707683 administration\NN\1133281 and\CC\1740 the\DT\1740 mechanism\NN\13446390 responsible\JJ\1740 for\IN\1740 this\DT\1740 effect\NN\34213 .\.\1740
D009020_D007859 CID Ginsenoside\NN\1740 Rg1\NN\1740 restores\VBZ\1631072 the\DT\1740 <e2>impairment\NN\7296428 of\IN\1740 learning</e2>\NN\5701944 induced\VBN\1627355 by\IN\1740 chronic\JJ\1740 <e1>morphine</e1>\NN\2707683 administration\NN\1133281 in\IN\13603305 rats\NNS\2329401 .\.\1740
D009020_D007859 CID The\DT\1740 aim\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 investigate\VB\644583 the\DT\1740 effect\NN\34213 of\IN\1740 Rg1\NN\1740 on\IN\1740 <e2>learning\NN\5701944 impairment</e2>\NN\7296428 by\IN\1740 chronic\JJ\1740 <e1>morphine</e1>\NN\2707683 administration\NN\1133281 and\CC\1740 the\DT\1740 mechanism\NN\13446390 responsible\JJ\1740 for\IN\1740 this\DT\1740 effect\NN\34213 .\.\1740
D036145_D007859 NONE Rg1\NN\1740 ,\,\1740 as\IN\14622893 a\DT\13649268 <e1>ginsenoside</e1>\NN\1740 extracted\VBN\173338 from\IN\1740 Panax\NNP\11585340 ginseng\NNP\13125117 ,\,\1740 could\MD\1740 ameliorate\VB\126264 spatial\JJ\1740 <e2>learning\NN\5701944 impairment</e2>\NN\7296428 .\.\1740
18768591
D004317_D009404 CID Serum-\NN\1740 and\CC\1740 glucocorticoid-inducible\JJ\1740 kinase\NN\14732946 1\CD\13741022 in\IN\13603305 <e1>doxorubicin-induced</e1>\JJ\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 .\.\1740
D004317_D009404 CID <e1>Doxorubicin</e1>\NN\2716866 treatment\NN\654885 resulted\VBD\2633881 in\IN\13603305 heavy\JJ\1740 proteinuria\NN\14299637 (\-LRB-\1740 >\NNS\1740 100\CD\13745420 mg\NN\13717155 protein/mg\NN\1740 crea\NNS\1740 )\-RRB-\1740 in\IN\13603305 15/44\CD\1740 of\IN\1740 sgk1(+/+\-LRB-\1740 )\-RRB-\1740 and\CC\1740 15/44\CD\1740 of\IN\1740 sgk1(-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 leading\VBG\1752884 to\TO\1740 severe\JJ\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 with\IN\1740 ascites\NNS\14204950 ,\,\1740 lipidemia\NN\14299637 ,\,\1740 and\CC\1740 hypoalbuminemia\NN\1740 in\IN\13603305 both\DT\1740 genotypes\NNS\7941170 .\.\1740
D004317_D007674 NONE <e1>Doxorubicin-induced</e1>\JJ\1740 <e2>nephropathy</e2>\NN\14573196 leads\VBZ\1752884 to\TO\1740 epithelial\JJ\1740 sodium\NN\14625458 channel\NN\6251781 (ENaC)-dependent\JJ\1740 volume\NN\33615 retention\NN\809465 and\CC\1740 renal\JJ\1740 fibrosis\NN\14204950 .\.\1740
D004317_D016055 NONE <e1>Doxorubicin-induced</e1>\JJ\1740 nephropathy\NN\14573196 leads\VBZ\1752884 to\TO\1740 epithelial\JJ\1740 sodium\NN\14625458 channel\NN\6251781 (ENaC)-dependent\JJ\1740 <e2>volume\NN\33615 retention</e2>\NN\809465 and\CC\1740 renal\JJ\1740 fibrosis\NN\14204950 .\.\1740
D004317_D005355 NONE <e1>Doxorubicin-induced</e1>\JJ\1740 nephropathy\NN\14573196 leads\VBZ\1752884 to\TO\1740 epithelial\JJ\1740 sodium\NN\14625458 channel\NN\6251781 (ENaC)-dependent\JJ\1740 volume\NN\33615 retention\NN\809465 and\CC\1740 renal\JJ\1740 <e2>fibrosis</e2>\NN\14204950 .\.\1740
D012964_D007674 NONE Doxorubicin-induced\JJ\1740 <e2>nephropathy</e2>\NN\14573196 leads\VBZ\1752884 to\TO\1740 epithelial\JJ\1740 <e1>sodium</e1>\NN\14625458 channel\NN\6251781 (ENaC)-dependent\JJ\1740 volume\NN\33615 retention\NN\809465 and\CC\1740 renal\JJ\1740 fibrosis\NN\14204950 .\.\1740
D012964_D016055 NONE Doxorubicin-induced\JJ\1740 nephropathy\NN\14573196 leads\VBZ\1752884 to\TO\1740 epithelial\JJ\1740 <e1>sodium</e1>\NN\14625458 channel\NN\6251781 (ENaC)-dependent\JJ\1740 <e2>volume\NN\33615 retention</e2>\NN\809465 and\CC\1740 renal\JJ\1740 fibrosis\NN\14204950 .\.\1740
D012964_D005355 NONE Doxorubicin-induced\JJ\1740 nephropathy\NN\14573196 leads\VBZ\1752884 to\TO\1740 epithelial\JJ\1740 <e1>sodium</e1>\NN\14625458 channel\NN\6251781 (ENaC)-dependent\JJ\1740 volume\NN\33615 retention\NN\809465 and\CC\1740 renal\JJ\1740 <e2>fibrosis</e2>\NN\14204950 .\.\1740
D000450_D005355 NONE The\DT\1740 <e1>aldosterone-sensitive</e1>\JJ\1740 serum-\NN\1740 and\CC\1740 glucocorticoid-inducible\JJ\1740 kinase\NN\14732946 SGK1\NN\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 participate\VB\2367363 in\IN\13603305 the\DT\1740 stimulation\NN\242808 of\IN\1740 ENaC\NN\1740 and\CC\1740 to\TO\1740 mediate\VB\761713 renal\JJ\1740 <e2>fibrosis</e2>\NN\14204950 following\VBG\1835496 mineralocorticoid\NN\14751417 and\CC\1740 salt\NN\14818238 excess\NN\5119367 .\.\1740
D004317_D011507 CID <e1>Doxorubicin</e1>\NN\2716866 treatment\NN\654885 resulted\VBD\2633881 in\IN\13603305 heavy\JJ\1740 <e2>proteinuria</e2>\NN\14299637 (\-LRB-\1740 >\NNS\1740 100\CD\13745420 mg\NN\13717155 protein/mg\NN\1740 crea\NNS\1740 )\-RRB-\1740 in\IN\13603305 15/44\CD\1740 of\IN\1740 sgk1(+/+\-LRB-\1740 )\-RRB-\1740 and\CC\1740 15/44\CD\1740 of\IN\1740 sgk1(-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 leading\VBG\1752884 to\TO\1740 severe\JJ\1740 nephrotic\JJ\1740 syndrome\NN\5870365 with\IN\1740 ascites\NNS\14204950 ,\,\1740 lipidemia\NN\14299637 ,\,\1740 and\CC\1740 hypoalbuminemia\NN\1740 in\IN\13603305 both\DT\1740 genotypes\NNS\7941170 .\.\1740
D004317_D001201 CID <e1>Doxorubicin</e1>\NN\2716866 treatment\NN\654885 resulted\VBD\2633881 in\IN\13603305 heavy\JJ\1740 proteinuria\NN\14299637 (\-LRB-\1740 >\NNS\1740 100\CD\13745420 mg\NN\13717155 protein/mg\NN\1740 crea\NNS\1740 )\-RRB-\1740 in\IN\13603305 15/44\CD\1740 of\IN\1740 sgk1(+/+\-LRB-\1740 )\-RRB-\1740 and\CC\1740 15/44\CD\1740 of\IN\1740 sgk1(-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 leading\VBG\1752884 to\TO\1740 severe\JJ\1740 nephrotic\JJ\1740 syndrome\NN\5870365 with\IN\1740 <e2>ascites</e2>\NNS\14204950 ,\,\1740 lipidemia\NN\14299637 ,\,\1740 and\CC\1740 hypoalbuminemia\NN\1740 in\IN\13603305 both\DT\1740 genotypes\NNS\7941170 .\.\1740
D004317_D006949 CID <e1>Doxorubicin</e1>\NN\2716866 treatment\NN\654885 resulted\VBD\2633881 in\IN\13603305 heavy\JJ\1740 proteinuria\NN\14299637 (\-LRB-\1740 >\NNS\1740 100\CD\13745420 mg\NN\13717155 protein/mg\NN\1740 crea\NNS\1740 )\-RRB-\1740 in\IN\13603305 15/44\CD\1740 of\IN\1740 sgk1(+/+\-LRB-\1740 )\-RRB-\1740 and\CC\1740 15/44\CD\1740 of\IN\1740 sgk1(-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 leading\VBG\1752884 to\TO\1740 severe\JJ\1740 nephrotic\JJ\1740 syndrome\NN\5870365 with\IN\1740 ascites\NNS\14204950 ,\,\1740 <e2>lipidemia</e2>\NN\14299637 ,\,\1740 and\CC\1740 hypoalbuminemia\NN\1740 in\IN\13603305 both\DT\1740 genotypes\NNS\7941170 .\.\1740
D004317_D034141 CID <e1>Doxorubicin</e1>\NN\2716866 treatment\NN\654885 resulted\VBD\2633881 in\IN\13603305 heavy\JJ\1740 proteinuria\NN\14299637 (\-LRB-\1740 >\NNS\1740 100\CD\13745420 mg\NN\13717155 protein/mg\NN\1740 crea\NNS\1740 )\-RRB-\1740 in\IN\13603305 15/44\CD\1740 of\IN\1740 sgk1(+/+\-LRB-\1740 )\-RRB-\1740 and\CC\1740 15/44\CD\1740 of\IN\1740 sgk1(-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 leading\VBG\1752884 to\TO\1740 severe\JJ\1740 nephrotic\JJ\1740 syndrome\NN\5870365 with\IN\1740 ascites\NNS\14204950 ,\,\1740 lipidemia\NN\14299637 ,\,\1740 and\CC\1740 <e2>hypoalbuminemia</e2>\NN\1740 in\IN\13603305 both\DT\1740 genotypes\NNS\7941170 .\.\1740
D000450_D009404 NONE Plasma\NN\5398023 <e1>aldosterone</e1>\NN\14751863 levels\NNS\4916342 increased\VBD\169651 in\IN\13603305 <e2>nephrotic</e2>\JJ\1740 mice\NNS\2329401 of\IN\1740 both\DT\1740 genotypes\NNS\7941170 and\CC\1740 was\VBD\836236 followed\VBN\1835496 by\IN\1740 increased\VBN\169651 SGK1\NN\1740 protein\NN\14944888 expression\NN\4679549 in\IN\13603305 sgk1(+/+\-RRB-\1740 )\-RRB-\1740 mice\NNS\2329401 .\.\1740
D012964_D015430 NONE Urinary\JJ\1740 <e1>sodium</e1>\NN\14625458 excretion\NN\13466586 reached\VBD\2005948 signficantly\RB\1740 lower\JJR\1740 values\NNS\5941423 in\IN\13603305 sgk1(+/+\-RRB-\1740 )\-RRB-\1740 mice\NNS\2329401 (\-LRB-\1740 15\CD\13745420 +/-\CC\1740 5\CD\13741022 mumol/mg\NN\1740 crea\NNS\1740 )\-RRB-\1740 than\IN\1740 in\IN\13603305 sgk1(-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 (\-LRB-\1740 35\CD\1740 +/-\CC\1740 5\CD\13741022 mumol/mg\NN\1740 crea\NNS\1740 )\-RRB-\1740 and\CC\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 a\DT\13649268 significantly\RB\1740 higher\JJR\1740 body\NN\19128 <e2>weight\NN\5009170 gain</e2>\NN\13576355 in\IN\13603305 sgk1(+/+\-RRB-\1740 )\-RRB-\1740 compared\VBN\644583 with\IN\1740 sgk1(-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 (\-LRB-\1740 +\CC\1740 6.6\CD\1740 +/-\CC\1740 0.7\CD\1740 vs.\CC\1740 +\CC\1740 4.1\CD\1740 +/-\CC\1740 0.8\CD\1740 g\NN\13717155 )\-RRB-\1740 .\.\1740
D014508_D009404 NONE During\IN\1740 the\DT\1740 course\NN\883297 of\IN\1740 <e2>nephrotic\JJ\1740 syndrome</e2>\NN\5870365 ,\,\1740 serum\NN\5397468 <e1>urea</e1>\NN\14727670 concentrations\NNS\4916342 increased\VBD\169651 significantly\RB\1740 faster\JJR\1740 in\IN\13603305 sgk1(-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 than\IN\1740 in\IN\13603305 sgk1(+/+\-RRB-\1740 )\-RRB-\1740 mice\NNS\2329401 leading\VBG\1752884 to\TO\1740 uremia\NN\14204950 and\CC\1740 a\DT\13649268 reduced\VBN\441445 median\JJ\1740 survival\NN\13961642 in\IN\13603305 sgk1(-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 (\-LRB-\1740 29\CD\13745420 vs.\CC\1740 40\CD\13745420 days\NNS\15140892 in\IN\13603305 sgk1(+/+\-RRB-\1740 )\-RRB-\1740 mice\NNS\2329401 )\-RRB-\1740 .\.\1740
D014508_D014511 NONE During\IN\1740 the\DT\1740 course\NN\883297 of\IN\1740 nephrotic\JJ\1740 syndrome\NN\5870365 ,\,\1740 serum\NN\5397468 <e1>urea</e1>\NN\14727670 concentrations\NNS\4916342 increased\VBD\169651 significantly\RB\1740 faster\JJR\1740 in\IN\13603305 sgk1(-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 than\IN\1740 in\IN\13603305 sgk1(+/+\-RRB-\1740 )\-RRB-\1740 mice\NNS\2329401 leading\VBG\1752884 to\TO\1740 <e2>uremia</e2>\NN\14204950 and\CC\1740 a\DT\13649268 reduced\VBN\441445 median\JJ\1740 survival\NN\13961642 in\IN\13603305 sgk1(-/-\NN\1740 )\-RRB-\1740 mice\NNS\2329401 (\-LRB-\1740 29\CD\13745420 vs.\CC\1740 40\CD\13745420 days\NNS\15140892 in\IN\13603305 sgk1(+/+\-RRB-\1740 )\-RRB-\1740 mice\NNS\2329401 )\-RRB-\1740 .\.\1740
1967484
D013469_D004421 CID <e1>Sulpiride-induced</e1>\JJ\1740 <e2>tardive\JJ\1740 dystonia</e2>\NN\1740 .\.\1740
D013469_D004421 CID We\PRP\1740 studied\VBD\630380 a\DT\13649268 37-year-old\JJ\1740 man\NN\9605289 who\WP\8299493 developed\VBD\1753788 persistent\JJ\1740 segmental\JJ\1740 <e2>dystonia</e2>\NN\1740 within\IN\1740 2\CD\13741022 months\NNS\15113229 after\IN\1740 starting\VBG\2009433 <e1>sulpiride</e1>\NN\1740 therapy\NN\657604 .\.\1740
D013469_D004421 CID We\PRP\1740 could\MD\1740 not\RB\1740 find\VB\2163746 any\DT\1740 previous\JJ\1740 reports\NNS\6470073 of\IN\1740 <e1>sulpiride-induced</e1>\JJ\1740 <e2>tardive\JJ\1740 dystonia</e2>\NN\1740 .\.\1740
D013469_D004409 NONE Although\IN\1740 initially\RB\1740 thought\VBN\670261 to\TO\1740 be\VB\836236 free\JJ\1740 of\IN\1740 extrapyramidal\JJ\1740 side\NN\8630039 effects\NNS\13245626 ,\,\1740 <e1>sulpiride-induced</e1>\JJ\1740 <e2>tardive\JJ\1740 dyskinesia</e2>\NN\14084880 and\CC\1740 parkinsonism\NN\14085708 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 occasionally\RB\1740 .\.\1740
D013469_D010302 NONE Although\IN\1740 initially\RB\1740 thought\VBN\670261 to\TO\1740 be\VB\836236 free\JJ\1740 of\IN\1740 extrapyramidal\JJ\1740 side\NN\8630039 effects\NNS\13245626 ,\,\1740 <e1>sulpiride-induced</e1>\JJ\1740 tardive\JJ\1740 dyskinesia\NN\14084880 and\CC\1740 <e2>parkinsonism</e2>\NN\14085708 have\VBP\2108377 been\VBN\836236 reported\VBN\831651 occasionally\RB\1740 .\.\1740
12707296
D001120_D006973 NONE <e1>L-arginine</e1>\NN\1740 transport\NN\3575240 in\IN\13603305 humans\NNS\31264 with\IN\1740 cortisol-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D001120_D006973 NONE A\DT\13649268 deficient\JJ\1740 <e1>L-arginine-nitric</e1>\JJ\1740 oxide\NN\14818238 system\NN\3575240 is\VBZ\836236 implicated\VBN\2677097 in\IN\13603305 cortisol-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D001120_D006973 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 cortisol-induced\JJ\1740 <e2>increases\NNS\13576355 in\IN\13603305 blood\NN\5397468 pressure</e2>\NN\11419404 are\VBP\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 abnormalities\NNS\14034177 in\IN\13603305 the\DT\1740 <e1>l-arginine</e1>\NN\1740 transport\NN\3575240 system\NN\3575240 .\.\1740
D006854_D006973 NONE L-arginine\NN\1740 transport\NN\3575240 in\IN\13603305 humans\NNS\31264 with\IN\1740 <e1>cortisol-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D006854_D006973 NONE A\DT\13649268 deficient\JJ\1740 L-arginine-nitric\JJ\1740 oxide\NN\14818238 system\NN\3575240 is\VBZ\836236 implicated\VBN\2677097 in\IN\13603305 <e1>cortisol-induced</e1>\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D006854_D006973 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 <e1>cortisol-induced</e1>\JJ\1740 <e2>increases\NNS\13576355 in\IN\13603305 blood\NN\5397468 pressure</e2>\NN\11419404 are\VBP\836236 not\RB\1740 associated\VBN\628491 with\IN\1740 abnormalities\NNS\14034177 in\IN\13603305 the\DT\1740 l-arginine\NN\1740 transport\NN\3575240 system\NN\3575240 .\.\1740
D009569_D006973 NONE A\DT\13649268 deficient\JJ\1740 <e1>L-arginine-nitric\JJ\1740 oxide</e1>\NN\14818238 system\NN\3575240 is\VBZ\836236 implicated\VBN\2677097 in\IN\13603305 cortisol-induced\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
2440413
D001556_D012640 NONE Differential\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>gamma-hexachlorocyclohexane</e1>\JJ\1740 (\-LRB-\1740 lindane\NN\14919948 )\-RRB-\1740 on\IN\1740 pharmacologically-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D001556_D012640 NONE Differential\JJ\1740 effects\NNS\13245626 of\IN\1740 gamma-hexachlorocyclohexane\JJ\1740 (\-LRB-\1740 <e1>lindane</e1>\NN\14919948 )\-RRB-\1740 on\IN\1740 pharmacologically-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 .\.\1740
D001556_D012640 NONE <e1>Gamma-hexachlorocyclohexane</e1>\JJ\1740 (\-LRB-\1740 gamma-HCH\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 active\JJ\1740 ingredient\NN\3081021 of\IN\1740 the\DT\1740 insecticide\NN\14980215 lindane\NN\14919948 ,\,\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 decrease\VB\169651 <e2>seizure</e2>\JJ\1740 threshold\NN\15265518 to\TO\1740 pentylenetrazol\JJ\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 and\CC\1740 conversely\RB\1740 increase\VB\169651 threshold\JJ\1740 to\TO\1740 PTZ-induced\JJ\1740 seizures\NNS\14081375 24\CD\13745420 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 (\-LRB-\1740 Vohland\NNP\1740 et\FW\1740 al.\FW\1740 1981\CD\1740 )\-RRB-\1740 .\.\1740
D001556_D012640 NONE <e1>Gamma-hexachlorocyclohexane</e1>\JJ\1740 (\-LRB-\1740 gamma-HCH\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 active\JJ\1740 ingredient\NN\3081021 of\IN\1740 the\DT\1740 insecticide\NN\14980215 lindane\NN\14919948 ,\,\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 decrease\VB\169651 seizure\JJ\1740 threshold\NN\15265518 to\TO\1740 pentylenetrazol\JJ\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 and\CC\1740 conversely\RB\1740 increase\VB\169651 threshold\JJ\1740 to\TO\1740 PTZ-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 24\CD\13745420 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 (\-LRB-\1740 Vohland\NNP\1740 et\FW\1740 al.\FW\1740 1981\CD\1740 )\-RRB-\1740 .\.\1740
D001556_D012640 NONE Gamma-hexachlorocyclohexane\JJ\1740 (\-LRB-\1740 <e1>gamma-HCH</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 active\JJ\1740 ingredient\NN\3081021 of\IN\1740 the\DT\1740 insecticide\NN\14980215 lindane\NN\14919948 ,\,\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 decrease\VB\169651 <e2>seizure</e2>\JJ\1740 threshold\NN\15265518 to\TO\1740 pentylenetrazol\JJ\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 and\CC\1740 conversely\RB\1740 increase\VB\169651 threshold\JJ\1740 to\TO\1740 PTZ-induced\JJ\1740 seizures\NNS\14081375 24\CD\13745420 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 (\-LRB-\1740 Vohland\NNP\1740 et\FW\1740 al.\FW\1740 1981\CD\1740 )\-RRB-\1740 .\.\1740
D001556_D012640 NONE Gamma-hexachlorocyclohexane\JJ\1740 (\-LRB-\1740 <e1>gamma-HCH</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 active\JJ\1740 ingredient\NN\3081021 of\IN\1740 the\DT\1740 insecticide\NN\14980215 lindane\NN\14919948 ,\,\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 decrease\VB\169651 seizure\JJ\1740 threshold\NN\15265518 to\TO\1740 pentylenetrazol\JJ\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 and\CC\1740 conversely\RB\1740 increase\VB\169651 threshold\JJ\1740 to\TO\1740 PTZ-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 24\CD\13745420 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 (\-LRB-\1740 Vohland\NNP\1740 et\FW\1740 al.\FW\1740 1981\CD\1740 )\-RRB-\1740 .\.\1740
D001556_D012640 NONE Gamma-hexachlorocyclohexane\JJ\1740 (\-LRB-\1740 gamma-HCH\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 active\JJ\1740 ingredient\NN\3081021 of\IN\1740 the\DT\1740 insecticide\NN\14980215 <e1>lindane</e1>\NN\14919948 ,\,\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 decrease\VB\169651 <e2>seizure</e2>\JJ\1740 threshold\NN\15265518 to\TO\1740 pentylenetrazol\JJ\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 and\CC\1740 conversely\RB\1740 increase\VB\169651 threshold\JJ\1740 to\TO\1740 PTZ-induced\JJ\1740 seizures\NNS\14081375 24\CD\13745420 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 (\-LRB-\1740 Vohland\NNP\1740 et\FW\1740 al.\FW\1740 1981\CD\1740 )\-RRB-\1740 .\.\1740
D001556_D012640 NONE Gamma-hexachlorocyclohexane\JJ\1740 (\-LRB-\1740 gamma-HCH\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 active\JJ\1740 ingredient\NN\3081021 of\IN\1740 the\DT\1740 insecticide\NN\14980215 <e1>lindane</e1>\NN\14919948 ,\,\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 decrease\VB\169651 seizure\JJ\1740 threshold\NN\15265518 to\TO\1740 pentylenetrazol\JJ\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 and\CC\1740 conversely\RB\1740 increase\VB\169651 threshold\JJ\1740 to\TO\1740 PTZ-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 24\CD\13745420 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 (\-LRB-\1740 Vohland\NNP\1740 et\FW\1740 al.\FW\1740 1981\CD\1740 )\-RRB-\1740 .\.\1740
D001556_D012640 NONE Gamma-hexachlorocyclohexane\JJ\1740 (\-LRB-\1740 gamma-HCH\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 active\JJ\1740 ingredient\NN\3081021 of\IN\1740 the\DT\1740 insecticide\NN\14980215 lindane\NN\14919948 ,\,\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 decrease\VB\169651 <e2>seizure</e2>\JJ\1740 threshold\NN\15265518 to\TO\1740 pentylenetrazol\JJ\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 <e1>gamma-HCH</e1>\NN\1740 and\CC\1740 conversely\RB\1740 increase\VB\169651 threshold\JJ\1740 to\TO\1740 PTZ-induced\JJ\1740 seizures\NNS\14081375 24\CD\13745420 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 (\-LRB-\1740 Vohland\NNP\1740 et\FW\1740 al.\FW\1740 1981\CD\1740 )\-RRB-\1740 .\.\1740
D001556_D012640 NONE Gamma-hexachlorocyclohexane\JJ\1740 (\-LRB-\1740 gamma-HCH\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 active\JJ\1740 ingredient\NN\3081021 of\IN\1740 the\DT\1740 insecticide\NN\14980215 lindane\NN\14919948 ,\,\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 decrease\VB\169651 seizure\JJ\1740 threshold\NN\15265518 to\TO\1740 pentylenetrazol\JJ\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 <e1>gamma-HCH</e1>\NN\1740 and\CC\1740 conversely\RB\1740 increase\VB\169651 threshold\JJ\1740 to\TO\1740 PTZ-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 24\CD\13745420 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 (\-LRB-\1740 Vohland\NNP\1740 et\FW\1740 al.\FW\1740 1981\CD\1740 )\-RRB-\1740 .\.\1740
D001556_D012640 NONE Gamma-hexachlorocyclohexane\JJ\1740 (\-LRB-\1740 gamma-HCH\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 active\JJ\1740 ingredient\NN\3081021 of\IN\1740 the\DT\1740 insecticide\NN\14980215 lindane\NN\14919948 ,\,\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 decrease\VB\169651 <e2>seizure</e2>\JJ\1740 threshold\NN\15265518 to\TO\1740 pentylenetrazol\JJ\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 and\CC\1740 conversely\RB\1740 increase\VB\169651 threshold\JJ\1740 to\TO\1740 PTZ-induced\JJ\1740 seizures\NNS\14081375 24\CD\13745420 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 <e1>gamma-HCH</e1>\NN\1740 (\-LRB-\1740 Vohland\NNP\1740 et\FW\1740 al.\FW\1740 1981\CD\1740 )\-RRB-\1740 .\.\1740
D001556_D012640 NONE Gamma-hexachlorocyclohexane\JJ\1740 (\-LRB-\1740 gamma-HCH\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 active\JJ\1740 ingredient\NN\3081021 of\IN\1740 the\DT\1740 insecticide\NN\14980215 lindane\NN\14919948 ,\,\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 decrease\VB\169651 seizure\JJ\1740 threshold\NN\15265518 to\TO\1740 pentylenetrazol\JJ\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 and\CC\1740 conversely\RB\1740 increase\VB\169651 threshold\JJ\1740 to\TO\1740 PTZ-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 24\CD\13745420 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 <e1>gamma-HCH</e1>\NN\1740 (\-LRB-\1740 Vohland\NNP\1740 et\FW\1740 al.\FW\1740 1981\CD\1740 )\-RRB-\1740 .\.\1740
D001556_D012640 NONE In\IN\13603305 this\DT\1740 study\NN\635850 ,\,\1740 the\DT\1740 severity\NN\5036394 of\IN\1740 response\NN\11410625 to\TO\1740 other\JJ\1740 <e2>seizure-inducing</e2>\JJ\1740 agents\NNS\7347 was\VBD\836236 tested\VBN\670261 in\IN\13603305 mice\NNS\2329401 1\CD\13741022 and\CC\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 intraperitoneal\JJ\1740 administration\NN\1133281 of\IN\1740 80\CD\13745420 mg/kg\NN\1740 <e1>gamma-HCH</e1>\NN\1740 .\.\1740
D001556_D012640 NONE One\CD\13741022 hour\NN\15154774 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>gamma-HCH</e1>\NN\1740 ,\,\1740 the\DT\1740 activity\NN\30358 of\IN\1740 <e2>seizure-inducing</e2>\JJ\1740 agents\NNS\7347 was\VBD\836236 increased\VBN\169651 ,\,\1740 regardless\RB\1740 of\IN\1740 their\PRP$\1740 mechanism\NN\13446390 ,\,\1740 while\IN\15122231 24\CD\13745420 h\NN\14622893 after\IN\1740 gamma-HCH\NN\1740 a\DT\13649268 differential\JJ\1740 response\NN\11410625 was\VBD\836236 observed\VBN\2163746 .\.\1740
D001556_D012640 NONE One\CD\13741022 hour\NN\15154774 after\IN\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 gamma-HCH\NN\1740 ,\,\1740 the\DT\1740 activity\NN\30358 of\IN\1740 <e2>seizure-inducing</e2>\JJ\1740 agents\NNS\7347 was\VBD\836236 increased\VBN\169651 ,\,\1740 regardless\RB\1740 of\IN\1740 their\PRP$\1740 mechanism\NN\13446390 ,\,\1740 while\IN\15122231 24\CD\13745420 h\NN\14622893 after\IN\1740 <e1>gamma-HCH</e1>\NN\1740 a\DT\13649268 differential\JJ\1740 response\NN\11410625 was\VBD\836236 observed\VBN\2163746 .\.\1740
D001556_D012640 NONE The\DT\1740 pharmacological\JJ\1740 challenge\NN\13927383 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 tolerance\NN\5032565 may\MD\15209706 occur\VB\2623529 to\TO\1740 <e2>seizure</e2>\VB\1740 activity\NN\30358 induced\VBN\1627355 by\IN\1740 PTZ\NN\1740 and\CC\1740 PTX\NN\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 <e1>gamma-HCH</e1>\NN\1740 ,\,\1740 since\IN\1740 the\DT\1740 response\NN\11410625 to\TO\1740 only\RB\1740 these\DT\1740 two\CD\13741022 seizure-inducing\JJ\1740 agents\NNS\7347 is\VBZ\836236 decreased\VBN\169651 .\.\1740
D001556_D012640 NONE The\DT\1740 pharmacological\JJ\1740 challenge\NN\13927383 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 tolerance\NN\5032565 may\MD\15209706 occur\VB\2623529 to\TO\1740 seizure\VB\1740 activity\NN\30358 induced\VBN\1627355 by\IN\1740 PTZ\NN\1740 and\CC\1740 PTX\NN\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 <e1>gamma-HCH</e1>\NN\1740 ,\,\1740 since\IN\1740 the\DT\1740 response\NN\11410625 to\TO\1740 only\RB\1740 these\DT\1740 two\CD\13741022 <e2>seizure-inducing</e2>\JJ\1740 agents\NNS\7347 is\VBZ\836236 decreased\VBN\169651 .\.\1740
D001556_D012640 NONE The\DT\1740 in\FW\13603305 vitro\FW\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 the\DT\1740 site\NN\8673395 responsible\JJ\1740 for\IN\1740 the\DT\1740 decrease\NN\7296428 in\IN\13603305 <e2>seizure</e2>\JJ\1740 activity\NN\30358 24\CD\13745420 h\NN\14622893 after\IN\1740 <e1>gamma-HCH</e1>\NN\1740 may\MD\15209706 be\VB\836236 the\DT\1740 GABA-A\NN\1740 receptor-linked\JJ\1740 chloride\NN\14818238 channel\NN\6251781 .\.\1740
D010433_D012640 CID Gamma-hexachlorocyclohexane\JJ\1740 (\-LRB-\1740 gamma-HCH\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 active\JJ\1740 ingredient\NN\3081021 of\IN\1740 the\DT\1740 insecticide\NN\14980215 lindane\NN\14919948 ,\,\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 decrease\VB\169651 <e2>seizure</e2>\JJ\1740 threshold\NN\15265518 to\TO\1740 pentylenetrazol\JJ\1740 (\-LRB-\1740 <e1>PTZ</e1>\NN\1740 )\-RRB-\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 and\CC\1740 conversely\RB\1740 increase\VB\169651 threshold\JJ\1740 to\TO\1740 PTZ-induced\JJ\1740 seizures\NNS\14081375 24\CD\13745420 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 (\-LRB-\1740 Vohland\NNP\1740 et\FW\1740 al.\FW\1740 1981\CD\1740 )\-RRB-\1740 .\.\1740
D010433_D012640 CID Gamma-hexachlorocyclohexane\JJ\1740 (\-LRB-\1740 gamma-HCH\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 active\JJ\1740 ingredient\NN\3081021 of\IN\1740 the\DT\1740 insecticide\NN\14980215 lindane\NN\14919948 ,\,\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 decrease\VB\169651 seizure\JJ\1740 threshold\NN\15265518 to\TO\1740 pentylenetrazol\JJ\1740 (\-LRB-\1740 <e1>PTZ</e1>\NN\1740 )\-RRB-\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 and\CC\1740 conversely\RB\1740 increase\VB\169651 threshold\JJ\1740 to\TO\1740 PTZ-induced\JJ\1740 <e2>seizures</e2>\NNS\14081375 24\CD\13745420 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 (\-LRB-\1740 Vohland\NNP\1740 et\FW\1740 al.\FW\1740 1981\CD\1740 )\-RRB-\1740 .\.\1740
D010433_D012640 CID Gamma-hexachlorocyclohexane\JJ\1740 (\-LRB-\1740 gamma-HCH\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 active\JJ\1740 ingredient\NN\3081021 of\IN\1740 the\DT\1740 insecticide\NN\14980215 lindane\NN\14919948 ,\,\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 decrease\VB\169651 <e2>seizure</e2>\JJ\1740 threshold\NN\15265518 to\TO\1740 pentylenetrazol\JJ\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 and\CC\1740 conversely\RB\1740 increase\VB\169651 threshold\JJ\1740 to\TO\1740 <e1>PTZ-induced</e1>\JJ\1740 seizures\NNS\14081375 24\CD\13745420 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 (\-LRB-\1740 Vohland\NNP\1740 et\FW\1740 al.\FW\1740 1981\CD\1740 )\-RRB-\1740 .\.\1740
D010433_D012640 CID Gamma-hexachlorocyclohexane\JJ\1740 (\-LRB-\1740 gamma-HCH\NN\1740 )\-RRB-\1740 ,\,\1740 the\DT\1740 active\JJ\1740 ingredient\NN\3081021 of\IN\1740 the\DT\1740 insecticide\NN\14980215 lindane\NN\14919948 ,\,\1740 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 decrease\VB\169651 seizure\JJ\1740 threshold\NN\15265518 to\TO\1740 pentylenetrazol\JJ\1740 (\-LRB-\1740 PTZ\NN\1740 )\-RRB-\1740 3\CD\13741022 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 and\CC\1740 conversely\RB\1740 increase\VB\169651 threshold\JJ\1740 to\TO\1740 <e1>PTZ-induced</e1>\JJ\1740 <e2>seizures</e2>\NNS\14081375 24\CD\13745420 h\NN\14622893 after\IN\1740 exposure\NN\5042871 to\TO\1740 gamma-HCH\NN\1740 (\-LRB-\1740 Vohland\NNP\1740 et\FW\1740 al.\FW\1740 1981\CD\1740 )\-RRB-\1740 .\.\1740
D010433_D012640 CID <e2>Seizure</e2>\NN\14081375 activity\NN\30358 due\IN\5174653 to\TO\1740 <e1>PTZ</e1>\NN\1740 and\CC\1740 picrotoxin\NN\1740 (\-LRB-\1740 PTX\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 decreased\VBN\169651 ;\:\1740 however\RB\1740 ,\,\1740 seizure\JJ\1740 activity\NN\30358 due\JJ\1740 to\TO\1740 3-mercaptopropionic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 bicuculline\NN\1740 (\-LRB-\1740 BCC\NN\1740 )\-RRB-\1740 ,\,\1740 methyl\NN\14617189 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 DMCM\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 strychnine\NN\14712692 (\-LRB-\1740 STR\NN\1740 )\-RRB-\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 control\NN\5190804 .\.\1740
D010433_D012640 CID Seizure\NN\14081375 activity\NN\30358 due\IN\5174653 to\TO\1740 <e1>PTZ</e1>\NN\1740 and\CC\1740 picrotoxin\NN\1740 (\-LRB-\1740 PTX\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 decreased\VBN\169651 ;\:\1740 however\RB\1740 ,\,\1740 <e2>seizure</e2>\JJ\1740 activity\NN\30358 due\JJ\1740 to\TO\1740 3-mercaptopropionic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 bicuculline\NN\1740 (\-LRB-\1740 BCC\NN\1740 )\-RRB-\1740 ,\,\1740 methyl\NN\14617189 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 DMCM\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 strychnine\NN\14712692 (\-LRB-\1740 STR\NN\1740 )\-RRB-\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 control\NN\5190804 .\.\1740
D010433_D012640 CID The\DT\1740 pharmacological\JJ\1740 challenge\NN\13927383 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 tolerance\NN\5032565 may\MD\15209706 occur\VB\2623529 to\TO\1740 <e2>seizure</e2>\VB\1740 activity\NN\30358 induced\VBN\1627355 by\IN\1740 <e1>PTZ</e1>\NN\1740 and\CC\1740 PTX\NN\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 gamma-HCH\NN\1740 ,\,\1740 since\IN\1740 the\DT\1740 response\NN\11410625 to\TO\1740 only\RB\1740 these\DT\1740 two\CD\13741022 seizure-inducing\JJ\1740 agents\NNS\7347 is\VBZ\836236 decreased\VBN\169651 .\.\1740
D010433_D012640 CID The\DT\1740 pharmacological\JJ\1740 challenge\NN\13927383 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 tolerance\NN\5032565 may\MD\15209706 occur\VB\2623529 to\TO\1740 seizure\VB\1740 activity\NN\30358 induced\VBN\1627355 by\IN\1740 <e1>PTZ</e1>\NN\1740 and\CC\1740 PTX\NN\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 gamma-HCH\NN\1740 ,\,\1740 since\IN\1740 the\DT\1740 response\NN\11410625 to\TO\1740 only\RB\1740 these\DT\1740 two\CD\13741022 <e2>seizure-inducing</e2>\JJ\1740 agents\NNS\7347 is\VBZ\836236 decreased\VBN\169651 .\.\1740
D010852_D012640 CID <e2>Seizure</e2>\NN\14081375 activity\NN\30358 due\IN\5174653 to\TO\1740 PTZ\NN\1740 and\CC\1740 <e1>picrotoxin</e1>\NN\1740 (\-LRB-\1740 PTX\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 decreased\VBN\169651 ;\:\1740 however\RB\1740 ,\,\1740 seizure\JJ\1740 activity\NN\30358 due\JJ\1740 to\TO\1740 3-mercaptopropionic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 bicuculline\NN\1740 (\-LRB-\1740 BCC\NN\1740 )\-RRB-\1740 ,\,\1740 methyl\NN\14617189 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 DMCM\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 strychnine\NN\14712692 (\-LRB-\1740 STR\NN\1740 )\-RRB-\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 control\NN\5190804 .\.\1740
D010852_D012640 CID Seizure\NN\14081375 activity\NN\30358 due\IN\5174653 to\TO\1740 PTZ\NN\1740 and\CC\1740 <e1>picrotoxin</e1>\NN\1740 (\-LRB-\1740 PTX\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 decreased\VBN\169651 ;\:\1740 however\RB\1740 ,\,\1740 <e2>seizure</e2>\JJ\1740 activity\NN\30358 due\JJ\1740 to\TO\1740 3-mercaptopropionic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 bicuculline\NN\1740 (\-LRB-\1740 BCC\NN\1740 )\-RRB-\1740 ,\,\1740 methyl\NN\14617189 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 DMCM\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 strychnine\NN\14712692 (\-LRB-\1740 STR\NN\1740 )\-RRB-\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 control\NN\5190804 .\.\1740
D010852_D012640 CID <e2>Seizure</e2>\NN\14081375 activity\NN\30358 due\IN\5174653 to\TO\1740 PTZ\NN\1740 and\CC\1740 picrotoxin\NN\1740 (\-LRB-\1740 <e1>PTX</e1>\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 decreased\VBN\169651 ;\:\1740 however\RB\1740 ,\,\1740 seizure\JJ\1740 activity\NN\30358 due\JJ\1740 to\TO\1740 3-mercaptopropionic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 bicuculline\NN\1740 (\-LRB-\1740 BCC\NN\1740 )\-RRB-\1740 ,\,\1740 methyl\NN\14617189 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 DMCM\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 strychnine\NN\14712692 (\-LRB-\1740 STR\NN\1740 )\-RRB-\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 control\NN\5190804 .\.\1740
D010852_D012640 CID Seizure\NN\14081375 activity\NN\30358 due\IN\5174653 to\TO\1740 PTZ\NN\1740 and\CC\1740 picrotoxin\NN\1740 (\-LRB-\1740 <e1>PTX</e1>\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 decreased\VBN\169651 ;\:\1740 however\RB\1740 ,\,\1740 <e2>seizure</e2>\JJ\1740 activity\NN\30358 due\JJ\1740 to\TO\1740 3-mercaptopropionic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 bicuculline\NN\1740 (\-LRB-\1740 BCC\NN\1740 )\-RRB-\1740 ,\,\1740 methyl\NN\14617189 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 DMCM\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 strychnine\NN\14712692 (\-LRB-\1740 STR\NN\1740 )\-RRB-\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 control\NN\5190804 .\.\1740
D010852_D012640 CID The\DT\1740 pharmacological\JJ\1740 challenge\NN\13927383 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 tolerance\NN\5032565 may\MD\15209706 occur\VB\2623529 to\TO\1740 <e2>seizure</e2>\VB\1740 activity\NN\30358 induced\VBN\1627355 by\IN\1740 PTZ\NN\1740 and\CC\1740 <e1>PTX</e1>\NN\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 gamma-HCH\NN\1740 ,\,\1740 since\IN\1740 the\DT\1740 response\NN\11410625 to\TO\1740 only\RB\1740 these\DT\1740 two\CD\13741022 seizure-inducing\JJ\1740 agents\NNS\7347 is\VBZ\836236 decreased\VBN\169651 .\.\1740
D010852_D012640 CID The\DT\1740 pharmacological\JJ\1740 challenge\NN\13927383 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 tolerance\NN\5032565 may\MD\15209706 occur\VB\2623529 to\TO\1740 seizure\VB\1740 activity\NN\30358 induced\VBN\1627355 by\IN\1740 PTZ\NN\1740 and\CC\1740 <e1>PTX</e1>\NN\1740 24\CD\13745420 h\NN\14622893 after\IN\1740 gamma-HCH\NN\1740 ,\,\1740 since\IN\1740 the\DT\1740 response\NN\11410625 to\TO\1740 only\RB\1740 these\DT\1740 two\CD\13741022 <e2>seizure-inducing</e2>\JJ\1740 agents\NNS\7347 is\VBZ\836236 decreased\VBN\169651 .\.\1740
D015097_D012640 CID <e2>Seizure</e2>\NN\14081375 activity\NN\30358 due\IN\5174653 to\TO\1740 PTZ\NN\1740 and\CC\1740 picrotoxin\NN\1740 (\-LRB-\1740 PTX\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 decreased\VBN\169651 ;\:\1740 however\RB\1740 ,\,\1740 seizure\JJ\1740 activity\NN\30358 due\JJ\1740 to\TO\1740 <e1>3-mercaptopropionic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 bicuculline\NN\1740 (\-LRB-\1740 BCC\NN\1740 )\-RRB-\1740 ,\,\1740 methyl\NN\14617189 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 DMCM\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 strychnine\NN\14712692 (\-LRB-\1740 STR\NN\1740 )\-RRB-\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 control\NN\5190804 .\.\1740
D015097_D012640 CID Seizure\NN\14081375 activity\NN\30358 due\IN\5174653 to\TO\1740 PTZ\NN\1740 and\CC\1740 picrotoxin\NN\1740 (\-LRB-\1740 PTX\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 decreased\VBN\169651 ;\:\1740 however\RB\1740 ,\,\1740 <e2>seizure</e2>\JJ\1740 activity\NN\30358 due\JJ\1740 to\TO\1740 <e1>3-mercaptopropionic\JJ\1740 acid</e1>\NN\14818238 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 bicuculline\NN\1740 (\-LRB-\1740 BCC\NN\1740 )\-RRB-\1740 ,\,\1740 methyl\NN\14617189 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 DMCM\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 strychnine\NN\14712692 (\-LRB-\1740 STR\NN\1740 )\-RRB-\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 control\NN\5190804 .\.\1740
D015097_D012640 CID <e2>Seizure</e2>\NN\14081375 activity\NN\30358 due\IN\5174653 to\TO\1740 PTZ\NN\1740 and\CC\1740 picrotoxin\NN\1740 (\-LRB-\1740 PTX\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 decreased\VBN\169651 ;\:\1740 however\RB\1740 ,\,\1740 seizure\JJ\1740 activity\NN\30358 due\JJ\1740 to\TO\1740 3-mercaptopropionic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>MPA</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 bicuculline\NN\1740 (\-LRB-\1740 BCC\NN\1740 )\-RRB-\1740 ,\,\1740 methyl\NN\14617189 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 DMCM\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 strychnine\NN\14712692 (\-LRB-\1740 STR\NN\1740 )\-RRB-\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 control\NN\5190804 .\.\1740
D015097_D012640 CID Seizure\NN\14081375 activity\NN\30358 due\IN\5174653 to\TO\1740 PTZ\NN\1740 and\CC\1740 picrotoxin\NN\1740 (\-LRB-\1740 PTX\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 decreased\VBN\169651 ;\:\1740 however\RB\1740 ,\,\1740 <e2>seizure</e2>\JJ\1740 activity\NN\30358 due\JJ\1740 to\TO\1740 3-mercaptopropionic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 <e1>MPA</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 bicuculline\NN\1740 (\-LRB-\1740 BCC\NN\1740 )\-RRB-\1740 ,\,\1740 methyl\NN\14617189 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 DMCM\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 strychnine\NN\14712692 (\-LRB-\1740 STR\NN\1740 )\-RRB-\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 control\NN\5190804 .\.\1740
D001640_D012640 CID <e2>Seizure</e2>\NN\14081375 activity\NN\30358 due\IN\5174653 to\TO\1740 PTZ\NN\1740 and\CC\1740 picrotoxin\NN\1740 (\-LRB-\1740 PTX\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 decreased\VBN\169651 ;\:\1740 however\RB\1740 ,\,\1740 seizure\JJ\1740 activity\NN\30358 due\JJ\1740 to\TO\1740 3-mercaptopropionic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 <e1>bicuculline</e1>\NN\1740 (\-LRB-\1740 BCC\NN\1740 )\-RRB-\1740 ,\,\1740 methyl\NN\14617189 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 DMCM\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 strychnine\NN\14712692 (\-LRB-\1740 STR\NN\1740 )\-RRB-\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 control\NN\5190804 .\.\1740
D001640_D012640 CID Seizure\NN\14081375 activity\NN\30358 due\IN\5174653 to\TO\1740 PTZ\NN\1740 and\CC\1740 picrotoxin\NN\1740 (\-LRB-\1740 PTX\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 decreased\VBN\169651 ;\:\1740 however\RB\1740 ,\,\1740 <e2>seizure</e2>\JJ\1740 activity\NN\30358 due\JJ\1740 to\TO\1740 3-mercaptopropionic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 <e1>bicuculline</e1>\NN\1740 (\-LRB-\1740 BCC\NN\1740 )\-RRB-\1740 ,\,\1740 methyl\NN\14617189 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 DMCM\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 strychnine\NN\14712692 (\-LRB-\1740 STR\NN\1740 )\-RRB-\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 control\NN\5190804 .\.\1740
D001640_D012640 CID <e2>Seizure</e2>\NN\14081375 activity\NN\30358 due\IN\5174653 to\TO\1740 PTZ\NN\1740 and\CC\1740 picrotoxin\NN\1740 (\-LRB-\1740 PTX\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 decreased\VBN\169651 ;\:\1740 however\RB\1740 ,\,\1740 seizure\JJ\1740 activity\NN\30358 due\JJ\1740 to\TO\1740 3-mercaptopropionic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 bicuculline\NN\1740 (\-LRB-\1740 <e1>BCC</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 methyl\NN\14617189 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 DMCM\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 strychnine\NN\14712692 (\-LRB-\1740 STR\NN\1740 )\-RRB-\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 control\NN\5190804 .\.\1740
D001640_D012640 CID Seizure\NN\14081375 activity\NN\30358 due\IN\5174653 to\TO\1740 PTZ\NN\1740 and\CC\1740 picrotoxin\NN\1740 (\-LRB-\1740 PTX\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 decreased\VBN\169651 ;\:\1740 however\RB\1740 ,\,\1740 <e2>seizure</e2>\JJ\1740 activity\NN\30358 due\JJ\1740 to\TO\1740 3-mercaptopropionic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 bicuculline\NN\1740 (\-LRB-\1740 <e1>BCC</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 methyl\NN\14617189 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 DMCM\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 strychnine\NN\14712692 (\-LRB-\1740 STR\NN\1740 )\-RRB-\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 control\NN\5190804 .\.\1740
C034818_D012640 CID <e2>Seizure</e2>\NN\14081375 activity\NN\30358 due\IN\5174653 to\TO\1740 PTZ\NN\1740 and\CC\1740 picrotoxin\NN\1740 (\-LRB-\1740 PTX\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 decreased\VBN\169651 ;\:\1740 however\RB\1740 ,\,\1740 seizure\JJ\1740 activity\NN\30358 due\JJ\1740 to\TO\1740 3-mercaptopropionic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 bicuculline\NN\1740 (\-LRB-\1740 BCC\NN\1740 )\-RRB-\1740 ,\,\1740 <e1>methyl\NN\14617189 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate</e1>\NN\1740 (\-LRB-\1740 DMCM\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 strychnine\NN\14712692 (\-LRB-\1740 STR\NN\1740 )\-RRB-\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 control\NN\5190804 .\.\1740
C034818_D012640 CID Seizure\NN\14081375 activity\NN\30358 due\IN\5174653 to\TO\1740 PTZ\NN\1740 and\CC\1740 picrotoxin\NN\1740 (\-LRB-\1740 PTX\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 decreased\VBN\169651 ;\:\1740 however\RB\1740 ,\,\1740 <e2>seizure</e2>\JJ\1740 activity\NN\30358 due\JJ\1740 to\TO\1740 3-mercaptopropionic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 bicuculline\NN\1740 (\-LRB-\1740 BCC\NN\1740 )\-RRB-\1740 ,\,\1740 <e1>methyl\NN\14617189 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate</e1>\NN\1740 (\-LRB-\1740 DMCM\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 strychnine\NN\14712692 (\-LRB-\1740 STR\NN\1740 )\-RRB-\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 control\NN\5190804 .\.\1740
C034818_D012640 CID <e2>Seizure</e2>\NN\14081375 activity\NN\30358 due\IN\5174653 to\TO\1740 PTZ\NN\1740 and\CC\1740 picrotoxin\NN\1740 (\-LRB-\1740 PTX\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 decreased\VBN\169651 ;\:\1740 however\RB\1740 ,\,\1740 seizure\JJ\1740 activity\NN\30358 due\JJ\1740 to\TO\1740 3-mercaptopropionic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 bicuculline\NN\1740 (\-LRB-\1740 BCC\NN\1740 )\-RRB-\1740 ,\,\1740 methyl\NN\14617189 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 <e1>DMCM</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 strychnine\NN\14712692 (\-LRB-\1740 STR\NN\1740 )\-RRB-\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 control\NN\5190804 .\.\1740
C034818_D012640 CID Seizure\NN\14081375 activity\NN\30358 due\IN\5174653 to\TO\1740 PTZ\NN\1740 and\CC\1740 picrotoxin\NN\1740 (\-LRB-\1740 PTX\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 decreased\VBN\169651 ;\:\1740 however\RB\1740 ,\,\1740 <e2>seizure</e2>\JJ\1740 activity\NN\30358 due\JJ\1740 to\TO\1740 3-mercaptopropionic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 bicuculline\NN\1740 (\-LRB-\1740 BCC\NN\1740 )\-RRB-\1740 ,\,\1740 methyl\NN\14617189 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 <e1>DMCM</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 strychnine\NN\14712692 (\-LRB-\1740 STR\NN\1740 )\-RRB-\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 control\NN\5190804 .\.\1740
D013331_D012640 CID <e2>Seizure</e2>\NN\14081375 activity\NN\30358 due\IN\5174653 to\TO\1740 PTZ\NN\1740 and\CC\1740 picrotoxin\NN\1740 (\-LRB-\1740 PTX\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 decreased\VBN\169651 ;\:\1740 however\RB\1740 ,\,\1740 seizure\JJ\1740 activity\NN\30358 due\JJ\1740 to\TO\1740 3-mercaptopropionic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 bicuculline\NN\1740 (\-LRB-\1740 BCC\NN\1740 )\-RRB-\1740 ,\,\1740 methyl\NN\14617189 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 DMCM\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 <e1>strychnine</e1>\NN\14712692 (\-LRB-\1740 STR\NN\1740 )\-RRB-\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 control\NN\5190804 .\.\1740
D013331_D012640 CID Seizure\NN\14081375 activity\NN\30358 due\IN\5174653 to\TO\1740 PTZ\NN\1740 and\CC\1740 picrotoxin\NN\1740 (\-LRB-\1740 PTX\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 decreased\VBN\169651 ;\:\1740 however\RB\1740 ,\,\1740 <e2>seizure</e2>\JJ\1740 activity\NN\30358 due\JJ\1740 to\TO\1740 3-mercaptopropionic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 bicuculline\NN\1740 (\-LRB-\1740 BCC\NN\1740 )\-RRB-\1740 ,\,\1740 methyl\NN\14617189 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 DMCM\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 <e1>strychnine</e1>\NN\14712692 (\-LRB-\1740 STR\NN\1740 )\-RRB-\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 control\NN\5190804 .\.\1740
D013331_D012640 CID <e2>Seizure</e2>\NN\14081375 activity\NN\30358 due\IN\5174653 to\TO\1740 PTZ\NN\1740 and\CC\1740 picrotoxin\NN\1740 (\-LRB-\1740 PTX\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 decreased\VBN\169651 ;\:\1740 however\RB\1740 ,\,\1740 seizure\JJ\1740 activity\NN\30358 due\JJ\1740 to\TO\1740 3-mercaptopropionic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 bicuculline\NN\1740 (\-LRB-\1740 BCC\NN\1740 )\-RRB-\1740 ,\,\1740 methyl\NN\14617189 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 DMCM\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 strychnine\NN\14712692 (\-LRB-\1740 <e1>STR</e1>\NN\1740 )\-RRB-\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 control\NN\5190804 .\.\1740
D013331_D012640 CID Seizure\NN\14081375 activity\NN\30358 due\IN\5174653 to\TO\1740 PTZ\NN\1740 and\CC\1740 picrotoxin\NN\1740 (\-LRB-\1740 PTX\NN\1740 )\-RRB-\1740 was\VBD\836236 significantly\RB\1740 decreased\VBN\169651 ;\:\1740 however\RB\1740 ,\,\1740 <e2>seizure</e2>\JJ\1740 activity\NN\30358 due\JJ\1740 to\TO\1740 3-mercaptopropionic\JJ\1740 acid\NN\14818238 (\-LRB-\1740 MPA\NN\1740 )\-RRB-\1740 ,\,\1740 bicuculline\NN\1740 (\-LRB-\1740 BCC\NN\1740 )\-RRB-\1740 ,\,\1740 methyl\NN\14617189 6,7-dimethoxy-4-ethyl-B-carboline-3-carboxylate\NN\1740 (\-LRB-\1740 DMCM\NN\1740 )\-RRB-\1740 ,\,\1740 or\CC\3541091 strychnine\NN\14712692 (\-LRB-\1740 <e1>STR</e1>\NN\1740 )\-RRB-\1740 was\VBD\836236 not\RB\1740 different\JJ\1740 from\IN\1740 control\NN\5190804 .\.\1740
D005680_D012640 NONE The\DT\1740 in\FW\13603305 vitro\FW\1740 data\NNS\7951464 suggest\VBP\1010118 that\IN\1740 the\DT\1740 site\NN\8673395 responsible\JJ\1740 for\IN\1740 the\DT\1740 decrease\NN\7296428 in\IN\13603305 <e2>seizure</e2>\JJ\1740 activity\NN\30358 24\CD\13745420 h\NN\14622893 after\IN\1740 gamma-HCH\NN\1740 may\MD\15209706 be\VB\836236 the\DT\1740 <e1>GABA-A</e1>\NN\1740 receptor-linked\JJ\1740 chloride\NN\14818238 channel\NN\6251781 .\.\1740
1527456
D008012_D014012 NONE Treatment\NN\654885 of\IN\1740 <e2>tinnitus</e2>\NN\14299637 by\IN\1740 intratympanic\JJ\1740 instillation\NN\320852 of\IN\1740 <e1>lignocaine</e1>\NN\1740 (\-LRB-\1740 lidocaine\NN\3681148 )\-RRB-\1740 2\CD\13741022 per\IN\1740 cent\NN\13662703 through\IN\1740 ventilation\NN\248977 tubes\NNS\3089014 .\.\1740
D008012_D014012 NONE Treatment\NN\654885 of\IN\1740 <e2>tinnitus</e2>\NN\14299637 by\IN\1740 intratympanic\JJ\1740 instillation\NN\320852 of\IN\1740 lignocaine\NN\1740 (\-LRB-\1740 <e1>lidocaine</e1>\NN\3681148 )\-RRB-\1740 2\CD\13741022 per\IN\1740 cent\NN\13662703 through\IN\1740 ventilation\NN\248977 tubes\NNS\3089014 .\.\1740
D008012_D014012 NONE This\DT\1740 paper\NN\14580897 presents\VBZ\2137132 the\DT\1740 results\NNS\34213 of\IN\1740 treating\VBG\2376958 <e2>IST</e2>\NN\1740 by\IN\1740 intratympanic\JJ\1740 instillation\NN\320852 of\IN\1740 <e1>lignocaine</e1>\NN\1740 (\-LRB-\1740 lidocaine\NN\3681148 )\-RRB-\1740 2\CD\13741022 per\IN\1740 cent\NN\13662703 through\IN\1740 a\DT\13649268 grommet\NN\3323703 ,\,\1740 for\IN\1740 five\CD\13741022 weekly\JJ\1740 courses\NNS\883297 .\.\1740
D008012_D014012 NONE This\DT\1740 paper\NN\14580897 presents\VBZ\2137132 the\DT\1740 results\NNS\34213 of\IN\1740 treating\VBG\2376958 <e2>IST</e2>\NN\1740 by\IN\1740 intratympanic\JJ\1740 instillation\NN\320852 of\IN\1740 lignocaine\NN\1740 (\-LRB-\1740 <e1>lidocaine</e1>\NN\3681148 )\-RRB-\1740 2\CD\13741022 per\IN\1740 cent\NN\13662703 through\IN\1740 a\DT\13649268 grommet\NN\3323703 ,\,\1740 for\IN\1740 five\CD\13741022 weekly\JJ\1740 courses\NNS\883297 .\.\1740
2515254
D005996_D008881 CID Twenty\CD\13745420 common\JJ\1740 <e2>migraine</e2>\NN\14326607 patients\NNS\9898892 received\VBD\2210855 a\DT\13649268 one\CD\13741022 sided\VBD\733632 frontotemporal\JJ\1740 application\NN\947128 of\IN\1740 <e1>nitroglycerin</e1>\NN\15015501 (\-LRB-\1740 10\CD\13745420 patients\NNS\9898892 )\-RRB-\1740 or\CC\3541091 placebo\NN\3740161 ointment\NN\4074482 (\-LRB-\1740 10\CD\13745420 patients\NNS\9898892 )\-RRB-\1740 in\IN\13603305 a\DT\13649268 double\JJ\1740 blind\NN\7942152 study\NN\635850 .\.\1740
D005996_D008881 CID Early\JJ\1740 onset\NN\7325190 <e2>migraine</e2>\NN\14326607 attacks\NNS\955060 were\VBD\836236 induced\VBN\1627355 by\IN\1740 <e1>nitroglycerin</e1>\NN\15015501 in\IN\13603305 seven\CD\13741022 out\IN\66636 of\IN\1740 10\CD\13745420 patients\NNS\9898892 versus\CC\1740 no\DT\7204911 patient\NN\9898892 in\IN\13603305 the\DT\1740 placebo\NN\3740161 group\NN\2137 .\.\1740
D005996_D008881 CID Subsequently\RB\1740 20\CD\13745420 <e2>migraine</e2>\NN\14326607 patients\NNS\9898892 ,\,\1740 who\WP\8299493 developed\VBD\1753788 an\DT\6697703 early\JJ\1740 onset\NN\7325190 attack\NN\955060 with\IN\1740 frontotemporal\JJ\1740 <e1>nitroglycerin</e1>\NN\15015501 ,\,\1740 received\VBD\2210855 the\DT\1740 drug\NN\14778436 in\IN\13603305 a\DT\13649268 second\JJ\1740 induction\NN\7450842 test\NN\5798043 at\IN\14622893 other\JJ\1740 body\NN\19128 areas\NNS\8630985 .\.\1740
D005996_D008881 CID Thus\RB\1740 the\DT\1740 <e2>migraine-inducing</e2>\JJ\1740 effect\NN\34213 of\IN\1740 <e1>nitroglycerin</e1>\NN\15015501 seems\VBZ\2604760 to\TO\1740 depend\VB\2604760 on\IN\1740 direct\JJ\1740 stimulation\NN\242808 of\IN\1740 the\DT\1740 habitual\JJ\1740 site\NN\8673395 of\IN\1740 pain\NN\14299637 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 the\DT\1740 frontotemporal\JJ\1740 region\NN\27167 is\VBZ\836236 of\IN\1740 crucial\JJ\1740 importance\NN\5138488 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 a\DT\13649268 migraine\NN\14326607 crisis\NN\14411243 .\.\1740
D005996_D008881 CID Thus\RB\1740 the\DT\1740 migraine-inducing\JJ\1740 effect\NN\34213 of\IN\1740 <e1>nitroglycerin</e1>\NN\15015501 seems\VBZ\2604760 to\TO\1740 depend\VB\2604760 on\IN\1740 direct\JJ\1740 stimulation\NN\242808 of\IN\1740 the\DT\1740 habitual\JJ\1740 site\NN\8673395 of\IN\1740 pain\NN\14299637 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 the\DT\1740 frontotemporal\JJ\1740 region\NN\27167 is\VBZ\836236 of\IN\1740 crucial\JJ\1740 importance\NN\5138488 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 a\DT\13649268 <e2>migraine</e2>\NN\14326607 crisis\NN\14411243 .\.\1740
D005996_D010146 NONE Thus\RB\1740 the\DT\1740 migraine-inducing\JJ\1740 effect\NN\34213 of\IN\1740 <e1>nitroglycerin</e1>\NN\15015501 seems\VBZ\2604760 to\TO\1740 depend\VB\2604760 on\IN\1740 direct\JJ\1740 stimulation\NN\242808 of\IN\1740 the\DT\1740 habitual\JJ\1740 site\NN\8673395 of\IN\1740 <e2>pain</e2>\NN\14299637 ,\,\1740 suggesting\VBG\1010118 that\IN\1740 the\DT\1740 frontotemporal\JJ\1740 region\NN\27167 is\VBZ\836236 of\IN\1740 crucial\JJ\1740 importance\NN\5138488 in\IN\13603305 the\DT\1740 development\NN\248977 of\IN\1740 a\DT\13649268 migraine\NN\14326607 crisis\NN\14411243 .\.\1740
20080983
C048833_D012893 NONE OBJECTIVE\NN\5980875 :\:\1740 The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 the\DT\1740 effect\NN\34213 of\IN\1740 morning-dosed\JJ\1740 <e1>modafinil</e1>\NN\1740 on\IN\1740 sleep\NN\14034177 and\CC\1740 <e2>daytime\NN\15113229 sleepiness</e2>\NN\14015731 in\IN\13603305 chronic\JJ\1740 cocaine\NN\3492717 users\NNS\7846 .\.\1740
C048833_D012893 NONE <e1>Modafinil</e1>\NNP\1740 was\VBD\836236 associated\VBN\628491 with\IN\1740 increased\VBN\169651 daytime\NN\15113229 sleep\NN\14034177 latency\NN\15269513 ,\,\1740 as\IN\14622893 measured\VBN\697589 by\IN\1740 the\DT\1740 Multiple\JJ\1740 Sleep\NNP\14034177 Latency\NNP\15269513 Test\NNP\5798043 ,\,\1740 and\CC\1740 a\DT\13649268 nearly\RB\1740 significant\JJ\1740 decrease\NN\7296428 in\IN\13603305 subjective\JJ\1740 <e2>daytime\NN\15113229 sleepiness</e2>\NN\14015731 .\.\1740
C048833_D012893 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Morning-dosed\JJ\1740 <e1>modafinil</e1>\NN\1740 promotes\VBZ\2556126 nocturnal\JJ\1740 sleep\NN\14034177 ,\,\1740 normalizes\NNS\1740 sleep\NN\14034177 architecture\NN\2913152 ,\,\1740 and\CC\1740 decreases\VBZ\169651 <e2>daytime\NN\15113229 sleepiness</e2>\NN\14015731 in\IN\13603305 abstinent\JJ\1740 cocaine\NN\3492717 users\NNS\7846 .\.\1740
D003042_D012893 CID OBJECTIVE\NN\5980875 :\:\1740 The\DT\1740 purpose\NN\5980875 of\IN\1740 the\DT\1740 present\JJ\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 the\DT\1740 effect\NN\34213 of\IN\1740 morning-dosed\JJ\1740 modafinil\NN\1740 on\IN\1740 sleep\NN\14034177 and\CC\1740 <e2>daytime\NN\15113229 sleepiness</e2>\NN\14015731 in\IN\13603305 chronic\JJ\1740 <e1>cocaine</e1>\NN\3492717 users\NNS\7846 .\.\1740
D003042_D012893 CID CONCLUSIONS\NNS\5837957 :\:\1740 Morning-dosed\JJ\1740 modafinil\NN\1740 promotes\VBZ\2556126 nocturnal\JJ\1740 sleep\NN\14034177 ,\,\1740 normalizes\NNS\1740 sleep\NN\14034177 architecture\NN\2913152 ,\,\1740 and\CC\1740 decreases\VBZ\169651 <e2>daytime\NN\15113229 sleepiness</e2>\NN\14015731 in\IN\13603305 abstinent\JJ\1740 <e1>cocaine</e1>\NN\3492717 users\NNS\7846 .\.\1740
3125768
D015760_D009127 CID Intracranial\JJ\1740 pressure\NN\11419404 increases\VBZ\169651 during\IN\1740 <e1>alfentanil-induced</e1>\JJ\1740 <e2>rigidity</e2>\NN\5023233 .\.\1740
D015760_D009127 CID Intracranial\JJ\1740 pressure\NN\11419404 (\-LRB-\1740 ICP\NN\1740 )\-RRB-\1740 was\VBD\836236 measured\VBN\697589 during\IN\1740 <e1>alfentanil-induced</e1>\JJ\1740 <e2>rigidity</e2>\NN\5023233 in\IN\13603305 rats\NNS\2329401 .\.\1740
D015760_D009127 CID These\DT\1740 observations\NNS\996969 suggest\VBP\1010118 that\IN\1740 <e2>rigidity</e2>\NN\5023233 should\MD\1740 be\VB\836236 prevented\VBN\1740 when\WRB\1740 <e1>alfentanil</e1>\JJ\1740 ,\,\1740 and\CC\1740 ,\,\1740 presumably\RB\1740 ,\,\1740 other\JJ\1740 opiates\NNS\3808564 ,\,\1740 are\VBP\836236 used\VBN\1156834 in\IN\13603305 the\DT\1740 anesthetic\JJ\1740 management\NN\1123598 of\IN\1740 patients\NNS\9898892 with\IN\1740 ICP\NN\1740 problems\NNS\14408086 .\.\1740
C032943_D009127 NONE These\DT\1740 variables\NNS\2452 returned\VBD\1835496 to\TO\1740 baseline\NN\7260623 when\WRB\1740 <e2>rigidity</e2>\NN\5023233 was\VBD\836236 abolished\VBN\1740 with\IN\1740 <e1>metocurine</e1>\NN\1740 .\.\1740
20698227
D012254_D000743 NONE Can\MD\3094503 angiogenesis\NN\13489037 be\VB\836236 a\DT\13649268 target\NN\7258332 of\IN\1740 treatment\NN\654885 for\IN\1740 <e1>ribavirin</e1>\NN\2725367 associated\JJ\1740 <e2>hemolytic\JJ\1740 anemia</e2>\NN\14189204 ?\.\1740
D012254_D006461 NONE BACKGROUND/AIMS\JJ\1740 :\:\1740 Recently\RB\1740 <e1>ribavirin</e1>\NN\2725367 has\VBZ\2108377 been\VBN\836236 found\VBN\2426171 to\TO\1740 inhibit\VB\2510337 angiogenesis\NN\13489037 and\CC\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 angiogenesis\NN\13489037 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 sunitinib\NN\1740 and\CC\1740 sorafenib\NN\1740 have\VBP\2108377 been\VBN\836236 found\VBN\2426171 to\TO\1740 cause\VB\1617192 acute\JJ\1740 <e2>hemolysis</e2>\NN\13509528 .\.\1740
C473478_D006461 CID BACKGROUND/AIMS\JJ\1740 :\:\1740 Recently\RB\1740 ribavirin\NN\2725367 has\VBZ\2108377 been\VBN\836236 found\VBN\2426171 to\TO\1740 inhibit\VB\2510337 angiogenesis\NN\13489037 and\CC\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 angiogenesis\NN\13489037 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 <e1>sunitinib</e1>\NN\1740 and\CC\1740 sorafenib\NN\1740 have\VBP\2108377 been\VBN\836236 found\VBN\2426171 to\TO\1740 cause\VB\1617192 acute\JJ\1740 <e2>hemolysis</e2>\NN\13509528 .\.\1740
C471405_D006461 CID BACKGROUND/AIMS\JJ\1740 :\:\1740 Recently\RB\1740 ribavirin\NN\2725367 has\VBZ\2108377 been\VBN\836236 found\VBN\2426171 to\TO\1740 inhibit\VB\2510337 angiogenesis\NN\13489037 and\CC\1740 a\DT\13649268 number\NN\5107765 of\IN\1740 angiogenesis\NN\13489037 inhibitors\NNS\20090 such\JJ\1740 as\IN\14622893 sunitinib\NN\1740 and\CC\1740 <e1>sorafenib</e1>\NN\1740 have\VBP\2108377 been\VBN\836236 found\VBN\2426171 to\TO\1740 cause\VB\1617192 acute\JJ\1740 <e2>hemolysis</e2>\NN\13509528 .\.\1740
C100416_D019698 NONE METHODS\NNS\5616786 :\:\1740 Fourteen\CD\13745420 patients\NNS\9898892 <e2>chronically\RB\1740 infected\VBN\2316868 with\IN\1740 hepatitis\NN\14127211 C\NN\13714184 virus</e2>\NN\9312843 were\VBD\836236 treated\VBN\2376958 by\IN\1740 <e1>pegylated\JJ\1740 interferon\NN\2725367 alpha\NN\6828818 2a</e1>\NN\1740 and\CC\1740 ribavirin\NN\2725367 .\.\1740
D012254_D019698 NONE METHODS\NNS\5616786 :\:\1740 Fourteen\CD\13745420 patients\NNS\9898892 <e2>chronically\RB\1740 infected\VBN\2316868 with\IN\1740 hepatitis\NN\14127211 C\NN\13714184 virus</e2>\NN\9312843 were\VBD\836236 treated\VBN\2376958 by\IN\1740 pegylated\JJ\1740 interferon\NN\2725367 alpha\NN\6828818 2a\NN\1740 and\CC\1740 <e1>ribavirin</e1>\NN\2725367 .\.\1740
D012254_D019698 NONE CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 study\NN\635850 in\IN\13603305 the\DT\1740 literature\NN\6362953 investigating\VBG\644583 a\DT\13649268 link\NN\13792579 between\IN\1740 angiogenesis\NN\13489037 soluble\JJ\1740 markers\NNS\21939 and\CC\1740 <e1>ribavirin</e1>\NN\2725367 induced\VBD\1627355 anemia\NN\14189204 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>hepatitis\NN\14127211 C</e2>\NN\13714184 and\CC\1740 we\PRP\1740 could\MD\1740 not\RB\1740 find\VB\2163746 any\DT\1740 relation\NN\2137 .\.\1740
D012254_D000740 NONE CONCLUSION\NN\5837957 :\:\1740 This\DT\1740 is\VBZ\836236 the\DT\1740 first\JJ\1740 study\NN\635850 in\IN\13603305 the\DT\1740 literature\NN\6362953 investigating\VBG\644583 a\DT\13649268 link\NN\13792579 between\IN\1740 angiogenesis\NN\13489037 soluble\JJ\1740 markers\NNS\21939 and\CC\1740 <e1>ribavirin</e1>\NN\2725367 induced\VBD\1627355 <e2>anemia</e2>\NN\14189204 in\IN\13603305 patients\NNS\9898892 with\IN\1740 hepatitis\NN\14127211 C\NN\13714184 and\CC\1740 we\PRP\1740 could\MD\1740 not\RB\1740 find\VB\2163746 any\DT\1740 relation\NN\2137 .\.\1740
18261172
D020123_D011507 CID Development\NN\248977 of\IN\1740 <e2>proteinuria</e2>\NN\14299637 after\IN\1740 switch\NN\3096960 to\TO\1740 <e1>sirolimus-based</e1>\JJ\1740 immunosuppression\NN\13973990 in\IN\13603305 long-term\JJ\1740 cardiac\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 .\.\1740
D020123_D011507 CID The\DT\1740 novel\JJ\1740 immunosuppressive\JJ\1740 (\-LRB-\1740 IS\NN\1740 )\-RRB-\1740 drug\NN\14778436 <e1>sirolmus</e1>\NN\1740 (\-LRB-\1740 Srl\NN\1740 )\-RRB-\1740 lacks\VBZ\1740 nephrotoxic\JJ\1740 effects\NNS\13245626 ;\:\1740 however\RB\1740 ,\,\1740 <e2>proteinuria</e2>\NN\14299637 associated\VBN\628491 with\IN\1740 Srl\NNP\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 following\VBG\1835496 renal\JJ\1740 transplantation\NN\671351 .\.\1740
D020123_D011507 CID The\DT\1740 novel\JJ\1740 immunosuppressive\JJ\1740 (\-LRB-\1740 IS\NN\1740 )\-RRB-\1740 drug\NN\14778436 sirolmus\NN\1740 (\-LRB-\1740 <e1>Srl</e1>\NN\1740 )\-RRB-\1740 lacks\VBZ\1740 nephrotoxic\JJ\1740 effects\NNS\13245626 ;\:\1740 however\RB\1740 ,\,\1740 <e2>proteinuria</e2>\NN\14299637 associated\VBN\628491 with\IN\1740 Srl\NNP\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 following\VBG\1835496 renal\JJ\1740 transplantation\NN\671351 .\.\1740
D020123_D011507 CID The\DT\1740 novel\JJ\1740 immunosuppressive\JJ\1740 (\-LRB-\1740 IS\NN\1740 )\-RRB-\1740 drug\NN\14778436 sirolmus\NN\1740 (\-LRB-\1740 Srl\NN\1740 )\-RRB-\1740 lacks\VBZ\1740 nephrotoxic\JJ\1740 effects\NNS\13245626 ;\:\1740 however\RB\1740 ,\,\1740 <e2>proteinuria</e2>\NN\14299637 associated\VBN\628491 with\IN\1740 <e1>Srl</e1>\NNP\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 following\VBG\1835496 renal\JJ\1740 transplantation\NN\671351 .\.\1740
D020123_D011507 CID In\IN\13603305 cardiac\JJ\1740 transplantation\NN\671351 ,\,\1740 the\DT\1740 incidence\NN\13821570 of\IN\1740 <e2>proteinuria</e2>\NN\14299637 associated\VBN\628491 with\IN\1740 <e1>Srl</e1>\NN\1740 is\VBZ\836236 unknown\JJ\1740 .\.\1740
D020123_D011507 CID Thus\RB\1740 ,\,\1740 <e2>proteinuria</e2>\NN\14299637 may\MD\15209706 develop\VB\1753788 in\IN\13603305 cardiac\JJ\1740 transplant\NN\5267548 patients\NNS\9898892 after\IN\1740 switch\NN\3096960 to\IN\1740 <e1>Srl</e1>\NNP\1740 ,\,\1740 which\WDT\1740 may\MD\15209706 have\VB\2108377 an\DT\6697703 adverse\JJ\1740 effect\NN\34213 on\IN\1740 renal\JJ\1740 function\NN\13783581 in\IN\13603305 these\DT\1740 patients\NNS\9898892 .\.\1740
D020123_D011507 CID <e1>Srl</e1>\NN\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 ACEi/ARB\NN\1740 therapy\NN\657604 and\CC\1740 patients\NNS\9898892 monitored\VBN\2169352 for\IN\1740 <e2>proteinuria</e2>\NN\14299637 and\CC\1740 increased\VBD\169651 renal\JJ\1740 dysfunction\NN\14204950 .\.\1740
D020123_D007674 NONE The\DT\1740 novel\JJ\1740 immunosuppressive\JJ\1740 (\-LRB-\1740 IS\NN\1740 )\-RRB-\1740 drug\NN\14778436 <e1>sirolmus</e1>\NN\1740 (\-LRB-\1740 Srl\NN\1740 )\-RRB-\1740 lacks\VBZ\1740 <e2>nephrotoxic</e2>\JJ\1740 effects\NNS\13245626 ;\:\1740 however\RB\1740 ,\,\1740 proteinuria\NN\14299637 associated\VBN\628491 with\IN\1740 Srl\NNP\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 following\VBG\1835496 renal\JJ\1740 transplantation\NN\671351 .\.\1740
D020123_D007674 NONE The\DT\1740 novel\JJ\1740 immunosuppressive\JJ\1740 (\-LRB-\1740 IS\NN\1740 )\-RRB-\1740 drug\NN\14778436 sirolmus\NN\1740 (\-LRB-\1740 <e1>Srl</e1>\NN\1740 )\-RRB-\1740 lacks\VBZ\1740 <e2>nephrotoxic</e2>\JJ\1740 effects\NNS\13245626 ;\:\1740 however\RB\1740 ,\,\1740 proteinuria\NN\14299637 associated\VBN\628491 with\IN\1740 Srl\NNP\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 following\VBG\1835496 renal\JJ\1740 transplantation\NN\671351 .\.\1740
D020123_D007674 NONE The\DT\1740 novel\JJ\1740 immunosuppressive\JJ\1740 (\-LRB-\1740 IS\NN\1740 )\-RRB-\1740 drug\NN\14778436 sirolmus\NN\1740 (\-LRB-\1740 Srl\NN\1740 )\-RRB-\1740 lacks\VBZ\1740 <e2>nephrotoxic</e2>\JJ\1740 effects\NNS\13245626 ;\:\1740 however\RB\1740 ,\,\1740 proteinuria\NN\14299637 associated\VBN\628491 with\IN\1740 <e1>Srl</e1>\NNP\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 following\VBG\1835496 renal\JJ\1740 transplantation\NN\671351 .\.\1740
D020123_D007674 NONE <e1>Srl</e1>\NN\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 ACEi/ARB\NN\1740 therapy\NN\657604 and\CC\1740 patients\NNS\9898892 monitored\VBN\2169352 for\IN\1740 proteinuria\NN\14299637 and\CC\1740 increased\VBD\169651 <e2>renal\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D000806_D011507 NONE <e1>ACE\NN\13741022 inhibitor</e1>\NN\20090 and\CC\1740 angiotensin-releasing\JJ\1740 blocker\NN\10101634 (\-LRB-\1740 ARB\NN\9882007 )\-RRB-\1740 therapy\NN\657604 reduced\VBD\441445 <e2>proteinuria</e2>\NN\14299637 development\NN\248977 .\.\1740
D000806_D011507 NONE Srl\NN\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 <e1>ACEi/ARB</e1>\NN\1740 therapy\NN\657604 and\CC\1740 patients\NNS\9898892 monitored\VBN\2169352 for\IN\1740 <e2>proteinuria</e2>\NN\14299637 and\CC\1740 increased\VBD\169651 renal\JJ\1740 dysfunction\NN\14204950 .\.\1740
D057911_D011507 NONE ACE\NN\13741022 inhibitor\NN\20090 and\CC\1740 <e1>angiotensin-releasing\JJ\1740 blocker</e1>\NN\10101634 (\-LRB-\1740 ARB\NN\9882007 )\-RRB-\1740 therapy\NN\657604 reduced\VBD\441445 <e2>proteinuria</e2>\NN\14299637 development\NN\248977 .\.\1740
D057911_D011507 NONE ACE\NN\13741022 inhibitor\NN\20090 and\CC\1740 angiotensin-releasing\JJ\1740 blocker\NN\10101634 (\-LRB-\1740 <e1>ARB</e1>\NN\9882007 )\-RRB-\1740 therapy\NN\657604 reduced\VBD\441445 <e2>proteinuria</e2>\NN\14299637 development\NN\248977 .\.\1740
D057911_D011507 NONE Srl\NN\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 <e1>ACEi/ARB</e1>\NN\1740 therapy\NN\657604 and\CC\1740 patients\NNS\9898892 monitored\VBN\2169352 for\IN\1740 <e2>proteinuria</e2>\NN\14299637 and\CC\1740 increased\VBD\169651 renal\JJ\1740 dysfunction\NN\14204950 .\.\1740
D000806_D007674 NONE Srl\NN\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 <e1>ACEi/ARB</e1>\NN\1740 therapy\NN\657604 and\CC\1740 patients\NNS\9898892 monitored\VBN\2169352 for\IN\1740 proteinuria\NN\14299637 and\CC\1740 increased\VBD\169651 <e2>renal\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
D057911_D007674 NONE Srl\NN\1740 should\MD\1740 be\VB\836236 used\VBN\1156834 with\IN\1740 <e1>ACEi/ARB</e1>\NN\1740 therapy\NN\657604 and\CC\1740 patients\NNS\9898892 monitored\VBN\2169352 for\IN\1740 proteinuria\NN\14299637 and\CC\1740 increased\VBD\169651 <e2>renal\JJ\1740 dysfunction</e2>\NN\14204950 .\.\1740
7834920
D012293_D005921 CID Crescentic\JJ\1740 fibrillary\JJ\1740 <e2>glomerulonephritis</e2>\NN\14113798 associated\VBN\628491 with\IN\1740 intermittent\JJ\1740 <e1>rifampin</e1>\NN\2716205 therapy\NN\657604 for\IN\1740 pulmonary\JJ\1740 tuberculosis\NN\14127211 .\.\1740
D012293_D005921 CID This\DT\1740 case\NN\7283608 study\NN\635850 reveals\VBZ\2137132 an\DT\6697703 unusual\JJ\1740 finding\NN\43195 of\IN\1740 rapidly\RB\1740 proliferative\JJ\1740 crescentic\JJ\1740 <e2>glomerulonephritis</e2>\NN\14113798 in\IN\13603305 a\DT\13649268 patient\NN\9898892 treated\VBN\2376958 with\IN\1740 <e1>rifampin</e1>\NN\2716205 who\WP\8299493 had\VBD\2108377 no\DT\7204911 other\JJ\1740 identifiable\JJ\1740 causes\NNS\7323922 for\IN\1740 developing\VBG\1753788 this\DT\1740 disease\NN\14061805 .\.\1740
D012293_D005921 CID This\DT\1740 report\NN\6470073 documents\VBZ\1000214 the\DT\1740 unusual\JJ\1740 occurrence\NN\29378 of\IN\1740 rapidly\RB\1740 progressive\JJ\1740 <e2>glomerulonephritis</e2>\NN\14113798 with\IN\1740 crescents\NNS\13867641 and\CC\1740 fibrillar\JJ\1740 glomerulonephritis\NN\14113798 in\IN\13603305 a\DT\13649268 patient\NN\9898892 treated\VBN\2376958 with\IN\1740 <e1>rifampin</e1>\NN\2716205 .\.\1740
D012293_D005921 CID This\DT\1740 report\NN\6470073 documents\VBZ\1000214 the\DT\1740 unusual\JJ\1740 occurrence\NN\29378 of\IN\1740 rapidly\RB\1740 progressive\JJ\1740 glomerulonephritis\NN\14113798 with\IN\1740 crescents\NNS\13867641 and\CC\1740 fibrillar\JJ\1740 <e2>glomerulonephritis</e2>\NN\14113798 in\IN\13603305 a\DT\13649268 patient\NN\9898892 treated\VBN\2376958 with\IN\1740 <e1>rifampin</e1>\NN\2716205 .\.\1740
D012293_D014397 NONE Crescentic\JJ\1740 fibrillary\JJ\1740 glomerulonephritis\NN\14113798 associated\VBN\628491 with\IN\1740 intermittent\JJ\1740 <e1>rifampin</e1>\NN\2716205 therapy\NN\657604 for\IN\1740 <e2>pulmonary\JJ\1740 tuberculosis</e2>\NN\14127211 .\.\1740
D012293_D014397 NONE This\DT\1740 patient\NN\9898892 underwent\VBD\109660 a\DT\13649268 10-month\JJ\1740 regimen\NN\5898568 of\IN\1740 <e1>rifampin</e1>\NN\2716205 and\CC\1740 isoniazid\NNS\2716205 for\IN\1740 <e2>pulmonary\JJ\1740 tuberculosis</e2>\NN\14127211 and\CC\1740 was\VBD\836236 discovered\VBN\2163746 to\TO\1740 have\VB\2108377 developed\VBN\1753788 signs\NNS\6643763 of\IN\1740 severe\JJ\1740 renal\JJ\1740 failure\NN\66216 five\CD\13741022 weeks\NNS\15113229 after\IN\1740 completion\NN\556313 of\IN\1740 therapy\NN\657604 .\.\1740
D012293_D051437 CID This\DT\1740 patient\NN\9898892 underwent\VBD\109660 a\DT\13649268 10-month\JJ\1740 regimen\NN\5898568 of\IN\1740 <e1>rifampin</e1>\NN\2716205 and\CC\1740 isoniazid\NNS\2716205 for\IN\1740 pulmonary\JJ\1740 tuberculosis\NN\14127211 and\CC\1740 was\VBD\836236 discovered\VBN\2163746 to\TO\1740 have\VB\2108377 developed\VBN\1753788 signs\NNS\6643763 of\IN\1740 severe\JJ\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 five\CD\13741022 weeks\NNS\15113229 after\IN\1740 completion\NN\556313 of\IN\1740 therapy\NN\657604 .\.\1740
D007538_D014397 NONE This\DT\1740 patient\NN\9898892 underwent\VBD\109660 a\DT\13649268 10-month\JJ\1740 regimen\NN\5898568 of\IN\1740 rifampin\NN\2716205 and\CC\1740 <e1>isoniazid</e1>\NNS\2716205 for\IN\1740 <e2>pulmonary\JJ\1740 tuberculosis</e2>\NN\14127211 and\CC\1740 was\VBD\836236 discovered\VBN\2163746 to\TO\1740 have\VB\2108377 developed\VBN\1753788 signs\NNS\6643763 of\IN\1740 severe\JJ\1740 renal\JJ\1740 failure\NN\66216 five\CD\13741022 weeks\NNS\15113229 after\IN\1740 completion\NN\556313 of\IN\1740 therapy\NN\657604 .\.\1740
D007538_D051437 NONE This\DT\1740 patient\NN\9898892 underwent\VBD\109660 a\DT\13649268 10-month\JJ\1740 regimen\NN\5898568 of\IN\1740 rifampin\NN\2716205 and\CC\1740 <e1>isoniazid</e1>\NNS\2716205 for\IN\1740 pulmonary\JJ\1740 tuberculosis\NN\14127211 and\CC\1740 was\VBD\836236 discovered\VBN\2163746 to\TO\1740 have\VB\2108377 developed\VBN\1753788 signs\NNS\6643763 of\IN\1740 severe\JJ\1740 <e2>renal\JJ\1740 failure</e2>\NN\66216 five\CD\13741022 weeks\NNS\15113229 after\IN\1740 completion\NN\556313 of\IN\1740 therapy\NN\657604 .\.\1740
11928786
D016642_D064420 NONE <e1>Bupropion</e1>\NN\1740 (\-LRB-\1740 Zyban\NN\1740 )\-RRB-\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D016642_D064420 NONE Bupropion\NN\1740 (\-LRB-\1740 <e1>Zyban</e1>\NN\1740 )\-RRB-\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
D003975_D012640 NONE Recurrent\JJ\1740 <e2>seizures</e2>\NNS\14081375 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>diazepam</e1>\NN\2830852 and\CC\1740 broad\JJ\1740 complex\JJ\1740 tachycardia\NN\14110674 was\VBD\836236 successfully\RB\1740 treated\VBN\2376958 with\IN\1740 adenosine\NN\14964367 .\.\1740
D003975_D013610 NONE Recurrent\JJ\1740 seizures\NNS\14081375 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>diazepam</e1>\NN\2830852 and\CC\1740 broad\JJ\1740 complex\JJ\1740 <e2>tachycardia</e2>\NN\14110674 was\VBD\836236 successfully\RB\1740 treated\VBN\2376958 with\IN\1740 adenosine\NN\14964367 .\.\1740
D000241_D012640 NONE Recurrent\JJ\1740 <e2>seizures</e2>\NNS\14081375 were\VBD\836236 treated\VBN\2376958 with\IN\1740 diazepam\NN\2830852 and\CC\1740 broad\JJ\1740 complex\JJ\1740 tachycardia\NN\14110674 was\VBD\836236 successfully\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>adenosine</e1>\NN\14964367 .\.\1740
D000241_D013610 NONE Recurrent\JJ\1740 seizures\NNS\14081375 were\VBD\836236 treated\VBN\2376958 with\IN\1740 diazepam\NN\2830852 and\CC\1740 broad\JJ\1740 complex\JJ\1740 <e2>tachycardia</e2>\NN\14110674 was\VBD\836236 successfully\RB\1740 treated\VBN\2376958 with\IN\1740 <e1>adenosine</e1>\NN\14964367 .\.\1740
D016642_D020258 NONE <e1>Zyban</e1>\NNP\1740 caused\VBD\1617192 significant\JJ\1740 <e2>neurological\JJ\1740 and\CC\1740 cardiovascular\JJ\1740 toxicity</e2>\NN\13576101 in\IN\13603305 overdose\NN\1740 .\.\1740
D016642_D002318 NONE <e1>Zyban</e1>\NNP\1740 caused\VBD\1617192 significant\JJ\1740 <e2>neurological\JJ\1740 and\CC\1740 cardiovascular\JJ\1740 toxicity</e2>\NN\13576101 in\IN\13603305 overdose\NN\1740 .\.\1740
D016642_D062787 NONE <e1>Zyban</e1>\NNP\1740 caused\VBD\1617192 significant\JJ\1740 neurological\JJ\1740 and\CC\1740 cardiovascular\JJ\1740 toxicity\NN\13576101 in\IN\13603305 <e2>overdose</e2>\NN\1740 .\.\1740
3560095
D005480_D001171 NONE <e1>Flurbiprofen</e1>\NN\3828465 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e2>juvenile\NN\7846 rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 .\.\1740
D005480_D001171 NONE Thirty-four\NN\1740 patients\NNS\9898892 with\IN\1740 <e2>juvenile\NN\7846 rheumatoid\JJ\1740 arthritis</e2>\NN\14171682 ,\,\1740 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>flurbiprofen</e1>\NN\3828465 at\IN\14622893 a\DT\13649268 maximum\NN\13653902 dose\NN\3740161 of\IN\1740 4\CD\13741022 mg/kg/day\NN\1740 ,\,\1740 had\VBD\2108377 statistically\RB\1740 significant\JJ\1740 decreases\NNS\7296428 from\IN\1740 baseline\NN\7260623 in\IN\13603305 6\CD\13741022 arthritis\NN\14171682 indices\NNS\13850304 after\IN\1740 12\CD\13745420 weeks\NNS\15113229 of\IN\1740 treatment\NN\654885 .\.\1740
D005480_D001168 NONE Thirty-four\NN\1740 patients\NNS\9898892 with\IN\1740 juvenile\NN\7846 rheumatoid\JJ\1740 arthritis\NN\14171682 ,\,\1740 who\WP\8299493 were\VBD\836236 treated\VBN\2376958 with\IN\1740 <e1>flurbiprofen</e1>\NN\3828465 at\IN\14622893 a\DT\13649268 maximum\NN\13653902 dose\NN\3740161 of\IN\1740 4\CD\13741022 mg/kg/day\NN\1740 ,\,\1740 had\VBD\2108377 statistically\RB\1740 significant\JJ\1740 decreases\NNS\7296428 from\IN\1740 baseline\NN\7260623 in\IN\13603305 6\CD\13741022 <e2>arthritis</e2>\NN\14171682 indices\NNS\13850304 after\IN\1740 12\CD\13745420 weeks\NNS\15113229 of\IN\1740 treatment\NN\654885 .\.\1740
8701950
D016559_D000743 CID <e2>Microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia</e2>\NN\14189204 complicating\VBG\126264 <e1>FK506</e1>\NN\1740 (\-LRB-\1740 tacrolimus\NN\1740 )\-RRB-\1740 therapy\NN\657604 .\.\1740
D016559_D000743 CID <e2>Microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia</e2>\NN\14189204 complicating\VBG\126264 FK506\NN\1740 (\-LRB-\1740 <e1>tacrolimus</e1>\NN\1740 )\-RRB-\1740 therapy\NN\657604 .\.\1740
D016559_D000743 CID We\PRP\1740 describe\VBP\1001294 3\CD\13741022 episodes\NNS\7283608 of\IN\1740 <e2>microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia</e2>\NN\14189204 (\-LRB-\1740 MAHA\NN\9654687 )\-RRB-\1740 in\IN\13603305 2\CD\13741022 solid\JJ\1740 organ\NN\5220461 recipients\NNS\9764201 under\IN\1740 <e1>FK506</e1>\NN\1740 (\-LRB-\1740 tacrolimus\NN\1740 )\-RRB-\1740 therapy\NN\657604 .\.\1740
D016559_D000743 CID We\PRP\1740 describe\VBP\1001294 3\CD\13741022 episodes\NNS\7283608 of\IN\1740 microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 (\-LRB-\1740 <e2>MAHA</e2>\NN\9654687 )\-RRB-\1740 in\IN\13603305 2\CD\13741022 solid\JJ\1740 organ\NN\5220461 recipients\NNS\9764201 under\IN\1740 <e1>FK506</e1>\NN\1740 (\-LRB-\1740 tacrolimus\NN\1740 )\-RRB-\1740 therapy\NN\657604 .\.\1740
D016559_D000743 CID We\PRP\1740 describe\VBP\1001294 3\CD\13741022 episodes\NNS\7283608 of\IN\1740 <e2>microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia</e2>\NN\14189204 (\-LRB-\1740 MAHA\NN\9654687 )\-RRB-\1740 in\IN\13603305 2\CD\13741022 solid\JJ\1740 organ\NN\5220461 recipients\NNS\9764201 under\IN\1740 FK506\NN\1740 (\-LRB-\1740 <e1>tacrolimus</e1>\NN\1740 )\-RRB-\1740 therapy\NN\657604 .\.\1740
D016559_D000743 CID We\PRP\1740 describe\VBP\1001294 3\CD\13741022 episodes\NNS\7283608 of\IN\1740 microangiopathic\JJ\1740 hemolytic\JJ\1740 anemia\NN\14189204 (\-LRB-\1740 <e2>MAHA</e2>\NN\9654687 )\-RRB-\1740 in\IN\13603305 2\CD\13741022 solid\JJ\1740 organ\NN\5220461 recipients\NNS\9764201 under\IN\1740 FK506\NN\1740 (\-LRB-\1740 <e1>tacrolimus</e1>\NN\1740 )\-RRB-\1740 therapy\NN\657604 .\.\1740
D016559_D000743 CID In\IN\13603305 both\DT\1740 cases\NNS\7283608 ,\,\1740 discontinuation\NN\209943 of\IN\1740 <e1>FK506</e1>\NN\1740 and\CC\1740 treatment\NN\654885 with\IN\1740 plasma\NN\5398023 exchange\NN\11409059 ,\,\1740 fresh\JJ\1740 frozen\JJ\1740 plasma\NN\5398023 replacement\NN\196485 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 aspirin\NN\2707683 ,\,\1740 and\CC\1740 dipyridamole\NN\1740 led\VBD\1752884 to\TO\1740 resolution\NN\6470073 of\IN\1740 <e2>MAHA</e2>\NN\9654687 .\.\1740
D016559_D000743 CID In\IN\13603305 one\CD\13741022 patient\NN\9898892 ,\,\1740 reintroduction\NN\7217349 of\IN\1740 <e1>FK506</e1>\NN\1740 led\VBD\1752884 to\TO\1740 rapid\JJ\1740 recurrence\NN\7342049 of\IN\1740 <e2>MAHA</e2>\NN\9654687 .\.\1740
D016559_D000743 CID <e1>FK506-associated</e1>\JJ\1740 <e2>MAHA</e2>\NN\9654687 is\VBZ\836236 probably\RB\1740 rare\JJ\1740 but\CC\1740 physicians\NNS\10305802 must\MD\9367203 be\VB\836236 aware\JJ\1740 of\IN\1740 this\DT\1740 severe\JJ\1740 complication\NN\1073995 .\.\1740
D016559_D000743 CID In\IN\13603305 our\PRP$\1740 experience\NN\5984287 and\CC\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 literature\NN\6362953 ,\,\1740 <e1>FK506</e1>\NN\1740 does\VBZ\1640855 not\RB\1740 seem\VB\2604760 to\TO\1740 cross-react\VB\1740 with\IN\1740 cyclosporin\NN\1740 A\NN\13649268 (\-LRB-\1740 CyA\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 immuno-suppressive\JJ\1740 drug\NN\14778436 already\RB\1740 known\VBN\2110220 to\TO\1740 induce\VB\1627355 <e2>MAHA</e2>\NN\9654687 .\.\1740
D000305_D000743 NONE In\IN\13603305 both\DT\1740 cases\NNS\7283608 ,\,\1740 discontinuation\NN\209943 of\IN\1740 FK506\NN\1740 and\CC\1740 treatment\NN\654885 with\IN\1740 plasma\NN\5398023 exchange\NN\11409059 ,\,\1740 fresh\JJ\1740 frozen\JJ\1740 plasma\NN\5398023 replacement\NN\196485 ,\,\1740 <e1>corticosteroids</e1>\NNS\14745635 ,\,\1740 aspirin\NN\2707683 ,\,\1740 and\CC\1740 dipyridamole\NN\1740 led\VBD\1752884 to\TO\1740 resolution\NN\6470073 of\IN\1740 <e2>MAHA</e2>\NN\9654687 .\.\1740
D001241_D000743 NONE In\IN\13603305 both\DT\1740 cases\NNS\7283608 ,\,\1740 discontinuation\NN\209943 of\IN\1740 FK506\NN\1740 and\CC\1740 treatment\NN\654885 with\IN\1740 plasma\NN\5398023 exchange\NN\11409059 ,\,\1740 fresh\JJ\1740 frozen\JJ\1740 plasma\NN\5398023 replacement\NN\196485 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 <e1>aspirin</e1>\NN\2707683 ,\,\1740 and\CC\1740 dipyridamole\NN\1740 led\VBD\1752884 to\TO\1740 resolution\NN\6470073 of\IN\1740 <e2>MAHA</e2>\NN\9654687 .\.\1740
D004176_D000743 NONE In\IN\13603305 both\DT\1740 cases\NNS\7283608 ,\,\1740 discontinuation\NN\209943 of\IN\1740 FK506\NN\1740 and\CC\1740 treatment\NN\654885 with\IN\1740 plasma\NN\5398023 exchange\NN\11409059 ,\,\1740 fresh\JJ\1740 frozen\JJ\1740 plasma\NN\5398023 replacement\NN\196485 ,\,\1740 corticosteroids\NNS\14745635 ,\,\1740 aspirin\NN\2707683 ,\,\1740 and\CC\1740 <e1>dipyridamole</e1>\NN\1740 led\VBD\1752884 to\TO\1740 resolution\NN\6470073 of\IN\1740 <e2>MAHA</e2>\NN\9654687 .\.\1740
D016572_D000743 NONE In\IN\13603305 our\PRP$\1740 experience\NN\5984287 and\CC\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 literature\NN\6362953 ,\,\1740 FK506\NN\1740 does\VBZ\1640855 not\RB\1740 seem\VB\2604760 to\TO\1740 cross-react\VB\1740 with\IN\1740 <e1>cyclosporin\NN\1740 A</e1>\NN\13649268 (\-LRB-\1740 CyA\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 immuno-suppressive\JJ\1740 drug\NN\14778436 already\RB\1740 known\VBN\2110220 to\TO\1740 induce\VB\1627355 <e2>MAHA</e2>\NN\9654687 .\.\1740
D016572_D000743 NONE In\IN\13603305 our\PRP$\1740 experience\NN\5984287 and\CC\1740 according\VBG\2657219 to\IN\1740 the\DT\1740 literature\NN\6362953 ,\,\1740 FK506\NN\1740 does\VBZ\1640855 not\RB\1740 seem\VB\2604760 to\TO\1740 cross-react\VB\1740 with\IN\1740 cyclosporin\NN\1740 A\NN\13649268 (\-LRB-\1740 <e1>CyA</e1>\NN\1740 )\-RRB-\1740 ,\,\1740 an\DT\6697703 immuno-suppressive\JJ\1740 drug\NN\14778436 already\RB\1740 known\VBN\2110220 to\TO\1740 induce\VB\1627355 <e2>MAHA</e2>\NN\9654687 .\.\1740
18809400
D008063_D028361 NONE <e1>Alpha-lipoic\JJ\1740 acid</e1>\NN\14818238 prevents\VBZ\1740 <e2>mitochondrial\JJ\1740 damage</e2>\NN\7296428 and\CC\1740 neurotoxicity\NN\1740 in\IN\13603305 experimental\JJ\1740 chemotherapy\NN\661091 neuropathy\JJ\1740 .\.\1740
D008063_D028361 NONE The\DT\1740 study\NN\635850 investigates\VBZ\644583 if\IN\1740 <e1>alpha-lipoic\JJ\1740 acid</e1>\NN\14818238 is\VBZ\836236 neuroprotective\JJ\1740 against\IN\1740 chemotherapy\NN\661091 induced\JJ\1740 neurotoxicity\NN\1740 ,\,\1740 if\IN\1740 <e2>mitochondrial\JJ\1740 damage</e2>\NN\7296428 plays\VBZ\1072262 a\DT\13649268 critical\JJ\1740 role\NN\719494 in\IN\13603305 toxic\JJ\1740 neurodegenerative\JJ\1740 cascade\NN\9475292 ,\,\1740 and\CC\1740 if\IN\1740 neuroprotective\JJ\1740 effects\NNS\13245626 of\IN\1740 alpha-lipoic\JJ\1740 acid\NN\14818238 depend\NN\1740 on\IN\1740 mitochondria\NN\5445668 protection\NN\407535 .\.\1740
D008063_D028361 NONE The\DT\1740 study\NN\635850 investigates\VBZ\644583 if\IN\1740 alpha-lipoic\JJ\1740 acid\NN\14818238 is\VBZ\836236 neuroprotective\JJ\1740 against\IN\1740 chemotherapy\NN\661091 induced\JJ\1740 neurotoxicity\NN\1740 ,\,\1740 if\IN\1740 <e2>mitochondrial\JJ\1740 damage</e2>\NN\7296428 plays\VBZ\1072262 a\DT\13649268 critical\JJ\1740 role\NN\719494 in\IN\13603305 toxic\JJ\1740 neurodegenerative\JJ\1740 cascade\NN\9475292 ,\,\1740 and\CC\1740 if\IN\1740 neuroprotective\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>alpha-lipoic\JJ\1740 acid</e1>\NN\14818238 depend\NN\1740 on\IN\1740 mitochondria\NN\5445668 protection\NN\407535 .\.\1740
D008063_D028361 NONE <e1>Alpha-lipoic\JJ\1740 acid</e1>\NN\14818238 exerts\VBZ\1158872 neuroprotective\JJ\1740 effects\NNS\13245626 against\IN\1740 chemotherapy\NN\661091 induced\JJ\1740 neurotoxicity\NN\1740 in\IN\13603305 sensory\JJ\1740 neurons\NNS\5430628 :\:\1740 it\PRP\6125041 rescues\VBZ\2551832 the\DT\1740 <e2>mitochondrial\JJ\1740 toxicity</e2>\NN\13576101 and\CC\1740 induces\VBZ\1627355 the\DT\1740 expression\NN\4679549 of\IN\1740 frataxin\NN\1740 ,\,\1740 an\DT\6697703 essential\JJ\1740 mitochondrial\JJ\1740 protein\NN\14944888 with\IN\1740 anti-oxidant\JJ\1740 and\CC\1740 chaperone\NN\9614684 properties\NNS\32613 .\.\1740
D008063_D020258 NONE <e1>Alpha-lipoic\JJ\1740 acid</e1>\NN\14818238 prevents\VBZ\1740 mitochondrial\JJ\1740 damage\NN\7296428 and\CC\1740 <e2>neurotoxicity</e2>\NN\1740 in\IN\13603305 experimental\JJ\1740 chemotherapy\NN\661091 neuropathy\JJ\1740 .\.\1740
D008063_D020258 NONE The\DT\1740 study\NN\635850 investigates\VBZ\644583 if\IN\1740 <e1>alpha-lipoic\JJ\1740 acid</e1>\NN\14818238 is\VBZ\836236 neuroprotective\JJ\1740 against\IN\1740 chemotherapy\NN\661091 induced\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 ,\,\1740 if\IN\1740 mitochondrial\JJ\1740 damage\NN\7296428 plays\VBZ\1072262 a\DT\13649268 critical\JJ\1740 role\NN\719494 in\IN\13603305 toxic\JJ\1740 neurodegenerative\JJ\1740 cascade\NN\9475292 ,\,\1740 and\CC\1740 if\IN\1740 neuroprotective\JJ\1740 effects\NNS\13245626 of\IN\1740 alpha-lipoic\JJ\1740 acid\NN\14818238 depend\NN\1740 on\IN\1740 mitochondria\NN\5445668 protection\NN\407535 .\.\1740
D008063_D020258 NONE The\DT\1740 study\NN\635850 investigates\VBZ\644583 if\IN\1740 alpha-lipoic\JJ\1740 acid\NN\14818238 is\VBZ\836236 neuroprotective\JJ\1740 against\IN\1740 chemotherapy\NN\661091 induced\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 ,\,\1740 if\IN\1740 mitochondrial\JJ\1740 damage\NN\7296428 plays\VBZ\1072262 a\DT\13649268 critical\JJ\1740 role\NN\719494 in\IN\13603305 toxic\JJ\1740 neurodegenerative\JJ\1740 cascade\NN\9475292 ,\,\1740 and\CC\1740 if\IN\1740 neuroprotective\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>alpha-lipoic\JJ\1740 acid</e1>\NN\14818238 depend\NN\1740 on\IN\1740 mitochondria\NN\5445668 protection\NN\407535 .\.\1740
D008063_D020258 NONE <e1>Alpha-lipoic\JJ\1740 acid</e1>\NN\14818238 exerts\VBZ\1158872 neuroprotective\JJ\1740 effects\NNS\13245626 against\IN\1740 chemotherapy\NN\661091 induced\JJ\1740 <e2>neurotoxicity</e2>\NN\1740 in\IN\13603305 sensory\JJ\1740 neurons\NNS\5430628 :\:\1740 it\PRP\6125041 rescues\VBZ\2551832 the\DT\1740 mitochondrial\JJ\1740 toxicity\NN\13576101 and\CC\1740 induces\VBZ\1627355 the\DT\1740 expression\NN\4679549 of\IN\1740 frataxin\NN\1740 ,\,\1740 an\DT\6697703 essential\JJ\1740 mitochondrial\JJ\1740 protein\NN\14944888 with\IN\1740 anti-oxidant\JJ\1740 and\CC\1740 chaperone\NN\9614684 properties\NNS\32613 .\.\1740
D008063_D009422 NONE <e1>Alpha-lipoic\JJ\1740 acid</e1>\NN\14818238 prevents\VBZ\1740 mitochondrial\JJ\1740 damage\NN\7296428 and\CC\1740 neurotoxicity\NN\1740 in\IN\13603305 experimental\JJ\1740 chemotherapy\NN\661091 <e2>neuropathy</e2>\JJ\1740 .\.\1740
D008063_D009410 NONE The\DT\1740 study\NN\635850 investigates\VBZ\644583 if\IN\1740 <e1>alpha-lipoic\JJ\1740 acid</e1>\NN\14818238 is\VBZ\836236 neuroprotective\JJ\1740 against\IN\1740 chemotherapy\NN\661091 induced\JJ\1740 neurotoxicity\NN\1740 ,\,\1740 if\IN\1740 mitochondrial\JJ\1740 damage\NN\7296428 plays\VBZ\1072262 a\DT\13649268 critical\JJ\1740 role\NN\719494 in\IN\13603305 <e2>toxic\JJ\1740 neurodegenerative\JJ\1740 cascade</e2>\NN\9475292 ,\,\1740 and\CC\1740 if\IN\1740 neuroprotective\JJ\1740 effects\NNS\13245626 of\IN\1740 alpha-lipoic\JJ\1740 acid\NN\14818238 depend\NN\1740 on\IN\1740 mitochondria\NN\5445668 protection\NN\407535 .\.\1740
D008063_D009410 NONE The\DT\1740 study\NN\635850 investigates\VBZ\644583 if\IN\1740 alpha-lipoic\JJ\1740 acid\NN\14818238 is\VBZ\836236 neuroprotective\JJ\1740 against\IN\1740 chemotherapy\NN\661091 induced\JJ\1740 neurotoxicity\NN\1740 ,\,\1740 if\IN\1740 mitochondrial\JJ\1740 damage\NN\7296428 plays\VBZ\1072262 a\DT\13649268 critical\JJ\1740 role\NN\719494 in\IN\13603305 <e2>toxic\JJ\1740 neurodegenerative\JJ\1740 cascade</e2>\NN\9475292 ,\,\1740 and\CC\1740 if\IN\1740 neuroprotective\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>alpha-lipoic\JJ\1740 acid</e1>\NN\14818238 depend\NN\1740 on\IN\1740 mitochondria\NN\5445668 protection\NN\407535 .\.\1740
D017239_D010523 CID We\PRP\1740 used\VBD\1156834 an\DT\6697703 in\FW\13603305 vitro\FW\1740 model\NN\5888929 of\IN\1740 chemotherapy\NN\661091 induced\JJ\1740 <e2>peripheral\JJ\1740 neuropathy</e2>\NN\14204950 that\WDT\1740 closely\RB\1740 mimic\VBP\1742886 the\DT\1740 in\FW\13603305 vivo\FW\1740 condition\NN\24720 by\IN\1740 exposing\VBG\2110927 primary\JJ\1740 cultures\NNS\7966140 of\IN\1740 dorsal\NN\1740 root\NN\13087625 ganglion\NN\5462674 (\-LRB-\1740 DRG\NN\1740 )\-RRB-\1740 sensory\JJ\1740 neurons\NNS\5430628 to\TO\1740 <e1>paclitaxel</e1>\NN\1740 and\CC\1740 cisplatin\NN\1740 ,\,\1740 two\CD\13741022 widely\RB\1740 used\VBN\1156834 and\CC\1740 highly\RB\1740 effective\JJ\1740 chemotherapeutic\JJ\1740 drugs\NNS\14778436 .\.\1740
D002945_D010523 CID We\PRP\1740 used\VBD\1156834 an\DT\6697703 in\FW\13603305 vitro\FW\1740 model\NN\5888929 of\IN\1740 chemotherapy\NN\661091 induced\JJ\1740 <e2>peripheral\JJ\1740 neuropathy</e2>\NN\14204950 that\WDT\1740 closely\RB\1740 mimic\VBP\1742886 the\DT\1740 in\FW\13603305 vivo\FW\1740 condition\NN\24720 by\IN\1740 exposing\VBG\2110927 primary\JJ\1740 cultures\NNS\7966140 of\IN\1740 dorsal\NN\1740 root\NN\13087625 ganglion\NN\5462674 (\-LRB-\1740 DRG\NN\1740 )\-RRB-\1740 sensory\JJ\1740 neurons\NNS\5430628 to\TO\1740 paclitaxel\NN\1740 and\CC\1740 <e1>cisplatin</e1>\NN\1740 ,\,\1740 two\CD\13741022 widely\RB\1740 used\VBN\1156834 and\CC\1740 highly\RB\1740 effective\JJ\1740 chemotherapeutic\JJ\1740 drugs\NNS\14778436 .\.\1740
D008063_D001480 NONE This\DT\1740 approach\NN\940842 allowed\VBD\797697 investigating\VBG\644583 the\DT\1740 efficacy\NN\5199286 of\IN\1740 <e1>alpha-lipoic\JJ\1740 acid</e1>\NN\14818238 in\IN\13603305 preventing\VBG\1740 <e2>axonal\JJ\1740 damage</e2>\NN\7296428 and\CC\1740 apoptosis\NN\11486178 and\CC\1740 the\DT\1740 function\NN\13783581 and\CC\1740 ultrastructural\JJ\1740 morphology\NN\6037666 of\IN\1740 mitochondria\NN\5445668 after\IN\1740 exposure\NN\5042871 to\TO\1740 toxic\JJ\1740 agents\NNS\7347 and\CC\1740 alpha-lipoic\JJ\1740 acid\NN\14818238 .\.\1740
D008063_D001480 NONE This\DT\1740 approach\NN\940842 allowed\VBD\797697 investigating\VBG\644583 the\DT\1740 efficacy\NN\5199286 of\IN\1740 alpha-lipoic\JJ\1740 acid\NN\14818238 in\IN\13603305 preventing\VBG\1740 <e2>axonal\JJ\1740 damage</e2>\NN\7296428 and\CC\1740 apoptosis\NN\11486178 and\CC\1740 the\DT\1740 function\NN\13783581 and\CC\1740 ultrastructural\JJ\1740 morphology\NN\6037666 of\IN\1740 mitochondria\NN\5445668 after\IN\1740 exposure\NN\5042871 to\TO\1740 toxic\JJ\1740 agents\NNS\7347 and\CC\1740 <e1>alpha-lipoic\JJ\1740 acid</e1>\NN\14818238 .\.\1740
D002945_D028361 NONE Our\PRP$\1740 results\NNS\34213 demonstrate\VBP\2137132 that\IN\1740 both\CC\1740 <e1>cisplatin</e1>\NN\1740 and\CC\1740 paclitaxel\NN\1740 cause\VBP\1617192 early\JJ\1740 <e2>mitochondrial\JJ\1740 impairment</e2>\NN\7296428 with\IN\1740 loss\NN\13252973 of\IN\1740 membrane\NN\4188643 potential\NN\14481929 and\CC\1740 induction\NN\7450842 of\IN\1740 autophagic\JJ\1740 vacuoles\NNS\5303402 in\IN\13603305 neurons\NNS\5430628 .\.\1740
D002945_D028361 NONE In\IN\13603305 conclusion\NN\5837957 <e2>mitochondrial\JJ\1740 toxicity</e2>\NN\13576101 is\VBZ\836236 an\DT\6697703 early\JJ\1740 common\JJ\1740 event\NN\23100 both\CC\1740 in\IN\13603305 paclitaxel\NN\1740 and\CC\1740 <e1>cisplatin</e1>\NN\1740 induced\VBN\1627355 neurotoxicity\NN\1740 .\.\1740
D017239_D028361 NONE Our\PRP$\1740 results\NNS\34213 demonstrate\VBP\2137132 that\IN\1740 both\CC\1740 cisplatin\NN\1740 and\CC\1740 <e1>paclitaxel</e1>\NN\1740 cause\VBP\1617192 early\JJ\1740 <e2>mitochondrial\JJ\1740 impairment</e2>\NN\7296428 with\IN\1740 loss\NN\13252973 of\IN\1740 membrane\NN\4188643 potential\NN\14481929 and\CC\1740 induction\NN\7450842 of\IN\1740 autophagic\JJ\1740 vacuoles\NNS\5303402 in\IN\13603305 neurons\NNS\5430628 .\.\1740
D017239_D028361 NONE In\IN\13603305 conclusion\NN\5837957 <e2>mitochondrial\JJ\1740 toxicity</e2>\NN\13576101 is\VBZ\836236 an\DT\6697703 early\JJ\1740 common\JJ\1740 event\NN\23100 both\CC\1740 in\IN\13603305 <e1>paclitaxel</e1>\NN\1740 and\CC\1740 cisplatin\NN\1740 induced\VBN\1627355 neurotoxicity\NN\1740 .\.\1740
D017239_D020258 NONE In\IN\13603305 conclusion\NN\5837957 mitochondrial\JJ\1740 toxicity\NN\13576101 is\VBZ\836236 an\DT\6697703 early\JJ\1740 common\JJ\1740 event\NN\23100 both\CC\1740 in\IN\13603305 <e1>paclitaxel</e1>\NN\1740 and\CC\1740 cisplatin\NN\1740 induced\VBN\1627355 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D002945_D020258 NONE In\IN\13603305 conclusion\NN\5837957 mitochondrial\JJ\1740 toxicity\NN\13576101 is\VBZ\836236 an\DT\6697703 early\JJ\1740 common\JJ\1740 event\NN\23100 both\CC\1740 in\IN\13603305 paclitaxel\NN\1740 and\CC\1740 <e1>cisplatin</e1>\NN\1740 induced\VBN\1627355 <e2>neurotoxicity</e2>\NN\1740 .\.\1740
D008063_D010523 NONE These\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 <e1>alpha-lipoic\JJ\1740 acid</e1>\NN\14818238 might\MD\5029706 reduce\VB\441445 the\DT\1740 risk\NN\14541044 of\IN\1740 developing\VBG\1753788 <e2>peripheral\JJ\1740 nerve\NN\5475681 toxicity</e2>\NN\13576101 in\IN\13603305 patients\NNS\9898892 undergoing\VBG\109660 chemotherapy\NN\661091 and\CC\1740 encourage\VBP\2556126 further\JJ\1740 confirmatory\JJ\1740 clinical\JJ\1740 trials\NNS\786195 .\.\1740
11961407
D014443_D009401 NONE GLEPP1\NN\1740 receptor\NN\5225602 <e1>tyrosine</e1>\NN\14601829 phosphatase\NN\14732946 (\-LRB-\1740 Ptpro\NN\1740 )\-RRB-\1740 in\IN\13603305 rat\NN\2329401 PAN\NN\3101986 <e2>nephrosis</e2>\NN\14304060 .\.\1740
D011692_D009401 CID GLEPP1\NN\1740 receptor\NN\5225602 tyrosine\NN\14601829 phosphatase\NN\14732946 (\-LRB-\1740 Ptpro\NN\1740 )\-RRB-\1740 in\IN\13603305 rat\NN\2329401 <e1>PAN</e1>\NN\3101986 <e2>nephrosis</e2>\NN\14304060 .\.\1740
D011692_D009401 CID <e1>Puromycin\NN\1740 aminonucleoside</e1>\NN\1740 <e2>nephrosis</e2>\NN\14304060 was\VBD\836236 induced\VBN\1627355 by\IN\1740 single\JJ\1740 intraperitoneal\JJ\1740 injection\NN\320852 of\IN\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 PAN\NN\3101986 ,\,\1740 20\CD\13745420 mg/100\CD\1740 g\NN\13717155 BW\NN\973077 )\-RRB-\1740 .\.\1740
D011692_D009401 CID Puromycin\NN\1740 aminonucleoside\NN\1740 <e2>nephrosis</e2>\NN\14304060 was\VBD\836236 induced\VBN\1627355 by\IN\1740 single\JJ\1740 intraperitoneal\JJ\1740 injection\NN\320852 of\IN\1740 <e1>puromycin\NN\1740 aminonucleoside</e1>\NN\1740 (\-LRB-\1740 PAN\NN\3101986 ,\,\1740 20\CD\13745420 mg/100\CD\1740 g\NN\13717155 BW\NN\973077 )\-RRB-\1740 .\.\1740
D011692_D009401 CID Puromycin\NN\1740 aminonucleoside\NN\1740 <e2>nephrosis</e2>\NN\14304060 was\VBD\836236 induced\VBN\1627355 by\IN\1740 single\JJ\1740 intraperitoneal\JJ\1740 injection\NN\320852 of\IN\1740 puromycin\NN\1740 aminonucleoside\NN\1740 (\-LRB-\1740 <e1>PAN</e1>\NN\3101986 ,\,\1740 20\CD\13745420 mg/100\CD\1740 g\NN\13717155 BW\NN\973077 )\-RRB-\1740 .\.\1740
D011692_D011507 CID Tissues\NNS\5220461 were\VBD\836236 analyzed\VBN\78760 at\IN\14622893 0\CD\13741022 ,\,\1740 5\CD\13741022 ,\,\1740 7\CD\13741022 ,\,\1740 11\CD\13745420 ,\,\1740 21\CD\13745420 ,\,\1740 45\CD\1740 ,\,\1740 80\CD\13745420 and\CC\1740 126\CD\1740 days\NNS\15140892 after\IN\1740 <e1>PAN</e1>\NN\3101986 injection\NN\320852 so\IN\6868043 as\IN\14622893 to\TO\1740 include\VB\690614 both\CC\1740 the\DT\1740 acute\JJ\1740 phase\NN\15113229 of\IN\1740 <e2>proteinuria</e2>\NN\14299637 associated\VBN\628491 with\IN\1740 foot\NN\5563034 process\NN\407535 effacement\NN\13526110 (\-LRB-\1740 days\NNS\15140892 5\CD\13741022 -\SYM\1740 11\CD\13745420 )\-RRB-\1740 and\CC\1740 the\DT\1740 chronic\JJ\1740 phase\NN\15113229 of\IN\1740 proteinuria\NN\14299637 associated\VBN\628491 with\IN\1740 glomerulosclerosis\NN\1740 (\-LRB-\1740 days\NNS\15140892 45\CD\1740 -\SYM\1740 126\CD\1740 )\-RRB-\1740 .\.\1740
D011692_D011507 CID Tissues\NNS\5220461 were\VBD\836236 analyzed\VBN\78760 at\IN\14622893 0\CD\13741022 ,\,\1740 5\CD\13741022 ,\,\1740 7\CD\13741022 ,\,\1740 11\CD\13745420 ,\,\1740 21\CD\13745420 ,\,\1740 45\CD\1740 ,\,\1740 80\CD\13745420 and\CC\1740 126\CD\1740 days\NNS\15140892 after\IN\1740 <e1>PAN</e1>\NN\3101986 injection\NN\320852 so\IN\6868043 as\IN\14622893 to\TO\1740 include\VB\690614 both\CC\1740 the\DT\1740 acute\JJ\1740 phase\NN\15113229 of\IN\1740 proteinuria\NN\14299637 associated\VBN\628491 with\IN\1740 foot\NN\5563034 process\NN\407535 effacement\NN\13526110 (\-LRB-\1740 days\NNS\15140892 5\CD\13741022 -\SYM\1740 11\CD\13745420 )\-RRB-\1740 and\CC\1740 the\DT\1740 chronic\JJ\1740 phase\NN\15113229 of\IN\1740 <e2>proteinuria</e2>\NN\14299637 associated\VBN\628491 with\IN\1740 glomerulosclerosis\NN\1740 (\-LRB-\1740 days\NNS\15140892 45\CD\1740 -\SYM\1740 126\CD\1740 )\-RRB-\1740 .\.\1740
D011692_D005921 NONE Tissues\NNS\5220461 were\VBD\836236 analyzed\VBN\78760 at\IN\14622893 0\CD\13741022 ,\,\1740 5\CD\13741022 ,\,\1740 7\CD\13741022 ,\,\1740 11\CD\13745420 ,\,\1740 21\CD\13745420 ,\,\1740 45\CD\1740 ,\,\1740 80\CD\13745420 and\CC\1740 126\CD\1740 days\NNS\15140892 after\IN\1740 <e1>PAN</e1>\NN\3101986 injection\NN\320852 so\IN\6868043 as\IN\14622893 to\TO\1740 include\VB\690614 both\CC\1740 the\DT\1740 acute\JJ\1740 phase\NN\15113229 of\IN\1740 proteinuria\NN\14299637 associated\VBN\628491 with\IN\1740 foot\NN\5563034 process\NN\407535 effacement\NN\13526110 (\-LRB-\1740 days\NNS\15140892 5\CD\13741022 -\SYM\1740 11\CD\13745420 )\-RRB-\1740 and\CC\1740 the\DT\1740 chronic\JJ\1740 phase\NN\15113229 of\IN\1740 proteinuria\NN\14299637 associated\VBN\628491 with\IN\1740 <e2>glomerulosclerosis</e2>\NN\1740 (\-LRB-\1740 days\NNS\15140892 45\CD\1740 -\SYM\1740 126\CD\1740 )\-RRB-\1740 .\.\1740
11581460
D005283_D016055 CID Bladder\NN\5515670 <e2>retention\NN\809465 of\IN\1740 urine</e2>\NN\14853947 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 continuous\JJ\1740 intravenous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>fentanyl</e1>\NN\2707683 :\:\1740 2\CD\13741022 case\NN\7283608 reports\NNS\6470073 .\.\1740
D005283_D009127 NONE Various\NNP\1740 reported\VBD\831651 side\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>fentanyl</e1>\JJ\1740 administration\NN\1133281 include\VBP\690614 <e2>chest\JJ\1740 wall\NN\3894379 rigidity</e2>\NN\5023233 ,\,\1740 hypotension\NN\14057371 ,\,\1740 respiratory\JJ\1740 depression\NN\14373582 ,\,\1740 and\CC\1740 bradycardia\NN\14110674 .\.\1740
D005283_D007022 CID Various\NNP\1740 reported\VBD\831651 side\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>fentanyl</e1>\JJ\1740 administration\NN\1133281 include\VBP\690614 chest\JJ\1740 wall\NN\3894379 rigidity\NN\5023233 ,\,\1740 <e2>hypotension</e2>\NN\14057371 ,\,\1740 respiratory\JJ\1740 depression\NN\14373582 ,\,\1740 and\CC\1740 bradycardia\NN\14110674 .\.\1740
D005283_D012131 CID Various\NNP\1740 reported\VBD\831651 side\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>fentanyl</e1>\JJ\1740 administration\NN\1133281 include\VBP\690614 chest\JJ\1740 wall\NN\3894379 rigidity\NN\5023233 ,\,\1740 hypotension\NN\14057371 ,\,\1740 <e2>respiratory\JJ\1740 depression</e2>\NN\14373582 ,\,\1740 and\CC\1740 bradycardia\NN\14110674 .\.\1740
D005283_D001919 CID Various\NNP\1740 reported\VBD\831651 side\JJ\1740 effects\NNS\13245626 of\IN\1740 <e1>fentanyl</e1>\JJ\1740 administration\NN\1133281 include\VBP\690614 chest\JJ\1740 wall\NN\3894379 rigidity\NN\5023233 ,\,\1740 hypotension\NN\14057371 ,\,\1740 respiratory\JJ\1740 depression\NN\14373582 ,\,\1740 and\CC\1740 <e2>bradycardia</e2>\NN\14110674 .\.\1740
D005283_D001745 CID Here\RB\1740 ,\,\1740 2\CD\13741022 cases\NNS\7283608 of\IN\1740 <e2>urinary\JJ\1740 bladder\NN\5515670 retention</e2>\NN\809465 leading\VBG\1752884 to\TO\1740 renal\JJ\1740 pelvocalyceal\NN\1740 dilatation\NN\14034177 mimicking\VBG\1742886 hydronephrosis\NN\14204950 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>fentanyl</e1>\NN\2707683 are\VBP\836236 reported\VBN\831651 .\.\1740
D005283_D006869 NONE Here\RB\1740 ,\,\1740 2\CD\13741022 cases\NNS\7283608 of\IN\1740 urinary\JJ\1740 bladder\NN\5515670 retention\NN\809465 leading\VBG\1752884 to\TO\1740 renal\JJ\1740 pelvocalyceal\NN\1740 dilatation\NN\14034177 mimicking\VBG\1742886 <e2>hydronephrosis</e2>\NN\14204950 as\IN\14622893 a\DT\13649268 result\NN\34213 of\IN\1740 continuous\JJ\1740 infusion\NN\14589223 of\IN\1740 <e1>fentanyl</e1>\NN\2707683 are\VBP\836236 reported\VBN\831651 .\.\1740
2024540
D004656_D006333 NONE Design\NN\927261 and\CC\1740 analysis\NN\633864 of\IN\1740 the\DT\1740 HYPREN-trial\NN\1740 :\:\1740 safety\NN\13920835 of\IN\1740 <e1>enalapril</e1>\NN\2673637 and\CC\1740 prazosin\NN\2698769 in\IN\13603305 the\DT\1740 initial\JJ\1740 treatment\NN\654885 phase\NN\15113229 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>congestive\JJ\1740 heart\NN\5919034 failure</e2>\NN\66216 .\.\1740
D011224_D006333 NONE Design\NN\927261 and\CC\1740 analysis\NN\633864 of\IN\1740 the\DT\1740 HYPREN-trial\NN\1740 :\:\1740 safety\NN\13920835 of\IN\1740 enalapril\NN\2673637 and\CC\1740 <e1>prazosin</e1>\NN\2698769 in\IN\13603305 the\DT\1740 initial\JJ\1740 treatment\NN\654885 phase\NN\15113229 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>congestive\JJ\1740 heart\NN\5919034 failure</e2>\NN\66216 .\.\1740
D000806_D006333 NONE Since\IN\1740 the\DT\1740 introduction\NN\235435 of\IN\1740 <e1>angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitors</e1>\NNS\20090 into\IN\1740 the\DT\1740 adjunctive\JJ\1740 treatment\NN\654885 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>congestive\JJ\1740 heart\NN\5919034 failure</e2>\NN\66216 ,\,\1740 cases\NNS\7283608 of\IN\1740 severe\JJ\1740 hypotension\NN\14057371 ,\,\1740 especially\RB\1740 on\IN\1740 the\DT\1740 first\JJ\1740 day\NN\15154774 of\IN\1740 treatment\NN\654885 ,\,\1740 have\VBP\2108377 occasionally\RB\1740 been\VBN\836236 reported\VBN\831651 .\.\1740
D000806_D007022 CID Since\IN\1740 the\DT\1740 introduction\NN\235435 of\IN\1740 <e1>angiotensin\NN\4522421 converting\NN\1740 enzyme\NN\14723628 (\-LRB-\1740 ACE\NN\13741022 )\-RRB-\1740 inhibitors</e1>\NNS\20090 into\IN\1740 the\DT\1740 adjunctive\JJ\1740 treatment\NN\654885 of\IN\1740 patients\NNS\9898892 with\IN\1740 congestive\JJ\1740 heart\NN\5919034 failure\NN\66216 ,\,\1740 cases\NNS\7283608 of\IN\1740 severe\JJ\1740 <e2>hypotension</e2>\NN\14057371 ,\,\1740 especially\RB\1740 on\IN\1740 the\DT\1740 first\JJ\1740 day\NN\15154774 of\IN\1740 treatment\NN\654885 ,\,\1740 have\VBP\2108377 occasionally\RB\1740 been\VBN\836236 reported\VBN\831651 .\.\1740
D000806_D007022 CID To\TO\1740 assess\VB\670261 the\DT\1740 safety\NN\13920835 of\IN\1740 the\DT\1740 <e1>ACE\NN\13741022 inhibitor</e1>\NN\20090 enalapril\NN\2673637 a\DT\13649268 multicenter\NN\1740 ,\,\1740 randomized\VBN\278117 ,\,\1740 prazosin-controlled\JJ\1740 trial\NN\786195 was\VBD\836236 designed\VBN\1631534 that\IN\1740 compared\VBD\644583 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 symptomatic\JJ\1740 <e2>hypotension</e2>\NN\14057371 on\IN\1740 the\DT\1740 first\JJ\1740 day\NN\15154774 of\IN\1740 treatment\NN\654885 .\.\1740
D004656_D007022 NONE To\TO\1740 assess\VB\670261 the\DT\1740 safety\NN\13920835 of\IN\1740 the\DT\1740 ACE\NN\13741022 inhibitor\NN\20090 <e1>enalapril</e1>\NN\2673637 a\DT\13649268 multicenter\NN\1740 ,\,\1740 randomized\VBN\278117 ,\,\1740 prazosin-controlled\JJ\1740 trial\NN\786195 was\VBD\836236 designed\VBN\1631534 that\IN\1740 compared\VBD\644583 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 symptomatic\JJ\1740 <e2>hypotension</e2>\NN\14057371 on\IN\1740 the\DT\1740 first\JJ\1740 day\NN\15154774 of\IN\1740 treatment\NN\654885 .\.\1740
D004656_D007022 NONE Patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 <e1>enalapril</e1>\NN\2673637 experienced\VBN\2108377 clinically\RB\1740 and\CC\1740 statistically\RB\1740 significantly\RB\1740 less\RBR\1740 symptomatic\JJ\1740 <e2>hypotension</e2>\NN\14057371 (\-LRB-\1740 5.2\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 the\DT\1740 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 prazosin\NN\2698769 (\-LRB-\1740 12.9\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D011224_D007022 CID To\TO\1740 assess\VB\670261 the\DT\1740 safety\NN\13920835 of\IN\1740 the\DT\1740 ACE\NN\13741022 inhibitor\NN\20090 enalapril\NN\2673637 a\DT\13649268 multicenter\NN\1740 ,\,\1740 randomized\VBN\278117 ,\,\1740 <e1>prazosin-controlled</e1>\JJ\1740 trial\NN\786195 was\VBD\836236 designed\VBN\1631534 that\IN\1740 compared\VBD\644583 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 symptomatic\JJ\1740 <e2>hypotension</e2>\NN\14057371 on\IN\1740 the\DT\1740 first\JJ\1740 day\NN\15154774 of\IN\1740 treatment\NN\654885 .\.\1740
D011224_D007022 CID Patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 enalapril\NN\2673637 experienced\VBN\2108377 clinically\RB\1740 and\CC\1740 statistically\RB\1740 significantly\RB\1740 less\RBR\1740 symptomatic\JJ\1740 <e2>hypotension</e2>\NN\14057371 (\-LRB-\1740 5.2\CD\1740 %\NN\1740 )\-RRB-\1740 than\IN\1740 the\DT\1740 patients\NNS\9898892 who\WP\8299493 received\VBD\2210855 <e1>prazosin</e1>\NN\2698769 (\-LRB-\1740 12.9\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
19300402
D001920_D006930 NONE <e1>Bradykinin</e1>\NNP\1740 receptors\NNS\5225602 antagonists\NNS\7846 and\CC\1740 nitric\JJ\1740 oxide\NN\14818238 synthase\NN\1740 inhibitors\NNS\20090 in\IN\13603305 vincristine\NN\3917455 and\CC\1740 streptozotocin\NN\1740 induced\VBD\1627355 <e2>hyperalgesia</e2>\NN\1740 in\IN\13603305 chemotherapy\NN\661091 and\CC\1740 diabetic\JJ\1740 neuropathy\JJ\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D001920_D006930 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 results\NNS\34213 of\IN\1740 this\DT\1740 paper\NN\14580897 confirm\VBP\1011725 that\IN\1740 inhibition\NN\1068773 of\IN\1740 <e1>bradykinin</e1>\NN\1740 receptors\NNS\5225602 and\CC\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 but\CC\1740 not\RB\1740 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 activity\NN\30358 reduces\VBZ\441445 <e2>diabetic\JJ\1740 hyperalgesia</e2>\NN\1740 .\.\1740
D001920_D006930 NONE It\PRP\6125041 was\VBD\836236 also\RB\1740 shown\VBN\2137132 that\IN\1740 both\DT\1740 products\NNS\3076708 of\IN\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 and\CC\1740 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 activation\NN\13561719 as\RB\1740 well\RB\1740 as\IN\14622893 <e1>bradykinin</e1>\NN\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 <e2>hyperalgesia</e2>\NN\1740 produced\VBN\1617192 by\IN\1740 vincristine\NN\3917455 .\.\1740
D001920_D006930 NONE In\IN\13603305 streptozotocin-induced\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 ,\,\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 participates\VBZ\2367363 in\IN\13603305 pronociceptive\JJ\1740 activity\NN\30358 of\IN\1740 <e1>bradykinin</e1>\NN\1740 ,\,\1740 whereas\IN\1740 in\IN\13603305 vincristine-induced\JJ\1740 hyperalgesia\NN\1740 bradykinin\NN\1740 seemed\VBD\2604760 to\TO\1740 activate\VB\1641914 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 pathway\NN\5483677 .\.\1740
D001920_D006930 NONE In\IN\13603305 streptozotocin-induced\JJ\1740 hyperalgesia\NN\1740 ,\,\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 participates\VBZ\2367363 in\IN\13603305 pronociceptive\JJ\1740 activity\NN\30358 of\IN\1740 <e1>bradykinin</e1>\NN\1740 ,\,\1740 whereas\IN\1740 in\IN\13603305 vincristine-induced\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 bradykinin\NN\1740 seemed\VBD\2604760 to\TO\1740 activate\VB\1641914 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 pathway\NN\5483677 .\.\1740
D001920_D006930 NONE In\IN\13603305 streptozotocin-induced\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 ,\,\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 participates\VBZ\2367363 in\IN\13603305 pronociceptive\JJ\1740 activity\NN\30358 of\IN\1740 bradykinin\NN\1740 ,\,\1740 whereas\IN\1740 in\IN\13603305 vincristine-induced\JJ\1740 hyperalgesia\NN\1740 <e1>bradykinin</e1>\NN\1740 seemed\VBD\2604760 to\TO\1740 activate\VB\1641914 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 pathway\NN\5483677 .\.\1740
D001920_D006930 NONE In\IN\13603305 streptozotocin-induced\JJ\1740 hyperalgesia\NN\1740 ,\,\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 participates\VBZ\2367363 in\IN\13603305 pronociceptive\JJ\1740 activity\NN\30358 of\IN\1740 bradykinin\NN\1740 ,\,\1740 whereas\IN\1740 in\IN\13603305 vincristine-induced\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 <e1>bradykinin</e1>\NN\1740 seemed\VBD\2604760 to\TO\1740 activate\VB\1641914 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 pathway\NN\5483677 .\.\1740
D001920_D003929 NONE <e1>Bradykinin</e1>\NNP\1740 receptors\NNS\5225602 antagonists\NNS\7846 and\CC\1740 nitric\JJ\1740 oxide\NN\14818238 synthase\NN\1740 inhibitors\NNS\20090 in\IN\13603305 vincristine\NN\3917455 and\CC\1740 streptozotocin\NN\1740 induced\VBD\1627355 hyperalgesia\NN\1740 in\IN\13603305 chemotherapy\NN\661091 and\CC\1740 <e2>diabetic\JJ\1740 neuropathy</e2>\JJ\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D001920_D003929 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 influence\NN\5190804 of\IN\1740 an\DT\6697703 irreversible\JJ\1740 inhibitor\NN\20090 of\IN\1740 constitutive\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NOArg\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 a\DT\13649268 relatively\RB\1740 selective\JJ\1740 inhibitor\NN\20090 of\IN\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NIL\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 and\CC\1740 a\DT\13649268 relatively\RB\1740 specific\JJ\1740 inhibitor\NN\20090 of\IN\1740 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 7-NI\CD\1740 ;\:\1740 0.1\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 on\IN\1740 antihyperalgesic\JJ\1740 action\NN\30358 of\IN\1740 selective\JJ\1740 antagonists\NNS\7846 of\IN\1740 B2\NN\1740 and\CC\1740 B1\NN\1740 receptors\NNS\5225602 :\:\1740 D-Arg-[Hyp3,Thi5,D-Tic7,Oic8\NN\1740 ]\-RRB-\1740 <e1>bradykinin</e1>\NN\1740 (\-LRB-\1740 HOE\NN\4451818 140\CD\1740 ;\:\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 or\CC\3541091 des\VBZ\1740 Arg10\NN\1740 HOE\NN\4451818 140\CD\1740 (\-LRB-\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 respectively\RB\1740 ,\,\1740 in\IN\13603305 model\NN\5888929 of\IN\1740 <e2>diabetic\JJ\1740 (\-LRB-\1740 streptozotocin-induced\JJ\1740 )\-RRB-\1740 and\CC\1740 toxic\JJ\1740 (\-LRB-\1740 vincristine-induced\JJ\1740 )\-RRB-\1740 neuropathy</e2>\RB\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
D009569_D006930 NONE Bradykinin\NNP\1740 receptors\NNS\5225602 antagonists\NNS\7846 and\CC\1740 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 synthase\NN\1740 inhibitors\NNS\20090 in\IN\13603305 vincristine\NN\3917455 and\CC\1740 streptozotocin\NN\1740 induced\VBD\1627355 <e2>hyperalgesia</e2>\NN\1740 in\IN\13603305 chemotherapy\NN\661091 and\CC\1740 diabetic\JJ\1740 neuropathy\JJ\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D009569_D006930 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 results\NNS\34213 of\IN\1740 this\DT\1740 paper\NN\14580897 confirm\VBP\1011725 that\IN\1740 inhibition\NN\1068773 of\IN\1740 bradykinin\NN\1740 receptors\NNS\5225602 and\CC\1740 inducible\JJ\1740 <e1>NO</e1>\NN\7204911 synthase\NN\1740 but\CC\1740 not\RB\1740 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 activity\NN\30358 reduces\VBZ\441445 <e2>diabetic\JJ\1740 hyperalgesia</e2>\NN\1740 .\.\1740
D009569_D006930 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 results\NNS\34213 of\IN\1740 this\DT\1740 paper\NN\14580897 confirm\VBP\1011725 that\IN\1740 inhibition\NN\1068773 of\IN\1740 bradykinin\NN\1740 receptors\NNS\5225602 and\CC\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 but\CC\1740 not\RB\1740 neuronal\JJ\1740 <e1>NO</e1>\NN\7204911 synthase\NN\1740 activity\NN\30358 reduces\VBZ\441445 <e2>diabetic\JJ\1740 hyperalgesia</e2>\NN\1740 .\.\1740
D009569_D006930 NONE It\PRP\6125041 was\VBD\836236 also\RB\1740 shown\VBN\2137132 that\IN\1740 both\DT\1740 products\NNS\3076708 of\IN\1740 inducible\JJ\1740 <e1>NO</e1>\NN\7204911 synthase\NN\1740 and\CC\1740 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 activation\NN\13561719 as\RB\1740 well\RB\1740 as\IN\14622893 bradykinin\NN\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 <e2>hyperalgesia</e2>\NN\1740 produced\VBN\1617192 by\IN\1740 vincristine\NN\3917455 .\.\1740
D009569_D006930 NONE It\PRP\6125041 was\VBD\836236 also\RB\1740 shown\VBN\2137132 that\IN\1740 both\DT\1740 products\NNS\3076708 of\IN\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 and\CC\1740 neuronal\JJ\1740 <e1>NO</e1>\NN\7204911 synthase\NN\1740 activation\NN\13561719 as\RB\1740 well\RB\1740 as\IN\14622893 bradykinin\NN\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 <e2>hyperalgesia</e2>\NN\1740 produced\VBN\1617192 by\IN\1740 vincristine\NN\3917455 .\.\1740
D009569_D006930 NONE In\IN\13603305 streptozotocin-induced\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 ,\,\1740 inducible\JJ\1740 <e1>NO</e1>\NN\7204911 synthase\NN\1740 participates\VBZ\2367363 in\IN\13603305 pronociceptive\JJ\1740 activity\NN\30358 of\IN\1740 bradykinin\NN\1740 ,\,\1740 whereas\IN\1740 in\IN\13603305 vincristine-induced\JJ\1740 hyperalgesia\NN\1740 bradykinin\NN\1740 seemed\VBD\2604760 to\TO\1740 activate\VB\1641914 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 pathway\NN\5483677 .\.\1740
D009569_D006930 NONE In\IN\13603305 streptozotocin-induced\JJ\1740 hyperalgesia\NN\1740 ,\,\1740 inducible\JJ\1740 <e1>NO</e1>\NN\7204911 synthase\NN\1740 participates\VBZ\2367363 in\IN\13603305 pronociceptive\JJ\1740 activity\NN\30358 of\IN\1740 bradykinin\NN\1740 ,\,\1740 whereas\IN\1740 in\IN\13603305 vincristine-induced\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 bradykinin\NN\1740 seemed\VBD\2604760 to\TO\1740 activate\VB\1641914 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 pathway\NN\5483677 .\.\1740
D009569_D006930 NONE In\IN\13603305 streptozotocin-induced\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 ,\,\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 participates\VBZ\2367363 in\IN\13603305 pronociceptive\JJ\1740 activity\NN\30358 of\IN\1740 bradykinin\NN\1740 ,\,\1740 whereas\IN\1740 in\IN\13603305 vincristine-induced\JJ\1740 hyperalgesia\NN\1740 bradykinin\NN\1740 seemed\VBD\2604760 to\TO\1740 activate\VB\1641914 neuronal\JJ\1740 <e1>NO</e1>\NN\7204911 synthase\NN\1740 pathway\NN\5483677 .\.\1740
D009569_D006930 NONE In\IN\13603305 streptozotocin-induced\JJ\1740 hyperalgesia\NN\1740 ,\,\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 participates\VBZ\2367363 in\IN\13603305 pronociceptive\JJ\1740 activity\NN\30358 of\IN\1740 bradykinin\NN\1740 ,\,\1740 whereas\IN\1740 in\IN\13603305 vincristine-induced\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 bradykinin\NN\1740 seemed\VBD\2604760 to\TO\1740 activate\VB\1641914 neuronal\JJ\1740 <e1>NO</e1>\NN\7204911 synthase\NN\1740 pathway\NN\5483677 .\.\1740
D009569_D003929 NONE Bradykinin\NNP\1740 receptors\NNS\5225602 antagonists\NNS\7846 and\CC\1740 <e1>nitric\JJ\1740 oxide</e1>\NN\14818238 synthase\NN\1740 inhibitors\NNS\20090 in\IN\13603305 vincristine\NN\3917455 and\CC\1740 streptozotocin\NN\1740 induced\VBD\1627355 hyperalgesia\NN\1740 in\IN\13603305 chemotherapy\NN\661091 and\CC\1740 <e2>diabetic\JJ\1740 neuropathy</e2>\JJ\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D009569_D003929 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 influence\NN\5190804 of\IN\1740 an\DT\6697703 irreversible\JJ\1740 inhibitor\NN\20090 of\IN\1740 constitutive\JJ\1740 <e1>NO</e1>\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NOArg\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 a\DT\13649268 relatively\RB\1740 selective\JJ\1740 inhibitor\NN\20090 of\IN\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NIL\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 and\CC\1740 a\DT\13649268 relatively\RB\1740 specific\JJ\1740 inhibitor\NN\20090 of\IN\1740 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 7-NI\CD\1740 ;\:\1740 0.1\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 on\IN\1740 antihyperalgesic\JJ\1740 action\NN\30358 of\IN\1740 selective\JJ\1740 antagonists\NNS\7846 of\IN\1740 B2\NN\1740 and\CC\1740 B1\NN\1740 receptors\NNS\5225602 :\:\1740 D-Arg-[Hyp3,Thi5,D-Tic7,Oic8\NN\1740 ]\-RRB-\1740 bradykinin\NN\1740 (\-LRB-\1740 HOE\NN\4451818 140\CD\1740 ;\:\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 or\CC\3541091 des\VBZ\1740 Arg10\NN\1740 HOE\NN\4451818 140\CD\1740 (\-LRB-\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 respectively\RB\1740 ,\,\1740 in\IN\13603305 model\NN\5888929 of\IN\1740 <e2>diabetic\JJ\1740 (\-LRB-\1740 streptozotocin-induced\JJ\1740 )\-RRB-\1740 and\CC\1740 toxic\JJ\1740 (\-LRB-\1740 vincristine-induced\JJ\1740 )\-RRB-\1740 neuropathy</e2>\RB\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
D009569_D003929 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 influence\NN\5190804 of\IN\1740 an\DT\6697703 irreversible\JJ\1740 inhibitor\NN\20090 of\IN\1740 constitutive\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NOArg\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 a\DT\13649268 relatively\RB\1740 selective\JJ\1740 inhibitor\NN\20090 of\IN\1740 inducible\JJ\1740 <e1>NO</e1>\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NIL\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 and\CC\1740 a\DT\13649268 relatively\RB\1740 specific\JJ\1740 inhibitor\NN\20090 of\IN\1740 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 7-NI\CD\1740 ;\:\1740 0.1\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 on\IN\1740 antihyperalgesic\JJ\1740 action\NN\30358 of\IN\1740 selective\JJ\1740 antagonists\NNS\7846 of\IN\1740 B2\NN\1740 and\CC\1740 B1\NN\1740 receptors\NNS\5225602 :\:\1740 D-Arg-[Hyp3,Thi5,D-Tic7,Oic8\NN\1740 ]\-RRB-\1740 bradykinin\NN\1740 (\-LRB-\1740 HOE\NN\4451818 140\CD\1740 ;\:\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 or\CC\3541091 des\VBZ\1740 Arg10\NN\1740 HOE\NN\4451818 140\CD\1740 (\-LRB-\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 respectively\RB\1740 ,\,\1740 in\IN\13603305 model\NN\5888929 of\IN\1740 <e2>diabetic\JJ\1740 (\-LRB-\1740 streptozotocin-induced\JJ\1740 )\-RRB-\1740 and\CC\1740 toxic\JJ\1740 (\-LRB-\1740 vincristine-induced\JJ\1740 )\-RRB-\1740 neuropathy</e2>\RB\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
D009569_D003929 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 influence\NN\5190804 of\IN\1740 an\DT\6697703 irreversible\JJ\1740 inhibitor\NN\20090 of\IN\1740 constitutive\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NOArg\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 a\DT\13649268 relatively\RB\1740 selective\JJ\1740 inhibitor\NN\20090 of\IN\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NIL\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 and\CC\1740 a\DT\13649268 relatively\RB\1740 specific\JJ\1740 inhibitor\NN\20090 of\IN\1740 neuronal\JJ\1740 <e1>NO</e1>\NN\7204911 synthase\NN\1740 (\-LRB-\1740 7-NI\CD\1740 ;\:\1740 0.1\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 on\IN\1740 antihyperalgesic\JJ\1740 action\NN\30358 of\IN\1740 selective\JJ\1740 antagonists\NNS\7846 of\IN\1740 B2\NN\1740 and\CC\1740 B1\NN\1740 receptors\NNS\5225602 :\:\1740 D-Arg-[Hyp3,Thi5,D-Tic7,Oic8\NN\1740 ]\-RRB-\1740 bradykinin\NN\1740 (\-LRB-\1740 HOE\NN\4451818 140\CD\1740 ;\:\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 or\CC\3541091 des\VBZ\1740 Arg10\NN\1740 HOE\NN\4451818 140\CD\1740 (\-LRB-\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 respectively\RB\1740 ,\,\1740 in\IN\13603305 model\NN\5888929 of\IN\1740 <e2>diabetic\JJ\1740 (\-LRB-\1740 streptozotocin-induced\JJ\1740 )\-RRB-\1740 and\CC\1740 toxic\JJ\1740 (\-LRB-\1740 vincristine-induced\JJ\1740 )\-RRB-\1740 neuropathy</e2>\RB\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
D014750_D006930 CID Bradykinin\NNP\1740 receptors\NNS\5225602 antagonists\NNS\7846 and\CC\1740 nitric\JJ\1740 oxide\NN\14818238 synthase\NN\1740 inhibitors\NNS\20090 in\IN\13603305 <e1>vincristine</e1>\NN\3917455 and\CC\1740 streptozotocin\NN\1740 induced\VBD\1627355 <e2>hyperalgesia</e2>\NN\1740 in\IN\13603305 chemotherapy\NN\661091 and\CC\1740 diabetic\JJ\1740 neuropathy\JJ\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D014750_D006930 CID It\PRP\6125041 was\VBD\836236 also\RB\1740 shown\VBN\2137132 that\IN\1740 both\DT\1740 products\NNS\3076708 of\IN\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 and\CC\1740 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 activation\NN\13561719 as\RB\1740 well\RB\1740 as\IN\14622893 bradykinin\NN\1740 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 <e2>hyperalgesia</e2>\NN\1740 produced\VBN\1617192 by\IN\1740 <e1>vincristine</e1>\NN\3917455 .\.\1740
D014750_D006930 CID In\IN\13603305 streptozotocin-induced\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 ,\,\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 participates\VBZ\2367363 in\IN\13603305 pronociceptive\JJ\1740 activity\NN\30358 of\IN\1740 bradykinin\NN\1740 ,\,\1740 whereas\IN\1740 in\IN\13603305 <e1>vincristine-induced</e1>\JJ\1740 hyperalgesia\NN\1740 bradykinin\NN\1740 seemed\VBD\2604760 to\TO\1740 activate\VB\1641914 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 pathway\NN\5483677 .\.\1740
D014750_D006930 CID In\IN\13603305 streptozotocin-induced\JJ\1740 hyperalgesia\NN\1740 ,\,\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 participates\VBZ\2367363 in\IN\13603305 pronociceptive\JJ\1740 activity\NN\30358 of\IN\1740 bradykinin\NN\1740 ,\,\1740 whereas\IN\1740 in\IN\13603305 <e1>vincristine-induced</e1>\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 bradykinin\NN\1740 seemed\VBD\2604760 to\TO\1740 activate\VB\1641914 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 pathway\NN\5483677 .\.\1740
D014750_D003929 NONE Bradykinin\NNP\1740 receptors\NNS\5225602 antagonists\NNS\7846 and\CC\1740 nitric\JJ\1740 oxide\NN\14818238 synthase\NN\1740 inhibitors\NNS\20090 in\IN\13603305 <e1>vincristine</e1>\NN\3917455 and\CC\1740 streptozotocin\NN\1740 induced\VBD\1627355 hyperalgesia\NN\1740 in\IN\13603305 chemotherapy\NN\661091 and\CC\1740 <e2>diabetic\JJ\1740 neuropathy</e2>\JJ\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D013311_D006930 CID Bradykinin\NNP\1740 receptors\NNS\5225602 antagonists\NNS\7846 and\CC\1740 nitric\JJ\1740 oxide\NN\14818238 synthase\NN\1740 inhibitors\NNS\20090 in\IN\13603305 vincristine\NN\3917455 and\CC\1740 <e1>streptozotocin</e1>\NN\1740 induced\VBD\1627355 <e2>hyperalgesia</e2>\NN\1740 in\IN\13603305 chemotherapy\NN\661091 and\CC\1740 diabetic\JJ\1740 neuropathy\JJ\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D013311_D006930 CID In\IN\13603305 <e1>streptozotocin-induced</e1>\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 ,\,\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 participates\VBZ\2367363 in\IN\13603305 pronociceptive\JJ\1740 activity\NN\30358 of\IN\1740 bradykinin\NN\1740 ,\,\1740 whereas\IN\1740 in\IN\13603305 vincristine-induced\JJ\1740 hyperalgesia\NN\1740 bradykinin\NN\1740 seemed\VBD\2604760 to\TO\1740 activate\VB\1641914 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 pathway\NN\5483677 .\.\1740
D013311_D006930 CID In\IN\13603305 <e1>streptozotocin-induced</e1>\JJ\1740 hyperalgesia\NN\1740 ,\,\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 participates\VBZ\2367363 in\IN\13603305 pronociceptive\JJ\1740 activity\NN\30358 of\IN\1740 bradykinin\NN\1740 ,\,\1740 whereas\IN\1740 in\IN\13603305 vincristine-induced\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 bradykinin\NN\1740 seemed\VBD\2604760 to\TO\1740 activate\VB\1641914 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 pathway\NN\5483677 .\.\1740
D013311_D003929 CID Bradykinin\NNP\1740 receptors\NNS\5225602 antagonists\NNS\7846 and\CC\1740 nitric\JJ\1740 oxide\NN\14818238 synthase\NN\1740 inhibitors\NNS\20090 in\IN\13603305 vincristine\NN\3917455 and\CC\1740 <e1>streptozotocin</e1>\NN\1740 induced\VBD\1627355 hyperalgesia\NN\1740 in\IN\13603305 chemotherapy\NN\661091 and\CC\1740 <e2>diabetic\JJ\1740 neuropathy</e2>\JJ\1740 rat\NN\2329401 model\NN\5888929 .\.\1740
D009569_D010523 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 influence\NN\5190804 of\IN\1740 an\DT\6697703 irreversible\JJ\1740 inhibitor\NN\20090 of\IN\1740 constitutive\JJ\1740 <e1>NO</e1>\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NOArg\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 a\DT\13649268 relatively\RB\1740 selective\JJ\1740 inhibitor\NN\20090 of\IN\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NIL\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 and\CC\1740 a\DT\13649268 relatively\RB\1740 specific\JJ\1740 inhibitor\NN\20090 of\IN\1740 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 7-NI\CD\1740 ;\:\1740 0.1\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 on\IN\1740 antihyperalgesic\JJ\1740 action\NN\30358 of\IN\1740 selective\JJ\1740 antagonists\NNS\7846 of\IN\1740 B2\NN\1740 and\CC\1740 B1\NN\1740 receptors\NNS\5225602 :\:\1740 D-Arg-[Hyp3,Thi5,D-Tic7,Oic8\NN\1740 ]\-RRB-\1740 bradykinin\NN\1740 (\-LRB-\1740 HOE\NN\4451818 140\CD\1740 ;\:\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 or\CC\3541091 des\VBZ\1740 Arg10\NN\1740 HOE\NN\4451818 140\CD\1740 (\-LRB-\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 respectively\RB\1740 ,\,\1740 in\IN\13603305 model\NN\5888929 of\IN\1740 <e2>diabetic\JJ\1740 (\-LRB-\1740 streptozotocin-induced\JJ\1740 )\-RRB-\1740 and\CC\1740 toxic\JJ\1740 (\-LRB-\1740 vincristine-induced\JJ\1740 )\-RRB-\1740 neuropathy</e2>\RB\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
D009569_D010523 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 influence\NN\5190804 of\IN\1740 an\DT\6697703 irreversible\JJ\1740 inhibitor\NN\20090 of\IN\1740 constitutive\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NOArg\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 a\DT\13649268 relatively\RB\1740 selective\JJ\1740 inhibitor\NN\20090 of\IN\1740 inducible\JJ\1740 <e1>NO</e1>\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NIL\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 and\CC\1740 a\DT\13649268 relatively\RB\1740 specific\JJ\1740 inhibitor\NN\20090 of\IN\1740 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 7-NI\CD\1740 ;\:\1740 0.1\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 on\IN\1740 antihyperalgesic\JJ\1740 action\NN\30358 of\IN\1740 selective\JJ\1740 antagonists\NNS\7846 of\IN\1740 B2\NN\1740 and\CC\1740 B1\NN\1740 receptors\NNS\5225602 :\:\1740 D-Arg-[Hyp3,Thi5,D-Tic7,Oic8\NN\1740 ]\-RRB-\1740 bradykinin\NN\1740 (\-LRB-\1740 HOE\NN\4451818 140\CD\1740 ;\:\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 or\CC\3541091 des\VBZ\1740 Arg10\NN\1740 HOE\NN\4451818 140\CD\1740 (\-LRB-\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 respectively\RB\1740 ,\,\1740 in\IN\13603305 model\NN\5888929 of\IN\1740 <e2>diabetic\JJ\1740 (\-LRB-\1740 streptozotocin-induced\JJ\1740 )\-RRB-\1740 and\CC\1740 toxic\JJ\1740 (\-LRB-\1740 vincristine-induced\JJ\1740 )\-RRB-\1740 neuropathy</e2>\RB\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
D009569_D010523 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 influence\NN\5190804 of\IN\1740 an\DT\6697703 irreversible\JJ\1740 inhibitor\NN\20090 of\IN\1740 constitutive\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NOArg\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 a\DT\13649268 relatively\RB\1740 selective\JJ\1740 inhibitor\NN\20090 of\IN\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NIL\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 and\CC\1740 a\DT\13649268 relatively\RB\1740 specific\JJ\1740 inhibitor\NN\20090 of\IN\1740 neuronal\JJ\1740 <e1>NO</e1>\NN\7204911 synthase\NN\1740 (\-LRB-\1740 7-NI\CD\1740 ;\:\1740 0.1\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 on\IN\1740 antihyperalgesic\JJ\1740 action\NN\30358 of\IN\1740 selective\JJ\1740 antagonists\NNS\7846 of\IN\1740 B2\NN\1740 and\CC\1740 B1\NN\1740 receptors\NNS\5225602 :\:\1740 D-Arg-[Hyp3,Thi5,D-Tic7,Oic8\NN\1740 ]\-RRB-\1740 bradykinin\NN\1740 (\-LRB-\1740 HOE\NN\4451818 140\CD\1740 ;\:\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 or\CC\3541091 des\VBZ\1740 Arg10\NN\1740 HOE\NN\4451818 140\CD\1740 (\-LRB-\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 respectively\RB\1740 ,\,\1740 in\IN\13603305 model\NN\5888929 of\IN\1740 <e2>diabetic\JJ\1740 (\-LRB-\1740 streptozotocin-induced\JJ\1740 )\-RRB-\1740 and\CC\1740 toxic\JJ\1740 (\-LRB-\1740 vincristine-induced\JJ\1740 )\-RRB-\1740 neuropathy</e2>\RB\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
D001920_D010523 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 influence\NN\5190804 of\IN\1740 an\DT\6697703 irreversible\JJ\1740 inhibitor\NN\20090 of\IN\1740 constitutive\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NOArg\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 a\DT\13649268 relatively\RB\1740 selective\JJ\1740 inhibitor\NN\20090 of\IN\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NIL\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 and\CC\1740 a\DT\13649268 relatively\RB\1740 specific\JJ\1740 inhibitor\NN\20090 of\IN\1740 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 7-NI\CD\1740 ;\:\1740 0.1\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 on\IN\1740 antihyperalgesic\JJ\1740 action\NN\30358 of\IN\1740 selective\JJ\1740 antagonists\NNS\7846 of\IN\1740 B2\NN\1740 and\CC\1740 B1\NN\1740 receptors\NNS\5225602 :\:\1740 D-Arg-[Hyp3,Thi5,D-Tic7,Oic8\NN\1740 ]\-RRB-\1740 <e1>bradykinin</e1>\NN\1740 (\-LRB-\1740 HOE\NN\4451818 140\CD\1740 ;\:\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 or\CC\3541091 des\VBZ\1740 Arg10\NN\1740 HOE\NN\4451818 140\CD\1740 (\-LRB-\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 respectively\RB\1740 ,\,\1740 in\IN\13603305 model\NN\5888929 of\IN\1740 <e2>diabetic\JJ\1740 (\-LRB-\1740 streptozotocin-induced\JJ\1740 )\-RRB-\1740 and\CC\1740 toxic\JJ\1740 (\-LRB-\1740 vincristine-induced\JJ\1740 )\-RRB-\1740 neuropathy</e2>\RB\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
C065679_D003929 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 influence\NN\5190804 of\IN\1740 an\DT\6697703 irreversible\JJ\1740 inhibitor\NN\20090 of\IN\1740 constitutive\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NOArg\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 a\DT\13649268 relatively\RB\1740 selective\JJ\1740 inhibitor\NN\20090 of\IN\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NIL\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 and\CC\1740 a\DT\13649268 relatively\RB\1740 specific\JJ\1740 inhibitor\NN\20090 of\IN\1740 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 7-NI\CD\1740 ;\:\1740 0.1\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 on\IN\1740 antihyperalgesic\JJ\1740 action\NN\30358 of\IN\1740 selective\JJ\1740 antagonists\NNS\7846 of\IN\1740 B2\NN\1740 and\CC\1740 B1\NN\1740 receptors\NNS\5225602 :\:\1740 D-Arg-[Hyp3,Thi5,D-Tic7,Oic8\NN\1740 ]\-RRB-\1740 bradykinin\NN\1740 (\-LRB-\1740 <e1>HOE\NN\4451818 140</e1>\CD\1740 ;\:\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 or\CC\3541091 des\VBZ\1740 Arg10\NN\1740 HOE\NN\4451818 140\CD\1740 (\-LRB-\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 respectively\RB\1740 ,\,\1740 in\IN\13603305 model\NN\5888929 of\IN\1740 <e2>diabetic\JJ\1740 (\-LRB-\1740 streptozotocin-induced\JJ\1740 )\-RRB-\1740 and\CC\1740 toxic\JJ\1740 (\-LRB-\1740 vincristine-induced\JJ\1740 )\-RRB-\1740 neuropathy</e2>\RB\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
C065679_D010523 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 influence\NN\5190804 of\IN\1740 an\DT\6697703 irreversible\JJ\1740 inhibitor\NN\20090 of\IN\1740 constitutive\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NOArg\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 a\DT\13649268 relatively\RB\1740 selective\JJ\1740 inhibitor\NN\20090 of\IN\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NIL\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 and\CC\1740 a\DT\13649268 relatively\RB\1740 specific\JJ\1740 inhibitor\NN\20090 of\IN\1740 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 7-NI\CD\1740 ;\:\1740 0.1\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 on\IN\1740 antihyperalgesic\JJ\1740 action\NN\30358 of\IN\1740 selective\JJ\1740 antagonists\NNS\7846 of\IN\1740 B2\NN\1740 and\CC\1740 B1\NN\1740 receptors\NNS\5225602 :\:\1740 D-Arg-[Hyp3,Thi5,D-Tic7,Oic8\NN\1740 ]\-RRB-\1740 bradykinin\NN\1740 (\-LRB-\1740 <e1>HOE\NN\4451818 140</e1>\CD\1740 ;\:\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 or\CC\3541091 des\VBZ\1740 Arg10\NN\1740 HOE\NN\4451818 140\CD\1740 (\-LRB-\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 respectively\RB\1740 ,\,\1740 in\IN\13603305 model\NN\5888929 of\IN\1740 <e2>diabetic\JJ\1740 (\-LRB-\1740 streptozotocin-induced\JJ\1740 )\-RRB-\1740 and\CC\1740 toxic\JJ\1740 (\-LRB-\1740 vincristine-induced\JJ\1740 )\-RRB-\1740 neuropathy</e2>\RB\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
C065679_D010523 NONE Moreover\RB\1740 ,\,\1740 L-NOArg\NN\1740 and\CC\1740 7-NI\CD\1740 but\CC\1740 not\RB\1740 L-NIL\NN\1740 intensify\VBP\153263 antihyperalgesic\JJ\1740 activity\NN\30358 of\IN\1740 <e1>HOE\NN\4451818 140</e1>\CD\1740 or\CC\3541091 des-Arg10HOE\NN\1740 140\CD\1740 in\IN\13603305 <e2>toxic\JJ\1740 neuropathy</e2>\NN\14204950 .\.\1740
C078665_D003929 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 influence\NN\5190804 of\IN\1740 an\DT\6697703 irreversible\JJ\1740 inhibitor\NN\20090 of\IN\1740 constitutive\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NOArg\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 a\DT\13649268 relatively\RB\1740 selective\JJ\1740 inhibitor\NN\20090 of\IN\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NIL\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 and\CC\1740 a\DT\13649268 relatively\RB\1740 specific\JJ\1740 inhibitor\NN\20090 of\IN\1740 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 7-NI\CD\1740 ;\:\1740 0.1\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 on\IN\1740 antihyperalgesic\JJ\1740 action\NN\30358 of\IN\1740 selective\JJ\1740 antagonists\NNS\7846 of\IN\1740 B2\NN\1740 and\CC\1740 B1\NN\1740 receptors\NNS\5225602 :\:\1740 D-Arg-[Hyp3,Thi5,D-Tic7,Oic8\NN\1740 ]\-RRB-\1740 bradykinin\NN\1740 (\-LRB-\1740 HOE\NN\4451818 140\CD\1740 ;\:\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 or\CC\3541091 <e1>des\VBZ\1740 Arg10\NN\1740 HOE\NN\4451818 140</e1>\CD\1740 (\-LRB-\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 respectively\RB\1740 ,\,\1740 in\IN\13603305 model\NN\5888929 of\IN\1740 <e2>diabetic\JJ\1740 (\-LRB-\1740 streptozotocin-induced\JJ\1740 )\-RRB-\1740 and\CC\1740 toxic\JJ\1740 (\-LRB-\1740 vincristine-induced\JJ\1740 )\-RRB-\1740 neuropathy</e2>\RB\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
C078665_D010523 NONE PURPOSE\NNP\5980875 :\:\1740 The\DT\1740 influence\NN\5190804 of\IN\1740 an\DT\6697703 irreversible\JJ\1740 inhibitor\NN\20090 of\IN\1740 constitutive\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NOArg\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 a\DT\13649268 relatively\RB\1740 selective\JJ\1740 inhibitor\NN\20090 of\IN\1740 inducible\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 L-NIL\NN\1740 ;\:\1740 1.0\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 and\CC\1740 a\DT\13649268 relatively\RB\1740 specific\JJ\1740 inhibitor\NN\20090 of\IN\1740 neuronal\JJ\1740 NO\NN\7204911 synthase\NN\1740 (\-LRB-\1740 7-NI\CD\1740 ;\:\1740 0.1\CD\1740 mg/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 ,\,\1740 on\IN\1740 antihyperalgesic\JJ\1740 action\NN\30358 of\IN\1740 selective\JJ\1740 antagonists\NNS\7846 of\IN\1740 B2\NN\1740 and\CC\1740 B1\NN\1740 receptors\NNS\5225602 :\:\1740 D-Arg-[Hyp3,Thi5,D-Tic7,Oic8\NN\1740 ]\-RRB-\1740 bradykinin\NN\1740 (\-LRB-\1740 HOE\NN\4451818 140\CD\1740 ;\:\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 or\CC\3541091 <e1>des\VBZ\1740 Arg10\NN\1740 HOE\NN\4451818 140</e1>\CD\1740 (\-LRB-\1740 70\CD\13745420 nmol/kg\NN\1740 ip\NN\5999797 )\-RRB-\1740 respectively\RB\1740 ,\,\1740 in\IN\13603305 model\NN\5888929 of\IN\1740 <e2>diabetic\JJ\1740 (\-LRB-\1740 streptozotocin-induced\JJ\1740 )\-RRB-\1740 and\CC\1740 toxic\JJ\1740 (\-LRB-\1740 vincristine-induced\JJ\1740 )\-RRB-\1740 neuropathy</e2>\RB\1740 was\VBD\836236 investigated\VBN\644583 .\.\1740
C078665_D010523 NONE Moreover\RB\1740 ,\,\1740 L-NOArg\NN\1740 and\CC\1740 7-NI\CD\1740 but\CC\1740 not\RB\1740 L-NIL\NN\1740 intensify\VBP\153263 antihyperalgesic\JJ\1740 activity\NN\30358 of\IN\1740 HOE\NN\4451818 140\CD\1740 or\CC\3541091 <e1>des-Arg10HOE\NN\1740 140</e1>\CD\1740 in\IN\13603305 <e2>toxic\JJ\1740 neuropathy</e2>\NN\14204950 .\.\1740
D001920_D009437 NONE Therefore\RB\1740 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 small\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>bradykinin</e1>\NN\1740 receptor\NN\5225602 antagonists\NNS\7846 and\CC\1740 NO\NN\7204911 synthase\NN\1740 inhibitors\NNS\20090 can\MD\3094503 be\VB\836236 effective\JJ\1740 in\IN\13603305 alleviation\NN\7492516 of\IN\1740 <e2>neuropathic\JJ\1740 pain</e2>\NN\14299637 ,\,\1740 even\RB\1740 in\IN\13603305 hospital\NN\3739518 care\NN\575741 .\.\1740
D009569_D009437 NONE Therefore\RB\1740 ,\,\1740 concomitant\JJ\1740 administration\NN\1133281 of\IN\1740 small\JJ\1740 doses\NNS\3740161 of\IN\1740 bradykinin\NN\1740 receptor\NN\5225602 antagonists\NNS\7846 and\CC\1740 <e1>NO</e1>\NN\7204911 synthase\NN\1740 inhibitors\NNS\20090 can\MD\3094503 be\VB\836236 effective\JJ\1740 in\IN\13603305 alleviation\NN\7492516 of\IN\1740 <e2>neuropathic\JJ\1740 pain</e2>\NN\14299637 ,\,\1740 even\RB\1740 in\IN\13603305 hospital\NN\3739518 care\NN\575741 .\.\1740
11642480
D015283_D004409 CID <e2>Palpebral\JJ\1740 twitching</e2>\VBG\10054 in\IN\13603305 a\DT\13649268 depressed\JJ\1740 adolescent\JJ\1740 on\IN\1740 <e1>citalopram</e1>\NN\1740 .\.\1740
D015283_D004409 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 favorable\JJ\1740 response\NN\11410625 to\TO\1740 treatment\NN\654885 with\IN\1740 <e1>citalopram</e1>\NN\1740 by\IN\1740 a\DT\13649268 15-year-old\JJ\1740 boy\NN\9624168 with\IN\1740 major\JJ\1740 depression\NN\14373582 who\WP\8299493 exhibited\VBD\2632167 <e2>palpebral\JJ\1740 twitching</e2>\NN\14360459 during\IN\1740 his\PRP$\1740 first\JJ\1740 2\CD\13741022 weeks\NNS\15113229 of\IN\1740 treatment\NN\654885 .\.\1740
D015283_D003866 NONE Palpebral\JJ\1740 twitching\VBG\10054 in\IN\13603305 a\DT\13649268 <e2>depressed</e2>\JJ\1740 adolescent\JJ\1740 on\IN\1740 <e1>citalopram</e1>\NN\1740 .\.\1740
D015283_D003865 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 favorable\JJ\1740 response\NN\11410625 to\TO\1740 treatment\NN\654885 with\IN\1740 <e1>citalopram</e1>\NN\1740 by\IN\1740 a\DT\13649268 15-year-old\JJ\1740 boy\NN\9624168 with\IN\1740 <e2>major\JJ\1740 depression</e2>\NN\14373582 who\WP\8299493 exhibited\VBD\2632167 palpebral\JJ\1740 twitching\NN\14360459 during\IN\1740 his\PRP$\1740 first\JJ\1740 2\CD\13741022 weeks\NNS\15113229 of\IN\1740 treatment\NN\654885 .\.\1740
15859940
D016572_D064420 NONE Other\JJ\1740 causes\NNS\7323922 include\VBP\690614 drug-related\JJ\1740 (\-LRB-\1740 <e1>cyclosporine</e1>\NN\1740 ,\,\1740 tacrolimus\NN\1740 )\-RRB-\1740 <e2>toxicity</e2>\NN\13576101 ,\,\1740 procoagulant\JJ\1740 status\NN\24720 ,\,\1740 and\CC\1740 antibody-mediated\JJ\1740 rejection\NN\30358 .\.\1740
D016559_D064420 NONE Other\JJ\1740 causes\NNS\7323922 include\VBP\690614 drug-related\JJ\1740 (\-LRB-\1740 cyclosporine\NN\1740 ,\,\1740 <e1>tacrolimus</e1>\NN\1740 )\-RRB-\1740 <e2>toxicity</e2>\NN\13576101 ,\,\1740 procoagulant\JJ\1740 status\NN\24720 ,\,\1740 and\CC\1740 antibody-mediated\JJ\1740 rejection\NN\30358 .\.\1740
D016572_D057049 CID We\PRP\1740 found\VBD\2426171 that\IN\1740 the\DT\1740 most-frequent\JJ\1740 cause\NN\7323922 of\IN\1740 <e2>thrombotic\JJ\1740 microangiopathy</e2>\NN\1740 was\VBD\836236 drug\NN\14778436 related\JJ\1740 ,\,\1740 secondary\JJ\1740 mainly\RB\1740 to\TO\1740 <e1>cyclosporine</e1>\NN\1740 .\.\1740
8595686
D013874_D010146 NONE <e1>Thiopentone</e1>\NN\1740 pretreatment\NN\1740 for\IN\1740 propofol\NN\1740 injection\NN\320852 <e2>pain</e2>\NN\14299637 in\IN\13603305 ambulatory\JJ\1740 patients\NNS\9898892 .\.\1740
D013874_D010146 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 lidocaine\NN\3681148 reduces\VBZ\441445 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 propofol\NN\1740 injection\NN\320852 <e2>pain</e2>\NN\14299637 in\IN\13603305 ambulatory\JJ\1740 patients\NNS\9898892 whereas\IN\1740 <e1>thiopentone</e1>\NN\1740 only\RB\1740 reduces\VBZ\441445 its\PRP$\6125041 severity\NN\5036394 .\.\1740
D015742_D010146 CID Thiopentone\NN\1740 pretreatment\NN\1740 for\IN\1740 <e1>propofol</e1>\NN\1740 injection\NN\320852 <e2>pain</e2>\NN\14299637 in\IN\13603305 ambulatory\JJ\1740 patients\NNS\9898892 .\.\1740
D015742_D010146 CID This\DT\1740 study\NN\635850 investigated\VBD\644583 <e1>propofol</e1>\NN\1740 injection\NN\320852 <e2>pain</e2>\NN\14299637 in\IN\13603305 patients\NNS\9898892 undergoing\VBG\109660 ambulatory\JJ\1740 anaesthesia\NN\14034177 .\.\1740
D015742_D010146 CID We\PRP\1740 conclude\VBP\628491 that\IN\1740 lidocaine\NN\3681148 reduces\VBZ\441445 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 <e1>propofol</e1>\NN\1740 injection\NN\320852 <e2>pain</e2>\NN\14299637 in\IN\13603305 ambulatory\JJ\1740 patients\NNS\9898892 whereas\IN\1740 thiopentone\NN\1740 only\RB\1740 reduces\VBZ\441445 its\PRP$\6125041 severity\NN\5036394 .\.\1740
D008012_D010146 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 <e1>lidocaine</e1>\NN\3681148 reduces\VBZ\441445 the\DT\1740 incidence\NN\13821570 and\CC\1740 severity\NN\5036394 of\IN\1740 propofol\NN\1740 injection\NN\320852 <e2>pain</e2>\NN\14299637 in\IN\13603305 ambulatory\JJ\1740 patients\NNS\9898892 whereas\IN\1740 thiopentone\NN\1740 only\RB\1740 reduces\VBZ\441445 its\PRP$\6125041 severity\NN\5036394 .\.\1740
11263551
D016572_D010146 CID The\DT\1740 reduction\NN\351485 of\IN\1740 <e1>cyclosporine-</e1>\NN\1740 or\CC\3541091 tacrolimus\NN\1740 trough\NN\9366017 levels\NNS\4916342 and\CC\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 led\VBD\1752884 to\TO\1740 relief\NN\7492516 of\IN\1740 <e2>pain</e2>\NN\14299637 .\.\1740
D016572_D010146 CID The\DT\1740 Calcineurin-inhibitor\NN\1740 Induced\VBD\1627355 <e2>Pain</e2>\NN\14299637 Syndrome\NN\5870365 (\-LRB-\1740 CIPS\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 but\CC\1740 severe\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 <e1>cyclosporine</e1>\NN\1740 or\CC\3541091 tacrolimus\NN\1740 and\CC\1740 is\VBZ\836236 accurately\RB\1740 diagnosed\VBN\644583 by\IN\1740 its\PRP$\6125041 typical\JJ\1740 presentation\NN\1027379 ,\,\1740 magnetic\JJ\1740 resonance\NN\11419404 imaging\NN\5765159 and\CC\1740 bone\NN\5286536 scans\NNS\635850 .\.\1740
D016559_D010146 CID The\DT\1740 reduction\NN\351485 of\IN\1740 cyclosporine-\NN\1740 or\CC\3541091 <e1>tacrolimus</e1>\NN\1740 trough\NN\9366017 levels\NNS\4916342 and\CC\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 calcium\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 led\VBD\1752884 to\TO\1740 relief\NN\7492516 of\IN\1740 <e2>pain</e2>\NN\14299637 .\.\1740
D016559_D010146 CID The\DT\1740 Calcineurin-inhibitor\NN\1740 Induced\VBD\1627355 <e2>Pain</e2>\NN\14299637 Syndrome\NN\5870365 (\-LRB-\1740 CIPS\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 but\CC\1740 severe\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 cyclosporine\NN\1740 or\CC\3541091 <e1>tacrolimus</e1>\NN\1740 and\CC\1740 is\VBZ\836236 accurately\RB\1740 diagnosed\VBN\644583 by\IN\1740 its\PRP$\6125041 typical\JJ\1740 presentation\NN\1027379 ,\,\1740 magnetic\JJ\1740 resonance\NN\11419404 imaging\NN\5765159 and\CC\1740 bone\NN\5286536 scans\NNS\635850 .\.\1740
D002118_D010146 NONE The\DT\1740 reduction\NN\351485 of\IN\1740 cyclosporine-\NN\1740 or\CC\3541091 tacrolimus\NN\1740 trough\NN\9366017 levels\NNS\4916342 and\CC\1740 the\DT\1740 administration\NN\1133281 of\IN\1740 <e1>calcium</e1>\NN\14625458 channel\NN\6251781 blockers\NNS\10101634 led\VBD\1752884 to\TO\1740 relief\NN\7492516 of\IN\1740 <e2>pain</e2>\NN\14299637 .\.\1740
D016572_-1 NONE The\DT\1740 Calcineurin-inhibitor\NN\1740 Induced\VBD\1627355 Pain\NN\14299637 Syndrome\NN\5870365 (\-LRB-\1740 <e2>CIPS</e2>\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 but\CC\1740 severe\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 <e1>cyclosporine</e1>\NN\1740 or\CC\3541091 tacrolimus\NN\1740 and\CC\1740 is\VBZ\836236 accurately\RB\1740 diagnosed\VBN\644583 by\IN\1740 its\PRP$\6125041 typical\JJ\1740 presentation\NN\1027379 ,\,\1740 magnetic\JJ\1740 resonance\NN\11419404 imaging\NN\5765159 and\CC\1740 bone\NN\5286536 scans\NNS\635850 .\.\1740
D016559_-1 NONE The\DT\1740 Calcineurin-inhibitor\NN\1740 Induced\VBD\1627355 Pain\NN\14299637 Syndrome\NN\5870365 (\-LRB-\1740 <e2>CIPS</e2>\NN\1740 )\-RRB-\1740 is\VBZ\836236 a\DT\13649268 rare\JJ\1740 but\CC\1740 severe\JJ\1740 side\NN\8630039 effect\NN\34213 of\IN\1740 cyclosporine\NN\1740 or\CC\3541091 <e1>tacrolimus</e1>\NN\1740 and\CC\1740 is\VBZ\836236 accurately\RB\1740 diagnosed\VBN\644583 by\IN\1740 its\PRP$\6125041 typical\JJ\1740 presentation\NN\1027379 ,\,\1740 magnetic\JJ\1740 resonance\NN\11419404 imaging\NN\5765159 and\CC\1740 bone\NN\5286536 scans\NNS\635850 .\.\1740
2572625
C084599_D056486 CID <e1>Clotiazepam-induced</e1>\JJ\1740 acute\JJ\1740 <e2>hepatitis</e2>\NN\14127211 .\.\1740
C084599_D056486 CID We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 acute\JJ\1740 <e2>hepatitis</e2>\NN\14127211 with\IN\1740 extensive\JJ\1740 hepatocellular\JJ\1740 necrosis\NN\11444117 ,\,\1740 7\CD\13741022 months\NNS\15113229 after\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 administration\NN\1133281 of\IN\1740 <e1>clotiazepam</e1>\NN\1740 ,\,\1740 a\DT\13649268 thienodiazepine\NN\1740 derivative\NN\5802185 .\.\1740
C084599_D056486 CID The\DT\1740 administration\NN\1133281 of\IN\1740 several\JJ\1740 benzodiazepines\NNS\3771443 ,\,\1740 chemically\RB\1740 related\JJ\1740 to\TO\1740 <e1>clotiazepam</e1>\VB\1740 ,\,\1740 did\VBD\1640855 not\RB\1740 interfere\VB\2451370 with\IN\1740 recovery\NN\7357388 and\CC\1740 did\VBD\1640855 not\RB\1740 induce\VB\1627355 any\DT\1740 relapse\NN\66636 of\IN\1740 <e2>hepatitis</e2>\NN\14127211 .\.\1740
C084599_D056486 CID This\DT\1740 observation\NN\996969 shows\VBZ\2137132 that\WDT\1740 <e1>clotiazepam</e1>\NN\1740 can\MD\3094503 induce\VB\1627355 acute\JJ\1740 <e2>hepatitis</e2>\NN\14127211 and\CC\1740 suggests\VBZ\1010118 that\IN\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 cross\NN\4341686 hepatotoxicity\NN\1740 between\IN\1740 clotiazepam\NN\1740 and\CC\1740 several\JJ\1740 benzodiazepines\NNS\3771443 .\.\1740
C084599_D056486 CID This\DT\1740 observation\NN\996969 shows\VBZ\2137132 that\WDT\1740 <e1>clotiazepam</e1>\NN\1740 can\MD\3094503 induce\VB\1627355 acute\JJ\1740 hepatitis\NN\14127211 and\CC\1740 suggests\VBZ\1010118 that\IN\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 cross\NN\4341686 <e2>hepatotoxicity</e2>\NN\1740 between\IN\1740 clotiazepam\NN\1740 and\CC\1740 several\JJ\1740 benzodiazepines\NNS\3771443 .\.\1740
C084599_D056486 CID This\DT\1740 observation\NN\996969 shows\VBZ\2137132 that\WDT\1740 clotiazepam\NN\1740 can\MD\3094503 induce\VB\1627355 acute\JJ\1740 <e2>hepatitis</e2>\NN\14127211 and\CC\1740 suggests\VBZ\1010118 that\IN\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 cross\NN\4341686 hepatotoxicity\NN\1740 between\IN\1740 <e1>clotiazepam</e1>\NN\1740 and\CC\1740 several\JJ\1740 benzodiazepines\NNS\3771443 .\.\1740
C084599_D056486 CID This\DT\1740 observation\NN\996969 shows\VBZ\2137132 that\WDT\1740 clotiazepam\NN\1740 can\MD\3094503 induce\VB\1627355 acute\JJ\1740 hepatitis\NN\14127211 and\CC\1740 suggests\VBZ\1010118 that\IN\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 cross\NN\4341686 <e2>hepatotoxicity</e2>\NN\1740 between\IN\1740 <e1>clotiazepam</e1>\NN\1740 and\CC\1740 several\JJ\1740 benzodiazepines\NNS\3771443 .\.\1740
C084599_D047508 NONE We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 acute\JJ\1740 hepatitis\NN\14127211 with\IN\1740 <e2>extensive\JJ\1740 hepatocellular\JJ\1740 necrosis</e2>\NN\11444117 ,\,\1740 7\CD\13741022 months\NNS\15113229 after\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 administration\NN\1133281 of\IN\1740 <e1>clotiazepam</e1>\NN\1740 ,\,\1740 a\DT\13649268 thienodiazepine\NN\1740 derivative\NN\5802185 .\.\1740
C013295_D056486 NONE We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 acute\JJ\1740 <e2>hepatitis</e2>\NN\14127211 with\IN\1740 extensive\JJ\1740 hepatocellular\JJ\1740 necrosis\NN\11444117 ,\,\1740 7\CD\13741022 months\NNS\15113229 after\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 administration\NN\1133281 of\IN\1740 clotiazepam\NN\1740 ,\,\1740 a\DT\13649268 <e1>thienodiazepine</e1>\NN\1740 derivative\NN\5802185 .\.\1740
C013295_D047508 NONE We\PRP\1740 report\VBP\831651 the\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 patient\NN\9898892 who\WP\8299493 developed\VBD\1753788 acute\JJ\1740 hepatitis\NN\14127211 with\IN\1740 <e2>extensive\JJ\1740 hepatocellular\JJ\1740 necrosis</e2>\NN\11444117 ,\,\1740 7\CD\13741022 months\NNS\15113229 after\IN\1740 the\DT\1740 onset\NN\7325190 of\IN\1740 administration\NN\1133281 of\IN\1740 clotiazepam\NN\1740 ,\,\1740 a\DT\13649268 <e1>thienodiazepine</e1>\NN\1740 derivative\NN\5802185 .\.\1740
D001569_D056486 NONE The\DT\1740 administration\NN\1133281 of\IN\1740 several\JJ\1740 <e1>benzodiazepines</e1>\NNS\3771443 ,\,\1740 chemically\RB\1740 related\JJ\1740 to\TO\1740 clotiazepam\VB\1740 ,\,\1740 did\VBD\1640855 not\RB\1740 interfere\VB\2451370 with\IN\1740 recovery\NN\7357388 and\CC\1740 did\VBD\1640855 not\RB\1740 induce\VB\1627355 any\DT\1740 relapse\NN\66636 of\IN\1740 <e2>hepatitis</e2>\NN\14127211 .\.\1740
D001569_D056486 NONE This\DT\1740 observation\NN\996969 shows\VBZ\2137132 that\WDT\1740 clotiazepam\NN\1740 can\MD\3094503 induce\VB\1627355 acute\JJ\1740 <e2>hepatitis</e2>\NN\14127211 and\CC\1740 suggests\VBZ\1010118 that\IN\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 cross\NN\4341686 hepatotoxicity\NN\1740 between\IN\1740 clotiazepam\NN\1740 and\CC\1740 several\JJ\1740 <e1>benzodiazepines</e1>\NNS\3771443 .\.\1740
D001569_D056486 NONE This\DT\1740 observation\NN\996969 shows\VBZ\2137132 that\WDT\1740 clotiazepam\NN\1740 can\MD\3094503 induce\VB\1627355 acute\JJ\1740 hepatitis\NN\14127211 and\CC\1740 suggests\VBZ\1010118 that\IN\1740 there\EX\27167 is\VBZ\836236 no\DT\7204911 cross\NN\4341686 <e2>hepatotoxicity</e2>\NN\1740 between\IN\1740 clotiazepam\NN\1740 and\CC\1740 several\JJ\1740 <e1>benzodiazepines</e1>\NNS\3771443 .\.\1740
10406016
C007789_D002543 NONE Effect\NN\34213 of\IN\1740 <e1>fucoidan</e1>\JJ\1740 treatment\NN\654885 on\IN\1740 collagenase-induced\JJ\1740 <e2>intracerebral\JJ\1740 hemorrhage</e2>\NN\14285662 in\IN\13603305 rats\NNS\2329401 .\.\1740
C007789_D002543 NONE We\PRP\1740 tested\VBD\670261 the\DT\1740 sulfated\VBN\115157 polysaccharide\NN\14792703 <e1>fucoidan</e1>\JJ\1740 ,\,\1740 which\WDT\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 reduce\VB\441445 inflammatory\JJ\1740 brain\NN\5462674 damage\NN\7296428 ,\,\1740 in\IN\13603305 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 <e2>intracerebral\JJ\1740 hemorrhage</e2>\NN\14285662 induced\VBN\1627355 by\IN\1740 injection\NN\320852 of\IN\1740 bacterial\JJ\1740 collagenase\NN\14732946 into\IN\1740 the\DT\1740 caudate\NN\5497363 nucleus\NN\5445668 .\.\1740
C007789_D001925 NONE We\PRP\1740 tested\VBD\670261 the\DT\1740 sulfated\VBN\115157 polysaccharide\NN\14792703 <e1>fucoidan</e1>\JJ\1740 ,\,\1740 which\WDT\1740 has\VBZ\2108377 been\VBN\836236 reported\VBN\831651 to\TO\1740 reduce\VB\441445 inflammatory\JJ\1740 <e2>brain\NN\5462674 damage</e2>\NN\7296428 ,\,\1740 in\IN\13603305 a\DT\13649268 rat\NN\2329401 model\NN\5888929 of\IN\1740 intracerebral\JJ\1740 hemorrhage\NN\14285662 induced\VBN\1627355 by\IN\1740 injection\NN\320852 of\IN\1740 bacterial\JJ\1740 collagenase\NN\14732946 into\IN\1740 the\DT\1740 caudate\NN\5497363 nucleus\NN\5445668 .\.\1740
C007789_D020141 CID <e1>Fucoidan-treated</e1>\JJ\1740 rats\NNS\2329401 exhibited\VBD\2632167 evidence\NN\5816287 of\IN\1740 <e2>impaired\JJ\1740 blood\NN\5397468 clotting</e2>\NN\13518963 and\CC\1740 hemodilution\NN\1740 ,\,\1740 had\VBD\2108377 larger\JJR\1740 hematomas\NNS\14317720 ,\,\1740 and\CC\1740 tended\VBD\2604760 to\TO\1740 have\VB\2108377 less\JJR\1740 inflammation\NN\14299637 in\IN\13603305 the\DT\1740 vicinity\NN\8648322 of\IN\1740 the\DT\1740 hematoma\NN\14317720 after\IN\1740 three\CD\13741022 days\NNS\15140892 .\.\1740
C007789_D020141 CID <e1>Fucoidan-treated</e1>\JJ\1740 rats\NNS\2329401 exhibited\VBD\2632167 evidence\NN\5816287 of\IN\1740 impaired\JJ\1740 blood\NN\5397468 clotting\NN\13518963 and\CC\1740 <e2>hemodilution</e2>\NN\1740 ,\,\1740 had\VBD\2108377 larger\JJR\1740 hematomas\NNS\14317720 ,\,\1740 and\CC\1740 tended\VBD\2604760 to\TO\1740 have\VB\2108377 less\JJR\1740 inflammation\NN\14299637 in\IN\13603305 the\DT\1740 vicinity\NN\8648322 of\IN\1740 the\DT\1740 hematoma\NN\14317720 after\IN\1740 three\CD\13741022 days\NNS\15140892 .\.\1740
C007789_D006406 NONE <e1>Fucoidan-treated</e1>\JJ\1740 rats\NNS\2329401 exhibited\VBD\2632167 evidence\NN\5816287 of\IN\1740 impaired\JJ\1740 blood\NN\5397468 clotting\NN\13518963 and\CC\1740 hemodilution\NN\1740 ,\,\1740 had\VBD\2108377 larger\JJR\1740 <e2>hematomas</e2>\NNS\14317720 ,\,\1740 and\CC\1740 tended\VBD\2604760 to\TO\1740 have\VB\2108377 less\JJR\1740 inflammation\NN\14299637 in\IN\13603305 the\DT\1740 vicinity\NN\8648322 of\IN\1740 the\DT\1740 hematoma\NN\14317720 after\IN\1740 three\CD\13741022 days\NNS\15140892 .\.\1740
C007789_D006406 NONE <e1>Fucoidan-treated</e1>\JJ\1740 rats\NNS\2329401 exhibited\VBD\2632167 evidence\NN\5816287 of\IN\1740 impaired\JJ\1740 blood\NN\5397468 clotting\NN\13518963 and\CC\1740 hemodilution\NN\1740 ,\,\1740 had\VBD\2108377 larger\JJR\1740 hematomas\NNS\14317720 ,\,\1740 and\CC\1740 tended\VBD\2604760 to\TO\1740 have\VB\2108377 less\JJR\1740 inflammation\NN\14299637 in\IN\13603305 the\DT\1740 vicinity\NN\8648322 of\IN\1740 the\DT\1740 <e2>hematoma</e2>\NN\14317720 after\IN\1740 three\CD\13741022 days\NNS\15140892 .\.\1740
C007789_D007249 NONE <e1>Fucoidan-treated</e1>\JJ\1740 rats\NNS\2329401 exhibited\VBD\2632167 evidence\NN\5816287 of\IN\1740 impaired\JJ\1740 blood\NN\5397468 clotting\NN\13518963 and\CC\1740 hemodilution\NN\1740 ,\,\1740 had\VBD\2108377 larger\JJR\1740 hematomas\NNS\14317720 ,\,\1740 and\CC\1740 tended\VBD\2604760 to\TO\1740 have\VB\2108377 less\JJR\1740 <e2>inflammation</e2>\NN\14299637 in\IN\13603305 the\DT\1740 vicinity\NN\8648322 of\IN\1740 the\DT\1740 hematoma\NN\14317720 after\IN\1740 three\CD\13741022 days\NNS\15140892 .\.\1740
12820454
D016729_D000740 CID All\DT\1740 patients\NNS\9898892 received\VBD\2210855 CAB\NN\3079741 [\-LRB-\1740 <e1>leuprolide\NN\1740 acetate</e1>\NN\15010703 (\-LRB-\1740 LHRH-A\NN\1740 )\-RRB-\1740 3.75\CD\1740 mg\NN\13717155 ,\,\1740 intramuscularly\RB\1740 ,\,\1740 every\DT\1740 28\CD\13745420 days\NNS\15140892 plus\CC\4723816 250\CD\1740 mg\NN\13717155 flutamide\NN\1740 ,\,\1740 tid\NN\1740 ,\,\1740 per\IN\1740 Os\NNP\5249636 ]\-RRB-\1740 and\CC\1740 were\VBD\836236 evaluated\VBN\670261 for\IN\1740 <e2>anemia</e2>\NN\14189204 by\IN\1740 physical\JJ\1740 examination\NN\633864 and\CC\1740 laboratory\NN\4602044 tests\NNS\5798043 at\IN\14622893 baseline\NN\7260623 and\CC\1740 4\CD\13741022 subsequent\JJ\1740 intervals\NNS\33615 (\-LRB-\1740 1\CD\13741022 ,\,\1740 2\CD\13741022 ,\,\1740 3\CD\13741022 and\CC\1740 6\CD\13741022 months\NNS\15113229 post-CAB\NN\1740 )\-RRB-\1740 .\.\1740
D016729_D000740 CID All\DT\1740 patients\NNS\9898892 received\VBD\2210855 CAB\NN\3079741 [\-LRB-\1740 leuprolide\NN\1740 acetate\NN\15010703 (\-LRB-\1740 <e1>LHRH-A</e1>\NN\1740 )\-RRB-\1740 3.75\CD\1740 mg\NN\13717155 ,\,\1740 intramuscularly\RB\1740 ,\,\1740 every\DT\1740 28\CD\13745420 days\NNS\15140892 plus\CC\4723816 250\CD\1740 mg\NN\13717155 flutamide\NN\1740 ,\,\1740 tid\NN\1740 ,\,\1740 per\IN\1740 Os\NNP\5249636 ]\-RRB-\1740 and\CC\1740 were\VBD\836236 evaluated\VBN\670261 for\IN\1740 <e2>anemia</e2>\NN\14189204 by\IN\1740 physical\JJ\1740 examination\NN\633864 and\CC\1740 laboratory\NN\4602044 tests\NNS\5798043 at\IN\14622893 baseline\NN\7260623 and\CC\1740 4\CD\13741022 subsequent\JJ\1740 intervals\NNS\33615 (\-LRB-\1740 1\CD\13741022 ,\,\1740 2\CD\13741022 ,\,\1740 3\CD\13741022 and\CC\1740 6\CD\13741022 months\NNS\15113229 post-CAB\NN\1740 )\-RRB-\1740 .\.\1740
D005485_D000740 CID All\DT\1740 patients\NNS\9898892 received\VBD\2210855 CAB\NN\3079741 [\-LRB-\1740 leuprolide\NN\1740 acetate\NN\15010703 (\-LRB-\1740 LHRH-A\NN\1740 )\-RRB-\1740 3.75\CD\1740 mg\NN\13717155 ,\,\1740 intramuscularly\RB\1740 ,\,\1740 every\DT\1740 28\CD\13745420 days\NNS\15140892 plus\CC\4723816 250\CD\1740 mg\NN\13717155 <e1>flutamide</e1>\NN\1740 ,\,\1740 tid\NN\1740 ,\,\1740 per\IN\1740 Os\NNP\5249636 ]\-RRB-\1740 and\CC\1740 were\VBD\836236 evaluated\VBN\670261 for\IN\1740 <e2>anemia</e2>\NN\14189204 by\IN\1740 physical\JJ\1740 examination\NN\633864 and\CC\1740 laboratory\NN\4602044 tests\NNS\5798043 at\IN\14622893 baseline\NN\7260623 and\CC\1740 4\CD\13741022 subsequent\JJ\1740 intervals\NNS\33615 (\-LRB-\1740 1\CD\13741022 ,\,\1740 2\CD\13741022 ,\,\1740 3\CD\13741022 and\CC\1740 6\CD\13741022 months\NNS\15113229 post-CAB\NN\1740 )\-RRB-\1740 .\.\1740
2476560
D001556_D012532 NONE Treatment\NN\654885 for\IN\1740 <e2>scabies</e2>\NNS\14174549 is\VBZ\836236 usually\RB\1740 initiated\VBN\1617192 by\IN\1740 general\JJ\1740 practitioners\NNS\10480253 ;\:\1740 most\JJS\1740 consider\VB\689344 <e1>lindane</e1>\NN\14919948 (\-LRB-\1740 gamma\NN\6828818 benzene\NN\14767996 hexachloride\NN\1740 )\-RRB-\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 choice\NN\5788149 .\.\1740
D001556_D012532 NONE Treatment\NN\654885 for\IN\1740 <e2>scabies</e2>\NNS\14174549 is\VBZ\836236 usually\RB\1740 initiated\VBN\1617192 by\IN\1740 general\JJ\1740 practitioners\NNS\10480253 ;\:\1740 most\JJS\1740 consider\VB\689344 lindane\NN\14919948 (\-LRB-\1740 <e1>gamma\NN\6828818 benzene\NN\14767996 hexachloride</e1>\NN\1740 )\-RRB-\1740 the\DT\1740 treatment\NN\654885 of\IN\1740 choice\NN\5788149 .\.\1740
D001556_D002493 CID Evidence\NN\5816287 is\VBZ\836236 accumulating\VBG\2281093 that\DT\1740 <e1>lindane</e1>\NN\14919948 can\MD\3094503 be\VB\836236 <e2>toxic\JJ\1740 to\TO\1740 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system</e2>\NN\3575240 and\CC\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 aplastic\JJ\1740 anaemia\NN\14299637 .\.\1740
D001556_D000741 CID Evidence\NN\5816287 is\VBZ\836236 accumulating\VBG\2281093 that\DT\1740 <e1>lindane</e1>\NN\14919948 can\MD\3094503 be\VB\836236 toxic\JJ\1740 to\TO\1740 the\DT\1740 central\JJ\1740 nervous\JJ\1740 system\NN\3575240 and\CC\1740 may\MD\15209706 be\VB\836236 associated\VBN\628491 with\IN\1740 <e2>aplastic\JJ\1740 anaemia</e2>\NN\14299637 .\.\1740
3560096
D013467_D006947 CID <e2>Hyperkalemia</e2>\NN\14299637 associated\VBN\628491 with\IN\1740 <e1>sulindac</e1>\NN\3828465 therapy\NN\657604 .\.\1740
D013467_D006947 CID We\PRP\1740 describe\VBP\1001294 4\CD\13741022 patients\NNS\9898892 in\IN\13603305 whom\WP\1740 <e2>hyperkalemia</e2>\NN\14299637 ranging\VBG\2604760 from\IN\1740 6.1\CD\1740 to\TO\1740 6.9\CD\1740 mEq/l\NN\1740 developed\VBD\1753788 within\IN\1740 3\CD\13741022 to\TO\1740 8\CD\13741022 days\NNS\15140892 of\IN\1740 <e1>sulindac</e1>\NN\3828465 administration\NN\1133281 .\.\1740
D013467_D006947 CID As\IN\14622893 no\DT\7204911 other\JJ\1740 medications\NNS\3247620 known\VBN\2110220 to\TO\1740 effect\NN\34213 serum\NN\5397468 potassium\NN\14625458 had\VBD\2108377 been\VBN\836236 given\VBN\2327200 concomitantly\RB\1740 ,\,\1740 this\DT\1740 course\NN\883297 of\IN\1740 events\NNS\23100 is\VBZ\836236 suggestive\JJ\1740 of\IN\1740 a\DT\13649268 cause-and-effect\JJ\1740 relationship\NN\31921 between\IN\1740 <e1>sulindac</e1>\NN\3828465 and\CC\1740 <e2>hyperkalemia</e2>\NN\14299637 .\.\1740
D007213_D006947 CID <e2>Hyperkalemia</e2>\NN\14299637 has\VBZ\2108377 recently\RB\1740 been\VBN\836236 recognized\VBN\686447 as\IN\14622893 a\DT\13649268 complication\NN\1073995 of\IN\1740 nonsteroidal\JJ\1740 antiinflammatory\JJ\1740 agents\NNS\7347 (\-LRB-\1740 NSAID\NN\2721538 )\-RRB-\1740 such\JJ\1740 as\IN\14622893 <e1>indomethacin</e1>\NN\3828465 .\.\1740
D011188_D006947 NONE As\IN\14622893 no\DT\7204911 other\JJ\1740 medications\NNS\3247620 known\VBN\2110220 to\TO\1740 effect\NN\34213 serum\NN\5397468 <e1>potassium</e1>\NN\14625458 had\VBD\2108377 been\VBN\836236 given\VBN\2327200 concomitantly\RB\1740 ,\,\1740 this\DT\1740 course\NN\883297 of\IN\1740 events\NNS\23100 is\VBZ\836236 suggestive\JJ\1740 of\IN\1740 a\DT\13649268 cause-and-effect\JJ\1740 relationship\NN\31921 between\IN\1740 sulindac\NN\3828465 and\CC\1740 <e2>hyperkalemia</e2>\NN\14299637 .\.\1740
1009330
C004658_D003556 NONE The\DT\1740 results\NNS\34213 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 the\DT\1740 degradation\NN\199130 product\NN\3076708 <e1>p-choloroaniline</e1>\NN\1740 is\VBZ\836236 not\RB\1740 a\DT\13649268 significant\JJ\1740 factor\NN\7326557 in\IN\13603305 chlorhexidine-digluconate\JJ\1740 associated\JJ\1740 erosive\JJ\1740 <e2>cystitis</e2>\NN\14566129 .\.\1740
C010882_D003556 CID The\DT\1740 results\NNS\34213 have\VBP\2108377 shown\VBN\2137132 that\IN\1740 the\DT\1740 degradation\NN\199130 product\NN\3076708 p-choloroaniline\NN\1740 is\VBZ\836236 not\RB\1740 a\DT\13649268 significant\JJ\1740 factor\NN\7326557 in\IN\13603305 <e1>chlorhexidine-digluconate</e1>\JJ\1740 associated\JJ\1740 erosive\JJ\1740 <e2>cystitis</e2>\NN\14566129 .\.\1740
D007612_D003556 CID A\DT\13649268 high\JJ\1740 percentage\NN\13815742 of\IN\1740 <e1>kanamycin-colistin</e1>\JJ\1740 and\CC\1740 povidone-iodine\JJ\1740 irrigations\NNS\1057200 were\VBD\836236 associated\VBN\628491 with\IN\1740 erosive\JJ\1740 <e2>cystitis</e2>\NN\14566129 and\CC\1740 suggested\VBD\1010118 a\DT\13649268 possible\JJ\1740 complication\NN\1073995 with\IN\1740 human\JJ\1740 usage\NN\407535 .\.\1740
D003091_D003556 CID A\DT\13649268 high\JJ\1740 percentage\NN\13815742 of\IN\1740 <e1>kanamycin-colistin</e1>\JJ\1740 and\CC\1740 povidone-iodine\JJ\1740 irrigations\NNS\1057200 were\VBD\836236 associated\VBN\628491 with\IN\1740 erosive\JJ\1740 <e2>cystitis</e2>\NN\14566129 and\CC\1740 suggested\VBD\1010118 a\DT\13649268 possible\JJ\1740 complication\NN\1073995 with\IN\1740 human\JJ\1740 usage\NN\407535 .\.\1740
D011206_D003556 CID A\DT\13649268 high\JJ\1740 percentage\NN\13815742 of\IN\1740 kanamycin-colistin\JJ\1740 and\CC\1740 <e1>povidone-iodine</e1>\JJ\1740 irrigations\NNS\1057200 were\VBD\836236 associated\VBN\628491 with\IN\1740 erosive\JJ\1740 <e2>cystitis</e2>\NN\14566129 and\CC\1740 suggested\VBD\1010118 a\DT\13649268 possible\JJ\1740 complication\NN\1073995 with\IN\1740 human\JJ\1740 usage\NN\407535 .\.\1740
C005253_D003556 NONE <e1>Picloxydine</e1>\NN\1740 irrigations\NNS\1057200 appeared\VBD\2604760 to\TO\1740 have\VB\2108377 a\DT\13649268 lower\JJR\1740 incidence\NN\13821570 of\IN\1740 erosive\JJ\1740 <e2>cystitis</e2>\NN\14566129 but\CC\1740 further\JJ\1740 studies\NNS\635850 would\MD\1740 have\VB\2108377 to\TO\1740 be\VB\836236 performed\VBN\2367363 before\IN\1740 it\PRP\6125041 could\MD\1740 be\VB\836236 recommended\VBN\875394 for\IN\1740 use\NN\407535 in\IN\13603305 urological\JJ\1740 procedures\NNS\407535 .\.\1740
19387625
D002211_D010146 NONE Attentional\JJ\1740 modulation\NN\7044917 of\IN\1740 perceived\VBN\591115 <e2>pain</e2>\NN\14299637 intensity\NN\5090441 in\IN\13603305 <e1>capsaicin-induced</e1>\JJ\1740 secondary\JJ\1740 hyperalgesia\NN\1740 .\.\1740
D002211_D010146 NONE However\RB\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 not\RB\1740 known\VBN\2110220 that\IN\1740 how\WRB\1740 <e2>pain</e2>\NN\14299637 intensity\NN\5090441 ratings\NNS\5733583 are\VBP\836236 affected\VBN\126264 by\IN\1740 attention\NN\5701944 in\IN\13603305 <e1>capsaicin-induced</e1>\JJ\1740 secondary\JJ\1740 hyperalgesia\NN\1740 .\.\1740
D002211_D010146 NONE Our\PRP$\1740 findings\NNS\7951464 ,\,\1740 showing\VBG\2137132 no\DT\7204911 interaction\NN\37396 between\IN\1740 <e1>capsaicin</e1>\NN\15032661 treatment\NN\654885 and\CC\1740 attentional\JJ\1740 modulation\NN\7044917 suggest\VBP\1010118 that\IN\1740 capsaicin-induced\JJ\1740 secondary\JJ\1740 hyperalgesia\NN\1740 and\CC\1740 attention\NN\5701944 might\MD\5029706 affect\VB\126264 mechanical\JJ\1740 <e2>pain</e2>\NN\14299637 through\IN\1740 independent\JJ\1740 mechanisms\NNS\13446390 .\.\1740
D002211_D010146 NONE Our\PRP$\1740 findings\NNS\7951464 ,\,\1740 showing\VBG\2137132 no\DT\7204911 interaction\NN\37396 between\IN\1740 capsaicin\NN\15032661 treatment\NN\654885 and\CC\1740 attentional\JJ\1740 modulation\NN\7044917 suggest\VBP\1010118 that\IN\1740 <e1>capsaicin-induced</e1>\JJ\1740 secondary\JJ\1740 hyperalgesia\NN\1740 and\CC\1740 attention\NN\5701944 might\MD\5029706 affect\VB\126264 mechanical\JJ\1740 <e2>pain</e2>\NN\14299637 through\IN\1740 independent\JJ\1740 mechanisms\NNS\13446390 .\.\1740
D002211_D006930 CID Attentional\JJ\1740 modulation\NN\7044917 of\IN\1740 perceived\VBN\591115 pain\NN\14299637 intensity\NN\5090441 in\IN\13603305 <e1>capsaicin-induced</e1>\JJ\1740 secondary\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 .\.\1740
D002211_D006930 CID However\RB\1740 ,\,\1740 it\PRP\6125041 is\VBZ\836236 not\RB\1740 known\VBN\2110220 that\IN\1740 how\WRB\1740 pain\NN\14299637 intensity\NN\5090441 ratings\NNS\5733583 are\VBP\836236 affected\VBN\126264 by\IN\1740 attention\NN\5701944 in\IN\13603305 <e1>capsaicin-induced</e1>\JJ\1740 secondary\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 .\.\1740
D002211_D006930 CID Furthermore\RB\1740 ,\,\1740 it\PRP\6125041 was\VBD\836236 found\VBN\2426171 that\IN\1740 the\DT\1740 magnitude\NN\4916342 of\IN\1740 attentional\JJ\1740 modulation\NN\7044917 in\IN\13603305 secondary\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 is\VBZ\836236 very\RB\1740 similar\JJ\1740 to\TO\1740 that\DT\1740 of\IN\1740 <e1>capsaicin-untreated</e1>\JJ\1740 ,\,\1740 control\NN\5190804 condition\NN\24720 .\.\1740
D002211_D006930 CID Our\PRP$\1740 findings\NNS\7951464 ,\,\1740 showing\VBG\2137132 no\DT\7204911 interaction\NN\37396 between\IN\1740 <e1>capsaicin</e1>\NN\15032661 treatment\NN\654885 and\CC\1740 attentional\JJ\1740 modulation\NN\7044917 suggest\VBP\1010118 that\IN\1740 capsaicin-induced\JJ\1740 secondary\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 and\CC\1740 attention\NN\5701944 might\MD\5029706 affect\VB\126264 mechanical\JJ\1740 pain\NN\14299637 through\IN\1740 independent\JJ\1740 mechanisms\NNS\13446390 .\.\1740
D002211_D006930 CID Our\PRP$\1740 findings\NNS\7951464 ,\,\1740 showing\VBG\2137132 no\DT\7204911 interaction\NN\37396 between\IN\1740 capsaicin\NN\15032661 treatment\NN\654885 and\CC\1740 attentional\JJ\1740 modulation\NN\7044917 suggest\VBP\1010118 that\IN\1740 <e1>capsaicin-induced</e1>\JJ\1740 secondary\JJ\1740 <e2>hyperalgesia</e2>\NN\1740 and\CC\1740 attention\NN\5701944 might\MD\5029706 affect\VB\126264 mechanical\JJ\1740 pain\NN\14299637 through\IN\1740 independent\JJ\1740 mechanisms\NNS\13446390 .\.\1740
18821488
C080436_D064420 NONE <e2>Toxicity</e2>\NN\13576101 in\IN\13603305 rhesus\NN\2487347 monkeys\NNS\2469914 following\VBG\1835496 administration\NN\1133281 of\IN\1740 the\DT\1740 <e1>8-aminoquinoline</e1>\NN\1740 8-[(4-amino-l-methylbutyl)amino]-\JJ\1740 5-(l-hexyloxy)-6-methoxy-4-methylquinoline\NN\1740 (\-LRB-\1740 WR242511\NN\1740 )\-RRB-\1740 .\.\1740
C068820_D064420 NONE <e2>Toxicity</e2>\NN\13576101 in\IN\13603305 rhesus\NN\2487347 monkeys\NNS\2469914 following\VBG\1835496 administration\NN\1133281 of\IN\1740 the\DT\1740 8-aminoquinoline\NN\1740 <e1>8-[(4-amino-l-methylbutyl)amino]-\JJ\1740 5-(l-hexyloxy)-6-methoxy-4-methylquinoline</e1>\NN\1740 (\-LRB-\1740 WR242511\NN\1740 )\-RRB-\1740 .\.\1740
C068820_D064420 NONE <e2>Toxicity</e2>\NN\13576101 in\IN\13603305 rhesus\NN\2487347 monkeys\NNS\2469914 following\VBG\1835496 administration\NN\1133281 of\IN\1740 the\DT\1740 8-aminoquinoline\NN\1740 8-[(4-amino-l-methylbutyl)amino]-\JJ\1740 5-(l-hexyloxy)-6-methoxy-4-methylquinoline\NN\1740 (\-LRB-\1740 <e1>WR242511</e1>\NN\1740 )\-RRB-\1740 .\.\1740
C068820_D064420 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 <e1>WR242511</e1>\NN\1740 should\MD\1740 not\RB\1740 be\VB\836236 pursued\VBN\2367363 as\IN\14622893 a\DT\13649268 pretreatment\NN\1740 for\IN\1740 CN\NN\1740 poisoning\NN\14034177 unless\IN\1740 the\DT\1740 anti-CN\JJ\1740 characteristics\NNS\5849040 of\IN\1740 this\DT\1740 compound\NN\5869584 can\MD\3094503 be\VB\836236 successfully\RB\1740 dissociated\VBN\2431320 from\IN\1740 those\DT\1740 producing\VBG\1617192 undesirable\JJ\1740 <e2>toxicity</e2>\NN\13576101 .\.\1740
C068820_D008708 NONE RESULTS\NNS\34213 :\:\1740 The\DT\1740 selected\VBN\697589 doses\NNS\3740161 of\IN\1740 <e1>WR242511</e1>\NN\1740 ,\,\1740 which\WDT\1740 produced\VBD\1617192 significant\JJ\1740 <e2>methemoglobinemia</e2>\NN\1740 in\IN\13603305 beagle\JJ\1740 dogs\NNS\2083346 in\IN\13603305 earlier\JJR\1740 studies\NNS\635850 conducted\VBN\2436349 elsewhere\RB\1740 ,\,\1740 produced\VBD\1617192 very\RB\1740 little\JJ\1740 MHb\NN\1740 (\-LRB-\1740 mean\NN\6021761 <\XX\1740 2.0\CD\1740 %\NN\1740 )\-RRB-\1740 in\IN\13603305 the\DT\1740 rhesus\NN\2487347 monkey\NN\2469914 .\.\1740
C068820_D006456 CID Furthermore\RB\1740 ,\,\1740 transient\JJ\1740 <e2>hemoglobinuria</e2>\NN\14299637 was\VBD\836236 noted\VBN\1009240 approximately\RB\1740 60\CD\13745420 minutes\NNS\6502378 postinjection\NN\1740 of\IN\1740 <e1>WR242511</e1>\NN\1740 (\-LRB-\1740 3.5\CD\1740 or\CC\3541091 7.0\CD\1740 mg/kg\NN\1740 )\-RRB-\1740 ,\,\1740 and\CC\1740 2\CD\13741022 lethalities\NNS\4790449 occurred\VBD\2623529 (\-LRB-\1740 one\CD\13741022 IV\CD\13741022 and\CC\1740 one\CD\13741022 PO\NN\14625458 )\-RRB-\1740 following\VBG\1835496 the\DT\1740 7.0\CD\1740 mg/kg\NN\1740 dose\NN\3740161 .\.\1740
C068820_D011041 NONE It\PRP\6125041 is\VBZ\836236 concluded\VBN\628491 that\IN\1740 <e1>WR242511</e1>\NN\1740 should\MD\1740 not\RB\1740 be\VB\836236 pursued\VBN\2367363 as\IN\14622893 a\DT\13649268 pretreatment\NN\1740 for\IN\1740 CN\NN\1740 <e2>poisoning</e2>\NN\14034177 unless\IN\1740 the\DT\1740 anti-CN\JJ\1740 characteristics\NNS\5849040 of\IN\1740 this\DT\1740 compound\NN\5869584 can\MD\3094503 be\VB\836236 successfully\RB\1740 dissociated\VBN\2431320 from\IN\1740 those\DT\1740 producing\VBG\1617192 undesirable\JJ\1740 toxicity\NN\13576101 .\.\1740
3782049
D008972_D012206 CID A\DT\13649268 case\NN\7283608 of\IN\1740 massive\JJ\1740 <e2>rhabdomyolysis</e2>\NN\1740 following\VBG\1835496 <e1>molindone</e1>\NN\3713736 administration\NN\1133281 .\.\1740
D008972_D012206 CID The\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 schizophrenic\JJ\1740 patient\NN\9898892 is\VBZ\836236 reported\VBN\831651 to\TO\1740 illustrate\VB\955601 massive\JJ\1740 <e2>rhabdomyolysis</e2>\NN\1740 and\CC\1740 subsequent\JJ\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 following\VBG\1835496 <e1>molindone</e1>\NN\3713736 administration\NN\1133281 .\.\1740
D008972_D012559 NONE The\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 <e2>schizophrenic</e2>\JJ\1740 patient\NN\9898892 is\VBZ\836236 reported\VBN\831651 to\TO\1740 illustrate\VB\955601 massive\JJ\1740 rhabdomyolysis\NN\1740 and\CC\1740 subsequent\JJ\1740 acute\JJ\1740 renal\JJ\1740 failure\NN\66216 following\VBG\1835496 <e1>molindone</e1>\NN\3713736 administration\NN\1133281 .\.\1740
D008972_D058186 CID The\DT\1740 case\NN\7283608 of\IN\1740 a\DT\13649268 schizophrenic\JJ\1740 patient\NN\9898892 is\VBZ\836236 reported\VBN\831651 to\TO\1740 illustrate\VB\955601 massive\JJ\1740 rhabdomyolysis\NN\1740 and\CC\1740 subsequent\JJ\1740 <e2>acute\JJ\1740 renal\JJ\1740 failure</e2>\NN\66216 following\VBG\1835496 <e1>molindone</e1>\NN\3713736 administration\NN\1133281 .\.\1740
8690168
D006497_D003928 NONE Reduction\NN\351485 of\IN\1740 <e1>heparan\NN\1740 sulphate-associated</e1>\JJ\1740 anionic\JJ\1740 sites\NNS\8673395 in\IN\13603305 the\DT\1740 glomerular\JJ\1740 basement\NN\3365991 membrane\NN\4188643 of\IN\1740 rats\NNS\2329401 with\IN\1740 streptozotocin-induced\JJ\1740 <e2>diabetic\JJ\1740 nephropathy</e2>\NN\14573196 .\.\1740
D013311_D003928 CID Reduction\NN\351485 of\IN\1740 heparan\NN\1740 sulphate-associated\JJ\1740 anionic\JJ\1740 sites\NNS\8673395 in\IN\13603305 the\DT\1740 glomerular\JJ\1740 basement\NN\3365991 membrane\NN\4188643 of\IN\1740 rats\NNS\2329401 with\IN\1740 <e1>streptozotocin-induced</e1>\JJ\1740 <e2>diabetic\JJ\1740 nephropathy</e2>\NN\14573196 .\.\1740
D006497_D003920 NONE <e1>Heparan\NN\1740 sulphate-associated</e1>\JJ\1740 anionic\JJ\1740 sites\NNS\8673395 in\IN\13603305 the\DT\1740 glomerular\JJ\1740 basement\NN\3365991 membrane\NN\4188643 were\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 8\CD\13741022 months\NNS\15113229 after\IN\1740 induction\NN\7450842 of\IN\1740 <e2>diabetes</e2>\NNS\14075199 by\IN\1740 streptozotocin\NN\1740 and\CC\1740 in\IN\13603305 age-\JJ\1740 adn\JJ\1740 sex-matched\JJ\1740 control\NN\5190804 rats\NNS\2329401 ,\,\1740 employing\VBG\1740 the\DT\1740 cationic\JJ\1740 dye\NN\14984973 cuprolinic\JJ\1740 blue\JJ\1740 .\.\1740
D006497_D003920 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 in\IN\13603305 <e2>streptozotocin-diabetic</e2>\JJ\1740 rats\NNS\2329401 with\IN\1740 an\DT\6697703 increased\VBN\169651 urinary\JJ\1740 albumin\NN\14736972 excretion\NN\13466586 ,\,\1740 a\DT\13649268 reduced\VBN\441445 <e1>heparan\NN\1740 sulphate</e1>\NN\15010703 charge\NN\972621 barrier/density\NN\1740 is\VBZ\836236 found\VBN\2426171 at\IN\14622893 the\DT\1740 lamina\NN\5581349 rara\NNS\1740 externa\NN\1740 of\IN\1740 the\DT\1740 glomerular\JJ\1740 basement\NN\3365991 membrane\NN\4188643 .\.\1740
D013311_D003920 NONE Heparan\NN\1740 sulphate-associated\JJ\1740 anionic\JJ\1740 sites\NNS\8673395 in\IN\13603305 the\DT\1740 glomerular\JJ\1740 basement\NN\3365991 membrane\NN\4188643 were\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 8\CD\13741022 months\NNS\15113229 after\IN\1740 induction\NN\7450842 of\IN\1740 <e2>diabetes</e2>\NNS\14075199 by\IN\1740 <e1>streptozotocin</e1>\NN\1740 and\CC\1740 in\IN\13603305 age-\JJ\1740 adn\JJ\1740 sex-matched\JJ\1740 control\NN\5190804 rats\NNS\2329401 ,\,\1740 employing\VBG\1740 the\DT\1740 cationic\JJ\1740 dye\NN\14984973 cuprolinic\JJ\1740 blue\JJ\1740 .\.\1740
D013311_D003920 NONE We\PRP\1740 conclude\VBP\628491 that\IN\1740 in\IN\13603305 <e2><e1>streptozotocin-diabetic</e1></e2>\JJ\1740 rats\NNS\2329401 with\IN\1740 an\DT\6697703 increased\VBN\169651 urinary\JJ\1740 albumin\NN\14736972 excretion\NN\13466586 ,\,\1740 a\DT\13649268 reduced\VBN\441445 heparan\NN\1740 sulphate\NN\15010703 charge\NN\972621 barrier/density\NN\1740 is\VBZ\836236 found\VBN\2426171 at\IN\14622893 the\DT\1740 lamina\NN\5581349 rara\NNS\1740 externa\NN\1740 of\IN\1740 the\DT\1740 glomerular\JJ\1740 basement\NN\3365991 membrane\NN\4188643 .\.\1740
C015445_D003920 NONE Heparan\NN\1740 sulphate-associated\JJ\1740 anionic\JJ\1740 sites\NNS\8673395 in\IN\13603305 the\DT\1740 glomerular\JJ\1740 basement\NN\3365991 membrane\NN\4188643 were\VBD\836236 studied\VBN\630380 in\IN\13603305 rats\NNS\2329401 8\CD\13741022 months\NNS\15113229 after\IN\1740 induction\NN\7450842 of\IN\1740 <e2>diabetes</e2>\NNS\14075199 by\IN\1740 streptozotocin\NN\1740 and\CC\1740 in\IN\13603305 age-\JJ\1740 adn\JJ\1740 sex-matched\JJ\1740 control\NN\5190804 rats\NNS\2329401 ,\,\1740 employing\VBG\1740 the\DT\1740 cationic\JJ\1740 dye\NN\14984973 <e1>cuprolinic\JJ\1740 blue</e1>\JJ\1740 .\.\1740
1468485
D010100_D006470 NONE Hyperbaric\JJ\1740 <e1>oxygen</e1>\NN\14622893 therapy\NN\657604 for\IN\1740 control\NN\5190804 of\IN\1740 intractable\JJ\1740 cyclophosphamide-induced\JJ\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
D010100_D003556 NONE Hyperbaric\JJ\1740 <e1>oxygen</e1>\NN\14622893 therapy\NN\657604 for\IN\1740 control\NN\5190804 of\IN\1740 intractable\JJ\1740 cyclophosphamide-induced\JJ\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
D003520_D006470 CID Hyperbaric\JJ\1740 oxygen\NN\14622893 therapy\NN\657604 for\IN\1740 control\NN\5190804 of\IN\1740 intractable\JJ\1740 <e1>cyclophosphamide-induced</e1>\JJ\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
D003520_D006470 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 intractable\JJ\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 due\JJ\1740 to\TO\1740 <e1>cyclophosphamide</e1>\NN\1740 therapy\NN\657604 for\IN\1740 Wegener\NNP\1740 's\POS\1740 granulomatosis\NN\1740 .\.\1740
D003520_D006470 CID In\IN\13603305 future\NN\28270 ,\,\1740 this\DT\1740 form\NN\6286395 of\IN\1740 therapy\NN\657604 can\MD\3094503 offer\VB\2327200 a\DT\13649268 safe\JJ\1740 alternative\NN\5788149 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e1>cyclophosphamide-induced</e1>\JJ\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
D003520_D003556 CID Hyperbaric\JJ\1740 oxygen\NN\14622893 therapy\NN\657604 for\IN\1740 control\NN\5190804 of\IN\1740 intractable\JJ\1740 <e1>cyclophosphamide-induced</e1>\JJ\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
D003520_D003556 CID We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 intractable\JJ\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 due\JJ\1740 to\TO\1740 <e1>cyclophosphamide</e1>\NN\1740 therapy\NN\657604 for\IN\1740 Wegener\NNP\1740 's\POS\1740 granulomatosis\NN\1740 .\.\1740
D003520_D003556 CID In\IN\13603305 future\NN\28270 ,\,\1740 this\DT\1740 form\NN\6286395 of\IN\1740 therapy\NN\657604 can\MD\3094503 offer\VB\2327200 a\DT\13649268 safe\JJ\1740 alternative\NN\5788149 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 <e1>cyclophosphamide-induced</e1>\JJ\1740 <e2>hemorrhagic\JJ\1740 cystitis</e2>\NN\14566129 .\.\1740
D003520_D014890 NONE We\PRP\1740 report\VBP\831651 a\DT\13649268 case\NN\7283608 of\IN\1740 intractable\JJ\1740 hemorrhagic\JJ\1740 cystitis\NN\14566129 due\JJ\1740 to\TO\1740 <e1>cyclophosphamide</e1>\NN\1740 therapy\NN\657604 for\IN\1740 <e2>Wegener\NNP\1740 's\POS\1740 granulomatosis</e2>\NN\1740 .\.\1740
D015237_D006470 NONE Conservative\JJ\1740 treatment\NN\654885 ,\,\1740 including\VBG\690614 bladder\NN\5515670 irrigation\NN\1057200 with\IN\1740 physiological\JJ\1740 saline\NN\14849367 and\CC\1740 instillation\NN\320852 of\IN\1740 <e1>prostaglandin\NN\5414534 F2\NN\1740 alpha</e1>\NN\6828818 ,\,\1740 failed\VBD\1798936 to\TO\1740 totally\RB\1740 control\VB\2422663 <e2>hemorrhage</e2>\NN\14285662 .\.\1740
88336
D002719_D013375 NONE Three\CD\13741022 patients\NNS\9898892 received\VBD\2210855 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>chlormethiazole</e1>\NN\1740 for\IN\1740 alcohol\NN\7881800 <e2>withdrawal\NN\7206096 symptoms</e2>\NNS\5823932 ,\,\1740 and\CC\1740 one\PRP\13741022 took\VBD\2367363 a\DT\13649268 suicidal\JJ\1740 overdose\NN\1740 of\IN\1740 nitrazepam\NN\2830852 .\.\1740
D002719_D062787 NONE Three\CD\13741022 patients\NNS\9898892 received\VBD\2210855 high\JJ\1740 doses\NNS\3740161 of\IN\1740 <e1>chlormethiazole</e1>\NN\1740 for\IN\1740 alcohol\NN\7881800 withdrawal\NN\7206096 symptoms\NNS\5823932 ,\,\1740 and\CC\1740 one\PRP\13741022 took\VBD\2367363 a\DT\13649268 suicidal\JJ\1740 <e2>overdose</e2>\NN\1740 of\IN\1740 nitrazepam\NN\2830852 .\.\1740
D002719_D062787 NONE The\DT\1740 patient\NN\9898892 with\IN\1740 nitrazepam\NN\2830852 <e2>overdose</e2>\NN\1740 and\CC\1740 two\CD\13741022 of\IN\1740 those\DT\1740 with\IN\1740 <e1>chlormethiazole</e1>\NN\1740 intoxication\NN\14034177 conformed\VBN\109660 to\TO\1740 the\DT\1740 criteria\NNS\13577171 of\IN\1740 '\``\1740 alpha\NN\6828818 coma\NN\5678932 '\''\1740 ,\,\1740 showing\VBG\2137132 non-reactive\JJ\1740 generalized\JJ\1740 or\CC\3541091 frontally\RB\1740 predominant\JJ\1740 alpha\NN\6828818 activity\NN\30358 in\IN\13603305 the\DT\1740 EEG\NN\7000195 .\.\1740
D000431_D013375 NONE Three\CD\13741022 patients\NNS\9898892 received\VBD\2210855 high\JJ\1740 doses\NNS\3740161 of\IN\1740 chlormethiazole\NN\1740 for\IN\1740 <e1>alcohol</e1>\NN\7881800 <e2>withdrawal\NN\7206096 symptoms</e2>\NNS\5823932 ,\,\1740 and\CC\1740 one\PRP\13741022 took\VBD\2367363 a\DT\13649268 suicidal\JJ\1740 overdose\NN\1740 of\IN\1740 nitrazepam\NN\2830852 .\.\1740
D000431_D062787 NONE Three\CD\13741022 patients\NNS\9898892 received\VBD\2210855 high\JJ\1740 doses\NNS\3740161 of\IN\1740 chlormethiazole\NN\1740 for\IN\1740 <e1>alcohol</e1>\NN\7881800 withdrawal\NN\7206096 symptoms\NNS\5823932 ,\,\1740 and\CC\1740 one\PRP\13741022 took\VBD\2367363 a\DT\13649268 suicidal\JJ\1740 <e2>overdose</e2>\NN\1740 of\IN\1740 nitrazepam\NN\2830852 .\.\1740
D009567_D013375 NONE Three\CD\13741022 patients\NNS\9898892 received\VBD\2210855 high\JJ\1740 doses\NNS\3740161 of\IN\1740 chlormethiazole\NN\1740 for\IN\1740 alcohol\NN\7881800 <e2>withdrawal\NN\7206096 symptoms</e2>\NNS\5823932 ,\,\1740 and\CC\1740 one\PRP\13741022 took\VBD\2367363 a\DT\13649268 suicidal\JJ\1740 overdose\NN\1740 of\IN\1740 <e1>nitrazepam</e1>\NN\2830852 .\.\1740
D009567_D062787 CID Three\CD\13741022 patients\NNS\9898892 received\VBD\2210855 high\JJ\1740 doses\NNS\3740161 of\IN\1740 chlormethiazole\NN\1740 for\IN\1740 alcohol\NN\7881800 withdrawal\NN\7206096 symptoms\NNS\5823932 ,\,\1740 and\CC\1740 one\PRP\13741022 took\VBD\2367363 a\DT\13649268 suicidal\JJ\1740 <e2>overdose</e2>\NN\1740 of\IN\1740 <e1>nitrazepam</e1>\NN\2830852 .\.\1740
D009567_D062787 CID The\DT\1740 patient\NN\9898892 with\IN\1740 <e1>nitrazepam</e1>\NN\2830852 <e2>overdose</e2>\NN\1740 and\CC\1740 two\CD\13741022 of\IN\1740 those\DT\1740 with\IN\1740 chlormethiazole\NN\1740 intoxication\NN\14034177 conformed\VBN\109660 to\TO\1740 the\DT\1740 criteria\NNS\13577171 of\IN\1740 '\``\1740 alpha\NN\6828818 coma\NN\5678932 '\''\1740 ,\,\1740 showing\VBG\2137132 non-reactive\JJ\1740 generalized\JJ\1740 or\CC\3541091 frontally\RB\1740 predominant\JJ\1740 alpha\NN\6828818 activity\NN\30358 in\IN\13603305 the\DT\1740 EEG\NN\7000195 .\.\1740
D009567_D003128 CID The\DT\1740 patient\NN\9898892 with\IN\1740 <e1>nitrazepam</e1>\NN\2830852 overdose\NN\1740 and\CC\1740 two\CD\13741022 of\IN\1740 those\DT\1740 with\IN\1740 chlormethiazole\NN\1740 intoxication\NN\14034177 conformed\VBN\109660 to\TO\1740 the\DT\1740 criteria\NNS\13577171 of\IN\1740 '\``\1740 alpha\NN\6828818 <e2>coma</e2>\NN\5678932 '\''\1740 ,\,\1740 showing\VBG\2137132 non-reactive\JJ\1740 generalized\JJ\1740 or\CC\3541091 frontally\RB\1740 predominant\JJ\1740 alpha\NN\6828818 activity\NN\30358 in\IN\13603305 the\DT\1740 EEG\NN\7000195 .\.\1740
D002719_D003128 CID The\DT\1740 patient\NN\9898892 with\IN\1740 nitrazepam\NN\2830852 overdose\NN\1740 and\CC\1740 two\CD\13741022 of\IN\1740 those\DT\1740 with\IN\1740 <e1>chlormethiazole</e1>\NN\1740 intoxication\NN\14034177 conformed\VBN\109660 to\TO\1740 the\DT\1740 criteria\NNS\13577171 of\IN\1740 '\``\1740 alpha\NN\6828818 <e2>coma</e2>\NN\5678932 '\''\1740 ,\,\1740 showing\VBG\2137132 non-reactive\JJ\1740 generalized\JJ\1740 or\CC\3541091 frontally\RB\1740 predominant\JJ\1740 alpha\NN\6828818 activity\NN\30358 in\IN\13603305 the\DT\1740 EEG\NN\7000195 .\.\1740
9334596
D013739_D007172 NONE PURPOSE\NNP\5980875 :\:\1740 We\PRP\1740 reviewed\VBD\644583 the\DT\1740 results\NNS\34213 of\IN\1740 serum\NN\5397468 <e1>testosterone</e1>\NN\14747587 and\CC\1740 prolactin\NN\5410315 determination\NN\43195 in\IN\13603305 1,022\CD\1740 patients\NNS\9898892 referred\VBN\730052 because\IN\1740 of\IN\1740 <e2>erectile\JJ\1740 dysfunction</e2>\NN\14204950 and\CC\1740 compared\VBD\644583 the\DT\1740 data\NNS\7951464 with\IN\1740 history\NN\15120823 ,\,\1740 results\NNS\34213 of\IN\1740 physical\JJ\1740 examination\NN\633864 ,\,\1740 other\JJ\1740 etiological\JJ\1740 investigations\NNS\5797597 and\CC\1740 effects\NNS\13245626 of\IN\1740 endocrine\NN\5404728 therapy\NN\657604 to\TO\1740 refine\VB\205885 the\DT\1740 rules\NNS\5835747 of\IN\1740 cost-effective\JJ\1740 endocrine\NN\5404728 screening\NN\6887726 and\CC\1740 to\TO\1740 pinpoint\VB\2286204 actual\JJ\1740 responsibility\NN\1123598 for\IN\1740 hormonal\JJ\1740 abnormalities\NNS\14034177 .\.\1740
D013739_D007172 NONE Most\JJS\1740 of\IN\1740 the\DT\1740 other\JJ\1740 low\JJ\1740 <e1>testosterone</e1>\NN\14747587 levels\NNS\4916342 seemed\VBD\2604760 to\TO\1740 result\VB\2633881 from\IN\1740 nonorganic\JJ\1740 hypothalamic\JJ\1740 dysfunction\NN\14204950 because\IN\1740 of\IN\1740 normal\JJ\1740 serum\NN\5397468 luteinizing\NN\1740 hormone\NN\5404728 and\CC\1740 prolactin\NN\5410315 and\CC\1740 to\TO\1740 have\VB\2108377 only\RB\1740 a\DT\13649268 small\JJ\1740 role\NN\719494 in\IN\13603305 <e2>erectile\JJ\1740 dysfunction</e2>\NN\14204950 (\-LRB-\1740 definite\JJ\1740 improvement\NN\7359599 in\IN\13603305 only\RB\1740 16\CD\13745420 of\IN\1740 44\CD\1740 [\-LRB-\1740 36\CD\1740 %\NN\1740 ]\-RRB-\1740 after\IN\1740 androgen\NN\14745635 therapy\NN\657604 ,\,\1740 normal\JJ\1740 morning\NN\15113229 or\CC\3541091 nocturnal\JJ\1740 erections\NNS\14037619 in\IN\13603305 30\CD\13745420 %\NN\1740 and\CC\1740 definite\JJ\1740 vasculogenic\JJ\1740 contributions\NNS\786195 in\IN\13603305 42\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
D013739_D007172 NONE CONCLUSIONS\NNS\5837957 :\:\1740 Low\JJ\1740 prevalences\NNS\4764412 and\CC\1740 effects\NNS\13245626 of\IN\1740 low\JJ\1740 <e1>testosterone</e1>\NN\14747587 and\CC\1740 high\JJ\1740 prolactin\NN\5410315 in\IN\13603305 <e2>erectile\JJ\1740 dysfunction</e2>\NN\14204950 can\MD\3094503 not\RB\1740 justify\VB\1012073 their\PRP$\1740 routine\JJ\1740 determination\NN\43195 .\.\1740
D013739_D020018 CID Every\DT\1740 patient\NN\9898892 was\VBD\836236 screened\VBN\2533282 for\IN\1740 <e1>testosterone</e1>\NN\14747587 and\CC\1740 451\CD\1740 were\VBD\836236 screened\VBN\2533282 for\IN\1740 prolactin\NN\5410315 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 <e2>low\JJ\1740 sexual\JJ\1740 desire</e2>\NN\26192 ,\,\1740 gynecomastia\NN\14501726 or\CC\3541091 testosterone\NN\14747587 less\JJR\1740 than\IN\1740 4\CD\13741022 ng./ml\NN\1740 .\.\1740
D013739_D020018 CID Every\DT\1740 patient\NN\9898892 was\VBD\836236 screened\VBN\2533282 for\IN\1740 testosterone\NN\14747587 and\CC\1740 451\CD\1740 were\VBD\836236 screened\VBN\2533282 for\IN\1740 prolactin\NN\5410315 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 <e2>low\JJ\1740 sexual\JJ\1740 desire</e2>\NN\26192 ,\,\1740 gynecomastia\NN\14501726 or\CC\3541091 <e1>testosterone</e1>\NN\14747587 less\JJR\1740 than\IN\1740 4\CD\13741022 ng./ml\NN\1740 .\.\1740
D013739_D020018 CID Determining\VBG\1645601 <e1>testosterone</e1>\NN\14747587 only\RB\1740 in\IN\13603305 cases\NNS\7283608 of\IN\1740 <e2>low\JJ\1740 sexual\JJ\1740 desire</e2>\NN\26192 or\CC\3541091 abnormal\JJ\1740 physical\JJ\1740 examination\NN\633864 would\MD\1740 have\VB\2108377 missed\VBN\1825237 40\CD\13745420 %\NN\1740 of\IN\1740 the\DT\1740 cases\NNS\7283608 with\IN\1740 low\JJ\1740 testosterone\NN\14747587 ,\,\1740 including\VBG\690614 37\CD\1740 %\NN\1740 of\IN\1740 those\DT\1740 subsequently\RB\1740 improved\VBN\126264 by\IN\1740 androgen\NN\14745635 therapy\NN\657604 .\.\1740
D013739_D020018 CID Determining\VBG\1645601 testosterone\NN\14747587 only\RB\1740 in\IN\13603305 cases\NNS\7283608 of\IN\1740 <e2>low\JJ\1740 sexual\JJ\1740 desire</e2>\NN\26192 or\CC\3541091 abnormal\JJ\1740 physical\JJ\1740 examination\NN\633864 would\MD\1740 have\VB\2108377 missed\VBN\1825237 40\CD\13745420 %\NN\1740 of\IN\1740 the\DT\1740 cases\NNS\7283608 with\IN\1740 low\JJ\1740 <e1>testosterone</e1>\NN\14747587 ,\,\1740 including\VBG\690614 37\CD\1740 %\NN\1740 of\IN\1740 those\DT\1740 subsequently\RB\1740 improved\VBN\126264 by\IN\1740 androgen\NN\14745635 therapy\NN\657604 .\.\1740
D013739_D020018 CID We\PRP\1740 now\RB\1740 advocate\VBP\875394 that\IN\1740 before\IN\1740 age\NN\4916342 50\CD\13745420 years\NNS\15144371 <e1>testosterone</e1>\NN\14747587 be\VB\836236 determined\VBN\1645601 only\RB\1740 in\IN\13603305 cases\NNS\7283608 of\IN\1740 <e2>low\JJ\1740 sexual\JJ\1740 desire</e2>\NN\26192 and\CC\1740 abnormal\JJ\1740 physical\JJ\1740 examination\NN\633864 but\CC\1740 that\IN\1740 it\PRP\6125041 be\VB\836236 measured\VBN\697589 in\IN\13603305 all\DT\1740 men\NNS\8208016 older\JJR\1740 than\IN\1740 50\CD\13745420 years\NNS\15144371 .\.\1740
D013739_D020018 CID Prolactin\NN\5410315 should\MD\1740 be\VB\836236 determined\VBN\1645601 only\RB\1740 in\IN\13603305 cases\NNS\7283608 of\IN\1740 <e2>low\JJ\1740 sexual\JJ\1740 desire</e2>\NN\26192 ,\,\1740 gynecomastia\NN\14501726 and/or\CC\1740 <e1>testosterone</e1>\NN\14747587 less\JJR\1740 than\IN\1740 4\CD\13741022 ng./ml\NN\1740 .\.\1740
D013739_D006177 NONE Every\DT\1740 patient\NN\9898892 was\VBD\836236 screened\VBN\2533282 for\IN\1740 <e1>testosterone</e1>\NN\14747587 and\CC\1740 451\CD\1740 were\VBD\836236 screened\VBN\2533282 for\IN\1740 prolactin\NN\5410315 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 low\JJ\1740 sexual\JJ\1740 desire\NN\26192 ,\,\1740 <e2>gynecomastia</e2>\NN\14501726 or\CC\3541091 testosterone\NN\14747587 less\JJR\1740 than\IN\1740 4\CD\13741022 ng./ml\NN\1740 .\.\1740
D013739_D006177 NONE Every\DT\1740 patient\NN\9898892 was\VBD\836236 screened\VBN\2533282 for\IN\1740 testosterone\NN\14747587 and\CC\1740 451\CD\1740 were\VBD\836236 screened\VBN\2533282 for\IN\1740 prolactin\NN\5410315 on\IN\1740 the\DT\1740 basis\NN\13790712 of\IN\1740 low\JJ\1740 sexual\JJ\1740 desire\NN\26192 ,\,\1740 <e2>gynecomastia</e2>\NN\14501726 or\CC\3541091 <e1>testosterone</e1>\NN\14747587 less\JJR\1740 than\IN\1740 4\CD\13741022 ng./ml\NN\1740 .\.\1740
D013739_D006177 NONE Prolactin\NN\5410315 should\MD\1740 be\VB\836236 determined\VBN\1645601 only\RB\1740 in\IN\13603305 cases\NNS\7283608 of\IN\1740 low\JJ\1740 sexual\JJ\1740 desire\NN\26192 ,\,\1740 <e2>gynecomastia</e2>\NN\14501726 and/or\CC\1740 <e1>testosterone</e1>\NN\14747587 less\JJR\1740 than\IN\1740 4\CD\13741022 ng./ml\NN\1740 .\.\1740
C004648_D007006 NONE Endocrine\NN\5404728 therapy\NN\657604 consisted\VBD\2603699 of\IN\1740 <e1>testosterone\NN\14747587 heptylate</e1>\NN\1740 or\CC\3541091 human\JJ\1740 chorionic\JJ\1740 gonadotropin\NN\5407119 for\IN\1740 <e2>hypogonadism</e2>\NN\14076126 and\CC\1740 bromocriptine\NN\1740 for\IN\1740 hyperprolactinemia\NN\1740 .\.\1740
C004648_D006966 NONE Endocrine\NN\5404728 therapy\NN\657604 consisted\VBD\2603699 of\IN\1740 <e1>testosterone\NN\14747587 heptylate</e1>\NN\1740 or\CC\3541091 human\JJ\1740 chorionic\JJ\1740 gonadotropin\NN\5407119 for\IN\1740 hypogonadism\NN\14076126 and\CC\1740 bromocriptine\NN\1740 for\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 .\.\1740
D001971_D007006 NONE Endocrine\NN\5404728 therapy\NN\657604 consisted\VBD\2603699 of\IN\1740 testosterone\NN\14747587 heptylate\NN\1740 or\CC\3541091 human\JJ\1740 chorionic\JJ\1740 gonadotropin\NN\5407119 for\IN\1740 <e2>hypogonadism</e2>\NN\14076126 and\CC\1740 <e1>bromocriptine</e1>\NN\1740 for\IN\1740 hyperprolactinemia\NN\1740 .\.\1740
D001971_D006966 NONE Endocrine\NN\5404728 therapy\NN\657604 consisted\VBD\2603699 of\IN\1740 testosterone\NN\14747587 heptylate\NN\1740 or\CC\3541091 human\JJ\1740 chorionic\JJ\1740 gonadotropin\NN\5407119 for\IN\1740 hypogonadism\NN\14076126 and\CC\1740 <e1>bromocriptine</e1>\NN\1740 for\IN\1740 <e2>hyperprolactinemia</e2>\NN\1740 .\.\1740
D013739_D010911 NONE Two\CD\13741022 <e2>pituitary\JJ\1740 tumors</e2>\NNS\14234074 were\VBD\836236 discovered\VBN\2163746 after\IN\1740 <e1>testosterone</e1>\NN\14747587 determination\NN\43195 .\.\1740
D013739_D007027 NONE Most\JJS\1740 of\IN\1740 the\DT\1740 other\JJ\1740 low\JJ\1740 <e1>testosterone</e1>\NN\14747587 levels\NNS\4916342 seemed\VBD\2604760 to\TO\1740 result\VB\2633881 from\IN\1740 nonorganic\JJ\1740 <e2>hypothalamic\JJ\1740 dysfunction</e2>\NN\14204950 because\IN\1740 of\IN\1740 normal\JJ\1740 serum\NN\5397468 luteinizing\NN\1740 hormone\NN\5404728 and\CC\1740 prolactin\NN\5410315 and\CC\1740 to\TO\1740 have\VB\2108377 only\RB\1740 a\DT\13649268 small\JJ\1740 role\NN\719494 in\IN\13603305 erectile\JJ\1740 dysfunction\NN\14204950 (\-LRB-\1740 definite\JJ\1740 improvement\NN\7359599 in\IN\13603305 only\RB\1740 16\CD\13745420 of\IN\1740 44\CD\1740 [\-LRB-\1740 36\CD\1740 %\NN\1740 ]\-RRB-\1740 after\IN\1740 androgen\NN\14745635 therapy\NN\657604 ,\,\1740 normal\JJ\1740 morning\NN\15113229 or\CC\3541091 nocturnal\JJ\1740 erections\NNS\14037619 in\IN\13603305 30\CD\13745420 %\NN\1740 and\CC\1740 definite\JJ\1740 vasculogenic\JJ\1740 contributions\NNS\786195 in\IN\13603305 42\CD\1740 %\NN\1740 )\-RRB-\1740 .\.\1740
1919871
D001241_D007681 CID <e2>Renal\JJ\1740 papillary\NN\1740 necrosis</e2>\NN\11444117 (\-LRB-\1740 RPN\NN\1740 )\-RRB-\1740 and\CC\1740 a\DT\13649268 decreased\VBN\169651 urinary\JJ\1740 concentrating\NN\1740 ability\NN\4723816 developed\VBN\1753788 during\IN\1740 continuous\JJ\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>aspirin</e1>\NN\2707683 and\CC\1740 paracetamol\NN\1740 in\IN\13603305 female\JJ\1740 Fischer\NNP\1740 344\CD\1740 rats\NNS\2329401 .\.\1740
D001241_D007681 CID Renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 (\-LRB-\1740 <e2>RPN</e2>\NN\1740 )\-RRB-\1740 and\CC\1740 a\DT\13649268 decreased\VBN\169651 urinary\JJ\1740 concentrating\NN\1740 ability\NN\4723816 developed\VBN\1753788 during\IN\1740 continuous\JJ\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 <e1>aspirin</e1>\NN\2707683 and\CC\1740 paracetamol\NN\1740 in\IN\13603305 female\JJ\1740 Fischer\NNP\1740 344\CD\1740 rats\NNS\2329401 .\.\1740
D000082_D007681 CID <e2>Renal\JJ\1740 papillary\NN\1740 necrosis</e2>\NN\11444117 (\-LRB-\1740 RPN\NN\1740 )\-RRB-\1740 and\CC\1740 a\DT\13649268 decreased\VBN\169651 urinary\JJ\1740 concentrating\NN\1740 ability\NN\4723816 developed\VBN\1753788 during\IN\1740 continuous\JJ\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 aspirin\NN\2707683 and\CC\1740 <e1>paracetamol</e1>\NN\1740 in\IN\13603305 female\JJ\1740 Fischer\NNP\1740 344\CD\1740 rats\NNS\2329401 .\.\1740
D000082_D007681 CID Renal\JJ\1740 papillary\NN\1740 necrosis\NN\11444117 (\-LRB-\1740 <e2>RPN</e2>\NN\1740 )\-RRB-\1740 and\CC\1740 a\DT\13649268 decreased\VBN\169651 urinary\JJ\1740 concentrating\NN\1740 ability\NN\4723816 developed\VBN\1753788 during\IN\1740 continuous\JJ\1740 long-term\JJ\1740 treatment\NN\654885 with\IN\1740 aspirin\NN\2707683 and\CC\1740 <e1>paracetamol</e1>\NN\1740 in\IN\13603305 female\JJ\1740 Fischer\NNP\1740 344\CD\1740 rats\NNS\2329401 .\.\1740
8955532
D001920_D006973 NONE Role\NN\719494 of\IN\1740 activation\NN\13561719 of\IN\1740 <e1>bradykinin</e1>\NN\1740 B2\NN\1740 receptors\NNS\5225602 in\IN\13603305 disruption\NN\1066163 of\IN\1740 the\DT\1740 blood-brain\JJ\1740 barrier\NN\3839993 during\IN\1740 acute\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D001920_D006973 NONE The\DT\1740 goal\NN\5809192 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 determine\VB\1645601 the\DT\1740 role\NN\719494 of\IN\1740 synthesis/release\NN\1740 of\IN\1740 <e1>bradykinin</e1>\NN\1740 to\TO\1740 activate\VB\1641914 B2\NN\1740 receptors\NNS\5225602 in\IN\13603305 disruption\NN\1066163 of\IN\1740 the\DT\1740 blood-brain\JJ\1740 barrier\NN\3839993 during\IN\1740 acute\JJ\1740 <e2>hypertension</e2>\NN\14057371 .\.\1740
D001920_D006973 NONE These\DT\1740 findings\NNS\7951464 suggest\VBP\1010118 that\IN\1740 disruption\NN\1066163 of\IN\1740 the\DT\1740 blood-brain\JJ\1740 barrier\NN\3839993 during\IN\1740 acute\JJ\1740 <e2>hypertension</e2>\NN\14057371 is\VBZ\836236 not\RB\1740 related\JJ\1740 to\TO\1740 the\DT\1740 synthesis/release\NN\1740 of\IN\1740 <e1>bradykinin</e1>\NN\1740 to\TO\1740 activate\VB\1641914 B2\NN\1740 receptors\NNS\5225602 .\.\1740
D003911_D006973 NONE Permeability\NN\4940146 of\IN\1740 the\DT\1740 blood-brain\JJ\1740 barrier\NN\3839993 was\VBD\836236 quantitated\VBN\1740 by\IN\1740 clearance\NN\5089947 of\IN\1740 fluorescent-labeled\JJ\1740 <e1>dextran</e1>\NN\1740 before\IN\1740 and\CC\1740 during\IN\1740 phenylephrine-induced\JJ\1740 acute\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 vehicle\NN\3100490 and\CC\1740 Hoe-140\NN\1740 (\-LRB-\1740 0.1\CD\1740 microM\NN\1740 )\-RRB-\1740 .\.\1740
D010656_D006973 CID Permeability\NN\4940146 of\IN\1740 the\DT\1740 blood-brain\JJ\1740 barrier\NN\3839993 was\VBD\836236 quantitated\VBN\1740 by\IN\1740 clearance\NN\5089947 of\IN\1740 fluorescent-labeled\JJ\1740 dextran\NN\1740 before\IN\1740 and\CC\1740 during\IN\1740 <e1>phenylephrine-induced</e1>\JJ\1740 acute\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 vehicle\NN\3100490 and\CC\1740 Hoe-140\NN\1740 (\-LRB-\1740 0.1\CD\1740 microM\NN\1740 )\-RRB-\1740 .\.\1740
C065679_D006973 NONE Permeability\NN\4940146 of\IN\1740 the\DT\1740 blood-brain\JJ\1740 barrier\NN\3839993 was\VBD\836236 quantitated\VBN\1740 by\IN\1740 clearance\NN\5089947 of\IN\1740 fluorescent-labeled\JJ\1740 dextran\NN\1740 before\IN\1740 and\CC\1740 during\IN\1740 phenylephrine-induced\JJ\1740 acute\JJ\1740 <e2>hypertension</e2>\NN\14057371 in\IN\13603305 rats\NNS\2329401 treated\VBN\2376958 with\IN\1740 vehicle\NN\3100490 and\CC\1740 <e1>Hoe-140</e1>\NN\1740 (\-LRB-\1740 0.1\CD\1740 microM\NN\1740 )\-RRB-\1740 .\.\1740
19037603
D019259_D012216 NONE Prophylactic\JJ\1740 use\NN\407535 of\IN\1740 <e1>lamivudine</e1>\NN\3834836 with\IN\1740 chronic\JJ\1740 immunosuppressive\JJ\1740 therapy\NN\657604 for\IN\1740 <e2>rheumatologic\JJ\1740 disorders</e2>\NNS\14034177 .\.\1740
D019259_D012216 NONE The\DT\1740 objective\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 report\VB\831651 our\PRP$\1740 experience\NN\5984287 concerning\VBG\1740 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 the\DT\1740 prophylactic\JJ\1740 administration\NN\1133281 of\IN\1740 <e1>lamivudine</e1>\NN\3834836 in\IN\13603305 hepatitis\NN\14127211 B\NN\1355326 virus\NN\9312843 surface\NN\21939 antigen\NN\20090 (\-LRB-\1740 HBs\NN\14888884 Ag\NN\14821043 )\-RRB-\1740 positive\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>rheumatologic\JJ\1740 disease</e2>\NN\14061805 .\.\1740
D019259_D012216 NONE From\IN\1740 June\NNP\15209706 2004\CD\1740 to\IN\1740 October\NNP\15209706 2006\CD\1740 ,\,\1740 11\CD\13745420 HBs\NN\14888884 Ag\NN\14821043 positive\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>rheumatologic\JJ\1740 diseases</e2>\NNS\14061805 ,\,\1740 who\WP\8299493 were\VBD\836236 on\IN\1740 both\CC\1740 immunosuppressive\JJ\1740 and\CC\1740 prophylactic\JJ\1740 <e1>lamivudine</e1>\NN\3834836 therapies\NNS\657604 ,\,\1740 were\VBD\836236 retrospectively\RB\1740 assessed\VBN\670261 .\.\1740
D006514_D012216 NONE The\DT\1740 objective\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 report\VB\831651 our\PRP$\1740 experience\NN\5984287 concerning\VBG\1740 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 the\DT\1740 prophylactic\JJ\1740 administration\NN\1133281 of\IN\1740 lamivudine\NN\3834836 in\IN\13603305 <e1>hepatitis\NN\14127211 B\NN\1355326 virus\NN\9312843 surface\NN\21939 antigen</e1>\NN\20090 (\-LRB-\1740 HBs\NN\14888884 Ag\NN\14821043 )\-RRB-\1740 positive\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>rheumatologic\JJ\1740 disease</e2>\NN\14061805 .\.\1740
D006514_D012216 NONE The\DT\1740 objective\NN\5980875 of\IN\1740 this\DT\1740 study\NN\635850 was\VBD\836236 to\TO\1740 report\VB\831651 our\PRP$\1740 experience\NN\5984287 concerning\VBG\1740 the\DT\1740 effectiveness\NN\5190804 of\IN\1740 the\DT\1740 prophylactic\JJ\1740 administration\NN\1133281 of\IN\1740 lamivudine\NN\3834836 in\IN\13603305 hepatitis\NN\14127211 B\NN\1355326 virus\NN\9312843 surface\NN\21939 antigen\NN\20090 (\-LRB-\1740 <e1>HBs\NN\14888884 Ag</e1>\NN\14821043 )\-RRB-\1740 positive\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>rheumatologic\JJ\1740 disease</e2>\NN\14061805 .\.\1740
D006514_D012216 NONE From\IN\1740 June\NNP\15209706 2004\CD\1740 to\IN\1740 October\NNP\15209706 2006\CD\1740 ,\,\1740 11\CD\13745420 <e1>HBs\NN\14888884 Ag</e1>\NN\14821043 positive\JJ\1740 patients\NNS\9898892 with\IN\1740 <e2>rheumatologic\JJ\1740 diseases</e2>\NNS\14061805 ,\,\1740 who\WP\8299493 were\VBD\836236 on\IN\1740 both\CC\1740 immunosuppressive\JJ\1740 and\CC\1740 prophylactic\JJ\1740 lamivudine\NN\3834836 therapies\NNS\657604 ,\,\1740 were\VBD\836236 retrospectively\RB\1740 assessed\VBN\670261 .\.\1740
809711
D010656_D009203 NONE Reversal\NN\199130 by\IN\1740 <e1>phenylephrine</e1>\NN\2682038 of\IN\1740 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 of\IN\1740 intravenous\JJ\1740 nitroglycerin\NN\15015501 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>acute\JJ\1740 myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D010656_D009203 NONE Our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 addition\NN\3081021 of\IN\1740 <e1>phenylephrine</e1>\NN\2682038 to\TO\1740 nitroglycerin\NN\15015501 is\VBZ\836236 not\RB\1740 beneficial\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>acute\JJ\1740 myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D005996_D009203 NONE Reversal\NN\199130 by\IN\1740 phenylephrine\NN\2682038 of\IN\1740 the\DT\1740 beneficial\JJ\1740 effects\NNS\13245626 of\IN\1740 intravenous\JJ\1740 <e1>nitroglycerin</e1>\NN\15015501 in\IN\13603305 patients\NNS\9898892 with\IN\1740 <e2>acute\JJ\1740 myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D005996_D009203 NONE <e1>Nitroglycerin</e1>\NNP\15015501 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 reduce\VB\441445 ST-segment\JJ\1740 elevation\NN\7445480 during\IN\1740 <e2>acute\JJ\1740 myocardial\JJ\1740 infarction</e2>\NN\14204950 ,\,\1740 an\DT\6697703 effect\NN\34213 potentiated\VBD\229605 in\IN\13603305 the\DT\1740 dog\NN\2083346 by\IN\1740 agents\NNS\7347 that\WDT\1740 reverse\VBP\109660 nitroglycerin-induced\JJ\1740 hypotension\NN\14057371 .\.\1740
D005996_D009203 NONE Nitroglycerin\NNP\15015501 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 reduce\VB\441445 ST-segment\JJ\1740 elevation\NN\7445480 during\IN\1740 <e2>acute\JJ\1740 myocardial\JJ\1740 infarction</e2>\NN\14204950 ,\,\1740 an\DT\6697703 effect\NN\34213 potentiated\VBD\229605 in\IN\13603305 the\DT\1740 dog\NN\2083346 by\IN\1740 agents\NNS\7347 that\WDT\1740 reverse\VBP\109660 <e1>nitroglycerin-induced</e1>\JJ\1740 hypotension\NN\14057371 .\.\1740
D005996_D009203 NONE Ten\CD\13745420 patients\NNS\9898892 with\IN\1740 acute\JJ\1740 transmural\JJ\1740 <e2>myocardial\JJ\1740 infarctions</e2>\NNS\14204950 received\VBD\2210855 intravenous\JJ\1740 <e1>nitroglycerin</e1>\NN\15015501 ,\,\1740 sufficient\JJ\1740 to\TO\1740 reduce\VB\441445 mean\VB\928630 arterial\JJ\1740 pressure\NN\11419404 from\IN\1740 107\CD\1740 +/-\CC\1740 6\CD\13741022 to\TO\1740 85\CD\1740 +/-\CC\1740 6\CD\13741022 mm\NN\13649268 Hg\NNP\14625458 (\-LRB-\1740 P\NN\14622893 less\JJR\1740 than\IN\1740 0.001\CD\1740 )\-RRB-\1740 ,\,\1740 for\IN\1740 60\CD\13745420 minutes\NNS\6502378 .\.\1740
D005996_D009203 NONE Our\PRP$\1740 results\NNS\34213 suggest\VBP\1010118 that\IN\1740 addition\NN\3081021 of\IN\1740 phenylephrine\NN\2682038 to\TO\1740 <e1>nitroglycerin</e1>\NN\15015501 is\VBZ\836236 not\RB\1740 beneficial\JJ\1740 in\IN\13603305 the\DT\1740 treatment\NN\654885 of\IN\1740 patients\NNS\9898892 with\IN\1740 <e2>acute\JJ\1740 myocardial\JJ\1740 infarction</e2>\NN\14204950 .\.\1740
D005996_D007022 CID <e1>Nitroglycerin</e1>\NNP\15015501 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 reduce\VB\441445 ST-segment\JJ\1740 elevation\NN\7445480 during\IN\1740 acute\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 ,\,\1740 an\DT\6697703 effect\NN\34213 potentiated\VBD\229605 in\IN\13603305 the\DT\1740 dog\NN\2083346 by\IN\1740 agents\NNS\7347 that\WDT\1740 reverse\VBP\109660 nitroglycerin-induced\JJ\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
D005996_D007022 CID Nitroglycerin\NNP\15015501 has\VBZ\2108377 been\VBN\836236 shown\VBN\2137132 to\TO\1740 reduce\VB\441445 ST-segment\JJ\1740 elevation\NN\7445480 during\IN\1740 acute\JJ\1740 myocardial\JJ\1740 infarction\NN\14204950 ,\,\1740 an\DT\6697703 effect\NN\34213 potentiated\VBD\229605 in\IN\13603305 the\DT\1740 dog\NN\2083346 by\IN\1740 agents\NNS\7347 that\WDT\1740 reverse\VBP\109660 <e1>nitroglycerin-induced</e1>\JJ\1740 <e2>hypotension</e2>\NN\14057371 .\.\1740
17600377
C524754_D003072 NONE A\DT\13649268 novel\JJ\1740 compound\NN\5869584 ,\,\1740 <e1>maltolyl\NN\1740 p-coumarate</e1>\NN\1740 ,\,\1740 attenuates\VBZ\224901 <e2>cognitive\JJ\1740 deficits</e2>\NNS\5113133 and\CC\1740 shows\VBZ\2137132 neuroprotective\JJ\1740 effects\NNS\13245626 in\FW\13603305 vitro\FW\1740 and\CC\1740 in\FW\13603305 vivo\FW\1740 dementia\NN\14395018 models\NNS\5888929 .\.\1740
C524754_D003072 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 investigated\VBD\644583 whether\IN\1740 <e1>maltolyl\JJ\1740 p-coumarate</e1>\NN\1740 could\MD\1740 improve\VB\126264 <e2>cognitive\JJ\1740 decline</e2>\NN\13458571 in\IN\13603305 scopolamine-injected\JJ\1740 rats\NNS\2329401 and\CC\1740 in\IN\13603305 amyloid\NN\15053867 beta\NN\6828818 peptide(1\NN\1740 -\HYPH\1740 42)-infused\JJ\1740 rats\NNS\2329401 .\.\1740
C524754_D003072 NONE <e1>Maltolyl\JJ\1740 p-coumarate</e1>\NN\1740 was\VBD\836236 found\VBN\2426171 to\TO\1740 attenuate\VB\224901 <e2>cognitive\JJ\1740 deficits</e2>\NNS\5113133 in\IN\13603305 both\DT\1740 rat\NN\2329401 models\NNS\5888929 using\VBG\1156834 passive\JJ\1740 avoidance\NN\203342 test\NN\5798043 and\CC\1740 to\TO\1740 reduce\VB\441445 apoptotic\JJ\1740 cell\NN\3080309 death\NN\7296428 observed\VBN\2163746 in\IN\13603305 the\DT\1740 hippocampus\NN\5462674 of\IN\1740 the\DT\1740 amyloid\NN\15053867 beta\NN\6828818 peptide(1\NN\1740 -\HYPH\1740 42)-infused\JJ\1740 rats\NNS\2329401 .\.\1740
C524754_D003072 NONE Taking\VBG\2367363 these\DT\1740 in\FW\13603305 vitro\FW\1740 and\CC\1740 in\FW\13603305 vivo\FW\1740 results\NNS\34213 together\RB\1740 ,\,\1740 our\PRP$\1740 study\NN\635850 suggests\VBZ\1010118 that\IN\1740 <e1>maltolyl\JJ\1740 p-coumarate</e1>\NN\1740 is\VBZ\836236 a\DT\13649268 potentially\RB\1740 effective\JJ\1740 candidate\NN\10450303 against\IN\1740 Alzheimer\NN\1740 's\POS\1740 disease\NN\14061805 that\WDT\1740 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 wide\JJ\1740 spread\JJ\1740 neuronal\JJ\1740 death\NN\7296428 and\CC\1740 progressive\JJ\1740 <e2>decline\NN\13458571 of\IN\1740 cognitive\JJ\1740 function</e2>\NN\13783581 .\.\1740
C524754_D003704 NONE A\DT\13649268 novel\JJ\1740 compound\NN\5869584 ,\,\1740 <e1>maltolyl\NN\1740 p-coumarate</e1>\NN\1740 ,\,\1740 attenuates\VBZ\224901 cognitive\JJ\1740 deficits\NNS\5113133 and\CC\1740 shows\VBZ\2137132 neuroprotective\JJ\1740 effects\NNS\13245626 in\FW\13603305 vitro\FW\1740 and\CC\1740 in\FW\13603305 vivo\FW\1740 <e2>dementia</e2>\NN\14395018 models\NNS\5888929 .\.\1740
D012601_D003072 CID In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 investigated\VBD\644583 whether\IN\1740 maltolyl\JJ\1740 p-coumarate\NN\1740 could\MD\1740 improve\VB\126264 <e2>cognitive\JJ\1740 decline</e2>\NN\13458571 in\IN\13603305 <e1>scopolamine-injected</e1>\JJ\1740 rats\NNS\2329401 and\CC\1740 in\IN\13603305 amyloid\NN\15053867 beta\NN\6828818 peptide(1\NN\1740 -\HYPH\1740 42)-infused\JJ\1740 rats\NNS\2329401 .\.\1740
C544092_D003072 NONE In\IN\13603305 the\DT\1740 present\JJ\1740 study\NN\635850 ,\,\1740 we\PRP\1740 investigated\VBD\644583 whether\IN\1740 maltolyl\JJ\1740 p-coumarate\NN\1740 could\MD\1740 improve\VB\126264 <e2>cognitive\JJ\1740 decline</e2>\NN\13458571 in\IN\13603305 scopolamine-injected\JJ\1740 rats\NNS\2329401 and\CC\1740 in\IN\13603305 <e1>amyloid\NN\15053867 beta\NN\6828818 peptide(1\NN\1740 -\HYPH\1740 42)-infused</e1>\JJ\1740 rats\NNS\2329401 .\.\1740
C544092_D003072 NONE Maltolyl\JJ\1740 p-coumarate\NN\1740 was\VBD\836236 found\VBN\2426171 to\TO\1740 attenuate\VB\224901 <e2>cognitive\JJ\1740 deficits</e2>\NNS\5113133 in\IN\13603305 both\DT\1740 rat\NN\2329401 models\NNS\5888929 using\VBG\1156834 passive\JJ\1740 avoidance\NN\203342 test\NN\5798043 and\CC\1740 to\TO\1740 reduce\VB\441445 apoptotic\JJ\1740 cell\NN\3080309 death\NN\7296428 observed\VBN\2163746 in\IN\13603305 the\DT\1740 hippocampus\NN\5462674 of\IN\1740 the\DT\1740 <e1>amyloid\NN\15053867 beta\NN\6828818 peptide(1\NN\1740 -\HYPH\1740 42)-infused</e1>\JJ\1740 rats\NNS\2329401 .\.\1740
C524754_D000544 NONE Taking\VBG\2367363 these\DT\1740 in\FW\13603305 vitro\FW\1740 and\CC\1740 in\FW\13603305 vivo\FW\1740 results\NNS\34213 together\RB\1740 ,\,\1740 our\PRP$\1740 study\NN\635850 suggests\VBZ\1010118 that\IN\1740 <e1>maltolyl\JJ\1740 p-coumarate</e1>\NN\1740 is\VBZ\836236 a\DT\13649268 potentially\RB\1740 effective\JJ\1740 candidate\NN\10450303 against\IN\1740 <e2>Alzheimer\NN\1740 's\POS\1740 disease</e2>\NN\14061805 that\WDT\1740 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 wide\JJ\1740 spread\JJ\1740 neuronal\JJ\1740 death\NN\7296428 and\CC\1740 progressive\JJ\1740 decline\NN\13458571 of\IN\1740 cognitive\JJ\1740 function\NN\13783581 .\.\1740
C524754_D009410 NONE Taking\VBG\2367363 these\DT\1740 in\FW\13603305 vitro\FW\1740 and\CC\1740 in\FW\13603305 vivo\FW\1740 results\NNS\34213 together\RB\1740 ,\,\1740 our\PRP$\1740 study\NN\635850 suggests\VBZ\1010118 that\IN\1740 <e1>maltolyl\JJ\1740 p-coumarate</e1>\NN\1740 is\VBZ\836236 a\DT\13649268 potentially\RB\1740 effective\JJ\1740 candidate\NN\10450303 against\IN\1740 Alzheimer\NN\1740 's\POS\1740 disease\NN\14061805 that\WDT\1740 is\VBZ\836236 characterized\VBN\609683 by\IN\1740 wide\JJ\1740 spread\JJ\1740 <e2>neuronal\JJ\1740 death</e2>\NN\7296428 and\CC\1740 progressive\JJ\1740 decline\NN\13458571 of\IN\1740 cognitive\JJ\1740 function\NN\13783581 .\.\1740
10526274
C056507_D002289 NONE <e1>Gemcitabine</e1>\NN\1740 plus\CC\4723816 vinorelbine\NN\1740 in\IN\13603305 <e2>nonsmall\NN\1740 cell\NN\3080309 lung\NN\5528060 carcinoma</e2>\NN\14239918 patients\NNS\9898892 age\NN\4916342 70\CD\13745420 years\NNS\15144371 or\CC\3541091 older\JJR\1740 or\CC\3541091 patients\NNS\9898892 who\WP\8299493 can\MD\3094503 not\RB\1740 receive\VB\2210855 cisplatin\NN\1740 .\.\1740
C056507_D002289 NONE In\IN\13603305 the\DT\1740 current\JJ\1740 study\NN\635850 the\DT\1740 efficacy\NN\5199286 and\CC\1740 toxicity\NN\13576101 of\IN\1740 the\DT\1740 combination\NN\7951464 of\IN\1740 <e1>GEM</e1>\NN\2743547 and\CC\1740 VNB\NN\1740 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 <e2>NSCLC</e2>\NN\1740 or\CC\3541091 those\DT\1740 with\IN\1740 some\DT\1740 contraindication\NN\5819149 to\IN\1740 receiving\VBG\2210855 cisplatin\NN\1740 were\VBD\836236 assessed\VBN\670261 .\.\1740
C030852_D002289 NONE Gemcitabine\NN\1740 plus\CC\4723816 <e1>vinorelbine</e1>\NN\1740 in\IN\13603305 <e2>nonsmall\NN\1740 cell\NN\3080309 lung\NN\5528060 carcinoma</e2>\NN\14239918 patients\NNS\9898892 age\NN\4916342 70\CD\13745420 years\NNS\15144371 or\CC\3541091 older\JJR\1740 or\CC\3541091 patients\NNS\9898892 who\WP\8299493 can\MD\3094503 not\RB\1740 receive\VB\2210855 cisplatin\NN\1740 .\.\1740
C030852_D002289 NONE In\IN\13603305 the\DT\1740 current\JJ\1740 study\NN\635850 the\DT\1740 efficacy\NN\5199286 and\CC\1740 toxicity\NN\13576101 of\IN\1740 the\DT\1740 combination\NN\7951464 of\IN\1740 GEM\NN\2743547 and\CC\1740 <e1>VNB</e1>\NN\1740 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 <e2>NSCLC</e2>\NN\1740 or\CC\3541091 those\DT\1740 with\IN\1740 some\DT\1740 contraindication\NN\5819149 to\IN\1740 receiving\VBG\2210855 cisplatin\NN\1740 were\VBD\836236 assessed\VBN\670261 .\.\1740
D002945_D002289 NONE Gemcitabine\NN\1740 plus\CC\4723816 vinorelbine\NN\1740 in\IN\13603305 <e2>nonsmall\NN\1740 cell\NN\3080309 lung\NN\5528060 carcinoma</e2>\NN\14239918 patients\NNS\9898892 age\NN\4916342 70\CD\13745420 years\NNS\15144371 or\CC\3541091 older\JJR\1740 or\CC\3541091 patients\NNS\9898892 who\WP\8299493 can\MD\3094503 not\RB\1740 receive\VB\2210855 <e1>cisplatin</e1>\NN\1740 .\.\1740
D002945_D002289 NONE In\IN\13603305 the\DT\1740 current\JJ\1740 study\NN\635850 the\DT\1740 efficacy\NN\5199286 and\CC\1740 toxicity\NN\13576101 of\IN\1740 the\DT\1740 combination\NN\7951464 of\IN\1740 GEM\NN\2743547 and\CC\1740 VNB\NN\1740 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 <e2>NSCLC</e2>\NN\1740 or\CC\3541091 those\DT\1740 with\IN\1740 some\DT\1740 contraindication\NN\5819149 to\IN\1740 receiving\VBG\2210855 <e1>cisplatin</e1>\NN\1740 were\VBD\836236 assessed\VBN\670261 .\.\1740
D002945_D002289 NONE METHODS\NNS\5616786 :\:\1740 Forty-nine\JJ\1740 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 <e2>NSCLC</e2>\NN\1740 were\VBD\836236 included\VBN\690614 ,\,\1740 38\CD\1740 of\IN\1740 whom\WP\1740 were\VBD\836236 age\NN\4916342 >\NNS\1740 /=\NN\1740 70\CD\13745420 years\NNS\15144371 and\CC\1740 11\CD\13745420 were\VBD\836236 age\NN\4916342 <\XX\1740 70\CD\13745420 years\NNS\15144371 but\CC\1740 who\WP\8299493 had\VBD\2108377 some\DT\1740 contraindication\NN\5819149 to\IN\1740 receiving\VBG\2210855 <e1>cisplatin</e1>\NN\1740 .\.\1740
C030852_D064420 NONE Recent\JJ\1740 reports\NNS\6470073 indicate\VBP\952524 that\IN\1740 single\JJ\1740 agent\NN\7347 therapy\NN\657604 with\IN\1740 <e1>vinorelbine</e1>\NN\1740 (\-LRB-\1740 VNB\NN\1740 )\-RRB-\1740 or\CC\3541091 gemcitabine\NN\1740 (\-LRB-\1740 GEM\NN\2743547 )\-RRB-\1740 may\MD\15209706 obtain\VB\2210855 a\DT\13649268 response\NN\11410625 rate\NN\13815152 of\IN\1740 20\CD\13745420 -\SYM\1740 30\CD\13745420 %\NN\1740 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 ,\,\1740 with\IN\1740 acceptable\JJ\1740 <e2>toxicity</e2>\NN\13576101 and\CC\1740 improvement\NN\7359599 in\IN\13603305 symptoms\NNS\5823932 and\CC\1740 quality\NN\24264 of\IN\1740 life\NN\13954253 .\.\1740
C030852_D064420 NONE Recent\JJ\1740 reports\NNS\6470073 indicate\VBP\952524 that\IN\1740 single\JJ\1740 agent\NN\7347 therapy\NN\657604 with\IN\1740 vinorelbine\NN\1740 (\-LRB-\1740 <e1>VNB</e1>\NN\1740 )\-RRB-\1740 or\CC\3541091 gemcitabine\NN\1740 (\-LRB-\1740 GEM\NN\2743547 )\-RRB-\1740 may\MD\15209706 obtain\VB\2210855 a\DT\13649268 response\NN\11410625 rate\NN\13815152 of\IN\1740 20\CD\13745420 -\SYM\1740 30\CD\13745420 %\NN\1740 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 ,\,\1740 with\IN\1740 acceptable\JJ\1740 <e2>toxicity</e2>\NN\13576101 and\CC\1740 improvement\NN\7359599 in\IN\13603305 symptoms\NNS\5823932 and\CC\1740 quality\NN\24264 of\IN\1740 life\NN\13954253 .\.\1740
C030852_D064420 NONE In\IN\13603305 the\DT\1740 current\JJ\1740 study\NN\635850 the\DT\1740 efficacy\NN\5199286 and\CC\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 the\DT\1740 combination\NN\7951464 of\IN\1740 GEM\NN\2743547 and\CC\1740 <e1>VNB</e1>\NN\1740 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 NSCLC\NN\1740 or\CC\3541091 those\DT\1740 with\IN\1740 some\DT\1740 contraindication\NN\5819149 to\IN\1740 receiving\VBG\2210855 cisplatin\NN\1740 were\VBD\836236 assessed\VBN\670261 .\.\1740
C056507_D064420 NONE Recent\JJ\1740 reports\NNS\6470073 indicate\VBP\952524 that\IN\1740 single\JJ\1740 agent\NN\7347 therapy\NN\657604 with\IN\1740 vinorelbine\NN\1740 (\-LRB-\1740 VNB\NN\1740 )\-RRB-\1740 or\CC\3541091 <e1>gemcitabine</e1>\NN\1740 (\-LRB-\1740 GEM\NN\2743547 )\-RRB-\1740 may\MD\15209706 obtain\VB\2210855 a\DT\13649268 response\NN\11410625 rate\NN\13815152 of\IN\1740 20\CD\13745420 -\SYM\1740 30\CD\13745420 %\NN\1740 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 ,\,\1740 with\IN\1740 acceptable\JJ\1740 <e2>toxicity</e2>\NN\13576101 and\CC\1740 improvement\NN\7359599 in\IN\13603305 symptoms\NNS\5823932 and\CC\1740 quality\NN\24264 of\IN\1740 life\NN\13954253 .\.\1740
C056507_D064420 NONE Recent\JJ\1740 reports\NNS\6470073 indicate\VBP\952524 that\IN\1740 single\JJ\1740 agent\NN\7347 therapy\NN\657604 with\IN\1740 vinorelbine\NN\1740 (\-LRB-\1740 VNB\NN\1740 )\-RRB-\1740 or\CC\3541091 gemcitabine\NN\1740 (\-LRB-\1740 <e1>GEM</e1>\NN\2743547 )\-RRB-\1740 may\MD\15209706 obtain\VB\2210855 a\DT\13649268 response\NN\11410625 rate\NN\13815152 of\IN\1740 20\CD\13745420 -\SYM\1740 30\CD\13745420 %\NN\1740 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 ,\,\1740 with\IN\1740 acceptable\JJ\1740 <e2>toxicity</e2>\NN\13576101 and\CC\1740 improvement\NN\7359599 in\IN\13603305 symptoms\NNS\5823932 and\CC\1740 quality\NN\24264 of\IN\1740 life\NN\13954253 .\.\1740
C056507_D064420 NONE In\IN\13603305 the\DT\1740 current\JJ\1740 study\NN\635850 the\DT\1740 efficacy\NN\5199286 and\CC\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 the\DT\1740 combination\NN\7951464 of\IN\1740 <e1>GEM</e1>\NN\2743547 and\CC\1740 VNB\NN\1740 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 NSCLC\NN\1740 or\CC\3541091 those\DT\1740 with\IN\1740 some\DT\1740 contraindication\NN\5819149 to\IN\1740 receiving\VBG\2210855 cisplatin\NN\1740 were\VBD\836236 assessed\VBN\670261 .\.\1740
D002945_D064420 NONE In\IN\13603305 the\DT\1740 current\JJ\1740 study\NN\635850 the\DT\1740 efficacy\NN\5199286 and\CC\1740 <e2>toxicity</e2>\NN\13576101 of\IN\1740 the\DT\1740 combination\NN\7951464 of\IN\1740 GEM\NN\2743547 and\CC\1740 VNB\NN\1740 in\IN\13603305 elderly\JJ\1740 patients\NNS\9898892 with\IN\1740 advanced\JJ\1740 NSCLC\NN\1740 or\CC\3541091 those\DT\1740 with\IN\1740 some\DT\1740 contraindication\NN\5819149 to\IN\1740 receiving\VBG\2210855 <e1>cisplatin</e1>\NN\1740 were\VBD\836236 assessed\VBN\670261 .\.\1740
6692345
D001241_D001749 NONE The\DT\1740 co-administration\NN\1740 of\IN\1740 <e1>aspirin</e1>\NN\2707683 with\IN\1740 N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide\NN\1740 (\-LRB-\1740 FANFT\NN\1740 )\-RRB-\1740 to\TO\1740 rats\NNS\2329401 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 reduced\VBN\441445 incidence\NN\13821570 of\IN\1740 FANFT-induced\JJ\1740 <e2>bladder\NN\5515670 carcinomas</e2>\NNS\14239918 but\CC\1740 a\DT\13649268 concomitant\JJ\1740 induction\NN\7450842 of\IN\1740 forestomach\NN\1740 tumors\NNS\14234074 .\.\1740
D001241_D013274 NONE The\DT\1740 co-administration\NN\1740 of\IN\1740 <e1>aspirin</e1>\NN\2707683 with\IN\1740 N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide\NN\1740 (\-LRB-\1740 FANFT\NN\1740 )\-RRB-\1740 to\TO\1740 rats\NNS\2329401 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 reduced\VBN\441445 incidence\NN\13821570 of\IN\1740 FANFT-induced\JJ\1740 bladder\NN\5515670 carcinomas\NNS\14239918 but\CC\1740 a\DT\13649268 concomitant\JJ\1740 induction\NN\7450842 of\IN\1740 <e2>forestomach\NN\1740 tumors</e2>\NNS\14234074 .\.\1740
D005200_D001749 CID The\DT\1740 co-administration\NN\1740 of\IN\1740 aspirin\NN\2707683 with\IN\1740 <e1>N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide</e1>\NN\1740 (\-LRB-\1740 FANFT\NN\1740 )\-RRB-\1740 to\TO\1740 rats\NNS\2329401 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 reduced\VBN\441445 incidence\NN\13821570 of\IN\1740 FANFT-induced\JJ\1740 <e2>bladder\NN\5515670 carcinomas</e2>\NNS\14239918 but\CC\1740 a\DT\13649268 concomitant\JJ\1740 induction\NN\7450842 of\IN\1740 forestomach\NN\1740 tumors\NNS\14234074 .\.\1740
D005200_D001749 CID The\DT\1740 co-administration\NN\1740 of\IN\1740 aspirin\NN\2707683 with\IN\1740 N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide\NN\1740 (\-LRB-\1740 <e1>FANFT</e1>\NN\1740 )\-RRB-\1740 to\TO\1740 rats\NNS\2329401 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 reduced\VBN\441445 incidence\NN\13821570 of\IN\1740 FANFT-induced\JJ\1740 <e2>bladder\NN\5515670 carcinomas</e2>\NNS\14239918 but\CC\1740 a\DT\13649268 concomitant\JJ\1740 induction\NN\7450842 of\IN\1740 forestomach\NN\1740 tumors\NNS\14234074 .\.\1740
D005200_D001749 CID The\DT\1740 co-administration\NN\1740 of\IN\1740 aspirin\NN\2707683 with\IN\1740 N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide\NN\1740 (\-LRB-\1740 FANFT\NN\1740 )\-RRB-\1740 to\TO\1740 rats\NNS\2329401 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 reduced\VBN\441445 incidence\NN\13821570 of\IN\1740 <e1>FANFT-induced</e1>\JJ\1740 <e2>bladder\NN\5515670 carcinomas</e2>\NNS\14239918 but\CC\1740 a\DT\13649268 concomitant\JJ\1740 induction\NN\7450842 of\IN\1740 forestomach\NN\1740 tumors\NNS\14234074 .\.\1740
D005200_D013274 CID The\DT\1740 co-administration\NN\1740 of\IN\1740 aspirin\NN\2707683 with\IN\1740 <e1>N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide</e1>\NN\1740 (\-LRB-\1740 FANFT\NN\1740 )\-RRB-\1740 to\TO\1740 rats\NNS\2329401 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 reduced\VBN\441445 incidence\NN\13821570 of\IN\1740 FANFT-induced\JJ\1740 bladder\NN\5515670 carcinomas\NNS\14239918 but\CC\1740 a\DT\13649268 concomitant\JJ\1740 induction\NN\7450842 of\IN\1740 <e2>forestomach\NN\1740 tumors</e2>\NNS\14234074 .\.\1740
D005200_D013274 CID The\DT\1740 co-administration\NN\1740 of\IN\1740 aspirin\NN\2707683 with\IN\1740 N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide\NN\1740 (\-LRB-\1740 <e1>FANFT</e1>\NN\1740 )\-RRB-\1740 to\TO\1740 rats\NNS\2329401 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 reduced\VBN\441445 incidence\NN\13821570 of\IN\1740 FANFT-induced\JJ\1740 bladder\NN\5515670 carcinomas\NNS\14239918 but\CC\1740 a\DT\13649268 concomitant\JJ\1740 induction\NN\7450842 of\IN\1740 <e2>forestomach\NN\1740 tumors</e2>\NNS\14234074 .\.\1740
D005200_D013274 CID The\DT\1740 co-administration\NN\1740 of\IN\1740 aspirin\NN\2707683 with\IN\1740 N-[4-(5-nitro-2-furyl)-2-thiazolyl]-formamide\NN\1740 (\-LRB-\1740 FANFT\NN\1740 )\-RRB-\1740 to\TO\1740 rats\NNS\2329401 resulted\VBD\2633881 in\IN\13603305 a\DT\13649268 reduced\VBN\441445 incidence\NN\13821570 of\IN\1740 <e1>FANFT-induced</e1>\JJ\1740 bladder\NN\5515670 carcinomas\NNS\14239918 but\CC\1740 a\DT\13649268 concomitant\JJ\1740 induction\NN\7450842 of\IN\1740 <e2>forestomach\NN\1740 tumors</e2>\NNS\14234074 .\.\1740
D005200_D063646 NONE The\DT\1740 present\JJ\1740 results\NNS\34213 are\VBP\836236 consistent\JJ\1740 with\IN\1740 the\DT\1740 carcinogenicity\NN\1740 experiment\NN\641820 suggesting\VBG\1010118 that\IN\1740 different\JJ\1740 mechanisms\NNS\13446390 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 <e1>FANFT</e1>\NN\1740 <e2>carcinogenesis</e2>\NN\1740 in\IN\13603305 the\DT\1740 bladder\NN\5515670 and\CC\1740 forestomach\NN\1740 ,\,\1740 and\CC\1740 that\IN\1740 aspirin\NN\2707683 's\POS\1740 effect\NN\34213 on\IN\1740 FANFT\NN\1740 in\IN\13603305 the\DT\1740 forestomach\NN\1740 is\VBZ\836236 not\RB\1740 due\JJ\1740 to\TO\1740 an\DT\6697703 irritant\JJ\1740 effect\NN\34213 associated\VBN\628491 with\IN\1740 increased\VBN\169651 cell\NN\3080309 proliferation\NN\13489037 .\.\1740
D005200_D063646 NONE The\DT\1740 present\JJ\1740 results\NNS\34213 are\VBP\836236 consistent\JJ\1740 with\IN\1740 the\DT\1740 carcinogenicity\NN\1740 experiment\NN\641820 suggesting\VBG\1010118 that\IN\1740 different\JJ\1740 mechanisms\NNS\13446390 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 FANFT\NN\1740 <e2>carcinogenesis</e2>\NN\1740 in\IN\13603305 the\DT\1740 bladder\NN\5515670 and\CC\1740 forestomach\NN\1740 ,\,\1740 and\CC\1740 that\IN\1740 aspirin\NN\2707683 's\POS\1740 effect\NN\34213 on\IN\1740 <e1>FANFT</e1>\NN\1740 in\IN\13603305 the\DT\1740 forestomach\NN\1740 is\VBZ\836236 not\RB\1740 due\JJ\1740 to\TO\1740 an\DT\6697703 irritant\JJ\1740 effect\NN\34213 associated\VBN\628491 with\IN\1740 increased\VBN\169651 cell\NN\3080309 proliferation\NN\13489037 .\.\1740
D001241_D063646 NONE The\DT\1740 present\JJ\1740 results\NNS\34213 are\VBP\836236 consistent\JJ\1740 with\IN\1740 the\DT\1740 carcinogenicity\NN\1740 experiment\NN\641820 suggesting\VBG\1010118 that\IN\1740 different\JJ\1740 mechanisms\NNS\13446390 are\VBP\836236 involved\VBN\2676054 in\IN\13603305 FANFT\NN\1740 <e2>carcinogenesis</e2>\NN\1740 in\IN\13603305 the\DT\1740 bladder\NN\5515670 and\CC\1740 forestomach\NN\1740 ,\,\1740 and\CC\1740 that\IN\1740 <e1>aspirin</e1>\NN\2707683 's\POS\1740 effect\NN\34213 on\IN\1740 FANFT\NN\1740 in\IN\13603305 the\DT\1740 forestomach\NN\1740 is\VBZ\836236 not\RB\1740 due\JJ\1740 to\TO\1740 an\DT\6697703 irritant\JJ\1740 effect\NN\34213 associated\VBN\628491 with\IN\1740 increased\VBN\169651 cell\NN\3080309 proliferation\NN\13489037 .\.\1740
2950248
D004176_D017202 NONE <e1>Dipyridamole-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 .\.\1740
D004176_D017202 NONE To\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 this\DT\1740 has\VBZ\2108377 not\RB\1740 previously\RB\1740 been\VBN\836236 reported\VBN\831651 as\IN\14622893 a\DT\13649268 side\JJ\1740 effect\NN\34213 of\IN\1740 preoperative\JJ\1740 <e1>dipyridamole</e1>\NN\1740 therapy\NN\657604 ,\,\1740 although\IN\1740 dipyridamole-induced\JJ\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 has\VBZ\2108377 been\VBN\836236 demonstrated\VBN\2137132 to\TO\1740 occur\VB\2623529 in\IN\13603305 animals\NNS\4475 and\CC\1740 humans\NNS\31264 with\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 .\.\1740
D004176_D017202 NONE To\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 this\DT\1740 has\VBZ\2108377 not\RB\1740 previously\RB\1740 been\VBN\836236 reported\VBN\831651 as\IN\14622893 a\DT\13649268 side\JJ\1740 effect\NN\34213 of\IN\1740 preoperative\JJ\1740 dipyridamole\NN\1740 therapy\NN\657604 ,\,\1740 although\IN\1740 <e1>dipyridamole-induced</e1>\JJ\1740 <e2>myocardial\JJ\1740 ischemia</e2>\NN\14195315 has\VBZ\2108377 been\VBN\836236 demonstrated\VBN\2137132 to\TO\1740 occur\VB\2623529 in\IN\13603305 animals\NNS\4475 and\CC\1740 humans\NNS\31264 with\IN\1740 coronary\JJ\1740 artery\NN\5417975 disease\NN\14061805 .\.\1740
D004176_D000787 CID <e2>Angina</e2>\JJ\1740 and\CC\1740 ischemic\JJ\1740 electrocardiographic\JJ\1740 changes\NNS\7283608 occurred\VBD\2623529 after\IN\1740 administration\NN\1133281 of\IN\1740 oral\JJ\1740 <e1>dipyridamole</e1>\NN\1740 in\IN\13603305 four\CD\13741022 patients\NNS\9898892 awaiting\VBG\1740 urgent\JJ\1740 myocardial\JJ\1740 revascularization\NN\1740 procedures\NNS\407535 .\.\1740
D004176_D003324 NONE To\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 this\DT\1740 has\VBZ\2108377 not\RB\1740 previously\RB\1740 been\VBN\836236 reported\VBN\831651 as\IN\14622893 a\DT\13649268 side\JJ\1740 effect\NN\34213 of\IN\1740 preoperative\JJ\1740 <e1>dipyridamole</e1>\NN\1740 therapy\NN\657604 ,\,\1740 although\IN\1740 dipyridamole-induced\JJ\1740 myocardial\JJ\1740 ischemia\NN\14195315 has\VBZ\2108377 been\VBN\836236 demonstrated\VBN\2137132 to\TO\1740 occur\VB\2623529 in\IN\13603305 animals\NNS\4475 and\CC\1740 humans\NNS\31264 with\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 .\.\1740
D004176_D003324 NONE To\IN\1740 our\PRP$\1740 knowledge\NN\23100 ,\,\1740 this\DT\1740 has\VBZ\2108377 not\RB\1740 previously\RB\1740 been\VBN\836236 reported\VBN\831651 as\IN\14622893 a\DT\13649268 side\JJ\1740 effect\NN\34213 of\IN\1740 preoperative\JJ\1740 dipyridamole\NN\1740 therapy\NN\657604 ,\,\1740 although\IN\1740 <e1>dipyridamole-induced</e1>\JJ\1740 myocardial\JJ\1740 ischemia\NN\14195315 has\VBZ\2108377 been\VBN\836236 demonstrated\VBN\2137132 to\TO\1740 occur\VB\2623529 in\IN\13603305 animals\NNS\4475 and\CC\1740 humans\NNS\31264 with\IN\1740 <e2>coronary\JJ\1740 artery\NN\5417975 disease</e2>\NN\14061805 .\.\1740
D004176_D007511 NONE Epicardial\JJ\1740 coronary\JJ\1740 collateral\NN\13287984 vessels\NNS\5246511 were\VBD\836236 demonstrated\VBN\2137132 in\IN\13603305 all\DT\1740 four\CD\13741022 patients\NNS\9898892 ;\:\1740 a\DT\13649268 coronary\JJ\1740 "\``\1740 steal\JJ\1740 "\``\1740 phenomenon\NN\29677 may\MD\15209706 be\VB\836236 the\DT\1740 mechanism\NN\13446390 of\IN\1740 the\DT\1740 <e1>dipyridamole-induced</e1>\JJ\1740 <e2>ischemia</e2>\NN\14195315 observed\VBN\2163746 .\.\1740
18791946
D002939_D013921 CID Severe\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 and\CC\1740 haemolytic\JJ\1740 anaemia\NN\14299637 associated\VBN\628491 with\IN\1740 <e1>ciprofloxacin</e1>\NN\2716866 :\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 with\IN\1740 fatal\JJ\1740 outcome\NN\7291312 .\.\1740
D002939_D013921 CID This\DT\1740 case\NN\7283608 report\NN\6470073 shows\VBZ\2137132 that\IN\1740 <e1>ciprofloxacin</e1>\NN\2716866 may\MD\15209706 precipitate\VB\1642924 life-threatening\JJ\1740 <e2>thrombocytopenia</e2>\NN\14189204 and\CC\1740 haemolytic\JJ\1740 anaemia\NN\14299637 ,\,\1740 even\RB\1740 in\IN\13603305 the\DT\1740 early\JJ\1740 phases\NNS\15113229 of\IN\1740 treatment\NN\654885 and\CC\1740 without\IN\1740 apparent\JJ\1740 previous\JJ\1740 exposures\NNS\5042871 .\.\1740
D002939_D000743 CID Severe\JJ\1740 thrombocytopenia\NN\14189204 and\CC\1740 <e2>haemolytic\JJ\1740 anaemia</e2>\NN\14299637 associated\VBN\628491 with\IN\1740 <e1>ciprofloxacin</e1>\NN\2716866 :\:\1740 a\DT\13649268 case\NN\7283608 report\NN\6470073 with\IN\1740 fatal\JJ\1740 outcome\NN\7291312 .\.\1740
D002939_D000743 CID This\DT\1740 case\NN\7283608 report\NN\6470073 shows\VBZ\2137132 that\IN\1740 <e1>ciprofloxacin</e1>\NN\2716866 may\MD\15209706 precipitate\VB\1642924 life-threatening\JJ\1740 thrombocytopenia\NN\14189204 and\CC\1740 <e2>haemolytic\JJ\1740 anaemia</e2>\NN\14299637 ,\,\1740 even\RB\1740 in\IN\13603305 the\DT\1740 early\JJ\1740 phases\NNS\15113229 of\IN\1740 treatment\NN\654885 and\CC\1740 without\IN\1740 apparent\JJ\1740 previous\JJ\1740 exposures\NNS\5042871 .\.\1740
D002939_D015746 CID A\DT\13649268 30-year\JJ\1740 old\JJ\1740 Caucasian\JJ\1740 man\NN\9605289 reported\VBN\831651 with\IN\1740 <e2>abdominal\JJ\1740 pain</e2>\NN\14299637 and\CC\1740 jaundice\NN\14299637 after\IN\1740 3-day\JJ\1740 administration\NN\1133281 of\IN\1740 oral\JJ\1740 <e1>ciprofloxacin</e1>\NN\2716866 for\IN\1740 a\DT\13649268 suspect\NN\7846 of\IN\1740 urinary\JJ\1740 tract\NN\8574314 infection\NN\14052046 .\.\1740
D002939_D007565 CID A\DT\13649268 30-year\JJ\1740 old\JJ\1740 Caucasian\JJ\1740 man\NN\9605289 reported\VBN\831651 with\IN\1740 abdominal\JJ\1740 pain\NN\14299637 and\CC\1740 <e2>jaundice</e2>\NN\14299637 after\IN\1740 3-day\JJ\1740 administration\NN\1133281 of\IN\1740 oral\JJ\1740 <e1>ciprofloxacin</e1>\NN\2716866 for\IN\1740 a\DT\13649268 suspect\NN\7846 of\IN\1740 urinary\JJ\1740 tract\NN\8574314 infection\NN\14052046 .\.\1740
D002939_D014552 NONE A\DT\13649268 30-year\JJ\1740 old\JJ\1740 Caucasian\JJ\1740 man\NN\9605289 reported\VBN\831651 with\IN\1740 abdominal\JJ\1740 pain\NN\14299637 and\CC\1740 jaundice\NN\14299637 after\IN\1740 3-day\JJ\1740 administration\NN\1133281 of\IN\1740 oral\JJ\1740 <e1>ciprofloxacin</e1>\NN\2716866 for\IN\1740 a\DT\13649268 suspect\NN\7846 of\IN\1740 <e2>urinary\JJ\1740 tract\NN\8574314 infection</e2>\NN\14052046 .\.\1740
17344566
D019821_D003161 CID <e1>Simvastatin-induced</e1>\JJ\1740 bilateral\JJ\1740 leg\NN\5560244 <e2>compartment\NN\13910384 syndrome</e2>\NN\5870365 and\CC\1740 myonecrosis\NN\11486708 associated\VBN\628491 with\IN\1740 hypothyroidism\NN\14059928 .\.\1740
D019821_D003161 CID A\DT\13649268 54-year-old\JJ\1740 hypothyroid\JJ\1740 male\JJ\1740 taking\VBG\2367363 thyroxine\NN\5413241 and\CC\1740 <e1>simvastatin</e1>\NN\3676175 presented\VBN\2137132 with\IN\1740 bilateral\JJ\1740 leg\NN\5560244 <e2>compartment\NN\13910384 syndrome</e2>\NN\5870365 and\CC\1740 myonecrosis\NN\11486708 .\.\1740
D019821_D009135 NONE <e1>Simvastatin-induced</e1>\JJ\1740 bilateral\JJ\1740 leg\NN\5560244 compartment\NN\13910384 syndrome\NN\5870365 and\CC\1740 <e2>myonecrosis</e2>\NN\11486708 associated\VBN\628491 with\IN\1740 hypothyroidism\NN\14059928 .\.\1740
D019821_D009135 NONE A\DT\13649268 54-year-old\JJ\1740 hypothyroid\JJ\1740 male\JJ\1740 taking\VBG\2367363 thyroxine\NN\5413241 and\CC\1740 <e1>simvastatin</e1>\NN\3676175 presented\VBN\2137132 with\IN\1740 bilateral\JJ\1740 leg\NN\5560244 compartment\NN\13910384 syndrome\NN\5870365 and\CC\1740 <e2>myonecrosis</e2>\NN\11486708 .\.\1740
D019821_D007037 NONE <e1>Simvastatin-induced</e1>\JJ\1740 bilateral\JJ\1740 leg\NN\5560244 compartment\NN\13910384 syndrome\NN\5870365 and\CC\1740 myonecrosis\NN\11486708 associated\VBN\628491 with\IN\1740 <e2>hypothyroidism</e2>\NN\14059928 .\.\1740
D019821_D007037 NONE A\DT\13649268 54-year-old\JJ\1740 <e2>hypothyroid</e2>\JJ\1740 male\JJ\1740 taking\VBG\2367363 thyroxine\NN\5413241 and\CC\1740 <e1>simvastatin</e1>\NN\3676175 presented\VBN\2137132 with\IN\1740 bilateral\JJ\1740 leg\NN\5560244 compartment\NN\13910384 syndrome\NN\5870365 and\CC\1740 myonecrosis\NN\11486708 .\.\1740
D013974_D007037 NONE A\DT\13649268 54-year-old\JJ\1740 <e2>hypothyroid</e2>\JJ\1740 male\JJ\1740 taking\VBG\2367363 <e1>thyroxine</e1>\NN\5413241 and\CC\1740 simvastatin\NN\3676175 presented\VBN\2137132 with\IN\1740 bilateral\JJ\1740 leg\NN\5560244 compartment\NN\13910384 syndrome\NN\5870365 and\CC\1740 myonecrosis\NN\11486708 .\.\1740
D013974_D003161 NONE A\DT\13649268 54-year-old\JJ\1740 hypothyroid\JJ\1740 male\JJ\1740 taking\VBG\2367363 <e1>thyroxine</e1>\NN\5413241 and\CC\1740 simvastatin\NN\3676175 presented\VBN\2137132 with\IN\1740 bilateral\JJ\1740 leg\NN\5560244 <e2>compartment\NN\13910384 syndrome</e2>\NN\5870365 and\CC\1740 myonecrosis\NN\11486708 .\.\1740
D013974_D009135 NONE A\DT\13649268 54-year-old\JJ\1740 hypothyroid\JJ\1740 male\JJ\1740 taking\VBG\2367363 <e1>thyroxine</e1>\NN\5413241 and\CC\1740 simvastatin\NN\3676175 presented\VBN\2137132 with\IN\1740 bilateral\JJ\1740 leg\NN\5560244 compartment\NN\13910384 syndrome\NN\5870365 and\CC\1740 <e2>myonecrosis</e2>\NN\11486708 .\.\1740
